and the second				<u> </u>
Last Name Aakhus	First Name Svend	Session Title Emerging Applications of Echocardiography	Presentation Title Effect of Changing Strain Software Versions on Longitudinal Assessment of LV Function	Disclosures Nothing to Disclose
Aaronson	Keith	Kanu and Docey Chatterjee Lecture and Seminal Talks in Heart Failure: I Wanna New	Assessment of EV Function Co-Chair	RESEARCH/RESEARCH GRANTS - HeartWare/Medtronic,Thoratec/St Jude
Aaronson	Keith	Drug: Updated Heart Failure Guidelines 13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	RESEARCH/RESEARCH GRANTS -
Abadir	Sylvia	Clinical Team 7 Atrial Fibrillation in Young and Unusual Populations: Children and Adult Congenital	Co-Chair	HeartWare/Medtronic,Thoratec/St Jude Nothing to Disclose
Aban	Inmaculada	Heart Disease Non Invasive Imaging: MR Characterization	Left Ventricular Torsion Shear Angle Volume Approach for Non-	Nothing to Disclose
		and Function	Invasive Evaluation of Diastolic Dysfunction in Preserved Ejection Fraction	-
Aban	Inmaculada	Emerging Developments in HFpEF and Arryhthmias	Left Ventricular Mechanical Properties Assessed by Single Beat Method in Early Stages of Diastolic Dysfunction/Heart Failure With Preserved Ejection Fraction	Nothing to Disclose
Abbadi	Deepika	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Coronary Artery Mycotic Aneurysm: A Rare Presentation of Tricuspid Valve Endocarditis	Nothing to Disclose
Abbara	Suhny	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team	Suggested Reviewer	OTHER - Elsevier / Amirsys; RESEARCH/RESEARCH GRANTS - Philips
Abbas	Amr	Arrhythmias and Clinical EP: Devices 4	Pacemaker-Induced Tricuspid Regurgitation Is Uncommon Immediate Post-Implant	SPEAKER'S BUREAU - Lantheus Imaging
Abbas	Amr	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low- Flow Severe Aortic Stenosis and Less Reverse Remodeling After	SPEAKER'S BUREAU - Lantheus Imaging
Abbas	Syed	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	TAVR: A Partner 2 Trial Analysis Peripheral Endothelial Function Assessment of Patients on Ticagrelor Versus Clopidogrel Who Have Undergone Percutaneous Coronary Intervention: A Randomized, Crossover Study	Nothing to Disclose
Abbasi	Fahim	Diabetes and Other Issues in Cardiovascular	Insulin Resistance Associates With Adverse Cardiac Remodeling in	Nothing to Disclose
Abbasi	Mostafa	Prevention Valvular Heart Disease: Aortic Stenosis	the Absence of Hypertension in Young South Asians Valve Thrombosis Following Transcatheter Aortic Valve Replacement: Implications of Reduced Cardiac Output	Nothing to Disclose
Abbasi	Siddique	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Natural Disasters and Risk of Myocaardial Infarction: A Systematic Review and Meta-Analysis	Nothing to Disclose
Abbate	Antonio	Coronary Artery Disease Making Progress in Understanding Heart	Arterial Elastance Drives Ventilatory Inefficiency in Systolic Heart	CONSULTANT FEES/HONORARIA - GSK,Janssen,Novartis;
Abbate	Antonio	Failure Interdisciplinary Cardiovascular Team Collaboratives in Care	Failure Management of Obesity in Patients With Diastolic Dysfunction	OTHER - Swedish Orphan Biovitrum CONSULTANT FEES/HONORARIA - GSK, Janssen, Novartis;
Abbate	Antonio	Emerging Developments in HFpEF and	Early Diastolic Mitral Annular Velocity at Peak Exercise Determines	OTHER - Swedish Orphan Biovitrum CONSULTANT FEES/HONORARIA - GSK, Janssen, Novartis;
Abbott	Brian	Arryhthmias Nuclear Cardiology: Current Applications and	Peak Aerobic Exercise Capacity in Heart Failure With Preserved Ejection Fraction ACC Talk: Nuclear Cardiology in 2017	OTHER - Swedish Orphan Biovitrum Nothing to Disclose
		Best Practices: Joint Symposium of the American Society of Nuclear Cardiology and the American College of Cardiology	,	v
Abbott Abbott	Brian J.	30. Non Invasive Imaging: Nuclear Team 1 Fellows Bootcamp: Interventional Basics	Suggested Reviewer Quality and Reporting for Fellows	Nothing to Disclose CONSULTANT FEES/HONORARIA - DynaMed,UpToDate;
Abbott	J.	Aorto-iliac Disease and Treatment: Practice at	Co-Chair	DATA SAFETY MONITORING BOARD - Pfizer CONSULTANT FEES/HONORARIA - DynaMed,UpToDate;
Abbott	J.	"The Edge" in Peripheral Intervention Valvular Disease Populations at Risk	National and Regional Trends in Surgical Aortic Valve Replacement	DATA SAFETY MONITORING BOARD - Pfizer CONSULTANT FEES/HONORARIA - DynaMed,UpToDate;
Abbott	J.	Interventional Cardiology: Translation and Pre-	in the TAVR Era Intramyocardial Autologous CD34+ Cell Therapy for Refractory	DATA SAFETY MONITORING BOARD - Pfizer CONSULTANT FEES/HONORARIA - DynaMed,UpToDate;
Abbott	J.	Clinical Research PCI for NSTEMI and Complex Patients With	Angina: A Meta-Analysis Thirty-Day Readmission Rate and Cost After Percutaneous	DATA SAFETY MONITORING BOARD - Pfizer CONSULTANT FEES/HONORARIA - DynaMed,UpToDate;
		Multiple Co-Morbidities Coronary Intervention in Interventional	Coronary Intervention in the United States: A National Readmission Database Analysis Angiography Versus Optical Coherence Tomography Guided	DATA SAFETY MONITORING BOARD - Pfizer CONSULTANT FEES/HONORARIA - DynaMed,UpToDate;
Abbott	J.	Cardiology: Advanced Device Use	Percutaneous Coronary Intervention: A Meta-Analysis of Clinical Outcomes	DATA SAFETY MONITORING BOARD - Pfizer
Abbott	J.	Interventional Cardiology: TAVR 2	Association of Chronic Renal Insufficiency With In-Hospital Outcomes of Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - DynaMed,UpToDate; DATA SAFETY MONITORING BOARD - Pfizer
Abbott	J.	Interventional Cardiology: TAVR 3	Infective Endocarditis After Transcatheter Aortic Valve Replacement: Insights From the Nationwide Readmissions Database	CONSULTANT FEES/HONORARIA - DynaMed,UpToDate; DATA SAFETY MONITORING BOARD - Pfizer
Abbott	J.	Highlights in Vascular Medicine Research	Thirty-Day Readmissions Following Endovascular or Surgical Treatment for Critical Limb Ischemia: Analysis of the Nationwide Readmissions Database	CONSULTANT FEES/HONORARIA - DynaMed,UpToDate; DATA SAFETY MONITORING BOARD - Pfizer
Abbott	J.	18. Interventional Cardiology: Carotid and Endovascular Intervention Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - DynaMed,UpToDate; DATA SAFETY MONITORING BOARD - Pfizer
Abbott	J.	26. Interventional Cardiology: Vascular Access and Complications Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - DynaMed,UpToDate; DATA SAFETY MONITORING BOARD - Pfizer
Abchee	Antoine	Population Specific Cardiomyopathies: From Exomes to Databases	Targeted and Exome Sequencing of 27 Lebanese Patients With Cardiomyopathies: Novel Variants in Known Genes, and Potential	Nothing to Disclose
Abd Alamir	Moshrik	Which Test Is Best for Pain in the Chest?	Novel Genes Downstream Testing Utilization Following Obstructive Coronary Computed Tomographic Angiography (CCTA) in the ED Evaluation	Nothing to Disclose
Abdallah	Hany	Post-CAD/MI: Making Tough Predictions About the Future	of Low to Intermediate Risk Acute Chest Pain The Burden of Coronary Artery Disease in Those With Human Immunodeficiency Virus as Demonstrated by Need for	Nothing to Disclose
Abdallah	Mouin	Acute Heart Failure: Evaluating Strategies to	Percutaneous Coronary Intervention Impact of an Inpatient Electronic Medical Record Heart Failure	Nothing to Disclose
Abdel Hay	Mohamed Ayman	Prevent Readmissions FIT Clinical Decision Making: Non-Invasive	Checklist on Readmissions Think Syndromic	Nothing to Disclose
Abdelghani	Mohammad	Imaging and Valvular Heart Disease Updates in Stable Ischemic Heart Disease	Coronary Calcification as a Mechanism of Plaque/Media Shrinkage: A Multimodality Intracoronary Imaging Study	Nothing to Disclose
Abdelghany	Mahmoud	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	A multimodality intracoronary imaging Study Cardioembolic Stroke Due to Takotsubo Cardiomyopathy, Truly Rare or Under-Recognized?	Nothing to Disclose
Abdelhadi	Naser	Disease, and Vascular Medicine Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Association Between Circulating Progenitor Cells and Outcomes in Patients With Coronary Artery Disease	Nothing to Disclose
Abdelhadi	Naser	Coronary Artery Disease Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Inflammatory Response to Mental Stress and Mental Stress Induced Myocardial Ischemia	Nothing to Disclose
Abdelhadi	Naser	Coronary Artery Disease The Evolving World of LVADs, Transplant and	Progenitor Cells and Clinical Outcomes in Patients With Heart	Nothing to Disclose
Abdelhadi	Naser	Other Novel Discoveries Unusual Presentations of ACS	Failure Circulating Progenitor Cells Levels and Outcomes in Acute	Nothing to Disclose
	l		Myocardial Infarction	-

Contract of the contract of th				
Abdel-Karim	Abdul-Rahman	Session Title FIT Clinical Decision Making: Interventional	Presentation Title Death of Stethoscopes Under the Ruling of Door-to-Balloon Time	Disclosures Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine		
Abdel-Latif	Ahmed	Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI	Sphingosine-1 Phosphate Is a Novel Biomarker That Correlates With Stem Cell Mobilization and Clinical Outcomes in Patients With ST-Elevation Myocardial Infarction	Nothing to Disclose
Abdelrahim	Elsheikh	Valvular Heart Disease: Aortic Stenosis	Outcomes and Their Predictors in Acute Transcatheter Aortic Heart Valve-in-Transcatheter Aortic Heart Valve Therapy	Nothing to Disclose
Abdelrahim Abdelrahman	Elsheikh Mohamed	Interventional Cardiology: TAVR 3 Arrhythmias and Clinical EP: Devices 4	Predictors of Late Bleeding in the TAVR Population Cardiac Resynchronization Therapy (CRT) Upgrade in Patients With	Nothing to Disclose Nothing to Disclose
			Pacemakers Is Associated With Higher Mortality Compared to De- Novo	-
Abdelsalam	Mahmoud	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prognostic Value of Segment Involvement Score Compared to Other Measures of Coronary Atherosclerosis by Computed Tomography: A Systematic Review and Meta-Analysis	Nothing to Disclose
Abdelsalam	Murad	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	External Femoral-Femoral Bypass for Acute Limb Ischemia	Nothing to Disclose
Abdel-Wahab	Mohamed	Late-Breaking Clinical Trials: Interventional	FFR Guided Acute Complete Revascularization Versus Culprit Lesion Only Treatment in Patients Presenting With ST-Segment Elevation Myocardial Infarction and Multi Vessel Disease: The COMPARE-ACUTE Trial	CONSULTANT FEES/HONORARIA - Boston Scientific
Abdel-Wahab	Mohamed	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	CONSULTANT FEES/HONORARIA - Boston Scientific
Abdel-Wahab	Mohamed	Interventional Cardiology: TAVR 3	Does Balloon Predilatation Influence Outcome With the Lotus Valve: 30-Day Results From the RESPOND Study	CONSULTANT FEES/HONORARIA - Boston Scientific
Abdi Ali	Ahmed	Non Invasive Imaging: MR Characterization and Function	Defining Risk Associated With Left Ventricular Hypertrophy Patterns as Assessed by Cardiac Magnetic Resonance Imaging	Nothing to Disclose
Abdi Ali	Ahmed	Updates in Stable Ischemic Heart Disease	Beta Blocker Post ACS in Patients With Preserved Left Ventricular Systolic Function	Nothing to Disclose
Abdul	Fairoz	Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI	A Ticagrelor Loading Results in Increased Plasma S-Nitrosothiols Formation Acutely in Patients With Stable Angina Undergoing Pci but Not on Chronic Therapy: Possible Evidence of an Acute Pleiotropic Effect	Nothing to Disclose
Abdullah	Shuaib	Highlighted Original Research: Prevention and the Year in Review	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 16,721 Patients From 33 Randomized Clinical Trials	RESEARCH/RESEARCH GRANTS - DalCor, Pfizer inc
Abdullah	Shuaib	Innovations in Advocacy and Patient Centered Care	Diverse Perspectives and Training Paths in Cardiology: An Analysis of Authorship in the <i>Journal of the American College of Cardiology</i>	RESEARCH/RESEARCH GRANTS - DalCor,Pfizer Inc
Abdullah	Shuaib	Advances in Chronic Total Occlusion Intervention	Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions Improves Peak Oxygen Uptake During Cardiopulmonary Exercise Testing	RESEARCH/RESEARCH GRANTS - DalCor,Pfizer Inc
Abdullah	Shuaib	32. Prevention: Clinical Team 1	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - DalCor,Pfizer Inc
Abdul-Nour	Khaled	Vascular Medicine: Aortic and Peripheral Artery Diseases	Acute Aortic Dissection in Patients Without a History of Hypertension	Nothing to Disclose
Abdulsalam	Nashwa	FIT Clinical Decision Making: Arrhythmias and	A Case of Unexplained Syncope and Type 1 Inducible Brugada	Nothing to Disclose
Abdulsalam	Nashwa	Electrophysiology FIT Clinical Decision Making: Arrhythmias and	Syndrome Transient Brugada Pattern in Diabetic Ketoacidosis	Nothing to Disclose
Abdur Rehman	Karim	Electrophysiology Obesity Management in 2017: Weighing the	A Meta-Analysis of Cardiovascular Safety of FDA Approved Anti	Nothing to Disclose
Abella	Benjamin	Issues Clinical Challenges in the Cardiac Care Unit (CCU)	Obesity Drugs Update in Neuroprognostication Following Out-of-hospital Cardiac Arrest	CONSULTANT FEES/HONORARIA - Bard,Physio-Control Inc.; OTHER - CardioReady; RESEARCH/RESEARCH GRANTS - American Heart Association,CR Bard,Medtronic Foundation,NIH
Aberra	Tsion	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Improvement in Cholesterol Efflux Capacity Is Associated With a Reduction in Aortic Wall Thickness by MRI Independent of	NHLBI,PCORI Nothing to Disclose
Abeysekera	Jayani	Impact of Prenatal Environment on Congenital Heart Disease	Traditional CV Risk Factors Umbilical Arterial Blood Flow in the Third Trimester and Its Association With Clinical and Neurodevelopmental Outcomes in	Nothing to Disclose
Abhishek	Fnu	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Children With Critical Neonatal Congenital Heart Disease Impact of Treatment Crossovers on Clinical Outcomes in the Rate and Rhythm Control Strategies for Atrial Fibrillation: InsightsFrom the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) Trial	CONSULTANT FEES/HONORARIA - MEDTRONIC, MEDTRONIC; RESEARCH/RESEARCH GRANTS - MEDTRONIC
Abi Khalil	Charbel	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	High Blood Pressure on Discharge From Acute Decompensated Heart Failure in Patients With Type 2 Diabetes Is Associated With	Nothing to Disclose
Abi Khalil	Charbel	Arrhythmias and Clinical EP: AF Miscellaneous	Decreased 12-Month Mortality: Findings From the Gulf-Care Influence of Beta-Blockers on Mortality in Chronic Heart Failure Patients With Atrial Fibrillation: Findings From the Gulf-Safe	Nothing to Disclose
Abi-Samra	Freddy	and Surgical Issues Nuclear Cardiology: Coronary Flow	Reduced Flow Capacity as Measured by Cardiac Positron Emission Tomography Predicts Ventricular Tachyarrhythmia in Patients With	Nothing to Disclose
Abisogun	Akinniran	PCI for NSTEMI and Complex Patients With	an ICD Management and Outcomes of Non-ST Elevation Myocardial	Nothing to Disclose
Abisogun	Akinniran	Multiple Co-Morbidities Interventional Cardiology: PCI in Complex Patients	Infarction in Patients Hospitalized for Non-Cardiac Conditions Outcomes After Invasive Management of Inpatient Onset of Non ST- Elevation Myocardial Infarction	Nothing to Disclose
Abisse	Saddam	Tricuspid Regurgitation: Signals in Plain Sight	Echocardiographic Predictors of Tricuspid Ring Failure	Nothing to Disclose
Abizaid	Alexandre	Interventional Live Case Session VI: Bioresorbable Scaffolds and Imaging from St. Vincent Hospital (Indianapolis, IN)	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,MEDTRONIC,REVA Medical
Abizaid	Alexandre	New Perspectives on Structural Valve Disease: International Perspectives From the Emirates Cardiac Society, Latin American Society of Interventional Cardiology (SOLACI), and American College of Cardiology	Novel TAVR Technologies Tested in South America	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,MEDTRONIC,REVA Medical
Abizaid	Alexandre	Bioresorbable Vascular Scaffolds, Bioresorbable Polymer and Polymer Free Metallic DES	Bioresorbable Polymer and Polymer Free Metallic DES	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,MEDTRONIC,REVA Medical
Abizaid	Alexandre	Highlighted Original Research: Interventional Cardiology and the Year in Review	Clinical, Angiographic and Procedural Correlates of Absorb Scaffold Thrombosis: A Matched Multicenter Registry Analysis	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,MEDTRONIC,REVA Medical
Abizaid	Alexandre	Coronary Intervention in Interventional	Intravascular Imaging Comparison of Two Metallic Limus-Eluting	CONSULTANT FEES/HONORARIA - Abbott, Boston
Although	late ende	Cardiology: Advanced Device Use	Stents Abluminally Coated With Biodegradable Polymers: IVUS and OCT Results of the DESTINY Trial	Scientific,MEDTRONIC,REVA Medical
Abizaid	Alexandre	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Independent Pre Procedural Echocardiographic Predictors of Mitral Valve Restenosis After Percutaneous Mitral Balloon Valvuloplasty in a Large Consecutive Cohort Followed Up to Two Decades	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,MEDTRONIC,REVA Medical
Abizaid	Alexandre	Interventional Cardiology: Structural Heart Disease	Initial Results and Long-Term Follow-Up of Percutaneous Mitral Valvuloplasty in Patients With Pulmonary Hypertension	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,MEDTRONIC,REVA Medical
1		1		

				<u> </u>
Last Name Abizaid	First Name Alexandre	Session Title	Presentation Title Final 3-Year Clinical Outcomes of Patients Treated With Everolimus-	Disclosures CONSULTANT FEES/HONORARIA - Abbott, Boston
Abizaid	Alexandre	Refining PCI Technique and Outcomes	Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents: A Propensity Score Comparison of Patients Enrolled in the	Scientific,MEDTRONIC,REVA Medical
Abizaid	Alexandre	Frontiers in Mitral Valve Disease and Treatment	Extend and SPIRIT Trials Predictors of Immediate and Very Late Events After Percutaneous Mitral Valvuloplasty	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,MEDTRONIC,REVA Medical
Abizaid	Alexandre	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,MEDTRONIC,REVA Medical
Abnousi	Freddy	Team 1 Young Investigator Awards Competition:	Racial Differences in Quality of Care and Outcomes After Acute	Nothing to Disclose
Abo Bakr	Mohamed	Outcomes Research Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Coronary Syndrome A New Score for Prediction of Slow/No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients With Acute	Nothing to Disclose
Aboeata	Ahmed	Arrhythmias and Clinical EP: Devices 2	Myocardial Infarction Role of Implantable Defibrillators in Primary Prevention of Mortality	Nothing to Disclose
Abolbashari	Mehran	FIT Clinical Decision Making: Prevention, Adult	in Non-Ischemic Cardiomyopathy Patients Double Right Coronary Artery Engendering Inadequate Blood Supply to the Inferior Left Ventricular Wall	Nothing to Disclose
Abou	Rachid	Congenital and Congenital Heart Disease Innovative Use of Echocardiography	Left Ventricular Systolic Recovery After St-Segment Elevation	Nothing to Disclose
		- ' '	Myocardial Infarction: Effect of Guideline-Based Therapy	-
Abou	Rachid	Non Invasive Imaging: MR Scar and Perfusion	Functional Consequences of Myocardial Scar After Myocardial Infarction: Characterization of Myocardial Scar Extent With Late Gadolinium Contrast Enhanced Cardiac Magnetic Resonance and Impact on Multilayer Global Longitudinal Strain on Speckle Tracking Echocardiography	Nothing to Disclose
Abou Ziki	Maen	Arrhythmias and Clinical EP: Basic 4	Deleterious Mutations in SCN10A Are Associated With Long QT Syndrome	Nothing to Disclose
Aboulhosn	Jamil	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Safety and Feasibility of Melody Transcatheter Pulmonary Valve Replacement in the Native Right Ventricular Outflow Tract: A Multicenter Study	CONSULTANT FEES/HONORARIA - Actelion Pharmaceuticals,Edward Lifesciences; RESEARCH/RESEARCH GRANTS - Actelion Pharmaceuticals
Abouzaki	Nayef	Making Progress in Understanding Heart Failure	Arterial Elastance Drives Ventilatory Inefficiency in Systolic Heart Failure	Nothing to Disclose
Aboyans	Victor	Highlighted Original Research: Vascular Medicine and the Year in Review	Co-Chair	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Bayer Healthcare Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,Bristol-Myers Squibb Company ,Novartis Corporation,Přizer Inc
Aboyans	Victor	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Impact of Renin-Angiotensin System Blockers on Long Term Survival Following Isolated Aortic Valve Replacement for Aortic Stenosis	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Bayer Healthcare Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,Bristol-Myers Squibb Company ,Novartis Corporation,Pizer Inc
Aboyans	Victor	Novel Determinants of Outcomes in VHD	Electrocardiographic Strain Is Associated With Reduced Survival After Surgical Aortic Valve Replacement for Aortic Stenosis	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Bayer Healthcare Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,Bristol-Myers Squibb Company ,Novartis Corporation,Pfizer Inc
Abraham	Maria Roselle	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Triglyceride Glucose Index Is an Independent Risk Factor for Hypertension	Nothing to Disclose
Abraham	Theodore	Advances in HCM, PPCM and Other Cardiomyopathies	Risk Profiles and Clinical Outcomes in Patients With Non- Obstructive, Labile and Obstructive Hypertrophic Cardiomyopathy	Nothing to Disclose
Abraham	William	FIT Forum: Mix and Mingle	 b>Heart Failure	CONSULTANT FEES/HONORARIA - Abbott Vascular, MEDTRONIC, Novartis, St. Jude Medical
Abraham	William	Featured Clinical Research III	Paroxysmal Atrial Fibrillation Is Associated With Worse Clinical Outcomes Than Persistent/Permanent Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction	CONSULTANT FEES/HONORARIA - Abbott Vascular,MEDTRONIC,Novartis,St. Jude Medical
Abraham	William	Can You See Me Now? Sensors For Monitoring Heart Failure	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular, MEDTRONIC, Novartis, St. Jude Medical
Abraham	William	Transcatheter Mitral Valve Replacement	Medical Rx Will Be Able to Treat the Majority of These Patients	CONSULTANT FEES/HONORARIA - Abbott Vascular, MEDTRONIC, Novartis, St. Jude Medical
Abraham	William	Core Curriculum: Mending the Failing Heart	"Unbreak My Heart:" Strategies to Reduce Rehospitalization	CONSULTANT FEES/HONORARIA - Abbott Vascular, MEDTRONIC, Novartis, St. Jude Medical
Abraham	William	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	High Procedural and Device Related Success With the CardioMEMS HF System for Heart Failure: Observations From the CardioMEMS™ Post Approval Study	CONSULTANT FEES/HONORARIA - Abbott Vascular,MEDTRONIC,Novartis,St. Jude Medical
Abramowitz	Yigal	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	Nothing to Disclose
Abramowitz	Yigal	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries	Nothing to Disclose
Abramowitz	Yigal	Refining TAVR Outcomes	Frame Geometry and Hemodynamic Findings of Sapien 3 Transcatheter Heart Valve in Patients With Bicuspid Aortic Valve	Nothing to Disclose
Abrams	Dominic	Atrial Fibrillation in Young and Unusual Populations: Children and Adult Congenital	Disease Panelist	OTHER - Johnson & Donson
Abrams	Dominic	Heart Disease Atrial Fibrillation in Young and Unusual	Can we Successfully Ablate Atrial Fibrillation in ACHD?	OTHER - Johnson & Donson
Abreu-Gonzalez	Pedro	Populations: Children and Adult Congenital Heart Disease Timely Topics in Acute Coronary Syndromes	Time to Treatment With Melatonin and Infarct Size in Patients With	Nothing to Disclose
, SIGG-GUIIZAREZ	. curo	Table 1 opios in Acute Corollary Syndromes	ST-Segment Elevation Myocardial Infarction: Insights From the MARIA (Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty) Trial	g to Disclose
Abualsuod	Amjad	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	treated with Anglopiasty) That Does Post Pci Ffr Carry the Same Prognostic Weight as Non- Ischemic Ffr in Deferred Lesions?	Nothing to Disclose
Abuannadi	Mohammad	Advances in HCM, PPCM and Other Cardiomyopathies	Ischemic Fit in Deterred Lesions? Systemic Arterial Pulsatility Index (SAPi) Predicts Adverse Outcomes in Advanced Heart Failure Patients	Nothing to Disclose
Abuarqoub	Ahmad	Changing the Natural History of Valve Disease With Medical Therapy	Statins Use and Long Term Outcome Post Surgical Aortic Valve Replacement	Nothing to Disclose
Abudayyeh	Islam	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Glycemic Control in Insulin and Non-Insulin Dependent Diabetic Patients With ST Elevation Myocardial Infarction Predicts Time to	Nothing to Disclose
Abudayyeh	Islam	Coronary Artery Disease Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Presentation Ischemic Time and Risk Factors Associated With the Incidence of Cardiogenic Shock in Patients Presenting With ST Elevation Myocardial Infarction	Nothing to Disclose
Abudayyeh	Islam	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Impact of Demographics and Socioeconomic Status on Mode of Transportation and Time to Presentation in Patients With ST Elevation Myocardial Infarction	Nothing to Disclose
Abudayyeh	Islam	Interventional Cardiology: TAVR 2	Impact of the Presence of Coronary Artery Disease and Timing of Revascularization on Outcomes of Patients Undergoing Trans- Catheter Aortic Valve Replacement: Insights From STS/ACC TVT Registry	Nothing to Disclose
Abudayyeh	Islam	Innovations in Advocacy and Patient Centered Care	Status of Early Career Academic Cardiology: A Global Perspective	Nothing to Disclose
Abu-Fadel Abu-Fadel	Mazen Mazen	Logistical Challenges in STEMI Contemporary Role of Intracoronary Imaging:	Co-Chair Case Presentation: Plaque Prolapse and Clinical Consequences	Nothing to Disclose Nothing to Disclose
, Sur lauci		Candid Conversation with Peers	Saus Frederication. Fraque Fredrapse and Official Consequences	Treating to Discitor

Contract of the Contract of th				
Last Name Abu-Fadel	First Name Mazen	Session Title Head to Toe: Outcomes of Endovascular	Presentation Title Atherectomy Is Associated With Lower Rates of Repeat Intervention	Disclosures Nothing to Disclose
Abu-Fadel	Mazen	Interventions Head to Toe: Outcomes of Endovascular Interventions	After Below Knee Peripheral Vascular Intervention Utilization of Distal Embolic Protection in Infrainguinal Peripheral	Nothing to Disclose
Abu-Fadel	Mazen	Head to Toe: Outcomes of Endovascular	Arterial Intervention: Insights From the Multicenter XLPAD Registry Association of Cigarette Smoking With Procedural Cost of Lower	Nothing to Disclose
Abu-Fadel	Mazen	Interventions Endovascular Therapy: Running From Risk	Extremity Endovascular Intervention Predictors of Procedural Complications in Infrainguinal	Nothing to Disclose
Abu-Fadel	Mazen	Highlights in Vascular Medicine Research	Endovascular Interventions Comparative Assessment of Subintimal Versus Intraluminal	Nothing to Disclose
Abu-Fadel	Mazen	Acute and Stable Ischemic Heart Disease:	Crossing of Infrainguinal Chronic Total Occlusion Lesions Suggested Reviewer	Nothing to Disclose
		Clinical Team 1 FIT Clinical Decision Making Reviewers 1	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Abuzaid Acampado	Ahmed Eduardo	Interventional Cardiology: Translation and Pre-	Endothelial Maturation and Function Following Implantation of	Nothing to Disclose
		Clinical Research	Abluminal Coating Biodegradable Polymer Based Sirolimus-Eluting Metallic Stent Versus Conformal Coating Durable Polymer Based Everolimus Eluting Stent	
Acampado	Eduardo	Refining PCI Technique and Outcomes	mTors Inhibitors Increase Endothelial Permeability and Prevent Maturation: Uncovering the Mechanism of Neoatherosclerosis in Drug Eluting Stents	Nothing to Disclose
Aceros	Henry	Novel Imaging and Therapies in Heart Failure	Novel Infarct Sparing Drug Protects the Heart Against Ischemia- Reperfusion (I/R) Injury	Nothing to Disclose
Acevedo Acharya	Monica Gayatri	33. Prevention: Hypertension Team 2 Novel Echocardiographic Methods for	Suggested Reviewer Subclinical Myocardial Alterations in Cardiac Sarcoidosis	SPEAKER'S BUREAU - Novartis Corporation Nothing to Disclose
Acharya	Tushar	Assessing Cardiac Function FIT Clinical Decision Making: Non-Invasive	The Pulmonary Embolism That Wasn't: A Case of Pulmonary	Nothing to Disclose
		Imaging and Valvular Heart Disease	Pseudo-Sequestration	-
Acharya	Tushar	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Reversible Severe Right Heart Failure and Tricuspid Regurgitation From Thyrotoxicosis	Nothing to Disclose
Achenbach	Stephan	Non Invasive Imaging: Prognostic Implications of CT Angiography	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	RESEARCH/RESEARCH GRANTS - Siemens Medical Solutions
Achenbach	Stephan	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team 3	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Siemens Medical Solutions
Achrekar	Abinash	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Seeing Is Believing: Utilizing Multiple Imaging Modalities in Difficult to Characterize Left Ventricle Outflow Obstruction	CONSULTANT FEES/HONORARIA - Pfizer/BMS
Acker	Michael	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic Surgical Trials Network	CONSULTANT FEES/HONORARIA - HeartWare, Thoratec
Acker	Michael	Structural Heart Disease: Difficult Choices for the Heart Team	Very Low EF, Severe MR - Repair, Replace, Transplant, +/-MCS Transfer? Oh My!	CONSULTANT FEES/HONORARIA - HeartWare,Thoratec
Acker	Michael	Controversies in Mitral Valve Surgery: Joint Symposium of the Society of Thoracic Surgeons and the American College of	Panelist	CONSULTANT FEES/HONORARIA - HeartWare,Thoratec
Acker	Michael	Cardiology The Nuts and Bolts of Pulmonary Hypertension	Panelist	CONSULTANT FEES/HONORARIA - HeartWare, Thoratec
Acker	Michael		Surgical Considerations for Patients with Pulmonary Hypertension	CONSULTANT FEES/HONORARIA - HeartWare, Thoratec
Acker	Michael	in Left Heart Disease Young Investigator Awards Competition: Basic	Due to Vavular Heart Disease LVAD-Associated von Willebrand Factor Degradation Fragments	CONSULTANT FEES/HONORARIA - HeartWare, Thoratec
		and Translational Science	Alter Angiogenesis: A Mechanistic Link Between LVAD Support, Gastrointestinal Angiodysplasia, and Bleeding?	
Ackerman	Michael	The Abnormal ECG: Should I Worry about Sudden Death Risk in this Patient	QT Intervals: The Long and Short of It	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation, Gilead Sciences, Inc. Invitae, MEDTRONIC, MyoKardia, St. Jude Medical, Inc.; OTHER - AliveCor, Transgenomic (FAMILLION); RESEARCH/RESEARCH GRANTS - National Institutes of Health
Ackerman	Michael	The Athlete with Heart Disease: A Case Based Approach	An Arrythmic Death: Long QT	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation, Gilead Sciences, inc. Invitae, MEDTRONIC, MyoKardia, St. Jude Medical, Inc.; OTHER - AliveCor, Transgenomic (FAMILION); RESEARCH/RESEARCH GRANTS - National Instit
Ackerman	Michael	Improving Outcomes in the Athlete With Cardiovascular Disease	Exercise Testing in Pediatric Patients: Objective Versus Subjective Effort	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation, Gilead Sciences, inc. Invitae, MEDTRONIC, MyoKardia, St. Jude Medical, Inc.; OTHER - AliveCor, Transgenomic (FAMILLON); RESEARCH/RESEARCH GRANTS - National Institutes of Health
Ackerman	Michael	04. Arrhythmias and Clinical EP: Basic Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation, Gilead Sciences, Inc. Invitae,MEDTRONIC,MyoKardia,St. Jude Medical, Inc.; OTHER - AliveCor, Transgenomic (FAMILION); RESEARCH/RESEARCH GRANTS - National Institutes of Health
Acquatella	Harry	13. Heart Failure and Cardiomyopathies: Clinical Team 8	Suggested Reviewer	Nothing to Disclose
Ad	Niv	Changing the Natural History of Valve Disease With Medical Therapy	Association of Blood Glucose and Hemoglobin A1C Level With Surgical Outcomes: Should Glycemic Control Be Modified?	CONSULTANT FEES/HONORARIA - MEDTRONIC; OTHER - LIVANOVA,Nido Surgical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Left Atrial Appendage Occlusion, LLC; SPEAKER'S BUREAU - AtriCure,LIVANOVA
Ad	Niv	The Challenges of Outcome Prediction in Valvular Heart Disease	How Well Does the STS Risk Score Predict Late Survival After Cardiac Surgery?	Occusioni, LLC, SPEARER'S BUREAU - Alficule; LIVANOVA CONSULTANT FEES/HONORARIA - MEDTRONIC; OTHER - LIVANOVA, Nido Surgical; OWNERSHIP INTEREST/PARTNERSHIP/PRICIPAL - Left Atrial Appendage Occlusion, LLC; SPEAKER'S BUREAU - AtriCure, LIVANOVA
Adabag	Selcuk	Updates on Risk Factors for Cardiovascular Disease	Frailty as a Risk Factor for Cardiovascular Versus Non- Cardiovascular Mortality in Elderly Men: Results From the Outcomes of Sleep Disorders in Older Men (MrOS Sleep) Study	Nothing to Disclose
Adabag	Selcuk	Interventional Cardiology: PCI and TAVR in Complex Patients	Calcification in the Basal Septum, but Not Membranous Septal Length, Predicts AV Conduction Disturbance and Pacemaker Implantation Following Transcatheter Aortic Valve Replacement	Nothing to Disclose
Adachi	lki	Congenital Heart Disease: Innovations in	With a Balloon-Expandable Valve (S3) Is a Pulsatile Glenn an Adequate Alternative for Long-Term	Nothing to Disclose
Adami	Elizabeth	Single Ventricle Heart Disease Highlighted Original Research: Non Invasive Imaging and the Year in Review	Palliation in Patients With Single Ventricle Physiology? The Association of High Risk Plaque Features and Non-Invasive Fractional Flow Reserve Derived From Coronary Computed	Nothing to Disclose
			Tomography Angiography in Patients With Acute Chest Pain: Results From the ROMICAT II Trial	
Adamo	Francesco	Improving Outcomes in the Athlete With Cardiovascular Disease	EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students	Nothing to Disclose
Adamo	Luigi	Making Progress in Understanding Heart Failure	Global Longitudinal Strain Predicts Sustained Recovery of LV Ejection Fraction in Heart Failure Patients on Evidence Based Medical Therapies	Nothing to Disclose

and a				
Adams	First Name David	Session Title Joint American College of Cardiology/New England Journal of Medicine Late-Breaking	Presentation Title Panelist	Disclosures OTHER - Edwards Lifesciences,MEDTRONIC; RESEARCH/RESEARCH GRANTS -
Adams	David	Clinical Trials Transcatheter Mitral Valve Replacement	For Which Patients Do We Need TMVR: Who Is High Risk in 2017?	MEDTRONIC,MEDTRONIC,NeoChord OTHER - Edwards Lifesciences,MEDTRONIC; RESEARCH/RESEARCH GRANTS -
Adams	David	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Effect of Baseline Aortic Regurgitation on Mortality in the Core Valve US Pivotal High Risk Trial	MEDTRONIC,MEDTRONIC,NeoChord OTHER - Edwards Lifesciences,MEDTRONIC; RESEARCH/RESEARCH GRANTS -
Adams	David	Infectious Endocarditis: Comprehensive	Long-Term Benefits of Repair Versus Replacement for Acute Native	MEDTRONIC,MEDTRONIC,NeoChord OTHER - Edwards Lifesciences,MEDTRONIC;
Adams	David	Perspectives 24. Interventional Cardiology: Mitral and	Mitral Valve Endocarditis Suggested Reviewer	RESEARCH/RESEARCH GRANTS - MEDTRONIC,MEDTRONIC,NeoChord OTHER - Edwards Lifesciences,MEDTRONIC;
Adams	Kirkwood	Structural Heart Disease Team 2 Heart Failure and Cardiomyopathies: Is Heart	Influence of Low Versus High Dose on the Association of Loop	RESEARCH/RESEARCH GRANTS - MEDTRONIC,MEDTRONIC,NeoChord CONSULTANT FEES/HONORARIA - Amgen Inc.,Merck
Adams	Kirkwood	Failure With a Normal EF for Real?	Influence of Low Petsus right bose on the Association of Loop Durrectic and Mortality in Patients With Heart Failure: Insights From the UNITE-HF Registry	CONSULTAIN TEST/ICHONARIA - Antiget in IC., whetck ∓amp; Co., Inc., Novartis Corporation, Relypsa, Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Amgen, Cardiorentis, DCRI, Novartis Corporation, Otsuka, ROCHE DX
Adams	Kirkwood	14. Heart Failure and Cardiomyopathies: Therapy Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen Inc.,Merck & Co., Inc.,Novartis Corporation, Relypsa,Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Amgen,Cardiorentis,DCRI,Novartis Corporation,Otsuka,ROCHE DX
Adamson	Philip	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Optimal Risk Stratification Pathways for Patients With Suspected Acute Coronary Syndrome	RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals
Adamson	Philip	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Age and the Effectiveness of Risk Stratification and Diagnostic Thresholds for Myocardial Infarction With High-Sensitivity Cardiac Troponin	RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals
Adamson	Philip	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	High-Sensitivity Cardiac Troponin and the Classification of Myocardial Infarction	RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals
Adamson	Philip	Blips, Trops, and Chips: New Ways to Diagnose CAD	High-Sensitivity Cardiac Troponin I and the Diagnosis of Obstructive Coronary Artery Disease in Patients With Suspected Stable Angina	RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals
Adatya	Sirtaz	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics	Nothing to Disclose
Adatya	Sirtaz	Innovative Use of Echocardiography	Assessment of Left Ventricular Rotational Mechanics Post-LVAD	Nothing to Disclose
Adatya	Sirtaz	13. Heart Failure and Cardiomyopathies:	Implantation Using 3D Echocardiography Suggested Reviewer	Nothing to Disclose
Aday	Aaron	Clinical Team 4 Maximally Effective Vascular Care: Vascular Collaborative Team Care in Action	Case Presentation #4: 47-year-old Diabetic Smoker with Great Toe Gangrene	Nothing to Disclose
Aday	Aaron	Clinical Assessment and Revascularization for Critical Limb Ischemia	Rest Pain and Vascular Wounds: Methods to Evaluate Limb Perfusion	Nothing to Disclose
Aday	Aaron	Highlighted Original Research: Vascular Medicine and the Year in Review	A Critical Evaluation of Exercise Testing in Diagnosing Peripheral Artery Disease	Nothing to Disclose
Addetia	Karima	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Implementation of a Wideband Late Gadolinium Enhancement Implementation of a Wideband Late Gadolinium Enhancement Cardiac Magnetic Resonance Protocol to Improve Assessment of Myocardial Scar in Patients With Implantable Cardioverter Defibrillators	Nothing to Disclose
Addetia	Karima	Valvular Heart Disease: Aortic Regurgitation	Left Ventricular Mechanical Properties in Patients With Severe Aortic Insufficiency and Normal Ejection Fraction: Impact on Survival	Nothing to Disclose
Addetia	Karima	Innovative Use of Echocardiography	Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography	Nothing to Disclose
Addettia	Karima	The Tricuspid Valve: Not Forgotten, Just Misunderstood	Case: Pacer-induced TR	Nothing to Disclose
Addison	Daniel	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Natural Disasters and Risk of Myocaardial Infarction: A Systematic Review and Meta-Analysis	Nothing to Disclose
Addison	Daniel	Innovations in Cardiovascular Risk Assessment and Reduction	Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African Americans: The Jackson Heart Study	Nothing to Disclose
Addo	Тауо	21. Interventional Cardiology: Coronary Intervention: Devices Team 1	Suggested Reviewer	SPEAKER'S BUREAU - Astra Zeneca, Medicure, Merck & Amp; amp; Co., Inc.
Adelborg	Kasper	Vascular Medicine: Venous Disease	Risk of Cancer After Upper-Extremity Deep Vein Thrombosis: A Population-Based Cohort Study	Nothing to Disclose
Adelborg	Kasper	Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering Therapies	17-Year Nationwide Trends in Antihypertensive Drug Use in Denmark	Nothing to Disclose
Adelborg	Kasper	Advances in Pathophysiology and Treatment of Thrombosis	Risk of Cancer After Lower Limb Arterial Thrombosis: A Population- Based Cohort Study	Nothing to Disclose
Adelstein	Evan	Arrhythmias and Clinical EP: AF Ablation	Characterization of Pulmonary Vein Reconnection Post Cryoballoon Ablation	Nothing to Disclose
Adeola	Oluwaseun	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Hemodynamic Management of Septic Shock in Hypertrophic Cardiomyopathy	Nothing to Disclose
Ades	Matthew	Interventional Complexity and Complications	Non-Femoral Access Is Associated With 30-Day Mortality in Frail	Nothing to Disclose
Adhikari	Shubash	Arrhythmias and Clinical EP: Devices 2	Patients Undergoing Transcatheter Aortic Valve Replacement Persistent Gender Disparities in Implantable Cardioverter-	Nothing to Disclose
Adil	Amina	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Defibrillator Therapy Mitral Regurgitation Secondary to Mitral Arcade in Two Brothers	Nothing to Disclose
Adil	Amina	Interventional Cardiology: PCI and TAVR in Complex Patients	The Risk of Adverse Coronary Events Is Higher in Patients With Severe Obstructive Sleep Apnea Following Percutaneous Coronary	Nothing to Disclose
Adler	Eric	Heart Failure Patient Care: Transitioning the Cost, Care and Context: Joint Heart Failure Society of America and American College of Cardiology	Intervention The Caregiver: What Do They Need From the Team?	CONSULTANT FEES/HONORARIA - MEDTRONIC
Adler	Eric	Put Your Codon! Genetic Insights Into Heart Failure	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - MEDTRONIC
Adler	Eric	12. Heart Failure and Cardiomyopathies: Basic Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC
Adusumalli	Srinath	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic	Trends in Catheter Directed Thrombolysis and Systemic Thrombolysis for Pulmonary Embolism Treatment: 2004-2014	Nothing to Disclose
Afilalo	Jonathan	Disease and the Year in Review Structural Heart Disease: Difficult Choices for	Older adults with VHD, Comorbidity: Predictive Markers for Both	Nothing to Disclose
Afilalo	Jonathan	the Heart Team Cardiovascular Procedures That Push the	Favorable and Futile Procedural Outcomes Panelist	Nothing to Disclose
Afilalo	Jonathan	Line: High-Risk or Futility of Care? Cardiovascular Procedures That Push the	High Risk vs. Futility in Valvular procedures (TAVR/Mitraclip)	Nothing to Disclose
l	1	Line: High-Risk or Futility of Care?	- , , , , , , , , , , , , , , , , , , ,	=

Leaf Marcon Applied Common Common Processor Common Proce	Const.				l .
April			Session Title		
Model Appel Model Appel Model Apple Model	Апаю	Jonathan	Interventional Cardiology: TAVR 4	Adults Undergoing Transcatheter Aortic Valve Replacement:	Nothing to Disclose
	Afilalo	Jonathan	Interventional Complexity and Complications	Non-Femoral Access Is Associated With 30-Day Mortality in Frail	Nothing to Disclose
Money U.S. Million Program Purchassandrig Need Money L.S. Million Bookson Name (March Money Company) Money L.S. Million Money Company (Ma	Afolabi	Abigail	Timely Topics in Acute Coronary Syndromes	Systemic Pentraxin 3 Is a Potential Biomarker to Differentiate Plaque Erosion From Plaque Rupture in Acute Coronary Syndrome	Nothing to Disclose
Control Lists For Character States Assert States Section States Control States Cont	Afonso	Luis		Left Ventricular Mass Index and Other Independent Predictors of	Nothing to Disclose
March Marc	Afonso	Luis	FIT Clinical Decision Making: Non-Invasive		Nothing to Disclose
	Afonso	Luis		Things to Consider When Shopping for a Shunt: A Diagnostic	Nothing to Disclose
April	Afonso	Luis			Nothing to Disclose
Person Resultanciance State Person Assertanciance State Person Assertanciance See See See See See See See See See S	Afonso	Luis	Valve, Left Atrial Appendage and HOCM Acute Heart Failure: Evaluating Strategies to		Nothing to Disclose
Congressia and Congressia Search Diseased Alteria de la Cife Circle Diseased Newford Aprillement and Informative Control of Detection (Congressia) Alteria de Cife Circle Diseased Newford (Congressia) Alteria de Cife Cife Cife Cife Cife Cife Cife Cif			Prevent Readmissions	Failure Patients and Impact of the ACC/AHA Management Guidelines: Insight From the National Inpatient Sample (NIS)	-
Anterior Description of the Company	Afonso	Luis			Nothing to Disclose
Morse Use Provided Carbon Confedence and Personal Personal Confedence of Early New York Confedence of E	Afonso	Luis			Nothing to Disclose
Service House Cardedays P.C. and TANK III	Afonso	Luis	Innovations in Cardiovascular Risk Assessment	Hemodynamic Predictors of Left Ventricular Mass Index in the	Nothing to Disclose
Approach List	Afonso	Luis	Interventional Cardiology: PCI and TAVR in	Economic Implications of Late Discharge After Transcatheter Aortic	Nothing to Disclose
Montre List Misternational Cardiology / NAPS Control Recommend Montre Control Recommend Mon	Afonso	Luis	Interventional Cardiology: PCI and TAVR in	Predictors of Early Discharge Home After Transcatheter Aortic	Nothing to Disclose
Abosed Lis Semplang Developments in Fig.Fig. and Septimization Burdon of Clasticis. Next Failure in the United Noting to Disclose (2017-2017). Applan Extra Listin Standard Septimization of Clasticis (Next Failure in the United Noting to Disclose (2017-2017). Applan Extra Listin Standard Septimization (1) Septimizat	Afonso	Luis		Transcatheter Versus Surgical Aortic Valve Replacement in	Nothing to Disclose
Afferson Use The Interaction of Delibers and ASCOV. Afferson Use The Interaction of Deliberson Chinese Team 1 A Novel Benanders and Research State Perputation. Afferson Use The Interaction of Deliberson Chinese Team 1 A Novel Benanders Associated Research Interaction. Afferson Use The Interaction of Deliberson Chinese Team 1 A Novel Benanders Associated Research Interaction. Afferson Use The Interaction of Deliberson Interaction. Afferson Use The Interaction of Deliberson Interaction. Afferson Use The Interaction of Deliberson Interaction. Afferson Interaction of Team 1 Amendment of Interaction. Afferson Interaction. Again Team Interaction. Against Interactio	Afonso	Luis		Hospitalization Burden of Diastolic Heart Failure in the United	Nothing to Disclose
Above Care Internetion of Distance and ACVID Act Personal Process of Care Distance Care Care Care Care Care Care Care Car	Afonso	Luis		Novel Echocardiographic Variables in the Diagnosis of Acute	Nothing to Disclose
Domaines and Risk Prediction Tools Alters Al	Afonso	Luis	The Intersection of Diabetes and ASCVD		Nothing to Disclose
Affair Affair Asim Fractional and Novel Factors Used to Assess Precision of an Used to the Testerinal Concess Projection File Cland Decision Nature, Arrhytmian and Entertophysics of the Concess Projection of Compete Heart Block Entertophysics of Provided Projection Nature, Arrhytmian and Entertophysics of Provided Projection (Concess) Approach (Con	Afonso	Luis			Nothing to Disclose
Actail Assim PT Cincard Discontinuity Markey Profession and PT Contract Discontinuity Markey Profession and Pt Cincard Discontinuity Markey Profession and Pt Contract Discontinuity Markey Pt Contract Discontinuity Markey Pt Contract Pt Contrac					
Selection Nuthammad Arthythmiss and Clinical EP-Devices 2 Comprehensive Strategy is Reduce the Incidence of Lead Nothing to Disclose	Afrai	l A a a i a a	Coronary Artery Disease		Nathing to Displace
Again Tes Story of the Adult Congential Heart Anthymnia by Bacteria Story of the Adult Congential Heart Anthymnia Butter & Story of the Adult Congential Heart Anthymnia Butter & Story of the Adult Congential Heart Story of the Adult Politics Adult Adult Politics Adult Politics Adult Politics (William Congential Heart Story of the Adult Politics Adult Politics (William Congential Heart Story of the Adult Fortion Politics (William Congential Heart Story of the Adult Fortion Politics (William Congential Heart Story of the Adult Fortion Politics (William Congential Heart Story of the Adult Fortion Politics (William Congential Heart Story of the Adult Fortion Politics (William Congential Heart Story of the Adult Fortion Politics (William Congential Heart Story of the Adult Fortion Politics (William Congential Heart Story of the Adult Fortion Politics (William Congential Heart Story of the Adult Fortion Politics (William Congential Heart Story of the Adult Fortion Politics (William Congential Heart Story of the Adult Fortion Politics (William Congential Heart Story of the Adult Fortion Politics (William Congential Heart Story of the Adult Fortion Politics (William Congential Heart Story of the Adult Fortion Politics (William Congential Heart Story of the Adult Fortion Politics (William Congential Heart Story of the Adult Fortion			Electrophysiology		
Disease Patient and EP Againval Ajay Coronary Angogaphy, Intra-Vascular Imaging, Intra-Vascular Imaging Coronary Angogaphy, Intra-Vascular Imaging Coronary Angogaphy			-	Dislodgment for Cardiac Implantable Electronic Devices	
Revescularization and Outcomes Slocks Presenting for Coronary Angrography Agarwal Anual Present Anua		*	Disease Patient and EP		
Agarwal Anustree Desease Patient and EP Procedure of Proceedings of Area Tachyarrhythmiss in Adult Desease Patient and EP Procedure of Procedure on Affections of Afrail Tachyarrhythmiss in Adult Procedure of Procedure on Affections of Afrail Tachyarrhythmiss in Adult Procedure of Procedure on Affections of Afrail Tachyarrhythmiss in Adult Procedure of Procedure on Affections of Afrail Tachyarrhythmiss in Adult Procedure of Procedure on Affections of Afrail Tachyarrhythmiss in Adult Procedure of Procedure on Affections of Programs of Affections of Programs of Affections of Programs of Programs of Programs of Programs of Programs of Procedure of Procedure on Affections of Programs of Programs of Procedure of Procedure on Affections of Programs of Procedure of Procedure on Affections of Programs of Procedure of Procedure on Affections of Programs of Procedure of Programs of Procedure of Procedure on Affections of Procedure on Affections of Procedure of Programs of Procedure of Procedure on Affections on Affections on Affections on Affecting on Affections on Affecting on Affecti	Agarwal	Ajay	Revascularization and Outcomes	Blocks Presenting for Coronary Angiography	Nothing to Disclose
Agarwal Anushree The Story of the Adult Congental Heart Disease February Congental Agarwal Anushree Adult Patents Win Congental Heart Disease Morally in Pregnant Women With Congental Heart Disease Adult Patents Win Congental Heart Disease Morally in Pregnant Women With Congental Heart Disease Adult Patents Win Congental Heart Disease Adult Patents Patents Adult Portant Patents Adult Portants Adult Portants Patents Adult Patents Patents Adult Paten	Agarwal	Ajay			Nothing to Disclose
Agarwal Anushree Adult Patents With Congential Heart Disease: Morbin to Pregnant Women With Congential Heart Disease: A Nothing to Disclose Subanysis of the Colifornia Pregnancy Action (Congential Heart Disease): A Nothing to Disclose Congential Heart Disease: A Nothing to Disclose Congential Anushree Redefining the "F" Word Congential and Congential Heart Disease: A Congent Previou	Agarwal	Anushree			Nothing to Disclose
Agarwal Anushree Fontain in the Modern World Cincian Features of Elevated Body Mass Index and its Association With Nothing to Disclose Agarwal Anushree Redefining the "F" Word Prevalence and Predictors of Pacemaker Placement in Adult April Prevalence and Predictors of Pacemaker Placement in Adult April Prevalence and Predictors of Pacemaker Placement in Adult April Prevalence and Predictors of Pacemaker Placement in Adult April Prevalence and Predictors of Pacemaker Placement in Adult April Prevalence and Predictors of Pacemaker Placement in Adult April Prevalence and Predictors of Pacemaker Placement in Adult April Prevalence and Predictors of Pacemaker Placement in Adult April Prevalence and Pacemaker Placement in Adult Placemaker in Adult Placemaker in Adult Placemaker Placemaker in Adult Placemaker in	Agarwal	Anushree		Subanalysis of the California Pregnancy-Associated Mortality	Nothing to Disclose
Agarwal Anshree Redefining the "F" Word Frovince Prevention, Adult Fontal Patients of Pacemaker Placement in Adult Fontal Patients Frontal Pat	Agarwal	Anushree	Fontan in the Modern World	Prevalence of Elevated Body Mass Index and Its Association With	Nothing to Disclose
Agarwal Chirag Non Invasive Imaging: MR Characterization Agarwal Chirag Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension Non Invasive Imaging: MR Structure and Valuudiar Heart Disease. Agarwal Chirag Non Invasive Imaging: MR Structure and Valuudiar Heart Disease. Magarwal Megha Interventional Complexity and Complications Complications (Complexity and Complexity and Complications Complications Following Acute Myocardial Infarction in the United States Agarwal Nayan Fit Clinical Decision Making: Non-Invasive Imaging and Valuudiar Heart Diseases. Magarwal PRACHI Featured Clinical Research I Featured	Agarwal	Anushree	Redefining the "F" Word	Prevalence and Predictors of Pacemaker Placement in Adult	Nothing to Disclose
Chirag Non Invasive Imaging: MR Characterization and Function Aganwal Chirag Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension Aganwal Chirag Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension Aganwal Chirag Non Invasive Imaging: MR Structure and Valuvular Heart Disease Aganwal Chirag Non Invasive Imaging: MR Structure and Valuvular Heart Disease Its Severity of Heart Failure Aganwal Megha Interventional Complexity and Complications Aganwal Megha Interventional Complexity and Complications Aganwal Nayan FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Aganwal PRACHI Featured Clinical Research 1 Featured Clinical Res	Agarwal	Arpit		Exit Procedure for Fetal Mediastinal Teratoma With Large	Nothing to Disclose
Agarwal Chiag Non Invasive Imaging: IMR Heart Failure and Pulmonary Hypertension and Assesses the Severity of Heart Failure With Preserved Ejection Fraction Detects Increased Interstitutial Myocardial Fibrosis and Assesses the Severity of Heart Failure With Preserved Ejection Fraction Detects Increased Interstitutial Myocardial Fibrosis and Assesses the Severity of Heart Failure With Preserved Ejection Fraction Detects Increased Interstitutial Myocardial Fibrosis and Assesses the Severity of Heart Failure With Preserved Ejection Fraction Detects Increased Interstitutial Myocardial Fibrosis and Assesses the Severity of Heart Failure With Preserved Ejection Fraction Detects Increased Interstitutial Myocardial Fibrosis and Assesses the Severity of Heart Failure With Preserved Ejection Fraction Detects Increased Interstitutial Myocardial Fibrosis and Myocardial					
Pulmonary Hypertension Fraction Detects Increased Interstitial Myocardial Fibrosis and Assesses the Severible Agarwal Chirag Non Invasive Imaging, MR Structure and Mild Rheumatic Valvular Head Tiblease Myocardial Fibrosis A T1 Mapping Study	Agarwal	Chirag	and Function	Myocarditis	Nothing to Disclose
Agarwal Chirag Non Invasive Imaging: MR Structure and Valuduar Heart Disease Is Associated With Interstitial Mothing to Disclose Myocardial Fibrosa. A Ti Mapping Study Agarwal Megha Interventional Complexity and Complications Complexity and Complications Complexity and Complications Post Percutaneous Coronary Intervention Complexity and Complications Post Percutaneous Coronary Intervention Complexity and Complications Post Percutaneous Coronary Intervention Complexity and Complications Provided Infarction in the United States Agarwal Nayan FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Agarwal PRACHI Featured Clinical Research I Cardiac Pneumonia: Acute Mitral Regurgitation as a Rare Cause of Right Upper Lung Lobe Infiltrate Featured Clinical Research I Testing Safety and Efficacy: The Randomized Exploratory Study of Exercise Training in Hypertrophic Cardiomyopathry (RESET-HCM) Agarwal Shikhar Highlighted Original Research: Vascular Medicine and the Year in Review Schemia Changing Trends of Atherosclerotic Risk Factors Among Patients With Critical Limb Interventional Cardiology: Intravascular Physiology and Endothelial Function Agarwal Shiv Kumar Interventional Cardiology: Intravascular Physiology and Endothelial Function Agarwal Shiv Kumar Interventional Cardiology: Intravascular Physiology and Endothelial Function Agarwal Shiv Kumar Heart Failure and Cardiomyopathies: What Next When All Else Is Failing? Agarwal Sunil Updates on Risk Factors for Cardiovascular Risk Assessment Index Proposition of Cardiology: Beyond Perfusion Agarwal Sunil Innovations in Cardiovascular Risk Assessment and Reduction Agarwal Sunil Innovations in Cardiovascular Risk Assessment and Reduction Agarwal Sunil Innovations in Cardiovascular Risk Assessment and Reduction Agarwal Sunil Innovations in Cardiovascular Risk Assessment and Reduction Agarwal Sinia Fradyman Afrial Fibrillation and VT: Unique Populations Analysis of Cardiomy Application Factor of Sunday Privine Heart Sunday Application	Agarwal	Chirag		Fraction Detects Increased Interstitial Myocardial Fibrosis and	Nothing to Disclose
Agarwal Megha Interventional Complexity and Complications Sender Differences in Post Percutaneous Coronary Intervention SALARY - Amgen Complexition States Cardiac Presumonia: Acute Mitral Regurgitation as a Rare Cause of Right Upper Lung Lobe Infiltrate Nothing to Disclose Right Upper Lung Lobe Infiltrate Regulation as a Rare Cause of Right Upper Lung Lobe Infiltrate Regulation States Regulation of Regulation Regu	Agarwal	Chirag		Mild Rheumatic Valvular Heart Disease Is Associated With Interstitial	Nothing to Disclose
Agarwal PRACHI Fri Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Right Upper Lung Lobe Infittrate Agarwal PRACHI Featured Clinical Research I Featured Clinical Research I Testing Safety and Efficacy. The Randomized Exploratory Study of Exercise Training in Hypertrophic Cardiomyopathy (RESET-HCM) Agarwal Shikhar Highighted Original Research: Vascular Medicine and the Year in Review Medicine and the Year in Review Ischemia Shikhar New Perspectives on CAD Risk Factors Changing Trends of Atherosclerotic Risk Factors Among Patients With Critical Limb Ischemia Nothing to Disclose With Acute Myocardial Infarction and Acute Ischemic Stroke Agarwal Shiv Kumar Interventional Cardiology: Intravascular Agarwal Shiv Kumar Interventional Cardiology: Stent Failure Agarwal Shiv Kumar Interventional Cardiology: Stent Failure Agarwal Shiv Kumar Heart Failure and Cardiology Stent Failure Agarwal Shiv Kumar Heart Failure and Cardiology Stent Failure Agarwal Shiv Kumar Heart Failure and Cardiology part Shiv Mate Next When All Else Is Failing? Agarwal Sunil Updates on Risk Factors for Cardiovascular Disease Report Shiv Shiv Shir Shiv Shiv Shiv Shiv Shiv Shiv Shiv Shiv	Agarwal	Megha		Gender Differences in Post Percutaneous Coronary Intervention Complications Following Acute Myocardial Infarction in the United	SALARY - Amgen
Agarwal PRACHI Featured Clinical Research I Testing Safety and Efficacy: The Randomized Exploratory Study of Exercise Training in Hypertrophic Cardiomyopathy (RESET-HCM) Agarwal Shikhar Highlighted Original Research: Vascular Medicine and the Year in Review Interventional Cardiology: Intravascular Physiology and Endoduleal Function and Acute Interventional Cardiology: Intravascular Physiology and Endoduleal Function Physiology and Predictors of 30-Day Unplanned Readmission Rates After Left Ventricular Assist Device Placement Agarwal Sunil Update on Risk Factors for Cardiovascular Retinopathy and Risk of Sudden Cardiac Death: The ARIC Study Nothing to Disclose Agarwal Sunil Nuclear Cardiology: Beyond Perfusion Comparison of CZT SPECT and Cardiac MR Derived Cardiac Nothing to Disclose Agarwal Sunil Innovations in Cardiovascular Risk Assessment Prior Carebrovascular Events Compared to Controls Agarwal Pradyumna Atrial Fibrillation and VT: Unique Populations and Solutions Analysis of Randomized Controlled Studies After Left Centrolloges Studies Analysis of Randomized Controlled Studies Agarbaria Fibrillation and Maintenance of Sinus Rhythm: Meta-Analysis of Randomized Controlled Studies Agarbaria Fibrillation and Maintenance of Sinus Rhythm: Meta-Analy	Agarwal	Nayan		Cardiac Pneumonia: Acute Mitral Regurgitation as a Rare Cause of	Nothing to Disclose
Medicine and the Year in Review Ischemia Shikhar New Perspectives on CAD Risk Factors Changing Trends of Atherosclerotic Risk Factors Among Patients With Acute Myocardial Infarction and Acute Ischemic Stroke	Agarwal	PRACHI		Testing Safety and Efficacy: The Randomized Exploratory Study of	Nothing to Disclose
Agarwal Shikhar New Perspectives on CAD Risk Factors Changing Trends of Atherosclerotic Risk Factors Among Patients With Acute Myocardial Infarction and Acute Ischemic Stroke Agarwal Shiv Kumar Interventional Cardiology: Intravascular Physiology and Endothelial Function Vein Graft Lesions Agarwal Shiv Kumar Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Agarwal Shiv Kumar Heart Failure and Cardiomyopathies: What Next When All Else Is Failing: Affected Lesions? Agarwal Sunil Updates on Risk Factors for Cardiovascular Disease Agarwal Sunil Undear Cardiology: Beyond Perfusion Agarwal Sunil Innovations in Cardiovascular Residuation and Volumes in Patients With Significantly Reduced Election Fraction Agarwal Sunil Innovations in Cardiovascular Risk Assessment and Reduction Agarwal Sunil Innovations and Acute Isolatory Agarwal Program Progra	Agarwal	Shikhar			Nothing to Disclose
Agarwal Shiv Kumar Interventional Cardiology: Intravascular Physiology and Endothelial Function Vein Graft Lesions Does Post Poi Fir Carry the Same Prognostic Weight as Non-Interventional Cardiology: Stent Failure Does Post Poi Fir Carry the Same Prognostic Weight as Non-Interventional Cardiology: Stent Failure Does Post Poi Fir Carry the Same Prognostic Weight as Non-Interventional Cardiology: Stent Failure Does Post Poi Fir Carry the Same Prognostic Weight as Non-Interventional Cardiology: Stent Failure Does Post Poi Fir Carry the Same Prognostic Weight as Non-Interventional Cardiology and Predictors of 30-Day Unplanned Readmission Rates After Left Ventricular Assist Device Placement Nothing to Disclose Agarwal Sunil Nuclear Cardiology: Beyond Perfusion Comparison of CZT SPECT and Cardiac MR Derived Cardiac Function and Volumes in Patients With Significantly Reduced Ejection Fraction Agarwal Sunil Innovations in Cardiovascular Risk Assessment Agarwal Sunil Innovations in Cardiovascular Risk Assessment Prior Carebrovascular Events Compared to Controls Agasthi Pradyumna Atrial Fibrillation and VT: Unique Populations and Solutions (Artial Fibrillation and Maintenance of Sinus Rhythm: Meta-Analysis of Randomized Controlled Studies Agbor-Etang Brian Fit Clinical Decision Making: Prevention, Adult	Agarwal	Shikhar		Changing Trends of Atherosclerotic Risk Factors Among Patients	Nothing to Disclose
Agarwal Shiv Kumar Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Interventional Cardiology and Predictors of 30-Day Unplanned Readmission Rates After Left Ventricular Assist Device Placement Next When All Else Is Failing? Agarwal Sunil Updates on Risk Factors for Cardiovascular Disease Agarwal Sunil Nuclear Cardiology: Beyond Perfusion Retinopathy and Risk of Sudden Cardiac Death: The ARIC Study Disease Agarwal Sunil Nuclear Cardiology: Beyond Perfusion Comparison of CZT SPECT and Cardiac MR Derived Cardiac Perfusion Fautions With Significantly Reduced Ejection Fraction and Volumes in Patients With Significantly Reduced Ejection Fraction Agarwal Sunil Innovations in Cardiovascular Risk Assessment and Reduction Optical Coherence Tomography of Culprit Lesions in Patients With Prior Cerebrovascular Events Compared to Controls Agasthi Pradyumna Atrial Fibrillation and VT: Unique Populations and Solutions Agist Fibrillation and Maintenance of Sinus Rhythm: Meta-Analysis of Randomized Controlled Studies Agbor-Etang Brian Fit Clinical Decision Making: Prevention, Adult	Agarwal	Shiv Kumar		Outcomes of Fractional Flow Reserve Based Deferral in Saphenous	Nothing to Disclose
Agarwal Shiv Kumar Heart Failure and Cardiomyopathies: What Next When All Elise Is Failing? Agarwal Sunil Updates on Risk Factors for Cardiovascular Disease Agarwal Sunil Nuclear Cardiology: Beyond Perfusion Comparison of CZT SPECT and Cardiac MR Derived Cardiac Function and Volumes in Patients With Significantly Reduced Siection Fraction Agarwal Sunil Innovations in Cardiovascular Risk Assessment and Reduction Optical Coherence Tomography of Culprit Lesions in Patients With Prior Cerebrovascular Events Compared to Controls Agasthi Pradyumna Atrial Fibrillation and VT: Unique Populations and Solutions Agian Filt Clinical Decision Making: Prevention, Adult Analysis of Randomized Controlled Studies Apometical Events Company Artery Arising From Right Coronary Sinus Nothing to Disclose	Agarwal	Shiv Kumar	Interventional Cardiology: Stent Failure	Does Post Pci Ffr Carry the Same Prognostic Weight as Non-	Nothing to Disclose
Next When All Else is Failing? After Left Ventricular Assist Device Placement Sunit Updates on Risk Factors for Cardiovascular Retinopathy and Risk of Sudden Cardiac Death: The ARIC Study Nothing to Disclose		Shiv Kumar	Heart Failure and Cardiomyopathies: What	Etiology and Predictors of 30-Day Unplanned Readmission Rates	Nothing to Disclose
Agarwal Sunil Nuclear Cardiology: Beyond Perfusion Comparison of CZT SPECT and Cardiac MR Derived Cardiac Function and Volumes in Patients With Significantly Reduced Election Fraction Agarwal Sunil Innovations in Cardiovascular Risk Assessment Optical Coherence Tomography of Culprit Lesions in Patients With Prior Cardiovascular Events Compared to Controls Agasthi Pradyumna Athiat Pibrillation and VT: Unique Populations and Solutions of Atrial Fibrillation and Maintenance of Sinus Rhythm: Meta-Analysis of Randomized Controlled Studies Agbor-Etang Brian FIT Clinical Decision Making: Prevention, Adult			Next When All Else Is Failing?	After Left Ventricular Assist Device Placement	Nothing to Disclose
Agarwal Sunil Innovations in Cardiovascular Risk Assessmeth Optical Coherence Tomography of Culprit Lesions in Patients With and Reduction Prior Cerebrovascular Events Compared to Controls Agasthi Pradyumna Atrial Fibrillation and VT: Unique Populations and Solutions Agor-Etang Brian FIT Clinical Decision Making: Prevention, Adult Inomalous Left Coronary Artery Arising From Right Coronary Sinus Nothing to Disclose FIT Clinical Decision Making: Prevention, Adult Inomalous Left Coronary Artery Arising From Right Coronary Sinus Nothing to Disclose			Disease	Comparison of CZT SPECT and Cardiac MR Derived Cardiac	
and Reduction Prior Cerebrovascular Events Compared to Controls Agasthi Pradyumna Atrial Fibrillation and VT: Unique Populations and Solutions Artial Fibrillation and Maintenance of Sinus Rhythm: Meta-Analysis of Randomized Controlled Studies Agbor-Etang Brian FIT Clinical Decision Making: Prevention, Adult Incorpary Artery Arising From Right Coronary Sinus Nothing to Disclose	Aganwal	Sunil	Innovations in Cardiovascular Disk Assessment	Ejection Fraction	Nothing to Disclose
and Solutions of Atria Fibrillation and Maintenance of Sinus Rhythm: Meta- Analysis of Randomized Controlled Studies Agbor-Etang Brian FIT Clinical Decision Making: Prevention, Adult Anomalous Left Coronary Artery Arising From Right Coronary Sinus Nothing to Disclose			and Reduction	Prior Cerebrovascular Events Compared to Controls	
			and Solutions	of Atrial Fibrillation and Maintenance of Sinus Rhythm: Meta- Analysis of Randomized Controlled Studies	
	Agbor-Etang	Brian			Nothing to Disclose

and a				l_	
Last Name Agbor-Etang	First Name Brian	Session Title FIT Clinical Decision Making: Interventional	Presentation Title Transcatheter Aortic Valve Replacement in a Patient With Very	Disclosures Nothing to Disclose	
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Mobile Aortic Valve Mass		
Aggarwal	Bhuvnesh	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Pulmonary Hypertension in Left Atrial Sarcoma	Nothing to Disclose	
Aggarwal	Kul	Arrhythmias and Clinical EP: Devices 1	Implantable Cardioverter Defibrillator for the Prevention of Mortality	RESEARCH/RESEARCH GRANTS - Astra Zen	eca,Merck;
			in Non-Ischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials	SPEAKER'S BUREAU - Astra Zeneca	
Aggarwal	Kul	Arrhythmias and Clinical EP: Devices 1	Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients Undergoing Cardiac Implantable Electronic Device Implantation: A Meta-Analysis	RESEARCH/RESEARCH GRANTS - Astra Zen SPEAKER'S BUREAU - Astra Zeneca	
Aggarwal	Kul	Arrhythmias and Clinical EP: Anticoagulation Issues	Meta-Analysis on the Efficacy and Safety of New Oral Anticoagulants Compared With Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation	RESEARCH/RESEARCH GRANTS - Astra Zen SPEAKER'S BUREAU - Astra Zeneca	ieca,Merck;
Aggarwal	Kul	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Pseudohypotension Due to Bilateral Subclavian Artery Stenosis	RESEARCH/RESEARCH GRANTS - Astra Zen SPEAKER'S BUREAU - Astra Zeneca	ieca,Merck;
Aggarwal	Nimisha	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Unusual Presentation for Primary Bacterial Percarditis	Nothing to Disclose	
Aggarwal	Sanjeev	Vascular Access and Hemostasis Issues	TAVR Using Transcarotid Vascular Access: In-Hospital and Intermediate Term Outcomes	Nothing to Disclose	
Aggarwal	Sanjeev	Interventional Cardiology: TAVR 3	Prosthetic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter	Nothing to Disclose	
Aggarwal	Saurabh	Advances in HCM, PPCM and Other	Valve-in-Valve Implantation Impact of Obesity on the Outcomes of Stress Cardiomyopathy: An	Nothing to Disclose	
Aggarwal	Saurabh	Cardiomyopathies Heart Failure and Cardiomyopathies: Heart	Analysis of National Inpatient Sample Sequential Inhibition of Renin-Angiotensin System in Heart Failure Is	Nothing to Disclose	
		Failure Is Just a Revolving Door	Associated With Enhanced Net Benefit at a Cost of Increased Adverse Events: A Systematic Meta-Analysis		
Aggarwal	Sourabh	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Impact of Hereditary Causes of Thrombosis on Ischemic Stroke Between the Years 2008 Through 2012: Nationwide Inpatient Sample Data Analysis	Nothing to Disclose	
Aggarwal	Vikas	Head to Toe: Outcomes of Endovascular Interventions	Contemporary Nationwide Trends in Inferior Vena Cava Filter Implantation Rates in the United States and the Effect of Food and Drug Administration Advisory	Nothing to Disclose	
Aggarwal	Vikas	Venous Investigation: The Dark Side	Nationwide Contemporary Trends in Adjunctive Angioplasty and Stenting at the Time of Catheter Directed Thrombolysis in Patients	Nothing to Disclose	
Aggarwal	Vikas	Venous Investigation: The Dark Side	With Proximal Lower Extremity Deep Vein Thrombosis Sex Differences in the Use of Inferior Vena Cava Filters in Patients With Proximal Lower Extremity Deep Vein Thrombosis in the United	Nothing to Disclose	
Aggarwal	Vikas	Advances in Pathophysiology and Treatment of Thrombosis	States Intracranial Hemorrhage in Patients Treated With Catheter Directed Thrombolysis	Nothing to Disclose	
Aggeli	Constadina	Nuclear Cardiology: Beyond Perfusion	Increased Subclinical Systemic AND Vascular Inflammation in Familial Combined Hyperlipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission	Nothing to Disclose	
Aggeli	Constantina	Advances in Cholesterol Measurement and Management	Tomography Study Beneficial Effect of Statin Therapy on Carotid Wall Temperatures in Patients With Familial Hyperlipidemia Syndromes: Results From a	Nothing to Disclose	
Aggeli	Constantina	Interventional Cardiology: TAVR 2	Randomized Trial The Effect of Mixed Aortic Valve Disease in Clinical Outcomes After	Nothing to Disclose	
Aggeli	Constantina	Advances in HCM, PPCM and Other Cardiomyopathies	Transcatheter Aortic Valve Replacement Unique Characteristics of the Mitral Valve in Patients With Hypertrophic Cardiomyopathy Have Emerged Using Real-Time	Nothing to Disclose	
Agha	Ahmad	Non Invasive Imaging: Expanding Clinical Applications	Three Dimensional Transesophageal Echocardiography Aortic Valve Calcification Predicts Paravalvular Aortic Regurgitation After Self-Expanding Transcatheter Aortic Valve Replacement	Nothing to Disclose	
Aghajanian	Amir	FIT Clinical Decision Making: Arrhythmias and	Recurrent Syncope: An Unusual Presentation of Lymphoma	Nothing to Disclose	
Agnelli	Giancarlo	Electrophysiology Fibrillatory Arrhythmias: Outcomes With	Treatment and Outcomes of Patients With Nonvalvular Atrial	Nothing to Disclose	
		Contemporary Practice	Fibrillation According to Guideline-Defined Anticoagulation Thresholds: Results From the GARFIELD-AF Registry		
Agnes	Gianluca	Improving Outcomes in the Athlete With Cardiovascular Disease	EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students	Nothing to Disclose	
Agnihotri	Kanishk	Arrhythmias and Clinical EP: Basic 3	Seasonal Trends in Sudden Cardiac Death: A Study From the Largest Inpatient Database	Nothing to Disclose	
Agnihotri	Kanishk	Innovative Approaches for Reducing Risk and	Atrial Fibrillation Is Associated With Worse Outcomes in Patients With Cirrhosis	Nothing to Disclose	
Agnihotri	Kanishk	Improving Outcomes With Ablation Timely Topics in Acute Coronary Syndromes	Percutaneous Coronary Intervention Is Associated With Decreased	Nothing to Disclose	
Agnihotri	Kanishk	CAD in Unique Patient Populations	Mortality in NSTEMI Patients With Advanced CKD Trends in Prevalence and In-Hospital Mortality of NSTEMI Patients With Solid Tumor Cancer: The Nationwide Analysis From 1998-	Nothing to Disclose	
Agrawal	Akanksha	Emerging Applications of Echocardiography	2013 Dobutamine Stress Echocardiography as a Predictor of Cardiovascular Morbidity and Mortality Post Orthotopic Liver	Nothing to Disclose	
Agrawal	Harsh	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Transplantation Combined Migraine and Platypnea-Orthodeoxia Syndrome Due to Combined Atrial Septal Defect and Patent Foramen Ovale	Nothing to Disclose	
Agrawal	Harsh	FIT Clinical Decision Making: Prevention, Adult	41-Year-Old Patient With Double Inlet Left Ventricle Without	Nothing to Disclose	
Agrawal	Harsh	Congenital and Congenital Heart Disease FIT Clinical Decision Making: Prevention, Adult	Pulmonic Stenosis Presenting With Eisenmenger's Syndrome Double Right Coronary Artery Engendering Inadequate Blood	Nothing to Disclose	
Agraval	Hitaah	Congenital and Congenital Heart Disease	Supply to the Inferior Left Ventricular Wall	Nothing to Displace	
Agrawal	Hitesh	Non Invasive Imaging: Role of Exercise Testing	Stress Myocardial Perfusion Imaging in Anomalous Aortic Origin of a Coronary Artery: Results Following a Standardized Approach		
Agrawal	Sahil	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Temporal Trends and Outcomes of Emergent Coronary Artery Bypass Graft Surgery for ST-Segement Elevation Myocardial Infarction	Nothing to Disclose	
Agrawal	Sahil	Interventional Cardiology: TAVR 2	Comparison of In-Hospital Outcomes of Transcatheter Aortic Valve Replacement in Men and Women	Nothing to Disclose	
Agrawal	Sahil	Advances in HCM, PPCM and Other Cardiomyopathies	Cardiomyopathy	Nothing to Disclose	
Agrawal	Sahil	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Cardiomyopathy Impact of Atrial Fibrillation on Outcomes in Patients Hospitalized With ST-Segment Elevation Myocardial Infarction	Nothing to Disclose	
A	Cabil	Syndrome		Nothing to Display	
Agrawal	Sahil	Timely Topics in Acute Coronary Syndromes	Routine Invasive Versus Conservative Strategy for Elderly Patients Aged>75 Years With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS): A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose	

and a				
Last Name Agrawal	First Name Sahil	Session Title Antithrombotic Therapy in Ischemic Heart	Presentation Title Role of Anticoagulation Therapy After Anterior Wall ST-Elevation	Disclosures Nothing to Disclose
Agrawai	Sami	Disease	Myocardial Infraction in Preventing LV Thrombus: A Meta-Analysis and Meta-Regression	Nothing to Disclose
Agrawal	Sahil	Interventional Cardiology: TAVR 4	Outcomes of Trans-Catheter Aortic Valve Replacement in	Nothing to Disclose
Agrawal	Sahil	Optimizing the Care of ACS Patients	Nonagenarians Weekend Versus Weekday Presentation for ST-Segment Elevation	Nothing to Disclose
			Myocardial Infarction: Findings From a United States Nationwide Analysis	
Agrawal	Sahil	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Cardiovascular Complications and In-Hospital Outcomes of Chagas' Disease in the United States From 2003-2011	Nothing to Disclose
Agrawal	Yashwant	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Impact of Hereditary Causes of Thrombosis on Ischemic Stroke Between the Years 2008 Through 2012: Nationwide Inpatient	Nothing to Disclose
Agricolo	Eustachia	The Tricuspid Valve: Not Forgotten, Just	Sample Data Analysis The Spectrum of Acquired Tricuspid Valve Disease	CONSULTANT FEES/HONORARIA - 4Tech Cardio Ltd., Valtech,
Agricola	Eustachio	Misunderstood		
Agrogiannis	George	Changing the Natural History of Valve Disease With Medical Therapy	ŕ	Nothing to Disclose
Agrogiannis	George	Nuclear Cardiology: Beyond Perfusion	In Vivo Correlation of Carotid Temperatures and Pet/Fdg Uptake in Patients Undergoing Carotid Endarterectomy: Validation With Histology	Nothing to Disclose
Agudelo	Juan Fernando	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Holter Findings in Orthotopic Heart Transplantation Patients: Results From a Cohort of the Most Important Heart Transplant Referral Center in Colombia, South America	Nothing to Disclose
Aguilar	David	Non Invasive Imaging: MR Characterization and Function	Elevated Myocardial Extracellular Volume Fraction (ECV) and Its Prognostic Significance in Diabetic Individuals	CONSULTANT FEES/HONORARIA - Bristol-Myers Squibb
Aguilar	David	13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Bristol-Myers Squibb
Aguilar Pulido	David Alfonso	Clinical Team 7 FIT Clinical Decision Making: Non-Invasive	Left Atrium Undifferentiated Pleomorphic Sarcoma Mimicking Septal	Nothing to Disclose
Aguirre	Aaron	Imaging and Valvular Heart Disease Interventional Cardiology: Intravascular	Asymmetric Hypertrophic Cardiomiopathy Neointimal Pattern and Clinical Outcome After Drug-Eluting Stent	Nothing to Disclose
		Physiology and Endothelial Function	Implantation: Comparison Between First Generation and Second Generation Drug-Eluting Stents	-
Aguirre	Aaron	The Inside View: Learning From Intracoronary Imaging	Prevalence and Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A Four-Year Follow-Up Study	Nothing to Disclose
Ahlman	Mark	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Aortic Vascular Inflammation by 18-FDG PET/CT Associates With High-Risk Coronary Plaques in Young Psoriasis Patients	Nothing to Disclose
Ahlman	Mark	Vascular Medicine: New Insights Into Aortic and Peripheral Artery Diseases	Improvement in Cholesterol Efflux Capacity Is Associated With Improvement in Vascular Inflammation by 18- FDG PET CT in	Nothing to Disclose
Ahlman	Mark	Non Invasive Imaging: MR Heart Failure and	Psoriasis Improvement in Cholesterol Efflux Capacity Is Associated With a	Nothing to Disclose
Allillali		Pulmonary Hypertension	Reduction in Aortic Wall Thickness by MRI Independent of Traditional CV Risk Factors	-
Ahlman	Mark	Updates on Risk Factors for Cardiovascular Disease	Visceral but Not Subcutaneous Adipose Tissue Associates With Vascular Inflammation by 18-FDG PET/CT in Psoriasis	Nothing to Disclose
Ahmad	Amier	Interventional Cardiology: TAVR 3	Risk of Adverse Outcomes in Treatment Modalities for Severe Aortic Stenosis in Randomized Control Trials: Direct and Indirect Comparisons	Nothing to Disclose
Ahmad	Faraz	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Sudden Cardiac Death Risk Distribution in the United States Population: Results From the National Health and Nutrition Examination Survey (NHANES), 2005-2012	Nothing to Disclose
Ahmad	Faraz	FIT Clinical Decision Making Reviewers 2	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Ahmad	Hasan	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Change in Aortomitral Annular Angle and Anterior Mitral Valve Leaflet Length After Transcatheter Aortic Valve Replacement:	Nothing to Disclose
Ahmad	Hasan	Interventional Cardiology: TAVR 4	Implications for Transcatheter Mitral Valve Replacement? Predictors of New Persistent Left Bundle Branch Block After	Nothing to Disclose
Ahmad	Mirza Mujadil	Emerging Applications of Echocardiography	Edwards Sapien 3 Transcatheter Aortic Valve Replacement Dilated Mid-Ascending Aorta in Hypertrophic Cardiomyopathy Is Associated With Dynamic Left Ventricular Outflow Tract Obstruction	Nothing to Disclose
Ahmad	Mirza Mujadil	Vascular Medicine: Emerging Concepts in	and Not With Genetic Abnormalities Normal Diameter of the Ascending Aorta in Adults: The Impact of	Nothing to Disclose
Ahmad	Mirza Nubair	Clinical Vascular Diseases Emerging Applications of Echocardiography	Stricter Criteria on Selection of Subjects Free of Disease Dilated Mid-Ascending Aorta in Hypertrophic Cardiomyopathy Is	Nothing to Disclose
			Associated With Dynamic Left Ventricular Outflow Tract Obstruction and Not With Genetic Abnormalities	ŭ
Ahmad	Mirza Nubair	Nuclear Cardiology: Beyond Perfusion	The Increasing Burden of Amyloidosis From Apex to Base: New Insights From Technetium-99m Pyrophosphate Imaging	Nothing to Disclose
Ahmad	Mirza Nubair	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Normal Diameter of the Ascending Aorta in Adults: The Impact of Stricter Criteria on Selection of Subjects Free of Disease	Nothing to Disclose
Ahmad	Muhammad	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes		Nothing to Disclose
Ahmad	Tariq	Young Investigator Awards Competition: Clinical Investigations	Advanced Analytics Predicted Outcomes, Identified Clinically Distinct Subgroups, and Detected Heterogeneity in Response to	Nothing to Disclose
Ahmad	Tariq	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Therapy in a Cohort of More Than 40,000 Heart Failure Patients Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Associated Eosinophilic Myocarditis Treated With	Nothing to Disclose
Ahmad	Tariq Ali	FIT Clinical Decision Making: Non-Invasive	Tofacitinib an Oral Janus (JAK) Kinase Inhibitor Transcatheter Tricuspid Valve Replacement: "Forgotten	Nothing to Disclose
Ahmad	Zahid	Imaging and Valvular Heart Disease Current Issues in Cardiovascular	Valve", Challenging Management With Limited Treatment Options - Time to Gather Evidence Health Disparities Among Patients With Familial	CONSULTANT FEES/HONORARIA - Genzyme
		Epidemiology, Disparities, and Safety	Hypercholesterolemia in the CASCADE-FH Patient Registry	Corporation,Regeneron,SANOFI; SPEAKER'S BUREAU - Amgen Inc.,Genzyme Corporation
Ahmadi	Amir	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Fractional Flow Reserve Is a Sensitive but Not a Specific Detector of a High Risk Plaques	Nothing to Disclose
Ahmadi	Amir	Non Invasive Imaging: Prognostic Implications of CT Angiography	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	Nothing to Disclose
Ahmadi	Amir	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Atherosclerotic Plaque Morphology Is Associated With Impaired Myocardial Blood Flow and Fractional Flow Reserve, Independent of Lympol Destruction	Nothing to Disclose
Ahmadi	Amir	Noninvasive Assessment of Coronary Flow	of Luminal Obstruction Can Necrotic Core Volume Explain Ischemia Coronary Stenosis	Nothing to Disclose
Ahmed	Ali	Reserve: Clinical Implications Making Progress in Understanding Heart	Mismatch in Some Cases? Orthopnea or Paroxysmal Nocturnal Dyspnea in Older Adults	Nothing to Disclose
		Failure	Without Prevalent Heart Failure Is a Predictor, but Not an Independent Risk Factor for Incident Heart Failure: Insights From the Cardiovascular Health Study	
Ahmed	Ali	FIT Clinical Decision Making: Non-Invasive	Pneumopericardium: A Rare Presentation of Gastro-Pericardial Fistula	Nothing to Disclose
Ahmed	Ali	Imaging and Valvular Heart Disease Acute Heart Failure: Evaluating Strategies to	Among Older Heart Failure (HF) Patients With In-Hospital Acute	Nothing to Disclose
		Prevent Readmissions	Kidney Injury (AKI), an Improvement in Kidney Function Is Associated With a Higher Risk of Post-Discharge Mortality but Not Readmission	

and a					
Last Name Ahmed	First Name Ali	Session Title Advances in Lipid Management	Presentation Title Hydrophilic Versus Lipophilic Statins in Coronary Artery Disease	Disclosures Nothing to Disclose	
Fillined	-ui	Advances in Epid Management	Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of	Nothing to Disclose	
Ahmed	Ali	FIT Clinical Decision Making: Heart Failure and	Randomized Controlled Trials Combined Heart-Kidney Transplantation in a Patient With Human	Nothing to Disclose	
Allinea		Pulmonary Hypertension	Immunodeficiency Virus	,	
Ahmed	Ali	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Management of Takotsubo Cardiomyopathy Complicated by Left Ventricular Outflow Tract Obstruction	Nothing to Disclose	
Ahmed	Ali	Heart Failure and Cardiomyopathies: Heart	Clinical Effectiveness of Spironolactone in Hospitalized Older	Nothing to Disclose	
		Failure Is Just a Revolving Door	Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or Equal to 30 mL/min/1.73 m ²) Patients With Heart Failure		
Ahmed	Ali	Heart Failure and Cardiomyopathies: Heart	Chronic Alpha Blocker Use and Outcomes in Older Male Medicare	Nothing to Disclose	
Ahmed	Ali	Failure Is Just a Revolving Door The Evolving World of LVADs, Transplant and	Beneficiaries Hospitalized for Heart Failure Arrhythmias in Hospitalized Heart Transplanted Patients: A United	Nothing to Disclose	
		Other Novel Discoveries	States National Study		
Ahmed	Ali	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Chagas Heart Disease: A United States National Study	Nothing to Disclose	
Ahmed	Ali	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Spontaneous Coronary Artery Dissection in a Transplanted Heart	Nothing to Disclose	
Ahmed	Ali	Why Can't We Be Friends? Controversies in Heart Failure Management	Adverse Outcomes With Use of Hydralazine and Nitrate Combination Therapy in Hospitalized Older Non-Black Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)	Nothing to Disclose	
Ahmed	Aliy	Heart Failure and Cardiomyopathies: Heart	Heart Failure Hospitalization (HFH) Despite Digoxin Therapy Versus	Nothing to Disclose	
		Failure Is Just a Revolving Door	No HFH Despite Placebo in the Digitalis Investigation Group (DIG) Trial: Insights Into Risk Factors for HFH in HF and Reduced Ejection Fraction (HFrEF)		
Ahmed	Ameera	Angina in the Absence of Obstructive CAD.	Case Presentation: Coronary Vasospasm	Nothing to Disclose	
Ahmed	Amjad	What Do We Do With These Patients? Innovations in Advocacy and Patient Centered	Correlation Between Frailty and Non-Invasive Coronary Flow	Nothing to Disclose	
	•	Care	Reserve: A Cross Sectional Study	-	
Ahmed	Amjad	Non Invasive Imaging: Role of Exercise Testing	Using Machine Learning to Define the Association Between Cardiorespiratory Fitness and All-Cause Mortality: The FIT (Henry Ford Exercise Testing) Project	Nothing to Disclose	
Ahmed	Amjad	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Non-Invasive Coronary Flow Reserve Predicts Major Adverse Cardiac Events in Patients With Prior Coronary Artery Bypass Grafting	Nothing to Disclose	
Ahmed	Amjad	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Non-Invasive Coronary Flow Reserve Predicts Incident Atrial Fibrillation	Nothing to Disclose	
Ahmed	Amjad	Imaging With Cardiac CT: The Case for	Incremental Prognostic Value of Coronary Calcium Scoring in	Nothing to Disclose	
Ahmed	Amjad	Calcium Risky Business: Predicting Outcomes in Heart	Patients Undergoing 82-Rubidium Myocardial Perfusion Imaging Chronotropic Incompetence and Long-Term Risk of Heart Failure:	Nothing to Disclose	
		Failure	The Henry Ford Exercise Testing Project		
Ahmed	Haitham	Non Invasive Imaging: Role of Exercise Testing	Using Machine Learning to Define the Association Between Cardiorespiratory Fitness and All-Cause Mortality: The FIT (Henry Ford Exercise Testing) Project	Nothing to Disclose	
Ahmed	Haitham	Risky Business: Predicting Outcomes in Heart Failure	Chronotropic Incompetence and Long-Term Risk of Heart Failure: The Henry Ford Exercise Testing Project	Nothing to Disclose	
Ahmed	Mustafa	Innovations in Practice Management and Social Media	Unlocking the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for	Nothing to Disclose	
Ahmed	Nadeem	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Today's Complex Care Delivery Prognostic Significance of Co-Existing Persistent Edema and Hemorrhage at 6 Months in Survivors of ST-Elevation Myocardial Infarction	Nothing to Disclose	
Ahmed	Nadeem	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Current Smoking, Microvascular Pathology and Adverse Outcome After Acute ST-Segment Elevation Myocardial Infarction: New	Nothing to Disclose	
Ahmed	Nadeem	Syndrome Non Invasive Imaging: MR Structure and	Pathophysiological Insights Hypertension, Microvascular Pathology and Prognosis in Patients	Nothing to Disclose	
Ahn	Chul Min	Valuvular Heart Disease Considerations in Antiplatelet Therapy and in	With an Acute ST-Segment Elevation Myocardial Infarction Association Between Duration of Dual Antiplatelet Therapy and	Nothing to Disclose	
Ahn	Chul-Min	ACS Head to Toe: Outcomes of Endovascular	Angiographic Multi-Vessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents Comparison of Aortic Remodeling After Thoracic Endovascular	Nothing to Disclose	
		Interventions	Repair Between Acute/Subacute Versus Chronic Type B Aortic Dissection	-	
Ahn	Jung-Min	Late-Breaking Clinical Trials: Interventional	Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With Coronary Chronic Total Occlusion: DECISION CTO Randomized Trial	Nothing to Disclose	
Ahn	Jung-Min	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Anatomic Versus Ischemic Burden in Predicting Outcomes of Coronary Artery Disease: Data From IRIS-FFR Registry	Nothing to Disclose	
Ahn	Jung-Min	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	The Prognostic Implications of Current Periprocedural Myocardial Infarction Definitions in Patients Underwent Percutaneous Conronary Intervention With Unprotected Left Main Coronary Artery	Nothing to Disclose	
Ahn	Jung-Min	Advances in Lipid Management	Disease Lower Mortality in Patients With Vasospastic Angina Who Receive	Nothing to Disclose	
Ahn	Jung-Min	Refining PCI Technique and Outcomes	Statin Therapy: Data From the Asan Vasospastic Angina Registry External Validation of DAPT Score in Two Large Cohorts	Nothing to Disclose	
Ahn	Jung-Min	CAD in Unique Patient Populations	Mortality of Patients With Previous Stroke Undergoing Drug-Eluting	Nothing to Disclose	
Ahn	Taehoon	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Stent Implantation Prognostic Value of Soluble ST2 in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous	Nothing to Disclose	
Ahn	Taehoon	Interventional Cardiology: Structural Heart	Coronary Intervention Effect of PFO Closure for Prevention of Recurrent Stroke or TIA in	Nothing to Disclose	
Ahn	Taehoon	Disease Unusual Presentations of ACS	Highly Selected Patients With Cryptogenic Stroke The Role of Coronary Response to Nitrate in Patients With	Nothing to Disclose	
Ahsan	Irfan	FIT Clinical Decision Making: Non-Invasive	Suspected Vasospastic Angina A "Mind Blowing" Case of Left Atrial-Esophageal	Nothing to Disclose	
Aida	Hiroshi	Imaging and Valvular Heart Disease Imaging the Athlete's Heart	Fistula Leading to Tension Pneumocephalus and Sudden Death Differential American-Style Football Training Intensities and Cardiac	-	
Aida	Hiroshi	Imaging the Athlete's Heart	and Vascular Remodeling Patterns Sleep Disordered Breathing and Cardiovascular Correlates in	Nothing to Disclose	
Aida	Hiroshi	Traditional and Novel Factors Used to Assess	Collegiate American Style Football Participants Association Between Circulating Progenitor Cells and Outcomes in	Nothing to Disclose Nothing to Disclose	
		the Risk of, and Used for the Treatment of, Coronary Artery Disease	Patients With Coronary Artery Disease	-	
Aida	Hiroshi	Updates on Risk Factors for Cardiovascular Disease	Central Obesity Predicts Circulating Progenitor Cell Levels	Nothing to Disclose	
Aida	Hiroshi	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Progenitor Cells and Clinical Outcomes in Patients With Heart Failure	Nothing to Disclose	
Aida	Hiroshi	Unusual Presentations of ACS	Circulating Progenitor Cells Levels and Outcomes in Acute	Nothing to Disclose	
Aihara	Hideaki	Endovascular Therapy: Running From Risk	Myocardial Infarction Impact of Decrease in Blood Pressure After Endovascular Therapy	Nothing to Disclose	
		l	for Renal Artery Stenosis		



Ailawadi Gorav Featured Clinical Research II: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral CONSULTANT FEES/HONORARIA - Abbott, AtriCure, Edwards Valve Repair in the United States Usine State	Contract of the contract of th				l
Dispared power of Michael Last English	Last Name Ailawadi	Gorav	Session Title Featured Clinical Research II: Interventional		
Amada Oose	Ailawadi	Gorav	England Journal of Medicine Late-Breaking	Replacement: A Randomized Trial From the Cardiothoracic	Lifesciences,MEDTRONIC,Mitralign; SPEAKER'S BUREAU - St.
American Nation (Carboting Concessations of Clarect Ann Accessed VIII) American (Carboting Concessations of Clarect Ann Accessed VIII) American (Carboting Concessations Concessations Concessations Concessations) American (Carboting Concessations Concessations) American (Carboting Concessations) American (Carboti	Ailawadi	Gorav			CONSULTANT FEES/HONORARIA - Abbott, AtriCure, Edwards Lifesciences, MEDTRONIC, Mitralign; SPEAKER'S BUREAU - St.
Allesters Series	Aimo	Alberto		Ventricular Reverse Remodeling and Clinical Outcomes Following	
Assertion	Aintablian	Tamar		Angiographic Dye Prior to Combined Heart-Kidney Donation Does	Nothing to Disclose
Albert Spring Anderson in Christian Coloration (Coloration Coloration Colorat	Airaksinen	Juhani		Three-Year Results From the EVOLVE II Randomized Trial: Late Clinical Outcomes With Bioresorbable Compared to Permanent	Nothing to Disclose
Agen Security Agent Security Securit	Airhart	Sophia		Health Status Benefits of Successful Chronic Total Occlusion PCI in Patients With Depressed Left Ventricular Systolic Function: Insights	Nothing to Disclose
Agen Service Confidence of the	Aiyer	Aryan		Ideal Cardiovascular Health Metrics in Couples: A Community-	Nothing to Disclose
Ayen Samer with Continue (Personal Continue) (Ajala	Oluremi	Innovations in Cardiovascular Risk Assessment	Ideal Cardiovascular Health Metrics in Couples: A Community-	Nothing to Disclose
Agein Taskel Angular Company of Research I have five and process of the process o	Ajam	Samer	Highlighted Original Research: Heart Failure	Higher Beta-Blocker Dose Versus Lower Heart Rate in Patients With	Nothing to Disclose
April Teres in capacity (organization) and process processors (see a processor) and processors (organization) and processors (Ajam	Samer			Nothing to Disclose
Any promise foreign in the event of the control of	Ajam	Tarek	Highlighted Original Research: Heart Failure	Higher Beta-Blocker Dose Versus Lower Heart Rate in Patients With	Nothing to Disclose
Agroupe Marson Note Introductional Cardiology TAVR 1 Song Afric Valve Annuals for Transactivities Active Valve Cardiology Professional Cardiology Prof	Ajam	Tarek			Nothing to Disclose
Agrono Marsan Ag	Ajmone Marsan	Nina		Sizing Aortic Valve Annulus for Transcatheter Aortic Valve Prosthesis Selection: Impact of Aortic Valve Calcification Burden on the Agreement Between Automated 3-Dimensional Transesophageal Echocardiography and Multid	Nothing to Disclose
Aleaska Takashi Takash	Ajmone Marsan	Nina	Innovative Use of Echocardiography		Nothing to Disclose
Alara Fadd OH. Arrhymniae and Clinical EP-Basic Team 11 Fadd OH. Arrhymniae and Clinical EP-Basic Team 12 Fadd OH. Arrhymniae and Clinical EP-Basic Team 11 Fadd OH. Arrhymniae and Clinical EP-Basic Team 12 Fadd OH. Arrhymniae Arrhymniae Team 12 Fadd OH. Arrhymniae	-			Myocardial Infarction: Effect of Guideline-Based Therapy	
Assaka Joseph Arhythmise and Clinical EP- Basic 4 Joseph Assaka I fakashi Interventional Cardiology Intravascular Physiology and Endothelial Function Companion of Very Late Vascular Response Beyond 2 Years After Joseph Assaka Physiology and Endothelial Function Companion of Very Late Vascular Response Beyond 2 Years After Joseph Assaka Assaka I fakashi	7 ymone marean		To the state of th	Infarction: Characterization of Myocardial Scar Extent With Late Gadolinium Contrast Enhanced Cardiac Magnetic Resonance and Impact on Multilayer Global Longitudinal Strain on Speckle Tracking	
Assaka Takashi Interventional Cardiology, Intravascular Physology and Endothelial Function Syndrome Syndrome Consultation Services and Eds. An OCT Sub Study of Physology and Endothelial Function See Highest Industrial Services and Eds. An OCT Sub Study of Physology and Endothelial Function Be HEXT See Highest Industrial Services and Eds. An OCT Sub Study of Physology and Endothelial Function In the HEXT Assaka Takashi Novel Mechanisms Underlying Isolamis- Reperfusion Injury in AMI Novel Mechanisms Underlying Isolamis- Reperfusion In	Akar	Fadi	04. Arrhythmias and Clinical EP: Basic Team 1		Nothing to Disclose
Akasaka Taksahi Interventional Cardiology, intervascular Physiology and Endohelial Function Semitimplication Between EES and BES: An OCT Sub-Study of John Manual Physiology and Endohelial Function Semitimplication Between EES and BES: An OCT Sub-Study of John Manual Physiology and Endohelial Function Semitimplication Semitimplication Semit	Akar	Joseph	Arrhythmias and Clinical EP: Basic 4		CONSULTANT FEES/HONORARIA - Biosense Webster
Reperfusion Injury in AMI Supparable Aman Am	Akasaka	Takastii		Stent Implantation Between EES and BES: An OCT Sub-Study of	Japan, Abbot Vascular Japan, Abbot Vascular Japan, Boehringer- Ingelheim, Japan, Inc., Daiichi Sankyo Phamaceutical Company, Goodman Inc.; Sent Jude Medical Japan, Terumo Inc.; RESEARCH/IRESEARCH GRANTS - Abbot Vascular Japan, Astellas Pharma Inc, Bayer Yakulini, Ltd, Boston Scientific Japan, Daiichi-Sankyo Phamaceutical Company, Foundation for Biomedical Research and Innovation, Goodman Inc, Otsuka Pharmaceutical, Pfizer Japan Inc, Sent Jude Medical
FFR.ssub-CTr/slub-: Learnings From the International ADVANCE Registry FFR.ssub-CTr/slub-: Learnings From the International ADVANCE Registry FFR.ssub-CTr/slub-: Learnings From the International ADVANCE Registry From Bench to Bedside FFR.ssub-CTr/slub-: Learnings From the International ADVANCE Registry FFR.ssub-CTr/slub-: Learnings From the International Registry Abbot Vascular Japan Abend Vascular Japa			Reperfusion Injury in AMI		CONSULTANT FEES/HONORARIA Abbot Vascular Japan, Abbot Vascular Japan, Abbot Vascular Japan, Boehringer- Ingelheim, Japan, Inc., Dainchi Sankyo Pharmaceutical Company, Goodman Inc., Sent Jude Medical Japan, Terumo Inc.; RESEARCH/FRESEARCH GRANTS - Abbot Vascular Japan, Astellas Pharma Inc, Bayer Yakuhin, Ltd, Boston Scientific Japan, Daichi-Sankyo Phamaceutical Company, Foundation for Biomedical Research and Innovation, Goodman Inc, Otsuka Pharmaceutical, Pfizer Japan Inc, Sent Jude Medical Japan, Terumo Inc.
Interventional CT/MR Team 1 Interventional LT/MAT FEES/HONGARIA - Actelion Interventional LT/MAT FEES/HONGARIA - Actelion Interventional CT/MR Team 1 Interventional LT/MAT FEES/HONGARIA - Actelion Interventional CT/MAT FEES/HONGARIA - Actelion Interventional LT/MAT FEES/HONGARIA - Actelion Interventional CT/MAT Feed CT/MAT FEES/HONGARIA - Actelion Interventional CT/MAT Feed CT/MAT FEES/HONGARIA - Actelion Interv				FFR _{CT} : Learnings From the International ADVANCE Registry	Japan, Abbot Vascular Japan, Abbot Vascular Japan, Boehringer- Ingelheim, Japan, Inc., Daiichi Sankyo Phamaceutical Company, Goodman Inc., Sent Jude Medical Japan, Terumo Inc.; RESEARCH/IRESEARCH GRANTS - Abbot Vascular Japan, Astellas Pharma Inc, Bayer Yakuhin, Ltd, Boston Scientific Japan, Daiichi-Sankyo Phamaceutical Company, Foundation for Biomedical Research and Innovation, Goodman Inc, Otsuka Pharmaceutical, Pfizer Japan Inc, Sent Jude Medical Japan, Terumo Inc.
Akbal Ozgur Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease Hemodynamic Characteristics in Relation to Survival in Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: Insights From Euphrates Study Akbal Ozgur Understanding Pulmonary Vascular Disease: From Bench to Bedside Precapillary Pulmonary Hypertension Regardless of the Background Treatment Improves Clinical Status and Neurohumoral Measures in Clinical Worsening Episodes of Precapillary Pulmonary Hypertension Regardless of the Background Treatments: Insights From Euphrates Study Akbal Ozgur Understanding Pulmonary Vascular Disease: From Bench to Bedside The Impaired Endothelium—Dependent and Endothelium—Independent Systemic Arterial Vasodilatory Reserve in Pulmonary Hypertension Regardless of the Clinical Group Akbal Ozgur Predicting the Future: Observations and Discoveries From Registries and Databases Ozgur Predicting the Future: Observations and Discoveries From Registries and Databases			Interventional CT/MR Team 1		Japan,Abbot Vascular Japan,Abbot Vascular Japan,Boehringer- Ingelheim, Japan, Inc,Dalichi Sankyo Phamaceutical Company,Goodman Inc,Sent Jude Medical Japan, Terumo Inc.; RESEARCH/IRESEARCH GRANTS - Abbot Vascular Japan,Astellas Pharma Inc,Bayer Yakuhin, Ltd,Boston Scientific Japan,Dalichi-Sankyo Phamaceutical Company,Foundation for Biomedical Research and Innovation,Goodman Inc,Otsuka Pharmaceutical,Pfizer Japan Inc,Sent Jude Medical Japan,Terumo Inc.
Impact of Congenital Heart Disease					
Akbal Ozgur Understanding Pulmonary Vascular Disease: From Bench to Bedside Akbal Ozgur Understanding Pulmonary Vascular Disease: From Bench to Bedside Akbal Ozgur Understanding Pulmonary Vascular Disease: From Bench to Bedside Akbal Ozgur Understanding Pulmonary Vascular Disease: From Bench to Bedside Akbal Ozgur Understanding Pulmonary Vascular Disease: From Bench to Bedside Akbal Ozgur Predicting the Future: Observations and Discoveries From Registries and Databases Ozgur Predicting the Future: Observations and Discoveries From Registries and Databases				Hemodynamic Characteristics in Relation to Survival in Pulmonary Arterial Hypertension Associated With Congenital Heart Disease:	2
Akbal Ozgur Understanding Pulmonary Vascular Disease: From Bench to Bedside Home Independent and Endothelium-Dependent and Endothelium-Dependent and Endothelium-Dependent and Endothelium-Dependent Systemic Arterial Vasodilatory Reserve in Pulmonary Hypertension Regardless of the Clinical Group Akbal Ozgur Predicting the Future: Observations and Discoveries From Registries and Databases Occupant Pulmonary Hypertension: Insights OSSULTANT FEES/HONORARIA - Actelion CONSULTANT FEES/HONORARIA - Actelion OSSULTANT FEES/HONORARIA - ACTELION FEES/HONORARIA - ACTELION FE	Akbal	Ozgur		Short-Term Intravenous Iloprost Treatment Improves Clinical Status and Neurohumoral Measures in Clinical Worsening Episodes of Precapillary Pulmonary Hypertension Regardless of the	CONSULTANT FEES/HONORARIA - Actelion
Akbal Ozgur Predicting the Future: Observations and Discoveries From Registries and Databases Oradient, May Predict Survival in Pulmonary Hypertension: Insights CONSULTANT FEES/HONORARIA - Actelion CONSULTANT FEES/HONORARIA - Actelion	Akbal	Ozgur	From Bench to Bedside	The Impaired Endothelium-Dependent and Endothelium- Independent Systemic Arterial Vasodilatory Reserve in Pulmonary Hypertension Regardless of the Clinical Group	CONSULTANT FEES/HONORARIA - Actelion
	Akbal	Ozgur		Pulmonary Vascular Resistance, but Not Diastolic Pulmonary Gradient, May Predict Survival in Pulmonary Hypertension: Insights	CONSULTANT FEES/HONORARIA - Actelion

September 1				l l
Akbal	Ozgur	Session Title Predicting the Future: Observations and Discoveries From Registries and Databases	Presentation Title The Correlates and Prognostic Impact of Pulmonary Arterial Pulse Pressures, Diastolic and Transpulmonary Pressure Gradients in	Disclosures CONSULTANT FEES/HONORARIA - Actelion
Akbal	Ozgur	Predicting the Future: Observations and Discoveries From Registries and Databases	Pulmonary Hypertension: Insights From Euphrates Study An Ignored but Not Unusual Complication of Severe Pulmonary Hypertension - Ostial Compression of Left Main Coronary Artery by	CONSULTANT FEES/HONORARIA - Actelion
Akcevin	Atif	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Aneurysmal Pulmonary Artery: Insights From Euphrates Study Survival Analysis From THALES Study, A Large Nation-Wide Registry on Pulmonary Arterial Hypertension Associated With	Nothing to Disclose
Akdemir	Ramazan	Venous Investigation: The Dark Side	Congenital Heart Disease Ipsilateral Resting Venous Lactate Levels Decreased After Successful Percutaneous Revascularization of the Limb in Patients	Nothing to Disclose
Akers	Scott	Emerging Developments in HFpEF and	Suffering Intermittent Claudication Effect of Diabetes Mellitus on Pulsatile Arterial Load and	Nothing to Disclose
Akhter	Mohammed	Arryhthmias Highlighted Original Research: Interventional	Hemodynamics in HFpEF Safety of Same Day Discharge Following PCI for Non-ST Elevation	Nothing to Disclose
Akhter	Mohammed	Cardiology and the Year in Review FIT Clinical Decision Making: Prevention, Adult	Acute Coronary Syndromes Coronary Cameral Fistulas and Coronary Artery Aneurysms in a	Nothing to Disclose
		Congenital and Congenital Heart Disease	Contemporary Patterns of GP IIIb/IIIa Inhibitor Use in Patients With	-
Akhter	Mohammed	Optimizing the Care of ACS Patients	Acute Myocardial Infarction Undergoing PCI: Insights From the TRANSLATE ACS Study	Nothing to Disclose
Akhter	Mohammed	Anti-Platelet Therapies: Always a Sticky Topic	Antiplatelet Therapy Changes for MI Patients With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS Study	Nothing to Disclose
Akhter	Nausheen	Advances in Imaging to Assess Cardiotoxicity	Speckle-Tracking Strain Imaging in Breast Cancer Patients Treated With Newer Non-Anthracycline, Trastuzumab-Based Regimens	SPEAKER'S BUREAU - Epsilon
Akiba	Yohei	Unusual Presentations of ACS	Trend of Use in Transradial Intervention Among Elderly Patients in Japan According to Their Pre-Procedural Bleeding Risk	Nothing to Disclose
Akin	Sakir	Heart Failure and Cardiomyopathies: What	A Weaning Marker From Veno-Arterial Extra Corporeal Membrane	Nothing to Disclose
Akin	Sakir	Next When All Else Is Failing? FIT Clinical Decision Making: Heart Failure and		Nothing to Disclose
		Pulmonary Hypertension	Patients With Left Ventricular Assist Devices by Use of Sublingual Microcirculatory Imaging	
Akin	Sakir	Why Can't We Be Friends? Controversies in	A Novel Score to Predict Outcome in Patients Supported by Veno-	Nothing to Disclose
Akinapelli	Abhilash	Heart Failure Management FIT Clinical Decision Making: Non-Invasive	Arterial Extracorporeal Membrane Oxygenation In the Forest of Comorbidities, Always Look for the Wild Type	Nothing to Disclose
Akinapelli	Abhilash	Imaging and Valvular Heart Disease Arrhythmias and Clinical EP: Devices 2	Role of Implantable Defibrillators in Primary Prevention of Mortality	Nothing to Disclose
·		-	in Non-Ischemic Cardiomyopathy Patients	
Akinboro	Oladimeji	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Coronary Artery Bypass Graft Surgery With or Without Left Atrial Appendage (LAA) Excision for Atrial Fibrillation: A CHA2DS2VASc Matched Analysis of Thromboembolic Outcomes in a National Database	Nothing to Disclose
Akinjero	Akintunde	Advances in HCM, PPCM and Other Cardiomyopathies	Hyperthyroidism Increases the Risk of Takotsubo Cardiomyopathy Among Hospitalized U.S. Patients	Nothing to Disclose
Akintoye	Emmanuel	Making Progress in Understanding Heart	Left Ventricular Mass Index and Other Independent Predictors of	Nothing to Disclose
Akintoye	Emmanuel	Failure Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Incident Heart Failure National Trends in Admissions and In-Hospital Mortality in Heart Failure Patients and Impact of the ACC/AHA Management	Nothing to Disclose
Akintoye	Emmanuel	Acute Heart Failure: Evaluating Strategies to	Guidelines: Insight From the National Inpatient Sample (NIS) Seasonal Variation in In-Patient Mortality, Cost of Hospitalization and	Nothing to Disclose
Akintoye	Emmanuel	Prevent Readmissions Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Length of Stay in Heart Failure Patients in the United States Impact of Hospital Ownership on In-Patient Mortality and Cost of Hospitalization in Patients Admitted for Heart Failure: Insight From	Nothing to Disclose
Akintoye	Emmanuel	Acute Heart Failure: Evaluating Strategies to	the National Inpatient Sample (NIS) Regional Variation in Hospitalization Outcomes Among Patients	Nothing to Disclose
Akintoye	Emmanuel	Prevent Readmissions Innovations in Cardiovascular Risk Assessment	Admitted for Heart Failure in the United States Hemodynamic Predictors of Left Ventricular Mass Index in the	Nothing to Disclose
		and Reduction	General Population	
Akintoye	Emmanuel	Interventional Cardiology: PCI and TAVR in Complex Patients	Economic Implications of Late Discharge After Transcatheter Aortic Catheter Implantation	Nothing to Disclose
Akintoye	Emmanuel	Interventional Cardiology: TAVR 3	Transcatheter Versus Surgical Aortic Valve Replacement in Diabetes Mellitus: From the Nationwide Inpatient Sample	Nothing to Disclose
Akintoye	Emmanuel	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		Nothing to Disclose
Akintoye	Emmanuel	Insights From Echocardiography Use	Novel Echocardiographic Variables in the Diagnosis of Acute	Nothing to Disclose
Akintoye	Emmanuel	Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools	Pulmonary Embolism A Novel Biomarker Score for Cardiovascular Risk-Reclassification: Primary ASCVD Prevention in the Intermediate-Risk Population	Nothing to Disclose
Akintoye	Ololade	Coarctation of the Aorta, from Repair to	Case Presentation: Neonatal Coarctation	Nothing to Disclose
Akintoye	Ololade	Lifelong Care Congenital Heart Disease: Innovations in	Does Tricuspid Annular Plane Systolic Excursion (TAPSE)	Nothing to Disclose
Ako		Single Ventricle Heart Disease Antiplatelet and Antithrombotic Agents in	Adequately Describe Right Ventricular Function in Hypoplastic Left Heart Syndrome? Stent Edge Strut on Normal Segment Is Less Covered in Early	CONSULTANT FEES/HONORARIA - Abbott Vascular, Astra
AKO	Junya	Ischemic Heart Disease	Phase After Drug Eluting Stent Implantation	Zeneca, Boeringer Ingelheim, Terumor, RESEARCH/HRESEARCH GRANTS - Dainippon-Sumitomo, MEDTRONIC, Pfizer; SPEAKER'S BUREAU - Bristol Meyers Squib, Daiichi- Sankyo, Kowa Pharmaceutical, MSD, SANOFI
Ako	Junya	Unusual Presentations of ACS	Lower Eicosapentaenoic Acid to Arachidonic Acid Ratio Is Associated With Intraplaque Cholesterol Crystals: An Optical Coherence Tomography Study	CONSULTANT FEES/HONORARIA - Abbott Vascular, Astra Zeneca, Boeringer Ingelheim, Terumo; RESEARCH/RESEARCH GRANTS - Dainippon-Sumitiomo, MEDTRONIC, Prizer; SPEAKER'S BUREAU - Bristol Meyers Squib, Daiichi-Sankvo Kowa Pharmaceutical MSD SANOT
Akoum	Nazem	Stoke and Atrial Fibrillation: Innocent Bystander or Essential Ingredient	Debate Con: Atrial Fibrillation Is Simply a Marker of Risk	Nothing to Disclose
Akoum	Nazem	Novel Arrhythmia Diagnostics, Therapeutics,	ACC Poster Moderator	Nothing to Disclose
Akrawinthawong	Krittapoom	and "Wearables FIT Clinical Decision Making: Arrhythmias and	Neurogenic Orthostatic Hypotension as an Unexpected Etiology of	Nothing to Disclose
_		Electrophysiology	Recurrent Syncope Obscured by Atrial Flutter	
Akrawinthawong	Krittapoom	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Unexpected Atrial Thrombus Discovered Post Intraoperative Maze Procedure: The Dilemma of Thrombus Screening Before	Nothing to Disclose
Akrawinthawong	Krittapoom	FIT Clinical Decision Making: Arrhythmias and Clinical Electrophysiology	Percutaneous Pulmonary Vein Isolation Voltage-Dependent Inappropriate Right Ventricular Capture by Right Atrial Lead Pacing as a Cause of Cardiac Resynchronization	Nothing to Disclose
Aksoy	Olcay	Interventional Cardiology: TAVR 1	Therapy Non-Responder The Use of Magnetic Resonance Imaging With Ferumoxytol for	CONSULTANT FEES/HONORARIA - Actelion
,oy	Jiody	and ventional cardiology. LAVIC I	Annulus Sizing in Patients With Chronic Kidney Disease Undergoing Transcatheter Aortic Valve Replacement	SS. SSETMENT LEEDS TO NOTATION - ACCESSOR

		la i au		
Last Name Aksoy	Olcay	Session Title The Evolving World of LVADs, Transplant and	Presentation Title Incidence and Factors Associated With New-Onset	Disclosures CONSULTANT FEES/HONORARIA - Actelion
Aksoy	Olcay	Other Novel Discoveries 02. Acute and Stable Ischemic Heart Disease:	Cardiomyopathies Following Liver Transplantation Suggested Reviewer	CONSULTANT FEES/HONORARIA - Actelion
Aktemur	Tugba	Clinical Team 1 Imaging Pulmonary Vascular Disease Plus the	Clinical, Biochemical, Neurohumoral, Echocardiographic and	Nothing to Disclose
		Impact of Congenital Heart Disease	Hemodynamic Characteristics in Relation to Survival in Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: Insights From Euphrates Study	
Aktemur	Tugba	Understanding Pulmonary Vascular Disease: From Bench to Bedside	Short-Term Intravenous lioprost Treatment Improves Clinical Status and Neurohumoral Measures in Clinical Worsening Episodes of Precapillary Pulmonary Hypertension Regardless of the Background Treatments: Insights From Euphrates Study	Nothing to Disclose
Aktemur	Tugba	Predicting the Future: Observations and Discoveries From Registries and Databases	Pulmonary Vascular Resistance, but Not Diastolic Pulmonary Gradient, May Predict Survival in Pulmonary Hypertension: Insights From Euphrates Study	Nothing to Disclose
Aktemur	Tugba	Predicting the Future: Observations and Discoveries From Registries and Databases	The Correlates and Prognostic Impact of Pulmonary Arterial Pulse Pressures, Diastolic and Transpulmonary Pressure Gradients in Pulmonary Hypertension: Insights From Euphrates Study	Nothing to Disclose
Al Azzoni	Ashraf	Vascular Access and Hemostasis Issues	Assessment of the Safety of Performing Coronary Angioplasty Without Interrupting Oral Anticoagulants	Nothing to Disclose
Al Azzoni	Ashraf	Novel Developments in Acute Coronary Syndromes	Incidence and Predictors of No Reflow Phenomenon: Insights From the TOTAL Trial	Nothing to Disclose
Al Badarin	Firas	Engage @ ACC.17 Studio: FIT Jeopardy Battle		SPEAKER'S BUREAU - Lantheus Medical Imaging
Al Badri	Ahmed	of the State Chapters III Non Invasive Imaging: MR Scar and Perfusion	Hyperemic Subendocardial-to-Subepicardial Perfusion Ratio as a Surrogate Marker for Coronary Endothelial Dysfunction: Initial	Nothing to Disclose
Al Badri	Ahmed	Non Invasive Imaging: MR Scar and Perfusion	Results in Women With Microvascular Dysfunction Assessment of Myocardial Perfusion Reserve Index Using	Nothing to Disclose
Al Badri	Ahmed	The Evolving World of LVADs, Transplant and	Adenosine Versus Regadenoson Among Healthy Female Subjects Prognostic Risk Factors for Heart Failure Hospitalization in Women	Nothing to Disclose
		Other Novel Discoveries	Without Obstructive Coronary Disease: An Ancillary Study From the Women's Ischemia Syndrome Evaluation (WISE)	
Al Habib	Khalid	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	High Blood Pressure on Discharge From Acute Decompensated Heart Failure in Patients With Type 2 Diabetes Is Associated With Decreased 12-Month Mortality: Findings From the Gulf-Care	CONSULTANT FEES/HONORARIA - Novartis Corporation
Al Habib	Khalid	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Do Women Benefit From Early Coronary Artery Bypass Graft and Percutaneous Coronary Interventions in Acute Coronary Syndromes: Answers From the Second Gulf Registry of Acute Coronary Events	CONSULTANT FEES/HONORARIA - Novartis Corporation
Al Mheid	Ibhar	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Inflammatory Response to Mental Stress and Mental Stress Induced Myocardial Ischemia	Nothing to Disclose
Al Mheid	lbhar	Updates on Risk Factors for Cardiovascular Disease	Changes in Body Fat Distribution Is Associated With Oxidative Stress	Nothing to Disclose
Al Rifai	Mahmoud	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Coronary Artery Calcium and Incident Hypertension in a Population- Based Cohort: The Multi-Ethnic Study of Atherosclerosis	Nothing to Disclose
Al Shamiri	Mostafa	Diabetes, Hyperlipidemia, and Coronary Artery Disease, Prevention and Treatment: International Perspectives From the Japanese College of Cardiology, Saudi Heart Association, and American College of	Standard Anti-platelet Dosing is Not Effective in CAD Patients	Nothing to Disclose
Al Solaiman	Firas	Cardiology FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Anomalous Presentation of Acute Coronary Syndrome: Successful Thrombolysis in a Patient Presenting With Inferior STEMI and	Nothing to Disclose
		Disease, and Vascular Medicine	Anomalous Right Coronary Artery	
Al Suwaidi	Jassim	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	High Blood Pressure on Discharge From Acute Decompensated Heart Failure in Patients With Type 2 Diabetes Is Associated With Decreased 12-Month Mortality: Findings From the Gulf-Care	Nothing to Disclose
Al Suwaidi	Jassim	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Influence of Beta-Blockers on Mortality in Chronic Heart Failure Patients With Atrial Fibrillation: Findings From the Gulf-Safe	Nothing to Disclose
Al'Aref	Subhi	Innovations in Cardiovascular Risk Assessment and Reduction	Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	Nothing to Disclose
Al'Aref	Subhi	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography: The CONFIRM Registry	Nothing to Disclose
Al'Aref	Subhi	Non Invasive Imaging: New Technologies	Optimal Method for Necrotic Core Identification in Coronary Plaque With Dual-Energy Computed Tomography. Material Decomposition and Atomic Number	Nothing to Disclose
Aladin	Amer	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Coronary Artery Calcium and Incident Hypertension in a Population- Based Cohort: The Multi-Ethnic Study of Atherosclerosis	Nothing to Disclose
Al-Ahmad	Amin	Arrhythmias and Clinical EP: AF Ablation	Long-Term Risk of Recurrent Arrhythmia in Patients With Typical Atrial Flutter Undergoing Pulmonary Vein Antrum Isolation or Cavo- Tricuspid Isthmus Ablation With Permanent Isolation	CONSULTANT FEES/HONORARIA - Medtronic, Inc
Al-Ahmad	Amin	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Left Atrial Appendage Flow Velocity to Predict Persistent Left Atrial Appendage Isolation	CONSULTANT FEES/HONORARIA - Medtronic, Inc
Alam	Mahboob	Interventional Cardiology: PCI in Complex Patients	Clinical Outcomes of Patients With Human Immune Deficiency Virus After Coronary Revascularization: A Systematic Review and Meta-Analysis	SPEAKER'S BUREAU - Jannssen
Alam	Samir	Arrhythmias and Clinical EP: Basic 3	Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome	Nothing to Disclose
Alam	Samir	01. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Al'Aref	Subhi	Basic Team 1 Non Invasive Imaging: Coronary Calcium	Incremental Utility of Coronary Computed Tomographic	Nothing to Disclose
		Scoring and CV Risk Assessment	Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry	
Al'Aref	Subhi	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography: The CONFIRM (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	Nothing to Disclose
Al'Aref	Subhi	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prognostic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry	Nothing to Disclose
Al'Aref	Subhi	Non Invasive Imaging: Prognostic Implications of CT Angiography	Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Death: A Comparison to a Histologic Reference Standard	Nothing to Disclose

and the same of th				
Al'Aref	First Name Subhi	Session Title Diabetes and Other Issues in Cardiovascular Prevention	Presentation Title Implications of Statin Therapy Among Smokers With Severe Coronary Artery Calcification: An Analysis of the CONFIRM Registry	Disclosures Nothing to Disclose
Alashry	Mahmoud	New Technologies in Echocardiography	Novel Echocardiographic Measurements Detect Increased Myocardial Stiffness in Patients With Severe Organic Mitral Regurgitation	Nothing to Disclose
Alasnag	Mirvat Khaldoon	FIT Clinical Decision Making Reviewers 4 Radial Access Mini-Symposium II	ACC FIT Clinical Decision Making Reviewer Case Presentation: Radial CHIP, Retrograde CTO	Nothing to Disclose CONSULTANT FEES/HONORARIA - Abbott
Alaswad		Contemporary Role of Intracoronary Imaging:		Cardiovascular, Boston Scientific, Terumo
Alaswad	Khaldoon	Candid Conversation with Peers	Panelist	CONSULTANT FEES/HONORARIA - Abbott Cardiovascular,Boston Scientific,Terumo
Alaswad	Khaldoon	Contemporary Role of Intracoronary Imaging: Candid Conversation with Peers	OCT Guided PCI - Precision Stenting	CONSULTANT FEES/HONORARIA - Abbott Cardiovascular,Boston Scientific,Terumo
Alaswad	Khaldoon	Great Debates in Ischemia 2017	Revascularization is Appropriate for Chronic Total Occlusion with Ischemia: PRO	CONSULTANT FEES/HONORARIA - Abbott Cardiovascular,Boston Scientific,Terumo
Alaswad	Khaldoon	The Best Coronary and Peripheral Interventional Challenging Cases	ACC Panelist	CONSULTANT FEES/HONORARIA - Abbott Cardiovascular,Boston Scientific,Terumo
Alaswad	Khaldoon	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Innovative Technique to Achieve Hemostasis With Large Bore Access for Percutaneous Hemodynamic Support Devices	CONSULTANT FEES/HONORARIA - Abbott Cardiovascular,Boston Scientific,Terumo
Alaswad	Khaldoon	Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	CONSULTANT FEES/HONORARIA - Abbott Cardiovascular,Boston Scientific,Terumo
Alaswad	Khaldoon	Advances in Chronic Total Occlusion Intervention	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	CONSULTANT FEES/HONORARIA - Abbott Cardiovascular,Boston Scientific,Terumo
Al-Badri	Ahmed	Angina in the Absence of Obstructive CAD. What Do We Do With These Patients?	Case Presentation: Endothelial Dysfunction	Nothing to Disclose
Albaghdadi	Aymen	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Combined Migraine and Platypnea-Orthodeoxia Syndrome Due to Combined Atrial Septal Defect and Patent Foramen Ovale	Nothing to Disclose
Albaghdadi	Aymen	Hormones and Heart Failure	Long-Term Exogenous Brain Natriuretic Peptide After Myocardial Infarction Interferes With Restorative Cardiac Remodeling	Nothing to Disclose
Albaghdadi	Mazen	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Digit Ischemia Work-Up and an Uncommon Diagnosis: Hypothenar Hammer Syndrome	Nothing to Disclose
Albaghdadi	Mazen	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Successful Intra-Aortic Balloon Pump-Supported Percutaneous Coronary Intervention in a Patient With a Late Presenting Myocardial Infarction, Multivessel Coronary Artery Disease Complicated by Heparin-Induced Thrombocytopenia, Biventricular Thrombus, and Refractory Ventricular Arrhythmia	Nothing to Disclose
Al-Bawardy	Rasha	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Digit Ischemia Work-Up and an Uncommon Diagnosis: Hypothenar Hammer Syndrome	Nothing to Disclose
Albert	Chonyang	Making Progress in Understanding Heart Failure	Exercise Intolerance and Proportional Pulse Pressure Response in Patients With Chronic Heart Failure	Nothing to Disclose
Albert	Christine	Nuclear Cardiology: Prognosis	Myocardial Scar but Not Ischemia Predicts Defibrillator Shocks and Sudden Cardiac Death in Patients With Reduced Left Ventricular Ejection Fraction	RESEARCH/RESEARCH GRANTS - American Heart Association,NIH,St. Jude Medical
Albert	David	FIT Forum: Mix and Mingle	 	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AliveCor
Albert	Nancy	Readmission in Heart Failure: Questions Unanswered	Human Connection to Prevent Readmissions - Navigators and Nurses	RESEARCH/RESEARCH GRANTS - Novartis; SPEAKER'S
Albert	Nancy	Heart Failure and Cardiomyopathies: Is Heart	Heart Failure With Reduced Ejection Fraction Care Patterns in the	BUREAU - Novartis Corporation RESEARCH/RESEARCH GRANTS - Novartis; SPEAKER'S
Albert	Nancy	Failure With a Normal EF for Real? Cardiovascular Team Cases: Team 2	Outpatient Practice Setting: Initial Findings From CHAMP-HF Suggested Reviewer	BUREAU - Novartis Corporation RESEARCH/RESEARCH GRANTS - Novartis; SPEAKER'S
Alberts	Mark	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Rates of Oral Anticoagulant Use, While Improving Over Time, Remain Low Among Hospitalized Patients With Atrial Fibrillation	BUREAU - Novartis Corporation CONSULTANT FEES/HONDRARIA - Boerhinger Ingelheim Bristol Myers Squibb Daiichi Sankyo, Genentech, Jansseen, Medscape, MEDTRONIC, Merck, Por tola; SPEAKER'S BUREAU - Boerhinger Ingelheim, Bristol Myers Squibb, Chiesi, Genentech, Janssen Pharmaceuticals, Inc, Pfizer
Albertucci	Mario	26. Interventional Cardiology: Vascular Access and Complications Team 2	Suggested Reviewer	Nothing to Disclose
Alcocer Gamba	Marco	Updates on Risk Factors for Cardiovascular Disease	Association of Anxious and Depressive Symptomatology With Cardiovascular Disease Among Patients From Different States in Mexico: REDECAR Study	Nothing to Disclose
Alcocer Gamba	Marco Antonio	STEMI in the Emerging World: International Perspectives From the Cardiological Society of India, Mexican Society of Cardiology, and American College of Cardiology	The Usefulness of DAPT Score in Antiplatelet Therapy After ACS	Nothing to Disclose
Al-Damluji	Mohammed		Percutaneous Coronary Intervention in Adults Age 75 Years or Older With ST Elevation Myocardial Infarction and Cardiogenic Shock	Nothing to Disclose
Al-Damluji	Mohammed	Interventional Cardiology: PCI and TAVR in Complex Patients	Utilization of Heart Teams in the United States: Results From the Translating Outstanding Performance in Percutaneous Coronary Intervention (TOP PCI) Study	Nothing to Disclose
Aldea-Perona	Ana	Timely Topics in Acute Coronary Syndromes	Time to Treatment With Melatonin and Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction: Insights From the MARIA (Melatonin Adjunct in the acute myocaRdial Infarction	Nothing to Disclose
Alderman	Michael	Controversies in Hypertension	treated with Angioplasty) Trial Should Dietary Sodium be Restricted to Lower Blood Pressure? Not Necessarily!	Nothing to Disclose
Alderwish	Edris	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	A Multi-Modality Approach Using Noninvasive and Invasive Techniques in the Treatment of a Patient With a Complicated Intra-	Nothing to Disclose
Alderwish	Edris	Which Test Is Best for Pain in the Chest?	Cardiac Mass Downstream Testing Utilization Following Obstructive Coronary Computed Tomographic Angiography (CCTA) in the ED Evaluation of Low to Intermediate Risk Acute Chest Pain	Nothing to Disclose
Aldrugh	Summer	Highlighted Original Research: Interventional Cardiology and the Year in Review	or Low to Intermediate RISK Acute Cnest Pain Safety of Same Day Discharge Following PCI for Non-ST Elevation Acute Coronary Syndromes	Nothing to Disclose
Alehan	Dursun	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Sunvival Analysis From THALES Study, A Large Nation-Wide Registry on Pulmonary Arterial Hypertension Associated With Congenital Heart Disease	Nothing to Disclose
Alemayehu	Mistre	Uncovering the Intricacies of Vascular Function	Congenital Heart Disease Ticagrelor Improves Microvascular Function: Results of a Cross- Over Study	Nothing to Disclose
Alemi	Farrokh	Assessing the Clinical Impact of Blood Pressure Lowering Therapies	Over Study Guidelines Allowing Control of Hypertension in Non-Diabetics Greater Than 60 Years Old at up to 150 mmHg Average Systolic Blood Pressure Increases Patient Mortality in Veterans	Nothing to Disclose
Alencherry	Ben	Arrhythmias and Clinical EP: AF Miscellaneous	Risk of Atrial Fibrillation in Human Immunodeficiency Virus Infection in the Era of Antiretroviral Therapy	Nothing to Disclose
Aleong	Ryan	and Surgical Issues Atrial Fibrillation and VT: Unique Populations	Presence of Mid-Myocardial Substrate Is Associated With Need for	Nothing to Disclose
		and Solutions	Multiple Ablations in Patients With Non-Ischemic Cardiomyopathy and Ventricular Arrhythmias	

Circular Trains Circle Trains Circular Trains Circular Trains Circular Trains Circular Trains Circular Trains Circular Trains Circle Trains Circular Trains Circular Trains Circle Trains Circle Trains Circle Trains Circle Trains Circle Trains Circle Trains Circl	Aleong Ryan Aleong Ryan Aleong Ryan Aleong Ryan Aleong Ryan Alexander John Alexander John Alexander John Alexander John Alexander John Alexander Karen Alexander Karen Alexander Karen Alexander Karen Alexander Karen Alexander Karen Alexander Faren Alexander Faren Alexander Faren Alexander Faren Alexander Faren Alexander Feta Alexander Feta Alexander Feta Alexander Feta Alexander Frick Alexander Frick Alexanderson Rosas Frick Alexandru Dragos	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Atrial Fibrillation and VT: Incorporating Novel	Early Recurrence of Ventricular Tachycardia Predicts Increased	Nothing to Disclose
Assertion Ansertion	Alexander John Alexander Karen Alexander Tetaen Alexander Karen Alexander Karen Alexander Karen Alexander Karen Alexander Feta Alexander Thomas Alexander Thomas Alexander Thomas Alexander Thomas Alexander Thomas Alexanderson Rosas Erick Alexandru Dragos Alexandru Dragos Alexis Jeffrey Alexopoulos Dimitrios Alexopoulos Dimitrios Alexopoulos Dimitrios	Atrial Fibrillation and VT: Incorporating Novel S	Mortality Among Patients With Severe Heart Failure	
Absender Anne Service Commendation in Patients With Left Vertically Systems (Defaulture) Commendation in Patients With Left Vertically Systems (Defaulture) Anne Greating Critical Trains Annual Service	Alexander John Alexander John Alexander John Alexander John Alexander John Alexander John Alexander Karen Alexander Karen Alexander Karen Alexander Karen Alexander Karen Alexander Karen Alexander Taren Alexander Karen Alexander Taren Alexander Peta Alexander Peta Alexander Peta Alexander Peta Alexander Taren Alexander Peta Alexander Pet		Safety and Outcomes of Catheter Ablation for Treatment of Refractory Ventricular Arrhythmias in Patients With Advanced Heart	Nothing to Disclose
Absender John Geberge Cincell Trisse Design and Modelly in Patients With Apil Enditions With and John Common Comm	Alexander John Alexander John Alexander John Alexander John Alexander John Alexander Karen Alexander Taren Alexander Karen Alexander Karen Alexander Karen Alexander Karen Alexander Karen Alexander Karen Alexander Taren Alexander Peta Alexander Peta Alexander Peta Alexanderson Rosas Erick Alexandru Dragos Alexandru Dragos Alexis Jeffrey Alexopoulos Dimitrios Alexopoulos Dimitrios Alfadhii Jarrah	Joint American College of Cardiology/New L England Journal of Medicine Late-Breaking L	Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery With Cardiopulmonary Bypass:	RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim,Bristol Myers Squibb,CSL Behring ,SANOFI,Tenax
Assander John John John Assander John Antitytimies and Circuit EP. Alticosypation Assander John Antitytimies and Circuit EP. Alticosypation Assander John Antitytimies and Circuit EP. Alticosypation Inscription Assander John Antitytimies and Circuit EP. Alticosypation Inscription Antitytimies and Circuit EP. Alticosypation Assander John Antitytimies and Circuit EP. Alticosypation Antitytimies and Circuit EP. Alticosypation Assander Antitytimies and Circuit EP. Alticosypation Antitytimies	Alexander John Alexander John Alexander John Alexander John Alexander Karen Alexander Taren Alexander Karen Alexander Karen Alexander Karen Alexander Karen Alexander Karen Alexander Feta Alexander Peta Alexander Peta Alexander Peta Alexanderson Rosas Erick Alexanderson Rosas Erick Alexanderson Rosas Erick Alexanderson Rosas Erick Alexandru Dragos			CONSULTANT FEES/HONORARIA - Bristol Myers Squibb,CSL Behring, Pfizer Inc,Portola,VasoPrep Surgical; RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim,Bristol Myers Squibb,CSL Behring, SANOFI,Tenax
Appeaban Version Worfein for Areal Fibrillation: Results From the Seating, Plane Inc. (FORMY 5. department) ARRISTON ITE TOWN ARRISTON ITEM ARRISTON	Alexander John Alexander John Alexander John Alexander Karen Alexander Taren Alexander Matthew Alexander Peta Alexander Thomas Alexanderson Rosas Erick Alexanderson Rosas Erick Alexandru Dragos		Undergoing Cardiac Surgery With Cardiopulmonary Bypass:	CONSULTANT FEES/HONORARIA - Bristol Myers Squibb,CSL Behring ,Pfizer Inc,Portola,VasoPrep Surgical; RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim,Bristol Myers Squibb,CSL Behring ,SANOFI,Tenax
and Surgical Issues With Appares Outcomes With Afridi Fibrillation. Results From the ARSISTOTE Trial ARSISTOTE Trial ARSISTACH ASSOCIATION TO THE PROPERTY OF THE P	Alexander John Alexander John Alexander Karen Alexander Haren Alexander Hatthew Alexander Peta Alexander Thomas Alexanderson Rosas Erick Alexanderson Rosas Erick Alexandru Dragos	Issues	Apixaban Versus Warfarin for Atrial Fibrillation: Results From the	RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim,Bristol Myers Squibb,CSL Behring ,SANOFI,Tenax
Disease Disease Hospatidication in Patients With Persperative Myocardial Inforction Following CARG Surgery RESEARCH/RESEARCH (RESIARCH/RESEARCH (RESIARCH/RESEARCH (RESIARCH/RESEARCH (RESIARCH/RESEARCH RESIARCH/RESEARCH RESIARCH/RESEARCH/RESEARCH RESIARCH/RESEARCH/R	Alexander John Alexander Karen Alexander Matthew Alexander Peta Alexander Thomas Alexander Thomas Alexander Erick Alexanderson Rosas Erick Alexanderson Rosas Erick Alexanderson Rosas Erick Alexanderson Rosas Erick Alexandru Dragos	and Surgical Issues	With Adverse Outcomes With Atrial Fibrillation: Results From the ARISTOTLE Trial	CONSULTANT FEES/HONORARIA - Bristol Myers Squibb,CSL Behring Pfizer Inc Portola, VasoPrep Surgical; RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim, Bristol Myers Squibb,CSL Behring ,SANOFI,Tenax Therapeutics
Clinical Team 4 FIT Forum: Mix and Mingle Clinical Team 4 FIT Forum: Mix and Mingle Clinical Team 4 Clinical Team 4 FIT Forum: Mix and Mingle Clinical Team 5 Clinical Team 4 FIT Forum: Mix and Mingle Clinical Team 4 FIT Clinical Team 5 FIT Clinical Team 5 FIT Clinical Team 4 FIT Clinical Team 4 FIT Clinical Team 4 FIT Clinical Team 5 FIT Clinical Team 4 FIT Clinical Team 4 FIT Clinical Team 5 FIT Clinical Team 4 FIT Clinical Team 5 FIT Clinical Team 5 FIT Clinical Team 4 FIT Clinical Team 4 FIT Clinical Team 5 FIT	Alexander Karen Alexander Matthew Alexander Peta Alexander Thomas Alexander Thomas Alexander Thomas Erick Alexanderson Rosas Erick Alexandru Dragos Alexandru Dragos Alexis Jeffrey Alexopoulos Dimitrios Alexopoulos Dimitrios	Disease F	Hospitalization in Patients With Perioperative Myocardial Infarction Following CABG Surgery	RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim,Bristol Myers Squibb,CSL Behring ,SANOFI,Tenax Therapeutics
Alexander Karen Fit Forum: Mix and Mingle Stockholments Street Really a Sex Difference in CV Presentation. Care, and Outcomes? Alexander CV Presentation. Care, and Outcomes? STEMI Diemmas: You Be the Judge Advanced Age/Advanced Dementia Presenting with STEM. Is RESEARCH/RESEARCH GRANTS - glead, Regenero Averation Research Re	Alexander Karen Alexander Karen Alexander Karen Alexander Karen Alexander Karen Alexander Karen Alexander Matthew Alexander Peta Alexander Thomas Alexander Thomas Alexander Frick Alexanderson Rosas Erick Alexandru Dragos Alexandru Dragos Alexis Jeffrey Alexopoulos Dimitrios Alexopoulos Dimitrios		Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim,Bristol Myers Squibb,CSL Behring ,SANOFI,Tenax
Alexander Karen Overseatation, Care, and Outcomes? Alexander Karen STEM Ditermas: You Be the Judge Advanced Age/Advanced Dementia Presenting with STEM: is RESEARCH/RESEARCH GRANTS - gliead, Regenero Aventis. Alexander Karen Grands of Care' Co-Char Research Care Care Care Care Care Care Care Care	Alexander Karen Alexander Karen Alexander Karen Alexander Karen Alexander Matthew Alexander Peta Alexander Thomas Alexander Thomas Alexanderson Rosas Erick Alexandru Dragos	FIT Forum: Mix and Mingle	Geriatric 	RESEARCH/RESEARCH GRANTS - gilead,Regeneron,Sanofi
Alexander Agene STEMI Diemmas: You Be the Judge Advanced AgeAdvanced Dementia Presenting with STEMI: Is Advander Agene Cardiovascular Procedures That Push the Line: High-Risk of Fullity of Care? Alexander Agene Cardiovascular Procedures That Push the Line: High-Risk of Fullity of Care? Alexander Agene Cardiovascular Procedures That Push the Line: High-Risk of Fullity of Care? Alexander Agene Cardiovascular Procedures That Push the Line: High-Risk of Fullity of Care? Alexander Agene Cardiovascular Procedures That Push the Line: High-Risk of Fullity of Care? Alexander Agene Cardiovascular Procedures That Push the Cardiovascular Procedures That Push that Push the Cardiovascular Procedures That Push the Cardiovascular Procedures That Push that P	Alexander Karen Alexander Karen Alexander Karen Alexander Matthew Alexander Peta Alexander Thomas Alexander Thomas Alexanderson Rosas Erick Alexandru Dragos Alexandru Dragos Alexandru Dragos Alexis Jeffrey Alexopoulos Dimitrios Alexopoulos Dimitrios Alfadhii Jarrah		Co-Chair	RESEARCH/RESEARCH GRANTS - gilead,Regeneron,Sanofi
Alexander Karen Cardiovasoular Procedures That Push the Line: High-Raks for Fullity of Care? Alexander Karen Innovations in Advocacy and Patient Centered Care Innovations Innovati	Alexander Karen Alexander Karen Alexander Matthew Alexander Peta Alexander Thomas Alexanderson Rosas Erick Alexandru Dragos	STEMI Dilemmas: You Be the Judge		RESEARCH/RESEARCH GRANTS - gilead,Regeneron,Sanofi
Alexander Karen (anovations in Advocacy and Patient Centered Care (an Care A Ca	Alexander Karen Alexander Matthew Alexander Peta Alexander Peta Alexander Thomas Alexanderson Rosas Erick Alexandru Dragos	Cardiovascular Procedures That Push the		RESEARCH/RESEARCH GRANTS - gilead,Regeneron,Sanofi
Cinical Team 5	Alexander Matthew Alexander Peta Alexander Thomas Alexanderson Rosas Erick Alexandru Dragos	Innovations in Advocacy and Patient Centered D		RESEARCH/RESEARCH GRANTS - gilead,Regeneron,Sanofi
Alexander Matthew The Evolving World of LVADs, Transplant and Myocarditis and Rhabdomyolysis Incidence With Immune Other Novel Discoserées Checkpoint Inhibitors and Rhabdomyolysis Incidence With Immune Other Novel Discoserées Checkpoint Inhibitors and Perspectives Pediatric Heart Surgery Length of Stay Pediatric Heart Surgery Le	Alexander Peta Alexander Thomas Alexanderson Rosas Erick Alexandru Dragos		Suggested Reviewer	RESEARCH/RESEARCH GRANTS - gilead,Regeneron,Sanofi
Alexander Peta Congenital Heart Disease: Progress in Prediction Tool for Congenital Heart Surgery Research (RESEARCH	Alexander Thomas Alexanderson Rosas Erick Alexanderson Rosas Erick Alexanderson Rosas Erick Alexanderson Rosas Erick Alexandru Dragos	The Evolving World of LVADs, Transplant and		
Alexander Thomas Global Perspectives in the Treatment of ST Elevation Mycardial Infarction: Successes, Failures, and Challenges Alexanderson Rosas Erick STEMI in the Emerging World: International Perspectives From the Cardiological Society of India, Mexican Society of Cardiology, and American College of Cardiology. And Perspectives From the Cardiology, and American College of Cardiology, and American College of Cardiology. And Perspectives From the Cardiology, and American College of Cardiology. And Perspectives From the Cardiology and American College of Cardiology. And Perspectives From the Cardiology and American College of Cardiology. And Perspectives From the Cardiology and American College of Cardiology. And Perspectives From the Cardiology and American College of Cardiology. And Perspectives From the Cardiology and American College of Cardiology. And Perspective From the Cardiology and American College of Cardiology. Perspectives From the Cardiology and American College of Cardiology and American College of Cardiology. Perspective From the Cardiology and Perspective Frenches From From Perspective From the Cardiology and Perspective From the Cardiology and Perspective From the Expension Assessed by Optical Coherence Tomography Alexandru Dragos Interventional Cardiology: PCI in Complex Patients Alexandru Dragos Interventional Cardiology: PCI in Complex Patients Alexandru Dragos Interventional Cardiology: PCI in Complex Procedural Calcium Fracture and its Effect on Stent Expansion Assessed by Optical Coherence Tomography Alexandru Dragos What's New in the World of STEMI? Delays in Absorption, Morphine and Crushing Consultation Fracture Framaceuticals, Inc. The Medicines Alexandru Dragos What's New in the World of STEMI? Delays in Absorption, Morphine and Crushing Pharmaceuticals, Inc. The Medicines Alfadhii Jarrah Fitcinc	Alexanderson Rosas Erick Alexanderson Rosas Erick Alexanderson Rosas Erick Alexanderson Rosas Erick Alexandru Dragos Alexandru Dragos Alexandru Dragos Alexis Jeffrey Alexopoulos Dimitrios Alexopoulos Dimitrios	Congenital Heart Disease: Progress in F		RESEARCH/RESEARCH GRANTS - Tenax Therapeutics
Alexanderson Rosas Erick STEMI in the Emerging World: International Perspectives From the Cardiological Society of India, Mexican Society of Cardiology, and American College of Cardiology, and American College of Cardiology, and American College of Cardiology, and Arrythmias Alexanderson Rosas Erick Erick Erick Erick Erick Erick Erick Erick Erick FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Alexanderson Rosas Erick Non Invasive Imaging: MR Structure and Valuvular Heart Disease Alexandru Dragos Interventional Cardiology: TAVR 3 The Natural History of Paravalvular Regurgitation After Transarterial Valve Implantation for Severe Aortic Stenosis: One Center Experience Alexandru Dragos Interventional Cardiology: PCI in Complex Patients Alexandru Dragos Dragos Inte	Alexanderson Rosas Erick Alexanderson Rosas Erick Alexanderson Rosas Erick Alexandru Dragos Alexandru Dragos Alexandru Dragos Alexis Jeffrey Alexopoulos Dimitrios Alexandru Dragos Alexandru Dragos Alexis Jeffrey Alexandru Dragos	Global Perspectives in the Treatment of ST	Delivering STEMI Care for a Billion People: The Indian Experience	Nothing to Disclose
Alexanderson Rosas Erick Emerging Developments in HFpEF and Arryhthmias Diagnostic Utility of Goldberger's Electrocardiographic Triad in Predicting Left Ventricular Dysfunction in Chagas' Heart Disease Alexanderson Rosas Erick Fit Clinical Decision Making: Heart Failure and Left Main Coronary Artery Compression Syndrome Nothing to Disclose Alexanderson Rosas Erick Non Invasive Imaging: MR Structure and Valuvular Heart Disease Alexandru Dragos Interventional Cardiology: TAVR 3 The Natural History of Paravalvular Regurgitation After Transarterial Valve Implantation for Severe Aortic Stenosis: One Center Experience Alexandru Dragos Interventional Cardiology: PCI in Complex Patients Alexandru Dragos Interventional Cardiology: PCI in Complex Patients Procedural Calcium Fracture and Its Effect on Stent Expansion Patients With Research From Expansion Patients With Research From Expansion Patients With Resistant Hypertension: Data From National Multicenter 1-Year-Follow-Up Study Alfadhli Jarrah Fit Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicines Alfadhli Darrah From Interventional Cardiology Acute and Stable Ischemic Heart Disease a	Alexanderson Rosas Erick Alexanderson Rosas Erick Alexandru Dragos Alexandru Dragos Alexis Jeffrey Alexopoulos Dimitrios Alexopoulos Dimitrios Alfadhii Jarrah	STEMI in the Emerging World: International Perspectives From the Cardiological Society of India, Mexican Society of Cardiology, and	Co-Chair	Nothing to Disclose
Alexanderson Rosas Erick FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Alexanderson Rosas Erick Non Invasive Imaging: MR Structure and Valuvular Heart Disease Alexandru Dragos Interventional Cardiology: TAVR 3 The Natural History of Paravalvular Regurgitation After Transarterial Valve Implantation for Severe Aortic Stenosis: One Center Experience Alexandru Dragos Interventional Cardiology: PCI in Complex Valve Implantation for Severe Aortic Stenosis: One Center Experience Alexandru Dragos Interventional Cardiology: PCI in Complex Alexis Jeffrey The Evolving World of LVADs, Transplant and Other Novel Discoveries Alexopoulos Dimitrios What's New in the World of STEMI? Delays in Absorption, Morphine and Crushing Alexopoulos Dimitrios Novel Mechanical Devices for the Treatment and Assessment of Hypertension Cardiology, Acute and Stable Ischemic Heart Disease, and Valse Disease and Multicenter Trial of a Transfermoral System for Miltral Valve OTHER - Valtech Cardio Ltd Frontiers in Mitral Valve Disease and Multicenter Trial of a Transfermoral System for Mitral Valve ORS Fragmentation Predicts Myocardial Fibrosis, Left Ventricular Tachycardia in Chagas´ Disease Nothing to Disclose RESEARCH/RESEARCH GRANTS - CSL Behring RESEARCH/RESEA	Alexanderson Rosas Erick Alexandru Dragos Alexandru Dragos Alexis Jeffrey Alexopoulos Dimitrios Alexopoulos Dimitrios Alfadhii Jarrah	Emerging Developments in HFpEF and		Nothing to Disclose
Alexandru Dragos Interventional Cardiology: TAVR 3 The Natural History of Paravalvular Regurgitation After Transarterial Valvular Heart Disease Alexandru Dragos Interventional Cardiology: TAVR 3 The Natural History of Paravalvular Regurgitation After Transarterial Valve Implantation for Severe Aortic Stenosis: One Center Experience Alexandru Dragos Interventional Cardiology: PCI in Complex Patients Alexandru Dragos Interventional Cardiology: PCI in Complex Patients Alexandru Dragos Interventional Cardiology: PCI in Complex Procedural Calcium Fracture and Its Effect on Stent Expansion Nothing to Disclose Alexis Jeffrey The Evolving World of LVADs, Transplant and Other Novel Discoveries Alexopoulos Dimitrios What's New in the World of STEMI? Delays in Absorption, Morphine and Crushing Alexopoulos Dimitrios Novel Mechanical Devices for the Treatment and Assessment of Hypertension Denervation in Patients With Resistant Hypertension: Data From National Multicenter 1-Year-Follow-Up Study Alfadhli Jarrah FIT Clinical Decision Making: interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicines Alfieri Ottavio Foreiters in Mitral Valve Disease and Multicenter Trial of a Transfemoral System for Mitral Valve OTHER - Valtech Cardio Ltd	Alexandru Dragos Alexandru Dragos Alexis Jeffrey Alexopoulos Dimitrios Alexopoulos Dimitrios Alfadhli Jarrah	FIT Clinical Decision Making: Heart Failure and L	Left Main Coronary Artery Compression Syndrome	Nothing to Disclose
Valve Implantation for Severe Aortic Stenosis: One Center Experience Alexandru Dragos Interventional Cardiology: PCI in Complex Patients Assessed by Optical Coherence Tomography Assessed by Optical Coherence Tomography Alexis Jeffrey The Evolving World of LVADs, Transplant and Other Novel Discoveries What's New in the World of STEMI? Delays in Absorption, Morphine and Crushing Delays in Absorption, Morphine and Crushing CONSULTANT FEES/HONORARIA - Astra Zeneca, Be Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, The Medicines Alfadhli Jarrah FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Alfieri Ottavio Valve Implantation for Severe Aortic Stenosis: One Center Experience Experience Experience Experience Astenator Assessed by Optical Coherence Tomography Consultant Feesindon Assessance In Patents Delays in Absorption, Morphine and Crushing Consultant Feesindon Astra Zeneca, Be Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, The Medicines Nothing to Disclose Orther - Valtech Cardio Ltd Orther - Valtech Cardio Ltd	Alexandru Dragos Alexis Jeffrey Alexopoulos Dimitrios Alexopoulos Dimitrios Alfadhli Jarrah	Non Invasive Imaging: MR Structure and		Nothing to Disclose
Alexis Dragos Interventional Cardiology; PCI in Complex Procedural Calcium Fracture and Its Effect on Stent Expansion Assessed by Optical Coherence Tomography Alexis Jeffrey The Evolving World of LVADs, Transplant and Other Novel Discoveries Change in Renal Function During Extended Follow-Up After Left Ventricular Assist Device Implantation Ventricular Assist Device Implantation Consult Tant FreeSiHONORARIA - Astra Zeneca, Bate Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, The Medicines Alexopoulos Dimitrios Novel Mechanical Devices for the Treatment and Assessment of Hypertension Alfadhli Jarrah FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Alfieri Ottavio Frontiers in Mitral Valve Disease and Multicenter Trial of a Transfemoral System for Mitral Valve OTHER - Valtech Cardio Ltd OT	Alexis Jeffrey Alexopoulos Dimitrios Alexopoulos Dimitrios Alfadhli Jarrah		Valve Implantation for Severe Aortic Stenosis: One Center	Nothing to Disclose
Alexopoulos Dimitrios What's New in the World of STEMI? Delays in Absorption, Morphine and Crushing Consultant FEES/HONORARIA - Astra Zeneca, Be Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc,The Medicines National Multicenter 1-Year-Follow-Up Study Alfadhli Jarrah FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Foreign in Miral Valve Disease and Multicenter Trial of a Transfermoral System for Mitral Valve OTHER - Valtech Cardio Ltd RESEARCH/RESEARCH GRANTS - CSL Behring Ventricular Assist Device Implantation CONSULTANT FEES/HONORARIA - Astra Zeneca, Be Healthcare Pharmaceuticals, Inc,The Medicines National Multicenter 1-Year-Follow-Up Study Alfadhli Jarrah FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Alfieri Ottavio The Voltavio Multicenter Trial of a Transfemoral System for Mitral Valve OTHER - Valtech Cardio Ltd	Alexopoulos Dimitrios Alexopoulos Dimitrios Alfadhii Jarrah	Interventional Cardiology: PCI in Complex F	Procedural Calcium Fracture and Its Effect on Stent Expansion	Nothing to Disclose
Alexopoulos Dimitrios What's New in the World of STEMI? Delays in Absorption, Morphine and Crushing CONSULTANT FEES/HONORARIA - Astra Zeneca, Be Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, The Medicines Alexopoulos Dimitrios Novel Mechanical Devices for the Treatment and Assessment of Hypertension Denervation in Patients With Resistant Hypertension: Data From National Multicenter 1-Year-Follow-Up Study Alfadhli Jarrah FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Alfieri Ottavio Frontiers in Mitral Valve Disease and Multicenter Trial of a Transfermoral System for Mitral Valve OTHER - Valtech Cardio Ltd	Alexopoulos Dimitrios Alfadhli Jarrah	The Evolving World of LVADs, Transplant and	Change in Renal Function During Extended Follow-Up After Left	RESEARCH/RESEARCH GRANTS - CSL Behring
Alfadhii Darrah FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Alfieri Ottavio Tomical Devices for the Treatment and Assessment of Hypertension Data Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, The Medicines Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Alfieri Ottavio Frontiers in Mitral Valve Disease and Multicenter Trial of a Transfemoral System for Mitral Valve OTHER - Valtech Cardio Ltd	Alfadhli Jarrah			
Alfadhli Jarrah FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Alfieri Ottavio Frontiers in Mitral Valve Disease and Multicenter Trial of a Transfemoral System for Mitral Valve OTHER - Valtech Cardio Ltd		and Assessment of Hypertension	Denervation in Patients With Resistant Hypertension: Data From a	CONSULTANT FEES/HONORARIA - Astra Zeneca,Bayer Healthcare Pharmaceuticals,Boehringer Ingelheim
Alfieri Ottavio Frontiers in Mitral Valve Disease and Multicenter Trial of a Transfemoral System for Mitral Valve OTHER - Valtech Cardio Ltd	1	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart		
	Alfieri Ottavio	Frontiers in Mitral Valve Disease and		OTHER - Valtech Cardio Ltd
Alfonso Carlos Updates on Risk Factors for Cardiovascular Hospital Admissions for Chest Pain Associated With Cocaine use in Nothing to Disclose	Alfonso Carlos	Updates on Risk Factors for Cardiovascular		Nothing to Disclose
Disease the United States Alfonso Carlos Atrial Fibrillation and VT: Specific Situations Perioperative Administration of Amiodarone or Beta Blockers in Nothing to Disclose Cardiac Surgery: Which is More Effective in Reducing Postoperative	Alfonso Carlos	Atrial Fibrillation and VT: Specific Situations F and Newer Outcome Measures	Perioperative Administration of Amiodarone or Beta Blockers in Cardiac Surgery: Which Is More Effective in Reducing Postoperative	Nothing to Disclose
Atrial Fibrillation? Alfonso Carlos Arrhythmias and Clinical EP: Syncope and Mortality Rates and Cost of Hospital Admissions for Syncope in the Nothing to Disclose	Alfonso Carlos	Arrhythmias and Clinical EP: Syncope and	Mortality Rates and Cost of Hospital Admissions for Syncope in the	Nothing to Disclose
Alfonso Carlos Interventional Complexity and Complications Variability in Transfemoral Access for Coronary Angiography and Nothing to Disclose	Alfonso Carlos		Variability in Transfemoral Access for Coronary Angiography and	Nothing to Disclose
Alfonso Fernando Timely Topics in Acute Coronary Syndromes A New Prognosis Score to Predict Mortality in Patients Over 75 Nothing to Disclose	Alfonso Fernando			Nothing to Disclose
Years Old Undergoing Primary Angioplasty in Cardiogenic Shock	Alfonso Fernando	o Timely Topics in Acute Coronary Syndromes		Trouming to Discisso
Pre-clinical Research Team 1		o Timely Topics in Acute Coronary Syndromes A o 25. Interventional Cardiology: Translation and	Years Old Undergoing Primary Angioplasty in Cardiogenic Shock	-

Care Street				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Algaze	Claudia	Predicting Outcomes in Pediatric Heart Disase	Insurance Type Is Associated With Longer Hospital Duration but Similar Mortality Among Children Undergoing Congenital Heart Surgery	Nothing to Disclose
Alghamdi	Ali	International CV Centers of Excellence: Leveraging the NCDR for Achieving High Quality Care	The Impact of the NCDR on Procedural Outcome	Nothing to Disclose
Alharethi	Rami	Advances in HCM, PPCM and Other Cardiomyopathies	Extended Course of Recovery in Patients With Peripartum Cardiomyopathy Assessed by Left Ventricular Wall Distensibility	Nothing to Disclose
Alhede	Christina	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Risk Assessment of Recurrent Atrial Fibrillation After Antiarrhythmic Medication or Catheter Ablation: The Impact of Age and Supraventricular Ectopic Complexes	Nothing to Disclose
Al-Hijji	Mohammed	Valvular Disease Populations at Risk	Isolated Tricuspid Valve Surgery: National Trends and Outcomes	Nothing to Disclose
Al-Hijji	Mohammed	Insights From Echocardiography Use	Echocardiographic Parameters of Myocardial Performance After Transapical Versus Transfemoral Transcatheter Aortic Valve Replacement	Nothing to Disclose
Ali	Mahmoud	Valvular Heart Disease: Endocarditis	Infective Endocarditis Following Transcutaneous Aortic Valve Implantation: Clinical, Echocardiographic and Hemodynamic Features	Nothing to Disclose
Ali	Mahmoud	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Innovative Technique to Achieve Hemostasis With Large Bore Access for Percutaneous Hemodynamic Support Devices	Nothing to Disclose
Ali	Mahmoud	Valvular Heart Disease: Aortic Stenosis	Outcomes and Their Predictors in Acute Transcatheter Aortic Heart Valve-in-Transcatheter Aortic Heart Valve Therapy	Nothing to Disclose
Ali	Mahmoud	Interventional Cardiology: TAVR 3	Comparative Outcome of Paravalvular Leak Following Surgical Versus Transcatheter Aortic Valve Replacement	Nothing to Disclose
Ali	Mohamed	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Facilitation of Stent Delivery With the GuideLiner Catheter	Nothing to Disclose
Ali	Nisreen	Non Invasive Imaging: Expanding Clinical Applications	Aortic Valve Calcification Predicts Paravalvular Aortic Regurgitation After Self-Expanding Transcatheter Aortic Valve Replacement	Nothing to Disclose
Ali	Sanjida	Assessing the Clinical Impact of Blood	Cardiovascular Outcomes With Nebivolol, Atenolol and Metoprolol	SALARY - Allergan
Ali	Sanjida	Pressure Lowering Therapies Assessing the Clinical Impact of Blood	in Patients With Hypertension: A Large, Retrospective, Propensity Score-Matched Cohort Study Additivity of Nebivolot/Valsartan Single-Pill Combinations Versus	SALARY - Allergan
Ali	-	Pressure Lowering Therapies Featured Clinical Research I	Other Approved Single-Pill Combinations for Hypertension Results of MRI-Based Screening Study of 5130 Candidates for	Nothing to Disclose
All	Syed	Featured Clinical Research I	Sports Participation	Nothing to disclose
Ali	Ziad	Interventional Live Case Session V: Complex Coronary and Physiology from Mid-America Heart Institute (Kansas City, Missouri)	Panelist	CONSULTANT FEES/HONORARIA - Acist Medical, St Jude Medical; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - VitaBx Inc; OTHER - Shockwave Medical; RESEARCH/RESEARCH GRANTS - St Jude Medical
Ali	Ziad	Complications of PCI: Case Reviews	Case Presentation: Inadequate Lesion Preparation Before Stenting	CONSULTANT FEES/HONORARIA - Acist Medical, St Jude Medical; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - VitaBx Inc; OTHER - Shockwave Medical; RESEARCH/RESEARCH GRANTS - St Jude Medical
Ali	Ziad	Contemporary Role of Intracoronary Imaging: Candid Conversation with Peers	Co-Chair	CONSULTANT FEES/HONORARIA - Acist Medical, St Jude Medical; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - VitaBx Inc; OTHER - Shockwave Medical; RESEARCH/RESEARCH GRANTS - St Jude Medical
Ali	Ziad	Contemporary Role of Intracoronary Imaging: Candid Conversation with Peers	Intracoronary Imaging to Determine the Causes of isR and ST	CONSULTANT FEES/HONORARIA - Acist Medical, St Jude Medical; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - VitaBx inc; OTHER - Shockwave Medical; RESEARCH/RESEARCH GRANTS - St Jude Medical
Ali	Ziad	Interventional Cardiology: Intravascular	Optical Coherence Tomography Assessment of Coronary	CONSULTANT FEES/HONORARIA - Acist Medical, St Jude
		Physiology and Endothelial Function	Atherectomy Effect: Comparison Between Orbital and Rotational Atherectomy in Severely Calcified Lesions	Medical; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - VitaBx Inc; OTHER - Shockwave Medical; RESEARCH/RESEARCH GRANTS - St Jude Medical
Ali	Ziad	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Morphologic Patterns of In-Stent Chronic Total Occlusions: An Intravascular Ultrasound Study	CONSULTANT FEES/HONORARIA - Acist Medical, St Jude Medical; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - VitaBx Inc; OTHER - Shockwave Medical; RESEARCH/RESEARCH GRANTS - St Jude Medical
Ali	Ziad	Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	CONSULTANT FEES/HONORARIA - Acist Medical, St Jude Medical; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - VitaBx Inc; OTHER - Shockwave Medical; RESEARCH/RESEARCH GRANTS - St Jude Medical
Ali	Ziad	The Inside View: Learning From Intracoronary Imaging	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Acist Medical, St Jude Medical; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - VitaBx Inc; OTHER - Shockwave Medical; RESEARCH/RESEARCH GRANTS - St Jude Medical
Ali	Ziad	25. Interventional Cardiology: Translation and Pre-clinical Research Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Acist Medical, St Jude Medical; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - VitaBx Inc; OTHER - Shockwave Medical; PESSABCH/RESEABCH GRANTS - St Jude Medical; PESSABCH/RESEABCH GRANTS - St Jude Medical; PESSABCH/RESEABCH GRANTS - St Jude Medical;
Alipour	Pouria	Arrhythmias and Clinical EP: AF Ablation	Determination of the Ideal Contact Force Required During	RESEARCH/RESEARCH GRANTS - St Jude Medical Nothing to Disclose
Alipour	Pouria	Atrial Fibrillation and VT: Unique Populations	Pulmonary Vein Antrum Isolation (PVAI) Evaluation of Long-Term Success Rate of Outflow Tract Ablation in	Nothing to Disclose
Alipour	Pouria	and Solutions Atrial Fibrillation and VT: Incorporating Novel	Patients With Ventricular Tachycardia Effects of Induction Before Ventricular Tachycardia Ablation on	Nothing to Disclose
Alishetti	Shudhanshu	Risks Toward Decision Making FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Long-Term Success Rate Bacterial Endocarditis in a Patient With Repaired Tetralogy of Fallot: A Rare Case of a Homograft Right Ventricle to Pulmonary Artery Conduit Acute Obstruction	Nothing to Disclose
Alishetti	Shudhanshu	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	The Geneticist With Unfortunate Genes: Coronary Artery Disease in Myotonic Dystrophy	Nothing to Disclose
Aliyu	Zakari	Novel Echocardiographic Methods for Assessing Cardiac Function	Biventricular Cardiac Function in Sub-Saharan Africans With Sickle Cell Disease	Nothing to Disclose
Aljizeeri	Ahmed	Innovations in Advocacy and Patient Centered Care	Cerribisease Correlation Between Frailty and Non-Invasive Coronary Flow Reserve: A Cross Sectional Study	Nothing to Disclose
Aljizeeri	Ahmed	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Non-Invasive Coronary Flow Reserve Predicts Major Adverse Cardiac Events in Patients With Prior Coronary Artery Bypass	Nothing to Disclose
Aljizeeri	Ahmed	Noninvasive Assessment of Coronary Flow	Grafting Non-Invasive Coronary Flow Reserve Predicts Incident Atrial	Nothing to Disclose
Aljizeeri	Ahmed	Reserve: Clinical Implications Imaging With Cardiac CT: The Case for	Fibrillation Incremental Prognostic Value of Coronary Calcium Scoring in	Nothing to Disclose
Aljohani	Sami	Calcium The Best Structural Interventional Challenging	Patients Undergoing 82-Rubidium Myocardial Perfusion Imaging Late Manifestation of Eisenmenger Physiology After Atrial Septal	Nothing to Disclose
Aljohani	Sami	Cases The Best Coronary and Peripheral	Defect Closure AngioVac Extraction of Inferior Vena Cava and Renal Vein	Nothing to Disclose
Aljohani	Sami	Interventional Challenging Cases Valvular Heart Disease: Endocarditis	Trend and Outcomes of Infective Endocarditis Treated With Surgical	Nothing to Disclose
			Valvular Replacement Insight From the Nationwide Inpatient Sample	
Aljohani	Sami	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	The Feasibility and Safety of Same Day Discharge for All Comers After Elective Percutaneous Coronary Interventions	Nothing to Disclose

Last Name Aljohani	First Name Sami	Session Title Interventional Cardiology: TAVR 2	Presentation Title Outcomes of Transcatheter and Surgical Aortic Valve Replacement	Disclosures Nothing to Disclose
		3,	in Patients With Hepatic Cirrhosis: Insight From Nationwide Inpatient Sample	,
Aljohani	Sami	Outcomes in Valvular Heart Disease	Increasing Healthcare Resource Utilization After Valve Replacement Surgery in the United States	Nothing to Disclose
Aljohani	Sami	Outcomes in Valvular Heart Disease	Trends and Outcomes of Permanent Pacemaker Implantation After Mitral Valve Replacement: A 10 Year U.S. Analysis	Nothing to Disclose
Aljohani	Sami	Outcomes in Valvular Heart Disease	Trends and Outcomes in Dialysis Requiring Acute Kidney Injury After Aortic Valve Replacement Insight From the Nationwide Inpatient Sample	Nothing to Disclose
Aljohani	Sami	Novel Determinants of Outcomes in VHD	Racial Disparity in Aortic Valve Replacement Outcomes: Insight From National Inpatient Sample	Nothing to Disclose
Aljohani	Sami	Valvular Heart Disease With CKD or Cirrhosis	Trends and Outcomes of Aortic Valve Replacement in Patient With End Stage Renal Disease on Hemodialysis: A 10-Year U.S. Perspective	Nothing to Disclose
Aljohani	Sami	Valvular Heart Disease With CKD or Cirrhosis	Trends and Outcomes of Mitral Valve Replacement in Patients With Hepatic Cirrhosis: Insight From National Inpatient Sample	Nothing to Disclose
Aljohani	Sami	Sex Disparity in VHD Outcomes	Contemporary Trends and Outcomes of Isolated Aortic Valve Replacement in Females in The United States: Understanding the Gender Gap	Nothing to Disclose
Al-Kazaz	Mohamed	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Left Ventricular Outflow Tract Obstruction Post ST-Elevation Myocardial Infarction as a Cause for Shock and the Role of Bedside Echocardiography in Guiding Therapy	Nothing to Disclose
Al-Khafaji	Nawfal	Arrhythmias and Clinical EP: Ventricular Tachycardia	Therapeutic Hypothermia for In-Hospital Cardiac Arrest: A Meta- Analysis	Nothing to Disclose
Al-Khafaji	Nawfal	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Sequential Inhibition of Renin-Angiotensin System in Heart Failure Is Associated With Enhanced Net Benefit at a Cost of Increased Adverse Events: A Systematic Meta-Analysis	Nothing to Disclose
Al-Khalidi	Hussein	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Outcomes in Patients With Diabetes Mellitus and Suspected Coronary Artery Disease Following Non-Invasive Testing: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	Nothing to Disclose
Al-Khalidi	Hussein	Innovations in Practice Management and Social Media	Accelerator 2 SUSTAIN, A U.S. Regional Systems of Care Demonstration Project for Post-Discharge STEMI Patients: Preliminary Data, Methods and Design	Nothing to Disclose
Al-Khalidi	Hussein	Novel Developments in Acute Coronary Syndromes	First Medical Contact to Device Time in STEMI Patients Presenting With Cardiogenic Shock: Insights From Mission, a Lifeline STEMI Systems Accelerator	Nothing to Disclose
Alkhalil	Ahmad	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		Nothing to Disclose
Alkhalil	Ahmad		Dissolve It or Take It Out: Excellent Outcome of Right-Sided Heart Clot In-Transit	Nothing to Disclose
Alkhalil	Ahmad	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Comparison of In-Hospital Outcomes of Septic Shock Patients With and Without Atrial Fibrillation: A Retrospective Propensity-Matched Analysis	Nothing to Disclose
Al-Khatib	Sana	Ventricular Arrhythmias in the Coronary Care Unit: Contemporary Solutions to an Old Problem	Co-Chair	Nothing to Disclose
Al-Khatib	Sana	Making Progress in Understanding Heart Failure	The Role of Baseline Versus Long-Term Follow-Up Ejection Fraction in Predicting Adverse Events Among Primary Prevention Implantable Cardioverter Defibrillator Recipients	Nothing to Disclose
Alkhoder	Ayman	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Association Between Circulating Progenitor Cells and Outcomes in Patients With Coronary Artery Disease	Nothing to Disclose
Alkhoder	Ayman	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Inflammatory Response to Mental Stress and Mental Stress Induced Myocardial Ischemia	Nothing to Disclose
Alkhoder	Ayman	Updates on Risk Factors for Cardiovascular Disease	Central Obesity Predicts Circulating Progenitor Cell Levels	Nothing to Disclose
Alkhoder	Ayman	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Progenitor Cells and Clinical Outcomes in Patients With Heart Failure	Nothing to Disclose
Alkhoder	Ayman	Unusual Presentations of ACS	Circulating Progenitor Cells Levels and Outcomes in Acute Myocardial Infarction	Nothing to Disclose
Alkhouli	Mohamad	The Best Structural Interventional Challenging Cases	Late Manifestation of Eisenmenger Physiology After Atrial Septal Defect Closure	Nothing to Disclose
Alkhouli	Mohamad	The Best Coronary and Peripheral Interventional Challenging Cases	AngioVac Extraction of Inferior Vena Cava and Renal Vein Thrombosis	Nothing to Disclose
Alkhouli	Mohamad	Valvular Heart Disease: Endocarditis	Trend and Outcomes of Infective Endocarditis Treated With Surgical Valvular Replacement Insight From the Nationwide Inpatient Sample	Nothing to Disclose
Alkhouli	Mohamad	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	The Feasibility and Safety of Same Day Discharge for All Comers After Elective Percutaneous Coronary Interventions	Nothing to Disclose
Alkhouli	Mohamad	Interventional Cardiology: TAVR 2	Outcomes of Transcatheter and Surgical Aortic Valve Replacement in Patients With Hepatic Cirrhosis: Insight From Nationwide Inpatient Sample	
Alkhouli	Mohamad	Outcomes in Valvular Heart Disease	Increasing Healthcare Resource Utilization After Valve Replacement Surgery in the United States	Nothing to Disclose
Alkhouli	Mohamad	Outcomes in Valvular Heart Disease	Trends and Outcomes of Permanent Pacemaker Implantation After Mitral Valve Replacement: A 10 Year U.S. Analysis	Nothing to Disclose
Alkhouli	Mohamad	Outcomes in Valvular Heart Disease	Trends and Outcomes in Dialysis Requiring Acute Kidney Injury After Aortic Valve Replacement Insight From the Nationwide Inpatient Sample	Nothing to Disclose
Alkhouli	Mohamad	Novel Determinants of Outcomes in VHD	Racial Disparity in Aortic Valve Replacement Outcomes: Insight From National Inpatient Sample	Nothing to Disclose
Alkhouli	Mohamad	Valvular Heart Disease With CKD or Cirrhosis	Trends and Outcomes of Aortic Valve Replacement in Patient With End Stage Renal Disease on Hemodialysis: A 10-Year U.S. Perspective	Nothing to Disclose
Alkhouli	Mohamad	Valvular Heart Disease With CKD or Cirrhosis	Trends and Outcomes of Mitral Valve Replacement in Patients With Hepatic Cirrhosis: Insight From National Inpatient Sample	Nothing to Disclose
Alkhouli	Mohamad	Sex Disparity in VHD Outcomes	Contemporary Trends and Outcomes of Isolated Aortic Valve Replacement in Females in The United States: Understanding the Gender Gap	Nothing to Disclose
Alkhouli	Mohamad	Frontiers in Mitral Valve Disease and Treatment	Long Term Outcomes of Patients Undergoing Percutaneous and Surgical Mitral Paravalvular Leak Repair	Nothing to Disclose
Alla	Venkata	Arrhythmias and Clinical EP: Ventricular Tachycardia	Therapeutic Hypothermia for In-Hospital Cardiac Arrest: A Meta- Analysis	Nothing to Disclose
Alla	Venkata	Measuring Success in Cardiac Rehabilitation	Ariarysis Wrist Activity Tracking Devices and Support Programs: A Meta- Analysis	Nothing to Disclose
Alla	Venkata	Atrial Fibrillation and VT: Unique Populations and Solutions	Sotalol Versus Other Anti-Arrhythmic Medications for Cardioversion of Atrial Fibrillation and Maintenance of Sinus Rhythm: Meta-	Nothing to Disclose
Alla	Venkata	Advances in HCM, PPCM and Other	Analysis of Randomized Controlled Studies Impact of Obesity on the Outcomes of Stress Cardiomyopathy: An	Nothing to Disclose
L	l	Cardiomyopathies	Analysis of National Inpatient Sample	

Last Name Alla	First Name Venkata	Session Title Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Presentation Title Sotalol Versus Other Anti-Arrhythmic Agents for Prevention of Post-Operative Supraventricular Arrhythmias After Cardiac Surgery: Meta-	Disclosures Nothing to Disclose
Alla	Venkata	Insights From Echocardiography Use	Analysis of Randomized Controlled Studies Trends and Use of Echocardiography in Patients With ->Staphylococcus Aureus- ->Bacteremia: An Analysis Using the Nationwide Inpatient Sample (NIS) Data	Nothing to Disclose
Alla	Venkata	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Sequential Inhibition of Renin-Angiotensin System in Heart Failure Is Associated With Enhanced Net Benefit at a Cost of Increased Adverse Events: A Systematic Meta-Analysis	Nothing to Disclose
Alla	Venkata	Arrhythmias and Heart Failure	Prognostic Impact of Premature Atrial Complexes in the General Population: A Meta-Analysis of Observational Studies	Nothing to Disclose
Allam	Adel	Featured Clinical Research I	Native South American Tsimane Have the Lowest Levels of	Nothing to Disclose
Al-Lamee	Rasha	Interventional Live Case Session V: Complex Coronary and Physiology from Mid-America Heart Institute (Kansas City, Missouri)	Coronary Atherosclerosis Ever Reported Co-Chair	CONSULTANT FEES/HONORARIA - Philips Volcano
Al-Lamee	Rasha	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International Multicentre iFR GRADIENT Registry	Nothing to Disclose
Allan	Catherine	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Prediction Tool for Congenital Heart Surgery Length of Stay	Nothing to Disclose
Allan	Victoria	Arrhythmias and Clinical EP: Basic 1	NOACs Versus Warfarin Use in the Management of Atrial Fibrillation	Nothing to Disclose
Allaqaband	Suhail	Considerations in Antiplatelet Therapy and in	Patients Contemporary Outcomes of Anterior Segment ST-Elevation	Nothing to Disclose
Allaqaband	Suhail	ACS Vascular Access and Hemostasis Issues	Myocardial Infarction: A Large 10-Year Tertiary Care Experience Clinical Efficacy of SoftSeal-STF Hemostatic Pad With Short Hold Time Compared to Traditional Manual Compression After	Nothing to Disclose
Allaqaband	Suhail	Advances in HCM, PPCM and Other Cardiomyopathies	Transfemoral Catheterization Marked Respiratory Related Variation in LVOT Gradients in Hypertrophic Cardiomyopathy in Obese HCM Patients With Sleep-	Nothing to Disclose
Allaqaband	Suhail	Interventional Cardiology: PCI and TAVR in Complex Patients	Disordered Breathing The Risk of Adverse Coronary Events Is Higher in Patients With Severe Obstructive Sleep Apnea Following Percutaneous Coronary Intervention	Nothing to Disclose
Allaqaband	Suhail	Percutaneous Coronary Intervention: Lessons From the Real World	Outcomes in Patients Undergoing Cardiac Catheterization and	Nothing to Disclose
Allaqaband	Suhail	Mechanisms of Vascular Inflammation in Atherogenesis	Therapeutic Hypothermia After Cardiac Arrest Comparative Study on Catheter-Directed Thrombolysis - Continuous Tissue Plasminogen Activator Versus Angiojet Catheter Power Pulse Spray Rheolytic Thrombectomy Outcome Study: Single-	Nothing to Disclose
Allen	Joe	Innovations in Practice Management and Social Media	Center Experience Unlocking the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for	Nothing to Disclose
Allen	Keith	Vascular Access and Hemostasis Issues	Today's Complex Care Delivery TAVR Using Transcarotid Vascular Access: In-Hospital and	SPEAKER'S BUREAU - Edwards
Allen	Keith	Interventional Cardiology: TAVR 3	Intermediate Term Outcomes Prosthetic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter	SPEAKER'S BUREAU - Edwards
Allen	Larry	Cardiogenic Shock: Drugs to Devices	Valve-in-Valve Implantation Panelist	CONSULTANT FEES/HONORARIA - Janssen Scientific Affairs, Johnson and Johnson, Novartis, ZS Pharma; RESEARCH/RESEARCH GRANTS - American Heart Association, NIH NHLBI, PCORI; SALARY - University of Colorado Anschutz Medical Center
Allen	Larry	Cardiogenic Shock: Drugs to Devices	Prolonging the Inevitable: Incorporating Palliative Care Earlier in the Dying Process	CONSULTANT FEES/HONORARIA - Janssen Scientific Affairs, Johnson and Johnson, Novartis, ZS Pharma; RESEARCH/RESEARCH GRANTS - American Heart Association, NIH NHLBI, PCORI; SALARY - University of Colorado Anschutz Medical Center
Allen	Larry	Readmission in Heart Failure: Questions Unanswered	Are Readmissions so Bad? Any Alternate Metrics?	CONSULTANT FEES/HONORARIA - Janssen Scientific Affairs, Johnson and Johnson, Novartis, ZS Pharma; RESEARCH/IRESEARCH GRANTS - American Heart Association, NIH NHLBI, PCORI; SALARY - University of Colorado Anschutz Medical Center
Allen	Larry	Young Investigator Awards Competition: Outcomes Research	Judge	CONSULTANT FEES/HONORARIA - Janssen Scientific Affairs, Johnson and Johnson, Novartis, ZS Pharma; RESEARCH/IRESEARCH GRANTS - American Heart Association, NIH NHLBI, PCORI; SALARY - University of Colorado Anschutz Medical Center
Allen	Larry	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Early Recurrence of Ventricular Tachycardia Predicts Increased Mortality Among Patients With Severe Heart Failure	CONSULTANT FEES/HONORARIA - Janssen Scientific Affairs, Johnson and Johnson, Novartis, ZS Pharma; RESEARCH/IRESEARCH GRANTS - American Heart Association, NIH NHLBI, PCORI; SALARY - University of Colorado Anschutz Medical Center
Allen	Larry	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Safety and Outcomes of Catheter Ablation for Treatment of Refractory Ventricular Arrhythmias in Patients With Advanced Heart Failure	CONSULTANT FEES/HONORARIA - Janssen Scientific Affairs, Johnson and Johnson, Novartis, ZS Pharma; RESEARCH/IRESEARCH GRANTS - American Heart Association, NIH NHLBI, PCORI; SALARY - University of Colorado Anschutz Medical Center
Allen	Larry	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)	CONSULTANT FEES/HONORARIA - Janssen Scientific Affairs, Johnson and Johnson,Novartis 2S Pharma; RESEARCH/IRESEARCH GRANTS - American Heart Association,NIH NHLBI,PCORI; SALARY - University of Colorado Anschutz Medical Center
Allen	Larry	Next Steps to Optimal Medical Therapy for Heart Failure Patients	Heart Failure Case Challenges	CONSULTANT FEES/HONORARIA - Janssen Scientific Affairs, Johnson and Johnson, Novartis, ZS Pharma; RESEARCH/IRESEARCH GRANTS - American Heart Association, NIH NHLBI, PCORI; SALARY - University of Colorado Anschutz Medical Center
Allen	Larry	14. Heart Failure and Cardiomyopathies: Therapy Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Janssen Scientific Affairs, Johnson and Johnson, Novartis, ZS Pharma; RESEARCH/IRESEARCH GRANTS - American Heart Association, NIH NHLBI, PCORI; SALARY - University of Colorado Anschutz Medical Center
Allen	Norrina	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Impact of Medical Liability Reform on Coronary Artery Disease Testing and Intervention	Nothing to Disclose
Alli	Oluseun	Coronary Artery Disease Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologists and the American	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular, Edwards Lifesciences
Alli	Oluseun	College of Cardiology 17. Interventional Cardiology: Aortic Valve	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular,Edwards
	1	Disease Team 2		Lifesciences

		9.40		
Last Name Allison	First Name John	Session Title Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Presentation Title Correlation of Right Atrial Enlargement on Ecg to Right Atrial Volume by Echocardiography in Patients With Pulmonary	Disclosures Nothing to Disclose
Allison	Thomas	Improving Outcomes in the Athlete With	Hypertension Exercise Testing in Pediatric Patients: Objective Versus Subjective	Nothing to Disclose
Allison	Thomas	Cardiovascular Disease Imaging the Athlete's Heart	Effort Acute Coronary Syndromes During Endurance Sports: Olmsted	Nothing to Disclose
Allison	Thomas	Nuclear Cardiology: Beyond Perfusion	County Experience The Impact of Cardiopulmonary Testing on Downstream Evaluation in Patients Who Undergo Myocardial Perfusion Imaging	Nothing to Disclose
Allison	Thomas	Non Invasive Imaging: Role of Exercise Testing	Exercise Test Predicts Both Cardiovascular and Non-Cardiovascular Mortality in Patients Without Cardiovascular Disease	Nothing to Disclose
Allison	Thomas	Atrial Fibrillation, Anticoagulation and Novel	CHA2DS2-VASc Score Predicts Incident Atrial Fibrillation/Flutter in	Nothing to Disclose
Allison	Thomas	Device Therapies Obesity Management in 2017: Weighing the	a Referral Population Digital Health Intervention Usage Improves Weight loss in a Dose-	Nothing to Disclose
Allison	Thomas	Issues New Perspectives on CAD Risk Factors	Dependent Fashion Coronary Artery Disease Patients With Concurrent Psychiatric	Nothing to Disclose
Allman	Richard	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Disorders at Greater Risk for Mortality Among Older Heart Failure (HF) Patients With In-Hospital Acute Kidney Injury (AKI), an Improvement in Kidney Function Is Associated With a Higher Risk of Post-Discharge Mortality but Not Readmission	Nothing to Disclose
Allman	Richard	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Chronic Alpha Blocker Use and Outcomes in Older Male Medicare Beneficiaries Hospitalized for Heart Failure	Nothing to Disclose
Allocco	Dominic	Interventional Cardiology: TAVR 3	Does Balloon Predilatation Influence Outcome With the Lotus Valve: 30-Day Results From the RESPOND Study	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Boston Scientific Corporation; SALARY - Boston Scientific Corporation
Allocco	Dominic	Refining PCI Technique and Outcomes	Three-Year Results From the EVOLVE II Randomized Trial: Late Clinical Outcomes With Bioresorbable Compared to Permanent Polymer Everolimus-Eluting	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Boston Scientific Corporation; SALARY - Boston Scientific Corporation
Allred	James	Novel Arrhythmia Diagnostics, Therapeutics, and "Wearables	Incidence of Implantable Loop Recorders Upgraded to Pacemakers/Implanted Cardiac Defibrillators	CONSULTANT FEES/HONORARIA - MEDTRONIC; SPEAKER'S BUREAU - Bristol-Myers Squibb Company ,Janssen Pharmaceuticals, Inc
Almaghraby	Abdallah	FIT Clinical Decision Making: Non-Invasive	Think Syndromic	Pharmaceuticals, inc Nothing to Disclose
Almahameed	Soufian	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Arrhythmias and	Ventricular Tachycardia Triggered by Loperamide and Famotidine	Nothing to Disclose
Al-Mallah	Mouaz	Electrophysiology Multimodality Imaging in Heart Diseases: International Perspectives From the Gulf Heart Association, Thai Heart Association, and American College of Cardiology	Abuse What is the Role of Imaging in New Onset Cardiomyopathy?	CONSULTANT FEES/HONORARIA - GE Healthcare,Pfizer,Philips
Al-Mallah	Mouaz	Patient-Centered Imaging: Quality of Cardiac	Co-Chair	CONSULTANT FEES/HONORARIA - GE Healthcare,Pfizer,Philips
Al-Mallah	Mouaz	CT Evidence Clinical Applications of Cardiac MRI in 2017	Assessment of Pericardial Disease	CONSULTANT FEES/HONORARIA - GE
Al-Mallah	Mouaz	Great Debates in Cardiac MRI	Co-Chair	Healthcare,Pfizer,Philips CONSULTANT FEES/HONORARIA - GE
Al-Mallah	Mouaz	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Normal Findings on Noninvasive Cardiac Assessment and the Prediction of Heart Failure: The Multi-Ethnic Study of	Healthcare,Pfizer,Philips CONSULTANT FEES/HONORARIA - GE Healthcare,Pfizer,Philips
Al-Mallah	Mouaz	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Atherosclerosis (MESA) Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography: The CONFIRM (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	CONSULTANT FEES/HONORARIA - GE Healthcare, Pfizer, Philips
Al-Mallah	Mouaz	Innovations in Advocacy and Patient Centered	Correlation Between Frailty and Non-Invasive Coronary Flow	CONSULTANT FEES/HONORARIA - GE
Al-Mallah	Mouaz	Care Non Invasive Imaging: Role of Exercise Testing	Reserve: A Cross Sectional Study Using Machine Learning to Define the Association Between Cardiorespiratory Fitness and All-Cause Mortality: The FIT (Henry Ford Exercise Testing) Project	Healthcare, Pfizer, Philips CONSULTANT FEES/HONORARIA - GE Healthcare, Pfizer, Philips
Al-Mallah	Mouaz	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Non-Invasive Coronary Flow Reserve Predicts Major Adverse Cardiac Events in Patients With Prior Coronary Artery Bypass	CONSULTANT FEES/HONORARIA - GE Healthcare, Pfizer, Philips
Al-Mallah	Mouaz	Noninvasive Assessment of Coronary Flow	Grafting Non-Invasive Coronary Flow Reserve Predicts Incident Atrial	CONSULTANT FEES/HONORARIA - GE
Al-Mallah	Mouaz	Reserve: Clinical Implications Imaging With Cardiac CT: The Case for	Fibrillation Incremental Prognostic Value of Coronary Calcium Scoring in	Healthcare,Pfizer,Philips CONSULTANT FEES/HONORARIA - GE
Al-Mallah	Mouaz	Calcium Risky Business: Predicting Outcomes in Heart	Patients Undergoing 82-Rubidium Myocardial Perfusion Imaging Chronotropic Incompetence and Long-Term Risk of Heart Failure:	Healthcare,Pfizer,Philips CONSULTANT FEES/HONORARIA - GE
Al-Mallah	Mouaz	Failure 27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team	The Henry Ford Exercise Testing Project Suggested Reviewer	Healthcare,Pfizer,Philips CONSULTANT FEES/HONORARIA - GE Healthcare,Pfizer,Philips
Almeida	Alejandra	Updates on Risk Factors for Cardiovascular Disease	Association of Anxious and Depressive Symptomatology With Cardiovascular Disease Among Patients From Different States in	Nothing to Disclose
Almeida	Osório	Advances in Lipid Management	Mexico: REDECAR Study Impact of Statin Therapy on Collagen Turnover and Left Ventricle Function After ST-Elevation Myocardial Infarction: A Randomized	Nothing to Disclose
Almeida-Morais	Luis	Innovations in Pediatric Catheterization and	Clinical Trial Percutaneous Patent Foramen Ovale Closure Benefit: Is Right	Nothing to Disclose
Almendral	Jesus	EP: Mending, Fixing and Predicting Everything you Wanted to Know About Heart	Patient Selection the Answer? Co-Chair	Nothing to Disclose
Almendral	Jesus	Transplant but Were Afraid to Ask FIT Clinical Decision Making: Heart Failure and	An Unusual Case of Anemia in a Heart Transplant Patient	Nothing to Disclose
Almendral	Jesus	Pulmonary Hypertension Advanced Therapies = Advanced Trouble:	ACC Poster Moderator	Nothing to Disclose
Almendral	Jesus	VAD and Transplant Challenges 13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	Nothing to Disclose
Almohdar	Safaa	Clinical Team 1 Multimodality Imaging in Heart Diseases: International Perspectives From the Gulf Heart Association, Thai Heart Association, and	Imaging Patients With Chest Pain: A Multimodality Approach	Nothing to Disclose
Almomani	Ahmed	American College of Cardiology Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Correlation Between Echocardiographic Pulmonary Artery Pressure Estimates and Right Heart Catheterization Measurements in Patients Undergoing Liver Transplant Evaluation: A Single Center Study	Nothing to Disclose
Almomani	Ahmed	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Outcomes of Fractional Flow Reserve Based Deferral in Saphenous Vein Graft Lesions	Nothing to Disclose
Almomani	Ahmed	Interventional Cardiology: Stent Failure	Does Post Pci Ffr Carry the Same Prognostic Weight as Non-	Nothing to Disclose
Almond	Christopher	Analysis by Intravascuar Imaging 10. Congenital Heart Disease: Pediatric Team	Ischemic Ffr in Deferred Lesions? Suggested Reviewer	Nothing to Disclose
Almustafa	Ahmed	The Best Coronary and Peripheral Interventional Challenging Cases	AngioVac Extraction of Inferior Vena Cava and Renal Vein Thrombosis	Nothing to Disclose
	1	Interventional challenging cases	THINHOODS	i

and the second				l l
Last Name Almustafa	First Name Ahmed	Session Title Valvular Heart Disease: Endocarditis	Presentation Title Trend and Outcomes of Infective Endocarditis Treated With Surgical	Disclosures Nothing to Disclose
Aimustala	Anned		Valvular Replacement Insight From the Nationwide Inpatient Sample	5
Almustafa	Ahmed	Interventional Cardiology: TAVR 2	Outcomes of Transcatheter and Surgical Aortic Valve Replacement in Patients With Hepatic Cirrhosis: Insight From Nationwide Inpatient Sample	Nothing to Disclose
Almustafa	Ahmed	Outcomes in Valvular Heart Disease	Increasing Healthcare Resource Utilization After Valve Replacement Surgery in the United States	Nothing to Disclose
Almustafa	Ahmed	Outcomes in Valvular Heart Disease	Trends and Outcomes of Permanent Pacemaker Implantation After Mitral Valve Replacement: A 10 Year U.S. Analysis	Nothing to Disclose
Almustafa	Ahmed	Outcomes in Valvular Heart Disease	Trends and Outcomes in Dialysis Requiring Acute Kidney Injury After Aortic Valve Replacement Insight From the Nationwide Inpatient Sample	Nothing to Disclose
Almustafa	Ahmed	Novel Determinants of Outcomes in VHD	Racial Disparity in Aortic Valve Replacement Outcomes: Insight From National Inpatient Sample	Nothing to Disclose
Almustafa	Ahmed	Valvular Heart Disease With CKD or Cirrhosis	Trends and Outcomes of Aortic Valve Replacement in Patient With End Stage Renal Disease on Hemodialysis: A 10-Year U.S. Perspective	Nothing to Disclose
Almustafa	Ahmed	Valvular Heart Disease With CKD or Cirrhosis	Trends and Outcomes of Mitral Valve Replacement in Patients With Hepatic Cirrhosis: Insight From National Inpatient Sample	Nothing to Disclose
Almustafa	Ahmed	Sex Disparity in VHD Outcomes	Contemporary Trends and Outcomes of Isolated Aortic Valve Replacement in Females in The United States: Understanding the Gender Gap	Nothing to Disclose
Almuwaqqat	Zakaria	Advances in Chronic Total Occlusion Intervention	Performance of J-CTO and PROGRESS CTO Scores in Predicting Angiographic Success and Long-Term Clinical Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions	Nothing to Disclose
Almuwaqqat	Zakaria	Unusual Presentations of ACS	Circulating Progenitor Cells Levels and Outcomes in Acute Myocardial Infarction	Nothing to Disclose
Alnaimat	Saed	FIT Clinical Decision Making: Interventional	Systemic Lupus Erythematosus Dissecting the Human Body	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine		
Al-Nooryani	Arif	New Perspectives on Structural Valve Disease: International Perspectives From the Emirates Cardiac Society, Latin American Society of Interventional Cardiology (SOLACI), and American College of Cardiology	Complex Coronary Intervention Using Robotics: UAE Experience	Nothing to Disclose
Alonso	Alvaro	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Stroke Among Whites and Blacks: The Atherosclerosis Risk In Communities (ARIC) Study	Nothing to Disclose
Alonso	Joaquin	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years	Nothing to Disclose
Alpendurada	Francisco	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Cardiovascular Magnetic Resonance in Survivors of Sudden Cardiac Arrest: 14 Year Experience From a Tertiary Referral Centre in the United Kingdom	Nothing to Disclose
Alpert	Craig	Teaching with Intent: Secrets from the Masters	Co-Chair	Nothing to Disclose
Alpert	Craig	Teaching with Intent: Secrets from the Masters	Welcome and Overview of Faculty Development Intensive	Nothing to Disclose
Alpert	Craig	Teaching with Intent: Secrets from the Masters	Co-Chair	Nothing to Disclose
Alpert	Craig	Teaching with Intent: Secrets from the Masters	Empowering your Powerpoint	Nothing to Disclose
Alpert	Craig	Teaching with Intent: Secrets from the Masters	Co-Chair	Nothing to Disclose
Alpert	Craig	Teaching with Intent: Secrets from the Masters	Intensive Summary	Nothing to Disclose
Alpert	Craig	Palliative Care for the 99% II: Skillbuilding: PC Encounters: What Would you do? Part I	Co-Chair	Nothing to Disclose
Alpert	Craig	Innovations in Education	Teaching Tomorrow's Teachers: An Innovative Model of Clinician-	Nothing to Disclose
Alpert	Craig	FIT Clinical Decision Making Reviewers 1	Educator Development for Trainees ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Alpert	Joseph	The Art and the Science of Decision Making in Coronary Artery Disease	The Art: To Be or not to Be an MI? How Do I Define Thee?	CONSULTANT FEES/HONORARIA - Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Daichi Pharmaceuticals, Daichii Sankyo, Exeter CME, Johnson & Amp; amp; Johnson, MedIQ communications company, NaCCME, CME company, Omnia/Prova CME company, Roche Diagnostics, Sanofi-Aventis, Servier Pharmaceuticals, ZS Pharma, ZS Pharma; DATA SAFETY MONITORING BOARD - Bayer Pharma, DATA SAFETY MONITORING BOARD - Bayer Pharma, Juha Clinical Research Institute, Genzyme Corporation, Janssen pharma, Janssen Pharmaceuticals, Inc, Novo Nordisk Inc., TiMI clinical research group; RESEARCH/RESEARCH GRANTS - ZS Pharma; SALARY - Ejsevier
Alpert	Joseph	Clinical Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen, Astra Zeneca, Bayer, Boehringer, Ingelheim, Daichi Pharmaceuticals, Daichii Sankyo, Exeter CME, Johnson & Mamp, amp, Johnson, MediC communications company, NACCME, CME company, Omnia/Prova CME company, Roche Diagnostics, Sanofi-Aventis, Servier Pharmaceuticals, ZS Pharma, ZS Pharma, DATA SAFETY MONITORING BOARD - Bayer Pharma, Duke Clinical Research Institute, Genzyme Corporation, Janssen pharma, Janssen Pharmaceuticals, Inc, Novo Nordisk Inc., TiMI clinical research group; RESEARCH/RESEARCH GRANTS - ZS Pharma; SALARY - Elsewier
Alqahtani	Fahad	The Best Structural Interventional Challenging Cases	Late Manifestation of Eisenmenger Physiology After Atrial Septal Defect Closure	Nothing to Disclose
Alqahtani	Fahad	Valvular Heart Disease: Endocarditis	Trend and Outcomes of Infective Endocarditis Treated With Surgical Valvular Replacement Insight From the Nationwide Inpatient Sample	Nothing to Disclose
Alqahtani	Fahad	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	The Feasibility and Safety of Same Day Discharge for All Comers After Elective Percutaneous Coronary Interventions	Nothing to Disclose
Alqahtani	Fahad	Interventional Cardiology: TAVR 2	Outcomes of Transcatheter and Surgical Aortic Valve Replacement in Patients With Hepatic Cirrhosis: Insight From Nationwide Inpatient Sample	Nothing to Disclose
Alqahtani	Fahad	Outcomes in Valvular Heart Disease	Increasing Healthcare Resource Utilization After Valve Replacement Surgery in the United States	Nothing to Disclose
Alqahtani	Fahad	Outcomes in Valvular Heart Disease	Trends and Outcomes of Permanent Pacemaker Implantation After Mitral Valve Replacement: A 10 Year U.S. Analysis	Nothing to Disclose
Alqahtani	Fahad	Outcomes in Valvular Heart Disease	Trends and Outcomes in Dialysis Requiring Acute Kidney Injury	Nothing to Disclose
			After Aortic Valve Replacement Insight From the Nationwide Inpatient Sample	

Contract of the second				
Last Name Alqahtani	First Name Fahad	Session Title Novel Determinants of Outcomes in VHD	Presentation Title Racial Disparity in Aortic Valve Replacement Outcomes: Insight	Disclosures Nothing to Disclose
•			From National Inpatient Sample	
Alqahtani	Fahad	Valvular Heart Disease With CKD or Cirrhosis	Trends and Outcomes of Aortic Valve Replacement in Patient With End Stage Renal Disease on Hemodialysis: A 10-Year U.S. Perspective	Nothing to Disclose
Alqahtani	Fahad	Valvular Heart Disease With CKD or Cirrhosis	Trends and Outcomes of Mitral Valve Replacement in Patients With Hepatic Cirrhosis: Insight From National Inpatient Sample	Nothing to Disclose
Alqahtani	Fahad	Sex Disparity in VHD Outcomes	Contemporary Trends and Outcomes of Isolated Aortic Valve	Nothing to Disclose
Al-Qaisi	Saifuldeen	Innovative Approaches for Reducing Risk and	Replacement in Females in The United States: Understanding the Gender Gap Watchman Device Associated Thrombi: A Novel Treatment	Nothing to Disclose
Ai-Qaisi	Salluideen	Improving Outcomes With Ablation	Approach	Nothing to Disclose
Alqarqaz	Mohammad	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Innovative Technique to Achieve Hemostasis With Large Bore Access for Percutaneous Hemodynamic Support Devices	Nothing to Disclose
Alqasrawi	Musab	Interventional Cardiology: TAVR 1	Prognostic Value of Right Ventricular Function Assessed by Cardiac Computed Tomography in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Alqasrawi	Musab	Non Invasive Imaging: Expanding Clinical Applications	Diagnostic Accuracy of Coronary Computed Tomography Angiography in Aortic Stenosis Patients Referred for Aortic Valve Replacement: Systematic Review and Meta-Analysis	Nothing to Disclose
Alraies	M. Chadi	Considerations in Antiplatelet Therapy and in ACS	Trends in Discharge and Outcome of Dual Antiplatelet Therapy Post Percutaneous Intervention in High Bleeding Risk Population	Nothing to Disclose
Alraies	M. Chadi	Considerations in Antiplatelet Therapy and in ACS	Outpatient Trends in Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Primary Percutaneous Coronary Intervention	Nothing to Disclose
Alraies	M. Chadi	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	In-Stent Restenosis of Drug-Eluting Stents: Incidence, Lesion Characteristics and Outcomes in Contemporary Practice Over the Last Decade - How Are They Different From De Novo Lesions?	Nothing to Disclose
Alraies	M. Chadi	Interventional Cardiology: TAVR 2	Racial Disparities and Temporal Trends in Demographics and Clinical Characteristics of Patients Screened for Transcatheter Aortic Valve Replacement	Nothing to Disclose
Alraies	M. Chadi	Interventional Cardiology: TAVR 3	Antithrombotic Therapy Differences and Associated Outcomes in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Alraies	M. Chadi	Interventional Cardiology: PCI in Complex Patients	Long-Term Mortality in Percutaneous Coronary Intervention of Saphenous Vein Grafts From Real-World Registry Data	Nothing to Disclose
Alruwaili	Fayez	Interventional Cardiology: Translation and Pre- Clinical Research	Non-Invasive Point-of-Care Method for Measuring Left-Ventricular Stroke-Volume Using a Passive Electromagnetic Skin Patch Sensor	Nothing to Disclose
Alsara	Osama	FIT Clinical Decision Making: Non-Invasive	Cardiac Pneumonia: Acute Mitral Regurgitation as a Rare Cause of	Nothing to Disclose
Al-Shaibi	Khaled	Imaging and Valvular Heart Disease Diabetes, Hyperlipidemia, and Coronary Artery	Right Upper Lung Lobe Infiltrate Revascularization Should be Applied in All Diabetics With Coronary	Nothing to Disclose
		Disease, Prevention and Treatment: International Perspectives From the Japanese College of Cardiology, Saudi Heart Association, and American College of Cardiology	Artery Disease	
Alshammari	Bader	Non Invasive Imaging: MR Structure and	Quantitative Measurements on Cardiac Magnetic Resonance to	Nothing to Disclose
Alshawabkeh	Laith	Valuvular Heart Disease Things That Matter in Adult Congenital Heart	Differentiate Benign Versus Malignant Masses: A Pilot Study Red Cell Distribution Width Predicts Adverse Outcomes in Adults	Nothing to Disclose
		Disease	With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank	
Alsheikh-Ali	Alawi	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	High Blood Pressure on Discharge From Acute Decompensated Heart Failure in Patients With Type 2 Diabetes Is Associated With Decreased 12-Month Mortality: Findings From the Gulf-Care	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,Pfizer Inc; RESEARCH/RESEARCH GRANTS - MEDTRONIC
Alsidawi	Said	Valvular Heart Disease: Aortic Stenosis	Bicuspid Versus Tricuspid Aortic Valve Stenosis: Comparative Study of Clinical Characteristics and Outcomes Following Aortic Valve Replacement in an Age-Matched Cohort	Nothing to Disclose
Altheeb	Zaid	FIT Clinical Decision Making: Arrhythmias and	Phenytoin in Treatment of Methadone-Induced Torsades de Pointes	Nothing to Disclose
Althouse	Andrew	Electrophysiology Arrhythmias and Clinical EP: Devices 2	Persistent Gender Disparities in Implantable Cardioverter-	Nothing to Disclose
Althouse	Andrew	Nuclear Cardiology: Beyond Perfusion	Defibrillator Therapy Regional Right Ventricular (RV) Function as Determined by Gated	Nothing to Disclose
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Blood Pool SPECT (GBPS) Provides Additive Value to Evaluation of Patients Undergoing Left Ventricular Assist Device (LVAD) Implantation	•
Althouse	Andrew	Predicting the Future: Observations and	Pulmonary Vascular Resistance Predicts Mortality in End-Stage	Nothing to Disclose
Althouse	Andrew	Discoveries From Registries and Databases Innovations in Cardiovascular Risk Assessment	Renal Disease Patients With Pulmonary Hypertension Ideal Cardiovascular Health Metrics in Couples: A Community-	Nothing to Disclose
Althouse	Andrew	and Reduction Nuclear Cardiology: Quality	Based Population Study	Nothing to Disclose
			Physicians	-
Althouse	Andrew	The Challenges of Outcome Prediction in Valvular Heart Disease	Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era	Nothing to Disclose
Althouse	Andrew	TAVR Outcomes Prognostication	Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit	Nothing to Disclose
Althouse	Andrew	Emerging Applications for Imaging Cardiac	Predictors of a Positive Technetium Pyrophosphate Scan in Patients	Nothing to Disclose
Altinier	Alessandro	Amyloidosis: Nuclear Cardiology Updates in Stable Ischemic Heart Disease	With Suspected Cardiac Amyloidosis The Close Relationship Between Drug Intolerance and Major Cardiac and Cerebrovascular Events After an Acute Coronary	Nothing to Disclose
Alton	Gwen	Impact of Prenatal Environment on Congenital Heart Disease	Syndrome or Coronary Revascularization Umbilical Arterial Blood Flow in the Third Trimester and Its Association With Clinical and Neurodevelopmental Outcomes in	Nothing to Disclose
AlTurki	Ahmed	Arrhythmias and Clinical EP: Devices 3	Children With Critical Neonatal Congenital Heart Disease Predicting Electrocardiographic and Echocardiographic Response to Cardiac Resynchronization Therapy: The Use of Strict Left	Nothing to Disclose
Alu	Maria	Highlighted Original Research: Interventional Cardiology and the Year in Review	Bundle Branch Block Criteria Implications of Worsening Right Ventricular Function Following Transcatheter or Surgical Aortic Valve Replacement: Insights From	Nothing to Disclose
Alu	Maria	Interventional Cardiology: TAVR 1	PARTNER2A Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: Insights From PARTNER 2A Trial	CONSULTANT FEES/HONORARIA - Claret Medical
Alu	Maria	Non Invasive Imaging: Expanding Clinical	Does Patient Prosthesis Mismatch Defined by CT LVOT Area	Nothing to Disclose
		Applications	Predict Downstream Clinical Outcomes?	-
Alu	Maria	Interventional Cardiology: TAVR 2	Worsening Tricuspid Regurgitation and Increased Mortality After Aortic Valve Replacement: Insights From PARTNER2A	CONSULTANT FEES/HONORARIA - Claret Medical
Alvarez	Rene	Heart Failure and Cardiomyopathies: Clinical Team 1	Suggested Reviewer	Nothing to Disclose
Alvarez	Silvia	Congenital Heart Disease: New Diagnostic	The Incremental Benefit of Color Tissue Doppler Imaging in Fetal	Nothing to Disclose
L	1	Approaches in Congenital Heart Disease	Rhythm Assessment	<u>L</u>

Avery Control Control					
Concessor processor proces	Alvarez Acosta	First Name Luis			Disclosures Nothing to Disclose
The control Morket or Energy Control Morket or England Control	Alviar	Carlos	Coronary Intervention in Interventional	Catecholaminergic Polymorphic Ventricular Tachycardia Veno-Arterial ECMO Program for Refractory Cardiogenic Shock in	Nothing to Disclose
Street Votes of December 1 Carlot May Annual Processor Company Annual	Alviar	Carlos		Large Tertiary Academic Center	Nathing to Disclose
Appelle (Charles) From Every Appelled or College Control Medicine From Control Management (Charles) From Control Manag	Aly		Clinical Vascular Diseases FIT Clinical Decision Making: Interventional	Sodium Nitroprusside in Patients With Aortic Dissection	-
Control Contro	AL	Decide .	Disease, and Vascular Medicine		
Temps				Chagas Cardiomyopathy	-
Accept Notices Present			Updates on Pulmonary Embolism	The Long-Term Prognostic Value of Highly Sensitive Cardiac	
Marced Ma	Alzayer	Hussain		Assessment of the Safety of Performing Coronary Angioplasty	Nothing to Disclose
Cardiology, Autor and Black in Extract Feet International Control of Processing and Autor Control of Processing and Processin	Alzayer	Hussain	Pulmonary Hypertension	Use	Nothing to Disclose
Amero Medical Personagement in Acute Coursey Services and Coursey Services and Course Services Service	Al-Zubaidi	Muhanad	Cardiology, Acute and Stable Ischemic Heart		Nothing to Disclose
Outcomes of Persulations of ACS Intelligent Presentations of ACS Intelligent Presentation Presentations of ACS Intelligent Presentation Presentations of ACS Intelligent Presentations of ACS Intelligent Presentation Presentation Presentations of ACS Intelligent Presentation Presentation Presentation Presentations of ACS Intelligent Presentation Presenta	Amano	Hideo	Novel Developments in Acute Coronary	Patients With ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Annural in Annua Predicting the Future Observations and Discourse For Future States of Principle Discourse For Future States Annual Projects on Registers and Disbasses and Disbasses States With Covere Kniewy Educate A. Close Sectional Study Dispasses on Principle and Circuit EP Anticognision of Principle Dispasses on the States of Principle Dispasses on the States Annual Principle Dispasses on the States Dispasses Di				Outcomes of Percutaneous Coronary Intervention: A Report From Japanese Nationwide Registry	-
Discourage From Registers and Databaseas Profession Mark Chrome Carlow Discourse A Creater Sectional Study Profession Mark Study Pro				FFR _{CT} : Learnings From the International ADVANCE Registry	-
Percer Arthylminisa and Clinical EP: Anticogujustion Antibusia Versitatesh Diseash Vascular Madicine: Novel Risk Measures in Antibusia Versitatesh Diseash Vascular Madicine: Novel Risk Measures in Antibusia Versitatesh Diseash North Seventhalian Vascular Madicine: Novel Risk Measures in Antibusia Versitatesh Diseash North Seventhalian			Discoveries From Registries and Databases	Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample	-
Anabid Verhalation II Sharath Anabid			Disease	Risk Factors	-
Ambard Venkasteri Bharath Non Invasive Insagrag, Mil Scar and Pertuston Non Invasive Insagrag, Mil Scar and Pertuston Non Invasive Insagrag (Mil Scar and Pertuston Non Invasive Insagrag (Mil Scar and Pertuston March Insagrage) (Mil Scar and Pertuston March Insagrage) (Mil Scar and Pertuston March Insagrage) (Mil Scar and VF Incorporating Novel Scale) (Mil Scar)			Issues	Populations of Rivaroxaban-Treated Patients With Nonvalvular Atrial Fibrillation in ROCKET AF and XANTUS	-
Amberdekar Amrut Incorositive Approaches for Reducing Risk and Cultiforms of California Amberdekar (Incorositive Approaches for Reducing Risk and Incorositive Approaches (Incorositive Approaches (Incorositive Approaches) (Incorositive Approac			Arterial Diseases	Artery Disease: The Multi-Ethnic Study of Atherosclerosis	-
Ambardekar Amut Amut Arian Fertiliana Arian Arian Fertiliana Arian Arian Fertiliana Arian Arian Fertiliana Arian				The Multi-Ethnic Study of Atherosclerosis (MESA)	-
Refractory Vertincular Arrhythmess in Patients With Advanced Heart Falur States and Prevention Prev			Improving Outcomes With Ablation	Mortality Among Patients With Severe Heart Failure	-
Prevention Gluseppe Stroke and AFT Trinking About the Heart Treatment Post Aca?	Ambardekar	Amrut		Refractory Ventricular Arrhythmias in Patients With Advanced Heart	Nothing to Disclose
Andrew Aute Heart Failure: Evaluating Strategies to Prevent Readmissions Perfections of Early Versus Lafe Readmissions Perfections of Persection Perfections Perfections Perfections Perfections Percents Versus Acadmissions Perfections	Ambegaonkar	Baishali			-
Ambrosy Andrew Prevent Readmissions Prevent Readmissions Ambrosy Andrew Prevent Readmissions Ambrosy Andrew Prevent Readmissions Acceptable and Cardiolegal Spatial Prevent Readmissions Acceptable and Cardiolegal Spatial Prevent Readmissions	Ambrosio	Giuseppe	Stroke and AF: Thinking About the Heart	Nonvalvular Atrial Fibrillation: Results From the GARFIELD-AF	ACRAF,Bayer,Menarini,Merck,Sanofi-Aventis; OTHER - Merck,Novartis Corporation; SPEAKER'S BUREAU -
Prevent Readmissions	Ambrosy	Andrew		Among Patients Hospitalized for Acute Heart Failure: Insights From	
Prevent Readmissions Failure (Clinical Decision Making: Arrhythmiss and Electrophysiology Ambrosy Andrew FiTC Clinical Decision Making: Arrhythmiss and Electrophysiology Ambrosy Andrew Wity Cart We Be Friends? Controversies in Heart Failure Management Hort Failure Management Ambrosy Andrew The Old and the New Impact of Heart Failure Drug Therapies Drug Therapies Trial Amdur Richard Assessing the Clinical Impact of Blood Pressure Lowering Therapies Amenitya Kisaki Interventional Cardiology, Intravascular Physiology and Endothelial Function Amenitya Kisaki Interventional Cardiology, Angiography Intravascular Impiging and Interventional Cardiology, P.Cl in Complex Patients Amenitya Kisaki Amenity	Ambrosy	Andrew		Heart Failure and Cardiorenal Syndrome: Insights From CARRESS-	Nothing to Disclose
Electrophysiology	Ambrosy	Andrew	Prevent Readmissions	Failure (Clinical Characteristics, Initial Therapies and Outcomes):	Nothing to Disclose
Heart Failure Management Death or Hospitalization in Ambulatory Heart Failure Patients With a Reduced Ejection Fracious Control of Heart Failure Patients With Advanced Heart Failure Patients Drug Therapies Drug Therapies Drug Therapies Drug Therapies Drug Therapies Drug Therapies Guidelines Allowing Control of Hypertension in Non-Diabetics Greater Than 60 Years Old at up to 150 mmHg Average Systolic Blood Pressure Increased Pressure Increased P	-		Electrophysiology	-	•
Drug Therapies	Ambrosy	Andrew		Death or Hospitalization in Ambulatory Heart Failure Patients With a	Nothing to Disclose
Pressure Lowering Therapies Greater Than 60 Years Old at up to 150 mmHg Average Systolic Blood Pressure Increases Patient Mortality in Veterans Amemiya Kisaki Interventional Cardiology: Intravascular Physiology and Endothelial Function Alterectomy Effect Deprison Between Orbital and Rotational Alterectomy Effect Lesions Amemiya Kisaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Amemiya Kisaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Advances in Chronic Total Occlusion Intervention Advances in Chronic Total Occlusion Intervention The Impact of Recanalization of Chronic Total Occuluded Coronary Artery on Electrophysiological Substrate of Left Ventricle Amemiya Kisaki Interventional Cardiology: PCI in Complex Patients Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome Amin Alpesh Arrhythmias and Clinical EP: Anticoagulation Issues Interventional Complexity and Complications Amin Alpesh Arrist Fibrillation Tables Intelligent Population Amin Alpesh Atrial Fibrillation, Anticoagulation and Novel Device Therapies Felicityness and Safety of Apixaban, Dabigatran, Rivaroxaban Company Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Company Meraging Risks to Patients, Providers, and Managing Risks to Patients, Providers, and Companies Teach Company Morthological Substrate of Crotal Occulations Amemiya Amemiya Amemiya Amemiya Amita Fibrillation Apatical Providers, and Morthological Reventional Cardiology: Pool in Complex Company Morthological Substrates Control Frediction Intervention Complexity and Compileations of Major Bleeding and Associated Costs Among Oral Anticoagulant-Naï,ve Non-Valvular Artial Fibrillation Patients in the US Medicare Population Amin Alpesh Amin Alpesh Artial Fibrillation, Anticoagulation and Novel Device Therapies Fe	Ambrosy	Andrew		Failure and a Reduced Ejection Fraction: Insights From the FIGHT Trial	Nothing to Disclose
Amemiya Kisaki Interventional Cardiology: Intravascular Physiology and Endothelial Function Atherectomy In Severely Calcified Lesions (Kisaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR (Kisaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR (Kisaki Advances in Chronic Total Occlusion Intervention I	Amdur		Pressure Lowering Therapies	Greater Than 60 Years Old at up to 150 mmHg Average Systolic Blood Pressure Increases Patient Mortality in Veterans	-
Amemiya Kisaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/IMR Afvances in Chronic Total Occlusions Intervention Interve	Amemiya		Physiology and Endothelial Function	Optical Coherence Tomography Assessment of Coronary Atherectomy Effect: Comparison Between Orbital and Rotational Atherectomy in Severely Calcified Lesions	Ü
Intervention Artery on Electrophysiological Substrate of Left Ventricle Artery in Electrophysiological Substrate of Left Ventricle Chronic Stent Recoil During Follow-Up in Severely Calcified Coronary Artery Lesions: An Optical Coherence Tomography Study Antery Lesions: An Optical Coherence Tomography Study Artery Lesions: An Optical Coherence Tomography Study Antery Lesions	Amemiya		Intravascular Imaging and Interventional CT/MR	Morphologic Patterns of In-Stent Chronic Total Occlusions: An Intravascular Ultrasound Study	-
Amezcua-Guerra Luis Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome Amin Alpesh Arrhythmias and Clinical EP: Anticoagulation Issues Amin Alpesh Interventional Complexity and Complications Amin Alpesh Arrial Fibrillation, Anticoagulation and Novel Device Therapies Amin Alpesh Arrial Fibrillation, Anticoagulation and Novel Device Therapies Amin Alpesh Arrial Fibrillation, Anticoagulation and Novel Device Therapies Amin Amin Amit Amit PCI in the Era of Public Accountability: Managing Risks to Patients, Providers, and Device Therapies Devivation and Validation of a Simple Inflammation Based Risk Score for Predicting In-Hospital Mortality in Acute Coronary Syndrome Real-World Comparison of Major Bleeding and Associated Cots Arrhythmias and Clinical EP: Anticoagulation of Real-World Comparison of Major Bleeding and Associated Cots Arrhythmias and Clinical EP: Anticoagulation of Real-World Comparison of Major Bleeding and Associated Cots Arrhythmias and Clinical EP: Anticoagulation and Real-World Comparison of Major Bleeding and Associated Cots Arrhythmias and Clinical EP: Anticoagulation and Real-World Comparison of Major Bleeding and Associated Cots Arrhythmias and Clinical EP: Anticoagulation and Real-World Comparison of Major Bleeding and Associated Cots Arrhythmias and Clinical EP: Anticoagulation and Bristol-Myers Squib Company Terumo; RESEARCH/RESEARCH GRANTS - Novosys, Otsuka, Pfizer/BMS Research Grants - Pfizer Inc., and Bristol-Myers Squib Company Amin Amin Amin Amin Amin Among Non-Valvular Artial Fibrillation Patients in the US Medicare Population PCI in the Era of Public Accountability: Managing Risks to Patients, Providers, and	Amemiya	Kisaki			Nothing to Disclose
Features of Patients With Acute Coronary Syndrome Amin Alpesh Arrhythmias and Clinical EP: Anticoagulation Issues Armong Oral Anticoagulant-Na8#239:ve Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin in the US Medicare Population Amin Alpesh Atrial Fibrillation, Anticoagulation and Novel Device Therapies Amin Amit Amit Amit Amit Amit Amit Amit Amit	Amemiya	Kisaki	Patients	Coronary Artery Lesions: An Optical Coherence Tomography Study	Nothing to Disclose
Amin Alpesh Arrhythmias and Clinical EP: Anticoagulation Issues Real-World Comparison of Major Bleeding and Associated Costs Among Oral Anticoagulant-Naï ve Non-Valvular Atrial Pibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin in the US Medicare Population Complexity and Complexity and Complications Interventional Complexity and Complications of States Amin Alpesh Atrial Fibrillation, Anticoagulation and Novel Device Therapies Amin Amit PCI in the Era of Public Accountability: Amin Amit PCI in the Era of Public Accountability: Managing Risks to Patients, Providers, and Real-World Comparison of Major Bleeding and Associated Costs Among Oral Anticoagulation Algoraban, Dabigatran, Rivaroxaban, or Warfarin in the US Medicare Population RESEARCH/RESEARCH GRANTS - Novosys, Otsuka, Pfizer/BMS RESEARCH/RESEARCH GRANTS - Novo	Amezcua-Guerra	Luis	Features of Patients With Acute Coronary Syndrome	Score for Predicting In-Hospital Mortality in Acute Coronary	Nothing to Disclose
Amin Alpesh Interventional Complexity and Complications Gender Differences in Post Percutaneous Coronary Intervention Complexity and Complications Following Acute Myocardial Infarction in the United Novosys, Otsuka, Prizer/BMS Atrial Fibrillation, Anticoagulation and Novel Device Therapies Amin Amit PCI in the Era of Public Accountability: Managing Risks to Patients, Providers, and Managing Risks to Patients, Providers, and	Amin	Alpesh	Arrhythmias and Clinical EP: Anticoagulation	Among Oral Anticoagulant-Naïve Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or	
Amin Alpesh Atrial Fibrillation, Anticoagulation and Novel Device Therapies Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban CONSULTANT FEES/HONORARIA - Pfizer Inc., and Bristol-Compared to Warfarin Among Non-Valvular Atrial Fibrillation Myers Squibb Company Amin PCI in the Era of Public Accountability: Patients in the US Medicare Population Amaging Risks to Patients, Providers, and Managing Risks to Patients, Providers, and	Amin	Alpesh	Interventional Complexity and Complications	Gender Differences in Post Percutaneous Coronary Intervention Complications Following Acute Myocardial Infarction in the United	
Amin Amit PCI in the Era of Public Accountability. Panelist CONSULTANT FEES/HONORARIA - AstraZeneca Managing Risks to Patients, Providers, and Pharmaceuticals, Medicines Company, Terumo;	Amin	Alpesh		Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Compared to Warfarin Among Non-Valvular Atrial Fibrillation	
	Amin	Amit	Managing Risks to Patients, Providers, and		Pharmaceuticals, Medicines Company, Terumo;

Annual Month	Contract of				<u> </u>
Managing (Basis De Nisten Products, and Control Professor Learners Control) processor Learners Control		First Name Amit	Session Title PCI in the Era of Public Accountability:	Presentation Title Cath Lab Economics: Strategies to Improve the Value of Care for	Disclosures CONSULTANT FEES/HONORARIA - AstraZeneca
Among Parlament Company Intervention Lessons Among Parlament Company Intervention Lessons Among Parlament Company Intervention Lessons Among Parlament Company Appealment of Embeddings Among Parlament Company Appealment of Embeddings Among Parlament Company Appealment of Embeddings Among Parlament Company Appealment Company Parlament Parlament Company Appealment Company Parlament Parlament Company Appealment Company Parlament Parlament Company Parlament Parlament Company Parlament Company Parlament Parlament Company Parlament Parlament Parlament Company Parlament Parlament Company Parlament Parlament Parlament Company Parlament Parlament Parlament Company Parlament Parlament Company Parlament Parlament Parlament Company Parlament Parlament Company Parlament Parlament Parlament Company Parlament Parlament Parlament Parlament Company Parlament Pa			Managing Risks to Patients, Providers, and		Pharmaceuticals, Medicines Company, Terumo;
Amenie Oseane Antife Deserve Antife Comp. 1 Persone Antife Deserve Antife Comp. 2 Persone Antife Deserve Antife Comp. 2 Persone Antife Deserve Antife Deserve Antife Comp. 2 Persone Antife Deserve Antife Deserve Antife Comp. 2 Persone Antife Deserve Deserve Antife Deserve Antife Deserve Deserve Anti	Amin	Amit	Percutaneous Coronary Intervention: Lessons	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Medicines Company,Terumo;
Mescale and Will Company of Amina and Million Cardiology (Mayor Perfusion) Personal Policy of Security Report Perfusion (Programs of National Cardiology) Personal Policy of Security Report Perfusion (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardiology (Programs of National Cardiology) Personal Policy of National Cardio	Amin	Zahid	09. Congenital Heart Disease: Adult Team 2	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Volcano CONSULTANT FEES/HONORARIA - Edwards Lifesciences,SJM
American Control of Security (1997) in Control of Security (1997)	Ammar	Khawaja Afzal	Emerging Applications of Echocardiography	Associated With Dynamic Left Ventricular Outflow Tract Obstruction	Nothing to Disclose
Moment Monage And Mona	Ammar	Khawaja Afzal	Nuclear Cardiology: Beyond Perfusion	The Increasing Burden of Amyloidosis From Apex to Base: New	Nothing to Disclose
Amment Ament	Ammar	Khawaja Afzal		Normal Diameter of the Ascending Aorta in Adults: The Impact of	Nothing to Disclose
Amenian Ame	Ammar	Khawaja Afzal		Gabapentinoids Therapy Is Associated With Higher Doses of	Nothing to Disclose
Ammental American File Circuit Designer (March Company American) American File Circuit Designer (March Com	Ammar	Khawaja Afzal	FIT Clinical Decision Making: Valvular Heart Disease and Pericardial Disease	Auscultation Guided Imaging Is Superior to Transthoracic and Transesophageal Echocardiography: A Case for 'Sound Guides	Nothing to Disclose
Congenital field Disease What I Andro. Nester Voorable Nester Disease From Emonits Voorable Nester Disease From Emonits Voorable Nester Disease From Emonits Of Cinical Christophic Andro. When I Compress Studies Of Cinical Christophic Andro. When Michael Colors Anno Nation May 1 Disease From the Third Dealed and Besond From Charles Disease May 1 Disease From the Third Dealed and Besond From Charles Disease May 1 Disease From the Third Dealed and Disease May 1 Disease From the Third Dealed and Posson May 1 Disease From the Third Hard Disease May 1 Disease May 1 Disease From the Third Anno May 1 Disease From the Third Disease May 1 Disease From the Third Disease May 1 Disease May 1 Disease From the Third Disease May 1 Dis	Ammash	Naser		Chest Pain in a Patient With Anomalous Left Anterior Descending Coronary Artery, Myocardial Bridging and Vasoconstriction: Identification of the Culprit Etiology and Management of a	Nothing to Disclose
Ammath Neer Valual art National Disease. And is Sinovated in Confidence Companies Study in Disclose (inclinated Chamachers and Customers Privated Pattern Study April 1987). Ammath Neer Cardinal Heart Disease. To the Tried Chamachers of Direct Current Cardinal Pattern Study. Ammath Mark Mark Mayer Various Cardinally, TAPR 1 and Cardinal Pattern Study. Ammath Mark Mayer Various Cardinal Pattern Study. Ammath Mark Mayer Various Cardinal Pattern Study. Ammath Mayer Various Cardinal Pattern Study. Ammath Mark Mark Mark Mark Mark Mark Mark Mark	Ammash	Naser	Congenital Heart Disease: What Is Aorta,		Nothing to Disclose
Ammanh Neser Conspired Hard Dessels on 1 Part Part of Control Audit Will Congestion (April 1997) (Control Audit 19	Ammash	Naser		of Clinical Characteristics and Outcomes Following Aortic Valve	Nothing to Disclose
Amor Marth Miguel Interventional Cardiology TAVR 1 Assessment of Right Solder feed mechanisms Pleanables as Prediction No. Affecting to Disclose of Early Outcome After Transcriations (Carlo Value Replacement) Amor Marth Miguel Interventional Cardiology Testing and English Solder feed and Provided Testing Solder (Carlo Value Replacement) Amportable Interventional Cardiology Solder Production and Noval English Solder feed and Provided Solder Solders (Carlo Value Solders) Amportable Interventional Cardiology Solders (Carlo Value Solders) Amportable Interventional Cardiology Solders (Carlo Value Solders) Amportable Interventional Cardiology Solders (Carlo Value Solders) Amortical Carlo Value Solders (Carlo Value Solders) Amortical Cardiology Solders (Carlo Value Solders) Amortical Carlo Value Solders (Cardiology Solders) Amortical Carlo Value Cardiology Solders (Cardiolog	Ammash	Naser		Outcomes of Direct Current Cardioversion in Adults With Congenital	Nothing to Disclose
Becomprison Daniel	Amor	Martin Miguel		Assessment of Right Sided Hemodynamic Parameters as Predictors	Nothing to Disclose
Amponesh Daniel Traditional and Novel Factors Used to Assess Preference Tube (1) (Appended Company of the Preference Tube (1) (Appended Company After) (Descare Descared Tube (1) (Appended Company After) (Descared Company	Amor	Martin Miguel			Nothing to Disclose
Amponsah Daniel fradicional and Novel Factors Used to Assess the Risk of an Used for the Treatment of, and the Risk of an Used for the Treatment of, and the Risk of an Used for the Treatment of, and the Risk of an Used for the Treatment of, and the Risk of an Used for the Treatment of, and the Risk of an Used for the Treatment of, and the Risk of an Used for the Treatment of, and the Risk of an Used for the Treatment of, and the Risk of an Used for the Treatment of, and the Risk of an Used for the Treatment of, and the Risk of an Used for the Treatment of, and the Risk of an Used for the Treatment of, and the Risk of an Used for the Treatment of, and the Risk of an Used for the Treatment of, and the Risk of an Used for the Treatment of, and the Risk of the Risk o	Amponsah	Daniel	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Glycemic Control in Insulin and Non-Insulin Dependent Diabetic Patients With ST Elevation Myocardial Infarction Predicts Time to	Nothing to Disclose
Amponsah Daniel Traditional and Novel Facilita Lakes Laked to Assess the Risk of, and Used for the Treatment off. Commany Afterly Decision to Risk of Amount of Commany Afterly Decision to Risk of the Risk of Amount off. Commany Afterly Decision to Risk of the Risk of Amount of Risk of Commany Afterly Decision to Risk of Amount of Risk of Risk of Amount of Risk of	Amponsah	Daniel	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Ischemic Time and Risk Factors Associated With the Incidence of Cardiogenic Shock in Patients Presenting With ST Elevation	Nothing to Disclose
Amrotok Slephen Feeling the Pressure - Tough Cases in Hypertension in Plant with Chronic Korthy Disease? Amrotok Slephen Gurrent Seuse in Cardiovascular Endemonary Pattern with Chronic Korthy Disease? Amracel Slephen Gurrent Seuse in Cardiovascular Endemonary Disease in Cardiovascular Endemonary Disease in Cardiovascular Endemonary Disease in Cardiovascular Endemonary Disease in Cardiovascular Endemonary Corticos Cardiovascular Endemonary Cardiovascular Cardiovascular Endemonary Cardiovascular	Amponsah	Daniel	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Impact of Demographics and Socioeconomic Status on Mode of Transportation and Time to Presentation in Patients With ST	Nothing to Disclose
Epidemotogy, Disparities, and Safety Advances in Chronic Total Coclusion Intervention Intervention Intervention Intervention Debates: in Thore Really a Sax Officence in Obstances of Patentiation, Care, and Outcomes? Obstances of Patentiation, Care, and Outcomes. Obstances of Patentiation, Care,	Amrock	Stephen	Feeling the Pressure - Tough Cases in	Case Presentation: High Blood Pressure, Low GFR. How do I	Nothing to Disclose
Arranseelu Suwetha Advances in Chronn Total Occlusion Intervention of Coronary Intervention of Coronary Coronary Intervention of Coronary Coronary Intervention of Coronary Coronary Intervention Carl Coronary Coronary Intervention Carl Coronary Coronary Intervention Carl Coronary Coronary Intervention of Coronary Coronary Intervention Carl Coronary Coronary Intervention of Coronary Intervention Intervention of Coronary Intervention Interventi	Amrock	Stephen			Nothing to Disclose
Ansterdam Ezra Obebates is There Really a Sex Difference in CV Presentation. Care, and Outcomes? Ansterdam Ezra OZ. Acute and Stable Ischemic Heart Disease: Clinical Team? Arabtawi Abdel FIT Clinical Decision Making: Arrhythmias and Sectorophysiologing, Applications in Novel Sectorophysiologing, Applications in Novel Disease States and Clinical Senarios Anagnostopoulos Constantinos Nuclear Cardiology: Beyond Perfusion Increased Subclinical Systemic AND Vascular Inflammation in Familia Combined Pyepripolemia Compared to Interception Increased Subclinical Systemic AND Vascular Inflammation in Familia Combined Pyepripolemia Compared to Interception Increased Subclinical Systemic AND Vascular Inflammation in Familia Combined Pyepripolemia Increased Subclinical Systemic AND Vascular Inflammation in Familia Combined Pyepripolemia Inspirator Constantinos Nuclear Cardiology: Beyond Perfusion Increased Subclinical Systemia AND Vascular Inflammation	Amsavelu	Suwetha	Advances in Chronic Total Occlusion	Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions Improves Peak Oxygen Uptake During Cardiopulmonary	Nothing to Disclose
Ansterdam Ezra	Amsterdam	Ezra			CONSULTANT FEES/HONORARIA - Relypsa
Anabtawi Abdel Efrt Clinical Decision Making, Arrhythmisa and Losse of Brugada Syndrome Presenting as Setzure Disorder Nothing to Disclose Electrophysiology Anagnostopoulos Constantinos Disease States and Clinical Scenarios Changing the Natural History of Valve Disease States and Clinical Scenarios Changing the Natural History of Valve Disease States and Clinical Scenarios Changing the Natural History of Valve Disease Subtervant Clinical Econarios Changing the Natural History of Valve Disease Subtinical Systemic AND Vascular Inflammation in Familial Combined Hyperlipidemias Compared to Heterozygous Program of Constantinos Constantinos Constantinos Constantinos Constantinos Nuclear Cardiology: Beyond Perfusion Nuclear Cardiology: Beyond Perfusion Increased Subclinical Systemic AND Vascular Inflammation in Familial Combined Hyperlipidemia Compared to Heterozygous Increased Subclinical Systemic AND Vascular Inflammation in Familial Combined Hyperlipidemia Compared to Heterozygous Constantinos Constantinos Constantinos Constantinos Cutting Edge Vascular Medicine Anand Atul Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome Anand Atul Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Amsterdam	Ezra	02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Relypsa
Anagnostopoulos Constantinos Nuclear Cardiology. Beyond Perfusion Increased Subclinical Systemic AND Vascual an Inflammation in Familial Combined Hyperipidemia Compared to Heterozygous Hypercholesterolemia: Instalpita Formar a Positror Emission Constantinos Constantinos Nuclear Cardiology. Beyond Perfusion Parallela Combined Hyperipidemia Compared to Heterozygous Hypercholesterolemia: Instalpita Formar a Positror Emission Constantinos Nuclear Cardiology. Beyond Perfusion Parallela Combined Hyperipidemia Compared to Heterozygous Parallel Hyperipidemia (Cardiol Temperatures and Petrifog Uptake in Patents Undergoing Cardiol Temperatures and Petrifog Uptake in Patents With Suspected Actae Company Syndromes Petrifogenia Cardiology Undergoing Cardiology Undergoing Cardiology Undergoing Cardiology Undergoing Cardiology Undergoing Cardiology U	Anabtawi	Abdel	FIT Clinical Decision Making: Arrhythmias and	A Case of Brugada Syndrome Presenting as Seizure Disorder	Nothing to Disclose
Anagnostopoulos Constantinos Changing the Natural History of Valve Disease With Medical Therapy Anagnostopoulos Constantinos Nuclear Cardiology, Beyond Perfusion Familia Combined Hyperlipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission Tomorgany Study Anagnostopoulos Constantinos Nuclear Cardiology, Beyond Perfusion In Vivo Correlation of Carotial Temperatures and Petif-6g Uptake in Patients Undergroiping Carotife Endarterectomy, Validation With Historogy Anagnostopoulos Constantinos Cutting Edge Vascular Medicine Patients Undergroiping Carotife Endarterectomy, Validation With Historogy Anagnostopoulos Constantinos Cutting Edge Vascular Medicine Patients Undergroiping Carotife Endarterectomy, Validation With Historogy Anagnostopoulos Constantinos Cutting Edge Vascular Medicine Patients Undergroiping Carotife Endarterectomy, Validation With Historogy Anand Atul Cardiac Arrest, Diabetes, and Other High Risk Peatures of Patients With Acute Coronary Syndromes Patients With Acute Coronary Syndromes, Diagnosis, Management and Outcomes Acute Coronary Syndromes, Diagnosis, Management and Outcomes Anand Atul Acute Coronary Syndromes, Diagnosis, Management and Outcomes Anand Atul Acute Coronary Syndromes, Diagnosis, Management and Outcomes Anangement and Outcomes Anangement Analy Control Acute Coronary Syndromes, Diagnosis, Management Analy Control Acute Coronary Syndromes Diagnosis,	Anagnostopoulos	Constantinos	Non Invasive Imaging: Applications in Novel	Fluorodeoxyglucose Uptake AND Visceral Adipose Tissue Biological	Nothing to Disclose
Anagnostopoulos Constantinos Nuclear Cardiology: Beyond Perfusion Familial Combined Hypercholesteriplicemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission Tomography Study. Anagnostopoulos Constantinos Nuclear Cardiology: Beyond Perfusion In Vivo Correlation of Cardiol Emperatures and Pet/Fdg Uptake in Patients Undergoing Cardiol Endarterectomy. Validation With Histology Anagnostopoulos Constantinos Cutting Edge Vascular Medicine Familial Combined Hyperilpidemia Is Characterized by Higher Afterial AND Hepatis Fluoredoxyguous Paline Compared to Heterozygous Familia Combined Hyperilpidemia Is Characterized by Higher Afterial AND Hepatis Fluoredoxyguous Paline Compared to Heterozygous Familia Combined Hyperilpidemia Is Characterized by Higher Afterial AND Hepatis Fluoredoxyguous Paline Compared to Heterozygous Familia Combined Hyperilpidemia Is Characterized by Higher Afterial AND Hepatis Fluoredoxyguous Paline Compared to Heterozygous Familia Combined Hyperilpidemia Is Characterized by Higher Afterial AND Hepatis Fluoredoxyguous Paline Compared to Heterozygous Familia Combined Hyperilpidemia Is Characterized by Higher Afterial AND Hepatis Fluoredoxyguous Paline Compared to Heterozygous Familia Combined Hyperilpidemia Is Characterized by Higher Afterial AND Hepatis Fluoredoxyguous Paline Paline Paline Compared to Heterozygous Familia Combined Hyperilpidemia Is Characterized by Higher Afterial AND Hepatis Fluoredoxyguous Paline	Anagnostopoulos	Constantinos			Nothing to Disclose
Hypercholesterolemia: Insights From a Postton Emission Tomography Study	Anagnostopoulos	Constantinos			Nothing to Disclose
Patients Undergoing Carotid Endarterectomy. Validation With Histology Anagnostopoulos Constantinos Cutting Edge Vascular Medicine Familial Combined Hyperlipidemia Is Characterized by Higher Arterial AND Hepatic Fluorodeoxyglucose Uptake Compared to Heterozygora Familial Hypercholesterolemia Anand Atul Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndromes Anand Atul Acute Coronary Syndromes, Diagnosis, Management and Outcomes Management and Outcomes Anand Atul Acute Coronary Syndromes, Diagnosis, Management and Outcomes Anand Atul Acute Coronary Syndromes, Diagnosis, Management and Outcomes Anand Atul Acute Coronary Syndromes, Diagnosis, Management and Outcomes Anand Atul Acute Coronary Syndromes, Diagnosis, Management and Outcomes Anand Atul Acute Coronary Syndromes, Diagnosis, Management and Outcomes Anand Atul Acute Coronary Syndromes, Diagnosis, Management and Outcomes Anand Inder The Evolving World of LVADs, Transplant and Other Novel Discoveries Anand Inderjit 13. Heart Failure and Cardiomyopathies: Clinical Team 7 Anand Anand Alship Arrhythmias and Clinical EP: Devices 1 Anand Anand Vidhu Arrhythmias and Clinical EP: Devices 1 Anand Arrhythmias and Clinical EP: A Miscellaneous and Surgical Issues Ananthakrishna Rajiv Coronary Intervention in Interventional Cardiology, Core Concepts Patients Wint Heart Failure in Abuti-Ethnic Asian Population: A Meta-Analysis Safety and Efficacy of Small World Clinical Fractic Aprospective With August Practical A		0		Hypercholesterolemia: Insights From a Positron Emission Tomography Study	N. W. C. D. C. C.
Anand Atul Coronary Syndrome, Diagnosis, Management and Outcomes Management and Outcomes Manand Inder Inder The Evolving World of LVADs, Transplant and Other Novel Discoveries Anand Inder The Evolving World of LVADs, Transplant and Other High Risk Inder Failure and Cardionyopathies: Clinical Team 7 Anand Inder Rish Arrhythmias and Clinical EP: AF Miscellaneous Anand Rishi Arrhythmias and Clinical EP: AF Miscellaneous Anand Rijv Coronary Intervention: Drug Eluting Stent and Safety Accidence and Predictions of Targets Des Fastility With 2 and Disclose Management And Outcomes				Patients Undergoing Carotid Endarterectomy: Validation With Histology	
Features of Patients With Acute Coronary Syndrome Acute Coronary Syndrome Acute Coronary Syndrome Acute Coronary Syndromes, Diagnosis, Management and Outcomes Age and the Effectiveness of Risk Stratification and Diagnostic Thresholds for Myocardial Infarction With High-Sensitivity Cardiac Troponin Nothing to Disclose				Arterial AND Hepatic Fluorodeoxyglucose Uptake Compared to Heterozygous Familial Hypercholesterolemia	-
Management and Outcomes			Features of Patients With Acute Coronary Syndrome	Acute Coronary Syndrome	Nothing to Disclose
Management and Outcomes Myocardial Infarction at Presentation?	Anand	Atul		Thresholds for Myocardial Infarction With High-Sensitivity Cardiac	Nothing to Disclose
Anand Atul Acute Coronary Syndromes, Diagnosis, Management and Outcomes Myocardial Infarction Anand Inder The Evolving World of LVADs, Transplant and Otter Novel Discoveries Anand Inderjit 13. Heart Failure and Cardiomyopathies: Clinical Team 7 Anand Rishi Arrhythmias and Clinical EP: Devices 1 Insertion of a Miniaturized Insertable Cardiac Monitor Outside the Traditional Hospital Setting: Results From the RIO 2 International Study Anand Vidhu Arrhythmias and Clinical EP: AF Miscellaneous Association Between Body Mass Index and Outcomes Among Patients With Prevalent Airial Fibrillation: A Meta-Analysis Ananthakrishna Rajiv Coronary Intervention: Drug Eluting Stent and Safefolds Ananthakrishna Rajiv Coronary Intervention in Interventional Cardiology: Core Concepts Ananthakrishna Rajiv Coronary Intervention in Interventional Cardiology: Core Concepts Ananthakrishna Province Analysis Application of Myocardial Infarction Myocardial Infarction Myocardial Infarction Myocardial Infarction Myocardial Infarction Myocardial Infarction (Consultational Study Analysis) Ananthakrishna Rajiv Coronary Interventional Cardiology: Core Concepts Ananthakrishna Rajiv Coronary Intervention in Interventional Cardiology: Core Concepts Ananthakrishna Rajiv Coronary Intervention in Interventional Cardiology: Core Concepts Ananthakrishna Rajiv Coronary Intervention in Interventional Cardiology: Core Concepts Ananthakrishna Rajiv Coronary Intervention in Interventional Cardiology: Core Concepts Ananthakrishna Rajiv Coronary Stent: A Prospective All-Comers Registry Coronary Stent: A Prospective All	Anand	Atul		Is It Safe to Use High-Sensitivity Cardiac Troponin T to Rule out	Nothing to Disclose
Anand Inder The Évolving World of LVADs, Transplant and Other Novel Discoveries Anand Inderjit 13. Heart Failure and Cardiomyopathies: Clinical Team 7 Anand Rishi Arrhythmias and Clinical EP: Devices 1 Anand Vidhu Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Anand Vidhu Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Ananthakrishna Rajiv Coronary Intervention: Drug Eluting Stent and Safeflods Ananthakrishna Rajiv Coronary Intervention in Interventional Cardiology: Core Concepts Arrhythmias and Clinical EP: AF Miscellaneous Apropulation Receiving the SYNERGY Coronary Stent: A Prospetive All-Comers Registry Arrhythmias and Clinical EP: AF Miscellaneous Ananthakrishna Rajiv Coronary Intervention in Interventional Cardiology: Core Concepts Ananthakrishna Rajiv Coronary Intervention in Interventional Cardiology: Core Concepts Arrhythmias And Eluting Stent and Sufficiency of Small Vessel Stenting With 2 mm Drug Cardiology: Core Concepts Arrhythmias and Clinical EP: AF Miscellaneous Ananthakrishna Cardiology: Core Concepts Ananthakrishna Rajiv Coronary Interventional Cardiology: Core Concepts Arrhythmias and Clinical EP: Devices 1 Insertion of a Miniaturized Insertable Cardiac Monitor Outside the Traditional Hospital Setting: Results From the RIO 2 International Study Amanthakrishna Rejiv Arrhythmias and Clinical EP: Devices 1 Arrhythmias and Clinical EP: Devices 1 Insertion of a Miniaturized Insertable Cardiac Monitor Outside the Traditional Hospital Setting: Results From the RIO 2 International Study Amanthakrishna Arrhythmias and Clinical EP: Devices 1 Arrhythmias and Clinical EP: Devices 1 Arrhythmias and Clinical EP: Devices 1 Amgen. ConSult. Arrhythmias Amgen. Consultant Amgen. Amgen. Amgen. Amgen. Amgen. Consultant Amgen. Amg	Anand	Atul	Acute Coronary Syndromes, Diagnosis,	High-Sensitivity Cardiac Troponin and the Classification of	Nothing to Disclose
Anand Inderjit 13. Heart Failure and Cardiomyopathies: Suggested Reviewer Consult_TANT_FEES/HONORARIA - Amgen_Cyberonics, Novartis_zensun Anand Rishi Arrhythmias and Clinical EP: Devices 1 Insertion of a Miniaturized Insertable Cardiac Monitor Outside the Traditional Hospital Setting: Results From the RIO 2 International Study Anand Vidhu Arrhythmias and Clinical EP: AF Miscellaneous Association Between Body Mass Index and Outcomes Among Patients With Prevalent Atrial Fibrillation: A Meta-Analysis Ananthakrishna Rajiv Coronary Intervention: Drug Eluting Stent and Scaffolds Ananthakrishna Rajiv Coronary Intervention in Interventional Cardiology: Core Concepts Ananthakrishna Rajiv Coronary Intervention in Interventional Cardiology: Core Concepts Ananthakrishna Rajiv Coronary Intervention in Interventional Cardiology: Core Concepts Ananthakrishna Rajiv Coronary Intervention in Interventional Cardiology: Core Concepts Ananthakrishna Cardiology: Core Concepts An	Anand	Inder	The Evolving World of LVADs, Transplant and		
Anand Rishi Arrhythmias and Clinical EP: Devices 1 Insertion of a Miniaturized Insertable Cardiac Monitor Outside the Traditional Hospital Setting: Results From the RIO 2 International Study Anand Vidhu Arrhythmias and Clinical EP: AF Miscellaneous Association Between Body Mass Index and Outcomes Among and Surgical Issues Patients With Prevalent Atrial Fibrillation: A Meta-Analysis Ananthakrishna Rajiv Coronary Intervention: Drug Eluting Stent and Safety and Efficacy of Small Vessel Stenting With 2 mm Drug Eluting Stents in Real World Clinical Practice Ananthakrishna Rajiv Coronary Intervention in Interventional Cardiology: Core Concepts Asian Population Receiving the SYNERGY Coronary Stent: A Prospective All-Comers Registry	Anand	Inderjit	13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	CONSULTANT FEES/HONORARIA -
Anand Vidhu Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues and Surgical Issues Patients With Prevalent Atrial Fibrillation: A Meta-Analysis Ananthakrishna Rajiv Coronary Intervention: Drug Eluting Stent and Scaffolds Eluting Stents in Real World Clinical Practice Ananthakrishna Rajiv Coronary Intervention in Interventional Cardiology: Core Concepts Rail Vessel Stenting With 2 mm Drug Nothing to Disclose Safety and Efficacy of Small Vessel Stenting With 2 mm Drug Eluting Stents in Real World Clinical Practice For Surgicial Stents in Real World Clinical Practice Ananthakrishna Rajiv Coronary Interventional Incidence and Predictors of Target Lesion Failure in a Multi-Ethnic Asian Population Receiving the SYNERGY Coronary Stent: A Prospective All-Comers Registry	Anand	Rishi		Traditional Hospital Setting: Results From the RIO 2 International	
Ananthakrishna Rajiv Coronary Intervention: Drug Eluting Stent and Safety and Efficacy of Small Vessel Stenting With 2 mm Drug Scaffolds Ananthakrishna Rajiv Coronary Intervention in Interventional Incidence and Predictors of Target Lesion Failure in a Multi-Ethnic Cardiology: Core Concepts Asian Population Receiving the SYNERGY Coronary Stent: A Prospective All-Comers Registry	Anand	Vidhu		Association Between Body Mass Index and Outcomes Among	Nothing to Disclose
Ananthakrishna Rajiv Coronary Intervention in Interventional Incidence and Predictors of Target Lesion Failure in a Multi-Ethnic Cardiology: Core Concepts Asian Population Receiving the SYNERGY Coronary Stent: A Prospective All-Comers Registry	Ananthakrishna	Rajiv	Coronary Intervention: Drug Eluting Stent and	Safety and Efficacy of Small Vessel Stenting With 2 mm Drug	Nothing to Disclose
	Ananthakrishna	Rajiv	Coronary Intervention in Interventional	Incidence and Predictors of Target Lesion Failure in a Multi-Ethnic Asian Population Receiving the SYNERGY Coronary Stent: A	Nothing to Disclose
Interim Analysis of a Single Centre Observational Study From	Anantharaj	Avinash	Interventional Complexity and Complications	Initial Experience of 265 Cases of Trans Ulnar Access Angioplasty: Interim Analysis of a Single Centre Observational Study From	Nothing to Disclose
	Ananthasubramaniam	Karthikeyan	Prosthetic Valve Assessment: Real or Illusion?	Prosthetic Endocarditis: New Methods for Diagnosis and Indications	RESEARCH/RESEARCH GRANTS - Astellas Pharma US Inc , GE Healthcare, Alnylam Pharmaceuticals ,Heart Metabolics

The state of the s				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Ananthasubramaniam	Karthikeyan	Innovations in Cardiovascular Risk Assessment and Reduction	Do Cardiovascular Health Screening Programs and Focused Counseling Have Impact on Patient Habits and Lifestyle Change?	RESEARCH/RESEARCH GRANTS - Astellas Pharma US Inc , GE Healthcare, Alnylam Pharmaceuticals ,Heart Metabolics
A	IZ - 11-7	Lecture 5 to 10 to	Early Results of the Heart Smart Screening Program	DEGEAROUS DESCRIPTION ASSESSMENT OF THE PROPERTY OF THE PROPER
Ananthasubramaniam	Karthikeyan	Insights From Echocardiography Use	Impact of Echo Contrast Agents on Ventricular Assist Devices (VAD) Hemodynamics: Are They Safe to Use?	RESEARCH/RESEARCH GRANTS - Astellas Pharma US Inc , GE Healthcare, Alnylam Pharmaceuticals ,Heart Metabolics
Ananthasubramaniam	Karthikeyan	30. Non Invasive Imaging: Nuclear Team 2	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Astellas Pharma US Inc ,
Anastasia	Emily	The Art and the Science of Decision Making in	Panelist	GE Healthcare, Alnylam Pharmaceuticals ,Heart Metabolics Nothing to Disclose
	•	Coronary Artery Disease		
Anavekar	Nandan	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Utility of Cardiac Computed Tomography Scanning in the Diagnosis and Pre-Operative Evaluation of Patients With Infective Endocarditis	Nothing to Disclose
Anavekar	Nandan	FIT Clinical Decision Making: Heart Failure and	Diagnosis of Myotonic Dystrophy Type 1 in a Patient Presenting With	Nothing to Disclose
		Pulmonary Hypertension	Stress-Induced Cardiomyopathy: Importance of Obtaining Family History and Having a Low Threshold of Suspicion	
Anavekar	Nandan	Interdisciplinary Cardiovascular Care in	Mediastinal Mass Infiltrating the Heart	Nothing to Disclose
Anaya	Paul	Complex Scenarios Arrhythmias and Heart Failure	Can the Ventricular-Arterial Coupling Ratio Predict Response to	Nothing to Disclose
Acchai	Delice		Cardiac Resynchronization Therapy for Patients Meeting Class IIa Indications?	NATION POLICE
Anchan	Rajeev	Innovative Use of Echocardiography	A Comparison of Two-Dimensional Echocardiography Parameters With Cardiac Magnetic Resonance Imaging in the Assessment of Right Ventricular Function Post Orthotopic Heart Transplantation	Nothing to Disclose
Anchouche	Khalil	Non Invasive Imaging: Expanding Clinical	Dual-Energy Coronary Computed Tomography Evaluation of High-	Nothing to Disclose
		Applications	Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients: Validation with Histopathologic Gold Standard	
Anchouche	Khalil	Non Invasive Imaging: Coronary Calcium	Incremental Utility of Coronary Computed Tomographic	Nothing to Disclose
		Scoring and CV Risk Assessment	Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired	
			Renal Function: The CONFIRM Registry	
Anchouche	Khalil	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta,	Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography: The	Nothing to Disclose
		Artery and Anomalous?	CONFIRM (COronary CT Angiography Evaluation For Clinical	
Anchouche	Khalil	Innovations in Cardiovascular Risk Assessment	Outcomes: An InteRnational Multicenter) Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve	Nothing to Disclose
, and to desire	T G G G G G G G G G G G G G G G G G G G	and Reduction	Asymptomatic Patients With Non-Obstructive Coronary Artery	Treating to Discisso
			Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (COronary CT Angiography	
			Evaluation For Clinical Outcomes: An InteRnational Multicenter)	
Anchouche	Khalil	Non Invasive Imaging: Prognostic Implications	Registry Prognostic Utility of Coronary Computed Tomographic Angiography	Nothing to Disclose
Androudie	Midil	of CT Angiography	Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry	Nothing to Disclose
A = = b = = b =	Khalil	Non Invasive Imaging: Prognostic Implications	Prognosis of Obstructive and Non-Obstructive Stents by Coronary	Nething to Displace
Anchouche	Kildili	of CT Angiography	Computed Tomographic Angiography: The CONFIRM Registry	Nothing to Disclose
Anchouche	Khalil	Non Invasive Imaging: Prognostic Implications	Quantitative Measurement of Coronary Intra-Plaque Necrotic Core	Nothing to Disclose
		of CT Angiography	by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Death: A Comparison to a Histologic Reference Standard	
Anchouche	Khalil	Diabetes and Other Issues in Cardiovascular Prevention	Implications of Statin Therapy Among Smokers With Severe	Nothing to Disclose
		Frevention	Coronary Artery Calcification: An Analysis of the CONFIRM Registry	
Anchouche	Khalil	Non Invasive Imaging: New Technologies	Optimal Method for Necrotic Core Identification in Coronary Plaque With Dual-Energy Computed Tomography: Material Decomposition and Atomic Number	Nothing to Disclose
Andell	Pontus	Novel Developments in Acute Coronary	Prehospital Administration of Heparin Reduces the Risk of Vessel	CONSULTANT FEES/HONORARIA - AstraZeneca
		Syndromes	Occlusion in Patients With ST Elevation Myocardial Infarction: Secondary Analysis of the TASTE Trial	Pharmaceuticals
Andersen	Ditte	Innovative Use of Echocardiography	The Left Atrium Emptying Fraction as a Predictor of Cardiovascular	Nothing to Disclose
			Morbidity and Mortality in a Low Risk General Population	
Andersen	Karl	Updates on Risk Factors for Cardiovascular	Carotid Plaque Area Is Increased in Patients With Acute Coronary	RESEARCH/RESEARCH GRANTS - Amgen Inc., Novartis
Andersen	Mads	Disease Emerging Developments in HFpEF and	Syndrome and Dysglycemia Arterial Reserve Limitations in Heart Failure With Preserved Ejection	Corporation,Novartis Corporation Nothing to Disclose
		Arryhthmias	Fraction and the Beneficial Effects of Sodium Nitrite	-
Anderson	Allen	Innovations in Practice Management and Social Media	Heart Failure Care Transitions: Queuing Theory-Based Cost- Effectiveness Analysis of Outpatient Clinic Capacity Sizing	CONSULTANT FEES/HONORARIA - GE Healthcare; RESEARCH/RESEARCH GRANTS - St Jude, Stemedica;
				SPEAKER'S BUREAU - Amgen, Arbor Pharmaceuticals, Novartis
Anderson	Allen	Acute Heart Failure: Evaluating Strategies to	Screening of Patients With Simple Clinical Parameters Early in	Corporation CONSULTANT FEES/HONORARIA - GE Healthcare;
		Prevent Readmissions	Hospitalization Is Highly Sensitive for Detection of Heart Failure	RESEARCH/RESEARCH GRANTS - St Jude, Stemedica;
			Hospitalization	SPEAKER'S BUREAU - Amgen, Arbor Pharmaceuticals, Novartis Corporation
Anderson	Allen	Innovations in Advocacy and Patient Centered	Impact of Multidisciplinary Heart Failure Transitional Care	CONSULTANT FEES/HONORARIA - GE Healthcare;
		Care	Interventions on Disparities in 30-Day Readmission Rates	RESEARCH/RESEARCH GRANTS - St Jude, Stemedica; SPEAKER'S BUREAU - Amgen, Arbor Pharmaceuticals, Novartis
				Corporation
Anderson Anderson	David H. Vernon	Innovations in Education 02. Acute and Stable Ischemic Heart Disease:	A Novel Educational Approach for Novice Echocardiographers Suggested Reviewer	Nothing to Disclose DATA SAFETY MONITORING BOARD - MedPace Medical
		Clinical Team 3		Devices
Anderson	Jeffrey	Late-Breaking Clinical Trials	GIFT of Warfarin: Benefit of Pharmacogenetic Dosing	CONSULTANT FEES/HONORARIA - Medicines Company,Sanofi-Aventis
Anderson	Jeffrey	Five Controversies in Single Ventricle	There Exists a Single Best Practice to Reducing Interstage Mortality	Nothing to Disclose
Anderson	Jeffrey	Management Interventional Cardiology: Translation and Pre-	Both the Novel NMR Biomarker of Inflammation, GlycA, and HS-	CONSULTANT FEES/HONORARIA - Medicines
	,	Clinical Research	CRP Are Independent and Additive Predictors of Future	Company, Sanofi-Aventis
			Cardiovascular Events Among Patients Undergoing Coronary Angiography: Results From the Intermountain Heart Collaborative	
			Study	
Anderson	Jeffrey	Congenital Heart Disease: Advances in Quality Improvement for Pediatric Cardiac Care	Revenue Return on Investment for Center Involvement in a Quality Improvement Collaborative for a Rare Disease: National Pediatric	Nothing to Disclose
		,	Cardiology Quality Improvement Collaborative	
Anderson	Jeffrey	Congenital Heart Disease: Advances in Quality Improvement for Pediatric Cardiac Care	Standardizing the Care of Outpatient Pediatric Syncope and Dizziness: A Lesson in Utilization and Charge Reduction	Nothing to Disclose
		•	-	
Anderson	Jeffrey	Non Invasive Imaging: Prognostic Implications	Prediction of Future Cardiovascular Risk by Analysis of Various CT	CONSULTANT FEES/HONORARIA - Medicines
		of CT Angiography	Coronary Angiography-Determined Quantitative Plaque Compositional Characteristics Among Patients With Diabetes	Company,Sanofi-Aventis
			Enrolled in the FACTOR-64 Study: The Importance of the Calcified	
Anderson	Jeffrey	Finding Out What Works in Pediatric and	Coronary Plaque Reduction in Interstage Growth Failure in Infants With Hypoplastic	Nothing to Disclose
	'	Congenital Heart Disease	Left Heart Syndrome and Impact on Stage 2 Outcomes: A Report	-
			From the National Pediatric Cardiology Quality Improvement Collaborative	
•			-	

Last Name Anderson	First Name Jeffrey	Session Title 11. Congenital Heart Disease: Therapy Team	Presentation Title Suggested Reviewer	Disclosures Nothing to Disclose
Anderson	Julie	1 Toward Precision Medicine in the Treatment of	Prognostic Importance of Blood Pressure and Heart Rate in Chronic	SALARY - GlaxoSmithKline
Anderson	Julie	Elevated Blood Pressure	Obstructive Pulmonary Disease: The SUMMIT Trial High-Sensitivity Cardiac Troponin I and Risk of Cardiovascular	SALARY - GlaxoSmithKline
		and Reduction	Events in Patients With COPD and Heightened Cardiovascular Risk: A Biomarker Sub-Study of the SUMMIT Trial	
Anderson	R. David	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Cardiac Pneumonia: Acute Mitral Regurgitation as a Rare Cause of Right Upper Lung Lobe Infiltrate	CONSULTANT FEES/HONORARIA - Johnson & Donson & Donson
Anderson	R. David	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Percutaneous Coronary Intervention of a Recently Repaired Anomalous Left Coronary Artery Arising From the Pulmonary Artery in an Adult Patient	CONSULTANT FEES/HONORARIA - Johnson & Dong; Johnson
Anderson	R. David	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Early Invasive Strategy and In-Hospital Survival of Diabetics With Non-ST-Elevation Myocardial Infarction: A Contemporary National Insight	CONSULTANT FEES/HONORARIA - Johnson & Donson & Donson & Donson
Anderson	Richard	Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI	A Ticagrelor Loading Results in Increased Plasma S-Nitrosothiols Formation Acutely in Patients With Stable Angina Undergoing Pci but Not on Chronic Therapy: Possible Evidence of an Acute Pleiotropic Effect	Nothing to Disclose
Anderson	Todd	Strategies for Prevention of Cardiovascular Disease: International Perspectives From the Canadian Cardiovascular Society, Cardiac Society of Australia and New Zealand, and American College of Cardiology	CCS Canadian Dyslipidemia Guidelines Update - What is New?	Nothing to Disclose
Andersson	Daniel	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Association Between Erectile Dysfunction and Death or Cardiovascular Outcomes After Myocardial Infarction	Nothing to Disclose
Ando	Kenji	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Long-Term Vascular Response to Permanent Polymer Everolimus- Eluting Stent Compared With Biodegradable Polymer Biolimus- Eluting Stent: Five-Year Follow-Up Optical Coherence Tomography Study	Nothing to Disclose
Ando	Kenji	Coronary Intervention in Interventional Cardiology: Core Concepts	Incidence and Clinical Impact of Longitudinal Stent Deformation After the PROMUS Element Platinum Chromium-Everolimus Eluting Stent Implantation	Nothing to Disclose
Ando	Kenji	Interventional Cardiology: PCI in Complex Patients	Three-Year Clinical Outcomes of the XIENCE/PROMUS Cobalt- Chromium Everolimus-Eluting Stent in Patients Treated With In- Stent Restenosis	Nothing to Disclose
Ando	Kenji	Unusual Presentations of ACS	The Impact of Residual Syntax Score in ACS Patients With LV	Nothing to Disclose
Ando	Kenji	Endovascular Therapy: Running From Risk	Dysfunction Impact of Decrease in Blood Pressure After Endovascular Therapy	Nothing to Disclose
Ando	Kenji	Peripheral Arterial Disease, Risk, and	for Renal Artery Stenosis Impact of Clinical Frailty for Patients With Critical Limb Ischemia	Nothing to Disclose
Ando	Tomo	Outcomes Interventional Cardiology: TAVR 3	Transcatheter Versus Surgical Aortic Valve Replacement in	Nothing to Disclose
Ando'	Giuseppe	Antithrombotic Therapy in Ischemic Heart	Diabetes Mellitus: From the Nationwide Inpatient Sample Time-Trends in Antithrombotic Management of Patients With	Nothing to Disclose
		Disease	AF/Flutter Treated With Coronary Stents: An International Multicenter Restrospective Analysis	-
Andrei	Adin-Cristian	Finding Out What Works in Pediatric and Congenital Heart Disease	Prevalence and Risk Factors Associated With Chronic Kidney Disease in Patients With Single Ventricle Congenital Heart Disease After Fontan Palliation	Nothing to Disclose
Andrei Carvalho	Sposito	Advances in Lipid Management	Impact of Statin Therapy on Collagen Turnover and Left Ventricle Function After ST-Elevation Myocardial Infarction: A Randomized Clinical Trial	CONSULTANT FEES/HONORARIA - Amgen Inc.,AstraZeneca Pharmaceuticals,Janssen Pharmaceuticals, Inc,Sanofi-Aventis
Andrei Carvalho	Sposito	Non Invasive Imaging: MR Scar and Perfusion	Doxorubicin-Associated Cardiac Tissue Remodeling in Breast Cancer Patients: A Cardiac Magnetic Resonance Study	CONSULTANT FEES/HONORARIA - Amgen Inc., AstraZeneca Pharmaceuticals, Janssen Pharmaceuticals, Inc, Sanofi-Aventis
Andreini	Daniele	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Prognostic Stratification in Patients With ST-Elevation Myocardial Infaction Over Transthoracic Echocardiography by CMR	SPEAKER'S BUREAU - GE Healthcare
Andreini	Daniele	Non Invasive Imaging: Prognostic Implications of CT Angiography	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	SPEAKER'S BUREAU - GE Healthcare
Andreini	Daniele	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Diagnostic Value of Qt Evaluation in Anterior ST Segment Elevation Myocardial Infarction for Prediction of Myocardial Salvage Index, as Compared to CMR	SPEAKER'S BUREAU - GE Healthcare
Andrews	Jack	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Multi-Modality Imaging Assessment of a Left Ventricular Mass	Nothing to Disclose
Andrikopoulou	Efstathia	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Double Chamber Right Ventricle as a Complication of Ventricular Septal Defect	Nothing to Disclose
Andrikou	E.	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Left Ventricular Mass Versus Pulse Wave Velocity as Predictors of Coronary Artery Disease in Patients With Essential Hypertension:	Nothing to Disclose
Andrikou	E.		Data From a Greek 6-Year-Follow-Up Study Predictors of New-Onset Atrial Fibrillation in Essential Hypertensives	Nothing to Disclose
Angchaisuksiri	Pantep	Elevated Blood Pressure Stroke and AF: Thinking About the Heart	The Prescribing of Antiplatelet Therapy Only in Patients With Nonvalvular Atrial Fibrillation: Results From the GARFIELD-AF	Nothing to Disclose
Angel	Brett	Arrhythmias and Clinical EP: Devices 1	Registry Increased Shock Impedance Is Associated With Failed Subcutaneous Implantable Cardioverter Defibrillator Defibrillation	Nothing to Disclose
Angeli	Daniel	Updates on Risk Factors for Cardiovascular	Threshold Testing Relationship Between High School Athletic Participation and Adult	Nothing to Disclose
Angeli	Stephen	Disease Updates on Risk Factors for Cardiovascular	Fitness and Metabolic Health Relationship Between High School Athletic Participation and Adult	Nothing to Disclose
Angelini	Paolo	Disease Featured Clinical Research I	Fitness and Metabolic Health Results of MRI-Based Screening Study of 5130 Candidates for	Nothing to Disclose
Angermann	Christiane	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Sports Participation Representativeness of the Paradigm Heart Failure Population in Real Life	CONSULTANT FEES/HONORARIA - Novartis Pharma,Resmed,Vifor, RESEARCH/RESEARCH GRANTS - Alere,Boehringer Ingelheim Pharmaceuticals, Inc,Lundbeck Inc.
Angers-Goulet	Alexandre	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Comparison of Triple Antithrombotic Therapy to Ticagrelor-Based Dual Antiplatelet Therapy for Left Ventricle Dysfunction Following	Nothing to Disclose
Angiolillo	Dominick	STEMI Dilemmas: You Be the Judge	STEMI Using Natural Randomization: A Retrospective Pilot Study Fast and Furious: Antiplatelet Choices in STEMI Patients with Expected E2B < 30 Minutes	CONSULTANT FEES/HONORARIA - Abbott Vascular and PLx Pharma,Bayer, Amgen, Sanofi, Eli Lilly, Daiichi-Sankyo, The Medicines Company, AstraZeneca, Merck; DATA SAFETY MONITORING BOARD - Johnson and Johnson; CeloNova; St. Jude; RESEARCH/RESEARCH GRANTS - Glaxo Smith Kline, E Lilly, Daiichi-Sankyo, The Medicines Company, AstraZeneca, Janssen Pharmaceuticals, Inc., Osprey Medical, Inc., Novartis, CSL Behring, and Gilead



-				
Last Name Angiolillo	First Name Dominick	Session Title Timing and Duration of DAPT: Controversy	Presentation Title	Disclosures CONSULTANT FEES/HONORARIA - Abbott Vascular and PLx
Angioillio	Dominick	and Consensus	Co-Chair	Pharma,Bayer, Amgen, Sanofi, Eli Lilly, Dalichi-Sankyo, The Medicines Company, AstraZeneca, Merck; DATA SAFETY MONITORING BOARD - Johnson and Johnson; CeloNova; St. Jude; RESEARCH/RESEARCH GRANTS - Glavo Smith Kline, E Lilly, Dalichi-Sankyo, The Medicines Company, AstraZeneca, Janssen Pharmaceuticals, Inc., Osprey Medical, Inc., Novartis, CSL Behring, and Gilead
Angiolillo	Dominick	Interrupting DAPT for Surgery, Afib, or Bleeding	Panelist	Columing, and oriean Columnia, and orient Consult Anti-FEES/HONORARIA - Abbott Vascular and PLx Pharma, Bayer, Amgen, Sanofi, Eli Lilly, Dalichi-Sankyo, The Medicines Company, AstraZeneca, Merci, DATA SAFETY MONITORING BOARD - Johnson and Johnson; CeloNova; St. Jude; RESEARCH/RESEARCH GRANTS - Glaxo Smith Kline, E Lilly, Dalichi-Sankyo, The Medicines Company, AstraZeneca, Janssen Pharmaceuticals, Inc., Osprey Medical, Inc., Novartis, CSL Behring, and Gilead
Angiolillo	Dominick	Interrupting DAPT for Surgery, Afib, or Bleeding	Cangrelor for PCI and for Bridging	CONSULTANT FEES/HONORARIA - Abbott Vascular and PLX Pharma, Bayer, Amgen, Sanofi, Eli Lilly, Daiichi-Sankyo, The Medicines Company, AstraZeneca, Merck; DATA SAFETY MONITORING BOARD - Johnson and Johnson; CeloNova; St. Jude; RESEARCH/RESEARCH GRANTS - Glaxo Smith Kline, E Lilly, Daiichi-Sankyo, The Medicines Company, AstraZeneca, Janssen Pharmaceuticals, Inc., Osprey Medical, Inc., Novartis, CSL Behring, and Gilead
Angiolillo	Dominick	25. Interventional Cardiology: Translation and Pre-clinical Research Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular and PLx Pharma, Bayer, Amgen, Sanofi, Eli Lilly, Daiichi-Sankyo, The Medicines Company, AstraZeneca, Merck; DATA SAFETY MONITORING BOARD - Johnson and Johnson; CeloNova; St. Jude; RESEARCH/RESEARCH GRANTS - Glaxo Smith Kline, E Lilly, Daiichi-Sankyo, The Medicines Company, AstraZeneca, Janssen Pharmaceuticals, Inc., Osprey Medical, Inc., Novartis, CSL Behring, and Gilead
Angoulvant	Denis	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Incident Atrial Fibrillation According to Gender In Patients With Ischemic Stroke: A Nationwide Cohort Study	CONSULTANT FEES/HONORARIA - Amgen, Astra Zeneca, Bayer, BMS/Pfizer, Lilly, MSD, Novartis, servier
Angoulvant	Denis	Considerations in Antiplatelet Therapy and in ACS	Use of Modern Scores to Evaluate Individual Risk/Benefit of Prolonged Dual Anti-Platelet Therapy May Modify Dual Anti-Platelet Therapy Duration in ST-Segment Elevation Myocardial Infarction Patients	CONSULTANT FEES/HONORARIA - Amgen,Astra Zeneca,Bayer,BMS/Pfizer,Lilly,MSD,Novartis,servier
Angoulvant	Denis	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Ischemic and Bleeding Events in the Real World Population of Stented Patients in the FAST-MI 2005 Cohort	CONSULTANT FEES/HONORARIA - Amgen, Astra Zeneca, Bayer, BMS/Pfizer, Lilly, MSD, Novartis, servier
Angoulvant	Denis	Stroke and AF: Thinking About the Heart	Predictors of Incident Atrial Fibrillation in Patients With Ischemic Stroke: A Nationwide Cohort Study	CONSULTANT FEES/HONORARIA - Amgen, Astra Zeneca, Bayer, BMS/Pfizer, Lilly, MSD, Novartis, servier
Anker	Stefan	Heart Failure: Implementing the Guidelines Into Practice; A Clinical Case-Based Symposium: International Perspectives From the European Society of Cardiology and the American College of Cardiology	Co-Chair	CONSULTANT FEES/HONORARIA - Bayer, Brahms GmbH, Janssen – J&, amp, J, Novartis, St Jude Medical, Vifor
Anker	Stefan	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Among Older Heart Failure (HF) Patients With In-Hospital Acute Kidney Injury (AKI), an Improvement in Kidney Function Is Associated With a Higher Risk of Post-Discharge Mortality but Not Readmission	CONSULTANT FEES/HONORARIA - Bayer,Brahms GmbH,Janssen – J&J,Novartis,St Jude Medical,Vifor
Anker	Stefan	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Clinical Effectiveness of Spironolactone in Hospitalized Older Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or Equal to 30 mL/min/1.73 m ²) Patients With Heart Failure	CONSULTANT FEES/HONORARIA - Bayer,Brahms GmbH,Janssen – J&J,Novartis,St Jude Medical,Vifor
Anker	Stefan	Why Can't We Be Friends? Controversies in Heart Failure Management	Adverse Outcomes With Use of Hydralazine and Nitrate Combination Therapy in Hospitalized Older Non-Black Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)	CONSULTANT FEES/HONORARIA - Bayer,Brahms GmbH,Janssen – J&J,Novartis,St Jude Medical,Vifor
Anker	Stefan	Why Can't We Be Friends? Controversies in Heart Failure Management	Association Between Serum Potassium Level and Outcomes in Heart Failure With Reduced Ejection Fraction: A Cohort Study From the Swedish Heart Failure Registry	CONSULTANT FEES/HONORARIA - Bayer,Brahms GmbH,Janssen – J&J,Novartis,St Jude Medical,Vifor
Anker	Stefan	 Heart Failure and Cardiomyopathies: Clinical Team 6 	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Bayer,Brahms GmbH,Janssen – J&J,Novartis,St Jude Medical,Vifor
Annemans	Lieven	Acute Coronary Syndromes, Diagnosis,	Predictors of Ischemic Events Within and After 1 Year After an	CONSULTANT FEES/HONORARIA - AstraZeneca
Annex	Brian	Management and Outcomes 41. Vascular Medicine: Venous Disease Team 1	Acute Coronary Syndrome: Results From the EPICOR Registry Suggested Reviewer	Pharmaceuticals CONSULTANT FEES/HONORARIA - Aastrom, DSMB,Anges MG,AstraZeneca
Anokwute	Chiedozie	Nuclear Cardiology: Prognosis	The Prognostic Value of Serial Stress Myocardial Perfusion Imaging in Asymptomatic End-Stage Renal Disease Patients Awaiting Kidney Transolantation	Pharmaceuticals,Athresys,Celgene,Sulfagenix,Theravance, Inc. Nothing to Disclose
Anouti	Khalil	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Phlegmasia Cerulea Dolens: A Painful Blue Foot in the Setting of Normal Arterial Circulation	Nothing to Disclose
Ansah	Deidra	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	"Doctor Google" and the New Era of Patient Empowerment Through Internet Resources	Nothing to Disclose
Ansari	Mohammad	Head to Toe: Outcomes of Endovascular Interventions	Analysis of Outcomes for Bioresorbable Vascular Scaffold Use for the Treatment of Peripheral Vascular Disease	Nothing to Disclose
Ansari	Mohammad	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease		Nothing to Disclose
Ansel	Gary	26. Interventional Cardiology: Vascular Access and Complications Team 2		CONSULTANT FEES/HONORARIA - 480 BioMed, Abbott Vascular Solutions, AngioSlide Ltd., Atheromed, Afrium medical, Best Doctors, Biocardia, Boston Scientific, capture medical, Cardinal Health, Cardiovascular Systems Inc., Daiichi Sankyo, Lake Region Medical, MEDTRONIC, Vatrix Medical Veryan/Novate, vladis wire, WL Gore; DATA SAFETY MONITORING BOARD - javelin medical; OTHER - Cook Medical, VMP Physicians, Inc.; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - emboli tech; RESEARCH/RESEARCH GRANTS - enable injections, Surmodics; SPEAKER'S BUREAU - WL Gore
Ansell	Jack	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Does Frailty Alter the Benefits of Oral Anticoagulation in Patients With Atrial Fibrillation?	CONSULTANT FEES/HONORARIA - Alere Inc,Boehringer Ingelheim,Bristol Myers Squibb,Daiichi Sankyo,Instrumentation Laboratories,Janssen,Perosphere Inc,Pfizer,Roche Diagnostics
Ansell	Jack	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)	CONSULTANT FEES/HONORARIA - Alere Inc,Boehringer Ingelheim,Bristol Myers Squibb,Daiichi Sankyo,Instrumentation Laboratories,Janssen,Perosphere Inc,Pfizer,Roche Diagnostics
Anstrom	Kevin	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery With Cardiopulmonary Bypass: Primary Results of the LEVO-CTS Trial	CONSULTANT FEES/HONORARIA - gilead, GSK, Pitzer; DATA SAFETY MONITORING BOARD - Vertex, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Biscardia; RESEARCH/RESEARCH GRANTS - AstraZeneca,BMS,Eli Lilly,MEDTRONIC

Last Name	First Name	Session Title	Presentation Title	Disclosures
Anstrom	Kevin	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Rates of Oral Anticoagulant Use, While Improving Over Time, Remain Low Among Hospitalized Patients With Atrial Fibrillation	CONSULTANT FEES/HONORARIA - gilead, GSK, Pfizer; DATA SAFETY MONITORING BOARD - Vertex, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Biscardia; RESEARCH/RESEARCH GRANTS - AstraZeneca, BMS, Eli
Anstrom	Kevin	Heart Failure and Cardiomyopathies: Is Heart	Surrogate Endpoints and the Differential Response to ASV for Sleep	Lilly,MEDTRONIC CONSULTANT FEES/HONORARIA - gilead,GSK,Pfizer; DATA
		Failure With a Normal EF for Real?	Apnea in HFrEF Versus HFpEF in the CAT-HF Trial	SAFETY MONITORING BOARD - Vertex, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Biscardia; RESEARCH/RESEARCH GRANTS - AstraZeneca,BMS,Eii Lilly,MEDTRONIC
Anstrom	Kevin	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Impact of Glucagon Like Peptide-1 Agonist Therapy on Heart Rate in Advanced Systolic Heart Failure: An Analysis From the Functional Impact of GLP-1 for Heart Failure Treatment Study	CONSULTANT FEES/HONORARIA - gilead, GSK, Pfizer; DATA SAFETY MONITORING BOARD - Vertex, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Biscardia; RESEARCH/IRESEARCH GRANTS - AstraZeneca, BMS, Eli LIII, MEDTRONIC
Anter	Elad	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	Nothing to Disclose
Anthopoulos	Prodromos	4 Interventional Cardiology: PCI and TAVR in Complex Patients	Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the Bravo-3 Randomized Trial	SALARY - The Medicines Company
Anthopoulos	Prodromos	Interventional Cardiology: PCI in Complex Patients	Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated Heparin Following Transcatheter Aortic Valve Replacement: Results From the Bravo-3 Randomized Trial	SALARY - The Medicines Company
Antman	Elliott	Recent ACS Trials: Relevance to My Daily Practice	Co-Chair	RESEARCH/RESEARCH GRANTS - Astra Zeneca, Dalichi Sankyo, Eli Lilly and Company
Antman	Elliott	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial	RESEARCH/RESEARCH GRANTS - Astra Zeneca,Daiichi Sankyo,Eli Lilly and Company
Antman	Elliott	Atrial Fibrillation and VT: Unique Populations	Outcomes of Asian Patients With Atrial Fibrillation Compared to Non-	RESEARCH/RESEARCH GRANTS - Astra Zeneca, Daiichi
Antman	Elliott	and Solutions Arrhythmias and Clinical EP: AF Miscellaneous	Asians in the ENGAGE AF-TIMI 48 Trial Association of Genetic Risk Score with Burden of Atrial Fibrillation:	Sankyo,Eli Lilly and Company RESEARCH/RESEARCH GRANTS - Astra Zeneca,Daiichi
Antman	Elliott	and Surgical Issues Stroke and AF: Thinking About the Heart	An ENGAGE AF-TIMI 48 Analysis Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation	Sankyo,Eli Lilly and Company RESEARCH/RESEARCH GRANTS - Astra Zeneca,Daiichi
		-	and Active Malignancy: An Analysis of ENGAGE AF - Timi 48 Randomized Clinical Trial	Sankyo,Eli Lilly and Company
Antoine	Clémence	Making Progress in Understanding Heart Failure	Is Frailty a Mirror of Underlying Hemodynamic Alteration in Patients With Left Ventricular Dysfunction?	Nothing to Disclose
Antoine	Clémence	Valvular Heart Disease: Mitral Valve Disease	Left Atrium Volume Index Measurement in Routine Practice: Does It Independently Impact Survival of Degenerative Mitral Valve Disease?	Nothing to Disclose
Antoine	Clémence	Valvular Heart Disease: Mitral Valve Disease	Quantitation of Degenerative Mitral Regurgitation: Reserved to the Specialized Few or Applicable to Routine Clinical Practice?	Nothing to Disclose
Antoniades	Charalambos	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Prognostic Implications of Epicardial Fat Volume Quantification in Acute Pericarditis	RESEARCH/RESEARCH GRANTS - SANOFI
Antoniades	Charalambos	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Association of Abdominal Aortic Wall Inflammation, Hepatic Fluorodeoxyglucose Uptake AND Visceral Adipose Tissue Biological Activity in Patients With Dyslipidemias	RESEARCH/RESEARCH GRANTS - SANOFI
Antonopoulos	Alexios	Diabetes and Endothelial Dysfucntion in Heart Failure	Association of Endothelial Dysfunction With Biomarkers of Inflammation, Myocardial Fibrosis and Left Ventricle Strain in Patients With Heart Failure	Nothing to Disclose
Antonopoulos	Alexis	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Prognostic Implications of Epicardial Fat Volume Quantification in Acute Pericarditis	Nothing to Disclose
Antonopoulos	Alexis	MicroRNAs and Beyond in Vascular Medicine	Association of Endothelial Dysfunction and Arterial Wall Elastic Properties With Systemic Inflammation in Patients With Pseudoexfoliative Glaucoma	Nothing to Disclose
Antonopoulos	Alexis	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Vascular Function of Conduit Arteries Is Associated With Progress of Diabetic Retinopathy in Type 2 Diabetes	Nothing to Disclose
Antonopoulos	Alexis	Vascular Access and Hemostasis Issues	Endothelial Dysfunction Post Transradial Access Coronary Catheterization: A Clinical Study and Meta-Analysis of Published	Nothing to Disclose
Antzelevitch	Charles	04. Arrhythmias and Clinical EP: Basic Team 1	Literature Suggested Reviewer	CONSULTANT FEES/HONORARIA - GILEAD Sciences; RESEARCH/RESEARCH GRANTS - Buchang Group,Gilead
Anugu	Viswajit Reddy	Current Issues in Cardiovascular	In-Hospital Outcomes and Hospitalizations for Acute Rheumatic	Scienes,Pharmacyclics Nothing to Disclose
Anugu	Viswajit Reddy	Epidemiology, Disparities, and Safety Current Issues in Cardiovascular	Heart Disease: A United States National Study Prevalence and In-Hospital Outcomes of Uremic and Dialysis	Nothing to Disclose
Anugu	Viswajit Reddy	Epidemiology, Disparities, and Safety The Evolving World of LVADs, Transplant and	Pericarditis: A United States National Study Arrhythmias in Hospitalized Heart Transplanted Patients: A United	Nothing to Disclose
Anugula	Dixitha	Other Novel Discoveries Atrial Fibrillation and VT: Unique Populations	States National Study Sotalol Versus Other Anti-Arrhythmic Medications for Cardioversion	Nothing to Disclose
Anugula	Dixitha	and Solutions Atrial Fibrillation and VT: Incorporating Novel	of Atrial Fibrillation and Maintenance of Sinus Rhythm: Meta- Analysis of Randomized Controlled Studies Sotalol Versus Other Anti-Arrhythmic Agents for Prevention of Post-	Nothing to Disclose
		Risks Toward Decision Making	Operative Supraventricular Arrhythmias After Cardiac Surgery: Meta- Analysis of Randomized Controlled Studies	
Anugula	Dixitha	Arrhythmias and Heart Failure	Prognostic Impact of Premature Atrial Complexes in the General Population: A Meta-Analysis of Observational Studies	Nothing to Disclose
Anuwatworn	Amornpol	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Comparison of Procedural Efficacy of Coronary Angiography in Octogenarian, Nonagenarian and General Population	Nothing to Disclose
Anuwatworn	Amornpol	Interventional Complexity and Complications	Patient Characteristics as Predictors of Transradial Approach Failure During Coronary Angiography Procedures	Nothing to Disclose
Anuwatworn	Amornpol	Interventional Complexity and Complications	The Effect of Body Mass Index on Procedural Efficacy in Transfemoral Versus Transradial Coronary Angiography	Nothing to Disclose
Anuwatworn	Amornpol	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Spontaneous Coronary Artery Dissection in Alport Syndrome	Nothing to Disclose
Anwaruddin	Saif	Frontier in New Transcatheter Techniques	Panelist	CONSULTANT FEES/HONORARIA - Edwards Lifesciences Medtronic. LLC
Anwaruddin	Saif	Transcatheter Mitral Valve Replacement	Case Presentation: Mitral TAVR (Ring or Valve)	CONSULTANT FEES/HONORARIA - Edwards
Anwaruddin	Saif	Interventional Cardiology: TAVR 1	TAVR Is Safe and Improves Cardiac Function in Patients With	Lifesciences,Medtronic, LLC CONSULTANT FEES/HONORARIA - Edwards
Anwaruddin	Saif	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology	Extremely Low Ejection Fractions Suggested Reviewer	Lifesciences,Medtronic, LLC CONSULTANT FEES/HONORARIA - Edwards Lifesciences,Medtronic, LLC
Anyanwu	Ani	Team 1 Highlighted Original Research: Vascular Medicine and the Year in Review	the Human Aorta That Exhibit Diminished Angiogenic Potential in	Nothing to Disclose
Aoi	Shunsuke	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Patients With Ascending Aortic Aneurysms Synergistic Effects of Coronary Calcification and Inflammation on Risks for Adverse Cardiovascular Events After PCI: Results From a	Nothing to Disclose
Aoki	Jiro		Large Single-Center Registry Elevated Right Sided Heart Pressure Is Associated With Malnutrition	Nothing to Disclose
		Other Novel Discoveries	in Heart Failure Patients With Reduced Ejection Fraction	

And The Contrag World of Lower Service State of Personage of Andrew Contrage World Personage Of Andrew Contrage Of Andrew Contrage World Personage Of Andrew Contrage Of Andrew C	Contract of the second				
Control Contro		First Name	Session Title The Evolving World of I VADs Transplant and	Presentation Title	Disclosures Nothing to Disclose
Approach Security Community Communit	AON	3110			Nothing to Disclose
Traggios Charles (Charles) Cha	Aonuma	Takanori			Nothing to Disclose
Consideration Consideratio				Hypertension in Japanese Population	
Section 2015 And 1920 Inches A	Aoun	Reem			Nothing to Disclose
Southeappoint of the Control of The American Control o				Performance Coronary Equipment	
Section of the sectio	Apaijai	Nattayaporn	Interventional Cardiology: Translation and Pre-		Nothing to Disclose
Acting to the company of the company			Clinical Research		
Service Servic	Apaijai	Nattayaporn		Lack of Testosterone in Obese-Insulin Resistant Condition	Nothing to Disclose
Appel Javenine Control			Failure		
Source Codespoed against Long Term Modeling and Encoundergraphs Response in CRY	Apor	Astrid	Heart Failure and Cardiomyopathies: Heart		Nothing to Disclose
Social Debugs State of Security Proposes Andrew Andr			Failure Gadgets Galore		
Notice Cruthrigh, Programs - Value of Service	Appel	Lawrence	Controversies in Hypertension		Nothing to Disclose
Applingsine Robert Fallouse Bootscamp Perspetated Validation Disease and Structural Heart Diseases Applingsine Robert Management of the Perspetated Validation Diseases and Structural Heart Diseases Applingsine Robert Management Man				Yes!	
Touchage the control of the control	Appis	Andrew	Nuclear Cardiology: Prognosis		Nothing to Disclose
Disease and Structural Heart Disease Propriegate Notest Not				Transplantation	
Newspream Paper Newspream Pa	Applegate	Robert		TAVR	
Economics in a New Ear. A Just Operation and Interventions and the intervention and the inter			Management		
Apprograft Robert Ro	Applegate	Robert		Co-Chair	
Appropries Robert Rober					RESEARCH/RESEARCH GRANTS - ADDOLL VASCUIAI
Meletring Call Liu La Leadership and incommon as have been a Act of Symposium common as have been a Act of Symposium and Interventional and the American Codings of Calledon and the American Codings of Calledon and Sharp Andrews (1994) and Interventional Candidators (1994) and Interventional Candid			and Interventions and the American College of		
Economics in a false Era. A Joint Symposium by the Society of Cardiology Cardiology and Policy Symposium by the Society of Cardiology Cardiology and Policy Symposium by the Standardon Phylogopa Symposium in Palarte Will Los Gooden Cardiology Cardiology and Policy Symposium in Palarte Will Los Gooden Cardiology Cardiol	Applegate	Robert		Integrating Expensive Technologies in the Cath Lab Budget	CONSULTANT FEES/HONORARIA - Abbott Vascular:
and intervancions and the American College of Contections of Plates Contections at Plates Propulations and Severe Andrea States Propulations and Severe Andrea States Propulations Propulations and Plates Plates Plates Propulations and Plates	, approgato	T CODOIC	Economics in a New Era: A Joint Symposium	Integrating Experience recombined on the east East East Section	
Contribution Robert Valvalar Disease Applications at Rate Valvalar Disease Applications at Rate Application Robert Valvalar Disease Applications at Rate Valvalar Disease Application at Rate Service Application Robert Valvalar Disease Application Robert Valvalar Disease Application Robert Valvalar Disease Application Robert File International Cardiology Comptive Performational Cardiology Performational Cardiology Performance Cardiology Comptive C					
Preserved Left Ventrolutar Ejection Praction and Severe And Server And Severe			Cardiology		
Services After Annie Verwitzung Franz (1994) Robert Vahrdar Heart Disease Antic Stenois Surger Risk Server Juverge Enchanteringsprite Severity of Antic Science Control Server Antic Stenois and Preserved Lett Vertricular Fundon Science Antic Stenois Anticome Lett Vertricular Fundon Science Antic Stenois Anticome Lett Vertricular Fundon Science Anticome Science Anti	Applegate	Robert	Valvular Disease Populations at Risk		
Applegate Robert Valvalar Heart Desase Antro Sistrose Surgest Res Scores Curvey Economy of Potential Processors (CARSULT ANT FERSANOVCRANIA - Abbott Vascular Scores Antro Sistrose and Preserved Left Verificable Foruntial Cardiology Complex Applegate Robert Robert Applegate Robert Robert Robert Applegate Robert R					RESEARCH/RESEARCH GRANTS - ADDOLL VASCUIAI
Sown-Actic Stenoces and Presenced Left VentroLiar Function Application Public Team 1 Patentic Commodifies Team 1 Patentic Commodifies Team 1 Application Applicati	Applegate	Robert	Valvular Heart Disease: Aortic Stenosis	Surgical Risk Scores Outweigh Echocardiographic Severity of Aortic	
Applegate Robert 15, proventional characteristics (Company Applegate Robert 15, proventional Challenging Cases: Fram 1 Applegate Robert 15, proventional Challenging Cases: Fram 15, proventional Challenging Cases: Fram 1 Applegate Robert 15, proventional Challenging Cases: Fram 1 Applegate Robert 15, prove					RESEARCH/RESEARCH GRANTS - Abbott Vascular
Pelentel Concribition Team 1 Applopate Robert Interventional Challenging Cases Reviewer Applopate Robert Interventional Challenging Cases Reviewer Applopate Robert Interventional Challenging Cases Reviewer Applopate Robert Rob					
Appropriate Personal Chailerging Case Team 1 AC Chailerging Case Team 2 Appropriate Constitution of the Chair and Peripheral Annex Diseases. Appropriate Constitution of the Chair and Peripheral Chair and State Inches Making Interventional Cardiology Acute and State Inches In	Applegate	Robert		Suggested Reviewer	
Appe Nachwel Processor States of Perspetral Appearance of Perspetral P	Applegate	Robert		ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular;
Active Diseases Referenciated Decision Maxing: Interventional Condition, Acute and Obelies Decision Maxing: Interventional Condition, Acute and Obelies Concernal Anguing. Application Melissa Concernal Anguing Management (Concernal Anguing) Revescularization and Outcomes Revescularization and Outcomes Acquino Melissa Concernal Anguing May Management (Concernal Anguing) Revescularization and Outcomes Reves	Annon	lehangir	Vascular Medicine: Aortic and Perinheral	Uncontrolled Hypertension in Acute Aartic Dissection Follow Un	
Aquino Melissa Coronary Angography, intra-Vascular Medical Melissa Coronary Angography, intra-Vascular Indiagna, Adaption Melissa Coronary Angography, intra-Vascular Inaging, Adaption Melissa Inaging, and Valuration and Outcomes and Large Report Melissa Inaging, and Valuration Melissa Inaging, and	Арроо	Jenangii			Notifing to Disclose
Melissa Cononary Angography, Intra Viscoular Maging, Revisional Experimental Cardiology, Proceedings of Patients With Melissa Revisional Experimental Cardiology, Proceedings of Patients With Melissa Revisional Cardiology, Proceedings of Patients With Melissa Cononary Angography, Intra Viscoular Imaging, Revisional Cardiology, Proceedings of Patients Cardiology, Proceedings of Patients With Melissa Cononary Angography, Intra Viscoular Imaging, Revisional Cardiology, Proceedings of Patients Cardiology, Proceedings of Patients (Patients of Patients of Pat	Apte	Nachiket		Spontaneous Coronary Artery Dissection in Alport Syndrome	Nothing to Disclose
Aquino Melissa Coronary Angiographyr, Infan Vasocular Imaging, Magographic Phenotype and Clinical Outcomes of Patients With Nothing to Disclose Multiplication and Outcomes of Melissa Coronary Angiographyr, Infan Vasocular Imaging, White Blood Cell Court and Najor Adverse Cardiovascular Events Angion (Males and Coronary Angiographyr, Infan Vasocular Imaging, Mark V					
Aquino Melissa Coronary Angography, Intra-Vascular Imagina, White Blood Cell Court and Major Adverse Cardiovascular Events Nothing to Disclose Revescularization and Outcomes Arguino Melissa Coronary Angography, Intra-Vascular Imagina, Philine Blood Cell Court and Major Adverse Cardiovascular Events Access Centerpolary Extra- Insights From the PAXES Study Aquino Melissa Timety Topics in Acute Coronary Syndromes With Percularianous Coronary Internation and Inflammation on Registry Aquino Melissa Timety Topics in Acute Coronary Syndromes With Percularianous Coronary Internation on Cardiology, PCI in Complex Palents Anguino Melissa Televentrional Cardiology, TAVR 4 Transcardiology, Anguino Melissa Transpale Palents Transpale Melissa Televentrional Cardiology, TAVR 4 Transcardiology, TAVR 4 Transcardiology, Anguino Melissa Transp	Aquino	Melissa	Coronary Angiography, Intra-Vascular Imaging,		Nothing to Disclose
Revescularization and Outcomes Aguino Melissa Coronary Angiography, Iritar-Vascular Imaging From the PASIS Study Revision and Outcomes Revision and Outcom	Aguino	Melissa			Nothing to Disclose
Aquino Melissa Coronary Angiography, Intra-Vascular Imaging Revisevers and Large Single-Center Registry Medical Property of the Procession of the Procession of the Property of the Procession of the Property of the Procession of the Property of the Procession o	1.			After Percutaneous Coronary Intervention in the Contemporary Era:	3
Revascularization and Outcomes Risks for Adverse Cardiovascular Events After PC: Results From a Large Single-Center Registry Aquino Melissa Timely Topics in Acute Coronary Syndromes Very Policy Coronary Intervention of Acute Coronary Intervention Very Policy Coronary Int	Aguino	Melissa	Coronary Angiography, Intra-Vascular Imaging		Nothing to Disclose
Aquino Melissa Timely Topics in Acute Coronary Syndromes With Percutaneous Coronary Intervention of Acute Coronary May Percutaneous Coronary Intervention of Acute Coronary Syndromes (May Percutaneous Coronary Intervention of Acute Coronary Syndromes) (May Percutaneous Coronary Intervention of Acute Coronary Intervention of Acute Coronary Syndromes) (May Percutaneous Coronary Intervention of Acute Coronary Intervention of Acute Coronary Syndromes) (May Percutaneous Coronary Intervention of Syndromes) (May Percut	1.			Risks for Adverse Cardiovascular Events After PCI: Results From a	3
Melissa Interventional Cardiology, PCI in Complex Patients Interventional Cardiology, PCI in Complex Patients Interventional Cardiology, PCI in Complex Patients Identification of Patients Interventional Cardiology, TAVR 4 Interventional Cardiology, TAVR 3 Interventional Cardiology, TAVR 4 Interventional Cardiology, TAVR 3 Interventional Cardiology, PCI in Complex Patients Interventional Cardiology, PCI in Complex Patients Interventional Cardiology, Angiography, Intravascular Imaging and Interventional Cardiology, Angiography, Intravascular Imaging and Interventional Cardiology, TAVR 4 Interventional Cardiology, Angiography, Intravascular Imaging and Interventional Cardiology, TAVR 4 Interventional Cardiology, Angiography, Intravascular Imaging and Interventional Cardiology, TAVR 4 Interventional Cardiology, Angiography, Intravascular Imaging and Interventional Cardiology, TAVR 4 Interventional Cardiology, Cardiology, Angiography, Intravascular	Aguino	Melissa	Timely Topics in Acute Coronary Syndromes		Nothing to Disclose
Aquino Melissa Interventional Cardiology; PCI in Complex Patents Patents Aragam Jayashri 28, Non Invasive Imaging; Echo Team 1 Aragam A	Aquillo	Weilood	Timely Topics in Acute Goronary Cyndronics	With Percutaneous Coronary Intervention for Acute Coronary	Houring to Disclose
Patients Aragam Jayashri Jayashri 28, Non Invasive Imaging: Echo Team 1 Aragam Krishna FTC Clinical Decision Making Reviewers 3 Aragam Krishna FTC Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Arai Andrew FTC Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Arai Andrew FTC Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Arai Andrew Mon Invasive Imaging: MR Heart Fallure and Pulmonary Physicians Making: Non-Invasive Imaging And Valvular Heart Disease Arai Andrew Roman Making: Non-Invasive Imaging: MR Heart Fallure and Pulmonary Hysiertension Arai Andrew FTC Clinical Decision Making: Non-Invasive Imaging: MR Heart Fallure and Pulmonary Hysiertension Arai Andrew FTC Clinical Decision Making: Non-Invasive Imaging: MR Heart Fallure and Pulmonary Hysiertension Arai Andrew Sp. Non Invasive Imaging: MR Heart Fallure and Pulmonary Hysiertension Arai Andrew Sp. Non Invasive Imaging: MR Team 1 Suggested Reviewer Right Heart Fallure and Pulmonary Hysiertension Sp. Arai Pathanide Interventional Cardiology: TAWR 4 Arai Takahide Interventional Cardiology: TAWR 4 Arai Interventional Cardiology: TAWR 4 Arai Interventional Cardiology: TAWR 3 Arai Andrew Salman Interventional Cardiology: TAWR 3 Arai Andrew Salman Interventional Cardiology: TAWR 4 Arai Andrew Salman Interventional Cardiology: TAWR 4 Arai Interventional Cardiology: Arai Arai Interventional Cardi	Aguino	Melicea	Interventional Cardiology: PCI in Complex		Nothing to Disclose
Aragam Krishna FTC Clinical Decision Making Reviewers 3 Aragi Andrew FTTC Clinical Decision Making Reviewer FTC Clinical Decision Making Reviewer FTC Clinical Decision Making Non-Invasive Inaging and Valvular Heart Disease FTC Clinical Decision Making Non-Invasive Inaging and Valvular Heart Disease FTC Clinical Decision Making Non-Invasive Inaging and Valvular Heart Disease FTC Clinical Decision Making Non-Invasive Inaging and Valvular Heart Disease FTC Clinical Decision Making Non-Invasive Inaging Making Non-Invasive Inaging Making Prevention, Advinary Invasive Inaging MR Heart Failure and Pulmonary Hypertension Prom Thyroloxicosis Cardiovoscular Magnetic Resonance in the Evaluation of Fibrofatty Infiltration for Arrhythrogenic Right Verticular Dysglassis/Cardiomyogathy (ARVDC) Arai Andrew FTC Clinical Decision Making Prevention, Advinary Invasive Invaging MR Heart Failure and Pulmonary Hypertension (Congential and Congential Heart Disease) Arai Andrew FTC Clinical Decision Making Prevention, Advinary Invasive Invaging MR Heart Failure and Pulmonary Hypertension (Congential Evalve Invasive Invaging MR Team 1 (Arvance of Physical Exam in Identifying a Coronary-Cameral Fistual Interventional Cardiology TAVR 4 (Inportance of Physical Exam in Identifying a Coronary-Cameral Fistual Interventional Cardiology TAVR 4 (Inportance of Physical Exam in Identifying a Coronary-Cameral Fistual Interventional Cardiology TAVR 4 (Inportance of Physical Exam in Identifying a Coronary-Cameral Fistual Interventional Cardiology TAVR 4 (Inportance of Physical Exam in Identifying a Coronary-Cameral Fistual Interventional Cardiology TAVR 4 (Inportance of Physical Exam in Identifying a Coronary-Cameral Fistual Interventional Cardiology TAVR 4 (Inportance Interventional	Aquillo	Iviciissa	Patients	and Males After Percutaneous Coronary Intervention	Nothing to Disclose
Arai Andrew FIT Clinical Decision Making; Non-Invasive Imaging and Valvalural Heart Disease Pseudo-Sequestration Productions Imaging and Valvalural Heart Disease Pseudo-Sequestration Productions Imaging and Valvalural Heart Disease Pseudo-Sequestration Pulmonary Hypertension Promotypotation Productions Pr	Aragam				
Imaging and Valvular Heart Disease	Aragam Arai			The Pulmonary Embolism That Wasn't: A Case of Pulmonary	
Imaging and Valvular Heart Disease Arai Andrew Andrew Non Invasive Imaging, MR Heart Failure and Pulmonary Hypertension Pulmonary Hyperte	Arai	Androw	Imaging and Valvular Heart Disease	Pseudo-Sequestration	•
Arai Andrew Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension Pulmonary Hyp	Midi	Andrew		From Thyrotoxicosis	RESEARCH/RESEARCH GRANTS - Bayer, Siemens
Arai Andrew FIT Clinical Decision Making: Prevention, Adult Importance of Physical Exam in Identifying a Coronary-Cameral Fishula Andrew 29. Non Invasive Imaging: MR Team 1 Suggested Reviewer Arai Takahide Interventional Cardiology: TAVR 4 Transcatheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Interventional Cardiology: TAVR 3 Transcatcheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Interventional Cardiology: TAVR 3 Transcatcheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Interventional Cardiology: TAVR 3 Transcatcheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Interventional Cardiology: TAVR 3 Transcatcheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Interventional Cardiology: TAVR 3 Transcatcheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Interventional Cardiology: TAVR 3 Transcatcheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Interventional Cardiology: TAVR 3 Transcatcheter Aortic Valve Implantation in Changas' Heart Disease Interventional Cardiology: PCI in Complex Araki Hiroshi Interventional Cardiology: PCI in Complex Patients	Arai	Andrew	Non Invasive Imaging: MR Heart Failure and	Cardiovascular Magnetic Resonance in the Evaluation of Fibrofatty	RESEARCH/RESEARCH GRANTS - Bayer, Siemens
Arai Andrew FIT Clinical Decision Making: Prevention, Adult Importance of Physical Exam in Identifying a Coronary-Cameral RESEARCH/RESEARCH GRANTS - Bayer, Siemens Fistula Arai Andrew 29. Non Invasive Imaging: MR Team 1 Transcatheter Aortic Valve Implantation in Patients With an Interventional Cardiology: TAVR 4 Transcatheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Arain Salman Interventional Cardiology: TAVR 3 Transpalcal TAVR in Men but Not in Women Araiza Garaygordobil Diego Emerging Developments in HFpEF and Arrythmias Chronic Total Occulused Coronary Arrythmias Araki Hiroshi Advances in Chronic Total Occulusion Intervention Arrythmias Interventional Cardiology: PCI in Complex Chronic Stent Recoil During Follow-Up in Severely Calcified Coronary Artery Lesions: An Optical Coherence Tomography Study Araki Makoto Interventional Cardiology: Agiography, Intravascular Imaging and Interventional Cardiology: TAVR 4 Transcatheter Aortic Valve Implantation in Chages Heart Diseases Araki Makoto Unusual Presentations of ACS Compars and Prevention Cardiology: TAVR 4 Transcatheter Aortic Valve Implantation in Patients Nothing to Disclose Araki Makoto Unusual Presentations of ACS Compars Artery Lesions: An Optical Coherence Tomography-Defined Insterventional Cardiology: Agiography, Intravascular Imaging and Interventional Cardiology: TAVR 4 Transcatheter Aortic Valve Implantation in Patients With an Innovations in Practice Management and Social Media On Innovations in Practice Management and Social Media On Innovations in Practice Management and Juan Innovations in Practice Management and Juan 14. Heart Failure and Cardiomyopathies: Suggested Reviewer Consultation in Patients With an Extremely Standard Provided Patients Consultation in Patients With an Interventional Cardiomyopathies: Suggested Reviewer Consultation in Patients Patients Consultation in Patients Patients Patients Patienter Patients Patienter Patients Patienter Patients Patienter Patienter Patienter Patienter Patienter Patiente			Pulmonary Hypertension		
Arai Andrew 29. Non Invasive Imaging: MR Team 1 Takahide Interventional Cardiology: TAVR 4 Arain Takahide Interventional Cardiology: TAVR 4 Arain Salman Interventional Cardiology: TAVR 3 Arain Diego Emerging Developments in HFpEF and Arryhthmias Arain	Arai	Andrew		Importance of Physical Exam in Identifying a Coronary-Cameral	RESEARCH/RESEARCH GRANTS - Bayer, Siemens
Arain Takahide Interventional Cardiology: TAVR 4 Extremely Small Annulus Salman Interventional Cardiology: TAVR 3 Transcatheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Salman Interventional Cardiology: TAVR 3 Transcatheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Salman Interventional Cardiology: TAVR 3 Transcatheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Nothing to Disclose Compared to Transfermoral TAVR in Men but Not in Women Nothing to Disclose Compared to Transfermoral TAVR in Men but Not in Women Nothing to Disclose Patients Predicting Left Ventricular Dysfunction in Chagas' Heart Disease The Impact of Recanalization of Chronic Total Occuluded Coronary Nothing to Disclose Intervention Intervention Intervention Coronary Aftery on Electrophysiological Substrate of Left Ventricle Araki Hiroshi Interventional Cardiology: PCI in Complex Patients Chronic Stent Recoil During Follow-Up in Severely Calcified Coronary Aftery Lesions: An Optical Coherence Tomography Subdivided Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Assessed by Serial Intravascular Ultrasound Examinations in Late and Very Late Drug-Eliufing Stent Failure Araki Makoto Unusual Presentations of ACS Comparison Between Angioscopic and Optical Coherence Tomography Subdivided Interventional Cardiology: TAVR 4 Extremely Small Annulus Intervention in Patients With an Extremely Small Annulus Unional Innovations in Practice Management and Social Media Unional Innovations in Practice Management and Social Media Unional Interventional Cardiomyopathies: Suggested Reviewer Consultant FEES/HONORARIA - Zoll Implementation for Smarter Management and Resource Use for Today's Complex Care Delivery Consultant FEES/HONORARIA - Zoll			Congenital and Congenital Heart Disease	Fistula	
Extremely Small Annulus	Arai				
Arain Salman Interventional Cardiology: TAVR 3 Transapical TAVR is Associated With Higher Morbidity and Mortality Compared to Transfernoral TAVR in Men but Not in Women Nothing to Disclose Araiza Garaygordobil Diego Emerging Developments in HFpEF and Arryhthmias Predicting Left Ventricular Dysfunction in Chagas' Heart Disease Araki Hiroshi Advances in Chronic Total Occlusion Intervention Interventional Cardiology: PCI in Complex Patients Chronic Stent Recoil During Follow-Up in Severely Calcified Coronary Artery on Electrophysiological Substrate of Left Ventricle Araki Makoto Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Seenal Intravascular Imaging and Interventional Cardiology: Angiography Seenal Intravascular Imaging and Interventional Cardiology: Angiography Seenal Intravascular Intravas	Arai	Takahide	Interventional Cardiology: TAVR 4		Nothing to Disclose
Araiza Garaygordobil Diego Emerging Developments in HFpEF and Arryhthmias Araiza Garaygordobil Hiroshi Advances in Chronic Total Occlusion Intervention Intervention Araki Hiroshi Interventional Cardiology: PCI in Complex Patients Araki Makoto Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: PCI in Complex Araki Makoto Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography Intravascular Imaging Angiography Intravascular Imaging Angiography Intravascular Imaging Angiography Intravascular Imaging Angiogr	Arain	Salman	Interventional Cardiology: TAVR 3	Transapical TAVR Is Associated With Higher Morbidity and Mortality	Nothing to Disclose
Araki Hiroshi Advances in Chronic Total Occlusion The Impact of Recanalization of Chronic Total Occluded Coronary Nothing to Disclose Araki Hiroshi Interventional Cardiology: PCI in Complex Patients Araki Hiroshi Interventional Cardiology: PCI in Complex Patients Araki Makoto Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Araki Makoto Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Araki Makoto Unusual Presentations of ACS Comparison Between Angioscopic and Optical Coherence Araki Makoto Unusual Presentations of ACS Comparison Between Angioscopic and Optical Coherence Tomography Study Araki Motoharu Interventional Cardiology: TAVR 4 Transcatheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Aranda Juan Innovations in Practice Management and Social Media Uniox Scanding the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for Today's Complex Care Delivery Aranda Juan 14. Heart Failure and Cardiomyopathies: Suggested Reviewer Consult Tars Excelled Process Consult Tars Excelled Reviewer Consult Tars Excelled Process Patients Tars Excelled Reviewer Consult Tars Excelled Process Patients Tars Excelled Reviewer Consult Tars Excelled Reviewer Consult Tars Excelled Reviewer Consult Tars Excelled Process Patients Tars Excelled Process Patients Tars Excelled Reviewer Consult Tars Excelled Process Patients Tars Excelled Process Patients Tars Patients				Compared to Transfemoral TAVR in Men but Not in Women	
Araki Hiroshi Advances in Chronic Total Occlusion The Impact of Recanalization of Chronic Total Occluded Coronary Nothing to Disclose Araki Hiroshi Interventional Cardiology: PCI in Complex Patients Araki Hiroshi Interventional Cardiology: PCI in Complex Patients Araki Makoto Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Araki Makoto Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Araki Makoto Unusual Presentations of ACS Comparison Between Angioscopic and Optical Coherence Araki Makoto Unusual Presentations of ACS Comparison Between Angioscopic and Optical Coherence Tomography Study Araki Motoharu Interventional Cardiology: TAVR 4 Transcatheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Aranda Juan Innovations in Practice Management and Social Media Uniox Scanding the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for Today's Complex Care Delivery Aranda Juan 14. Heart Failure and Cardiomyopathies: Suggested Reviewer Consult Tars Excelled Process Consult Tars Excelled Reviewer Consult Tars Excelled Process Patients Tars Excelled Reviewer Consult Tars Excelled Process Patients Tars Excelled Reviewer Consult Tars Excelled Reviewer Consult Tars Excelled Reviewer Consult Tars Excelled Process Patients Tars Excelled Process Patients Tars Excelled Reviewer Consult Tars Excelled Process Patients Tars Excelled Process Patients Tars Patients	Araiza Garaygordobil	Diego			Nothing to Disclose
Intervention Artery on Electrophysiological Substrate of Left Ventricle Araki Hiroshi Interventional Cardiology: PCI in Complex Patients Chronic Stent Recoil During Follow-Up in Severely Calcified Coronary Artery Lesions: An Optical Coherence Tomography Study Araki Makoto Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Araki Makoto Unusual Presentations of ACS Comparison Between Optical Coherence Tomography-Defined In- Seesal During Stent Failure Araki Makoto Unusual Presentations of ACS Comparison Between Angioscopic and Optical Coherence Tomographic Assessment of Instent Restenosis Araki Motoharu Interventional Cardiology: TAVR 4 Transcatheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Unlocking the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for Today's Complex Care Delivery Aranda Juan Interventional Cardiomyopathies: Unclaim Section Practice Management and Cardiomyopathies: Aranda Juan Interventional Cardiomyopathies: Interventional Cardiomyopathies: Aranda Juan Interventional Cardiomyopathies: Interventional Cardiomyopathies: Aranda Juan Interventional Cardiomyopathies: Interventional Cardiomyopathies: Interventional Cardiomyopathies: Interventional Cardiomyopathies: Aranda Juan Interventional Cardiomyopathies: Interv		-	Arryhthmias	Predicting Left Ventricular Dysfunction in Chagas' Heart Disease	-
Araki Hiroshi Interventional Cardiology: PCI in Complex Coronary Artery Lesions: An Optical Coherence Tomography Study Araki Makoto Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CTMR Assessed by Serial Intravascular Unisual Presentations of ACS Comparison Between Angioscopic and Optical Coherence Tomography-Defined Instent Remodeling Assessed by Serial Intravascular Ultrasound Examinations in Late and Very Late Drug-Eluting Stent Failure Araki Makoto Unusual Presentations of ACS Comparison Between Angioscopic and Optical Coherence Tomography-Defined Instent Restancial Programment of Instent Restancial Programment of Instent Restancial Programment of Instent Restancial Programment of Instent Restancial Instent Restancial Innovations in Practice Management and Social Media Unicoking the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for Today's Complex Care Delivery Aranda Juan 14. Heart Failure and Cardiomyopathies: Sugested Reviewer Consultant Fees/Honoraria - Zoll	Arakı	HIFOShi			Notning to Disclose
Patients Coronary Artery Lesions: An Optical Coherence Tomography Study Araki Makoto Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Assessed by Serial Intravascular Itravascular Itravas					
Araki Makoto Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Selationship Between Optical Coherence Tomography-Defined In-Stent Arterial Remodeling Assessed by Serial Intravascular Ultrasound Examinations in Late and Very Late Drug-Eutling Stent Failure Araki Makoto Unusual Presentations of ACS Comparison Between Angioscopic and Optical Coherence Tomographic Assessment of Instent Restenosis Araki Motoharu Interventional Cardiology: TAVR 4 Transcathler Aortic Valve Implantation in Patients With an Extremely Small Annulus Aranda Juan Innovations in Practice Management and Social Media Unusual Presentations of Acronal Social Media Unusual Presentation of Smarter Management and Resource Use for Today's Complex Care Delivery Aranda Juan 14. Heart Failure and Cardiomyopathies: Suggested Reviewer CONSULTANT FEES/HONORARIA - Zoll	Araki	Hıroshi			Nothing to Disclose
Intravascular Imaging and Interventional CTMR Assessment of Interventional CTMR Assessment of Instent Restancial Remodeling Araki Makoto Unusual Presentations of ACS Comparison Between Angioscopic and Optical Coherence Tomographic Assessment of Instent Restancial Programment of				. ,	
Assessed by Serial Intravascular Ultrasound Examinations in Late and Very Late Drug-Eluting Stent Failure Araki Makoto Unusual Presentations of ACS Comparison Between Angioscopic and Optical Coherence Tomographic Assessment of Instent Restenosis Araki Motoharu Interventional Cardiology: TAVR 4 Transcatheter Aortic Valve Implantation in Pattents With an Extremely Small Annulus Aranda Juan Innovations in Practice Management and Social Media Unlocking the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for Today's Complex Care Delivery Aranda Juan 14. Heart Failure and Cardiomyopathies: Suggested Reviewer CONSULTANT FEES/HONORARIA - Zoll	Araki	Makoto			Nothing to Disclose
Araki Makoto Unusual Presentations of ACS Comparison Between Angioscopic and Optical Coherence Tomographic Assessment of Instent Restenosis Araki Motoharu Interventional Cardiology: TAVR 4 Transcatheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Aranda Juan Innovations in Practice Management and Social Media Unlocking the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for Today's Complex Care Delivery Aranda Juan 14. Heart Failure and Cardiomyopathies: Sugested Reviewer CONSULTANT FEES/HONORARIA - Zoll				Assessed by Serial Intravascular Ultrasound Examinations in Late	
Araki Motoharu Interventional Cardiology: TAVR 4 Transcatheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Aranda Juan Innovations in Practice Management and Social Media Today Complex Care Delivery Aranda Juan 14. Heart Failure and Cardiomyopathies: Suggested Reviewer Consultations in Statement Restences OTHER - Edwards Life Science Extremely Small Annulus Unlocking the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for Today's Complex Care Delivery Aranda Juan 14. Heart Failure and Cardiomyopathies: Suggested Reviewer CONSULTANT FEES/HONORARIA - Zoll	Araki	Makata	Uniquel Presentations of ACC	and Very Late Drug-Eluting Stent Failure	Nothing to Displace
Araki Motoharu Interventional Cardiology: TAVR 4 Transcatheter Aortic Valve Implantation in Patients With an Extremely Small Annulus Aranda Juan Innovations in Practice Management and Social Media Unlocking the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for Today's Complex Care Delivery Aranda Juan 14. Heart Failure and Cardiomyopathies: Sugested Reviewer CONSULTANT FEES/HONORARIA - Zoll	Maki	IVIAKULU	Unusual Presentations of ACS		Induling to Disclose
Aranda Juan Innovations in Practice Management and Social Media Unlocking the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for Today's Complex Care Delivery Aranda Juan 14. Heart Failure and Cardiomyopathies: Suggested Reviewer CONSULTANT FEES/HONORARIA - Zoll	Araki	Motoharu	Interventional Cardiology: TAVR 4	Transcatheter Aortic Valve Implantation in Patients With an	OTHER - Edwards Life Science
Social Media Implementation for Smarter Management and Resource Use for Today's Complex Care Delivery Aranda Juan 14. Heart Failure and Cardiomyopathies: Sugested Reviewer CONSULTANT FEES/HONORARIA - Zoll	Aranda	Juan	Innovations in Practice Management and		CONSULTANT FEES/HONORARIA - Zoli
Aranda Juan 14. Heart Failure and Cardiomyopathies: Suggested Reviewer CONSULTANT FEES/HONORARIA - Zoll	**			Implementation for Smarter Management and Resource Use for	
	Aranda	Juan	14. Heart Failure and Cardiomyonathies		CONSULTANT FEES/HONORARIA - Zoli
					The state of the s



Last Name	First Name	Session Title	Presentation Title	Disclosures
Arantes	Flavia	Emerging Basic Science in Ischemic Heart Disease	Platelet Aggregability, Coagulation, Fibrinolysis and Inflammation in Patients With Coronary Artery Disease and Previous Cerebrovascular Ischemic Event	Nothing to Disclose
Arantes	Flavia	Antithrombotic Therapy in Ischemic Heart Disease	Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease	Nothing to Disclose
Arany Araoz	Zoltan Philip	Pregnancy and Heart Disease Novel Determinants of Outcomes in VHD	Peripartum Cardiomyopathy – Genetic Basis Impact of Aortic Valve Calcification and Sex on Hemodynamic Progression and Clinical Outcomes in Aortic Stenosis	Nothing to Disclose Nothing to Disclose
Araujo	Claudio	I Can Do WHAT After My Heart Attack?	Panelist	OTHER - Inbrasport
Araujo Araujo	Claudio Claudio	I Can Do WHAT After My Heart Attack? Hearts and Soles: Multimodality Imaging in	When Can I Have Sex? ACC Poster Moderator	OTHER - Inbrasport OTHER - Inbrasport
-	Ciaddio	Athletes		
Arbab-Zadeh	Armin	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Calcium Characteristics as Predictors of Major Adverse Cardiac Events in Symptomatic Patients: Insights From the CORE320 Multinational Study	CONSULTANT FEES/HONORARIA - Lead Physicians,LEK consulting
Arbune	Amit	Advances in HCM, PPCM and Other Cardiomyopathies	Takotsubo Cardiomyopathy (TCM) Increases Risk of Lethal Arrhythmias	Nothing to Disclose
Arbune	Amit	FIT Clinical Decision Making: Arrhythmias and Clinical Electrophysiology	Paradoxical Hypertensive Adverse Reaction to Nitroglycerine During Tilt Table Test Unmasking Undiagnosed Pheochromocytoma: A Case Report	Nothing to Disclose
Ardati	Amer	Interdisciplinary Cardiovascular Team Collaboratives in Care	Leveraging Our Strengths: Clinical Pharmacist Mediated PCSK9 Utilization	CONSULTANT FEES/HONORARIA - CSI,St. Jude Medical
Arena	Giulia	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Relationship Between Fractional Flow Reserve (FFR) and Coronary Flow Reserve (CFR) by PET in Identifying Coronary Stenosis Causing Myocardial Ischemia	Nothing to Disclose
Arena	Ross	Making Progress in Understanding Heart Failure	Arterial Elastance Drives Ventilatory Inefficiency in Systolic Heart Failure	Nothing to Disclose
Arena	Ross	Measuring Success in Cardiac Rehabilitation	Search for the Super-Responder: Progressive Increases in Fitness and an Association With Lower Mortality	Nothing to Disclose
Arena	Ross	Emerging Developments in HFpEF and Arryhthmias	Early Diastolic Mitral Annular Velocity at Peak Exercise Determines Peak Aerobic Exercise Capacity in Heart Failure With Preserved	Nothing to Disclose
Arena	Ross	Obesity Management in 2017: Weighing the Issues	Ejection Fraction Fitness and the Obesity Paradox in Cardiac Rehabilitation: How Does Weight Loss Factor in?	Nothing to Disclose
Arenas	Ivan	Insights Into Ischemic Heart Disease: Stable to Erosive Plaques	Urinary Lead Excretion Correlates With Overall Toxic Metal Excretion in Patients With Coronary Artery Disease: A Sentinel Biomarker?	Nothing to Disclose
Arendt	Katherine	Pregnancy and Heart Disease	Panelist	Nothing to Disclose
Arendt	Katherine	Pregnancy and Heart Disease	Cardiovascular Emergencies in Pregnancy	Nothing to Disclose
Argenziano	Michael	17. Interventional Cardiology: Aortic Valve Disease Team 3	Suggested Reviewer	Nothing to Disclose
Argueta	Erwin	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Recurrent Atrial Myxoma, Right Atriotomy and Sinus Node Dysfunction	Nothing to Disclose
Argulian Argulian	Edgar Edgar	Unusual Presentations of ACS Which Test Is Best for Pain in the Chest?	Clinical Outcomes of the Treatment of Cocaine Induced Chest Pain With Beta Blockers: A Meta-Analysis Outcomes in Patient With Chest Pain Evaluated Using Coronary	Nothing to Disclose Nothing to Disclose
Argullari	Eugai		Computed Tomography Angiography Versus Stress Imaging: A Meta-Analysis of Randomized Trials	Notifing to Disclose
Arias-Mendoza	Alexandra	STEMI in the Emerging World: International Perspectives From the Cardiological Society of India, Mexican Society of Cardiology, and American College of Cardiology	STEMI Reperfusion in Developing Countries	Nothing to Disclose
Arias-Mendoza	Alexandra	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Derivation and Validation of a Simple Inflammation Based Risk Score for Predicting In-Hospital Mortality in Acute Coronary Syndrome	Nothing to Disclose
Ariti	Cono	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study	Nothing to Disclose
Ariyachaipanich	Aekarach	Heart Failure and Cardiomyopathies: Is Heart	Effect of Coenzyme Q10 on Left Ventricular Remodeling and	Nothing to Disclose
Ariyachaipanich	Aekarach	Failure With a Normal EF for Real? Emerging Applications of Echocardiography	Mortality in Patients With Heart Failure: A Meta-Analysis Echocardiographic Assessment of Right Ventricular Function in Acute Right Ventricular Failure Identified by Hemodynamic Criteria	Nothing to Disclose
Ariyachaipanich	Aekarach	Innovations in Advocacy and Patient Centered	Impact of Gender on Outcomes Among Patients With Acute Coronary Syndrome Undergoing Primary Percutaneous Coronary	Nothing to Disclose
Ariyarathna	Nilshan	Care Innovative Approaches for Reducing Risk and	Intervention in Southeast Asia	Nothing to Disclose
		Improving Outcomes With Ablation	A Systematic Review and Meta-Analysis	,
Ariyarathna	Nilshan	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Catheter Ablation Versus Medical Therapy for Treatment of VT Associated With Structural Heart Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Armstrong	Aimee	Six Years of Making an IMPACT	Panelist	CONSULTANT FEES/HONORARIA - Abbott,B. Braun Interventional Systems Inc.,Edwards Lifesciences; RESEARCH/RESEARCH GRANTS - Abbott,Edwards Lifesciences,MEDTRONIC,pfm medical, Inc.
Armstrong	Aimee	Six Years of Making an IMPACT	Making an IMPACT: Using the Registry for QI	CONSULTANT FEES/HONORARIA - Abbott, B. Braun Interventional Systems Inc., Edwards Lifesciences; RESEARCH/RESEARCH GRANTS - Abbott, Edwards Lifesciences, MEDTRONIC, pfm medical, Inc.
Armstrong	Aimee	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Safety and Feasibility of Melody Transcatheter Pulmonary Valve Replacement in the Native Right Ventricular Outflow Tract: A Multicenter Study	CONSULTANT FEES/HONORARIA - Abbott, B. Braun Interventional Systems Inc., Edwards Lifesciences; RESEARCH/RESEARCH GRANTS - Abbott, Edwards Lifesciences, MEDTRONIC, pfm medical, Inc.
Armstrong	Ehrin	Fellows Bootcamp: Peripheral Vascular Disease and Structural Heart Disease Management	Infrapopliteal and CLI	CONSULTANT FEES/HONORARIA - Abbott Vascular, Abiomed, Boston Scientific, Cardiovascular Systems, MEDTRONIC, Spectranetics
Armstrong	Ehrin	Controversies and Strategies for Endovascular Treatment of the Femoropopliteal Segment	How to Treat Complex FP Disease: PTA, DCB, Atherectomy, Stent but Little Comparative Data. Is There Such a Thing as "Best Practice?"	CONSULTANT FEES/HONORARIA - Abbott Vascular, Abiomed, Boston Scientific, Cardiovascular Systems, MEDTRONIC, Spectranetics
Armstrong	Ehrin	Controversies and Strategies for Endovascular Treatment of the Femoropopliteal Segment	Vascular Access Options for Femoropopliteal Intervention: How I Decide on Point of Access, Orientation of Sheath, Interventional “:Platform" and Patient Position	CONSULTANT FEES/HONORARIA - Abbott Vascular, Abiomed, Boston Scientiffic, Cardiovascular Systems, MEDTRONIC, Spectranetics
Armstrong	Ehrin	Recent ACS Trials: Relevance to My Daily Practice	EARLY BAMI: Role of Beta Blockers in STEMI	Systems, MEDTRONIC, Spectranetics CONSULTANT FEES/HONORARIA - Abbott Vascular, Abiomed, Boston Scientific, Cardiovascular Systems, MEDTRONIC, Spectranetics
Armstrong	Ehrin	Contemporary Role of Intracoronary Imaging: Candid Conversation with Peers	The Value Proposition of Intracoronary Imaging in Contemporary Practice	CONSULTANT FEES/HONORARIA - Abbott Vascular, Abiomed, Boston Scientific, Cardiovascular Systems, MEDTRONIC, Spectranetics
Armstrong	Ehrin	The Best Coronary and Peripheral Interventional Challenging Cases	ACC Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular,Abiomed,Boston Scientific,Cardiovascular
Armstrong	Ehrin	Head to Toe: Outcomes of Endovascular Interventions	Atherectomy Is Associated With Lower Rates of Repeat Intervention After Below Knee Peripheral Vascular Intervention	Systems,MEDTRONIC,Spectranetics CONSULTANT FEES/HONORARIA - Abbott Vascular,Abiomed,Boston Scientific,Cardiovascular Systems,MEDTRONIC,Spectranetics
				1.1.

Last Name Armstrong	First Name Ehrin	Session Title Head to Toe: Outcomes of Endovascular	Presentation Title Utilization of Distal Embolic Protection in Infrainguinal Peripheral	Disclosures CONSULTANT FEES/HONORARIA - Abbott
		Interventions	Arterial Intervention: Insights From the Multicenter XLPAD Registry	Vascular, Abiomed, Boston Scientific, Cardiovascular Systems, MEDTRONIC, Spectranetics
Armstrong	Ehrin	Head to Toe: Outcomes of Endovascular Interventions	Association of Cigarette Smoking With Procedural Cost of Lower Extremity Endovascular Intervention	CONSULTANT FEES/HONORARIA - Abbott Vascular, Abiomed, Boston Scientific, Cardiovascular Systems, MEDTRONIC, Spectranetics
Armstrong	Ehrin	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Coronary Atherectomy for Treatment of Calcified Coronary Artery Lesions is Associated With Increased Procedural Success and Lower Procedural Complication Rates: Insights From a National Veteran Cohort	CONSULTANT FEES/HONORARIA - Abbott Vascular, Abiomed, Boston Scientific, Cardiovascular Systems, MEDTRONIC, Spectranetics
Armstrong	Ehrin	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Contemporary Use of Laser During Percutaneous Coronary Intervention: Results From the Laser Veterans Affairs (LAVA) Multicenter Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular, Abiomed, Boston Scientific, Cardiovascular
Armstrong	Ehrin	Endovascular Therapy: Running From Risk	Predictors of Procedural Complications in Infrainguinal Endovascular Interventions	Systems, MEDTRONIC, Spectranetics CONSULTANT FEES/HONORARIA - Abbott Vascular, Abiomed, Boston Scientific, Cardiovascular Systems, MEDTRONIC, Spectranetics
Armstrong	Ehrin	Highlights in Vascular Medicine Research	Comparative Assessment of Subintimal Versus Intraluminal Crossing of Infrainguinal Chronic Total Occlusion Lesions	CONSULTANT FEES/HONORARIA - Abbott Vascular,Abiomed,Boston Scientific,Cardiovascular
Armstrong	Ehrin	02. Acute and Stable Ischemic Heart Disease: Clinical Team 4	Suggested Reviewer	Systems,MEDTRONIC,Spectranetics CONSULTANT FEES/HONORARIA - Abbott Vascular,Abiomed,Boston Scientific,Cardiovascular
Armstrong	Paul	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Timing and Clinical Predictors of Early Versus Late Readmission Among Patients Hospitalized for Acute Heart Failure: Insights From ASCEND-HF	Systems.MEDTRONIC.Spectranetics CONSULTANT FEES/HONORARIA - Merck; DATA SAFETY MONITORING BOARD - MAST Theraputics; OTHER - AstraZeneca; RESEARCH/RESEARCH GRANTS - Bayer,Merck,Sanofi-Aventis
Armstrong	Paul	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Real World Relationships Between Baseline Q Waves, Time From Symptom Onset and Clinical Outcomes in ST-Segment Elevation Myocardial Infarction Patients: Insight From the Vital Heart Response Registry	CONSULTANT FEES/HONORARIA - Merck; DATA SAFETY MONITORING BOARD - MAST Theraputics; OTHER - AstraZeneca; RESEARCH/RESEARCH GRANTS - Bayer, Merck, Sanofi-Aventis
Armstrong	Paul	02. Acute and Stable Ischemic Heart Disease: Clinical Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Merck; DATA SAFETY MONITORING BOARD - MAST Theraputics; OTHER - AstraZeneca; RESEARCH/RESEARCH GRANTS - Bayer, Merck, Sanofi-Aventis
Arnaout	M. Samir	Population Specific Cardiomyopathies: From Exomes to Databases	Targeted and Exome Sequencing of 27 Lebanese Patients With Cardiomyopathies: Novel Variants in Known Genes, and Potential Novel Genes	Nothing to Disclose
Arnold	Suzanne	Featured Clinical Research II: Interventional	Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data	Nothing to Disclose
Arnold	Suzanne	Innovations in Valvular Heart Disease Diagnosis and Treatment	Improving QoL Prediction Post-TAVR?	Nothing to Disclose
Arnold	Suzanne	Updates in Stable Ischemic Heart Disease	Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-World Impact of the Leader Trial on Improving Cardiovascular Outcomes in Patients With Diabetes at High Cardiovascular Risk	Nothing to Disclose
Arnold	Suzanne	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Reliability and Responsiveness of Seattle Angina Questionnaire in Women With Coronary Artery Disease	Nothing to Disclose
Arnold	Suzanne	Emerging Developments in HFpEF and		Nothing to Disclose
Arnold	Suzanne	Arryhthmias Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	HFpEF: A Static or Dynamic Phenomenon? Current More Important Than Past: Interpreting Serial Heart Failure Specific Health Status in Heart Failure Patients With Reduced Ejection Fraction	Nothing to Disclose
Arnson	Yoav	Non Invasive Imaging: Coronary Calcium	Coronary Artery Calcium in the Elderly: Prevalence, Severity, and	Nothing to Disclose
Arnson	Yoav	Scoring and CV Risk Assessment Non Invasive Imaging: New Technologies	Association With All-Cause Mortality Improvement in LDL is Associated With Decrease in Non-Calcified Plaque Volume on CTA as Measured by Automated Quantitative Software	Nothing to Disclose
Arnson	Yoav	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Relationship Between Whole Vessel Quantitative Plaque Characteristics and Noninvasive Fractional Flow Reserve From Coronary Computed Tomography Angiography	Nothing to Disclose
Arnson	Yoav	Imaging With Cardiac CT: The Case for	Hormone Replacement Therapy Is Associated With Less Coronary	Nothing to Disclose
Aronis	Konstantinos	Calcium Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Atherosclerosis and Lower Mortality Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Stroke Among Whites and Blacks: The Atherosclerosis Risk In	Nothing to Disclose
Aronow	Herbert	Fellows Bootcamp: Peripheral Vascular Disease and Structural Heart Disease	Communities (ARIC) Study Renal, Carotid, Subclavian	Nothing to Disclose
Aronow	Herbert	Management Debates on Current Hot Topics in Coronary	Co-Chair	Nothing to Disclose
Aronow	Herbert	Intervention Born To Run: Geographic Variation in PAD	Co-Chair	Nothing to Disclose
Aronow	Herbert	Diagnosis, Treatment and Outcomes Born To Run: Geographic Variation in PAD	Patient PAD Resources: Cardiosmart as a Tool for Educating the	Nothing to Disclose
Aronow	Herbert	Diagnosis, Treatment and Outcomes Core Curriculum: Head to Toe Catheter Based	PAD Patient Chair	Nothing to Disclose
Aronow	Herbert	Interventions Interventional Cardiology: Translation and Pre-	Intramyocardial Autologous CD34+ Cell Therapy for Refractory	Nothing to Disclose
Aronow	Herbert	Clinical Research Coronary Intervention in Interventional Cardiology: Advanced Device Use	Angina: A Meta-Analysis Angiography Versus Optical Coherence Tomography Guided Percutaneous Coronary Intervention: A Meta-Analysis of Clinical	Nothing to Disclose
Aronow	Herbert	Interventional Cardiology: TAVR 3	Outcomes Infective Endocarditis After Transcatheter Aortic Valve Replacement. Insights From the Nationwide Readmissions	Nothing to Disclose
Aronow	Herbert	Highlights in Vascular Medicine Research	Database Thirty-Day Readmissions Following Endovascular or Surgical Treatment for Critical Limb Ischemia: Analysis of the Nationwide	Nothing to Disclose
Aronow	Herbert	39. Vascular Medicine: Endovascular Therapy	Readmissions Database Suggested Reviewer	Nothing to Disclose
Aronow	Wilbert	Team 1 Making Progress in Understanding Heart	Orthopnea or Paroxysmal Nocturnal Dyspnea in Older Adults	Nothing to Disclose
		Failure	Without Prevalent Heart Failure Is a Predictor, but Not an Independent Risk Factor for Incident Heart Failure: Insights From the Cardiovascular Health Study	·
Aronow	Wilbert	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Pneumopericardium: A Rare Presentation of Gastro-Pericardial Fistula	Nothing to Disclose
Aronow	Wilbert	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Multidisciplinary Approach for Endocarditis in Pregnancy	Nothing to Disclose
Aronow	Wilbert	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	In-Hospital Outcomes and Hospitalizations for Acute Rheumatic Heart Disease: A United States National Study	Nothing to Disclose
Aronow	Wilbert	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Prevalence and In-Hospital Outcomes of Uremic and Dialysis Pericarditis: A United States National Study	Nothing to Disclose

Last Name F				•
	First Name	Session Title	Presentation Title	Disclosures
Aronow	Wilbert	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Among Older Heart Failure (HF) Patients With In-Hospital Acute Kidney Injury (AKI), an Improvement in Kidney Function Is	Nothing to Disclose
		r revent readmissions	Associated With a Higher Risk of Post-Discharge Mortality but Not Readmission	
Aronow V	Wilbert	Interventional Cardiology: TAVR 2	Association of Chronic Renal Insufficiency With In-Hospital Outcomes of Transcatheter Aortic Valve Replacement	Nothing to Disclose
Aronow V	Wilbert	Advances in Lipid Management	Hydrophilic Versus Lipophilic Statins in Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Aronow V	Wilbert	Features of Patients With Acute Coronary	Sex Differences in Revascularization and In-Hospital Outcomes of Non-ST-Segment Elevation Myocardial Infarction in the United States	Nothing to Disclose
Aronow V	Wilbert	Syndrome Interventional Cardiology: TAVR 3	Regional Variations in In-Hospital Outcomes and Healthcare Resource Utilization in Patients Undergoing Transcatheter Aortic	Nothing to Disclose
Aronow V	Wilbert	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Valve Replacement in the United States Combined Heart-Kidney Transplantation in a Patient With Human Immunodeficiency Virus	Nothing to Disclose
Aronow	Wilbert		Management of Takotsubo Cardiomyopathy Complicated by Left Ventricular Outflow Tract Obstruction	Nothing to Disclose
Aronow V	Wilbert	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Verticular Continuor Hact Obstudents Association of Academic Year-End Changeover With Survival Rates After In-Hospital Cardiac Arrest: An Examination of the "July Effect"	Nothing to Disclose
Aronow V	Wilbert	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Heart Failure Hospitalization (HFH) Despite Digoxin Therapy Versus No HFH Despite Placebo in the Digitalis Investigation Group (DIG) Trial: Insights Into Risk Factors for HFH in HF and Reduced Ejection Fraction (HFTEF)	Nothing to Disclose
Aronow V	Wilbert	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Clinical Effectiveness of Spironolactone in Hospitalized Older Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or Equal to 30 mL/min/1.73 m ²) Patients With Heart Failure	Nothing to Disclose
Aronow	Wilbert	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Chronic Alpha Blocker Use and Outcomes in Older Male Medicare Beneficiaries Hospitalized for Heart Failure	Nothing to Disclose
Aronow	Wilbert		Arrhythmias in Hospitalized Heart Transplanted Patients: A United States National Study	Nothing to Disclose
Aronow V	Wilbert	The Evolving World of LVADs, Transplant and	Chagas Heart Disease: A United States National Study	Nothing to Disclose
Aronow V	Wilbert	Other Novel Discoveries FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Spontaneous Coronary Artery Dissection in a Transplanted Heart	Nothing to Disclose
Aronow V	Wilbert	Disease, and Vascular Medicine Why Can't We Be Friends? Controversies in Heart Failure Management	Adverse Outcomes With Use of Hydralazine and Nitrate Combination Therapy in Hospitalized Older Non-Black Patients With	Nothing to Disclose
Arora C	Garima	Interventional Cardiology: TAVR 3	Heart Failure and Reduced Ejection Fraction (HFrEF) Risk of Adverse Outcomes in Treatment Modalities for Severe Aortic Stenosis in Randomized Control Trials: Direct and Indirect	Nothing to Disclose
Arora N	Millie		Comparisons Insulin Resistance Associates With Adverse Cardiac Remodeling in	Nothing to Disclose
Arora F	Pankaj	Prevention Interventional Cardiology: TAVR 3	the Absence of Hypertension in Young South Asians Risk of Adverse Outcomes in Treatment Modalities for Severe Aortic Stenosis in Randomized Control Trials: Direct and Indirect	Nothing to Disclose
Arora F	Rohit	Arrhythmias and Clinical EP: Devices 1	Comparisons Lower All-Cause Mortality in Younger Patients With Prophylactic Implantable Cardioverter Defibrillator Compared to Elderly Subjects:	Nothing to Disclose
Arora F	Rohit	Atrial Fibrillation and VT: Unique Populations and Solutions	A Systemic Review and Meta-Analysis Reduced Mortality Benefit With Prophylactic Implantable Cardioverter Defibrillator in Nonischemic Cardiomyopathy: A	Nothing to Disclose
Arora F	Rohit	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Systematic Review and Meta-Analysis Sequential Inhibition of Renin-Angiotensin System in Heart Failure Is Associated With Enhanced Net Benefit at a Cost of Increased	Nothing to Disclose
Arora F	Rohit	Can CABG Patch CAD?	Adverse Events: A Systematic Meta-Analysis Minimally Invasive CABG Reduces Target Vessel Revascularizations in Comparison to PCI Without Increased Major	Nothing to Disclose
Arora S	Sameer	Novel Developments in Acute Coronary Syndromes	Adverse Events: A Meta-Analysis of Randomized Trials Comparison of Troponin Peaks Between Type 1 and Type 2 Myocardial Infarction	Nothing to Disclose
Arora S	Sameer	Unusual Presentations of ACS	Differing Outcomes of Type 1 and Type 2 Myocardial Infarction and Their Impact on Overall Non-ST Elevation Myocardial Infarction Mortality Rates	Nothing to Disclose
Arora S	Shilpkumar	Arrhythmias and Clinical EP: Basic 1	Nortanity Rates Atrial Fibrillation in Patients With Non-STEMI: Insights From a National Database	Nothing to Disclose
Arora S	Shilpkumar	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	National Database Predictors of 90-Day Readmission and In Hospital Mortality Amongst Patients Undergoing Percutaneous Coronary Interventions: Insights From a National Database	Nothing to Disclose
Arora S	Shilpkumar	Structural Heart Interventions: Focus on Mitral	Insights Into Outcomes With Intracardiac Echocardiogram Use in	Nothing to Disclose
Arora	Shilpkumar	Valve, Left Atrial Appendage and HOCM Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Structural Interventions Transcatheter Mitral Valve Repair (Mitraclip) in United States: Etiologies and Predictors of Readmission and In-Hospital Mortality	Nothing to Disclose
Arora S	Shilpkumar	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	From the Nationwide Readmission Database Transcatheter Mitral Valve Repair (Mitra Clip) in United States: Length of Stay and Cost of Hospitalizations From the Nationwide	Nothing to Disclose
Arora S	Shilpkumar	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Readmission Database Identifying the Etiologies and Trends of 30 Day Readmissions in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients: A	Nothing to Disclose
Arora S	Shilpkumar	Innovative Approaches for Reducing Risk and	National Population-Based Cohort Study Atrial Fibrillation Is Associated With Worse Outcomes in Patients	Nothing to Disclose
Arora S	Shilpkumar	Improving Outcomes With Ablation Timely Topics in Acute Coronary Syndromes	With Cirrhosis Percutaneous Coronary Intervention Is Associated With Decreased	Nothing to Disclose
Arora S	Shilpkumar	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Mortality in NSTEMI Patients With Advanced CKD Impact of Cardiac Devices on Readmission and Short Term Mortality in Patients With Heart Failure With Reduced Ejection	Nothing to Disclose
Arora S	Shilpkumar	Unusual Presentations of ACS	Fraction: A Nationwide Study Clinical Outcomes of the Treatment of Cocaine Induced Chest Pain	Nothing to Disclose
Arora S	Shilpkumar	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	With Beta Blockers: A Meta-Analysis CHADS ₂ and CHA ₂ DS ₂ VASc Scores as Predictors of Length of Stay and Cost of Care in Hospitalised Atrial Fibrillation	Nothing to Disclose
Arora S	Shilpkumar	CAD in Unique Patient Populations	Patients: Insights From a National Database Trends in Prevalence and In-Hospital Mortality of NSTEMI Patients	Nothing to Disclose
Arrebola A	Antonio	Timely Topics in Acute Coronary Syndromes	With Solid Tumor Cancer: The Nationwide Analysis From 1998- 2013 A New Prognosis Score to Predict Mortality in Patients Over 75	Nothing to Disclose
Initebula I/	TITUTIO	Timely Topics in Acute Coronary Syndromes	A New Prognosis Score to Predict Mortality in Patients Over 75 Years Old Undergoing Primary Angioplasty in Cardiogenic Shock	Induming to Disclose
	Satpal	Post-CAD/MI: Making Tough Predictions About	Unravelling the Mechanisms of Mental Stress Induced Myocardial	Nothing to Disclose





and the same of th				
Arribas	First Name Fernando	Session Title Arrhythmias and Clinical EP: Devices 1	Presentation Title Late Occurrence of Phrenic Nerve Stimulation: A Potential Pitfall	Disclosures Nothing to Disclose
Arrighi	James	Engage @ ACC.17 Studio: FIT Jeopardy Battle	Among Super Responders? Judge	Nothing to Disclose
Arrighi	James	of the State Chapters I 30. Non Invasive Imaging: Nuclear Team 2	Suggested Reviewer	Nothing to Disclose
Arruda-Olson	Adelaide	FIT Clinical Decision Making: Heart Failure and	A Rare Disease Presenting With Hypertension and Acute Heart	Nothing to Disclose
Arruda-Olson	Adelaide	Pulmonary Hypertension Non Invasive Imaging: Role of Exercise Testing	Failure Exercise Test Predicts Both Cardiovascular and Non-Cardiovascular Mortality in Patients Without Cardiovascular Disease	Nothing to Disclose
Arruda-Olson	Adelaide	Vascular Medicine: Aortic and Peripheral	Association of Ankle Brachial Index With Limb Outcomes in Peripheral Artery Disease: A Community-Based Study	Nothing to Disclose
Arsanjani	Reza	Artery Diseases FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Pathologic Plumbing: Utilizing Multi-Modality Imaging in the Diagnosis of a Patient With Pulmonary Vein to Azygos System	Nothing to Disclose
Arundel	Cherinne	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Fistula and Decompensated Valvular Cardiomyopathy Heart Failure Hospitalization (HFH) Despite Digoxin Therapy Versus No HFH Despite Placebo in the Digitalis Investigation Group (DIG) Trial: Insights Into Risk Factors for HFH in HF and Reduced Ejection	Nothing to Disclose
Arundel	Cherinne	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Fraction (HFrEF) Clinical Effectiveness of Spironolactone in Hospitalized Older Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or Equal to 30 mL/min/1.73 m ²) Patients With Heart Failure	Nothing to Disclose
Arundel	Cherinne	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Chronic Alpha Blocker Use and Outcomes in Older Male Medicare Beneficiaries Hospitalized for Heart Failure	Nothing to Disclose
Arundel	Cherinne	Why Can't We Be Friends? Controversies in Heart Failure Management	Adverse Outcomes With Use of Hydralazine and Nitrate Combination Therapy in Hospitalized Older Non-Black Patients With	Nothing to Disclose
Arya	Arash	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Heart Failure and Reduced Ejection Fraction (HFrEF) Cardiac Magnetic Resonance Imaging After Radiofrequency Ablation of Ventricular Arrhythmias in Human Patients: Defining the Substrate and Visualizing the Outcome	Nothing to Disclose
Aryana	Arash	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Sousdate and visualizing the Outcome 5-Year Outcomes of a Staged Hybrid Surgical and Catheter-Based Ablation Approach for Treatment of Long-Standing Persistent Atrial Fibrillation	CONSULTANT FEES/HONORARIA - St. Jude Medical
Asano	Taku	Updates in Stable Ischemic Heart Disease	Coronary Calcification as a Mechanism of Plaque/Media Shrinkage: A Multimodality Intracoronary Imaging Study	Nothing to Disclose
Asano	Taku	Coronary Intervention: Drug Eluting Stent and Scaffolds	Early, Late and Very Late Incidence of Bioresorbable Scaffold Thrombosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials and Observational Registries	Nothing to Disclose
Asch	Federico	Structural Heart Interventions: What Does the Imager Need to know	Identifying Complications with Imaging During Structural Heart Interventions	Nothing to Disclose
Asch	Federico	28. Non Invasive Imaging: Echo Team 1	Suggested Reviewer Etiology, Patient Characteristics and Surgical Outcomes of Acute	Nothing to Disclose
Asfari Asgar	Mohammad Maysara Anita	Valvular Heart Disease: Aortic Regurgitation Interventional Live Case Session I: Structural	Panelist	Nothing to Disclose CONSULTANT FEES/HONORARIA - Abbott Vascular, Abbott
A	A -: t-	Transmission from Cleveland Clinic (Cleveland, Ohio)	Danalist	Vascular,Gore,MEDTRONIC
Asgar	Anita	Challenging Anatomies: Does TAVR Device Choice Matter	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular, Abbott Vascular, Gore, MEDTRONIC
Asgar	Anita	Interventional Cardiology: TAVR 4	Serum Albumin as an Incremental Predictor of Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement: Results From the Multicenter Frailty-AVR Study	CONSULTANT FEES/HONORARIA - Abbott Vascular, Abbott Vascular, Gore, MEDTRONIC
Asgar	Anita	Interventional Cardiology: PCI in Complex Patients	Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated Heparin Following Transcatheter Aortic Valve Replacement: Results From the Bravo-3 Randomized Trial	CONSULTANT FEES/HONORARIA - Abbott Vascular, Abbott Vascular, Gore, MEDTRONIC
Asghar	Omar	Cardiomyopathies	A Case of Familial Dilated Cardiomyopathy With a Reversible Phenotype: The Utility of Genetic Testing and Genotype-Specific Treatment	Nothing to Disclose
Asher Asher	Elad Elad	Interventional Cardiology: TAVR 4 Interventional Cardiology: TAVR 4	Transacatheter Aortic Valve Replacement And Malignancy Rapid Ventricular Pacing During TAVR Is Associated With Poor	Nothing to Disclose Nothing to Disclose
Asher	Elad	Anti-Platelet Therapies: Always a Sticky Topic	Short- and Long-Term Outcome Chewing Versus Traditional Swallowing of Ticagrelor to Accelerate Platelet Inhibition in ST Elevation Myocardial Infarction: The	Nothing to Disclose
Ashiki	Masatoshi	Heart Failure and Cardiomyopathies: What	CHEERS-STEMI Study Spironolactone Therapy for Cardiomyopathy in Duchenne Muscular	Nothing to Disclose
Ashley	Euan	Next When All Else Is Failing? Featured Clinical Research I	Dystrophy Testing Safety and Efficacy: The Randomized Exploratory Study of Exercise Training in Hypertrophic Cardiomyopathy (RESET-HCM)	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Personalis
Ashley	Euan	Imaging the Athlete's Heart	Addressing Reference Echocardiographic Parameters in Athletic Screening: A College Football-Based Study Focusing on the	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Ashley	Euan	Innovative Use of Echocardiography	Implications of Race and Correction for Body Composition Identifying the Optimal Echocardiographic Variables to Predict	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Ashlan	F		Outcome Through Correlation Mapping in Patients With Dilated Cardiomyopathy	Personalis
Ashley	Euan	Advances in HCM, PPCM and Other Cardiomyopathies	Integrating Myocardial Strain and Exercise Performance Into Prognostication of Hypertrophic Cardiomyopathy	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Personalis
Ashley	Euan	Advances in HCM, PPCM and Other Cardiomyopathies	Systolic Dysfunction Without LV Dilatation in a Cohort of Patients With Lamin A/C Cardiomyopathy	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Personalis
Ashley	Euan	Interdisciplinary Cardiovascular Care in Complex Scenarios	Interdisciplinary Peripartum Care of the Patient With Diastolic Heart Failure in Non-Obstructive Hypertrophic Cardiomyopathy	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Personalis
Ashraf	Said	FIT Clinical Decision Making: Non-Invasive	Things to Consider When Shopping for a Shunt: A Diagnostic	Nothing to Disclose
Ashraf	Said	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Arrhythmias and	Challenge Hiatal Hernia: An Unconventional but Potentially Curable Cause of	Nothing to Disclose
Ashraf	Said	Electrophysiology Emerging Developments in HFpEF and	Atrial Arrhythmias Hospitalization Burden of Diastolic Heart Failure in the United	Nothing to Disclose
Ashton	Veronica	Arryhthmias Highlighted Original Research: Pulmonary	States: 2007-2012 A Benefit-Risk Analysis of Recurrent Venous Thromboembolism in	SALARY - Janssen Scientific Affairs LLC
		Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Patients Who Continued Versus Discontinued Rivaroxaban Therapy After an Initial Six-Month Therapy	
Ashton	Veronica	Antithrombotic Therapy in Ischemic Heart Disease	Rivaroxaban Users Have Significantly Less Treatment Discontinuation Compared With Users of Other Oral Anticoagulants in Non-Valvular Atrial Fibrillation	SALARY - Janssen Scientific Affairs LLC
Ashvetiya	Tamara	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	In Non-Valvular Atrial Fibrillation The Relationship Between Depression and Adverse Cardiovascular Events: Examining Serotonin-Driven Platelet Activation as a Factor	Nothing to Disclose
Asirvatham	Samuel	Coronary Artery Disease Heart Rhythm Disorders: Today and Tomorrow		CONSULTANT FEES/HONORARIA - Abiomed, AtriCure, Biosense Webster, Biotronik, Boston Scientific, Elsevier, Medtelligence, MEDTRONIC, Sanofi Aventis, St. Jude Medical, Wolters Kluwer, Zoll
Asirvatham	Samuel	Common Arrhythmia Problems: The Experts Approach	Panelist	CONSULTANT FEES/HONORARIA - Abiomed, AtriCure, Biosense Webster, Biotronik, Boston Scientific, Elsewier, Medtelligence, MEDTRONIC, Sanofi Aventis, St. Jude Medical, Wolters Kluwer, Zoll

Contract of the second				I
Last Name Asirvatham	First Name Samuel	Session Title Innovative Approaches for Reducing Risk and	Presentation Title Time in Therapeutic Range Predicts Mortality and Cerebrovascular	Disclosures CONSULTANT FEES/HONORARIA -
Asiivatriani	Samuel	Improving Outcomes With Ablation	Events in Atrial Fibrillation Patients Treated With Warfarin	Abiomed,AtriCure,Biosense Webster,Biotronik,Boston
				Scientific,Elsevier,Medtelligence,MEDTRONIC,Sanofi Aventis,St. Jude Medical,Wolters Kluwer,Zoll
Asirvatham	Samuel	Arrhythmias and Clinical EP: Basic 4	External Cooling of the Myocardium Slows Electrical Conduction and Terminates Atrial Fibrillation	CONSULTANT FEES/HONORARIA - Abiomed, AtriCure, Biosense Webster, Biotronik, Boston
			and Terminates Athair Ishination	Scientific, Elsevier, Medtelligence, MEDTRONIC, Sanofi Aventis, St.
Asirvatham	Samuel	Congenital Heart Disease: To the Third	Outcomes of Direct Current Cardioversion in Adults With Congenital	Jude Medical, Wolters Kluwer, Zoll CONSULTANT FEES/HONORARIA -
		Decade and Beyond	Heart Disease	Abiomed,AtriCure,Biosense Webster,Biotronik,Boston Scientific,Elsevier,Medtelligence,MEDTRONIC,Sanofi Aventis,St.
				Jude Medical, Wolters Kluwer, Zoll
Asirvatham	Samuel	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abiomed,AtriCure,Biosense Webster,Biotronik,Boston
		1		Scientific, Elsevier, Medtelligence, MEDTRONIC, Sanofi Aventis, St. Jude Medical, Wolters Kluwer, Zoll
Asleh	Rabea	The Evolving World of LVADs, Transplant and	Effects of Diabetes Mellitus on Clinical Outcomes After Left	Nothing to Disclose
		Other Novel Discoveries	Ventricular Assist Device Implantation: A Single Institutional 9-Year Experience	
Asleh	Rabea	Advanced Therapies = Advanced Trouble:	Sirolimus-Based Immunosuppression Mitigates Progression of Cardiac Allograft Vasculopathy and Improves Cardiac Outcomes	Nothing to Disclose
		VAD and Transplant Challenges	After Heart Transplantation: A Single Center 15-Year Follow-Up	
Asnani	Aarti	Highlighted Original Research: Heart Failure	Study Changes in Citric Acid Metabolism Are Associated With the	Nothing to Disclose
		and Cardiomyopathies and the Year in Review	Development of Anthracycline-Induced Cardiotoxicity in Mice and in	
Aspelund	Thor	Updates on Risk Factors for Cardiovascular	Patients Carotid Plaque Area Is Increased in Patients With Acute Coronary	Nothing to Disclose
Asrress	Kaleab	Disease Post-CAD/MI: Making Tough Predictions About	Syndrome and Dysglycemia Unravelling the Mechanisms of Mental Stress Induced Myocardial	Nothing to Disclose
		the Future	Ischaemia: Novel Insights From Intracoronary Measurements During	
Assad	Tufik	Highlighted Original Research: Pulmonary	Cardiac Catheterisation Racial Differences in Patients Referred for Right Heart	Nothing to Disclose
		Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Catheterization and Risk of Pulmonary Hypertension	
Assad	Tufik	Imaging Pulmonary Vascular Disease Plus the	Lack of a Tricuspid Regurgitation Velocity and Pulmonary	Nothing to Disclose
Assali	Abid	Impact of Congenital Heart Disease Refining TAVR Outcomes	Hypertension: Absence of Evidence Is Not Evidence of Absence The Association of Coronary Artery Disease Severity and Pre	Nothing to Disclose
			Procedural Completeness of Revasclarization on Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement	
Assar	Manish	FIT Clinical Decision Making: Arrhythmias and	Takotsubo Cardiomyopathy in the Setting of Complete Heart Block	Nothing to Disclose
Asthana	Niraj	Electrophysiology New Technologies in Echocardiography	The Effect of Transcatheter Aortic Valve Replacement on	Nothing to Disclose
			Subclinical Cardiac Function Using Speckle Tracking Echocardiography	
Asthana	Vishwaratn	Acute Heart Failure: Evaluating Strategies to	Educational Strategy for Management of Heart Failure Markedly	Nothing to Disclose
		Prevent Readmissions	Reduces 90-Day Emergency Department and Hospital Readmissions in Un- and Underinsured Patients	
Asti	Deepak	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Bidirectional Ventricular Tachycardia in Critically III Patients on Vasopressors	Nothing to Disclose
Astsaturov	Artem	FIT Clinical Decision Making: Prevention, Adult	A Mistaken Case of Ventricular Septal Defect: Importance of	Nothing to Disclose
		Congenital and Congenital Heart Disease	Physical Examination	
Atallah	Joseph	Impact of Prenatal Environment on Congenital Heart Disease	Umbilical Arterial Blood Flow in the Third Trimester and Its Association With Clinical and Neurodevelopmental Outcomes in	Nothing to Disclose
Alexade	Address		Children With Critical Neonatal Congenital Heart Disease	Notice to Bright
Atanda	Adebayo	Novel Echocardiographic Methods for Assessing Cardiac Function	Biventricular Cardiac Function in Sub-Saharan Africans With Sickle Cell Disease	Nothing to Disclose
Atanda	Adebayo	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Comparative Effects of Metoprolol and Nebivolol on Blood Pressure Control in African-Americans	Nothing to Disclose
Atar	Dan	Stroke and AF: Thinking About the Heart	The Prescribing of Antiplatelet Therapy Only in Patients With Nonvalvular Atrial Fibrillation: Results From the GARFIELD-AF	CONSULTANT FEES/HONORARIA - Bayer Healthcare,BMS/Pfizer,Boehringer-Ingelheim,Cardiome,Dayichi-
			Registry	Sankyo,Nycomed-Taceda
Athappan	Ganesh	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Inferior Vena Cava Thrombosis Complicating Vena Cava Filter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and	Nothing to Disclose
Athar	Syed	Disease, and Vascular Medicine FIT Clinical Decision Making: Interventional	Heparin Induced Thrombocytopenia Radial Artery Occlusion Recanalization Prior to Coronary	Nothing to Disclose
Autai	Oyeu	Cardiology, Acute and Stable Ischemic Heart	Angiography	Trouming to Disclose
Atkins	Donita	Disease, and Vascular Medicine Highlighted Original Research: Arrhythmias	Peri-Procedural Use of Novel Oral Anticoagulation Agents During	Nothing to Disclose
Atkins	Donita	and Clinical EP and the Year in Review Arrhythmias and Clinical EP: Devices 1	Cardiac Device Implantation: Are They Safe? Implantable Cardioverter Defibrillator for the Prevention of Mortality	Nothing to Disclose
AKIIIS	Donita	Armydiinias and Cillical Er. Devices 1	in Non-Ischemic Cardiomyopathy: A Meta-Analysis of Randomized	Nothing to Disclose
Atkins	Donita	Arrhythmias and Clinical EP: Devices 1	Controlled Trials Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus	Nothing to Disclose
			Warfarin in Patients Undergoing Cardiac Implantable Electronic Device Implantation: A Meta-Analysis	-
Atkins	Donita	Arrhythmias and Clinical EP: Devices 2	Impact of Left Atrial Appendage Occlusion on Left Atrial Function	Nothing to Disclose
Atkins	Donita	Arrhythmias and Clinical EP: Devices 2	Real World Battery Longevity of St. Jude Medical Implantable Cardioverter-Defibrillators Included in the Advisory for Premature	Nothing to Disclose
Atkins	Donita	Atrial Fibrillation and VT: Unique Populations	Battery Depletion Use of an Esophageal Retractor to Prevent Thermal Injuries During	Nothing to Disclose
		and Solutions	Atrial Fibrillation Ablation: A Multi-Center Experience	-
Atkins	Donita	Atrial Fibrillation and VT: Unique Populations and Solutions	Sotalol Versus Other Anti-Arrhythmic Medications for Cardioversion of Atrial Fibrillation and Maintenance of Sinus Rhythm: Meta-	Nothing to Disclose
Atkins	Donita	Arrhythmias and Clinical EP: Anticoagulation	Analysis of Randomized Controlled Studies Meta-Analysis on the Efficacy and Safety of New Oral	Nothing to Disclose
	20	Issues	Anticoagulants Compared With Vitamin K Antagonists in Patients	
Atkins	Donita	Arrhythmias and Clinical EP: AF Miscellaneous	Undergoing Cardioversion for Atrial Fibrillation CHADS2 Score Predicts Outcomes of Radiofrequency Catheter	Nothing to Disclose
Atkins	Donita	and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous	Ablation in Patients With Atrial Fibrillation Left Atrial Appendage Ligation With Lariat Device: A Systematic	Nothing to Disclose
		and Surgical Issues	Review and Meta-Analysis	,
Atkins	Donita	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Efficacy of Catheter Ablation of Atrial Fibrillation in the Setting of Systolic Dysfunction: A Meta-Analysis of Randomized Control Trials	Nothing to Disclose
Atkins	Donita	Atrial Fibrillation and VT: Incorporating Novel	Sotalol Versus Other Anti-Arrhythmic Agents for Prevention of Post-	Nothing to Disclose
	25	Risks Toward Decision Making	Operative Supraventricular Arrhythmias After Cardiac Surgery: Meta-	
Atkins	Donita	Atrial Fibrillation, Anticoagulation and Novel	Analysis of Randomized Controlled Studies Safety Profiles of Percutaneous Left Atrial Appendage Closure	Nothing to Disclose
		Device Therapies	Devices: An Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database From	
AH-f	Facaba	Asstallant Fallings F. et aller Charles	2009 - 2016	Nothing to Displace
Atlaf	Faseeha	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Admission Types Among Patients With Heart Failure Cared for by Accountable Care Organizations: Variation by Performance on a	Nothing to Disclose
		•	Measure of Risk Standardized Acute Admission Rates	1

Atluri	First Name Pavan	Session Title Life After LVAD - The Good, The Bad and The	Presentation Title Co-Chair	Disclosures CONSULTANT FEES/HONORARIA - HeartWare
Atluri	Pavan	Ugly Young Investigator Awards Competition: Basic and Translational Science	LVAD-Associated von Willebrand Factor Degradation Fragments Alter Angiogenesis: A Mechanistic Link Between LVAD Support,	CONSULTANT FEES/HONORARIA - HeartWare
Atreya	Auras	FIT Clinical Decision Making: Heart Failure and	Gastrointestinal Angiodysplasia, and Bleeding? Complete Thrombotic Occlusion of TAVR Valve in Patient With	Nothing to Disclose
Attieh	Kathy	Pulmonary Hypertension Personalized Skills Center: Drill and Practice	Continuous Flow LVAD Heart Songs Moderator	Nothing to Disclose
Attili	Anil	(Heart Songs, ECG, Hand-Held Echo) Featured Clinical Research I	Testing Safety and Efficacy: The Randomized Exploratory Study of Exercise Training in Hypertrophic Cardiomyopathy (RESET-HCM)	Nothing to Disclose
Attinger-Toller	Adrian	Interventional Cardiology: Structural Heart	Syntax Score II in Patients With Coronary Artery Disease	Nothing to Disclose
Atwal	Gurdeep	Disease Bridge From the Basics: Translational	Undergoing Mitraclip: A New Approach to Risk Stratification Role of Microtubule Cytoskeleton as a Novel Target Against Hypoxia	Nothing to Disclose
Atwater	Brett	Research in Pulmonary Hypertension 08. Arrhythmias and Clinical EP:	Induced Pulmonary Hypertension Suggested Reviewer	CONSULTANT FEES/HONORARIA - Biotronik,Boston
		Supraventricular/Ventricular Arrhythmias Team 1		Scientific,Medtronic Inc.,St. Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific,Medtronic Inc ,St Jude Medical
Atz	Andrew	Five Controversies in Single Ventricle Management	Co-Chair	Nothing to Disclose
Atz	Andrew	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Detection of Heart Failure With Preserved Ejection Fraction in Single Ventricle Physiology. Insights From the Pediatric Heart Network Fontan Cross-Sectional Study Public Use Dataset	Nothing to Disclose
Augostini	Ralph	Arrhythmias and Clinical EP: Devices 2	Comprehensive Strategy to Reduce the Incidence of Lead Dislodgment for Cardiac Implantable Electronic Devices	Nothing to Disclose
Augostini	Ralph	Arrhythmias and Clinical EP: Devices 3	Cryoballoon Versus Radiofrequency Ablation of Atrial Fibrillation: In- Lab Complication Rates at a Large Volume Electrophysiology Center	Nothing to Disclose
Aung	Thein	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Long Term Mortality Rates of U.S. Veterans With Bundle Branch Blocks Presenting for Coronary Angiography	Nothing to Disclose
Aung	Thein	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Simple Atrial Flutter Ablation Causing Cardiogenic Shock, Mitral Regurgitation and Complete Heart Block	Nothing to Disclose
Aung	Thein	FIT Clinical Decision Making: Arrhythmias and	Sources of Inappropriate ICD Shocks, Look for Inside and Outside	Nothing to Disclose
Aung	Thein	Electrophysiology Innovations in Advocacy and Patient Centered	of the Heart Long Term Mortality Rates of Premature Coronary Artery Disease in	Nothing to Disclose
Aurigemma	Gerard	Care Innovative Use of Echocardiography	Young U.S. Veteran Population Left Atrial Function Index as a Predictor of Cardiovascular Disease and Atrial Fibrillation: Data From the Framingham Offspring Study	Nothing to Disclose
Aurigemma	Gerard	28. Non Invasive Imaging: Echo Team 1	Suggested Reviewer	Nothing to Disclose
Auseon	Alex	Core Curriculum: Imaging the Heart: Choosing Wisely	Chair	Nothing to Disclose
Auseon	Alex	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	How a Cardiologist Diagnosed a Pheochromocytoma: Catecholamine-Induced Myocarditis	Nothing to Disclose
Austin	Erin	Young Investigator Awards Competition: Clinical Investigations	Scanning the Phenome to Uncover Pleiotropic Effects of <i>PCSK9</i>	Nothing to Disclose
Auyoung	Matthew	Novel Echocardiographic Methods for Assessing Cardiac Function	Clinical Validation of ASE 2016 Guidelines for Evaluating Left Ventricular Diastolic Dysfunction	Nothing to Disclose
Avanzas	Pablo	Interventional Cardiology: TAVR 2	Effect of Body Mass Index on Mortality After Transcatheter Aortic Valve Implantation: J-Shaped Curve	Nothing to Disclose
Avenatti	Eleonora	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Successful Management of Acute Salmonella Aortitis	Nothing to Disclose
Avenatti	Eleonora	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	3D Printed Patient-Specific Multi-Material Modeling of Mitral Valve	Nothing to Disclose
Avenatti	Eleonora	FIT Clinical Decision Making: Heart Failure and	Apparatus Patient With a Systolic Murmur and Shock: Importance of the	Nothing to Disclose
Averna	Maurizio	Pulmonary Hypertension The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Physical Alirocumab Efficacy and Safety in Patients With Hypercholesterolemia and With or Without Clinical Atherosclerotic Cardiovascular Disease: Pooled Analysis of 10 ODYSSEY Randomized Trials	Nothing to Disclose
Avezbadalov	Azriel	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Smoking Increases the Recurrence of Atrial Fibrillation After Cryoablation Using the Arctic Front Advance Catheter	Nothing to Disclose
Avezum	Alvaro	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Aortic Stenosis, but Not Mitral or Aortic Regurgitation, Is Associated With Adverse Outcomes With Atrial Fibrillation: Results From the ARISTOTLE Trial	Nothing to Disclose
Avila Vanzzini	Nydia	The Challenges of Outcome Prediction in Valvular Heart Disease	Right Ventricle Free Wall Strain Predicts Post-Surgical Low Cardiac Output Syndrome in Patients Undergoing Aortic Valve Replacement	Nothing to Disclose
Avula	Harshith	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Hyperthyroidism Unmasks a Symptomatic Anomalous Coronary Artery	Nothing to Disclose
Avula	Harshith	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Constrictive Pericarditis Due to Kawasaki Disease	Nothing to Disclose
Awamleh	Paula	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years	Nothing to Disclose
Awamleh	Paula	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Incidence, Clinical Profile and Prognosis of Patients With Myocardial Infarction With Non-Obstructive Coronary Arteries in the Real World	Nothing to Disclose
Awuor	Stephen	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Flecainide Toxicity	Nothing to Disclose
Axel	Leon	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Genetic Testing for Diagnosis of Progressive Cardiac Conduction Disease	Nothing to Disclose
Axel	Leon	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	ST-Segment Elevation and Cardiac Magnetic Resonance Imaging Findings in Myocardial Infarction With Non-Obstructive Coronary Arteries	Nothing to Disclose
Ayach	Bill	Unusual Presentations of ACS	Characteristics of Acute Coronary Syndrome Presentation in Young Patients	Nothing to Disclose
Ayers	Colby	Imaging the Athlete's Heart	Pooled Cohort Equation and Coronary Artery Calcium in Retired National Football League Athletes	Nothing to Disclose
Ayers	Colby	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Relationship of Biomarkers of Oxidized Lipoproteins to Ethnicity, Subclinical Atherosclerosis and Cardiovascular Events Over a 10.5 Year Follow-Up in the Dallas Heart Study	Nothing to Disclose
Ayers	Colby	Updates on Risk Factors for Cardiovascular Disease	Association of Objectively Measured Sedentary Time, Physical Activity and Cardiorespiratory Fitness Levels with Cardiometabolic Risk Factors and Cardiac Structure and Function: Findings From the	Nothing to Disclose
Ayers	Colby	Updates on Risk Factors for Cardiovascular	Dallas Heart Study Is There a Link Between Family History of Cardiometabolic Disease	Nothing to Disclose
Ayers	Colby	Disease Acute Coronary Syndromes, Diagnosis,	and Body Fat Profile? Burden of 30-Day Readmissions in Acute Myocardial Infarction and	Nothing to Disclose
Ayers	Colby	Management and Outcomes Innovations in Advocacy and Patient Centered	Heart Failure in the United States: A National Perspective Racial and Ethnic Differences in Cardiovascular Biomarkers	Nothing to Disclose
Ayera	COIDY	Care	radial and Eurile Dinerences in Cardiovascular Biomarkers	Troding to Disclose

Last Name Ayers	First Name Colby	Session Title Hearts and Soles: Multimodality Imaging in	Presentation Title Ascending Aortic Dimensions in Former National Football League	Disclosures Nothing to Disclose
•	•	Athletes	Athletes	
Ayinde	Hakeem	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Hemodynamic Management of Septic Shock in Hypertrophic Cardiomyopathy	Nothing to Disclose
Aykent	Kazim	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Unusual Presentation of Psuedo Stemi	Nothing to Disclose
Aymong	Eve	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Renal Function-Based Contrast Dosing to Define "Prognostic" Contrast Dose Limits for Percutaneous Coronary Intervention - The Prognostic Implication of the Contrast Volume: Glomerular Filtration Ratio in 44,082 Patients From the British Columbia Cardiac Registry	Nothing to Disclose
Aymong	Eve	Acute Coronary Syndromes, Diagnosis,	Angiographic Healing of Spontaneous Coronary Artery Dissection	Nothing to Disclose
Ayoub	Chadi	Management and Outcomes Innovative Use of Echocardiography	The Association Between Echocardiographic Laboratory	Nothing to Disclose
Ayoub	Chadi	Non Invasive Imaging: Prognostic Implications	Accreditation and the Quality of Imaging and Reporting Prognostic Value of Segment Involvement Score Compared to	Nothing to Disclose
		of CT Angiography	Other Measures of Coronary Atherosclerosis by Computed Tomography: A Systematic Review and Meta-Analysis	-
Ayzenbart	Vira	Emerging Applications of Echocardiography	Association Between Global Echocardiography-Based Cardiac Calcium Score and the Clinical Outcomes After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Azadani	Ali	Valvular Heart Disease: Aortic Stenosis	Valve Thrombosis Following Transcatheter Aortic Valve Replacement: Implications of Reduced Cardiac Output	Nothing to Disclose
Azadani	Peyman	Valvular Heart Disease: Aortic Stenosis	Valve Thrombosis Following Transcatheter Aortic Valve Replacement: Implications of Reduced Cardiac Output	Nothing to Disclose
Azar	Rabih	02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Sanofi-Aventis, Pfizer,
Azarbal	Babak	Clinical Team 2 Revascularization and Myocardial Preservation	Percutaneous Coronary Intervention With Everolimus-Eluting Stents	MSD, Bohringer, Eli Lilly, AstraZeneca Nothing to Disclose
		in Acute and Stable Ischemic Heart Disease	for the Treatment of Cardiac Allograft Vasculopathy and the Impact of Diabetes Mellitus on Stent and Target Lesion Patency	
Azarbal	Babak	Non Invasive Imaging: MR Scar and Perfusion	Hyperemic Subendocardial-to-Subepicardial Perfusion Ratio as a Surrogate Marker for Coronary Endothelial Dysfunction: Initial Results in Women With Microvascular Dysfunction	Nothing to Disclose
Azari	Bani	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Associated Eosinophilic Myocarditis Treated With Tofacitinib an Oral Janus (JAK) Kinase Inhibitor	Nothing to Disclose
Azevedo Coutinho	Maria	Emerging Applications for Imaging Cardiac Amyloidosis: Nuclear Cardiology	How Useful Is ^{99m} Tc-DPD Scintigraphy in Diagnosis of Cardiac Amyloidosis in Transthyretin V30M Familial Amyloid Polyneuropathy?	Nothing to Disclose
Aziz	Ahmed	Unusual Presentations of ACS	Gender Differences in Patients With Vasomotor Disorders According to Acetylcholine Provocation in a European Population	Nothing to Disclose
Aziz	Emad	Arrhythmias and Clinical EP: Devices 3	Epicardial Lead Migration to the Spine With Development of	Nothing to Disclose
Azizi	Zahra	Arrhythmias and Clinical EP: AF Ablation	Vertebral Abscess Determination of the Ideal Contact Force Required During	Nothing to Disclose
Azizi	Zahra	Atrial Fibrillation and VT: Unique Populations	Pulmonary Vein Antrum Isolation (PVAI) Evaluation of Long-Term Success Rate of Outflow Tract Ablation in	Nothing to Disclose
Azizi	Zahra	and Solutions Atrial Fibrillation and VT: Incorporating Novel	Patients With Ventricular Tachycardia Effects of Induction Before Ventricular Tachycardia Ablation on	Nothing to Disclose
Azzouz	Muhammad Soubhi	Risks Toward Decision Making Arrhythmias and Clinical EP: Ventricular	Long-Term Success Rate Therapeutic Hypothermia for In-Hospital Cardiac Arrest: A Meta-	Nothing to Disclose
		Tachycardia	Analysis	-
Azzouz	Muhammad Soubhi	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	In the Forest of Comorbidities, Always Look for the Wild Type	Nothing to Disclose
Azzouz	Muhammad Soubhi	Measuring Success in Cardiac Rehabilitation	Wrist Activity Tracking Devices and Support Programs: A Meta- Analysis	Nothing to Disclose
Azzouz	Muhammad Soubhi	Arrhythmias and Clinical EP: Devices 2	Role of Implantable Defibrillators in Primary Prevention of Mortality in Non-Ischemic Cardiomyopathy Patients	Nothing to Disclose
Baan	Jan	Non Invasive Imaging: Expanding Clinical Applications	Prevention of Contrast-Induced Nephropathy for Computed Tomography (CT)-Scanning in TAVR Work-Up: One-Hour Hydration With Sodium Bicarbonate Is Not Inferior to 24-Hour Saline	Nothing to Disclose
Babaliaros	Vasilis	Imaging Transcatheter Mitral Valve Repair and	Hydration Panelist	CONSULTANT FEES/HONORARIA - Edwards Lifesciences:
		Replacement		SPEAKER'S BUREAU - Abbott Vascular
Babaliaros	Vasilis	The Forgotten Valves: Therapies for Triscuspid and Pulmonic Valve	Co-Chair	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular
Babaliaros	Vasilis	Moderated, Case-Based TAVR Management	Case Presentation: TAVR in Those with a Prominent Left Ventricular Septum	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular
Babaliaros	Vasilis	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Pulmonary Venous Waveforms Predict Ventricular Remodeling After Percutaneous Mitral Valve Repair	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular
Babaliaros	Vasilis	TAVR Outcomes Prognostication	Predictors and Clinical Outcomes of Next-Day Discharge After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular
Baber	Usman	Complications of PCI: Case Reviews	Case Presentation: Vessel Dissection	Nothing to Disclose
Baber	Usman	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Atherosclerotic Plaque Morphology in Response to High Intensity Lipid Lowering Therapy by Multimodality Imaging Among Women and Men: A YELLOW-II Sub-study	Nothing to Disclose
Baber	Usman	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Comparing PCI Outcomes in the Very Elderly: Does Age Matter? A Report From Outcomes of Septuagenarians, Octogenarians and Nonagenarians After PCI	Nothing to Disclose
Baber	Usman	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Clinical Outcomes Associated With Impella Versus IABP Use in Stable Patients Undergoing High Risk Percutaneous Coronary Intervention	Nothing to Disclose
Baber	Usman	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Impella or Intra-Aortic Balloon Pump Support in Patients Undergoing High Risk Percutaneous Coronary Intervention: A Real World Single Center Experience	Nothing to Disclose
Baber	Usman	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease:	Nothing to Disclose
Baber	Usman	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Results From the PROMETHEUS Study Angiographic Phenotype and Clinical Outcomes of Patients With Malionancy Undergoing PCI	Nothing to Disclose
Baber	Usman	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study	Nothing to Disclose
Baber	Usman	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Synergistic Effects of Coronary Calcification and Inflammation on Risks for Adverse Cardiovascular Events After PCI: Results From a	Nothing to Disclose
Baber	Usman	Interventional Cardiology: Stent Failure	Large Single-Center Registry Multimodality Intravascular Imaging to Evaluate Plaque	Nothing to Disclose
Baber	Usman	Analysis by Intravascuar Imaging Novel Developments in Acute Coronary	Characteristics in Patients With Diabetes Mellitus Trends in Incidence and Mortality Associated With Acute Kidney	Nothing to Disclose
		Syndromes	Injury in Patients Undergoing PCI for Acute Coronary Syndrome	
Baber	Usman	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: From the WIN-TAVI Registry	Nothing to Disclose

				<u> </u>
Last Name Baber	First Name Usman	Session Title Cutting Edge Vascular Medicine	Presentation Title Proprotein Convertase Subtilisin Kexin Type 9 Protein Expression Is	Disclosures Nothing to Disclose
Babei	Osman	Outling Eage Vascular Medicine	Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Fibrous Plaques	Techning to Discusse
Baber	Usman	Innovations in Cardiovascular Risk Assessment and Reduction		Nothing to Disclose
Baber	Usman	Interventional Cardiology: PCI and TAVR in Complex Patients	Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the Bravo-3 Randomized Trial	Nothing to Disclose
Baber	Usman	Timely Topics in Acute Coronary Syndromes	Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions	Nothing to Disclose
Baber	Usman	Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes	Nothing to Disclose
Baber	Usman	Non Invasive Imaging: Prognostic Implications of CT Angiography	Cyntionics The Relationship Between Pericardial Adipose Tissue Volume, Atherosclerotic Plaque Type and Cardiovascular Risk: A High Risk Plaque Biolmage Sub-Study	Nothing to Disclose
Baber	Usman	Optimizing the Care of ACS Patients	Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population	Nothing to Disclose
Baber	Usman	Interventional Complexity and Complications	Prediction of Acute Kidney Injury in Patients Undergoing Coronary Intervention Using Calculation of Serum Osmolality	Nothing to Disclose
Baber	Usman	Interventional Cardiology: PCI in Complex Patients	Risk and Impact of Diabetes Mellitus on Ischemic Events in Females and Males After Percutaneous Coronary Intervention	Nothing to Disclose
Baber	Usman	Interventional Cardiology: PCI in Complex Patients	Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated Heparin Following Transcatheter Aortic Valve Replacement: Results From the Bravo-3 Randomized Trial	Nothing to Disclose
Baber	Usman	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Countering the Anti-Platelet Effects of Ticagrelor With Platelet Concentrates Within 48 Hours of a Loading Dose: Ex Vivo Testing of Time-Effect on Functional Recovery in Patients With Cardiovascular Disease	Nothing to Disclose
Baber	Usman	02. Acute and Stable Ischemic Heart Disease: Clinical Team 6	Suggested Reviewer	Nothing to Disclose
Baca-Motes	Katie	Innovations in Practice Management and Social Media	Remote Digital Recruitment and Enrollment in a Nationwide Trial of Screening for Undiagnosed Atrial Fibrillation Using a Self-Applied ECG Recording Patch Sensor: Lessons From the mSToPS Trial	Nothing to Disclose
Baccara-Dinet	Marie	Advances in Cholesterol Measurement and Management	Alirocumab Titration Strategy Allows Individualized LDL-C Reduction in a Real World Setting: Results From ODYSSEY OLE (LONG TERM Cohort)	SALARY - SANOFI,SANOFI
Baccara-Dinet	Marie	Advances in Cholesterol Measurement and Management	On-Treatment LDL-C Levels When Alirocumab Dose Is Decreased From 150 to 75 mg Every 2 Weeks in Patients With Heterozygous Familial Hypercholesterolemia: Results From ODYSSEY OLE	SALARY - SANOFI, SANOFI
Baccara-Dinet	Marie	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Alirocumab Efficacy and Safety in Patients With Hypercholesterolemia and With or Without Clinical Atherosclerotic Cardiovascular Disease: Pooled Analysis of 10 ODYSSEY Randomized Trials	SALARY - SANOFI, SANOFI
Baccara-Dinet	Marie	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Alirocumab Treatment in a Real World Setting: Safety Update From an Open-Label Treatment Extension to the ODYSSEY Program for Patients With Heterozygous Familial Hypercholesterolemia	SALARY - SANOFI,SANOFI
Baccara-Dinet	Marie	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy in South Korea and Taiwan	SALARY - SANOFI,SANOFI
Bach	Richard	02. Acute and Stable Ischemic Heart Disease: Clinical Team 4	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Eli Lilly,Novo Nordisk; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,GlaxoSmithKline,Merck & amp; Co., Inc.,Volcano
Bacha	Emile	A Night at the Movies with Some Congenital Heart Surgeons How Do They Actually Do That?: Joint Symposium of the American Association for Thoracic Surgeons and the American College of Cardiology	Panelist (Panel Discussion I)	CONSULTANT FEES/HONORARIA - CorMatrix
Bacha	Emile	A Night at the Movies with Some Congenital Heart Surgeons How Do They Actually Do That?: Joint Symposium of the American Association for Thoracic Surgeons and the American College of Cardiology	Optimal Management of the Cyanotic Neonatal Tetralogy of Fallot Patient: Neonatal Complete Repair (with Accompanying Surgical Video)	CONSULTANT FEES/HONORARIA - CorMatrix
Bacha	Emile	Engage @ ACC.17 Studio:The Newlywed Game for Pediatric Cardiac Providers	Participant, Team 2	CONSULTANT FEES/HONORARIA - CorMatrix
Bacha	Emile	Congenital Heart Disease: Pediatric Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - CorMatrix
Bacharach	J. Michael	41. Vascular Medicine: Venous Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - W L Gore & amp; amp; Associates; RESEARCH/RESEARCH GRANTS - Astra Zeneca Bayer, Bolton Medical, Endologix, National Institute of Health, St. Jude, Trivascular, Veryan, W. L. Gore & amp; amp; Associates; SPEAKER'S BUREAU - Boston Scientific, Bristol Myers Squibb
Backer	Carl	A Night at the Movies with Some Congenital Heart Surgeons How Do They Actually Do That?: Joint Symposium of the American Association for Thoracic Surgeons and the American College of Cardiology	Panelist (Panel Discussion II)	Nothing to Disclose
Backer	Carl	A Night at the Movies with Some Congenital Heart Surgeons How Do They Actually Do That?: Joint Symposium of the American Association for Thoracic Surgeons and the American College of Cardiology	Optimal Management of the Complete Atrioventricular Canal Patient: 848220-Australian 848221; One Patch Repair (with Direct Obliteration of the VSD, without Patch) (with Accompanying Surgical Video)	Nothing to Disclose
Badano	Luigi	28. Non Invasive Imaging: Echo Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - GE Healthcare; DATA SAFETY MONITORING BOARD - Edwards Life Sciences; OTHER - Sorin Cardio
Baddour	Larry	Valvular Heart Disease: Endocarditis	Infective Endocarditis Following Transcutaneous Aortic Valve Implantation: Clinical, Echocardiographic and Hemodynamic Features	OTHER - Massachusetts Medical Society,UpToDate, Inc.
Baddour	Larry	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Utility of Cardiac Computed Tomography Scanning in the Diagnosis and Pre-Operative Evaluation of Patients With Infective Endocarditis	OTHER - Massachusetts Medical Society, UpToDate, Inc.
Badheka	Apurva	Arrhythmias and Clinical EP: Basic 1	Atrial Fibrillation in Patients With Non-STEMI: Insights From a National Database	Nothing to Disclose
Badheka	Apurva	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Predictors of 90-Day Readmission and In Hospital Mortality Amongst Patients Undergoing Percutaneous Coronary Interventions: Insights From a National Database	Nothing to Disclose
Badheka	Apurva	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Insights Into Outcomes With Intracardiac Echocardiogram Use in Structural Interventions	Nothing to Disclose

Last Name Badheka	First Name	Session Title Structural Heart Interventions: Focus on Mitral	Presentation Title Transcatheter Mitral Valve Repair (Mitraclip) in United States:	Disclosures Nothing to Disclose
Васпека	Apurva	Valve, Left Atrial Appendage and HOCM	Transcarrieter mitral valve Repair (mitracip) in Ornied States. Etiologies and Predictors of Readmission and In-Hospital Mortality From the Nationwide Readmission Database	Nothing to Disclose
Badheka	Apurva	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Transcatheter Mitral Valve Repair (Mitra Clip) in United States: Length of Stay and Cost of Hospitalizations From the Nationwide Readmission Database	Nothing to Disclose
Badheka	Apurva	Innovative Approaches for Reducing Risk and	Atrial Fibrillation Is Associated With Worse Outcomes in Patients	Nothing to Disclose
Badheka	Apurva	Improving Outcomes With Ablation Timely Topics in Acute Coronary Syndromes	With Cirrhosis Percutaneous Coronary Intervention Is Associated With Decreased	Nothing to Disclose
Badheka	Apurva	Heart Failure and Cardiomyopathies: What	Mortality in NSTEMI Patients With Advanced CKD Impact of Cardiac Devices on Readmission and Short Term	Nothing to Disclose
		Next When All Else Is Failing?	Mortality in Patients With Heart Failure With Reduced Ejection Fraction: A Nationwide Study	-
Badhwar	Nitish	Arrhythmias and Clinical EP: Devices 3	Transcatheter Closure of Residual Left Atrial Appendage Leaks Following Lariat Device Closure	CONSULTANT FEES/HONORARIA - Biosense Webster, Senterheart, St Jude Medical
Badhwar	Vinay	Late-Breaking Clinical Trials	Comparative Effectiveness of Left Atrial Appendage Occlusion Among Atrial Fibrillation Patients Undergoing Cardiac Surgery: A Report From the Society of Thoracic Surgeons Adult Cardiac Surgery Database	Nothing to Disclose
Badhwar	Vinay	Valvular Heart Disease Guidelines The	What Now? - Addressing the AS and MR Gaps; What's Useful? -	Nothing to Disclose
Badhwar	Vinay	Evidence and the Gaps Post FDA Release Prosthetic Valve	Using VHD Tools to Support Clinical Practice Panelist	Nothing to Disclose
Badhwar	Vinay	Surveillance - Watching for Signals Interventional Cardiology: TAVR 2	Outcomes of Transcatheter and Surgical Aortic Valve Replacement	Nothing to Disclose
	-		in Patients With Hepatic Cirrhosis: Insight From Nationwide Inpatient Sample	-
Badhwar	Vinay	Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment	Chair	Nothing to Disclose
Badhwar	Vinay	Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment	Opening Remarks	Nothing to Disclose
Badhwar	Vinay	Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment	Guideline Drive Care: Room for Clarity	Nothing to Disclose
Badhwar	Vinay	Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment	Interactive Case Challenge in the Management of MR	Nothing to Disclose
Badhwar	Vinay	Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment	Panelist	Nothing to Disclose
Badhwar	Vinay	Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and	Conclusion	Nothing to Disclose
Badhwar	Vinay	Treatment Engage @ ACC.17 Studio: Ask the Valvular	Faculty	Nothing to Disclose
Badhwar	Vinay	Heart Disease Experts Novel Determinants of Outcomes in VHD	Racial Disparity in Aortic Valve Replacement Outcomes: Insight	Nothing to Disclose
Badhwar	Vinay	Valvular Heart Disease With CKD or Cirrhosis	From National Inpatient Sample Trends and Outcomes of Mitral Valve Replacement in Patients With	Nothing to Disclose
Badhwar	Vinay	Sex Disparity in VHD Outcomes	Hepatic Cirrhosis: Insight From National Inpatient Sample Contemporary Trends and Outcomes of Isolated Aortic Valve	Nothing to Disclose
			Replacement in Females in The United States: Understanding the Gender Gap	-
Badimon	Juan	Non Invasive Imaging: MR Characterization and Function	Myocardial Oxygenation Using Blood Level-Oxygen Dependent Sequence in Magnetic Resonance Determines Myocardial Energetics and Capillary Density	RESEARCH/RESEARCH GRANTS - AstraZeneca
Badimon	Juan	Non Invasive Imaging: MR Characterization and Function	T1 Mapping Assesses Diagnosis, Severity and Prognosis in Acute Myocarditis	RESEARCH/RESEARCH GRANTS - AstraZeneca
Badimon	Juan	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	T1 Mapping in Patients With Heart Failure With Preserved Ejection Fraction Detects Increased Interstitial Myocardial Fibrosis and Assesses the Severity of Heart Failure	RESEARCH/RESEARCH GRANTS - AstraZeneca
Badimon	Juan	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Normalizing Platelet Reactivity of Cardiovascular Patients on Ticagrelor Therapy Using Fresh Platelets: Ex Vivo Testing of the Functional Recovery Attained Within 48-Hours of Stopping Treatment	RESEARCH/RESEARCH GRANTS - AstraZeneca
Badimon	Juan	Cutting Edge Vascular Medicine	Proprotein Convertase Subtilisin Kexin Type 9 Protein Expression Is Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Fibrous Plaques	RESEARCH/RESEARCH GRANTS - AstraZeneca
Badimon	Juan	Non Invasive Imaging: MR Structure and	Mild Rheumatic Valvular Heart Disease Is Associated With Interstitial	RESEARCH/RESEARCH GRANTS - AstraZeneca
Badimon	Juan	Valuvular Heart Disease Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Myocardial Fibrosis: A T1 Mapping Study Countering the Anti-Platelet Effects of Ticagrelor With Platelet Concentrates Within 48 Hours of a Loading Dose: Ex Vivo Testing of Time-Effect on Functional Recovery in Patients With Cardiovascular Disease	RESEARCH/RESEARCH GRANTS - AstraZeneca
Badimon	Lina	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Acute Coronary Syndrome: The Risk to Be Young and Women	Nothing to Disclose
Bae	Han-Jun	Syndrome Arrhythmias and Clinical EP: Anticoagulation Issues	Noac Adherence of the Patients With Nonvalvular Atrial Fibrillation in Real Practice	Nothing to Disclose
Bae	Richard	Valvular Disease Populations at Risk	Surgical Risk and Therapy of Severe Symptomatic Degenerative Mitral Valve Regurgitation in the Contemporary Era	SPEAKER'S BUREAU - Abbott Vascular
Bae	Richard	Valvular Heart Disease: Mitral Valve Disease	Guideline-Adherence and Survival for Asymptomatic Patients With Severe Mitral Valve Regurgitation	SPEAKER'S BUREAU - Abbott Vascular
Bae	Richard	Interventional Cardiology: TAVR 4	Minimalist Approach to Cardiac Anesthesia and Outcome in Patients Undergoing Transcatheter Aortic Valve Replacement	SPEAKER'S BUREAU - Abbott Vascular
Baez Hernandez	Nathanya	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Successful Hybrid Procedure in a Case of Unrepaired Hypoplastic Left Heart Syndrome	Nothing to Disclose
Baez Hernandez	Nathanya	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Severe Ebstein's Anomaly Successfully Palliated With the Starnes Procedure	Nothing to Disclose
Baffa	Jeanne	The Story of the Adult Congenital Heart Disease Patient and EP	Acquired Long-Term Cardiac Rhythm and Conduction Abnormalities After Arterial Switch Operation	CONSULTANT FEES/HONORARIA - Merck Manual
Baffa	Jeanne	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Abnormalities Arter Arterial Switch Operation Too Close for Comfort: Aortopulmonary Fistula After Balloon Dilation in Arterial Switch With LeCompte Maneuver	CONSULTANT FEES/HONORARIA - Merck Manual
Bagai	Akshay	02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Baggiano	Andrea	Clinical Team 3 Non Invasive Imaging: MR Heart Failure and	Prognostic Stratification in Patients With ST-Elevation Myocardial	Nothing to Disclose
Baggiano	Andrea	Pulmonary Hypertension Non Invasive Imaging: MR Structure and	Infaction Over Transthoracic Echocardiography by CMR Diagnostic Value of Qt Evaluation in Anterior ST Segment Elevation	Nothing to Disclose
		Valuvular Heart Disease	Myocardial Infarction for Prediction of Myocardial Salvage Index, as Compared to CMR	

Last Name	First Name	Session Title	Presentation Title	Disclosures
Baggish	Aaron	Sports and Exercise: Athletes with Congenital/Valvular Heart Disease Challenging Guidelines in Daily Practice	Panelist	Nothing to Disclose
Baggish	Aaron	Sports and Exercise: Athletes with Congenital/Valvular Heart Disease Challenging Guidelines in Daily Practice	Eligibility Guidelines in Valvular Heart Disease: Is There Ample Evidence?	Nothing to Disclose
Baggish	Aaron	The Athlete with Heart Disease: A Case Based Approach	Triathlete with Chest Pain	Nothing to Disclose
Baggish	Aaron	Imaging the Athlete's Heart	Differential American-Style Football Training Intensities and Cardiac and Vascular Remodeling Patterns	Nothing to Disclose
Baggish	Aaron	Imaging the Athlete's Heart	Sleep Disordered Breathing and Cardiovascular Correlates in Collegiate American Style Football Participants	Nothing to Disclose
Baggish	Aaron	Hearts and Soles: Multimodality Imaging in Athletes	Temporal Sequence of Athlete's Heart Regression During Prescribed Exercise Detraining: <i>Diagnostic Implications</i>	Nothing to Disclose
Baggish	Aaron	31. Non Invasive Imaging: Sports and Exercise Team 1	Suggested Reviewer	Nothing to Disclose
Bagiella	Emilia	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic Surgical Trials Network	Nothing to Disclose
Bagnola	Aaron	Palliative Care for the 99% II: Skillbuilding: PC Encounters: What Would you do? Part I	Panelist	Nothing to Disclose
Bagnola	Aaron	Palliative Care for the 99% III: Skillbuilding: PC Encounters: What Would you do? Part II	Panelist	Nothing to Disclose
Bagur	Rodrigo	Interventional Cardiology: TAVR 3	Meta-Analysis on Cerebral Embolic Protection Devices During Transcatheter Aortic Valve Implantation	Nothing to Disclose
Bahia	Amit	Innovations in Education	Tobacco Cessation: A Knowledge, Attitude and Practice (KAP) Survey Among Residents	Nothing to Disclose
Bahl	Vinay	Insights Into Ischemic Heart Disease: Stable to Erosive Plaques	Immuno-Histopathology of Intracoronary Thrombus Aspirated During Primary Percutaneous Intervention for ST Elevation Myocardial Infarction and Its Clinical Significance	Nothing to Disclose
Bai	Rong	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Left Atrial Appendage Flow Velocity to Predict Persistent Left Atrial Appendage Isolation	Nothing to Disclose
Bailey	Alison	Change is Good! Lifestyle Strategies in the Patient with ASCVD and Diabetes	Co-Chair	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - American Association of Cardiovascular and Pulmonary Rehabilitation
Bailey	Alison	Preventing ASCVD in Diabetes: Are These New Drugs for Real?	Co-Chair	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - American Association of Cardiovascular and Pulmonary Rehabilitation
Bailey	Alison	Lifestyle Changes to Reduce Cardiovascular Risk	Co-Chair	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - American Association of Cardiovascular and Pulmonary Rehabilitation
Bailey	Alison	FIT Forum: Stump the Professor	First Case on Biventricular Mechanical Circulatory Support With Impella CP and Impella RP for a Patient With Acute Myocardial Infarction Induced Cardiogenic Shock	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - American Association of Cardiovascular and Pulmonary Rehabilitation
Bailey	Alison	The Great K Debate Continues: Updates and Controversies in Heart Failure Management	Chair	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - American Association of Cardiovascular and Pulmonary Rehabilitation
Bailey	Alison	The Great K Debate Continues: Updates and Controversies in Heart Failure Management	Introduction to Session and ARS Technology: CME Done Differently	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - American Association of Cardiovascular and Pulmonary Rehabilitation
Bailey	Alison	The Great K Debate Continues: Updates and Controversies in Heart Failure Management	Case Challenges: Caring for the Hyper K Patient - from Drugs to Dialysis	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - American Association of Cardiovascular and Pulmonary Rehabilitation
Bailey	Alison	The Great K Debate Continues: Updates and Controversies in Heart Failure Management	Concluding Remarks	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - American Association of Cardiovascular and Pulmonary Rehabilitation
Bailey	Alison	Engage @ ACC.17 Studio: FIT Jeopardy Battle of the State Chapters I	Judge	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - American Association of Cardiovascular and Pulmonary Rehabilitation
Bailey	Alison	34. Prevention: Rehabilitation Team 1	Suggested Reviewer	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - American Association of Cardiovascular and Pulmonary Rehabilitation
Bailey	Kent	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Socioeconomic Environment and Digital Health Tool Usage and Outcomes: Is There a Digital Divide?	DATA SAFETY MONITORING BOARD - Novartis, Novartis
Bailey	Simone	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Facing a Giant: Asymptomatic Progression of a Right Coronary Artery Aneurysm	Nothing to Disclose
Bailey	Steven	Fellows Bootcamp: Interventional Basics	Basics of Stent Design	DATA SAFETY MONITORING BOARD - Boston Scientific
Bailey	Steven	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology Team 1	Suggested Reviewer	DATA SAFETY MONITORING BOARD - Boston Scientific
Bainey	Kevin	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Characterization and Outcomes of Spontaneous Coronary Artery Dissection Patients Presenting With an Acute Coronary Syndrome: Insights From the ACALM Registry	Nothing to Disclose
Bainey	Kevin	Novel Developments in Acute Coronary Syndromes	Utility of Unfractionated Heparin in Transradial Cardiac Catheterization: A Systematic Review and Meta-Analysis of Randomized Studies	Nothing to Disclose
Bainey	Kevin	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Real World Relationships Between Baseline Q Waves, Time From Symptom Onset and Clinical Outcomes in ST-Segment Elevation Myocardial Infarction Patients: Insight From the Vital Heart	Nothing to Disclose
Bair	Tami	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Response Registry The Association of Depression at Any Time to the Risk of Death Following Coronary Artery Disease Diagnosis: The Intermountain INSPIRE Registry	Nothing to Disclose
Bair	Tami	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	The Intermountain Major Adverse Cardiovascular Events Risk Scores Effectively and Efficiently Predict 1- to 3- Year Post-Stent MACE in Non-Myocardial Infarction Patients	Nothing to Disclose
Bair	Tami	Atrial Fibrillation, Anticoagulation and Novel Device Theraples	Long Term Outcomes and Risk Stratification in Atrial Fibrillation Patients With Low Risk Chads ₂ ≤1 With Antithrombotic Therapy	Nothing to Disclose
Baird	Christopher	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Aortic Valve Repair in the Pediatric Population: Midterm Outcomes Comparing Leaflet Repair Using Autologous Pericardium Versus Porcine Intestinal Submucosa (CorMatrix [®])	Nothing to Disclose
Baird	Christopher	Predicting Outcomes in Pediatric Heart Disase	Risk Stratification of Children Undergoing Valve-Sparing Repair of Tetralogy of Fallot	Nothing to Disclose



and a				l .
Last Name Bairey Merz	First Name C. Noel	Session Title Late-Breaking Clinical Trials: Deep Dive I	Presentation Title Panelist	Disclosures CONSULTANT FEES/HONORARIA - 5th Annual Flagstaff Cardiology Symposium, Beaumont 7th Annual Heart Disease, C3 Company, European Horizon 2020, Florida Hospital (fecture), gliead, Harold Buchwald Heart Health - Winnipeg, INOVA, Korean Cardiology Society, Medscape (consulting), PCP Symposium - Santa Rose, Research Triangle Institute (RTI) International, Sanofi-Aventis, Tufts Nicholson University of Colorado, University of Utah, Valley Health Grand Rounds, VBWG, Washington University, WomenHeart; OTHER - NIH-CASE: RESEARCH/RESEARCH GRANTS - FAMRI, Microvascular, Normal Control, RWISE, WISE HFPEF; SPEAKER'S BUREAU - Expert Exchange, Practice Pont Communications (flectures), Pri-Med (fectures)
Bairey Merz	C. Noel	Debates: Is There Really a Sex Difference in CV Presentation, Care, and Outcomes?	We Need Women's Heart Health Clinics: PRO	CONSULTANT FEES/HONORARIA - 5th Annual Flagstaff Cardiology Symposium, Beaumont 7th Annual Heart Disease ,C3 Company, European Horizon 2020, Florida Hospital (lecture), gilead, Harold Buchwald Heart Health - Winnipeg, INOVA, Korean Cardiology Society, Medscape (consulting), PCP Symposium - Santa Rose, Research Triangle Institute (RTI) International, Sanofi-Aventis, Tufts Nicholson University of Colorado, University of Vlath, Valley Health Grand Rounds, VBWG, Washington University, WomenHeart; OTHER - NIH-CASE; RESEARCH/RESEARCH GRANTS - FAMRI, Microvascular, Normal Control, RWISE, WISE HFPEF; SPEAKER'S BUREAU - Expert Exchange, Practice Pont Communications (lectures), Pri-Med (lectures)
Bairey Merz	C. Noel	Angina in the Absence of Obstructive CAD. What Do We Do With These Patients?	Expert Review: Evaluating for and Treating Microvascular Dysfunction	CONSULTANT FEES/HONORARIA - 5th Annual Flagstaff Cardiology Symposium, Beaumont 7th Annual Heart Disease ,C3 Company, European Horizon 2020, Florida Hospital (lecture), gliead, Harold Buchwald Heart Health - Winnipeg, INOVA Korean Cardiology Society, Medscape (consulting), PCP Symposium - Santa Rose, Research Triangle Institute (RTI) International, Sanofi-Aventis, Tufts Nicholson University of Colorado, University of Vlah, Valley Health Grand Rounds, VBWG, Washington University, WomenHeart; OTHER - NIH-CASE; RESEARCH/RESEARCH GRANTS - FAMRI, Microvascular, Normal Control, RWISE, WISE HFPEF; SPEAKER'S BUREAU - Expert Exchange, Practice Pont Communications (lectures), Pri-Med (lectures)
Bairey Merz	C. Noel	Beyond the Usual Suspects - Other Dimensions in Prevention	Co-Chair	CONSULTANT FEES/HONORARIA - 5th Annual Flagstaff Cardiology Symposium, Beaumont 7th Annual Flagstaff Cardiology Symposium, Beaumont 7th Annual Heart Disease ,C3 Company, European Horizon 2020, Florida Hospital (lecture), gliead, Harold Buchwald Heart Health - Winnipeg, INOVA Korean Cardiology Society, Medscape (consulting), PCP Symposium - Santa Rose, Research Triangle Institute (RTI) International, Sanofi-Aventis, Tutfs Nicholson University of Colorado, University of Vallay Health Grand Rounds, VBWG, Washington University, WomenHeart; OTHER - NIH-CASE; RESEARCH RESEARCH GRANTS - FAMRI, Microvascular, Normal Control, RWISE, WISE HFPEF; SPEAKER'S BUREAU - Expert Exchange, Practice Pont Communications (lectures), Pri-Med (lectures)
Bairey Merz	C. Noel	Core Curriculum: Imaging the Heart: Choosing Wisely	Assessing Ischemia: Does Gender Matter	CONSULTANT FEES/HONORARIA - 5th Annual Flagstaff Cardiology Symposium, Beaumont 7th Annual Heart Disease ,C3 Company, European Horizon 2020, Florida Hospital (lecture), gliead, Harold Buchwald Heart Health - Winnipeg, INOVA Korean Cardiology Society, Medscape (consulting), PCP Symposium - Santa Rose, Research Triangle Institute (RTI) International, Sanofi-Aventis, Tufts Nicholson University of Colorado, University of Vlath, Valley Health Grand Rounds, VBWG, Washington University, WomenHeart; OTHER - NIH-CASE; RESEARCH/RESEARCH GRANTS - FAMRI, Microvascular, Normal Control, RWISE, WISE HFPEF; SPEAKER'S BUREAU - Expert Exchange, Practice Pont Communications (lectures), Pri-Med (lectures)
Bairey Merz	C. Noel	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Coronary Microvascular Dysfunction Is Related to Left Ventricular Concentric Remodeling and Diastolic Dysfunction: From the WISE-CVD Study	CONSULTANT FEES/HONORARIA - 5th Annual Flagstaff Cardiology Symposium, Beaumont 7th Annual Heart Disease ,C3 Company, European Horizon 2020, Florida Hospital (lecture), gliead, Harold Buchwald Heart Health - Winnipeg, INOVA Korean Cardiology Society, Medscape (consulting), PCP Symposium - Santa Rose, Research Triangle Institute (RTI) International, Sanoff-Aventis, Tufts Nicholson University of Colorado, University of Vlath, Valley Health Grand Rounds, VBWG, Washington University, WomenHeart; OTHER - NIH-CASE, RESEARCH (RESEARCH GRANTS - FAMRI, Microvascular, Normal Control, RWISE, WISE HFPEF; SPEAKER'S BUREAU - Expert Exchange, Practice Pont Communications (lectures), Pri-Med (lectures)
Bairey Merz	C. Noel	Non Invasive Imaging: MR Scar and Perfusion	Hyperemic Subendocardial-to-Subepicardial Perfusion Ratio as a Surrogate Marker for Coronary Endothelial Dysfunction: Initial Results in Women With Microvascular Dysfunction	CONSULTANT FEES/HONORARIA - 5th Annual Flagstaff Cardiology Symposium, Beaumont 7th Annual Heart Disease ,C3 Company, European Horizon 2020, Florida Hospital (lecture), gilead, Harold Buchwald Heart Health - Winnipeg, INOVA, Korean Cardiology Society, Medscape (consulting), PCP Symposium - Santa Rose, Research Triangle Institute (RTI) International, Sanofi-Aventis, Tufts Nicholson University of Colorado, University of Vlath, Valley Health Grand Rounds, VBWG, Washington University, WomenHeart; OTHER - NIH-CASE; RESEARCH/RESEARCH GRANTS - FAMRI, Microvascular, Normal Control, RWISE, WISE HFPEF; SPEAKER'S BUREAU - Expert Exchange, Practice Pont Communications (lectures), Pri-Med (lectures)
Bairey Merz	C. Noel	Non Invasive Imaging: MR Scar and Perfusion	Assessment of Myocardial Perfusion Reserve Index Using Adenosine Versus Regadenoson Among Healthy Female Subjects	Communications (sectiones), Pri-index (sectione) of the Communications (sectiones) of the Communications of th

and the second				
Last Name Bairey Merz	First Name C. Noel	Session Title The Evolving World of LVADs, Transplant and	Presentation Title Prognostic Risk Factors for Heart Failure Hospitalization in Women	Disclosures CONSULTANT FEES/HONORARIA - 5th Annual Flagstaff
		Other Novel Discoveries	Without Obstructive Coronary Disease: An Ancillary Study From the Women's Ischemia Syndrome Evaluation (WISE)	Cardiology Symposium, Beaumont 7th Annual Heart Disease, C3 Company, European Horizon 2020, Florida Hospital (lecture), gilead, Harold Buchwald Hearth Health - Winnipeg, INOVA, Korean Cardiology Society, Medscape (consulting), PCP Symposium - Santa Rose, Research Triangle Institute (RTI) International, Sanofi-Aventis, Tufts Nicholson University of Colorado, University of Vlath, Valley Health Grand Rounds, VBWG, Washington University, WomenHeart; OTHER - NIH-CASE; RESEARCH/RESEARCH GRANTS - FAMRI, Microvascular, Normal Control, RWISE, WISE HFPEF; SPEAKER'S BUREAU - Expert Exchange, Practice Pont Communications (lectures), Pri-Med (lectures)
Bairey Merz	C. Noel	02. Acute and Stable Ischemic Heart Disease: Clinical Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - 5th Annual Flagstaff Cardiology Symposium, Beaumont 7th Annual Heart Disease, C3 Company, European Horizon 2020, Florida Hospital (lecture), gliead, Harold Buchwald Heart Health - Winnipeg, INOVA, Korean Cardiology Society, Medscape (consulting), PCP Symposium - Santa Rose, Research Triangle Institute (RTI) Internaltional, Sanofi-Aventis, Tufts Nicholson , University of Colorado, University of Utah, Valley Health Grand Rounds, VBWG, Washington University, WomenHeart; OTHER-NIH-CASE; RESEARCH/RESEARCH (BRANTS - FAMRI, Microvascular, Normal Control, RWISE, WISE HFPEF; SPEAKER'S BUREAU - Expert Exchange, Practice Pont Communications (lectures), Pri-Med (lectures)
Bajaj	Anurag	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Efficacy of Phosphodiesterase-5 Inhibitor in Patients With Heart Failure With Preserved Ejection Fraction: A Meta-Analysis	Nothing to Disclose
Bajaj	Mandeep	Diabetes and Endothelial Dysfucntion in Heart Failure	Dapagliflozin Attenuates Diabetic Cardiomyopathy and the Activation of the NLRP3/ASC Inflammasome in Mice With Type-2 Diabetes: A Glucose-Lowering and SGLT-2 Independent Effect	RESEARCH/RESEARCH GRANTS - Amylin Pharmaceuticals, Eli- Lilly
Bajaj	Mandeep	Emerging Basic Science in Ischemic Heart Disease	DPP4 Inhibition by Linagliptin Prevents Cardiac Dysfunction and Inflammation by Targeting the NIrp3/Asc Inflammasome	RESEARCH/RESEARCH GRANTS - Amylin Pharmaceuticals, Eli
Bajaj	Navkaranbir	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Integrating Hyperemic Myocardial Blood Flow and Coronary Flow Reserve for Predicting Cardiovascular Mortality Outcomes in Patients With Known or Suspected Ischemic Heart Disease	Nothing to Disclose
Bajaj	Navkaranbir	Nuclear Cardiology: Prognosis	Myocardial Scar but Not Ischemia Predicts Defibrillator Shocks and Sudden Cardiac Death in Patients With Reduced Left Ventricular Ejection Fraction	Nothing to Disclose
Bajaj	Navkaranbir	Interventional Cardiology: TAVR 3	Risk of Adverse Outcomes in Treatment Modalities for Severe Aortic Stenosis in Randomized Control Trials: Direct and Indirect Comparisons	Nothing to Disclose
Bajaj	Navkaranbir	Emerging Developments in HFpEF and Arryhthmias	Influence of Left Ventricular Ejection Fraction on Cause-Specific Mortality in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial	Nothing to Disclose
Bajaj	Navkaranbir	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Relationship of Coronary Flow Reserve With Body Mass Index and Adverse Outcomes in Patients Without Overt Ischemic Heart Disease: Implications for Metabolic Surgery Eligibility	Nothing to Disclose
Bajaj	Navkaranbir	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Association Between Coronary Flow Reserve and Adverse Cardiovascular Events Along a Continuum of Metabolic Disease in Symptomatic Patients Without Overt Coronary Artery Disease	Nothing to Disclose
Bajraktari	Gani	Advances in Lipid Management	Hydrophilic Versus Lipophilic Statins in Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Bajwa	Farhan	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Acute Pulmonary and Paradoxical Embolism Treated With Catheter Based Thrombectomy	Nothing to Disclose
Bajwa	Farhan	Technical Advances in Transthoracic Echocardiography	Safety of Perflutren-Based Echocardiographic Contrast Agent Administration in the Setting of a Patent Foramen Ovale (PFO): A Multicenter Study Conducted in Tertiary Care Centers Based in the New York/Chicago Metropolitan Areas	Nothing to Disclose
Bajwa	Tanvir	Considerations in Antiplatelet Therapy and in ACS	Contemporary Outcomes of Anterior Segment ST-Elevation Myocardial Infarction: A Large 10-Year Tertiary Care Experience	Nothing to Disclose
Bajwa	Tanvir	Vascular Access and Hemostasis Issues	Clinical Efficacy of SoftSeal-STF Hemostatic Pad With Short Hold Time Compared to Traditional Manual Compression After Transfemoral Catheterization	Nothing to Disclose
Bajwa	Tanvir	Interventional Cardiology: PCI and TAVR in Complex Patients	The Risk of Adverse Coronary Events Is Higher in Patients With Severe Obstructive Sleep Apnea Following Percutaneous Coronary Intervention	Nothing to Disclose
Bajwa	Tanvir	Interventional Complexity and Complications	Percutaneous Femoral Artery Access Strategies in Patients Undergoing Peripheral Vascular Intervention: Trends of Use and In- Hospital Outcomes	Nothing to Disclose
Bajwa		From the Real World	Outcomes in Patients Undergoing Cardiac Catheterization and Therapeutic Hypothermia After Cardiac Arrest	Nothing to Disclose
Bajwa	Tanvir	Mechanisms of Vascular Inflammation in Atherogenesis	Comparative Study on Catheter-Directed Thrombolysis - Continuous Tissue Plasminogen Activator Versus Angiojet Catheter Power Pulse Spray Rheolytic Thrombectomy Outcome Study. Single- Center Experience	·
Baker	Brian	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	SALARY - Daiichi Sankyo, Inc.
Baker	Brian	Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes	SALARY - Daiichi Sankyo, Inc.
Baker	Michael	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Comparison of Transesophageal Echocardiography and Computed Tomography Angiography for Left Atrial Appendage Evaluation Prior to WATCHMAN Implantation	Nothing to Disclose
Baker	William	Atrial Fibrillation in Young and Unusual Populations: Children and Adult Congenital Heart Disease	Latest Phramacological Treatments for Atrial Fibrillation	RESEARCH/RESEARCH GRANTS - Agency for Healthcare Research & Description (Quality)
Bakhos	Lara	Non Invasive Imaging: Expanding Clinical Applications	Aortic Valve Calcification Predicts Paravalvular Aortic Regurgitation After Self-Expanding Transcatheter Aortic Valve Replacement	Nothing to Disclose
Bakhsh	M. Umair	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Unusual Presentation of Psuedo Stemi	Nothing to Disclose
Bakhshi	Hooman	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Association of Coronary Artery Calcium With Incident Peripheral Artery Disease: The Multi-Ethnic Study of Atherosclerosis	Nothing to Disclose
Bakhshi	Hooman	Non Invasive Imaging: MR Scar and Perfusion	Association of Right Atrial Function With Incident Atrial Fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA)	Nothing to Disclose
Bakitas	Marie	Innovations in Advocacy and Patient Centered Care	Describing Collaboration Between Cardiology and Palliative Care: A National Survey Study of Current Practices, Challenges and Barriers	Nothing to Disclose
Bakken	Mark	Maximally Effective Vascular Care: Vascular Collaborative Team Care in Action	Case Presentation #2: Panelist	Nothing to Disclose



(M. The second				
Bakker-Arkema	Rebecca	Session Title Diabetes and Other Issues in Cardiovascular	Presentation Title Effect of Gemcabene on Insulin Sensitivity in Nondiabetic, Obese	Disclosures SALARY - Gemphire Therapeutics Inc
Bakris	George	Prevention The Intersection of Diabetes and ASCVD	Subjects Average Clinician Measured Blood Pressure Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes Following Acute	RESEARCH/RESEARCH GRANTS - AbbVie, Inc.,Janssen,Bayer, Relypsa
Bakris	George	33. Prevention: Hypertension Team 1	Coronary Syndromes in the EXAMINE Trial Suggested Reviewer	RESEARCH/RESEARCH GRANTS - AbbVie, Inc.,Janssen,Bayer, Relypsa
Baksi	John	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Cardiovascular Magnetic Resonance in Survivors of Sudden Cardiac Arrest: 14 Year Experience From a Tertiary Referral Centre in the United Kingdom	Nothing to Disclose
Balachandran	Kanarath	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Decision Making Using Fractional Flow Reserve Is Associated With Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With Nstemi	Nothing to Disclose
Balachandran	Parvathi	Advances in Cholesterol Measurement and	Physician Perspectives on Clinical Decision Support for Familial	Nothing to Disclose
Balachandran	Parvathi	Management Innovations in Practice Management and	Hypercholesterolemia Mining Electronic Health Records for Familial Hypercholesterolemia	Nothing to Disclose
Balachandran	Parvathi	Social Media Contemporary Issues in Familial	in eMERGE Network Familial Hypercholesterolemia: Awareness, Detection and Control in	Nothing to Disclose
Balaji	Seshadri	Hypercholesterolemia 10. Congenital Heart Disease: Pediatric Team	the Community Suggested Reviewer	RESEARCH/RESEARCH GRANTS - MEDTRONIC
Balakrishnan	Iswaree	Unusual Presentations of ACS	Prevalence and Evolution of Sleep Disordered Breathing in Acute	Nothing to Disclose
Balakrishnan	Iswaree	FIT Clinical Decision Making: Acute Coronary Syndrome and Vascular Medicine	Myocardial Infarction "Balanced Ischemia" on ECG in Dual Territory STEMI	Nothing to Disclose
Balakrishnan	Revathi	35. Pulmonary Hypertension and Pulmonary	Suggested Reviewer	Nothing to Disclose
Balan	Prakash	Thrombo-embolic Disease Team 1 Challenging Anatomies: Does TAVR Device	Co-Chair	Nothing to Disclose
Balan	Prakash	Choice Matter Interventional Cardiology: PCI and TAVR in	Predicting Risk Factors for Permanent Pacemaker Placement	Nothing to Disclose
Balan	Prakash	Complex Patients Interventional Cardiology: PCI and TAVR in	Following Transcatheter Aortic Valve Replacement: A UTHealth Experience Timing and Algorithm of Permanent Pacemaker Implantation After	Nothing to Disclose
Balan	Prakash	Complex Patients Interventional Cardiology: TAVR 3	TAVR Transapical TAVR Is Associated With Higher Morbidity and Mortality	Nothing to Disclose
Balan	Tukusii	interventional dardiology. 174410	Compared to Transfemoral TAVR in Men but Not in Women	Nothing to Bischood
Balan	Prakash	The Challenges of Outcome Prediction in Valvular Heart Disease	Gender-Based Outcomes in Diabetics Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Balderas	Karla	The Challenges of Outcome Prediction in Valvular Heart Disease	Right Ventricle Free Wall Strain Predicts Post-Surgical Low Cardiac Output Syndrome in Patients Undergoing Aortic Valve Replacement	Nothing to Disclose
Balfour	Pelbreton	Blips, Trops, and Chips: New Ways to Diagnose CAD	Incremental Diagnostic Accuracy of High Frequency QRS Analysis Over ST-Analysis for Myocardial Ischemia: Multi-Center Prospective Cohort	Nothing to Disclose
Balghith	Mohammed	Diabetes, Hyperlipidemia, and Coronary Artery Disease, Prevention and Treatment: International Perspectives From the Japanese College of Cardiology, Saudi Heart Association, and American College of Cardiology	Co-Chair	SPEAKER'S BUREAU - King SAUD bin Abdulaziz university for health science
Balkan	Wayne	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Role of Gender on Mesenchymal Stem Cell Therapy in Non- lschemic Dilated Cardiomyopathy: A Sub-Analysis of the POSEIDON-DCM Trial	Nothing to Disclose
Ball	Timothy	Changing the Natural History of Valve Disease With Medical Therapy	Rates of Mechanical Valve Thrombosis After Discontinuation of Anticoagulation	Nothing to Disclose
Balla	Sudarshan	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	41-Year-Old Patient With Double Inlet Left Ventricle Without Pulmonic Stenosis Presenting With Eisenmenger's Syndrome	Nothing to Disclose
Ballantyne	Christie	Prevention of ASCVD Over the Lifespan: A Case-based Approach	Synome Panelist	CONSULTANT FEES/HONORARIA - Abbott Diagnostic, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Isly, Esperion, Ionis, Matinas BioPharma Inc, Merck & amp; amp; Company, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo; OTHER - Roche; RESEARCH/IRESEARCH GRANTS - Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo
Ballantyne	Christie	Harnessing the Power of Genetics to Prevent ASCVD	Severe Hypercholesterolemia: Does the Genotype Matter?	CONSULTANT FEES/HONORARIA - Abbott Diagnostic,Amarin,Amgen,AstraZeneca,Boehringer Ingelheim,Eli Lilly,Esperion,Ionis,Matinas BiOPharma Inc,Merck & Company,Novartis,Pfizer,Regeneron,Roche Diagnostic,Sanofi- Synthelabo; OTHER - Roche; RESEARCH/IRESEARCH GRANTS - Abbott Diagnostic, Amarin,Amgen,Eli Lilly,Esperion,Ionis,Novartis,Pfizer,Regeneron,Roche Diagnostic,Sanofi-Synthelabo
Ballantyne	Christie	Coming to Consensus in a New Era: The Role of Non-statin Therapies in ASCVD Risk Reduction	Panelist	CONSULTANT FEES/HONORARIA - Abbott Diagnostic, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Illy, Esperion, Ionis, Matinas BioPharma Inc. Merck & amp; amp; Company, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo; OTHER - Roche; RESEARCH/RESEARCH GRANTS - Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo
Ballantyne	Christie	Advances in Cholesterol Measurement and Management	Association of Remnant-Like Particle Cholesterol and Low-Density Lipoprotein Triglyceride With Incidence of Cardiovascular Events: The ARIC Study<⊳	CONSULTANT FEES/HONORARIA - Abbott Diagnostic,Amarin,Amgen,AstraZeneca,Boehringer Ingelheim,Eli Iliy,Esperion,Ionis,Matinas BioPharma Inc,Merck & Company,Novartis,Pfizer,Regeneron,Roche Diagnostic,Sanofi- Synthelabo; OTHER - Roche; RESEARCH/RESEARCH GRANTS - Abbott Diagnostic,Amarin,Amgen,Eli Liliy,Esperion,Ionis,Novartis,Pfizer,Regeneron,Roche Diagnostic,Sanofi-Synthelabo
Ballantyne	Christie	Markers of Prognosis Associated With Elevated Blood Pressure	Isolated Systolic Hypertension and Pulse Pressure Are Associated With High-Sensitivity Cardiac Troponin-T and NT-pro BNP in Older Adults	CONSULTANT FEES/HONORARIA - Abbott Diagnostic,Amarin,Amgen,AstraZeneca,Boehringer Ingelheim,Eli Iliy,Esperion,Ionis,Matinas BioPharma Inc,Merck & Company,Novartis,Pfizer,Regeneron,Roche Diagnostic,Sanofi- Synthelabo; OTHER - Roche; RESEARCH/IRESEARCH GRANTS - Abbott Diagnostic,Amarin,Amgen,Eli Lilly,Esperion,Ionis,Novartis,Pfizer,Regeneron,Roche Diagnostic,Sanofi-Synthelabo

and the second				<u> </u>
Last Name Ballantyne	First Name Christie	Session Title Arrhythmias and Clinical EP: AF Miscellaneous	Presentation Title Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation	Disclosures CONSULTANT FEES/HONORARIA - Abbott
Ý		and Surgical Issues	and Stroke Among Whites and Blacks: The Atherosclerosis Risk In Communities (ARIC) Study	Diagnostic, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Esperion, Ionis, Matinas BioPharman Inc, Merck & Amp; amp; Company, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo; OTHER - Roche; RESEARCH/RESEARCH GRANTS - Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo
Ballantyne	Christie	Recent Trends in Combination Therapy: Managing Cholesterol Even in the Most Resistant	The Impact of the Days Late-Breaking Clinical Trial	CONSULTANT FEES/HONORARIA - Abbott Diagnostic, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Esperion, Jonis, Matinas BiOPharma Inc, Merck & amp;amp; Company, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo; OTHER - Roche; RESEARCH/IRESEARCH GRANTS - Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo
Ballantyne	Christie	Contemporary Issues in Familial Hypercholesterolemia	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Abbott Diagnostic, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Esperion, Ionis, Matinas BioPharma Inc. Merck & Amp; amp; Company, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi- Synthelabo; OTHER - Roche; RESEARCH/RESEARCH GRANTS - Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo
Ballantyne	Christie	Improving Risk Assessment in Atherosclerosis	Development and Validation of Prediction Models With Non- Traditional Markers for 10-Year Risk of Ischemic Leg Amputation Among Persons With Diabetes: The Atherosclerosis Risk In Communities (ARIC) Study	CONSULTANT FEES/HONORARIA - Abbott Diagnostic, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Esperion, Ionis, Matinas BioPharma Inc. Merck & Amp; amp; Company, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi- Synthelabo; OTHER - Roche; RESEARCH/RESEARCH GRANTS - Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo
Ballantyne	Christie	32. Prevention: Clinical Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Diagnostic, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Esperion, Ionis, Matinas BioPharma Inc, Merck & amp; amp; Company, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo; OTHER - Roche; RESEARCH/RESEARCH GRANTS - Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo
Balter	Stephen	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Estimating Cancer Risk Associated With Ionizing Radiation Exposure During Atrial Fibrillation Ablation	Nothing to Disclose
Bamberger	Charlotte	Advances in Cholesterol Measurement and	The Effect of PCSK9 Inhibition on LDL-Subfractions in Patients With	Nothing to Disclose
Bamberger	Charlotte	Management Updates on Risk Factors for Cardiovascular Disease	Severe LDL-Hypercholesterolemia Walnut-Enriched Diet Reduces Lipids in Healthy Caucasian Subjects, Independent of Recommended Macronutrient	Nothing to Disclose
Banach	Maciej	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Replacement Edoxaban Therapy Increases Treatment Satisfaction and Reduces Utilization of Health Care Resources: An Analysis From the Edoxaban versus warfariN in subjectS UndeRgoing cardiovErsion of Artiar Eibrilation (EMSURE-AF) Study	CONSULTANT FEES/HONORARIA - Abbott Laboratories (Abbott Vascular),Amgen Inc.,Esperion,Merck & Co., Inc.,Resverlogx,SANOFI; RESEARCH/RESEARCH GRANTS - Dailchi Sanky, Valleant
Banach	Maciej	Advances in Lipid Management	Hydrophilic Versus Lipophilic Statins in Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials	CONSULTANT FEES/HONORARIA - Abbott Laboratories (Abbott Vasculan),Amgen Inc.,Esperion,Merck & Co., Inc.,Resverlogix,SANOFI; RESEARCH/RESEARCH GRANTS - Daiichi Sankyo,Valleant
Banai	Shmuel	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Absence of Clinical Triggering in Diabetic Patients With ST-Segment Elevation Myocardial Infarction Predicts Multiple Vessel Coronary Disease and Is Associated With Increased Mortality	Nothing to Disclose
Banchs	Javier	Core Curriculum: Decisions on Afib: From	Lifestyle Changes to Prevent Atrial Fibrillation: From Drinks to Sleep	Nothing to Disclose
Banday	Wamiq Y.	Prevention to Cure Considerations in Antiplatelet Therapy and in	Contemporary Outcomes of Anterior Segment ST-Elevation	Nothing to Disclose
Bandera	Francesco	Emerging Applications of Echocardiography	Myocardial Infarction: A Large 10-Year Tertiary Care Experience Functional and Hemodynamic Response During Exercise in Heart	Nothing to Disclose
Bandettini	W. Patricia	FIT Clinical Decision Making: Non-Invasive	Failure Intermediate Versus Reduced Ejection Fraction The Pulmonary Embolism That Wasn't: A Case of Pulmonary	Nothing to Disclose
Bandettini	W. Patricia	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Non-Invasive	Pseudo-Sequestration Reversible Severe Right Heart Failure and Tricuspid Regurgitation	Nothing to Disclose
Bandettini	W. Patricia	Imaging and Valvular Heart Disease Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	From Thyrotoxicosis Cardiovascular Magnetic Resonance in the Evaluation of Fibrofatty Infiltration for Arrhythmogenic Right Ventricular	Nothing to Disclose
Bandstein	Nadia	Acute Coronary Syndromes, Diagnosis,	Dysplasia/Cardiomyopathy (ARVD/C) High-Sensitivity Cardiac Troponin T Levels and Long-Term Mortality	Nothing to Disclose
Banerjee	Amal	Management and Outcomes STEMI in the Emerging World: International Perspectives From the Cardiological Society of India, Mexican Society of Cardiology, and American College of Cardiology	in Patients With Chest Pain Thrombolysis in STEMI: Indian Scenario	Nothing to Disclose
Banerjee	Anirban	ACC International Conferences Best Posters	Assessment of Left Ventricular Strain and Its Clinical Correlations in Isolated Left Ventricular Non-Compaction	Nothing to Disclose
Banerjee	Anirban	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Left Atrial Stiffness: A New Noninvasive Index That May Serve as a Surrogate Marker of Left Ventricular Diastolic Dysfunction in	Nothing to Disclose
Banerjee	Dipanjan	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Children Hemophagocytic Lymphohistiocytosis Associated With Implantation of Ventricular Assist Devices and Outcomes Following Subsequent	RESEARCH/RESEARCH GRANTS - HeartWare, Thoratec
Banerjee	Dipanjan	Advanced Therapies = Advanced Trouble:	Orthotropic Heart Transplantation (OHT) Differential Outcomes of Temporary Mechanical Circulatory Support	RESEARCH/RESEARCH GRANTS - HeartWare,Thoratec
Banerjee	Dipanjan	VAD and Transplant Challenges 13. Heart Failure and Cardiomyopathies:	Devices by Procedural Timing and Clinical Indication Suggested Reviewer	RESEARCH/RESEARCH GRANTS - HeartWare, Thoratec
Banerjee	Kinjal	Clinical Team 5 Interventional Cardiology: TAVR 1	Novel Plane of Measurement to Evaluate Accurate Valve Size in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Banerjee	Kinjal	Valvular Heart Disease: Mitral Valve Disease	Warfarin Use and Progression of Mitral Annular Calcification	Nothing to Disclose
Banerjee	Kinjal	Interventional Cardiology: TAVR 2	Impact of Active Coronary Artery Disease on the Early and 1 Year Mortality of Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis	Nothing to Disclose
Banerjee	Kinjal	Interventional Cardiology: TAVR 2	Outcomes of Transcatheter Aortic Valve Replacement Without Balloon Predilation: A Systematic Review and Meta-Analysis	Nothing to Disclose
Banerjee	Kinjal	Interventional Cardiology: TAVR 3	Comparison of Acute Elastic Recoil Between CoreValve and SAPIEN 3 Valves in Transcatheter Aortic Valve Replacement	Nothing to Disclose



and the same of th					
Last Name	First Name	Session Title	Presentation Title	Disclosures	
Banerjee	Riju	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Comparison of In-Hospital Outcomes of Septic Shock Patients With and Without Atrial Fibrillation: A Retrospective Propensity-Matched Analysis	Nothing to Disclose	
Banerjee	Subhash	Aorto-iliac Disease and Treatment: Practice at "The Edge" in Peripheral Intervention	All Hands on Deck: How to Prevent or Manage Complications of Aorto-iliac Intervention	CONSULTANT FEES/HONORARIA - Boston : OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation,Merck & Demp; Co., In BUREAU - CSI,MEDTRONIC	NCIPAL - Mdcare S - Boston
Banerjee	Subhash	Contemporary Role of Intracoronary Imaging: Candid Conversation with Peers	Co-Chair	CONSULTANT FEES/HONORARIA - Boston: OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation,Merck & Dempire Co., In BUREAU - CSI,MEDTRONIC	NCIPAL - Mdcare S - Boston
Banerjee	Subhash	Contemporary Role of Intracoronary Imaging: Candid Conversation with Peers	FFR, IVUS, NIRS or OCT: Selecting One for My Lab or Should I Have It All	CONSULTANT FEES/HONORARIA - Boston: OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation, Merck & amp; amp; Co., II BUREAU - CSI, MEDTRONIC	NCIPAL - Mdcare S - Boston
Banerjee	Subhash	Clinical Assessment and Revascularization for Critical Limb Ischemia	Endovascular Revascularization for CLI Current and Future Therapies	CONSULTANT FEES/HONORARIA - Boston : OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation, Merck & amp; amp; Co., II BUREAU - CSI, MEDTRONIC	NCIPAL - Mdcare S - Boston
Banerjee	Subhash	Interrupting DAPT for Surgery, Afib, or Bleeding	Panelist	CONSULTANT FEES/HONORARIA - Boston: OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation, Merck & amp; amp; Co., II BUREAU - CSI, MEDTRONIC	NCIPAL - Mdcare S - Boston
Banerjee	Subhash	Interrupting DAPT for Surgery, Afib, or Bleeding	Interruption of DAPT Due to Need for Surgery	CONSULTANT FEES/HONORARIA - Boston : OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation, Merck & December 1988 (1988) BUREAU - CSI.MEDTRONIC	NCIPAL - Mdcare S - Boston
Banerjee	Subhash	Core Curriculum: ACS: What Would You Do?	Pharmacologic Options: Update on Antiplatelet Therapies in ACS	CONSULTANT FEES/HONORARIA - Boston : OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation, Merck & December 1981 - CS. MEDTRONIC BUREAU - CSI. MEDTRONIC	NCIPAL - Mdcare S - Boston
Banerjee	Subhash	Highlighted Original Research: Prevention and the Year in Review	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 16,721 Patients From 33 Randomized Clinical Trials	CONSULTANT FEES/HONORARIA - Boston : OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation, Merck & amp; amp; Co., In BUREAU - CSI, MEDTRONIC	NCIPAL - Mdcare S - Boston
Banerjee	Subhash	Head to Toe: Outcomes of Endovascular Interventions	Atherectomy is Associated With Lower Rates of Repeat Intervention After Below Knee Peripheral Vascular Intervention	CONSULTANT FEES/HONORARIA - Boston: OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation, Merck & amp; amp; Co., In BUREAU - CSI.MEDTRONIC	NCIPAL - Mdcare S - Boston
Banerjee	Subhash	Head to Toe: Outcomes of Endovascular Interventions	Utilization of Distal Embolic Protection in Infrainguinal Peripheral Arterial Intervention: Insights From the Multicenter XLPAD Registry	CONSULTANT FEES/HONORARIA - Boston: OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation,Merck & Dempire Co., In BUREAU - CSI,MEDTRONIC	NCIPAL - Mdcare S - Boston
Banerjee	Subhash	Head to Toe: Outcomes of Endovascular Interventions	Association of Cigarette Smoking With Procedural Cost of Lower Extremity Endovascular Intervention	CONSULTANT FEES/HONORARIA - Boston: OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation,Merck & Dry; 200, II BUREAU - CSI,MEDTRONIC	NCIPAL - Mdcare 'S - Boston nc.; SPEAKER'S
Banerjee	Subhash	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Coronary Atherectomy for Treatment of Calcified Coronary Artery Lesions Is Associated With Increased Procedural Success and Lower Procedural Complication Rates: Insights From a National Veteran Cohort	CONSULTANT FEES/HONORARIA - Boston : OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation, Merck & Demp; Co., In BUREAU - CSI, MEDTRONIC	NCIPAL - Mdcare 'S - Boston nc.; SPEAKER'S
Banerjee	Subhash	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Contemporary Use of Laser During Percutaneous Coronary Intervention: Results From the Laser Veterans Affairs (LAVA) Multicenter Registry	CONSULTANT FEES/HONORARIA - Boston : OWNERSHIP INTERESTIPARTINERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation,Merck & Co., In BUREAU - CSI,MEDTRONIC	NCIPAL - Mdcare 'S - Boston nc.; SPEAKER'S
Banerjee	Subhash	Coronary Intervention in Interventional Cardiology: Advanced Device Use	A Meta-Analysis of Contemporary Lesion Modification Strategies During Percutaneous Coronary Intervention in 244,665 Patients From 21 Studies	CONSULTANT FEES/HONORARIA - Boston : OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation,Merck & mp;amp; Co., In BUREAU - CSI,MEDTRONIC	NCIPAL - Mdcare 'S - Boston nc.; SPEAKER'S
Banerjee	Subhash	Innovations in Advocacy and Patient Centered Care	Diverse Perspectives and Training Paths in Cardiology: An Analysis of Authorship in the <i>→Journal of the American College of Cardiology</i>	CONSULTANT FEES/HONORARIA - Boston : OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation,Merck & mp;amp; Co., In BUREAU - CSI,MEDTRONIC	NCIPAL - Mdcare 'S - Boston nc.; SPEAKER'S
Banerjee	Subhash	Advances in Chronic Total Occlusion Intervention	Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions Improves Peak Oxygen Uptake During Cardiopulmonary Exercise Testing	Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation, Merck & Description of the BUREAU - CSI, MEDTRONIC	NCIPAL - Mdcare 'S - Boston nc.; SPEAKER'S
Banerjee	Subhash	Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	CONSULTANT FEES/HONORARIA - Boston : OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation, Merck & amp; amp; Co., II BUREAU - CSI, MEDTRONIC	NCIPAL - Mdcare S - Boston
Banerjee	Subhash	Advances in Chronic Total Occlusion Intervention	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	CONSULTANT FEES/HONORARIA - Boston: OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation, Merck & Demp; Co., II BUREAU - CSI, MEDTRONIC	NCIPAL - Mdcare S - Boston
Banerjee	Subhash	Interventional Complexity and Complications	Variability in Transfemoral Access for Coronary Angiography and Interventions: Results From an International Survey	CONSULTANT FEES/HONORARIA - Boston: OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation, Merck & amp; amp; Co., II BUREAU - CSI,MEDTRONIC	NCIPAL - Mdcare 'S - Boston nc.; SPEAKER'S
Banerjee	Subhash	Endovascular Therapy: Running From Risk	Predictors of Procedural Complications in Infrainguinal Endovascular Interventions	CONSULTANT FEES/HONORARIA - Boston : OWNERSHIP INTEREST/PARTNERSHIP/PRI Global LLC; RESEARCH/RESEARCH GRANT Scientific Corporation, Merck & amp; amp; Co., II BUREAU - CSI, MEDTRONIC	NCIPAL - Mdcare S - Boston

				<u> </u>
Last Name Banerjee	First Name Subhash	Session Title Highlights in Vascular Medicine Research	Presentation Title Comparative Assessment of Subintimal Versus Intraluminal	Disclosures CONSULTANT FEES/HONORARIA - Boston Scientific:
Bancijee	Gubriasii	Ingringino in vascala medicine rescarci	Crossing of Infrainguinal Chronic Total Occlusion Lesions	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Mdcare Global LLC; RESEARCH/RESEARCH GRANTS - Boston Scientific Corporation, Merck & Dr., amp; Co., Inc.; SPEAKER'S BUREAU - CSI, MEDTRONIC
Banerjee	Subhash	02. Acute and Stable Ischemic Heart Disease: Clinical Team 4	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Mdcare Global LLC; RESEARCH/RESEARCH GRANTS - Boston
				Scientific Corporation,Merck & Duramp; Co., Inc.; SPEAKER'S BUREAU - CSI,MEDTRONIC
Banfi	Carlo	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Silent Cerebral Microbleeds During TAVR: Insight From a Prospective Cerebral MRI Cohort	Nothing to Disclose
Banga	Gunjan	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Sudden Cardiac Arrest in a Patient With Thyroid Storm	Nothing to Disclose
Bangalore	Sripal	Late-Breaking Clinical Trials: Deep Dive I	Panelist	CONSULTANT FEES/HONORARIA - Abbott Laboratories Abbot Vascular,Boerhringer Ingelheim, Daiichi Sankyo, Gilead Sciences, Inc., Merck & Co., Inc.,Pfizer; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,NHLBI
Bangalore	Sripal	Great Debates in Ischemia 2017	Chronic Renal Failure Patients Benefit From Revascularization for Ischemia: CON	CONSULTANT FEES/HONORARIA - Abbott Laboratories Abbot Vascular, Boerhringer Ingelheim, Daiichi Sankyo, Gilead Sciences, Inc., Merck & Bamp; amp; Co., Inc., Pfizer; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, NHLBI
Bangalore	Sripal	02. Acute and Stable Ischemic Heart Disease: Clinical Team 4	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Abbot Vascular, Boerhringer Ingelheim, Dailchi Sankyo, Gilead Sciences, Inc., Merck Aampiamp; Co., Inc., Pfizer, RESEARCH/RESEARCH GRANTS - Abbott Laboratories, NHLBI
Bangalore Prakash	Pradeep	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Calcium Sensitivity and Myocardial Function After Neonatal Cardiac Surgery	Nothing to Disclose
Bangalore Prakash	Pradeep	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Unusual Electrocardiographic Findings in an Infant With Extreme Hypercalcemia	Nothing to Disclose
Banka	Puja	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Prediction Tool for Congenital Heart Surgery Length of Stay	Nothing to Disclose
Banka	Puja	Arrhythmias and Clinical EP: Devices 1	Coronary Artery Compression by Epicardial Leads: More Common Than We Think	Nothing to Disclose
Banka	Sahil	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Eptifibatide for Treatment of Mechanical Aortic Valve Thrombus: A Novel Therapeutic Approach	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Vitalis LLC
Banning	Adrian	Highlighted Original Research: Interventional Cardiology and the Year in Review	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	Nothing to Disclose
Banning	Adrian	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Differences and Level of Agreement in SYNTAX Score Assessment Between Site Operators and Angiographic Core Laboratory	Nothing to Disclose
Banning	Adrian	Refining PCI Technique and Outcomes	Readers: Insights From the EXCEL Trial Treatment of Left Main Coronary Artery Disease in Patients With Diabetes: 3-Year Outcomes Comparing CABG and PCI With Exercising Fluting Starts From the EXCEL Starts.	Nothing to Disclose
Banning	Adrian	Refining PCI Technique and Outcomes	Everolimus-Eluting Stents From the EXCEL Study Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory	Nothing to Disclose
Banning	Amerjeet	Interventional Cardiology: PCI in Complex	Assessment: Insights From the EXCEL Trial Development of a Novel Side-Branch Stent: In-Vitro Study	Nothing to Disclose
Bano	Shah	Patients Arrhythmias and Clinical EP: AF Miscellaneous	Association Between Body Mass Index and Outcomes Among	Nothing to Disclose
Bansal	Eric	and Surgical Issues FIT Clinical Decision Making: Interventional	Patients With Prevalent Atrial Fibrillation: A Meta-Analysis Treatment of Refractory Coronary Artery Spasm With Percutaneous	Nothing to Disclose
Bansal	Eric	Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Clinical Decision Making: Interventional	Coronary Intervention Therapeutic Dilemma in a Case With Coronary Artery Aneurysm	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	and Large Thrombus Burden	
Bansilal	Sameer	New Insights Into Prediction and Treatment of Hypertension	Dietary Sodium Intake Among United States Adults With Hypertension, 1999-2012	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals
Bansilal	Sameer	02. Acute and Stable Ischemic Heart Disease: Clinical Team 5	Suggested Reviewer	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals
Bao	Haikun	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Admission Types Among Patients With Heart Failure Cared for by Accountable Care Organizations: Variation by Performance on a	Nothing to Disclose
Bao	Huihui	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Measure of Risk Standardized Acute Admission Rates Serum Homocysteine Lowering by Long-Term Low-Dose Folic Acid: New Insight on ≺i>MTHFRFoene-Folate Interaction From China Stroke Primary Prevention Trial	Nothing to Disclose
Bapat	Vinayak	TAVR for Degenerated Surgical Valves: What You Need to Know from A to Z	TAVR in Prior Surgical Mitral Valve Ring	CONSULTANT FEES/HONORARIA - Boston Scientiffic,Boston Scientiffic; RESEARCH/RESEARCH GRANTS - Boston Scientiffic,Edwards Lifesciences,Sorin Group; SPEAKER'S
Baquero	Giselle	Vascular Access and Hemostasis Issues	Efficacy and Safety of Transulnar Compared to Transradial Arterial Access in Patients Undergoing Coronary Angiography: A Systematic Review and Meta-Analysis	BUREAU - Edwards Lifesciences, Sorin Group Nothing to Disclose
Barac	Ana	FIT Forum: Mix and Mingle	Cardio-Oncology	Nothing to Disclose
Barac	Ana	Imaging of Cancer-Treatment Associated CV Toxicity: Applying Guidelines to Clinical Practice	Cancer-treatment related LV dysfunction in clinical practice.	Nothing to Disclose
Barac	Ana	Vasculo-Oncology: What You Need to Know About Vascular and Thrombotic Complications of Cancer and Cancer Therapeutics	Chemotherapeutic Associated Hypertension: Clinical Evaluation and Management	Nothing to Disclose
Barac	Ana	Heart Failure and Cancer Care	Co-Chair	Nothing to Disclose
Barac	Ana	Heart Failure and Cancer Care	Case Presentation: Cardiomyopathy with Herceptin – When Should You Stop Herceptin, If Ever? Evidence to Practice Roundtable Discussion	Nothing to Disclose
Barac	Ana	28. Non Invasive Imaging: Echo Team 1	Suggested Reviewer	Nothing to Disclose
Barac Barakat	Ana Mohamad	FIT Clinical Decision Making Reviewers 6 Imaging the Athlete's Heart	ACC FIT Clinical Decision Making Reviewer General Population Screening for Sudden Cardiac Death in Young Individuals: Is It Feasible, Is It Justifiable & How Much Does It	Nothing to Disclose Nothing to Disclose
Barake	Walid	Percutaneous Coronary Intervention: Lessons	Cost? Nine Year Trends in Cause-Specific Mortality After Percutaneous	Nothing to Disclose
Daidke	vvallu	From the Real World	Nine Year Trends in Cause-specific Mortality After Percutaneous Coronary Intervention: Observations From the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Registry	Treating to DISCHOSE
Baran	David	Cardiogenic Shock: Drugs to Devices	Panelist Panelist	CONSULTANT FEES/HONORARIA - Maquet, Otsuka, TandemLife; RESEARCH/RESEARCH GRANTS Astellas Pharma US; SPEAKER'S BUREAU - Novartis Corporation



and the second				l
Last Name	First Name	Session Title	Presentation Title	Disclosures CONSULTANT FEES/HONORARIA -
Baran	David	Cardiogenic Shock: Drugs to Devices	Short-Term Mechanical Support in CardiogenicShockSo Many Devices	Waquet, Otsuka, TandemLife; RESEARCH/RESEARCH GRANTS - Astellas Pharma US; SPEAKER'S BUREAU - Novartis Corporation
Baran	David	Give Me a Beat! Mechanical Support of Cardiogenic Shock	Treating Cardiogenic Shock: Challenging Cases and Complications	CONSULTANT FEES/HONORARIA - Maquet, Otsuka, TandemLife; RESEARCH/RESEARCH GRANTS - Astellas Pharma US; SPEAKER'S BUREAU - Novartis
Baran	David	Everything you Wanted to Know About Heart Transplant but Were Afraid to Ask	Panelist	Corporation CONSULTANT FEES/HONORARIA - Maquet, Otsuka, TandemLife; RESEARCH/RESEARCH GRANTS Astellas Pharma US; SPEAKER'S BUREAU - Novartis
Baran	David	Everything you Wanted to Know About Heart Transplant but Were Afraid to Ask	Immunosuppression 101	Corporation CONSULTANT FEES/HONORARIA - Maquet, Ofsuka, TandemLife; RESEARCH/RESEARCH GRANTS Astellas Pharma US; SPEAKER'S BUREAU - Novartis
Baran	David	Emerging Developments in HFpEF and	Is Continuous Outpatient Milrinone Therapy Appropriate in Stage D	Corporation CONSULTANT FEES/HONORARIA -
		Arryhthmias	Heart Failure Patients With Underlying Ventricular Tachycardia	Maquet,Otsuka,TandemLife; RESEARCH/RESEARCH GRANTS - Astellas Pharma US; SPEAKER'S BUREAU - Novartis Corporation
Baran	David	Advanced Therapies = Advanced Trouble: VAD and Transplant Challenges	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Maquet, Otsuka, TandemLife; RESEARCH/RESEARCH GRANTS - Astellas Pharma US; SPEAKER'S BUREAU - Novartis Corporation
Baran	David	13. Heart Failure and Cardiomyopathies: Clinical Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Maquet, Otsuka, TandemLife; RESEARCH/RESEARCH GRANTS - Astellas Pharma US; SPEAKER'S BUREAU - Novartis Corporation
Barasch	Eddy	Interventional Cardiology: TAVR 3	The Natural History of Paravalvular Regurgitation After Transarterial Valve Implantation for Severe Aortic Stenosis: One Center Experience	Nothing to Disclose
Barbant	Sophie	Novel Echocardiographic Methods for Assessing Cardiac Function	Clinical Validation of ASE 2016 Guidelines for Evaluating Left Ventricular Diastolic Dysfunction	Nothing to Disclose
Barbanti	Marco	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	CONSULTANT FEES/HONORARIA - Edwards Lifesciences
Barbanti	Marco	Challenging Anatomies: Does TAVR Device	Management for Bicuspid Versus Tricuspid Aortic Valve Stenosis Management of Left Ventricular Outflow Tract Calcium	CONSULTANT FEES/HONORARIA - Edwards Lifesciences
Barbanti	Marco	Choice Matter 17. Interventional Cardiology: Aortic Valve	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Edwards Lifesciences
Barbash	Israel	Disease Team 1 Interventional Cardiology: TAVR 4	Transacatheter Aortic Valve Replacement And Malignancy	Nothing to Disclose
Barbash	Israel	Interventional Cardiology: TAVR 4 Anti-Platelet Therapies: Always a Sticky Topic	Rapid Ventricular Pacing During TAVR Is Associated With Poor Short- and Long-Term Outcome Chewing Versus Traditional Swallowing of Ticagrelor to Accelerate	Nothing to Disclose
Barbash	Israel		Platelet Inhibition in ST Elevation Myocardial Infarction: The CHEERS-STEMI Study	Nothing to Disclose
Barbash	Issi	Refining TAVR Outcomes	The Association of Coronary Artery Disease Severity and Pre Procedural Completeness of Revasclarization on Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Barbati	Giulia	Updates in Stable Ischemic Heart Disease	The Close Relationship Between Drug Intolerance and Major Cardiac and Cerebrovascular Events After an Acute Coronary Syndrome or Coronary Revascularization	Nothing to Disclose
Barbati	Giulia	Predicting Outcomes in Cardiac Rehabilitation Patients	Predictors of Major Adverse Cardiac Events in Long-Term Follow- Up After Cardiac Rehabilitation	Nothing to Disclose
Barbayannis	Georgia	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Association Between Myocardial Infarction Hospital Process of Care Scores With Clinical Outcomes in a Statewide Study	Nothing to Disclose
Barbeau	Gerald	19. Interventional Cardiology: Complex	Suggested Reviewer	Nothing to Disclose
Barbieri	Lucia	Patients/Comorbidities Team 1 Interventional Cardiology: TAVR 2	Dual Antiplatelet Therapy Versus Single Antiplatelet Regimen With or Without Anticoagulation in Transcatheter Aortic Valve	Nothing to Disclose
Barbosa	Carlos	Nuclear Cardiology: Prognosis	Replacement: Indirect Comparison and Meta-Analysis Rest Myocardial Perfusion Imaging in the Management of Chest Pain: A Feasible and Secure Protocol in a Brazilian Emergency	Nothing to Disclose
Barbosa	Carlos	Emerging Basic Science in Ischemic Heart Disease	Department Platelet Aggregability, Coagulation, Fibrinolysis and Inflammation in Patients With Coronary Artery Disease and Previous	Nothing to Disclose
Barbosa	Carlos	Antithrombotic Therapy in Ischemic Heart Disease	Cerebrovascular Ischemic Event Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery	Nothing to Disclose
Bar-Cohen	Yaniv	Fibrillatory Arrhythmias: Outcomes With	Disease Contemporary Causes and Outcomes of Out of Hospital Ventricular	Nothing to Disclose
Bardaji	Alfredo	Contemporary Practice Acute Coronary Syndromes, Diagnosis,	Fibrillation in Pediatric Patients	Nothing to Disclose
-		Management and Outcomes	Coronary Syndrome in Whom the Diagnosis Is Not Confirmed	-
Barker	Colin	Interventional Cardiology: TAVR 2	Platelets and von Willebrand Factor Interactions After Transcatheter Aortic Valve Replacement (TAVR): Association With Thrombocytopenia and Thrombosis	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,MEDTRONIC
Barker	Colin	36. Valvular Heart Disease: Clinical Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific, MEDTRONIC
Barker Barker	Piers Piers	Precision Medicine: It's Hot, But What Is It? Precision Medicine: It's Hot, But What Is It?	Panelist Can Computational Fluid Dynamic Assessment Impact	Nothing to Disclose Nothing to Disclose
Barnes	Geoffrey	Challenging the Standard of Care: Emerging Concepts in VTE Treatment and Prevention	Management of Anomalous Coronary Arteries? Co-Chair	CONSULTANT FEES/HONORARIA - Aralez, BMS/Pfizer, Portola; RESEARCH/RESEARCH GRANTS - Blue Cross Blue Shield of
Barnes	Geoffrey	Maximally Effective Vascular Care: Vascular Collaborative Team Care in Action	Co-Chair	Michigan,BMS/Pfizer CONSULTANT FEES/HONORARIA - Aralez,BMS/Pfizer,Portola; RESEARCH/RESEARCH GRANTS - Blue Cross Blue Shield of
Barnes	Geoffrey	Maximally Effective Vascular Care: Vascular Collaborative Team Care in Action	Case Presentation #1: Panel Discussion Moderator	Michigan,BMS/Pfizer CONSULTANT FEES/HONORARIA - Aralez,BMS/Pfizer,Portola; RESEARCH/RESEARCH GRANTS - Blue Cross Blue Shield of
Barnes	Geoffrey	Vasculo-Oncology: What You Need to Know About Vascular and Thrombotic Complications of Cancer and Cancer Therapeutics	Debate: Optimal Treatment Approaches to Cancer-Induced Thrombosis: VKA vs LMWH vs DOACs: Pro-DOACs	Michigan,BMS/Pfizer CONSULTANT FEES/HONORARIA - Aralez,BMS/Pfizer,Portola; RESEARCH/RESEARCH GRANTS - Blue Cross Blue Shield of Michigan,BMS/Pfizer
Barnes	Geoffrey	Multi-Disciplinary Care for Acute Pulmonary Embolism: The PE Response Team (PERT)	Panelist	CONSULTANT FEES/HONORARIA - Aralez,BMS/Pfizer,Portola; RESEARCH/RESEARCH GRANTS - Blue Cross Blue Shield of
Barnes	Geoffrey	Model Innovation in Practice Management, Advocacy, and Education	Evaluating the Role of Anticoagulation Clinical Pharmacists for Coordinating Periprocedural Anticoagulation	Michigan,BMS/Pfizer CONSULTANT FEES/HONORARIA - Aralez,BMS/Pfizer,Portola; RESEARCH/RESEARCH GRANTS - Blue Cross Blue Shield of
Barnes	Geoffrey	40. Vascular Medicine: Non Coronary Arterial Disease Team 1	Suggested Reviewer	Michigan,BMS/Pfizer CONSULTANT FEES/HONORARIA - Aralez,BMS/Pfizer,Portola; RESEARCH/RESEARCH GRANTS - Blue Cross Blue Shield of
Barnett	Christopher	Evolution of Critical Care Cardiology and the	Preparing for Evolving Roles of the Cardiologist in the CICU	Michigan,BMS/Pfizer Nothing to Disclose
L	<u> </u>	CICU	. 5 5	

Carlot Control				<u> </u>
Last Name Barnett	First Name Christopher	Session Title Demystifying and Managing Pulmonary Hypertension and RV Dysfunction: It Takes a	Presentation Title Co-Chair	Disclosures Nothing to Disclose
Barnhart	Huiman	Village Innovative Use of Echocardiography	The Impact of Rigorous Quality Improvement on 3D Echocardiography Image and Data Quality in an International Multisite Randomized Trial	Nothing to Disclose
Baron	Suzanne	Featured Clinical Research II: Interventional	Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data	CONSULTANT FEES/HONORARIA - Edwards Life Sciences,Medicure,St. Jude Medical Inc.
Baron	Suzanne	Vascular Access and Hemostasis Issues	TAVR Using Transcarotid Vascular Access: In-Hospital and Intermediate Term Outcomes	CONSULTANT FEES/HONORARIA - Edwards Life Sciences, Medicure, St. Jude Medical Inc.
Baron	Suzanne	Interventional Cardiology: TAVR 3	Prosthetic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter	CONSULTANT FEES/HONORARIA - Edwards Life Sciences, Medicure, St. Jude Medical Inc.
Baron	Suzanne	FIT Clinical Decision Making Reviewers 5	Valve-in-Valve Implantation ACC FIT Clinical Decision Making Reviewer	CONSULTANT FEES/HONORARIA - Edwards Life
Baron	Tomasz	Valvular Heart Disease: Mitral Valve Disease	Volumetric Quantification of Regurgitant Volume in Asymptomatic	Sciences,Medicure,St. Jude Medical Inc. Nothing to Disclose
			Severe Degenerative Mitral Regurgitation by Echocardiography and Cardiac MRI With Independent Validation of Forward Stroke Volume by Positron Emission Tomography	
BARON ESQUIVIAS	GONZALO	Late-Breaking Clinical Trials	Randomized Placebo Controlled Trial of Closed Loop Stimulation in Recurrent Reflex Vasovagal Syncope (SPAIN Study)	Nothing to Disclose
Barr	Susan	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	e-Counseling for Self-Care Adherence Adds Therapeutic Benefit for Hypertension: The REACH Trial	Nothing to Disclose
Barrabes	Jose	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Bimodal Prognosis of Patients Hospitalized With Suspected Acute Coronary Syndrome in Whom the Diagnosis Is Not Confirmed	Nothing to Disclose
Barrera Bustillos	Manuel	Updates on Risk Factors for Cardiovascular Disease	Association of Anxious and Depressive Symptomatology With Cardiovascular Disease Among Patients From Different States in Mexico: REDECAR Study	Nothing to Disclose
Barrero	Carlos	02. Acute and Stable Ischemic Heart Disease: Clinical Team 5	Suggested Reviewer	Nothing to Disclose
Barrett	Michael	Personalized Skills Center: Drill and Practice (Heart Songs, ECG, Hand-Held Echo)	Heart Songs Moderator	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MED- ED Consulting, Inc
Barrett	Michael	Personalized Skills Center: Drill and Practice	Heart Songs Moderator	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MED-
Barrett	Michael	(Heart Songs, ECG, Hand-Held Echo) Personalized Skills Center: Drill and Practice	Heart Songs Moderator	ED Consulting, Inc OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MED-
Barrett	Michael		In an Era of TAVR How Can Cardiology Fellow Auscultation Skills	ED Consulting, Inc OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MED-
Barretto	Antonio	and Education Making Progress in Understanding Heart	Be Improved Lipid Transfer to HDL in Patients With Heart Failure Was Diminished	ED Consulting, Inc Nothing to Disclose
Barringhaus	Kurt	Failure Highlighted Original Research: Interventional	and Is Correlated With Severity of the Disease Safety of Same Day Discharge Following PCI for Non-ST Elevation	Nothing to Disclose
Barringhaus	Kurt	Cardiology and the Year in Review Novel Developments in Acute Coronary Syndromes	Acute Coronary Syndromes Comparison of Clinical Outcomes: Bivalirudin With Transfemoral Versus Heparin With Transradial in Patients With ST Segment	Nothing to Disclose
Barros-Gomes	Sergio	New Technologies in Echocardiography	Elevation Myocardial Infarction Dynamic Changes of Mitral Apparatus in Acute Myocardial Infarction With Ischemic Mitral Regurgitation: Prospective 3D Quantitative	Nothing to Disclose
Barsness	Gregory	Innovations in Practice Management and	Echocardiographic Study Severity of Illness Assessment in the Cardiac Intensive Care Unit	Nothing to Disclose
Barsness	Gregory	Social Media Innovative Use of Echocardiography	(CICU): Application of the APACHE IV Predicted Mortality Score Systolic Function and Cardiac Output on Echocardiography Do Not	Nothing to Disclose
Barsness	Gregory	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Predict Mortality After Cardiac Arrest Contemporary Utilization of Immediate Coronary Angiography in the Management of Out-of-Hospital Cardiac Arrest	Nothing to Disclose
Barsness	Gregory	Syndrome Insights From Echocardiography Use	Diastolic Dysfunction by Doppler Echocardiography Predicts	Nothing to Disclose
Barsness	Gregory	02. Acute and Stable Ischemic Heart Disease:	Mortality after Cardiac Arrest Suggested Reviewer	Nothing to Disclose
Barsoum	Emad	Clinical Team 5 FIT Clinical Decision Making: Arrhythmias and	Bidirectional Ventricular Tachycardia in Critically III Patients on	Nothing to Disclose
Bart	Bradley	Electrophysiology Acute Heart Failure: Evaluating Strategies to	Vasopressors Effect of Pulmonary Pressure Monitoring (CardioMEMS Heart	RESEARCH/RESEARCH GRANTS - Gambro,Otsuka
Ddit	bradiey	Prevent Readmissions	Failure System, St. Jude Medical) on Hospital Admissions and Emergency Department Visits: A Multicenter Real World Experience	RESEARCH/RESEARCH GRAINTS - Galliulo, Olsuka
Bart	Bradley	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Hemoconcentration During Management of Patients With Acute Heart Failure and Cardiorenal Syndrome: Insights From CARRESS- HF	RESEARCH/RESEARCH GRANTS - Gambro, Otsuka
Bart	Bradley	Innovative Use of Echocardiography	Prognostic Utility of Hand-Carried Ultrasound Compared to Clinical and Laboratory Assessment of Decongestion to Predict Outcomes in Hospitalized Patients With Heart Failure	RESEARCH/RESEARCH GRANTS - Gambro, Otsuka
Bart	Bradley	Insights From Echocardiography Use	Comparison of Clinical Exam, Patient Symptoms and Hand-Carried Ultrasound in Assessing Decongestion of Hospitalized Patients With Heart Failure	RESEARCH/RESEARCH GRANTS - Gambro, Otsuka
Bartaula	Rajiv	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Anomalous Origin of Right Coronary Artery From Contralateral Cusp With Hypercoagulable State	Nothing to Disclose
Bartels	Dorothee B.	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Persistence With Therapy in Patients With Atrial Fibrillation: The GLORIA-AF Registry	Nothing to Disclose
Bartels	Dorothee B.	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Rates of Stroke and Bleeding With Dabigatran 150 and 110 mg BID in Clinical Practice: The GLORIA-AF Registry	Nothing to Disclose
Bartholomew	John	41. Vascular Medicine: Venous Disease Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Portola Pharmaceuticals
Bartko	Philipp	Novel Determinants of Outcomes in VHD	Relationship Between Proximal Aorta Morphology and Progression	Nothing to Disclose
Bartoli	Carlo	Young Investigator Awards Competition: Basic and Translational Science	Rate of Aortic Stenosis LVAD-Associated von Willebrand Factor Degradation Fragments Alter Angiogenesis: A Mechanistic Link Between LVAD Support,	Nothing to Disclose
Barton	David	Innovative Use of Echocardiography	Gastrointestinal Angiodysplasia, and Bleeding? The Predictive Value of Microvascular Defects Observed During Demand Stress Myocardial Contrast Echocardiography and Quantitative Measurements of Stenosis and Microvascular	Nothing to Disclose
Bartorelli	Antonio	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Resistance Obtained During Invasive Hemodynamics Renal Replacement Therapy in Patients With Acute Myocardial Infarction: Rate of Use, Clinical Predictors and Relationship With In-	CONSULTANT FEES/HONORARIA - advisory board member- Abbott Vascular
Bartorelli	Antonio	Refining PCI Technique and Outcomes	Hospital Mortality Final 3-Year Clinical Outcomes of Patients Treated With Everolimus- Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents: A Propensity Score Comparison of Patients Enrolled in the Evend and SPIRIT Trails	CONSULTANT FEES/HONORARIA - advisory board member- Abbott Vascular
Bartus	Krzysztof	Transcatheter Mitral Valve Repair	Extend and SPIRIT Trials Harpoon Chordal Replacement: Case and Overview	CONSULTANT FEES/HONORARIA - Harpoon Medical Inc; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Harpoon Medical Inc.



Carry Comment				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Bartz	Peter	Highlighted Original Research: Congenital	Re-Intervention During the Interstage Period: A Report From the	Nothing to Disclose
		Heart Disease and the Year in Review	National Pediatric Cardiology Quality Improvement Collaborative	
Bartz	Peter	Congenital Heart Disease Surgery: Updates	Anatomic Repair of Congenitally Corrected Transposition Results in	Nothing to Disclose
		and Innovations	Excellent Survival and Functional Status at Intermediate Term	
	<u> </u>		Follow-Up	
Bartz	Peter	Congenital Heart Disease: To the Third	Neurocognitive Impairment Is Common in the Adult With Congenital	Nothing to Disclose
		Decade and Beyond	Heart Disease: Identification Using a Novel Clinical Questionnaire	
D P.	A 411. 1	TAME A		Note: A Production
Barvalia	Mihir	Interventional Cardiology: TAVR 1	Assessment of Right Sided Hemodynamic Parameters as Predictors	Nothing to Disclose
			of Early Outcomes After Transcatheter Aortic Valve Replacement	
D I.	D'	A I T D	A de Tire Birere la Tirere A a la circa Tirella Tire Correla Co	
Bashir	Riyaz	Aorto-iliac Disease and Treatment: Practice at	Aorto-iliac Disease: Is There Any Lesion That Is Too Complex for	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
	-	"The Edge" in Peripheral Intervention	Endovascular Intervention?	Thrombolex
Bashir	Riyaz	Head to Toe: Outcomes of Endovascular	Contemporary Nationwide Trends in Inferior Vena Cava Filter	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
		Interventions	Implantation Rates in the United States and the Effect of Food and	Thrombolex
D. I.	D: -	Wasser Land Control The Book City	Drug Administration Advisory	OMMEDOLUD INTEREST DARTHEROLUD DRINOIDAL
Bashir	Riyaz	Venous Investigation: The Dark Side	Nationwide Contemporary Trends in Adjunctive Angioplasty and	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
			Stenting at the Time of Catheter Directed Thrombolysis in Patients	Thrombolex
D. I.	D: -	Wasser Land Control The Book City	With Proximal Lower Extremity Deep Vein Thrombosis	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Bashir	Riyaz	Venous Investigation: The Dark Side	Sex Differences in the Use of Inferior Vena Cava Filters in Patients With Proximal Lower Extremity Deep Vein Thrombosis in the United	Thrombolex
			States	THIOHIDOIEX
Bashir	Divor	FIT Clinical Decision Making: Interventional	Inferior Vena Cava Thrombosis Complicating Vena Cava Filter	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Dasilii	Riyaz			Thrombolex
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and	THIOHIDOIEX
Doobir	Divor		Heparin Induced Thrombocytopenia	OWNEDSHIP INTEREST/DARTNERSHIP/PRINCIPAL
Bashir	Riyaz	Advances in Pathophysiology and Treatment of	Intracranial Hemorrhage in Patients Treated With Catheter Directed	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Dankin	Caria	Thrombosis	Thrombolysis	Thrombolex
Bashir	Sania	FIT Clinical Decision Making: Arrhythmias and	An Exciting Wide Complex Tachycardia	Nothing to Disclose
Darkers	Th	Electrophysiology	Education	Nothing to Displace
Bashore	Thomas	FIT Forum: Mix and Mingle	Education Pulmanan Vascular Response to Nitria Ovide and Subsequent	Nothing to Disclose
Bashore	Thomas	Understanding Pulmonary Vascular Disease:	Pulmonary Vascular Response to Nitric Oxide and Subsequent	Nothing to Disclose
İ	İ	From Bench to Bedside	Response to Advanced Medical Therapy in Incident Patients With	
Pasila	lon	Appending the Clinical Insent of Street	Pulmonary Hypertension Cardiovascular Outcomes With Nebivolol, Atendol and Metoprolol	DECEADOU/DECEADOU ODANTO FELSE CONTRACTOR
Basile	Jan	Assessing the Clinical Impact of Blood		RESEARCH/RESEARCH GRANTS - Eli Lilly and Company;
İ	İ	Pressure Lowering Therapies	in Patients With Hypertension: A Large, Retrospective, Propensity	SPEAKER'S BUREAU - Amgen Inc., Arbor, Janssen
Pookor	Chankar	The Story of the Adult Connection to	Score-Matched Cohort Study	Pharmaceuticals, Inc
Baskar	Shankar	The Story of the Adult Congenital Heart Disease Patient and EP	Arrhythmia Burden & Outcomes in Eisenmenger Syndrome	Nothing to Disclose
Davisor:	Labandor		O and the Management of Comments of Commen	Nothing to Displace
Baskaran	Lohendran	Non Invasive Imaging: Prognostic Implications	Quantitative Measurement of Coronary Intra-Plaque Necrotic Core	Nothing to Disclose
		of CT Angiography	by Coronary CT Angiography in Victims of Autopsy-Proven Sudden	
1	1		Coronary Death: A Comparison to a Histologic Reference Standard	
_				
Basman	Craig	The Best Coronary and Peripheral	Recurrent Spontaneous Coronary Artery Dissection in a Patient With	Nothing to Disclose
		Interventional Challenging Cases	Fibromuscular Dysplasia	
Basman	Craig	FIT Clinical Decision Making: Interventional	Severe Dissection Propagation During Diagnostic Angiography of a	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart	Young Female Presenting With Self Limiting Chest Pain: A Case of	
		Disease, and Vascular Medicine	Spontaneous Coronary Artery Dissection	
Basman	Craig	Engage @ ACC.17 Studio: FIT Jeopardy Battle	Moderator	Nothing to Disclose
		of the State Chapters II		
Basra	Sukhdeep	Vascular Access and Hemostasis Issues	Real-Time Ultrasound Versus Fluoroscopy Guided Access for	Nothing to Disclose
			Transcatheter Aortic Valve Replacement With the Sapien 3 Valve	
Basra	Sukhdeep	FIT Clinical Decision Making Reviewers 5	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Bass	Theodore	Training for Interventional Procedures: Who	Why: Impact of Operator Volume: Are Criteria Useful?	Nothing to Disclose
		Should Do What, Where, When, How, and		
		Why		
Bass	Theodore	26. Interventional Cardiology: Vascular Access	Suggested Reviewer	Nothing to Disclose
_		and Complications Team 2		
Bassand	Jean-Pierre	Fibrillatory Arrhythmias: Outcomes With	Treatment and Outcomes of Patients With Nonvalvular Atrial	SPEAKER'S BUREAU - Aspen
		Contemporary Practice	Fibrillation According to Guideline-Defined Anticoagulation	
_			Thresholds: Results From the GARFIELD-AF Registry	
Bassand	Jean-Pierre	Atrial Fibrillation, Anticoagulation and Novel	Early Mortality in Patients With New Onset Atrial Fibrillation: Results	SPEAKER'S BUREAU - Aspen
		Device Therapies	From the GARFIELD-AF Registry	
Bassand	Jean-Pierre	Stroke and AF: Thinking About the Heart	The Prescribing of Antiplatelet Therapy Only in Patients With	SPEAKER'S BUREAU - Aspen
			Nonvalvular Atrial Fibrillation: Results From the GARFIELD-AF	
Danail	O.:illaaa	Innovative Assessables (C. D. J. C. D. J.	Registry	Nothing to Displace
Bassil	Guillaume	Innovative Approaches for Reducing Risk and	Outcomes of Remote Magnetic Navigation-Guided Catheter	Nothing to Disclose
İ	İ	Improving Outcomes With Ablation	Ablation of Left Ventricular Summit Arrhythmias Accessible via the	
Dartieses	Deebel	Insperior the Athletele III and	Coronary Venous System	Nothing to Displace
Bastiaenen	Rachel	Imaging the Athlete's Heart	General Population Screening for Sudden Cardiac Death in Young	Nothing to Disclose
1	1		Individuals: Is It Feasible, Is It Justifiable & How Much Does It	
Postiony	Alexandra	Antiplotolet and Antithress hatta Assatz	Cost?	Nothing to Dicalogo
Bastiany	Alexandra	Antiplatelet and Antithrombotic Agents in	Comparison of Triple Antithrombotic Therapy to Ticagrelor-Based	Nothing to Disclose
İ	İ	Ischemic Heart Disease	Dual Antiplatelet Therapy for Left Ventricle Dysfunction Following STEMI Using Natural Randomization: A Retrospective Pilot Study	
Batal	Omar	Highlighted Original Research: Pulmonary	Simplified Measures of Right Ventricular and Atrial Remodeling Are	Nothing to Disclose
Daidi	Onlai	Hypertension and Venous Thrombo-embolic	Predictive of Outcomes in Patients With Pulmonary Hypertension	Induling to Disclose
1	1	Disease and the Year in Review	reactive or Outcomes in Fatients with Fulfitonary hypertension	
Pateman	Timothy		Suggested Reviewer	CONSULTANT FEES/HONORARIA -
Bateman	Timothy	30. Non Invasive Imaging: Nuclear Team 2	Suggested Reviewer	JubilantDraxImage,Lantheus; OWNERSHIP
İ	İ			INTEREST/PARTNERSHIP/PRINCIPAL - CVIT;
İ	İ			RESEARCH/RESEARCH GRANTS - Astellas Pharma
İ	İ			US,Astellas Pharma US,GE Medical Imaging
Bates	Eric	Debates on Current Hot Topics in Coronary	Debate Con: Most CTOs Do Not Need to be Opened Because	CONSULTANT FEES/HONORARIA - Medscape
Dates	LIIG		There Are No Trials Supporting It!	GONGOLTANT FEEGITIONORARIA - Medscape
Potos	Erio	Intervention Logistical Challenges in STEMI		CONSULTANT FEES/HONORARIA - Medscape
Bates	Eric		Panelist Management of Non Culprit Artery in STEMI: What about Medical	
Bates	Eric	Controversies in ACS Guidelines	Management of Non Culprit Artery in STEMI: What about Medical	CONSULTANT FEES/HONORARIA - Medscape
Pates	Eric	Great Debates in Isohomic 2047	Therapy and an Ischemia Guided Approach?	CONSULTANT EEES/HONODADIA M
Bates	Eric	Great Debates in Ischemia 2017	Patients with Severe Asymptomatic Anterior IschemiaShould	CONSULTANT FEES/HONORARIA - Medscape
Pates	Eric	Innovation in Practice Management Advance	Undergo PCI: Pro	CONSULTANT EEES/HONODADIA M
Bates	Eric	Innovation in Practice Management, Advocacy,	Effect of an Online Continuing Medical Education and Clinician	CONSULTANT FEES/HONORARIA - Medscape
İ	İ	and Education	Coaching Quality Improvement Initiative on Antiplatelet Medication	
	İ		Adherence and Hospital Readmissions in Patients With Acute	
Detec	Esta	A5 later anti-rel O of the	Coronary Syndrome	CONCULTANT FEEGUS NO PARIA A .
Bates	Eric	15. Interventional Cardiology:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Medscape
	İ	ACS/AMI/Hemodynamics and Pharmacology		
D. C.	es.	Team 1	Land Olympia Company	CONOUNTANT FFFOURIOUS CONTRACTOR
Bates	Eric	Interventional Challenging Cases: Team 1	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Medscape
Bates	Mark	Novel Mechanical Devices for the Treatment	Endovascular Carotid Barostimulation for Resistant Hypertension: A	CONSULTANT FEES/HONORARIA - Vascular Dynamics,W.L.
	İ	and Assessment of Hypertension	Safety and Proof-of-Principle Cohort Study	Gore; OFFICER, DIRECTOR, TRUSTEE, OR OTHER
	İ			FIDUCIARY ROLE - Celonova Biosciences ; OTHER - Cook
I	I			Medical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
			II	Nexeon MedSystems
Potro	Anion	EIT Clinical Decision Metric at Architecture	A Copp of Defibrillation Threshold Tasting Failure With	Nothing to Disclose
Batra	Anjan	FIT Clinical Decision Making: Arrhythmias and	A Case of Defibrillation Threshold Testing Failure With	Nothing to Disclose
Batra	Anjan	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	A Case of Defibrillation Threshold Testing Failure With Subcutaneous Implantable Defibrillator Implantation in a Hypertrophic Cardiomyopathy Patient	Nothing to Disclose

and a				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Batsis	John	Predicting Outcomes in Cardiac Rehabilitation Patients	The Association Between Waist-Hip Ratio With Long-Term Cardiovascular Events in Patients With Coronary Artery Disease: A Population-Based Historical Cohort Study	Nothing to Disclose
Batsis	Maria	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Mitral Valve Phase Contrast Imaging Is a More Reproducible Method of Determining Cardiac Rest Periods for Whole-Heart Coronary Magnetic Resonance Angiography in Congenital Heart Disease Than 4 Chamber Cine	Nothing to Disclose
Battle	Robert	Sports and Exercise: Athletes with Congenital/Valvular Heart Disease Challenging Guidelines in Daily Practice	Co-Chair	Nothing to Disclose
Battle	Robert	Pregnancy Complicated by Valvular/Congenital Heart Disease: Clinical Management and Challenging Cases	Co-Chair	Nothing to Disclose
Battle	Robert	31. Non Invasive Imaging: Sports and Exercise Team 1	Suggested Reviewer	Nothing to Disclose
Batty	Jonathan	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Frail Older Patients Have a Greater Improvement in Physical Quality of Life Than Robust Patients at One Year Following Invasive Treatment for Non-ST Elevation Acute Coronary Syndrome	Nothing to Disclose
Bauch	Terry	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	A Novel Approach to Pre-Procedural Planning of Percutaneous Interventions: Value of 3D Printing and Fluoroscopic Evaluation	Nothing to Disclose
Baudouy	Delphine	Innovative Use of Echocardiography	Early Detection of Cardiac Involvement in Sarcoidosis With 2-	Nothing to Disclose
Bauer	Fabrice	Interventional Cardiology: TAVR 4	Dimensional Speckle-Tracking Echocardiography Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between	Nothing to Disclose
Baum	Seth	Advances in Lipid Management	2010 and 2014 at Rouen University Hospital Treatment Effects of Alirocumab as an Add-On to Maximally Tolerated Dose of Statin in Patients With Heterozygous Familial Hypercholesterolemia and/or Atherosclerotic Cardiovascular	CONSULTANT FEES/HONORARIA - Aegerion and Genzyme, Amgen Inc., AstraZeneca, New Haven Pharmaceuticals, Sanofi-Aventis; SPEAKER'S BUREAU - Merck
Baum	Seth	Innovations in Advocacy and Patient Centered Care	Disease Characteristics of Patients Approved and Denied Access to PCSK9i Therapy by Payers	& Co., Inc. CONSULTANT FEES/HONORARIA - Aegerion and Genzyme,Amgen Inc.,AstraZeneca,New Haven Pharmaceuticals,Sanofi-Aventis; SPEAKER'S BUREAU - Merck
Baumbach	Andreas	Considerations in Antiplatelet Therapy and in ACS	Bivalirudin Versus Heparin in Primary PCI: Clinical Outcomes and Cost Analysis From a Large Retrospective Cohort	& Co., Inc. CONSULTANT FEES/HONORARIA - Boston Scientific,Keystone Heart,MEDTRONIC,The Medicines Company; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Keystone Heart; RESEARCH/RESEARCH GRANTS - Astra Zeneca
Baumbach	Andreas	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Predictors of Survival From Out-of-Hospital Cardiac Arrest	CONSULTANT FEES/HONORARIA - Boston Scientific,Keystone Heart,MEDTRONIC,The Medicines Company, OWNERSHIP INTEREST/PARTNERSHIP/PRINC/PA - Keystone Heart; RESEARCH/RESEARCH GRANTS - Astra Zeneca
Bavaria	Joseph	The Spectrum of Aortic Regurgitation and Aortic Pathology	Bicuspid Aortic Valve and Aortopathy	RESEARCH/RESEARCH GRANTS - CyotoSorbents, Edwards Lifescience, MEDTRONIC, Medtronic Vascular, Vascutek, W.L. Gore
Bavaria	Joseph	Post FDA Release Prosthetic Valve Surveillance - Watching for Signals	Panelist	RESEARCH/RESEARCH GRANTS - CyotoSorbents,Edwards Lifescience,MEDTRONIC,Medtronic Vascular,Vascutek,W.L. Gore
Bavaria	Joseph	Interventional Cardiology: TAVR 1	TAVR Is Safe and Improves Cardiac Function in Patients With Extremely Low Ejection Fractions	RESEARCH/RESEARCH GRANTS - CyotoSorbents,Edwards Lifescience,MEDTRONIC,Medtronic Vascular,Vascutek,W.L. Gore
Bavaria	Joseph	Engage @ ACC.17 Studio: Ask the Valvular Heart Disease Experts	Faculty	RESEARCH/RESEARCH GRANTS - CyotoSorbents,Edwards Lifescience,MEDTRONIC,Medtronic Vascular,Vascutek,W.L. Gore
Bavaria	Joseph	17. Interventional Cardiology: Aortic Valve Disease Team 1	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - CyotoSorbents,Edwards Lifescience,MEDTRONIC,Medtronic Vascular,Vascutek,W.L. Gore
Bavishi	Chirag	Coronary Intervention: Drug Eluting Stent and Scaffolds	Efficacy and Safety of Everolimus-Eluting Stents Versus Slow- Release Zotarolimus-Eluting Stents: A Direct Comparison Meta- Analysis of 29,286 Patients - Years of Follow-Up From Randomized Controlled Trials	Nothing to Disclose
Bavishi	Chirag	Unusual Presentations of ACS	Clinical Outcomes of the Treatment of Cocaine Induced Chest Pain With Beta Blockers: A Meta-Analysis	Nothing to Disclose
Bavishi	Chirag	Which Test Is Best for Pain in the Chest?	Outcomes in Patient With Chest Pain Evaluated Using Coronary Computed Tomography Angiography Versus Stress Imaging: A Meta-Analysis of Randomized Trials	Nothing to Disclose
Bavry	Anthony	Imaging for TAVR: Homing in on the Real	Panelist	CONSULTANT FEES/HONORARIA - American College of Cardiology; RESEARCH/RESEARCH GRANTS - gilead
Bavry	Anthony	Imaging for TAVR: Homing in on the Real Issues	Case Presentation: Bring Your Best Clinical Judgment- Identify Valve Position, Function and Immediate Complications After	CONSULTANT FEES/HONORARIA - American College of Cardiology; RESEARCH/RESEARCH GRANTS - gilead
Bavry	Anthony	Interventional Cardiology: TAVR 3	Deployment Prosthetic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter Valve-in-Valve Implantation	CONSULTANT FEES/HONORARIA - American College of Cardiology; RESEARCH/RESEARCH GRANTS - gilead
Bavry	Anthony	Interventional Cardiology: TAVR 4	Depression as a Potential Therapeutic Target to Improve Quality of	CONSULTANT FEES/HONORARIA - American College of
Bavry	Anthony	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Life After Transcatheter Aortic Valve Replacement Coronary Artery Bypass Graft Pseudoaneurysm From Saphenous Vein Graft Stent Rupture	Cardiology; RESEARCH/RESEARCH GRANTS - gilead CONSULTANT FEES/HONORARIA - American College of Cardiology; RESEARCH/RESEARCH GRANTS - gilead
Bavry	Anthony	Disease, and Vascular Medicine PCI Strategies and Outcomes Unique to Women	Early Invasive Strategy Versus Initial Conservative Strategy in Women With Non-ST-Elevation Acute Coronary Syndrome: A	CONSULTANT FEES/HONORARIA - American College of Cardiology; RESEARCH/RESEARCH GRANTS - gilead
Bavry	Anthony	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology	Propensity Score Matched Nationwide Analysis Suggested Reviewer	CONSULTANT FEES/HONORARIA - American College of Cardiology; RESEARCH/RESEARCH GRANTS - gilead
Bax	Jeroen	Team 1 Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve	Nothing to Disclose
Вах	Jeroen	Interventional Cardiology: TAVR 1	Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis Sizing Aortic Valve Annulus for Transcatheter Aortic Valve Prosthesis Selection: Impact of Aortic Valve Calcification Burden on the Agreement Between Automated 3-Dimensional Transesophageal Echocardiography and Multidetector Row	Nothing to Disclose
Bax	Jeroen	Novel Echocardiographic Methods for	Computed Tomography Prognostic Implications of Left Ventricular Global Longitudinal Strain	Nothing to Disclose
		Assessing Cardiac Function	in Stage 4 and 5 Chronic Kidney Disease Patients	
Bax	Jeroen	Innovative Use of Echocardiography	Left Ventricular Systolic Recovery After St-Segment Elevation Myocardial Infarction: Effect of Guideline-Based Therapy	Nothing to Disclose
Bax	Jeroen	Non Invasive Imaging: MR Scar and Perfusion	Functional Consequences of Myocardial Scar After Myocardial Infarction: Characterization of Myocardial Scar Extent With Late Gadolinium Contrast Enhanced Cardiac Magnetic Resonance and Impact on Multilayer Global Longitudinal Strain on Speckle Tracking Echocardiography	Nothing to Disclose



Contract of the second				
Last Name Bax	First Name Jeroen	Session Title Unusual Presentations of ACS	Presentation Title Incidence and Predictors of Lesion Specific Ischemia by	Disclosures Nothing to Disclose
Dax	Jeroen	Unusual Fresentations of ACS	FFR _{CT} : Learnings From the International ADVANCE Registry	Nothing to Disclose
Bax	Jeroen	Leading Us Astray? Pacemakers in Cardiomyopathies	Functional Mitral Regurgitation and Cardiac Resynchronization Therapy: Evolution and Impact on Outcome	Nothing to Disclose
Bax	Jeroen	06. Arrhythmias and Clinical EP: Other Team 2	Suggested Reviewer	Nothing to Disclose
Bayat	Maryam	Arrhythmias and Clinical EP: Anticoagulation	Evaluation of Apixaban in Patients on Dialysis	Nothing to Disclose
Bayissa	Yohannes	Issues Interventional Cardiology: TAVR 1	Prognostic Value of Right Ventricular Function Assessed by Cardiac	Nothing to Disclose
Dayissa		u u	Computed Tomography in Patients Undergoing Transcatheter Aortic Valve Replacement	Hotting to Disclose
Bayoumi	Essraa	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Clinical Effectiveness of Spironolactone in Hospitalized Older Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or Equal to 30 mL/min/1.73 m ²) Patients With Heart Failure	Nothing to Disclose
Bays	Harold	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Alirocumab Efficacy and Safety in Patients With Hypercholesterolemia and With or Without Clinical Atherosclerotic Cardiovascular Disease: Pooled Analysis of 10 ODYSSEY Randomized Trials	CONSULTANT FEES/HONORARIA - Alnylam, Amarin, Amgen, AstraZeneca, Bristol Myers Squibb, Catabasis, Eli Ll, Ionis, Isis, Merck, Novartis, Novo Nordisk Inc., Omthera, Regeneron, Sanofi-Aventis; RESEARCH/RESEARCH GRANTS - Amarin, Amgen, Ardea, Arisaph, AstraZeneca, Bristol Myers Squibb, Catabasis, Cymabay, Eisai, Elcelyx, Eli Lilly, Esperion, Ferrer Chiltern, gliead, GSK, Hanmi, Hisun, Hoffman LaRoche, Home Access, Janssen, Johnson and Johnson, Kowa, Merck, Nektar, Novartis, Novo Nordisk, Omthera, Orexigen, Pfizer, Pronova, Regeneron, Sanofi- Aventis, Takeda, Vivus; SPEAKER'S BUREAU - Amarin, Amgen, Eisai, Merck, Regeneron, SANOFI, Takeda Pharmaceuticals North America, Inc
Bayturan	Ozgur	16. Interventional Cardiology: Angiography and Interventional CT/MR Team 1	Suggested Reviewer	Nothing to Disclose
Baz	Jose	Timely Topics in Acute Coronary Syndromes	A New Prognosis Score to Predict Mortality in Patients Over 75 Years Old Undergoing Primary Angioplasty in Cardiogenic Shock	Nothing to Disclose
Bazavan	Mugurel		A Possible Simple Solution to a Challenging Problem in	Nothing to Disclose
Bazzano	Lydia	Pulmonary Hypertension Vascular Medicine: Aortic and Peripheral	Management of Acute Decompensated Heart Failure Racial (Black-White) Disparities in the Contribution of The Long-	Nothing to Disclose
		Artery Diseases	Term Burden of Cholesterol from Childhood on Adult Ankle- Brachial Index Decline: The Bogalusa Heart Study	-
Bdeir	М	ACC International Conferences Best Posters	Nurse-Led Cardiovascular Disease Management Program Impact of	Nothing to Disclose
Beall	Allan	FIT Clinical Decision Making: Prevention, Adult	30-Day Readmission in Patients With Heart Failure Bypass Grafts to Patent Coronary Arteries	Nothing to Disclose
Beanlands	Rob	Congenital and Congenital Heart Disease Noninvasive Assessment of Coronary Flow	In the Presence of Significant Epicardial Coronary Disease,	CONSULTANT FEES/HONORARIA - DRAXImage,Lantheus
		Reserve: Clinical Implications	Diabetes Mellitus Is Further Associated With Reduced Myocardial Flow Reserve	Medical Imaging; RESEARCH/RESEARCH GRANTS - DRAXImage,GE Healthcare,Lantheus Medical Imaging
Beanlands	Rob S.	PET Myocardial Perfusion Imaging: Practical Considerations- A Case-Based Discussion	Panelist	CONSULTANT FEES/HONORARIA - DRAXImage,Lantheus Medical Imaging; RESEARCH/RESEARCH GRANTS - DRAXImage,GE Healthcare,Lantheus Medical Imaging
Beanlands	Rob S.	PET Myocardial Perfusion Imaging: Practical Considerations- A Case-Based Discussion	PET Myocardial Perfusion Imaging Cases	CONSULTANT FEES/HONORARIA - DRAXImage,Lantheus Medical Imaging; RESEARCH/RESEARCH GRANTS - DRAXImage,GE Healthcare,Lantheus Medical Imaging
Beanlands	Rob S.	30. Non Invasive Imaging: Nuclear Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - DRAXImage,Lantheus Medical Imaging; RESEARCH/RESEARCH GRANTS - DRAXImage,GE Healthcare,Lantheus Medical Imaging
Beaser	Andrew	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Electroanatomic Characterization of Hypoplastic Left Heart Ventricular Tachycardia: Transaortic Transmembranous Ventricular Septal Approach via Magnetic Navigation	Nothing to Disclose
Beasley	Gary	Innovations in Education	MurmurQuiz: A Tool for Cardiac Auscultation Training and	Nothing to Disclose
Beaubrun	Anne	Diabetes and Other Issues in Cardiovascular	Evaluation Comparison of the Use of Cardiovascular Risk Equations by Health	SALARY - Amgen, Inc.
Beauchesne	Luc	Prevention Vascular Medicine: New Insights Into Aortic	Technology Assessment Bodies and Clinical Guidelines Sex Differences in Thoracic Aortic Aneurysm Growth: Role of Aortic	Nothing to Disclose
		and Peripheral Artery Diseases	Stiffness	-
Beaudoin	Jonathan	Frontiers in Mitral Valve Disease and Treatment	Significant Mitral Regurgitation in Patients Undergoing Transcatheter Aortic Valve Replacement: Evolution and Imaging Predictors of Improvement	Nothing to Disclose
Beaven	Bryan	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Interstage Resource Utilization of Infants With Single Ventricle: Results of a Crossover Study	Nothing to Disclose
Beaver	Thomas	Interventional Cardiology: TAVR 3	Prosthetic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter	Nothing to Disclose
Beaver	Timothy	Insights From Echocardiography Use	Valve-in-Valve Implantation Advances in 3D Echocardiography: Automated Software Improves the Learning Curve and Clinical Implementation in a Real World	Nothing to Disclose
Pagyara	Croin	PPIs in the Era of Prolonged DAPT Should	Setting for Quantitative Assessment of Left Ventricular Ejection Fraction	Nothing to Displace
Beavers	Craig	We or Shouldn't We?: Pharmacology III	Debate Con: Not So Fast - PPIs and DAPT Should Not Always Be Co-Prescribed	Nothing to Disclose
Beavers Bech	Craig Jan	Fellows Bootcamp: Interventional Basics Novel Echocardiographic Methods for Assessing Cardiac Function	Interventional Pharmacology Coronary Microvascular Dysfunction Affects the Myocardial Contractile Reserve in Women With Angina and No Obstructive	Nothing to Disclose Nothing to Disclose
Becher	Harald	Congenital Heart Disease: Innovations in	Coronary Artery Disease Right Ventricular Remodelling in Hypoplastic Left Heart Syndrome:	CONSULTANT FEES/HONORARIA - Bracco
Bechlioulis	Aris	Single Ventricle Heart Disease Cardiac Arrest, Diabetes, and Other High Risk	Impact of the Norwood and Hybrid Procedures Pro-Inflammatory Interleukin-1 Genotypes Affect the Association of	Nothing to Disclose
Decimodits	פוורק	Features of Patients With Acute Coronary Syndrome	C-Reactive Protein for Angiographically Determinedcoronary Artery Disease and Cardiovascular Events	
Becker	Jason	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Myocarditis and Rhabdomyolysis Incidence With Immune Checkpoint Inhibitors	Nothing to Disclose
Becker	Richard	Arrhythmias and Clinical EP: Anticoagulation Issues	Thrombolytic Therapy in Anticoagulated Patients: Case Series From Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim, Daiichi-Sankyo, Portola; RESEARCH/RESEARCH
Beckerman	James	Sports and Exercise: Athletes with Congenital/Valvular Heart Disease Challenging	(ROCKET AF) Co-Chair	GRANTS - AstraZeneca Nothing to Disclose
Beckerman	James	Guidelines in Daily Practice The Athlete with Heart Disease: A Case Based	Panelist	Nothing to Disclose
Beckman	Joshua	Approach When Anticoagulation Needs to be Stopped What Are the Options? Pharmacology II	Managing Anticoagulation in the Periprocedural Patient: Does It Have to Be So Difficult?	CONSULTANT FEES/HONORARIA - Astra Zeneca,Merck,SANOFI; RESEARCH/RESEARCH GRANTS -
Beckman	Joshua	FIT Forum: Mix and Mingle	Peripheral Vascular Disease	Pristol Myers Squibb CONSULTANT FEES/HONORARIA - Astra
	1-3000	Statil mix and mingle	- Ing. I adduct Stocker	Zeneca,Merck,SANOFI; RESEARCH/RESEARCH GRANTS - Bristol Myers Squibb

Contract of the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Beckman	Joshua	Vasculo-Oncology: What You Need to Know	Endothelial Dysfunction and Atherosclerosis Related to Cancer	CONSULTANT FEES/HONORARIA - Astra
		About Vascular and Thrombotic Complications of Cancer and Cancer Therapeutics	Therapies: How is it Relevant in Clinical Practice?	Zeneca,Merck,SANOFI; RESEARCH/RESEARCH GRANTS - Bristol Myers Squibb
Beckman	Joshua	Clinical Assessment and Revascularization for Critical Limb Ischemia	Co-Chair	CONSULTANT FEES/HONORARIA - Astra Zeneca,Merck,SANOFI; RESEARCH/RESEARCH GRANTS - Bristol Myers Squibb
Beckman	Joshua	Born To Run: Geographic Variation in PAD Diagnosis, Treatment and Outcomes	Screening, Diagnosis and Prevalence: Insights from the PORTRAIT Registry and Beyond	CONSULTANT FEES/HONORARIA - Astra Zeneca,Merck,SANOFI; RESEARCH/RESEARCH GRANTS - Bristol Myers Squibb
Beckman	Joshua	Improving Risk Assessment in Atherosclerosis	N-Terminal Pro B-Type Natriuretic Peptide, Race, and Flow- Mediated Dilation: Multi-Ethnic Study of Atherosclerosis	CONSULTANT FEES/HONORARIA - Astra Zeneca,Merck,SANOFI; RESEARCH/RESEARCH GRANTS - Bristol Myers Squibb
Beckman	Joshua	38. Vascular Medicine: Basic Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Astra Zeneca,Merck,SANOFI; RESEARCH/RESEARCH GRANTS -
Веесу	Ashley	Non Invasive Imaging: Expanding Clinical Applications	Dual-Energy Coronary Computed Tomography Evaluation of High- Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients:	Bristol Myers Squibb Nothing to Disclose
Веесу	Ashley	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Validation with Histopathologic Gold Standard Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry	Nothing to Disclose
Beecy	Ashley	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography: The CONFIRM (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	Nothing to Disclose
Веесу	Ashley	Innovations in Cardiovascular Risk Assessment and Reduction	Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	Nothing to Disclose
Beecy	Ashley	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prognostic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry	Nothing to Disclose
Веесу	Ashley	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography: The CONFIRM Registry	Nothing to Disclose
Веесу	Ashley	Non Invasive Imaging: Prognostic Implications of CT Angiography	Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Death: A Comparison to a Histologic Reference Standard	Nothing to Disclose
Веесу	Ashley	Diabetes and Other Issues in Cardiovascular Prevention	Implications of Statin Therapy Among Smokers With Severe Coronary Artery Calcification: An Analysis of the CONFIRM Registry	Nothing to Disclose
Веесу	Ashley	Non Invasive Imaging: New Technologies	Optimal Method for Necrotic Core Identification in Coronary Plaque With Dual-Energy Computed Tomography: Material Decomposition and Atomic Number	Nothing to Disclose
Beedupalli	Jagan	Vascular Access and Hemostasis Issues	Standard Versus Low-Dose Heparin Use on Access-Related Complications After Coronary Angiography Through Radial Access: A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Beer	Dominik	Contemporary Issues in Familial Hypercholesterolemia	The Hidden Burden of EHR-Identified Familial Hypercholesterolemia: Mortality and Clinical Outcomes	Nothing to Disclose
Beg	Faheemullah	Put Your Codon! Genetic Insights Into Heart Failure	Circulating Free and Exosomal MicroRNAs as Biomarkers of Systemic Response to Heart Failure	Nothing to Disclose
Beheim	Bret	Featured Clinical Research I	Native South American Tsimane Have the Lowest Levels of Coronary Atherosclerosis Ever Reported	Nothing to Disclose
Behere	Shashank	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Too Close for Comfort: Aortopulmonary Fistula After Balloon Dilation in Arterial Switch With LeCompte Maneuver	Nothing to Disclose
Behere	Shashank	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	So Excited He Just Can't Hide It: Acquired Fasciculoventricular Preexcitation in Danon Disease	Nothing to Disclose
Behere	Shashank	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	A Giant Strikes Back: Recurrent Thrombosis of Recanalized Giant Aneursym in Kawasaki Disease	Nothing to Disclose
Behfar	Atta	Disease, and Vascular Medicine Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Acute Myocardial Infarction in Patients on Chronic Innate Immunosuppression Therapy	Nothing to Disclose
Behfar	Atta	04. Arrhythmias and Clinical EP: Basic Team 1	Suggested Reviewer	Nothing to Disclose
Behr	Elijah	Cardiac Channelopathies: Novel Therapeutics and Clinical Challenges	Appropriate Primary Prophylactic Implantation of Defibrillator in Patients With Brugada Syndrome: Is There Any Difference Between Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events	RESEARCH/RESEARCH GRANTS - Biotronik,St Jude Medical
Behuria	Supreeti	Timely Topics in Acute Coronary Syndromes	Emergency Room Evaluation of Patients With Cardiac Complaints and New Left Bundle Branch Block: The Utility of the Sgarbossa and Modified Sgarbossa Criteria	Nothing to Disclose
Beigel	Roy	Trends in Coronary Syndromes: International Perspectives From the ACC Great Britain and Ireland Chapter, Israel Heart Society, and American College of Cardiology	Temporal Trends in NSTE-ACS	Nothing to Disclose
Beigel	Roy	Anti-Platelet Therapies: Always a Sticky Topic	Chewing Versus Traditional Swallowing of Ticagrelor to Accelerate Platelet Inhibition in ST Elevation Myocardial Infarction: The CHEERS-STEMI Study	Nothing to Disclose
Beinborn	Doug	Arrhythmias and Clinical EP: Basic 4	External Cooling of the Myocardium Slows Electrical Conduction and Terminates Atrial Fibrillation	Nothing to Disclose
Bejan-Angoulvant	Theodora	Considerations in Antiplatelet Therapy and in ACS	Use of Modern Scores to Evaluate Individual Risk/Benefit of Prolonged Dual Anti-Platelet Therapy May Modify Dual Anti-Platelet Therapy Duration in ST-Segment Elevation Myocardial Infarction Patients	Nothing to Disclose
Belbase	Ram	Advances in HCM, PPCM and Other	Impact of Obesity on the Outcomes of Stress Cardiomyopathy: An	Nothing to Disclose
Belbase	Ram	Cardiomyopathies Insights From Echocardiography Use	Analysis of National Inpatient Sample Trends and Use of Echocardiography in Patients With <>Staphylococcus Aureus <ir> In Analysis Using the </ir>	Nothing to Disclose
Belcher	Arianna	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Nationwide Inpatient Sample (NIS) Data Multiple Biomarkers for Predicting Major Adverse Cardiac Events in Ar-Risk Patients Undergoing Diagnostic Coronary Angiography: Results From the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study	Nothing to Disclose

Management and Outcomes Findings in Myocardial Infarction With Non-Obstructive Coronary Arteries BUREAU - Servier Laboratories	Congress of the congress of th				
Personal Processor Control and Chicago Congregory Processor Congregory P				Presentation Title	
According to Control and Control of Grades and Control of Control	Beleslin	Branko		FFR, CFR, iFR: Competitors or Allies in Invasive Functional Arena	Nothing to Disclose
House Marie Services of Spoul and Andread Confess of Cologo of Marie Services (Confess of Marie Services) (Confess					
Bell			Republic of Srpska, and American College of		
Services of Control of	Dall	A stain a		Head Corne Medante	Nething to Displace
Ballot Control of Notice of Action of Notice o	Bell	Adrian		Heart Songs Moderator	Nothing to Disclose
Selection Contents of Contents	Bella	Jonathan	Traditional and Novel Factors Used to Assess	Relationship Between Marijuana Use and Hospitalization for Acute	Nothing to Disclose
State Coops Significant County of Research Mark Household Control State Coops Significant County of Research Mark Household State Coops Significant County of Research Mark Household State Coops Significant County of Research Mark Household State Coops Significant County of Research Mark Household State Coops Significant County of Research Mark Household State Coops Significant County of Research Mark Household State Coops Significant County of Research Mark Household State County of Research Mar				Coronary Syndrome	
Service Continued to Continue Processor of the Service	Beller	George		Co-Chair	OTHER - Locus Health
Displace CATE Contingence of Justice Con			Imaging and the Year in Review		
And Control Control Character Perfection of Control Control Character Control Character Control Character	Beller	George			OTHER - Locus Health
States (Paulin) The Contingroup of Policians Newbork of Controlling of Control (Pauling Con			Diagnose CAD		
SEGO Matter March William And William And William And William And William And William And William And William And William And William And William And Concerns yell-referred And Concerns yell-referred And Concerns yell-referred And Concerns yell-referred And John Concerns yell-referred And John Concerns yell-referred And John Concerns yell-referred And John Concerns of Andrews And Programme Report of Andrews And Conference Report Repor	Bellera	Ricardo	The Challenges of Outcome Prediction in	Gender-Based Outcomes in Diabetics Undergoing Transcatheter	Nothing to Disclose
Bellemen Unite Control of March Control	D. II.	No. (-P-			Notice to Breaters
Debugsine Debugsine Debugsine Color Trees Produced Color Services					
Mercane Control Colorone More Discourse Control Colorone More State And and State State Statemen Heart Diseases State August Colorone More August Colorone State August Colorone More August Colorone State August Colorone State August Colorone State State August Colorone State State August Colorone State State State State State State State State St					
Settlemen State of Settlemen State Settlemen S	Beltrame	John			RESEARCH/RESEARCH GRANTS - Astra Zeneca; SPEAKER'S
Septiment on the control of the cont			Management and Outcomes		BUREAU - Servier Laboratories
Secretary Specified Secret	Beltrame	John	02. Acute and Stable Ischemic Heart Disease:		RESEARCH/RESEARCH GRANTS - Astra Zeneca; SPEAKER'S
Ben-Asset Springer Value of International Policies Value of Internatio					
Description Consider					
Disease Bencharre Lipia Acade heart Failure Failure (Failure) Pricent Reduntations Pricent Reduntation Pricent Reduntation Pricent Reduntation Bencharre Lipia Accompanies (See Disease Annoigh Failure) Bencharre Bibl. Accompanies (See Disease Annoigh Failure) Bibl. Accompanies (See Disease Annoigh Failure) Bibl. Accompanies (See Disease Annoigh Failure) Bibl. Accompanies (See Disease Annoigh Failure) Bibl. Accompanies (See Disease Annoigh Failure) Bibl. Accompanies (See Disease Annoigh Failure) Bibl. Accompanies (See Disease Annoigh Failure) Bibl. Accompanies (See Disease Annoigh Failure) Bibl. Accompanies (See Disease Annoigh Failure) Bibl. Accompanies (See Disease Annoigh Failure) Bibl. Accompanies (See Disease Annoigh Failure) Bibl. Accompanies (See Disease Annoigh Failure) Bibl. Accompanies (See Disease Annoigh Failure) Bibl. Accompanies (See Disease Annoigh Failure) Bibl. Accompanies (See Disease Annoigh Failure) Bibl. Bi	DCI171330	Lydi	Valvalai Ficari Discase. Notae Regargitation		The Service of the Control of Service of Edwards Ellessiences
Notice MEDICAGS Build, Peaces VIVI Heart Fairer, Count for by Proving to Disclose Provent Recommendors Vivinities for Province On a Management of the Province	Benavides Gonzalez	Mario		Association of Anxious and Depressive Symptomatology With	Nothing to Disclose
Servicioni (Lilya Necesification Carellance Serviciating Strategies to Monte Need Failure Carellance (Serviciating Service) (Minister) Properties (Service) (Minister) Properties (Service) (Minister) Properties (Service) (Minister) Properties (Minister)			Disease		
Person Repolations on Management of the Cardiology TAVR 2 Ullian Repolations of Management of Management (Management Accordance) (Management Accordan	Benchetrit	Liliya	Acute Heart Failure: Evaluating Strategies to		Nothing to Disclose
Service III III III III III III III III III I		[*		Accountable Care Organizations: Variation by Performance on a	•
Sex-Dor Stak Considerations in Antiplashed Thorapy and in Tremos in Disburghouse and Outcome of Dual Antiplashed Thorapy Proceedings of Considerations in Antiplashed Thorapy and in Considerations in Antiplashed Thorapy and in Consequence Conseque	Panak	Lillian	Interportional Cardiology TAVE 2		Nothing to Disclose
Ser-Dor Bak Considerations in Antipalated Therapy and in Academatics in Antipalated Therapy and in Academatics in Antipalated Therapy and in Academatics in	DETICK	Lmidfi	interventional Cardiology: TAVR 2		INOUTHING TO DISCIOSE
ACS	Ben-Dor	Itsik	Considerations in Antiplatelet Therapy and in	Trends in Discharge and Outcome of Dual Antiplatelet Therapy Post	Nothing to Disclose
ACS Concessors Syndrome and Primary Perculamensis Concessory Bilk POTOR YNSTEMI and Complex Persistent With Multiple Co-Mondibles Multiple Co-Mondibles Multiple Co-Mondibles Multiple Co-Mondibles Multiple Co-Mondibles Mile Venerical Cardiology TAVR 2 Bilk Without Considered Cardiology TAVR 3 Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology Tavr 4 Mile Venerical Cardiology					-
Ber-Dor Bisk Hervertional Cardology TAVR 3 Ber-Dor Bisk Hervertional Cardology TaVR 3 Ber-Dor Bisk Hervertional Cardology TaVR 3 Ber-Dor Bisk Hervertional Cardology TaVR 3 Ber-Dor Bisk Hervertional Cardology TaVR 3 Ber-Dor Bisk Tavr 3 Bisk Tavr 3 Ber-Dor Bisk Tavr 3 Bisk Tavr 3 Bisk Tavr 3 Bisk Tavr 3 Bisk Tavr	Ben-Dor	ILSIK			INOUTHING TO DISCIOSE
Ber-Dor Balk Interventional Cardiology TAVR 2 Common Characteristics and Outcomes in Contemporary Produce Over the Last Decade - New They pofferent prince Delivous teaching to Delivous Content of Cardiology TAVR 2 Common Cardiology TAVR 3 Common Cardiology TavR 3 Common Cardiology TavR 3 Common Cardiology TavR 3 Common Cardiology TavR 3 Common Cardiology TavR 3 Common Cardiology TavR 3 Common Cardiology TavR 3 Common Cardiology TavR 3 Common Cardiology TavR 3 Common Cardiology TavR 3 Common Cardiology TavR 3 Common Cardiology TavR 3 Common			7,00		
Leaf Decade - How Are They Different From De Novo Leasons?	Ben-Dor	Itsik			Nothing to Disclose
Ben-Dor Bak Interventional Cardiology, TAVR 2 (Clinical Chramaticentes of Peters Society Consend for Transphase and Clinical Chramaticentes of Peters Society Consend for Transphase and Clinical Chramaticentes of Peters Society Consended for Transphase and Maningriphic Disclose Patients (Mark Christian Consended for Transphase Andre Valve Patients (Mark Christian C			Multiple Co-Morbidities		
Bern Dor Isia Interventional Cardiology, TAVR 3 Interventional Cardiology, TAVR 3 Interventional Cardiology, TAVR 3 Interventional Cardiology, TAVR 3 Interventional Cardiology, TAVR 3 Interventional Cardiology, TAVR 3 Interventional Cardiology, TAVR 3 Interventional Cardiology, TAVR 3 Interventional Cardiology, TAVR 3 Interventional Cardiology, TAVR 3 Interventional Cardiology, TAVR 3 Interventional Cardiology, TAVR 3 Interventional Cardiology, PC In Complex Patients State Patients State Patients State Patients Interventional Cardiology, PC	Ben-Dor	Itsik	Interventional Cardiology: TAVR 2		Nothing to Disclose
Beh-Dor Bak			3,	Clinical Characteristics of Patients Screened for Transcatheter	
Patients With Arola Fabrillation Undergoing Transcatillater Andre New Fabrillation Undergoing Transcatillater Andre New Fabrillation Undergoing Transcatillater Andre New Fabrillation Undergoing Transcatillater Andre New Fabrillation Under Patients (April 1997) (1997)	Pon Dor	Itaile	Interventional Cardiology: TAVD 2		Nothing to Displace
Ber-Dor Itsisk Interventional Cardiology TAVR 3 Aber benderational Cardiology TAVR 3 Aber benderational Cardiology PC in Complex Peters 1 Supplemental Foundation Policy PC in Complex Peters 1 Supplemental Foundation Policy PC in Complex Peters 1 Supplemental Foundation Policy PC in Complex Peters 1 Supplemental Foundation Policy PC in Complex Peters 1 Supplemental Foundation Policy PC in Complex Peters 2 Supplemental Foundation Policy PC in Complex Peters 2 Supplemental Foundation PC in Peters 2 Supplemental Policy PC in Complex PC in Policy PC in Complex PC in Policy PC in Complex PC in Policy PC in Complex PC in Policy PC in Complex PC in Policy PC in Complex PC in Policy PC in Complex PC in Policy PC in Complex PC in Policy PC in Complex PC in Policy PC in Complex PC in Policy PC in P	Ben-Dor	IISIK	Interventional Cardiology: TAVR 3		Nothing to Disclose
Bern-Dor Itsix Interventional Cardiology, PCI in Complex Constitution of the Control of Subsequent Control of				Valve Replacement	
Bern-Dor Bask Interventional Cardiology, PCI in Complex Long-Term Mortally in Percutaneous Coronary Intervention of Spelents Bern-Dor Bask Interventional Cardiology, Anglography and Suggested Reviewer Northing to Disclose	Ben-Dor	Itsik	Interventional Cardiology: TAVR 3		Nothing to Disclose
Berneto Italia Incomposito in Receive Interventional Cardiology Angiography and Incompositor in Receive Interventional Cardiology Angiography and Incompositor in Receive Interventional Cardiology Angiography and Incompositor in Receive Interventional Cardiology Angiography and Incompositor in Receive Interventional Cardiology (Interventional Cardiology I	Ben-Dor	Itsik	Interventional Cardiology: PCI in Complex		Nothing to Disclose
Benes Lane Innovations in Risk Assessment Novel Biomarkers and Risk Prediction Tools Progression of Percurdial Adopose Tissue. The CARDIA Study Progression of	5011 501		Patients		Trouming to Discrete
Benes	Ben-Dor	Itsik		Suggested Reviewer	Nothing to Disclose
Benetos Georgios Advances in Cholesterol Measurement and Management Cholesterol Measurement and Management Management Patients With Familial Hypertipidemia Syndromes Results From a Nothing to Disclose Patients With Familial Hypertipidemia Syndromes Results From a Nothing to Disclose Patients With Familial Hypertipidemia Syndromes Results From a Nothing to Disclose Disease States and Clinical Scenarios Novel Diseases States and Clinical Scenarios Activity in Patients With Disclose Disease States and Clinical Scenarios Activity in Patients With Disclose States and Clinical Activity in Patients With Disclose States Stociaged Activity in Patients With Disclose States Stociaged Activity in Patients With Disclose States Micropara Activity in Patients With Disclose States Micropara Activity in Patients With Disclose States Micropara States With Disclose States Micropara States With Disclose States Micropara States With Disclose States Micropara States With Disclose States Micropara States With Disclose States Micropara States With Disclose States Wit	Renes	Lane		Association of 10-Year Change in Cardiovascular Risk Factors With	Nothing to Disclose
Management Patients With Familial Hyperipidemial Syndromes Results From a Randomized Trial Randomized Tr	501100	20110			Trouming to Discrete
Management Patients With Familial Hyperipidemial Syndromes Results From a Randomized Trial Randomized Tr	_				
Benetos Georgios Non invasive imaging: Applications in Novel Disease States and Clinical Scenarios Disease States and Clinical Scenarios Plucordeoxyglucose Uptake AND Visceral Adipose Tissue Biological Advisional Andrea Maria Ma	Benetos	Georgios			Nothing to Disclose
Disease States and Clinical Scenarios Fluorodeoxyglucose Uptake AND Visceral Adjopsed Tissue Biological Activity in Patients With Dyslipotes Tissue Biological Activity in Patients With Disease States Min Audio (Proposed Patients) Francisco Cornary Artery Disease With Medical Therapy Benetos Georgios Nuclear Cardiology, Beyond Perfusion Parter Cornary Disease Cornary Artery Disease Cornary Artery Disease Cornary Artery Disease Cornary Artery Disease Cornary Artery Disease Cornary Artery Disease Cornary Artery Disease Cornary Artery Disease Cornary Artery Disease Cornary Artery Disease Cornary Artery Disease Cornary Artery Disease Cornary Cornary Disease Cornary Cornary Disease Cornary Cornary Disease Cornary Cornary Disease Cornary Cornary Disease Cornary Cornary Disease Cornary Cornary Disease Cornary Cornary Disease Cornary Cornary Disease Cornary Cornary Disease Cornary Cornary Disease Cornary Cornary Disease Cornary Cornary Disease Cornary Cornary Cornary Disease Cornary Cornary Disease Cornary Cornary Disease Cornary Cornary Disease Cornary Cornary Disease Cornary Corna			managomon		
Benetos Georgios Traditional and Novel Factors Used to Assession the Risk of, and Used for the Treatment of, Coronary Artery Disease Carotiof Flaque Inflammation in Palents With Disbetes Melitius and Nothing to Disclose Coronary Artery Disease Carotion Flaque Inflammation in Palents With Disbetes Melitius and Nothing to Disclose With Medical Therapy. Benetos Georgios Changing the Natural History of Valve Disease With Medical Therapy. Benetos Georgios Nuclear Cardiology, Beyond Perfusion Flammation in Familial Combined Hyperipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Postfron Emission Tomography Study. Benetos Georgios Nuclear Cardiology, Beyond Perfusion In Nothing to Disclose Phypercholesterolemia: Insights From a Postfron Emission Palents Undergoing Cardiot Endarterectory, Validation With Histology. Benetos Georgios Cutting Edge Vascular Medicine Familial Combined Hyperipidemia to Characterized by Higher Alterial AND Hepatic Fluorodeoxyglucose Uptake Compared to Heterozygous Familial Hypercholesterolemia: Combined Hypercholesterolemia Palents Ower 75 Years Benetari Giovanni Making Progress in Understanding Heart Failure Giovanni Making Progress in Understanding Heart Failure Giovanni Making Progress in Understanding Heart Failure Giovanni Valvular Heart Disease: Mitral Valve Disease Heart Giovanni Valvular Heart Disease: Mitral Valve Disease Giovanni Valvular Heart Disease: Mitral Valve Disease Giovanni Palents Ower Failure Giovanni Palents Ower Failure Giovanni Palents Ower Failure Giovanni Palents Ower Failure Giovanni Palents Ower Failure Giovanni Palents Ower Failure Giovanni Palents Ower Failure Giovanni Palents Ower Failure Giovanni Palents Ower Failure Giovanni Palents Ower Failure Giovanni Palents Ower Failure Giovanni Palents Ower Failure Giovanni Palents Ower Failure Giovanni Palents Ower Failure Giovanni Palents Ower Failure Giovanni Palents Ower Failure Giovanni Palents Ower Failure Palent Ower Failure Giovanni Palents Ower Failure Giovanni Palents Mitral Valve Dis	Benetos	Georgios			Nothing to Disclose
Benetos Georgios Traditional and Novel Factors Used to Assessa the Risk of, and Used for the Treatment of, Coronary Artery Disease Changing the Natural History of Valve Bisease With Medical Therapy . Benetos Georgios Nuclear Cardiology: Beyond Perfusion In Familiat Combined Hyperipidemia Compared to Heterozygous Properties of Heritago and Properties of Properties			Disease States and Clinical Scenarios		
the Risk of, and Used for the Treatment of, Coronary Artery Disease Benetos Georgios Changing the Natural History of Valve Disease Benetos Georgios Nuclear Cardiology; Beyond Perfusion Familial Combined Hyperlipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission Tomography Study Benetos Georgios Nuclear Cardiology; Beyond Perfusion Increased Subclinical Systemic AND Vascular Inflammation in Familial Combined Hyperlipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission Tomography Study Benetos Georgios Nuclear Cardiology; Beyond Perfusion Increased Subclinical Systemic AND Vascular Inflammation in Familial Combined Hyperlipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission Tomography Study Benetos Georgios Cutting Edge Vascular Medicine Palentos Undergoing Cardiol Endanterectomy, Validation With Histology Arrhythmias and Clinical EP: Devices 1 Palentos And Perfusion Increased Subclinical And Perfusion of Cardiol Endanterectomy, Validation With Histology Arrhythmias and Clinical EP: Devices 1 Palentos And Perfusion Increased Subclinical And Perfusion of Cardiol Endanterectomy, Validation With Histology Arrhythmias and Clinical EP: Devices 1 Palentos And Perfusion Increased Subclinical And Perfusion Increased Subclinical And Perfusion Increased Subclinical And Perfusion Increased Subclinical And Perfusion Increased Perfusion Increased Perfusion Increased Subclinical Systemic And Perfusion Increased Perfusion I	Benetos	Georgios	Traditional and Novel Factors Used to Assess		Nothing to Disclose
Benetos Georgios Changing the Natural History of Valve Disease With Medical Therapy		-		Coronary Artery Disease	-
Benetos Georgios Nuclear Cardiology: Beyond Perfusion Familial Combined Hyperflipidemia Compared to Heterozygous Hypercholesterolemia: One Compared to Heterozygous Hypercholesterolemia: One Missis From a Postitish From a Postit	Renetos	Georgies		Zoledronic Acid Inhibits Acrtic Valve Calcification: A DET/CT Study	Nothing to Disclose
Benetos Georgios Nuclear Cardiology: Beyond Perfusion Increased Subclinical Systemic AND Vascular Inflammation in Familial Combined Phipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission Tomography Study North Phipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission Northing to Disclose Phipidemia Compared to Heterozygous Familial Combined Myth Histology Northing to Disclose Phipidemia Institute Phipide	20110100	Congres	With Medical Therapy	25.53. Onlo Asia Innibito Asiatic Valve Galonication. A FET/CT Study	
Benetos Georgios Nuclear Cardiology: Beyond Perfusion In Vivo Correlation of Carotal Temperatures and PetiFdg Uptake in Patients Undergoing Carotal Endarterectomy: Validation With Histology and Perfusion In Vivo Correlation of Carotal Temperatures and PetiFdg Uptake in Patients Undergoing Carotal Endarterectomy: Validation With Histology In Vivo Correlation of Carotal Endarterectomy: Validation With Histology In Vivo Correlation of Carotal Endarterectomy: Validation With Histology In Vivo Correlation of Carotal Endarterectomy: Validation With Histology In Vivo Correlation of Carotal Endarterectomy: Validation With Histology In Vivo Correlation of Carotal Endarterectomy: Validation With Histology In Vivo Correlation of Carotal Endarterectomy: Validation With Histology In Vivo Compared to Heterozygous Familial Ambients of Carotal Endarterectory of Histology In Vivo Carotal Ambients of Carotal Endarterectory of Histology In Vivo Carotal Ambients of Carotal Endarterectory of Histology In Vivo Carota	Benetos	Georgios	Nuclear Cardiology: Beyond Perfusion	Increased Subclinical Systemic AND Vascular Inflammation in	Nothing to Disclose
Benetos Georgios Nuclear Cardiology: Beyond Perfusion In Vivo Correlation of Carotid Temperatures and PetiFdg Uptake in Paleinst Undergoing Carotid Endarterectomy. Validation With Histology Histology (Carotid Endarterectomy. Validation With Histology (Carotid Endarterectomy. Validation With Histology (Carotid Endarterectomy. Validation With Histology (Carotid Endarterectomy. Validation With Histology (Carotid Endarterectomy. Validation With Histology (Carotid Endarterectomy. Validation With Histology (Carotid Endarterectomy. Validation With Histology (Carotid Endarterectomy. Validation With Histology (Carotid Endarterectomy. Validation With Histology (Carotid Endarterectomy. Validation With Histology (Carotid Endarterectomy. Validation With Histology (Carotid Endarterectomy. Validation With Histology (Carotid Endarterectomy. Validation With Histology (Carotid Endarterectomy. Validation With Histology (Carotid Endarterectomy. Validation With Histology (Carotid Endarterectomy. Validation Disclose With Histology (Carotid Endarterectomy. Validation Paleints) (Carotid					
Benetos Georgios Nuclear Cardiology: Beyond Perfusion In Vivo Correlation of Carolid Temperatures and PetFGg Uptake in Patients Undergo Carolid Endarterectomy. Validation With Histology Patients Undergo Carolid Endarterectomy. Validation With Histology Patients Undergo Carolid Endarterectomy. Validation With Histology Patients Undergo Carolid Endarterectomy. Validation With Histology Patients Undergo Carolid Endarterectomy. Validation With Histology Patients Undergo Carolid Endarterectomy. Validation With Histology Patients With Carolidory (Patients) Patients With Carolidory (Patients) Patients With Carolidory (Patients) Patients With Carolidory (Patients) Patients With Carolidory (Patients) Patients With Ventricular Dysfunction: Intercept (Patients) Patients With Ventricular Dysfunction: Patients (Patients) Patients With Ventricular Dysfunction: Patients Patients (Patients) Patients Patients (Patients) Patients) Patients Patients (Patients) Patients Patients (Patients) Patients Patients (Patients) Patients Patients (Patients) Patients) Patients Patients (Patients) Patients Patients) Patients Patients (Patients) Patients Patients (Patients) Patients) Patients Patients (Patients) Patients Patients (Patients) Patients) Patients Patients (Patients) Patients (Patients) Patients) Patients (Patients) Patients) Patients (Patients) Patients) Patients (Patients) Patients) Patients (Patients) Patients) Patients (Patients) Patients (Patients) Patients (Patients) Patients (Patients) Patients) Patients (Patients)					
Benetos Georgios Cutting Edge Vascular Medicine Familial Combined Hypertipidemia is Characterized by Higher Arterial AND Hepatic Fluorodeoxyglucose Uptake Compared to Heterozygous Familial Hypercholesterolemia Benezel-Mazuecos Juan Arrhythmias and Clinical EP: Devices 1 Pharmacological Treatment Alone Versus Treatment Combined With Implantable Cardioverter-Defibrillator Therapy in Patients Over 75 Years Benfari Giovanni Making Progress in Understanding Heart Failure Understanding Heart Failure Information of Survival? Benfari Giovanni Making Progress in Understanding Heart Failure Benfari Giovanni Valvular Heart Disease: Mitral Valve Disease Valvular Heart Disease: Mitral Valve Disease Governor Progression Walvular Heart Disease: Mitral Valve Disease Governor Progression	Benetos	Georgios	Nuclear Cardiology: Beyond Perfusion	In Vivo Correlation of Carotid Temperatures and Pet/Fdg Uptake in	Nothing to Disclose
Benetos Georgios Cutting Edge Vascular Medicine Familial Combined Hyperlipidemia Is Characterized by Higher Arterial AND Hepatic Fluorodeoxyglucose Uptake Compared to Heterozygous Familial Hypercholesterolemia					
Arthal AND Hepatic Fluorodeoxyglucose Uptake Compared to Heterozygous Familial Hypercholesterolemia Benezet-Mazuecos Juan Arrhythmias and Clinical EP: Devices 1 Pharmacological Treatment Alone Versus Treatment Combined With Implantable Cardioverter-Defibrillator Therapy in Patients Over 75 Years Benfari Giovanni Making Progress in Understanding Heart Failure Benfari Giovanni Making Progress in Understanding Heart Inderstanding Heart Failure Benfari Giovanni Making Progress in Understanding Heart Inderstanding Heart Failure Benfari Giovanni Walvular Heart Disease: Mitral Valve Disease Salure Benfari Giovanni Valvular Heart Disease: Mitral Valve Disease Salure Benfari Giovanni Valvular Heart Disease: Mitral Valve Disease Salure Salure Muth Left Ventricular Dysfunction: Province Clinical Practice: Does It Independently Impact Survival of Degenerative Mitral Regurgitation: Reserved to the Specialized Few or Applicable to Routine Clinical Practice? Benfari Giovanni New Technologies in Echocardiography Mitral Annular Disjunction Prevalence and Physiologic Consequences in Degenerative Mitral Regurgitation: A Dynamic 3- Dimensional Echocardiographic Study Mitral Annular Disjunction Prevalence and Physiologic Consequences in Degenerative Mitral Regurgitation: A Dynamic 3- Dimensional Echocardiographic Study Atrial Fibrillation Link to Excess Mortality in Patients With Left Ventricular Dysfunction: Linked to Rapid Ventricular Response or Independent Prognostic Raker? Benfari Giovanni Technical Advances in Transthoracic Echocardiography Echocardiography Echocardiography Benge Cassandra Ilrika Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering Mypertension Self-Management: Mobile-Phone Self-Reports Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Mothing to Disclose Nothing to Disclose Mothing to Disclose Mothing to Disclose Mothing to Disclose Mothing to Disclose Mothing to Disclose Mo	Benetos	Georgios	Cutting Edge Vascular Medicine		Nothing to Disclose
Parmacological Treatment Alone Versus Treatment Combined With Implantable Cardioverter-Defibrillator Therapy in Patients Over 75 Years		3	3 .3	Arterial AND Hepatic Fluorodeoxyglucose Uptake Compared to	<u> </u>
With Implantable Cardioverter-Defibrillator Therapy in Patients Over 75 Years	Repozet Mezur	luan	Arrhythmiae and Clinical ED: Devices 4		Nothing to Disclose
Senfari Giovanni Making Progress in Understanding Heart Left Atrial Enlargement in Patients With Ventricular Dysfunction: Nothing to Disclose Innocent Bystander or Meaningful Determinant of Survival? Nothing to Disclose Senfari Giovanni Making Progress in Understanding Heart Senfari Senfari Senfari Senfari Senfari Senfari Senfari Senfari Senfari Giovanni Valvular Heart Disease: Mitral Valve Disease Left Atrium Volume Index Measurement in Routine Practice: Does It Independently Impact Survival of Degenerative Mitral Valve Disease? Ouantitation of Degenerative Mitral Regurgitation: Reserved to the Specialized Few or Applicable to Routine Clinical Practice? Nothing to Disclose Senfari Giovanni New Technologies in Echocardiography Mitral Annular Heagurgitation: Apynamic 3-Dimensional Echocardiographic Study Atrial Fibrillation Link to Excess Mortality in Patients With Left Nothing to Disclose Nothing to Disclose Consequences in Degenerative Mitral Regurgitation: Apynamic 3-Dimensional Echocardiographic Study Atrial Fibrillation Link to Excess Mortality in Patients With Left Nothing to Disclose Nothing t	Deriezet-iviazuecos	Judii	Armyulmias and Clinical EP: Devices 1		inouning to Disclose
Benfari Giovanni Making Progress in Understanding Heart Left Atrial Enlargement in Patients With Ventricular Dysfunction: Innocent Bystander or Meaningful Determinant of Survival?		<u></u>		75 Years	
Benfari Giovanni Making Progress in Understanding Heart S Fraitty a Mirror of Underfying Hemodynamic Alteration in Patients Nothing to Disclose With Left Ventricular Dysfunction? With Left Ventricular Dysfunction? With Left Ventricular Dysfunction? Working to Disclose With Left Ventricular Dysfunction? With Left Ventricular Dysfunction? Working to Disclose Disclose	Benfari	Giovanni			Nothing to Disclose
Failure	Benfari	Giovanni			Nothing to Disclose
Benfari Giovanni Valvular Heart Disease: Mitral Valve Disease Benfari Giovanni Valvular Heart Disease: Mitral Valve Disease Benfari Giovanni Valvular Heart Disease: Mitral Valve Disease Benfari Giovanni Valvular Heart Disease: Mitral Valve Disease Benfari Giovanni New Technologies in Echocardiography Mitral Annular Disjunction Prevalence and Physiologic Consequences in Depenerative Mitral Regurgitation: A Dynamic 3- Dimensional Echocardiographic Study Atrial Finuliation Link to Excess Mortality in Patients With Left Ventricular Dysfunction: Linked to Rapid Ventricular Response or Independent Prognostic Marker? Benfari Giovanni Technical Advances in Transthoracic Echocardiography Echocardiography Echocardiography Benge Cassandra Interdisciplinary Cardiovascular Team Collaboratives in Care Bengtsson Ulrika Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering Mortinal Cardiovascular Cardiovascular Marker Patient Patient Morting to Disclose Nothing to Disclose			Failure	With Left Ventricular Dysfunction?	
Disease? Disease? Disease? Disease? Disease? Disease? Disease? Disease? Disease Quantitation of Degenerative Mitral Regurgitation: Reserved to the Specialized Few or Applicable to Routine Clinical Practice? Nothing to Disclose Disea	Benfari	Giovanni	Valvular Heart Disease: Mitral Valve Disease	Left Atrium Volume Index Measurement in Routine Practice: Does It	Nothing to Disclose
Benfari Giovanni Valvular Heart Disease: Mitral Valve Disease Quantitation of Degenerative Mitral Regurgitation: Reserved to the Specialized Few or Applicable to Routine Clinical Practice? Benfari Giovanni New Technologies in Echocardiography Mitral Anular Disjunction Prevalence and Physiologic Consequences in Degenerative Mitral Regurgitation: A Dynamic 3-Dimensional Echocardiographic Study Benfari Giovanni Emerging Developments in HFpEF and Arrighthmias Arrighthmias Arrighthmias Arrighthmias Arrighthmias Arrighthmias Profundion: Linked to Rapid Ventricular Response or Independent Prognostic Marker? Benfari Giovanni Technical Advances in Transthoracic Echocardiography Echoc					
Specialized Few or Applicable to Routine Clinical Practice?	Benfari	Giovanni	Valvular Heart Disease: Mitral Valve Disease	Quantitation of Degenerative Mitral Regurgitation: Reserved to the	Nothing to Disclose
Consequences in Degenerative Mitral Regurgitation: A Dynamic 3-Dimensional Echocardiographic Study	D (0'	No. To be desired to E. C. C. C. C. C. C. C. C. C. C. C. C. C.		Notice to Produce
Dimensional Echocardiographic Study	Bentari	Giovanni	New Technologies in Echocardiography		Notning to Disclose
Benfari Giovanni Emerging Developments in HFpEF and Arrial Fibrillation Link to Excess Mortality in Patients With Left Ventricular Dysfunction: Linked to Rapid Ventricular Response or Independent Prognostic Marker? Benfari Giovanni Technical Advances in Transthoracic E/e' Short- and Long-Term Independent Prognostic Role in Patients With Left Ventricular Dysfunction Benge Cassandra Interdisciplinary Cardiovascular Team Collaboratives in Care Management of a Complex Heart Failure Patient Collaboratives in Care Management of a Complex Heart Failure Patient Movel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering Mover Patient Principation in Clinical Consultations Movel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering Mover Patient Principation in Clinical Consultations					
Independent Prognostic Marker? Independent Prognostic Marker?	Benfari	Giovanni		Atrial Fibrillation Link to Excess Mortality in Patients With Left	Nothing to Disclose
Benfari Giovanni Technical Advances in Transthoracic E/e' Short- and Long-Term Independent Prognostic Role in Patients With Left Ventricular Dysfunction Patients With Left Ventricular Dysfunction Patients With Left Ventricular Dysfunction Patients With Left Ventricular Dysfunction Patients With Left Ventricular Dysfunction Patients With Left Ventricular Dysfunction Nothing to Disclose Nothing to Disclose Management of a Complex Heart Failure Patient Power States Patient Ventricular Dysfunction Nothing to Disclose Physical Power Ventricular Dysfunction Physical			Arryhthmias		
Echocardiography Patients With Left Ventricular Dysfunction Patients With Left Ventricular Dysfunction Patients With Left Ventricular Dysfunction Patients With Left Ventricular Dysfunction Patients Ventricular Dysfunction Patients Ventricular Dysfunction Patients Ventricular Dysfunction Patients Ventricular Dysfunction Patients Ventricular Oroselection Patients Ventricular Vent	Benfari	Giovanni	Technical Advances in Transthoracic		Nothing to Disclose
Collaboratives in Care Management of a Complex Heart Failure Patient Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering Improve Patient Participation in Clinical Consultations Collaboratives in Care Management of a Complex Heart Failure Patient Hypertension Self-Management: Mobile-Phone Self-Reports Nothing to Disclose Mothi			Echocardiography	Patients With Left Ventricular Dysfunction	
Bengtsson Ulrika Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering Improve Patient Participation in Clinical Consultations Hypertension Self-Management: Mobile-Phone Self-Reports Improve Patient Participation in Clinical Consultations	Benge	Cassandra	Interdisciplinary Cardiovascular Team		Nothing to Disclose
Adherence to Blood Pressure Lowering Improve Patient Participation in Clinical Consultations	Bengtsson	Ulrika			Nothing to Disclose
Therapies	J	_	Adherence to Blood Pressure Lowering		<u> </u>
	L	I	Therapies		



and the second				l l
Last Name Benjafield	First Name Adam	Session Title Heart Failure and Cardiomyopathies: Is Heart	Presentation Title Surrogate Endpoints and the Differential Response to ASV for Sleep	Disclosures RESEARCH/RESEARCH GRANTS - Resmed; SALARY -
Benjamin	Emelia	Failure With a Normal EF for Real? Beyond the Usual Suspects - Other	Apnea in HFrEF Versus HFpEF in the CAT-HF Trial Panelist	Resmed Nothing to Disclose
Benjamin	Emelia	Dimensions in Prevention Beyond the Usual Suspects - Other	We've Got Rhythm! Prevention of Atrial Fibrillation	Nothing to Disclose
		Dimensions in Prevention	•	-
Benjamin	Emelia	Innovative Use of Echocardiography	Effect of Left Atrial Remodeling on Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study	Nothing to Disclose
Benjamin	Emelia	Innovative Use of Echocardiography	Left Atrial Function Index as a Predictor of Cardiovascular Disease and Atrial Fibrillation: Data From the Framingham Offspring Study	Nothing to Disclose
Bennett	Courtney	Innovations in Practice Management and Social Media	Severity of Illness Assessment in the Cardiac Intensive Care Unit (CICU): Application of the APACHE IV Predicted Mortality Score	Nothing to Disclose
Bennett	Courtney	Personalized Skills Center: Drill and Practice	Heart Songs Moderator	Nothing to Disclose
Bennett	Joanne	(Heart Songs, ECG, Hand-Held Echo) Interventional Cardiology: TAVR 1	"Cusp Overlap" View Facilitates Accurate Fluoro-	Nothing to Disclose
Bennett	Joanne	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Guided Implantation of Self-Expanding Valve in TAVR Change in Aortomitral Annular Angle and Anterior Mitral Valve Leaflet Length After Transcatheter Aortic Valve Replacement:	Nothing to Disclose
Bennett	Joanne	Interventional Cardiology: TAVR 4	Implications for Transcatheter Mitral Valve Replacement? Predictors of New Persistent Left Bundle Branch Block After	Nothing to Disclose
Bennett	Mosi	Acute Heart Failure: Evaluating Strategies to	Edwards Sapien 3 Transcatheter Aortic Valve Replacement Effect of Pulmonary Pressure Monitoring (CardioMEMS Heart	Nothing to Disclose
Definett	WOSI	Prevent Readmissions	Failure System, St. Jude Medical) on Hospital Admissions and Emergency Department Visits: A Multicenter Real World Experience	Notifing to Disclose
Ben-Shoshan	Jeremy	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Absence of Clinical Triggering in Diabetic Patients With ST-Segment Elevation Myocardial Infarction Predicts Multiple Vessel Coronary Disease and Is Associated With Increased Mortality	Nothing to Disclose
Benson	Carol	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Early Hemodynamic Changes After Fetal Aortic Stenosis Valvuloplasty Are Associated With Biventricular Circulation at Birth	Nothing to Disclose
Benson	Lee	Innovations in Pediatric Catheterization and	Ductal Origin of an Isolated Pulmonary Artery: Initial Stenting	CONSULTANT FEES/HONORARIA - Medtronic Inc
Ben-Yehuda	Ori	EP: Mending, Fixing and Predicting Highlighted Original Research: Interventional	Followed by Unifocalization Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome	CONSULTANT FEES/HONORARIA - Merck & Dr., amp; Co.,
Ben-Yehuda	Ori	Cardiology and the Year in Review Complex Coronary Intervention: Left	After PCI of Left Main Coronary Artery Disease: The EXCEL Trial Differences and Level of Agreement in SYNTAX Score Assessment	Inc.; SPEAKER'S BUREAU - Merck & Description (Co., Inc.) CONSULTANT FEES/HONORARIA - Merck & Description (Co.,
		Main/Bifurcations and Multivessel Disease	Between Site Operators and Angiographic Core Laboratory Readers: Insights From the EXCEL Trial	Inc.; SPEAKER'S BUREAU - Merck & Department of the service of the
Ben-Yehuda	Ori	Interventional Cardiology: PCI and TAVR in Complex Patients	Long-Term Adverse Ischemic Outcomes After Percutaneous Coronary Intervention Among Patients With Versus Without Prior Coronary Artery Bypass Grafting: Analysis From 17 Randomized Trials	CONSULTANT FEES/HONORARIA - Merck & Demp; Co., Inc.; SPEAKER'S BUREAU - Merck & Demp; Co., Inc.
Ben-Yehuda	Ori	Refining PCI Technique and Outcomes	Treatment of Left Main Coronary Artery Disease in Patients With Diabetes: 3-Year Outcomes Comparing CABG and PCI With Everolimus-Eluting Stents From the EXCEL Study	CONSULTANT FEES/HONORARIA - Merck & Description (Co., Inc.; SPEAKER'S BUREAU - Merck & Description) (Co., Inc.)
Ben-Yehuda	Ori	Refining PCI Technique and Outcomes	Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory Assessment: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - Merck & Description (Co., Inc.; SPEAKER'S BUREAU - Merck & Description (Co., Inc.)
Benz	Dominik	Non Invasive Imaging: Expanding Clinical Applications	Computed Tomography-Derived Corrected Contrast Opacification Decrease Predicts Reduced Relative Flow Reserve Derived From PET Myocardial Perfusion Imaging	Nothing to Disclose
Benz	Dominik	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Prospective Evaluation of Low-Dose Coronary Calcium Scoring With	Nothing to Disclose
Benz	Dominik	Non Invasive Imaging: Prognostic Implications of CT Angiography	Reduced Tube Voltage Long-Term Prognostic Value of Computed Tomography-Derived Corrected Contrast Opacification Decrease in Patients With	Nothing to Disclose
Benz	Michael	FIT Clinical Decision Making: Heart Failure and	Coronary Stenosis Acute Pulmonary and Paradoxical Embolism Treated With Catheter	Nothing to Disclose
Beohar	Nirat	Pulmonary Hypertension Challenging Anatomies: Does TAVR Device	Based Thrombectomy Panelist	Nothing to Disclose
Beohar	Nirat	Choice Matter		-
Beonar	Milat	Interventional Cardiology: TAVR 2	The Impact of Preoperative Renal Dysfunction on the Outcomes of Patients Undergoing Surgical Versus Transcatheter Aortic Valve Replacement: An Analysis From the CoreValve US Pivotal High Risk Trial	Nothing to Disclose
Beohar	Nirat	Refining TAVR Outcomes	Incidence and Outcomes of Patients Requiring Surgical Bail-Out During Transcatheter Aortic Valve Replacement: A Report From the NCDR® STS/ACC Transcatheter Valve Therapy (TVT)	Nothing to Disclose
Beohar	Nirat	17. Interventional Cardiology: Aortic Valve	Registry Suggested Reviewer	Nothing to Disclose
Beran	Elisabeth	Disease Team 1 Finding Out What Works in Pediatric and Congenital Heart Disease	Morphological Appearance and Repair Strategies of Tricuspid Regurgitation in Patients With Univentricular Heart and a Systemic	Nothing to Disclose
Berenbom	Loren	Arrhythmias and Clinical EP: Devices 2	Right Ventricle Real World Battery Longevity of St. Jude Medical Implantable Cardioverter-Defibrillators Included in the Advisory for Premature	Nothing to Disclose
Berg	David	STEMI Dilemmas: You Be the Judge	Battery Depletion Case Presentation: Winning the Battle, Losing the War? Management of Patient Who Develops Acute Shock Following	Nothing to Disclose
Berg	David	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Successful PCI for Inferior Wall MI Platypnea-Orthodeoxia in a Leukemia Patient With a Tricuspid Valve Mass	Nothing to Disclose
Berg	Nancy	Common Arrhythmia Problems: The Experts	Case Presentation	Nothing to Disclose
Berg	William	Approach Coronary Intervention in Interventional	Three-Year Outcomes in ‘:Real-World’: Patients	Nothing to Disclose
Doily	YY IIIIQIII	Cardiology: Advanced Device Use	Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus U.S. Post-Approval Study (PE- Plus PAS)	THOUTHING TO DISCUSSE
Bergenstal	Richard	The Intersection of Diabetes and ASCVD	Average Clinician Measured Blood Pressure Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes Following Acute Coronary Syndromes in the EXAMINE Trial	Nothing to Disclose
Berger	Jeffrey	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	A Benefit-Risk Analysis of Recurrent Venous Thromboembolism in Patients Who Continued Versus Discontinued Rivaroxaban Therapy After an Initial Six-Month Therapy	CONSULTANT FEES/HONORARIA - Janssen Pharmaceuticals, Inc,Merck & Damp; Co., Inc., Takeda; RESEARCH/RESEARCH GRANTS - Astra Zenica
Berger	Jeffrey	Interventional Cardiology: PCI in Complex Patients	Impact of Comorbid Coronary Artery Disease and Severe Peripheral Artery Disease on Major Adverse Cardiovascular Events	CONSULTANT FEES/HONORARIA - Janssen Pharmaceuticals, Inc,Merck & Double Co., Inc., Takeda;
Berger	Jeffrey	40. Vascular Medicine: Non Coronary Arterial Disease Team 2	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Astra Zenica CONSULTANT FEES/HONORARIA - Janssen Pharmaceuticals, Inc,Merck & Dramp; Co., Inc., Takeda;
Porgor	loffroy C		Ingramontal Disk of Isabamia Stralia Cora Tima in Nanth Di	RESEARCH/RESEARCH GRANTS - Astra Zenica
Berger	Jeffrey S.	Making Progress in Understanding Heart Failure	Incremental Risk of Ischemic Stroke Over Time in Newly Diagnosed Heart Failure Patients Without Atrial Fibrillation	CONSULTANT FEES/HONORARIA - Janssen Pharmaceuticals, Inc,Merck & Co., Inc,Takeda; RESEARCH/RESEARCH GRANTS - Astra Zenica



WASHINGTON, DC | MARCH 17 - 19 2017

Last Name	First Name	Session Title	Presentation Title	Disclosures
Berger	John	Finding Out What Works in Pediatric and Congenital Heart Disease	Risk of Catastrophic Outcome Following Cardiac Catheterization for Pulmonary Hypertension: An Analysis of Data From the Impact Registry	Nothing to Disclose
Berger	Peter	Global Perspectives in the Treatment of ST Elevation Myocardial Infarction: Successes, Failures, and Challenges	Panelist	CONSULTANT FEES/HONORARIA - Janssen, Medicure; RESEARCH/RESEARCH GRANTS - Janssen, Janssen
Berger	Peter	Logistical Challenges in STEMI	Panelist	CONSULTANT FEES/HONORARIA - Janssen, Medicure; RESEARCH/RESEARCH GRANTS - Janssen, Janssen
Berger	Peter	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Rates of Oral Anticoagulant Use, While Improving Over Time, Remain Low Among Hospitalized Patients With Atrial Fibrillation	CONSULTANT FEES/HONORARIA - Janssen, Medicure; RESEARCH/RESEARCH GRANTS - Janssen, Janssen
Berger	Peter	Arrhythmias and Clinical EP: Basic 5	A Clinical Prediction Model for Time in Therapeutic Range While on	CONSULTANT FEES/HONORARIA - Janssen, Medicure;
Berger	Peter	02. Acute and Stable Ischemic Heart Disease:	Warfarin in Newly Diagnosed Atrial Fibrillation Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Janssen, Janssen CONSULTANT FEES/HONORARIA - Janssen, Medicure;
Bergersen	Lisa	Clinical Team 3 Highlighted Original Research: Congenital Heart Disease and the Year in Review	Safety and Feasibility of Melody Transcatheter Pulmonary Valve Replacement in the Native Right Ventricular Outflow Tract: A	RESEARCH/RESEARCH GRANTS - Janssen, Janssen CONSULTANT FEES/HONORARIA - 480 Biomedical Inc
Bergersen	Lisa	Congenital Heart Disease: Progress in	Multicenter Study Prediction Tool for Congenital Heart Surgery Length of Stay	CONSULTANT FEES/HONORARIA - 480 Biomedical Inc
Bergersen	Lisa	Pediatric Heart Surgery 10. Congenital Heart Disease: Pediatric Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - 480 Biomedical Inc
Bergin	James	2 Advances in HCM, PPCM and Other	Systemic Arterial Pulsatility Index (SAPi) Predicts Adverse	Nothing to Disclose
Bergman	Geoffrey	Cardiomyopathies Interventional Cardiology: TAVR 1	Outcomes in Advanced Heart Failure Patients Baseline Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Increased Mortality After	Nothing to Disclose
Bergman	Geoffrey	Interventional Cardiology: TAVR 2	Transcatheter Aortic Valve Replacement Does Intra-Aortic Balloon Pump Placement During Hospitalization Course for Transcatheter Aortic Valve Replacement Portent a	Nothing to Disclose
Bergman	Geoffrey	Interventional Cardiology: TAVR 3	Worse Clinical Outcome? Periprocedural Blood Transfusions in Patients Undergoing	Nothing to Disclose
Bergman	Geoffrey	Outcomes in Valvular Heart Disease	Transcatheter Aortic Valve Replacement In-Hospital Clinical Outcomes Following Concomitant Coronary	Nothing to Disclose
	·		Artery Bypass Graft and Heart Valve Surgery in Women	ů
Bergmark	Brian	Highlighted Original Research: Prevention and the Year in Review	Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial	Nothing to Disclose
Bergmark	Brian	Post-CAD/MI: Making Tough Predictions About the Future	Risk Stratification With the TIMI Risk Score for Secondary Prevention Among Patients With Diabetes and Elevated Cardiovascular Risk	Nothing to Disclose
Berkovitch	Anat	Interventional Cardiology: TAVR 4 Arrhythmias and Clinical EP: Anticoagulation	Transacatheter Aortic Valve Replacement And Malignancy	Nothing to Disclose
Berkowitz	Scott	Issues	Thrombolytic Therapy in Anticoagulated Patients: Case Series From Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET AF)	SALARY - Bayer HealthCare Pharmaceuticals - Employed by
Berlacher	Kathryn	Innovations in Education	Beat Blasts: A Multicenter Study of an Electrocardiogram Email Curriculum for Medicine Residents	Nothing to Disclose
Berlacher	Kathryn	Engage @ ACC.17 Studio: Cardiology Contest	Cardiology Contestant	Nothing to Disclose
Berliner	Jennifer	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Subclavian Artery Stenosis Precipitating Ischemic Cardiomyopahty	Nothing to Disclose
Berlowitz	Michael	Diabetes and Other Issues in Cardiovascular Prevention	Patients Leaving Against Medical Advice: Can We Prevent Unnecessary Testing and Reduce Costs in the Evaluation of Acute Ischemic Heart Disease?	Nothing to Disclose
Berman	Daniel	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Subclinical Leaffet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical Center -software royalties, Molecular Dynamics; RESEARCH/RESEARCH GRANTS - Astellas Pharma US, Inc.,Bayer Healthcare Pharmaceuticals, Siemens Medical Solutions
Berman	Daniel	Great Debates in Cardiac CT	Co-Chair	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical Center -software royalties, Molecular Dynamics; RESEARCH/RESEARCH GRANTS - Astellas Pharma US, Inc., Bayer Healthcare Pharmaceuticals, Siemens Medical Solutions
Berman	Daniel	Core Curriculum: Imaging the Heart: Choosing Wisely	Anatomical and Functional Assessment with CTA: Are Diagnositic Caths a Way of the Past?	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical Center - software royalties, Milecular Dynamics; RESEARCH/RESEARCH GRANTS - Astellas Pharma US, Inc. Bayer Healthcare Pharmaceuticals, Siemens Medical Solutions
Berman	Daniel	Revascularization and Outcomes	Coronary Microvascular Dysfunction Is Related to Left Ventricular Concentric Remodeling and Diastolic Dysfunction: From the WISE-CVD Study	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical Center-software royalties, Molecular Dynamics; RESEARCH/RESEARCH GRANTS - AStellas Pharma US, Inc., Bayer Healthcare Pharmaceuticals, Siemens Medical Solutions
Berman	Daniel	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium in the Elderly: Prevalence, Severity, and Association With All-Cause Mortality	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical Center -software royalties, Molecular Dynamics; RESEARCH/RESEARCH GRANTS - Astellas Pharma US, Inc., Bayer Healthcare Pharmaceuticals, Siemens Medical Solutions
Berman	Daniel	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography: The CONFIRM (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical Center software royalties, Molecular Dynamics; RESEARCH/RESEARCH GRANTS - Astellas Pharma US, Inc. Bayer Healthcare Pharmaceuticals, Siemens Medical Solutions
Berman	Daniel	Non Invasive Imaging: MR Scar and Perfusion	Hyperemic Subendocardial-to-Subepicardial Perfusion Ratio as a Surrogate Marker for Coronary Endothelial Dysfunction: Initial Results in Women With Microvascular Dysfunction	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical Center software royalties, Molecular Dynamics; RESEARCH/RESEARCH GRANTS - Astellas Pharma US, Inc. Bayer Healthcare Pharmaceuticals, Siemens Medical Solutions
Berman	Daniel	Non Invasive Imaging: MR Scar and Perfusion	Assessment of Myocardial Perfusion Reserve Index Using Adenosine Versus Regadenoson Among Healthy Female Subjects	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical Center -software royalties, Molecular Dynamics; RESEARCH/RESEARCH GRANTS - Astellas Pharma US, Inc.,Bayer Healthcare Pharmaceuticals, Siemens Medical Solutions
Berman	Daniel	Nuclear Cardiology: Quality	Rest Scan Does Not Improve Automatic Machine Learning Prediction of Major Adverse Coronary Events After High Speed Myocardial Perfusion Imaging	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical Center software royalties, Molecular Dynamics; RESEARCH/RESEARCH GRANTS - Astellas Pharma US, Inc. Bayer Healthcare Pharmaceuticals, Siemens Medical Solutions
Berman	Daniel	Non Invasive Imaging: Prognostic Implications of CT Angiography	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical Center -software royalties, Molecular Dynamics; RESEARCH/RESEARCH GRANTS - Astellas Pharma US, Inc. Bayer Healthcare Pharmaceuticals, Siemens Medical Solutions

The state of the s				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Berman	Daniel	Non Invasive Imaging: Prognostic Implications of CT Angiography	Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical Center - software royalties, Molecular Dynamics; RESEARCH/RESEARCH GRANTS - Astellas Pharma US, Inc.,Bayer Healthcare Pharmaceuticals, Siemens Medical
				Solutions
Berman	Daniel	Nuclear Cardiology: Coronary Flow	Precisely Controlled Arterial CO2 Can Potentiate Myocardial Blood	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical
			Flow to the Same Extent as Adenosine: A Preclinical Study in Canines With 13N-Ammonia PET	Center - software royalties, Molecular Dynamics; RESEARCH/RESEARCH GRANTS - Astellas Pharma US, Inc.,Bayer Healthcare Pharmaceuticals, Siemens Medical Solutions
Berman	Daniel	Nuclear Cardiology: Coronary Flow	Patient Motion Significantly Affects Measurements of Quantitative Global Regional Myocardial Blood Flow Assessment by Dynamic Pet	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical Center -software royalties, Molecular Dynamics; RESEARCH/RESEARCH GRANTS - Astellas Pharma US, Inc., Bayer Healthcare Pharmaceuticals, Siemens Medical Solutions
Berman	Daniel	Non Invasive Imaging: New Technologies	improvement in LDL is Associated With Decrease in Non-Calcified Plaque Volume on CTA as Measured by Automated Quantitative Software	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical Center-software oyalites, Molecular Dynamics, RESEARCH/IRESEARCH GRANTS - Astellas Pharma US, Inc., Bayer Healthcare Pharmaceuticals, Siemens Medical Solutions
Berman	Daniel	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Relationship Between Whole Vessel Quantitative Plaque Characteristics and Noninvasive Fractional Flow Reserve From Coronary Computed Tomography Anglography	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical Center -software royalties, Molecular Dynamics; RESEARCH/RESEARCH GRANTS - Astellas Pharma US, Inc. Bayer Healthcare Pharmaceuticals, Siemens Medical Solutions
Berman	Daniel	Imaging With Cardiac CT: The Case for Calcium	Hormone Replacement Therapy is Associated With Less Coronary Atherosclerosis and Lower Mortality	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical Center -software royalties, Molecular Dynamics; RESEARCH/RESEARCH GRANTS - Astellas Pharma US, Inc., Bayer Healthcare Pharmaceuticals, Siemens Medical Solutions
Berman	Daniel	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Cedars Sinai Medical Center-software royalties, Molecular Dynamics; RESEARCH/IRESEARCH GRANTS - Astellas Pharma US, Inc., Bayer Healthcare Pharmaceuticals, Siemens Medical Solutions
Berman	Darren	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Safety and Feasibility of Melody Transcatheter Pulmonary Valve Replacement in the Native Right Ventricular Outflow Tract: A Multicenter Study	Nothing to Disclose
Bermejo	Javier	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Echocardiographic Predictors for In-Hospital and 1-Year Outcomes in Left-Sided Infective Endocarditis: An Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort Study	Nothing to Disclose
Bermudez	Christian	Cardiogenic Shock: Drugs to Devices	Co-Chair	Nothing to Disclose
Bermudez	Edmund	33. Prevention: Hypertension Team 2	Suggested Reviewer	Nothing to Disclose
Bernard	Michael	Nuclear Cardiology: Coronary Flow	Reduced Flow Capacity as Measured by Cardiac Positron Emission Tomography Predicts Ventricular Tachyarrhythmia in Patients With an ICD	Nothing to Disclose
Berndsen	Nicole	Congenital Heart Disease: Advances in Quality Improvement for Pediatric Cardiac Care	Making Perioperative Handoff Communication Count by Improving Safety and Quality in a New Congenital Heart Program	Nothing to Disclose
Bernick	Jordan	Novel Developments in Acute Coronary Syndromes	Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Berry	Colin	Featured Clinical Research I	MR-INFORM: Stress Perfusion Imaging to Guide the Management of Patients With Stable Coronary Artery Disease	RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals,Novartis Corporation,St Jude Medical
Berry	Colin	Great Debates in Cardiac MRI	Debate Con: T1 and T2 Mapping: Ready for Widespread Utilization?	RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals,Novartis Corporation,St Jude Medical
Berry	Colin	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Prognostic Significance of Co-Existing Persistent Edema and Hemorrhage at 6 Months in Survivors of ST-Elevation Myocardial Infarction	RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals,Novartis Corporation,St Jude Medical
Berry	Colin	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Decision Making Using Fractional Flow Reserve Is Associated With Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With Nstemi	RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals,Novartis Corporation,St Jude Medical
Berry	Colin	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Segmental Circumferential Strain Derived From DENSE Predicts Improvement of Left Ventricular Function Post ST Elevation Myocardial Infarction: The BHF MR-MI Study	RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals,Novartis Corporation,St Jude Medical
Berry	Colin	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Intravascular Ultrasound Assessment of the Effects of Rotational Atherectomy in Calcified Coronary Artery Lesions	RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals,Novartis Corporation,St Jude Medical
Berry	Colin	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Current Smoking, Microvascular Pathology and Adverse Outcome After Acute ST-Segment Elevation Myocardial Infarction: New	RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals, Novartis Corporation, St Jude Medical
Веггу	Colin	Syndrome Acute Coronary Syndromes, Diagnosis,	Pathophysiological Insights Incidence and Prognostic Implications of the Presence of Multiple	RESEARCH/RESEARCH GRANTS - AstraZeneca
Dame	Calia	Management and Outcomes Non Invasive Imaging: MR Structure and	Complex Plaques in Survivors of ST-Elevation Myocardial Infarction Hypertension, Microvascular Pathology and Prognosis in Patients	Pharmaceuticals,Novartis Corporation,St Jude Medical RESEARCH/RESEARCH GRANTS - AstraZeneca
Berry	Colin	Valuvular Heart Disease	With an Acute ST-Segment Elevation Myocardial Infarction	Pharmaceuticals, Novartis Corporation, St Jude Medical
Berry	Jarett	Updates on Risk Factors for Cardiovascular Disease	Association of Objectively Measured Sedentary Time, Physical Activity and Cardiorespiratory Fitness Levels with Cardiometabolic Risk Factors and Cardiac Structure and Function: Findings From the Dallas Heart Study	CONSULTANT FEES/HONORARIA - Nihon; SPEAKER'S BUREAU - Merck
Berry	Jarett	Acute Coronary Syndromes, Diagnosis,	Burden of 30-Day Readmissions in Acute Myocardial Infarction and Heart Failure in the United States: A National Perspective	CONSULTANT FEES/HONORARIA - Nihon; SPEAKER'S
Berry	Jarett	Management and Outcomes 32. Prevention: Clinical Team 1	Heart Failure in the United States: A National Perspective Suggested Reviewer	BUREAU - Merck CONSULTANT FEES/HONORARIA - Nihon; SPEAKER'S BUREAU - Merck
Bersohn	Malcolm	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Myocardial Fragility in Ehlers Danlos Syndrome	BOREAU - Meltok DATA SAFETY MONITORING BOARD - Novartis; RESEARCH/RESEARCH GRANTS - Actelion, Biotronik, gilead, MEDTRONIC, Pfizer, St. Jude Medical, United Therapeutics
Berti	Sergio	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Previous Major Gastrointestinal Bleeding: Insight From the Amplatzer Cardiac Plug Multicenter Registry	Medical, United Therapeutics CONSULTANT FEES/HONORARIA - St. Jude Medical - Edwards Lifesciences
Bertog	Stefan	Interventional Cardiology: PCI and TAVR in Complex Patients	Calcification in the Basal Septum, but Not Membranous Septal Length, Predicts AV Conduction Disturbance and Pacemaker Implantation Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve (S3)	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cardiorenal LLC
Bertolami	Adriana	Advances in Cholesterol Measurement and Management	Effect of Nutraceuticals Combined With Statins on LDL Cholesterol Depends on the Sterol Synthesizer/Absorber Profile of the Patients	Nothing to Disclose
Bertolet	Barry	Refining PCI Technique and Outcomes	Three-Year Results From the EVOLVE II Randomized Trial: Late Clinical Outcomes With Bioresorbable Compared to Permanent Polymer Everolimus-Eluting	Nothing to Disclose
Bertoni	Alain	Making Progress in Understanding Heart Failure	Impact of Malignant Left Ventricular Function on Incident Heart Failure With Reduced Versus Preserved Ejection Fraction: The MESA Study	Nothing to Disclose
L	l	<u> </u>	INIESA SUUUY	

Last Name Bertoni	First Name Alain	Session Title Making Progress in Understanding Heart	Presentation Title Impact of Malignant Left Ventricular Function on Incident Heart	Disclosures Nothing to Disclose
		Failure	Failure in Older Adults: The MESA Study	
Bertoni	Alain	Innovations in Cardiovascular Risk Assessment and Reduction	Impact of Malignant Left Ventricular Hypertrophy on Incident Asymptomatic Left Ventricular Dysfunction: The MESA Study	Nothing to Disclose
Bertrand	Olivier	Complex PCI in 2017	Developments in Lesion Assessment: FFR (Opsens, Assist); IVUS Optimization	CONSULTANT FEES/HONORARIA - Opsens
Bertrand	Olivier	Peripheral Arterial Disease, Risk, and Outcomes	Transradial Versus Transpedal Access Approach for Endovascular Intervention of Superficial Femoral Artery Chronic Total Occlusion	CONSULTANT FEES/HONORARIA - Opsens
Berul	Charles	Atrial Fibrillation in Young and Unusual Populations: Children and Adult Congenital	Co-Chair	Nothing to Disclose
Berul	Charles	Heart Disease 11. Congenital Heart Disease: Therapy Team	Suggested Reviewer	Nothing to Disclose
		1		
Bessac	Laurence	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Lower On-Treatment Low-Density Lipoprotein Cholesterol Is Associated With Lower Cardiovascular Risk in Very High Risk Patients With Atherosclerotic Cardiovascular Disease: Analyses From the ODYSSEY Trials	SALARY - SANOFI
Bessac	Laurence	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Lower On-Treatment Low-Density Lipoprotein Cholesterol Is Associated With Lower Cardiovascular Risk in Women: Analyses From the ODYSSEY Trials of Alirocumab Versus Control	SALARY - SANOFI
Best	Patricia	PCI Strategies and Outcomes Unique to	Postpartum and Pregnancy-Associated Spontaneous Coronary	Nothing to Disclose
Betancur	Julian	Women Nuclear Cardiology: Quality	Artery Dissection: Presentation, Clinical Features and Outcomes Rest Scan Does Not Improve Automatic Machine Learning Prediction of Major Adverse Coronary Events After High Speed	Nothing to Disclose
Betancur	Julian	Nuclear Cardiology: Coronary Flow	Myocardial Perfusion Imaging Patient Motion Significantly Affects Measurements of Quantitative Global Regional Myocardial Blood Flow Assessment by Dynamic	Nothing to Disclose
Beton	Osman	Arrhythmias and Clinical EP: Anticoagulation	Pet Local Tranexamic Acid for Prevention of Bleeding Complications	OTHER - none
		Issues	During Cardiac Device Implantation of Patients on Chronic Direct Oral Anticoagulants	
Bettega	Marcelo	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Statin-Induced Hepatitis in a Secondary Prevention Patient With Severe Hypercholesterolemia	Nothing to Disclose
Bettencourt De Sousa	Nuno	Featured Clinical Research I	MR-INFORM: Stress Perfusion Imaging to Guide the Management of Patients With Stable Coronary Artery Disease	Nothing to Disclose
Bettinger	Nicolas	Interventional Cardiology: TAVR 4	Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital	Nothing to Disclose
Beutner	Katherine	Interdisciplinary Cardiovascular Care in	Interdisciplinary Peripartum Care of the Patient With Diastolic Heart	Nothing to Disclose
Bezerra	Hiram	Complex Scenarios Contemporary Role of Intracoronary Imaging:	Failure in Non-Obstructive Hypertrophic Cardiomyopathy Case Presentation: Incomplete Stent Apposition versus Inadequate	Nothing to Disclose
Bhakta	Deepak	Candid Conversation with Peers Innovations in Education	Stent Expansion Update on the ABIM's Competency Based Pilot in Internal Medicine-	Nothing to Disclose
			Cardiology	
Bhairaam	U Anil	Making Progress in Understanding Heart Failure Vascular Medicine: Emerging Concepts in	Prognostic Role of Neutrophil to Lymphocyte Ratio in Predicting Outcomes in Patients With Chronic Heart Failure Influence of Family History of Aortic Disease on Type B Aortic	Nothing to Disclose
Bhan		Clinical Vascular Diseases	Dissection	Nothing to Disclose
Bhan	Anil	Vascular Medicine: Aortic and Peripheral Artery Diseases	Acute Aortic Dissection in Patients Without a History of Hypertension	Nothing to Disclose
Bhardwaj	Aishwarya	Non Invasive Imaging: Prognostic Implications of CT Angiography	HEART Score Does Not Predict the Severity of Anatomical Coronary Artery Disease in Patients Presenting to the Emergency Department With Chest Pain	Nothing to Disclose
Bhardwaj	Bhaskar	Highlighted Original Research: Interventional	New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve	Nothing to Disclose
Bhardwaj	Bhaskar	Cardiology and the Year in Review Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Replacement: Incidence, Anticoagulant Strategy, and Outcomes Outcomes of Concomitant Acute Kidney Injury and Hospital Acquired Anemia in Patients With Myocardial Infarction: The	Nothing to Disclose
Bhargava	Balram	Syndrome Insights Into Ischemic Heart Disease: Stable to Erosive Plaques	TRIUMPH Study Immuno-Histopathology of Intracoronary Thrombus Aspirated During Primary Percutaneous Intervention for ST Elevation Myocardial Infarction and Its Clinical Significance	Nothing to Disclose
Bhargava	Mandeep	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	Nothing to Disclose
Bharmi	Rupinder	2 Featured Clinical Research III	Reduction in Heart Failure Hospitalizations With Ambulatory Hemodynamic Monitoring Seen in Clinical Trials Is Maintained in the	SALARY - Employee
Bhat	Ashwini	Contemporary Issues in Familial	'Real World' Familial Hypercholesterolemia: Awareness, Detection and Control in	Nothing to Disclose
		Hypercholesterolemia	the Community	-
Bhat	Geetha	13. Heart Failure and Cardiomyopathies: Clinical Team 7	Suggested Reviewer	Nothing to Disclose
Bhatheja	Samit	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Atherosclerotic Plaque Morphology in Response to High Intensity Lipid Lowering Therapy by Multimodality Imaging Among Women and Men: A YELLOW-II Sub-study	Nothing to Disclose
Bhatia	Nirmanmoh	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Temporal Trends and Outcomes of Emergent Coronary Artery Bypass Graft Surgery for ST-Segement Elevation Myocardial Infarction	Nothing to Disclose
Bhatia	Nirmanmoh	Interventional Cardiology: TAVR 2	Comparison of In-Hospital Outcomes of Transcatheter Aortic Valve Replacement in Men and Women	Nothing to Disclose
Bhatia	Nirmanmoh	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Atrial Fibrillation on Outcomes in Patients Hospitalized With ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Bhatia	Nirmanmoh	Antithrombotic Therapy in Ischemic Heart Disease	Role of Anticoagulation Therapy After Anterior Wall ST-Elevation Myocardial Infraction in Preventing LV Thrombus: A Meta-Analysis and Meta-Regression	Nothing to Disclose
Bhatia	Nirmanmoh	Advances in Chronic Total Occlusion Intervention	Trends and In-Hospital Outcomes of Patients Admitted With ST Elevation Myocardial Infarction and Chronic Total Occlusions: Insights From a National Database	Nothing to Disclose
Bhatia	Nirmanmoh	FIT Clinical Decision Making: Acute Coronary	Takayasu Arteritis Presenting as Syncope and "Pseudo-	Nothing to Disclose
Bhatia	Subir	Syndrome and Vascular Medicine Arrhythmias and Clinical EP: Basic 1	Hypotension" in a Young Caucasian Woman Atrial Fibrillation in Patients With Non-STEMI: Insights From a	Nothing to Disclose
	Subir	Innovative Approaches for Reducing Risk and	National Database Atrial Fibrillation Is Associated With Worse Outcomes in Patients	ů .
Bhatia		Improving Outcomes With Ablation	With Cirrhosis	Nothing to Disclose
Bhatia	Subir	Timely Topics in Acute Coronary Syndromes	Percutaneous Coronary Intervention Is Associated With Decreased Mortality in NSTEMI Patients With Advanced CKD	Nothing to Disclose
Bhatia	Subir	CAD in Unique Patient Populations	Trends in Prevalence and In-Hospital Mortality of NSTEMI Patients With Solid Tumor Cancer: The Nationwide Analysis From 1998-2013	Nothing to Disclose
Bhatla	Puneet	Precision Medicine: It's Hot, But What Is It?	Panelist	Nothing to Disclose
Bhatla	Puneet	Precision Medicine: It's Hot, But What Is It?	Can Finite Element Modelling Impact Transcatheter Interventions?	Nothing to Disclose



and the second				<u> </u>
Last Name Bhatnagar	First Name Udit	Session Title Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Presentation Title Comparison of Procedural Efficacy of Coronary Angiography in Octogenarian, Nonagenarian and General Population	Disclosures Nothing to Disclose
Bhatnagar	Udit	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	A Case of Bilateral External Iliac Obstruction in Pediatric Male Patient Managed With Angioplasty With a Drug Eluting Balloon	Nothing to Disclose
Bhatt	Ami	Disease, and Vascular Medicine Healthcare Innovation for Your Practice: Focus on Personalized Digital Health	Co-Chair	Nothing to Disclose
Bhatt	Ami	Healthcare Innovation for Your Practice: Focus	ACC-Talk: Connected Again	Nothing to Disclose
Bhatt	Ami	on Personalized Digital Health Update in ACHD: The Time for Change is Now	Panelist	Nothing to Disclose
Bhatt	Ami	Patient-Centered Care in Adult Congenital	Panelist	Nothing to Disclose
Bhatt	Ami	Heart Disease Patient-Centered Care in Adult Congenital	Debate: The End of the Ultimate Fighter: Palliative Care in Adult	Nothing to Disclose
Bhatt	Ami	Heart Disease Engage @ ACC.17 Studio:The Newlywed	Congenital Heart Disease (Pro) Co-Chair	Nothing to Disclose
3hatt	Ami	Game for Pediatric Cardiac Providers 09. Congenital Heart Disease: Adult Team 1	Suggested Reviewer	Nothing to Disclose
Shatt	Ankeet	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Alternating Bundle Branch Block: Clinical Considerations	Nothing to Disclose
Shatt	Ankeet	Why Can't We Be Friends? Controversies in Heart Failure Management	Prevalent Digoxin Use Is Not Associated With Increased Risk of Death or Hospitalization in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction	Nothing to Disclose
Bhatt	Deepak	Cardiovascular Update for the Clinician I: Coronary Artery Disease – Challenges in 2017 (A Symposium by Dr. Valentin Fuster)	STEMI 2 - Complete Versus Culprit Lesion Only Primary PCI is FFR of Non-culprit Lesions Part of the Deal?	Cardiology, CTHER - Belvoir Publications, Cardax Clinical Cardiology, Elsevier, HMP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & Bamp, amp; Co., Inc., Regado Biosciences, Slack Publications/Cardiology Resear Foundation, WebMD; RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers Squibb, Eisai, Ethicon, FlowCo, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer Inc, PLx
Bhatt	Deepak	Joint American College of Cardiology/Journal	Panelist	Pharma,Roche,Sanofi Aventis,Takeda,The Medicines Company CONSULTANT FEES/HONORARIA - Elsevier Practice Update
	Sooper	of the American Medical Association Late- Breaking Clinical Trials		Cardiology; OTHER - Belvoir Publications, Cardax, Clinical Cardiology, Elsevier, HMP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & Ampp.amp; Co., Inc., Regado Biosciences, Slack Publications/Cardiology Resear Foundation, WebMD; RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Satra Zeneca, Bristol Myers Squibb, Eisai, Ethicon, FlowCo, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer Inc, PLx Pharma, Roche, Sanofi Aventis, Takeda, The Medicines Company
Bhatt	Deepak	Issues in the Treatment of Coronary Disease: Joint Symposium of the American Heart Association and the American College of Cardiology	Panelist	CONSULTANT FEES/HONORARIA - Elsevier Practice Update Cardiology, OTHER - Belvoir Publications, Cardax Clinical Cardiology, Elsevier, HMP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & Descriptions, Cardiology, Resear Foundation, WebMD; RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers Squibb, Eisai, Ethicon, FlowCo, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer Inc, PLx Pharma, Roche, Sandfi Aventis, Takeda, The Medicines Compan
Bhatt	Deepak	Issues in the Treatment of Coronary Disease:	When to Stent, Bypass or Leave Alone	CONSULTANT FEES/HONORARIA - Elsevier Practice Update
		Joint Symposium of the American Heart Association and the American College of Cardiology		Cardiology, CTHER - Belvoir Publications, Cardax, Clinical Cardiology, Elsevier, HMP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & Amp, amp; Co., Inc., Regado Biosciences, Slack Publications/Cardiology Resear Foundation, WebMD; RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers Squibb, Eisai, Ethicon, FlowCo, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer Inc, PLx Pharma, Roche, Sanofi Aventis, Takeda, The Medicines Compan
Bhatt	Deepak	Mechanical Support, Hemodynamic Support for Shock in High Risk Subsets; Hemodynamic Compromise	Co-Chair	CONSULTANT FEES/HONORARIA - Elsevier Practice Update Cardiology, OTHER - Belvoir Publications, Cardax, Clinical Cardiology, Elsevier, HMP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & Johnson, Co., Inc., Regado Biosciences, Salack Publications/Cardiology Resear Foundation, WebMD; RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers Squibb, Eisai, Ethicon, FlowCo, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer Inc, PLx Pharma, Roche, Sandfi Aventis, Takeda, The Medicines Compan
Bhatt	Deepak	The Evolution of Angioplasty – 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	The Evolution of ACS/STEMI Care and Adjunct Pharmacotherapy	CONSULTANT FEES/HONORARIA - Elsevier Practice Update Cardiology, CTHER - Belvoir Publications, Cardax Clinical Cardiology, Elsevier, HMP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & Descriptions, Cardiology, Medscape Cardiology, Merck & Descriptions, Cardiology, Reseal Foundation, WebMD; RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers Squibb, Elsaic, Elbricon, FlowCo, Forest Laboratories, Ischemis, MEDTRONIC, Pfizer Inc, PLx Pharma, Roche, Sandi Aventis, Takeda, The Medicines Compan
Bhatt	Deepak	What's New in the World of STEMI?	Co-Chair	Pharma, Roche, Sanoin Aventis, Jakeda, I ne Medicines Computal CONSULTANT FEES/HONORARIA - Elsewier Practice Update Cardiology, CTHER - Belvoir Publications, Cardax, Clinical Cardiology, Elsewier, HMP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & Bamp; Co., Inc., Regado Biosciences, Slack Publications/Cardiology Resear Foundation, WebMD; RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Satra Zeneca, Bristol Myers Squibb, Eisai, Ethicon, FlowCo, Forest Laboratories, Ischemis, MEDTRONIC, Pfizer Inc, PLx Pharma, Roche, Sanofi Aventis, Takeda, The Medicines Compan
Bhatt	Deepak	Highlighted Original Research: Prevention and the Year in Review	Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial	CONSULTANT FEES/HONORARIA - Elsevier Practice Update Cardiology, CTHER - Belvoir Publications, Cardax, Clinical Cardiology, Elsevier, HMP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & Bamp, amp; Co., Inc., Regado Biosciences, Slack Publications/Cardiology Resear Foundation, WebMD; RESPARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers Squibb, Eisai, Ethicon, FlowCo, Forest Laboratories, Ischemix, MeDTRONIC, Pfizer Inc, PLx Pharma, Roche, Sanofi Aventis, Takeda, The Medicines Compan



The state of the s					
Last Name Bhatt	First Name Deepak	Session Title Young Investigator Awards Competition: Outcomes Research	Presentation Title A Hospital Level Analysis of 30-Day Readmission Rates for Heart Failure Patients and Long-Term Survival Among Highest and Lowest Performing Hospitals, Findings From Get With the Guidelines-Heart Failure	Disclosures CONSULTANT FEES/HONORARIA - Elsevi CARIOLOGY, OTHER - Belvoir Publications, Ca Cardiology, Elsevier, HMP communications, Jo Cardiology, Medscape Cardiology, Merck &ar Inc., Regado Biosciences, Slack Publications/f	rdax,Clinical urnal of Invasive ip;amp; Co., Cardiology Research
Divis				Foundation, WebMD; RESEARCH/RESEARC Amarin, Amgen Inc., Astra Zeneca, Bristol Mye Squibb, Eisai, Ethicon, FlowCo, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer In Pharma, Roche, Sanofi Aventis, Takeda, The M	rs c,PLx ledicines Company
Bhatt	Deepak	Interventional Cardiology: TAVR 1	Impact of Flow, Gradient, and Left Ventricular Function on Outcomes After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Elsew Cardiology, CTHER - Belvoir Publications, Ca Cardiology, Medscape Cardiology, Merck &am Inc., Regado Biosciences, Slack Publications/ Foundation, WebMD; RESEARCH/RESEARC Amarin, Amgen Inc., Satra Zeneca, Bristol Mye Squibb, Eisal, Ethicon, FlowCo, Forest Laboratories, Ischemis, MEDTRONIC, Pfizer In Pharma, Roche, Sanofi Aventis, Takeda, The Means Pharma, Roche, Sanofi Aventis, Takeda, The Means Amarin, American Satra Pharma, Roche, Sanofi Aventis, Takeda, The Means American Satra Pharma, Roche, Sanofi Aventis, Takeda, The Means American Satra Pharma, Roche, Sanofi Aventis, Takeda, The Means American Satra Pharma, Roche, Sanofi Aventis, Takeda, The Means American Satra Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Sanofi Aventis, Takeda, The Means American Pharma, Roche, Pharma, Roche, Pharma, Roche, Pharma, Roche, Pharma, Pharma, Pharma, Pharma, Pharma, Pharma, Pharma, Pharma, Pharma, Pharma, Pharma, Pharma, Pharma, Pharma, Pharma, Pharma, Pharma, Phar	rdax,Clinical urnal of Invasive p;amp; Co., Cardiology Research H GRANTS - rs c,PLx ledicines Company
Bhatt	Deepak	Making Progress in Understanding Heart Failure	Orthopnea or Paroxysmal Nocturnal Dyspnea in Older Adults Without Prevalent Heart Failure Is a Precitor, but Not an Independent Risk Factor for Incident Heart Failure: Insights From the Cardiovascular Health Study	CONSULTANT FEES/HONORARIA - Elsewi Cardiology, OTHER - Belvoir Publications, Ca Cardiology, Medscape Cardiology, Merck &am Inc., Regado Biosciences, Slack Publications/ Foundation, WebMD; RESEARCH/RESEARC Amarin, Ampan Inc., Satra Zeneca, Bristol Mye Squibb, Eisal, Ethicon, FlowCo, Forest Laboratories, Ischemis, MEDTRONIC, Pfizer In Pharma, Roche, Sanofi Aventis, Takeda, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, The Merch, Sanofi Aventis, Sanofi Aventis, Sanofi Aventis,	rdax,Clinical urnal of Invasive p;amp; Co., Cardiology Research :H GRANTS - rs c,PLx
Bhatt	Deepak	Innovations in Practice Management and Social Media	Impact of Electronic Health Records on the Quality of Outpatient Cardiovascular Care Delivery in India: Insights From the American College of Cardiology's PINNACLE India Quality Improvement Program (PIQIP)	CONSULTANT FEES/HONORARIA - Elsew Cardiology, CTHER - Belvoir Publications, Ca Cardiology, Medscape Cardiology, Merck &am Inc., Regado Biosciences, Slack Publications/C Foundation, WebMD; RESEARCH/RESEARC Amarin, Amgen Inc., Astra Zeneca, Bristol Mye Squibb, Eisal, Ethicon, FlowCo, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer In Pharma, Roche, Sanofi Aventis, Takeda, The Medica, The Medica, The Medica, The Medica, Programmers, Cardiology, Control Pharma, Roche, Sanofi Aventis, Takeda, The Medica, Programs, P	rdax,Clinical urnal of Invasive p;amp; Co., Cardiology Research GRANTS - rs
Bhatt	Deepak	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Lipid Abnormalities in Young Patients With Myocardial Infarction	CONSULTANT FEES/HONORARIA - Elsevi Cardiology, OTHER - Belvoir Publications, Zo Cardiology, Medscape Cardiology, Merck &an Inc., Regado Biosciences, Slack Publications/ Foundation, WebMD; RESEARCH/RESEARC Amarin, Amgen Inc., Astra Zeneca, Bristol Mye Squibb, Eisal, Ethicon, FlowCo, Forest Laboratories, Ischemix, MEDTROMIC, Pfizer In Pharma, Roche, Sanofi Aventis, Takeda, The Medica, The Medical, The Medical, The Medical Cardiology, Control of Cardiology, Control of Cardiology, Control of Cardiology, Cardiolo	rdax,Clinical urnal of Invasive p;amp; Co., cardiology Research :H GRANTS - rs c,PLx
Bhatt	Deepak	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Women Who Experience Myocardial Infarction at a Young Age Have Worse Survival Compared With Men	CONSULTANT FEES/HONORARIA - Elsevi Cardiology, OTHER - Belvoir Publications, Cardiology, Elsevier, HMP communications, Jo Cardiology, Medscape Cardiology, Merck &am Inc., Regado Biosciences, Slack Publications/ Foundation, WebMD; RESEARCH/RESEARC Amarin, Amgen Inc., Astra Zeneca, Bristol Mye Squibb, Eisal, Ethicon, FlowCo, Forest Laboratories, Ischemix, MEDTROMIC, Pfizer In Pharma, Roche, Sanofi Aventis, Takeda, The Medican, The Medica	rdax,Clinical urnal of Invasive p;amp; Co., Cardiology Research GRANTS - rs
Bhatt	Deepak	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Thirty-Day Readmission Rate and Cost After Percutaneous Coronary Intervention in the United States: A National Readmission Database Analysis	CONSULTANT FEES/HONORARIA - Elsevi Cardiology, OTHER - Belvoir Publications, Cardiology, Elsevier, HMP communications, Jo Cardiology, Medscape Cardiology, Medscape Cardiology, Merck &am Inc., Regado Biosciences, Slack Publications/(Foundation, WebMD; RESEARCH/RESEARC, Amarin, Ampan Inc., Satra Zeneca, Bristol Mye Squibb, Eisai, Ethicon, FlowCo, Forest Laboratories, Ischemis, MEDTRONIC, Pfizer In Pharma, Roche, Sanofi Aventis, Takeda, The M.	rdax,Clinical urnal of Invasive p;amp; Co., Zardiology Research H GRANTS - rs c,PLx ledicines Company
Bhatt	Deepak	Revascularization and Outcomes	Impact of Periprocedural Myocardial Infarction in Contemporary PCI: Pooled Patient-Level Data From the CHAMPION Trials	CONSULTANT FEES:HONORARIA - Elsewi Cardiology, CTHER - Belvoir Publications, Ca Cardiology, Blesevier, HMP communications, Jo Cardiology, Medscape Cardiology, Merck &am Inc., Regado Biosciences, Slack Publications/ Foundation, WebMD; RESEARCH/RESEARC, Amarin, Ampen Inc., Satra Zeneca, Bristol Mye Squibb, Eisai, Ethicon, FlowCo, Forest Laboratories, Ischemis, MEDTRONIC, Pfizer In Pharma, Roche, Sanofi Aventis, Takeda, The M	rdax,Clinical urnal of Invasive ip;amp; Co., Cardiology Research H GRANTS - rs
Bhatt	Deepak	Interventional Cardiology: TAVR 2	Association of Chronic Renal Insufficiency With In-Hospital Outcomes of Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Elsew Cardiology, CTHER - Belvoir Publications, Ca Cardiology, Medscape Cardiology, Merck &am Inc., Regado Biosciences, Slack Publications/C Foundation, WebMD; RESEARCH/RESEARC Amarin, Amgen Inc., Astra Zeneca, Bristol Mye Squibb, Eisal, Ethicon, FlowCo, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer In Pharma, Roche, Sanofi Aventis, Takeda, The Medica, The Medica, The Medica, The Medica, Programmers, Cardiology, Control Pharma, Roche, Sanofi Aventis, Takeda, The Medica, Programs, P	rdax,Clinical urnal of Invasive p;amp; Co., Cardiology Research GRANTS - rs
Bhatt	Deepak	Advances in Lipid Management	Hydrophilic Versus Lipophilic Statins in Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials	CONSULTANT FEES/HONORARIA - Elsevi	er Practice Update rdax,Clinical urnal of Invasive p;amp; Co., Cardiology Research H GRANTS - rs

and the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Bhatt	Deepak	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Sex Differences in Revascularization and In-Hospital Outcomes of Non-ST-Segment Elevation Myocardial Infarction in the United States	CONSULTANT FEES/HONORARIA - Elsevier Practice Update Cardiology, OTHER - Belvoir Publications, Cardax, Clinical Cardiology, Elsevier, I-MIP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & amp; amp; Co., Inc., Regado Biosciences, Slack Publications/Cardiology Research Foundation, WebMD; RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers Squibb, Eisa, Ethicon, FlowCo, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer Inc., PLx Pharma, Roche, Sandf Aventis, Takeda, The Medicines Company
Bhatt	Deepak	Interventional Cardiology: TAVR 3	Regional Variations in In-Hospital Outcomes and Healthcare Resource Utilization in Patients Undergoing Transcatheter Aortic Valve Replacement in the United States	CONSULTANT FEES/HONORARIA - Elsewier Practice Update Cardiology, OTHER - Belvoir Publications, Cardax, Clinical Cardiology, Elsewier, I-MP Communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & amp; amp; Co., Inc., Regado Biosciences, Stack Publications/Cardiology Research Foundation, WebMD; RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers Squibb, Eisai, Elhicon, FlowCo, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer Inc., PLx Pharma, Roche, Sandf. Avents, Taked. The Medicines Company
Bhatt	Deepak	Interventional Cardiology: TAVR 3	Role of Hospital Volume in Identifying Low and High-performing Surgical Valve Centers in the United States	CONSULTANT FEES/HONORARIA - Elsevier Practice Update Cardiology, OTHER - Belvoir Publications, Cardax Clinical Cardiology, Elsevier, HMP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & amp, amp; Co., Inc., Regado Biosciences, Stack Publications/Cardiology Research Foundation, WebMD; RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers Squibb, Eisai, Ethicon, FlowCo, Forest Laboratories, Ischemix, MED/TRONIC, Pfizer Inc., PLx Pharma, Roche, Sanofi Aventis, Takeda, The Medicines Company
Bhatt	Deepak	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Association of Academic Year-End Changeover With Survival Rates After In-Hospital Cardiac Arrest: An Examination of the "July Effect"	CONSULTANT FEES/HONORARIA - Elsevier Practice Update Cardiology, OTHER - Belvoir Publications, Cardax, Clinical Cardiology, Elsevier, HMP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & amp, amp; Co., Inc., Regado Biosciences, Slack Publications/Cardiology Research Foundation, WebMD, RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers Squibb, Eisa, Ethicon, FlowCo, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer Inc., PLx Pharma, Roche, Sandf. Aventis, Takeda, The Medicines Company
Bhatt	Deepak	Optimizing the Care of ACS Patients	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin: Insights From CHAMPION PHOENIX	CONSULTANT FEES/HONORARIA - Elsevier Practice Update Cardiology, CTHER - Belvoir Publications, Cardax Clinical Cardiology, Besvier, HMP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & amp, amp; Co., Inc., Regado Biosciences, Slack Publications/Cardiology Research Foundation, WebMD; RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers Quibb, Eisa, Ethicon, FlowCo, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer Inc., PLx Pharma, Roche, Sandf Aventis, Takeda, The Medicines Company
Bhatt	Deepak	Optimizing the Care of ACS Patients	Weekend Versus Weekday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide Analysis	CONSULTANT FEES/HONORARIA - Elsevier Practice Update Cardiology, OTHER - Belvoir Publications, Cardax, Clinical Cardiology, Elsevier, HMP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & amp.amp. Co., Inc., Regado Biosciences, Slack Publications/Cardiology Research Foundation, WebMD; RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers Squibb, Eisal, Ethicon, FlowCo, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer Inc., PLx Pharma, Roche, Sandf. Avents, Takeda, The Medicines Company
Bhatt	Deepak	Heart Failure and Cardiomyopathies: Heart Failure is Just a Revolving Door	Heart Failure Hospitalization (HFH) Despite Digoxin Therapy Versus No HFH Despite Placebo in the Digitalis Investigation Group (DIG) Trial: Insights Into Risk Factors for HFH in HF and Reduced Ejection Fraction (HFrEF)	CONSULTANT FEES/HONORARIA - Elsevier Practice Update Cardiology, CTHER - Belvoir Publications, Cardax, Clinical Cardiology, Elsevier, HMP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & amp.amp; Co., Inc., Regado Biosciences, Slack Publications/Cardiology Research Foundation, WebMD; RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers Squibb, Eisa, Ethicon, FlowCo, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer Inc, PLx Pharma, Roche, Sandf Aventis, Takeda, The Medicines Company
Bhatt	Deepak	Unusual Presentations of ACS	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival	CONSULTANT FEES/HONORARIA - Elsevier Practice Update Cardiology, OTHER - Belvoir Publications, Cardax, Clinical Cardiology, Elsevier, I-MIP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & amp; amp; Co., Inc., Regado Biosciences, Slack Publications/Cardiology Research Foundation, WebMD; RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers Squibb, Eisai, Elhicon, FlowCo, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer Inc., PLx Pharma, Roche, Sandf. Avents, Takeda, The Medicines Company
Bhatt	Deepak	the Future	One-Year Mortality increased in Patients With Peri-Procedural Myocardial Infarction: Insights From the CHAMPION Trials	CONSULTANT FEES/HONORARIA - Elsewier Practice Update Cardiology, OTHER - Belvoir Publications, Cardax, Clinical Cardiology, Elsewier, HMP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & amp, amp; Co., Inc., Regado Biosciences, Stack Publications/Cardiology Research Foundation, WebMD; RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers Squibb, Eisai, Ethicon, FlowCo, Forest Laboratories, Ischemik, MED/TROMIC, Pfizer Inc., PLx Pharma, Roche, Sanofi Aventis, Takeda, The Medicines Company
Bhatt	Deepak	Post-CAD/Ml: Making Tough Predictions About the Future	Risk Stratification With the TIMI Risk Score for Secondary Prevention Among Patients With Diabetes and Elevated Cardiovascular Risk	CONSULTANT FEES/HONORARIA - Elsevier Practice Update Cardiology, GTHER. Belvoir Publications, Cardax, Clinical Cardiology, Elsevier, HMP communications, Journal of Invasive Cardiology, Medscape Cardiology, Merck & Despray, Co., Inc., Regado Biosciences, Slack Publications/Cardiology, Research Foundation, WebMD, RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers Squibb, Eisai, Ethicon, FlowCo, Forest Laboratories, Ischemis, MEDTRONIC, Pfizer Inc, PLx Pharma, Roche, Sanofi Aventis, Takeda, The Medicines Company

Last Name	First Name	Session Title	Presentation Title	Disclosures
Bhatt	Deepak	Innovation in Practice Management, Advocacy, and Education	Effect of an Online Continuing Medical Education and Clinician Coaching Quality Improvement Initiative on Antiplatelet Medication	CONSULTANT FEES/HONORARIA - Elsevier Practice Update Cardiology; OTHER - Belvoir Publications, Cardax, Clinical
			Adherence and Hospital Readmissions in Patients With Acute	Cardiology, Elsevier, HMP communications, Journal of Invasive
			Coronary Syndrome	Cardiology, Medscape Cardiology, Merck & Deprimental Control of Cardiology, Medscape Cardiology, Merck & Deprimental Cardiology, Medscape Cardiology, Medscape Cardiology, Medscape Cardiology, Medscape Cardiology, Medscape Cardiology, Medscape Cardiology, Medscape Cardiology, Merck & Deprimental Cardiology, Medscape Cardiology, Merck & Deprimental Cardiology, Medscape Cardiology, Merck & Deprimental Cardiology, Medscape Cardiology, Merck & Deprimental Cardiology, Medscape Cardiology, Merck & Deprimental Ca
				Foundation, WebMD; RESEARCH/RESEARCH GRANTS -
				Amarin,Amgen Inc.,Astra Zeneca,Bristol Myers
				Squibb, Eisai, Ethicon, Flow Co, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer Inc, PLx
				Pharma,Roche,Sanofi Aventis,Takeda,The Medicines Company
Bhatt	Deepak	Anti-Platelet Therapies: Always a Sticky Topic	Ischemic Events Occur Early in Patients Undergoing PCI and Are	CONSULTANT FEES/HONORARIA - Elsevier Practice Update
			Reduced With Cangrelor: Findings From CHAMPION PHOENIX	Cardiology; OTHER - Belvoir Publications, Cardax, Clinical Cardiology, Elsevier, HMP communications, Journal of Invasive
				Cardiology, Medscape Cardiology, Merck & Damp; amp; Co.,
				Inc.,Regado Biosciences,Slack Publications/Cardiology Research Foundation,WebMD; RESEARCH/RESEARCH GRANTS -
				Amarin, Amgen Inc., Astra Zeneca, Bristol Myers
				Squibb, Eisai, Ethicon, FlowCo, Forest Laboratories, Ischemix, MEDTRONIC, Pfizer Inc, PLx
				Pharma,Roche,Sanofi Aventis,Takeda,The Medicines Company
Bhatt	Deepak	15. Interventional Cardiology:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Elsevier Practice Update
		ACS/AMI/Hemodynamics and Pharmacology Team 1		Cardiology, OTHER - Belvoir Publications, Cardax, Clinical Cardiology, Elsevier, HMP communications, Journal of Invasive
		roam r		Cardiology, Medscape Cardiology, Merck & Damp; Co.,
				Inc.,Regado Biosciences,Slack Publications/Cardiology Research
				Foundation, WebMD; RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., Astra Zeneca, Bristol Myers
				Squibb, Eisai, Ethicon, Flow Co, Forest
				Laboratories, Ischemix, MEDTRONIC, Pfizer Inc, PLx Pharma, Roche, Sanofi Aventis, Takeda, The Medicines Company
Bhatt	Digant	Vascular Access and Hemostasis Issues	Mid Femoral Head Is Not the Ideal Fluroscopic Landmark for	Nothing to Disclose
Phott	Digent	EIT Clinical Decision Making: Interventional	Common Femoral Artery Puncture	Nothing to Displace
Bhatt	Digant	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	A Rare Case of Chronic Persistent Troponin Elevation	Nothing to Disclose
		Disease, and Vascular Medicine		
Bhatt	Parloop	Interventional Complexity and Complications	Evaluation of a New Radiation Protection Technology (Cardio- TRAP®) in Transradial Percutaneous Coronary Intervention	Nothing to Disclose
			Procedures	
Bhatt	Parva		Fulminant Myocarditis With Cardiogenic Shock From Eosinophilic Myocarditis: Successfully Treated With Immunosuppresive Therapy	Nothing to Disclose
		Pulmonary Hypertension	With Complete Recovery of Cardiac Function	
Bhatt	Shivani	Congenital Heart Disease: New Diagnostic	Right Ventricular Contractile Reserve Is Reduced in Children and	Nothing to Disclose
		Approaches in Congenital Heart Disease	Adolescents With Tetralogy of Fallot: A Stress Echocardiographic Study	
Bhattacharya	Priyanka	Emerging Developments in HFpEF and	Effect of Diabetes Mellitus on Pulsatile Arterial Load and	Nothing to Disclose
Phattachania	Drivanka	Arryhthmias Diabetes and Other Issues in Cardiovascular	Hemodynamics in HFpEF Predictive Risk Stratification Using HEART and Thrombolysis in	Nothing to Displace
Bhattacharya	Priyanka	Prevention	Myocardial Infarction Scores in Low Risk Chest Pain Patients: An	Nothing to Disclose
			Urban Community Based Hospital Study	
Bhattacharya	Sanjeeb	Pulmonary Hypertension	Hypopituitarism as a Cause of a Severe Cardiomyopathy	Nothing to Disclose
Bhattacharya	Sanjeeb	FIT Clinical Decision Making: Heart Failure and	Worsening Hypoxia After Therapy Initiation in Pulmonary Arterial	Nothing to Disclose
Bhatti	Sabha	Pulmonary Hypertension Imaging Pulmonary Vascular Disease Plus the	Hypertension Correlation Between Echocardiographic Pulmonary Artery Pressure	Nothing to Disclose
Dilatti	Sabila	Impact of Congenital Heart Disease	Estimates and Right Heart Catheterization Measurements in	Nothing to Disclose
			Patients Undergoing Liver Transplant Evaluation: A Single Center Study	
Bhatti	Sabha	FIT Clinical Decision Making: Valvular Heart	Clinical Decision Making: Acute Thrombosis of the Mechanical Mitral	Nothing to Disclose
		Disease and Pericardial Disease	Valve	-
Bhatty	Osman	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	In the Forest of Comorbidities, Always Look for the Wild Type	Nothing to Disclose
Bhave	Nicole	28. Non Invasive Imaging: Echo Team 1	Suggested Reviewer	Nothing to Disclose
Bhave	Prashant	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Gender Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Medicare Patients With Newly Diagnosed Arial Fibrillation:	Nothing to Disclose
		improving Outcomes with Abiation	A Propensity Matched Analysis	
Bhave	Prashant	Engage @ ACC.17 Studio: FIT Jeopardy Battle	Moderator	Nothing to Disclose
Bhavnani	Sanjeev	of the State Chapters I Healthcare Innovation for Your Practice: Focus	California Dreamin'the Promise of Big Data	Nothing to Disclose
		on Personalized Digital Health		-
Bhimaraj	Arvind	Featured Clinical Research III	Reduction in Heart Failure Hospitalizations With Ambulatory Hemodynamic Monitoring Seen in Clinical Trials Is Maintained in the	CONSULTANT FEES/HONORARIA - St.Jude Medical
			'Real World'	
Bhimaraj	Arvind	Acute Cardiogenic Shock: Progress, Paradigm,	How and When to Use a PA Catheter in Cardiogenic Shock	CONSULTANT FEES/HONORARIA - St.Jude Medical
Bhimaraj	Arvind	and Unresolved Problems FIT Clinical Decision Making: Heart Failure and	Cardiac Recovery Post Left Ventricular Assist Device in a Patient	CONSULTANT FEES/HONORARIA - St.Jude Medical
		Pulmonary Hypertension	With Orthotopic Liver Transplantation	
Bhinder	Jasjit	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Downstream Effects of False Positive Activation of the Cardiac Catheterization Lab	Nothing to Disclose
Bhinder	Jasjit	Technical Advances in Transthoracic Echocardiography	Safety of Perflutren-Based Echocardiographic Contrast Agent Administration in the Setting of a Patent Foramen Ovale (PFO); A	Nothing to Disclose
į.			Auminionation in the Setting of a Patent Foramen Ovale (PFO): A	İ
		Zonoda diography	Multicenter Study Conducted in Tertiary Care Centers Based in the	
			New York/Chicago Metropolitan Areas	
Bhirud	Ashwin	The Best Structural Interventional Challenging	New York/Chicago Metropolitan Areas Late Manifestation of Eisenmenger Physiology After Atrial Septal	Nothing to Disclose
Bhirud Bhirud	Ashwin Ashwin		New York/Chicago Metropolitan Areas Late Manifestation of Eisenmenger Physiology After Atrial Septal Defect Closure Trend and Outcomes of Infective Endocarditis Treated With Surgical	
		The Best Structural Interventional Challenging Cases	New York/Chicago Metropolitan Areas' Late Manifestation of Eisenmenger Physiology After Atrial Septal Defect Closure Trend and Outcomes of Infective Endocarditis Treated With Surgical Valvular Replacement Insight From the Nationwide Inpatient	ů .
		The Best Structural Interventional Challenging Cases	New York/Chicago Metropolitan Areas Late Manifestation of Eisenmenger Physiology After Atrial Septal Defect Closure Trend and Outcomes of Infective Endocarditis Treated With Surgical Valvular Replacement Insight From the Nationwide Inpatient Sample Increasing Healthcare Resource Utilization After Valve	ů .
Bhirud Bhirud	Ashwin Ashwin	The Best Structural Interventional Challenging Cases Valvular Heart Disease: Endocarditis Outcomes in Valvular Heart Disease	New York/Chicago Metropolitan Areas' Late Manifestation of Eisenmenger Physiology After Atrial Septal Defect Closure Trend and Outcomes of Infective Endocarditis Treated With Surgical Valvular Replacement Insight From the Nationwide Inpatient Sample Increasing Healthcare Resource Utilization After Valve Replacement Surgery in the United States	Nothing to Disclose Nothing to Disclose
Bhirud	Ashwin	The Best Structural Interventional Challenging Cases Valvular Heart Disease: Endocarditis	New York/Chicago Metropolitan Areas Late Manifestation of Eisenmenger Physiology After Atrial Septal Defect Closure Trend and Outcomes of Infective Endocarditis Treated With Surgical Valvular Replacement Insight From the Nationwide Inpatient Sample Increasing Healthcare Resource Utilization After Valve	Nothing to Disclose
Bhirud Bhirud	Ashwin Ashwin	The Best Structural Interventional Challenging Cases Valvular Heart Disease: Endocarditis Outcomes in Valvular Heart Disease	New York/Chicago Metropolitan Areas' Late Manifestation of Eisenmenger Physiology After Atrial Septal Defect Closure Trend and Outcomes of Infective Endocarditis Treated With Surgical Valvular Replacement Insight From the Nationwide Inpatient Sample Increasing Healthcare Resource Utilization After Valve Replacement Surgery in the United States Trends and Outcomes of Permanent Pacemaker Implantation After Mitral Valve Replacement: A 10 Year U.S. Analysis Trends and Outcomes of Aortic Valve Replacement in Patient With	Nothing to Disclose Nothing to Disclose
Bhirud Bhirud	Ashwin Ashwin Ashwin	The Best Structural Interventional Challenging Cases Valvular Heart Disease: Endocarditis Outcomes in Valvular Heart Disease Outcomes in Valvular Heart Disease	New York/Chicago Metropolitan Areas Late Manifestation of Eisenmenger Physiology After Atrial Septal Defect Closure Trend and Outcomes of Infective Endocarditis Treated With Surgical Valvular Replacement Insight From the Nationwide Inpatient Sample Increasing Healthcare Resource Utilization After Valve Replacement Surgery in the United States Trends and Outcomes of Permanent Pacemaker Implantation After Mitral Valve Replacement: A 10 Year U.S. Analysis Trends and Outcomes of Aortic Valve Replacement in Patient With End Stage Renal Disease on Hemodialysis: A 10-Year U.S.	Nothing to Disclose Nothing to Disclose Nothing to Disclose
Bhirud Bhirud	Ashwin Ashwin Ashwin	The Best Structural Interventional Challenging Cases Valvular Heart Disease: Endocarditis Outcomes in Valvular Heart Disease Outcomes in Valvular Heart Disease	New York/Chicago Metropolitan Areas Late Manifestation of Eisenmenger Physiology After Atrial Septal Defect Closure Trend and Outcomes of Infective Endocarditis Treated With Surgical Valvular Replacement Insight From the Nationwide Inpatient Sample Increasing Healthcare Resource Utilization After Valve Replacement Surgery in the United States Trends and Outcomes of Permanent Pacemaker Implantation After Mitral Valve Replacement. A 10 Year U.S. Analysis Trends and Outcomes of Aortic Valve Replacement in Patient With End Stage Renal Disease on Hemodialysis: A 10-Year U.S. Perspective Comparing Outcomes in COPD Patients Undergoing TAVR and	Nothing to Disclose Nothing to Disclose Nothing to Disclose
Bhirud Bhirud Bhirud Bhirud Bhirud	Ashwin Ashwin Ashwin Viraj	The Best Structural Interventional Challenging Cases Valvular Heart Disease: Endocarditis Outcomes in Valvular Heart Disease Outcomes in Valvular Heart Disease Valvular Heart Disease Vilvular Heart Disease With CKD or Cirrhosis Interventional Cardiology: TAVR 3	New York/Chicago Metropolitan Areas' Late Manifestation of Eisenmenger Physiology After Atrial Septal Defect Closure Trend and Outcomes of Infective Endocarditis Treated With Surgical Valvular Replacement Insight From the Nationwide Inpatient Sample Increasing Healthcare Resource Utilization After Valve Replacement Surgery in the United States Trends and Outcomes of Permanent Pacemaker Implantation After Mitral Valve Replacement. 4 10 Year U.S. Analysis Trends and Outcomes of Aortic Valve Replacement in Patient With End Stage Renal Disease on Hemodialysis: A 10-Year U.S. Perspective Companing Outcomes in COPD Patients Undergoing TAVR and SAVR: A Propensity Matched Analyses	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Bhirud Bhirud Bhirud	Ashwin Ashwin Ashwin Ashwin	The Best Structural Interventional Challenging Cases Valvular Heart Disease: Endocarditis Outcomes in Valvular Heart Disease Outcomes in Valvular Heart Disease Valvular Heart Disease With CKD or Cirrhosis Interventional Cardiology: TAVR 3 FIT Clinical Decision Making: Arrhythmias and	New York/Chicago Metropolitan Areas Late Manifestation of Eisenmenger Physiology After Atrial Septal Defect Closure Trend and Outcomes of Infective Endocarditis Treated With Surgical Valvular Replacement Insight From the Nationwide Inpatient Sample Increasing Healthcare Resource Utilization After Valve Replacement Surgery in the United States Trends and Outcomes of Permanent Pacemaker Implantation After Mitral Valve Replacement. A 10 Year U.S. Analysis Trends and Outcomes of Aortic Valve Replacement in Patient With End Stage Renal Disease on Hemodialysis: A 10-Year U.S. Perspective Comparing Outcomes in COPD Patients Undergoing TAVR and	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Bhirud Bhirud Bhirud Bhirud Bhirud	Ashwin Ashwin Ashwin Viraj	The Best Structural Interventional Challenging Cases Valvular Heart Disease: Endocarditis Outcomes in Valvular Heart Disease Outcomes in Valvular Heart Disease Valvular Heart Disease Valvular Heart Disease Interventional Cardiology: TAVR 3 FIT Clinical Decision Making: Arrhythmias and Electrophysiology FIT Clinical Decision Making: Interventional	New York/Chicago Metropolitan Areas' Late Manifestation of Eisenmenger Physiology After Atrial Septal Defect Closure Trend and Outcomes of Infective Endocarditis Treated With Surgical Valvular Replacement Insight From the Nationwide Inpatient Sample Increasing Healthcare Resource Utilization After Valve Replacement Surgery in the United States Trends and Outcomes of Permanent Pacemaker Implantation After Mitral Valve Replacement. 4 10 Year U.S. Analysis Trends and Outcomes of Aortic Valve Replacement in Patient With End Stage Renal Disease on Hemodialysis: A 10-Year U.S. Perspective Companing Outcomes in COPD Patients Undergoing TAVR and SAVR: A Propensity Matched Analyses	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Bhirud Bhirud Bhirud Bhirud Bhise Bhogal	Ashwin Ashwin Ashwin Viraj Sukhdeep	The Best Structural Interventional Challenging Cases Valvular Heart Disease: Endocarditis Outcomes in Valvular Heart Disease Outcomes in Valvular Heart Disease Valvular Heart Disease With CKD or Cirrhosis Interventional Cardiology: TAVR 3 FIT Clinical Decision Making: Arrhythmias and Electrophysiology FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	New York/Chicago Metropolitan Areas' Late Manifestation of Eisenmenger Physiology After Atrial Septal Defect Closure Trend and Outcomes of Infective Endocarditis Treated With Surgical Valvular Replacement Insight From the Nationwide Inpatient Sample Increasing Healthcare Resource Utilization After Valve Replacement Surgery in the United States Trends and Outcomes of Permanent Pacemaker Implantation After Mitral Valve Replacement. A 10 Year U.S. Analysis Trends and Outcomes of Aortic Valve Replacement in Patient With End Stage Renal Disease on Hemodialysis: A 10-Year U.S. Perspective Comparing Outcomes in COPD Patients Undergoing TAVR and SAVR: A Propensity Matched Analyses A Rare Cause of Syncope	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Bhirud Bhirud Bhirud Bhirud Bhise Bhogal	Ashwin Ashwin Ashwin Viraj Sukhdeep	The Best Structural Interventional Challenging Cases Valvular Heart Disease: Endocarditis Outcomes in Valvular Heart Disease Outcomes in Valvular Heart Disease Valvular Heart Disease Valvular Heart Disease Interventional Cardiology: TAVR 3 FIT Clinical Decision Making: Arrhythmias and Electrophysiology FIT Clinical Decision Making: Interventional	New York/Chicago Metropolitan Areas' Late Manifestation of Eisenmenger Physiology After Atrial Septal Defect Closure Trend and Outcomes of Infective Endocarditis Treated With Surgical Valvular Replacement Insight From the Nationwide Inpatient Sample Increasing Healthcare Resource Utilization After Valve Replacement Surgery in the United States Trends and Outcomes of Permanent Pacemaker Implantation After Mitral Valve Replacement. A 10 Year U.S. Analysis Trends and Outcomes of Aortic Valve Replacement in Patient With End Stage Renal Disease on Hemodialysis: A 10-Year U.S. Perspective Comparing Outcomes in COPD Patients Undergoing TAVR and SAVR: A Propensity Matched Analyses A Rare Cause of Syncope	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose

and the second				<u> </u>
Last Name	First Name	Session Title	Presentation Title Orthopnea or Paroxysmal Nocturnal Dyspnea in Older Adults	Disclosures
Bhyan	Poonam	Making Progress in Understanding Heart Failure	Without Prevalent Heart Failure Is a Predictor, but Not an Independent Risk Factor for Incident Heart Failure: Insights From the Cardiovascular Health Study	Nothing to Disclose
Bhyan	Poonam	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	ine Lardiovascular Health Study Among Older Heart Failure (HF) Patients With In-Hospital Acute Kidney Injury (AKI), an Improvement in Kidney Function Is Associated With a Higher Risk of Post-Discharge Mortality but Not Readmission	Nothing to Disclose
Bhyan	Poonam	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Heart Failure Hospitalization (HFH) Despite Digoxin Therapy Versus No HFH Despite Placebo in the Digitalis Investigation Group (DIG) Trial: Insights Into Risk Factors for HFH in HF and Reduced Ejection Fraction (HFrEF)	Nothing to Disclose
Bi	Xiaoming	Nuclear Cardiology: Coronary Flow	Precisely Controlled Arterial CO2 Can Potentiate Myocardial Blood Flow to the Same Extent as Adenosine: A Preclinical Study in Canines With 13N-Ammonia PET	SALARY - Full-time Employee of Siemens Healthcare
Bian	Jiang	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Risk Prediction for In-Hospital Mortality in Women With ST-Elevation Myocardial Infarction: A Machine Learning Approach	Nothing to Disclose
Biasucci	Luigi	Emerging Basic Science in Ischemic Heart Disease	Imbalance Between E-NOS and MRP4 Gene Expression in Type 2 Diabetes Mellitus May Explain the Higher Risk of NSTEMI in Diabetic Subjects	RESEARCH/RESEARCH GRANTS - Astra Zeneca,scgering- plough
Biasucci	Luigi	Insights Into Ischemic Heart Disease: Stable to	Hyaluronic Acid, Hyaluronidase-2 and Acute Coronary Syndromes:	RESEARCH/RESEARCH GRANTS - Astra Zeneca,scgering-
Biasucci	Luigi	Erosive Plaques Unusual Presentations of ACS	Possible Correlation With Plaque Erosion Matrix Metalloproteinase 9 Drives the Shedding of CD31 in Acute Coronary Syndromes	plough RESEARCH/RESEARCH GRANTS - Astra Zeneca,scgering- plough
Bickel	Trenton	Advanced Therapies = Advanced Trouble: VAD and Transplant Challenges	Independent Association of Symptomatic Peripheral Arterial Disease for Adverse Outcomes, Poor Graft Survival and Length of Hospital Stay Following Heart Transplantation: An Analysis of 22,820 Heart Transplants From the UNOS Database	Nothing to Disclose
Biddle Biederman	Martha	34. Prevention: Rehabilitation Team 1	Suggested Reviewer Cardiac Amyloidosis Masquerading as Severe Low-Flow, Low-	Nothing to Disclose CONSULTANT FEES/HONORARIA - Merck: OTHER - Osiris:
	Robert	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Gradient, Low-Ejection Fraction Aortic Stenosis: "All That Glitters Is Not Gold"	RESEARCH/RESEARCH GRANTS - Merck,NHLBI/NIH, AHA
Biederman	Robert	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	An Unprecedented Case of Primary Cardiac Lymphoma Exclusive to the Left Ventricle: A Diagnostic and Therapeutic Challenge	CONSULTANT FEES/HONORARIA - Merck; OTHER - Osiris; RESEARCH/RESEARCH GRANTS - Merck.NHLBI/NIH. AHA
Biederman	Robert	Non Invasive Imaging: MR Heart Failure and	Non-Invasive Quantification of Cardiac Output With Phase Velocity	CONSULTANT FEES/HONORARIA - Merck; OTHER - Osiris;
Biederman	Robert	Pulmonary Hypertension Advances in Pulmonary Arterial Hypertension	Mapping in Patients With Pulmonary Hypertension A Cross Comparison Study of Right Ventricular Hypertrophy With Electrocardiography and Cardiac Magnetic Resonance in Patients With Dulmonary Hypertension	RESEARCH/RESEARCH GRANTS - Merck, NHLBI/NIH, AHA CONSULTANT FEES/HONORARIA - Merck; OTHER - Osiris; RESEARCH/RESEARCH GRANTS - Merck, NHLBI/NIH, AHA
Biederman	Robert	Arrhythmias and Clinical EP: Basic 5	With Pulmonary Hypertension Pulmonary Vein Remodeling Following Pulmonary Vein Isolation in Patients With Atrial Fibrillation Are They an Epiphenomena a Predictive Cardiac MRI Study	CONSULTANT FEES/HONORARIA - Merck; OTHER - Osiris; RESEARCH/RESEARCH GRANTS - Merck,NHLBI/NIH, AHA
Biederman	Robert	Insights Into Ischemic Heart Disease: Stable to	Clinical Operating Points for Non-Invasive Cardiac Imaging	CONSULTANT FEES/HONORARIA - Merck; OTHER - Osiris;
Bier	Benjamin	Erosive Plaques Unusual Presentations of ACS	Modalities Lead to Low Detection of Coronary Artery Disease Survival of Patients Referred for Emergent Cardiac Catheterization for ST-Elevation Myocardial Infarction Without Culprit Lesions	RESEARCH/RESEARCH GRANTS - Merck,NHLBI/NIH, AHA Nothing to Disclose
Bier	Benjamin	Interdisciplinary Cardiovascular Care in Complex Scenarios	Thirteen Lives: Massive Pulmonary Embolism Causing Twelve Episodes of Cardiac Arrest Managed by an Interdisciplinary	Nothing to Disclose
Biering-Sorensen	Tor	Emerging Applications of Echocardiography	Pulmonary Embolism Consult Team Ratio of Transmittal Early Filling Velocity to Early Diastolic Strain Rate Predicts Long Term Risk of Cardiovascular Morbidity and Mortality in a Low Risk General Population	Nothing to Disclose
Biering-Sorensen	Tor	Innovative Use of Echocardiography	Usefulnes of Left Ventricular Speckle Tracking Echocardiography in Diagnosing Paroxysmal Atrial Fibrillation in Ischemic Stroke and Transient Ischemic Attack Patients	Nothing to Disclose
Biering-Sorensen	Tor	Innovative Use of Echocardiography	The Left Atrium Emptying Fraction as a Predictor of Cardiovascular Morbidity and Mortality in a Low Risk General Population	Nothing to Disclose
Biering-Sorensen	Tor	Innovative Use of Echocardiography	Presence of Post-Systolic Shortening by Tissue Doppler Imaging is an Independent Predictor of Heart Failure in Patients Following ST- Segment Elevation Myocardial Infarction	Nothing to Disclose
Biering-Sorensen	Tor	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Cardiac Myosin Activator, Omecamtiv Mecarbil, Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure (COSMIC-HF)	Nothing to Disclose
Biering-Sørensen	Tor	Making Progress in Understanding Heart Failure	NT-proBNP, Left Ventricular Structure and Function, and Long- Term Cardiovascular Events: Insights From a Prospective Population-Based Cohort Study	Nothing to Disclose
Biering-Sørensen	Tor	Insights From Echocardiography Use	Layer-Specific Strain Analysis by Two-Dimensional Speckle Tracking Echocardiography: Improvement of Coronary Artery Disease Diagnostics in Patients With Stable Angina Pectoris	Nothing to Disclose
Bierzynski	Adam	Congenital and Congenital Heart Disease	Giant Right Coronary Artery Aneurysm Associated With a Coronary Cameral Fistula to the Right Atrium	Nothing to Disclose
Biesbroek	Paul	Advances in Chronic Total Occlusion Intervention	Effects of Successful Percutaneous Coronary Intervention of Chronic Total Occlusions on Myocardial Perfusion and Left Ventricular Function	Nothing to Disclose
Biga	Cathleen	Public Reporting and NCDR: The Decision to Report Your Data Before the Feds Decide	From NCDR to Patient Experience, What do you Recommend to Report?	Nothing to Disclose
Biga	Cathleen	Mentoring the Care Team: FITs, Early Career Professionals and CV Team Members	Mentoring the Early Career Professional: Cardiovascular Team Member	Nothing to Disclose
Biggs	Eleanor	Arrhythmias and Clinical EP: Basic 1	NOACs Versus Warfarin Use in the Management of Atrial Fibrillation Patients	Nothing to Disclose
Bilchick	Kenneth	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Changes in Renal Perfusion Pressure During Hemodynamically Guided Therapy Is Associated With Worsening Renal Function	RESEARCH/RESEARCH GRANTS - American College of Cardiology
Bilchick	Kenneth	Advances in HCM, PPCM and Other	Systemic Arterial Pulsatility Index (SAPi) Predicts Adverse	RESEARCH/RESEARCH GRANTS - American College of
Bilchick	Kenneth	Cardiomyopathies Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Outcomes in Advanced Heart Failure Patients Impact of Cardiogenic Shock with or without Mechanical Circulatory Support on Short-Term and Long-Term Survival in Heart Failure Hospitalizations	Cardiology RESEARCH/RESEARCH GRANTS - American College of Cardiology
Bilchick	Kenneth	Advances in Pulmonary Arterial Hypertension	Hospitalizations Pulmonary-Systemic Pulse Pressure Ratio Is Associated With	RESEARCH/RESEARCH GRANTS - American College of
Bin Abdulhak	Aref	Non Invasive Imaging: Expanding Clinical Applications	Adverse Clinical Outcomes in Group 1 Pulmnonary Hypertension Diagnostic Accuracy of Coronary Computed Tomography Angiography in Aortic Stenosis Patients Referred for Aortic Valve	Cardiology Nothing to Disclose
Binongo	Jose	TAVR Outcomes Prognostication	Replacement: Systematic Review and Meta-Analysis Predictors and Clinical Outcomes of Next-Day Discharge After	Nothing to Disclose
_		_	Transcatheter Aortic Valve Replacement	
Biondi-Zoccai	Giuseppe	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Provisional Versus Elective Two-Stenting Strategy for Unprotected True Left Main Bifurcation Lesions: A Sub-Study From Fails 2 Study	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,Novartis Corporation,St. Jude Medical; OTHER - DirectFlow Medical
Birati	Edo	Give Me a Beat! Mechanical Support of Cardiogenic Shock	Short-term Mechanical Support Cardiogenic ShockSo Many Devices	CONSULTANT FEES/HONORARIA - Luitpold Pharmaceuticals, Inc.
· · · · · · · · · · · · · · · · · · ·		·	·	· · · · · · · · · · · · · · · · · · ·



First Name Edo	Session Title Imaging Pulmonary Vascular Disease Plus the	Presentation Title RVOT-VTI/PASP: A Novel Non-Invasive Metric of Pulmonary Arterial	Disclosures CONSULTANT FEES/HONORARIA - Luitpold Pharmaceuticals,
	Impact of Congenital Heart Disease	Compliance and Diastolic Pressure Gradient Status in Heart Failure	Inc.
Edo	The Old and the New: Impact of Heart Failure	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Luitpold Pharmaceuticals,
Jared	Drug Therapies FIT Clinical Decision Making: Arrhythmias and	Syncone in the Setting of Two Zehras	Inc. Nothing to Disclose
	Electrophysiology		-
Ulrika	06. Arrhythmias and Clinical EP: Other Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Biotronik, MEDTRONIC, St Jude Medical; RESEARCH/RESEARCH GRANTS - MEDTRONIC, St Jude Medical
Trevor	Redefining the "F" Word	Cardiopulmonary Exercise Testing for Surgical Risk Stratification in	Nothing to Disclose
Yochai	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Correlation of Right Atrial Enlargement on Ecg to Right Atrial Volume by Echocardiography in Patients With Pulmonary	RESEARCH/RESEARCH GRANTS - Astra Zenca; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals,DSI
Yochai	Diabetes and Endothelial Dysfucntion in Heart Failure	Dapagliflozin Attenuates Diabetic Cardiomyopathy and the Activation of the NLRP3/ASC Inflammasome in Mice With Type-2	RESEARCH/RESEARCH GRANTS - Astra Zenca; SPEAKER'S BUREAU - Astra Zenca Pharmaceuticals, DSI
Yochai	Emerging Basic Science in Ischemic Heart	DPP4 Inhibition by Linagliptin Prevents Cardiac Dysfunction and	RESEARCH/RESEARCH GRANTS - Astra Zenca; SPEAKER'S
Yochai			BUREAU - AstraZeneca Pharmaceuticals,DSI RESEARCH/RESEARCH GRANTS - Astra Zenca; SPEAKER'S
	Clinical Team 5		BUREAU - AstraZeneca Pharmaceuticals, DSI
NIII	Managing Cholesterol Even in the Most Resistant	Case Challenge wodel	CONSULTANT FEES/HONORARIA - Jones & Description (Consultant) Bartlett Learning; SALARY - University of Houston College of Pharmacy, Walgreens
Kim	Cardiovascular Team Cases: Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Jones & Digramp; Bartlett Learning; SALARY - University of Houston College of Pharmacy, Walgreens
Simone	Refining PCI Technique and Outcomes	Comparison of Verapamil Versus Heparin Therapy on Procedural Success During Transradial Coronary Procedures (Vermut Study)	Nothing to Disclose
Nanette	Advances in HCM, PPCM and Other	Extended Remission and Late Re-Decompensation of Dilated	CONSULTANT FEES/HONORARIA - Telomere Diagnostics,
	Cardiomyopathies	Cardiomyopathy Associated With a Novel Ribonucleic Acid Binding Motif Protein 20 (RBM20) Mutation	Inc.; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - C&C BioPharma, Ltd.
Abhishek	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of Electrocardiogram Changes on Mortality in Asymptomatic	Nothing to Disclose
Abbas	Arrhythmias and Clinical EP: Ventricular	Impact of Arrhythmia Duration and Index Left Ventricular Ejection	Nothing to Disclose
Fadi	-	Arrhythmia-Induced Cardiomyopathy	Nothing to Disclose
	Exomes to Databases	Cardiomyopathies: Novel Variants in Known Genes, and Potential Novel Genes	-
Cynthia	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Acute Decompensated Heart Failure: The Journey From Patients' Perspective	SPEAKER'S BUREAU - CHF Solutions
Marcio	Advances in Cholesterol Measurement and Management	Statin Eligibility in Primary Prevention: From a Risk-Based Strategy to a Personalized Approach Based on the Predicted Cardiovascular	Nothing to Disclose
Marcio	Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	Physical Activity Level Changes and the Occurrence of Non- Alcoholic Fatty-Liver Disease: A Prospective Longitudinal Follow Up	Nothing to Disclose
Marcio	Contemporary Issues in Familial Hypercholesterolemia	Achilles Tendon Xanthomas Are Independently Associated With Severity of Subclinical Coronary Atherosclerosis in Familial	Nothing to Disclose
Thomas	The Evolving World of LVADs, Transplant and	Sleep Duration and Quality in Heart Failure Patients	Nothing to Disclose
John	Other Novel Discoveries Controversies in ACS Guidelines	Panelist	Nothing to Disclose
John	Optimizing the Care of ACS Patients	Safety of Heparin Compared With Bivalirudin in Patients Undergoing	Nothing to Disclose
John	02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Vera	Clinical Team 3	The role of Aspirin in Primary Prevention - not Anymore Risks	RESEARCH/RESEARCH GRANTS - Amgen, Astra Zeneca, Astra
Volu	Great Bebutes in Frederica Guidology	Outweigh Benefits	Zeneca,Bayer Healthcare,DalCor,Eli Lilly,Pfizer,Sanofi Aventis; SPEAKER'S BUREAU - PRIME Education Inc.
Vera	Core Curriculum: Healthcare for the Masses	Chair	RESEARCH/RESEARCH GRANTS - Amgen, Astra Zeneca, Astra Zeneca, Bayer Healthcare, DalCor, Eli Lilly, Pfizer, Sanofi Aventis; SPEAKER'S BUREAU - PRIME Education Inc.
Vera	Advances in Cholesterol Measurement and	Psychosocial Factors and Statin Intolerance: Data From the	RESEARCH/RESEARCH GRANTS - Amgen, Astra Zeneca, Astra
	Management	REasons for Geographic And Racial Differences in Stroke (REGARDS) Study	Zeneca,Bayer Healthcare,DalCor,Eli Lilly,Pfizer,Sanofi Aventis; SPEAKER'S BUREAU - PRIME Education Inc.
Vera	Advances in Lipid Management	Use of High-Intensity Statin Therapy Post-Acute Coronary	RESEARCH/RESEARCH GRANTS - Amgen, Astra Zeneca, Astra
		Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9	Zeneca,Bayer Healthcare,DalCor,Eli Lilly,Pfizer,Sanofi Aventis; SPEAKER'S BUREAU - PRIME Education Inc.
Vera	Acute Coronary Syndromes, Diagnosis,	Trends in the Use of High-Intensity Statin Therapy After Myocardial	RESEARCH/RESEARCH GRANTS - Amgen, Astra Zeneca, Astra
	IMANAGEMENT AND OUTCOMES	Intarction, 2011-2014	Zeneca,Bayer Healthcare,DalCor,Eli Lilly,Pfizer,Sanofi Aventis; SPEAKER'S BUREAU - PRIME Education Inc.
Vera	33. Prevention: Hypertension Team 2	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Amgen, Astra Zeneca, Astra Zeneca, Bayer Healthcare, DalCor, Eli Lilly, Pfizer, Sanofi Aventis; SPEAKER'S BUREAU - PRIME Education Inc.
Thorarinn	Updates on Risk Factors for Cardiovascular	Carotid Plaque Area Is Increased in Patients With Acute Coronary	Nothing to Disclose
Bernard	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Syndrome and Dysglycemia Impact of Medical Liability Reform on Coronary Artery Disease Testing and Intervention	Nothing to Disclose
i	Coronary Artery Disease	Co-Chair	CONSULTANT FEES/HONORARIA - ipca,J and J,MSD,National
Henry	Emerging Concepts in Evaluation and		
Henry	Emerging Concepts in Evaluation and Management of Hypertension		Football League, Novartis, PhaseBio, servier, Takeda; RESEARCH/RESEARCH GRANTS - MEDTRONIC; SPEAKER'S BUREAU - Novartis
Henry Jennifer		Utilization of a Clinical Ladder Process as a Strategy to Facilitate the Orientation of an Advanced Practice Provider Into a Cardiology	RESEARCHÎRESEARCH GRANTS - MEDTRONIC; SPEAKER'S BUREAU - Novartis
·	Management of Hypertension Innovations in Practice Management and		RESEARCH/RESEARCH GRANTS - MEDTRONIC; SPEAKER'S BUREAU - Novartis Nothing to Disclose
	Edo Edo Jared Ulrika Trevor Yochai Yochai Yochai Yochai Yochai Yochai Kim Kim Simone Nanette Abhishek Abbas Fadi Cynthia Marcio Marcio Thomas John John John Vera Vera Vera Vera Thorarinn	Edo Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease Edo The Old and the New: Impact of Heart Failure Drug Therapies Jared FIT Clinical Decision Making: Arrhythmias and Electrophysiology Ulrika 06. Arrhythmias and Clinical EP: Other Team 2 Trevor Redefining the "F" Word Yochai Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease Plus the Impact of Congenital Heart Disease Plus the Impact of Congenital Heart Disease Plus the Impact of Congenital Heart Disease Plus the Impact of Congenital Heart Disease Yochai Diabetes and Endothelial Dysfucntion in Heart Fallure Yochai Emerging Basic Science in Ischemic Heart Disease: Clinical Team 5 Kim Recent Trends in Combination Therapy: Managing Cholesterol Even in the Most Resistant Cardiovascular Team Cases: Team 2 Simone Refining PCI Technique and Outcomes Nanette Advances in HCM, PPCM and Other Cardiowyopathies Abhas Arrhythmias and Clinical EP: Ventricular Tachycardia Fadi Population Specific Cardiomyopathies: From Exomes to Databases Cynthia Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Marcio Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine Marcio Contemporary Issues in Familial Hypercholesterolemia Thomas The Evolving World of LVADs, Transplant and Other Novel Discoveries John Controversies in ACS Guidelines John Optimizing the Care of ACS Patients Vera Advances in Cholesterol Measurement and Management Vera Advances in Cholesterol Measurement and Management Vera Advances in Cholesterol Measurement and Management Vera Advances in Cholesterol Measurement and Management Disease Traditional and Novel Discoveries John Optimizing the Care of ACS Patients Vera Taditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, the Refinence of Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Imaging Pulmonary Vascular Disease Plus the Impact of Congrenal Heart Disease (Congeliners and Disastor) Pressure Gradent Status in Heart Failure Disease Plus the Impact of Congeliners and Disastor Pressure Gradent Status in Heart Failure Disease Plus the Impact of Congeliners and Disastor Pressure Gradent Status in Heart Failure Plus Disease Plus the Impact of Pulmonary Vascular Disease Plus the Impact of Congelinal Heart Disease Plus the Impact of Congelinal Plus the Impact of Congelinal Plus the Impact of Congelinal Plus the Impact of Congelinal Plus the Impact of Congelinal Plus the Impact of Plus the Impact of Plus the Impact of Congelinal Plus the Impact of Plus the

WASHINGTON, DC | MARCH 17 - 19 2017

Last Name	First Name	Session Title	Presentation Title	Disclosures
Blackman	Marc	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Among Older Heart Failure (HF) Patients With In-Hospital Acute Kidney Injury (AKI), an Improvement in Kidney Function Is	Nothing to Disclose
			Associated With a Higher Risk of Post-Discharge Mortality but Not Readmission	
Blackman	Marc	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Heart Failure Hospitalization (HFH) Despite Digoxin Therapy Versus No HFH Despite Placebo in the Digitalis Investigation Group (DIG) Trial: Insights Into Risk Factors for HFH in HF and Reduced Ejection Fraction (HFrEF)	
Blackman	Marc	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Clinical Effectiveness of Spironolactone in Hospitalized Older Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or Equal to 30 mL/min/1.73 m ²) Patients With Heart Failure	Nothing to Disclose
Blackman	Marc	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Chronic Alpha Blocker Use and Outcomes in Older Male Medicare Beneficiaries Hospitalized for Heart Failure	Nothing to Disclose
Blackman	Marc	Why Can't We Be Friends? Controversies in Heart Failure Management	Adverse Outcomes With Use of Hydralazine and Nitrate Combination Therapy in Hospitalized Older Non-Black Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)	Nothing to Disclose
Blackstone	Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C	Panelist	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Blackstone	Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C	Risk Stratification for Heart Failure Patients Undergoing Cardiac Surgery	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Blaha	Michael	Challenges in Cardiac CT: Case-Based Discussions	The Asymptomatic Patient: Risk Factor Score or Calcium Score?	CONSULTANT FEES/HONORARIA - Amgen,MedImmune, Inc,Novartis Corporation,Siemens
Blaha	Michael Michael	Great Debates in Preventive Cardiology Great Debates in Cardiac CT	Risk Assessment in Primary Prevention of ASCVD - Optimal Risk Assessment Includes Coronary Artery Calcium Scoring Co-Chair	CONSULTANT FEES/HONORARIA - Amgen,MedImmune, Inc,Novartis Corporation,Siemens CONSULTANT FEES/HONORARIA - Amgen,MedImmune,
Didild	Micriaei	Great Debates III Cardiac CT	CO-Citali	Inc, Novartis Corporation, Siemens
Blaha	Michael	Arrhythmias and Clinical EP: Basic 1	Variation in the Use of Direct Oral Anticoagulants and Associated Cost Implications: Findings From the Medical Expenditure Panel Survey 2010 to 2013	CONSULTANT FEES/HONORARIA - Amgen, MedImmune, Inc, Novartis Corporation, Siemens
Blaha	Michael	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Coronary Artery Calcium and Incident Hypertension in a Population- Based Cohort: The Multi-Ethnic Study of Atherosclerosis	CONSULTANT FEES/HONORARIA - Amgen, Medimmune, Inc, Novartis Corporation, Siemens
Blaha	Michael	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium and Estimated Cardiovascular Disease Risk in Five Racial/Ethnic Groups Living in the US: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA)	CONSULTANT FEES/HONORARIA - Amgen,MedImmune, Inc,Novartis Corporation,Siemens
Blaha	Michael	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Calcium Characteristics as Predictors of Major Adverse Cardiac Events in Symptomatic Patients: Insights From the CORE320 Multinational Study	CONSULTANT FEES/HONORARIA - Amgen,MedImmune, Inc,Novartis Corporation,Siemens
Blaha	Michael	Innovations in Cardiovascular Risk Assessment and Reduction		CONSULTANT FEES/HONORARIA - Amgen, MedImmune, Inc, Novartis Corporation, Siemens
Blaha	Michael	Non Invasive Imaging: Role of Exercise Testing	Using Machine Learning to Define the Association Between Cardiorespiratory Fitness and All-Cause Mortality: The FIT (Henry Ford Exercise Testing) Project	CONSULTANT FEES/HONORARIA - Amgen, MedImmune, Inc, Novartis Corporation, Siemens
Blaha	Michael	Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Amgen, MedImmune, Inc, Novartis Corporation, Siemens
Blaha	Michael	Risky Business: Predicting Outcomes in Heart Failure	Chronotropic Incompetence and Long-Term Risk of Heart Failure: The Henry Ford Exercise Testing Project	CONSULTANT FEES/HONORARIA - Amgen, MedImmune, Inc, Novartis Corporation, Siemens
Blaha	Michael	32. Prevention: Clinical Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen, MedImmune, Inc, Novartis Corporation, Siemens
Blais	Danielle	PPIs in the Era of Prolonged DAPT Should We or Shouldn't We?: Pharmacology III	Debate: Pro - PPIs Should be Prescribed in All Patients with Prolonged DAPT - the Data Speak for Themselves	Nothing to Disclose
Blanchard	Daniel	Advances in HCM, PPCM and Other Cardiomyopathies	The Prevalence and Clinical Significance of Compacted Myocardium in Dilated Cardiomyopathy: A Contrast Echocardiography Study	Nothing to Disclose
Blanco	Roberto	Timely Topics in Acute Coronary Syndromes	A New Prognosis Score to Predict Mortality in Patients Over 75 Years Old Undergoing Primary Angioplasty in Cardiogenic Shock	Nothing to Disclose
Blanke	Philipp	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	CONSULTANT FEES/HONORARIA - Circle Imaging, Edwards Lifesciences Inc, Neovasc Inc., Tedyne Holdings
Blanke	Philipp	Interventional Cardiology: TAVR 1	Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: Insights From PARTNER 2A Trial	CONSULTANT FEES/HONORARIA - Circle Imaging,Edwards Lifesciences Inc,Neovasc Inc.,Tedyne Holdings
Blanke	Philipp	Non Invasive Imaging: Expanding Clinical Applications	Does Patient Prosthesis Mismatch Defined by CT LVOT Area Predict Downstream Clinical Outcomes?	CONSULTANT FEES/HONORARIA - Circle Imaging, Edwards Lifesciences Inc, Neovasc Inc., Tedyne Holdings
Blanke	Philipp	Non Invasive Imaging: Prognostic Implications of CT Angiography	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	CONSULTANT FEES/HONORARIA - Circle Imaging,Edwards Lifesciences Inc,Neovasc Inc.,Tedyne Holdings
Blanke	Philipp	Unusual Presentations of ACS	Incidence and Predictors of Lesion Specific Ischemia by FFR _{CT} : Learnings From the International ADVANCE Registry	CONSULTANT FEES/HONORARIA - Circle Imaging, Edwards Lifesciences Inc, Neovasc Inc., Tedyne Holdings
Blankenberg	Stefan	MicroRNAs and Beyond in Vascular Medicine	Disturbed Expression of Immunoregulatory Long Noncoding RNAs in Circulating Immune Cells From Patients With Early Myocardial Infarction	Nothing to Disclose
Blankenship	James	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	<∀⊳ < For Profile of Diagnostic Coronary Bypass Angiography	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Astra Zeneca, Boston Scientific, GlaxoSmithKline, Hamilton Health Sciences, Medinal LTD, Orexigen Therapeutics/Takeda, St Jude Medical, Stentys, Inc, Takeda Pharmaceuticals
Blankenship	James	02. Acute and Stable Ischemic Heart Disease: Clinical Team 5	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Astra Zeneca Boston Scientific, GlaxoSmithKline, Hamilton Health Sciences, Medinal LTD, Orexigen Therapeutics/Takeda, St Jude Medical, Stentys, Inc, Takeda Pharmaceuticals
Blankstein	Ron	Imaging of Myocardial Blood Flow: A Multimodality Approach	CT Assessment of MBF: Not Just a Research Tool Anymore	CONSULTANT FEES/HONORARIA - Neograft Technologies, Inc,EKOS Corporation, Stealth Peptides Inc.; RESEARCH/RESEARCH GRANTS - Gilead Sciences, Inc.
Blankstein	Ron	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Integrating Hyperemic Myocardial Blood Flow and Coronary Flow Reserve for Predicting Cardiovascular Mortality Outcomes in Patients With Known or Suspected Ischemic Heart Disease	CONSULTANT FEES/HONORARIA - Neograft Technologies, Inc.EKOS Corporation, Stealth Peptides Inc.; RESEARCH/RESEARCH GRANTS - Gilead Sciences, Inc.
Blankstein	Ron	Young Investigator Awards Competition: Clinical Investigations	Impaired Coronary Flow Reserve Is Associated With Diastolic Dysfunction and HFpEF Outcomes in Patients Without Overt CAD	CONSULTANT FEES/HONORARIA - Neograft Technologies, Inc.EKOS Corporation, Stealth Peptides Inc.; RESEARCH/RESEARCH GRANTS - Gilead Sciences, Inc.
Blankstein	Ron	Arrhythmias and Clinical EP: Basic 1	Variation in the Use of Direct Oral Anticoagulants and Associated Cost Implications: Findings From the Medical Expenditure Panel Survey 2010 to 2013	CONSULTANT FEES/HONORARIA - Neograft Technologies, Inc.EKOS Corporation, Stealth Peptides Inc.; RESEARCH/RESEARCH GRANTS - Gilead Sciences, Inc.
Blankstein	Ron	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Lipid Abnormalities in Young Patients With Myocardial Infarction	CONSULTANT FEES/HONORARIA - Neograft Technologies, Inc. EKOS Corporation, Stealth Peptides Inc.; RESEARCH/RESEARCH GRANTS - Gilead Sciences, Inc.

Blankstein Ron Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Rori Blauwet Revin Bleiziffer Sabine Bleiziffer Sabine Bliden Kevin			
Blankstein Ron Blauwet Ira Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Revin Bleiziffer Sabine Bleiziffer Sabine Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Peter Blook Peter Blook Peter Bloom Dirk Bloom Dirk Bloomer Tyler Bloomer Tyler Bloomer Tyler Bloomer Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David	Session Title	Presentation Title	Disclosures
Blankstein Ron Blankstein Ron Blankstein Ron Blankstein Ron Blankstein Ron Blankstein Ron Blankstein Ron Blankstein Ron Blankstein Ron Blankstein Ron Blankstein Ron Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Revin Bleiziffer Sabine Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Peter Blook Peter Blook Peter Blook Peter Bloom Dirk Bloom Dirk Bloomer Tyler Bloomer Tyler Bloomer Tyler Bloomer Tyler Bloomer Tyler Bloomer Tyler Bloomer David Bluemke David Bluemke David Bluemke Bluemk	Nuclear Cardiology: Prognosis	Myocardial Scar but Not Ischemia Predicts Defibrillator Shocks and Sudden Cardiac Death in Patients With Reduced Left Ventricular Ejection Fraction	CONSULTANT FEES/HONORARIA - Neograft Technologies, Inc,EKOS Corporation,Stealth Peptides Inc.; RESEARCH/RESEARCH GRANTS - Gilead Sciences, Inc.
Blankstein Ron Blankstein Ron Blankstein Ron Blankstein Ron Blanton Robert Blase Amy Blau Ira Blau Ira Blau Ira Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Sabine Bleiziffer Sabine Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Feer Block Peter Block Peter Blom Dirk Blomstrand Peter Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	Innovations in Cardiovascular Risk Assessment and Reduction	Election Fraction Cost-Effectiveness of Coronary Artery Calcium Testing Among Statin Candidates According to the American College of Cardiology and American Heart Association Cholesterol Guidelines	CONSULTANT FEES/HONORARIA - lead Scientes, inc. CONSULTANT FEES/HONORARIA - Neograft Technologies, Inc,EKOS Corporation,Stealth Peptides Inc.; RESEARCH/RESEARCH GRANTS - Gilead Sciences, Inc.
Blankstein Ron Blankstein Ron Blankstein Ron Blanton Robert Blase Amy Blau Ira Blau Ira Blau Ira Blau Ira Blauwet Lori Blauwet Lori Blauwet Lori Blausall Burns Bleiziffer Sabine Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Feer Blook Peter Blook Peter Blook Peter Bloom Dirk Bloom Dirk Bloom Tyler Bloomer Tyler Bloomer Tyler Bloomer Tyler Bloomer David Bluemke David Bluemke Bluemke David Bluemke	Unusual Presentations of ACS	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival	CONSULTANT FEES/HONORARIA - Neograft Technologies, Inc,EKOS Corporation,Stealth Peptides Inc.; RESEARCH/RESEARCH GRANTS - Gilead Sciences, Inc.
Blankstein Ron Blanton Robert Blase Amy Blau Ira Blau Ira Blau Ira Blau Ira Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Lori Blausall Burns Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Ferer Block Peter Block Peter Blom Dirk Blomstrand Peter Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bloomer Fyler Bluemke David Bluemke David Bluemke David Bluemke David	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Relationship of Coronary Flow Reserve With Body Mass Index and Adverse Outcomes in Patients Without Overt Ischemic Heart Disease: Implications for Metabolic Surgery Eligibility	CONSULTANT FEES/HONORARIA - Neograft Technologies, Inc. ECS Corporation, Stealth Peptides Inc.; RESEARCH/RESEARCH GRANTS - Gilead Sciences, Inc.
Blanton Robert Blase Amy Blau Ira Blau Ira Blau Ira Blaum Caroline Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Sabine Bleiziffer Sabine Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Feer Block Peter Block Peter Blom Dirk Blom Dirk Blom Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke Bluemke David Bluemke Bluemke David Bluemke Blow Blauwet Lori	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Cardiovascular Events Along a Continuum of Metabolic Disease in Symptomatic Patients Without Overt Coronary Artery Disease	CONSULTANT FEES/HONORARIA - Neograft Technologies, Inc. EKOS Corporation, Stealth Peptides Inc.; RESEARCH/RESEARCH GRANTS - Gilead Sciences, Inc.
Blase Amy Blau Ira Blau Ira Blau Ira Blaum Caroline Blauwet Lori Blauwet Lori Blauwet Burns Bleiziffer Sabine Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Marissa Block Peter Blook Peter Bloom Dirk Bloom Dirk Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke Blaum Ira Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Lori Burns Bu	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team	Symptomatic Patients Without Overt Coronary Artery Disease Suggested Reviewer	CONSULTANT FEES/HONORARIA - Gliead Sciences; Inc. CONSULTANT FEES/HONORARIA - Neograft Technologies, Inc,EKOS Corporation, Stealth Peptides Inc.; RESEARCH/RESEARCH GRANTS - Gilead Sciences, Inc.
Blau Ira Blau Ira Blau Ira Blau Ira Blaum Caroline Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Sabine Bleiziffer Sabine Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Peter Block Peter Block Peter Blom Dirk Blom Dirk Bloomer Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	12. Heart Failure and Cardiomyopathies: Basic Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Ironwood Pharmaceuticals; RESEARCH/RESEARCH GRANTS - Novartis Corporation
Blau Ira Blaum Caroline Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Blaxall Burns Bleiziffer Sabine Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Dirk Bliden Marissa Block Peter Block Peter Blom Dirk Blom Dirk Blom Dirk Blom Dirk Blomer Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	Heart Failure and Cardiomyopathies: Is Heart	Surrogate Endpoints and the Differential Response to ASV for Sleep	SALARY - Resmed
Blau Ira Blaum Caroline Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Blaxall Burns Bleiziffer Sabine Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Dirk Bliden Marissa Block Peter Block Peter Blom Dirk Blom Dirk Blom Dirk Blom Dirk Blomer Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	Failure With a Normal EF for Real? Arrhythmias and Clinical EP: Basic 3	Apnea in HFrEF Versus HFpEF in the CAT-HF Trial Entropy of Fibrillatory Waves Contributes to Differentiating	Nothing to Disclose
Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Lori Blawall Burns Bleiziffer Sabine Bleiziffer Sabine Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Marissa Block Peter Block Peter Blom Dirk Blom Dirk Blom Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	Arrhythmias and Clinical EP: Basic 4	Paroxysmal From Persistent and Permanent Atrial Fibrillation Efficacy of Scattergram Analysis for Classifying Subtypes of Atrial	Nothing to Disclose
Blauwet Lori Blauwet Lori Blauwet Lori Blauwet Lori Blaxall Burns Bleiziffer Sabine Bleiziffer Sabine Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Marissa Block Peter Block Peter Blom Dirk Blom Dirk Blom Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	•	Fibrillation by Fourier Transform of Fibrillatory Waves	-
Blauwet Lori Blauwet Lori Blawall Burns Bleiziffer Sabine Bleiziffer Sabine Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Marisa Block Peter Block Peter Blom Dirk Blom Dirk Blom Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Burns Bur	Interventional Cardiology: TAVR 2	Direct Home Discharge and Likelihood of 30-Day Hospital Readmission After Transcatheter Aortic Valve Replacement ITAVR): Findings From the STS/ACC TVT Registry	Nothing to Disclose
Blauwet Blawall Blawall Burns Bleiziffer Sabine Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Bliden Kevin Bliden Bliden Marissa Block Peter Block Dirk Blom Dirk Blom Dirk Blom Dirk Blom Dirk Blom Blom Dirk Blom Dirk Blom Blom Dirk Blom Blom Dirk Blom Blom Dirk Blom Blom Dirk Blom Blom Dirk Blom Blom Dirk Blom Blom Dirk Blom Blom Blom Dirk Blom Blom Blom Dirk Blom Blom Blom Dirk Blom Blom Blom Dirk Blom Blom Blom Blom Dirk Blom Blom Blom Blom Blom Dirk Blom Blom Blom Blom Blom Blom Blom Blom	Novel Echocardiographic Methods for	Subclinical Myocardial Alterations in Cardiac Sarcoidosis	Nothing to Disclose
Blaxall Burns Bleiziffer Sabine Bleiziffer Sabine Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Marissa Block Peter Block Peter Blom Dirk Blom Dirk Blom Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	Assessing Cardiac Function Advances in HCM, PPCM and Other	Extended Course of Recovery in Patients With Peripartum	Nothing to Disclose
Blaxall Burns Bleiziffer Sabine Bleiziffer Sabine Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Marissa Block Peter Block Peter Blom Dirk Blom Dirk Blom Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	Cardiomyopathies 28. Non Invasive Imaging: Echo Team 1	Cardiomyopathy Assessed by Left Ventricular Wall Distensibility Suggested Reviewer	Nothing to Disclose
Bleiziffer Sabine Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Marisa Block Peter Block Peter Blom Dirk Blom Dirk Blom Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	Heart Failure and Cardiomyopathies: Basic Team 1	Suggested Reviewer	Nothing to Disclose
Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Marissa Block Peter Block Peter Blom Dirk Blom Dirk Blom Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	Nothing to Disclose
Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Marissa Block Peter Block Peter Blom Dirk Blom Dirk Blom Tyler Bloomer Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	Interventional Cardiology: TAVR 3	Does Balloon Predilatation Influence Outcome With the Lotus Valve: 30-Day Results From the RESPOND Study	Nothing to Disclose
Bliden Kevin Bliden Kevin Bliden Kevin Bliden Kevin Bliden Marissa Block Peter Block Peter Blom Dirk Blom Dirk Blom Dirk Blom Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	Biomarkers and Targets for Ischemic Heart Disease	Serial Assessment of Thrombogenicity and Hemodynamics in Patients With Type II Diabetes Observed in a Clinical Research Unit: Evidence for Circadian Changes in Clot Formation	Nothing to Disclose
Bliden Kevin Bliden Kevin Bliden Kevin Blieden Marissa Block Peter Block Peter Blom Dirk Blom Dirk Blom Dirk Blomstrand Peter Blood Alexander Bloomer Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease	Assessment of Thrombogenicity and Antithrombotic Drug Response at the Bedside in Patients Presenting With Ischemic Stroke, TIA or Intracranial Hemorrhage	Nothing to Disclose
Bliden Kevin Blieden Marissa Block Peter Block Peter Blom Dirk Blom Dirk Blomstrand Peter Blood Alexander Bloomer Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David	Advances in Lipid Management	HDL3: A Marker of Coronary Artery Disease Severity and Inflammation in Patients on Statin Therapy	Nothing to Disclose
Blieden Marissa Block Peter Block Peter Block Peter Blom Dirk Blom Dirk Blom Alexander Bloomer Tyler Bloomer Tyler Bloomer Tyler Bloemer David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Early Coronary Angiography in Patients With Out-of-Hospital Cardiac Arrest Without ST-Elevation Myocardial Infarction: A Meta- Analysis of 1,460 Patients	Nothing to Disclose
Block Peter Block Peter Blom Dirk Blom Dirk Blom Dirk Blomstrand Peter Blood Alexander Bloomer Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	Novel Arrhythmia Diagnostics, Therapeutics, and "Wearables	Pauses Detected by Insertable Cardiac Monitors in Patients With Atrial Fibrillation	Nothing to Disclose
Block Peter Blom Dirk Blom Dirk Blomstrand Peter Blood Alexander Bloomer Tyler Bloomer Tyler Bloomer Tyler Bloomer David Bluemke David Bluemke David Bluemke David Bluemke David	Diabetes and Other Issues in Cardiovascular Prevention	Comparison of the Use of Cardiovascular Risk Equations by Health Technology Assessment Bodies and Clinical Guidelines	Nothing to Disclose
Blom Dirk Blom Dirk Blomstrand Peter Blood Alexander Bloomer Tyler Bloomer Tyler Bloomer Tyler Bloomer David Bluemke David Bluemke David Bluemke David Bluemke David	TAVR Outcomes Prognostication	Predictors and Clinical Outcomes of Next-Day Discharge After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Blom Dirk Blomstrand Peter Blood Alexander Bloomer Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	17. Interventional Cardiology: Aortic Valve	Suggested Reviewer	Nothing to Disclose
Blomstrand Peter Blood Alexander Bloomer Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David Bluemke David	Disease Team 2 Advances in Cholesterol Measurement and Management	Impact of Evolocumab Therapy in Patients With Discordance Between LDL-C and LDL-P	CONSULTANT FEES/HONORARIA - Aegerion Pharmaceuticals,Amgen,AstraZeneca,Gemphire,MSD,Sanofi- Aventis; RESEARCH/RESEARCH GRANTS - Aegerion/Lomitapide,Amgen/Evolocumab,EliL Lilly,Sanofi/Regeneron (Alirocumab)
Bloomer Tyler Bloomer Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David	Advances in Lipid Management	Treatment Effects of Alirocumab as an Add-On to Maximally Tolerated Dose of Statin in Patients With Heterozygous Familial Hypercholesterolemia and/or Atherosclerotic Cardiovascular Disease	CONSULTANT FEES/HONORARIA - Aegerion Pharmaceuticals,Amgen,AstraZeneca,Gemphire,MSD,Sanofi- Aventis; RESEARCH/RESEARCH GRANTS - Aegerion/Lomitapide,Amgen/Evolocumab,EliL Lilly,Sanofi/Regeneron (Alirocumab)
Bloomer Tyler Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Overweight and Obesity Impairs Left Ventricular Systolic and Diastolic Function in Patients With Type 2 Diabetes	Nothing to Disclose
Bloomer Tyler Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David	Understanding Pulmonary Vascular Disease: From Bench to Bedside	Pulmonary Vascular Response to Nitric Oxide and Subsequent Response to Advanced Medical Therapy in Incident Patients With Pulmonary Hypertension	Nothing to Disclose
Bloomer Tyler Bluemke David Bluemke David Bluemke David Bluemke David	Vascular Access and Hemostasis Issues	Access Site and Bleeding Outcomes With Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Pulmonary Embolism: Internal Jugular Versus Common Femoral Vein	Nothing to Disclose
Bluemke David Bluemke David Bluemke David Bluemke David	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Myocarditis and Rhabdomyolysis Incidence With Immune Checkpoint Inhibitors	Nothing to Disclose
Bluemke David Bluemke David Bluemke David	FIT Clinical Decision Making: Arrhythmias and	Pacing-Induced Cardiomyopathy From a Transcatheter Leadless	Nothing to Disclose
Bluemke David Bluemke David	Clinical Electrophysiology Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Pacemaker Following Transcatheter Aortic Valve Replacement Aortic Vascular Inflammation by 18-FDG PET/CT Associates With High-Risk Coronary Plaques in Young Psoriasis Patients	OTHER - Philips, Siemens
Bluemke David	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Normal Findings on Noninvasive Cardiac Assessment and the Prediction of Heart Failure: The Multi-Ethnic Study of	OTHER - Philips, Siemens
	Vascular Medicine: Novel Risk Measures in	Atherosclerosis (MESA) Association of Coronary Artery Calcium With Incident Peripheral	OTHER - Philips,Siemens
Bluemke David	Arterial Diseases Non Invasive Imaging: MR Scar and Perfusion	Artery Disease: The Multi-Ethnic Study of Atherosclerosis Association of Right Atrial Function With Incident Atrial Fibrillation:	OTHER - Philips,Siemens
	Non Invasive Imaging: Prognostic Implications of CT Angiography	The Multi-Ethnic Study of Atherosclerosis (MESA) Prediction of Future Cardiovascular Risk by Analysis of Various CT Coronary Angiography-Determined Quantitative Plaque Compositional Characteristics Among Patients With Diabetes Enrolled in the FACTOR-64 Study: The Importance of the Calcified Coronary Plaque	OTHER - Philips,Siemens
Bluemke David Blum Kay	29. Non Invasive Imaging: MR Team 2 12. Heart Failure and Cardiomyopathies: Basic	Suggested Reviewer Suggested Reviewer	OTHER - Philips,Siemens Nothing to Disclose
Blumberg Emily	Team 1 Life After LVAD - The Good, The Bad and The Ugly	Management of Infectious Complications Following LVAD	CONSULTANT FEES/HONORARIA - Merck & Discussion (co., Inc.; DATA SAFETY MONITORING BOARD - Bristol Myers

Last Name	First Name	Session Title	Presentation Title	Disclosures
Blume	Elizabeth	Innovations in Advocacy and Patient Centered Care	Describing Collaboration Between Cardiology and Palliative Care: A National Survey Study of Current Practices, Challenges and Barriers	Nothing to Disclose
Blumenkrants	Dmitry	Hearts and Soles: Multimodality Imaging in Athletes	Global & Basal Longitudinal Strain in NFL Combine Participants	Nothing to Disclose
Blumenthal	Roger	Joint American College of Cardiology/Journal of the American Medical Association Late-	Panelist	Nothing to Disclose
Blumenthal	Roger	Breaking Clinical Trials Prevention of ASCVD Over the Lifespan: A	Panelist	Nothing to Disclose
Blumenthal	Roger	Case-based Approach Highlighted Original Research: Prevention and the Year in Review	Year in Review Speaker	Nothing to Disclose
Blumenthal	Roger	Advances in Cholesterol Measurement and Management	Comparison of the Novel Method Versus the Friedewald Equation in Estimating Low-Density Lipoprotein-Cholesterol Based on Fasting	Nothing to Disclose
Blumenthal	Roger	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Status Coronary Artery Calcium and Incident Hypertension in a Population- Based Cohort: The Multi-Ethnic Study of Atherosclerosis	Nothing to Disclose
Blumenthal	Roger	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium and Estimated Cardiovascular Disease Risk in Five Racial/Ethnic Groups Living in the US: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA)	Nothing to Disclose
Blumenthal	Roger	Innovations in Cardiovascular Risk Assessment and Reduction	Cost-Effectiveness of Coronary Artery Calcium Testing Among Statin Candidates According to the American College of Cardiology and American Heart Association Cholesterol Guidelines	Nothing to Disclose
Blumenthal	Roger	32. Prevention: Clinical Team 2	Suggested Reviewer	Nothing to Disclose
Blumer	Vanessa	Why Can't We Be Friends? Controversies in Heart Failure Management	Cardiac Resynchronization Therapy in Inotropic-Dependent Heart Failure Patients: A Systematic Review and Meta-Analysis	Nothing to Disclose
Во	Xu	Timely Topics in Acute Coronary Syndromes	Effect of Coronary Dominance on 2-Year Outcomes After Percutaneous Coronary Intervention in Patients With Acute	Nothing to Disclose
Bober	Robert	Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering Therapies	Coronary Syndrome Hypertension Control Is Strongly Influenced by Patient's Health Capability	CONSULTANT FEES/HONORARIA - Bracco; RESEARCH/RESEARCH GRANTS - Bracco
Bober	Robert	Nuclear Cardiology: Coronary Flow	Reduced Flow Capacity as Measured by Cardiac Positron Emission Tomography Predicts Ventricular Tachyarrhythmia in Patients With an ICD	CONSULTANT FEES/HONORARIA - Bracco; RESEARCH/RESEARCH GRANTS - Bracco
Bob-Manuel	Tamunoinemi	Innovations in Advocacy and Patient Centered Care	Prolonged Inter-facility Transfer Times and Hospital Length of Stay in Insured Patients with ST-elevation Myocardial Infarction	Nothing to Disclose
Boccara	Franck	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Proprotein Convertase Subtilisin Kexin Type 9 Regulation in Human Immunodeficiency Virus-Infected Patients Under Protease Inhibitors	CONSULTANT FEES/HONORARIA - Amgen,SANOFI; SPEAKER'S BUREAU - gilead,ViiV heathcare
Bocchi	Edimar	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Efficacy and Safety Profile of Ivabradine in Heart Failure Due to Chagas´ Heart Disease: A Post-Hoc Analysis of the SHIFT Trial	OTHER - servier; RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals, Inc; SPEAKER'S BUREAU - Novartis
Bockeria	Leo	Advances in Pulmonary Arterial Hypertension	Long-Term Results of Interatrial Septum Fenestration With Stent Implantation in Idiopathic Pulmonary Arterial Hypertension	Nothing to Disclose
Bockeriya	Olga	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Time-to-Event Meta-Analysis for Bypass Grafting Versus Stenting in Multivessel Disease in Contemporary Era	Nothing to Disclose
Bockeriya	Olga	Innovations in Advocacy and Patient Centered Care	Safety and Feasibility of a Mobile Cardiac Clinic: First of Its Kind in Russia	Nothing to Disclose
Bodde	Mathijs	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Plasma LDL-Cholesterol Level Is Independently Associated With Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention	Nothing to Disclose
Bode	Christoph	Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials	A Randomized Trial Evaluating Clinically Significant Bleeding With Low-Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, for Patients After Acute Coronary Syndromes	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Bayer,Daiichi Sankyo
Bode	Kerstin	FIT Clinical Decision Making: Heart Failure and	Isolated Cardiac Sarcoidosis Mimicking Hypertrophic	Nothing to Disclose
Bodegard	Johan	Pulmonary Hypertension Featured Clinical Research III	Cardiomyopathy Lower Rates of Hospitalization for Heart Failure and All-Cause	SALARY - AstraZeneca Pharmaceuticals
Boden	William	FIT Forum: Mix and Mingle	Death in New Users of SGLT-2 Inhibitors: The CVD-REAL Study Clinical Research	CONSULTANT FEES/HONORARIA - Abbvie, Amgen Inc., AstraZeneca Pharmaceuticals, CardioDX, Janssen
Boden	William	Great Debates in Ischemia 2017	Patients with Severe Asymptomatic Anterior Ischemia Should Undergo PCI: Con	Pharmaecuticals; OTHER - Arisaph Pharmaceuticals CONSULTANT FEES/HONORARIA - Abbvie,Amgen Inc. AstraZeneca Pharmaceuticals.CardioDX.Janssen
Boden	William		Suggested Reviewer	Pharmaceuticals; OTHER - Arisaph Pharmaceuticals CONSULTANT FEES/HONORARIA - Abbvie, Amgen
Rodí	Vicente	Therapy Team 3 Acute Coronary Syndromes, Diagnosis,	Bimodal Prognosis of Patients Hospitalized With Suspected Acute	Inc.,AstraZeneca Pharmaceuticals,CardioDX,Janssen Pharmaceuticals; OTHER - Arisaph Pharmaceuticals Nothing to Disclose
Bodí	Vicente	Management and Outcomes	Coronary Syndrome in Whom the Diagnosis Is Not Confirmed	-
Boe	Brian	Six Years of Making an IMPACT	How You Can Make an IMPACT: How to Use the Registry for Research	Nothing to Disclose
Boeddinghaus	Jasper	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Direct Comparison of Cardiac Myosin-Binding Protein C to Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction	Nothing to Disclose
Boehm	Erin	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Aortic Valve Replacement as a Treatment for Acute Renal Failure and Transfusion-Dependent Anemia: A Unique Presentation of <i>Bartonella Quintana</i>	Nothing to Disclose
Boehm	Michael	Systemic Organ Involvement in Heart Failure: International Perspectives From the German Cardiac Society, Hellenic Society of Cardiology, and American College of Cardiology	Co-morbidities in Heart Failure	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,MEDTRONIC, servier, St. Jude, Vífor
Boehm	Michael	13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen; OTHER - Novartie
Boehmer	John	Clinical Team 3 FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Aspergillus Endocarditis and Locked-In Syndrome: Rare Complications After Orthotopic Heart Transplant	Corporation, servier CONSULTANT FEES/HONORARIA - Boston Scientific; DATA SAFETY MONITORING BOARD - St. Jude Medical; RESEARCH/RESEARCH GRANTS - MEDTRONIC, St. Jude Medical
Boekstegers	Peter	Interventional Cardiology: PCI in Complex Patients	Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated Heparin Following Transcatheter Aortic Valve Replacement: Results From the Bravo-3 Randomized Trial	CONSULTANT FEES/HONORARIA - MEDTRONIC
Boersma	Lucas	Atrial Fibrillation and VT: Unique Populations and Solutions	Low Stroke Incidence in Persistent Atrial Fibrillation Ablation With Multi-Electrode Phased Radio-Frequency Technology: Preliminary Results From VICTORY AF Study	CONSULTANT FEES/HONORARIA - Bostron Scientific, Medtronic
Boerwinkle	Eric	Advances in Cholesterol Measurement and Management	Association of Remnant-Like Particle Cholesterol and Low-Density Lipoprotein Triglyceride With Incidence of Cardiovascular Events: The ARIC Study <i></i>	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Codified Genomics
	•	•		

WASHINGTON, DC | MARCH 17 - 19 2017

Last Name	First Name	Session Title	Presentation Title	Disclosures
Boetker	Hans Erik	PCI for NSTEMI and Complex Patients With	Prognostic Value of Coronary Computed Tomography Angiography,	Nothing to Disclose
		Multiple Co-Morbidities	Myocardial Perfusion Imaging and Invasive Coronary Angiography in Kidney Transplantation Candidates: A Prospective Cohort Study	
Boettcher	Morten	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Risk Stratification of Patients Suspected of Coronary Artery Disease Using an Acoustic Detection Algorithm	Nothing to Disclose
Boettcher	Morten	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Prognostic Value of Coronary Computed Tomography Angiography, Myocardial Perfusion Imaging and Invasive Coronary Angiography in Kidney Transplantation Candidates: A Prospective Cohort Study	Nothing to Disclose
Boey	Elaine	New Technologies in Echocardiography	Novel Non-Invasive Left Ventricular Stiffness Index in Patients With	Nothing to Disclose
Bogaev	Roberta	FIT Clinical Decision Making: Heart Failure and	Low-Flow Compared to Normal-Flow Severe Aortic Stenosis With Preserved Left Ventricular Ejection Fraction SynCardia Meets CardioMEMS: A Loeffler's Story	SPEAKER'S BUREAU - Amgen Inc., Novartis
	Roberta	Cardiomyopathies 13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	SPEAKER'S BUREAU - Amgen Inc., Novartis
Bogard Fuentes	Carlos Alberto	Clinical Team 3	Left Main Coronary Artery Compression Syndrome	Nothing to Disclose
-		Pulmonary Hypertension		-
Bogdan	Andrada	Interventional Cardiology: TAVR 4	Rapid Ventricular Pacing During TAVR Is Associated With Poor Short- and Long-Term Outcome	Nothing to Disclose
Boggio	Enrico	Emerging Developments in HFpEF and Arryhthmias	Prognostic Role of Ventricular-Arterial Coupling in Patients With Left Ventricular Dysfunction Submitted to Cardiac Resynchronization Therapy	Nothing to Disclose
Bogle	Brittany	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Sudden Cardiac Death Risk Distribution in the United States Population: Results From the National Health and Nutrition Examination Survey (NHANES), 2005-2012	Nothing to Disclose
Bogle	Richard	02. Acute and Stable Ischemic Heart Disease: Clinical Team 7	Suggested Reviewer	Nothing to Disclose
Bogsrud	Martin	Advances in Cholesterol Measurement and Management	Only Eight Percent of Very High-Risk Familial Hypercholesterolemia Patients Achieve LDL-Cholesterol Target Despite Being on Maximal Conventional Lipid-Lowering Therapy	Nothing to Disclose
Bogsrud	Martin	Advances in Cholesterol Measurement and	Real-Life PCSK9 Experience: 65% Treatment Target Attainment in Familial Hypercholesterolemia Patients	Nothing to Disclose
Bogun	Frank	Management Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Anticoagulation Protocol After Radiofrequency Ablation of Infarct- Related Ventricular Tachycardia: Institutional Experience and	CONSULTANT FEES/HONORARIA - Biotronik,Bosten Scientific,St Jude
Bogun	Frank	06. Arrhythmias and Clinical EP: Other Team 1	Outcomes Suggested Reviewer	CONSULTANT FEES/HONORARIA - Biotronik,Bosten Scientific,St Jude
Bohula	Erin	Evolution of Critical Care Cardiology and the CICU	Preparing for Evolving Roles of the Cardiologist in the CICU	CONSULTANT FEES/HONORARIA - Merck; RESEARCH/RESEARCH GRANTS - Eisai
Bohula	Erin	Post-CAD/MI: Making Tough Predictions About the Future	Risk Stratification With the TIMI Risk Score for Secondary Prevention Among Patients With Diabetes and Elevated Cardiovascular Risk	CONSULTANT FEES/HONORARIA - Merck; RESEARCH/RESEARCH GRANTS - Eisai
Bohula	Erin	03. Acute and Stable Ischemic Heart Disease: Therapy Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Merck; RESEARCH/RESEARCH GRANTS - Eisai
Bohun	Claudine	Congenital Heart Disease: New Diagnostic	Impact of Maternal Diabetes on First & Early Second Trimester	Nothing to Disclose
Boilard	Anne-Julie	Approaches in Congenital Heart Disease Novel Determinants of Outcomes in VHD	Fetal Cardiovascular Health Pre-Operative Longitudinal Strain and Strain Rate as Predictors of Impaired Post-Operative Ejection Fraction in Patients Operated for	Nothing to Disclose
Bois	John	Nuclear Cardiology: Beyond Perfusion	Pure Aortic Regurgitation The Impact of Cardiopulmonary Testing on Downstream Evaluation in Patients Who Undergo Myocardial Perfusion Imaging	Nothing to Disclose
Bojalil	Rafael	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Derivation and Validation of a Simple Inflammation Based Risk Score for Predicting In-Hospital Mortality in Acute Coronary	Nothing to Disclose
Bokhari	Sabahat	Syndrome Nuclear Cardiology: Beyond Perfusion	Syndrome	Nothing to Disclose
Bokhari	Sabahat	Emerging Applications for Imaging Cardiac	Viability Images ACC Poster Moderator	Nothing to Disclose
Bokhari	Sabahat	Amyloidosis: Nuclear Cardiology Emerging Applications for Imaging Cardiac	Fluorine-18 Sodium Fluoride Positron Emission Tomography for	Nothing to Disclose
		Amyloidosis: Nuclear Cardiology	Imaging Transthyretin Cardiac Amyloidosis	
Boklage	Susan	Advances in Cholesterol Measurement and Management	Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol	SALARY - Regeneron Pharmaceuticals, Inc.
Boklage	Susan	Advances in Cholesterol Measurement and Management	Understanding the Predictors of Achieving LDL-C Targets When Adding Ezetimibe in High Risk Patients	SALARY - Regeneron Pharmaceuticals, Inc.
Boklage	Susan	Acute Coronary Syndromes, Diagnosis,	Statin Utilization Patterns During Inpatient Admissions for Acute	SALARY - Regeneron Pharmaceuticals, Inc.
Boler	Amber	Management and Outcomes FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Coronary Syndrome (ACS) Azygos Vein Isolation as Treatment for a Complex Case of Atrial Arrhythmia	Nothing to Disclose
Bolin	Elijah	Congenital Heart Disease: New Diagnostic	Short Axis Diastolic Ventricular Area Ratio as a New Index in	Nothing to Disclose
Bolivar Malachias	Marcus Vinicius	Approaches in Congenital Heart Disease Emerging Issues in CV Disease Management:	Screening Patients With Repaired Tetralogy of Fallot Economic Growth, Income and Cardiovascular Disease	CONSULTANT FEES/HONORARIA - Biolab, Novartis
Solital Malasmas	marcae vinisae	International Perspectives From the Brazilian Society of Cardiology, Turkish Society of Cardiology, and American College of Cardiology	Economic States, mostly data discussion and states and	Corporation,Sanofi-Aventis
Bolivar Malachias	Marcus Vinicius	Global Perspectives in the Treatment of ST Elevation Myocardial Infarction: Successes, Failures, and Challenges	STEMI Telemedicine in the Tropics: The Brazilian Experience	CONSULTANT FEES/HONORARIA - Biolab, Novartis Corporation, Sanofi-Aventis
Bolling	Steven	Surgical Therapies for Heart Failure Patients: Stage A-C	Panelist	CONSULTANT FEES/HONORARIA - Abbott, Medtronics, Sorin; OTHER - Edwards, Millipede
Bolling	Steven	Surgical Therapies for Heart Failure Patients: Stage A-C	Debate Pro: Mitral Valve Surgery Should Always Be Considered for the Patient with Reduced Ejection Fraction	CONSULTANT FEES/HONORARIA - Abbott, Medtronics, Sorin; OTHER - Edwards, Millipede
Bolling	Steven	The Tricuspid Valve: The New Frontier	Tricuspid Valve Repair: Risks, Benefits, and Opportunities in Surgical and Percutaneous Options	OTHER - Edwards, Millipede CONSULTANT FEES/HONORARIA - Abbott, Medtronics, Sorin; OTHER - Edwards, Millipede
Bolling	Steven	The Forgotten Valves: Therapies for Triscuspid and Pulmonic Valve	Pulmonic Stenosis and Regurgitation: When to Fix and Why?	CONSULTANT FEES/HONORARIA - Abbott, Medtronics, Sorin; OTHER - Edwards, Millipede
Bolling	Steven	The Tricuspid Valve: Not Forgotten, Just	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott, Medtronics, Sorin;
Bolling	Steven	Misunderstood 24. Interventional Cardiology: Mitral and	Suggested Reviewer	OTHER - Edwards, Millipede CONSULTANT FEES/HONORARIA - Abbott, Medtronics, Sorin;
Bollmann	Andreas	Structural Heart Disease Team 2 Atrial Fibrillation and VT: Specific Situations	Cardiac Magnetic Resonance Imaging After Radiofrequency	OTHER - Edwards,Millipede Nothing to Disclose
Bolog	Mihaela	and Newer Outcome Measures Novel Echocardiographic Methods for	Ablation of Ventricular Arrhythmias in Human Patients: Defining the Substrate and Visualizing the Outcome Cut Off Value of Rest Left Ventricular Global Longitudinal Strain Is	Nothing to Disclose
		Assessing Cardiac Function	Important in Selecting High Risk Patients With Stable Symptoms and Normal Left Ventricular Systolic Function	
Bommana	Sudharani	Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	Peri-Procedural Use of Novel Oral Anticoagulation Agents During Cardiac Device Implantation: Are They Safe?	Nothing to Disclose

Control of the Contro				
Last Name Bommana	First Name Sudharani	Session Title Arrhythmias and Clinical EP: Devices 1	Presentation Title Implantable Cardioverter Defibrillator for the Prevention of Mortality	Disclosures Nothing to Disclose
Boninana	Oddinarani	Annythmas and Simical Et . Devices 1	in Non-Ischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Bommana	Sudharani	Arrhythmias and Clinical EP: Devices 1	Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients Undergoing Cardiac Implantable Electronic Device Implantation: A Meta-Analysis	Nothing to Disclose
Bommana	Sudharani	Arrhythmias and Clinical EP: Devices 2	Real World Battery Longevity of St. Jude Medical Implantable Cardioverter-Defibrillators Included in the Advisory for Premature Battery Depletion	Nothing to Disclose
Bommana	Sudharani	Atrial Fibrillation and VT: Unique Populations and Solutions	Use of an Esophageal Retractor to Prevent Thermal Injuries During Atrial Fibrillation Ablation: A Multi-Center Experience	Nothing to Disclose
Bommana	Sudharani	Atrial Fibrillation and VT: Unique Populations and Solutions	Sotatol Versus Other Anti-Arrhythmic Medications for Cardioversion of Atrial Fibrillation and Maintenance of Sinus Rhythm: Meta-Analysis of Randomized Controlled Studies	Nothing to Disclose
Bommana	Sudharani	Arrhythmias and Clinical EP: Anticoagulation Issues	Meta-Analysis on the Efficacy and Safety of New Oral Anticoagulants Compared With Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation	Nothing to Disclose
Bommana	Sudharani	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	CHADS2 Score Predicts Outcomes of Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation	Nothing to Disclose
Bommana	Sudharani	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues		Nothing to Disclose
Bommana	Sudharani	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Efficacy of Catheter Ablation of Atrial Fibrillation in the Setting of Systolic Dysfunction: A Meta-Analysis of Randomized Control Trials	Nothing to Disclose
Bommana	Sudharani	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Sotalol Versus Other Anti-Arrhythmic Agents for Prevention of Post- Operative Supraventricular Arrhythmias After Cardiac Surgery: Meta- Analysis of Randomized Controlled Studies	Nothing to Disclose
Bommana	Sudharani	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Safety Profiles of Percutaneous Left Atrial Appendage Closure Devices: An Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database From 2009 - 2016	Nothing to Disclose
Bommer	William	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Percutaneous Coronary Intervention (PCI) Outcomes and Hospital Outliers in California	SPEAKER'S BUREAU - Amgen Inc.,Boehringer Ingelheim,Bristol Meyers Squibb,Pfizer,Regeneron
Bonaca	Marc Marc	Maximally Effective Vascular Care: Vascular Collaborative Team Care in Action Meet the New LE PAD Guidelines: Case-	Case Presentation #3: Panelist	ONSULTANT FEES/HONORARIA - AstraZeneca, Bayer, Merck, Roche; RESEARCH/RESEARCH GRANTS - AstraZeneca, Bayer, Merck, Roche; RESEARCH/RESEARCH GRANTS - AstraZeneca, Beckman Coulter, Dailichi Sankyo Co Lid, Johnson and Johnson, Merck and Co, Nanosphere, Ortho- Clinical Diagnostics, Roche Diagnostics, Siemens Medical Solutions, Singulex CONSULTANT FEES/HONORARIA -
Bonaca	marc	Based Examples of Optimal Vascular Care	Medical Therapy for LE PAD: Kitchen Sink or Selective Approach?	CONSULTAIN TESE/INDIVOKARIA - AstraZeneca, Bayer, Merck, Roche; RESEARCH/RESEARCH GRANTS - AstraZeneca, Beckman Coulter, Daiichi Sankyo Co Ltd., Johnson and Johnson, Merck and Co, Nanosphere, Ortho- Clinical Diagnostics, Roche Diagnostics, Siemens Medical Solutions, Singulex
Bonaca	Marc	Test Yourself with Questions: General Cardiology Module 14	Faculty	CONSULTANT FEES/HONORARIA - AstraZeneca, Bayer, Merck, Roche; RESEARCH/RESEARCH GRANTS - AstraZeneca, Beckman Coulter, Dalichi Sankyo Co Ltd., Johnson and Johnson, Merck and Co, Nanosphere, Ortho- Clinical Diagnostics, Roche Diagnostics, Siemens Medical Solutions, Singulex
Bonaca	Marc	Vascular Medicine: Aortic and Peripheral Artery Diseases	Acute Aortic Dissection in Patients Without a History of Hypertension	CONSULTANT FEES/HONORARIA - AstraZeneca, Bayer, Merck, Roche; RESEARCH/RESEARCH GRANTS - AstraZeneca, Beckman Coulter, Daiichi Sankyo Co Ltd., Johnson and Johnson, Merck and Co, Nanosphere, Ortho- Clinical Diagnostics, Roche Diagnostics, Siemens Medical Solutions, Singulex
Bonaca	Marc	40. Vascular Medicine: Non Coronary Arterial Disease Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - AstraZeneca, Bayer, Merck, Roche; RESEARCH/RESEARCH GRANTS - AstraZeneca, Beckman Coulter, Daiichi Sankyo Co Ltd., Johnson and Johnson, Merck and Co, Nanosphere, Ortho- Clinical Diagnostics, Roche Diagnostics, Siemens Medical Solutions, Singulex
Bonafede	Machaon	Diabetes and Other Issues in Cardiovascular Prevention	Clinical Characteristics of Early Adopters of Proprotein Convertase Subtilisin/Kexin Type 9 inhibitors (PCSK9i)	Nothing to Disclose
Bonan	Raoul	17. Interventional Cardiology: Aortic Valve Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC
Bonan	Raoul	Interventional Challenging Cases: Team 1	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC CONSULTANT FEES/HONORARIA -
Bonello	Laurent	Recent ACS Trials: Relevance to My Daily Practice	ANTARCTIC: Platelet Monitoring in ACS	Abbott,AstraZeneca,Boston,Medicine company,MEDTRONIC,St Jude
Bonow	Robert	Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster)	Panelist	DATA SAFETY MONITORING BOARD - Harvard Clinical Research Institute; OTHER - gilead, JAMA
Bonow	Robert	Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster)	Asymptomatic Aortic Valvular Stenosis Diagnostic Approaches and Therapeutic Strategies b> (LF,LG,LEF) Therapeutic Strategies Therapeutic Strategies Therapeutic Strategies Asymptomatic Aortic Valvular Stenosis Diagnostic Approaches and Therapeutic Strategies	DATA SAFETY MONITORING BOARD - Harvard Clinical Research Institute; OTHER - gilead, JAMA
Bonow	Robert	FIT Forum: Mix and Mingle	Imaging	DATA SAFETY MONITORING BOARD - Harvard Clinical Research Institute; OTHER - gilead, JAMA
Bonow	Robert	Late-Breaking Clinical Trials: Deep Dive I	Panelist	DATA SAFETY MONITORING BOARD - Harvard Clinical Research Institute; OTHER - gilead, JAMA
Bonow	Robert	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Panelist	DATA SAFETY MONITORING BOARD - Harvard Clinical Research Institute; OTHER - gilead, JAMA
Bonow	Robert	TAVR Changing the Paradigm for the Treatment of Valve Disease	Panelist	DATA SAFETY MONITORING BOARD - Harvard Clinical Research Institute; OTHER - gilead, JAMA
Bonow	Robert	TAVR Changing the Paradigm for the Treatment of Valve Disease	Update of the ACC AUC for Aortic Stenosis	DATA SAFETY MONITORING BOARD - Harvard Clinical Research Institute; OTHER - gilead, JAMA
Bonow	Robert	Valvular Heart Disease Guidelines The Evidence and the Gaps	What Changed? - The Scope of the VHD Focused Update: BAV/Aortopathy	DATA SAFETY MONITORING BOARD - Harvard Clinical Research Institute; OTHER - qilead, JAMA
Bonow	Robert	Prosthetic Valve Assessment: Real or Illusion?	Co-Chair	DATA SAFETY MONITORING BOARD - Harvard Clinical Research Institute; OTHER - gilead, JAMA
Bonow	Robert	Prosthetic Valve Assessment: Real or Illusion?	Review of ACC Guidelines for Prosthetic Valve Disease	DATA SAFETY MONITORING BOARD - Harvard Clinical Research Institute; OTHER - gilead, JAMA
Bonow	Robert	37. Valvular Heart Disease: Therapy Team 1	Suggested Reviewer	DATA SAFETY MONITORING BOARD - Harvard Clinical Research Institute; OTHER - gilead, JAMA
Book	Wendy	Five Controversies in Single Ventricle Management	Vasodilator Therapy Should be Used Routinely in Fontan Patients	Nothing to Disclose
Book	Wendy	Fontan in the Modern World	Towards a Better Predictive Model of Adverse Events in Adult Fontan Patients	Nothing to Disclose
Book Book	Wendy Wendy	Redefining the "F" Word Redefining the "F" Word	Biomarker Profile in Adults With Fontan Circulation Adults With Congenital Heart Disease: Lost in Care	Nothing to Disclose Nothing to Disclose
Book	Wendy	Congenital Heart Disease: To the Third Decade and Beyond	Red Blood Cell Distribution Width and Outcomes in Fontan Patients	Nothing to Disclose
	1	Decade and DeyONG	i	

and a				
Last Name Book	First Name Wendy	Session Title Congenital Heart Disease: To the Third	Presentation Title Prevalence and Incidence of Heart Failure in Adolescents and	Disclosures Nothing to Disclose
	·	Decade and Beyond Considerations in Antiplatelet Therapy and in	Adults With Repaired Tetralogy of Fallot	-
Booker	Jeff	ACS	Effects of Ticagrelor Versus Clopidogrel in Fibrinolytic-Treated STEMI Patients Undergoing Early PCI	Nothing to Disclose
Boppana	Venkata Subbarao	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Management of Pulmonary Artery Graft Occlusion Using High Performance Coronary Equipment	Nothing to Disclose
Borden	William	How to Redesign a Care Delivery Team in Preparation for MACRA and MIPS	Panelist	Nothing to Disclose
Borden	William	How to Redesign a Care Delivery Team in Preparation for MACRA and MIPS	The Perspective of the Practicing Cardiologist	Nothing to Disclose
Borden	William	33. Prevention: Hypertension Team 2	Suggested Reviewer	Nothing to Disclose
Border	William	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Does Tricuspid Annular Plane Systolic Excursion (TAPSE) Adequately Describe Right Ventricular Function in Hypoplastic Left Heart Syndrome?	Nothing to Disclose
Border	William	Therapeutic Advances in Congenital Heart Disease	Improved Exercise Performance in Pediatric Fontan Patients After Cardiac Rehabilitation	Nothing to Disclose
Borer	Jeffrey	Disease The Spectrum of Aortic Regurgitation and Aortic Pathology	Co-Chair	CONSULTANT FEES/HONORARIA - Amgen ARMGO gillead, Karger AG (publisher), Laboratoires Servier, Novartis, Sarepta; DATA SAFETY MONITORING BOARD - GlaxoSmithKline; OTHER - AstraZeneca Pharmaceuticals, Pfizer, Takeda; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Biomarin
Borer	Jeffrey	The Spectrum of Aortic Regurgitation and Aortic Pathology	Review of Guidelines: When to Intervene on Aortic Regurgitation	CONSULTANT FEES/HONORARIA - Amgen, ARMGO, Igliead, Karger AG (publisher), Laboratoires Servier, Novartis, Sarepta; DATA SAFETY MONITORING BOARD - GlaxoSmithKline; OTHER - AstraZeneca Pharmaceuticals, Pfizer, Takeda; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Biomarin
Borger	Michael	Transcatheter Mitral Valve Repair	Neochord Chordal Replacement: Case and Overview	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,MEDTRONIC,St. Jude Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Borger	Michael	Mitral Valve Guidelines: Closing Knowledge Gaps	How Should We Be Treating Secondary MR in 2017?	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,MEDTRONIC,St. Jude Medical;
Borger	Michael	17. Interventional Cardiology: Aortic Valve Disease Team 1	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences CONSULTANT FEES/HONORARIA - Edwards Lifesciences.MEDTRONIC.St. Jude Medical:
Borges-Neto	Salvador	Nuclear Cardiology: Prognosis	The Prognostic Value of Diastolic and Systolic Mechanical Left Ventricular Dyssynchrony Among Patients With Coronary Heart	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences SPEAKER'S BUREAU - GE Health
Borkon	A. Michael	Vascular Access and Hemostasis Issues	Disease TAVR Using Transcarotid Vascular Access: In-Hospital and	Nothing to Disclose
Borkon	A. Michael	Interventional Cardiology: TAVR 3	Intermediate Term Outcomes Prosthetic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter	Nothing to Disclose
Borlaug	Barry	The Nuts and Bolts of Pulmonary Hypertension in Left Heart Disease	Valve-in-Valve Implantation Panelist	CONSULTANT FEES/HONORARIA - Amgen,Merck; RESEARCH/RESEARCH GRANTS - Aires
Borlaug	Barry	The Nuts and Bolts of Pulmonary Hypertension in Left Heart Disease	Prevalence of pulmonary HTN in HFpEF: How Much of a Problem Is It?	Pharmaceuticals, GlaxoSmithKline, MEDTRONIC CONSULTANT FEES/HONORARIA - Amgen, Merck; RESEARCH/RESEARCH GRANTS - Aires Pharmaceuticals, GlaxoSmithKline, MEDTRONIC
Borlaug	Barry	Emerging Developments in HFpEF and Arryhthmias	The Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: An Invasive-Echocardiographic Study	CONSULTANT FEES/HONORARIA - Amgen,Merck; RESEARCH/RESEARCH GRANTS - Aires Pharmaceuticals,GlaxoSmithKline,MEDTRONIC
Borlaug	Barry	Emerging Developments in HFpEF and Arryhthmias	Arterial Reserve Limitations in Heart Failure With Preserved Ejection Fraction and the Beneficial Effects of Sodium Nitrite	CONSULTANT FEES/HONORARIA - Amgen,Merck; RESEARCH/RESEARCH GRANTS - Aires Pharmaceuticals,GlaxoSmithKline,MEDTRONIC
Borlaug	Barry	Emerging Developments in HFpEF and Arryhthmias	Utility of Cardiopulmonary Exercise Testing to Diagnose and Phenotype Heart Failure With Preserved Ejection Fraction	CONSULTANT FEES/HONORARIA - Amgen,Merck; RESEARCH/RESEARCH GRANTS - Aires Pharmaceuticals,GlaxoSmithKline,MEDTRONIC
Borlaug	Barry	The Old and the New: Impact of Heart Failure Drug Therapies	Liraglutide and Weight Loss Among Patients With Advanced Heart Failure and a Reduced Ejection Fraction: Insights From the FIGHT Trial	CONSULTANT FEES/HONORARIA - Amgen,Merck; RESEARCH/RESEARCH GRANTS - Aires Pharmaceuticals,GlaxoSmithKline,MEDTRONIC
Borne	Ryan	Atrial Fibrillation and VT: Unique Populations and Solutions	Presence of Mid-Myocardial Substrate Is Associated With Need for Multiple Ablations in Patients With Non-Ischemic Cardiomyopathy and Ventricular Arrhythmias	Nothing to Disclose
Bortnick	Anna	Interventional Cardiology: TAVR 2	Association of Chronic Renal Insufficiency With In-Hospital Outcomes of Transcatheter Aortic Valve Replacement	Nothing to Disclose
Bortnick	Anna	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Sex Differences in Revascularization and In-Hospital Outcomes of Non-ST-Segment Elevation Myocardial Infarction in the United	Nothing to Disclose
Bortnick	Anna	Syndrome Interventional Cardiology: TAVR 3	States Regional Variations in In-Hospital Outcomes and Healthcare Resource Utilization in Patients Undergoing Transcatheter Aortic Valve Replacement in the United States	Nothing to Disclose
Bortnick	Anna	Antithrombotic Therapy in Ischemic Heart Disease	Role of Anticoagulation Therapy After Anterior Wall ST-Elevation Myocardial Infraction in Preventing LV Thrombus: A Meta-Analysis and Meta-Regression	Nothing to Disclose
Bortnick	Anna	Optimizing the Care of ACS Patients	Weekend Versus Weekday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide Analysis	Nothing to Disclose
Bortnick	Anna	19. Interventional Cardiology: Complex Patients/Comorbidities Team 1	Analysis Suggested Reviewer	Nothing to Disclose
Bortone	Alessandro	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Admission Plasma Glucose Level on Myocardial Perfusion in St-Segment Elevation Myocardial Infarction (STEMI) Patients	Nothing to Disclose
Bortone	Alessandro	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Time Related Benefit of Antiplatelet Therapy on Coronary Reperfusion in ST-Elevation Myocardial Infarction (STEMI) Patients	Nothing to Disclose
Borzak	Steven	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Electromechanical Activation Time via HemoTag and 2D Echocardiography: Correlation With Tricuspid Regurgitation Peak Velocity and Implications for Diagnosis and Clinical Practice	Nothing to Disclose
Bose	Rupan	Diabetes and Other Issues in Cardiovascular Prevention	Insulin Resistance Associates With Adverse Cardiac Remodeling in the Absence of Hypertension in Young South Asians	Nothing to Disclose
Bossard	Matthias	Novel Developments in Acute Coronary Syndromes	Utility of Unfractionated Heparin in Transradial Cardiac Catheterization: A Systematic Review and Meta-Analysis of Randomized Studies	Nothing to Disclose
Bossard	Matthias	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Mineralocorticoid Receptor Antagonists in Patients With Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Trials	Nothing to Disclose
Bossone	Eduardo	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Influence of Family History of Aortic Disease on Type B Aortic Dissection	Nothing to Disclose
Bossone	Eduardo	Vascular Medicine: Aortic and Peripheral	Predictive Factors for Rapid Aortic Growth Following Acute Type A	Nothing to Disclose
		Artery Diseases	Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection	



and a				
Bossone	First Name Eduardo	Session Title Vascular Medicine: Aortic and Peripheral	Presentation Title Acute Aortic Dissection in Patients Without a History of Hypertension	Disclosures Nothing to Disclose
Bossone Botker	Eduardo Hans	Artery Diseases 28. Non Invasive Imaging: Echo Team 5 Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Suggested Reviewer Risk Stratification of Patients Suspected of Coronary Artery Disease Using an Acoustic Detection Algorithm	Nothing to Disclose CONSULTANT FEES/HONORARIA - CellAegis
Botker	Hans	Coronary Artery Disease Novel Imaging and Therapies in Heart Failure	Effect of Paroxetine Treatment on Left Ventricular Remodeling in an In Vivo Rat Model of Myocardial Infarction	CONSULTANT FEES/HONORARIA - CellAegis
Botker	Hans	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Cardiac Myosin-Binding Protein C as Alternative to Cardiac Troponin T for the Diagnosis of Acute Myocardial Infarction in the Very Early Phase	CONSULTANT FEES/HONORARIA - CellAegis
Bouchelouche	Kirsten	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Prognostic Value of Coronary Computed Tomography Angiography, Myocardial Perfusion Imaging and Invasive Coronary Angiography in Kidney Transplantation Candidates: A Prospective Cohort Study	Nothing to Disclose
Boudoulas	Konstantinos	Core Curriculum: Revascularization in Special Populations	Optimal Revascularization of the Diabetic Patient with CAD	CONSULTANT FEES/HONORARIA - GE Healthcare
Bouhzam	Najime	Interventional Cardiology: TAVR 4	Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital	Nothing to Disclose
Boura	Judith	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Is There an Association Between Vitamin D Deficiency and Disease Severity on Coronary CT Angiography?	Nothing to Disclose
Boura	Judith	Non Invasive Imaging: Expanding Clinical Applications	Are There Sex Differences in Management of Coronary Artery Disease After Coronary CT Angiography?	Nothing to Disclose
Boura	Judith	Which Test Is Best for Pain in the Chest?	Coronary CT Angiography in the Emergency Department Provides an Opportune Window for Initiation of Evidence-Based Medical Therapy	Nothing to Disclose
Bourge	Robert	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	High Procedural and Device Related Success With the CardioMEMS HF System for Heart Failure: Observations From the CardioMEMS™ Post Approval Study	CONSULTANT FEES/HONORARIA - CardioMEMS, St. Jude Medical, Gilead, United Therapeutics; OTHER - United Therapeutics; RESEARCH/RESEARCH GRANTS - Medtronic, CardioMEMS, United Therapeutics, Novartis, Bayer, Gilead, Actelion
Bourge	Robert	35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - CardioMEMS, St. Jude Medical, Gilead, United Therapeutics; OTHER. United Therapeutics; RESEARCH/RESEARCH GRANTS - Meditronic, CardioMEMS, United Therapeutics, Novartis, Bayer, Gilead, Actelion
Bourouki	Evgenia	MicroRNAs and Beyond in Vascular Medicine	Association of Endothelial Dysfunction and Arterial Wall Elastic Properties With Systemic Inflammation in Patients With Pseudoexfoliative Glaucoma	Nothing to Disclose
Bourque	Jamieson	Blips, Trops, and Chips: New Ways to Diagnose CAD	Incremental Diagnostic Accuracy of High Frequency QRS Analysis Over ST-Analysis for Myocardial Ischemia: Multi-Center Prospective Cohort	RESEARCH/RESEARCH GRANTS - Astellas Pharma US
Boutagy	Nabil	Non Invasive Imaging: Expanding Clinical Applications	Computed Tomographic Angiography Can Reliably Assess Epicardial Coronary Vasoreactivity in Response to Adenosine and Dobutamine	Nothing to Disclose
Bove	Alfred	Resistant Hypertension in the Pulmonary and Systemic Beds: International Perspectives From the ACC Argentina Chapter, Korean Society of Cardiology, and American College of Cardiology	Co-Chair	CONSULTANT FEES/HONORARIA - Elsevier publishing Co,Insight Telehealth Inc,Merck Manual; CWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Insight Telehealth, LLC; RESEARCH/RESEARCH GRANTS - Merck Shering Plough
Bove	Alfred	Resistant Hypertension in the Pulmonary and Systemic Beds: International Perspectives From the ACC Argentina Chapter, Korean Society of Cardiology, and American College of Cardiology	introduction to Session	CONSULTANT FEES/HONORARIA - Elsevier publishing Co,Insight Telehealth Inc,Merck Manual; CWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Insight Telehealth, LLC; RESEARCH/RESEARCH GRANTS - Merck Shering Plough
Bove	Alfred	Engage @ ACC.17 Studio: Cardiology Contest	Cardiology Contestant	CONSULTANT FEES/HONORARIA - Elsevier publishing Co,Insight Teleheath inc,Merck Manual; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Insight Telehealth, LLC; RESEARCH/RESEARCH GRANTS - Merck Shering Plough
Bowdish	Michael	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic Surgical Trials Network	RESEARCH/RESEARCH GRANTS - HeartWare,MEDTRONIC
Bowman	Jessica	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Utility of Genetic Testing in Infants With Isolated Congenital Heart Disease	Nothing to Disclose
Boyd	Jack	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		Nothing to Disclose
Boyd	Jack	Engage @ ACC.17 Studio: Heart Teams in Action: Complex Coronary Revascularization	Stanford Surgeon	Nothing to Disclose
Boyd Boyd	Jack Jack	Can CABG Patch CAD? Can CABG Patch CAD?	ACC Poster Moderator Effectiveness of a Second Arterial Conduit for Multi Vessel Coronary	Nothing to Disclose Nothing to Disclose
Boyle	Noel	Ventricular Arrhythmias in the Coronary Care Unit: Contemporary Solutions to an Old	Bypass: A State-Wide Analysis of 60,897 Patients Role of Autonomic Intervention in the Coronary Care Unit	CONSULTANT FEES/HONORARIA - Boston Scientific,St. Jude Medical; SPEAKER'S BUREAU - Janssen Pharmaceuticals, Inc
Boyle	Noel	Problem Arrhythmias and Clinical EP: Devices 3	Safety of Cardiac Magnetic Resonance Imaging With Non-	CONSULTANT FEES/HONORARIA - Boston Scientific,St. Jude
Boyle	Noel	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Conditional Cardiac Implantable Electronic Devices Suggested Reviewer	Medical; SPEAKER'S BUREAU - Janssen Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boston Scientific,St. Jude Medical; SPEAKER'S BUREAU - Janssen Pharmaceuticals, Inc
Bozkurt	Biykem	Teaching with Intent: Secrets from the Masters	Panelist	Nothing to Disclose
Bozkurt	Biykem	Teaching with Intent: Secrets from the Masters	360 Degree Feedback Session (Attending)	Nothing to Disclose
Bozkurt Bozkurt	Biykem Biykem	Featured Clinical Research III Update in ACHD: The Time for Change is Now	Panelist ACHD Guideline Highlights: Review of Class I Recommendations in	Nothing to Disclose Nothing to Disclose
Bozkurt	Biykem	Recognition of Specific Etiologies and	the Updated ACHD Guidelines Panelist	Nothing to Disclose
		Phenotypes in Heart Failure: Time for Precision		-
Bozkurt	Biykem	Recognition of Specific Etiologies and Phenotypes in Heart Failure: Time for Precision	Etiology of Cardiomyopathy Matters: One Treatment Does not Fit All	-
Bozkurt	Biykem	Next Steps to Optimal Medical Therapy for Heart Failure Patients	Heart Failure Case Challenges	Nothing to Disclose
Bozkurt	Biykem	13. Heart Failure and Cardiomyopathies: Clinical Team 8	Suggested Reviewer	Nothing to Disclose
Brachmann	Johannes	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Increased Rate of Previous Stroke in Asymptomatic/Minimally Symptomatic Versus Symptomatic Patients With Newly Detected Atrial Fibrillation Worldwide: Results From the GLORIA-AF Registry	RESEARCH/RESEARCH GRANTS - St. Jude Medical; SPEAKER'S BUREAU - Biotronik
Bradford	Natalie	Arrhythmias and Clinical EP: Devices 2	AngioVac Cannula for Management of Device Related Vegetative	Nothing to Disclose
L	l	l	Growth	



Last Name Bradham				
Braunam		Session Title	Presentation Title Spontaneous Purulent Pericarditis Due to Methicillin-Resistant	Disclosures
1	William	Interdisciplinary Cardiovascular Care in Complex Scenarios	Staphylococcus Aureus: A Case Report and Discussion	Nothing to Disclose
Bradley	Andrew	Non Invasive Imaging: MR Heart Failure and	Cardiovascular Magnetic Resonance in the Evaluation of Fibrofatty	Nothing to Disclose
		Pulmonary Hypertension	Infiltration for Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C)	
Bradley	Elisa	Coarctation of the Aorta, from Repair to	Case Presentation: Exercise Hypertension	Nothing to Disclose
	Er.	Lifelong Care		Note: A District
Bradley	Elisa	Adult Patients With Congenital Heart Disease: How Do They Compare?	Obstructive Sleep Apnea in Adult Congenital Heart Disease: Who Is at Risk?	Nothing to Disclose
Bradley	Elisa	Understanding Pulmonary Vascular Disease:	Potential Mediators of Right Heart Failure in Pulmonary Arterial	Nothing to Disclose
Bradley	Steven	From Bench to Bedside What is the PROMISE of ISCHEMIA: A 2017	Hypertension Douglas P. Zipes, MD, MACC, Distinguished Young Scientist	Nothing to Disclose
bradiey	Steven	Update on Stable Angina and the Douglas P.	Lecture: Ensuring Patients Receive the Right Therapy at the Right	Nothing to Disclose
		Zipes, MD, MACC, Distinguished Young	Time	
Bradley	Steven	Scientist Awardee Lecture Current Issues in Cardiovascular	A Retrospective Descriptive Analysis of PCI Patients by Indication for	Nothing to Disclose
		Epidemiology, Disparities, and Safety	Treatment, Comorbidities, and Lipid Therapy Using Real-World,	-
Brady	Peter	Quickfire ECG for Experts	Linked NCDR Registry and Pharmacy Claims Data Co-Chair	Nothing to Disclose
Brady	Peter	Controversies in Device Therapy	Co-Chair	Nothing to Disclose
Brady	Peter	Syncope: Challenges and Pitfalls: A Case- based Approach	Co-Chair	Nothing to Disclose
Brady	Peter	Test Yourself with Questions: Guidelines	Faculty	Nothing to Disclose
Drody	Dator	Module 3: Atrial Fibrillation	Co-Chair	Nothing to Disclose
Brady	Peter	Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	Co-Criaii	Nothing to Disclose
Brady	Peter	FIT Clinical Decision Making: Arrhythmias and	Syncope With Phenytoin: Sometimes It's Not a Seizure!	Nothing to Disclose
Brady	Peter	Electrophysiology ECG Screening and Risk Prediction	Wolff-Parkinson-White Pattern and Sudden Cardiac Death: A	Nothing to Disclose
Siddy	. 0.0.	200 oor oor mig and receive rounds	Retrospective Cohort Community Study From Olmsted County,	realing to Biocioco
Brady	Peter	05. Arrhythmias and Clinical EP: Devices	Minnesota Suggested Reviewer	Nothing to Disclose
Drauy	1 0101	Team 1		Housing to Disclose
Braghiroli	Joao	Innovative Approaches for Reducing Risk and	Endo-Epicardial Versus Endocardial-Only Approach for First	Nothing to Disclose
		Improving Outcomes With Ablation	Ventricular Tachycardia Ablation: A Systematic Review and Meta- Analysis of Safety and Efficacy Outcomes	
Brainin	Philip	Innovative Use of Echocardiography	Presence of Post-Systolic Shortening by Tissue Doppler Imaging is	Nothing to Disclose
	i		an Independent Predictor of Heart Failure in Patients Following ST- Segment Elevation Myocardial Infarction	
Branch	Kelley	FIT Clinical Decision Making: Non-Invasive	B-Cell Lymphoma Associated Pericardial Tamponade With	RESEARCH/RESEARCH GRANTS - Bayer
Desark	Kallan	Imaging and Valvular Heart Disease	Conversion to Chylous Effusion During Pregnancy	RESEARCH/RESEARCH GRANTS - Bayer
Branch Branch	Kelley Kelley	Which Test Is Best for Pain in the Chest? 27. Non Invasive Imaging: CT/Multimodality,	ACC Poster Moderator Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Bayer
	1	Angiography, and Non-CT Angiography Team		•
Brandani	Laura	Resistant Hypertension in the Pulmonary and	Resistant Hypertension: A Diagnostic and Therapeutic Challenge	Nothing to Disclose
Brandani	Ladia	Systemic Beds: International Perspectives	Treeseast Type telleles. A Bagileese and The apeals chameinge	ricaling to Biodicco
		From the ACC Argentina Chapter, Korean Society of Cardiology, and American College		
		of Cardiology		
Brandt	Eric	Advances in Cholesterol Measurement and	The Effect of PCSK9 Inhibition on Sterol Absorption in a Cohort of	Nothing to Disclose
Brandt	Roland	Management 36. Valvular Heart Disease: Clinical Team 2	Real World Patients Suggested Reviewer	SPEAKER'S BUREAU - Philips Medical Systems,St. Jude
Brar	Somjot	Percutaneous Coronary Intervention: Lessons	ACC Poster Moderator	Nothing to Disclose
Brass	Neil	From the Real World Cardiac Arrest, Diabetes, and Other High Risk	Real World Relationships Between Baseline Q Waves, Time From	CONSULTANT FEES/HONORARIA - Astra Zeneca
Diass	IVEII	Features of Patients With Acute Coronary	Symptom Onset and Clinical Outcomes in ST-Segment Elevation	CONSOLITANT I ELOTIONORANIA - Astra Zerieta
		Syndrome	Myocardial Infarction Patients: Insight From the Vital Heart	
Bratanoff	Margret	New Technologies in Echocardiography	Response Registry Automated Detection of Mitral Valve Annular and Leaflet Geometry:	Nothing to Disclose
_	-		Echocardiography and CT Comparison	
Braun	Daniel	Frontiers in Mitral Valve Disease and Treatment	Transcatheter Treatment of Severe Tricuspid Regurgitation Using the MitraClip System in Patients With and Without Pacemaker	CONSULTANT FEES/HONORARIA - Abbott Vascular
			Leads	
Braunwald	Eugene	Surgical Therapies for Heart Failure Patients:	Leads Co-Chair	CONSULTANT FEES/HONORARIA - Merck & Description (no
Braunwald	Eugene			compensation), The Medicines Co., Medscape, Novartis
Braunwald	Eugene	Surgical Therapies for Heart Failure Patients:		compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance, RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Daiichi Sankyo,
		Surgical Therapies for Heart Failure Patients: Stage A-C	Co-Chair	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & amp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis
Braunwald Braunwald	Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & mp; amp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONORARIA - Merck & mp; amp; co (no compensation), The Medicines Co., Medscape, Novartis
		Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Bampanp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONORARIA - Merck & Bamp; amp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH
		Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & mp; amp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONORARIA - Merck & mp; amp; co (no compensation), The Medicines Co., Medscape, Novartis
		Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First	compensation). The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDRARIA - Merck & Degramp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDRARIA - Merck & Degramp; Co (no CONSULTANT FEES/HONDRARIA - Merck & Degramp; Co (no
Braunwald	Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & mp.amp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHONDRARIA - Merck & mp.amp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & amp; amp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDRARIA - Merck & amp; amp; co. (no compensation), The Medicines Co., Medscape, Novartis
Braunwald	Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARIAL - Merck & Degramp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDRARIAL - Merck & Degramp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Grant Start Zeneca, Merck & Degramp; Co., Dalichi Sankyo, GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo,
Braunwald Braunwald	Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp, Co., Daiichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHONDRARIA - Merck & Degramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Daiichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDRARIA - Merck & Degramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Daiichi Sankyo, Glaxo Smith Kline, Duke University and Novartis
Braunwald	Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARIAL - Merck & Degramp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDRARIAL - Merck & Degramp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Grant Start Zeneca, Merck & Degramp; Co., Dalichi Sankyo, GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo,
Braunwald Braunwald	Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Traditional and Novel Factors Used to Assess	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial Cystatin C Is Associated With the Risk of Adverse Outcomes	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Dengramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONORARIA - Merck & Dengramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Dengramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONORARIA - Merck & Dengramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Dengramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONORARIA - Merck & Dengramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore; RESEARCH/RESEARCH (Uncompensated), and Theravanore; RESEARCH/RESEARCH (Uncompensated), and Theravanore; RESEARCH/RESEARCH
Braunwald Braunwald	Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial Cystatin C Is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp, Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAIR - Merck & Jampamp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp, Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAIR - Merck & Jampamp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDRARIA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (CONSULTANT FEES/HONDRARIA - Merck & Jampamp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Jampamp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo,
Braunwald Braunwald	Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Atrial Fibrillation and VT: Unique Populations	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial Cystatin C Is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial Outcomes of Asian Patients With Atrial Fibrillation Compared to Non-	compensation). The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHONOPARIA - Merck & Degramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHONOPARIA - Merck & Degramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHONOPARIA - Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (CONSULTANT FEESHONOPARIA - Merck & Degramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (CONSULTANT FEESHONOPARIA - Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (CONSULTANT FEESHONOPARIA) and Novartis (CONSULTANT FEESHONOPARIA).
Braunwald Braunwald Braunwald	Eugene Eugene Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial Cystatin C Is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp, Co., Daiichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDRARIA - Merck & Degramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Daiichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDRARIA - Merck & Degramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Degramp; Co., Daiichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDRARIA - Merck & Degramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Degramp; Co., Daiichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Degramp; Co., Daiichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (CONSULTANT FEES/HONDRARIA - Merck & Daiichi Sankyo, Glaxo Smith Kline, Duke University and Novartis
Braunwald Braunwald Braunwald	Eugene Eugene Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Atrial Fibrillation and VT: Unique Populations	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial Cystatin C Is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial Outcomes of Asian Patients With Atrial Fibrillation Compared to Non-	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp, Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAILA - Merck & Jampamp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAILA - Merck & Jampamp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAILA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (CONSULTANT FEES/HONDARAILA - Merck & Jampamp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo,
Braunwald Braunwald Braunwald Braunwald	Eugene Eugene Eugene Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Atrial Fibrillation and VT: Unique Populations and Solutions	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial Cystatin C Is Associated With the Risk of Adverse Outcomes Independent of Setablished and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial Outcomes of Asian Patients With Atrial Fibrillation Compared to Non-Asians in the ENGAGE AF-TIMI 48 Trial	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore, RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Description (Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (CONSULTANT FEES/HONO/RARIA - Merck & Description), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore, RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Description), Concompensation), The Medicines Co., Medscape, Novartis (CONSULTANT FEES/HONORARIA - Merck & Description), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore, RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Description), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore, RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Description), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore, RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Description), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore, RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Description), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore, RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Description), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore, RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Description), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore, RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Description), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore, RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Description), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore, RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Description), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore, RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Description), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanore, RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Description), The Medicines Co., Medscape, Novarti
Braunwald Braunwald Braunwald	Eugene Eugene Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Atrial Fibrillation and VT: Unique Populations	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial Cystatin C Is Associated With the Risk of Adverse Outcomes Independent of Setablished and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial Outcomes of Asian Patients With Atrial Fibrillation Compared to Non-Asians in the ENGAGE AF-TIMI 48 Trial	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp, Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAIA - Merck & Jampamp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp, Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAIA - Merck & Jampamp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAIA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (CONSULTANT FEES/HONDARAIA - Merck & Jampamp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo,
Braunwald Braunwald Braunwald Braunwald	Eugene Eugene Eugene Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Atrial Fibrillation and VT: Unique Populations and Solutions Post-CAD/MI: Making Tough Predictions About	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial Cystatin C Is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial Outcomes of Asian Patients With Atrial Fibrillation Compared to Non-Asians in the ENGAGE AF-TIMI 48 Trial	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Degramp; Co., Daiichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDRARIA - Merck & Degramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Daiichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (CONSULTANT FEES/HONORARIA - Merck & Degramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Daiichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (CONSULTANT FEES/HONORARIA - Merck & Degramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Degramp; Co., Daiichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Degramp; Co., Daiichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensation), The Medicines Co., Medscape, Novartis (Uncompensation), The Medicines Co., Medscape, Novartis (Uncompensation), The Medicines Co., Medscape, Novartis (Uncompensation), The Medicines Co., Medscape, Novartis (Dos Sutta), The Medicines Co., Medscape, Novartis (Uncompensation), The Medicines Co., Medscape, Novartis (Uncompensation), The Medicines Co., Medscape, Novartis (Uncompensation), The Medicines Co., Medscape, Novartis (Uncompensation), The Medicines Co., Medscape, Novartis (Uncompensation), The Medicines Co., Medscape, Novartis (Uncompensation), The Medicines Co., Medscape, Novartis (Uncompensation), The Medicines Co., Medscape, Novartis (Uncompensation), The Medicines Co., Medscape, Novartis (Uncompensation), The Medicines Co., Medscape, Novartis (Uncompensation), The Medicines Co., Medscape, Novartis (Uncompensation), The Medicines Co.
Braunwald Braunwald Braunwald Braunwald	Eugene Eugene Eugene Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Atrial Fibrillation and VT: Unique Populations and Solutions Post-CAD/MI: Making Tough Predictions About	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial Cystatin C is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial Outcomes of Asian Patients With Atrial Fibrillation Compared to Non-Asians in the ENGAGE AF-TIMI 48 Trial Risk Stratification With the TIMI Risk Score for Secondary Prevention Among Patients With Diabetes and Elevated	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHONDRARIA - Merck & Jampamp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHONDRARIA - Merck & Jampamp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHONDRARIA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHONDRARIA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (CONSULTANT FEESHONDRARIA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (CONSULTANT FEESHONDRARIA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (CONSULTANT FEESHONDRARIA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (CONSULTANT FEESHONDRARIA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (CONSULTANT FEESHONDRARIA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (CONSULTANT FEESHONDRARIA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Unicompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Ja
Braunwald Braunwald Braunwald Braunwald	Eugene Eugene Eugene Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Atrial Fibrillation and VT: Unique Populations and Solutions Post-CAD/MI: Making Tough Predictions About	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial Cystatin C Is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial Outcomes of Asian Patients With Atrial Fibrillation Compared to Non-Asians in the ENGAGE AF-TIMI 48 Trial Risk Stratification With the TIMI Risk Score for Secondary Prevention Among Patients With Diabetes and Elevated Cardiovascular Risk Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation	compensation). The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHROUPARIA. Amerck & Degramp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHROUPARIA. Amerck & Degramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHROUPARIAL. Amerck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHROUPARIAL. Amerck & Degramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHROUPARIAL. Amerck & Degramp; Co. (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHROUPARIAL. Amerck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHROUPARIAL on Movartis CONSULTANT FEESHROUPARIAL on Movartis CONSULTANT FEESHROUPARIAL on Movartis CONSULTANT FEESHROUPARIAL on Movartis CONSULTANT FEESHROUPARIAL on Movartis CONSULTANT FEESHROUPARIAL on Movartis CONSULTANT FEESHROUPARIAL Amerck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHROUPARANCE; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Degramp; Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEESHROUPARIAL Amerck & Degramp; Co.,
Braunwald Braunwald Braunwald Braunwald Braunwald	Eugene Eugene Eugene Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Atrial Fibrillation and VT: Unique Populations and Solutions Post-CAD/MI: Making Tough Predictions About the Future	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial Cystatin C is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial Outcomes of Asian Patients With Atrial Fibrillation Compared to Non-Asians in the ENGAGE AF-TIMI 48 Trial Risk Stratification With the TIMI Risk Score for Secondary Prevention Among Patients With Diabetes and Elevated Cardiovascular Risk Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Active Malignancy: An Analysis of ENGAGE AF-Timi 48	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravanoe; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Despension of Consultant FEESHONO/RARIA - Merck & Despension of Consultant FEESHONO/RARIA - Merck & Despension of Consultant FEESHONO/RARIA - Merck & Despension of Consultant FEESHONO/RARIA - Merck & Despension of Consultant States of Consultant State
Braunwald Braunwald Braunwald Braunwald Braunwald	Eugene Eugene Eugene Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Atrial Fibrillation and VT: Unique Populations and Solutions Post-CAD/MI: Making Tough Predictions About the Future	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial Cystatin C Is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial Outcomes of Asian Patients With Atrial Fibrillation Compared to Non-Asians in the ENGAGE AF-TIMI 48 Trial Risk Stratification With the TIMI Risk Score for Secondary Prevention Among Patients With Diabetes and Elevated Cardiovascular Risk Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAIR - Merck & Jampamp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAIR - Merck & Jampamp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAIR - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAIR - Merck & Jampamp; Co., O acompensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAIR - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAIR - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAIR - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo,
Braunwald Braunwald Braunwald Braunwald Braunwald	Eugene Eugene Eugene Eugene Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Atrial Fibrillation and VT: Unique Populations and Solutions Post-CAD/MI: Making Tough Predictions About the Future Stroke and AF: Thinking About the Heart	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial Cystatin C Is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial Outcomes of Asian Patients With Atrial Fibrillation Compared to Non-Asians in the ENGAGE AF-TIMI 48 Trial Risk Stratification With the TIMI Risk Score for Secondary Presentation Active Mailingnancy: An Analysis of ENGAGE AF - Timi 48 Randomized Clinical Trial	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Description (Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDRARIA - Merck & Description (Consultant FEES
Braunwald Braunwald Braunwald Braunwald Braunwald	Eugene Eugene Eugene Eugene	Surgical Therapies for Heart Failure Patients: Stage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Atrial Fibrillation and VT: Unique Populations and Solutions Post-CAD/MI: Making Tough Predictions About the Future	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial Cystatin C is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial Outcomes of Asian Patients With Atrial Fibrillation Compared to Non-Asians in the ENGAGE AF-TIMI 48 Trial Risk Stratification With the TIMI Risk Score for Secondary Prevention Among Patients With Diabetes and Elevated Cardiovascular Risk Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Active Malignancy: An Analysis of ENGAGE AF-Timi 48	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp, Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAILA - Merck & Jampamp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAILA - Merck & Jampamp; Co (no compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAILA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAILA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAILA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAILA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAILA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDARAILA - Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke University and Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Jampamp; Co., Daichi Sankyo, Glaxo Smith Kline, Duke Univer
Braunwald Braunwald Braunwald Braunwald Braunwald	Eugene Eugene Eugene Eugene Eugene	Surgical Therapies for Heart Failure Patients: Slage A-C Highlighted Original Research: Prevention and the Year in Review Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Atrial Fibrillation and VT: Unique Populations and Solutions Post-CAD/MI: Making Tough Predictions About the Future Stroke and AF: Thinking About the Heart The Spectrum of Aortic Regurgitation and	Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial Cystatin C Is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial Outcomes of Asian Patients With Atrial Fibrillation Compared to Non-Asians in the ENGAGE AF-TIMI 48 Trial Risk Stratification With the TIMI Risk Score for Secondary Presentation Active Mailingnancy: An Analysis of ENGAGE AF - Timi 48 Randomized Clinical Trial	compensation), The Medicines Co., Medscape, Novartis (Uncompensated), and Theravance; RESEARCH/RESEARCH (GRANTS - Astra Zeneca, Merck & Description (Co., Dalichi Sankyo, Glaxo Smith Kline, Duke University and Novartis CONSULTANT FEES/HONDRARIA - Merck & Description (Consultant FEES

0				
Last Name Braverman	First Name Alan	Session Title Vascular Medicine: Aortic and Peripheral Artery Diseases	Presentation Title Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of	Disclosures Nothing to Disclose
Braverman	Alan	Vascular Medicine: Aortic and Peripheral	Acute Aortic Dissection Uncontrolled Hypertension in Acute Aortic Dissection Follow-Up	Nothing to Disclose
Braverman	Alan	Artery Diseases Advancing Our Understanding of Aortic	ACC Poster Moderator	Nothing to Disclose
Bravo	Paco	Disease Highlighted Original Research: Non Invasive Imaging and the Year in Review	Integrating Hyperemic Myocardial Blood Flow and Coronary Flow Reserve for Predicting Cardiovascular Mortality Outcomes in	Nothing to Disclose
Bravo	Paco	Nuclear Cardiology: Prognosis	Patients With Known or Suspected Ischemic Heart Disease Myocardial Scar but Not Ischemia Predicts Defibrillator Shocks and Sudden Cardiac Death in Patients With Reduced Left Ventricular	Nothing to Disclose
Bravo	Paco	Noninvasive Assessment of Coronary Flow	Ejection Fraction Relationship of Coronary Flow Reserve With Body Mass Index and	Nothing to Disclose
		Reserve: Clinical Implications	Adverse Outcomes in Patients Without Overt Ischemic Heart Disease: Implications for Metabolic Surgery Eligibility	-
Bravo	Paco	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Association Between Coronary Flow Reserve and Adverse Cardiovascular Events Along a Continuum of Metabolic Disease in Symptomatic Patients Without Overt Coronary Artery Disease	Nothing to Disclose
Brawner	Clinton	Non Invasive Imaging: Role of Exercise Testing	Using Machine Learning to Define the Association Between Cardiorespiratory Fitness and All-Cause Mortality: The FIT (Henry Ford Exercise Testing) Project	Nothing to Disclose
Brawner	Clinton	Risky Business: Predicting Outcomes in Heart Failure	Chronotropic Incompetence and Long-Term Risk of Heart Failure: The Henry Ford Exercise Testing Project	Nothing to Disclose
Breathett	Khadijah	Advances in HCM, PPCM and Other	Systemic Arterial Pulsatility Index (SAPi) Predicts Adverse Outcomes in Advanced Heart Failure Patients	Nothing to Disclose
Brecht	Tom	Cardiomyopathies Acute Heart Failure: Evaluating Strategies to	A Simple Predictive Score for Pre-Admission Identification of Risk of	Nothing to Disclose
Breinholt	John	Prevent Readmissions Interventional Cardiology: Angiography, Intravascular Imaging and Interventional	30-Day Hospital Readmission or Death in Heart Failure Technique and Utility of CT Angiography Fluoroscopy Image Fusion to Guide Percutaneous Pulmonary Valve Implantation in Adults	RESEARCH/RESEARCH GRANTS - Abbott Vascular
Breinholt	John	CT/MR FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Closure of a Ventricular Septal Defect Complicated by Hemolysis Requiring Transcatheter Retrieval of Amplatzer Occluder	RESEARCH/RESEARCH GRANTS - Abbott Vascular
Breitbart	Roger	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Idiopathic Fascicular Left Ventricular Tachycardia and Dilated Cardiomyopathy: An Unusual Combination in a 19-Year-Old College	Nothing to Disclose
Breithardt	Guenter	Arrhythmias and Clinical EP: Anticoagulation Issues	Athlete Thrombolytic Therapy in Anticoagulated Patients: Case Series From Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation	CONSULTANT FEES/HONORARIA - Consultant to Bayer Health Care, J&J, Sanofi-Aventis
Bremer	Merri	Innovative Use of Echocardiography	(ROCKET AF) The Association Between Echocardiographic Laboratory	Nothing to Disclose
Bremner	Doug	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Accreditation and the Quality of Imaging and Reporting Inflammatory Response to Mental Stress and Mental Stress Induced Myocardial Ischemia	Nothing to Disclose
Brener	Sorin	Coronary Artery Disease 15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology	Suggested Reviewer	CONSULTANT FEES/HONORARIA - AstraZeneca,Daiichi Sankyo
Brener	Sorin	Team 1 Interventional Challenging Cases: Team 1	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - AstraZeneca,Daiichi
Brennan	Alice	Coronary Intervention in Interventional	Facilitation of Stent Delivery With the GuideLiner Catheter	Sankyo Nothing to Disclose
Brennan	Angela	Cardiology: Advanced Device Use Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Outcomes of Pre-Loading Versus In-Lab Loading With Prasugrel and Ticagrelor in Patients With Acute Coronary Syndromes (ACS)	Nothing to Disclose
Brennan	J. Matthew	Featured Clinical Research II: Interventional	Undergoing Percutaneous Coronary Intervention (PCI) Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis	Nothing to Disclose
Brennan	J. Matthew	Featured Clinical Research II: Interventional	From Two US Registries Linked to Medicare Data Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus	Nothing to Disclose
Brennan	J. Matthew	Late-Breaking Clinical Trials	Native Aortic Stenosis From the STS/ACC TVT Registry Comparative Effectiveness of Left Atrial Appendage Occlusion Among Atrial Fibrillation Patients Undergoing Cardiac Surgery: A Report From the Society of Thoracic Surgeons Adult Cardiac	Nothing to Disclose
Brenner	Daniel	Interventional Cardiology: TAVR 1	Surgery Database The Inflammasome Pathway Is Associated With Adverse Ventricular Remodeling Following Transcatheter Aortic Valve Replacement	Nothing to Disclose
Bress	Adam	New Insights Into Prediction and Treatment of	Cost-Effectiveness of Intensive Blood Pressure Goals in Patients	Nothing to Disclose
Breuer	Christopher	Hypertension Surgical and Transcatheter Valve Therapy for Congenital Heart Disease	With Prior Cardiovascular Disease Panelist	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Cook Biomedical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Lyst Therapeutics; RESEARCH/RESEARCH GRANTS - Gunze limited
Breuer	Christopher	Surgical and Transcatheter Valve Therapy for Congenital Heart Disease	Tissue Engineering Heart Valves for Fetuses	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Cook Biomedical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Lyst Therapeutics; RESEARCH/RESEARCH GRANTS - Gunze limited
Breuer	Christopher	Cutting Edge Vascular Medicine	Transmural Macrophage Migration in Tissue Engineered Vascular Graft Promotes Extracellular Matrix Formation for Vascular Remodeling More Than Host Circulating Inflammatory Cell Migration	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Cook Biomedical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Lyst Therapeutics; RESEARCH/RESEARCH GRANTS - Gunze limited
Briasoulis	Alexandros	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	National Trends in Admissions and In-Hospital Mortality in Heart Failure Patients and Impact of the ACC/AHA Management Guidelines: Insight From the National Inpatient Sample (NIS)	Nothing to Disclose
Briasoulis	Alexandros	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Seasonal Variation in In-Patient Mortality, Cost of Hospitalization and Length of Stay in Heart Failure Patients in the United States	Nothing to Disclose
Briasoulis	Alexandros	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Impact of Hospital Ownership on In-Patient Mortality and Cost of Hospitalization in Patients Admitted for Heart Failure: Insight From the National Inpatient Sample (NIS)	Nothing to Disclose
Briasoulis	Alexandros	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Regional Variation in Hospitalization Outcomes Among Patients Admitted for Heart Failure in the United States	Nothing to Disclose
Briasoulis	Alexandros	Interventional Cardiology: PCI and TAVR in	Economic Implications of Late Discharge After Transcatheter Aortic	Nothing to Disclose
Briasoulis	Alexandros	Complex Patients Interventional Cardiology: TAVR 3	Catheter Implantation Transcatheter Versus Surgical Aortic Valve Replacement in	Nothing to Disclose
Briasoulis	Alexandros	Emerging Developments in HFpEF and	Diabetes Mellitus: From the Nationwide Inpatient Sample Hospitalization Burden of Diastolic Heart Failure in the United	Nothing to Disclose
Briasoulis	Alexandros	Arryhthmias The Evolving World of LVADs, Transplant and Other Novel Discoveries	States: 2007-2012 Effects of Diabetes Mellitus on Clinical Outcomes After Left Ventricular Assist Device Implantation: A Single Institutional 9-Year	Nothing to Disclose
Briasoulis	Alexandros	Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools	Experience A Novel Biomarker Score for Cardiovascular Risk-Reclassification: Primary ASCVD Prevention in the Intermediate-Risk Population	Nothing to Disclose

WASHINGTON, DC | MARCH 17 - 19 2017

and the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Briasoulis	Alexandros	Advanced Therapies = Advanced Trouble:	Sirolimus-Based Immunosuppression Mitigates Progression of	Nothing to Disclose
		VAD and Transplant Challenges	Cardiac Allograft Vasculopathy and Improves Cardiac Outcomes After Heart Transplantation: A Single Center 15-Year Follow-Up Study	
Briceno	David	Antithrombotic Therapy in Ischemic Heart Disease	Role of Anticoagulation Therapy After Anterior Wall ST-Elevation Myocardial Infraction in Preventing LV Thrombus: A Meta-Analysis and Meta-Regression	Nothing to Disclose
Briceno	David	Optimizing the Care of ACS Patients	Weekend Versus Weekday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide Analysis	Nothing to Disclose
Brickner	M. Beth	Coarctation of the Aorta, from Repair to Lifelong Care	Co-Chair	Nothing to Disclose
Brieke	Andreas	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Early Recurrence of Ventricular Tachycardia Predicts Increased Mortality Among Patients With Severe Heart Failure	Nothing to Disclose
Brieke	Andreas	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Safety and Outcomes of Catheter Ablation for Treatment of Refractory Ventricular Arrhythmias in Patients With Advanced Heart Failure	Nothing to Disclose
Briffa	Tom	Advances in HCM, PPCM and Other Cardiomyopathies	Non-Familial Hypertrophic Cardiomyopathy: Prevalence, Natural History and Clinical Implications	Nothing to Disclose
Briggs	Andrew	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Modelling the U.S. Population Health Benefits of Further Low- Density Lipoprotein Cholesterol Reduction With Alirocumab Among Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia Patients With Elevated Low-Density Lipoprotein Cholesterol	Nothing to Disclose
Brigham	Kenneth	Updates on Risk Factors for Cardiovascular Disease	Central Obesity Predicts Circulating Progenitor Cell Levels	Nothing to Disclose
Brigham	Kenneth	Updates on Risk Factors for Cardiovascular Disease	Changes in Body Fat Distribution Is Associated With Oxidative Stress	Nothing to Disclose
Briguori	Carlo	Challenging PCI: Tips and Tricks from the Experts	Co-Chair	Nothing to Disclose
Briguori	Carlo	Challenging PCI: Tips and Tricks from the Experts	Case Presentation: Proximal Tortuosity, Difficulty Delivering Stent	Nothing to Disclose
Briguori	Carlo	Great Debates in Ischemia 2017	Chronic Renal Failure Patients Benefit From Revascularization for Ischemia: PRO	Nothing to Disclose
Brilakis	Emmanouil	Fellows Bootcamp: Coronary Disease Management	CHIP/High Complexity: CTO	CONSULTANT FEES/HONORARIA - Abbott Vascular,Asahi,Cardinal Health,Elsevier,GE Healthcare,St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific,Infraredx; SALARY - MEDTRONIC
Brilakis	Emmanouil	Contemporary Role of Intracoronary Imaging: Candid Conversation with Peers	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular, Asahi, Cardinal Health, Elsevier, GE Healthcare, St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific, Infraredx; SALARY - MEDTRONIC
Brilakis	Emmanouil	Contemporary Role of Intracoronary Imaging: Candid Conversation with Peers	Intracoronary Imaging During Primary PCI	CONSULTANT FEES/HONORARIA - Abbott Vascular, Asahi, Cardinal Health, Elsevier, GE Healthcare, St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific, Infraredx; SALARY - MEDTRONIC
Brilakis	Emmanouil	Mastering Cath Lab Leadership and Economics in a New Era: A Joint Symposium by the Society of Cardiovascular Angiography and Interventions and the American College of Cardiology	New Technologies to Address Cath Lab Hazards?	CONSULTANT FEES/HONORARIA - Abbott Vascular Asahi, Cardinal Health, Elsevier, GE Healthcare, St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific, Infraredx; SALARY - MEDTRONIC
Brilakis	Emmanouil	Highlighted Original Research: Prevention and the Year in Review	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 16,721 Patients From 33 Randomized Clinical Trals	CONSULTANT FEES/HONORARIA - Abbott Vascular, Asahi, Cardinal Health, Elsevier, GE Healthcare, St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific, Infraredx; SALARY - MEDTRONIC
Brilakis	Emmanouil	Head to Toe: Outcomes of Endovascular Interventions	Atherectomy Is Associated With Lower Rates of Repeat Intervention After Below Knee Peripheral Vascular Intervention	CONSULTANT FEES/HONORARIA - Abbott Vascular, Asahi, Cardinal Health, Elsevier, GE Healthcare, St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific, Infraredx; SALARY - MEDTRONIC
Brilakis	Emmanouil	Head to Toe: Outcomes of Endovascular Interventions	Utilization of Distal Embolic Protection in Infrainguinal Peripheral Arterial Intervention: Insights From the Multicenter XLPAD Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular, Asahi, Cardinal Health, Elsevier, GE Healthcare, St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific, Infraredx; SALARY - MEDTRONIC
Brilakis	Emmanouil	Head to Toe: Outcomes of Endovascular Interventions	Association of Cigarette Smoking With Procedural Cost of Lower Extremity Endovascular Intervention	CONSULTANT FEES/HONORARIA - Abbott Vascular, Asahi, Cardinal Health, Elsevier, GE Healthcare, St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific, Infraredx; SALARY - MEDTRONIC
Brilakis	Emmanouil	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Contemporary Use of Laser During Percutaneous Coronary Intervention: Results From the Laser Veterans Affairs (LAVA) Multicenter Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular, Asahi, Cardinal Health, Elsevier, GE Healthcare, St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific, Infraredx; SALARY - MEDTRONIC
Brilakis	Emmanouil	Coronary Intervention in Interventional Cardiology: Advanced Device Use	A Meta-Analysis of Contemporary Lesion Modification Strategies During Percutaneous Coronary Intervention in 244,665 Patients From 21 Studies	CONSULTANT FEES/HONORARIA - Abbott Vascular, Asahi, Cardinal Health, Elsevier, GE Healthcare, St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific, Infraredx; SALARY - MEDTRONIC
Brilakis	Emmanouil	Innovations in Advocacy and Patient Centered Care	Diverse Perspectives and Training Paths in Cardiology: An Analysis of Authorship in the <i>→Journal of the American College of Cardiology</i>	CONSULTANT FEES/HONORARIA - Abbott Vascular, Asahi, Cardinal Health, Elsevier, GE Healthcare, St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific, Infraredx; SALARY - MEDTRONIC
Brilakis	Emmanouil	Advances in Chronic Total Occlusion Intervention	Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions Improves Peak Oxygen Uptake During Cardiopulmonary Exercise Testing	CONSULTANT FEES/HONORARIA - Abbott Vascular, Asahi, Cardinal Health, Elsevier, GE Healthcare, St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific, Infraredx; SALARY - MEDTRONIC
Brilakis	Emmanouil	Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular Asahi, Cardinal Health, Elsevier, GE Healthcare, St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific, Infraredx; SALARY - MEDTRONIC
Brilakis	Emmanouil	Advances in Chronic Total Occlusion Intervention	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular,Asahi,Cardinal Health,Elsevier,GE Healthcare,St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific,Infraredx;
Brilakis	Emmanouil	Interventional Complexity and Complications	Variability in Transfemoral Access for Coronary Angiography and Interventions: Results From an International Survey	SALARY - MEDTRONIC CONSULTANT FEES/HONORARIA - Abbott Vascular Asahi, Cardinal Health, Elsevier, GE Healthcare, St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific, Infraredx; SALARY - MEDTRONIC
Brilakis	Emmanouil	Endovascular Therapy: Running From Risk	Predictors of Procedural Complications in Infrainguinal Endovascular Interventions	CONSULTANT FEES/HONORARIA - Abbott Vascular Asahi, Cardinal Health, Elsevier, GE Healthcare, St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific, Infraredx; SALARY - MEDTRONIC
Brilakis	Emmanouil	Highlights in Vascular Medicine Research	Comparative Assessment of Subintimal Versus Intraluminal Crossing of Infrainguinal Chronic Total Occlusion Lesions	CONSULTANT FEES/HONORARIA - Abbott Vascular, Asahi, Cardinal Health, Elsevier, GE Healthcare, St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific, Infraredx; SALARY - MEDTRONIC

Carl Street				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Brilakis	Emmanouil	20. Interventional Cardiology: Coronary Intervention: CTO Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular,Asahi, Cardinal Health,Elsevier,GE Healthcare,St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific,Infraredx; SALARY - MEDTRONIC
Brilakis	Emmanouil	Interventional Challenging Cases: Team 1	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular Asahi, Cardinal Health, Elsevier, GE Healthcare, St Jude; RESEARCH/RESEARCH GRANTS - Boston Scientific, Infraredx; SALARY - MEDTRONIC
Brili	Styliani	Innovative Use of Echocardiography	Impact on Long Term Mortality of Persistent Pulmonary Hypertension After Transcatheter Aortic Valve Implantation	Nothing to Disclose
Briller	Joan	The Consequences of Sex: Women and Pregnancy Across the Spectrum	Panelist	Nothing to Disclose
Briller	Joan	Novel Echocardiographic Methods for Assessing Cardiac Function	Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain	Nothing to Disclose
Brindis	Ralph	International CV Centers of Excellence: Leveraging the NCDR for Achieving High Quality Care	Co-Chair	Nothing to Disclose
Brindis	Ralph	International CV Centers of Excellence: Leveraging the NCDR for Achieving High Quality Care	Introduction to Session	Nothing to Disclose
Brindis	Ralph	International CV Centers of Excellence: Leveraging the NCDR for Achieving High Quality Care	Conclusion	Nothing to Disclose
Brindis	Ralph	Assuring Quality in the Cath Lab: Documentation, Appropriate Use, Peer Review, and Public Reporting	Debate Pro: Quality Assurance in the Cath Lab, More External Oversight Is Needed	Nothing to Disclose
Brindis	Ralph	PCI in the Era of Public Accountability: Managing Risks to Patients, Providers, and Institutions	Co-Chair	Nothing to Disclose
Brindis	Ralph	Post FDA Release Prosthetic Valve Surveillance - Watching for Signals	NCDR Registries - Can Device Durability Be Seen?	Nothing to Disclose
Brindis	Ralph	Innovations in Practice Management and Social Media	Unlocking the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for	Nothing to Disclose
Brindis	Ralph	Engage @ ACC.17 Studio: Cardiology Contest	Today's Complex Care Delivery Cardiology Contestant	Nothing to Disclose
Brindis	Ralph	02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Brinkman	Matthew	Clinical Team 6 Interventional Cardiology: PCI and TAVR in Complex Patients	Refining the Classification of Severe, Symptomatic Aortic Stenosis Using Flow and Gradient Measurements to Predict Outcomes Post-	Nothing to Disclose
Brinkman	Matthew	TAVR Outcomes Prognostication	Transcatheter Aortic Valve Replacement High Baseline Valvuloarterial Impedence Predicts Worse 1-Year	Nothing to Disclose
Brinkman	William	Vascular Access and Hemostasis Issues	Outcomes After Transcatheter Aortic Valve Replacement Real-Time Ultrasound Versus Fluoroscopy Guided Access for	Nothing to Disclose
Brinkman	William	Prosthetic Valve Thrombosis: TAVR, Bio, Mech Now What?!	Transcatheter Aortic Valve Replacement With the Sapien 3 Valve Incidence of Valve Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves by 4D CT Imaging	CONSULTANT FEES/HONORARIA - Medtronic endovascular; SPEAKER'S BUREAU - Edwards Lifesciences,WL Gore
Brinster	Derek	Highlighted Original Research: Valvular Heart	Effect of Baseline Aortic Regurgitation on Mortality in the Core Valve	
Brinster	Derek	Disease and the Year in Review FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	US Pivotal High Risk Trial An Unexpected Guest in the Right Ventricle	Nothing to Disclose
Brinton	Eliot	Disease, and Vascular Medicine Great Debates in Preventive Cardiology	Fasting vs Non-fasting Lipid Testing - not so Fast, We Still Need to Fast	CONSULTANT FEES/HONORARIA - Akcea/lonis,Alexion,Amarin,Aralez,Arisaph,AstraZeneca,Kastle,S anofi-Aventis; SPEAKER'S BUREAU - Alexion,Amarin,Amgen
Brinza	Ellen	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Family History of Arterial Disorders in Patients With Spontaneous Coronary Artery Dissection	Inc.,Janssen,Kowa,Merck,Regeneron,Sanofi-Aventis Nothing to Disclose
Briongos-Figuero	Sem	Arrhythmias and Clinical EP: Devices 1	Pharmacological Treatment Alone Versus Treatment Combined With Implantable Cardioverter-Defibrillator Therapy in Patients Over 75 Years	Nothing to Disclose
Brisco-Bacik	Meredith	Salt, Water and the Kidney in Heart Failure	Panelist	Nothing to Disclose
Brisco-Bacik Briston	Meredith David	Salt, Water and the Kidney in Heart Failure	Implications of Changes in Renal Function in Heart Failure Obstructive Sleep Apnea in Adult Congenital Heart Disease: Who Is	Nothing to Disclose Nothing to Disclose
Briston	David	Adult Patients With Congenital Heart Disease: How Do They Compare?	at Risk?	Nothing to disclose
Brito Jr.	Fabio	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	High Non-High-Density Lipoprotein Cholesterol Levels Predict Enhanced Periprocedural Inflammatory Response Following Percutaneous Coronary Intervention in Stable Ischemic Heart Disease Patients	OTHER - Edwards Lifesciences, MEDTRONIC
Brittain	Evan	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Racial Differences in Patients Referred for Right Heart Catheterization and Risk of Pulmonary Hypertension	Nothing to Disclose
Brittain	Evan	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Lack of a Tricuspid Regurgitation Velocity and Pulmonary Hypertension: Absence of Evidence Is Not Evidence of Absence	Nothing to Disclose
Brittain	Evan	Markers of Prognosis Associated With Elevated Blood Pressure	Direct Transition to Dilated Cardiomyopathy Without Antecedent Left Ventricular Hypertrophy Is Uncommon Among Hypertensive Subjects in a Large Clinical Cohort	Nothing to Disclose
Broberg	Craig	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	An Interesting Case of Sudden Cardiac Death in a Patient With Tetralogy of Fallot	RESEARCH/RESEARCH GRANTS - Actelion
Brodie	Bruce	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Platelet Reactivity and Outcomes After PCI of Saphenous Vein Grafts Versus Native Coronary Arteries: The ADAPT-DES Study	Nothing to Disclose
Brodie	Bruce	Advances in Chronic Total Occlusion Intervention	Is Platelet Reactivity Associated With Ischemic Events Following Successful Chronic Total Occlusion Percutaneous Coronary Intervention	Nothing to Disclose
Brodov	Yafim	Non Invasive Imaging: Expanding Clinical Applications	Impact of Different Calcium Locations of Mitral Annulus and Aortic Valve Cusps on Risk of Conduction Disturbances After Transcatheter Aortic Valve Implantation	Nothing to Disclose
Broedl	Uli	Innovations in Cardiovascular Risk Assessment and Reduction		SALARY - Boehringer Ingelheim
Broersen	Alexander	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Coronary Artery Calcium Progression With Coronary Plaque Progression Determined by Quantitative Coronary Artery Plaque Analysis	Nothing to Disclose
Broman	Michael	FIT Forum: Scholarship and Education	How My Grant Was Funded	Nothing to Disclose
Broman	Michael	Arrhythmias and Clinical EP: Basic 2	Atrial Fibrillation Is Associated With Severe Metabolic Disruption in Atrial Myocardium in Patients With Heart Failure	Nothing to Disclose
Broman	Michael	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Electroanatomic Characterization of Hypoplastic Left Heart Ventricular Tachycardia: Transaortic Transmembranous Ventricular Septal Approach via Magnetic Navigation	Nothing to Disclose
Brook	Robert	33. Prevention: Hypertension Team 1	Suggested Reviewer	OTHER - GSK
Brooks	Kristen	Innovations in Cardiovascular Risk Assessment and Reduction	Counseling Have Impact on Patient Habits and Lifestyle Change?	Nothing to Disclose
	1		Early Results of the Heart Smart Screening Program	



Contract of the second				<u> </u>
Last Name Brooks	First Name Paul	Session Title Congenital Heart Disease: New Diagnostic	Presentation Title The Incremental Benefit of Color Tissue Doppler Imaging in Fetal	Disclosures Nothing to Disclose
Brothers	Julie	Approaches in Congenital Heart Disease 10. Congenital Heart Disease: Pediatric Team	Rhythm Assessment Suggested Reviewer	CONSULTANT FEES/HONORARIA - Aegerion Pharmaceuticals
Brothers	Julie	1		-
Broughton	Stephen	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Normal Findings on Noninvasive Cardiac Assessment and the Prediction of Heart Failure: The Multi-Ethnic Study of Atherosclerosis (MESA)	Nothing to Disclose
Brouse	Sara	When Anticoagulation Needs to be Stopped What Are the Options? Pharmacology II	Case Presentation: A Perioperative Patient that Needs to Have Anticoagulation Managed	Nothing to Disclose
Brouse	Sara	When Anticoagulation Needs to be Stopped	Reprise of the Case	Nothing to Disclose
Brouwer	Marc	What Are the Options? Pharmacology II Arrhythmias and Clinical EP: AF Miscellaneous	Novel Approach for Risk Differentiation in Atrial Fibrillation Patients	Nothing to Disclose
Brouwer	Tom	and Surgical Issues Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	With Polypharmacy Chronic Performance of Communicating Leadless Anti-Tachycardia Pacemaker and Subcutaneous Implantable Cardioverter	Nothing to Disclose
Brown	Adam	Non Invasive Imaging: Prognostic Implications of CT Angiography	Defibrillator Computed Tomography Coronary Angiography Derived Plaque Morphology Predicts Major Adverse Cardiovascular Events: Insights From a 19,943 Patient Meta-Analysis	Nothing to Disclose
Brown	Alan	Coming to Consensus in a New Era: The Role of Non-statin Therapies in ASCVD Risk Reduction	Panelist	CONSULTANT FEES/HONORARIA - Aksea,Amgen Inc.,Astra Zeneca,Kastle,Regeneron
Brown	Alan	Advances in Lipid Management	Alirocumab in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program	CONSULTANT FEES/HONORARIA - Aksea,Amgen Inc.,Astra Zeneca,Kastle,Regeneron
Brown	Allen	Emerging Applications of Echocardiography	Clinical Characteristics and Changes of Valvuloarterial Impedence Severity in Patients Undergoing Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis	Nothing to Disclose
Brown	Chase	Interventional Cardiology: TAVR 1	TAVR Is Safe and Improves Cardiac Function in Patients With Extremely Low Ejection Fractions	Nothing to Disclose
Brown	David	Congenital Heart Disease: Advances in Quality Improvement for Pediatric Cardiac Care	Revenue Return on Investment for Center Involvement in a Quality Improvement Collaborative for a Rare Disease: National Pediatric Cardiology Quality Improvement Collaborative	Nothing to Disclose
Brown	David	Vascular Access and Hemostasis Issues	Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve	CONSULTANT FEES/HONORARIA - Edwards Lifesciences, st.Jude; OWNERSHIP MITEREST/PARTNERSHIP/PRINCIPAL - Cardiaq Venture Technologies, The Heart Hospital Baylor Plano, Transeptal Solutions LTD; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Artium medical, Boehringer Ingelheim Pharmaceuticals, Inc, Boston Scientific, CeloNova BioSciences Inc, DirectFlow, Edwards Lifesciences, Gilead Sciences, Inc. Heartflow, ReyStone Heart LTD, MEDTRONIC, Osprey Medical
Brown	David	Prosthetic Valve Thrombosis: TAVR, Bio, Mech Now What?!	Incidence of Valve Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves by 4D CT Imaging	CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St.ude; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cardiaq Venture Technologies, The Heart Hospital Baylor Plano, Transeptal Solutions LTD; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Afrium medical, Boehringer Ingelheim Pharmaceuticals, Inc, Boston Scientific, CeloNova BioSciences Inc, DirectFlow, Edwards Lifesciences, Gilead Sciences, Inc. Heartflow, KeyStone Heart LTD, MEDTRONIC, Osprey Medical
Brown	David	Finding Out What Works in Pediatric and Congenital Heart Disease	Reduction in Interstage Growth Failure in Infants With Hypoplastic Left Heart Syndrome and Impact on Stage 2 Outcomes: A Report From the National Pediatric Cardiology Quality Improvement Collaborative	Nothing to Disclose
Brown	David	03. Acute and Stable Ischemic Heart Disease: Therapy Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Edwards Lifesciences, st.Jude; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cardiaq Venture Technologies, The Heart Hospital Baylor Plano, Transeptal Solutions LTD; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Afrium medical, Boehringer Ingelheim Pharmaceuticals, Inc, Boston Scientific, CeloNova BioSciences Inc, DirectFlow, Edwards Lifesciences, Gilead Sciences, Inc.
Brown	Eddie	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional	<i><i><i>> Improving the Safety Profile of Diagnostic Coronary Bypass Angiography</i></i></i>	,Heartflow,KeyStone Heart LTD,MEDTRONIC,Osprey Medical Nothing to Disclose
Brown	James	CT/MR Congenital Heart Disease: Advances in Quality	Standardizing the Care of Outpatient Pediatric Syncope and	Nothing to Disclose
		Improvement for Pediatric Cardiac Care	Dizziness: A Lesson in Utilization and Charge Reduction	
Brown	John	Interventional Cardiology: TAVR 3	Initial Use of the Evolut Pro Self-Expanding Transcatheter Aortic Valve <i></i>	Nothing to Disclose
Brown	Marcel	Hearts and Soles: Multimodality Imaging in	Temporal Sequence of Athlete's Heart Regression During	Nothing to Disclose
Brown	Phillip	Athletes Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in	Prescribed Exercise Detraining: <i>Diagnostic Implications</i> Understanding Readmissions in Medicare Beneficiaries During the 90-Day Follow-Up Period Following an AMI Admission	OTHER - HealthTrust Purchasing Group, L.P., d/b/a Cardiac Data Solutions, Inc., Atlanta, GA
Brown	Phillip	Review Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	What is the Impact of Complications During the Index Hospitalization on Resource Utilization During the 90-Day Follow-Up Period Associated With CABG Surgery Among Medicare Beneficiaries?	OTHER - HealthTrust Purchasing Group, L.P., d/b/a Cardiac Data Solutions, Inc., Atlanta, GA
Brown	Phillip	Acute Coronary Syndromes, Diagnosis,	Medicare Reimbursement Associated With an AMI Hospitalization	OTHER - HealthTrust Purchasing Group, L.P., d/b/a Cardiac
Brown		Management and Outcomes	and 90-Days Post-Discharge A Network-Based Approach to Measuring the Reported Impact of	Data Solutions, Inc., Atlanta, GA
1	Sherry-Ann	Innovations in Cardiovascular Risk Assessment	A Network-based Approach to Measuring the Reported Impact of	Nothing to Disclose
Brown	,	and Reduction	Disclosing Genetic Risk for Coronary Heart Disease	5
Brown	Todd	and Reduction Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Disclosing Genetic Risk for Coronary Heart Disease Trends in the Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011-2014	RESEARCH/RESEARCH GRANTS - Amgen, Inc.,Omthera
Brown Brown Brown	,	and Reduction Acute Coronary Syndromes, Diagnosis,	Disclosing Genetic Risk for Coronary Heart Disease Trends in the Use of High-Intensity Statin Therapy After Myocardial	5
Brown	Todd Todd	and Reduction Acute Coronary Syndromes, Diagnosis, Management and Outcomes 34. Prevention: Rehabilitation Team 1	Disclosing Genetic Risk for Coronary Heart Disease Trends in the Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011-2014 Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Amgen, Inc., Omthera RESEARCH/RESEARCH GRANTS - Amgen, Inc., Omthera Nothing to Disclose OTHER - Edward Lifesciences; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aegis
Brown Brown	Todd W. Morris	and Reduction Acute Coronary Syndromes, Diagnosis, Management and Outcomes 34. Prevention: Rehabilitation Team 1 Highlighted Original Research: Interventional Cardiology and the Year in Review	Disclosing Genetic Risk for Coronary Heart Disease Trends in the Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011-2014 Suggested Reviewer Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial Suggested Reviewer Frequency and Predictors of Cholesterol Goal Attainment in Patients With Coronary Heart Disease: Results From the	RESEARCH/RESEARCH GRANTS - Amgen, Inc.,Omthera RESEARCH/RESEARCH GRANTS - Amgen, Inc.,Omthera Nothing to Disclose OTHER - Edward Lifesciences; OWNERSHIP
Brown Brown Bruce	Todd Todd W. Morris Charles	and Reduction Acute Coronary Syndromes, Diagnosis, Management and Outcomes 34. Prevention: Rehabilitation Team 1 Highlighted Original Research: Interventional Cardiology and the Year in Review 28. Non Invasive Imaging: Echo Team 2 Advances in Cholesterol Measurement and	Disclosing Genetic Risk for Coronary Heart Disease Trends in the Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011-2014 Suggested Reviewer Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial Suggested Reviewer Frequency and Predictors of Cholesterol Goal Attainment in	RESEARCH/RESEARCH GRANTS - Amgen, Inc.,Omthera RESEARCH/RESEARCH GRANTS - Amgen, Inc.,Omthera Nothing to Disclose OTHER - Edward Lifesciences; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aegis Medical,NeoChord

Carlot Control				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Brudi	Philippe	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South-Africa, Middle East and China: Results of the Dyslipidemia International Study (DYSIS)	SALARY - Merck & Department of the Salary - Merck &
Brudi	Philippe	Diabetes and Other Issues in Cardiovascular	Does Concomitant Diabetes Mellitus Impact the Cholesterol	SALARY - Merck & Dr., Inc.
Bruemmer	Dennis	Prevention Preventing ASCVD in Diabetes: Are These	Treatment Post Acs? TZDs and CV Risk: Time for a Reappraisal?	Nothing to Disclose
Brugada	Josep	New Drugs for Real? Cardiac Channelopathies: Novel Therapeutics and Clinical Challenges	Eficacy and Safety of Flecainide to Reduce Exercise-Induced Ventricular Arrhythmias and the Arrhythmic Window in Patients With	Nothing to Disclose
Brugada-Terradellas	Ramon	Cardiac Channelopathies: Novel Therapeutics and Clinical Challenges	Catecholaminergic Polymorphic Ventricular Tachycardia Eficacy and Safety of Flecainide to Reduce Exercise-Induced Ventricular Arrhythmias and the Arrhythmic Window in Patients With	CONSULTANT FEES/HONORARIA - ferrer Incode
Brugaletta	Salvatore	Highlighted Original Research: Interventional	Catecholaminergic Polymorphic Ventricular Tachycardia Clinical, Angiographic and Procedural Correlates of Absorb Scaffold	Nothing to Disclose
Brugaletta	Salvatore	Cardiology and the Year in Review Timely Topics in Acute Coronary Syndromes	Thrombosis: A Matched Multicenter Registry Analysis A New Prognosis Score to Predict Mortality in Patients Over 75	Nothing to Disclose
Bruining	Nico	Updates in Stable Ischemic Heart Disease	Years Old Undergoing Primary Angioplasty in Cardiogenic Shock Coronary Calcification as a Mechanism of Plaque/Media Shrinkage:	CONSULTANT FEES/HONORARIA - Biotronik;
Brunetti	Marissa	Highlighted Original Research: Congenital Heart Disease and the Year in Review	A Multimodality Intracoronary Imaging Study Characteristics, Risk Factors and Outcomes of Extracorporeal Membrane Oxygenation Use in the Pediatric Cardiac Intensive Care	RESEARCH/RESEARCH GRANTS - Abbott Vacular, Biotronik Nothing to Disclose
Bruno	Giulia	Novel Echocardiographic Methods for	Unit Subclinical Myocardial Alterations in Cardiac Sarcoidosis	Nothing to Disclose
Bruno	Pasqualina	Assessing Cardiac Function Improving Outcomes in the Athlete With Cardiovascular Disease	EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000	Nothing to Disclose
Brush	John	Cardiovascular Team Cases: Team 2	Young Italian Students Suggested Reviewer	Nothing to Disclose
Bryniarski	Krzysztof	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Association Between Syntax Score, and Pre- and Post-Stenting Optical Coherence Tomography Findings in Stable Angina Patients	Nothing to Disclose
Buber	Yonatan	Highlighted Original Research: Interventional Cardiology and the Year in Review	Percutaneous Closure of Patent Foramen Ovale Is Associated With Lower Incidence Cryptogenic Strokes Among Patients With Inherited Thrombophialias Treated With Anticoagulant or Antiaggregant Therapy	Nothing to Disclose
Bubor	Yoni	Innovations in Advocacy and Patient Centered Care	Status of Early Career Academic Cardiology: A Global Perspective	Nothing to Disclose
Bucciarelli-Ducci	Chiara	Featured Clinical Research I	MR-INFORM: Stress Perfusion Imaging to Guide the Management of Patients With Stable Coronary Artery Disease	CONSULTANT FEES/HONORARIA - Circle Cardiovascular
Bucciarelli-Ducci	Chiara	Cardiovascular Magnetic Resonance A Fast and Reliable Method to Change Patients' Therapy. Joint Symposium of the Society for Cardiovascular Magnetic Resonance and the American College of Cardiology	or Patients with Statile Coronary Artery Disease Co-Chair	Imaging,Circle Cardiovascular Imaging CONSULTANT FEES/HONORARIA - Circle Cardiovascular Imaging,Circle Cardiovascular Imaging
Bucciarelli-Ducci	Chiara	Cardiovascular Magnetic Resonance A Fast and Reliable Method to Change Patients' Therapy: Joint Symposium of the Society for Cardiovascular Magnetic Resonance and the American College of Cardiology	Case Presentation /ACC Talk	CONSULTANT FEES/HONORARIA - Circle Cardiovascular Imaging, Circle Cardiovascular Imaging
Bucciarelli-Ducci	Chiara	Great Debates in Cardiac MRI	Debate Con: Cardiac MRI and DNA DS Breaks	CONSULTANT FEES/HONORARIA - Circle Cardiovascular Imaging, Circle Cardiovascular Imaging
Buch	Eric	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	Nothing to Disclose
Buchanan	Donna	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Reliability and Responsiveness of Seattle Angina Questionnaire in Women With Coronary Artery Disease	Nothing to Disclose
Buchanan	Donna	Coronary Artery Disease Optimizing Treatment of Peripheral Artery Disease	Smoking Behavior and Access to Smoking Cessation Support Following a Diagnosis of Peripheral Arterial Disease: Insights From the International PORTRAIT Registry	Nothing to Disclose
Buchanan	Kyle	Considerations in Antiplatelet Therapy and in ACS	Trends in Discharge and Outcome of Dual Antiplatelet Therapy Post Percutaneous Intervention in High Bleeding Risk Population	Nothing to Disclose
Buchanan	Kyle	Considerations in Antiplatelet Therapy and in ACS	Outpatient Trends in Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Primary Percutaneous Coronary	Nothing to Disclose
Buchanan	Kyle	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Intervention In-Stent Restenosis of Drug-Eluting Stents: Incidence, Lesion Characteristics and Outcomes in Contemporary Practice Over the	Nothing to Disclose
Buchanan	Kyle	Interventional Cardiology: TAVR 2	Last Decade - How Are They Different From De Novo Lesions? Racial Disparities and Temporal Trends in Demographics and Clinical Characteristics of Patients Screened for Transcatheter	Nothing to Disclose
Buchanan	Kyle	Interventional Cardiology: TAVR 3	Aortic Valve Replacement Antithrombotic Therapy Differences and Associated Outcomes in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic	Nothing to Disclose
Buchanan	Kyle	Interventional Cardiology: PCI in Complex Patients	Valve Replacement Long-Term Mortality in Percutaneous Coronary Intervention of Saphenous Vein Grafts From Real-World Registry Data	Nothing to Disclose
Buchbinder	Maurice	17. Interventional Cardiology: Aortic Valve Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular, micardia ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - M Valve inc; SPEAKER'S BUREAU - Abbott Vascular, Boston scientific corporation inc
Buckley	Christopher	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	The Intracavitary Coronary Artery: A Rare Anomaly With Implications for Invasive Cardiac Procedures - Demonstration by Coronary Computed Tomography Angiography	Nothing to Disclose
Buckley	Jessica	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Coronary Computer Vandagaphy Angospaphy Radiotracer Imaging Allows for Assessment of Serial Changes in Angiosome Foot Perfusion Following Revascularization and Predicts Limb Salvage Outcomes in Patients With Critical Limb Ischemia	Nothing to Disclose
Buckley	Jessica	Nuclear Cardiology: Beyond Perfusion	Radiotracer Imaging of Angiosome Foot Perfusion Correlates With Ankle-Brachial Index and Differentiates Critical Limb Ischemia Patients From Healthy Subjects	Nothing to Disclose
Buckley	Leo	Making Progress in Understanding Heart Failure	Arterial Elastance Drives Ventilatory Inefficiency in Systolic Heart Failure	Nothing to Disclose
Buckley	Leo	Interdisciplinary Cardiovascular Team Collaboratives in Care	Management of Obesity in Patients With Diastolic Dysfunction	Nothing to Disclose
Buckley	Leo	Emerging Developments in HFpEF and Arryhthmias	Early Diastolic Mitral Annular Velocity at Peak Exercise Determines Peak Aerobic Exercise Capacity in Heart Failure With Preserved	Nothing to Disclose
Budoff	Matthew	Non Invasive Imaging: Applications in Novel	Ejection Fraction Impact of Cardiac Troponin I on the Presence of the Coronary	CONSULTANT FEES/HONORARIA - Janssen, Pfizer;
Budoff	Matthew	Disease States and Clinical Scenarios Non Invasive Imaging: Expanding Clinical	Artery Plaque in Rheumatoid Arthritis patients The Utility of Left Atrial Appendage Hounsfield Unit and the Ratio of	RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca CONSULTANT FEES/HONORARIA - Janssen,Pfizer;
		Applications	Left Atrial Appendage/Ascending Aorta Hounsfield Unit for Detecting Left Atrial Appendage Thrombus	RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca



and the second				
Last Name Budoff	First Name Matthew	Session Title Non Invasive Imaging: Expanding Clinical	Presentation Title The Association of Ischemia on Single Photon Emission Computed	Disclosures CONSULTANT FEES/HONORARIA - Janssen.Pfizer:
5445		Applications	Tomography-Myocardial Perfusion Image and Fractional Flow Reserve by Coronary Computed Tomographic Angiography	RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca
Budoff	Matthew	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Association of Coronary Artery Calcium With Incident Peripheral Artery Disease: The Multi-Ethnic Study of Atherosclerosis	CONSULTANT FEES/HONORARIA - Janssen, Pfizer; RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca
Budoff	Matthew	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Based Cohort: The Multi-Ethnic Study of Atherosclerosis	CONSULTANT FEES/HONORARIA - Janssen,Pfizer; RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca
Budoff	Matthew	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Prognostic Value of Protein Biomarkers Predict Risk of Coronary Heart Disease Events: Results From Multi-Ethnic Study of Atherosclerosis (MESA)	CONSULTANT FEES/HONORARIA - Janssen,Pfizer; RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca
Budoff	Matthew	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Total Testosterone With Progression of Carotid Atherosclerosis and Coronary Artery Calcium Score: The Multi- Ethnic Study of Atherosclerosis	CONSULTANT FEES/HONORARIA - Janssen,Pfizer; RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca
Budoff	Matthew	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Coronary Artery Calcium Progression With Coronary Plaque Progression Determined by Quantitative Coronary Artery Plaque Analysis	CONSULTANT FEES/HONORARIA - Janssen, Pfizer; RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca
Budoff	Matthew	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium and Estimated Cardiovascular Disease Risk in Five Racial/Ethnic Groups Living in the US: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA)	CONSULTANT FEES/HONORARIA - Janssen,Pfizer; RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca
Budoff	Matthew	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium Scores for Atherosclerotic Cardiovascular Disease Risk Stratification in Smokers: MESA	CONSULTANT FEES/HONORARIA - Janssen,Pfizer; RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca
Budoff	Matthew	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	­The Utility of Minimal Coronary Artery Calcification for Predicting Carotid Artery Disease: Results From the Multi-Ethnic Study of Atherosclerosis (MESA)	CONSULTANT FEES/HONORARIA - Janssen, Pfizer; RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca
Budoff	Matthew	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography. The CONFIRM (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	CONSULTANT FEES/HONORARIA - Janssen, Pfizer; RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca
Budoff	Matthew	Innovations in Cardiovascular Risk Assessment and Reduction	Association of Coronary Calcium, Carolid Wall Thickness and Carolid Plaque Progression With Low Density Lipoprotein and High Density Lipoprotein Particle Concentration Measured by Ion Mobility Testing: The Multi-Ethnic Study of Atherosclerosis (MESA)	CONSULTANT FEES/HONORARIA - Janssen,Pfizer; RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca
Budoff	Matthew	Innovations in Cardiovascular Risk Assessment and Reduction	The Prognostic Value of CPET: Association With Coronary Artery Calcium Score	CONSULTANT FEES/HONORARIA - Janssen, Pfizer; RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca
Budoff	Matthew	Non Invasive Imaging: Prognostic Implications of CT Angiography	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	CONSULTANT FEES/HONORARIA - Janssen,Pfizer; RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca
Budoff	Matthew	Non Invasive Imaging: Role of Exercise Testing	The Non-Invasive Physiological Detection of Myocardial Ischemia in Coronary Artery Disease	CONSULTANT FEES/HONORARIA - Janssen, Pfizer; RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca
Budoff	Matthew	Imaging With Cardiac CT: The Case for Calcium	Coronary Artery Calcium on Noncontrast Thoracic CT Scans and All- Cause Mortality: The Copd Gene Cohort	CONSULTANT FEES/HONORARIA - Janssen,Pfizer; RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca
Budoff	Matthew	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Janssen,Pfizer; RESEARCH/RESEARCH GRANTS - General Electric; SPEAKER'S BUREAU - Astra Zeneca
Buechel	Ronny	Non Invasive Imaging: Expanding Clinical Applications	Computed Tomography-Derived Corrected Contrast Opacification Decrease Predicts Reduced Relative Flow Reserve Derived From PET Myocardial Perfusion Imaging	Nothing to Disclose
Buechel	Ronny	Non Invasive Imaging: Coronary Calcium	Prospective Evaluation of Low-Dose Coronary Calcium Scoring With	Nothing to Disclose
Buechel	Ronny	Scoring and CV Risk Assessment Non Invasive Imaging: Prognostic Implications of CT Angiography	Reduced Tube Voltage Long-Term Prognostic Value of Computed Tomography-Derived Corrected Contrast Opacification Decrease in Patients With Coronary Stenosis	Nothing to Disclose
Buelow	Matthew	Highlighted Original Research: Congenital	Re-Intervention During the Interstage Period: A Report From the	Nothing to Disclose
Bueno	Hector	Heart Disease and the Year in Review Heart Failure: Implementing the Guidelines Into Practice; A Clinical Case-Based Symposium: International Perspectives From the European Society of Cardiology and the American College of Cardiology	National Pediatric Cardiology Quality Improvement Collaborative A Case of Cardiogenic Shock After Myocardial Infarction	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Astra- Zeneca, Bayer Healthcare, BMS-Pfizer, Ferrer, MEDSCAPE- theherat.org, Novartis, servier; RESEARCH/RESEARCH GRANTS - Astra-Zeneca
Bueno	Héctor	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of a Switch From Dual Antiplatelet Therapy to Single Antiplatelet Therapy in Diabetes and Non-Diabetes Post ACS: Insights From the EPICOR and EPICOR-Asia Studies	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Astra- Zeneca, Bayer Healthcare, BMS-Pfizer, Ferrer, MEDSCAPE- theherat.org, Novartis, servier; RESEARCH/RESEARCH GRANTS - Astra-Zeneca
Bueno	Héctor	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Predictors of Ischemic Events Within and After 1 Year After an Acute Coronary Syndrome: Results From the EPICOR Registry	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Astra- Zeneca, Bayer Healthcare, BMS-Pfizer, Ferrer, MEDSCAPE- theherat.org, Novartis, servier; RESEARCH/RESEARCH GRANTS - Astra-Zeneca
Bueno	Héctor	Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools	Predictive Values of the Ideal Cardiovascular Health and the Fuster- BEWAT Scores for Detecting Subclinical Atherosclerosis in Healthy Individuals	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Astra- Zeneca, Bayer Healthcare, BMS-Pfizer, Ferrer, MEDSCAPE- theherat.org, Novartis, servier; RESEARCH/RESEARCH GRANTS - Astra-Zeneca
Bueno Campa	Jesus	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Left Atrium Undifferentiated Pleomorphic Sarcoma Mimicking Septal Asymmetric Hypertrophic Cardiomiopathy	
Buescher	Melissa	Arrhythmias and Clinical EP: Devices 4	Asymmetric Hypetropnic Cardiomiopathy An Investigation of the Evolution of Implantable Cardiac Monitors: A Comparison of Reveal XT TM and Reveal LINQ*sup>TM*Sup>Based on Accuracy Measurements and Patient Outcomes Post-Device Implant	Nothing to Disclose
Buescher	Melissa	Arrhythmias and Clinical EP: Devices 4	High Battery Impedance in the Pacemaker Dependent Patient: Early Recognition and Collaborative Management of InSync III CRT-P Device Failures	Nothing to Disclose
Bugiardini	Raffaele	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Acute Coronary Syndrome: The Risk to Be Young and Women	Nothing to Disclose
Bui	Christine	Congenital Heart Disease: To the Third	Long-Term Follow-Up in Adult Survivors of Pulmonary Atresia With	Nothing to Disclose
Bui	Quang	Decade and Beyond 19. Interventional Cardiology: Complex	Intact Ventricular Septum Suggested Reviewer	Nothing to Disclose
Bukartyk	Jan	Patients/Comorbidities Team 1 Diabetes and Other Issues in Cardiovascular Prevention	Rapid Rise in Insulin Secretion After Energy Drink Intake in Healthy Adults: A Randomized, Double Blind, Placebo Controlled Clinical Trial	Nothing to Disclose
Bukhman	Gene	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Capacity for Heart Failure Diagnosis and Treatment in Sub-Saharan Africa: Analysis of the Access, Bottlenecks, Costs, and Equity Study in Kenya and Uganda	Nothing to Disclose
Bulathsinghala	Charles	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		Nothing to Disclose



Contract of the contract of th				l .
Last Name Bulathsinghala	First Name Marie	Session Title FIT Clinical Decision Making: Arrhythmias and	Presentation Title That Is Not a Seizure, It's VT: A Unique Presentation of Acquired	Disclosures Nothing to Disclose
Bulathsinghala	Marie	Electrophysiology FIT Clinical Decision Making: Heart Failure and	Long QT Syndrome Aspergillus Endocarditis and Locked-In Syndrome: Rare	Nothing to Disclose
Bull	Jonca	Pulmonary Hypertension Are We There Yet? The Long Journey to	Complications After Orthotopic Heart Transplant Panelist	Nothing to Disclose
Bull		Health Equity: Part I		
	Jonca	Are We There Yet? The Long Journey to Health Equity: Part I	Disparities in CVD : Impact of Race , Ethnicity and Social Determinants	Nothing to Disclose
Bumgarner	Joseph	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Baseline Characteristics, Management and Outcomes in Mitral Valve Prolapse With Manifest Ventricular Automaticity	Nothing to Disclose
Bumrah	Karandeep	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	An Exciting Wide Complex Tachycardia	Nothing to Disclose
Bunch	Т	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Long Term Outcomes and Risk Stratification in Atrial Fibrillation Patients With Low Risk Chads ₂ ≤1 With Antithrombotic Therapy	RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim Pharmaceuticals, Inc
Bunch	T. Jared	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim Pharmaceuticals, Inc
Bundy	Jacob	Innovations in Practice Management and	Radiation Exposure Among Non-Physician Staff Members During	Nothing to Disclose
Bundy	Jacob	Social Media Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Cardiac Catheterization and the Impact of Proactive Shielding Variation in Intracoronary Lipid-Rich Plaque Detected by Near- Infrared Spectroscopy in Asymptomatic Individuals With High	Nothing to Disclose
Burchill	Luke	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Coronary Artery Calcium Scores An Interesting Case of Sudden Cardiac Death in a Patient With Tetralogy of Fallot	Nothing to Disclose
Burke	David	Great Minds Think Differently: Multidisciplinary	Pre-procedural Imaging Considerations to Predict Post Procedural	Nothing to Disclose
Burke	Joseph	Approach to Imaging Novel Echocardiographic Methods for Assessing Cardiac Function	Outcomes: PPM, PVL, Root Upture Comparison of the Effects of Balloon Expandable and Self Expandable Transcatheter Aortic Valve Replacement on the Dimensions of the Mitral Valve Annulus and Mitral Regurgitation	Nothing to Disclose
Burke	M. Nicholas	Chronic Total Occlusion PCI: A Case-Based	Severity Case Presentation: Antegrade Dissection/Re-entry Step-by-step	Nothing to Disclose
Burke	M. Nicholas	Review of Contemporary Techniques Coronary Intervention in Interventional Cardiology: Advanced Device Use	A Meta-Analysis of Contemporary Lesion Modification Strategies During Percutaneous Coronary Intervention in 244,665 Patients	Nothing to Disclose
Burke	Martin	05. Arrhythmias and Clinical EP: Devices Team 1	From 21 Studies Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific, Inc., Zoll; RESEARCH/RESEARCH GRANTS - Boston Scientific, Inc.
Burkhardt	John	Arrhythmias and Clinical EP: AF Ablation	Long-Term Risk of Recurrent Arrhythmia in Patients With Typical Atrial Flutter Undergoing Pulmonary Vein Antrum Isolation or Cavo-	CONSULTANT FEES/HONORARIA - Boeringer-Ingelheim; SPEAKER'S BUREAU - Biosense Webster, Janssen
Burkhardt	John	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Tricuspid Isthmus Ablation With Permanent Isolation Left Atrial Appendage Flow Velocity to Predict Persistent Left Atrial Appendage Isolation	Pharmaceuticals, Inc,Zoll CONSULTANT FEES/HONORARIA - Boeringer-Ingelheim; SPEAKER'S BUREAU - Biosense Webster,Janssen
Burkhoff	Daniel	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics	Pharmaceuticals, Inc,ZoII CONSULTANT FEES/HONORARIA - BackBeat,Cardiac Implants LLC,Corvia / DC Devices,HeartWare,Sensible Medical;
Burkhoff	Daniel	12. Heart Failure and Cardiomyopathies: Basic		OTHER - Abiomed CONSULTANT FEES/HONORARIA - BackBeat,Cardiac
Burnett	John	Team 1 Salt, Water and the Kidney in Heart Failure	Co-Chair	Implants LLC,Corvia / DC Devices,HeartWare,Sensible Medical; OTHER - Abiomed CONSULTANT FEES/HONORARIA - AstraZeneca
				Pharmaceuticals, Ironwood, Novartis Pharmaceuticals corporation, Theravance, Inc.; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Zumbro Discovery
Burnett	John	Young Investigator Awards Competition: Basic and Translational Science	NPA7, a First in Class Dual Receptor Activator With Cardio- Renoprotective Properties <i> In Vivo</i>	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Ironwood, Novartis Pharmaceuticals corporation, Theravance, Inc.; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Zumbro Discovery
Burnett	John	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Intrarenal Renin Angiotensin System Activation: Pathophysiologic and Therapeutic Implications in Acute Decompensated Heart Failure	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Ironwood, Novartis Pharmaceuticals corporation, Theravance, Inc.; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Zumbro Discovery
Burnett	John	12. Heart Failure and Cardiomyopathies: Basic Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Ironwood, Novartis Pharmaceuticals corporation, Theravance, Inc.; OWNERSHIP
Burns	Leah	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Heart Failure Phenotyping by Latent Class Analysis Identifies Subpopulations at High Risk of Mortality and Readmissions: Insights	INTEREST/PARTNERSHIP/PRINCIPAL - Zumbro Discovery SALARY - Bristol Myers Squibb
Burns	Marcus	Interventional Cardiology: TAVR 4	From a Real World Database Minimalist Approach to Cardiac Anesthesia and Outcome in Patients	Nothing to Disclose
Burton	Tanya	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Undergoing Transcatheter Aortic Valve Replacement Stress Myocardial Perfusion Imaging Versus Exercise Treadmill Testing: Comparison of Clinical and Economic Outcomes in Real-	RESEARCH/RESEARCH GRANTS - Astellas
Burudpakdee	Chakkarin	Advances in Cholesterol Measurement and Management	World Emergency Department Settings Contrasting US Patients With a Fill Versus a Prescription for Alirocumab: Early Evidence From Administrative Claims, EMR and	Nothing to Disclose
Burwash	lan	36. Valvular Heart Disease: Clinical Team 3	Lab Data Suggested Reviewer	Nothing to Disclose
Bush	Michelle	Emerging Applications of Echocardiography	Dilated Mid-Ascending Aorta in Hypertrophic Cardiomyopathy Is Associated With Dynamic Left Ventricular Outflow Tract Obstruction and Not With Genetic Abnormalities	Nothing to Disclose
Busman	Denise	Logistical Challenges in STEMI	Panelist	Nothing to Disclose
Busuttil	Ronald	Other Novel Discoveries	Incidence and Factors Associated With New-Onset Cardiomyopathies Following Liver Transplantation	Nothing to Disclose
Butler	Javed	The Heavy Heart: Practicing Heart Fallure Cardiology in an Obesity Epidemic	Panelist	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc, CardioCell, CYRx, Janssen, Lutipold Pharmaceuticals, Inc, Meditonics, Merck & Bamp, amp; Co., Inc., Novartis, Pharmaln, Relypsa, ZS Pharma; DATA SAFETY MONITORING BOARD - Amgen, Bristol-Myers Squibb Company; OTHER - Mediscape; SPEAKER'S BUREAU - Novartis Corporation
Butler	Javed	The Heavy Heart: Practicing Heart Failure Cardiology in an Obesity Epidemic	Should We Advise Obese Patients with Heart Failure to Lose Weight	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc, CardioCell, CVRx, Janssen, Luitpold Pharmaceuticals, Inc, Medtronics, Merck & amp; amp; Co., Inc., Novartis, Pharmaln, Relypsa, ZS Pharma; DATA SAFETY MONITORING BOARD - Amgen, Bristol-Myers Squibb Company; OTHER - Medscape; SPEAKER'S BUREAU - Novartis Corporation



Contract of the second				<u> </u>
Last Name Butler	First Name Javed	Session Title Readmission in Heart Failure: Questions Unanswered	Presentation Title Debate: Disparities in Readmission: It is not Only the Hospitals Fault, Pro	Disclosures CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc, CardioCell, CVRx, Janssen, Lutipold Pharmaceuticals, Inc, Medtronics, Merck & Agmoramo: Co.
				Inc., Novartis, PharmaIn, Relypsa, ZS Pharma; DATA SAFETY MONITORING BOARD - Amgen, Bristol-Myers Squibb Company; OTHER - Medscape; SPEAKER'S BUREAU - Novartis Corporation
Butler	Javed	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Heart Failure With Reduced Ejection Fraction Care Patterns in the Outpatient Practice Setting: Initial Findings From CHAMP-HF	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc, CardioCell, CVRx, Janssen, Luipold Pharmaceuticals, Inc, Medtronics, Merck, & Co., Inc, Novartis, Pharmaln, Relypsa, ZS Pharma; DATA SAFETY MONITORING BOARD - Amgen, Bristol-Myers Squibb Company; OTHER - Medscape; SPEAKER'S BUREAU - Novartis Corporation
Butler	Javed	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Rationale and Methods of the Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE-HF) Study	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc, CardioCell, CVRx, Janssen, Luitpold Pharmaceuticals, Inc, Medtronics, Merck, & Co., Inc, Novaris, Pharmaln, Relyssa, ZS Pharma; DATA SAFETY MONITORING BOARD - Amgen, Bristol-Myers Squibb Company; OTHER - Medscape; SPEAKER'S BUREAU - Novartis Corporation
Butler	Javed	Making Progress in Understanding Heart Failure	Orthopnea or Paroxysmal Nocturnal Dyspnea in Older Adults Without Prevalent Heart Failure Is a Predictor, but Not an Independent Risk Factor for Incident Heart Failure: Insights From the Cardiovascular Health Study	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Bayer, Boberinger Ingelheim Pharmaceuticals, Inc, Cardio Cell, CVRx, Janssen, Luitpold Pharmaceuticals, Inc, Meditronics, Merck, & Co., Inc, Novartis, Pharmain, Relypsa, ZS Pharma; DATA SAFETY MONITORING BOARD - Amgen, Bristol-Myers Squiibb Company; OTHER - Medscape; SPEAKER'S BUREAU - Novartis Corporation
Butler	Javed	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Hemoconcentration During Management of Patients With Acute Heart Failure and Cardiorenal Syndrome: Insights From CARRESS- HF	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Bayer,Boehringer Ingelheim Pharmaceuticals, Inc,CardioCell,CVRx,Janssen,Luitpold Pharmaceuticals, Inc,Medtronics,Merck, & Co., Inc.,Novaris,Pharmain,Reybsa,ZS Pharma; DATA SAFETY MONITORING BOARD - Amgen,Bristol-Myers Squibb Company; OTHER - Medscape; SPEAKER'S BUREAU - Novartis Corporation
Butler	Javed	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Time of Presentation Among Patients Hospitalized for Acute Heart Failure (Clinical Characteristics, Initial Therapies and Outcomes): Insights From ASCEND-HF	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Bayer,Boehringer Ingelheim Pharmaceuticals, Inc,CardioCell,CVRx,Janssen,Luitpold Pharmaceuticals, Inc,Medtronics,Merck, & Co., Inc,Novaris,Pharmaln,Relyssa,ZS Pharma; DATA SAFETY MONITORING BOARD - Amgen,Bristol-Myers Squibb Company; OTHER - Medscape; SPEAKER'S BUREAU - Novartis Corporation
Butler	Javed	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Among Older Heart Failure (HF) Patients With In-Hospital Acute Kidney Injury (AKI), an Improvement in Kidney Function Is Associated With a Higher Risk of Post-Discharge Mortality but Not Readmission	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc, CardioCell, CVRx, Janssen, Luitpold Pharmaceuticals, Inc, Medtronics, Merck, & Co., Inc, Novartis, Pharmaln, Relyssa, ZS Pharma; DATA SAFETY MONITORING BOARD - Amgen, Bristol-Myers Squiibb Company; OTHER - Medscape; SPEAKER'S BUREAU - Novartis Corporation
Butler	Javed	Interventional Cardiology: TAVR 2	Impact of Chronic Kidney Disease on Mortality in Adults Undergoing Balloon Aortic Valvuloplasty	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Bayer,Boehringer Ingelheim Pharmaceuticals, Inc,CardioCell,CVRx,Janssen,Lutipold Pharmaceuticals, Inc,Medtronics,Merck, & Co., Inc,Novartis,Pharmain,Relypsa,ZS Pharma; DATA SAFETY MONITORING BOARD - Amgen,Bristol-Myers Squibb Company; OTHER - Medscape; SPEAKER'S BUREAU - Novartis Corporation
Butler	Javed	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Heart Failure Hospitalization (HFH) Despite Digoxin Therapy Versus No HFH Despite Placebo in the Digitalis Investigation Group (DIG) Trial: Insights Into Risk Factors for HFH in HF and Reduced Ejection Fraction (HFrEF)	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc, CardioCell, CVRX, Janssen, Lutipold Pharmaceuticals, Inc, Medtronics, Merck, & Co., Inc., Novartis, Pharmain, Relypsa, ZS Pharma; DATA SAFETY MONITORING BOARD - Amgen, Bristol-Ilwyers Squibb Company; OTHER - Medscape; SPEAKER'S BUREAU - Novartis Corporation
Butler	Javed	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Clinical Effectiveness of Spironolactone in Hospitalized Older Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or Equal to 30 mL/min/1.73 m ²) Patients With Heart Failure	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Bayer, Boberinger Ingelheim Pharmaceuticals, Inc, Cardio Cell, CVRx, Janssen, Luitpold Pharmaceuticals, Inc, Medtronics, Merck, & Co. Inc., Novartis, Pharmain, Relypsa, ZS Pharma; DATA SAFETY MONITORING BOARD - Amgen, Bristol-Ilwyers Squibb Company; OTHER - Medscape; SPEAKER'S BUREAU - Novartis Corporation
Butler	Javed	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Chronic Alpha Blocker Use and Outcomes in Older Male Medicare Beneficiaries Hospitalized for Heart Failure	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Bayer,Boehringer Ingelheim Pharmaceuticals, Inc,CardioCell,CVRX_Janssen,Lutipold Pharmaceuticals, Inc,Medtronics,Merck & Co. Inc.,Novartis,Pharmain,Relypsa,ZS Pharma; DATA SAFETY MONITORING BOARD - Amgen,Bristol-IMyers Squibb Company; OTHER - Medscape; SPEAKER'S BUREAU - Novartis Corporation
Butler	Javed	Why Can't We Be Friends? Controversies in Heart Failure Management	Adverse Outcomes With Use of Hydralazine and Nitrate Combination Therapy in Hospitalized Older Non-Black Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc, CardioCell, CVRX, Janssen, Lutipold Pharmaceuticals, Inc, Meditonics, Merck, & Co. Inc, Novartis, Pharmaln, Relypsa, ZS Pharma; DATA SAFETY MONITORING BOARD - Amgen, Bristol-Myers Squiibb Company; OTHER - Medscape; SPEAKER'S BUREAU - Novartis Corporation
Butler	Javed	14. Heart Failure and Cardiomyopathies: Therapy Team 2	Suggested Reviewer	COONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc, CardioCell, CVRx, Janssen, Luitpold Pharmaceuticals, Inc, Medtronics, Merck & Amp; amp; Co., Inc., Novartis, Pharmaln, Relypsa, ZS Pharma; DATA SAFETY MONITORING BOARD - Amgen, Bristol-Myers Squibb Company; OTHER - Medscape; SPEAKER'S BUREAU - Novartis Corporation

Cont.				
Last Name Butt	First Name Jawad Haider	Session Title Coronary Angiography, Intra-Vascular Imaging,	Presentation Title Return to Work Following Coronary Artery Bypass Grafting: A	Disclosures Nothing to Disclose
Butt	Jawad Haider	Revascularization and Outcomes Coronary Angiography, Intra-Vascular Imaging,	Nationwide Study Short- and Long-Term Cause of Death Following Coronary Artery	Nothing to Disclose
		Revascularization and Outcomes	Bypass Grafting in a Cohort of 33,980 Patients: A Nationwide Study	· ·
Buxton	Alfred	05. Arrhythmias and Clinical EP: Devices Team 2	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Biosense- Webster, MEDTRONIC
Buys	Emmanuel	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Changes in Citric Acid Metabolism Are Associated With the Development of Anthracycline-Induced Cardiotoxicity in Mice and in	Nothing to Disclose
Byku	Mirnela	Novel Mechanisms Underlying Ischemia-	Patients PGC1 Beta Variants and Physical Activity: Of Mice and Men	Nothing to Disclose
Byrd	James	Reperfusion Injury in AMI Toward Precision Medicine in the Treatment of		Nothing to Disclose
Byrd	Katherine	Elevated Blood Pressure Acute Heart Failure: Evaluating Strategies to	Obstructive Pulmonary Disease: The SUMMIT Trial Acute Decompensated Heart Failure: The Journey From	Nothing to Disclose
Byrne	Robert	Prevent Readmissions Interventional Complexity and Complications	Patients' Perspective Variability in Transfemoral Access for Coronary Angiography and	CONSULTANT FEES/HONORARIA - B. Braun, Biotronik, Boston
Byrne	Ryan	Interdisciplinary Cardiovascular Care in	Interventions: Results From an International Survey Spontaneous Purulent Pericarditis Due to Methicillin-Resistant	Scientific Nothing to Disclose
Byrne	Timothy	Complex Scenarios Structural Heart Interventions: Focus on Mitral	Staphylococcus Aureus: A Case Report and Discussion Comparing TEE With Angiographic Sizing of WATCHMAN Device	Nothing to Disclose
Bytyci	Ibadete	Valve, Left Atrial Appendage and HOCM Advances in Lipid Management	for Left Atrial Appendage Closure Hydrophilic Versus Lipophilic Statins in Coronary Artery Disease	Nothing to Disclose
			Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials	-
Byun	Jae Kyeong	Novel Developments in Acute Coronary Syndromes	Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Diabetic Hypertensive Acute Myocardial Infarction Patients: Results From the Korea Acute Myocardial Infarction Registry (KAMIR)	Nothing to Disclose
Byun	Jae Kyeong	Timely Topics in Acute Coronary Syndromes	Predictors of Mortality in Acute Myocardial Infarction Patients With Unprotected Left Main Coronary Artery Disease	Nothing to Disclose
Byun	Jae Kyeong	Advances in Chronic Total Occlusion Intervention	Impact of Percutaneous Coronary Intervention for Chronic Total Occlusion Patients With Near-Normal Left Ventricular Function	Nothing to Disclose
Byung Kwan	Lim	From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease	Filmasartan Protect Cardiac Myocyte Damage in Ischemic Heart Diseases	Nothing to Disclose
Cabrera	Javier	Acute Coronary Syndromes, Diagnosis,	Steep Decrease in the Rate of Myocardial Infarction From 2000 to	Nothing to Disclose
Cabrera	Javier	Management and Outcomes Acute Coronary Syndromes, Diagnosis,	2008 Association Between Myocardial Infarction Hospital Process of Care	Nothing to Disclose
Cabrera	Javier	Management and Outcomes Unusual Presentations of ACS	Scores With Clinical Outcomes in a Statewide Study Decrease in the Rate of MI Case Fatality From 2000 to 2014	Nothing to Disclose
Cabrera	Javier	New Insights Into Prediction and Treatment of Hypertension	The U-Shaped Relationship of Body Mass Index With All-Cause Mortality at Eight Years in the ALLHAT	Nothing to Disclose
Cacace	Cristina	Advances in HCM, PPCM and Other Cardiomyopathies	Tako Tsubo Cardiomyopathy or Myocarditis?	Nothing to Disclose
Cacace	Cristina	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Reperfusion Delays in Women With STEMI	Nothing to Disclose
Cademartiri	Filippo	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography. The CONFIRM (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	CONSULTANT FEES/HONORARIA - Siemens
Cadet	Justine	FIT Forum: Scholarship and Education	Behind the Curtain: Insights into JACC Publication Processes and Opportunities for FITs	Nothing to Disclose
Cadigan	John	Surgical and Transcatheter Valve Therapy for Congenital Heart Disease	Panelist	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - The Boston ECG Project
Cadigan	John	Surgical and Transcatheter Valve Therapy for Congenital Heart Disease	ACC-Talk: Transcatheter Valve Therapy: The Perspective of a Physician as a Father of a Patient	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - The Boston ECG Project
Cadigan	John	Surgical and Transcatheter Valve Therapy for Congenital Heart Disease	Transcatheter Valve Therapy: The Perspective of a Patient Whose Father is a Cardiologist	Nothing to Disclose
Caffarelli	Anthony	The Spectrum of Aortic Regurgitation and Aortic Pathology	Acute Aortic Syndromes: Update in Management	SPEAKER'S BUREAU - Edwards Life Sciences
Caforio	Alida	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Role of Endomyocardial Biopsy in Patients With Structural Heart Disease and Normal Coronary Arteries Presenting With Ventricular	Nothing to Disclose
Cai	Wenbin	Interventional Cardiology: Translation and Pre-	Arrhythmias Host Intestinal Epithelium Derived MiRNAs Shape the Microbiota	Nothing to Disclose
Cai	Wenbin	Clinical Research Impact of Prenatal Environment on Congenital	and Its Implication in Cardiovascular Diseases Maternal Exosomal miRNAs in Diabetes Contribute to the Cardiac	Nothing to Disclose
Cainzos-Achirica	Miguel	Heart Disease Non Invasive Imaging: Coronary Calcium	Development Deficiency Coronary Artery Calcium and Estimated Cardiovascular Disease	Nothing to Disclose
04.12507.01.11.104	mguo.	Scoring and CV Risk Assessment	Risk in Five Racial/Ethnic Groups Living in the US: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA)	
Cairns	John	Novel Developments in Acute Coronary Syndromes	Incidence and Predictors of No Reflow Phenomenon: Insights From the TOTAL Trial	CONSULTANT FEES/HONORARIA - BMS,Boerhinger Ingelheim Canada; DATA SAFETY MONITORING BOARD - Bayer; RESEARCH/RESEARCH GRANTS - Astra Zeneca,Medtronic Inc ,Sanofi Aventis
calabrò	paolo	Featured Clinical Research II: Interventional	Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD Matrix Study	Nothing to Disclose
Calenda	Brandon	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease		Nothing to Disclose
Calhoon	John	01. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Calhoun	David	Basic Team 1 Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Antihypertensive Treatment Failure Not Attributable to Persistent Intravascular Fluid Retention as Determined by MRI-Measured	CONSULTANT FEES/HONORARIA - Novartis, Valencia Technologies; RESEARCH/RESEARCH GRANTS -
Calhoun	David	33. Prevention: Hypertension Team 2	Intracardiac Volumes Suggested Reviewer	MEDTRONIC,ReCor Medical CONSULTANT FEES/HONORARIA - Novartis,Valencia Technologies; RESEARCH/RESEARCH GRANTS -
Califf	Robert	Are We There Yet? The Long Journey to	ACC-Talk: Achieving Health Equity - What We Need to Do	MEDTRONIC, ReCor Medical Nothing to Disclose
Califf	Robert	Health Equity: Part III	Acute and Stable Ischemic Heart Disease Legend	Nothing to Disclose
Caliskan	Kadir	Stable Heart Disease Legends Arrhythmias and Clinical EP: Devices 1	Long-Term Outcome of Noncompaction Cardiomyopathy Patients	Nothing to Disclose
Caliskan	Kadir	Heart Failure and Cordiomics - Miss.	With Implantable Cardioverter-Defibrillators Compared With Patients With Diated or Hypertrophic Cardiomyopathy	Nothing to Disclose
Caliskan	Kadir	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	A Weaning Marker From Veno-Arterial Extra Corporeal Membrane Oxygenation Using a Novel Microcirculatory Imaging	Nothing to Disclose
Colinkon	Vadir		A Newal Mathed for Early Identification of Control Towns	Nothing to Displace
Caliskan	Kadir	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension The Evolving World of LVADs, Transplant and	A Novel Method for Early Identification of Cardiac Tamponade in Patients With Left Ventricular Assist Devices by Use of Sublingual Microcirculatory Imaging Older Age Combined With Reduced Renal Function Has a Strong	Nothing to Disclose Nothing to Disclose



Last Name	First Name	Session Title	Presentation Title	Disclosures
Caliskan	Kadir	The Evolving World of LVADs, Transplant and	Sudden and Fatal Malfunction After Continuous-Flow Left	Nothing to Disclose
		Other Novel Discoveries	Ventricular Assist Devices: An Urgent Call for Regular Inspections	
Caliskan	Kadir	Why Can't We Be Friends? Controversies in	A Novel Score to Predict Outcome in Patients Supported by Veno-	Nothing to Disclose
		Heart Failure Management	Arterial Extracorporeal Membrane Oxygenation	
Caliskan	Kadir	Advanced Therapies = Advanced Trouble:	Acute Kidney Injury Is Highly Frequent Early After Left Ventricular	Nothing to Disclose
		VAD and Transplant Challenges	Assist Device Implantation With High Morbidity and Mortality Rates:	
Caliskan	Kadir	Advanced Therapies = Advanced Trouble:	A Multicentre Study Proteinuria in Patients Receiving Left Ventricular Assist Devices Is	Nothing to Disclose
Caliskali	Nauli	VAD and Transplant Challenges	Highly Associated With Renal Failure and Mortality	Nothing to Disclose
Calkins	Hugh	Late-Breaking Clinical Trials	Safety and Efficacy of Uninterrupted Anticoagulation With	CONSULTANT FEES/HONORARIA - Abbott, AtriCure, Boehringer
Gainario	ug	Edito Broaking Chinoar Thato	Dabigatran Etexilate Versus Warfarin in Patients Undergoing	Ingelheim Pharmaceuticals, Inc,MEDTRONIC;
			Catheter Ablation of Atrial Fibrillation: The RE-CIRCUIT Study	RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim
				Pharmaceuticals, Inc,St Jude Medical
Calkins	Hugh	Late-Breaking Clinical Trials: Deep Dive II	Safety and Efficacy of Uninterrupted Anticoagulation With	CONSULTANT FEES/HONORARIA - Abbott, AtriCure, Boehringer
			Dabigatran Etexilate Versus Warfarin in Patients Undergoing	Ingelheim Pharmaceuticals, Inc,MEDTRONIC;
			Catheter Ablation of Atrial Fibrillation: The RE-CIRCUIT Study	RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim
Calkins	Hugh	Ventricular Arrhythmias and Sudden Death	Appropriate Implantable Cardioverter Defibrillator Interventions in	Pharmaceuticals, Inc,St Jude Medical CONSULTANT FEES/HONORARIA - Abbott,AtriCure,Boehringer
Caikiiis	riugii	Prevention	Probands and Family Members With Arrhythmogenic Right	Ingelheim Pharmaceuticals, Inc,MEDTRONIC;
		T TOTOMON	Ventricular Cardiomyopathy Dysplasia	RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim
			, , , , , , , , , , , , , , , , , , ,	Pharmaceuticals, Inc,St Jude Medical
Calkins	Hugh	07. Arrhythmias and Clinical EP: Sports and	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott, AtriCure, Boehringer
		Exercise Team 1		Ingelheim Pharmaceuticals, Inc,MEDTRONIC;
				RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim
Callaban	Thomas	Genetic Testing for Cardiomyopathies	Case Presentation in Arrhythmogenic Right Ventricular Dysplasia	Pharmaceuticals, Inc,St Jude Medical CONSULTANT FEES/HONORARIA - Biotronik,St Jude
Callahan Callahan	Thomas Thomas	08. Arrhythmias and Clinical EP:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Biotronik,St Jude
Gallarian	momus	Supraventricular/Ventricular Arrhythmias Team	ouggested Newer	OCHOCE PART LEGITION OF GRANT - BIOLOGIA, OF GRAC
		3		
Calland	James Forrest	Arrhythmias and Clinical EP: Syncope and	Continuous Monitoring of Cardiorespiratory Dynamics Detects	Nothing to Disclose
		Other EP Issues	Clinical Deterioration in Acute Care Patients	
Callans	David	Cardiovascular Update for the Clinician IV:	Panelist	CONSULTANT FEES/HONORARIA - Biosense
		Electrical Failure 2017 Rhythm Disorders (A		Webster, Biotronik, Boston Scientific, MEDTRONIC, St. Jude
		Symposium by Valentin Fuster)		Medical; DATA SAFETY MONITORING BOARD - Hansen
Callans	David	Cardiovascular Update for the Clinician IV:	Atrial Fibrillation- Catheter Ablation Who?, How?, When?	Medical,Impulse Dynamics,nContact,St. Jude Medical CONSULTANT FEES/HONORARIA - Biosense
Callalis	Daviu	Electrical Failure 2017 Rhythm Disorders (A	Atlair ibiliation- Catheter Abiation Wilds, Flows, Whens	Webster, Biotronik, Boston Scientific, MEDTRONIC, St. Jude
		Symposium by Valentin Fuster)		Medical: DATA SAFETY MONITORING BOARD - Hansen
		, , , , , , , , , , , , , , , , , , , ,		Medical,Impulse Dynamics,nContact,St. Jude Medical
Callans	David	Atrial Fibrillation, Anticoagulation and Novel	Anticoagulation Use and Incidence of Cerebrovascular Events and	CONSULTANT FEES/HONORARIA - Biosense
		Device Therapies	Major Bleeding After Catheter Ablation in Patients With Persistent	Webster,Biotronik,Boston Scientific,MEDTRONIC,St. Jude
			and Longstanding Persistent Atrial Fibrillation	Medical; DATA SAFETY MONITORING BOARD - Hansen
0.11	D. 11	00 Ast the description of OlivinateD	0	Medical,Impulse Dynamics,nContact,St. Jude Medical
Callans	David	08. Arrhythmias and Clinical EP:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Biosense Webster,Biotronik,Boston Scientific,MEDTRONIC,St. Jude
		Supraventricular/Ventricular Arrhythmias Team		Medical; DATA SAFETY MONITORING BOARD - Hansen
				Medical, Impulse Dynamics,nContact,St. Jude Medical
Calle Muller	Carlos	Logistical Challenges in STEMI	Fit Case #3: Patient Presenting with Simultaneous STEMI and CVA	Nothing to Disclose
		ů ů	,	Ÿ
Callister	Tracy	Things That Begin With an "A" in Adult	Long-Term Cardiovascular Outcomes in Patients With Anomalous	SPEAKER'S BUREAU - General Electric HealthCare
		Congenital Heart Disease: What Is Aorta,	Coronary Arteries Wisualized by Coronary CT Angiography: The	
		Artery and Anomalous?	CONFIRM (COronary CT Angiography Evaluation For Clinical	
Callister	T	Non levesire levesire. December levelineties	Outcomes: An InteRnational Multicenter) Registry Smoking and its Relationship With Long Term Events: Further	SPEAKER'S BUREAU - General Electric HealthCare
Callister	Tracy	Non Invasive Imaging: Prognostic Implications of CT Angiography	Insights From the CONFIRM (Coronary CT Angiography Evaluation	SPEAKER 5 BUREAU - General Electric HealthCare
		or or Angiography	For Clinical Outcomes: An International Multicenter) Registry	
			To omnour outcomes. The international management (Trogically	
Calverley	Peter	Toward Precision Medicine in the Treatment of	Prognostic Importance of Blood Pressure and Heart Rate in Chronic	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
,		Elevated Blood Pressure	Obstructive Pulmonary Disease: The SUMMIT Trial	Pharmaceuticals, Inc,GSK,Takeda Pharmaceuticals North
				America, Inc
Calverley	Peter		High-Sensitivity Cardiac Troponin I and Risk of Cardiovascular	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
		and Reduction	Events in Patients With COPD and Heightened Cardiovascular Risk:	Pharmaceuticals, Inc,GSK,Takeda Pharmaceuticals North
Cabrillo Argüelles	Oscar	The Challenges of Outcome Prediction in	A Biomarker Sub-Study of the SUMMIT Trial Right Ventricle Free Wall Strain Predicts Post-Surgical Low Cardiac	America, Inc Nothing to Disclose
Calvillo Argüelles	Oscar	Valvular Heart Disease	Output Syndrome in Patients Undergoing Aortic Valve Replacement	Nothing to Disclose
		Valvulai Fleatt Disease	Output Syndrome in Fatients Ondergoing Adultic Valve Replacement	
Camacho	Alvaro	Updates on Risk Factors for Cardiovascular	Association of Anxious and Depressive Symptomatology With	RESEARCH/RESEARCH GRANTS - Armstrong Laboratories,
		Disease	Cardiovascular Disease Among Patients From Different States in	Mexico
			Mexico: REDECAR Study	
Cameron	James	Non Invasive Imaging: Prognostic Implications	Computed Tomography Coronary Angiography Derived Plaque	Nothing to Disclose
		of CT Angiography	Morphology Predicts Major Adverse Cardiovascular Events: Insights	
			From a 19,943 Patient Meta-Analysis	
Camici	Paolo	Highlighted Original Research: Non Invasive	Integrating Hyperemic Myocardial Blood Flow and Coronary Flow	CONSULTANT FEES/HONORARIA - General Electric Health
		Imaging and the Year in Review	Reserve for Predicting Cardiovascular Mortality Outcomes in Patients With Known or Suspected Ischemic Heart Disease	Care,Servier International
Camm	A. John	Stoke and Atrial Fibrillation: Innocent	Stoke Risk and Atrial Fibrillation: What do the Clinical Trials Tell Us?	CONSULTANT FEES/HONORARIA - Bayer, Biotronik, Boehringer
ou	7 001	Bystander or Essential Ingredient	A Personal Perspective	Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi, Incarda
		,		Therapeutics, MEDTRONIC, Menarini, Milestone, Mitsubishi, Novartis
		1		,Richmond Pharmacology,Sanofi Aventis,servier,St Jude
İ		1		Medical,Takeda; SPEAKER'S BUREAU - Pfizer
	ļ			
Camm	A. John	Contemporary Management of Anticoagulation in High-risk Patients with Atrial Fibrillation	State of the Art	CONSULTANT FEES/HONORARIA - Bayer, Biotronik, Boehringer
		in High-risk Patients with Atrial Fibrillation		Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi, Incarda
İ		1		Therapeutics, MEDTRONIC, Menarini, Milestone, Mitsubishi, Novartis . Richmond Pharmacology, Sanofi Aventis, servier, St Jude
İ		1		Medical, Takeda; SPEAKER'S BUREAU - Pfizer
İ		1		
Camm	A. John	Fibrillatory Arrhythmias: Outcomes With	Treatment and Outcomes of Patients With Nonvalvular Atrial	CONSULTANT FEES/HONORARIA - Bayer, Biotronik, Boehringer
1		Contemporary Practice	Fibrillation According to Guideline-Defined Anticoagulation	Ingelheim,Boston Scientific,Bristol Myers Squibb,Daiichi,Incarda
1		1	Thresholds: Results From the GARFIELD-AF Registry	Therapeutics, MEDTRONIC, Menarini, Milestone, Mitsubishi, Novartis
		1		Richmond Pharmacology, Sanofi Aventis, servier, St Jude
		1		Medical,Takeda; SPEAKER'S BUREAU - Pfizer
Camm	A John	Arrhythmiae and Clinical ED: Antioografia-	Real-World Versus Randomized Trial Outcomes in Similar	CONSULTANT FEES/HONORARIA - Bayer,Biotronik,Boehringer
Camm	A. John	Arrhythmias and Clinical EP: Anticoagulation	Real-World Versus Randomized Trial Outcomes in Similar Populations of Rivaroxaban-Treated Patients With Nonvalvular Atrial	Ingelheim,Boston Scientific,Bristol Myers Squibb,Daiichi,Incarda
İ		Issues	Fibrillation in ROCKET AF and XANTUS	Ingelneim, Boston Scientific, Bristol Myers Squibb, Dailchi, incarda Therapeutics, MEDTRONIC, Menarini, Milestone, Mitsubishi, Novartis
İ		1	DIMENSI II INCONET AII WIIG ANTI UU	Richmond Pharmacology,Sanofi Aventis,servier,St Jude
		1		Medical, Takeda; SPEAKER'S BUREAU - Pfizer
	<u> </u>			
Camm	A. John	Antithrombotic Therapy in Ischemic Heart	Time-Trends in Antithrombotic Management of Patients With	CONSULTANT FEES/HONORARIA - Bayer, Biotronik, Boehringer
		Disease	AF/Flutter Treated With Coronary Stents: An International	Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi, Incarda
İ		1	Multicenter Restrospective Analysis	Therapeutics, MEDTRONIC, Menarini, Milestone, Mitsubishi, Novartis
		1		Richmond Pharmacology,Sanofi Aventis,servier,St Jude, Medical,Takeda; SPEAKER'S BUREAU - Pfizer
1		1		INICUIOGI, I ANGUA, OF EAREN O DUNEAU - MIZEI
	1	1		



and a				<u> </u>
Last Name Camm	First Name A. John	Session Title Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Presentation Title ACC Poster Moderator	Disclosures CONSULTANT FEES/HONORARIA - Bayer,Biotronik,Boehringer Ingelheim, Boston Scientific,Bristol Myers Squibb,Dalichi,Incarda Therapeutics,MEDTRONIC,Menarini,Milestone,Mitsubishi,Novartis,Richmond Pharmacology,Sanof Aventis,servier,St Jude Medical,Takeda; SPEAKER'S BUREAU - Přízer
Camm	A. John	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Early Mortality in Patients With New Onset Atrial Fibrillation: Results From the GARFIELD-AF Registry	CONSULTANT FEES/HONORARIA - Bayer,Biotronik,Boehringer Ingelheim,Boston Scientific,Bristol Myers Squibb,Daiichi,Incarda Therapeutics,MEDTRONIC,Menarini,Milestone,Milsubishi,Novartis,Richmond Pharmacology,Sanofi Aventis,
Camm	A. John	Stroke and AF: Thinking About the Heart	The Prescribing of Antiplatelet Therapy Only in Patients With Nonvalvular Atrial Fibrillation: Results From the GARFIELD-AF Registry	CONSULTANT FEES/HONORARIA - Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi, Incarda Therapeutics, MEDTRONIC, Menarini, Milestone, Mitsubishi, Novartis Richmond Pharmacology, Sanofi Aventis, servier, St Jude Medical, Takeda; SPEAKER'S BUREAU - Pfizer
Campagnoli	Tania	Nuclear Cardiology: Prognosis	The Prognostic Value of Serial Stress Myocardial Perfusion Imaging in Asymptomatic End-Stage Renal Disease Patients Awaiting Kidney Transplantation	Nothing to Disclose
Campbell	Charles	FIT Forum: Stump the Professor	First Case on Biventricular Mechanical Circulatory Support With Impella CP and Impella RP for a Patient With Acute Myocardial Infarction Induced Cardiogenic Shock	Nothing to Disclose
Campbell	Kevin	Are We There Yet? The Long Journey to Health Equity: Part III	Engaging Patients in Their CV Care: Mobile Devices and Beyond	CONSULTANT FEES/HONORARIA - Biotronik,St Jude Medical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Alive Cor
Campbell	Kevin	Social Media and the Cardiovascular Professionals: Lessons Learned and Future Applications	Co-Chair	CONSULTANT FEES/HONORARIA - Biotronik,St Jude Medical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Alive Cor
Campbell	Kevin	Social Media and the Cardiovascular Professionals: Lessons Learned and Future Applications	Panelist	CONSULTANT FEES/HONORARIA - Biotronik, St Jude Medical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Alive Cor
Campbell	Kevin	Social Media and the Cardiovascular Professionals: Lessons Learned and Future Applications	ACC-Talk: Social Media, Medicine and the FDAEvolving Regulation	CONSULTANT FEES/HONORARIA - Biotronik,St Jude Medical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Alive Cor
Campbell	Robert	Value, Advocacy and the Future of Adult Congenital and Pediatric Cardiology	Co-Chair	Nothing to Disclose
Campbell	Robert	Value, Advocacy and the Future of Adult Congenital and Pediatric Cardiology	Panel Introduction:Toward a Better Understanding of Long-Term CHD Care Outcomes: Lessons Learnedfrom CHD Community Day	Nothing to Disclose
Campia	Umberto	Vascular Diagnoses Cardiologists Should not Miss: A Case-based Approach	Co-Chair	SPEAKER'S BUREAU - BMS-Pfizer,BMS-Pfizer
Campia	Umberto	Vasculo-Oncology: What You Need to Know About Vascular and Thrombotic Complications of Cancer and Cancer Therapeutics	Co-Chair	SPEAKER'S BUREAU - BMS-Pfizer,BMS-Pfizer
Campia	Umberto	Optimizing Treatment of Peripheral Artery	ACC Poster Moderator	SPEAKER'S BUREAU - BMS-Pfizer,BMS-Pfizer
Campia	Umberto	Disease Improving Risk Assessment in Atherosclerosis	ACC Poster Moderator	SPEAKER'S BUREAU - BMS-Pfizer,BMS-Pfizer
Campia	Umberto	40. Vascular Medicine: Non Coronary Arterial	Suggested Reviewer	SPEAKER'S BUREAU - BMS-Pfizer,BMS-Pfizer
Campodonico	Jeness	Disease Team 1 Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Renal Replacement Therapy in Patients With Acute Myocardial Infarction: Rate of Use, Clinical Predictors and Relationship With In-Hospital Mortality	Nothing to Disclose
Campodonico	Jeness	Post-CAD/MI: Making Tough Predictions About the Future		Nothing to Disclose
Campos	Enrique	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Bypass Grafts to Patent Coronary Arteries	Nothing to Disclose
Campuzano Larrea	Oscar	Cardiac Channelopathies: Novel Therapeutics and Clinical Challenges	Eficacy and Safety of Flecainide to Reduce Exercise-Induced Ventricular Arrhythmias and the Arrhythmic Window in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia	Nothing to Disclose
Can	Levent	Advances in Pulmonary Arterial Hypertension	Comparisons of Invasive and Non-Invasive Cardiac Output Measurment Methods in Pulmonary Hypertension	Nothing to Disclose
Canada	Justin	Making Progress in Understanding Heart Failure	Arterial Elastance Drives Ventilatory Inefficiency in Systolic Heart Failure	Nothing to Disclose
Canada	Justin	Emerging Developments in HFpEF and Arryhthmias	Early Diastolic Mitral Annular Velocity at Peak Exercise Determines Peak Aerobic Exercise Capacity in Heart Failure With Preserved Ejection Fraction	Nothing to Disclose
Canan	Timothy	The Best Structural Interventional Challenging Cases	Microcoil Embolization of an Aortic Root Pseudoaneurysm Through a Transthoracic Approach	Nothing to Disclose
Candeloro	Christina	Multi-Disciplinary Care for Acute Pulmonary Embolism: The PE Response Team (PERT) Model	Panelist	Nothing to Disclose
Cannom	David	07. Arrhythmias and Clinical EP: Sports and Exercise Team 1	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Boston Scientific - PI for MADIT-CRT & DESCRIPTION RIT at Good Samaritan; SPEAKER'S BUREAU - Boston Scientific - Speakers Bureau, Medtronic - Speakers Bureau, Sanoft-Aventis
Cannon	Bryan	ECG Screening in Athletes: The Great Debate	Debate: ECG Screening Should Be Routinely Performed in Athletes, Con	DATA SAFETY MONITORING BOARD - MEDTRONIC; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Mayo Support SErvices Texas
Cannon	Bryan	Test Yourself with Questions: Pediatric Cardiology	Faculty	DATA SAFETY MONITORING BOARD - MEDTRONIC; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Mayo Support SErvices Texas
Cannon	Bryan	Ventricular Arrhythmias and Sudden Death Prevention	ACC Poster Moderator	DATA SAFETY MONITORING BOARD - MEDTRONIC; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Mayo Support SErvices Texas
Cannon	Bryan	05. Arrhythmias and Clinical EP: Devices Team 1	Suggested Reviewer	DATA SAFETY MONITORING BOARD - MEDTRONIC; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Mayo Support SErvices Texas
Cannon	Christopher	Making Progress in Understanding Heart Failure	Serial Assessment of Heart Rate and Beta Blocker Use in Chronic Heart Failure Patients With Reduced Ejection Fraction in a Large Integrated Healthcare Network	CONSULTANT FEES/HONORARIA - Alnylam, Amgen, Arisaph, Arisaph, AstraZeneca, BMS, Boehringer- Ingelheim, GSK, Kowa, Lipimedix, Merck, Pfizer, Regeneron/Sanofi , Takeda: RESEARCH/RESEARCH GRANTS - Amgen, BMS, Boehringer-Ingelheim, Dailchi Sankyo, Janssen Pharmaceuticals, Inc. Merck, Takeda
Cannon	Christopher	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Lower On-Treatment Low-Density Lipoprotein Cholesterol Is Associated With Lower Cardiovascular Risk in Very High Risk Patients With Atherosclerotic Cardiovascular Disease: Analyses From the ODYSSEY Trials	CONSULTANT FEES/HONORARIA - Alnylam, Amgen, Arisaph, Arisaph, AstraZeneca, BMS, Boehringer- Ingelheim, GSK, Kowa, Lipimedix, Merck, Pfizer, Regeneron/Sanofi , Takeda: RESEARCH/RESEARCH GRANTS - Amgen, BMS, Boehringer-Ingelheim, Dailchi Sankyo, Janssen Pharmaceuticals, Inc. Merck, Takeda

and a				<u> </u>
Last Name	First Name	Session Title Traditional and Novel Factors Used to Assess	Presentation Title Cvstatin C Is Associated With the Risk of Adverse Outcomes	Disclosures
Cannon	Christopher	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Cystain C is Associated with the Kisk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial	CONSULTANT FEES/HONORARIA - Alnylam,Amgen,Arisaph,Arisaph,AstraZeneca,BMS,Boehringer- Ingelheim, GSK,Kowa,Lipimedix,Merck,Pfizer,Regeneron/Sanofi Takeda; RESEARCH/RESEARCH GRANTS -
				Amgen,BMS,Boehringer-Ingelheim,Daiichi Sankyo,Janssen Pharmaceuticals, Inc,Merck,Takeda
Cannon	Christopher	Advances in Lipid Management	Ezetimibe Real-World Effectiveness at Reaching Low-Density Lipoprotein Goal Among Patients With Atherosclerotic Cardiovascular Disease: A Retrospective Database Study in the United States	CONSULTANT FEES/HONORARIA - Alnylam, Amgen, Arisaph, Arisaph, AstraZeneca, BMS, Boehringer- Ingelheim, GSK, Kowa, Lipimedix, Merck, Pfizer, Regeneron/Sanofi , Takeda; RESEARCH/RESEARCH GRANTS - Amgen, BMS, Boehringer-Ingelheim, Daiichi Sankyo, Janssen Pharmaceuticals, Inc. Merck, Takeda
Cannon	Christopher	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Lower On-Treatment Low-Density Lipoprotein Cholesterol Is Associated With Lower Cardiovascular Risk in Women: Analyses From the ODYSSEY Trials of Alirocumab Versus Control	CONSULTANT FEES/HONORARIA - Alnylam Amgen Arisaph, Arisaph, AstraZeneca, BMS, Boehringer- Ingelheim, GSK, Kowa Lipimedi, Merck, Pfizer, Regeneron/Sanofi, Takeda; RESEARCH/RESEARCH GRANTS - Amgen, BMS, Boehringer-Ingelheim, Dalichi Sankyo, Janssen Pharmaceuticals, Inc.Merck, Takeda
Cannon	Christopher	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Early Versus Late Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome: Insights From the Examine Trial	CONSULTANT FEES/HONORARIA - Alnylam Amgen Arisaph, Arisaph, AstraZeneca, BMS, Boehringer- Ingelheim, GSK, Kowa, Lipimedii, Merck, Pfizer, Regeneron/Sanofi, Takeda; RESEARCH/RESEARCH GRANTS - Amgen, BMS, Boehringer-Ingelheim, Dalichi Sankyo, Janssen Pharmaceuticals, Inc.Merck, Takeda
Cannon	Christopher	Breakthrough Therapies: Your Role in Protecting the Heart of Your Patients with Diabetes	Chair	CONSULTANT FEES/HONORARIA - Alnylam Amgen Arisaph, Arisaph, AstraZeneca, BMS, Boehringer- Ingelheim, GSK, Kowa Lipimedix, Merok, Pfizer, Regeneron/Sanofi, Takeda; RESEARCH/RESEARCH GRANTS - Amgen, BMS, Boehringer-Ingelheim, Daiichi Sankyo, Janssen Pharmaceuticals, Inc. Merck, Takeda
Cannon	Christopher	Breakthrough Therapies: Your Role in Protecting the Heart of Your Patients with Diabetes	introduction to Session and ARS Technology: CME Done Differently	CONSULTANT FEES/HONORARIA - Alnylam, Amgen, Arisaph, Asisaph, AsiraZeneca, BMS, Boehringer- Ingelheim, GSK, Kowa, Lipimedix, Merck, Pfizer, Regeneron/Sanofi , Takeda; RESEARCH/RESEARCH GRANTS - Amgen, BMS, Boehringer-Ingelheim, Dalichi Sankyo, Janssen Pharmaceuticals, Inc. Merck, Takeda
Cannon	Christopher	Breakthrough Therapies: Your Role in Protecting the Heart of Your Patients with Diabetes	Pragmatic Conversations: Your Role in Protecting the Heart - Panel Debate	CONSULTANT FEES/HONORARIA - Alnylam, Amgen, Arisaph, Arisaph, AstraZeneca, BMS, Boehringer- Ingelheim, GSK, Kowa, Lipimedii, Merck, Pfizer, Regeneron/Sanofi , Takeda; RESEARCH/RESEARCH GRANTS - Amgen, BMS, Boehringer-Ingelheim, Dailichi Sankyo, Janssen Pharmaceuticals, Inc.Merck, Takeda
Cannon	Christopher	Breakthrough Therapies: Your Role in Protecting the Heart of Your Patients with Diabetes	Concluding Remarks	CONSULTANT FEES/HONORARIA - Alnylam, Amgen, Arisaph, AsiraZeneca, BMS, Boehringer- Ingelheim, GSK, Kowa, Lipimedix, Merck, Pfizer, Regeneron/Sanofi, Takeda; RESEARCH/RESEARCH GRANTS- Amgen, BMS, Boehringer-Ingelheim, Daiichi Sankyo, Janssen Pharmaceuticals, Inc, Merck, Takeda
Cannon	Christopher	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	impact of Statin Intolerance Rates on Need for Ezetimibe and/or PCSK9 Inhibitors for Meeting Low-Density Lipoprotein Goals in a Real-World Cohort With Atherosclerotic Cardiovascular Disease	CONSULTANT FEES/HONORARIA - Alnylam, Amgen, Arisaph, Astra Zeneca, BMS, Boehringer- Ingelheim, GSK, Kowa, Lipimedix, Merck, Pfizer, Regeneron/Sanofi , Takeda: RESEARCH/RESEARCH GRANTS - Amgen, BMS, Boehringer-Ingelheim, Dailchi Sankyo, Janssen Pharmaceuticals, Inc. Merck, Takeda
Cannon	Christopher	Innovation in Practice Management, Advocacy, and Education	Effect of an Online Continuing Medical Education and Clinician Coaching Quality Improvement Initiative on Antiplatelet Medication Adherence and Hospital Readmissions in Patients With Acute Coronary Syndrome	CONSULTANT FEES/HONORARIA - Alnylam,Amgen,Arisaph,Arisaph,AstraZeneca,BMS,Boehringer- Ingelheim,GSK,Kowa,Lipimedix,Merck,Pfizer,Regeneron/Sanofi ,Takeda: RESEARCH/RESEARCH GRANTS - Amgen,BMS,Boehringer-Ingelheim,Daiichi Sankyo,Janssen Pharmaceuticals, Inc.Merck,Takeda
Cannon	Christopher	The Intersection of Diabetes and ASCVD	Average Clinician Measured Blood Pressure Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes Following Acute Coronary Syndromes in the EXAMINE Trial	CONSULTANT FEES/HONORARIA - Alnylam, Amgen, Arisaph, AsiraZeneca, BMS, Boehringer- Ingelheim, GSK, Kowa, Lipimedix, Merck, Pfizer, Regeneron/Sanofi, Takeda; RESEARCH/RESEARCH GRANTS- Amgen, BMS, Boehringer-Ingelheim, Daiichi Sankyo, Janssen Pharmaceuticals, Inc, Merck, Takeda
Cannon	Christopher	Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Alnylam Amgen Arisaph, Arisaph, AstraZeneca, BMS, Boehringer- Ingelheim, GSK, Kowa Lipimedix, Merok, Pfizer, Regeneron/Sanofi, Takeda; RESEARCH/RESEARCH GRANTS - Amgen, BMS, Boehringer-Ingelheim, Daiichi Sankyo, Janssen Pharmaceuticals, Inc. Merck, Takeda
Cannon	Louis	Refining PCI Technique and Outcomes	Three-Year Results From the EVOLVE II Randomized Trial: Late Clinical Outcomes With Bioresorbable Compared to Permanent Polymer Everolimus-Eluting	CONSULTANT FEES/HONORARIA - Abbott Boston Scientific,MEDTRONIC; EQUITY INTERESTS/STOCK OPTIONS Boston Scientific,MEDTRONIC; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - CV Ingenuity,Kona Medicai; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Autonomix, BioStar FP, PEF and BioStar Ventures II, BioStar Ventures IIA, BioStar Ventures Fund III, bioStar ventures; RESEARCH/RESEARCH GRANTS - Abbott Vascular; SPEAKER'S BUREAU - Abbott Vascular,Boston Scientific,MEDTRONIC
Cano	Manuel	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Independent Predictors of Mace at Different Time Points After the Treatment of Non-Selected Patients With Drug-Eluting Stents: An Analysis of the Desire Registry	Nothing to Disclose
Canobbio	Mary	Patient-Centered Care in Adult Congenital Heart Disease	Panelist	Nothing to Disclose
Canobbio	Mary	Patient-Centered Care in Adult Congenital Heart Disease	Advising and Empowering the Patients about Sex, Pregnancy, Birth Control and Parenthood: They are Part of Life	Nothing to Disclose
Cantor	Warren	Global Perspectives in the Treatment of ST Elevation Myocardial Infarction: Successes, Failures, and Challenges	Control and Parentnood: They are Part of Life Single-payor STEMI Systems of Care: The Canadian Experience	CONSULTANT FEES/HONORARIA - Astra Zeneca,Bayer Healthcare Pharmaceuticals
Cantor	Warren	Considerations in Antiplatelet Therapy and in ACS	Effects of Ticagrelor Versus Clopidogrel in Fibrinolytic-Treated STEMI Patients Undergoing Early PCI	CONSULTANT FEES/HONORARIA - Astra Zeneca,Bayer Healthcare Pharmaceuticals
Cantor	Warren	Interventional Complexity and Complications	Variability in Transfemoral Access for Coronary Angiography and	CONSULTANT FEES/HONORARIA - Astra Zeneca, Bayer
		, , ,	Interventions: Results From an International Survey	Healthcare Pharmaceuticals
Canty Canty	John John	FIT Forum: Mix and Mingle Molecular Imaging in Heart Failure	Basic Science Imaging of Myocardial Innervation	Nothing to Disclose Nothing to Disclose
Cao	Jie	16. Interventional Cardiology: Angiography and Interventional CT/MR Team 1	Suggested Reviewer	Nothing to Disclose
Capodanno	Davide	Coronary Intervention: Drug Eluting Stent and Scaffolds	Early, Late and Very Late Incidence of Bioresorbable Scaffold Thrombosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials and Observational Registries	CONSULTANT FEES/HONORARIA - Abbott Vascular, Aspen, Astra Zeneca, Cordis, Daichi Sankyo, DirectFlow Medical, Eli-Lilly, Sanofi Aventis; SPEAKER'S BUREAU - Bayer

and a				<u> </u>
Last Name Capodanno	First Name Davide	Session Title 15. Interventional Cardiology:	Presentation Title Suggested Reviewer	Disclosures CONSULTANT FEES/HONORARIA - Abbott
		ACS/AMI/Hemodynamics and Pharmacology Team 2		Vascular, Aspen, Astra Zeneca, Cordis, Daichi Sankyo, Direct Flow Medical, Eli-Lilly, Sanofi Aventis; SPEAKER'S BUREAU - Bayer
Capoulade	Romain	Novel Determinants of Outcomes in VHD	Impact of Aortic Valve Calcification and Sex on Hemodynamic Progression and Clinical Outcomes in Aortic Stenosis	Nothing to Disclose
Capoulade	Romain	Novel Determinants of Outcomes in VHD	Relationship Between Proximal Aorta Morphology and Progression Rate of Aortic Stenosis	Nothing to Disclose
Cappato	Riccardo	06. Arrhythmias and Clinical EP: Other Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Bayer Healthcare Pharmaceuticals, Biosense Webster, Inc., Boehringer Ingelheim Pharmaceuticals, Inc, Boston Scientific Corp., MEDTRONIC, Pfizer Inc, St. Jude Medical
Cappola	Thomas	The Old and the New: Impact of Heart Failure Drug Therapies	Liraglutide and Weight Loss Among Patients With Advanced Heart Failure and a Reduced Ejection Fraction: Insights From the FIGHT Trial	CONSULTANT FEES/HONORARIA - Teva
Capranzano	Piera	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: From the WIN-TAVI Registry	Nothing to Disclose
Caprihan	Rupa	Non Invasive Imaging: Expanding Clinical Applications	Does Patient Prosthesis Mismatch Defined by CT LVOT Area Predict Downstream Clinical Outcomes?	Nothing to Disclose
Caprihan	Rupa	Interventional Cardiology: PCI and TAVR in Complex Patients	Long-Term Adverse Ischemic Outcomes After Percutaneous Coronary Intervention Among Patients With Versus Without Prior Coronary Artery Bypass Grafting: Analysis From 17 Randomized Trials	Nothing to Disclose
Carabello Carabello	Blase Blase	FIT Forum: Mix and Mingle Valvular Heart Disease Guidelines The	Education What Changed? - The Scope of the VHD Focused Update: Mitral	DATA SAFETY MONITORING BOARD - Edwards DATA SAFETY MONITORING BOARD - Edwards
		Evidence and the Gaps	Regur.	
Carabello	Blase	Core Curriculum: Valvular Heart Disease Management Issues	Chair	DATA SAFETY MONITORING BOARD - Edwards
Carabello Carabello	Blase Blase	FIT Forum: Stump the Professor FIT Clinical Decision Making: Non-Invasive	Stump the Professor Judge An Unusual Extrinsic Pulmonary Artery Compression Caused by	DATA SAFETY MONITORING BOARD - Edwards DATA SAFETY MONITORING BOARD - Edwards
Carabello	Blase	Imaging and Valvular Heart Disease 17. Interventional Cardiology: Aortic Valve	Traumatic Cardiac Hernia Suggested Reviewer	DATA SAFETY MONITORING BOARD - Edwards
		Disease Team 1		
Carberry	Jaclyn	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Prognostic Significance of Co-Existing Persistent Edema and Hemorrhage at 6 Months in Survivors of ST-Elevation Myocardial Infarction	Nothing to Disclose
Carberry	Jaclyn	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Decision Making Using Fractional Flow Reserve Is Associated With Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With Nstemi	Nothing to Disclose
Carberry	Jaclyn	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Incidence and Prognostic Implications of the Presence of Multiple Complex Plaques in Survivors of ST-Elevation Myocardial Infarction	Nothing to Disclose
Carbone	Salvatore	Making Progress in Understanding Heart Failure	Arterial Elastance Drives Ventilatory Inefficiency in Systolic Heart Failure	Nothing to Disclose
Carbone	Salvatore	Interdisciplinary Cardiovascular Team Collaboratives in Care	Management of Obesity in Patients With Diastolic Dysfunction	Nothing to Disclose
Carbone	Salvatore	Emerging Developments in HFpEF and Arryhthmias	Early Diastolic Mitral Annular Velocity at Peak Exercise Determines Peak Aerobic Exercise Capacity in Heart Failure With Preserved	Nothing to Disclose
Cardinale	Daniela	Heart Failure and Cancer Care	Ejection Fraction Case Presentation: How to Detect Cardiac Injury with Cardiotoxic Chemotherapy — Is Ejection Fraction Still the Gold Standard?	Nothing to Disclose
Cardoso	Rhanderson	Arrhythmias and Clinical EP: Ventricular	Evidence to Practice Roundtable Discussion Percutaneous Epicardial Mapping and Ablation of Ventricular	Nothing to Disclose
Cardoso	Rhanderson	Tachycardia Heart Failure and Cardiomyopathies: Heart	Tachycardia: A Systematic Review of Safety Outcomes A Meta-Analysis of Randomized Controlled Trials on Vagus Nerve	Nothing to Disclose
Cardoso	Rhanderson	Failure Gadgets Galore Advances in HCM, PPCM and Other Cardiomyopathies	Stimulation for the Heart Failure Management Extended Remission and Late Re-Decompensation of Dilated Cardiomyopathy Associated With a Novel Ribonucleic Acid Binding	Nothing to Disclose
Cardoso	Rhanderson	Cutting Edge Vascular Medicine	Motif Protein 20 (RBM20) Mutation A Meta-Analysis of Bivalirudin Versus Argatroban for the Treatment	Nothing to Disclose
Cardoso	Rhanderson	Innovative Approaches for Reducing Risk and	of Heparin-Induced Thrombocytopenia Endo-Epicardial Versus Endocardial-Only Approach for First	Nothing to Disclose
		Improving Outcomes With Ablation	Ventricular Tachycardia Ablation: A Systematic Review and Meta- Analysis of Safety and Efficacy Outcomes	
Cardozo	Shaun	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	In-Hospital Outcomes After MitraClip Implantation in the United States: 2010-2012	Nothing to Disclose
Cardozo	Shaun	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	A Rush of Blood to the Head: Anomalous Superior Vena Cava Drainage to Left Atrium	Nothing to Disclose
Cardozo	Shaun	Interventional Cardiology: PCI and TAVR in Complex Patients	Economic Implications of Late Discharge After Transcatheter Aortic Catheter Implantation	Nothing to Disclose
Cardozo	Shaun	Emerging Developments in HFpEF and Arryhthmias	Hospitalization Burden of Diastolic Heart Failure in the United States: 2007-2012	Nothing to Disclose
Carhart	Robert	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Cardioembolic Stroke Due to Takotsubo Cardiomyopathy, Truly Rare or Under-Recognized?	Nothing to Disclose
Carlisle	Adam	Disease, and Vascular Medicine FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Recurrent Atrial Myxomas of Carney Complex: Pleading the Fifth	Nothing to Disclose
Carlquist	John	Arrhythmias and Clinical EP: AF Miscellaneous		Nothing to Disclose
Carlsen	Jorn	and Surgical Issues Advances in Pulmonary Arterial Hypertension	Recurrence of Atrial Fibrillation Exercise During Cardiac Magnetic Resonance Imaging Dilates the Right Ventricle and Compresses the Left Ventricle in Pulmonary	RESEARCH/RESEARCH GRANTS - Actelion
Carlsen	Jorn	Advances in Pulmonary Arterial Hypertension	Arterial Hypertension Optimizing Assessment of Right Ventricular Stroke Volume Using Flow Cardiovascular Magnetic Resonance Imaging in Pulmonary	RESEARCH/RESEARCH GRANTS - Actelion
Carlson	Kathleen	Novel Echocardiographic Methods for Assessing Cardiac Function	Arterial Hypertension Echocardiographic Evidence for Left Ventricular Recovery After Refractory Ventricular Fibrillation Cardiac Arrest Treated With	Nothing to Disclose
Carlson	Kathleen	New Technologies in Echocardiography	Primary Angioplasty and Extracorporeal Membrane Oxygenation Transthoracic Echocardiography to Guide Extracorporeal Membrane Oxygenation Decannulation After Refractory Ventricular Fibrillation Cardiac Arrest Treated With Primary Angioplasty: A Turndown Protocol	Nothing to Disclose
Carlson	Selma	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Capacity for Heart Failure Diagnosis and Treatment in Sub-Saharan Africa: Analysis of the Access, Bottlenecks, Costs, and Equity Study	Nothing to Disclose
Carison			in Kenya and Uganda	
Carlsson	Axel	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	in Kenya and Uganda Risk of Readmissions After Myocardial Infarction in Women Versus Men	Nothing to Disclose

Contract of the second				l
Last Name Carr	First Name Jeffrey	Session Title Current Issues in Cardiovascular	Presentation Title Underutilization of Statin Therapy Among Participants in a Lung	Disclosures Nothing to Disclose
Can	beiney	Epidemiology, Disparities, and Safety	Cancer Screening Program With a High Incidence of Cardiovascular Events	Nothing to Disclose
Carr	John	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium Scores for Atherosclerotic Cardiovascular Disease Risk Stratification in Smokers: MESA	Nothing to Disclose
Carr	John	Innovations in Cardiovascular Risk Assessment	Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in	Nothing to Disclose
Carr	John	and Reduction Non Invasive Imaging: Prognostic Implications	African Americans: The Jackson Heart Study Coronary Artery Structural Remodeling by Computed Tomography	Nothing to Disclose
		of CT Angiography	and Echocardiographic Left Ventricular Mass Changes Over the Next 5 Years: The Coronary Artery Risk Development in Young Adults (CARDIA) Study	
Carr	John	Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools	Association of 10-Year Change in Cardiovascular Risk Factors With Progression of Pericardial Adipose Tissue: The CARDIA Study	Nothing to Disclose
Carr	John	Improving Risk Assessment in Atherosclerosis	N-Terminal Pro B-Type Natriuretic Peptide, Race, and Flow- Mediated Dilation: Multi-Ethnic Study of Atherosclerosis	Nothing to Disclose
Carreras	Edward	Interventional Cardiology: TAVR 1	Impact of Flow, Gradient, and Left Ventricular Function on Outcomes After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Carreras	Edward	Interventional Cardiology: TAVR 3	The Incidence of Permanent Pacemaker Implantation With SAPIEN 3 Heart Valve - Implantation Depth: The Higher the Better?	Nothing to Disclose
Carrero	Juan Jesus	Why Can't We Be Friends? Controversies in Heart Failure Management	Association Between Serum Potassium Level and Outcomes in Heart Failure With Reduced Ejection Fraction: A Cohort Study From the Swedish Heart Failure Registry	Nothing to Disclose
Carrick	David	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Prognostic Significance of Co-Existing Persistent Edema and Hemorrhage at 6 Months in Survivors of ST-Elevation Myocardial Infarction	Nothing to Disclose
Carrick	David	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Segmental Circumferential Strain Derived From DENSE Predicts Improvement of Left Ventricular Function Post ST Elevation Myocardial Infarction: The BHF MR-MI Study	Nothing to Disclose
Carrick	David	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Current Smoking, Microvascular Pathology and Adverse Outcome After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights	Nothing to Disclose
Carrick	David	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Incidence and Prognostic Implications of the Presence of Multiple Complex Plaques in Survivors of ST-Elevation Myocardial Infarction	Nothing to Disclose
Carrick	David	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Hypertension, Microvascular Pathology and Prognosis in Patients With an Acute ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Carroll	Brett	Updates on Pulmonary Embolism Management in 2017	Evaluation of Right Ventricular Strain by Echocardiography, Computed Tomography, and Electrocardiography in Patients With Acute Pulmonary Embolism	Nothing to Disclose
Carroll	Brett	Arrhythmias and Clinical EP: AF Ablation	Association of Adverse Clinical Outcomes in Patients With Acute Pulmonary Embolism and Coronary Artery Calcifications Visualized on Computed Tomography	Nothing to Disclose
Carroll	Brett	Interdisciplinary Cardiovascular Care in Complex Scenarios	Thirteen Lives: Massive Pulmonary Embolism Causing Twelve Episodes of Cardiac Arrest Managed by an Interdisciplinary Pulmonary Embolism Consult Team	Nothing to Disclose
Carroll	Brett	Highlights in Vascular Medicine Research	ACC Poster Moderator	Nothing to Disclose
Carroll	John	Featured Clinical Research II: Interventional	Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data	CONSULTANT FEES/HONORARIA - Philips healthcare; DATA SAFETY MONITORING BOARD - Tendyne; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, EvalveAbbott Structural Heart Disease, MEDTRONIC, Philips healthcare; St Jude Medical Corp
Carroll	John	Featured Clinical Research II: Interventional	Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis From the STS/ACC TVT Registry	CONSULTANT FEES/HONORARIA - Philips healthcare; DATA SAFETY MONITORING BOARD - Tendyne; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, Evalve/Abbott Structural Heart Disease, MEDTRONIC, Philips healthcare, St Jude Medical Corp
Carroll	John	Challenging Anatomies: Does TAVR Device Choice Matter	Panelist	CONSULTANT FEES/HONORARIA - Philips healthcare; DATA SAFETY MONITORING BOARD - Tendyne; RESEARCH/IRESEARCH GRANTS - Edwards Lifesciences, Evalve/Abbott Structural Heart Disease, MEDTRONIC, Philips healthcare, St Jude Medical Corp
Carroll	John	PFO Closure, PV Leak, and VSD Repair	Co-Chair	CONSULTANT FEES/HONORARIA - Philips healthcare; DATA SAFETY MONITORING BOARD - Tendyne; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, Evalve/Abbott Structural Heart Disease, MEDTRONIC, Philips healthcare, St Jude Medical Corp
Carroll	John	PFO Closure, PV Leak, and VSD Repair	Current State of the Data for PFO Closure After Cryptogenic Stroke	CONSULTANT FEES/HONORARIA - Philips healthcare; DATA SAFETY MONITORING BOARD - Tendyne; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, Evalve/Abbott Structural Heart Disease, MEDTRONIC, Philips healthcare; St Jude Medical Corp
Carroll	John	Post FDA Release Prosthetic Valve Surveillance - Watching for Signals	ACC-STS TAVR Registry: Prosthetic signals?	CONSULTANT FEES/HONORARIA - Philips healthcare; DATA SAFETY MONITORING BOARD - Tendyne; RESEARCH/IRESEARCH GRANTS - Edwards Lifesciences, Evalve/Abbott Structural Heart Disease, MEDTRONIC, Philips healthcare, St Jude Medical Corp
Carroll	John	Novel Echocardiographic Methods for Assessing Cardiac Function	Comparison of the Effects of Balloon Expandable and Self Expandable Transcatheter Aortic Valve Replacement on the Dimensions of the Mitral Valve Annulus and Mitral Regurgitation Severity	CONSULTANT FEES/HONORARIA - Philips healthcare; DATA SAFETY MONITORING BOARD - Tendyne; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, Evalve/Abbott Structural Heart Disease, MEDTRONIC, Philips healthcare, St Jude Medical Corp
Carroll	John	Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment	Panelist	CONSULTANT FEES/HONORARIA. Philips healthcare; DATA SAFETY MONITORING BOARD - Tendyne; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, Evalve/Abbott Structural Heart Disease, MEDTRONIC, Philips healthcare, St Jude Medical Corp
Carroll	John	17. Interventional Cardiology: Aortic Valve Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Philips healthcare; DATA SAFETY MONITORING BOARD - Tendyne; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, Evalve/Abbott Structural Heart Disease, MEDTRONIC, Philips healthcare, St Jude Medical Corp
Carrozza	Joseph	Interventional Challenging Cases: Team 1	ACC Challenging Case Reviewer	DATA SAFETY MONITORING BOARD - CardioVascular Research Foundation, CardioVascular Research Foundation, Duke Clinical Research Institute
Carruthers	David	Imaging the Athlete's Heart	Pooled Cohort Equation and Coronary Artery Calcium in Retired National Football League Athletes	Nothing to Disclose
Carruthers	David	Hearts and Soles: Multimodality Imaging in Athletes	Ascending Aortic Dimensions in Former National Football League Athletes	Nothing to Disclose
Carson	April	Advances in Cholesterol Measurement and	Psychosocial Factors and Statin Intolerance: Data From the	Nothing to Disclose
		Management	REasons for Geographic And Racial Differences in Stroke (REGARDS) Study	

1				
Carron	First Name	Session Title Novel Developments in Acute Coronary	Presentation Title Compliance and Bleeding Using Updated AHA and ACC Heparin	Disclosures Nothing to Disclose
Carson	Michael	Syndromes	Dosing Guidelines for Non-ST Elevation Myocardial Infarction Patients	Nothing to Disclose
Caruso	Mario	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Caught Between a Thrombus and a Hard Place: Thrombolysis as First Line Therapy for the Management of Prosthetic Valve Thrombosis	Nothing to Disclose
Carver	Joseph	FIT Forum: Mix and Mingle	Cardio Oncology	Nothing to Disclose
Carver	Joseph	Heart Failure and Cancer Care	Case Presentation: Cardiomyopathy with Herceptin When Should You Stop Herceptin, If Ever? Evidence to Practice Roundtable Discussion	Nothing to Disclose
Casadei	Barbara	Who Should Benefit From Preventive	Co-Chair	Nothing to Disclose
		Cardiology?: International Perspectives From the European Society of Cardiology and the American College of Cardiology		•
Casale	Paul	Trends in Coronary Syndromes: International Perspectives From the ACC Great Britain and Ireland Chapter, Israel Heart Society, and	Co-Chair	Nothing to Disclose
Casale	Paul	American College of Cardiology Trends in Coronary Syndromes: International	Introduction to Session	Nothing to Disclose
		Perspectives From the ACC Great Britain and Ireland Chapter, Israel Heart Society, and American College of Cardiology		
Casale	Paul	How to Redesign a Care Delivery Team in	Co-Chair	Nothing to Disclose
Casale	Paul	Preparation for MACRA and MIPS Value, Advocacy and the Future of Adult	Panelist	Nothing to Disclose
		Congenital and Pediatric Cardiology		
Casale	Paul	Value, Advocacy and the Future of Adult Congenital and Pediatric Cardiology	Overview of MACRA	Nothing to Disclose
Casale	Paul	Core Curriculum: Special Topic: Practical Tips: Changes in Healthcare Affecting My Practice	Nuts and Bolts of MACRA	Nothing to Disclose
Cascino	Thomas	FIT Clinical Decision Making Reviewers 5	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Cascio Case	Wayne Brian	48th Annual Louis F. Bishop Lecture FIT Clinical Decision Making: Multimodality	Panelist Gerbode Defect Leading to a Diagnosis of Endocarditis	Nothing to Disclose Nothing to Disclose
		Imaging		,
Casella	Michela	Arrhythmias and Clinical EP: AF Ablation	Long-Term Risk of Recurrent Arrhythmia in Patients With Typical Atrial Flutter Undergoing Pulmonary Vein Antrum Isolation or Cavo- Tricuspid Isthmus Ablation With Permanent Isolation	Nothing to Disclose
Casella	Samuel	Congenital Heart Disease Surgery: Updates and Innovations	Targeted Increase in Pulmonary Blood Flow in a Bidirectional Glenn Circulation	Nothing to Disclose
Casey	Donald	02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Casala	Cianagria	Clinical Team 6 Coronary Syndromes Revisited: International	Angtomical or Eurotional Approach in the Diagnosis and Prognesis	Nothing to Displace
Casolo	Giancarlo	Coronary Syndromes Revisited: international Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology	Anatomical or Functional Approach in the Diagnosis and Prognosis of Chronic CAD	Nothing to Disclose
Caspi	Oren	Evolving Therapies in Heart Failure: Gazing	Stem Cells in Heart Failure: Any Closer to Reality?	Nothing to Disclose
Casquero Dominguez	Sara	Into the Crystal Ball Interventional Cardiology: TAVR 1	Pacing Over Guidewire, Stepwise to Minimalism in Tavi: A Single	Nothing to Disclose
Caran Daminawa	Abai		Center Experience	Nething to Displace
Casso Dominguez	Abel	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Early Versus Delayed Invasive Intervention for Non-ST Segment Elevation Myocardial Infarction in Patients Older Than 80 Years: A Nationwide Analysis	Nothing to Disclose
Casso Dominguez	Abel	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Impact of End Stage Renal Disease in Patients Hospitalized for Systolic and Diastolic Heart Failure: A Nationwide Analysis of 2013	Nothing to Disclose
Casso Dominguez	Abel	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Early Versus Delayed Invasive Intervention for Non-ST Segment Elevation Myocardial Infarction Patients: A Nationwide Analysis	Nothing to Disclose
Castano	Adam	Emerging Applications for Imaging Cardiac	Fluorine-18 Sodium Fluoride Positron Emission Tomography for	SALARY - ACC / Merck Fellowship in Cardiovascular Disease
Castallanaa	Luia	Amyloidosis: Nuclear Cardiology	Imaging Transthyretin Cardiac Amyloidosis	Nething to Displace
Castellanos	Luis	Predicting Outcomes in Cardiac Rehabilitation Patients	Non-White Patients With Coronary Heart Disease Have Worse Cardiac Rehabilitation Participation Than White Patients	Nothing to Disclose
Castro	Inar	Advances in Cholesterol Measurement and Management	Effect of Nutraceuticals Combined With Statins on LDL Cholesterol Depends on the Sterol Synthesizer/Absorber Profile of the Patients	Nothing to Disclose
Castro	Pablo	The Burden of Heart Failure: International Perspectives From the Chilean Society of Cardiology, Colombian Society of Cardiology, and American College of Cardiology	Traditional and New Biomarkers in CHF	Nothing to Disclose
Castro	Renata	Innovative Use of Echocardiography	Echocardiographic Parameters Associated With Quality of Life in	Nothing to Disclose
Castro Dominguez	Yulanka	FIT Clinical Decision Making: Heart Failure and	Ambulatory Patients With Heart Failure Effusive-Constrictive Pericarditis in a Patient With Hypereosinophilic	Nothing to Disclose
Catapano	Alberico	Pulmonary Hypertension Highlighted Original Research: Prevention and	Syndrome Genetic Target Validation for ATP-Citrate Lyase Inhibition	CONSULTANT FEES/HONORARIA - Aegerion, Amgen
		the Year in Review	,	Inc.,AstraZeneca Pharmaceuticals,Merck & Damp; Co., Inc.,Pfizer Inc,Sanofi-Aventis
Catov	Janet	The Consequences of Sex: Women and Pregnancy Across the Spectrum	Utilizing Pregnancy as a Women's First Physiological Stress Test: What happens if She Fails?	Nothing to Disclose
Cauchi	Matthew	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Endarteritis Complicating Aortic Coarctation Diagnosed by Transesophageal Echocardiogram	Nothing to Disclose
Cauchi	Matthew	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Murphy's Law Incarnate: The Case of the Disintegrating Coronary Artery	Nothing to Disclose
Caughey	Melissa	PCI for NSTEMI and Complex Patients With	Management and Outcomes of Non-ST Elevation Myocardial	Nothing to Disclose
Caughey	Melissa	Multiple Co-Morbidities Acute Heart Failure: Evaluating Strategies to	Infarction in Patients Hospitalized for Non-Cardiac Conditions Readmissions for Patients Discharged With Acute Decompensated	Nothing to Disclose
		Prevent Readmissions	Heart Failure and Reduced Versus Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study	
Caughey	Melissa	Interventional Cardiology: PCI in Complex Patients	Outcomes After Invasive Management of Inpatient Onset of Non ST- Elevation Myocardial Infarction	INOUTHING TO DISCLOSE
Caughron	Норе	TAVR Outcomes Prognostication	Predictors and Clinical Outcomes of Next-Day Discharge After	Nothing to Disclose
Cavalcante	Joao	Aortic Stenosis: Overview of the	Transcatheter Aortic Valve Replacement Expanding the Diagnostic Toolbox for Aortic Stenosis	Nothing to Disclose
Cavalcante	Joao	Hemodynamics and Ventricular Response The Challenges of Outcome Prediction in	Poor Agreement Between Transthoracic Echocardiography and	Nothing to Disclose
		Valvular Heart Disease	Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era	-
Cavalcante	Joao	TAVR Outcomes Prognostication	Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit	Nothing to Disclose
Cavalcante	Rafael	PCI Strategies and Outcomes Unique to	Sex Differences in Outcomes After Stenting or Bypass Surgery for	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
	l	Women	Unprotected Left Main Disease	ROLE - Boston Scientific

and the second				l
Last Name Cavender	First Name Matthew	Session Title Featured Clinical Research III	Presentation Title Lower Rates of Hospitalization for Heart Failure and All-Cause	Disclosures CONSULTANT FEES/HONORARIA - AstraZeneca
			Death in New Users of SGLT-2 Inhibitors: The CVD-REAL Study	Pharmaceuticals, Merck & Damp; Co., Inc.
Cavender	Matthew	Vascular Access and Hemostasis Issues	Radial Versus Femoral Access for Coronary Angiography and Risk of Stroke: Findings From the LATITUDE-TIMI 60 Trial	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Merck & Do., Inc.
Cavender	Matthew	Unusual Presentations of ACS	Differing Outcomes of Type 1 and Type 2 Myocardial Infarction and Their Impact on Overall Non-ST Elevation Myocardial Infarction Mortality Rates	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Merck & Donamp; Co., Inc.
Cavender	Matthew	Anti-Platelet Therapies: Always a Sticky Topic	Ischemic Events Occur Early in Patients Undergoing PCI and Are	CONSULTANT FEES/HONORARIA - AstraZeneca
Cavender	Matthew	02. Acute and Stable Ischemic Heart Disease:	Reduced With Cangrelor: Findings From CHAMPION PHOENIX Suggested Reviewer	Pharmaceuticals,Merck & Description (Co., Inc.) CONSULTANT FEES/HONORARIA - AstraZeneca
Cavareagli	Yuksel	Clinical Team 6 Heart Failure and Cardiomyopathies: Heart	Potential Clinical Application of LCZ696 in Real Life Clinical Practice	Pharmaceuticals,Merck & Department of the Consultant FEES/HONORARIA - AstraZeneca
Cavusoglu	Tuksei	Failure Is Just a Revolving Door	Potential Clinical Application of ICC2096 in Real Life Clinical Fractice Based on 2016 ACC/AHA/HFSA and ESC Heart Failure Guidelines Criteria: Results From TREAT HF Study	CONSULTANT FEESTIONORARIA - ASTAZENECA Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Novartis Corporation, Otsuka Pharmaceutical Co., Roche Diagnostics, servier
Cawthon	Peggy	Updates on Risk Factors for Cardiovascular Disease	Frailty as a Risk Factor for Cardiovascular Versus Non- Cardiovascular Mortality in Elderly Men: Results From the Outcomes of Sleep Disorders in Older Men (MrOS Sleep) Study	Nothing to Disclose
Cayla	Guillaume	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Discriminant Value of the DAPT Score to Predict Long-Term Ischemic and Bleeding Events in the Real World Population of Stented Patients in the FAST-MI 2005 Cohort	Nothing to Disclose
Cayla	Guillaume	Antithrombotic Therapy in Ischemic Heart Disease	Long-Term Outcome With Oral Anticoagulants With or Without Dual Antiplatelet Therapy After AMI: The Fast-Mi 2010 Registry	Nothing to Disclose
Caze	Cecile	Considerations in Antiplatelet Therapy and in ACS	Use of Modern Scores to Evaluate Individual Risk/Benefit of Prolonged Dual Anti-Platelet Therapy May Modify Dual Anti-Platelet Therapy Duration in ST-Segment Elevation Myocardial Infarction Patients	Nothing to Disclose
Cecchi	Enrico	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Echocardiographic Predictors for In-Hospital and 1-Year Outcomes in Left-Sided Infective Endocarditis: An Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort Study	Nothing to Disclose
Cecere	Milena	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Renal Replacement Therapy in Patients With Acute Myocardial Infarction: Rate of Use, Clinical Predictors and Relationship With In- Hospital Mortality	Nothing to Disclose
Celli	Bartolome	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Prognostic Importance of Blood Pressure and Heart Rate in Chronic Obstructive Pulmonary Disease: The SUMMIT Trial	CONSULTANT FEES/HONORARIA - Glaxo Smith Kline
Celli	Bartolome	Innovations in Cardiovascular Risk Assessment	High-Sensitivity Cardiac Troponin I and Risk of Cardiovascular	CONSULTANT FEES/HONORARIA - Glaxo Smith Kline
		and Reduction	Events in Patients With COPD and Heightened Cardiovascular Risk: A Biomarker Sub-Study of the SUMMIT Trial	
Cenko	Edina	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Acute Coronary Syndrome: The Risk to Be Young and Women	Nothing to Disclose
Ceponiene	Indre	Non Invasive Imaging: Expanding Clinical Applications	The Association of Ischemia on Single Photon Emission Computed Tomography-Myocardial Perfusion Image and Fractional Flow	Nothing to Disclose
			Reserve by Coronary Computed Tomographic Angiography	
Ceponiene	Indre	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Prognostic Value of Protein Biomarkers Predict Risk of Coronary Heart Disease Events: Results From Multi-Ethnic Study of Atherosclerosis (MESA)	Nothing to Disclose
Ceponiene	Indre	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Total Testosterone With Progression of Carotid Atherosclerosis and Coronary Artery Calcium Score: The Multi- Ethnic Study of Atherosclerosis	Nothing to Disclose
Ceponiene	Indre	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Coronary Artery Calcium Progression With Coronary Plaque Progression Determined by Quantitative Coronary Artery Plaque Analysis	Nothing to Disclose
Ceponiene	Indre	Innovations in Cardiovascular Risk Assessment and Reduction	Association of Coronary Calcium, Carotid Wall Thickness and Carotid Plaque Progression With Low Density Lipoprotein and High Density Lipoprotein Particle Concentration Measured by Ion Mobility Testing: The Multi-Ethnic Study of Atherosclerosis (MESA)	Nothing to Disclose
Cerbin	Lukasz	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Time of Presentation Among Patients Hospitalized for Acute Heart Failure (Clinical Characteristics, Initial Therapies and Outcomes): Insights From ASCEND-HF	Nothing to Disclose
Cercek	Bojan	02. Acute and Stable Ischemic Heart Disease: Clinical Team 9	Suggested Reviewer	Nothing to Disclose
Cerda	Martin	FIT Clinical Decision Making: Non-Invasive	Cardiac Magnetic Resonance Imaging Illustrating an Asymptomatic,	Nothing to Disclose
Cerqueira	Manuel	Imaging and Valvular Heart Disease PET Myocardial Perfusion Imaging: Practical	Large Inferobasilar Left Ventricular Aneurysm PET Myocardial Perfusion Imaging Cases	CONSULTANT FEES/HONORARIA - Astellas Pharma US;
Cerqueira	Manuel	Considerations- A Case-Based Discussion Nuclear Cardiology: Current Applications and Best Practices: Joint Symposium of the American Society of Nuclear Cardiology and	Nuclear Cardiology: Risk Stratification	SPEAKER'S BUREAU - Astellas Pharma US CONSULTANT FEES/HONORARIA - Astellas Pharma US; SPEAKER'S BUREAU - Astellas Pharma US
Cerqueira	Manuel	the American College of Cardiology Radiation from Diagnostic Imaging: Risk-	Co-Chair	CONSULTANT FEES/HONORARIA - Astellas Pharma US;
Cerqueira	Manuel	benefit Analysis Highlighted Original Research: Non Invasive Imaging and the Year in Review	Stress Myocardial Perfusion Imaging Versus Exercise Treadmill Testing: Comparison of Clinical and Economic Outcomes in Real-	SPEAKER'S BUREAU - Astellas Pharma US CONSULTANT FEES/HONORARIA - Astellas Pharma US; SPEAKER'S BUREAU - Astellas Pharma US
Cerrato	Enrico	Featured Clinical Research II: Interventional	World Emergency Department Settings Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD Matrix Study	Nothing to Disclose
Cerrato	Enrico	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Syndromes: The RAD Matrix Study Provisional Versus Elective Two-Stenting Strategy for Unprotected True Left Main Bifurcation Lesions: A Sub-Study From Fails 2 Study	Nothing to Disclose
Cerrone	Marina	FIT Clinical Decision Making: Arrhythmias and	Genetic Testing for Diagnosis of Progressive Cardiac Conduction	Nothing to Disclose
Cesena	Fernando	Electrophysiology Advances in Cholesterol Measurement and Management	Disease Statin Eligibility in Primary Prevention: From a Risk-Based Strategy to a Personalized Approach Based on the Predicted Cardiovascular	Nothing to Disclose
Cestoni	Abby	Innovations in Advocacy and Patient Centered Care	Benefit Describing Collaboration Between Cardiology and Palliative Care: A National Survey Study of Current Practices, Challenges and Barriers	Nothing to Disclose
Cetta	Frank	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Delivery and Management of Complete Ectopia Cordis: A Multidisciplinary Approach	Nothing to Disclose
Cha	Yong-Mei	Tough Clinical Problems in Patients with	Who Needs a Leadless Pacemaker?	Nothing to Disclose
Chackerian	Bryce	Implantable Electronic Devices Updates on Risk Factors for Cardiovascular Disease	A Vaccine-Based Strategy for Reducing Cardiovascular Disease Risk Factors	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Agiivax, Inc; RESEARCH/RESEARCH GRANTS - MedImmune, Inc
Chacon-Portillo	Martin	Congenital Heart Disease: Innovations in	Is a Pulsatile Glenn an Adequate Alternative for Long-Term	Nothing to Disclose
Chae	Claudia	Single Ventricle Heart Disease 32. Prevention: Clinical Team 2	Palliation in Patients With Single Ventricle Physiology? Suggested Reviewer	Nothing to Disclose
	,	1		g Diodiooc

Last Name Chae	First Name			
	Sanders	Session Title Arrhythmias and Clinical EP: Devices 3	Presentation Title Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention	Disclosures CONSULTANT FEES/HONORARIA - St. Jude; RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals, Inc; SPEAKER'S BUREAU - Bristol Myers, Janssen
Chae	Sanders	Diabetes and Other Issues in Cardiovascular Prevention	Patients Leaving Against Medical Advice: Can We Prevent Unnecessary Testing and Reduce Costs in the Evaluation of Acute	Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - St. Jude; RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals,
Chag	Milan	Interventional Complexity and Complications	Ischemic Heart Disease? Evaluation of a New Radiation Protection Technology (Cardio-	Inc; SPEAKER'S BUREAU - Bristol Myers, Janssen Pharmaceuticals, Inc Nothing to Disclose
Charia	Maria.	Biolog Business Boodistics Outcomes in Head	TRAP®) in Transradial Percutaneous Coronary Intervention Procedures	Nething to Displace
Chagin	Kevin Navtej	Risky Business: Predicting Outcomes in Heart Failure Technical Advances in Transthoracic	The HOSPITAL Readmission Model Poorly Predicts 30-Day Rehospitalization in Heart Failure Stroke Volume Determined Flow Reserve Does Not Predict the	Nothing to Disclose Nothing to Disclose
		Echocardiography	True Severity of Low-Flow Low-Gradient Aortic Stenosis and Is Not a Robust Marker of Contractile Reserve in Patients Undergoing Low- Dose Dobutamine Echocardiography	
Chaikriangkrai	Kongkiat	Non Invasive Imaging: Expanding Clinical Applications	Diagnostic Accuracy of Coronary Computed Tomography Angiography in Aortic Stenosis Patients Referred for Aortic Valve Replacement: Systematic Review and Meta-Analysis	Nothing to Disclose
Chaikriangkrai	Kongkiat	Things That Matter in Adult Congenital Heart Disease	Gender Differences in Rates of Hospitalizations for Decompensated Heart Failure Among Adults With Congenital Heart Diseases in the United States: A 15 Year Experience	Nothing to Disclose
Chait	Robert	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Electromechanical Activation Time via HemoTag and 2D Echocardiography: Correlation With Tricuspid Regurgitation Peak Velocity and Implications for Diagnosis and Clinical Practice	Nothing to Disclose
Chait	Robert	Innovative Use of Echocardiography	Global Longitudinal Strain as a Predictor of Survival in Sepsis- Induced Myocardial Dysfunction: A Meta-Analysis	Nothing to Disclose
Chaitman	Bernard	02. Acute and Stable Ischemic Heart Disease: Clinical Team 9	Suggested Reviewer	DATA SAFETY MONITORING BOARD - SANOFI; OTHER - Johnson and Johnson, Lilly, Merck, NovoNordisc, Relypsa, Sepracor Inc. (renamed Sunovion Pharmaceuticals Inc)
Chaker	Zakeih	The Best Coronary and Peripheral Interventional Challenging Cases	AngioVac Extraction of Inferior Vena Cava and Renal Vein Thrombosis	Nothing to Disclose
Chaker	Zakeih	Novel Determinants of Outcomes in VHD	Racial Disparity in Aortic Valve Replacement Outcomes: Insight From National Inpatient Sample	Nothing to Disclose
Chaker	Zakeih	Sex Disparity in VHD Outcomes	Contemporary Trends and Outcomes of Isolated Aortic Valve Replacement in Females in The United States: Understanding the Gender Gap	Nothing to Disclose
Chakrabarty	Shouvik	Innovations in Education	Update on the ABIM's Competency Based Pilot in Internal Medicine- Cardiology	Nothing to Disclose
Chakravarty	Tarun	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	Nothing to Disclose
Chakravarty	Tarun	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries	Nothing to Disclose
Chakravarty	Tarun	Refining TAVR Outcomes	Frame Geometry and Hemodynamic Findings of Sapien 3 Transcatheter Heart Valve in Patients With Bicuspid Aortic Valve Disease	Nothing to Disclose
Chaliki	Hari	Valvular Heart Disease: Aortic Stenosis	Can Older Patients With Symptomatic Severe Aortic Stenosis Undergo Emergency Non-Cardiac Surgery With an Acceptable Risk?	Nothing to Disclose
Chalmers	John	Hypertension: Evolving Evidence, Changing Guidelines	Panelist	RESEARCH/RESEARCH GRANTS - Actelion, servier
Chalmers	John	Guidelines Hypertension: Evolving Evidence, Changing Guidelines	Panelist Finding Common Ground in the Management of Hypertension	RESEARCH/RESEARCH GRANTS - Actelion,servier
		Guidelines Hypertension: Evolving Evidence, Changing Guidelines Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Panelist Finding Common Ground in the Management of Hypertension Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin	RESEARCH/RESEARCH GRANTS - Actelion, servier Nothing to Disclose
Chalmers	John	Guidelines Hypertension: Evolving Evidence, Changing Guidelines Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Highlights in Vascular Medicine Research	Panelist Finding Common Ground in the Management of Hypertension Time in Therapeutic Range Predicts Mortality and Cerebrovascular	RESEARCH/RESEARCH GRANTS - Actelion,servier
Chalmers Chamberlain	John Alanna	Guidelines Hypertension: Evolving Evidence, Changing Guidelines Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Panelist Finding Common Ground in the Management of Hypertension Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin The Addition of Renal Impairment to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without	RESEARCH/RESEARCH GRANTS - Actelion, servier Nothing to Disclose
Chamberlain Chamberlain	John Alanna Alanna	Guidelines Hypertension: Evolving Evidence, Changing Guidelines Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Highlights in Vascular Medicine Research Assuring Quality in the Cath Lab: Documentation, Appropriate Use, Peer	Panelist Finding Common Ground in the Management of Hypertension Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin The Addition of Renal Impairment to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Atrial Fibrillation Assessing Quality in Your Lab: Role of Peer Review and	RESEARCH/RESEARCH GRANTS - Actelion, servier Nothing to Disclose Nothing to Disclose
Chalmers Chamberlain Chamberlain Chambers	John Alanna Alanna Charles	Guidelines Hypertension: Evolving Evidence, Changing Guidelines Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Highlights in Vascular Medicine Research Assuring Quality in the Cath Lab: Documentation, Appropriate Use, Peer Review, and Public Reporting Mastering Cath Lab Leadership and Economics in a New Era: A Joint Symposium by the Society of Cardiovascular Angiography and Interventions and the American College of	Panelist Finding Common Ground in the Management of Hypertension Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin The Addition of Renal Impairment to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Atrial Fibrillation Assessing Quality in Your Lab: Role of Peer Review and Accreditation Co-Chair Three-Year Outcomes in 'Real-World' Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus U.S. Post-Approval Study (PE-	RESEARCH/RESEARCH GRANTS - Actelion,servier Nothing to Disclose Nothing to Disclose Nothing to Disclose
Chalmers Chamberlain Chamberlain Chambers Chambers	John Alanna Alanna Charles Charles	Guidelines Hypertension: Evolving Evidence, Changing Guidelines Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Highlights in Vascular Medicine Research Assuring Quality in the Cath Lab: Documentation, Appropriate Use, Peer Review, and Public Reporting Mastering Cath Lab Leadership and Economics in a New Era: A Joint Symposium by the Society of Cardiovascular Angiography and Interventions and the American College of Cardiology Coronary Intervention in Interventional Cardiology: Advanced Device Use Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in	Panelist Finding Common Ground in the Management of Hypertension Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin The Addition of Renal Impairment to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Artial Fibrillation Assessing Quality in Your Lab: Role of Peer Review and Accreditation Co-Chair Three-Year Outcomes in 'Real-World' Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting	RESEARCH/RESEARCH GRANTS - Actelion, servier Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Cardiovascular Systems, Inc.; DATA SAFETY MONITORING BOARD - Boston
Chalmers Chamberlain Chamberlain Chambers Chambers Chambers	John Alanna Alanna Charles Charles	Guidelines Hypertension: Evolving Evidence, Changing Guidelines Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Highlights in Vascular Medicine Research Assuring Quality in the Cath Lab: Documentation, Appropriate Use, Peer Review, and Public Reporting Mastering Cath Lab Leadership and Economics in a New Era: A Joint Symposium by the Society of Cardiovascular Angiography and Interventions and the American College of Cardiology Coronary Intervention in Interventional Cardiology: Advanced Device Use Highlighted Original Research: Acute and	Panelist Finding Common Ground in the Management of Hypertension Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin The Addition of Renal Impairment to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Artial Fibrillation Assessing Quality in Your Lab: Role of Peer Review and Accreditation Co-Chair Three-Year Outcomes in 'Real-World' Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus U.S. Post-Approval Study (PE-Plus PAS) Cannabis Abuse and Risk for Myocardial Infarction: A Population Based Study	RESEARCH/RESEARCH GRANTS - Actelion, servier Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Cardiovascular Systems, Inc.; DATA SAFETY MONITORING BOARD - Boston Scientific, Covidian; OTHER - Vascular Solutions
Chalmers Chamberlain Chamberlain Chambers Chambers Chambers Chambers	John Alanna Alanna Charles Charles Jeffrey Ahmad Tarek	Guidelines Hypertension: Evolving Evidence, Changing Guidelines Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Highlights in Vascular Medicine Research Assuring Quality in the Cath Lab: Documentation, Appropriate Use, Peer Review, and Public Reporting Mastering Cath Lab Leadership and Economics in a New Era: A Joint Symposium by the Society of Cardiovascular Angiography and Interventions and the American College of Cardiology Coronary Intervention in Interventional Cardiology: Advanced Device Use Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Arrhythmias and Clinical EP: AF Miscellaneous	Panelist Finding Common Ground in the Management of Hypertension Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin The Addition of Renal Impairment to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Atrial Fibrillation Assessing Quality in Your Lab: Role of Peer Review and Accreditation Co-Chair Three-Year Outcomes in 'Real-World' Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus U.S. Post-Approval Study (PE-Plus PAS) Cannabis Abuse and Risk for Myocardial Infarction: A Population Based Study Risk of Atrial Fibrillation in Human Immunodeficiency Virus Infection in the Era of Antiretroviral Therapy Intravascular Imaging Comparison of Two Metallic Limus-Eluting Stents Abluminally Coated With Biodegradable Polymers: IVUS and	RESEARCH/RESEARCH GRANTS - Actelion, servier Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Cardiovascular Systems, Inc.; DATA SAFETY MONITORING BOARD - Boston Scientific, Covidian; OTHER - Vascular Solutions Nothing to Disclose
Chalmers Chamberlain Chamberlain Chambers Chambers Chambers Chambers Chambers Chambers	John Alanna Alanna Charles Charles Jeffrey Ahmad Tarek Ahmad Tarek	Guidelines Hypertension: Evolving Evidence, Changing Guidelines Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Highlights in Vascular Medicine Research Assuring Quality in the Cath Lab: Documentation, Appropriate Use, Peer Review, and Public Reporting Mastering Cath Lab Leadership and Economics in a New Era: A Joint Symposium by the Society of Cardiovascular Angiography and Interventions and the American College of Cardiology Coronary Intervention in Interventional Cardiology: Advanced Device Use Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Coronary Intervention in Interventional	Panelist Finding Common Ground in the Management of Hypertension Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin The Addition of Renal Impairment to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Atrial Fibrillation Assessing Quality in Your Lab: Role of Peer Review and Accreditation Co-Chair Three-Year Outcomes in 'Real-World' Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus U.S. Post-Approval Study (PE-Plus PAS) Cannabis Abuse and Risk for Myocardial Infarction: A Population Based Study Risk of Atrial Fibrillation in Human Immunodeficiency Virus Infection in the Era of Antiretroviral Therapy Intravascular Imaging Comparison of Two Metallic Limus-Eluting	RESEARCH/RESEARCH GRANTS - Actelion, servier Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Cardiovascular Systems, Inc.; DATA SAFETY MONITORING BOARD - Boston Scientific, Covidian; OTHER - Vascular Solutions Nothing to Disclose Nothing to Disclose
Chalmers Chamberlain Chamberlain Chambers Chambers Chambers Chambers Chami Chami Chami	John Alanna Alanna Charles Charles Jeffrey Ahmad Tarek Ahmad Tarek Daniel	Guidelines Hypertension: Evolving Evidence, Changing Guidelines Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Highlights in Vascular Medicine Research Assuring Quality in the Cath Lab: Documentation, Appropriate Use, Peer Review, and Public Reporting Mastering Cath Lab Leadership and Economics in a New Era: A Joint Symposium by the Society of Cardiovascular Angiography and Interventions and the American College of Cardiology Coronary Intervention in Interventional Cardiology: Advanced Device Use Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Coronary Intervention in Interventional Cardiology: Advanced Device Use FIT Clinical Decision Making: Non-Invasive	Panelist Finding Common Ground in the Management of Hypertension Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin The Addition of Renal Impairment to the CHA2DS2-WASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Atrial Fibrillation Assessing Quality in Your Lab: Role of Peer Review and Accreditation Co-Chair Three-Year Outcomes in 'Real-World' Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus U.S. Post-Approval Study (PE-Plus PAS) Cannabis Abuse and Risk for Myocardial Infarction: A Population Based Study Risk of Atrial Fibrillation in Human Immunodeficiency Virus Infection in the Era of Antiretroviral Therapy Intravascular Imaging Comparison of Two Metallic Limus-Eluting Stents Abluminally Coated With Biodegradable Polymers: IVUS and OCT Results of the DESTINY Trial Candida Tropicalis Endocarditis and Thrombocytopenia: A Fatal	RESEARCH/RESEARCH GRANTS - Actelion, servier Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Cardiovascular Systems, Inc.; DATA SAFETY MONITORING BOARD - Boston Scientific, Covidian; OTHER - Vascular Solutions Nothing to Disclose Nothing to Disclose Nothing to Disclose
Chalmers Chamberlain Chamberlain Chambers Chambers Chambers Chambers Chami Chami Chami Chamie Chamie	John Alanna Alanna Charles Charles Charles Jeffrey Ahmad Tarek Ahmad Tarek Daniel Mohammed	Guidelines Hypertension: Evolving Evidence, Changing Guidelines Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Highlights in Vascular Medicine Research Assuring Quality in the Cath Lab: Documentation, Appropriate Use, Peer Review, and Public Reporting Mastering Cath Lab Leadership and Economics in a New Era: A Joint Symposium by the Society of Cardiovascular Angiography and Interventions and the American College of Cardiology Coronary Intervention in Interventional Cardiology: Advanced Device Use Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Coronary Intervention in Interventional Cardiology: Advanced Device Use FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Coronary Angiography, Inter-Vascular Imaging, Coronary Angiography, Inter-Vascular Imaging,	Panelist Finding Common Ground in the Management of Hypertension Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin The Addition of Renal Impairment to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Atrial Fibrillation Assessing Quality in Your Lab: Role of Peer Review and Accreditation Co-Chair Three-Year Outcomes in 'Real-World' Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus U.S. Post-Approval Study (PE-Plus PAS) Cannabis Abuse and Risk for Myocardial Infarction: A Population Based Study Risk of Atrial Fibrillation in Human Immunodeficiency Virus Infection in the Era of Antiretroviral Therapy Intravascular Imaging Comparison of Two Metallic Limus-Eluting Stents Abluminally Coated With Biodegradable Polymers: IVUS and OCT Results of the DESTINY Trial Candida Tropicalis Endocarditis and Thrombocytopenia: A Fatal Association Renal Function-Based Contrast Dosing to Define "Prognostic" Contrast Dose Limits for Percutaneous Coronary Intervention - The Prognostic Implication of the Contrast Volume: Clomerular Filtration	RESEARCH/RESEARCH GRANTS - Actelion, servier Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Cardiovascular Systems, Inc.; DATA SAFETY MONITORING BOARD - Boston Scientific, Covidian; OTHER - Vascular Solutions Nothing to Disclose Nothing to Disclose Nothing to Disclose
Chalmers Chamberlain Chamberlain Chambers Chambers Chambers Chami Chami Chami Chami Chami Chami Chami Chami Chami Chami Chami	John Alanna Alanna Charles Charles Charles Jeffrey Ahmad Tarek Ahmad Tarek Daniel Mohammed Albert	Guidelines Hypertension: Evolving Evidence, Changing Guidelines Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Highlights in Vascular Medicine Research Assuring Quality in the Cath Lab: Documentation, Appropriate Use, Peer Review, and Public Reporting Mastering Cath Lab Leadership and Economics in a New Era: A Joint Symposium by the Society of Cardiovascular Angiography and Interventions and the American College of Cardiology Coronary Intervention in Interventional Cardiology: Advanced Device Use Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Coronary Intervention in Interventional Cardiology: Advanced Device Use FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Panelist Finding Common Ground in the Management of Hypertension Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin The Addition of Renal Impairment to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Arrial Fibrillation Assessing Quality in Your Lab: Role of Peer Review and Accreditation Co-Chair Three-Year Outcomes in 'Real-World' Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus U.S. Post-Approval Study (PE-Plus PAS) Cannabis Abuse and Risk for Myocardial Infarction: A Population Based Study Risk of Atrial Fibrillation in Human Immunodeficiency Virus Infection in the Era of Antiretroviral Therapy Intravascular Imaging Comparison of Two Metallic Limus-Eluting Stents Abluminally Coated With Biodegradable Polymers: IVUS and OCT Results of the DESTINY Trial Candida Tropicalis Endocarditis and Thrombocytopenia: A Fatal Association Renal Function-Based Contrast Dosing to Define *Prognostic* Contrast Dose Limits for Percutaneous Coronary Intervention - The Prognostic Implication of the Contrast Volume: Glomerular Filtration Ratio in 44,082 Patients From the British Columbia Cardiac Registry Transcatheter Tricuspid Valve Replacement: "Forgotten	RESEARCH/RESEARCH GRANTS - Actelion, servier Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Cardiovascular Systems, Inc.; DATA SAFETY MONITORING BOARD - Boston Scientific, Covidian; OTHER - Vascular Solutions Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Chalmers Chamberlain Chamberlain Chambers Chambers Chambers Chambers Chami Chami Chami Chami Chami Chami Chami Chami Chamsi-Pasha Chan	John Alanna Alanna Charles Charles Charles Ahmad Tarek Ahmad Tarek Daniel Mohammed Albert Eric	Guidelines Hypertension: Evolving Evidence, Changing Guidelines Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Highlights in Vascular Medicine Research Assuring Quality in the Cath Lab: Documentation, Appropriate Use, Peer Review, and Public Reporting Mastering Cath Lab Leadership and Economics in a New Era: A Joint Symposium by the Society of Cardiovascular Angiography and Interventions and the American College of Cardiology Coronary Intervention in Interventional Cardiology: Advanced Device Use Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Novel Echocardiographic Methods for Assessing Cardiac Function Challenges in Percutaneous Interventions: International Perspectives From the Hong Kong College of Cardiology, Singapore Cardiac Society, and American College of Cardiology	Panelist Finding Common Ground in the Management of Hypertension Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin The Addition of Renal Impairment to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Artial Fibrillation Assessing Quality in Your Lab: Role of Peer Review and Accreditation Co-Chair Three-Year Outcomes in 'Real-World' Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus U.S. Post-Approval Study (PE-Plus PAS) Cannabis Abuse and Risk for Myocardial Infarction: A Population Based Study Risk of Atrial Fibrillation in Human Immunodeficiency Virus Infection in the Era of Antiretroviral Therapy Intravascular Imaging Comparison of Two Metallic Limus-Eluting Stents Abluminally Coated With Biodegradable Polymers: IVUS and OCT Results of the DESTINY Trial Candida Tropicalis Endocarditis and Thrombocytopenia: A Fatal Association Renal Function-Based Contrast Dosing to Define "Prognostic" Contrast Dose Limits for Percutaneous Coronary Intervention - The Prognostic Implication of the Contrast Volume: Glomerular Filtration Ratio in 44,082 Patients From the British Columbia Cardiac Registry Transcatheter Tricuspiel Valve Replacement: "Forgotten Valve– Challenging Management With Elimited Transcatnent Options - Time to Gather Evidence 2d Speckle Tracking Echocardiography in Identifying the Degree of Recoverability of Sub Clinical Right Vertricular Dysfunction in	RESEARCH/RESEARCH GRANTS - Actelion, servier Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Cardiovascular Systems, Inc.; DATA SAFETY MONITORING BOARD - Boston Scientific, Covidian; OTHER - Vascular Solutions Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Chalmers Chamberlain Chamberlain Chambers Chambers Chambers Chambers Chami Chami Chami Chami Chami Chami Chami Chami Chami Chami Chan Chan	John Alanna Alanna Charles Charles Charles Jeffrey Ahmad Tarek Ahmad Tarek Daniel Mohammed Albert Eric Jonathan	Guidelines Hypertension: Evolving Evidence, Changing Guidelines Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Highlights in Vascular Medicine Research Assuring Quality in the Cath Lab: Documentation, Appropriate Use, Peer Review, and Public Reporting Mastering Cath Lab Leadership and Economics in a New Era: A Joint Symposium by the Society of Cardiovascular Angiography and Interventions and the American College of Cardiology Coronary Intervention in Interventional Cardiology: Advanced Device Use Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Coronary Intervention in Interventional Cardiology: Advanced Device Use FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Novel Echocardiographic Methods for Assessing Cardiac Function Challenges in Percutaneous Interventions: International Perspectives From the Hong Kong College of Cardiology, Singapore Cardiac Society, and American College of	Panelist Finding Common Ground in the Management of Hypertension Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin The Addition of Renal Impairment to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Arrial Fibrillation Assessing Quality in Your Lab: Role of Peer Review and Accreditation Co-Chair Three-Year Outcomes in 'Real-World' Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus U.S. Post-Approval Study (PE-Plus PAS) Cannabis Abuse and Risk for Myocardial Infarction: A Population Based Study Risk of Artial Fibrillation in Human Immunodeficiency Virus Infection in the Era of Antiretroviral Therapy Intravascular Imaging Comparison of Two Metallic Limus-Eluting Stents Abluminally Coated With Biodegradable Polymers: IVUS and OCT Results of the DESTINY Trial Candida Tropicalis Endocarditis and Thrombocytopenia: A Fatal Association Renal Function-Based Contrast Dosing to Define "Prognostic" Contrast Dose Limits for Percutaneous Coronary Intervention - The Prognostic Implication of the Contrast Volume: Glomerular Filtration Ratio n44,082 Patients From the British Columbia Cardiac Registry Transcatheter Tricuspid Valve Replacement: "Forgotten Valve" Challenging Management With Limited Treatment Options - Time to Gather Evidence 24 Speckle Tracking Echocardiography in Identifying the Degree of Recoverability of Sub Clinical Right Ventricular Dysfunction in Patients With Newly Diagnosed Osa Receiving Cpap Therapy Is There Any Role for Thrombectomy Devices in Primary PCt A	RESEARCH/RESEARCH GRANTS - Actelion,servier Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Cardiovascular Systems, Inc.; DATA SAFETY MONITORING BOARD - Boston Scientific, Covidian; OTHER - Vascular Solutions Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose

and the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures DESCADOURSESADOU CRANTS Ricconcers
Chan	Koo	Coronary Intervention in Interventional Cardiology: Core Concepts	Incidence and Predictors of Target Lesion Failure in a Multi-Ethnic Asian Population Receiving the SYNERGY Coronary Stent: A Prospective All-Comers Registry	RESEARCH/RESEARCH GRANTS - Biosensors
Chan	Kwan-Leung	Vascular Medicine: New Insights Into Aortic and Peripheral Artery Diseases	Sex Differences in Thoracic Aortic Aneurysm Growth: Role of Aortic Stiffness	Nothing to Disclose
Chan	Kwan-Leung	Valvular Heart Disease: Mitral Valve Disease	Prognostic Significance of Mitral Stenosis Indices on Outcomes in Patients Following Mitral Valve Repair for Degenerative Mitral Regurgitation	Nothing to Disclose
Chan	Mark	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes		CONSULTANT FEES/HONORARIA - Astra-Zeneca,Bayer- Singapore,Eli-Lilly/Daichii-Sankyo Alliance; RESEARCH/RESEARCH GRANTS - Bayer-Japan
Chan	Mark	Coronary Intervention: Drug Eluting Stent and Scaffolds	Safety and Efficacy of Small Vessel Stenting With 2 mm Drug Eluting Stents in Real World Clinical Practice	CONSULTANT FEES/HONORARIA - Satya-Japan CONSULTANT FEES/HONORARIA - Astra-Zeneca,Bayer- Singapore,Eil-Lilly/Daichii-Sankyo Alliance; RESEARCH/RESEARCH GRANTS - Bayer-Japan
Chan	Mark	Coronary Intervention in Interventional Cardiology: Core Concepts	Incidence and Predictors of Target Lesion Failure in a Multi-Ethnic Asian Population Receiving the SYNERGY Coronary Stent: A	CONSULTANT FEES/HONORARIA - Astra-Zeneca,Bayer- Singapore,Eil-Lilly/Daichii-Sankyo Alliance; RESEARCH/RESEARCH GRANTS - Bayer-Japan
Chan	Mark	Unusual Presentations of ACS	Prospective All-Comers Registry Prevalence and Evolution of Sleep Disordered Breathing in Acute Myocardial Infarction	CONSULTANT FEES/HONORARIA - Astra-Zeneca,Bayer- Singapore,Eil-Lilly/Daichii-Sankyo Alliance; RESEARCH/RESEARCH GRANTS - Bayer-Japan
Chan	Michael	Challenges in Percutaneous Interventions: International Perspectives From the Hong Kong College of Cardiology, Singapore Cardiac Society, and American College of Cardiology	Practical Approach to Lesion With Heavy Thrombus Burden During Primary PCI	Nothing to Disclose
Chan	Paul	Highlighted Original Research: Vascular Medicine and the Year in Review	Non-Adherence to the Joint ACC/AHA 2013 Lipid Performance Guidelines in Peripheral Arterial Disease: Insights From the PORTRAIT Registry	CONSULTANT FEES/HONORARIA - Optum Rx
Chan	Paul	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)	CONSULTANT FEES/HONORARIA - Optum Rx
Chan	Paul Siu Him	32. Prevention: Clinical Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Optum Rx
Chan	Siu Him	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Cardiac Troponin-I: A Retrospective Analysis	Nothing to Disclose
Chan	Will	Highlighted Original Research: Prevention and the Year in Review	Lifelong Burden of Vitamin D Deficiency Increases Clinical Cardiac Events and Death Unraveled by an Exome Chip-Derived Multi-Loci Genetic Risk Score: A Mendelian-Randomized Study	Nothing to Disclose
Chan	Wing	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Heart Failure With Reduced Ejection Fraction Care Patterns in the Outpatient Practice Setting: Initial Findings From CHAMP-HF	SALARY - Employee of Novartis Pharmaceuticals Corporation
Chanani	Nikhil	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Transcatheter Ductal Stenting Versus Surgical Systemic-to- Pulmonary Artery Shunts: Altering Dogma at a High-Volume Institution	Nothing to Disclose
Chandarana	Anish	Interventional Complexity and Complications	Evaluation of a New Radiation Protection Technology (Cardio- TRAP®) in Transradial Percutaneous Coronary Intervention Procedures	Nothing to Disclose
Chandra	Navin	Imaging the Athlete's Heart	General Population Screening for Sudden Cardiac Death in Young Individuals: Is It Feasible, Is It Justifiable & How Much Does It Cost?	Nothing to Disclose
Chandra	Navin	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Renal Function-Based Contrast Dosing to Define "Prognostic" Contrast Dose Limits for Percutaneous Coronary Intervention - The Prognostic Implication of the Contrast Volume: Glomerular Filtration Ratio in 44,082 Patients From the British Columbia Cardiac Registry	Nothing to Disclose
Chandra	Navin	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Variation in Practice and Concordance With Guideline Criteria for Length of Stay After Elective Percutaneous Coronary Intervention	Nothing to Disclose
Chandra	Sandeep	Arrhythmias and Clinical EP: Anticoagulation Issues	Marked Physician Variability in Oral Anticoagulant Treatment Choices Reflect Significant Differences in Atrial Fibrillation Patient Characteristics	Nothing to Disclose
Chandrasekaran	Krishnaswamy	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Utility of Cardiac Computed Tomography Scanning in the Diagnosis and Pre-Operative Evaluation of Patients With Infective Endocarditis	Nothing to Disclose
Chandrasekhar	Jaya	STEMI Dilemmas: You Be the Judge	Case Presentation: Performing Primary PCI on Patients with Active NOAC Therapy: A Trapeze Act?	Nothing to Disclose
Chandrasekhar	Jaya	Considerations in Antiplatelet Therapy and in	Effect of Thrombotic and Bleeding Risk According to Platelet	Nothing to Disclose
Chandrasekhar	Jaya	ACS Coronary Intervention in Interventional Cardiology: Advanced Device Use	Reactivity on 2-Year Mortality: The ADAPT-DES Study Clinical Outcomes Associated With Impella Versus IABP Use in Stable Patients Undergoing High Risk Percutaneous Coronary Intervention	Nothing to Disclose
Chandrasekhar	Jaya	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Impella or Intra-Aortic Balloon Pump Support in Patients Undergoing High Risk Percutaneous Coronary Intervention: A Real World Single Center Experience	Nothing to Disclose
Chandrasekhar	Jaya	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	Nothing to Disclose
Chandrasekhar	Jaya	Coronary Angiography, Intra-Vascular Imaging,	Angiographic Phenotype and Clinical Outcomes of Patients With Malignancy Undergoing PCI	Nothing to Disclose
Chandrasekhar	Jaya	Revascularization and Outcomes Novel Developments in Acute Coronary	Trends in Incidence and Mortality Associated With Acute Kidney	Nothing to Disclose
Chandrasekhar	Jaya	Syndromes Interventional Cardiology: TAVR 2	Injury in Patients Undergoing PCI for Acute Coronary Syndrome Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve	Nothing to Disclose
Chandrasekhar	Jaya	Interventional Cardiology: PCI and TAVR in Complex Patients	Replacement: From the WIN-TAVI Registry Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the	Nothing to Disclose
Chandrasekhar	Jaya	Timely Topics in Acute Coronary Syndromes	Bravo-3 Randomized Trial Predictors of High Intensity Statin Use After Percutaneous Coronary	Nothing to Disclose
Chandrasekhar	Jaya	Timely Topics in Acute Coronary Syndromes	Interventions Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary	Nothing to Disclose
Chandrasekhar	Jaya	Optimizing the Care of ACS Patients	Syndromes Underutilization of High Intensity Statins in a Contemporary High	Nothing to Disclose
Chandrasekhar	Jaya	Interventional Complexity and Complications	Risk PCI Population Prediction of Acute Kidney Injury in Patients Undergoing Coronary	Nothing to Disclose
		Interventional Cardiology: PCI in Complex	Intervention Using Calculation of Serum Osmolality Risk and Impact of Diabetes Mellitus on Ischemic Events in Females	-
Chandrasekhar	Jaya	Interventional Cardiology: PCI in Complex Patients Interventional Cardiology: PCI in Complex Patients	Risk and Impact of Diabetes Mellitus on Ischemic Events in Females and Males After Percutaneous Coronary Intervention Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated Heparin Following Transcatheter Aortic Valve Replacement: Results	Nothing to Disclose Nothing to Disclose
Chandrashekar	Pranav	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Heparin Following Transcameter Aortic Valve Replacement: Results From the Bravo-3 Randomized Trial Isolated Tricuspid Valve Surgery: Repair Versus Replacement	Nothing to Disclose
Chandrashekar	Pranav	Valvular Disease Populations at Risk	Isolated Tricuspid Valve Surgery: National Trends and Outcomes	Nothing to Disclose
Chandrashekar	Pranav	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Contemporary Utilization of Immediate Coronary Angiography in the Management of Out-of-Hospital Cardiac Arrest	Nothing to Disclose
Chandrashekar	Pranav	Sex Disparity in VHD Outcomes	Gender Differences in Isolated Tricuspid Valve Surgery	Nothing to Disclose



Const.				<u> </u>
Last Name Chandrashekar	First Name Rakshita	Session Title Advances in HCM, PPCM and Other	Presentation Title Population Demographics of Patients Diagnosed With Peripartum	Disclosures Nothing to Disclose
	Y. S.	Cardiomyopathies Behind the Curtain: Inside Look into JACC and	Cardiomyopathy: Study Involving 1,450 Patients	-
Chandrashekhar		Peer-reviewed Publishing	Co-Chair	Nothing to Disclose
Chang	David	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Percutaneous Coronary Intervention With Everolimus-Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy and the Impact of Diabetes Mellitus on Stent and Target Lesion Patency	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AbbVie, Inc.,abt
Chang	Donald	Emerging Developments in HFpEF and Arryhthmias	Bleeding Risk of Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation and Heart Failure	Nothing to Disclose
Chang	Hsien-Yuan	Innovations in Cardiovascular Risk Assessment	The Impact of Echocardiography Parameter on the Outcome in	Nothing to Disclose
Chang	Hyuk-Jae	and Reduction Non Invasive Imaging: New Technologies	Patients Receiving Non-Cardiac Surgery Novel Three-Dimensional Geometric Method Using Computed Tomography for Predicting the Incomplete Occlusion of Left Atrial	Nothing to Disclose
Chang	lan	Advances in HCM, PPCM and Other	Appendage Closure Utility of Routine Serum Free Light Chain Assay for Amyloidosis in	Nothing to Disclose
Chang	Patricia	Cardiomyopathies Acute Heart Failure: Evaluating Strategies to	Patients With Heart Failure Readmissions for Patients Discharged With Acute Decompensated	Nothing to Disclose
		Prevent Readmissions	Heart Failure and Reduced Versus Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study	-
Chang Channick	Su Min Richard	28. Non Invasive Imaging: Echo Team 2 35. Pulmonary Hypertension and Pulmonary	Suggested Reviewer Suggested Reviewer	Nothing to Disclose CONSULTANT FEES/HONORARIA - Actelion Pharmaceuticals
Chao	Ting-Hsing	Thrombo-embolic Disease Team 2 The PCSK9 Revolution: New Insights Into	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group	Ltd,Bayer Healthcare Pharmaceuticals; RESEARCH/RESEARCH GRANTS - Actelion Pharmaceuticals Ltd,Bayer Healthcare Pharmaceuticals,United Therapeutics SPEAKER'S BUREAU - Abbott Laboratories,AstraZeneca
		Evaluation and Treatment	Study to Evaluate the Efficacy and Safety of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy in South Korea and Taiwan	Pharmaceuticals,Bayer Healthcare Pharmaceuticals,Boehringer- Ingelheim,Daiichi Sankyo,King Pharmaceuticals, Inc. (now part of Pfizer - October 2010),Merok & Co., Inc.,Novartis Corporation,Otsuka Pharmaceutical Co.,Sanofi-Aventis
Chao	Tze-Fan	Atrial Fibrillation and VT: Unique Populations and Solutions	Outcomes of Asian Patients With Atrial Fibrillation Compared to Non- Asians in the ENGAGE AF-TIMI 48 Trial	Nothing to Disclose
Chaparro	Sandra	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Perioperative Administration of Amiodarone or Beta Blockers in Cardiac Surgery: Which Is More Effective in Reducing Postoperative Atrial Fibrillation?	Nothing to Disclose
Chaparro	Sandra	Why Can't We Be Friends? Controversies in	Cardiac Resynchronization Therapy in Inotropic-Dependent Heart	Nothing to Disclose
Chapman	Andrew	Heart Failure Management Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Failure Patients: A Systematic Review and Meta-Analysis Optimal Risk Stratification Pathways for Patients With Suspected Acute Coronary Syndrome	CONSULTANT FEES/HONORARIA - Abbott Laboratories
Chapman	Andrew	Syndrome Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Age and the Effectiveness of Risk Stratification and Diagnostic Thresholds for Myocardial Infarction With High-Sensitivity Cardiac	CONSULTANT FEES/HONORARIA - Abbott Laboratories
Chapman	Andrew	Acute Coronary Syndromes, Diagnosis,	Troponin Is It Safe to Use High-Sensitivity Cardiac Troponin T to Rule out	CONSULTANT FEES/HONORARIA - Abbott Laboratories
Chapman	Andrew	Management and Outcomes Acute Coronary Syndromes, Diagnosis,	Myocardial Infarction at Presentation? High-Sensitivity Cardiac Troponin and the Classification of	CONSULTANT FEES/HONORARIA - Abbott Laboratories
		Management and Outcomes	Myocardial Infarction	
Chapoy	Hector	Diabetes and Endothelial Dysfucntion in Heart Failure	Hypothyroidism Modulates Mitochondrial Calcium Uniporter Expression and Causes Cardioprotection Decresing Mitochondrial Permeability Transition Pore Opening	Nothing to Disclose
Charalambous	Marinos	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Cardiogenic Shock Secondary to Acute Right Ventricular Failure From latrogenic Right Coronary Artery Dissection Managed With Impella CP and Impella RP	Nothing to Disclose
Chareonthaitawee	Panithaya	PET Myocardial Perfusion Imaging: Practical Considerations- A Case-Based Discussion	Panelist	Nothing to Disclose
Chareonthaitawee	Panithaya	PET Myocardial Perfusion Imaging: Practical Considerations- A Case-Based Discussion	PET Myocardial Perfusion Imaging Cases	Nothing to Disclose
Chareonthaitawee	Panithaya	Nuclear Cardiology: Beyond Perfusion	The Impact of Cardiopulmonary Testing on Downstream Evaluation in Patients Who Undergo Myocardial Perfusion Imaging	Nothing to Disclose
Chareonthaitawee	Panithaya	30. Non Invasive Imaging: Nuclear Team 1	Suggested Reviewer	Nothing to Disclose
Charitakis	Konstantinos	Head to Toe: Outcomes of Endovascular Interventions	Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease	Nothing to Disclose
Charitakis	Konstantinos	Venous Investigation: The Dark Side	3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis	Nothing to Disclose
Charlton	Sandy	Fibrillatory Arrhythmias: Outcomes With	Effective Control of Atrial Fibrillation Can Be Achieved With Very	SALARY - Medtronic, Inc
Charnigo	Richard	Contemporary Practice Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Low Doses of Amiodarone The Benign Nature of Discharge Hyponatremia in Heart Failure Patients With Normal Admission Sodium: Analysis From the	RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals
Chatterjee	Arka	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	TGA) and Pulmonary Stenosis Due to Pulmonary Artery Conduit	Nothing to Disclose
Chatterjee	Neal	Making Progress in Understanding Heart Failure	Stenosis and Atrial Septal Defect Circulating Concentrations of Orexin A Are Associated With Left Ventricular Reverse Remodeling and Clinical Outcomes Following	Nothing to Disclose
Chatterjee	Saurav	Valvular Disease Populations at Risk	Cardiac Resynchronization Therapy National and Regional Trends in Surgical Aortic Valve Replacement	Nothing to Disclose
Chatterjee	Saurav	Head to Toe: Outcomes of Endovascular Interventions	in the TAVR Era Contemporary Nationwide Trends in Inferior Vena Cava Filter Implantation Rates in the United States and the Effect of Food and	Nothing to Disclose
Chatterjee	Saurav	Venous Investigation: The Dark Side	Drug Administration Advisory Nationwide Contemporary Trends in Adjunctive Angioplasty and Stenting at the Time of Catheter Directed Thrombolysis in Patients	Nothing to Disclose
Chatterjee	Saurav	Venous Investigation: The Dark Side	With Proximal Lower Extremity Deep Vein Thrombosis Sex Differences in the Use of Inferior Vena Cava Filters in Patients With Proximal Lower Extremity Deep Vein Thrombosis in the United	Nothing to Disclose
	I		States	Nothing to Disclose
Chatterjee	Saurav	Advances in Pathophysiology and Treatment of		
-	Saurav	Thrombosis	Thrombolysis Suggested Reviewer	Nothing to Disclose
Chatterjee	Saurav	Thrombosis 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1	Thrombolysis Suggested Reviewer	•
Chatterjee Chattipakorn	Saurav Nipon	Thrombosis 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1 Interventional Cardiology: Translation and Pre- Clinical Research	Thrombolysis Suggested Reviewer Combined Prebiotics and Probiotics Treatment Is Not Superior to Single Regimen for Cardioprotection in Obese-Insulin Resistant Rats	Nothing to Disclose
Chattipakorn Chattipakorn	Saurav Nipon Nipon	Thrombosis 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1 Interventional Cardiology: Translation and Pre- Clinical Research Updates in Stable Ischemic Heart Disease	Thrombolysis Suggested Reviewer Combined Prebiotics and Probiotics Treatment Is Not Superior to Single Regimen for Cardioprotection in Obese-Insulin Resistant Rats Vagus Nerve Stimulation Requires Both Ipsilateral and Contralateral Efferent Vagal Activity to Fully Exert Its Cardioprotection Against Cardiac Ischemia/Reperfusion Injury	Nothing to Disclose Nothing to Disclose
Chatterjee Chattipakorn	Saurav Nipon	Thrombosis 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1 Interventional Cardiology: Translation and Pre- Clinical Research	Thrombolysis Suggested Reviewer Combined Prebiotics and Probiotics Treatment Is Not Superior to Single Regimen for Cardioprotection in Obese-Insulin Resistant Rats Vagus Nerve Stimulation Requires Both Ipsilateral and Contralateral Efferent Vagal Activity to Fully Exert Its Cardioprotection Against	Nothing to Disclose

Contract of the second				<u> </u>
Last Name	First Name	Session Title	Presentation Title	Disclosures
Chattipakorn	Nipon	Emerging Developments in HFpEF and Arryhthmias	Decreased Heart Rate Variability Is Associated With Increased Cardiac Iron Deposit Determined by Cardiac T2* MRI and Decreased Left Ventricular Function in Transfusion Dependent	Nothing to Disclose
Chattipakorn	Nipon	Antithrombotic Therapy in Ischemic Heart Disease	Thalassemia Patients High-Dose Humanin Analogue Applied During Ischemia Provides Cardioprotection Against Ischemia-Reperfusion Injury Through Attenuating Mitochondrial Dysfunction	Nothing to Disclose
Chattipakorn	Nipon	Hormones and Heart Failure	Retendanty Milociolidia Dystinction Estrogen Deprivation Aggravates Cardiometabolic Dysfunction and Intracellular Calcium Dyshomeostasis in Obese-Insulin Resistance Rats	Nothing to Disclose
Chattipakorn	Siriporn	Interventional Cardiology: Translation and Pre- Clinical Research	Combined Prebiotics and Probiotics Treatment Is Not Superior to Single Regimen for Cardioprotection in Obese-Insulin Resistant	Nothing to Disclose
Chattipakorn	Siriporn	Updates in Stable Ischemic Heart Disease	Rats Vagus Nerve Stimulation Requires Both Ipsilateral and Contralateral Efferent Vagal Activity to Fully Exert Its Cardioprotection Against	Nothing to Disclose
Chattipakorn	Siriporn	Diabetes and Endothelial Dysfucntion in Heart	Cardiac Ischemia/Reperfusion Injury Lack of Testosterone in Obese-Insulin Resistant Condition	Nothing to Disclose
-		Failure	Aggravates Cardiometabolic Dysfunction Through the Impairment of Cardiac Mitochondrial Function	-
Chattipakorn	Siriporn	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Beta-Cryptoxanthin Exerts Better Cardioprotection Against Cardiac Ischemia-Reperfusion Injury Than Astaxanthin via Protecting Mitochondrial Dysfunction in Mice	Nothing to Disclose
Chattipakorn	Siriporn	Emerging Developments in HFpEF and Arryhthmias	Decreased Heart Rate Variability Is Associated With Increased Cardiac Iron Deposit Determined by Cardiac T2* MRI and Decreased Left Ventricular Function in Transfusion Dependent Thalassemia Patients	Nothing to Disclose
Chattipakorn	Siriporn	Antithrombotic Therapy in Ischemic Heart Disease	High-Dose Humanin Analogue Applied During Ischemia Provides Cardioprotection Against Ischemia-Reperfusion Injury Through Attenuating Mitochondrial Dysfunction	Nothing to Disclose
Chattipakorn	Siriporn	Hormones and Heart Failure	Estrogen Deprivation Aggravates Cardiometabolic Dysfunction and Intracellular Calcium Dyshomeostasis in Obese-Insulin Resistance Rats	Nothing to Disclose
Chaturvedi	Abhishek	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Small Dense Low Density Lipoprotein Particle Number Relates to Coronary Plaque Burden Independent of Traditional Cardiovascular Risk Factors in Psoriasis	Nothing to Disclose
Chaturvedi	Abhishek	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Aortic Vascular Inflammation by 18-FDG PET/CT Associates With High-Risk Coronary Plaques in Young Psoriasis Patients	Nothing to Disclose
Chaturvedi	Abhishek	Vascular Medicine: New Insights Into Aortic and Peripheral Artery Diseases	Improvement in Cholesterol Efflux Capacity Is Associated With Improvement in Vascular Inflammation by 18- FDG PET CT in	Nothing to Disclose
Chaturvedi	Abhishek	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Psoriasis Improvement in Cholesterol Efflux Capacity Is Associated With a Reduction in Aortic Wall Thickness by MRI Independent of	Nothing to Disclose
Chaturvedi	Abhishek	Updates on Risk Factors for Cardiovascular	Traditional CV Risk Factors Visceral but Not Subcutaneous Adipose Tissue Associates With	Nothing to Disclose
Chaturvedi	Rajiv	Disease Innovations in Pediatric Catheterization and	Vascular Inflammation by 18-FDG PET/CT in Psoriasis Ductal Origin of an Isolated Pulmonary Artery: Initial Stenting	Nothing to Disclose
Chatzikyriakou	Sofia	EP: Mending, Fixing and Predicting	Followed by Unifocalization Left Atrial Appendage Occlusion Facilitated by Three Dimensional	Nothing to Disclose
-		Non Invasive Imaging: Expanding Clinical Applications	Rotational Angiography Alone Is Safe and Anatomically Superior to Trasoesophageal Echocardiography	-
Chatzizisis	Yiannis	Innovative Use of Echocardiography	The Predictive Value of Microvascular Defects Observed During Demand Stress Myocardial Contrast Echocardiography and Quantitative Measurements of Stenosis and Microvascular Resistance Obtained During Invasive Hemodynamics	Nothing to Disclose
Chaudhari	Sameer	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Aortic Dissection: To Spare or Not to Spare the Aortic Valve????	Nothing to Disclose
Chaudhari	Sameer	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	A Mistaken Case of Ventricular Septal Defect: Importance of Physical Examination	Nothing to Disclose
Chaudhari	Sameer	FIT Clinical Decision Making: Arrhythmias and	Syncope in Elderly: How About Checking Carotid	Nothing to Disclose
Chaudhary	Arbind	Electrophysiology FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Hypersensitivity??? Anomalous Origin of Right Coronary Artery From Contralateral Cusp With Hypercoagulable State	Nothing to Disclose
Chaudhary	Rahul	Biomarkers and Targets for Ischemic Heart Disease	Serial Assessment of Thrombogenicity and Hemodynamics in Patients With Type II Diabetes Observed in a Clinical Research Unit:	Nothing to Disclose
Chaudhary	Rahul	Advances in Lipid Management	Evidence for Circadian Changes in Clot Formation HDL3: A Marker of Coronary Artery Disease Severity and	Nothing to Disclose
Chaudhary	Rahul	Cardiac Arrest, Diabetes, and Other High Risk	Inflammation in Patients on Statin Therapy Early Coronary Angiography in Patients With Out-of-Hospital	Nothing to Disclose
Chaudhary	Rahul	Features of Patients With Acute Coronary Syndrome Diabetes and Other Issues in Cardiovascular	Cardiac Arrest Without ST-Elevation Myocardial Infarction: A Meta- Analysis of 1,460 Patients Prevention of Venous Thromboembolism in Hospitalized Patients:	Nothing to Disclose
		Prevention	From Inadequate to Over-Prophylaxis	-
Chaudhary	Rahul	Diabetes and Other Issues in Cardiovascular Prevention	Venous Thromboembolism Prophylaxis: Need of Continuous Assessment Due to Changes in Risk During the Same Hospitalization	Nothing to Disclose
Chaudhry	Farooq	Technical Advances in Transthoracic Echocardiography	Safety of Perflutren-Based Echocardiographic Contrast Agent Administration in the Setting of a Patent Foramen Ovale (PFO): A Multicenter Study Conducted in Tertiary Care Centers Based in the New York/Chicago Metropolitan Areas	CONSULTANT FEES/HONORARIA - Lantheus Medical Imaging; RESEARCH/RESEARCH GRANTS - Bracco
Chaudhry	G. Muqtada	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Congenital Double-Chambered Left Ventricle Presenting as Monomorphic Ventricular Tachycardia	Nothing to Disclose
Chaudhry	G. Muqtada	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Does the Convergent Ablation Procedure Affect Left Atrial Contractile Function?	Nothing to Disclose
Chaudhry	Jawad	Interventional Cardiology: PCI and TAVR in Complex Patients	Comparison of Radiation Exposure Between Interventional and Noninvasive Cardiologist During Structural Cardiac Interventions	Nothing to Disclose
Chaudhry	Kashif	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Does the Convergent Ablation Procedure Affect Left Atrial Contractile Function?	Nothing to Disclose
Chaudhry	Muhammad	Vascular Access and Hemostasis Issues	Mid Femoral Head Is Not the Ideal Fluroscopic Landmark for	Nothing to Disclose
Chaudhry	Muhammad	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Common Femoral Artery Puncture A Rare Case of Chronic Persistent Troponin Elevation	Nothing to Disclose
Chaudhuri	Debanik	Disease, and Vascular Medicine FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Anomalous Origin of Right Coronary Artery From Contralateral Cusp With Hypercoagulable State	SALARY - SUNY Upstate Medical University
Chaudhuri	Debanik	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Cardioembolic Stroke Due to Takotsubo Cardiomyopathy, Truly Rare or Under-Recognized?	SALARY - SUNY Upstate Medical University
Chawla	Dhruv	Disease, and Vascular Medicine FIT Clinical Decision Making: Heart Failure and	Cardiac Amyloidosis Masquerading as Hypertrophic	Nothing to Disclose
		Cardiomyopathies	Cardiomyopathy: The Importance of Multimodality Imaging	

		Session Title	Presentation Title	Disclosures
Chazal	Richard	Opening Session and the Joint American	Welcome, Introduction, Acknowledgments and In Memoria	Nothing to Disclose
		College of Cardiology and Journal of American College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture		
Obs. of	D'aband		100 B	Notice to Broade
Chazal	Richard	Opening Session and the Joint American College of Cardiology and Journal of American	ACC Presidential Address	Nothing to Disclose
		College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture		
Chazal	Richard	Opening Session and the Joint American	Chair	Nothing to Disclose
		College of Cardiology and Journal of American College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture		
Chazal	Richard	Business Meeting of the College	Introductory Remarks by the College President	Nothing to Disclose
Chazal	Richard	Strategies for Prevention of Cardiovascular Disease: International Perspectives From the	Co-Chair	Nothing to Disclose
		Canadian Cardiovascular Society, Cardiac Society of Australia and New Zealand, and American College of Cardiology		
Chazal	Richard	Strategies for Prevention of Cardiovascular	Introduction to Session	Nothing to Disclose
		Disease: International Perspectives From the Canadian Cardiovascular Society, Cardiac Society of Australia and New Zealand, and		
Chanal	Dishard	American College of Cardiology	Co Chair	Nething to Displace
Chazal		Who Should Benefit From Preventive Cardiology?: International Perspectives From the European Society of Cardiology and the American College of Cardiology	Co-Chair	Nothing to Disclose
Cheatham	Sharon	Surgical and Transcatheter Valve Therapy for	Co-Chair	CONSULTANT FEES/HONORARIA - 480 BioMedical, Medtronic,
Cheema	Asim	Congenital Heart Disease Considerations in Antiplatelet Therapy and in	Effects of Ticagrelor Versus Clopidogrel in Fibrinolytic-Treated	Inc,NuMed, Inc.,Occlutech International Nothing to Disclose
		ACS	STEMI Patients Undergoing Early PCI	-
Cheema	Baljash	Imaging the Athlete's Heart	Deformation Analysis Can Be Performed on Post-Exercise Images in National Basketball Association Draft Eligible Players With Good Reproducibility	Nothing to Disclose
Cheema	Omar	FIT Clinical Decision Making: Heart Failure and Cardiomyopathies		Nothing to Disclose
Cheeran	Daniel	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	The Prognostic Role of Prior Heart Failure Hospitalizations in Patients With Severe Symptomatic and Recurrent Heart Failure:	Nothing to Disclose
Q.			Insights From ESCAPE	Notice to Breaker
Cheeran	Daniel	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Cardiac Atrophy: A Novel Mechanism for Duchenne Muscular Dystrophy (DMD)-Associated Cardiomyopathy	Nothing to Disclose
Cheetham	T. Craig	Advances in Cholesterol Measurement and Management	Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol	RESEARCH/RESEARCH GRANTS - Amgen Inc.,Bristol-Myers Squibb Company
Cheetirala	Venkatesh	Valvular Heart Disease: Aortic Stenosis	Can Older Patients With Symptomatic Severe Aortic Stenosis Undergo Emergency Non-Cardiac Surgery With an Acceptable Risk?	Nothing to Disclose
Chelu	Mihail	Arrhythmias and Clinical EP: Basic 2	Utility of an Esophageal Screening Protocol in Preventing Atrio-	Nothing to Disclose
Chen	Alessandra	Predicting Outcomes in Cardiac Rehabilitation	Esophageal Fistula After Atrial Fibrillation Ablation The Effect of Body Composition on Cardiovascular Outcomes in	Nothing to Disclose
Chen	Allan	Patients Emerging Applications of Echocardiography	Cardiac Rehabilitation Patients With Coronary Heart Disease Clinical Characteristics and Changes of Valvuloarterial Impedence Severity in Patients Undergoing Transcatheter Aortic Valve	Nothing to Disclose
Chen	Allan	FIT Clinical Decision Making Reviewers 1	Replacement for Severe Aortic Stenosis ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Chen	Anita	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Ten-Year Mortality of Acute Myocardial Infarction Patients Treated in U.S. Community Practice	Nothing to Disclose
Chen	Anita	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Hospital Variation in Targeted Temperature Management for Acute Myocardial Infarction Patients Complicated by Out-of-Hospital Cardiac Arrest in the U.S.	Nothing to Disclose
Chen	Anita	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	U.S. Community Practice	Nothing to Disclose
Chen	Chen	Syndrome MicroRNAs and Beyond in Vascular Medicine	Mir-30c Protects Diabetic Nephropathy by Suppressing Epithelial-to-	Nothing to Disclose
Chen	Chen	Diabetes and Endothelial Dysfucntion in Heart Failure	Mesenchymal Transition in Db/db Mice Cardio-Protective Effects of Trimetazidine in Lps-Induced Sepsis by Promoting Neutrophils Migration in Heart Through Regulation Cxcr2	Nothing to Disclose
Chen	Cheng-Han	Interventional Cardiology: PCI and TAVR in	Expression Refining the Classification of Severe, Symptomatic Aortic Stenosis	Nothing to Disclose
		Complex Patients	Using Flow and Gradient Measurements to Predict Outcomes Post- Transcatheter Aortic Valve Replacement	-
Chen	Cheng-Han	TAVR Outcomes Prognostication	High Baseline Valvuloarterial Impedence Predicts Worse 1-Year Outcomes After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Chen	Chen-Huan	Emerging Developments in HFpEF and Arryhthmias	The Role of Pulmonary Function Test in Patients With Heart Failure With Preserved Ejection Fraction: Looking Beyond Chronic Obstruction Pulmonary Disease	CONSULTANT FEES/HONORARIA - Novartis, Sanofi Aventis, AstraZeneca, Merck, Servier, Takeda, Pfizer; RESEARCH/RESEARCH GRANTS - Microlife Co., Ltd
Chen	Chunguang	Emerging Applications of Echocardiography	A New Modified Continuity Equation for Calculation of Aortic Valve Area by Integrating 3-D Measurements of LVOT Planimetry and	Nothing to Disclose
Chen	Chunguang	Emerging Applications of Echocardiography	LVOT Flow Mapping Direct Comparison of Aortic Valve Area by 3-D TEE Planimetry and	Nothing to Disclose
Chen	Chunguang	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	4-D Dynamic Cardiac CT Planimetry A Mistaken Case of Ventricular Septal Defect: Importance of Physical Examination	Nothing to Disclose
Chen	Chunguang	Interventional Cardiology: PCI and TAVR in Complex Patients	Non-Trans Femoral Trans Catheter Aortic Valve Replacement in Nonagenarians With Severe Aortic Stenosis: A Matched Case-	Nothing to Disclose
Chen	Fang	Considerations in Antiplatelet Therapy and in ACS	Control Pilot Study The Serial Platelet Function Testing Predicts Long-Term Prognosis Among Patients Undergoing Complex Percutaneous Coronary	Nothing to Disclose
Chen	Не	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Intervention Impact of Gender Difference in Clinical Presentation on Long-Term Outcomes in Chinese Patients Undergoing Percutaneous Coronary	Nothing to Disclose
Ol.		Syndrome	Intervention	Notice to Produce
Chen	He	Timely Topics in Acute Coronary Syndromes	Effect of Coronary Dominance on 2-Year Outcomes After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome	Nothing to Disclose
Chen	Hong	From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease	Mutations in SCAP and AGXT2 Revealed by Exome Sequencing a Pedigree With Premature Myocardial Infarction	Nothing to Disclose
Chen	Hong			Nothing to Disclose

Last Name	First Name	Session Title	Presentation Title	Disclosures
Chen	Horng	Young Investigator Awards Competition: Basic and Translational Science	Judge	CONSULTANT FEES/HONORARIA - UPTODATE Inc; OTHER - Zumbro Discovery; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Anexon, Capricor Therapeutics, Co Founder Zumbro Discovery
Chen	Horng	Making Progress in Understanding Heart Failure	Incidence of Preclinical (Stage A and B) Heart Failure in the General Population	CONSULTANT FEES/HONORARIA - UPTODATE Inc; OTHER - Zumbro Discovery, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Anexon, Capricor Therapeutics, Co Founder Zumbro Discovery
Chen	Horng	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Neurohumoral Activation and Long-Term Cardiovascular Outcomes in Chronic Kidney Disease: A Population-Based Cohort	CONSULTANT FEES/HONORARIA - UPTODATE Inc; OTHER - Zumbro Discovery; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Anexon, Capricor Therapeutics, Co Founder Zumbro Discovery
Chen	Jia-Yuan	Cutting Edge Vascular Medicine	Transplanted Perivascular Adipose Tissue Promotes Destabilization of Atherosclerotic Plaque in Apolipoprotein E-Deficient Mice	Nothing to Disclose
Chen	Jin-Ling	Novel Imaging and Therapies in Heart Failure	Evaluation of Left Ventricular Systolic Function After Renal Sympathetic Denervation by Layer-Specific Two-Dimensional	Nothing to Disclose
Chen	Jin-Ling	Emerging Basic Science in Ischemic Heart Disease	Speckle Tracking Imaging Thrombolysis in Coronary Micro-Circulation Occlusion by Dodecafluoropentane Acoustic Vaporizable Nano-Droplet With	Nothing to Disclose
Chen	Jiyan	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Ultrasound Irradiation The Contrast Volume to Creatinine Clearance Ratio Predicts Contrast-Induced Nephropathy in Patients With Chronic Kidney	Nothing to Disclose
Chen	Jonathan	09. Congenital Heart Disease: Adult Team 2	Disease Undergoing Percutaneous Coronary Intervention Suggested Reviewer	OTHER - MEDTRONIC
Chen	Kevin	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Normalizing Platelet Reactivity of Cardiovascular Patients on Ticagrelor Therapy Using Fresh Platelets: Ex Vivo Testing of the Functional Recovery Attained Within 48-Hours of Stopping	Nothing to Disclose
Chen	Lei	Interventional Cardiology: Translation and Pre- Clinical Research	Treatment Boron Based Hgf Memetic Molecule Has Cardioprotective Role Against Ischemia-Reperfusion Injury	Nothing to Disclose
Chen	Leway	The Evolving World of LVADs, Transplant and	Change in Renal Function During Extended Follow-Up After Left	CONSULTANT FEES/HONORARIA - Thoratec;
Chen	Ligong	Other Novel Discoveries Current Issues in Cardiovascular Enidemiology, Disparities, and Safety	Ventricular Assist Device Implantation Use of Recommended and Contraindicated Statins in HIV Patients	RESEARCH/RESEARCH GRANTS - St. Jude Medical, Thoratec SALARY - Amgen, Inc
Chen	Lin	Epidemiology, Disparities, and Safety Updates on Risk Factors for Cardiovascular Disease	Retinopathy and Risk of Sudden Cardiac Death: The ARIC Study	Nothing to Disclose
Chen	Marcus	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	The Pulmonary Embolism That Wasn't: A Case of Pulmonary Pseudo-Sequestration	Nothing to Disclose
Chen	Marcus	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Cardiovascular Magnetic Resonance in the Evaluation of Fibrofatty Infiltration for Arrhythmogenic Right Ventricular	Nothing to Disclose
Chen	Marcus	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Dysplasia/Cardiomyopathy (ARVD/C) Importance of Physical Exam in Identifying a Coronary-Cameral Fistula	Nothing to Disclose
Chen	Marcus	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Calcium Characteristics as Predictors of Major Adverse Cardiac Events in Symptomatic Patients: Insights From the	Nothing to Disclose
Chen	Phetcharat	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	CORE320 Multinational Study Increased Tumor Necrosis Factor-α Levels in Patients With Continuous-Flow Left Ventricular Assist Devices Mediate Vascular	Nothing to Disclose
Chen	Sarah	Current Issues in Cardiovascular	Instability and Are Associated With Higher Non-Surgical Bleeding Ethnicity, Marital Status, and Neighborhood Poverty Influence	Nothing to Disclose
Chen	Sean	Epidemiology, Disparities, and Safety Arrhythmias and Clinical EP: Anticoagulation Issues	Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation	Nothing to Disclose
Chen	Shaoliang	22. Interventional Cardiology: Coronary Intervention: Left Main, Multivessel, Bifurcation	(ROCKET AF) Suggested Reviewer	CONSULTANT FEES/HONORARIA - Microport Co.
Chen	Shih-Ann	Team 2 Atrial Fibrillation and VT: Unique Populations and Solutions	Outcomes of Asian Patients With Atrial Fibrillation Compared to Non- Asians in the ENGAGE AF-TIMI 48 Trial	Nothing to Disclose
Chen	Shiqun	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	The Contrast Volume to Creatinine Clearance Ratio Predicts Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Chen	Stephanie	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Hyperthyroidism Unmasks a Symptomatic Anomalous Coronary Artery	Nothing to Disclose
Chen	Stephanie	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Constrictive Pericarditis Due to Kawasaki Disease	Nothing to Disclose
Chen	Tiffany	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	B-Cell Lymphoma Associated Pericardial Tamponade With Conversion to Chylous Effusion During Pregnancy	Nothing to Disclose
Chen	Yang-Xin	Cutting Edge Vascular Medicine	Transplanted Perivascular Adipose Tissue Promotes Destabilization of Atherosclerotic Plaque in Apolipoprotein E-Deficient Mice	Nothing to Disclose
Chen	Yanmei	Put Your Codon! Genetic Insights Into Heart Failure	A Human Fetal Up-Regulated LncRNA Triggers Endogenous Heart Regeneration by Dephosphorylation of Mitotic Centromere- Associated Kinesin	Nothing to Disclose
Chen	Yimin	Beans, Beans, Good for Your Heart	Associated Kinesin Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection	Nothing to Disclose
Chen	Yuefeng	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Combined Migraine and Platypnea-Orthodeoxia Syndrome Due to Combined Atrial Septal Defect and Patent Foramen Ovale	Nothing to Disclose
Chen	Yuefeng	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Double Right Coronary Artery Engendering Inadequate Blood Supply to the Inferior Left Ventricular Wall	Nothing to Disclose
Chen	Yuefeng	Hormones and Heart Failure	Long-Term Exogenous Brain Natriuretic Peptide After Myocardial Infarction Interferes With Restorative Cardiac Remodeling	Nothing to Disclose
Cheng	Guangmimng	Interventional Cardiology: Translation and Pre-	Boron Based Hgf Memetic Molecule Has Cardioprotective Role	Nothing to Disclose
Cheng	Hao-Min	Clinical Research Emerging Developments in HFpEF and Arryhthmias	Against Ischemia-Reperfusion Injury The Role of Pulmonary Function Test in Patients With Heart Failure With Preserved Ejection Fraction: Looking Beyond Chronic	Nothing to Disclose
Cheng	Jerry	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Obstruction Pulmonary Disease Relationship Between Incident Heart Failure and Dropout Rate in Randomized Clinical Trials of Antihypertensive Therapy	Nothing to Disclose
Cheng	Jie	Prevent Readmissions Atrial Fibrillation and VT: Unique Populations and Solutions	The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional	RESEARCH/RESEARCH GRANTS - St. Jude Medical, Inc
Cheng	Jie	Arrhythmias and Clinical EP: AF Miscellaneous	Experience Left Atrial Appendage Ligation With Lariat Device: A Systematic	RESEARCH/RESEARCH GRANTS - St. Jude Medical, Inc
Cheng	Jie	and Surgical Issues Ventricular Arrhythmias and Sudden Death Prevention	Review and Meta-Analysis Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A	RESEARCH/RESEARCH GRANTS - St. Jude Medical, Inc
Cheng	Jun-Jack	Late-Breaking Clinical Trials: Interventional	Thirteen Year Institutional Experience Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With Coronary Chronic Total Occlusion: DECISION CTO Randomized	Nothing to Disclose
	<u> </u>	1	Trial	

				l .
Last Name Cheng	First Name Paul	Session Title Heart Failure and Cardiomyopathies: What	Presentation Title Hemophagocytic Lymphohistiocytosis Associated With Implantation	Disclosures Nothing to Disclose
_		Next When All Else Is Failing?	of Ventricular Assist Devices and Outcomes Following Subsequent Orthotropic Heart Transplantation (OHT)	
Cheng	Qi	Interventional Cardiology: Translation and Pre- Clinical Research	Endothelial Maturation and Function Following Implantation of Abluminal Coating Biodegradable Polymer Based Sirolimus-Eluting Metallic Stent Versus Conformal Coating Durable Polymer Based Everolimus Eluting Stent	Nothing to Disclose
Cheng	Richard	Logistical Challenges in STEMI	Fit Case #2: Cardiac Arrest Patient in A Hospital Without Primary PCI Capability	Nothing to Disclose
Cheng	Richard	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Percutaneous Coronary Intervention With Everolimus-Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy and the Impact	Nothing to Disclose
Cheng	Susan	Innovative Use of Echocardiography	of Diabetes Mellitus on Stent and Target Lesion Patency Left Atrial Function Index as a Predictor of Cardiovascular Disease and Atrial Fibrillation: Data From the Framingham Offspring Study	Nothing to Disclose
Cheng	Wen	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries	Nothing to Disclose
Cheng	Wen	Refining TAVR Outcomes	Frame Geometry and Hemodynamic Findings of Sapien 3 Transcatheter Heart Valve in Patients With Bicuspid Aortic Valve Disease	Nothing to Disclose
Cheng	Xiaoshu	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Serum Homocysteine Lowering by Long-Term Low-Dose Folic Acid: New Insight on <i>MTHFR</i> Gene-Folate Interaction From China Stroke Primary Prevention Trial	Nothing to Disclose
Cheng	Xiaoshu	Diabetes and Other Issues in Cardiovascular Prevention	Efficacy of Folic Acid Supplementation on the Reduction of Stroke Risk: Interaction With Platelet Count	Nothing to Disclose
Chen-Scarabelli	Carol	From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease	Cardioplegic Arrest Is Associated With Overexpression of Opioid Receptors Delta and Kappa in Diabetic and Non-Diabetic Patients Undergoing On-Pump Cardiac Surgery	Nothing to Disclose
Chenzbraun	Adrian	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Poor Performance of Historical Prediction Models in Patients Investigated for Chest Pain: A Single Centre Experience in a Large Cohort of Patients	Nothing to Disclose
Chernomordik	Fernando	Non Invasive Imaging: Expanding Clinical Applications	Impact of Different Calcium Locations of Mitral Annulus and Aortic Valve Cusps on Risk of Conduction Disturbances After Transcatheter Aortic Valve Implantation	Nothing to Disclose
Chernovolenko	Margarita	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Patients With Advanced Heart Failure Receiving a Left Ventricular Assist Device	Nothing to Disclose
Chetcuti	Stanley	Interventional Cardiology: TAVR 2	The Impact of Preoperative Renal Dysfunction on the Outcomes of Patients Undergoing Surgical Versus Transcatheter Aortic Valve Replacement: An Analysis From the CoreValve US Pivotal High Risk Trial	CONSULTANT FEES/HONORARIA - MEDTRONIC
Cheung	Christopher	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Clinical Outcomes of Acute Ischemic Stroke Patients Stratified by Cardiac Troponin-I: A Retrospective Analysis	Nothing to Disclose
Cheung	Jim	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Pitfalls in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy: Importance of Epicardial Voltage Mapping	CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik, MEDTRONIC; RESEARCH/RESEARCH GRANTS - Biotronik
Cheung	Jim	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System	CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik, MEDTRONIC; RESEARCH/RESEARCH GRANTS - Biotronik
Cheung	Jim	Stroke and AF: Thinking About the Heart	Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy: Insights Into Rates and Timing of Thrombus Resolution	CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik, MEDTRONIC; RESEARCH/RESEARCH GRANTS - Biotronik
Cheung	Jim	FIT Clinical Decision Making: Arrhythmias and Clinical Electrophysiology	A Novel Complication and Treatment Strategy in Pacemaker- Induced Superior Vena Cava Syndrome	CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik, MEDTRONIC; RESEARCH/RESEARCH GRANTS - Biotronik
Cheung	Yan Yi	Updates on Risk Factors for Cardiovascular Disease	Obstructive Sleep Apnea and Coronary Risk in Health Screening Clinic	Nothing to Disclose
Cheung	Yiu-Fai	Adult Patients With Congenital Heart Disease: How Do They Compare?	Right and Left Ventricular Mechanics Are Altered in Adolescents and Adults Late After Repair of Subarterial Ventricular Septal Defects	Nothing to Disclose
Chevalier	Bernard	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular,Cordis,MEDTRONIC,Terumo; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Colibri
Chew	Derek	Young Investigator Awards Competition: Outcomes Research	Cost Effectiveness of Continuous Flow Left Ventricular Assist Devices for Destination Therapy in End Stage Heart Failure Patients Ineligible for Cardiac Transplantation	Nothing to Disclose
Chew	Derek	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Coronary Artery Disease in Individuals With Human Immunodeficiency Virus Compared to a Seronegative Cohort	Nothing to Disclose
Chew	Derek	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	The Presence of Fragmented QRS Complexes Early After Acute Myocardial Infarction Is Associated With Subsequent Lack of Favorable Left Ventricular Remodeling	Nothing to Disclose
Chhabra	Lovely	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Left Main Coronary Artery Vasospasm Causing Complete Heart Block?? Dye Don't Lie!	Nothing to Disclose
Chhatriwalla	Adnan	Vascular Access and Hemostasis Issues	TAVR Using Transcarotid Vascular Access: In-Hospital and Intermediate Term Outcomes	OTHER - Edwards Lifesciences, Medtronic Inc ,St Jude Medical; SPEAKER'S BUREAU - Abbott Laboratories
Chhatriwalla	Adnan	Interventional Cardiology: TAVR 3	Prosthetic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter Valve-in-Valve Implantation	OTHER - Edwards Lifesciences, Medtronic Inc ,St Jude Medical; SPEAKER'S BUREAU - Abbott Laboratories
Chhatriwalla	Adnan	TAVR Outcomes Prognostication	ACC Poster Moderator	OTHER - Edwards Lifesciences, Medtronic Inc ,St Jude Medical;
Chhatriwalla	Adnan	37. Valvular Heart Disease: Therapy Team 1	Suggested Reviewer	SPEAKER'S BUREAU - Abbott Laboratories OTHER - Edwards Lifesciences, Medtronic Inc ,St Jude Medical; SPEAKER'S BUREAU Abbott Laboratories
Chiang	Chem-En	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy in South Korea and Taiwan	SPEAKER'S BUREAU - Abbott Laboratories CONSULTANT FEES/HONORARIA - Astrazeneca, Bayer, Boehringer Ingelheim, Chugai, DaiichiSankyo, GSK, MSD, Novartis, Pfizer, Roche, Sanofi-aventis, Servier, Tanabe, Takeda, TTY
Chiang	I-Hui	FIT Clinical Decision Making: Non-Invasive	Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid	Nothing to Disclose
Chiche	Olivier	Imaging and Valvular Heart Disease Frontiers in Mitral Valve Disease and Treatment	Angiosarcoma Significant Mitral Regurgitation in Patients Undergoing Transcatheter Aortic Valve Replacement: Evolution and Imaging Predictors of	Nothing to Disclose
Chieffo	Alaide	Interventional Live Case Session IV: Complex Coronary Transmission from St. Vincent	Improvement Panelist	Nothing to Disclose
Chieffo	Alaide	Hospital (Indianapolis, IN) Controversies Surrounding TAVR: 2017 and	Gender Based Difference in Outcomes: Should TAVR be	Nothing to Disclose
Chieffo	Alaide	Beyond Complex Coronary Intervention: Left	Recommended as 1st Line Therapy for Women Provisional Versus Elective Two-Stenting Strategy for Unprotected	Nothing to Disclose
		Main/Bifurcations and Multivessel Disease	True Left Main Bifurcation Lesions: A Sub-Study From Fails 2 Study	

Contract of the second				<u> </u>
Last Name	First Name	Session Title	Presentation Title	Disclosures
Chieffo	Alaide	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study	Nothing to Disclose
Chieffo	Alaide	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: From the WIN-TAVI Registry	Nothing to Disclose
Chieffo	Alaide	22. Interventional Cardiology: Coronary Intervention: Left Main, Multivessel, Bifurcation Team 1	Suggested Reviewer	Nothing to Disclose
Chikwe	Joanna	Highlighted Original Research: Vascular Medicine and the Year in Review	CD90 Marks a Population of Adventitial Mesenchymal Stem Cells in the Human Aorta That Exhibit Diminished Angiogenic Potential in Patients With Ascending Aortic Aneurysms	Nothing to Disclose
Chikwe	Joanna	Infectious Endocarditis: Comprehensive	Long-Term Benefits of Repair Versus Replacement for Acute Native Mitral Valve Endocarditis	Nothing to Disclose
Chilimuri	Sridhar	Perspectives Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Relationship Between Marijuana Use and Hospitalization for Acute Coronary Syndrome	Nothing to Disclose
Chin	Chee Yang	Coronary Artery Disease FIT Clinical Decision Making: Acute Coronary Syndrome and Vascular Medicine	"Balanced Ischemia" on ECG in Dual Territory STEMI	Nothing to Disclose
Chin	Michael	Overcoming Today's Challenges to Launching and Growing Your Academic Medical Career: An Interactive Tutorial	Thriving in Academia I: Clinician-Investigator	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - TransCellular Therapeutics
Chin	Michael	12. Heart Failure and Cardiomyopathies: Basic Team 1	Suggested Reviewer	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - TransCellular Therapeutics
Chin	Ronald	Insights From Echocardiography Use	Advances in 3D Echocardiography: Automated Software Improves the Learning Curve and Clinical Implementation in a Real World Setting for Quantitative Assessment of Left Ventricular Ejection Fraction	Nothing to Disclose
Ching	Chi Keong	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Takayasu's Arteritis Causing Coronary Artery Vasospasm and Cardiac Arrest	Nothing to Disclose
Chinitz	Larry	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Genetic Testing for Diagnosis of Progressive Cardiac Conduction Disease	Nothing to Disclose
Chinnadurai	Ponraj	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Technique and Utility of CT Angiography Fluoroscopy Image Fusion to Guide Percutaneous Pulmonary Valve Implantation in Adults	SALARY - Research Scientist, Siemens Medical Solutions USA Inc.
Chinnadurai	Ponraj	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Closure of a Ventricular Septal Defect Complicated by Hemolysis Requiring Transcatheter Retrieval of Amplatzer Occluder	SALARY - Research Scientist, Siemens Medical Solutions USA Inc.
Chinnaiyan	Kavitha	Great Debates in Cardiac CT	Debate: Coronary CTA is the Test of Choice in Low-intermediate Risk Acute Chest Pain, Con	Nothing to Disclose
Chinnaiyan	Kavitha	Great Debates in Cardiac CT	Rebuttal, Con	Nothing to Disclose
Chinnaiyan	Kavitha	Imaging of Chest Pain in the Emergency Department	Coronary CTA: Test of Choice In Low-to-Intermediate Risk Patients	Nothing to Disclose
Chinnaiyan	Kavitha	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Is There an Association Between Vitamin D Deficiency and Disease Severity on Coronary CT Angiography?	Nothing to Disclose
Chinnaiyan	Kavitha	Non Invasive Imaging: Expanding Clinical Applications	Are There Sex Differences in Management of Coronary Artery Disease After Coronary CT Angiography?	Nothing to Disclose
Chinnaiyan	Kavitha	Things That Begin With an "A" in Adult	Long-Term Cardiovascular Outcomes in Patients With Anomalous	Nothing to Disclose
,		Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Coronary Arteries Wisualized by Coronary CT Angiography: The CONFIRM (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	
Chinnaiyan	Kavitha	Non Invasive Imaging: Prognostic Implications of CT Angiography	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	Nothing to Disclose
Chinnaiyan	Kavitha	Which Test Is Best for Pain in the Chest?	Coronary CT Angiography in the Emergency Department Provides an Opportune Window for Initiation of Evidence-Based Medical Therapy	Nothing to Disclose
Chipkin	Stuart	Change is Good! Lifestyle Strategies in the Patient with ASCVD and Diabetes	Panelist	Nothing to Disclose
Chipkin	Stuart	Change is Good! Lifestyle Strategies in the Patient with ASCVD and Diabetes	Exercise for Glycemic Control: How Much and When?	Nothing to Disclose
Chiquie Borges	Jorge	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Digit Ischemia Work-Up and an Uncommon Diagnosis: Hypothenar Hammer Syndrome	Nothing to Disclose
Chirapongsathorn	Sakkarin	Updates on Risk Factors for Cardiovascular Disease	Association Between Short and Long Sleep Duration and Cardiovascular Outcomes? A Systematic Review and Meta-Analysis	Nothing to Disclose
Chirinos	Julio	Emerging Developments in HFpEF and Arryhthmias	Effect of Diabetes Mellitus on Pulsatile Arterial Load and Hemodynamics in HFpEF	CONSULTANT FEES/HONORARIA - Bristol-Myers Squiibb Company, Fukuda Denshi, Highpoint Pharmaceuticals, Merck & amp; amp; Co., Inc., Microsoft Research, OPKO Healthcare, Sanfift, Vital Labs; OTHER - Mast Therapeutics
Chirinos Medina	Julio	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Arterial Stiffness is increased at Intermediate Altitude: The INTERVENCION Trial	CONSULTANT FEES/HONORARIA - Bristol-Myers Squibb Company, Fukuda Denshi, Highpoint Pharmaceuticals, Merck & mp; amp; Co., Inc., Microsoft Research, OPKO Healthcare, Sanifit, Vital Labs; OTHER - Mast Therapeutics
Chirumamilla	Sravya	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Subacute Stroke From Multiple Cardiac Papillary Fibroelastoma With Post-Operative Recurrence	Nothing to Disclose
Chiswell	Karen	Considerations in Antiplatelet Therapy and in ACS	Dual Antiplatelet Therapy Utilization and Cardiovascular Outcomes Among Black and White Patients Treated With Drug Eluting Stents	Nothing to Disclose
Chitsaz	Sam	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Non ST-Segment Elevation Myocardial Infarction Secondary to Paradoxical Embolism via a Patent Foramen Ovale	Nothing to Disclose
Chiu	Albert	Arrhythmias and Clinical EP: Devices 3	Prospective Cryoballoon Dosing Study Based on Time-to-Isolation	Nothing to Disclose
Chiu	Michael	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Kidney Function, Angiotensin-Converting-Enzyme Inhibitor or Angiotensin II Receptor Blocker Use, and Survival Following Hospitalization for Heart Failure: A Cohort Study	Nothing to Disclose
Cho	David	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	A Confusing Case of Pulmonary Hypertension With Mixed Valvular Disease and Cryptogenic Cirrhosis	Nothing to Disclose
Cho	Goo-Yeong	Emerging Applications of Echocardiography	Effect of Changing Strain Software Versions on Longitudinal Assessment of LV Function	Nothing to Disclose
Cho	In-Jeong	Updates on Risk Factors for Cardiovascular Disease	Influence of Body Weight Changes on All-Cause and Cardiovascular Mortality in Middle-Aged Adults	Nothing to Disclose
Cho	In-Jeong	Valvular Heart Disease: Aortic Stenosis	Comparisons of Flow-Gradient Patterns in Severe Aortic Stenosis Between Bicuspid Aortic Valves and Tricuspid Aortic Valves	Nothing to Disclose
Cho	Jeong-Gwan	Highlighted Original Research: Arrhythmias	Renal Nerve Denervation Suppress Ventricular Arrhythmia in a	Nothing to Disclose
Cho	Leslie	and Clinical EP and the Year in Review Valvular Heart Disease: Mitral Valve Disease	Porcine Model After Acute Myocardial Infarction Gender Differences in the Etiology of Mitral Valve Disease	CONSULTANT FEES/HONORARIA - Amgen;
Cho	Leslie	Acute Heart Failure: Evaluating Strategies to	Identifying Non-Heart Failure Patients With Elevated NT-proBNP	RESEARCH/RESEARCH GRANTS - Amgen, Esperion, Lilly CONSULTANT FEES/HONORARIA - Amgen;
Cho	Leslie	Prevent Readmissions Updates on Risk Factors for Cardiovascular	Levels in the Outpatient Setting: Opportunities for Prevention Declining Survival With Decreasing Exercise Time on Treadmill:	RESEARCH/RESEARCH GRANTS - Amgen, Esperion, Lilly CONSULTANT FEES/HONORARIA - Amgen;
		Disease	Lessons From a 25-Year Cohort	RESEARCH/RESEARCH GRANTS - Amgen, Esperion, Lilly



Contract of the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Cho	Leslie	Vascular Medicine: Emerging Concepts in	Clevedipine as a Therapeutic and Cost-Effective Alternative to	CONSULTANT FEES/HONORARIA - Amgen;
		Clinical Vascular Diseases	Sodium Nitroprusside in Patients With Aortic Dissection	RESEARCH/RESEARCH GRANTS - Amgen, Esperion, Lilly
Cho	Leslie	FIT Clinical Decision Making: Heart Failure and	Pulmonary Hypertension in Left Atrial Sarcoma	CONSULTANT FEES/HONORARIA - Amgen;
		Pulmonary Hypertension		RESEARCH/RESEARCH GRANTS - Amgen, Esperion, Lilly
Cho	Leslie	Physical Activity and Prevention of	Referral for Pharmacologic Testing, a Marker of Poor Exercise	CONSULTANT FEES/HONORARIA - Amgen;
		Cardiometabolic Disease: Exercise Is Medicine	Capacity, Confers a Higher Risk of Short and Long Term Mortality	RESEARCH/RESEARCH GRANTS - Amgen, Esperion, Lilly
Ol .	Mr. O.	0	Than Most Traditional Cardiac Risk Factors Except Age	Note: A Production
Cho	Min Soo	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	The Prognostic Implications of Current Periprocedural Myocardial Infarction Definitions in Patients Underwent Percutaneous	Nothing to Disclose
		Main/Bilurcations and Multivessel Disease		
			Conronary Intervention With Unprotected Left Main Coronary Artery Disease	
Ob-	Vees Ulieses	Nan lavasiva lavasiva Garagas Calaiva		Nothing to Displace
Cho	Yoon-Hyeong	Non Invasive Imaging: Coronary Calcium	Smoking as a Key Predictor of CAD Among Asymptomatic and	Nothing to Disclose
Ob-	V	Scoring and CV Risk Assessment Interventional Cardiology: Stent Failure	Extremely Low Coronary Artery Calcium Score Patients Five Year Outcomes of Fractional Flow Reserve Guided Versus	Nothing to Displace
Cho	Yunkyeong	Analysis by Intravascuar Imaging	Intravascular Ultrasound Guided Percutaneous Coronary	Nothing to Disclose
		Analysis by intravascual imaging	Intervention in Intermediate Coronary Artery Disease	
Cho	Yun-Kyeong	Arrhythmias and Clinical EP: Anticoagulation	Noac Adherence of the Patients With Nonvalvular Atrial Fibrillation	Nothing to Disclose
CIIO	run-reyeong	Issues	in Real Practice	Nothing to Disclose
Choe	Jeong Cheon	Considerations in Antiplatelet Therapy and in	Comparison of Bleeding Rates and Clinical Outcomes Between	Nothing to Disclose
Onoc	ocong oncon	ACS	Ticagrelor and Prasugrel in Patients With Acute Coronary Syndrome	Nothing to Disclose
		7.00	Undergoing Percutaneous Coronary Intervention: A Propensity	
			Score-Matched Analysis	
Choi	Andrew	Non Invasive Imaging: MR Heart Failure and	Cardiovascular Magnetic Resonance in the Evaluation of Fibrofatty	Nothing to Disclose
		Pulmonary Hypertension	Infiltration for Arrhythmogenic Right Ventricular	J
		, , , , , , , , , , , , , , , , , , , ,	Dysplasia/Cardiomyopathy (ARVD/C)	
Choi	Andrew	FIT Clinical Decision Making: Multimodality	Bridging the Gap: Multimodality Imaging in a 56 Year Old Patient	Nothing to Disclose
		Imaging	With Sudden Death	
Choi	Brian	FIT Clinical Decision Making: Multimodality	Bridging the Gap: Multimodality Imaging in a 56 Year Old Patient	CONSULTANT FEES/HONORARIA - RegeneRx
		Imaging	With Sudden Death	Biopharmaceuticals; OFFICER, DIRECTOR, TRUSTEE, OR
				OTHER FIDUCIARY ROLE - Madeleine Pharmaceuticals
Choi	Byoung Geol	Novel Developments in Acute Coronary	Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor	Nothing to Disclose
	l	Syndromes	and Angiotensin Receptor Blocker in Diabetic Hypertensive Acute	
			Myocardial Infarction Patients: Results From the Korea Acute	
			Myocardial Infarction Registry (KAMIR)	
Choi	Byoung Geol	Timely Topics in Acute Coronary Syndromes	Predictors of Mortality in Acute Myocardial Infarction Patients With	Nothing to Disclose
			Unprotected Left Main Coronary Artery Disease	3
Choi	Byoung Geol	Advances in Chronic Total Occlusion	Impact of Percutaneous Coronary Intervention for Chronic Total	Nothing to Disclose
		Intervention	Occlusion Patients With Near-Normal Left Ventricular Function	-
Choi	Byung-II	Arrhythmias and Clinical EP: Basic 3	Entropy of Fibrillatory Waves Contributes to Differentiating	Nothing to Disclose
		-	Paroxysmal From Persistent and Permanent Atrial Fibrillation	
Choi	Byung-II	Arrhythmias and Clinical EP: Basic 4	Efficacy of Scattergram Analysis for Classifying Subtypes of Atrial	Nothing to Disclose
			Fibrillation by Fourier Transform of Fibrillatory Waves	
Choi	Calvin	FIT Clinical Decision Making: Interventional	Coronary Artery Bypass Graft Pseudoaneurysm From Saphenous	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart	Vein Graft Stent Rupture	
		Disease, and Vascular Medicine		
Choi	Cheol Ung	Novel Developments in Acute Coronary	Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor	OTHER - none
	-	Syndromes	and Angiotensin Receptor Blocker in Diabetic Hypertensive Acute	
			Myocardial Infarction Patients: Results From the Korea Acute	
			Myocardial Infarction Registry (KAMIR)	
Choi	Cheol Ung	Timely Topics in Acute Coronary Syndromes	Predictors of Mortality in Acute Myocardial Infarction Patients With	OTHER - none
			Unprotected Left Main Coronary Artery Disease	
Choi	Cheol Ung	Advances in Chronic Total Occlusion	Impact of Percutaneous Coronary Intervention for Chronic Total	OTHER - none
	_	Intervention	Occlusion Patients With Near-Normal Left Ventricular Function	
Choi	Donghoon	Head to Toe: Outcomes of Endovascular	Comparison of Aortic Remodeling After Thoracic Endovascular	Nothing to Disclose
		Interventions	Repair Between Acute/Subacute Versus Chronic Type B Aortic	
			Dissection	
Choi	Donghoon	Considerations in Antiplatelet Therapy and in	Association Between Duration of Dual Antiplatelet Therapy and	Nothing to Disclose
		ACS	Angiographic Multi-Vessel Disease on Outcomes in Patients Treated	
			With Newer-Generation Drug-Eluting Stents	
Choi	Dong-Ju	From Diet to Drugs: Mechanistic Insight Into	Fimasartan Protect Cardiac Myocyte Damage in Ischemic Heart	Nothing to Disclose
		Ischemic Heart Disease	Diseases	
Choi	Dong-Ju	Emerging Developments in HFpEF and	Risk of Stroke and Thromboembolism for Heart Failure With and	Nothing to Disclose
	-	Arryhthmias	Without Atrial Fibrillation	
Choi	James	Advances in Chronic Total Occlusion	The Impact of Epicardial Collateral Use on the Outcomes of Chronic	Nothing to Disclose
		Intervention	Total Occlusion Percutaneous Coronary Intervention: Insights From	
			a Contemporary Multicenter Registry	
Choi	James	Advances in Chronic Total Occlusion	Application and Outcomes of the Hybrid Approach to Chronic Total	Nothing to Disclose
		Intervention	Occlusion Percutaneous Coronary Intervention: An Update From a	
Choi	So Voor	Novel Davelonments in Annts Original	Contemporary Multicenter U.S. Registry	Nothing to Displace
Choi	Se Yeon	Novel Developments in Acute Coronary	Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor	Nothing to Disclose
		Syndromes	and Angiotensin Receptor Blocker in Diabetic Hypertensive Acute Myocardial Infarction Patients: Results From the Korea Acute	
Choi	Se Yeon	Timely Topics in Acute Coronary Syndromes	Myocardial Infarction Registry (KAMIR) Predictors of Mortality in Acute Myocardial Infarction Patients With	Nothing to Disclose
51101	06 16011	ramely Topics at Acute Coronary Syndromes	Unprotected Left Main Coronary Artery Disease	Trouming to Disclose
Choi	Se Yeon	Advances in Chronic Total Occlusion	Impact of Percutaneous Coronary Intervention for Chronic Total	Nothing to Disclose
		Intervention	Occlusion Patients With Near-Normal Left Ventricular Function	
Choi	Seungbum	Understanding Pulmonary Vascular Disease:	Apelin-13 Co-Treatment With Umbilical Cord Blood-Derived	Nothing to Disclose
-		From Bench to Bedside	Mesenchymal Stem Cells Improves Engrafted Cell Survival and	J
			Inhibits Macrophage Activation in Pulmonary Arterial Hypertension	
			Murine Model	
Choi	Seungbum	Bridge From the Basics: Translational	What Kind of Mesenchymal Stem Cell Is Promising in the	Nothing to Disclose
	_	Research in Pulmonary Hypertension	Prevention of Pulmonary Arterial Hypertension in a Murine Model?	
Chokshi	Aalap	FIT Clinical Decision Making Reviewers 7	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Chon	Min Ku	Arrhythmias and Clinical EP: Basic 3	Atrial Fibrillation Cycle Length Measured by Transesophageal	Nothing to Disclose
			Echocardiography: A Predictor for Maintaining Sinus Rhythm After	
	<u> </u>		DC Cardioversion	
Chong	Aun-Yeong	Novel Developments in Acute Coronary	Efficacy and Safety of Bivalirudin in Patients Undergoing	CONSULTANT FEES/HONORARIA - Asculsciences
		Syndromes	Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment	
	ļ		Elevation Myocardial Infarction	
Chong	Aun-Yeong	Noninvasive Assessment of Coronary Flow	In the Presence of Significant Epicardial Coronary Disease,	CONSULTANT FEES/HONORARIA - Asculsciences
		Reserve: Clinical Implications	Diabetes Mellitus Is Further Associated With Reduced Myocardial	
	l		Flow Reserve	
Chothani	Ankit	Cardiac Arrest, Diabetes, and Other High Risk	Impact of Gender on Mortality and Percutaneous Coronary	Nothing to Disclose
1		Features of Patients With Acute Coronary	Intervention in Non ST-Segment Elevation Myocardial Infarction: A	
		Syndrome	Nationwide Analysis	
			Non ST-Segment Elevation Myocardial Infarction Patient Outcomes	Nothing to Disclose
Chothani	Ankit	Acute Coronary Syndromes, Diagnosis,		
		Management and Outcomes	in Teaching Hospital: A Nationwide Analysis	-
Chothani	Ankit Li-Dek	Management and Outcomes The Inside View: Learning From Intracoronary		Nothing to Disclose
Chou	Li-Dek	Management and Outcomes The Inside View: Learning From Intracoronary Imaging	in Teaching Hospital: A Nationwide Analysis Hybrid IVUS/OCT: "Probing " the Future	Nothing to Disclose
		Management and Outcomes The Inside View: Learning From Intracoronary Imaging Predicting Outcomes in Cardiac Rehabilitation	in Teaching Hospital: A Nationwide Analysis Hybrid IVUS/OCT: "Probing" the Future Lower Educational Levels May Be an Important Determinant of	Nothing to Disclose RESEARCH/RESEARCH GRANTS - CVS Caremark,Merck
Chou	Li-Dek	Management and Outcomes The Inside View: Learning From Intracoronary Imaging	in Teaching Hospital: A Nationwide Analysis Hybrid IVUS/OCT: "Probing " the Future	Nothing to Disclose RESEARCH/RESEARCH GRANTS - CVS Caremark,Merck & Co., Inc.,NHLBI,PhRMA,Robert Wood Johnson
Chou	Li-Dek Niteesh	Management and Outcomes The Inside View: Learning From Intracoronary Imaging Predicting Outcomes in Cardiac Rehabilitation Patients	in Teaching Hospital: A Nationwide Analysis Hybrid IVUS/OCT: “:Probing" the Future Lower Educational Levels May Be an Important Determinant of Adherence to Evidenced-Based Therapies in Post-MI Patients	Nothing to Disclose RESEARCH/RESEARCH GRANTS - CVS Caremark,Merck & Co., Inc.,NHLBI,PhRMA,Robert Wood Johnson Foundation
Chou	Li-Dek	Management and Outcomes The Inside View: Learning From Intracoronary Imaging Predicting Outcomes in Cardiac Rehabilitation	in Teaching Hospital: A Nationwide Analysis Hybrid IVUS/OCT: "Probing" the Future Lower Educational Levels May Be an Important Determinant of	Nothing to Disclose RESEARCH/RESEARCH GRANTS - CVS Caremark,Merck & Co., Inc.,NHLBI,PhRMA,Robert Wood Johnson

Contract of the second				<u> </u>
Last Name Choudhuri	First Name Indrajit	Session Title Innovative Approaches for Reducing Risk and	Presentation Title Incremental Value of Estimated Glomerular Filtration Rate in	Disclosures Nothing to Disclose
Chodulan	indrajit	Improving Outcomes With Ablation	Improving Stroke Risk Stratification in Patients With and Without Atrial Fibrillation Considered to Be Low Risk by CHA ₂ DS ₂ VSCore	reduing to Disclose
Chow	Benjamin	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prognostic Value of Segment Involvement Score Compared to Other Measures of Coronary Atherosclerosis by Computed Tomography: A Systematic Review and Meta-Analysis	OTHER - TeraRecon; RESEARCH/RESEARCH GRANTS - CV Diagnostix,GE Healthcare
Chow	Benjamin J.	Challenges in Cardiac CT: Case-Based Discussions	Co-Chair	OTHER - TeraRecon; RESEARCH/RESEARCH GRANTS - CV Diagnostix,GE Healthcare
Chowdhury	Devyani	Advances in Cholesterol Measurement and Management	Lipid Levels and Vascular Function in Young Individuals, Heterozygous or Homozygous for an <i>APOB </i> C.1058G>A	Nothing to Disclose
Chowdhury	Devyani	Congenital Heart Disease: New Diagnostic	Modified Newborn Pulse Oximetry Screening for Out-of-Hospital	Nothing to Disclose
Chowdhury	Mohsin	Approaches in Congenital Heart Disease FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Births Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Associated Eosinophilic Myocarditis Treated With Tofactitnib an Oral Janus (JAK) Kinase Inhibitor	Nothing to Disclose
Chowdhury	Shahryar	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Detection of Heart Failure With Preserved Ejection Fraction in Single Ventricle Physiology: Insights From the Pediatric Heart Network Fontan Cross-Sectional Study Public Use Dataset	Nothing to Disclose
Christen	Thomas	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Three-Year Outcomes in 'Real-World' Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus U.S. Post-Approval Study (PE- Plus PAS)	SALARY - Full time employee of Boston Scientific Corporation
Christen	Thomas	Refining PCI Technique and Outcomes	Three-Year Results From the EVOLVE II Randomized Trial: Late Clinical Outcomes With Bioresorbable Compared to Permanent Polymer Everolimus-Eluting	SALARY - Full time employee of Boston Scientific Corporation
Christensen	Barbara	Public Reporting and NCDR: The Decision to Report Your Data Before the Feds Decide	Where is this Data and What do I do?	Nothing to Disclose
Christensen	Thomas	Highlighted Original Research: Non Invasive	Integrating Hyperemic Myocardial Blood Flow and Coronary Flow	Nothing to Disclose
Christer	Thomas	Imaging and the Year in Review	Reserve for Predicting Cardiovascular Mortality Outcomes in Patients With Known or Suspected Ischemic Heart Disease	Nething to Displace
Christensen	Thomas	Nuclear Cardiology: Prognosis	Myocardial Scar but Not Ischemia Predicts Defibrillator Shocks and Sudden Cardiac Death in Patients With Reduced Left Ventricular Ejection Fraction	Nothing to Disclose
Christenson	Robert	Making Progress in Understanding Heart Failure	Impact of Malignant Left Ventricular Function on Incident Heart Failure With Reduced Versus Preserved Ejection Fraction: The MESA Study	CONSULTANT FEES/HONORARIA - Instrumentation Laboratories Inc,Roche Diagnostics Systems,Siemens Medical Diagnostics
Christenson	Robert	Making Progress in Understanding Heart Failure	Impact of Malignant Left Ventricular Function on Incident Heart Failure in Older Adults: The MESA Study	CONSULTANT FEES/HONORARIA - Instrumentation Laboratories Inc,Roche Diagnostics Systems,Siemens Medical Diagnostics
Christenson	Robert	Innovations in Cardiovascular Risk Assessment and Reduction	Asymptomatic Left Ventricular Dysfunction: The MESA Study	CONSULTANT FEES/HONORARIA - Instrumentation Laboratories Inc,Roche Diagnostics Systems,Siemens Medical Diagnostics
Christia	Panagiota	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Persistent Hemodynamic Instability After Repaired Heart Injury Due to Penetrating Trauma: No Valvulopathy? Look Again	Nothing to Disclose
Christiansen	Evald	Late-Breaking Clinical Trials: Interventional	Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve Guided Intervention (IFR-SWEDEHEART): A Multicenter, Prospective, Registry-Based Randomized Clinical Trial	Nothing to Disclose
Christiansen	Morten	New Perspectives on CAD Risk Factors	A Genetic Risk Score Predicts Cardiovascular Events in Patients With Stable Coronary Artery Disease	Nothing to Disclose
Christopher	Sanah	Making Progress in Understanding Heart Failure	Arterial Elastance Drives Ventilatory Inefficiency in Systolic Heart Failure	Nothing to Disclose
Christopoulos	Georgios	Nuclear Cardiology: Beyond Perfusion	The Impact of Cardiopulmonary Testing on Downstream Evaluation in Patients Who Undergo Myocardial Perfusion Imaging	Nothing to Disclose
Christow	Steffen	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Increased Rate of Previous Stroke in Asymptomatic/Minimally Symptomatic Versus Symptomatic Patients With Newly Detected Atrial Fibrillation Worldwide: Results From the GLORIA-AF Registry	Nothing to Disclose
Chrysohoou	Christine	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Omega-3 Polyunsaturated Fatty Acids May Favorably Affect Inflammatory Biomarkers & Novel Indices of Left Ventricle Function in Patients With Heart Failure	Nothing to Disclose
Chrysohoou	Christine	Diabetes and Endothelial Dysfucntion in Heart Failure	Association of Endothelial Dysfunction With Biomarkers of Inflammation, Myocardial Fibrosis and Left Ventricle Strain in Patients With Heart Failure	Nothing to Disclose
Chu	Antony	Innovation in Practice Management, Advocacy, and Education	Using Mobile Device Technology and Spaced Education Adaptive Learning Algorithms to Teach ECG Interpretation	Nothing to Disclose
Chu	Vivian	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Echocardiographic Predictors for In-Hospital and 1-Year Outcomes in Left-Sided Infective Endocarditis: An Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort	Nothing to Disclose
Chua	Serene	Vascular Medicine: Novel Risk Measures in	Study Sarcopenia and Vascular Function Among Community Elderly	Nothing to Disclose
Chua	Serene	Arterial Diseases Diabetes and Other Issues in Cardiovascular	Adiposity, Leanness or Both? Characterizing Measures of Adiposity	Nothing to Disclose
Chugh	Aman	Prevention 08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	and Leanness With Cardiovascular Remodeling Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Biosense Webster,MEDTRONIC
Chugh	Monica	2 FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	The Fontan Fiasco: Strategies for Thromboembolic Management	Nothing to Disclose
Chugh	Sumeet	Arrhythmias and Clinical EP: Ventricular	Health Insurance Expansion and Incidence of Out-of-Hospital	Nothing to Disclose
Chugh	Sumeet	Tachycardia FIT Clinical Decision Making: Arrhythmias and	Cardiac Arrest: A Pilot Study in a US Metropolitan Community Wide Complex Tachycardia in a 51-Year-Old Man: Ventricular	Nothing to Disclose
Chui	Philip	Electrophysiology Advances in Cholesterol Measurement and Management	Tachycardia Until Proven Otherwise? Combined LDL-C and Lipoprotein (a) Levels in Prediction of Residual Atherosclerotic Cardiovascular Disease Risk: The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes)	Nothing to Disclose
Chui	Philip	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Predicting Cardiovascular Risk in Statin-Treated Patients: The AIM- HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Residual Risk Score	Nothing to Disclose
Chun	Kook Jin	Arrhythmias and Clinical EP: Basic 3	Atrial Fibrillation Cycle Length Measured by Transesophageal Echocardiography: A Predictor for Maintaining Sinus Rhythm After DC Cardioversion	Nothing to Disclose
Chung	Eugene	ECG Screening in Athletes: The Great Debate	Co-Chair	Nothing to Disclose
Chung	Eugene	The Abnormal ECG: Should I Worry about Sudden Death Risk in this Patient	Co-Chair	Nothing to Disclose
Chung	Eugene	The Abnormal ECG: Should I Worry about Sudden Death Risk in this Patient	Early Repolarization: Normal Variant, Brugada, or Something in Between	Nothing to Disclose





and a				l l
Last Name Chung	First Name Eugene	Session Title Atrial Fibrillation and VT: Unique Populations	Presentation Title Association Between Atrial Fibrillation and Sudden Cardiac Death: A	Disclosures Nothing to Disclose
Chung	Eugene	and Solutions FIT Clinical Decision Making: Arrhythmias and	Systematic Review and Meta-Analysis Complete Heart Block on an Athlete's Screening ECG: Reason to	Nothing to Disclose
Chung	Eugene	Electrophysiology 31. Non Invasive Imaging: Sports and Exercise	Restrict? Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston
Chung	Hyemoon	Team 1 Coronary Angiography, Intra-Vascular Imaging,	Comparison of Timing of Non-Culprit Lesion Percutaneous	Scientific,MEDTRONIC Nothing to Disclose
Chung	Hyemoon	Revascularization and Outcomes Markers of Prognosis Associated With	Coronary Intervention in Myocardial Infarction Patients Incidence of Subclinical Atherosclerosis in Patients With Resistant	Nothing to Disclose
		Elevated Blood Pressure	Hypertension	
Chung	Hyemoon	Innovations in Cardiovascular Risk Assessment and Reduction	The Predictive Value of Aortic Arch Calcification on Chest X-Ray for Cardiovascular Events in Comparison With the Coronary Artery Calcium Score and the Framingham Risk Score	Nothing to Disclose
Chung	Jennifer	Vascular Medicine: New Insights Into Aortic and Peripheral Artery Diseases	Differentiating Between Familial and Sporadic Thoracic Aortic Aneurysms and Dissections	Nothing to Disclose
Chung	Jonathan	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Small Dense Low Density Lipoprotein Particle Number Relates to Coronary Plaque Burden Independent of Traditional Cardiovascular Risk Factors in Psoriasis	Nothing to Disclose
Chung	Jonathan	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Aortic Vascular Inflammation by 18-FDG PET/CT Associates With High-Risk Coronary Plaques in Young Psoriasis Patients	Nothing to Disclose
Chung	Jonathan	Vascular Medicine: New Insights Into Aortic and Peripheral Artery Diseases	Improvement in Cholesterol Efflux Capacity Is Associated With Improvement in Vascular Inflammation by 18- FDG PET CT in	Nothing to Disclose
Chung	Jonathan	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Psoriasis Improvement in Cholesterol Efflux Capacity Is Associated With a Reduction in Aortic Wall Thickness by MRI Independent of	Nothing to Disclose
Chung	Jonathan	Updates on Risk Factors for Cardiovascular	Traditional CV Risk Factors Visceral but Not Subcutaneous Adipose Tissue Associates With	Nothing to Disclose
Chung	Mina	Disease Role of Newer ICD Technologies for the	Vascular Inflammation by 18-FDG PET/CT in Psoriasis Panelist	CONSULTANT FEES/HONORARIA - Biotronik,Boston
, and the second		Prevention of Sudden Cardiac Death		Scientific,MEDTRONIC,St. Jude Medical,Zoll; DATA SAFETY MONITORING BOARD - Amarin; OTHER - UpToDate; RESEARCH/RESEARCH GRANTS - Zoll
Chung	Mina	Role of Newer ICD Technologies for the Prevention of Sudden Cardiac Death	Should We Use a Vest in Newly Diagnosed Nonischemic Cardiomyopathy Patients?	CONSULTANT FEES/HONORARIA - Biotronik,Boston Scientific,MEDTRONIC,St. Jude Medical,Zoli; DATA SAFETY MONITORING BOARD - Amarin; OTHER - UpToDate; RESEARCH/RESEARCH GRANTS - Zoll
Chung	Mina	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Biotronik, Boston Scientific, MEDTRONIC, St. Jude Medical, Zoli; DATA SAFETY MONITORING BOARD - Amarin; OTHER - UpToDate; RESEARCH/RESEARCH GRANTS - Zoll
Chung	Namsik	Updates on Risk Factors for Cardiovascular Disease	Influence of Body Weight Changes on All-Cause and Cardiovascular Mortality in Middle-Aged Adults	Nothing to Disclose
Chung	Namsik	Valvular Heart Disease: Aortic Stenosis	Comparisons of Flow-Gradient Patterns in Severe Aortic Stenosis Between Bicuspid Aortic Valves and Tricuspid Aortic Valves	Nothing to Disclose
Chung	Wendy	Young Investigator Awards Competition: Basic and Translational Science	Impact of Damaging de Novo Variants on Clinical Outcomes in Congenital Heart Disease	Nothing to Disclose
Chung	Wook-Jin	Understanding Pulmonary Vascular Disease: From Bench to Bedside	Apelin-13 Co-Treatment With Umbilical Cord Blood-Derived Mesenchymal Stem Cells Improves Engrafted Cell Survival and Inhibits Macrophage Activation in Pulmonary Arterial Hypertension Murine Model	Nothing to Disclose
Chung	Wook-Jin	Bridge From the Basics: Translational Research in Pulmonary Hypertension	What Kind of Mesenchymal Stem Cell Is Promising in the Prevention of Pulmonary Arterial Hypertension in a Murine Model?	Nothing to Disclose
Chyu Ciccarelli	Kuang-Yuh Giovanni	38. Vascular Medicine: Basic Team 2 MicroRNAs and Beyond in Vascular Medicine	Suggested Reviewer Colchicine Exerts Antithrombotic Properties in oxLDL-Treated Endothelial Cells via Inhibition of Tissue Factor Expression and	Nothing to Disclose Nothing to Disclose
Ciccotto	Sarah	EIT Clinical Decision Making: Heart Failure and	Pulmonary Hypertension as the Initial Clinical Presentation of	Nothing to Disclose
Cicek		Pulmonary Hypertension Imaging Pulmonary Vascular Disease Plus the	Pompe's Disease	
	Sertac	Impact of Congenital Heart Disease	Survival Analysis From THALES Study, A Large Nation-Wide Registry on Pulmonary Arterial Hypertension Associated With Congenital Heart Disease	Nothing to Disclose
Cilingiroglu	Mehmet	Head to Toe: Outcomes of Endovascular Interventions	Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease	Nothing to Disclose
Cilingiroglu	Mehmet	Venous Investigation: The Dark Side	3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis	Nothing to Disclose
Cimmino	Giovanni	Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI	Activating Stimuli Modulate Pre-mRNA Maturation in Platelets: A Novel Mechanism That Regulates Platelet Function?	Nothing to Disclose
Cimmino	Giovanni	MicroRNAs and Beyond in Vascular Medicine	Colchicine Exerts Antithrombotic Properties in oxLDL-Treated Endothelial Cells via Inhibition of Tissue Factor Expression and	Nothing to Disclose
Cimmino	Giovanni	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Activity Relationship Between Fractional Flow Reserve (FFR) and Coronary Flow Reserve (CFR) by PET in Identifying Coronary Stenosis	Nothing to Disclose
Cimmino	Giovanni	Cutting Edge Vascular Medicine	Causing Myocardial Ischemia Colchicine Inhibits Platelet Aggregation <i>In Vitro </i> With Cofilin and LIM Domain Kinase 1, the Main Kinases Involved in	Nothing to Disclose
Cimmino	Giovanni	Antithrombotic Therapy in Ischemic Heart Disease	Cytoskeleton Rearrangement Time-Trends in Antithrombotic Management of Patients With AF/Flutter Treated With Coronary Stents: An International	Nothing to Disclose
Cingolani	Eugenio	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Multicenter Restrospective Analysis Wide Complex Tachycardia in a 51-Year-Old Man: Ventricular Tachycardia Until Proven Otherwise?	Nothing to Disclose
Cinque	Alessandra	Improving Outcomes in the Athlete With Cardiovascular Disease		Nothing to Disclose
Cirillo	Plinio	Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI		Nothing to Disclose
Cirillo	Plinio	MicroRNAs and Beyond in Vascular Medicine	Colchicine Exerts Antithrombotic Properties in oxLDL-Treated Endothelial Cells via Inhibition of Tissue Factor Expression and Activity	Nothing to Disclose
Cirillo	Plinio	Cutting Edge Vascular Medicine	Colchicine Inhibits Platelet Aggregation <i>In Vitro </i> With Cofilin and LIM Domain Kinase 1, the Main Kinases Involved in Cytoskeleton Rearrangement	Nothing to Disclose
Ciszek	Boguslawa	New Technologies in Echocardiography		Nothing to Disclose
Civitello	Andrew	Atrial Fibrillation and VT: Unique Populations and Solutions	The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience	Nothing to Disclose
Civitello	Andrew	Ventricular Arrhythmias and Sudden Death Prevention	Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience	Nothing to Disclose
Civitello	Andrew	FIT Clinical Decision Making: Heart Failure and Cardiomyopathies	SynCardia Meets CardioMEMS: A Loeffler's Story	Nothing to Disclose
	•			

Contract of the contract of th				l l
Last Name Claggett	First Name Brian	Session Title Emerging Developments in HFpEF and	Presentation Title Influence of Left Ventricular Ejection Fraction on Cause-Specific	Disclosures Nothing to Disclose
Olaggett	bhan	Arryhthmias	Mortality in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial	
Clapp	Brian	Post-CAD/MI: Making Tough Predictions About the Future	Unravelling the Mechanisms of Mental Stress Induced Myocardial Ischaemia: Novel Insights From Intracoronary Measurements During Cardiac Catheterisation	Nothing to Disclose
Clarey	Austin	Innovations in Practice Management and Social Media	Radiation Exposure Among Non-Physician Staff Members During Cardiac Catheterization and the Impact of Proactive Shielding	Nothing to Disclose
Clarey	Austin	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Variation in Intracoronary Lipid-Rich Plaque Detected by Near- Infrared Spectroscopy in Asymptomatic Individuals With High Coronary Artery Calcium Scores	Nothing to Disclose
Clark	David	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Outcomes of Pre-Loading Versus In-Lab Loading With Prasugrel and Ticagrelor in Patients With Acute Coronary Syndromes (ACS) Undergoing Percutaneous Coronary Intervention (PCI)	Nothing to Disclose
Clark	Donald	Advances in Cholesterol Measurement and Management	Atherogenic Lipoprotein Variability Correlates With Coronary Atheroma Progression: Insights From Serial Intravascular	Nothing to Disclose
Clarke	Bernard	The Story of the Adult Congenital Heart Disease Patient and EP	Ultrasonography Prevalence and Predictors of Atrial Tachyarrhythmias in Adult Fontan Patients	Nothing to Disclose
Clarke	Bernard	Fontan in the Modern World	Prevalence of Elevated Body Mass Index and Its Association With Clinical Features in Adult Fontan Patients	Nothing to Disclose
Clarke	Bernard	Redefining the "F" Word	Prevalence and Predictors of Pacemaker Placement in Adult Fontan Patients	Nothing to Disclose
Clarke	Sarah	Trends in Coronary Syndromes: International Perspectives From the ACC Great Britain and Ireland Chapter, Israel Heart Society, and	Co-Chair	Nothing to Disclose
Clarke	Sarah	American College of Cardiology International CV Centers of Excellence: Leveraging the NCDR for Achieving High Quality Care	Co-Chair	Nothing to Disclose
Clarke	Sarah	International CV Centers of Excellence: Leveraging the NCDR for Achieving High Quality Care	Introduction to Session	Nothing to Disclose
Clarke	Sarah	International CV Centers of Excellence: Leveraging the NCDR for Achieving High Quality Care	Conclusion	Nothing to Disclose
Clarke	Sarah	Great Minds Think Differently: Multidisciplinary Approach to Controversies in Cardiology	Co-Chair	CONSULTANT FEES/HONORARIA - Edwards Lifescience,MEDTRONIC
Clarke	Sarah	Great Minds Think Differently: Multidisciplinary Approach to Imaging	Pre-procedure Planning: Case Based Imaging. TAVR	CONSULTANT FEES/HONORARIA - Edwards Lifescience,MEDTRONIC
Clarke	Sarah	TAVR Changing the Paradigm for the Treatment of Valve Disease	Panelist	CONSULTANT FEES/HONORARIA - Edwards Lifescience,MEDTRONIC
Clarke	Sarah	Cardiovascular Procedures That Push the Line: High-Risk or Futility of Care?	Panelist	Nothing to Disclose
Clavel	Marie-Annick	Aortic Stenosis: Overview of the Hemodynamics and Ventricular Response	Severe Aortic Stenosis in the Guidelines: the Confusing D Subgroups	Nothing to Disclose
Clavel	Marie-Annick	Interventional Cardiology: TAVR 1	Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: Insights From PARTNER 2A Trial	Nothing to Disclose
Clavel	Marie-Annick	New Technologies in Echocardiography	Mitral Annular Disjunction Prevalence and Physiologic Consequences in Degenerative Mitral Regurgitation: A Dynamic 3- Dimensional Echocardiographic Study	Nothing to Disclose
Clavel	Marie-Annick	Interventional Cardiology: TAVR 4	Clinical Study of the Impact of Preexisting Patient-Prosthesis Mismatch on Valve-in-Valve Performance	Nothing to Disclose
Clavel	Marie-Annick	Novel Determinants of Outcomes in VHD	Impact of Aortic Valve Calcification and Sex on Hemodynamic Progression and Clinical Outcomes in Aortic Stenosis	Nothing to Disclose
Clavel	Marie-Annick	Novel Determinants of Outcomes in VHD	Pre-Operative Longitudinal Strain and Strain Rate as Predictors of Impaired Post-Operative Ejection Fraction in Patients Operated for Pure Aortic Regurgitation	Nothing to Disclose
Clavel	Marie-Annick	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low- Flow Severe Aortic Stenosis and Less Reverse Remodeling After TAVR: A Partner 2 Trial Analysis	Nothing to Disclose
Clavell	Alfredo	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Effects of Diabetes Mellitus on Clinical Outcomes After Left Ventricular Assist Device Implantation: A Single Institutional 9-Year Experience	Nothing to Disclose
Clavell	Alfredo	Advanced Therapies = Advanced Trouble: VAD and Transplant Challenges	Sirolimus-Based Immunosuppression Mitigates Progression of Cardiac Allograft Vasculopathy and Improves Cardiac Outcomes After Heart Transplantation: A Single Center 15-Year Follow-Up	Nothing to Disclose
Clavijo	Leonardo	Arrhythmias and Clinical EP: Anticoagulation Issues	Study Does Stroke Risk Influence the Decision to Anticoagulate Post Percutaneous Coronary Intervention Patients With Atrial Fibrillation: A Review of 3850 Patients	CONSULTANT FEES/HONORARIA - AstraZeneca,MEDTRONIC; RESEARCH/RESEARCH GRANTS - Aztrazeneca
Cleland	John	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Cardiovascular Magnetic Resonance in Survivors of Sudden Cardiac Arrest: 14 Year Experience From a Tertiary Referral Centre in the United Kingdom	CONSULTANT FEES/HONORARIA - Bayer, Biotronik, GSK, Johnson & Bamp;amp; Johnson, MEDTRONIC, MSD, St Jude Medical, Stealth Biotherapeutics, Zoll, ZS Pharma; RESEARCH/RESEARCH GRANTS - Amgen, Biosense- Webster, Biotronik, MSD, Novartis, Philips, Roche, servier, Torrent, Vifor
Clementy	Nicolas	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Incident Atrial Fibrillation According to Gender In Patients With Ischemic Stroke: A Nationwide Cohort Study	CONSULTANT FEES/HONORARIA - Saint Jude Medical, Medtronic, Boston Scientific
Clementy	Nicolas	Stroke and AF: Thinking About the Heart	Predictors of Incident Atrial Fibrillation in Patients With Ischemic Stroke: A Nationwide Cohort Study	CONSULTANT FEES/HONORARIA - Saint Jude Medical, Medtronic, Boston Scientific
Cleuziou	Julie	Finding Out What Works in Pediatric and Congenital Heart Disease	Morphological Appearance and Repair Strategies of Tricuspid Regurgitation in Patients With Univentricular Heart and a Systemic Right Ventricle	Nothing to Disclose
Cleve	Jayne	Stress Echocardiography: Best Practices and Emerging Applications	Technical Tips and Tricks During Stress Echo	SPEAKER'S BUREAU - Lantheus
Cleveland	Joseph	Cardiovascular Update for the Clinician II: Chronic Coronary and Systemic Disease (A Symposium by Valentin Fuster)	Panelist	RESEARCH/RESEARCH GRANTS - HeartWare Corporation,St. Jude
Cleveland	Joseph	Cardiovascular Update for the Clinician II: Chronic Coronary and Systemic Disease (A Symposium by Valentin Fuster)	 	RESEARCH/RESEARCH GRANTS - HeartWare Corporation,St. Jude
Cleveland	Joseph	Should I Stay or Should I Go? Tough Cases in MCS and Transplant	Co-Chair	RESEARCH/RESEARCH GRANTS - HeartWare Corporation,St. Jude
Clevenger	Joshua	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Baseline Characteristics, Management and Outcomes in Mitral Valve Prolapse With Manifest Ventricular Automaticity	Nothing to Disclose
Clopton	Paul	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Relationship of Biomarkers of Oxidized Lipoproteins to Ethnicity, Subclinical Atherosclerosis and Cardiovascular Events Over a 10.5 Year Follow-Up in the Dallas Heart Study	Nothing to Disclose
Clouse	Melvin	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Calcium Characteristics as Predictors of Major Adverse Cardiac Events in Symptomatic Patients: Insights From the CORE320 Multinational Study	Nothing to Disclose
	•	•		



and the same of th				
	First Name	Session Title	Presentation Title	Disclosures
Cluckey	Andrew	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Success Rates by Ablation Lesion Set of Catheter Ablation for Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta- Analysis Study Cohort	Nothing to Disclose
Cluckey	Andrew	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Secular Trends in Reported Success Rates of Catheter Ablation for Non-Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort	Nothing to Disclose
,	Andrew	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Inclusion of Women in Studies of Catheter Ablation for Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort	Nothing to Disclose
Cluff	Kim	Interventional Cardiology: Translation and Pre- Clinical Research	Non-Invasive Point-of-Care Method for Measuring Left-Ventricular Stroke-Volume Using a Passive Electromagnetic Skin Patch Sensor	Nothing to Disclose
	Michael Lawrenz	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Fibrosing Mediastinitis-Related Pulmonary Artery and Vein Stenosis Limiting Chemotherapy	Nothing to Disclose
Coady	Sean	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Risk of Hospitalization or Death Due to Heart Failure With Intensive Glucose-Lowering Therapy in Diabetic Women: Subgroup Analyses by History of Cardiovascular Disease in the ACCORD Trial	Nothing to Disclose
Coats	Nancy	State of the Art Nuclear Cardiology: SPECT Myocardial Perfusion Imaging	Supervising the Stress Test	SPEAKER'S BUREAU - Astellas Pharma US
Coffman	Joseph	Emerging Applications of Echocardiography	Clinical Characteristics and Changes of Valvuloarterial Impedence Severity in Patients Undergoing Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis	Nothing to Disclose
Cohen	Ander	Challenging the Standard of Care: Emerging Concepts in VTE Treatment and Prevention	Extended Pharmacological Thromboprophylaxis at Hospital Discharge for High Risk Medical Patients	CONSULTANT FEES/HONORARIA - Aspen Europe CIS,Bayer Healthcare Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,Bristol-Myers Squibb Company, Daiichi Sankyo,GlaxoSmithKline,Janssen Pharmaceuticals, Inc,Johnson & Daimping, Johnson,Leo Pharma,ONO Pharmaceuticals,Pfizer Inc,Portola Pharmaceuticals,Sanofi Aventis,Takeda Pharmaceuticals North America, Inc,XO1
Cohen	Ariel	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Proprotein Convertase Subtilisin Kexin Type 9 Regulation in Human Immunodeficiency Virus-Infected Patients Under Protease Inhibitors	CONSULTANT FEES/HONORARIA - AstraZeneca, Bayer Pharma, Bohninger-ingelheim, Daiichi Sankyo, GlaxoSmithKline, Sanofi-Aventis; RESEARCH/RESEARCH GRANTS - RESICARD
	David	Opening Session and the Joint American College of Cardiology and Journal of American College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture	Panelist	CONSULTANT FEES/HONORARIA - Cardinal Health,Edwards Lifesciences,MEDTRONIC,St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Astra Zeneca,Biomet, Inc.,Boston Scientific,Cardiovascular Systems, Inc. (CSI),Daiichi-Sankyo,Edwards Lifesciences,Eli Lilly,MEDTRONIC,Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	David	Featured Clinical Research II: Interventional	Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data	CONSULTANT FEES/HONORARIA - Cardinal Health,Edwards Lifesciences, MEDTRONIC, St. Jude Medicial; RESEARCH/RESEARCH GRANTS - Abbott Vascular Astra Zeneca,Biomet, Inc.,Boston Scientific,Cardiovascular Systems, Inc. (CSI), Daith-Sankyo,Cawards Lifesciences,Eli Lilly,MEDTRONIC,Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	David	Overuse, Underuse or Just Right? Fundamental Debates in High Risk PCI in 2017	Co-Chair	CONSULTANT FEES/HONORARIA - Cardinal Health, Edwards Lifesciences, MEDTRONIC, St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular Astra Zeneca, Blomet, Inc., Boston Scientific, Cardiovascular Systems, Inc. (CSI), Daichi-Sanky, Calwards Lifesciences, Eli Lilly, MEDTRONIC, Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	David	Left Main PCI: Why? When? How?	Co-Chair	CONSULTANT FEES/HONORARIA - Cardinal Health,Edwards Lifesciences,MEDTRONIC,St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Astra Zeneca,Biomet, Inc.,Boston Scientific,Cardiovascular Systems, inc. (CSI),Dalichi-Sankyo,Edwards Lifesciences,Eli Lilly,MEDTRONIC,Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	David	Dyslipidemias: A Potpourri of Complexities	Keynote Lecture: The Neglected CVD Risk FactorNAFLD	CONSULTANT FEES/HONORARIA - Amarin, Ardelyx, Genzyme Corporation, Intercept , Janssen Pharmaceuticals, Inc; DATA SAFETY MONITORING BOARD - Aegerion, Epserion
Cohen	David	Highlighted Original Research: Interventional Cardiology and the Year in Review	New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: Incidence, Anticoagulant Strategy, and Outcomes	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; RESEARCH/RESEARCH GRANTS - BMS/Sanofi,Boston Scientific.Eli Lilly
Cohen	David	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Patterns of Angina and Antianginal Medication Use Among Patients Following MI Treated With PCI: Insights From TRANSLATE-ACS	CONSULTANT FEES/HONORARIA - Cardinal Health,Edwards Lifesciences,MEDTRONIC,St. Jude Medical; RESEARCH/RESSARCH GRANTS - Abbott Vascular,Astra Zeneca,Biomet, Inc.,Boston Scientific,Cardiovascular Systems, Inc. (CSI),Daiichi-Sankyo,Edwards Lifesciences,Eli Lilly,MEDTRONIC,Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	David	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Understanding Readmissions in Medicare Beneficiaries During the 90-Day Follow-Up Period Following an AMI Admission	CONSULTANT FEES/HONORARIA - Cardinal Health,Edwards Lifesciences,MEDTRONIC,St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Astra Zeneca,Biomet, Inc.,Boston Scientific,Cardiovascular Systems, Inc. (CSI),Daiichi-Sankyo,Edwards Lifesciences,Eli Lilly,MEDTRONIC,Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	David	Young Investigator Awards Competition: Outcomes Research	Judge	CONSULTANT FEES/HONORARIA - Cardinal Health,Edwards Lifesciences,MEDTRONIC,St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Astra Zeneca,Biomet, Inc.,Boston Scientific,Cardiovascular Systems, Inc. (CSI),Daiichi-Sankyo,Edwards Lifesciences,Eli Lilly,MEDTRONIC,Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
	David	Revascularization and Outcomes	What is the Impact of Complications During the Index Hospitalization on Resource Utilization During the 90-Day Follow-Up Period Associated With CABG Surgery Among Medicare Beneficiaries?	CONSULTANT FEES/HONORARIA - Cardinal Health,Edwards Lifesciences,MEDTRONIC,St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Astra Zeneca,Biomet, Inc.,Boston Scientific,Cardiovascular Systems, Inc. (CSI),Daiichi-Sankyo,Edwards Lifesciences,Eli Lilly,MEDTRONIC,Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	David	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study	CONSULTANT FEES/HONORARIA - Cardinal Health, Edwards Lifesciences, MEDTRONIC, St. Jude Medical; RESEARCH/IRESEARCH GRANTS - Abbott Vascular, Astra Zeneca Biomet, Inc., Boston Scientific, Cardiovascular Systems, Inc. (CSI), Daiichi-Sankyo, Edwards Lifesciences, Eli Lilly, MEDTRONIC, Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca



WASHINGTON, DC | MARCH 17 - 19 2017

and the				
Last Name Cohen	First Name David	Session Title Vascular Access and Hemostasis Issues	Presentation Title TAVR Using Transcarotid Vascular Access: In-Hospital and Intermediate Term Outcomes	Disclosures CONSULTANT FEES/HONORARIA - Cardinal Health,Edwards Lifesciences,MEDTRONIC,St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Astra Zeneca,Biomet, Inc.,Boston Scientific,Cardiovascular Systems, Inc. (CSI),Daiichi-Sankyo,Edwards Lifesciences,Eli Lilly,MEDTRONIC,Merck, Inc.; SPEAKER'S BUREAU - Astra
Cohen	David	Interventional Cardiology: TAVR 2	Impact of the Presence of Coronary Artery Disease and Timing of Revascularization on Outcomes of Patients Undergoing Trans-Catheter Aortic Valve Replacement: Insights From STS/ACC TVT Registry	Zeneca CONSULTANT FEES/HONORARIA - Cardinal Health,Edwards Lifesciences,MEDTRONIC,St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Astra Zeneca,Biomet, Inc.,Boston Scientific,Cardiovascular Systems, Inc. (CSI),Daiichi-Sankyo,Edwards Lifesciences,Eli Lilly,MEDTRONIC,Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	David	Interventional Cardiology: TAVR 2	Direct Home Discharge and Likelihood of 30-Day Hospital Readmission After Transcatheter Aortic Valve Replacement (TAVR): Findings From the STS/ACC TVT Registry	CONSULTANT FEES/HONORARIA - Cardinal Health, Edwards Lifesciences, MEDTRONIC, St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Astra Zeneca, Biomet, Inc., Boston Scientific, Cardiovascular Systems, Inc. (CSI), Daiichi-Sankyo, Edwards Lifesciences, Eii Lilly, MEDTRONIC, Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	David	Coronary Intervention: Drug Eluting Stent and Scaffolds	A Cost-Effective Analysis of Short Duration Dual Anti-Platelet Therapy (Dapt) With a Bioabsorbable Polymer Stent Platform Versus Longer Duration Dapt With a Durable Polymer Drug-Eluting Stent in a Patient Population Undergoing Elective Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Cardinal Health,Edwards Lifesciences,MEDTRONIC, St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Astra Zeneca,Biomet, Inc.,Boston Scientific,Cardiovascular Systems, Inc. (CSI),Daiichi-Sankyo,Edwards Lifesciences,Eii Lilly,MEDTRONIC,Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	David	Interventional Cardiology: TAVR 3	Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry	CONSULTANT FEES/HONORARIA - Cardinal Health, Edwards Lifesciences, MEDTRONIC, St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Astra Zeneca, Biomet, Inc., Boston Scientific, Cardiovascular Systems, Inc. (CSI), Daiichi-Sankyo, Edwards Lifesciences, Eii Lilly, MEDTRONIC, Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	David	Interventional Cardiology: TAVR 3	Prosthetic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter Valve-in-Valve Implantation	CONSULTANT FEES/HONORARIA - Cardinal Health,Edwards Lifesciences,MEDTRONIC, St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular Astra Zeneca,Biomet, Inc.,Boston Scientific,Cardiovascular Systems, Inc. (CSI),Daiichi-Sankyo,Edwards Lifesciences,Eii Lilly,MEDTRONIC,Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	David	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Medicare Reimbursement Associated With an AMI Hospitalization and 90-Days Post-Discharge	CONSULTANT FEES/HONORARIA - Cardinal Health,Edwards Lifesciences,MEDTRONIC,St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Astra Zeneca,Biomet, Inc.,Boston Scientific,Cardiovascular Systems, Inc. (CSI),Daiichi-Sankyo,Edwards Lifesciences,Eii Lilly,MEDTRONIC,Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	David	Advances in Chronic Total Occlusion Intervention	Association of Stress Test Risk Classification With Health Status Change After Chronic Total Occlusion PCI: Insights From the OPEN- CTO Registry	CONSULTANT FEES/HONORARIA - Cardinal Health,Edwards Lifesciences,MEDTRONIC,St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Astra Zeneca,Biomet, Inc.,Boston Scientific,Cardiovascular Systems, Inc. (CSI),Daiichi-Sankyo,Edwards Lifesciences,Eii Lilly,MEDTRONIC,Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	David	Refining PCI Technique and Outcomes	Appropriate Use Criteria and Health Status Outcomes After CTO PCI: Results From the OPEN CTO Registry	CONSULTANT FEES/HONORARIA - Cardinal Health,Edwards Lifesciences,MEDTRONIC St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular.Astra Zeneca,Biomet, Inc.,Boston Scientific,Cardiovascular Systems, Inc. (CSI),Daichi-Sankyo,Edwards Lifesciences,Eii Lilly,MEDTRONIC.Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	David	Peripheral Arterial Disease, Risk, and Outcomes	Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes: A Report From the STS/TVT Registry	CONSULTANT FEES/HONORARIA - Cardinal Health, Edwards Lifesciences, MEDTRONIC, St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Astra Zeneca, Biomet, Inc., Boston Scientific, Cardiovascular Systems, Inc. (CSI), Daiichi-Sankyo, Edwards Lifesciences, Eii Lilly, MEDTRONIC, Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	David	17. Interventional Cardiology: Aortic Valve Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Cardinal Health, Edwards Lifesciences, MEDTRONIC, St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Astra Zeneca, Biomet, Inc., Boston Scientific, Cardiovascular Systems, Inc. (CSI), Daiichi-Sankyo, Edwards Lifesciences, Eli Lilly, MEDTRONIC, Merck, Inc.; SPEAKER'S BUREAU - Astra Zeneca
Cohen	Marc	Interventional Cardiology: TAVR 1	Assessment of Right Sided Hemodynamic Parameters as Predictors of Early Outcomes After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Janssen,Maquet; RESEARCH/RESEARCH GRANTS - Edwards; SPEAKER'S BUREAU - AstraZeneca,BMS,Boehringer Ingelheim,DSVILIIIy,Janssen,Novartis Corporation
Cohen	Marc	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Statin Intensity and Outcome in Patients With Acute Heart Failure With Preserved Ejection Fraction	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Aanssen, Maquet, RESEARCH/RESEARCH GRANTS - Edwards, SPEAKER'S BUREAU - AstraZeneca, BMS, Boehringer Ingelheim, DSVILIIIy, Janssen, Novartis Corporation
Cohen	Marc	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Aortic Dissection: To Spare or Not to Spare the Aortic Valve????	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Janssen, Maquet; RESEARCH/RESEARCH GRANTS - Edwards; SPEAKER'S BUREAU - AstraZeneca, BMS, Boehringer Ingelheim, DSI/Lilly, Janssen, Novartis Corporation
Cohen	Marc	Emerging Applications of Echocardiography	A New Modified Continuity Equation for Calculation of Aortic Valve Area by Integrating 3-D Measurements of LVOT Planimetry and LVOT Flow Mapping	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Janssen, Maquet; RESEARCH/RESEARCH GRANTS - Edwards; SPEAKER'S BUREAU - AstraZeneca, BMS, Boehringer Ingelheim, DSI/Lilly, Janssen, Novartis Corporation
Cohen	Marc	Emerging Applications of Echocardiography	Direct Comparison of Aortic Valve Area by 3-D TEE Planimetry and 4-D Dynamic Cardiac CT Planimetry	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Janssen, Maquet; RESEARCH/RESEARCH GRANTS - Edwards; SPEAKER'S BUREAU - AstraZeneca, BMS, Boehringer Ingelheim, DSI/Lilly, Janssen, Novartis Corporation

Contract of the Contract of th				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Cohen	Marc	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Late Presentation of Total Anomalous Pulmonary Venous Connection	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals_Janssen_Maquet, RESEARCH/RESEARCH GRANTS - Edwards; SPEAKER'S BUREAU - AstraZeneca_BMS_Boehringer
Cohen	Marc	Changing the Natural History of Valve Disease	Statins Use and Long Term Outcome Post Surgical Aortic Valve	Ingelheim,DSI/Lilly,Janssen,Novartis Corporation CONSULTANT FEES/HONORARIA - AstraZeneca
		With Medical Therapy	Replacement	Pharmaceuticals,Janssen,Maquet, RESEARCH/RESEARCH GRANTS - Edwards; SPEAKER'S BUREAU - AstraZeneca,BMS,Boehringer Ingelheim,DSI/Lilly,Janssen,Novartis Corporation
Cohen	Marc	Pulmonary Hypertension	Percutaneous Management of Severe Aortic Insufficiency Complicating Prolonged Left Ventricular Assist Device Support	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Janssen, Maquet, RESEARCH/RESEARCH GRANTS - Edwards; SPEAKER'S BUREAU - AstraZeneca, BMS, Boehringer Ingelheim, DSI/LIII, Janssen, Novartis Corporation
Cohen	Marc	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Coil Embolization of latrogenic Pulmonary Artery Pseudoaneurysm	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Janssen, Maquet, RESEARCH/RESEARCH GRANTS - Edwards, SPEAKER S BUREAU - AstraZeneca, BMS, Boehringer Ingelheim, DSILIII, Janssen, Novartis Corporation
Cohen	Marc	03. Acute and Stable Ischemic Heart Disease: Therapy Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Janssen,Maquet, RESEARCH/RESEARCH GRANTS - Edwards; SPEAKER'S BUREAU - AstraZeneca,BMS,Boehringer Ingelheim,DSI/Lilly,Janssen,Novartis Corporation
Cohen	Martin	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Change in Aortomitral Annular Angle and Anterior Mitral Valve Leaflet Length After Transcatheter Aortic Valve Replacement: Implications for Transcatheter Mitral Valve Replacement?	Nothing to Disclose
Cohen	Martin	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Sinus Node Dysfunction in Batten Disease: A Rare Manifestation of a Rare Disease	Nothing to Disclose
Cohen	Martin	Interventional Cardiology: TAVR 4	Predictors of New Persistent Left Bundle Branch Block After Edwards Sapien 3 Transcatheter Aortic Valve Replacement	Nothing to Disclose
Cohen	Mauricio	Interventional Live Case Session VI: Bioresorbable Scaffolds and Imaging from St. Vincent Hospital (Indianapolis, IN)	Panelist	CONSULTANT FEES/HONORARIA - Abiomed Accumed, MEDTRONIC, Merit Medical, Terumo Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca; SPEAKER'S BUREAU - MEDTRONIC
Cohen	Mauricio	Fellows Bootcamp: Interventional Basics	Co-Chair	CONSULTANT FEES/HONORARIA - Abiomed Accumed, MEDTRONIC, Merit Medical, Terumo Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca; SPEAKER'S BUREAU - MEDTRONIC
Cohen	Mauricio	Fellows Bootcamp: Peripheral Vascular Disease and Structural Heart Disease Management	Co-Chair	CONSULTANT FEES/HONORARIA - Abiomed Accumed, MEDTRONIC, Merit Medical, Terumo Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca; SPEAKER'S BUREAU - MEDTRONIC
Cohen	Mauricio	Fellows Bootcamp: Coronary Disease Management	CHIP/Complications	CONSULTANT FEES/HONORARIA - Abiomed, Accumed, MEDTRONIC, Merit Medical, Terumo Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca; SPEAKER'S BUREAU - MEDTRONIC
Cohen	Mauricio	Practicum on Tools for CHIP (Complex and Higher-Risk Procedures in Indicated Patients)	Co-Chair	CONSULTANT FEES/HONORARIA - Abiomed Accumed, MEDTRONIC, Merit Medical, Terumo Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca; SPEAKER'S BUREAU - MEDTRONIC
Cohen	Mauricio	The Best Structural Interventional Challenging Cases	ACC Co-Chair	CONSULTANT FEES/HONORARIA - Abiomed Accumed, MEDTRONIC, Merit Medical, Terumo Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca; SPEAKER'S BUREAU - MEDTRONIC
Cohen	Mauricio	Updates on Risk Factors for Cardiovascular Disease	Hospital Admissions for Chest Pain Associated With Cocaine use in the United States	CONSULTANT FEES/HONORARIA - Abiomed Accumed, MEDTRONIC, Merit Medical, Terumo Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca; SPEAKER'S BUREAU - MEDTRONIC
Cohen	Mauricio	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Perioperative Administration of Amiodarone or Beta Blockers in Cardiac Surgery: Which Is More Effective in Reducing Postoperative Atrial Fibrillation?	CONSULTANT FEES/HONORARIA - Abiomed Accumed, MEDTRONIC, Merit Medical, Terumo Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca; SPEAKER'S BUREAU - MEDTRONIC
Cohen	Mauricio	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Mortality Rates and Cost of Hospital Admissions for Syncope in the United States	CONSULTANT FEES/HONORARIA - Abiomed Accumed, MEDTRONIC, Merit Medical, Terumo Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca; SPEAKER'S BUREAU - MEDTRONIC
Cohen	Mauricio	Interventional Complexity and Complications	Variability in Transfemoral Access for Coronary Angiography and Interventions: Results From an International Survey	CONSULTANT FEES/HONORARIA - Abiomed, Accumed, MEDTRONIC, Merit Medical, Terumo Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca; SPEAKER'S BUREAU - MEDTRONIC
Cohen	Mauricio	02. Acute and Stable Ischemic Heart Disease: Clinical Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abiomed, Accumed, MEDTRONIC, Merit Medical, Terumo Medical; RESSEARCH/RESEARCH GRANTS - Astra Zeneca; SPEAKER'S BUREAU - MEDTRONIC
Cohen	Mauricio	Interventional Challenging Cases: Team 1	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Abiomed Accumed, MEDTRONIC, Merit Medical, Terumo Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca; SPEAKER'S BUREAU - MEDTRONIC
Cohen	Scott	Congenital Heart Disease: To the Third Decade and Beyond	Neurocognitive Impairment Is Common in the Adult With Congenital Heart Disease: Identification Using a Novel Clinical Questionnaire	Nothing to Disclose
Coisne	Augustin	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Silent Cerebral Microbleeds During TAVR: Insight From a Prospective Cerebral MRI Cohort	Nothing to Disclose
Cokic	Ivan	Non Invasive Imaging: MR Characterization and Function	An Unrestrained Proinflammatory M1 Macrophage Population Induced by Iron Nanocrystals Impairs Myocardial Healing After Hemorrhagic Infarction	Nothing to Disclose
Cokic	Ivan	Diabetes and Endothelial Dysfucntion in Heart Failure	Mast Cell-Dependent Conversion of Siderophages Into Foam Cells Is a Hallmark of Early Fat Infiltration in Hemorrhagic Myocardial Infarctions	Nothing to Disclose
Cokic	Ivan	Biomarkers and Targets for Ischemic Heart Disease	Fat Accumulation in the Peri-Infarct Border Zone of Hemorrhagic Myocardial Infarction Is Mediated by Persistent Iron Deposits	Nothing to Disclose
Cokic	Ivan	Emerging Basic Science in Ischemic Heart Disease	Myocardial Hemorrhage After Coronary Ischemia-Reperfusion Leads to an Iron-Mediated, Self-Perpetuating Loop of Foam Cell and Ceroid Accumulation	Nothing to Disclose
Cokic	Ivan	Nuclear Cardiology: Coronary Flow	Precisely Controlled Arterial CO2 Can Potentiate Myocardial Blood Flow to the Same Extent as Adenosine: A Preclinical Study in Canines With 13N-Ammonia PET	Nothing to Disclose
Cokkinos	Dennis	Changing the Natural History of Valve Disease With Medical Therapy	Zoledronic Acid Inhibits Aortic Valve Calcification: A PET/CT Study	OTHER - none
Colaco	Nalini	ACC Research Awards	Role of PCSK9 in the Development ofHIV-Associated Atherosclerosis	Nothing to Disclose

Contract of the second				
Last Name	First Name	Session Title		Disclosures
Colan	Steven	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Validation of Technical Performance Score for Long-Term Outcomes in Congenital Heart Surgery: 10 Year Follow-Up Data	Nothing to Disclose
Colan	Steven	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Technical Performance Score Can Predict Post-Discharge Reinterventions in Partial and Transitional Atrioventricular Septal Defect Repair	Nothing to Disclose
Colan	Steven	Advances in HCM, PPCM and Other	Long-Term Outcomes of Childhood Left Ventricular Non-	Nothing to Disclose
Colantonio	Lisandro	Cardiomyopathies Advances in Cholesterol Measurement and	Compaction: Results From a National Population-Based Study Prevalence and Correlates of Statin Side Effects and Willingness to	Nothing to Disclose
Colanionio	Lisariuro	Management Measurement and	Be Re-Challenged on a Statin: Data From the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study	Nothing to Disclose
Colantonio	Lisandro	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Use of Recommended and Contraindicated Statins in HIV Patients	Nothing to Disclose
Cole	Jason	Non Invasive Imaging: Expanding Clinical Applications	Tomography-Myocardial Perfusion Image and Fractional Flow Reserve by Coronary Computed Tomographic Angiography	Nothing to Disclose
Coleman	Craig	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Effectiveness and Safety of Apixaban and Rivaroxaban Versus Warfarin for the Secondary Prevention of Stroke or Systemic Embolism Among Nonvalvular Atrial Fibrillation Patients	CONSULTANT FEES/HONORARIA - BIPI; RESEARCH/RESEARCH GRANTS - Bayer Pharma AG, Janssen Pharmaceuticals, Inc
Colen	Timothy	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease		Nothing to Disclose
Colen	Timothy	Congenital Heart Disease: New Diagnostic	The Incremental Benefit of Color Tissue Doppler Imaging in Fetal	Nothing to Disclose
Colen	Timothy	Approaches in Congenital Heart Disease Congenital Heart Disease: New Diagnostic	Rhythm Assessment Cardiovascular Health of Offspring of Diabetic Mothers From the	Nothing to Disclose
Coleii	Timodity	Approaches in Congenital Heart Disease	Fetus Through Late Infancy Stages	Nothing to Disclose
Coles	Adrian	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Outcomes in Patients With Diabetes Mellitus and Suspected Coronary Artery Disease Following Non-Invasive Testing: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study	Nothing to Disclose
Coles	Adrian	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	for Evaluation of Chest Pain) Time of Presentation Among Patients Hospitalized for Acute Heart Failure (Clinical Characteristics, Initial Therapies and Outcomes): Insights From ASCEND-HF	Nothing to Disclose
Coles	Adrian	New Perspectives on CAD Risk Factors	Discordances Between Predicted and Actual Risk of Adverse Events	Nothing to Disclose
			in Obese Patients With Suspected Cardiac Ischemia: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	
Collet	Carlos	Updates in Stable Ischemic Heart Disease		Nothing to Disclose
Collet	Carlos	Coronary Intervention: Drug Eluting Stent and Scaffolds	Early, Late and Very Late Incidence of Bioresorbable Scaffold Thrombosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials and Observational Registries	Nothing to Disclose
Collings	Shuk-Li	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	What Are the Differences in Oral Anticoagulant Treatment Persistence in Non-Valvular Atrial Fibrillation in Europe? Real-World	Nothing to Disclose
Collins	Bradley	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Studies in Three European Countries Lipid Abnormalities in Young Patients With Myocardial Infarction	Nothing to Disclose
Collins	Bradley	Current Issues in Cardiovascular		Nothing to Disclose
Collins	Bradley	Epidemiology, Disparities, and Safety Unusual Presentations of ACS	Have Worse Survival Compared With Men Type 2 Myocardial Infarction in Young Patients Portends a Worse	Nothing to Disclose
Collins	Kathryn	10. Congenital Heart Disease: Pediatric Team	Long-Term Survival	Nothing to Disclose
		1	-	
Collins	Ronnie Thomas	Congenital Heart Disease: Progress in Pediatric Heart Surgery Congenital Heart Disease: New Diagnostic	Congenital Heart Surgery in Patients With Trisomy 13 Associated With Lower In-Hospital Mortality Short Axis Diastolic Ventricular Area Ratio as a New Index in	Nothing to Disclose Nothing to Disclose
Collins	Tyrone	Approaches in Congenital Heart Disease Interventional Cardiology: TAVR 2	Screening Patients With Repaired Tetralogy of Fallot Transcatheter Aortic Valve Replacement in End Stage Liver Disease	
Colman	Jack	Congenital Heart Disease: To the Third	Twenty Year Trends in Maternal and Perinatal Complications in	Nothing to Disclose
Colombo	Antonio	Decade and Beyond Interventional Live Case Session VI:	Pregnant Women With Heart Disease Co-Chair	Nothing to Disclose
		Bioresorbable Scaffolds and Imaging from St. Vincent Hospital (Indianapolis, IN)		3
Colombo	Antonio	Late-Breaking Clinical Trials: Interventional Surgical Therapies for Heart Failure Patients:	Panelist Rebuttal, Pro	Nothing to Disclose Nothing to Disclose
Colombo	Antonio	Stage A-C	Rebultal, Pro	Nothing to Discrose
Colombo	Antonio	Surgical Therapies for Heart Failure Patients: Stage A-C	Debate Pro: CABG Has A Limited Role in the Management of HF Patients	Nothing to Disclose
Colombo	Antonio	Left Main PCI: Why? When? How?	Panelist	Nothing to Disclose
Colombo Colombo	Antonio Antonio	Left Main PCI: Why? When? How? Complex Coronary Intervention: Left		Nothing to Disclose Nothing to Disclose
		Main/Bifurcations and Multivessel Disease	True Left Main Bifurcation Lesions: A Sub-Study From Fails 2 Study	Ç
Colombo	Antonio	Revascularization and Outcomes	After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study	Nothing to Disclose
Colombo	Antonio	Interventional Cardiology: PCI and TAVR in Complex Patients	Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the Bravo-3 Randomized Trial	1
Colombo	Antonio	Stable Heart Disease Legends		Nothing to Disclose
Colombo	Antonio	Frontiers in Mitral Valve Disease and Treatment	Multicenter Trial of a Transfemoral System for Mitral Valve Annuloplasty: Up-to-2-Year Follow-Up Results	Nothing to Disclose
Colombo	Antonio	22. Interventional Cardiology: Coronary Intervention: Left Main, Multivessel, Bifurcation Team 2	Suggested Reviewer	Nothing to Disclose
Colombo	Jamie		Cost-Analysis of Outpatient Cardiac Catheterization in Infants With Single Ventricle Congenital Heart Disease	Nothing to Disclose
Colombo	Jamie	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	A Biventricular Assist Device is an Effective Rescue Device After Cardiac Surgery	Nothing to Disclose
Colombo	Paolo	14. Heart Failure and Cardiomyopathies:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Laboratories
Colpitts	Michelle	Therapy Team 1 Heart Failure and Cardiomyopathies: Is Heart	Chemotherapy Induced Cardiotoxicity, Its Prevention, Treatment and	Nothing to Disclose
Colpitts	Michelle	Failure With a Normal EF for Real? Innovations in Advocacy and Patient Centered	Risk Factors Low-Risk Chest Pain Pathway: Outcomes and Implications in a	Nothing to Disclose
		Care	Large Community Cohort	-
Colvin	Monica	14. Heart Failure and Cardiomyopathies: Therapy Team 3	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - CareDx
Comenzo	Raymond	Advances in HCM, PPCM and Other Cardiomyopathies	With Light Chain Amyloidosis: Results From the Phase 1/2 Study	Nothing to Disclose
Conaway	Mark	Acute Coronary Syndromes, Diagnosis,		Nothing to Disclose
	L	Management and Outcomes	Myocardial Infarction (AMI)	

Carl Street				
Last Name Conceicao	First Name Raquel	Session Title Advances in Cholesterol Measurement and	Presentation Title Statin Eligibility in Primary Prevention: From a Risk-Based Strategy	Disclosures Nothing to Disclose
Conceidad	itaquei	Management Management	to a Personalized Approach Based on the Predicted Cardiovascular Benefit	Nothing to Disclose
Conceicao	Raquel	Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	Physical Activity Level Changes and the Occurrence of Non- Alcoholic Fatty-Liver Disease: A Prospective Longitudinal Follow Up Study	Nothing to Disclose
Concepcion	Roberto	The Burden of Heart Failure: International Perspectives From the Chilean Society of Cardiology, Colombian Society of Cardiology, and American College of Cardiology	Co-Chair	Nothing to Disclose
Condado Contreras	Jose	TAVR Outcomes Prognostication	Predictors and Clinical Outcomes of Next-Day Discharge After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Congia	Michela	Advances in HCM, PPCM and Other Cardiomyopathies	Tako Tsubo Cardiomyopathy or Myocarditis?	Nothing to Disclose
Congia	Michela	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Reperfusion Delays in Women With STEMI	Nothing to Disclose
Conklin	Lori	Vascular Medicine: Aortic and Peripheral Artery Diseases	Uncontrolled Hypertension in Acute Aortic Dissection Follow-Up	Nothing to Disclose
Conley	Sheila	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Troponin Elevation Following Elective PCI Predicts Long Term Survival	Nothing to Disclose
Connelly	Margery	Nevascuria (Zardioi and Outcomes) Interventional Cardiology: Translation and Pre- Clinical Research	Sourivan Both the Novel NMR Biomarker of Inflammation, GlycA, and HS- CRP Are Independent and Additive Predictors of Future Cardiovascular Events Among Patients Undergoing Coronary Angiography: Results From the Intermountain Heart Collaborative Study	SALARY - Employee of LipoScience,LabCorp
Connolly	Heidi	Pregnancy Complicated by Valvular/Congenital Heart Disease: Clinical Management and Challenging Cases	Panelist	Nothing to Disclose
Connolly	Heidi	Valvular Heart Disease: Endocarditis	Infective Endocarditis Following Transcutaneous Aortic Valve Implantation: Clinical, Echocardiographic and Hemodynamic Features	Nothing to Disclose
Connolly	Heidi	Innovations in Pediatric Catheterization and EP: Mending, Fixing and Predicting	Outcome of Preoperative Electrophysiology Study in Patients With Ebstein Anomaly	Nothing to Disclose
Connolly	Heidi	Fontan in the Modern World	Cardiopulmonary Exercise Test in Adults With Prior Fontan Operation: The Prognostic Value of Serial Testing	Nothing to Disclose
Connolly	Heidi	Congenital Heart Disease: To the Third Decade and Beyond	Outcomes of Direct Current Cardioversion in Adults With Congenital Heart Disease	Nothing to Disclose
Connolly	Heidi	Congenital Heart Disease: To the Third Decade and Beyond	Outcomes of Non-Cardiac Procedures in Adult Fontan Patients	Nothing to Disclose
Connolly	Heidi	Prosthetic Valve Thrombosis: TAVR, Bio, Mech Now What?!	Outcome of Anticoagulation Therapy for Bioprosthetic Valve Thrombosis: A Prospective Study	Nothing to Disclose
Connolly	Heidi	Advancing Our Understanding of Aortic Disease	Intracranial Aneurysms in Patients With Bicuspid Aortic Valve: Prevalence and Predictors of Occurence	Nothing to Disclose
Connolly	Heidi	Things That Matter in Adult Congenital Heart Disease	Outcomes of Cardiac Pacing in the Adult Fontan Population	Nothing to Disclose
Connor	Jean	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Prediction Tool for Congenital Heart Surgery Length of Stay	Nothing to Disclose
Constantinescu	Alina	Arrhythmias and Clinical EP: Devices 1	Long-Term Outcome of Noncompaction Cardiomyopathy Patients With Implantable Cardioverter-Defibrillators Compared With Patients With Dilated or Hypertrophic Cardiomyopathy	Nothing to Disclose
Constantinescu	Alina	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Sudden and Fatal Malfunction After Continuous-Flow Left Ventricular Assist Devices: An Urgent Call for Regular Inspections	Nothing to Disclose
Constantinescu	Alina	Why Can't We Be Friends? Controversies in Heart Failure Management	A Novel Score to Predict Outcome in Patients Supported by Veno- Arterial Extracorporeal Membrane Oxygenation	Nothing to Disclose
Conte	Antonio	Nuclear Cardiology: Coronary Flow	Precisely Controlled Arterial CO2 Can Potentiate Myocardial Blood Flow to the Same Extent as Adenosine: A Preclinical Study in Canines With 13N-Ammonia PET	Nothing to Disclose
Conte	John	Interventional Cardiology: TAVR 2	The Impact of Preoperative Renal Dysfunction on the Outcomes of Patients Undergoing Surgical Versus Transcatheter Aortic Valve Replacement: An Analysis From the CoreValve US Pivotal High Risk Trial	OTHER - MEDTRONIC; RESEARCH/RESEARCH GRANTS - MEDTRONIC
Conte	Stefano	Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI	Activating Stimuli Modulate Pre-mRNA Maturation in Platelets: A Novel Mechanism That Regulates Platelet Function?	Nothing to Disclose
Conte	Stefano	MicroRNAs and Beyond in Vascular Medicine	Colchicine Exerts Antithrombotic Properties in oxLDL-Treated Endothelial Cells via Inhibition of Tissue Factor Expression and Activity	Nothing to Disclose
Conte	Stefano	Cutting Edge Vascular Medicine	Colchicine Inhibits Platelet Aggregation <i>In Vitro </i> by Interfering With Cofilin and LIM Domain Kinase 1, the Main Kinases Involved in Cytoskeleton Rearrangement	Nothing to Disclose
Conti	C. Richard	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Septic Cardiac Tamponade as a Rare Presentation of Acute Infective Endocarditis	Nothing to Disclose
Conti	C. Richard	01. Acute and Stable Ischemic Heart Disease: Basic Team 1	Suggested Reviewer	Nothing to Disclose
Contino	Chase	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Eptifibatide for Treatment of Mechanical Aortic Valve Thrombus: A Novel Therapeutic Approach	Nothing to Disclose
Contractor	Tahmeed	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	An Unusual Case of Far-Field P-Wave Oversensing Leading to Ventricular Overpacing and Undersensing of Sustained Ventricular Tachvcardia	Nothing to Disclose
Contreras	Johanna	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	T1 Mapping in Patients With Heart Failure With Preserved Ejection Fraction Detects Increased Interstitial Myocardial Fibrosis and Assesses the Severity of Heart Failure	CONSULTANT FEES/HONORARIA - Novartis Corporation; SPEAKER'S BUREAU - gilead, Novartis Corporation
Contreras	Johanna	13. Heart Failure and Cardiomyopathies: Clinical Team 4	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Novartis Corporation; SPEAKER'S BUREAU - gilead, Novartis Corporation
Contursi	Miranda	Hearts and Soles: Multimodality Imaging in Athletes	Temporal Sequence of Athlete's Heart Regression During Prescribed Exercise Detraining: <i>Diagnostic Implications</i>	Nothing to Disclose
Cook	Christopher	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Instantaneous Wave-Free Ratio Scout Pullback (IFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International Multicentre IFR GRADIENT Registry	Nothing to Disclose
Cook	Scott	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Acute Embolic MI: A Rare Complication of Giant Cell Arteritis	Nothing to Disclose
Cook	Stuart	Young Investigator Awards Competition: Clinical Investigations	Integrated Analysis of the Clinical Manifestations and Phenotypic Drivers of Titin Cardiomyopathy	Nothing to Disclose
Cook	Stuart	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Cardiovascular Magnetic Resonance in Survivors of Sudden Cardiac Arrest: 14 Year Experience From a Tertiary Referral Centre	Nothing to Disclose
Cook-Wiens	Galen	Non Invasive Imaging: MR Scar and Perfusion	in the United Kingdom Assessment of Myocardial Perfusion Reserve Index Using	Nothing to Disclose
Cook-Wiens	Galen	The Evolving World of LVADs, Transplant and	Adenosine Versus Regadenoson Among Healthy Female Subjects Prognostic Risk Factors for Heart Failure Hospitalization in Women	Nothing to Disclose
		Other Novel Discoveries	Without Obstructive Coronary Disease: An Ancillary Study From the Women's Ischemia Syndrome Evaluation (WISE)	

				l l
Last Name Cools	First Name Frank	Session Title Stroke and AF: Thinking About the Heart	Presentation Title The Prescribing of Antiplatelet Therapy Only in Patients With	Disclosures CONSULTANT FEES/HONORARIA - Bayer Healthcare
Cools	FIGUR	Stoke and Ar. Thinking About the Heart	Nonvalvular Atrial Fibrillation: Results From the GARFIELD-AF	Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals,
C	1	Had Tanina and Count Dahatas in Bulancas	Registry	Inc,Bristol-Myers Squibb Company
Coons	James	Hot Topics and Great Debates in Pulmonary Hypertension	Upfront Combination Therapy in PAH: Why Do it, When to Do it and How to Get it Done	Nothing to Disclose
Cooper	Daniel	Ventricular Arrhythmias in the Coronary Care	Role of Anti-arrhythmic Drug Therapy in the Coronary ICU	CONSULTANT FEES/HONORARIA - Biotronik, MEDTRONIC, St.
		Unit: Contemporary Solutions to an Old Problem		Jude Medical
Cooper	Daniel	Atrial Fibrillation, Anticoagulation and Novel	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Biotronik, MEDTRONIC, St.
Cooper	Howard	Device Therapies FIT Clinical Decision Making: Non-Invasive	Pneumopericardium: A Rare Presentation of Gastro-Pericardial	Jude Medical Nothing to Disclose
Соорег	nowaru	Imaging and Valvular Heart Disease	Fistula	Nothing to Disclose
Cooper	Howard	FIT Clinical Decision Making: Non-Invasive	Multidisciplinary Approach for Endocarditis in Pregnancy	Nothing to Disclose
Cooper	Howard	Imaging and Valvular Heart Disease Current Issues in Cardiovascular	Prevalence and In-Hospital Outcomes of Uremic and Dialysis	Nothing to Disclose
		Epidemiology, Disparities, and Safety	Pericarditis: A United States National Study	
Cooper	Howard	Interventional Cardiology: TAVR 3	Regional Variations in In-Hospital Outcomes and Healthcare Resource Utilization in Patients Undergoing Transcatheter Aortic	Nothing to Disclose
			Valve Replacement in the United States	
Cooper	Howard	FIT Clinical Decision Making: Heart Failure and		Nothing to Disclose
Cooper	Howard	Pulmonary Hypertension FIT Clinical Decision Making: Heart Failure and	Immunodeficiency Virus Management of Takotsubo Cardiomyopathy Complicated by Left	Nothing to Disclose
		Pulmonary Hypertension	Ventricular Outflow Tract Obstruction	
Cooper	Howard	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Association of Academic Year-End Changeover With Survival Rates After In-Hospital Cardiac Arrest: An Examination of the "July Effect"	Nothing to Disclose
		5 this 2. 155055	The in the plan earlier three three transfer or the early Eller	
Cooper	Howard	The Evolving World of LVADs, Transplant and	Arrhythmias in Hospitalized Heart Transplanted Patients: A United	Nothing to Disclose
Cooper	Howard	Other Novel Discoveries The Evolving World of LVADs, Transplant and	States National Study Chagas Heart Disease: A United States National Study	Nothing to Disclose
		Other Novel Discoveries	-	
Cooper	Howard	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Spontaneous Coronary Artery Dissection in a Transplanted Heart	Nothing to Disclose
		Disease, and Vascular Medicine		
Cooper	Joshua	Test Yourself with Questions: General	Faculty	CONSULTANT FEES/HONORARIA - Biosense
Cooper	Joshua	Cardiology Module 15 07. Arrhythmias and Clinical EP: Sports and	Suggested Reviewer	Webster,Biotronik,Boston Scientific,MEDTRONIC,St. Jude CONSULTANT FEES/HONORARIA - Biosense
		Exercise Team 1		Webster, Biotronik, Boston Scientific, MEDTRONIC, St. Jude
Cooper	Lauren	Why Can't We Be Friends? Controversies in Heart Failure Management	Association Between Serum Potassium Level and Outcomes in Heart Failure With Reduced Ejection Fraction: A Cohort Study From	Nothing to Disclose
		rieart i ailuie Wariagement	the Swedish Heart Failure Registry	
Cooper	Lauren	The Old and the New: Impact of Heart Failure	Liraglutide and Weight Loss Among Patients With Advanced Heart	Nothing to Disclose
		Drug Therapies	Failure and a Reduced Ejection Fraction: Insights From the FIGHT Trial	
Cooper	Lawton	Acute Heart Failure: Evaluating Strategies to	Risk of Hospitalization or Death Due to Heart Failure With Intensive	Nothing to Disclose
		Prevent Readmissions	Glucose-Lowering Therapy in Diabetic Women: Subgroup Analyses by History of Cardiovascular Disease in the ACCORD Trial	
			by history of Cardiovascular Disease in the ACCOND Thai	
Cooper	Lawton	New Perspectives on CAD Risk Factors	Discordances Between Predicted and Actual Risk of Adverse Events	Nothing to Disclose
			in Obese Patients With Suspected Cardiac Ischemia: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for	
			Evaluation of Chest Pain)	
Cooper	Leslie	Novel Echocardiographic Methods for	Subclinical Myocardial Alterations in Cardiac Sarcoidosis	Nothing to Disclose
Cooper	Leslie	Assessing Cardiac Function Novel Echocardiographic Methods for	Racial Differences in Left Ventricular Recovery in Patients With	Nothing to Disclose
		Assessing Cardiac Function	Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain	
Cooper	Leslie	Advances in HCM, PPCM and Other	Multi-Fetal Gestation, Breastfeeding, Delivery Method and	Nothing to Disclose
осоро.	20010	Cardiomyopathies	Myocardial Recovery in Peripartum Cardiomyopathy: Results From	Trouming to Shoroco
Cooper	Leslie	13. Heart Failure and Cardiomyopathies:	the Multicenter IPAC Study Suggested Reviewer	Nothing to Disclose
Соореі	Lesile	Clinical Team 2	Suggested Neviewei	Nothing to Disclose
Cooper	Robert	Advances in HCM, PPCM and Other	Younger Age, Positive Family History and Reverse Curve	Nothing to Disclose
		Cardiomyopathies	Morphology Predict Informative Results From Gene Panel Analysis for Hypertrophic Cardiomyopathy (HCM)	
Cooper	Stephanie	FIT Clinical Decision Making: Prevention, Adult	Palliative Care: A Critical Treatment Tool for Decision Making in	CONSULTANT FEES/HONORARIA - UpToDate
		Congenital and Congenital Heart Disease	Advanced Heart Disease	
Cooper-DeHoff	Rhonda	Effective Medication Management in the Older	Co-Chair	Nothing to Disclose
		Adults with CVD: Pharmacology Program I		
Cooper-DeHoff	Rhonda	When Anticoagulation Needs to be Stopped	Co-Chair	Nothing to Disclose
		What Are the Options? Pharmacology II		
Cooper-DeHoff	Rhonda	PPIs in the Era of Prolonged DAPT Should We or Shouldn't We?: Pharmacology III	Co-Chair	Nothing to Disclose
Cooper-DeHoff	Rhonda	Contemporary Management of Anticoagulation	To Anticoagulate or not to Anticoagulate: Balancing Benefits-risks in	Nothing to Disclose
1		in High-risk Patients with Atrial Fibrillation	Complicated Patients :Case-based Learning with ARS	
Cooper-DeHoff	Rhonda	Case Studies from the Guidelines for Clinicians	Top 10 Cardiac Medication Blunders	Nothing to Disclose
				,
Cooper-DeHoff	Rhonda	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Cardiomyopathy Associated With Targeted Anticancer Therapies in Electronic Health Records	Nothing to Disclose
Cooper-DeHoff	Rhonda	New Insights Into Prediction and Treatment of	Relationship Between Diastolic Blood Pressure and All-Cause	Nothing to Disclose
1		Hypertension	Mortality With Lower Systolic Blood Pressure Among Hypertensive Patients With Coronary Artery Disease: Long-Term Follow-Up of the	
			US Cohort of the International Verapamil SR-Trandolapril Study	
Connect Dalling	Dhaada	Condinuos dos Toom Const. Toom 4	(INVEST)	Nothing to Displace
Cooper-DeHoff Coplan	Rhonda Mitchell	Cardiovascular Team Cases: Team 1 Highlighted Original Research: Heart Failure	Suggested Reviewer Increased Tumor Necrosis Factor-α Levels in Patients With	Nothing to Disclose Nothing to Disclose
		and Cardiomyopathies and the Year in Review	Continuous-Flow Left Ventricular Assist Devices Mediate Vascular	· · · · · · · · · · · · · · · · · · ·
Coplan	Mitchell	Young Investigator Awards Competition:	Instability and Are Associated With Higher Non-Surgical Bleeding A Bundled Intervention Including Early Consultation With a	Nothing to Disclose
Соріан	wittell	Outcomes Research	Cardiologist in the Emergency Department to Reduce Re-	INOUTHING TO DISCHOSE
1			Hospitalizations and Healthcare Cost for High-Risk Urban Patients	
Coppola	John	Heart Failure and Cardiomyopathies: Is Heart	With Acute Decompensated Heart Failure Efficacy of Phosphodiesterase-5 Inhibitor in Patients With Heart	CONSULTANT FEES/HONORARIA - Terumo
		Failure With a Normal EF for Real?	Failure With Preserved Ejection Fraction: A Meta-Analysis	
Coram	Rita	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Thirty-Day Readmission Rate and Cost After Percutaneous Coronary Intervention in the United States: A National Readmission	Nothing to Disclose
		•	Database Analysis	
Corban	Michel	FIT Clinical Decision Making: Non-Invasive	Prompt Recognition and Intervention for Cardiac Tamponade	Nothing to Disclose
		Imaging and Valvular Heart Disease	Secondary to Gastro-Pericardial Fistula: A Successful Heart Team Effort	
	1	l .	penon.	

Contract of the contract of th				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Corban	Michel	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Chest Pain in a Patient With Anomalous Left Anterior Descending Coronary Artery, Myocardial Bridging and Vasoconstriction:	Nothing to Disclose
		Congenital and Congenital Heart Disease	Identification of the Culprit Etiology and Management of a Challenging Combination	
Corban	Michel	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Stress-Induced Cardiomyopathy: Importance of Obtaining Family	Nothing to Disclose
Cordero-Reyes	Andrea	Diabetes and Endothelial Dysfucntion in Heart Failure	History and Having a Low Threshold of Suspicion Interleukin 18 Impairs Excitation Contraction Coupling in Cardiomyocytes and Predicts Mortality in Acute Decompensated	Nothing to Disclose
Cordova	Francisco	Unusual Presentations of ACS	Heart Failure Characteristics of Acute Coronary Syndrome Presentation in Young	Nothing to Disclose
Coresh	Josef	Advances in Cholesterol Measurement and Management	Patients Association of Remnant-Like Particle Cholesterol and Low-Density Lipoprotein Triglyceride With Incidence of Cardiovascular Events:	Nothing to Disclose
Coresh	Josef	Updates on Risk Factors for Cardiovascular	The ARIC Study<⊳ Retinopathy and Risk of Sudden Cardiac Death: The ARIC Study	Nothing to Disclose
Carrah	laast	Disease	Development and Malidation of Development Madala With Name	Nething to Displace
Coresh	Josef	Improving Risk Assessment in Atherosclerosis	Development and Validation of Prediction Models With Non- Traditional Markers for 10-Year Risk of Ischemic Leg Amputation Among Persons With Diabetes: The Atherosclerosis Risk In Communities (ARIC) Study	Nothing to Disclose
Corley	Alyssa	Highlights in Vascular Medicine Research	Cancer and Arterial Thrombosis Risk: Insights From the 2012 National Inpatient Sample	Nothing to Disclose
Cornelussen	Richard	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Myocardial Contractile Reserve Verified With Dual Chamber Right Ventricular Pacing Predicts Response to Cardiac Resynchronization Therapy	SALARY - Medtronic plc
Cornwell	William	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Early Recurrence of Ventricular Tachycardia Predicts Increased Mortality Among Patients With Severe Heart Failure	Nothing to Disclose
Cornwell	William	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Safety and Outcomes of Catheter Ablation for Treatment of Refractory Ventricular Arrhythmias in Patients With Advanced Heart	Nothing to Disclose
Coromilas	James	FIT Clinical Decision Making: Arrhythmias and	Failure Searching for a Trigger in Resistant Ventricular Tachycardia in Post	Nothing to Disclose
Corotto	Paul	Electrophysiology Heart Failure and Cardiomyopathies: What	Acute Myocardial Infarction Impact of Cardiogenic Shock with or without Mechanical Circulatory	Nothing to Disclose
Corotto		Next When All Else Is Failing?	Support on Short-Term and Long-Term Survival in Heart Failure Hospitalizations	Nothing to Disclose
Corrado	Domenico	The Athlete with Heart Disease: A Case Based Approach	ARVC in Athletes	Nothing to Disclose
Corrado	Domenico	Cardiac Channelopathies: Novel Therapeutics	Appropriate Primary Prophylactic Implantation of Defibrillator in	Nothing to Disclose
		and Clinical Challenges	Patients With Brugada Syndrome: Is There Any Difference Between Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events	
Correa	Adolfo	Innovations in Cardiovascular Risk Assessment and Reduction	Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African Americans: The Jackson Heart Study	Nothing to Disclose
Correa	Ashish	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Downstream Effects of False Positive Activation of the Cardiac Catheterization Lab	Nothing to Disclose
Correa	Ashish	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Etiology and Predictors of 30-Day Unplanned Readmission Rates After Left Ventricular Assist Device Placement	Nothing to Disclose
Correa	Rafael	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Holter Findings in Orthotopic Heart Transplantation Patients: Results From a Cohort of the Most Important Heart Transplant Referral	Nothing to Disclose
Correa Gaviria	Simon	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Center in Colombia, South America Cystatin C Is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial	Nothing to Disclose
Corriere	Matthew	Meet the New LE PAD Guidelines: Case- Based Examples of Optimal Vascular Care	Co-Chair	Nothing to Disclose
Corrigan	Frank	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Pulmonary Venous Waveforms Predict Ventricular Remodeling After Percutaneous Mitral Valve Repair	Nothing to Disclose
Corrigan	Frank	Updates on Risk Factors for Cardiovascular Disease	Central Obesity Predicts Circulating Progenitor Cell Levels	Nothing to Disclose
Corrigan	Frank	Updates on Risk Factors for Cardiovascular Disease	Changes in Body Fat Distribution Is Associated With Oxidative Stress	Nothing to Disclose
Corrigan	Frank	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Reverse Takotsubo Cardiomyopathy Associated With Mediastinal Paraganglioma	Nothing to Disclose
Corrigan	Frank	TAVR Outcomes Prognostication	Predictors and Clinical Outcomes of Next-Day Discharge After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Corso	Paul	Interventional Cardiology: TAVR 3	Acute Aortic Regurgitation Post-Transcatheter Aortic Valve Replacement: Impact of Various Treatment Strategies	Nothing to Disclose
Cortes	Marcelino	Arrhythmias and Clinical EP: Devices 1	Pharmacological Treatment Alone Versus Treatment Combined With Implantable Cardioverter-Defibrillator Therapy in Patients Over	Nothing to Disclose
cortese	Bernardo	Featured Clinical Research II: Interventional	75 Years Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD Matrix Study	Nothing to Disclose
Cortese	Bernardo	Highlighted Original Research: Interventional Cardiology and the Year in Review	Syndromes: Ine RAD Matrix Study Clinical, Angiographic and Procedural Correlates of Absorb Scaffold Thrombosis: A Matched Multicenter Registry Analysis	Nothing to Disclose
Cortez-Dias	Nuno	Emerging Applications for Imaging Cardiac Amyloidosis: Nuclear Cardiology	How Useful Is ^{99m} Tc-DPD Scintigraphy in Diagnosis of Cardiac Amyloidosis in Transthyretin V30M Familial Amyloid Polyneuropathy?	Nothing to Disclose
Corvaja	Nicola	Complex PCI in 2017	Panelist	Nothing to Disclose
Corvaja	Nicola	21. Interventional Cardiology: Coronary Intervention: Devices Team 2	Suggested Reviewer	Nothing to Disclose
Corya Cosentino	Andi Nicola	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making Acute Coronary Syndromes, Diagnosis,	Intravenous Amiodarone for Prevention of Atrial Fibrillation Following Esophagectomy: A Propensity Score-Matched Analysis Ranal Replacement Therapy in Patients With Acute Macardial	Nothing to Disclose Nothing to Disclose
Cosenuil0		Management and Outcomes	Renal Replacement Therapy in Patients With Acute Myocardial Infarction: Rate of Use, Clinical Predictors and Relationship With In- Hospital Mortality	
Cosentino	Nicola	Post-CAD/MI: Making Tough Predictions About the Future	A New Score for Risk Stratification of Patients With Acute Myocardial Infarction Based on the PEGASUS-TIMI 54 Criteria	Nothing to Disclose
Cosgrove	Nora	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Incidence of Bacterial Endocarditis in Relation to Changes in Guidelines	Nothing to Disclose
Cosgrove	Nora	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Association Between Myocardial Infarction Hospital Process of Care Scores With Clinical Outcomes in a Statewide Study	Nothing to Disclose
Coskun	Ahmet	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Association of Coronary Epicardial Endothelial Dysfunction With Low Endothelial Shear Stress in Patients With Mild Coronary Atherosclerosis Who Presented With Chest Pain	Nothing to Disclose
Costa	Jose de Ribamar	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Independent Predictors of Mace at Different Time Points After the Treatment of Non-Selected Patients With Drug-Eluting Stents: An Analysis of the Desire Registry	Nothing to Disclose
Costa	Jose de Ribamar	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Intravascular Imaging Comparison of Two Metallic Limus-Eluting Stents Abluminally Coated With Biodegradable Polymers: IVUS and	Nothing to Disclose
	Î	1	OCT Results of the DESTINY Trial	

and a				l
Last Name	First Name	Session Title	Presentation Title	Disclosures
Costa	Jose de Ribamar	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Independent Pre Procedural Echocardiographic Predictors of Mitral Valve Restenosis After Percutaneous Mitral Balloon Valvuloplasty in a Large Consecutive Cohort Followed Up to Two Decades	Nothing to Disclose
Costa	Jose de Ribamar	Interventional Cardiology: Structural Heart Disease	Initial Results and Long-Term Follow-Up of Percutaneous Mitral Valvuloplasty in Patients With Pulmonary Hypertension	Nothing to Disclose
Costa	Jose de Ribamar	Refining PCI Technique and Outcomes		Nothing to Disclose
Costa	Jose de Ribamar	Frontiers in Mitral Valve Disease and Treatment	Predictors of Immediate and Very Late Events After Percutaneous Mitral Valvuloplasty	Nothing to Disclose
Costa	Marco	23. Interventional Cardiology: IVUS and Intravascular Physiology Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - CardioKinetix
Costa	Ricardo	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Independent Predictors of Mace at Different Time Points After the Treatment of Non-Selected Patients With Drug-Eluting Stents: An Analysis of the Desire Registry	Nothing to Disclose
Costa	Ricardo	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Intravascular Imaging Comparison of Two Metallic Limus-Eluting Stents Abluminally Coated With Biodegradable Polymers: IVUS and IOCT Results of the DESTINY Trial	Nothing to Disclose
Costa	Salvatore	Test Yourself with Questions: Guidelines Module 1: Valvular	Faculty	Nothing to Disclose
Costa	Salvatore	Insights From Echocardiography Use	Advances in 3D Echocardiography: Automated Software Improves the Learning Curve and Clinical Implementation in a Real World Setting for Quantitative Assessment of Left Ventricular Ejection Fraction	Nothing to Disclose
Costa	Salvatore	Valvular Heart Disease With CKD or Cirrhosis	ACC Poster Moderator	Nothing to Disclose
Costa	Salvatore	Tricuspid Regurgitation: Signals in Plain Sight	ACC Poster Moderator	Nothing to Disclose
Costa	Salvatore	36. Valvular Heart Disease: Clinical Team 3	Suggested Reviewer	Nothing to Disclose
Costabel	Juan	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	High Sensitive Troponin T, Grace Score and Timi Score to Predict Adverse Cardiovascular Events	Nothing to Disclose
Costantini	Costantino	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Clinical Outcomes After Implantation of Absorb BVS in a Real World Setting, With Pre- and Post-Dilatation, Guided by Intravascular Ultrasound & Optical Coherence Tomography	
Costantini	Costantino	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Clinical Outcomes After Implantation of Absorb BVS in a Real World Setting, With Pre- and Post-Dilatation, Guided by Intravascular Ultrasound & Optical Coherence Tomography	
Costanzo	Maria Rosa	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	High Procedural and Device Related Success With the CardioMEMS HF System for Heart Failure: Observations From the CardioMEMS™ Post Approval Study	CONSULTANT FEES/HONORARIA - MEDTRONIC, Saint Jude Medical, St. Jude Medical; RESEARCH/RESEARCH GRANTS - Novartis
Coste	Pierre	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Discriminant Value of the DAPT Score to Predict Long-Term Ischemic and Bleeding Events in the Real World Population of Stented Patients in the FAST-MI 2005 Cohort	Nothing to Disclose
Costeas	Constantinos	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Syncope in Elderly: How About Checking Carotid Hypersensitivity???	Nothing to Disclose
Côté	Nancy	Novel Determinants of Outcomes in VHD	Pre-Operative Longitudinal Strain and Strain Rate as Predictors of Impaired Post-Operative Ejection Fraction in Patients Operated for Pure Aortic Regurgitation	Nothing to Disclose
Couper	Gregory	Give Me a Beat! Mechanical Support of	Co-Chair	CONSULTANT FEES/HONORARIA - HeartWare,
Couri	Daniel	Cardiogenic Shock Personalized Skills Center: Drill and Practice	Heart Songs Moderator	Inc,Thoratec/St Jude Nothing to Disclose
Coutinho	Thais	(Heart Songs, ECG, Hand-Held Echo) Vascular Medicine: New Insights Into Aortic and Peripheral Artery Diseases	Sex Differences in Thoracic Aortic Aneurysm Growth: Role of Aortic Stiffness	Nothing to Disclose
Covassin	Naima	Diabetes and Other Issues in Cardiovascular Prevention	Rapid Rise in Insulin Secretion After Energy Drink Intake in Healthy Adults: A Randomized, Double Blind, Placebo Controlled Clinical Trial	Nothing to Disclose
Cowger	Jennifer	13. Heart Failure and Cardiomyopathies: Clinical Team 7	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Thoratec
Cowherd	Michael	Atrial Fibrillation and VT: Unique Populations and Solutions	Presence of Mid-Myocardial Substrate Is Associated With Need for Multiple Ablations in Patients With Non-Ischemic Cardiomyopathy and Ventricular Arrhythmias	Nothing to Disclose
Cowherd	Michael	Innovative Approaches for Reducing Risk and	Early Recurrence of Ventricular Tachycardia Predicts Increased	Nothing to Disclose
Cowherd	Michael	Improving Outcomes With Ablation Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Mortality Among Patients With Severe Heart Failure Safety and Outcomes of Catheter Ablation for Treatment of Refractory Ventricular Arrhythmias in Patients With Advanced Heart	Nothing to Disclose
Cowherd	Michael	The PCSK9 Revolution: New Insights Into	Failure Implications of the FDA Approval of PCSK9 Inhibitors for	Nothing to Disclose
Cowper	Patricia	Evaluation and Treatment Highlighted Original Research: Acute and	Contemporary Cardiovascular Practice: Findings From the NCDR [®] Research to Practice (R2P) Project Ten-Year Mortality of Acute Myocardial Infarction Patients Treated in	RESEARCH/RESEARCH GRANTS - AGA Medical,
Cowper	Patricia	Stable Ischemic Heart Disease and the Year in Review Insights From Echocardiography Use	U.S. Community Practice Universal Use of Contrast to Detect Left Ventricular Thrombus in	LLC,AstraZeneca,Bristol Myers Squibb/Pfizer,Eli Lilly,Tenax Therapeutics RESEARCH/RESEARCH GRANTS - AGA Medical,
			Patients With Reduced Ejection Fraction Is Not Associated With Improved Clinical or Cost-Effectiveness Outcomes	LLC,AstraZeneca,Bristol Myers Squibb/Pfizer,Eli Lilly,Tenax Therapeutics
Cox	Christopher	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Calcium Characteristics as Predictors of Major Adverse Cardiac Events in Symptomatic Patients: Insights From the CORE320 Multinational Study	Nothing to Disclose
Cox	David	Interventional Live Case Session VI: Bioresorbable Scaffolds and Imaging from St. Vincent Hospital (Indianapolis, IN)	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific, Medtronic, Inc, the Medicines Co
Cox	David	Debates: Is There Really a Sex Difference in CV Presentation, Care, and Outcomes?	There is a Gender Bias in Cardiac Care: PRO	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific, Medtronic, Inc, the Medicines Co
Cox	David	PCI in the Era of Public Accountability: Managing Risks to Patients, Providers, and Institutions	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,Medtronic,Inc,theMedicinesCo
Cox	David	PCI in the Era of Public Accountability: Managing Risks to Patients, Providers, and Institutions	Staying on Top of Your Game: Maintaining Your Skillset in the Face of Declining Volumes	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,Medtronic,Inc,theMedicinesCo
Cox	David	What's New in the World of STEMI?	Debate: Pro for Aspiration	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,Medtronic,Inc,theMedicinesCo
Cox	David	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Platelet Reactivity and Outcomes After PCI of Saphenous Vein Grafts Versus Native Coronary Arteries: The ADAPT-DES Study	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,Medtronic,Inc,theMedicinesCo
Cox	David	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Atrial Fibrillation on Outcomes in Patients Hospitalized With ST-Segment Elevation Myocardial Infarction	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,Medtronic,Inc,theMedicinesCo
Cox	David	Advances in Chronic Total Occlusion Intervention	Is Platelet Reactivity Associated With Ischemic Events Following Successful Chronic Total Occlusion Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,Medtronic,Inc,theMedicinesCo
Cox	Jafna	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Concomitant Use of Antiplatelet and Oral Anticoagulation Among Patients With Atrial Fibrillation: Insights From the Prospective SPRINT-AF Registry	CONSULTANT FEES/HONORARIA - Bayer,Boehringer Ingelheim,Pfizer/BMS partnership; RESEARCH/RESEARCH GRANTS - Bayer
	<u>i</u>	1	OF THIS I -AF INEURIN	OIVINIO - DAYEI

and a				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Coylewright	Megan	Featured Clinical Research II: Interventional	Panelist Page hing Consensus: Incorporating Patient Preferences into the	CONSULTANT FEES/HONORARIA - Boston Scientific CONSULTANT FEES/HONORARIA - Boston Scientific
Coylewright	Megan	Contemporary Management of Anticoagulation in High-risk Patients with Atrial Fibrillation	Reaching Consensus: Incorporating Patient Preferences into the Choice for Anticoagulation Therapy: Case-based Learning with ARS	CONSULTANT FEES/HONORARIA - BUSION SCIENTIA
Coylewright	Megan	Core Curriculum: Valvular Heart Disease Management Issues	Shared Decision Making in AS: TAVR versus SAVR	CONSULTANT FEES/HONORARIA - Boston Scientific
Coylewright	Megan	Interventional Cardiology: TAVR 4	Depression as a Potential Therapeutic Target to Improve Quality of Life After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Boston Scientific
Coylewright	Megan	02. Acute and Stable Ischemic Heart Disease: Clinical Team 6	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific
Coyne	Jennifer	Prevention of ASCVD Over the Lifespan: A Case-based Approach	My 32 Year Old Female Patient with Metabolic Syndrome and LDL- C of 145 mg/dL. How Should I Treat?	Nothing to Disclose
Crabbe	Deborah	Venous Investigation: The Dark Side	Sex Differences in the Use of Inferior Vena Cava Filters in Patients With Proximal Lower Extremity Deep Vein Thrombosis in the United States	Nothing to Disclose
Cramer	Jonathan	Adult Patients With Congenital Heart Disease: How Do They Compare?	Decreased Hepatic Elasticity in Young Adults After Biventricular Repair of Congenital Heart Disease	Nothing to Disclose
Crawford	Michael	Feeling the Pressure - Tough Cases in Hypertension	Co-Chair	Nothing to Disclose
	Michael	33. Prevention: Hypertension Team 2	Suggested Reviewer	Nothing to Disclose
Crawford	R.	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Coronary Artery Disease Learning and Algorithm Development Study: Early Analysis of Ejection Fraction Evaluation	Nothing to Disclose
Crawford	Thomas	Emerging Applications of Echocardiography	Understanding the Role of Strain Imaging in the Early Detection of Chagas Cardiomyopathy	Nothing to Disclose
Crea	Filippo	Emerging Basic Science in Ischemic Heart Disease	Imbalance Between E-NOS and MRP4 Gene Expression in Type 2 Diabetes Mellitus May Explain the Higher Risk of NSTEMI in Diabetic Subjects	Nothing to Disclose
Crea	Filippo	Insights Into Ischemic Heart Disease: Stable to	Hyaluronic Acid, Hyaluronidase-2 and Acute Coronary Syndromes: Possible Correlation With Plaque Erosion	Nothing to Disclose
Crea	Filippo	Erosive Plaques Unusual Presentations of ACS	Matrix Metalloproteinase 9 Drives the Shedding of CD31 in Acute	Nothing to Disclose
Creager	Mark	Issues in the Treatment of Coronary Disease:	Coronary Syndromes Co-Chair	Nothing to Disclose
		Joint Symposium of the American Heart Association and the American College of Cardiology		Tourney to Discission
Cremer	Paul	Highlighted Original Research: Interventional Cardiology and the Year in Review	Implications of Worsening Right Ventricular Function Following Transcatheter or Surgical Aortic Valve Replacement: Insights From PARTNER2A	Nothing to Disclose
Cremer	Paul	Updates on Risk Factors for Cardiovascular Disease	Declining Survival With Decreasing Exercise Time on Treadmill: Lessons From a 25-Year Cohort	Nothing to Disclose
Cremer	Paul	Arrhythmias and Clinical EP: Devices 3	Variability in Left Ventricular Ejection Fraction by Radionuclide Multigated Acquisition Scan Versus Echocardiography: Implications for Primary Prevention Implantable Cardioverter Defibrillators	Nothing to Disclose
Cremer	Paul	Interventional Cardiology: TAVR 2	Worsening Tricuspid Regurgitation and Increased Mortality After Aortic Valve Replacement: Insights From PARTNER2A	Nothing to Disclose
Cremer	Paul	Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	Referral for Pharmacologic Testing, a Marker of Poor Exercise Capacity, Confers a Higher Risk of Short and Long Term Mortality Than Most Traditional Cardiac Risk Factors Except Age	Nothing to Disclose
Cresci	Sharon	Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI	PGC1 Beta Variants and Physical Activity: Of Mice and Men	Nothing to Disclose
Cribbs	Marc	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Exertional Hypoxemia in levo-Transposition of the Great Arteries (I-TGA) and Pulmonary Stenosis Due to Pulmonary Artery Conduit	Nothing to Disclose
Cribbs	Marc	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Stenosis and Atrial Septal Defect Double Chamber Right Ventricle as a Complication of Ventricular Septal Defect	Nothing to Disclose
Cribbs	Marc	Things That Matter in Adult Congenital Heart Disease	ACC Poster Moderator	Nothing to Disclose
Crim	Courtney	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Prognostic Importance of Blood Pressure and Heart Rate in Chronic Obstructive Pulmonary Disease: The SUMMIT Trial	SALARY - Glaxo Smith kline, LLC
Crim	Courtney	Innovations in Cardiovascular Risk Assessment and Reduction		SALARY - Glaxo Smith kline, LLC
Crim	Matthew	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Refractory Electrical Storm as the Initial Presentation of Presumed Cardiac Sarcoidosis Treated With Left Stellate Ganglion Block	Nothing to Disclose
Criqui	Michael	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Association of Coronary Artery Calcium With Incident Peripheral Artery Disease: The Multi-Ethnic Study of Atherosclerosis	Nothing to Disclose
Cristobal	Carmen	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years	Nothing to Disclose
Crivera		Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	A Benefit-Risk Analysis of Recurrent Venous Thromboembolism in Patients Who Continued Versus Discontinued Rivaroxaban Therapy After an Initial Six-Month Therapy	SALARY - Janssen Scientific Affairs , LLC
Crivera	Concetta	Antithrombotic Therapy in Ischemic Heart Disease	Rivaroxaban Users Have Significantly Less Treatment Discontinuation Compared With Users of Other Oral Anticoagulants in Non-Valvular Atrial Fibrillation	SALARY - Janssen Scientific Affairs , LLC
Crivera	Concetta	Interventional Cardiology: PCI in Complex Patients	Impact of Comorbid Coronary Artery Disease and Severe Peripheral Artery Disease on Major Adverse Cardiovascular Events	SALARY - Janssen Scientific Affairs , LLC
Crocamo	Antonio	Improving Outcomes in the Athlete With Cardiovascular Disease	The Heart Sentinel App for Automatic Detection and Alerting in Cardiac Arrest During Outdoor Sports: Ventricular Fibrillation Simulations and Preliminary Data in Athletes	Nothing to Disclose
Croce	Kevin	Considerations in Antiplatelet Therapy and in ACS	Impact of Coronary Anatomical Complexity on the Effect of Extended Duration Dual Antiplatelet Therapy: An Analysis From the Dual Antiplatelet Therapy Study	CONSULTANT FEES/HONORARIA - St Jude Medical; RESEARCH/RESEARCH GRANTS - Ariad
Crock	Frederick	The Challenges of Outcome Prediction in Valvular Heart Disease	Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era	Nothing to Disclose
Crock	Frederick	TAVR Outcomes Prognostication	Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit	Nothing to Disclose
Croft	Lori	Nuclear Cardiology: Beyond Perfusion	Comparison of CZT SPECT and Cardiac MR Derived Cardiac Function and Volumes in Patients With Significantly Reduced Ejection Fraction	Nothing to Disclose
Crosland	William	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Long-Term Outcomes of Alcohol Septal Ablation in Young Patients With Hypertrophic Cardiomyopathy	Nothing to Disclose
Crosland	William	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Reverse Takotsubo Cardiomyopathy Reverse Takotsubo Cardiomyopathy Associated With Mediastinal Paraganglioma	Nothing to Disclose
Cross	Russell	Non Invasive Imaging: MR Characterization and Function	Validation of CMR-Derived Left Ventricular Strain Measurements by Free-Breathing Motion-Corrected Cine Imaging	Nothing to Disclose
Cross	Russell	Imaging the Athlete's Heart	Free-Breathing MRI Evaluation of Cardiac Volume Measurements	Nothing to Disclose
			During In-Scanner Exercise	

Company	Contract of the second				<u> </u>
The Tenung Vision To Tenung Vision Vision To Tenung Vision To Tenung Vision To Tenung Vision To Tenung Vision To Tenung Vision To Tenung Vision To Tenung Vision To Tenung Vision Vision To Tenung Vision To Tenung Vision To Tenung Vision To Tenung Vision To Tenung Vision Vision Vision To Tenung Vision Vision To Tenung Vision Vision To Tenung Vision Vision To Tenung Vision Vision To Tenung Vision Vision To Tenung Vision Vision To Tenung Vision Vision To Tenung Vision Vision To Tenung Vision Vision To Tenung Vision Vision To Tenung Vision Vision To Tenung Vision Vision To Tenung Vision Vision To Tenung Vision Vision To Tenung Vision Vision To Tenung Vision Vision Vision To Tenung Vision Vision To Tenung Vision Vision To Tenung Vision	Last Name Crossley	First Name	Session Title Arrhythmias and Clinical EP: AF Ablation	Presentation Title Use of Dabigatran Etexilate to Prevent Stroke and	
South Lab Note Lab Proposed or Company Analysis in Note Proposed Proposed or Company Analysis Proposed or Company An	Crossiey	George	Armyuumas and Oimeal EP. AF Abiation	Thromboembolism in Patients Undergoing Left Atrial Catheter Ablation Procedures for Paroxysmal or Persistent (Non-Permanent)	Inc ; OTHER - Bayer Healthcare, Janssen Pharmaceuticals,
Service Loss Implying the Cognitive Cogniti	Crowley	Anna Lisa	The Tricuspid Valve: The New Frontier	Essential Pre-procedural Echocardiography Criteria of Tricuspid	RESEARCH/RESEARCH GRANTS - Bellerophon Therapeutics
Construction of Contract Contr	Crowley	Anna Lisa		Echocardiographic Predictors for In-Hospital and 1-Year Outcomes in Left-Sided Infective Endocarditis: An Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort Study	
Joseph	Crowley	Anna Lisa	Innovative Use of Echocardiography	Echocardiography Image and Data Quality in an International	RESEARCH/RESEARCH GRANTS - Bellerophon Therapeutics
Pergeducia From in ACC certal filtion on A fee Cologs? Amend Cologs of Condition on Amend Cologs of Condition in Patient With Any In Patients Amend Cologs of Condition in Accidence of Cologs of Condition in Patient With Any In Patients Amend Cologs of Condition in Accidence of Cologs of Condition in Patient With Any In Patients Amend Cologs of Condition in Accidence of Cologs of	Crowley	Anna Lisa	FIT Clinical Decision Making Reviewers 6	ACC FIT Clinical Decision Making Reviewer	RESEARCH/RESEARCH GRANTS - Bellerophon Therapeutics
Simulation of the control of the con	Crowley	James	Perspectives From the ACC Great Britain and Ireland Chapter, Israel Heart Society, and		Nothing to Disclose
Description of State and Long-Term Monatorial in Auto-Coursely (Michael Course) Annual Course of State and Long-Term Monatorial in Auto-Coursely (Michael Course) Annual Course of State and Long-Term Monatorial Annual Coursely (Michael Course) Annual Coursel State and Long-Term Monatorial Annual Coursely (Michael Course) Annual Coursel Coursel (Michael Course) Annual Coursel Coursel (Michael Course) Annual Coursel Coursel (Michael Course) Annual Coursel Coursel (Michael Course) Annual Coursel Coursel (Michael Course) Annual Coursel Coursel (Michael Course) Annual Coursel (Michael Course) Annual Coursel (Michael Course) Annual Coursel (Michael Course) Annual Coursel (Michael Coursel) Annual Coursel	Cruz-Gonzalez	Ignacio	Structural Heart Interventions: Focus on Mitral	and Previous Major Gastrointestinal Bleeding: Insight From the	Nothing to Disclose
Jose Jose International Contrology TWFT Passing Dark Colonials (Passing an Arthritish Revenament, International Proposition From the Pilippin Proposition From the Pilippin Proposition From the Pilippin Proposition From the Pilippin Proposition From the Pilippin Proposition From the Pilippin Proposition From the Pilippin Proposition From Proposition From the Pilippin Proposition From Propo	Csanadi	Zoltan		Predictors of Short- and Long-Term Mortality in Acute Coronary	Nothing to Disclose
International Proposition From the Prilippion Tachyland (Principle of Proposition Proposit	Cubero	Jose		Pacing Over Guidewire, Stepwise to Minimalism in Tavi: A Single	Nothing to Disclose
Duty Surgician Control SP Base 1 During Ministry of Control SP Base 1 During Ministry	Cuculich	Phillip	International Perspectives From the Philippine Heart Association, Russian Society of Cardiology, and American College of Cardiology		
Strategy Antifythmen and Chinced EP: Base 1 MicrosWA226 From Pispose Human Meenterlymal Selen Celss Demonstrated China Control Prisonal Control Control Prisonal Control Control Prisonal Control Control Prisonal Control Control Prisonal Control Control Prisonal Control Control Prisonal Control P	Cui	Shanyu	Arrhythmias and Clinical EP: Basic 1	Proarrhythmic Remodeling by Restoration of Acetylated Tubulin in	Nothing to Disclose
Date of the control o	Cui	Shanyu	Arrhythmias and Clinical EP: Basic 1	MicroRNA-26a From Hypoxic Human Mesenchymal Stem Cells: Derived Microvesicles Enhance Cardiac Conduction Following	Nothing to Disclose
Trust (1997) (19	Cui	Yimin		Efficacy and Safety of Novel Oral P2y ₁₂ Receptor Inhibitors in St-Segment Elevation Myocardial Infarction Patients	Nothing to Disclose
Joseph Michael Mericage the Care Team FTE, Early Career Professionals and CV Team Members Parties of Care University of Professionals and CV Team Members Parties of Care University of Professionals and CV Team Members Parties of Professionals and CV Team Members Parties of Professionals and Company Parties of Professionals and Profess	Cui	Yuxia		Mutations in SCAP and AGXT2 Revealed by Exome Sequencing a	Nothing to Disclose
Dutlen Michael Pout of Care Ultrasound (POCUS): The Paeled Fulture or a Fast? Fulture or a Fast of Fa	Cullen	Michael	Mentoring the Care Team: FITs, Early Career		Nothing to Disclose
Dutien Michael Point of Care Ultrasound POCUS) The Pagnesia Capabilities of POCUS 140x Good at 7 Putture of a Pagnesia Capabilities of POCUS 140x Good at 7 Putture of a Pagnesia Capabilities of POCUS 140x Good at 7 Putture of a Pagnesia Capabilities of PoCUS 140x Good at 7 Putture of a Pagnesia Capabilities of PoCUS 140x Good at 7 Putture of a Pagnesia Capabilities of PoCUS 140x Good at 7 Putture of a Pagnesia Capabilities of PoCUS 140x Good at 7 Putture of a Pagnesia Capabilities of PoCUS 140x Good at 7 Putture of a Pagnesia Capabilities of PoCUS 140x Good at 7 Putture of a Pagnesia Capabilities of PoCUS 140x Good at 7 Putture of a Pagnesia Capabilities of PoCUS 140x Good at 7 Putture of a Pagnesia Capabilities of PoCUS 140x Good at 7 Putture of a Pagnesia Capabilities of PoCUS 140x Good at 7 Putture of a Pagnesia Capabilities of PoCUS 140x Good at 7 Putture of a Pagnesia Capabilities of PoCUS 140x Good at 7 Putture of a Pagnesia Capabilities of PoCUS 140x Good at 7 Putture of Apagnesia Capabilities of PoCUS 140x Good at 7 Putture of a Pagnesia Capabilities of PoCUS 140x Good at 7 Putture of a Pagnesia Capabilities of PoCUS 140x Good at 7 Putture of a Pagnesia Capabilities of PoCUS 140x Good at 7 Putture of Apagnesia Capabilities of PoCUS 140x Good at 7 Putture of Apagnesia Capabilities of PoCUS 140x Good at 7 Putture of Apagnesia Capabilities of PoCUS 140x Good at 7 Putture of Apagnesia Capabilities of PoCUS 140x Good at 7 Putture of Apagnesia Capabilities of PoCUS 140x Good at 7 Putture of Apagnesia Capabilities of PoCUS 140x Good at 7 Putture of Apagnesia Capabilities of PoCUS 140x Good at 7 Putture of Apagnesia Capabilities of PoCUS 140x Good at 7 Putture of Apagnesia Capabilities of PoCUS 140x Good at 7 Putture of Apagnesia Capabilities of PoCUS 140x Good at 7 Putture of Apagnesia Capabilities of PoCUS 140x Good at 7 Putture of Apagnesia Capabilities of PoCUS 140x Good at 7 Putture of Apagnesia Capabilities of PoCUS 140x Good at 7 Putture o	Cullen	Michael	Point of Care Ultrasound (POCUS): The	Panelist	Nothing to Disclose
Association Selvenen Cardiology Fellowahly Applicantis-88217. Nothing to Disclose United Michael Innovations in Education Absociation Selvenen Cardiology Fellowahly Applicantis-88217. Nothing to Disclose Innovations in Education Characteristics and Subsequent Clinical Performance Congenital Heart Disease Congenity of Congenity (Congenity) (Congenity	Cullen	Michael	Point of Care Ultrasound (POCUS): The	The Diagnostic Capabilities of POCUS: How Good is it?	Nothing to Disclose
Michael Incovations in Education Fearching Tomorrow's Teachers: An Incovative Model of Clinician Nothing to Disclose	Cullen	Michael			Nothing to Disclose
Sulfer Michael Engage @ ACC 17 Studio Simulation I - Compatible Heart Disease Conference Compatible Heart Disease Conference Compatible Heart Disease Conference Conferen	Cullen	Michael	Innovations in Education	Teaching Tomorrow's Teachers: An Innovative Model of Clinician-	Nothing to Disclose
Engage @ ACC.17 Studies Simulation Session Co-Chair	Cullen	Michael			Nothing to Disclose
Seven	Cullen	Michael	Engage @ ACC.17 Studio: Simulation Session	Co-Chair	Nothing to Disclose
Siable ischemic Heart Disease and the Year in 90-Day Follow-Up Period Following an AMI Admission Review Review. Coronary Angiography, Intra-Vascular Imaging, What is the Impact of Complications During the 90-Day Follow-Up Period Associated With CASG Surgery Annong Medicare Benchinesers? Autor Coronary Syndromes, Diagnosis, Management and Cutomes Silven Autor Coronary Syndromes, Diagnosis, Management and Cutomes Surpha Olivera Jussiely Imely Topics in Acute Coronary Syndromes, Diagnosis, Management and Cutomes Surpha Olivera Jussiely Imely Topics in Acute Coronary Syndromes, Diagnosis, Management and Cutomes Surpha Olivera Jussiely Imely Topics in Acute Coronary Syndromes, Diagnosis, Management and Cutomes Surpha Olivera Jussiely Imely Topics in Acute Coronary Syndromes Cunnington Colin The Story of the Adult Coronary Syndromes Disease Patient and EP Forum North Forum In the Modern World Prevalence and Predictors of Asia Tachyarrhydmiss in Adult Prevalence and Predictors of Asia Tachyarrhydmiss in Adult Forum Prevalence of Elevated Body Mass Index and its Association With RESEARCH/RESEARCH GRANTS - BioMarin Pharmaceutical Inc. Coronary Angiography, Intra-Vascular Imaging Revealcularization and Outcomes Curricto Alejandro Current Issues in Cardiovascular Prevalence and Predictors of Pacemater Placement in Adult Forum Reserve (CFR) by FET in Identifying Coronary Stenosis Curricto Anne Fill Forum Mix and Mingle Anne Fill Forum Mix and Mingle Anne Ommon Arrhydmia Problems: The Experts Approach Anne One Coronary Angiography, Intra-Vascular Imaging Suggested Reviewer Coronary Stenosis Coronary Angiography Intra-Vascular Imaging Curricts Anne One Anne Anne One Coronary Angiography Intra-Vascular Imaging Curricts Anne One Coronary Angiography Intra-Vascular Imaging Curricts Anne One Coronary Angiography, Intra-Vascular Imaging Curricts Anne One Coronary Angiography, Intra-Vascular Imaging Curricts Anne One Coronary Angiography, Intra-Vascular Imaging Curricts An			FIT Clinical Decision Making Reviewers 3		
Revascularization and Outcomes Anone Steven Acute Coronary Syndromes, Diagnosis, Maragement and Outcomes Anone Oliveira Jussely Timely Topics in Acute Coronary Syndromes, Diagnosis, Maragement and Outcomes Timely Topics in Acute Coronary Syndromes, Diagnosis, Maragement and Outcomes Timely Topics in Acute Coronary Syndromes, Place of Part Syndromes, Diagnosis, and 90-Days Post-Discharges Lounington Colin The Story of the Adult Congenital Heart Disease Patient and EP Prevalence and Prevalence of Related Disperities in Repertusion and Mortality Prevalence and Prevalence of Related Disperities in Repertusion and Mortality Prevalence and Prevalence of Related Disperities in Repertusion and Mortality Prevalence and Prevalence of Related Disperities in Adult Congenital Heart Disease Patient and EP Prevalence and Predictors of Pacemaker Placement in Adult Coronary Angiography, Intra-Vascular Imaging, Related Disperities in Adult Portain Patients Curcicio Alberto Coronary Angiography, Intra-Vascular Imaging, Related Disperities in Adult Portain Patients Curcicio Alejandro Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Anne Time Torum: Mix and Mingle The Supraventricular Ventrolicular Armythmias Problems: The Experts Approach Anne Ommon Arrhythmia Problems: The Experts Approach Anne Ommon Arrhythmia Problems: The Experts Approach Anne Ommon Arrhythmias and Clinical EP Suggested Reviewer Suggested Reviewer Outside Jeptha Arrhythmias and Clinical EP Suggested Reviewer Outside Jeptha Arrhythmias and Heart Failure Curdis Jeptha Arrhythmias and Heart Failure Curcicio Nick Pithology and Endothelial Function Physiology and Endothelial Function Physiology and Endothelial Function And Endothelial Function Anne Arrhythmias and Heart Failure Curcicio Nick Pithology and Endothelial Function Physiology and Endothelial Function Physiology and Endothelial Function Physiology and Endothelial Function Physiology and Endothelial Function Physiology and Endothe	Culler	Steven	Stable Ischemic Heart Disease and the Year in		Nothing to Disclose
Management and Outcomes Management and	Culler	Steven		on Resource Utilization During the 90-Day Follow-Up Period	Nothing to Disclose
Timely Topics in Acute Coronary Syndromes Flath Insurance Related Disparties in Reperfusion and Mortality for Patients With ST Segment Evaluation (No. 2016) in Sergipe, Brazil	Culler	Steven			Nothing to Disclose
Prevalence and Perdictors of Afrial Tachyarrhythmiss in Adult Disease Patient and EP Fontan Patients Prevalence and Fleense Prevalence of Elevated Body Mass Index and Its Association With Clinical Features in Adult Fontan Patients Prevalence of Elevated Body Mass Index and Its Association With RESEARCH GRANTS - BioMarin Pharmaceutical Inc. Prevalence and Clinical Features in Adult Fontan Patients Prevalence and Clinical Features in Adult Fontan Patients Prevalence and Clinical Features in Adult Fontan Patients Prevalence and Clinical Features in Adult Fontan Patients Prevalence and Clinical Significance of Electrocardiographic Nothing to Disclose Prevalence and Clinical Significance of Electrocardiographic Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years Prevalence and Clinical Significance of Electroc	Cunha Oliveira	Jussiely		Health Insurance Related Disparities in Reperfusion and Mortality for Patients With ST Segment Elevation Myocardial Infarction in	Nothing to Disclose
Conington Colin Fontan in the Modern World Cinical Features in Adult Fontan Patients Inc. Curonington Colin Redefining the "F" Word Prevalence of Elevated Body Mass Index and its Association With Inc. Curocolo Alberto Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Causing Mycardial Ischemia Causing Mycardial Ischemia Causing Mycardial Ischemia Causing Mycardial Ischemia Causing Mycardial Ischemia Causing Mycardial Ischemia Pervalence and Clinical Significance of Electrocardiographic Causing Mycardial Ischemia Prevalence and Clinical Significance of Electrocardiographic Causing Mycardial Ischemia Prevalence and Clinical Significance of Electrocardiographic Causing Mycardial Ischemia Prevalence and Clinical Significance of Electrocardiographic Sankyo, MEDTRONIC, St. Jude Medical, DATA SAFETY MONITORING BOARD - Meditronic, inc.; RESEARCH/RESEARCH GRANTS - BlobMarin Pharmaceutical Inc. Curtis Anne Common Arrhythmia Problems: The Experts Approach Approach Approach Approach Suggested Reviewer Suggested Reviewer Consultant Fees Honororania, Suggested Reviewer Consultant Fees Honororania, Suggested Reviewer Consultant Fees Honororania, Suggested Reviewer Consultant Fees Honororania, Suggested Reviewer Consultant Fees Honororania, Suggested Reviewer Consultant Fees Honororania, Suggested Reviewer Consultant Fees Honororania, Suggested Reviewer Consultant Fees Honororania, Suggested Reviewer Consultant Fees Honororania, Suggested Reviewer Consultant Fees Honororania, Suggested Reviewer Consultant Fees Honororania, Suggested Reviewer Consultant Fees Honororania, Suggested Reviewer Consultant Fees Honororania, Inc.; RESEARCH/RESEARCH GRANTS - Buston Medical Consultant Fees Honororania, Inc.; Research Honororania, Suggested Reviewer Consultant Fees Honororania, Inc.; Research Honororania, Suggested Reviewer Consultant Fees Honororania, Inc.; Research Honororania, Suggested Reviewer Consultant Fees Honororania, Inc.; Research Honororania, Suggested Reviewer Consultant Fees Honororania, Inc.;	Cunnington	Colin		Prevalence and Predictors of Atrial Tachyarrhythmias in Adult	
Colin Redefining the "F" Word Prevalence and Predictors of Pacemaker Placement in Adult RESEARCH/RESEARCH GRANTS - BioMarin Pharmaceutical Inc.	Cunnington	Colin		Prevalence of Elevated Body Mass Index and Its Association With	RESEARCH/RESEARCH GRANTS - BioMarin Pharmaceutical
Curcio Alejandro Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Flow Reserve (FFR) App ET in Identifying Coronary Stenosis Causing Myocardial Ischemia Curcio Alejandro Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Anne FIT Forum: Mix and Mingle Selectrophysiologys/lb> Anne FIT Forum: Mix and Mingle Selectrophysiologys/lb> Consultant FEES/HONORARIA - Daiichi Sankyo, MEDTRONIC, St. Jude Medical; DATA SAFETY MONITORING BOARD - Meditronic, Inc.; RESEARCH/RESEARCH GRANTS - St. Jude Medical Curtis Anne Common Arrhythmia Problems: The Experts Approach Curtis Anne Os. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team 2 Curtis Jeptha Interventional Cardiology: PCI and TAVR in Complex Patients Curtis Jeptha Arrhythmias and Heart Failure Ouderform Forus Experts Author Selection Therapy: An Analysis From the NCDR Curtis Jeptha Interventional Cardiology: Intravascular Physiology and Endothelial Function Making Jengerated Reviseuer United States: Results From the Complex Patients Curtis Jeptha Deptha Out-Patients Curtis Jeptha Ou	Cunnington	Colin	Redefining the "F" Word	Prevalence and Predictors of Pacemaker Placement in Adult	RESEARCH/RESEARCH GRANTS - BioMarin Pharmaceutical
Anne FIT Forum: Mix and Mingle S-Electrophysiology Durtis Anne FIT Forum: Mix and Mingle S-Electrophysiology FIT Forum: Mix and Mingle S-Electrophysiology S-Electrophysiology Descriptions of the state of th	Cuocolo	Alberto		Relationship Between Fractional Flow Reserve (FFR) and Coronary Flow Reserve (CFR) by PET in Identifying Coronary Stenosis	
Curtis Anne FiT Forum: Mix and Mingle	Curcio	Alejandro		Prevalence and Clinical Significance of Electrocardiographic	Nothing to Disclose
Curtis Anne Common Arrhythmia Problems: The Experts Approach Co-Chair Co-Chair Co-Chair Co-Chair Co-Chair Co-Chair Sapproach C	Curtis	Anne			Sankyo,MEDTRONIC,St. Jude Medical; DATA SAFETY MONITORING BOARD - Medtronic, Inc.;
Curtis Anne 08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team 2 Curtis Jeptha Interventional Cardiology: PCI and TAVR in Complex Patients Curtis Jeptha Arrhythmias and Heart Failure Quadripolar Versus Bipolar Left Ventricular Leads in Cardiac Resynchronization Therapy: An Analysis From the NCDR Curtis Jeptha O2. Acute and Stable Ischemic Heart Disease: Clinical Team 1 Curzen Nick Interventional Cardiology: Intravascular Physiology and Endothelial Function Decision Making Using Fractional Flow Reserve Is Associated With Anglographic Guided Decision Making Amongst Patients With Nstem! Suggested Reviewer CONSULTANT FEES/HONGARIA - Daichi Sankyo, MEDTRONIC, St. Jude Medical Sankyo, MEDTRONIC, Sankyo, MEDTRONIC, Sankyo, MEDTRONIC PATA SAFETY MONITORING BOARD - Meditoric, RESEARCH/RESEARCH GRANTS - S. Jude Medical OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MED	Curtis	Anne		Co-Chair	CONSULTANT FEES/HONORARIA - Daiichi Sankyo,MEDTRONIC,St. Jude Medical; DATA SAFETY MONITORING BOARD - Medtronic, Inc.;
Deptha Interventional Cardiology: PCI and TAVR in Complex Patients Utilization of Heart Teams in the United States: Results From the Translating Outstanding Performance in Percutaneous Coronary Intervention (TOP PCI) Study	Curtis	Anne		Suggested Reviewer	CONSULTANT FEES/HONORARIA - Daiichi Sankyo,MEDTRONIC,St. Jude Medical; DATA SAFETY MONITORING BOARD - Medtronic, Inc.;
Curtis Jeptha Arrhythmias and Heart Failure Quadripolar Versus Bipolar Left Ventricular Leads in Cardiac MEDTRONIC. Curtis Jeptha 02. Acute and Stable Ischemic Heart Disease: Clinical Team 1 Curzen Nick Interventional Cardiology: Intravascular Physiology and Endothelial Function Nstem Note Note National Cardiology and Endothelial Function Nstem Note National Cardiology: Intravascular Companies Compani	Curtis	Jeptha		Translating Outstanding Performance in Percutaneous Coronary	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Suggested Reviewer OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MEDTRONIC Curzen	Curtis	Jeptha	Arrhythmias and Heart Failure	Quadripolar Versus Bipolar Left Ventricular Leads in Cardiac	
Curzen Nick Interventional Cardiology: Intravascular Physiology and Endothelial Function Eugenia Functional Flow Reserve Is Associated With Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With Nstemi CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,Haemonetics,Heartflow,MEDTRONIC,St Jude Medical Scientific,Heartflow,MEDTRONIC,St Jude Medical Scientific,Heartflow,MEDTRONIC,St Jude Medical	Curtis	Jeptha			OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
	Curzen	Nick	Interventional Cardiology: Intravascular	Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific, Haemonetics, Heartflow, MEDTRONIC, St Jude Medical; RESEARCH/RESEARCH GRANTS - Boston
Guidelines	Cushman	William	Hypertension: Evolving Evidence, Changing		Scientific,Heartflow,MEDTRONIC,St Jude Medical OTHER - Takeda; RESEARCH/RESEARCH GRANTS - Lilly



| ACC.17

WASHINGTON, DC FRI•SAT•SUN

Contract of the second				<u> </u>
Last Name Cushman	First Name William	Session Title Hypertension: Evolving Evidence, Changing	Presentation Title SPRINTing to Success: An International Perspective on	Disclosures OTHER - Takeda; RESEARCH/RESEARCH GRANTS - Lilly
Cushman	William	Guidelines Controversies in Hypertension	Hypertension Guidelines SPRINT - Do These Results Translate to Practice in the Real	OTHER - Takeda; RESEARCH/RESEARCH GRANTS - Lilly
Cushman	William	Emerging Concepts in Evaluation and	World? Yes! Co-Chair	OTHER - Takeda, RESEARCH/RESEARCH GRANTS - Lilly OTHER - Takeda; RESEARCH/RESEARCH GRANTS - Lilly
		Management of Hypertension		-
Cushman	William	The Intersection of Diabetes and ASCVD	Average Clinician Measured Blood Pressure Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes Following Acute Coronary Syndromes in the EXAMINE Trial	OTHER - Takeda; RESEARCH/RESEARCH GRANTS - Lilly
Cushman Cutice	William Tammy	33. Prevention: Hypertension Team 1 Atrial Fibrillation, Anticoagulation and Novel	Suggested Reviewer Real World Evaluation of Major Bleeding Risk and Costs for All	OTHER - Takeda; RESEARCH/RESEARCH GRANTS - Lilly SALARY - Bristol-Myers Squibb Company
		Device Therapies	Causes and Bleeding-Related Health Services Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Apixaban or Warfarin	, , , , , , , , , , , , , , , , , , , ,
Cutlip	Donald	Considerations in Antiplatelet Therapy and in ACS	Impact of Coronary Anatomical Complexity on the Effect of Extended Duration Dual Antiplatelet Therapy: An Analysis From the Dual Antiplatelet Therapy Study	RESEARCH/RESEARCH GRANTS - Boston Scientific,CELONOVA,MEDTRONIC
Czer	Lawrence	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Angiographic Dye Prior to Combined Heart-Kidney Donation Does Not Appear to Harm Donor Kidney Function After Transplant	RESEARCH/RESEARCH GRANTS - St. Jude Medical
Czosek	Richard	Congenital Heart Disease: Advances in Quality Improvement for Pediatric Cardiac Care	Standardizing the Care of Outpatient Pediatric Syncope and Dizziness: A Lesson in Utilization and Charge Reduction	Nothing to Disclose
Czosek	Richard	Congenital Heart Disease: Novel Insights in Pediatric Cardiology	Rhythm Abnormalities in Children and Young Adults With Marfan Syndrome	Nothing to Disclose
D'Ascenzo	Fabrizio	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Provisional Versus Elective Two-Stenting Strategy for Unprotected True Left Main Bifurcation Lesions: A Sub-Study From Fails 2 Study	Nothing to Disclose
Da Luz	Protasio	32. Prevention: Clinical Team 2	Suggested Reviewer	Nothing to Disclose
Dabhadkar	Kaustubh	Unusual Presentations of ACS	National Trends in Admissions for Chest Pain Evaluation: 2006 - 2013	Nothing to Disclose
Dadabaev	Gulamzhan	Advances in Pulmonary Arterial Hypertension	Long-Term Results of Interatrial Septum Fenestration With Stent Implantation in Idiopathic Pulmonary Arterial Hypertension	Nothing to Disclose
Dagenais	Francois	Novel Determinants of Outcomes in VHD	Pre-Operative Longitudinal Strain and Strain Rate as Predictors of Impaired Post-Operative Ejection Fraction in Patients Operated for Pure Aortic Regurgitation	Nothing to Disclose
Daggubati	Ramesh	Maintenance of Clinical Competencies in Invasive Coronary Imaging and Coronary	Case Presentation: IVUS	CONSULTANT FEES/HONORARIA - Abbott, Abiomed, Astra Zeneca, Cardiac Assist, Janssen, MEDTRONIC
D'Agostino	Ralph	Physiology The Evolving World of LVADs, Transplant and Other Novel Discoveries	Frequency of Transition From Stage A to B or C Heart Failure After Potentially Cardiotoxic Chemotherapy	CONSULTANT FEES/HONORARIA - Cubist Pharmaceuticals, Inc., Edwards Lifesciences Ltd, GlaxoSmithKline, Novartis
D'Agostino	Ralph	Advances in Imaging to Assess Cardiotoxicity	Decreases in Left Ventricular Mass and Not Left Ventricular Ejection	Corporation,Rockwell Medical, Inc.,Salix Pharmaceuticals, Ltd CONSULTANT FEES/HONORARIA - Cubist Pharmaceuticals,
D Agostino	Карп	Advances in imaging to Assess Cardiotoxicity	Fraction Are Associated With Heart Failure Symptoms in Cancer Patients Six Months After Potentially Cardiotoxic Chemotherapy	Inc.,Edwards Lifesciences Ltd,GlaxoSmithKline,Novartis Corporation,Rockwell Medical, Inc.,Salix Pharmaceuticals, Ltd
Dahal	Khagendra	Vascular Access and Hemostasis Issues	Standard Versus Low-Dose Heparin Use on Access-Related Complications After Coronary Angiography Through Radial Access: A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Dahlstrom	Ulf	Highlighted Original Research: Heart Failure	Mortality and Morbidity in Patients With Heart Failure and Reduced	Nothing to Disclose
		and Cardiomyopathies and the Year in Review	Ejection Fraction Exposed to Digoxin: Comprehensive Data According to Atrial Fibrillation in 23,708 Patients From the Swedish Heart Failure Registry	
Dahlstrom	Ulf	Why Can't We Be Friends? Controversies in Heart Failure Management	Association Between Serum Potassium Level and Outcomes in Heart Failure With Reduced Ejection Fraction: A Cohort Study From the Swedish Heart Failure Registry	Nothing to Disclose
Dahou	Abdellaziz	Town Hall Meeting: Pitfalls of Assessing Valvular Heart Disease Severity	Case: Low Flow Aortic Stenosis: Real or Pseudo	Nothing to Disclose
Dahou	Abdellaziz	Interventional Cardiology: TAVR 4	Clinical Study of the Impact of Preexisting Patient-Prosthesis	Nothing to Disclose
Dai	Dadi (David)	Featured Clinical Research II: Interventional	Mismatch on Valve-in-Valve Performance Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis	Nothing to Disclose
Dai	Dadi (David)	Highlighted Original Research: Interventional	From Two US Registries Linked to Medicare Data New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve	Nothing to Disclose
		Cardiology and the Year in Review	Replacement: Incidence, Anticoagulant Strategy, and Outcomes	-
Dai	Kazuoki	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Differences in Chronic Angioscopic Findings With Different Stent Types in Patients With and Without Diabetes Mellitus: Sub-Analysis of a Report From Japanese Multicenter Registry	Nothing to Disclose
Dai	Shengchuan		How a Cardiologist Diagnosed a Pheochromocytoma:	Nothing to Disclose
Dai	Shengchuan	Pulmonary Hypertension Cardiac Channelopathies: Novel Therapeutics	Catecholamine-Induced Myocarditis Compound <i>SCN5A</i> Mutation and <i>FGF12</i> Variation	Nothing to Disclose
Dai	Xuming	and Clinical Challenges PCI for NSTEMI and Complex Patients With	Cause Brugada Syndrome Management and Outcomes of Non-ST Elevation Myocardial	Nothing to Disclose
	, ,	Multiple Co-Morbidities	Infarction in Patients Hospitalized for Non-Cardiac Conditions	-
Dai	Xuming	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Recurrent Syncope: An Unusual Presentation of Lymphoma	Nothing to Disclose
Dai	Xuming	Interventional Cardiology: PCI in Complex Patients	Outcomes After Invasive Management of Inpatient Onset of Non ST- Elevation Myocardial Infarction	Nothing to Disclose
Daida	Hiroyuki	Unusual Presentations of ACS	Combined Serum Albumin and C-Rective Protein Levels Predict Long-Term Outcomes in Patients With Coronary Artery Disease After a First Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Asteras, Astora Zeneca, Daiichi-Sankyo, Kowa, Mochida, Phizer, Shering-Plough, Takeda; RESEARCH/RESEARCH GRANTS - Astellas Pharma Inc., AstraZeneca K.K., Bayer Yakuhin, Ltd, Kissei Pharmaceutical Co., Ltd., KOWA PHARMACEUTICAL COMPAN: LTD., Kyowa Medex Co., Ltd., Medex Co., Ltd., Kyowa Medex Co., Ltd., Mosor Medex Co., Ltd., Stanking K.K., Cisuka Pharmaceutical Co., Ltd., Public Health Research Foundation, sanofi-aventis K.K., SANWA KAGAKU KENKYUSHO CO., LTD., Schering-Plough Corporation, Shionogi & Co., Ltd., Takeda Pharmaceutical Co., Ltd., The Waksman Foundation of Japan INC.
Daida	Hiroyuki	CAD in Unique Patient Populations	Prognostic Impact of Geriatric Nutritional Risk Index in Patients Undergoing Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Asteras, Astora Zeneca, Daiichi-Sankyo, Kowa, Mochida, Phizer, Shering-Plough, Takeda; RESEARCH/RESEARCH GRANTS - Astellas Pharma Inc., AstraZeneca K.K., Bayer Yakuhin, Ltd, Kissei Pharmaceutical Co., Ltd., KOWA PHARMACEUTICAL COMPAN LTD., Kyowa Medex Co., Ltd., Kyowa Medex Co., Ltd., MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Avoartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Public Health Research Foundation, sanofi-aventis K.K., SANWA KAGAKU KENKYUSHO CO., LTD., Schering-Plough Corporation, Shionogi & Demouration Co., Ltd., The Waksman Foundation conditions are considered to the Condition of the Conditio
				of Japan INC.

and a				l
Last Name Daimee	First Name Usama	Session Title Highlighted Original Research: Heart Failure	Presentation Title Sustained Clinical Benefit of Cardiac Resynchronization Therapy in	Disclosures Nothing to Disclose
Dailliee	Osama	and Cardiomyopathies and the Year in Review	Patients With Relatively Preserved Ejection Fraction: A MADIT-CRT	Nothing to Disclose
D. C. C.		The Foot is West Clarks	Long-Term Follow-Up Sub-Study	Note: A Product
Daimee	Usama	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Change in Renal Function During Extended Follow-Up After Left Ventricular Assist Device Implantation	Nothing to Disclose
Dalal	Pratik	FIT Clinical Decision Making: Prevention, Adult	Patent Ductus Arteriosus: An Unusual Cause of High Output	Nothing to Disclose
		Congenital and Congenital Heart Disease	Cardiac Failure in an Elderly Patient	
Dal-Bianco	Jacob	Mitral Valve Guidelines: Closing Knowledge	Case Presentation for Panel Discussion: 78 Year Old with Flail	Nothing to Disclose
		Gaps	Leaflet, Moderate MS and AS	
Dal-Bianco Dalcoquio	Jacob Talia	36. Valvular Heart Disease: Clinical Team 2 Revascularization and Myocardial Preservation	Suggested Reviewer The Role of Oral Beta Blocker in a Real-World Population With Non-	Nothing to Disclose Nothing to Disclose
Balcoquio	Tana	in Acute and Stable Ischemic Heart Disease	ST Segment Elevation Acute Coronary Syndromes	Nothing to Disclose
D. L	T. P.	A Charles The Control of the Control	Effects of the Market M	Notice to Breaters
Dalçoquio	Talia	Antithrombotic Therapy in Ischemic Heart Disease	Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery	Nothing to Disclose
			Disease	
Daley	Carly	Innovations in Practice Management and Social Media	Designing Tailored Health Messaging to Enhance Patient-Centered Care in Non-Valvular Atrial Fibrillation	Nothing to Disclose
D'Alfonso	Sabrina	Uncovering the Intricacies of Vascular Function	Ticagrelor Improves Microvascular Function: Results of a Cross-	Nothing to Disclose
Daly	Richard	The Evolving World of LVADs, Transplant and	Over Study Effects of Diabetes Mellitus on Clinical Outcomes After Left	OTHER - Neochord, Inc.
Daiy	Kicilaiu	Other Novel Discoveries	Ventricular Assist Device Implantation: A Single Institutional 9-Year	OTTER - Neochord, Inc.
Deli	Dishard	Advanced Theoretics - Advanced Travella	Experience	OTHER Needed In
Daly	Richard	Advanced Therapies = Advanced Trouble: VAD and Transplant Challenges	Sirolimus-Based Immunosuppression Mitigates Progression of Cardiac Allograft Vasculopathy and Improves Cardiac Outcomes	OTHER - Neochord, Inc.
			After Heart Transplantation: A Single Center 15-Year Follow-Up	
D'Ambrosi	Alessandra	Improving Outcomes in the Athlete With	Study EKG Abnormalities Distribution Between Competitive Athletes, Non	Nothing to Disclose
D'AIIIDIOSI	Alessaliula	Cardiovascular Disease	Competitive Athletes and Non Athletes in a Population of 12,000	Notifing to Disclose
Damilio:	Abdulla		Young Italian Students	Nething to Displace
Damluji	Abdulla	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Percutaneous Coronary Intervention in Adults Age 75 Years or Older With ST Elevation Myocardial Infarction and Cardiogenic	Nothing to Disclose
			Shock	
Damluji	Abdulla	Interventional Complexity and Complications	Variability in Transfemoral Access for Coronary Angiography and Interventions: Results From an International Survey	Nothing to Disclose
Damp	Julie	Teaching with Intent: Secrets from the Masters	Panelist	Nothing to Disclose
		III		-
Damp	Julie	Teaching with Intent: Secrets from the Masters	Simulation: Patient Encounter (Patient's Family Member)	Nothing to Disclose
Damp	Julie	Feeling the Pressure - Tough Cases in	Panelist	Nothing to Disclose
D	lulia.	Hypertension	Desired Differences in Left Ventria des Deservas in Definite With	Nothing to Displace
Damp	Julie	Novel Echocardiographic Methods for Assessing Cardiac Function	Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain	Nothing to Disclose
		-		
Damp	Julie	Innovations in Education	Update on the ABIM's Competency Based Pilot in Internal Medicine- Cardiology	Nothing to Disclose
Damp	Julie	Innovation in Practice Management, Advocacy,	ACC Poster Moderator	Nothing to Disclose
D	lulia.	and Education	Constant Davisson	Nothing to Displace
Damp	Julie	42. Spotlight on Special Topics: Education, Innovation, Advocacy, Social Media,	Suggested Reviewer	Nothing to Disclose
		Leadership and Practice Management Team 1		
Damrongwatanasuk	Rongras	FIT Clinical Decision Making: Non-Invasive	Global Longitudinal Strain (GLS) Imaging to Detect and Monitor Left	Nothing to Disclose
Dailifoligwalariasuk	Rongras	Imaging and Valvular Heart Disease	Ventricular Function After Direct Cardiac Radiation	Notifing to Disclose
Damrongwatanasuk	Rongras	FIT Clinical Decision Making: Heart Failure and	Successful Treatment of Checkpoint Inhibitor Induced Myocarditis	Nothing to Disclose
		Pulmonary Hypertension	and Cardiomyopathy With Steroids, Beta-Blockers and ACE Inhibitors	
Damrongwatanasuk	Rongras	The Evolving World of LVADs, Transplant and	Cardiovascular Toxicities Associated With Adoptive Cell Therapy	Nothing to Disclose
Dan	Dan	Other Novel Discoveries 08. Arrhythmias and Clinical EP:	and Interleukin-2 Infusion for Advanced Stage Melanoma Suggested Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC; DATA
Daii	Dali	Supraventricular/Ventricular Arrhythmias Team	Suggested Neviewei	SAFETY MONITORING BOARD - St Jude
D I	B. a. b. S. a.	5	A 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	Note: A Product
Danad	Ibrahim	Nuclear Cardiology: Quality	Automatic SPECT Analysis Compared to Expert Visual Scoring for the Detection of Coronary Artery Disease	Nothing to Disclose
Danad	Ibrahim	Noninvasive Assessment of Coronary Flow	Atherosclerotic Plaque Morphology Is Associated With Impaired	Nothing to Disclose
		Reserve: Clinical Implications	Myocardial Blood Flow and Fractional Flow Reserve, Independent of Luminal Obstruction	
Danchin	Nicolas	Coronary Angiography, Intra-Vascular Imaging,	Discriminant Value of the DAPT Score to Predict Long-Term	Nothing to Disclose
]]	Revascularization and Outcomes	Ischemic and Bleeding Events in the Real World Population of	
Danchin	Nicolas	Antithrombotic Therapy in Ischemic Heart	Stented Patients in the FAST-MI 2005 Cohort Long-Term Outcome With Oral Anticoagulants With or Without Dual	Nothing to Disclose
		Disease	Antiplatelet Therapy After AMI: The Fast-Mi 2010 Registry	
Danchin	Nicolas	Unusual Presentations of ACS	Characteristics and Outcomes of Patients Discharged Without Statins After an Acute Myocardial Infarction: An Analysis From the	Nothing to Disclose
			Combined FAST-MI 2005-2010 Cohorts	
Danciu	Sorin	FIT Clinical Decision Making: Prevention, Adult		Nothing to Disclose
]]	Congenital and Congenital Heart Disease		
Danciu	Sorin		A Possible Simple Solution to a Challenging Problem in	Nothing to Disclose
Daneault	Benoit	Pulmonary Hypertension Antiplatelet and Antithrombotic Agents in	Management of Acute Decompensated Heart Failure Comparison of Triple Antithrombotic Therapy to Ticagrelor-Based	CONSULTANT FEES/HONORARIA - AstraZeneca
Dalleduit	DETION	Ischemic Heart Disease	Dual Antiplatelet Therapy for Left Ventricle Dysfunction Following	Pharmaceuticals,Bayer Healthcare Pharmaceuticals,Boehringer
Danal	Darkara		STEMI Using Natural Randomization: A Retrospective Pilot Study	Ingelheim Pharmaceuticals, Inc, Novartis Corporation
Danek	Barbara	Highlighted Original Research: Prevention and the Year in Review	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors on Clinical Outcomes in Patients With	Nothing to Disclose
]		Hypercholesterolemia: A Meta-Analysis of 16,721 Patients From 33	
Danek	Barbara	Coronary Intervention in Interventional	Randomized Clinical Trials Contemporary Use of Laser During Percutaneous Coronary	Nothing to Disclose
Danek	Daivala	Cardiology: Advanced Device Use	Intervention: Results From the Laser Veterans Affairs (LAVA)	Induling to Disclose
D !	D. J		Multicenter Registry	Note: A Broden
Danek	Barbara	Coronary Intervention in Interventional Cardiology: Advanced Device Use	A Meta-Analysis of Contemporary Lesion Modification Strategies During Percutaneous Coronary Intervention in 244,665 Patients	Nothing to Disclose
		0,	From 21 Studies	
Danek	Barbara	Innovations in Advocacy and Patient Centered	Diverse Perspectives and Training Paths in Cardiology: An Analysis	Nothing to Disclose
	1	Care	of Authorship in the <i>Journal of the American College of Cardiology</i>	
Danek	Barbara	Advances in Chronic Total Occlusion	Percutaneous Coronary Intervention of Coronary Chronic Total	Nothing to Disclose
	1	Intervention	Occlusions Improves Peak Oxygen Uptake During Cardiopulmonary Exercise Testing	
Danek	Barbara	Advances in Chronic Total Occlusion	Application and Outcomes of the Hybrid Approach to Chronic Total	Nothing to Disclose
]	Intervention	Occlusion Percutaneous Coronary Intervention: An Update From a	
Danek	Barbara	Endovascular Therapy: Running From Risk	Contemporary Multicenter U.S. Registry Predictors of Procedural Complications in Infrainguinal	Nothing to Disclose
	1		Endovascular Interventions	•

Contract of the Contract of th				
Last Name Danenberg	First Name Haim	Session Title Refining TAVR Outcomes	Presentation Title The Association of Coronary Artery Disease Severity and Pre Procedural Completeness of Revasclarization on Mortality in Patients Undercoing Transcatheter Aortic Valve Replacement	Disclosures CONSULTANT FEES/HONORARIA - MEDTRONIC
Danese	Mark	Diabetes and Other Issues in Cardiovascular Prevention	Observed Versus Predicted Cardiovascular Event Rates in Primary Prevention Diabetic Patients Receiving High-Intensity Statins in the United Kingdom	RESEARCH/RESEARCH GRANTS - Amgen Inc.
Danford	David	Adult Patients With Congenital Heart Disease: How Do They Compare?	Decreased Hepatic Elasticity in Young Adults After Biventricular Repair of Congenital Heart Disease	Nothing to Disclose
Danford	David	10. Congenital Heart Disease: Pediatric Team	Suggested Reviewer	Nothing to Disclose
Dang	Geetanjali	Updates on Pulmonary Embolism Management in 2017	The Long-Term Prognostic Value of Highly Sensitive Cardiac Troponin I in Patients With Acute Pulmonary Embolism	Nothing to Disclose
Dang	Geetanjali	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Incommental Value of Estimated Glomerular Filtration Rate in Incremental Value of Estimated Glomerular Filtration Rate in Improving Stroke Risk Stratification in Patients With and Without Atrial Fibrillation Considered to Be Low Risk by CHAcsub-2-4/sub-DS-sub-2e/sub-VASc Score	Nothing to Disclose
Dang	Yu-Xuan	Predicting Outcomes in Cardiac Rehabilitation Patients	Non-White Patients With Coronary Heart Disease Have Worse Cardiac Rehabilitation Participation Than White Patients	Nothing to Disclose
Dangas	George	Interventional Live Case Session II: CTO Transmission from Mid-America Heart Institute (Kansas City, Missouri)	Panelist discharge and the panelist discharge an	CONSULTANT FEES/HONORARIA - Abiomed, Boston Scientific, Cardiovascular Systems Inc, Janssen Pharmaceuticals, Inc, MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca, Bayer Healthcare Pharmaceuticals, Dailchi Sankyo
Dangas	George	Practicum on Tools for CHIP (Complex and Higher-Risk Procedures in Indicated Patients)	Left Main PCI for the Masses: Simple Concepts and Tools	CONSULTANT FEES/HONORARIA - Abiomed Boston Scientific, Cardiovascular Systems Inc. Janssen Pharmaceuticals, Inc.MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca Bayer Healthcare Pharmaceuticals, Dalichi Sankyo
Dangas	George	Complex PCI in 2017	Co-Chair	CONSULTANT FEES/HONORARIA - Abiomed,Boston Scientific,Cardiovascular Systems Inc,Janssen Pharmaceuticals, Inc,MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca,Bayer Healthcare Pharmaceuticals,Daiichi Sankyo
Dangas	George	Complex PCI in 2017	Calcified Vessels: Techniques for Dealing with Calcium and Differences Between Devices	CONSULTANT FEES/HONORARIA - Abiomed Boston Scientific, Cardiovascular Systems Inc. Janssen Pharmaceuticals, Inc.MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca Bayer Healthcare Pharmaceuticals, Dalichi Sankyo
Dangas	George	Interrupting DAPT for Surgery, Afib, or Bleeding	Co-Chair	CONSULTANT FEES/HONORARIA - Abiomed Boston Scientific, Cardiovascular Systems Inc. Janssen Pharmaceuticals, Inc.,MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca Bayer Healthcare Pharmaceuticals, Dailichi Sankyo
Dangas	George	Interrupting DAPT for Surgery, Afib, or Bleeding	What to Do When the DAPT Patient Is Bleeding	CONSULTANT FEES/HONORARIA - Abiomed Boston Scientific, Cardiovascular Systems Inc. Janssen Pharmaceuticals, Inc.MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca, Bayer Healthcare Pharmaceuticals, Dalichi Sankyo
Dangas	George	Bioresorbable Vascular Scaffolds, Bioresorbable Polymer and Polymer Free Metallic DES	Co-Chair	CONSULTANT FEES/HONORARIA - Abiomed Boston Scientific,Cardiovascular Systems Inc.,Janssen Pharmaceuticals, Inc,MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca,Bayer Healthcare Pharmaceuticals,Dailichi Sankyo
Dangas	George	Considerations in Antiplatelet Therapy and in ACS	Effect of Thrombotic and Bleeding Risk According to Platelet Reactivity on 2-Year Mortality: The ADAPT-DES Study	CONSULTANT FEES/HONORARIA - Abiomed, Boston Scientific, Cardiovascular Systems Inc., Janssen Pharmaceuticals, Inc, MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca, Bayer Healthcare Pharmaceuticals, Dailichi Sankyo
Dangas	George	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Comparing PCI Outcomes in the Very Elderly: Does Age Matter? A Report From Outcomes of Septuagenarians, Octogenarians and Nonagenarians After PCI	CONSULTANT FEES/HONORARIA - Abiomed Boston Scientific,Cardiovascular Systems Inc.,Janssen Pharmaceuticals, Inc,MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca,Bayer Healthcare Pharmaceuticals,Dailichi Sankyo
Dangas	George	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Clinical Outcomes Associated With Impella Versus IABP Use in Stable Patients Undergoing High Risk Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Abiomed Boston Scientific, Cardiovascular Systems Inc, Janssen Pharmaceuticals, Inc, MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca, Bayer Healthcare Pharmaceuticals, Dailichi Sankyo
Dangas	George	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Impella or Intra-Aortic Balloon Pump Support in Patients Undergoing High Risk Percutaneous Coronary Intervention: A Real World Single Center Experience	CONSULTANT FEES/HONORARIA - Abiomed Boston Scientific, Cardiovascular Systems Inc. Janssen Pharmaceuticals, Inc.MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca, Bayer Healthcare Pharmaceuticals, Dalichi Sankyo
Dangas	George	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Angiographic Phenotype and Clinical Outcomes of Patients With Malignancy Undergoing PCI	CONSULTANT FEES/HONORARIA - Abiomed Boston Scientific, Cardiovascular Systems Inc, Janssen Pharmaceuticals, Inc, MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca, Bayer Healthcare Pharmaceuticals, Dalichi Sankyo
Dangas	George	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study	CONSULTANT FEES/HONORARIA - Abiomed Boston Scientific,Cardiovascular Systems Inc.,Janssen Pharmaceuticals, Inc,MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca,Bayer Healthcare Pharmaceuticals,Dailichi Sankyo
Dangas	George	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Synergistic Effects of Coronary Calcification and Inflammation on Risks for Adverse Cardiovascular Events After PCI: Results From a Large Single-Center Registry	CONSULTANT FEES/HONORARIA - Abiomed Boston Scientific,Cardiovascular Systems Inc.,Janssen Pharmaceuticals, Inc,MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca,Bayer Healthcare Pharmaceuticals,Dailichi Sankyo
Dangas	George	Novel Developments in Acute Coronary Syndromes	Trends in Incidence and Mortality Associated With Acute Kidney Injury in Patients Undergoing PCI for Acute Coronary Syndrome	CONSULTANT FEES/HONORARIA - Abiomed, Boston Scientific, Cardiovascular Systems inc, Janssen Pharmaceuticals, Inc, MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca, Bayer Healthcare Pharmaceuticals, Dalichi Sankyo
Dangas	George	Interventional Cardiology: PCI and TAVR in Complex Patients	Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the Bravo-3 Randomized Trial	CONSULTANT FEES/HONORARIA - Abiomed, Boston Scientific, Cardiovascular Systems Inc, Janssen Pharmaceuticals, Inc, MEDTRONIC; OTHER - Claret, RESEARCH/RESEARCH GRANTS - Astra-Zeneca, Bayer Healthcare Pharmaceuticals, Dailchi Sankyo
Dangas	George	Timely Topics in Acute Coronary Syndromes	Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions	CONSULTANT FEES/HONORARIA - Abiomed,Boston Scientific,Cardiovascular Systems Inc,Janssen Pharmaceuticals, Inc,MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca,Bayer Healthcare Pharmaceuticals, Daiichi Sankyo

and a				
Last Name Dangas	First Name George	Session Title Optimizing the Care of ACS Patients	Presentation Title Underutilization of High Intensity Statins in a Contemporary High	Disclosures CONSULTANT FEES/HONORARIA - Abiomed, Boston
Dangas	George	Optimizing the Gale of AGG Fatients	Risk PCI Population	Scientific, Cardiovascular Systems Inc., Janssen Pharmaceuticals, Inc, MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca. Baver Healthcare
				Pharmaceuticals,Daiichi Sankyo
Dangas	George	Interventional Complexity and Complications	Prediction of Acute Kidney Injury in Patients Undergoing Coronary Intervention Using Calculation of Serum Osmolality	CONSULTANT FEES/HONORARIA - Abiomed, Boston Scientific, Cardiovascular Systems Inc, Janssen Pharmaceuticals,
			and one of contract of court contract,	Inc, MEDTRONIC; OTHER - Claret, RESEARCH/RESEARCH GRANTS - Astra-Zeneca, Bayer Healthcare Pharmaceuticals, Daiichi Sankyo
Dangas	George	Interventional Cardiology: PCI in Complex	Risk and Impact of Diabetes Mellitus on Ischemic Events in Females	CONSULTANT FEES/HONORARIA - Abiomed, Boston
		Patients	and Males After Percutaneous Coronary Intervention	Scientific, Cardiovascular Systems Inc, Janssen Pharmaceuticals, Inc, MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca, Bayer Healthcare Pharmaceuticals, Dailichi Sankyo
Dangas	George	Interventional Cardiology: PCI in Complex	Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated	CONSULTANT FEES/HONORARIA - Abiomed, Boston
		Patients	Heparin Following Transcatheter Aortic Valve Replacement: Results From the Bravo-3 Randomized Trial	Scientific, Cardiovascular Systems Inc., Janssen Pharmaceuticals, Inc, MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca, Bayer Healthcare Pharmaceuticals, Daiichi Sankyo
Dangas	George	21. Interventional Cardiology: Coronary Intervention: Devices Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abiomed Boston Scientific, Cardiovascular Systems Inc., Janssen Pharmaceuticals, Inc, MEDTRONIC; OTHER - Claret; RESEARCH/RESEARCH GRANTS - Astra-Zeneca, Bayer Healthcare Pharmaceuticals, Dalichi Sankyo
Daniels	Curt	FIT Forum: Mix and Mingle	Congenital HD Pediatric and Adult	Nothing to Disclose
Daniels	Curt	Update in ACHD: The Time for Change is Now	Co-Chair	Nothing to Disclose
Daniels	Curt	Update in ACHD: The Time for Change is Now	Rome Was Not Built in a Day: How We Think About Adult Congenital Heart Disease and the Foundation of the New Guidelines	Nothing to Disclose
Daniels	Curt	Patient-Centered Care in Adult Congenital	Co-Chair	Nothing to Disclose
Daniels	Curt	Heart Disease Core Curriculum: Moving from the Basics to Advanced Cases in Pulmonary Hypertension	What's Love Got to Do With It? PH and Pregnancy	Nothing to Disclose
Daniels Daniels	Curt Curtis	09. Congenital Heart Disease: Adult Team 1 Adult Patients With Congenital Heart Disease:	Suggested Reviewer Obstructive Sleep Apnea in Adult Congenital Heart Disease: Who Is	Nothing to Disclose Nothing to Disclose
		How Do They Compare?	at Risk?	
Daniels	Curtis	Finding Out What Works in Pediatric and Congenital Heart Disease	Timely Detection of Pulmonary Arterial Hypertension in Patients With Repaired Congenital Heart Disease: Interim Results From the ACHD-QuERI Registry	Nothing to Disclose
Daniels	Lori	Beyond the Usual Suspects - Other Dimensions in Prevention	Panelist	CONSULTANT FEES/HONORARIA - Relypsa,Siemens; SPEAKER'S BUREAU - Critical Diagnostics,Janssen Pharmaceuticals, Inc,Roche
Daniels	Lori	Beyond the Usual Suspects - Other Dimensions in Prevention	Wake up to Prevention - Sleep Apnea Basics for the Cardiologist	CONSULTANT FEES/HONORARIA - Relypsa, Siemens; SPEAKER'S BUREAU - Critical Diagnostics, Janssen Pharmaceuticals, Inc, Roche
Daniels	Lori	Making Progress in Understanding Heart Failure	Impact of Malignant Left Ventricular Function on Incident Heart Failure With Reduced Versus Preserved Ejection Fraction: The MESA Study	CONSULTANT FEES/HONORARIA - Relypsa,Siemens; SPEAKER'S BUREAU - Critical Diagnostics,Janssen Pharmaceuticals, Inc,Roche
Daniels	Lori	Making Progress in Understanding Heart Failure	Impact of Malignant Left Ventricular Function on Incident Heart Failure in Older Adults: The MESA Study	CONSULTANT FEES/HONORARIA - Relypsa,Siemens; SPEAKER'S BUREAU - Critical Diagnostics,Janssen Pharmaceuticals, Inc,Roche
Daniels	Lori	Innovations in Cardiovascular Risk Assessment and Reduction	Impact of Malignant Left Ventricular Hypertrophy on Incident Asymptomatic Left Ventricular Dysfunction: The MESA Study	CONSULTANT FEES/HONORARIA - Relypsa, Siemens; SPEAKER'S BUREAU - Critical Diagnostics, Janssen Pharmaceuticals, Inc, Roche
Daniels	Lori	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Sex Differences in Atrial Structural Remodeling and Serum Markers of Fibrosis at Presentation for Catheter Ablation	CONSULTANT FEES/HONORARIA - Relypsa,Siemens; SPEAKER'S BUREAU - Critical Diagnostics,Janssen Pharmaceuticals, Inc,Roche
Daniels	Lori	Improving Risk Assessment in Atherosclerosis	N-Terminal Pro B-Type Natriuretic Peptide, Race, and Flow- Mediated Dilation: Multi-Ethnic Study of Atherosclerosis	CONSULTANT FEES/HONORARIA - Relypsa,Siemens; SPEAKER'S BUREAU - Critical Diagnostics,Janssen Pharmaceuticals, Inc,Roche
Daniels	Lori	32. Prevention: Clinical Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Relypsa,Siemens; SPEAKER'S BUREAU - Critical Diagnostics,Janssen Pharmaceuticals, Inc,Roche
Dao	Catherine	Interventional Cardiology: TAVR 1	Remodeling Following Transcatheter Aortic Valve Replacement	Nothing to Disclose
Daoud	Emile	Arrhythmias and Clinical EP: Devices 2	Comprehensive Strategy to Reduce the Incidence of Lead Dislodgment for Cardiac Implantable Electronic Devices	CONSULTANT FEES/HONORARIA - Biosense- Webster, Medtronic Inc., St Jude Medical; RESEARCH/RESEARCH GRANTS - Biosense Webster, Boston
Daoud	Emile	Arrhythmias and Clinical EP: Devices 3	Cryoballoon Versus Radiofrequency Ablation of Atrial Fibrillation: In- Lab Complication Rates at a Large Volume Electrophysiology Center	Scientific CONSULTANT FEES/HONORARIA - Biosense- Webster, Medtronic Inc., St Jude Medical; RESEARCH/RESEARCH GRANTS - Biosense Webster, Boston
Dardari	Zeina	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Coronary Artery Calcium and Incident Hypertension in a Population- Based Cohort: The Multi-Ethnic Study of Atherosclerosis	Scientific Nothing to Disclose
Dardari	Zeina	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium and Estimated Cardiovascular Disease Risk in Five Racial/Ethnic Groups Living in the US: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study	Nothing to Disclose
Darden	Douglas	FIT Clinical Decision Making: Arrhythmias and	and the Multi-Ethnic Study of Atherosclerosis (MESA) Stiff Left Atrial Syndrome Following Multiple Ablations Diagnosed	Nothing to Disclose
Darsaklis	Konstadina	Electrophysiology FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	With Invasive Hemodynamic Exercise Testing latrogenic Diversion of Inferior Vena Cava to Left Atrium After Surgical Closure of Atrial Septal Defect	Nothing to Disclose
Darsaklis	Konstadina	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Right Ventricular Outflow Tract Obstruction Caused by Isolated Sinus of Valsalva Aneurysm	Nothing to Disclose
	1	, , , , , , , , , , , , , , , , , , ,	·	
Darze	Eduardo	Measuring Success in Cardiac Rehabilitation	Stair Step Test and Sitting Rising Chair Test as Predictors of Maximal Oxigen Uptake	Nothing to Disclose
Das	Rajiv	Featured Clinical Research I	MR-INFORM: Stress Perfusion Imaging to Guide the Management	Nothing to Disclose
Das	Rajiv	Interventional Cardiology: Intravascular Physiology and Endothelial Function	of Patients With Stable Coronary Artery Disease Decision Making Using Fractional Flow Reserve Is Associated With Lower Rates of Incomplete Revascularization Compared With	Nothing to Disclose
	<u>1</u>		Angiographic Guided Decision Making Amongst Patients With Nstemi	
Das	Sandeep	Interventional Cardiology: TAVR 3	Role of Hospital Volume in Identifying Low and High-performing Surgical Valve Centers in the United States	Nothing to Disclose
Das	Sandeep	Antithrombotic Therapy in Ischemic Heart Disease	Ticagrelor Adherence After Drug Eluting Stent Placement at a Large Academic Medical Center	Nothing to Disclose
Das	Sandeep	Acute Coronary Syndromes, Diagnosis,	Burden of 30-Day Readmissions in Acute Myocardial Infarction and	Nothing to Disclose
		Management and Outcomes	Heart Failure in the United States: A National Perspective	



Last Name Das	First Name Sandeep	Session Title 02. Acute and Stable Ischemic Heart Disease:	Presentation Title Suggested Reviewer	Disclosures Nothing to Disclose
Dasgupta	Noel	Clinical Team 1 Advances in HCM, PPCM and Other	Differential Effects of Amyloidosis on Right Ventricular Longitudinal	Nothing to Disclose
Dash		Cardiomyopathies Diabetes and Other Issues in Cardiovascular	and Circumferential Fiber Function Insulin Resistance Associates With Adverse Cardiac Remodeling in	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
	Rajesh	Prevention	the Absence of Hypertension in Young South Asians	HealthPals
Dau	Nhu Quyen	Arrhythmias and Clinical EP: Anticoagulation Issues	Evaluation of Apixaban in Patients on Dialysis	Nothing to Disclose
Daubeney	Piers	Advances in HCM, PPCM and Other Cardiomyopathies	Long-Term Outcomes of Childhood Left Ventricular Non- Compaction: Results From a National Population-Based Study	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - DMNoMore
Daubert	James	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Alternating Bundle Branch Block: Clinical Considerations	CONSULTANT FEES/HONORARIA - Biosense-Webster, Bostor Scientific, CardioFocus, gilead, Heart Metabolics, MEDTRONIC, Zol DATA SAFETY MONITORING BOARD - gilead, St. Jude Medical, VytronUS; RESEARCH/RESEARCH GRANTS - ARCA biopharma, Inc., Biosense-Webster, Boston Scientific, gilead, MEDTRONIC, St. Jude Medical
Daubert	James	Arrhythmias and Clinical EP: Sports and Exercise Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Biosense-Webster, Bostor Scientific, CardioFocus, gilead, Heart Metabolics, MEDTRONIC, Zol DATA SAFETY MONITORING BOARD - gilead, St. Jude Medical, VyfronUS; RESEARCH/RESEARCH GRANTS - ARCA biopharma, Inc., Biosense-Webster, Boston Scientific, gilead, MEDTRONIC, St. Jude Medical
Daubert	Melissa	The Art and the Science of Decision Making in Coronary Artery Disease		Nothing to Disclose
Daubert	Melissa	Innovative Use of Echocardiography	Artery Disease The Impact of Rigorous Quality Improvement on 3D Echocardiography Image and Data Quality in an International	Nothing to Disclose
Dauerman	Harold	19. Interventional Cardiology: Complex	Multisite Randomized Trial Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston
Daugherty	John	Patients/Comorbidities Team 1 Understanding Pulmonary Vascular Disease:	Potential Mediators of Right Heart Failure in Pulmonary Arterial	Scientific,MEDTRONIC Nothing to Disclose
Daugherty	Stacie	From Bench to Bedside Feeling the Pressure - Tough Cases in	Hypertension Co-Chair	Nothing to Disclose
Daugherty	Stacie	Hypertension Advances in Lipid Management	Implications of the IMPROVE-IT Trial for Contemporary	Nothing to Disclose
			Cardiovascular Practice: An NCDR [®] Research to Practice (R2P) Project	-
Daugherty Davenport	Stacie Eddie	32. Prevention: Clinical Team 1 Highlighted Original Research: Non Invasive	Suggested Reviewer Screening for Cardiovascular Disease in High Risk Occupations:	Nothing to Disclose Nothing to Disclose
David	Garcia-Dorado	Imaging and the Year in Review Atrial Fibrillation and VT: Unique Populations	The United States Air Force Approach Cardiac Resynchronization Is Associated With Reduction in the Rate	Nothing to Disclose
Davidge	Sandra	and Solutions Congenital Heart Disease: New Diagnostic	of Icd Therapies, While Improves Ventricular Function Cardiovascular Health of Offspring of Diabetic Mothers From the	Nothing to Disclose
		Approaches in Congenital Heart Disease	Fetus Through Late Infancy Stages	-
Davidovich	Daniel	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Effect of Pulmonary Pressure Monitoring (CardioMEMS Heart Failure System, St. Jude Medical) on Hospital Admissions and Emergency Department Visits: A Multicenter Real World Experience	Nothing to Disclose
Davidson	Charles	Interventional Live Case Session IV: Complex Coronary Transmission from St. Vincent	Panelist	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - ROXWOOD; RESEARCH/RESEARCH GRANTS -
Davidson	Charles	Hospital (Indianapolis, IN) The Tricuspid Valve: The New Frontier	Case Presentation: Percutaneous Tricuspid Valve Repair with a Direct Transcatheter Annuloplasty System	Edwards,Mitralign OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - ROXWOOG; RESEARCH/RESEARCH GRANTS -
Davidson	Charles	Innovations in Practice Management and Social Media	Heart Failure Care Transitions: Queuing Theory-Based Cost- Effectiveness Analysis of Outpatient Clinic Capacity Sizing	Edwards,Mitralign OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - ROXWOOG; RESEARCH/RESEARCH GRANTS -
Davidson	Charles	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Screening of Patients With Simple Clinical Parameters Early in Hospitalization Is Highly Sensitive for Detection of Heart Failure Hospitalization	Edwards, Mitralign OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Roxwood; RESEARCH/RESEARCH GRANTS - Edwards, Mitralign
Davidson	Charles	Interventional Cardiology: TAVR 2	Intensity of Statin Therapy and Outcomes After Transcatheter Aortic Valve Replacement	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Roxwood; RESEARCH/RESEARCH GRANTS -
Davidson	Charles	Innovations in Advocacy and Patient Centered Care	Impact of Multidisciplinary Heart Failure Transitional Care Interventions on Disparities in 30-Day Readmission Rates	Edwards,Mitralign OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Roxwood; RESEARCH/RESEARCH GRANTS -
Davidson	Michael	Advances in Cholesterol Measurement and	The Effect of PCSK9 Inhibition on Sterol Absorption in a Cohort of	Edwards,Mitralign CONSULTANT FEES/HONORARIA -
Davidson	Michael	Management Traditional and Novel Factors Used to Assess	Real World Patients Lower On-Treatment Low-Density Lipoprotein Cholesterol Is	Amgen,AstraZeneca,Merck & Do., Inc.,Sanofi-Aventis CONSULTANT FEES/HONORARIA -
		the Risk of, and Used for the Treatment of, Coronary Artery Disease	Associated With Lower Cardiovascular Risk in Very High Risk Patients With Atherosclerotic Cardiovascular Disease: Analyses From the ODYSSEY Trials	Amgen,AstraZeneca,Merck & Dec., Inc.,Sanofi-Aventis
Davidson	Michael	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Lower On-Treatment Low-Density Lipoprotein Cholesterol Is Associated With Lower Cardiovascular Risk in Women: Analyses From the ODYSSEY Trials of Alirocumab Versus Control	CONSULTANT FEES/HONORARIA - Amgen,AstraZeneca,Merck & Dec., Inc.,Sanofi-Aventis
Davidson	Michael	32. Prevention: Clinical Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen, AstraZeneca, Merck & Damp; Co., Inc., Sanofi-Aventis
Davidson	William	Which Test Is Best for Pain in the Chest?	A False-Positive Stress Echocardiogram Is NOT the Same as a Negative Result	Nothing to Disclose
Davies	John	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International	CONSULTANT FEES/HONORARIA - Boston Scientific
Davies	Justin	Late-Breaking Clinical Trials: Interventional	Multicentre iFR GRADIENT Registry Primary Results of DEFINE-FLAIR: A Multi-Centre, Prospective, International, Randomized, Blinded Comparison of Clinical Outcomes and Cost Efficiencies of iFR and FFR Decision-Making	CONSULTANT FEES/HONORARIA - MEDTRONIC, Volcano Corp.; OTHER - Volcano Corp.; RESEARCH/RESEARCH GRANTS - MEDTRONIC, Volcano Corp.
Davies	Justin	Late-Breaking Clinical Trials: Deep Dive I	for Physiological Guided Coronary Revascularization Primary Results of DEFINE-FLAIR: A Multi-Centre, Prospective, International, Randomized, Blinded Comparison of Clinical Outcomes and Cost Efficiencies of iFR and FFR Decision-Making	CONSULTANT FEES/HONORARIA - MEDTRONIC, Volcano Corp.; OTHER - Volcano Corp.; RESEARCH/RESEARCH GRANTS - MEDTRONIC, Volcano Corp.
Davies	Justin	Maintenance of Clinical Competencies in Invasive Coronary Imaging and Coronary Physiology	for Physiological Guided Coronary Revascularization IFR	CONSULTANT FEES/HONORARIA - MEDTRONIC, Volcano Corp.; OTHER - Volcano Corp.; RESEARCH/RESEARCH CRANTS MEDTRONIC Volcano Corp.
Davies	Justin	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Instantaneous Wave-Free Ratio Scout Pullback (IFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International	GRANTS - MEDTRONIC, Volcano Corp. CONSULTANT FEES/HONORARIA - MEDTRONIC, Volcano Corp.; OTHER - Volcano Corp.; RESEARCH/RESEARCH GRANTS - MEDTRONIC, Volcano Corp.
Davies	Justin	23. Interventional Cardiology: IVUS and	Multicentre iFR GRADIENT Registry Suggested Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC, Volcano
Davies	Michael	Intravascular Physiology Team 1 The Intersection of Diabetes and ASCVD	Effects of Canagliflozin Versus Glimepiride on Inflammatory	Corp.; OTHER - Volcano Corp.; RESEARCH/RESEARCH GRANTS - MEDTRONIC, Volcano Corp. SALARY - Janssen Pharmaceuticals, Inc
			Biomarkers and Chemokines in Patients With Type 2 Diabetes Mellitus	



Contract of the contract of th				l l
Last Name Davies	First Name Rhian	Session Title Updates on Pulmonary Embolism	Presentation Title Does Thrombolysis Reduce Mortality in Patients With Intermediate	Disclosures Nothing to Disclose
Davies	Ryan	Management in 2017 Five Controversies in Single Ventricle	Risk Pulmonary Embolism? A Trial Sequential Analysis Heart Transplantation is a Realistic Option for Teens and Adults with	Nothing to Disclose
	-	Management	Falling Fontan Left Atrium Undifferentiated Pleomorphic Sarcoma Mimicking Septal	-
Davila Flores	Pedro Gerardo	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Asymmetric Hypertrophic Cardiomiopathy	-
Davila-Roman	Victor	Late-Breaking Clinical Trials	GIFT of Warfarin: Benefit of Pharmacogenetic Dosing	CONSULTANT FEES/HONORARIA - Boston Scientific,St. Jude Medical,ValveXchange
Davis	Andrew	Advances in HCM, PPCM and Other Cardiomyopathies	Long-Term Outcomes of Childhood Left Ventricular Non- Compaction: Results From a National Population-Based Study	OTHER - MEDTRONIC,MEDTRONIC,St Jude Medical
Davis	Barry	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Toward Identifying Personalized Prognosis in Hypertension: Variation in Early Responses in the Antihypertensive and Lipid-	DATA SAFETY MONITORING BOARD - Amgen,Amgen Inc.,Merck,Regeneron; OTHER - LifeTech
Davis	Barry	New Insights Into Prediction and Treatment of	Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) The U-Shaped Relationship of Body Mass Index With All-Cause	DATA SAFETY MONITORING BOARD - Amgen, Amgen
Davis	John	Hypertension Vascular Access and Hemostasis Issues	Mortality at Eight Years in the ALLHAT TAVR Using Transcarotid Vascular Access: In-Hospital and	Inc.,Merck,Regeneron; OTHER - LifeTech Nothing to Disclose
Davis	Margot	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Intermediate Term Outcomes Hemophagocytic Lymphohistiocytosis Associated With Implantation of Ventricular Assist Devices and Outcomes Following Subsequent Orthotropic Heart Transplantation (OHT)	Nothing to Disclose
Davis	Melinda	Advances in HCM, PPCM and Other	Breastfeeding Is Not Associated With Worse Outcomes in	Nothing to Disclose
Davlouros	P.	Cardiomyopathies Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Peripartum Cardiomyopathy Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study	Nothing to Disclose
Dawkins	Keith	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Three-Year Outcomes in 'Real-World' Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus U.S. Post-Approval Study (PE- Plus PAS)	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation; SALARY - Boston Scientific Corporation
Dawkins	Keith	Interventional Cardiology: TAVR 3	Does Balloon Predilatation Influence Outcome With the Lotus Valve: 30-Day Results From the RESPOND Study	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation: SALARY - Boston Scientific Corporation
Dawkins	Keith	Refining PCI Technique and Outcomes	Three-Year Results From the EVOLVE II Randomized Trial: Late	CONSULTANT FEES/HONORARIA - Boston Scientific
			Clinical Outcomes With Bioresorbable Compared to Permanent Polymer Everolimus-Eluting	Corporation; SALARY - Boston Scientific Corporation
Dawn	Buddhadeb	Interventional Cardiology: TAVR 1	Safety and Efficacy of Using Pressure Wire With Dobutamin Infusion in Themoynamic Assessment of Low Flow Low Gradient Aortic Stenosis	Nothing to Disclose
Dawn	Buddhadeb	Interventional Cardiology: Translation and Pre- Clinical Research	Boron Based Hgf Memetic Molecule Has Cardioprotective Role Against Ischemia-Reperfusion Injury	Nothing to Disclose
Dawn	Buddhadeb	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Timely Use of Right Heart Catheterization Is Associated With Reduced In-Hospital Mortality in Patients With Congestive Heart Failure: Insight From the United States National Inpatient Sample Database	Nothing to Disclose
Dawn	Buddhadeb	Updates on Risk Factors for Cardiovascular Disease	Prevalence of Abnormal Ankle Brachial Index in Obese and Non- Obese Subjects, and Association of Abnormal Ankle Brachial Index With All-Cause and Cardiovascular Mortality in These Groups: Results From National Health and Nutrition Examination Survey 1999-2000	Nothing to Disclose
Dawn	Buddhadeb	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	CHADS2 Score Predicts Outcomes of Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation	Nothing to Disclose
Dawn	Buddhadeb	Interventional Cardiology: PCI and TAVR in Complex Patients	Hemodynamic Assessment of Low Flow, Low Gradient Severe Aortic Stenosis With Preserved EF Using a Pressure Wire	Nothing to Disclose
Dawn	Buddhadeb	Interventional Cardiology: Structural Heart Disease	The Impact of Transaortic Gradient and Transaortic Flow on the Discrepancy Between Echocardiographic and Cardiac Cardiac Cardiac Cardiac Cardiac Cardiac Cardiac Election Fraction	Nothing to Disclose
Dawn	Buddhadeb	Diabetes and Other Issues in Cardiovascular Prevention	Association of Ankle Brachial Index and Hemoglobin A1c With All- Cause and Cardiovascular Mortality: Results From the National Health and Nutrition Examination Survey 1999 to 2000	Nothing to Disclose
Dawn	Buddhadeb	Advanced Therapies = Advanced Trouble: VAD and Transplant Challenges	Independent Association of Symptomatic Peripheral Arterial Disease for Adverse Outcomes, Poor Graft Survival and Length of Hospital Stay Following Heart Transplantation: An Analysis of 22,820 Heart Transplants From the UNOS Database	Nothing to Disclose
Day	John	Controversies in Arrhythmia Management: Joint Symposium of the Heart Rhythm Society and the American College of Cardiology		Nothing to Disclose
Day	John	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Long Term Outcomes and Risk Stratification in Atrial Fibrillation Patients With Low Risk Chads ₂ ≤1 With Antithrombotic Therapy	Nothing to Disclose
Day	Sharlene	Featured Clinical Research I	Testing Safety and Efficacy: The Randomized Exploratory Study of Exercise Training in Hypertrophic Cardiomyopathy (RESET-HCM)	Nothing to Disclose
Day	Sharlene	The Athlete with Heart Disease: A Case Based	Cardiomyopathy in Athletes	Nothing to Disclose
De Backer	Ole	Approach Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve	Nothing to Disclose
De Barros E Silva	Pedro	International CV Centers of Excellence: Leveraging the NCDR for Achieving High	Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis How We Built a Center of Excellence? - The Totalcor Experience	Nothing to Disclose
De Barros E. Silva	Pedro	Quality Care Innovation in Practice Management, Advocacy,	Improvement in Quality Indicators Using NCDR® Registries:	Nothing to Disclose
De Barros E. Silva	Pedro	and Education Which Test Is Best for Pain in the Chest?	First International Experience Coronary Computed Tomography Angiography in the Emergency Room: Rapid Exclusion of Coronary Artery Disease and the Fast Diagnosis of Acute Myocarditis Using Late Enhancement by	Nothing to Disclose
de Boer	lan	Innovations in Cardiovascular Risk Assessment	Computed Tomography Vitamin D Levels and Autoantibodies in the Multi-Ethnic Study of	Nothing to Disclose
De Bruyne	Bernard	and Reduction Unusual Presentations of ACS	Atherosclerosis (MESA): Implications for Cardiovascular Disease Incidence and Predictors of Lesion Specific Ischemia by FFR _{CT} : Learnings From the International ADVANCE	Nothing to Disclose
De Caterina	Raffaele	Late-Breaking Clinical Trials	Registry Digoxin and Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, Daiichi Sankyo, Eli Lilly and Company, fees for lecturing on apixaban from Bristol Myers-Squibb and Pfizer, and has been an investigator in the ARISTOTLE trial , Novartis Corporation; RESEARCH/IRESEARCH GRANTS - Roche
De Caterina	Raffaele	Challenging the Standard of Care: Emerging Concepts in VTE Treatment and Prevention	Triple Therapy for Patients Who Require Anticoagulation and Dual Antiplatelet Therapy	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, Dalichi Sankyo, Eli Lilly and Company, fees for lecturing on apixaban from Bristol Myers-Squibb and Pfizer, and has been an investigator in the ARISTOTLE trial , Novartis Corporation; RESEARCH/IRESEARCH GRANTS - Roche

and a				
Last Name De Ciccio	First Name Ignacio	Session Title Atrial Fibrillation and VT: Unique Populations and Solutions	Presentation Title A Retrospective Study of the Effect of Colchicine Administration Timing on the Incidence of Post-Operative Atrial Fibrillation After a	Disclosures Nothing to Disclose
De Cicco	Ignacio	The Challenges of Outcome Prediction in	Non Transplant Cardiac Surgery Gender-Based Outcomes in Diabetics Undergoing Transcatheter	Nothing to Disclose
de Faria	Eliana	Valvular Heart Disease Advances in Lipid Management	Aortic Valve Replacement Impact of Statin Therapy on Collagen Turnover and Left Ventricle Function After ST-Elevation Myocardial Infarction: A Randomized Clinical Trial	Nothing to Disclose
De Ferrari	Gaetano	Late-Breaking Clinical Trials	Digoxin and Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?	CONSULTANT FEES/HONORARIA - Amgen,Boston Scientific,Menarini,Merck
De Ferrari	Gaetano	Advances in Cholesterol Measurement and Management	Frequency and Predictors of Cholesterol Goal Attainment in Patients With Coronary Heart Disease: Results From the Dyslipidemia International Study II	CONSULTANT FEES/HONORARIA - Amgen,Boston Scientific,Menarini,Merck
De Ferrari	Gaetano	Advances in Cholesterol Measurement and Management	Dysuppenna mineranoria subury Low LDL. Cholesterol Target Value Attainment at the Time of Acute Coronary Syndrome (ACS) and Even 4 Months After the Acute Event Due to Lack of Adjustment in Lipid Lowering Treatment: Results From the Dyslipidemia International Study II ACS	CONSULTANT FEES/HONORARIA - Amgen,Boston Scientific,Menarini,Merck
de Groot	Joris	Special Hearts: The Challenge of Heart Failure in Congenital Heart Disease	SCD Prevention and CRT in ACHD: Do the Guidelines Apply?	CONSULTANT FEES/HONORARIA - AtriCure,atricure Inc,Daiichi Sankyo,Daiichi Sankyo
De Jesus	Tais	New Technologies in Echocardiography	Novel Echocardiographic Measurements Detect Increased Myocardial Stiffness in Patients With Severe Organic Mitral Regurgitation	Nothing to Disclose
De La Cruz Luque	Celso	Advances in HCM, PPCM and Other Cardiomyopathies	Extended Remission and Late Re-Decompensation of Dilated Cardiomyopathy Associated With a Novel Ribonucleic Acid Binding Motif Protein 20 (RBM20) Mutation	Nothing to Disclose
de la Torre Hernandez	Jose	Timely Topics in Acute Coronary Syndromes	A New Prognosis Score to Predict Mortality in Patients Over 75 Years Old Undergoing Primary Angioplasty in Cardiogenic Shock	CONSULTANT FEES/HONORARIA - Boston Sci, ABBOTT Vascular, Biotronik, Lilly, Cordynamic, Cordis
de la Torre-Hernandez	Jose	Timely Topics in Acute Coronary Syndromes	Time to Treatment With Melatonin and Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction: Insights From the MARIA (Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty) Trial	CONSULTANT FEES/HONORARIA - Boston Sci, ABBOTT Vascular, Biotronik, Lilly, Cordynamic, Cordis
De Larochellière	Robert	Interventional Cardiology: TAVR 4	Clinical Study of the Impact of Preexisting Patient-Prosthesis Mismatch on Valve-in-Valve Performance	Nothing to Disclose
de Lemos	James	Making Progress in Understanding Heart Failure	Impact of Malignant Left Ventricular Function on Incident Heart Failure With Reduced Versus Preserved Ejection Fraction: The MESA Study	CONSULTANT FEES/HONORARIA - Abbott Diagnostics; DATA SAFETY MONITORING BOARD - Novo Nordisc; OTHER - Amgen, Cardiorentis, Radiometer, Siemen's Diagnostics; RESEARCH/RESEARCH GRANTS - Abbott Diagnostics, Roche Diagnostics
de Lemos	James	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Relationship of Biomarkers of Oxidized Lipoproteins to Ethnicity, Subclinical Atherosclerosis and Cardiovascular Events Over a 10.5 Year Follow-Up in the Dallas Heart Study	CONSULTANT FEES/HONORARIA - Abbott Diagnostics; DATA SAFETY MONITORING BOARD - Novo Nordisc; OTHER Amgen, Cardiorentis, Radiometer, Siemen's Diagnostics; RESEARCH/RESEARCH GRANTS - Abbott Diagnostics, Roche Diagnostics
de Lemos	James	Innovations in Cardiovascular Risk Assessment and Reduction	Impact of Malignant Left Ventricular Hypertrophy on Incident Asymptomatic Left Ventricular Dysfunction: The MESA Study	CONSULTANT FEES/HONORARIA - Abbott Diagnostics; DATA SAFETY MONITORING BOARD - Novo Nordisc; OTHER - Amgen, Cardiorentis, Radiometer, Siemen's Diagnostics; RESEARCH/IRESEARCH GRANTS - Abbott Diagnostics, Roche Diagnostics
de Lemos	James	Interventional Cardiology: TAVR 3	Role of Hospital Volume in Identifying Low and High-performing Surgical Valve Centers in the United States	CONSULTANT FEES/HONORARIA - Abbott Diagnostics; DATA SAFETY MONITORING BOARD - Novo Nordisc; OTHER - Amgen, Cardiorentis, Radiometer, Siemen's Diagnostics; RESEARCH/RESEARCH GRANTS - Abbott Diagnostics, Roche Diagnostics
de Lemos	James	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Burden of 30-Day Readmissions in Acute Myocardial Infarction and Heart Failure in the United States: A National Perspective	CONSULTANT FEES/HONORARIA. Abbott Diagnostics; DATA SAFETY MONITORING BOARD - Novo Nordisc; OTHER - Amgen, Cardiorentis, Radiometer, Siemen's Diagnostics; RESEARCH/RESEARCH GRANTS - Abbott Diagnostics, Roche Diagnostics
de Lemos	James	Innovations in Advocacy and Patient Centered Care	Racial and Ethnic Differences in Cardiovascular Biomarkers	CONSULTANT FEES/HONORARIA - Abbott Diagnostics; DATA SAFETY MONITORING BOARD - Novo Nordisc; OTHER - Amgen, Cardiorentis, Radiometer, Siemen's Diagnostics; RESEARCH/RESEARCH GRANTS - Abbott Diagnostics, Roche Diagnostics
de Los Rios Ibarra	Manuel	Updates on Risk Factors for Cardiovascular Disease	Association of Anxious and Depressive Symptomatology With Cardiovascular Disease Among Patients From Different States in Mexico: REDECAR Study	Nothing to Disclose
De Luca	Giuseppe	Interventional Cardiology: TAVR 2	Dual Antiplatelet Therapy Versus Single Antiplatelet Regimen With or Without Anticoagulation in Transcatheter Aortic Valve Replacement: Indirect Comparison and Meta-Analysis	Nothing to Disclose
De Marchena	Eduardo	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Comparison of False Versus True ST Elevation Myocardial Infarction Activation Rates in Patients Having Pre-Activation Point of	CONSULTANT FEES/HONORARIA - Aegis; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - tendyne medical Inc.
De Marchena	Eduardo	Unusual Presentations of ACS	Care Troponin Levels Trends Associated With False ST-Elevation Myocardial Infarction Activation	CONSULTANT FEES/HONORARIA - Aegis; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - tendyne medical Inc.
De Marco	Teresa	Deciphering Pulmonary Hypertension Due to Left Heart Disease: Have Hope Oh Ye Who Enter	Co-Chair	INTERESTRANT FEESTHONORARIA - Acteliny ille inequal into CONSULTANT FEESTHONORARIA - Acteling, IBELLEROPHON Cardikinetix/Harvard Clinical Research Institute, gilead, St. Jude, Theranova; RESEARCH/RESEARCH GRANTS - Lung Biotechnology/Pizer, REATA
De Metrio	Monica	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Renal Replacement Therapy in Patients With Acute Myocardial Infarction: Rate of Use, Clinical Predictors and Relationship With In-	Nothing to Disclose
De Metrio	Monica	Post-CAD/MI: Making Tough Predictions About the Future	Hospital Mortality A New Score for Risk Stratification of Patients With Acute Myocardial Infarction Based on the PEGASUS-TIMI 54 Criteria	Nothing to Disclose
De Michelis	Nathalie	28. Non Invasive Imaging: Echo Team 5	Suggested Reviewer	Nothing to Disclose
De Potter	Tom	Non Invasive Imaging: Expanding Clinical Applications	Left Atrial Appendage Occlusion Facilitated by Three Dimensional Rotational Angiography Alone Is Safe and Anatomically Superior to Trasoesophageal Echocardiography	Nothing to Disclose
De Schutter De Schutter	Alban Alban	Measuring Success in Cardiac Rehabilitation FIT Clinical Decision Making: Heart Failure and	Search for the Super-Responder: Progressive Increases in Fitness and an Association With Lower Mortality Use of TandemHeart as a Bridge to Surgery in a Patient With	Nothing to Disclose Nothing to Disclose
		Pulmonary Hypertension	Combined Obstructive and Cardiogenic Shock Due to Mechanical Mitral Valve Thrombosis	, and the second
De Schutter	Alban	Obesity Management in 2017: Weighing the Issues	Fitness and the Obesity Paradox in Cardiac Rehabilitation: How Does Weight Loss Factor in?	Nothing to Disclose
De Vecchi	Federica	Emerging Developments in HFpEF and Arryhthmias	Prognostic Role of Ventricular-Arterial Coupling in Patients With Left Ventricular Dysfunction Submitted to Cardiac Resynchronization Therapy	-
de Waha	Suzanne	Non Invasive Imaging: MR Characterization and Function	Prognostic Value and Determinants of Left Atrial Function Assessed by Cardiac Magnetic Resonance in St-Segment Elevation Myocardial Infarction	Nothing to Disclose
de Waha	Suzanne	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Antecedent Hypertension and Myocardial Injury in Patients With Reperfused ST-Elevation Myocardial Infarction	Nothing to Disclose
de Waha	Suzanne	Novel Developments in Acute Coronary Syndromes	Outcome of Elderly Patients Undergoing Extracorporeal Life Support in Refractory Cardiogenic Shock	Nothing to Disclose

de Winter Ro Deal Ba Dean Ste Dearani Jo: Dearani Jo: DeBacker Ole Dec G. Dec G. Dec G.	arbara arbara teven beseph ceph ceph de de de de de de de de de d	Coronary Intervention: Drug Eluting Stent and Scaffolds Finding Out What Works in Pediatric and Congenital Heart Disease Vasculo-Oncology: What You Need to Know About Vascular and Thrombotic Complications of Cancer and Cancer Therapeutics Adult Patients With Congenital Heart Disease: How Do They Compare? FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster)	Presentation Title Early, Late and Very Late Incidence of Bioresorbable Scaffold Thrombosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials and Observational Registries Prevalence and Risk Factors Associated With Chronic Kidney Disease in Patients With Single Ventricle Congenital Heart Disease After Fontan Palliation Management of Edema in the Patient with Cancer Exercise Capacity After Repair of Ebstein Anomaly in Adults: The Cone Era Delivery and Management of Complete Ectopia Cordis: A Multidisciplinary Approach Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries Panelist Systolic Dysfunction Early Diagnosis and Therapeutic Advances. Neprilysin inhibitors and Follow-up Clinical / Therapeutic Approaches to Three Specific Cardiomiopathies: Acute/Subacute Myocarditis, AL/TTRAmyloid,	Disclosures Nothing to Disclose OTHER - Tactile Systems OTHER - Tactile Systems Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Riverside partners, LLC CONSULTANT FEES/HONORARIA - Riverside partners, LLC
Deal Ba Dean Ste Dearani Jo: Dearani Jo: DeBacker Ole Dec G. Dec G. Dec G.	arbara teven oseph oseph le . William . William . William . William	Scaffolds Finding Out What Works in Pediatric and Congenital Heart Disease Vasculo-Oncology: What You Need to Know About Vascular and Thrombotic Complications of Cancer and Cancer Therapeutics Adult Patients With Congenital Heart Disease: How Do They Compare? FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster)	Thrombosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials and Observational Registries Prevalence and Risk Factors Associated With Chronic Kidney Disease in Patients With Single Ventricle Congenital Heart Disease After Fontan Palliation Management of Edema in the Patient with Cancer Exercise Capacity After Repair of Ebstein Anomaly in Adults: The Cone Era Delivery and Management of Complete Ectopia Cordis: A Multidisciplinary Approach Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries Panelist Systolic Dysfunction Early Diagnosis and Therapeutic Advances. Neprilysin inhibitors and Follow-up Clinical / Therapeutic Approaches to Three Specific	Nothing to Disclose OTHER - Tactile Systems Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Riverside partners, LLC CONSULTANT FEES/HONORARIA - Riverside partners, LLC
Dean Ste Dearani Jo: Dearani Jo: DeBacker Oli Dec G. Dec G. Dec G. Dec G. Dec G. Dec G.	teven Dseph Dseph Ie William William William William William	Congenital Heart Disease Vasculo-Oncology: What You Need to Know About Vascular and Thrombotic Complications of Cancer and Cancer Therapeutics Adult Patients With Congenital Heart Disease: How Do They Compare? FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster)	Disease in Patients With Single Ventricle Congenital Heart Disease After Fontan Palliation Management of Edema in the Patient with Cancer Exercise Capacity After Repair of Ebstein Anomaly in Adults: The Cone Era Delivery and Management of Complete Ectopia Cordis: A Multidisciplinary Approach Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries Panelist Systolic Dysfunction Early Diagnosis and Therapeutic Advances. Neprilysin Inhibitors and Follow-up Clinical / Therapeutic Approaches to Three Specific	OTHER - Tactile Systems Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Riverside partners, LLC CONSULTANT FEES/HONORARIA - Riverside partners, LLC
Dearani Jo: Dearani Jo: DeBacker Oli Dec G. Dec G. Dec G. Dec G. Dec G.	oseph seph le . William . William . William	About Vascular and Thrombotic Complications of Cancer and Cancer Therapeutics Adult Patients With Congenital Heart Disease: How Do They Compare? FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster)	Exercise Capacity After Repair of Ebstein Anomaly in Adults: The Cone Era Delivery and Management of Complete Ectopia Cordis: A Multidisciplinary Approach Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries Panelist Systolic Dysfunction Early Diagnosis and Therapeutic Advances. Neprilysin Inhibitors and Follow-up Clinical / Therapeutic Approaches to Three Specific	Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Riverside partners, LLC CONSULTANT FEES/HONORARIA - Riverside partners, LLC
Dearani Jo: DeBacker Old Dec G. Dec G. Dec G. Dec G. Dec G.	oseph le . William . William . William . William	How Do They Compare? FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster)	Cone Era Delivery and Management of Complete Ectopia Cordis: A Multidisciplinary Approach Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries Panelist Systolic Dysfunction Early Diagnosis and Therapeutic Advances. Neprilysin inhibitors and Follow-up Clinical / Therapeutic Approaches to Three Specific	Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Riverside partners, LLC CONSULTANT FEES/HONORARIA - Riverside partners, LLC
DeBacker Old Dec G. Dec G. Dec G. Dec G. Dec G.	seph le . William . William . William . William	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster)	Delivery and Management of Complete Ectopia Cordis: A Multidisciplinary Approach Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries Panelist Systolic Dysfunction Early Diagnosis and Therapeutic Advances. Neprilysin Inhibitors and Follow-up Clinical / Therapeutic Approaches to Three Specific	Nothing to Disclose CONSULTANT FEES/HONORARIA - Riverside partners, LLC CONSULTANT FEES/HONORARIA - Riverside partners, LLC
Dec G. Dec G. Dec G. Dec G. Dec G.	. William . William . William . William . William	England Journal of Medicine Late-Breaking Clinical Trials Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster)	Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries Panelist Systolic Dysfunction Early Diagnosis and Therapeutic Advances. Neprilysin inhibitors and Follow-up Clinical / Therapeutic Approaches to Three Specific	CONSULTANT FEES/HONORARIA - Riverside partners, LLC CONSULTANT FEES/HONORARIA - Riverside partners, LLC
Dec G. Dec G.	. William . William . William . William . William . William	Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster)	Panelist Systolic Dysfunction Early Diagnosis and Therapeutic Advances. Neprilysin inhibitors and Follow-up Clinical / Therapeutic Approaches toThree Specific	CONSULTANT FEES/HONORARIA - Riverside partners, LLC
Dec G.	. William . William . William	Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster)	Neprilysin inhibitors and Follow-up Clinical / Therapeutic Approaches toThree Specific	•
Dec G.	. William . William . William	Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster)		CONCULTANT EEEC/HONODADIA Diverside andrew 110
	. William . William		Non-Compaction	CONSULTANT FEES/HONORARIA - Riverside partners, LLC
Dec G.	. William	Can You See Me Now? Sensors For	Co-Chair	CONSULTANT FEES/HONORARIA - Riverside partners, LLC
		Monitoring Heart Failure Recognition of Specific Etiologies and Phenotypes in Heart Failure: Time for	Greater Precision: The MOGE(S) Classification for Phenotype- Genotype of Cardiomyopathy	CONSULTANT FEES/HONORARIA - Riverside partners, LLC
Decker Ca		Precision	Reliability and Responsiveness of Seattle Angina Questionnaire in	Nothing to Disclose
	İ	the Risk of, and Used for the Treatment of, Coronary Artery Disease	Women With Coronary Artery Disease	-
		ű	Impact of Balloon Pre-Dilatation on Hemodynamics and Clinical Outcomes After Transcatheter Aortic Valve Replacement With the Self-Expanding CoreValve Prosthesis	Nothing to Disclose
Deedwania Pra		Failure	Orthopnea or Paroxysmal Nocturnal Dyspnea in Older Adults Without Prevalent Heart Failure Is a Predictor, but Not an Independent Risk Factor for Incident Heart Failure: Insights From the Cardiovascular Health Study	CONSULTANT FEES/HONORARIA - Amgen,Amgen,Pfizer Inc.
Deedwania Pra		Prevent Readmissions	Among Older Heart Failure (HF) Patients With In-Hospital Acute Kidney Injury (AKI), an Improvement in Kidney Function Is Associated With a Higher Risk of Post-Discharge Mortality but Not Readmission	CONSULTANT FEES/HONORARIA - Amgen,Amgen,Pfizer Inc.
			Heart Failure Hospitalization (HFH) Despite Digoxin Therapy Versus No HFH Despite Placebo in the Digitalis Investigation Group (DIG) Trial: Insights Into Risk Factors for HFH in HF and Reduced Ejection Fraction (HFrEF)	CONSULTANT FEES/HONORARIA - Amgen,Amgen,Pfizer Inc.
Deedwania Pra		Failure Is Just a Revolving Door	Clinical Effectiveness of Spironolactone in Hospitalized Older Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or Equal to 30 mL/min/1.73 m ²) Patients With Heart Failure	CONSULTANT FEES/HONORARIA - Amgen,Amgen,Pfizer Inc.
Deedwania Pra		Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Chronic Alpha Blocker Use and Outcomes in Older Male Medicare Beneficiaries Hospitalized for Heart Failure	CONSULTANT FEES/HONORARIA - Amgen,Amgen,Pfizer Inc.
Deedwania Pra	rakash	Breakthrough Therapies: Your Role in Protecting the Heart of Your Patients with	Preventing ASCVD in Diabetes: Are These New Drugs for Real?	CONSULTANT FEES/HONORARIA - Amgen,Amgen,Pfizer Inc.
Deedwania Pra	rakash		Pragmatic Conversations: Your Role in Protecting the Heart - Panel Debate	CONSULTANT FEES/HONORARIA - Amgen,Amgen,Pfizer Inc.
Deedwania Pra	rakash	Diabetes Why Can't We Be Friends? Controversies in Heart Failure Management	Adverse Outcomes With Use of Hydralazine and Nitrate Combination Therapy in Hospitalized Older Non-Black Patients With	CONSULTANT FEES/HONORARIA - Amgen,Amgen,Pfizer Inc.
Deering Th	Į,	Controversies in Arrhythmia Management: Joint Symposium of the Heart Rhythm Society and the American College of Cardiology	Heart Failure and Reduced Ejection Fraction (HFrEF) Co-Chair	CONSULTANT FEES/HONORARIA - MEDTRONIC, Zywie; DATA SAFETY MONITORING BOARD - St. Jude Medical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCI/PAL - Corflatrix, SPEAKER'S BUREAU - Society for Cardiovascular Patient Care
Defaria Yeh Do			A Pragmatic Approach to Selecting the Right Professional Practice after Fellowship	Nothing to Disclose
Defaria Yeh Do		The Consequences of Sex: Women and	Creating a Cardio-Obstetrics Team	Nothing to Disclose
Defaria Yeh Do	oreen	Pregnancy Across the Spectrum Core Curriculum: Rhythm and the Blues: Still Young at Heart	Managing the Failing Heart in the Blue Patient	Nothing to Disclose
DeFilippi Ch	hristopher	Young Investigator Awards Competition: Clinical Investigations	Chair	CONSULTANT FEES/HONORARIA - Metanomics,Ortho Diagnostics,Radiometer,Roche Diagnostics,Siemens,Thermo- Fisher; OTHER - UpToDate; RESEARCH/RESEARCH GRANTS - Roche Diagnostics
DeFilippi Ch		Failure	Impact of Malignant Left Ventricular Function on Incident Heart Failure With Reduced Versus Preserved Ejection Fraction: The MESA Study	CONSULTANT FEES/HONORARIA - Metanomics, Ortho Diagnostics, Radiometer, Roche Diagnostics, Siemens, Thermo- Fisher; OTHER - UpToDate; RESEARCH/RESEARCH GRANTS - Roche Diagnostics
DeFilippi Ch		Making Progress in Understanding Heart Failure	Impact of Malignant Left Ventricular Function on Incident Heart Failure in Older Adults: The MESA Study	CONSULTANT FEES/HONORARIA - Metanomics, Ortho Diagnostics, Radiometer, Roche Diagnostics, Siemens, Thermo- Fisher, OTHER - UpToDate; RESEARCH/RESEARCH GRANTS - Roche Diagnostics
DeFilippi Ch		Innovations in Cardiovascular Risk Assessment and Reduction	Impact of Malignant Left Ventricular Hypertrophy on Incident Asymptomatic Left Ventricular Dysfunction: The MESA Study	NOCITE DIAGNOSCIE CONSULTANT FEES/HONORARIA - Metanomics, Ortho Diagnostics, Radiometer, Roche Diagnostics, Siemens, Thermo- Fisher, O'HER - UpToDate; RESEARCH/RESEARCH GRANTS - Roche Diagnostics
DeFranco An		Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	Nothing to Disclose
DeFranco An	nthony	Timely Topics in Acute Coronary Syndromes	Results From the PROMETHED Study Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes	Nothing to Disclose
Deftereos Sp		Failure Is Just a Revolving Door	Clinical Effectiveness of Spironolactone in Hospitalized Older Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or Equal to 30 mL/min/1.73 m ²) Patients With Heart Failure	Nothing to Disclose
deGoma En	mil	32. Prevention: Clinical Team 3	Suggested Reviewer	SALARY - Akebia Therapeutics



and a				
Last Name Deharo	First Name Pierre	Session Title Considerations in Antiplatelet Therapy and in	Presentation Title Bivalirudin Versus Heparin in Primary PCI: Clinical Outcomes and	Disclosures Nothing to Disclose
Dehghani	Payam	ACS Considerations in Antiplatelet Therapy and in	Cost Analysis From a Large Retrospective Cohort Effects of Ticagrelor Versus Clopidogrel in Fibrinolytic-Treated	Nothing to Disclose
		ACS	STEMI Patients Undergoing Early PCI	-
Dehmer	Gregory	Assuring Quality in the Cath Lab: Documentation, Appropriate Use, Peer Review, and Public Reporting	Co-Chair	Nothing to Disclose
Dehmer	Gregory	Public Reporting and NCDR: The Decision to Report Your Data Before the Feds Decide	Co-Chair	Nothing to Disclose
Dehmer	Gregory	Public Reporting and NCDR: The Decision to Report Your Data Before the Feds Decide	Transparency: the ins and outs of your data	Nothing to Disclose
Dehmer	Gregory	Training for Interventional Procedures: Who Should Do What, Where, When, How, and	When: Putting AUC into Practice	Nothing to Disclose
Dehmer	Gregory	Why 02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Deitelzweig	Steven	Clinical Team 6 Atrial Fibrillation, Anticoagulation and Novel	Real World Evaluation of Major Bleeding Risk and Costs for All	CONSULTANT FEES/HONORARIA - Jannsen,pfizer pharma;
		Device Therapies	Causes and Bleeding-Related Health Services Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Apixaban or Warfarin	RESEARCH/RESEARCH GRANTS - Bristol Myers Squibb,Portola
deKemp	Robert	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	In the Presence of Significant Epicardial Coronary Disease, Diabetes Mellitus Is Further Associated With Reduced Myocardial Flow Reserve	CONSULTANT FEES/HONORARIA - Jubilant DRAXimage; OTHER - INVIA Medical Solutions; RESEARCH/RESEARCH GRANTS - GE Healthcare
Del Castillo	Maygen	FIT Clinical Decision Making: Non-Invasive	Cerebral Embolization From Caseous Mitral Annular Calcification	Nothing to Disclose
Del Core	Michael	Imaging and Valvular Heart Disease Arrhythmias and Clinical EP: Ventricular	Therapeutic Hypothermia for In-Hospital Cardiac Arrest: A Meta-	Nothing to Disclose
Del Franco	Annamaria	Tachycardia Refining PCI Technique and Outcomes	Analysis Comparison of Verapamil Versus Heparin Therapy on Procedural	Nothing to Disclose
			Success During Transradial Coronary Procedures (Vermut Study)	1
del Nido	Pedro	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Aortic Valve Repair in the Pediatric Population: Midterm Outcomes Comparing Leaflet Repair Using Autologous Pericardium Versus Porcine Intestinal Submucosa (CorMatrix [®])	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CorAux Technolgies, Nido Surgical
del Nido	Pedro	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Validation of Technical Performance Score for Long-Term Outcomes in Congenital Heart Surgery: 10 Year Follow-Up Data	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CorAux Technolgies, Nido Surgical
del Nido	Pedro	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Technical Performance Score Can Predict Post-Discharge Reinterventions in Partial and Transitional Atrioventricular Septal Defect Repair	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CorAux Technolgies, Nido Surgical
del Nido	Pedro	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Bereich Repail Residual Atrioventricular Valve Regurgitation Pre-Discharge Is Associated With Post-Discharge Reinterventions Following Complete Atrio Ventricular Septal Defect Repair	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CorAux Technolgies, Nido Surgical
del Nido	Pedro	Congenital Heart Disease Surgery: Updates and Innovations	Targeted Increase in Pulmonary Blood Flow in a Bidirectional Glenn Circulation	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CorAux Technolgies, Nido Surgical
del Nido	Pedro	Predicting Outcomes in Pediatric Heart Disase	Risk Stratification of Children Undergoing Valve-Sparing Repair of	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CorAux
dela Espriella-Juan	Rafael	Non Invasive Imaging: MR Scar and Perfusion	Tetralogy of Fallot Mean Pulmonary Artery Velocity Estimated by Cardiac Magnetic Resonance as an Early Prognostic Indicator in Heart Failure With Reduced Ejection Fraction Irrespective of Right Ventricular Function	Technolgies,Nido Surgical Nothing to Disclose
DeLago	Augustin	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography: The CONFIRM (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	Nothing to Disclose
DeLago	Augustin	Non Invasive Imaging: Prognostic Implications of CT Angiography	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	Nothing to Disclose
DeLarochellière	Robert	Frontiers in Mitral Valve Disease and Treatment	Significant Mitral Regurgitation in Patients Undergoing Transcatheter Aortic Valve Replacement: Evolution and Imaging Predictors of Improvement	Nothing to Disclose
DeLeon	Joshua	Cutting Edge Vascular Medicine	Pro-Atherogenic Properties of Plasma From Patients With Type 1	Nothing to Disclose
Delgado	Diego	From Cardiovascular Risk Factors to Acute and Stable Coronary Syndrome: International Perspectives From the Inter-American Society of Cardiology, National Heart Association of Malaysia, and American College of Cardiology	Diabetes Mellitus: Effects on Macrophage Lipid Handling Co-Chair	Nothing to Disclose
Delgado	Glenda	Antithrombotic Therapy in Ischemic Heart Disease	Shorter- Versus Longer-Duration Triple Antithrombotic Therapy for Patients With Coronary Stents Who Require Oral Anticoagulation: An Updated Comprehensive Meta-Analysis	Nothing to Disclose
Delgado	Victoria	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	SPEAKER'S BUREAU - Abbott Vascular
Delgado	Victoria	Interventional Cardiology: TAVR 1	Sizing Aortic Valve Annulus for Transcatheter Aortic Valve Prosthesis Selection: Impact of Aortic Valve Calcification Burden on the Agreement Between Automated 3-Dimensional Transesophageal Echocardiography and Multidetector Row Computed Tomography	SPEAKER'S BUREAU - Abbott Vascular
Delgado	Victoria	Novel Echocardiographic Methods for Assessing Cardiac Function	Prognostic Implications of Left Ventricular Global Longitudinal Strain in Stage 4 and 5 Chronic Kidney Disease Patients	SPEAKER'S BUREAU - Abbott Vascular
Delgado	Victoria	Innovative Use of Echocardiography	Left Ventricular Systolic Recovery After St-Segment Elevation	SPEAKER'S BUREAU - Abbott Vascular
Delgado	Victoria	Non Invasive Imaging: MR Scar and Perfusion	Myocardial Infarction: Effect of Guideline-Based Therapy Functional Consequences of Myocardial Scar After Myocardial Infarction: Characterization of Myocardial Scar Extent With Late Gadolinium Contrast Enhanced Cardiac Magnetic Resonance and Impact on Multilayer Global Longitudinal Strain on Speckle Tracking Echocardiography	SPEAKER'S BUREAU - Abbott Vascular
Delgado Delgado	Victoria Victoria	Novel Determinants of Outcomes in VHD Leading Us Astray? Pacemakers in	ACC Poster Moderator Functional Mitral Regurgitation and Cardiac Resynchronization	SPEAKER'S BUREAU - Abbott Vascular SPEAKER'S BUREAU - Abbott Vascular
Deliaravris		Cardiomyopathies	Therapy: Evolution and Impact on Outcome	
Deliargyris	Efthymios	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of Periprocedural Myocardial Infarction in Contemporary PCI: Pooled Patient-Level Data From the CHAMPION Trials Cangrelor Versus Clopidogrel on a Background of Unfractionated	SALARY - Full Time Employee for The Medicines Company
Deliargyris Deliargyris	Efthymios Efthymios	Optimizing the Care of ACS Patients Interventional Cardiology: PCI in Complex	Heparin: Insights From CHAMPION PHOENIX Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated	SALARY - Full Time Employee for The Medicines Company Nothing to Disclose
Della Bella	Paolo	Patients Fibrillatory Arrhythmias: Outcomes With	Heparin Following Transcatheter Aortic Valve Replacement: Results From the Bravo-3 Randomized Trial Role of Endomyocardial Biopsy in Patients With Structural Heart	CONSULTANT FEES/HONORARIA - Biosense Webster, St Jude
Della Siega	Anthony	Contemporary Practice Coronary Angiography, Intra-Vascular Imaging,	Disease and Normal Coronary Arteries Presenting With Ventricular Arrhythmias Renal Function-Based Contrast Dosing to Define "Prognostic"	Medical; RESEARCH/RESEARCH GRANTS - MEDTRONIC Nothing to Disclose
	•	Revascularization and Outcomes	Contrast Dose Limits for Percutaneous Coronary Intervention - The Prognostic Implication of the Contrast Volume: Glomerular Filtration Ratio in 44,082 Patients From the British Columbia Cardiac Registry	•



Contract of the Contract of th				
Last Name Dello Russo	First Name Antonio	Session Title Arrhythmias and Clinical EP: AF Ablation	Presentation Title Long-Term Risk of Recurrent Arrhythmia in Patients With Typical Atrial Flutter Undergoing Pulmonary Vein Antrum Isolation or Cavo-	Disclosures Nothing to Disclose
Delport	Rhena	Global Perspectives in the Treatment of ST Elevation Myocardial Infarction: Successes,	Tricuspid Isthmus Ablation With Permanent Isolation Access to STEMI Care: The South African Experience	Nothing to Disclose
DeLuca	Albert	Failures, and Challenges Nuclear Cardiology: Beyond Perfusion	Reduced Dose Oral Glucose Load Yields Excellent Myocardial PET	Nothing to Disclose
Demaerschalk	Bart	Highlights in Vascular Medicine Research	Viability Images The Addition of Renal Impairment to the CHA2DS2-VASc Score as	RESEARCH/RESEARCH GRANTS - Genentech
D. M. C.	A officer	A L	a Predictor of Thromboembolism and Mortality in Patients Without Atrial Fibrillation	
DeMaria	Anthony	Advances in HCM, PPCM and Other Cardiomyopathies	The Prevalence and Clinical Significance of Compacted Myocardium in Dilated Cardiomyopathy: A Contrast Echocardiography Study	CONSULTANT FEES/HONORARIA - Bracco, Resmed; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Sotera; OTHER - ResMed Foundation; RESEARCH/RESEARCH GRANTS - Acusphere, Inc., Angioblast Systems, Inc., Cardiovascular Biotherapeutics, General Electric Medical Systems, Gilead Sciences, Inc. , Lantheus; SPEAKER'S BUREAU - Zoll Pharmaceutical
DeMartini	Tony	Advances in Chronic Total Occlusion Intervention	Hemodynamically-Supported PCI of Chronic Total Occlusions: A Case Series	SALARY - Boston Scientific
Demchenko	Elena	Cutting Edge Vascular Medicine	A Novel Necroptosis Inhibitors (Necrosulfonamide and Necrostatin- 1s) Demonstrate Therapeutic Potential for Myocardial Ischemia- Reperfusion Injury	Nothing to Disclose
Demirel	Muhittin	Understanding Pulmonary Vascular Disease: From Bench to Bedside	The Impaired Endothelium-Dependent and Endothelium- Independent Systemic Arterial Vasodilatory Reserve in Pulmonary	Nothing to Disclose
Dendi	Raghuveer	Arrhythmias and Clinical EP: Devices 2	Hypertension Regardless of the Clinical Group Real World Battery Longevity of St. Jude Medical Implantable Cardioverter-Defibrillators Included in the Advisory for Premature	Nothing to Disclose
Dendi	Raghuveer	Atrial Fibrillation and VT: Unique Populations	Battery Depletion Use of an Esophageal Retractor to Prevent Thermal Injuries During	Nothing to Disclose
Denney	Thomas	and Solutions Non Invasive Imaging: MR Characterization	Atrial Fibrillation Ablation: A Multi-Center Experience Left Ventricular Torsion Shear Angle Volume Approach for Non-	Nothing to Disclose
		and Function	Invasive Evaluation of Diastolic Dysfunction in Preserved Ejection Fraction	
Denney	Thomas	Emerging Developments in HFpEF and Arryhthmias	Left Ventricular Mechanical Properties Assessed by Single Beat Method in Early Stages of Diastolic Dysfunction/Heart Failure With Preserved Ejection Fraction	Nothing to Disclose
DeNofrio	David	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Co-Chair	CONSULTANT FEES/HONORARIA - HeartWare, Inc.,Thoratec Corporation
DeNofrio	David	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Impact of Glucagon Like Peptide-1 Agonist Therapy on Heart Rate in Advanced Systolic Heart Failure: An Analysis From the Functional Impact of GLP-1 for Heart Failure Treatment Study	CONSULTANT FEES/HONORARIA - HeartWare, Inc.,Thoratec Corporation
DeNofrio	David	Heart Failure and Cardiomyopathies: Clinical Team 5	Suggested Reviewer	CONSULTANT FEES/HONORARIA - HeartWare, Inc., Thoratec Corporation
Dent Denveiak	John	28. Non Invasive Imaging: Echo Team 2	Suggested Reviewer Sex Differences in Atrial Structural Remodeling and Serum Markers	Nothing to Disclose
Denysiak Deo	Jacqueline Rajat	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Test Yourself with Questions: Guidelines	Sex Differences in Athan Structural Remodeling and Serum Markers of Fibrosis at Presentation for Catheter Ablation Faculty	Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
		Module 3: Atrial Fibrillation	•	Pharmaceuticals, Inc,Janssen Pharmaceuticals, Inc
DePalma DePasquale	Sondra Eugene	Cardiovascular Team Cases: Team 1 13. Heart Failure and Cardiomyopathies:	Suggested Reviewer Suggested Reviewer	Nothing to Disclose Nothing to Disclose
Depre	Christophe	Clinical Team 5 Put Your Codon! Genetic Insights Into Heart	Genetics of Heart Rate Observational Study (GenHRate)	Nothing to Disclose
Depta	Jeremiah	Failure The Evolving World of LVADs, Transplant and Other Novel Discoveries	Coronary Artery Disease Learning and Algorithm Development Study: Early Analysis of Ejection Fraction Evaluation	Nothing to Disclose
Desai	Aken	Innovations in Practice Management and Social Media	Formal CPR Status Policy and Process Increased Documentation Rates	Nothing to Disclose
Desai	Akshay	Palliative Care for the 99% I: Promoting Palliative Care: The Why and What of PC Therapy	Panelist	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Cheetah Medical, Inc., Janssen Pharmaceuticals, Inc,Medscape Cardiology,Merck,Novartis Corporation,Relypsa,SANOFI,St. Jude Medical, Inc.; RESEARCH/RESEARCH GRANTS - Novartis
Desai	Akshay	Featured Clinical Research III	Paroxysmal Atrial Fibrillation Is Associated With Worse Clinical Outcomes Than Persistent/Permanent Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Cheetah Medical, Inc., Janssen Pharmaceuticals, Inc,Medscape Cardiology,Merck,Novartis Corporation,Relypsa,SANOFI,St. Jude Medical, Inc.;
Desai	Akshay	Featured Clinical Research III	Reduction in Heart Failure Hospitalizations With Ambulatory Hemodynamic Monitoring Seen in Clinical Trials Is Maintained in the 'Real World'	RESEARCH/RESEARCH GRANTS - Novartis CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, (Cheetah Medical, Inc., Janssen Pharmaceuticals, Inc., Medscape Cardiology, Merck, Novartis Corporation, Relypsa, SANOFI, Ist. Jude Medical, Inc., RESEARCH/RESEARCH GRANTS - Novartis
Desai	Akshay	Test Yourself with Questions: Guidelines Module 4: Stable Ischemic Heart Disease	Faculty	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Cheetah Medical, Inc.,Janssen Pharmaceuticals, Inc,Medscape Cardiology,Merck,Novartis Corporation,Relypsa,SANOFI,St. Jude Medical, Inc.; RESEARCH/RESEARCH GRANTS - Novartis
Desai	Akshay	Test Yourself with Questions: Guidelines Module 4: Stable Ischemic Heart Disease	Moderator	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Cheetah Medical, Inc., Janssen Pharmaceuticals, Inc., Medscape Cardiology, Merck, Novartis Corporation, Relypsa, SANOFI, St. Jude Medical, Inc.; RESEARCH/RESEARCH GRANTS - Novartis
Desai	Akshay	Innovative Use of Echocardiography	Echocardiographic Parameters Associated With Quality of Life in Ambulatory Patients With Heart Failure	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Cheetah Medical, Inc.,Janssen Pharmaceuticals, Inc.,Medscape Cardiology,Merck,Novartis Corporation,Relypsa,SANOFI,St. Jude Medical, Inc.; RESEARCH/RESEARCH GRANTS - Novartis
Desai	Akshay	Emerging Developments in HFpEF and Arryhthmias	influence of Left Ventricular Ejection Fraction on Cause-Specific Mortality in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Cheetah Medical, Inc., Janssen Pharmaceuticals, Inc., Medscape Cardiology, Merck, Novartis Corporation, Relypsa, SANOFI, St. Jude Medical, Inc.; RESEARCH/RESEARCH GRANTS - Novartis
Desai	Akshay	Next Steps to Optimal Medical Therapy for Heart Failure Patients	Review the Current Landscape	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Cheetah Medical, Inc., Janssen Pharmaceuticals, Inc., Medscape Cardiology, Merck, Novartis Corporation, Relypsa, SANOFI, St. Jude Medical, Inc.; RESEARCH/RESEARCH GRANTS - Novartis
Desai	Akshay	Next Steps to Optimal Medical Therapy for Heart Failure Patients	Heart Failure Case Challenges	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Cheetah Medical, Inc., Janssen Pharmaceuticals, Inc., Medscape Cardiology, Merck, Novartis Corporation, Relypsa, SANOFI, St. Jude Medical, Inc.; RESEARCH/RESEARCH GRANTS - Novartis

Carry Contract of the Carry Contract of the				I
Last Name Desai	First Name Akshay	Session Title Engage @ ACC.17 Studio: Simulation Session	Presentation Title Simulation Faculty	Disclosures CONSULTANT FEES/HONORARIA - AstraZeneca
Desai	Aksilay	II: Acute Heart Failure	Simulation 1 activy	Pharmaceuticals, Cheetah Medical, Inc., Janssen
				Pharmaceuticals, Inc,Medscape Cardiology,Merck,Novartis Corporation,Relypsa,SANOFI,St. Jude Medical, Inc.;
				RESEARCH/RESEARCH GRANTS - Novartis
Desai	Akshay	The Old and the New: Impact of Heart Failure Drug Therapies	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Cheetah Medical, Inc., Janssen
		Drug Therapies		Pharmaceuticals, Inc,Medscape Cardiology,Merck,Novartis
				Corporation,Relypsa,SANOFI,St. Jude Medical, Inc.; RESEARCH/RESEARCH GRANTS - Novartis
Desai	Akshay	The Old and the New: Impact of Heart Failure	Influence of Sacubitril/Valsartan on Glycemic Control in Patients	CONSULTANT FEES/HONORARIA - AstraZeneca
		Drug Therapies	With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction	Pharmaceuticals, Cheetah Medical, Inc., Janssen Pharmaceuticals, Inc, Medscape Cardiology, Merck, Novartis
			11 action	Corporation, Relypsa, SANOFI, St. Jude Medical, Inc.;
Desai	Akshay	13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Novartis CONSULTANT FEES/HONORARIA - AstraZeneca
Desai	ritoriay	Clinical Team 8	Suggested Neviewer	Pharmaceuticals, Cheetah Medical, Inc., Janssen
				Pharmaceuticals, Inc,Medscape Cardiology,Merck,Novartis Corporation,Relypsa,SANOFI,St. Jude Medical, Inc.;
				RESEARCH/RESEARCH GRANTS - Novartis
Desai	Dhaval	Percutaneous Coronary Intervention: Lessons From the Real World	Outcomes in Patients Undergoing Cardiac Catheterization and Therapeutic Hypothermia After Cardiac Arrest	Nothing to Disclose
Desai	Dhaval	FIT Clinical Decision Making: Valvular Heart	Auscultation Guided Imaging Is Superior to Transthoracic and	Nothing to Disclose
		Disease and Pericardial Disease	Transesophageal Echocardiography: A Case for 'Sound Guides Ultrasound'	
Desai	Milind	Challenges in Cardiac CT: Case-Based	Suspected Native and Prosthetic Valve Complications: The Role of	Nothing to Disclose
Desai	Milind	Discussions Non Invasive Imaging: MR Scar and Perfusion	Cardiac CT Incremental Prognostic Utility of Late Gadolinium Enhancement in	Nothing to Disclose
			Hypertrophic Cardiomyopathy	<u> </u>
Desai	Milind	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Pulmonary Hypertension in Left Atrial Sarcoma	Nothing to Disclose
Desai	Milind	Insights From Echocardiography Use	Aortic Regurgitation Negatively Affects Left Ventricular Mechanics	Nothing to Disclose
Desai	Milind	Novel Determinants of Outcomes in VHD	After Transcatheter Aortic Valve Replacement Valvuloarterial Impedance and Left Ventricular Global Longitudinal	Nothing to Disclose
- 550.			Strain Provide Incremental Prognostic Value in Patients With	
			Significant Aortic Stenosis and Preserved Left Ventricular Ejection Fraction	
Desai	Milind	TAVR Outcomes Prognostication	Cardiac Plasticity Predicts Outcome After Transcatheter Aortic	Nothing to Disclose
Desai	Milind	Novel Arrhythmia Diagnostics, Therapeutics,	Valve Replacement in Patients With Severe Aortic Stenosis Variable Accuracy of Commercially Available Wearable Heart Rate	Nothing to Disclose
		and "Wearables	Monitors	-
Desai	Milind	17. Interventional Cardiology: Aortic Valve Disease Team 3	Suggested Reviewer	Nothing to Disclose
Desai	Nayan	Updates on Pulmonary Embolism	Ultrasound Accelerated Catheter Directed Lytic Therapy for	Nothing to Disclose
		Management in 2017	Management of Pulmonary Embolism: Impact of Procedural Timing on Echocardiographic Outcomes and Safety	
Desai	Nihar	FIT Forum: Scholarship and Education	How to Build a Research Portfolio	Nothing to Disclose
Desai	Nihar	Young Investigator Awards Competition: Clinical Investigations	Advanced Analytics Predicted Outcomes, Identified Clinically Distinct Subgroups, and Detected Heterogeneity in Response to	Nothing to Disclose
Di	Nihaa	ACC Passant Assanta	Therapy in a Cohort of More Than 40,000 Heart Failure Patients	Nething to Displace
Desai	Nihar	ACC Research Awards	Reducing Readmissions after AMI and HF:Determining How and Deciding If It Matters	Nothing to Disclose
Desai	Nihar	Arrhythmias and Clinical EP: Basic 1	Variation in the Use of Direct Oral Anticoagulants and Associated	Nothing to Disclose
			Cost Implications: Findings From the Medical Expenditure Panel Survey 2010 to 2013	
Desai Desai	Nihar Nimesh	FIT Clinical Decision Making Reviewers 4 Prosthetic Valve Assessment: Real or Illusion?	ACC FIT Clinical Decision Making Reviewer Changing Prosthetic Valve Algorithms in the Era of Transcatheter	Nothing to Disclose CONSULTANT FEES/HONORARIA -
Desai	Nilliesii	Prostretic valve Assessment. Near of illusion:	Solutions	Edwards,Gore,MEDTRONIC,St Jude; RESEARCH/RESEARCH
Desai	Nimesh	Interventional Cardiology: TAVR 1	TAVR Is Safe and Improves Cardiac Function in Patients With	GRANTS - Cook CONSULTANT FEES/HONORARIA -
Doddi	111110011	and rondonal cardiology.	Extremely Low Ejection Fractions	Edwards,Gore,MEDTRONIC,St Jude; RESEARCH/RESEARCH
Desai	Nimesh	Engage @ ACC.17 Studio: Heart Teams in	Penn Surgeon	GRANTS - Cook CONSULTANT FEES/HONORARIA -
		Action: Complex Coronary Revascularization		Edwards,Gore,MEDTRONIC,St Jude; RESEARCH/RESEARCH
Desai	Nimesh	24. Interventional Cardiology: Mitral and	Suggested Reviewer	GRANTS - Cook CONSULTANT FEES/HONORARIA -
		Structural Heart Disease Team 2		Edwards,Gore,MEDTRONIC,St Jude; RESEARCH/RESEARCH
Desai	Nirmit	Valvular Heart Disease: Aortic Stenosis	Outcomes and Their Predictors in Acute Transcatheter Aortic Heart	GRANTS - Cook Nothing to Disclose
			Valve-in-Transcatheter Aortic Heart Valve Therapy	-
Desai	Salil	FIT Clinical Decision Making: Arrhythmias and Clinical Electrophysiology	A Novel Complication and Treatment Strategy in Pacemaker- Induced Superior Vena Cava Syndrome	Nothing to Disclose
Desai	Santosh	FIT Clinical Decision Making: Non-Invasive	Pathologic Plumbing: Utilizing Multi-Modality Imaging in the	Nothing to Disclose
		Imaging and Valvular Heart Disease	Diagnosis of a Patient With Pulmonary Vein to Azygos System Fistula and Decompensated Valvular Cardiomyopathy	
Desai	Santosh	Highlights in Vascular Medicine Research	The Addition of Renal Impairment to the CHA2DS2-VASc Score as	Nothing to Disclose
	<u> </u>		a Predictor of Thromboembolism and Mortality in Patients Without Atrial Fibrillation	
Desai	Shashank	Should I Stay or Should I Go? Tough Cases in	Selection Strategy in Drug Refractory Ventricular Arrhythmia	RESEARCH/RESEARCH GRANTS - Thoratec, Corp;
Desai	Shashank	MCS and Transplant Should I Stay or Should I Go? Tough Cases in	Selection Strategy in Restrictive Cardiomyopathy	SPEAKER'S BUREAU - Thoratec RESEARCH/RESEARCH GRANTS - Thoratec, Corp;
		MCS and Transplant		SPEAKER'S BUREAU - Thoratec
Desai	Shashank	Should I Stay or Should I Go? Tough Cases in MCS and Transplant	Selection Strategy in Severe Cardiomyopathy with Chronic Kidney Disease	RESEARCH/RESEARCH GRANTS - Thoratec, Corp; SPEAKER'S BUREAU - Thoratec
Desai	Shashank	Should I Stay or Should I Go? Tough Cases in	Selection Strategy in Biventricular Dysfunction and Pulmonary	RESEARCH/RESEARCH GRANTS - Thoratec, Corp; SPEAKER'S BUREAU - Thoratec
Desai	Shashank	MCS and Transplant Everything you Wanted to Know About Heart	Hypertension Panelist	RESEARCH/RESEARCH GRANTS - Thoratec, Corp;
	Shashank	Transplant but Were Afraid to Ask		SPEAKER'S BUREAU - Thoratec RESEARCH/RESEARCH GRANTS - Thoratec, Corp;
Desai	OHASHAHK	Heart Failure and Cardiomyopathies: Clinical Team 1	Suggested Reviewer	SPEAKER'S BUREAU - Thoratec
Desai	Vrunda	Innovations in Education	Cardiology Fellow Training and Perspective of the Informed Consent Process	Nothing to Disclose
Desch	Steffen	Non Invasive Imaging: MR Characterization	Prognostic Value and Determinants of Left Atrial Function Assessed	Nothing to Disclose
		and Function	by Cardiac Magnetic Resonance in St-Segment Elevation	
Desch	Steffen	Non Invasive Imaging: MR Heart Failure and	Myocardial Infarction Antecedent Hypertension and Myocardial Injury in Patients With	Nothing to Disclose
Desch	Steffen	Pulmonary Hypertension Novel Developments in Acute Coronary	Reperfused ST-Elevation Myocardial Infarction Impact of Timing of Intra-Aortic Balloon Counterpulsation on	Nothing to Disclose
Descii	Siellell	Syndromes	Mortality in Cardiogenic Shock: A Sub-Analysis of the IABP-SHOCK	Induming to Disclose
Desch	Steffen	Novel Developments in Acute Coronary	II-Trial Mild Hypothermia in Cardiogenic Shock Complicating Myocardial	Nothing to Disclose
Desch		Syndromes	Infarction: The Randomized SHOCK-COOL Pilot Trial	-
Desek	Steffen	Novel Developments in Acute Coronary	Outcome of Elderly Patients Undergoing Extracorporeal Life Support in Refractory Cardiogenic Shock	Nothing to Disclose
Desch		Syndromes		



				'
Last Name Deshmukh	First Name Abhishek	Session Title Arrhythmias and Clinical EP: Basic 1	Presentation Title Atrial Fibrillation in Patients With Non-STEMI: Insights From a	Disclosures Nothing to Disclose
		,	National Database	ŭ
Deshmukh	Abhishek	Structural Heart Interventions: Focus on Mitral	Insights Into Outcomes With Intracardiac Echocardiogram Use in Structural Interventions	Nothing to Disclose
Deshmukh	Abhishek	Valve, Left Atrial Appendage and HOCM Structural Heart Interventions: Focus on Mitral	Structural Interventions Transcatheter Mitral Valve Repair (Mitraclip) in United States:	Nothing to Disclose
D COMMUNICATION OF THE PROPERTY OF THE PROPERT	, monor	Valve, Left Atrial Appendage and HOCM	Etiologies and Predictors of Readmission and In-Hospital Mortality	Trouming to Discussion
Deshmukh	Abhishek	Structural Heart Interventions: Esque on Mitral	From the Nationwide Readmission Database Transcatheter Mitral Valve Repair (Mitra Clip) in United States:	Nothing to Disclose
Desninukn	Abhishek	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Length of Stay and Cost of Hospitalizations From the Nationwide	Nothing to Disclose
			Readmission Database	
Deshmukh	Abhishek	Arrhythmias and Clinical EP: Basic 3	Seasonal Trends in Sudden Cardiac Death: A Study From the Largest Inpatient Database	Nothing to Disclose
Deshmukh	Abhishek	Innovative Approaches for Reducing Risk and	Atrial Fibrillation Is Associated With Worse Outcomes in Patients	Nothing to Disclose
		Improving Outcomes With Ablation	With Cirrhosis	-
Deshmukh	Abhishek	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Complication Rates of Epicardial Ventricular Tachycardia Ablation: A Pooled Analysis	Nothing to Disclose
Deshmukh	Abhishek	Timely Topics in Acute Coronary Syndromes	Percutaneous Coronary Intervention Is Associated With Decreased	Nothing to Disclose
Deshmukh	Abbishali	Head Falling and Condings on this What	Mortality in NSTEMI Patients With Advanced CKD	Nething to Displace
Desninukn	Abhishek	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Impact of Cardiac Devices on Readmission and Short Term Mortality in Patients With Heart Failure With Reduced Ejection	Nothing to Disclose
		-	Fraction: A Nationwide Study	
Deshmukh	Abhishek	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	CHADS ₂ and CHA ₂ DS ₂ VASc Scores as Predictors of	Nothing to Disclose
		Device Therapies	Length of Stay and Cost of Care in Hospitalised Atrial Fibrillation	
			Patients: Insights From a National Database	
Deshmukh	Abhishek	CAD in Unique Patient Populations	Trends in Prevalence and In-Hospital Mortality of NSTEMI Patients With Solid Tumor Cancer: The Nationwide Analysis From 1998-	Nothing to Disclose
			2013	
Deshmukh	Amrish	Atrial Fibrillation and VT: Specific Situations	Incidence, Predictors, and Outcome of Postoperative Atrial	Nothing to Disclose
		and Newer Outcome Measures	Fibrillation in Patients Receiving Continuous Flow Left Ventricular Assist Devices	
Desiderio	Michael	Innovations in Practice Management and	Addition of Multimedia to Post-PCI Education: Patient Perception	Nothing to Disclose
Dasimana	Doniel	Social Media	Versus Performance	Nothing to Displace
DeSimone	Daniel	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Utility of Cardiac Computed Tomography Scanning in the Diagnosis and Pre-Operative Evaluation of Patients With Infective Endocarditis	Nothing to Disclose
			·	
DeStephan	Christine	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Looking for a Clot: Paget-Schroetter Syndrome as Cause of Chronic Thromboembolic Pulmonary Hypertension	Nothing to Disclose
Desvigne Nickens	Patrice	Acute Heart Failure: Evaluating Strategies to	Risk of Hospitalization or Death Due to Heart Failure With Intensive	Nothing to Disclose
		Prevent Readmissions	Glucose-Lowering Therapy in Diabetic Women: Subgroup Analyses	·
			by History of Cardiovascular Disease in the ACCORD Trial	
Deswal	Anita	Distinct Phenotypes in HFpEF: Beyond	Co-Chair	OTHER - Aurora Health Care. Inc.
B	A - 11 -	Ejection Fraction	December 1	OTHER A SHARW BY ON A SHARW
Deswal Deswal	Anita Anita	Salt, Water and the Kidney in Heart Failure Salt, Water and the Kidney in Heart Failure	Panelist The Cardiorenal Syndrome: Is it All About the Hemodynamics?	OTHER - Aurora Health Care. Inc. OTHER - Aurora Health Care. Inc.
Deswal	Anita	Test Yourself with Questions: General	Faculty	OTHER - Aurora Health Care. Inc.
Deuteek	Charre	Cardiology Module 14	Disht Cided Assessed Dethress Measured in a sel DDDth	Nething to Displace
Deutsch	Steven	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Right Sided Accessory Pathway Masquerading as LBBB with Cardiomyopathy: "Cure" With Catheter Ablation	Nothing to Disclose
Devabhakthuni	Sandeep	Why Can't We Be Friends? Controversies in	Duration of Oral Loop Diuretics and 30-Day Readmission in Patients	Nothing to Disclose
Devarai	Srikant	Heart Failure Management Highlighted Original Research: Heart Failure	With Acute Decompensated Heart Failure	Nothing to Disclose
Devaraj	Srikant	and Cardiomyopathies and the Year in Review	Higher Beta-Blocker Dose Versus Lower Heart Rate in Patients With Heart Failure Due to Systolic Dysfunction	Nothing to Disclose
Devaraj	Srikant	Emerging Developments in HFpEF and Arryhthmias	Higher Ambulatory Heart Rates Predict Increased Long Term Mortality in Patients With Hfref	Nothing to Disclose
Devaraj	Srikant	Put Your Codon! Genetic Insights Into Heart	Circulating Free and Exosomal MicroRNAs as Biomarkers of	Nothing to Disclose
•		Failure	Systemic Response to Heart Failure	
Devereaux	P.J.	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking	Relationship Between High Sensitive Troponin T Measurements and 30-Day Mortality After Noncardiac Surgery	RESEARCH/RESEARCH GRANTS - Abbott Diagnostics,Boehringer Ingelheim,Roche Diagnostics
		Clinical Trials	bo-bay workality Arter Norloandiae ourgery	Diagnostics, Boerninger ingenterin, Noone Diagnostics
Devereux	Richard	The Spectrum of Aortic Regurgitation and	Syndromic and Inflammatory Aortopathies	CONSULTANT FEES/HONORARIA - Merck & Dryamp; Co.,
Devereux	Richard	Aortic Pathology Assessing the Clinical Impact of Blood	Effect of Antihypertensive Therapy on Development of Incident	Inc. CONSULTANT FEES/HONORARIA - Merck & December 2015.
		Pressure Lowering Therapies	Conduction System Disease in Hypertensive Patients: The LIFE	Inc.
Dougrau	Dishard	- '	Study	
Devereux	Richard	Interventional Cardiology: TAVR 2	Does Intra-Aortic Balloon Pump Placement During Hospitalization Course for Transcatheter Aortic Valve Replacement Portent a	CONSULTANT FEES/HONORARIA - Merck & Discourage (Co., Inc.
			Worse Clinical Outcome?	
Devereux	Richard	Interventional Cardiology: TAVR 3	Periprocedural Blood Transfusions in Patients Undergoing	CONSULTANT FEES/HONORARIA - Merck & Description (Co., June 2017)
Devireddy	Chandan	Novel Mechanical Devices for the Treatment	Transcatheter Aortic Valve Replacement Endovascular Carotid Barostimulation for Resistant Hypertension: A	Inc. CONSULTANT FEES/HONORARIA - MEDTRONIC, Vascular
		and Assessment of Hypertension	Safety and Proof-of-Principle Cohort Study	Dynamics
Devireddy	Chandan	TAVR Outcomes Prognostication	Predictors and Clinical Outcomes of Next-Day Discharge After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - MEDTRONIC, Vascular
Devlin	James	Arrhythmias and Clinical EP: AF Miscellaneous	Association of Genetic Risk Score with Burden of Atrial Fibrillation:	Dynamics SALARY - Celera
		and Surgical Issues	An ENGAGE AF-TIMI 48 Analysis	
DeVore	Adam	Test Yourself with Questions: General Cardiology Module 14	Faculty	CONSULTANT FEES/HONORARIA - Novartis Corporation; RESEARCH/RESEARCH GRANTS - American Heart
		Cardiology Module 14		Association, Amgen Inc., Novartis Corporation
DeVore	Adam	Young Investigator Awards Competition:	A Hospital Level Analysis of 30-Day Readmission Rates for Heart	CONSULTANT FEES/HONORARIA - Novartis Corporation;
1		Outcomes Research	Failure Patients and Long-Term Survival Among Highest and Lowest Performing Hospitals, Findings From Get With the	RESEARCH/RESEARCH GRANTS - American Heart Association, Amgen Inc., Novartis Corporation
			Guidelines-Heart Failure	, account in the interpretation of portation
DeVore	Adam	Heart Failure and Cardiomyopathies: Is Heart	Heart Failure With Reduced Ejection Fraction Care Patterns in the	CONSULTANT FEES/HONORARIA - Novartis Corporation;
1		Failure With a Normal EF for Real?	Outpatient Practice Setting: Initial Findings From CHAMP-HF	RESEARCH/RESEARCH GRANTS - American Heart Association, Amgen Inc., Novartis Corporation
DeVore	Adam	Acute Heart Failure: Evaluating Strategies to	Hemoconcentration During Management of Patients With Acute	CONSULTANT FEES/HONORARIA - Novartis Corporation;
1		Prevent Readmissions	Heart Failure and Cardiorenal Syndrome: Insights From CARRESS-	RESEARCH/RESEARCH GRANTS - American Heart
DeVore	Adam	Acute Heart Failure: Evaluating Strategies to	HF The Impact of the Current Versus Prior Cardiac Resynchronization	Association, Amgen Inc., Novartis Corporation CONSULTANT FEES/HONORARIA - Novartis Corporation;
50,010	, adm	Prevent Readmissions	Guidelines on the Proportion of Hospitalized Heart Failure Patients	RESEARCH/RESEARCH GRANTS - American Heart
DeVess	Adam		Eligible for Therapy	Association, Amgen Inc., Novartis Corporation
DeVore	Adam	Why Can't We Be Friends? Controversies in Heart Failure Management	Association Between Serum Potassium Level and Outcomes in Heart Failure With Reduced Ejection Fraction: A Cohort Study From	CONSULTANT FEES/HONORARIA - Novartis Corporation; RESEARCH/RESEARCH GRANTS - American Heart
		-	the Swedish Heart Failure Registry	Association, Amgen Inc., Novartis Corporation
DeVore	Adam	The Old and the New: Impact of Heart Failure	Liraglutide and Weight Loss Among Patients With Advanced Heart	CONSULTANT FEES/HONORARIA - Novartis Corporation;
1		Drug Therapies	Failure and a Reduced Ejection Fraction: Insights From the FIGHT Trial	RESEARCH/RESEARCH GRANTS - American Heart Association, Amgen Inc., Novartis Corporation
Devraj	Mithun	Arrhythmias and Clinical EP: AF Miscellaneous	Is There a Role for Invasive Electrophysiology Studies in Patients	Nothing to Disclose
		and Surgical Issues	With Conduction Abnormalities Following Transcatheter Aortic Valve	
DeVries	James	Coronary Angiography, Intra-Vascular Imaging,	Replacement? Troponin Elevation Following Elective PCI Predicts Long Term	Nothing to Disclose
		Revascularization and Outcomes	Survival	=



				<u> </u>
Last Name DeVries	First Name James	Session Title Peripheral Arterial Disease, Risk, and	Presentation Title ACC Poster Moderator	Disclosures Nothing to Disclose
Dewitt	Elizabeth	Outcomes Arrhythmias and Clinical EP: Devices 1	Coronary Artery Compression by Epicardial Leads: More Common	Nothing to Disclose
Dey	Amit	Non Invasive Imaging: Applications in Novel	Than We Think Small Dense Low Density Lipoprotein Particle Number Relates to	Nothing to Disclose
		Disease States and Clinical Scenarios	Coronary Plaque Burden Independent of Traditional Cardiovascular Risk Factors in Psoriasis	-
Dey	Amit	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Aortic Vascular Inflammation by 18-FDG PET/CT Associates With High-Risk Coronary Plaques in Young Psoriasis Patients	Nothing to Disclose
Dey	Amit	Vascular Medicine: New Insights Into Aortic and Peripheral Artery Diseases	Improvement in Cholesterol Efflux Capacity Is Associated With Improvement in Vascular Inflammation by 18- FDG PET CT in Psoriasis	Nothing to Disclose
Dey	Amit	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Improvement in Cholesterol Efflux Capacity Is Associated With a Reduction in Aortic Wall Thickness by MRI Independent of Traditional CV Risk Factors	Nothing to Disclose
Dey	Amit	Updates on Risk Factors for Cardiovascular Disease	Visceral but Not Subcutaneous Adipose Tissue Associates With Vascular Inflammation by 18-FDG PET/CT in Psoriasis	Nothing to Disclose
Dey	Damini	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium in the Elderly: Prevalence, Severity, and Association With All-Cause Mortality	Nothing to Disclose
Dey	Damini	Nuclear Cardiology: Quality	Rest Scan Does Not Improve Automatic Machine Learning Prediction of Major Adverse Coronary Events After High Speed	Nothing to Disclose
Dey	Damini	Nuclear Cardiology: Coronary Flow	Myccardial Perfusion Imaging Precisely Controlled Arterial CO2 Can Potentiate Myocardial Blood Flow to the Same Extent as Adenosine: A Preclinical Study in Canines With 13N-Ammonia PET	Nothing to Disclose
Dey	Damini	Nuclear Cardiology: Coronary Flow	Patient Motion Significantly Affects Measurements of Quantitative Global Regional Myocardial Blood Flow Assessment by Dynamic	Nothing to Disclose
Dey	Damini	Non Invasive Imaging: New Technologies	Pet Improvement in LDL Is Associated With Decrease in Non-Calcified Plaque Volume on CTA as Measured by Automated Quantitative	Nothing to Disclose
Dey	Damini	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Software Relationship Between Whole Vessel Quantitative Plaque Characteristics and Noninvasive Fractional Flow Reserve From	Nothing to Disclose
Dey	Damini	Imaging With Cardiac CT: The Case for	Coronary Computed Tomography Angiography Hormone Replacement Therapy Is Associated With Less Coronary	Nothing to Disclose
Dharmakumar	Rohan	Calcium Non Invasive Imaging: MR Characterization	Atherosclerosis and Lower Mortality An Unrestrained Proinflammatory M1 Macrophage Population	Nothing to Disclose
		and Function	Induced by Iron Nanocrystals Impairs Myocardial Healing After Hemorrhagic Infarction	-
Dharmakumar	Rohan	Diabetes and Endothelial Dysfucntion in Heart Failure	Mast Cell-Dependent Conversion of Siderophages Into Foam Cells Is a Hallmark of Early Fat Infiltration in Hemorrhagic Myocardial Infarctions	Nothing to Disclose
Dharmakumar	Rohan	Biomarkers and Targets for Ischemic Heart Disease	Fat Accumulation in the Peri-Infarct Border Zone of Hemorrhagic Myocardial Infarction Is Mediated by Persistent Iron Deposits	Nothing to Disclose
Dharmakumar	Rohan	Emerging Basic Science in Ischemic Heart Disease	Myocardial Hemorrhage After Coronary Ischemia-Reperfusion Leads to an Iron-Mediated, Self-Perpetuating Loop of Foam Cell and Ceroid Accumulation	Nothing to Disclose
Dharmakumar	Rohan	Nuclear Cardiology: Coronary Flow	Precisely Controlled Arterial CO2 Can Potentiate Myocardial Blood Flow to the Same Extent as Adenosine: A Preclinical Study in Canines With 13N-Ammonia PET	Nothing to Disclose
Dharmarajan	Kumar	Core Curriculum: Special Topic: Cardiac Issues During The Golden Years and Beyond	Heart Failure in the Elderly	OTHER - Clover Health
Dharmarajan	Kumar	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Admission Types Among Patients With Heart Failure Cared for by Accountable Care Organizations: Variation by Performance on a Measure of Risk Standardized Acute Admission Rates	OTHER - Clover Health
Dhawan	Rahul	Arrhythmias and Clinical EP: Ventricular Tachycardia	Impact of Arrhythmia Duration and Index Left Ventricular Ejection Fraction on Recovery of Left Ventricular Function in Patients With	Nothing to Disclose
Dhoble	Abhijeet	Interventional Cardiology: TAVR 3	Arrhythmia-Induced Cardiomyopathy Transapical TAVR Is Associated With Higher Morbidity and Mortality Compared to Transfemoral TAVR in Men but Not in Women	Nothing to Disclose
Dhoble	Abhijeet	Interventional Cardiology: TAVR 3	Comparing Outcomes in COPD Patients Undergoing TAVR and	Nothing to Disclose
Dhoble	Abhijeet	The Challenges of Outcome Prediction in	SAVR: A Propensity Matched Analyses Gender-Based Outcomes in Diabetics Undergoing Transcatheter	Nothing to Disclose
Dhruva	Sanket	Valvular Heart Disease Traditional and Novel Factors Used to Assess	Aortic Valve Replacement Effectiveness of Coronary CT Angiography Versus Standard Care	Nothing to Disclose
Dhruva	Sanket	the Risk of, and Used for the Treatment of, Coronary Artery Disease Toward Precision Medicine in the Treatment of	for the Assessment of Patients With Suspected Coronary Artery Disease: A Trial Sequential Analysis Toward Identifying Personalized Prognosis in Hypertension:	Nothing to Disclose
Driruva	Sanket	Elevated Blood Pressure	Variation in Early Responses in the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)	-
Dhutia	Harshil	Imaging the Athlete's Heart	General Population Screening for Sudden Cardiac Death in Young Individuals: Is It Feasible, Is It Justifiable & How Much Does It Cost?	Nothing to Disclose
Dhutia	Harshil	Hearts and Soles: Multimodality Imaging in Athletes	The Mixed Race Athlete's ECG: Not So Black and White	Nothing to Disclose
Di Biase	Luigi	Late-Breaking Clinical Trials: Deep Dive II	Panelist	CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik, Boston Scientific, Consultant, St Jude Medical, Janssen Pharmaceuticals, Inc, MEDTRONIC, Pfizer
Di Biase	Luigi	Arrhythmias and Clinical EP: Devices 1	Implantable Cardioverter Defibrillator for the Prevention of Mortality in Non-Ischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials	Inc, Stereotaxis; OTHER - EpiEP CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik, Boston Scientific, Consultant, St Jude Medical, Janssen Pharmaceuticals, Inc, MEDTRONIC, Pfizer
Di Biase	Luigi	Arrhythmias and Clinical EP: Devices 1	Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients Undergoing Cardiac Implantable Electronic Device Implantation: A Meta-Analysis	Inc, Stereotaxis; OTHER - EpiEP CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik, Boston Scientific, Consultant, St Jude Medical, Janssen Pharmaceuticals, Inc, MEDTRONIC, Pfizer
Di Biase	Luigi	Arrhythmias and Clinical EP: AF Ablation	Long-Term Outcome of Pulmonary Vein Isolation With and Without	Inc, Stereotaxis; OTHER - EpiEP CONSULTANT FEES/HONORARIA - Biosense
	3 '	,	Focal Impulse and Rotor Modulation (FIRM) Mapping: Results From a Meta-Analysis	Webster, Biotronik, Boston Scientific, Consultant, St Jude Medical, Janssen Pharmaceuticals, Inc, MEDTRONIC, Pfizer Inc, Stereotaxis; OTHER - EpiEP
Di Biase	Luigi	Arrhythmias and Clinical EP: AF Ablation	Long-Term Risk of Recurrent Arrhythmia in Patients With Typical Atrial Flutter Undergoing Pulmonary Vein Antrum Isolation or Cavo- Tricuspid Isthmus Ablation With Permanent Isolation	CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik, Boston Scientific, Consultant, St Jude Medical, Janssen Pharmaceuticals, Inc,MEDTRONIC, Pfizer Inc, Stereotaxis; OTHER - EpIEP
Di Biase	Luigi	Atrial Fibrillation and VT: Unique Populations and Solutions	Use of an Esophageal Retractor to Prevent Thermal Injuries During Atrial Fibrillation Ablation: A Multi-Center Experience	CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik, Boston Scientific, Consultant, St Jude Medical, Janssen Pharmaceuticals, Inc, MEDTRONIC, Pfizer Inc, Stereotaxis; OTHER - EpiEP
Di Biase	Luigi	Arrhythmias and Clinical EP: Anticoagulation Issues	Meta-Analysis on the Efficacy and Safety of New Oral Anticoagulants Compared With Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation	CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik, Boston Scientific, Consultant, St Jude Medical, Janssen Pharmaceuticals, Inc, MEDTRONIC, Pfizer Inc, Stereotaxis, OTHER - EpiEP

and a				<u> </u>
Last Name Di Biase	First Name Luigi	Session Title Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Presentation Title CHADS2 Score Predicts Outcomes of Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation	Disclosures CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik, Boston Scientific, Consultant, St Jude Medical, Janssen Pharmaceuticals, Inc, MEDTRONIC, Pfizer Inc, Stereotasis, OTHER - EpiEP
Di Biase	Luigi	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Efficacy of Catheter Ablation of Atrial Fibrillation in the Setting of Systolic Dysfunction: A Meta-Analysis of Randomized Control Trials	Inc., Siere eulaws, O'HER - EpiEP CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik, Boston Scientific, Consultant, St Jude Medical, Janssen Pharmaceuticals, Inc, MEDTRONIC, Pfizer Inc, Stereotaws; O'HER - EpiEP
Di Biase	Luigi	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Left Atrial Appendage Flow Velocity to Predict Persistent Left Atrial Appendage Isolation	CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik, Boston Scientific, Consultant, St Jude Medical, Janssen Pharmaceuticals, Inc, MEDTRONIC, Pfizer Inc, Stereotaxis; OTHER - EpiEP
Di Biase	Luigi	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Safety Profiles of Percutaneous Left Atrial Appendage Closure Devices: An Analysis of the Food and Drug Administration Marundacturer and User Facility Device Experience Database From 2009 - 2016	CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik, Boston Scientific, Consultant, St Jude Medical, Janssen Pharmaceuticals, Inc,MEDTRONIC, Pfizer Inc, Stereotaxis; OTHER - EpiEP
Di Biase	Luigi	Innovation in Practice Management, Advocacy, and Education	Importance of Twitter During Cardiology Conferences	CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik, Boston Scientific, Consultant, St Jude Medical, Janssen Pharmaceuticals, Inc, MEDTRONIC, Pfizer Inc, Stereotaxis; OTHER - EpiEP
Di Carli	Marcelo	What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young	Panelist	RESEARCH/RESEARCH GRANTS - Spectrum Dynamics
Di Carli	Marcelo	Scientist Awardee Lecture PET Myocardial Perfusion Imaging: Practical	PET Myocardial Perfusion Imaging Cases	RESEARCH/RESEARCH GRANTS - Spectrum Dynamics
Di Carli	Marcelo	Considerations- A Case-Based Discussion PET Myocardial Perfusion Imaging: Practical	Panelist	RESEARCH/RESEARCH GRANTS - Spectrum Dynamics
Di Carli	Marcelo	Considerations- A Case-Based Discussion Nuclear Cardiology: Current Applications and Best Practices: Joint Symposium of the American Society of Nuclear Cardiology and the American College of Cardiology	Cardiac PET: Let's Go with the Flow	RESEARCH/RESEARCH GRANTS - Spectrum Dynamics
Di Carli	Marcelo	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Integrating Hyperemic Myocardial Blood Flow and Coronary Flow Reserve for Predicting Cardiovascular Mortality Outcomes in Patients With Known or Suspected Ischemic Heart Disease	RESEARCH/RESEARCH GRANTS - Spectrum Dynamics
Di Carli	Marcelo	Young Investigator Awards Competition: Clinical Investigations	Impaired Coronary Flow Reserve Is Associated With Diastolic Dysfunction and HFpEF Outcomes in Patients Without Overt CAD	RESEARCH/RESEARCH GRANTS - Spectrum Dynamics
Di Carli	Marcelo	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Lipid Abnormalities in Young Patients With Myocardial Infarction	RESEARCH/RESEARCH GRANTS - Spectrum Dynamics
Di Carli	Marcelo	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Women Who Experience Myocardial Infarction at a Young Age Have Worse Survival Compared With Men	RESEARCH/RESEARCH GRANTS - Spectrum Dynamics
Di Carli	Marcelo	Nuclear Cardiology: Prognosis	Myocardial Scar but Not Ischemia Predicts Defibrillator Shocks and Sudden Cardiac Death in Patients With Reduced Left Ventricular Ejection Fraction	RESEARCH/RESEARCH GRANTS - Spectrum Dynamics
Di Carli	Marcelo	Unusual Presentations of ACS	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival	RESEARCH/RESEARCH GRANTS - Spectrum Dynamics
Di Carli	Marcelo	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Relationship of Coronary Flow Reserve With Body Mass Index and Adverse Outcomes in Patients Without Overt Ischemic Heart Disease: Implications for Metabolic Surgery Eligibility	RESEARCH/RESEARCH GRANTS - Spectrum Dynamics
Di Carli	Marcelo	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Disease: Implications for Metabolic Surgery Engiolity Association Between Coronary Flow Reserve and Adverse Cardiovascular Events Along a Continuum of Metabolic Disease in Symptomatic Patients Without Overt Coronary Artery Disease	RESEARCH/RESEARCH GRANTS - Spectrum Dynamics
Di Carli Di Eusanio	Marcelo Marco	30. Non Invasive Imaging: Nuclear Team 2 Vascular Medicine: Novel Risk Measures in	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Spectrum Dynamics Nothing to Disclose
		Arterial Diseases	Body Mass Index and Acute Aortic Dissection	· ·
Di Eusanio	Marco	Vascular Medicine: Aortic and Peripheral Artery Diseases	Uncontrolled Hypertension in Acute Aortic Dissection Follow-Up	Nothing to Disclose
Di Mario	Carlo	Recent ACS Trials: Relevance to My Daily Practice	PRAGUE-18: Ticagrelor vs. Prasugrel in STEMI	CONSULTANT FEES/HONORARIA - Abbott Vascular, Eli Lilly, MEDTRONIC, St.Jude; RESEARCH/RESEARCH GRANTS - Biosensors, Shockwave
Di Mario	Carlo	Controversies in ACS Guidelines	What's New and Controversial in ACS Guidelines: The European Perspective	CONSULTANT FEES/HONORARIA - Abbott Vascular, Eli Lilly, MEDTRONIC, St.Jude; RESEARCH/RESEARCH GRANTS - Biosensors, Shockwave
Di Mario	Carlo	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International Multicentre iFR GRADIENT Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular, Eli Lilly, MEDTRONIC, StJude; RESEARCH/RESEARCH GRANTS - Biosensors, Shockwave
Di Mario	Carlo	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular, Eli Lilly, MEDTRONIC, St.Jude; RESEARCH/RESEARCH GRANTS - Biosensors, Shockwave
Di Salvo	Thomas	The Forgotten Chamber: The Right Ventricle in Heart Failure	How To Assess RV Function: Imaging, Hemodynamics, or Both?	Nothing to Disclose
Di Segni	Mattia	Non Invasive Imaging: Expanding Clinical Applications	Impact of Different Calcium Locations of Mitral Annulus and Aortic Valve Cusps on Risk of Conduction Disturbances After Transcatheter Aortic Valve Implantation	Nothing to Disclose
Di Stefano	Cristina	Novel Echocardiographic Methods for Assessing Cardiac Function	Subclinical Myocardial Alterations in Cardiac Sarcoidosis	Nothing to Disclose
Diamond	Jamie	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Platelet Reactivity and Outcomes After PCI of Saphenous Vein Grafts Versus Native Coronary Arteries: The ADAPT-DES Study	Nothing to Disclose
Diamond	Jamie	Interventional Cardiology: PCI and TAVR in Complex Patients	Long-Term Adverse Ischemic Outcomes After Percutaneous Coronary Intervention Among Patients With Versus Without Prior Coronary Artery Bypass Grafting: Analysis From 17 Randomized Trials	Nothing to Disclose
Dias	Andre	Emerging Applications of Echocardiography	Dobutamine Stress Echocardiography as a Predictor of Cardiovascular Morbidity and Mortality Post Orthotopic Liver Transplantation	Nothing to Disclose
Diaz	Larry	Clinical Assessment and Revascularization for Critical Limb Ischemia	Case Discussion: Enrolled in BEST CLI	CONSULTANT FEES/HONORARIA - MEDTRONIC
Diaz	Larry	26. Interventional Cardiology: Vascular Access and Complications Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC
Diaz de la Llera	Luis-S.	Interventional Cardiology: TAVR 1	Pacing Over Guidewire, Stepwise to Minimalism in Tavi: A Single	Nothing to Disclose
Dibu	George	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Center Experience Coronary Artery Bypass Graft Pseudoaneurysm From Saphenous Vein Graft Stent Rupture	Nothing to Disclose
Dick	Alexander	Vascular Medicine: New Insights Into Aortic	Sex Differences in Thoracic Aortic Aneurysm Growth: Role of Aortic	Nothing to Disclose
Dick	Alexander	and Peripheral Artery Diseases Novel Developments in Acute Coronary Syndromes	Stiffness Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment	Nothing to Disclose
Dickens	Carolyn	Interdisciplinary Cardiovascular Team Collaboratives in Care	Elevation Myocardial Infarction Poor Adherence in Young Patients With Heart Failure	Nothing to Disclose
Dickens	Carolyn	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	How a Cardiologist Diagnosed a Pheochromocytoma: Catecholamine-Induced Myocarditis	Nothing to Disclose



Contract of the second				I
Last Name Dickens	First Name Carolyn	Session Title Interdisciplinary Cardiovascular Care in	Presentation Title Simple Technology Improves Access and Outcomes for Patients	Disclosures Nothing to Disclose
Dickens	•	Complex Scenarios Interdisciplinary Cardiovascular Team Care	With Low Socioeconomic Status Homelessness and Heart Failure: A Novel Prescription	Nothing to Disclose
	Carolyn	Delivery: Quality, Safety, and Satisfaction	·	
Dickens	Carolyn	Interdisciplinary Cardiovascular Team Care Delivery: Quality, Safety, and Satisfaction	Heart Failure Hotline as an Innovation to Address Medication Issues	Nothing to Disclose
Dickerman	Stuart		Echocardiographic Predictors for In-Hospital and 1-Year Outcomes in Left-Sided Infective Endocarditis: An Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort Study	Nothing to Disclose
Dickerson	Heather	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Is a Pulsatile Glenn an Adequate Alternative for Long-Term Palliation in Patients With Single Ventricle Physiology?	Nothing to Disclose
Dickstein	Kenneth	Featured Clinical Research III	Paroxysmal Atrial Fibrillation Is Associated With Worse Clinical Outcomes Than Persistent/Permanent Atrial Fibrillation in Patients	Nothing to Disclose
Didier	Romain	Interventional Cardiology: TAVR 3	With Heart Failure and Reduced Ejection Fraction Acute Aortic Regurgitation Post-Transcatheter Aortic Valve Replacement: Impact of Various Treatment Strategies	Nothing to Disclose
Diederichsen	Axel	The Evolving World of LVADs, Transplant and Other Novel Discoveries	High-Sensitivity Troponin-T, Left Ventricular Size and Function, and Long-Term Outcomes in Clinically Stable, Apparently Healthy Older Subjects	Nothing to Disclose
Diener	Hans-Christoph	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Persistence With Therapy in Patients With Atrial Fibrillation: The GLORIA-AF Registry	CONSULTANT FEES/HONGRARIA - Abbott, Allergan, AstraZeneca, Bayer Vital, BMS, Boenringer Ingelheim, CoAxia, Corimmun, Covidien, Daichii-Sankyo, D-Pharm, EV3, Fresenius, GlaxoSmithKline, Janssen Cilag, Knoll, MSD, Medtronic, MindFrame, Neurobiological Technologies, Novartis, Novo-Nordisk, Paion, Parke-Davis, Pitzer, Sanofi-Aventis, Schering-Plough, Servier, Solvay, Thrombogenics, Wyeth and Yamanouchi
Diener	Hans-Christoph	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Increased Rate of Previous Stroke in Asymptomatic/Minimally Symptomatic Versus Symptomatic Patients With Newly Detected Atrial Fibrillation Worldwide: Results From the GLORIA-AF Registry	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
Diener	Hans-Christoph	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Rates of Stroke and Bleeding With Dabigatran 150 and 110 mg BID in Clinical Practice: The GLORIA-AF Registry	CONSULTANT FEES/HONORARIA - Abbott, Allergan, AstraZeneca, Bayer Vital, BMS, Boehringer Ingelheim, CoAxia, Corimmun, Covidien, Daichi-Sankyo, D-Pharm, EV3, Fresenius, GlaxoSmithKline, Janssen Cilag, Knoll, MSD, Medtronic, MindFrame, Neurobiological Technologies, Novartis, Novo-Nordisk, Paion, Parke-Davis, Pitzer, Sanofi-Aventis, Schering-Plough, Servier, Solvay, Thrombogenics, Wyeth and Yamanouchi
Diercks	Deborah	02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Janssen, Novartis; RESEARCH/RESEARCH GRANTS - Roche, Siemens
Dieter	Robert	Clinical Team 5 Interventional Challenging Cases: Team 1	ACC Challenging Case Reviewer	Nothing to Disclose
Dietzius	Harold	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine		Nothing to Disclose
Diez	Jose	02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Difede	Darcy	Clinical Team 6 Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Role of Gender on Mesenchymal Stem Cell Therapy in Non- Ischemic Dilated Cardiomyopathy: A Sub-Analysis of the	CONSULTANT FEES/HONORARIA - BDS
Dilsizian	Vasken	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	POSEIDON-DCM Trial ACC Poster Moderator	RESEARCH/RESEARCH GRANTS - GE Healthcare, Siemens
Dilsizian	Vasken	30. Non Invasive Imaging: Nuclear Team 2	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - GE Healthcare, Siemens
DiMarco	John	06. Arrhythmias and Clinical EP: Other Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Novartis; DATA SAFETY MONITORING BOARD - Celgene Corporation
Dimayuga Dimitriadis	Paul Kyriakos	38. Vascular Medicine: Basic Team 2 Toward Precision Medicine in the Treatment of	Suggested Reviewer Left Ventricular Mass Versus Pulse Wave Velocity as Predictors of	Nothing to Disclose Nothing to Disclose
		Elevated Blood Pressure	Coronary Artery Disease in Patients With Essential Hypertension: Data From a Greek 6-Year-Follow-Up Study	-
Dimitriadis Dimitropoulos	Kyriakos Efstathios	Toward Precision Medicine in the Treatment of Elevated Blood Pressure Diabetes and Endothelial Dysfucntion in Heart	Predictors of New-Onset Atrial Fibrillation in Essential Hypertensives Association of Endothelial Dysfunction With Biomarkers of	Nothing to Disclose Nothing to Disclose
Dinardo		Failure	Inflammation, Myocardial Fibrosis and Left Ventricle Strain in Patients With Heart Failure	-
	James	Congenital Heart Disease: Progress in Pediatric Heart Surgery	A Red Cell Preservation Strategy Reduces Postoperative Transfusions in Pediatric Heart Surgery Patients	Nothing to Disclose
Dinardo	James	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Prediction Tool for Congenital Heart Surgery Length of Stay	Nothing to Disclose
Ding	Lillian	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Renal Function-Based Contrast Dosing to Define "Prognostic" Contrast Dose Limits for Percutaneous Coronary Intervention - The Prognostic Implication of the Contrast Volume: Glomerular Filtration Ratio in 44,082 Patients From the British Columbia Cardiac Registry	Nothing to Disclose
Ding	Rongjing	7th Annual ACC China Chapter Session: Endless Change and Evolution in Cardiovascular Prevention and Rehabilitation	China Cardiopulmonary Prevention and Rehabilitation Registry 2016	Nothing to Disclose
Dinov	Borislav	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Cardiac Magnetic Resonance Imaging After Radiofrequency Ablation of Ventricular Arrhythmias in Human Patients: Defining the Substrate and Visualizing the Outcome	Nothing to Disclose
Dinov	Borislav	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Substrate and Visualizing the Cottonie Isolated Cardiac Sarcoidosis Mimicking Hypertrophic Cardiomyopathy	Nothing to Disclose
Dinwoodey	Danya	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Congenital Double-Chambered Left Ventricle Presenting as Monomorphic Ventricular Tachycardia	Nothing to Disclose
Dionne-Odom	James	Innovations in Advocacy and Patient Centered Care	Describing Collaboration Between Cardiology and Palliative Care: A National Survey Study of Current Practices, Challenges and Barriers	Nothing to Disclose
DiOrio	Matthew	Congenital Heart Disease: Progress in	Prediction Tool for Congenital Heart Surgery Length of Stay	Nothing to Disclose
DiPalo	Katherine	Pediatric Heart Surgery Interdisciplinary Cardiovascular Team Care Delivery: Quality, Safety, and Satisfaction	Patient Navigator Team Approach Successfully Reduces 30-Day Heart Failure Readmission Rate	CONSULTANT FEES/HONORARIA - Relypsa
Discepola	Vanessa	Optimizing the Care of ACS Patients	Pervalence and Clinical Impact of Thrombocytopenia in Patients With Acute Coronary Syndromes: A Systematic Review and Meta- Analysis	Nothing to Disclose
DiScipio	Anthony	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Is CABG the Best Revascularization Strategy Among All Diabetics Subgroups With Multi-Vessel Disease in the Modern Era? A Multi-	Nothing to Disclose
DiScipio	Anthony	Vascular Medicine: Emerging Concepts in	Center Analysis Influence of Family History of Aortic Disease on Type B Aortic	Nothing to Disclose
Dispenzieri	Angela	Clinical Vascular Diseases Advances in HCM, PPCM and Other Cardiomyopathies	Dissection Utility of Routine Serum Free Light Chain Assay for Amyloidosis in Patients With Heart Failure	RESEARCH/RESEARCH GRANTS - Alnylam,Celgene,Jannsen,King Pharmaceuticals, Inc. (now part of Pfizer - October 2010),Roche,Takeda Pharmaceuticals North America, Inc.

	First Name	Session Title	Presentation Title	Disclosures
Divekar	Abhay	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	"Doctor Google" and the New Era of Patient Empowerment Through Internet Resources	Nothing to Disclose
		Disease, and Vascular Medicine		
Diwan	Abhinav	Cardiac Fibrosis and Heart Failure: The Next	Impaired Autophagic Flux Contributes to the Accumulation of	Nothing to Disclose
Dixit	Sanjay	Frontier Controversies in Atrial Fibrillation Management	Ubiquitinated Proteins in a Mouse Model of Heart Failure Anticoagulation and Stroke Prevention After Catheter Ablation of	Nothing to Disclose
	canjay	-	Atrial Fibrillation	-
Dixit	Sanjay	Atrial Fibrillation, Anticoagulation and Novel	Anticoagulation Use and Incidence of Cerebrovascular Events and Major Bleeding After Catheter Ablation in Patients With Persistent	Nothing to Disclose
		Device Therapies	and Longstanding Persistent Atrial Fibrillation	
Dixon	Dave	Young Investigator Awards Competition:	Comparison of a Pharmacist-Physician Collaborative Care Model to	Nothing to Disclose
		Outcomes Research	Standard Care on the Time to Reach Goal Blood Pressure for Patients With Hypertension	
Dixon	Dave	Making Progress in Understanding Heart	Arterial Elastance Drives Ventilatory Inefficiency in Systolic Heart	Nothing to Disclose
D'	D	Failure	Failure Management of Obesity in Patients With Diastolic Dysfunction	Nullean to Brooker
Dixon	Dave	Interdisciplinary Cardiovascular Team Collaboratives in Care	IManagement of Obesity in Patients With Diastolic Dysfunction	Nothing to Disclose
Dixon	Dave	Emerging Developments in HFpEF and	Early Diastolic Mitral Annular Velocity at Peak Exercise Determines	Nothing to Disclose
		Arryhthmias	Peak Aerobic Exercise Capacity in Heart Failure With Preserved Ejection Fraction	
Dixon	Dave	Novel Strategies for Assessing and Improving	Comparison of a Pharmacist-Physician Collaborative Care Model to	Nothing to Disclose
		Adherence to Blood Pressure Lowering	Standard Care on the Time to Reach Goal Blood Pressure for	
Dixon	Jennifer	Therapies Redefining the "F" Word	Patients Presenting With Urgent Hypertension Cardiopulmonary Exercise Testing for Surgical Risk Stratification in	Nothing to Disclose
		-	Adults With Congenital Heart Disease	
Dixon	Simon	Featured Clinical Research III	Outcomes for 15,259 US Patients With Acute MI Cardiogenic Shock (AMICS) Supported With Impella	Nothing to Disclose
Dixon	Simon	Considerations in Antiplatelet Therapy and in	Readmission and Long-Term Mortality in Older Patients Treated	Nothing to Disclose
		ACS	With Ticagrelor Versus Prasugrel After Percutaneous Coronary	
			Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium	
Dixon	Simon	Percutaneous Coronary Intervention: Lessons	Outcomes After Percutaneous Coronary Intervention Among	Nothing to Disclose
		From the Real World	Patients With a History of Transient Ischemic Attack or	
			Cerebrovascular Accident: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium	
Dixon	Simon	22. Interventional Cardiology: Coronary	Suggested Reviewer	Nothing to Disclose
		Intervention: Left Main, Multivessel, Bifurcation Team 1		
Djordjevic-Dikic	Ana	Coronary Syndromes Revisited: International	Noninvasive Functional and Prognostic Estimation of CAD in	Nothing to Disclose
		Perspectives From the ACC Italy Chapter,	Challenging Pathological Scenarios	
		ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of		
		Cardiology		
Djousse	Luc	The Heavy Heart: Practicing Heart Failure	Panelist	RESEARCH/RESEARCH GRANTS - Amarin Pharma Inc,Merck
Djousse	Luc	Cardiology in an Obesity Epidemic The Heavy Heart: Practicing Heart Failure	The Epidemiology of Heart Failure and Obesity	& Co., Inc. RESEARCH/RESEARCH GRANTS - Amarin Pharma Inc,Merck
-		Cardiology in an Obesity Epidemic		& Co., Inc.
Djousse	Luc	Updates on Risk Factors for Cardiovascular Disease	Walking Pace Is Inversely Associated With Risk of Death and Cardiovascular Disease: The Physicians' Health Study	RESEARCH/RESEARCH GRANTS - Amarin Pharma Inc, Merck & Eamp; amp; Co., Inc.
Djousse	Luc	Predicting the Future: Observations and	Pulmonary Hypertension Is Associated With a Higher Risk of Heart	RESEARCH/RESEARCH GRANTS - Amarin Pharma Inc,Merck
		Discoveries From Registries and Databases	Failure and Mortality in Patients With Chronic Kidney Disease: The	& Co., Inc.
Djousse	Luc	Emerging Developments in HFpEF and	Jackson Heart Study Serum Sodium Is Associated With Mortality in Heart Failure With	RESEARCH/RESEARCH GRANTS - Amarin Pharma Inc,Merck
•		Arryhthmias	Preserved Ejection Fraction in the U.S. Veteran Population	& Co., Inc.
Dlott	Richard	Measuring Success in Cardiac Rehabilitation	Success of a Home-Based Cardiac Rehabilitation Program in a Population of Nearly 4 Million	Nothing to Disclose
Dmitriev	Yuri	Cutting Edge Vascular Medicine	A Novel Necroptosis Inhibitors (Necrosulfonamide and Necrostatin-	Nothing to Disclose
			1s) Demonstrate Therapeutic Potential for Myocardial Ischemia-	
Do	Duc	Arrhythmias and Clinical EP: Devices 3	Reperfusion Injury Safety of Cardiac Magnetic Resonance Imaging With Non-	Nothing to Disclose
_			Conditional Cardiac Implantable Electronic Devices	
Do	Jacquelyn-My	Making Progress in Understanding Heart Failure	Home Telehealth Reduces Adverse Outcomes in Heart Failure	Nothing to Disclose
Do	Victor	Congenital Heart Disease: New Diagnostic	Cardiovascular Health of Offspring of Diabetic Mothers From the	Nothing to Disclose
Dobesh	Paul	Approaches in Congenital Heart Disease When Anticoagulation Needs to be Stopped	Fetus Through Late Infancy Stages Anticoagulation Reversing Agents: What's the Latest and	CONSULTANT FEES/HONORARIA - AstraZeneca
Dobesii	r aui	What Are the Options? Pharmacology II	Greatest?	Pharmaceuticals,Boehringer Ingelheim,Daiichi Sankyo,
				Inc, Janssen Pharmaceuticals, Pfizer
Dobrzynski	Jeanne	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Relationship Between Incident Heart Failure and Dropout Rate in Randomized Clinical Trials of Antihypertensive Therapy	Nothing to Disclose
Doddamani	Sanjay	Acute Heart Failure: Evaluating Strategies to	Heart Failure Phenotyping by Latent Class Analysis Identifies	Nothing to Disclose
		Prevent Readmissions	Subpopulations at High Risk of Mortality and Readmissions: Insights From a Real World Database	
Dodson	John	Cardiac Rehab in 2017: Tailoring The	Panelist	CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals
Dadasa		Approach to the Times	Heart Directolis Description on Toy of the Control	
Dodson	John	Novel Echocardiographic Methods for Assessing Cardiac Function	Use of Diastolic Parameters on Transthoracic Echocardiogram to Predict Left Atrial Appendage Thrombus in Patients With Atrial	CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals
		-	Fibrillation	
Dodson	John	Interventional Cardiology: TAVR 2	Direct Home Discharge and Likelihood of 30-Day Hospital Readmission After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals
			(TAVR): Findings From the STS/ACC TVT Registry	
Doherty	Caroline	Palliative Care for the 99% II: Skillbuilding: PC	Interdisciplinary Palliative Care and Decision Making in Aortic	Nothing to Disclose
Doherty	Caroline	Encounters: What Would you do? Part I Palliative Care for the 99% III: Skillbuilding: PC	Stenosis Co-Chair	Nothing to Disclose
		Encounters: What Would you do? Part II		5
Doherty	Caroline	Palliative Care for the 99% III: Skillbuilding: PC Encounters: What Would you do? Part II	Palliative Care in the Heart Failure Patient Interdisciplinary Panel	Nothing to Disclose
Doherty	Caroline	Effective Medication Management in the Older	Case Presentation: Case of an older patient with multiple chronic	Nothing to Disclose
		Adults with CVD: Pharmacology Program I	conditions, including several CV conditions (atrial fibrillation, hypertension, diabetes, heart failure, chronicrenal disease,	
			osteoarthritis, etc) and a long list of drugs	
Dohi	Kaoru	Diabetes, Hyperlipidemia, and Coronary Artery	Acute Effects of Sodium-glucose Cotransporter 2 Inhibitor on	Nothing to Disclose
		Disease, Prevention and Treatment: International Perspectives From the Japanese	Hemodynamic, Neurohumoral and Body Fluid Regulation in Patients With Type 2 Diabetes Mellitus and Stable Heart Failure	
		College of Cardiology, Saudi Heart		
		Association, and American College of Cardiology		
Dohi	Tomotaka	Unusual Presentations of ACS	Combined Serum Albumin and C-Rective Protein Levels Predict	Nothing to Disclose
	1	1	Long-Term Outcomes in Patients With Coronary Artery Disease	
Dohi	Tomotaka	CAD in Unique Patient Populations	After a First Percutaneous Coronary Intervention Prognostic Impact of Geriatric Nutritional Risk Index in Patients	Nothing to Disclose
Dohi	Tomotaka	CAD in Unique Patient Populations	Prognostic Impact of Geriatric Nutritional Risk Index in Patients Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Dohi Doi	Tomotaka Yoshinori	CAD in Unique Patient Populations FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Prognostic Impact of Geriatric Nutritional Risk Index in Patients Undergoing Percutaneous Coronary Intervention	Nothing to Disclose Nothing to Disclose

Contract of the second				l .
Last Name Doimo	First Name Sara	Session Title Updates in Stable Ischemic Heart Disease	Presentation Title The Close Relationship Between Drug Intolerance and Major	Disclosures Nothing to Disclose
			Cardiac and Cerebrovascular Events After an Acute Coronary Syndrome or Coronary Revascularization	
Doimo	Sara	Predicting Outcomes in Cardiac Rehabilitation Patients	Predictors of Major Adverse Cardiac Events in Long-Term Follow- Up After Cardiac Rehabilitation	Nothing to Disclose
Doing	Anthony	Advances in Chronic Total Occlusion	The Impact of Epicardial Collateral Use on the Outcomes of Chronic	Nothing to Disclose
		Intervention	Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	
Doing	Anthony	Advances in Chronic Total Occlusion Intervention	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	Nothing to Disclose
Dokainish	Hisham	28. Non Invasive Imaging: Echo Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals
Dolan	Brigid	FIT Forum: Acing the Transition: What FITs Need to Know to Launch A Successful Career	Negotiating Contracts	Nothing to Disclose
Dolgner	Stephen	Therapeutic Advances in Congenital Heart	Stable Incidence of Endocarditis in Pediatric Patients Before and	Nothing to Disclose
Doll	Jacob	Disease Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	After the 2007 Endocarditis Prophylaxis Guidelines Bleeding and Premature Antiplatelet Therapy Discontinuation After Myocardial Infarction Among Patients With Chronic Kidney Disease	RESEARCH/RESEARCH GRANTS - Gilead Sciences, Inc.
Doll	Jacob	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Patient-REported Preferences Affecting Revascularization Decisions (PREPARED): A Pilot Randomized Study of Shared Decision-	RESEARCH/RESEARCH GRANTS - Gilead Sciences, Inc.
Dolmatova	Elena	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Making Trends in Utilization of Inpatient Palliative Care Services and Racial Disparity of Disposition to Hospice Care Among Patients With Heart	Nothing to Disclose
Dolmatova	Elena	New Insights Into Prediction and Treatment of	Failure in the United States Between 2003 and 2012 Dietary Sodium Intake Among United States Adults With	Nothing to Disclose
Domaradzki	Lisa	Hypertension FIT Clinical Decision Making: Heart Failure and	Hypertension, 1999-2012 Adderall Induced Cardiomyopathy Resulting in a Stressful Exam	Nothing to Disclose
Domaradzki	Lisa	Pulmonary Hypertension FIT Clinical Decision Making: Heart Failure and	Night Cardiogenic Shock as the Initial Presentation of Pheochromocytoma	Nothing to Disclose
		Pulmonary Hypertension		3
Domei	Takenori	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Long-Term Vascular Response to Permanent Polymer Everolimus- Eluting Stent Compared With Biodegradable Polymer Biolimus- Eluting Stent: Five-Year Follow-Up Optical Coherence Tomography Study	Nothing to Disclose
Domei	Takenori	Coronary Intervention in Interventional Cardiology: Core Concepts	Incidence and Clinical Impact of Longitudinal Stent Deformation After the PROMUS Element Platinum Chromium-Everolimus Eluting Stent Implantation	Nothing to Disclose
Domei	Takenori	Interventional Cardiology: PCI in Complex Patients	Three-Year Clinical Outcomes of the XIENCE/PROMUS Cobalt- Chromium Everolimus-Eluting Stent in Patients Treated With In- Stent Restenosis	Nothing to Disclose
Dominguez	Beatriz	The Challenges of Outcome Prediction in Valvular Heart Disease	Right Ventricle Free Wall Strain Predicts Post-Surgical Low Cardiac Output Syndrome in Patients Undergoing Aortic Valve Replacement	Nothing to Disclose
Dominguez-Rodriguez	Alberto	Timely Topics in Acute Coronary Syndromes	Time to Treatment With Melatonin and Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction: Insights From the MARIA (Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty) Trial	Nothing to Disclose
Don	Creighton	Coronary Intervention in Interventional Cardiology: Core Concepts	Combined Drug-Eluting Balloon and Brachytherapy to Treat In-Stent Restenosis: Early Safety and Efficacy	CONSULTANT FEES/HONORARIA - MEDTRONIC; SPEAKER'S BUREAU - Cardiovascular Solutions Inc
Donato	Leslie	Innovations in Cardiovascular Risk Assessment	Plasma Ceramide Concentrations Predict Risk of Cardiovascular	CONSULTANT FEES/HONORARIA - DiaDexus
Dondi	Maurizio	and Reduction Nuclear Cardiology: Quality	Events Worldwide Variation in the Use of Nuclear Cardiology Camera	Nothing to Disclose
			Technology, Reconstruction Software, and Acquisition Protocols: Findings From the IAEA Nuclear Cardiology Protocols Study (INCAPS)	
Donnellan	Joyce	Innovations in Education	Teaching Tomorrow's Teachers: An Innovative Model of Clinician- Educator Development for Trainees	Nothing to Disclose
D'Onofrio	Gail	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Mechanisms of Acute Myocardial Infarction in Young Women and Discharge Medication Patterns	Nothing to Disclose
Donovan	Claire	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Influence of Cardiac Arrest and Cardiogenic Shock on Outcomes Among 4,500 Consecutive ST Elevation Myocardial Infarction	Nothing to Disclose
_		Syndrome	Patients	
Donovan	Claire	Timely Topics in Acute Coronary Syndromes	Outcome and Characteristics of Shockable Versus Non-Shockable Cardiac Arrest in ST Elevation Myocardial Infarction at a Regional Transfer Center	Nothing to Disclose
Dookhan	Christina	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Comparison of False Versus True ST Elevation Myocardial Infarction Activation Rates in Patients Having Pre-Activation Point of Care Troponin Levels	Nothing to Disclose
Dookhan	Christina	Unusual Presentations of ACS	Trends Associated With False ST-Elevation Myocardial Infarction	Nothing to Disclose
Dooley	Daniel	Making Progress in Understanding Heart Failure	Activation Orthopnea or Paroxysmal Nocturnal Dyspnea in Older Adults Without Prevalent Heart Failure Is a Predictor, but Not an Independent Risk Factor for Incident Heart Failure: Insights From	Nothing to Disclose
Dooley	Daniel	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	the Cardiovascular Health Study Among Older Heart Failure (HF) Patients With In-Hospital Acute Kidney Injury (AKI), an Improvement in Kidney Function Is Associated With a Higher Risk of Post-Discharge Mortality but Not	Nothing to Disclose
Dooley	Daniel	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Readmission Heart Failure Hospitalization (HFH) Despite Digoxin Therapy Versus No HFH Despite Placebo in the Digitalis Investigation Group (DIG) Trial: Insights Into Risk Factors for HFH in HF and Reduced Ejection Fraction (HFTEF)	Nothing to Disclose
Dooley	Daniel	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Clinical Effectiveness of Spironolactone in Hospitalized Older Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or Equal to 30 mL/min/1.73 m ²) Patients With Heart Failure	Nothing to Disclose
Dooley	Daniel	Heart Failure and Cardiomyopathies: Heart	Chronic Alpha Blocker Use and Outcomes in Older Male Medicare	Nothing to Disclose
Dooley	Daniel	Failure Is Just a Revolving Door Why Can't We Be Friends? Controversies in Heart Failure Management	Beneficiaries Hospitalized for Heart Failure Adverse Outcomes With Use of Hydralazine and Nitrate Combination Therapy in Hospitalized Older Non-Black Patients With	Nothing to Disclose
Doorey	Andrew	Interventional Cardiology: TAVR 1	Heart Failure and Reduced Ejection Fraction (HFrEF) Safety and Efficacy of Using Pressure Wire With Dobutamin Infusion in Themoynamic Assessment of Low Flow Low Gradient Aortic	Nothing to Disclose
Doorey	Andrew	Interventional Cardiology: PCI and TAVR in	Stenosis Hemodynamic Assessment of Low Flow, Low Gradient Severe	Nothing to Disclose
Doorey	Andrew	Complex Patients Interventional Cardiology: Structural Heart	Aortic Stenosis With Preserved EF Using a Pressure Wire The Impact of Transaortic Gradient and Transaortic Flow on the	Nothing to Disclose
Doorey	Andrew	Disease	Discrepancy Between Echocardiographic and Cardiac	· · · · · · · · · · · · · · · · · · ·



| ACC.17

WASHINGTON, DC | FRI•SAT•SUN

Carried States				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Doran	Jesse	Innovations in Education	Beat Blasts: A Multicenter Study of an Electrocardiogram Email Curriculum for Medicine Residents	Nothing to Disclose
Dorbala	Sharmila	PET Myocardial Perfusion Imaging: Practical Considerations- A Case-Based Discussion	Panelist	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - General Electric; RESEARCH/RESEARCH GRANTS - Astellas Pharma US Inc
Dorbala	Sharmila	PET Myocardial Perfusion Imaging: Practical Considerations- A Case-Based Discussion	PET Myocardial Perfusion Imaging Cases	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - General Electric; RESEARCH/RESEARCH GRANTS - Astellas Pharma US Inc
Dorbala	Sharmila	Nuclear Cardiology: Current Applications and Best Practices: Joint Symposium of the American Society of Nuclear Cardiology and the American College of Cardiology	Cardiac PET in Systemic Diseases	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - General Electric; RESEARCH/RESEARCH GRANTS - Astellas Pharma US Inc
Dorbala	Sharmila	FIT Forum: Stump the Professor	Use of ¹⁸ F-Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for Diagnosing Prosthetic Valve Perivalvular Abscess	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - General Electric; RESEARCH/RESEARCH GRANTS - Astellas Pharma US Inc
Dorbala	Sharmila	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Integrating Hyperemic Myocardial Blood Flow and Coronary Flow Reserve for Predicting Cardiovascular Mortality Outcomes in Patients With Known or Suspected Ischemic Heart Disease	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - General Electric; RESEARCH/RESEARCH GRANTS - Astellas Pharma US Inc
Dorbala	Sharmila	Young Investigator Awards Competition: Clinical Investigations	Impaired Coronary Flow Reserve Is Associated With Diastolic Dysfunction and HFpEF Outcomes in Patients Without Overt CAD	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - General Electric; RESEARCH/RESEARCH GRANTS - Astellas Pharma US Inc
Dorbala	Sharmila	Nuclear Cardiology: Prognosis	Myocardial Scar but Not Ischemia Predicts Defibrillator Shocks and Sudden Cardiac Death in Patients With Reduced Left Ventricular Ejection Fraction	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - General Electric; RESEARCH/RESEARCH GRANTS - Astellas Pharma US Inc
Dorbala	Sharmila	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Relationship of Coronary Flow Reserve With Body Mass Index and Adverse Outcomes in Patients Without Overt Ischemic Heart Disease: Implications for Metabolic Surgery Eligibility	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - General Electric; RESEARCH/RESEARCH GRANTS - Astellas Pharma US Inc
Dorbala	Sharmila	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Association Between Coronary Flow Reserve and Adverse Cardiovascular Events Along a Continuum of Metabolic Disease in Symptomatic Patients Without Overt Coronary Artery Disease	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - General Electric; RESEARCH/RESEARCH GRANTS - Astellas Pharma US Inc
Dorbala	Sharmila	Emerging Applications for Imaging Cardiac Amyloidosis: Nuclear Cardiology	ACC Poster Moderator	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - General Electric; RESEARCH/RESEARCH GRANTS - Astellas Pharma IUS Inc.
Dorbala	Sharmila	30. Non Invasive Imaging: Nuclear Team 1	Suggested Reviewer	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - General Electric; RESEARCH/RESEARCH GRANTS - Astellas Pharma US Inc
Dorfman	Adam	10. Congenital Heart Disease: Pediatric Team	Suggested Reviewer	Nothing to Disclose
Dorian	Paul	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Concomitant Use of Antiplatelet and Oral Anticoagulation Among Patients With Atrial Fibrillation: Insights From the Prospective SPRINT-AF Registry	CONSULTANT FEES/HONORARIA - sanofi-aventis , Bayer, BMS, Pfizer, Servier, Boehringer-Ingleheim
Doris	Mhairi	Non Invasive Imaging: Coronary Calcium	Coronary Artery Calcium in the Elderly: Prevalence, Severity, and	Nothing to Disclose
Doris	Mhairi	Scoring and CV Risk Assessment Non Invasive Imaging: New Technologies	Association With All-Cause Mortality Improvement in LDL Is Associated With Decrease in Non-Calcified Plaque Volume on CTA as Measured by Automated Quantitative	Nothing to Disclose
Doris	Mhairi	Imaging With Cardiac CT: The Case for	Software Hormone Replacement Therapy Is Associated With Less Coronary	Nothing to Disclose
Doris	Mhairi Katrina	Calcium Noninvasive Assessment of Coronary Flow	Atherosclerosis and Lower Mortality Relationship Between Whole Vessel Quantitative Plaque	Nothing to Disclose
Doros	Gheorghe	Reserve: Clinical Implications Making Progress in Understanding Heart	Characteristics and Noninvasive Fractional Flow Reserve From Coronary Computed Tomography Angiography Serial Assessment of Heart Rate and Beta Blocker Use in Chronic	Nothing to Disclose
	-	Failure	Heart Failure Patients With Reduced Ejection Fraction in a Large Integrated Healthcare Network	_
Doros	Gheorghe	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Association Between Predicted Risk of Recurrent Ischemic Events and Achievement of Secondary Prevention Goals After PCI	Nothing to Disclose
Doros	Gheorghe	Advances in HCM, PPCM and Other Cardiomyopathies	VE/VCO2 Is a Powerful Predictor of Mortality in Wild-Type Transthyretin Amyloidosis	Nothing to Disclose
dos Santos Filho	Raul Dias	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Statin-Induced Hepatitis in a Secondary Prevention Patient With Severe Hypercholesterolemia	CONSULTANT FEES/HONORARIA - Amgen,Biolab,Boehringer Ingelheim Pharmaceuticals, Inc,Eli-Lilly,Genzyme,Kowa,Pfizer,Sanofi/Regeneron; SPEAKER'S BUREAU - Merck,Praxis Laboratories
Doshi	Rahul	Arrhythmias and Clinical EP: Anticoagulation Issues	Does Stroke Risk Influence the Decision to Anticoagulate Post Percutaneous Coronary Intervention Patients With Atrial Fibrillation: A Review of 3850 Patients	CONSULTANT FEES/HONORARIA - Boston Scientific, Johnson & Dongamp; Johnson, St. Jude Medical, Zoll
Doshi	Rajkumar	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	More Bleeding and Myocardial Infarctions Post-PCI in Patients With BMI Over 30	Nothing to Disclose
Doshi	Rajkumar	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Comparison of IABP With pLVAD in the Setting of Complex PCI and Cardiogenic Shock	Nothing to Disclose
Doshi	Rajkumar	Novel Developments in Acute Coronary	Transradial Access Is Superior to Femoral Access Among Patients	Nothing to Disclose
Doshi	Rajkumar	Syndromes Antithrombotic Therapy in Ischemic Heart	With Acute Coronary Syndrome Bivalirudin and Unfractionated Heparin Have Equivalent Outcomes	Nothing to Disclose
Doshi	Rajkumar	Disease Optimizing the Care of ACS Patients	in Non-Acute Coronary Syndrome Patients Unfractionated Heparin Is Superior to Bivalirudin in Transradial	Nothing to Disclose
Doshi	Rajkumar	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Patients With Acute Coronary Syndrome Bivalirudin Versus Unfractionated Heparin Monotherapy in Percutaneous Coronary Intervention: A Comparison of Acute	Nothing to Disclose
Doss	Emile	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Adverse Outcomes 33 Year Old Female With Sudden Cardiac Arrest	Nothing to Disclose
Doster	Kristin	Disease, and Vascular Medicine Interdisciplinary Cardiovascular Team Care	See You in 7: An Advanced Practice Provider Post PCI Clinic	Nothing to Disclose
Dougherty	Anne	Delivery: Quality, Safety, and Satisfaction Atrial Fibrillation and VT: Unique Populations and Solutions	Improving Transition of Care A Retrospective Study of the Effect of Colchicine Administration Timing on the Incidence of Post-Operative Atrial Fibrillation After a	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Biomarin Pharmaceuticals; RESEARCH/RESEARCH GRANTS -
Douglas	John	Structural Heart Interventions: Focus on Mitral	Non Transplant Cardiac Surgery Long-Term Outcomes of Alcohol Septal Ablation in Young Patients	Biotronik Nothing to Disclose
-		Valve, Left Atrial Appendage and HOCM	With Hypertrophic Cardiomyopathy	-
Douglas	Pamela	Cardiovascular Update for the Clinician II: Chronic Coronary and Systemic Disease (A Symposium by Valentin Fuster)	Panelist	CONSULTANT FEES/HONORARIA - CardioDX (Spouse), Elsevier (Spouse), Genome Magazine (spouse), Elsevier (Spouse), Genome Magazine (spouse), Interleukin Genetics (spouse), omicia (spouse), Pappas Ventures (Spouse), UpToDate; DATA SAFETY MONITORING BOARD - GE Healthcare; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere, Host Response, omicia (spouse), Origin Commercial Advisors; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioDX (Spouse); RESEARCH/RESEARCH GRANTS - 23andMe, Abbott, BMS, Edwards Lifesciences, gilead, Ibis Biosciences, Singulex



Last Name Douglas Douglas	First Name Pamela Pamela	Session Title Cardiovascular Update for the Clinician II: Chronic Coronary and Systemic Disease (A Symposium by Valentin Fuster) Featured Clinical Research I	Presentation Title Chest Pain Evaluation: No Test, Stress Test or CT Angio? Panelist	Disclosures CONSULTANT FEES/HONORARIA - CardioDX (Spouse), Elsevier (Spouse), Genome Magazine (spouse), Interleukin Genetics (spouse), omicia (spouse), Pappas Ventures (Spouse), Jufo Tabate, DATA SAFETY MONITORING BOARD - GE Healthcare; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere, Host Response, omicia (spouse), Origin Commercial Advisors; OWNERSHIP INTEREST/PARTINERSHIP/PRINCIPAL - CardioDX (Spouse), RESEARCH/RESSARCH GRANTS - 23 and Me, Abbott, BMS, Edwards Lifesciences, gilead, libis Biosciences, Singulex CONSULTANT FEES/HONORARIA - CardioDX (Spouse), Elsevier (Spouse), Genome Magazine (spouse), Interleukin Genetics (spouse), Omicia (spouse), Pappas Ventures (Spouse), UpToDate; DATA SAFETY MONITORING DARD, CBR FLeathcare; OFFICER DIRECTOR TRUSTEE OR
Douglas	Pamela	FIT Forum: Mix and Mingle	Imaging	BOARD - GE Healthcare: OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere, Host Response, omicia (spouse), Origin Commercial Advisors; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioDX (Spouse); RESEARCH/RESEARCH GRANTS - 23 and Me. Abbott, BMS, Edwards Lifesciences, gilead, Ibis Biosciences, Singulex CONSULTANT FEES/HONORARIA - CardioDX (Spouse), Elsevier (Spouse), Genome Magazine (spouse), Interleukin Genetics (spouse), omicia (spouse), Pappas Ventures (Spouse), UpToDate; DATA SAFETY MONITORING BOARD - GE Healthcare; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere, Host Response, omicia (spouse), Origin Commercial Advisors; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Douglas	Pamela	Late-Breaking Clinical Trials: Deep Dive I	Co-Chair	LarioloX (spouse); RESEARCH/IRESEARCH (KRANTS - 123andMe Abbott,BMS, Edwards Lifesciences,gliead,lbis Biosciences,Singulex (CONSULTANT FEES/HONORARIA - CardioDX (Spouse),Elsevier (Spouse),Genome Magazine (spouse),Elsevier (Spouse),Genome Magazine (spouse),Despouse),Unitorieuklin Genetics (spouse),omicia (spouse),Pappas Ventures (Spouse),Unitorieuklin Genetics (spouse),Omicia (spouse),Pappas Ventures (Spouse),Unitorieuklin Genetics (Spouse),Despouse), Despouse, Despouse, Despouse, Origin Commercial Advisors; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioDX (Spouse); RESEARCH/IRESEARCH GRANTS - 23andMe Abbott,BMS,Edwards Lifesciences,gilead,Ibis Biosciences, Singulex
Douglas	Pamela Pamela	Late-Breaking Clinical Trials: Deep Dive I	Panelist Coronary CTA Angiography enables therapeutic decision making	Blosciences.singulex CONSULTANT FEES/HONORARIA - CardioDX (Spouse),Elsevier (Spouse),Genome Magazine (spouse),Interleukin Genetics (spouse),omicia (spouse),Pappas Ventures (Spouse),UpToDate; DATA SAFETY MONITORING BOARD - GE Healthcare; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere,Host Response,omicia (spouse),Origin Commercial Advisors; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioDX (Spouse); RESEARCH/RESSARCH GRANTS - 23andMe,Abbott,BMS,Edwards Lifesciences,gilead,Ibis Biosciences,Singulex CONSULTANT FEES/HONORARIA - CardioDX
Douglas	Pamela Pamela	Clinical Utility of Lardials C1 in 2017; Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology WIC Brown Bag Lunch Session: Publishing,	Loronary C I A Angiography enables therapeutic decision making that reduces hard events- Lessons from Scot-Heart and Promise Interacting with the C-Suite: How to Negotiate the Minefields	CONSULTAIN TEES/HUNURARIA - CardioDX (Spouse), Elsevier (Spouse), Genome Magazine (spouse), Interleukin Genetics (spouse), omicia (spouse), Pappas ventures (Spouse), UpToDate: DATA SAFETY MONITORING BOARD - GE Healthcare; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere; Host Response, omicia (spouse), Origin Commercial Advisors; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioDX (Spouse); RESEARCH/RESESARCH GRANTS - 23andMe, Abbott, BMS, Edwards Lifesciences, gilead, Ibis Biosciences, Singulex CONSULTANT FEES/HONORARIA - CardioDX
Douglas		Social Media and Negotiating the C-Suite: Tools for Success in Academia and Private Practice		(Spouse), Elsevier (Spouse), Genome Magazine (spouse), Interleukin Genetics (spouse), micia (spouse), Pappas Ventures (Spouse), UpToDate; DATA SAFETY MONITORING BOARD - GE Healthcare; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere; Alere; Alere; OTHER FIDUCIARY ROLE - Alere; OTHER - Alere; Alere; OTHER - INTEREST/PARTNERSHIPP/RINCIPAL - CardioDX (Spouse); RESEARCH/RESEARCH GRANTS - 23andMe, Abbott, BMS, Edwards Lifesciences, gilead, libs Biosciences, Singulex
Douglas	Pamela	Radiation from Diagnostic Imaging: Risk- benefit Analysis	Co-Chair	CONSULTANT FEES/HONORARIA - CardioDX (Spouse), Elsevier (Spouse), Genome Magazine (spouse), Elsevier (Spouse), Genome Magazine (spouse), Interleukin Genetics (spouse), omicia (spouse), Pappas Ventures (Spouse), Up ToDate; DATA SAFETY MONITORING BOARD - GE Healthcare; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere, Host Response, omicia (spouse), Origin Commercial Advisors; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioDX (Spouse); RESEARCH/RESEARCH GRANTS - 23andMe, Abbott, BMS, Edwards Lifesciences, gilead, lbis Biosciences, Singulex
Douglas	Pamela	Highlighted Original Research: Interventional Cardiology and the Year in Review	Implications of Worsening Right Ventricular Function Following Transcatheter or Surgical Aortic Valve Replacement: Insights From PARTNER2A	CONSULTANT FEES/HONORARIA - CardioDX (Spouse), Elsevier (Spouse), Genome Magazine (spouse), Elsevier (Spouse), Genome Magazine (spouse), Interleukin Genetics (spouse), omicia (spouse), Pappas Ventures (Spouse), Up ToDate; DATA SAFETY MONITORING BOARD - GE Healthcare; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere, Host Response, omicia (spouse), Origin Commercial Advisors; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioDX (Spouse); RESEARCH/RESEARCH GRANTS - 23andMe, Abbott, BMS, Edwards Lifesciences, gliead, lbis Biosciences, Singulex



Contract of the contract of th				
Last Name Douglas Douglas	First Name Pamela	Session Title Interventional Cardiology: TAVR 1 Traditional and Novel Factors Used to Assess	Presentation Title Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: Insights From PARTNER 2A Trial Outcomes in Patients With Diabetes Mellitus and Suspected	Disclosures CONSULTANT FEES/HONORARIA - CardioDX (Spouse),Elsevier (Spouse),Genome Magazine (spouse),Interleukin Genetics (spouse),omicia (spouse),Pappas Ventures (Spouse),UpToDate; DATA SAFETY MONITORING BOARD - GE Healthcare; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere,Host Response,omicia (spouse),Origin Commercial Advisors; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioDX (Spouse); RESEARCH/RESESARCH GRANTS - 23andMe Abbott,BMS,Edwards Lifesciences,gilead,libis Biosciences,Singulex CONSULTANT FEES/HONORARIA - CardioDX
		the Risk of, and Used for the Treatment of, Coronary Artery Disease	Coronary Artery Disease Following Non-Invasive Testing: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	(Spouse), Elsevier (Spouse), Genome Magazine (spouse), Interleukin Genetics (spouse), omicia (spouse), Pappas Ventures (Spouse), Up To Date: DATA SAFETY MONITORING BOARD - GE Healthcare; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere, Alex - Alexe; OTHER - MIDEN SEARCH (SPOUSE), Origin Commercial Advisors; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioDX (Spouse), RESEARCH/RESEARCH GRANTS - 23 and Me, Abbott, BMS, Edwards Lifesciences, gliead, libis Biosciences, Singulex
Douglas	Pamela	Non Invasive Imaging: Expanding Clinical Applications	Does Patient Prosthesis Mismatch Defined by CT LVOT Area Predict Downstream Clinical Outcomes?	CONSULTANT FEES/HONORARIA - CardioDX (Spouse), Elsevier (Spouse), Genome Magazine (spouse), Elsevier (Spouse), Genome Magazine (spouse), Interleukin Genetics (spouse), omicia (spouse), Pappas Ventures (Spouse), Up ToDate; DATA SAFETY MONITORING BOARD - GE Healthcare; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere, Host Response, omicia (spouse), Origin Commercial Advisors; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioDX (Spouse); RESEARCH/RESEARCH GRANTS - 23andMe Abbott, BMS, Edwards Lifesciences, gliead, Ibis Biosciences, Singulex
Douglas	Pamela	Interventional Cardiology: TAVR 2	Worsening Tricuspid Regurgitation and Increased Mortality After Aortic Valve Replacement: Insights From PARTNER2A	CONSULTANT FEES/HONORARIA - CardioDX (Spouse), Elsevier (Spouse), Genome Magazine (spouse), Interleukin Genetics (spouse), omicia (spouse), Pappas Ventures (Spouse), Up1 ToDate; DATA SAFETY MONITORING BOARD - GE Healthcare; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere, Host Response, omicia (spouse), Origin Commercial Advisors; OWNERSHIP INTEREST/PATNERSHIP/PRINCIPAL - CardioDX (Spouse); RESEARCH/RESEARCH GRANTS - 23andMe, Abbott, BMS, Edwards Lifesciences, gilead, libis Biosciences, Singulex
Douglas	Pamela	Innovative Use of Echocardiography	The Impact of Rigorous Quality Improvement on 3D Echocardiography Image and Data Quality in an International Multisite Randomized Trial	CONSULTANT FEES/HONORARIA - CardioDX (Spouse), Elsevier (Spouse), Genome Magazine (spouse), Interleukin Genetics (spouse), unicia (spouse), Pappas Ventures (Spouse), Up1 ToDate; DATA SAFETY MONITORING BOARD - GE Healthcare; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere, Host Response, omicia (spouse), Origin Commercial Advisors; OWNERSHIP INTEREST/PATNERSHIP/PRINCIPAL - CardioDX (Spouse); RESEARCH/RESEARCH GRANTS - 23andMe, Abbott, BMS, Edwards Lifesciences, gilead, libis Biosciences, Singulex
Douglas	Pamela	Insights From Echocardiography Use	Universal Use of Contrast to Detect Left Ventricular Thrombus in Patients With Reduced Ejection Fraction is Not Associated With Improved Clinical or Cost-Effectiveness Outcomes	CONSULTANT FEES/HONORARIA - CardioDX (Spouse), Elsevier (Spouse), Genome Magazine (spouse), Elsevier (Spouse), Genome Magazine (spouse), Pappas Ventures (Spouse), UpToDate; DATA SAFETY MONITORING BOARD - GE Healthcare; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere, Host Response, omicia (spouse), Origin Commercial Advisors; OWNERSHIP INTEREST/PARTNERSHIPP/RINCIPAL - CardioDX (Spouse); RESEARCH/RESEARCH GRANTS - 23andMe, Abbott, BMS, Edwards Lifesciences, gilead, libis Biosciences, Singulex
Douglas	Pamela	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low- Flow Severe Aortic Stenosis and Less Reverse Remodeling After TAVR: A Partner 2 Trial Analysis	CONSULTANT FEES/HONORARIA - CardioDX (Spouse), Elsevier (Spouse), Genome Magazine (spouse), Elsevier (Spouse), Genome Magazine (spouse), Interleukin Genetics (spouse), omicia (spouse), Pappas Ventures (Spouse), Up1 ToDate; DATA SAFETY MONITORING BOARD - GE Healthcare; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere, Host Response, omicia (spouse), Origin Commercial Advisors; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioDX (Spouse); RESEARCH/RESEARCH GRANTS - 23andMe, Abbott, BMS, Edwards Lifesciences, gilead, libis Biosciences, Singulex
Douglas	Pamela	New Perspectives on CAD Risk Factors	Discordances Between Predicted and Actual Risk of Adverse Events in Obese Patients With Suspected Cardiac Ischemia: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	CONSULTANT FEES/HONORARIA - CardioDX (Spouse), Elsevier (Spouse), Genome Magazine (spouse), Elsevier (Spouse), Genome Magazine (spouse), Pappas (spouse), Pappas Ventures (Spouse), Up1 ToDate; DATA SAFETY MONITORING BOARD - GE Healthcare; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Alere; OTHER - Alere, Host Response, omicia (spouse), Origin Commercial Advisors; OWNERSHIP INTEREST/PARTNERSHIPP/RINCIPAL - CardioDX (Spouse); RESEARCH/RESEARCH GRANTS - 23 and Me, Abbott, BMS, Edwards Lifesciences, gilead, libis Biosciences, Singulex
Douketis	James	41. Vascular Medicine: Venous Disease Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Bayer,BMS- Pfizer,Boehringer-Ingelheim,Pfizer,Sanofi-Aventis
Doukky	Rami	Updates on Pulmonary Embolism Management in 2017	The Long-Term Prognostic Value of Highly Sensitive Cardiac Troponin I in Patients With Acute Pulmonary Embolism	Nothing to Disclose
Doukky	Rami	Nuclear Cardiology: Prognosis	The Prognostic Value of Serial Stress Myocardial Perfusion Imaging in Asymptomatic End-Stage Renal Disease Patients Awaiting Kidney	Nothing to Disclose
Doukky	Rami	Arrhythmias and Heart Failure	Transplantation Quadripolar Versus Bipolar Left Ventricular Leads in Cardiac Resynchronization Therapy: An Analysis From the NCDR	Nothing to Disclose
Doutriaux	Maxime	Interventional Cardiology: TAVR 4	Resylicitionization Therapy. An Alianysis From the NCDK Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital	Nothing to Disclose
Dow	Alan	Young Investigator Awards Competition: Outcomes Research	Comparison of a Pharmacist-Physician Collaborative Care Model to Standard Care on the Time to Reach Goal Blood Pressure for Patients With Hypertension	Nothing to Disclose
L	<u> </u>	l .	ratients with hypertension	l .

Control of the contro				<u> </u>
Last Name Dow	First Name Alan	Session Title Novel Strategies for Assessing and Improving	Presentation Title Comparison of a Pharmacist-Physician Collaborative Care Model to	Disclosures Nothing to Disclose
Dow	Aldii	Adherence to Blood Pressure Lowering Therapies	Standard Care on the Time to Reach Goal Blood Pressure for Patients Presenting With Urgent Hypertension	Nothing to Disclose
Doyle	Daniel	Interventional Cardiology: TAVR 4	Clinical Study of the Impact of Previsiting Patient-Prosthesis Mismatch on Valve-in-Valve Performance	Nothing to Disclose
Doyle	Daniel	Frontiers in Mitral Valve Disease and	Significant Mitral Regurgitation in Patients Undergoing Transcatheter	Nothing to Disclose
		Treatment	Aortic Valve Replacement: Evolution and Imaging Predictors of Improvement	
Doyle	Mark	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Non-Invasive Quantification of Cardiac Output With Phase Velocity Mapping in Patients With Pulmonary Hypertension	Nothing to Disclose
Doyle	Mark	Advances in Pulmonary Arterial Hypertension	A Cross Comparison Study of Right Ventricular Hypertrophy With Electrocardiography and Cardiac Magnetic Resonance in Patients With Pulmonary Hypertension	Nothing to Disclose
Doyle	Mark	Arrhythmias and Clinical EP: Basic 5	Pulmonary Vein Remodeling Following Pulmonary Vein Isolation in Patients With Atrial Fibrillation Are They an Epiphenomena a Predictive Cardiac MRI Study	Nothing to Disclose
Doyle	Mark	Insights Into Ischemic Heart Disease: Stable to Erosive Plagues	Clinical Operating Points for Non-Invasive Cardiac Imaging Modalities Lead to Low Detection of Coronary Artery Disease	Nothing to Disclose
Drachman	Douglas	Interventional Live Case Session V: Complex	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular,
		Coronary and Physiology from Mid-America Heart Institute (Kansas City, Missouri)		Inc.,Corindus Vascular Robotics,St. Jude Medical; DATA SAFETY MONITORING BOARD - Prairie Education & Coperative
Drachman	Douglas	Fellows Bootcamp: Interventional Basics	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular, Inc.,Corindus Vascular Robotics,St. Jude Medical; DATA SAFETY MONITORING BOARD - Prairie Education & DATA Research Cooperative
Drachman	Douglas	FIT Forum: Mix and Mingle	Peripheral Vascular Disease	CONSULTANT FEES/HONORARIA - Abbott Vascular, Inc.,Corindus Vascular Robotics,St. Jude Medical; DATA SAFETY MONITORING BOARD - Prairie Education & DATA Research Cooperative
Drachman	Douglas	Controversies and Strategies for Endovascular Treatment of the Femoropopliteal Segment	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular, Inc.,Corindus Vascular Robotics,St. Jude Medical; DATA SAFETY MONITORING BOARD - Prairie Education & DATA
Drachman	Douglas	Meet the New LE PAD Guidelines: Case-	LE Revascularization for Claudication: When, How and Why.	Research Cooperative CONSULTANT FEES/HONORARIA - Abbott Vascular,
		Based Examples of Optimal Vascular Care		Inc.,Corindus Vascular Robotics,St. Jude Medical; DATA SAFETY MONITORING BOARD - Prairie Education & Coperative Research Cooperative
Drachman	Douglas	Highlights in Vascular Medicine Research	Thirty-Day Readmissions Following Endovascular or Surgical Treatment for Critical Limb Ischemia: Analysis of the Nationwide Readmissions Database	CONSULTANT FEES/HONORARIA - Abbott Vascular, Inc., Corindus Vascular Robotics, St. Jude Medical; DATA SAFETY MONITORING BOARD - Prairie Education & Company; Research Cooperative
Drachman	Douglas	21. Interventional Cardiology: Coronary Intervention: Devices Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular, Inc.,Corindus Vascular Robotics,St. Jude Medical; DATA SAFETY MONITORING BOARD - Prairie Education & Damp; amp; Research Cooperative
Drachman	Douglas	Interventional Challenging Cases: Team 1	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular, Inc.,Corindus Vascular Robotics,St. Jude Medical; DATA SAFETY MONITORING BOARD - Prairie Education & DATA Research Cooperative
Drager	Luciano	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Obstructive Sleep Apnea and Diabetes Mellitus Have Synergistic Effects on Adverse Cardiac and Cerebrovascular Events in Patients Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Drakopoulou	Maria	Changing the Natural History of Valve Disease With Medical Therapy	Zoledronic Acid Inhibits Aortic Valve Calcification: A PET/CT Study	Nothing to Disclose
Drakopoulou	Maria	Interventional Cardiology: TAVR 2	The Effect of Mixed Aortic Valve Disease in Clinical Outcomes After	Nothing to Disclose
Drakopoulou	Maria	Innovative Use of Echocardiography	Transcatheter Aortic Valve Replacement Impact on Long Term Mortality of Persistent Pulmonary	Nothing to Disclose
Drakos	Stavros	FIT Clinical Decision Making: Heart Failure and	Hypertension After Transcatheter Aortic Valve Implantation Complete Thrombotic Occlusion of TAVR Valve in Patient With	RESEARCH/RESEARCH GRANTS - AbioMed Inc, HeartWare
Dranow	Elizabeth	Pulmonary Hypertension Novel Developments in Acute Coronary	Continuous Flow LVAD Central Fractional Pulse Pressure Predicts Cardiac Power Index in	Inc,Thoratec Nothing to Disclose
		Syndromes Eugene Braunwald Lecture on Future	Patients With Acute Coronary Syndrome Eugene Braunwald Lecture: Data Sharing in Clinical Trials	Nothing to Disclose
Drazen	Jeffrey	Directions in Cardiovascular Medicine and the Best of JACC Journals	Eugene Braunwald Lecture: Data Sharing in Clinical Thais	Nothing to Disclose
Drazner	Mark	The Forgotten Chamber: The Right Ventricle in	Co-Chair	OTHER - Up To Date; OWNERSHIP
Drazner	Mark	Heart Failure Core Curriculum: Mending the Failing Heart	Revised Medicine Cabinet: New Additions to the Pharmacologic	INTEREST/PARTNERSHIP/PRINCIPAL - Trevena OTHER - Up To Date; OWNERSHIP
Drazner	Mark	Novel Echocardiographic Methods for	Armamentarium in CHF Management Racial Differences in Left Ventricular Recovery in Patients With	INTEREST/PARTNERSHIP/PRINCIPAL - Trevena OTHER - Up To Date; OWNERSHIP
		Assessing Cardiac Function	Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain	INTEREST/PARTNERSHIP/PRINCIPAL - Trevena
Drazner	Mark	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	The Prognostic Role of Prior Heart Failure Hospitalizations in Patients With Severe Symptomatic and Recurrent Heart Failure: Insights From ESCAPE	OTHER - Up To Date; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Trevena
Drazner	Mark	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Stiff Left Atrial Syndrome Following Multiple Ablations Diagnosed With Invasive Hemodynamic Exercise Testing	OTHER - Up To Date; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Trevena
Drazner	Mark	Interventional Cardiology: TAVR 3	Role of Hospital Volume in Identifying Low and High-performing Surgical Valve Centers in the United States	OTHER - Up To Date; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Trevena
Drazner	Mark	Emerging Developments in HFpEF and Arryhthmias	Cardiovascular Ottoches in Heart Failure With Preserved Ejection Fraction: Insights From the TOPCAT Trial	OTHER - Up To Date; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Trevena
Drazner	Mark	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Cardiac Altrophy: A Novel Mechanism for Duchenne Muscular Dystrophy (DMD)-Associated Cardiomyopathy	OTHER - Up To Date; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Trevena
Drazner	Mark	14. Heart Failure and Cardiomyopathies:	Suggested Reviewer	OTHER - Up To Date; OWNERSHIP
Drexel	Heinz	Therapy Team 3 Updates on Risk Factors for Cardiovascular Disease	The Visceral Adiposity Index Predicts Cardiovascular Events Both in Coronary Artery Disease Patients With and in Coronary Artery Disease Patients Without Diabetes	INTEREST/PARTNERSHIP/PRINCIPAL - Trevena Nothing to Disclose
Drexel	Heinz	Innovations in Cardiovascular Risk Assessment and Reduction	ProBNP Strongly Predicts Future Vascular Events in Angiographied Coronary Patients With as Well as in Those Without the Metabolic	Nothing to Disclose
Drexel	Heinz	Diabetes and Other Issues in Cardiovascular	Syndrome Non-Alcoholic Fatty Liver Disease Strongly Predicts Incident	Nothing to Disclose
	Heinz	Prevention Diabetes and Other Issues in Cardiovascular	Diabetes in Patients With Coronary Artery Disease Single and Joint Effects of Obesity and of the Metabolic Syndrome	Nothing to Disclose
Drexel	TICHIZ		on the Development of Diabetes in Patients With Coronary	
		Prevention	Atherosclerosis	
Drexel Drexel	Heinz	Prevention Diabetes and Other Issues in Cardiovascular Prevention The Intersection of Diabetes and ASCVD		Nothing to Disclose Nothing to Disclose



Contract of the Contract of th				
Last Name Dreyer	First Name Rachel	Session Title Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Presentation Title Mechanisms of Acute Myocardial Infarction in Young Women and Discharge Medication Patterns	Disclosures Nothing to Disclose
Dreyer	Rachel	Syndrome Innovations in Cardiovascular Risk Assessment	High-Sensitivity C-reactive Protein and Health Status Outcomes	Nothing to Disclose
Driessen	Roel	and Reduction Nuclear Cardiology: Quality	After Myocardial Infarction Automatic SPECT Analysis Compared to Expert Visual Scoring for	Nothing to Disclose
Driessen	Roel	Advances in Chronic Total Occlusion Intervention	the Detection of Coronary Artery Disease Effects of Successful Percutaneous Coronary Intervention of Chronic Total Occlusions on Myocardial Perfusion and Left	Nothing to Disclose
Driessen	Roel	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Ventricular Function Atherosclerotic Plaque Morphology Is Associated With Impaired Myocardial Blood Flow and Fractional Flow Reserve, Independent	Nothing to Disclose
Driscoll	David	Adult Patients With Congenital Heart Disease:	of Luminal Obstruction Exercise Capacity After Repair of Ebstein Anomaly in Adults: The	Nothing to Disclose
Drogosz	Monika	How Do They Compare? Highlighted Original Research: Congenital	Cone Era Early Hemodynamic Changes After Fetal Aortic Stenosis	Nothing to Disclose
	Laura	Heart Disease and the Year in Review	Valvuloplasty Are Associated With Biventricular Circulation at Birth Non-Fernoral Access Is Associated With 30-Day Mortality in Frail	Nothing to Disclose
Drudi	Laura	Interventional Complexity and Complications Healthcare Innovation for Your Practice: Focus	Patients Undergoing Transcatheter Aortic Valve Replacement Co-Chair	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
Druz Druz	Regina	on Personalized Digital Health Healthcare Innovation for Your Practice: Focus	I am a Hybrid! Leveraging Personalized Medicine into Practice	ROLE - NisitMD,Inc OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
	Regina	on Personalized Digital Health		ROLE - iVisitMD,Inc
Druz	Regina	30. Non Invasive Imaging: Nuclear Team 2	Suggested Reviewer	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - MisitMD, Inc
Drye	Elizabeth	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Admission Types Among Patients With Heart Failure Cared for by Accountable Care Organizations: Variation by Performance on a Measure of Risk Standardized Acute Admission Rates	Nothing to Disclose
Duarte	Valeria	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Perivalvular Leak in Repaired Tetralogy of Fallot	Nothing to Disclose
Dubner	Sergio	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Persistence With Therapy in Patients With Atrial Fibrillation: The GLORIA-AF Registry	CONSULTANT FEES/HONORARIA - Boehringer Inghelgeim; RESEARCH/RESEARCH GRANTS - St Jude Medical
Dubner	Sergio	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Rates of Stroke and Bleeding With Dabigatran 150 and 110 mg BID in Clinical Practice: The GLORIA-AF Registry	CONSULTANT FEES/HONORARIA - Boehringer Inghelgeim; RESEARCH/RESEARCH GRANTS - St Jude Medical
Ducharme	Anique	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Allograft Vasculopathy Over 25 Years Following Cardiac Transplantation: A Single Center Experience	Nothing to Disclose
Dudek	Dariusz	Interventional Challenging Cases: Team 1	ACC Challenging Case Reviewer	SPEAKER'S BUREAU - Abbott Vascular
Dudley	Joel	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Atherosclerotic Plaque Morphology in Response to High Intensity Lipid Lowering Therapy by Multimodality Imaging Among Women and Men: A YELLOW-II Sub-study	CONSULTANT FEES/HONORARIA - Janssen Pharmaceuticals, Inc,LAM Therapeutics
Dudley	Joel	The Inside View: Learning From Intracoronary Imaging	Investigation of Novel Drug Targets Implicated in High-Dose Statin Therapy From Yellow-II Trial: Towards Personalized Lipid Lowering Therapies	CONSULTANT FEES/HONORARIA - Janssen Pharmaceuticals, Inc,LAM Therapeutics
Dudley Jr.	Samuel	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Impact of Treatment Crossovers on Clinical Outcomes in the Rate and Rhythm Control Strategies for Atrial Fibrillation: InsightsFrom the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) Trial	OTHER - intellectual property, intellectual property; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - 3PrimeDx
Dudley Jr.	Samuel	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Ventricular Assist Device Decreases Abnormal Cardiac Sodium Channel mRNA Splicing	OTHER - intellectual property,intellectual property; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - 3PrimeDx
Dudzinski	David	Multi-Disciplinary Care for Acute Pulmonary Embolism: The PE Response Team (PERT) Model	PE Management in the Academic Setting	Nothing to Disclose
Duell	Bart	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Health Disparities Among Patients With Familial Hypercholesterolemia in the CASCADE-FH Patient Registry	CONSULTANT FEES/HONORARIA - Genzyme Corporation,Kaneka,Retrophin,Sanofi-Aventis; RESEARCH/RESEARCH GRANTS - Bristol-Myers Squibb Company, Genzyme Corporation,Pfizer Pharmaceuticals
Duell	Barton	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Discordant Response of Low Density Lipoprotein Cholesterol and Lp(a) Levels to Monoclonal Antibodies Targeting Proprotein Convertase Subtilisin/Kexin Type 9	CONSULTANT FEES/HONORARIA - Genzyme Corporation,Kaneka,Retrophin,Sanofi-Aventis; RESEARCH/RESEARCH GRANTS - Bristol-Myers Squibb Company, Genzyme Corporation,Pfizer Pharmaceuticals
Duffy	Brendan	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	A Rare Case of Chronic Persistent Troponin Elevation	Nothing to Disclose
Duffy	Danielle	Updates in Stable Ischemic Heart Disease	CSL112 Enhances the Ability of Serum to Efflux Cholesterol in Patients With Moderate Renal Impairment	RESEARCH/RESEARCH GRANTS - Aegerion, Amgen, Forest Laboratories, Pfizer Inc, Regeneron; SALARY - CSL Behring
Duffy	Peter	Mastering Cath Lab Leadership and Economics in a New Era: A Joint Symposium by the Society of Cardiovascular Angiography and Interventions and the American College of Cardiology	MACRA and Bundle Payments for PCI: Impact on Quality?	CONSULTANT FEES/HONORARIA - Volcano Corp
Duffy	Peter	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Platelet Reactivity and Outcomes After PCI of Saphenous Vein Grafts Versus Native Coronary Arteries: The ADAPT-DES Study	CONSULTANT FEES/HONORARIA - Volcano Corp
Duffy	Peter	Advances in Chronic Total Occlusion Intervention	Is Platelet Reactivity Associated With Ischemic Events Following Successful Chronic Total Occlusion Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Volcano Corp
Duffy	Stephen	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Outcomes of Pre-Loading Versus In-Lab Loading With Prasugrel and Ticagrelor in Patients With Acute Coronary Syndromes (ACS) Undergoing Percutaneous Coronary Intervention (PCI)	Nothing to Disclose
Dufour	Robert	Advances in Cholesterol Measurement and Management	Orderigonia Perduarieous Gordany Intervention (PCI) Alirocumab Titration Strategy Allows Individualized LDL-C Reduction in a Real World Setting: Results From ODYSSEY OLE (LONG TERM Cohort)	CONSULTANT FEES/HONORARIA - Aegerion, Amgen Inc., Regeneron Pharmaceuticals, Sanofi-Aventis; SPEAKER'S BUREAU - Amgen Inc., Biovail Corporation (has merged with Valeant Pharmaceuticals), Sanofi-Aventis
Dufour	Robert	Advances in Cholesterol Measurement and Management	On-Treatment LDL-C Levels When Alirocumab Dose Is Decreased From 150 to 75 mg Every 2 Weeks in Patients With Heterozygous Familial Hypercholesterolemia: Results From ODYSSEY OLE	Valeati Fraimiaceuticals, Satini-revenus CONSULTANT FEES/HONORARIA - Aegerion,Amgen Inc.,Regeneron Pharmaceuticals,Sanofi-Aventis; SPEAKER'S BUREAU - Amgen Inc.,Biovail Corporation (has merged with Valeant Pharmaceuticals), Sanofi-Aventis
Dufour	Robert	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Alirocumab Treatment in a Real World Setting: Safety Update From an Open-Label Treatment Extension to the ODYSSEY Program for Patients With Heterozygous Familial Hypercholesterolemia	Valeatin Frial mileculudats J., Sartion-Peventus CONSULTANT FEES/HONORARIA - Aegerion, Amgen Inc., Regeneron Pharmaceuticals, Sanofi-Aventis; SPEAKER'S BUREAU - Amgen Inc., Biovail Corporation (has merged with Valeant Pharmaceuticals). Sanofi-Aventis
Dukkipati	Srinivas	Heart Rhythm Disorders: Today and Tomorrow	Co-Chair	RESEARCH/RESEARCH GRANTS - Biosense Webster
Dukkipati	Srinivas	Controversies in Atrial Fibrillation Management	Should Every Patient with AF Who Cannot Take Anticoagulants Get a WATCHMAN	RESEARCH/RESEARCH GRANTS - Biosense Webster
Dulas	Matthew	Valvular Disease Populations at Risk	Surgical Risk and Therapy of Severe Symptomatic Degenerative Mitral Valve Regurgitation in the Contemporary Era	Nothing to Disclose
Dulas	Matthew	Valvular Heart Disease: Mitral Valve Disease	Guideline-Adherence and Survival for Asymptomatic Patients With Severe Mitral Valve Regurgitation	Nothing to Disclose
Dumitrescu	Mihaela	Novel Echocardiographic Methods for Assessing Cardiac Function	Cut Off Value of Rest Left Ventricular Global Longitudinal Strain Is Important in Selecting High Risk Patients With Stable Symptoms	Nothing to Disclose
L	l	1	and Normal Left Ventricular Systolic Function	

and a				l
Last Name Dumont	First Name Eric	Session Title Interventional Cardiology: TAVR 4	Presentation Title Clinical Study of the Impact of Preexisting Patient-Prosthesis	Disclosures Nothing to Disclose
Dumonteil	Nicolas	Interventional Cardiology: TAVR 2	Mismatch on Valve-in-Valve Performance Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: From the WIN-TAVI Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular,Biotronik,Boston Scientific; OTHER - Edwards Lifescience,MEDTRONIC
Dumonteil	Nicolas	Interventional Cardiology: PCI and TAVR in Complex Patients	Replacement. From the Wilst-TAVI Registry Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the Bravo-3 Randomized Trial	CONSULTANT FEES/HONORARIA - Abbott Vascular, Biotronik, Boston Scientific; OTHER - Edwards Lifescience, MEDTRONIC
Dunbar Matos	Christina	Personalized Skills Center: Drill and Practice (Heart Songs, ECG, Hand-Held Echo)	Heart Songs Moderator	Nothing to Disclose
Dunlap	Stephanie	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Influence of Low Versus High Dose on the Association of Loop Diurectic and Mortality in Patients With Heart Failure: Insights From the UNITE-HF Registry	RESEARCH/RESEARCH GRANTS - Cardioxyl, Inc.,National Institutes of Health,Novartis, Inc.,Res-Med; SPEAKER'S BUREAU - Otsuka, Inc.
Dunlay	Shannon	The Old and the New: Impact of Heart Failure Drug Therapies	Liraglutide and Weight Loss Among Patients With Advanced Heart Failure and a Reduced Ejection Fraction: Insights From the FIGHT Trial	Nothing to Disclose
Dunn	Steven	Cardiovascular Team Cases: Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Medicines Company
Dunning	Allison	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Timing and Clinical Predictors of Early Versus Late Readmission Among Patients Hospitalized for Acute Heart Failure: Insights From ASCEND-HF	Nothing to Disclose
Dunnington	Gansevoort	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Outcomes of the Hybrid Video-Assisted Thoracoscopic Surgery (VATS) Maze Followed by Catheter Ablation in Patients With Persistent and Longstanding Persistent Atrial Fibrillation: Clinical Results From a High-Volume Center	CONSULTANT FEES/HONORARIA - AtriCure
Dupont	Laust	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Risk Stratification of Patients Suspected of Coronary Artery Disease Using an Acoustic Detection Algorithm	Nothing to Disclose
Dupont	Matthias	Making Progress in Understanding Heart Failure	Intravascular Volume Expansion in Patients With Heart Failure and Reduced Ejection Fraction Is Not Revealed by Changes in Cardiac Filling Pressures	Nothing to Disclose
Dupont	Matthias	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Cardiac Resynchronization Therapy With Versus Without a Defibrillator: Clinical Insights From Device Interrogation and Mode of Death Analysis	Nothing to Disclose
Dupont	Matthias	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Bioimpedance Algorithms in Implantable Electronic Cardiac Devices: Relevant Diagnostics or Waste of Time?	Nothing to Disclose
Dupre	Matthew	Innovation in Practice Management, Advocacy, and Education	Early Defibrillation by First-Responders in Relation to Fire Stations: Optimal Benefit According to Location	Nothing to Disclose
Duprez	Daniel	Innovations in Cardiovascular Risk Assessment and Reduction	Association Between Serum Collagen Biomarkers and Coronary Artery Calcium: The Multi-Ethnic Study of Atherosclerosis (MESA)	RESEARCH/RESEARCH GRANTS - Pfizer, Sanofi-Aventis, Regeneron, Astra-Zeneca
Duprez	Daniel	Non Invasive Imaging: Prognostic Implications of CT Angiography	Coronary Artery Structural Remodeling by Computed Tomography and Echocardiographic Left Ventricular Mass Changes Over the Next 5 Years: The Coronary Artery Risk Development in Young Adults (CARDIA) Study	RESEARCH/RESEARCH GRANTS - Pfizer, Sanofi-Aventis, Regeneron, Astra-Zeneca
Duprez	Daniel	New Insights Into Prediction and Treatment of Hypertension	Collagen Turnover Markers Predict New Onset of Hypertension in Normotensive Subjects: The Multi-Ethnic Study of Atherosclerosis	RESEARCH/RESEARCH GRANTS - Pfizer, Sanofi-Aventis, Regeneron,Astra-Zeneca
Durand	Eric	Interventional Cardiology: TAVR 4	Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital	Nothing to Disclose
Durand	Jean-Bernard	Imaging of Cancer-Treatment Associated CV Toxicity: Applying Guidelines to Clinical Practice	Panelist	Nothing to Disclose
Durand	Jean-Bernard	Heart Failure and Cancer Care	Case Presentation: Cardiomyopathy with Herceptin – When Should You Stop Herceptin, If Ever? Evidence to Practice Roundtable Discussion	Nothing to Disclose
Durand	Jean-Bernard	Optimizing the Care of ACS Patients	Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients	Nothing to Disclose
Durham	Katherine	Vascular Access and Hemostasis Issues	Distal Perfusion Is Maintained in Veteran Subjects Undergoing Transradial Cardiac Catheterization	Nothing to Disclose
Dutta	Tanya	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Change in Aortomitral Annular Angle and Anterior Mitral Valve Leaflet Length After Transcatheter Aortic Valve Replacement: Implications for Transcatheter Mitral Valve Replacement?	Nothing to Disclose
Dutta	Tanya	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Sinus Node Dysfunction in Batten Disease: A Rare Manifestation of a Rare Disease	Nothing to Disclose
Dutta	Tanya	Interventional Cardiology: TAVR 4	Predictors of New Persistent Left Bundle Branch Block After Edwards Sapien 3 Transcatheter Aortic Valve Replacement	Nothing to Disclose
Duvernoy	Claire	Overcoming Today's Challenges to Launching and Growing Your Academic Medical Career: An Interactive Tutorial	Panelist	Nothing to Disclose
Duvernoy	Claire	WIC Brown Bag Lunch Session: Publishing, Social Media and Negotiating the C-Suite: Tools for Success in Academia and Private Practice	Co-Chair	Nothing to Disclose
Duvernoy	Claire	WIC Brown Bag Lunch Session: Publishing, Social Media and Negotiating the C-Suite: Tools for Success in Academia and Private Practice	Welcome and Introductions	Nothing to Disclose
Dvir	Danny	Palliative Care for the 99% I: Promoting Palliative Care: The Why and What of PC Therapy	Debate: Palliative Care gets People to Refuse Procedures and die Sooner!	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,MEDTRONIC
Dvir	Danny	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,MEDTRONIC
Dvir	Danny	TAVR for Degenerated Surgical Valves: What You Need to Know from A to Z	Panelist	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,MEDTRONIC
Dvir	Danny	Structural Heart Disease: Difficult Choices for the Heart Team	Valve-in-valve: Deciding if Possible; Approach and Which Valve to Choose	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,MEDTRONIC
Dvir	Danny	Non Invasive Imaging: Expanding Clinical Applications	Does Patient Prosthesis Mismatch Defined by CT LVOT Area Predict Downstream Clinical Outcomes?	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,MEDTRONIC
Dweck	Marc	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Multi-Modality Imaging Assessment of a Left Ventricular Mass	Nothing to Disclose
Dweck	Marc	Advances in Imaging to Assess Cardiotoxicity	^{99m} Tc-Duramycin Imaging Detects Doxorubicin Cardiac Injury Before Onset of Ventricular Dysfunction	Nothing to Disclose
Dwivedi	Aeshita	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Successful Balloon Valvuloplasty for Subacute Unilateral Pleural Effusion in Ebstein Anomaly	Nothing to Disclose
Dybvig	Ane	Advances in Cholesterol Measurement and Management	Real-Life PCSK9 Experience: 65% Treatment Target Attainment in Familial Hypercholesterolemia Patients	Nothing to Disclose
Dzavik	Vladimir	Complex PCI in 2017	Bifurcation PCI	CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Astra Zeneca
Dzavik	Vladimir	Novel Developments in Acute Coronary Syndromes	Incidence and Predictors of No Reflow Phenomenon: Insights From the TOTAL Trial	CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Astra Zeneca
Dzavik	Vladimir	Novel Developments in Acute Coronary Syndromes	One-Year Outcome of Acute Stent Thrombosis: Insights From the Total Trial	CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Astra Zeneca
Dzavik	Vladimir	Interventional Challenging Cases: Team 1	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Astra Zeneca



Last Name Eagle	First Name Kim	Session Title Vascular Medicine: Novel Risk Measures in	Presentation Title Body Mass Index and Acute Aortic Dissection	Disclosures RESEARCH/RESEARCH GRANTS - GORE, Medtronic
Lagie	Kiiii	Arterial Diseases	,	·
Eagle	Kim	Innovations in Education	Teaching Tomorrow's Teachers: An Innovative Model of Clinician- Educator Development for Trainees	RESEARCH/RESEARCH GRANTS - GORE, Medtronic
Eagle	Kim	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Influence of Family History of Aortic Disease on Type B Aortic Dissection	RESEARCH/RESEARCH GRANTS - GORE, Medtronic
Eagle	Kim	Beans, Beans, Good for Your Heart	Analysis of the Timing of Thoracic Endovascular Aortic Repair and	RESEARCH/RESEARCH GRANTS - GORE, Medtronic
Eagle	Kim	Vascular Medicine: Aortic and Peripheral Artery Diseases	Its Indications and Outcomes in Type B Aortic Dissection Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of	RESEARCH/RESEARCH GRANTS - GORE, Medtronic
Eagle	Kim	Vascular Medicine: Aortic and Peripheral	Acute Aortic Dissection Uncontrolled Hypertension in Acute Aortic Dissection Follow-Up	RESEARCH/RESEARCH GRANTS - GORE, Medtronic
Eagle	Kim	Artery Diseases Vascular Medicine: Aortic and Peripheral	Acute Aortic Dissection in Patients Without a History of Hypertension	RESEARCH/RESEARCH GRANTS - GORE, Medtronic
		Artery Diseases	·	
Eapen	Zubin	Interventional Cardiology: PCI in Complex Patients	Impact of Comorbid Coronary Artery Disease and Severe Peripheral Artery Disease on Major Adverse Cardiovascular Events	CONSULTANT FEES/HONORARIA - Amgen Inc.,Cytokinetics,Janssen,Novartis; OTHER - CareMore Health System
Earing	Michael	Congenital Heart Disease: To the Third Decade and Beyond	Neurocognitive Impairment Is Common in the Adult With Congenital Heart Disease: Identification Using a Novel Clinical Questionnaire	SPEAKER'S BUREAU - Actelion Pharmaceuticals
Earls	James	Non Invasive Imaging: Expanding Clinical Applications	Dual-Energy Coronary Computed Tomography Evaluation of High- Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients: Validation with Histopathologic Gold Standard	Nothing to Disclose
Earls	James	Non Invasive Imaging: Prognostic Implications of CT Angiography	Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Death: A Comparison to a Histologic Reference Standard	Nothing to Disclose
Earls	James	Non Invasive Imaging: New Technologies	Optimal Method for Necrotic Core Identification in Coronary Plaque With Dual-Energy Computed Tomography: Material Decomposition and Atomic Number	Nothing to Disclose
Earnest	Matthew	Interventional Cardiology: Structural Heart Disease	Safety and Feasibility of Rotational Atherectomy in Elderly Patients With Severe Aortic Stenosis and Calcific Coronary Artery Disease Undergoing Evaluation for Transcatheter Aortic Valve Replacement	SPEAKER'S BUREAU - St. Jude Medical
Ebara	Seitarou	Interventional Cardiology: PCI in Complex Patients	Chronic Stent Recoil During Follow-Up in Severely Calcified Coronary Artery Lesions: An Optical Coherence Tomography Study	Nothing to Disclose
Ebell	Mark	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Wireless Monitoring for Heart Failure Patients: A Meta-Analysis	Nothing to Disclose
Eberhardt	Robert	40. Vascular Medicine: Non Coronary Arterial Disease Team 2	Suggested Reviewer	Nothing to Disclose
Eberhart	Lenora	Heart Failure and Cardiomyopathies: Is Heart	Chemotherapy Induced Cardiotoxicity, Its Prevention, Treatment and	Nothing to Disclose
Eberhart	Lenora	Failure With a Normal EF for Real? Innovations in Advocacy and Patient Centered	Risk Factors Low-Risk Chest Pain Pathway: Outcomes and Implications in a	Nothing to Disclose
Ebert	Elizabeth	Care FIT Clinical Decision Making: Non-Invasive	Large Community Cohort Successful Percutaneous Valve-In-Valve Intervention for Bio-	Nothing to Disclose
		Imaging and Valvular Heart Disease	Prosthetic Mitral Valve Failure	-
Ebner	Ben	Which Test Is Best for Pain in the Chest?	Coronary CT Angiography in the Emergency Department Provides an Opportune Window for Initiation of Evidence-Based Medical Therapy	Nothing to Disclose
Ebong	lmo	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Acute Limb Ischemia in a Previously Undiagnosed Case of Mid- Ventricular Non-Obstructive Hypertrophic Cardiomyopathy	Nothing to Disclose
Ebunlomo	Ebun	Innovations in Education	Hands-On Transradial Access Skill Training on a Novel Cadaveric	Nothing to Disclose
Eby	Elizabeth	Arrhythmias and Clinical EP: Devices 2	Model: Findings and Recommendations Antibacterial Envelope Is Associated With Medical Cost Savings in Patients at High Risk for Cardiovascular Implantable Electronic	SALARY - MEDTRONIC
Eccleston	David	32. Prevention: Clinical Team 3	Device Infection Suggested Reviewer	Nothing to Disclose
Echeverria Correa	Luis Eduardo	The Burden of Heart Failure: International Perspectives From the Chilean Society of Cardiology, Colombian Society of Cardiology, and American College of Cardiology	Chagas is Coming: Five Things That a Cardiologist in Non-Endemic Countries Needs to Know	Nothing to Disclose
Eckel	Robert	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Lower On-Treatment Low-Density Lipoprotein Cholesterol Is Associated With Lower Cardiovascular Risk in Very High Risk Patients With Atherosclerotic Cardiovascular Disease: Analyses From the ODYSSEY Trials	CONSULTANT FEES/HONORARIA - Merck,Novo Nordisk; OTHER - Uniqure
Eckel	Robert	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Lower On-Treatment Low-Density Lipoprotein Cholesterol Is Associated With Lower Cardiovascular Risk in Women: Analyses	CONSULTANT FEES/HONORARIA - Merck,Novo Nordisk; OTHER - Uniqure
Eckersley	Luke	Syndrome Congenital Heart Disease: Innovations in	From the ODYSSEY Trials of Alirocumab Versus Control Right Ventricular Remodelling in Hypoplastic Left Heart Syndrome:	RESEARCH/RESEARCH GRANTS - General Electric
Eckhardt	Lee	Single Ventricle Heart Disease Arrhythmias and Clinical EP: Devices 3	Impact of the Norwood and Hybrid Procedures Outcomes Following Implant of Semi-Permanent Pacemaker	Nothing to Disclose
Economy	Katherine	Pregnancy Complicated by	Versus Temporary Pacemaker Maternal Fetal Medicine	Nothing to Disclose
Economy	Katherine	Valvular/Congenital Heart Disease: Clinical Management and Challenging Cases Pregnancy Complicated by	Vaginal Delivery or Cesarean Section: How Do We Decide?	Nothing to Disclose
		Valvular/Congenital Heart Disease: Clinical Management and Challenging Cases		-
Edelman	Elazer	Valvular Heart Disease: Aortic Regurgitation	Analysis of Diastolic Vortex Flow as a Marker of Ventricular Deterioration in Aortic Regurgitation	CONSULTANT FEES/HONORARIA - ATRIUM/Maquet, Canon, Micell, Neovasc Inc.; RESEARCH/RESEARCH GRANTS - Abiomed, Boston Scientific, Cardiatis, Edwards Life Sciences, MEDTRONIC
Edgerton	James	Can CABG Patch CAD?	Bias From Categorizing Body Mass Index When Assessing the Association With Post-CABG Mortality	CONSULTANT FEES/HONORARIA - AtriCure; SPEAKER'S BUREAU - AtriCure
Edmiston	Blair	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Discordant Response of Low Density Lipoprotein Cholesterol and Lp(a) Levels to Monoclonal Antibodies Targeting Proprotein Convertase Subtilisin/Kexin Type 9	Nothing to Disclose
Edupuganti	Mohan	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Outcomes of Fractional Flow Reserve Based Deferral in Saphenous Vein Graft Lesions	Nothing to Disclose
•	t	Interventional Cardiology: Stent Failure	Does Post Pci Ffr Carry the Same Prognostic Weight as Non-	Nothing to Disclose
Edupuganti	Mohan		Ischemic Ffr in Deferred Lesions?	Nothing to Disclose
Edupuganti Edvardsen	Thor	Analysis by Intravascuar Imaging Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Myocardial Contractile Reserve Verified With Dual Chamber Right Ventricular Pacing Predicts Response to Cardiac Resynchronization	Nothing to Disclose
		Heart Failure and Cardiomyopathies: Heart	Myocardial Contractile Reserve Verified With Dual Chamber Right Ventricular Pacing Predicts Response to Cardiac Resynchronization Therapy Effects of Diabetes Mellitus on Clinical Outcomes After Left Ventricular Assist Device Implantation: A Single Institutional 9-Year Experience	Nothing to Disclose

Congress of the Congress of th				
Last Name Edwards	Fred Fred	Session Title Featured Clinical Research II: Interventional	Presentation Title Real-World Comparative Effectiveness of Transcatheter Versus	Disclosures Nothing to Disclose
			Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data	
Edwards	Isheeka	Emerging Applications of Echocardiography	A New Modified Continuity Equation for Calculation of Aortic Valve Area by Integrating 3-D Measurements of LVOT Planimetry and LVOT Flow Mapping	Nothing to Disclose
Edwards	Isheeka	Emerging Applications of Echocardiography	Direct Comparison of Aortic Valve Area by 3-D TEE Planimetry and 4-D Dynamic Cardiac CT Planimetry	Nothing to Disclose
Edwards	Katharine	Understanding Spontaneous Coronary Artery Dissection (SCAD): What We Know, What We Don't Know	The Psychological Aftermath: How Best to Help Patients Through the Trauma	Nothing to Disclose
Edwards Edwards	Nicola William	Nuclear Cardiology: Prognosis Valvular Heart Disease: Aortic Stenosis	Serial Myocardial Perfusion Imaging in End-Stage Renal Disease Bicuspid Versus Tricuspid Aortic Valve Stenosis: Comparative Study	Nothing to Disclose
			of Clinical Characteristics and Outcomes Following Aortic Valve Replacement in an Age-Matched Cohort	
Effron	Mark	Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Eli Lilly and Company; SALARY - Eli Lilly and Company
Effron	Mark	Optimizing the Care of ACS Patients	Contemporary Patterns of GP Ilb/Illa Inhibitor Use in Patients With Acute Myocardial Infarction Undergoing PCI: Insights From the TRANSLATE ACS Study	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Eli Lilly and Company; SALARY - Eli Lilly and Company
Effron	Mark	Anti-Platelet Therapies: Always a Sticky Topic	Antiplatelet Therapy Changes for MI Patients With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS Study	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Eli Lilly and Company; SALARY - Eli Lilly and Company
Egan	Brent	Assessing the Clinical Impact of Blood Pressure Lowering Therapies	Cardiovascular Outcomes With Nebivolol, Atenolol and Metoprolol in Patients With Hypertension: A Large, Retrospective, Propensity Score-Matched Cohort Study	Nothing to Disclose
Egan	Brent	32. Prevention: Clinical Team 3	Suggested Reviewer	Nothing to Disclose
Egbe	Alexander	Innovations in Pediatric Catheterization and EP: Mending, Fixing and Predicting	Outcome of Preoperative Electrophysiology Study in Patients With Ebstein Anomaly	Nothing to Disclose
Egbe	Alexander	Fontan in the Modern World	Cardiopulmonary Exercise Test in Adults With Prior Fontan Operation: The Prognostic Value of Serial Testing	Nothing to Disclose
Egbe	Alexander	Congenital Heart Disease: To the Third Decade and Beyond	Outcomes of Direct Current Cardioversion in Adults With Congenital Heart Disease	-
Egbe	Alexander	Congenital Heart Disease: To the Third Decade and Beyond	Outcomes of Non-Cardiac Procedures in Adult Fontan Patients	Nothing to Disclose
Egbe	Alexander	Prosthetic Valve Thrombosis: TAVR, Bio, Mech Now What?!	Outcome of Anticoagulation Therapy for Bioprosthetic Valve Thrombosis: A Prospective Study	Nothing to Disclose
Egbe	Alexander	Advancing Our Understanding of Aortic Disease	Intracranial Aneurysms in Patients With Bicuspid Aortic Valve: Prevalence and Predictors of Occurence	Nothing to Disclose
Egbe	Alexander	Things That Matter in Adult Congenital Heart Disease	Outcomes of Cardiac Pacing in the Adult Fontan Population	Nothing to Disclose
Egnatovich	Jeffrey	Novel Developments in Acute Coronary Syndromes	Compliance and Bleeding Using Updated AHA and ACC Heparin Dosing Guidelines for Non-ST Elevation Myocardial Infarction Patients	Nothing to Disclose
Egom	Emmanuel	Understanding Pulmonary Vascular Disease: From Bench to Bedside	New Insights and New Hope for Pulmonary Arterial Hypertension: Natriuretic Peptides Clearance Receptor as a Novel Therapeutic Target for a Complex Disease	Nothing to Disclose
Egorova	Natalia	Infectious Endocarditis: Comprehensive Perspectives	Long-Term Benefits of Repair Versus Replacement for Acute Native Mitral Valve Endocarditis	Nothing to Disclose
Egrie	Glenn	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Bacterial Endocarditis in a Patient With Repaired Tetralogy of Fallot: A Rare Case of a Homograft Right Ventricle to Pulmonary Artery Conduit Acute Obstruction	Nothing to Disclose
Egrie	Glenn	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Ventricular Fibrillation Arrest From an Atrioesophageal Fistula: A Unique Clinical Presentation	Nothing to Disclose
Ehdaie	Ashkan	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Wide Complex Tachycardia in a 51-Year-Old Man: Ventricular Tachycardia Until Proven Otherwise?	Nothing to Disclose
Ehrlich	Marek	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Body Mass Index and Acute Aortic Dissection	Nothing to Disclose
Ehrlich	Marek	Beans, Beans, Good for Your Heart	Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection	Nothing to Disclose
Ehrman	Jonathan	Non Invasive Imaging: Role of Exercise Testing		Nothing to Disclose
Ehrman	Jonathan	Risky Business: Predicting Outcomes in Heart Failure	Chronotropic Incompetence and Long-Term Risk of Heart Failure: The Henry Ford Exercise Testing Project	Nothing to Disclose
Ehteshami-Afshar	Solmaz	Making Progress in Understanding Heart Failure	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF	Nothing to Disclose
Eijsvogels	Thijs	I Can Do WHAT After My Heart Attack?	Panelist	Nothing to Disclose
Eijsvogels Eikelboom	Thijs John	I Can Do WHAT After My Heart Attack? Stroke and AF: Thinking About the Heart	Do I Have to Go to Cardiac Rehab? The Prescribing of Antiplatelet Therapy Only in Patients With Nonvalvular Atrial Fibrillation: Results From the GARFIELD-AF Registry	Nothing to Disclose CONSULTANT FEES/HONORARIA - Astra Zeneca, Bayer Healthcare Pharmaceuticals, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Eli-Lilly, GlawSmithKline, Haemoscope Pitzer Inc, Sanofi-Aventis, FESEARCH/BRSEARCH GRANTS - Bayer Healthcare Pharmaceuticals, Boehringer-Ingelheim, Bristol- Myers Squibb, GlawoSmithKline, Pfizer, Sanofi-Aventis
Einstein	Andrew	Radiation from Diagnostic Imaging: Risk- benefit Analysis	Panelist	RESEARCH/RESEARCH GRANTS - GE Healthcare, Philips Medical Systems, Toshiba America Medical Systems
Einstein	Andrew	Radiation from Diagnostic Imaging: Risk- benefit Analysis	Radiation Risks: Observational Data	RESEARCH/RESEARCH GRANTS - GE Healthcare,Philips Medical Systems,Toshiba America Medical Systems
Einstein	Andrew	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Estimating Cancer Risk Associated With Ionizing Radiation Exposure During Atrial Fibrillation Ablation	RESEARCH/RESEARCH GRANTS - GE Healthcare, Philips Medical Systems, Toshiba America Medical Systems
Einstein	Andrew	Nuclear Cardiology: Quality	Worldwide Variation in the Use of Nuclear Cardiology Camera Technology, Reconstruction Software, and Acquisition Protocols: Findings From the IAEA Nuclear Cardiology Protocols Study (INCAPS)	RESEARCH/RESEARCH GRANTS - GE Healthcare,Philips Medical Systems,Toshiba America Medical Systems
Eisen	Howard	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		Nothing to Disclose
Eisen	Howard	13. Heart Failure and Cardiomyopathies: Clinical Team 5	Suggested Reviewer	Nothing to Disclose
Eisenhauer	Andrew	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Is CABG the Best Revascularization Strategy Among All Diabetics Subgroups With Multi-Vessel Disease in the Modern Era? A Multi- Center Analysis	Nothing to Disclose
Eitel	Charlotte	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Antecedent Hypertension and Myocardial Injury in Patients With Reperfused ST-Elevation Myocardial Infarction	Nothing to Disclose
Eitel	Ingo	Non Invasive Imaging: MR Characterization and Function	Prognostic Value and Determinants of Left Atrial Function Assessed by Cardiac Magnetic Resonance in St-Segment Elevation Myocardial Infarction	Nothing to Disclose
Eitel	Ingo	Non Invasive Imaging: MR Heart Failure and	Antecedent Hypertension and Myocardial Injury in Patients With	Nothing to Disclose
	1	Pulmonary Hypertension	Reperfused ST-Elevation Myocardial Infarction	

Contract of the second				
Last Name Eitel	First Name Ingo	Session Title Novel Developments in Acute Coronary	Presentation Title Impact of Timing of Intra-Aortic Balloon Counterpulsation on	Disclosures Nothing to Disclose
	3.	Syndromes	Mortality in Cardiogenic Shock: A Sub-Analysis of the IABP-SHOCK	
Eitel	Ingo	Novel Developments in Acute Coronary	Mild Hypothermia in Cardiogenic Shock Complicating Myocardial	Nothing to Disclose
Eitel	Ingo	Syndromes Novel Developments in Acute Coronary	Infarction: The Randomized SHOCK-COOL Pilot Trial Outcome of Elderly Patients Undergoing Extracorporeal Life	Nothing to Disclose
		Syndromes	Support in Refractory Cardiogenic Shock	-
Ekblond	Annette	Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells	Adipose Derived Stromal Cells for Refractory Angina: Results From MyStromalCell Trial	Nothing to Disclose
Ekeruo	ljeoma	Interventional Cardiology: PCI and TAVR in Complex Patients	Predicting Risk Factors for Permanent Pacemaker Placement Following Transcatheter Aortic Valve Replacement: A UTHealth Experience	Nothing to Disclose
Ekeruo	ljeoma	Interventional Cardiology: PCI and TAVR in	Timing and Algorithm of Permanent Pacemaker Implantation After	Nothing to Disclose
El Hammiri	Ayoub	Complex Patients Interventional Cardiology: Intravascular	TAVR Appropriateness of Coronary Artery Bypass Grafting Based on	Nothing to Disclose
		Physiology and Endothelial Function Innovations in Cardiovascular Risk Assessment	Fractional Flow Reserve Lesions Assessment Association of Coronary Calcium, Carotid Wall Thickness and	Nothing to Disclose
El Khoudary	Samar	and Reduction	Association of Coloniary Carlottin, Carlottin Varian intensess and Carotid Plaque Progression With Low Density Lipoprotein and High Density Lipoprotein Particle Concentration Measured by Ion Mobility Testing: The Multi-Ethnic Study of Atherosclerosis (MESA)	Noulling to Disclose
El Mallah	Wael	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Combined Migraine and Platypnea-Orthodeoxia Syndrome Due to Combined Atrial Septal Defect and Patent Foramen Ovale	Nothing to Disclose
El Sabbagh	Abdallah	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Prompt Recognition and Intervention for Cardiac Tamponade Secondary to Gastro-Pericardial Fistula: A Successful Heart Team Effort	Nothing to Disclose
El Sabbagh	Abdallah	FIT Clinical Decision Making: Non-Invasive	Atrial Fibrillation in Aortic Stenosis: A Diagnostic and Therapeutic	Nothing to Disclose
El Sabbagh	Abdallah	Imaging and Valvular Heart Disease Structural Heart Interventions: Focus on Mitral	Challenge 3D Printing for Procedural Simulation of Transcatheter Mitral Valve	Nothing to Disclose
El Sabbagh	Abdallah	Valve, Left Atrial Appendage and HOCM Prosthetic Valve Thrombosis: TAVR, Bio,	Replacement in Patients With Mitral Annular Calcification Poor Outcome of Thrombolysis in Right-Sided Mechanical Valve	Nothing to Disclose
		Mech Now What?!	Thrombosis: Largest Single Center Experience	
El Sakr	Fredy	Interventional Complexity and Complications	Timing Matters - Hydration Strategies to Reduce Contrast Induced Nephropathy After Peripheral Vascular Interventions: Observations From the Blue Cross Blue Shield Cardiovascular Consortium (BMC2)	Nothing to Disclose
El Sakr El Sharkawy	Fredy Eman	FIT Clinical Decision Making Reviewers 6 FIT Clinical Decision Making: Non-Invasive	ACC FIT Clinical Decision Making Reviewer Think Syndromic	Nothing to Disclose Nothing to Disclose
•		Imaging and Valvular Heart Disease	•	-
El Tallawi	Kinan Carlos	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Severe Aortic Insufficiency Due to a Perimembranous Ventricular Septal Defect	Nothing to Disclose
Elashery	Ahmad Ramy	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Rare but Aggressive Cause of Infective Endocarditis Lead to Double Valve Disease and Glomerulonephritis	Nothing to Disclose
Elashery	Ahmad Ramy	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Unusual Presentation of Psuedo Stemi	Nothing to Disclose
Elassal	Joseph	Advances in Cholesterol Measurement and Management	Contemporary Patterns of Lipid Testing in Primary and Secondary Prevention Patients: Insights From the PALM Registry	SALARY - Regeneron Pharmaceuticals, Inc
Elassal	Joseph	Advances in Cholesterol Measurement and	Understanding the Predictors of Achieving LDL-C Targets When	SALARY - Regeneron Pharmaceuticals, Inc
Elassal	Joseph	Management Advances in Cholesterol Measurement and Management	Adding Ezetimibe in High Risk Patients Contrasting US Patients With a Fill Versus a Prescription for Alirocumab: Early Evidence From Administrative Claims, EMR and Lab Data	SALARY - Regeneron Pharmaceuticals, Inc
Elassal	Joseph	Advances in Lipid Management	Alirocumab in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program	SALARY - Regeneron Pharmaceuticals, Inc
Elassal	Joseph	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Statin Utilization Patterns During Inpatient Admissions for Acute Coronary Syndrome (ACS)	SALARY - Regeneron Pharmaceuticals, Inc
Elayi	Samy	Arrhythmias and Clinical EP: Devices 1	Characteristics and Clinical Predictors of 11,569 Pneumothoraces Associated With Cardiac Implantable Electronic Device Procedures:	Nothing to Disclose
Elayi	Samy	Coronary Intervention in Interventional	Results From a Large National Database QRS Duration Alterations After Left Ventricular Assist Device	Nothing to Disclose
elayi	Samy	Cardiology: Advanced Device Use Heart Failure and Cardiomyopathies: Heart	Implantation in Patients With Advanced Heart Disease Guideline-Directed Medical Therapy Before CRT: Is It Always	Nothing to Disclose
		Failure Gadgets Galore	Necessary?	,
elayi	Samy	Arrhythmias and Heart Failure	Can the Ventricular-Arterial Coupling Ratio Predict Response to Cardiac Resynchronization Therapy for Patients Meeting Class Ila Indications?	Nothing to Disclose
Elbadawi	Ayman	Arrhythmias and Clinical EP: Devices 1	Characteristics and Clinical Predictors of 11,569 Pneumothoraces Associated With Cardiac Implantable Electronic Device Procedures: Results From a Large National Database	Nothing to Disclose
Elbadawi	Ayman	Population Specific Cardiomyopathies: From Exomes to Databases	Racial Differences in Heart Failure Admissions & Outcomes Among Patients With HIV	Nothing to Disclose
Elbadawi	Ayman	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Coronary Artery Bypass Graft Surgery after Acute ST Elevation Myocardial Infarction: How Early is Too Early?	Nothing to Disclose
Elbadawi	Ayman	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Valvular Surgery With or Without Left Atrial Appendage Excision for Atrial Fibrillation: A CHA2DS2VASc Matched Analysis of Thromboembolic Outcomes in a National Database	Nothing to Disclose
Elbadawi	Ayman	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Coronary Artery Bypass Graft Surgery With or Without Left Atrial Appendage (LAA) Excision for Atrial Fibrillation: A CHA2DS2VASc Matched Analysis of Thromboembolic Outcomes in a National Database	Nothing to Disclose
Elbadawi	Ayman	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Outcomes of Intra-Aortic Balloon Pump Use in Myocarditis Complicated by Cardiogenic Shock	Nothing to Disclose
Elbadawi	Ayman	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Association Between Asian Ethnicity and a Higher Rate of Blood Transfusion in ST-Elevation Myocardial Infarction	Nothing to Disclose
Elberg	Jens Jørgen	Fixing the Heart One Cell at a Time: The	Adipose Derived Stromal Cells for Refractory Angina: Results From	Nothing to Disclose
El-Chami	Mikhael	Ongoing Promise of Stem Cells Heart Rhythm Disorders: Today and Tomorrow	MyStromalCell Trial Case Studies: Leadless Pacemakers. Is Now That Time for	CONSULTANT FEES/HONORARIA - Boston
Elci	Okan	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Widespread Implantation, or is it Best for Selected Patients? Right Ventricular Contractile Reserve Is Reduced in Children and Adolescents With Tetralogy of Fallot: A Stress Echocardiographic	Scientific,MEDTRONIC Nothing to Disclose
Elder	Mahir	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Study Ultrasound Assisted Catheter Directed Thrombolysis and Percutaneous Right Ventricular Mechanical Assist Device for the Management of Massive Pulmonary Embolism With Refractory Right Ventricular Failure: Playing Chess With Pulmonary Embolism	Nothing to Disclose
Elder	Robert	Fontan in the Modern World	Towards a Better Predictive Model of Adverse Events in Adult	Nothing to Disclose
Elder	Robert	Finding Out What Works in Pediatric and	Fontan Patients ACC Poster Moderator	Nothing to Disclose
İ		Congenital Heart Disease		



Last Name	First Name	Session Title	Presentation Title	Disclosures
Eleid	Mackram	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Acute Changes in Left Atrial Pressure Following MitraClip are Associated With Long Term Improvement in 6 Min Walk Distance	Nothing to Disclose
Eleid	Mackram	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Transcatheter Mitral Valve Repair (Mitraclip) in United States: Etiologies and Predictors of Readmission and In-Hospital Mortality From the Nationwide Readmission Database	Nothing to Disclose
Eleid	Mackram	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Transcatheter Mitral Valve Repair (Mitra Clip) in United States: Length of Stay and Cost of Hospitalizations From the Nationwide	Nothing to Disclose
Eleid	Mackram	Structural Heart Interventions: Focus on Mitral	Readmission Database 3D Printing for Procedural Simulation of Transcatheter Mitral Valve	Nothing to Disclose
Eleid	Mackram	Valve, Left Atrial Appendage and HOCM Interventional Cardiology: TAVR 2	Replacement in Patients With Mitral Annular Calcification Prognostic Value of Baseline N-Terminal Prohormone Type Natriuretic Peptide Measurement in Chronic Lung Disease Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Eleid	Mackram	Interventional Cardiology: TAVR 3	Comparative Outcome of Paravalvular Leak Following Surgical Versus Transcatheter Aortic Valve Replacement	Nothing to Disclose
Eleid	Mackram	Insights From Echocardiography Use	Echocardiographic Parameters of Myocardial Performance After Transapical Versus Transfemoral Transcatheter Aortic Valve Replacement	Nothing to Disclose
Elfawal	Reham	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of Electrocardiogram Changes on Mortality in Asymptomatic Patients With Sepsis and Elevated Troponin	Nothing to Disclose
Elgendy	Islam	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Septic Cardiac Tamponade as a Rare Presentation of Acute Infective Endocarditis	Nothing to Disclose
Elgendy	Islam	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Early Invasive Strategy and In-Hospital Survival of Diabetics With Non-ST-Elevation Myocardial Infarction: A Contemporary National Insight	Nothing to Disclose
Elgendy	Islam	PCI Strategies and Outcomes Unique to Women	Early Invasive Strategy Versus Initial Conservative Strategy in Women With Non-ST-Elevation Acute Coronary Syndrome: A Propensity Score Matched Nationwide Analysis	Nothing to Disclose
El-Hayek	Georges	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Early Versus Delayed Invasive Intervention for Non-ST Segment Elevation Myocardial Infarction Patients: A Nationwide Analysis	Nothing to Disclose
Eliasson	Arn	Interdisciplinary Cardiovascular Team Collaboratives in Care	Multidisciplinary Cardiovascular Team Review Captures Preclinical Disease	Nothing to Disclose
Eliasson	Arn	Diabetes and Other Issues in Cardiovascular Prevention	Arresting Insulin Resistance With an Integrative Health Intervention	Nothing to Disclose
Elinoff	Jason	The OMICS in Pulmonary Hypertension	Panelist	Nothing to Disclose
Elinoff	Jason	The OMICS in Pulmonary Hypertension	Genomics: Meta-analysis of Blood Expression Profiling Studies in PulmonaryArterial Hypertension	Nothing to Disclose
Elizaga	Jaime	Timely Topics in Acute Coronary Syndromes	A New Prognosis Score to Predict Mortality in Patients Over 75 Years Old Undergoing Primary Angioplasty in Cardiogenic Shock	Nothing to Disclose
Elkayam	Uri	The Consequences of Sex: Women and Pregnancy Across the Spectrum	Co-Chair	SPEAKER'S BUREAU - Amgen Inc., Arbor, Janssen Pharmaceuticals, Inc, Novartis Corporation, ZS Pharma
Elkayam	Uri	The Consequences of Sex: Women and Pregnancy Across the Spectrum	Post-Pregnancy Complications: Dissection & Cardiomyopathy	SPEAKER'S BUREAU - Amgen Inc., Arbor, Janssen Pharmaceuticals, Inc, Novartis Corporation, ZS Pharma
Elkayam	Uri	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Challenges During Pregnancy With Marfan Syndrome and an Ascending Aortic Aneurysm	SPEAKER'S BUREAU - Amgen Inc.,Arbor,Janssen Pharmaceuticals, Inc,Novartis Corporation,ZS Pharma
Elkayam	Uri	Advances in HCM, PPCM and Other Cardiomyopathies	Multi-Fetal Gestation, Breastfeeding, Delivery Method and Myocardial Recovery in Peripartum Cardiomyopathy: Results From the Multicenter IPAC Study	SPEAKER'S BUREAU - Amgen Inc., Arbor, Janssen Pharmaceuticals, Inc, Novartis Corporation, ZS Pharma
Elkin	Rachel	Understanding Pulmonary Vascular Disease: From Bench to Bedside	Pulmonary Vascular Response to Nitric Oxide and Subsequent Response to Advanced Medical Therapy in Incident Patients With Pulmonary Hypertension	Nothing to Disclose
Elkoustaf	Rachid	Updates in Stable Ischemic Heart Disease	Diet and Ischemic Burden: A Comparative Analysis of a Plant Based Regimen Versus a Mediterranean Regimen in Patients With Coronary Artery Disease	Nothing to Disclose
Ellenbogen	Kenneth	Late-Breaking Clinical Trials	Panelist	CONSULTANT FEES/HONORARIA - American Heart Association AtriCure, Biosense Webster, Biotronik, Boston Science, Heart Rhythm Society, Janssen, MEDTRONIC, Pfizer, Sentra Heart, St. Jude Medical; DATA SAFETY MONITORING BOARD - MEDTRONIC; OTHER - Expert Witness/Testimony, RESEARCH/RESEARCH GRANTS - AtriCure, Dailichi Sankyo, Medtronic, Boston Science, Biosense Webster, NIH
Ellenbogen	Kenneth	Common Arrhythmia Problems: The Experts Approach	Panelist	CONSULTANT FEES/HONORARIA - American Heart Association, AtriCure, Biosense Webster, Biotronik, Boston Science, Heart Rhythm Society, Janssen, MEDTRONIC, Pfizer, Sentra Heart, St. Jude Medicai; DATA SAFETY MONITORING BOARD - MEDTRONIC; OTHER - Expert Witness/Testimony; RESEARCH/RESEARCH GRANTS - AtriCure, Dailichi Sankyo, Medtronic, Boston Science, Biosense Webster, NiH
Ellenbogen	Kenneth	Quickfire ECG for Experts	Panelist	CONSULTANT FEES/HONORARIA - American Heart Association, AtriCure, Biosense Webster, Biotronik, Boston Science, Heart Rhythm Society, Janssen, MEDTRONIC, Pfizer, Sentra Heart, St. Jude Medicai; DATA SAFETY MONITORING BOARD - MEDTRONIC; OTHER - Expert Witness/Testimony, RESEARCH/RESEARCH GRANTS - AtriCure, Dailchi Sankyo, Medtronic, Boston Science, Biosense Webster, NIH
Ellenbogen	Kenneth	Controversies in Atrial Fibrillation Management	Co-Chair	CONSULTANT FEES/HONORARIA - American Heart Association, AtriCure, Biosense Webster, Biotronik, Boston Science, Heart Rhythm Society, Janssen, MEDTRONIC, Pfizer, Sentra Heart, St. Jude Medicai; DATA SAFETY MONITORING BOARD - MEDTRONIC; OTHER - Expert Witness/Testimony; RESEARCH/RESEARCH GRANTS - AtriCure, Dailchi Sankyo, Medtronic, Boston Science, Biosense Webster, NIH
Ellenbogen	Kenneth	Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	Co-Chair	CONSULTANT FEES/HONORARIA - American Heart Association, AtriCure, Biosense Webster, Biotronik, Boston Science, Heart Rhythm Society, Janssen, MEDTRONIC, Pfizer, Sentra Heart, St. Jude Medicai: DATA SAFETY MONITORING BOARD - MEDTRONIC; OTHER - Expert Witness/Testimony; RESEARCH/RESEARCH GRANTS - AtriCure, Dalichi Sankyo, Medtronic, Boston Science, Biosense Webster, NIH
Ellenbogen	Kenneth	Atrial Fibrillation and VT: Unique Populations and Solutions	Risk Score Model for Predicting Occurrence of Complications in Patients Undergoing Atrial Fibrillation Ablation	CONSULTANT FEES/HONORARIA - American Heart Association, AtriCure, Biosense Webster, Biotronik, Boston Science, Heart Rhythm Society, Janssen, MEDTRONIC, Pfizer, Sentra Heart, St. Jude Medicai; DATA SAFETY MONITORING BOARD - MEDTRONIC; OTHER - Expert Witness/Testimony; RESEARCH/RESEARCH GRANTS - AtriCure, Dalichi Sankyo, Medtronic, Boston Science, Biosense Webster, NIH

Last Name	First Name	Session Title	Presentation Title	Disclosures
Ellenbogen	Kenneth	Atrial Fibrillation and VT: Unique Populations and Solutions	Difference in Quality of Life Outcomes Between Atrial Fibrillation Catheter Ablation and Anti Arrhythmic Drugs: A Systematic Review	CONSULTANT FEES/HONORARIA - American Heart Association, AtriCure, Biosense Webster, Biotronik, Boston
		and conduction	and Meta-Analysis	Science,Heart Rhythm
				Society, Janssen, MEDTRONIC, Pfizer, Sentra Heart, St. Jude Medical; DATA SAFETY MONITORING BOARD - MEDTRONIC
				OTHER - Expert Witness/Testimony; RESEARCH/RESEARCH
				GRANTS - AtriCure, Daiichi Sankyo, Medtronic, Boston Science,
Ellenbogen	Kenneth	05. Arrhythmias and Clinical EP: Devices	Suggested Reviewer	Biosense Webster, NIH CONSULTANT FEES/HONORARIA - American Heart
Liionbogon	110111011	Team 1	- Suggestion Notional	Association, AtriCure, Biosense Webster, Biotronik, Boston
				Science,Heart Rhythm Society,Janssen,MEDTRONIC,Pfizer,Sentra Heart,St. Jude
				Medical; DATA SAFETY MONITORING BOARD - MEDTRONIC
				OTHER - Expert Witness/Testimony; RESEARCH/RESEARCH
				GRANTS - AtriCure, Daiichi Sankyo, Medtronic, Boston Science, Biosense Webster, NIH
Ellinor	Patrick	Atrial Fibrillation and VT: Incorporating Novel	Factors Predicting Longer Time to Anticoagulation Following a New	CONSULTANT FEES/HONORARIA - Bayer Healthcare
		Risks Toward Decision Making	Diagnosis of Atrial Fibrillation	Pharmaceuticals, Quest Diagnostics; RESEARCH/RESEARCH GRANTS - Bayer Healthcare Pharmaceuticals
Ellinor	Patrick	FIT Clinical Decision Making: Interventional	Successful Intra-Aortic Balloon Pump-Supported Percutaneous	CONSULTANT FEES/HONORARIA - Bayer Healthcare
		Cardiology, Acute and Stable Ischemic Heart	Coronary Intervention in a Patient With a Late Presenting Myocardial	Pharmaceuticals, Quest Diagnostics; RESEARCH/RESEARCH
		Disease, and Vascular Medicine	Infarction, Multivessel Coronary Artery Disease Complicated by Heparin-Induced Thrombocytopenia, Biventricular Thrombus, and	GRANTS - Bayer Healthcare Pharmaceuticals
			Refractory Ventricular Arrhythmia	
Elliott	Daniel	Innovations in Practice Management and Social Media	Predicting Readmission Risk Following Percutaneous Coronary Intervention at the Time of Admission	Nothing to Disclose
Elliott	Daniel	Innovations in Practice Management and	Predicting Readmission Risk Following Coronary Artery Bypass	Nothing to Disclose
Eu. a		Social Media	Surgery at the Time of Admission	OTUED Assessed to
Elliott	Mary	Advances in Cholesterol Measurement and Management	Impact of Evolocumab Therapy in Patients With Discordance Between LDL-C and LDL-P	OTHER - Amgen Ltd
Ellis	Christopher	Arrhythmias and Clinical EP: AF Ablation	Use of Dabigatran Etexilate to Prevent Stroke and	CONSULTANT FEES/HONORARIA - Sentre Heart
			Thromboembolism in Patients Undergoing Left Atrial Catheter Ablation Procedures for Paroxysmal or Persistent (Non-Permanent)	Inc,Spectranetics, Inc; RESEARCH/RESEARCH GRANTS -
			Atrial Fibrillation and Left Atrial Flutter	atricure Inc,Boehringer Ingelheim,Boston Scientific,Medtronic In
Ellis	Christopher	Structural Heart Interventions: Focus on Mitral	Comparison of Transesophageal Echocardiography and Computed	CONSULTANT FEES/HONORARIA - Sentre Heart
		Valve, Left Atrial Appendage and HOCM	Tomography Angiography for Left Atrial Appendage Evaluation Prior to WATCHMAN Implantation	Inc,Spectranetics, Inc; RESEARCH/RESEARCH GRANTS - atricure Inc,Boehringer Ingelheim,Boston Scientific,Medtronic In-
			to WATCHWAR Implantation	autoure inc, boerninger ingenienn, boston ocientino, wedironic in
Ellis	Christopher	FIT Clinical Decision Making: Arrhythmias and	Pacing-Induced Cardiomyopathy From a Transcatheter Leadless	CONSULTANT FEES/HONORARIA - Sentre Heart
		Clinical Electrophysiology	Pacemaker Following Transcatheter Aortic Valve Replacement	Inc, Spectranetics, Inc; RESEARCH/RESEARCH GRANTS - atricure Inc, Boehringer Ingelheim, Boston Scientific, Medtronic Inc
				autoure me, been miger ingeniem, bester desertatio, weather inc
Ellis	Howard	Post-CAD/MI: Making Tough Predictions About		Nothing to Disclose
		the Future	Ischaemia: Novel Insights From Intracoronary Measurements During Cardiac Catheterisation	
Ellis	Jennifer	Focus on Structural and Valvular Heart	Co-Chair	Nothing to Disclose
		Disease: Joint Symposium of the Association		
		of Black Cardiologists and the American College of Cardiology		
Ellis	Stephen	Interventional Live Case Session VI:	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston
		Bioresorbable Scaffolds and Imaging from St. Vincent Hospital (Indianapolis, IN)		Scientific,MEDTRONIC; OTHER - MEDTRONIC; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Boston
				Scientific
Ellis	Stephen	Late-Breaking Clinical Trials: Interventional	Everolimus-Eluting Bioresorbable Vascular Scaffolds in Patients	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston
			With Coronary Artery Disease: Two-Year Outcomes From the ABSORB III Trial	Scientific,MEDTRONIC; OTHER - MEDTRONIC; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Boston
				Scientific
Ellis	Stephen	Late-Breaking Clinical Trials: Deep Dive I	Everolimus-Eluting Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Disease: Two-Year Outcomes From the	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific, MEDTRONIC; OTHER - MEDTRONIC;
			ABSORB III Trial	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston
				Scientific
Ellis	Stephen	Complications of PCI: Case Reviews	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific, MEDTRONIC; OTHER - MEDTRONIC;
				RESEARCH/RESEARCH GRANTS - Abbott Vascular,Boston
Ellis	Charles	Training for later actional Decoders Wiles	When Control of Final and	Scientific CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston
EIIIS	Stephen	Training for Interventional Procedures: Who Should Do What, Where, When, How, and	Where: Centers of Excellence	Scientific,MEDTRONIC; OTHER - MEDTRONIC;
		Why		RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston
Ellis	Stephen	Bioresorbable Vascular Scaffolds.	Absorb-BVS: Clinical Trial and Registry Update	Scientific CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston
Lina	Stephen	Bioresorbable Polymer and Polymer Free	2005010-070. Ollilloar Thai and Negistry Opuate	Scientific, MEDTRONIC; OTHER - MEDTRONIC;
		Metallic DES		RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston
Ellis	Stephen	Highlighted Original Research: Interventional	Clinical, Angiographic and Procedural Correlates of Absorb Scaffold	Scientific CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston
	Сорнон	Cardiology and the Year in Review	Thrombosis: A Matched Multicenter Registry Analysis	Scientific,MEDTRONIC; OTHER - MEDTRONIC;
			1	RESEARCH/RESEARCH GRANTS - Abbott Vascular,Boston
Ellis	Stephen	15. Interventional Cardiology:	Suggested Reviewer	Scientific CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston
		ACS/AMI/Hemodynamics and Pharmacology		Scientific,MEDTRONIC; OTHER - MEDTRONIC;
		Team 3		RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston Scientific
Elmann	Ellie	FIT Clinical Decision Making: Non-Invasive	Unloading the Left Ventricle: A Case of Mechanical Circulatory	Nothing to Disclose
		Imaging and Valvular Heart Disease	Support in Acute Aortic Insufficiency	-
Elmaraezy	Ahmed	ACC International Conferences Best Posters	Transcatheter Aortic Valve Replacement Versus Surgical AorticValve Replacement in Aortic Stenosis Patients at Low to	Nothing to Disclose
			Moderate Risk of Surgery: A Meta-Analysis of 25,737 Patients' Data	
Elmoria -	Page	TAVE for Documental Committee or an armount of the committee or an armount of the committee or an armount of the committee or an armount of the committee or an armount of the committee or an armount of the committee or an armount of the committee or an armount of the committee or an armount of the committee or an armount of the committee or an armount of the committee or an armount of the committee or an armount of the committee or an armount of the committee or an armount of the committee or an armount of the committee or armou	Panalist	Nothing to Displace
Elmariah	Sammy	TAVR for Degenerated Surgical Valves: What You Need to Know from A to Z	Panelist	Nothing to Disclose
Elmariah	Sammy	Aortic Stenosis: Overview of the	Case: Low Flow Low Gradient AS	Nothing to Disclose
Elmariah	Sammy	Hemodynamics and Ventricular Response Interventional Cardiology: TAVR 4	Depression as a Potential Therapeutic Target to Improve Quality of	Nothing to Disclose
andi	Sammy	crrontional dardiology. 1AVIC4	Life After Transcatheter Aortic Valve Replacement	
Elmariah	Sammy	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low-	Nothing to Disclose
			Flow Severe Aortic Stenosis and Less Reverse Remodeling After TAVR: A Partner 2 Trial Analysis	
Elshazly	Mohamed	Advances in Cholesterol Measurement and	Atherogenic Lipoprotein Variability Correlates With Coronary	Nothing to Disclose
•		Management	Atheroma Progression: Insights From Serial Intravascular	
Elsheshtawy	Moustafa	FIT Clinical Decision Making: Non-Invasive	Ultrasonography Sudden Hemodynamic Collapse in Hypertrophic Obstructive	Nothing to Disclose
		Imaging and Valvular Heart Disease	Cardiomyopathy	· ·
Eltchaninoff	Helene	Interventional Cardiology: TAVR 4	Incidence, Predictive and Prognostic Factors of Hopitalization for	OTHER - Edwards Lifesciences
			Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital	
	-	•	,	



September 1				
Last Name Eltchaninoff	First Name Helene	Session Title 17. Interventional Cardiology: Aortic Valve	Presentation Title Suggested Reviewer	Disclosures OTHER - Edwards Lifesciences
El-Turaby	Fady	Disease Team 2 Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Comparison of Triple Antithrombotic Therapy to Ticagrelor-Based Dual Antiplatelet Therapy for Left Ventricle Dysfunction Following	Nothing to Disclose
Emami	Hamed		STEMI Using Natural Randomization: A Retrospective Pilot Study Effusive-Constrictive Pericarditis in a Patient With Hypereosinophilic	Nothing to Disclose
Emani	Sitaram	Pulmonary Hypertension FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Syndrome Melody Valve Placement for Mitral Valve Dysplasia Syndrome	CONSULTANT FEES/HONORARIA - Teva Pharmaceuticals
Emani	Sitaram	Predicting Outcomes in Pediatric Heart Disase	Risk Stratification of Children Undergoing Valve-Sparing Repair of Tetralogy of Fallot	CONSULTANT FEES/HONORARIA - Teva Pharmaceuticals
Emert	Martin	Arrhythmias and Clinical EP: Devices 2	Real World Battery Longevity of St. Jude Medical Implantable Cardioverter-Defibrillators Included in the Advisory for Premature	Nothing to Disclose
Emery	Michael	FIT Forum: Mix and Mingle	Battery Depletion Sports Cardiology	Nothing to Disclose
Emery	Michael	I Can Do WHAT After My Heart Attack? I Can Do WHAT After My Heart Attack?	Panelist Can I Run a Marathon?	Nothing to Disclose Nothing to Disclose
Emery Emery	Michael Michael	The Athlete with Heart Disease: A Case Based	Co-Chair	Nothing to Disclose
Emery	Michael	Approach Improving Outcomes in the Athlete With Cardiovascular Disease	American Heart Association Preparticipation Cardiovascular Screening of Competitive Athletes History Elements Applied to a	Nothing to Disclose
Emery	Michael	Hearts and Soles: Multimodality Imaging in	Diverse International Screening Program Global & Basal Longitudinal Strain in NFL Combine Participants	Nothing to Disclose
Emery	Michael	Athletes 31. Non Invasive Imaging: Sports and Exercise	Suggested Reviewer	Nothing to Disclose
•		Team 1		-
End	Christopher	Interventional Complexity and Complications	Characteristics and Outcomes of Patients With Clinically Silent Peri- Procedural Hemoglobin Drops as Compared to Patients With Overt Bleeding Following Percutaneous Coronary Intervention	Nothing to Disclose
Endo	Ayaka	Unusual Presentations of ACS	Trend of Use in Transradial Intervention Among Elderly Patients in Japan According to Their Pre-Procedural Bleeding Risk	Nothing to Disclose
Ene Jr.	Elena	Arrhythmias and Clinical EP: Devices 2	Left Bunde Branch Block Is Incomplete in the Majority of Patients With Heart Failure Due to Systolic Left Ventricle Dysfunction: A Simple Intraprocedural Demonstration	Nothing to Disclose
Enfield	Kyle	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Continuous Monitoring of Cardiorespiratory Dynamics Detects Clinical Deterioration in Acute Care Patients	Nothing to Disclose
Eng	Marvin	Interventional Cardiology: TAVR 2	Death and Dialysis Risk After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Eng	Marvin	Valvular Heart Disease: Aortic Stenosis	Outcomes and Their Predictors in Acute Transcatheter Aortic Heart Valve-in-Transcatheter Aortic Heart Valve Therapy	Nothing to Disclose
Eng	Marvin	Interventional Cardiology: Structural Heart Disease	Transcatheter Mitral Valve-in-Ring Implantation After Failure of Surgical Mitral Ring Annuloplasty	Nothing to Disclose
Eng	Marvin	Interventional Cardiology: TAVR 3	Predictors of Late Bleeding in the TAVR Population	Nothing to Disclose
Engberding	Niels	34. Prevention: Rehabilitation Team 1	Suggested Reviewer Exercise Intolerance and Proportional Pulse Pressure Response in	Nothing to Disclose
Engelman	Timothy	Making Progress in Understanding Heart Failure	Patients With Chronic Heart Failure	Nothing to Disclose
Engler	Renata	Interdisciplinary Cardiovascular Team Collaboratives in Care	Multidisciplinary Cardiovascular Team Review Captures Preclinical Disease	Nothing to Disclose
Engler	Renata	Diabetes and Other Issues in Cardiovascular Prevention	Arresting Insulin Resistance With an Integrative Health Intervention	Nothing to Disclose
Engstrøm	Thomas	Post-CAD/MI: Making Tough Predictions About the Future	Midregional Proadrenomedullin: A Prognostic Marker of Mortality and Heart Failure in Patients With ST-Segment Elevation Myocardial Infarction	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,St. Jude,Zealand Pharma; SPEAKER'S BUREAU - Bayer Healthcare Pharmaceuticals
Engvall	Jan	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Overweight and Obesity Impairs Left Ventricular Systolic and Diastolic Function in Patients With Type 2 Diabetes	Nothing to Disclose
Enos	James	Imaging the Athlete's Heart	Free-Breathing MRI Evaluation of Cardiac Volume Measurements During In-Scanner Exercise	Nothing to Disclose
Enriquez	Jonathan	02. Acute and Stable Ischemic Heart Disease: Clinical Team 6	Suggested Reviewer	Nothing to Disclose
Enriquez-Sarano	Maurice	Imaging in Valvular Heart Disease: Applying Guidelines to Clinical Practice and What to do if They Don't Fit	Co-Chair	RESEARCH/RESEARCH GRANTS - Edwards LLC
Enriquez-Sarano	Maurice	Valvular Heart Disease: Mitral Valve Disease	Left Atrium Volume Index Measurement in Routine Practice: Does It Independently Impact Survival of Degenerative Mitral Valve Disease?	RESEARCH/RESEARCH GRANTS - Edwards LLC
Enriquez-Sarano	Maurice	Valvular Heart Disease: Mitral Valve Disease	Quantitation of Degenerative Mitral Regurgitation: Reserved to the	RESEARCH/RESEARCH GRANTS - Edwards LLC
Enriquez-Sarano	Maurice	Valvular Heart Disease: Aortic Stenosis	Specialized Few or Applicable to Routine Clinical Practice? Bicuspid Versus Tricuspid Aortic Valve Stenosis: Comparative Study of Clinical Characteristics and Outcomes Following Aortic Valve	RESEARCH/RESEARCH GRANTS - Edwards LLC
Enriquez-Sarano	Maurice	Valvular Heart Disease: Aortic Stenosis	Replacement in an Age-Matched Cohort Sinus Rhythm Versus Atrial Fibrillation & It Clinical Profile and Natural History of Patients With Severe Aortic Stenosis Managed Medically	RESEARCH/RESEARCH GRANTS - Edwards LLC
Enriquez-Sarano	Maurice	New Technologies in Echocardiography	Dynamic Changes of Mitral Apparatus in Acute Myocardial Infarction With Ischemic Mitral Regurgitation: Prospective 3D Quantitative Echocardiographic Study	RESEARCH/RESEARCH GRANTS - Edwards LLC
Enriquez-Sarano	Maurice	Novel Determinants of Outcomes in VHD	Impact of Aortic Valve Calcification and Sex on Hemodynamic Progression and Clinical Outcomes in Aortic Stenosis	RESEARCH/RESEARCH GRANTS - Edwards LLC
Ephrem	Georges	Six Years of Making an IMPACT	Co-Chair	Nothing to Disclose
Ephrem Ephrem	Georges Georges	Redefining the "F" Word FIT Clinical Decision Making: Interventional	Biomarker Profile in Adults With Fontan Circulation When Giving Birth Unveils Birth Defects: A Tale of Coronary	Nothing to Disclose Nothing to Disclose
25	- Coo. goo	Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Abnormalities	The state of the s
Ephrem	Georges	Congenital Heart Disease: To the Third Decade and Beyond	Red Blood Cell Distribution Width and Outcomes in Fontan Patients	Nothing to Disclose
Ephrem	Georges	Things That Matter in Adult Congenital Heart Disease	Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult	Nothing to Disclose
Epstein	Andrew	Controversies in Device Therapy	Congenital Heart Biobank What Should I do with This Patient Who Has a non Functional Lead?	CONSULTANT FEES/HONORARIA - Zoll; DATA SAFETY MONITORING BOARD - Boston Scientific,MEDTRONIC,St. Jude Medical/Abbott; RESEARCH/RESEARCH GRANTS - Biotronik,Boston Scientific,MEDTRONIC,St. Jude Medical/Abbott
Epstein	Andrew	Role of Newer ICD Technologies for the Prevention of Sudden Cardiac Death	Panelist	CONSULTANT FEES/HONORARIA - Zoll; DATA SAFETY MONITORING BOARD - Boston Scientific,MEDTRONIC,St. Jude Medical/Abbott, RESEARCH/RESEARCH GRANTS - Biotronik,Boston Scientific,MEDTRONIC,St. Jude Medical/Abbott
Epstein	Andrew	Role of Newer ICD Technologies for the Prevention of Sudden Cardiac Death	Who Are the Best Patients for a Wearable Cardioverter Defibrillator?	CONSULTANT FEES/HONORARIA - ZOII; DATA SAFETY MONITORING BOARD - Boston Scientific, MEDTRONIC, St. Jude Medical/Abbott, RESEARCH/RESEARCH GRANTS - Biotronik, Boston Scientific, MEDTRONIC, St. Jude Medical/Abbott



and a				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Epstein	Shilpi	Congenital Heart Disease Surgery: Updates and Innovations	Promoting Pulmonary Arterial Growth via Right Ventricular to Pulmonary Artery Conduit Placement in Children With Pulmonary Atresia and Hypoplastic Pulmonary Arteries	Nothing to Disclose
Erande	Ashwini	Interventional Complexity and Complications	Gender Differences in Post Percutaneous Coronary Intervention Complications Following Acute Myocardial Infarction in the United States	Nothing to Disclose
Erbel	Raimund	FIT Clinical Decision Making Reviewers 4	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Ergene	Asim	Emerging Issues in CV Disease Management: International Perspectives From the Brazilian Society of Cardiology, Turkish Society of Cardiology, and American College of Cardiology	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Amgen Inc. AstraZeneca Pharmaceuticals,Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc,Novartis Corporation,Piezer Inc,servier; SPEAKER'S BUREAU - Sandoz Inc,Sandof-Aventis
Erglis	Andrejs	Refining PCI Technique and Outcomes	Three-Year Results From the EVOLVE II Randomized Trial: Late Clinical Outcomes With Bioresorbable Compared to Permanent Polymer Everolimus-Eluting	CONSULTANT FEES/HONORARIA - Abbott Vascular,Biosensors,Biotronik,Boston Scientific,Cordis J&J,MEDTRONIC
Ergui	lan	Insights Into Ischemic Heart Disease: Stable to Erosive Plaques	Urinary Lead Excretion Correlates With Overall Toxic Metal Excretion in Patients With Coronary Artery Disease: A Sentinel Biomarker?	Nothing to Disclose
Eric	Van Belle	Interventional Cardiology: PCI in Complex Patients	Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated Heparin Following Transcatheter Aortic Valve Replacement: Results From the Bravo-3 Randomized Trial	CONSULTANT FEES/HONORARIA - Saint Jude Medical, Volcano
Erickson	Lori	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Interstage Resource Utilization of Infants With Single Ventricle: Results of a Crossover Study	Nothing to Disclose
Erlinge	David	Late-Breaking Clinical Trials: Interventional	Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve Guided Intervention (IFR-SWEDEHEART): A Multicenter,	SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals
Erlinge	David	Novel Developments in Acute Coronary Syndromes	Prospective, Registry-Based Randomized Clinical Trial Prehospital Administration of Heparin Reduces the Risk of Vessel Occlusion in Patients With ST Elevation Myocardial Infarction:	SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals
Ermis	Peter	Redefining the "F" Word	Secondary Analysis of the TASTE Trial Use of Novel Oral Anticoagulants in Adult Fontan Patients	Nothing to Disclose
Ermis	Peter	Congenital Heart Disease: To the Third Decade and Beyond	Long-Term Follow-Up in Adult Survivors of Pulmonary Atresia With Intact Ventricular Septum	Nothing to Disclose
Erol	Cetin	03. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Erqou	Sebhat	Therapy Team 1 Innovations in Cardiovascular Risk Assessment	Ideal Cardiovascular Health Metrics in Couples: A Community-	Nothing to Disclose
Erthal	Fernanda	and Reduction Non Invasive Imaging: Prognostic Implications	Based Population Study Prognostic Value of Segment Involvement Score Compared to Other Measures of Coronary Atherosclerosis by Computed	Nothing to Disclose
Erwin	John	of CT Angiography Valvular Heart Disease Guidelines The	Tomography: A Systematic Review and Meta-Analysis What Changed? - The Scope of the VHD Focused Update: IE	Nothing to Disclose
		Evidence and the Gaps		-
Erwin	John	Town Hall Meeting: Pitfalls of Assessing Valvular Heart Disease Severity	Case: Degenerative Mitral Stenosis	Nothing to Disclose
Erwin	John	Case Studies from the Guidelines for Clinicians		Nothing to Disclose
Erwin	John	Case Studies from the Guidelines for Clinicians		Nothing to Disclose
Erwin	John	42. Spotlight on Special Topics: Education, Innovation, Advocacy, Social Media, Leadership and Practice Management Team 1	Suggested Reviewer	Nothing to Disclose
Erwin	Patricia	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prognostic Value of Segment Involvement Score Compared to Other Measures of Coronary Atherosclerosis by Computed Tomography: A Systematic Review and Meta-Analysis	Nothing to Disclose
Escaned	Javier	Late-Breaking Clinical Trials: Interventional	Primary Results of DEFINE-FLAIR: A Multi-Centre, Prospective, International, Randomized, Blinded Comparison of Clinical Outcomes and Cost Efficiencies of iFR and FFR Decision-Making for Physiological Guided Coronary Revascularization	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Astra Zeneca, Boston Scientiffic, Volcano Corporation; OTHER - MEDTRONIC, Orbes-Neich
Escaned	Javier	Coronary Physiology and Microcirculation	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Astra Zeneca, Boston Scientiffic, Volcano Corporation; OTHER - MEDTRONIC, Orbes-Neich
Escaned	Javier	Coronary Physiology and Microcirculation	Does the Interventional Cardiologist Have to be Concerned with the Microcirculation?	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Astra Zeneca, Boston Scientiffic, Volcano Corporation; OTHER - MEDTRONIC. Orbes-Neich
Escaned	Javier	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International Multicentre iFR GRADIENT Registry	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Astra Zeneca, Boston Scientiffic, Volcano Corporation; OTHER - MEDTRONIC, Orbes-Neich
Escaned	Javier	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Provisional Versus Elective Two-Stenting Strategy for Unprotected True Left Main Bifurcation Lesions: A Sub-Study From Fails 2 Study	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Astra Zeneca, Boston Scientific, Volcano Corporation; OTHER -
Escaned	Javier	23. Interventional Cardiology: IVUS and Intravascular Physiology Team 1	Suggested Reviewer	MEDTRONIC,Orbes-Neich CONSULTANT FEES/HONORARIA - Abbott Laboratories,Astra Zeneca,Boston Scientiific,Volcano Corporation; OTHER -
Escolar	Gines	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Normalizing Platelet Reactivity of Cardiovascular Patients on Ticagrelor Therapy Using Fresh Platelets: Ex Vivo Testing of the Functional Recovery Attained Within 48-Hours of Stopping Treatment	MEDTRONIC, Orbes-Neich Nothing to Disclose
Escolar	Gines	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Treadment Countering the Anti-Platelet Effects of Ticagrelor With Platelet Concentrates Within 48 Hours of a Loading Dose: Ex Vivo Testing of Time-Effect on Functional Recovery in Patients With Cardiovascular Disease	Nothing to Disclose
Eske Bruun	Niels	Valvular Heart Disease: Endocarditis	Disease Risk of Infective Endocarditis Associated With Concomitant Pacemaker Among Patients Undergoing Aortic Valve Replacement: A Nationwide Study	Nothing to Disclose
Eske Bruun	Niels	Infectious Endocarditis: Comprehensive Perspectives	A Nationwide Study Risk Factors Associated With Infective Endocarditis After Aortic Valve Replacement	Nothing to Disclose
Esparragoza Fox	Cecilia	FIT Clinical Decision Making: Heart Failure and		Nothing to Disclose
Espinosa Pascual	María Jesús	Pulmonary Hypertension Coronary Angiography, Intra-Vascular Imaging,	Incidence, Clinical Profile and Prognosis of Patients With Myocardial	Nothing to Disclose
		Revascularization and Outcomes	Infarction With Non-Obstructive Coronary Arteries in the Real World	
Esposito	Michele	Novel Developments in Acute Coronary Syndromes	Right-Sided Ventriculo-Arterial Coupling Indices Are Associated With Clinical Outcomes Among Patients Receiving Biventricular Impella (BiPella) Support for Cardiogenic Shock	Nothing to Disclose
Essebag Esselstyn	Vidal	Arrhythmias and Clinical EP: Devices 3	Predicting Electrocardiographic and Echocardiographic Response to Cardiac Resynchronization Therapy: The Use of Strict Left Bundle Branch Block Criteria	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, Boston Scientific, Bristol-Myers Squibb Company MEDTRONIC, Pfizer, SANOFI, St Jude Medical; RESEARCH/RESEARCH GRANTS - Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb Company ,MEDTRONIC, Pfizer, St. Jude Medical
	Caldwell	Lifestyle Changes to Reduce Cardiovascular	Nutrition for Prevention and Reversal of CVD	Nothing to Disclose

(Mary and and and and and and and and and and				
Estep	Jerry	Session Title Diabetes and Endothelial Dysfucntion in Heart Failure	Presentation Title Interleukin 18 Impairs Excitation Contraction Coupling in Cardiomyocytes and Predicts Mortality in Acute Decompensated Heart Failure	Disclosures CONSULTANT FEES/HONORARIA - Maquet,MEDTRONIC,St Jude; SPEAKER'S BUREAU - Amgen,Novartis
Estep	Jerry	FIT Clinical Decision Making: Heart Failure and	Cardiac Recovery Post Left Ventricular Assist Device in a Patient With Orthotopic Liver Transplantation	CONSULTANT FEES/HONORARIA - Maquet,MEDTRONIC,St Jude; SPEAKER'S BUREAU - Amgen,Novartis
Estep	Jerry	Pulmonary Hypertension 13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Maquet, MEDTRONIC, St
Esterbrooks	Dennis	Clinical Team 7 FIT Clinical Decision Making: Non-Invasive	In the Forest of Comorbidities, Always Look for the Wild Type	Jude; SPEAKER'S BUREAU - Amgen,Novartis Nothing to Disclose
Estes	N.	Imaging and Valvular Heart Disease Common Arrhythmia Problems: The Experts	Panelist	CONSULTANT FEES/HONORARIA - Boston
Estes	N.	Approach Quickfire ECG for Experts	Panelist	Scientific,MEDTRONIC,Saint Jude Medical CONSULTANT FEES/HONORARIA - Boston
Estes	N.	Role of Newer ICD Technologies for the	Panelist	Scientific,MEDTRONIC,Saint Jude Medical CONSULTANT FEES/HONORARIA - Boston
Estes	N.	Prevention of Sudden Cardiac Death Role of Newer ICD Technologies for the	What Does the Future Hold for Leadless Pacing and ICDs?	Scientific,MEDTRONIC,Saint Jude Medical CONSULTANT FEES/HONORARIA - Boston
Estes	N. A.	Prevention of Sudden Cardiac Death Late-Breaking Clinical Trials	Co-Chair	Scientific,MEDTRONIC,Saint Jude Medical CONSULTANT FEES/HONORARIA - Boston
Estes	N. A.	Fibrillatory Arrhythmias: Outcomes With	Antiarrhythmic Medications for Atrial Fibrillation Appear Reasonably	Scientific,MEDTRONIC,Saint Jude Medical CONSULTANT FEES/HONORARIA - Boston
Estes	N. A.	Contemporary Practice Arrhythmias and Clinical EP: Basic 2	Safe in Hypertrophic Cardiomyopathy Atrial Fibrillation Is Associated With Low Cardiovascular Mortality in	Scientific,MEDTRONIC,Saint Jude Medical CONSULTANT FEES/HONORARIA - Boston
Estes	N. A.	07. Arrhythmias and Clinical EP: Sports and	Hypertrophic Cardiomyopathy Suggested Reviewer	Scientific,MEDTRONIC,Saint Jude Medical CONSULTANT FEES/HONORARIA - Boston
		Exercise Team 1		Scientific,MEDTRONIC,Saint Jude Medical
Esteves	William	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Increased Left Atrial Compliance Is an Independent Predictor of Improved Functional Capacity After Percutaneous Mitral Valvuloplasty	Nothing to Disclose
Eteiba	Hany	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Prognostic Significance of Co-Existing Persistent Edema and Hemorrhage at 6 Months in Survivors of ST-Elevation Myocardial Infarction	Nothing to Disclose
Eteiba	Hany	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Decision Making Using Fractional Flow Reserve Is Associated With Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With Nstemi	Nothing to Disclose
Eteiba	Hany	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Segmental Circumferential Strain Derived From DENSE Predicts Improvement of Left Ventricular Function Post ST Elevation Myocardial Infarction: The BHF MR-MI Study	Nothing to Disclose
Eteiba	Hany	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Current Smoking, Microvascular Pathology and Adverse Outcome After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights	Nothing to Disclose
Eteiba	Hany	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Hypertension, Microvascular Pathology and Prognosis in Patients With an Acute ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Etheridge	Susan	Atrial Fibrillation in Young and Unusual Populations: Children and Adult Congenital Heart Disease	Panelist	OTHER - Up-To-Date
Etheridge	Susan	Test Yourself with Questions: Pediatric	Faculty	OTHER - Up-To-Date
Etheridge	Susan	Cardiology Congenital Heart Disease: Innovations in	Do Pediatric Cardiologists Follow the Sports Restriction	OTHER - Up-To-Date
Etheridge	Susan	Single Ventricle Heart Disease 11. Congenital Heart Disease: Therapy Team	Recommendations for Children With a Bicuspid Aortic Valve? Suggested Reviewer	OTHER - Up-To-Date
Etiwy	Muhammad	Novel Arrhythmia Diagnostics, Therapeutics,	Variable Accuracy of Commercially Available Wearable Heart Rate	Nothing to Disclose
Eto	Masahiko	and "Wearables Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering	Monitors Effect of Gene Polymorphism of Calpain-10 on the Risk of Hypertension in Japanese Population	Nothing to Disclose
Ettedgui	Jose	Therapies FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Perivalvular Leak in Repaired Tetralogy of Fallot	CONSULTANT FEES/HONORARIA - Proctor for AGA Medical (now St. Jude Medical) for interventional devices
Ettinger	Steven	02. Acute and Stable Ischemic Heart Disease: Clinical Team 5	Suggested Reviewer	Nothing to Disclose
Evangelista	Arturo	Vascular Medicine: Emerging Concepts in	Influence of Family History of Aortic Disease on Type B Aortic	Nothing to Disclose
Evangelista	Arturo	Clinical Vascular Diseases Vascular Medicine: Aortic and Peripheral Artery Diseases	Dissection Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of	Nothing to Disclose
Evangelista	Julianne	Exercise in Congenital Heart Disease	Acute Aortic Dissection The 5 Most Controversial Changes in the AHA/ACC Guidelines for	Nothing to Disclose
Evangelista	Lorraine	Heart Failure Patient Care: Transitioning the Cost, Care and Context: Joint Heart Failure Society of America and American College of	Exercise in Congenital Heart Disease Managing the Minutiae: PCP, ANP, RN, HFMD Singing Kumbaya	Nothing to Disclose
Evangelista	Lorraine	Cardiology Advances in HCM, PPCM and Other	High Versus Standard Protein Diets in Obese Patients With Heart	Nothing to Disclose
Evangelista Masip	Artur	Cardiomyopathies Vascular Medicine: Aortic and Peripheral	Failure: Effects on Chronic Disease Risks Acute Aortic Dissection in Patients Without a History of Hypertension	Nothing to Disclose
Evans	David	Artery Diseases Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	What Are the Differences in Oral Anticoagulant Treatment Persistence in Non-Valvular Atrial Fibrillation in Europe? Real-World	SALARY - Bristol-Myers Squibb Company
Evans	Jonathan	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Studies in Three European Countries Glycemic Control in Insulin and Non-Insulin Dependent Diabetic Patients With ST Elevation Myocardial Infarction Predicts Time to	Nothing to Disclose
Evans	Jonathan	Coronary Artery Disease Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Presentation Ischemic Time and Risk Factors Associated With the Incidence of Cardiogenic Shock in Patients Presenting With ST Elevation	Nothing to Disclose
Evans	Jonathan	Coronary Artery Disease Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Myocardial Infarction Impact of Demographics and Socioeconomic Status on Mode of Transportation and Time to Presentation in Patients With ST	Nothing to Disclose
Evans	Kaleigh	Coronary Artery Disease Put Your Codon! Genetic Insights Into Heart Failure	Elevation Myocardial Infarction Genetics of Heart Rate Observational Study (GenHRate)	Nothing to Disclose
Evans	Michael	Arrhythmias and Clinical EP: Basic 5	A Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation	SPEAKER'S BUREAU - Janssen Pharmaceuticals, Inc
Everett	Allen	The OMICS in Pulmonary Hypertension	Panelist	CONSULTANT FEES/HONORARIA - ImmunArray Ltd
Everett Everett	Allen Brendan	The OMICS in Pulmonary Hypertension Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	Proteomics: Translational Potential in Pulmonary Hypertension ACC Poster Moderator	CONSULTANT FEES/HONORARIA - ImmunArray Ltd CONSULTANT FEES/HONORARIA - Abbott Diagnostics,Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Novartis
Everett	Brendan	32. Prevention: Clinical Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Diagnostics,Roche
Evgenia	Mpourouki	Diabetes and Endothelial Dysfucntion in Heart Failure	Association of Endothelial Dysfunction With Biomarkers of Inflammation, Myocardial Fibrosis and Left Ventricle Strain in	Diagnostics; RESEARCH/RESEARCH GRANTS - Novartis Nothing to Disclose
Ewald	Gregory	13. Heart Failure and Cardiomyopathies:	Patients With Heart Failure Suggested Reviewer	CONSULTANT FEES/HONORARIA - HeartWare,St Jude;
	1	Clinical Team 8		RESEARCH/RESEARCH GRANTS - BioControl,XDx



Congress of the Congress of th				<u> </u>
Last Name	First Name	Session Title Young Investigator Awards Competition:	Presentation Title Cost Effectiveness of Continuous Flow Left Ventricular Assist	Disclosures OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Exner	Derek	Outcomes Research	Devices for Destination Therapy in End Stage Heart Failure Patients Ineligible for Cardiac Transplantation	Analytics for Life; RESEARCH/RESEARCH GRANTS - GE Healthcare, Heart Force Medical, Medtronic Inc ,St Jude Medical
Exner	Derek	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	The Presence of Fragmented QRS Complexes Early After Acute Myocardial Infarction Is Associated With Subsequent Lack of Favorable Left Ventricular Remodeling	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Analytics for Life; RESEARCH/RESEARCH GRANTS - GE Healthcare, Heart Force Medical, Medtronic Inc ,St Jude Medical
Eyvazian	Vaughn	Arrhythmias and Clinical EP: Devices 3	Safety of Cardiac Magnetic Resonance Imaging With Non- Conditional Cardiac Implantable Electronic Devices	Nothing to Disclose
Eyvazian	Vaughn	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Incidence and Factors Associated With New-Onset Cardiomyopathies Following Liver Transplantation	Nothing to Disclose
Ezekowitz	Justin	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Timing and Clinical Predictors of Early Versus Late Readmission Among Patients Hospitalized for Acute Heart Failure: Insights From	CONSULTANT FEES/HONORARIA - Abbott Labs, Astra- Zeneca, Bristol-Meyers-Squibb, Novartis, Pfizer, servier;
Fooler: to	l		ASCEND-HF	RESEARCH/RESEARCH GRANTS - Amgen,Bayer Healthcare Pharmaceuticals,Merck & Do., Inc.
Ezekowitz	Justin	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	The Impact of the Current Versus Prior Cardiac Resynchronization Guidelines on the Proportion of Hospitalized Heart Failure Patients Eligible for Therapy	CONSULTANT FEES/HONORARIA - Abbott Labs, Astra- Zeneca, Bristol-Meyers-Squibb, Novartis, Pfizer, servier; RESEARCH/RESEARCH GRANTS - Amgen, Bayer Healthcare Pharmaceuticals, Merck & Description (Description).
Ezekowitz	Justin	Unusual Presentations of ACS	The High Cost of Low Acuity Non ST-Segment Elevation Acute Coronary Syndrome Admissions to the Coronary Care Unit: An Analysis of National Population Health Data	CONSULTANT FEES/HONORARIA - Abbott Labs, Astra- Zeneca, Bristol-Meyers-Squibb, Novartis, Pfizer, servier; RESEARCH/RESEARCH GRANTS - Amgen, Bayer Healthcare Pharmaceuticals, Merck & Bamp; amp; Co., Inc.
Ezekowitz	Michael	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Edoxaban Therapy Increases Treatment Satisfaction and Reduces Utilization of Health Care Resources: An Analysis From the Edoxaban versus warfariN in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) Study	CONSULTANT FEES/HONÖRARIA - Aegerion, Amgen nc., ARMETHEON, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Coherex, Dalichi Sankyo, gilead, J& amp; J. Janssen Scientific Affairs, Medtronics, Merck, Pfizer, Pozen Inc, SANOFI; RESEARCH/RESEARCH GRANTS - Portola
Ezekowitz	Michael	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)	CONSULTANT FEES/HONORARIA - Aegerion, Amgen Inc., ARMETHEON, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Coherex, Dalichi Sankyo, gilead, J& amp; J, Janssen Scientific Affias, Medtronics, Merck, Piizer, Pozen Inc, SANOFI; RESEARCH/RESEARCH GRANTS - Portola
Ezhumalai	Babu	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Techniques and Outcomes of Bioresorbable Vascular Scaffolds in the Treatment of Coronary Bifurcation Lesions: One Scaffold Strategy Versus Two Scaffold Strategy	Nothing to Disclose
F. H.	Jose	Timely Topics in Acute Coronary Syndromes	Health Insurance Related Disparities in Reperfusion and Mortality for Patients With ST Segment Elevation Myocardial Infarction in Sergipe, Brazil	Nothing to Disclose
Faber	Lothar	13. Heart Failure and Cardiomyopathies: Clinical Team 7	Suggested Reviewer	Nothing to Disclose
Fabrizio	Carly	Interdisciplinary Cardiovascular Care in Complex Scenarios	Hand-Foot-and-Mouth (and Heart) Disease: Coxsackievirus A6 as a Recently Recognized Cause of Acute Myocarditis	Nothing to Disclose
Fach	Andreas	Interventional Cardiology: PCI and TAVR in Complex Patients	Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the Bravo-3 Randomized Trial	Nothing to Disclose
Faddis	Mitchell	Tough Clinical Problems in Patients with	Clinical Implications from New Insights into CRT	RESEARCH/RESEARCH GRANTS - MEDTRONIC, Stereotaxis,
Fadia	Ankur	Implantable Electronic Devices FIT Clinical Decision Making Reviewers 1	ACC FIT Clinical Decision Making Reviewer	Inc Nothing to Disclose
Fadreguilan	Erdie	New Strategies in Arrhythmias Management: International Perspectives From the Philippine Heart Association, Russian Society of Cardiology, and American College of Cardiology	Non-Conventional Treatment of Brugada Syndrome	Nothing to Disclose
Faggioni	Michela	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Clinical Outcomes Associated With Impella Versus IABP Use in Stable Patients Undergoing High Risk Percutaneous Coronary Intervention	Nothing to Disclose
Faggioni	Michela	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	Nothing to Disclose
Faggioni	Michela	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Angiographic Phenotype and Clinical Outcomes of Patients With Malignancy Undergoing PCI	Nothing to Disclose
Faggioni	Michela	Timely Topics in Acute Coronary Syndromes	Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions	Nothing to Disclose
Faggioni	Michela	Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes	Nothing to Disclose
Faggioni	Michela	Optimizing the Care of ACS Patients	Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population	Nothing to Disclose
Faggioni	Michela	Interventional Complexity and Complications	Prediction of Acute Kidney Injury in Patients Undergoing Coronary Intervention Using Calculation of Serum Osmolality	Nothing to Disclose
Faillace	Robert	FIT Clinical Decision Making: Non-Invasive	Persistent Hemodynamic Instability After Repaired Heart Injury Due	Nothing to Disclose
Faizer	Rumi	Imaging and Valvular Heart Disease Maximally Effective Vascular Care: Vascular Collaborative Team Care in Action	to Penetrating Trauma: No Valvulopathy? Look Again Case Presentation #3: Panel Discussion Moderator	CONSULTANT FEES/HONORARIA - Medtronic Inc
Faletra	Francesco	Controversies in Mitral Valve Surgery: Joint Symposium of the Society of Thoracic Surgeons and the American College of Cardiology	Panelist	CONSULTANT FEES/HONORARIA - Philips; OTHER - none
Faletra	Francesco	Controversies in Mitral Valve Surgery: Joint Symposium of the Society of Thoracic Surgeons and the American College of Cardiology	Rescuing the Later Failed Perfect Repair Non-operatively	CONSULTANT FEES/HONORARIA - Philips; OTHER - none
Falk	Rodney	Advances in HCM, PPCM and Other Cardiomyopathies	Misdiagnosis of Cardiac Amyloidosis Type by Standard Immunohistochemistry	CONSULTANT FEES/HONORARIA - Alnylam Pharmaceuticals,lonis Pharmaceuticals; RESEARCH/RESEARCH GRANTS - Alnylam Pharmaceuticals
Falk	Rodney	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Prevalence of Monoclonal Gammopathy of Unknown Significance in Wild Type Transthyretin Amyloidosis Patients	CONSULTANT FEES/HONORARIA - Alnylam Pharmaceuticals, Ionis Pharmaceuticals; RESEARCH/RESEARCH GRANTS - Alnylam Pharmaceuticals
Falkentoft	Alexander Christian	Post-CAD/MI: Making Tough Predictions About the Future	Midregional Proadrenomedullin: A Prognostic Marker of Mortality and Heart Failure in Patients With ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Fan	Fangfang	Diabetes and Other Issues in Cardiovascular Prevention	Efficacy of Folic Acid Supplementation on the Reduction of Stroke Risk: Interaction With Platelet Count	Nothing to Disclose
Fan	Yan	Valvular Disease Populations at Risk	Risk Stratification Predicts Survival in Patients With Low Gradient Preserved Left Ventricular Ejection Fraction and Severe Aortic Stenosis After Aortic Valve Intervention	Nothing to Disclose
Fan	Yan	Valvular Heart Disease: Aortic Stenosis	Sterioss Auter Adult varie intervention Sturgical Risk Scores Outweigh Echocardiographic Severity of Aortic Stenosis for Determining Prognosis in Patients With Low Gradient Severe Aortic Stenosis and Preserved Left Ventricular Function	Nothing to Disclose
Fanari	Zaher	Coronary Physiology and Microcirculation	Case Presentation: Physiology Measurements in STEMI- Clinical Examples	Nothing to Disclose
Fanari	Zaher	Interventional Cardiology: TAVR 1	Examples Safety and Efficacy of Using Pressure Wire With Dobutamin Infusion in Themoynamic Assessment of Low Flow Low Gradient Aortic	Nothing to Disclose
	1	Ī	In Themoynamic Assessment of Low Flow Low Gradient Aortic Stenosis	



and a				<u> </u>
Last Name Fanari	First Name Zaher	Session Title Innovations in Practice Management and	Presentation Title Predicting Readmission Risk Following Percutaneous Coronary	Disclosures Nothing to Disclose
Fanari	Zaher	Social Media Innovations in Practice Management and	Intervention at the Time of Admission Predicting Readmission Risk Following Coronary Artery Bypass	Nothing to Disclose
Fanari	Zaher	Social Media Interventional Cardiology: PCI and TAVR in	Surgery at the Time of Admission Hemodynamic Assessment of Low Flow, Low Gradient Severe	Nothing to Disclose
Fanari	Zaher	Complex Patients Interventional Cardiology: Structural Heart	Aortic Stenosis With Preserved EF Using a Pressure Wire The Impact of Transaortic Gradient and Transaortic Flow on the	Nothing to Disclose
		Disease	Discrepancy Between Echocardiographic and Cardiac Catheterization Evaluation of Severe Aortic Stenosis With Preserved Ejection Fraction	
Fanaroff	Alexander	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Patterns of Angina and Antianginal Medication Use Among Patients Following MI Treated With PCI: Insights From TRANSLATE-ACS	Nothing to Disclose
Fanaroff	Alexander	Anti-Platelet Therapies: Always a Sticky Topic	Antiplatelet Therapy Changes for MI Patients With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS Study	Nothing to Disclose
Fanaroff	Alexander	Peripheral Arterial Disease, Risk, and Outcomes	Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes: A Report From the STS/TVT Registry	Nothing to Disclose
Fang	James	Debates on Current Hot Topics in Coronary Intervention	Debate Con: No, Medical Therapy is Still the Gold Standard	CONSULTANT FEES/HONORARIA - Accorda; DATA SAFETY MONITORING BOARD - Actelion,capricor,CardioCell,National Institutes of Health
Fang	James	The Nuts and Bolts of Pulmonary Hypertension in Left Heart Disease	Co-Chair	CONSULTANT FEES/HONORARIA - Accorda; DATA SAFETY MONITORING BOARD - Actelion,capricor,CardioCell,National Institutes of Health
Fang	James	Test Yourself with Questions: Guidelines Module 4: Stable Ischemic Heart Disease	Faculty	CONSULTANT FEES/HONORARIA - Accorda; DATA SAFETY MONITORING BOARD - Actelion, capricor, CardioCell, National Institutes of Health
Fang	James	Test Yourself with Questions: Guidelines Module 4: Stable Ischemic Heart Disease	Chair	CONSULTANT FEES/HONORARIA - Accorda; DATA SAFETY MONITORING BOARD - Actelion,capricor,CardioCell,National Institutes of Health
Fang	James	Emerging Developments in HFpEF and Arryhthmias	Influence of Left Ventricular Ejection Fraction on Cause-Specific Mortality in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial	CONSULTANT FEES/HONORARIA - Accorda; DATA SAFETY MONITORING BOARD - Actelion,capricor,CardioCell,National Institutes of Health
Fanikos	John	Maximally Effective Vascular Care: Vascular Collaborative Team Care in Action	Case Presentation #1: Panelist	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc,Portola
Fanola	Christina	Highlighted Original Research: Prevention and the Year in Review	Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial	Nothing to Disclose
Fanola	Christina	Stroke and AF: Thinking About the Heart	Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Active Malignancy: An Analysis of ENGAGE AF - Timi 48 Randomized Clinical Trial	Nothing to Disclose
Fanola Farag	Christina Mohamed	38. Vascular Medicine: Basic Team 1 Antiplatelet and Antithrombotic Agents in	Suggested Reviewer Comparative Effects of Different P2Y ₁₂ Inhibitors on	Nothing to Disclose Nothing to Disclose
Farawi	Ahmed	Ischemic Heart Disease Interventional Complexity and Complications	Global Thrombotic Status in Coronary Artery Disease Characteristics and Outcomes of Patients With Clinically Silent Peri- Procedural Hemoglobin Drops as Compared to Patients With Overt	Nothing to Disclose
Farb	Andrew	The Evolution of Angioplasty 40 Years of Innovation: Joint Symposium of TCT and the	Bleeding Following Percutaneous Coronary Intervention The Evolution of Evidence-based Medicine and FDA Interaction	Nothing to Disclose
Farber	Adam	American College of Cardiology FIT Clinical Decision Making: Non-Invasive	Successful Percutaneous Valve-In-Valve Intervention for Bio-	Nothing to Disclose
Farber-Eger	Eric	Imaging and Valvular Heart Disease Highlighted Original Research: Pulmonary	Prosthetic Mitral Valve Failure Racial Differences in Patients Referred for Right Heart	Nothing to Disclose
		Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Catheterization and Risk of Pulmonary Hypertension	
Farber-Eger	Eric	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Lack of a Tricuspid Regurgitation Velocity and Pulmonary Hypertension: Absence of Evidence Is Not Evidence of Absence	Nothing to Disclose
Farber-Eger	Eric	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Underutilization of Statin Therapy Among Participants in a Lung Cancer Screening Program With a High Incidence of Cardiovascular Events	Nothing to Disclose
Farber-Eger	Eric	Markers of Prognosis Associated With Elevated Blood Pressure	Direct Transition to Dilated Cardiomyopathy Without Antecedent Left Ventricular Hypertrophy Is Uncommon Among Hypertensive Subjects in a Large Clinical Cohort	Nothing to Disclose
Fareed	Jawed	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Retrospective Analysis of Thrombogenic Biomarkers in Patients With Atrial Fibrillation Treated With Novel Oral Anticoagulants	Nothing to Disclose
Fares	Maan	Interventional Cardiology: TAVR 3	Comparison of Acute Elastic Recoil Between CoreValve and SAPIEN 3 Valves in Transcatheter Aortic Valve Replacement	Nothing to Disclose
Farhan	Serdar	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Clinical Outcomes Associated With Impella Versus IABP Use in Stable Patients Undergoing High Risk Percutaneous Coronary Intervention	Nothing to Disclose
Farhan	Serdar	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Impella or Intra-Aortic Balloon Pump Support in Patients Undergoing High Risk Percutaneous Coronary Intervention: A Real World Single Center Experience	Nothing to Disclose
Farhan	Serdar	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	Nothing to Disclose
Farhan	Serdar	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Angiographic Phenotype and Clinical Outcomes of Patients With Malignancy Undergoing PCI	Nothing to Disclose
Farhan	Serdar	Novel Developments in Acute Coronary Syndromes	Trends in Incidence and Mortality Associated With Acute Kidney Injury in Patients Undergoing PCI for Acute Coronary Syndrome	Nothing to Disclose
Farhan	Serdar	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Gender Differences in Short- and Long-Term Mortality in the Vienna STEMI Registry	Nothing to Disclose
Farhan	Serdar	Interventional Cardiology: PCI and TAVR in Complex Patients	Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the Bravo-3 Randomized Trial	Nothing to Disclose
Farhan	Serdar	Timely Topics in Acute Coronary Syndromes	Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions	Nothing to Disclose
Farhan	Serdar	Optimizing the Care of ACS Patients	Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population	Nothing to Disclose
Farhan	Serdar	Interventional Complexity and Complications	Prediction of Acute Kidney Injury in Patients Undergoing Coronary Intervention Using Calculation of Serum Osmolality	Nothing to Disclose
Farhan	Serdar	Interventional Cardiology: PCI in Complex Patients	Risk and Impact of Diabetes Mellitus on Ischemic Events in Females and Males After Percutaneous Coronary Intervention	Nothing to Disclose
Farhat	Salman	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	and males Arter Percutaneous Coronary Intervention A "Mind Blowing" Case of Left Atrial-Esophageal Fistula Leading to Tension Pneumocephalus and Sudden Death	Nothing to Disclose
Farivar	Robert	Valvular Disease Populations at Risk	Surgical Risk and Therapy of Severe Symptomatic Degenerative	Nothing to Disclose
Farivar	Robert	Valvular Heart Disease: Mitral Valve Disease	Mitral Valve Regurgitation in the Contemporary Era Guideline-Adherence and Survival for Asymptomatic Patients With	Nothing to Disclose
Farivar	Robert	Interventional Cardiology: TAVR 4	Severe Mitral Valve Regurgitation Minimalist Approach to Cardiac Anesthesia and Outcome in Patients	Nothing to Disclose
Farjo	Peter	PCI for NSTEMI and Complex Patients With	The Feasibility and Safety of Same Day Discharge for All Comers	Nothing to Disclose
			Minimalist Approach to Cardiac Anesthesia and Outcome in Patients Undergoing Transcatheter Aortic Valve Replacement	

and a				<u> </u>
<u>Last Name</u> Farkouh	First Name Michael	Session Title Highlighted Original Research: Prevention and the Year in Review	Presentation Title PCSK9 Variants and Neurocognitive Impairment: Data From the REasons for Geographic and Racial Differences in Stroke	Disclosures RESEARCH/RESEARCH GRANTS - Amgen
Farkouh	Michael	Acute Coronary Syndromes, Diagnosis,	(REGARDS) Study Trends in the Use of High-Intensity Statin Therapy After Myocardial	RESEARCH/RESEARCH GRANTS - Amgen
Farkouh	Michael	Management and Outcomes 02. Acute and Stable Ischemic Heart Disease:	Infarction, 2011-2014 Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Amgen
Farmer	Steven	Clinical Team 7 Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Impact of Medical Liability Reform on Coronary Artery Disease Testing and Intervention	Nothing to Disclose
Farnier	Michel	Advances in Cholesterol Measurement and Management	Alirocumab Titration Strategy Allows Individualized LDL-C Reduction in a Real World Setting: Results From ODYSSEY OLE (LONG TERM Cohort)	Nothing to Disclose
Farnier	Michel	Advances in Cholesterol Measurement and Management	On-Treatment LDL-C Levels When Alirocumab Dose Is Decreased From 150 to 75 mg Every 2 Weeks in Patients With Heterozygous Familial Hypercholesterolemia: Results From ODYSSEY OLE	Nothing to Disclose
Farnier	Michel	Advances in Lipid Management	Alirocumab Reduces Major Cardiovascular Events in Individuals With Atherosclerotic Cardiovascular Disease: A Post-Hoc Analysis of ODYSSEY LONG TERM	Nothing to Disclose
Farnier	Michel	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Alirocumab Treatment in a Real World Setting: Safety Update From an Open-Label Treatment Extension to the ODYSSEY Program for Patients With Heterozygous Familial Hypercholesterolemia	Nothing to Disclose
Farooq	Shausha	Imaging the Athlete's Heart	Acute Coronary Syndromes During Endurance Sports: Olmsted County Experience	Nothing to Disclose
Farooq	Shausha	Non Invasive Imaging: Role of Exercise Testing		Nothing to Disclose
Farooqi Farooqi	Kanwal Kanwal	Precision Medicine: It's Hot, But What Is It? Precision Medicine: It's Hot, But What Is It?	Panelist Can Segmental Computational Modeling impact Assessment of	Nothing to Disclose Nothing to Disclose
			VAD Placement and Transplant Assessment in Patients with CHD?	5
Farre	Jeronimo	Arrhythmias and Clinical EP: Devices 1	Pharmacological Treatment Alone Versus Treatment Combined With Implantable Cardioverter-Defibrillator Therapy in Patients Over 75 Years	CONSULTANT FEES/HONORARIA - development of an educational e-learning portal ecgcorner.com
Farrell	Laurie	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Changes in Citric Acid Metabolism Are Associated With the Development of Anthracycline-Induced Cardiotoxicity in Mice and in Patients	Nothing to Disclose
Farrell	Laurie	Advances in HCM, PPCM and Other Cardiomyopathies	Diagnostic Value of Metabolite Profiling in Hypertrophic Cardiomyopathy	Nothing to Disclose
Farrell	Mary Beth	Nuclear Cardiology: Quality	Increasing Equipment Vintage Predicts Poor Laboratory Quality and Delay in Accreditation: An Evaluation by IAC Echocardiography and Nuclear Accreditation Status	Nothing to Disclose
Farzaneh-Far	Afshin	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Apical Hypertrophic Cardiomyopathy: A Case of Mimicry	Nothing to Disclose
Farzaneh-Far	Afshin	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Heart Rate Response During Regadenoson Stress Cardiac Magnetic Resonance Imaging Is a Predictor of Adverse Cardiovascular Outcomes	Nothing to Disclose
Fatima	Kaneez	Obesity Management in 2017: Weighing the Issues	A Meta-Analysis of Cardiovascular Safety of FDA Approved Anti Obesity Drugs	Nothing to Disclose
Fatusin	Oluwatosin	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Melody Valve Placement for Mitral Valve Dysplasia Syndrome	Nothing to Disclose
Fauber	Nancy	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Prediction of 30-Day Readmissions in Patients Admitted for Acute Myocardial Infarction (AMI)	Nothing to Disclose
Fauchier	Laurent	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Incident Atrial Fibrillation According to Gender In Patients With Ischemic Stroke: A Nationwide Cohort Study	CONSULTANT FEES/HONORARIA - Bayer,Boehringer Ingelheim,MEDTRONIC,Novartis,Pfizer Inc
Fauchier	Laurent	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	What Are the Differences in Oral Anticoagulant Treatment Persistence in Non-Valvular Atrial Fibrillation in Europe? Real-World Studies in Three European Countries	CONSULTANT FEES/HONORARIA - Bayer,Boehringer Ingelheim,MEDTRONIC,Novartis,Pfizer Inc
Fauchier	Laurent	Stroke and AF: Thinking About the Heart	Predictors of Incident Atrial Fibrillation in Patients With Ischemic Stroke: A Nationwide Cohort Study	CONSULTANT FEES/HONORARIA - Bayer,Boehringer Ingelheim,MEDTRONIC,Novartis,Pfizer Inc
Favale	Stefano	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Admission Plasma Glucose Level on Myocardial Perfusion in St-Segment Elevation Myocardial Infarction (STEMI) Patients	Nothing to Disclose
Favale	Stefano	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Time Related Benefit of Antiplatelet Therapy on Coronary Reperfusion in ST-Elevation Myocardial Infarction (STEMI) Patients	Nothing to Disclose
Fayad	Zahi	Non Invasive Imaging: Prognostic Implications of CT Angiography	The Relationship Between Pericardial Adipose Tissue Volume, Atherosclerotic Plaque Type and Cardiovascular Risk: A High Risk Plaque Biolmage Sub-Study	Nothing to Disclose
Faza	Nadeen	FIT Clinical Decision Making: Heart Failure and Cardiomyopathies	SynCardia Meets CardioMEMS: A Loeffler's Story	Nothing to Disclose
Fazio	Sergio	Are We There Yet? Update on Trials Testing New Therapeutics for Prevention of ASCVD	Co-Chair	CONSULTANT FEES/HONORARIA - Kowa,Merck & Dr., Inc.,Sanofi-Aventis
Fazio	Sergio	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Discordant Response of Low Density Lipoprotein Cholesterol and Lp(a) Levels to Monoclonal Antibodies Targeting Proprotein Convertase Subtilisin/Kexin Type 9	CONSULTANT FEES/HONORARIA - Kowa,Merck & Dec., Inc.,Sanofi-Aventis
Fazzari	Melissa	Innovations in Advocacy and Patient Centered Care	Patient Perceptions on the Impact of Caffeine Consumption After a Myocardial Infarction or Percutaneous Coronary Intervention	Nothing to Disclose
Fearon	William	Interventional Live Case Session V: Complex Coronary and Physiology from Mid-America Heart Institute (Kansas City, Missouri)	Co-Chair	CONSULTANT FEES/HONORARIA - Heartflow; RESEARCH/RESEARCH GRANTS - ACIST,MEDTRONIC,St. Jude Medical
Fearon	William	Late-Breaking Clinical Trials: Interventional	Panelist	CONSULTANT FEES/HONORARIA - Heartflow; RESEARCH/RESEARCH GRANTS - ACIST, MEDTRONIC, St. Jude Medical
Fearon	William	Recent ACS Trials: Relevance to My Daily Practice	DANAMI 3 - PRIMULTI: FFR Use in STEMI	CONSULTANT FEES/HONORARIA - Heartflow; RESEARCH/RESEARCH GRANTS - ACIST,MEDTRONIC,St. Jude Medical
		Coronary Physiology for the Assessment of	Panelist	CONSULTANT FEES/HONORARIA - Heartflow; RESEARCH/RESEARCH GRANTS - ACIST,MEDTRONIC,St.
Fearon	William	Stable CAD		Jude Medical
Fearon Fearon	William		What's New in FFR? Contemporary FFR Studies	Jude Medical CONSULTANT FEES/HONORARIA - Heartflow; RESEARCH/RESEARCH GRANTS - ACIST,MEDTRONIC,St. Jude Medical
		Stable CAD Coronary Physiology for the Assessment of	What's New in FFR? Contemporary FFR Studies Co-Chair	CONSULTANT FEES/HONORARIA - Heartflow; RESEARCH/RESEARCH GRANTS - ACIST, MEDTRONIC, St. Jude Medical CONSULTANT FEES/HONORARIA - Heartflow; RESEARCH/RESEARCH GRANTS - ACIST, MEDTRONIC, St.
Fearon	William	Stable CAD Coronary Physiology for the Assessment of Stable CAD		CONSULTANT FEES/HONORARIA - Heartflow; RESEARCH/RESEARCH GRANTS - ACIST,MEDTRONIC,St. Jude Medical CONSULTANT FEES/HONORARIA - Heartflow;



Congress of				l l
Last Name Fearon	First Name William	Session Title Interventional Cardiology: TAVR 1	Presentation Title The Inflammasome Pathway Is Associated With Adverse Ventricular Remodeling Following Transcatheter Aortic Valve Replacement	Disclosures CONSULTANT FEES/HONORARIA - Heartflow; RESEARCH/RESEARCH GRANTS - ACIST, MEDTRONIC, St.
				Jude Medical
Fearon	William	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Sex Differences in the Risk Factors for Endothelial and Microvascular Dysfunction in Patients With Angina in the Absence of Obstructive Coronary Artery Disease	CONSULTANT FEES/HONORARIA - Heartflow; RESEARCH/RESEARCH GRANTS - ACIST,MEDTRONIC,St. Jude Medical
Fearon	William	Interventional Cardiology: TAVR 4	Depression as a Potential Therapeutic Target to Improve Quality of Life After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Heartflow; RESEARCH/RESEARCH GRANTS - ACIST,MEDTRONIC,St. Jude Medical
Fearon	William	Engage @ ACC.17 Studio: Heart Teams in Action: Complex Coronary Revascularization	Stanford interventionalist	CONSULTANT FEES/HONORARIA - Heartflow; RESEARCH/RESEARCH GRANTS - ACIST,MEDTRONIC,St. Jude Medical
Fearon	William	23. Interventional Cardiology: IVUS and Intravascular Physiology Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Heartflow; RESEARCH/RESEARCH GRANTS - ACIST,MEDTRONIC,St. Jude Medical
Fearon	William	Interventional Challenging Cases: Team 1	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Heartflow; RESEARCH/RESEARCH GRANTS - ACIST,MEDTRONIC,St.
Fedele	Francesco	ECG Screening in Athletes: The Great Debate	Pro	Jude Medical Nothing to Disclose
Fedele Fedele	Francesco Francesco	Clinical Applications of Cardiac MRI in 2017 Improving Outcomes in the Athlete With Cardiovascular Disease	Assessment of Coronary Artery Disease EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students	Nothing to Disclose Nothing to Disclose
Fedele Fedson	Francesco Savitri	ECG Screening and Risk Prediction Recognition of Specific Etiologies and Phenotypes in Heart Failure: Time for	ACC Poster Moderator Co-Chair	Nothing to Disclose Nothing to Disclose
Fedson	Savitri	Precision Non Invasive Imaging: MR Scar and Perfusion	Multimodality Analysis of Abnormal Myocardial Perfusion in Post-	Nothing to Disclose
			Heart Transplant Recipients	
Fefer Fefer	Paul Paul	Interventional Cardiology: TAVR 4 Interventional Cardiology: TAVR 4	Transacatheter Aortic Valve Replacement And Malignancy Rapid Ventricular Pacing During TAVR Is Associated With Poor	Nothing to Disclose Nothing to Disclose
		3,	Short- and Long-Term Outcome	-
Fefer	Paul	Anti-Platelet Therapies: Always a Sticky Topic	Chewing Versus Traditional Swallowing of Ticagrelor to Accelerate Platelet Inhibition in ST Elevation Myocardial Infarction: The CHEERS-STEMI Study	Nothing to Disclose
Feher	Attila	Non Invasive Imaging: Expanding Clinical Applications	Computed Tomographic Angiography Can Reliably Assess Epicardial Coronary Vasoreactivity in Response to Adenosine and Dobutamine	Nothing to Disclose
Feigenbaum Feigenbaum	Harvey Harvey	FIT Forum: Mix and Mingle Advances in HCM. PPCM and Other	Imaging Differential Effects of Amyloidosis on Right Ventricular Longitudinal	Nothing to Disclose Nothing to Disclose
=		Cardiomyopathies	and Circumferential Fiber Function	,
Feigenbaum Feinberg	Harvey Micha	Hearts and Soles: Multimodality Imaging in Athletes Interventional Cardiology: TAVR 4	Global & Basal Longitudinal Strain in NFL Combine Participants Transacatheter Aortic Valve Replacement And Malignancy	Nothing to Disclose Nothing to Disclose
Feinstein	Matthew	Making Progress in Understanding Heart Failure	Associations of HIV Related Factors With Adjudicated Heart Failure (HF) in an Electronic Cohort of HIV-Infected (HIV+) Persons	Nothing to Disclose
Feinstein	Matthew	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Atrial Fibrillation (AF) and Atrial Flutter (AFL) Prevalence and Characteristics for Persons With Human Immunodeficiency Virus (HIV+) and Matched Uninfected Controls	Nothing to Disclose
Feit	Frederick	Great Debates in Ischemia 2017	Revascularization is Appropriate for Chronic Total Occlusion with lschemia: CON	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Boston Scientific, Johnson and Johnson, MEDTRONIC, The Medicines Company
Feit	Frederick	21. Interventional Cardiology: Coronary Intervention: Devices Team 2	Suggested Reviewer	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Boston Scientific, Johnson and Johnson, MEDTRONIC, The Medicines Company
Feld	Gregory		Sex Differences in Atrial Structural Remodeling and Serum Markers	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
Feld	Gregory	and Surgical Issues 08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	of Fibrosis at Presentation for Catheter Ablation Suggested Reviewer	ROLE - Perminova. Inc. OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Perminova. Inc.
Feldman	Arthur	4 Put Your Codon! Genetic Insights Into Heart Failure	G-Protein Receptor Kinase 5 Polymorphisms and Outcomes in the African American Heart Failure Trial: Results From the Genetic Risk Assessment of Heart Failure in African-Americans Sub-Study	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Renovacor, Inc.; SPEAKER'S BUREAU - Abbott Laboratories
Feldman	Charles	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Association of Coronary Epicardial Endothelial Dysfunction With Low Endothelial Shear Stress in Patients With Mild Coronary Atherosclerosis Who Presented With Chest Pain	Nothing to Disclose
Feldman	Dmitriy	Head to Toe: Outcomes of Endovascular Interventions	Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals; SPEAKER'S BUREAU - Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, MEDTRONIC, Pfizer, The
Feldman	Dmitriy	Interventional Cardiology: TAVR 1	Baseline Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Increased Mortality After Transcatheter Aortic Valve Replacement	Medicines Company CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals; SPEAKER'S BUREAU - Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, MEDTRONIC, Pfizer, The Medicines Company
Feldman	Dmitriy	Interventional Cardiology: TAVR 2	The Influence of Gender on In-Hospital Clinical Outcomes in Hispanics Following Surgical and Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals; SPEAKER'S BUREAU - Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, MEDTRONIC, Pfizer, The Medicines Company
Feldman	Dmitriy	Interventional Cardiology: TAVR 2	Does Intra-Aortic Balloon Pump Placement During Hospitalization Course for Transcatheter Aortic Valve Replacement Portent a Worse Clinical Outcome?	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals; SPEAKER'S BUREAU - Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, MEDTRONIC, Pfizer, The Medicines Company
Feldman	Dmitriy	Interventional Cardiology: PCI and TAVR in Complex Patients	Management of Patients With Cardiac Arrest in New York Before and After Public Reporting Policy Changes	Neducines Company CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals; SPEAKER'S BUREAU - Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, MEDTRONIC, Pfizer, The Medicines Company
Feldman	Dmitriy	Interventional Cardiology: TAVR 3	Periprocedural Blood Transfusions in Patients Undergoing Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals; SPEAKER'S BUREAU - Abbott Vascular,Bristol Myers Squibb,Daiichi Sankyo,Eli Lilly,MEDTRONIC,Pfizer,The
Feldman	Dmitriy	Innovations in Advocacy and Patient Centered Care	Status of Early Career Academic Cardiology: A Global Perspective	Medicines Company CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals; SPEAKER'S BUREAU - Abbott Vascular, Bristol Myers Squibb, Dalichi Sankyo, Eli Lilly, MEDTRONIC, Pfizer, The Medicines Company
Feldman	Dmitriy	Outcomes in Valvular Heart Disease	In-Hospital Clinical Outcomes Following Concomitant Coronary Artery Bypass Graft and Heart Valve Surgery in Women	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals; SPEAKER'S BUREAU - Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, MEDTRONIC, Pfizer, The Medicines Company
Feldman	Dmitriy	Sex Disparity in VHD Outcomes	The Impact of Gender on In-Hospital Clinical Outcomes Following Isolated Mitral or Aortic Heart Valve Surgery	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals; SPEAKER'S BUREAU - Abbott Vascular,Bristol Myers Squibb,Daiichi Sankyo,Eli Lilly,MEDTRONIC,Pfizer,The Medicines Company
			·	·



Last Name Feldman	First Name Dmitriy	Session Title 26. Interventional Cardiology: Vascular Access and Complications Team 2	Presentation Title Suggested Reviewer	Disclosures CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals; SPEAKER'S BUREAU - Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, MEDTRONIC, Pfizer, The Medicines Company
Feldman	Dmitriy	FIT Clinical Decision Making Reviewers 2	ACC FIT Clinical Decision Making Reviewer	Medicines Company CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals; SPEAKER'S BUREAU - Abbott Vascular, Bristol Myers Squibb, Dailichi Sankyo, Eli Lilly, MEDTRONIC, Pfizer, The Medicines Company
Feldman	Jeremy	Predicting the Future: Observations and Discoveries From Registries and Databases	Trends in Pulmonary Hypertension Hospitalizations: Insights From a National Database	CONSULTANT FEES/HONORARIA - GILEAD Sciences,MEDTRONIC,United Therapeutics
Feldman	Marc	Maintenance of Clinical Competencies in Invasive Coronary Imaging and Coronary	OCT Imaging: Principles	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Admittance Technologies; SPEAKER'S BUREAU - St. Jude
Feldman	Ted	Physiology Featured Clinical Research II: Interventional	Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral	Medical CONSULTANT FEES/HONORARIA - Abbott,Boston
reuman	reu	r eather Gillical Nesearch II. Interventional	Valve Repair in the United States	Scientrific,Edwards,WL Gore; RESEARCH/RESEARCH GRANTS - Abbott,Boston Scientific Corporation,Edwards,WL Gore
Feldman	Ted	Frontier in New Transcatheter Techniques	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott, Boston Scieintrific, Edwards, WL Gore ; RESEARCH/RESEARCH GRANTS - Abbott, Boston Scientific Corporation, Edwards, WL Gore
Feldman	Ted	The Evolution of Angioplasty 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	The Evolution of Structural Heart Disease Management	CONSULTANT FEES/HONORARIA - Abbott, Boston Scieintrific, Edwards, WL Gore; RESEARCH/RESEARCH GRANTS - Abbott, Boston Scientific Corporation, Edwards, WL Gore
Feldman	Ted	PFO Closure, PV Leak, and VSD Repair	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott, Boston Scieintrific, Edwards, WL Gore ; RESEARCH/RESEARCH GRANTS - Abbott, Boston Scientific Corporation, Edwards, WL Gore
Feldman	Ted	PFO Closure, PV Leak, and VSD Repair	Technical Considerations for PFO Closure: Available Devices and Size Selection	CONSULTANT FEES/HONORARIA - Abbott,Boston Scieintrific,Edwards,WL Gore ; RESEARCH/RESEARCH GRANTS - Abbott,Boston Scientific Corporation,Edwards,WL
Feldman	Ted	Transcatheter Mitral Valve Replacement	Case Presentation: Mitral TAVR in Native Valve	Gore CONSULTANT FEES/HONORARIA - Abbott, Boston Scieintriffic, Edwards, WL Gore ; RESEARCH/RESEARCH GRANTS - Abbott, Boston Scientific Corporation, Edwards, WL Gore
Feliberti	Jason	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Searching for a Trigger in Resistant Ventricular Tachycardia in Post Acute Myocardial Infarction	Nothing to Disclose
Feliberti	Jason	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	An Unusual Case of Anemia in a Heart Transplant Patient	Nothing to Disclose
Felker	G. Michael	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Rationale and Methods of the Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE-HF) Study	CONSULTANT FEES/HONORARIA - Amgen,Bristol Myers Squibb, GSK,MEDTRONIC,MyoKardia,Novartis,Stealth,Trevena; RESEARCH/RESEARCH GRANTS - Amgen,Otsuka,Roche Diannostics
Felker	G. Michael	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Timing and Clinical Predictors of Early Versus Late Readmission Among Patients Hospitalized for Acute Heart Failure: Insights From ASCEND-HF	CONSULTANT FEES/HONORARIA - Amgen, Bristol Myers Squibb, GSK, MEDTRONIC, MyoKardia, Novartis, Stealth, Trevena; RESEARCH/RESEARCH GRANTS - Amgen, Otsuka, Roche Diagnostics
Felker	G. Michael	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Hemoconcentration During Management of Patients With Acute Heart Failure and Cardiorenal Syndrome: Insights From CARRESS- HF	CONSULTANT FEES/HONORARIA - Amgen,Bristol Myers Squibb, GSK,MEDTRONIC, MyoKardia, Novartis, Stealth, Trevena; RESEARCH/RESEARCH GRANTS - Amgen,Otsuka,Roche Diagnostics
Felker	G. Michael	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Cardiac Myosin Activator, Omecamtiv Mecarbil, Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure (COSMIC-HF)	CONSULTANT FEES/HONORARIA - Amgen, Bristol Myers Squibb, GSK, MEDTRONIC, MyoKardia, Novartis, Stealth, Trevena; RESEARCH/RESEARCH GRANTS - Amgen, Otsuka, Roche Diagnostics
Felker	Michael	Recognition of Specific Etiologies and Phenotypes in Heart Failure: Time for Precision	Panelist	CONSULTANT FEES/HONORARIA - Amgen,Bristol Myers Squibb, GSK,MEDTRONIC,MyoKardia,Novartis,Stealth,Trevena; RESEARCH/RESEARCH GRANTS - Amgen,Otsuka,Roche Diagnostics
Felker	Michael	Recognition of Specific Etiologies and Phenotypes in Heart Failure: Time for Precision	The Role of Biomarkers in Heart Failure: Holy Grail or Holy Cow?	CONSULTANT FEES/HONORARIA - Amgen,Bristol Myers Squibb, GSK,MEDTRONIC,MyoKardia,Novartis,Stealth,Trevena; RESEARCH/RESEARCH GRANTS - Amgen,Otsuka,Roche Diagnostics
Felker	Michael	13. Heart Failure and Cardiomyopathies: Clinical Team 8	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen,Bristol Myers Squibb,GSK,MEDTRONIC,MyoKardia,Novartis,Stealth,Trevena; RESEARCH/RESEARCH GRANTS - Amgen,Otsuka,Roche
Feltes	Timothy	Test Yourself with Questions: Pediatric Cardiology	Co-Chair	Diagnostics Nothing to Disclose
Fender	Erin		Isolated Tricuspid Valve Surgery: Repair Versus Replacement	Nothing to Disclose
Fender	Erin Erin	Valvular Disease Populations at Risk FIT Clinical Decision Making: Heart Failure and	Isolated Tricuspid Valve Surgery: National Trends and Outcomes A Rare Disease Presenting With Hypertension and Acute Heart	Nothing to Disclose Nothing to Disclose
Fender	Erin	Pulmonary Hypertension	Failure	ů
Fender Fender	Erin Erin	Sex Disparity in VHD Outcomes Tricuspid Regurgitation: Signals in Plain Sight	Gender Differences in Isolated Tricuspid Valve Surgery Isolated Functional Tricuspid Regurgitation: A Population in Need of	Nothing to Disclose Nothing to Disclose
Fender	Erin	FIT Clinical Decision Making Reviewers 2	Treatment ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Feng	Cheng	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Change in Aortomitral Annular Angle and Anterior Mitral Valve Leaflet Length After Transcatheter Aortic Valve Replacement: Implications for Transcatheter Mitral Valve Replacement?	Nothing to Disclose
Feng	Cheng	Interventional Cardiology: TAVR 4	Predictors of New Persistent Left Bundle Branch Block After Edwards Sapien 3 Transcatheter Aortic Valve Replacement	Nothing to Disclose
Feng	Ke	Non Invasive Imaging: MR Scar and Perfusion	Incremental Prognostic Utility of Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy	Nothing to Disclose
Fengler	Karl	Novel Developments in Acute Coronary Syndromes	Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: The Randomized SHOCK-COOL Pilot Trial	Nothing to Disclose
Ferdinand	Keith	Are We There Yet? The Long Journey to Health Equity: Part III	Co-Chair	CONSULTANT FEES/HONORARIA - Amgen Inc.,Boerhinger Ingelheim,Eli Lilly,Novartis Corporation,Quantum Genomics,Sanofi-Aventis
Ferdinand	Keith	Are We There Yet? The Long Journey to Health Equity: Part III	Case Presentation: Highlighting Disparities in CV Care	CONSULTANT FEES/HONORARIA - Amgen Inc.,Boerhinger Ingelheim,Eli Lilly,Novartis Corporation,Quantum Genomics,Sanof-August TANT FEES/HONORARIA - Amgen Inc., Boerhinger CONSULTANT FEES/HONORARIA - Amgen Inc., Boerhinger
Ferdinand	Keith	Are We There Yet? The Long Journey to Health Equity: Part III	Session Summary	CONSULTANT FEES/HONORARIA - Amgen Inc.,Boerhinger Ingelheim,Eli Lilly,Novartis Corporation,Quantum Genomics,Sanofi-Aventis
Ferdinand	Keith	Controversies in Hypertension	Co-Chair	CONSULTANT FEES/HONORARIA - Amgen Inc.,Boerhinger Ingelheim,Eli Lilly,Novartis Corporation,Quantum Genomics,Sanofi-Aventis
Ferdinand	Keith	32. Prevention: Clinical Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen Inc.,Boerhinger Ingelheim,Eli Lilly,Novartis Corporation,Quantum Genomics,Sanofi-Aventis

WASHINGTON, DC | MARCH 17 - 19 2017

Last Name	First Name	Session Title	Presentation Title	Disclosures
Ference	Brian	Harnessing the Power of Genetics to Prevent ASCVD	Leveraging Genetic Epidemiology to Understand Cardiovascular Risk – What Have Nature's Randomized Trials Taught Us?	CONSULTANT FEES/HONORARIA - American College of Cardiology, Amgen Inc., Ionis Pharmaceuticals, Merck & Do., Inc.; RESEARCH/RESEARCH GRANTS - Esperion, Merck & Description, Inc. of Cardiology, Inc.
Ference	Brian	Emerging Concepts in Evaluation and Management of Hypertension	Panelist	CONSULTANT FEES/HONORARIA - American College of Cardiology, Amgen Inc., Ionis Pharmaceuticals, Merck & Dr., Inc.; RESEARCH/RESEARCH GRANTS - Esperion, Merck & Dr., Inc.; Research (Fann); Co., Inc.; Leave (Fann); Co., Inc.
Ference	Brian	Emerging Concepts in Evaluation and Management of Hypertension	Can earlier and longer blood pressure lowering improve primary prevention: implications from a naturally randomized HOPE-3 trial	CONSULTANT FEES/HONORARIA - American College of Cardiology, Amgen Inc., Ionis Pharmaceuticals, Merck & Description, Inc., RESEARCH/RESEARCH GRANTS - Esperion, Merck & Description, Inc., Inc.
Ference	Brian	Highlighted Original Research: Prevention and the Year in Review	Genetic Target Validation for ATP-Citrate Lyase Inhibition	CONSULTANT FEES/HONORARIA - American College of Cardiology, Amgen Inc., Ionis Pharmaceuticals, Merck & Double, Co., Inc.; RESEARCH/RESEARCH GRANTS - Esperion, Merck & Double, Co., Inc.; Research/Research Grants - Esperion, Merck & Double, Co., Inc.
Ference	Brian	33. Prevention: Hypertension Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - American College of Cardiology, Amgen Inc., Ionis Pharmaceuticals, Merck & Camp; Amp; Inc.; RESEARCH/RESEARCH GRANTS - Esperion, Merck & Camp; Co., Inc.
Ferencik	Maros	Highlighted Original Research: Non Invasive Imaging and the Year in Review	The Association of High Risk Plaque Features and Non-Invasive Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography in Patients With Acute Chest Pain: Results From the ROMICAT II Trial	Nothing to Disclose
Fergus	Icilma	Are We There Yet? The Long Journey to Health Equity: Part II	Case Presentation: Highlight the Importance of Culture, Language and Health Literacy in Shared Decision-making and Medication and Treatment Adherence in Improving CV Outcomes	Nothing to Disclose
Fergus	Icilma	Are We There Yet? The Long Journey to	Panelist Panelist	Nothing to Disclose
Fernandes	Amanda	Health Equity: Part II Heart Failure and Cardiomyopathies: Heart	A Meta-Analysis of Randomized Controlled Trials on Vagus Nerve	Nothing to Disclose
Fernandes	Fabio	Failure Gadgets Galore Population Specific Cardiomyopathies: From	Stimulation for the Heart Failure Management Air Pollution in Myocardial Remodeling	Nothing to Disclose
Fernandes	Gilson	Exomes to Databases Heart Failure and Cardiomyopathies: Heart	A Meta-Analysis of Randomized Controlled Trials on Vagus Nerve	Nothing to Disclose
Fernandes	Gilson	Failure Gadgets Galore Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Stimulation for the Heart Failure Management Endo-Epicardial Versus Endocardial-Only Approach for First Ventricular Tachycardia Ablation: A Systematic Review and Meta-	Nothing to Disclose
Fernandes	Susan	Predicting Outcomes in Pediatric Heart Disase	Analysis of Safety and Efficacy Outcomes Insurance Type Is Associated With Longer Hospital Duration but Similar Mortality Among Children Undergoing Congenital Heart	Nothing to Disclose
Fernandez	Ricardo	Arrhythmias and Clinical EP: Syncope and	Surgery Holter Findings in Orthotopic Heart Transplantation Patients: Results	Nothing to Disclose
Farmandan	Charley	Other EP Issues Interventional Cardiology: TAVR 1	From a Cohort of the Most Important Heart Transplant Referral Center in Colombia, South America	Nathing to Displace
Fernandez	Stanley	interventional Cardiology. TAVR 1	Intraoperative Change in Myocardial Contractility With Transcatheter Aortic Valve Replacement Predicts Cardiovascular Outcomes	Nothing to Disclose
Fernandez	Stanley	Interventional Cardiology: TAVR 1	Temporal Change in Myocardial Contractility After Transcatheter Aortic Valve Replacement and Its Relationship With Quality of Life	Nothing to Disclose
Fernandez	Stanley	Non Invasive Imaging: Prognostic Implications of CT Angiography	HEART Score Does Not Predict the Severity of Anatomical Coronary Artery Disease in Patients Presenting to the Emergency Department With Chest Pain	Nothing to Disclose
Fernández Olmo	M. Rosa	Interventional Cardiology: TAVR 1	Pacing Over Guidewire, Stepwise to Minimalism in Tavi: A Single Center Experience	Nothing to Disclose
Fernandez-Alonso	Camilo	Vascular Medicine: Aortic and Peripheral Artery Diseases	Racial (Black-White) Disparities in the Contribution of The Long- Term Burden of Cholesterol from Childhood on Adult Ankle- Brachial Index Decline: The Bogalusa Heart Study	Nothing to Disclose
Fernandez-Alonso	Camilo	Uncovering the Intricacies of Vascular Function		Nothing to Disclose
Fernández-Alvira	Juan Miguel	Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools	Predictive Values of the Ideal Cardiovascular Health and the Fuster- BEWAT Scores for Detecting Subclinical Atherosclerosis in Healthy Individuals	Nothing to Disclose
Fernandez-Friera	Leticia	Highlights in Vascular Medicine Research	Global Plaque Burden by Carotid and Femoral 3D Vascular Ultrasound: The PESA (Progression and Early Detection of Subclinical Atherosclerosis) Study	Nothing to Disclose
Fernandez-Friera	Leticia	Improving Risk Assessment in Atherosclerosis	Subclinical Atherosclerosis in the Absence of Cardiovascular Risk Factors: Pre-Risk Status in the PESA (Progression of Early Subclinical Atherosclerosis) Study	Nothing to Disclose
Fernández-Friera	Leticia	Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools	Predictive Values of the Ideal Cardiovascular Health and the Fuster- BEWAT Scores for Detecting Subclinical Atherosclerosis in Healthy Individuals	Nothing to Disclose
Fernández-Jiménez	Rodrigo	Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools		Nothing to Disclose
Fernandez-Ortiz	Antonio	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Bimodal Prognosis of Patients Hospitalized With Suspected Acute Coronary Syndrome in Whom the Diagnosis Is Not Confirmed	CONSULTANT FEES/HONORARIA - BoehringerIngelheim,Cordis J&J,Daiichi Sankyo Inc,Eli Llily Co,GlaxoSmithKline,Sanofi-Aventis; RESEARCH/RESEARCH GRANTS - Sanofi-Aventis
Feroz	Ahmed	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of Electrocardiogram Changes on Mortality in Asymptomatic Patients With Sepsis and Elevated Troponin	Nothing to Disclose
Ferrando	Mónica	Non Invasive Imaging: MR Scar and Perfusion	Mean Pulmonary Artery Velocity Estimated by Cardiac Magnetic Resonance as an Early Prognostic Indicator in Heart Failure With Reduced Ejection Fraction Irrespective of Right Ventricular Function	Nothing to Disclose
Ferrari	Aline	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	The Role of Oral Beta Blocker in a Real-World Population With Non- ST Segment Elevation Acute Coronary Syndromes	Nothing to Disclose
Ferrari	Aline	Antithrombotic Therapy in Ischemic Heart Disease	Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease	Nothing to Disclose
Ferrari	Emile	Updates on Pulmonary Embolism Management in 2017	Diuretics Versus Fluid Loading in Acute Submassive Pulmonary Embolism	Nothing to Disclose
Ferrari	Emile	Innovative Use of Echocardiography	Early Detection of Cardiac Involvement in Sarcoidosis With 2- Dimensional Speckle-Tracking Echocardiography	Nothing to Disclose
Ferrari	Victor	Imaging and Infections: International Perspectives From the Spanish Society of Cardiology, Venezuelan Society of Cardiology,	Advanced Imaging and Cardiac Infections: Tools for the Present and Future	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Society for Cardiovascular Magnetic Resonance
		and American College of Cardiology		
Ferrari	Victor		Co-Chair	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
	Victor Victor	and American College of Cardiology	Co-Chair Panelist	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Society for Cardiovascular Magnetic Resonance OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Society for Cardiovascular Magnetic Resonance

(P) Townson				l .
Last Name Ferrari	First Name Victor	Session Title Engage @ ACC.17 Studio: Heart Teams in	Presentation Title Participant Penn Imaging	Disclosures OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
		Action: Complex Coronary Revascularization		ROLE - Society for Cardiovascular Magnetic Resonance
Ferrari	Victor	29. Non Invasive Imaging: MR Team 2	Suggested Reviewer	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Society for Cardiovascular Magnetic Resonance
Ferreira	Alexandre	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Comparison of False Versus True ST Elevation Myocardial Infarction Activation Rates in Patients Having Pre-Activation Point of Care Troponin Levels	RESEARCH/RESEARCH GRANTS - PI in clinical trial
Ferreira	Alexandre	Unusual Presentations of ACS	Trends Associated With False ST-Elevation Myocardial Infarction	RESEARCH/RESEARCH GRANTS - PI in clinical trial
Ferreira	Scott	FIT Clinical Decision Making: Arrhythmias and	Activation Neurogenic Orthostatic Hypotension as an Unexpected Etiology of	SPEAKER'S BUREAU - MEDTRONIC
Farmina	C#	Electrophysiology	Recurrent Syncope Obscured by Atrial Flutter	CDEAVED'S BUDEAU MEDTRONIC
Ferreira	Scott	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Unexpected Atrial Thrombus Discovered Post Intraoperative Maze Procedure: The Dilemma of Thrombus Screening Before Percutaneous Pulmonary Vein Isolation	SPEAKER'S BUREAU - MEDTRONIC
Ferreira	Scott	FIT Clinical Decision Making: Arrhythmias and Clinical Electrophysiology	Voltage-Dependent Inappropriate Right Ventricular Capture by Right Atrial Lead Pacing as a Cause of Cardiac Resynchronization Therapy Non-Responder	SPEAKER'S BUREAU - MEDTRONIC
Ferreira Neto	Alfredo	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Independent Pre Procedural Echocardiographic Predictors of Mitral Valve Restenosis After Percutaneous Mitral Balloon Valvuloplasty in a Large Consecutive Cohort Followed Up to Two Decades	Nothing to Disclose
Ferreira Neto	Alfredo	Interventional Cardiology: Structural Heart	Initial Results and Long-Term Follow-Up of Percutaneous Mitral	Nothing to Disclose
Ferreira Neto	Alfredo	Disease Frontiers in Mitral Valve Disease and	Valvuloplasty in Patients With Pulmonary Hypertension Predictors of Immediate and Very Late Events After Percutaneous	Nothing to Disclose
Fi	Inna Luia	Treatment	Mitral Valvuloplasty	CONCULTANT FFFC/HONODADIA Abbett Astro-Zeroes
Ferreiro	Jose Luis	Novel Developments in Acute Coronary Syndromes	Underuse of Potent Oral P2y ₁₂ Inhibitors in Women With an Acute Coronary Syndrome, Despite Having a Higher Risk Profile Than Male Patients	CONSULTANT FEES/HONORARIA - Abbott,AstraZeneca Pharmaceuticals; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals,Daiichi Sankyo
Ferrick	Kevin	Arrhythmias and Clinical EP: AF Miscellaneous	Diabetes Mellitus and the Development of Atrial Fibrillation in	Nothing to Disclose
Ferrieres	Jean	and Surgical Issues Diabetes and Other Issues in Cardiovascular	Hispanics, Blacks and Whites Does Concomitant Diabetes Mellitus Impact the Cholesterol	Nothing to Disclose
Ferrières	Jean	Prevention Advances in Cholesterol Measurement and	Treatment Post Acs? Frequency and Predictors of Cholesterol Goal Attainment in	Nothing to Disclose
		Management	Patients With Coronary Heart Disease: Results From the Dyslipidemia International Study II	
Ferrières	Jean	Advances in Cholesterol Measurement and Management	Low LDL-Cholesterol Target Value Attainment at the Time of Acute Coronary Syndrome (ACS) and Even 4 Months After the Acute Event Due to Lack of Adjustment in Lipid Lowering Treatment: Results From the Dyslipidemia International Study II ACS	Nothing to Disclose
Ferrières	Jean	Advances in Cholesterol Measurement and Management	Improvement of LDL-Cholesterol Goal Attainment in High-Risk Patients in Europe and Middle East Between 2008-09 and 2013-14: Results of DYSIS and DYSIS II CHD	Nothing to Disclose
Ferrières	Jean	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South-Africa, Middle East and China: Results of the Dyslipidemia International Study (DYSIS)	Nothing to Disclose
Ferrières	Jean	Unusual Presentations of ACS	Characteristics and Outcomes of Patients Discharged Without Statins After an Acute Myocardial Infarction: An Analysis From the Combined FAST-MI 2005-2010 Cohorts	Nothing to Disclose
Ferrira	Vanessa	Cardiovascular Magnetic Resonance A Fast and Reliable Method to Change Patients' Therapy. Joint Symposium of the Society for Cardiovascular Magnetic Resonance and the American College of Cardiology	CMR in the Guidelines Europe	Nothing to Disclose
Ferro	Charles	Nuclear Cardiology: Prognosis	Serial Myocardial Perfusion Imaging in End-Stage Renal Disease	Nothing to Disclose
Fett	James	Novel Echocardiographic Methods for Assessing Cardiac Function	Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain	Nothing to Disclose
Fett	James	Advances in HCM, PPCM and Other Cardiomyopathies	Multi-Fetal Gestation, Breastfeeding, Delivery Method and Myocardial Recovery in Peripartum Cardiomyopathy: Results From the Multicenter IPAC Study	Nothing to Disclose
Fetterly	Kenneth	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Integrated Use of Perfusion SPECT/CTA Fusion Imaging and Pulmonary Balloon Angioplasty for Chronic Pulmonary Thromboembolism	Nothing to Disclose
Feuchtner	Gudrun	Non Invasive Imaging: Prognostic Implications of CT Angiography	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	RESEARCH/RESEARCH GRANTS - Medtronic Inc
Field	Michael	Arrhythmias and Clinical EP: Devices 3	Outcomes Following Implant of Semi-Permanent Pacemaker	Nothing to Disclose
Fifer	Michael	How Hypertrophic Cardiomyopathy Became A Contemporary Treatable Genetic Heart	Versus Temporary Pacemaker Panelist	CONSULTANT FEES/HONORARIA - MyoKardia; RESEARCH/RESEARCH GRANTS - gilead
Fifer	Michael	Disease Advances in HCM, PPCM and Other	Diagnostic Value of Metabolite Profiling in Hypertrophic	CONSULTANT FEES/HONORARIA - MyoKardia;
		Cardiomyopathies	Cardiomyopathy	RESEARCH/RESEARCH GRANTS - gilead
Fifer	Michael	Innovations in Advocacy and Patient Centered Care	Employing the Multidisciplinary Heart Team Approach for Complex Coronary Artery Disease: A Single Center Experience	CONSULTANT FEES/HONORARIA - MyoKardia; RESEARCH/RESEARCH GRANTS - gilead
Figueredo	Vincent	Emerging Applications of Echocardiography	Dobutamine Stress Echocardiography as a Predictor of Cardiovascular Morbidity and Mortality Post Orthotopic Liver	SPEAKER'S BUREAU - CardioDX,Sanofi Regeneron
Figueredo	Vincent	Acute Heart Failure: Evaluating Strategies to	Transplantation Seasonal and Regional Variations in Heart Failure Admissions and	SPEAKER'S BUREAU - CardioDX,Sanofi Regeneron
Figueredo	Vincent	Prevent Readmissions Updates on Risk Factors for Cardiovascular	Mortality in the United States Cannabis Use Predicts Risks of Heart Failure and Cerebrovascular	SPEAKER'S BUREAU - CardioDX,Sanofi Regeneron
Figueredo	Vincent	Disease Coronary Intervention in Interventional	Accidents: Results from the National Inpatient Sample White Blood Cell Count to Platelet Ratio: A Novel Biomarker of	SPEAKER'S BUREAU - CardioDX,Sanofi Regeneron
Filardo	Giovanni	Cardiology: Core Concepts Vascular Access and Hemostasis Issues	Outcomes in Patients With Circulatory Support on Left Ventricular Impella Assist Devices Real-Time Ultrasound Versus Fluoroscopy Guided Access for	RESEARCH/RESEARCH GRANTS - Gilead Sciences, Inc.
			Transcatheter Aortic Valve Replacement With the Sapien 3 Valve	
Filardo	Giovanni	Can CABG Patch CAD?	Bias From Categorizing Body Mass Index When Assessing the Association With Post-CABG Mortality	Nothing to Disclose
Filipiak	Krzysztof	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	First Serial 12- and 24-Month Optical Coherence Tomography Assessment of Stemi Patients After the Generation of Absorb Bioresorbable Vascular Scaffold Implantation	Nothing to Disclose
Filippatos	Gerasimos	Recognition of Specific Etiologies and Phenotypes in Heart Failure: Time for Precision	Co-Chair	DATA SAFETY MONITORING BOARD - Bayer; OTHER - Bayer, Cardiorentis, MEDTRONIC, Novartis, servier, Vifor
Filippatos	Gerasimos	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Clinical Effectiveness of Spironolactone in Hospitalized Older Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or Equal to 30 mL/min/1.73 m ²) Patients With Heart Failure	DATA SAFETY MONITORING BOARD - Bayer; OTHER - Bayer, Cardiorentis, MEDTRONIC, Novartis, servier, Vifor



Contract of the contract of th				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Filippatos	Gerasimos	Why Can't We Be Friends? Controversies in Heart Failure Management	Adverse Outcomes With Use of Hydralazine and Nitrate Combination Therapy in Hospitalized Older Non-Black Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)	DATA SAFETY MONITORING BOARD - Bayer; OTHER - Bayer, Cardiorentis, MEDTRONIC, Novartis, servier, Vifor
Filis	Konstantinos	Nuclear Cardiology: Beyond Perfusion	In Vivo Correlation of Carotid Temperatures and Pet/Fdg Uptake in Patients Undergoing Carotid Endarterectomy: Validation With	Nothing to Disclose
Finch	Caleb	Featured Clinical Research I	Histology Native South American Tsimane Have the Lowest Levels of	Nothing to Disclose
Finegan	Tracy	Innovations in Advocacy and Patient Centered Care	Coronary Atherosclerosis Ever Reported Prevalence of Chagas Disease Among Relatives of Positive Cases	Nothing to Disclose
Finizola Flores	Vicente Jesus	Imaging and Infections: International	in Los Angeles, CA Dengue and Heart Disease	Nothing to Disclose
		Perspectives From the Spanish Society of Cardiology, Venezuelan Society of Cardiology, and American College of Cardiology		
Fink	Noam	Interventional Cardiology: TAVR 4	Transacatheter Aortic Valve Replacement And Malignancy	Nothing to Disclose
Fink	Noam	Interventional Cardiology: TAVR 4	Rapid Ventricular Pacing During TAVR Is Associated With Poor Short- and Long-Term Outcome	Nothing to Disclose
Finkelstein	Ariel	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Absence of Clinical Triggering in Diabetic Patients With ST-Segment Elevation Myccardial Infarction Predicts Multiple Vessel Coronary Disease and Is Associated With Increased Mortality	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,MEDTRONIC
Finn	Aloke	Head to Toe: Outcomes of Endovascular Interventions	Safety and Efficacy of Zilver PTX Drug Eluting Stent Implantation Following Drug Coated Balloon Inflation Versus POBA in Healthy Swine Model	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Gore; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Boston Scientific, Medtronic Vascular
Finn	Aloke	Interventional Cardiology: Translation and Pre- Clinical Research	Endothelial Maturation and Function Following Implantation of Abluminal Coating Biodegradable Polymer Based Sirolimus-Eluting Metallic Stent Versus Conformal Coating Durable Polymer Based Everolimus Eluting Stent	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Gore; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Boston Scientific, Medtronic Vascular
Finn	Aloke	Population Specific Cardiomyopathies: From Exomes to Databases	Racial Difference in Genetic Variants Associated With Hypertrophic Cardiomyopathy	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Gore; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Boston
Finn	Aloke	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Pathological Features of Left Main Stent Thrombosis	Scientific, Medtronic Vascular CONSULTANT FEES/HONORARIA - Abbott Laboratories, Gore; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Boston
Finn	Aloke	Coronary Intervention: Drug Eluting Stent and Scaffolds	Long-Term Pathological Result of Everolimus-Eluting Stent Versus Silolimus-Eluting Stent and Bare Metal Stent	Scientific, Medtronic Vascular CONSULTANT FEES/HONORARIA - Abbott Laboratories, Gore; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Boston Scientific, Medtronic Vascular
Finn	Aloke	Unusual Presentations of ACS	Molecular Autopsy of Plaque Erosion-Induced Sudden Cardiac Death in Young Adults (18-35 Years Old)	Scientific, Medtronic Vascular CONSULTANT FEES/HONORARIA - Abbott Laboratories, Gore; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Boston Scientific, Medtronic Vascular
Finn	Aloke	Refining PCI Technique and Outcomes	mTors Inhibitors Increase Endothelial Permeability and Prevent Maturation: Uncovering the Mechanism of Neoatherosclerosis in Drug Eluting Stents	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Gore; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Boston Scientific, Medtronic Vascular
Finn	Aloke	PCI Strategies and Outcomes Unique to Women	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Gore; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Boston Scientific, Medtronic Vascular
Finn	Aloke	25. Interventional Cardiology: Translation and Pre-clinical Research Team 1	Suggested Reviewer	Scientific, Wedtronic Vascular CONSULTANT FEES/HONORARIA - Abbott Laboratories, Gore; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Boston Scientific, Medtronic Vascular
Finn	Gustafsson	Kanu and Docey Chatterjee Lecture and Seminal Talks in Heart Failure: I Wanna New	Who, When and Why Add on Ivabradine	Nothing to Disclose
		Drug: Updated Heart Failure Guidelines		
Finn	Matthew	Advances in Chronic Total Occlusion Intervention	Is Platelet Reactivity Associated With Ischemic Events Following Successful Chronic Total Occlusion Percutaneous Coronary Intervention	Nothing to Disclose
Finocchiaro	Gherardo	Advances in HCM, PPCM and Other Cardiomyopathies	Integrating Myocardial Strain and Exercise Performance Into Prognostication of Hypertrophic Cardiomyopathy	CONSULTANT FEES/HONORARIA - Biotronik Italia
Fintel	Dan	Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells	ACC Poster Moderator	SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals, Bristol- Myers Squibb Company ,Daiichi Sankyo, Janssen Pharmaceuticals, Inc, Merck & Do., Inc., Pfizer Inc
Fintel	Dan	03. Acute and Stable Ischemic Heart Disease: Therapy Team 1	Suggested Reviewer	SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals, Bristol- Myers Squibb Company ,Daiichi Sankyo, Janssen Pharmaceuticals, Inc, Merck & Do., Inc., Pfizer Inc
Firstenberg	Michael	Interventional Cardiology: PCI and TAVR in	Timing and Algorithm of Permanent Pacemaker Implantation After	CONSULTANT FEES/HONORARIA - ALLMED, Johnson
Fischbein	Michael	Complex Patients Interventional Cardiology: TAVR 1	TAVR The Inflammasome Pathway Is Associated With Adverse Ventricular Remodeling Following Transcatheter Aortic Valve Replacement	& Johnson / Ethicon,Maquet Cardiovascular Inc Nothing to Disclose
Fischer-Nielsen	Anne	Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells	Adipose Derived Stromal Cells for Refractory Angina: Results From MyStromalCell Trial	Nothing to Disclose
Fischman	David	Interventional Cardiology: TAVR 1	Hands Down: Operator Hand Versus Torso Radiation Exposure	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Boston
Fischman	David	Interventional Cardiology: TAVR 1	During Transcatheter Aortic Valve Replacement Provider Radiation Exposure During Transcatheter Aortic Valve	Scientific,MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Boston
Fiser	Wesley	FIT Clinical Decision Making: Valvular Heart	Replacement Clinical Decision Making: Acute Thrombosis of the Mechanical Mitral	Scientific,MEDTRONIC Nothing to Disclose
	•	Disease and Pericardial Disease	Valve	CONSULTANT FEES/HONORARIA -
Fish	Frank	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Catecholaminergic Polymorphic Ventricular Tachycardia and Peri- Partum Cardiomyopathy: A Perfect Sympathetic Storm?	Johnson&Johnson/Biosense-Webster
Fish	Matthews	Nuclear Cardiology: Quality	Rest Scan Does Not Improve Automatic Machine Learning Prediction of Major Adverse Coronary Events After High Speed Myocardial Perfusion Imaging	CONSULTANT FEES/HONORARIA - Spectrum Dynamics
Fisher	Daniel	Novel Developments in Acute Coronary Syndromes	Comparison of Clinical Outcomes: Bivalirudin With Transfemoral Versus Heparin With Transradial in Patients With ST Segment Elevation Myocardial Infarction	Nothing to Disclose
Fisher	John	New Strategies in Arrhythmias Management: International Perspectives From the Philippine Heart Association, Russian Society of Cardiology, and American College of Cardiology	Co-Chair	CONSULTANT FEES/HONORARIA - MEDTRONIC; OTHER - Biotronik,Boston Scientific/GDT,MEDTRONIC,St Jude Medical
Fisher	John	Cardiology New Strategies in Arrhythmias Management: International Perspectives From the Philippine Heart Association, Russian Society of Cardiology, and American College of Cardiology	Introduction to Session	CONSULTANT FEES/HONORARIA - MEDTRONIC; OTHER - Biotronik, Boston Scientific/GDT, MEDTRONIC, St Jude Medical
Fisher	John	Ventricular Arrhythmias in the Coronary Care Unit: Contemporary Solutions to an Old Problem	Co-Chair	CONSULTANT FEES/HONORARIA - MEDTRONIC; OTHER - Biotronik, Boston Scientific/GDT, MEDTRONIC, St Jude Medical
Fisher	John	Controversies in Device Therapy	Co-Chair	CONSULTANT FEES/HONORARIA - MEDTRONIC; OTHER -
Fisher	John	Arrhythmias and Clinical EP: AF Miscellaneous		Biotronik,Boston Scientific/GDT,MEDTRONIC,St Jude Medical CONSULTANT FEES/HONORARIA - MEDTRONIC; OTHER -
Fisher	John	and Surgical Issues 06. Arrhythmias and Clinical EP: Other Team 1	Hispanics, Blacks and Whites Suggested Reviewer	Biotronik,Boston Scientific/GDT,MEDTRONIC,St Jude Medical CONSULTANT FEES/HONORARIA - MEDTRONIC; OTHER -
	l	1		Biotronik,Boston Scientific/GDT,MEDTRONIC,St Jude Medical



Fisher	Joseph	Session Title Nuclear Cardiology: Coronary Flow	Presentation Title Precisely Controlled Arterial CO2 Can Potentiate Myocardial Blood Flow to the Same Extent as Adenosine: A Preclinical Study in	Disclosures Nothing to Disclose
Fisher	Mary	Population Specific Cardiomyopathies: From	Canines With 13N-Ammonia PET Racial Differences in Heart Failure Admissions & Outcomes	Nothing to Disclose
Fisher	Perry	Exomes to Databases Timely Topics in Acute Coronary Syndromes	Among Patients With HIV Emergency Room Evaluation of Patients With Cardiac Complaints	Nothing to Disclose
Fisher	Stacy	FIT Clinical Decision Making: Prevention, Adult	and New Left Bundle Branch Block: The Utility of the Sgarbossa and Modified Sgarbossa Criteria Important Hemodynamic Considerations in the Management of an	Nothing to Disclose
		Congenital and Congenital Heart Disease	Adult With Unrepaired Pentalogy of Fallot Presenting With Necrotizing Fasciitis and Sepsis	-
Fisher	Westby	Social Media and the Cardiovascular Professionals: Lessons Learned and Future Applications	Panelist	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Practicing Physicians of America
Fisher	Westby	Social Media and the Cardiovascular Professionals: Lessons Learned and Future Applications	ACC-Talk: Legal Implications of Social Media Use in Medicine: Case Studies from My Experience as the "Blogfather"	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Practicing Physicians of America
Fisher-Hoch	Susan	Vascular Medicine: New Insights Into Aortic and Peripheral Artery Diseases	The Prevalence of Subclinical Lower Extremity Peripheral Arterial Disease in Mexican Americans: Results From the Cameron County Hispanic Cohort Study	Nothing to Disclose
Fitchett	David	Highlighted Original Research: Prevention and the Year in Review	Consistent Effect of Empagliflozin on Composite Outcomes Related to Heart Failure: Results From EMPA-REG OUTCOME	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,Merck & Co., Inc.,Novo Nordisk Inc.,Sanofi-Aventis
Fitchett	David	Innovations in Cardiovascular Risk Assessment and Reduction	Are the Cardiovascular Risk Reductions Seen With Empagliflozin in the EMPA-REG OUTCOME Trial Explained by Conventional Cardiovascular Risk Factors?	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,Merck & Co., Inc.,Novo Nordisk Inc.,Sanofi-Aventis
Fitzgerald	Peter	The Evolution of Angioplasty — 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	Panelist	CONSULTANT FEES/HONORARIA - cornidus; OTHER - Heartflow; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,Cardinal Health
Fitzgerald	Peter	Head to Toe: Outcomes of Endovascular Interventions	Peri-Strut Low Intensity Area Predicts Neointimal Progression Associated With Late Enlargement of Self-Expanding Nitinol Stents in Superficial Femoral Arteries: An Optical Coherence Tomography Study	CONSULTANT FEES/HONORARIA - cornidus; OTHER - Heartflow; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Cardinal Health
Fitzgerald-Butt	Sara	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Utility of Genetic Testing in Infants With Isolated Congenital Heart Disease	Nothing to Disclose
Fitzgibbons	Timothy	FIT Clinical Decision Making: Non-Invasive	Distered With No Contractile Reserve	Nothing to Disclose
Fitzmaurice	David	Imaging and Valvular Heart Disease Atrial Fibrillation, Anticoagulation and Novel	Early Mortality in Patients With New Onset Atrial Fibrillation: Results	CONSULTANT FEES/HONORARIA - Bayer,Bohringer
Fitzsimmons	Samantha	Device Therapies The Story of the Adult Congenital Heart	From the GARFIELD-AF Registry Arrhythmia Burden & Outcomes in Eisenmenger Syndrome	Ingelheim,Pfizer/BMS,Roche diagnostics UK Nothing to Disclose
Fiuzat	Mona	Disease Patient and EP Heart Failure and Cardiomyopathies: Is Heart	Surrogate Endpoints and the Differential Response to ASV for Sleep	CONSULTANT FEES/HONORARIA - Resmed;
Flachskampf	Frank	Failure With a Normal EF for Real? Echocardiographic Assessment of LV Diastolic	Apnea in HFrEF Versus HFpEF in the CAT-HF Trial Diastolic Dysfunction: A Separate Clinical Entity?	RESEARCH/RESEARCH GRANTS - Critical Diagnostics,Otsuka,Roche Diagnostics
riadiskampi	Frank	Function The New ASE/EACVI Guidelines 2016 Update: Joint Symposium of the American Society of Echocardiography and the American College of Cardiology	Diastoric Dysturiculori. A Separate Cirricar Erruty?	Nothing to Disclose
Flachskampf	Frank	Valvular Heart Disease: Mitral Valve Disease	Volumetric Quantification of Regurgitant Volume in Asymptomatic Severe Degenerative Mitral Regurgitation by Echocardiography and Cardiac MRI With Independent Validation of Forward Stroke Volume by Positron Emission Tomography	Nothing to Disclose
Flaherty	James	Interventional Cardiology: TAVR 2	Intensity of Statin Therapy and Outcomes After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Flaker	Greg	When Anticoagulation Needs to be Stopped What Are the Options? Pharmacology II	Contemporary Practice Highlights a Need for Clinical Pathways in Periprocedural Anticoagulation	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc
Flamm	Scott	Non Invasive Imaging: MR Characterization and Function	Time Varying Effect of Total Scar on Mortality in Patients With Cardiomyopathy Undergoing Cardiac Resynchronization Therapy	CONSULTANT FEES/HONORARIA - Renova Therapeutics; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Cryothermic, Inc., Precision Image Analysis; OTHER - Bayer Healthcare Pharmaceuticals
Flamm	Scott	Non Invasive Imaging: MR Scar and Perfusion	Incremental Prognostic Utility of Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy	CONSULTANT FEES/HONORARIA - Renova Therapeutics; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Cryothermic, Inc., Precision Image Analysis; OTHER - Bayer Healthcare Pharmaceuticals
Flatt	David	Ventricular Arrhythmias and Sudden Death Prevention	Prophylactic Defibrillator Implantation in Patients With Non-Ischemic Cardiomyopathy: An Updated Comprehensive Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Fleck	Desiree	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Impact of Home Monitoring Program on Interstage Mortality and Stage II Outcomes	Nothing to Disclose
Fleg	Jerome	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Risk of Hospitalization or Death Due to Heart Failure With Intensive Glucose-Lowering Therapy in Diabetic Women: Subgroup Analyses by History of Cardiovascular Disease in the ACCORD Trial	Nothing to Disclose
Fleg	Jerome	Emerging Developments in HFpEF and Arryhthmias	Influence of Left Ventricular Ejection Fraction on Cause-Specific Mortality in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial	Nothing to Disclose
Fleg	Jerome	Emerging Developments in HFpEF and Arryhthmias	Effects of Age and Comorbidities on Outcomes in Patients With Heart Failure From HF-ACTION	Nothing to Disclose
Flego	Davide	Insights Into Ischemic Heart Disease: Stable to	Hyaluronic Acid, Hyaluronidase-2 and Acute Coronary Syndromes:	Nothing to Disclose
Flego	Davide	Erosive Plaques Unusual Presentations of ACS	Possible Correlation With Plaque Erosion Matrix Metalloproteinase 9 Drives the Shedding of CD31 in Acute	Nothing to Disclose
Fleischmann	Dominik	Challenges in Cardiac CT: Case-Based Discussions	Coronary Syndromes Suspected LVAD and Other Circulatory Support System Complications: The Role of Cardiac CT	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - iSchemaView Inc.; RESEARCH/RESEARCH GRANTS - General
Fleishman	Craig	10. Congenital Heart Disease: Pediatric Team	Suggested Reviewer	Electric Health Care, Siemens Medical Solutions OTHER - W.L. Gore Medical
Fleming	Gregory	2 Engage @ ACC.17 Studio:The Newlywed	Participant, Team 4	Nothing to Disclose
Fletcher	Ross	Game for Pediatric Cardiac Providers Assessing the Clinical Impact of Blood	Guidelines Allowing Control of Hypertension in Non-Diabetics	Nothing to Disclose
	Ross	Pressure Lowering Therapies Acute Heart Failure: Evaluating Strategies to	Greater Than 60 Years Old at up to 150 mmHg Average Systolic Blood Pressure Increases Patient Mortality in Veterans Among Older Heart Failure (HF) Patients With In-Hospital Acute	-
Fletcher		Prevent Readmissions	Kidney Injury (AKI), an Improvement in Kidney Function Is Associated With a Higher Risk of Post-Discharge Mortality but Not Readmission	Nothing to Disclose
Flint	Nir	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Absence of Clinical Triggering in Diabetic Patients With ST-Segment Elevation Myocardial Infarction Predicts Multiple Vessel Coronary Disease and Is Associated With Increased Mortality	-
Floh	Alejandro	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Standardization of Peri-Operative Management After Norwood Operation Has Not Improved 1 Year Outcomes	Nothing to Disclose

Florea	Victoria	Session Title Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Presentation Title The Role of Gender on Mesenchymal Stem Cell Therapy in Non- Ischemic Dilated Cardiomyopathy: A Sub-Analysis of the	Disclosures Nothing to Disclose
Flores	Eduardo	Novel Developments in Acute Coronary Syndromes	POSEIDON-DCM Trial Mild Therapeutic Hypothermia and Stent Thrombosis: Ticagrelor Better Than Clopidogrel in Patients With Percutaneous Coronary Intervention After Cardiac Arrest	OTHER - ninguna
Flores	Eduardo	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Therapeutic Hypothermia in Post-Cardiac Arrest Syndrome: Role of Neuron-Specific Enolase as Early Predictor of Neurological Status at Discharge	OTHER - ninguna
Flores	Erica	Arrhythmias and Clinical EP: Devices 3	Prospective Cryoballoon Dosing Study Based on Time-to-Isolation	Nothing to Disclose
Flores	Ferdinand	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Impact of Cardiac Troponin I on the Presence of the Coronary Artery Plaque in Rheumatoid Arthritis patients	Nothing to Disclose
Flueckiger	Peter	Valvular Heart Disease: Aortic Stenosis	Surgical Risk Scores Outweigh Echocardiographic Severity of Aortic Stenosis for Determining Prognosis in Patients With Low Gradient Severe Aortic Stenosis and Preserved Left Ventricular Function	Nothing to Disclose
Foley	David	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	The RAC Sign: Retroaortic Anomalous Coronary Artery Visualization by Transthoracic Echocardiography	Nothing to Disclose
Foley	David	Arrhythmias and Clinical EP: Devices 4	Safety of Left Atrial Appendage Closure in an Unselected High Risk Cohort: Results From the Beaumont Hospital Left Atrial Appendage Closure Registry	SPEAKER'S BUREAU - Beaumont Hospital Dublin Ireland
Foley	Thomas	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	3D Printing for Procedural Simulation of Transcatheter Mitral Valve Replacement in Patients With Mitral Annular Calcification	Nothing to Disclose
Foley	Thomas	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	The RAC Sign: Retroaortic Anomalous Coronary Artery Visualization by Transthoracic Echocardiography	Nothing to Disclose
Foley	Thomas		Integrated Use of Perfusion SPECT/CTA Fusion Imaging and Pulmonary Balloon Angioplasty for Chronic Pulmonary Thromboembolism	Nothing to Disclose
Follansbee	William	Emerging Applications for Imaging Cardiac	Predictors of a Positive Technetium Pyrophosphate Scan in Patients	Nothing to Disclose
Folsom	Aaron	Amyloidosis: Nuclear Cardiology Updates on Risk Factors for Cardiovascular	With Suspected Cardiac Amyloidosis Retinopathy and Risk of Sudden Cardiac Death: The ARIC Study	Nothing to Disclose
Folsom	Aaron	Disease Improving Risk Assessment in Atherosclerosis	Development and Validation of Prediction Models With Non- Traditional Markers for 10-Year Risk of Ischemic Leg Amputation Among Persons With Diabetes: The Atherosclerosis Risk In	Nothing to Disclose
Foltz	Tiffany	Arrhythmias and Clinical EP: Anticoagulation Issues	Communities (ARIC) Study Marked Physician Variability in Oral Anticoagulant Treatment Choices Reflect Significant Differences in Atrial Fibrillation Patient Characteristics	Nothing to Disclose
Fonarow	Gregg	Readmission in Heart Failure: Questions Unanswered	Characteristics Co-Chair	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIHNIAID, Novartis
Fonarow	Gregg	Diabetes and Heart Failure: Are We Hitting The Sweet Spot	Panelist	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	Diabetes and Heart Failure: Are We Hitting The Sweet Spot	Pharmacological Glycemic Management is an Important Component of Heart Failure Therapy, Pro	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Patterns of Angina and Antianginal Medication Use Among Patients Following MI Treated With PCI: Insights From TRANSLATE-ACS	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Ten-Year Mortality of Acute Myocardial Infarction Patients Treated in U.S. Community Practice	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	Young Investigator Awards Competition: Outcomes Research	A Hospital Level Analysis of 30-Day Readmission Rates for Heart Failure Patients and Long-Term Survival Among Highest and Lowest Performing Hospitals, Findings From Get With the Guidelines-Heart Failure	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Heart Failure With Reduced Ejection Fraction Care Patterns in the Outpatient Practice Setting: Initial Findings From CHAMP-HF	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	Making Progress in Understanding Heart Failure	Orthopnea or Paroxysmal Nocturnal Dyspnea in Older Adults Without Prevalent Heart Failure is a Predictor, but Not an Independent Risk Factor for Incident Heart Failure: Insights From the Cardiovascular Health Study	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Examination of hs-CRP Elevation in Patients With History of Myocardial Infarction in the U.S.	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Thirty-Day Readmission Rate and Cost After Percutaneous Coronary Intervention in the United States: A National Readmission Database Analysis	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	The Impact of the Current Versus Prior Cardiac Resynchronization Guidelines on the Proportion of Hospitalized Heart Failure Patients Eligible for Therapy	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Among Older Heart Failure (HF) Patients With In-Hospital Acute Kidney Injury (AKI), an Improvement in Kidney Function Is Associated With a Higher Risk of Post-Discharge Mortality but Not Readmission	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIHMIAID, Novartis
Fonarow	Gregg	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Invasive Management Strategies and Anti-Thrombotic Treatments in Patients With NSTE-ACS in China	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Does Frailty Alter the Benefits of Oral Anticoagulation in Patients With Atrial Fibrillation?	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	Interventional Cardiology: TAVR 2	Association of Chronic Renal Insufficiency With In-Hospital Outcomes of Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	Advances in HCM, PPCM and Other Cardiomyopathies	High Versus Standard Protein Diets in Obese Patients With Heart Failure: Effects on Chronic Disease Risks	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis



Contract of the second				
Last Name Fonarow	First Name Gregg	Session Title Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Presentation Title Incidence of Recurrent Myocardial Infarction Among Older Adults in U.S. Community Practice	Disclosures CONSULTANT FEES/HONORARIA - Amgen,Janssen,MEDTRONIC,Novartis,St. Jude Medical,ZS Pharma; RESEARCH/RESEARCH GRANTS -
Fonarow	Gregg	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Sex Differences in Revascularization and In-Hospital Outcomes of Non-ST-Segment Elevation Myocardial Infarction in the United States	MEDTRONIC.NHLBI.NIH/NIAID.Novartis CONSULTANT FEES/HONORARIA - Amgen,Janssen,MEDTRONIC.Novartis,St. Jude Medical,ZS Pharms; RESEARCH/RESEARCH GRANTS - MEDTRONIC.NHLB.NIHI/NIAID.Novartis
Fonarow	Gregg	Interventional Cardiology: TAVR 3	Regional Variations in In-Hospital Outcomes and Healthcare Resource Utilization in Patients Undergoing Transcatheter Aortic Valve Replacement in the United States	ONSULTANT FEES/HONDRARIA - CONSULTANT FEES/HONDRARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIHNIAID, Novartis
Fonarow	Gregg	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Burden of 30-Day Readmissions in Acute Myocardial Infarction and Heart Failure in the United States: A National Perspective	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Association of Academic Year-End Changeover With Survival Rates After In-Hospital Cardiac Arrest: An Examination of the "July Effect"	CONSULTANT FEES/HONORARIA - Amgen,Janssen,MEDTRONIC,Novartis,St. Jude Medical,ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC,NHLBI,NIH/NIAID,Novartis
Fonarow	Gregg	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)	CONSULTANT FEES/HONORARIA - Amgen,Janssen,MEDTRONIC,Novartis,St. Jude Medical,ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC,MHLBI,NIHNIAID,Novartis
Fonarow	Gregg	Optimizing the Care of ACS Patients	Weekend Versus Weekday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide Analysis	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Heart Failure Hospitalization (HFH) Despite Digoxin Therapy Versus No HFH Despite Placebo in the Digitalis Investigation Group (DIG) Trial: Insights Into Risk Factors for HFH in HF and Reduced Ejection Fraction (HFrEF)	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Clinical Effectiveness of Spironolactone in Hospitalized Older Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or Equal to 30 mL/min/1.73 m ²) Patients With Heart Failure	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIHNIAID, Novartis
Fonarow	Gregg	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Chronic Alpha Blocker Use and Outcomes in Older Male Medicare Beneficiaries Hospitalized for Heart Failure	CONSULTANT FEES/HONORARIA - Amgen, Janssen, MEDTRONIC, Novartis, St. Jude Medical, ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC, NHLBI, NIH/NIAID, Novartis
Fonarow	Gregg	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Arrhythmias in Hospitalized Heart Transplanted Patients: A United States National Study	CONSULTANT FEES/HONORARIA - Amgen,Janssen,MEDTRONIC,Novartis,St. Jude Medical,ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC,NHLBI,NIH/NIAID,Novartis
Fonarow	Gregg	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Chagas Heart Disease: A United States National Study	CONSULTANT FEES/HONORARIA - Amgen,Janssen,MEDTRONIC,Novartis,St. Jude Medical,ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC,NHLBI,NIH/NIAID,Novartis
Fonarow	Gregg	Why Can't We Be Friends? Controversies in Heart Failure Management	Adverse Outcomes With Use of Hydralazine and Nitrate Combination Therapy in Hospitalized Older Non-Black Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)	CONSULTANT FEES/HONORARIA - Amgen,Janssen,MEDTRONIC,Novartis,St. Jude Medical,ZS Pharma; RESEARCH/RESEARCH GRANTS - MEDTRONIC,NHLBI,NIHNIAID,Novartis
Fong	Pete	Vascular Access and Hemostasis Issues	Access Site and Bleeding Outcomes With Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Pulmonary Embolism:	Nothing to Disclose
Fongemie	Justin	Coming to Consensus in a New Era: The Role of Non-statin Therapies in ASCVD Risk Reduction	Internal Jugular Versus Common Femoral Vein ASCVD Risk in DiaBetes: not So Sweet	Nothing to Disclose
Fonseca	Keila	Population Specific Cardiomyopathies: From Exomes to Databases	Air Pollution in Myocardial Remodeling	Nothing to Disclose
Fonseka	Natasha	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Hemitruncus Arteriosus: A Rare Case of Hypoxia in Pregnancy	Nothing to Disclose
Fontana	Gregory	Controversies Surrounding TAVR: 2017 and Beyond	Challenges Associated with Postoperative Thrombus Following TAVR	CONSULTANT FEES/HONORARIA - Edwards Lifesciences, MEDTRONIC, St Jude Medical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Entourage Medical; SPEAKER'S BUREAU - Sorin
Fontenia	Adolfo	Arrhythmias and Clinical EP: Devices 1	Late Occurrence of Phrenic Nerve Stimulation: A Potential Pitfall Among Super Responders?	Nothing to Disclose
Forbes	Thomas	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Things to Consider When Shopping for a Shunt: A Diagnostic Challenge	CONSULTANT FEES/HONORARIA - AGA medical,B. Braun Medical,Cook Corp,Gore Corporation,MEDTRONIC,Siemens
Ford	Claudia	Great Minds Think Differently: Multidisciplinary Approach to Advanced Therapies	Panelist	Nothing to Disclose
Ford	lan	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Prognostic Significance of Co-Existing Persistent Edema and Hemorrhage at 6 Months in Survivors of ST-Elevation Myocardial Infarction	CONSULTANT FEES/HONORARIA - Amgen,Novo Nordisk,Servier; DATA SAFETY MONITORING BOARD - Boston Scientific,GSK,the clinical research institute; RESEARCH/RESEARCH GRANTS - Amgen,GSK,servier,Vifor
Ford	lan	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Current Smoking, Microvascular Pathology and Adverse Outcome After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights	CONSULTANT FEES/HONORARIA - Amgen,Novo Nordisk, servier; DATA SAFETY MONITORING BOARD - Boston Scientific,GSK,the clinical research institute; RESEARCH/RESEARCH GRANTS - Amgen,GSK,servier,Vifor
Ford	lan	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Incidence and Prognostic Implications of the Presence of Multiple Complex Plaques in Survivors of ST-Elevation Myocardial Infarction	CONSULTANT FEES/HONORARIA - Amgen,Novo Nordisk, servier; DATA SAFETY MONITORING BOARD - Boston Scientific,GSK,the clinical research institute; RESEARCH/RESEARCH GRANTS - Amgen,GSK,servier,Vifor
Ford	lan	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Hypertension, Microvascular Pathology and Prognosis in Patients With an Acute ST-Segment Elevation Myocardial Infarction	CONSULTANT FEES/HONORARIA - Amgen, Novo Nordisk, servier; DATA SAFETY MONITORING BOARD - Boston Scientific, GSK, the clinical research institute; RESEARCH/RESEARCH GRANTS - Amgen, GSK, servier, Vifor
Forde-McLean	Rhondalyn	Kanu and Docey Chatterjee Lecture and Seminal Talks in Heart Failure: I Wanna New Drug: Updated Heart Failure Guidelines	Co-Chair	CONSULTANT FEES/HONORARIA - Merck & Deck & D
Fordyce	Christopher	Innovations in Practice Management and Social Media	Accelerator 2 SUSTAIN, A U.S. Regional Systems of Care Demonstration Project for Post-Discharge STEMI Patients: Preliminary Data, Methods and Design	CONSULTANT FEES/HONORARIA - Bayer
Fordyce	Christopher	Novel Developments in Acute Coronary Syndromes	First Medical Contact to Device Time in STEMI Patients Presenting With Cardiogenic Shock: Insights From Mission, a Lifeline STEMI Systems Accelerator	CONSULTANT FEES/HONORARIA - Bayer
Fordyce	Christopher	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Hospital Variation in Targeted Temperature Management for Acute Myocardial Infarction Patients Complicated by Out-of-Hospital Cardiac Arrest in the U.S.	CONSULTANT FEES/HONORARIA - Bayer
Fordyce	Christopher	Innovation in Practice Management, Advocacy, and Education	Early Defibrillation by First-Responders in Relation to Fire Stations: Optimal Benefit According to Location	CONSULTANT FEES/HONORARIA - Bayer

				<u> </u>
Last Name Forfia	First Name Paul	Session Title Hot Topics and Great Debates in Pulmonary	Presentation Title Debate: Be it Resolved: Treatment of PAH Should Focus on Right	Disclosures CONSULTANT FEES/HONORARIA -
TOTILA	raui	Hypertension	Ventricular Performance, Not on the Pulmonary Vascular Occlusion (Pro)	Actelion,Bayer,gilead,United Therapeutics
Forfia	Paul	The Forgotten Chamber: The Right Ventricle in Heart Failure	Drug Therapy and Device Options in Acute RV Failure	CONSULTANT FEES/HONORARIA - Actelion,Bayer,gilead,United Therapeutics
Forfia	Paul	The Nuts and Bolts of Pulmonary Hypertension in Left Heart Disease	Co-Chair	CONSULTANT FEES/HONORARIA - Actelion,Bayer,gilead,United Therapeutics
Forfia	Paul	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	RVOT-VTI/PASP: A Novel Non-Invasive Metric of Pulmonary Arterial Compliance and Diastolic Pressure Gradient Status in Heart Failure	CONSULTANT FEES/HONORARIA - Actelion,Bayer,gilead,United Therapeutics
Forfia	Paul	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	With Preserved Ejection Fraction Hemitruncus Arteriosus: A Rare Case of Hypoxia in Pregnancy	CONSULTANT FEES/HONORARIA - Actelion,Bayer,gilead,United Therapeutics
Forfia	Paul	Finding Out What Works in Pediatric and Congenital Heart Disease	Timely Detection of Pulmonary Arterial Hypertension in Patients With Repaired Congenital Heart Disease: Interim Results From the ACHD-QuERI Registry	CONSULTANT FEES/HONORARIA - Actelion,Bayer,gilead,United Therapeutics
Forfia	Paul	35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Actelion,Bayer,gilead,United Therapeutics
Forleo	Giovanni	Arrhythmias and Clinical EP: AF Ablation	Long-Term Risk of Recurrent Arrhythmia in Patients With Typical Atrial Flutter Undergoing Pulmonary Vein Antrum Isolation or Cavo- Tricuspid Isthmus Ablation With Permanent Isolation	CONSULTANT FEES/HONORARIA - St Jude Medical
	Daniel	FIT Forum: Mix and Mingle	Geriatric 	Nothing to Disclose
Forman	Daniel	Structural Heart Disease: Difficult Choices for the Heart Team	Panelist	Nothing to Disclose
Forman	Daniel	Cardiac Rehab in 2017: Tailoring The Approach to the Times	Co-Chair	Nothing to Disclose
Forman	Daniel	Core Curriculum: Special Topic: Cardiac Issues During The Golden Years and Beyond	Cardiac Rehabilitation in Older Adults with CVD: Underutilized Opportunity to Enhance Care	Nothing to Disclose
Forman	Daniel	Emerging Developments in HFpEF and Arryhthmias	Effects of Age and Comorbidities on Outcomes in Patients With Heart Failure From HF-ACTION	Nothing to Disclose
Forouzandeh	Farshad	Advances in Chronic Total Occlusion Intervention	Performance of J-CTO and PROGRESS CTO Scores in Predicting Angiographic Success and Long-Term Clinical Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions	Nothing to Disclose
Forouzandeh	Farshad	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Revascularization in an Athlete Youth With Complex Aneurysmal Coronary Stenosis	Nothing to Disclose
Forrest	John	Interventional Cardiology: TAVR 3	Initial Use of the Evolut Pro Self-Expanding Transcatheter Aortic Valve <i></i>	CONSULTANT FEES/HONORARIA - Edwards Lifesciences.Medtronic Inc
Fortier	Annik	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Valves 12-717 Changes in Prevalence, Progression and Outcomes of Coronary Allograft Vasculopathy Over 25 Years Following Cardiac Transplantation: A Single Center Experience	Nothing to Disclose
Fortman	Robin	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Screening of Patients With Simple Clinical Parameters Early in Hospitalization is Highly Sensitive for Detection of Heart Failure Hospitalization	Nothing to Disclose
Fortman	Robin	Interdisciplinary Cardiovascular Team Collaboratives in Care	Multidisciplinary Heart Failure Transitional Care Team to Impact Readmissions	Nothing to Disclose
Fortman	Robin	Innovations in Advocacy and Patient Centered Care	Impact of Multidisciplinary Heart Failure Transitional Care Interventions on Disparities in 30-Day Readmission Rates	Nothing to Disclose
Fortuin	David	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Comparison of Two-Year Outcomes in Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Treatment of Unprotected Left Main Coronary Artery Disease in Elderty Patients: A Meta-Analysis	Nothing to Disclose
Fosbøl	Emil	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Return to Work Following Coronary Artery Bypass Grafting: A Nationwide Study	Nothing to Disclose
Foster	Courtney	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Integrating Hyperemic Myocardial Blood Flow and Coronary Flow Reserve for Predicting Cardiovascular Mortality Outcomes in Patients With Known or Suspected Ischemic Heart Disease	Nothing to Disclose
Foster	Courtney	Young Investigator Awards Competition: Clinical Investigations	Impaired Coronary Flow Reserve Is Associated With Diastolic Dysfunction and HFpEF Outcomes in Patients Without Overt CAD	Nothing to Disclose
Foster	Courtney	Nuclear Cardiology: Prognosis	Myocardial Scar but Not Ischemia Predicts Defibrillator Shocks and Sudden Cardiac Death in Patients With Reduced Left Ventricular	Nothing to Disclose
Foster	Courtney	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Ejection Fraction Relationship of Coronary Flow Reserve With Body Mass Index and Adverse Outcomes in Patients Without Overt Ischemic Heart Disease: Implications for Metabolic Surgery Eligibility	Nothing to Disclose
Foster	Courtney	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Association Between Coronary Flow Reserve and Adverse Cardiovascular Events Along a Continuum of Metabolic Disease in	Nothing to Disclose
Foster	Elyse	The Story of the Adult Congenital Heart Disease Patient and EP	Symptomatic Patients Without Overt Coronary Artery Disease Prevalence and Predictors of Atrial Tachyarrhythmias in Adult Fontan Patients	CONSULTANT FEES/HONORARIA - gilead; RESEARCH/RESEARCH GRANTS - Abbott
Foster	Elyse	Adult Patients With Congenital Heart Disease: How Do They Compare?	Mortality in Pregnant Women With Congenital Heart Disease: A Subanalysis of the California Pregnancy-Associated Mortality Review	Vascular,MEDTRONIC CONSULTANT FEES/HONORARIA - gilead; RESEARCH/RESEARCH GRANTS - Abbott Vascular,MEDTRONIC
Foster	Elyse	Fontan in the Modern World	Prevalence of Elevated Body Mass Index and Its Association With Clinical Features in Adult Fontan Patients	Vascular, MED RONIC CONSULTANT FEES/HONORARIA - gilead; RESEARCH/RESEARCH GRANTS - Abbott Vascular, MEDTRONIC
Foster	Elyse	Redefining the "F" Word	Prevalence and Predictors of Pacemaker Placement in Adult Fontan Patients	Vascular,MEDTRONIC CONSULTANT FEES/HONORARIA - gilead; RESEARCH/RESEARCH GRANTS - Abbott Vascular,MEDTRONIC
Fotheringham	James	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Investigating the Smoker's Paradox by Gender: Differences in Survival Following Acute ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Fotheringham	James	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Increased Risk of Acute ST-Segment Myocardial Infarction in Female Smokers: A Contemporary Demographic Study	Nothing to Disclose
Fotiadis	Dimitris	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Association of Coronary Epicardial Endothelial Dysfunction With Low Endothelial Shear Stress in Patients With Mild Coronary Atherosclerosis Who Presented With Chest Pain	Nothing to Disclose
Foussas	Stefanos	Systemic Organ Involvement in Heart Failure: International Perspectives From the German Cardiac Society, Hellenic Society of Cardiology, and American College of Cardiology	Ameroscierosis who Presented with Chest Pain Co-Chair	Nothing to Disclose
Fowler	Vance	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Echocardiographic Predictors for In-Hospital and 1-Year Outcomes in Left-Sided Infective Endocarditis: An Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort Study	CONSULTANT FEES/HONORARIA - Novartis, Affinium, Theravance, Trius, Durata, ; RESEARCH/RESEARCH GRANTS - MedImmune; Novartis; Forest;
Fox	Henrik	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Sleep Duration and Quality in Heart Failure Patients	Nothing to Disclose
Fox	John	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Predictors of Flow-Limiting Fractional Flow Reserve in Coronary Lesions With Intermediate Instantaneous Wave-Free Ratio	SPEAKER'S BUREAU - AstraZeneca

Last Name				
Fov	First Name	Session Title	Presentation Title	Disclosures
Fox	Keith	Advances in Cholesterol Measurement and Management	Consistent Low-Density Lipoprotein Cholesterol Lowering Efficacy of Alirocumab in High and Very High Cardiovascular Risk Patients With	CONSULTANT FEES/HONORARIA - Astra Zeneca,Bayer,Janssen,Merck & Dong, amp; Co., Inc.,sanofi-
		managomom.	Low-Density Lipoprotein Cholesterol >100/70 mg/dL at Baseline	aventis/regeneron; RESEARCH/RESEARCH GRANTS - Eli Lilly,GSK
Fox	Keith	Arrhythmias and Clinical EP: Anticoagulation	Thrombolytic Therapy in Anticoagulated Patients: Case Series From	CONSULTANT FEES/HONORARIA - Astra
		Issues	Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation	Zeneca,Bayer,Janssen,Merck & Deneca,Bayer,Janssen,Merck & Deneca,Bayer,Janssen,Merck & Deneca,Bayer,Janssen,Merck & Deneca,Bayer,Janssen,Merck & Deneca,Bayer,Janssen,Merck & Deneca,Bayer,Janssen,Merck & Deneca,Bayer,Janssen,Merck & Deneca,Bayer,Janssen,Merck & Deneca,Bayer,Dene
			(ROCKET AF)	aventis/regeneron; RESEARCH/RESEARCH GRANTS - Eli Lilly,GSK
Fox	Keith	Antithrombotic Therapy in Ischemic Heart	Time-Trends in Antithrombotic Management of Patients With	CONSULTANT FEES/HONORARIA - Astra
		Disease	AF/Flutter Treated With Coronary Stents: An International	Zeneca,Bayer,Janssen,Merck & Deneca,Bayer,Janssen,Merck & Deneca,Bayer,Janssen,Merck & Deneca,Bayer,Janssen,Merck & Deneca,Bayer,Janssen,Merck & Deneca,Bayer,Janssen,Merck & Deneca,Bayer,Janssen,Merck & Deneca,Bayer,Janssen,Merck & Deneca,Bayer,Janssen,Merck & Deneca,Bayer,Dene
			Multicenter Restrospective Analysis	aventis/regeneron; RESEARCH/RESEARCH GRANTS - Eli Lilly,GSK
Foy	Andrew	Great Debates in Cardiac CT	Debate: Calcium Scoring Outperforms Risk Scores for Optimizing	Nothing to Disclose
,			Appropriate Primary Preventative Therapies and Should be More	3
Env	Androw	Traditional and Novel Factors Used to Assess	Broadly Performed, Con	Nothing to Disclose
Foy	Andrew	the Risk of, and Used for the Treatment of,	Effectiveness of Coronary CT Angiography Versus Standard Care for the Assessment of Patients With Suspected Coronary Artery	Nothing to Disclose
		Coronary Artery Disease	Disease: A Trial Sequential Analysis	
Foy	Andrew	Updates on Pulmonary Embolism	Does Thrombolysis Reduce Mortality in Patients With Intermediate	Nothing to Disclose
Foy	Andrew	Management in 2017 Complex Coronary Intervention: Left	Risk Pulmonary Embolism? A Trial Sequential Analysis Assessing Inter-Rater Agreement of Experienced Interventional	Nothing to Disclose
,		Main/Bifurcations and Multivessel Disease	Cardiologists on Culprit Vessel in Patients With Multivessel Disease	
F		Facility of the state of the st	and Acute Non-STEMI	Number of Product
Foy	Andrew	Emerging Applications of Echocardiography	HEART Score Classification and Predictive Accuracy of Stress Echocardiography in a Contemporary ED Observation Unit Cohort	Nothing to Disclose
Foy	Andrew	Interventional Cardiology: TAVR 2	Death and Dialysis Risk After Transcatheter Aortic Valve	Nothing to Disclose
			Replacement	-
Foy	Andrew	FIT Clinical Decision Making: Interventional	Post Prandial Angina Pectoris: An Uncommon Presentation of	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Severe Coronary Artery Disease	
Foy	Andrew	Which Test Is Best for Pain in the Chest?	A False-Positive Stress Echocardiogram Is NOT the Same as a	Nothing to Disclose
	Object	Literature de la lacción de lacción de la lacción de la lacción de lacción de la lacción de lacci	Negative Result	Notice to Produce
Fraccaro	Chiara	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve	Nothing to Disclose
			Replacement: From the WIN-TAVI Registry	
Fradley	Michael	FIT Clinical Decision Making: Non-Invasive	Global Longitudinal Strain (GLS) Imaging to Detect and Monitor Left	Nothing to Disclose
Eradlay	Michael	Imaging and Valvular Heart Disease Arrhythmias and Clinical EP: Devices 3	Ventricular Function After Direct Cardiac Radiation Differences Among African Americans and White Patients	Nothing to Disclose
Fradley	Wilchael	Armytiinias and Cililical EF. Devices 3	Undergoing Implantable Cardioverter Defibrillator Implantation for	Nothing to Disclose
			Primary Prevention	
Fradley	Michael		Successful Treatment of Checkpoint Inhibitor Induced Myocarditis	Nothing to Disclose
		Pulmonary Hypertension	and Cardiomyopathy With Steroids, Beta-Blockers and ACE Inhibitors	
Fradley	Michael	The Evolving World of LVADs, Transplant and	Cardiovascular Toxicities Associated With Adoptive Cell Therapy	Nothing to Disclose
		Other Novel Discoveries	and Interleukin-2 Infusion for Advanced Stage Melanoma	-
France	Rita	New Technologies in Echocardiography	Accuracy and Reproducibility of Automated 3D Echocardiographic	Nothing to Disclose
			Analysis of Left Ventricular Size and Ejection Fraction in Childhood Cancer Survivors	
Francese	Dominic	Vascular Access and Hemostasis Issues	Mortality, Length of Stay, and Cost Implications of Procedural	Nothing to Disclose
			Bleeding After Contemporary Percutaneous Interventions Involving	
Franchi	Francesco	STEMI Dilemmas: You Be the Judge	Large-Bore Catheters Case Presentation: Fast and Furious - Antiplatelet Choices in STEMI	Nothing to Disclose
	1 141100000	e i zim zilominac. Tod zo tilo oddge	Patients with Expected E2B Time < 30 Minutes	Trouming to 2 looi ood
Franci	Andre	Emerging Basic Science in Ischemic Heart	Platelet Aggregability, Coagulation, Fibrinolysis and Inflammation in	Nothing to Disclose
		Disease	Patients With Coronary Artery Disease and Previous Cerebrovascular Ischemic Event	
Franci	Andre	Antithrombotic Therapy in Ischemic Heart	Effects of Low Molecular Weight Heparin Versus Dabigatran on	Nothing to Disclose
		Disease	Platelet Aggregation in Patients With Stable Coronary Artery	-
Francis	Gary	Salt, Water and the Kidney in Heart Failure	Disease Co-Chair	CONSULTANT FEES/HONORARIA - Amgen, Capricorn; DATA
Trancis	Gury	oat, water and the Nortey in reduct and c	o onai	SAFETY MONITORING BOARD - Merck & Damp; Co.,
				Inc.,Novartis
Franco Pelaez	Juan Antonio	Arrhythmias and Clinical EP: Devices 1	Pharmacological Treatment Alone Versus Treatment Combined With Implantable Cardioverter-Defibrillator Therapy in Patients Over	Nothing to Disclose
			75 Years	
Frank	Lowell	FIT Clinical Decision Making: Prevention, Adult	Unusual Presentation for Primary Bacterial Percarditis	Nothing to Disclose
		Congenital and Congenital Heart Disease		
Frankel	David	Meeting of the Minds: HF and EP Decision	A High Risk Patient for Atrial Fibrillation Ablation	SPEAKER'S BUREAU - Boston Scientific, Bristol-Myers Squibb
		Making for Complex Patients	· ·	Company
Frankel	David	Atrial Fibrillation, Anticoagulation and Novel	Anticoagulation Use and Incidence of Cerebrovascular Events and	SPEAKER'S BUREAU - Boston Scientific, Bristol-Myers Squibb
		Device Therapies	Major Bleeding After Catheter Ablation in Patients With Persistent and Longstanding Persistent Atrial Fibrillation	Company
Franken	Marcelo	International CV Centers of Excellence:	Panelist	Nothing to Disclose
		Leveraging the NCDR for Achieving High		=
Franklin	Ram/	Quality Care	Evaluation of the CardioSmart Population Health Management	Nothing to Disclose
ı ıalıkılı	Barry	Innovations in Cardiovascular Risk Assessment and Reduction	Initiative: Changes in Health Risks and Participant Satisfaction	Nothing to Disclose
	Wayne	Highlighted Original Research: Congenital	Year in Review Speaker	RESEARCH/RESEARCH GRANTS - MEDTRONIC,St. Jude
Franklin		Heart Disease and the Year in Review		Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Baye
Franklin		Healt Disease and the Teal III Neview		
	Wavne		Use of Novel Oral Anticoagulants in Adult Fontan Patients	RESEARCH/RESEARCH GRANTS - MEDTRONIC St. Jude
Franklin	Wayne	Redefining the "F" Word	Use of Novel Oral Anticoagulants in Adult Fontan Patients	RESEARCH/RESEARCH GRANTS - MEDTRONIC,St. Jude Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals,Baye
Franklin	-	Redefining the "F" Word	-	Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals,Baye
	Wayne	Redefining the "F" Word Congenital Heart Disease: To the Third	Long-Term Follow-Up in Adult Survivors of Pulmonary Atresia With	Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals,Baye RESEARCH/RESEARCH GRANTS - MEDTRONIC,St. Jude
Franklin	-	Redefining the "F" Word Congenital Heart Disease: To the Third Decade and Beyond	Long-Term Follow-Up in Adult Survivors of Pulmonary Atresia With Intact Ventricular Septum	Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals,Baye RESEARCH/RESEARCH GRANTS - MEDTRONIC,St. Jude Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals,Baye
Franklin	-	Redefining the "F" Word Congenital Heart Disease: To the Third Decade and Beyond Demystifying and Managing Pulmonary	Long-Term Follow-Up in Adult Survivors of Pulmonary Atresia With	Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Bayer RESEARCH/RESEARCH GRANTS - MEDTRONIC, St. Jude Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Bayer CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcare
Franklin	Wayne	Redefining the "F" Word Congenital Heart Disease: To the Third Decade and Beyond Demystifying and Managing Pulmonary Hypertension and RV Dysfunction: It Takes a	Long-Term Follow-Up in Adult Survivors of Pulmonary Atresia With Intact Ventricular Septum	Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Baye RESEARCH/RESEARCH GRANTS - MEDTRONIC, St. Jude Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Baye CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcare Pharmaceuticals, St. Jude Medical; DATA SAFETY MONITORINC
Franklin	Wayne	Redefining the "F" Word Congenital Heart Disease: To the Third Decade and Beyond Demystifying and Managing Pulmonary	Long-Term Follow-Up in Adult Survivors of Pulmonary Atresia With Intact Ventricular Septum	Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Bayer RESEARCH/RESEARCH GRANTS - MEDTRONIC, St. Jude Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Bayer CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcare Pharmaceuticals, St Jude Medical; DATA SAFETY MONITORING BOARD - United Therapeutics; RESEARCH/RESEARCH
Franklin Franklin	Wayne	Redefining the "F" Word Congenital Heart Disease: To the Third Decade and Beyond Demystifying and Managing Pulmonary Hypertension and RV Dysfunction: It Takes a	Long-Term Follow-Up in Adult Survivors of Pulmonary Atresia With Intact Ventricular Septum	Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals,Bayer RESEARCH/RESEARCH GRANTS - MEDTRONIC,St. Jude Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals,Bayer CONSULTANT FEES/HONORARIA - Actelion,Bayer Healthcan Pharmaceuticals,St Jude Medical; DATA SAFETY MONITORINI BOARD - United Therapeutics; RESEARCH/RESEARCH GRANTS - Actelion,glead,MEDTRONIC,United Therapeutics
Franklin Franklin	Wayne	Redefining the "F" Word Congenital Heart Disease: To the Third Decade and Beyond Demystifying and Managing Pulmonary Hypertension and RV Dysfunction: It Takes a Village FIT Clinical Decision Making: Heart Failure and	Long-Term Follow-Up in Adult Survivors of Pulmonary Atresia With Intact Ventricular Septum Personalized Medicine in the Treatment of PAH Integrated Use of Perfusion SPECT/CTA Fusion Imaging and	Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals,Baye RESEARCH/RESEARCH GRANTS - MEDTRONIC,St. Jude Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals,Baye CONSULTANT FEES/HONORARIA - Actelion,Bayer Healthcare Pharmaceuticals,St. Jude Medical; DATA SAFETY MONITORING BOARD - United Therapeutics; RESEARCH/RESEARCH GRANTS - Actelion,gilead,MEDTRONIC,United Therapeutics CONSULTANT FEES/HONORARIA - Actelion,Bayer Healthcare
Franklin Franklin Frantz	Wayne	Redefining the "F" Word Congenital Heart Disease: To the Third Decade and Beyond Demystifying and Managing Pulmonary Hypertension and RV Dysfunction: It Takes a Village	Long-Term Follow-Up in Adult Survivors of Pulmonary Atresia With Intact Ventricular Septum Personalized Medicine in the Treatment of PAH Integrated Use of Perfusion SPECT/CTA Fusion Imaging and Pulmonary Balloon Angioplasty for Chronic Pulmonary	Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Bayer RESEARCH/RESEARCH GRANTS - MEDTRONIC, St. Jude Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Bayer CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcar Pharmaceuticals, St Jude Medical; DATA SAFETY MONITORING BOARD - United Therapeutics; RESEARCH/RESEARCH GRANTS - Actelion, gliead, MEDTRONIC, United Therapeutics CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcar Pharmaceuticals, St Jude Medical; DATA SAFETY MONITORING
Franklin Franklin Frantz	Wayne	Redefining the "F" Word Congenital Heart Disease: To the Third Decade and Beyond Demystifying and Managing Pulmonary Hypertension and RV Dysfunction: It Takes a Village FIT Clinical Decision Making: Heart Failure and	Long-Term Follow-Up in Adult Survivors of Pulmonary Atresia With Intact Ventricular Septum Personalized Medicine in the Treatment of PAH Integrated Use of Perfusion SPECT/CTA Fusion Imaging and	Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Baye RESEARCH/RESEARCH GRANTS - MEDTRONIC, St. Jude Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Baye CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcar Pharmaceuticals, St Jude Medical; DATA SAFETY MONITORINE BOARD - United Therapeutics; RESEARCH/RESEARCH GRANTS - Actelion, gilead, MEDTRONIC, United Therapeutics CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcar Pharmaceuticals, St Jude Medical; DATA SAFETY MONITORINE BOARD - United Therapeutics; RESEARCH/RESEARCH BOARD - United Therapeutics; RESEARCH/RESEARCH
Franklin Franklin Frantz Frantz	Wayne Robert Robert	Redefining the "F" Word Congenital Heart Disease: To the Third Decade and Beyond Demystifying and Managing Pulmonary Hypertension and RV Dysfunction: It Takes a Village FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Long-Term Follow-Up in Adult Survivors of Pulmonary Atresia With Intact Ventricular Septum Personalized Medicine in the Treatment of PAH Integrated Use of Perfusion SPECT/CTA Fusion Imaging and Pulmonary Balloon Angioplasty for Chronic Pulmonary Thromboembolism	Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Baye RESEARCH/RESEARCH GRANTS - MEDTRONIC, St. Jude Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Baye CONSULTANT FEES/HONGARIA - Actelion, Bayer Healthcar Pharmaceuticals, St Jude Medical; DATA SAFETY MONITORING BOARD - United Therapeutics; RESEARCH/RESEARCH GRANTS - Actelion, gilead, MEDTRONIC, United Therapeutics CONSULTANT FEES/HONGARIA - Actelion, Bayer Healthcar Pharmaceuticals, St Jude Medical; DATA SAFETY MONITORING BOARD - United Therapeutics; RESEARCH/RESEARCH GRANTS - Actelion, gilead, MEDTRONIC, United Therapeutics
Franklin Franklin Frantz	Wayne	Redefining the "F" Word Congenital Heart Disease: To the Third Decade and Beyond Demystifying and Managing Pulmonary Hypertension and RV Dysfunction: It Takes a Village FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension 35. Pulmonary Hypertension and Pulmonary	Long-Term Follow-Up in Adult Survivors of Pulmonary Atresia With Intact Ventricular Septum Personalized Medicine in the Treatment of PAH Integrated Use of Perfusion SPECT/CTA Fusion Imaging and Pulmonary Balloon Angioplasty for Chronic Pulmonary	Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Baye RESEARCH/RESEARCH GRANTS - MEDTRONIC, St. Jude Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Baye CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcare Pharmaceuticals, St Jude Medical; DATA SAFETY MONITORING BOARD - United Therapeutics; RESEARCH/RESEARCH GRANTS - Actelion, gliead, MEDTRONIC, United Therapeutics CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcare Pharmaceuticals, St Jude Medical; DATA SAFETY MONITORING BOARD - United Therapeutics; RESEARCH/RESEARCH GRANTS - Actelion, gliead, MEDTRONIC, United Therapeutics CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcare CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcare
Franklin Franklin Frantz Frantz	Wayne Robert Robert	Redefining the "F" Word Congenital Heart Disease: To the Third Decade and Beyond Demystifying and Managing Pulmonary Hypertension and RV Dysfunction: It Takes a Village FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Long-Term Follow-Up in Adult Survivors of Pulmonary Atresia With Intact Ventricular Septum Personalized Medicine in the Treatment of PAH Integrated Use of Perfusion SPECT/CTA Fusion Imaging and Pulmonary Balloon Angioplasty for Chronic Pulmonary Thromboembolism	Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Baye RESEARCH/RESEARCH GRANTS - MEDTRONIC, St. Jude Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals, Baye CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcar Pharmaceuticals, St Jude Medical; DATA SAFETY MONITORING BOARD - United Therapeutics; RESEARCH/RESEARCH GRANTS - Actelion, gilead, MEDTRONIC, United Therapeutics CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcar Pharmaceuticals, St Jude Medical; DATA SAFETY MONITORING BOARD - United Therapeutics; RESEARCH/RESEARCH GRANTS - Actelion, gilead, MEDTRONIC, United Therapeutics CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcar Pharmaceuticals, St Jude Medical; DATA SAFETY MONITORING CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcar Pharmaceuticals, St Jude Medical; DATA SAFETY MONITORING
Franklin Franklin Frantz Frantz	Wayne Robert Robert	Redefining the "F" Word Congenital Heart Disease: To the Third Decade and Beyond Demystifying and Managing Pulmonary Hypertension and RV Dysfunction: It Takes a Village FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension 35. Pulmonary Hypertension and Pulmonary	Long-Term Follow-Up in Adult Survivors of Pulmonary Atresia With Intact Ventricular Septum Personalized Medicine in the Treatment of PAH Integrated Use of Perfusion SPECT/CTA Fusion Imaging and Pulmonary Balloon Angioplasty for Chronic Pulmonary Thromboembolism	Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals,Baye RESEARCH/RESEARCH GRANTS - MEDTRONIC,St. Jude Medical; SPEAKER'S BUREAU - Actelion Pharmaceuticals,Baye CONSULTANT FEES/HONORARIA - Actelion,Bayer Healthcar Pharmaceuticals,St Jude Medical; DATA SAFETY MONITORING BOARD - United Therapeutics; RESEARCH/RESEARCH GRANTS - Actelion,gliead,MEDTRONIC,United Therapeutics CONSULTANT FEES/HONORARIA - Actelion,Bayer Healthcar Pharmaceuticals,St Jude Medical; DATA SAFETY MONITORING BOARD - United Therapeutics; RESEARCH/RESEARCH GRANTS - Actelion,gliead,MEDTRONIC,United Therapeutics CONSULTANT FEES/HONORARIA - Actelion,Bayer Healthcar CONSULTANT FEES/HONORARIA - Actelion,Bayer Healthcar

				l l
Last Name Fraser	First Name Charles	Session Title A Night at the Movies with Some Congenital	Presentation Title Panelist (Panel Discussion I)	Disclosures OTHER - none
Fraser	Charles	Heart Surgeons How Do They Actually Do	Parietist (Pariet Discussion I)	OTHER - none
		That?: Joint Symposium of the American		
		Association for Thoracic Surgeons and the American College of Cardiology		
Fraser	Charles	A Night at the Movies with Some Congenital	Optimal Management of the Cyanotic Neonatal Tetralogy of Fallot	OTHER - none
		Heart Surgeons How Do They Actually Do	Patient: Neonatalshunt, to be Followed by Subsequent Repair (with	
		That?: Joint Symposium of the American Association for Thoracic Surgeons and the	Accompanying Surgical Video)	
		American College of Cardiology		
Fraser	Charles	Congenital Heart Disease: Innovations in	Is a Pulsatile Glenn an Adequate Alternative for Long-Term	OTHER - none
Fraser	Charles	Single Ventricle Heart Disease Non Invasive Imaging: Role of Exercise Testing	Palliation in Patients With Single Ventricle Physiology? Stress Myocardial Perfusion Imaging in Anomalous Aortic Origin of a	OTHER - none
114001	Onanoo		Coronary Artery: Results Following a Standardized Approach	
Frazier	O. Howard	FIT Clinical Decision Making: Heart Failure and Cardiomyopathies	SynCardia Meets CardioMEMS: A Loeffler's Story	CONSULTANT FEES/HONORARIA - Abiomed
Freedman	Barry	Diabetes and Other Issues in Cardiovascular	Blood Pressure Indices and Cardiovascular Mortality in Diabetics	Nothing to Disclose
		Prevention	and Non Diabetics	
Freedman	Jane	Innovations in Cardiovascular Risk Assessment and Reduction	Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African Americans: The Jackson Heart Study	CONSULTANT FEES/HONORARIA - Abbvie
Freeman	Andrew	Emerging CV Problems in the Developing	Nutrition and Lifestyle: The Best (and Cheapest) Way to Better CV	SPEAKER'S BUREAU - Boheringer Ingleheim
		World: International Perspectives From the	Health	
		ACC Bangladesh Chapter, Indonesian Heart Association, and American College of		
		Cardiology		
Freeman	Andrew	Lifestyle Changes to Reduce Cardiovascular	Co-Chair	SPEAKER'S BUREAU - Boheringer Ingleheim
Freeman	Andrew	Risk Core Curriculum: Healthcare for the Masses	Innovative Tools to Improve Patient Compliance	SPEAKER'S BUREAU - Boheringer Ingleheim
Freeman	Andrew	Innovations in Advocacy and Patient Centered	Status of Early Career Academic Cardiology: A Global Perspective	SPEAKER'S BUREAU - Boheringer Ingleheim
Eroomon	Androw	Care Personalized Skills Center: Drill and Practice	Heart Songs Moderator	CDEAVED'S DUDEAU Paparing In-In-In-In-In-In-In-In-In-In-In-In-In-I
Freeman	Andrew	(Heart Songs, ECG, Hand-Held Echo)	i reart Sorigs Moderator	SPEAKER'S BUREAU - Boheringer Ingleheim
Freeman	Andrew	32. Prevention: Clinical Team 1	Suggested Reviewer	SPEAKER'S BUREAU - Boheringer Ingleheim
Freeman Freeman	Andrew James	FIT Clinical Decision Making Reviewers 1 Atrial Fibrillation and VT: Incorporating Novel	ACC FIT Clinical Decision Making Reviewer Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation:	SPEAKER'S BUREAU - Boheringer Ingleheim Nothing to Disclose
riceiliali	Jailles	Risks Toward Decision Making	Insights From the Outcomes Registry for Better Informed Treatment	Nothing to disclose
_		· ·	of Atrial Fibrillation (ORBIT-AF)	
Freeman	Rosario	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Endocarditis? When Positron Emission Tomography Makes the Final Diagnosis	Nothing to Disclose
Freeman	Wilbur	Vascular Medicine: Venous Disease	Low Dose Systemic Thrombolysis and New Oral Anticoagulants in	Nothing to Disclose
			the Treatment of Large Thrombi in the Right Heart	
Freitas	Aguinaldo	Heart Failure and Cardiomyopathies: Clinical Team 4	Suggested Reviewer	Nothing to Disclose
Freixa	Xavier	Structural Heart Interventions: Focus on Mitral	Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation	Nothing to Disclose
		Valve, Left Atrial Appendage and HOCM	and Previous Major Gastrointestinal Bleeding: Insight From the	-
Fremes	Stephen	Joint American College of Cardiology/New	Amplatzer Cardiac Plug Multicenter Registry Levosimendan in Patients With Left Ventricular Systolic Dysfunction	Nothing to Disclose
Temes	осрнен	England Journal of Medicine Late-Breaking	Undergoing Cardiac Surgery With Cardiopulmonary Bypass:	Nothing to Disclose
F	L'arter	Clinical Trials	Primary Results of the LEVO-CTS Trial	Notice to Breaters
Freud	Lindsay	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Melody Valve Placement for Mitral Valve Dysplasia Syndrome	Nothing to Disclose
Freund	Monique	Stress Echocardiography: Best Practices and	Stress Echo and Pulmonary Hypertension: What do the Findings	Nothing to Disclose
Freund	Monique	Emerging Applications Prosthetic Valve Thrombosis: TAVR, Bio,	Mean? ACC Poster Moderator	Nothing to Disclose
	· ·	Mech Now What?!		
Friberg	Leif	Stroke and AF: Thinking About the Heart	Risk of Stroke in Women and Men With Atrial Fibrillation and Only One Additional CHA2DS2-VASc Risk Factor	Nothing to Disclose
Friede	Kevin	Antiplatelet and Antithrombotic Agents in	The Effect of Race on the Antiplatelet Effects of Ticagrelor and	Nothing to Disclose
E. A.	IZ. S.	Ischemic Heart Disease	Aspirin	Notice to Breaters
Friede Friedlander	Kevin Ira	Anti-Platelet Therapies: Always a Sticky Topic Vascular Access and Hemostasis Issues	Influence of Sex on Platelet Response to Aspirin and Ticagrelor Mid Femoral Head Is Not the Ideal Fluroscopic Landmark for	Nothing to Disclose RESEARCH/RESEARCH GRANTS - Aultman Hospital
			Common Femoral Artery Puncture	
Friedman	Daniel	Late-Breaking Clinical Trials	Comparative Effectiveness of Left Atrial Appendage Occlusion	OTHER - Boston Scientific,St. Jude Medical
			Among Atrial Fibrillation Patients Undergoing Cardiac Surgery: A Report From the Society of Thoracic Surgeons Adult Cardiac	
			Surgery Database	
Friedman	Daniel	Making Progress in Understanding Heart Failure	The Role of Baseline Versus Long-Term Follow-Up Ejection Fraction in Predicting Adverse Events Among Primary Prevention	OTHER - Boston Scientific,St. Jude Medical
		railule	Implantable Cardioverter Defibrillator Recipients	
Friedman	John	Joint American College of Cardiology/New	Subclinical Leaflet Thrombosis in Transcatheter and Surgical	Nothing to Disclose
		England Journal of Medicine Late-Breaking Clinical Trials	Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries	
Friedman	John	Non Invasive Imaging: Coronary Calcium	Coronary Artery Calcium in the Elderly: Prevalence, Severity, and	Nothing to Disclose
		Scoring and CV Risk Assessment	Association With All-Cause Mortality	
Friedman	John	Non Invasive Imaging: New Technologies	Improvement in LDL Is Associated With Decrease in Non-Calcified Plaque Volume on CTA as Measured by Automated Quantitative	Nothing to Disclose
			Software	
Friedman	John	Noninvasive Assessment of Coronary Flow	Relationship Between Whole Vessel Quantitative Plaque	Nothing to Disclose
		Reserve: Clinical Implications	Characteristics and Noninvasive Fractional Flow Reserve From Coronary Computed Tomography Angiography	
Friedman	John	Imaging With Cardiac CT: The Case for	Hormone Replacement Therapy Is Associated With Less Coronary	Nothing to Disclose
Friedman	Kevin	Calcium Coarctation of the Aorta, from Repair to	Atherosclerosis and Lower Mortality Standardized Surveillance and Follow-up of Coarctation of the Aorta	Nothing to Disclose
i ncuman	TXGVIII	Lifelong Care	otanidaratzed our veniance and i onow-up or coarctation of the Aorta	Trouming to Discluse
Friedman	Kevin	Highlighted Original Research: Congenital	Early Hemodynamic Changes After Fetal Aortic Stenosis	Nothing to Disclose
		Heart Disease and the Year in Review	Valvuloplasty Are Associated With Biventricular Circulation at Birth	
Friedman	Paul	Controversies in Arrhythmia Management:	Should ICDs Be Replaced at the Time of Battery Depletion if the	CONSULTANT FEES/HONORARIA - Aegis,Leadex,NeoChord;
		Joint Symposium of the Heart Rhythm Society	Ejection Fraction Is Now > 40%?	OTHER - Preventice, Sorin; RESEARCH/RESEARCH GRANTS -
		and the American College of Cardiology		MEDTRONIC,St. Jude Medical
Friedman	Paul	Arrhythmias and Clinical EP: Basic 4	External Cooling of the Myocardium Slows Electrical Conduction	CONSULTANT FEES/HONORARIA - Aegis, Leadex, NeoChord;
			and Terminates Atrial Fibrillation	OTHER - Preventice, Sorin; RESEARCH/RESEARCH GRANTS -
Friedman	Paul	Novel Arrhythmia Diagnostics, Therapeutics,	ACC Poster Moderator	MEDTRONIC,St. Jude Medical CONSULTANT FEES/HONORARIA - Aegis,Leadex,NeoChord;
		and "Wearables		OTHER - Preventice, Sorin; RESEARCH/RESEARCH GRANTS -
Friedman	Paul	08. Arrhythmias and Clinical EP:	Suggested Reviewer	MEDTRONIC,St. Jude Medical CONSULTANT FEES/HONORARIA - Aegis,Leadex,NeoChord;
i ilcumdii	i aui	Supraventricular/Ventricular Arrhythmias Team	ouggested ivenemen	OTHER - Preventice, Sorin; RESEARCH/RESEARCH GRANTS -
		5		MEDTRONIC,St. Jude Medical
Friedman	Scott	Highlights in Vascular Medicine Research	Cancer and Arterial Thrombosis Risk: Insights From the 2012	Nothing to Disclose
<u> </u>	1	1	National Inpatient Sample	



Congress of the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures CONSULTANT FEES/HONORARIA - Circle Cardiovascular
Friedrich	Matthias	Cardiovascular Magnetic Resonance A Fast and Reliable Method to Change Patients' Therapy: Joint Symposium of the Society for Cardiovascular Magnetic Resonance and the	Chest Pain -But Normal Coronaries	Imaging, Circle Cardiovascular Imaging Inc. (CMR software development)
Friedrich	Matthias	American College of Cardiology Clinical Applications of Cardiac MRI in 2017	Assessment of Myocarditis	CONSULTANT FEES/HONORARIA - Circle Cardiovascular
			·	Imaging,Circle Cardiovascular Imaging Inc. (CMR software development)
Friedrich	Matthias	29. Non Invasive Imaging: MR Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Circle Cardiovascular Imaging, Circle Cardiovascular Imaging Inc. (CMR software development)
Frishman	William	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Arrhythmias in Hospitalized Heart Transplanted Patients: A United States National Study	Nothing to Disclose
Frishman	William	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Chagas Heart Disease: A United States National Study	Nothing to Disclose
Fritzlen	John	Interventional Cardiology: PCI in Complex Patients	Clinical Presentation, Natural History and Management of Coronary Artery Ectasia	Nothing to Disclose
Frobert	Ole	Late-Breaking Clinical Trials: Interventional	Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve Guided Intervention (IFR-SWEDEHEART): A Multicenter, Prospective, Registry-Based Randomized Clinical Trial	Nothing to Disclose
Frobert	Ole	Novel Developments in Acute Coronary Syndromes	Prehospital Administration of Heparin Reduces the Risk of Vessel Occlusion in Patients With ST Elevation Myocardial Infarction: Secondary Analysis of the TASTE Trial	Nothing to Disclose
Froehlich	James	Vascular Diagnoses Cardiologists Should not Miss: A Case-based Approach	Thrombotic Coronary Occlusion: Not Always Plaque Rupture	CONSULTANT FEES/HONORARIA - Boeringer- Ingelheim, Bristol-Meyers Squibb, Janssen Pharamaceuticals, Merck, Novartis, Pfizer, Sanofi-Aventis; RESEARCH/IRESEARCH GRANTS - Blue Cross/Blue Shield of Michigan, BMS, Fibromuscular Disease Society of America, Pfizer Inc
Froehlich	James	Vasculo-Oncology: What You Need to Know About Vascular and Thrombotic Complications of Cancer and Cancer Therapeutics	Anticoagulation Strategies in the Cancer Patient with Aggressive Thromboses (Includes Case Presentations)	CONSULTANT FEES/HONORARIA - Boeringer- Ingelheim, Bristol-Meyers Squibb, Janssen Pharamaceuticals, Merck, Novartis, Pfizer, Sanofi-Aventis; RESEARCH/RESEARCH GRANTS - Blue Cross/Blue Shield of Michigan, BMS, Fibromuscular Disease Society of America, Pfizer Inc
Froehlich	James	Advancing Our Understanding of Aortic Disease	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Boeringer- Ingelheim, Bristol-Meyers Squibb, Janssen Pharamaceuticals, Merck, Novartis, Pfizer, Sanofi-Aventis; RESEARCH/RESEARCH GRANTS - Blue Cross/Blue Shield of Michigan, BMS, Fibromuscular Disease Society of America, Pfizer Inc
Froehlich	James	38. Vascular Medicine: Basic Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boeringer- Ingelheim, Bristol-Meyers Squibb, Janssen Pharamaceuticals, Merck, Novartis, Pfizer, Sanofi-Aventis; RESEARCH/RESEARCH GRANTS - Blue Cross/Blue Shield of Michigan, BMS, Fibromuscular Disease Society of America, Pfizer Inc
Froelicher	Victor	Imaging the Athlete's Heart	Addressing Reference Echocardiographic Parameters in Athletic Screening: A College Football-Based Study Focusing on the Implications of Race and Correction for Body Composition	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cardea Associates Inc
Froelicher	Victor	ECG Screening and Risk Prediction	ECG Screening of Young Adults for Sudden Cardiac Death Risk in Primary Care Offices	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cardea Associates Inc
Froeschl	Michael	Novel Developments in Acute Coronary Syndromes	Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Frohlich	Bruno	Featured Clinical Research I	Native South American Tsimane Have the Lowest Levels of Coronary Atherosclerosis Ever Reported	Nothing to Disclose
Frohlich	Thomas	Novel Echocardiographic Methods for Assessing Cardiac Function	Clinical Validation of ASE 2016 Guidelines for Evaluating Left Ventricular Diastolic Dysfunction	Nothing to Disclose
Frommelt	Michele	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Exome Sequencing Reveals Novel Variants in <i>TMEM59L</i> and <i>KLHL26</i> Associated With a Familial Case of Ebstein’s Anomaly and Left Ventricular Noncompaction	Nothing to Disclose
Frommelt	Peter	Congenital Heart Disease Surgery: Updates and Innovations	Anatomic Repair of Congenitally Corrected Transposition Results in Excellent Survival and Functional Status at Intermediate Term Follow-Up	Nothing to Disclose
Fry	Edward	Mentoring the Care Team: FITs, Early Career Professionals and CV Team Members	Co-Chair	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - athenahealth, Bayer Healthcare Pharmaceuticals, Community Health Systems, Gilead Sciences, Inc., Johnson & Dengamp; Johnson, McKesson, Pfizer Inc, Saint Jude Medical, The Heart Center of Indiana, LLC, Watson Pharmaceuticals, Inc. (now Actavis, Inc)
Frydland	Martin	Features of Patients With Acute Coronary Syndrome	Association Between QRS Duration on Prehospital Electrocardiogram and Early Outcome in Patients With ST Segment Elevation Myocardial Infarction	Nothing to Disclose
Frydland	Martin	Post-CAD/MI: Making Tough Predictions About the Future	Midregional Proadrenomedullin: A Prognostic Marker of Mortality and Heart Failure in Patients With ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Fu	Qi	Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	The Impact of Lifelong Exercise Training "Dose" on the Ventricular- Arterial Coupling	Nothing to Disclose
Fuchs	Andreas	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries	Nothing to Disclose
Fuchs	Margaret	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Syncope With Phenytoin: Sometimes It's Not a Seizure!	Nothing to Disclose
Fuchs	Margaret		A Rare Disease Presenting With Hypertension and Acute Heart Failure	Nothing to Disclose
Fudim	Marat	Making Progress in Understanding Heart Failure	The Role of Baseline Versus Long-Term Follow-Up Ejection Fraction in Predicting Adverse Events Among Primary Prevention Implantable Cardioverter Defibrillator Recipients	CONSULTANT FEES/HONORARIA - Coridea; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cibiem Inc.; RESEARCH/RESEARCH GRANTS - American Heart Association
Fudim	Marat	Nuclear Cardiology: Prognosis	The Prognostic Value of Diastolic and Systolic Mechanical Left Ventricular Dyssynchrony Among Patients With Coronary Heart Disease	CONSULTANT FEES/HONORARIA - Coridea; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cibiem Inc.; RESEARCH/RESEARCH GRANTS - American Heart Association
Fudim	Marat	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Timing and Clinical Predictors of Early Versus Late Readmission Among Patients Hospitalized for Acute Heart Failure: Insights From ASCEND-HF	CONSULTANT FEES/HONORARIA - Coridea; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cibiem Inc.; RESEARCH/RESEARCH GRANTS - American Heart Association
Fudim	Marat	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Hemoconcentration During Management of Patients With Acute Heart Failure and Cardiorenal Syndrome: Insights From CARRESS- HF	CONSULTANT FEES/HONORARIA - Coridea; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cibiem Inc.; RESEARCH/RESEARCH GRANTS - American Heart Association
	1	ı	1	

and the same				<u> </u>
Last Name Fudim	First Name Marat	Session Title Why Can't We Be Friends? Controversies in	Presentation Title Prevalent Digoxin Use Is Not Associated With Increased Risk of	Disclosures CONSULTANT FEES/HONORARIA - Coridea; OWNERSHIP
i ddiiii	iviarat	Heart Failure Management	Death or Hospitalization in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction	INTEREST/PARTNERSHIP/PRINCIPAL - Cibiem Inc.; RESEARCH/RESEARCH GRANTS - American Heart Association
Fuernau	Georg	Non Invasive Imaging: MR Characterization and Function	Prognostic Value and Determinants of Left Atrial Function Assessed by Cardiac Magnetic Resonance in St-Segment Elevation Myocardial Infarction	Nothing to Disclose
Fuernau	Georg	Non Invasive Imaging: MR Heart Failure and	Antecedent Hypertension and Myocardial Injury in Patients With	Nothing to Disclose
Fuernau	Georg	Pulmonary Hypertension Novel Developments in Acute Coronary	Reperfused ST-Elevation Myocardial Infarction Impact of Timing of Intra-Aortic Balloon Counterpulsation on	Nothing to Disclose
-		Syndromes	Mortality in Cardiogenic Shock: A Sub-Analysis of the IABP-SHOCK	
Fuernau	Georg	Novel Developments in Acute Coronary Syndromes	Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: The Randomized SHOCK-COOL Pilot Trial	Nothing to Disclose
Fuernau	Georg	Novel Developments in Acute Coronary Syndromes	Outcome of Elderly Patients Undergoing Extracorporeal Life Support in Refractory Cardiogenic Shock	Nothing to Disclose
Fughhi	Ibtihaj	Nuclear Cardiology: Prognosis	The Prognostic Value of Serial Stress Myocardial Perfusion Imaging in Asymptomatic End-Stage Renal Disease Patients Awaiting Kidney	Nothing to Disclose
Fujii	Satoshi	Vascular Medicine: Aortic and Peripheral Artery Diseases	Transplantation Molecular Determinants of Functional Changes and Fibrosis Determined by Novel Automated Oscillometric Approach to Measure Brachial Artery Vascular Volume Elastic Modulus in	Nothing to Disclose
Fujimaki	Haruka	Tricuspid Regurgitation: Signals in Plain Sight	Chronic Kidney Disease Impact of Atrial Fibrillation on Tricuspid Valve Annular Morphology in Patients With Left Sided Heart Valve Disease	Nothing to Disclose
Fujimori	Yoshiharu	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Impact of Saline Induced Pd/Pa Ratio for Predicting Functional Significance of Intermediate Coronary Artery Stenosis Assesed by Fractional Flow Reserve	Nothing to Disclose
Fujimoto	Yoshihide	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Fraculonal Flow Reserve Semi-Quantitative Evaluation of Coronary Arterial Patency After Implantation of a Metallic Stent: A Comparison Between 320 Slice CT and Invasive Coronary Angiogram With Consideration of Stent Size, Length, and Type, as Well as the Specific Coronary Artery Implanted	Nothing to Disclose
Fujino	Akiko	Interventional Cardiology: PCI in Complex Patients	Procedural Calcium Fracture and Its Effect on Stent Expansion Assessed by Optical Coherence Tomography	Nothing to Disclose
Fujino	Yusuke	Complex Coronary Intervention: Left	Impact of Kissing Balloon Inflation After Single Stent Implantation for	Nothing to Disclose
Fujiyoshi	Kazuhiro	Main/Bifurcations and Multivessel Disease Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Left Main Distal Bifurcation Lesions: New Tokyo Registry Stent Edge Strut on Normal Segment Is Less Covered in Early Phase After Drug Eluting Stent Implantation	Nothing to Disclose
Fujiyoshi	Kazuhiro	Unusual Presentations of ACS	Lower Eicosapentaenoic Acid to Arachidonic Acid Ratio Is Associated With Intraplaque Cholesterol Crystals: An Optical	Nothing to Disclose
Fukuda	Keiichi	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Coherence Tomography Study Compliance to Updated AHA/ACC Quality Measures Among Patients With Atrial Fibrillation in Japan and Its Association With Their Quality of Life	Nothing to Disclose
Fukuda	Keiichi	Interventional Cardiology: TAVR 4	Transcatheter Aortic Valve Implantation in Patients With an	Nothing to Disclose
Fukuda	Keiichi	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Extremely Small Annulus Performance of the MAGGIC Heart Failure Risk Score in Japanese Acute Heart Failure Patients: A Report From the West Tokyo Heart	Nothing to Disclose
Fukuda	Keiichi	Unusual Presentations of ACS	Failure Registry C-Reactive Protein in Non-ST Elevation Myocardial Infarction Patients Is Useful in Improving Discrimination of Conventional Risk	Nothing to Disclose
Fukuda	Keiichi	Unusual Presentations of ACS	Score: A Report From Multicenter PCI Registry Trend of Use in Transradial Intervention Among Elderly Patients in	Nothing to Disclose
Fukuhara	Shinichi	The Spectrum of Aortic Regurgitation and	Japan According to Their Pre-Procedural Bleeding Risk Case: Tearing Chest Pain Radiating to the Back	Nothing to Disclose
Fukushima	Kenji	Aortic Pathology Nuclear Cardiology: Coronary Flow	Patient Based Territorial Coronary Flow Analysis by Voronoi	Nothing to Disclose
Fukushima	Kenji	Non Invasive Imaging: MR Structure and	Algorithm With ¹³ N Ammonia PET CTA Fusion Cardiac Diffusion Weighted Image in Patients With Cardiac	Nothing to Disclose
Fuller	Stephanie	Valuvular Heart Disease Perspectives on Congenital Heart Disease: International Perspectives From the Caribbean Cardiac Society, Peruvian Society of Cardiology, and American College of Cardiology	Sarcoidosis: Comparison to ^{18-/sup>F-fludeoxyglcose PET Congenital Heart Surgery: Care and Development}	Nothing to Disclose
Fuller	Stephanie	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Impact of Home Monitoring Program on Interstage Mortality and Stage II Outcomes	Nothing to Disclose
Fuller	Stephanie	Engage @ ACC.17 Studio:The Newlywed Game for Pediatric Cardiac Providers	Participant, Team 1	Nothing to Disclose
Fuller	Stephanie	09. Congenital Heart Disease: Adult Team 1	Suggested Reviewer Timing and Algorithm of Permanent Pacemaker Implantation After	Nothing to Disclose
Fullerton	David	Interventional Cardiology: PCI and TAVR in Complex Patients	TAVR	Nothing to Disclose
Fulton	Brian	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Using Cardiac Magnetic Resonance Imaging and Transthoracic Echocardiography to Predict Presence of Papillary Muscle-Based Ventricular Ectopy in Mitral Valve Prolapse	Nothing to Disclose
Funabashi	Nobusada	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Semi-Quantitative Evaluation of Coronary Arterial Patency After Implantation of a Metallic Stent: A Comparison Between 320 Slice CT and Invasive Coronary Angiogram With Consideration of Stent Size, Length, and Type, as Well as the Specific Coronary Artery Implanted	Nothing to Disclose
Funabashi	Nobusada	Insights From Echocardiography Use	Quantitative Distinction of LV Myocardium Classified by Presence or Absence of Fibrotic Change and/or Hypertrophic Change Confirmed by Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy and 2D Speckle Tracking TTE	Nothing to Disclose
Funabashi	Nobusada	Insights From Echocardiography Use	Quantitative Differentiation of LV Myocardium With and Without Layer-Specific Fibrosis on CMR in Hypertrophic Cardiomyopathy Using Layer-Specific Strain TTE Analysis	Nothing to Disclose
Funabashi	Nobusada	Non Invasive Imaging: New Technologies	Using Layer-Specinic Scalar IT 2 Arenysis A Novel 3D Myocardial Strain Determined by Existing 320-Slice CT Data Enhances Visual Assessment of Late Enhancement on CT for the Detection of Left Ventricular Myocardial Fibrosis in Non Ischemic Cardiomyopathy	Nothing to Disclose
Funabashi	Nobusada	Non Invasive Imaging: New Technologies	Improved Diagnosis of Detection of Late Enhancement in Left Ventricular Myocardium Using 2nd Generation 320-Slice CT Reconstructed With FIRST in Non-Ischemic Cardiomyopathy	Nothing to Disclose
Fung	Anthony	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Reculsionated with First in Introduction to Define "Prognostic" Renal Function-Based Contrast Dosing to Define "Prognostic" Contrast Dose Limits for Percutaneous Coronary Intervention - The Prognostic Implication of the Contrast Volume: Glomerular Filtration Ratio in 44,082 Patients From the British Columbia Cardiac Registry	Nothing to Disclose
			Toward Identifying Personalized Prognosis in Hypertension:	

Seales Title Se	-				
And Parl American Centry of Corpology Corpolog	Last Name	First Name	Session Title	Presentation Title	Disclosures
Englander Samual of Medical Latin Granting Part 1990 Par			Advances in Imaging to Assess Cardiotoxicity		Nothing to Disclose
States Sta	Furie	Karen	England Journal of Medicine Late-Breaking	Replacement: A Randomized Trial From the Cardiothoracic	Nothing to Disclose
Particle Particle	Furlan	Stefanie		Global Longitudinal Strain as a Predictor of Survival in Sepsis-	Nothing to Disclose
Section XIVIN Concess with Concess which to Disease and Process or	Furtado	Remo		The Role of Oral Beta Blocker in a Real-World Population With Non-	Nothing to Disclose
Filed on Company of the Process of the Company of t	Furtado	Remo		Patients With Coronary Artery Disease and Previous	Nothing to Disclose
Cardon Vacation Control (Control Contr	Furtado	Remo		Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery	Nothing to Disclose
Fig. 12 Academ Confidence (Lipson Legislate for the Climace) Fig. 12 Academ Vacada	Fuster	Valentin	Coronary Artery Disease – Challenges in 2017		Nothing to Disclose
Finder Valentin Cardiovaccular blogder for the Christon R. Complete Compl	Fuster	Valentin	Cardiovascular Update for the Clinician I: Coronary Artery Disease – Challenges in 2017		Nothing to Disclose
Fueber Valentin Consideration (Company Company	Fuster	Valentin	Cardiovascular Update for the Clinician II: Chronic Coronary and Systemic Disease (A	Chair	Nothing to Disclose
Content	Fuster	Valentin	Cardiovascular Update for the Clinician II: Chronic Coronary and Systemic Disease (A		Nothing to Disclose
Condemonate States of Telephone Notices In Vision In Control (Control States In Vision In Control States In Vision In Control (Control States In Vision In Control States In Vision In Control States In Vision In Control States In Vision In Control States In Control	Fuster	Valentin	Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A	Chair	Nothing to Disclose
Cardiovascular Update for the Circulan IV	Fuster	Valentin	Cardiovascular Update for the Clinician IV: Electrical Failure 2017 Rhythm Disorders (A	Chair	Nothing to Disclose
Valentin	Fuster	Valentin	Cardiovascular Update for the Clinician IV: Electrical Failure 2017 Rhythm Disorders (A		Nothing to Disclose
Filater Valentin Condessoular Update for the Crincian Valentin Dissection Purpose and Management Valentin Congress of Cardiovasy and Journal of Annexa (Cardiovas) and Journal of Annexa (Cardiovas) and Journal of Annexa (Cardiovas) and Journal of Annexa (Cardiovas) and Journal of Annexa (Cardiovas) and Journal of Annexa (Cardiovas) and Journal of Annexa (Cardiovas) and Journal of Annexa (Cardiovas) and Journal of Annexa (Cardiovas) and Journal of Annexa (Cardiovas) and Journal of Annexa (Cardiovas) and Journal of Annexa (Cardiovas) and Journal of Annexa (Cardiovas) and Medicine and the Section Process (Cardiovas) and Medicine and the Section Process (Cardiovas) and Medicine and the Discotors (Cardiovas) and Medicine and the Discotors (Cardiovas) and Medicine and the Discotors (Cardiovas) and Medicine and the Discotors (Cardiovas) and Medicine and the Discotors (Cardiovas) and Medicine and the Discotors (Cardiovas) and Medicine and the Discotors (Cardiovas) and Medicine and the Discotors (Cardiovas) and Medicine and the Discotors (Cardiovas) and Medicine and the Discotors (Cardiovas) and Medicine and the Section Process (Cardiovas) and Medicine and the Section Process (Cardiovas) and Medicine and the Section Process (Cardiovas) and Medicine and the Valentin (Cardiovas) and Medicine and the Valentin (Cardiovas) and Medicine and the Valentin (Cardiovas) and Medicine and the Valentin (Cardiovas) and Medicine and the Valentin (Cardiovas) and Medicine and the Valentin (Cardiovas) and Medicine and the Valentin (Cardiovas) and Medicine and the Valentin (Cardiovas) and Medicine and the Valentin (Cardiovas) and Medicine and the Valentin (Cardiovas) and Medicine and the Valentin (Cardiovas) and Medicine and the Valentin (Cardiovas) and Medicine and the Valentin (Cardiovas) and Medicine and the Valentin (Cardiovas) and Medicine and the Valentin (Cardiovas) and Medicine and the Valentin (Cardiovas) and Medicine (Cardiovas) and Medicine (Cardiovas) and Medicine (Cardiovas) and Medicine (Cardiovas) and Medicine (Cardiovas) and	Fuster	Valentin	Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017	Chair	Nothing to Disclose
Co-Chair Valentin	Fuster	Valentin	Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017		Nothing to Disclose
Fuster Valentin Beet of JACC Journals Decides and Cardiovascular Medicine and the Beet of JACC Journals Control State of JACC Journals Decides and Cardiovascular Medicine and the Beet of JACC Journals Decides and Cardiovascular Medicine and the Beet of JACC Journals Decides and Cardiovascular Medicine and the Beet of JACC Journals Decides and Cardiovascular Medicine and the Beet of JACC Journals Decides and Cardiovascular Medicine and the Beet of JACC Journals Decides and Cardiovascular Medicine and the Beet of JACC Journals Reside Look Into JACC and Interest Decides and Cardiovascular Medicine and the Verant Part of Look JACC and Pere-reviewed Publishing Highlighted Original Research Vacuation Medicine and the Verant Newton Medicine and the Verant Newton Medicine and the Verant Newton Medicine and the Verant Newton Medicine and the Verant Newton Medicine and the Verant Newton Medicine and the Verant Newton Medicine and the Verant Newton Medicine and the Verant Newton Medicine and the Verant Newton Medicine And the Verant Newton Medicine and the Verant Newton Medicine and the Verant Newton Medicine and the Verant Newton Medicine and the Verant Newton Medicine and the Verant Newton Medicine And the Verant Newton Medicine and the Verant Newton Medicine And the Verant Newton Medicine and the Verant Newton Medicine and the Verant Newton Medicine and the Verant Newton Medicine and the Verant Newton Medicine and Cardiovascular Newton Medicine And Turnol Medicine And T	Fuster	Valentin	Opening Session and the Joint American College of Cardiology and Journal of American College of Cardiology Late-Breaking Clinical	Co-Chair	Nothing to Disclose
Fuster Valentin Declared in Cardiovascular Medicine and the Seet of JACC sharmwald Lecture on Future Development of Cardiovascular Medicine and the Seet of JACC sharmwald Lecture on Future Development on Cardiovascular Medicine and the Best of JACC sharmwald Lecture on Future Development on Cardiovascular Medicine and the Best of JACC sharmwald Lecture on Future Development on Cardiovascular Medicine and the Best of JACC sharmwald Lecture on Future Development on Cardiovascular Medicine and the Seet of JACC sharmwald Lecture on Future Development on Cardiovascular Medicine and the Seet of JACC sharmwald Lecture on Future Development on Cardiovascular Medicine and the Vasin this JACC and sharmwald Lecturer. Jeffrey Drazen, MM Nothing to Disclose Plaster Valentin Plastification of Cardiovascular Medicine and the Vasin in Review Plastification of Adventical Mesenchymal Stem Cells in Nothing to Disclose Wester Washing and Cardiovascular Medicine and the Vasin in Review Plastification of Adventical Mesenchymal Stem Cells in Nothing to Disclose Wester Washing and Cardiovascular Medicine and the Vasin in Review Plastification of Adventical Mesenchymal Stem Cells in Nothing to Disclose Wester Washing and Cardiovascular Medicine and the Vasin in Review Plastification of Adventical Mesenchymal Stem Cells in Nothing to Disclose Wester Washing Adventication and Cardiovascular Medicine and the Vasin Review Speaker State of Medicine and the Vasin Review Speaker State of Medicine and Cardiovascular Medicine and Cardiovascular Medicine and Cardiovascular Medicine and Cardiovascular Medicine and Cardiovascular Medicine and Cardiovascular Plasters and Cardiovascular Plasters and Cardiovascular Plasters and Cardiovascular Plasters and Cardiovascular Plasters and Cardiovascular Plasters and Cardiovascular Plasters and Cardiovascular Plasters and Cardiovascular Plasters and Cardiovascular Plasters and Cardiovascular Plasters and Cardiovascular Plasters and Cardiovascular Plasters and Cardiovascular Plasters and Cardiovascular Plast	Fueter	Valentin	EIT Forum: Mix and Mingle	Clinical Bassarah	Nothing to Dicologo
Fuster Valentin Eugene Braumeal Lecture on Future Eugene Braumeal Lecture on Future Best of JACC Journals Eugene Braumeal Lecture on Future Best of JACC Journals Eugene Braumeal Lecture on Future Best of JACC Journals Eugene Braumeal Lecture on Future Directions in Cardiovascular Medicine and the Best of JACC Journals Eugene Braumeal Lecture on Future Directions in Cardiovascular Medicine and the Best of JACC Journals Eugene Braumeal Lecture on Future Directions in Cardiovascular Medicine and the Best of JACC Journals Eugene Braumeal Lecture on Future Directions in Cardiovascular Medicine and the Best of JACC Journals Eugene Braumeal Lecture on Future Uselentin Fuster Valentin Highlighted Original Research: Vascular Highlighted Original Research: Vascular Medicine and the Year in Review Highlighted Original Research: Acute and Every Every Highlighted Original Research: Acute and Every Highlighted Original					
Directions in Cardiovascular Medicine and the Best of JACC Journals			Directions in Cardiovascular Medicine and the Best of JACC Journals		-
Directions in Cardiovascular Medicine and the Best of AACC Journals			Directions in Cardiovascular Medicine and the Best of JACC Journals		-
Fuster Valentin Highlighted Original Research: Vascular Medicine and the Year in Review Highlighted Original Research: Vascular Medicine and the Year in Review Highlighted Original Research: Acute and Stable Isohemic Heart Disease and the Year in Review Speaker Valentin Highlighted Original Research: Acute and Stable Isohemic Heart Disease and the Year in Review Speaker Valentin Nohi hyaevie Imaging: MR Characterization and Function Non invasive Imaging: MR Characterization and Function Non invasive Imaging: MR Characterization and Function Non invasive Imaging: MR Heart Failure and Pulmonary Hypertension Acute Myocardial Chapters Speaker Valentin Non invasive Imaging: MR Heart Failure and Pulmonary Hypertension Acute Myocardial Pulmonary Hypertension Acut			Directions in Cardiovascular Medicine and the Best of JACC Journals	-	-
Medicine and the Year in Review Tester Valentin Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Year in Year in Year Year in Year Year in Year Year in Year Y	Fuster	Valentin		Insights into JACC and its Selection Process	Nothing to Disclose
Valentin	Fuster	Valentin	Highlighted Original Research: Vascular	the Human Aorta That Exhibit Diminished Angiogenic Potential in	Nothing to Disclose
Valentin Non Invasive Imaging: MR Characterization and Function Sequence in Magneties Myocardial Coxygenation Using Blood Level-Oxygen Dependent Nothing to Disclose	Fuster	Valentin	Stable Ischemic Heart Disease and the Year in		Nothing to Disclose
Fuster Valentin Non Invasive Imaging: IMR Characterization and Function Fuster Valentin Non Invasive Imaging: IMR Characterization Assesses Diagnosis, Sevently and Prognosis in Acute Nothing to Disclose Pulmonary Hypertension Fuster Valentin Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Revascularization and Outcomes Revascularization and Outcomes Revascularization and Outcomes Revascularization and Outcomes Revascularization and Outcomes Revascularization and Outcomes Revascularization and Outcomes Revascularization and Outcomes Revascularization and Outcomes Revascularization and Outcomes Revascularization and Outcomes Revascularization and Outcomes Revascularization and Outcomes Revascularization and Outcomes Revascularization Recovery Atlained Within 48-Hours of Stopping Treatment Proprotein Convertase Subtilisin Kexin Type 9 Protein Expression Is Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Fibrous Plaques Fuster Valentin Non Invasive Imaging: Prognostic Implications In Realtanoship Between Pericardial Adipose Tissue Volume, Atherosclerotic Plaque Type and Cardiovascular Risk: A High Risk Plaque Blomage U-Study Fuster Valentin Non Invasive Imaging: MR Structure and Mild Rheumatic Valvular Heart Disease Associated With Intersitial Nothing to Disclose Mocardial Fibros. 4 T1 Mapping Study Fuster Valentin Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease Associated With Intersitial Nothing to Disclose Concentrates With A BHOUR Study Platelet Concentrates With Cardiovascular Disease Fuster Valentin FitT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease Cardiology, Acute and Stable Ischemic Heart Disease Cardiology, Acute and Stable Ischemic Research Using Atheroscience of Ergonavine Positivity and Curative Vagotomy Fuster Valentin The Inside View: Learning From Intracoronary Prevalence and Cardiovascular Plaque Detected by Optical Coherence Tomography. A Four-Year Follow-Up Study Fuster Valentin	Fuster	Valentin	Non Invasive Imaging: MR Characterization	Sequence in Magnetic Resonance Determines Myocardial	Nothing to Disclose
Fuster Valentin Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Revascularization and Outcomes Progression Revascularization and Outcomes Progression Revascularization and Outcomes Progression Revascularity of Cardiovascular Patients on Ticagrefor Therapy Using Fresh Platelets. Ex Vivo Testing of the Functional Recovery Attained Within 48-Hours of Stopping Fuster Valentin Cutting Edge Vascular Medicine Proprotein Convertase Subtilisin Kevin Type 9 Protein Expression Is Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Fibrous Plaques Fuster Valentin Non Invasive Imaging: Prognostic Implications of CT Angiography Atherosclerotic Plaque Substilisin Kevin Type 9 Protein Expression Is Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Fibrous Plaques Fuster Valentin Non Invasive Imaging: MR Structure and Valuvular Heart Disease Myocardial Fibrosis: A T1 Mapping Study Fuster Valentin Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease Myocardial Fibrosis: A T1 Mapping Study Fuster Valentin Fit Clinical Decision Making: Interventional Concentrated of a Loading Dose: Ex Vivo Testing of Time-Effect on Functional Recovery in Patients With Cardiovascular Disease, and Vascular Medicine Fuster Valentin Highlights in Vascular Medicine Research Ultrasound: The PESA (Progression and Early Detection of Subdy Imaging) Fuster Valentin The Inside View: Learning From Intracoronary Imaging Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools Brown And Assessing Cardiovascular Fedicine Subdinical Atherosclerosis) Study Frester Valentin Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools Brown And Assessment: Novel Biomarkers and Risk Prediction Tools Brown And Assessment: Novel Biomarkers and Risk Prediction Tools	Fuster	Valentin		T1 Mapping Assesses Diagnosis, Severity and Prognosis in Acute	Nothing to Disclose
Fuster Valentin Coronary Anglography, Intra-Vascular Imaging, Revascularization and Outcomes Tecaptor Therapy Using Fresh Platelets: Ex Vivo Testing of the Functional Recovery Attained Within 48-Hours of Stopping Fuster Valentin Cutting Edge Vascular Medicine Proprofesion Convertase Subtilisin Kexin Type 9 Protein Expression Is Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Fibrous Plaques Fuster Valentin Non Invasive Imaging: Prognostic Implications of CT Angiography The Relationship Between Pericardial Adipose Tissus Volume, Atherosclerotic Plaque Type and Cardiovascular Risk: A High Risk Plaque Biolimage Sub-Study Fuster Valentin Non Invasive Imaging: MR Structure and Valuvular Heart Disease Myocardial Fibrosis: A 11 Mapping Study Fuster Valentin Antiplatelet and Antithrombotic Agents in Schemic Heart Disease In Schemic Heart Disease In Schemic Heart Disease In Schemic Heart Disease In Filt Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Fuster Valentin Highlights in Vascular Medicine Research Highlights in Vascular Medicine Research User In Heart Disease In Highlights in Vascular Medicine Research User In Heart Disease In Highlights in Vascular Medicine Research Imaging Prevalence and Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A Four-Year Follow-Up Study Fuster Valentin The Inside View: Learning From Intracoronary Predictive Values of the Ideal Cardiovascular Health and the Fuster-Nothing to Disclose Individual Atherosclerosis in Healthy Fuster Valentin Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools Furdictive Values of the Ideal Cardiovascular Health and the Fuster-Nothing to Disclose Individual Atherosclerosis in Healthy Fuster Valentin Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools	Fuster	Valentin		Fraction Detects Increased Interstitial Myocardial Fibrosis and	Nothing to Disclose
Fuster Valentin Cutting Edge Vascular Medicine Proprotein Convertase Subtilisin Kexin Type 9 Protein Expression Is Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Increased in Lipid Relation Plaques Compared to Increased in Lipid Relation Plaques Positivity and Countering the Anti-Platelet Effects of Ticagrelor With Platelet Effects of Ticagrelor With	Fuster	Valentin		Normalizing Platelet Reactivity of Cardiovascular Patients on Ticagrelor Therapy Using Fresh Platelets: Ex Vivo Testing of the Functional Recovery Attained Within 48-Hours of Stopping	Nothing to Disclose
Fuster Valentin Non Invasive Imaging: Prognostic Implications of CT Anglography Fuster Valentin Non Invasive Imaging: MR Structure and Mild Rheumatic Valvular Heart Disease Is Associated With Interstitial Nothing to Disclose Walentin Non Invasive Imaging: MR Structure and Mild Rheumatic Valvular Heart Disease Is Associated With Interstitial Nothing to Disclose Walentin Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease Is Associated With Interstitial Nothing to Disclose Walentin Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease Is Associated With Interstitial Nothing to Disclose Walentin Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease Is Antiplatelet Effects of Ticagrelor With Platelet Concentrates Within 48 Hours of a Loading Dose: Ex Vivo Testing of Time-Effect on Functional Recovery in Patients With Cardiovascular Diseases Fuster Valentin FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease Is Associated Within 48 Hours of a Loading Dose: Ex Vivo Testing of Time-Effect on Functional Recovery in Patients With Cardiovascular Diseases Occurative Vagotomy Fuster Valentin Highlights in Vascular Medicine Curative Vagotomy Fuster Valentin The Inside View: Learning From Intracoronary Imaging Fuster Valentin The Inside View: Learning From Intracoronary Prevalence and Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A Four-Year Follow-Up Study Fuster Valentin Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools BUWAT Scores for Detecting Subclinical Atherosclerosis in Healthy	Fuster	Valentin	Cutting Edge Vascular Medicine	Proprotein Convertase Subtilisin Kexin Type 9 Protein Expression Is Increased in Lipid Rich Human Atherosclerotic Plaques Compared	Nothing to Disclose
Fuster Valentin Non Invasive Imaging: MR Structure and Micd Rheumatic Valvular Heart Disease is Associated With Interstitial Nothing to Disclose National Valuurar Heart Disease and Valuurar Heart Disease is Associated With Interstitial Nothing to Disclose Valuentin Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease Concentrates Within 48 Hours of a Loading Dose: Ex Vivo Testing of Time-Effect on Functional Recovery in Patients With Cardiovascular Disease Fuster Valentin FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Fuster Valentin Highlights in Vascular Medicine Research Ultrasound: The PESA (Progression and Early Detection of Subclinical Atherosclerosis) Study Fuster Valentin The Inside View: Learning From Intracoronary Prevalence and Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A Four-Year Follow-Up Study Fuster Valentin Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools MIcd Rheumatic Valvular Heart Disease is Associated With Interstitial Nothing to Disclose Countering Study Nothing to Disclose Votation Associated With Interstitial Nothing to Disclose Votation Associated With Interstitial Nothing to Disclose Votation Associated With Interstitial Nothing to Disclose Votation Associated With Interstitial Nothing to Disclose Votation Associated With Interstitial Nothing to Disclose Votation Associated With Interstitial Nothing to Disclose Votation Associated With Interstitial Nothing to Disclose Votation Associated With Interstitial Nothing to Disclose Votation Associated With Interstitial Nothing to Disclose Votation Associated With Interstitial Nothing to Disclose Votation Associated With Interstitial Nothing to Disclose Votation Associated With Interstitial Nothing to Disclose Votation Associated With Interstitial Nothing to Disclose Votation Associated With Interstitial Nothing to Disclose Votation Associated With Interstitial Nothing to Disclose Votat	Fuster	Valentin		The Relationship Between Pericardial Adipose Tissue Volume, Atherosclerotic Plaque Type and Cardiovascular Risk: A High Risk Plaque Biolmage Sub-Study	-
Fuster Valentin Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease Countering the Anti-Platelet Effects of Ticagrelor With Platelet Concentrates Within 48 Hours of a Loading Dose: Ex Vivo Testing of Time-Effect on Functional Recovery in Patients With Cardiovascular Disease Fuster Valentin FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Fuster Valentin Highlights in Vascular Medicine Research Ultrasound: The PESA (Progression and Early Detection of Subclinical Atherosclerosis) Study Fuster Valentin The Inside View: Learning From Intracoronary Imaging Fuster Valentin Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools EWAT Scores for Detecting Subclinical Atherosclerosis in Healthy Countering the Anti-Platelet Effects of Ticagrapior With Platelet Concentrates Within 48 Hours of a Loading Dose: Ex Vivo Testing of Time-Effect on Functional Recovery in Patients With Cardiovascular Disease Countering the Anti-Platelet Effects of Ticagrapior With Platelet Concentrates Within 48 Hours of a Loading Dose: Ex Vivo Testing of Time-Effect on Functional Recovery in Patients With Cardiovascular Disease Countering the Anti-Platelet Effects of Ticagrapior With Platelet Concentrates Within 48 Hours of Recovery in Patients With Cardiovascular Disease Nothing to Disclose Nothing to Disclose Disclose Disclose Disclose Disclose Disclose SeWAT Scores for Detecting Subclinical Atherosclerosis in Healthy	Fuster	Valentin		Mild Rheumatic Valvular Heart Disease Is Associated With Interstitial	Nothing to Disclose
Fuster Valentin FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Diseases, and Vascular Medicine Fuster Valentin Highlights in Vascular Medicine Research Ultrasound: The PESA (Progression and Early Detection of Subclinical Atherosclerosis) Study Fuster Valentin The Inside View: Learning From Intracoronary Imaging Prevalence and Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A Four-Year Follow-Up Study Fuster Valentin Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools BEWAT Scores for Detecting Subclinical Atherosclerosis in Healthy	Fuster	Valentin	Antiplatelet and Antithrombotic Agents in	Countering the Anti-Platelet Effects of Ticagrelor With Platelet Concentrates Within 48 Hours of a Loading Dose: Ex Vivo Testing of Time-Effect on Functional Recovery in Patients With Cardiovascular	Nothing to Disclose
Fuster Valentin Highlights in Vascular Medicine Research Global Plaque Burden by Carotid and Femoral 3D Vascular Nothing to Disclose Ultrasound: The PESA (Progression and Early Detection of Subclinical Atherosclerosis) Study Fuster Valentin The Inside View: Learning From Intracoronary Prevalence and Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A Four-Year Follow-Up Study Fuster Valentin Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools BEWAT Scores for Detecting Subclinical Atherosclerosis in Healthy	Fuster	Valentin	Cardiology, Acute and Stable Ischemic Heart	Vasospastic Angina: A Rare Case of Ergonavine Positivity and	Nothing to Disclose
Fuster Valentin The Inside View: Learning From Intracoronary Prevalence and Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A Four-Year Follow-Up Study Fuster Valentin Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools EWAT Scores for Detecting Subclinical Atherosclerosis in Healthy	Fuster	Valentin		Ultrasound: The PESA (Progression and Early Detection of	Nothing to Disclose
Biomarkers and Risk Prediction Tools BEWAT Scores for Detecting Subclinical Atherosclerosis in Healthy	Fuster	Valentin		Prevalence and Clinical Significance of Lipid-Rich Plaque Detected	Nothing to Disclose
Individuals	Fuster	Valentin		BEWAT Scores for Detecting Subclinical Atherosclerosis in Healthy	Nothing to Disclose

Contract of the contract of th				
Last Name Fuster	First Name Valentin	Session Title Improving Risk Assessment in Atherosclerosis	Presentation Title Subclinical Atherosclerosis in the Absence of Cardiovascular Risk	Disclosures Nothing to Disclose
rusier	vaienun	improving Risk Assessment in Ameroscierosis	Subclinical Atherosclerosis in the Absence of Cardiovascular Risk Factors: Pre-Risk Status in the PESA (Progression of Early Subclinical Atherosclerosis) Study	Nothing to Disclose
Fusto	Antonio	Improving Outcomes in the Athlete With Cardiovascular Disease	EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students	Nothing to Disclose
Fynn-Thompson	Francis	Congenital Heart Disease: Progress in	A Red Cell Preservation Strategy Reduces Postoperative	Nothing to Disclose
Fynn-Thompson	Francis	Pediatric Heart Surgery Arrhythmias and Clinical EP: Devices 1	Transfusions in Pediatric Heart Surgery Patients Coronary Artery Compression by Epicardial Leads: More Common	Nothing to Disclose
Gaca	Jeffrey	Late-Breaking Clinical Trials	Than We Think Comparative Effectiveness of Left Atrial Appendage Occlusion	Nothing to Disclose
			Among Atrial Fibrillation Patients Undergoing Cardiac Surgery: A Report From the Society of Thoracic Surgeons Adult Cardiac Surgery Database	
Gaca	Jeffrey	TAVR for Degenerated Surgical Valves: What You Need to Know from A to Z	Co-Chair	Nothing to Disclose
Gaca	Jeffrey	Interventional Cardiology: TAVR 4	Predictors of Mortality After TAVR in a "Real World" Setting	Nothing to Disclose
Gacad	Vincent	The Challenges of Outcome Prediction in Valvular Heart Disease	Gender-Based Outcomes in Diabetics Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Gaddipati	Vamsi	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	An Incidentally Detected Right Ventricular Pseudoaneurysm	Nothing to Disclose
Gaemperli	Oliver	Non Invasive Imaging: Expanding Clinical Applications	Computed Tomography-Derived Corrected Contrast Opacification Decrease Predicts Reduced Relative Flow Reserve Derived From	SPEAKER'S BUREAU - Abbott Vascular, Biosensors
Gaemperli	Oliver	Non Invasive Imaging: Coronary Calcium	PET Myocardial Perfusion Imaging Prospective Evaluation of Low-Dose Coronary Calcium Scoring With	SPEAKER'S BUREAU - Abbott Vascular, Biosensors
Gaemperli	Oliver	Scoring and CV Risk Assessment Non Invasive Imaging: Prognostic Implications	Reduced Tube Voltage Long-Term Prognostic Value of Computed Tomography-Derived	SPEAKER'S BUREAU - Abbott Vascular, Biosensors
		of CT Angiography	Corrected Contrast Opacification Decrease in Patients With Coronary Stenosis	
Gafford	Ellin	Palliative Care for the 99% I: Promoting Palliative Care: The Why and What of PC Therapy	Panelist	Nothing to Disclose
Gafford	Ellin	Palliative Care for the 99% II: Skillbuilding: PC Encounters: What Would you do? Part I	Panelist	Nothing to Disclose
Gafford	Ellin	Palliative Care for the 99% III: Skillbuilding: PC	Panelist	Nothing to Disclose
Gafoor	Sameer	Encounters: What Would you do? Part II The Tricuspid Valve: The New Frontier	Current Landscape of Transcatheter Tricuspid Valve Repair	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston
Gafoor	Sameer	TAVR: What We've Learned and Where We	The Heart Team in 2017: Fact or Fiction?	Scientific,MEDTRONIC CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston
		Think We're Going!		Scientific,MEDTRONIC
Gafoor	Sameer	PFO Closure, PV Leak, and VSD Repair	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific, MEDTRONIC
Gafoor	Sameer	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Previous Major Gastrointestinal Bleeding: Insight From the Amplatzer Cardiac Plug Multicenter Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,MEDTRONIC
Gage	Brian	Late-Breaking Clinical Trials	GIFT of Warfarin: Benefit of Pharmacogenetic Dosing	RESEARCH/RESEARCH GRANTS - GenMarkDx supplied the
Gaggin	Hanna	Making Progress in Understanding Heart Failure	Circulating Concentrations of Orexin A Are Associated With Left Ventricular Reverse Remodeling and Clinical Outcomes Following Cardiac Resynchronization Therapy	eSensor instrument for genotyping CONSULTANT FEES/HONGRARIA - Amgen,Ortho Clinical,Roche Diagnostics; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - MGH Cardiology Board Review Book,MGH Cardiology Board Review Course; OTHER - EchoSense,Radiometer; RESEARCH/RESEARCH GRANTS - Portola,Roche Diagnostics
Gaggin	Hanna	Making Progress in Understanding Heart Failure	Serial Assessment of Heart Rate and Beta Blocker Use in Chronic Heart Failure Patients With Reduced Ejection Fraction in a Large Integrated Healthcare Network	CONSULTANT FÉES/HONORARIA - Amgen, Ortho Clinical, Roche Diagnostics; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - MGH Cardiology Board Review Book, MGH Cardiology Board Review Course; OTHER - EchoSense, Radiometer; RESEARCH/RESEARCH GRANTS - Portola, Roche Diagnostics
Gaggin	Hanna	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Multiple Biomarkers for Predicting Major Adverse Cardiac Events in At-Risk Patients Undergoing Diagnostic Coronary Angiography: Results From the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study	CONSULTANT FEES/HONORARIA - Amgen,Ortho Clinical,Roche Diagnostics; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - MGH Cardiology Board Review Book,MGH Cardiology Board Review Course; OTHER - EchoSense,Radiometer; RESEARCH/RESEARCH GRANTS - Portola,Roche Diagnostics
Gaglia	Michael	Interventional Cardiology: TAVR 3	Antithrombotic Therapy Differences and Associated Outcomes in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement	SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals
Gaibazzi	Nicola	Improving Outcomes in the Athlete With	The Heart Sentinel App for Automatic Detection and Alerting in	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
		Cardiovascular Disease	Cardiac Arrest During Outdoor Sports: Ventricular Fibrillation Simulations and Preliminary Data in Athletes	PARACHUTE software app co-founder
Gaies	Michael	Post-Surgical Care of Children with CHD: From ICU to Your Office		Nothing to Disclose
Gaies	Michael	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Characteristics, Risk Factors and Outcomes of Extracorporeal Membrane Oxygenation Use in the Pediatric Cardiac Intensive Care	Nothing to Disclose
Gajulapalli	Rama Dilip	Advances in HCM, PPCM and Other	Unit Takotsubo Cardiomyopathy (TCM) Increases Risk of Lethal	Nothing to Disclose
Gal	Dana	Cardiomyopathies Arrhythmias and Clinical EP: Basic 5	Arrhythmias Tachyarrhythmia Not Associated With Mortality During Single	Nothing to Disclose
Galagudza	Michael	Cutting Edge Vascular Medicine	Ventricle Reconstruction A Novel Necroptosis Inhibitors (Necrosulfonamide and Necrostatin- 1s) Demonstrate Therapeutic Potential for Myocardial Ischemia-	Nothing to Disclose
Galán	David	Coronary Angiography, Intra-Vascular Imaging,	Reperfusion Injury Incidence, Clinical Profile and Prognosis of Patients With Myocardial	Nothing to Disclose
Galassi	Alfrado	Revascularization and Outcomes 20. Interventional Cardiology: Coronary	Infarction With Non-Obstructive Coronary Arteries in the Real World	Nothing to Disclose
Galassi	Alfredo	Intervention: CTO Team 1	Suggested Reviewer	Nothing to Disclose
Galazka	Patrycja	FIT Forum: Stump the Professor	Use of ¹⁸ F-Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for Diagnosing Prosthetic Valve Perivalvular Abscess	Nothing to Disclose
Galbraith	Diane	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Ventricular Arrhythmia at Primary PCI for ST-Elevation Myocardial Infarction Predicts 30-Day but Not Long-Term Mortality	Nothing to Disclose
Galbraith	Diane	Percutaneous Coronary Intervention: Lessons From the Real World	Nine Year Trends in Cause-Specific Mortality After Percutaneous Coronary Intervention: Observations From the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Registry	Nothing to Disclose
Galenko	Oxana	Interventional Cardiology: Translation and Pre- Clinical Research	INFTROMONIAN REGISTRY BOTH THE NOVEL NAME SIGNATURE OF INFTRUMENTAL SIGNATURE CARD Are Independent and Additive Predictors of Future Cardiovascular Events Among Patients Undergoing Coronary Angiography: Results From the Intermountain Heart Collaborative Study	Nothing to Disclose
Galenko	Oxana	Arrhythmias and Clinical EP: AF Miscellaneous	Circulating MicroRNA Patterns Are Associated With Post-Ablation	Nothing to Disclose
L		and Surgical Issues	Recurrence of Atrial Fibrillation	

Last Name Galié	First Name Nazzareno	Session Title Deciphering Pulmonary Hypertension Due to	Presentation Title Debate: Combined Post- and Precapillary Pulmonary Hypertension	Disclosures CONSULTANT FEES/HONORARIA - Actelion Pharmaceuticals
		Left Heart Disease: Have Hope Oh Ye Who Enter	Should Be Treated (Con)	Ltd,Bayer Healthcare Pharmaceuticals,Eli Lilly and Company,GlaxoSmithKline,Pfizer Inc
Galié	Nazzareno	Demystifying and Managing Pulmonary Hypertension and RV Dysfunction: It Takes a Village	Panelist	CONSULTANT FEES/HONORARIA - Actelion Pharmaceuticals Ltd,Bayer Healthcare Pharmaceuticals,Eli Lilly and Company,GlaxoSmithKline,Pfizer Inc
Galié	Nazzareno	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Year in Review Speaker	CONSULTANT FEES/HONORARIA - Actelion Pharmaceuticals Ltd,Bayer Healthcare Pharmaceuticals,Eli Lilly and Company,GlaxoSmithKline,Pfizer Inc
Galin	Ira	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Facing a Giant: Asymptomatic Progression of a Right Coronary Artery Aneurysm	SPEAKER'S BUREAU - BMS/Pfizer
Galindo-Uribe	Jaime	ACC International Conferences Best Posters	HER2 Positive Breast Cancer and Subclinical Cardiotoxicity by Echocardiogram 2D Strain: Does Chemotherapy Sequence Matter?	Nothing to Disclose
Gallinghouse	G.	Atrial Fibrillation and VT: Incorporating Novel	Left Atrial Appendage Flow Velocity to Predict Persistent Left Atrial	Nothing to Disclose
Gallo	Francesco	Risks Toward Decision Making Refining PCI Technique and Outcomes	Appendage Isolation Comparison of Verapamil Versus Heparin Therapy on Procedural Success During Transradial Coronary Procedures (Vermut Study)	Nothing to Disclose
Galper	Benjamin	Coronary Intervention: Drug Eluting Stent and Scaffolds	A Cost-Effective Analysis of Short Duration Dual Anti-Platelet Therapy (Dapt) With a Bioabsorbable Polymer Stent Platform Versus Longer Duration Dapt With a Durable Polymer Drug-Eluting Stent in a Patient Population Undergoing Elective Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Keystone Heart
Galve Basilio	Enrique	Atrial Fibrillation and VT: Unique Populations and Solutions	Cardiac Resynchronization Is Associated With Reduction in the Rate of Icd Therapies, While Improves Ventricular Function	Nothing to Disclose
Gamberdella	Jacqueline	Great Minds Think Differently: Multidisciplinary	Panelist	Nothing to Disclose
Gamberdella	Jacqueline	Approach to Imaging Great Minds Think Differently: Multidisciplinary	Co-Chair	Nothing to Disclose
Gamboa	David	Approach to Advanced Therapies Congenital Heart Disease: Novel Insights in	Rhythm Abnormalities in Children and Young Adults With Marfan	Nothing to Disclose
Gammelsrud	Lars Ove	Pediatric Cardiology Heart Failure and Cardiomyopathies: Heart	Syndrome Myocardial Contractile Reserve Verified With Dual Chamber Right	SALARY - Medtronic Inc.
		Failure Gadgets Galore	Ventricular Pacing Predicts Response to Cardiac Resynchronization Therapy	
Gammie	James	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Peripheral Anatomic Distribution of Thrombus Does Not Adversely Affect Outcomes in Patients Undergoing Surgical Pulmonary Embolectomy for Submassive and Massive Pulmonary Embolism	CONSULTANT FEES/HONORARIA - Sorin Group, Inc.; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Correx, Inc., harpoon, inc.; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Ganatra	Sarju	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Challenges in Ibrutinib Associated Atrial Fibrillation	Nothing to Disclose
Ganatra	Sarju	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Expanding the Role of Dexrazoxane for Cardioprotection: Use in a Patient With Pre-Existing Systolic Dysfunction and No Prior Anthracycline Exposure	Nothing to Disclose
Gandhi	Devang	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Aortic Dissection: To Spare or Not to Spare the Aortic Valve????	Nothing to Disclose
Gandhi	Himali	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	ST-Segment Elevation and Cardiac Magnetic Resonance Imaging Findings in Myocardial Infarction With Non-Obstructive Coronary Arteries	Nothing to Disclose
Gandhi	Himali	Unusual Presentations of ACS	Takotsubo Cardiomyopathy Versus Apical Infarction in Patients With Myocardial Infarction and Non-Obstructive Coronary Artery Disease (MINOCA)	Nothing to Disclose
Gandhi	Parul	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Multiple Biomarkers for Predicting Major Adverse Cardiac Events in At-Risk Patients Undergoing Diagnostic Coronary Angiography: Results From the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study	Nothing to Disclose
Gandhi	Rupali	Value, Advocacy and the Future of Adult Congenital and Pediatric Cardiology	Co-Chair	Nothing to Disclose
Gandhi	Rupali	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Severe Ebstein's Anomaly Successfully Palliated With the Starnes Procedure	Nothing to Disclose
Gandhi	Sanjay	Valvular Disease Populations at Risk	Risk Stratification Predicts Survival in Patients With Low Gradient Preserved Left Ventricular Ejection Fraction and Severe Aortic Stenosis After Aortic Valve Intervention	Nothing to Disclose
Gandotra	Charu	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Risk of Hospitalization or Death Due to Heart Failure With Intensive Glucose-Lowering Therapy in Diabetic Women: Subgroup Analyses by History of Cardiovascular Disease in the ACCORD Trial	Nothing to Disclose
Ganguli	Shankho	Head to Toe: Outcomes of Endovascular Interventions	Use of Viabahn Endograft for Repair of Popliteal Artery Aneurysm: Largest Single Center Experience	Nothing to Disclose
Gannon	Stephen	FIT Clinical Decision Making: Arrhythmias and Clinical Electrophysiology	Sudden Unexpected Death in Epilepsy and Long QT Syndrome	Nothing to Disclose
Gannuscio	Jacqueline	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Chronic Alpha Blocker Use and Outcomes in Older Male Medicare	SPEAKER'S BUREAU - Otsuka Pharmaceutical
Gans	Christopher	Interdisciplinary Cardiovascular Team Care	Beneficiaries Hospitalized for Heart Failure Heart Failure Hotline as an Innovation to Address Medication Issues	Nothing to Disclose
Ganz	Peter	Delivery: Quality, Safety, and Satisfaction Advances in Lipid Management	Early Detection of the Unexpected, Harmful, Pharmacologic Effects of Torcetrapib: A Retrospective Proteomics Analysis of Plasma	CONSULTANT FEES/HONORARIA - AUM Cardiovascular,ltamar Medical; RESEARCH/RESEARCH
Ganz	Peter	38. Vascular Medicine: Basic Team 2	Samples From the ILLUMINATE Trial Suggested Reviewer	GRANTS - Somalogic CONSULTANT FEES/HONORARIA - AUM Cardiovascular, Itamar Medical; RESEARCH/RESEARCH
Gao	Fei	Vascular Medicine: Novel Risk Measures in	Sarcopenia and Vascular Function Among Community Elderly	GRANTS - Somalogic Nothing to Disclose
Gao	Fei	Arterial Diseases Diabetes and Other Issues in Cardiovascular	Adiposity, Leanness or Both? Characterizing Measures of Adiposity	Nothing to Disclose
Gao	Runlin	Prevention 36. Valvular Heart Disease: Clinical Team 3	and Leanness With Cardiovascular Remodeling Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Astra-
Garasic	Joseph	40. Vascular Medicine: Non Coronary Arterial Disease Team 2	Suggested Reviewer	Zeneca,MicroPort,Venous MedTech (Hangzhou, China) OTHER - Advanced Clinical Investigations, Inc.,Boehringer Ingelheim Pharmaceuticals, Inc,Siemens, Inc.; OWNERSHIP
Garb	Jane	Novel Developments in Acute Coronary Syndromes	Comparison of Clinical Outcomes: Bivalirudin With Transfemoral Versus Heparin With Transradial in Patients With ST Segment	INTEREST/PARTNERSHIP/PRINCIPAL - Ostial Corporation Nothing to Disclose
Garberich	Ross	Valvular Disease Populations at Risk	Elevation Myocardial Infarction Surgical Risk and Therapy of Severe Symptomatic Degenerative	Nothing to Disclose
Garberich	Ross	Valvular Heart Disease: Mitral Valve Disease	Mitral Valve Regurgitation in the Contemporary Era Guideline-Adherence and Survival for Asymptomatic Patients With Severe Mitral Valve Regurgitation	Nothing to Disclose
Garberich	Ross	Cardiac Arrest, Diabetes, and Other High Risk	Influence of Cardiac Arrest and Cardiogenic Shock on Outcomes	Nothing to Disclose
		Features of Patients With Acute Coronary Syndrome	Among 4,500 Consecutive ST Elevation Myocardial Infarction Patients	

Last Name	First Name	Session Title	Presentation Title	Disclosures
Garberich	Ross	Timely Topics in Acute Coronary Syndromes	Outcome and Characteristics of Shockable Versus Non-Shockable Cardiac Arrest in ST Elevation Myocardial Infarction at a Regional Transfer Center	Nothing to Disclose
Garberich	Ross	Arrhythmias and Clinical EP: Devices 4	An investigation of the Evolution of Implantable Cardiac Monitors: A Comparison of Reveal XT-sup>TM Comparison Reveal XT-sup>TM LINQ ^{TM Sup> and Reveal Accuracy Measurements and Patient Outcomes Post-Device Implant}	Nothing to Disclose
Garberich	Ross	Interventional Cardiology: TAVR 4	Minimalist Approach to Cardiac Anesthesia and Outcome in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Garberich	Ross	Advancing Our Understanding of Aortic Disease	Clinical and Pathologic Findings of Aortic Dissection at Autopsy: Review of 338 Cases Over 6 Decades	Nothing to Disclose
Garbo	Roberto	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Provisional Versus Elective Two-Stenting Strategy for Unprotected True Left Main Bifurcation Lesions: A Sub-Study From Fails 2 Study	CONSULTANT FEES/HONORARIA - Boston scientific, Volcano Europe, Terumo
Garcia	Daniel	Head to Toe: Outcomes of Endovascular Interventions	Analysis of Outcomes for Bioresorbable Vascular Scaffold Use for the Treatment of Peripheral Vascular Disease	Nothing to Disclose
Garcia	Daniel	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Comparison of Biodegradable Drug Eluting Polymer Stents and Durable Polymer Drug Eluting Stent for the Treatment of CAD: A Meta-Analysis of RCT's	Nothing to Disclose
Garcia	Fermin	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Anticoagulation Use and Incidence of Cerebrovascular Events and Major Bleeding After Catheter Ablation in Patients With Persistent and Longstanding Persistent Atrial Fibrillation	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,St Jude Medical; SPEAKER'S BUREAU - Biosense Webster
Garcia	Fermin	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,St Jude Medical; SPEAKER'S BUREAU - Biosense Webster
Garcia	Hector	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Optical Coherence Tomography Guided Percutaneous Coronary Intervention Compared With Other Imaging Guidance: A Meta- Analysis	Nothing to Disclose
Garcia	Jose	Which Test Is Best for Pain in the Chest?	Coronary Computed Tomography Angiography in the Emergency Room: Rapid Exclusion of Coronary Artery Disease and the Fast Diagnosis of Acute Myocarditis Using Late Enhancement by Computed Tomography	Nothing to Disclose
Garcia	Julio	Valvular Heart Disease: Aortic Regurgitation	Analysis of Diastolic Vortex Flow as a Marker of Ventricular Deterioration in Aortic Regurgitation	Nothing to Disclose
Garcia	Karolain	ECG Screening and Risk Prediction	Wolff-Parkinson-White Pattern and Sudden Cardiac Death: A Retrospective Cohort Community Study From Olmsted County, Minnesota	Nothing to Disclose
Garcia	Lawrence	Controversies and Strategies for Endovascular Treatment of the Femoropopliteal Segment	Co-Chair	CONSULTANT FEES/HONORARIA - Boston Scientific,Pathway Medical/BSC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Arsenal Medical,CVI,Essential Medical,Primacea,Scion Cardiovascular ,spirox,Syntervention,TissueGen Inc; RESEARCH/RESEARCH GRANTS - ev3/Covidien/Medronic.iDev/Abbott
Garcia	Lawrence	41. Vascular Medicine: Venous Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific,Pathway Medical/BSC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Arsenal Medical,CVI,Essential Medical,Primacea,Scion Cardiovascular ,spirox,Syntervention,TissueGen Inc; RESEARCH/RESEARCH GRANTS - ev3/Covidien/Medtronic,IDev/Abbott
Garcia	Mario	What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture	Non-invasive Risk Stratification in Stable Angina: Anatomical Perspective	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Pfizer
Garcia	Mario	Interventional Cardiology: TAVR 2	Association of Chronic Renal Insufficiency With In-Hospital Outcomes of Transcatheter Aortic Valve Replacement	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Pfizer
Garcia	Mario	Innovative Use of Echocardiography	High Prevalence of Apical Hypertrophic Cardiomyopathy Noted in Non-White Patients Referred for Clinical Echocardiography	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Pfizer
Garcia	Mario	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Sex Differences in Revascularization and In-Hospital Outcomes of Non-ST-Segment Elevation Myocardial Infarction in the United States	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Pfizer
Garcia	Mario	Interventional Cardiology: TAVR 3	Regional Variations in In-Hospital Outcomes and Healthcare Resource Utilization in Patients Undergoing Transcatheter Aortic Valve Replacement in the United States	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Pfizer
Garcia	Mario	Non Invasive Imaging: Prognostic Implications of CT Angiography	The Relationship Between Pericardial Adipose Tissue Volume, Atherosclerotic Plaque Type and Cardiovascular Risk: A High Risk Plaque Biolmage Sub-Study	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Pfizer
Garcia	Mario	Antithrombotic Therapy in Ischemic Heart Disease	Role of Anticoagulation Therapy After Anterior Wall ST-Elevation Myocardial Infraction in Preventing LV Thrombus: A Meta-Analysis and Meta-Regression	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Pfizer
Garcia	Mario	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Association of Academic Year-End Changeover With Survival Rates After In-Hospital Cardiac Arrest: An Examination of the "July Effect"	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Pfizer
Garcia	Mario	Optimizing the Care of ACS Patients	Weekend Versus Weekday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide Analysis	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Pfizer
Garcia Garcia	Mario Santiago	28. Non Invasive Imaging: Echo Team 2 Interventional Cardiology: PCI and TAVR in Complex Patients	Suggested Reviewer Calcification in the Basal Septum, but Not Membranous Septal Length, Predicts AV Conduction Disturbance and Pacemaker Implantation Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve (S3)	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Pfizer CONSULTANT FEES/HONORARIA - Surmodics
Garcia	Santiago	Advances in Chronic Total Occlusion Intervention	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	CONSULTANT FEES/HONORARIA - Surmodics
Garcia Camarero	Tamara	Timely Topics in Acute Coronary Syndromes	A New Prognosis Score to Predict Mortality in Patients Over 75 Years Old Undergoing Primary Angioplasty in Cardiogenic Shock	Nothing to Disclose
Garcia Ropero	Alvaro	Arrhythmias and Clinical EP: Devices 1	Pharmacological Treatment Alone Versus Treatment Combined With Implantable Cardioverter-Defibrillator Therapy in Patients Over 75 Years	Nothing to Disclose
Garcia-Camarero	Tamara	Timely Topics in Acute Coronary Syndromes	Time to Treatment With Melatonin and Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction: Insights From the MARIA (Melatonin Adjunct in the acute myocaRdial Infarction	Nothing to Disclose
García-González	María Pilar	Non Invasive Imaging: MR Scar and Perfusion	treated with Angioplasty) Trial Mean Pulmonary Artery Velocity Estimated by Cardiac Magnetic Resonance as an Early Prognostic Indicator in Heart Failure With Reduced Ejection Fraction Irrespective of Right Ventricular Function	Nothing to Disclose
Garcia-Rivas	Gerardo	Diabetes and Endothelial Dysfucntion in Heart Failure	Hypothyroidism Modulates Mitochondrial Calcium Uniporter Expression and Causes Cardioprotection Decresing Mitochondrial Permeability Transition Pore Opening	Nothing to Disclose
Garcia-Saiz	Maria del Mar	Timely Topics in Acute Coronary Syndromes	Time to Treatment With Melatonin and Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction: Insights From the MARIA (Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty) Trial	Nothing to Disclose
Gardin	Julius	02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	OTHER - Les Laboratories Servier; SPEAKER'S BUREAU -
	1	Clinical Team 2	l .	GILEAD Sciences



Contract of the contract of th				
Last Name Gardner	First Name Monique	Session Title Congenital Heart Disease: Innovations in	Presentation Title Impact of Home Monitoring Program on Interstage Mortality and	Disclosures Nothing to Disclose
		Single Ventricle Heart Disease	Stage II Outcomes	-
Garg	Aakash	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Temporal Trends and Outcomes of Emergent Coronary Artery Bypass Graft Surgery for ST-Segement Elevation Myocardial Infarction	Nothing to Disclose
Garg	Aakash	Interventional Cardiology: TAVR 2	Comparison of In-Hospital Outcomes of Transcatheter Aortic Valve Replacement in Men and Women	Nothing to Disclose
Garg	Aakash	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Impact of Atrial Fibrillation on Outcomes in Patients Hospitalized With ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Garg	Aakash	Syndrome Timely Topics in Acute Coronary Syndromes	Routine Invasive Versus Conservative Strategy for Elderly Patients Aged>75 Years With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS): A Meta-Analysis of Randomized Controlled	Nothing to Disclose
Garg	Abhishek	FIT Clinical Decision Making: Arrhythmias and	Trials Vagal Nerve Stimulator Therapy: An Unusual Cause of	Nothing to Disclose
Garg	Jalaj	Electrophysiology Updates on Risk Factors for Cardiovascular	Symptomatic Bradycardia Cannabis Use Predicts Risks of Heart Failure and Cerebrovascular	Nothing to Disclose
Garg	Jalaj	Disease Predicting the Future: Observations and	Accidents: Results from the National Inpatient Sample Clinical Burden and Cost Analysis of Pulmonary Hypertension in	Nothing to Disclose
		Discoveries From Registries and Databases	Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample	Ç
Garg	Lohit	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Temporal Trends and Outcomes of Emergent Coronary Artery Bypass Graft Surgery for ST-Segement Elevation Myocardial Infarction	Nothing to Disclose
Garg	Lohit	Interventional Cardiology: TAVR 2	Comparison of In-Hospital Outcomes of Transcatheter Aortic Valve Replacement in Men and Women	Nothing to Disclose
Garg	Lohit	Advances in HCM, PPCM and Other	Childbirth Related Complications in Women With Hypertrophic	Nothing to Disclose
Garg	Lohit	Cardiomyopathies Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Cardiomyopathy Impact of Atrial Fibrillation on Outcomes in Patients Hospitalized With ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Garg	Lohit	Syndrome Timely Topics in Acute Coronary Syndromes	Routine Invasive Versus Conservative Strategy for Elderly Patients	Nothing to Disclose
Suly	es.at	Topics in reduct coloniary syndrollies	Aged>75 Years With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS): A Meta-Analysis of Randomized Controlled Trials	. Coming to Dissilose
Garg	Lohit	Advances in Chronic Total Occlusion Intervention	Trends and In-Hospital Outcomes of Patients Admitted With ST Elevation Myocardial Infarction and Chronic Total Occlusions: Insights From a National Database	Nothing to Disclose
Garg	Lohit	Interventional Cardiology: TAVR 4	Outcomes of Trans-Catheter Aortic Valve Replacement in	Nothing to Disclose
Garg	Lohit	The Evolving World of LVADs, Transplant and	Nonagenarians Cardiovascular Complications and In-Hospital Outcomes of Chagas'	Nothing to Disclose
Garg	Nadish	Other Novel Discoveries Novel Echocardiographic Methods for	Disease in the United States From 2003-2011 Clinical and Echocardiographic Predictors of Atrial Fibrillation in	Nothing to Disclose
Garg	Neetika	Assessing Cardiac Function Interventional Cardiology: TAVR 2	Trauma Patients Comparative Outcomes of Transcatheter Versus Surgical Aortic	Nothing to Disclose
Garg	Neetika	Vascular Medicine: Aortic and Peripheral	Valve Replacement in Chronic Kidney Disease Regional Differences in Clinical Outcomes and Resource Utilization	Nothing to Disclose
Garg	Pallav	Artery Diseases Coronary Intervention: Drug Eluting Stent and	After Acute Ischemic Stroke Hospitalizations in the United States A Cost-Effective Analysis of Short Duration Dual Anti-Platelet	Nothing to Disclose
		Scaffolds	Therapy (Dapt) With a Bioabsorbable Polymer Stent Platform Versus Longer Duration Dapt With a Durable Polymer Drug-Eluting Stent in a Patient Population Undergoing Elective Percutaneous Coronary Intervention	
Garg	Pallav	Infectious Endocarditis: Comprehensive Perspectives	Infective Endocarditis Hospitalizations and Antibiotic Prophylaxis Rate Before and After the 2007 American Heart Association Guidelines Revision	Nothing to Disclose
Garg	Sonia	Emerging Developments in HFpEF and Arryhthmias	The Association of Thick Left Ventricular Hypertrophy With Cardiovascular Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From the TOPCAT Trial	Nothing to Disclose
Garg	Sonia	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Cardiac Atrophy: A Novel Mechanism for Duchenne Muscular Dystrophy (DMD)-Associated Cardiomyopathy	Nothing to Disclose
Garg	Sushil	Updates on Risk Factors for Cardiovascular Disease	Impact of Exercise and Pharmacologic Interventions on Changes in Visceral Adiposity: A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Garg	Vidu	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Utility of Genetic Testing in Infants With Isolated Congenital Heart Disease	Nothing to Disclose
Garg	Vinisha	FIT Clinical Decision Making: Arrhythmias and	Myocardial Fragility in Ehlers Danlos Syndrome	Nothing to Disclose
Garratt	Kirk	Electrophysiology Overuse, Underuse or Just Right? Fundamental Debates in High Risk PCI in 2017	Chronic Total Occlusion PCI: Just Because We Can, Doesn't Mean We Should	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,CELONOVA,Daicih-Sankyo/Eli Lilly,The Medicines Company, DATA SAFETY MONITORING BOARD - Abbott Laboratories,Jarvik Heart, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Guidded Delivery Systems,LifeCuff Technologies (formerly IRT)
Garratt	Kirk	Mastering Cath Lab Leadership and Economics in a New Era: A Joint Symposium by the Society of Cardiovascular Angiography and Interventions and the American College of Cardiology	Effective Strategies for Success of the Medical Director	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation, CELONOVA, Dalichi-Sankyo/Eli Lilly, The Medicines Company, DATA SAFETY MONITORING BOARD - Abbott Laboratories, Jarvik Heart; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Guided Delivery Systems, LifeCuff Technologies (formerly IRT)
Garratt	Kirk	Mastering Cath Lab Leadership and Economics in a New Era: A Joint Symposium by the Society of Cardiovascular Angiography and Interventions and the American College of Cardiology	Can the Cath Lab be a Value Proposition?	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation, CELONOVA, Dalichi-Sankyo/Eli Lilly, The Medicines Company, DATA SAFETY MONITORING BOARD - Abbott Laboratories, Jarvik Heart; OWNERSHIP INTEREST/PARTNERSHIP/PRIO(PIAL - Guided Delivery Systems, Lifecuff Technologies (formerly IRT)
Garratt	Kirk	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation, CELONOVA, Dailchi-Sankyo/Eli Lilly, The Medicines Company, DATA SAFETY MONITORING BOARD - Abbott Laboratories, Jarvik Heart; OWNERSHIP INTEREST/PARTNERSHIP/PRIO/PAL - Guided Delivery Systems, Lifecuff Technologies (formerly IRT)
Garratt	Kirk	Interventional Challenging Cases: Team 2	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation, CELONOVA, Dalichi-Sankyo/Eli Lilly, The Medicines Company, DATA SAFETY MONITORING BOARD - Abbott Laboratories, Jarvik Heart; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Guided Delivery Systems, LifeCuff Technologies (formerly IRT)
Garry	Daniel	12. Heart Failure and Cardiomyopathies: Basic Team 1	Suggested Reviewer	Nothing to Disclose
Garshick	Michael	Novel Echocardiographic Methods for	Use of Diastolic Parameters on Transthoracic Echocardiogram to	Nothing to Disclose
		Assessing Cardiac Function	Predict Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation	

Congress of the same				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Garza	Dahlia	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Treatment With Patiromer Decreases Aldosterone in Patients With Heart Failure, Chronic Kidney Disease, and Hyperkalemia on RAAS Inhibitors	Nothing to Disclose
Garzillo	Cibele	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	High Non-High-Density Lipoprotein Cholesterol Levels Predict Enhanced Periprocedural Inflammatory Response Following Percutaneous Coronary Intervention in Stable Ischemic Heart Disease Patients	Nothing to Disclose
Gass	Alan	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Pneumopericardium: A Rare Presentation of Gastro-Pericardial Fistula	Nothing to Disclose
Gass	Alan	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Combined Heart-Kidney Transplantation in a Patient With Human Immunodeficiency Virus	Nothing to Disclose
Gass	Alan	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Arrhythmias in Hospitalized Heart Transplanted Patients: A United States National Study	Nothing to Disclose
Gass	Alan	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Chagas Heart Disease: A United States National Study	Nothing to Disclose
Gass	Alan	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Spontaneous Coronary Artery Dissection in a Transplanted Heart	Nothing to Disclose
Gates	Linda	Core Curriculum: Special Topic: Practical Tips: Changes in Healthcare Affecting My Practice	Practical Tips: Documenting/Coding with MACRA	Nothing to Disclose
Gati	Sabiha	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Myocardial Fibrosis & Ventricular Arrhythmias in Athletes	Nothing to Disclose
Gati	Sabiha	Hearts and Soles: Multimodality Imaging in Athletes	The Mixed Race Athlete's ECG: Not So Black and White	Nothing to Disclose
Gatto	Maria Chiara	Improving Outcomes in the Athlete With Cardiovascular Disease	EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students	Nothing to Disclose
Gaudet	Daniel	Harnessing the Power of Genetics to Prevent ASCVD	Genetic Insights into Triglyceride Related Risk and Treatment	CONSULTANT FEES/HONORARIA - Aegerion, Akcea, Amgen, Chiesi, Cymabay, Ionis, Regeneron, Sanofi- Aventis, Uniqure; RESEARCH/RESEARCH GRANTS - Akcea, Amgen, Astra Zeneca, CCRN, Cerenis, Chiesi, Cymabay, DalCor Pharma, Esperion, Gemphire, GSK, Ionis Pharmaceuticals, Pfizer, Regeneron, Sanofi-Aventis
Gaudet	Daniel	Are We There Yet? Update on Trials Testing New Therapeutics for Prevention of ASCVD	Panelist	CONSULTANT FEES/HONORARIA - Aegerion, Akcea, Amgen, Chiesi, Cymabay, Ionis, Regeneron, Sanofi- Aventis, Linquer; RESEARCH/RESEARCH GRANTS - Akcea, Amgen, Astra Zeneca, CCRN, Cerenis, Chiesi, Cymabay, DalCor Pharma, Esperion, Gemphire, GSK, Ionis Pharmaceuticals, Pfizer, Regeneron, Sanofi-Aventis
Gaudet	Daniel	Are We There Yet? Update on Trials Testing New Therapeutics for Prevention of ASCVD	Antisense Therapeutics - Make Sense or Nonsense?	CONSULTANT FEES/HONORARIA - Aegerion Akcea Amgen, Chiesi, Cymabay, Ionis, Regeneron, Sanofi- Aventis, Uniqure; RESEARCH/RESEARCH GRANTS - Akcea, Amgen, Astra Zeneca, CCRN, Cerenis, Chiesi, Cymabay, DalCor Pharma, Esperion, Gemphire, GSK, Ionis Pharmaceuticals, Pfizer, Regeneron, Sanofi-Aventis
Gaudian	Katie	Interdisciplinary Cardiovascular Team Care Delivery: Quality, Safety, and Satisfaction	See You in 7: An Advanced Practice Provider Post PCI Clinic Improving Transition of Care	Nothing to Disclose
Gaur	Sara	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Fractional Flow Reserve Is a Sensitive but Not a Specific Detector of a High Risk Plaques	Nothing to Disclose
Gaur	Sara	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Can Necrotic Core Volume Explain Ischemia Coronary Stenosis Mismatch in Some Cases?	Nothing to Disclose
Gautam	Sandeep	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Sarcoidosis Presenting as Complete Heart Block in a Young Morbidly Obese Patient With Severe Obstructive Sleep Apnea and on Beta Blocker	Nothing to Disclose
Gautam	Sandeep	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Pseudohypotension Due to Bilateral Subclavian Artery Stenosis	Nothing to Disclose
Gauvreau	Kimberlee	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Aortic Valve Repair in the Pediatric Population: Midterm Outcomes Comparing Leaflet Repair Using Autologous Pericardium Versus Porcine Intestinal Submucosa (CorMatrix ^{®:})	Nothing to Disclose
Gauvreau	Kimberlee	Congenital Heart Disease: Progress in Pediatric Heart Surgery	A Red Cell Preservation Strategy Reduces Postoperative Transfusions in Pediatric Heart Surgery Patients	Nothing to Disclose
Gauvreau	Kimberlee	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Validation of Technical Performance Score for Long-Term Outcomes in Congenital Heart Surgery: 10 Year Follow-Up Data	Nothing to Disclose
Gauvreau	Kimberlee	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Prediction Tool for Congenital Heart Surgery Length of Stay	Nothing to Disclose
Gauvreau	Kimberlee	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Technical Performance Score Can Predict Post-Discharge Reinterventions in Partial and Transitional Atrioventricular Septal Defect Repair	Nothing to Disclose
Gauvreau	Kimberlee	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Residual Atrioventricular Valve Regurgitation Pre-Discharge Is Associated With Post-Discharge Reinterventions Following Complete Atrio Ventricular Septal Defect Repair	Nothing to Disclose
Gavin	Michael	Unusual Presentations of ACS	Survival of Patients Referred for Emergent Cardiac Catheterization for ST-Elevation Myocardial Infarction Without Culprit Lesions	SALARY - Best Doctors
Gaynor	J. William	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Characteristics, Risk Factors and Outcomes of Extracorporeal Membrane Oxygenation Use in the Pediatric Cardiac Intensive Care Unit	Nothing to Disclose
Gaziano	J. Michael	Updates on Risk Factors for Cardiovascular Disease	Walking Pace Is Inversely Associated With Risk of Death and Cardiovascular Disease: The Physicians' Health Study	CONSULTANT FEES/HONORARIA - Bayer; RESEARCH/RESEARCH GRANTS - Amarin, Pfizer
Gaziano	J. Michael	Predicting the Future: Observations and Discoveries From Registries and Databases	Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study	CONSULTANT FEES/HONORARIA - Bayer; RESEARCH/RESEARCH GRANTS - Amarin,Pfizer
Gaziano	J. Michael	Emerging Developments in HFpEF and Arryhthmias	Serum Sodium Is Associated With Mortality in Heart Failure With Preserved Ejection Fraction in the U.S. Veteran Population	CONSULTANT FEES/HONORARIA - Bayer; RESEARCH/RESEARCH GRANTS - Amarin, Pfizer
Gaziano	Thomas	Diabetes, Hyperlipidemia, and Coronary Artery Disease, Prevention and Treatment: International Perspectives From the Japanese College of Cardiology, Saudi Heart Association, and American College of Cardiology	A Global Perspective on Managing Diabetics With Coronary Artery Disease	OTHER - AstraZeneca Pharmaceuticals
Gaziano	Thomas	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Management of Cardiovascular Disease in Sub-Saharan Africa: Data From the HAALSI (Health and Aging in Africa: Longitudinal Studies of INDEPTH Communities) Study	OTHER - AstraZeneca Pharmaceuticals
Ge	Junbo	New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology	Co-Chair	RESEARCH/RESEARCH GRANTS - Research grants



Last Name Ge	First Name Junbo	Session Title New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of	Presentation Title Introduction to Session	Disclosures RESEARCH/RESEARCH GRANTS - Research grants
Ge	Junbo	Cardiology Biomarkers and Targets for Ischemic Heart Disease	Mir-499 Protects the Rat Heart Against Ischemia/Reperfusion Injury Through Pdcd4 During Ischemic Postconditioning-Regulated	Nothing to Disclose
Ge	Junbo	Coronary Angiography, Intra-Vascular Imaging,	Invasive Management Strategies and Anti-Thrombotic Treatments in	RESEARCH/RESEARCH GRANTS - Research grants
Ge	Junbo	Revascularization and Outcomes 20. Interventional Cardiology: Coronary	Patients With NSTE-ACS in China Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Research grants
Geft	Dael	Intervention: CTO Team 1 Non Invasive Imaging: Applications in Novel	Angiographic Dye Prior to Combined Heart-Kidney Donation Does	Nothing to Disclose
Gehi	Anil	Disease States and Clinical Scenarios Innovative Approaches for Reducing Risk and	Not Appear to Harm Donor Kidney Function After Transplant Estimating Cancer Risk Associated With Ionizing Radiation	CONSULTANT FEES/HONORARIA - Biotronik,St. Jude
Gelb	Bruce	Improving Outcomes With Ablation Precision Medicine: It's Hot, But What Is It?	Exposure During Atrial Fibrillation Ablation Panelist	Medical,Zoll, Inc OTHER - Correlegan,GeneDx,LabCorp,Prevention Genetics;
Gelb	Bruce	Precision Medicine: It's Hot, But What Is It?	Introduction to Precision Medicine - as it Exists in the Current ERA	RESEARCH/RESEARCH GRANTS - Shire OTHER - Correlegan, GeneDx, LabCorp, Prevention Genetics; RESEARCH/RESEARCH GRANTS - Shire
Gelfand	Joel	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Aortic Vascular Inflammation by 18-FDG PET/CT Associates With High-Risk Coronary Plaques in Young Psoriasis Patients	CONSULTANT FEES/HONORARIA - Online CONSULTANT FEES/HONORARIA - Abbott, Abbott, Amgen, centocor, Merck, Pfizer; RESEARCH/RESEARCH GRANTS - Amgen, Novartis
Gelijns	Annetine	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic Surgical Trials Network	Nothing to Disclose
Geller	Bram	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Trends in Catheter Directed Thrombolysis and Systemic Thrombolysis for Pulmonary Embolism Treatment: 2004-2014	Nothing to Disclose
Geller	Hallie	Advances in HCM, PPCM and Other Cardiomyopathies	Misdiagnosis of Cardiac Amyloidosis Type by Standard Immunohistochemistry	Nothing to Disclose
Geller	Hallie	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Prevalence of Monoclonal Gammopathy of Unknown Significance in Wild Type Transthyretin Amyloidosis Patients	Nothing to Disclose
Gellert	George	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Wild Type Harisinyreum Arrhytoliosis Patients Comparing TEE With Angiographic Sizing of WATCHMAN Device for Left Atrial Appendage Closure	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,MEDTRONIC,Philips healthcare; SPEAKER'S BUREAU - The Medicines Company
Gemignani	Anthony	Highlights in Vascular Medicine Research	Cancer and Arterial Thrombosis Risk: Insights From the 2012 National Inpatient Sample	Nothing to Disclose
Generati	Greta	Emerging Applications of Echocardiography	Functional and Hemodynamic Response During Exercise in Heart Failure Intermediate Versus Reduced Ejection Fraction	Nothing to Disclose
Genereux	Philippe	Great Minds Think Differently: Multidisciplinary Approach to Controversies in Cardiology	Panelist	CONSULTANT FEES/HONORARIA - Boston Scientific, Cardiovascular Solutions Inc., Edwards Lifesciences, MEDTRONIC, Saranas; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - SIG.NUM, SoundBite Medical Solution Inc.; SPEAKER'S BUREAU - Tryton Medical
Genereux	Philippe	TAVR Changing the Paradigm for the Treatment of Valve Disease	Co-Chair	CONSULTANT FEES/HONORARIA - Boston Scientific, Cardiovascular Solutions Inc., Edwards Lifesciences, MEDTRONIC, Saranas; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - SIG, NUM, SoundBite Medical Solution Inc.; SPEAKER'S BUREAU - Tryton Medical
Genereux	Philippe	TAVR Changing the Paradigm for the Treatment of Valve Disease	Asymptomatic Severe Aortic Stenosis: Should They Be Offered TAVR?	CONSULTANT FEES/HONORARIA - Boston Scientific,Cardiovascular Solutions Inc.,Edwards Lifesciences,MEDTRONIC,Saranas; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - SIG,NUM,SoundBite Medical Solution Inc.; SPEAKER'S BUREAU - Tryton Medical
Genereux	Philippe	Complex PCI in 2017	Panelist	CONSULTANT FEES/HONORARIA - Boston Scientific, Cardiovascular Solutions Inc., Edwards Lifesciences, MEDTRONIc, Saranas; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - SIG, NUM, SoundBite Medical Solution Inc.; SPEAKER'S BUREAU - Tryton Medical
Genereux	Philippe	Aortic Stenosis: Overview of the Hemodynamics and Ventricular Response	Asymptomatic Aortic Stenosis: Is Watchful Waiting the Answer?	CONSULTANT FEES/HONORARIA - Boston Scientific, Cardiovascular Soulitons Inc., Edwards Lifesciences, MEDTRONIC, Saranas; OWNERSHIP INTEREST/PARTNESHIP/PIRIOIPAL - SIG NUM, SoundBite Medical Solution Inc.; SPEAKER'S BUREAU - Tryton Medical
Genereux	Philippe	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Differences and Level of Agreement in SYNTAX Score Assessment Between Site Operators and Angiographic Core Laboratory Readers: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - Boston Scientific, Cardiovascular Solutions Inc., Edwards Lifesciences, MEDTRONIC, Saranas; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - SIG, NIM, SoundBite Medical Solution Inc.; SPEAKER'S BUREAU - Tryton Medical
Genereux	Philippe	Interventional Cardiology: TAVR 4	Serum Albumin as an Incremental Predictor of Mortality in Older Adults Undergoing Transcatheter Aorit Valve Replacement: Results From the Multicenter Frailty-AVR Study	CONSULTANT FEES/HONORARIA - Boston Scientific, Cardiovascular Soultions Inc., Edwards Lifesciences, MEDTRONIC, Saranas; OWNERSHIP INTEREST/PARTNERSHIP/PRIOIPAL - SIG, NUM, SoundBite Medical Solution Inc.; SPEAKER'S BUREAU - Tryton Medical
Genereux	Philippe	Refining PCI Technique and Outcomes	Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory Assessment: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - Boston Scientific, Cardiovascular Solutions Inc., Edwards Lifesciences, MEDTRONIC, Saranas; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - SIG NUM, SoundBite Medical Solution Inc.; SPEAKER'S BUREAU - Tryton Medical
Geng	Yong-Jian	Mechanisms of Vascular Inflammation in Atherogenesis	Baculoviruses-Mediated Superoxide Dismutase Gene Therapy Inhibits Smooth Muscle Cell Proliferation, Migration, Inflammation, and Reactive Oxygen Species in Balloon-Injured Arteries	Nothing to Disclose
Gentry	James	Imaging the Athlete's Heart	Pooled Cohort Equation and Coronary Artery Calcium in Retired National Football League Athletes	Nothing to Disclose
Gentry	James	Hearts and Soles: Multimodality Imaging in Athletes	Ascending Aortic Dimensions in Former National Football League Athletes	Nothing to Disclose
Georgakopoulos	Alexandros	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Association of Abdominal Aortic Wall Inflammation, Hepatic Fluorodeoxyglucose Uptake AND Visceral Adipose Tissue Biological Activity in Patients With Dyslipidemias	Nothing to Disclose
Georgakopoulos	Alexandros	Nuclear Cardiology: Beyond Perfusion	Increased Subclinical Systemic AND Vascular Inflammation in Familial Combined Hyperlipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission Tomography Study	Nothing to Disclose
Georgakopoulos	Alexandros	Nuclear Cardiology: Beyond Perfusion	In Vivo Correlation of Carotid Temperatures and Pet/Fdg Uptake in Patients Undergoing Carotid Endarterectomy: Validation With Histology	Nothing to Disclose
Georgakopoulos	Alexandros	Cutting Edge Vascular Medicine	Familial Combined Hyperlipidemia Is Characterized by Higher Arterial AND Hepatic Fluorodeoxyglucose Uptake Compared to Heterozygous Familial Hypercholesterolemia	Nothing to Disclose
George	Augustine	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	An Interesting Case of Cor Triatriatum Dexter Facilitating Paradoxical Embolism and Ischemic Stroke	OTHER - Biotronik Inc., Cardiovascular Systems Inc.
George	Barbara	Innovations in Advocacy and Patient Centered Care	Patient Perceptions on the Impact of Caffeine Consumption After a Myocardial Infarction or Percutaneous Coronary Intervention	Nothing to Disclose



Last Name George	First Name Bennet	Session Title Population Specific Cardiomyopathies: From	Presentation Title Racial Differences in Heart Failure Admissions & Outcomes	Disclosures Nothing to Disclose
George		Exomes to Databases	Among Patients With HIV	· ·
George	Isaac	Frontier in New Transcatheter Techniques	Devices in Trials in the US: The Lotus, Directflow, Portico TAVR Valves	CONSULTANT FEES/HONORARIA - Bolton Medical,Edwards Lifesciences,MEDTRONIC; DATA SAFETY MONITORING BOARD - Tendyne Medical; OTHER - Direct Flow Medical
George	Isaac	TAVR for Degenerated Surgical Valves: What You Need to Know from A to Z	TAVR in Prior Surgical Mitral Valve Ring	CONSULTANT FEES/HONORARIA - Bolton Medical Edwards Lifesciences, MEDTRONIC; DATA SAFETY MONITORING BOARD - Tendyne Medical; OTHER - Direct Flow Medical
George	Isaac	Transcatheter Mitral Valve Replacement	Review of TAVR Valves in Mitral Rings and Valves	CONSULTANT FEES/HONORARIA - Bolton Medical,Edwards Lifesciences,MEDTRONIC; DATA SAFETY MONITORING
George	Isaac	Interventional Cardiology: PCI and TAVR in Complex Patients	Refining the Classification of Severe, Symptomatic Aortic Stenosis Using Flow and Gradient Measurements to Predict Outcomes Post-	BOARD - Tendyne Medical; OTHER - Direct Flow Medical CONSULTANT FEES/HONORARIA - Bolton Medical,Edwards Lifesciences,MEDTRONIC; DATA SAFETY MONITORING
George	Isaac	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Replacement Initial Use of the Evolut Pro Self-Expanding Transcatheter Aortic Valve <i></i>	BOARD - Tendyne Medical; OTHER - Direct Flow Medical CONSULTANT FEES/HONORARIA - Bolton Medical,Edwards Lifesciences,MEDTRONIC; DATA SAFETY MONITORING
George	Isaac	TAVR Outcomes Prognostication	High Baseline Valvuloarterial Impedence Predicts Worse 1-Year Outcomes After Transcatheter Aortic Valve Replacement	BOARD - Tendyne Medical; OTHER - Direct Flow Medical CONSULTANT FEES/HONORARIA - Bolton Medical, Edwards Lifesciences, MEDTRONIC; DATA SAFETY MONITORING
George	Isaac	Prosthetic Valve Thrombosis: TAVR, Bio, Mech Now What?!	ACC Poster Moderator	BOARD - Tendyne Medical; OTHER - Direct Flow Medical CONSULTANT FEES/HONORARIA - Bolton Medical, Edwards Lifesciences, MEDTRONIC; DATA SAFETY MONITORING
George	Jon	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula	BOARD - Tendyne Medical; OTHER - Direct Flow Medical CONSULTANT FEES/HONORARIA - Abbott Laboratories, Abiomed Avinger, Boston
Georgekutty	Justin	Disease, and Vascular Medicine Redefining the "F" Word	Use of Novel Oral Anticoagulants in Adult Fontan Patients	Scientific,Cook,CSI,Gore,Spectranetics,Volcano Nothing to Disclose
Georgiopoulos	Georgios	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Omega-3 Polyunsaturated Fatty Acids May Favorably Affect Inflammatory Biomarkers & Novel Indices of Left Ventricle Function in Patients With Heart Failure	Nothing to Disclose
Georgiopoulos	Georgios	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Insights on Diastolic Dysfunction of Treated Hypertensive Patients: Focusing on Hypertension Control & Treatment Resistance	Nothing to Disclose
Georgiopoulou	Vasiliki	Advances in HCM, PPCM and Other Cardiomyopathies	Living in a Food Desert Is Associated With an Early Hazard of Death and Hospitalization in Heart Failure Patients	-
Gepner	Adam	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Total Testosterone With Progression of Carotid Atherosclerosis and Coronary Artery Calcium Score: The Multi- Ethnic Study of Atherosclerosis	Nothing to Disclose
Gerardin	Jennifer Jennifer	Redefining the "F" Word	Biomarker Profile in Adults With Fontan Circulation	Nothing to Disclose Nothing to Disclose
Gerardin Gerardin	Jennifer	Redefining the "F" Word Congenital Heart Disease: To the Third	Adults With Congenital Heart Disease: Lost in Care Red Blood Cell Distribution Width and Outcomes in Fontan Patients	Nothing to Disclose Nothing to Disclose
Gerardo	García-Rivas	Decade and Beyond Diabetes and Endothelial Dysfucntion in Heart	Interleukin 18 Impairs Excitation Contraction Coupling in	Nothing to Disclose
		Failure	Cardiomyocytes and Predicts Mortality in Acute Decompensated Heart Failure	-
Gerckens	Ulrich	Interventional Cardiology: TAVR 3	Does Balloon Predilatation Influence Outcome With the Lotus Valve: 30-Day Results From the RESPOND Study	CONSULTANT FEES/HONORARIA - Boston Scientific; OTHER Medtronic CoreValve
Gerdts	Eva	Aortic Stenosis: Overview of the Hemodynamics and Ventricular Response	Genetics and Biology of Aortic Stenosis	CONSULTANT FEES/HONORARIA - Merck Shering Plough
Gerhard-Herman	Marie	Highlighted Original Research: Vascular Medicine and the Year in Review	A Critical Evaluation of Exercise Testing in Diagnosing Peripheral Artery Disease	Nothing to Disclose
Gerhard-Herman	Marie	Improving Risk Assessment in Atherosclerosis	ACC Poster Moderator	Nothing to Disclose
Gerhard-Herman	Marie	40. Vascular Medicine: Non Coronary Arterial Disease Team 2	Suggested Reviewer	Nothing to Disclose
Germain	Guillaume	Making Progress in Understanding Heart	Incremental Risk of Ischemic Stroke Over Time in Newly Diagnosed	RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals
Germain	Guillaume	Failure Antithrombotic Therapy in Ischemic Heart Disease	Heart Failure Patients Without Atrial Fibrillation Rivaroxaban Users Have Significantly Less Treatment Discontinuation Compared With Users of Other Oral Anticoagulants	RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals Inc
Germano	Guido	Nuclear Cardiology: Quality	in Non-Valvular Atrial Fibrillation Rest Scan Does Not Improve Automatic Machine Learning Prediction of Major Adverse Coronary Events After High Speed	OTHER - Cedars-Sinai Medical Center
Germano	0	Nuclear Cardiology: Coronary Flow	Myocardial Perfusion Imaging Patient Motion Significantly Affects Measurements of Quantitative	OTHER - Cedars-Sinai Medical Center
	Guido	,	Global Regional Myocardial Blood Flow Assessment by Dynamic Pet	
Gersh	Bernard	Interventional Live Case Session II: CTO Transmission from Mid-America Heart Institute (Kansas City, Missouri)	Panelist	CONSULTANT FEES/HONORARIA - Xenon Pharmaceuticals; DATA SAFETY MONITORING BOARD - Armetheon Inc, Baxter Helathcare Corporation, CardioVascular Research Foundation, Janssen Research & Amp, amp; Development, MEDTRONIC, Mount Sinai St. Lukes, Teva Pharmaceuticals, Thrombosis Research Institute; OTHER - Boston Scientific, Cipla Limited, Janssen Scientific Affairs LLC, St. Jude Medical, Inc.
Gersh	Bernard	TAVR Changing the Paradigm for the Treatment of Valve Disease	We Are Not Ready for TAVR Yet in Low Risk Because There is No Long-term Data	CONSULTANT FEES/HONORARIA - Xenon Pharmaceuticals; DATA SAFETY MONITORING BOARD - Armetheon Inc, Baxter Helathcare Corporation, CardioVascular Research Foundation, Janssen Research & amp;amp; Development, MEDTRONIC, Mount Sinai St. Lukes, Teva Pharmaceuticals, Thrombosis Research Institute; OTHER - Boston Scientific, Cipla Limited, Janssen Scientific Affairs LLC, St. Jude Medical, Inc.
Gersh	Bernard	Atrial Fibrillation in Young and Unusual Populations: Children and Adult Congenital Heart Disease	Panelist	CONSULTANT FEES/HONORARIA - Xenon Pharmaceuticals; DATA SAFETY MONITORING BOARD - Armetheon Inc, Baxter Helathcare Corporation, CardioVascular Research Foundation, Janssen Research & amp; amp; Development, MEDTRONIC, Mount Sinai St. Lukes, Teva Pharmaceuticals, Thrombosis Research Institute; OTHER - Boston Scientific, Cipla Limited, Janssen Scientific Affairs LLC, St. Jude Medical, Inc.
Gersh	Bernard	Atrial Fibrillation in Young and Unusual Populations: Children and Adult Congenital Heart Disease	Morbidity, Mortality and Treatment of Atrial Fibrillation in Hypertrophic Cardiomyopathy	CONSULTANT FEES/HONORARIA - Xenon Pharmaceuticals; DATA SAFETY MONITORING BOARD - Armetheon Inc, Baxter Helathcare Corporation, CardioVascular Research Foundation, Janssen Research & amp; amp; Development, MEDTRONIC, Mount Sinai St. Lukes, Teva Pharmaceuticals, Thrombosis Research Institute; OTHER - Boston Scientific, Cipla Limited, Janssen Scientific Affairs LLC,St. Jude Medical, Inc.

				<u> </u>
Last Name	First Name	Session Title	Presentation Title	Disclosures
Gersh	Bernard	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Utility of Cardiac Computed Tomography Scanning in the Diagnosis and Pre-Operative Evaluation of Patients With Infective Endocarditis	CONSULTANT FEES/HONORARIA - Xenon Pharmaceuticals; DATA SAFETY MONITORING BOARD - Armetheon Inc,Baxter Helathcare Corporation,CardioVascular Research Foundation,Janssen Research & amp,amp; Development,MEDTRONIC,Mount Sinai St. Lukes,Teva Pharmaceuticals,Thrombosis Research Institute; OTHER - Boston Scientific,Cipla Limited,Janssen Scientific Affairs LLC,St.
Gersh	Bernard	Arrhythmias and Clinical EP: Anticoagulation Issues	Use of Interacting Drugs Did Not Modify Treatment Effects of Apixaban Versus Warfarin for Atrial Fibrillation: Results From the ARISTOTLE Trial	Jude Medical, Inc. CONSULTANT FEES/HONORARIA - Xenon Pharmaceuticals; DATA SAFETY MONITORING BOARD - Armetheon Inc, Baxter Helathcare Corporation, CardioVascular Research Foundation, Janssen Research & Ampn, amp; Development, MEDTRONIC, Mount Sinal St. Lukes, Teva Pharmaceuticals, Thrombosis Research Institute; OTHER - Boston Scientific, Cipila Limited, Janssen Scientific Affairs LLC, St. Jude Medical, Inc.
Gersh	Bernard	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Does Frailty Alter the Benefits of Oral Anticoagulation in Patients With Atrial Fibrillation?	CONSULTANT FEES/HONORARIA - Xenon Pharmaceuticals; DATA SAFETY MONITORING BOARD - Armetheon Inc, Baxter Helathcare Corporation, CardioVascular Research Foundation, Janssen Research & amp, amp; Development.MEDTRONIC.Mount Sinai St. Lukes, Teva Pharmaceuticals , Thrombosis Research Institute; OTHER - Boston Scientific, Cipia Limited, Janssen Scientific Affairs LLC, St. Jude Medical, Inc.
Gersh	Bernard	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Aortic Stenosis, but Not Mitral or Aortic Regurgitation, is Associated With Adverse Outcomes With Atrial Fibrillation: Results From the ARISTOTLE Trial	CONSULTANT FEES/HONORARIA - Xenon Pharmaceuticals; DATA SAFETY MONITORING BOARD - Armetheon Inc, Baxter Helathcare Corporation, CardioVascular Research Foundation, Janssen Research & amp, amp; Development, MEDTRONIC, Mount Sinai St. Lukes, Teva Pharmaceuticals, Thrombosis Research Institute; OTHER - Boston Scientific, Cipila Limited, Janssen Scientific Affairs LLC, St. Jude Medical, Inc.
Gersh	Bernard	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin	CONSULTANT FEES/HONORARIA - Xenon Pharmaceuticals; DATA SAFETY MONITORING DARD - Armetheon Inc, Baxter Helathcare Corporation, Cardio/Vascular Research Foundation, Janssen Research & amp,amp; Development, MEDTRONIC, Mount Sinal St. Lukes, Teva Pharmaceuticals, Thrombosis Research Institute; OTHER - Boston Scientific, Cipila Limited, Janssen Scientific Affairs LLC, St. Jude Medical, Inc.
Gersh	Bernard	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)	CONSULTANT FEES/HONORARIA - Xenon Pharmaceuticals; DATA SAFETY MONITORING BOARD - Armetheon Inc, Baxter Helathcare Corporation, Cardio/Vascular Research Foundation, Janssen Research & amp, amp; Development, MEDTRONIC, Mount Sinal St. Lukes, Teva Pharmaceuticals, Thrombosis Research Institute; OTHER - Boston Scientific, Cipila Limited, Janssen Scientific Affairs LLC, St. Jude Medical, Inc.
Gersh	Bernard	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	CHA2DS2-VASc Score Predicts Incident Atrial Fibrillation/Flutter in a Referral Population	CONSULTANT FEES/HONORARIA - Xenon Pharmaceuticals; DATA SAFETY MONITORING BOARD - Armetheon Inc, Baxter Helathcare Corporation, CardioVascular Research Foundation, Janssen Research & amp, amp; Development. MEDTRONIC. Mount Sinai St. Lukes, Teva Pharmaceuticals , Thrombosis Research Institute; OTHER - Boston Scientific, Cipia Limited, Janssen Scientific Affairs LLC, St. Jude Medical, Inc.
Gershlick	Anthony	Interventional Live Case Session IV: Complex Coronary Transmission from St. Vincent Hospital (Indianapolis, IN)	Panelist	CONSULTANT FEES/HONORARIA - Abbott,Astra Zenica,Boehringer Ingleheim,Boston Scientific,Cordis,Eli Lilly,MEDTRONIC
Gershlick	Anthony	Controversies in ACS Guidelines	Management of Non Culprit Artery in STEMI: PCI at the Time of Primary PCI is the Most Efficient Way to go!	CONSULTANT FEES/HONORARIA - Abbott,Astra Zenica,Boehringer Ingleheim,Boston Scientific,Cordis,Eli Lilly,MEDTRONIC
Gershlick	Anthony	What's New in the World of STEMI?	Debate: Pro for Complete Revasc	CÓNSULTANT FEES/HONORARIA - Abbott,Astra Zenica,Boehringer Ingleheim,Boston Scientific,Cordis,Eli Lilly,MEDTRONIC
Gershlick	Anthony	Highlighted Original Research: Interventional Cardiology and the Year in Review	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	CÓNSULTANT FEES/HONORARIA - Abbott,Astra Zenica,Boehringer Ingleheim,Boston Scientific,Cordis,Eli Lilly,MEDTRONIC
Gershlick	Anthony	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Differences and Level of Agreement in SYNTAX Score Assessment Between Site Operators and Angiographic Core Laboratory Readers: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - Abbott,Astra Zenica,Boehringer Ingleheim,Boston Scientific,Cordis,Eli Lilly,MEDTRONIC
Gershlick	Anthony	Interventional Cardiology: PCI in Complex Patients	Development of a Novel Side-Branch Stent: In-Vitro Study	CÓNSULTANT FEES/HONORARIA - Abbott,Astra Zenica,Boehringer Ingleheim,Boston Scientific,Cordis,Eli Lilly,MEDTRONIC
Gershlick	Anthony	Refining PCI Technique and Outcomes	Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory Assessment: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - Abbott,Astra Zenica,Boehringer Ingleheim,Boston Scientific,Cordis,Eli Lilly,MEDTRONIC
Gerstenfeld	Edward	Late-Breaking Clinical Trials	Safety and Efficacy of Uninterrupted Anticoagulation With Dabigatran Etexilate Versus Warfarin in Patients Undergoing Catheter Ablation of Atrial Fibrillation: The RE-CIRCUIT Study	CONSULTANT FEES/HONORARIA - Biosense- Webster, Boehringer-Ingelheim, MEDTRONIC, St Jude Medical; RESEARCH/RESEARCH GRANTS - Biosense- Webster, MEDTRONIC, St Jude Medical
Gerstenfeld	Edward	The Story of the Adult Congenital Heart Disease Patient and EP	Prevalence and Predictors of Atrial Tachyarrhythmias in Adult Fontan Patients	CONSULTANT FEES/HONORARIA - Biosense- Webster, Boehringer-Ingelheim, MEDTRONIC, St Jude Medical; RESEARCH/RESEARCH GRANTS - Biosense- Webster, MEDTRONIC, St Jude Medical
Gerstenfeld	Edward	Redefining the "F" Word	Prevalence and Predictors of Pacemaker Placement in Adult Fontan Patients	CONSULTANT FEES/HONORARIA - Biosense- Webster, Boehringer-Ingelheim, MEDTRONIC, St Jude Medical; RESEARCH/RESEARCH GRANTS - Biosense- Webster, MEDTRONIC, St Jude Medical
Gerszten	Robert	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Changes in Citric Acid Metabolism Are Associated With the Development of Anthracycline-Induced Cardiotoxicity in Mice and in Patients	Nothing to Disclose
Gerszten	Robert	Advances in HCM, PPCM and Other	Diagnostic Value of Metabolite Profiling in Hypertrophic	Nothing to Disclose
Gertner	Michael	Cardiomyopathies Interventional Cardiology: Translation and Pre-	Cardiomyopathy Deliverability and Safety of a Novel Non-Invasive, Ultrasound-Based	Nothing to Disclose
Gertz	Morie	Clinical Research Advances in HCM, PPCM and Other	Renal Nerve Ablation System in a Large Preclinical Model via Histopathological Evaluation NEOD001 Demonstrates Cardiac Biomarker Responses in Patients	CONSULTANT FEES/HONORARIA - Celgene, Millenium
		Cardiomyopathies	With Light Chain Amyloidosis: Results From the Phase 1/2 Study	-
Gertz	Zachary	Interventional Cardiology: TAVR 1	Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: Insights From PARTNER 2A Trial	SPEAKER'S BUREAU - Edwards Lifesciences

Contract of the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Gertz	Zachary	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low- Flow Severe Aortic Stenosis and Less Reverse Remodeling After TAVR: A Partner 2 Trial Analysis	SPEAKER'S BUREAU - Edwards Lifesciences
Gertz	Zachary	24. Interventional Cardiology: Mitral and Structural Heart Disease Team 2	Suggested Reviewer	SPEAKER'S BUREAU - Edwards Lifesciences
Gervacio	Giselle	New Strategies in Arrhythmias Management:	SUDS/Brugada Syndrome in the General Population in the	Nothing to Disclose
		International Perspectives From the Philippine Heart Association, Russian Society of Cardiology, and American College of Cardiology	Philippines	
Geske	Jeffrey	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Tracing the Cause of Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia	CONSULTANT FEES/HONORARIA - MyoKardia, Inc
Geske	Jeffrey	FIT Clinical Decision Making: Valvular Heart Disease and Pericardial Disease	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - MyoKardia, Inc
Geske	Jeffrey	FIT Clinical Decision Making Reviewers 2	ACC FIT Clinical Decision Making Reviewer	CONSULTANT FEES/HONORARIA - MyoKardia, Inc
Geva Geva	Tal Tal	Precision Medicine: It's Hot, But What Is It? Highlighted Original Research: Congenital	Co-Chair Aortic Valve Repair in the Pediatric Population: Midterm Outcomes	Nothing to Disclose Nothing to Disclose
		Heart Disease and the Year in Review	Comparing Leaflet Repair Using Autologous Pericardium Versus Porcine Intestinal Submucosa (CorMatrix [®])	-
Ghadri	Jelena	Risky Business: Predicting Outcomes in Heart Failure	A Novel Clinical Score (InterTAK Score) to Distinguish Takotsubo Syndrome From Acute Coronary Syndrome	Nothing to Disclose
Ghahramani	Mehrdad	Emerging Applications of Echocardiography	HEART Score Classification and Predictive Accuracy of Stress Echocardiography in a Contemporary ED Observation Unit Cohort	Nothing to Disclose
Ghahramani	Mehrdad	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Hydroxychloroquine Overdose Presenting as Acquired QT Interval Prolongation and Torsade de Pointes	Nothing to Disclose
Ghahramani	Mehrdad	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		Nothing to Disclose
Ghahramani	Mehrdad	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		Nothing to Disclose
Ghannam	Michael	FIT Clinical Decision Making: Arrhythmias and	Risk Stratification of Sudden Cardiac Death in Hypertrophic	Nothing to Disclose
Gharib	Wissam	PCI for NSTEMI and Complex Patients With	Cardiomyopathy The Feasibility and Safety of Same Day Discharge for All Comers	Nothing to Disclose
Gharib	Wissam	Multiple Co-Morbidities Valvular Heart Disease With CKD or Cirrhosis	After Elective Percutaneous Coronary Interventions Trends and Outcomes of Aortic Valve Replacement in Patient With	Nothing to Disclose
			End Stage Renal Disease on Hemodialysis: A 10-Year U.S. Perspective	-
Ghatak	Abhijit	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Comparison of False Versus True ST Elevation Myocardial Infarction Activation Rates in Patients Having Pre-Activation Point of Care Troponin Levels	Nothing to Disclose
Ghatak	Abhijit	Unusual Presentations of ACS	Trends Associated With False ST-Elevation Myocardial Infarction Activation	Nothing to Disclose
Gheorghiade	Mihai	14. Heart Failure and Cardiomyopathies: Therapy Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Bayer Schering Pharma AG, Novartis Pharma AG, Otsuka Pharmaceuticals, Cardiocell, Stealth Peptides, Takeda Pharma
Ghetiya	Shreya	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	'Coughing Up of Lung Tissue': A Rare Case of Plastic Bronchitis	Nothing to Disclose
Ghetiya	Shreya	Novel Developments in Acute Coronary Syndromes	Compliance and Bleeding Using Updated AHA and ACC Heparin Dosing Guidelines for Non-ST Elevation Myocardial Infarction Patients	Nothing to Disclose
Gholitabar	Farid	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Low Socioeconomic Status Is Associated With Increased Inpatient Mortality With Non ST-Elevation Myocardial Infarction: A Nationwide Analysis	Nothing to Disclose
Gholitabar	Farid	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Patients With Non ST-Segment Elevation Myocardial Infarction Utilizing Medicare/Medicaid Have Lower Adjusted Odds of In- Hospital Mortality: A Nationwide Analysis	Nothing to Disclose
Gholitabar	Farid	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Gender on Mortality and Percutaneous Coronary Intervention in Non ST-Segment Elevation Myocardial Infarction: A Nationwide Analysis	Nothing to Disclose
Gholitabar	Farid	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Non ST-Segment Elevation Myocardial Infarction Patient Outcomes in Teaching Hospital: A Nationwide Analysis	Nothing to Disclose
Gholitabar	Farid	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Adjusted Odds of Inpatient Mortality for Non-ST Elevation Myocardial Infarction Is Not Affected by Day of Admission: A Nationwide Analysis	Nothing to Disclose
Gholitabar	Farid	Post-CAD/MI: Making Tough Predictions About the Future	The Burden of Coronary Artery Disease in Those With Human Immunodeficiency Virus as Demonstrated by Need for Percutaneous Coronary Intervention	Nothing to Disclose
Gholkar	Gunjan	Arrhythmias and Clinical EP: Devices 4	Long-Term Use of the Wearable Cardiovertor Defibrillator in ICD	Nothing to Disclose
Ghosh	Pradeepto	Vascular Access and Hemostasis Issues	Explant Patients Mid Femoral Head Is Not the Ideal Fluroscopic Landmark for	Nothing to Disclose
Ghosh	Pradeepto	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Common Femoral Artery Puncture A Rare Case of Chronic Persistent Troponin Elevation	Nothing to Disclose
Ghoshhajra	Brian	Disease, and Vascular Medicine Understanding Spontaneous Coronary Artery Dissection (SCAD): What We Know, What We Don't Know	Making the Diagnosis:What Does it Look Like,What Diagnostic Tests are Best?	CONSULTANT FEES/HONORARIA - MEDTRONIC, Siemens Healthcare
Ghoshhajra	Brian	Highlighted Original Research: Non Invasive Imaging and the Year in Review	The Association of High Risk Plaque Features and Non-Invasive Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography in Patients With Acute Chest Pain: Results From the ROMICAT II Trial	CONSULTANT FEES/HONORARIA - MEDTRONIC, Siemens Healthcare
Ghoshhajra	Brian	Novel Determinants of Outcomes in VHD	Results From the ROMICAT II That Relationship Between Proximal Aorta Morphology and Progression Rate of Aortic Stenosis	CONSULTANT FEES/HONORARIA - MEDTRONIC, Siemens Healthcare
Ghosn	Mohamad	Non Invasive Imaging: MR Characterization	Elevated Myocardial Extracellular Volume Fraction (ECV) and Its	Nothing to Disclose
Ghumman	Saad Sultan	and Function Interventional Complexity and Complications	Prognostic Significance in Diabetic Individuals Use of the RenalGuard System to Prevent Contrast Induced Kidney	Nothing to Disclose
Ghumman	Saad Sultan	Endovascular Therapy: Running From Risk	Injury: A Meta-Analysis Contrast-Induced Nephropathy Following Peripheral Angiography With Carbon Dioxide Versus Iodinated Contrast Media: A Systematic	Nothing to Disclose
Giannakoulas	George	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Review and Meta-Analysis of Current Literature Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Previous Major Gastrointestinal Bleeding: Insight From the Amplatzer Cardiac Plug Multicenter Registry	CONSULTANT FEES/HONORARIA - Actelion, AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc,Eli Lilly and Company, GlaxoSmithKline, Menarini, MSD, Novartis Corporation, Pfizer Inc, Sanofi-Aventis, servier
Giannakoulas	George	Predicting the Future: Observations and Discoveries From Registries and Databases	Left Ventricular Filling Rate Predicts Clinical Failure in Patients With Precapillary Pulmonary Hypertension	CONSULTANT FEES/HONORARIA - Actelion, AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Boehringer ingelheim Pharmaceuticals, Inc, Eli Lilly and Company, CilaxoSmithKline, Menarini, MSD, Novartis Corporation, Pizer Inc, Sanofi-Aventis, servi-
Gianni	Carola	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Left Atrial Appendage Flow Velocity to Predict Persistent Left Atrial Appendage Isolation	Nothing to Disclose
Gianni	Carola	Innovation in Practice Management, Advocacy, and Education	Importance of Twitter During Cardiology Conferences	Nothing to Disclose
L	I	and Education	<u> </u>	l .



Contract of the second					
Last Name Gibbs	First Name Simon	Session Title Demystifying and Managing Pulmonary Hypertension and RV Dysfunction: It Takes a	Presentation Title Panelist	Disclosures Nothing to Disclose	
Gibson	C. Michael	Village Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	A Randomized Trial Evaluating Clinically Significant Bleeding With Low-Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, for Patients After Acute Coronary Syndromes	CONSULTANT FEES/HONORARIA - Bayer Corporation, BCRI, CardioVascular Research and Company, Gilead Sciences, Inc., Jansser Inc., Johnson Carp., Now McNeil, Pfizer, Pharma Mar, Roche Diagnostic. Hospital, St. Jude Medical Corp., The Medicine Company, WebMD; OTHER - UpToDate in C. Medicine; RESEARCH (RESEARCH GRANTS Corporation, Dayer Corporation, CSL Behring Pharmaceuticals, Inc., Johnson & Bamp-amp, J. Pharmaceuticals, St. Jude's Medical, Stealth I	n Pharmaceuticals, to Nordisk Inc.,Ortho s,St. Francis se ardiovascular S - Angel Medical Ilkaria, Inc.,Janssen thnson Corp.,Portola
Gibson	C. Michael	Interrupting DAPT for Surgery, Afib, or Bleeding	Panelist	CONSULTANT FEES/HONORARIA - Bayer Corporation, BCRI, CardioVascular Research and Company, Gilead Sciences, Inc., Jansser Inc., Johnson & Bamp; Johnson Corp., Now McNeil, Pizer, Pharma Mar, Roche Diagnostic: Hospital, St. Jude Medical Corp., The Medicine Company, WebMD; O'THER - UpToDate in C. Medicine; RESEARCH/RESEARCH GRANTS Corporation, Bayer Corporation, CSL Behring Pharmaceuticals, Inc., Johnson & Bamp; amp; Johnsmaceuticals, Inc., Johnson & Bamp; amp; Johnsmaceuticals, St. Jude's Medical , Stealth I	n Pharmaceuticals, to Nordisk Inc.,Ortho s,St. Francis ses ardiovascular S - Angel Medical Ilkaria, Inc.,Janssen ohnson Corp.,Portola
Gibson	C. Michael	Interrupting DAPT for Surgery, Afib, or Bleeding	Atrial Fib	CONSULTANT FEES/HONORARIA - Bayer Corporation, BCRI, Cardio/Vascular Research and Company, Gilead Sciences, Inc., Jansser Inc., Johnson & Bamp; Johnson Corp., Now McNeil, Pitzer, Pharma Mar, Roche Diagnostic Hospital, St. Jude Medical Corp., The Medicine Company, WebMD; O'THER - UpToDate in C. Medicine; RESEARCH/RESEARCH GRANTS Corporation, Bayer Corporation, CSL Behring Pharmaceuticals, Inc., Johnson & Bamp; amp; Johnsmaceuticals, Inc., Johnson & Bamp; amp; Johnsmaceuticals, St. Jude's Medical , Stealth I	n Pharmaceuticals, to Nordisk Inc.,Ortho s,St. Francis ardiovascular S - Angel Medical Ilkaria, Inc.,Janssen bhnson Corp.,Portola
Gibson	C. Michael	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of Periprocedural Myocardial Infarction in Contemporary PCI: Pooled Patient-Level Data From the CHAMPION Trials	CONSULTANT FEES/HONORARIA - Bayer Corporation, BCRI, Cardio/Vascular Research and Company, Gilead Sciences, Inc., Jansser Inc., Johnson & Bamp; Johnson Corp., Now McNeil, Pizer, Pharma Mar, Roche Diagnostic Hospital, St. Jude Medical Corp., The Medicine Company, WebMD; O'THER - UpToDate in C. Medicine; RESEARCH/RESEARCH GRANTS Corporation, Bayer Corporation, CSL Behring Pharmaceuticals, Inc., Johnson & Bamp; amp; Johnsmaceuticals, Inc., Johnson & Bamp; amp; Johnsmaceuticals, St. Jude's Medical , Stealth f	n Pharmaceuticals, to Nordisk Inc.,Ortho s,St. Francis ses ardiovascular S - Angel Medical lkaria, Inc.,Janssen ohnson Corp.,Portola
Gibson	C. Michael	Diabetes and Other Issues in Cardiovascular Prevention	Extended Duration Betrixaban Reduces the Risk of Venous Thromboembolism Versus Standard Duration Enoxaparin in the Post Parenteral Period Among Hospitalized Medically III Patients	CONSULTANT FEES/HONORARIA - Bayer Corporation, BCRI, Cardio/Saculiar Research and Company, Gilead Sciences, Inc., Jansser Inc., Johnson & Bamp; Johnson Corp., Now McNeil, Pizer, Pharma Mar, Roche Diagnostichospital, St. Jude Medical Corp., The Medicine Company, WebMD; OTHER - UpToDate in C. Medicine; RESEARCH/RESEARCH GRANTS Corporation, Bayer Corporation, CSL Behring Pharmaceuticals, Inc., Johnson & Bamp; amp; Johnsmaceuticals, Inc., Johnson & Bamp; Johnsmaceuticals, Inc., Johnson & Bamp; Johnsmaceuticals, Inc., Johnson & Bamp; Johnsmaceuticals, Inc., Johnson & Bamp; Johnsmaceuticals, Inc., Johnson & Bamp; Johnsmaceuticals, Inc., Johnson & Bamp; Johnsmaceuticals, Inc., Johnson & Bamp; Johnsmaceuticals, Inc., Johnson & Bamp; Johnsmaceuticals, Inc., Johnson & Bamp; Johnson	n Pharmaceuticals, to Nordisk Inc.,Ortho s,St. Francis ses ardiovascular S - Angel Medical Ilkaria, Inc.,Janssen ohnson Corp.,Portola
Gibson	C. Michael	Optimizing the Care of ACS Patients	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin: Insights From CHAMPION PHOENIX	CONSULTANT FEES/HONORARIA - Bayer Corporation, BCRI, Cardio Vascular Research and Company, Gilead Sciences, Inc., Jansser Inc., Johnson & Amp; Johnson Corp., Nov McNeil, Pfizer, Pharma Mar, Roche Diagnostic: Hospital, St. Jude Medical Corp., The Medicine Company, WebMD; OTHER - UpToDate in C. Medicine; RESEARCH/RESEARCH GRANTS Corporation, Bayer Corporation, CSL Behring Pharmaceuticals, Inc., Johnson & Langer, St. Jude's Medical, Stealth f	n Pharmaceuticals, b Nordisk Inc.,Ortho s,St. Francis se ardiovascular S - Angel Medical Ilkaria, Inc.,Janssen bhnson Corp.,Portola
Gibson	C. Michael	Post-CAD/MI: Making Tough Predictions About the Future	One-Year Mortality Increased in Patients With Peri-Procedural Myocardial Infarction: Insights From the CHAMPION Trials	CONSULTANT FEES/HONORARIA - Bayer Corporation, BCRI, Cardio/Vascular Research and Company, Gilead Sciences, Inc., Jansser Inc., Johnson & Bamp; Johnson Corp., Nov McNeil, Pfizer, Pharma Mar, Roche Diagnostic Hospital, St. Jude Medical Corp., The Medicine Company, WebMD; OTHER - UpToDate in C. Medicine; RESEARCH/RESEARCH GRANT Corporation, Bayer Corporation, CSL Behring Pharmaceuticals, Inc., Johnson & Bamp; Johnson & Company, St. Medical, Stealth f	n Pharmaceuticals, to Nordisk Inc.,Ortho s,St. Francis ses ardiovascular S - Angel Medical Ilkaria, Inc.,Janssen ohnson Corp.,Portola
Gibson	C. Michael	Anti-Platelet Therapies: Always a Sticky Topic	Ischemic Events Occur Early in Patients Undergoing PCI and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX	CONSULTANT FEES/HONORARIA - Bayer Corporation, BCRI, CardioVascular Research and Company, Gilead Sciences, Inc., Jansser Inc., Johnson & Amp; Johnson Corp., Nov McNeil, Pfizer, Pharma Mar, Roche Diagnostic Hospital, St. Jude Medical Corp., The Medicine Company, WebMD; OTHER - UpToDate in C. Medicine; RESEARCH/RESEARCH GRANT Corporation, Bayer Corporation, CSL Behring, Pharmaceuticals, Inc., Johnson & Mamp; amp; Johnson & Mamp; Johnson & Medical, Stealth f	n Pharmaceuticals, b Nordisk Inc.,Ortho s,St. Francis se ardiovascular S - Angel Medical Ilkaria, Inc.,Janssen bhnson Corp.,Portola
Gidding	Samuel	Advances in Cholesterol Measurement and Management	Lipid Levels and Vascular Function in Young Individuals, Heterozygous or Homozygous for an <i>APOB </i> C.1058G>A Variant	CONSULTANT FEES/HONORARIA - Reger	nxbio
Gidding	Samuel	Insights From Echocardiography Use	Relation of Left Ventricular Remodeling to Left Ventricular Diastolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	CONSULTANT FEES/HONORARIA - Reger	nxbio

Contract of the second				I
Last Name Gidding	First Name Samuel	Session Title Insights From Echocardiography Use	Presentation Title Relation of Left Ventricular Remodeling to Left Ventricular Systolic	Disclosures CONSULTANT FEES/HONORARIA - Regenxbio
			Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	
Gidea	Claudia	FIT Clinical Decision Making: Heart Failure and	Percutaneous Management of Severe Aortic Insufficiency	Nothing to Disclose
Gidea	Claudia	Pulmonary Hypertension FIT Clinical Decision Making: Interventional	Complicating Prolonged Left Ventricular Assist Device Support Coil Embolization of latrogenic Pulmonary Artery Pseudoaneurysm	Nothing to Disclose
Oid-ca-i	Umaah	Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Idealife in the Efficience and Tourier of 20 Day Deader in incidence	Mathian & Displace
Gidwani	Umesh	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Identifying the Etiologies and Trends of 30 Day Readmissions in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients: A National Population-Based Cohort Study	Nothing to Disclose
Gidwani	Umesh	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Impact of Cardiac Devices on Readmission and Short Term Mortality in Patients With Heart Failure With Reduced Ejection Fraction: A Nationwide Study	Nothing to Disclose
Giglia	Therese	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Impact of Home Monitoring Program on Interstage Mortality and Stage II Outcomes	Nothing to Disclose
Gilard	Martine	Considerations in Antiplatelet Therapy and in ACS	Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multi-Vessel Disease on Outcomes in Patients Treated	Nothing to Disclose
071	Margari		With Newer-Generation Drug-Eluting Stents	Notice to Produce
Gilard	Martine	Interventional Cardiology: TAVR 4	Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital	Nothing to Disclose
Gilchrist Gilchrist	lan lan	Radial Access Mini-Symposium I Updates on Pulmonary Embolism	Venous Procedures from the Arm Does Thrombolysis Reduce Mortality in Patients With Intermediate	Nothing to Disclose Nothing to Disclose
Gilchrist	lan	Management in 2017 Complex Coronary Intervention: Left	Risk Pulmonary Embolism? A Trial Sequential Analysis Assessing Inter-Rater Agreement of Experienced Interventional	Nothing to Disclose
	lan	Main/Bifurcations and Multivessel Disease	Cardiologists on Culprit Vessel in Patients With Multivessel Disease and Acute Non-STEMI	-
Gilchrist	lan	Vascular Access and Hemostasis Issues	Efficacy and Safety of Transulnar Compared to Transradial Arterial Access in Patients Undergoing Coronary Angiography: A Systematic Review and Meta-Analysis	Nothing to Disclose
Gilchrist	lan	Interventional Cardiology: TAVR 2	Death and Dialysis Risk After Transcatheter Aortic Valve	Nothing to Disclose
Gilchrist	lan	Which Test Is Best for Pain in the Chest?	Replacement A False-Positive Stress Echocardiogram Is NOT the Same as a	Nothing to Disclose
Gilchrist	lan	Interventional Cardiology: Coronary Intervention: Left Main, Multivessel, Bifurcation	Negative Result Suggested Reviewer	Nothing to Disclose
Cilobriot	lon	Team 1 Interventional Challenging Cases: Team 2	ACC Challenging Coss Reviewer	Nothing to Disclose
Gilchrist Giles	Ian Thomas	Uncovering the Intricacies of Vascular Function	ACC Challenging Case Reviewer Dapagliflozin Improves Arterial Stiffness in Patients With Type 2 Diabetes Mellitus	CONSULTANT FEES/HONORARIA - Forest Labs; RESEARCH/RESEARCH GRANTS - Allergan; SALARY -
Giles	Wayne	Are We There Yet? The Long Journey to Health Equity: Part III	Healthy People 2020: Race, Ethnicity and Beyond	AstraZeneca Pharmaceuticals Nothing to Disclose
Giles Gilham	Wayne Dean	48th Annual Louis F. Bishop Lecture Highlights in Vascular Medicine Research	Panelist Apabetalone (RVX-208) Lowers Cardiovascular Disease (CVD) in	Nothing to Disclose SALARY - Resverlogix
			Diabetes Mellitus by a Mechanism Involving Microbiome Mediated Activity on the Complement Pathway	-
Gill	John	Interdisciplinary Cardiovascular Team Care	See You in 7: An Advanced Practice Provider Post PCI Clinic	Nothing to Disclose
Gillam	Linda	Delivery: Quality, Safety, and Satisfaction How to Redesign a Care Delivery Team in	Improving Transition of Care Co-Chair	RESEARCH/RESEARCH GRANTS - Bracco, Edwards
Gillam	Linda	Preparation for MACRA and MIPS How to Redesign a Care Delivery Team in	Introduction to Session & Overview of MACRA	Lifesciences,MEDTRONIC RESEARCH/RESEARCH GRANTS - Bracco,Edwards
Gillam	Linda	Preparation for MACRA and MIPS Structural Heart Interventions: What Does the	Co-Chair	Lifesciences,MEDTRONIC RESEARCH/RESEARCH GRANTS - Bracco,Edwards
Gillam	Linda	Imager Need to know Town Hall Meeting: Pitfalls of Assessing	Discussion Leader	Lifesciences,MEDTRONIC RESEARCH/RESEARCH GRANTS - Bracco,Edwards
Gillam	Linda	Valvular Heart Disease Severity Mitral Valve Guidelines: Closing Knowledge	Co-Chair	Lifesciences,MEDTRONIC RESEARCH/RESEARCH GRANTS - Bracco,Edwards
Gillam	Linda	Gaps Mitral Valve Guidelines: Closing Knowledge	Discussion Leader	Lifesciences,MEDTRONIC RESEARCH/RESEARCH GRANTS - Bracco,Edwards
Gillam	Linda	Gaps Interventional Cardiology: TAVR 4	Depression as a Potential Therapeutic Target to Improve Quality of	Lifesciences,MEDTRONIC RESEARCH/RESEARCH GRANTS - Bracco,Edwards
Gillam	Linda	Engage @ ACC.17 Studio: Cardiology Contest	Life After Transcatheter Aortic Valve Replacement Cardiology Contestant	Lifesciences,MEDTRONIC RESEARCH/RESEARCH GRANTS - Bracco,Edwards
		3 3 3		Lifesciences,MEDTRONIC
Gillam	Linda	17. Interventional Cardiology: Aortic Valve Disease Team 2	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Bracco, Edwards Lifesciences, MEDTRONIC
Gille	Andreas	Updates in Stable Ischemic Heart Disease	CSL112 Enhances the Ability of Serum to Efflux Cholesterol in Patients With Moderate Renal Impairment	SALARY - Employee of CSL Limited
Gillespie	Matthew	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Safety and Feasibility of Melody Transcatheter Pulmonary Valve Replacement in the Native Right Ventricular Outflow Tract: A Multicenter Study	CONSULTANT FEES/HONORARIA - MEDTRONIC,WL Gore
Gillespie	Matthew	11. Congenital Heart Disease: Therapy Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC,WL Gore
Gillinov	A.	Valvular Heart Disease: Mitral Valve Disease	Gender Differences in the Etiology of Mitral Valve Disease	CONSULTANT FEES/HONORARIA - Abbott,AtriCure,CryoLife ,Edwards Lifesciences,MEDTRONIC,PleuraFlow; SPEAKER'S
Gillinov	A.	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Pulmonary Hypertension in Left Atrial Sarcoma	BUREAU - St. Jude Medical CONSULTANT FEES/HONORARIA - Abbott, AtriCure, CryoLife ,Edwards Lifesciences, MEDTRONIC, PleuraFlow; SPEAKER'S
Gillinov	A.	Novel Determinants of Outcomes in VHD	Valvuloarterial Impedance and Left Ventricular Global Longitudinal	BUREAU - St. Jude Medical CONSULTANT FEES/HONORARIA - Abbott,AtriCure,CryoLife
			Strain Provide Incremental Prognostic Value in Patients With Significant Aortic Stenosis and Preserved Left Ventricular Ejection Fraction	,Edwards Lifesciences,MEDTRONIC,PleuraFlow; SPEAKER'S BUREAU - St. Jude Medical
Gillinov	Α.	Novel Arrhythmia Diagnostics, Therapeutics, and "Wearables	Variable Accuracy of Commercially Available Wearable Heart Rate Monitors	CONSULTANT FEES/HONORARIA - Abbott,AtriCure,CryoLife ,Edwards Lifesciences,MEDTRONIC,PleuraFlow; SPEAKER'S BUREAU - St. Jude Medical
Gilman	Robert	Emerging Applications of Echocardiography	Understanding the Role of Strain Imaging in the Early Detection of	Nothing to Disclose
Gilon	Dan	Vascular Medicine: Aortic and Peripheral	Chagas Cardiomyopathy Acute Aortic Dissection in Patients Without a History of Hypertension	Nothing to Disclose
Gilotra	Nisha	Artery Diseases Test Yourself with Questions: General	Faculty	Nothing to Disclose
Gilotra	Nisha	Cardiology Module 14 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	A Bridge Over Water: Successful Implementation of a Heart Failure Bridge Clinic (HFBC) to Reduce Heart Failure (HF) Hospitalizations	Nothing to Disclose
Gimeno	Federico	Timely Topics in Acute Coronary Syndromes	A New Prognosis Score to Predict Mortality in Patients Over 75	Nothing to Disclose
Ginde	Salil	Redefining the "F" Word	Years Old Undergoing Primary Angioplasty in Cardiogenic Shock Cardiopulmonary Exercise Testing for Surgical Risk Stratification in	Nothing to Disclose
			Adults With Congenital Heart Disease Neurocognitive Impairment Is Common in the Adult With Congenital	-
Ginde	Salil	Congenital Heart Disease: To the Third Decade and Beyond	Neurocognitive impairment is Common in the Adult With Congenital Heart Disease: Identification Using a Novel Clinical Questionnaire	Nothing to Disclose
	•	•	•	



and a				
Last Name Ginde	First Name Salil	Session Title 11. Congenital Heart Disease: Therapy Team	Presentation Title Suggested Reviewer	Disclosures Nothing to Disclose
Gindi	Ryan	1 FIT Clinical Decision Making: Heart Failure and		Nothing to Disclose
	-	Pulmonary Hypertension		-
Ginns	Jonathan	Congenital Heart Disease: To the Third Decade and Beyond	The Systemic Right Ventricle in Transposition of the Great Arteries: What Can We Learn From Serial Imaging?	Nothing to Disclose
Ginsberg	Henry	Harnessing the Power of Genetics to Prevent ASCVD	Co-Chair	CONSULTANT FEES/HONORARIA - AstraZeneca, Boerhinger Ingelheim, Bristol Myers Squibb, Eli Lilly, Jlanssan, Kowa, Merck Pharmaceuticals, Novartis, Pfizer, Regeneron, Reverlogix, SanofiAve ntis-Regeneron; RESEARCH/RESEARCH GRANTS - Merck Pharmaceuticals, Sanofi-Genzyme, Sanofi-Regeneron
Ginsberg	Henry	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Lower On-Treatment Low-Density Lipoprotein Cholesterol Is Associated With Lower Cardiovascular Risk in Very High Risk Patients With Atherosclerotic Cardiovascular Disease: Analyses From the ODYSSEY Trials	CONSULTANT FEES/HONORARIA - AstraZeneca, Boerhinger Ingelheim, Bristol Myers Squibb, Eli Lilly, Anssan, Kowa, Merck Pharmaceuticals, Novartis, Pfizer, Regeneron, Reverlogix, SanofiAve ntis-Regeneron; RESEARCH/RESEARCH GRANTS - Merck Pharmaceuticals, Sanofi-Genzyme, Sanofi-Regeneron
Ginsberg	Henry	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Lower On-Treatment Low-Density Lipoprotein Cholesterol is Associated With Lower Cardiovascular Risk in Women: Analyses From the ODYSSEY Trials of Alirocumab Versus Control	CONSULTANT FEES/HONORARIA - AstraZeneca, Boerhinger Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssan, Kowa, Merck Pharmaceuticals, Novartis, Pfizer, Regeneron, Reverlogix, SanofiAve nits-Regeneron; RESEARCH/RESEARCH GRANTS - Merck Pharmaceuticals, Sanofi-Genzyme, Sanofi-Regeneron
Ginsberg	Henry	The Intersection of Diabetes and ASCVD	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - AstraZeneca, Boerhinger ingelheim, Bristol Myers Squibb, Eil Lilly, Janssan, Kowa, Merck Pharmaceuticals, Novartis, Prizer, Regeneron, Reverlogis, SanofiAve nits-Regeneror; RESEARCH/RESEARCH GRANTS - Merck Pharmaceuticals, Sanofi-Genzyme, Sanofi-Regeneron
Ginwala-Hasan	Naeema	Non Invasive Imaging: Prognostic Implications of CT Angiography	The Relationship Between Pericardial Adipose Tissue Volume, Atherosclerotic Plaque Type and Cardiovascular Risk: A High Risk Plaque Biolmage Sub-Study	Nothing to Disclose
Giri	Jay	Recent ACS Trials: Relevance to My Daily Practice	Panelist	CONSULTANT FEES/HONORARIA - AngioDynamics; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Giri	Jay	The Forgotten Valves: Therapies for Triscuspid and Pulmonic Valve	Acute Pulmonary Embolism: Focus on the PERT (Pulmonary Embolism Response Team)	CONSULTANT FEES/HONORARIA - AngioDynamics; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Giri	Jay	The Forgotten Valves: Therapies for Triscuspid	Case Presentation: Catheter-Based Treatment of Acute Pulmonary	CONSULTANT FEES/HONORARIA - AngioDynamics;
Giri	Jay	and Pulmonic Valve Multi-Disciplinary Care for Acute Pulmonary	Embolism Co-Chair	RESEARCH/RESEARCH GRANTS - St. Jude Medical CONSULTANT FEES/HONORARIA - AngioDynamics;
	<u> </u>	Embolism: The PE Response Team (PERT) Model		RESEARCH/RESEARCH GRANTS - St. Jude Medical
Giri	Jay	Multi-Disciplinary Care for Acute Pulmonary Embolism: The PE Response Team (PERT) Model	PE Management: Further Research Efforts from a Legend in the Field - Interviewer	CONSULTANT FEES/HONORARIA - AngioDynamics; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Giri	Jay	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Trends in Catheter Directed Thrombolysis and Systemic Thrombolysis for Pulmonary Embolism Treatment: 2004-2014	CONSULTANT FEES/HONORARIA - AngioDynamics; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Giri	Jay	Interventional Cardiology: TAVR 1	TAVR Is Safe and Improves Cardiac Function in Patients With Extremely Low Ejection Fractions	CONSULTANT FEES/HONORARIA - AngioDynamics; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Giri	Jay	18. Interventional Cardiology: Carotid and	Suggested Reviewer	CONSULTANT FEES/HONORARIA - AngioDynamics; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Girotra	Saket	Endovascular Intervention Team 1 Innovative Approaches for Reducing Risk and	Gender Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Medicare Patients With Newly Diagnosed Arial Fibrillation:	Nothing to Disclose
		Improving Outcomes With Ablation	A Propensity Matched Analysis	
Girotra	Saket	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Burden of 30-Day Readmissions in Acute Myocardial Infarction and Heart Failure in the United States: A National Perspective	Nothing to Disclose
Gislason	Gunnar	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Vitamin K Antagonist or Dabigatran in Patients With Atrial Fibrillation: The Importance of Time in Therapeutic Range	Nothing to Disclose
Gislason	Gunnar	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Evidence Based Therapy and Its Relation to Workforce Attachment Following First Hospitalization for Heart Failure	Nothing to Disclose
Gitt	Anselm	Advances in Cholesterol Measurement and Management	Frequency and Predictors of Cholesterol Goal Attainment in Patients With Coronary Heart Disease: Results From the Dyslipidemia International Study II	CONSULTANT FEES/HONORARIA - AstraZeneca,BMS,Novartis,NovoNordisk,Pfizer Inc; RESEARCH/RESEARCH GRANTS - MSD; SPEAKER'S BUREAU - Daiichi-Sankyo,Lilly,Sanofi Aventis
Gitt	Anselm	Advances in Cholesterol Measurement and Management	Low LDL-Cholesterol Target Value Attainment at the Time of Acute Coronary Syndrome (ACS) and Even 4 Months After the Acute Event Due to Lack of Adjustment in Lipid Lowering Treatment:	CONSULTANT FEES/HONORARIA - AstraZeneca,BMS,Novartis,NovoNordisk,Pfizer Inc; RESEARCH/RESEARCH GRANTS - MSD; SPEAKER'S
Gitt	Anselm	Advances in Cholesterol Measurement and Management	Results From the Dyslipidemia International Study II ACS Improvement of LDL-Cholesterol Goal Attainment in High-Risk Patients in Europe and Middle East Between 2008-09 and 2013-14: Results of DYSIS and DYSIS II CHD	BUREAU - Daiichi-Sankyo,Lilly,Sanofi Aventis CONSULTANT FEES/HONORARIA - AstraZeneca,BMS,Novartis,NovoNordisk,Pfizer Inc; RESEARCH/RESEARCH GRANTS - MSD; SPEAKER'S
Gitt	Anselm	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South-Africa, Middle East and China: Results of the Dyslipidemia International Study (DYSIS)	BUREAU - Daiichi-Sankyo,Lilly,Sanofi Aventis CONSULTANT FEES/HONORARIA - AstraZeneca,BMS,Novartis,NovoNordisk,Pfizer Inc; RESEARCH/RESEARCH GRANTS - MSD; SPEAKER'S
Gitt	Anselm	Diabetes and Other Issues in Cardiovascular Prevention	Does Concomitant Diabetes Mellitus Impact the Cholesterol Treatment Post Acs?	BUREAU - Daiichi-Sankyo,Lilly,Sanofi Aventis CONSULTANT FEES/HONORARIA - AstraZeneca,BMS,Novarlis,NovoNordisk,Pfizer Inc; RESEARCH/RESEARCH GRANTS - MSD; SPEAKER'S
Giudici	Michael	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Gender Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Medicare Patients With Newly Diagnosed Arial Fibrillation:	BUREAU - Daiichi-Sankyo,Lilly,Sanofi Aventis RESEARCH/RESEARCH GRANTS - Boston Scientific
Giudici	Michael	Things That Matter in Adult Congenital Heart Disease	A Propensity Matched Analysis Gender Differences in Rates of Hospitalizations for Decompensated Heart Failure Among Adults With Congenital Heart Diseases in the United States: A 15 Year Experience	RESEARCH/RESEARCH GRANTS - Boston Scientific
Giudici	Michael	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	United States: A 15 Year Experience Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Boston Scientific
Giugliano	Robert	Opening Session and the Joint American College of Cardiology and Journal of American College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture	Primary Results of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial	CONSULTANT FEES/HONORARIA - American College of Cardiology, Amgen, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb Company, CVS Caremank, Daiichi Sankyo, GlaxoSmithKline, Lexicon, Merck, Pfizer, Portola, St Jude Medical; RESEARCH/RESEARCH GRANTS - Amgen
Giugliano	Robert	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	Primary Results of EBBINGHAUS, a Cognitive Study of Patients Enrolled in the FOURIER Trial	CONSULTANT FEES/HONORARIA - American College of Cardiology, Amgen, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb Company, CVS Caremark, Dailchi Sankyo, GlaxoSmithkline, Lexicon, Merck, Pfizer, Portola, St. Jude Medical; RESEARCH/RESEARCH GRANTS - Amgen
Giugliano	Robert	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First Experience From the ENGAGE AF TIMI 48 Trial	CONSULTANT FEES/HONORARIA - American College of Cardiology, Amgen, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb Company, CVS Caremark, Daiichi Sankyo, GlaxoSmithKline, Lexicon, Merck, Pfizer, Portola, St Jude Medical; RESEARCH/RESEARCH GRANTS - Amgen

Last Name Giugliano	First Name			
Giugliano	FIRST Name	Session Title	Presentation Title	Disclosures
	Robert	Atrial Fibrillation and VT: Unique Populations	Outcomes of Asian Patients With Atrial Fibrillation Compared to Non-	CONSULTANT FEES/HONORARIA - American College of
		and Solutions	Asians in the ENGAGE AF-TIMI 48 Trial	Cardiology,Amgen,Boehringer Ingelheim Pharmaceuticals,
				Inc,Bristol-Myers Squibb Company ,CVS Caremark,Daiichi
				Sankyo,GlaxoSmithKline,Lexicon,Merck,Pfizer,Portola,St Jude
Circlina	Dahad	Assistance and Olivinal ED. AE Mines II and the	Association of County Bioli County Burden of Atrial Fibrillation	Medical; RESEARCH/RESEARCH GRANTS - Amgen
Giugliano	Robert	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Association of Genetic Risk Score with Burden of Atrial Fibrillation: An ENGAGE AF-TIMI 48 Analysis	CONSULTANT FEES/HONORARIA - American College of Cardiology, Amgen, Boehringer Ingelheim Pharmaceuticals,
		and Surgical issues	All ENGAGE AF-1 IIVII 46 Allalysis	Inc,Bristol-Myers Squibb Company ,CVS Caremark,Daiichi
				Sankyo,GlaxoSmithKline,Lexicon,Merck,Pfizer,Portola,St Jude
				Medical; RESEARCH/RESEARCH GRANTS - Amgen
Giugliano	Robert	Stroke and AF: Thinking About the Heart	Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation	CONSULTANT FEES/HONORARIA - American College of
		ğ	and Active Malignancy: An Analysis of ENGAGE AF - Timi 48	Cardiology,Amgen,Boehringer Ingelheim Pharmaceuticals,
			Randomized Clinical Trial	Inc,Bristol-Myers Squibb Company ,CVS Caremark,Daiichi
				Sankyo,GlaxoSmithKline,Lexicon,Merck,Pfizer,Portola,St Jude
				Medical; RESEARCH/RESEARCH GRANTS - Amgen
Giugliano	Robert	02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - American College of
		Clinical Team 7		Cardiology, Amgen, Boehringer Ingelheim Pharmaceuticals,
				Inc,Bristol-Myers Squibb Company ,CVS Caremark,Daiichi Sankyo,GlaxoSmithKline,Lexicon,Merck,Pfizer,Portola,St Jude
				Medical; RESEARCH/RESEARCH GRANTS - Amgen
Giustino	Gennaro	Coronary Intervention in Interventional	Clinical Outcomes Associated With Impella Versus IABP Use in	Nothing to Disclose
		Cardiology: Advanced Device Use	Stable Patients Undergoing High Risk Percutaneous Coronary	
			Intervention	
Giustino	Gennaro	Coronary Intervention in Interventional	Impella or Intra-Aortic Balloon Pump Support in Patients	Nothing to Disclose
		Cardiology: Advanced Device Use	Undergoing High Risk Percutaneous Coronary Intervention: A Real	
a	_		World Single Center Experience	
Giustino	Gennaro	Coronary Angiography, Intra-Vascular Imaging,	Angiographic Phenotype and Clinical Outcomes of Patients With	Nothing to Disclose
Giuetino	Gennaro	Revascularization and Outcomes	Malignancy Undergoing PCI Prediction of Acute Kidney Injury in Patients Undergoing Coronary	Nothing to Disclose
Giustino	Gennaro	Interventional Complexity and Complications	Prediction of Acute Kidney Injury in Patients Undergoing Coronary Intervention Using Calculation of Serum Osmolality	Nothing to Disclose
Giustino	Gennaro	Interventional Cardiology: PCI in Complex	Risk and Impact of Diabetes Mellitus on Ischemic Events in Females	Nothing to Disclose
Cidduito	Cominio	Patients	and Males After Percutaneous Coronary Intervention	Totaling to Disciose
Givertz	Michael	Genetic Testing for Cardiomyopathies	Case Presentation in Familial Dilated Cardiomyopathy	CONSULTANT FEES/HONORARIA - Merck
Givertz	Michael	Pregnancy and Heart Disease	Co-Chair	CONSULTANT FEES/HONORARIA - Merck
Givertz	Michael	Innovative Use of Echocardiography	Echocardiographic Parameters Associated With Quality of Life in	CONSULTANT FEES/HONORARIA - Merck
			Ambulatory Patients With Heart Failure	
Givertz	Michael	13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Merck
		Clinical Team 5		<u></u>
Giza	Dana	Making Progress in Understanding Heart	Stress Induced Cardiomyopathy Triggered by Chemotherapy: When	Nothing to Disclose
0:	D	Failure	Should Cancer Therapy Be Restarted?	Nothing to Displace
Giza	Dana	Optimizing the Care of ACS Patients	Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients	Nothing to Disclose
			Perculaneous Coronary Intervention in Cancer Patients	
Gjeka	Rudin	FIT Clinical Decision Making: Prevention, Adult	An Interesting Case of Cor Triatriatum Dexter Facilitating	Nothing to Disclose
Gjeka	Rudiii	Congenital and Congenital Heart Disease	Paradoxical Embolism and Ischemic Stroke	Notifing to Disclose
		Congenital and Congenital Flear Disease	T dradoxical Embolism and isolicime offorc	
Gjeka	Rudin	FIT Clinical Decision Making: Interventional	External Femoral-Femoral Bypass for Acute Limb Ischemia	Nothing to Disclose
-,-		Cardiology, Acute and Stable Ischemic Heart	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	3
		Disease, and Vascular Medicine		
Glass	Christopher	Young Investigator Awards Competition: Basic	Cell-Specific Discrimination of Desmosterol and Desmosterol	Nothing to Disclose
		and Translational Science	Mimetics Confers Selective Regulation of LXR and SREBP	
			Pathways in Macrophages	
Glatz	Andrew	Finding Out What Works in Pediatric and	Risk of Catastrophic Outcome Following Cardiac Catheterization for	Nothing to Disclose
		Congenital Heart Disease	Pulmonary Hypertension: An Analysis of Data From the Impact	
	Mette	Adult Patients With Congenital Heart Disease:	Registry Risk of Stroke in Adult Patients With Congenital Heart Disease	Nothing to Disclose
Glavind Bülow				Nothing to Disclose
Glavind Bülow				
Glavind Bülow Pedersen		How Do They Compare?	Compared With the General Population: A Danish Nationwide	
Pedersen	Thomas		Population-Based Cohort Study	RESEARCH/RESEARCH GRANTS - Boston Scientific.Cook
	Thomas	Beans, Beans, Good for Your Heart		RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC
Pedersen	Thomas		Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and	
Pedersen Gleason		Beans, Beans, Good for Your Heart	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection	Medical,MEDTRONIC
Pedersen Gleason		Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity. Clinical Applications in the TAVR Era	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC
Pedersen Gleason		Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook
Pedersen Gleason Gleason	Thomas	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC
Pedersen Gleason Gleason Gleason	Thomas Thomas	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC
Pedersen Gleason Gleason	Thomas	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook
Pedersen Gleason Gleason Gleason Gleason	Thomas Thomas Thomas	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC
Pedersen Gleason Gleason Gleason Gleason Glicason Glicason	Thomas Thomas Thomas Julie	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose
Pedersen Gleason Gleason Gleason Gleason	Thomas Thomas Thomas	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuity to Simple Predictive Score for Pre-Admission Identification of Risk of	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC
Pedersen Gleason Gleason Gleason Gleason Gleason Glickstein Glikklich	Thomas Thomas Thomas Julie	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity. Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose
Pedersen Gleason Gleason Gleason Gleason Gleason Glickstein Glikkich	Thomas Thomas Thomas Julie Richard	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose Nothing to Disclose
Pedersen Gleason Gleason Gleason Gleason Glickstein Gliklich Glinel Mortreuil	Thomas Thomas Thomas Julie Richard Bastien	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopfalization for Congestive Heart Failure in Patients Implanted With Tavr Between	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pedersen Gleason Gleason Gleason Gleason Gleason Glickstein Glikklich	Thomas Thomas Thomas Julie Richard	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Roueu University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose Nothing to Disclose
Pedersen Gleason Gleason Gleason Gleason Glickstein Gliklich Glinel Mortreuil	Thomas Thomas Thomas Julie Richard Bastien	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pedersen Gleason Gleason Gleason Gleason Glickstein Gliklich Glinel Mortreuil	Thomas Thomas Thomas Julie Richard Bastien Chris	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivallirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Mycardial Infarction	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pedersen Gleason Gleason Gleason Gleason Glickstein Gliklich Glinel Mortreuil	Thomas Thomas Thomas Julie Richard Bastien	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped —	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
Pedersen Gleason Gleason Gleason Gleason Glickstein Gliklich Glinel Mortreuil Glover Gluckman	Thomas Thomas Thomas Julie Richard Bastien Chris	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc
Pedersen Gleason Gleason Gleason Gleason Glickstein Gliklich Glinel Mortreuil Glover	Thomas Thomas Thomas Julie Richard Bastien Chris	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia-	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Roueu University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation Is an Independent Predictor	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
Pedersen Gleason Gleason Gleason Gleason Glickstein Gliklich Glinel Mortreuil Glover Gluckman	Thomas Thomas Thomas Julie Richard Bastien Chris	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc
Pedersen Gleason Gleason Gleason Gleason Glickstein Gliklich Glinel Mortreuil Glover Gluckman Gluckman	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia-Reperfusion Injury in AMI	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc
Pedersen Gleason Gleason Gleason Gleason Glickstein Gliklich Glinel Mortreuil Glover Gluckman	Thomas Thomas Thomas Julie Richard Bastien Chris	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia-Reperfusion Injury in AMI Advances in Cholesterol Measurement and	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bhailurdin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
Pedersen Gleason Gleason Gleason Gleason Glickstein Gliklich Glinel Mortreuil Glover Gluckman Gluckman	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia-Reperfusion Injury in AMI	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc
Pedersen Gleason Gleason Gleason Gleason Glickstein Gliklich Glinel Mortreuil Glover Gluckman Gluckman	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia-Reperfusion Injury in AMI Advances in Cholesterol Measurement and	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bhailurdin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc
Pedersen Gleason Gleason Gleason Gleason Glickstein Glikkich Glinel Mortreuil Glover Gluckman Gluckman	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped – What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia-Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in Arterial Diseases	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy: Post-Commercialization Study Ocular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc Nothing to Disclose
Pedersen Gleason Gleason Gleason Gleason Glickstein Glikkich Glinel Mortreuil Glover Gluckman Gluckman	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Right Ventricle-Pulmonary Artery Coupling in Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy. Post-Commercilatation Study Ocular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia Alirocumab in High-Risk Patients With Baseline LDL-C ≥160	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc Nothing to Disclose
Pedersen Gleason Gleason Gleason Gleason Glickstein Glikkich Glinel Mortreuil Glover Gluckman Gluckman Gluckman Glueck	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles Charles	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped – What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia-Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in Arterial Diseases	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy: Post-Commercialization Study Ocular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc Nothing to Disclose
Pedersen Gleason Gleason Gleason Gleason Gleason Glickstein Glikklich Glinel Mortreuil Glover Gluckman Gluckman Gluckman Gluck Glueck Glueck	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles Charles Charles	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia-Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in Arterial Diseases Advances in Lipid Management	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated Cholestero Lowering Therapy: Post-Commercialization Study Ocular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia Alirocumab in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pedersen Gleason Gleason Gleason Gleason Glickstein Glikkich Glinel Mortreuil Glover Gluckman Gluckman Gluckman Glueck	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles Charles	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped – What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia-Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in Arterial Diseases	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive Score for Pre-Admission Identification for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panellst Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy: Post-Commercialization Study Coular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia Alirocumab in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc Nothing to Disclose
Pedersen Gleason Gleason Gleason Gleason Gleason Glickstein Glikkich Glinel Mortreuil Glover Gluckman Gluckman Gluckman Gluck Glueck Glueck Go	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles Charles Alan	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in Arterial Diseases Advances in Lipid Management Updates in Stable Ischemic Heart Disease	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumba and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy: Post-Commercialization Study Ocular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia Alirocumba in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC ROTION OF SCIENTIFIC COOK Medical, MEDTRONIC ROTION OF SCIENTIFIC COOK Medical, MEDTRONIC ROTION OF SCIENTIFIC COOK Medical, MEDTRONIC ROTION OF SCIENTIFIC COOK ROTION OF SCIENTIF
Pedersen Gleason Gleason Gleason Gleason Gleason Glickstein Glikklich Glinel Mortreuil Glover Gluckman Gluckman Gluckman Gluck Glueck Glueck	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles Charles Charles	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia-Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in Arterial Diseases Advances in Lipid Management Updates in Stable Ischemic Heart Disease Updates on Risk Factors for Cardiovascular	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maxmal Tolerated Cholesterol Lowering Therapy: Post-Commercialization Study Ocular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thromboxhilia Alirocumab in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program Predictors of Long-Term Resource Utilization After Incident Percutaneous Coronary Intervention	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pedersen Gleason Gleason Gleason Gleason Gleason Glickstein Glikich Glinel Mortreuil Glover Gluckman Gluckman Gluckman Gluck Glueck Glueck Go	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles Charles Alan	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in Arterial Diseases Advances in Lipid Management Updates in Stable Ischemic Heart Disease	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumba and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy: Post-Commercialization Study Ocular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia Alirocumba in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - CSL Behring , Genentech
Pedersen Gleason Gleason Gleason Gleason Gleason Glickstein Gliklich Glinel Mortreuil Glover Gluckman Gluckman Gluckman Gluck Glueck Glueck Go Go	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles Charles Charles Alan Alan	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valrular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped—What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia-Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in Arterial Diseases Advances in Lipid Management Updates in Stable Ischemic Heart Disease Updates on Risk Factors for Cardiovascular Disease	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Right One Predictive Score for Pre-Admission Identification of Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy: Post-Commercialization Study Ocular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia Alirocumab in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program Predictors of Long-Term Resource Utilization After Incident Percutaneous Coronary Intervention Levels of Obesity and Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Community-Based Cohort	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - CSL Behring ,Genentech RESEARCH/RESEARCH GRANTS - CSL Behring ,Genentech
Pedersen Gleason Gleason Gleason Gleason Glickstein Glikklich Glinel Mortreuil Glover Gluckman Gluckman Gluckman Glueck Glueck Go	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles Charles Alan	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia-Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in Arterial Diseases Advances in Stable Ischemic Heart Disease Updates on Risk Factors for Cardiovascular Disease Atrial Fibrillation and VT: Specific Situations	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy: Post-Commercialization Study Coular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia Alirocumab in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program Predictors of Long-Term Resource Utilization After Incident Percutaneous Coronary Intervention Levels of Obesity and Accuracy of the Atherosclerotic Cardiovascular Risk Equation in	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - CSL Behring , Genentech
Pedersen Gleason Gleason Gleason Gleason Gleason Gleason Glickstein Glikklich Glinel Mortreuil Glover Gluckman Gluckman Gluckman Gluck Glueck Glueck Go Go	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles Charles Charles Alan Alan	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped – What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia-Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in Arterial Diseases Advances in Stable Ischemic Heart Disease Updates on Risk Factors for Cardiovascular Disease Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumba and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy: Post-Commercialization Study Ocular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia Alirocumba in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program Predictors of Long-Term Resource Utilization After Incident Percutaneous Coronary Intervention Levels of Obesity and Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Community-Based Cohort With Artial Fibrillation?	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc Nothing to Disclose Nothing to Disclose Nothing to Disclose Research/Research Grants - CSL Behring , Genentech RESEARCH/RESEARCH GRANTS - CSL Behring , Genentech
Pedersen Gleason Gleason Gleason Gleason Gleason Glickstein Gliklich Glinel Mortreuil Glover Gluckman Gluckman Gluckman Gluck Glueck Glueck Go	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles Charles Charles Alan Alan	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in Arterial Diseases Advances in Lipid Management Updates in Stable Ischemic Heart Disease Updates on Risk Factors for Cardiovascular Disease Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive Score for Pre-Admission Identification for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy: Post-Commercialization Study Ocular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia Alirocumab in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program Predictors of Long-Term Resource Utilization After Incident Percutaneous Coronary Intervention Levels of Obesity and Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Community-Based Cohort Does Frailty Alter the Benefits of Oral Anticoagulation in Patients With Atrial Fibrillation? Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation:	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - CSL Behring ,Genentech RESEARCH/RESEARCH GRANTS - CSL Behring ,Genentech
Pedersen Gleason Gleason Gleason Gleason Gleason Gleason Glickstein Glikkich Glinel Mortreuil Glover Gluckman Gluckman Gluckman Gluck Glueck Glueck Go Go	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles Charles Charles Alan Alan	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped – What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia-Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in Arterial Diseases Advances in Stable Ischemic Heart Disease Updates on Risk Factors for Cardiovascular Disease Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumba and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy: Post-Commercialization Study Ocular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia Alirocumba in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program Predictors of Long-Term Resource Utilization After Incident Percutaneous Coronary Intervention Levels of Obesity and Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Community-Based Cohort With Artial Fibrillation?	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc Nothing to Disclose Nothing to Disclose Nothing to Disclose Research/Research Grants - CSL Behring , Genentech RESEARCH/RESEARCH GRANTS - CSL Behring , Genentech
Pedersen Gleason Gleason Gleason Gleason Gleason Gleason Glickstein Glikkich Glinel Mortreuil Glover Gluckman Gluckman Gluckman Gluck Glueck Glueck Go Go	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles Charles Charles Alan Alan	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia-Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in Arterial Diseases Advances in Lipid Management Updates in Stable Ischemic Heart Disease Updates on Risk Factors for Cardiovascular Disease Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making Current Issues in Cardiovascular	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab in High-Risk Patients With Baseline LDL-C ##8805;160 mg/dL: Findings From the Compassionate Use Program Predictors of Long-Term Resource Utilization After Incident Percutaneous Coronary Intervention Levels of Obesity and Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Community-Based Cohort Does Frailty Alter the Benefits of Oral Anticoagulation in Patients With Atrial Fibrillation? Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Arial Fibrillation (ORBIT-AF)	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc Nothing to Disclose Nothing to Disclose Nothing to Disclose Research/Research Grants - CSL Behring , Genentech RESEARCH/RESEARCH GRANTS - CSL Behring , Genentech
Pedersen Gleason Gleason Gleason Gleason Gleason Glickstein Glikich Glinel Mortreuil Glover Gluckman Gluckman Gluckman Gluck Glueck Go Go Go	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles Charles Charles Alan Alan Alan Alan	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in Arterial Diseases Advances in Lipid Management Updates in Stable Ischemic Heart Disease Updates on Risk Factors for Cardiovascular Disease Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hoptalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy. Post-Commercialization Study Ocular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia Alirocumab in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program Predictors of Long-Term Resource Utilization After Incident Percutaneous Coronary Intervention Levels of Obesity and Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Community-Based Cohort Does Frailty After the Benefits of Oral Anticoagulation in Patients With Atrial Fibrillation? Nusance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) The SHIVA Follow-Up Study: 10-Year Incidence	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - CSL Behring ,Genentech RESEARCH/RESEARCH GRANTS - CSL Behring ,Genentech RESEARCH/RESEARCH GRANTS - CSL Behring ,Genentech
Pedersen Gleason Gleason Gleason Gleason Gleason Gleason Glickstein Gliklich Glinel Mortreuil Glover Gluckman Gluckman Gluckk Gluck Go Go Go Go Go	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles Charles Charles Alan Alan Alan Alan Sanjay	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in Arterial Diseases Advances in Lipid Management Updates in Stable Ischemic Heart Disease Updates on Risk Factors for Cardiovascular Disease Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making Current Issues in Cardiovascular Epidemiology, Dispartites, and Safety	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panellst Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy: Post-Commercialization Study Ocular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia Alirocumab in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program Predictors of Long-Term Resource Utilization After Incident Percutaneous Coronary Intervention Levels of Obesity and Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Larg	Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific, Cook Medical, MEDTRONIC ROthing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc Rothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - CSL Behring ,Genentech RESEARCH/RESEARCH GRANTS - CSL Behring ,Genentech RESEARCH/RESEARCH GRANTS - CSL Behring ,Genentech
Pedersen Gleason Gleason Gleason Gleason Gleason Gleason Glickstein Glikkich Glinel Mortreuil Glover Gluckman Gluckman Gluckman Gluck Glueck Go Go Go	Thomas Thomas Thomas Julie Richard Bastien Chris Tyler Tyler Charles Charles Charles Alan Alan Alan Alan	Beans, Beans, Good for Your Heart The Challenges of Outcome Prediction in Valvular Heart Disease Vascular Medicine: Aortic and Peripheral Artery Diseases TAVR Outcomes Prognostication Innovations in Education Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Interventional Cardiology: TAVR 4 Novel Developments in Acute Coronary Syndromes When Anticoagulation Needs to be Stopped — What Are the Options? Pharmacology II Novel Mechanisms Underlying Ischemia-Reperfusion Injury in AMI Advances in Cholesterol Measurement and Management Vascular Medicine: Novel Risk Measures in Arterial Diseases Advances in Lipid Management Updates in Stable Ischemic Heart Disease Updates on Risk Factors for Cardiovascular Disease Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making Current Issues in Cardiovascular	Population-Based Cohort Study Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Fellow Outpatient Clinic: Discontinuing the Discontinuity A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure Incidence, Predictive and Prognostic Factors of Hoptalization for Congestive Heart Failure in Patients Implanted With Tavr Between 2010 and 2014 at Rouen University Hospital Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction Panelist 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy. Post-Commercialization Study Ocular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia Alirocumab in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program Predictors of Long-Term Resource Utilization After Incident Percutaneous Coronary Intervention Levels of Obesity and Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Community-Based Cohort Does Frailty After the Benefits of Oral Anticoagulation in Patients With Atrial Fibrillation? Nusance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) The SHIVA Follow-Up Study: 10-Year Incidence	Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC RESEARCH/RESEARCH GRANTS - Boston Scientific,Cook Medical,MEDTRONIC Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - CSL Behring ,Genentech RESEARCH/RESEARCH GRANTS - CSL Behring ,Genentech RESEARCH/RESEARCH GRANTS - CSL Behring ,Genentech

Congress of the congress of th				<u> </u>
Last Name Goda	First Name Akiko	Session Title Highlighted Original Research: Pulmonary	Presentation Title Simplified Measures of Right Ventricular and Atrial Remodeling Are	Disclosures Nothing to Disclose
		Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Predictive of Outcomes in Patients With Pulmonary Hypertension	
Goedemans	Laurien	Non Invasive Imaging: MR Scar and Perfusion	Functional Consequences of Myocardial Scar After Myocardial Infarction: Characterization of Myocardial Scar Extent With Late Gadolinium Contrast Enhanced Cardiac Magnetic Resonance and Impact on Multilayer Global Longitudinal Strain on Speckle Tracking Echocardiography	Nothing to Disclose
Goel	Kashish	Valvular Heart Disease: Endocarditis	Infective Endocarditis Following Transcutaneous Aortic Valve Implantation: Clinical, Echocardiographic and Hemodynamic Features	Nothing to Disclose
Goel	Kashish	Interventional Cardiology: TAVR 2	Association of Chronic Renal Insufficiency With In-Hospital Outcomes of Transcatheter Aortic Valve Replacement	Nothing to Disclose
Goel	Kashish	Innovative Use of Echocardiography	E/e' > 15 Performs Poorly in Patients With Elevated Left Filling Pressures and Atrial Fibrillation/Flutter: A Simultaneous Doppler-Catheterization Study	Nothing to Disclose
Goel	Kashish	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Sex Differences in Revascularization and In-Hospital Outcomes of Non-ST-Segment Elevation Myocardial Infarction in the United States	Nothing to Disclose
Goel	Kashish	Interventional Cardiology: TAVR 3	Regional Variations in In-Hospital Outcomes and Healthcare Resource Utilization in Patients Undergoing Transcatheter Aortic Valve Replacement in the United States	Nothing to Disclose
Goel	Kashish	Insights From Echocardiography Use	Miscalculation of Right Atrial Pressure by Echocardiography in Patients With Structural Heart Disease: A Simultaneous Echocardiography-Catheterization Study	Nothing to Disclose
Goel	Kashish	Prosthetic Valve Thrombosis: TAVR, Bio, Mech Now What?!	Poor Outcome of Thrombolysis in Right-Sided Mechanical Valve Thrombosis: Largest Single Center Experience	Nothing to Disclose
Goel	Sachin	02. Acute and Stable Ischemic Heart Disease: Clinical Team 2	Suggested Reviewer	SPEAKER'S BUREAU - Sanofi-Aventis, Regeneron
Goessi	Mario	Great Minds Think Differently: Multidisciplinary Approach to Advanced Therapies	Transcatheter Technologies to Manage Tricuspid Regurgitation	Nothing to Disclose
Goessl	Mario	Interventional Cardiology: TAVR 4	Minimalist Approach to Cardiac Anesthesia and Outcome in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Goessi	Mario Andreas	37. Valvular Heart Disease: Therapy Team 1	Suggested Reviewer Edoxaban Therapy Increases Treatment Satisfaction and Reduces	Nothing to Disclose
Goette	Andreas	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Utilization of Health Care Resources: An Analysis From the Edoxaban versus warfariN in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) Study	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc. Bristol-Myers Squibb Company, Daiichi Sankyo, Pfzer Inc; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Berlin Chemie, Boehringer Ingelheim Pharmaceuticals, Inc.Bristol-Myers Squibb Company, Daiichi Sankyo, MEDTRONIC, Pfzer Inc, Sanofi-Aventis
Goff	David	Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools	Association of 10-Year Change in Cardiovascular Risk Factors With Progression of Pericardial Adipose Tissue: The CARDIA Study	Nothing to Disclose
Gogas	Bill	Advances in Chronic Total Occlusion Intervention	Performance of J-CTO and PROGRESS CTO Scores in Predicting Angiographic Success and Long-Term Clinical Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions	Nothing to Disclose
Gogo	Prospero	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	New-Onset Platypnea Orthodeoxia and Old Patent Foramen Ovale: Close It or Not to Close It?	Nothing to Disclose
Gogo	Prospero	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Looking for a Clot: Paget-Schroetter Syndrome as Cause of Chronic Thromboembolic Pulmonary Hypertension	Nothing to Disclose
Goitein	Orly	Non Invasive Imaging: Expanding Clinical Applications	Impact of Different Calcium Locations of Mitral Annulus and Aortic Valve Cusps on Risk of Conduction Disturbances After Transcatheter Aortic Valve Implantation	Nothing to Disclose
Gokhroo	Rajendra	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	A New Proposed Comprehensive Coronary Artery Lesion Description (CALD) Code System and Coronary Artery Angiographic Segmental (CAAS) Classification - A Mathematical Model: Indian Society of Cardiology (ISC) Working Group Code for PhysiciansÙ Ease	Nothing to Disclose
Gokhroo	Rajendra	Interventional Complexity and Complications	Initial Experience of 265 Cases of Trans Ulnar Access Angioplasty: Interim Analysis of a Single Centre Observational Study From AJULAST (AJmer ULnar Angioplasty Study) Cohort	Nothing to Disclose
Golamari	Reshma	Diabetes and Other Issues in Cardiovascular Prevention	Predictive Risk Stratification Using HEART and Thrombolysis in Myocardial Infarction Scores in Low Risk Chest Pain Patients: An Urban Community Based Hospital Study	Nothing to Disclose
Golba	Krzysztof	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Frailty as a Predictor of Negative Outcomes After Cardiac Resynchronization Therapy	Nothing to Disclose
Golbari	Shervin	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Unloading the Left Ventricle: A Case of Mechanical Circulatory Support in Acute Aortic Insufficiency	Nothing to Disclose
Golbari	Shervin	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Acute Pulmonary and Paradoxical Embolism Treated With Catheter Based Thrombectomy	Nothing to Disclose
Golbari	Shervin	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Comparison of In-Hospital Outcomes of Septic Shock Patients With and Without Atrial Fibrillation: A Retrospective Propensity-Matched Analysis	Nothing to Disclose
Gold	Michael	Controversies in Arrhythmia Management: Joint Symposium of the Heart Rhythm Society and the American College of Cardiology	Should Patients with Right Bundle Branch Block Receive CRT?	RESEARCH/RESEARCH GRANTS - Boston Scientific,St Jude Medical
Gold	Michael	FIT Clinical Decision Making Reviewers 3	ACC FIT Clinical Decision Making Reviewer	RESEARCH/RESEARCH GRANTS - Boston Scientific, St Jude
Goldberg	Anne	Advances in Cholesterol Measurement and Management	Contemporary Patterns of Lipid Testing in Primary and Secondary Prevention Patients: Insights From the PALM Registry	Medical CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals Merck Optum Rx, Sanofi-Aventis; RESEARCH/RESEARCH GRANTS - Amarin,Amgen,Genentech/Roche,Glaxo-Smith- Kline,Ionis,ISIS/Genzyme,Merck,Pfizer Inc,Regeneron (now part of Sanofi-Aventis)
Goldberg	Anne	Advances in Lipid Management	Alirocumab in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Merck,Optum Rx,Sanofi-Aventis; RESEARCH/RESEARCH GRANTS -
				Amarin,Amgen,Genentech/Roche,Glaxo-Smith- Kline,Ionis,ISIS/Genzyme,Merck,Pfizer Inc,Regeneron (now part of Sanofi-Aventis)
Goldberg	Lee	Resistant Hypertension in the Pulmonary and Systemic Beds: International Perspectives From the ACC Argentina Chapter, Korean Society of Cardiology, and American College of Cardiology	Systemic and Pulmonary Hypertension - Impact on Ventricular Function	Kline,lonis,IŠIS/Genzyme,Merck,Pfizer Inc,Regeneron (now part of Sanoft-Aventis) CONSULTANT FEES/HONORARIA - MEDTRONIC,St. Jude; RESEARCH/RESEARCH GRANTS - Respircardia
Goldberg	Lee	Systemic Beds: International Perspectives From the ACC Argentina Chapter, Korean Society of Cardiology, and American College		Kline,Ionis,ISIS/Genzyme,Merck,Pfizer Inc,Regeneron (now part of Sanofi-Aventis) CONSULTANT FEES/HONORARIA - MEDTRONIC,St. Jude;

WASHINGTON, DC | MARCH 17 - 19 2017

Last Name	First Name	Session Title	Presentation Title	Disclosures
Goldberg	Lee	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Co-Chair	CONSULTANT FEES/HONORARIA - MEDTRONIC,St. Jude; RESEARCH/RESEARCH GRANTS - Respircardia
Goldberg	Lee	14. Heart Failure and Cardiomyopathies: Therapy Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC,St. Jude; RESEARCH/RESEARCH GRANTS - Respircardia
Goldberg	Lee	Interventional Challenging Cases: Team 2	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC,St. Jude; RESEARCH/RESEARCH GRANTS - Respircardia
Goldberg	Sarah	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Idiopathic Fascicular Left Ventricular Tachycardia and Dilated Cardiomyopathy: An Unusual Combination in a 19-Year-Old College	Nothing to Disclose
Goldberg	Steven	17. Interventional Cardiology: Aortic Valve Disease Team 2	Athlete Suggested Reviewer	CONSULTANT FEES/HONORARIA - St. Jude; OTHER - Cardiac Dimensions, Inc
Goldberger	Jeffrey	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Sudden Cardiac Death Risk Distribution in the United States Population: Results From the National Health and Nutrition Examination Survey (NHANES), 2005-2012	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Path to Improved Risk Stratification
Goldberger	Jeffrey	Updates on Risk Factors for Cardiovascular Disease	Hospital Admissions for Chest Pain Associated With Cocaine use in the United States	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Path to Improved Risk Stratification
Goldberger	Jeffrey	Why Can't We Be Friends? Controversies in Heart Failure Management	Cardiac Resynchronization Therapy in Inotropic-Dependent Heart Failure Patients: A Systematic Review and Meta-Analysis	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Path to Improved Risk Stratification
Goldberger	Jeffrey	FIT Clinical Decision Making Reviewers 7	ACC FIT Clinical Decision Making Reviewer	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Path to Improved Risk Stratification
Goldberger Goldberger	Zachary Zachary	Syncope: What's New Engage @ ACC.17 Studio: FIT Jeopardy Battle	Syncope Monitoring: What Monitor for Which Patient?	Nothing to Disclose Nothing to Disclose
Goldberger	Zacilaly	of the State Chapters IV	iwoder ator	Nothing to Disclose
Goldenberg	llan	Diabetes and Other Issues in Cardiovascular Prevention	Impaired Fasting Glucose Is the Major Determinant of the 20-Year Mortality Risk Associated With Metabolic Syndrome in Non-Diabetic Patients With Stable Coronary Artery Disease	Nothing to Disclose
Goldfarb	Michael	Interventional Cardiology: TAVR 4	Serum Albumin as an Incremental Predictor of Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement: Results From the Multicenter Frailty-AVR Study	Nothing to Disclose
Goldhaber	Joshua	12. Heart Failure and Cardiomyopathies: Basic Team 1	Suggested Reviewer	Nothing to Disclose
Goldhaber	Samuel	FIT Forum: Mix and Mingle	Thrombosis	CONSULTANT FEES/HONORARIA - Bayer,BMS,Boeringer Ingelheim, Daiichi Sankyo,Janssen,Portola; RESEARCH/RESEARCH GRANTS - BMS,BTG,Daiichi,NHLBI,Thrombosis Research Institute
Goldhaber	Samuel	Challenging the Standard of Care: Emerging Concepts in VTE Treatment and Prevention	Managing Life-threatening Bleeding in Patients Taking Non-vitamin K Oral Anticoagulants: When and How to Use Reversal Agents	CONSULTANT FEES/HONORARIA - Bayer,BMS,Boeringer Ingelheim,Daiichi Sankyo,Janssen,Portola; RESEARCH/RESEARCH GRANTS - BMS,BTG,Daiichi,NHLBI,Thrombosis Research Institute
Goldhaber	Samuel	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Treatment and Outcomes of Patients With Nonvalvular Atrial Fibrillation According to Guideline-Defined Anticoagulation Thresholds: Results From the GARFIELD-AF Registry	CONSULTANT FEES/HONORARIA - Bayer,BMS,Boeringer Ingelheim,Daiichi Sankyo,Janssen,Portola; RESEARCH/RESEARCH GRANTS - BMS,BTG,Daiichi,INHLBI,Thrombosis Research Institute
Goldhaber	Samuel	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Prior Hospitalization Within 30 Days Predicts Increased Frequency of Death, Stroke, and Bleeding in Advanced Elderly Outpatients With Atrial Fibrillation	CONSULTANT FEES/HONORARIA - Bayer,BMS,Boeringer Ingelheim,Daiichi Sankyo,Janssen,Portola; RESEARCH/RESEARCH GRANTS - BMS,BTG,Daiichi,JNHLBI,Thrombosis Research Institute
Goldhaber	Samuel	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Early Mortality in Patients With New Onset Atrial Fibrillation: Results From the GARFIELD-AF Registry	CONSULTANT FEES/HONORARIA - Bayer,BMS,Boeringer Ingelheim,Daiichi Sankyo,Janssen,Portola; RESEARCH/RESEARCH GRANTS - BMS,BTG,Daiichi,JNHLBI,Thrombosis Research Institute
Goldman	Elie	Coarctation of the Aorta, from Repair to Lifelong Care	The Patient Experience	Nothing to Disclose
Goldman	Martin	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Acute Echo-Guided Management of Cardiogenic Shock After Anterior Myocardial Infarction Complicated by Dynamic Left Ventricular Outflow Tract Obstruction	Nothing to Disclose
Goldman	Martin	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Left Ventricular Outflow Tract Obstruction Post ST-Elevation Myocardial Infarction as a Cause for Shock and the Role of Bedside Echocardiography in Guiding Therapy	Nothing to Disclose
Goldman	Mitchell	Innovations in Education	Update on the ABIM's Competency Based Pilot in Internal Medicine- Cardiology	Nothing to Disclose
Goldmuntz	Elizabeth	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Right Ventricular Contractile Reserve Is Reduced in Children and Adolescents With Tetralogy of Fallot: A Stress Echocardiographic	Nothing to Disclose
Goldschmidt	Marc	Emerging Developments in HFpEF and Arryhthmias	Study Is Continuous Outpatient Milrinone Therapy Appropriate in Stage D Heart Failure Patients With Underlying Ventricular Tachycardia	Nothing to Disclose
Goldsmith	Steven	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Effect of Pulmonary Pressure Monitoring (CardioMEMS Heart Failure System, St. Jude Medical) on Hospital Admissions and Emergency Department Visits: A Multicenter Real World Experience	CONSULTANT FEES/HONORARIA - Ostuka; RESEARCH/RESEARCH GRANTS - St. Jude Medical; SPEAKER'S BUREAU - Novartis
Goldsmith	Steven	Innovative Use of Echocardiography	Prognostic Utility of Hand-Carried Ultrasound Compared to Clinical and Laboratory Assessment of Decongestion to Predict Outcomes in Hospitalized Patients With Heart Failure	CONSULTANT FEES/HONORARIA - Ostuka; RESEARCH/RESEARCH GRANTS - St. Jude Medical; SPEAKER'S BUREAU - Novartis
Goldsmith	Steven	Insights From Echocardiography Use	Comparison of Clinical Exam, Patient Symptoms and Hand-Carried Ultrasound in Assessing Decongestion of Hospitalized Patients With Heart Failure	CONSULTANT FEES/HONORARIA - Ostuka; RESEARCH/RESEARCH GRANTS - St. Jude Medical; SPEAKER'S BUREAU - Novartis
Goldstein	Bryan	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Safety and Feasibility of Melody Transcatheter Pulmonary Valve Replacement in the Native Right Ventricular Outflow Tract: A Multicenter Study	CONSULTANT FEES/HONORARIA - B Braun Medical Inc, Gore Medical, St. Jude Medical
Goldstein	Bryan	Engage @ ACC.17 Studio:The Newlywed Game for Pediatric Cardiac Providers	Participant, Team 1	CONSULTANT FEES/HONORARIA - B Braun Medical Inc,Gore Medical,St. Jude Medical
Goldstein	Bryan	Congenital Heart Disease: Pediatric Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - B Braun Medical Inc,Gore Medical,St. Jude Medical
Goldstein	Daniel	Evolving Therapies in Heart Failure: Gazing Into the Crystal Ball	Next Generation LVADs: Smaller, Lighter, Better	RESEARCH/RESEARCH GRANTS - St Jude Medical
Goldstein	James	Arrhythmias and Clinical EP: Devices 4	Pacemaker-Induced Tricuspid Regurgitation Is Uncommon	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - ECLS,
Goldstone	Andrew	Can CABG Patch CAD?	Bypass: A State-Wide Analysis of 60,897 Patients	Inc Nothing to Disclose
Goldsweig	Andrew	Interventional Cardiology: TAVR 3	Infective Endocarditis After Transcatheter Aortic Valve Replacement: Insights From the Nationwide Readmissions Database	Nothing to Disclose
Golestaneh	Safieh	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		Nothing to Disclose
Golino	Paolo	Novel Mechanisms Underlying Ischemia-	Activating Stimuli Modulate Pre-mRNA Maturation in Platelets: A	Nothing to Disclose
Golino	Paolo	Reperfusion Injury in AMI MicroRNAs and Beyond in Vascular Medicine	Novel Mechanism That Regulates Platelet Function? Colchicine Exerts Antithrombotic Properties in oxLDL-Treated Endothelial Cells via Inhibition of Tissue Factor Expression and	Nothing to Disclose
Golino	Paolo	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Activity Relationship Between Fractional Flow Reserve (FFR) and Coronary Flow Reserve (CFR) by PET in Identifying Coronary Stenosis	Nothing to Disclose
]	. tovascularization and Outcomes	Causing Myocardial Ischemia	

Contract of the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Golino	Paolo	Cutting Edge Vascular Medicine	Colchicine Inhibits Platelet Aggregation <i>In Vitro </i> With Cofilin and LIM Domain Kinase 1, the Main Kinases Involved in Cytoskeleton Rearrangement	Nothing to Disclose
Golive	Anjani	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Long Term Outcomes and Risk Stratification in Atrial Fibrillation Patients With Low Risk Chads ₂ ≤1 With Antithrombotic Therapy	Nothing to Disclose
Golwala	Harsh	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Thirty-Day Readmission Rate and Cost After Percutaneous Coronary Intervention in the United States: A National Readmission Database Analysis	Nothing to Disclose
Golzar	Jaafer	Great Minds Think Differently: Multidisciplinary Approach to Controversies in Cardiology	Case Presentation: Algorithms for the Treatment of ISR in the Peripheral SX	CONSULTANT FEES/HONORARIA - Avinger, Boston Scientific, MEDTRONIC
Golzar	Jaafer	Great Minds Think Differently: Multidisciplinary Approach to Imaging	Panelist	CONSULTANT FEES/HONORARIA - Avinger, Boston Scientific, MEDTRONIC
Golzar	Jaafer	Great Minds Think Differently: Multidisciplinary Approach to Imaging	Case Presentation: The Use of Imaging in PVD When Is DUS/CTA/Angio Appropriate?	CONSULTANT FEES/HONORARIA - Avinger, Boston Scientific, MEDTRONIC
Gomadam	Pallavi	Valvular Heart Disease: Aortic Stenosis	Surgical Risk Scores Outweigh Echocardiographic Severity of Aortic	Nothing to Disclose
			Stenosis for Determining Prognosis in Patients With Low Gradient Severe Aortic Stenosis and Preserved Left Ventricular Function	
Gomadam	Pallavi	Diabetes and Other Issues in Cardiovascular Prevention	Blood Pressure Indices and Cardiovascular Mortality in Diabetics and Non Diabetics	Nothing to Disclose
Gomberg-Maitland	Mardi	Deciphering Pulmonary Hypertension Due to Left Heart Disease: Have Hope Oh Ye Who Enter	Making Sense of the Sensor: Monitoring Options for Combined Post- and Precapillary Pulmonary Hypertension - So What?	CONSULTANT FEES/HONORARIA - Arena, Bayer Healthcare Pharmaceuticals, gilead, MEDTRONIC, Merck & amp; amp; Co., Inc., UCB, United Therapeutics; DATA SAFETY MONITORING BOARD - REATA; OTHER - Actelion
Gomberg-Maitland	Mardi	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Co-Chair	CONSULTANT FEES/HONORARIA - Arena, Bayer Healthcare Pharmaceuticals, gilead, MEDTRONIC, Merck & amp; amp; Co., Inc., UCB, United Therapeutics; DATA SAFETY MONITORING BOARD - REATA; OTHER - Actelion
Gomez	Joanne Michelle	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Recurrence of Cardiac Sarcoidosis Post-Orthotropic Heart Transplant in the Background of Allograft Rejection	Nothing to Disclose
Gomez Doblas	Juan Jose	Imaging and Infections: International Perspectives From the Spanish Society of Cardiology, Venezuelan Society of Cardiology, and American College of Cardiology	Risk Stratification and Timing for Surgery in Éndocarditis	Nothing to Disclose
Gomez-Doblas	Juan Jose	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years	Nothing to Disclose
Goncalvez-Alvarez	Silvia	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Cardiovascular Health of Offspring of Diabetic Mothers From the Fetus Through Late Infancy Stages	Nothing to Disclose
Gong	Yan	Novel Imaging and Therapies in Heart Failure	Global Longitudinal Strain in Patients With New Left Ventricular Systolic Dysfunction After Anticancer Targeted Therapies	Nothing to Disclose
Gong	Yan	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Cardiomyopathy Associated With Targeted Anticancer Therapies in Electronic Health Records	Nothing to Disclose
Gong	Yan	New Insights Into Prediction and Treatment of Hypertension	Relationship Between Diastolic Blood Pressure and All-Cause Mortality With Lower Systolic Blood Pressure Among Hypertensive Patients With Coronary Artery Disease: Long-Term Follow-Up of the US Cohort of the International Verapamil SR-Trandolapril Study (INVEST)	Nothing to Disclose
Gongora	Carlos	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Early Versus Delayed Invasive Intervention for Non-ST Segment Elevation Myocardial Infarction in Patients Older Than 80 Years: A Nationwide Analysis	Nothing to Disclose
Gongora	Carlos	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Impact of End Stage Renal Disease in Patients Hospitalized for Systolic and Diastolic Heart Failure: A Nationwide Analysis of 2013	Nothing to Disclose
Gongora	Carlos	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Low Socioeconomic Status Is Associated With Increased Inpatient Mortality With Non ST-Elevation Myocardial Infarction: A Nationwide Analysis	Nothing to Disclose
Gongora	Carlos	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Patients With Non ST-Segment Elevation Myocardial Infarction Utilizing Medicare/Medicaid Have Lower Adjusted Odds of In- Hospital Mortality: A Nationwide Analysis	Nothing to Disclose
Gongora	Carlos	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Adjusted Odds of Inpatient Mortality for Non-ST Elevation Myocardial Infarction Is Not Affected by Day of Admission: A Nationwide Analysis	Nothing to Disclose
Gongora	Carlos	Unusual Presentations of ACS	Stress Induced Cardiomyopathy (Takotsubo Cardiomyopathy): Mortality, Gender and Admission Month Based on a Nationwide Sample During 2013	Nothing to Disclose
Gongora	Carlos	Unusual Presentations of ACS	Clinical Outcomes of the Treatment of Cocaine Induced Chest Pain With Beta Blockers: A Meta-Analysis	Nothing to Disclose
Gongora	Carlos	Which Test Is Best for Pain in the Chest?	Outcomes in Patient With Chest Pain Evaluated Using Coronary Computed Tomography Angiography Versus Stress Imaging: A Meta-Analysis of Randomized Trials	Nothing to Disclose
Gonska	Birgid	Interventional Cardiology: TAVR 3	Apixaban in Atrial Fibrillation Patients With Renal Insufficiency After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Gonska	Birgid	Interventional Cardiology: TAVR 3	One Year Outcome in Patients Undergoing Transfemoral Aortic Valve Replacement (TAVR) With the Repositionable and Retrievable Boston Scientific Lotus Valve Compared With the Balloon-Expandable Edwards Sapien 3 Device	Nothing to Disclose
Gonska	Birgid	Refining TAVR Outcomes	Significant Reduction of Cerebral Ischemic Events With the Sentinel Cerebral Emboli Protection Device in Patients With Transcatheter Aortic Valve Replacement	Nothing to Disclose
Gonzales	Holly	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Hypertrophic and Failing From Flailing: Selecting the Right Surgery in Hypertrophic Cardiomyopathy With Mitral Valve Disease	Nothing to Disclose
Gonzalez	Elena	Diabetes and Endothelial Dysfucntion in Heart Failure	Interleukin 18 Impairs Excitation Contraction Coupling in Cardiomyocytes and Predicts Mortality in Acute Decompensated Heart Failure	Nothing to Disclose
Gonzalez	Maday	Antithrombotic Therapy in Ischemic Heart Disease	Role of Anticoagulation Therapy After Anterior Wall ST-Elevation Myocardial Infraction in Preventing LV Thrombus: A Meta-Analysis and Meta-Regression	Nothing to Disclose
Gonzalez	Maday	Beans, Beans, Good for Your Heart	Percutaneous Renal Denervation for Resistant Hypertension: An Updated Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Gonzalez	Waddy	Innovative Use of Echocardiography	High Prevalence of Apical Hypertrophic Cardiomyopathy Noted in Non-White Patients Referred for Clinical Echocardiography	Nothing to Disclose
González	Victoria	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Incidence, Clinical Profile and Prognosis of Patients With Myocardial Infarction With Non-Obstructive Coronary Arteries in the Real World	Nothing to Disclose
Gonzalez Bonilla	Hilda	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Scimitar Syndrome in an Adult With Multiple Unsuccessful Surgical Repairs	Nothing to Disclose
Gonzalez Bonilla	Hilda Mariana	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Quantitative Measurements on Cardiac Magnetic Resonance to	Nothing to Disclose
	<u>i </u>	Valuvular Heart Disease	Differentiate Benign Versus Malignant Masses: A Pilot Study	<u>L</u>

Last Name	First Name	Session Title	Presentation Title	Disclosures
Gonzalez Carta	Karina	Imaging and Infections: International Perspectives From the Spanish Society of	Co-Chair	Nothing to Disclose
		Cardiology, Venezuelan Society of Cardiology, and American College of Cardiology		
Gonzalez Carta	Karina	Imaging the Athlete's Heart	Acute Coronary Syndromes During Endurance Sports: Olmsted	Nothing to Disclose
Gonzalez Carta	Karina	Emerging Developments in HFpEF and	County Experience Myocarditis, Heart Failure and Arrhythmias in Patients With Zika	Nothing to Disclose
Gonzalez Carta	Karina	Arryhthmias	Exercise Test Predicts Both Cardiovascular and Non-Cardiovascular	Nothing to Disclose
			Mortality in Patients Without Cardiovascular Disease	-
Gonzalez Carta	Karina	New Perspectives on CAD Risk Factors	Coronary Artery Disease Patients With Concurrent Psychiatric Disorders at Greater Risk for Mortality	Nothing to Disclose
González Ferreiro	Rocío	Interventional Cardiology: TAVR 2	RenalGuard System for the Prevention of Contrast-Induced Nephropathy in Patients at High and Very-High Risk Undergoing Transcatheter Aortic Valve Implantation	Nothing to Disclose
González Ferreiro	Rocío	Interventional Cardiology: TAVR 2	Effect of Body Mass Index on Mortality After Transcatheter Aortic Valve Implantation: J-Shaped Curve	Nothing to Disclose
Gonzalez Juanatey	Jose Ramon	Interventional Cardiology: TAVR 2	RenalGuard System for the Prevention of Contrast-Induced Nephropathy in Patients at High and Very-High Risk Undergoing Transcatheter Aortic Valve Implantation	Nothing to Disclose
Gonzalez Juanatey	Jose Ramon	Interventional Cardiology: TAVR 2	Effect of Body Mass Index on Mortality After Transcatheter Aortic	Nothing to Disclose
Gonzalez-Gonzalez	Julia	Timely Topics in Acute Coronary Syndromes	Valve Implantation: J-Shaped Curve Time to Treatment With Melatonin and Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction: Insights From the MARIA (Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty) Trial	Nothing to Disclose
Gonzalez-Pacheco	Hector	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Derivation and Validation of a Simple Inflammation Based Risk Score for Predicting In-Hospital Mortality in Acute Coronary	Nothing to Disclose
Goodlin	Sarah	Syndrome Palliative Care for the 99% III: Skillbuilding: PC Encounters: What Would you do? Part II	Syndrome Co-Chair	CONSULTANT FEES/HONORARIA - Novartis
Goodlin	Sarah	Innovations in Advocacy and Patient Centered Care	Describing Collaboration Between Cardiology and Palliative Care: A National Survey Study of Current Practices, Challenges and Barriers	CONSULTANT FEES/HONORARIA - Novartis
Goodlin	Sarah	13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Novartis
	Andrew	Clinical Team 4 Novel Determinants of Outcomes in VHD		Nothing to Disclose
Goodman	Andrew	Novel Determinants of Outcomes in VHD	Valvuloarterial Impedance and Left Ventricular Global Longitudinal Strain Provide Incremental Prognostic Value in Patients With Significant Aortic Stenosis and Preserved Left Ventricular Ejection Fraction	Nothing to Disclose
Goodman	Jack	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	e-Counseling for Self-Care Adherence Adds Therapeutic Benefit for Hypertension: The REACH Trial	Nothing to Disclose
Goodman	Shaun	Advances in Lipid Management	Use of High-Intensity Statin Therapy Post-Acute Coronary Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody, Versus Placebo: Interim Baseline Data	CONSULTANT FEES/HONORARIA - Amgen Inc., Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Ferring Pharmaceuticals, Merck, SANOFI; DATA SAFETY MONITORING BOARD - GlaxoSmithKline, Matrizyme; RESEARCH/RESEARCH GRANTS - Amgen Inc., GOAL, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, Regeneron, SANOFI, servier, Tenax Pharmaceuticals
Goodman	Shaun	03. Acute and Stable Ischemic Heart Disease: Therapy Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen Inc., Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Llily, Ferring Pharmaceuticals, Merck, SANOFI; DATA SAFETY MONITORING BOARD - GlaxoSmithKline, Matrizyme; RESEARCH/RESEARCH GRANTS - Amgen Inc., GOAL, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Llily, GlaxoSmithKline, Novartis, Pfizer, Regeneron, SANOFI, servier, Tenax Pharmaceuticals
Goodney	Philp	Born To Run: Geographic Variation in PAD Diagnosis, Treatment and Outcomes	Medical Therapy: The NCDR and VQI Registry Experience	Nothing to Disclose
Goodrich	Erica	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Cystatin C Is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An	Nothing to Disclose
Goodrich	Kate	Coronary Artery Disease How to Redesign a Care Delivery Team in	Analysis From the SOLID-TIMI 52 Trial Panelist	Nothing to Disclose
Goodrich	Kate	Preparation for MACRA and MIPS How to Redesign a Care Delivery Team in	The CMS Perspective on MACRA	Nothing to Disclose
Gopal	Aasha	Preparation for MACRA and MIPS Technical Advances in Transthoracic Echocardiography	Safety of Perflutren-Based Echocardiographic Contrast Agent Administration in the Setting of a Patent Foramen Ovale (PFO): A Multicenter Study Conducted in Tertiary Care Centers Based in the	Nothing to Disclose
Gopal	Ambarish	Prosthetic Valve Thrombosis: TAVR, Bio,	New York/Chicago Metropolitan Areas Incidence of Valve Leaflet Thrombosis in Transcatheter and	Nothing to Disclose
Gopal	Deepika	Mech Now What?! Prosthetic Valve Thrombosis: TAVR, Bio,	Surgical Bioprosthetic Aortic Valves by 4D CT Imaging Incidence of Valve Leaflet Thrombosis in Transcatheter and	Nothing to Disclose
		Mech Now What?! Vascular Access and Hemostasis Issues	Surgical Bioprosthetic Aortic Valves by 4D CT Imaging	Nothing to Disclose
Gopalakrishnan Gopalakrishnan	Prabhakaran Prabhakaran	Vascular Access and Hemostasis Issues FIT Clinical Decision Making: Interventional	Mid Femoral Head Is Not the Ideal Fluroscopic Landmark for Common Femoral Artery Puncture A Rare Case of Chronic Persistent Troponin Elevation	Nothing to Disclose Nothing to Disclose
•		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	·	-
Gopinathannair	Rakesh	Arrhythmias and Clinical EP: Ventricular Tachycardia	Impact of Arrhythmia Duration and Index Left Ventricular Ejection Fraction on Recovery of Left Ventricular Function in Patients With Arrhythmia-Induced Cardiomyopathy	CONSULTANT FEES/HONORARIA - AltaThera Pharma,Boston Scientific,HealthTrust PG,St. Jude Medical; SPEAKER'S BUREAU - Bristol-Myers Squibb Company ,Pfizer Inc,Zoll Medica
Gopinathannair	Rakesh	Innovations in Advocacy and Patient Centered Care	Status of Early Career Academic Cardiology: A Global Perspective	CONSULTANT FEES/HONORARIA - AltaThera Pharma,Boston Scientific,HealthTrust PG,St. Jude Medical; SPEAKER'S BUREAU - Bristol-Myers Squibb Company ,Pfizer Inc,Zoll Medica
Goransson	Christoffer	Advances in Pulmonary Arterial Hypertension	Exercise During Cardiac Magnetic Resonance Imaging Dilates the Right Ventricle and Compresses the Left Ventricle in Pulmonary	RESEARCH/RESEARCH GRANTS - Actelion Danmark
Goransson	Christoffer	Advances in Pulmonary Arterial Hypertension	Arterial Hypertension Optimizing Assessment of Right Ventricular Stroke Volume Using Flow Cardiovascular Magnetic Resonance Imaging in Pulmonary	RESEARCH/RESEARCH GRANTS - Actelion Danmark
Gorbachevskiy	Sergey	Advances in Pulmonary Arterial Hypertension	Arterial Hypertension Long-Term Results of Interatrial Septum Fenestration With Stent	Nothing to Disclose
Gorcsan	John	Distinct Phenotypes in HFpEF: Beyond	Implantation in Idiopathic Pulmonary Arterial Hypertension Diagnostic Evaluation of Patients with Dyspnea and Normal LVEF	RESEARCH/RESEARCH GRANTS - Biotronik,GE Corp.,Hitachi
		Ejection Fraction		Aloka,MEDTRONIC,Toshiba
Gorcsan	John	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Simplified Measures of Right Ventricular and Atrial Remodeling Are Predictive of Outcomes in Patients With Pulmonary Hypertension	RESEARCH/RESEARCH GRANTS - Biotronik,GE Corp.,Hitachi Aloka,MEDTRONIC,Toshiba



Contract of the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Gorcsan	John	Novel Echocardiographic Methods for Assessing Cardiac Function	Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain	RESEARCH/RESEARCH GRANTS - Biotronik,GE Corp.,Hitachi Aloka,MEDTRONIC,Toshiba
Gorcsan	John	Advances in HCM, PPCM and Other	Extended Course of Recovery in Patients With Peripartum	RESEARCH/RESEARCH GRANTS - Biotronik,GE Corp.,Hitachi
Gorcsan	John	Cardiomyopathies New Technologies in Echocardiography	Cardiomyopathy Assessed by Left Ventricular Wall Distensibility Assessment of Right Ventricular Energy Loss and Efficiency Using	Aloka,MEDTRONIC,Toshiba RESEARCH/RESEARCH GRANTS - Biotronik,GE Corp.,Hitachi
Gorcsan	John		Novel Vector Flow Mapping When the Liver Gets Sacked by the Heart Sac: A Diagnostic	Aloka,MEDTRONIC,Toshiba RESEARCH/RESEARCH GRANTS - Biotronik,GE Corp.,Hitachi
Gorcsan	John	Pulmonary Hypertension 28. Non Invasive Imaging: Echo Team 2	Challenge of Mixed Heart and Liver Pathology Suggested Reviewer	Aloka,MEDTRONIC,Toshiba RESEARCH/RESEARCH GRANTS - Biotronik,GE Corp.,Hitachi
Gorcyca	Katherine	Advances in Cholesterol Measurement and	Contrasting US Patients With a Fill Versus a Prescription for	Aloka,MEDTRONIC,Toshiba SALARY - SANOFI
		Management	Alirocumab: Early Evidence From Administrative Claims, EMR and Lab Data	
Gordin	Jonathan	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Incidence and Factors Associated With New-Onset Cardiomyopathies Following Liver Transplantation	Nothing to Disclose
Gordon	Neil	Innovations in Cardiovascular Risk Assessment and Reduction	Evaluation of the CardioSmart Population Health Management Initiative: Changes in Health Risks and Participant Satisfaction	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - PrevCan, Inc; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - INTERVENT International, LLC
Gordon	Paul	Interventional Cardiology: TAVR 3	Infective Endocarditis After Transcatheter Aortic Valve Replacement: Insights From the Nationwide Readmissions Database	RESEARCH/RESEARCH GRANTS - Abbott Vascular,Accumetrics ,Eli Lilly,Roche,SANOFI
Gordon	Steve	Valvular Heart Disease: Endocarditis	Comparison of Non-Surgical and Surgical Therapy for Prosthetic Valve Endocarditis: A Propensity Score-Adjusted Study	DATA SAFETY MONITORING BOARD - Thoratec
Gordon	Steve	Valvular Heart Disease: Aortic Regurgitation	Etiology, Patient Characteristics and Surgical Outcomes of Acute Severe Aortic Regurgitation	DATA SAFETY MONITORING BOARD - Thoratec
Gorenek	Bulent	Stoke and Atrial Fibrillation: Innocent Bystander or Essential Ingredient	Co-Chair	Nothing to Disclose
Gorenek	Bulent	Stroke and AF: Thinking About the Heart	ACC Poster Moderator	Nothing to Disclose
Gorgis	Sarah	Interventional Cardiology: TAVR 3	Predictors of Late Bleeding in the TAVR Population	Nothing to Disclose
Gori	Tommaso	Highlighted Original Research: Interventional Cardiology and the Year in Review	Clinical, Angiographic and Procedural Correlates of Absorb Scaffold Thrombosis: A Matched Multicenter Registry Analysis	Nothing to Disclose
Gormsen	Lars	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Prognostic Value of Coronary Computed Tomography Angiography, Myocardial Perfusion Imaging and Invasive Coronary Angiography in Kidney Transplantation Candidates: A Prospective Cohort Study	Nothing to Disclose
Gornik	Heather	Vascular Diagnoses Cardiologists Should not Miss: A Case-based Approach	Case Presentation: Young Patient with Multivessel Dissection and Aneurysms	OTHER - Summit Doppler Systems; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Zin Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca
Gornik	Heather	Maximally Effective Vascular Care: Vascular Collaborative Team Care in Action	Co-Chair	OTHER - Summit Doppler Systems; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Zin Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca
Gornik	Heather	Maximally Effective Vascular Care: Vascular Collaborative Team Care in Action	Case Presentation #4: Panel Discussion Moderator	OTHER - Summit Doppler Systems; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Zin Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca
Gornik	Heather	Meet the New LE PAD Guidelines: Case- Based Examples of Optimal Vascular Care	Performing the 'Perfect' Vascular H and P	OTHER - Summit Doppler Systems; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Zin Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca
Gornik	Heather	Highlighted Original Research: Vascular Medicine and the Year in Review	Year in Review Speaker	OTHER - Summit Doppler Systems; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Zin Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca
Gornik	Heather	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Family History of Arterial Disorders in Patients With Spontaneous Coronary Artery Dissection	OTHER - Summit Doppler Systems; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Zin Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca
Gornik	Heather	40. Vascular Medicine: Non Coronary Arterial Disease Team 1	Suggested Reviewer	OTHER - Summit Doppler Systems; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Zin Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca
Gorog	Diana	Antithrombotic Therapy in Ischemic Heart Disease	Changes in Thrombotic Parameters in Patients With Refractory Angina and Raised Lipoprotein(a) Treated With Lipoprotein Apheresis	RESEARCH/RESEARCH GRANTS - Bayer; SPEAKER'S BUREAU - Bayer
Gorog	Diana	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Comparative Effects of Different P2Y ₁₂ Inhibitors on Global Thrombotic Status in Coronary Artery Disease	RESEARCH/RESEARCH GRANTS - Bayer; SPEAKER'S BUREAU - Bayer
Gosavi	Sucheta	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Combined Migraine and Platypnea-Orthodeoxia Syndrome Due to Combined Atrial Septal Defect and Patent Foramen Ovale	Nothing to Disclose
Gosavi	Sucheta	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Double Right Coronary Artery Engendering Inadequate Blood Supply to the Inferior Left Ventricular Wall	Nothing to Disclose
Gosch	Kensey	Advances in Chronic Total Occlusion	Association of Stress Test Risk Classification With Health Status	Nothing to Disclose
		Intervention	Change After Chronic Total Occlusion PCI: Insights From the OPEN- CTO Registry	
Gosch	Kensey	Advances in Chronic Total Occlusion Intervention	Patients With Depressed Left Ventricular Systolic Function: Insights From the OPEN-CTO Registry	Nothing to Disclose
Gosling	Rebecca	Considerations in Antiplatelet Therapy and in ACS	Comparison of P2y ₁₂ Inhibitors for Mortality and Stent Thrombosis in Patients With Acute Coronary Syndromes: Single Centre Study of 10,793 Consecutive 'Real-World' Patients	Nothing to Disclose
Gossett	Jeffrey	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Patients Congenital Heart Surgery in Patients With Trisomy 13 Associated With Lower In-Hospital Mortality	Nothing to Disclose
Gossett	Jeffrey	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Short Axis Diastolic Ventricular Area Ratio as a New Index in Screening Patients With Repaired Tetralogy of Fallot	Nothing to Disclose
Gössl	Mario	Valvular Disease Populations at Risk	Surgical Risk and Therapy of Severe Symptomatic Degenerative Mitral Valve Regurgitation in the Contemporary Era	Nothing to Disclose
Gössl	Mario	Valvular Heart Disease: Mitral Valve Disease	Guideline-Adherence and Survival for Asymptomatic Patients With Severe Mitral Valve Regurgitation	Nothing to Disclose
Goswami	Nilesh	Interventional Challenging Cases: Team 2	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientfic,MEDTRONIC
Goswami	Robi	The Evolving World of LVADs, Transplant and	Coronary Artery Disease Learning and Algorithm Development	RESEARCH/RESEARCH GRANTS - Analytics 4 life
Goswami	Rohan	Other Novel Discoveries Interventional Cardiology: Structural Heart	Study: Early Analysis of Ejection Fraction Evaluation Outcomes of Early Versus Delayed Transcatheter Closure of Post-	Nothing to Disclose
Götberg	Matthias	Disease Late-Breaking Clinical Trials: Interventional	Myocardial Infarction Ventricular Septal Defect Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve	CONSULTANT FEES/HONORARIA - Boston
			Guided Intervention (IFR-SWEDEHEART): A Multicenter, Prospective, Registry-Based Randomized Clinical Trial	Scientific,MEDTRONIC,Volcano Corp; RESEARCH/RESEARCH GRANTS - Volcano Corp
Götberg	Matthias	Late-Breaking Clinical Trials: Deep Dive I	Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve Guided Intervention (IFR-SWEDEHEART): A Multicenter, Prospective, Registry-Based Randomized Clinical Trial	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,Volcano Corp; RESEARCH/RESEARCH GRANTS - Volcano Corp
Goto	Shinya	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Early Mortality in Patients With New Onset Atrial Fibrillation: Results From the GARFIELD-AF Registry	CONSULTANT FEES/HONORARIA - Astellas, AstraZenneca, Bayer, Daiichi-Sankyo, Pfeizer, Sanofi- Aventis, Takeda; RESEARCH/RESEARCH GRANTS - Sanofi- Aventis



Contract of				<u> </u>
Last Name Gottlieb	First Name Stephen	Session Title Acute Heart Failure: Evaluating Strategies to	Presentation Title Severe Physical Inactivity Persists Following Acute Heart Failure in	Disclosures CONSULTANT FEES/HONORARIA - BMS:
		Prevent Readmissions	Patients With Sleep Disordered Breathing	RESEARCH/RESEARCH GRANTS - Alnylam,Amgen,Novartis,Pfizer,Resmed,Respicardia
Gottlieb	Stephen	Why Can't We Be Friends? Controversies in Heart Failure Management	Duration of Oral Loop Diuretics and 30-Day Readmission in Patients With Acute Decompensated Heart Failure	CONSULTANT FEES/HONORARIA - BMS; RESEARCH/RESEARCH GRANTS - Alnylam,Amgen,Novartis,Pfizer,Resmed,Respicardia
Gottlieb	Stephen	13. Heart Failure and Cardiomyopathies: Clinical Team 7	Suggested Reviewer	CONSULTANT FEES/HONORARIA - BMS; RESEARCH/RESEARCH GRANTS - Alnylam,Amgen,Novartis,Pfizer,Resmed,Respicardia
Goudar	Suma	Congenital Heart Disease: Innovations in	Interstage Resource Utilization of Infants With Single Ventricle:	Nothing to Disclose
Gouliopoulos	Nikolaos	Single Ventricle Heart Disease MicroRNAs and Beyond in Vascular Medicine	Results of a Crossover Study Association of Endothelial Dysfunction and Arterial Wall Elastic Properties With Systemic Inflammation in Patients With	Nothing to Disclose
Gouliopoulos	Nikolaos	Vascular Medicine: Novel Risk Measures in	Pseudoexfoliative Glaucoma Vascular Function of Conduit Arteries Is Associated With Progress	Nothing to Disclose
Gouliopoulos	Nikolaos	Arterial Diseases Uncovering the Intricacies of Vascular Function	of Diabetic Retinopathy in Type 2 Diabetes The Impact of Natural Chios Mastic Supplementation on Endothelial	Nothing to Disclose
Goyal	Abhinav	Making Progress in Understanding Heart	Function and Arterial Stiffness in Smokers Ambulatory Actigraphy Monitoring of Patients With Heart Failure	CONSULTANT FEES/HONORARIA - ZS Pharma
		Failure	With Reduced Ejection Fraction Predicts 6-Minute Walk Distance	
Goyal	Abhinav	Updates in Stable Ischemic Heart Disease	Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-World Impact of the Leader Trial on Improving Cardiovascular Outcomes in Patients With Diabetes at High Cardiovascular Risk	CONSULTANT FEES/HONORARIA - ZS Pharma
Goyal	Abhinav	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Hospital Variation in Targeted Temperature Management for Acute Myocardial Infarction Patients Complicated by Out-of-Hospital Cardiac Arrest in the U.S.	CONSULTANT FEES/HONORARIA - ZS Pharma
Grace	Andrew	Tough Clinical Problems in Patients with	Co-Chair	CONSULTANT FEES/HONORARIA - Boston Scientific
Grace	Andrew	Implantable Electronic Devices Cardiac Channelopathies: Novel Therapeutics	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Boston Scientific
Gradman	Alan	and Clinical Challenges Assessing the Clinical Impact of Blood Pressure Lowering Therapies	Cardiovascular Outcomes With Nebivolol, Atenolol and Metoprolol in Patients With Hypertension: A Large, Retrospective, Propensity	CONSULTANT FEES/HONORARIA - Daiichi-Sankyo,Forest Laboratories,Novartis,Takeda
Gradman	Alan	Assessing the Clinical Impact of Blood	Score-Matched Cohort Study Additivity of Nebivolol/Valsartan Single-Pill Combinations Versus	CONSULTANT FEES/HONORARIA - Daiichi-Sankyo,Forest
		Pressure Lowering Therapies	Other Approved Single-Pill Combinations for Hypertension	Laboratories, Novartis, Takeda
Gradus-Pizlo	Irmina	Novel Determinants of Outcomes in VHD	Impact of Moderate Mitral Regurgitation on Patients: Mortality May Be Underestimated - Analysis of Clinical Data Repositories	RESEARCH/RESEARCH GRANTS - Abbott Vascular
Grady	Kathleen	Treatment Strategies for End Stage Heart Failure: Medications, Machines and Everything in Between	Erasing the Fear: Palliative Care is Sometimes the Right Choice	Nothing to Disclose
Grady	Kathleen	Everything you Wanted to Know About Heart Transplant but Were Afraid to Ask	Panelist	Nothing to Disclose
Grady	Kathleen	Everything you Wanted to Know About Heart	Quality of Life After Transplant	Nothing to Disclose
Græsdal	Asgeir	Transplant but Were Afraid to Ask Advances in Cholesterol Measurement and Management	Only Eight Percent of Very High-Risk Familial Hypercholesterolemia Patients Achieve LDL-Cholesterol Target Despite Being on Maximal	CONSULTANT FEES/HONORARIA - MSD,Novartis Corporation,Sanofi-Aventis; RESEARCH/RESEARCH GRANTS -
Graesdal	Asgeir	Advances in Cholesterol Measurement and Management	Conventional Lipid-Lowering Therapy Real-Life PCSK9 Experience: 65% Treatment Target Attainment in Familial Hypercholesterolemia Patients	Amgen Inc. CONSULTANT FEES/HONORARIA - MSD, Novartis Corporation, Sanofi-Aventis; RESEARCH/RESEARCH GRANTS -
Graf	Tobias	Novel Developments in Acute Coronary	Outcome of Elderly Patients Undergoing Extracorporeal Life	Amgen Inc. Nothing to Disclose
Grafton	Gillian	Syndromes FIT Clinical Decision Making Reviewers 6	Support in Refractory Cardiogenic Shock ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Graham	Eric	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Detection of Heart Failure With Preserved Ejection Fraction in Single Ventricle Physiology: Insights From the Pediatric Heart Network Fontan Cross-Sectional Study Public Use Dataset	Nothing to Disclose
Graham	lan	Who Should Benefit From Preventive Cardiology?: International Perspectives From the European Society of Cardiology and the American College of Cardiology	Strategies and Risk Estimation	CONSULTANT FEES/HONORARIA - World Health Organisation
Graham	Michelle	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Coronary Artery Disease in Individuals With Human Immunodeficiency Virus Compared to a Seronegative Cohort	Nothing to Disclose
Graham	Susan	Non Invasive Imaging: Prognostic Implications of CT Angiography	HEART Score Does Not Predict the Severity of Anatomical Coronary Artery Disease in Patients Presenting to the Emergency Department With Chest Pain	Nothing to Disclose
Gramze	Nickalaus	Valvular Heart Disease: Mitral Valve Disease	Inter-Study Reproducibility of Mitral Regurgitation Quantitation Using	Nothing to Disclose
Grando-Ting	Jennifer	Special Hearts: The Challenge of Heart Failure	Cardiac Magnetic Resonance Imaging Challenging ACHD Case: What Should I Do?	Nothing to Disclose
Granger	Bradi	in Congenital Heart Disease Innovations in Practice Management and Social Media	Accelerator 2 SUSTAIN, A U.S. Regional Systems of Care Demonstration Project for Post-Discharge STEMI Patients:	RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals
Granger	Christopher	Late-Breaking Clinical Trials	Preliminary Data, Methods and Design Digoxin and Mortality in Patients With Atrial Fibrillation With and	CONSULTANT FEES/HONORARIA -
Granger	Christopher		Without Heart Failure: Does Serum Digoxin Concentration Matter?	AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Eli Lijk, Gilead Sciences, Inc. (BlaxoSmithkine, Hoffman LaRoche, Janssen, Medtronic Inc Novartis, Pfizer, The Medicines Company, Verseon; RESEARCH/RESEARCH GRANTS - ARMETHEON, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi, GlaxoSmithKline, Janssen Pharmaceuticals, Medtronic Foundation, Novartis Corporation, Pfizer, The Medicines Company
Granger	Christopher	Global Perspectives in the Treatment of ST Elevation Myocardial Infarction: Successes, Failures, and Challenges	Co-Chair	CONSULTANT FEES/HONORARIA - AstraZenea, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiicht Sankyo, Eli Lilly, Gilead Sciences, Inc. , GlaxoSmithkline, Hoffman LaRoche, Janssen, Medtronic Inc. , Novartis, Pfizer, The Medicines Company, Verseon; RESEARCH/RESEARCH GRANTS - ARMETHEON, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi, GlaxoSmithkline, Janssen Pharmaceuticals, Medtronic Foundation, Novartis Corporation, Pfizer, The Medicines Company
Granger	Christopher	The Art and the Science of Decision Making in Coronary Artery Disease	The Art: Single, Dual, or Triple Therapy - What is Best?	CONSULTANT FEES/HONORARIA - AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Inc., GlaxoSmithKline, Hoffman LaRoche, Janssen, Medtronic Inc, Novarlis, Pfizer, The Medicines Company, Verseon; RESEARCH/RESEARCH GRANTS - ARMETHEON, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi, GlaxoSmithKline, Janssen Pharmaceuticals, Medtronic Foundation, Novartis Corporation, Pfizer, The Medicines Company

and the				
Last Name	First Name Christopher	Session Title Stoke and Atrial Fibrillation: Innocent	Presentation Title Debate Pro: Atrial Fibrillation is Essential for Embolic Stroke	Disclosures CONSULTANT FEES/HONORARIA -
Granger	Cinsupre	Bystander or Essential Ingredient	Debate FTO. Authar Profitiguori is Essertual for Embolic Stroke	CONSULTANT PESS/TONOMANA ASTAZENCE, BISTON ASTAZENCE, BISTON Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Inc. (SlaxoSmithkine, Hoffman LaRoche, Janssen, Medtronic Inc. Novartis, Pfizer, The Medicines Company, Verseon; RESEARCH/RESEARCH GRANTS - ARMETHEON, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi, GlaxoSmithKline, Janssen Pharmaceuticals, Medtronic Foundation, Novartis Corporation, Pfizer, The Medicines Company
Granger	Christopher	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Rates of Oral Anticoagulant Use, While Improving Over Time, Remain Low Among Hospitalized Patients With Atrial Fibrillation	CONSULTANT FEES/HONORARIA - AstraZeneca,Bayer,Boehringer Ingelheim,Boston Scientific,Bristol Myers Squibb,Dalichi Sankyo,Eil Lilly,Gilead Sciences, Inc. GlaxoSmithKline,Hoffman LaRoche,Janssen,Medtronic Inc. Novartis,Picer,The Medicines Company,Verseor; RESEARCH/RESEARCH GRANTS - ARMETHEON,Astra Zeneca,Bayer,Boehringer Ingelheim,Bristol Myers Squibb,Daichi,GlaxoSmithKline,Janssen Pharmaceuticals,Medtronic Foundation,Novartis Corporation,Pitzer,The Medicines Company
Granger	Christopher	Innovations in Practice Management and Social Media	Accelerator 2 SUSTAIN, A U.S. Regional Systems of Care Demonstration Project for Post-Discharge STEMI Patients: Preliminary Data, Methods and Design	CONSULTANT FEES/HONORARIA - AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Inc. GlaxoSmithKline, Hoffman LaRoche, Janssen, Meditronic Inc. Novartis, Picer, The Medicines Company, Verseon; RESEARCH/RESEARCH GRANTS - ARMETHEON, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi, GlaxoSmithKline, Janssen Pharmaceuticals, Meditronic Foundation, Novartis Corporation, Pifezr, The Medicines Company
Granger	Christopher	Arrhythmias and Clinical EP: Anticoagulation Issues	Use of Interacting Drugs Did Not Modify Treatment Effects of Apixaban Versus Warfarin for Atrial Fibrillation: Results From the ARISTOTLE Trial	CONSULTANT FEES/HONORARIA - AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Inc. GlaxoSmithKline, Hoffman LaRoche, Janssen, Meditronic Inc. Novartis, Pilec; The Medicines Company, Verseon; RESEARCH/RESEARCH GRANTS - ARMETHEON, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi, GlaxoSmithKline, Janssen Pharmaceuticals, Meditronic Foundation, Novartis Corporation, Pizer, The Medicines Company
Granger	Christopher	Novel Developments in Acute Coronary Syndromes	First Medical Contact to Device Time in STEMI Patients Presenting With Cardiogenic Shock: Insights From Mission, a Lifeline STEMI Systems Accelerator	CONSULTANT FEES/HONORARIA - AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Inc. GlaxoSmithKline, Hoffman LaRoche, Janssen, Meditronic Inc. Novartis, Pilec, The Medicines Company, Verseon; RESEARCH/RESEARCH GRANTS - ARMETHEON, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi, GlaxoSmithKline, Janssen Pharmaceuticals, Meditronic Foundation, Novartis Corporation, Pifezr, The Medicines Company
Granger	Christopher	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Hospital Variation in Targeted Temperature Management for Acute Myocardial Infarction Patients Complicated by Out-of-Hospital Cardiac Arrest in the U.S.	CONSULTANT FEES/HONORARIA— AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Inc., GlaxoSmithKline, Hoffman LaRoche, Janssen, Meditronic Inc, Novartis, Pitzer, The Medicines Company, Verseon; RESEARCH/RESEARCH GRANTS - ARMETHEON, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi, GlaxoSmithKline, Janssen Pharmaceuticals, Meditronic Foundation, Novartis Corporation, Pitzer, The Medicines Company
Granger	Christopher	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Aortic Stenosis, but Not Mitral or Aortic Regurgitation, is Associated With Adverse Outcomes With Atrial Fibrillation: Results From the ARISTOTLE Trial	CONSULTANT FEES/HONORARIA - AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Inc. GlaxoSmithKline, Hoffman LaRoche, Janssen, Meditronic Inc. Novartis, Pilec, The Medicines Company, Verseon; RESEARCH/RESEARCH GRANTS - ARMETHEON, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi, GlaxoSmithKline, Janssen Pharmaceuticals, Meditronic Foundation, Novartis Corporation, Pifezr, The Medicines Company
Granger	Christopher	Innovation in Practice Management, Advocacy, and Education	Early Defibrillation by First-Responders in Relation to Fire Stations: Optimal Benefit According to Location	CONSULTANT FEES/HONORARIA - AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Inc. GlaxoSmithKline, Hoffman LaRoche, Janssen, Meditronic Inc. Novartis, Picer, The Medicines Company, Verseor; RESEARCH/RESEARCH GRANTS - ARMETHEON, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi, GlaxoSmithKline, Janssen Pharmaceuticals, Meditronic Foundation, Novartis Corporation, Pizer, The Medicines Company
Granger	Christopher	03. Acute and Stable Ischemic Heart Disease: Therapy Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Inc., GlaxoSmithKline, Hoffman LaRoche, Janssen, Meditronic Inc, Novartis, Picer, The Medicines Company, Verseon; RESEARCH/RESEARCH GRANTS - ARMETHEON, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi, GlaxoSmithKline, Janssen Pharmaceuticals, Meditronic Foundation, Novartis Corporation, Pizer, The Medicines Company
Granger	Matthew	Adult Patients With Congenital Heart Disease: How Do They Compare?	Obstructive Sleep Apnea in Adult Congenital Heart Disease: Who Is at Risk?	Nothing to Disclose
Gräni	Christoph	Non Invasive Imaging: Expanding Clinical Applications	Computed Tomography-Derived Corrected Contrast Opacification Decrease Predicts Reduced Relative Flow Reserve Derived From PET Myocardial Perfusion Imaging	Nothing to Disclose
Gräni	Christoph	Non Invasive Imaging: Coronary Calcium	Prospective Evaluation of Low-Dose Coronary Calcium Scoring With	Nothing to Disclose
		Scoring and CV Risk Assessment	Reduced Tube Voltage	
Gräni	Christoph	Scoring and CV Risk Assessment Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Coronary Calcium	Reduced Tube Voltage Long-Term Prognostic Value of Computed Tomography-Derived Corrected Contrast Opacification Decrease in Patients With Coronary Stenosis Coronary Artery Calcium in the Elderly: Prevalence, Severity, and	Nothing to Disclose



Carry Control				
Last Name Gransar	First Name Heidi	Session Title Non Invasive Imaging: Coronary Calcium	Presentation Title Incremental Utility of Coronary Computed Tomographic	Disclosures Nothing to Disclose
Gransar	Heidi	Non invasive imaging: Coronary Calcium Scoring and CV Risk Assessment	Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry	Notning to Disclose
Gransar	Heidi	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography. The CONFIRM (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	Nothing to Disclose
Gransar	Heidi	Innovations in Cardiovascular Risk Assessment and Reduction	Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	Nothing to Disclose
Gransar	Heidi	Non Invasive Imaging: Prognostic Implications of CT Angiography	Neglay Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	Nothing to Disclose
Gransar	Heidi	Non Invasive Imaging: Prognostic Implications of CT Angiography	Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry	Nothing to Disclose
Gransar	Heidi	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prognostic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry	Nothing to Disclose
Gransar	Heidi	Non Invasive Imaging: Prognostic Implications	Prognosis of Obstructive and Non-Obstructive Stents by Coronary	Nothing to Disclose
Gransar	Heidi	of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Computed Tomographic Angiography: The CONFIRM Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Death: A Comparison to a Histologic Reference Standard	Nothing to Disclose
Gransar	Heidi	Diabetes and Other Issues in Cardiovascular Prevention	Implications of Statin Therapy Among Smokers With Severe Coronary Artery Calcification: An Analysis of the CONFIRM Registry	Nothing to Disclose
Gransar	Heidi	Non Invasive Imaging: New Technologies	Improvement in LDL Is Associated With Decrease in Non-Calcified Plaque Volume on CTA as Measured by Automated Quantitative Software	Nothing to Disclose
Gransar	Heidi	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Relationship Between Whole Vessel Quantitative Plaque Characteristics and Noninvasive Fractional Flow Reserve From Coronary Computed Tomography Angiography	Nothing to Disclose
Gransar	Heidi	Imaging With Cardiac CT: The Case for Calcium	Hormone Replacement Therapy Is Associated With Less Coronary Atherosclerosis and Lower Mortality	Nothing to Disclose
Grant	Josh	Novel Imaging and Therapies in Heart Failure	Unmasking Diastolic Failure	Nothing to Disclose
Grant	Josh	Advances in HCM, PPCM and Other Cardiomyopathies	Increased Prevalence of Left Ventricular Noncompaction in Certain Populations May Confer Increased Risk of Catastrophic Events	Nothing to Disclose
Grant	Marian	Palliative Care for the 99% I: Promoting Palliative Care: The Why and What of PC Therapy	PC for the 99%: The FEDS say YES!	Nothing to Disclose
Grantham	James	Interventional Live Case Session II: CTO Transmission from Mid-America Heart Institute (Kansas City, Missouri)	Live Case Operator	CONSULTANT FEES/HONORARIA - Abbott Vasular inc, Asahi- intecc, Boston Scientific, Vascular Solutions; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Corindus Vascular Robotics; RESEARCH/RESEARCH GRANTS Boston Scientific; SALARY - Corindus Vascular Robotics
Grantham	James	Interventional Live Case Session V: Complex Coronary and Physiology from Mid-America Heart Institute (Kansas City, Missouri)	Live Case Operator	CONSULTANT FEES/HONORARIA - Abbott Vasular inc, Asahi- intecc, Boston Scientific, Vascular Solutions; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Corindus Vascular Robotics; RESEARCH/RESEARCH GRANTS Boston Scientific; SALARY - Corindus Vascular Robotics
Grantham	James	Advances in Chronic Total Occlusion Intervention	Association of Stress Test Risk Classification With Health Status Change After Chronic Total Occlusion PCI: Insights From the OPEN- CTO Registry	CONSULTANT FEES/HONORARIA - Abbott Vasular inc, Asahi- Intecc, Boston Scientific, Vascular Solutions; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Corindus Vascular Robotics; RESEARCH/RESEARCH GRANTS Boston Scientific; SALARY - Corindus Vascular Robotics
Grantham	James	Advances in Chronic Total Occlusion Intervention	Impact of Sex on Physical Limitation & Patient Health Status After Chronic Total Occlusion Percutaneous Coronary Intervention: Propensity Matched Substudy of OPEN-CTO Registry	CONSULTANT FEES/HONORARIA - Abbott Vasular inc, Asahi- Intecc, Boston Scientific, Vascular Solutions; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Corindus Vascular Robotics; RESEARCH/RESEARCH GRANTS Boston Scientific; SALARY - Corindus Vascular Robotics
Grantham	James	Advances in Chronic Total Occlusion Intervention	Health Status Benefits of Successful Chronic Total Occlusion PCI in Patients With Depressed Left Ventricular Systolic Function: Insights From the OPEN-CTO Registry	CONSULTANT FEES/HONORARIA - Abbott Vasular inc, Asahi- Intecc, Boston Scientific, Vascular Solutions; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Corindus Vascular Robotics; RESEARCH/RESEARCH GRANTS Boston Scientific; SALARY - Corindus Vascular Robotics
Grantham	James	Refining PCI Technique and Outcomes	Appropriate Use Criteria and Health Status Outcomes After CTO PCI: Results From the OPEN CTO Registry	CONSULTANT FEES/HONORARIA - Abbott Vasular inc, Asahi- Intecc, Boston Scientific, Vascular Solutions; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Corindus Vascular Robotics; RESEARCH/RESEARCH GRANTS Boston Scientific; SALARY - Corindus Vascular Robotics
Graupner	Catherine	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years	Nothing to Disclose
Gray	Bruce	39. Vascular Medicine: Endovascular Therapy	Suggested Reviewer	Nothing to Disclose
Gray	Huon	Team 1 16th Annual Maseri-Florio International Lecture	16th Annual Maseri-Florio International Lecture: ACC International:	Nothing to Disclose
Gray	Robert	Highlighted Original Research: Congenital Heart Disease and the Year in Review	an Overseas Perspective Safety and Feasibility of Melody Transcatheter Pulmonary Valve Replacement in the Native Right Ventricular Outflow Tract: A	Nothing to Disclose
Gray	William	39. Vascular Medicine: Endovascular Therapy Team 1	Multicenter Study Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular,Intact Vascular,Sentreheart, OTHER - 480 Medical,Biocardia Inc.,Boston Scientific,Contego Medical,CREST / NIH,MEDTRONIC,Silk Road,WL Gore; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Coherex Medical; RESEARCH/RESEARCH GRANTS - COrdis
Grayburn	Paul	TAVR for Degenerated Surgical Valves: What You Need to Know from A to Z	TAVR in Prior Surgical Tricuspid Valve Replacement	CONSULTANT FEES/HONORARIA - Abbott Vascular, Tendyne; OTHER - NeoChord, Valtech Cardio; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston Scientific, MEDTRONIC, Tendyne

				<u> </u>
Last Name Grayburn	Paul	Session Title The Tricuspid Valve: The New Frontier	Presentation Title Co-Chair	Disclosures CONSULTANT FEES/HONORARIA - Abbott Vascular, Tendyne;
				OTHER - NeoChord, Valtech Cardio; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston Scientific, MEDTRONIC, Tendyne
Grayburn	Paul	Stress Echocardiography: Best Practices and Emerging Applications	Using Stress Echo to Assess Mitral Regurgitation	CONSULTANT FEES/HONORARIA - Abbott Vascular, Tendyne; OTHER - NeoChord, Valtech Cardio; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston Scientific, MEDTRONIC, Tendyne
Grayburn	Paul	Town Hall Meeting: Pitfalls of Assessing Valvular Heart Disease Severity	Discussion Leader	CONSULTANT FEES/HONORARIA - Abbott Vascular, Tendyne; OTHER - NeoChord, Valtech Cardio; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston Scientific, MEDTRONIC, Tendyne
Grayburn	Paul	Town Hall Meeting: Pitfalls of Assessing Valvular Heart Disease Severity	Discussion Leader	CONSULTANT FEES/HONORARIA - Abbott Vascular, Tendyne; OTHER - NeoChord, Valtech Cardio; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston Scientific, MEDTRONIC, Tendyne
Grayburn	Paul	Mitral Valve Guidelines: Closing Knowledge Gaps	How Should We Quantify MR in Primary versus Secondary MR	CONSULTANT FEES/HONORARIA - Abbott Vascular, Tendyne; OTHER - NeoChord, Valtech Cardio; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston Scientific, MEDTRONIC, Tendyne
Grayburn	Paul	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Effect of Baseline Aortic Regurgitation on Mortality in the Core Valve US Pivotal High Risk Trial	
Grayburn	Paul	Vascular Access and Hemostasis Issues	Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve	CONSULTANT FEES/HONORARIA - Abbott Vascular, Tendyne; OTHER - NeoChord, Valtech Cardio; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston Scientific, MEDTRONIC, Tendyne
Grayburn	Paul	Prosthetic Valve Thrombosis: TAVR, Bio, Mech Now What?!	Incidence of Valve Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves by 4D CT Imaging	CONSULTANT FEES/HONORARIA - Abbott Vascular, Tendyne; OTHER - NeoChord, Valtech Cardio; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston Scientific, MEDTRONIC, Tendyne
Grayver	Evelina	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Early Unloading With Impella Support in Acute MI With Cardiogenic Shock Linked to Decreased Infarct Size, In-Hospital Mortality, and Hospital Length of Stay	Nothing to Disclose
Grazi	Marco	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Renal Replacement Therapy in Patients With Acute Myocardial Infarction: Rate of Use, Clinical Predictors and Relationship With In- Hospital Mortality	Nothing to Disclose
Greason	Kevin	Valvular Heart Disease: Endocarditis	Infective Endocarditis Following Transcutaneous Aortic Valve Implantation: Clinical, Echocardiographic and Hemodynamic Features	Nothing to Disclose
Greason	Kevin	Interventional Cardiology: TAVR 2	Prognostic Value of Baseline N-Terminal Prohormone Type Natriuretic Peptide Measurement in Chronic Lung Disease Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Greason	Kevin	Valvular Heart Disease: Aortic Stenosis	Bicuspid Versus Tricuspid Aortic Valve Stenosis: Comparative Study of Clinical Characteristics and Outcomes Following Aortic Valve Replacement in an Age-Matched Cohort	Nothing to Disclose
Greason	Kevin	Interventional Cardiology: TAVR 3	Comparative Outcome of Paravalvular Leak Following Surgical Versus Transcatheter Aortic Valve Replacement	Nothing to Disclose
Greason	Kevin	Beans, Beans, Good for Your Heart	Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection	Nothing to Disclose
Greason	Kevin	Engage @ ACC.17 Studio: Heart Teams in	Mayo Surgeon	Nothing to Disclose
Greason	Kevin	Action: Complex Coronary Revascularization Can CABG Patch CAD?	ACC Poster Moderator	Nothing to Disclose
Grech	Ever	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Investigating the Smoker's Paradox by Gender: Differences in Survival Following Acute ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Green	Jacqueline	Engage @ ACC.17 Studio: Meet the Acute and Stable Heart Disease Legends	FIT Interviewer (Interventional Fellow)	Nothing to Disclose
Green	Patrick	Non Invasive Imaging: MR Characterization and Function	Elevated Myocardial Extracellular Volume Fraction (ECV) and Its Prognostic Significance in Diabetic Individuals	Nothing to Disclose
Green	Philip	Cardiovascular Procedures That Push the Line: High-Risk or Futility of Care?	Panelist	Nothing to Disclose
Green	Philip	Cardiovascular Procedures That Push the Line: High-Risk or Futility of Care?	High Risk vs. Futility in Revascularization (PCI/CABG)	Nothing to Disclose
Green	Philip	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Morphologic Patterns of In-Stent Chronic Total Occlusions: An Intravascular Ultrasound Study	Nothing to Disclose
Greenbaum	Adam	Moderated, Case-Based TAVR Management	Case Presentation: Transcaval TAVR	CONSULTANT FEES/HONORARIA - Transmural Systems, Inc.; OTHER - Edwards Lifesciences, St. Jude Medical; RESEARCH/RESEARCH GRANTS - St. Jude Medical; SPEAKER'S BUREAU - Abiomed
Greenbaum	Adam	Interventional Cardiology: TAVR 2	Death and Dialysis Risk After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Transmural Systems, Inc.; OTHER - Edwards Lifesciences,St. Jude Medical; RESEARCHRESEARCH GRANTS - St. Jude Medical; SPEAKER'S BUREAU - Abiomed
Greenbaum	Adam	Valvular Heart Disease: Aortic Stenosis	Outcomes and Their Predictors in Acute Transcatheter Aortic Heart Valve-in-Transcatheter Aortic Heart Valve Therapy	CONSULTANT FEES/HONORARIA - Transmural Systems, Inc.; OTHER - Edwards Lifesciences,St. Jude Medical; RESEARCH/RESEARCH GRANTS - St. Jude Medical; SPEAKER'S BUREAU - Abiomed
Greenbaum	Adam	Interventional Cardiology: Structural Heart Disease	Transcatheter Mitral Valve-in-Ring Implantation After Failure of Surgical Mitral Ring Annuloplasty	CONSULTANT FEES/HONORARIA - Transmural Systems, Inc.; OTHER - Edwards Lifesciences, St. Jude Medical; RESEARCH/RESEARCH GRANTS - St. Jude Medical; SPEAKER'S BUREAU - Abiomed
Greenbaum	Adam	Interventional Cardiology: TAVR 3	Predictors of Late Bleeding in the TAVR Population	CONSULTANT FEES/HONORARIA - Transmural Systems, Inc.; OTHER - Edwards Lifesciences, St. Jude Medical; RESEARCH/RESEARCH GRANTS - St. Jude Medical; SPEAKER'S BUREAU - Abiomed
Greenbaum	Adam	17. Interventional Cardiology: Aortic Valve Disease Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Transmural Systems, Inc.; OTHER - Edwards Lifesciences, St. Jude Medical; RESEARCH/RESEARCH GRANTS - St. Jude Medical; SPEAKER'S BUREAU - Abiomed
Greenbaum	Arieh	Nuclear Cardiology: Beyond Perfusion	Comparison of CZT SPECT and Cardiac MR Derived Cardiac Function and Volumes in Patients With Significantly Reduced Ejection Fraction	Nothing to Disclose
Greenberg	Barry	Emerging Developments in HFpEF and Arryhthmias	Differences Between Ethnic Groups in Comorbidities Do Not Influence Readmission Risk in Patients With Heart Failure and Preserved Ejection Fraction	CONSULTANT FEES/HONORARIA - Astra Zeneca, C and C, Janssen Pharmaceuticals, inc, Mesoblast, Novartis, Teva, zensun; DATA SAFETY MONITORING BOARD - Amgen; SPEAKER'S BUREAU - Novartis Corporation, Otsuka, Otsuka Pharmaceutical Co.
Greene	Stephen	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Hemoconcentration During Management of Patients With Acute Heart Failure and Cardiorenal Syndrome: Insights From CARRESS- HF	Nothing to Disclose

and a				<u> </u>
Last Name Greene	First Name Stephen	Session Title Acute Heart Failure: Evaluating Strategies to	Presentation Title Time of Presentation Among Patients Hospitalized for Acute Heart	Disclosures Nothing to Disclose
Greene	Зернен	Prevent Readmissions	Failure (Clinical Characteristics, Initial Therapies and Outcomes): Insights From ASCEND-HF	Nothing to Disclose
Greene	Stephen	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Alternating Bundle Branch Block: Clinical Considerations	Nothing to Disclose
Greene	Stephen	Why Can't We Be Friends? Controversies in Heart Failure Management	Prevalent Digoxin Use Is Not Associated With Increased Risk of Death or Hospitalization in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction	Nothing to Disclose
Greenwood	John	Featured Clinical Research I	MR-INFORM: Stress Perfusion Imaging to Guide the Management of Patients With Stable Coronary Artery Disease	Nothing to Disclose
Greenwood	John	Great Debates in Cardiac MRI	Debate Pro: Stress MRI is the Test of Choice for Ischemia Assessment	Nothing to Disclose
Greet	Brian	Atrial Fibrillation and VT: Unique Populations and Solutions	The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience	Nothing to Disclose
Greet	Brian	Ventricular Arrhythmias and Sudden Death Prevention	Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience	Nothing to Disclose
Gregoric	Igor	The Challenges of Outcome Prediction in Valvular Heart Disease	Gender-Based Outcomes in Diabetics Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Greig	Douglas	The Burden of Heart Failure: International Perspectives From the Chilean Society of Cardiology, Colombian Society of Cardiology, and American College of Cardiology	Which Are the Best Policies to Improve Adherence and Prevent Rehospitalization in Patients With Recent Acute Heart Failure?	Nothing to Disclose
Greil	Gerald	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Mitral Valve Phase Contrast Imaging Is a More Reproducible Method of Determining Cardiac Rest Periods for Whole-Heart Coronary Magnetic Resonance Angiography in Congenital Heart Disease Than 4 Chamber Cine	Nothing to Disclose
Grewal	Vikram	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	The Way to a Man's Heart: Through His Quadriceps	Nothing to Disclose
Grewal	Vikram		A Rare Cause of Myocardial Injury in a Patient With Systemic Lupus Erythematosus: Hydroxychloroquine Induced Cardiomyopathy	Nothing to Disclose
Grewal	Vikram	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Blocked Artery, or Blocked Bowel?!	Nothing to Disclose
Grey	Scott	Interventional Complexity and Complications	Timing Matters - Hydration Strategies to Reduce Contrast Induced Nephropathy After Peripheral Vascular Interventions: Observations From the Blue Cross Blue Shield Cardiovascular Consortium (BMC2)	Nothing to Disclose
Grier	Elizabeth	Advances in Imaging to Assess Cardiotoxicity	Speckle-Tracking Strain Imaging in Breast Cancer Patients Treated With Newer Non-Anthracycline, Trastuzumab-Based Regimens	Nothing to Disclose
Grieten	Lars	Innovations in Practice Management and Social Media	Evaluating Smartphone Based Photoplesythmography as a Screening Solution for Atrial Fibrillation: A Digital Tool to Detect Afib?	Nothing to Disclose
Grieten	Lars	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Bioimpedance Algorithms in Implantable Electronic Cardiac Devices: Relevant Diagnostics or Waste of Time?	Nothing to Disclose
Griffin	Brian	Non Invasive Imaging: MR Characterization and Function	Time Varying Effect of Total Scar on Mortality in Patients With Cardiomyopathy Undergoing Cardiac Resynchronization Therapy	Nothing to Disclose
Griffin	Brian	Valvular Heart Disease: Aortic Regurgitation	Etiology, Patient Characteristics and Surgical Outcomes of Acute Severe Aortic Regurgitation	Nothing to Disclose
Griffin	Brian	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Baseline Characteristics, Management and Outcomes in Mitral Valve Prolapse With Manifest Ventricular Automaticity	Nothing to Disclose
Griffin	Brian	Insights From Echocardiography Use	Aortic Regurgitation Negatively Affects Left Ventricular Mechanics After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Griffin	Brian	Novel Determinants of Outcomes in VHD	Valvuloarterial Impedance and Left Ventricular Global Longitudinal Strain Provide Incremental Prognostic Value in Patients With Significant Aortic Stenosis and Preserved Left Ventricular Ejection Fraction	Nothing to Disclose
Griffin	Brian	TAVR Outcomes Prognostication	Cardiac Plasticity Predicts Outcome After Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis	Nothing to Disclose
Griffith	Bartley	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Peripheral Anatomic Distribution of Thrombus Does Not Adversely Affect Outcomes in Patients Undergoing Surgical Pulmonary Embolectomy for Submassive and Massive Pulmonary Embolism	Nothing to Disclose
Grimaldi	Maria Chiara	Emerging Basic Science in Ischemic Heart Disease	Imbalance Between E-NOS and MRP4 Gene Expression in Type 2 Diabetes Mellitus May Explain the Higher Risk of NSTEMI in Diabetic Subjects	Nothing to Disclose
Grimm	Richard	Insights From Echocardiography Use	Acrtic Regurgitation Negatively Affects Left Ventricular Mechanics After Transcatheter Acrtic Valve Replacement	CONSULTANT FEES/HONORARIA - Abbott Laboratories
Grimm	Richard	TAVR Outcomes Prognostication	Cardiac Plasticity Predicts Outcome After Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis	CONSULTANT FEES/HONORARIA - Abbott Laboratories
Grimm Grines	Richard Cindy	28. Non Invasive Imaging: Echo Team 2 Interventional Live Case Session IV: Complex Coronary Transmission from St. Vincent Hospital (Indianapolis, IN)	Suggested Reviewer Panelist	CONSULTANT FEES/HONORARIA - Abbott Laboratories CONSULTANT FEES/HONORARIA - Abbott Vascular, Inc.,Boston Scientific,Volcano Group; SALARY - Journal of Interventional Cardiology
Grines	Cindy	Featured Clinical Research III	Outcomes for 15,259 US Patients With Acute MI Cardiogenic Shock (AMICS) Supported With Impella	CONSULTANT FEES/HONORARIA - Abbott Vascular, Inc.,Boston Scientific,Volcano Group; SALARY - Journal of Interventional Cardiology
Grines	Cindy	Debates: Is There Really a Sex Difference in CV Presentation, Care, and Outcomes?	Women Are Less Likely to Get Secondary Prevention Medications and Cardiac Rehab: CON	CONSULTANT FEES/HONORARIA - Abbott Vascular, Inc.,Boston Scientific,Volcano Group; SALARY - Journal of Interventional Cardiology
Grines	Cindy	Challenging PCI: Tips and Tricks from the Experts	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular, Inc.,Boston Scientific,Volcano Group; SALARY - Journal of Interventional Cardiology
Grines	Cindy	Core Curriculum: Revascularization in Special Populations	Coronary Revascularization in the Eldery: Where Age Is No Barrier	CONSULTANT FEES/HONORARIA - Abbott Vascular, Inc.,Boston Scientific,Volcano Group; SALARY - Journal of Interventional Cardiology
		Structural Heart Interventions: Focus on Mitral	In-Hospital Outcomes After MitraClip Implantation in the United States: 2010-2012	CONSULTANT FEES/HONORARIA - Abbott Vascular, Inc.,Boston Scientific,Volcano Group; SALARY - Journal of
Grines	Cindy	Valve, Left Atrial Appendage and HOCM		Interventional Cardiology
Grines Grines	Cindy	Interventional Cardiology: PCI and TAVR in Complex Patients	Economic Implications of Late Discharge After Transcatheter Aortic Catheter Implantation	CONSULTANT FEES/HONORARIA - Abbott Vascular, Inc.,Boston Scientific,Volcano Group; SALARY - Journal of Interventional Cardiology
		Interventional Cardiology: PCI and TAVR in	Economic Implications of Late Discharge After Transcatheter Aortic	CONSULTANT FEES/HONORARIA - Abbott Vascular, Inc.,Boston Scientific,Volcano Group; SALARY - Journal of
Grines	Cindy	Interventional Cardiology: PCI and TAVR in Complex Patients Interventional Cardiology: PCI and TAVR in	Economic Implications of Late Discharge After Transcatheter Aortic Catheter Implantation Predictors of Early Discharge Home After Transcatheter Aortic	CONSULTANT FEES/HONORARIA - Abbott Vascular, Inc.,Boston Scientific,Volcano Group; SALARY - Journal of Interventional Cardiology CONSULTANT FEES/HONORARIA - Abbott Vascular, Inc.,Boston Scientific,Volcano Group; SALARY - Journal of

				<u> </u>
Last Name Grise	First Name Mark	Session Title Novel Developments in Acute Coronary	Presentation Title Right-Sided Ventriculo-Arterial Coupling Indices Are Associated	Disclosures Nothing to Disclose
Glise	IVIdIK	Syndromes	With Clinical Outcomes Among Patients Receiving Biventricular Impella (BiPella) Support for Cardiogenic Shock	Nothing to Disclose
Groarke	John	Vasculo-Oncology: What You Need to Know	What is New in the Management of Radiation-Induced Vascular	RESEARCH/RESEARCH GRANTS - Amgen Inc.
		About Vascular and Thrombotic Complications of Cancer and Cancer Therapeutics	Disease	
Groarke	John	Young Investigator Awards Competition: Clinical Investigations	Impaired Coronary Flow Reserve Is Associated With Diastolic Dysfunction and HFpEF Outcomes in Patients Without Overt CAD	RESEARCH/RESEARCH GRANTS - Amgen Inc.
Groba Marco	María del Val	Cardiac Channelopathies: Novel Therapeutics and Clinical Challenges	Eficacy and Safety of Flecainide to Reduce Exercise-Induced Ventricular Arrhythmias and the Arrhythmic Window in Patients With	Nothing to Disclose
		-	Catecholaminergic Polymorphic Ventricular Tachycardia	
Grobbee	Diederick	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Association Between Homeostasis Model Assessment of Insulin Resistance and Survival in Diabetic Patients With Acute Coronary Syndromes: Insights From the AleCardio Trial	RESEARCH/RESEARCH GRANTS - Research grant from Roche pharma to conduct the Alecardio RCT
Grodin	Justin	Making Progress in Understanding Heart Failure	Exercise Intolerance and Proportional Pulse Pressure Response in Patients With Chronic Heart Failure	Nothing to Disclose
Grodin	Justin	Making Progress in Understanding Heart Failure	Impact of Proportional Pulse Pressure on Exercise Tolerance and Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction	Nothing to Disclose
Grodin	Justin	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	The Prognostic Role of Prior Heart Failure Hospitalizations in Patients With Severe Symptomatic and Recurrent Heart Failure: Insights From ESCAPE	Nothing to Disclose
Grodin	Justin	Emerging Developments in HFpEF and Arryhthmias	Paradoxical Impact of Proportional Pulse Pressure on Mortality in Patients With Heart Failure With Preserved Ejection Fraction	Nothing to Disclose
Grodin	Justin	Emerging Developments in HFpEF and Arryhthmias	The Association of Thick Left Ventricular Hypertrophy With Cardiovascular Outcomes in Heart Failure With Preserved Ejection	Nothing to Disclose
Grodin	Justin	The Evolving World of LVADs, Transplant and	Fraction: Insights From the TOPCAT Trial Cardiac Atrophy: A Novel Mechanism for Duchenne Muscular	Nothing to Disclose
		Other Novel Discoveries	Dystrophy (DMD)-Associated Cardiomyopathy	-
Grodin	Justin	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Circulating Intestinal Fatty Acid-Binding Protein (I-FABP) Levels Portends Higher Risk of Adverse Clinical Outcomes in Advanced Decompensated Heart Failure	Nothing to Disclose
Grodin	Justin	14. Heart Failure and Cardiomyopathies: Therapy Team 3	Suggested Reviewer	Nothing to Disclose
Groeneveld	Peter	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic	Trends in Catheter Directed Thrombolysis and Systemic Thrombolysis for Pulmonary Embolism Treatment: 2004-2014	CONSULTANT FEES/HONORARIA - Statistical Horizons, Inc.
Grogan	Martha	Disease and the Year in Review Advances in HCM, PPCM and Other	Utility of Routine Serum Free Light Chain Assay for Amyloidosis in	CONSULTANT FEES/HONORARIA - Pfizer:
Groh	Mark	Cardiomyopathies Joint American College of Cardiology/New	Patients With Heart Failure Cerebral Embolic Protection Devices During Surgical Aortic Valve	RESEARCH/RESEARCH GRANTS - Alnylam, Pfizer CONSULTANT FEES/HONORARIA - St Jude Medical; OTHER -
		England Journal of Medicine Late-Breaking Clinical Trials	Replacement: A Randomized Trial From the Cardiothoracic Surgical Trials Network	Edward's Life Sciences
Groo	Vicki	Interdisciplinary Cardiovascular Team Collaboratives in Care	Leveraging Our Strengths: Clinical Pharmacist Mediated PCSK9 Utilization	SPEAKER'S BUREAU - Bristol Myers Squibb,Pfizer
Groo	Vicki	Interdisciplinary Cardiovascular Team Collaboratives in Care	Poor Adherence in Young Patients With Heart Failure	SPEAKER'S BUREAU - Bristol Myers Squibb,Pfizer
Groo	Vicki	Interdisciplinary Cardiovascular Care in Complex Scenarios	Simple Technology Improves Access and Outcomes for Patients With Low Socioeconomic Status	SPEAKER'S BUREAU - Bristol Myers Squibb,Pfizer
Groo	Vicki	Interdisciplinary Cardiovascular Team Care Delivery: Quality, Safety, and Satisfaction	Homelessness and Heart Failure: A Novel Prescription	SPEAKER'S BUREAU - Bristol Myers Squibb,Pfizer
Groo	Vicki	Interdisciplinary Cardiovascular Team Care Delivery: Quality, Safety, and Satisfaction	Heart Failure Hotline as an Innovation to Address Medication Issues	SPEAKER'S BUREAU - Bristol Myers Squibb,Pfizer
Gropler	Robert	PET Myocardial Perfusion Imaging: Practical Considerations- A Case-Based Discussion	Co-Chair	CONSULTANT FEES/HONORARIA - Biomedical Systems, Sanofi-Aventis
Gropler	Robert	Molecular Imaging in Heart Failure	Imaging of Hypoxia and ROS	CONSULTANT FEES/HONORARIA - Biomedical Systems, Sanofi-Aventis
Gropler	Robert	30. Non Invasive Imaging: Nuclear Team 1	Suggested Reviewer	Systems, Sanofi-Aventis CONSULTANT FEES/HONORARIA - Biomedical Systems, Sanofi-Aventis
Gross	Coleman	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Treatment With Patiromer Decreases Aldosterone in Patients With Heart Failure, Chronic Kidney Disease, and Hyperkalemia on RAAS	SALARY - Relypsa
Gross	Myron	Innovations in Cardiovascular Risk Assessment	Inhibitors Association Between Serum Collagen Biomarkers and Coronary	Nothing to Disclose
Gross	Myron	and Reduction New Insights Into Prediction and Treatment of	Artery Calcium: The Multi-Ethnic Study of Atherosclerosis (MESA) Collagen Turnover Markers Predict New Onset of Hypertension in	Nothing to Disclose
0		Hypertension	Normotensive Subjects: The Multi-Ethnic Study of Atherosclerosis	OTHER EL WILLY WENT DONIG
Grossi	Eugene	Controversies in Mitral Valve Surgery: Joint Symposium of the Society of Thoracic Surgeons and the American College of Cardiology	Ischemic MR: Do nothing, repair or replace?	OTHER - Edwards Lifescience,MEDTRONIC
Grossman	Paul	Interventional Complexity and Complications	Timing Matters - Hydration Strategies to Reduce Contrast Induced Nephropathy After Peripheral Vascular Interventions: Observations From the Blue Cross Blue Shield Cardiovascular Consortium	RESEARCH/RESEARCH GRANTS - Medtronic Cardiovascular
Grossman	Paul	39. Vascular Medicine: Endovascular Therapy	(BMC2) Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Medtronic Cardiovascular
Grove	Erik	Team 1 New Perspectives on CAD Risk Factors	A Genetic Risk Score Predicts Cardiovascular Events in Patients	CONSULTANT FEES/HONORARIA - AstraZeneca
			With Stable Coronary Artery Disease	Pharmaceuticals,Bayer Healthcare Pharmaceuticals,Boehringer ingelheim Pharmaceuticals, Inc,Bristol-Myers Squibb Company; SPEAKER'S BUREAU - Bayer Healthcare Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,Pfizer Inc.
Grover	Abhinav	Diabetes and Other Issues in Cardiovascular Prevention	Self-Reported Morisky Eight Item Medication Adherence Scale for Statins Concords With Pill Count Method and Correlates With Serum Lipid Profile Parameters and Serum Hydroxymethylglutaryl Coenzyme A Reductase Levels	Nothing to Disclose
Grover	Frederick	FIT Forum: Mix and Mingle	CT Surgery	CONSULTANT FEES/HONORARIA - Somalution
Grover	Frederick	Featured Clinical Research II: Interventional	Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis From the STS/ACC TVT Registry	CONSULTANT FEES/HONORARIA - Somalution
Grover	Frederick	Post FDA Release Prosthetic Valve Surveillance - Watching for Signals	STS Database - Can We Track the Valves ala ASCERT?	CONSULTANT FEES/HONORARIA - Somalution
Grover	Frederick	Engage @ ACC.17 Studio: Heart Teams in Action: Complex Coronary Revascularization	Co-Chair	CONSULTANT FEES/HONORARIA - Somalution
Grover	Frederick	Engage @ ACC.17 Studio: Meet the Acute and	Acute and Stable Ischemic Heart Disease Legend	CONSULTANT FEES/HONORARIA - Somalution
Grover	Frederick	Stable Heart Disease Legends 01. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Somalution
Grover	Peeyush	Basic Team 1 FIT Clinical Decision Making: Non-Invasive	Distinguishing True Versus Pseudo Aortic Valve Stenosis in a	Nothing to Disclose
Groves	Daniel	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Non-Invasive	Patient With No Contractile Reserve Reversible Severe Right Heart Failure and Tricuspid Regurgitation	Nothing to Disclose
Groves	Daniel	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Prevention, Adult	From Thyrotoxicosis Importance of Physical Exam in Identifying a Coronary-Cameral	Nothing to Disclose
		Congenital and Congenital Heart Disease	Fistula	

Last Name	First Name	Session Title	Presentation Title	Disclosures
Grube	Eberhard	Interventional Live Case Session I: Structural Transmission from Cleveland Clinic	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,Claret,InSeal,LIVANOVA,Millipede; OTHER -
		(Cleveland, Ohio)		Keystone,kona,Shockwave,Valtech; SPEAKER'S BUREAU -
		(Oleveland, Onio)		Boston Scientific,LIVANOVA,Medtronic Core
				Valve,Millipede,Mitralign
Grube	Eberhard	Controversies Surrounding TAVR: 2017 and	Panelist	CONSULTANT FEES/HONORARIA - Abbott, Boston
		Beyond		Scientific, Claret, In Seal, LIVANOVA, Millipede; OTHER -
				Keystone,kona,Shockwave,Valtech; SPEAKER'S BUREAU - Boston Scientific,LIVANOVA,Medtronic Core
				Valve.Millipede.Mitralign
Grube	Eberhard	The Evolution of Angioplasty 40 Years of	The Physician as Inventor	CONSULTANT FEES/HONORARIA - Abbott, Boston
		Innovation: Joint Symposium of TCT and the		Scientific, Claret, InSeal, LIVANOVA, Millipede; OTHER -
		American College of Cardiology		Keystone,kona,Shockwave,Valtech; SPEAKER'S BUREAU -
				Boston Scientific, LIVANOVA, Medtronic Core
Grube	Eberhard	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Implantation in Patients With Bicuspid	Valve,Millipede,Mitralign CONSULTANT FEES/HONORARIA - Abbott,Boston
Orabe	Ebernara	interventional duratiology. 174414 5	Aortic Valve Stenosis Utilizing the Next Generation Fully Retrievable	Scientific,Claret,InSeal,LIVANOVA,Millipede; OTHER -
			and Repositionable Valve System: Early Results From the	Keystone,kona,Shockwave,Valtech; SPEAKER'S BUREAU -
			Multicenter Pol-Tavi Registry	Boston Scientific,LIVANOVA,Medtronic Core
0.1.	Et a francis	Literatura Politica	Latin Annual Color Latin Matter Dr. Programme Color Color	Valve,Millipede,Mitralign
Grube	Eberhard	Interventional Cardiology: PCI in Complex Patients	Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated Heparin Following Transcatheter Aortic Valve Replacement: Results	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,Claret,InSeal,LIVANOVA,Millipede; OTHER -
		dichis	From the Bravo-3 Randomized Trial	Keystone,kona,Shockwave,Valtech; SPEAKER'S BUREAU -
				Boston Scientific,LIVANOVA,Medtronic Core
				Valve,Millipede,Mitralign
Grube	Eberhard	17. Interventional Cardiology: Aortic Valve	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott, Boston
		Disease Team 2		Scientific, Claret, InSeal, LIVANOVA, Millipede; OTHER - Keystone, kona, Shockwave, Valtech; SPEAKER'S BUREAU -
				Boston Scientific, LIVANOVA, Medtronic Core
				Valve,Millipede,Mitralign
Gruberg	Luis	Interventional Cardiology: TAVR 2	Impact of Chronic Kidney Disease on Mortality in Adults Undergoing	CONSULTANT FEES/HONORARIA - Janssen; SPEAKER'S
			Balloon Aortic Valvuloplasty	BUREAU - AstraZeneca
Grunewald	Marilyn	Interdisciplinary Cardiovascular Team	Multidisciplinary Cardiovascular Team Review Captures Preclinical	Nothing to Disclose
Grupowald	Marilyn	Collaboratives in Care Diabetes and Other Issues in Cardiovascular	Disease Arresting Insulin Resistance With an Integrative Health Intervention	Nothing to Disclose
Grunewald	Marilyn	Diabetes and Other Issues in Cardiovascular Prevention	Arresting Insulin Resistance With an Integrative Health Intervention	Nothing to Disclose
Guallar	Eliseo	Advances in Cholesterol Measurement and	Comparison of the Novel Method Versus the Friedewald Equation in	Nothing to Disclose
1		Management	Estimating Low-Density Lipoprotein-Cholesterol Based on Fasting	J
	<u> </u>	_	Status	
Guallar	Eliseo	Non Invasive Imaging: Coronary Calcium	Coronary Artery Calcium and Estimated Cardiovascular Disease	Nothing to Disclose
		Scoring and CV Risk Assessment	Risk in Five Racial/Ethnic Groups Living in the US: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study	
			and the Multi-Ethnic Study of Atherosclerosis (MESA)	
Guallar	Eliseo	Innovations in Cardiovascular Risk Assessment	Vitamin D Levels and Autoantibodies in the Multi-Ethnic Study of	Nothing to Disclose
		and Reduction	Atherosclerosis (MESA): Implications for Cardiovascular Disease	5
Guallar	Eliseo	Arrhythmias and Clinical EP: AF Miscellaneous		Nothing to Disclose
		and Surgical Issues	and Stroke Among Whites and Blacks: The Atherosclerosis Risk In	
0	\M/===h:	Asida Caranas Sindanas Diagramia	Communities (ARIC) Study	Nething to Displace
Guan	Wenchi	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Time to Acute Care Among Patients With Acute Myocardial Infarction in China: A Report From China Patient-Centered	Nothing to Disclose
		wanagement and Odtomics	Evaluative Assessment of Cardiac Events Prospective Study of	
			Acute Myocardial Infarction	
Guandalini	Gustavo	FIT Clinical Decision Making: Arrhythmias and	Genetic Testing for Diagnosis of Progressive Cardiac Conduction	Nothing to Disclose
		Electrophysiology	Disease	
Guangzhi	Cong	Insights Into Ischemic Heart Disease: Stable to	Hyperhomocystienmia Accelerated Formation of Unstable Plaque in	Nothing to Disclose
		Erosive Plaques	ApoE Double Knock Mice Associtated With Alternation of Global Dimethylated Histone H3 and Lysine 9	
Guaricci	Andrea Igoren	Non Invasive Imaging: MR Heart Failure and	Prognostic Stratification in Patients With ST-Elevation Myocardial	Nothing to Disclose
		Pulmonary Hypertension	Infaction Over Transthoracic Echocardiography by CMR	5
Guaricci	Andrea Igoren	Non Invasive Imaging: MR Structure and	Diagnostic Value of Qt Evaluation in Anterior ST Segment Elevation	Nothing to Disclose
		Valuvular Heart Disease	Myocardial Infarction for Prediction of Myocardial Salvage Index, as Compared to CMR	
Guazzi	Marco	The Forgotten Chamber: The Right Ventricle in	RV Failure in HFpEF: Therapeutic and Prognostic Implications	Nothing to Disclose
Guazzi	Iviaico	Heart Failure	TV Failure in this per . Therapeduc and Prognostic implications	Nothing to Disclose
Guazzi	Marco	Emerging Applications of Echocardiography	Functional and Hemodynamic Response During Exercise in Heart	Nothing to Disclose
			Failure Intermediate Versus Reduced Ejection Fraction	-
Gudnason	Vilmundur	Updates on Risk Factors for Cardiovascular	Carotid Plaque Area Is Increased in Patients With Acute Coronary	Nothing to Disclose
0	Marian	Disease	Syndrome and Dysglycemia	CONCULTANT FEEGUIONORABIA EL CALLEGA
Guerrero	Mayra	Interventional Live Case Session III: Structural	Panelist	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
		Transmission from Cleveland Clinic (Cleveland, Ohio)		NEGLANOI INLOCANOR GRANTO - EGWARDS EILESCIERCES
Guerrero	Mayra	TAVR for Degenerated Surgical Valves: What	Panelist	CONSULTANT FEES/HONORARIA - Edwards Lifesciences;
	•	You Need to Know from A to Z		RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Guerrero	Мауга	Imaging Transcatheter Mitral Valve Repair and	Mitral Valve in Native Mitral Valve: How to Avoid LVOT Obstruction	CONSULTANT FEES/HONORARIA - Edwards Lifesciences;
0	Marian	Replacement	Deview of TAVD Velves is Notice 15 (1)	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Guerrero	Mayra	Transcatheter Mitral Valve Replacement	Review of TAVR Valves in Native Mitral Valve	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Guerrero	Mayra	Engage @ ACC.17 Studio: Ask the Valvular	Faculty	CONSULTANT FEES/HONORARIA - Edwards Lifesciences;
		Heart Disease Experts	4	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Guerrero	Mayra	17. Interventional Cardiology: Aortic Valve	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Edwards Lifesciences;
	 	Disease Team 2		RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Guers	John	Arrhythmias and Clinical EP: Basic 3	α _{1A} -Adrenergic Receptor Overexpression	Nothing to Disclose
			Protects Against the Development of Arrhythmias Following Coronary Artery Occlusion	
Guetta	Victor	Interventional Cardiology: TAVR 4	Transacatheter Aortic Valve Replacement And Malignancy	Nothing to Disclose
Guetta	Victor	Interventional Cardiology: TAVR 4	Rapid Ventricular Pacing During TAVR Is Associated With Poor	Nothing to Disclose
		5,	Short- and Long-Term Outcome	-
Guetta	Victor	Refining TAVR Outcomes	The Association of Coronary Artery Disease Severity and Pre	Nothing to Disclose
			Procedural Completeness of Revasclarization on Mortality in	
Guetta	Victor	Anti-Platelet Therapies: Always a Sticky Topic	Patients Undergoing Transcatheter Aortic Valve Replacement Chewing Versus Traditional Swallowing of Ticagrelor to Accelerate	Nothing to Disclose
Cuciia	. 10101	and rate of Therapies. Always a Sticky Topic	Platelet Inhibition in ST Elevation Myocardial Infarction: The	. Totaling to Disciose
	<u> 1 </u>	<u> </u>	CHEERS-STEMI Study	
Guglielmo	Marco	Non Invasive Imaging: MR Heart Failure and	Prognostic Stratification in Patients With ST-Elevation Myocardial	Nothing to Disclose
0 . 15.1.		Pulmonary Hypertension	Infaction Over Transthoracic Echocardiography by CMR	Notice to Breaker
Guglielmo	Marco	Non Invasive Imaging: MR Structure and	Diagnostic Value of Qt Evaluation in Anterior ST Segment Elevation	Nothing to Disclose
		Valuvular Heart Disease	Myocardial Infarction for Prediction of Myocardial Salvage Index, as Compared to CMR	
	Move	Should I Stay or Should I Go? Tough Cases in	Panelist	Nothing to Disclose
Gualin			1	
Guglin	Maya	MCS and Transplant		<u> </u>
Guglin Guglin	Maya	Coronary Intervention in Interventional	QRS Duration Alterations After Left Ventricular Assist Device	Nothing to Disclose
Guglin	Maya	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Implantation in Patients With Advanced Heart Disease	-
		Coronary Intervention in Interventional		Nothing to Disclose Nothing to Disclose

Gugin Aleya Napra Fallus and Contracting prophers: What Name A State of Contracting Contra						
Cognition Cogn	Last Name Guglin	First Name Maya	Session Title Heart Failure and Cardiomyopathies: Heart	Presentation Title Guideline-Directed Medical Therapy Before CRT: Is It Always	Disclosures Nothing to Disclose	
Section of Section of East Parison Court Section of Court	Gualin	Maya			Nothing to Disclose	
Ober 1 State Control State			Next When All Else Is Failing?	Complicated by Cardiogenic Shock	-	
Amenda Control			Clinical Team 1		-	
Guidean De Company Controlle (1985) de la company de la co	Guha	Santanu	Perspectives From the Cardiological Society of India, Mexican Society of Cardiology, and	Co-Chair	Nothing to Disclose	
Granter Store Common Control C	Guibone	Kimberly	Great Minds Think Differently: Multidisciplinary	Co-Chair	CONSULTANT FEES/HONORARIA - MEDT	RONIC
Carbon Control Neuroper on Control Memorane of any of Neuroper on Control Processor of Neuroper on	Guidera	Steve	19. Interventional Cardiology: Complex	Suggested Reviewer	Nothing to Disclose	
Currenties of Currenties and Continue properties of the Continue properties properties of the Continue properties properties properties properties propertie	Guild	Cameron		Association of Remnant-Like Particle Cholesterol and Low-Density	Nothing to Disclose	
Clargacy Order Organics	Guimarães	Guilherme		The ARIC Study <i></i>	Nothing to Disclose	
Cut Supple Services of Control			Failure Is Just a Revolving Door	Chagas´ Heart Disease: A Post-Hoc Analysis of the SHIFT Trial		
Oversign Williams Oversi	_		Cardiology: Advanced Device Use	Implantation in Patients With Advanced Heart Disease		
More Marris Continue Cont	Gul	Sajjad			Nothing to Disclose	
County C	Gulati	Gunsagar			Nothing to Disclose	
Golde Methol Get Hole Bette Exercise to Promote CV Passible Method (Section 1998) Control (Gulati	Martha	Debates: Is There Really a Sex Difference in		SALARY - REATA	
Guidel Martha Get from the Basel Fearrise to Premote CV. The Foundairs of Youth Fearrise Professor Security (CV.) Bellet Tental 2. Guidel Martha Get Security (CV.) Bellet Tental 2. Guidel Selet Tental 2. Bellet Tental 2.	Gulati	Martha		Panelist	SALARY - REATA	
Guital Northal Processor of Softe Informative Heart Diseases Suggested Reviewer Su	Gulati	Martha		The Fountain of Youth? Exercise Recommendations for the Elderly	SALARY - REATA	
Guida Say What New he World of STEM? Culda Say What New he World of STEM? Culda Say What New he World of STEM? Culda Say What New he World of STEM? Culda Say Pff Cincia Decision Making Heef Fallure and Programma in These Mandate for One Versus the Other Nothing to Disclose Williams and Programma in These Mandate for One Versus the Other Nothing to Disclose Williams and Programma in These Mandate for One Versus the Other Nothing to Disclose Williams and Programma in These Mandate for One Versus the Other Nothing to Disclose Williams and Programma in These Mandate for One Versus the Other Nothing to Disclose Williams and Programma in Common to Disclose Williams and Programma in Common to Disclose Accordance from the ACC Bully Chapter. ACC Consordan Chapter of Section and Chapter Accordance in Common to Disclose Accordance from the ACC Bully Chapter. ACC Consordan Chapter of Section and Chapter Accordance in Common to Chapter of Section and Chapter One Chapter of Section and Chapter of Section and Chapter of Section and Chapter One Chapter of Section and Chapter One Chapter of Section and Chapter One Chapter of Section and Chapter One Chapter of Section and Chapter One Chapter of Section and Chapter One Chapter of Section and Chapter One Chapter of Section and Chapter One Chapter of Section and Chapter One Chapter of Section and Chapter One Chapter of Section Accordance of Section Programma and Chapter One C			Health	•		
Dissection (ScAD). What the flow, what the four victors from the control of STEM? Guidel Rajay Vord's here in the World of STEM? Guidel Ray PC Clinical Design Making-Healt Failure and Integrated Less of Perfusion SPECTICTA Fascer Imaging and Authority hypertension. Guidel Ray PC Stretteges and Outcomes Unraje to Integrated Less of Perfusion SPECTICTA Fascer Imaging and Cardinology Programs of Perfusion SPECTICTA Fascer Imaging and Cardinology Programs of Perfusion SPECTICTA Fascer Imaging and Cardinology Programs of Perfusion SPECTICTA Fascer Imaging and Cardinology Programs of Perfusion SPECTICTA Fascer Imaging and Cardinology Programs of Perfusion SPECTICTA Fascer Imaging and Cardinology Programs of Perfusion SPECTICTA Fascer Imaging and Cardinology Programs of Perfusion SPECTICTA Fascer Imaging and Cardinology Programs of Perfusion SPECTICTA Fascer Imaging and Cardinology Programs of Perfusion SPECTICTA Fascer Imaging and Section Programs Consciously Programs of Perfusion SPECTICTA Fascer Imaging and Section Programs Cardinology Programs of Perfusion SPECTICTA Fascer Imaging and Section Programs Consciously Programs of Perfusion SPECTICTA Fascer Imaging and Perfusion SPECTICTA Fascer Imaging and Cardinology Programs of Perfusion SPECTICTA Fascer Imaging Cardinology Programs of Perfusion SPECTICTA Fascer Imaging Cardinology Programs of Perfusion SPECTICTA Fascer Imaging Cardinology Programs of Perfusion SPECTICTA Fascer Imaging Cardinology Programs of Perfusion SPECTICTA Fascer Imaging Cardinology Programs of Perfusion SPECTICTA Fascer Imaging Cardinology Programs of Perfusion SPECTICTA Fascer Imaging Cardinology Programs of Perfusion SPECTICTA Fascer Imaging Cardinology Programs of Perfusion SPECTICTA Fascer Imaging Cardinology Programs of Perfusion SPECTICTA Fascer Imaging Cardinology Programs of Perfusion SPECTICTA Fascer Imaging Cardinology Programs of Perfusion SPECTICTA Fascer Imaging Cardinology Programs of Perfusion SPECTICTA Fascer Imaging Cardinology Programs of Perfusion SPECTICTA Fascer Imaging			Basic Team 2			
Guidal Rajuv Pictimization Decision Making Heart Faiture and Numbrook Projection Making Heart Faiture and Numbrook Projection Making Proje	Gulati	Rajiv	Dissection (SCAD): What We Know, What We Don't Know	To Treat or Not to Treat: PCI, CABG, or Conservative Management	Nothing to Disclose	
Pulmonary Hyperferoison Pulmonary Hyperferoison Pulmonary Hyperferoison Pulmonary Hyperferoison Courtain Syndromes Revisible international Country Morein Republic of Synsar, and American College of Carthology. Republic of Synsar, and American College of Carthology. Republic of Synsar, and American College of Carthology. Republic of Synsar, and American College of Carthology. Republic of Synsar, and American College of Carthology. Republic of Synsar, and American College of Carthology. Republic of Synsar, and American College of Carthology. Republic of Synsar, and American College of Carthology. Republic of Synsar, and American College of Carthology. Republic of Synsar, and American College of Carthology. Guinassekarian Pleased Interventional Carthology FUR 11 Interventional Carthology FUR 12	Gulati	Rajiv	What's New in the World of STEMI?	Radial Versus Femoral: Is There Mandate for One Versus the Other	Nothing to Disclose	
Guitacia Raju Pic Standejes and Outcomes Unique to Women Women Women Women Anny Desearch Neederland, Christal February Associated Sportaneous Coronary Anny Desearch Neederland, Christal February Associated Sportaneous Coronary Anny Desearch Neederland, Christal February Anny Desearch Neederland, Christal February Anny Desearch Republic of Sprake, and American College of Republic of Sprake, and American College of Republic of Sprake, and American College of Republic of Sprake, and American College of Republic of Republic of Sprake, and American College of Republic of Republic of Sprake, and American College of Republic of Republic of Sprake, and American College of Republic of Republic of Sprake, and American College of Republic of Republic of Sprake and Republic of Sprak	Gulati	Rajiv		Pulmonary Balloon Angioplasty for Chronic Pulmonary	Nothing to Disclose	
Gulkarov Ibraf Perspectives From the ACC bigs (Postage) Perspectives From the ACC bigs (Postage) Perspectives From the ACC bigs (Postage) Perspectives From the ACC bigs (Postage) Perspectives From the ACC bigs (Postage) Republic of Sipaka, and American Corlinge of Cardiology TANR 3 Interventional Cardiology TANR 3 Interventional Cardiology TANR 3 Interventional Cardiology TANR 3 Interventional Cardiology TANR 3 Interventional Cardiology TANR 3 Interventional Cardiology TANR 3 Interventional Cardiology TANR 3 Interventional Cardiology TANR 3 Interventional Cardiology Fol and TANR in Thempsyanan Assessment of Low Flow Low Gradient Andre Shonous Will Presented Filter Branch Cardiology Fol and TANR in Thempsyanan Assessment of Low Flow Low Gradient Speed on Low Gradient Speed Cardionney Depter And Interventional Cardiology Poli in Complex Policy and Interventional Cardiology Poli in Complex Policy and Interventional Cardiology Poli in Complex Policy and Interventional Cardiology Poli in Complex Policy and Interventional Cardiology Poli in Complex Policy and Interventional Cardiology Poli	Gulati	Rajiv		Postpartum and Pregnancy-Associated Spontaneous Coronary	Nothing to Disclose	
ACC Consortium Chapter of Serbia and Agaption of Systems and American College of Republic of Systems, and American College of Agaption of Systems and American College of American College	Gulizia	Michele			Nothing to Disclose	
Gunasekaran Prasad Interventional Cardiology, TAVR 1 Safety and Efficacy of Usery Pressure Wire With Dobulamin Infusion Nothing to Disclose Interventional Cardiology, PCI and TAVR in Complex Patients Gunasekaran Prasad Interventional Cardiology, PCI and TAVR in Complex Patients Gunasekaran Prasad Interventional Cardiology, PCI and TAVR in Disclose Gunasekaran Prasad Interventional Cardiology, Strutural Heart Disclose Interventional Cardiology, PCI in Complex Patients Andre General Prasad Interventional Cardiology, PCI in Complex Patients Andre General Prasad Interventional Cardiology, PCI in Complex Patients Andre General Prasad Interventional Cardiology, PCI in Complex Patients Andre General Prasad Interventional Cardiology, PCI in Complex Patients Andre General Prasad Interventional Cardiology, PCI in Complex Patients Andre General Prasad Interventional Cardiology, PCI in Complex Patients Andre General Prasad Interventional Cardiology, PCI in Complex Patients Andre General Prasad Interventional Cardiology, PCI in Complex Patients Andre General Prasad Interventional Cardiology, PCI in Complex Patients Andre General Prasad Interventional Cardiology, PCI in Complex Patients Andre General Prasad Interventional Cardiology, PCI in Complex Patients Andre General Prasad Interventional Cardiology, PCI in Complex Patients ACS Curo Liang Interventional Cardiology, PCI in Complex Patients ACS Curo Liang Interventional Cardiology, PCI in Complex Patients ACS Curo Liang Interventional Cardiology, PCI in Complex Patients ACS Curo Liang Interventional Cardiology, PCI in Complex Patients ACS Curo Liang Interventional Cardiology, PCI in Complex Patients ACS Curo Liang Interventional Cardiology, PCI in Complex Patients ACS Curo Liang Interventional Cardiology, PCI in Complex Patients ACS Curo Reference Occurrence Poor Certain Accusate Accusate Accustic Accusti			ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of			
Safety and Efficacy of Using Pressure We Will Dobustians International Cardiology, PCI and TAVR in Interventional Cardiology, PCI and TAVR in Complex Fasters Compact Fasters	Gulkarov	losif	Interventional Cardiology: TAVR 3		Nothing to Disclose	
Gunasekaran Prasad Interventional Cardiology: PCI and TAWR Hemodynamic Assessment of Low Flows Pressure We're Nothing to Disclose	Gunasekaran	Prasad	Interventional Cardiology: TAVR 1	Safety and Efficacy of Using Pressure Wire With Dobutamin Infusion in Themoynamic Assessment of Low Flow Low Gradient Aortic	Nothing to Disclose	
Prasad Interventional Cardiology, Structural Heart Disease	Gunasekaran	Prasad		Hemodynamic Assessment of Low Flow, Low Gradient Severe	Nothing to Disclose	
Carbeterization Evaluation of Severe Acris Cleroses With Preserved [Ediction Fraction] Gunasekaran Prasad Interventional Cardiology; PCI in Complex Patients Advanced Therapies = Advanced Trouble: A Patients Advanced Therapies = Advanced Trouble: A Patients Advanced Therapies = Advanced Trouble: A Patients Advanced Therapies = Advanced Trouble: A Patients Advanced Therapies = Advanced Trouble: A Patients Advanced Therapies = Advanced Trouble: A Patients Advanced Therapies = Advanced Trouble: A Patients Advanced Therapies = Advanced Trouble: A Patients Advanced Therapies = Advanced Trouble: A Patients Advanced Therapies = Advanced Trouble: A Patients Advanced Therapies = Advanced Trouble: A Patients Advanced Therapies = Advanced Trouble: A Patients Gunasekaran Prasad FIT Clinical Decision Making Reviewers	Gunasekaran	Prasad	Interventional Cardiology: Structural Heart	The Impact of Transaortic Gradient and Transaortic Flow on the	Nothing to Disclose	
Patients Advanced Throspies - Advanced Trouble: VAD and Transplant Challenges Advanced Trouble: VAD and Transplant Challenges National Challenges			Disease	Catheterization Evaluation of Severe Aortic Stenosis With Preserved		
Prasad	Gunasekaran	Prasad			Nothing to Disclose	
Guna Prasad Fit Clinical Decision Making Reviewers 5 ACC Fit Clinical Decision Making Reviewer Nothing to Disclose	Gunasekaran	Prasad		Independent Association of Symptomatic Peripheral Arterial Disease for Adverse Outcomes, Poor Graft Survival and Length of Hospital Stay Following Heart Transplantation: An Analysis of 22,820 Heart	Nothing to Disclose	
ACS Thrombosis in Patients With Acute Coronary Syndromes: Single Centre Study of 10,793 Consequetive & 882-16:Real-World&88217: Patients Overland				ACC FIT Clinical Decision Making Reviewer		
Development of a Novel Side-Branch Stent: In-Viro Study	Gunn	Julian		Thrombosis in Patients With Acute Coronary Syndromes: Single Centre Study of 10,793 Consecutive 'Real-World'	Nothing to Disclose	
Liang	Gunn	Julian			Nothing to Disclose	
Liang Population Specific Cardiomyopathies: From Exomes to Databases Cardiomyopathy	Guo	Liang	Interventional Cardiology: Translation and Pre-	Abluminal Coating Biodegradable Polymer Based Sirolimus-Eluting Metallic Stent Versus Conformal Coating Durable Polymer Based	Nothing to Disclose	
Liang	Guo	Liang		Racial Difference in Genetic Variants Associated With Hypertrophic	Nothing to Disclose	
Liang Refining PCI Technique and Outcomes mTors Inhibitors Increase Endothelial Permeability and Prevent Maturation: Uncovering the Mechanism of Neoatherosclerosis in Disclose Nothing to Disclose	Guo	Liang		Molecular Autopsy of Plaque Erosion-Induced Sudden Cardiac	Nothing to Disclose	
Guo Rui-Qiang Novel Imaging and Therapies in Heart Failure Sympathetic Denervation by Layer-Specific Two-Dimensional Speckle Tracking Imaging Synchropathy Evaluation of Left Ventricular Systolic Function After Renal Sympathetic Denervation by Layer-Specific Two-Dimensional Speckle Tracking Imaging Emerging Basic Science in Ischemic Heart Disease Patient and Ep Dodecafluoropentane Acoustic Vaporizable Nano-Droplet With Ultrasound Irradiation Ultrasound Irradiation Sectly of Transvenous Lead Removal in Adult Congenital Heart Disease Patient and EP Devices 3 Safety of Transvenous Lead Removal In Adult Congenital Heart Disease In the US Disease in the US Disease in the US Disease In the US D	Guo	Liang	Refining PCI Technique and Outcomes	mTors Inhibitors Increase Endothelial Permeability and Prevent	Nothing to Disclose	
Sympathetic Denervation by Layer-Specific Two-Dimensional Speckle Tracking Imaging Guo Rui-Qiang Emerging Basic Science in Ischemic Heart Disease Disease Undergring Disease Patient and EP Disease Patient and EP Disease In the US Safety of Transvenous Lead Removal in Adult Congenital Heart Disease Patient and EP Disease in the US Safety of Transvenous Lead Removal in Adult Congenital Heart Disease Patient and EP Disease in the US Safety of Transvenous Lead Removal in Adult Congenital Heart Disease in the US Safety of Transvenous Lead Removal Among Nonagenarians Nothing to Disclose Disease Patient and EP Devices 3 Safety of Transvenous Lead Removal Among Nonagenarians Nothing to Disclose Disease In the US Vision Specific Co-Morbidities Confrast-Induced Nephropathy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention Whole Genome Sequencing in Four Hypertrophic Cardiomyopathy Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention Whole Genome Sequencing in Four Hypertrophic Cardiomyopathy Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention Comparison of Clinical Characteristics and Long-Term Outcomes in Patients With Chronic Kidney Patients With Sudden Cardiac Death Comparison of Clinical Characteristics and Long-Term Outcomes in Patients With Patients With Natrial Vision Disclose Patients With Natrial Vision Locations Predict Left Atrial Appendage Thrombus in Patients With Atrial	Guo	Rui-Oiang	Novel Imaging and Theranies in Heart Failure	Drug Eluting Stents	Nothing to Disclose	
Disease Dodecafluoropentane Acoustic Vaporizable Nano-Droplet With Ultrasound Irradiation Guo Xiaofan The Story of the Adult Congenital Heart Disease Patient and EP Disease Patient and EP Disease In the US Guo Xiaofan Arrhythmias and Clinical EP: Devices 3 Safety of Transvenous Lead Removal in Adult Congenital Heart Disease in the US Guo Xiaosheng PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities Confortast-Induced Nephropathy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention Guo Xiying Population Specific Cardiomyopathies: From Exomes to Databases Families With Sudden Cardiac Death Guo Xiying Advances in HCM, PPCM and Other Cardiomyopathies With Sudden Cardiac Death Guo Yu Novel Echocardiographic Methods for Use of Disease Information Predict Left Atrial Appendage Thrombus in Patients With Atrial		-		Sympathetic Denervation by Layer-Specific Two-Dimensional Speckle Tracking Imaging	-	
Disease Patient and EP			Disease	Dodecafluoropentane Acoustic Vaporizable Nano-Droplet With Ultrasound Irradiation	-	
Substance PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities Mothing to Disclose Nothing to Disclose Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention Whole Genome Sequencing in Four Hypertrophic Cardiomyopathy Nothing to Disclose No	Gu0		Disease Patient and EP	Disease in the US		
Multiple Co-Morbidities Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention Xiying Population Specific Cardiomyopathies: From Exomes to Databases Pamilies With Sudden Cardiac Death Advances in HCM, PPCM and Other Cardiomyopathies Patients With Hypertrophic Cardiomyopathy Nothing to Disclose Patients With Hypertrophic Cardiomyopathy With Different Obstruction Locations Wu Novel Echocardiographic Methods for Assessing Cardiac Function Predict Left Atrial Appendage Thrombus in Patients With Atrial			Arrhythmias and Clinical EP: Devices 3 PCI for NSTEMI and Complex Patients With			
Exomes to Databases Families With Sudden Cardiac Death Guo Xiying Advances in HCM, PPCM and Other Camparison of Clinical Characteristics and Long-Term Outcomes in Nothing to Disclose Patients With Hypertrophic Cardiomyopathy With Different Obstruction Locations Guo Yu Novel Echocardiographic Methods for Assessing Cardiac Function Predict Left Atrial Appendage Thrombus in Patients With Atrial			Multiple Co-Morbidities	Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention		
Cardiomyopathies Patients With Hypertrophic Cardiomyopathy With Different Obstruction Locations Guo Yu Novel Echocardiographic Methods for Use of Diastolic Parameters on Transthoracic Echocardiogram to Assessing Cardiac Function Predict Left Atrial Appendage Thrombus in Patients With Atrial			Exomes to Databases	Families With Sudden Cardiac Death	-	
Assessing Cardiac Function Predict Left Atrial Appendage Thrombus in Patients With Atrial			Cardiomyopathies	Patients With Hypertrophic Cardiomyopathy With Different Obstruction Locations		
	Guo	Yu		Predict Left Atrial Appendage Thrombus in Patients With Atrial	Nothing to Disclose	

WASHINGTON, DC | MARCH 17 - 19 2017

Contract of the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Gupta	Ankur	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Integrating Hyperemic Myocardial Blood Flow and Coronary Flow Reserve for Predicting Cardiovascular Mortality Outcomes in Patients With Known or Suspected Ischemic Heart Disease	Nothing to Disclose
Gupta	Ankur	Nuclear Cardiology: Prognosis		Nothing to Disclose
Gupta	Ankur	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Relationship of Coronary Flow Reserve With Body Mass Index and Adverse Outcomes in Patients Without Overt Ischemic Heart Disease: Implications for Metabolic Surgery Eliqibility	Nothing to Disclose
Gupta	Ankur	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Association Between Coronary Flow Reserve and Adverse Cardiovascular Events Along a Continuum of Metabolic Disease in	Nothing to Disclose
Gupta	Anuj	Core Curriculum: Head to Toe Catheter Based Interventions	Symptomatic Patients Without Overt Coronary Artery Disease Renal Artery Stenosis: Is There Evidence to Revascularize?	OTHER - Seimens
Gupta	Deepak	Improving Risk Assessment in Atherosclerosis	N-Terminal Pro B-Type Natriuretic Peptide, Race, and Flow- Mediated Dilation: Multi-Ethnic Study of Atherosclerosis	Nothing to Disclose
Gupta	Himanshu	Non Invasive Imaging: MR Characterization and Function	Left Ventricular Torsion Shear Angle Volume Approach for Non- Invasive Evaluation of Diastolic Dysfunction in Preserved Ejection Fraction	RESEARCH/RESEARCH GRANTS - NIH
Gupta	Himanshu	Emerging Developments in HFpEF and Arryhthmias	Left Ventricular Mechanical Properties Assessed by Single Beat Method in Early Stages of Diastolic Dysfunction/Heart Failure With Preserved Ejection Fraction	RESEARCH/RESEARCH GRANTS - NIH
Gupta	Kamal	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Timely Use of Right Heart Catheterization Is Associated With Reduced In-Hospital Mortality in Patients With Congestive Heart Failure: Insight From the United States National Inpatient Sample Database	Nothing to Disclose
Gupta	Kamal	Updates on Risk Factors for Cardiovascular Disease	Prevalence of Abnormal Ankle Brachial Index in Obese and Non- Obese Subjects, and Association of Abnormal Ankle Brachial Index With All-Cause and Cardiovascular Mortality in These Groups: Results From National Health and Nutrition Examination Survey 1999-2000	Nothing to Disclose
Gupta	Kamal	Interventional Cardiology: Structural Heart Disease	Safety and Feasibility of Rotational Atherectomy in Elderly Patients With Severe Aortic Stenosis and Calcific Coronary Artery Disease Undergoing Evaluation for Transcatheter Aortic Valve Replacement	Nothing to Disclose
Gupta	Kamal	Diabetes and Other Issues in Cardiovascular Prevention	Association of Ankle Brachial Index and Hemoglobin A1c With All- Cause and Cardiovascular Mortality: Results From the National Health and Nutrition Examination Survey 1999 to 2000	Nothing to Disclose
Gupta	Kamal	Interventional Cardiology: PCI in Complex Patients	Clinical Presentation, Natural History and Management of Coronary Artery Ectasia	Nothing to Disclose
Gupta	Kamal	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Management of Impacted Intramyocardial Shrapnel Due to Gunshot Wound	Nothing to Disclose
Gupta	Kiran	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Real World Evaluation of Major Bleeding Risk and Costs for All Causes and Bleeding-Related Health Services Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Apixaban or Warfarin	Nothing to Disclose
Gupta	Milan	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Concomitant Use of Antiplatelet and Oral Anticoagulation Among Patients With Atrial Fibrillation: Insights From the Prospective SPRINT-AF Registry	CONSULTANT FEES/HONORARIA - Bayer,Boehringer,bristol myers squibb/pfizer alliance; RESEARCH/RESEARCH GRANTS Bayer
Gupta	Rajeev	Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering Therapies		Nothing to Disclose
Gupta	Ramesh	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Long-Term Therapy With Elamipretide Normalizes Activation of the Mitochondrial Signal Transducer and Activator of Transcription 3 (mSTAT3) in of Left Ventricular Myocardium of Dogs With Chronic Heart Failure	Nothing to Disclose
Gupta	Sanjaya	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	A Challenging Cardiomyopathy Diagnosis: Do Not Be Anchored by an Initial Impression	Nothing to Disclose
Gupta	Satya	Interventional Complexity and Complications	Evaluation of a New Radiation Protection Technology (Cardio- TRAP®) in Transradial Percutaneous Coronary Intervention Procedures	Nothing to Disclose
Gupta	Saurabh	22. Interventional Cardiology: Coronary Intervention: Left Main, Multivessel, Bifurcation	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Edwards,MEDTRONIC; RESEARCH/RESEARCH GRANTS - Biotronik
Gupta	Tanush	Team 2 Interventional Cardiology: TAVR 2	Comparison of In-Hospital Outcomes of Transcatheter Aortic Valve Replacement in Men and Women	Nothing to Disclose
Gupta	Tanush	Interventional Cardiology: TAVR 2	Association of Chronic Renal Insufficiency With In-Hospital Outcomes of Transcatheter Aortic Valve Replacement	Nothing to Disclose
Gupta	Tanush	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Sex Differences in Revascularization and In-Hospital Outcomes of Non-ST-Segment Elevation Myocardial Infarction in the United States	Nothing to Disclose
Gupta	Tanush	Timely Topics in Acute Coronary Syndromes	Routine Invasive Versus Conservative Strategy for Elderly Patients Aged>75 Years With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS): A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Gupta	Tanush	Interventional Cardiology: TAVR 3	Regional Variations in In-Hospital Outcomes and Healthcare Resource Utilization in Patients Undergoing Transcatheter Aortic Valve Replacement in the United States	Nothing to Disclose
Gupta	Tanush	Antithrombotic Therapy in Ischemic Heart Disease	Role of Anticoagulation Therapy After Anterior Wall ST-Elevation Myocardial Infraction in Preventing LV Thrombus: A Meta-Analysis and Meta-Regression	Nothing to Disclose
Gupta	Tanush	Arrhythmias and Clinical EP: Syncope and Other EP Issues	and Meta-Regression Association of Academic Year-End Changeover With Survival Rates After In-Hospital Cardiac Arrest: An Examination of the "July Effect"	Nothing to Disclose
Gupta	Tanush	Optimizing the Care of ACS Patients	Weekend Versus Weekday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide Analysis	Nothing to Disclose
Gupta	Vishal	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Impact of Hereditary Causes of Thrombosis on Ischemic Stroke Between the Years 2008 Through 2012: Nationwide Inpatient Sample Data Analysis	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim GmbH, Eli Lilly and Company, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - ASI Inc., Neuralieve; SPEAKER'S BUREAU - Janssen Pharmaceutical Inc.
Gupta-Bala	Santosh	FIT Clinical Decision Making: Non-Invasive	Eptifibatide for Treatment of Mechanical Aortic Valve Thrombus: A	Nothing to Disclose
Gurbel	Paul	Imaging and Valvular Heart Disease Controversies in ACS Guidelines	Novel Therapeutic Approach Optimal Timing of Coronary Angiography in Patients with Non ST Elevation ACS: The Sooner the Better- Including on Weekends!	CONSULTANT FEES/HONORARIA - Bayer,Boehringer Ingelheim,Coramed,Merck; RESEARCH/RESEARCH GRANTS - Coramed,Haemonetics,HCRI,Merck,New Haven Phamaceuticals,NIH
Gurbel	Paul	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Platelet Reactivity and Outcomes After PCI of Saphenous Vein Grafts Versus Native Coronary Arteries: The ADAPT-DES Study	Pnamaceuticals, NiH CONSULTANT FEES/HONORARIA - Bayer, Boehringer Ingelheim, Coramed, Merck; RESEARCH/RESEARCH GRANTS - Coramed, Haemonetics, HCRI, Merck, New Haven Phamaceuticals, NiH



Control of the Contro				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Gurbel	Paul	Biomarkers and Targets for Ischemic Heart Disease	Serial Assessment of Thrombogenicity and Hemodynamics in Patients With Type II Diabetes Observed in a Clinical Research Unit: Evidence for Circadian Changes in Clot Formation	CONSULTANT FEES/HONORARIA - Bayer,Boehringer Ingelheim,Coramed,Merck; RESEARCH/RESEARCH GRANTS - Coramed,Haemonetics,HCRI,Merck,New Haven Phamaceuticals,NIH
Gurbel	Paul	From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease	Assessment of Thrombogenicity and Antithrombotic Drug Response at the Bedside in Patients Presenting With Ischemic Stroke, TIA or Intracranial Hemorrhage	CONSULTANT FEES/HONORARIA - Bayer, Boehringer Ingelheim, Coramed, Merck; RESEARCH/RESEARCH GRANTS - Coramed, Haemonetics, HCRI, Merck, New Haven Phamaceuticals, NIH
Gurbel	Paul	Advances in Lipid Management	HDL3: A Marker of Coronary Artery Disease Severity and Inflammation in Patients on Statin Therapy	CONSULTANT FEES/HONORARIA - Bayer, Boehringer Ingelheim, Coramed, Merck; RESEARCH/RESEARCH GRANTS - Coramed, Haemonetics, HCRI, Merck, New Haven Phamaceuticals, NIH
Gurbel	Paul	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Early Coronary Angiography in Patients With Out-of-Hospital Cardiac Arrest Without ST-Elevation Myocardial Infarction: A Meta- Analysis of 1,460 Patients	CONSULTANT FEES/HONORARIA - Bayer,Boehringer Ingelheim,Coramed,Merck; RESEARCH/RESEARCH GRANTS - Coramed,Haemonetics,HCRI,Merck,New Haven Phamaceuticals,NIH
Gurbel	Paul	22. Interventional Cardiology: Coronary Intervention: Left Main, Multivessel, Bifurcation Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Bayer, Boehringer Ingelheim, Coramed, Merck; RESEARCH/RESEARCH GRANTS - Coramed, Haemonetics, HCRI, Merck, New Haven Phamaceuticals, NIH
Gurevich	Sergey	Interventional Cardiology: PCI and TAVR in Complex Patients	Calcification in the Basal Septum, but Not Membranous Septal Length, Predicts AV Conduction Disturbance and Pacemaker Implantation Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve (S3)	Nothing to Disclose
Gurm	Hitinder	The Fundamentals of ACS Trials—Pitfalls in	Process Measures like Door-to-Balloon do not matter in 2017: Pro	CONSULTANT FEES/HONORARIA - Osprey Medical
Gurm	Hitinder	Cardiovascular Endpoints Considerations in Antiplatelet Therapy and in ACS	Readmission and Long-Term Mortality in Older Patients Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium	CONSULTANT FEES/HONORARIA - Osprey Medical
Gurm	Hitinder	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Percutaneous Coronary Intervention in Patients With Recent Gastrointestinal Bleeding: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium	CONSULTANT FEES/HONORARIA - Osprey Medical
Gurm	Hitinder	Interventional Complexity and Complications	Timing Matters - Hydration Strategies to Reduce Contrast Induced Nephropathy After Peripheral Vascular Interventions: Observations From the Blue Cross Blue Shield Cardiovascular Consortium (BMC2)	CONSULTANT FEES/HONORARIA - Osprey Medical
Gurm	Hitinder	Percutaneous Coronary Intervention: Lessons From the Real World	Outcomes After Percutaneous Coronary Intervention Among Patients With a History of Transient Ischemic Attack or Cerebrovascular Accident: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium	CONSULTANT FEES/HONORARIA - Osprey Medical
Gurm	Hitinder	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Osprey Medical
Gurujal	Ravi	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Go or No Go for TAVR? Sinus of Valsalva Aneurysm of the Noncoronary Cusp With Fibroelastoma and Severe Aortic Stenosis	Nothing to Disclose
Gurven	Michael	Featured Clinical Research I	Native South American Tsimane Have the Lowest Levels of Coronary Atherosclerosis Ever Reported	Nothing to Disclose
Gurvitz	Michelle	Update in ACHD: The Time for Change is Now	Models of Care: Guideline Perspective on Patient Centered Care and Management	Nothing to Disclose
Gurwitz	Jerry	Effective Medication Management in the Older Adults with CVD: Pharmacology Program I	Panelist	Nothing to Disclose
Gustafsson	lda	Novel Echocardiographic Methods for Assessing Cardiac Function	Coronary Microvascular Dysfunction Affects the Myocardial Contractile Reserve in Women With Angina and No Obstructive Coronary Artery Disease	Nothing to Disclose
Gutierrez Yanez	Jose	ACC International Conferences Best Posters	Comparison of Different Lung Ultrasound Methodologies for Pulmonary Congestion Evaluation in Heart Failure Outpatients	Nothing to Disclose
Gutierrez Yanez	Jose	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Long Follow-Up of Patients With Structural Heart Disease and Syncope: Does the Syncope Cause Matters?	Nothing to Disclose
Guyton	John	Advances in Cholesterol Measurement and Management	Alirocumab Titration Strategy Allows Individualized LDL-C Reduction in a Real World Setting: Results From ODYSSEY OLE (LONG TERM Cohort)	CONSULTANT FEES/HONORARIA - Amgen Inc.,Regeneron; RESEARCH/RESEARCH GRANTS - Amarin,Amgen Inc.,Regeneron,Sanofi-Aventis
Guyton	John	Advances in Cholesterol Measurement and Management	On-Treatment LDL-C Levels When Alirocumab Dose Is Decreased From 150 to 75 mg Every 2 Weeks in Patients With Heterozygous Familial Hypercholesterolemia: Results From ODYSSEY OLE	CONSULTANT FEES/HONORARIA - Amgen Inc.,Regeneron; RESEARCH/RESEARCH GRANTS - Amarin,Amgen Inc.,Regeneron,Sanofi-Aventis
Guyton	John	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Alirocumab Treatment in a Real World Setting: Safety Update From an Open-Label Treatment Extension to the ODYSSEY Program for Patients With Heterozygous Familial Hypercholesterolemia	CONSULTANT FEES/HONORARIA - Amgen Inc.,Regeneron; RESEARCH/RESEARCH GRANTS - Amarin,Amgen Inc.,Regeneron,Sanofi-Aventis
Guyton	Robert	Issues in the Treatment of Coronary Disease: Joint Symposium of the American Heart Association and the American College of Cardiology	Panelist	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Guyton	Robert	Issues in the Treatment of Coronary Disease: Joint Symposium of the American Heart Association and the American College of Cardiology	All Arterial CABG: What Does the Data Show?	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Guyton Guyton	Robert Robert	Transcatheter Mitral Valve Replacement TAVR Outcomes Prognostication	Co-Chair Predictors and Clinical Outcomes of Next-Day Discharge After	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Gyenes	Dora	Congenital Heart Disease: New Diagnostic	Transcatheter Aortic Valve Replacement Impact of Maternal Diabetes on First & Early Second Trimester Earl Configuracy Labelth	Nothing to Disclose
Gyenes	Dora	Approaches in Congenital Heart Disease Impact of Prenatal Environment on Congenital Heart Disease	Fetal Cardiovascular Health Umbilical Arterial Blood Flow in the Third Trimester and Its Association With Clinical and Neurodevelopmental Outcomes in	Nothing to Disclose
На	Jong-Won	Valvular Heart Disease: Aortic Stenosis	Children With Critical Neonatal Congenital Heart Disease Comparisons of Flow-Gradient Patterns in Severe Aortic Stenosis Between Bicuspid Aortic Valves and Tricuspid Aortic Valves	Nothing to Disclose
Haack-Sørensen	Mandana	Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells	Adipose Derived Stromal Cells for Refractory Angina: Results From MyStromalCell Trial	Nothing to Disclose
Haag	Elizabeth	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Optical Coherence Tomography Assessment of Coronary Atherectomy Effect: Comparison Between Orbital and Rotational Atherectomy in Severely Calcified Lesions	Nothing to Disclose
Haag	Elizabeth	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	The Effectiveness of Excimer Laser Angioplasty to Treat Coronary In-Stent Restenosis With Peri-Stent Calcium as Assessed by Optical Coherence Tomography	Nothing to Disclose
Haag	Elizabeth	Interventional Cardiology: PCI in Complex Patients	Procedural Calcium Fracture and Its Effect on Stent Expansion Assessed by Optical Coherence Tomography	Nothing to Disclose
Haas	Sylvia	Arrhythmias and Clinical EP: Anticoagulation Issues	Real-World Versus Randomized Trial Outcomes in Similar Populations of Rivaroxaban-Treated Patients With Nonvalvular Atrial	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,BMS,Daiichi Sankyo,Sanofi-Aventis
Haas	Sylvia	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Fibrillation in ROCKET AF and XANTUS Early Mortality in Patients With New Onset Atrial Fibrillation: Results From the GARFIELD-AF Registry	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,BMS,Daiichi Sankyo,Sanofi-Aventis
			•	-

State of the control	and a				<u> </u>
Project of Conjoint Hand Residence Part Of State of Conjoint Hand Resid	Last Name	First Name	Session Title	Presentation Title	
Section 1. Section 1.	Habash	Fuad			Nothing to Disclose
Sealer of the control				Patients Undergoing Liver Transplant Evaluation: A Single Center	
Service Control of Con					
Signer of the control	Habash	Fuad	Arrhythmias and Clinical EP: Devices 3		Nothing to Disclose
Description of the control forces of the con	Habib	Anwer	25. Interventional Cardiology: Translation and		Nothing to Disclose
Lead Scale In Vision Communication Control Con			Pre-clinical Research Team 1		
mentanted Confesionarios de Present Marco Feste Falour ent Confesionarios de Present Marco Feste Falour ent Confesionarios de Present Part Confesionarios de Present Part Confesionarios de Present Part Confesionarios de Present Part Confesionarios de Present Part Confesionarios de Present Part Confesionarios Part C	Habib	Gilbert			Nothing to Disclose
SSED SED INSECT Place of Conference in Internal Walls of Conference in Protect Visit Authority Places in Conference in Protect Visit Authority Places in Conference in Protection (Conference in Conference in Protection Conference in Conferen			Biocado ana no roai in review		
The Asset With a Antonium Fire Orband - With Processing Street Control of Control Part Control of Control of Control Part Control of Control of Control of Control Part Control of Control Part Control of Control Part Control of Control Part Control of Control Part Control of Con					
South Charles Chargog by & Natural Relief (1997 of 1998) Charles Charl	Habib	Habib			Nothing to Disclose
Social Control (1997) Foreign and Extra Port Miller (1997) Foreign a	Habib	Mirette	Changing the Natural History of Valve Disease	Statins Use and Long Term Outcome Post Surgical Aortic Valve	Nothing to Disclose
About Marchan Control on Training Control on Control	Haabaasa dab	Dani			Nothing to Displace
Stockenswitch Fig. 19 Stockenswitch Fig. 20 Stocke	Hacilatiiovitcii	Roly		Invocatoral Perfusion imaging. The value Proposition	Nothing to Disclose
Schammuch Rey Congress of Many Congress of Many Congress of Many Congress of Many Progress	Hachamovitch	Rory	What is the PROMISE of ISCHEMIA: A 2017		Nothing to Disclose
Scriett Ausbrach Laber (1997) The Political Vision - Ny 1 files as a Transposer Recipient Scrietter (1997) The Political Vision - Ny 1 files as a Transposer Recipient Scrietter (1997) The Political Vision - Ny 1 files as a Transposer Recipient Scrietter (1997) The Political Vision - Ny 1 files as a Transposer Recipient Scrietter (1997) The Political Vision - Ny 1 files as a Transposer Recipient Scrietter (1997) The Political Vision - Ny 1 files as a Transposer Recipient Scrietter (1997) The Political Vision - Ny 1 files as a Transposer Recipient Scrietter (1997) The Political Vision - Ny 1 files as a Transposer Recipient Scrietter (1997) The Political Vision - Ny 1 files as a Transposer Recipient Scrietter (1997) The Political Vision - Ny 1 files as a Transposer Recipient Scrietter (1997) The Political Vision - Ny 1 files as a Transposer Recipient Scrietter (1997) The Political Vision - Ny 1 files as a Transposer Recipient Scrietter (1997) The Political Vision - Ny 1 files as a Transposer Recipient Scrietter (1997) The Political Vision - Ny 1 files as a Transposer Recipient County of the Scrietter (1997) The Political Vision - Ny 1 files as a Transposer Recipient (1997) The Political Vision - Ny 1 files as a Transposer Recipient (1997) The Political Vision - Ny 1 files as a Transposer Recipient (1997) The Political Vision - Ny 1 files as a Transposer Recipient (1997) The Political Vision - Ny 1 files as a Transposer Recipient (1997) The Political Vision - Ny 1 files as a Transposer Recipient (1997) The Political Vision - Ny 1 files as a Transposer Political Vision - Ny 1 files as a Transposer Political Vision - Ny 1 files as a Transposer Recipient (1997) The Political Vision - Ny 1 files as a Transposer Political Vision - Ny 1 files as a Transposer Political Vision - Ny 1 files as a Transposer Political Vision - Ny 1 files as a Transposer Political Vision - Ny 1 files as a Transposer Political Vision - Ny 1 files as a Transposer Political Vision - Ny 1 files as a Transposer Political Vision - Ny 1 files as a Tr				Perspective	
Transcissed in Art Vas Albart D. Ass. Noting to Printer Vas House Albard D. Ass. Noting to Printer Vas House Albard D. Ass. Noting to Disclose Noting to Printer Vas House Albard D. Ass. Noting to Disclose Noting to Printer Vas House Albard D. Ass. Noting to Disclose Noting to D					
Septimentally Broy Septimental Septimental Production of Part	Hachamovitch	Rory		The Patient Voice - My Life as a Transplant Recipient	Nothing to Disclose
State of Soles Multimodally Imaging to Market product Soles (Soles Soles World) All Anthony and Soles Multimodally Imaging to Market Soles (Soles So	Hachamovitch	Rory		Pooled Cohort Equation and Coronary Artery Calcium in Retired	Nothing to Disclose
Andrees Winner Winner Winn		·		National Football League Athletes	-
State Wenter State Printings of Circles EP Antecoagus and State Course C	Hachamovitch	Rory			Nothing to Disclose
Section Weren Personal Persona	Hacke	Werner			CONSULTANT FEES/HONORARIA - Baver
Statis Postitiation, Adenaugations and the Section (ACS) Committee of Statis Postitiation, Adenaugation and the Section (ACS) Assessino (Accessing to Project Committee) Assessino (Accessing to Pr		1		Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation	
Section III Edicate Processor Annual Processor Sections Annual Processor Sections Annual Processor Sections Annual Processor Sections Section	Hacke	Werner	Atrial Fibrillation Anticoagulation and Novel		CONSULTANT FEES/HONORAPIA Payer
Stacker III Golde Invocations in Advancey and Finderfor Centered Possess of Center Cen	IIdone	vvcillel			OCHOOLIANT I LLOHIONORARIA - DAYEI
Masahino Propositiog and Emborated Function Projecting and Emborated Function Projecting and Emborated Function Projecting and Emborated Function Projecting and Emborated Function Projecting and Emborated Function Projecting and Emborated Function Projecting and Emborated Function Projecting and Emborated Function Projecting and Emborated Function Projecting Function Projecting and Emborated Function Projecting Function Projecti	Hackler III	Eddie	Innovations in Advocacy and Patient Centered		Nothing to Disclose
Absahro Masahr	Hada	Masahiro		Relationship Retween Coronary Physiological Parameters and	Nothing to Disclose
Assahro Bernerotroal Carelotogy, Perseascular Springer of Masahro Bernerotroal Carelotogy, Perseascular Springer of Masahro Bernerotroal Carelotogy, Angiography CTART Besser in Nocl-eff Mate Learning Besser in Nocl-eff Mate Learning Besser in Nocl-eff Mate Learning Besser in Nocl-eff Mate Learning Besser in Nocl-eff Mate Learning Besser in Nocl-eff Mate Learning Besser in Nocl-eff Mate Learning Besser in Nocl-eff Mate Learning Besser in Nocl-eff Mate Learning Besser in Nocl-eff Mate Learning Besser in Nocl-eff Mate Lear		Masarino			Trouming to Disciose
Physicings and Enrichmental Function Missanito Missan	Hada	Manahian			Nathing to Displace
Interventional Cardiology Anglography (CTAR) Unusual Presentations of ACS CTAR (Contract Contracts) Unusual Presentations of ACS Interventional Cardiology Anglography (CTAR) Unusual Presentations of ACS Interventional Cardiology Anglography (CTAR) Unusual Presentations of ACS Interventional Cardiology Anglography (CTAR) Unusual Presentations of ACS Interventional Cardiology Anglography (CTAR) Unusual Presentations of ACS Interventional Cardiology Anglography (CTAR) Unusual Presentations of ACS Interventional Cardiology Anglography (CTAR) Unusual Presentations of ACS Interventional Cardiology Anglography (CTAR) Unusual Presentations of ACS Interventional Cardiology Anglography (CTAR) Inte	Hada	Masahiro			Nothing to Disclose
Introductorial magning and federace inclined in the control of Tribital Colorany Analysis (Septiment Controllary Analysis) and the certain Controllary Analysis (Concern) Analysis (Septiment Colorany Concern) Analysis (Septiment Colorany Concern) Analysis (Septiment Colorany Concern) Analysis (Septiment Colorany Concern) Analysis (Septiment Colorany Concern) Analysis (Septiment Colorany C				Reserve in Non-Left Main Lesions	
International Cartifology, Anapography, Intravascular Inageng and Interventional Cartifology, Anapography, Intravascular Inageng and Interventional Cartifology, Anapography, Intravascular Inageng and Interventional Cartifology, Anapography, Intravascular Inageng and Interventional Cartifology, Anapography, Intravascular Inageng and Interventional Cartifology, Anapography, Intravascular Inageng and Interventional Cartifology, Anapography, Intravascular Inageng and Interventional Cartifology, Anapography, Intravascular Inageng and Interventional Cartifology, Anapography, Intravascular Inageng and Interventional Cartifology, Anapography, Intravascular Inageng and Interventional Cartifology, Inter	Hada	Masahiro		Usefulness of Optical Coherence Tomography-Derived	Nothing to Disclose
Interventional Cardiology Angegraphy, Enterventional Cardiology Angegraphy, Enterventional Cardiology Angegraphy (Interventional Cardiology Angegraphy Cardiology) (Interventional Cardiology) (Interv				Coronary Artery Stenosis and Determinants of Mismatch: Head-to-	
Introvascular imaging and Inderventional CTARK Install Presentations of ACS Install Presentati					
Assessed by Serial Infravescular Ultrasound Examinations in Late and Very Let Drug-Eduring Serial Plant Seria	Hada	Masahiro			Nothing to Disclose
Masahiro Unusual Presentators of ACS Predictors and Circuita Significance of High-Sendariby Cardiacy Nothing to Disclose					
Incomer Personal Residence of ACS Multimodal (Concern) Image Presentations of ACS Multimodal (Concern) Image Presentations of ACS Multimodal (Concern) Image Presentations of ACS Comparison of Neorisma Appearance Assessed by Optical Conference Tomography Debeteen Bare-Metal Sterits and Sirorimus- Eduling Bitter Sterin Image Presentations of ACS Comparison of Neorisma Appearance Assessed by Optical Concerns Presentations of ACS Patrimodal Presentations of Acts Patrimodal Presentations of Acts Patrimodal Presentations of Acts Patrimodal Presentations of Acts Patrimodal Presentations of Acts Patrimodal Presentations of Acts Patrimodal Presentations of Acts Compeniation of Neorisma Appearance Assessed by Optical Concerns Patrimodal Presentations of Acts Comparison of Neorisma Appearance Assessed by Optical Concerns Patrimodal Presentations of Acts Concerns Patrimodal Presentations of Patrimodal Presentations of Patrimodal Presentations of Patrimodal Presentations of Patrimodal Presentations of Patrimodal Presentations of Patrimodal Presentations of Patrimodal Presentations of Patrimodal Presentations of Patrimo	D. J.		U I D		Null Control Broden
Masahiro Unsual Presentations of ACS Multimodality Corrorary Imaging to Predict Perspondental Mycocard Merice (Esche Percultances) Corrorary National Necessal Affect (Esche Percultances) Corrorary National Necessal Affect (Esche Percultances) Corrorary National Necessal Affect (Esche Percultances) Corrorary National Necessal Affect (Esche Percultances) Corrorary National Necessal Affect (Corrorational Necessal Nec	паца	Iviasaniro	Unusual Presentations of ACS		Nothing to Disclose
India a Masahiro Unusual Presentations of ACS Companion of Nonhitmal Appearance Assessed by Optical Coherence Control of Nonhitmal Appearance Assessed by Optical Coherence Control of Nonhitmal Appearance Assessed by Optical Coherence Control of Nonhitmal Appearance Assessed by Optical Coherence Control of Nonhitmal Appearance Assessed by Optical Coherence Control of Nonhitmal Appearance Assessed by Optical Coherence Control of Nonhitmal Coherence Control of Nonhitmal Coherence Control of Nonhitmal Coherence Control of Nonhitmal Coherence Control of Nonhitmal Coherence Coherence Coherence Control of Nonhitmal Coherence	Hada	Masahiro	Unusual Presentations of ACS	Multimodality Coronary Imaging to Predict Periprocedural	Nothing to Disclose
Massimo					
ladadi Oyus Afficiancia Decision Making: Heart Failure and Purposerosinophic Endourocardial Florosis Minimizing Autority (Corporary Syndrome) fadamitizisy Martin Imaginary Hoperiterision After yand Anomalous? fadamitizisy Martin Non invasive Imaging: Prognostic Implications of CT Anapography: Prognostic Implications of CT Anapography: Prognostic Implications of CT Anapography: Prognostic Implications of CT Anapography: Prognostic Implications of CT Anapography: Prognostic Implications of CT Anapography: Prognostic Implications of CT Anapography: Prognostic Implications of CT Anapography: Prognostic Implications of CT Anapography: Prognostic Implications of CT Anapography: Prognostic Implications of CT Anapography: Prognostic Implications of CT Anapography: Prognostic Implications of CT Anapography: Prognostic Implications of CT Anapography: Prognostic Implications of CT Anapography: Prognostic Implications of CT Anapography: Prognostic Implications of Company and Prognostic Implications of Prognostic Anapography: Prognostic Implications of Prognostic Anapography: Prognostic Implications of Prognostic Anapography: Prognostic Implications of Prognostic Anapography: Prognostic Implications of Prognostic Anapography: Prognostic Implications of Prognostic Anapography: Prognostic Implications of Prognostic Anapography: Prognostic Implications of Prognostic Anapography: Prognostic Implications of Prognostic Anapography: Prognostic Implications of Prognostic Anapography: Prognostic Implications of Prognostic Anapography: Prognostic Implications of Prognostic Anapography: Prognostic Implications of Prognostic Anapography: Prognostic Implications of Prognostic Anapography: Prognostic Implications of Prognostic Anapography: Prognostic Implications of Prognostic Anapography: Prognostic Implications of Prognostic Implications of Prognostic Implications of Prognostic Implications of Prognostic Implications of Prognostic Implications of Prognostic Implications of Prognostic Implications of Prognostic Implications of Prognos	Hada	Masahiro	Unusual Presentations of ACS		Nothing to Disclose
Fire Clinical Decision Making, Heart Failure and Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Nothing to Disclose Decisione Decis					
Pulmonary Hypertension	Hadadi	Cvrus	FIT Clinical Decision Making: Heart Failure and		Nothing to Disclose
Conjented Heart Disease: What Is Aorta, Arreys and Anomabus? Cornary Arteries Wisualized by Coronary CT Angography. The CONFRIM (Coronary CT Angography. The Conformation of Conformation of Conformation			Pulmonary Hypertension	Coronary Syndrome	-
Artery and Anomabus? CONFIRM (Coronary CT Angiography Evaluation For Clinical Quictomes: An Interfendational Multicenter, Registry Another and Cardiory and State	Hadamitzky	Martin			Nothing to Disclose
Non Invasive Imaging: Prognostic Implications of CT Angiography (27 Angiography Evaluation of CT Angiography Evaluation of CT Angiography Evaluation of CT Angiography Evaluation of CT Angiography Evaluation of CT Angiography Evaluation of CT Angiography Evaluation of CT Angiography Evaluation of CT Angiography Evaluation of CT Angiography Evaluation of CT Angiography Evaluation of CT Angiography Evaluation of CT Angiography Evaluation of CT Angiography Evaluation of CT Angiography Evaluation of CT Angiography Evaluation and Chronic Total Occlusions: Instellate From a National Database Interventional Cardiology: TAVR 1				CONFIRM (COronary CT Angiography Evaluation For Clinical	
laddad Elias Advances in Chronic Total Occlusion Intervention Interven	11-12-1	M	No. 1		Null'and Braden
For Clinical Outcomes An International Multicentery Registry	Hadamitzky	Martin			Nothing to Disclose
Intervention					
Intervention	Haddad	Elico	Advances in Chronic Total Cockysion	Transa and In Hasnital Outcomes of Patients Admitted With ST	Nothing to Disclose
Interventional Cardiology: TAVR 1 The Inflammasome Pathway is Associated With Adverse Ventricular Remodeling Following Transcatheter Acritic Valve Replacement	Tlaudau	Lilas			Nothing to Disclose
Remodeling Following Transcatheter Aortic Valve Replacement		<u> </u>		Insights From a National Database	lu au como de la como
Francois Imaging the Athlete's Heart Addressing Reference Echocardiographic Parameters in Athletic Screening A College Football-Based Study Focusing on the Implications of Rac and Correction for Body Composition Implications of Rac and Correction for Body Composition Implications of Rac and Correction for Body Composition Implications of Rac and Correction for Body Composition Integrating Myocardial Strain and Exercise Performance Into Prognetication of Hypertrophic Cardiomyopathy Francois Advances in HCM, PPCM and Other Cardiomyopathy Integrating Myocardial Strain and Exercise Performance Into Prognetication of Hypertrophic Cardiomyopathy Francois Advances in HCM, PPCM and Other Prognetication of Hypertrophic Cardiomyopathy Francois Advances in HCM, PPCM and Other Prognetication of Hypertrophic Cardiomyopathy Francois Advances in HCM, PPCM and Other Prognetication of Hypertrophic Cardiomyopathy Francois Cardiomyopathies Cardiomyopathies Cardiomyopathy Francois III, Heart Failure and Cardiomyopathies Clinical Team 3 (Cardiomyopathy) Systolic Dysfunction Without LV Dilatation in a Cohort of Patients With Lamin AC Cardiomyopathy Systolic Dysfunction Without LV Dilatation in a Cohort of Patients With Lamin AC Cardiomyopathy Systolic Dysfunction Without LV Dilatation in a Cohort of Patients With Lamin AC Cardiomyopathy Systolic Dysfunction Without LV Dilatation in a Cohort of Patients With Lamin AC Cardiomyopathy Systolic Dysfunction Without LV Dilatation in a Cohort of Patients With Lamin AC Cardiomyopathy Nothing to Disclose Chirclical Team 3 (Cardiomyopathy) Systolic Dysfunction Without LV Dilatation in a Cohort of Patients With Patients With Patients With Acute Coronary Systolical Failure in Patients With Patients With Acute Coronary Syndrome and Dyspoyacemial Heart Disease FIT Clinical Decision Making: Prevention, Adult Bypass Grafts to Patient Coronary Activities Cardiomyopathy Syndrome and Dyspoyacemial Heart Disease FIT Clinical Decision Making: Prevention, Adult Bypass Grafts to Patient Swit	Haddad	Francois	Interventional Cardiology: TAVR 1		Nothing to Disclose
Screening: A College Football-Based Study Focusing on the Implications of Race and Correction for Body Composition					
Implications of Race and Correction for Body Composition Identifying the Spinal Echocardiographic Variables to Predict Outcome Through Correlation Mapping in Patients With Dilated Cardiomyopathy Integrating Mycardial Strain and Exercise Performance into Nothing to Disclose Prognostication of Hypertrophic Cardiomyopathy Nothing to Disclose Prognostication of Hypertrophic Cardiomyopathy Systolic Dyston Without Lt Dilatation in a Cohort of Patients Nothing to Disclose Prognostication of Hypertrophic Cardiomyopathy Nothing to Disclose Prognostication of Hypertrophic Cardiomyopathy Nothing to Disclose Prognostication of Hypertrophic Cardiomyopathy Nothing to Disclose Prognostication of Hypertrophic Cardiomyopathy Nothing to Disclose Prognostication of Hypertrophic Cardiomyopathy Nothing to Disclose Prognostication of Hypertrophic Cardiomyopathy Nothing to Disclose Prognostication of Hypertrophic Cardiomyopathy Nothing to Disclose Prognostication of Hypertrophic Cardiomyopathy Nothing to Disclose Prognostication of Hypertrophic Cardiomyopathy Nothing to Disclose Prognostication Prognostication of Hypertrophic Cardiomyopathy Nothing to Disclose Prognostication Prognosticatio	Haddad	Francois	Imaging the Athlete's Heart		Nothing to Disclose
Francois Innovative Use of Echocardiography Identifying the Optimal Echocardiographic Variables to Predict Outcome Through Correlation Mapping in Patients With Dilated Cardiomyopathy Nothing to Disclose		1			
Cardiomyopathy	Haddad	Francois	Innovative Use of Echocardiography	Identifying the Optimal Echocardiographic Variables to Predict	Nothing to Disclose
Integrating Myocardial Strain and Exercise Performance Into Nothing to Disclose Cardiomyopathies Advances in HCM, PPCM and Other Cardiomyopathies Advances in HCM, PPCM and Other Systolic Dysfunction Without LV Dilatation in a Cohort of Patients With Lamin A/C Cardiomyopathy Sugisted Reviewer Nothing to Disclose Mothing to Mothing to Mothing to Mothin					
Francois	Haddad	Francois		Integrating Myocardial Strain and Exercise Performance Into	Nothing to Disclose
Cardiomyopathies With Lamin A/C Cardiomyopathy	Haddad	Eroposio			Nothing to Displace
Suggested Reviewer Nothing to Disclose	пациац	Francois			Inouning to Disclose
Najah Cutting Edge Vascular Medicine Vitamin D Attenuates Myocardial Injury Following Ischemia Repertusion with Modulates Erkt-2 Signaling Pathway Nothing to Disclose Repertusion with Modulates Erkt-2 Signaling Pathway Nothing to Disclose Predicting the Future: Observations and Discoveries From Registries and Databases Left Ventricular Filling Rate Predicts Clinical Failure in Patients With Nothing to Disclose Precapillary Pulmonary Hypertension A Heart Touched by Many Hands Nothing to Disclose Nothing to Disclose A Heart Touched by Many Hands Nothing to Disclose Nothing to D	Haddad	Francois	13. Heart Failure and Cardiomyopathies:		Nothing to Disclose
Reperfusion via Modulates Erkt.2 Signaling Pathway Ladigmittiades Stavros Predicting the Future: Observations and Discoveries From Registries and Databases Hadley Michelle FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease Haegeli Laurent Arrhythmias and Clinical EP: AF Ablation High Density Mapping for Gap Identification After Pulmonary Vein Isolation Bypass Grafts to Patient Coronary Arteries Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Steinar Updates on Risk Factors for Cardiovascular Disease Lagan Peter FIT Clinical Decision Making: Prevention, Adult Congenital Heart Disease Syndrome and Dysglycemia ACC Poster Moderator Mortality and Morbidity in Patients With Heart Failure and Reduced Ejection Fraction Exposed to Digoxin: Comprehensive Data Mortality and Morbidity in Patients With Heart Failure and Reduced Ejection Fraction Exposed to Digoxin: Comprehensive Data Mortality and Morbidity in Patients With Heart Failure and Reduced Ejection Fraction Exposed to Digoxin: Comprehensive Data Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Mortality and Morbidity in Patients With Heart Failure and Reduced Ejection Fraction Exposed to Digoxin: Comprehensive Data ACC Poster Moderator Mortality and Morbidity in Patients With Heart Failure and Reduced Ejection Fraction Exposed to Digoxin: Comprehensive Data ACC Poster Moderator Mortality and Morbidity in Patients With Heart Failure and Reduced Ejection Fraction Exposed to Digoxin: Comprehensive Data ACC Poster Moderator Mortality and Morbidity in Patients With Heart Failure and Reduced Ejection Fraction Exposed to Digoxin: Comprehensive Data ACC Poster Moderator Mortality and Morbidity in Patients With Heart Failure and Reduced Ejection Fraction Exposed to Digoxin: Comprehensive Data	Hadi	Najah		Vitamin D Attenuates Myocardial Injury Following Ischemia	Nothing to Disclose
Discoveries From Registries and Databases Precapillary Pulmonary Hypertension		-		Reperfusion via Modulates Erk1-2 Signaling Pathway	-
Hadley Michelle FIT Clinical Decision Making: Prevention, Adult A Heart Touched by Many Hands Nothing to Disclose Laurent Arrhythmias and Clinical EP: AF Ablation High Density Mapping for Gap Identification After Pulmonary Vein Isolation Haery Cameron FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease Hafthorsson Steinar Updates on Risk Factors for Cardiovascular Disease Hagan Peter FIT Clinical Decision Making: Multimodality Imaging Hage Camilla Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review According to Attra Flailuration to Agric Patients With Heart Failure and Reduced Ejection Fraction Exposed to Digoxin: Comprehensive Data Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Proceeding to Patients From the Swedish	Hadjimiltiades	Stavros			Nothing to Disclose
Congenital and Congenital Heart Disease	Hadley	Michelle			Nothing to Disclose
Isolation Isol	-				
Isolation Isol	Haegeli	Laurent	Arrhythmias and Clinical EP: AF Ablation	High Density Mapping for Gap Identification After Pulmonary Vein	Nothing to Disclose
Congenital and Congenital Heart Disease			•	Isolation	ů .
Hafthorsson Steinar Updates on Risk Factors for Cardiovascular Disease Syndrome and Dysglycemia ACC Poster Moderator Mothing to Disclose Syndrome and Dysglycemia ACC Poster Moderator Mothing to Disclose Unaging ACC Poster Moderator Mothing to Disclose Mothing to Disclose Mothing to Disclose Mothing to Disclose India Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review According to Atrial Fibrillation in 23,709.8 Patients From the Swedish	Haery	Cameron		Bypass Grafts to Patent Coronary Arteries	Nothing to Disclose
Disease Syndrome and Dysglycemia ACC Poster Moderator Nothing to Disclose			Congenital and Congenital Pleast Disease		
Acc Poster Moderator Nothing to Disclose	Hafthorsson	Steinar			Nothing to Disclose
lmaging Hage Camilla Highlighted Original Research: Heart Failure And Mortality and Morbidity in Patients With Heart Failure and Reduced and Cardiomyopathies and the Year in Review Ejection Fraction Exposed to Digoxin: Comprehensive Data According to Atrial Fibrillation in 23,708 Patients From the Swedish	Hagan	Peter			Nothing to Disclose
and Cardiomyopathies and the Year in Review Ejection Fraction Exposed to Digoxin: Comprehensive Data According to Atrial Fibrillation in 23,708 Patients From the Swedish			Imaging		-
According to Atrial Fibrillation in 23,708 Patients From the Swedish	Hage	Camilla			Nothing to Disclose
			and the real in Neview	According to Atrial Fibrillation in 23,708 Patients From the Swedish	

Last Name Hage	First Name Fadi	Session Title 30. Non Invasive Imaging: Nuclear Team 2	Presentation Title Suggested Reviewer	Disclosures RESEARCH/RESEARCH GRANTS - Astellas Pharma Global
=				Development, Novartis Pharmaceuticals
Hagemann	Christoffer	Insights From Echocardiography Use	Layer-Specific Strain Analysis by Two-Dimensional Speckle Tracking Echocardiography: Improvement of Coronary Artery Disease Diagnostics in Patients With Stable Angina Pectoris	Nothing to Disclose
Hagiwara	Nobuhisa	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Rapid Resolution of Tendon Xanthomas in Elder Heterozygous Familial Hyperchorestelemia Treated With Evolocumab	Nothing to Disclose
Hagiwara	Nobuhisa	Optimizing the Care of ACS Patients	Novel Utilization of DAPT Score as a Predictor of Long-Term Clinical Outcomes in Hemodialysis Patients on Prolonged Dual	Nothing to Disclose
Hagiwara	Nobuhisa	Interventional Cardiology: PCI in Complex	Antiplatelet Therapy After Coronary Intervention Predictors for 2-Year Cardiovascular Events After Rotablation in	Nothing to Disclose
Hagiwara	Nobuhisa	Patients Nuclear Cardiology: Coronary Flow	Severe Calcified Lesion Patient Based Territorial Coronary Flow Analysis by Voronoi	Nothing to Disclose
Hagiwara	Nobuhisa	Non Invasive Imaging: MR Structure and	Algorithm With ¹³ N Ammonia PET CTA Fusion Cardiac Diffusion Weighted Image in Patients With Cardiac	Nothing to Disclose
Hagler	Donald	Valuvular Heart Disease Predicting Outcomes in Pediatric Heart Disase	Sarcoidosis: Comparison to ¹⁸ F-fludeoxyglcose PET Growth Dynamics of Aorta in Bicuspid Aortic Valve Patients From	Nothing to Disclose
Hahn	Rebecca	Aortic Stenosis: Overview of the Hemodynamics and Ventricular Response	Infancy to Young Adult Age Panelist	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular,Boston Scientific,GE Medical
Hahn	Rebecca	The Tricuspid Valve: Not Forgotten, Just Misunderstood	Transcatheter Options for Tricuspid Regurgitation	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular, Boston Scientific, GE Medical
Hahn	Rebecca	Prosthetic Valve Assessment: Real or Illusion?	Co-Chair	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular, Boston Scientific, GE Medical
Hahn	Rebecca	Prosthetic Valve Assessment: Real or Illusion?	High Gradients Following Surgical Valve Replacement	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular, Boston Scientific, GE Medical
Hahn	Rebecca	Post FDA Release Prosthetic Valve Surveillance - Watching for Signals	Co-Chair	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular, Boston Scientific, GE Medical
Hahn	Rebecca	Highlighted Original Research: Interventional Cardiology and the Year in Review	Implications of Worsening Right Ventricular Function Following Transcatheter or Surgical Aortic Valve Replacement: Insights From PARTNER2A	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular, Boston Scientific, GE Medical
Hahn	Rebecca	Interventional Cardiology: TAVR 1	Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: Insights From PARTNER 2A Trial	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular, Boston Scientific, GE Medical
Hahn	Rebecca	Non Invasive Imaging: Expanding Clinical Applications	Does Patient Prosthesis Mismatch Defined by CT LVOT Area Predict Downstream Clinical Outcomes?	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular, Boston Scientific, GE Medical
Hahn	Rebecca	Interventional Cardiology: TAVR 2	Worsening Tricuspid Regurgitation and Increased Mortality After Aortic Valve Replacement: Insights From PARTNER2A	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular, Boston Scientific, GE Medical
Hahn	Rebecca	Interventional Cardiology: PCI and TAVR in Complex Patients	Refining the Classification of Severe, Symptomatic Aortic Stenosis Using Flow and Gradient Measurements to Predict Outcomes Post- Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular, Boston Scientific, GE Medical
Hahn	Rebecca	Engage @ ACC.17 Studio: Ask the Valvular Heart Disease Experts	Co-Chair	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular, Boston Scientific, GE Medical
Hahn	Rebecca	TAVR Outcomes Prognostication	High Baseline Valvuloarterial Impedence Predicts Worse 1-Year Outcomes After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular, Boston Scientific, GE Medical
Hahn	Rebecca	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low- Flow Severe Aortic Stenosis and Less Reverse Remodeling After TAVR: A Partner 2 Trial Analysis	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular, Boston Scientific, GE Medical
Hahn	Rebecca	37. Valvular Heart Disease: Therapy Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular, Boston Scientific, GE Medical
Haig	Caroline	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Prognostic Significance of Co-Existing Persistent Edema and Hemorrhage at 6 Months in Survivors of ST-Elevation Myocardial Infarction	Nothing to Disclose
Haig	Caroline	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Segmental Circumferential Strain Derived From DENSE Predicts Improvement of Left Ventricular Function Post ST Elevation Myocardial Infarction: The BHF MR-MI Study	Nothing to Disclose
Haig	Caroline	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Current Smoking, Microvascular Pathology and Adverse Outcome After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights	Nothing to Disclose
Haig	Caroline	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Incidence and Prognostic Implications of the Presence of Multiple Complex Plaques in Survivors of ST-Elevation Myocardial Infarction	Nothing to Disclose
Haig	Caroline	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Hypertension, Microvascular Pathology and Prognosis in Patients With an Acute ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Haik	Bruce	Interventional Cardiology: TAVR 1	Assessment of Right Sided Hemodynamic Parameters as Predictors of Early Outcomes After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Haik	Bruce	Emerging Applications of Echocardiography	A New Modified Continuity Equation for Calculation of Aortic Valve Area by Integrating 3-D Measurements of LVOT Planimetry and LVOT Flow Mapping	Nothing to Disclose
Haik	Bruce	Emerging Applications of Echocardiography	Direct Comparison of Aortic Valve Area by 3-D TEE Planimetry and 4-D Dynamic Cardiac CT Planimetry	Nothing to Disclose
Hainer	Jon	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Integrating Hyperemic Myocardial Blood Flow and Coronary Flow Reserve for Predicting Cardiovascular Mortality Outcomes in Patients With Known or Suspected Ischemic Heart Disease	Nothing to Disclose
Hainer	Jon	Young Investigator Awards Competition: Clinical Investigations	Impaired Coronary Flow Reserve Is Associated With Diastolic Dysfunction and HFpEF Outcomes in Patients Without Overt CAD	Nothing to Disclose
Hainer	Jon	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Lipid Abnormalities in Young Patients With Myocardial Infarction	Nothing to Disclose
Hainer	Jon	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Women Who Experience Myocardial Infarction at a Young Age Have Worse Survival Compared With Men	Nothing to Disclose
Hainer	Jon	Nuclear Cardiology: Prognosis	Myocardial Scar but Not Ischemia Predicts Defibrillator Shocks and Sudden Cardiac Death in Patients With Reduced Left Ventricular Ejection Fraction	Nothing to Disclose
Hainer	Jon	Unusual Presentations of ACS	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival	Nothing to Disclose
Hainer	Jon	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Relationship of Coronary Flow Reserve With Body Mass Index and Adverse Outcomes in Patients Without Overt Ischemic Heart Disease: Implications for Metabolic Surgery Eliqibility	Nothing to Disclose
Hainer	Jon	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Association Between Coronary Flow Reserve and Adverse Cardiovascular Events Along a Continuum of Metabolic Disease in Symptomatic Patients Without Overt Coronary Artery Disease	Nothing to Disclose



Control of the contro				l
Last Name Haines	First Name David	Session Title Atrial Fibrillation and VT: Unique Populations and Solutions	Presentation Title Paroxysmal or Persistent: A Tale of Two Flutters	Disclosures OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - nContact, RESEARCH/RESEARCH GRANTS - ARCA Pharmaceutical,Boston
Hainstock	Michael	Congenital Heart Disease: Advances in Quality Improvement for Pediatric Cardiac Care	Cost-Analysis of Outpatient Cardiac Catheterization in Infants With Single Ventricle Congenital Heart Disease	Scientific,CardioFocus,MEDTRONIC,Toray Nothing to Disclose
Hajjar	Roger	Evolving Therapies in Heart Failure: Gazing	HF Trials in Gene Therapy: Promising or Promise Lost?	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Hajjar	Roger	Into the Crystal Ball Non Invasive Imaging: MR Characterization and Function	Myocardial Oxygenation Using Blood Level-Oxygen Dependent Sequence in Magnetic Resonance Determines Myocardial	Nanocor OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Nanocor
Hajjar	Roger	Heart Failure and Cardiomyopathies: Is Heart	Energetics and Capillary Density LV Unloading Using Impella CP Improves LA Pressure, Function,	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Hajjar	Roger	Failure With a Normal EF for Real? Novel Developments in Acute Coronary	and Stiffness in Ischemic Pig Model LV Unloading using an Impella CP Improves Coronary Flow and	Nanocor OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Hakeem	Abdul	Syndromes Imaging Pulmonary Vascular Disease Plus the	Infarct Zone Perfusion Correlation Between Echocardiographic Pulmonary Artery Pressure	Nanocor Nothing to Disclose
		Impact of Congenital Heart Disease	Estimates and Right Heart Catheterization Measurements in Patients Undergoing Liver Transplant Evaluation: A Single Center Study	
Hakeem	Abdul	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Outcomes of Fractional Flow Reserve Based Deferral in Saphenous Vein Graft Lesions	Nothing to Disclose
Hakeem	Abdul	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Does Post Pci Ffr Carry the Same Prognostic Weight as Non- Ischemic Ffr in Deferred Lesions?	Nothing to Disclose
Hakemi	Emad	Updates on Pulmonary Embolism Management in 2017	The Long-Term Prognostic Value of Highly Sensitive Cardiac Troponin I in Patients With Acute Pulmonary Embolism	Nothing to Disclose
Hakemi	Emad	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Systemic Lupus Erythematosus Dissecting the Human Body	Nothing to Disclose
Hakemi	Emad	Arrhythmias and Heart Failure	Quadripolar Versus Bipolar Left Ventricular Leads in Cardiac	Nothing to Disclose
Hakgor	Aykun	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Resynchronization Therapy: An Analysis From the NCDR Clinical, Biochemical, Neurohumoral, Echocardiographic and Hemodynamic Characteristics in Relation to Survival in Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: Insights From Euphrates Study	CONSULTANT FEES/HONORARIA - Bayer
Hakgor	Aykun	Understanding Pulmonary Vascular Disease: From Bench to Bedside	Short-Term Intravenous lioprost Treatment Improves Clinical Status and Neurohumoral Measures in Clinical Worsening Episodes of Precapillary Pulmonary Hypertension Regardless of the Background Treatments: Insights From Euphrates Study	CONSULTANT FEES/HONORARIA - Bayer
Hakgor	Aykun	Understanding Pulmonary Vascular Disease: From Bench to Bedside	The Impaired Endothelium-Dependent and Endothelium- Independent Systemic Arterial Vasodilatory Reserve in Pulmonary Hypertension Regardless of the Clinical Group	CONSULTANT FEES/HONORARIA - Bayer
Hakgor	Aykun	Predicting the Future: Observations and Discoveries From Registries and Databases	Pulmonary Vascular Resistance, but Not Diastolic Pulmonary Gradient, May Predict Survival in Pulmonary Hypertension: Insights From Euphrates Study	CONSULTANT FEES/HONORARIA - Bayer
Hakgor	Aykun	Predicting the Future: Observations and Discoveries From Registries and Databases	The Correlates and Prognostic Impact of Pulmonary Arterial Pulse Pressures, Diastolic and Transpulmonary Pressure Gradients in Pulmonary Hypertension: Insights From Euphrates Study	CONSULTANT FEES/HONORARIA - Bayer
Hakgor	Aykun	Predicting the Future: Observations and Discoveries From Registries and Databases	An Ignored but Not Unusual Complication of Severe Pulmonary Hypertension - Ostial Compression of Left Main Coronary Artery by Aneurysmal Pulmonary Artery: Insights From Euphrates Study	CONSULTANT FEES/HONORARIA - Bayer
Hakim	Zaher	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease		Nothing to Disclose
Hakimi	Matthew	Innovations in Cardiovascular Risk Assessment and Reduction	The Prognostic Value of CPET: Association With Coronary Artery Calcium Score	Nothing to Disclose
Hakimi	Matthew	Non Invasive Imaging: Role of Exercise Testing	The Non-Invasive Physiological Detection of Myocardial Ischemia in Coronary Artery Disease	Nothing to Disclose
Hakimian	Stephanie	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Electromechanical Activation Time via HemoTag and 2D Echocardiography: Correlation With Tricuspid Regurgitation Peak Velocity and Implications for Diagnosis and Clinical Practice	Nothing to Disclose
Halabi	Abdul	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	External Femoral-Femoral Bypass for Acute Limb Ischemia	Nothing to Disclose
Haldis	Thomas	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Twelve Month Follow-Up Data From the ONYX CORE Trial: Angiographic and Clinical Performance of Next Generation Resolute	SPEAKER'S BUREAU - Edwards
Hale	Benjamin	Vascular Medicine: Emerging Concepts in	Onyx Drug-Eluting Stent Kommerell Diverticulum Across the Ages: Destined for Dilation?	Nothing to Disclose
Haleem	Kamran	Clinical Vascular Diseases Hearts and Soles: Multimodality Imaging in	Assessment of Coronary Atherosclerosis Using Calcium Scores in	Nothing to Disclose
Hall	lan	Athletes Considerations in Antiplatelet Therapy and in ACS	Short and Long Distance Runners Comparison of P2y-sub>12-/sub> Inhibitors for Mortality and Stent Thrombosis in Patients With Acute Coronary Syndromes: Single Centre Study of 10,793 Consecutive 'Real-World'	Nothing to Disclose
Hall	Michael	Predicting the Future: Observations and Discoveries From Registries and Databases	Patients Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study	Nothing to Disclose
Hall Hall	Michael Shelley	29. Non Invasive Imaging: MR Team 2 Surgical Therapies for Heart Failure Patients:	Suggested Reviewer Co-Chair	Nothing to Disclose CONSULTANT FEES/HONORARIA - Abiomed,St Jude; SPEAKER'S BUREAU - CareDx,Novartis Corporation
Haller	Christoph	Stage A-C Redefining the "F" Word	Late Complications and Cardiopulmonary Performance in Adults With Fontan Physiology: Rv-Dominant Versus Those With Lv- Dominant or Unseptated Ventricles	SPEAKER'S BUREAU - CareDx, Novartis Corporation Nothing to Disclose
Halliday	Brian	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Cardiovascular Magnetic Resonance in Survivors of Sudden Cardiac Arrest: 14 Year Experience From a Tertiary Referral Centre in the United Kingdom	Nothing to Disclose
Halliday	Christopher	Highlights in Vascular Medicine Research	In the United Alrigorni Apabetalone (RVX-208) Lowers Cardiovascular Disease (CVD) in Diabetes Mellitus by a Mechanism Involving Microbiome Mediated Activity on the Complement Pathway	SALARY - Resverlogix Corp.
Halon	David	Advances in Cholesterol Measurement and Management	Clinical Features and Gaps in the Management of Familial Hypercholesterolemia With Prevalent Cardiovascular Disease	OTHER - AstraZeneca Pharmaceuticals,Bayer,Population Health Research Institute
Halon	David	Non Invasive Imaging: Prognostic Implications of CT Angiography	Can We Identify Plaques That Will Cause Acute Coronary Syndromes? An 8 Year Prospective Study Based on CT Angiography in Asymptomatic Diabetics	OTHER - AstraZeneca Pharmaceuticals,Bayer,Population Health Research Institute
Halperin	Jonathan	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	Panelist	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,Boehringer Ingelheim,Boehringer Ingelheim,Boston Scientific,MEDTRONIC,Medtronic, Inc.,Ortho- McNeil-Janssen,Ortho-McNeil-Janssen Pharmaceuticals, Inc.,Pfizer
Halperin	Jonathan	Syncope: What's New	Co-Chair	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,Boehringer Ingelheim,Boehringer Ingelheim,Boston Scientific,MEDTRONIC,Medtronic, Inc.,Ortho- McNeil-Janssen,Ortho-McNeil-Janssen Pharmaceuticals, Inc.,Pfizer,Ffizer, Inc.

Contract of the contract of th				
Last Name	First Name	Session Title	Presentation Title	Disclosures CONSULTANT FEES/HONORARIA - Bayer Healthcare
Halperin	Jonathan	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Persistence With Therapy in Patients With Atrial Fibrillation: The GLORIA-AF Registry	Pharmaceuticals,Boehringer Ingelheim,Boehringer Ingelheim,Boston Scientific,MEDTRONIC,Medtronic, Inc.,Ortho-McNeil-Janssen,Ortho-McNeil-Janssen Pharmaceuticals,
Halassia	Jonathan	Atrial Citallation and VT. Union Benedations	Desdistant of Askinson Joseph Description in Deticate With Addia	Inc.,Pfizer,Pfizer, Inc. CONSULTANT FEES/HONORARIA - Bayer Healthcare
Halperin		Atrial Fibrillation and VT: Unique Populations and Solutions	Predictors of Anticoagulant Prescription in Patients With Atrial Fibrillation in North America: The GLORIA-AF Registry	Pharmaceuticals,Boehringer Ingelheim,Boehringer Ingelheim,Boston Scientific,MEDTRONIC,Medtronic, Inc.,Ortho-McNeil-Janssen,Ortho-McNeil-Janssen Pharmaceuticals, Inc.,Pfizer,Pfizer, Inc.
Halperin	Jonathan	Arrhythmias and Clinical EP: Anticoagulation Issues	Thrombolytic Therapy in Anticoagulated Patients: Case Series From Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET AF)	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals Boehringer Ingelheim. Boehringer Ingelheim, Boston Scientific, MEDTRONIC, Medtronic, Inc., Ortho- McNeil-Janssen, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Pifzer, Pizzer, Inc.
Halperin	Jonathan	Innovations in Cardiovascular Risk Assessment and Reduction	Optical Coherence Tomography of Culprit Lesions in Patients With Prior Cerebrovascular Events Compared to Controls	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, Boehringer Ingelheim, Boston Scientific, MEDTRONIC, Medtronic, Inc., Ortho- McNeil-Janssen, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Pfizer, Pfizer, Inc.
Halperin	Jonathan	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Rates of Stroke and Bleeding With Dabigatran 150 and 110 mg BID in Clinical Practice: The GLORIA-AF Registry	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, Boehringer Ingelheim, Boston Scientific, MEDTRONIC, Meditronic, Inc., Ortho- McNeil-Janssen, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Přízer, Přízer, Inc.
Halpern	Dan	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Successful Balloon Valvuloplasty for Subacute Unilateral Pleural Effusion in Ebstein Anomaly	Nothing to Disclose
Halsey	Joy	Interdisciplinary Cardiovascular Team Collaboratives in Care	Multidisciplinary Cardiovascular Team Review Captures Preclinical	Nothing to Disclose
Halsey	Joy	Diabetes and Other Issues in Cardiovascular	Disease Arresting Insulin Resistance With an Integrative Health Intervention	Nothing to Disclose
Hama Amin	Ali	Prevention The Best Structural Interventional Challenging	Late Manifestation of Eisenmenger Physiology After Atrial Septal	Nothing to Disclose
		Cases PCI for NSTEMI and Complex Patients With	Defect Closure	
Hama Amin	Ali	Multiple Co-Morbidities	The Feasibility and Safety of Same Day Discharge for All Comers After Elective Percutaneous Coronary Interventions	Nothing to Disclose
Hama Amin	Ali	Interventional Cardiology: TAVR 2	Outcomes of Transcatheter and Surgical Aortic Valve Replacement in Patients With Hepatic Cirrhosis: Insight From Nationwide Inpatient Sample	Nothing to Disclose
Hama Amin	Ali	Novel Determinants of Outcomes in VHD	Racial Disparity in Aortic Valve Replacement Outcomes: Insight From National Inpatient Sample	Nothing to Disclose
Hama Amin	Ali	Valvular Heart Disease With CKD or Cirrhosis	Trends and Outcomes of Mitral Valve Replacement in Patients With Hepatic Cirrhosis: Insight From National Inpatient Sample	Nothing to Disclose
Hama Amin	Ali	Sex Disparity in VHD Outcomes	Contemporary Trends and Outcomes of Isolated Aortic Valve Replacement in Females in The United States: Understanding the Gender Gap	Nothing to Disclose
Hamad	Eman	The Forgotten Chamber: The Right Ventricle in	Challenging Case of RV Failure	Nothing to Disclose
Hamadeh	Issam	Heart Failure The Evolving World of LVADs, Transplant and	Cardiomyopathy Associated With Targeted Anticancer Therapies in	Nothing to Disclose
Hamaya	Rikuta	Other Novel Discoveries Interventional Cardiology: Intravascular	Electronic Health Records Relationship Between Coronary Physiological Parameters and	Nothing to Disclose
		Physiology and Endothelial Function	Cardiac Biomarkers in Patients Undergoing Invasive Coronary Angiography	
Hamaya	Rikuta	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Significance of Microcirculatory Resistance in Visual-Functional Mismatch Between Coronary Angiography and Fractional Flow Reserve in Non-Left Main Lesions	Nothing to Disclose
Hamaya	Rikuta	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Usefulness of Optical Coherence Tomography-Derived Morphometric Assessment to Predict Physiological Significance of Coronary Artery Stenosis and Determinants of Mismatch: Head-to- Head Comparison With Intravascular Ultrasound	Nothing to Disclose
Hamaya	Rikuta	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Relationship Between Optical Coherence Tomography-Defined In- Stent Neoatherosclerosis and Out-Stent Arterial Remodeling Assessed by Serial Intravacular Ultrasound Examinations in Late and Very Late Drug-Eluting Stent Failure	Nothing to Disclose
Hamaya	Rikuta	Unusual Presentations of ACS	Predictors and Clinical Significance of High-Sensitivity Cardiac Troponin-I Elevation After Diagnostic Coronary Angiography	Nothing to Disclose
Hamaya	Rikuta	Unusual Presentations of ACS	Multimodality Coronary Imaging to Predict Periprocedural Myocardial Necrosis After Elective Percutaneous Coronary Intervention	Nothing to Disclose
Hamaya	Rikuta	Unusual Presentations of ACS	Comparison of Neointimal Appearance Assessed by Optical Coherence Tomography Between Bare-Metal Stents and Sirolimus-	Nothing to Disclose
Hambrook	John	Therapeutic Advances in Congenital Heart		Nothing to Disclose
Hamburg	Naomi	Disease Vascular Diagnoses Cardiologists Should not Miss: A Case-based Approach	Cardiac Rehabilitation Case Presentation: Patient with Hypertension and Absent Pulse	CONSULTANT FEES/HONORARIA - Welchs; OTHER - Acceleron Pharma; RESEARCH/RESEARCH GRANTS - Everest Genomics,Hersheys,Unex
Hamburg	Naomi	Highlighted Original Research: Vascular Medicine and the Year in Review	Co-Chair	CONSULTANT FEES/HONORARIA - Welchs; OTHER - Acceleron Pharma; RESEARCH/RESEARCH GRANTS - Everest Genomics,Hersheys,Unex
Hamburg	Naomi	Optimizing Treatment of Peripheral Artery Disease	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Welchs; OTHER - Acceleron Pharma; RESEARCH/RESEARCH GRANTS - Everest Genomics,Hersheys,Unex
Hamburg	Naomi	Uncovering the Intricacies of Vascular Function	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Welchs; OTHER - Acceleron Pharma; RESEARCH/RESEARCH GRANTS - Everest Genomics,Hersheys,Unex
Hamburg	Naomi	40. Vascular Medicine: Non Coronary Arterial Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Welchs; OTHER - Acceleron Pharma; RESEARCH/RESEARCH GRANTS - Everest Genomics, Hershevs, Unex
Hamburger	Robert	Novel Imaging and Therapies in Heart Failure	Global Longitudinal Strain in Patients With New Left Ventricular Systolic Dysfunction After Anticancer Targeted Therapies	Nothing to Disclose
Hamdan	Mohamed	Syncope: Challenges and Pitfalls: A Case- based Approach	Panelist	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - ClinicNotes, LLC,F2 Solutions, Inc
Hamdan	Mohamed	Syncope: Challenges and Pitfalls: A Case-	80 Year Old Female with DM HFpEF RBBB and LAFB with a Fall	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Hameed	Afshan	based Approach The Consequences of Sex: Women and	High Cardiovascular Risk Pregnancy; Who's at risk? Who Should	ClinicNotes, LLC,F2 Solutions, Inc Nothing to Disclose
Hameed	Afshan	Pregnancy Across the Spectrum Adult Patients With Congenital Heart Disease: How Do They Compare?	Terminate? Mortality in Pregnant Women With Congenital Heart Disease: A Subanalysis of the California Pregnancy-Associated Mortality Review	Nothing to Disclose
Hamershock	Rose	Atrial Fibrillation and VT: Unique Populations	Outcomes of Asian Patients With Atrial Fibrillation Compared to Non-	Nothing to Disclose
Hamilton	David	and Solutions Traditional and Novel Factors Used to Assess	Asians in the ENGAGE AF-TIMI 48 Trial Glycemic Control in Insulin and Non-Insulin Dependent Diabetic	Nothing to Disclose
		the Risk of, and Used for the Treatment of, Coronary Artery Disease	Patients With ST Elevation Myocardial Infarction Predicts Time to Presentation	

(M. A. C.)				<u> </u>
Last Name Hamilton	First Name David	Session Title Traditional and Novel Factors Used to Assess	Presentation Title Ischemic Time and Risk Factors Associated With the Incidence of	Disclosures Nothing to Disclose
	Savia	the Risk of, and Used for the Treatment of, Coronary Artery Disease	Cardiogenic Shock in Patients Presenting With ST Elevation Myocardial Infarction	. Teating to Discour
Hamilton	David	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Impact of Demographics and Socioeconomic Status on Mode of Transportation and Time to Presentation in Patients With ST Elevation Myocardial Infarction	Nothing to Disclose
Hamilton	Michele	Advances in HCM, PPCM and Other Cardiomyopathies	High Versus Standard Protein Diets in Obese Patients With Heart Failure: Effects on Chronic Disease Risks	Nothing to Disclose
Hamm	Christian	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of Periprocedural Myocardial Infarction in Contemporary PCI: Pooled Patient-Level Data From the CHAMPION Trials	CONSULTANT FEES/HONORARIA - Abbott,AstraZeneca,Boehringer Ingelheim,Brahms,Daiichi Sankyo,GSK,MEDTRONIC,SHS; SPEAKER'S BUREAU - Burez Lilly, Sanoffa, August
Hamm	Christian	Optimizing the Care of ACS Patients	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin: Insights From CHAMPION PHOENIX	Bayer, Lilly,SanoflAventis CONSULTANT FEES/HONORARIA - Abbott,AstraZeneca,Boehringer Ingelheim,Brahms,Daiichi Sankyo,GSK,MEDTRONIC,SHS; SPEAKER'S BUREAU - Bayer,Lilly,SanoflAventis
Hamm	Christian	Post-CAD/MI: Making Tough Predictions About the Future	One-Year Mortality Increased in Patients With Peri-Procedural Myocardial Infarction: Insights From the CHAMPION Trials	CONSULTANT FEES/HONORARIA - Abbott,AstraZeneca,Boehringer Ingelheim,Brahms,Daiichi Sankyo,GSK,MEDTRONIC,SHS; SPEAKER'S BUREAU - Bayer,Lilly,SanofiAventis
Hamm	Christian	Anti-Platelet Therapies: Always a Sticky Topic	Ischemic Events Occur Early in Patients Undergoing PCI and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX	CONSULTANT FEES/HONORARIA - Abbott,AstraZeneca,Boehringer Ingelheim,Brahms,Daiichi Sankyo,GSK,MEDTRONIC,SHS; SPEAKER'S BUREAU - Bayer,Lilly,SanofiAventis
Hamm	Christian	02. Acute and Stable Ischemic Heart Disease: Clinical Team 7	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott,AstraZeneca,Boehringer Ingelheim,Brahms,Daiichi Sankyo,GSK,MEDTRONIC,SHS; SPEAKER'S BUREAU - Bayer,Lilly,SanofiAventis
Hammad	Basma	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Think Syndromic	Nothing to Disclose
Hammadah	Muhammad	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Association Between Circulating Progenitor Cells and Outcomes in Patients With Coronary Artery Disease	Nothing to Disclose
Hammadah	Muhammad	Coronary Artery Disease Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Inflammatory Response to Mental Stress and Mental Stress Induced Myocardial Ischemia	Nothing to Disclose
Hammadah	Muhammad	Coronary Artery Disease Updates on Risk Factors for Cardiovascular Disease	Changes in Body Fat Distribution Is Associated With Oxidative Stress	Nothing to Disclose
Hammadah	Muhammad	The Evolving World of LVADs, Transplant and	Progenitor Cells and Clinical Outcomes in Patients With Heart	Nothing to Disclose
Hammadah	Muhammad	Other Novel Discoveries Unusual Presentations of ACS	Failure Circulating Progenitor Cells Levels and Outcomes in Acute	Nothing to Disclose
Hammami	Sumaya	Interventional Cardiology: TAVR 1	Myocardial Infarction Safety and Efficacy of Using Pressure Wire With Dobutamin Infusion in Themoynamic Assessment of Low Flow Low Gradient Aortic Stenosis	Nothing to Disclose
Hammami	Sumaya	Interventional Cardiology: PCI and TAVR in	Hemodynamic Assessment of Low Flow, Low Gradient Severe	Nothing to Disclose
Hammami	Sumaya	Complex Patients Interventional Cardiology: Structural Heart	Aortic Stenosis With Preserved EF Using a Pressure Wire The Impact of Transaortic Gradient and Transaortic Flow on the	Nothing to Disclose
		Disease	Discrepancy Between Echocardiographic and Cardiac Catheterization Evaluation of Severe Aortic Stenosis With Preserved Ejection Fraction	,
Hammarsten	Ola	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	High-Sensitivity Cardiac Troponin T Levels and Long-Term Mortality in Patients With Chest Pain	Nothing to Disclose
Hammerstingl	Christoph	Interventional Live Case Session IV: Complex Coronary Transmission from St. Vincent Hospital (Indianapolis, IN)	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular, Cardiac Dimensions, MEDTRONIC, Mitralign, Valtech
Hammerstingl	Christoph	The Tricuspid Valve: The New Frontier	Case Presentation: Mitraclip Repair of the Tricuspid Valve	CONSULTANT FEES/HONORARIA - Abbott Vascular, Cardiac
Hamzeh	lhab	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Correlation of Right Atrial Enlargement on Ecg to Right Atrial Volume by Echocardiography in Patients With Pulmonary	Dimensions,MEDTRONIC,Mitralign,Valtech Nothing to Disclose
Hamzeh	lhab	Interventional Cardiology: PCI in Complex Patients	Hypertension Clinical Outcomes of Patients With Human Immune Deficiency Virus After Coronary Revascularization: A Systematic Review and Meta-	Nothing to Disclose
Han	Donghee	Non Invasive Imaging: Expanding Clinical Applications	Analysis Dual-Energy Coronary Computed Tomography Evaluation of High-Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients:	Nothing to Disclose
Han	Donghee	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Validation with Histopathologic Gold Standard Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired	Nothing to Disclose
Han	Donghee	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Renal Function: The CONFIRM Registry Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography: The CONFIRM (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicentery Registry	Nothing to Disclose
Han	Donghee	Innovations in Cardiovascular Risk Assessment and Reduction	Atheroscleric Cardiovascular Disease Risk in Statin-Nas#239; we Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	Nothing to Disclose
Han	Donghee	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prognostic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry	Nothing to Disclose
Han	Donghee	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography: The CONFIRM Registry	Nothing to Disclose
Han	Donghee	Or CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Computed Tomologianic Anglogiaphy. The CONTRINI Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Death: A Comparison to a Histologic Reference Standard	Nothing to Disclose
Han	Donghee	Diabetes and Other Issues in Cardiovascular Prevention	Implications of Statin Therapy Among Smokers With Severe Coronary Artery Calcification: An Analysis of the CONFIRM Registry	Nothing to Disclose
Han	Donghee	Non Invasive Imaging: New Technologies	Optimal Method for Necrotic Core Identification in Coronary Plaque With Dual-Energy Computed Tomography: Material Decomposition	Nothing to Disclose
Han	Frederick	Arrhythmias and Clinical EP: Basic 2	and Atomic Number Utility of an Esophageal Screening Protocol in Preventing Atrio-	Nothing to Disclose
Han	Frederick	Arrhythmias and Clinical EP: Basic 5	Esophageal Fistula After Atrial Fibrillation Ablation Cryoballoon Ablation Targeting Left Atrial Fibrosis Produces Similar	Nothing to Disclose
Han	Frederick	08. Arrhythmias and Clinical EP:	Outcomes in Paroxysmal and Persistent Atrial Fibrillation Suggested Reviewer	Nothing to Disclose
		Supraventricular/Ventricular Arrhythmias Team 4		

and a				<u> </u>
Han	First Name Seongwook	Session Title Arrhythmias and Clinical EP: Anticoagulation	Presentation Title Noac Adherence of the Patients With Nonvalvular Atrial Fibrillation	Disclosures Nothing to Disclose
Han	Seongwook	Issues Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	in Real Practice Five Year Outcomes of Fractional Flow Reserve Guided Versus Intravascular Ultrasound Guided Percutaneous Coronary	Nothing to Disclose
Han	Seung Hwan	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Intervention in Intermediate Coronary Artery Disease Prognostic Value of Soluble ST2 in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention	Nothing to Disclose
Han	Seung-Hwan	Unusual Presentations of ACS	The Role of Coronary Response to Nitrate in Patients With Suspected Vasospastic Angina	Nothing to Disclose
Han	Yaling	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Diabetes Mellitus on Antithrombotic Management Patterns and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndrome: Insight From the EPICOR Asia Study	Nothing to Disclose
Han	Yuchi	The Forgotten Valves: Therapies for Triscuspid		RESEARCH/RESEARCH GRANTS - General Electric, Gilead Sciences. Inc.
Han	Yuchi	and Pulmonic Valve Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Using Cardiac Magnetic Resonance Imaging and Transthoracic Echocardiography to Predict Presence of Papillary Muscle-Based	RESEARCH/RESEARCH GRANTS - General Electric, Gilead Sciences, Inc.
Handa	Aman	Predicting the Future: Observations and Discoveries From Registries and Databases	Ventricular Ectopy in Mitral Valve Prolapse Trends in Pulmonary Hypertension Hospitalizations: Insights From a National Database	Nothing to Disclose
Handa	Nobuhiro	Head to Toe: Outcomes of Endovascular Interventions	Late Intervention After Endovascular Aneurysm Repair for Abdominal Aortic Aneurysm: National Hospital Organization Network Study in Japan	Nothing to Disclose
Handberg	Eileen	Case Studies from the Guidelines for Clinicians	Cases in General Cardiology	CONSULTANT FEES/HONORARIA - Amgen; OTHER - Amarin,Amgen,AstraZeneca,Boerhinger Ingleheim,Daiichi Sankyo,Sanofi/Aventis; RESEARCH/RESEARCH GRANTS - gilead,in/ENTIVE Health,MEDTRONIC,Merck and Co.
Handberg	Eileen	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Coronary Microvascular Dysfunction Is Related to Left Ventricular Concentric Remodeling and Diastolic Dysfunction: From the WISE-CVD Study	GONSULTANT FEESHONDORARIIA - Amgen; OTHER- Amarin, Amgen, AstraZeneca, Boerhinger Ingleheim, Daiichi Sankyo, Sanofi/Aventis; RESEARCH/RESEARCH GRANTS - qilead, in/ENTIVE Health, MEDTRONIC, Merck and Co.
Handberg	Eileen	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Prognostic Risk Factors for Heart Failure Hospitalization in Women Without Obstructive Coronary Disease: An Ancillary Study From the Women's Ischemia Syndrome Evaluation (WISE)	GONSULTANT FEES/HONORARIA - Amgen; OTHER - Amarin, Amgen, AstraZeneca, Boerhinger Ingleheim, Daiichi Sankyo, Sanofi/Aventis; RESEARCH/RESEARCH GRANTS - Igilead, in/ENTIVE Health, MEDTRONIC, Merck and Co.
Handberg	Eileen	New Insights Into Prediction and Treatment of Hypertension	Relationship Between Diastolic Blood Pressure and All-Cause Mortality With Lower Systolic Blood Pressure Among Hypertensive Patients With Coronary Artery Disease: Long-Term Follow-Up of the US Cohort of the International Verapamil SR-Trandolapril Study (INVEST)	GONSULTANT FEES/HONORARIA - Amgen: OTHER - Amarin, Amgen, AstraZeneca, Boerhinger Ingleheim, Dailichi Sankyo, Sanofi/Aventis; RESEARCH/RESEARCH GRANTS - gilead,in/VENTI/VE Health, MEDTRONIC, Merck and Co.
Handberg	Eileen	Cardiovascular Team Cases: Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen; OTHER - Amarin, Amgen, AstraZeneca, Boerhinger Ingleheim, Daiichi Sankyo, Sanofi/Aventis; RESEARCH/RESEARCH GRANTS - gllead, in/VENTIVE Health, MEDTRONIC, Merck and Co.
Hanif	Bashir	Variations in Management of STEMI: International Perspectives From the Egyptian Society of Cardiology, Pakistan Cardiac Society, and American College of Cardiology	Is Primary PCI a Viable Option for Pakistan?	Nothing to Disclose
Hanke	Samuel	Congenital Heart Disease: Advances in Quality Improvement for Pediatric Cardiac Care	Standardizing the Care of Outpatient Pediatric Syncope and Dizziness: A Lesson in Utilization and Charge Reduction	Nothing to Disclose
Hanke	Samuel	Finding Out What Works in Pediatric and Congenital Heart Disease	Reduction in Interstage Growth Failure in Infants With Hypoplastic Left Heart Syndrome and Impact on Stage 2 Outcomes: A Report From the National Pediatric Cardiology Quality Improvement Collaborative	Nothing to Disclose
Hankey	Graeme	Arrhythmias and Clinical EP: Anticoagulation Issues	Thrombolytic Therapy in Anticoagulated Patients: Case Series From Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET AF)	SPEAKER'S BUREAU - Bayer Healthcare Pharmaceuticals
Hankins	Shelley	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Management of Massive Hemoptysis in Post Chemotherapy Post Transplant Patient With Extracorporeal Membrane Oxygenation (ECMO)	Nothing to Disclose
Hanley-Yanez	Karen	Put Your Codon! Genetic Insights Into Heart Failure	G-Protein Receptor Kinase 5 Polymorphisms and Outcomes in the African American Heart Failure Trial: Results From the Genetic Risk Assessment of Heart Failure in African-Americans Sub-Study	Nothing to Disclose
Hanna	Mazen	Advances in HCM, PPCM and Other Cardiomyopathies	Atrial Thrombus in Patients With Cardiac Amyloidosis: Prevalence and Implications for Therapy	CONSULTANT FEES/HONORARIA - PROTHENA PHARMACEUTICALS
Hanna	Michael	Late-Breaking Clinical Trials	Digoxin and Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?	SALARY - Bristol-Myers Squibb
Hanna	Michael	Arrhythmias and Clinical EP: Anticoagulation Issues	Use of Interacting Drugs Did Not Modify Treatment Effects of Apixaban Versus Warfarin for Atrial Fibrillation: Results From the ARISTOTLE Trial	SALARY - Bristol-Myers Squibb
Hanna	Michael	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Aortic Stenosis, but Not Mitral or Aortic Regurgitation, Is Associated With Adverse Outcomes With Atrial Fibrillation: Results From the ARISTOTLE Trial	SALARY - Bristol-Myers Squibb
Hanna	Nicholas	Great Minds Think Differently: Multidisciplinary Approach to Controversies in Cardiology	Case Presentation: Completeness of Revascularization Is it Necessary? Case Based Options for Treating Complex Coronary Disease	Nothing to Disclose
Hannawi	Bashar	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Cardiac Recovery Post Left Ventricular Assist Device in a Patient With Orthotopic Liver Transplantation	Nothing to Disclose
Hanotin	Corinne	Advances in Lipid Management	Use of High-Intensity Statin Therapy Post-Acute Coronary Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9	SALARY - Employee
Hansen	Henrik	Unusual Presentations of ACS	Monoclonal Antibody, Versus Placebo: Interim Baseline Data Gender Differences in Patients With Vasomotor Disorders According to Acetylcholine Provocation in a European Population	Nothing to Disclose
Hansen	Henrik Steen	Novel Echocardiographic Methods for Assessing Cardiac Function	According to Acetylcholine Provocation in a European Population Coronary Microvascular Dysfunction Affects the Myocardial Contractile Reserve in Women With Angina and No Obstructive Coronary Artery Disease	Nothing to Disclose
Hansen	James	Interventional Cardiology: TAVR 2	Death and Dialysis Risk After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Hansen	Rikke	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Replacement Association Between QRS Duration on Prehospital Electrocardiogram and Early Outcome in Patients With ST Segment Elevation Myocardial Infarction	Nothing to Disclose
Hansen	Steen	Novel Developments in Acute Coronary Syndromes	First Medical Contact to Device Time in STEMI Patients Presenting With Cardiogenic Shock: Insights From Mission, a Lifeline STEMI Systems Accelerator	Nothing to Disclose
ļ				
Hansen	Steen	Innovation in Practice Management, Advocacy, and Education	Early Defibrillation by First-Responders in Relation to Fire Stations:	Nothing to Disclose
Hansen Hansen	Steen Thomas	Innovation in Practice Management, Advocacy, and Education Innovative Use of Echocardiography	Early Detrorliation by First-Responders in Relation to Fire Stations: Optimal Benefit According to Location Presence of Post-Systolic Shortening by Tissue Doppler Imaging is an Independent Predictor of Heart Failure in Patients Following ST- Segment Elevation Myocardial Infarction	Nothing to Disclose Nothing to Disclose

The same of the sa				
Last Name Har	Bryan	Session Title Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Presentation Title Ventricular Arrhythmia at Primary PCI for ST-Elevation Myocardial Infarction Predicts 30-Day but Not Long-Term Mortality	Disclosures Nothing to Disclose
Hara	Hidehiko	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Evaluation of Hemoconcentration Based Bioelectrical Vectorial Impedance Analysis Is Useful Risk Stratification in Acute	Nothing to Disclose
Hara	Hidehiko	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Decompensated Heart Failure Body Fat Percentage Evaluated by a Bioelectrical Impedance Analysis Provides Prognostic Value in Acute Heart Failure: Beyond	Nothing to Disclose
Hara	Kazuhiro	The Evolving World of LVADs, Transplant and Other Novel Discoveries	on the "Obesity Paradox" Elevated Right Sided Heart Pressure Is Associated With Malnutrition in Heart Failure Patients With Reduced Ejection Fraction	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim, Daiichi-Sankyo, Takeda Pharmaceuticals, Inc, Tanabe-
Hara	Kazuhiro	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Identifying Novel Phenotypes of Acute Decompensated Heart Failure Using Cluster Analysis of Clinical Variables	Mitsubishi CONSULTANT FEES/HONORARIA - Boehringer Ingelheim,Daiichi-Sankyo,Takeda Pharmaceuticals, Inc,Tanabe-
Harada	Tomoo	Arrhythmias and Clinical EP: Devices 4	A New Suture Material in the Field of Cardiac Device Implantation	Mitsubishi Nothing to Disclose
Harahsheh	Ashraf	Core Curriculum: Rhythm and the Blues: Still	Simple versus Complex CHD: When to Refer to a Specialist?	Nothing to Disclose
Harari	Emanuel	Young at Heart Interventional Cardiology: Translation and Pre- Clinical Research	Endothelial Maturation and Function Following Implantation of Abluminal Coating Biodegradable Polymer Based Sirolimus-Eluting Metallic Stent Versus Conformal Coating Durable Polymer Based Everolimus Eluting Stent	Nothing to Disclose
Harari	Emanuel	Population Specific Cardiomyopathies: From	Racial Difference in Genetic Variants Associated With Hypertrophic	Nothing to Disclose
Harari	Emanuel	Exomes to Databases Complex Coronary Intervention: Left	Cardiomyopathy Pathological Features of Left Main Stent Thrombosis	Nothing to Disclose
Harari	Emanuel	Main/Bifurcations and Multivessel Disease Coronary Intervention: Drug Eluting Stent and	Long-Term Pathological Result of Everolimus-Eluting Stent Versus	Nothing to Disclose
Harari	Emanuel	Scaffolds Unusual Presentations of ACS	Silolimus-Eluting Stent and Bare Metal Stent Molecular Autopsy of Plaque Erosion-Induced Sudden Cardiac	Nothing to Disclose
Harari	Emanuel	Refining PCI Technique and Outcomes	Death in Young Adults (18-35 Years Old) mTors Inhibitors Increase Endothelial Permeability and Prevent Maturation: Uncovering the Mechanism of Neoatherosclerosis in	Nothing to Disclose
Harb	Serge	Non Invasive Imaging: MR Characterization	Drug Eluting Stents Time Varying Effect of Total Scar on Mortality in Patients With	Nothing to Disclose
Harb	Serge	and Function Valvular Heart Disease: Aortic Regurgitation	Cardiomyopathy Undergoing Cardiac Resynchronization Therapy Etiology, Patient Characteristics and Surgical Outcomes of Acute	Nothing to Disclose
Harb	Serge	Updates on Risk Factors for Cardiovascular	Severe Aortic Regurgitation Declining Survival With Decreasing Exercise Time on Treadmill:	Nothing to Disclose
Harb	Serge	Disease Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	Lessons From a 25-Year Cohort Referral for Pharmacologic Testing, a Marker of Poor Exercise Capacity, Confers a Higher Risk of Short and Long Term Mortality	Nothing to Disclose
Hardin	Ashley	Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	Than Most Traditional Cardiac Risk Factors Except Age The Impact of Lifelong Exercise Training "Dose" on the Ventricular- Arterial Coupling	Nothing to Disclose
The offer	Elizabeth (Null Control Production
Hardin Hardin	Elizabeth Elizabeth	FIT Forum: Mix and Mingle Making Progress in Understanding Heart	Co-Chair High Risk, Stage B Heart Failure: A Distinct Hemodynamic Profile	Nothing to Disclose Nothing to Disclose
Hare	Joshua	Failure FIT Forum: Mix and Mingle	Basic Science	CONSULTANT FEES/HONORARIA - Vestion, Inc.; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Biscayne Pharmaceuticals,Heart Genomics, Longeveron,Vestion, Inc.; RESEARCH/RESEARCH GRANTS - NHLBI
Hare	Joshua	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Role of Gender on Mesenchymal Stem Cell Therapy in Non- lschemic Dilated Cardiomyopathy: A Sub-Analysis of the POSEIDON-DCM Trial	CONSULTANT FEES/HONORARIA - Vestion, Inc.; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Biscayne Pharmaceuticals,Heart Genomics,Longeveron,Vestion, Inc.; RESEARCH/RESEARCH GRANTS - NHLBI
Hare	Joshua	12. Heart Failure and Cardiomyopathies: Basic Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Vestion, Inc.; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Biscayne Pharmaceuticals,Heart Genomics,Longeveron,Vestion, Inc.; RESEARCH/RESEARCH GRANTS - NHLBI
Hargrett	Michael	Innovations in Cardiovascular Risk Assessment and Reduction	Evaluation of the CardioSmart Population Health Management Initiative: Changes in Health Risks and Participant Satisfaction	Nothing to Disclose
Harhash	Ahmed	Emerging Developments in HFpEF and Arryhthmias	Is Continuous Outpatient Milrinone Therapy Appropriate in Stage D	Nothing to Disclose
Harikrishnan	Prakash	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Heart Failure Patients With Underlying Ventricular Tachycardia Change in Aortomitral Annular Angle and Anterior Mitral Valve Leaflet Length After Transcatheter Aortic Valve Replacement:	Nothing to Disclose
Harikrishnan	Prakash	FIT Clinical Decision Making: Arrhythmias and	Implications for Transcatheter Mitral Valve Replacement? Sinus Node Dysfunction in Batten Disease: A Rare Manifestation of	Nothing to Disclose
Harikrishnan	Prakash	The Evolving World of LVADs, Transplant and	a Rare Disease Arrhythmias in Hospitalized Heart Transplanted Patients: A United	Nothing to Disclose
Harikrishnan	Prakash		States National Study Chagas Heart Disease: A United States National Study	Nothing to Disclose
Harinstein	Matthew	Other Novel Discoveries The Challenges of Outcome Prediction in Valvular Heart Disease	Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary	Nothing to Disclose
Harinstein	Matthew	TAVR Outcomes Prognostication	Hypertension Severity: Clinical Applications in the TAVR Era Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in	Nothing to Disclose
Hariri	Babak	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking	TAVR Patients: Time to Integrate the Right Side Unit Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY	Nothing to Disclose
Harish	Abhinav	Clinical Trials Vascular Medicine: Aortic and Peripheral	Registries Uncontrolled Hypertension in Acute Aortic Dissection Follow-Up	Nothing to Disclose
Harjai	Kishore	Artery Diseases PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	A Novel Approach to Pre-Procedural Planning of Percutaneous Interventions: Value of 3D Printing and Fluoroscopic Evaluation	CONSULTANT FEES/HONORARIA - Boston Scientific; OTHER - Boston Scientific; OWNERSHIP
Harjai	Kishore	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Replacement Patients With Atrial Fibrillation Are at High Risk for Stroke and Bleeding: A Rationale for Consideration of Transcatheter Aortic Valve Replacement and Left	INTEREST/PARTNERSHIP/PRINCIPAL - aucmonkey.com CONSULTANT FEES/HONORARIA - Boston Scientific; OTHER - Boston Scientific; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - aucmonkey.com
Harjai	Kishore	03. Acute and Stable Ischemic Heart Disease: Therapy Team 2	Atrial Appendage Closure as Complementary Therapies Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific; OTHER - Boston Scientific; OWNERSHIP
Harland	Daniel	FIT Clinical Decision Making: Non-Invasive	Athlete's Heart Versus Apical Hypertrophic Cardiomyopathy: Look	INTEREST/PARTNERSHIP/PRINCIPAL - aucmonkey.com Nothing to Disclose
Harold	John	Imaging and Valvular Heart Disease Kanu and Docey Chatterjee Lecture and Seminal Talks in Heart Failure: I Wanna New	Administration of Dr. Kanu Chatterjee	Nothing to Disclose
Harold	John	Drug: Updated Heart Failure Guidelines	The Impact of Aging on CV Core	Nothing to Displace
Harold	John	Core Curriculum: Special Topic: Cardiac Issues During The Golden Years and Beyond	The Impact of Aging on CV Care	Nothing to Disclose



Contract of the second					
Last Name	First Name	Session Title	Presentation Title	Disclosures	
Harper	Mariko	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Unusual Transcatheter Aortic Valve Replacement Complication: Aorto-RV Cameral Fistula	Nothing to Disclose	
Harper	Mariko	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	An Unusual Case of Hypoxia: Platypnea-Orthodeoxia Syndrome	Nothing to Disclose	
Harrell	Travis	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Acute Lupus Myocarditis Treated With High Dose Steroids and Mycophenolate Mofetil	Nothing to Disclose	
Harrington	Douglas	Considerations in Antiplatelet Therapy and in ACS	Novel Biomarker Algorithmic Panel Measuring Permutations of Immune Response to Cardiac Endothelial Injury and Global Risk Factors Identifies Patients at Risk of Acute Coronary Syndrome	CONSULTANT FEES/HONORARIA - Telomere I DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY Discovery Biosciences	
Harrington	Douglas	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Prognostic Value of Protein Biomarkers Predict Risk of Coronary Heart Disease Events: Results From Multi-Ethnic Study of Atherosclerosis (MESA)	CONSULTANT FEES/HONORARIA - Telomere Director, Trustee, or other fiduciary Discovery Biosciences	
Harrington	Meagan	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Integrating Hyperemic Myocardial Blood Flow and Coronary Flow Reserve for Predicting Cardiovascular Mortality Outcomes in Patients With Known or Suspected Ischemic Heart Disease	Nothing to Disclose	
Harrington	Meagan	Nuclear Cardiology: Prognosis	Myocardial Scar but Not Ischemia Predicts Defibrillator Shocks and Sudden Cardiac Death in Patients With Reduced Left Ventricular Ejection Fraction	Nothing to Disclose	
Harrington	Meagan	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Relationship of Coronary Flow Reserve With Body Mass Index and Adverse Outcomes in Patients Without Overt Ischemic Heart Disease: Implications for Metabolic Surgery Eligibility	Nothing to Disclose	
Harrington	Meagan	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Association Between Coronary Flow Reserve and Adverse Cardiovascular Events Along a Continuum of Metabolic Disease in Symptomatic Patients Without Overt Coronary Artery Disease	Nothing to Disclose	
Harrington	Robert	FIT Forum: Mix and Mingle	Clinical Research	CONSULTANT FEES/HONORARIA - Adverse Ev Inc., Gilead Sciences, Inc., Merck, The Medicines C Health, WebMD; DATA SAFETY MONITORING BK AStraZeneca, BMS, Janssen R and D; OFFICER, D TRUSTEE, OR OTHER FIDUCIARY ROLE - Scar Path (Evidint); OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Elemen Science, MyoKardia; RESEARCH/RESEARCH GR Behring, GSK, Merck, Novartis Corporation, Portola, Aventis, The Medicines Company	company,Vida OARD - DIRECTOR, nadu,Signal at RANTS - CSL
Harrington	Robert	Featured Clinical Research II: Interventional	Chair	CONSULTANT FEES/HONORARIA - Adverse Ev Inc., Gilead Sciences, Inc., Merck, The Medicines Health, WebMD; DATA SAFETY MONITORING BK AstraZeneca, BMS, Janssen R and D; OFFICER, D TRUSTEE, OR OTHER FIDUCIARY ROLE - Scar Path (Evidint); OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Elemen Science, MyoKardia; RESEARCH/RESEARCH GR Behring, GSK, Merck, Novartis Corporation, Portola, Aventis, The Medicines Company	company,Vida OARD - DIRECTOR, nadu,Signal at RANTS - CSL
Harrington	Robert	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery With Cardiopulmonary Bypass: Primary Results of the LEVO-CTS Trial	CONSULTANT FEES/HONORARIA - Adverse Ev Inc., Gilead Sciences, Inc., Merck, The Medicines C Health, WebMD; DATA SAFETY MONITORING BK AStraZeneca, BMS, Janssen R and D; OFFICER, D TRUSTEE, OR OTHER FIDUCIARY ROLE - Scar Path (Evidint); OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Elemen Science, MyoKardia; RESEARCH/RESEARCH GR Behring, GSK, Merck, Novartis Corporation, Portola, Aventis, The Medicines Company	company,Vida OARD - DIRECTOR, nadu,Signal at RANTS - CSL
Harrington	Robert	Challenges in Percutaneous Interventions: International Perspectives From the Hong Kong College of Cardiology, Singapore Cardiac Society, and American College of Cardiology	Co-Chair	CONSULTANT FEES/HONORARIA - Adverse Ev Inc., Gilead Sciences, Inc., Merck, The Medicines C Health, WebMD; DATA SAFETY MONITORING BI ASTAZENECA, BMS, JAINSSEN R and D; OFFICER, D TRUSTEE, CN OTHER FIDUCIARY ROLE - Scar Path (Evidint); OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Elemen Science, MyoKardia; RESEARCH/RESEARCH GR Behring, GSK, Merck, Novartis Corporation, Portola, Aventis, The Medicines Company	company,Vida OARD - DIRECTOR, nadu,Signal ot RANTS - CSL
Harrington	Robert	Challenges in Percutaneous Interventions: International Perspectives From the Hong Kong College of Cardiology, Singapore Cardiac Society, and American College of Cardiology	Introduction to Session	CONSULTANT FEES/HONORARIA - Adverse EV Inc., Gilead Sciences, Inc., Merck, The Medicines C Health, WebMD; DATA SAFETY MONITORING BI ASTAZENECA, BMS, Janssen R and D; OFFICER, D TRUSTEE, OR OTHER FIDUCIARY ROLE - Scar Path (Ewdint); OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Elemen Science, Myokardia; RESEARCH/RESEARCH GR Behring, GSK, Merck, Novartis Corporation, Portola, Aventis, The Medicines Company	company,Vida OARD - DIRECTOR, nadu,Signal at RANTS - CSL
Harrington	Robert	Overcoming Today's Challenges to Launching and Growing Your Academic Medical Career: An Interactive Tutorial	Co-Chair	CONSULTANT FEES/HO/NORÂRIA - Adverse Evinc., Gilead Sciences, inc., Merck, The Medicines C Health, WebMD; DATA SAFETY MONITORING BK AStráZeneca, BMS, Janssen R and D; OFFICER, D TRUSTEE, OR OTHER FIDUCIARY ROLE - Scar Path (Evidint); OWNERSHIP (NTEREST/PARTNERSHIP/PRINCIPAL - Elemen Science, MyoKardia; RESEARCH/RESEARCH GR Behring, GSK, Merck, Novartis Corporation, Portola, Aventis, The Medicines Company	company,Vida DARD - DIRECTOR, nadu,Signal at AANTS - CSL Sanofi-
Harrington	Robert	Issues in the Treatment of Coronary Disease: Joint Symposium of the American Heart Association and the American College of Cardiology	Panelist	CONSULTANT FEES/HONORÁRIA - Adverse Ev Inc., Gilead Sciences, Inc., Merck, The Medicines C Health, WebMD; DATA SAFETY MONITORING BK AstraZeneca, BMS, Janssen R and D; OFFICER, D TRUSTEE, OR OTHER FIDUCIARY ROLE - Scar Path (Evidini; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Elemen Science, MyoKardia; RESEARCH/RESEARCH GR Behring, GSK, Merck, Novatris Corporation, Portola, Aventis, The Medicines Company	company,Vida OARD - DIRECTOR, nadu,Signal at RANTS - CSL



Contract of the second					
Last Name Harrington	First Name Robert	Session Title Issues in the Treatment of Coronary Disease: Joint Symposium of the American Heart Association and the American College of Cardiology	Presentation Title DAPT: What and how Long?	Disclosures CONSULTANT FEES/HONORARIA - Advers, Inc., Gilead Sciences, Inc., Merck, The Medicine Health, WebMD; DATA SAFETY MONITORING AstraZeneca, BMS, Janssen R and D; OFFICE! TRUSTEE, OR OTHER FIDUCIARY ROLE - S Path (Evidint); OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Eler Science, MyoKardia; RESEARCH/RESEARCH Behring, GSK, Merck, Novarits Corporation, Port Aventis, The Medicines Company	es Company, Vida 6 BOARD - R, DIRECTOR, icanadu, Signal ment GRANTS - CSL ola, Sanofi-
Harrington	Robert	The Evolution of Angioplasty – 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	The Evolution of Evidence-based Medicine and FDA Interaction	CONSULTANT FEES/HONORARIA - Advers Inc., Glead Sciences, inc., Merck.The Medicine Health, WebMD; DATA SAFETY MONITORING ASTAZENECA, BMS, Janssen R and D; OFFICE! TRUSTEE, OR O'THER FIDUCIARY ROLE - Path (Evidint); OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Eler Science, MyoKardia; RESEARCH/RESEARCH Behring, GSK, Merck, Novartis Corporation, Port Aventis, The Medicines Company	es Company, Vida 6 BOARD - 8, DIRECTOR, 9 Canadu, Signal 1 ment 1 GRANTS - CSL 1 ola, Sanofi-
Harrington	Robert	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Nativity Status and Cardiovascular Disease Mortality Among Hispanics	CONSULTANT FEES/HONDRARIA - Advers, inc., Gilead Sciences, inc., Merck, The Medicini Health, WebMD; DATA SAFETY MONITORING AstraZeneca, BMS, Janssen R and D; OFFICET TRUSTEE, OR OTHER FIDUCIARY ROLE - Path (Evidint); OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Eler Science, MyoKardia; RESEARCH/RESEARCH Behring, GSK, Merck, Novartis Corporation, Port Aventis, The Medicines Company	es Company, Vida 6 BOARD - R, DIRECTOR, icanadu, Signal nent GRANTS - CSL ola, Sanofi-
Harrington	Robert	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of Periprocedural Myocardial Infarction in Contemporary PCI: Pooled Patient-Level Data From the CHAMPION Trials	CONSULTANT FEES/HONORARIA - Advers Inc., Gilead Sciences, Inc., Merck, The Medicine Health, WebMD; DATA SAFETY MONITORING ASTAZENECA, BMS, Janssen R and D; OFFICE! TRUSTEE, OR O'THER FIDUCIARY ROLE - Path (Evidint); OWNERSHIP MITEREST/PARTNERSHIP/PRINCIPAL - Eler Science, MyoKardia; RESEARCH/RESEARCH Behring, GSK, Merck, Novartis Corporation, Port Aventis, The Medicines Company	es Company,Vida 6 BOARD - R, DIRECTOR, canadu,Signal nent GRANTS - CSL
Harrington	Robert	Advances in Lipid Management	Use of High-Intensity Statin Therapy Post-Acute Coronary Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Adirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody, Versus Placebo: Interim Baseline Data	CONSULTANT FEES/HONORARIA - Adverst Inc., Gilead Sciences, Inc., Merck, The Medicine Health, WebMD; DATA SAFETY MONITORIN ASTAZeneca, BMS, Janssen R and D; OFFICE! TRUSTEE, OR OTHER FIDUCIARY ROLE - SPAIN, (Evidint); OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Eler Science, MyoKardia; RESEARCH/RESEARCH Bethring, GSK, Merck, Novartis Corporation, Port Aventis, The Medicines Company	es Company,Vida 6 BOARD - R, DIRECTOR, canadu,Signal nent GRANTS - CSL
Harrington	Robert	Optimizing the Care of ACS Patients	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin: Insights From CHAMPION PHOENIX	CONSULTANT FEES/HONORARIA - Advers Inc., Glead Sciences, inc., Merck, The Medicine Health, WebMD; DATA SAFETY MONITORING ASTAZENECA, BMS, Janssen R and D; OFFICE! TRUSTEE, OR OTHER FIDUCIARY ROLE - Path (Evidint); OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Eler Science, MyoKardia; RESEARCH/RESEARCH Behring, GSK, Merck, Novartis Corporation, Porl Aventis, The Medicines Company	es Company,Vida 6 BOARD - R, DIRECTOR, canadu,Signal nent GRANTS - CSL
Harrington	Robert	Post-CAD/MI: Making Tough Predictions About the Future	One-Year Mortality Increased in Patients With Peri-Procedural Myocardial Infarction: Insights From the CHAMPION Trials	CONSULTANT FEES/HONORARIA - Advers Inc., Glead Sciences, inc., Merck, The Medicine Health, WebMD; DATA SAFETY MONITORINC ASTAZENECA, BMS, Janssen R and D; OFFICE! TRUSTEE, OR OTHER FIDUCIARY ROLE - 9 Path (Evidint); OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Eler Science, MyoKardia; RESEARCH/RESSEARCH Behring, GSK, Merck, Novartis Corporation, Port Aventis, The Medicines Company	es Company,Vida 6 BOARD - R, DIRECTOR, canadu,Signal nent GRANTS - CSL
Harrington	Robert	Anti-Platelet Therapies: Always a Sticky Topic	Ischemic Events Occur Early in Patients Undergoing PCI and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX	CONSULTANT FEES/HONORARIA - Advers Inc., Gliead Sciences, inc., Merck, The Medicine Health, WebMD; DATA SAFETY MONITORINC ASTRAZENECA, BMS, Janssen R and D; OFFICE! TRUSTEE, OR O'THER FIDUCIARY NOLE - 2 Path (Evidint); OWNERSHIP NTEREST/PARTNERSHIP/PRINCIPAL - Eler Science, MyoKardia; RESEARCH/RESEARCH Behring, GSK, Merck, Novartis Corporation, Porl Aventis, The Medicines Company	es Company,Vida B BOARD - R, DIRECTOR, Icanadu,Signal nent GRANTS - CSL
Harrington	Robert	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Advers Inc., Gliead Sciences, inc., Merck, The Medicine Health, WebMD; DATA SAFETY MONITORINC ASTRAZENECA, BMS, Janssen R and D; OFFICE! TRUSTEE, OR O'THER FIDUCIARY NOLE - Path (Evidint); OWNERSHIP NTEREST/PARTNERSHIP/PRINCIPAL - Eler Science, MyoKardia; RESEARCH/RESEARCH Behring, GSK, Merck, Novartis Corporation, Porl Aventis, The Medicines Company	es Company,Vida 6 BOARD - 7, DIRECTOR, icanadu,Signal nent GRANTS - CSL ola,Sanofi-
Harrington	Robert	Interventional Challenging Cases: Team 2	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORÁRIA - Advers Inc., Gilead Sciences, Inc., Merck, The Medicine Health, WebMD; DATA SAETY MONITORINA StraZeneca, BMS, Janssen R and D; OFFICEI TRUSTEE, OR OTHER FIDUCIARY ROLE - S Path (Evidini; OWNERSHIP) INTEREST/PARTNERSHIP/PRINCIPAL - Eler Science, MyoKardia; RESEARCH/RESEARCH Behring, GSK, Merck, Novaritis Corporation, Porf Aventis, The Medicines Company	es Company,Vida 6 BOARD - R, DIRECTOR, ccanadu,Signal nent GRANTS - CSL

				l
Last Name	First Name Robert	Session Title FIT Clinical Decision Making Reviewers 4	Presentation Title ACC FIT Clinical Decision Making Reviewer	Disclosures CONSULTANT FEES/HONORARIA - Adverse Events, Amgen
Harrington	Robert	FIT Clinical Decision Making Reviewers 4	ACC FTI CIIIICAI DECISIOTI MAKIITY REVIEWEI	Inc., Gilead Sciences, Inc., Merck, The Medicines Company, Vida
				Health, WebMD; DATA SAFETY MONITORING BOARD -
				AstraZeneca,BMS,Janssen R and D; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Scanadu,Signal
				Path (Evidint); OWNERSHIP
				INTEREST/PARTNERSHIP/PRINCIPAL - Element Science, MyoKardia; RESEARCH/RESEARCH GRANTS - CSL
				Behring ,GSK,Merck,Novartis Corporation,Portola,Sanofi-
				Aventis, The Medicines Company
Harrington	Robert	LBCT reviewers	LB Reviewer	CONSULTANT FEES/HONORARIA - Adverse Events, Amgen Inc., Gilead Sciences, Inc., Merck, The Medicines Company, Vida
				Health, WebMD; DATA SAFETY MONITORING BOARD -
				AstraZeneca,BMS,Janssen R and D; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Scanadu,Signal
				Path (Evidint); OWNERSHIP
				INTEREST/PARTNERSHIP/PRINCIPAL - Element Science,MyoKardia; RESEARCH/RESEARCH GRANTS - CSL
				Behring ,GSK,Merck,Novartis Corporation,Portola,Sanofi-
				Aventis, The Medicines Company
Harris	lan	The Story of the Adult Congenital Heart Disease Patient and EP	Safety of Transvenous Lead Removal in Adult Congenital Heart Disease in the US	Nothing to Disclose
Harris	lan	The Story of the Adult Congenital Heart	Prevalence and Predictors of Atrial Tachyarrhythmias in Adult	Nothing to Disclose
Harris	lan	Disease Patient and EP Adult Patients With Congenital Heart Disease:	Fontan Patients Mortality in Pregnant Women With Congenital Heart Disease: A	Nothing to Disclose
i idilis	iaii	How Do They Compare?	Subanalysis of the California Pregnancy-Associated Mortality	Nothing to Disclose
11		FIT OF THE PARTY MALE PROPERTY AND IN	Review	Notice to Produce
Harris	lan	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Coronary Artery Fistula in Pulmonary Atresia With Intact Ventricular Septum Physiology: To Close or Not To Close ?	Nothing to Disclose
Harris	lan	Fontan in the Modern World	Prevalence of Elevated Body Mass Index and Its Association With Clinical Features in Adult Fontan Patients	Nothing to Disclose
Harris	lan	Redefining the "F" Word	Prevalence and Predictors of Pacemaker Placement in Adult	Nothing to Disclose
		_	Fontan Patients	
Harris	Kevin	Valvular Disease Populations at Risk	Surgical Risk and Therapy of Severe Symptomatic Degenerative Mitral Valve Regurgitation in the Contemporary Era	Nothing to Disclose
Harris	Kevin	Valvular Heart Disease: Mitral Valve Disease	Guideline-Adherence and Survival for Asymptomatic Patients With	Nothing to Disclose
Harria	Kovin	Vascular Medicine: Emerging Concepts in	Severe Mitral Valve Regurgitation Influence of Family History of Aortic Disease on Type B Aortic	Nothing to Disclose
Harris	Kevin	Clinical Vascular Diseases	Dissection	Nothing to Disclose
Harris	Kevin	Beans, Beans, Good for Your Heart	Analysis of the Timing of Thoracic Endovascular Aortic Repair and	Nothing to Disclose
Harris	Kevin	Interventional Cardiology: TAVR 4	Its Indications and Outcomes in Type B Aortic Dissection Minimalist Approach to Cardiac Anesthesia and Outcome in Patients	Nothing to Disclose
			Undergoing Transcatheter Aortic Valve Replacement	
Harris	Kevin	Vascular Medicine: Aortic and Peripheral Artery Diseases	Acute Aortic Dissection in Patients Without a History of Hypertension	Nothing to Disclose
Harris	Kevin	Advancing Our Understanding of Aortic	Clinical and Pathologic Findings of Aortic Dissection at Autopsy:	Nothing to Disclose
	D. H	Disease	Review of 338 Cases Over 6 Decades	OMMEDOLUB INTERESTIDARENCE DE INCIDAL. A
Harrison	David	Advances in Lipid Management	Cardiologist Perspectives in Treatment of Dyslipidemia Patients With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Other	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Amgen Inc.; SALARY - Amgen Inc
			Lipid Lowering Therapies	
Harrison	David	Advances in Lipid Management	Persistence and Adherence With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Clinical Practice	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Amgen Inc.; SALARY - Amgen Inc
Harrison	David	Innovations in Advocacy and Patient Centered	Characteristics of Patients Approved and Denied Access to PCSK9i	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Amgen
Harrisan	David	Care	Therapy by Payers	Inc.; SALARY - Amgen Inc OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Amgen
Harrison	David	Diabetes and Other Issues in Cardiovascular Prevention	Clinical Characteristics of Early Adopters of Proprotein Convertase Subtilisin/Kexin Type 9 inhibitors (PCSK9i)	Inc.; SALARY - Amgen Inc
Harrison	J. Kevin	Highlighted Original Research: Interventional	New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve	DATA SAFETY MONITORING BOARD - CardiaQ;
		Cardiology and the Year in Review	Replacement: Incidence, Anticoagulant Strategy, and Outcomes	RESEARCH/RESEARCH GRANTS - Boston Scientific Corp,Direct Flow Medical,Edwards Corp,MEDTRONIC,St Jude
				Medical
Harrison	J. Kevin	Interventional Cardiology: TAVR 2	The Impact of Preoperative Renal Dysfunction on the Outcomes of Patients Undergoing Surgical Versus Transcatheter Aortic Valve	DATA SAFETY MONITORING BOARD - CardiaQ; RESEARCH/RESEARCH GRANTS - Boston Scientific
			Replacement: An Analysis From the CoreValve US Pivotal High	Corp,Direct Flow Medical,Edwards Corp,MEDTRONIC,St Jude
H	LIZ	Literational Continue TAME	Risk Trial	Medical Medical Report Of the Control of the Contro
Harrison	J. Kevin	Interventional Cardiology: TAVR 2	Impact of Balloon Pre-Dilatation on Hemodynamics and Clinical Outcomes After Transcatheter Aortic Valve Replacement With the	DATA SAFETY MONITORING BOARD - CardiaQ; RESEARCH/RESEARCH GRANTS - Boston Scientific
			Self-Expanding CoreValve Prosthesis	Corp,Direct Flow Medical,Edwards Corp,MEDTRONIC,St Jude
Harrison	J. Kevin	Refining TAVR Outcomes	Incidence and Outcomes of Patients Requiring Surgical Bail-Out	Medical DATA SAFETY MONITORING BOARD - CardiaQ;
	007111		During Transcatheter Aortic Valve Replacement: A Report From the	RESEARCH/RESEARCH GRANTS - Boston Scientific
			NCDR® STS/ACC Transcatheter Valve Therapy (TVT)	Corp,Direct Flow Medical,Edwards Corp,MEDTRONIC,St Jude
Harrison	J. Kevin	Peripheral Arterial Disease, Risk, and	Registry Peripheral Artery Disease and Transcatheter Aortic Valve	Medical DATA SAFETY MONITORING BOARD - CardiaQ;
		Outcomes	Replacement Outcomes: A Report From the STS/TVT Registry	RESEARCH/RESEARCH GRANTS - Boston Scientific
1				Corp,Direct Flow Medical,Edwards Corp,MEDTRONIC,St Jude Medical
Harrison	John	Highlighted Original Research: Valvular Heart	Surgery for Patients With Bicuspid Aortopathy: Validation of the	Nothing to Disclose
		Disease and the Year in Review	2016 ACC/AHA Guidelines Clarification	Nothing to Disclose
Harrison Harrison	John John		2016 ACC/AHA Guidelines Clarification Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry	Nothing to Disclose Nothing to Disclose
Harrison Harrison	John	Disease and the Year in Review Interventional Cardiology: TAVR 3 Interventional Cardiology: TAVR 4	2016 ACC/AHA Guidelines Clarification Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry Predictors of Mortality After TAVR in a "Real World" Setting	Nothing to Disclose Nothing to Disclose Nothing to Disclose
Harrison	John	Disease and the Year in Review Interventional Cardiology: TAVR 3 Interventional Cardiology: TAVR 4 Advances in Cholesterol Measurement and	2016 ACC/AHA Guidelines Clarification Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry Predictors of Mortality After TAVR in a "Real World" Setting Trends in Statin Use Among Adults in an Integrated Health Care	Nothing to Disclose Nothing to Disclose
Harrison Harrison	John John Teresa	Disease and the Year in Review Interventional Cardiology: TAVR 3 Interventional Cardiology: TAVR 4 Advances in Cholesterol Measurement and Management	2016 ACC/AHA Guidelines Clarification Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry Predictors of Mortality After TAVR in a "Real World" Setting Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Harrison Harrison	John	Disease and the Year in Review Interventional Cardiology: TAVR 3 Interventional Cardiology: TAVR 4 Advances in Cholesterol Measurement and Management Are We There Yet? The Long Journey to	2016 ACC/AHA Guidelines Clarification Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR. Insights From the STS/TVT Registry Predictors of Mortality After TAVR in a "Real World" Setting Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of	Nothing to Disclose Nothing to Disclose Nothing to Disclose
Harrison Harrison	John John Teresa	Disease and the Year in Review Interventional Cardiology: TAVR 3 Interventional Cardiology: TAVR 4 Advances in Cholesterol Measurement and Management	2016 ACC/AHA Guidelines Clarification Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry Predictors of Mortality After TAVR in a "Real World" Settling Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol Panelist TAVR Using Transcarotid Vascular Access: In-Hospital and	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose OTHER - Novartis Corporation, Pharmacy Times Continuing
Harrison Harrison Harrison Harshaw-Ellis Hart	John John Teresa Karol Anthony	Disease and the Year in Review Interventional Cardiology: TAVR 3 Interventional Cardiology: TAVR 4 Advances in Cholesterol Measurement and Management Are We There Yet? The Long Journey to Health Equity: Part II Vascular Access and Hemostasis Issues	2016 ACC/AHA Guidelines Clarification Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry Predictors of Mortality After TAVR in a "Real World" Setting Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol Panelist TAVR Using Transcarotid Vascular Access: In-Hospital and Intermediate Term Outcomes	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose OTHER - Novartis Corporation, Pharmacy Times Continuing Education Nothing to Disclose
Harrison Harrison Harrison Harrison	John John Teresa Karol	Disease and the Year in Review Interventional Cardiology: TAVR 3 Interventional Cardiology: TAVR 4 Advances in Cholesterol Measurement and Management Are We There Yet? The Long Journey to Health Equity: Part II	2016 ACC/AHA Guidelines Clarification Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry Predictors of Mortality After TAVR in a "Real World" Setting Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol Panelist TAVR Using Transcarotid Vascular Access: In-Hospital and Intermediate Term Outcomes Prosthretic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose OTHER - Novartis Corporation, Pharmacy Times Continuing Education
Harrison Harrison Harrison Harshaw-Ellis Hart Hart	John John Teresa Karol Anthony	Disease and the Year in Review Interventional Cardiology: TAVR 3 Interventional Cardiology: TAVR 4 Advances in Cholesterol Measurement and Management Are We There Yet? The Long Journey to Health Equity: Part II Vascular Access and Hemostasis Issues Interventional Cardiology: TAVR 3	2016 ACC/AHA Guidelines Clarification Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR. Insights From the STS/TVT Registry Predictors of Mortality After TAVR in a "Real World" Setting Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol Panelist TAVR Using Transcarotid Vascular Access: In-Hospital and Intermediate Term Outcomes Prosthetic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter Valve-in-Valve Implantation	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose OTHER - Novartis Corporation,Pharmacy Times Continuing Education Nothing to Disclose Nothing to Disclose
Harrison Harrison Harrison Harshaw-Ellis Hart	John John Teresa Karol Anthony	Disease and the Year in Review Interventional Cardiology: TAVR 3 Interventional Cardiology: TAVR 4 Advances in Cholesterol Measurement and Management Are We There Yet? The Long Journey to Health Equity: Part II Vascular Access and Hemostasis Issues Interventional Cardiology: TAVR 3	2016 ACC/AHA Guidelines Clarification Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry Predictors of Mortality After TAVR in a "Real World" Setting Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol Panelist TAVR Using Transcarotid Vascular Access: In-Hospital and Intermediate Term Outcomes Prosthretic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose OTHER - Novartis Corporation, Pharmacy Times Continuing Education Nothing to Disclose
Harrison Harrison Harrison Harshaw-Ellis Hart Hart	John John Teresa Karol Anthony	Disease and the Year in Review Interventional Cardiology: TAVR 3 Interventional Cardiology: TAVR 4 Advances in Cholesterol Measurement and Management Are We There Yet? The Long Journey to Health Equity: Part II Vascular Access and Hemostasis Issues Interventional Cardiology: TAVR 3 Imaging Transcatheter Mitral Valve Repair and Replacement Non Invasive Imaging: Expanding Clinical	2016 ACC/AHA Guidelines Clarification Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry Predictors of Mortality After TAVR in a "Real World" Setting Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol Panelist TAVR Using Transcarotid Vascular Access: In-Hospital and Intermediate Term Outcomes Prosthetic Surgical Tissue Valve Enlargement Using a High-Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter Valve-in-Valve Implantation Post-Procedural Echocardiography to Judge Mitraclip Results Dual-Energy Coronary Computed Tomography Evaluation of High-	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose OTHER - Novartis Corporation,Pharmacy Times Continuing Education Nothing to Disclose Nothing to Disclose
Harrison Harrison Harrison Harshaw-Ellis Hart Hart	John John Teresa Karol Anthony Chari	Disease and the Year in Review Interventional Cardiology: TAVR 3 Interventional Cardiology: TAVR 4 Advances in Cholesterol Measurement and Management Are We There Yet? The Long Journey to Health Equity: Part II Vascular Access and Hemostasis Issues Interventional Cardiology: TAVR 3 Imaging Transcatheter Mitral Valve Repair and Replacement	2016 ACC/AHA Guidelines Clarification Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry Predictors of Mortality After TAVR in a "Real World" Setting Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol Panelist TAVR Using Transcarotid Vascular Access: In-Hospital and Intermediate Term Outcomes Prosthetic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter Valve-in-Valve Implantation Post-Procedural Echocardiography to Judge Mitracilp Results Dual-Energy Coronary Computed Tomography Evaluation of High- Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients:	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose OTHER - Novartis Corporation,Pharmacy Times Continuing Education Nothing to Disclose Nothing to Disclose
Harrison Harrison Harrison Harshaw-Ellis Hart Hart	John John Teresa Karol Anthony Chari	Disease and the Year in Review Interventional Cardiology: TAVR 3 Interventional Cardiology: TAVR 4 Advances in Cholesterol Measurement and Management Are We There Yet? The Long Journey to Health Equity: Part II Vascular Access and Hemostasis Issues Interventional Cardiology: TAVR 3 Imaging Transcatheter Mitral Valve Repair and Replacement Non Invasive Imaging: Expanding Clinical	2016 ACC/AHA Guidelines Clarification Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry Predictors of Mortality After TAVR in a "Real World" Setting Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol Panelist TAVR Using Transcarotid Vascular Access: In-Hospital and Intermediate Term Outcomes Frosthetic Surgical Tissue Valve Enlargement Using a High-Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter Valve-in-Valve Implantation Post-Procedural Echocardiography to Judge Mitraclip Results Dual-Energy Coronary Computed Tomography Evaluation of High-Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients: Validation with Histopathoolgic Gold Standard Incremental Utility of Coronary Computed Tomographic	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose OTHER - Novartis Corporation,Pharmacy Times Continuing Education Nothing to Disclose Nothing to Disclose
Harrison Harrison Harrison Harshaw-Ellis Hart Hart Hart Hart	John John Teresa Karol Anthony Anthony Chari Briain	Disease and the Year in Review Interventional Cardiology: TAVR 3 Interventional Cardiology: TAVR 4 Advances in Cholesterol Measurement and Management Are We There Yet? The Long Journey to Health Equity: Part II Vascular Access and Hemostasis Issues Interventional Cardiology: TAVR 3 Imaging Transcatheter Mitral Valve Repair and Replacement Non Invasive Imaging: Expanding Clinical Applications	2016 ACC/AHA Guidelines Clarification Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry Predictors of Mortality After TAVR in a "Real World" Setting Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol Panelist TAVR Using Transcarotid Vascular Access: In-Hospital and Intermediate Term Outcomes Prosthetic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter Valve-in-Valve Implantation Post-Procedural Echocardiography to Judge Mitraclip Results Dual-Energy Cronary Computed Tomography Evaluation of High- Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients: Validation with Histopathologic Gold Standard Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Aterry Calcium Scoring for	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose OTHER - Novartis Corporation, Pharmacy Times Continuing Education Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Harrison Harrison Harrison Harshaw-Ellis Hart Hart Hart Hart	John John Teresa Karol Anthony Anthony Chari Briain	Disease and the Year in Review Interventional Cardiology: TAVR 3 Interventional Cardiology: TAVR 4 Advances in Cholesterol Measurement and Management Are We There Yet? The Long Journey to Health Equity: Part II Vascular Access and Hemostasis Issues Interventional Cardiology: TAVR 3 Imaging Transcatheter Mitral Valve Repair and Replacement Non Invasive Imaging: Expanding Clinical Applications Non Invasive Imaging: Coronary Calcium	2016 ACC/AHA Guidelines Clarification Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry Predictors of Mortality After TAVR in a "Real World" Setting Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol Panelist TAVR Using Transcarotid Vascular Access: In-Hospital and Intermediate Term Outcomes Prosthetic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter Valve-in-Valve Implantation Post-Procedural Echocardiography to Judge Mitraclip Results Dual-Energy Coronary Computed Tomography Evaluation of High- Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients: Validation with Histopathologic Gold Standard Incremental Utility of Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose OTHER - Novartis Corporation, Pharmacy Times Continuing Education Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Harrison Harrison Harrison Harshaw-Ellis Hart Hart Hart Hart	John John Teresa Karol Anthony Anthony Chari Briain	Disease and the Year in Review Interventional Cardiology: TAVR 3 Interventional Cardiology: TAVR 4 Advances in Cholesterol Measurement and Management Are We There Yet? The Long Journey to Health Equity: Part II Vascular Access and Hemostasis Issues Interventional Cardiology: TAVR 3 Imaging Transcatheter Mitral Valve Repair and Replacement Non Invasive Imaging: Expanding Clinical Applications Non Invasive Imaging: Coronary Calcium	2016 ACC/AHA Guidelines Clarification Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry Predictions of Mortality After TAVR in a "Real World" Setting Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol Panelist TAVR Using Transcarotid Vascular Access: In-Hospital and Intermediate Term Outcomes Prosthetic Surgical Tissue Valve Enlargement Using a High-Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter Valve-in-Valve Implantation Post-Procedural Echocardiography to Judge Mitraclip Results Dual-Energy Coronary Computed Tomography Evaluation of High-Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients: Validation with Histopathologic Gold Standard Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Aftery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Imparied	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose OTHER - Novartis Corporation, Pharmacy Times Continuing Education Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose

Hartaigh Bri Hartaigh Bri Hartaigh Bri Hartaigh Bri Hartaigh Bri	riain riain riain	Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Diabetes and Other Issues in Cardiovascular	Presentation Title Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography: The CONFIRM Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Death: A Comparison to a Histologic Reference Standard	Disclosures Nothing to Disclose Nothing to Disclose
Hartaigh Bri Hartaigh Bri Hartaigh Bri	riain riain	of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Diabetes and Other Issues in Cardiovascular	Computed Tomographic Angiography: The CONFIRM Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden	
Hartaigh Bri Hartaigh Bri Hertaigh Bri	riain ríain	of CT Angiography Diabetes and Other Issues in Cardiovascular	by Coronary CT Angiography in Victims of Autopsy-Proven Sudden	Involving to Disclose
Hartaigh Bri	fain			1
Hartaigh Bri		Prevention	Implications of Statin Therapy Among Smokers With Severe Coronary Artery Calcification: An Analysis of the CONFIRM Registry	Nothing to Disclose
		and Reduction	Atherosclerotic Cardiovascular Disease Risk in Statin-Naï.ve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Anglography: The CONFIRM-LT (COronary CT Anglography Evaluation For Clinical Outcomes: An International Multicenter)	Nothing to Disclose
Hartaigh Bri	fain	Non Invasive Imaging: New Technologies	Registry Optimal Method for Necrotic Core Identification in Coronary Plaque With Dual-Energy Computed Tomography: Material Decomposition	Nothing to Disclose
		Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	and Atomic Number Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography: The CONFIRM (COronary CT Angiography Evaluation For Clinical	Nothing to Disclose
Hartikainen Jul			Outcomes: An InteRnational Multicenter) Registry Risk Assessment of Recurrent Atrial Fibrillation After Antiarrhythmic Medication or Catheter Ablation: The Impact of Age and Supraventricular Ectopic Complexes	Nothing to Disclose
Hartman Ro		FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Double Chambered Right Ventricle Causing RVOT Obstruction in Adulthood: It Is Not Pulmonary Hypertension!	Nothing to Disclose
Hartmann An		13. Heart Failure and Cardiomyopathies: Clinical Team 6	Suggested Reviewer	Nothing to Disclose
Hartupee Ju			Impaired Autophagic Flux Contributes to the Accumulation of Ubiquitinated Proteins in a Mouse Model of Heart Failure	Nothing to Disclose
Haruta Se		The Evolving World of LVADs, Transplant and Other Novel Discoveries	Significance of ¹²³ I-BMIPP-Scintigraphy in the Recovery of Left Ventricular Systolic Dysfunction in Takotsubo Cardiomyopathy: Insight From the NEW TAKOTSUBO BMIPP Registry	Nothing to Disclose
Harville En		Vascular Medicine: Aortic and Peripheral Artery Diseases	Racial (Black-White) Disparities in the Contribution of The Long- Term Burden of Cholesterol from Childhood on Adult Ankle- Brachial Index Decline: The Bogalusa Heart Study	Nothing to Disclose
Harzand Ara		Young Investigator Awards Competition: Clinical Investigations	Feasibility of a Smartphone-Delivered Cardiac Rehabilitation Program Amongst Veterans	RESEARCH/RESEARCH GRANTS - Moving Analytics; SPEAKER'S BUREAU - Moving Analytics
Hasan Ah	nmed	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Risk of Hospitalization or Death Due to Heart Failure With Intensive Glucose-Lowering Therapy in Diabetic Women: Subgroup Analyses by History of Cardiovascular Disease in the ACCORD Trial	Nothing to Disclose
Hasan Ch			Comparing PCI Outcomes in the Very Elderly: Does Age Matter? A Report From Outcomes of Septuagenarians, Octogenarians and Nonagenarians After PCI	Nothing to Disclose
Hasan Ch		Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Angiographic Phenotype and Clinical Outcomes of Patients With Malignancy Undergoing PCI	Nothing to Disclose
Hasan Ch	houdhury	Interventional Cardiology: Stent Failure	Multimodality Intravascular Imaging to Evaluate Plaque	Nothing to Disclose
Hasan Ch		Analysis by Intravascuar Imaging Timely Topics in Acute Coronary Syndromes	Characteristics in Patients With Diabetes Mellitus Predictors of High Intensity Statin Use After Percutaneous Coronary	Nothing to Disclose
Hasan Ch	houdhury	Optimizing the Care of ACS Patients	Interventions Underutilization of High Intensity Statins in a Contemporary High	Nothing to Disclose
		•	Risk PCI Population Predictors of New Persistent Left Bundle Branch Block After	Nothing to Disclose
	erd		Edwards Sapien 3 Transcatheter Aortic Valve Replacement Echocardiographic Estimation of Mean Pulmonary Artery Pressure: A Comparison of Different Approaches to Predict Pulmonary	CONSULTANT FEES/HONORARIA - AstraZeneca,Bayer,Circulite,DC Devices ,Impulse
Hasenfuss Ge	erd		Hypertension Non-Coding RNAs Comprehensively Counteract Adverse Arterial Remodeling and Stiffening in Type 2 Diabetes	Dynamics,Novartis,servier CONSULTANT FEES/HONORARIA - AstraZeneca,Bayer,Circulite,DC Devices,Impulse Dynamics,Novartis,servier
Hashikata Ta			Stent Edge Strut on Normal Segment Is Less Covered in Early Phase After Drug Eluting Stent Implantation	Nothing to Disclose
Hashimoto Sa	atoshi	Interventional Cardiology: Intravascular	Impact of Saline Induced Pd/Pa Ratio for Predicting Functional Significance of Intermediate Coronary Artery Stenosis Assesed by	Nothing to Disclose
Hashimoto Sh		FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Fractional Flow Reserve Hyperdense Artery Sign on Computed Tomography in Acute Coronary Syndrome	Nothing to Disclose
Hashimoto Ta	akuya .	Antiplatelet and Antithrombotic Agents in		Nothing to Disclose
Hashimoto Ta		Unusual Presentations of ACS	Lower Eicosapentaenoic Acid to Arachidonic Acid Ratio Is Associated With Intraplaque Cholesterol Crystals: An Optical Coherence Tomography Study	Nothing to Disclose
Hasni Fa		FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		Nothing to Disclose
Hasnie Ali		Advances in Cholesterol Measurement and Management	Physician Perspectives on Clinical Decision Support for Familial Hypercholesterolemia	Nothing to Disclose
Hasoon Mo	ohammed		Use of the Impella CP Catheter for Refractory Cardiogenic Shock Following Acute Aortic Dissection and Surgical Repair	Nothing to Disclose
Hassager Ch	hristian	Cardiac Arrest, Diabetes, and Other High Risk	Association Between QRS Duration on Prehospital Electrocardiogram and Early Outcome in Patients With ST Segment Elevation Myocardial Infarction	CONSULTANT FEES/HONORARIA - Novartis,Teva
Hassan Ati		FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Sources of Inappropriate ICD Shocks, Look for Inside and Outside of the Heart	Nothing to Disclose
Hassan Ha	afeez	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Identifying the Etiologies and Trends of 30 Day Readmissions in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients: A National Population-Based Cohort Study	Nothing to Disclose
Hassan Ha	afeez		Clinical Outcomes of the Treatment of Cocaine Induced Chest Pain With Beta Blockers: A Meta-Analysis	Nothing to Disclose
Hassan Sa		Making Progress in Understanding Heart Failure		Nothing to Disclose
Hassan Wa Hassoun Pa	alid Sayed	Interventional Challenging Cases: Team 2	ACC Challenging Case Reviewer Debate: Be it Resolved: Treatment of PAH Should Focus on Right	Nothing to Disclose Nothing to Disclose
	I	Hypertension	Ventricular Performance, Not on the Pulmonary Vascular Occlusion (Con)	Nothing to Disclose Nothing to Disclose
Hassoun Pa Hassoun Pa	aul	The OMICS in Pulmonary Hypertension	Panelist ACC-Talk: PVDOMICS: What the Future may Hold	Nothing to Disclose
			Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions Improves Peak Oxygen Uptake During Cardiopulmonary	Nothing to Disclose

Hata	Tetsuya	Session Title FIT Clinical Decision Making: Non-Invasive	Presentation Title Hyperdense Artery Sign on Computed Tomography in Acute	Disclosures Nothing to Disclose
Hattler	Brack	Imaging and Valvular Heart Disease Acute Heart Failure: Evaluating Strategies to	Coronary Syndrome Severe Physical Inactivity Persists Following Acute Heart Failure in	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cryolife
Hattler	Brack	Prevent Readmissions 01. Acute and Stable Ischemic Heart Disease:	Patients With Sleep Disordered Breathing Suggested Reviewer	stock OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cryolife
Hauptman	Paul	Basic Team 2 Highlighted Original Research: Heart Failure	Mortality and Morbidity in Patients With Heart Failure and Reduced	stock CONSULTANT FEES/HONORARIA - Amgen,BioControl
		and Cardiomyopathies and the Year in Review	Ejection Fraction Exposed to Digoxin: Comprehensive Data According to Atrial Fibrillation in 23,708 Patients From the Swedish Heart Failure Registry	Medical,Otsuka America,Relypsa,St. Jude Medical; OTHER - Elsevier
Hauptman	Paul	Innovations in Advocacy and Patient Centered Care	Describing Collaboration Between Cardiology and Palliative Care: A National Survey Study of Current Practices, Challenges and Barriers	CONSULTANT FEES/HONORARIA - Amgen,BioControl Medical,Otsuka America,Relypsa,St. Jude Medical; OTHER - Elsevier
Hausenloy	Derek	Featured Clinical Research I	MR-INFORM: Stress Perfusion Imaging to Guide the Management of Patients With Stable Coronary Artery Disease	Nothing to Disclose
Hausleiter Hausleiter	Joerg	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous? Non Invasive Imaging: Prognostic Implications	Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography. The CONFIRM (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry Smoking and its Relationship With Long Term Events: Further	SPEAKER'S BUREAU - Abbott, Edwards Lifesciences SPEAKER'S BUREAU - Abbott, Edwards Lifesciences
Hadsicites	occig	of CT Angiography	Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	
Hausleiter	Joerg	Frontiers in Mitral Valve Disease and Treatment	Transcatheter Treatment of Severe Tricuspid Regurgitation Using the MitraClip System in Patients With and Without Pacemaker Leads	SPEAKER'S BUREAU - Abbott, Edwards Lifesciences
Hausleiter	Joerg	Frontiers in Mitral Valve Disease and Treatment	Multicenter Trial of a Transfemoral System for Mitral Valve Annuloplasty: Up-to-2-Year Follow-Up Results	SPEAKER'S BUREAU - Abbott, Edwards Lifesciences
Hausleiter	Jörg	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team	Suggested Reviewer	SPEAKER'S BUREAU - Abbott, Edwards Lifesciences
Haussig	Stephan	Interventional Cardiology: TAVR 2	Different Impact of Gender on Early and Late Outcome After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Haussig	Stephan	Interventional Cardiology: TAVR 2	Higher B-Type Natriuretic Peptide Levels Predict Occurrence of Acute Kidney Injury After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Haussig	Stephan	Interventional Cardiology: TAVR 2	Impact of Myocardial Injury Indicated by Increased Creatinine Kinase Myocardial Band Levels on the Outcome After Transcatheter Aortic Valve Replacement: Results From a Prospective Single Center Registry	Nothing to Disclose
Haussig	Stephan	Interventional Cardiology: TAVR 4	Impact of Cancer Disease on Outcome of Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Hausvater	Anais	Arrhythmias and Clinical EP: Basic 2	Atrial Fibrillation Is Associated With Low Cardiovascular Mortality in	Nothing to Disclose
Havranek	Edward	Lifestyle Changes to Reduce Cardiovascular	Hypertrophic Cardiomyopathy CV Health and Disease: Impact of Social Determinants	Nothing to Disclose
Hawa	Zafir	Risk Vascular Access and Hemostasis Issues	TAVR Using Transcarotid Vascular Access: In-Hospital and	Nothing to Disclose
Hawa	Zuhair	Vascular Access and Hemostasis Issues	Intermediate Term Outcomes TAVR Using Transcarotid Vascular Access: In-Hospital and	Nothing to Disclose
Hawatmeh	Amer	Heart Failure and Cardiomyopathies: Is Heart	Intermediate Term Outcomes Statin Intensity and Outcome in Patients With Acute Heart Failure	Nothing to Disclose
Hawatmeh	Amer	Failure With a Normal EF for Real? FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	With Preserved Ejection Fraction Late Presentation of Total Anomalous Pulmonary Venous Connection	Nothing to Disclose
Hawatmeh	Amer	Changing the Natural History of Valve Disease With Medical Therapy	Statins Use and Long Term Outcome Post Surgical Aortic Valve Replacement	Nothing to Disclose
Hawatmeh	Amer	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Coil Embolization of latrogenic Pulmonary Artery Pseudoaneurysm	Nothing to Disclose
Hawkey Hawkey	Marian Marian	Frontier in New Transcatheter Techniques Great Minds Think Differently: Multidisciplinary	Panelist Save Your Noggin: Cerebral Protection Device Overview	CONSULTANT FEES/HONORARIA - Edwards Lifesciences CONSULTANT FEES/HONORARIA - Edwards Lifesciences
		Approach to Advanced Therapies		
Hawkins	Beau	Controversies and Strategies for Endovascular Treatment of the Femoropopliteal Segment	Case Presentation: Complex Decision-making in Femoropopliteal Intervention	Nothing to Disclose
Hayashi	Masaomi	Unusual Presentations of ACS	The Impact of Residual Syntax Score in ACS Patients With LV Dysfunction	Nothing to Disclose
Hayashi	Nobuya	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Diabetes Mellitus on Antithrombotic Management Patterns and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndrome: Insight From the EPICOR Asia Study	SALARY - AstraZeneca Pharmaceuticals
Hayashi	Tetsuya	Mechanisms of Vascular Inflammation in Atherogenesis	Rivaroxaban Attenuates Cardiac Remodeling Due to Intermittent Hypoxia by Suppressing the Synergistic Effects of Par-1 and Par-2	Nothing to Disclose
Hayashida	Kentaro	Interventional Cardiology: TAVR 4	Transcatheter Aortic Valve Implantation in Patients With an Extremely Small Annulus	OTHER - Edwards Lifesciences
Hayashida	Kentaro	Unusual Presentations of ACS	C-Reactive Protein in Non-ST Elevation Myocardial Infarction Patients Is Useful in Improving Discrimination of Conventional Risk Score: A Report From Multicenter PCI Registry	OTHER - Edwards Lifesciences
Hayek	Emil	Atrial Fibrillation and VT: Unique Populations	Predictors of Anticoagulant Prescription in Patients With Atrial	Nothing to Disclose
Hayek	Salim	and Solutions Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Fibrillation in North America: The GLORIA-AF Registry Association Between Circulating Progenitor Cells and Outcomes in Patients With Coronary Artery Disease	Nothing to Disclose
Hayek Hayek	Salim Salim	Redefining the "F" Word The Evolving World of LVADs, Transplant and	Biomarker Profile in Adults With Fontan Circulation Progenitor Cells and Clinical Outcomes in Patients With Heart	Nothing to Disclose Nothing to Disclose
Hayek	Salim	Other Novel Discoveries Unusual Presentations of ACS	Failure Circulating Progenitor Cells Levels and Outcomes in Acute	Nothing to Disclose
Hayek	Salim	Congenital Heart Disease: To the Third	Myocardial Infarction Red Blood Cell Distribution Width and Outcomes in Fontan Patients	Nothing to Disclose
Hayes	David	Decade and Beyond 05. Arrhythmias and Clinical EP: Devices Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Biotronik, Boston Scientific, MEDTRONIC, Sorin Medical, St. Jude Medical, Wiley
	1		Coronary Artery Calcium in the Elderly: Prevalence, Severity, and	Blackwell; OTHER - Wiley Blackwell SPEAKER'S BUREAU - Astellas
Hayes	Sean	Non Invasive Imaging: Coronary Calcium		
		Scoring and CV Risk Assessment	Association With All-Cause Mortality	SPEAKER'S BUREAU - Astellas
Hayes Hayes	Sean			
		Scoring and CV Risk Assessment	Association With All-Cause Mortality Improvement in LDL Is Associated With Decrease in Non-Calcified Plaque Volume on CTA as Measured by Automated Quantitative	
Hayes	Sean	Scoring and CV Risk Assessment Non Invasive Imaging: New Technologies Imaging With Cardiac CT: The Case for	Association With All-Cause Mortality Improvement in LDL is Associated With Decrease in Non-Calcified Plaque Volume on CTA as Measured by Automated Quantitative Software Hormone Replacement Therapy is Associated With Less Coronary	SPEAKER'S BUREAU - Astellas

Security Security	1				<u> </u>
Security Conference Co	Last Name Hayes	First Name Sharonne	Session Title Are We There Yet? The Long Journey to	Presentation Title Moderator: Panel Discussion	Disclosures Nothing to Disclose
Secretary Control (Control War No Kook Nature View) Figure 1 Secretary Control (Control War No Kook Nature View) Figure 2 Secretary Control (Control War No Kook Nature View) Figure 3 Secretary Control (Control War No Kook Nature View) Figure 3 Secretary Control (Control War No Kook Nature View) Figure 3 Secretary Control (Control War No Kook Nature View) Figure 3 Secretary Control (Control War Nature View) Figure 3 Secretary Control (Control War Nature View) Figure 3 Secretary Control (Control War Nature View) Figure 3 Secretary Control (Control War Nature View) Figure 4 Secretary Control (Control War Nature View) Figure 4 Secretary Control (Control War Nature View) Figure 4 Secretary Control (Control War Nature View) Figure 4 Secretary Control (Control War Nature View) Figure 4 Secretary Control (Control War View) Figure 4 Secretary Control (Control War View) Figure 5 Secretary Control (Control War View) Figure 5 Secretary Control (Control War View) Figure 6 Secretary Control (Control War View) Figure 6 Secretary Control (Control War View) Figure 6 Secretary Control (Control War View) Figure 6 Secretary Control (Control War View) Figure 6 Secretary Control (Control War View) Figure 6 Secretary Control (Control War View) Figure 6 Secretary Control (Control War View) Figure 7 Secretary Control (Control War View) Figure 7 Secretary Control (Control War View) Figure 7 Secretary Control (Control War View) Figure 7 Secretary Control (Control War View) Figure 7 Secretary Control (Control War View) Figure 7 Secretary Control (Control War View) Figure 7 Secretary Control (Control War View) Figure 7 Secretary Control (Control War View) Figure 7 Secretary Control (Control War View) Figure 7 Secretary Control (Control War View) Figure 7 Secretary Control (Control War View) Figure 7 Secretary Control (Control War View) Figure 7 Secretary Control (Control War View) Figure 7 Secretary Control (Control War View) Figure 7 Secretary Control (Control War View) Figure 7 Secretary Control (C	•		Health Equity: Part III	CoChair	,
April 1997 Company C	nayes	Silatorine	Dissection (SCAD): What We Know, What We Don't Know	Co-Criaii	Nothing to Disclose
Name of the provider of the pr	Hayes	Sharonne			Nothing to Disclose
Segretary (1996) The common of the first of the control of the co	Haykowsky	Mark	Emerging Developments in HFpEF and	Age Specific Hemodynamic Features in HFPEF: Implications for	Nothing to Disclose
Store Store Anthonius and Circular Property Company Co	Haythe	Jennifer			Nothing to Disclose
The Section of the Community of Control Contro		Pohert		Safety of Transvenous Lead Removal Among Nonagenarians	Nothing to Disclose
Need (Monor) Formation and Colors (Monor) Formation (Monor) Format					
Need Council from Dispute Visions of Council C	He	Xin	The Intersection of Diabetes and ASCVD	C Anti-Diabetic Agents and Cardiovascular Outcomes in the Era of	Nothing to Disclose
Devices — Service Comment Christops (2) Mills and Christops (1) March Perfolion and VT. Urage Papatition Programs of Uniform P	Hood	Stuart		Novel Glucose-Lowing Drugs	Nothing to Disclose
March Set Persistence Activation Persistence P	rieau	Stuart	remining For Fedinique and Outcomes	Diabetes: 3-Year Outcomes Comparing CABG and PCI With	Nothing to Disclose
Historia Christopher (Schiedunger Christopher Christop	Healey	Jeff		Predictors of Anticoagulant Prescription in Patients With Atrial	Ingelheim, Boston Scientific, Bristol-Meyers-
The Impact of Encode Counting Provided Active Controlled Counting Non Invasion Reging Properting Clinical Counting Non Invasion Reging Properting Clinical Counting Provided Active Counting	Hearon	Christopher		High Risk, Stage B Heart Failure: A Distinct Hemodynamic Profile	
February Processor (Act of Control Control) Georgian Control	Hearon Jr.	Christopher	Physical Activity and Prevention of		Nothing to Disclose
The Control Position of Control Marky Intervention (1997) the University Birth Defects. A Title of Coronary Noting to Disclose Control Marky Intervention (1997) the University Birth Defects. A Title of Coronary Noting to Disclose Control Marky Intervention (1997) the Coronary Noting In	Hebert	Kathy			Nothing to Disclose
Consideration of Notice and Visional Market Colors Notice and Visional Microsoft Notice of Cardiom Williams of The Cardiom Section of Cardiom Section of Cardiom Section of Cardiom Section of Cardiom Section of Cardiom Section of Cardiom Section of Cardiom Section of Cardiom Section of Cardiom Section Section of Cardiom Section Section of Cardiom Section Section of Cardiom Section				to ICA	
Integrity Microarises CT. The Case for Long-Control Procession Control	Hebson	Camden	Cardiology, Acute and Stable Ischemic Heart		Nothing to Disclose
Marker Processor Process	Hecht	Harvey	Imaging With Cardiac CT: The Case for	ACC Poster Moderator	
Techbert Susan Purious tenging MR Teart Failure and Numerical Projection of the Susan Name (Particular Susan Name	Hecht	Harvey	27. Non Invasive Imaging: CT/Multimodality,	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Philips Medical Systems;
Pudmonny Hyperfenisor Neroblet State Non Invasion Imaging MR Scar and Perfator Revision Invasion Imaging MR Scar and Perfator Revision Invasion Imaging MR Scar and Perfator Revision Invasion Imaging MR Scar and Perfator Revision Invasion Imaging MR Scar and Perfator Revision Invasion Imaging MR Scar and Perfator Revision Invasion Imaging MR Scar and Perfator Revision Invasion Imaging MR Scar and Perfator Revision Invasion Imaging MR Scar and Perfator Revision Invasion Imaging MR Scar and Perfator Revision Imaging MR Scar Andrews Imaging Applications in Notes Imaging MR Scar Andrews Imaging MR Scar Andrews Imaging MR Scar Andrews Imaging MR Scar Andrews Imaging MR Scar Andrews Imaging MR Scar Andrews Imaging MR Scar Andrews Imaging MR Scar Andrews Imaging MR Scar Andrews Imaging MR Scar Andrews Imaging MR Scar Andrews Imaging MR Scar Andrews Imaging MR	Hookbort	Cupan	2	Normal Findings on Naninyasias Cardian Assessment and the	
Heckle Mark Persosuldurstation and Mylocardial Preservation A Robert of Stable Ischment Near Disease Personal Comment of Preservation A Robert of Stable Ischment Near Disease Personal Comment of Preservation A Robert of Stable Ischment Near Disease Personal Comment of Preservation Preservation Comment of Preservation Preservatio			Pulmonary Hypertension	Prediction of Heart Failure: The Multi-Ethnic Study of Atherosclerosis (MESA)	-
In Acute and Stable behavior. Heart Disease Heckle Mark University of Control States (1988) and the States of States in Saphrérious verification. Heckle Mark Timely Topics in Acute Coronary Syndromes Disease Heckle Mark Innovations in Advocacy and Patient Heart Disease Heckle Mark Innovations in Advocacy and Patient Ceretered Provincions of Advocacy and Patient Ceretered Innovations in Advocacy and Patient Ceretered Provincions in Advocacy and Patient Ceretered Innovation Ceretered Innovation Innovation Innovation Innovation Innovation Innovation Innovation Innovation	Heckbert	Susan	Non Invasive Imaging: MR Scar and Perfusion		Nothing to Disclose
Heckle Mark Interventional Cardiology Structural Heart Obleages Heckle Mark Timely Topics in Acute Coronary Syndromes Mocardial futerion Verificials Sepal Defect Mocardial futerion for Mocardia Sepal Defect Mark Admitroroblotic Therapy in Exhemic Heart Obleages Mark Coronary Syndromes Mark Coronary Syndromes Mark Coronary Syndromes Mark Coronary Syndromes Mark Coronary Syndromes Mark Coronary Syndromes Medicine of The ST Segment Elevation Mycocardial Infanction Nothing to Disclose Patents With Coronary Stenty With Coronary Stenty With Coronary Coronary Mark Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coronary Stenty With Mills Vision Coro	Heckle	Mark		An Updated Comprehensive Meta-Analysis Comparing Drug-Eluting Stents With Bare Metal Stents in Saphenous Vein Graft	Nothing to Disclose
Heckle Mark Timely Topics in Acute Coronary Syndromes Control Processing Patients Control P	Heckle	Mark		Outcomes of Early Versus Delayed Transcatheter Closure of Post-	Nothing to Disclose
Mark Mark Mark Disease Shorter- Vessus Longe-Duration Triple Antiformhotic Therapy to Disease Pathents With Corrans y Service With Rocquired Short With Rocquired Sho	Heckle	Mark			Nothing to Disclose
Disease Dise	Hackla	Mark	Antithromhotic Therany in Ischemic Heart		Nothing to Disclose
Care Nark Ventrious Arrhythmas and Sudden Death Prevention P			Disease	Patients With Coronary Stents Who Require Oral Anticoagulation: An Updated Comprehensive Meta-Analysis	-
Prevention Prevention Cardiomyopathy, An Updated Comprehensive Meta-Analysis of Randomized Controlled Trials An Updated Comprehensive Meta-Analysis of Randomized Trials An Updated Comprehensive Meta-Analysis of Randomized Trials An Updated Comprehensive Meta-Analysis of Randomized Trials An Updated Comprehensive Meta-Analysis of Randomized Trials An Updated Comprehensive Meta-Analysis of Randomized Trials An Updated Comprehensive Meta-Analysis of Randomized Trials An Updated Comprehensive Meta-Analysis of Randomized Profiled Present Profiled Profiled Profiled Present Profiled Present Profiled Present Profiled Present Profiled Present Profiled Present Profiled Present Profiled Present Profiled Present Profiled Present Profiled Present Profiled Present Profiled Present Profiled Present	Heckle	Mark			Nothing to Disclose
Heckle Mark Fining the Heart One Cell at a Time: The Ongoing Promise of Slein Cells Featured Clinical Research II: Interventional Meg Dik Featured Clinical Research II: Interventional Meg Dik Timely Topics in Acute Coronary Syndromes Meg Dix Timely Topics in Acute Coronary Syndromes Meg Dix Timely Topics in Acute Coronary Syndromes Meg Dix Timely Topics in Acute Coronary Syndromes Meg Dix Timely Topics in Acute Coronary Syndromes Meg Meg S. Roy Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios Fire Timely Disease States and Clinical Scenarios Fire Timely Fir Clinical Decision Meking Heart Falure and Pulmonary Hypertension Fire Intervention Meximal Medicine Pulmonary Hypertension Fire Clinical Decision Meking Heart Falure and Pulmonary Hypertension Fire Clinical Decision Meking Heart Falure and Pulmonary Hypertension Fire Clinical Decision Meking Heart Falure and Pulmonary Hypertension Fire Clinical Decision Meking Heart Falure and Pulmonary Hypertension Fire Clinical Decision Meking Acute Coronary Syndrome and Vascular Medicine Pulmonary Hypertension Fire Clinical Decision Meking Acute Coronary Syndrome and Vascular Medicine Pulmonary Hypertension Fire Clinical Decision Meking Acute Coronary Syndrome and Vascular Medicine Pulmonary Hypertension Fire Clinical Decision Meking Heart Falure and Post-Surgical Care of Children with CHD: Form ICU by Your Office Cost, Care and Context: Joint Heart Falure Society of America and American College of Cardiology Hedenreich Paul Heart Falure Falure Care: Transitioning the Cost Care and Context: Joint Heart Falure Society of America and American College of Cardiology Fire Clinical Post-Surgical Care of Cost Care and Context: Joint Heart Falure Society of America and American College of Cardiology Fire Medicine Paul Fire Fire Clinical Post-Surgical Care of Cost Care and Context: Joint Heart Falure Fire Clinical Post-Surgical Care of Cost Care and Cost Care and Cost Care and Cost Care and Cost Care and Cost Care and Cost Care and Cost Care and Co	Heckle	Mark		Cardiomyopathy: An Updated Comprehensive Meta-Analysis of	Nothing to Disclose
Meg Dik Timely Topics in Acute Coronary Syndromes Gender-Related Outcomes in Elderly (&B62, 76 Years) Patients Nothing to Disclose Presenting With Acute Coronary Syndromes. Results From the Swiss Acute Coronary Syndromes Results From the Swiss Acute Coronary Syndromes Results From the Swiss Acute Coronary Syndromes. Results From the Swiss Acute Coronary Syndromes. Results From the Swiss Acute Coronary Syndromes. Results From the Swiss Acute Coronary Syndromes. Results From the Swiss Acute Coronary Syndromes. Results From the Swiss Acute Coronary Syndromes. Results From the Swiss Acute Coronary Syndromes. Results From the Swiss Acute Coronary Syndromes. Results From the Swiss Acute Coronary Syndromes. Results From the Swiss Acute Coronary Syndromes. Results From the Swiss Acute Coronary Computed Tomography Articipation. With International Presentation Presentati	Heckle	Mark		An Updated Comprehensive Meta-Analysis of Randomized Trials	Nothing to Disclose
Dik	Heg	Dik	Featured Clinical Research II: Interventional		Nothing to Disclose
Hegde S. Roy Non Invasive Imaging: Applications in Novel Diseases States and Clinical Scenarios Explorations for Invasive Cardiac Procedures - Demonstration by Diseases States and Clinical Scenarios and Pulmonary Hypertension of Invasive Cardiac Procedures - Demonstration by Ozonary Computed Tomography Angiography Pulmonary Hypertension of Pulmonary Hype	Heg	Dik	Timely Topics in Acute Coronary Syndromes		Nothing to Disclose
Disease States and Clinical Scenarios Implications for Invasive Cardiac Procedures - Demonstration by Concentracy Computed Tomography Angiography Angiography				Swiss Acute Coronary Syndrome Cohort	-
Hegeman Timothy FIT Clinical Decision Making: Acute Coronary Takayasu Arteritis Presenting as Syncope and ≴.Pseudo-Nothing to Disclose Syndrome and Vascular Medicine Hypotension̵ in a Young Caucasian Woman Hehir David Post-Surgical Care of Children with CHD: From ICU to Young Caucasian Woman Heart Failure Patient Care: Transitioning the Cost, Care and Context: Joint Heart Failure Society of America and American College of Cardiology Heart Failure Society of America and American College of Cardiology Heart Failure Society of America and American College of Cardiology Heidenreich Paul Young Investigator Awards Competition: All Heart Failure Society of America and American College of Cardiology Young Investigator Awards Competition: All Heart Failure Society of America and American College of Cardiology Young Investigator Awards Competition: All Heart Failure Patients and Long-Term Sunvival Among Highest and Lowest Performing Hospitals, Findings From Get With the Guidelines-Heart Failure Avances in Cholesterol Measurement and Management Avances in Cholesterol Measurement and Management Avances in Cholesterol Measurement and Management Avances in Cholesterol Measurement and Paul Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Avances in Cholesterol Measurement and Prevent Readmissions of Prevent Readmissions and Newer Cutcome Measures Sunday Attrail Fibrillation and VT: Specific Situations and Newer Outcome Measures Sunday Attrail Fibrillation and VT: Specific Situations and Newer Outcome Measures Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Chohort Athales Study Cohort SMASH-AF Meta-Analysis Study Chohort SMASH-AF Meta-Analysis Study Chohort SMASH-AF Meta-Analysis Study Chohort SMASH-AF Meta-Analysis Study Chohort SMASH-AF Meta-Analysis Study Chohort SMASH-AF Meta-Analysis Study Chohort SMASH-AF Meta-Analysis Study Chohort SMASH-AF Meta-Analysis Study Chohort SMASH-AF Meta-Analysis Study Chohort SMASH-AF Meta-Analysis Study Chohort SMASH-AF Meta-Analysis Study Chohort SMASH-	Hegde	S. Roy	Disease States and Clinical Scenarios	Implications for Invasive Cardiac Procedures - Demonstration by Coronary Computed Tomography Angiography	Nothing to Disclose
Syndrome and Vascular Medicine	Hegeman	Timothy			Nothing to Disclose
Post-Surgical Care of Children with CHD: From ICU by Your Office From ICU by Your Office From ICU by Your Office From ICU by Your Office From ICU by Your Office Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Cost, Care and Context. Joint Heart Failure Pailu	Hegeman	Timothy			Nothing to Disclose
Heidenreich Paul Heart Failure Patient Care: Transitioning the Cost. Care and Context. Joint Heart Failure Society of America and American College of Cardiology Heidenreich Paul Heart Failure Patient Care: Transitioning the Cost. Care and Context. Joint Heart Failure Patient Care: Transitioning the Cost. Care and Context. Joint Heart Failure Society of America and American College of Cardiology Heidenreich Paul Young Investigator Awards Competition: Outcomes Research Outcomes Research Outcomes Research Paul Young Investigator Awards Competition: Outcomes Research Outcomes Research Paul Advances in Cholesterol Measurement and Management Advances in Cholesterol Measurement and Management Predictors of Stain Use for Patients With LDL Cholesterol Above 190m/glt. Insights From the Veterans Affairs Health Care System Paul Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Paul Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures Atrial Fibrillation in Studies of Catheter Ablation for Nor-Paroxysmal Artial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making Pibrillation of Volteming Study Cohort Heidenreich Paul Atrial Fibrillation and VT: Specific Situations Stoward Decision Making Fibrillation of Volteming Study Cohort Heidenreich Paul Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making Fibrillation of Nothern to Studies of Catheter Ablation for Atrial Fibrillation of Voltemen in Studies of Catheter Ablation for Atrial Fibrillation of Voltemen in Studies of Catheter Ablation for Nothing to Disclose Northing to Disclose Northing Catheter Ablation for Northing Study Cohort Heidenreich Paul Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures Proportion of Hospitalized Heart Failure Patients Filipide From the SMASH-AF Meta-Analysis Study Cohort Heidenreich Paul Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making Fibrillation of Women in Studies of Catheter Ablation for Atrial Position of	Hehir	David	Post-Surgical Care of Children with CHD:		Nothing to Disclose
Cardiology	Heidenreich	Paul	Heart Failure Patient Care: Transitioning the Cost, Care and Context: Joint Heart Failure	Co-Chair	Nothing to Disclose
Cardiology	Heidenreich	Paul	Cardiology Heart Failure Patient Care: Transitioning the Cost, Care and Context: Joint Heart Failure	What Constitutes "value care" in Heart Failure?	Nothing to Disclose
Lowest Performing Hospitals, Findings From Get With the Guidelines-Heart Failure Heidenreich Paul Young Investigator Awards Competition: Qualify of Care and Outcomes After Acute Coronary Syndrome Heidenreich Paul Advances in Cholesterol Measurement and Management Heidenreich Paul Fibrillation Arthythmias: Outcomes With Contemporary Practice Contemporary Practice Paul Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Frevent Readmissions Heidenreich Paul Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures Heidenreich Paul Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Fibrillation: Findings From the SMASH-AF Meta-Analysis Study	Heidenreich	Paul	Cardiology Young Investigator Awards Competition:		Nothing to Disclose
Outcomes Research Paul Advances in Cholesterol Measurement and Meanagement Heidenreich Paul Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Contemporary Practice Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Heidenreich Paul Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Contemporary Practice Advances in Cholesterol Measures Paul Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures Non-Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort Nothing to Disclose Nothing to Disclose Non-Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort Inclusion of Women in Studies of Catheter Ablation for Atrial Ricks Toward Decision Making Fibrillation: Findings From the SMASH-AF Meta-Analysis Study				Lowest Performing Hospitals, Findings From Get With the Guidelines-Heart Failure	
Heidenreich Paul Advances in Cholesterol Measurement and Management Heidenreich Paul Fibrillation; Arrhythmias: Outcomes With Contemporary Practice Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort Paul Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Prevent Readmissions Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures Analysis Study Cohort Paul Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures Analysis Study Cohort Paul Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Non-Paroxysmal Atrial Fibrillation Findings From the SMASH-AF Meta-Analysis Study Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose	Heidenreich	Paul		Racial Differences in Quality of Care and Outcomes After Acute	Nothing to Disclose
Heidenreich Paul Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Paroxysmal Arlair Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort Heidenreich Paul Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Eligible for Therapy Secular Trends in Reported Success Rates of Catheter Ablation for Nothing to Disclose	Heidenreich	Paul	Advances in Cholesterol Measurement and	Predictors of Statin Use for Patients With LDL Cholesterol Above	Nothing to Disclose
Heidenreich Paul Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Heidenreich Paul Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures Heidenreich Paul Atrial Fibrillation and VT: Incorporating Novel Heidenreich Paul Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making Fibrillation: Findings From the SMASH-AF Risks Toward Decision Making Fibrillation: Findings From the SMASH-AF Risks Toward Decision Making Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Fibrillation: Findings From the SMASH-AF Risks Toward Decision Making Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Fibrillation: Findings From the SMASH-AF Meta-Analysis Study	Heidenreich	Paul	Fibrillatory Arrhythmias: Outcomes With	Success Rates by Ablation Lesion Set of Catheter Ablation for Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta-	Nothing to Disclose
Prevent Readmissions Guidelines on the Proportion of Hospitalized Heart Failure Patients Eligible for Therapy Heidenreich Paul Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures Non-Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort Heidenreich Paul Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Nothing to Disclose Nothing to Disclose Fibrillation: Findings From the SMASH-AF Meta-Analysis Study	Heidenreich	Paul	Acute Heart Failure: Evaluating Strategies to		Nothing to Disclose
and Newer Outcome Measures Non-Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort Heidenreich Paul Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Nothing to Disclose Fibrillation: Findings From the SMASH-AF Meta-Analysis Study			Prevent Readmissions	Guidelines on the Proportion of Hospitalized Heart Failure Patients Eligible for Therapy	-
Risks Toward Decision Making Fibrillation: Findings From the SMASH-AF Meta-Analysis Study	Heidenreich		and Newer Outcome Measures	Non-Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort	
IVADIO II	Heidenreich	Paul			Nothing to Disclose

Last Name	First Name	Session Title	Presentation Title	Disclosures
Heikali	Daniel	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	New Onset Cardiomyopathy and Cardiogenic Shock Leading to a Diagnosis of Limb-Girdle Muscular Dystrophy 2I	Nothing to Disclose
Hein	Thet	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Obstructive Sleep Apnea and Diabetes Mellitus Have Synergistic Effects on Adverse Cardiac and Cerebrovascular Events in Patients Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Heinl	Robert	Updates on Risk Factors for Cardiovascular Disease	Changes in Body Fat Distribution Is Associated With Oxidative Stress	Nothing to Disclose
Heinle	Jeffrey	Congenital Heart Disease: Innovations in	Is a Pulsatile Glenn an Adequate Alternative for Long-Term	Nothing to Disclose
Heis	Zoe	Single Ventricle Heart Disease Arrhythmias and Clinical EP: Basic 3	Palliation in Patients With Single Ventricle Physiology? Impact of Obstructive Sleep Apnea Severity on Cardiac Events in	Nothing to Disclose
Haia		International Continues DCI and TAVD	Patients With Normal or Prolonged Ventricular Repolarization	-
Heis	Zoe	Interventional Cardiology: PCI and TAVR in Complex Patients	The Risk of Adverse Coronary Events Is Higher in Patients With Severe Obstructive Sleep Apnea Following Percutaneous Coronary Intervention	Nothing to Disclose
Heiss	Gerardo	Advances in Cholesterol Measurement and Management	Association of Remnant-Like Particle Cholesterol and Low-Density Lipoprotein Triglyceride With Incidence of Cardiovascular Events: The ARIC Study <i></i>	Nothing to Disclose
Heiss	Gerardo	Updates on Risk Factors for Cardiovascular Disease	Retinopathy and Risk of Sudden Cardiac Death: The ARIC Study	Nothing to Disclose
Heiss	Gerardo	Improving Risk Assessment in Atherosclerosis	Development and Validation of Prediction Models With Non- Traditional Markers for 10-Year Risk of Ischemic Leg Amputation Among Persons With Diabetes: The Atherosclerosis Risk In Communities (ARIC) Study	Nothing to Disclose
Heist	Edwin	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Impact of Treatment Crossovers on Clinical Outcomes in the Rate and Rhythm Control Strategies for Atrial Fibrillation: InsightsFrom the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) Trial	CONSULTANT FEES/HONORARIA - Biotronik,Boston Scientific,Pfizer Inc,St. Jude Medical; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Held	Claes	The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints	Bleeding in ACS Trials – What is the Most Appropriate Definition?	CONSULTANT FEES/HONORARIA - AstraZeneca,Bayer
Held	Claes	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Aortic Stenosis, but Not Mitral or Aortic Regurgitation, Is Associated With Adverse Outcomes With Atrial Fibrillation: Results From the	CONSULTANT FEES/HONORARIA - AstraZeneca,Bayer
Held	Claes	03. Acute and Stable Ischemic Heart Disease: Therapy Team 3	ARISTOTLE Trial Suggested Reviewer	CONSULTANT FEES/HONORARIA - AstraZeneca,Bayer
Heller	Gary	PET Myocardial Perfusion Imaging: Practical Considerations- A Case-Based Discussion	Panelist	CONSULTANT FEES/HONORARIA - JDI,Molecular Imaging Services,PMA Medical
Heller	Gary	PET Myocardial Perfusion Imaging: Practical	PET Myocardial Perfusion Imaging Cases	CONSULTANT FEES/HONORARIA - JDI, Molecular Imaging
Heller	Gary	Considerations- A Case-Based Discussion 30. Non Invasive Imaging: Nuclear Team 2	Suggested Reviewer	Services,PMA Medical CONSULTANT FEES/HONORARIA - JDI,Molecular Imaging
Heller	•	The Intersection of Diabetes and ASCVD	Average Clinician Measured Blood Pressure Predict Cardiovascular	Services,PMA Medical CONSULTANT FEES/HONORARIA - Eli Lilly and
	Simon		Outcomes in Patients With Type 2 Diabetes Following Acute Coronary Syndromes in the EXAMINE Trial	Company,Novo Nordisk Inc.,Takeda Pharmaceuticals North America, Inc; SPEAKER'S BUREAU - Boehringer Ingelheim Pharmaceuticals, Inc,Ei Lilly and Company,Novo Nordisk Inc.,Takeda Pharmaceuticals North America, Inc
Helikamp	Anne	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Examination of hs-CRP Elevation in Patients With History of Myocardial Infarction in the U.S.	Nothing to Disclose
Hellkamp	Anne	Arrhythmias and Clinical EP: Anticoagulation Issues	Thrombolytic Therapy in Anticoagulated Patients: Case Series From Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET AF)	Nothing to Disclose
Hellman	Joseph	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		Nothing to Disclose
Helmcke	Frederick	Advances in HCM, PPCM and Other Cardiomyopathies	Increased Prevalence of Left Ventricular Noncompaction in Certain Populations May Confer Increased Risk of Catastrophic Events	Nothing to Disclose
Helmke	Stephen	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Evaluation of Changes in Weight as Part of Frailty Assessment in Patients With Advanced Heart Failure Receiving a Left Ventricular Assist Device	Nothing to Disclose
Helmy	Tarek	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Management of Pulmonary Artery Graft Occlusion Using High Performance Coronary Equipment	CONSULTANT FEES/HONORARIA - Cardiac Foundation
Helqvist	Steffen	Fixing the Heart One Cell at a Time: The		Nothing to Disclose
Hendel	Robert	Ongoing Promise of Stem Cells Multimodality Imaging in Heart Diseases: International Perspectives From the Gulf Heart Association, Thai Heart Association, and	MyStromalCell Trial Co-Chair	CONSULTANT FEES/HONORARIA - Astellias Pharma
Hendel	Robert	American College of Cardiology Multimodality Imaging in Heart Diseases: International Perspectives From the Gulf Heart Association, Thai Heart Association, and	Introduction to Session	CONSULTANT FEES/HONORARIA - Astellias Pharma
Hendel	Robert	American College of Cardiology State of the Art Nuclear Cardiology: SPECT Myocardial Perfusion Imaging	Appropriate Use: Right Patient, Right Time	CONSULTANT FEES/HONORARIA - Astellias Pharma
Hendel	Robert	Great Debates in Cardiac CT	Debate: Coronary CTA Should Be the Initial Test for Stable Chest Pain, Con	CONSULTANT FEES/HONORARIA - Astellias Pharma
Henderson	Robert	Trends in Coronary Syndromes: International Perspectives From the ACC Great Britain and Ireland Chapter, Israel Heart Society, and American College of Cardiology	Myocardial Injury, Unstable Angina, NSTEMI - What are we Treating?	CONSULTANT FEES/HONORARIA - Quatum Imaging
Henderson	Robert	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Decision Making Using Fractional Flow Reserve Is Associated With Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With Nstemi	CONSULTANT FEES/HONORARIA - Quatum Imaging
Hendrickson	Benjamin	Adult Patients With Congenital Heart Disease: How Do They Compare?	Obstructive Sleep Apnea in Adult Congenital Heart Disease: Who Is at Risk?	Nothing to Disclose
Hengstenberg	Christian	Interventional Cardiology: PCI and TAVR in Complex Patients	at RISK? Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the Bravo-3 Randomized Trial	Nothing to Disclose
Hengstenberg	Christian	Interventional Cardiology: TAVR 3	Multicenter Evaluation of the ACURATE Neo Transfemoral Transcatheter Heart Valve: Clinical Results and Propensity Matched	Nothing to Disclose
Hengstenberg	Christian	Interventional Cardiology: TAVR 4	Comparison With SAPIEN 3 Multicenter Evaluation of Prosthesis Oversizing for the SAPIEN 3 Transcatheter Heart Valve: Impact on New Pacemaker	Nothing to Disclose
Hengstenberg	Christian	Interventional Cardiology: PCI in Complex Patients	Implantations Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated Heparin Following Transcatheter Aortic Valve Replacement: Results From the Bravo-3 Randomized Trial	Nothing to Disclose
Henkin	Stanislav	Vascular Medicine: Emerging Concepts in	Risk of Re-Dissection in Segmental Arterial Mediolysis	Nothing to Disclose
Henkin	Stanislav	Clinical Vascular Diseases FIT Clinical Decision Making: Interventional	Massive Embolism in Transit: Confirming the Destination	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine		



Control of the contro				
Last Name Hennessy	First Name Terence	Session Title Coronary Intervention in Interventional	Presentation Title Facilitation of Stent Delivery With the GuideLiner Catheter	Disclosures Nothing to Disclose
-		Cardiology: Advanced Device Use	•	
Henrikson	Charles	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	ECG Referral by a Cardiologist Is Associated With Life-Saving Effect in a Large Tertiary Healthcare System Patient Population	OTHER - Boston Scientific, MEDTRONIC, St Jude Medical; RESEARCH/RESEARCH GRANTS - Biosense Webster
Henrikson	Charles	Arrhythmias and Clinical EP: Devices 2	Antibacterial Envelope Is Associated With Medical Cost Savings in Patients at High Risk for Cardiovascular Implantable Electronic Device Infection	OTHER - Boston Scientific,MEDTRONIC,St Jude Medical; RESEARCH/RESEARCH GRANTS - Biosense Webster
Henriques	Jose	21. Interventional Cardiology: Coronary Intervention: Devices Team 1	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, BBraun
Henry	Ronald	Perspectives on Congenital Heart Disease: International Perspectives From the Caribbean Cardiac Society, Peruvian Society of Cardiology, and American College of	Co-Chair	Nothing to Disclose
Henry	Timothy	Cardiology Debates: Is There Really a Sex Difference in CV Presentation, Care, and Outcomes?	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular,Baxter,capricor,Cytori,Eli Lilly and Company,Medicines Company, RESEARCH/RESEARCH GRANTS - Aastrom,Baxter International Inc,Mesoblast
Henry	Timothy	Debates: Is There Really a Sex Difference in CV Presentation, Care, and Outcomes?	Women Have a Worse Prognosis Than Men Following STEMI: CON	CONSULTANT FEES/HONORARIA - Abbott Vascular, Baxter, capricor, Cytori, Eli Lilly and Company, Medicines Company, RESEARCH/RESEARCH GRANTS - Aastrom, Baxter International Inc, Mesoblast
Henry	Timothy	Logistical Challenges in STEMI	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular,Baxter,capricor,Cytori,Eli Lilly and Company,Medicines Company; RESEARCH/RESEARCH GRANTS - Aastrom,Baxter
Henry	Timothy	What's New in the World of STEMI?	Debate Pro: Stem Cells in MI- Hope or Hype	International Inc, Mesoblast CONSULTANT FEES/HONORARIA - Abbott Vascular, Baxter, capricor, Cytori, Eli Lilly and Company, Medicines Company, RESEARCH/RESEARCH GRANTS - Aastrom, Baxter International Inc, Mesoblast
Henry	Timothy	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Platelet Reactivity and Outcomes After PCI of Saphenous Vein Grafts Versus Native Coronary Arteries: The ADAPT-DES Study	CONSULTANT FEES/HONORARIA - Abbott Vascular, Baxter, capricor, Cytori, Eli Lilly and Company, Medicines Company, RESEARCH/RESEARCH GRANTS - Aastrom, Baxter International Inc, Mesoblast
Henry	Timothy	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	CONSULTANT FEES/HONORARIA - Abbott Vascular,Baxter,capricor,cytori,Eli Lilly and Company,Medicines Company, RESEARCH/RESEARCH GRANTS - Aastrom,Baxter International Inc,Mesoblast
Henry	Timothy	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study	CONSULTANT FEES/HONORARIA - Abbott Vascular,Baxter,capricor,cytori,Eli Lilly and Company,Medicines Company, RESEARCH/RESEARCH GRANTS - Aastrom,Baxter International Inc,Mesoblast
Henry	Timothy	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Hospital Variation in Targeted Temperature Management for Acute Myocardial Infarction Patients Complicated by Out-of-Hospital Cardiac Arrest in the U.S.	CONSULTANT FEES/HONORARIA - Abbott Vascular, Baxter, capricor, Cytori, Eli Lilly and Company, Medicines Company, RESEARCH/RESEARCH GRANTS - Aastrom, Baxter International Inc, Mesoblast
Henry	Timothy	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Influence of Cardiac Arrest and Cardiogenic Shock on Outcomes Among 4,500 Consecutive ST Elevation Myocardial Infarction Patients	CONSULTANT FEES/HONORARIA - Abbott Vascular, Baxter, capricor, Cytori, Eli Lilly and Company, Medicines Company, RESEARCH/RESEARCH GRANTS - Aastrom, Baxter International Inc, Mesoblast
Henry	Timothy	Timely Topics in Acute Coronary Syndromes	Outcome and Characteristics of Shockable Versus Non-Shockable Cardiac Arrest in ST Elevation Myocardial Infarction at a Regional Transfer Center	CONSULTANT FEES/HONORARIA - Abbott Vascular,Baxter,capricor,Cytori,Eli Lilly and Company,Medicines Company, RESEARCH/RESEARCH GRANTS - Aastrom,Baxter International Inc,Mesoblast
Henry	Timothy	Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes	CONSULTANT FEES/HONORARIA - Abbott Vascular,Baxter,capricor,Cytori,Eli Lilly and Company,Medicines Company, RESEARCH/RESEARCH GRANTS - Aastrom,Baxter International Inc,Mesoblast
Henry	Timothy	Advances in Chronic Total Occlusion Intervention	Is Platelet Reactivity Associated With Ischemic Events Following Successful Chronic Total Occlusion Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Abbott Vascular,Baxter,capricor,Cytori,Eil Lilly and Company,Medicines Company; RESEARCH/RESEARCH GRANTS - Aastrom,Baxter International Inc,Mesoblast
Henry	Timothy	Anti-Platelet Therapies: Always a Sticky Topic	Antiplatelet Therapy Changes for MI Patients With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS Study	CONSULTANT FEES/HONORARIA - Abbott Vascular,Baxter,capricor,Cytori,Eil Lilly and Company,Medicines Company, RESEARCH/RESEARCH GRANTS - Aastrom,Baxter International Inc,Mesoblast
Henry	Timothy	02. Acute and Stable Ischemic Heart Disease: Clinical Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular,Baxter,capricor,Cytori,Eli Lilly and Company,Medicines Company, RESEARCH/RESEARCH GRANTS - Aastrom,Baxter International Inc,Mesoblast
Hensen	Liselotte	Novel Echocardiographic Methods for Assessing Cardiac Function	Prognostic Implications of Left Ventricular Global Longitudinal Strain in Stage 4 and 5 Chronic Kidney Disease Patients	
Henzlova	Milena	Assessing Cardiac Function Nuclear Cardiology: Current Applications and Best Practices: Joint Symposium of the American Society of Nuclear Cardiology and the American College of Cardiology	In Sudge 4 and 5 Chronic Konley Disease Patients Contemporary SPECT Imaging: New Technologies and Protocols	Nothing to Disclose
Heo	Jeong Ho	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Clinical and Electrocardiographic Characteristics for Prediction of New-Onset Left Ventricular Dysfunction in Patients With Frequent Idiopathic Ventricular Premature Complex >10%	Nothing to Disclose
Heo	Ji Haeng	Therapeutic Advances in Congenital Heart Disease	Association of Fractures With Furosemide Therapy in Pediatric Medicaid Patients With Congenital Heart Disease	Nothing to Disclose
Her	Sung-Ho	Late-Breaking Clinical Trials: Interventional	Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With Corronary Chronic Total Occlusion: DECISION CTO Randomized Trial	Nothing to Disclose
Heringlake	Matthias	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery With Cardiopulmonary Bypass: Primary Results of the LEVO-CTS Trial	CONSULTANT FEES/HONORARIA - Amomed Pharma,MEDTRONIC,Orion Pharma,Tenax Pharma
Hermans	Maaike	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Plasma LDL-Cholesterol Level is independently Associated With Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention	Nothing to Disclose
Hermiller	James	Interventional Live Case Session IV: Complex Coronary Transmission from St. Vincent Hospital (Indianapolis, IN)	Live Case Operator	CONSULTANT FEES/HONORARIA - Consultant BSC, Abbott Vascular, Medtronic and St Jude, Edwards
Hermiller	James	Interventional Live Case Session VI: Bioresorbable Scaffolds and Imaging from St. Vincent Hospital (Indianapolis, IN)	Live Case Operator	CONSULTANT FEES/HONORARIA - Consultant BSC, Abbott Vascular, Medtronic and St Jude, Edwards
Hermiller	James	Interventional Cardiology: TAVR 2	Impact of Balloon Pre-Dilatation on Hemodynamics and Clinical Outcomes After Transcatheter Aortic Valve Replacement With the Self-Expanding CoreValve Prosthesis	CONSULTANT FEES/HONORARIA - Consultant BSC, Abbott Vascular, Medtronic and St Jude, Edwards
Hermiller	James	17. Interventional Cardiology: Aortic Valve Disease Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Consultant BSC, Abbott Vascular, Medtronic and St Jude, Edwards



Contract of the contract of th				<u> </u>
Last Name Hernandez	First Name Adrian	Session Title Featured Clinical Research III	Presentation Title Panelist	Disclosures CONSULTANT FEES/HONORARIA - Amgen Inc.,Bayer Corporation US,Boehringer Engelheim,Boston Scientific.gillead,Merck & Co., Inc.,Novaris,Pitzer,Pluristem Therapeutics, Inc.,Sensible; RESEARCH/RESEARCH GRANTS - Abbott Evalve,Aires Pharmaceuticals,Amgen,Amylin, Inc.,AstraZeneca,BMS,Genentech, Inc,GlaxoSmithKline,Merck & Co., Inc.,Novariis,Pitzer Inc,Portola,Roche Pharmaceuticals, Inc.,Scios, Inc.
Hernandez	Adrian	Young Investigator Awards Competition: Outcomes Research	A Hospital Level Analysis of 30-Day Readmission Rates for Heart Failure Patients and Long-Term Survival Among Highest and Lowest Performing Hospitals, Findings From Get With the Guidelines-Heart Failure	CONSULTANT FEES/HONORARIA - Amgen Inc.,Bayer Corporation US,Boehringer Engelheim, Boston Scientific, gliead, Merck & Ampp; amp; Co., Inc.,Novartis,Pfizer,Pluristem Therapeutics, Inc.,Sensible; RESEARCH/RESEARCH GRANTS - Abbott Evalve,Aires Pharmaceuticals,Amgen,Amylin, Inc.,AstraZeneca,BMS,Genentech, Inc,GlaxoSmithKline,Merck & Co., Inc.,Novartis,Pfizer Inc,Portola,Roche Pharmaceuticals, Inc.,Scios, Inc.
Hernandez	Adrian	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Heart Failure With Reduced Ejection Fraction Care Patterns in the Outpatient Practice Setting: Initial Findings From CHAMP-HF	CONSULTANT FEES/HONORARIA - Amgen Inc.,Bayer Corporation US,Boehringer Engelheim,Boston Scientific,gilead,Merck & Dengamp; Co., Inc.,Novariis,Pfizer,Pluristem Therapeutics, Inc.,Sensible; RESEARCH/RESEARCH GRANTS - Abbott Evalve,Aires Pharmaceuticals,Amgen,Amylin, Inc.,AstraZeneca,BMS,Genentech, Inc,GlaxoSmithKline,Merck & Dengamp; Co., Inc.,Novartis,Pfizer Inc,Portola,Roche Pharmaceuticals, Inc.,Scios, Inc.
Hernandez	Adrian	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Timing and Clinical Predictors of Early Versus Late Readmission Among Patients Hospitalized for Acute Heart Failure: Insights From ASCEND-HF	CONSULTANT FEES/HONORARIA - Amgen Inc.,Bayer Corporation US,Boehringer Engelheim,Boston Scientific,gilead,Merck & Dengamp; Co., Inc.,Novariis,Pfizer,Pluristem Therapeutics, Inc.,Sensible; RESEARCH/RESEARCH GRANTS - Abbott Evalve,Aires Pharmaceuticals,Amgen,Amylin, Inc.,AstraZeneca,BMS,Genentech, Inc,GlaxoSmithKline,Merck & Dengamp; Co., Inc.,Novariis,Pfizer Inc,Portola,Roche Pharmaceuticals, Inc.,Scios, Inc.
Hernandez	Adrian	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Hemoconcentration During Management of Patients With Acute Heart Failure and Cardiorenal Syndrome: Insights From CARRESS- HF	CONSULTANT FEES/HONORARIA - Amgen Inc.,Bayer Corporation US,Boehringer Engelheim,Boston Scientific,gilead,Merck &,zamp; Co., Inc.,Novartis,Pfizer,Pluristem Therapeutics, Inc.,Sensible; RESEARCH/RESEARCH GRANTS - Abbott Evalve,Aires Pharmaceuticals,Amgen,Amylin, Inc.,AstraZeneca,BMS,Genentech, Inc,GlaxoSmithKline,Merck &,amp; Co., Inc.,Novartis,Pfizer Inc,Portola,Roche Pharmaceuticals, Inc.,Scios, Inc.
Hernandez	Adrian	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Time of Presentation Among Patients Hospitalized for Acute Heart Failure (Clinical Characteristics, Initial Therapies and Outcomes): Insights From ASCEND-HF	CONSULTANT FEES/HONORARIA - Amgen Inc.,Bayer Corporation US,Boehringer Engelheim,Boston Scientific,gilead,Merck & Co., Inc.,Novartis,Pfizer,Pluristem Therapeutics, Inc.,Sensible; RESEARCH/RESEARCH GRANTS - Abbott Evalve,Aires Pharmaceuticals,Amgen,Amylin, Inc.,AstraZeneca,BMS,Genentech, Inc,GlaxoSmithKline,Merck & Co., Inc.,Novartis,Pfizer Inc,Portola,Roche Pharmaceuticals, Inc.,Scios, Inc.
Hernandez	Adrian	Why Can't We Be Friends? Controversies in Heart Failure Management	Association Between Serum Potassium Level and Outcomes in Heart Failure With Reduced Ejection Fraction: A Cohort Study From the Swedish Heart Failure Registry	CONSULTANT FEES/HONORARIA - Amgen Inc., Bayer Corporation US, Boehringer Engelheim, Boston Scientific, gillead, Merck & amp;amp; Co., Inc., Novartis, Pfizer, Pluristem Therapeutics, Inc., Sensible; RESEARCH/RESEARCH GRANTS - Abbott Evalve, Aires Pharmaceuticals, Amgen, Amylin, Inc., AstraZeneca, BMS, Genentech, Inc, GlaxoSmithKline, Merck & amp;amp; Co., Inc., Novartis, Pfizer Inc, Portola, Roche Pharmaceuticals, Inc., Scios, Inc.
Hernandez	Salvador	Innovations in Advocacy and Patient Centered	Prevalence of Chagas Disease Among Relatives of Positive Cases	Nothing to Disclose
Hernandez Afonso	Julio Salvador	Care Cardiac Channelopathies: Novel Therapeutics and Clinical Challenges	in Los Angeles, CA Eficacy and Safety of Flecainide to Reduce Exercise-Induced Ventricular Arrhythmias and the Arrhythmic Window in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia	Nothing to Disclose
Hernandez Enriquez	Marco	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Therapeutic Hypothermia in Post-Cardiac Arrest Syndrome: Role of Neuron-Specific Enolase as Early Predictor of Neurological Status at Discharge	Nothing to Disclose
Hernandez Garcia Hernandez Montfort	Jose Maria Jaime	Interventional Cardiology: TAVR 2	Effect of Body Mass Index on Mortality After Transcatheter Aortic Valve Implantation: J-Shaped Curve A Rare Cause of Myocardial Injury in a Patient With Systemic Lupus	Nothing to Disclose RESEARCH/RESEARCH GRANTS - Abiomed
		Pulmonary Hypertension	Erythematosus: Hydroxychloroquine Induced Cardiomyopathy	
Hernandez-Montfort	Jaime	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		RESEARCH/RESEARCH GRANTS - Abiomed
Herre	John	Great Minds Think Differently: Multidisciplinary Approach to Advanced Therapies	Panelist	Nothing to Disclose
Herre	John	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Impact of Surgical Bleeding on the Cost of Hospitalization for Left- Ventricular Assist Device Implantation	Nothing to Disclose
Herre	John	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Preoperative Predictors of Surgical Bleeding With Implantation of Durable Mechanical Circulatory Support Devices	Nothing to Disclose
Herrin	Jeph	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Admission Types Among Patients With Heart Failure Cared for by Accountable Care Organizations: Variation by Performance on a Measure of Risk Standardized Acute Admission Rates	Nothing to Disclose
Herrington	David	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium Scores for Atherosclerotic Cardiovascular Disease Risk Stratification in Smokers: MESA	CONSULTANT FEES/HONORARIA - Amarin
Herrmann	Howard	Featured Clinical Research II: Interventional	Panelist	CONSULTANT FEES/HONORARIA - Edwards Lifesciences, Leerink Swan, Wells Fargo, OTHER - Mass Medical Society, OWNERSHIP INTERESTIP/ARTHERSHIP/PRINCIPAL - Micro-Interventional Devices, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston Scientific Corporation, Edwards LifeSciences, Inc., MEDTRONIC, MitraSpan, St. Jude Medical
Herrmann	Howard	TAVR Changing the Paradigm for the Treatment of Valve Disease	Panelist	CONSULTANT FEES/HONORARIA - Edwards Lifesciences, Leerink Swan, Wells Fargo, OTHER - Mass Medical Society, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Micro-Interventional Devices, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston Scientific Corporation, Edwards LifeSciences, Inc., MEDTRONIC, MitraSpan, St Jude Medical

Control of the Contro				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Herrmann	Howard	TAVR Changing the Paradigm for the	TAVR in Those with a Low Ejection Fraction	CONSULTANT FEES/HONORARIA - Edwards
		Treatment of Valve Disease		Lifesciences, Leerink Swan, Wells Fargo; OTHER - Mass Medical Society; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
				Micro-Interventional Devices, Inc.: RESEARCH/RESEARCH
				GRANTS - Abbott Vascular, Boston Scientific
				Corporation, Edwards LifeSciences,
				Inc.,MEDTRONIC,MitraSpan,St Jude Medical
Herrmann	Howard	Transcatheter Mitral Valve Repair	Transcatheter Direct Annuloplasty: Current Update	CONSULTANT FEES/HONORARIA - Edwards Lifesciences, Leerink Swan, Wells Fargo: OTHER - Mass Medical
				Society: OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
				Micro-Interventional Devices, Inc.; RESEARCH/RESEARCH
				GRANTS - Abbott Vascular, Boston Scientific
				Corporation, Edwards LifeSciences,
				Inc.,MEDTRONIC,MitraSpan,St Jude Medical
Herrmann	Howard	PFO Closure, PV Leak, and VSD Repair	Case Presentation: Transcatheter Closure of latrogenic VSD Post-	CONSULTANT FEES/HONORARIA - Edwards
			TAVR	Lifesciences, Leerink Swan, Wells Fargo; OTHER - Mass Medical
				Society; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Micro-Interventional Devices, Inc.; RESEARCH/RESEARCH
				GRANTS - Abbott Vascular, Boston Scientific
				Corporation, Edwards LifeSciences,
				Inc.,MEDTRONIC,MitraSpan,St Jude Medical
Herrmann	Howard	Transcatheter Mitral Valve Replacement	Co-Chair	CONSULTANT FEES/HONORARIA - Edwards
				Lifesciences, Leerink Swan, Wells Fargo; OTHER - Mass Medical
				Society; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
				Micro-Interventional Devices, Inc.; RESEARCH/RESEARCH
				GRANTS - Abbott Vascular, Boston Scientific Corporation, Edwards LifeSciences,
				Inc.,MEDTRONIC,MitraSpan,St Jude Medical
Herrmann	Howard	Transcatheter Mitral Valve Replacement	Case Presentation: Mitral TMVR	CONSULTANT FEES/HONORARIA - Edwards
				Lifesciences, Leerink Swan, Wells Fargo; OTHER - Mass Medical
İ	İ			Society; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
	İ			Micro-Interventional Devices, Inc.; RESEARCH/RESEARCH
	İ			GRANTS - Abbott Vascular, Boston Scientific
	1	1		Corporation, Edwards LifeSciences,
				Inc.,MEDTRONIC,MitraSpan,St Jude Medical
Herrmann	Howard	Interventional Cardiology: TAVR 1	TAVR Is Safe and Improves Cardiac Function in Patients With Extremely Low Ejection Fractions	CONSULTANT FEES/HONORARIA - Edwards
			Extremely Low Ejection Fractions	Lifesciences, Leerink Swan, Wells Fargo; OTHER - Mass Medical Society; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
				Micro-Interventional Devices, Inc.; RESEARCH/RESEARCH
	İ			GRANTS - Abbott Vascular, Boston Scientific
				Corporation, Edwards LifeSciences,
				Inc.,MEDTRONIC,MitraSpan,St Jude Medical
Herrmann	Howard	Interventional Cardiology: TAVR 1	Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis	CONSULTANT FEES/HONORARIA - Edwards
			After Aortic Valve Replacement: Insights From PARTNER 2A Trial	Lifesciences,Leerink Swan,Wells Fargo; OTHER - Mass Medical
				Society; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
				Micro-Interventional Devices, Inc.; RESEARCH/RESEARCH
				GRANTS - Abbott Vascular, Boston Scientific Corporation, Edwards LifeSciences,
				Inc.,MEDTRONIC,MitraSpan,St Jude Medical
Herrmann	Howard	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low-	CONSULTANT FEES/HONORARIA - Edwards
			Flow Severe Aortic Stenosis and Less Reverse Remodeling After	Lifesciences, Leerink Swan, Wells Fargo; OTHER - Mass Medical
			TAVR: A Partner 2 Trial Analysis	Society; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
				Micro-Interventional Devices, Inc.; RESEARCH/RESEARCH
				GRANTS - Abbott Vascular, Boston Scientific
				Corporation,Edwards LifeSciences, Inc.,MEDTRONIC,MitraSpan,St Jude Medical
Herrmann	Howard	19. Interventional Cardiology: Complex	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Edwards
Heimaili	Tiowaru	Patients/Comorbidities Team 2	Juggested Neviewel	Lifesciences, Leerink Swan, Wells Fargo; OTHER - Mass Medical
		r duonio comorbidido ream 2		Society; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
				Micro-Interventional Devices, Inc.; RESEARCH/RESEARCH
				GRANTS - Abbott Vascular, Boston Scientific
				Corporation, Edwards LifeSciences,
				Inc.,MEDTRONIC,MitraSpan,St Jude Medical
Herrmann	Howard	24. Interventional Cardiology: Mitral and Structural Heart Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Edwards
		Structural Heart Disease Team 1		Lifesciences, Leerink Swan, Wells Fargo; OTHER - Mass Medical Society; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
				Micro-Interventional Devices, Inc.: RESEARCH/RESEARCH
				GRANTS - Abbott Vascular.Boston Scientific
				Corporation, Edwards LifeSciences,
				Inc.,MEDTRONIC,MitraSpan,St Jude Medical
Herrmann	Joerg	Making Progress in Understanding Heart	Stress Induced Cardiomyopathy Triggered by Chemotherapy: When	Nothing to Disclose
Herebberre	Devi	Failure	Should Cancer Therapy Be Restarted?	Nething to Displace
Hershberger	Ray	Genetic Testing for Cardiomyopathies	Panelist Constituting for Dilated Cordinavenethy, la it Boody for Brime	Nothing to Disclose
Hershberger	Ray	Genetic Testing for Cardiomyopathies	Genetic Testing for Dilated Cardiomyopathy: Is it Ready for Prime- time	Nothing to Disclose
Hershberger	Ray	14. Heart Failure and Cardiomyopathies:	Suggested Reviewer	Nothing to Disclose
oronoorgor	,	Therapy Team 1		
Herweg	Bengt	Arrhythmias and Clinical EP: Devices 3	Differences Among African Americans and White Patients	CONSULTANT FEES/HONORARIA - Biosense Webster
1 -	1 -		Undergoing Implantable Cardioverter Defibrillator Implantation for	
	ļ		Primary Prevention	
Herzog	Charles	FIT Clinical Decision Making: Interventional	Management of Impacted Intramyocardial Shrapnel Due to Gunshot	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - General
	İ	Cardiology, Acute and Stable Ischemic Heart	Wound	Electric,Merck; RESEARCH/RESEARCH GRANTS - Amgen
Horzog	Evol	Disease, and Vascular Medicine Cardiac Arrest. Diabetes, and Other High Risk	Low Cosing appropria Status In Approximated Will Increased to a first	Nothing to Displace
Herzog	Eyal	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Low Socioeconomic Status Is Associated With Increased Inpatient Mortality With Non ST-Elevation Myocardial Infarction: A Nationwide	Nothing to Disclose
	1	Syndrome	Analysis	
Herzog	Eyal	Cardiac Arrest, Diabetes, and Other High Risk	Patients With Non ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
	l '	Features of Patients With Acute Coronary	Utilizing Medicare/Medicaid Have Lower Adjusted Odds of In-	·· J
		Syndrome	Hospital Mortality: A Nationwide Analysis	
Herzog	Eyal	Acute Coronary Syndromes, Diagnosis,	Adjusted Odds of Inpatient Mortality for Non-ST Elevation	Nothing to Disclose
	1	Management and Outcomes	Myocardial Infarction Is Not Affected by Day of Admission: A	
Haraniet	l:	Total State of All Control Control	Nationwide Analysis	Nething to Displace
Hesaroieh	Iraj	Traditional and Novel Factors Used to Assess	Association Between Circulating Progenitor Cells and Outcomes in	Nothing to Disclose
	İ	the Risk of, and Used for the Treatment of, Coronary Artery Disease	Patients With Coronary Artery Disease	
Hesaroieh	Iraj	The Evolving World of LVADs, Transplant and	Progenitor Cells and Clinical Outcomes in Patients With Heart	Nothing to Disclose
		Other Novel Discoveries	Failure	Trouming to Discrete
Hesaroieh	Iraj	Unusual Presentations of ACS	Circulating Progenitor Cells Levels and Outcomes in Acute	Nothing to Disclose
			Myocardial Infarction	
Hess	Connie	Highlighted Original Research: Acute and	Patterns of Angina and Antianginal Medication Use Among Patients	Nothing to Disclose
	İ	Stable Ischemic Heart Disease and the Year in	Following MI Treated With PCI: Insights From TRANSLATE-ACS	
Uses	Canala	Review	Contract Dellara of OD III //III 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Nething to Displace
Hess	Connie	Optimizing the Care of ACS Patients	Contemporary Patterns of GP IIb/IIIa Inhibitor Use in Patients With Acute Myocardial Infarction Undergoing PCI: Insights From the	Nothing to Disclose
1	1	ĺ	TRANSLATE ACS Study	
	1	i e	I I MINOLATE ACC CIUUY	i e e e e e e e e e e e e e e e e e e e

Fig. 19 Douglas	Contract of the second				<u> </u>
Service Control of Service Contr		First Name Connie	Session Title PCI Strategies and Outcomes Unique to	Presentation Title ACC Poster Moderator	Disclosures Nothing to Disclose
Professional Part Services and	Hoss	Douglas	Women	S Nitroschemoglobin Levels After Transfusion Predict Outcome of	-
Figure 1997 Name of Controlled Programs of Co			Pediatric Heart Surgery	Pediatric BypassSurgery	
The Policy Description No. 1 page 12 p	Hess	Gregory		Treatment, Comorbidities, and Lipid Therapy Using Real-World,	Nothing to Disclose
Contemporary Contemporary Professor Professor Professor Day Bayes Section 1. Section of Professor In Professor Section	Hess	Paul	Nuclear Cardiology: Prognosis	Ventricular Dyssynchrony Among Patients With Coronary Heart	Nothing to Disclose
Ness Sustainen Jahren Steinen	Hess	Paul		Contemporary Cardiovascular Practice: Findings From the	Nothing to Disclose
Analyshmes and Cincard Dr. Anisopators and Cincard Dr. Anisopators and Service Services (Control of Services) Hassing Cabrielle 11 Congressed Hazer Diseases Throng Yard Services (Control of Services) Hassing Order Control of Services (Control of Services) Hassing Order Contro	Hess	Rachel		Cost-Effectiveness of Intensive Blood Pressure Goals in Patients	Nothing to Disclose
Findships Ostories The Cognitive Findships Designer Findships	Hess	Susanne	Arrhythmias and Clinical EP: Anticoagulation	Real-World Versus Randomized Trial Outcomes in Similar Populations of Rivaroxaban-Treated Patients With Nonvalvular Atrial	OTHER - Bayer Healthcare Pharmaceuticals
Procedure Proc	Hessling	Gabriele	11. Congenital Heart Disease: Therapy Team		Nothing to Disclose
Persistence Persistence	Heublein	Denise	1 Young Investigator Awards Competition: Basic	NPA7, a First in Class Dual Receptor Activator With Cardio-	Nothing to Disclose
Constant Present Constant Pr	Heublein	Denise	Acute Heart Failure: Evaluating Strategies to	Intrarenal Renin Angiotensin System Activation: Pathophysiologic and Therapeutic Implications in Acute Decompensated Heart	Nothing to Disclose
Reference Refe	Heusch	Gerd	01. Acute and Stable Ischemic Heart Disease:		CONSULTANT FEES/HONORARIA - servier
March Procedure	Hevdari	Rohby		Defining Risk Associated With Left Ventricular Hypertrophy Patterns	Nothing to Disclose
Henro Melian	*		and Function	as Assessed by Cardiac Magnetic Resonance Imaging	-
Incomparison Novel Developments in Acute Coronary Syndromes Paramaconnaste Strategy Following Floring Paramaconnaste Strategy Following Floring Paramaconnaste Strategy Following Floring Paramaconnaste Strategy Following Floring Paramaconnaste Strategy Following Floring Paramaconnaste Strategy Following Floring Paramaconnaste Strategy Following Floring Paramaconnaste Strategy Following Floring Paramaconnaste Strategy Following Floring Paramaconnaste Strategy Following Floring Strategy Following Floring Paramaconnaste Strategy Following Floring Strategy Flo	Heywood	J.	Featured Clinical Research III	Hemodynamic Monitoring Seen in Clinical Trials Is Maintained in the	Actelion,MEDTRONIC,Otsuka,St Jude,Thoratec; OTHER - St Jude Medical; RESEARCH/RESEARCH GRANTS - MEDTRONIC
Syndromes	Hiatt	William	1		RESEARCH/RESEARCH GRANTS - AstraZeneca,Bayer Healthcare Pharmaceuticals,CSI,Kyushu University,Pluristem;
Features of Patents With Autor Coronary Syndrome Syndrome Timery Topes in Acute Coronary Syndrome Patents Advin Timery Topes in Acute Coronary Syndrome Cardiac Arrest in ST Eventor Mycoardial Infection at Regional Timery Topes in Acute Coronary Syndrome Cardiac Arrest in ST Eventor Mycoardial Infection at Regional Transfer Center of Cardiac Arrest in ST Eventor Mycoardial Infection at Regional Transfer Center of Cardiac Arrest in ST Eventor Mycoardial Infection at Regional Transfer Center of Cardiac Arrest in ST Eventor Mycoardial Infection at Regional Transfer Center of Cardiac Arrest in ST Eventor Mycoardial Infection at Regional Transfer Center of Cardiac Arrest in ST Eventor Mycoardial Infection at Regional Transfer Center of Cardiac Arrest in ST Eventor Mycoardial Infection at Regional Transfer Center of Cardiac Arrest in ST Eventor Mycoardial Infection at Regional Transfer Center of Cardiac Arrest in ST Eventor Mycoardial Infection at Regional Transfer Center of Cardiac Arrest in ST Eventor Mycoardial Presidents in Transfer Center of Cardiac Arrest in ST Eventor Mycoardial Presidents in Transfer Center of Cardiac Arrest in ST Eventor Mycoardial Presidents in Transfer Center of Cardiac Arrest in Arrest	Hibbert	Benjamin		Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment	Nothing to Disclose
Hibbs	Hibbs	John	Features of Patients With Acute Coronary	Influence of Cardiac Arrest and Cardiogenic Shock on Outcomes Among 4,500 Consecutive ST Elevation Myocardial Infarction	Nothing to Disclose
Hickey Gave Hickey Gave Hickey Gave Hickey Gave Hickey Gave Hickey Gave Hickey Gave Hickey Hickey Hickey Gave Hickey Gave Hickey Hickey Hickey Hickey Gave Hickey Hidde Hidde Hide Hide Hickey Hide Hide Hide Hide Hide Hide Hide Hide	Hibbs	John		Outcome and Characteristics of Shockable Versus Non-Shockable Cardiac Arrest in ST Elevation Myocardial Infarction at a Regional	Nothing to Disclose
Proceeding the Future: Observations and Discovered From Registries and Distablasses Patricia Mortality in End-Stage Nothing to Disclose Nothing to	Hickey	Edward	Redefining the "F" Word	Late Complications and Cardiopulmonary Performance in Adults With Fontan Physiology: Rv-Dominant Versus Those With Lv-	Nothing to Disclose
Hicks Karen The Fundamentals of ACS Trials—Piffalls Rationale for Standarded Definitions - Regulatory Perspective Nothing to Disclose	Hickey	Gavin		Pulmonary Vascular Resistance Predicts Mortality in End-Stage	Nothing to Disclose
Hiddigo Ponce Luis Francisco Fit Clinical Decision Making Non-Invesse Imaging and Valvalar Head Disease Hidda Michinari Making Progress in Understanding Heart Faiture Heda Michinari Making Progress in Understanding Heart Faiture Hiddigo Michinari Fit Clinical Making Progress in Understanding Heart Faiture Hiddigo Michinari Fit Clinical Research Intervention of Cardiometabolic Disease: Exercise is Medicine Cardiometabolic Disease: Exercise is Medicine Cardiometabolic Disease: Exercise is Medicine Hidgins Andrew Valvular Heart Disease: Anche Regurgatation Cardiometabolic Disease: Exercise is Medicine Hidgins John ICan Do WHAT After My Heart Aftex? Parellati Hidgins John ICan Do WHAT After My Heart Aftex? Hidgins John ICan Do WHAT After My Heart Aftex? Hidgins John ICan Do WHAT After My Heart Aftex? Hidgins John Incontrol Use of Echocardiography Windiometabolic Use of Echocard	Hicks	Karen	The Fundamentals of ACS Trials—Pitfalls in		Nothing to Disclose
Michinari Making Progress in Understanding Heart High Risk, Stage B Heart Faiture: A Distinct Hemodynamic Profile High Risk, Stage B Heart Faiture: A Distinct Hemodynamic Profile High Risk, Stage B Heart Faiture: A Distinct Hemodynamic Profile High Risk, Stage B Heart Faiture: A Distinct Hemodynamic Profile Mohining to Disclose	Hidalgo Ponce	Luis Francisco		Multidisciplinary Approach for Endocarditis in Pregnancy	Nothing to Disclose
Failure Physical Activity and Prevention of Cardiometabolic Diseases: Exercise is Medicine Physical Activity and Prevention of Cardiometabolic Diseases: Exercise is Medicine Andrew Valvalar Heart Disease: Exercise is Medicine Andrew Valvalar Heart Disease: Exercise is Medicine Andrew Valvalar Heart Disease: Exercise is Medicine Andrew Valvalar Heart Disease: Andre Regurgitation Service Andre Regurgitation Service Andre Regurgitation Andrew Valvalar Heart Disease: Andre Regurgitation Service Andre Regurgitation Nothing to Disclose Nothing to Disclose Physiologis John I Can Do WHAT After My Heart Attack? When Can I Travel and Go to Allitude? Nothing to Disclose Nothing to		Michinari		High Risk Stage B Heart Failure: A Distinct Hemodynamic Profile	Nothing to Disclose
Higgins Andrew Valvular Heart Disease: Exercise Is Medicine Arterial Coupling Eliology, Patient Characteristics and Surgical Outcomes of Acute Severe Andre Regunstation Eliology, Patient Characteristics and Surgical Outcomes of Acute Severe Andre Regunstation Severe Andre Regunstation Severe Andre Regunstation Severe Andre Regunstation Severe Andre Regunstation Severe Andre Regunstation Severe Andre Regunstation Severe Andre Regunstation Severe Andre Regunstation Severe Andre Regunstation Severe Andre Regunstation Severe Andre Regunstation Severe Andre Regunstation Severe Andre Regunstation Severe Regunstation Severe Regulation Severe			Failure		-
Severe Antic Regurgitation Severe Antic Regurgitation Severe Antic Regurgitation Nothing to Disclose Higgins John I Can Do WHAT After My Heart Attack? Panelist			Cardiometabolic Disease: Exercise Is Medicine	Arterial Coupling	-
Higgins John I Can Do WHAT After My Heart Attack? When Can I Travel and Go to Altitude? Nothing to Disclose Innovative Use of Echocardiography A Comparison of Two-Disconsinal Echocardiography Parameters (Nothing to Disclose Nothing to Disclose With Cardiac Magnetic Resonance Imaging in the Assessment of Right Ventricular Function Post Orthotopic Heart Transplantation (Part Transplantation Post Orthotopic Heart Transplantation Post Orthotopic Heart Transplantation (Cardiology: Intravascular Physiology and Endothelial Function Phy	Higgins	Andrew	Valvular Heart Disease: Aortic Regurgitation		Nothing to Disclose
Robin Innovative Use of Echocardiography A Comparison of Two-Dimensional Echocardiography Parameters With Cardiac Magnetic in the Assessment of Right Ventriousiar Function Post Ortholopic Heart Transplantation				Panelist	
With Cardiac Magnetic Resonance Imaging in the Assessment of Right Ventricular Function Post Orthologic Heart Transplantation					
Higuma Takumi Interventional Cardiology. Intravascular Physiology and Endothelial Function (Sarpiana State Physiology and Endothelial Function (Sarpiana State Physiology and Endothelial Function (Sarpiana State Physiology and Endothelial Function (Sarpiana State Physiology and Endothelial Function (Sarpiana State Physiology and Endothelial Function (Sarpiana State Physiology and Endothelial Function (Sarpiana State Physiology and Endothelial Function (Sarpiana State Physiology and Endothelial Function (Sarpiana State Physiology and Endothelial Function (Sarpiana State Physiology and Endothelial Function Physiology and Endothelial Function (Sarpiana State Physiology and Endothelial Function Physiology and Endothelial Function (Sarpiana State Physiology and Endothelial Function Physiology and Endothelial Function Physiology and Endothelial Function (Sarpiana State Physiology and Endothelial Function Physiology and Endothelial Physiology and Endothelial Physiology and Endothelial Physiology and Endothelial Physiology and Endothelial Physiology and Endothelial Physiology and Endothelial Physiology and Endothelial Physiology and Endothelial Physiology and Endothelial Physiology and Endothelial Physiology and Endothelial Physiology and Endothelial Physiology and Endothelial Physiology and Endothelial Physiology and Endothelial Physiology and Endo	9		aniorativo oco er Estissaralography	With Cardiac Magnetic Resonance Imaging in the Assessment of	The string to Discusse
Higuma Takumi Interventional Cardiology: Intravascular Physiology and Endothelial Function Recipital Pattern and Clinical Outcome After Drug-Eluting Stent Implantation: Comparison Between First Generation and Second Generation Drug-Eluting Stents Higuma Takumi The Inside View: Learning From Intracoronary Prevalence and Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A Four-Year Follow-Up Study Hijazi Ziad Stroke and AF: Thinking About the Heart Risk Stroke in Women and Men With Atrial Fibrillation and Only One Additional CHA2DS2-VASC Risk Factor One Additional CHA2DS2-VASC Risk Factor Stroke and Overview Interventional Cardiology: Taking and Pulmonic Valve Procedural and Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A Four-Year Follow-Up Study One Additional CHA2DS2-VASC Risk Factor Stroke Plaque Detected on Place Placement Case and Only One Additional CHA2DS2-VASC Risk Factor Stroke and AF: Thinking About the Heart Procedural Additional CHA2DS2-VASC Risk Factor Stroke Plaque Detected on Place Placement Case and Overview Interventional Additional CHA2DS2-VASC Risk Factor Stroke Placement Case and Overview Interventional Cardiology Taking Placement Case and Overview Interventional Cardiology: Taking Procedural and Clinical Outcomes in Transcatheter Acritic Valve Replacement Feet Placement F	Higuchi	Keiko	Advances in Lipid Management	Ezetimibe Real-World Effectiveness at Reaching Low-Density Lipoprotein Goal Among Patients With Atherosclerotic	SALARY - Sanofi-Aventis
Higuma Takumi The Inside View: Learning From Intracoronary Imaging Prevalence and Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A Four-Year Follow-Up Study Optical Coherence Tomography: A Four-Year Follow-Up Study Optical Coherence Tomography: A Four-Year Follow-Up Study Optical Coherence Tomography: A Four-Year Follow-Up Study Optical Coherence Tomography: A Four-Year Follow-Up Study Optical Coherence Tomography: A Four-Year Follow-Up Study Optical Coherence Tomography: A Four-Year Follow-Up Study Optical Coherence Tomography: A Four-Year Follow-Up Study One Additional CHAZDS2-VASC Risk Factor One One Additional CHAZDS2-VASC Risk Factor One One Additional CHAZDS2-VASC Risk Factor One One Additional CHAZDS2-VASC Risk Factor One One Additional CHAZDS2-VASC Risk Factor One One One One One One One One One One	Higuma	Takumi		Neointimal Pattern and Clinical Outcome After Drug-Eluting Stent Implantation: Comparison Between First Generation and Second	Nothing to Disclose
Imaging by Optical Coherence Tomography: A Four-Year Follow-Up Study	Higuma	Takumi	The Inside View: Learning From Intracoronary	Prevalence and Clinical Significance of Lipid-Rich Plaque Detected	Nothing to Disclose
One Additional CHA2DS2-VASC Risk Factor and MSD; OTHER - Bristol-Myers Squibbl/Pfizer and Boethringer Ingelhe Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelhe Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelhe Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelhe Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelhe Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelhe Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelhe Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelhe Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelhe Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethring Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethring Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer And Solon, Gore, MEDTRONIC, Occlutech, St. Jude, Terumo Index. Squibble Bristol-Myers Squibbl/Pfizer and Boethringer Ingelheim, Bristol-Myers Squibbl/Pfizer And Solon, Gore, MEDTRONIC, Occlutech, St. Jude, Terumo	Hijazi	Ziad			CONSULTANT FFFS/HONORARIA - Bristol-Myers Squibb/Pfizer
And Pulmonic Valve Inc., Occlutech, Venus Medtech; OWNERSHIP NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve CONSULTANT FEES/HONORARIA - Boston, Gore, MEDTRONIC, Occlutech, St Jude, Terumo NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve NTEREST/PARTNERSHIP/PRINCIPAL - Colibri Heart Valve CONSULTANT FEES/HONORARIA - Boston, Gore, MEDTRONIC, Occlutech, St Jude, Terumo NTEREST/PARTNERSHIP/PRINCIPAL - CONSULTANT FEES/HONORARIA - Boston, Gore, MEDTRONIC, Occlutech, St Jude, Terumo NTEREST/PARTNERSHIP/PRINCIPAL - CONSULTANT FEES/HONORARIA - Boston, Gore, MEDTRONIC, Occlutech, St Jude, Terumo NTEREST/PARTNERSHIP/PRINCIPAL - CONSULTANT FEES/HONORARIA - Boston, Gore, MEDTRONIC, Occlutech, St Jude, Terumo NTEREST/PARTNERSHIP/PRINCIPAL - CONSULTANT FEES/HONORARIA - Boston, Gore, MEDTRONIC, Occlutech, St Jude, Terumo NTEREST/PARTNERSHIP/PRINCIPAL - CONSULTANT FEES/HONORARIA - Boston, Gore, MEDTRONIC, Occlutech, St Jude, Terumo NTEREST/PARTNERSHIP/PRINCIPAL - CONSULTANT FEES/HONORARIA - Boston, Gore, MEDTRONIC, Occlutech, St Jude, Terumo	1.1,02.1		out of the state o		and MSD; OTHER - Bristol-Myers Squibb/Pfizer and Boehringer Ingelheim,Bristol-Myers Squibb/Pfizer and Boehringer Ingelheim
Hildick-Smith David Featured Clinical Research II: Interventional Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis Hildick-Smith David Interventional Cardiology: TAVR 3 Does Balloon Predilatation Influence Outcome With the Lotus Valve: Boston, Gore, MEDTRONIC, Occlutech, St Jude, Terumo Hildick-Smith David Interventional Cardiology: PCI in Complex Patients Patient	Hijazi	Ziyad		Sapien Transcatheter PV Replacement: Case and Overview	Inc.,Occlutech,Venus Medtech; OWNERSHIP
Hildick-Smith David Interventional Cardiology: TAVR 3 Does Balloon Predilatation Influence Outcome With the Lotus Valve: 30-Day Results From the RESPOND Study Hildick-Smith David Interventional Cardiology: PCI in Complex Patients Patients Patients Patients Patients Patients Patients Patients Patients Patients Patients Patients Patients Patients Pollowing Transcatheter Aortic Valve Replacement: Results From the Bravo-3 Randomized Trial Boston, Gore, MEDTRONIC, Occlutech, St. Jude, Terumo From the Bravo-3 Randomized Trial Patients	Hildick-Smith	David	Featured Clinical Research II: Interventional		CONSULTANT FEES/HONORARIA -
Hildick-Smith David Interventional Cardiology: PCI in Complex Patients Patients Patients Patients Patients Patients Patients Patients Patients Pollowing Transcatheter Acritic Valve Replacement: Results Boston, Gore, MEDTRONIC, Occlutech, St Jude, Terumo From the Bravo-3 Randomized Trial Suggested Reviewer Suggested Reviewer Boston, Gore, MEDTRONIC, Occlutech, St Jude, Terumo Patients Pat	Hildick-Smith	David	Interventional Cardiology: TAVR 3	Does Balloon Predilatation Influence Outcome With the Lotus Valve:	CONSULTANT FEES/HONORARIA -
From the Bravo-3 Randomized Trial	Hildick-Smith	David		Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated	CONSULTANT FEES/HONORARIA -
Team 1 Michael Interventional Cardiology: TAVR 3 Multicenter Evaluation of the ACURATE Neo Transfemoral Transcatheter Heart Valve: Clinical Results and Propensity Matched Comparison With SAPIEN 3 Multicenter Evaluation of Prosthesis Oversizing for the SAPIEN 3 Transcatheter Heart Valve: Impact on New Pacemaker Implantations Multicenter Evaluation of Prosthesis Oversizing for the SAPIEN 3 Nothing to Disclose Transcatheter Heart Valve: Impact on New Pacemaker Implantations Multicenter Evaluation of Prosthesis Oversizing for the SAPIEN 3 Nothing to Disclose Transcatheter Heart Valve: Impact on New Pacemaker Multicenter Evaluation of Prosthesis Oversizing for the SAPIEN 3 Nothing to Disclose Transcatheter Heart Valve: Impact on New Pacemaker Multicenter Evaluation of the ACURATE Neo Transfermoral Nothing to Disclose Transcatheter Heart Valve: Impact on New Pacemaker Nothing to Disclose Transcatheter Heart Valve: Impact on New Pacemaker Nothing to Disclose Transcatheter Heart Valve: Impact on New Pacemaker Nothing to Disclose Nothing to Disclose Transcatheter Heart Valve: Impact on New Pacemaker Nothing to Disclose Transcatheter Heart Valve: Impact on New Pacemaker Nothing to Disclose	Hildick-Smith	David	22. Interventional Cardiology: Coronary	From the Bravo-3 Randomized Trial	CONSULTANT FEES/HONORARIA -
Transcatheter Heart Valve: Clinical Results and Propensity Matched Comparison With SAPIEN 3 Hilker Michael Interventional Cardiology: TAVR 4 Multicenter Evaluation of Prosthesis Oversizing for the SAPIEN 3 Transcatheter Heart Valve: Impact on New Pacemaker Implantations	Hilker	Michael	Team 1	Multicenter Evaluation of the ACURATE Neo Transfemoral	
Transcatheter Heart Valve: Impact on New Pacemaker Implantations				Transcatheter Heart Valve: Clinical Results and Propensity Matched Comparison With SAPIEN 3	
UTILI IAUISON I IEDZINIATORY ARTINVINIMIAS: OUTCOMES VVITN ICONTEMPORARY CAUSES and Outcomes of Out of Hospital Ventricular INothing to Disclose			-	Transcatheter Heart Valve: Impact on New Pacemaker Implantations	-
Contemporary Practice Fibrillation in Pediatric Patients			Contemporary Practice	Fibrillation in Pediatric Patients	-
Hill Garick Five Controversies in Single Ventricle Co-Chair Nothing to Disclose	Hill	Garick		Co-Chair	Nothing to Disclose





Contract of the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Hill	Garick	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Re-Intervention During the Interstage Period: A Report From the National Pediatric Cardiology Quality Improvement Collaborative	Nothing to Disclose
Hill	Joseph	Featured Clinical Research III	Panelist	Nothing to Disclose
Hill	Joseph	Heart Failure: From Pathophysiology to Socio- Economic Impact: International Perspectives From the Lebanese Cardiac Society, Taiwan Society of Cardiology, and American College of Cardiology	Heart Failure: The Path Ahead	Nothing to Disclose
Hill	Joseph	ACC Research Awards	Moderator	Nothing to Disclose
Hill	Joseph	12. Heart Failure and Cardiomyopathies: Basic Team 2	Suggested Reviewer	Nothing to Disclose
Hill	Kevin	Engage @ ACC.17 Studio:The Newlywed Game for Pediatric Cardiac Providers	Participant, Team 4	CONSULTANT FEES/HONORARIA - Kowa Pharmaceuticals,MyoKardia; RESEARCH/RESEARCH GRANTS gilead
Hill	Kevin	Therapeutic Advances in Congenital Heart Disease	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Kowa Pharmaceuticals,MyoKardia; RESEARCH/RESEARCH GRANTS gilead
Hill	Terence	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Veno-Arterial ECMO Program for Refractory Cardiogenic Shock in the Cardiac Intensive Care Unit: Feasibility and Outcome Data at a Large Tertiary Academic Center	Nothing to Disclose
Hilliard	Anthony	Test Yourself with Questions: Guidelines Module 4: Stable Ischemic Heart Disease	Faculty	SPEAKER'S BUREAU - Abiomed
Hilliard	Anthony	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Glycemic Control in Insulin and Non-Insulin Dependent Diabetic Patients With ST Elevation Myocardial Infarction Predicts Time to Presentation	SPEAKER'S BUREAU - Abiomed
Hilliard	Anthony	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Ischemic Time and Risk Factors Associated With the Incidence of Cardiogenic Shock in Patients Presenting With ST Elevation Myocardial Infarction	SPEAKER'S BUREAU - Abiomed
Hilliard	Anthony	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Impact of Demographics and Socioeconomic Status on Mode of Transportation and Time to Presentation in Patients With ST Elevation Myocardial Infarction	SPEAKER'S BUREAU - Abiomed
Hilliard	Anthony	Interventional Cardiology: TAVR 2	Impact of the Presence of Coronary Artery Disease and Timing of Revascularization on Outcomes of Patients Undergoing Trans- Catheter Aortic Valve Replacement: Insights From STS/ACC TVT	SPEAKER'S BUREAU - Abiomed
Hilliard	Anthony	FIT Clinical Decision Making: Acute Coronary Syndrome and Vascular Medicine	Registry ACC Poster Moderator	SPEAKER'S BUREAU - Abiomed
Hilliard	Anthony	O2. Acute and Stable Ischemic Heart Disease: Clinical Team 8	Suggested Reviewer	SPEAKER'S BUREAU - Abiomed
Hinch	Barbara	Interdisciplinary Cardiovascular Team Collaboratives in Care	An Interdisciplinary Approach to a Successful Transition Home: Heart Failure Transitions Program	Nothing to Disclose
Hindricks	Gerhard	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Cardiac Magnetic Resonance Imaging After Radiofrequency Ablation of Ventricular Arrhythmias in Human Patients: Defining the Substrate and Visualizing the Outcome	Nothing to Disclose
Hindricks	Gerhard		Isolated Cardiac Sarcoidosis Mimicking Hypertrophic	Nothing to Disclose
Hindricks	Gerhard	Pulmonary Hypertension Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Cardiomyopathy Risk Assessment of Recurrent Atrial Fibrillation After Antiarrhythmic Medication or Catheter Ablation: The Impact of Age and	Nothing to Disclose
Hines	Dionne	Advances in Lipid Management	Supraventricular Ectopic Complexes Persistence and Adherence With Proprotein Convertase	Nothing to Disclose
Hira	Ravi	Innovations in Advocacy and Patient Centered Care	Subtilisin/Kexin Type 9 Inhibitors in Clinical Practice Status of Early Career Academic Cardiology: A Global Perspective	SPEAKER'S BUREAU - Abiomed
Hiramori	Seiichi	Unusual Presentations of ACS	The Impact of Residual Syntax Score in ACS Patients With LV	Nothing to Disclose
Hirayama	Atsushi	Disease, Prévention and Treatment: International Perspectives From the Japanese College of Cardiology, Saudi Heart Association, and American College of Cardiology	Dysfunction Co-Chair	CONSULTANT FEES/HONORARIA - To-a eiyo Co.; SPEAKER'S BUREAU - Astellas Pharma Japan AstraZeneca Pharmaceuticals Bayer Heatlbracer Pharmaceuticals Boehringer Ingelheim Pharmaceuticals, Inc,Chugai Pharma ,Daiichi Sankyo,Dainipponsumitomo C 35., Ezai Co.,GE Health Care Japan,Kissei Co.,Kowa Co. Ltd.,MSD,Ono Pharma. Co. Ltd.,Otsuka Pharmaceutical Co.,Sanofi-Aventis,Sanwa Kagaku Kennkyusho Co.,Shionogi Pharma, Inc,Takeda Pharmaceuticals, Inc,Tanabe Mitsubishi Pharma
Hirayama	Atsushi	Cutting Edge Innovations in Cardiovascular Imaging: Joint Symposium of the Japanese Circulation Society and American College of Cardiology	Co-Chair	CONSULTANT FEES/HONORARIA - To-a eiyo Co.; SPEAKER S BUREAU - Astellas Pharma Japan,AstraZeneca Pharmaceuticals,Bayer Healthcare Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,Chugai Pharma, Dailichi Sankyo,Dainipponsumitomo Cås., Ezai Co.,GE Health Care Japan,Kissei Co.,Kowa Co. Ltd.,MSD,Ono Pharma. Co. Ltd.,Otsuka Pharmaceutical Co.,Sanofi-Aventis,Sanwa Kagaku Kennkyusho Co.,Shionogi Pharma, Inc,Takeda Pharmaceuticals, Inc,Tanabe Mitsubishi Pharma
Hirayama	Atsushi	Cutting Edge Innovations in Cardiovascular Imaging: Joint Symposium of the Japanese Circulation Society and American College of Cardiology	State of the Art Non-Obstructive Angioscopy	CONSULTANT FEES/HONORARIA - To-a eiyo Co.; SPEAKER'S BUREAU - Asteilas Pharma Japan, AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, Chugai Pharma, Daiichi Sankyo, Dainipponsumitomo C & "Ezai Co., GE Health Care Japan, Kissei Co., Kowa Co. Ltd., MSD, Ono Pharma. Co. Ltd., Otsuka Pharmaceutical Co., Sanofi-Aventis, Sanwa Kagaku Kennkyusho Co., Shionogi Pharma, Inc, Takeda Pharmaceuticals, Inc, Tanabe Mitsubishi Pharma
Hirayama	Atsushi	Nuclear Cardiology: Coronary Flow	Diagnostic Performance of Hybrid Assessment With Stress Only Myocardial Perfusion Single Photon Emission Computed Tomography Using Semiconductor Gamma Camera and Rest Myocardial Scar Findings Obtained From 320 Detector Row Computed Tomography	CONSULTANT FEES/HONORARIA - To-a eiyo Co.; SPEAKER'S BUREAU - Astellas Pharma Japan, Astrazeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, Chugai Pharma, Daiichi Sankyo, Danipponosumitomo C3a, "Ezai Co., GE Health Care Japan, Kissei Co., Kowa Co. Ltd., MSD, Ono Pharma. Co. Ltd., Otsuka Pharmaceutical Co., Sanofi-Aventis, Sanwa Kagaku Kennkyusho Co., Shionogi Pharma, Inc, Takeda Pharmaceuticals, Inc, Tanabe Mitsubishi Pharma
Hiremath	Murugesh Shantaveeraya	STEMI in the Emerging World: International Perspectives From the Cardiological Society of India, Mexican Society of Cardiology, and American College of Cardiology	Pharmaco Invasive Therapy in STEMI: Indian Experience	Nothing to Disclose
Hiro	Takafumi	Diabetes, Hyperlipidemia, and Coronary Artery Disease, Prevention and Treatment: International Perspectives From the Japanese College of Cardiology, Saudi Heart Association, and American College of Cardiology	Should the Strategy for Secondary Prevention of Coronary Artery Disease be Different in Diabetic Patients?: Lessons From Studies With Intravascular Imaging Modalities	CONSULTANT FEES/HONORARIA - Bayer Yakuhin, Ltd,Amgen Astellas BioPharma K.K,Astellas Pharma inc.,Kowa Co, Ltd,Kyowa Hakko Kini Co, Ltd.,Novaris Pharma K.K.,Sanofi K.K.,Sumitomo Dainippon Pharma Co., Ltd.; OTHER - Boston Scientific Co.



				I
Last Name	First Name	Session Title Cutting Edge Innovations in Cardiovascular	Presentation Title Future Technology of Intravascular Ultrasound and Optical Imaging	Disclosures CONSULTANT FEES/HONORARIA - Bayer Yakuhin,
Hiro	Takafumi	Imaging: Joint Symposium of the Japanese	Future Technology of Intravascular Oltrasound and Optical Imaging	Ltd,Amgen Astellas BioPharma K.K,Astellas Pharma Inc.,Kowa
		Circulation Society and American College of		Co, Ltd, Kyowa Hakko Kirin Co., Ltd., Novartis Pharma K.K., Sanofi
		Cardiology		K.K.,Sumitomo Dainippon Pharma Co., Ltd.; OTHER - Boston
Hiromasa	Takashi	Coronary Intervention in Interventional	Incidence and Clinical Impact of Longitudinal Stent Deformation	Scientific Co. Nothing to Disclose
Пігоппава	Idrasiii	Cardiology: Core Concepts	After the PROMUS Element Platinum Chromium-Everolimus Eluting	Nothing to Disclose
			Stent Implantation	
Hiromasa	Takashi	Interventional Cardiology: PCI in Complex	Three-Year Clinical Outcomes of the XIENCE/PROMUS Cobalt-	Nothing to Disclose
		Patients	Chromium Everolimus-Eluting Stent in Patients Treated With In- Stent Restenosis	
Hiroshi Miname	Marcio	FIT Clinical Decision Making: Prevention, Adult	Statin-Induced Hepatitis in a Secondary Prevention Patient With	Nothing to Disclose
		Congenital and Congenital Heart Disease	Severe Hypercholesterolemia	· · · · · · · · · · · · · · · · · · ·
Hirsch	Alex	Maximally Effective Vascular Care: Vascular	Case Presentation #2: Panel Discussion Moderator	CONSULTANT FEES/HONORARIA - Aralez, Astra Zeneca
HIISCH	Alan	Collaborative Team Care in Action	Case Presentation #2. Parier Discussion Moderator	Pharmaceuticals, Merck; OFFICER, DIRECTOR, TRUSTEE, OR
				OTHER FIDUCIARY ROLE - Tactile Medical;
				RESEARCH/RESEARCH GRANTS - Bayer Healthcare
Hirsch	Alan	Cardiac Rehab in 2017: Tailoring The	Going the Extra Mile: PAD Rehab	Pharmaceuticals, Pluristem CONSULTANT FEES/HONORARIA - Aralez, AstraZeneca
		Approach to the Times	9	Pharmaceuticals, Merck; OFFICER, DIRECTOR, TRUSTEE, OR
				OTHER FIDUCIARY ROLE - Tactile Medical;
				RESEARCH/RESEARCH GRANTS - Bayer Healthcare Pharmaceuticals,Pluristem
Hirsch	Alan	Clinical Assessment and Revascularization for	ACC Talk: Collaboration Among Specialists to Optimize Care of CLI	CONSULTANT FEES/HONORARIA - Aralez, Astra Zeneca
		Critical Limb Ischemia	Patients	Pharmaceuticals, Merck; OFFICER, DIRECTOR, TRUSTEE, OR
				OTHER FIDUCIARY ROLE - Tactile Medical; RESEARCH/RESEARCH GRANTS - Bayer Healthcare
				Pharmaceuticals, Pluristem
Hirsch	Alan	Born To Run: Geographic Variation in PAD	Provider PAD Resources: How Your State Can Help Disseminate	CONSULTANT FEES/HONORARIA - Aralez, Astra Zeneca
		Diagnosis, Treatment and Outcomes	the LE PAD Guidelines	Pharmaceuticals, Merck; OFFICER, DIRECTOR, TRUSTEE, OR
				OTHER FIDUCIARY ROLE - Tactile Medical; RESEARCH/RESEARCH GRANTS - Baver Healthcare
	<u> </u>			Pharmaceuticals, Pluristem
Hirsch	Alan	Improving Risk Assessment in Atherosclerosis	Development and Validation of Prediction Models With Non-	CONSULTANT FEES/HONORARIA - Aralez, AstraZeneca
			Traditional Markers for 10-Year Risk of Ischemic Leg Amputation Among Persons With Diabetes: The Atherosclerosis Risk In	Pharmaceuticals,Merck; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Tactile Medical:
			Communities (ARIC) Study	RESEARCH/RESEARCH GRANTS - Bayer Healthcare
			, ,	Pharmaceuticals, Pluristem
Hirsch	Alan	40. Vascular Medicine: Non Coronary Arterial Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Aralez, AstraZeneca Pharmaceuticals, Merck; OFFICER, DIRECTOR, TRUSTEE, OR
		Disease Team 1		OTHER FIDUCIARY ROLE - Tactile Medical;
				RESEARCH/RESEARCH GRANTS - Bayer Healthcare
	0.			Pharmaceuticals, Pluristem
Hirsch	Glenn	Effective Medication Management in the Older Adults with CVD: Pharmacology Program I	Co-Chair	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - TraveDoc
		Addits with CVD. Friamacology Frogram i		TTAVEDOC
Hirsch	Glenn	When Anticoagulation Needs to be Stopped	Co-Chair	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Hirsch	Clonn	What Are the Options? Pharmacology II PPIs in the Era of Prolonged DAPT Should	Co-Chair	TraveDoc OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
HISCH	Glenn	We or Shouldn't We?: Pharmacology III	CO-Citali	TraveDoc
Hirsch	Glenn	Test Yourself with Questions: Guidelines	Faculty	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
		Module 4: Stable Ischemic Heart Disease		TraveDoc
Hirshfeld	John	Interventional Cardiology: Complex Patients/Comorbidities Team 1	Suggested Reviewer	DATA SAFETY MONITORING BOARD - PLC Medical Systems RenalGard Trial
Но	Kalon	Assuring Quality in the Cath Lab:	Appropriate Use: Assuring the Physicians Best Judgement Prevails	OTHER - Apple,Google
		Documentation, Appropriate Use, Peer		
Но	Kheng-Thye	Review, and Public Reporting 27. Non Invasive Imaging: CT/Multimodality,	Suggested Reviewer	SPEAKER'S BUREAU - Siemens Healthcare
110	Kilelig-Tilye	Angiography, and Non-CT Angiography Team	Suggested Neviewel	SELANCINO DONCAO - Siemens rieditricare
		2		
Ho Ho	P. Michael Reginald	33. Prevention: Hypertension Team 2 FIT Clinical Decision Making: Arrhythmias and	Suggested Reviewer Flecainide and Traumatic Syncope: Don't Forget It	OTHER - Janssen Pharmaceuticals, Inc,Telligen CONSULTANT FEES/HONORARIA - MEDTRONIC,St. Jude;
110	rteginalu	Electrophysiology	r lecalifide and Tradifiatic Syncope. Don't Forget it	RESEARCH/RESEARCH GRANTS - MEDTRONIC,St. Jude
Hobson	Steven	Arrhythmias and Clinical EP: Devices 3	Epicardial Lead Migration to the Spine With Development of	Nothing to Disclose
Hochadel	Mathias	Hand Falling and Condings on others. Hand	Vertebral Abscess	Nothing to Disclose
nochadel	ividifilds	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Representativeness of the Paradigm Heart Failure Population in Real Life	Nothing to disclose
Hochman	Judith	FIT Forum: Mix and Mingle	Clinical Research	RESEARCH/RESEARCH GRANTS - Astra Zeneca
H. d	1 .20	Late Banding Office of Trials Band Birds	0.000	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca
Hochman	Judith	Late-Breaking Clinical Trials: Deep Dive I	Co-Chair	RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals
Hochman	Judith	Late-Breaking Clinical Trials: Deep Dive II	Co-Chair	RESEARCH/RESEARCH GRANTS - Astra Zeneca
		-		Pharmaceuticals
Hochman				
i	Judith	What is the PROMISE of ISCHEMIA: A 2017	Post-Debate Poll	RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals
	Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young	Posi-Debate Poli	RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals
		Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture		Pharmaceuticals
Hochman	Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017	Co-Chair	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca
Hochman		Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture		Pharmaceuticals
	Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture	Co-Chair	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals
Hochman		Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017		Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca
	Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P.	Co-Chair	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals
Hochman	Judith Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture	Co-Chair Pre-Debate Poll	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals
	Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017	Co-Chair	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca
Hochman	Judith Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Vipdate on Stable Angina and the Douglas P.	Co-Chair Pre-Debate Poll	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals
Hochman	Judith Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017	Co-Chair Pre-Debate Poll	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca
Hochman	Judith Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017	Co-Chair Pre-Debate Poll	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca
Hochman	Judith Judith Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Scientist Awardee Lecture	Co-Chair Pre-Debate Poll Pre-Debate Poll	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals
Hochman	Judith Judith Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Zipes, MD, MACC, Distinguished Young	Co-Chair Pre-Debate Poll Pre-Debate Poll	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca
Hochman Hochman	Judith Judith Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Scientist Awardee Lecture	Co-Chair Pre-Debate Poll Pre-Debate Poll	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals
Hochman Hochman Hochman	Judith Judith Judith Judith Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture Great Debates in Ischemia 2017	Co-Chair Pre-Debate Poll Pre-Debate Poll Post- Debate Poll Co-Chair	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals
Hochman Hochman	Judith Judith Judith Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture	Co-Chair Pre-Debate Poll Pre-Debate Poll Post- Debate Poll Co-Chair Direct Home Discharge and Likelihood of 30-Day Hospital	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals
Hochman Hochman Hochman	Judith Judith Judith Judith Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture Great Debates in Ischemia 2017	Co-Chair Pre-Debate Poll Pre-Debate Poll Post- Debate Poll Co-Chair Direct Home Discharge and Likelihood of 30-Day Hospital Readmission After Transcatheter Aortic Valve Replacement (TAVR): Findings From the STS/ACC TVTR Registry	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals
Hochman Hochman Hochman	Judith Judith Judith Judith Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture Great Debates in Ischemia 2017 Interventional Cardiology: TAVR 2 Interventional Cardiology: Structural Heart	Co-Chair Pre-Debate Poll Pre-Debate Poll Post- Debate Poll Co-Chair Direct Home Discharge and Likelihood of 30-Day Hospital Readmission After Transcatheter Aortic Valve Replacement (TAVR): Findings From the STS/ACC TVT Registry Safety and Feasibility of Rotational Atherectomy in Elderly Patients	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals
Hochman Hochman Hochman Hochman	Judith Judith Judith Judith Judith Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture Great Debates in Ischemia 2017 Interventional Cardiology: TAVR 2	Co-Chair Pre-Debate Poll Pre-Debate Poll Post- Debate Poll Post- Debate Poll Co-Chair Direct Home Discharge and Likelihood of 30-Day Hospital Readmission After Transcatheter Aortic Valve Replacement (TAVR): Findings From the STS/ACC TVT Registry Safety and Feasibility of Rotational Atherectomy in Elderly Patients With Severe Aortic Stenosis and Caloffic Coronary Artery Disease	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals
Hochman Hochman Hochman Hochman	Judith Judith Judith Judith Judith Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture Great Debates in Ischemia 2017 Interventional Cardiology: TAVR 2 Interventional Cardiology: Structural Heart	Co-Chair Pre-Debate Poll Pre-Debate Poll Post- Debate Poll Co-Chair Direct Home Discharge and Likelihood of 30-Day Hospital Readmission After Transcatheter Aortic Valve Replacement (TAVR): Findings From the STS/ACC TVT Registry Safety and Feasibility of Rotational Atherectomy in Elderly Patients	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals
Hochman Hochman Hochman Hochman	Judith Judith Judith Judith Judith Judith	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture Great Debates in Ischemia 2017 Interventional Cardiology: TAVR 2 Interventional Cardiology: Structural Heart Disease Interventional Cardiology: PCI in Complex	Co-Chair Pre-Debate Poll Pre-Debate Poll Post- Debate Poll Co-Chair Direct Home Discharge and Likelihood of 30-Day Hospital Readmission After Transcatheter Aortic Valve Replacement (TAVR): Findings From the STS/ACC TVT Registry Safety and Feasibility of Rotational Atherectomy in Elderly Patients With Severe Aortic Staves and Calcific Coronary Artery Disease Undergoing Evaluation for Transcatheter Aortic Valve Replacement Clinical Presentation, Natural History and Management of Coronary	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals
Hochman Hochman Hochman Hochman Hochman	Judith Judith Judith Judith Judith Judith Eric	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture Great Debates in Ischemia 2017 Interventional Cardiology: TAVR 2 Interventional Cardiology: Structural Heart Disease	Co-Chair Pre-Debate Poll Pre-Debate Poll Post- Debate Poll Co-Chair Direct Home Discharge and Likelihood of 30-Day Hospital Readmission After Transcatheter Aortic Valve Replacement (TAVR): Findings From the STS/ACC TVT Registry Safety and Feasibility of Rotational Atherectomy in Elderly Patients With Severe Aortic Stenosis and Calcific Coronary Artery Disease Undergoing Evaluation for Transcatheter Aortic Valve Replacement	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals RESEARCH/RESEARCH GRANTS - Astra Zeneca Pharmaceuticals Nothing to Disclose

Contract of the Contract of th				
Last Name Hodge	First Name David	Session Title Tricuspid Regurgitation: Signals in Plain Sight	Presentation Title Isolated Functional Tricuspid Regurgitation: A Population in Need of	Disclosures Nothing to Disclose
Hodson	Robert	Refining TAVR Outcomes	Treatment Concentric Left Ventricular Remodeling Is Associated With Low-	Nothing to Disclose
		-	Flow Severe Aortic Stenosis and Less Reverse Remodeling After TAVR: A Partner 2 Trial Analysis	Ç
Hoff	Jason	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	An Unusual Case of Far-Field P-Wave Oversensing Leading to Ventricular Overpacing and Undersensing of Sustained Ventricular Tachycardia	Nothing to Disclose
Hoff	Jason	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Radial Artery Occlusion Recanalization Prior to Coronary Angiography	Nothing to Disclose
Hofferberth	Sophie	Predicting Outcomes in Pediatric Heart Disase	Risk Stratification of Children Undergoing Valve-Sparing Repair of Tetralogy of Fallot	Nothing to Disclose
Hoffmann	Udo	Highlighted Original Research: Non Invasive Imaging and the Year in Review	The Association of High Risk Plaque Features and Non-Invasive Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography in Patients With Acute Chest Pain: Results From the ROMICAT II Trial	Nothing to Disclose
Hoffmann	Udo	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Outcomes in Patients With Diabetes Mellitus and Suspected Coronary Artery Disease Following Non-Invasive Testing: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	Nothing to Disclose
Hoffmann	Udo	Innovations in Cardiovascular Risk Assessment and Reduction	Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African Americans: The Jackson Heart Study	Nothing to Disclose
Hoffmann	Udo	New Perspectives on CAD Risk Factors	Discordances Between Predicted and Actual Risk of Adverse Events in Obese Patients With Suspected Cardiac Ischemia: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for	Nothing to Disclose
Hoffmayer	Kurt	Arrhythmias and Clinical EP: Devices 3	Evaluation of Chest Pain) Outcomes Following Implant of Semi-Permanent Pacemaker Versus Temporary Pacemaker	Nothing to Disclose
Hogue	Carol	Redefining the "F" Word	Adults With Congenital Heart Disease: Lost in Care	Nothing to Disclose
Hogue	Carol	Congenital Heart Disease: To the Third Decade and Beyond	Prevalence and Incidence of Heart Failure in Adolescents and Adults With Repaired Tetralogy of Fallot	Nothing to Disclose
Hohnloser	Stefan	Late-Breaking Clinical Trials	Safety and Efficacy of Uninterrupted Anticoagulation With Dabigatran Etexilate Versus Warfarin in Patients Undergoing Catheter Ablation of Atrial Fibrillation: The RE-CIRCUIT Study	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,Bristol Meyers Suibb, gilead,J&J,Medtronik,Pfizer,servier,St Jude Medical
Hohnloser	Stefan	Controversies in Arrhythmia Management: Joint Symposium of the Heart Rhythm Society and the American College of Cardiology	Should Anticoagulation be Started for Atrial Fibrillation Detected in Pacemaker Data Logs?	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,Bristol Meyers Suibb, gilead,J&J,Medtronik,Pfizer,servier,St Jude Medical
Hohnloser	Stefan	Arrhythmias and Clinical EP: Anticoagulation Issues	Use of Interacting Drugs Did Not Modify Treatment Effects of Apixaban Versus Warfarin for Atrial Fibrillation: Results From the ARISTOTLE Trial	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,Bristol Meyers Subb,gilead,J&J,Medtronik,Pfizer,servier,St Jude Medical
Hoit	Brian	28. Non Invasive Imaging: Echo Team 2	Suggested Reviewer	SPEAKER'S BUREAU - Philips
Hokama	Yohei	Unusual Presentations of ACS	Association Between Presentation Time and Short-Term Mortality in Patients With Cardiogenic Shock Complicating Acute Coronary Syndrome: From Jcs Shock Registry	Nothing to Disclose
Hokanson	John	Imaging With Cardiac CT: The Case for Calcium	Coronary Artery Calcium on Noncontrast Thoracic CT Scans and All- Cause Mortality: The Copd Gene Cohort	-
Hollenberg	Steven	Evolution of Critical Care Cardiology and the CICU	Morphogenesis and Morphology of the CICU	Nothing to Disclose
Hollowed	John	Novel Imaging and Therapies in Heart Failure	Rethinking the Role of Coronary Angiography in the Evaluation of Heart Failure With Reduced Ejection Fraction in Young Patients	Nothing to Disclose
Holm	Niels	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Risk Stratification of Patients Suspected of Coronary Artery Disease Using an Acoustic Detection Algorithm	RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Biosensors, Biotronik, Boston Scientific, Cordis, Elibir, Medis medical imaging, MEDTRONIC, REVA Medical, St. Jude Medical, St. Jude Medical, Vingmed Denmark; SPEAKER'S BUREAU - St. Jude Medical, Terumo
Holman	Rury	and Reduction	Are the Cardiovascular Risk Reductions Seen With Empagliflozin in the EMPA-REG OUTCOME Trial Explained by Conventional Cardiovascular Risk Factors?	CONSULTANT FEES/HONORARIA - Bayer, Eleclyx, Intarcia, Merck & amp; Co., Inc., Novartis, Novo Nordisk Inc.; DATA SAFETY MONITORING BOARD - GlaxoSmithKline, Janssen Pharmaceuticals, Inc, Takeda; RESEARCH/RESEARCH GRANTS - Bayer Healthcare Pharmaceuticals, Merck & amp; Co., Inc.
Holmes	Benjamin	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Underutilization of Statin Therapy Among Participants in a Lung Cancer Screening Program With a High Incidence of Cardiovascular Events	Nothing to Disclose
Holmes	Benjamin	Electrophysiology	Drug Induced QT Prolongation With Arsenic Trioxide in the Treatment of Acute Promyelocytic Leukemia	Nothing to Disclose
Holmes	David	Featured Clinical Research II: Interventional	Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data	OTHER - Technology licensed from Mayo Clinic to Boston Scientific.
Holmes	David	Featured Clinical Research II: Interventional	Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis From the STS/ACC TVT Registry	OTHER - Technology licensed from Mayo Clinic to Boston Scientific.
Holmes	David	Featured Clinical Research II: Interventional	Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Valve Repair in the United States	OTHER - Technology licensed from Mayo Clinic to Boston Scientific.
Holmes	David	Late-Breaking Clinical Trials	Comparative Effectiveness of Left Atrial Appendage Occlusion Among Atrial Fibrillation Patients Undergoing Cardiac Surgery: A Report From the Society of Thoracic Surgeons Adult Cardiac Surgery Database	OTHER - Technology licensed from Mayo Clinic to Boston Scientific.
Holmes	David	Variations in Management of STEMI: International Perspectives From the Egyptian Society of Cardiology, Pakistan Cardiac Society, and American College of Cardiology	Co-Chair	OTHER - Technology licensed from Mayo Clinic to Boston Scientific.
Holmes	David	Variations in Management of STEMI: International Perspectives From the Egyptian Society of Cardiology, Pakistan Cardiac Society, and American College of Cardiology	introduction to Session	OTHER - Technology licensed from Mayo Clinic to Boston Scientific.
Holmes	David	Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologists and the American College of Cardiology	Representation of Minorities in Clinical Trials and Registries in Structural Heart Disease	OTHER - Technology licensed from Mayo Clinic to Boston Scientific.
Holmes	David	Training for Interventional Procedures: Who Should Do What, Where, When, How, and Why	Co-Chair	OTHER - Technology licensed from Mayo Clinic to Boston Scientific.
Holmes	David	Post FDA Release Prosthetic Valve	Panelist	OTHER - Technology licensed from Mayo Clinic to Boston
Holmes	David	Surveillance - Watching for Signals Highlighted Original Research: Interventional Cardiology and the Year in Review	New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: Incidence, Anticoagulant Strategy, and Outcomes	Scientific. OTHER - Technology licensed from Mayo Clinic to Boston Scientific.
L	1	Loar alorogy and the Teat III IVENEW	proprocessions, moreonos, Anticoaguiant ou diegy, and Outcomes	coloriumb.

				l
Holmes	First Name David	Session Title Valvular Heart Disease: Endocarditis	Presentation Title Infective Endocarditis Following Transcutaneous Aortic Valve	OTHER - Technology licensed from Mayo Clinic to Boston
			Implantation: Clinical, Echocardiographic and Hemodynamic Features	Scientific.
Holmes	David	Engage @ ACC.17 Studio: Cardiology Contest	Cardiology Contestant	OTHER - Technology licensed from Mayo Clinic to Boston Scientific.
Holmes	David	Peripheral Arterial Disease, Risk, and Outcomes	Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes: A Report From the STS/TVT Registry	OTHER - Technology licensed from Mayo Clinic to Boston Scientific.
Holmes	David	19. Interventional Cardiology: Complex Patients/Comorbidities Team 1	Suggested Reviewer	OTHER - Technology licensed from Mayo Clinic to Boston Scientific.
Holmes	Holly	Effective Medication Management in the Older Adults with CVD: Pharmacology Program I	Panelist	Nothing to Disclose
Holmes	Sari	Changing the Natural History of Valve Disease With Medical Therapy	Association of Blood Glucose and Hemoglobin A1C Level With Surgical Outcomes: Should Glycemic Control Be Modified?	Nothing to Disclose
Holmes	Sari	The Challenges of Outcome Prediction in Valvular Heart Disease	How Well Does the STS Risk Score Predict Late Survival After Cardiac Surgery?	Nothing to Disclose
Holmvang	Lene	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Association Between QRS Duration on Prehospital Electrocardiogram and Early Outcome in Patients With ST Segment	RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals
Holmvang	Lene	Syndrome Post-CAD/MI: Making Tough Predictions About	Elevation Myocardial Infarction Midregional Proadrenomedullin: A Prognostic Marker of Mortality	RESEARCH/RESEARCH GRANTS - AstraZeneca
_		the Future	and Heart Failure in Patients With ST-Segment Elevation Myocardial Infarction	Pharmaceuticals
Holper	Elizabeth	Prosthetic Valve Thrombosis: TAVR, Bio, Mech Now What?!	Incidence of Valve Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves by 4D CT Imaging	CONSULTANT FEES/HONORARIA - Boston Scientific
Holper	Elizabeth	26. Interventional Cardiology: Vascular Access and Complications Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific
Holven	Kirsten	Advances in Cholesterol Measurement and Management	Only Eight Percent of Very High-Risk Familial Hypercholesterolemia Patients Achieve LDL-Cholesterol Target Despite Being on Maximal Conventional Lipid-Lowering Therapy	CONSULTANT FEES/HONORARIA - Amgen Inc.,Pronova; RESEARCH/RESEARCH GRANTS - Amgen Inc.,Mills DA,Olympic Seafood,Sanofi-Aventis,Tine DA
Holven	Kirsten	Advances in Cholesterol Measurement and Management	Real-Life PCSK9 Experience: 65% Treatment Target Attainment in Familial Hypercholesterolemia Patients	CONSULTANT FEES/HONORARIA - Amgen Inc.,Pronova; RESEARCH/RESEARCH GRANTS - Amgen Inc.,Mills DA,Olympic Seafood,Sanofi-Aventis,Tine DA
Holy	Erik	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	Nothing to Disclose
Holzamer	Andreas	Interventional Cardiology: TAVR 3	Multicenter Evaluation of the ACURATE Neo Transfemoral Transcatheter Heart Valve: Clinical Results and Propensity Matched	Nothing to Disclose
Holzamer	Andreas	Interventional Cardiology: TAVR 4	Comparison With SAPIEN 3 Multicenter Evaluation of Prosthesis Oversizing for the SAPIEN 3 Transcatheter Heart Valve: Impact on New Pacemaker	Nothing to Disclose
Holzer	Ralf	09. Congenital Heart Disease: Adult Team 1	Implantations Suggested Reviewer	Nothing to Disclose
Holzhey	David	Interventional Cardiology: TAVR 2	Different Impact of Gender on Early and Late Outcome After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Holzhey	David	Interventional Cardiology: TAVR 2	Higher B-Type Natriuretic Peptide Levels Predict Occurrence of Acute Kidney Injury After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Holzhey	David	Interventional Cardiology: TAVR 2	Impact of Myocardial Injury Indicated by Increased Creatinine Kinase Myocardial Band Levels on the Outcome After Transcatheter Aortic Valve Replacement: Results From a Prospective Single Center	Nothing to Disclose
Holzhey	David	Interventional Cardiology: TAVR 4	Registry Impact of Cancer Disease on Outcome of Patients Undergoing	Nothing to Disclose
Holzmann	Martin	Coronary Angiography, Intra-Vascular Imaging,	Transcatheter Aortic Valve Replacement Association Between Erectile Dysfunction and Death or	Nothing to Disclose
Holzmann	Martin	Revascularization and Outcomes Cardiac Arrest, Diabetes, and Other High Risk	Cardiovascular Outcomes After Myocardial Infarction Risk of Readmissions After Myocardial Infarction in Women Versus	Nothing to Disclose
		Features of Patients With Acute Coronary Syndrome	Men ·	-
Holzmann	Martin	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	High-Sensitivity Cardiac Troponin T Levels and Long-Term Mortality in Patients With Chest Pain	Nothing to Disclose
Homel	Peter	TAVR Outcomes Prognostication	Geriatric Assessment Tools and Outcome Prediction in Transcatheter Aortic Valve Replacement	Nothing to Disclose
Homma	Shunichi	PFO Closure, PV Leak, and VSD Repair	Debate: PFO Closure Should Be the Exception, Rather Than the Rule	Nothing to Disclose
Honarpour	Narimon	Opening Session and the Joint American College of Cardiology and Journal of American College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture	Primary Results of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial	SALARY - Amgen
Honarpour	Narimon	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	Primary Results of EBBINGHAUS, a Cognitive Study of Patients Enrolled in the FOURIER Trial	SALARY - Amgen
Honarpour	Narimon	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Cardiac Myosin Activator, Omecamtiv Mecarbil, Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure	SALARY - Amgen
Honda	Henry	The Evolving World of LVADs, Transplant and	(COSMIC-HF) Incidence and Factors Associated With New-Onset	Nothing to Disclose
Honda	Taku	Other Novel Discoveries Coronary Intervention in Interventional Cardiology: Core Concepts	Cardiomyopathies Following Liver Transplantation A Randomized Comparison of Frequency of Radial Artery Occlusion and Symptomatic Radial Artery Spasm Associated With Transradial Coronary Intervention Using 6.5-Fr Sheathless Guide Catheter-sup>TM Versus 6.0-Fr Glidesheath Slender-sup>TM	Nothing to Disclose
Honda	Yasuhiro	Head to Toe: Outcomes of Endovascular Interventions	Peri-Strut Low Intensity Area Predicts Neointimal Progression Associated With Late Enlargement of Self-Expanding Nitinol Stents in Superficial Femoral Arteries: An Optical Coherence Tomography Study	Nothing to Disclose
Honda	Yasuhiro	16. Interventional Cardiology: Angiography and Interventional CT/MR Team 1	Suggested Reviewer	Nothing to Disclose
Hong	Geu-Ru	Valvular Heart Disease: Aortic Stenosis	Comparisons of Flow-Gradient Patterns in Severe Aortic Stenosis Between Bicuspid Aortic Valves and Tricuspid Aortic Valves	Nothing to Disclose
Hong	Jonathan	Innovations in Cardiovascular Risk Assessment and Reduction	Cost-Effectiveness of Coronary Artery Calcium Testing Among Statin Candidates According to the American College of Cardiology and American Heart Association Cholesterol Guidelines	Nothing to Disclose
Hong	Jung Ae	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	The Prognostic Implications of Current Periprocedural Myocardial Infarction Definitions in Patients Underwent Percutaneous Conronary Intervention With Unprotected Left Main Coronary Artery Disease	Nothing to Disclose
Hong	Kui	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Serum Homocysteine Lowering by Long-Term Low-Dose Folic Acid: New Insight on <i>MTHFR</i> Gene-Folate Interaction From China Stroke Primary Prevention Trial	Nothing to Disclose
Hong	Mun	02. Acute and Stable Ischemic Heart Disease: Clinical Team 7	Suggested Reviewer	CONSULTANT FEES/HONORARIA - AstraZeneca; SPEAKER'S BUREAU - Chiesi
Hong	Myeong-Ki	Considerations in Antiplatelet Therapy and in ACS	Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multi-Vessel Disease on Outcomes in Patients Treated	Nothing to Disclose
			With Newer-Generation Drug-Eluting Stents	

Contract of the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Hongo	Richard	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Ventricular Fibrillation Arrest From an Atrioesophageal Fistula: A Unique Clinical Presentation	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,St. Jude Medical; SPEAKER'S BUREAU -
Hong-Zohlman	Susie	Making Progress in Understanding Heart Failure	Impact of Malignant Left Ventricular Function on Incident Heart Failure With Reduced Versus Preserved Ejection Fraction: The	Bristol-Myers Squibb Company ,Pfizer Nothing to Disclose
Hong-Zohlman	Susie	Making Progress in Understanding Heart	MESA Study Impact of Malignant Left Ventricular Function on Incident Heart	Nothing to Disclose
Hong-Zohlman	Susie	Failure Innovations in Cardiovascular Risk Assessment	Failure in Older Adults: The MESA Study Impact of Malignant Left Ventricular Hypertrophy on Incident	Nothing to Disclose
Honjo	Osami	and Reduction Congenital Heart Disease: Innovations in	Asymptomatic Left Ventricular Dysfunction: The MESA Study Standardization of Peri-Operative Management After Norwood	Nothing to Disclose
Honushefsky	Ashley	Single Ventricle Heart Disease Arrhythmias and Clinical EP: Basic 5	Operation Has Not Improved 1 Year Outcomes A Clinical Prediction Model for Time in Therapeutic Range While on	Nothing to Disclose
Hood	Stuart	Highlighted Original Research: Non Invasive	Warfarin in Newly Diagnosed Atrial Fibrillation Prognostic Significance of Co-Existing Persistent Edema and	Nothing to Disclose
Hood	Stuart	Imaging and the Year in Review Non Invasive Imaging: MR Heart Failure and	Hemorrhage at 6 Months in Survivors of ST-Elevation Myocardial Infarction Segmental Circumferential Strain Derived From DENSE Predicts	Nothing to Disclose
		Pulmonary Hypertension	Improvement of Left Ventricular Function Post ST Elevation Myocardial Infarction: The BHF MR-MI Study	-
Hood	Stuart	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Current Smoking, Microvascular Pathology and Adverse Outcome After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights	Nothing to Disclose
Hood	Stuart	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Incidence and Prognostic Implications of the Presence of Multiple Complex Plaques in Survivors of ST-Elevation Myocardial Infarction	Nothing to Disclose
Hood	Stuart	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Hypertension, Microvascular Pathology and Prognosis in Patients With an Acute ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Hoog	Meredith	Diabetes and Other Issues in Cardiovascular	Comparison of the Use of Cardiovascular Risk Equations by Health Technology Assessment Bodies and Clinical Guidelines	SALARY - Evidera
Hoogeveen	Ron	Prevention Advances in Cholesterol Measurement and Management	Association of Remnant-Like Particle Cholesterol and Low-Density Lipoprotein Triglyceride With Incidence of Cardiovascular Events:	RESEARCH/RESEARCH GRANTS - Denka Seiken, Ltd
Hoogeveen	Ron	Markers of Prognosis Associated With	The ARIC Study <i> Isolated Systolic Hypertension and Pulse Pressure Are Associated </i>	RESEARCH/RESEARCH GRANTS - Denka Seiken, Ltd
		Elevated Blood Pressure	With High-Sensitivity Cardiac Troponin-T and NT-pro BNP in Older Adults Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation	
Hoogeveen	Ron	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	and Stroke Among Whites and Blacks: The Atherosclerosis Risk In Communities (ARIC) Study	RESEARCH/RESEARCH GRANTS - Denka Seiken, Ltd
Hoogslag	Georgette	Innovative Use of Echocardiography	Left Ventricular Systolic Recovery After St-Segment Elevation Myocardial Infarction: Effect of Guideline-Based Therapy	Nothing to Disclose
Hook	Bruce	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Does the Convergent Ablation Procedure Affect Left Atrial Contractile Function?	CONSULTANT FEES/HONORARIA - MEDTRONIC
Hoover	Valerie	Interdisciplinary Cardiovascular Care in Complex Scenarios	Interdisciplinary Peripartum Care of the Patient With Diastolic Heart Failure in Non-Obstructive Hypertrophic Cardiomyopathy	Nothing to Disclose
Hopkins	Eugenia	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Replacement Patients With Atrial	SPEAKER'S BUREAU - Edwards Lifesciences
			Fibrillation Are at High Risk for Stroke and Bleeding: A Rationale for Consideration of Transcatheter Aortic Valve Replacement and Left Atrial Appendage Closure as Complementary Therapies	
Hopkins	William	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	New-Onset Platypnea Orthodeoxia and Old Patent Foramen Ovale: Close It or Not to Close It?	CONSULTANT FEES/HONORARIA - Actelion, Merck
Hopkins	William	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Looking for a Clot: Paget-Schroetter Syndrome as Cause of Chronic Thromboembolic Pulmonary Hypertension	CONSULTANT FEES/HONORARIA - Actelion, Merck
Hoppensteadt	Debra	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Retrospective Analysis of Thrombogenic Biomarkers in Patients With Atrial Fibrillation Treated With Novel Oral Anticoagulants	Nothing to Disclose
Hor	Kan	10. Congenital Heart Disease: Pediatric Team	Suggested Reviewer	Nothing to Disclose
Horack	Martin	Advances in Cholesterol Measurement and Management	Frequency and Predictors of Cholesterol Goal Attainment in Patients With Coronary Heart Disease: Results From the Dyslipidemia International Study II	Nothing to Disclose
Horack	Martin	Advances in Cholesterol Measurement and Management	Low LDL-Cholesterol Target Value Attainment at the Time of Acute Coronary Syndrome (ACS) and Even 4 Months After the Acute Event Due to Lack of Adjustment in Lipid Lowering Treatment: Results From the Dyslipidemia International Study II ACS	Nothing to Disclose
Horack	Martin	Advances in Cholesterol Measurement and Management	Improvement of LDL-Cholesterol Goal Attainment in High-Risk Patients in Europe and Middle East Between 2008-09 and 2013-14: Results of DYSIS and DYSIS II CHD	Nothing to Disclose
Horack	Martin	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South-Africa, Middle East and China: Results of the Dyslipidemia International Study (DYSIS)	Nothing to Disclose
Horack	Martin	Diabetes and Other Issues in Cardiovascular Prevention	Does Concomitant Diabetes Mellitus Impact the Cholesterol Treatment Post Acs?	Nothing to Disclose
Horblyuk	Ruslan	Arrhythmias and Clinical EP: Anticoagulation Issues	Bleeding Risk Among Japanese Non-Valvular Atrial Fibrillation Patients Initiated on Apixaban, Dabigatran, Rivaroxaban or Warfarin	SALARY - Pfizer Inc
Horgan	Stephen	Interdisciplinary Cardiovascular Care in	in the Real World Hand-Foot-and-Mouth (and Heart) Disease: Coxsackievirus A6 as a	Nothing to Disclose
Hori	Yusuke	Complex Scenarios Nuclear Cardiology: Coronary Flow	Recently Recognized Cause of Acute Myocarditis Diagnostic Performance of Hybrid Assessment With Stress Only Myocardial Perfusion Single Photon Emission Computed Tomography Using Semiconductor Gamma Camera and Rest Myocardial Scar Findings Obtained From 320 Detector Row	Nothing to Disclose
Horie	Kazunori	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Computed Tomography Instantaneous Wave-Free Ratio Scout Pullback (IFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International Multicentre IFR GRADIENT Registry	Nothing to Disclose
Horie	Kazunori	Coronary Intervention in Interventional Cardiology: Core Concepts	A Randomized Comparison of Frequency of Radial Artery Occlusion and Symptomatic Radial Artery Spasm Associated With Transradial Coronary Intervention Using 6.5-Fr Sheathless Guide Catheter TM Versus 6.0-Fr Glidesheath Slender TM	Nothing to Disclose
Horie	Kazunori	Coronary Intervention in Interventional Cardiology: Core Concepts	Comparison of Radial Artery Occlusion After Transradial Coronary Intervention Using a New Dedicated Radial Sheath Versus a Sheathless Guiding Catheter	Nothing to Disclose
Horiuchi	Yu	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Elevated Right Sided Heart Pressure Is Associated With Malnutrition In Heart Failure Patients With Reduced Ejection Fraction	Nothing to Disclose
Horiuchi	Yu	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Identifying Novel Phenotypes of Acute Decompensated Heart Failure Using Cluster Analysis of Clinical Variables	Nothing to Disclose
Horn	Benjamin	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula	Nothing to Disclose
		Disease, and Vascular Medicine	and man Output memorialysis Arterioverious Fistura	

Contract of the Contract of th				l l
Last Name Horn	First Name Evelyn	Session Title 13. Heart Failure and Cardiomyopathies: Clinical Team 3	Presentation Title Suggested Reviewer	Disclosures CONSULTANT FEES/HONORARIA - Abbott Laboratories, Actelion, Bayer Healthcare Pharmaceuticals, Janssen
Hornberger	Lisa	Congenital Heart Disease: New Diagnostic	Impact of Maternal Diabetes on First & Early Second Trimester	Pharmaceuticals, Inc Nothing to Disclose
Hornberger	Lisa	Approaches in Congenital Heart Disease Congenital Heart Disease: New Diagnostic	Fetal Cardiovascular Health The Incremental Benefit of Color Tissue Doppler Imaging in Fetal	Nothing to Disclose
Hornberger	Lisa	Approaches in Congenital Heart Disease Congenital Heart Disease: New Diagnostic	Rhythm Assessment Cardiovascular Health of Offspring of Diabetic Mothers From the	Nothing to Disclose
Hornberger	Lisa	Approaches in Congenital Heart Disease Impact of Prenatal Environment on Congenital Heart Disease	Fetus Through Late Infancy Stages Umbilical Arterial Blood Flow in the Third Trimester and Its Association With Clinical and Neurodevelopmental Outcomes in Children With Critical Neonatal Congenital Heart Disease	Nothing to Disclose
Horne	Benjamin	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	The Association of Depression at Any Time to the Risk of Death Following Coronary Artery Disease Diagnosis: The Intermountain INSPIRE Registry	OTHER - CareCentra/Scriplogix, Inc.; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals, CareCentra
Horne	Benjamin	Innovations in Practice Management and Social Media	Predicting 3-Year Risk of Incident Chronic Disease in Disease-Free Primary Care Patients: The Intermountain Chronic Disease Model (ICHRON)	OTHER - CareCentra/Scriplogix, Inc.; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals, CareCentra
Horne	Benjamin	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	The Intermountain Major Adverse Cardiovascular Events Risk Scores Effectively and Efficiently Predict 1- to 3- Year Post-Stent MACE in Non-Myocardial Infarction Patients	OTHER - CareCentra/Scriplogix, Inc.; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals, CareCentra
Horne	Benjamin	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Improvement of CHA ₂ DS ₂ -VASc Risk Stratification of Stroke and Mortality Using the Intermountain Risk Score Among Atrial Fibrillation Patients Undergoing Cardiac Catheterization	OTHER - CareCentra/Scriplogix, Inc.; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals, CareCentra
Horner	Sarah	Arrhythmias and Clinical EP: Devices 2	Comprehensive Strategy to Reduce the Incidence of Lead Dislodgment for Cardiac Implantable Electronic Devices	Nothing to Disclose
Homik	Christoph	Therapeutic Advances in Congenital Heart Disease	Effect of Obesity and Underweight Status on Perioperative Outcomes in Patients With Congenital Heart Disease: An Analysis of Data From the Society of Thoracic Surgeons Congenital Heart Surgery Database	Nothing to Disclose
Hornsby	Kyle	Improving Outcomes in the Athlete With Cardiovascular Disease	American Heart Association Preparticipation Cardiovascular Screening of Competitive Athletes History Elements Applied to a Diverse International Screening Program	Nothing to Disclose
Horowitz	John	Arrhythmias and Clinical EP: Anticoagulation Issues	Use of Interacting Drugs Did Not Modify Treatment Effects of Apixaban Versus Warfarin for Atrial Fibrillation: Results From the ARISTOTLE Trial	CONSULTANT FEES/HONORARIA - Bristol-Myers-Squibb
Horsley	Megan	Finding Out What Works in Pediatric and Congenital Heart Disease	Reduction in Interstage Growth Failure in Infants With Hypoplastic Left Heart Syndrome and Impact on Stage 2 Outcomes: A Report From the National Pediatric Cardiology Quality Improvement Collaborative	Nothing to Disclose
Horstkotte	Dieter	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Sleep Duration and Quality in Heart Failure Patients	Nothing to Disclose
Horstmanshof	Douglas	13. Heart Failure and Cardiomyopathies: Clinical Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Thoratec; RESEARCH/RESEARCH GRANTS - Novartis Corporation
Horton	Rodney	Arrhythmias and Clinical EP: AF Ablation	Long-Term Risk of Recurrent Arrhythmia in Patients With Typical Atrial Flutter Undergoing Pulmonary Vein Antrum Isolation or Cavo- Tricuspid Isthmus Ablation With Permanent Isolation	Nothing to Disclose
Horton	Rodney	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	CHADS2 Score Predicts Outcomes of Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation	Nothing to Disclose
Horton	Rodney	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Left Atrial Appendage Flow Velocity to Predict Persistent Left Atrial Appendage Isolation	Nothing to Disclose
Horvath	Sofia	Emerging Developments in HFpEF and Arryhthmias	Prevalence of Transthyretin Cardiac Amyloidosis in Patients With Heart Failure and Preserved Ejection Fraction Using the ^{99m} Tc-Pyrophosphate Scintigraphy	Nothing to Disclose
Horwich	Tamara	The Heavy Heart: Practicing Heart Failure Cardiology in an Obesity Epidemic	Panelist	Nothing to Disclose
Horwich	Tamara	The Heavy Heart: Practicing Heart Failure Cardiology in an Obesity Epidemic	Adipokines and Gut Hormones: Mediators of the OBesity-Heart Failure Relationship	Nothing to Disclose
Horwich	Tamara	Diabetes and Heart Failure: Are We Hitting The Sweet Spot	Panelist	Nothing to Disclose
Horwich	Tamara	Diabetes and Heart Failure: Are We Hitting The Sweet Spot	Epidemiology of Diabetes, Hyperglycemia and Heart Failure	Nothing to Disclose
Horwich	Tamara	Advances in HCM, PPCM and Other Cardiomyopathies	High Versus Standard Protein Diets in Obese Patients With Heart Failure: Effects on Chronic Disease Risks	Nothing to Disclose
Horwich	Tamara	Predicting Outcomes in Cardiac Rehabilitation Patients	The Effect of Body Composition on Cardiovascular Outcomes in Cardiac Rehabilitation Patients With Coronary Heart Disease	Nothing to Disclose
Horwich	Tamara	13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	Nothing to Disclose
Hosawa	Koji	Clinical Team 8 Endovascular Therapy: Running From Risk	The Impact of Patent Below the Knee Vessels on Stenting for	Nothing to Disclose
Hoshimoto	Koichi	Interventional Cardiology: PCI in Complex Patients	Chronic Total Occlusions in the Superficial Femoropopliteal Artery Chronic Stent Recoil During Follow-Up in Severely Calcified Coronary Artery Lesions: An Optical Coherence Tomography Study	Nothing to Disclose
Hoshino	Masahiro	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Relationship Between Coronary Physiological Parameters and Cardiac Biomarkers in Patients Undergoing Invasive Coronary Angiography	Nothing to Disclose
Hoshino	Masahiro	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Significance of Microcirculatory Resistance in Visual-Functional Mismatch Between Coronary Angiography and Fractional Flow Reserve in Non-Left Main Lesions	Nothing to Disclose
Hoshino	Masahiro	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Usefulness of Optical Coherence Tomography-Derived Morphometric Assessment to Predict Physiological Significance of Coronary Artery Stenosis and Determinants of Mismatch: Head-to-	Nothing to Disclose
Hoshino	Masahiro	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Head Comparison With Intravascular Ultrasound Relationship Between Optical Coherence Tomography-Defined In- Stent Neoatherosclerosis and Out-Stent Arterial Remodeling Assessed by Serial Intravascular Ultrasound Examinations in Late	Nothing to Disclose
Hoshino	Masahiro	Unusual Presentations of ACS	and Very Late Drug-Eluting Stent Failure Predictors and Clinical Significance of High-Sensitivity Cardiac	Nothing to Disclose
Hoshino	Masahiro	Unusual Presentations of ACS	Troponin-I Elevation After Diagnostic Coronary Angiography Multimodality Coronary Imaging to Predict Periprocedural Myocardial Necrosis After Elective Percutaneous Coronary Intervention	Nothing to Disclose
Hoshino	Masahiro	Unusual Presentations of ACS	Intervention Comparison of Neointimal Appearance Assessed by Optical Coherence Tomography Between Bare-Metal Stents and Sirolimus- Eluting Stents Beyond 10 Years From Implantation	Nothing to Disclose
Hosny	Kareem	Imaging the Athlete's Heart	Differential American-Style Football Training Intensities and Cardiac and Vascular Remodeling Patterns	Nothing to Disclose
Hosny	Kareem	Imaging the Athlete's Heart	Sleep Disordered Breathing and Cardiovascular Correlates in	Nothing to Disclose
Hosseinidehkordi	Seyedhamed	Unusual Presentations of ACS	Collegiate American Style Football Participants Clinical Outcomes of the Treatment of Cocaine Induced Chest Pain With Part Rickers, A Meta Analysis	Nothing to Disclose
Host	Nis	Novel Echocardiographic Methods for	With Beta Blockers: A Meta-Analysis Coronary Microvascular Dysfunction Affects the Myocardial Controllis Receive in Women With Angina and No Obstructive	Nothing to Disclose
		Assessing Cardiac Function	Contractile Reserve in Women With Angina and No Obstructive Coronary Artery Disease	

Last Name	First Name	Session Title	Presentation Title	Disclosures
Host	Nis	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Effect of Ramipril on Microvascular Function and Symptoms in Normotensive Women With Microvascular Angina: A Randomized Controlled Trial	Nothing to Disclose
Host	Nis	Innovative Use of Echocardiography	Usefulness of Left Ventricular Speckle Tracking Echocardiography in Diagnosing Paroxysmal Atrial Fibrillation in Ischemic Stroke and Transient Ischemic Attack Patients	Nothing to Disclose
Hou	Xiaofeng	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Super-Response to Cardiac Resynchronization Therapy in Heart Failure Patients With Left Bundle Branch Block and Homogeneous	Nothing to Disclose
Hou	Xiaofeng	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Left Ventricular Contraction Pattern Elevated Pulmonary Vascular Resistance Predicts Poor Response to Cardiac Resynchronization Therapy	Nothing to Disclose
Hou	Xiaofeng	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Assessment of Left Ventricular Contraction Patterns Using Gated SPECT MPI to Improve Cardiac Resynchronization Therapy Response	Nothing to Disclose
Hou	Xiaofeng	Leading Us Astray? Pacemakers in Cardiomyopathies	Spect Guided Lv Lead Placement for Incremental Benefits to Crt Efficacy: A Prospective Multicenter Randomized Controlled Trial	Nothing to Disclose
Hou	Yong	Diabetes and Other Issues in Cardiovascular Prevention	Efficacy of Folic Acid Supplementation on the Reduction of Stroke Risk: Interaction With Platelet Count	Nothing to Disclose
Houghtaling	Penny	Novel Arrhythmia Diagnostics, Therapeutics, and "Wearables	Variable Accuracy of Commercially Available Wearable Heart Rate Monitors	Nothing to Disclose
Houle	Helene	New Technologies in Echocardiography	Automated Detection of Mitral Valve Annular and Leaflet Geometry: Echocardiography and CT Comparison	SALARY - Siemens Healthcare employee
Houmsse	Mahmoud	Arrhythmias and Clinical EP: Devices 2	Comprehensive Strategy to Reduce the Incidence of Lead Dislodgment for Cardiac Implantable Electronic Devices	Nothing to Disclose
Houmsse	Mahmoud	Arrhythmias and Clinical EP: Devices 3		Nothing to Disclose
Houser	Steven	Cardiac Channelopathies: Novel Therapeutics and Clinical Challenges	ACC Poster Moderator	Nothing to Disclose
Housten-Harris	Traci	Demystifying and Managing Pulmonary Hypertension and RV Dysfunction: It Takes a Village	Panelist	CONSULTANT FEES/HONORARIA - Actelion, Gilead Sciences, Inc.
Hovingh	G. Kees	Advances in Cholesterol Measurement and Management	Alirocumab Titration Strategy Allows Individualized LDL-C Reduction in a Real World Setting: Results From ODYSSEY OLE (LONG TERM Cohort)	Nothing to Disclose
Hovingh	G. Kees	Advances in Cholesterol Measurement and Management	On-Treatment LDL-C Levels When Alirocumab Dose Is Decreased From 150 to 75 mg Every 2 Weeks in Patients With Heterozygous Familial Hypercholesterolemia: Results From ODYSSEY OLE	Nothing to Disclose
Hovingh	G. Kees	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Alirocumab Treatment in a Real World Setting: Safety Update From an Open-Label Treatment Extension to the ODYSSEY Program for Patients With Heterozygous Familial Hypercholesterolemia	Nothing to Disclose
Hovnanians	Ninel	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Cardiac Pneumonia: Acute Mitral Regurgitation as a Rare Cause of Right Upper Lung Lobe Infiltrate	Nothing to Disclose
Howard	Brian	Improving Outcomes in the Athlete With Cardiovascular Disease	Pre-Existing Cardiac Disease, Exercise, Male Sex, and Young Age Are Risk Factors for Sudden Death Following Energy Drink Consumption	Nothing to Disclose
Howarth	Andrew	Non Invasive Imaging: MR Characterization and Function	Defining Risk Associated With Left Ventricular Hypertrophy Patterns as Assessed by Cardiac Magnetic Resonance Imaging	SPEAKER'S BUREAU - Amgen Inc.
Howarth	Andrew	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	The Presence of Fragmented QRS Complexes Early After Acute Myocardial Infarction is Associated With Subsequent Lack of Favorable Left Ventricular Remodeling	SPEAKER'S BUREAU - Amgen Inc.
Howell	Sharon	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Pulmonary Venous Waveforms Predict Ventricular Remodeling After Percutaneous Mitral Valve Repair	Nothing to Disclose
Howlett	Jonathan	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Kidney Function, Angiotensin-Converting-Enzyme Inhibitor or Angiotensin II Receptor Blocker Use, and Survival Following Hospitalization for Heart Failure: A Cohort Study	CONSULTANT FEES/HONORARIA - Abbott, AstraZeneca, Meditronic Canada, Merck, Oksuka Canada, Pfizer, Servier Canada; RESEARCH/RESEARCH GRANTS - AstraZenaca, Servier Canada
Hoyt	Walter	Sports and Exercise: Athletes with Congenital/Valvular Heart Disease Challenging Guidelines in Daily Practice	Case Presentation: Masters Marathon Runner with Congenital Aortic Stenosis	Nothing to Disclose
Hoyt	Walter	Pregnancy Complicated by Valvular/Congenital Heart Disease: Clinical Management and Challenging Cases	Case Presentation:Third Trimester Pregnancy Complicated by Bicuspid Aortic Valve and Aortic Aneurysm	Nothing to Disclose
Hozumi	Takeshi	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Comparison of Very Late Vascular Response Beyond 2 Years After Stent Implantation Between EES and BES: An OCT Sub-Study of the NEXT	Nothing to Disclose
Hranitzky	Patrick	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Left Atrial Appendage Flow Velocity to Predict Persistent Left Atrial Appendage Isolation	Nothing to Disclose
Hristova	Krasimira	Emerging Applications of Echocardiography	Effect of Changing Strain Software Versions on Longitudinal Assessment of LV Function	Nothing to Disclose
Hrobowski Hrobowski	Tara Tara	Cardiogenic Shock: Drugs to Devices Cardiogenic Shock: Drugs to Devices	Panelist Treating Cardiogenic Shock: Challenging Cases and Complications	Nothing to Disclose Nothing to Disclose
Hsia	Henry	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC; DATA SAFETY MONITORING BOARD - VytronUS; RESEARCH/RESEARCH GRANTS - Biosense-Webster, MEDTRONIC; SPEAKER'S BUREAU - Biosense-Webster
Hsiao	Ruth	Emerging Developments in HFpEF and Arryhthmias	Differences Between Ethnic Groups in Comorbidities Do Not Influence Readmission Risk in Patients With Heart Failure and Preserved Ejection Fraction	Nothing to Disclose
Hsich	Eileen	Novel Echocardiographic Methods for Assessing Cardiac Function	Received Ejection Fraction Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain	Nothing to Disclose
Hsich	Eileen	14. Heart Failure and Cardiomyopathies: Therapy Team 2	Suggested Reviewer	Nothing to Disclose
Hsu	Daphne	Test Yourself with Questions: Pediatric Cardiology	Faculty	CONSULTANT FEES/HONORARIA - Bayer Pharmaceuticals, Novartis
Hsu	Daphne	Therapeutic Advances in Congenital Heart Disease	Safety of Enalapril in Infants: Data From the Pediatric Heart Network Infant With Single Ventricle Trial	
Hsu	Daphne	10. Congenital Heart Disease: Pediatric Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Bayer Pharmaceuticals,Novartis
Hsu	Jeffrey	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	A Confusing Case of Pulmonary Hypertension With Mixed Valvular Disease and Cryptogenic Cirrhosis	Nothing to Disclose
Hsu	Jeffrey	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		Nothing to Disclose
Hsu	Jin-Wen	Advances in Cholesterol Measurement and Management	Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol	Nothing to Disclose
Hsu	Jonathan	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues		CONSULTANT FEES/HONORARIA - Biotronik,MEDTRONIC,St. Jude Medical; RESEARCH/RESEARCH GRANTS - Biosense- Webster,Biotronik

(Marie Control of the				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Hsue	Priscilla	Unusual Presentations of ACS	Association of Cocaine and Amphetamine Use With Troponin I Concentrations	CONSULTANT FEES/HONORARIA - gilead; RESEARCH/RESEARCH GRANTS - Pfizer
Htun	Wah	FIT Clinical Decision Making: Acute Coronary	Use of Ultrasound Assisted Catheter Directed Thrombolysis in	Nothing to Disclose
Hu	Во	Syndrome and Vascular Medicine Emerging Basic Science in Ischemic Heart	Treatment of Aortic Thrombi Thrombolysis in Coronary Micro-Circulation Occlusion by	Nothing to Disclose
		Disease	Dodecafluoropentane Acoustic Vaporizable Nano-Droplet With Ultrasound Irradiation	-
Hu	Dan	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Atrial Fibrillation Associated to Wpw Syndrome in a Patient With Concomitant Brugada Syndrome	Nothing to Disclose
Hu	Dan	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Identification of Novel Mutations Associated With Cardiac <i>PRKAG2 </i> Syndrome	Nothing to Disclose
Hu	Dayi	7th Annual ACC China Chapter Session: Endless Change and Evolution in Cardiovascular Prevention and Rehabilitation	Co-Chair	Nothing to Disclose
Hu	Dayi	7th Annual ACC China Chapter Session: Endless Change and Evolution in	Introduction to Session	Nothing to Disclose
Hu	Wei-Syun	Cardiovascular Prevention and Rehabilitation Innovations in Cardiovascular Risk Assessment and Reduction	Cha ₂ Ds ₂ -Vasc Score for Ischemic Stroke Risk Stratification in Patients With Chronic Obstructive Pulmonary Disease With and Without Atrial Fibrillation: A Nationwide Cohort	Nothing to Disclose
Huang	Feiqiong	Vascular Medicine: Novel Risk Measures in	Study Sarcopenia and Vascular Function Among Community Elderly	Nothing to Disclose
Huang	Feiqiong	Arterial Diseases Diabetes and Other Issues in Cardiovascular	Adiposity, Leanness or Both? Characterizing Measures of Adiposity	Nothing to Disclose
Huang	Jennifer	Prevention Innovations in Education	and Leanness With Cardiovascular Remodeling Coronary Angiography Simulation Training Improves Image	Nothing to Disclose
			Interpretation Skills of Trainees Independent of Their Stage of Training	-
Huang	Runging	New Technologies in Echocardiography	Lipoproteins, Statin Therapy, Carotid Atherosclerotic Plaque Vulnerability and Stiffness: A Study of Novel Ultrasound Methods Utilizing Microbubble Contrast Enhancement and Shear Wave Elastography	Nothing to Disclose
Huang	Shi	Improving Risk Assessment in Atherosclerosis	N-Terminal Pro B-Type Natriuretic Peptide, Race, and Flow- Mediated Dilation: Multi-Ethnic Study of Atherosclerosis	Nothing to Disclose
Huang	Sihong	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Important Hemodynamic Considerations in the Management of an Adult With Unrepaired Pentalogy of Fallot Presenting With	Nothing to Disclose
Huang	Wei Ming	Emerging Developments in HFpEF and Arryhthmias	With Preserved Ejection Fraction: Looking Beyond Chronic	Nothing to Disclose
Huang	Xiangke	FIT Forum: Stump the Professor	Obstruction Pulmonary Disease First Case on Biventricular Mechanical Circulatory Support With Impella CP and Impella RP for a Patient With Acute Myocardial	Nothing to Disclose
Huang	Xiangke	The Great K Debate Continues: Updates and Controversies in Heart Failure Management	Infarction Induced Cardiogenic Shock Clinical Facilitator	Nothing to Disclose
Huang	Xiao	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Serum Homocysteine Lowering by Long-Term Low-Dose Folic Acid: New Insight on <i>MTHFR</i> Gene-Folate Interaction From China	Nothing to Disclose
Huang	Xiao	Diabetes and Other Issues in Cardiovascular Prevention	Stroke Primary Prevention Trial Efficacy of Folic Acid Supplementation on the Reduction of Stroke Risk: Interaction With Platelet Count	Nothing to Disclose
Huang	Xiaoyan	Innovations in Advocacy and Patient Centered	Transforming Cardiology Care Towards Patient-Centered Specialty	Nothing to Disclose
Huber	Ken	Care Fundamentals of LAA Closure	Practice Case Presentation: Complication of LAA Closure	CONSULTANT FEES/HONORARIA - Boston Scientific
Huber	Kurt	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Circulating Mitochondrial DNA Is Associated With Mortality in Patients With Acute Heart Failure	Nothing to Disclose
Huber	Kurt	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Gender Differences in Short- and Long-Term Mortality in the Vienna STEMI Registry	SPEAKER'S BUREAU - AstraZeneca,Boehringer Ingelheim Pharmaceuticals, Inc,Bristol-Myers Squibb Company ,Daiichi Sankyo,Pfizer Inc,Thermofisher
Huber	Kurt	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Copeptin and High-Sensitivity Troponin I in Patients With Chest Pain and Recent Syncope	Sankyo, Pitzer Inc, Thermonsher SPEAKER'S BUREAU - AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb Company, Daiichi Sankyo, Pfizer Inc, Thermofisher
Huczek	Zenon	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Implantation in Patients With Bicuspid Aortic Valve Stenosis Utilizing the Next Generation Fully Retrievable and Repositionable Valve System: Early Results From the Multicenter Pol-Tavi Registry	Nothing to Disclose
Huded	Chetan	Interventional Cardiology: TAVR 2	Intensity of Statin Therapy and Outcomes After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Huded	Chetan	Novel Determinants of Outcomes in VHD	Valvuloarterial Impedance and Left Ventricular Global Longitudinal Strain Provide Incremental Prognostic Value in Patients With Significant Aortic Stenosis and Preserved Left Ventricular Ejection	Nothing to Disclose
Hudson	Michael	Clinical Challenges in the Cardiac Care Unit	Fraction Co-Chair	Nothing to Disclose
Hudson	Michael	(CCU) Novel Developments in Acute Coronary	How Often Does Troponin Elevation Identify Acute Myocardial	Nothing to Disclose
Hudson	Michael	Syndromes Acute Coronary Syndromes, Diagnosis,	Infarction in the Emergency Department? Is Duration of Symptoms Predictive of Acute Myocardial Infarction?	Nothing to Disclose
Hueb	Whady	Management and Outcomes Revascularization and Myocardial Preservation	Cost-Effectiveness Analysis and Quality of Life of On-Pump and Off-	Nothing to Disclose
	-	in Acute and Stable Ischemic Heart Disease	Pump Stable Multivessel Coronary Artery Bypass Grafting: MASS III Trial 5-Year Follow-Up	-
Huggins	Gordon	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Impact of Glucagon Like Peptide-1 Agonist Therapy on Heart Rate in Advanced Systolic Heart Failure: An Analysis From the Functional Impact of GLP-1 for Heart Failure Treatment Study	Nothing to Disclose
Hughes	G. Chad	Highlighted Original Research: Interventional Cardiology and the Year in Review	New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: Incidence, Anticoagulant Strategy, and Outcomes	CONSULTANT FEES/HONORARIA - CryoLife ,MEDTRONIC,W.L Gore; SPEAKER'S BUREAU - Cook Medical
Hughes	G. Chad	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Surgery for Patients With Bicuspid Aortopathy: Validation of the 2016 ACC/AHA Guidelines Clarification	CONSULTANT FEES/HONORARIA - CryoLife ,MEDTRONIC,W.L Gore; SPEAKER'S BUREAU - Cook Medical
Hughes	G. Chad	Interventional Cardiology: TAVR 3	Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry	CONSULTANT FEES/HONORARIA - CryoLife ,MEDTRONIC,W.L Gore; SPEAKER'S BUREAU - Cook Medical
Hughes	G. Chad	Beans, Beans, Good for Your Heart	Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection	CONSULTANT FEES/HONORARIA - CryoLife ,MEDTRONIC,W.L Gore; SPEAKER'S BUREAU - Cook Medical
Hughes	G. Chad	Interventional Cardiology: TAVR 4	Predictors of Mortality After TAVR in a "Real World" Setting	CONSULTANT FEES/HONORARIA - CryoLife ,MEDTRONIC,W.L Gore; SPEAKER'S BUREAU - Cook Medical
Hughes	G. Chad	Vascular Medicine: Aortic and Peripheral Artery Diseases	Uncontrolled Hypertension in Acute Aortic Dissection Follow-Up	CONSULTANT FEES/HONORARIA - CryoLife ,MEDTRONIC,W.L Gore; SPEAKER'S BUREAU - Cook Medical
Hughes	G. Chad	Peripheral Arterial Disease, Risk, and Outcomes	Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes: A Report From the STS/TVT Registry	CONSULTANT FEES/HONORARIA - CryoLife ,MEDTRONIC,W.L Gore; SPEAKER'S BUREAU - Cook Medical
		1		1

Contract of the contract of th				l .
Last Name Hughes-Doichev	First Name Rachel	Session Title FIT Clinical Decision Making: Non-Invasive	Presentation Title Coronary Artery Mycotic Aneurysm: A Rare Presentation of	Disclosures Nothing to Disclose
Hui-Gen	Jin	Imaging and Valvular Heart Disease Heart Failure and Cardiomyopathies: Heart	Tricuspid Valve Endocarditis Percutaneous Renal Sympathetic Denervation Improves the	Nothing to Disclose
Hardell	Jiii	Failure Gadgets Galore	Cardiac Function And Reduces Icd (Electrical) Discharges in Severe Heart Failure Patients With Narrow Qrs Complexes and Icd Implantation	Notining to Disclose
Huisman	Marc	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Atherosclerotic Plaque Morphology Is Associated With Impaired Myocardial Blood Flow and Fractional Flow Reserve, Independent of Luminal Obstruction	Nothing to Disclose
Huisman	Menno	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Persistence With Therapy in Patients With Atrial Fibrillation: The GLORIA-AF Registry	Nothing to Disclose
Huisman	Menno	Atrial Fibrillation and VT: Unique Populations	Predictors of Anticoagulant Prescription in Patients With Atrial	Nothing to Disclose
Huisman	Menno	and Solutions Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Fibrillation in North America: The GLORIA-AF Registry Increased Rate of Previous Stroke in Asymptomatic/Minimally Symptomatic Versus Symptomatic Patients With Newly Detected Atrial Fibrillation Worldwide: Results From	Nothing to Disclose
Huisman	Menno	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Rates of Stroke and Bleeding With Dabigatran 150 and 110 mg BID in Clinical Practice: The GLORIA-AF Registry	Nothing to Disclose
Hull	Robert	Featured Clinical Research III	Reduction in Heart Failure Hospitalizations With Ambulatory Hemodynamic Monitoring Seen in Clinical Trials Is Maintained in the 'Real World'	Nothing to Disclose
Hulten	Edward	Nuclear Cardiology: Quality	Worldwide Variation in the Use of Nuclear Cardiology Camera Technology, Reconstruction Software, and Acquisition Protocols: Findings From the IAEA Nuclear Cardiology Protocols Study (INCAPS)	Nothing to Disclose
Hummel	Ellen	Cardiovascular Procedures That Push the Line: High-Risk or Futility of Care?	Panelist	Nothing to Disclose
Hummel	John	Arrhythmias and Clinical EP: Devices 2	Comprehensive Strategy to Reduce the Incidence of Lead Dislodgment for Cardiac Implantable Electronic Devices	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Medtronic, St Jude, Boston Scientific, Biosense Weberer, Medical Device Innovation, Topera; RESEARCH/IRESEARCH GRANTS - MEDTRONIC
Hummel	John	Atrial Fibrillation and VT: Unique Populations and Solutions	Low Stroke Incidence in Persistent Atrial Fibrillation Ablation With Multi-Electrode Phased Radio-Frequency Technology: Preliminary Results From VICTORY AF Study	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Medtronic, St Jude, Boston Scientific, Biosense Webster, Medical Device Innovation, Topera; RESEARCH/RESEARCH GRANTS - MEDTRONIC
Hummel	John	Arrhythmias and Clinical EP: Devices 3	Cryoballoon Versus Radiofrequency Ablation of Atrial Fibrillation: In- Lab Complication Rates at a Large Volume Electrophysiology Center	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Medtronic, St Jude, Boston Scientific, Biosense Webster, Medical Device Innovation, Topera; RESEARCH/RESEARCH GRANTS - MEDTRONIC
Hummel	Scott	Salt, Water and the Kidney in Heart Failure	Panelist	RESEARCH/RESEARCH GRANTS - Novartis Corporation, Pfizer Inc, PurFoods, LLC
Hummel	Scott	Salt, Water and the Kidney in Heart Failure	Sodium Controversies in Heart Failure	RESEARCH/RESEARCH GRANTS - Novartis Corporation, Pfizer Inc, PurFoods, LLC
Hummel	Scott	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Low Dietary Sodium Intake Is Associated With Low Energy Intake and Dietary Micronutrient Deficiency in Elderly Patients Hospitalized for Heart Failure	RESEARCH/RESEARCH GRANTS - Novartis Corporation,Pfizer Inc,PurFoods, LLC
Humphries	Karin	Unusual Presentations of ACS	Clinical Predictors of Recurrent Dissection After Spontaneous Coronary Artery Dissection	Nothing to Disclose
Hun Kim	Kye	Improving Outcomes in the Athlete With Cardiovascular Disease	American Heart Association Preparticipation Cardiovascular Screening of Competitive Athletes History Elements Applied to a Diverse International Screening Program	Nothing to Disclose
Hundley	W.	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Frequency of Transition From Stage A to B or C Heart Failure After Potentially Cardiotoxic Chemotherapy	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Prova; RESEARCH/RESEARCH GRANTS - Albus Imaging,Bracco Diagnostics,Siemens Research Corporation
Hundley	W.	Advances in Imaging to Assess Cardiotoxicity	Decreases in Left Ventricular Mass and Not Left Ventricular Ejection Fraction Are Associated With Heart Failure Symptoms in Cancer Patients Six Months After Potentially Cardiotoxic Chemotherapy	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Prova; RESEARCH/RESEARCH GRANTS - Albus Imaging,Bracco Diagnostics,Siemens Research Corporation
Hundley	W. Gregory	Imaging of Cancer-Treatment Associated CV Toxicity: Applying Guidelines to Clinical Practice	Evidence for MRI imaging for detection of CV disease during and after cancer treatment	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Prova; RESEARCH/RESEARCH GRANTS - Albus Imaging,Bracco Diagnostics,Siemens Research Corporation
Hundley	W. Gregory	Imaging of Myocardial Blood Flow: A Multimodality Approach	Co-Chair	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Prova; RESEARCH/RESEARCH GRANTS - Albus Imaging,Bracco Diagnostics,Siemens Research Corporation
Hundley	W. Gregory	Heart Failure and Cancer Care	Case Presentation: How to Detect Cardiac Injury with Cardiotoxic Chemotherapy – Is Ejection Fraction Still the Gold Standard? Evidence to Practice Roundtable Discussion	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Prova; RESEARCH/RESEARCH GRANTS - Albus Imaging,Bracco Diagnostics,Siemens Research Corporation
Hundley	W. Gregory	29. Non Invasive Imaging: MR Team 1	Suggested Reviewer	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Prova; RESEARCH/RESEARCH GRANTS - Albus Imaging,Bracco Diagnostics,Siemens Research Corporation
Hung	Chi-Sheng	Head to Toe: Outcomes of Endovascular Interventions	Long Term Clinical Outcomes After Endovascular Recanalization in Patients With Chronic Carotid Artery Occlusion	Nothing to Disclose
Hung	Chung-Lieh	The Evolving World of LVADs, Transplant and	Chronic Kidney Disease in Asian Patients With Heart Failure	Nothing to Disclose
Hung	Judy	Other Novel Discoveries Structural Heart Disease: Difficult Choices for	Severe AS and Mod-Sev MR, Comorbid pt - Can We Predict When	Nothing to Disclose
Hung	Judy	the Heart Team Town Hall Meeting: Pitfalls of Assessing	SAVR/TAVR Will Be Enough? Discussion Leader	Nothing to Disclose
Hung	Judy	Valvular Heart Disease Severity Imaging in Valvular Heart Disease: Applying Guidelines to Clinical Practice and What to do	Quantification of Mitral Regurgitation — Using all of the Tools in my Echo Lab	Nothing to Disclose
Hung	Judy	if They Don't Fit Highlighted Original Research: Valvular Heart	Co-Chair	Nothing to Disclose
Hung	Judy	Disease and the Year in Review Novel Determinants of Outcomes in VHD	Relationship Between Proximal Aorta Morphology and Progression	Nothing to Disclose
Hung	Judy	36. Valvular Heart Disease: Clinical Team 1	Rate of Aortic Stenosis Suggested Reviewer	Nothing to Disclose
Hunt	Sharon	 Heart Failure and Cardiomyopathies: Clinical Team 3 	Suggested Reviewer	Nothing to Disclose
Hunter	Amanda	Blips, Trops, and Chips: New Ways to Diagnose CAD	High-Sensitivity Cardiac Troponin I and the Diagnosis of Obstructive Coronary Artery Disease in Patients With Suspected Stable Angina	Nothing to Disclose
Hunter	Claire	Atrial Fibrillation and VT: Unique Populations and Solutions	Sotalol Versus Other Anti-Arrhythmic Medications for Cardioversion of Atrial Fibrillation and Maintenance of Sinus Rhythm: Meta-Analysis of Randomized Controlled Studies	RESEARCH/RESEARCH GRANTS - NIH, Novartis
Hunter	Claire	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Sotalol Versus Other Anti-Arrhythmic Agents for Prevention of Post- Operative Supraventricular Arrhythmias After Cardiac Surgery. Meta- Analysis of Randomized Controlled Studies	RESEARCH/RESEARCH GRANTS - NIH,Novartis
Huntley	Geoffrey	Valvular Heart Disease: Aortic Stenosis	Bicuspid Versus Tricuspid Aortic Valve Stenosis: Comparative Study of Clinical Characteristics and Outcomes Following Aortic Valve Replacement in an Age-Matched Cohort	Nothing to Disclose

				l l
Last Name Huo	First Name Yong	Session Title New Perspectives and Updates in STEMI Care:	Presentation Title Co-Chair	Disclosures Nothing to Disclose
Tido	Tong	Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology	Co-Citali	Notifing to Disclose
Huo	Yong	New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology	Introduction to Session	Nothing to Disclose
Huo	Yong	Assessing the Clinical Impact of Blood Pressure Lowering Therapies	Impact of Achieved Blood Pressure on First Stroke in Hypertensive Patients With Mild-to-Moderate Chronic Kidney Disease: A Post-Hoc Analysis of the China Stroke Primary Prevention Trial (CSPPT)	Nothing to Disclose
Huo	Yong	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of a Switch From Dual Antiplatelet Therapy to Single Antiplatelet Therapy in Diabetes and Non-Diabetes Post ACS: Insights From the EPICOR and EPICOR-Asia Studies	Nothing to Disclose
Huo	Yong	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Invasive Management Strategies and Anti-Thrombotic Treatments in Patients With NSTE-ACS in China	Nothing to Disclose
Huo	Yong	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Serum Homocysteine Lowering by Long-Term Low-Dose Folic Acid: New Insight on <i>MTHFR</i> Gene-Folate Interaction From China Stroke Primary Prevention Trial	Nothing to Disclose
Huo	Yong	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Diabetes Mellitus on Antithrombotic Management Patterns and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndrome: Insight From the EPICOR Asia Study	Nothing to Disclose
Huo	Yong	Innovations in Cardiovascular Risk Assessment	Joint Association of Maternal Plasma Folate and Cardiometabolic	Nothing to Disclose
Hur	David	and Reduction New Technologies in Echocardiography	Risk Factors With Child Blood Pressure Automated Detection of Mitral Valve Annular and Leaflet Geometry:	Nothing to Disclose
Hur	Seung Ho	Late-Breaking Clinical Trials: Interventional	Echocardiography and CT Comparison Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With	Nothing to Disclose
	_	ů	Coronary Chronic Total Occlusion: DECISION CTO Randomized Trial	
Hur	Seung-Ho	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Five Year Outcomes of Fractional Flow Reserve Guided Versus Intravascular Ultrasound Guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Disease	Nothing to Disclose
Hurwitz Hurwitz	Ben Jodie	Arrhythmias and Clinical EP: Devices 4 Contemporary Management of Anticoagulation	ECG Criteria for the Identification of Bi-Ventricular Pacing Co-Chair	Nothing to Disclose OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
		in High-risk Patients with Atrial Fibrillation		ROLE - medical City Dallas; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - The Heart Hospital Baylor Plano; SPEAKER'S BUREAU - MEDTRONIC
Hurwitz	Jodie	Interventional Cardiology: PCI and TAVR in Complex Patients	Timing and Algorithm of Permanent Pacemaker Implantation After TAVR	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - medical City Dallas; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - The Heart Hospital Baylor Plano; SPEAKER'S BUREAU - MEDTRONIC
Husain	Afshan	Emerging Applications of Echocardiography	Dilated Mid-Ascending Aorta in Hypertrophic Cardiomyopathy Is Associated With Dynamic Left Ventricular Outflow Tract Obstruction and Not With Genetic Abnormalities	Nothing to Disclose
Hussain	Azar	Understanding Pulmonary Vascular Disease: From Bench to Bedside	The In-Vitro Effect of Prostacyclin Analogues on Small Human Pulmonary Artery: Comparison With Phosphodiesterase Inhibitors	Nothing to Disclose
Hussain	Nasir	Imaging the Athlete's Heart	Acute Coronary Syndromes During Endurance Sports: Olmsted	Nothing to Disclose
Hussain	Nasir	Atrial Fibrillation, Anticoagulation and Novel	County Experience CHA2DS2-VASc Score Predicts Incident Atrial Fibrillation/Flutter in	Nothing to Disclose
Hussain	Shazia	Device Therapies Novel Developments in Acute Coronary	a Referral Population One-Year Outcome of Acute Stent Thrombosis: Insights From the	Nothing to Disclose
Hussain	Syed	Syndromes Valvular Heart Disease: Endocarditis	Total Trial Comparison of Non-Surgical and Surgical Therapy for Prosthetic	Nothing to Disclose
Hussaini	Asma	Great Minds Think Differently: Multidisciplinary	Valve Endocarditis: A Propensity Score-Adjusted Study Pre-procedure Planning and Procedural Guidance: Left Atrial	CONSULTANT FEES/HONORARIA - Abbott
Hussaini	Asma	Approach to Imaging Structural Heart Interventions: Focus on Mitral	Appendage Imaging Impact of Residual Left Atrial Appendage Trabeculations After	Laboratories,Boston Scientific CONSULTANT FEES/HONORARIA - Abbott
		Valve, Left Atrial Appendage and HOCM	WATCHMAN Device Implantation in Atrial Fibrillation Patients	Laboratories, Boston Scientific
Hussaini	Asma	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Anemia Predicts Mortality in Atrial Fibrillation Patients Undergoing Left Atrial Appendage Occlusion Using WATCHMAN Device	CONSULTANT FEES/HONORARIA - Abbott Laboratories,Boston Scientific
Hussaini	Asma	Interventional Cardiology: Structural Heart Disease	Long-Term Durability of Percutaneous Mitral Valve Repair Using MitraClip System: 8-Year Follow-Up	CONSULTANT FEES/HONORARIA - Abbott Laboratories,Boston Scientific
Hussaini	Sharmeen	Nuclear Cardiology: Beyond Perfusion	The Increasing Burden of Amyloidosis From Apex to Base: New	Nothing to Disclose
Hussaini	Sharmeen	Vascular Medicine: Emerging Concepts in	Insights From Technetium-99m Pyrophosphate Imaging Normal Diameter of the Ascending Aorta in Adults: The Impact of	Nothing to Disclose
Husser	Daniela	Clinical Vascular Diseases FIT Clinical Decision Making: Heart Failure and	Stricter Criteria on Selection of Subjects Free of Disease Isolated Cardiac Sarcoidosis Mimicking Hypertrophic	Nothing to Disclose
		Pulmonary Hypertension	Cardiomyopathy	
Husser	Oliver	Interventional Cardiology: TAVR 3	Multicenter Evaluation of the ACURATE Neo Transfemoral Transcatheter Heart Valve: Clinical Results and Propensity Matched Comparison With SAPIEN 3	
Husser	Oliver	Interventional Cardiology: TAVR 4	Multicenter Evaluation of Prosthesis Oversizing for the SAPIEN 3 Transcatheter Heart Valve: Impact on New Pacemaker Implantations	CONSULTANT FEES/HONORARIA - Symetis S.A.; OTHER - Edwards Lifesciences
Husser	Oliver	Interventional Cardiology: PCI in Complex Patients	Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated Heparin Following Transcatheter Aortic Valve Replacement: Results From the Bravo-3 Randomized Trial	CONSULTANT FEES/HONORARIA - Symetis S.A.; OTHER - Edwards Lifesciences
Husted	Steen	Arrhythmias and Clinical EP: Anticoagulation Issues	Use of Interacting Drugs Did Not Modify Treatment Effects of Apixaban Versus Warfarin for Atrial Fibrillation: Results From the ARISTOTLE Trial	CONSULTANT FEES/HONORARIA - AstraZeneca,Bayer,Boehringer Ingelheim,Pfizer; RESEARCH/RESEARCH GRANTS - GSK
Huston	Jessica	35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1	Suggested Reviewer	Nothing to Disclose
Hutchinson	Barbara	Emerging Issues in CV Disease Management: International Perspectives From the Brazilian Society of Cardiology, Turkish Society of Cardiology, and American College of	Emerging Issues in Cardiovascular Disease Management	Nothing to Disclose
Hutchison	Stuart	Cardiology Vascular Medicine: Aortic and Peripheral	Acute Aortic Dissection in Patients Without a History of Hypertension	Nothing to Disclose
Hutter	Adolph	Artery Diseases Hearts and Soles: Multimodality Imaging in	Temporal Sequence of Athlete's Heart Regression During	Nothing to Disclose
Huynh	Nick	Athletes Advancing Our Understanding of Aortic	Prescribed Exercise Detraining: <i>Diagnostic Implications</i> Clinical and Pathologic Findings of Aortic Dissection at Autopsy:	Nothing to Disclose
Huynh	Thao	Disease Blips, Trops, and Chips: New Ways to Diagnose CAD	Review of 338 Cases Over 6 Decades Artificial Intelligence to Diagnose Acute Coronary Syndromes: Insights From a Meta-Analysis of Machine Learning	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc; RESEARCH/RESEARCH GRANTS -
Hwang	Inyong	Revascularization and Myocardial Preservation	An Updated Comprehensive Meta-Analysis Comparing Drug-Eluting	Bayer Healthcare Pharmaceuticals, Bristol Myers Squibb Nothing to Disclose
		in Acute and Stable Ischemic Heart Disease	Stents With Bare Metal Stents in Saphenous Vein Graft Interventions	1
Hwang	Jin-Yong	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Coronary Angiography, Intra-Vascular Imaging,	Clinical Efficacy of High-Flow Oxygen Therapy Through Nasal Cannula in Patients With Acute Heart Failure Impact of Platelet-Fibrin Clot Strength on Occurrence of In-Stent	Nothing to Disclose Nothing to Disclose
Hwang	Jin-Yong	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of Platelet-Fibrin Clot Strength on Occurrence of In-Stent Restenosis in Patient With Drug Eluting Stent	Trouting to Disclose

Carried States				l l
Last Name Hwang	First Name Jin-Yong	Session Title Non Invasive Imaging: Prognostic Implications	Presentation Title Prognostic Value of Platelet-Fibrin Clot Strength on Occurrence of	Disclosures Nothing to Disclose
Hwang	Jin-Yong	of CT Angiography Antithrombotic Therapy in Ischemic Heart	Cardiovascular Events After Non-Cardiac Surgery Ticagrelor Versus Clopidogrel Is Associated With Better Recovery of	Nothing to Disclose
Hwang	Ki Won	Disease Arrhythmias and Clinical EP: Basic 3	LV Function After Acute Myocardial Infarction Atrial Fibrillation Cycle Length Measured by Transesophageal	Nothing to Disclose
			Echocardiography: A Predictor for Maintaining Sinus Rhythm After DC Cardioversion	·
Hwang	Seok-Jae	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Clinical Efficacy of High-Flow Oxygen Therapy Through Nasal Cannula in Patients With Acute Heart Failure	Nothing to Disclose
Hwang	Seok-Jae	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of Platelet-Fibrin Clot Strength on Occurrence of In-Stent Restenosis in Patient With Drug Eluting Stent	Nothing to Disclose
Hwang	Seok-Jae	Antithrombotic Therapy in Ischemic Heart Disease	Ticagrelor Versus Clopidogrel Is Associated With Better Recovery of LV Function After Acute Myocardial Infarction	Nothing to Disclose
Hyden	Marshall	Innovative Use of Echocardiography	With Cardiac Magnetic Resonance Imaging in the Assessment of Right Ventricular Function Post Orthotopic Heart Transplantation	Nothing to Disclose
Hyder	Omar	Highlights in Vascular Medicine Research	Thirty-Day Readmissions Following Endovascular or Surgical Treatment for Critical Limb Ischemia: Analysis of the Nationwide	Nothing to Disclose
Hylek	Elaine	Controversies in Atrial Fibrillation Management	Readmissions Database What I do with the CHADS-VASc 1 Patient? To Anticoagulate or not	CONSULTANT FEES/HONORARIA - Bayer,Boehringer
			Anticoagulate	Ingleheim,Bristol Myers Squibb,Daiichi Sankyo,MEDTRONIC,Pfizer,Portola; RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals, Inc
Hylek	Elaine	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Rates of Oral Anticoagulant Use, While Improving Over Time, Remain Low Among Hospitalized Patients With Atrial Fibrillation	CONSULTANT FEES/HONORARIA - Bayer,Boehringer Ingleheim,Bristol Myers Squibb,Daiichi Sankyo,MEDTRONIC,Pfizer,Portola; RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals, Inc
Hylek	Elaine	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Does Frailty Alter the Benefits of Oral Anticoagulation in Patients With Atrial Fibrillation?	CONSULTANT FEES/HONORARIA - Bayer,Boehringer Ingleheim,Bristol Myers Squibb,Daiichi Sankyo,MEDTRONIC,Pfizer,Portola; RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals, Inc
Hylek	Elaine	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)	CONSULTANT FEES/HONORARIA - Bayer,Boehringer Ingleheim,Bristol Myers Squibb, Daiichi Sankyo,MEDTRONIC,Pfizer,Portola; RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals, Inc
Hynes	Brian	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Facilitation of Stent Delivery With the GuideLiner Catheter	Nothing to Disclose
Hyodo	Makoto	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Long-Term Vascular Response to Permanent Polymer Everolimus- Eluting Stent Compared With Biodegradable Polymer Biolimus- Eluting Stent: Five-Year Follow-Up Optical Coherence Tomography Study	Nothing to Disclose
Hyodo	Makoto	Coronary Intervention in Interventional Cardiology: Core Concepts	Incidence and Clinical Impact of Longitudinal Stent Deformation After the PROMUS Element Platinum Chromium-Everolimus Eluting Stent Implantation	Nothing to Disclose
Hyodo	Makoto	Interventional Cardiology: PCI in Complex Patients	Three-Year Clinical Outcomes of the XIENCE/PROMUS Cobalt- Chromium Everolimus-Eluting Stent in Patients Treated With In- Stent Restenosis	Nothing to Disclose
Hyun Kuk	Kim	Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	Renal Nerve Denervation Suppress Ventricular Arrhythmia in a Porcine Model After Acute Myocardial Infarction	Nothing to Disclose
ladanza	Alessandro	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve	Nothing to Disclose
lakobishvili	Zaza	Trends in Coronary Syndromes: International	Replacement: From the WIN-TAVI Registry Temporal Trends in Pre-Hospital Management of STE-ACS	Nothing to Disclose
		Perspectives From the ACC Great Britain and Ireland Chapter, Israel Heart Society, and American College of Cardiology	· · · · ·	
lakovou	Ioannis	Revascularization and Outcomes	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study	Nothing to Disclose
lannatonne	Patrick	Blips, Trops, and Chips: New Ways to Diagnose CAD	Artificial Intelligence to Diagnose Acute Coronary Syndromes: Insights From a Meta-Analysis of Machine Learning	Nothing to Disclose
Ibanez	Borja	Cardiovascular Update for the Clinician I: Coronary Artery Disease – Challenges in 2017 (A Symposium by Dr. Valentin Fuster)	Panelist	Nothing to Disclose
Ibanez	Borja	Cardiovascular Update for the Clinician I: Coronary Artery Disease – Challenges in 2017 (A Symposium by Dr. Valentin Fuster)	 <td>Nothing to Disclose</td>	Nothing to Disclose
Ibañez	Borja	Highlights in Vascular Medicine Research	Global Plaque Burden by Carotid and Femoral 3D Vascular Ultrasound: The PESA (Progression and Early Detection of Subclinical Atherosclerosis) Study	Nothing to Disclose
Ibañez	Borja	Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools	Predictive Values of the Ideal Cardiovascular Health and the Fuster- BEWAT Scores for Detecting Subclinical Atherosclerosis in Healthy Individuals	Nothing to Disclose
Ibañez	Borja	Improving Risk Assessment in Atherosclerosis	Subclinical Atherosclerosis in the Absence of Cardiovascular Risk Factors: Pre-Risk Status in the PESA (Progression of Early Subclinical Atherosclerosis) Study	Nothing to Disclose
Ibebuogu	Uzoma	Interventional Cardiology: Structural Heart Disease	Outcomes of Early Versus Delayed Transcatheter Closure of Post- Myocardial Infarction Ventricular Septal Defect	Nothing to Disclose
Ibebuogu	Uzoma	Timely Topics in Acute Coronary Syndromes	Predictors of True ST-Segment Elevation Myocardial Infarction in Cocaine Positive Patients	Nothing to Disclose
Ibebuogu	Uzoma	Innovations in Advocacy and Patient Centered Care	Prolonged Inter-facility Transfer Times and Hospital Length of Stay in Insured Patients with ST-elevation Myocardial Infarction	Nothing to Disclose
Ibrahim	Ahmed	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Combined Migraine and Platypnea-Orthodeoxia Syndrome Due to Combined Atrial Septal Defect and Patent Foramen Ovale	Nothing to Disclose
Ibrahim	Ahmed	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Double Right Coronary Artery Engendering Inadequate Blood Supply to the Inferior Left Ventricular Wall	Nothing to Disclose
Ibrahim	Homam	Interventional Cardiology: TAVR 2	Platelets and von Willebrand Factor Interactions After Transcatheter Aortic Valve Replacement (TAVR): Association With Thrombocytopenia and Thrombosis	Nothing to Disclose
Ibrahim	Homam	Optimizing the Care of ACS Patients	Contemporary Patterns of GP IIb/IIIa Inhibitor Use in Patients With Acute Myocardial Infarction Undergoing PCI: Insights From the TRANSLATE ACS Study	Nothing to Disclose
Ibrahim	Nasrien	Making Progress in Understanding Heart Failure	Circulating Concentrations of Orexin A Are Associated With Left Ventricular Reverse Remodeling and Clinical Outcomes Following Cardiac Resynchronization Therapy	Nothing to Disclose
Ibrahim	Nasrien	Making Progress in Understanding Heart Failure	Serial Assessment of Heart Rate and Beta Blocker Use in Chronic Heart Failure Patients With Reduced Ejection Fraction in a Large Integrated Healthcare Network	Nothing to Disclose
Ibrahim	Nasrien	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Multiple Biomarkers for Predicting Major Adverse Cardiac Events in At-Risk Patients Undergoing Diagnostic Coronary Angiography: Results From the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study	Nothing to Disclose

Congress of				
Last Name Ibrahim	First Name Reda	Session Title Structural Heart Interventions: Focus on Mitral	Presentation Title Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation	Disclosures CONSULTANT FEES/HONORARIA - Abbott
ibranim	Reda	Valve, Left Atrial Appendage and HOCM	and Previous Major Gastrointestinal Bleeding: Insight From the Amplatzer Cardiac Plug Multicenter Registry	Laboratories, AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Boston Scientific, Bristol-Myers Squibb Compan ,Gore Medical; RESEARCH/RESEARCH GRANTS - MHICC
Igwe	Chinedu	Unusual Presentations of ACS	Outcomes of Immediate Versus Delayed Intervention in Patients	Nothing to Disclose
	Deievive	The Frenchise World of LVADs Transplant and	Presenting 24 -72 Hours After Myocardial Infarction Evaluation of Hemoconcentration Based Bioelectrical Vectorial	Nothing to Disclose
lijima	Raisuke	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Impedance Analysis Is Useful Risk Stratification in Acute Decompensated Heart Failure	-
lijima	Raisuke	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Body Fat Percentage Evaluated by a Bioelectrical Impedance Analysis Provides Prognostic Value in Acute Heart Failure: Beyond on the "Obesity Paradox"	Nothing to Disclose
Ijioma	Nkechinyere	Engage @ ACC.17 Studio: FIT Jeopardy Battle of the State Chapters I		Nothing to Disclose
Ijioma	Nkechinyere	FIT Clinical Decision Making Reviewers 4	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
ljsselhof	Rinske	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Residual Atrioventricular Valve Regurgitation Pre-Discharge Is Associated With Post-Discharge Reinterventions Following Complete Atrio Ventricular Septal Defect Repair	Nothing to Disclose
Ikeda	Nobutaka	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Evaluation of Hemoconcentration Based Bioelectrical Vectorial Impedance Analysis Is Useful Risk Stratification in Acute Decompensated Heart Failure	Nothing to Disclose
Ikeda	Nobutaka	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Body Fat Percentage Evaluated by a Bioelectrical Impedance Analysis Provides Prognostic Value in Acute Heart Failure: Beyond on the "Obesity Paradox"	Nothing to Disclose
Ikeda	Takanori	Novel Developments in Acute Coronary Syndromes	Left Ventricular End-Diastolic Pressure Predicts Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Independently of Left Ventricular Systolic Function	Nothing to Disclose
Ikemura	Nobuhiro	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Compliance to Updated AHA/ACC Quality Measures Among Patients With Atrial Fibrillation in Japan and Its Association With	Nothing to Disclose
Ikemura	Nobuhiro	Unusual Presentations of ACS	Their Quality of Life C-Reactive Protein in Non-ST Elevation Myocardial Infarction Patients Is Useful in Improving Discrimination of Conventional Risk	Nothing to Disclose
Ikemura	Nobuhiro	Unusual Presentations of ACS	Score: A Report From Multicenter PCI Registry Trend of Use in Transradial Intervention Among Elderly Patients in	Nothing to Disclose
			Japan According to Their Pre-Procedural Bleeding Risk	-
Ikonomidis Ikutomi	John Masayasu	36. Valvular Heart Disease: Clinical Team 1 Head to Toe: Outcomes of Endovascular	Suggested Reviewer Peri-Strut Low Intensity Area Predicts Neointimal Progression	Nothing to Disclose Nothing to Disclose
	-	Interventions	Associated With Late Enlargement of Self-Expanding Nitinol Stents in Superficial Femoral Arteries: An Optical Coherence Tomography Study	
Iliadis	Elias	Updates on Pulmonary Embolism Management in 2017	Ultrasound Accelerated Catheter Directed Lytic Therapy for Management of Pulmonary Embolism: Impact of Procedural Timing on Echocardiographic Outcomes and Safety	SPEAKER'S BUREAU - Bristol-Myers Squibb Company
Iliescu	Cezar	Head to Toe: Outcomes of Endovascular Interventions	Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease	Nothing to Disclose
Iliescu	Cezar	Making Progress in Understanding Heart Failure	Stress Induced Cardiomyopathy Triggered by Chemotherapy: When Should Cancer Therapy Be Restarted?	Nothing to Disclose
Iliescu	Cezar	Venous Investigation: The Dark Side	3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis	Nothing to Disclose
Iliescu	Cezar	Optimizing the Care of ACS Patients	Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients	Nothing to Disclose
Iliescu	Gloria	Making Progress in Understanding Heart Failure	Stress Induced Cardiomyopathy Triggered by Chemotherapy: When Should Cancer Therapy Be Restarted?	Nothing to Disclose
Illescas González	Edgar Alexander	Emerging Developments in HFpEF and	Diagnostic Utility of Goldberger's Electrocardiographic Triad in	Nothing to Disclose
Illescas González	Edgar Alexander	Arryhthmias Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Predicting Left Ventricular Dysfunction in Chagas' Heart Disease QRS Fragmentation Predicts Myocardial Fibrosis, Left Ventricular Dysfunction and Ventricular Tachycardia in Chagas´ Disease	Nothing to Disclose
llonze	Onyedika	Changing the Natural History of Valve Disease With Medical Therapy	Rates of Mechanical Valve Thrombosis After Discontinuation of Anticoagulation	Nothing to Disclose
lm	Eui	Considerations in Antiplatelet Therapy and in ACS	Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multi-Vessel Disease on Outcomes in Patients Treated	Nothing to Disclose
Im	Sung II	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	With Newer-Generation Drug-Eluting Stents Clinical and Electrocardiographic Characteristics for Prediction of New-Onset Left Ventricular Dysfunction in Patients With Frequent	Nothing to Disclose
Imamura	Teruhiko	Acute Heart Failure: Evaluating Strategies to	Idiopathic Ventricular Premature Complex >10% Correlation of Noninvasive Assessment of Lung Fluid Percentage	Nothing to Disclose
Imran	Tasnim	Prevent Readmissions Updates on Risk Factors for Cardiovascular	With Invasively Measured Hemodynamics Walking Pace Is Inversely Associated With Risk of Death and Cardiovacy Language. The Proceedings ##9217: Health Study	Nothing to Disclose
Imran	Tasnim	Disease Emerging Developments in HFpEF and	Cardiovascular Disease: The Physicians' Health Study Serum Sodium Is Associated With Mortality in Heart Failure With	Nothing to Disclose
Imundo	Jason	Arryhthmias FIT Clinical Decision Making: Arrhythmias and	Preserved Ejection Fraction in the U.S. Veteran Population That Is Not a Seizure, It's VT: A Unique Presentation of Acquired	Nothing to Disclose
Inage	Akio	Electrophysiology Redefining the "F" Word	Long QT Syndrome Evaluation of Right Ventricular Function in Fontan Physiology Using	Nothing to Disclose
		-	Feature Tracking Magnetic Resonance Strain, Strain Rate and Wall Motion Delay	-
Inampudi	Chakradhari	Things That Matter in Adult Congenital Heart Disease	Gender Differences in Rates of Hospitalizations for Decompensated Heart Failure Among Adults With Congenital Heart Diseases in the United States: A 15 Year Experience	
Inan	Omer	Can You See Me Now? Sensors For Monitoring Heart Failure	Panelist	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Physiowave
Inan	Omer	Can You See Me Now? Sensors For Monitoring Heart Failure	Haute Couture - Engineering the Future of Wearable Sensors	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Physiowave
Indik	Julia	Teaching with Intent: Secrets from the Masters II Late-Breaking Clinical Trials	Preparing to Chair a Session at the Annual Meeting (interviewer)	Nothing to Disclose
Indik Indik	Julia Julia	Test Yourself with Questions: General	Panelist Faculty	Nothing to Disclose Nothing to Disclose
Indik	Julia	Cardiology Module 14 Test Yourself with Questions: General Cardiology Module 14	Chair	Nothing to Disclose
Indik	Julia	Test Yourself with Questions: General Cardiology Module 14	Faculty	Nothing to Disclose
Indik	Julia	Innovations in Education	ACC In-Training Examination Predicts Outcomes on the ABIM Certification Examination	Nothing to Disclose
Indik	Julia	Engage @ ACC.17 Studio: Cardiology Contest		Nothing to Disclose
Indolfi	Ciro	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International	Nothing to Disclose

and a					
Last Name Infeld	First Name Margaret	Session Title FIT Clinical Decision Making: Arrhythmias and	Presentation Title Alternating Bundle Branch Block: Clinical Considerations	Disclosures Nothing to Disclose	
Infeld	Margaret	Electrophysiology Antiplatelet and Antithrombotic Agents in	The Effect of Race on the Antiplatelet Effects of Ticagrelor and	Nothing to Disclose	
	=	Ischemic Heart Disease	Aspirin	3	
Infeld Ingles	Margaret Jodie	Anti-Platelet Therapies: Always a Sticky Topic Advances in HCM, PPCM and Other	Influence of Sex on Platelet Response to Aspirin and Ticagrelor Non-Familial Hypertrophic Cardiomyopathy: Prevalence, Natural	Nothing to Disclose Nothing to Disclose	
Inglessis	Ignacio	Cardiomyopathies Surgical and Transcatheter Valve Therapy for Congenital Heart Disease	History and Clinical Implications Panelist	CONSULTANT FEES/HONORARIA - Edwar medical.MEDTRONIC,St Jude Medical; SPE/	
Inglessis	Ignacio	Surgical and Transcatheter Valve Therapy for	Update on Transcatheter Valve Therapy for the Native RVOT	Abiomed CONSULTANT FEES/HONORARIA - Edwar	rds
		Congenital Heart Disease		medical,MEDTRONIC,St Jude Medical; SPE/ Abiomed	
Inglessis	Ignacio	Imaging Transcatheter Mitral Valve Repair and Replacement	Panelist	CONSULTANT FEES/HONORARIA - Edwar medical,MEDTRONIC,St Jude Medical; SPE/ Abiomed	
Iniguez Romo	Andres	Imaging and Infections: International Perspectives From the Spanish Society of Cardiology, Venezuelan Society of Cardiology, and American College of Cardiology	Co-Chair	Nothing to Disclose	
Ino	Yasushi	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Comparison of Very Late Vascular Response Beyond 2 Years After Stent Implantation Between EES and BES: An OCT Sub-Study of the NEXT	Nothing to Disclose	
Inohara	Taku	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Compliance to Updated AHA/ACC Quality Measures Among Patients With Atrial Fibrillation in Japan and Its Association With Their Quality of Life	Nothing to Disclose	
Inohara	Taku	Interventional Complexity and Complications	Impact of Institutional and Operator Volume on Short-Term Outcomes of Percutaneous Coronary Intervention: A Report From Japanese Nationwide Registry	Nothing to Disclose	
Inohara	Taku	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Performance of the MAGGIC Heart Failure Risk Score in Japanese Acute Heart Failure Patients: A Report From the West Tokyo Heart	Nothing to Disclose	
Inotani	Satoshi	FIT Clinical Decision Making: Heart Failure and		Nothing to Disclose	
Inoue	Mamiko	Pulmonary Hypertension Vascular Medicine: Aortic and Peripheral	Critical to Save Lives of Patients Molecular Determinants of Functional Changes and Fibrosis	Nothing to Disclose	
		Artery Diseases	Determined by Novel Automated Oscillometric Approach to Measure Brachial Artery Vascular Volume Elastic Modulus in Chronic Kidney Disease		
Inoue	Naoto	Coronary Intervention in Interventional Cardiology: Core Concepts	A Randomized Comparison of Frequency of Radial Artery Occlusion and Symptomatic Radial Artery Spasm Associated With Transradial Coronary Intervention Using 6.5-Fr Sheathless Guide Catheter TM Versus 6.0-Fr Glidesheath Slender TM	Nothing to Disclose	
Inoue	Takafumi	Non Invasive Imaging: New Technologies	Medium Contrast Enhancement Pattern of Left Atrial Appendage in Cardiac CT Predicts Stroke Risk in Patients With Atrial Fibrillation	Nothing to Disclose	
Inzucchi	Silvio	Preventing ASCVD in Diabetes: Are These New Drugs for Real?	SGLT 2 Inhibitors: Lessons Learned from EMPA-REG	CONSULTANT FEES/HONORARIA - AstraZ Pharmaceuticals,Boehringer Ingelheim,Janssen,Lexicon,Merck,Poxel,San Therapeutics; DATA SAFETY MONITORING Intarcia,Novo Nordisk; SALARY - Elsevier	ofi-Aventis,VTV
Inzucchi	Silvio	Highlighted Original Research: Prevention and the Year in Review	Consistent Effect of Empagliflozin on Composite Outcomes Related to Heart Failure: Results From EMPA-REG OUTCOME	CONSULTANT FEES/HONORARIA - AstraZ Pharmaceuticals,Boehringer Ingelheim,Janssen,Lexicon,Merck,Poxel,San Therapeutics; DATA SAFETY MONITORING Intarcia,Novo Nordisk; SALARY - Elsevier	ofi-Aventis,VTV
Inzucchi	Silvio	Updates in Stable Ischemic Heart Disease	Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-World Impact of the Leader Trial on Improving Cardiovascular Outcomes in Patients With Diabetes at High Cardiovascular Risk	Nothing to Disclose	
lorgulescu	Corneliu Nicolae	Arrhythmias and Clinical EP: Devices 2	Left Bunde Branch Block Is Incomplete in the Majority of Patients With Heart Failure Due to Systolic Left Ventricle Dysfunction: A Simple Intraprocedural Demonstration	Nothing to Disclose	
losif	Koutagiar	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Association of Abdominal Aortic Wall Inflammation, Hepatic Fluorodeoxyglucose Uptake AND Visceral Adipose Tissue Biological Activity in Patients With Dyslipidemias	Nothing to Disclose	
losif	Koutagiar	Nuclear Cardiology: Beyond Perfusion	Increased Subclinical Systemic AND Vascular Inflammation in Familial Combined Hyperlipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission Tomography Study	Nothing to Disclose	
losif	Koutagiar	Cutting Edge Vascular Medicine	Familial Combined Hyperlipidemia Is Characterized by Higher Arterial AND Hepatic Fluorodeoxyglucose Uptake Compared to Heterozygous Familial Hypercholesterolemia	Nothing to Disclose	
lp	James	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System	Nothing to Disclose	
lp	James	Stroke and AF: Thinking About the Heart	Coronary verious system Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy: Insights Into Rates and Timing of Thrombus Resolution	Nothing to Disclose	
lp	James	FIT Clinical Decision Making: Arrhythmias and Clinical Electrophysiology	A Novel Complication and Treatment Strategy in Pacemaker- Induced Superior Vena Cava Syndrome	Nothing to Disclose	
Iqbal	Javaid	Considerations in Antiplatelet Therapy and in ACS	Through Superior Verla Cava Symothrie Comparison of P2y-sub-12-(sub-) Inhibitors for Mortality and Stent Thrombosis in Patients With Acute Coronary Syndromes: Single Centre Study of 10,793 Consecutive 'Real-World' Patients	Nothing to Disclose	
Iqbal	Javaid	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Investigating the Smoker's Paradox by Gender: Differences in Survival Following Acute ST-Segment Elevation Myocardial Infarction	Nothing to Disclose	
lqbal	Javaid	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Increased Risk of Acute ST-Segment Myocardial Infarction in Female Smokers: A Contemporary Demographic Study	Nothing to Disclose	
Iribarne	Alexander	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking	Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic	Nothing to Disclose	
Iribarne	Alexander	Clinical Trials Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Surgical Trials Network Is CABG the Best Revascularization Strategy Among All Diabetics Subgroups With Multi-Vessel Disease in the Modern Era? A Multi-	Nothing to Disclose	
Irwin-Weyant	Morgan	Imaging the Athlete's Heart	Center Analysis Differential American-Style Football Training Intensities and Cardiac	Nothing to Disclose	
Irwin-Weyant	Morgan	Imaging the Athlete's Heart	and Vascular Remodeling Patterns Sleep Disordered Breathing and Cardiovascular Correlates in	Nothing to Disclose	
*	=	<u> </u>	Collegiate American Style Football Participants	<u> </u>	

-				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Isawa	Tsuyoshi	Coronary Intervention in Interventional Cardiology: Core Concepts	A Randomized Comparison of Frequency of Radial Artery Occlusion and Symptomatic Radial Artery Spasm Associated With Transradial Coronary Intervention Using 6.5-Fr Sheathless Guide Catheter TM Versus 6.0-Fr Glidesheath Slender TM Versus 6.0-Fr Glidesheath	Nothing to Disclose
Isawa	Tsuyoshi	Coronary Intervention in Interventional Cardiology: Core Concepts	Comparison of Radial Artery Occlusion After Transradial Coronary Intervention Using a New Dedicated Radial Sheath Versus a Sheathless Guiding Catheter	Nothing to Disclose
Ishai	Amorina	Innovations in Cardiovascular Risk Assessment and Reduction	Resting Amygdalar Activity Associates With Future Changes in Adiposity: Implications for Atherosclerotic Disease	Nothing to Disclose
Ishak	Jack	Assessing the Clinical Impact of Blood	Additivity of Nebivolol/Valsartan Single-Pill Combinations Versus	Nothing to Disclose
Ishfaq	Muhammad	Pressure Lowering Therapies Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Other Approved Single-Pill Combinations for Hypertension Comparison of B-Type Natriuretic Peptide Assays for Identifying Adverse Events in Patients With Chronic Obstructive Pulmonary Disease: Meta-Analysis of Randomized and Non-Randomized Studies	Nothing to Disclose
Ishihara	Masaharu	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Differences in Chronic Angioscopic Findings With Different Stent Types in Patients With and Without Diabetes Mellitus: Sub-Analysis of a Report From Japanese Multicenter Registry	RESEARCH/RESEARCH GRANTS - Abbott Vascular Japan Co., Ltd., Astelias Pharma Inc., Bayer Yakuhin, Ltd., Boston Scientific Japan K.K., Eisai Co., Ltd., Fukuda Denshi Co., Ltd., Guda Denshi Co., Ltd., Guda Denshi Co., Ltd., Goodman Co., LTD., MID, Inc., Misubishi Tanabe Pharma Corporation, MCCHIDA PHARMACEUTICAL CO., LTD., MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Pizer Japan Inc., Sanofi K.K., Teijin Pharma Ltd.; SPEAKER'S BUREAU - Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., Kissei Pharmaceutical Co., Ltd., MSE K.K.
Ishikawa	Kiyotake	Non Invasive Imaging: MR Characterization and Function	Myocardial Oxygenation Using Blood Level-Oxygen Dependent Sequence in Magnetic Resonance Determines Myocardial Energetics and Capillary Density	Nothing to Disclose
Ishikawa	Kiyotake	Heart Failure and Cardiomyopathies: Is Heart	LV Unloading Using Impella CP Improves LA Pressure, Function,	Nothing to Disclose
Ishikawa	Kiyotake	Failure With a Normal EF for Real? Novel Developments in Acute Coronary	and Stiffness in Ischemic Pig Model LV Unloading using an Impella CP Improves Coronary Flow and	Nothing to Disclose
Ishmael	Richard	Syndromes Perspectives on Congenital Heart Disease: International Perspectives From the Caribbean Cardiac Society, Peruvian Society of Cardiology, and American College of Cardiology	Infarct Zone Perfusion Congenital Heart Disease in the Caribbean	Nothing to Disclose
Islam	Mohammad Nazrul	Emerging CV Problems in the Developing World: International Perspectives From the ACC Bangladesh Chapter, Indonesian Heart Association, and American College of Cardiology	Do Current Lipid Guidelines Apply to "South Asians"?	Nothing to Disclose
Isley	Michael	Interventional Cardiology: Structural Heart Disease	Transcatheter Mitral Valve-in-Ring Implantation After Failure of Surgical Mitral Ring Annuloplasty	Nothing to Disclose
Ismaeel	Hussain	Population Specific Cardiomyopathies: From Exomes to Databases	Targeted and Exome Sequencing of 27 Lebanese Patients With Cardiomyopathies: Novel Variants in Known Genes, and Potential Novel Genes	Nothing to Disclose
Ismail	Ammar	ACC International Conferences Best Posters	Transcatheter Aortic Valve Replacement Versus Surgical AorticValve Replacement in Aortic Stenosis Patients at Low to Moderate Risk of Surgery: A Meta-Analysis of 25,737 Patients' Data	Nothing to Disclose
Ismail	Omar	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Not All Shocks Are Created Equal: Acute Coronary Syndrome in the Setting of Panhypopituitarism	Nothing to Disclose
Isobe	Mitsuaki	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Significance of Microcirculatory Resistance in Visual-Functional Mismatch Between Coronary Angiography and Fractional Flow Reserve in Non-Left Main Lesions	Nothing to Disclose
Isobe	Mitsuaki	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Usefulness of Optical Coherence Tomography-Derived Morphometric Assessment to Predict Physiological Significance of Coronary Artery Stenosis and Determinants of Mismatch: Head-to- Head Comparison With Intravascular Ultrasound	Nothing to Disclose
Isobe	Mitsuaki	Insights From Echocardiography Use	Value of Automated and Semi-Automated Measurement by Novel Three-Dimensional Echocardiography Software for Aortic Annulus Sizing in Candidates of Transcatheter Aortic Valve Replacement: Comparison With Multi-Detector Computed Tomography	Nothing to Disclose
Isogawa	Akihiro	Insights From Echocardiography Use	Relation of Left Ventricular Remodeling to Left Ventricular Diastolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	Nothing to Disclose
Isogawa	Akihiro	Insights From Echocardiography Use	Relation of Left Ventricular Remodeling to Left Ventricular Systolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	Nothing to Disclose
Isomura	Naoei	Advances in Chronic Total Occlusion Intervention	The Impact of Recanalization of Chronic Total Occuluded Coronary Artery on Electrophysiological Substrate of Left Ventricle	Nothing to Disclose
Isomura	Naoei	Interventional Cardiology: PCI in Complex Patients	Chronic Stent Recoil During Follow-Up in Severely Calcified Coronary Artery Lesions: An Optical Coherence Tomography Study	Nothing to Disclose
Issa Isselbacher	Omar Eric	Arrhythmias and Clinical EP: Devices 4 Vascular Medicine: Novel Risk Measures in	ECG Criteria for the Identification of Bi-Ventricular Pacing Body Mass Index and Acute Aortic Dissection	Nothing to Disclose Nothing to Disclose
Isselbacher	Eric	Arterial Diseases Vascular Medicine: Emerging Concepts in	Influence of Family History of Aortic Disease on Type B Aortic	Nothing to Disclose
		Clinical Vascular Diseases	Dissection	
Isselbacher	Eric	Beans, Beans, Good for Your Heart	Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection	Nothing to Disclose
Isselbacher	Eric	Vascular Medicine: Aortic and Peripheral Artery Diseases	Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection	Nothing to Disclose
Isselbacher	Eric	Vascular Medicine: Aortic and Peripheral Artery Diseases	Uncontrolled Hypertension in Acute Aortic Dissection Follow-Up	Nothing to Disclose
Isselbacher	Eric	Vascular Medicine: Aortic and Peripheral Artery Diseases	Acute Aortic Dissection in Patients Without a History of Hypertension	Nothing to Disclose
Isselbacher	Eric	Novel Determinants of Outcomes in VHD	Relationship Between Proximal Aorta Morphology and Progression Rate of Aortic Stenosis	Nothing to Disclose
Itagaki	Shinobu	Infectious Endocarditis: Comprehensive	Long-Term Benefits of Repair Versus Replacement for Acute Native	Nothing to Disclose
Itchhaporia	Dipti	Perspectives Diabetes, Hyperlipidemia, and Coronary Artery Disease, Prevention and Treatment: International Perspectives From the Japanese College of Cardiology, Saudi Heart Association, and American College of	Mitral Valve Endocarditis Co-Chair	RESEARCH/RESEARCH GRANTS - St Judes Medical
1	1	Cardiology	<u>l</u>	

Contract of the second				
Last Name Itchhaporia	First Name Dipti	Session Title Diabetes, Hyperlipidemia, and Coronary Artery	Presentation Title Introduction to Session	Disclosures RESEARCH/RESEARCH GRANTS - St Judes Medical
пстпарона	Біріі	Disease, Prevention and Treatment: International Perspectives From the Japanese College of Cardiology, Saudi Heart	introduction to Session	RESEARCH/RESEARCH GRANTS - St Judes Medical
		Association, and American College of Cardiology		
Ito	Izumi		Primary Cardiac Lymphoma: Early Initiation of Chemotherapy Is Critical to Save Lives of Patients	Nothing to Disclose
Ito	Saki	Novel Determinants of Outcomes in VHD	Coexisting Co-Morbidities Exacerbate Left Ventricular Diastolic Dysfunction and Prognosis in Patients With Severe Aortic Stenosis	Nothing to Disclose
Ito	Seiji	Adult Patients With Congenital Heart Disease: How Do They Compare?	Factors Associated With Completion of Advanced Directives in Adults With Congenital Heart Disease	Nothing to Disclose
Ito	Yoichi	Vascular Medicine: Aortic and Peripheral	Molecular Determinants of Functional Changes and Fibrosis	Nothing to Disclose
		Artery Diseases	Determined by Novel Automated Oscillometric Approach to Measure Brachial Artery Vascular Volume Elastic Modulus in Chronic Kidney Disease	
Ivanov	Alexander	Highlighted Original Research: Non Invasive Imaging and the Year in Review	The Association of High Risk Plaque Features and Non-Invasive Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography in Patients With Acute Chest Pain: Results From the ROMICAT II Trial	Nothing to Disclose
Iversen	Kasper	Post-CAD/Ml: Making Tough Predictions About the Future	and Heart Failure in Patients With ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
lwai	Sei	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Sinus Node Dysfunction in Batten Disease: A Rare Manifestation of a Rare Disease	CONSULTANT FEES/HONORARIA - Biosense-Webster, Boston Scientific Corp., Medtronic, Inc.; DATA SAFETY MONITORING BOARD - Biotronik
lwai	Sei	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Arrhythmias in Hospitalized Heart Transplanted Patients: A United States National Study	CONSULTANT FEES/HONORARIA - Biosense-Webster, Boston Scientific Corp., Medtronic, Inc.; DATA SAFETY MONITORING BOARD - Biotronik
lx	Joachim	New Insights Into Prediction and Treatment of Hypertension	Collagen Turnover Markers Predict New Onset of Hypertension in Normotensive Subjects: The Multi-Ethnic Study of Atherosclerosis	Nothing to Disclose
lyengar	Rupa	Updates on Risk Factors for Cardiovascular Disease	Exposure to Particulate Matter in World Trade Center Law Enforcement and Its Relationship to Cardiovascular Risk	Nothing to Disclose
lyer	Arun	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Risk of Heart Failure in Systemic Sclerosis	Nothing to Disclose
lyer	Arun	Innovations in Cardiovascular Risk Assessment		Nothing to Disclose
lyer	Seethalakshmi	and Reduction Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Events in Systemic Lupus Erythematosus Intrarenal Renin Angiotensin System Activation: Pathophysiologic and Therapeutic Implications in Acute Decompensated Heart	Nothing to Disclose
lyer	Seethalakshmi	Young Investigator Awards Competition: Basic	Failure NPA7, a First in Class Dual Receptor Activator With Cardio-	Nothing to Disclose
lyer	(Seetha) Vijay	and Translational Science Interventional Cardiology: TAVR 1	Renoprotective Properties <i> In Vivo</i> Intraoperative Change in Myocardial Contractility With Transcatheter Aortic Valve Replacement Predicts Cardiovascular Outcomes	Nothing to Disclose
lyer	Vijay	Interventional Cardiology: TAVR 1	Temporal Change in Myocardial Contractility After Transcatheter	Nothing to Disclose
lyer	Vijay	Interventional Cardiology: TAVR 4	Aortic Valve Replacement and Its Relationship With Quality of Life Predictors of Poor Quality of Life After Transcatheter Aortic Valve	Nothing to Disclose
Izquierdo	Barbara	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Replacement Incidence, Clinical Profile and Prognosis of Patients With Myocardial Infarction With Non-Obstructive Coronary Arteries in the Real World	Nothing to Disclose
Izumi	Naoko	Arrhythmias and Clinical EP: Anticoagulation Issues	Bleeding Risk Among Japanese Non-Valvular Atrial Fibrillation Patients Initiated on Apixaban, Dabigatran, Rivaroxaban or Warfarin	SALARY - Pfizer Japan, Inc
Izzo	Brett	Markers of Prognosis Associated With Elevated Blood Pressure	in the Real World Direct Transition to Dilated Cardiomyopathy Without Antecedent Left Ventricular Hypertrophy Is Uncommon Among Hypertensive	Nothing to Disclose
Jabara	Jordan	Vascular Medicine: Novel Risk Measures in	Subjects in a Large Clinical Cohort Body Mass Index and Acute Aortic Dissection	Nothing to Disclose
Jabbour	Richard	Arterial Diseases Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Provisional Versus Elective Two-Stenting Strategy for Unprotected True Left Main Bifurcation Lesions: A Sub-Study From Fails 2 Study	Nothing to Disclose
Jaber	Wael	Highlighted Original Research: Interventional Cardiology and the Year in Review	Implications of Worsening Right Ventricular Function Following Transcatheter or Surgical Aortic Valve Replacement: Insights From	RESEARCH/RESEARCH GRANTS - Cleveland Clinic,Edwards
Jaber	Wael	Interventional Cardiology: TAVR 1	PARTNER2A Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis	RESEARCH/RESEARCH GRANTS - Cleveland Clinic, Edwards
			After Aortic Valve Replacement: Insights From PARTNER 2A Trial	
Jaber	Wael	Non Invasive Imaging: Expanding Clinical Applications	Does Patient Prosthesis Mismatch Defined by CT LVOT Area Predict Downstream Clinical Outcomes?	RESEARCH/RESEARCH GRANTS - Cleveland Clinic, Edwards
Jaber	Wael	Valvular Heart Disease: Aortic Regurgitation	Etiology, Patient Characteristics and Surgical Outcomes of Acute Severe Aortic Regurgitation	RESEARCH/RESEARCH GRANTS - Cleveland Clinic, Edwards
Jaber	Wael	Updates on Risk Factors for Cardiovascular Disease	Declining Survival With Decreasing Exercise Time on Treadmill: Lessons From a 25-Year Cohort	RESEARCH/RESEARCH GRANTS - Cleveland Clinic, Edwards
Jaber	Wael	Arrhythmias and Clinical EP: Devices 3	Variability in Left Ventricular Ejection Fraction by Radionuclide Multigated Acquisition Scan Versus Echocardiography. Implications for Primary Prevention Implantable Cardioverter Defibrillators	RESEARCH/RESEARCH GRANTS - Cleveland Clinic, Edwards
Jaber	Wael	Interventional Cardiology: TAVR 2	Worsening Tricuspid Regurgitation and Increased Mortality After Aortic Valve Replacement: Insights From PARTNER2A	RESEARCH/RESEARCH GRANTS - Cleveland Clinic, Edwards
Jaber	Wael	Advances in HCM, PPCM and Other	Atrial Thrombus in Patients With Cardiac Amyloidosis: Prevalence	RESEARCH/RESEARCH GRANTS - Cleveland Clinic, Edwards
Jaber	Wael	Cardiomyopathies Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	and Implications for Therapy Referral for Pharmacologic Testing, a Marker of Poor Exercise Capacity, Confers a Higher Risk of Short and Long Term Mortality	RESEARCH/RESEARCH GRANTS - Cleveland Clinic,Edwards
Jaber	Wael	New Perspectives on CAD Risk Factors	Than Most Traditional Cardiac Risk Factors Except Age Changing Trends of Atherosclerotic Risk Factors Among Patients	RESEARCH/RESEARCH GRANTS - Cleveland Clinic,Edwards
Jaber	Wissam	Advances in Chronic Total Occlusion	With Acute Myocardial Infarction and Acute Ischemic Stroke Performance of J-CTO and PROGRESS CTO Scores in Predicting	Nothing to Disclose
uauei	v4l22dili	Intervention	Angiographic Success and Long-Term Clinical Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions	Iroumy to Discluse
Jackevicius	Cynthia	Emerging Developments in HFpEF and	Bleeding Risk of Direct Oral Anticoagulants Compared With	Nothing to Disclose
Jackevicius	Cynthia	Arryhthmias The Old and the New: Impact of Heart Failure	Warfarin in Patients With Atrial Fibrillation and Heart Failure Safety of Alpha Blockers in Patients With Heart Failure	Nothing to Disclose
Jackson	Elizabeth	Drug Therapies Maximally Effective Vascular Care: Vascular	Case Presentation #2: Panelist	CONSULTANT FEES/HONORARIA - American College of
- Cashadii	LILLUSCOT	Collaborative Team Care in Action	CONTROL TENTION	Cardiology, McKesson, Inc., National Association for Continuing Education, Up-To-Date; OTHER - American Heart Association, Association, American Journal of Medicine, Elsevier Publishing, National Institutes of Health, Spry Publishing

Contract of the Contract of th				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Jackson	Elizabeth	Cardiac Rehab in 2017: Tailoring The Approach to the Times	Overcoming Barriers of Transportation, Cost, and Cognition: In- Home Programs and Mobile Devices	CONSULTANT FEES/HONORARIA - American College of Cardiology,McKesson, Inc.,NationalAssociation for Continuing Education,Up-To-Date; OTHER - American Heart Association,American Journal of Medicine,Elsevier
				Publishing, National Institutes of Health, Spry Publishing
Jackson	Elizabeth	Test Yourself with Questions: General	Faculty	CONSULTANT FEES/HONORARIA - American College of
		Cardiology Module 15		Cardiology,McKesson, Inc.,NationalAssociation for Continuing Education,Up-To-Date, OTHER - American Heart Association,American Journal of Medicine, Elsevier Publishing,National Institutes of Health,Spry Publishing
Jackson	Elizabeth	Advances in HCM, PPCM and Other Cardiomyopathies	Breastfeeding Is Not Associated With Worse Outcomes in Peripartum Cardiomyopathy	CONSULTANT FEES/HONORARIA - American College of Cardiology,McKesson, Inc.,NationalAssociation for Continuing Education,Up-To-Date; OTHER - American Heart Association,American Journal of Medicine,Elsevier
1	Et	0. 8:	ACC Party Market	Publishing, National Institutes of Health, Spry Publishing
Jackson	Elizabeth	Sex Disparity in VHD Outcomes	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - American College of Cardiology, McKesson, Inc., NationalAssociation for Continuing Education, Up-To-Date; OTHER - American Heart Association, American Journal of Medicine, Elsevier Publishing, National Institutes of Health, Spy Publishing
Jackson	Elizabeth	33. Prevention: Hypertension Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - American College of Cardiology, McKesson, Inc., National Association for Continuing Education, Ip-To-Date; OTHER - American Heart Association, American Journal of Medicine, Elsevier Publishing, National Institutes of Health, Spry Publishing
Jackson	Gregory	Coming to Consensus in a New Era: The Role of Non-statin Therapies in ASCVD Risk Reduction	Blurred Lines: The High-risk Patient with Subclinical Atherosclerosis	Nothing to Disclose
Jackson	Gregory	Recent Trends in Combination Therapy: Managing Cholesterol Even in the Most Resistant	Clinical Facilitator	Nothing to Disclose
Jackson	Marcia	Teaching with Intent: Secrets from the Masters I	"Backwards Planning": What does it mean? How do you do it?	CONSULTANT FEES/HONORARIA - Medscape CME; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CME by Design
Jackson	Marcia	Teaching with Intent: Secrets from the Masters I	Prepping the Audience for an Interactive Discussion	CONSULTANT FEES/HONORARIA - Medscape CME; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CME by Design
Jackson	Marcia	Teaching with Intent: Secrets from the Masters III	Simulation: Patient Encounter (Patient)	CONSULTANT FEES/HONORARIA - Medscape CME; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CME by Design
Jackson	Marcia	Teaching with Intent: Secrets from the Masters III	Characteristics of Effective Feedback	CONSULTANT FEES/HONORARIA - Medscape CME; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CME by Design
Jacob	Chris	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Impact of Hereditary Causes of Thrombosis on Ischemic Stroke Between the Years 2008 Through 2012: Nationwide Inpatient Sample Data Analysis	Nothing to Disclose
Jacob	Dexter	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Does 3-Hour Point of Care Troponin I Predict 6-Hour Point of Care Troponin I for Patients in a Chest Pain Unit	Nothing to Disclose
Jacob	Miriam	14. Heart Failure and Cardiomyopathies: Therapy Team 2	Suggested Reviewer	Nothing to Disclose
Jacob	Robert	Uncovering the Intricacies of Vascular Function	Atorvastatin Active Metabolite Inhibits Oxidation of ApoB-Containing	Nothing to Disclose
Jacobovitz	Shalom	Innovations in Education	Lipoprotein Particles of Different Sizes Measured <i>In Vitro</i> Under Hyperglycemic Conditions Teaching Tomorrow's Teachers: An Innovative Model of Clinician-	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
OGCODOVILE	Ondiom	iniovations in Eddeadon	Educator Development for Trainees	ROLE - Clene Nano Medicine
Jacobs	Alice	Global Perspectives in the Treatment of ST Elevation Myocardial Infarction: Successes, Failures, and Challenges	Mission Lifeline and the D2B Alliance: The United States Experience	OTHER - Acetylon; RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca
Jacobs	Alice	Overuse, Underuse or Just Right? Fundamental Debates in High Risk PCI in 2017	Stop Taking Futile Cases to the Cath Lab! Sometimes It Is Right to Say No	OTHER - Acetylon; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Astra Zeneca
Jacobs	Alice	Training for Interventional Procedures: Who Should Do What, Where, When, How, and Why	Co-Chair	OTHER - Acetylon; RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca
Jacobs	Alice	Training for Interventional Procedures: Who Should Do What, Where, When, How, and Why	What: Fellowship Training Standards	OTHER - Acetylon; RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca
Jacobs	Alice	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology Team 2	Suggested Reviewer	OTHER - Acetylon; RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca
Jacobs	David	Innovations in Cardiovascular Risk Assessment and Reduction	Association Between Serum Collagen Biomarkers and Coronary Artery Calcium: The Multi-Ethnic Study of Atherosclerosis (MESA)	Nothing to Disclose
Jacobs	David	Non Invasive Imaging: Prognostic Implications of CT Angiography	Coronary Artery Structural Remodeling by Computed Tomography and Echocardiographic Left Ventricular Mass Changes Over the Next 5 Years: The Coronary Artery Risk Development in Young Adults (CARDIA) Study	Nothing to Disclose
Jacobs	David	Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools	Association of 10-Year Change in Cardiovascular Risk Factors With Progression of Pericardial Adipose Tissue: The CARDIA Study	Nothing to Disclose
Jacobs	David	New Insights Into Prediction and Treatment of Hypertension	Collagen Turnover Markers Predict New Onset of Hypertension in Normotensive Subjects: The Multi-Ethnic Study of Atherosclerosis	Nothing to Disclose
Jacobs	Jeffrey	Late-Breaking Clinical Trials	Comparative Effectiveness of Left Atrial Appendage Occlusion Among Atrial Fibrillation Patients Undergoing Cardiac Surgery: A Report From the Society of Thoracic Surgeons Adult Cardiac Surgery Database	RESEARCH/RESEARCH GRANTS - COAST DSMB,NIH Grant Number: R01 HL122261
Jacobs	Jeffrey	Therapeutic Advances in Congenital Heart Disease	Effect of Obesity and Underweight Status on Perioperative Outcomes in Patients With Congenital Heart Disease: An Analysis of	RESEARCH/RESEARCH GRANTS - COAST DSMB,NIH Grant Number: R01 HL122261
Jacobs	Larry	Personalized Skills Center: Drill and Practice	Data From the Society of Thoracic Surgeons Congenital Heart Surgery Database Heart Songs Moderator	Nothing to Disclose
	•	(Heart Songs, ECG, Hand-Held Echo)	ů .	•
Jacobs	Larry Marshall	FIT Clinical Decision Making Reviewers 3	ACC FIT Clinical Decision Making Reviewer Effect of Obesity and Underweight Status on Perioperative	Nothing to Disclose Nothing to Disclose
Jacobs	ividi Si Idil	Therapeutic Advances in Congenital Heart Disease	Lettect of Obesity and Underweight Status on Perioperative Outcomes in Patients With Congenital Heart Disease: An Analysis of Data From the Society of Thoracic Surgeons Congenital Heart Surgery Database	Induling to Discluse
Jacobsen	Gordon	Novel Developments in Acute Coronary	How Often Does Troponin Elevation Identify Acute Myocardial	Nothing to Disclose
Jacobson	Jason	Syndromes FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Infarction in the Emergency Department? Sinus Node Dysfunction in Batten Disease: A Rare Manifestation of a Rare Disease	CONSULTANT FEES/HONORARIA - St Jude Medical advisory board; RESEARCH/RESEARCH GRANTS - Biosense Webster
Jacobson	Jason	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Arrhythmias in Hospitalized Heart Transplanted Patients: A United States National Study	BOARD, RESEARCH/RESEARCH GRANTS - Biosense Webster CONSULTANT FEES/HONORARIA - St Jude Medical advisory board; RESEARCH/RESEARCH GRANTS - Biosense Webster
Jacoby	Daniel		Effusive-Constrictive Pericarditis in a Patient With Hypereosinophilic Syndrome	CONSULTANT FEES/HONORARIA - Admera

I and Maria	E A Maria	Description Title	In the state of th	lett
Last Name Jacoby	Pirst Name Daniel	Session Title 12. Heart Failure and Cardiomyopathies: Basic	Presentation Title Suggested Reviewer	Disclosures CONSULTANT FEES/HONORARIA - Admera
Jadhav	Siddharth	Team 2 Non Invasive Imaging: Role of Exercise Testing		Nothing to Disclose
Jae K.	Oh	Valvular Heart Disease: Aortic Stenosis	Coronary Artery: Results Following a Standardized Approach Sinus Rhythm Versus Atrial Fibrillation & It Clinical Profile and Natural History of Patients With Severe Aortic Stenosis Managed	OTHER - Echo Core Lab for Medtronic Core Valve
Jafar	Omar	Hearts and Soles: Multimodality Imaging in	Medically Assessment of Coronary Atherosclerosis Using Calcium Scores in	Nothing to Disclose
Jaff	Michael	Athletes 18. Interventional Cardiology: Carotid and	Short and Long Distance Runners Suggested Reviewer	CONSULTANT FEES/HONORARIA - AOPA,Cardinal
		Endovascular Intervention Team 1		Health, Micell, Vascular Therapies, Volcano/Philips; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - VIVA Physicians Group; OTHER - Abbott Vascular, Boston Scientific, CBSET, Cordis, Medtronic Vascular, Novello; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - JanaCare, MC10, Northwind, PQ Bypass, Primacea, Sano V, Valiant Medical
Jaffe	Allan	The Art and the Science of Decision Making in Coronary Artery Disease	The Science: High-sensitivity Troponin	CONSULTANT FEES/HONORARIA - Abbott, Alere, Beckman- Coluter, ET Healthcare, Neurogenome X, Novartis, Roche, Siemens, sphingotec, heheart.org
Jaffe	Allan	Advances in HCM, PPCM and Other Cardiomyopathies	Utility of Routine Serum Free Light Chain Assay for Amyloidosis in Patients With Heart Failure	CONSULTANT FEES/HONORARIA - Abbott, Alere, Beckman- Coluter, ET Healthcare, Neurogenome X, Novartis, Roche, Siemens, sphingotec, heheart.org
Jaffe	Allan	Innovations in Cardiovascular Risk Assessment and Reduction	Plasma Ceramide Concentrations Predict Risk of Cardiovascular Events	CONSULTANT FEES/HONORARIA - Abbott, Alere, Beckman- Coluter, ET Healthcare, Neurogenome X, Novartis, Roche, Siemens, sphingotec, heheart.org
Jaffe	Allan	Blips, Trops, and Chips: New Ways to Diagnose CAD	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Abbott, Alere, Beckman- Coluter, ET Healthcare, Neurogenome X, Novartis, Roche, Siemens, sphingotec, heheart.org
Jaffe	Marc	Updates on Risk Factors for Cardiovascular Disease	Levels of Obesity and Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Community-Based Cohort	Nothing to Disclose
Jaffer	Farouc	Interventional Live Case Session V: Complex Coronary and Physiology from Mid-America Heart Institute (Kansas City, Missouri)	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific; RESEARCH/RESEARCH GRANTS - Canon, Siemens
Jaffer	Farouc	Chronic Total Occlusion PCI: A Case-Based Review of Contemporary Techniques	Case Presentation: Antegrade Wire Escalation Step-by-step	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific; RESEARCH/RESEARCH GRANTS - Canon, Siemens
Jaffer	Farouc	Bioresorbable Vascular Scaffolds, Bioresorbable Polymer and Polymer Free Metallic DES	Imaging and Deployment Strategy: Achieving Optimal Outcomes	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific; RESEARCH/RESEARCH GRANTS - Canon, Siemens
Jaffer	Farouc	The Best Coronary and Peripheral Interventional Challenging Cases	ACC Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific; RESEARCH/RESEARCH GRANTS - Canon, Siemens
Jaffer	Farouc	Innovations in Advocacy and Patient Centered Care	Employing the Multidisciplinary Heart Team Approach for Complex Coronary Artery Disease: A Single Center Experience	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific; RESEARCH/RESEARCH GRANTS - Canon, Siemens
Jaffer	Farouc	Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific; RESEARCH/RESEARCH GRANTS - Canon, Siemens
Jaffer	Farouc	Advances in Chronic Total Occlusion Intervention	a Contemporary Multicenter Registry Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific; RESEARCH/RESEARCH GRANTS - Canon,Siemens
Jaffer	Farouc	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Successful Intra-Aortic Balloon Pump-Supported Percutaneous Coronary Intervention in a Patient With a Late Presenting Myocardial Infarction, Multiwessel Coronary Artery Disease Complicated by Heparin-Induced Thrombocytopenia, Biventricular Thrombus, and Refractory Ventricular Arrhythmia	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific; RESEARCH/RESEARCH GRANTS - Canon, Siemens
Jaffer	Farouc	25. Interventional Cardiology: Translation and Pre-clinical Research Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific; RESEARCH/RESEARCH GRANTS - Canon, Siemens
Jagasia Jaguszewski	Dinesh Milosz	PFO Closure, PV Leak, and VSD Repair Risky Business: Predicting Outcomes in Heart	Post-TAVR Ventricuar Septal Defect: A New Clinical Entity? A Novel Clinical Score (InterTAK Score) to Distinguish Takotsubo	Nothing to Disclose Nothing to Disclose
Jahangir	Arshad	Failure Arrhythmias and Clinical EP: Basic 3	Syndrome From Acute Coronary Syndrome Impact of Obstructive Sleep Apnea Severity on Cardiac Events in	Nothing to Disclose
Jahangir	Arshad	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Patients With Normal or Prolonged Ventricular Repolarization Incremental Value of Estimated Glomerular Filtration Rate in Improving Stroke Risk Stratification in Patients With and Without Atrial Fibrillation Considered to Be Low Risk by	Nothing to Disclose
Jahangir	Arshad	Interventional Cardiology: PCI and TAVR in Complex Patients	CHA ₂ DS ₂ VASc Score The Risk of Adverse Coronary Events Is Higher in Patients With Severe Obstructive Sleep Apnea Following Percutaneous Coronary	Nothing to Disclose
Jahangir	Eiman	35. Pulmonary Hypertension and Pulmonary	Intervention Suggested Reviewer	Nothing to Disclose
Jain	Manish	Thrombo-embolic Disease Team 1 New Technologies in Echocardiography	New Hybrid Stress Echocardiography Protocol: A Non-Inferiority	Nothing to Disclose
Jain	Renuka	Advances in HCM, PPCM and Other Cardiomyopathies	Study Marked Respiratory Related Variation in LVOT Gradients in Hypertrophic Cardiomyopathy in Obese HCM Patients With Sleep-	Nothing to Disclose
Jain	Sandeep	Arrhythmias and Clinical EP: AF Ablation	Disordered Breathing Characterization of Pulmonary Vein Reconnection Post Cryoballoon Ablation	OTHER - MEDTRONIC; RESEARCH/RESEARCH GRANTS - MEDTRONIC
Jain	Sandeep	05. Arrhythmias and Clinical EP: Devices Team 1	Suggested Reviewer	OTHER - MEDTRONIC; RESEARCH/RESEARCH GRANTS - MEDTRONIC
Jain	Shashank	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Unloading the Left Ventricle: A Case of Mechanical Circulatory Support in Acute Aortic Insufficiency	Nothing to Disclose
Jain	Shashank	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Acute Pulmonary and Paradoxical Embolism Treated With Catheter Based Thrombectomy	Nothing to Disclose
Jain	Shashank	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Based I frombectomy Dissolve It or Take It Out: Excellent Outcome of Right-Sided Heart Clot In-Transit	Nothing to Disclose
Jain	Shashank	Pulmonary Hypertension Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Comparison of In-Hospital Outcomes of Septic Shock Patients With and Without Atrial Fibrillation: A Retrospective Propensity-Matched	Nothing to Disclose
Jain	Shashank	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Analysis ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected	Nothing to Disclose
Jain	Snigdha	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Burden of 30-Day Readmissions in Acute Myocardial Infarction and Heart Failure in the United States: A National Perspective	Nothing to Disclose
Jain	Tarun	Novel Developments in Acute Coronary	How Often Does Troponin Elevation Identify Acute Myocardial Infarction in the Emergency Department?	Nothing to Disclose
Jain	Tarun	Syndromes Interventional Cardiology: Structural Heart	Transcatheter Mitral Valve-in-Ring Implantation After Failure of	Nothing to Disclose
Jain	Venu	Disease Congenital Heart Disease: New Diagnostic	Surgical Mitral Ring Annuloplasty Impact of Maternal Diabetes on First & Early Second Trimester	Nothing to Disclose
]	Approaches in Congenital Heart Disease	Fetal Cardiovascular Health	

Contract of the Contract of th				
Last Name Jakala	First Name Jacek	Session Title Coronary Angiography, Intra-Vascular Imaging,	Presentation Title First Serial 12- and 24-Month Optical Coherence Tomography	Disclosures Nothing to Disclose
		Revascularization and Outcomes	Assessment of Stemi Patients After the Generation of Absorb Bioresorbable Vascular Scaffold Implantation	Š
Jalil Jalnapurkar	Jorge Sawan	38. Vascular Medicine: Basic Team 2 Young Investigator Awards Competition: Outcomes Research	Suggested Reviewer A Hospital Level Analysis of 30-Day Readmission Rates for Heart Failure Patients and Long-Term Survival Among Highest and Lowest Performing Hospitals, Findings From Get With the Guidelines-Heart Failure	Nothing to Disclose Nothing to Disclose
Jalnapurkar	Sawan	Non Invasive Imaging: MR Scar and Perfusion	Assessment of Myocardial Perfusion Reserve Index Using Adenosine Versus Regadenoson Among Healthy Female Subjects	Nothing to Disclose
Jamerson	Kenneth	33. Prevention: Hypertension Team 1	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - NIH, NIDDK, NHLBI
James	Stefan	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	A Randomized Trial Evaluating Clinically Significant Bleeding With Low-Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, for Patients After Acute Coronary Syndromes	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals, The Medicines Company, RESEARCH/RESEARCH GRANTS - Astra Zeneca, Gilead Sciences, Inc.
James	Stefan	Late-Breaking Clinical Trials: Interventional	Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve Guided Intervention (IFR-SWEDEHEART): A Multicenter, Prospective, Registry-Based Randomized Clinical Trial	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals, The Medicines Company, RESEARCH/RESEARCH GRANTS - Astra Zeneca, Gilead Sciences, Inc.
James	Stefan	The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints	Co-Chair	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals, The Medicines Company; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Gilead Sciences, Inc.
James	Stefan	Novel Developments in Acute Coronary Syndromes	Prehospital Administration of Heparin Reduces the Risk of Vessel Occlusion in Patients With ST Elevation Myocardial Infarction: Secondary Analysis of the TASTE Trial	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals, The Medicines Company, RESEARCH/RESEARCH GRANTS - Astra Zeneca, Gilead Sciences, Inc.
James	Stefan	03. Acute and Stable Ischemic Heart Disease: Therapy Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals, The Medicines Company, RESEARCH/RESEARCH GRANTS - Astra Zeneca, Gilead Sciences, Inc.
James	Stefan	Interventional Challenging Cases: Team 2	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals, The Medicines Company; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Gilead Sciences, Inc.
James	Stephanie	Innovations in Cardiovascular Risk Assessment and Reduction	Longitudinal Change in Soluble ST2 Versus B-type Natriuretic Peptide in Predicting Major Adverse Cardiovascular Events in Asymptomatic Patients in the Community	Nothing to Disclose
James	Todd	Arrhythmias and Clinical EP: AF Ablation	Novel Oral Anticoagulant Discontinuation Before Atrial Fibrillation Ablation and Excessive Heparin Requirements	Nothing to Disclose
Jan	M. Fuad	Head to Toe: Outcomes of Endovascular Interventions	Use of Viabahn Endograft for Repair of Popliteal Artery Aneurysm: Largest Single Center Experience	Nothing to Disclose
Jan	M. Fuad	Considerations in Antiplatelet Therapy and in	Contemporary Outcomes of Anterior Segment ST-Elevation	Nothing to Disclose
Jan	M. Fuad	ACS FIT Clinical Decision Making: Non-Invasive	Myocardial Infarction: A Large 10-Year Tertiary Care Experience Athlete's Heart Versus Apical Hypertrophic Cardiomyopathy: Look	Nothing to Disclose
Jan	M. Fuad	Imaging and Valvular Heart Disease Vascular Access and Hemostasis Issues	Again! Clinical Efficacy of SoftSeal-STF Hemostatic Pad With Short Hold Time Compared to Traditional Manual Compression After	Nothing to Disclose
Jan	M. Fuad	Advances in HCM, PPCM and Other Cardiomyopathies	Transfemoral Catheterization Marked Respiratory Related Variation in LVOT Gradients in Hypertrophic Cardiomyopathy in Obese HCM Patients With Sleep-	Nothing to Disclose
Jan	M. Fuad	Interventional Cardiology: PCI and TAVR in Complex Patients	Disordered Breathing The Risk of Adverse Coronary Events Is Higher in Patients With Severe Obstructive Sleep Apnea Following Percutaneous Coronary	Nothing to Disclose
Jan	M. Fuad	Percutaneous Coronary Intervention: Lessons	Intervention Outcomes in Patients Undergoing Cardiac Catheterization and	Nothing to Disclose
Jan	M. Fuad	From the Real World Mechanisms of Vascular Inflammation in Atherogenesis	Therapeutic Hypothermia After Cardiac Arrest Comparative Study on Catheter-Directed Thrombolysis - Continuous Tissue Plasminogen Activator Versus Angiojet Catheter Power Pulse Spray Rheolytic Thrombectomy Outcome Study: Single-	Nothing to Disclose
Janardhanan	Rajesh	FIT Clinical Decision Making: Heart Failure and	Center Experience Acute Limb Ischemia in a Previously Undiagnosed Case of Mid-	Nothing to Disclose
Janardhanan	Rajesh	Pulmonary Hypertension Engage @ ACC.17 Studio: FIT Jeopardy Battle	Ventricular Non-Obstructive Hypertrophic Cardiomyopathy Judge	Nothing to Disclose
		of the State Chapters III	-	-
Janardhanan Jang	Rajesh Albert	29. Non Invasive Imaging: MR Team 1 Understanding Pulmonary Vascular Disease: From Bench to Bedside	Suagested Reviewer Apelin-13 Co-Treatment With Umbilical Cord Blood-Derived Mesenchymal Stem Cells Improves Engrafted Cell Survival and Inhibits Macrophage Activation in Pulmonary Arterial Hypertension Murine Model	Nothing to Disclose Nothing to Disclose
Jang	lk-Kyung	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Implantation: Comparison Between First Generation and Second Generation Drug-Eluting Stents	CONSULTANT FEES/HONORARIA - LightLab Imaging/St. Jude,Lycotec; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Jang	lk-Kyung	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Association Between Syntax Score, and Pre- and Post-Stenting Optical Coherence Tomography Findings in Stable Angina Patients	CONSULTANT FEES/HONORARIA - LightLab Imaging/St. Jude,Lycotec; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Jang	lk-Kyung	Timely Topics in Acute Coronary Syndromes	Systemic Pentraxin 3 Is a Potential Biomarker to Differentiate Plaque Erosion From Plaque Rupture in Acute Coronary Syndrome Patients	CONSULTANT FEES/HONORARIA - LightLab Imaging/St. Jude,Lycotec; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Jang	lk-Kyung	The Inside View: Learning From Intracoronary Imaging	Prevalence and Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A Four-Year Follow-Up Study	CONSULTANT FEES/HONORARIA - LightLab Imaging/St. Jude,Lycotec; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Jang	lk-Kyung	19. Interventional Cardiology: Complex Patients/Comorbidities Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - LightLab Imaging/St. Jude,Lycotec; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Jang	lk-Kyung	Interventional Challenging Cases: Team 2	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - LightLab Imaging/St. Jude,Lycotec; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Jang	Jeong Yoon	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of Platelet-Fibrin Clot Strength on Occurrence of In-Stent Restenosis in Patient With Drug Eluting Stent	Nothing to Disclose
Jang	Jeong Yoon	Antithrombotic Therapy in Ischemic Heart Disease	Ticagrelor Versus Clopidogrel Is Associated With Better Recovery of LV Function After Acute Myocardial Infarction	Nothing to Disclose
Jang	Shin Yi	Current Issues in Cardiovascular	Prevalence of Cardiomyopathy in the Korean Population	Nothing to Disclose
Jang	Yangsoo	Epidemiology, Disparities, and Safety Considerations in Antiplatelet Therapy and in ACS	Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multi-Vessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents	Nothing to Disclose
Jansky	Petr	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues		Nothing to Disclose
Janssens	Luc	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International Multicentre iFR GRADIENT Registry	Nothing to Disclose

Last Name Januzzi				
ound221	First Name James	Session Title Beyond the Usual Suspects - Other	Presentation Title Panelist	Disclosures CONSULTANT FEES/HONORARIA - Critical
	James	Dimensions in Prevention	i diletti	Diagnostics, Novartis, Phillips, Roche Diagnostics, sphingotec;
ļ				DATA SAFETY MONITORING BOARD - Amgen, Boeringer
				Ingelheim, Janssen Pharmaceuticals, Inc; RESEARCH/RESEARCH GRANTS - Prevencio
Januzzi	James	Beyond the Usual Suspects - Other	Prevention of Heart Failure - What Are We Waiting for?	CONSULTANT FEES/HONORARIA - Critical
ounder.	damoo	Dimensions in Prevention	Trotonium or frouttrandro vinatvilo fro franting for:	Diagnostics, Novartis, Phillips, Roche Diagnostics, sphingotec;
l				DATA SAFETY MONITORING BOARD - Amgen,Boeringer
l				Ingelheim, Janssen Pharmaceuticals, Inc; RESEARCH/RESEARCH GRANTS - Prevencio
Januzzi	James	Imaging of Chest Pain in the Emergency	Imaging? Biomarkers and Clinical Data is All you need!	CONSULTANT FEES/HONORARIA - Critical
l		Department		Diagnostics, Novartis, Phillips, Roche Diagnostics, sphingotec;
l				DATA SAFETY MONITORING BOARD - Amgen, Boeringer Ingelheim, Janssen Pharmaceuticals, Inc;
				RESEARCH/RESEARCH GRANTS - Prevencio
Januzzi	James	Young Investigator Awards Competition:	Judge	CONSULTANT FEES/HONORARIA - Critical Diagnostics,Novartis,Phillips,Roche Diagnostics,sphingotec;
l		Clinical Investigations		DATA SAFETY MONITORING BOARD - Amgen, Boeringer
				Ingelheim, Janssen Pharmaceuticals, Inc;
Januzzi	James	Heart Failure and Cardiomyopathies: Is Heart	Rationale and Methods of the Prospective Study of Biomarkers,	RESEARCH/RESEARCH GRANTS - Prevencio CONSULTANT FEES/HONORARIA - Critical
Januzzi	James	Failure With a Normal EF for Real?	Symptom Improvement and Ventricular Remodeling During	Diagnostics, Novartis, Phillips, Roche Diagnostics, sphingotec;
l			Entresto Therapy for Heart Failure (PROVE-HF) Study	DATA SAFETY MONITORING BOARD - Amgen, Boeringer
				Ingelheim, Janssen Pharmaceuticals, Inc; RESEARCH/RESEARCH GRANTS - Prevencio
Januzzi	James	Making Progress in Understanding Heart	Circulating Concentrations of Orexin A Are Associated With Left	CONSULTANT FEES/HONORARIA - Critical
		Failure	Ventricular Reverse Remodeling and Clinical Outcomes Following	Diagnostics,Novartis,Phillips,Roche Diagnostics,sphingotec;
			Cardiac Resynchronization Therapy	DATA SAFETY MONITORING BOARD - Amgen, Boeringer Ingelheim, Janssen Pharmaceuticals, Inc;
l				RESEARCH/RESEARCH GRANTS - Prevencio
Januzzi	James	Making Progress in Understanding Heart	Serial Assessment of Heart Rate and Beta Blocker Use in Chronic	CONSULTANT FEES/HONORARIA - Critical
l	1	Failure	Heart Failure Patients With Reduced Ejection Fraction in a Large Integrated Healthcare Network	Diagnostics, Novartis, Phillips, Roche Diagnostics, sphingotec; DATA SAFETY MONITORING BOARD - Amgen, Boeringer
i	1		anagratou i louidiouro rectwork	Ingelheim, Janssen Pharmaceuticals, Inc;
ļ 	<u> </u>			RESEARCH/RESEARCH GRANTS - Prevencio
Januzzi	James	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Multiple Biomarkers for Predicting Major Adverse Cardiac Events in At-Risk Patients Undergoing Diagnostic Coronary Angiography:	CONSULTANT FEES/HONORARIA - Critical Diagnostics, Novartis, Phillips, Roche Diagnostics, sphingotec;
l	1	Coronary Artery Disease	Results From the Catheter Sampled Blood Archive in	DATA SAFETY MONITORING BOARD - Amgen,Boeringer
		, ,	Cardiovascular Diseases (CASABLANCA) Study	Ingelheim, Janssen Pharmaceuticals, Inc;
Januzzi	James	Innovations in Cardiovascular Risk Assessment	Longitudinal Change in Soluble ST2 Versus B-type Natriuretic	RESEARCH/RESEARCH GRANTS - Prevencio CONSULTANT FEES/HONORARIA - Critical
Januzzi	James	and Reduction	Peptide in Predicting Major Adverse Cardiovascular Events in	Diagnostics, Novartis, Phillips, Roche Diagnostics, sphingotec;
l			Asymptomatic Patients in the Community	DATA SAFETY MONITORING BOARD - Amgen, Boeringer
				Ingelheim, Janssen Pharmaceuticals, Inc; RESEARCH/RESEARCH GRANTS - Prevencio
Japp	Alan	FIT Clinical Decision Making: Non-Invasive	Multi-Modality Imaging Assessment of a Left Ventricular Mass	Nothing to Disclose
		Imaging and Valvular Heart Disease		•
Jaquiss Jarai	Robert Rudolf	09. Congenital Heart Disease: Adult Team 2 Arrhythmias and Clinical EP: Syncope and	Suggested Reviewer Copeptin and High-Sensitivity Troponin I in Patients With Chest Pain	Nothing to Disclose Nothing to Disclose
ouru.	rtado	Other EP Issues	and Recent Syncope	Trouming to Discrete
Jarcho	John	FIT Forum: Mix and Mingle	 Innovative Careers	Nothing to Disclose
Jarcho	John	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking	Co-Chair	Nothing to Disclose
		Clinical Trials		
Jarolim	Petr	Making Progress in Understanding Heart	Circulating Concentrations of Orexin A Are Associated With Left	CONSULTANT FEES/HONORARIA - Giner, Inc.;
l		Failure	Ventricular Reverse Remodeling and Clinical Outcomes Following Cardiac Resynchronization Therapy	RESEARCH/RESEARCH GRANTS - Abbott Laboratories, AstraZeneca LP, Daiichi Sankyo,
l			,	Inc.,GlaxoSmithKline,Merck & Dr., Inc.,Roche
				Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation
Jarolim	Petr	Current Issues in Cardiovascular	Lipid Abnormalities in Young Patients With Myocardial Infarction	CONSULTANT FEES/HONORARIA - Giner, Inc.;
l		Epidemiology, Disparities, and Safety		RESEARCH/RESEARCH GRANTS - Abbott
				Laboratories, AstraZeneca LP, Daiichi Sankyo, Inc., GlaxoSmithKline, Merck & Damp; amp; Co., Inc., Roche
				Diagnostics Corporation, Takeda Global Research and
				Development Center,Waters Technologies Corporation
Jarolim	Petr	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Women Who Experience Myocardial Infarction at a Young Age	
1				CONSULTANT FEES/HONORARIA - Giner, Inc.;
			Have Worse Survival Compared With Men	CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, AstraZeneca LP, Daiichi Sankyo,
			Have worse Survival Compared with Men	RESEARCH/RESEARCH GRANTS - Abbott Laboratories, AstraZeneca LP, Daiichi Sankyo, Inc., GlaxoSmithKline, Merck & Dept., amp; Co., Inc., Roche
			Have worse Survival Compared with Men	RESEARCH/RESEARCH GRANTS - Abbott Laboratories, AstraZeneca LP, Daiichi Sankyo, Inc., GlaxoSmithKline, Merck & amp;amp; Co., Inc., Roche Diagnostics Corporation, Takeda Global Research and
	Petr			RESEARCH/RESEARCH GRANTS - Abbott Laboratories, AstraZeneca LP, Daiichi Sankyo, Inc., GlaxoSmithKline, Merck & Dept., amp; Co., Inc., Roche
Jarolim	Petr	Unusual Presentations of ACS	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival	RESEARCH/RESEARCH GRANTS - Abbott Laboratories, AstraZeneca L.P.Daiichi Sankyo, Inc., GlaxoSmithKline, Merck & amp;amp; Co., Inc., Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott
	Petr		Type 2 Myocardial Infarction in Young Patients Portends a Worse	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Samp;amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, AstraZeneca LP,Daiichi Sankyo,
	Petr		Type 2 Myocardial Infarction in Young Patients Portends a Worse	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Bry, Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center,Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Bry, Bry, Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and
Jarolim		Unusual Presentations of ACS	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Emp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, AstraZeneca LP Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Emp; amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation
	Petr Upasana	Unusual Presentations of ACS Advances in HCM, PPCM and Other	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Bry, Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center,Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Bry, Bry, Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and
Jarolim		Unusual Presentations of ACS	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Emp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, AstraZeneca LP Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Emp; amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation
Jarolim	Upasana	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Filter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and	RESEARCH/IRESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlawSmithKline,Merck & Bamp;amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center,Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlawSmithKline,Merck & Bamp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center,Waters Technologies Corporation Nothing to Disclose
Jarolim Jarori Jarrett	Upasana Harish	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Filter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and Heparin Induced Thrombocytopenia	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Daiichi Sankyo, Daignostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Daiic
Jarolim Jarori Jarrett Jaspers Focks	Upasana Harish Jeroen	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Filter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and Heparin Induced Thrombocytopenia Novel Approach for Risk Differentiation in Atrial Fibrillation Patients With Polypharmacy	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlawSmithKline,Merck & Bamp,amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlawSmithKline,Merck & Bamp,amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation Nothing to Disclose Nothing to Disclose
Jarolim Jarori Jarrett	Upasana Harish	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Arrhythmias and Clinical EP: AF Miscellaneous	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Filter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and Heparin Induced Thrombocytopenia Novel Approach for Risk Differentiation in Atrial Fibrillation Patients With Polypharmacy Characteristics and Outcomes of Patients With Clinically Silent Peri-	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Daiichi Sankyo, Daignostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Daiic
Jarolim Jarori Jarrett Jaspers Focks	Upasana Harish Jeroen	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Filter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and Heparin Induced Thrombocytopenia Novel Approach for Risk Differentiation in Atrial Fibrillation Patients With Polypharmacy Characteristics and Outcomes of Patients With Clinically Silent Peri-Procedural Hemoglobin Drops as Compared to Patients With Over	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlawSmithKline,Merck & Bamp,amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlawSmithKline,Merck & Bamp,amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation Nothing to Disclose Nothing to Disclose
Jarolim Jarori Jarrett Jaspers Focks	Upasana Harish Jeroen	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Interventional Complexity and Complications Novel Developments in Acute Coronary	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Filter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and Heparin Induced Thrombocytopenia Novel Approach for Risk Differentiation in Atrial Fibrillation Patients With Polypharmacy Characteristics and Outcomes of Patients With Clinically Silent Peri-Procedural Hemoglobin Drops as Compared to Patients With Overt Bleeding Following Percutaneous Coronary Intervention	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlawSmithKline,Merck & Bamp,amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlawSmithKline,Merck & Bamp,amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation Nothing to Disclose Nothing to Disclose
Jarolim Jarori Jarrett Jaspers Focks Jaswaney Jauhar	Upasana Harish Jeroen Rahul	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Interventional Complexity and Complications Novel Developments in Acute Coronary Syndromes	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Fitter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and Heparin Induced Thrombocytopenia Novel Approach for Risk Differentiation in Atrial Fibrillation Patients With Polypharmacy Characteristics and Outcomes of Patients With Clinically Silent Peri-Procedural Hemoglobin Drops as Compared to Patients With Overt Bleeding Following Percutaneous Coronary Intervention Transradial Access is Superior to Femoral Access Among Patients With Acute Coronary Syndrome	RESEARCH/IRESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlawSmithKline,Merck & Bamp;amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlawSmithKline,Merck & Bamp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation Nothing to Disclose Nothing to Disclose Nothing to Disclose
Jarolim Jarori Jarrett Jaspers Focks Jaswaney	Upasana Harish Jeroen Rahul	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Interventional Complexity and Complications Novel Developments in Acute Coronary Syndromes Antithrombotic Therapy in Ischemic Heart	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Filter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and Heparin Induced Thrombosytopenia Novel Approach for Risk Differentiation in Atrial Fibrillation Patients With Polypharmacy Characteristics and Outcomes of Patients With Clinically Silent Peri-Procedural Hemoglobin Drops as Compared to Patients With Overt Bleeding Following Percutaneous Coronary Intervention Transradial Access is Superior to Femoral Access Among Patients With Acute Coronary Syndrome Bivalirudin and Unfractionated Heparin Have Equivalent Outcomes	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxxSmithKline,Merck & Samp;amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxxSmithKline,Merck & Samp;amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center,Waters Technologies Corporation Nothing to Disclose Nothing to Disclose Nothing to Disclose
Jarolim Jarori Jarrett Jaspers Focks Jaswaney Jauhar	Upasana Harish Jeroen Rahul	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Interventional Complexity and Complications Novel Developments in Acute Coronary Syndromes	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Filter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and Heparin Induced Thrombocytopenia Novel Approach for Risk Differentiation in Atrial Fibrillation Patients With Polypharmacy Characteristics and Outcomes of Patients With Clinically Silent Peri-Procedural Hemoglobin Drops as Compared to Patients With Overt Bleeding Following Percutaneous Coronary Intervention Transradial Access Is Superior to Femoral Access Among Patients With Acute Coronary Syndrome Bivalirudin and Unfractionated Heparin Have Equivalent Outcomes in Non-Acute Coronary Syndrome Patients Unfractionated Heparin is Superior to Bivalirudin in Transradial	RESEARCH/IRESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlawSmithKline,Merck & Bamp;amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlawSmithKline,Merck & Bamp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation Nothing to Disclose Nothing to Disclose Nothing to Disclose
Jarolim Jarori Jarrett Jaspers Focks Jaswaney Jauhar Jauhar	Upasana Harish Jeroen Rahul Rajiv Rajiv	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Interventional Complexity and Complications Novel Developments in Acute Coronary Syndromes Antithrombotic Therapy in Ischemic Heart Disease Optimizing the Care of ACS Patients	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Filter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and Heparin Induced Thrombocytopenia Novel Approach for Risk Differentiation in Atrial Fibrillation Patients With Polypharmacy Characteristics and Outcomes of Patients With Clinically Silent Peri-Procedural Hemoglobin Drops as Compared to Patients With Overt Bleeding Following Percutaneous Coronary Intervention Transradial Access Is Superior to Femoral Access Among Patients With Acute Coronary Syndrome Bivalirudin and Unfractionated Heparin Have Equivalent Outcomes in Non-Acute Coronary Syndrome Patients Unfractionated Heparin Is Superior to Bivalirudin in Transradial Patients With Acute Coronary Syndrome Patients	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP, Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Barny, Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Barny, Barny, Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center,Waters Technologies Corporation Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Jarolim Jarori Jarrett Jaspers Focks Jaswaney Jauhar	Upasana Harish Jeroen Rahul Rajiv	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Interventional Complexity and Complications Novel Developments in Acute Coronary Syndromes Antithrombotic Therapy in Ischemic Heart Disease Optimizing the Care of ACS Patients Antiplatelet and Antithrombotic Agents in	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Filter Retireval in the Setting of Vena Cava Pseudo-Aneurysm and Heparin Induced Thrombocytopenia Novel Approach for Risk Differentiation in Atrial Fibrillation Patients With Polypharmacy Characteristics and Outcomes of Patients With Clinically Silent Peri-Procedural Hemoglobin Drops as Compared to Patients With Overt Bleeding Following Percutaneous Coronary Intervention Transradial Access is Superior to Femoral Access Among Patients With Acute Coronary Syndrome Bivalirudin and Unfractionated Heparin Have Equivalent Outcomes in Non-Acute Coronary Syndrome Patients Unfractionated Heparin is Superior to Bivalirudin in Transradial Patients With Acute Coronary Syndrome	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxxSmithKline,Merck & Samp;amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center,Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxxSmithKline,Merck & Samp;amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center,Waters Technologies Corporation Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Jarolim Jarori Jarrett Jaspers Focks Jaswaney Jauhar Jauhar	Upasana Harish Jeroen Rahul Rajiv Rajiv	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Interventional Complexity and Complications Novel Developments in Acute Coronary Syndromes Antithrombotic Therapy in Ischemic Heart Disease Optimizing the Care of ACS Patients Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Filter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and Heparin Induced Thrombocytopenia Novel Approach for Risk Differentiation in Atrial Fibrillation Patients With Polypharmacy Characteristics and Outcomes of Patients With Clinically Silent Peri-Procedural Hemoglobin Drops as Compared to Patients With Overt Bleeding Following Percutaneous Coronary Intervention Transradial Access is Superior to Femoral Access Among Patients With Acute Coronary Syndrome Bivalirudin and Unfractionated Heparin Have Equivalent Outcomes in Non-Acute Coronary Syndrome Patients Unfractionated Heparin Is Superior to Bivalirudin in Transradial Patients With Acute Coronary Syndrome Bivalirudin Versus Unfractionated Heparin Monotherapy in Percutaneous Coronary Intervention: A Comparison of Acute Adverse Outcomes	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP, Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Barny, Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Barny, Barny, Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center,Waters Technologies Corporation Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Jarolim Jarori Jarrett Jaspers Focks Jaswaney Jauhar Jauhar	Upasana Harish Jeroen Rahul Rajiv Rajiv	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Isochemic Heart Disease, and Vascular Medicine Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Interventional Complexity and Complications Novel Developments in Acute Coronary Syndromes Antithrombotic Therapy in Ischemic Heart Disease Optimizing the Care of ACS Patients Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease FIT Clinical Decision Making: Interventional	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Filter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and Heparin Induced Thrombocytopenia Novel Approach for Risk Differentiation in Atrial Fibrillation Patients With Polypharmacy Characteristics and Outcomes of Patients With Clinically Silent Peri-Procedural Hemoglobin Drops as Compared to Patients With Overt Bleeding Following Percutaneous Coronary Intervention Transradial Access Is Superior to Femoral Access Among Patients With Acute Coronary Syndrome Bivalirudin and Unfractionated Heparin Have Equivalent Outcomes in Non-Acute Coronary Syndrome Patients Unfractionated Heparin is Superior to Bivalirudin in Transradial Patients With Acute Coronary Syndrome Bivalirudin Versus Unfractionated Heparin Monotherapy in Percutaneous Coronary Intervention: A Comparison of Acute Adverse Outcomes Cardiogenic Shock Secondary to Acute Right Ventricular Failure	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP, Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Barny, Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxoSmithKline,Merck & Barny, Barny, Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center,Waters Technologies Corporation Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Jarolim Jarori Jarrett Jaspers Focks Jaswaney Jauhar Jauhar Jauhar	Upasana Harish Jeroen Rahul Rajiv Rajiv Rajiv Rajiv	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Interventional Complexity and Complications Novel Developments in Acute Coronary Syndromes Antithrombotic Therapy in Ischemic Heart Disease Optimizing the Care of ACS Patients Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Filter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and Heparin Induced Thrombocytopenia Novel Approach for Risk Differentiation in Atrial Fibrillation Patients With Polypharmacy Characteristics and Outcomes of Patients With Clinically Silent Peri-Procedural Hemoglobin Drops as Compared to Patients With Overt Bleeding Following Percutaneous Coronary Intervention Transradial Access is Superior to Femoral Access Among Patients With Acute Coronary Syndrome Bivalirudin and Unfractionated Heparin Have Equivalent Outcomes in Non-Acute Coronary Syndrome Patients With Acute Coronary Syndrome Bivalirudin Versus Unfractionated Heparin Monotherapy in Percutaneous Coronary Intervention: A Comparison of Acute Adverse Outcomes Cardiogenic Shock Secondary to Acute Right Ventricular Failure From latrogenic Right Coronary Artery Dissection Managed With	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxxSmithKline,Merck & Samp;amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center,Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxxSmithKline,Merck & Samp;amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center,Waters Technologies Corporation Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Jarolim Jarori Jarrett Jaspers Focks Jaswaney Jauhar Jauhar Jauhar	Upasana Harish Jeroen Rahul Rajiv Rajiv Rajiv Rajiv	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Isochemic Heart Disease, and Vascular Medicine Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Interventional Complexity and Complications Novel Developments in Acute Coronary Syndromes Antithrombotic Therapy in Ischemic Heart Disease Optimizing the Care of ACS Patients Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease FIT Clinical Decision Making: Interventional	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Filter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and Heparin Induced Thrombocytopenia Novel Approach for Risk Differentiation in Atrial Fibrillation Patients With Polypharmacy Characteristics and Outcomes of Patients With Clinically Silent Peri-Procedural Hemoglobin Drops as Compared to Patients With Overt Bleeding Following Percutaneous Coronary Intervention Transradial Access Is Superior to Femoral Access Among Patients With Acute Coronary Syndrome Bivalirudin and Unfractionated Heparin Have Equivalent Outcomes in Non-Acute Coronary Syndrome Patients Unfractionated Heparin is Superior to Bivalirudin in Transradial Patients With Acute Coronary Syndrome Bivalirudin Versus Unfractionated Heparin Monotherapy in Percutaneous Coronary Intervention: A Comparison of Acute Adverse Outcomes Cardiogenic Shock Secondary to Acute Right Ventricular Failure	RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxxSmithKline,Merck & Samp;amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center,Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxxSmithKline,Merck & Samp;amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center,Waters Technologies Corporation Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Jarolim Jarori Jarrett Jaspers Focks Jaswaney Jauhar Jauhar Jauhar Jauhar	Upasana Harish Jeroen Rahul Rajiv Rajiv Rajiv Rajiv Rajiv Sean	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Interventional Complexity and Complications Novel Developments in Acute Coronary Syndromes Antithrombotic Therapy in Ischemic Heart Disease Optimizing the Care of ACS Patients Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Fitter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and Heparin Induced Thrombocytopenia Novel Approach for Risk Differentiation in Atrial Fibrillation Patients With Polypharmacy Characteristics and Outcomes of Patients With Clinically Silent Peri-Procedural Hemoglobin Drops as Compared to Patients With Overt Bleeding Following Percutaneous Coronary Intervention Transradial Access is Superior to Femoral Access Among Patients With Acute Coronary Syndrome Bivalirudin and Unfractionated Heparin Have Equivalent Outcomes in Non-Acute Coronary Syndrome Bivalirudin Versus Unfractionated Heparin Monotherapy in Percutaneous Coronary Intervention: A Comparison of Acute Adverse Outcomes Cardiogenic Shock Secondary to Acute Right Ventricular Failure From latrogenic Right Coronary Artery Dissection Managed With Impella CP and Impella RP Biventricular Stress Induced Cardiomyopathy Managed With Impella	RESEARCH/IRESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxxSmithKline,Merck & Samp;amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center,Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/IRESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlaxxSmithKline,Merck & Samp;amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center,Waters Technologies Corporation Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Jarolim Jarori Jarrett Jaspers Focks Jaswaney Jauhar Jauhar Jauhar Jauhar	Upasana Harish Jeroen Rahul Rajiv Rajiv Rajiv Rajiv Rajiv	Unusual Presentations of ACS Advances in HCM, PPCM and Other Cardiomyopathies FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Interventional Complexity and Complications Novel Developments in Acute Coronary Syndromes Antithrombotic Therapy in Ischemic Heart Disease Optimizing the Care of ACS Patients Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Clinical Decision Making: Heart Failure and	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function Inferior Vena Cava Thrombosis Complicating Vena Cava Filter Retrieval in the Setting of Vena Cava Pseudo-Aneurysm and Heparin Induced Thrombocytopenia Novel Approach for Risk Differentiation in Atrial Fibrillation Patients With Polypharmacy Characteristics and Outcomes of Patients With Clinically Silent Peri-Procedural Hemoglobin Drops as Compared to Patients With Overt Bleeding Following Percutaneous Coronary Intervention Transradial Access is Superior to Femoral Access Among Patients With Acute Coronary Syndrome Bivalirudin and Unfractionated Heparin Have Equivalent Outcomes in Non-Acute Coronary Syndrome Patients Unfractionated Heparin is Superior to Bivalirudin in Transradial Patients With Acute Coronary Syndrome Patients Unfractionated Heparin Monotherapy in Percutaneous Coronary Intervention: A Comparison of Acute Adverse Outcomes Cardiogenic Shock Secondary to Acute Right Ventricular Failure From latrogenic Right Coronary Artery Dissection Managed With Impella CP and Inverses Induced Cardiomyopathy Managed With Impella	RESEARCH/IRESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlawSmithKline,Merck & Bamp;amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation CONSULTANT FEES/HONORARIA - Giner, Inc.; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,AstraZeneca LP,Daiichi Sankyo, Inc.,GlawSmithKline,Merck & Bamp;amp; Co., Inc.,Roche Diagnostics Corporation, Takeda Global Research and Development Center, Waters Technologies Corporation Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose

Carried States				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Jayaram Jayaram	Natalie Natalie	Six Years of Making an IMPACT FIT Clinical Decision Making: Heart Failure and	Adjusting for Risk within IMPACT Acute Necrotizing Eosinophilic Myocarditis Presenting as Sudden	Nothing to Disclose Nothing to Disclose
oayaram	reduic	Pulmonary Hypertension	Cardiac Arrest in a Teenager	Two thing to Disclose
Jayawardena	Eranthi	Non Invasive Imaging: Applications in Novel	Impact of Cardiac Troponin I on the Presence of the Coronary	Nothing to Disclose
Jayawardena	Eranthi	Disease States and Clinical Scenarios Non Invasive Imaging: Expanding Clinical	Artery Plaque in Rheumatoid Arthritis patients The Utility of Left Atrial Appendage Hounsfield Unit and the Ratio of	Nothing to Disclose
oayamar aona		Applications	Left Atrial Appendage/Ascending Aorta Hounsfield Unit for Detecting Left Atrial Appendage Thrombus	The string to Discusse
Jayawardena	Eranthi	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Coronary Artery Calcium Progression With Coronary Plaque Progression Determined by Quantitative Coronary Artery Plaque Analysis	Nothing to Disclose
Jazayeri	Mohammad-Ali	Arrhythmias and Clinical EP: Devices 1	Implantable Cardioverter Defibrillator for the Prevention of Mortality in Non-Ischemic Cardiomyopathy: A Meta-Analysis of Randomized	Nothing to Disclose
Jazayeri	Mohammad-Ali	Arrhythmias and Clinical EP: Devices 1	Controlled Trials Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients Undergoing Cardiac Implantable Electronic	Nothing to Disclose
1	Mahamad Ali	And thering and Clinical ED. Daving 2	Device Implantation: A Meta-Analysis	Nething to Displace
Jazayeri Jazayeri	Mohammad-Ali Mohammad-Ali	Arrhythmias and Clinical EP: Devices 2 Arrhythmias and Clinical EP: Devices 2	Impact of Left Atrial Appendage Occlusion on Left Atrial Function Real World Battery Longevity of St. Jude Medical Implantable	Nothing to Disclose Nothing to Disclose
,.		,	Cardioverter-Defibrillators Included in the Advisory for Premature Battery Depletion	
Jazayeri	Mohammad-Ali	Atrial Fibrillation and VT: Unique Populations	Use of an Esophageal Retractor to Prevent Thermal Injuries During	Nothing to Disclose
Jazayeri	Mohammad-Ali	and Solutions Arrhythmias and Clinical EP: Anticoagulation	Atrial Fibrillation Ablation: A Multi-Center Experience Meta-Analysis on the Efficacy and Safety of New Oral	Nothing to Disclose
,		Issues	Anticoagulants Compared With Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation	
Jazayeri	Mohammad-Ali	Innovative Use of Echocardiography	Prognostic Utility of Hand-Carried Ultrasound Compared to Clinical and Laboratory Assessment of Decongestion to Predict Outcomes in Hospitalized Patients With Heart Failure	Nothing to Disclose
Jazayeri	Mohammad-Ali	FIT Clinical Decision Making: Arrhythmias and	Device-Related Thrombus Following Left Atrial Appendage Closure:	Nothing to Disclose
Jazayeri	Mohammad-Ali	Electrophysiology Innovative Approaches for Reducing Risk and	A Clinical Conundrum Efficacy of Catheter Ablation of Atrial Fibrillation in the Setting of	Nothing to Disclose
		Improving Outcomes With Ablation	Systolic Dysfunction: A Meta-Analysis of Randomized Control Trials	-
Jazayeri	Mohammad-Ali	Insights From Echocardiography Use	Comparison of Clinical Exam, Patient Symptoms and Hand-Carried Ultrasound in Assessing Decongestion of Hospitalized Patients With Heart Failure	Nothing to Disclose
Jazayeri	Mohammad-Ali	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Management of Impacted Intramyocardial Shrapnel Due to Gunshot Wound	Nothing to Disclose
Jazayeri	Mohammad-Ali	Disease, and Vascular Medicine Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Safety Profiles of Percutaneous Left Atrial Appendage Closure Devices: An Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database From	Nothing to Disclose
Jean	Ferrieres	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	2009 - 2016	Nothing to Disclose
Jeevanandam	Valluvan	Highlighted Original Research: Heart Failure	Stented Patients in the FAST-MI 2005 Cohort Increased Tumor Necrosis Factor-α Levels in Patients With	DATA SAFETY MONITORING BOARD - Thoratec
Jeevanandam	Valluvan	and Cardiomyopathies and the Year in Review Atrial Fibrillation and VT: Specific Situations	Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Instability and Are Associated With Higher Non-Surgical Bleeding Incidence, Predictors, and Outcome of Postoperative Atrial	DATA SAFETY MONITORING BOARD - Thoratec
		and Newer Outcome Measures	Fibrillation in Patients Receiving Continuous Flow Left Ventricular Assist Devices	
Jeevanandam	Valluvan	Innovative Use of Echocardiography	Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography	DATA SAFETY MONITORING BOARD - Thoratec
Jeevanandam	Valluvandam	Surgical Therapies for Heart Failure Patients: Stage A-C	Panelist	DATA SAFETY MONITORING BOARD - Thoratec
Jeevanandam	Valluvandam	Surgical Therapies for Heart Failure Patients:	Debate Con: CABG Has a Limited Role in the Management of HF	DATA SAFETY MONITORING BOARD - Thoratec
Jeevarethinam	Anand	Stage A-C Non Invasive Imaging: Prognostic Implications	Patients Carotid Plaque Is Predictive of Cardio Vascular Events in	Nothing to Disclose
occvar cu iii am		of CT Angiography	Asymptomatic Diabetes: A Prospective Study	-
Jefferies	John	Making Progress in Understanding Heart Failure	Contemporary Use of Heart Failure Medications in Pediatric Patients With Dilated Cardiomyopathy	CONSULTANT FEES/HONORARIA - Battelle, Genzyme Corporation, Janssen Pharmaceuticals, Inc, Novartis, Novartis
Jefferies	John	Heart Failure and Cardiomyopathies: What	Spironolactone Therapy for Cardiomyopathy in Duchenne Muscular	Corporation CONSULTANT FEES/HONORARIA - Battelle, Genzyme
		Next When All Else Is Failing?	Dystrophy	Corporation, Janssen Pharmaceuticals, Inc, Novartis, Novartis Corporation
Jefferies	John	Therapeutic Advances in Congenital Heart Disease	Improved Exercise Performance in Pediatric Fontan Patients After Cardiac Rehabilitation	CONSULTANT FEES/HONORARIA - Battelle,Genzyme Corporation,Janssen Pharmaceuticals, Inc,Novartis,Novartis Corporation
Jeffries	Neal	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking	Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic	Nothing to Disclose
loger	Dahan	Clinical Trials	Surgical Trials Network	Nothing to Displace
Jeger	Raban	Interventional Cardiology: PCI and TAVR in Complex Patients	Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the Bravo-3 Randomized Trial	Nothing to Disclose
Jellis	Christine	Valvular Heart Disease: Mitral Valve Disease	Gender Differences in the Etiology of Mitral Valve Disease	Nothing to Disclose
Jenkins	James	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Use of TandemHeart as a Bridge to Surgery in a Patient With Combined Obstructive and Cardiogenic Shock Due to Mechanical	CONSULTANT FEES/HONORARIA - AGA medical, Trivascular; SPEAKER'S BUREAU - Abbott
Jenkins	Kathy	2017 Dan G. McNamara Lecture: The Future of Congenital Heart Research: Keeping the	Mitral Valve Thrombosis Co-Chair	RESEARCH/RESEARCH GRANTS - Medtronic Corporation, Novartis, NuMed Corporation
Jenkins	Kathy	Patient-Centered Promise 2017 Dan G. McNamara Lecture: The Future	Introduction of Gail Pearson, MD, FACC	RESEARCH/RESEARCH GRANTS - Medtronic
lenkins	Kathy	of Congenital Heart Research: Keeping the Patient-Centered Promise Value, Advocacy and the Future of Adult	Panelist	Corporation,Novartis,NuMed Corporation RESEARCH/RESEARCH GRANTS - Medtronic
Jenkins	Kathy	Congenital and Pediatric Cardiology	i direliet	Corporation, Novartis, NuMed Corporation
Jenkins	Kathy	Value, Advocacy and the Future of Adult Congenital and Pediatric Cardiology	Optimal Clinical Outcomes and Value	RESEARCH/RESEARCH GRANTS - Medtronic
Jenkins	Trevor	The Tricuspid Valve: The New Frontier	Role of CT and MR in Imaging of Tricuspid Valve Disease	Corporation,Novartis,NuMed Corporation Nothing to Disclose
Jennings	Garry	Strategies for Prevention of Cardiovascular Disease: International Perspectives From the Canadian Cardiovascular Society, Cardiac Society of Australia and New Zealand, and	Primary and Secondary Preventative Strategies for CVD in Indigenous Australian Communities	Nothing to Disclose
Jensen	Henrik	American College of Cardiology New Perspectives on CAD Risk Factors	A Genetic Risk Score Predicts Cardiovascular Events in Patients	Nothing to Disclose
Jensen	Jan	Emerging Applications of Echocardiography	With Stable Coronary Artery Disease Ratio of Transmittal Early Filling Velocity to Early Diastolic Strain Rate Predicts Long Term Risk of Cardiovascular Morbidity and	Nothing to Disclose
Jensen	Jan	Innovative Use of Echocardiography	Mortality in a Low Risk General Population Presence of Post-Systolic Shortening by Tissue Doppler Imaging is	Nothing to Disclose
			an Independent Predictor of Heart Failure in Patients Following ST- Segment Elevation Myocardial Infarction	

and the second				
Last Name Jensen	First Name Jan	Session Title Atrial Fibrillation and VT: Incorporating Novel	Presentation Title Risk Assessment of Recurrent Atrial Fibrillation After Antiarrhythmic	Disclosures Nothing to Disclose
Jensen	Jan	Risks Toward Decision Making	Medication or Catheter Ablation: The Impact of Age and Supraventricular Ectopic Complexes	Nothing to Disclose
Jensen	Jan	Insights From Echocardiography Use	Layer-Specific Strain Analysis by Two-Dimensional Speckle Tracking Echocardiography: Improvement of Coronary Artery Disease Diagnostics in Patients With Stable Angina Pectoris	Nothing to Disclose
Jensen	Jan Skov	Innovative Use of Echocardiography	The Left Atrium Emptying Fraction as a Predictor of Cardiovascular Morbidity and Mortality in a Low Risk General Population	Nothing to Disclose
Jensen	Lisette	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Association Between QRS Duration on Prehospital Electrocardiogram and Early Outcome in Patients With ST Segment Elevation Myocardial Infarction	CONSULTANT FEES/HONORARIA - Abbott,St Jude Medical; RESEARCH/RESEARCH GRANTS - Biotronik,St Jude Medical,Terumo
Jentzer	Jacob	Test Yourself with Questions: General Cardiology Module 15	Faculty	Nothing to Disclose
Jentzer	Jacob	Test Yourself with Questions: General	Chair	Nothing to Disclose
Jentzer	Jacob	Cardiology Module 15 Innovations in Practice Management and	Severity of Illness Assessment in the Cardiac Intensive Care Unit	Nothing to Disclose
Jentzer	Jacob	Social Media Innovative Use of Echocardiography	(CICU): Application of the APACHE IV Predicted Mortality Score Systolic Function and Cardiac Output on Echocardiography Do Not Predict Mortality After Cardiac Arrest	Nothing to Disclose
Jentzer	Jacob	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome		Nothing to Disclose
Jentzer	Jacob	Insights From Echocardiography Use	Diastolic Dysfunction by Doppler Echocardiography Predicts	Nothing to Disclose
Jeon	Eun-Seok	From Diet to Drugs: Mechanistic Insight Into	Mortality after Cardiac Arrest Fimasartan Protect Cardiac Myocyte Damage in Ischemic Heart	Nothing to Disclose
Jeong	Hyeon Ju	Ischemic Heart Disease Non Invasive Imaging: Coronary Calcium	Diseases Smoking as a Key Predictor of CAD Among Asymptomatic and	Nothing to Disclose
_	•	Scoring and CV Risk Assessment	Extremely Low Coronary Artery Calcium Score Patients	
Jeong	Myung Ho	Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	Renal Nerve Denervation Suppress Ventricular Arrhythmia in a Porcine Model After Acute Myocardial Infarction	Nothing to Disclose
Jeong	Young-Hoon	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Clinical Efficacy of High-Flow Oxygen Therapy Through Nasal Cannula in Patients With Acute Heart Failure	CONSULTANT FEES/HONORARIA - Astra Zeneca, Daiichi Sankyo/Lilly, Sanofi-Aventis; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals, Daewoong Pharmaceuticals, Haemonetics, Hanmi Pharmaceuticals, Otsuka
Jeong	Young-Hoon	Coronary Angiography, Intra-Vascular Imaging,		CONSULTANT FEES/HONORARIA - Astra Zeneca, Daiichi
		Revascularization and Outcomes	Restenosis in Patient With Drug Eluting Stent	Sankyo/Lilly,Sanofi-Aventis; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals,Daewoong Pharmaceuticals,Haemonetics,Hanmi Pharmaceuticals,Otsuka
Jeong	Young-Hoon	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prognostic Value of Platelet-Fibrin Clot Strength on Occurrence of Cardiovascular Events After Non-Cardiac Surgery	CONSULTANT FEES/HONORARIA - Astra Zeneca, Daiichi Sankyo/Lilly, Sanofi-Aventis; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals, Daewoong Pharmaceuticals, Haemonetics, Hanmi Pharmaceuticals, Otsuka
Jeong	Young-Hoon	Antithrombotic Therapy in Ischemic Heart Disease	Ticagrelor Versus Clopidogrel Is Associated With Better Recovery of LV Function After Acute Myocardial Infarction	CONSULTANT FEES/HONORARIA - Astra Zeneca, Daiichi Sankyo/Lilly, Sanofi-Aventis; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals, Daewoong Pharmaceuticals, Haemonetics, Hanmi Pharmaceuticals, Otsuka
Jeon-Slaughter	Haekyung	Head to Toe: Outcomes of Endovascular	Atherectomy Is Associated With Lower Rates of Repeat Intervention	Nothing to Disclose
Jeon-Slaughter	Haekyung	Interventions Head to Toe: Outcomes of Endovascular Interventions	After Below Knee Peripheral Vascular Intervention Utilization of Distal Embolic Protection in Infrainguinal Peripheral Arterial Intervention: Insights From the Multicenter XLPAD Registry	Nothing to Disclose
Jeon-Slaughter	Haekyung	Head to Toe: Outcomes of Endovascular	Association of Cigarette Smoking With Procedural Cost of Lower	Nothing to Disclose
Jeon-Slaughter	Haekyung	Interventions Endovascular Therapy: Running From Risk	Extremity Endovascular Intervention Predictors of Procedural Complications in Infrainguinal	Nothing to Disclose
Jeon-Slaughter	Haekyung	Highlights in Vascular Medicine Research	Endovascular Interventions Comparative Assessment of Subintimal Versus Intraluminal Crossing of Infrainguinal Chronic Total Occlusion Lesions	Nothing to Disclose
Jeremias	Allen	Fellows Bootcamp: Interventional Basics	FFR/IVUS/OCT	CONSULTANT FEES/HONORARIA - Abbott,St Jude Medical,Volcano; SPEAKER'S BUREAU - Astra Zeneca
Jeremias	Allen	What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture	Debate: Non-invasive Risk Stratification is the Optimal Gatekeeper for Revascularization in Stable Angina: Con	CONSULTANT FEES/HONORARIA - Abbott,St Jude Medical,Volcano; SPEAKER'S BUREAU - Astra Zeneca
Jeremias	Allen	Coronary Physiology for the Assessment of	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott,St Jude
Jeremias	Allen	Stable CAD Coronary Physiology for the Assessment of	Proper FFR Analysis and Potential Pitfalls: Insights from the Core	Medical, Volcano; SPEAKER'S BUREAU - Astra Zeneca CONSULTANT FEES/HONORARIA - Abbott, St Jude
Jeremias	Allen	Stable CAD Coronary Physiology for the Assessment of	Lab Coronary Flow Versus Pressure as a Prognostic Indicator for Long	Medical, Volcano; SPEAKER'S BUREAU - Astra Zeneca CONSULTANT FEES/HONORARIA - Abbott, St Jude
Jeremias	Allen	Stable CAD Coronary Physiology and Microcirculation	Term Patient Outcomes Panelist	Medical,Volcano; SPEAKER'S BUREAU - Astra Zeneca CONSULTANT FEES/HONORARIA - Abbott,St Jude
				Medical, Volcano; SPEAKER'S BUREAU - Astra Zeneca
Jeremias	Allen	Coronary Physiology and Microcirculation	When FFR and iFR Disagree - Is Measuring Flow the Answer?	CONSULTANT FEES/HONORARIA - Abbott,St Jude Medical,Volcano; SPEAKER'S BUREAU - Astra Zeneca
Jeremias	Allen	Interventional Cardiology: TAVR 2	Impact of Chronic Kidney Disease on Mortality in Adults Undergoing Balloon Aortic Valvuloplasty	CONSULTANT FEES/HONORARIA - Abbott,St Jude Medical,Volcano; SPEAKER'S BUREAU - Astra Zeneca
Jeremias	Allen	16. Interventional Cardiology: Angiography and Interventional CT/MR Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott, St Jude Medical, Volcano; SPEAKER'S BUREAU - Astra Zeneca
Jeremias	Allen	23. Interventional Cardiology: IVUS and Intravascular Physiology Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott,St Jude Medical,Volcano; SPEAKER'S BUREAU - Astra Zeneca
Jering	Karola	Innovations in Cardiovascular Risk Assessment		Nothing to Disclose
Jermyn	Rita	and Reduction Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Atherosclerosis (MESA): Implications for Cardiovascular Disease High Procedural and Device Related Success With the CardioMEMS HF System for Heart Failure: Observations From the	SPEAKER'S BUREAU - St Jude
Jerosch-Herold	Michael	Imaging of Myocardial Blood Flow: A Multimodality Approach	CardioMEMS™ Post Approval Study Measuring flow with Cardiac MRI: Ready for Prime Time	Nothing to Disclose
Jerosch-Herold	Michael	Non Invasive Imaging: MR Scar and Perfusion	Doxorubicin-Associated Cardiac Tissue Remodeling in Breast Cancer Patients: A Cardiac Magnetic Resonance Study	Nothing to Disclose
Jessen	Michael	Interventional Cardiology: TAVR 3	Role of Hospital Volume in Identifying Low and High-performing	CONSULTANT FEES/HONORARIA - Quest Medical Inc
Jessup	Mariell	FIT Forum: Mix and Mingle	Surgical Valve Centers in the United States Heart Failure	SALARY - Leducq Fondation
Jessup	Mariell	Late-Breaking Clinical Trials: Deep Dive II Featured Clinical Research III	Panelist Panelist	SALARY - Leducq Fondation SALARY - Leducq Fondation
Jessup Jessup	Mariell Mariell	Featured Clinical Research III Kanu and Docey Chatterjee Lecture and Seminal Talks in Heart Failure: I Wanna New Drug: Updated Heart Failure Guidelines	Panelist Kanu and Docey Chatterjee Lecture - Learning from Our Past and Looking to the Future - Hope for Heart Failure	SALARY - Leducq Fondation SALARY - Leducq Fondation
Jessup	Mariell	Heart Failure and Cardiomyopathies: Clinical Team 2	Suggested Reviewer	SALARY - Leducq Fondation
Jessup	Mariell ling Vi	LBCT reviewers Head to Toe: Outcomes of Endovascular	LB Reviewer Improvement of Pituitary Function After Carotid Revascularization	SALARY - Leducq Fondation
Jhang	Jing-Yi	Interventions	for Abnormal Cerebral Perfusion	Nothing to Disclose
Jhun	Hye Yeon	Non Invasive Imaging: Expanding Clinical Applications	Diagnostic Accuracy of Coronary Computed Tomography Angiography in Aortic Stenosis Patients Referred for Aortic Valve Replacement: Systematic Review and Meta-Analysis	Nothing to Disclose

Jhund	Pardeep	Session Title Making Progress in Understanding Heart Failure	Presentation Title Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF	Disclosures CONSULTANT FEES/HONORARIA - Novartis Corporation
Jhund	Pardeep	Heart Failure and Cardiomyopathies: Heart	Effect of Sacubitril/Valsartan Compared With Enalapril, According to	CONSULTANT FEES/HONORARIA - Novartis Corporation
Jhund	Pardeep	Failure Is Just a Revolving Door Hormones and Heart Failure	Etiology in PARADIGM-HF Low Urinary Cgmp/Bnp Ratio Is Associated With Worse Outcomes in Heart Failure but Is Increased by Treatment With	CONSULTANT FEES/HONORARIA - Novartis Corporation
Ji	Ruiping	The Evolving World of LVADs, Transplant and	Sacubitril/Valsartan: An Analysis of Paradigm-HF Ventricular Assist Device Decreases Abnormal Cardiac Sodium	Nothing to Disclose
Jia	Shaobin	Other Novel Discoveries From Diet to Drugs: Mechanistic Insight Into	Channel mRNA Splicing Homocysteine Accelerated the Disorder of Lipid Metabolism via	Nothing to Disclose
Jia	Shaobin	Ischemic Heart Disease Insights Into Ischemic Heart Disease: Stable to	Regulating Pcsk9 and Lxrα-abca1/abcg1 Pathway Hyperhomocystienmia Accelerated Formation of Unstable Plaque in	Nothing to Disclose
Jia	Xiaoming	Erosive Plaques Interventional Cardiology: PCI in Complex	ApoE Double Knock Mice Associtated With Alternation of Global Dimethylated Histone H3 and Lysine 9 Clinical Outcomes of Patients With Human Immune Deficiency Virus	
	-	Patients	After Coronary Revascularization: A Systematic Review and Meta- Analysis	-
Jia	Yan	Novel Imaging and Therapies in Heart Failure	Evaluation of Left Ventricular Systolic Function After Renal Sympathetic Denervation by Layer-Specific Two-Dimensional Speckle Tracking Imaging	Nothing to Disclose
Jiang	Во	Cutting Edge Vascular Medicine	Rap1 Mediates Thrombin-Induced Proliferation and Focal Adhesion Formation in Smooth Muscle Cells	Nothing to Disclose
Jiang	Hong	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Atrial Fibrillation Associated to Wpw Syndrome in a Patient With Concomitant Brugada Syndrome	Nothing to Disclose
Jiang	Leng	FIT Clinical Decision Making: Multimodality Imaging	Ventricular Septal Dissection With Rupture and Large NeoCavity After Inferior ST Elevation Myccardial Infarction in a Patient With Recent Coronary Artery Bypass Grafts	Nothing to Disclose
Jiang	Lixin	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Time to Acute Care Among Patients With Acute Myocardial Infarction in China: A Report From China Patient-Centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction	Nothing to Disclose
Jiang	Ning	The Evolving World of LVADs, Transplant and	Ventricular Assist Device Decreases Abnormal Cardiac Sodium	Nothing to Disclose
Jilaihawi	Hasan	Other Novel Discoveries Joint American College of Cardiology/New England Journal of Medicine Late-Breaking	Channel mRNA Splicing Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical,Venus Medtech
Jilaihawi	Hasan	Clinical Trials Challenging Anatomies: Does TAVR Device	Registries Panelist	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St
Jilaihawi	Hasan	Choice Matter Challenging Anatomies: Does TAVR Device	Management of the Bicuspid Valve	Jude Medical, Venus Medtech CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St
		Choice Matter	- '	Jude Medical, Venus Medtech
Jilaihawi	Hasan	Prosthetic Valve Assessment: Real or Illusion?	Prosthetic Thrombus and Thrombotic Leaflet Thickening: Are These Related Entities?	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical,Venus Medtech
Jilaihawi	Hasan	Non Invasive Imaging: Expanding Clinical Applications	Does Patient Prosthesis Mismatch Defined by CT LVOT Area Predict Downstream Clinical Outcomes?	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical,Venus Medtech
Jilaihawi	Hasan	Refining TAVR Outcomes	Frame Geometry and Hemodynamic Findings of Sapien 3 Transcatheter Heart Valve in Patients With Bicuspid Aortic Valve Disease	CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical, Venus Medtech
Jimenez	David	Challenging the Standard of Care: Emerging Concepts in VTE Treatment and Prevention	Non-vitamin K Oral Anticoagulants for First-line Therapy of VTE: Incorporating the CHEST and ESC Guidelines into Clinical Practice	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,Bristol-Myers Squibb Company ,Daiichi Sankyo,Pfizer Inc,Sanofi-Aventis
Jimenez	Enrique	Vascular Access and Hemostasis Issues	Standard Versus Low-Dose Heparin Use on Access-Related Complications After Coronary Angiography Through Radial Access: A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Jimenez	Gustavo	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Normalizing Platelet Reactivity of Cardiovascular Patients on Ticagrelor Therapy Using Fresh Platelets: Ex Vivo Testing of the Functional Recovery Attained Within 48-Hours of Stopping Treatment	Nothing to Disclose
Jimenez	Gustavo	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Therapeutic Hypothermia in Post-Cardiac Arrest Syndrome: Role of Neuron-Specific Enolase as Early Predictor of Neurological Status at Discharge	Nothing to Disclose
Jimenez	Rosa Maria	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years	RESEARCH/RESEARCH GRANTS - HOSPITAL UNIVERSITARIO FUENLABRADA
Jin	Ping	From Diet to Drugs: Mechanistic Insight Into	Homocysteine Accelerated the Disorder of Lipid Metabolism via	Nothing to Disclose
Jinnouchi	Hiroyuki	Ischemic Heart Disease Interventional Cardiology: Intravascular Physiology and Endothelial Function	Regulating Pcsk9 and Lwα-abca1/abcq1 Pathway Long-Term Vascular Response to Permanent Polymer Everolimus- Eluting Stent Compared With Biodegradable Polymer Biolimus- Eluting Stent: Five-Year Follow-Up Optical Coherence Tomography Study	Nothing to Disclose
Jinnouchi	Hiroyuki	Interventional Cardiology: PCI in Complex Patients	Three-Year Clinical Outcomes of the XIENCE/PROMUS Cobalt- Chromium Everolimus-Eluting Stent in Patients Treated With In-	Nothing to Disclose
JIPESCU	DANIEL	FIT Clinical Decision Making: Arrhythmias and	Stent Restenosis Rare Case of Saw Palmetto Induced Complete Heart Block	Nothing to Disclose
Jivan	Arif	Electrophysiology Technical Advances in Transthoracic Echocardiography	Safety of Perflutren-Based Echocardiographic Contrast Agent Administration in the Setting of a Patent Foramen Ovale (PFO): A Multicenter Study Conducted in Tertiary Care Centers Based in the New York/Cincago Metropolit	Nothing to Disclose
Jneid	Hani	Heart Failure: From Pathophysiology to Socio- Economic Impact: International Perspectives From the Lebanese Cardiac Society, Taiwan Society of Cardiology, and American College of Cardiology	Co-Chair	Nothing to Disclose
Jneid	Hani	Heart Failure: From Pathophysiology to Socio- Economic Impact: International Perspectives From the Lebanese Cardiac Society, Taiwan Society of Cardiology, and American College of Cardiology	Introduction to Session	Nothing to Disclose
Jneid	Hani	Recent ACS Trials: Relevance to My Daily Practice	Panelist	Nothing to Disclose
Jneid	Hani	The Best Structural Interventional Challenging	ACC Panelist	Nothing to Disclose
Jneid	Hani	O2. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Jobanputra	Yash	Clinical Team 7 Interventional Cardiology: TAVR 1	Novel Plane of Measurement to Evaluate Accurate Valve Size in	Nothing to Disclose
Jobanputra	Yash	Interventional Cardiology: TAVR 2	Patients Undergoing Transcatheter Aortic Valve Replacement Impact of Active Coronary Artery Disease on the Early and 1 Year	Nothing to Disclose
		gj. // 2	Mortality of Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis	
Jobanputra	Yash	Interventional Cardiology: TAVR 2	Outcomes of Transcatheter Aortic Valve Replacement Without Balloon Predilation: A Systematic Review and Meta-Analysis	Nothing to Disclose
Jobanputra	Yash	Interventional Cardiology: TAVR 3	Comparison of Acute Elastic Recoil Between CoreValve and SAPIEN 3 Valves in Transcatheter Aortic Valve Replacement	Nothing to Disclose
Joergensen	Erik	Fixing the Heart One Cell at a Time: The	Adipose Derived Stromal Cells for Refractory Angina: Results From	Nothing to Disclose
L	<u> </u>	Ongoing Promise of Stem Cells	MyStromalCell Trial	

and the second				l
Last Name Jogu	First Name Hanumantha Rao	Session Title Considerations in Antiplatelet Therapy and in	Presentation Title Use of Antiplatelets and Anticoagulants in Septic Patients With	Disclosures Nothing to Disclose
Jogu	Hanumantha Rao	ACS Coronary Angiography, Intra-Vascular Imaging,	Troponin Elevation: Insights From Type II MI Study	Nothing to Disclose
		Revascularization and Outcomes	Patients With Sepsis and Elevated Troponin	
Johannessen	Arne	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Risk Assessment of Recurrent Atrial Fibrillation After Antiarrhythmic Medication or Catheter Ablation: The Impact of Age and Supraventricular Ectopic Complexes	Nothing to Disclose
Johansson	Magnus	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Echocardiographic Predictors for In-Hospital and 1-Year Outcomes in Left-Sided Infective Endocarditis: An Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort Study	Nothing to Disclose
John	Anitha	Pregnancy Complicated by Valvular/Congenital Heart Disease: Clinical Management and Challenging Cases	The Challenge of Anti-coagulation in the Pregnant Patient with Valvular/Congenital Heart Disease	Nothing to Disclose
John	Anitha	Focus on Structural and Valvular Heart	Update on the Management of Adult Congenital Heart Disease	Nothing to Disclose
		Disease: Joint Symposium of the Association of Black Cardiologists and the American College of Cardiology		
John	Anitha	Adult Patients With Congenital Heart Disease: How Do They Compare?	Factors Associated With Completion of Advanced Directives in Adults With Congenital Heart Disease	Nothing to Disclose
John John	Jenine Ranjit	FIT Clinical Decision Making Reviewers 7 New Technologies in Echocardiography	ACC FIT Clinical Decision Making Reviewer Transthoracic Echocardiography to Guide Extracorporeal	Nothing to Disclose RESEARCH/RESEARCH GRANTS - Thoratec . Heartware
John	rvariji	INEW Technologies in Echlocardiography	Membrane Oxygenation Decannulation After Refractory Ventricular Fibrillation Cardiac Arrest Treated With Primary Angioplasty: A Turndown Protocol	
John	Stendahl	Non Invasive Imaging: Expanding Clinical Applications	Computed Tomographic Angiography Can Reliably Assess Epicardial Coronary Vasoreactivity in Response to Adenosine and Dobutamine	Nothing to Disclose
Johnsen	Søren	Adult Patients With Congenital Heart Disease: How Do They Compare?	Risk of Stroke in Adult Patients With Congenital Heart Disease Compared With the General Population: A Danish Nationwide Population-Based Cohort Study	Nothing to Disclose
Johnson	Allen	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	New Shortness of Breath, Old Problems	Nothing to Disclose
Johnson	Allen	Redefining the "F" Word	Atrial Diastolic "Suction": An Important Contributor to	Nothing to Disclose
Johnson	Amber	Arrhythmias and Clinical EP: Devices 2	Fontan Circulation Persistent Gender Disparities in Implantable Cardioverter-	Nothing to Disclose
Johnson	Amber	Put Your Codon! Genetic Insights Into Heart	Defibrillator Therapy G-Protein Receptor Kinase 5 Polymorphisms and Outcomes in the	Nothing to Disclose
		Failure	African American Heart Failure Trial: Results From the Genetic Risk Assessment of Heart Failure in African-Americans Sub-Study	
Johnson	Benjamin	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Influence of Cardiac Arrest and Cardiogenic Shock on Outcomes Among 4,500 Consecutive ST Elevation Myocardial Infarction Patients	Nothing to Disclose
Johnson	Benjamin	Timely Topics in Acute Coronary Syndromes	Outcome and Characteristics of Shockable Versus Non-Shockable Cardiac Arrest in ST Elevation Myocardial Infarction at a Regional Transfer Center	Nothing to Disclose
Johnson	Chantel	New Perspectives on CAD Risk Factors	Coronary Artery Disease Patients With Concurrent Psychiatric Disorders at Greater Risk for Mortality	Nothing to Disclose
Johnson	Jonathan	Improving Outcomes in the Athlete With Cardiovascular Disease	Exercise Testing in Pediatric Patients: Objective Versus Subjective Effort	Nothing to Disclose
Johnson	Jonathan	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Delivery and Management of Complete Ectopia Cordis: A Multidisciplinary Approach	Nothing to Disclose
Johnson	Jonathan	Predicting Outcomes in Pediatric Heart Disase	Growth Dynamics of Aorta in Bicuspid Aortic Valve Patients From	Nothing to Disclose
Johnson	Kipp	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Infancy to Young Adult Age Atherosclerotic Plaque Morphology in Response to High Intensity Lipid Lowering Therapy by Multimodality Imaging Among Women	Nothing to Disclose
Johnson	Kipp	The Inside View: Learning From Intracoronary Imaging	and Men: A YELLOW-II Sub-study Investigation of Novel Drug Targets Implicated in High-Dose Statin Therapy From Yellow-II Trial: Towards Personalized Lipid Lowering Therapies	Nothing to Disclose
Johnson	Michelle	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	What Are the Differences in Oral Anticoagulant Treatment Persistence in Non-Valvular Atrial Fibrillation in Europe? Real-World	Nothing to Disclose
Johnson	Nils	Late-Breaking Clinical Trials: Interventional	Studies in Three European Countries Panelist	OTHER - Boston Scientific; RESEARCH/RESEARCH GRANTS -
Johnson	Nils	23. Interventional Cardiology: IVUS and	Suggested Reviewer	St Jude Medical, Volcano Corporation OTHER - Boston Scientific; RESEARCH/RESEARCH GRANTS -
		Intravascular Physiology Team 2 35. Pulmonary Hypertension and Pulmonary		St Jude Medical, Volcano Corporation
Johnson	Stacy	Thrombo-embolic Disease Team 2	Suggested Reviewer	Nothing to Disclose
Johnston	Peter	01. Acute and Stable Ischemic Heart Disease: Basic Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - AUM Cardiovascular, Inc,Biocardia, Inc
Jokhadar	Maan	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Recurrent Atrial Myxomas of Carney Complex: Pleading the Fifth	Nothing to Disclose
Jokhadar	Maan	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Refractory Electrical Storm as the Initial Presentation of Presumed Cardiac Sarcoidosis Treated With Left Stellate Ganglion Block	Nothing to Disclose
Jollis	James	Innovations in Practice Management and Social Media	Accelerator 2 SUSTAIN, A U.S. Regional Systems of Care Demonstration Project for Post-Discharge STEMI Patients: Preliminary Data, Methods and Design	Nothing to Disclose
Jollis	James	Novel Developments in Acute Coronary Syndromes	First Medical Contact to Device Time in STEMI Patients Presenting With Cardiogenic Shock: Insights From Mission, a Lifeline STEMI Systems Accelerator	Nothing to Disclose
Jollis	James	Innovation in Practice Management, Advocacy, and Education	Early Defibrillation by First-Responders in Relation to Fire Stations: Optimal Benefit According to Location	Nothing to Disclose
Jollis	James	03. Acute and Stable Ischemic Heart Disease: Therapy Team 2	Suggested Reviewer	Nothing to Disclose
Jolly	Sanjit	What's New in the World of STEMI?	Debate: Con for Aspiration	CONSULTANT FEES/HONORARIA - Astra Zeneca; RESEARCH/RESEARCH GRANTS - MEDTRONIC
Jolly	Sanjit	Vascular Access and Hemostasis Issues	Assessment of the Safety of Performing Coronary Angioplasty	CONSULTANT FEES/HONORARIA - Astra Zeneca;
Jolly	Sanjit	Novel Developments in Acute Coronary	Without Interrupting Oral Anticoagulants Incidence and Predictors of No Reflow Phenomenon: Insights From	RESEARCH/RESEARCH GRANTS - MEDTRONIC CONSULTANT FEES/HONORARIA - Astra Zeneca;
Jolly	Sanjit	Syndromes Novel Developments in Acute Coronary	the TOTAL Trial One-Year Outcome of Acute Stent Thrombosis: Insights From the	RESEARCH/RESEARCH GRANTS - MEDTRONIC CONSULTANT FEES/HONORARIA - Astra Zeneca;
Jolly	Sanjit	Syndromes Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Total Trial Mineralocorticoid Receptor Antagonists in Patients With Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of	RESEARCH/RESEARCH GRANTS - MEDTRONIC CONSULTANT FEES/HONORARIA - Astra Zeneca; RESEARCH/RESEARCH GRANTS - MEDTRONIC
Joly	Joanna	FIT Clinical Decision Making: Prevention, Adult	Randomized Trials Exertional Hypoxemia in levo-Transposition of the Great Arteries (I-	Nothing to Disclose
		Congenital and Congenital Heart Disease	TGA) and Pulmonary Stenosis Due to Pulmonary Artery Conduit Stenosis and Atrial Septal Defect	

Carl Street				<u> </u>
Last Name Jonas	First Name Richard	Session Title Therapeutic Advances in Congenital Heart	Presentation Title Effect of Obesity and Underweight Status on Perioperative	Disclosures Nothing to Disclose
Julias	Nicitalu	Disease	Outcomes in Patients With Congenital Heart Disease: An Analysis of Data From the Society of Thoracic Surgeons Congenital Heart Surgery Database	Notining to Disclose
Jones	Brandon	Interventional Cardiology: TAVR 1	Novel Plane of Measurement to Evaluate Accurate Valve Size in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Jones	Brandon	Interventional Cardiology: TAVR 2	Impact of Active Coronary Artery Disease on the Early and 1 Year Mortality of Patients Undergoing Transcatheter Aortic Valve	Nothing to Disclose
Jones	Brandon	Interventional Cardiology: TAVR 2	Replacement: A Systematic Review and Meta-Analysis Outcomes of Transcatheter Aortic Valve Replacement Without	Nothing to Disclose
Jones	Brandon	Interventional Cardiology: TAVR 3	Balloon Predilation: A Systematic Review and Meta-Analysis Comparison of Acute Elastic Recoil Between CoreValve and	Nothing to Disclose
Jones	Brandon	Insights From Echocardiography Use	SAPIEN 3 Valves in Transcatheter Aortic Valve Replacement Aortic Regurgitation Negatively Affects Left Ventricular Mechanics After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Jones	Brandon	TAVR Outcomes Prognostication	Cardiac Plasticity Predicts Outcome After Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis	Nothing to Disclose
Jones	David	Structural Heart Disease: Difficult Choices for the Heart Team	AI - Failing Homograft/Eggshell' Full Root Replacement, Cr 2.9 Options Anybody???	SPEAKER'S BUREAU - Edwards Lifesciences
Jones	Dean	Updates on Risk Factors for Cardiovascular Disease	Changes in Body Fat Distribution Is Associated With Oxidative Stress	Nothing to Disclose
Jones	Deanna	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Frequency of Transition From Stage A to B or C Heart Failure After Potentially Cardiotoxic Chemotherapy	Nothing to Disclose
Jones	Erika	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Idiopathic Effusive Constrictive Pericarditis in a Patient With Cystic Fibrosis: A Case Report With Multi-Modality Imaging	Nothing to Disclose
Jones	Erika	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Supravalvular Aortic Stenosis: A Rare Complication of Familial Hypercholesterolemia Presenting as Cardiogenic Shock	Nothing to Disclose
Jones	Erika	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Challenges During Pregnancy With Marfan Syndrome and an Ascending Aortic Aneurysm	Nothing to Disclose
Jones	Gail	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	An Interesting Case of Sudden Cardiac Death in a Patient With Tetralogy of Fallot	Nothing to Disclose
Jones	Lee	Updates on Risk Factors for Cardiovascular Disease	Associations Between Exercise Prior to and Around the Time of Cancer Diagnosis and Subsequent Cardiovascular Events in Women With Breast Cancer: A Women's Health Initiative (WHI) Analysis	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Exercise by Science
Jones	Peter	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Alirocumab Efficacy and Safety in Patients With Hypercholesterolemia and With or Without Clinical Atherosclerotic Cardiovascular Disease: Pooled Analysis of 10 ODYSSEY Randomized Trials	CONSULTANT FEES/HONORARIA - Amgen,Merck,Sanofi/Regeneron
Jones	Peter	The Intersection of Diabetes and ASCVD	Alirocumab Safety in Individuals With and Without Diabetes Mellitus: Pooled Data From 14 ODYSSEY Trials	CONSULTANT FEES/HONORARIA - Amgen,Merck,Sanofi/Regeneron
Jones	Philip	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Reliability and Responsiveness of Seattle Angina Questionnaire in Women With Coronary Artery Disease	Nothing to Disclose
Jones	Philip	Innovations in Cardiovascular Risk Assessment and Reduction	High-Sensitivity C-reactive Protein and Health Status Outcomes After Myocardial Infarction	Nothing to Disclose
Jones	Philip	Emerging Developments in HFpEF and Arryhthmias	Impact of Serial Heart Failure Health Status on Clinical Outcomes in HFpEF: A Static or Dynamic Phenomenon?	Nothing to Disclose
Jones	Philip	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Current More Important Than Past: Interpreting Serial Heart Failure Specific Health Status in Heart Failure Patients With Reduced Ejection Fraction	Nothing to Disclose
Jones	Philip	Optimizing Treatment of Peripheral Artery Disease	Smoking Behavior and Access to Smoking Cessation Support Following a Diagnosis of Peripheral Arterial Disease: Insights From the International PORTRAIT Registry	Nothing to Disclose
Jones	Ronald	Assessing the Clinical Impact of Blood Pressure Lowering Therapies	Guidelines Allowing Control of Hypertension in Non-Diabetics Greater Than 60 Years Old at up to 150 mmHg Average Systolic Blood Pressure Increases Patient Mortality in Veterans	Nothing to Disclose
Jones	Steven	Advances in Cholesterol Measurement and Management	Comparison of the Novel Method Versus the Friedewald Equation in Estimating Low-Density Lipoprotein-Cholesterol Based on Fasting Status	Nothing to Disclose
Jones	Steven	Advances in Cholesterol Measurement and Management	Impact of Evolocumab Therapy in Patients With Discordance Between LDL-C and LDL-P	Nothing to Disclose
Jones	Steven	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Stroke Among Whites and Blacks: The Atherosclerosis Risk In Communities (ARIC) Study	Nothing to Disclose
Jones	W.	Born To Run: Geographic Variation in PAD Diagnosis, Treatment and Outcomes	Outcomes: Insight from NCDR and VQI	CONSULTANT FEES/HONORARIA - Mondopoint; OTHER- Dailichi Sankyo; RESEARCH/RESEARCH GRANTS - American Heart Association, Astra Zeneca, Boston Scientific Corporation, Bristol Myers Squibb, Patient-Centered Outcomes Research Institute
Jones	W.	26. Interventional Cardiology: Vascular Access and Complications Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Mondopoint; OTHER- Dalichi Sanky; RESEARCH/RESEARCH GRANTS - American Heart Association, Astra Zeneca, Boston Scientific Corporation, Bristol Myers Squibb, Patient-Centered Outcomes Research Institute
Jones	William	Interventional Cardiology: TAVR 3	Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry	CONSULTANT FEES/HONORARIA - Mondopoint; OTHER- Dalichi Sankye; RESEARCH/FESEARCH GRANTS - American Heart Association,Astra Zeneca,Boston Scientific Corporation,Bristol Myers Squibb,Patient-Centered Outcomes Research Institute
Jones	William	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Patient-REported Preferences Affecting Revascularization Decisions (PREPARED): A Pilot Randomized Study of Shared Decision-Making	CONSULTANT FEES/HONORARIA - Mondopoint; OTHER- Dailchi Sankyo; RESEARCH/RESEARCH GRANTS - American Heart Association, Astra Zeneca, Boston Scientific Corporation, Bristol Myers Squibb, Patient-Centered Outcomes Research Institute
Jones	William	Peripheral Arterial Disease, Risk, and Outcomes	Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes: A Report From the STS/TVT Registry	CONSULTANT FEES/HONORARIA - Mondopoint, OTHER- Dailichi Sankyo; RESEARCH/RESEARCH GRANTS - American Heart Association, Astra Zeneca Boston Scientific Corporation, Bristol Myers Squibb, Patient-Centered Outcomes Research Institute
Jons	Christian	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Risk Assessment of Recurrent Atrial Fibrillation After Antiarrhythmic Medication or Catheter Ablation: The Impact of Age and Supraventricular Ectopic Complexes	CONSULTANT FEES/HONORARIA - Biotronik
Joodi	Golsa	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Ethnicity, Marital Status, and Neighborhood Poverty Influence Resuscitation of Out-of-Hospital Sudden Unexpected Deaths	Nothing to Disclose
Jordan	Jennifer	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Frequency of Transition From Stage A to B or C Heart Failure After Potentially Cardiotoxic Chemotherapy	Nothing to Disclose
Jordan	Jennifer	Advances in Imaging to Assess Cardiotoxicity	Decreases in Left Ventricular Mass and Not Left Ventricular Ejection Fraction Are Associated With Heart Failure Symptoms in Cancer Patients Six Months After Potentially Cardiotoxic Chemotherapy	Nothing to Disclose
Jordan	Jennifer	29. Non Invasive Imaging: MR Team 2	Suggested Reviewer	Nothing to Disclose



and a				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Jordan-Rios	Antonio	The Challenges of Outcome Prediction in Valvular Heart Disease	Right Ventricle Free Wall Strain Predicts Post-Surgical Low Cardiac Output Syndrome in Patients Undergoing Aortic Valve Replacement	Nothing to Disclose
Jorde	Ulrich	13. Heart Failure and Cardiomyopathies: Clinical Team 2	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Thoratec
lørgensen	Peter	Insights From Echocardiography Use	Layer-Specific Strain Analysis by Two-Dimensional Speckle Tracking Echocardiography: Improvement of Coronary Artery	CONSULTANT FEES/HONORARIA - Novartis Corporation
loseph	Eugene	The Evolving World of LVADs, Transplant and	Disease Diagnostics in Patients With Stable Angina Pectoris Comprehensive Next Generation Sequencing Assay for Identifying	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
loseph	Jacob	Other Novel Discoveries Making Progress in Understanding Heart Failure	Pathogenic Variants Associated With Cardiovascular Diseases Home Telehealth Reduces Adverse Outcomes in Heart Failure	Phosphorus CONSULTANT FEES/HONORARIA - Amgen Inc.
loseph	Jacob	Emerging Developments in HFpEF and Arryhthmias	Serum Sodium Is Associated With Mortality in Heart Failure With Preserved Ejection Fraction in the U.S. Veteran Population	Nothing to Disclose
Joseph	Lee	Interventional Cardiology: TAVR 2	Prevalence and Outcomes of Mitral Stenosis in Patients Undergoing Transcatheter Acrito Valve Replacement: Findings From the Society of Thoracis Surgeons/American College of Cardiology (STS/ACC) Transcatheter Valve Therapies (TVT) Registry	Nothing to Disclose
losephson	Richard	34. Prevention: Rehabilitation Team 1	Suggested Reviewer	Nothing to Disclose
Joshi	Aditya	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Small Dense Low Density Lipoprotein Particle Number Relates to Coronary Plaque Burden Independent of Traditional Cardiovascular Pick Forteen in Precision	Nothing to Disclose
Joshi	Aditya	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Risk Factors in Psoriasis Aortic Vascular Inflammation by 18-FDG PET/CT Associates With High-Risk Coronary Plaques in Young Psoriasis Patients	Nothing to Disclose
Joshi	Aditya	Vascular Medicine: New Insights Into Aortic and Peripheral Artery Diseases	Improvement in Cholesterol Efflux Capacity Is Associated With Improvement in Vascular Inflammation by 18- FDG PET CT in	Nothing to Disclose
Joshi	Aditya	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Psoriasis Improvement in Cholesterol Efflux Capacity Is Associated With a Reduction in Aortic Wall Thickness by MRI Independent of	Nothing to Disclose
Joshi	Aditya	Updates on Risk Factors for Cardiovascular	Traditional CV Risk Factors Visceral but Not Subcutaneous Adipose Tissue Associates With	Nothing to Disclose
Joshi	Francis	Disease Non Invasive Imaging: Prognostic Implications	Vascular Inflammation by 18-FDG PET/CT in Psoriasis The Relationship Between Pericardial Adipose Tissue Volume,	Nothing to Disclose
Joshi	Doro -	of CT Angiography	Atherosclerotic Plaque Type and Cardiovascular Risk: A High Risk Plaque Biolmage Sub-Study	Nothing to Diodoco
	Parag	Prevention of ASCVD Over the Lifespan: A Case-based Approach Imaging the Athlete's Heart	My 80 Year Old Patient with History of MI 10 Years Ago. Should I Default to Moderate Intensity Statin Therapy?	Nothing to Disclose
Joshi	Parag	0 0	Pooled Cohort Equation and Coronary Artery Calcium in Retired National Football League Athletes	Nothing to Disclose
Joshi	Parag	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium and Estimated Cardiovascular Disease Risk in Five Racial/Ethnic Groups Living in the US: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA)	Nothing to Disclose
Joshi	Parag	Hearts and Soles: Multimodality Imaging in Athletes	Ascending Aortic Dimensions in Former National Football League Athletes	Nothing to Disclose
Joshi	Parag	Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools	ACC Poster Moderator	Nothing to Disclose
Joshi	Parag	32. Prevention: Clinical Team 4	Suggested Reviewer	Nothing to Disclose
Joshi	Udit	Advances in Chronic Total Occlusion Intervention	Performance of J-CTO and PROGRESS CTO Scores in Predicting Angiographic Success and Long-Term Clinical Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions	Nothing to Disclose
Joung	Boyoung	Arrhythmias and Clinical EP: Basic 1	Exosome Derived From Atrial Fibrillation Patients Prevents Proarrhythmic Remodeling by Restoration of Acetylated Tubulin in Pacing Induced Tachycardia Model	Nothing to Disclose
Joung	Boyoung	Arrhythmias and Clinical EP: Basic 1	MicroRNA-26a From Hypoxic Human Mesenchymal Stem Cells: Derived Microvesicles Enhance Cardiac Conduction Following Myocardial Infarction	Nothing to Disclose
Joyce	Emer	Innovative Use of Echocardiography	Echocardiographic Parameters Associated With Quality of Life in Ambulatory Patients With Heart Failure	Nothing to Disclose
Joyce	Emer	 Heart Failure and Cardiomyopathies: Therapy Team 2 	Suggested Reviewer	Nothing to Disclose
Joynt	Karen	Assuring Quality in the Cath Lab: Documentation, Appropriate Use, Peer Review, and Public Reporting	Public Reporting Liability versus Accountability: Assuring This Is Done Correctly?	Nothing to Disclose
Joynt	Karen	Heart Failure Patient Care: Transitioning the Cost, Care and Context: Joint Heart Failure Society of America and American College of	CMS Bundled Payments Initiative and Network Agreements or CMS Viewpoint	Nothing to Disclose
Juarez Escobar	Karim	Cardiology FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Left Atrium Undifferentiated Pleomorphic Sarcoma Mimicking Septal	Nothing to Disclose
Juarez-Herrera	Ursulo	Updates on Risk Factors for Cardiovascular Disease	Asymmetric Hypertrophic Cardiomiopathy Association of Anxious and Depressive Symptomatology With Cardiovascular Disease Among Patients From Different States in	Nothing to Disclose
Jubran	Ayman	Advances in Cholesterol Measurement and	Mexico: REDECAR Study Clinical Features and Gaps in the Management of Familial	Nothing to Disclose
Judge	Daniel	Management FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Hypercholesterolemia With Prevalent Cardiovascular Disease HeartMate II Pump Stops: The Short to Short Phenomenon	CONSULTANT FEES/HONORARIA - Alnylam Pharmaceuticals,GlaxoSmithKline,Pfizer / FoldRx
Jue	Jennifer	Non Invasive Imaging: MR Structure and	Heart Rate Response During Regadenoson Stress Cardiac	Pharmaceuticals Nothing to Disclose
L.:	laneths:	Valuvular Heart Disease	Magnetic Resonance Imaging Is a Predictor of Adverse Cardiovascular Outcomes	Nothing to Displace
Jui	Jonathan	Arrhythmias and Clinical EP: Ventricular Tachycardia	Health Insurance Expansion and Incidence of Out-of-Hospital Cardiac Arrest: A Pilot Study in a US Metropolitan Community Novel Utilization of DAPT Score as a Predictor of Long-Term	Nothing to Disclose Nothing to Disclose
Jujo	Kentaro	Optimizing the Care of ACS Patients	Clinical Outcomes in Hemodialysis Patients on Prolonged Dual Antiplatelet Therapy After Coronary Intervention	· ·
Jujo	Kentaro	Interventional Cardiology: PCI in Complex Patients	Predictors for 2-Year Cardiovascular Events After Rotablation in Severe Calcified Lesion	Nothing to Disclose
Jukema	Johan	Novel Echocardiographic Methods for Assessing Cardiac Function	Prognostic Implications of Left Ventricular Global Longitudinal Strain in Stage 4 and 5 Chronic Kidney Disease Patients	CONSULTANT FEES/HONORARIA - Research grants from an was speaker on (CME accredited) meetings sponsored by Daiich Sankyo, Lilly, Merck-Schering-Plough, Pfizer, Sanofi Aventis; SPEAKER'S BUREAU - Research grants from and was speaker on (CME accredited) meetings sponsored by Daiichi Sankyo, Lilly Merck-Schering-Plough, Pfizer, Sanofi Aventis
Jukema	Johan	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Plasma LDL-Cholesterol Level Is Independently Associated With Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Research grants from an was speaker on (CME accredited) meetings sponsored by Dailo Sankyo, Lilly, Merck-Schering-Plough, Pfizer, Sanofi Aventis; SPEAKER'S BUREAU - Research grants from and was speaker on (CME accredited) meetings sponsored by Dailichi Sankyo, Lill Merck-Schering-Plough, Pfizer, Sanofi Aventis

Julia Calvo Julien Julien Julien Julien Julien	Justo Howard	Session Title Advances in Lipid Management	Presentation Title Use of High-Intensity Statin Therapy Post-Acute Coronary Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody, Versus Placebo: Interim Baseline Data	Disclosures CONSULTANT FEES/HONORARIA - Research grants from and was speaker on (CME accredited) meetings sponsored by Daiichi Sankyo, Lilly, Merck-Schering-Plough, Pfizer, Sanofi Aventis; SPEAKER'S BUREAU - Research grants from and was speaker
Julia Calvo Julien Julien Julien Julien Julien	Justo	Advances in Lipid Management	Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9	was speaker on (CME accredited) meetings sponsored by Daiichi Sankyo, Lilly, Merck-Schering-Plough, Pfizer, Sanofi Aventis;
Julien Julien Julien Julien Julien			Monoclonal Antibody, Versus Placebo: Interim Baseline Data	SPEAKER'S BUREAU - Research grants from and was speaker
Julien Julien Julien Julien Julien				on (CME accredited) meetings sponsored by Daiichi Sankyo, Lilly, Merck-Schering-Plough, Pfizer, Sanofi Aventis
Julien Julien Julien Julien Julien		Arrhythmias and Clinical EP: Devices 1	Late Occurrence of Phrenic Nerve Stimulation: A Potential Pitfall	Nothing to Disclose
Julien Julien Julien		Nuclear Cardiology: Beyond Perfusion	Among Super Responders? Reduced Dose Oral Glucose Load Yields Excellent Myocardial PET	Nothing to Disclose
Julien Julien	Howard	FIT Clinical Decision Making: Multimodality	Viability Images ACC Poster Moderator	Nothing to Disclose
Julien	Howard	Imaging FIT Clinical Decision Making Reviewers 2	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Julien	Maureen	Engage @ ACC.17 Studio: Heart Teams in Action: Complex Coronary Revascularization	Penn Advanced Practice Provider	OTHER - WL Gore
odiicii	Maureen	Blips, Trops, and Chips: New Ways to Diagnose CAD	ACC Poster Moderator	OTHER - WL Gore
Julien	Maureen	02. Acute and Stable Ischemic Heart Disease: Clinical Team 3	Suggested Reviewer	OTHER - WL Gore
Julio	Garcia	Novel Determinants of Outcomes in VHD	Relationship Between Proximal Aorta Morphology and Progression Rate of Aortic Stenosis	Nothing to Disclose
Jung	Christian	Novel Developments in Acute Coronary Syndromes	Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: The Randomized SHOCK-COOL Pilot Trial	Nothing to Disclose
Juni	Peter	Featured Clinical Research II: Interventional	Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD Matrix Study	RESEARCH/RESEARCH GRANTS - Astra Zeneca, Biosensors International, Biotronik, Eli Lilly and Company, The Medicines Company
Jüni	Peter	Timely Topics in Acute Coronary Syndromes	Gender-Related Outcomes in Elderly (> 75 Years) Patients Presenting With Acute Coronary Syndromes: Results From the Swiss Acute Coronary Syndrome Cohort	RESEARCH/RESEARCH GRANTS - Astra Zeneca,Biosensors International,Biotronik,Eli Lilly and Company,The Medicines Company
Jüni	Peter	Unusual Presentations of ACS	Non-Invasive Functional and Anatomical Diagnostic Testing for Patients With Low-Risk Acute Coronary Syndromes: A Network	RESEARCH/RESEARCH GRANTS - Astra Zeneca, Biosensors International, Biotronik, Eli Lilly and Company, The Medicines
Jurkiewicz	Julia	Personalized Skills Center: Drill and Practice	Meta-Analysis of Diagnostic Randomized Controlled Trials Heart Songs Moderator	Company Nothing to Disclose
Justo	Robert	(Heart Songs, ECG, Hand-Held Echo) Advances in HCM, PPCM and Other	Long-Term Outcomes of Childhood Left Ventricular Non-	Nothing to Disclose
Juthier	Francis	Cardiomyopathies Joint American College of Cardiology/New England Journal of Medicine Late Program	Compaction: Results From a National Population-Based Study Silent Cerebral Microbleeds During TAVR: Insight From a Prospective Cerebral MRI Cohort	Nothing to Disclose
Jutzy	Kenneth	England Journal of Medicine Late-Breaking Clinical Trials Traditional and Novel Factors Used to Assess	Prospective Cerebral MRI Cohort Glycemic Control in Insulin and Non-Insulin Dependent Diabetic	Nothing to Disclose
		the Risk of, and Used for the Treatment of, Coronary Artery Disease	Patients With ST Elevation Myocardial Infarction Predicts Time to Presentation	-
-	Kenneth	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Ischemic Time and Risk Factors Associated With the Incidence of Cardiogenic Shock in Patients Presenting With ST Elevation Myocardial Infarction	Nothing to Disclose
Jutzy	Kenneth	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Impact of Demographics and Socioeconomic Status on Mode of Transportation and Time to Presentation in Patients With ST Elevation Myocardial Infarction	Nothing to Disclose
Jutzy	Kenneth	Interventional Cardiology: TAVR 2	Impact of the Presence of Coronary Artery Disease and Timing of Revascularization on Outcomes of Patients Undergoing Trans- catheter Aortic Valve Replacement: Insights From STS/ACC TVT Registry	Nothing to Disclose
Jyothidasan	Amudhan	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Vagal Nerve Stimulator Therapy: An Unusual Cause of Symptomatic Bradycardia	Nothing to Disclose
Kaatz	Scott	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	A Benefit-Risk Analysis of Recurrent Venous Thromboembolism in Patients Who Continued Versus Discontinued Rivaroxaban Therapy After an Initial Six-Month Therapy	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim, Jansen/Johnson and Johnson, Portola, Roche; RESEARCH/RESEARCH GRANTS - Janssen; SPEAKER'S BUREAU - BMS, Boehringer-Ingelheim, CSL Behring DSJ, Jansen/Johnson and Johnson
Kabach	Amjad	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	In the Forest of Comorbidities, Always Look for the Wild Type	Nothing to Disclose
Kabagambe	Edmond	Non Invasive Imaging: Prognostic Implications	Coronary Artery Structural Remodeling by Computed Tomography and Echocardiographic Left Ventricular Mass Changes Over the Next 5 Years: The Coronary Artery Risk Development in Young	Nothing to Disclose
Kabbani	Samer	Heart Failure: From Pathophysiology to Socio-	Adults (CARDIA) Study The Economic Impact of Heart Failure on the Lebanese Healthcare	Nothing to Disclose
		Economic Impact: International Perspectives From the Lebanese Cardiac Society, Taiwan Society of Cardiology, and American College of Cardiology	System	
Kabbany	Mohammad Tarek		Improvement in Cholesterol Efflux Capacity Is Associated With Improvement in Vascular Inflammation by 18- FDG PET CT in	Nothing to Disclose
Kabbany	Mohammad Tarek	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Psoriasis Improvement in Cholesterol Efflux Capacity Is Associated With a Reduction in Aortic Wall Thickness by MRI Independent of	Nothing to Disclose
Kabbany	Mohammad Tarek	Updates on Risk Factors for Cardiovascular	Traditional CV Risk Factors Visceral but Not Subcutaneous Adipose Tissue Associates With	Nothing to Disclose
Kabir	Muammar	Disease Arrhythmias and Clinical EP: Basic 2	Vascular Inflammation by 18-FDG PET/CT in Psoriasis High Frequency Content of the Surface ECG Correlates With the	Nothing to Disclose
Kabirdas	Deepa	Updates in Stable Ischemic Heart Disease	Presence of Sympathetic Nerves in the Ventricles of the Heart ST Elevation Myocardial Infarction in Nonagenarians: Review of	Nothing to Disclose
Kabirdas	Deepa	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Outcomes in National Inpatient Database Ready for Take-Off ?	Nothing to Disclose
Kabour	Ameer	Why Can't We Be Friends? Controversies in Heart Failure Management	Mortality Effect of lcd in Primary Prevention of Non Ischemic	Nothing to Disclose
Kachur	Sergey	Measuring Success in Cardiac Rehabilitation	Cardiomyopathy: A Meta Analysis of Randomized Control Trials Search for the Super-Responder: Progressive Increases in Fitness and an Association With Lower Mortality	Nothing to Disclose
Kachur	Sergey	Obesity Management in 2017: Weighing the Issues	and an Association with cower Mortality Fitness and the Obesity Paradox in Cardiac Rehabilitation: How Does Weight Loss Factor in?	Nothing to Disclose
Kaczorowski	Janusz	Joint American College of Cardiology/Journal of the American Medical Association Late-	e-Counseling for Self-Care Adherence Adds Therapeutic Benefit for Hypertension: The REACH Trial	Nothing to Disclose
Kadian-Dodov	Daniella	Breaking Clinical Trials 40. Vascular Medicine: Non Coronary Arterial	Suggested Reviewer	Nothing to Disclose
Kadokami	Toshiaki	Disease Team 1 Unusual Presentations of ACS	Clinical Characteristics and In-Hospital Mortality of Very Elderly	Nothing to Disclose
Kadosh	Bernard	FIT Clinical Decision Making: Interventional	Patients With Cardiovascular Shock in Japan: The Results From Japanese Circulation Society Shock Registry An Unexpected Guest in the Right Ventricle	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	-	-
Kadota	Kazushige	Interventional Complexity and Complications	Impact of Institutional and Operator Volume on Short-Term Outcomes of Percutaneous Coronary Intervention: A Report From Japanese Nationwide Registry	Nothing to Disclose

Control of the contro				
Last Name Kadri	First Name Amer	Session Title Arrhythmias and Clinical EP: Ventricular	Presentation Title Therapeutic Hypothermia for In-Hospital Cardiac Arrest: A Meta-	Disclosures Nothing to Disclose
Kadri	Amer	Tachycardia Measuring Success in Cardiac Rehabilitation	Analysis Wrist Activity Tracking Devices and Support Programs: A Meta-	Nothing to Disclose
Kadri	Amer	Arrhythmias and Clinical EP: Syncope and	Analysis Two Birds, One Stone: Citalopram for Neurocardiogenic Syncope	Nothing to Disclose
Kadri	Nazih	Other EP Issues Arrhythmias and Clinical EP: Syncope and	and Irritable Bowel Syndrome Two Birds, One Stone: Citalopram for Neurocardiogenic Syncope	Nothing to Disclose
		Other EP Issues	and Irritable Bowel Syndrome Prognostic Value of Right Ventricular Function Assessed by Cardiac	
Kafa	Rami	Interventional Cardiology: TAVR 1	Computed Tomography in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Kafouris	Pavlos	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Association of Abdominal Aortic Wall Inflammation, Hepatic Fluorodeoxyglucose Uptake AND Visceral Adipose Tissue Biological Activity in Patients With Dyslipidemias	Nothing to Disclose
Kafouris	Pavlos	Nuclear Cardiology: Beyond Perfusion	Increased Subclinical Systemic AND Vascular Inflammation in Familial Combined Hyperlipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission	Nothing to Disclose
Kafouris	Pavlos	Cutting Edge Vascular Medicine	Tomography Study Familial Combined Hyperlipidemia Is Characterized by Higher Arterial AND Hepatic Fluorodeoxyglucose Uptake Compared to	Nothing to Disclose
Kageyama	Shigetaka	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Heterozygous Familial Hypercholesterolemia Direct Assessment of Mechanical Aortic and Mitral Valve Effective Orifice Area With High-Fidelity Pressure Wire for Decision of	Nothing to Disclose
Kahloon	Rehan	FIT Forum: Stump the Professor	Controversial Re-Valve Replacement First Case on Biventricular Mechanical Circulatory Support With	Nothing to Disclose
Kahn	Andrew	Advances in HCM, PPCM and Other	Impella CP and Impella RP for a Patient With Acute Myocardial Infarction Induced Cardiogenic Shock The Prevalence and Clinical Significance of Compacted	Nothing to Disclose
Kaier	Thomas	Cardiomyopathies Acute Coronary Syndromes, Diagnosis,	Myocardium in Dilated Cardiomyopathy: A Contrast Echocardiography Study Direct Comparison of Cardiac Myosin-Binding Protein C to Cardiac	Nothing to Disclose
		Management and Outcomes	Troponins for the Early Diagnosis of Acute Myocardial Infarction	-
Kaier	Thomas	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Cardiac Myosin-Binding Protein C as Alternative to Cardiac Troponin T for the Diagnosis of Acute Myocardial Infarction in the Very Early Phase	Nothing to Disclose
Kaila	Ken	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Clinical Outcomes of Acute Ischemic Stroke Patients Stratified by Cardiac Troponin-I: A Retrospective Analysis	Nothing to Disclose
Kaine	Stephen	Test Yourself with Questions: Pediatric Cardiology	Faculty	Nothing to Disclose
Kaiser	Clayton	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Influence of Family History of Aortic Disease on Type B Aortic Dissection	Nothing to Disclose
Kaiser	Daniel	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Outcomes of the Hybrid Video-Assisted Thoracoscopic Surgery (VATS) Maze Followed by Catheter Ablation in Patients With Persistent and Longstanding Persistent Atrial Fibrillation: Clinical	Nothing to Disclose
Kaitozis	Odysseas	Interventional Cardiology: TAVR 2	Results From a High-Volume Center The Effect of Mixed Aortic Valve Disease in Clinical Outcomes After	Nothing to Disclose
Kaitozis	Odysseas	Innovative Use of Echocardiography	Transcatheter Aortic Valve Replacement Impact on Long Term Mortality of Persistent Pulmonary	Nothing to Disclose
Kajii	Eiji	Novel Strategies for Assessing and Improving	Hypertension After Transcatheter Aortic Valve Implantation Effect of Gene Polymorphism of Calpain-10 on the Risk of	Nothing to Disclose
		Adherence to Blood Pressure Lowering Therapies	Hypertension in Japanese Population	-
Kajil	Mahesh	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Concomitant Use of Antiplatelet and Oral Anticoagulation Among Patients With Atrial Fibrillation: Insights From the Prospective SPRINT-AF Registry	Nothing to Disclose
Kaki	Amir	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Ultrasound Assisted Catheter Directed Thrombolysis and Percutaneous Right Ventricular Mechanical Assist Device for the Management of Massive Pulmonary Embolism With Refractory Right Ventricular Failure: Playing Chess With Pulmonary Embolism	CONSULTANT FEES/HONORARIA - Abbott Vascular Abiomed AstraZeneca, CSI, Terumo, Trireme Medical; SPEAKER'S BUREAU - Dalichi Sankyo, Novartis Corporation, The Med Co
Kakizaki	Ryota	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Stent Edge Strut on Normal Segment Is Less Covered in Early Phase After Drug Eluting Stent Implantation	Nothing to Disclose
Kakkar	Ajay	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Treatment and Outcomes of Patients With Nonvalvular Atrial Fibrillation According to Guideline-Defined Anticoagulation Thresholds: Results From the GARFIELD-AF Registry	CONSULTANT FEES/HONORARIA - Bayer Healthcare,Boehringher-Ingelheim Pharma,Daiichi Sankyo Europe ,Pfizer Inc.,Sanofi S.A.; RESEARCH/RESEARCH
Kakkar	Ajay	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Early Mortality in Patients With New Onset Atrial Fibrillation: Results From the GARFIELD-AF Registry	GRANTS - Bayer Healthcare,Boehringer-Ingelheim Pharma CONSULTANT FEES/HONORARIA - Bayer Healthcare,Boehringher-Ingelheim Pharma,Daiichi Sankyo Europe, Pfizer Inc.,Sanofi S.A.; RESEARCH/RESEARCH
Kakkar	Ajay	Stroke and AF: Thinking About the Heart	The Prescribing of Antiplatelet Therapy Only in Patients With Nonvalvular Atrial Fibrillation: Results From the GARFIELD-AF Registry	GRANTS - Bayer Healthcare,Boehringer-Ingelheim Pharma CONSULTANT FEES/HONORARIA - Bayer Healthcare,Boehringher-Ingelheim Pharma, Daiichi Sankyo Europe ,Pfizer Inc.,Sanofi S.A.; RESEARCH/RESEARCH
Kakouros	Nikolaos	The Best Structural Interventional Challenging	ACC Panelist	GRANTS - Bayer Healthcare,Boehringer-Ingelheim Pharma CONSULTANT FEES/HONORARIA - Abbott Vascular
Kakouros	Nikolaos	Cases Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI	Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery	CONSULTANT FEES/HONORARIA - Abbott Vascular
Kakuta	Tsunekazu	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Relationship Between Coronary Physiological Parameters and Cardiac Biomarkers in Patients Undergoing Invasive Coronary	Nothing to Disclose
Kakuta	Tsunekazu	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Angiography Significance of Microcirculatory Resistance in Visual-Functional Mismatch Between Coronary Angiography and Fractional Flow	Nothing to Disclose
Kakuta	Tsunekazu	Interventional Cardiology: Angiography,	Reserve in Non-Left Main Lesions Usefulness of Optical Coherence Tomography-Derived	Nothing to Disclose
		Intravascular Imaging and Interventional CT/MR	Morphometric Assessment to Predict Physiological Significance of Coronary Artery Stenosis and Determinants of Mismatch: Head-to-Head Comparison With Intravascular Ultrasound	
Kakuta	Tsunekazu	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Relationship Between Optical Coherence Tomography-Defined In- Stent Neoatherosclerosis and Out-Stent Arterial Remodeling Assessed by Serial Intravascular Ultrasound Examinations in Late and Very Late Drug-Eluting Stent Failure	Nothing to Disclose
Kakuta	Tsunekazu	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Comparison of Optical Coherence Tomography Versus Intravascular Ultrasound Detection of Tissue Protrusion and Acute Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent Implantation	Nothing to Disclose
Kakuta	Tsunekazu	Unusual Presentations of ACS	Comparison Between Angioscopic and Optical Coherence Tomographic Assessment of Instent Restenosis	Nothing to Disclose
Kakuta	Tsunekazu	Unusual Presentations of ACS	Predictors and Clinical Significance of High-Sensitivity Cardiac	Nothing to Disclose
Kakuta	Tsunekazu	Unusual Presentations of ACS	Troponin-I Elevation After Diagnostic Coronary Angiography Multimodality Coronary Imaging to Predict Periprocedural	Nothing to Disclose
			Myocardial Necrosis After Elective Percutaneous Coronary Intervention	

(M. Standard				l l
Last Name Kakuta	First Name Tsunekazu	Session Title Unusual Presentations of ACS	Presentation Title Comparison of Neointimal Appearance Assessed by Optical	Disclosures Nothing to Disclose
Nakula	i suriekazu	Unusual Presentations of ACS	Coherence Tomography Between Bare-Metal Stents and Sirolimus-	Nothing to Disclose
			Eluting Stents Beyond 10 Years From Implantation	
Kalahasti	Vidyasagar	Atrial Fibrillation and VT: Specific Situations	Baseline Characteristics, Management and Outcomes in Mitral	Nothing to Disclose
Kalamkar	Prachi	and Newer Outcome Measures FIT Clinical Decision Making: Non-Invasive	Valve Prolapse With Manifest Ventricular Automaticity An Unprecedented Case of Primary Cardiac Lymphoma Exclusive	Nothing to Disclose
Naidilikai	FIACIII	Imaging and Valvular Heart Disease	to the Left Ventricle: A Diagnostic and Therapeutic Challenge	Nothing to Disclose
Kalathiya	Rohan	FIT Clinical Decision Making Reviewers 7	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Kalavakunta	Jagadeesh	Vascular Medicine: Emerging Concepts in	Impact of Hereditary Causes of Thrombosis on Ischemic Stroke	Nothing to Disclose
		Clinical Vascular Diseases	Between the Years 2008 Through 2012: Nationwide Inpatient Sample Data Analysis	
Kalbfleisch	Steven	Arrhythmias and Clinical EP: Devices 2	Comprehensive Strategy to Reduce the Incidence of Lead	Nothing to Disclose
raibiioloon	Cloron	7 amyammad and dimidal El : Bondoo E	Dislodgment for Cardiac Implantable Electronic Devices	Trouming to Biocioco
Kalbfleisch	Steven	Arrhythmias and Clinical EP: Devices 3	Cryoballoon Versus Radiofrequency Ablation of Atrial Fibrillation: In-	Nothing to Disclose
			Lab Complication Rates at a Large Volume Electrophysiology	
Kali	Avinash	Non Invasive Imaging: MR Characterization	Center An Unrestrained Proinflammatory M1 Macrophage Population	Nothing to Disclose
raii	Aviilasii	and Function	Induced by Iron Nanocrystals Impairs Myocardial Healing After	Trouming to Disclose
			Hemorrhagic Infarction	
Kali	Avinash	Diabetes and Endothelial Dysfucntion in Heart	Mast Cell-Dependent Conversion of Siderophages Into Foam Cells	Nothing to Disclose
		Failure	Is a Hallmark of Early Fat Infiltration in Hemorrhagic Myocardial Infarctions	
Kali	Avinash	Biomarkers and Targets for Ischemic Heart	Fat Accumulation in the Peri-Infarct Border Zone of Hemorrhagic	Nothing to Disclose
		Disease	Myocardial Infarction Is Mediated by Persistent Iron Deposits	3
Kali	Avinash	Emerging Basic Science in Ischemic Heart	Myocardial Hemorrhage After Coronary Ischemia-Reperfusion	Nothing to Disclose
		Disease	Leads to an Iron-Mediated, Self-Perpetuating Loop of Foam Cell	
Kali	Avinash	Nuclear Cardiology: Coronary Flow	and Ceroid Accumulation Precisely Controlled Arterial CO2 Can Potentiate Myocardial Blood	Nothing to Disclose
r tuii	, wildon	Tradical Cardiology: Colonaly Flow	Flow to the Same Extent as Adenosine: A Preclinical Study in	Trouming to Brookers
			Canines With 13N-Ammonia PET	
Kalil	Renato	ACC International Conferences Best Posters	Comparison of Different Lung Ultrasound Methodologies for	Nothing to Disclose
Kalil-Filho	Roberto	Emerging Issues in CV Disease Management:	Pulmonary Congestion Evaluation in Heart Failure Outpatients Co-Chair	Nothing to Disclose
		International Perspectives From the Brazilian		
		Society of Cardiology, Turkish Society of		
		Cardiology, and American College of		
Kalil-Filho	Roberto	Cardiology Revascularization and Myocardial Preservation	The Role of Oral Beta Blocker in a Real-World Population With Non-	Nothing to Disclose
Naiii-Fiiiiu	Roberto	in Acute and Stable Ischemic Heart Disease	ST Segment Elevation Acute Coronary Syndromes	Nothing to Disclose
Kalil-Filho	Roberto	Coronary Angiography, Intra-Vascular Imaging,	High Non-High-Density Lipoprotein Cholesterol Levels Predict	Nothing to Disclose
		Revascularization and Outcomes	Enhanced Periprocedural Inflammatory Response Following	
			Percutaneous Coronary Intervention in Stable Ischemic Heart Disease Patients	
Kalil-Filho	Roberto	Emerging Basic Science in Ischemic Heart	Platelet Aggregability, Coagulation, Fibrinolysis and Inflammation in	Nothing to Disclose
		Disease	Patients With Coronary Artery Disease and Previous	
17 - 12 F26 -	D. L. d.	A CO. The Co.	Cerebrovascular Ischemic Event	N. R. C. L. B. C. L.
Kalil-Filho	Roberto	Antithrombotic Therapy in Ischemic Heart Disease	Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery	Nothing to Disclose
		Discuse	Disease	
Kalla	Aditi	Updates on Risk Factors for Cardiovascular	Cannabis Use Predicts Risks of Heart Failure and Cerebrovascular	Nothing to Disclose
		Disease	Accidents: Results from the National Inpatient Sample	
Kallend	David	Featured Clinical Research I	LDL-C Reduction From 6 to 9 Months Following Single or Second	OTHER - The Medicines Company; SALARY - The Medicines
Raileriu	David	l eathred Chillical Nesearch	Injection of Inclisiran a Novel siRNA Compound: Primary Efficacy	Company
			and Safety Outcomes of the ORION 1 Trial	p- y
Kallifatidis	Alexandros	Predicting the Future: Observations and	Left Ventricular Filling Rate Predicts Clinical Failure in Patients With	Nothing to Disclose
Kallikazaros	Ioannis	Discoveries From Registries and Databases Novel Mechanical Devices for the Treatment	Precapillary Pulmonary Hypertension Insights on Diastolic Dysfunction of Treated Hypertensive Patients:	Nothing to Disclose
Naiiikazaios	iodiiiis	and Assessment of Hypertension	Focusing on Hypertension Control & Treatment Resistance	Nothing to Disclose
Kallikazaros	Ioannis		Left Ventricular Mass Versus Pulse Wave Velocity as Predictors of	Nothing to Disclose
		Elevated Blood Pressure	Coronary Artery Disease in Patients With Essential Hypertension: Data From a Greek 6-Year-Follow-Up Study	
Kallur	Kamala Ramya	Revascularization and Myocardial Preservation	Downstream Effects of False Positive Activation of the Cardiac	Nothing to Disclose
	, ,	in Acute and Stable Ischemic Heart Disease	Catheterization Lab	3
Kalogeras	Konstantinos	From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease	Dietary Consumption of Olive Oil and Cardiovascular Outcome in Patients With Coronary Artery Disease	Nothing to Disclose
Kalogeropoulos	Andreas	Advances in HCM, PPCM and Other	Living in a Food Desert Is Associated With an Early Hazard of Death	Nothing to Disclose
		Cardiomyopathies	and Hospitalization in Heart Failure Patients	
	Andreas	Redefining the "F" Word	Biomarker Profile in Adults With Fontan Circulation Adults With Congenital Heart Disease: Lost in Care	Nothing to Disclose
Kalogeropoulos Kalogeropoulos	Andreas Andreas	Redefining the "F" Word The Evolving World of LVADs, Transplant and	Progenitor Cells and Clinical Outcomes in Patients With Heart	Nothing to Disclose Nothing to Disclose
• •		Other Novel Discoveries	Failure	
Kalogeropoulos	Andreas	Congenital Heart Disease: To the Third	Prevalence and Incidence of Heart Failure in Adolescents and	Nothing to Disclose
Kalaa	Thoodoroo	Decade and Beyond Toward Precision Medicine in the Treatment of	Adults With Repaired Tetralogy of Fallot	Nothing to Disclose
Kalos	Theodoros	I oward Precision Medicine in the Treatment of Elevated Blood Pressure	Left Ventricular Mass Versus Pulse Wave Velocity as Predictors of Coronary Artery Disease in Patients With Essential Hypertension:	Nothing to Disclose
<u></u>	<u></u>		Data From a Greek 6-Year-Follow-Up Study	
Kalra	Ankur	Innovations in Practice Management and	Impact of Electronic Health Records on the Quality of Outpatient	Nothing to Disclose
1		Social Media	Cardiovascular Care Delivery in India: Insights From the American	
1			College of Cardiology's PINNACLE India Quality Improvement Program (PIQIP)	
Kalra	Ankur	Unusual Presentations of ACS	Survival of Patients Referred for Emergent Cardiac Catheterization	Nothing to Disclose
			for ST-Elevation Myocardial Infarction Without Culprit Lesions	-
I/alaa	Mario	Manufac Madisina, AssCo. et D. Colore	Association of Apide Deschipting Mark Link O. Connect	Nothing to Displace
Kalra	Manju	Vascular Medicine: Aortic and Peripheral Artery Diseases	Association of Ankle Brachial Index With Limb Outcomes in Peripheral Artery Disease: A Community-Based Study	Nothing to Disclose
Kalra	Sanjog	Advances in Chronic Total Occlusion	Hemodynamically-Supported PCI of Chronic Total Occlusions: A	CONSULTANT FEES/HONORARIA - Abiomed, Servier Canada
		Intervention	Case Series	
Kaltenbach	Lisa	Highlighted Original Research: Acute and	Patterns of Angina and Antianginal Medication Use Among Patients	Nothing to Disclose
		Stable Ischemic Heart Disease and the Year in Review	Following MI Treated With PCI: Insights From TRANSLATE-ACS	
Kaltenbach	Lisa	Antiplatelet and Antithrombotic Agents in	Bleeding and Premature Antiplatelet Therapy Discontinuation After	Nothing to Disclose
		Ischemic Heart Disease	Myocardial Infarction Among Patients With Chronic Kidney Disease	9
Kaltanha i	Lina	Anti District Theory is Alice Office	Assistant Theorem Charles (Charles of the Barrer Charles of the Ba	Nothing to Displace
Kaltenbach	Lisa	Anti-Platelet Therapies: Always a Sticky Topic	Antiplatelet Therapy Changes for MI Patients With Recurrent Ischemic Events: Insights Into Contemporary Practice From the	Nothing to Disclose
			TRANSLATE-ACS Study	
Kamalesh	Masoor	Highlighted Original Research: Heart Failure	Higher Beta-Blocker Dose Versus Lower Heart Rate in Patients With	SPEAKER'S BUREAU - Amgen Inc.
		and Cardiomyopathies and the Year in Review	Heart Failure Due to Systolic Dysfunction	
Kamalesh	Masoor	Emerging Developments in HFpEF and	Higher Ambulatory Heart Rates Predict Increased Long Term	SPEAKER'S BUREAU - Amgen Inc.
Namaresii	ivid5UUI	Arryhthmias	Higher Ambulatory Heart Rates Predict Increased Long Term Mortality in Patients With Hfref	OF LANER O DUREAU - AMIGEN INC.
		. ,		

Const.				<u> </u>
Last Name Kamalesh	First Name Masoor	Session Title Put Your Codon! Genetic Insights Into Heart	Presentation Title Circulating Free and Exosomal MicroRNAs as Biomarkers of	Disclosures SPEAKER'S BUREAU - Amgen Inc.
Kamalov	German	Failure Arrhythmias and Clinical EP: Devices 3	Systemic Response to Heart Failure Cryoballoon Versus Radiofrequency Ablation of Atrial Fibrillation: In-	Nothing to Disclose
Namaiov	German	Armytimias and Chilical Er . Devices 3	Lab Complication Rates at a Large Volume Electrophysiology Center	Nothing to Disclose
Kamdar	Forum	Meeting of the Minds: HF and EP Decision Making for Complex Patients	Panelist	Nothing to Disclose
Kamdar	Forum	Meeting of the Minds: HF and EP Decision Making for Complex Patients	LVAD versus High Risk VT Ablation	Nothing to Disclose
Kamioka	Norihiko	TAVR Outcomes Prognostication	Predictors and Clinical Outcomes of Next-Day Discharge After	Nothing to Disclose
Kampaktsis	Polydoros	Interventional Cardiology: TAVR 1	Transcatheter Aortic Valve Replacement Baseline Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Increased Mortality After	Nothing to Disclose
Kampaktsis	Polydoros	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Replacement Transcatheter Aortic Valve Implantation Is Safe in Patients With Left	Nothing to Disclose
Kamperidis	Vasileios	Predicting the Future: Observations and	Atrial Thrombus or Spontaneous Echo Contrast Left Ventricular Filling Rate Predicts Clinical Failure in Patients With	Nothing to Disclose
Kanabur	Pratik	Discoveries From Registries and Databases Changing the Natural History of Valve Disease	Precapillary Pulmonary Hypertension Rates of Mechanical Valve Thrombosis After Discontinuation of	Nothing to Disclose
		With Medical Therapy	Anticoagulation	
Kanagasundram	Arvindh	Arrhythmias and Clinical EP: AF Ablation	Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism in Patients Undergoing Left Atrial Catheter Ablation Procedures for Paroxysmal or Persistent (Non-Permanent) Atrial Fibrillation and Left Atrial Flutter	Nothing to Disclose
Kanagasundram	Arvindh	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Idiopathic Ventricular Tachycardia Arising From the Left Ventricular Summit Treated With Endocardial Catheter Ablation Followed by Cardiac Sympathectomy	Nothing to Disclose
Kanaji	Yoshihisa	Interventional Cardiology: Intravascular	Relationship Between Coronary Physiological Parameters and	Nothing to Disclose
Kanaji	Yoshihisa	Physiology and Endothelial Function Interventional Cardiology: Intravascular	Cardiac Biomarkers in Patients Undergoing Invasive Coronary Angiography Significance of Microcirculatory Resistance in Visual-Functional	Nothing to Disclose
		Physiology and Endothelial Function	Mismatch Between Coronary Angiography and Fractional Flow Reserve in Non-Left Main Lesions	-
Kanaji	Yoshihisa	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Usefulness of Optical Coherence Tomography-Derived Morphometric Assessment to Predict Physiological Significance of Coronary Artery Stenosis and Determinants of Mismatch: Head-to- Head Comparison With Intravascular Ultrasound	Nothing to Disclose
Kanaji	Yoshihisa	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Relationship Between Optical Coherence Tomography-Defined In- Stent Neoatherosclerosis and Out-Stent Arterial Remodeling Assessed by Serial Intravascular Ultrasound Examinations in Late and Very Late Drug-Eluting Stent Failure	Nothing to Disclose
Kanaji	Yoshihisa	Unusual Presentations of ACS	Comparison Between Angioscopic and Optical Coherence	Nothing to Disclose
Kanaji	Yoshihisa	Unusual Presentations of ACS	Tomographic Assessment of Instent Restenosis Predictors and Clinical Significance of High-Sensitivity Cardiac	Nothing to Disclose
Kanaji	Yoshihisa	Unusual Presentations of ACS	Troponin-I Elevation After Diagnostic Coronary Angiography Multimodality Coronary Imaging to Predict Periprocedural	Nothing to Disclose
			Myocardial Necrosis After Elective Percutaneous Coronary Intervention	
Kanaji	Yoshihisa	Unusual Presentations of ACS	Comparison of Neointimal Appearance Assessed by Optical Coherence Tomography Between Bare-Metal Stents and Sirolimus- Eluting Stents Beyond 10 Years From Implantation	Nothing to Disclose
Kanaya	Alka	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium and Estimated Cardiovascular Disease Risk in Five Racial/Ethnic Groups Living in the US: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA)	Nothing to Disclose
Kandan	Sri Raveen	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Predictors of Survival From Out-of-Hospital Cardiac Arrest	Nothing to Disclose
Kandregula	Krishna	Interventional Cardiology: TAVR 1	Novel Plane of Measurement to Evaluate Accurate Valve Size in	Nothing to Disclose
Kandregula	Krishna	Interventional Cardiology: TAVR 2	Patients Undergoing Transcatheter Aortic Valve Replacement Impact of Active Coronary Artery Disease on the Early and 1 Year Mortality of Patients Undergoing Transcatheter Aortic Valve	Nothing to Disclose
Kandregula	Krishna	Interventional Cardiology: TAVR 2	Replacement: A Systematic Review and Meta-Analysis Outcomes of Transcatheter Aortic Valve Replacement Without	Nothing to Disclose
Kandregula	Krishna	Interventional Cardiology: TAVR 3	Balloon Predilation: A Systematic Review and Meta-Analysis Comparison of Acute Elastic Recoil Between CoreValve and	Nothing to Disclose
Kandzari	David	Interventional Live Case Session IV: Complex	SAPIEN 3 Valves in Transcatheter Aortic Valve Replacement Co-Chair	CONSULTANT FEES/HONORARIA - Boston
		Coronary Transmission from St. Vincent Hospital (Indianapolis, IN)		Scientific,MEDTRONIC,St. Jude
Kandzari Kandzari	David	Late-Breaking Clinical Trials: Interventional Great Minds Think Differently: Multidisciplinary	Panelist Panelist	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,St. Jude CONSULTANT FEES/HONORARIA - Boston
Natiuzati	David	Approach to Controversies in Cardiology	Fallelist	Scientific,MEDTRONIC,St. Jude
Kandzari	David	Left Main PCI: Why? When? How?	Co-Chair	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,St. Jude
Kandzari	David	Emerging Concepts in Evaluation and	Panelist	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,St. Jude
Kandzari	David	Management of Hypertension Emerging Concepts in Evaluation and Management of Hypertension	Avoiding Lifelong treatment: is mechanical treatment of blood	CONSULTANT FEES/HONORARIA - Boston
Kandzari	David	Management of Hypertension Highlighted Original Research: Interventional	pressure still a possibility? Co-Chair	Scientific,MEDTRONIC,St. Jude CONSULTANT FEES/HONORARIA - Boston
Kandzari	David	Cardiology and the Year in Review Highlighted Original Research: Interventional	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome	Scientific,MEDTRONIC,St. Jude CONSULTANT FEES/HONORARIA - Boston
Kandzari	David	Cardiology and the Year in Review Coronary Intervention in Interventional	After PCI of Left Main Coronary Artery Disease: The EXCEL Trial Three-Year Outcomes in 'Real-World' Patients	Scientific,MEDTRONIC,St. Jude CONSULTANT FEES/HONORARIA - Boston
		Cardiology: Advanced Device Use	Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus U.S. Post-Approval Study (PE- Plus PAS)	Scientific,MEDTRONIC,St. Jude
Kandzari	David	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Differences and Level of Agreement in SYNTAX Score Assessment Between Site Operators and Angiographic Core Laboratory Readers: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,St. Jude
Kandzari	David	Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,St. Jude
Kandzari	David	Advances in Chronic Total Occlusion Intervention	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,St. Jude
Kandzari	David	Refining PCI Technique and Outcomes	Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory Assessment: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,St. Jude
Kandzari	David	19. Interventional Cardiology: Complex Patients/Comorbidities Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,St. Jude
Kane	Garvan	Innovative Use of Echocardiography	The Association Between Echocardiographic Laboratory	Nothing to Disclose
			Accreditation and the Quality of Imaging and Reporting	

-				
Last Name Kane	First Name Garvan	Session Title Emerging Developments in HFpEF and	Presentation Title The Role of Diastolic Stress Testing in the Evaluation for Heart	Disclosures Nothing to Disclose
Nalle	GalVdII	Arryhthmias	Failure With Preserved Ejection Fraction: An Invasive-	Invitating to Discluse
Kane	Lauren	Congenital Heart Disease: Innovations in	Echocardiographic Study Is a Pulsatile Glenn an Adequate Alternative for Long-Term	Nothing to Disclose
Kanei	Yumiko	Single Ventricle Heart Disease Interventional Cardiology: Intravascular	Palliation in Patients With Single Ventricle Physiology? Predictors of Flow-Limiting Fractional Flow Reserve in Coronary	Nothing to Disclose
		Physiology and Endothelial Function	Lesions With Intermediate Instantaneous Wave-Free Ratio	-
Kanei	Yumiko	Timely Topics in Acute Coronary Syndromes	Emergency Room Evaluation of Patients With Cardiac Complaints and New Left Bundle Branch Block: The Utility of the Sgarbossa and Modified Sgarbossa Criteria	Nothing to Disclose
Kaneko	Tsuyoshi	Interventional Cardiology: TAVR 1	Impact of Flow, Gradient, and Left Ventricular Function on Outcomes After Transcatheter Aortic Valve Replacement	SPEAKER'S BUREAU - Edwards
Kaneko	Tsuyoshi	Interventional Cardiology: TAVR 3	The Incidence of Permanent Pacemaker Implantation With SAPIEN 3 Heart Valve - Implantation Depth: The Higher the Better?	SPEAKER'S BUREAU - Edwards
Kang	Donna	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Supravalvular Aortic Stenosis: A Rare Complication of Familial Hypercholesterolemia Presenting as Cardiogenic Shock	Nothing to Disclose
Kang	Doyoon	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Anatomic Versus Ischemic Burden in Predicting Outcomes of Coronary Artery Disease: Data From IRIS-FFR Registry	Nothing to Disclose
Kang	Do-Yoon	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	The Prognostic Implications of Current Periprocedural Myocardial Infarction Definitions in Patients Underwent Percutaneous Conronary Intervention With Unprotected Left Main Coronary Artery Disease	Nothing to Disclose
Kang	Do-Yoon	Advances in Lipid Management	Lower Mortality in Patients With Vasospastic Angina Who Receive Statin Therapy: Data From the Asan Vasospastic Angina Registry	Nothing to Disclose
Kang	Do-Yoon Do-Yoon	Refining PCI Technique and Outcomes CAD in Unique Patient Populations	External Validation of DAPT Score in Two Large Cohorts	Nothing to Disclose Nothing to Disclose
Kang		·	Mortality of Patients With Previous Stroke Undergoing Drug-Eluting Stent Implantation	
Kang	Huan Yean	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Not All Shocks Are Created Equal: Acute Coronary Syndrome in the Setting of Panhypopituitarism	Nothing to Disclose
Kang	Min Gyu	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Clinical Efficacy of High-Flow Oxygen Therapy Through Nasal Cannula in Patients With Acute Heart Failure	Nothing to Disclose
Kang	Min Gyu	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of Platelet-Fibrin Clot Strength on Occurrence of In-Stent Restenosis in Patient With Drug Eluting Stent	Nothing to Disclose
Kang	Min Gyu	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prognostic Value of Platelet-Fibrin Clot Strength on Occurrence of Cardiovascular Events After Non-Cardiac Surgery	Nothing to Disclose
Kang	Min Gyu	Antithrombotic Therapy in Ischemic Heart Disease	Ticagrelor Versus Clopidogrel Is Associated With Better Recovery of LV Function After Acute Myocardial Infarction	Nothing to Disclose
Kang	Se Hun	Interventional Cardiology: Intravascular	Anatomic Versus Ischemic Burden in Predicting Outcomes of	Nothing to Disclose
Kang	Se Hun	Physiology and Endothelial Function Advances in Lipid Management	Coronary Artery Disease: Data From IRIS-FFR Registry Lower Mortality in Patients With Vasospastic Angina Who Receive	Nothing to Disclose
Kang	Se Hun	Refining PCI Technique and Outcomes	Statin Therapy: Data From the Asan Vasospastic Angina Registry External Validation of DAPT Score in Two Large Cohorts	Nothing to Disclose
Kang	Se Hun	CAD in Unique Patient Populations	Mortality of Patients With Previous Stroke Undergoing Drug-Eluting	Nothing to Disclose
Kang	Si-Hyuck	Emerging Developments in HFpEF and	Stent Implantation Risk of Stroke and Thromboembolism for Heart Failure With and	Nothing to Disclose
Kang	Woong Chol	Arryhthmias Coronary Angiography, Intra-Vascular Imaging,	Without Atrial Fibrillation Prognostic Value of Soluble ST2 in Patients With ST-Segment	Nothing to Disclose
	-	Revascularization and Outcomes	Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention	
Kang	Woong Chol	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Prognostic Impact of Alkaline Phosphatase Measured at the Time of Presentation in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Kang	Woong Chol	Interventional Cardiology: Structural Heart Disease	Effect of PFO Closure for Prevention of Recurrent Stroke or TIA in Highly Selected Patients With Cryptogenic Stroke	Nothing to Disclose
Kanj	Mohamed	Atrial Fibrillation and VT: Specific Situations	Baseline Characteristics, Management and Outcomes in Mitral	Nothing to Disclose
Kanmanthareddy	Arun	and Newer Outcome Measures Measuring Success in Cardiac Rehabilitation	Valve Prolapse With Manifest Ventricular Automaticity Wrist Activity Tracking Devices and Support Programs: A Meta-	Nothing to Disclose
Kanmanthareddy	Arun	Arrhythmias and Clinical EP: Devices 2	Analysis Role of Implantable Defibrillators in Primary Prevention of Mortality	Nothing to Disclose
Kanmanthareddy	Arun	Atrial Fibrillation and VT: Unique Populations and Solutions	in Non-Ischemic Cardiomyopathy Patients Sotalol Versus Other Anti-Arrhythmic Medications for Cardioversion of Atrial Fibrillation and Maintenance of Sinus Rhythm: Meta- Analysis of Randomized Controlled Studies	Nothing to Disclose
Kanmanthareddy	Arun	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Sotalol Versus Other Anti-Arrhythmic Agents for Prevention of Post- Operative Supraventricular Arrhythmias After Cardiac Surgery: Meta-	Nothing to Disclose
Kanmanthareddy	Arun	Arrhythmias and Heart Failure	Analysis of Randomized Controlled Studies Prognostic Impact of Premature Atrial Complexes in the General Population: A Meta-Analysis of Observational Studies	Nothing to Disclose
Kansal	Mayank	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Apical Hypertrophic Cardiomyopathy: A Case of Mimicry	RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals, Inc
Kanter	Joshua	Finding Out What Works in Pediatric and Congenital Heart Disease	Risk of Catastrophic Outcome Following Cardiac Catheterization for Pulmonary Hypertension: An Analysis of Data From the Impact	
Kanter	Kirk	A Night at the Movies with Some Congenital Heart Surgeons How Do They Actually Do That?: Joint Symposium of the American Association for Thoracic Surgeons and the	Registry Co-Chair	Nothing to Disclose
Kanter	Kirk	American College of Cardiology A Night at the Movies with Some Congenital Heart Surgeons How Do They Actually Do That?: Joint Symposium of the American Association for Thoracic Surgeons and the	Panelist (Panel Discussion II)	Nothing to Disclose
Kanter	Kirk	American College of Cardiology A Night at the Movies with Some Congenital Heart Surgeons How Do They Actually Do That?: Joint Symposium of the American Association for Thoracic Surgeons and the	Optimal Management of the Complete Atrioventricular Canal Patient: Two-Patch Repair (with Accompanying Surgical Video)	Nothing to Disclose
Kanwal	Sunil	American College of Cardiology Emerging Applications of Echocardiography	A New Modified Continuity Equation for Calculation of Aortic Valve Area by Integrating 3-D Measurements of LVOT Planimetry and	Nothing to Disclose
Kanwal	Sunil	Emerging Applications of Echocardiography	LVOT Flow Mapping Direct Comparison of Aortic Valve Area by 3-D TEE Planimetry and	Nothing to Disclose
Kanzaria	Mitul	FIT Clinical Decision Making: Non-Invasive	4-D Dynamic Cardiac CT Planimetry A Rare Case of Isolated Renal Cell Carcinoma Metastasis to the	Nothing to Disclose
Kanzaria	Mitul	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Interventional	Left Ventricle ST Elevation Myocardial Infarction in a Young Adult: Expect the	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Unexpected	
Kao	Andrew	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Severe Physical Inactivity Persists Following Acute Heart Failure in Patients With Sleep Disordered Breathing	CONSULTANT FEES/HONORARIA - Celladon; SPEAKER'S BUREAU - CareDx
	David	Adult Patients With Congenital Heart Disease:	Worse Outcomes in Hospitalizations of Women With Turner	CONSULTANT FEES/HONORARIA - Gliimpse, Inc.; OTHER -





(A)				
Last Name Kao	First Name Hsien-Li	Session Title Head to Toe: Outcomes of Endovascular	Presentation Title Improvement of Pituitary Function After Carotid Revascularization	Disclosures Nothing to Disclose
Kao	Hsien-Li	Interventions Head to Toe: Outcomes of Endovascular	for Abnormal Cerebral Perfusion Long Term Clinical Outcomes After Endovascular Recanalization in	Nothing to Disclose
Кара	Suraj	Interventions Innovative Approaches for Reducing Risk and	Patients With Chronic Carotid Artery Occlusion Atrial Fibrillation Is Associated With Worse Outcomes in Patients	CONSULTANT FEES/HONORARIA - St. Jude Medical; OTHER
Kapa	Suraj	Improving Outcomes With Ablation Innovative Approaches for Reducing Risk and	With Cirrhosis Complication Rates of Epicardial Ventricular Tachycardia Ablation:	Boston Scientific, MEDTRONIC CONSULTANT FEES/HONORARIA - St. Jude Medical; OTHER
Кара	Suraj	Improving Outcomes With Ablation Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	A Pooled Analysis Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin	Boston Scientific,MEDTRONIC CONSULTANT FEES/HONORARIA - St. Jude Medical; OTHER Boston Scientific,MEDTRONIC
Кара	Suraj	Personalized Skills Center: Hands-On	Acute Coronary Syndrome	CONSULTANT FEES/HONORARIA - St. Jude Medical; OTHER
Кара	Suraj	Simulation - Acute Coronary Syndrome Personalized Skills Center: Hands-On Simulation - Acute Coronary Syndrome	Acute Coronary Syndrome	Boston Scientific,MEDTRONIC CONSULTANT FEES/HONORARIA - St. Jude Medical; OTHER Boston Scientific,MEDTRONIC
Кара	Suraj	Congenital Heart Disease: To the Third Decade and Beyond	Outcomes of Direct Current Cardioversion in Adults With Congenital Heart Disease	CONSULTANT FEES/HONORARIA - St. Jude Medical; OTHER Boston Scientific, MEDTRONIC
Кара	Suraj	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - St. Jude Medical; OTHER Boston Scientific, MEDTRONIC
Kapadia	Samir	Interventional Live Case Session I: Structural Transmission from Cleveland Clinic (Cleveland, Ohio)	Live Case Operator	OTHER - Abbott Laboratories,Boston Scientific,Claret,Edwards Life Sciences,St Jude Medical
Kapadia	Samir	Interventional Live Case Session III: Structural Transmission from Cleveland Clinic (Cleveland, Ohio)	Live Case Operator	OTHER - Abbott Laboratories,Boston Scientific,Claret,Edwards Life Sciences,St Jude Medical
Kapadia	Samir	Featured Clinical Research II: Interventional	Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis From the STS/ACC TVT Registry	OTHER - Abbott Laboratories,Boston Scientific,Claret,Edwards Life Sciences,St Jude Medical
Kapadia	Samir	Challenging Anatomies: Does TAVR Device Choice Matter	Mangement of Concomitant Coronary Artery Disease: Does the Valve Type Matter?	OTHER - Abbott Laboratories, Boston Scientific, Claret, Edwards Life Sciences, St Jude Medical
Kapadia	Samir	Advances in Cholesterol Measurement and Management	Atherogenic Lipoprotein Variability Correlates With Coronary Atheroma Progression: Insights From Serial Intravascular Ultrasonography	OTHER - Abbott Laboratories,Boston Scientific,Claret,Edwards Life Sciences,St Jude Medical
Kapadia	Samir	Interventional Cardiology: TAVR 1	Novel Plane of Measurement to Evaluate Accurate Valve Size in Patients Undergoing Transcatheter Aortic Valve Replacement	OTHER - Abbott Laboratories, Boston Scientific, Claret, Edwards Life Sciences, St Jude Medical
Kapadia	Samir	Valvular Heart Disease: Mitral Valve Disease	Warfarin Use and Progression of Mitral Annular Calcification	OTHER - Abbott Laboratories, Boston Scientific, Claret, Edwards Life Sciences, St Jude Medical
Kapadia	Samir	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	OTHER - Abbott Laboratories,Boston Scientific,Claret,Edwards Life Sciences,St Jude Medical
Kapadia	Samir	Interventional Cardiology: TAVR 2	Prevalence and Outcomes of Mitral Stenosis in Patients Undergoing Transcatheter Aortic Valve Replacement: Findings From the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) Transcatheter Valve Therapies (TVT) Registry	OTHER - Abbott Laboratories,Boston Scientific,Claret,Edwards Life Sciences,St Jude Medical
Kapadia	Samir	Interventional Cardiology: TAVR 2	Impact of Active Coronary Artery Disease on the Early and 1 Year Mortality of Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis	OTHER - Abbott Laboratories,Boston Scientific,Claret,Edwards Life Sciences,St Jude Medical
Kapadia	Samir	Interventional Cardiology: TAVR 2	Outcomes of Transcatheter Aortic Valve Replacement Without Balloon Predilation: A Systematic Review and Meta-Analysis	OTHER - Abbott Laboratories, Boston Scientific, Claret, Edwards Life Sciences, St Jude Medical
Kapadia	Samir	Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes	OTHER - Abbott Laboratories,Boston Scientific,Claret,Edwards Life Sciences,St Jude Medical
Kapadia	Samir	Interventional Cardiology: TAVR 3	Comparison of Acute Elastic Recoil Between CoreValve and SAPIEN 3 Valves in Transcatheter Aortic Valve Replacement	OTHER - Abbott Laboratories, Boston Scientific, Claret, Edwards Life Sciences, St Jude Medical
Kapadia	Samir	Interventional Cardiology: TAVR 3	Clinical Outcomes of Patients With Pacemaker Implantation After Transcatheter Aortic Valve Replacement: Meta-Analysis and Meta- Regression	OTHER - Abbott Laboratories,Boston Scientific,Claret,Edwards Life Sciences,St Jude Medical
Kapadia	Samir	Pulmonary Hypertension	Pulmonary Hypertension in Left Atrial Sarcoma	OTHER - Abbott Laboratories, Boston Scientific, Claret, Edwards Life Sciences, St Jude Medical
Kapadia	Samir	Interventional Cardiology: TAVR 4	Depression as a Potential Therapeutic Target to Improve Quality of Life After Transcatheter Aortic Valve Replacement	OTHER - Abbott Laboratories, Boston Scientific, Claret, Edwards Life Sciences, St Jude Medical
Kapadia	Samir	Insights From Echocardiography Use	Aortic Regurgitation Negatively Affects Left Ventricular Mechanics After Transcatheter Aortic Valve Replacement	OTHER - Abbott Laboratories, Boston Scientific, Claret, Edwards Life Sciences, St Jude Medical
Kapadia	Samir	TAVR Outcomes Prognostication	Cardiac Plasticity Predicts Outcome After Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis	OTHER - Abbott Laboratories, Boston Scientific, Claret, Edwards Life Sciences, St Jude Medical
Kapadia	Samir	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low- Flow Severe Aortic Stenosis and Less Reverse Remodeling After TAVR: A Partner 2 Trial Analysis	OTHER - Abbott Laboratories,Boston Scientific,Claret,Edwards Life Sciences,St Jude Medical
Kapadia	Samir	New Perspectives on CAD Risk Factors	Changing Trends of Atherosclerotic Risk Factors Among Patients With Acute Myocardial Infarction and Acute Ischemic Stroke	OTHER - Abbott Laboratories,Boston Scientific,Claret,Edwards Life Sciences,St Jude Medical
Kapadia	Samir	16. Interventional Cardiology: Angiography and Interventional CT/MR Team 1		OTHER - Abbott Laboratories, Boston Scientific, Claret, Edwards Life Sciences, St Jude Medical
Kapadia	Samir	Interventional Challenging Cases: Team 2	ACC Challenging Case Reviewer	OTHER - Abbott Laboratories,Boston Scientific,Claret,Edwards Life Sciences,St Jude Medical
Kaplan	Aaron	Imaging for Left Atrial Appendage and Paravalvular Leak Closure: A Case Based Approach	Co-Chair	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Conformal Medical, Tryton Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston
Kaplan	Aaron	Arrhythmias and Clinical EP: AF Ablation	Dofetilide Associated QT Prolongation: Actual Versus Ideal Body Weight to Calculate Dosing	Scientific, Edwards Lifesciences, MEDTRONIC OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Conformal Medical, Tryton Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston
Kaplan	Hillard	Featured Clinical Research I	Native South American Tsimane Have the Lowest Levels of	Scientific,Edwards Lifesciences,MEDTRONIC Nothing to Disclose
Kaplan	Rachel	New Technologies in Echocardiography	Coronary Atherosclerosis Ever Reported Automated Detection of Mitral Valve Annular and Leaflet Geometry: Echocardiography and CT Comparison	Nothing to Disclose
Kaple	Ryan	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Echocardiography and CT Companson Change in Aortomitral Annular Angle and Anterior Mitral Valve Leaflet Length After Transcatheter Aortic Valve Replacement: Implications for Transcatheter Mitral Valve Replacement?	Nothing to Disclose
Kapoor	Deepak	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Biventricular Stress Induced Cardiomyopathy Managed With Impella CP and Pulmonary Vasodilators	Nothing to Disclose
Kapoor	Divya	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		Nothing to Disclose
Kappetein	A.	TAVR Changing the Paradigm for the Treatment of Valve Disease	In the Era of TAVR: Who Is Low-risk for Surgical Aortic Valve Replacement	Nothing to Disclose
Kappetein Kappetein	A. A.	Left Main PCI: Why? When? How? Left Main PCI: Why? When? How?	Panelist Insights from SYNTAX and PRECOMBAT	Nothing to Disclose Nothing to Disclose
Kappetein	A. A.	Post FDA Release Prosthetic Valve	European Experience, CE, Mark, Registries- Tracking Prosthetic	Nothing to Disclose Nothing to Disclose
Kappetein	A.	Surveillance - Watching for Signals Highlighted Original Research: Interventional	Values Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome	Nothing to Disclose
- Managara		Cardiology and the Year in Review	After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	J.:

Last Name	First Name	Session Title	Presentation Title	Disclosures
Kappetein	A.	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Differences and Level of Agreement in SYNTAX Score Assessment Between Site Operators and Angiographic Core Laboratory Readers: Insights From the EXCEL Trial	Nothing to Disclose
Kappetein	A.	Refining PCI Technique and Outcomes	Treatment of Left Main Coronary Artery Disease in Patients With Diabetes: 3-Year Outcomes Comparing CABG and PCI With	Nothing to Disclose
Kappetein	A.	Refining PCI Technique and Outcomes	Everolimus-Eluting Stents From the EXCEL Study Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory	Nothing to Disclose
Kappetein	A.	17. Interventional Cardiology: Aortic Valve Disease Team 2	Assessment: Insights From the EXCEL Trial Suggested Reviewer	Nothing to Disclose
Kappetein	A.	Interventional Challenging Cases: Team 2	ACC Challenging Case Reviewer	Nothing to Disclose
Kappetein	Ari	PCI Strategies and Outcomes Unique to Women	Sex Differences in Outcomes After Stenting or Bypass Surgery for Unprotected Left Main Disease	Nothing to Disclose
Kapur	Navin	Fellows Bootcamp: Coronary Disease Management	CHIP/Hemodynamic Support	CONSULTANT FEES/HONORARIA - Maquet, Thoratec Inc; RESEARCH/RESEARCH GRANTS - Abiomed, Cardiac Assist, Maquet; SPEAKER'S BUREAU - Abiomed
Kapur	Navin	Acute Cardiogenic Shock: Progress, Paradigm, and Unresolved Problems	Co-Chair	CONSULTANT FEES/HONORARIA - Maquet, Thoratec Inc; RESEARCH/RESEARCH GRANTS - Abiomed, Cardiac Assist, Maquet; SPEAKER'S BUREAU - Abiomed
Kapur	Navin	Acute Cardiogenic Shock: Progress, Paradigm, and Unresolved Problems	Hemodynamic Profiles and Hemodynamic Pumps for Cardiogenic Shock: Which Pump for Which Patient?	CONSULTANT FEES/HONORARIA - Maquet, Thoratec Inc; RESEARCH/RESEARCH GRANTS - Abiomed, Cardiac Assist, Maquet; SPEAKER'S BUREAU - Abiomed
Kapur	Navin	Young Investigator Awards Competition: Basic and Translational Science	Rbmp9	CONSULTANT FEES/HONORARIA - Maquet, Thoratec Inc; RESEARCH/RESEARCH GRANTS - Abiomed, Cardiac
Kapur	Navin	Novel Developments in Acute Coronary Syndromes	Right-Sided Ventriculo-Arterial Coupling Indices Are Associated With Clinical Outcomes Among Patients Receiving Biventricular	Assist, Maquet; SPEAKER'S BUREAU - Abiomed CONSULTANT FEES/HONORARIA - Maquet, Thoratec Inc; RESEARCH/RESEARCH GRANTS - Abiomed, Cardiac
Kapur	Navin	Engage @ ACC.17 Studio: Simulation Session	Impella (BiPella) Support for Cardiogenic Shock Simulation Faculty	Assist,Maquet; SPEAKER'S BUREAU - Abiomed CONSULTANT FEES/HONORARIA - Maquet, Thoratec Inc;
Kapur	Navin	II: Acute Heart Failure 01. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Abiomed, Cardiac Assist, Maquet; SPEAKER'S BUREAU - Abiomed CONSULTANT FEES/HONORARIA - Maquet, Thoratec Inc;
		Basic Team 1		RESEARCH/RESEARCH GRANTS - Abiomed,Cardiac Assist,Maquet; SPEAKER'S BUREAU - Abiomed
Kapur	Vishal	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Angiographic Phenotype and Clinical Outcomes of Patients With Malignancy Undergoing PCI	Nothing to Disclose
Kapur	Vishal	Timely Topics in Acute Coronary Syndromes	Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions	Nothing to Disclose
Kapur	Vishal	Optimizing the Care of ACS Patients	Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population	Nothing to Disclose
Kar	Biswajit	Interventional Cardiology: PCI and TAVR in Complex Patients	Predicting Risk Factors for Permanent Pacemaker Placement Following Transcatheter Aortic Valve Replacement: A UTHealth Experience	Nothing to Disclose
Kar	Biswajit	Interventional Cardiology: TAVR 3	Transapical TAVR Is Associated With Higher Morbidity and Mortality Compared to Transfemoral TAVR in Men but Not in Women	Nothing to Disclose
Kar	Biswajit	The Challenges of Outcome Prediction in Valvular Heart Disease	Gender-Based Outcomes in Diabetics Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Kar	Saibal	Featured Clinical Research II: Interventional	Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Valve Repair in the United States	CONSULTANT FEES/HONORARIA - Abbott Vascular, Gore Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston Scientfic, Gore Medical, St Judes Medical
Kar	Saibal	Transcatheter Mitral Valve Repair	Multi-Clip Strategies	CONSULTANT FEES/HONORARIA - Abbott Vascular, Gore Medical; RESEARCH/RESEARCH GRANTS - Abbott
Kar	Saibal	PFO Closure, PV Leak, and VSD Repair	Case Presentation: Mitral PV Leak	Vascular,Boston Scientfic,Gore Medical,St Judes Medical CONSULTANT FEES/HONORARIA - Abbott Vascular,Gore Medical; RESEARCH/RESEARCH GRANTS - Abbott
Kar	Saibal	Fundamentals of LAA Closure	Panelist	Vascular,Boston Scientfic,Gore Medical,St Judes Medical CONSULTANT FEES/HONORARIA - Abbott Vascular,Gore Medical; RESEARCH/RESEARCH GRANTS - Abbott
Kar	Saibal	Fundamentals of LAA Closure	Patient Selection for LAA Closure: U.S. Perspective	Vascular,Boston Scientfic,Gore Medical,St Judes Medical CONSULTANT FEES/HONORARIA - Abbott Vascular,Gore Medical; RESEARCH/RESEARCH GRANTS - Abbott
Kar	Saibal	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Impact of Residual Left Atrial Appendage Trabeculations After WATCHMAN Device Implantation in Atrial Fibrillation Patients	Vascular,Boston Scientfic,Gore Medical,St Judes Medical CONSULTANT FEES/HONORARIA - Abbott Vascular,Gore Medical: RESEARCH/RESEARCH GRANTS - Abbott
Kar	Saibal	Structural Heart Interventions: Focus on Mitral	Anemia Predicts Mortality in Atrial Fibrillation Patients Undergoing	Vascular,Boston Scientfic,Gore Medical,St Judes Medical CONSULTANT FEES/HONORARIA - Abbott Vascular,Gore
Kar	Saibal	Valve, Left Atrial Appendage and HOCM Interventional Cardiology: Structural Heart	Left Atrial Appendage Occlusion Using WATCHMAN Device Long-Term Durability of Percutaneous Mitral Valve Repair Using	Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Boston Scientfic,Gore Medical,St Judes Medical CONSULTANT FEES/HONORARIA - Abbott Vascular,Gore
Ndi	Salbai	Disease	MitraClip System: 8-Year Follow-Up	Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Boston Scientfic,Gore Medical,St Judes Medical
Kar	Saibal	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Safety Profiles of Percutaneous Left Atrial Appendage Closure Devices: An Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database From 2009 - 2016	CONSULTANT FEES/HONORARIA - Abbott Vascular, Gore Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston Scientfic, Gore Medical, St Judes Medical
Kar	Subrata	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Double Right Coronary Artery Engendering Inadequate Blood Supply to the Inferior Left Ventricular Wall	Nothing to Disclose
Karacsonyi	Judit	Highlighted Original Research: Prevention and the Year in Review	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 16,721 Patients From 33 Randomized Clinical Trials	Nothing to Disclose
Karacsonyi	Judit	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Contemporary Use of Laser During Percutaneous Coronary Intervention: Results From the Laser Veterans Affairs (LAVA)	Nothing to Disclose
Karacsonyi	Judit	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Multicenter Registry A Meta-Analysis of Contemporary Lesion Modification Strategies During Percutaneous Coronary Intervention in 244,665 Patients From 21 Studies	Nothing to Disclose
Karacsonyi	Judit	Innovations in Advocacy and Patient Centered Care	Diverse Perspectives and Training Paths in Cardiology: An Analysis of Authorship in the <i>Journal of the American College of</i>	Nothing to Disclose
Karacsonyi	Judit	Advances in Chronic Total Occlusion Intervention	Cardiology Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions Improves Peak Oxygen Uptake During Cardiopulmonary Exercise Testing	Nothing to Disclose
Karacsonyi	Judit	Advances in Chronic Total Occlusion Intervention	Exercise Testing The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	Nothing to Disclose
Karacsonyi	Judit	Advances in Chronic Total Occlusion Intervention	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a	Nothing to Disclose
Karalis	Dean	Advances in Cholesterol Measurement and	Contemporary Multicenter U.S. Registry Understanding the Predictors of Achieving LDL-C Targets When	CONSULTANT FEES/HONORARIA - Regeneron, Sanofi-Aventi
	1	Management Measurement and	Adding Ezetimibe in High Risk Patients	Togotoro, canonination

and a				
Last Name Karalis	First Name Dean	Session Title The Intersection of Diabetes and ASCVD	Presentation Title Alirocumab Safety in Individuals With and Without Diabetes Mellitus:	Disclosures CONSULTANT FEES/HONORARIA - Regeneron, Sanofi-Aventis
Karas	Richard	Young Investigator Awards Competition: Basic	Pooled Data From 14 ODYSSEY Trials Rbmp9	CONSULTANT FEES/HONORARIA - Merck
Karatasakis	Aris	and Translational Science Highlighted Original Research: Prevention and the Year in Review	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 16,721 Patients From 33	Nothing to Disclose
Karatasakis	Aris	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Randomized Clinical Trials Contemporary Use of Laser During Percutaneous Coronary Intervention: Results From the Laser Veterans Affairs (LAVA) Multicenter Registry	Nothing to Disclose
Karatasakis	Aris	Coronary Intervention in Interventional Cardiology: Advanced Device Use	A Meta-Analysis of Contemporary Lesion Modification Strategies During Percutaneous Coronary Intervention in 244,665 Patients From 21 Studies	Nothing to Disclose
Karatasakis	Aris	Innovations in Advocacy and Patient Centered Care	Diverse Perspectives and Training Paths in Cardiology: An Analysis of Authorship in the <i>Journal of the American College of Cardiology</i>	Nothing to Disclose
Karatasakis	Aris	Advances in Chronic Total Occlusion Intervention	Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions Improves Peak Oxygen Uptake During Cardiopulmonary Exercise Testing	Nothing to Disclose
Karatasakis	Aris	Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	Nothing to Disclose
Karatasakis	Aris	Advances in Chronic Total Occlusion Intervention	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	Nothing to Disclose
Kargoli	Faraj	Markers of Prognosis Associated With Elevated Blood Pressure	Prevalence and Prognostic Significance of Cardiac Troponin-T Elevation in Patients Admitted With Hypertensive Crises	Nothing to Disclose
Kargoli	Faraj	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Diabetes Mellitus and the Development of Atrial Fibrillation in Hispanics, Blacks and Whites	Nothing to Disclose
Kargoli	Faraj	Antithrombotic Therapy in Ischemic Heart Disease	Role of Anticoagulation Therapy After Anterior Wall ST-Elevation Myocardial Infraction in Preventing LV Thrombus: A Meta-Analysis and Meta-Regression	Nothing to Disclose
Karimi	Ashkan	Interventional Cardiology: TAVR 3	Prosthetic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter Valve-in-Valve Implantation	Nothing to Disclose
Karki	Niraj	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Relationship Between Marijuana Use and Hospitalization for Acute Coronary Syndrome	Nothing to Disclose
Karlis	Dimitrios	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Omega-3 Polyunsaturated Fatty Acids May Favorably Affect Inflammatory Biomarkers & Novel Indices of Left Ventricle Function in Patients With Heart Failure	Nothing to Disclose
Karlsson	Sofia	Novel Developments in Acute Coronary Syndromes	Prehospital Administration of Heparin Reduces the Risk of Vessel Occlusion in Patients With ST Elevation Myocardial Infarction: Secondary Analysis of the TASTE Trial	Nothing to Disclose
Karmacharya	Paras	Vascular Access and Hemostasis Issues	Efficacy and Safety of Transulnar Compared to Transradial Arterial Access in Patients Undergoing Coronary Angiography: A Systematic Review and Meta-Analysis	Nothing to Disclose
Karmpaliotis	Dimitrios	Interventional Live Case Session II: CTO Transmission from Mid-America Heart Institute (Kansas City, Missouri)	Co-Chair	CONSULTANT FEES/HONORARIA - Asahi,Boston Scientific,Vascular Solutions; SPEAKER'S BUREAU - Abott Vascular,MEDTRONIC
Karmpaliotis	Dimitrios	Debates on Current Hot Topics in Coronary Intervention	Debate Pro: Most CTOs Should be Opened Because it Improves Outcomes!	CONSULTANT FEES/HONORARIA - Asahi,Boston Scientific,Vascular Solutions; SPEAKER'S BUREAU - Abott Vascular,MEDTRONIC
Karmpaliotis	Dimitrios	Chronic Total Occlusion PCI: A Case-Based Review of Contemporary Techniques	Co-Chair	CONSULTANT FEES/HONORARIA - Asahi,Boston Scientific,Vascular Solutions; SPEAKER'S BUREAU - Abott Vascular,MEDTRONIC
Karmpaliotis	Dimitrios	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Morphologic Patterns of In-Stent Chronic Total Occlusions: An Intravascular Ultrasound Study	CONSULTANT FEES/HONORARIA - Asahi,Boston Scientific,Vascular Solutions; SPEAKER'S BUREAU - Abott Vascular,MEDTRONIC
Karmpaliotis	Dimitrios	Advances in Chronic Total Occlusion Intervention	Is Platelet Reactivity Associated With Ischemic Events Following Successful Chronic Total Occlusion Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Asahi,Boston Scientific,Vascular Solutions; SPEAKER'S BUREAU - Abott Vascular,MEDTRONIC
Karmpaliotis	Dimitrios	Advances in Chronic Total Occlusion Intervention	Association of Stress Test Risk Classification With Health Status Change After Chronic Total Occlusion PCI: Insights From the OPEN- CTO Registry	CONSULTANT FEES/HONORARIA - Asahi,Boston Scientific,Vascular Solutions; SPEAKER'S BUREAU - Abott Vascular,MEDTRONIC
Karmpaliotis	Dimitrios	Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	CONSULTANT FEES/HONORARIA - Asahi,Boston Scientific,Vascular Solutions; SPEAKER'S BUREAU - Abott Vascular,MEDTRONIC
Karmpaliotis	Dimitrios	Advances in Chronic Total Occlusion Intervention	Hemodynamically-Supported PCI of Chronic Total Occlusions: A Case Series	CONSULTANT FEES/HONORARIA - Asahi,Boston Scientific,Vascular Solutions; SPEAKER'S BUREAU - Abott Vascular,MEDTRONIC
Karmpaliotis	Dimitrios	Advances in Chronic Total Occlusion Intervention Advances in Chronic Total Occlusion	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Microsoft U.S. Registry	CONSULTANT FEES/HONORARIA - Asahi,Boston Scientific,Vascular Solutions; SPEAKER'S BUREAU - Abott Vascular,MEDTRONIC CONSULTANT FEES/HONORARIA - Asahi,Boston
Karmpaliotis	Dimitrios	Advances in Chronic Total Occlusion Intervention	Performance of J-CTO and PROGRESS CTO Scores in Predicting Angiographic Success and Long-Term Clinical Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions	CONSULTANT FEES/HONORARIA - Asahi,Boston Scientific,Vascular Solutions; SPEAKER'S BUREAU - Abott Vascular,MEDTRONIC
Karmpaliotis	Dimitrios	Refining PCI Technique and Outcomes	Appropriate Use Criteria and Health Status Outcomes After CTO PCI: Results From the OPEN CTO Registry	CONSULTANT FEES/HONORARIA - Asahi,Boston Scientific,Vascular Solutions; SPEAKER'S BUREAU - Abott Vascular,MEDTRONIC
Karmpaliotis	Dimitrios	20. Interventional Cardiology: Coronary Intervention: CTO Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Asahi,Boston Scientific,Vascular Solutions; SPEAKER'S BUREAU - Abott Vascular,MEDTRONIC
Karon	Barry	Advances in HCM, PPCM and Other Cardiomyopathies	Utility of Routine Serum Free Light Chain Assay for Amyloidosis in Patients With Heart Failure	Nothing to Disclose
Karpouzas	George	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Impact of Cardiac Troponin I on the Presence of the Coronary Artery Plaque in Rheumatoid Arthritis patients	Nothing to Disclose
Karthikesan	Dharmaraj	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Arterty Plaque in Kneumatoia Artinitis patients Not All Shocks Are Created Equal: Acute Coronary Syndrome in the Setting of Panhypopituitarism	Nothing to Disclose
Karthikeyan	Ganesan	Nuclear Cardiology: Quality	Worldwide Variation in the Use of Nuclear Cardiology Camera Technology, Reconstruction Software, and Acquisition Protocols: Findings From the IAEA Nuclear Cardiology Protocols Study (INCAPS)	Nothing to Disclose
Karthikeyan	Ganesan	Insights Into Ischemic Heart Disease: Stable to Erosive Plaques	Immuno-Histopathology of Intracoronary Thrombus Aspirated During Primary Percutaneous Intervention for ST Elevation Myocardial Infarction and its Clinical Significance	Nothing to Disclose
Karumanchi	Ananth	Pregnancy and Heart Disease	Panelist	CONSULTANT FEES/HONORARIA - Thermofisher; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aggamin Therapeutics
Karumanchi	Ananth	Pregnancy and Heart Disease	Panelist	Nothing to Disclose

Last Name Karumanchi	First Name Ananth	Session Title Pregnancy and Heart Disease	Presentation Title Pre-emclampsia - Short and Long Term Cardiovascular Risks	Disclosures CONSULTANT FEES/HONORARIA - Thermofisher:
Naturialiciii	Ananui	Fregulaticy and heart disease	rie-eniciampsia - Short and Long Term Cardiovascular Risks	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aggamin
				Therapeutics
Karumanchi	Ananth	Pregnancy and Heart Disease	Pre-emclampsia - Short and Long Term Cardiovascular Risks	Nothing to Disclose
Karvounis	Haralampos	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Previous Major Gastrointestinal Bleeding: Insight From the	Nothing to Disclose
		varie, 2017 talai 7 pportaage alia 110 oliv	Amplatzer Cardiac Plug Multicenter Registry	
Karvounis	Haralampos	Predicting the Future: Observations and	Left Ventricular Filling Rate Predicts Clinical Failure in Patients With	Nothing to Disclose
Kashani	Mariam	Discoveries From Registries and Databases Interdisciplinary Cardiovascular Team	Precapillary Pulmonary Hypertension Multidisciplinary Cardiovascular Team Review Captures Preclinical	Nothing to Disclose
rasiani	Ividitatii	Collaboratives in Care	Disease	Trouming to Disclose
Kashani	Mariam	Diabetes and Other Issues in Cardiovascular	Arresting Insulin Resistance With an Integrative Health Intervention	Nothing to Disclose
Kashif	Mohammad	Prevention Refining TAVR Outcomes	Frame Geometry and Hemodynamic Findings of Sapien 3	Nothing to Disclose
T COST III	Worldmind	Tremming Provide Guldenines	Transcatheter Heart Valve in Patients With Bicuspid Aortic Valve	Nothing to Disclose
			Disease	
Kashyap	Moti	Advances in Cholesterol Measurement and Management	Combined LDL-C and Lipoprotein (a) Levels in Prediction of Residual Atherosclerotic Cardiovascular Disease Risk: The AlM-	CONSULTANT FEES/HONORARIA - Amarin, Merck; RESEARCH/RESEARCH GRANTS - Amgen, AstraZeneca, Eli
		Management	HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome	Lilly,Merck,SANOFI; SPEAKER'S BUREAU - Abbott,Amarin
			With Low HDL/High Triglycerides: Impact on Global Health	
Kashyap	Moti	Traditional and Novel Factors Used to Assess	Outcomes) Predicting Cardiovascular Risk in Statin-Treated Patients: The AIM-	CONSULTANT FEES/HONORARIA - Amarin, Merck;
radinjap	····ou	the Risk of, and Used for the Treatment of,	HIGH (Atherothrombosis Intervention in Metabolic Syndrome With	RESEARCH/RESEARCH GRANTS - Amgen, AstraZeneca, Eli
		Coronary Artery Disease	Low HDL/High Triglycerides: Impact on Global Health Outcomes)	Lilly,Merck,SANOFI; SPEAKER'S BUREAU - Abbott,Amarin
Kasiakogias	Alexandros	Novel Mechanical Devices for the Treatment	Residual Risk Score Blood Pressure Response to Catheter-Based Renal Sympathetic	Nothing to Disclose
radianogiad	, novariares	and Assessment of Hypertension	Denervation in Patients With Resistant Hypertension: Data From a	Thouming to Discusse
			National Multicenter 1-Year-Follow-Up Study	
Kasiakogias	Alexandros	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Insights on Diastolic Dysfunction of Treated Hypertensive Patients: Focusing on Hypertension Control & Treatment Resistance	Nothing to Disclose
		and Assessment of Trypertension	1 ocasing on rispercusion control aroo, ricament resistance	
Kasiakogias	Alexandros		Left Ventricular Mass Versus Pulse Wave Velocity as Predictors of	Nothing to Disclose
		Elevated Blood Pressure	Coronary Artery Disease in Patients With Essential Hypertension: Data From a Greek 6-Year-Follow-Up Study	
Kasiakogias	Alexandros	Toward Precision Medicine in the Treatment of		Nothing to Disclose
	0	Elevated Blood Pressure	Leave Town House Cities Williams Co. T. Co. Co. Co. Co. Co. Co. Co. Co. Co. Co	-
Kaspar	Georgy	Arrhythmias and Clinical EP: Devices 4	Long-Term Use of the Wearable Cardiovertor Defibrillator in ICD Explant Patients	Nothing to Disclose
Kass	Malek	Unusual Presentations of ACS	Characteristics of Acute Coronary Syndrome Presentation in Young	Nothing to Disclose
			Patients	
Kassas	Ibrahim	Highlighted Original Research: Interventional Cardiology and the Year in Review	Safety of Same Day Discharge Following PCI for Non-ST Elevation Acute Coronary Syndromes	Nothing to Disclose
Kasselman	Lora	Cutting Edge Vascular Medicine	Pro-Atherogenic Properties of Plasma From Patients With Type 1	Nothing to Disclose
			Diabetes Mellitus: Effects on Macrophage Lipid Handling	
Kassem	Mona	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Copeptin and High-Sensitivity Troponin I in Patients With Chest Pain and Recent Syncope	Nothing to Disclose
Kassi	Mahwash	FIT Clinical Decision Making: Prevention, Adult	Scimitar Syndrome in an Adult With Multiple Unsuccessful Surgical	Nothing to Disclose
		Congenital and Congenital Heart Disease	Repairs	-
Kassi	Mahwash	FIT Clinical Decision Making: Heart Failure and	Patient With a Systolic Murmur and Shock: Importance of the	Nothing to Disclose
Nassi	iviariwasii	Pulmonary Hypertension	Physical	Nothing to Disclose
Kassier	Adnan	Atrial Fibrillation and VT: Unique Populations	Paroxysmal or Persistent: A Tale of Two Flutters	Nothing to Disclose
Kassier	Adnan	and Solutions Insights From Echocardiography Use	Impact of Echo Contrast Agents on Ventricular Assist Devices (VAD)	Nothing to Disclose
rassici	Adnan	misights From Echocardiography osc	Hemodynamics: Are They Safe to Use?	Nothing to Disclose
Kastelein	John	Featured Clinical Research I	LDL-C Reduction From 6 to 9 Months Following Single or Second	CONSULTANT FEES/HONORARIA -
			Injection of Inclisiran a Novel siRNA Compound: Primary Efficacy and Safety Outcomes of the ORION 1 Trial	Amgen, Astra Zeneca, Cerenis, CSL Behring, Cymabay, Eli Lilly, Esperion, Gemphire, Isis, Novartis, Regeneron, Sanofi
			and Safety Suttomes of the Ortion 1 Than	Aventis, The Medicines Company
Kastelein	John	Joint American College of Cardiology/Journal	Effect of Serial Infusions of CER-001, a Pre-Beta High-Density	CONSULTANT FEES/HONORARIA -
		of the American Medical Association Late- Breaking Clinical Trials	Lipoprotein Mimetic on Coronary Atherosclerosis: Results of the CARAT Study	Amgen, Astra Zeneca, Cerenis, CSL Behring, Cymabay, Eli Lilly, Esperion, Gemphire, Isis, Novartis, Regeneron, Sanofi
		-	,	Aventis, The Medicines Company
Kastelein	John	Harnessing the Power of Genetics to Prevent	HDL – Causal, Confounded, or Confusing?	CONSULTANT FEES/HONORARIA -
		ASCVD		Amgen, Astra Zeneca, Cerenis, CSL Behring, Cymabay, Eli Lilly, Esperion, Gemphire, Isis, Novartis, Regeneron, Sanofi
				Aventis, The Medicines Company
Kastelein	John	Are We There Yet? Update on Trials Testing	Panelist	CONSULTANT FEES/HONORARIA -
		New Therapeutics for Prevention of ASCVD		Amgen, Astra Zeneca, Cerenis, CSL Behring, Cymabay, Eli Lilly, Esperion, Gemphire, Isis, Novartis, Regeneron, Sanofi
				Aventis, The Medicines Company
Kastelein	John	Are We There Yet? Update on Trials Testing	CETP inhibitors - Fundamentally flawed or Unmet Potential?	CONSULTANT FEES/HONORARIA -
		New Therapeutics for Prevention of ASCVD		Amgen,AstraZeneca,Cerenis,CSL Behring ,Cymabay,Eli Lilly,Esperion,Gemphire,Isis,Novartis,Regeneron,Sanofi
				Aventis, The Medicines Company
Kastelein	John	Advances in Lipid Management	Alirocumab Reduces Major Cardiovascular Events in Individuals	CONSULTANT FEES/HONORARIA -
			With Atherosclerotic Cardiovascular Disease: A Post-Hoc Analysis of ODYSSEY LONG TERM	Amgen, Astra Zeneca, Cerenis, CSL Behring, Cymabay, Eli Lilly, Esperion, Gemphire, Isis, Novartis, Regeneron, Sanofi
				Aventis,The Medicines Company
Kastl	Stefan	Making Progress in Understanding Heart	Growth Differentiation Factor-15 Is Associated With Mortality in	Nothing to Disclose
Kastl	Stefan	Failure Acute Heart Failure: Evaluating Strategies to	Patients With Severe Acute Heart Failure or Cardiogenic Shock Intestinal Fatty Acid Binding Protein Predicts Mortality in Patients	Nothing to Disclose
		Prevent Readmissions	With Acute Heart Failure or Cardiogenic Shock	-
Kastrati	Adnan	Interventional Cardiology: TAVR 3	Multicenter Evaluation of the ACURATE Neo Transfemoral	Nothing to Disclose
			Transcatheter Heart Valve: Clinical Results and Propensity Matched Comparison With SAPIEN 3	
Kastrati	Adnan	Interventional Cardiology: TAVR 4	Multicenter Evaluation of Prosthesis Oversizing for the SAPIEN 3	Nothing to Disclose
			Transcatheter Heart Valve: Impact on New Pacemaker	
Kastrati	Adnan	02. Acute and Stable Ischemic Heart Disease:	Implantations Suggested Reviewer	Nothing to Disclose
		Clinical Team 9		-
Kastrup	Jens	Novel Echocardiographic Methods for	Coronary Microvascular Dysfunction Affects the Myocardial	Nothing to Disclose
		Assessing Cardiac Function	Contractile Reserve in Women With Angina and No Obstructive Coronary Artery Disease	
Kastrup	Jens	Fixing the Heart One Cell at a Time: The	Adipose Derived Stromal Cells for Refractory Angina: Results From	Nothing to Disclose
·		Ongoing Promise of Stem Cells	MyStromalCell Trial	-
Kasula	Srikanth	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Does Post Pci Ffr Carry the Same Prognostic Weight as Non- lschemic Ffr in Deferred Lesions?	Nothing to Disclose
Kataruka	Akash	Innovation in Practice Management, Advocacy,	Evaluating the Role of Anticoagulation Clinical Pharmacists for	Nothing to Disclose
		and Education	Coordinating Periprocedural Anticoagulation	-
Katayama	Yosuke	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Comparison of Very Late Vascular Response Beyond 2 Years After Stent Implantation Between EES and BES: An OCT Sub-Study of	Nothing to Disclose
			the NEXT	
Katchi	Farhan	FIT Clinical Decision Making: Heart Failure and		Nothing to Disclose
	l .	Pulmonary Hypertension	Eosinophilic Granulomatosis With Polyangiitis	

Control of the Contro				<u> </u>
Last Name Katchi	First Name Tasleem	Session Title FIT Clinical Decision Making: Arrhythmias and	Presentation Title Sinus Node Dysfunction in Batten Disease: A Rare Manifestation of	Disclosures Nothing to Disclose
Kates	Andrew	Electrophysiology FIT Forum: Mix and Mingle	a Rare Disease Education	Nothing to Disclose
Kates	Andrew	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Chair	Nothing to Disclose
Kates	Andrew	Mentoring the Care Team: FITs, Early Career Professionals and CV Team Members	Mentoring the Early Career Professional in Academic Practice	Nothing to Disclose
Kates	Andrew	42. Spotlight on Special Topics: Education, Innovation, Advocacy, Social Media, Leadership and Practice Management Team 1	Suggested Reviewer	Nothing to Disclose
Kates	Andrew	LBCT reviewers	LB Reviewer	Nothing to Disclose
Kato	Nahoko	Insights From Echocardiography Use	Value of Automated and Semi-Automated Measurement by Novel Three-Dimensional Echocardiography Software for Aortic Annulus Sizing in Candidates of Transcatheter Aortic Valve Replacement: Comparison With Multi-Detector Computed Tomography	Nothing to Disclose
Kato	Ryuji	Mechanisms of Vascular Inflammation in Atherogenesis	Rivaroxaban Attenuates Cardiac Remodeling Due to Intermittent Hypoxia by Suppressing the Synergistic Effects of Par-1 and Par-2	Nothing to Disclose
Katsikeris	Fotis	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	The Way to a Man's Heart: Through His Quadriceps	Nothing to Disclose
Katsikeris	Fotis	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Blocked Artery, or Blocked Bowel?!	Nothing to Disclose
Katsuki	Toshiomi	Unusual Presentations of ACS	C-Reactive Protein in Non-ST Elevation Myocardial Infarction Patients Is Useful in Improving Discrimination of Conventional Risk Score: A Report From Multicenter PCI Registry	Nothing to Disclose
Katta	Natraj	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	41-Year-Old Patient With Double Inlet Left Ventricle Without Pulmonic Stenosis Presenting With Eisenmenger's Syndrome	Nothing to Disclose
Katta	Natraj	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Syriculonie Sarcoidosis Presenting as Complete Heart Block in a Young Morbidly Obese Patient With Severe Obstructive Sleep Apnea and on Beta Blocker	Nothing to Disclose
Katta	Natraj	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Pseudohypotension Due to Bilateral Subclavian Artery Stenosis	Nothing to Disclose
Kattoor	Ajoe	Innovations in Education	Tobacco Cessation: A Knowledge, Attitude and Practice (KAP)	Nothing to Disclose
Kattoor	Ajoe	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Survey Among Residents Complication Rates of Epicardial Ventricular Tachycardia Ablation: A Pooled Analysis	Nothing to Disclose
Katus	Hugo	Improving Outcomes with Adjation Systemic Organ Involvement in Heart Failure: International Perspectives From the German Cardiac Society, Hellenic Society of Cardiology, and American College of Cardiology	Biomarkers in Heart Failure: Beyond Natriuretic Peptides	CONSULTANT FEES/HONORARIA - Roche Diagnostics; OTHER - Roche Diagnostics; SPEAKER'S BUREAU - Abbott Laboratories, AstraZeneca Pharmaceuticals, Daiichi Sankyo
Katz	Jason	Meeting of the Minds: HF and EP Decision Making for Complex Patients	Co-Chair	RESEARCH/RESEARCH GRANTS - Thoratec Corporation
Katz	Jason	Acute Cardiogenic Shock: Progress, Paradigm,	Putting it All Together: The Shock Team	RESEARCH/RESEARCH GRANTS - Thoratec Corporation
Katz	Jason	and Unresolved Problems Evolution of Critical Care Cardiology and the	Morphogenesis and Morphology of the CICU	RESEARCH/RESEARCH GRANTS - Thoratec Corporation
Katz	Jason	Unusual Presentations of ACS	The High Cost of Low Acuity Non ST-Segment Elevation Acute Coronary Syndrome Admissions to the Coronary Care Unit: An	RESEARCH/RESEARCH GRANTS - Thoratec Corporation
Katz	Marc	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in	Analysis of National Population Health Data Understanding Readmissions in Medicare Beneficiaries During the 90-Day Follow-Up Period Following an AMI Admission	Nothing to Disclose
Katz	Marc	Review Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	What is the Impact of Complications During the Index Hospitalization on Resource Utilization During the 90-Day Follow-Up Period Associated With CABG Surgery Among Medicare Beneficiaries?	Nothing to Disclose
Katz	Marc	Acute Coronary Syndromes, Diagnosis,	Medicare Reimbursement Associated With an AMI Hospitalization	Nothing to Disclose
Katz	Marcelo	Management and Outcomes International CV Centers of Excellence: Leveraging the NCDR for Achieving High	and 90-Days Post-Discharge NCDR Registries: Moving Towards a Value Based Health Care in an ICOE in Brazil	Nothing to Disclose
Katz	Marcelo	Quality Care Coronary Angiography, Intra-Vascular Imaging,	High Non-High-Density Lipoprotein Cholesterol Levels Predict	Nothing to Disclose
raz.	Warecio	Revascularization and Outcomes	Enhanced Periprocedural Inflammatory Response Following Percutaneous Coronary Intervention in Stable Ischemic Heart Disease Patients	Houring to Escribe
Katz	Moshe	Anti-Platelet Therapies: Always a Sticky Topic		Nothing to Disclose
Katz	William	Nuclear Cardiology: Quality	Increasing Equipment Vintage Predicts Poor Laboratory Quality and Delay in Accreditation: An Evaluation by IAC Echocardiography and Nuclear Accreditation Status	Nothing to Disclose
Katz	William	The Challenges of Outcome Prediction in Valvular Heart Disease	Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era	Nothing to Disclose
Katz	William	TAVR Outcomes Prognostication	Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit	Nothing to Disclose
Katzoff	Michael	Arrhythmias and Clinical EP: Basic 3	Impact of Obstructive Sleep Apnea Severity on Cardiac Events in Patients With Normal or Prolonged Ventricular Repolarization	Nothing to Disclose
Kaufman	Elizabeth	06. Arrhythmias and Clinical EP: Other Team 2		Nothing to Disclose
Kaufman	James	Value, Advocacy and the Future of Adult Congenital and Pediatric Cardiology	Panelist	Nothing to Disclose
Kaufman	James	Value, Advocacy and the Future of Adult Congenital and Pediatric Cardiology	Panelist	Nothing to Disclose
Kaufman	James	Value, Advocacy and the Future of Adult Congenital and Pediatric Cardiology	Medicaid Strategies in Children's Health Care	Nothing to Disclose
Kaufman	James	Value, Advocacy and the Future of Adult	Medicaid Strategies in Children's Health Care	Nothing to Disclose
Kaufmann	Philipp	Congenital and Pediatric Cardiology Non Invasive Imaging: Expanding Clinical Applications	Computed Tomography-Derived Corrected Contrast Opacification Decrease Predicts Reduced Relative Flow Reserve Derived From PET Myocardial Perfusion Imaging	Nothing to Disclose
Kaufmann	Philipp	Non Invasive Imaging: Coronary Calcium	Prospective Evaluation of Low-Dose Coronary Calcium Scoring With	Nothing to Disclose
Kaufmann	Philipp	Scoring and CV Risk Assessment Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Reduced Tube Voltage Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography: The CONFIRM (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	Nothing to Disclose

Contract of the Contract of th				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Kaufmann	Philipp	Non Invasive Imaging: Prognostic Implications of CT Angiography	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	Nothing to Disclose
Kaufmann	Philipp	Non Invasive Imaging: Prognostic Implications of CT Angiography	Long-Term Prognostic Value of Computed Tomography-Derived Corrected Contrast Opacification Decrease in Patients With Coronary Stenosis	Nothing to Disclose
Kaufmann	Phillip	Great Debates in Cardiac MRI	Debate Pro: Cardiac MRI and DNA DS Breaks	Nothing to Disclose
Kaufmann	Phillip	Radiation from Diagnostic Imaging: Risk-	Panelist	Nothing to Disclose
		benefit Analysis		
Kaufmann	Phillip	Radiation from Diagnostic Imaging: Risk-	Radiation Risks: Non-ionizing Radiation	Nothing to Disclose
I/al	Dadasa	benefit Analysis	The High Cost of Law Assity New CT Comment Florestics Assite	Nothing to Displace
Kaul	Padma	Unusual Presentations of ACS	The High Cost of Low Acuity Non ST-Segment Elevation Acute Coronary Syndrome Admissions to the Coronary Care Unit: An Analysis of National Population Health Data	Nothing to Disclose
Kaul	Padma	Percutaneous Coronary Intervention: Lessons From the Real World	Nine Year Trends in Cause-Specific Mortality After Percutaneous Coronary Intervention: Observations From the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Registry	Nothing to Disclose
Kaul	Prashant	Radial Access Mini-Symposium I	Case Presentation: Complex Transradial PCI	CONSULTANT FEES/HONORARIA - Volcano Corp.
Kaul Kaul	Prashant Prashant	Radial Access Mini-Symposium II Practicum on Tools for CHIP (Complex and Higher-Risk Procedures in Indicated Patients)	Case Presentation: Radial CHIP, Atherectomy CTO PCI What You and Your Team Needs to Be Able to Complete the Task	CONSULTANT FEES/HONORARIA - Volcano Corp. CONSULTANT FEES/HONORARIA - Volcano Corp.
Kaul	Prashant	Coronary Physiology and Microcirculation	Is FFR/iFR Useful in the Assessment of the Non-Infarct Bed in Acute	CONSULTANT FEES/HONORARIA - Volcano Corp.
Kaul	Prashant	Interventional Complexity and Complications	NSTEMI and STEMI Characteristics and Outcomes of Patients With Clinically Silent Peri- Procedural Hemoglobin Drops as Compared to Patients With Overt	CONSULTANT FEES/HONORARIA - Volcano Corp.
			Bleeding Following Percutaneous Coronary Intervention	
Kaul	Sanjay	02. Acute and Stable Ischemic Heart Disease: Clinical Team 9	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boehringer-Ingelhiem, FDA Cardiorenal and Endocrine and Metabolic Advisory Panels, Novo Nordisk Inc., Respicardia, Sanofi-Aventis; OTHER - JNJ
Kaul	Sanjiv	Imaging of Myocardial Blood Flow: A Multimodality Approach	Echocardiographic Measurement of Myocardial Blood Flow	SPEAKER'S BUREAU - Bracco
Kaul	Sanjiv	Biomarkers and Targets for Ischemic Heart	Ultrasound Increases Myocardial Blood Flow in Acute Myocardial Ischemia Without Reducing Infarct Size	SPEAKER'S BUREAU - Bracco
Kaul	Sanjiv	Disease New Perspectives on CAD Risk Factors	Ischemia Without Reducing Infarct Size ACC Poster Moderator	SPEAKER'S BUREAU - Bracco
Kaul	Sanjiv	28. Non Invasive Imaging: Echo Team 3	Suggested Reviewer	SPEAKER'S BUREAU - Bracco
Kaur	Gagandeep	Arrhythmias and Clinical EP: Basic 2	Utility of an Esophageal Screening Protocol in Preventing Atrio-	Nothing to Disclose
	9		Esophageal Fistula After Atrial Fibrillation Ablation	· · · · · · · · · · · · · · · · · · ·
Kaur	Gagandeep	Arrhythmias and Clinical EP: Basic 5	Cryoballoon Ablation Targeting Left Atrial Fibrosis Produces Similar	Nothing to Disclose
Kavanagh	Katherine	Acute Coronary Syndromes, Diagnosis,	Outcomes in Paroxysmal and Persistent Atrial Fibrillation The Presence of Fragmented QRS Complexes Early After Acute	Nothing to Disclose
		Management and Outcomes	Myocardial Infarction Is Associated With Subsequent Lack of Favorable Left Ventricular Remodeling	-
Kaveti	Punita	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Hypertrophic Obstructive Cardiomyopathy-Like Pathophysiology Post Mitral Valve Repair	Nothing to Disclose
Kavousi	Maryam	Emerging Developments in HFpEF and	Sex Differences in Risk Factors for Longitudinal Changes in Left	Nothing to Disclose
Kawai	Kazuya	Arryhthmias FIT Clinical Decision Making: Heart Failure and	Ventricular Diastolic Function: The Rotterdam Study Primary Cardiac Lymphoma: Early Initiation of Chemotherapy Is	Nothing to Disclose
Tanai	riazuju	Pulmonary Hypertension	Critical to Save Lives of Patients	Trouming to Biodicoc
Kawaji	Keigo	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Implementation of a Wideband Late Gadolinium Enhancement Cardiac Magnetic Resonance Protocol to Improve Assessment of Myocardial Scar in Patients With Implantable Cardioverter Defibrillators	Nothing to Disclose
Kawamori	Hiroyuki	Refining TAVR Outcomes	Frame Geometry and Hemodynamic Findings of Sapien 3 Transcatheter Heart Valve in Patients With Bicuspid Aortic Valve Disease	Nothing to Disclose
Kawamoto	Hiroyoshi	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Provisional Versus Elective Two-Stenting Strategy for Unprotected True Left Main Bifurcation Lesions: A Sub-Study From Fails 2 Study	Nothing to Disclose
Kawamoto	Hiroyoshi	Endovascular Therapy: Running From Risk	The Impact of Patent Below the Knee Vessels on Stenting for Chronic Total Occlusions in the Superficial Femoropopliteal Artery	Nothing to Disclose
Kawamoto	Kris	Advances in HCM, PPCM and Other	Breastfeeding Is Not Associated With Worse Outcomes in	Nothing to Disclose
Kawasaki	Tomohiro	Cardiomyopathies Unusual Presentations of ACS	Peripartum Cardiomyopathy Incidence and Predictors of Lesion Specific Ischemia by FFR _{CT} : Learnings From the International ADVANCE	Nothing to Disclose
Kawata	Hiro	FIT Clinical Decision Making: Arrhythmias and	Registry A Case of Defibrillation Threshold Testing Failure With Subcutaneous Implantable Defibrillator Implantation in a	Nothing to Disclose
		Electrophysiology	Hypertrophic Cardiomyopathy Patient	
Kawata	Hiro	FIT Clinical Decision Making: Arrhythmias and Electrophysiology		Nothing to Disclose
Kawsara	Mohammad Akram	Valvular Heart Disease: Endocarditis	Trend and Outcomes of Infective Endocarditis Treated With Surgical Valvular Replacement Insight From the Nationwide Inpatient Sample	Nothing to Disclose
Kawsara	Mohammad Akram	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	The Feasibility and Safety of Same Day Discharge for All Comers After Elective Percutaneous Coronary Interventions	Nothing to Disclose
Kawsara	Mohammad Akram	Interventional Cardiology: TAVR 2	Outcomes of Transcatheter and Surgical Aortic Valve Replacement in Patients With Hepatic Cirrhosis: Insight From Nationwide Inpatient Sample	Nothing to Disclose
Kawsara	Mohammad Akram	Outcomes in Valvular Heart Disease	Trends and Outcomes in Dialysis Requiring Acute Kidney Injury After Aortic Valve Replacement Insight From the Nationwide Inpatient Sample	Nothing to Disclose
Kawsara	Mohammad Akram	Novel Determinants of Outcomes in VHD	Racial Disparity in Aortic Valve Replacement Outcomes: Insight	Nothing to Disclose
Kawsara	Mohammad Akram	Valvular Heart Disease With CKD or Cirrhosis	From National Inpatient Sample Trends and Outcomes of Mitral Valve Replacement in Patients With	Nothing to Disclose
Kawsara	Mohammad Akram	Sex Disparity in VHD Outcomes	Hepatic Cirrhosis: Insight From National Inpatient Sample Contemporary Trends and Outcomes of Isolated Aortic Valve Replacement in Females in The United States: Understanding the	Nothing to Disclose
Kawut	Steven	Non Invasive Imaging: MR Scar and Perfusion	Gender Gap Association of Right Atrial Function With Incident Atrial Fibrillation:	Nothing to Disclose
			The Multi-Ethnic Study of Atherosclerosis (MESA)	
Kay	Joseph	09. Congenital Heart Disease: Adult Team 2	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Actelion
Kay	W.	Exercise in Congenital Heart Disease	Co-Chair	Nothing to Disclose
Kaya	Hakki	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Potential Clinical Application of LCZ696 in Real Life Clinical Practice Based on 2016 ACC/AHA/HFSA and ESC Heart Failure Guidelines Criteria: Results From TREAT HF Study	Nothing to Disclose
Kayani	Gloria	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Treatment and Outcomes of Patients With Nonvalvular Atrial Fibrillation According to Guideline-Defined Anticoagulation Thresholds: Results From the GARFIELD-AF Registry	SALARY - Employed by Roche Products LTD until September 2012
Kayani	Gloria	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Early Mortality in Patients With New Onset Atrial Fibrillation: Results From the GARFIELD-AF Registry	SALARY - Employed by Roche Products LTD until September 2012
L		1= = Triorapido	process of an account regions	p=+ r=

and a				
Last Name Kayani	First Name Gloria	Session Title Stroke and AF: Thinking About the Heart	Presentation Title The Prescribing of Antiplatelet Therapy Only in Patients With Nonvalvular Atrial Fibrillation: Results From the GARFIELD-AF	Disclosures SALARY - Employed by Roche Products LTD until September 2012
Kaye	David	Emerging Developments in HFpEF and Arryhthmias	Registry Age Specific Hemodynamic Features in HFPEF: Implications for Therapy	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cardiac Dimensions Inc,Osprey Medical; RESEARCH/RESEARCH GRANTS - DC Devices
Kayikcioglu	Meral	Emerging Issues in CV Disease Management: International Perspectives From the Brazilian Society of Cardiology, Turkish Society of Cardiology, and American College of Cardiology	Familial Hypercholesterolemia in Turkey	Nothing to Disclose
Kayikcioglu	Meral	Advances in Pulmonary Arterial Hypertension	Comparisons of Invasive and Non-Invasive Cardiac Output Measurment Methods in Pulmonary Hypertension	Nothing to Disclose
Kaymaz	Cihangir	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Survival Analysis From THALES Study, A Large Nation-Wide Registry on Pulmonary Arterial Hypertension Associated With Congenital Heart Disease	Nothing to Disclose
Kaymaz	Cihangir	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Clinical, Biochemical, Neurohumoral, Echocardiographic and Hemodynamic Characteristics in Relation to Survival in Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: Insights From Euphrates Study	Nothing to Disclose
Kaymaz	Cihangir	Understanding Pulmonary Vascular Disease: From Bench to Bedside	Short-Term Intravenous lioprost Treatment Improves Clinical Status and Neurohumoral Measures in Clinical Worsening Episodes of Precapillary Pulmonary Hypertension Regardless of the Background Treatments: Insights From Euphrates Study	CONSULTANT FEES/HONORARIA - Bayer
Kaymaz	Cihangir	Understanding Pulmonary Vascular Disease: From Bench to Bedside	The Impaired Endothelium-Dependent and Endothelium- Independent Systemic Arterial Vasodilatory Reserve in Pulmonary Hypertension Regardless of the Clinical Group	Nothing to Disclose
Kaymaz	Cihangir	Predicting the Future: Observations and Discoveries From Registries and Databases	Pulmonary Vascular Resistance, but Not Diastolic Pulmonary Gradient, May Predict Survival in Pulmonary Hypertension: Insights From Euphrates Study	CONSULTANT FEES/HONORARIA - Bayer
Kaymaz	Cihangir	Predicting the Future: Observations and Discoveries From Registries and Databases	The Correlates and Prognostic Impact of Pulmonary Arterial Pulse Pressures, Diastolic and Transpulmonary Pressure Gradients in Pulmonary Hypertension: Insights From Euphrates Study	CONSULTANT FEES/HONORARIA - Bayer
Kaymaz	Cihangir	Predicting the Future: Observations and Discoveries From Registries and Databases	An Ignored but Not Unusual Complication of Severe Pulmonary Hypertension - Ostial Compression of Left Main Coronary Artery by Aneurysmal Pulmonary Artery: Insights From Euphrates Study	Nothing to Disclose
Kaza	Aditya	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Prediction Tool for Congenital Heart Surgery Length of Stay	Nothing to Disclose
Kaza	Aditya	Congenital Heart Disease Surgery: Updates and Innovations	Targeted Increase in Pulmonary Blood Flow in a Bidirectional Glenn Circulation	Nothing to Disclose
Kazmirczak	Luis Felipe	Novel Echocardiographic Methods for Assessing Cardiac Function	Echocardiographic Evidence for Left Ventricular Recovery After Refractory Ventricular Fibrillation Cardiac Arrest Treated With Primary Angioplasty and Extracorporeal Membrane Oxygenation	Nothing to Disclose
Kazmirczak	Luis Felipe	New Technologies in Echocardiography	Transthoracic Echocardiography to Guide Extracorporeal Membrane Oxygenation Decannulation After Refractory Ventricular Fibrillation Cardiac Arrest Treated With Primary Angioplasty: A Turndown Protocol	Nothing to Disclose
Kazuki	Tanaka	Optimizing the Care of ACS Patients	Novel Utilization of DAPT Score as a Predictor of Long-Term Clinical Outcomes in Hemodialysis Patients on Prolonged Dual Antiplatelet Therapy After Coronary Intervention	Nothing to Disclose
Kedev	Sasko	Novel Developments in Acute Coronary Syndromes	Incidence and Predictors of No Reflow Phenomenon: Insights From the TOTAL Trial	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,Meril,Terumo
Kedev	Sasko	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Acute Coronary Syndrome: The Risk to Be Young and Women	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,Meril,Terumo
Kedev	Sasko	18. Interventional Cardiology: Carotid and Endovascular Intervention Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,Meril,Terumo
Keech	Anthony	Opening Session and the Joint American College of Cardiology and Journal of American College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture	Primary Results of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial	CONSULTANT FEES/HONORARIA - Amgen Inc.,Mylan,Pfizer
Keech	Anthony	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	Primary Results of EBBINGHAUS, a Cognitive Study of Patients Enrolled in the FOURIER Trial	CONSULTANT FEES/HONORARIA - Amgen Inc.,Mylan,Pfizer
Keegan	Patricia	Great Minds Think Differently: Multidisciplinary Approach to Advanced Therapies	Update on Interventions for Congenital Heart Disease: Emerging Therapies for the Treatment of Pulmonic Stenosis	CONSULTANT FEES/HONORARIA - Abbott Lifesciences (Evalve), Edwards Lifesciences
Keegan	Patricia	Moderated, Case-Based TAVR Management	Panelist	CONSULTANT FEES/HONORARIA - Abbott Lifesciences (Evalve),Edwards Lifesciences
Keegan	Patricia	Case Studies from the Guidelines for Clinicians	Aortic Stenosis and Catheter Therapy Cases	CONSULTANT FEES/HONORARIA - Abbott Lifesciences (Evalve),Edwards Lifesciences
Keegan	Patricia	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Pulmonary Venous Waveforms Predict Ventricular Remodeling After Percutaneous Mitral Valve Repair	CONSULTANT FEES/HONORARIA - Abbott Lifesciences (Evalve), Edwards Lifesciences
Keegan	Patricia	TAVR Outcomes Prognostication	Predictors and Clinical Outcomes of Next-Day Discharge After	CONSULTANT FEES/HONORARIA - Abbott Lifesciences
Keeley	Ellen	Innovations in Practice Management and	Transcatheter Aortic Valve Replacement The Impact of Patient Activation in Patients Post-Myocardial Infarction	(Evalve),Edwards Lifesciences Nothing to Disclose
Keeley	Ellen	Social Media Acute Coronary Syndromes, Diagnosis,	Infarction Prediction of 30-Day Readmissions in Patients Admitted for Acute Myocardial Infarction (AMI)	Nothing to Disclose
Keita	Koseki	Management and Outcomes The Evolving World of LVADs, Transplant and Other Nevel Discovering	Psoas Muscle Mass Index Predicts Mortality in Patients With Heart	Nothing to Disclose
Keleshian	Vasken	Other Novel Discoveries Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Failure With Preserved Ejection Fraction Acute Myocardial Infarction in Patients on Chronic Innate Immunosuppression Therapy	Nothing to Disclose
Kelle	Angela	Syndrome FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Delivery and Management of Complete Ectopia Cordis: A Multidisciplinary Approach	Nothing to Disclose
Kelle	Angela	Congenital Heart Disease: Innovations in	Association of Increased Total Atrial Volume With Clinical Heart	Nothing to Disclose
Kelleman	Mike	Single Ventricle Heart Disease Highlighted Original Research: Congenital Heart Disease and the Year in Review	Failure Status in Hypoplastic Left Heart Syndrome Transcatheter Ductal Stenting Versus Surgical Systemic-to- Pulmonary Artery Shunts: Altering Dogma at a High-Volume Institution	Nothing to Disclose
Kelleman	Mike	Congenital Heart Disease Surgery: Updates and Innovations	Institution Long-Term Transplant-Free Survival for Arterial Switch Versus Atrial Switch in Treatment of Transposition of the Great Arteries: A Study From the Pediatric Cardiac Care Consortium	Nothing to Disclose
Keller	Stuart	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	Nothing to Disclose
Keller	Stuart	Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes	SALARY - Eli Lilly and Company
Kelli	Heval Mohamad	Updates on Risk Factors for Cardiovascular	Central Obesity Predicts Circulating Progenitor Cell Levels	Nothing to Disclose
	1	Disease	<u> </u>	I .



Last Name	First Name	Session Title	Presentation Title	Disclosures
Kellman	Peter	Non Invasive Imaging: MR Characterization and Function	Validation of CMR-Derived Left Ventricular Strain Measurements by Free-Breathing Motion-Corrected Cine Imaging	Nothing to Disclose
Kellman	Peter	Imaging the Athlete's Heart	Free-Breathing MRI Evaluation of Cardiac Volume Measurements	Nothing to Disclose
Kellman	Peter	Non Invasive Imaging: MR Heart Failure and	During In-Scanner Exercise Cardiovascular Magnetic Resonance in the Evaluation of Fibrofatty	Nothing to Disclose
reman	T Clor	Pulmonary Hypertension	Infiltration for Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C)	Techning to Discusse
Kells	Catherine	Strategies for Prevention of Cardiovascular	Co-Chair	Nothing to Disclose
		Disease: International Perspectives From the Canadian Cardiovascular Society, Cardiac Society of Australia and New Zealand, and American College of Cardiology		
Kelly	Faith	Timely Topics in Acute Coronary Syndromes	Evaluation of Exercise Response in Young Adults in a High Risk Occupation: Submaximal Invasive Cardiopulmonary Exercise	Nothing to Disclose
Kelly	Noreen	Maximally Effective Vascular Care: Vascular Collaborative Team Care in Action	Testing in Active Duty Soldiers Case Presentation #3: A 55 Year Old Woman with an Acute Type B Dissection, 4 cm AAA, and Atypical Back Pain	Nothing to Disclose
Kelly	Noreen	Traditional and Novel Factors Used to Assess	Multiple Biomarkers for Predicting Major Adverse Cardiac Events in	Nothing to Disclose
		the Risk of, and Used for the Treatment of, Coronary Artery Disease	At-Risk Patients Undergoing Diagnostic Coronary Angiography: Results From the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study	
Kelly	Rosemary	Interventional Cardiology: PCI and TAVR in Complex Patients	Calcification in the Basal Septum, but Not Membranous Septal Length, Predicts AV Conduction Disturbance and Pacemaker Implantation Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve (S3)	Nothing to Disclose
Kelsey	Sheryl	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Prognostic Risk Factors for Heart Failure Hospitalization in Women Without Obstructive Coronary Disease: An Ancillary Study From the Women's Ischemia Syndrome Evaluation (WISE)	Nothing to Disclose
Keltner	Emily	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Use of Wearable Cardioverter Defibrillator Associated With Clinical Guideline Compliance in Management of Heart Failure With Reduced Ejection Fraction	SALARY - Zoll
Kenchaiah	Satish	Innovations in Education	Tobacco Cessation: A Knowledge, Attitude and Practice (KAP) Survey Among Residents	Nothing to Disclose
Kenigsberg	Ben	Imaging of Cancer-Treatment Associated CV Toxicity: Applying Guidelines to Clinical Practice	Why Cardiologists Need to Engage - Epidemiology of Cancer Survivorship	Nothing to Disclose
Kennedy	Jamie	Advances in HCM, PPCM and Other	Systemic Arterial Pulsatility Index (SAPi) Predicts Adverse	Nothing to Disclose
Kennedy	Jamie	Cardiomyopathies FIT Clinical Decision Making: Heart Failure and	Outcomes in Advanced Heart Failure Patients Submassive Pulmonary Embolism With Concomitant Paradoxical	Nothing to Disclose
		Pulmonary Hypertension	Embolism Through Patent Foramen Ovale	-
Kennedy	Jamie	Advances in Pulmonary Arterial Hypertension	Pulmonary-Systemic Pulse Pressure Ratio Is Associated With Adverse Clinical Outcomes in Group 1 Pulmonary Hypertension	Nothing to Disclose
Kennedy	Kevin	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Outcomes of Concomitant Acute Kidney Injury and Hospital Acquired Anemia in Patients With Myocardial Infarction: The TRIUMPH Study	Nothing to Disclose
Kennedy	Kevin	Interventional Cardiology: PCI and TAVR in Complex Patients	Management of Patients With Cardiac Arrest in New York Before	Nothing to Disclose
Kennedy	Kevin	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	and After Public Reporting Policy Changes Implications of the FDA Approval of PCSK9 Inhibitors for Contemporary Cardiovascular Practice: Findings From the	Nothing to Disclose
Kennedy	Kevin	Highlights in Vascular Medicine Research	NCDR [®] Research to Practice (R2P) Project Thirty-Day Readmissions Following Endovascular or Surgical Treatment for Critical Limb Ischemia: Analysis of the Nationwide	Nothing to Disclose
Kennedy	Kevin	Optimizing Treatment of Peripheral Artery	Readmissions Database Nationwide Readmissions Following Lower Extremity Arterial	Nothing to Disclose
Kennedy	Kevin	Disease Finding Out What Works in Pediatric and Congenital Heart Disease	Procedures Risk of Catastrophic Outcome Following Cardiac Catheterization for Pulmonary Hypertension: An Analysis of Data From the Impact	Nothing to Disclose
		3	Registry	
Kerny Kereiakes	Damien Dean	09. Congenital Heart Disease: Adult Team 2 Interventional Live Case Session VI: Bioresorbable Scaffolds and Imaging from St. Vincent Hospital (Indianapolis, IN)	Suggested Reviewer Panelist	Nothing to Disclose CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific, HCRI, Micell Technologies, Inc., SANOFI, Svelte Medic Systems, Inc.; OTHER - Ablative Solutions, Inc.
Kereiakes	Dean	Late-Breaking Clinical Trials: Interventional	Everolimus-Eluting Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Disease: Two-Year Outcomes From the	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific, HCRI, Micell Technologies, Inc., SANOFI, Svelte Media
Kereiakes	Dean	Complex PCI in 2017	ABSORB III Trial Co-Chair	Systems, Inc.; OTHER - Ablative Solutions, Inc. CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,HCRI,Micell Technologies, Inc.,SANOFI,Svelte Medic
Kereiakes	Dean	Highlighted Original Research: Interventional	Clinical, Angiographic and Procedural Correlates of Absorb Scaffold	Systems, Inc.; OTHER - Ablative Solutions, Inc. CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston
		Cardiology and the Year in Review	Thrombosis: A Matched Multicenter Registry Analysis	Scientific,HCRI,Micell Technologies, Inc.,SANOFI,Svelte Medic Systems, Inc.; OTHER - Ablative Solutions, Inc.
Kereiakes	Dean	Considerations in Antiplatelet Therapy and in ACS	Impact of Coronary Anatomical Complexity on the Effect of Extended Duration Dual Antiplatelet Therapy: An Analysis From the Dual Antiplatelet Therapy Study	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific, HCRI, Micell Technologies, Inc., SANOFI, Svelte Medic Systems, Inc.; OTHER - Ablative Solutions, Inc.
Kereiakes	Dean	Refining PCI Technique and Outcomes	Three-Year Results From the EVOLVE II Randomized Trial: Late Clinical Outcomes With Bioresorbable Compared to Permanent Polymer Everolimus-Eluting	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific, HCRI, Micell Technologies, Inc., SANOFI, Svelte Medic Systems, Inc.; OTHER - Ablative Solutions, Inc.
Keren	Gad	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Absence of Clinical Triggering in Diabetic Patients With ST-Segment Elevation Myocardial Infarction Predicts Multiple Vessel Coronary Disease and Is Associated With Increased Mortality	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Medivalve
Keren	Gad	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Incidence and Outcomes of Early Left Ventricular Thrombus Formation Following ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Medivalve
Kern	Karl	Innovations in Education	Coronary Angiography Simulation Training Improves Image Interpretation Skills of Trainees Independent of Their Stage of Training	CONSULTANT FEES/HONORARIA - Physio-Control,Zoll Inc. SPEAKER'S BUREAU - Bard
Kern	Morton	FIT Forum: Mix and Mingle	 	CONSULTANT FEES/HONORARIA - Acist Medical, Merit Med Inc, Opsens Inc; SPEAKER'S BUREAU - Heartflow, St. Jude Medical Inc, Volcano Therapeutics
Kern	Morton	Late-Breaking Clinical Trials: Interventional	Co-Chair	CONSULTANT FEES/HONORARIA - Acist Medical, Merit Med Inc, Opsens Inc; SPEAKER'S BUREAU - Heartflow, St. Jude Medical Inc, Volcano Therapeutics
Kern	Morton	Coronary Physiology for the Assessment of Stable CAD	Co-Chair	CONSULTANT FEES/HONORARIA - Acist Medical, Merit Med Inc, Opsens Inc; SPEAKER'S BUREAU - Heartflow, St. Jude Medical Inc, Volcano Therapeutics
Kern	Morton	Coronary Physiology for the Assessment of Stable CAD	Case Presentation: My Best FFR Cases from the Last 20 Years	CONSULTANT FEES/HONORARIA - Acist Medical, Merit Med Inc, Opsens Inc; SPEAKER'S BUREAU - Heartflow, St. Jude Medical Inc, Volcano Therapeutics
Kern	Morton	Maintenance of Clinical Competencies in Invasive Coronary Imaging and Coronary	Case Presentation: FFR	CONSULTANT FEES/HONORARIA - Acist Medical, Merit Med Inc, Opsens Inc; SPEAKER'S BUREAU - Heartflow, St. Jude
Kern	Morton	Physiology What's New in the World of STEMI?	Case Presentation: FFR and Its Role in STEMI, If Any	Medical Inc, Volcano Therapeutics CONSULTANT FEES/HONORARIA - Acist Medical, Merit Med Inc, Opsens Inc; SPEAKER'S BUREAU - Heartflow, St. Jude
L				Medical Inc, Volcano Therapeutics

Last Name	First Name	Session Title	Presentation Title	Disclosures
Kern	Morton	19. Interventional Cardiology: Complex	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Acist Medical, Merit Medica
		Patients/Comorbidities Team 1		Inc,Opsens Inc; SPEAKER'S BUREAU - Heartflow,St. Jude Medical Inc,Volcano Therapeutics
Kerner	Arthur	Frontiers in Mitral Valve Disease and Treatment	Multicenter Trial of a Transfemoral System for Mitral Valve Annuloplasty: Up-to-2-Year Follow-Up Results	Nothing to Disclose
Kero	Tanja	Valvular Heart Disease: Mitral Valve Disease	Volumetric Quantification of Regurgitant Volume in Asymptomatic	Nothing to Disclose
			Severe Degenerative Mitral Regurgitation by Echocardiography and Cardiac MRI With Independent Validation of Forward Stroke Volume by Positron Emission Tomography	
Kesanakurthy	Srinivas	Coronary Angiography, Intra-Vascular Imaging,	Angiographic Phenotype and Clinical Outcomes of Patients With	Nothing to Disclose
Kesanakurthy	Srinivas	Revascularization and Outcomes Interventional Cardiology: Stent Failure	Malignancy Undergoing PCI Multimodality Intravascular Imaging to Evaluate Plaque	Nothing to Disclose
-		Analysis by Intravascuar Imaging	Characteristics in Patients With Diabetes Mellitus	
Kesanakurthy	Srinivas	Timely Topics in Acute Coronary Syndromes	Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions	Nothing to Disclose
Kesanakurthy	Srinivas	Optimizing the Care of ACS Patients	Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population	Nothing to Disclose
Keshishian	Allison	Arrhythmias and Clinical EP: Anticoagulation Issues	Real-World Comparison of Major Bleeding and Associated Costs Among Oral Anticoagulant-Naïve Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin in the US Medicare Population	SALARY - I am an employee of STATinMED Research, which is a paid consultant to Pfizer Inc, Bristol-Myers Squibb, the study sponsor.
Keshishian	Allison	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Compared to Warfarin Among Non-Valvular Atrial Fibrillation Patients in the US Medicare Population	SALARY - I am an employee of STATinMED Research, which is a paid consultant to Pfizer Inc, Bristol-Myers Squibb, the study sponsor.
Keshmiri	Hesam	FIT Clinical Decision Making: Heart Failure and	A Possible Simple Solution to a Challenging Problem in	Nothing to Disclose
Kesler	Kenneth	Pulmonary Hypertension Atrial Fibrillation and VT: Incorporating Novel	Management of Acute Decompensated Heart Failure Intravenous Amiodarone for Prevention of Atrial Fibrillation	Nothing to Disclose
		Risks Toward Decision Making	Following Esophagectomy: A Propensity Score-Matched Analysis	,
Kestenbaum	Bryan	Innovations in Cardiovascular Risk Assessment and Reduction	Vitamin D Levels and Autoantibodies in the Multi-Ethnic Study of Atherosclerosis (MESA): Implications for Cardiovascular Disease	Nothing to Disclose
Keteyian Keteyian	Steven Steven	I Can Do WHAT After My Heart Attack? Non Invasive Imaging: Role of Exercise Testing	Co-Chair Using Machine Learning to Define the Association Between	OTHER - Nimble Heart, Inc OTHER - Nimble Heart, Inc
Keteyian	Oleven	1 TOTAL INVASIVE III AYING. ROLE OF EXELLISE TESUNG	Cardiorespiratory Fitness and All-Cause Mortality: The FIT (Henry Ford Exercise Testing) Project	OTTER - Millible Healt, ille
Keteyian	Steven	Risky Business: Predicting Outcomes in Heart Failure	Chronotropic Incompetence and Long-Term Risk of Heart Failure: The Henry Ford Exercise Testing Project	OTHER - Nimble Heart, Inc
Keteyian	Steven	34. Prevention: Rehabilitation Team 1	Suggested Reviewer	OTHER - Nimble Heart, Inc
Keyvan	Nima	Improving Outcomes in the Athlete With Cardiovascular Disease	Pre-Existing Cardiac Disease, Exercise, Male Sex, and Young Age Are Risk Factors for Sudden Death Following Energy Drink Consumption	Nothing to Disclose
Kezbor	Safwan	Interventional Cardiology: Stent Failure	Multimodality Intravascular Imaging to Evaluate Plaque	Nothing to Disclose
Khachatryan	Tigran	Analysis by Intravascuar Imaging Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Characteristics in Patients With Diabetes Mellitus Glycemic Control in Insulin and Non-Insulin Dependent Diabetic Patients With ST Elevation Myocardial Infarction Predicts Time to	Nothing to Disclose
Khachatryan	Tigran	Coronary Artery Disease Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Presentation Ischemic Time and Risk Factors Associated With the Incidence of Cardiogenic Shock in Patients Presenting With ST Elevation	Nothing to Disclose
Khachatryan	Tigran	Coronary Artery Disease Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Myocardial Infarction Impact of Demographics and Socioeconomic Status on Mode of Transportation and Time to Presentation in Patients With ST	Nothing to Disclose
Khachatryan	Tigran	Coronary Artery Disease FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Elevation Myocardial Infarction Radial Artery Occlusion Recanalization Prior to Coronary Angiography	Nothing to Disclose
Khader	Shameer	Disease, and Vascular Medicine Interventional Cardiology: Intravascular Physiology and Endothelial Function	Atherosclerotic Plaque Morphology in Response to High Intensity Lipid Lowering Therapy by Multimodality Imaging Among Women	Nothing to Disclose
Khalid	Hussain	Acute Heart Failure: Evaluating Strategies to	and Men: A YELLOW-II Sub-study Risk of Heart Failure in Systemic Sclerosis	Nothing to Disclose
Khalid	Kainat	Prevent Readmissions FIT Clinical Decision Making: Non-Invasive	Coronary Artery Aneurysm in a Patient With Systemic Lupus	Nothing to Disclose
Khalid	Umair	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Interventional	Erythematosus Headache or Heartache: A Case of Reversible Cerebral	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Vasoconstriction Syndrome (RCVS) Likely Causing Coronary Vasospasms	
Khalighi	Koroush	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Long Term Sequelae of Kawasaki Disease	Nothing to Disclose
Khalil	Ramzi	The Best Structural Interventional Challenging	The First Case of Edward SAPIEN S3 Pulmonary Valve-in-Valve	Nothing to Disclose
Khalil	Ramzi	Cases FIT Clinical Decision Making: Non-Invasive	Deployment Cardiac Amyloidosis Masquerading as Severe Low-Flow, Low-	Nothing to Disclose
		Imaging and Valvular Heart Disease	Gradient, Low-Ejection Fraction Aortic Stenosis: "All That Glitters Is Not Gold"	
Khalili	Houman	Highlighted Original Research: Prevention and the Year in Review	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 16,721 Patients From 33 Randomized Clinical Trials	Nothing to Disclose
Khalili	Houman	Head to Toe: Outcomes of Endovascular	Atherectomy Is Associated With Lower Rates of Repeat Intervention	Nothing to Disclose
Khalili	Houman	Interventions Head to Toe: Outcomes of Endovascular Interventions	After Below Knee Peripheral Vascular Intervention Utilization of Distal Embolic Protection in Infrainguinal Peripheral Arterial Intervention: Insights From the Multicenter XLPAD Registry	Nothing to Disclose
Khalili	Houman	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Contemporary Use of Laser During Percutaneous Coronary Intervention: Results From the Laser Veterans Affairs (LAVA)	Nothing to Disclose
Khalili	Houman	Antithrombotic Therapy in Ischemic Heart	Multicenter Registry Ticagrelor Adherence After Drug Eluting Stent Placement at a	Nothing to Disclose
Khalili	Houman	Disease Innovations in Advocacy and Patient Centered	Large Academic Medical Center Diverse Perspectives and Training Paths in Cardiology. An Analysis	Nothing to Disclose
Khalili	Houman	Care Advances in Chronic Total Occlusion	of Authorship in the <i>Journal of the American College of Cardiology</i> Percutaneous Coronary Intervention of Coronary Chronic Total	Nothing to Disclose
		Intervention	Occlusions Improves Peak Oxygen Uptake During Cardiopulmonary Exercise Testing	
Khalili	Houman	Endovascular Therapy: Running From Risk	Predictors of Procedural Complications in Infrainguinal Endovascular Interventions	Nothing to Disclose
Khalique	Omar	Prosthetic Valve Assessment: Real or Illusion?	Case: Prosthetic Valve Regurgitation	CONSULTANT FEES/HONORARIA - Cardiac Implants,Edwards Lifesciences
Khalique	Omar	Interventional Cardiology: PCI and TAVR in	Refining the Classification of Severe, Symptomatic Aortic Stenosis	CONSULTANT FEES/HONORARIA - Cardiac Implants, Edwards
		Complex Patients	Using Flow and Gradient Measurements to Predict Outcomes Post- Transcatheter Aortic Valve Replacement	Lifesciences
Khalique	Omar	TAVR Outcomes Prognostication	High Baseline Valvuloarterial Impedence Predicts Worse 1-Year Outcomes After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Cardiac Implants, Edwards Lifesciences
Khambhati	Jay	Traditional and Novel Factors Used to Assess	Association Between Circulating Progenitor Cells and Outcomes in	Nothing to Disclose
		the Risk of, and Used for the Treatment of, Coronary Artery Disease	Patients With Coronary Artery Disease	

Last Name (Nambhada) Jay (Songenial nan Congenial Heart Desisson (Shambhada) Jay (Songenial nan Congenial Heart Desisson (Khambhada) Jupidates on Risk Factors for Cardiovascular (Desisse (Rhambhada) Jupidates on Risk Factors for Cardiovascular (Jupidates on Risk Factors for Cardiovascular (Jupidates on Risk Factors for Cardiovascular (Jupidates on Risk Factors for Cardiovascular (Jupidates on Risk Factors for Cardiovascular (Jupidates on Risk Factors for Cardiovascular (Jupidates on Risk Factors for Cardiovascular (Jupidates on Risk Factors for Cardiovascular (Jupidates on Risk Factors for Cardiovascular (Jupidates on Risk Factors for Cardiovascular (Rham (Jupidates on Risk Factors for Cardiovascular (Jupidates on Risk Factors for Cardiovascular (Jupidates on Risk Factors for Cardiovascular (Jupidates on Risk Factors for Cardiovascular (Jupidates on Risk Factors for Cardiovascular (Jupidates on Risk Factors for Cardiovascular (Jupidates on Risk) (J	
Congenital and Congenital reart Disease Khambhati Jay Updates in Stak Factors for Cardiovascular Chamseekaew Authamas Updates in Stable Ischemic Heart Disease Updates in Stable Ischemic Heart Disease Cardiology Acute and Stable Ischemic Heart Disease Efferent Vagal Activity for Fully Exert the Cardioprotection Against Cardiology Rham Abdur PCI for INSTEMI and Complex Patients With Multiple Co-Morbidiles Convolved International Cardiology Rham Abdur PCI for INSTEMI and Complex Patients With Multiple Co-Morbidiles Convolved International Cardiology Rham Abdur With Card We Be Frencies? Controvenses in Heart Falure Management of STEMI: International Perspectives From the Egyptian Society, and American College of Cardiology Rham Abigal FT Clinical Discision Making-Heart Failure and Pullicinical Pullicinical Pullicinical Pullicinical Pullicinical Pullicinical Pullicinical Pullicinical Pullicinical Pullicinical Pullicinical Pullicinical Pullicinical Pullicinical Pullicinical Pullicinical Pullicinical Pullicinical Pullicinical Pul	
Disease Namesekaew Juthamas Updates in Stable Ischemic Heart Disease Vagus Nerve Stimulation Requires Both jositateral and Contralateral Efferent Vagal Activity of Fully Sent Its Cardioprotection Against Cardiosis (Cardiosis Prevention, Adult National Prevention Adult Natio	
Volumense Volu	
Efferent Vagal Activity for Fully Eart Its Cardioprotection Against Cardiacy International Cardials International Procession Against Cardials International Procession Against Cardials International Procession Against Cardials International Procession Against Cardials International Procession Against Cardials International Procession International Procession International Procession International Procession International Procession International Procession International Procession International Procession International Procession International Procession International Procession International Procession International Procession International Internati	
Multiple Co-Morbidiles Moral Why Cart We Be Friends? Controversies in Heart Falure Management of TEM: Why Cart We Be Friends? Controversies in Heart Falure Management of TEM: Variations in Management of TEM: Variations in Management of TEM: Variations in Management of TEM: Variations in Management of TEM: Variations in Management of TEM: Variations in Management of TEM: Co-Chair Co-C	
Manual M	
Abid Variations in Management of STEMI: International Perspectives From the Syptian Society of Cardiology, Pakstan Cardiac Society, and American College of Cardiology and American College of Cardiology and American College of Cardiology and American College of Cardiology and American College of Cardiology and Experience of Congenital and Congenital Heart Disease FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Isochemic Heart Disease, and Vasabular Medicine FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Isochemic Heart Disease, and Vasabular Medicine FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Isochemic Heart Disease, and Vasabular Medicine FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Isochemic Heart Disease, and Vasabular Medicine FIT Clinical Decision Making: Interventional Cardiology, Polymore Making: Interventional Cardiology, Polymore Making: Interventional Cardiology Syndroms. Valuation of Treatment of Coronary Artery Disease Treatment of Evaluation and Treatment Research: Valuation and Treatment Research: Valuation and Treatment Research: Valuation and Treatment Research: Valuation and Treatment Research: Valuation and Treatment Research: Valuation American Polymore Making: Polymo	
Khan	
Pulmonary Hypertension Fit Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Pit Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Valvular Heart Disease Pit Clinical Decision Making: Heart Failure and Pulmonary Hypertension Pit Clinical Decision Making: Heart Failure and Pulmonary Hypertension Pit Clinical Decision Making: Heart Failure and Pulmonary Hypertension Pit Clinical Decision Making: Heart Failure and Pulmonary Hypertension Pit Connary Syndrome Pit Clinical Decision Making: Heart Failure and Pulmonary Hypertension Pit Clinical Decision Making: Heart Failure and Pulmonary Hypertension Pit Clinical Decision Making: Heart Failure and Pulmonary Hypertension Pit Clinical Decision Making: Heart Failure and Pulmonary Hypertension Pit Clinical Decision Making: Heart Pailure and Pulmonary Hypertension Pit Clinical Decision Making: Heart Pailure and Pulmonary Hypertension Pit Clinical Decision Making: Heart Pailure and Pulmonary Hypertension Pit Clinical Decision Making: Heart Pailure and Pulmonary Hypertension Pit Pulmonary Hypertension P	
Eesha FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Schemic Heart Disease, and Vascular Medicine Farrukh FIT Clinical Decision Making: Heart Failure and Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Nothing to Disclose Coronary Attent Police Pulmonary Hypertension Farrukh FIT Clinical Decision Making: Heart Failure and Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Nothing to Disclose Coronary Attent Police Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Nothing to Disclose Coronary Attent Police Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Nothing to Disclose Coronary Attent Police Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Nothing to Disclose Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Nothing to Disclose Pulmonary Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Nothing to Disclose Pulmonary Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Pulmonary Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Nothing to Disclose Pulmonary Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Pulmonary Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Pulmonary Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Pulmonary Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Pulmonary Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Pulmonary Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Pulmonary Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Pulmonary Hypereosinophilic Endomyocardial Fibrosis Mimicking Acute Pulmonary Hypereosinophilic Endomyocardial Fibrosis M	
Farrukh Firr Clinical Decision Making: Heart Failure and Hyporeosinophilic Endomyocardial Fibrosis Mimicking Acute Dufmonary Hypertension Coronary Atheron	
Irfan	
Khan	
Real-World Cohort With Atherosclerotic Cardiovascular Disease Real-World Cohort With Atherosclerotic Cardiovascular Disease Nothing to Disclose	
Complex Patients	
Disease and the Year in Review Resonance Khan Mohamamd Non Invasive Imaging: MR Structure and Quantitative Measurements on Cardiac Magnetic Resonance to Differentiate Benign Versus Malignant Masses: A Pilot Study Logarity of Miral Regurgitation and Function Khan Mohammad Non Invasive Imaging: MR Characterization and Function Khan Mohammad Valvular Heart Disease: Mitral Valve Disease Cardiac Magnetic Resonance Imaging: MR Characterization and Function Khan Mohammad Valvular Heart Disease: Mitral Valve Disease Cardiac Magnetic Resonance Imaging: MR Othing to Disclose Cardiac Magnetic Resonance Imaging Khan Muhammad Obesity Management in 2017: Weighing the Issues Khan Muhammad Afzal Vascular Medicine: Novel Risk Measures in Arterial Diseases African-Americans Khan Shaida The Evolving World of LVADs, Transplant and Other Novel Discoveries Khan Antithrombotic Therapy in Ischemic Heart Disease in Arican-Americans Khan Aleem Acute Coronary Syndromes, Diagnosis, Management and Outcomes Primary Mitral Regurgitation: Insights From Cardiovascular Magnetic Resonance Images Measures to Differentiate Benign Versus Malignant Masses: A Pilot Study Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Disease in African-Americans Nothing to Disclose Nothing to Disclose Oradiac Artrophy: A Novel Mechanism for Duchenne Muscular Dystrophy (DMD)-Associated Cardiomyopathy Changes in Thrombotic Parameters in Patients With Refractory Apieresis Apieresis Khand Aleem Acute Coronary Syndromes, Diagnosis, Management and Outcomes Management and Outcomes Apheresis Apheresis Apheresis Apheresis Apheresis (the Macros Study-	
Valuvular Heart Disease Differentiate Benign Versus Malignant Masses: A Pilot Study Subviva	
Elevated Myocardial Extracellular Volume Fraction (ECV) and its and Function Prognostic Significance in Diabetic Individuals Nothing to Disclose Prognostic Significance in Diabetic Individuals Nothing to Disclose Prognostic Significance in Diabetic Individuals Nothing to Disclose Prognostic Significance in Diabetic Individuals Nothing to Disclose Prognostic Significance in Diabetic Individuals Nothing to Disclose Prognostic Significance in Diabetic Individuals Nothing to Disclose Prognostic Significance in Diabetic Individuals Nothing to Disclose Prognostic Significance in Diabetic Individuals Nothing to Disclose Prognostic Significance in Diabetic Individuals Nothing to Disclose Prognostic Significance in Diabetic Individuals Nothing to Disclose Prognostic Significance Prognostic Significance in Diabetic Individuals Nothing to Disclose Prognostic Significance Pro	
Khan Mohammad Valvular Heart Disease: Mitral Valve Disease Inter-Study Reproducibility of Mitral Regurgitation Quantitation Using Nothing to Disclose Cardiac Magnetic Resonance Imaging Nothing to Disclose Cardiac Magnetic Resonance Imaging Nothing to Disclose Nothin	
Muhammad Obesity Management in 2017: Weighing the Issues A Meta-Analysis of Cardiovascular Safety of FDA Approved Anti Obesity Drugs	
Muhammad Afzal Vascular Medicine: Novel Risk Measures in Arterial Diseases Naiffold Capillaroscopy for the Identification of Microvascular Nothing to Disclose	
Khan	
Other Novel Discoveries Dystrophy (DMD)-Associated Cardiomyopathy	
Disease Angina and Raised Lipoprotein(a) Treated With Lipoprotein	
Management and Outcomes Single High Sensitivity Troponin T in Suspected Acute Coronary Syndromes: Prospective Cohort Study of Undetectable Troponin T Versus Low Risk Timi, Grace and Heart Scores (the Macros Study-	
Mersey Acute Coronary Syndrome Rule-Out Study)	
Khand Aleem Acute Coronary Syndromes, Diagnosis, Modified Heart Score Improves Early, Safe Discharge for Suspected Acute Coronary Syndromes: A Prospective Cohort Study With Recalibration of Risk Scores to Undetectable High Sensitivity Troponin T Limits	
Khandelwal Abha The Consequences of Sex: Women and Panelist Nothing to Disclose Pregnancy Across the Spectrum	
Khandelwal Abha Diabetes and Other Issues in Cardiovascular Insulin Resistance Associates With Adverse Cardiac Remodeling in Prevention Insulin Resistance Associates With Adverse Cardiac Remodeling in Prevention the Absence of Hypertension in Young South Asians	
Khandelwal Akshay Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Nothing to Disclose	
Review Khandelwal Akshay Considerations in Antiplatelet Therapy and in ACS Readmission and Long-Term Mortality in Older Patients Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium	
Khandelwal Akshay FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine State of Cardiology Acute and Stable Ischemic Heart Disease, and Vascular Medicine	
Khandelwal Akshay Engage @ ACC.17 Studio: Heart Teams in Action: Complex Coronary Revascularization Co-Chair Nothing to Disclose	
Khandelwal Akshay Engage @ ACC.17 Studio: Meet the Acute and Co-Chair Nothing to Disclose Stable Heart Disease Legends	
Khandelwal Akshay 03. Acute and Stable Ischemic Heart Disease: Suggested Reviewer Nothing to Disclose	
Khandheria Bijoy Advances in HCM, PPCM and Other Marked Respiratory Related Variation in LVOT Gradients in Cardiomyopathies Hypertrophic Cardiomyopathy in Obese HCM Patients With Sleep-Disordered Breathing	
Khandheria Bijoy K. Emerging Applications of Echocardiography Dilated Mid-Ascending Aorta in Hypertrophic Cardiomyopathy Is Associated With Dynamic Left Ventricular Outflow Tract Obstruction and Not With Genetic Abnormalities	
Khandheria Bijoy K. Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases Stricter Criteria on Selection of Subjects Free of Disease	
Khanna Amber Adult Patients With Congenital Heart Disease: Worse Outcomes in Hospitalizations of Women With Turner Nothing to Disclose	
How Do They Compare? Syndrome Compared to Women Without Turner Syndrome Khanna Amber FIT Clinical Decision Making: Arrhythmias and Atrio-Ventricular Pacing Dysynchrony Manifest as Pseudo-Pulsus Nothing to Disclose	
Electrophysiology Paradoxus Paradoxus Khariton Yevgeniy Highlighted Original Research: Vascular Non-Adherence to the Joint ACC/AHA 2013 Lipid Performance Nothing to Disclose Medicine and the Year in Review Guidelines in Peripheral Arterial Disease: Insights From the	
PORTRAIT Registry	
Arryhthmias HFpEF: A Static or Dynamic Phenomenon?	
Khariton Yevgeniy Advances in Chronic Total Occlusion Health Status Benefits of Successful Chronic Total Occlusion Patients With Depressed Left Ventricular Systolic Function: Insights From the OPEN-CTO Registry	

Heart In the cent of Controlled Programs Security S	(And)				
Square B. Auch Park Control Sport Notice of Control Sport S		First Name	Session Title Heart Failure and Cardiomyonathies: Heart	Presentation Title Current More Important Than Past: Interpreting Serial Heart Failure	Disclosures Nothing to Disclose
Formation of the Comment of Comme	Miditori	revgerily		Specific Health Status in Heart Failure Patients With Reduced Ejection Fraction	Nothing to Disclose
Part	Kharouta	Michael	Nuclear Cardiology: Prognosis	in Asymptomatic End-Stage Renal Disease Patients Awaiting Kidney	Nothing to Disclose
Comment of the Commen	Khattar	Rajdeep		True Severity of Low-Flow Low-Gradient Aortic Stenosis and Is Not a Robust Marker of Contractile Reserve in Patients Undergoing Low-	Nothing to Disclose
Group I County Author Devotor Congress from I Cheese I County Cou	Khawaja	Muhammed		Ischaemia: Novel Insights From Intracoronary Measurements During	CONSULTANT FEES/HONORARIA - St Jude Medical
Seyan Name Analys Freshols and VT. Inceptoday Polysolation (1997). A process of the first process of the proces	Khayat	Rami		Obstructive Sleep Apnea in Adult Congenital Heart Disease: Who Is	CONSULTANT FEES/HONORARIA - Respicardia, Widemed
Vereir Design Varie (Control Fundament VIII Langua Physiolisma) Vereir Design Varie (Control Fundament VIII Langua Physiolisma) Vereir Design Varie (Control Fundament VIII Langua Physiolisma) Vereir Design Varie (Control Fundament VIII Langua Physiolisma) Vereir Design Varie (Control Fundament VIII Langua Physiologisma) Vereir Design Varie (Control Fundament VIII Langua Physiologisma) Vereir Design Varie (Control Fundament VIII Langua Physiologisma) Vereir Design Varie (Control Fundament VIII Langua Physiologisma) Vereir Design Varie (Control Fundament VIII Langua Physiologisma) Vereir Design Varie (Control Fundament VIII Langua Physiologisma) Vereir Design Varie (Control Fundament VIII Langua Physiologisma) Vereir Design Varie (Control Fundament VIII Langua Physiologisma) Vereir Design Varie (Control Fundament VIII Langua Physiologisma) Vereir Design Varie (Control Fundament VIII Langua Physiologisma) Vereir Design Varie (Control Fundament VIII Langua Physiologisma) Vereir Design Varie (VIII Langua P	Khaykin	Yaariv		Determination of the Ideal Contact Force Required During	Nothing to Disclose
Variety April Perfolions on activity of the State of Michael Confessor (Michael Confessor) April Perfolions on activity of the State of Michael Confessor (Michael Confessor) Rest Confessor (Michael Confessor	Khaykin	Yaariv		Evaluation of Long-Term Success Rate of Outflow Tract Ablation in	Nothing to Disclose
Pastell American Pastel	Khaykin	Yaariv	Atrial Fibrillation and VT: Incorporating Novel	Effects of Induction Before Ventricular Tachycardia Ablation on	Nothing to Disclose
Name of Residual and VT Introportating bytes (Residual Contect Designate Part of Content	Khazanie	Prateeti	Innovative Approaches for Reducing Risk and	Early Recurrence of Ventricular Tachycardia Predicts Increased	Nothing to Disclose
Notes of the control	Khazanie	Prateeti	Atrial Fibrillation and VT: Incorporating Novel	Safety and Outcomes of Catheter Ablation for Treatment of Refractory Ventricular Arrhythmias in Patients With Advanced Heart	Nothing to Disclose
The roles (very Learning From Historycore) Foreign (1992) Fo	Khedraki	Rola			Nothing to Disclose
Aspesser to Entreal Impact of Blood Present International Control Present Court of Impact Service International Control Present Court of Impact Service International Control Present Court of Impact Service International Control International	Khedraki	Rola	The Inside View: Learning From Intracoronary	Hybrid IVUS/OCT: "Probing" the Future	Nothing to Disclose
Record Presents Increases Parlet Noticellanian Commendates and Contended BP APP Monoclamation of Commendates and Noticelland Annatories and Presentation of Parliamental Presentation of Parli	Kheirbek	Raya	Assessing the Clinical Impact of Blood		Nothing to Disclose
and Suggical Busines This Survy of the Author Cognidal Head Progenition and Production of Antal Tachyarrythmina in Adult Profit Cincia Decision Making "Prevention. Adult Profit Cincia Decision Making "Prevention. Adult Profit Cincia Decision Making "Prevention. Adult Profit Cincia Decision Making "Prevention. Adult Consultation." College Antaly Technique (Consultation. Adult Profit Cincia Decision. Provide Committed (Consultation. Adult Profit Cincia Decision. Adult Profit Cincia Decision. Redefining the "P" Word Redefining the "P" Word Redefining the "P" Word Redefining the "P" Word Redefining the "P" Word Redefining the "P" Word Redefining the "P" Word Redefining the "P" Word Redefining the "P" Word Redefining the "P" Word Redefining the "P" Word Redefining the "P" Word Redefining the "P" Word Redefining the "P" Word Redefining the "P" Word Redefin	Kheirbek	Rava		Blood Pressure Increases Patient Mortality in Veterans	Nothing to Disclose
Consequence Processor Pr			and Surgical Issues	Centenarians	,
Coorgenial and Congenital record Disease Ahmed Annel Posten in the Modern World Disease Previous of Previous and Previous Previous and Previous Previous and Previous Previous and Previous Previous and Previous			Disease Patient and EP	Fontan Patients	
Chemical Ahmed Redefining the "F-Word Providence and Proceedings of Providence and Proceded Providence of Proceded Providence of Proceded Providence of Proceded Providence of Proceded Providence of Proceded Providence of Proceded Providence of Proceded Providence of Proceded Providence of Proceded Providence of Proceded Providence of Proceded Providence of Proceded Providence of Proceded Providence of Proceded Pro	Kilelwa		Congenital and Congenital Heart Disease	Septum Physiology: To Close or Not To Close ?	Nothing to Disclose
The minutal Abhalheke Novel Determinants of Outcomes in VHD International Control Patients Properties of ASCVI) Over the Lifespan A Properties of ASCVI) Over the Lifespan A Properties of Ascalable Abhalheke Abh	Kheiwa	Ahmed	Fontan in the Modern World		Nothing to Disclose
Crear Amil Prevention of ASCVID Over the Lifespan A Parellation of AscVID Over the Lifespan A Parellation of AscVID Over the Lifespan A Parellation of AscVID Over the Lifespan A Parellation of AscVID Over the Lifespan A Parellation of AscVID Over the Lifespan A Parellation of AscVID Amil Modern Amil Control Control Modern Amil Control Control Modern Amil Control Control Modern Amil Control Control Modern Amil Control Control Modern Amil Control Contr	Kheiwa		-	Prevalence and Predictors of Pacemaker Placement in Adult Fontan Patients	
Case Debated Approach from Amit Gree Debates or Preventive Cardology from a Amit Core Curriculum: Healthouse for the Masses from Amit Gree Curriculum: Healthouse for the Masses from Amit Gree Curriculum: Healthouse for the Masses from Amit Gree Curriculum: Healthouse for the Masses from Amit Gree Curriculum: Healthouse for the Masses from Module 4: Stable Sichemic Med Construction (March Construction College Manual March Construction College Manual March Construction College Manual March Construction College Manual March Construction College Manual March Construction College Manual March Construction College Manual March College Manual Manual March College Manual March College Manual Ma	Khemka			Be Underestimated - Analysis of Clinical Data Repositories	
Core Curriculum: Healthcare for the Masses Del Manuel Prevention of Primary Prevention Nothing to Disclose	Khera				Nothing to Disclose
Amit	Khera	Amit	Great Debates in Preventive Cardiology		Nothing to Disclose
Module 4: Stable Isochemic Heart Disease Amit Traditional and Nover Factors Used to Assess the Risk of, and Used for the Treatment of Journal Medical Properties the Risk of and Used for the Treatment of Journal Medical Properties The Risk of and Used for the Treatment of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Medical Properties The Risk of Journal Properties	Khera				
Corroary Artery Disease financiations in Advocacy and Pattern Centered Cure Amit Cure Cure Cure Cure Cure Cure Cure Cure	Khera		Module 4: Stable Ischemic Heart Disease Traditional and Novel Factors Used to Assess	Relationship of Biomarkers of Oxidized Lipoproteins to Ethnicity,	
Care Amit 32, Prevention: Clinical Team 4 Supgested Reviewer Rohan Interventional Cardiology: TAVR 2 Valve Replacement of Chronic Kothey Disease Rohan Interventional Cardiology: TAVR 2 Valve Replacement of Chronic Kothey Disease Rohan Rohan Interventional Cardiology: TAVR 2 Valve Replacement of Chronic Kothey Disease Rohan Rohan Amit and Cardiology: TAVR 3 Rohan Amit and Cardiology: TAVR 3 Rohan Acute Coronary Syndromes, Diagnosis, Amplitumias Rohan Acute Coronary Syndromes, Diagnosis, Management and Outcomes Meragement and Outcomes Rohan Rohan Acute Coronary Syndromes, Diagnosis, Management and Outcomes Rohan Rohan Acute Coronary Syndromes, Diagnosis, Management and Outcomes Rohan Rohan Rohan Acute Coronary Syndromes, Diagnosis, Management and Outcomes Rohan Roha	Khera	Δmit	Coronary Artery Disease	Year Follow-Up in the Dallas Heart Study	Nothing to Disclose
Rohan Interventional Cardiology, TAVR 2 Comparative Outcomes of Transcanderer Versus Surgical April: Versus Replacement in Chronic Kidney Diseases Nothing to Disclose	Khera		Care		
Rolan Interventional Cardiology, TAVR 3 Role of Hospital Volume in Identifying Low and High-performing Nothing to Disclose Surgical Valve Centers in the Unity Developments of Management Rolan Emerging Developments in HFpEF and Aryththmias Acute Coronary Syndromes, Diagnosis, Ancute Coronary Syndromes, Diagnosis, Ancute Coronary Syndromes, Diagnosis, Ancute Coronary Syndromes, Diagnosis, Ancute Coronary Syndromes, Diagnosis, Ancute Coronary Syndromes, Diagnosis, Ancute Coronary Syndromes, Diagnosis, Ancute Coronary Syndromes, Diagnosis, Coronary Interventional Coronary Interventional Cardiology, Translation and Precipional Cardiology, Advanced Device Use Cardiology, Advanced Device Use Cardiology, Advanced Device Use Cardiology, Advanced Device Use Cardiology, TAVR 2 Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency With In-Hospital Coulomes Association of Chronic Renal Insufficiency W	Khera	Rohan		Comparative Outcomes of Transcatheter Versus Surgical Aortic	Nothing to Disclose
Rohan Emerging Developments in HFpEF and Arryththmias Implantable Cardioverter Defibrillators for the Prevention of Mortality Nothing to Disclose Prevention of Mortality Nothing to Disclose Prevention of Mortality Nothing to Disclose Prevention of Cardiology (1977) Prevention (Cardiology) (1977) Prevention (Cardiology) (1977) Prevention (Cardiology) (1977) Prevention (Cardiology) (1977) Prevention (Cardiology) (1977) Prevention (197	Khera	Rohan	Interventional Cardiology: TAVR 3	Role of Hospital Volume in Identifying Low and High-performing	Nothing to Disclose
Roban Acute Coronary Syndromes, Diagnosis, Management and Outcomes Heart Failure in the United States National Perspective Nothing to Disclose	Khera	Rohan		Implantable Cardioverter Defibrillators for the Prevention of Mortality in Patients With Non-Ischemic Cardiomyopathy: A Meta-Analysis of	Nothing to Disclose
Interventional Cardiology: Translation and Pre- Clinical Research	Khera	Rohan		Burden of 30-Day Readmissions in Acute Myocardial Infarction and	Nothing to Disclose
Carcinary Intervention in Interventional Cardiology, Advanced Device Up evaluations of Cardiology, Cardiology, Advanced Device Up evaluations of Cardiology, Cardiologo, Cardiology, Cardiologo, Car	Khera	Sahil	Interventional Cardiology: Translation and Pre-	Intramyocardial Autologous CD34+ Cell Therapy for Refractory	Nothing to Disclose
Arrhythmias and Clinical EP: Syncope and Other Independent of the Sabil Interventional Cardiology: TAVR 4 (Association of Chronic Renal Insufficiency With In-Hospital Outcomes of Nothing to Disclose Outcomes of Transcatheter Aortic Valve Replacement (Association of Chronic Renal Insufficiency With In-Hospital Outcomes of Nothing to Disclose Sex Differences (Association of Revascularization and In-Hospital Outcomes of Nothing to Disclose (Another Syndrome) Sahil Interventional Cardiology: TAVR 3 Regional Variations in In-Hospital Outcomes and Healthcare Resource Utilization in Patients Undergoing Transcatheter Aortic Valve Replacement in the United States Khera Sahil Interventional Cardiology: TAVR 3 Regional Variations in In-Hospital Outcomes and Healthcare Resource Utilization in Patients Undergoing Transcatheter Aortic Valve Replacement in the United States Khera Sahil Interventional Cardiology: TAVR 4 Predictors of New Persistent Left Bundle Branch Block After In-Hospital Cardiac Arrest: An Examination of the "July Effect" Khera Sahil Interventional Cardiology: TAVR 4 Predictors of New Persistent Left Bundle Branch Block After Edwards Sapien 3 Transcatheter Aortic Valve Replacement Weekend Versus Weekday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide Analysis Arrhythmias in Valvular Heart Disease Diagnosis and Treatment or Critical Limb Ischemia: Analysis of the Nationwide Readmissions Database Nothing to Disclose Treatment for Critical Limb Ischemia: Analysis of the Nationwide Readmissions Database Functional Mitral Regurgitation and Cardiac Resynchronization Therapy: Evolution and Impact on Outcome OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Folds LLC Nothing to Disclose Therapy: Evolution and Impact on Outcome Ownership to Disclose Therapy: Evolution and Impact on Outcome Patients With Artral Fibrillation Are They an Epiphenomena a Predictive Cardion Mitral Regurgitation Are They an Epiphenomena a Predictive Cardion States (States) and	Khera	Sahil	Coronary Intervention in Interventional	Angiography Versus Optical Coherence Tomography Guided	Nothing to Disclose
Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome Chera Sahil Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome Chera Sahil Interventional Cardiology: TAVR 3 Regional Variations in In-Hospital Outcomes and Healthcare Resource Utilization in Patients Undergoing Transcatheter Acrtic Valve Replacement in the United States Arrhythmias and Clinical EP: Syncope and Other EP Issues Association of Academic Year-End Changeover With Survival Rates Other EP Issues Association of Academic Year-End Changeover With Survival Rates After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest. An Examination of the "July Effect" After In-Hospital Cardiac Arrest	M	0.1.7		Outcomes	N. W. C. C. C.
Features of Patients With Acute Coronary Syndrome Shate States				Outcomes of Transcatheter Aortic Valve Replacement	
Resource Utilization in Patients Undergoing Transcatheter Aortic Valve Replacement in the United States (Acrea Sahil Arrhythmias and Clinical EP: Syncope and Other EP Issues After In-Hospital Cardiac Arrest: An Examination of the "July Effect" (Achera Sahil Interventional Cardiology: TAVR 4 Predictors of New Persistent Left Bundle Branch Block After Edwards Sapien 3 Transcatheter Aortic Valve Replacement (Achera Sahil Optimizing the Care of ACS Patients Weekend Versus Weekeday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide Analysis (Achera Sahil Highlights in Vascular Medicine Research Transfurction: Findings From a United States Nationwide Analysis (Achera Arash Innovations in Valvular Heart Disease Diagnosis and Treatment Edarding Us Astray? Pacemakers in Edarding Washinger Intervention: Pulmonary Vein Isolation in Patients With Arial Fibrillation and Impact on Outcome (Achidr Shimaa Arrhythmias and Clinical EP: Basic 5 Pulmonary Vein Remodeling Following Pulmonary Vein Isolation in Patients With Arial Fibrillation Are They an Epiphenomena a Predictive Cardiac MRI Study (Achitha Jayant Percutaneous Coronary Intervention: Lessons) Resource Uslate Acress An Examination of the "July Effect" Association of Academic Year-End Changeover With Survival Rates Nationariation of the "July Effect" Association of Academic Year-End Changeover With Survival Rates Nationariation of the "July Effect" After In-Hospital Cardiac Ares After Examination of the "July Effect" After In-Hospital Cardiac Ares After Examination of the "July Effect" After In-Hospital Cardiac Ares After Examination of the "July Effect" After In-Hospital Cardiac Ares After Examination of the "July Effect" After In-Hospital Cardiac Ares After Examination of the "July Effect" After In-Hospital After In-Hospital Area Placement After In-Hospital After In-Hospital Area Placement After In-Hospital Cardiac Area Placement Action In-Hospital Area Placement Association of Academic Placement P	Micia		Features of Patients With Acute Coronary Syndrome	Non-ST-Segment Elevation Myocardial Infarction in the United States	
After In-Hospital Cardiac Arrest: An Examination of the "July Effect" After In-Hospital Cardiac Arrest: An Examination of the "July Effect" After In-Hospital Cardiac Arrest: An Examination of the "July Effect" After In-Hospital Cardiac Arrest: An Examination of the "July Effect" After In-Hospital Cardiac Arrest: An Examination of the "July Effect" After In-Hospital Cardiac Arrest: An Examination of the "July Effect" After In-Hospital Cardiac Arrest: An Examination of the "July Effect" After In-Hospital Cardiac Arrest: An Examination of the "July Effect" After In-Hospital Cardiac Arrest: An Examination of the "July Effect" After In-Hospital Cardiac Arrest: An Examination of the "July Effect" After In-Hospital Cardiac After Edwards Saplen 3 Transcatheter Acritic Valve Replacement Acrity In Intervention: Valve Replacement Anothing to Disclose Anothing to Disclose Nothing to Disclose Nothing to Disclose Acrity Intervention: Inte	Khera	Sahil	Interventional Cardiology: TAVR 3	Resource Utilization in Patients Undergoing Transcatheter Aortic	Nothing to Disclose
Edwards Sapien 3 Transcatheter Aortic Valve Replacement	Khera	Sahil		Association of Academic Year-End Changeover With Survival Rates	Nothing to Disclose
Sahil Optimizing the Care of ACS Patients Weekend Versus Weekday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide Analysis	Khera	Sahil	Interventional Cardiology: TAVR 4		Nothing to Disclose
Khera Sahil Highlights in Vascular Medicine Research Thirty-Day Readmissions Following Endovascular or Surgical Treatment for Critical Limb Ischemia: Analysis of the Nationwide Readmissions Database Kheradvar Arash Innovations in Valvular Heart Disease Diagnosis and Treatment or Critical Limb Ischemia: Analysis of the Nationwide Readmissions Database Heart Valve Engineering: The Next Frontier OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Folda LLC Khidir Mand Leading Us Astray? Pacemakers in Cardiomyopathies Functional Mitral Regurgitation and Cardiac Resynchronization Therapy. Evolution and Impact on Outcome Khidr Shimaa Arrhythmias and Clinical EP: Basic 5 Pulmonary Vein Remodeling Following Pulmonary Vein Isolation in Patients With Atrial Fibrillation Are They an Epiphenomena a Predictive Cardiac MRI Study Khitha Jayant Vascular Access and Hemostasis Issues Clinical Efficacy of SoftSeal-STF Hemostatic Pad With Short Hold Time Compared to Traditional Manual Compression After Transferoral Catheterization Khitha Jayant Percutaneous Coronary Intervention: Lessons Outcomes in Patients Undergoing Cardiac Catheterization and Nothing to Disclose	Khera	Sahil	Optimizing the Care of ACS Patients	Weekend Versus Weekday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide	Nothing to Disclose
Arash Innovations in Valvular Heart Disease Heart Valve Engineering: The Next Frontier OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Foldation Chidir Mand Leading Us Astray? Pacemakers in Cardiomyopathies Functional Mitral Regurgitation and Cardiac Resynchronization Nothing to Disclose Nothing to Disclose	Khera	Sahil	Highlights in Vascular Medicine Research	Thirty-Day Readmissions Following Endovascular or Surgical Treatment for Critical Limb Ischemia: Analysis of the Nationwide	Nothing to Disclose
Mand Leading Us Astray? Pacemakers in Cardiomyopathies Functional Mitral Regurgitation and Cardiac Resynchronization Nothing to Disclose	Kheradvar	Arash			OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Folda
Khidr Shimaa Arrhythmias and Clinical EP: Basic 5 Pulmonary Vein Remodeling Following Pulmonary Vein Isolation in Patients With Atrial Fibrillation Are They an Epiphenomena a Predictive Cardiac MRI Study Nothing to Disclose Khitha Jayant Vascular Access and Hemostasis Issues Clinical Efficacy of SoftSeal-STF Hemostatic Pad With Short Hold Time Compared to Traditional Manual Compression After Transfermoral Catheterization Nothing to Disclose Khitha Jayant Percutaneous Coronary Intervention: Lessons Outcomes in Patients Undergoing Cardiac Catheterization and Nothing to Disclose	Khidir	Mand	Leading Us Astray? Pacemakers in		LLO
A Predictive Cardiac MRI Study Clinical Efficacy of SoftSeal-STF Hemostatic Pad With Short Hold Time Compared to Traditional Manual Compression After Transfermoral Catheterization Abitha Jayant Percutaneous Coronary Intervention: Lessons Outcomes in Patients Undergoing Cardiac Catheterization and Nothing to Disclose	Khidr	Shimaa		Pulmonary Vein Remodeling Following Pulmonary Vein Isolation in	Nothing to Disclose
Time Compared to Traditional Manual Compression After Transfemoral Catheterization Ahitha Jayant Percutaneous Coronary Intervention: Lessons Outcomes in Patients Undergoing Cardiac Catheterization and Nothing to Disclose	I/L iiL -	In read	Manufac Annua and Herritary	Predictive Cardiac MRI Study	Nething to Displace
Khitha Jayant Percutaneous Coronary Intervention: Lessons Outcomes in Patients Undergoing Cardiac Catheterization and Nothing to Disclose				Time Compared to Traditional Manual Compression After Transfemoral Catheterization	-
	Khitha	Jayant	Percutaneous Coronary Intervention: Lessons From the Real World		Nothing to Disclose



Last Name Khoo	First Name Nee Scze	Session Title Congenital Heart Disease: Innovations in	Presentation Title Right Ventricular Remodelling in Hypoplastic Left Heart Syndrome:	Disclosures Nothing to Disclose
		Single Ventricle Heart Disease	Impact of the Norwood and Hybrid Procedures	-
Khoo	Nee Scze	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	The Incremental Benefit of Color Tissue Doppler Imaging in Fetal Rhythm Assessment	Nothing to Disclose
Khoshhal	Sahal	Interdisciplinary Cardiovascular Team Collaboratives in Care	Heparin Induced Thrombocytopenia With Thrombosis: A Case Study	Nothing to Disclose
Khosla	Rajit	Hearts and Soles: Multimodality Imaging in	The Mixed Race Athlete's ECG: Not So Black and White	Nothing to Disclose
Khosla	Sandeep	Arrhythmias and Clinical EP: Devices 1	Lower All-Cause Mortality in Younger Patients With Prophylactic Implantable Cardioverter Defibrillator Compared to Elderly Subjects:	Nothing to Disclose
I/h a a l a	Candana	Undeten in Stable Indonesia Unort Diagram	A Systemic Review and Meta-Analysis Effect of Hospital Intervention on Smoking Cessation 30 Days After	Nething to Displace
Khosla	Sandeep	Updates in Stable Ischemic Heart Disease	Admission for Acute Coronary Syndrome	Nothing to Disclose
Khosla	Sandeep	Atrial Fibrillation and VT: Unique Populations and Solutions	Reduced Mortality Benefit With Prophylactic Implantable Cardioverter Defibrillator in Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis	Nothing to Disclose
Khosla	Sandeep	Can CABG Patch CAD?	Minimally Invasive CABG Reduces Target Vessel Revascularizations in Comparison to PCI Without Increased Major Adverse Events: A Meta-Analysis of Randomized Trials	Nothing to Disclose
Khoury	Shafik	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Incidence and Outcomes of Early Left Ventricular Thrombus Formation Following ST-Elevation Myocardial Infarction Treated	Nothing to Disclose
Khouzam	Rami	Timely Topics in Acute Coronary Syndromes	With Primary Percutaneous Coronary Intervention Predictors of True ST-Segment Elevation Myocardial Infarction in Cocaine Positive Patients	Nothing to Disclose
Khouzam	Rami	Innovations in Advocacy and Patient Centered Care	Prolonged Inter-facility Transfer Times and Hospital Length of Stay in Insured Patients with ST-elevation Myocardial Infarction	Nothing to Disclose
Khoynezhad	Ali	Vascular Medicine: Novel Risk Measures in	Body Mass Index and Acute Aortic Dissection	Nothing to Disclose
Khurshid	Shaan	Arterial Diseases Atrial Fibrillation and VT: Incorporating Novel	Factors Predicting Longer Time to Anticoagulation Following a New	Nothing to Disclose
	Jawad	Risks Toward Decision Making Interdisciplinary Cardiovascular Care in	Diagnosis of Atrial Fibrillation Mediastinal Mass Infiltrating the Heart	-
Kiani		Complex Scenarios	ů	Nothing to Disclose
Kida	Makoto	Arrhythmias and Clinical EP: Anticoagulation Issues	Bleeding Risk Among Japanese Non-Valvular Atrial Fibrillation Patients Initiated on Apixaban, Dabigatran, Rivaroxaban or Warfarin in the Real World	SALARY - Bristol-Myers Squibb
Kido	Takehiko	Advances in Chronic Total Occlusion Intervention	The Impact of Recanalization of Chronic Total Occuluded Coronary Artery on Electrophysiological Substrate of Left Ventricle	Nothing to Disclose
Kidwell	David	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Cardiac Myosin Binding Protein-C De-Phosphorylation Mediated Slowing of Cross-Detachment Worsens Heart Failure	Nothing to Disclose
Kiefer	Todd	Highlighted Original Research: Valvular Heart	Surgery for Patients With Bicuspid Aortopathy: Validation of the	Nothing to Disclose
Kiefer	Todd	Disease and the Year in Review Interventional Cardiology: TAVR 4	2016 ACC/AHA Guidelines Clarification Predictors of Mortality After TAVR in a "Real World" Setting	Nothing to Disclose
Kiener	Alex	Congenital Heart Disease Surgery: Updates and Innovations	Long-Term Transplant-Free Survival for Arterial Switch Versus Atrial Switch in Treatment of Transposition of the Great Arteries: A Study	
10	AP-1I		From the Pediatric Cardiac Care Consortium	CONOUNTANT FEFOURONOPARIA LI LA INVALIDA CTUER
Kiernan	Michael	Life After LVAD - The Good, The Bad and The Ugly	Co-Chair	CONSULTANT FEES/HONORARIA - HeartWare Inc.; OTHER - Thoratec Corp.
Kiernan	Michael	The Nuts and Bolts of Pulmonary Hypertension in Left Heart Disease	Panelist	CONSULTANT FEES/HONORARIA - HeartWare Inc.; OTHER - Thoratec Corp.
Kiernan	Michael	The Nuts and Bolts of Pulmonary Hypertension	Strategies to Reverse Pulmonary HTN: Role of LVADs and drugs?	CONSULTANT FEES/HONORARIA - HeartWare Inc.; OTHER -
Kiernan	Michael	in Left Heart Disease Novel Developments in Acute Coronary	Right-Sided Ventriculo-Arterial Coupling Indices Are Associated	Thoratec Corp. CONSULTANT FEES/HONORARIA - HeartWare Inc.; OTHER -
Viere	Minhaal	Syndromes	With Clinical Outcomes Among Patients Receiving Biventricular Impella (BiPella) Support for Cardiogenic Shock	Thoratec Corp.
Kiernan	Michael	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Impact of Glucagon Like Peptide-1 Agonist Therapy on Heart Rate in Advanced Systolic Heart Failure: An Analysis From the Functional Impact of GLP-1 for Heart Failure Treatment Study	CONSULTANT FEES/HONORARIA - HeartWare Inc.; OTHER - Thoratec Corp.
Kiernan	Thomas	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Facilitation of Stent Delivery With the GuideLiner Catheter	Nothing to Disclose
Kievit	Peter	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: From the WIN-TAVI Registry	Nothing to Disclose
Kihara	Yasuki	Innovations in Cardiovascular Risk Assessment	The Prognostic Value of CPET: Association With Coronary Artery	Nothing to Disclose
Kikuta	Yuetsu	and Reduction Interventional Cardiology: Intravascular	Calcium Score Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre-	CONSULTANT FEES/HONORARIA - Volcano
		Physiology and Endothelial Function	Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International Multicentre iFR GRADIENT Registry	
Kilbride	Sally	Innovations in Cardiovascular Risk Assessment and Reduction	High-Sensitivity Cardiac Troponin I and Risk of Cardiovascular Events in Patients With COPD and Heightened Cardiovascular Risk:	SALARY - GlaxoSmithKline
Kilic	Harun	Venous Investigation: The Dark Side	A Biomarker Sub-Study of the SUMMIT Trial lpsilateral Resting Venous Lactate Levels Decreased After Successful Percutaneous Revascularization of the Limb in Patients	Nothing to Disclose
Killu	Ammar	Common Arrhythmia Problems: The Experts Approach	Suffering Intermittent Claudication Case Presentation	Nothing to Disclose
Killu	Ammar	Innovative Approaches for Reducing Risk and	Complication Rates of Epicardial Ventricular Tachycardia Ablation:	Nothing to Disclose
Kilner	Philip	Improving Outcomes With Ablation Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	A Pooled Analysis Cardiovascular Magnetic Resonance in Survivors of Sudden Cardiac Arrest: 14 Year Experience From a Tertiary Referral Centre	Nothing to Disclose
Kim	Byeong-Keuk	Considerations in Antiplatelet Therapy and in ACS	in the United Kingdom Association Between Duration of Dual Antiplatelet Therapy and Anaiographic Multi-Vessel Disease on Outcomes in Patients Treated	Nothing to Disclose
Kim	Chang	Highlighted Original Research: Acute and	With Newer-Generation Drug-Eluting Stents Cannabis Abuse and Risk for Myocardial Infarction: A Population	Nothing to Disclose
16	Observa	Stable Ischemic Heart Disease and the Year in Review	Based Study	N. W. C. C. C.
Kim	Chang	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Risk of Heart Failure in Systemic Sclerosis	Nothing to Disclose
Kim	Chang	Innovations in Cardiovascular Risk Assessment and Reduction	Red Cell Distribution Width (RDW) Predicts Major Adverse Cardiac Events in Systemic Lupus Erythematosus	Nothing to Disclose
Kim	Chang	Arrhythmias and Clinical EP: AF Miscellaneous	Risk of Atrial Fibrillation in Human Immunodeficiency Virus Infection	Nothing to Disclose
Kim	Dae Hyun	and Surgical Issues Interventional Cardiology: TAVR 4	in the Era of Antiretroviral Therapy Serum Albumin as an Incremental Predictor of Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement:	Nothing to Disclose
Kim	Darae	Valvular Heart Disease: Aortic Stenosis	Results From the Multicenter Frailty-AVR Study Comparisons of Flow-Gradient Patterns in Severe Aortic Stenosis	Nothing to Disclose
Kim	David	FIT Clinical Decision Making: Arrhythmias and	Between Bicuspid Aortic Valves and Tricuspid Aortic Valves Third Degree Heart Block as the Initial Presentation of Cardiac	Nothing to Disclose
Kim	Dennis	Electrophysiology Highlighted Original Research: Congenital	Sarcoidosis Transcatheter Ductal Stenting Versus Surgical Systemic-to-	Nothing to Disclose
	_ 30	Heart Disease and the Year in Review	Pulmonary Artery Shunts: Altering Dogma at a High-Volume Institution	g to 5100000

Control Contro	Congress of the Congress of th				
Eschalation and Trialment C. File Description of Company Services (Company Services) File Description of C	Last Name			Presentation Title	Disclosures Nothing to Disclose
Conference of the Protect Post Depreciation control of Protection of the Protect Post Depreciation control of the Prote	MIII	D0119-200			Inothing to Discrose
Control Contro			1	Cardiovascular Risk Patients With Hypercholesterolemia Not	
Committee and Co					
Enter Control	Kim	Duk-Kyung	Current Issues in Cardiovascular		Nothing to Disclose
Consequent Programment Consequence (Consequence Conseq			Epidemiology, Disparities, and Safety		-
Company of Program of Encourage and American Contracting of Engineering Contracting Contra	Kim	Esther	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases		Nothing to Disclose
Mayor Control (1997) From Part Service of Acade Concern y Print Service (1997) From Part Service of Acade Concern y Print Service (1997) From Par	Kim	Eung Ju		Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor	Nothing to Disclose
Service Servic			Syndromes		
Company Comp					
Description of the common control of the com	Kim	Eung Ju	Timely Topics in Acute Coronary Syndromes	Predictors of Mortality in Acute Myocardial Infarction Patients With	Nothing to Disclose
Tourise Chem Number and Climical Chem Device Control Chem Number 2 (Climical Chem Number 2) (Cli	V:	Free Iv	Advances in Observin Total Confusion		Nething to Displace
Gene Department of the common	KIM	Eung Ju			Nothing to Disclose
Access the five frame is not explosed by Sintegers to 1 From 19	Kim	Gene		Atrial Fibrillation Is Associated With Severe Metabolic Disruption in	Nothing to Disclose
Min Golden Will Inspect Meanural Meanural Helescopring Will Inspect Meanural Meanural Helescopring Will Inspect Meanural Meanural Helescopring Min Mary SETAN Reference vols for Ea Justice Min Mary Certification of Meanural Meanura	V:	0	Assite Used Fellows Fredricks Observation to		Nething to Displace
Series Series (Series Series) Series Series (Series Series) Series Series (Series Series) Series Series (Series) Series Series Series (Series) Series Series Series (Series) Series Seri	NIII	Gene			Nothing to Disclose
STEAN Distances No. 16 to be abode the control of t	Kim	Gene		Assessment of Left Ventricular Rotational Mechanics Post-LVAD	Nothing to Disclose
Sign Concept Service Control of The Notice C	Kim	Henny	STEMI Dilammas: You Be the Judge		Nothing to Disclose
Controllegy Authorized Principles (Particlegy Authorized Principles (Parti	Kim				
Hypro Charal Updaces on Ref Rectation for Conformational Planet Conformation Planet Rectation for Conformation Planet Rectation for Conformation Planet Rectation for Conformation Planets and Confo			Cardiology: Advanced Device Use		-
Confessionation of Medical Exposition (Medical April April 1999) In Plyan Su Perhitatory Arriyelmines Culticones With Medical Confessional Programs of Account of Medical Exposition (Med					
ACS Applying Sir. Payman Sir.	Tairi	Trycon onling			Two thing to Disclose
With file-and connectation troug-Ellings betters With file-and connectation troug-Ellings betters With file-and connectation troug-Ellings betters With file-and connectation troug-Ellings betters With file-and connectation troug-Ellings betters With file-and connectation trought states by the state of the states of th	Kim	Hyo-Soo			
Form Hybrs Su Centemporary Precision Of Notice of Precision of Precision of Precision of Notice of Precision of Precision of Notice of Precision of Pr			ACS		Scientific, MED I RONIC
Contemporary Practice Mey-Map Ch Mayning Ch Markers of Progrosses Accessed With Markers of Progrosses Accessed With Markers of Progrosses Accessed With Markers of Progrosses Accessed With Markers of Progrosses Accessed With Markers of Progrosses Accessed With Markers of Progrosses Accessed With Markers of Progrosses Accessed With Markers of Progrosses Accessed With Markers of Progrosses Accessed With Markers of Progrosses Accessed With Markers of Progrosses Accessed With Markers of Progrosses Accessed With Markers of Progrosses Accessed With Markers of Progrosses Accessed With Markers With Norwalacus Annual Profitation Markers of Progrosses Accessed With Markers With Norwalacus Annual Profitation Markers of Progrosses Accessed With Markers of Progrosses Accesses With Norwalacus Annual Profitation Markers of Progrosses Accessed With Markers of Progrosses Accessed With Norwalacus Annual Profitation Markers of Progrosses Accessed With Markers of Markers of Markers of With Markers of Markers of With Markers of Markers of With	Kim	Hyun Su		Clinical and Electrocardiographic Characteristics for Prediction of	Nothing to Disclose
Hyrung Ch Common Appropriate Publisher Learning From Jang Ch From Jan			Contemporary Practice	New-Onset Left Ventricular Dysfunction in Patients With Frequent	
Concern intervention in hyborodical inflance on Patients Finance of Proposes accounted VIII in concentrate of the Concern in Proposed and Inflance VIII in enterior VIII in proceedings of Substitution of Concerns Affective VIII in an American Concerns Affective VIII in American Concerns Affective VIII in American Concerns Affective VIII in American Concerns Affective VIII in American Concerns Affective VIII in American Concerns Affective VIII in American Concerns Affective VIII in American Concerns Affective VIII in Ame	Kim	Hyung Oh	Coronary Angiography, Intra-Vascular Imaging		Nothing to Disclose
Flyung Ch Flyung Ch Flyung Ch Flyung Ch Flyungseop Arrhythmis and Cillical EP: Anticoaguillation Flyungseop Arrhythmis and Cillical EP: Anticoaguillation Flyungseop Arrhythmis and Cillical EP: Anticoaguillation Flyungseop Arrhythmis and Cillical EP: Anticoaguillation Flyungseop Arrhythmis and Cillical EP: Anticoaguillation Flyungseop Arrhythmis and Cillical EP: Anticoaguillation Flyungseop Arrhythmis and Cillical EP: Anticoaguillation Flyungseop Arrhythmis and Cillical EP: Anticoaguillation Flyungseop Arrhythmis and Cillical EP: Anticoaguillation Flyungseop Arrhythmis and Cillical EP: Anticoaguillation Flyungseop Arrhythmis and Cillical EP: Basc 3 Arrhythmis and Cillical EP: Basc			Revascularization and Outcomes	Coronary Intervention in Myocardial Infarction Patients	-
Figure (Sin Section Control Section Control Section Section Control Section Se	Kim	Hyung Oh			Nothing to Disclose
and Reduction Continues (EP - Anticonguistion) Antiphrines and Cilinate (EP - Anticonguistion) Interventional Continues (EP - Anticonguistion) Interventional Conditions, State of the Practic	Kim	Hyung Oh			Nothing to Disclose
Hyungeop Many Photography (Chicago Photography Carbon Chicago Photography Chicago Phot		,		Cardiovascular Events in Comparison With the Coronary Artery	
In the Practice Interventional Cardiology, Sent Failure Analysis by Interventional Cardiology, Sent Failure Analysis by Interventional Cardiology, Sent Failure Analysis by Interventional Cardiology, Sent Failure Analysis by Interventional Cardiology, Sent Failure Analysis of Sent Failure Analysi	Vim	Шиппппппп	Arrhythmias and Clinical ED: Anticognilation		Nothing to Displace
Hyungeop Menternethoral Cardiology: Ster Falure Analysis by Intravascular Imaging and Heaves and Cardiology Ster Falure Analysis by Intravascular Imaging Coronary Calcium Steramonary Calcium Society and Cardiology Steramonary Calcium Society and Cardiology Steramonary Calcium Society Steramonary Cardiology Steramonary Calcium Society Steramonary Cardiology Steramonary Calcium Society Steramonary Cardiology Steramonary Calcium Society Steramonary Cardiolog	NIII	Hyungseop			Nothing to Disclose
Min Hyun-Jin Non Invasive Imaging: Coronary Calcium Sorting and CV Ref. Accessment Antifyrimus and Curiosal Extra Season	Kim	Hyungseop		Five Year Outcomes of Fractional Flow Reserve Guided Versus	Nothing to Disclose
Similary Jan Non treases inagery Corronary Calcium Jeong Su Arrythmines and Cinical EP. Basic 3 Anni Fartifactor Cycle Length Measured by Transacophageal Arrythmines and Cinical EP. Basic 3 Anni Fartifactor Cycle Length Measured by Transacophageal Arrythmines and Cinical EP. Basic 3 Anni Fartifactor Cycle Length Measured by Transacophageal Arrythmines and Cinical EP. Basic 3 Anni Fartifactor Cycle Length Measured by Transacophageal Arrythmines and Cinical EP. Basic 3 Anni Fartifactor Cycle Length Measured by Transacophageal Both Comparative Outcomes of Angoldenian Converting Enzyme inhibitor. On December of the Measure Street of the Measured Street in Debetic Hyperteristies Acute Mycardial Infarction Industrial Measured By Transacophageal Advances in Chronic Total Occlusion Infrared Street Control of Total Occlusion Infrared Street Control of Total Occlusion Infrared Street Control of Total Occlusion Infrared Street Control of Total Occlusion Infrared Street Control of Total Occlusion Infrared Street Control of Total Occlusion Infrared Street Control of Total Occlusion Infrared Street Control of Total Occlusion Infrared Street Control of Total Occlusion Infrared Street Control of Total Occlusion Infrared Street Control of Total Occlusion Infrared Street Control of Total Occlusion Infrared Street Control of Total Occlusion Infrared Street Control of Total Occlusion Infrared Street Control of Total Occlusion Infrared Street Control of Total Occupants Infrared Street Control of Total Occupants Infrared Street Control of Total Occupants Infrared Street Control of Total Occupants Infrared Street Control of Total Occupants Infrared Street Control of Total Occupants Infrared Street Control of Total Occupants Infrared Street Control of Total Occupants Infrared Street Control of Total Occupants Infrared Street Control of Total Occupants Infrared Street Control of Total Occupants Infrared Street Control of Total Occupants Infrared Street Control of Total Occupants Infrared Street Control of Total Occupants Infrared Stree			Analysis by Intravascuar Imaging		
Scoring and CV Risk Assessment Scoring and CV Risk Assessment Jeong Su Arrighman and Cincian EP- Basa 3 Arrighman and Cincian EP- Basa 3 Arrighman and Cincian Cincian EP- Basa 3 Arrighman and Cincian EP- Basa 3 Arrighman and Cincian EP- Basa 3 Arrighman and Cincian EP- Basa 3 Arrighman and Cincian EP- Basa 3 Arrighman and Cincian EP- Basa 3 Arrighman and Cincian EP- Basa 3 Arrighman and Cincian EP- Basa 3 Arrighman and Cincian EP- Basa 3 Arrighman and Cincian EP- Basa 3 Arrighman and Cincian EP- Basa 3 Arrighman and Cincian EP- Basa 3 Arrighman Extra Ex	Kim	Hyun-Jin	Non Invasive Imaging: Coronary Calcium		Nothing to Disclose
Echocardiography A Predictor for Manifaring Shrus Ritythm Aller DC Cardiomeston Comparative Outcomest Synthomes Synt			Scoring and CV Risk Assessment	Extremely Low Coronary Artery Calcium Score Patients	-
OC Cardioversion Occurrency Syndromes Novel Developments in Acute Coronary Syndromes Occurrency Syndromes Oc	Kim	Jeong Su	Arrhythmias and Clinical EP: Basic 3		Nothing to Disclose
Syndromes Syndromes An Anjotonesia Receptor Blocker in Diabetic Hypertensive Acute Mycardial Infraction Respets; Results From Croser Acute Mycardial Infraction Respets; Results From Croser Acute Mycardial Infraction Respets; Results From Croser Acute Mycardial Infraction Respets; Results From Croser Acute Mycardial Infraction Respets; Results From Mycardial Infraction Respets; Results From Mycardial Infraction Respets; Results From Mycardial Infraction Respets; Results From Mycardial Infraction Respets; Results From Mycardial Infraction Respets; Results From Mycardial Infraction Respets; Results From Croser Acute Mycardial Infraction From Croser Infraction From Mycardial Infraction Folial Collaboration Infraction Pages Infraction Infraction Pages Infraction Infraction Pages Infraction Infraction Pages Infraction Infraction Pages Infraction Infraction Pages Infraction Infraction Pages Infraction Infraction Pages Infraction Infraction Pages Infraction Infraction Pages Infraction Infraction Pages Infraction I				DC Cardioversion	
Mycardial Infraction Patents: Results From the Korea Acute Mycardial Infraction Patents: Members from the Korea Acute Mycardial Infraction Patents With Mycardial Infraction Patents With Mycardial Infraction Patents My Myon Advences in Chronic Total Occusion Intervention Intervention Jan Won Advences in Chronic Total Occusion Intervention Coronary Angiography, Intra-vascular Imaging Revisacularization and Outcomes My Markers of Proposos Associated With Elevated Biocol Pressure And Reduction and Coronary Angiography, Intra-vascular Imaging And Markers of Proposos Associated With Elevated Biocol Pressure And Reduction and Coronary Angiography, Intra-vascular Installation Jan Bae And Reduction and Coronary Angiography, Intra-vascular Installation Jan Bae And Reduction and Coronary Angiography, Intra-vascular Installation Jan Bae And Reduction and Coronary Angiography, Intra-vascular Installation Angiography Angiography Angiography Angiography Angiography Angiography Angiography Angiography Angiography Angiography Angiography Angiography Angiography Angiography Angiography Angiography Angiography Angiography Angiography Angiography Angiography Angiograph	Kim	Jin Won			Nothing to Disclose
Mycardial Infarction Registry (KAMIR) Jin Won Timely Topics in Acute Coronary Syndromes Advances in Circinic Total Occlusion in Mycardial Interior on Circinic Total Advances in Circinic Total Occurrent Interior on Circinic Total Advances in Circinic Total Occurrent Interior			Syndromes		
Unprotected Left Main Coronary Artery Disease Intervention Advances in Chronic Total Occlusion Intervention Advances in Chronic Total Occlusion Intervention Advances in Chronic Total Occlusion Intervention Advances in Chronic Total Occlusion Intervention Annual Left Ventrocular Function Coronary Angiography, Intra-Vascular Imaging, Company Angiography of Non-Culprit Legislation Northing to Preclaments Coronary Intervention in Mycardial Intertion Patients Northing of Prognosia Associated With Indicated With Intervention in Mycardial Intertion Patients Northing of Prognosia Associated With Indicate Angiography Intra-Vascular Imaging of Non-Culprit Legislation in Mycardial Intervention in Mycardial Intervention on Cheet X-Ray for Uniting to Disclose Coronary Intervention in Mycardial Intervention on Cheet X-Ray for Uniting to Disclose Approach Imaging the Athlete's Heart Jonathan Imaging t				Myocardial Infarction Registry (KAMIR)	
Month Advances in Chronic Total Occlusion Impact of Perculaneous Coronary Intervention for Chronic Total Occlusion Patients With Near-Month Entire University Occursion Nothing to Disclose	Kim	Jin Won	Timely Topics in Acute Coronary Syndromes		Nothing to Disclose
Intervention	Kim	Jin Won	Advances in Chronic Total Occlusion		Nothing to Disclose
Revascularization and Outcomes			Intervention	Occlusion Patients With Near-Normal Left Ventricular Function	
In-Bae Markers of Prognoss Associated Wth Incidence of Subclinical Atheroscierosis in Patients With Resistant Nothing to Disclose Hypertension In-Bae Innovations in Cardiovascular Risk Assessment Properticular Value of Acric Arch Cacification on Cheet X-Ray for And Reduction And Reduction Acrid Arch Cacification on Cheet X-Ray for And Reduction Acrid Arch Cacification on Cheet X-Ray for And Reduction Acrid Arch Cacification on Cheet X-Ray for And Reduction Acrid Arch Cacification on Cheet X-Ray for And Reduction Acrid Arch Cacification on Cheet X-Ray for And Reduction Acrid Arch Cacification on Cheet X-Ray for And Reduction Acrid Arch Cacification on Cheet X-Ray for And Reduction Acrid Arch Cacification on Cheet X-Ray for Acrid Arch Cacification Arch Cacificatio	Kim	Jin-Bae			Nothing to Disclose
Elevated Blood Pressure Innovations in Cardiovascular Risk Assessment In Prepeticitive Value of Aortic Arch Calcification on Chest X-Ray for and Reduction Individual Risk Assessment In Prepeticitive Value of Aortic Arch Calcification on Chest X-Ray for Cardiovascular Events in Comparison With the Coronary Artery Calcium Score and the Framingham Risk Score Nothing to Disclose Approach Imaging the Alhelet's Heart Imaging	Kim	Jin-Bae			Nothing to Disclose
and Reduction Gardiovascular Events in Comparison With the Coronary Artery Galdium Score and the Framingham Risk Score Month Jonathan The Athlete with Heart Disease: A Case Based Approach With Jonathan Imaging the Athlete's Heart Jonathan Imaging the Athlete's Heart Jonathan Imaging the Athlete's Heart Jonathan Imaging the Athlete's Heart Jonathan Imaging the Athlete's Heart Jonathan Imaging the Athlete's Heart Jonathan The Evolving World of LVADs, Transplant and Other Nevol Discovered in Collegiated American Style Football Training Intensities and Cardious Councils In Training Intensities and Cardious Councils In Training Intensities and Cardious Councils Intensity Intensities and Cardious Councils Intensity Intensities and Cardious Councils Intensity Intensities and Cardious Councils Intensity I			Elevated Blood Pressure	Hypertension	•
Calcium Score and the Framingham Risk Score Jonathan The Athlete with Heart Disease: A Case Based Approach	Kim	Jin-Bae			Nothing to Disclose
Approach Approach			and reduction	Calcium Score and the Framingham Risk Score	
Imaging the Athlete's Heart Differential American-Style Football Training Intensities and Cardiac Nothing to Disclose and Vascular Remoding Patterns Sleep Disordered Breathing and Cardiovascular Correlates in Collegiate American Style Football Participants Nothing to Disclose Collegiate American Style Football Participants Nothing to Disclose Collegiate American Style Football Participants Nothing to Disclose Collegiate American Style Football Participants Nothing to Disclose Collegiate American Style Football Participants Nothing to Disclose Collegiate American Style Football Participants Nothing to Disclose Collegiate American Style Football Participants Nothing to Disclose Collegiate American Style Football Participants Nothing to Disclose Collegiate American Style Football Participants Nothing to Disclose Collegiate American Style Football Participants Nothing to Disclose Collegiate American Style Football Participants Nothing to Disclose Collegiate American Style Football Participants Nothing to Disclose Collegiate American Style Football Participants Nothing to Disclose Collegiate American Style Football Participants Nothing to Disclose Collegiate American Style Football Participants Nothing to Disclose Collegiate American Style Football Participants Collegiate American Style Football Participants Nothing to Disclose Collegiate American Style Football Participants Collegiate American Style Football Participants Collegiate American Style Football Participants Collegiate American Style Football Participants Collegiate American Style Football Participants Collegiate American Style Football Participants Collegiate American Style Football Participants Collegiate American Style Football Participants Collegiate American Style Football Participants Collegiate American Style Football Participants Collegiate American Style Football Participants Collegiate American Style Football Participants Collegiate American Style F	Kim	Jonathan			Nothing to Disclose
Armythmias and Clinical EP. Basic 3 Armythmias and Clinical EP. Basic 3 Armythmias and Clinical EP. Basic 3 Armythmias and Clinical EP. Basic 3 Armythmias and Clinical EP. Basic 3 Armythmias and Clinical EP. Basic 3 According and Cardiology. TAVR 1 According and Cardiology. TAVR 1 Identifying the Optimal Echocardiographic Midwid Adverse Ventricular Angles by Proceeding Frought Councer Inspection of Nothing to Disclose Identifying the Optimal Echocardiographic Adverse Ventricular Angles by Proceeding Inspection of Nothing to Disclose Interventional Cardiology. TAVR 1 Luke Interventional Cardiology. TAVR 1 Luke Interventional Cardiology. TAVR 1 Luke Interventional Cardiology. TAVR 1 Luke Interventional Cardiology. TAVR 1 Interventional Cardiology. TAVR 1 Baseline Absociated Mith According and Phypertrophy Is Associated More Angles and Incorpary and Interventional Cardiology. TAVR 1 Baseline Absociation Between Processing in Patients With Dilated Cardiomyoasthy Interventional Cardiology. TAVR 1 Luke Interventional Cardiology. TAVR 1 Interventional Cardiology. TAVR 1 Interventional Cardiology. TAVR 1 Interventional Cardiology. TAVR 1 Interventional Cardiology. TAVR 1 Interventional Cardiology. TAVR 4 Depression as a Potential Therapeuth Target to Improve Quality of Luke Interventional Cardiology. TAVR 1 Interventional Cardiology. TAVR 1 Interventional Cardiology. Stent Failure Analysis by Intravascuair Imaging in Interventional Cardiology. TAVR 1 Interventional Cardiology. TAVR 1 Interventional Cardiology. TAVR 1 Interventional Cardiology. TAVR 1 Interventional Cardiology. TAVR 1 Interventional Cardiology. TAVR 1 Interventional Cardiology. TAVR 1 Interventional Cardiology. TAVR 1 Interventional Cardiology. TAVR 1 Interventional Cardiology. TAVR 2 Interventional Cardiology. TAVR 2 Interventional Cardiology. TAVR 2 Interventional Cardiology. TAVR 2 Interventional Cardiology. TAVR 2 Interventional Cardiology. TAVR 2 Interventional Cardiology. TAVR 2 Interventional Card	Kim	Jonathan		Differential American-Style Football Training Intensities and Cardiac	Nothing to Disclose
Jonathan Imaging the Athlete's Heart Sleep Disordered Breathing and Cardiovascular Correlates in Orbiting to Disclose Collegiate Americanis Nicholand Participants Orbiting to Disclose Orbiting t	- Sull	Jonathall	and and Aunete a Fleart	and Vascular Remodeling Patterns	Trouming to Discrete
Jonathan The Evolving World of LVADs, Transplant and Other Nove Discoveries Other Nove Discoveries	Kim	Jonathan	Imaging the Athlete's Heart	Sleep Disordered Breathing and Cardiovascular Correlates in	Nothing to Disclose
Other Nove Discoveries	Kim	Jonathan	The Evolving World of LVADs. Transplant and	Progenitor Cells and Clinical Outcomes in Patients With Heart	Nothing to Disclose
Athletes Kim Jonathan 31. Non Invasive Imaging: Sports and Exercise Team 1 June Hong Arrhythmias and Clinical EP: Basic 3 Atrial Fibrillation Cycle Length Measured by Transesophageal Echocardiography: A Predictor for Maintaining Sinus Rhythm After DC Cardioversion Kim Jung-Sun Considerations in Antiplatelet Therapy and in ACS Kim Juyong Interventional Cardiology: TAVR 1 Juyong Innovative Use of Echocardiography Kim Juyong Innovative Use of Echocardiography Life After Transcatheter Andric Valve Replacement Kim Juyong Interventional Cardiology: TAVR 4 Juyong Interventional Cardiology: TAVR 4 Juyong Interventional Cardiology: TAVR 4 Juyong Interventional Cardiology: TAVR 4 Kim Juyong Interventional Cardiology: TAVR 4 Juyong Interventional Cardiology: TAVR 4 Juyong Interventional Cardiology: TAVR 4 Juyong Sa. Vascular Medicine: Basic Team 1 Suggested Reviewer Nothing to Disclose Life After Transcatheter Andric Valve Replacement Nothing to Disclose Life After Transcatheter Andric Valve Replacement Nothing to Disclose Nothing to Disclose Nothing to Disclose Life After Transcatheter Andric Valve Replacement Nothing to Disclose Life After Transcatheter Andric Valve Replacement Nothing to Disclose			Other Novel Discoveries	Failure	
Suggested Reviewer	Kim	Jonathan		ACC Poster Moderator	Nothing to Disclose
Team 1 Arrhythmias and Clinical EP: Basic 3 Atrial Fibrillation Cycle Length Measured by Transesophageal Echocardiography: A Predictor for Maintaining Sinus Rhythm After DC Cardioversion Considerations in Antiplatelet Therapy and in ACS With Mewer-Ceneration Drug-Eluting Stents With Mewer-Ceneration Drug-Eluting Stents With Mewer-Ceneration Drug-Eluting Stents The Inflammasome Pathway is Associated With Adverse Ventricular Remodeling Following Transcatheter Aortic Valve Replacement With Mewer-Ceneration Between Duration of Dual Antiplatelet Therapy and Anglographic Multi-Vessel Disease on Outcomes in Patients Treated With Newer-Ceneration Drug-Eluting Stents The Inflammasome Pathway is Associated With Adverse Ventricular Remodeling Following Transcatheter Aortic Valve Replacement With Dilated Cardiomyopathy Interventional Cardiology: TAVR 4 Depression as a Potential Therapeutic Target to Improve Quality of Life After Transcatheter Aortic Valve Replacement Xim Juyong 38. Vascular Medicine: Basic Team 1 Suggested Reviewer Kim Luke Interventional Cardiology: TAVR 1 Baseline Absence of Electrocardiographic Luke Interventional Cardiology: TAVR 2 Interventional Cardiology: TAVR 3 Baseline Absence of Electrocardiographic Luke Interventional Cardiology: TAVR 2 Interventional Cardiology: TAVR 3 Interventional Cardiology: TAVR 4 Interventional Cardiology: TAVR 3 Baseline Absence of Electrocardiographic Left Ventricular Hypertrophy is Associated With Increased Mortality After Transcatheter Aortic Valve Replacement Xim Luke Interventional Cardiology: TAVR 2 Interventional Cardiology: TAVR 2 Interventional Cardiology: TAVR 2 Interventional Cardiology: TAVR 2 Interventional Cardiology: TAVR 2 Interventional Cardiology: TAVR 2 Interventional Cardiology: TAVR 2 Interventional Cardiology: TAVR 2 Interventional Cardiology: TAVR 2 Interventional Cardiology: TAVR 2 Interventional Cardiology: TAVR 2 Interventional Cardiology: TAVR 2 Interventional Cardiology: TAVR 2 Interventional Cardiology:	Kim	Jonathan		Suggested Reviewer	Nothing to Disclose
Echocardiography A Predictor for Maintaining Sinus Rhythm After DC Cardioversion Vim Jung-Sun Considerations in Antiplatelet Therapy and in ACS With Mainter Considerations in Antiplatelet Therapy and in ACS With Mainter Consideration of Dual Antiplatelet Therapy and Angiographic Multi-Vessel Disease on Outcomes in Patients Treated With Mawerse Ventricular Remodeling Following Transcatheter Aortic Valve Replacement Vim Juyong Innovative Use of Echocardiography Inn	··		Team 1		-
DC Cardioversion	Kim	June Hong	Arrhythmias and Clinical EP: Basic 3		
Association Between Duration of Dual Antiplatelet Therapy and ACS ACS Anjographic Multi-Vessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents The Inflammasome Pathway is Associated With Adverse Ventricular Remodeling Following Transcatheter Aortic Valve Replacement Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Interventional Cardiology: TAVR 4 Depression as a Potential Therapeutic Target to Improve Quality of Life After Transcatheter Aortic Valve Replacement Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Intravascuar Ultrasound Guided Percutaneous Coronary Intervention Intermediate Cornary Aftery Disease Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Intravascualar Ultravascuar Guided Percutaneous Coronary Intervention in Intermediate Coronary Aftery Disease Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Transcatheter Aortic Valve Replacement Nothing to Disclose Nothing to Disclose Transcatheter Aortic Valve Replacement Transcatheter Aortic Valve Replacement The Influence of Gender on In-Hospital Clinical Outcomes in Hispancia Following Syrigical and Transcatheter Aortic Valve					ROLE - Tau-PNU Medical
ACS Anglographic Multi-Vessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents Kim Juyong Interventional Cardiology: TAVR 1 The Inflammasome Pathway Is Associated With Adverse Ventricular Remodeling Following Transcatheter Aortic Valve Replacement Kim Juyong Innovative Use of Echocardiography Identifying the Optimal Echocardiographic Variables to Predict Outcome Through Correlation Mapping in Patients With Dilated Cardiomyopathy Kim Juyong Interventional Cardiology: TAVR 4 Depression as a Potential Therapeutic Target to Improve Quality of Life After Transcatheter Aortic Valve Replacement Kim Juyong 38. Vascular Medicine: Basic Team 1 Suggested Reviewer Nothing to Disclose Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Intravascular Ultrasound Guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Disease Kim Luke Interventional Cardiology: TAVR 1 Baseline Absence of Electrocardiographic Left Ventricular Hypertrophy is Associated With Increased Mortality After Transcatheter Aortic Valve Replacement Nothing to Disclose Nothing to Disclose Nothing to Disclose Transcatheter Aortic Valve Replacement Nothing to Disclose Transcatheter Aortic Valve Replacement The Influence of Gender on In-Hospital Clinical Outcomes in Hispantos Following Surgical and Transcatheter Aortic Valve	Kim	Jung-Sun		Association Between Duration of Dual Antiplatelet Therapy and	CONSULTANT FEES/HONORARIA - Pfizer Inc
Interventional Cardiology: TAVR 1 The Inflammasome Pathway Is Associated With Adverse Ventricular Remodeling Following Transcatheter Aortic Valve Replacement		_		Angiographic Multi-Vessel Disease on Outcomes in Patients Treated	
Remodeling Following Transcatheter Aortic Valve Replacement Sim	Kim	Juvona	Interventional Cardiology: TAVR 1		Nothing to Disclose
Cutcome Through Correlation Mapping in Patients With Dilated Cardiomyopathy Mim Juyong Interventional Cardiology: TAVR 4 Depression as a Potential Therapeutic Target to Improve Quality of Disclose Life After Transcatheter Aortic Valve Replacement Suggested Reviewer Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Intravascual rultrasound Guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Disease Kim Luke Interventional Cardiology: TAVR 1 Baseline Absence of Electrocardiographic Left Ventricular Hypertophy is Associated With Increased Mortality After Transcatheter Aortic Valve Replacement The Influence of Gender on In-Hospital Clinical Outcomes in Hispanica Following Surgical and Transcatheter Aortic Valve		,9	Triving Saladology. 17411		
Cutcome Through Correlation Mapping in Patients With Dilated Cardiomyopathy Mim Juyong Interventional Cardiology: TAVR 4 Depression as a Potential Therapeutic Target to Improve Quality of Disclose Life After Transcatheter Aortic Valve Replacement Suggested Reviewer Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Intravascual rultrasound Guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Disease Kim Luke Interventional Cardiology: TAVR 1 Baseline Absence of Electrocardiographic Left Ventricular Hypertophy is Associated With Increased Mortality After Transcatheter Aortic Valve Replacement The Influence of Gender on In-Hospital Clinical Outcomes in Hispanica Following Surgical and Transcatheter Aortic Valve	V:		languation Han of Fahan and San and	Idealificanthe Online of Enhanced in the Market Co. 19	Nething to Displace
Cardiomyopathy	NIII	Juyong	innovative Use of Echocardiography		INOUTING to DISCIOSE
Life After Transcatheter Aortic Valve Replacement Life After Transcatheter Aortic Valve Replacement Life After Transcatheter Aortic Valve Replacement Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Interventional Cardiology: TAVR 1 Baseline Absence of Electrocardiographic Left Ventricular Hypertrophy is Associated With Increased Mortality After Transcatheter Aortic Valve Replacement Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Transcatheter Aortic Valve Replacement Nothing to Disclose Nothing to Disclose Nothing to Disclose The Influence of Gender on In-Hospital Clinical Outcomes in Hispants Following Surgical and Transcatheter Aortic Valve				Cardiomyopathy	
Kim Juyong 38. Vascular Medicine: Basic Team 1 Suggested Reviewer Five Year Outcomes of Fractional Flow Reserve Guided Versus Nothing to Disclose Kwon-Bae Interventional Cardiology: Stent Failure Five Year Outcomes of Fractional Flow Reserve Guided Versus Nothing to Disclose Intravascular Ultrasound Guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Disease Kim Luke Interventional Cardiology: TAVR 1 Baseline Absence of Electrocardiographic Left Ventricular Hypertophy is Associated With Increased Mortality After Transcatheter Aortic Valve Replacement Kim Luke Interventional Cardiology: TAVR 2 The Influence of Gender on In-Hospital Clinical Outcomes in Hispanics Following Surgical and Transcatheter Aortic Valve	Kim	Juyong	Interventional Cardiology: TAVR 4		Nothing to Disclose
Kim Kwon-Bae Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Intravascuar Imaging Intravascuar Imaging Intravascuar Imaging Intravascuar Imaging Intravascuar Imaging Intravascuar Imaging Intravascuar Imaging Intravascuar Imaging Intravascuar Imaging Intravascuar Imaging Intravascuar Imaging Intervention in Intermediate Coronary Artery Disease Example 2 Baseline Absence of Electrocardiographic Left Ventricular Hypertophy is Associated With Increased Mortality After Transcatheter Aortic Valve Replacement Example 2 Interventional Cardiology: TAVR 2 Inte	Kim	Juvona	38. Vascular Medicine: Basic Team 1		Nothing to Disclose
Analysis by Intravascuar Imaging Intravascular Ultrasound Guided Percutaneous Coronary Intervention in Intervention in Intervention in Intervention in Intervention in Intervention in Intervention in Intervention in Intervention in Intervention in Intervention in Intervention in Intervention in Intervention in Intervention in Intervention Int	Kim		Interventional Cardiology: Stent Failure	Five Year Outcomes of Fractional Flow Reserve Guided Versus	
Kim Luke Interventional Cardiology: TAVR 1 Baseline Absence of Electrocardiographic Left Ventricular Hypertrophy is Associated With Increased Mortality After Transcatheter Aortic Valve Replacement Luke Interventional Cardiology: TAVR 2 The Influence of Gender on In-Hospital Clinical Outcomes in Hispancis Following Surgical and Transcatheter Aortic Valve					
Hypertrophy Is Associated With Increased Mortality After Transcatheter Aortic Valve Replacement Luke Interventional Cardiology: TAVR 2 The Influence of Gender on In-Hospital Clinical Outcomes in Hispanics Following Surgical and Transcatheter Aortic Valve Hispanics Following Surgical and Transcatheter Aortic Valve	Kim	Luke	Interventional Cardiology: TAVR 1		Nothing to Disclose
Kim Luke Interventional Cardiology: TAVR 2 The Influence of Gender on In-Hospital Clinical Outcomes in Hispanics Following Surgical and Transcatheter Aortic Valve	•		3,	Hypertrophy Is Associated With Increased Mortality After	··· J =
Hispanics Following Surgical and Transcatheter Aortic Valve	Vim	Luko	Interportional Cardiology TAVE 2		Nothing to Disclose
	NIII	Luke	interventional Cardiology: TAVR 2		Induling to Disclose
		<u> </u>			

Contract of the contract of th				<u> </u>
Last Name Kim	First Name Luke	Session Title Interventional Cardiology: TAVR 2	Presentation Title Does Intra-Aortic Balloon Pump Placement During Hospitalization	Disclosures Nothing to Disclose
			Course for Transcatheter Aortic Valve Replacement Portent a Worse Clinical Outcome?	
Kim	Luke	Interventional Cardiology: TAVR 3	Periprocedural Blood Transfusions in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Kim	Luke	Outcomes in Valvular Heart Disease	In-Hospital Clinical Outcomes Following Concomitant Coronary	Nothing to Disclose
Kim	Luke	Sex Disparity in VHD Outcomes	Artery Bypass Graft and Heart Valve Surgery in Women The Impact of Gender on In-Hospital Clinical Outcomes Following	Nothing to Disclose
Kim	Melvie	Interventional Complexity and Complications	Isolated Mitral or Aortic Heart Valve Surgery Gender Differences in Post Percutaneous Coronary Intervention	Nothing to Disclose
			Complications Following Acute Myocardial Infarction in the United States	
Kim	Michael	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Severe Dissection Propagation During Diagnostic Angiography of a Young Female Presenting With Self Limiting Chest Pain: A Case of Spontaneous Coronary Artery Dissection	SPEAKER'S BUREAU - Abbott Vascular,Eli Lilly,Medicines Company,MEDTRONIC
Kim	Min Chul	Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	Renal Nerve Denervation Suppress Ventricular Arrhythmia in a Porcine Model After Acute Myocardial Infarction	Nothing to Disclose
Kim	Minsu	Understanding Pulmonary Vascular Disease: From Bench to Bedside	Apelin-13 Co-Treatment With Umbilical Cord Blood-Derived Mesenchymal Stem Cells Improves Engrafted Cell Survival and Inhibits Macrophage Activation in Pulmonary Arterial Hypertension Murine Model	Nothing to Disclose
Kim	Minsu	Interventional Cardiology: Structural Heart	Effect of PFO Closure for Prevention of Recurrent Stroke or TIA in	Nothing to Disclose
Kim	Minsu	Disease Unusual Presentations of ACS	Highly Selected Patients With Cryptogenic Stroke The Role of Coronary Response to Nitrate in Patients With	Nothing to Disclose
Kim	Moo Hyun	Late-Breaking Clinical Trials: Interventional	Suspected Vasospastic Angina Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With	Nothing to Disclose
		-	Coronary Chronic Total Occlusion: DECISION CTO Randomized Trial	
Kim	Myeong Gun	Bridge From the Basics: Translational Research in Pulmonary Hypertension	What Kind of Mesenchymal Stem Cell Is Promising in the Prevention of Pulmonary Arterial Hypertension in a Murine Model?	Nothing to Disclose
Kim	Nick	35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcare Pharmaceuticals SteadyMed; RESEARCH/RESEARCH GRANTS - BELLEROPHON ,Eiger, Gilead Sciences, Inc. ,Lung Botechnology, SPEAKER'S BUREAU - Actelion, Bayer Healthcare Pharmaceuticals
Kim	Peter	Making Progress in Understanding Heart Failure	Stress Induced Cardiomyopathy Triggered by Chemotherapy: When Should Cancer Therapy Be Restarted?	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Korean American Medical Association
Kim	Raymond	FIT Forum: Mix and Mingle	Imaging	CONSULTANT FEES/HONORARIA - Bayer; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Heart IT
Kim	Robert	Town Hall Meeting: Pitfalls of Assessing	Case: Valvular Pathology and HOCM	Nothing to Disclose
Kim	Robert	Valvular Heart Disease Severity Novel Determinants of Outcomes in VHD	ACC Poster Moderator	Nothing to Disclose
Kim	Seokhyeon	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Clinical and Electrocardiographic Characteristics for Prediction of New-Onset Left Ventricular Dysfunction in Patients With Frequent	Nothing to Disclose
Kim	Soo Hyun (Esther)	Uncovering the Intricacies of Vascular Function	Idiopathic Ventricular Premature Complex >10% ACC Poster Moderator	Nothing to Disclose
Kim	Soo-Joong	Coronary Angiography, Intra-Vascular Imaging,		Nothing to Disclose
Kim	Soo-Joong	Revascularization and Outcomes Markers of Prognosis Associated With	Coronary Intervention in Myocardial Infarction Patients Incidence of Subclinical Atherosclerosis in Patients With Resistant	Nothing to Disclose
Kim	Soo-Joong	Elevated Blood Pressure Innovations in Cardiovascular Risk Assessment	Hypertension The Predictive Value of Aortic Arch Calcification on Chest X-Ray for	Nothing to Disclose
		and Reduction	Cardiovascular Events in Comparison With the Coronary Artery Calcium Score and the Framingham Risk Score	
Kim	Sung Sik	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Optical Coherence Tomography Assessment of Coronary Atherectomy Effect: Comparison Between Orbital and Rotational Atherectomy in Severely Calcified Lesions	Nothing to Disclose
Kim	Sung Sik	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Intravascular Ultrasound Assessment of the Effects of Rotational Atherectomy in Calcified Coronary Artery Lesions	Nothing to Disclose
Kim	Sunghee	Therapeutic Advances in Congenital Heart Disease	Effect of Obesity and Underweight Status on Perioperative Outcomes in Patients With Congenital Heart Disease: An Analysis of	Nothing to Disclose
Kim	Sungeon	Highlighted Original Research: Arrhythmias	Data From the Society of Thoracic Surgeons Congenital Heart Surgery Database Renal Nerve Denervation Suppress Ventricular Arrhythmia in a	Nothing to Disclose
	Sungsoo	and Clinical EP and the Year in Review	Porcine Model After Acute Myocardial Infarction	-
Kim	Sungsoo	Arrhythmias and Clinical EP: Basic 3	Entropy of Fibrillatory Waves Contributes to Differentiating Paroxysmal From Persistent and Permanent Atrial Fibrillation	Nothing to Disclose
Kim	Sungsoo	Arrhythmias and Clinical EP: Basic 4	Efficacy of Scattergram Analysis for Classifying Subtypes of Atrial Fibrillation by Fourier Transform of Fibrillatory Waves	Nothing to Disclose
Kim	Susan	05. Arrhythmias and Clinical EP: Devices	Suggested Reviewer	Nothing to Disclose
Kim	Weon		Comparison of Timing of Non-Culprit Lesion Percutaneous	Nothing to Disclose
Kim	Weon	Revascularization and Outcomes Markers of Prognosis Associated With	Coronary Intervention in Myocardial Infarction Patients Incidence of Subclinical Atherosclerosis in Patients With Resistant	Nothing to Disclose
		Elevated Blood Pressure	Hypertension	Ÿ
Kim	Weon	Innovations in Cardiovascular Risk Assessment and Reduction	The Predictive Value of Aortic Arch Calcification on Chest X-Ray for Cardiovascular Events in Comparison With the Coronary Artery Calcium Score and the Framingham Risk Score	Nothing to Disclose
Kim	Won-Jang	Nuclear Cardiology: Beyond Perfusion	Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study	Nothing to Disclose
Kim	Won-Keun	Interventional Cardiology: TAVR 3	Multicenter Evaluation of the ACURATE Neo Transfemoral Transcatheter Heart Valve: Clinical Results and Propensity Matched	Nothing to Disclose
Kim	Won-Keun	Interventional Cardiology: TAVR 4	Comparison With SAPIEN 3 Multicenter Evaluation of Prosthesis Oversizing for the SAPIEN 3 Transcatheter Heart Valve: Impact on New Pacemaker	Nothing to Disclose
Kim	Waa Shik	Coronary Angiography, Intra-Vascular Imaging,	Implantations Comparison of Timing of Non-Culprit Lesion Percutaneous	Nothing to Disclose
Kim	Woo-Shik	Revascularization and Outcomes	Coronary Intervention in Myocardial Infarction Patients	Nothing to Disclose
Kim	Woo-Shik	Markers of Prognosis Associated With Elevated Blood Pressure	Incidence of Subclinical Atherosclerosis in Patients With Resistant Hypertension	Nothing to Disclose
Kim	Woo-Shik	Innovations in Cardiovascular Risk Assessment and Reduction	The Predictive Value of Aortic Arch Calcification on Chest X-Ray for Cardiovascular Events in Comparison With the Coronary Artery Calcium Score and the Framingham Risk Score	Nothing to Disclose
Kim	Yong-Jin	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography. The CONFIRM (COronary CT Angiography Evaluation For Clinical	Nothing to Disclose
Kim	Yoon-Nyun	Arrhythmias and Clinical EP: Anticoagulation	Outcomes: An InteRnational Multicenter) Registry Noac Adherence of the Patients With Nonvalvular Atrial Fibrillation	Nothing to Disclose
Kim	Yoon-Nyun	Issues Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	in Real Practice Five Year Outcomes of Fractional Flow Reserve Guided Versus Intravascular Ultrasound Guided Percutaneous Coronary	Nothing to Disclose
Kim	Voung Hak		Intervention in Intermediate Coronary Artery Disease	Nothing to Disclose
Kim	Young-Hak	Late-Breaking Clinical Trials: Interventional	Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With Coronary Chronic Total Occlusion: DECISION CTO Randomized Trial	Nothing to Disclose
·	· · · · · · · · · · · · · · · · · · ·	·	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·

CONTRACTOR OF THE PARTY OF THE				
Last Name Kim	First Name Young-Hak	Session Title Interventional Cardiology: Intravascular	Presentation Title Anatomic Versus Ischemic Burden in Predicting Outcomes of	Disclosures Nothing to Disclose
Kim	Young-Hak	Physiology and Endothelial Function Complex Coronary Intervention: Left	Coronary Artery Disease: Data From IRIS-FFR Registry The Prognostic Implications of Current Periprocedural Myocardial	Nothing to Disclose
Killi	Tourig-mak	Main/Bifurcations and Multivessel Disease	Infarction Definitions in Patients Underwent Percutaneous Conronary Intervention With Unprotected Left Main Coronary Artery Disease	Notining to Disclose
Kim	Young-Hak	Advances in Lipid Management	Lower Mortality in Patients With Vasospastic Angina Who Receive Statin Therapy: Data From the Asan Vasospastic Angina Registry	Nothing to Disclose
Kim Kim	Young-Hak	Refining PCI Technique and Outcomes CAD in Unique Patient Populations	External Validation of DAPT Score in Two Large Cohorts Mortality of Patients With Previous Stroke Undergoing Drug-Eluting	Nothing to Disclose Nothing to Disclose
	Young-Hak		Stent Implantation	
Kim	Yuli	Patient-Centered Care in Adult Congenital Heart Disease	Panelist	Nothing to Disclose
Kim	Yuli	Patient-Centered Care in Adult Congenital Heart Disease	Empowering and Educating Patients About their Health	Nothing to Disclose
Kim-Dopp	Meena	Diabetes and Other Issues in Cardiovascular Prevention	Quality and Access to Care for Cardiovascular Disease Prevalence in Women Veterans: Population Estimate Using Electronic Health Records	Nothing to Disclose
Kimmelstiel	Carey	Challenges in Percutaneous Interventions: International Perspectives From the Hong Kong College of Cardiology, Singapore Cardiac Society, and American College of Cardiology	Bivalirudin Should Be the Standard of Care as Opposed to Heparin in PCI	CONSULTANT FEES/HONORARIA - gilead
Kimmelstiel	Carey	Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - gilead
Kimmelstiel Kimura	Carey Kazuo	Interventional Challenging Cases: Team 2 The Evolving World of LVADs, Transplant and Other Novel Discoveries	ACC Challenging Case Reviewer B-Type Natriuretic Peptide Levels Is a Useful Prognostic Marker in the Patients With Eosinophilic Granulomatosis With Polyangitis	CONSULTANT FEES/HONORARIA - gilead RESEARCH/RESEARCH GRANTS - Astellas, Bayer Company, Daiichi-Sankyo company, Eli Lilly Japan, Kowa company, Mitsubishi Tanabe, MSD, Nihon-Boehringer - Ingelheim, On, Olsuka, Pitzer, Research Institute for Production Development, Sanofi-Aventis, Shionogi, Shionogi, Takeda, TOA EIYO Ltr, SPEAKERS BUREAU - AstraZeneca, Bayer, Daiichi- Sankyo, MSD, TOA EIYO Ltb.
Kimura	Takehiro	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Compliance to Updated AHA/ACC Quality Measures Among Patients With Atrial Fibrillation in Japan and Its Association With Their Quality of Life	Nothing to Disclose
Kimura	Takeshi	Highlighted Original Research: Interventional Cardiology and the Year in Review	Clinical, Angiographic and Procedural Correlates of Absorb Scaffold Thrombosis: A Matched Multicenter Registry Analysis	RESEARCH/RESEARCH GRANTS - ABBOTT Vascular.Terumo
Kimura	Takeshi	Interventional Cardiology: Intravascular	Comparison of Very Late Vascular Response Beyond 2 Years After	RESEARCH/RESEARCH GRANTS - ABBOTT
Vien	Talasahi	Physiology and Endothelial Function	Stent Implantation Between EES and BES: An OCT Sub-Study of the NEXT	Vascular,Terumo
Kimura	Takeshi	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Application of DAPT Score to Predict Ischemic and Bleeding Events in Japanese Patients Undergoing Drug-Eluting Stent Implantation: An Observation From a Pooled Cohort of the CREDO-Kyoto Cohort- 2, RESET, and NEXT Trials	RESEARCH/RESEARCH GRANTS - ABBOTT Vascular,Terumo
Kimura	Takumi	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Sex Differences in the Risk Factors for Endothelial and Microvascular Dysfunction in Patients With Angina in the Absence of Obstructive Coronary Artery Disease	Nothing to Disclose
Kimura	Toshiyuki	New Technologies in Echocardiography	Dynamic Changes of Mitral Apparatus in Acute Myocardial Infarction With Ischemic Mitral Regurgitation: Prospective 3D Quantitative Echocardiographic Study	Nothing to Disclose
Kindya	Bryan	The Evolving World of LVADs, Transplant and	Progenitor Cells and Clinical Outcomes in Patients With Heart Failure	Nothing to Disclose
Kindya	Bryan	Other Novel Discoveries Unusual Presentations of ACS	Circulating Progenitor Cells Levels and Outcomes in Acute Myocardial Infarction	Nothing to Disclose
King	Ingrid	Advances in HCM, PPCM and Other Cardiomyopathies	Long-Term Outcomes of Childhood Left Ventricular Non- Compaction: Results From a National Population-Based Study	Nothing to Disclose
King	Jordan	Arrhythmias and Clinical EP: Basic 5	Cryoballoon Ablation Targeting Left Atrial Fibrosis Produces Similar	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
King	Jordan	New Insights Into Prediction and Treatment of	Outcomes in Paroxysmal and Persistent Atrial Fibrillation Cost-Effectiveness of Intensive Blood Pressure Goals in Patients	Allergan, Inc,Catalyst Pharmaceuticals, Inc. OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
King	Marjorie	Hypertension 34. Prevention: Rehabilitation Team 1	With Prior Cardiovascular Disease Suggested Reviewer	Allergan, Inc,Catalyst Pharmaceuticals, Inc. Nothing to Disclose
King	Spencer	Eugene Braunwald Lecture on Future Directions in Cardiovascular Medicine and the Best of JACC Journals	Co-Chair	DATA SAFETY MONITORING BOARD - Abbott Laboratories, Capricor, Inc., Duke University - SAFE PCI Study, Harvard Clinical Research Institute - TRYTON Study, Merck & mp; amp; Company, Wyeth Pharmaceuticals
King	Spencer	Eugene Braunwald Lecture on Future Directions in Cardiovascular Medicine and the Best of JACC Journals	Best of JACC: Interventions in 2016	DATA SAFETY MONITORING BOARD - Abbott Laboratories, Capricor, Inc., Duke University - SAFE PCI Study, Harvard Clinical Research Institute - TRYTON Study, Merck & mp; amp; Company, Wyeth Pharmaceuticals
King	Spencer	Debates on Current Hot Topics in Coronary Intervention	Co-Chair	DATA SAFETY MONITORING BOARD - Abbott Laboratories, Capricor, Inc., Duke University - SAFE PCI Study, Harvard Clinical Research Institute - TRYTON Study, Merck & amp; Company, Wyeth Pharmaceuticals
King	Spencer	The Evolution of Angioplasty 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	Panelist	DATA SAFETY MONITORING BOARD - Abbott Laboratories, Capricor, Inc., Duke University - SAFE PCI Study, Harvard Clinical Research Institute - TRYTON Study, Merck & mp; amp; Company, Wyeth Pharmaceuticals
King	Spencer	Highlighted Original Research: Interventional Cardiology and the Year in Review	Year in Review Speaker	DATA SAFETY MONITORING BOARD - Abbott Laboratories, Capricor, Inc., Duke University - SAFE PCI Study, Harvard Clinical Research Institute - TRYTON Study, Merck & mp; amp; Company, Wyeth Pharmaceuticals
Kini	Annapoorna	Challenging PCI: Tips and Tricks from the	Case Presentation: Catheter Induced Spiral Dissection with Abrupt	Nothing to Disclose
Kini	Annapoorna	Experts Interventional Cardiology: Intravascular Physiology and Endothelial Function	Closure Atherosclerotic Plaque Morphology in Response to High Intensity Lipid Lowering Therapy by Multimodality Imaging Among Women and Men: A YELLOW-II Sub-study	Nothing to Disclose
Kini	Annapoorna	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	and Men: A YELLOW-II Sub-study Comparing PCI Outcomes in the Very Elderly: Does Age Matter? A Report From Outcomes of Septuagenarians, Octogenarians and Nonagenarians After PCI	Nothing to Disclose
Kini	Annapoorna	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Clinical Outcomes Associated With Impella Versus IABP Use in Stable Patients Undergoing High Risk Percutaneous Coronary Intervention	Nothing to Disclose
Kini	Annapoorna	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Impella or Intra-Aortic Balloon Pump Support in Patients Undergoing High Risk Percutaneous Coronary Intervention: A Real World Single Center Experience	Nothing to Disclose
Kini	Annapoorna	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	World Single Center Experience Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	Nothing to Disclose
Kini	Annapoorna	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Angiographic Phenotype and Clinical Outcomes of Patients With Malignancy Undergoing PCI	Nothing to Disclose
Kini	Annapoorna	Coronary Angiography, Intra-Vascular Imaging,	White Blood Cell Count and Major Adverse Cardiovascular Events	Nothing to Disclose
		Revascularization and Outcomes	After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study	

WASHINGTON, DC | MARCH 17 - 19 2017

Last Name	First Name	Session Title	Presentation Title	Disclosures
Kini	Annapoorna	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Synergistic Effects of Coronary Calcification and Inflammation on Risks for Adverse Cardiovascular Events After PCI: Results From a Large Single-Center Registry	Nothing to Disclose
Kini	Annapoorna	Interventional Cardiology: Stent Failure	Multimodality Intravascular Imaging to Evaluate Plaque	Nothing to Disclose
Kini	Annapoorna	Analysis by Intravascuar Imaging Novel Developments in Acute Coronary	Characteristics in Patients With Diabetes Mellitus Trends in Incidence and Mortality Associated With Acute Kidney	Nothing to Disclose
Kini	Annapoorna	Syndromes Cutting Edge Vascular Medicine	Injury in Patients Undergoing PCI for Acute Coronary Syndrome Proprotein Convertase Subtilisin Kexin Type 9 Protein Expression Is Increased in Lipid Rich Human Atherosclerotic Plaques Compared	Nothing to Disclose
Kini	Annapoorna	Innovations in Cardiovascular Risk Assessment	to Fibrous Plaques Optical Coherence Tomography of Culprit Lesions in Patients With	Nothing to Disclose
	·	and Reduction	Prior Cerebrovascular Events Compared to Controls	-
Kini	Annapoorna	Timely Topics in Acute Coronary Syndromes	Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions	Nothing to Disclose
Kini	Annapoorna	Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes	Nothing to Disclose
Kini	Annapoorna	Optimizing the Care of ACS Patients	Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population	Nothing to Disclose
Kini	Annapoorna	Interventional Complexity and Complications	Prediction of Acute Kidney Injury in Patients Undergoing Coronary Intervention Using Calculation of Serum Osmolality	Nothing to Disclose
Kini	Annapoorna	Interventional Cardiology: PCI in Complex Patients		Nothing to Disclose
Kini	Annapoorna	Highlights in Vascular Medicine Research	Morphological Features of Vascular Healing in Paclitaxel Coated Balloon Compared to Plain Old Balloon Angioplasty in Human Peripheral Artery Disease	Nothing to Disclose
Kini	Annapoorna	The Inside View: Learning From Intracoronary	Investigation of Novel Drug Targets Implicated in High-Dose Statin	Nothing to Disclose
		Imaging	Therapy From Yellow-II Trial: Towards Personalized Lipid Lowering Therapies	
Kinlay	Scott	Meet the New LE PAD Guidelines: Case- Based Examples of Optimal Vascular Care	Co-Chair	RESEARCH/RESEARCH GRANTS - MEDTRONIC, The Medicines Company
Kinlay	Scott	Highlighted Original Research: Vascular Medicine and the Year in Review	A Critical Evaluation of Exercise Testing in Diagnosing Peripheral Artery Disease	RESEARCH/RESEARCH GRANTS - MEDTRONIC, The Medicines Company
Kinlay	Scott	40. Vascular Medicine: Non Coronary Arterial Disease Team 2	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - MEDTRONIC, The Medicines Company
Kinney	Gene	Advances in HCM, PPCM and Other Cardiomyopathies	NEOD001 Demonstrates Cardiac Biomarker Responses in Patients With Light Chain Amyloidosis: Results From the Phase 1/2 Study	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Prothena; SALARY - Prothena
Kinney	Gregory	Imaging With Cardiac CT: The Case for	Coronary Artery Calcium on Noncontrast Thoracic CT Scans and All-	Nothing to Disclose
Kinno	Menhel	Calcium FIT Clinical Decision Making: Non-Invasive	Cause Mortality: The Copd Gene Cohort Unloading the Left Ventricle: A Case of Mechanical Circulatory	Nothing to Disclose
Kip	Kevin	Imaging and Valvular Heart Disease Emerging Applications of Echocardiography	Support in Acute Aortic Insufficiency Clinical Characteristics and Changes of Valvuloarterial Impedence	Nothing to Disclose
Kipp	Ryan	Arrhythmias and Clinical EP: Devices 3	Severity in Patients Undergoing Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis Outcomes Following Implant of Semi-Permanent Pacemaker	Nothing to Disclose
Kipperman	Robert	Interventional Cardiology: TAVR 3	Versus Temporary Pacemaker Initial Use of the Evolut Pro Self-Expanding Transcatheter Aortic	CONSULTANT FEES/HONORARIA - Abbott
			Valve <i></i>	Laboratories,Edwards,MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cephea
Kiramijyan	Sarkis	Interventional Cardiology: TAVR 3	Acute Aortic Regurgitation Post-Transcatheter Aortic Valve Replacement: Impact of Various Treatment Strategies	Nothing to Disclose
Kirby	Amanda	Controversies Surrounding TAVR: 2017 and Beyond	Panelist Panelist	CONSULTANT FEES/HONORARIA - MEDTRONIC
Kirchhof	Paulus	Arrhythmias and Clinical EP: Anticoagulation Issues	Real-World Versus Randomized Trial Outcomes in Similar Populations of Rivaroxaban-Treated Patients With Nonvalvular Atrial Fibrillation in ROCKET AF and XANTUS	CONSULTANT FEES/HONORARIA - consultant fees and honoraria from several drug and device companies. Details of all my relations with industry are disclosed on the web site of the ESC.; DATA SAFETY MONITORING BOARD - sanofi. Details of all my relations with industry are disclosed on the web site of the ESC.; RESEARCH/RESEARCH GRANTS - I have received support in the form of research grants from several drug and device companies to conduct investigator-initiated research projects and trials. Details of all my relations with industry are disclosed on the web site of the ESC.
Kirchner	Lester	Contemporary Issues in Familial Hypercholesterolemia	The Hidden Burden of EHR-Identified Familial Hypercholesterolemia: Mortality and Clinical Outcomes	Nothing to Disclose
Kirkpatrick	James	Palliative Care for the 99% I: Promoting Palliative Care: The Why and What of PC Therapy	Co-Chair	RESEARCH/RESEARCH GRANTS - Philips-site PI for study
Kirkpatrick	James	Innovations in Advocacy and Patient Centered Care	Describing Collaboration Between Cardiology and Palliative Care: A National Survey Study of Current Practices, Challenges and Barriers	RESEARCH/RESEARCH GRANTS - Philips-site PI for study
Kirolos	Irene	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Perioperative Administration of Amiodarone or Beta Blockers in Cardiac Surgery: Which Is More Effective in Reducing Postoperative Atrial Fibrillation?	Nothing to Disclose
Kirtane	Ajay	Interventional Live Case Session IV: Complex Coronary Transmission from St. Vincent Hospital (Indianapolis, IN)	Co-Chair	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, Eli Lilly, Glaxo SmithKline, MEDTRONIC, St. Jude Medical
Kirtane	Ajay	Debates on Current Hot Topics in Coronary Intervention	Debate Pro: Yes, the Data Favor Invasive Management and Revascularization for These Patients	Lary, Osazus Smitrikinie, MED TRONIC, St. Sude Medical RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, Eli Lilly, GlaxoSmithKline, MEDTRONIC, St. Jude Medical
Kirtane	Ajay	Practicum on Tools for CHIP (Complex and Higher-Risk Procedures in Indicated Patients)	Co-Chair	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, Eli
Kirtane	Ajay	Practicum on Tools for CHIP (Complex and Higher-Risk Procedures in Indicated Patients)	When and How to Use Hemodynamic Support for High Risk PCI	Lilly,GlaxoSmithKline,MEDTRONIC,St. Jude Medical RESEARCH/RESEARCH GRANTS - Abbott Vascular,Abiomed,Boston Scientific,Eli
Kirtane	Ajay	Considerations in Antiplatelet Therapy and in ACS	Effect of Thrombotic and Bleeding Risk According to Platelet Reactivity on 2-Year Mortality: The ADAPT-DES Study	Lilly,GlaxoSmithKline,MEDTRONIC,St. Jude Medical RESEARCH/RESEARCH GRANTS - Abbott Vascular,Abiomed,Boston Scientific,Eli
Kirtane	Ajay	Considerations in Antiplatelet Therapy and in ACS	Platelet Reactivity and Outcomes After PCI of Lesions With and Without In-Stent Restenosis: The ADAPT-DES Study	Lilly,GlaxoSmithKline,MEDTRONIC,St. Jude Medical RESEARCH/RESEARCH GRANTS - Abbott Vascular,Abiomed,Boston Scientific,Eli
Kirtane	Ajay	Interventional Cardiology: Angiography,	Morphologic Patterns of In-Stent Chronic Total Occlusions: An	Lilly,GlaxoSmithKline,MEDTRONIC,St. Jude Medical RESEARCH/RESEARCH GRANTS - Abbott
		Intravascular Imaging and Interventional CT/MR	Intravascular Ultrasound Study	Vascular,Abiomed,Boston Scientific,Eli Lilly,GlaxoSmithKline,MEDTRONIC,St. Jude Medical
Kirtane	Ajay	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Platelet Reactivity and Outcomes After PCI of Saphenous Vein Grafts Versus Native Coronary Arteries: The ADAPT-DES Study	RESEARCH/RESEARCH GRANTS - Abbott Vascular,Abiomed,Boston Scientific,Eli Lilly,GlaxoSmithKline,MEDTRONIC,St. Jude Medical
Kirtane	Ajay	Vascular Access and Hemostasis Issues	Mortality, Length of Stay, and Cost Implications of Procedural Bleeding After Contemporary Percutaneous Interventions Involving	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, Eli
			Large-Bore Catheters	Lilly,GlaxoSmithKline,MEDTRONIC,St. Jude Medical

Last Name	First Name	Session Title	Presentation Title	Disclosures
Kirtane	Ajay	Interventional Cardiology: PCI and TAVR in Complex Patients	Long-Term Adverse Ischemic Outcomes After Percutaneous Coronary Intervention Among Patients With Versus Without Prior Coronary Artery Bypass Grafting: Analysis From 17 Randomized Trials	RESEARCH/RESEARCH GRANTS - Abbott Vascular,Abiomed,Boston Scientific,Eli Lilly,GlaxoSmithKline,MEDTRONIC,St. Jude Medical
Kirtane	Ajay	Interventional Cardiology: TAVR 3	Role of Hospital Volume in Identifying Low and High-performing Surgical Valve Centers in the United States	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, Eli Lilly, GlaxoSmithKline, MEDTRONIC, St. Jude Medical
Kirtane	Ajay	Advances in Chronic Total Occlusion Intervention	Is Platelet Reactivity Associated With Ischemic Events Following Successful Chronic Total Occlusion Percutaneous Coronary Intervention	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, Eli Lilly, GlaxoSmithKline, MEDTRONIC, St. Jude Medical
Kirtane	Ajay	Advances in Chronic Total Occlusion Intervention	Association of Stress Test Risk Classification With Health Status Change After Chronic Total Occlusion PCI: Insights From the OPEN- CTO Registry	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, Eli Lilly, GlaxoSmithKline, MEDTRONIC, St. Jude Medical
Kirtane	Ajay	Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	RÉSEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, Eli Lilly, GlaxoSmithKline, MEDTRONIC, St. Jude Medical
Kirtane	Ajay	Advances in Chronic Total Occlusion Intervention	Hemodynamically-Supported PCI of Chronic Total Occlusions: A Case Series	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, Eli Lilly, GlaxoSmithKline, MEDTRONIC, St. Jude Medical
Kirtane	Ajay	Advances in Chronic Total Occlusion Intervention	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, Eli Lilly, GlaxoSmithKline, MEDTRONIC, St. Jude Medical
Kirtane	Ajay	Refining TAVR Outcomes	Incidence and Outcomes of Patients Requiring Surgical Bail-Out During Transcatheter Aortic Valve Replacement: A Report From the NCDR® STS/ACC Transcatheter Valve Therapy (TVT) Registry	RÉSEARCH/RESEARCH GRANTS - Abbott Vascular,Abiomed,Boston Scientific,Eli Lilly,GlaxoSmithKline,MEDTRONIC,St. Jude Medical
Kirtane	Ajay	20. Interventional Cardiology: Coronary Intervention: CTO Team 1	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, Eli Lilly, GlaxoSmithKline, MEDTRONIC, St. Jude Medical
Kirtane	Ajay	22. Interventional Cardiology: Coronary Intervention: Left Main, Multivessel, Bifurcation Team 1	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, Eli Lilly, GlaxoSmithKline, MEDTRONIC, St. Jude Medical
Kisaka	Tomohiko	Innovations in Cardiovascular Risk Assessment and Reduction	The Prognostic Value of CPET: Association With Coronary Artery Calcium Score	Nothing to Disclose
Kisaka	Tomohiko	Non Invasive Imaging: Role of Exercise Testing		Nothing to Disclose
Kishi	Satoru	Non Invasive Imaging: Prognostic Implications of CT Angiography	Coronary Artery Structural Remodeling by Computed Tomography and Echocardiographic Left Ventricular Mass Changes Over the Next 5 Years: The Coronary Artery Risk Development in Young Adults (CARDIA) Study	Nothing to Disclose
Kishi	Satoru	Insights From Echocardiography Use	Relation of Left Ventricular Remodeling to Left Ventricular Diastolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	Nothing to Disclose
Kishi	Satoru	Insights From Echocardiography Use	Relation of Left Ventricular Remodeling to Left Ventricular Systolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	Nothing to Disclose
Kita	Kenneth	Arrhythmias and Clinical EP: Anticoagulation Issues	Does Stroke Risk Influence the Decision to Anticoagulate Post Percutaneous Coronary Intervention Patients With Atrial Fibrillation: A Review of 3850 Patients	Nothing to Disclose
Kitabata	Hironori	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Comparison of Very Late Vascular Response Beyond 2 Years After Stent Implantation Between EES and BES: An OCT Sub-Study of the NEXT	Nothing to Disclose
Kitabata	Hironori	Unusual Presentations of ACS	Incidence and Predictors of Lesion Specific Ischemia by FFR _{CT} : Learnings From the International ADVANCE Registry	Nothing to Disclose
Kitai	Takeshi	Making Progress in Understanding Heart Failure	Exercise Intolerance and Proportional Pulse Pressure Response in Patients With Chronic Heart Failure	Nothing to Disclose
Kitai	Takeshi	Making Progress in Understanding Heart Failure	Impact of Proportional Pulse Pressure on Exercise Tolerance and Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction	Nothing to Disclose
Kitai	Takeshi	Updates on Risk Factors for Cardiovascular Disease	Association Between Short and Long Sleep Duration and Cardiovascular Outcomes? A Systematic Review and Meta-Analysis	Nothing to Disclose
Kitai	Takeshi	Emerging Developments in HFpEF and Arryhthmias	Paradoxical Impact of Proportional Pulse Pressure on Mortality in Patients With Heart Failure With Preserved Ejection Fraction	Nothing to Disclose
Kitai	Takeshi	Emerging Developments in HFpEF and Arryhthmias	The Association of Thick Left Ventricular Hypertrophy With Cardiovascular Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From the TOPCAT Trial	Nothing to Disclose
Kitai	Takeshi	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Circulating Intestinal Fatty Acid-Binding Protein (I-FABP) Levels Portends Higher Risk of Adverse Clinical Outcomes in Advanced Decompensated Heart Failure	Nothing to Disclose
Kithcart	Aaron	Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment	Clinical Facilitator	Nothing to Disclose
Kithcart	Aaron	Mechanisms of Vascular Inflammation in Atherogenesis	ACC Poster Moderator	Nothing to Disclose
Kithcart Kitkungvan	Aaron Danai	FIT Clinical Decision Making Reviewers 1 Highlighted Original Research: Valvular Heart	ACC FIT Clinical Decision Making Reviewer Diffuse Interstitial and Regional Replacement Fibrosis in Chronic	Nothing to Disclose Nothing to Disclose
Kitslaar	Pieter	Disease and the Year in Review Non Invasive Imaging: Coronary Calcium	Primary Mitral Regurgitation: Insights From Cardiovascular Magnetic Resonance Association of Coronary Artery Calcium Progression With Coronary	SALARY - Medis medical imaging systems b.v., Leiden, The
Kittipibul	Veraprapas	Scoring and CV Risk Assessment Heart Failure and Cardiomyopathies: Is Heart	Plaque Progression Determined by Quantitative Coronary Artery Plaque Analysis Effect of Coenzyme Q10 on Left Ventricular Remodeling and	Nothing to Disclose
·		Failure With a Normal EF for Real?	Mortality in Patients With Heart Failure: A Meta-Analysis	
Kittipibul	Veraprapas	Emerging Applications of Echocardiography	Echocardiographic Assessment of Right Ventricular Function in Acute Right Ventricular Failure Identified by Hemodynamic Criteria	Nothing to Disclose
Kittipibul	Veraprapas	Innovations in Advocacy and Patient Centered Care	Impact of Gender on Outcomes Among Patients With Acute Coronary Syndrome Undergoing Primary Percutaneous Coronary Intervention in Southeast Asia	Nothing to Disclose
Kittleson	Michelle	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Angiographic Dye Prior to Combined Heart-Kidney Donation Does Not Appear to Harm Donor Kidney Function After Transplant	Nothing to Disclose
Kittleson	Michelle	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Percutaneous Coronary Intervention With Everolimus-Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy and the Impact of Diabetes Mellitus on Stent and Target Lesion Patency	Nothing to Disclose
Kitzman	Dalane	Emerging Developments in HFpEF and Arryhthmias	Effects of Age and Comorbidities on Outcomes in Patients With Heart Failure From HF-ACTION	CONSULTANT FEES/HONORARIA - Abbvie,Bayer Healthcare Pharmaceuticals,Corviamedical,Forest Laboratories,GlaxoSmithKline,MEDTRONIC,Merck & Dramp; Co., Inc.,Relyps; OTHER - gilead,Relypsa; RESEARCH/RESEARCH GRANTS - Novartis



Carry Contract of the Contract				
Last Name Kiwan	First Name Ghassan	Session Title Heart Failure: From Pathophysiology to Socio-	Presentation Title Co-Chair	Disclosures
Niwari	Gnassan	Economic Impact: International Perspectives From the Lebanese Cardiac Society, Taiwan Society of Cardiology, and American College	Co-Criair	Nothing to Disclose
		of Cardiology		
Kizer	Jorge	Interventional Cardiology: TAVR 2	Association of Chronic Renal Insufficiency With In-Hospital Outcomes of Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - ClearView Healthcare Partners; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Gilead Sciences, Inc. ,Pfizer, Inc
Kizer	Jorge	Innovations in Cardiovascular Risk Assessment and Reduction	Association Between Serum Collagen Biomarkers and Coronary Artery Calcium: The Multi-Ethnic Study of Atherosclerosis (MESA)	CONSULTANT FEES/HONORARIA - ClearView Healthcare Partners; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Gilead Sciences, Inc. ,Pfizer, Inc
Kizer	Jorge	New Insights Into Prediction and Treatment of Hypertension	Collagen Turnover Markers Predict New Onset of Hypertension in Normotensive Subjects: The Multi-Ethnic Study of Atherosclerosis	CONSULTANT FEES/HONORARIA - ClearView Healthcare Partners; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Gilead Sciences, Inc., Pfizer, Inc
Kjaergaard	Jesper	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Association Between QRS Duration on Prehospital Electrocardiogram and Early Outcome in Patients With ST Segment Elevation Myocardial Infarction	Nothing to Disclose
Kjeldsen	Sverre	Assessing the Clinical Impact of Blood Pressure Lowering Therapies	Effect of Antihypertensive Therapy on Development of Incident Conduction System Disease in Hypertensive Patients: The LIFE Study	CONSULTANT FEES/HONORARIA - Bayer,MSD,Takeda
Kjellgren	Karin	Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering Therapies	Hypertension Self-Management: Mobile-Phone Self-Reports Improve Patient Participation in Clinical Consultations	Nothing to Disclose
Klapholz	Marc	Acute Heart Failure: Evaluating Strategies to	Trends in Utilization of Inpatient Palliative Care Services and Racial	CONSULTANT FEES/HONORARIA - St Jude: Steering
		Prevent Readmissions	Disparity of Disposition to Hospice Care Among Patients With Heart Failure in the United States Between 2003 and 2012	Committee: LAPTOP Trial; RESEARCH/RESEARCH GRANTS - Amorocyte, Cardioxyl: Cardioxyl Trial: PI,Cardioxyl: Cardioxyl Trial: PI,Corthera: RELAX AHF Trial: PI
Klapholz	Marc	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Comparison of In-Hospital Outcomes of Septic Shock Patients With and Without Atrial Fibrillation: A Retrospective Propensity-Matched Analysis	CONSULTANT FEES/HONORARIA - St Jude: Steering Committee: LAPTOP Trial; RESEARCH/RESEARCH GRANTS - Amorocyte, Cardioxyl: Cardioxyl Trial: PI, Cardioxyl: Cardioxyl Trial: PI, Corthera: RELAX AHF Trial: PI
Klarich	Kyle	Cutting Edge Innovations in Cardiovascular Imaging: Joint Symposium of the Japanese Circulation Society and American College of Cardiology	Cardiac Amyloid - Imaging for diagnosis in ATTR	Nothing to Disclose
Klarich	Kyle	Innovations in Education	Associations Between Cardiology Fellowship Applicants'	Nothing to Disclose
Klarich	Kyle	Advances in HCM, PPCM and Other	Characteristics and Subsequent Clinical Performance Utility of Routine Serum Free Light Chain Assay for Amyloidosis in	Nothing to Disclose
		Cardiomyopathies	Patients With Heart Failure	-
Klassen	Sheila	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Coronary Artery Disease in Individuals With Human Immunodeficiency Virus Compared to a Seronegative Cohort	Nothing to Disclose
Kleber	Marcus	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Circulating PCSK9 Is Not Associated With All-Cause and Cardiovascular Mortality	Nothing to Disclose
Kleiman	Neal	Frontier in New Transcatheter Techniques	Panelist	CONSULTANT FEES/HONORARIA - EII Lilly Inc, MEDTRONIC; OTHER - Mesoblast; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Boston Scientific, DirectFlow Medical, Merck-Schering
Kleiman	Neal	Imaging for TAVR: Homing in on the Real Issues	Valve Selection When Measurements Are at the Margin	Plough CONSULTANT FEES/HONORARIA - Eil Lilly Inc,MEDTRONIC; OTHER - Mesoblast; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,Boston Scientific,DirectFlow Medical,Merck-Schering
Kleiman	Neal	Controversies Surrounding TAVR: 2017 and	Co-Chair	Plough CONSULTANT FEES/HONORARIA - Eli Lilly Inc, MEDTRONIC;
Neman	iveal	Beyond	Co-Citali	OTHER - Mesoblast; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Boston Scientific, DirectFlow Medical, Merck-Schering Plough
Kleiman	Neal	Interventional Cardiology: TAVR 2	Platelets and von Willebrand Factor Interactions After Transcatheter Aortic Valve Replacement (TAVR): Association With Thrombocytopenia and Thrombosis	CONSULTANT FEES/HONORARIA - EII LIIIJ Inc, MEDTRONIC; OTHER - Mesoblast; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Boston Scientific, DirectFlow Medical, Merck-Schering Plough
Kleiman	Neal	Interventional Cardiology: TAVR 2	The Impact of Preoperative Renal Dysfunction on the Outcomes of Patients Undergoing Surgical Versus Transcatheter Aortic Valve Replacement: An Analysis From the CoreValve US Pivotal High Risk Trial	CONSULTANT FEES/HONORARIA - EII LIIIJ Inc, MEDTRONIC; OTHER - Mesoblast; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Boston Scientific, DirectFlow Medical, Merck-Schering Plough
Kleiman	Neal	Interventional Cardiology: TAVR 3	Initial Use of the Evolut Pro Self-Expanding Transcatheter Aortic Valve <i></i>	CONSULTANT FEES/HONORARIA - EII LIIIJ Inc,MEDTRONIC; OTHER - Mesoblast; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,Boston Scientific,DirectFlow Medical,Merck-Schering Plough
Kleiman	Neal	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Treatment of Refractory Coronary Artery Spasm With Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - EII LIIIJ Inc, MEDTRONIC; OTHER - Mesoblast; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Boston Scientific, DirectFlow Medical, Merck-Schering Plough
Kleiman	Neal	Refining TAVR Outcomes	Incidence and Outcomes of Patients Requiring Surgical Bail-Out During Transcatheter Aortic Valve Replacement: A Report From the NCDR® STS/ACC Transcatheter Valve Therapy (TVT) Registry	CONSULTANT FEES/HONORARIA - Eli Lilly Inc, MEDTRONIC;
Kleiman	Neal	02. Acute and Stable Ischemic Heart Disease: Clinical Team 7	Suggested Reviewer	CONSULTANT FEES/HONORARIA - EII Lilly Inc, MEDTRONIC; OTHER - Mesoblast; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Boston Scientific, DirectFlow Medical, Merck-Schering
Klein	Allan	Controversies in Echocardiography	Co-Chair	Plough Nothing to Disclose
Klein	Allan	Echocardiographic Assessment of LV Diastolic Function The New ASE/EACVI Guidelines 2016 Update: Joint Symposium of the American Society of Echocardiography and the American College of Cardiology	Co-Chair	Nothing to Disclose
Klein	Allan	Echocardiographic Assessment of LV Diastolic Function The New ASE/EACVI Guidelines 2016 Update: Joint Symposium of the American Society of Echocardiography and the American College of Cardiology	Dyspnea and Ascites After Coronary Bypass Surgery: Constriction, Restriction, or Both?	Nothing to Disclose
Klein	Allan	28. Non Invasive Imaging: Echo Team 3	Suggested Reviewer	Nothing to Disclose
Klein	Andrew	Aorto-iliac Disease and Treatment: Practice at "The Edge" in Peripheral Intervention	Co-Chair	Nothing to Disclose
Klein	Andrew	Innovations in Education	Beat Blasts: A Multicenter Study of an Electrocardiogram Email Curriculum for Medicine Residents	Nothing to Disclose
Klein	Andrew	26. Interventional Cardiology: Vascular Access	Suggested Reviewer	Nothing to Disclose
Klein	Barbara	and Complications Team 1 Updates on Risk Factors for Cardiovascular Disease	Retinopathy and Risk of Sudden Cardiac Death: The ARIC Study	Nothing to Disclose
Klein	George	06. Arrhythmias and Clinical EP: Other Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Biotronik, Boston
				Scientific,MEDTRONIC

Current Season is Cardiorecoular Car						
September 1 200 September 200		Disclosures Nothing to Disclose		Session Title Current Issues in Cardiovascular	First Name	Last Name Klein
Egedemicing_Dispatition_end_Subject New Words Standard Completed With Man No. 10 No.		· ·		Epidemiology, Disparities, and Safety		
Linear L		Nothing to Disclose			Josh	Klein
Committee of the Commit		Nothing to Disclose	Type 2 Myocardial Infarction in Young Patients Portends a Worse		Josh	Klein
Monthering Fear Fault Paul Carl You See the Nove? Sersion For Deep EFF Clinical Perspectives on Wearable Sersions Conference Paul Carl You See the Nove? Sersion For Deep EFF Clinical Perspectives on Wearable Sersions Carl Carl Carl Carl Carl Carl Carl Carl	bott,Boston	CONSULTANT FEES/HONORARIA - Abbott		Can You See Me Now? Sensors For	Liviu	Klein
Construction of the control of the c		Scientific,MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Info				
Mind Sheen in the World of STEMP One Updy One Updy One Stempter in the World of STEMP One Updy One Stempter in the World of STEMP One Updy One Stempter in the World of STEMP One Updy One Stempter in the World of STEMP One Updy One Stempter in the World of STEMP One Updy One Stempter in the World of STEMP One Updy One Stempter in the World of STEMP One Updy One Stempter in the World of STEMP One Updy One Stempter in the World of STEMP One One One One One One One One One One	bott,Boston		Does it Fit? Clinical Perspectives on Wearable Sensors	Can You See Me Now? Sensors For	Liviu	Klein
Commonstrate Comm		Scientific,MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Info				
See		Nothing to Disclose			Lloyd	Klein
Interventional CTAIR Tears						
None They Commare? Audits With Congental Heart Diseases Audits With Congental Heart Dise		Notifing to Disclose		Interventional CT/MR Team 1	Lloyd	Kleiii
General Concess Compensation Judice Disease Di		Nothing to Disclose			Nancy	Klein
Sopris and Exercise Affeites with Conjournal Architecture with Football Player with Conjournal Architecture (Conjournal A		Nothing to Disclose		Updates on Risk Factors for Cardiovascular	Ronald	Klein
Congestabli/Valuable Head To Desase Challenging and Andria Annexysm Guidelines to Dely Practice Guidelines to Dely Practice Guidelines to Dely Practice Frank Frank Interventional Cardiology, TAVR 1 Frank Interventional Cardiology, TAVR 1 Frank Interventional Cardiology, TAVR 1 Suny Andria Value Annuals for Transamberts Andre Value Suny Andria Value Annuals for Transamberts Andre Value Suny Andre Value Annuals for Transamberts Andre Value Suny Andre Value Annuals for Transamberts Andre Value Suny Andre Value Annuals for Transamberts Andre Value Suny Andre Value Annuals for Transamberts Andre Value Suny Andre Value Annuals for Transamberts Andre Value Suny Andre Value Annuals for Transamberts Andre Value Suny Andre Value Annuals for Transamberts Andre Value Suny Andre Value Annuals for Transamberts Andre Value Suny Andre Value Annuals for Transamberts Andre Value Suny Andre Value Annuals for Transamberts Andre Value Suny Andre Value Annuals for Transamberts Andre Value Suny Andre Value Annuals for Transamberts Andre Value Male Andre Value Annuals for Transamberts Andre Value Male Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Andre Value Annuals for Transamberts Annuals for Transamberts Annuals for Transamberts Annuals for Transamberts Annuals for Transamberts Annuals for Transamberts Annuals for Transamberts Annuals for Transamberts Annuals for Transamberts Annuals for Transamberts Annuals for Transamberts Annuals fo		Nothing to Disclose	High School Football Player with Congenital Aortic Regurgitation		Jake	Kleinmahon
Prevention			and Aortic Aneurysm	Congenital/Valvular Heart Disease Challenging Guidelines in Daily Practice		
Interventional Cardiology TAVR 1 Soing April C valve Annulus for Transcatheter April Valve Postbess Selection: Integrated of April Valve Colination Burden on the Agreement Between Automated 5-Dimensional Company of the April Colination Burden on the Agreement Between Automated 5-Dimensional Company of the April Colination Burden on the Agreement Between Automated 5-Dimensional Company of the April Colination Burden on the Agreement Between Automated 5-Dimensional Company of the April Colination Burden on the Agreement Between Automated 5-Dimensional Company of the April Colination Burden on the Agreement Between Automated 5-Dimensional Company of the April Colination Burden on the Agreement Between Automated 5-Dimensional Company of the April Colination Burden on the Agreement Between Automated 5-Dimensional Colination Burden on the Agreement Between Automated 5-Dimensional Colination Burden on the Agreement Between Automated 5-Dimensional Colination Burden on the Agreement Between Automated 5-Dimensional Colination Burden Colination Burde		Nothing to Disclose	Mortality Risk Associated With Metabolic Syndrome in Non-Diabetic		Robert	Klempfner
Computed Transgraphy Chad Highlighted Original Research: Valvular Heart Disease and the Year in Review Kilger Chad Prictinical Decision Making Non-invasive International Decision Making Non-invasive Managing and Valvular Heart Disease Firt Clinical Decision Making Transport Valvular Heart Disease Alexa Firt Clinical Decision Making Transport Valvular Heart Disease Firth Clinical Decision Making Transport Valvular Heart Disease Firth Clinical Decision Making Transport Valvular Heart Disease Firth Clinical Decision Making Transport Valvular Heart Disease Firth Clinical And Vascular Medical Decision Making Transport Valvular Heart Disease Firth Clinical And Vascular Medical Presented of Coronary Afterly Disease Firth Clinical And Vascular Medical Presented of Coronary Afterly Disease Firth Clinical And Vascular Medical Presented of Coronary Afterly Disease Firth Clinical And Vascular Medical Presented of Coronary Afterly Disease Firth Clinical And Used for the Terahement of Coronary Afterly Disease Firth Clinical And Vascular Medical Presentation of Coronary Afterly Disease Firth Clinical And Vascular Medical Presentation of Coronary Afterly Disease Firth Clinical And Vascular Medical Presentation of Coronary Afterly Disease Firth Clinical And Vascular Medical Presentation of Coronary Afterly Disease Firth Clinical And Vascular Medical Presentation of Coronary Afterly Disease Firth Clinical And Vascular Medical Presentation of Coronary Afterly Disease Firth Clinical And Vascular Medical Presentation of Coronary Afterly Disease Firth Clinical And Vascular Medical Presentation of Coronary After Presentation of Coronary Afterly Disease Firth Clinical And Vascular Medical Presentation of Coronary Afterly Disease Firth Clinical Presentation of Coronary Afterly Disease Firth Clinical Presentation of Coronary Afterly Presentation of Production of Presentation of Presentation of Assessment Office Presentation of Presentation of Presentation of Presentation of Presentation of Presentation of Presentation of Presentation of		Nothing to Disclose	Sizing Aortic Valve Annulus for Transcatheter Aortic Valve Prosthesis Selection: Impact of Aortic Valve Calcification Burden on the Agreement Between Automated 3-Dimensional	Interventional Cardiology: TAVR 1	Frank	Kley
Disease and the Verein Review US Protest High Test Tries US Protest High Test High Test Tries US Protest High Test High Test Tries US Protest High Test High Test Tries US Protest High Test High Test Tries US Protest High Test High Test Tries US Protest High Test High Test Tries US Protest High Test High Test High Test Tries US Protest High Test High Test High Test High Test Tries US Protest High Test Hi			Computed Tomography			
Fill Clinical Decision Making Non-Invasive Inflanging and Valvular Heart Disease Indinging and Valvular Heart Disease Inchinques in the Transferinor of a Patient With a Complicated Intra-Cardiac Making Fill Clinical Decision Making Interventional Cardiac Making Fill Clinical Decision Making Interventional Cardiac Making Fill Clinical Decision Making Interventional Cardiac Making Fill Clinical Decision Making Interventional Cardiac Making Fill Clinical Decision Making Interventional Cardiac Making Fill Clinical Decision Making Interventional Cardiac Making Fill Clinical Decision Making Interventional Cardiac Making Fill Clinical Decision Making Interventional Cardiac Making Fill Clinical Decision Making Interventional Cardiac Making Fill Clinical Decision Making Interventional Cardiac Making Fill Clinical Decision Making Interventional Cardiac Making Fill Clinical Making Interventional Cardiac Making Intervention Cardiac Making	e,St Jude Medical	SPEAKER'S BUREAU - Philips healthcare,St			Chad	Kliger
Fir Clinical Decision Making: Interventional Cardiology Acute and Stable Ischemic Heart Disease, and Vascular Medicine Clinical Decision Acuted Medicine Cardiology Acute and Stable Ischemic Heart Disease, and Vascular Medicine Klimchak	e,St Jude Medical	SPEAKER'S BUREAU - Philips healthcare,St	A Multi-Modality Approach Using Noninvasive and Invasive Techniques in the Treatment of a Patient With a Complicated Intra-	FIT Clinical Decision Making: Non-Invasive	Chad	Kliger
Alexa	e,St Jude Medical	SPEAKER'S BUREAU - Philips healthcare,St	An Unexpected Guest in the Right Ventricle	Cardiology, Acute and Stable Ischemic Heart	Chad	Kliger
the Risk of, and Used for the Treatment of, Coronary Artery Disease Coronary Artery Disease The PCSK9 Revolution: New Insights Into Evaluation and Treatment Evaluation and Treatment Evaluation and Treatment Evaluation and Treatment Evaluation Formation Evaluation and Treatment Evaluation and Treatment Evaluation and Treatment Evaluation and Evaluation and Evaluation and Treatment Evaluation and Treatment Evaluation and Treatment Evaluation and Treatment Evaluation and Treatment Evaluation and Treatment Evaluation and Treatment Evaluation and Treatment Evaluation and Treatment Evaluation and Treatment Evaluation and Treatment Evaluation and Treatment Evalu		SALARY - Axtria	Modelling the U.S. Population Health Benefits of Further Low-		Alexa	Klimchak
Final PCSK9 Revolution: New insights into Evaluation and Treatment Evaluation and Treatment PCSK9 Revolution: New insights into Evaluation and Treatment PCSK9 Rhibitors for Revolution: Queversity Lipoprotein Goals in Seal-World Cohort With Atherosclerotic Cardiovascular Disease Real-World Cohort With Atherosclerotic Cardiovascular Disease Palliative Care: The Why and What of PC Therapy Palliative Care: The Why and What of PC Therapy Palliative Care: The Why and What of PC Therapy Palliative Care: The Why and What of PC Therapy Palliative Care: The Why and What of PC Therapy Palliative Care: The Why and What of PC Therapy Palliative Care: The Why and What of PC Therapy Palliative Care			Density Lipoprotein Cholesterol Reduction With Alirocumab Among Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia Patients With Elevated Low-Density	the Risk of, and Used for the Treatment of,		
Kine Kristopher Updates in Stable Ischemic Heart Disease Elevation in Cardiac Troponin Rachel Palliathe Care for the 99% I: Promoting Palliathe Care: The Wifty and What of PC Therapy Klinedinst Rachel Palliathe Care for the 99% I: Skillbuilding: PC Therapy Klinedinst Rachel Palliathe Care: The Wifty and What of PC Therapy Klinedinst Rachel Palliathe Care: The Wifty and What of PC Therapy Kliner Dustin Predicing the Future: Observations and Discoveries From Registries and Databases Kliner Dustin The Challenges of Outcome Prediction in Valvular Heart Disease Programment P		SALARY - Axtria	mpact of Statin Intolerance Rates on Need for Ezetimibe and/or PCSK9 Inhibitors for Meeting Low-Density Lipoprotein Goals in a		Alexa	Klimchak
Rachel Palliative Care for the 99% I. Promoting Palliative Care: The Why and What of PC Therapy Panelist		Nothing to Disclose		Updates in Stable Ischemic Heart Disease	Kristopher	Kline
Palliative Care: The Why and What of PC Therapy Therapy		Nothing to Disclose	Elevation in Cardiac Troponin	Palliative Care for the 90% I: Promoting	Pachal	Klinedinet
Encounters: What Would you do? Part I Kliner Dustin Predicting the Future: Observations and Discoveries From Registries and Discoveries From Registries and Databases Kliner Dustin The Challenges of Outcome Prediction in Valvular Heart Disease Dustin The Challenges of Outcome Prediction in Valvular Heart Disease Kliner Dustin TAVR Outcomes Prognostication TAVR Outcomes Prognostication Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Kline-Rogers Eva Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Kline-Rogers Eva Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Klug Gert Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension Severity. Clinical Applications in the TAVR Era Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Rates of Oral Arthicoagulatur Use, While Improving Over Time, Remain Low Among Hospitalized Patients With Atrial Fibrillation Disclose Klug Gert Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension Klugman Darren Highinghted Original Research: Congenital Heart Disease and the Year in Review Unit Muclear Cardiology: Quality Advances in Chronic Total Occlusion Intervention Knaapen Paul Noninvasive Assessment of Coronary Flow Reserve, Independent Of Coronary Artery Disease Knaapen Paul Noninvasive Assessment of Coronary Flow Reserve, Independent Of Lumial Obstruction Knegt Martina Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials Encounters: Whith Pulmonary Hypertension Power Heart Disease Patients With Pulmonary Hypertension Agreement Phypertension From Cardiology-New England Journal of Medicine Late-Breaking Clinical Trials Encounters: Whith Pulmonary Hypertension Production From Reserve, Independent of Luminary Hypertension Production Coronary Flow Registries Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Noth		-		Palliative Care: The Why and What of PC Therapy		Killedilist
Registries Dustin Predicting the Future: Observations and Discoveries From Registries and Databases Pulmonary Vascular Resistance Predicts Mortality in End-Stage Nothing to Disclose Renal Disease Pulmonary Hypertension Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit TAVR Era Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit Tava Patients: Time to Integrate the Right Side Unit Tava Patients: Time to Integrate the Right Side Unit Tava Patients: Time to Integrate the Right Side Unit Tava Patients: Time to Integrate the Right Side Unit Tava Patients: Time to Integrate t		Nothing to Disclose	Panelist		Rachel	Klinedinst
Riliner		Nothing to Disclose		Predicting the Future: Observations and	Dustin	Kliner
Hypertension Severity, Clinical Applications in the TAVR Era		Nothing to Disclose			Dustin	Kliner
TAVR Patients: Time to Integrate the Right Side Unit Kline-Rogers Eva Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Rates of Oral Anticoagulant Use, While Improving Over Time, Remain Low Among Hospitalized Patients With Atrial Fibrillation Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Janssen Pharmaceuticals, Inc. OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA Anticoagulation Forum Physicians, Jansse		Nothing to Disclose	Hypertension Severity: Clinical Applications in the TAVR Era		Duetin	Kliner
Contemporary Practice Remain Low Among Hospitalized Patients With Afrial Fibrillation Physicians, Janssen Pharmaceuticals, Inc.; OFF DIRECTOR, TRUSTEE, OR OTHER FIDUCA Anticoagulation Forum Nothing to Disclose William Darren Highlighted Original Research: Congenital Heart Disease and the Year in Review Highlighted Original Research: Congenital Heart Disease and the Year in Review Winter Cardiology: Quality Automatic SPECT Analysis Compared to Expert Visual Scoring for the Detection of Coronary Artery Disease Knaapen Paul Advances in Chronic Total Occlusion Intervention Intervention Knaapen Paul Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications Alteroscierotic Plaque Morphology is Associated With Impaired Myocardial Blood Flow and Fractional Flow Reserve, Independent of Luminal Obstruction Knegt Martina Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials Highlighted Original Research: Prevention and Intervention Convertase Subtilisin-Kexin Type 9 Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose		_	TAVR Patients: Time to Integrate the Right Side Unit	_		
Klug	OFFICER,	Physicians, Janssen Pharmaceuticals, Inc; OF DIRECTOR, TRUSTEE, OR OTHER FIDUCIA			Eva	Kline-Rogers
Rightlighted Original Research: Congenital Heart Disease and the Year in Review Characteristics, Risk Factors and Outcomes of Extracorporeal Membrane Oxygenation Use in the Pediatric Cardiac Intensive Care Unit Membrane Oxygenation Use in the Pediatric Cardiac Intensive Care Unit Number of Paul Nuclear Cardiology; Quality Automatic SPECT Analysis Compared to Expert Visual Scoring for the Detection of Coronary Artery Disease		Nothing to Disclose			Gert	Klug
Heart Disease and the Year in Review Membrane Oxygenation Use in the Pediatric Cardiac Intensive Care Unit Knaapen Paul Nuclear Cardiology: Quality Automatic SPECT Analysis Compared to Expert Visual Scoring for the Detection of Coronary Artery Disease Knaapen Paul Advances in Chronic Total Occlusion Effects of Successful Percutaneous Coronary Intervention of Chronic Total Occlusions on Myocardial Perfusion and Left Ventricular Function Knaapen Paul Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications Myocardial Blood Flow and Fractional Flow Reserve, Independent of Luminal Obstruction Knegt Martina Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trails (Clinical Trails Reserve): Prevention and The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 Nothing to Disclose		Nothing to Disclose		Highlighted Original Research: Congenital	Darren	Klugman
the Detection of Coronary Artery Disease Knaapen Paul Advances in Chronic Total Occlusion Intervention Advances in Chronic Total Occlusion Intervention Chronic Total Occlusions on Myocardial Pertusion and Left Ventricular Function Ventricular Function Reserve: Clinical Implications Apocardial Blood Flow and Fractional Flow Reserve, Independent Of Luminal Obstruction Advances Anothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Apocardial Blood Flow and Fractional Flow Reserve, Independent of Luminal Obstruction Apocardial Blood Flow and Fractional Flow Reserve, Independent of Luminal Obstruction Finance Clinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries Knickelbine Thomas Highlighted Original Research: Prevention and		-	Jnit			
Roapen		-	the Detection of Coronary Artery Disease			·
Knaapen Paul Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications Myocardial Blood Flow and Fractional Flow Reserve, Independent of Luminal Obstruction Knegt Martina Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials Knickelbine Thomas Highlighted Original Research: Prevention and		Nothing to Disclose	Effects of Successful Percutaneous Coronary Intervention of Chronic Total Occlusions on Myocardial Perfusion and Left		Paul	Knaapen
Knegt Martina Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials Knickelbine Thomas Highlighted Original Research: Prevention and		Nothing to Disclose	Atherosclerotic Plaque Morphology Is Associated With Impaired Myocardial Blood Flow and Fractional Flow Reserve, Independent		Paul	Knaapen
Knickelbine Thomas Highlighted Original Research: Prevention and The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 Nothing to Disclose		Nothing to Disclose	Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY	England Journal of Medicine Late-Breaking	Martina	Knegt
the Year in Review Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 16,721 Patients From 33		Nothing to Disclose	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 nhibitors on Clinical Outcomes in Patients With	Highlighted Original Research: Prevention and	Thomas	Knickelbine
Randomized Clinical Trials Knickelbine Thomas Current Issues in Cardiovascular Health Disparities Among Patients With Familial Nothing to Disclose		Nothing to Disclose	Randomized Clinical Trials Health Disparities Among Patients With Familial		Thomas	Knickelbine
Epidemiology, Disparities, and Safety Hypercholesterolemia in the CASCADE-FH Patient Registry Knight Bradley Meeting of the Minds: HF and EP Decision Co-Chair CONSULTANT FEES/HONORARIA - Apama.	ama,Boston	CONSULTANT FEES/HONORARIA - Anama			Bradley	Knight
Making for Complex Patients Scientific, MEDTRONIC; SPEAKER'S BÜREAL Webster, Biotronik, Boston Scientific, MEDTRON	REAU - Biosense RONIC	Scientific, MEDTRONIC; SPEAKER'S BUREAU Webster, Biotronik, Boston Scientific, MEDTRON		Making for Complex Patients		
Knight Bradley Core Curriculum: Decisions on Afib: From Prevention to Cure Chair CONSULTANT FEES/HONORARIA - Apama Scientific, MeDTRONIC; SPEAKER'S BUREAL Webster, Biotronik, Boston Scientific, MEDTRON	REAU - Biosense RONIC	Scientific, MEDTRONIC; SPEAKER'S BUREAU Webster, Biotronik, Boston Scientific, MEDTRON		Prevention to Cure	-	
Knight Bradley 06. Arrhythmias and Clinical EP: Other Team 1 Suggested Reviewer CONSULTANT FEES/HONORARIA - Apama Scientific, MeDTRONIC; SPEAKER'S BUREAL Webster, Biotronik, Boston Scientific, MeDTRON Scientific, MeDTRON	ama,Boston REAU - Biosense	CONSULTANT FEES/HONORARIA - Apama Scientific,MEDTRONIC; SPEAKER'S BUREAL Webster,Biotronik,Boston Scientific,MEDTROI		·	-	
Knight Stacey Traditional and Novel Factors Used to Assess The Association of Depression at Any Time to the Risk of Death Following Coronary Artery Disease Diagnosis: The Intermountain Coronary Artery Disease HISPIRE Registry		Nothing to Disclose	Following Coronary Artery Disease Diagnosis: The Intermountain	the Risk of, and Used for the Treatment of,	Stacey	Knight
Knight Stacey Arrhythmias and Clinical EP: AF Miscellaneous Circulating MicroRNA Patterns Are Associated With Post-Ablation Nothing to Disclose					Ctanani	Mainh.

Proceded	and a				l
March Marc			Session Title	Presentation Title	Disclosures Nething to Disclose
March Marc	Knops	Reinoud		Pacemaker and Subcutaneous Implantable Cardioverter	Nothing to Disclose
Control Cont	Knowles	Joshua		Predictors of Statin Use for Patients With LDL Cholesterol Above	RESEARCH/RESEARCH GRANTS - Amgen
Action Contract Name of Contract Contract Name of Contrac	Knowles	Joshua	Epidemiology, Disparities, and Safety	Health Disparities Among Patients With Familial	-
Sciences Johnson Hope Proposed on a Cold Register (Section Cold Plant Follows) And Cold Plant Follows Co	Knowles	Joshua		Stanford Preventive Cardiologist	RESEARCH/RESEARCH GRANTS - Amgen
Screens Advanced March (1962) Whentier (1964) Whentier	Knowles	Joshua		ACC Poster Moderator	RESEARCH/RESEARCH GRANTS - Amgen
Proceedings of the Control of Section May 1 (1997) A control of Section Ma	Knowles	Joshua	38. Vascular Medicine: Basic Team 2	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Amgen
Acception Verify Acception of Displaces Acception Accept	Knudtson	Merril		Angiotensin II Receptor Blocker Use, and Survival Following	Nothing to Disclose
County of the New York of Section Committee of Food Engineering County of the New York of Section County of the New York of Section County	Knudtson	Merril		Ventricular Arrhythmia at Primary PCI for ST-Elevation Myocardial	Nothing to Disclose
Foreign-bias To county-Club			From the Real World	Coronary Intervention: Observations From the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Registry	
Reposit Between Hand De Control From En Parker Tong Court Charles Control From En Parker Tong Court Charles Control From En Parker Tong Court Charles Control From En Parker Tong Control	Ко	Dennis		Rate Before and After the 2007 American Heart Association	Nothing to Disclose
ACS ACS Serving Threatone in Heart Failure Colored Both Very Threatone in Heart Failure Colored Both North Heart Failure Colored Both North Heart Failure Colored Both North Heart Failure Colored Both	Ко	Young-Guk		Repair Between Acute/Subacute Versus Chronic Type B Aortic	Nothing to Disclose
No. 1 Provide Transplant of Insalar Fallure Carror (Conscious) (Co	Ko	Young-Guk		Association Between Duration of Dual Antiplatelet Therapy and	Nothing to Disclose
Winding County Security Sec	Kahashigawa	lon		With Newer-Generation Drug-Eluting Stents	DESEADOUDESEADOU CDANTS. COMPON
December 2012 - December 2012	-		Into the Crystal Ball	Box"?	Inc.,Novartis,TransMedics
Robustypase Jun Research Application and Mysocardial Preservation Personal Preservation Recommendati	Kobashigawa	Jon			
Scopering Scope	Kobashigawa	Jon	Revascularization and Myocardial Preservation	Percutaneous Coronary Intervention With Everolimus-Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy and the Impact	RESEARCH/RESEARCH GRANTS - CareDx,
Threaty rem 3 Professor Free Manual Colorates William (Professor Anthropal Verticular Section of Professor Anthrop	Kobashigawa	Jon	14. Heart Failure and Cardiomyopathies:		RESEARCH/RESEARCH GRANTS - CareDx,
Collegate No. 2			Therapy Team 3		Inc.,Novartis,TransMedics
Incorrection Socioseful Perculaneous Coronary Netwerentin Or Chrom Total Socioseful Perculaneous Coronary Netwerentin Or Chrom Total Socioseful Perculaneous Coronary Netwerentin Chrom Total Socioseful Perculaneous Coronary Network Socioseful Perculaneous Coronary Network Socioseful Perculaneous Coronary Network Socioseful Perculaneous Coronary Network Socioseful Perculaneous Coronary Network Socioseful Perculaneous Coronary Network Socioseful Perculaneous Coronary Network Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socioseful Perculaneous Coronary Angelogram With Consideration of Steril Socieseful Perculaneous Coronary Angelogram With Consideration Coronary Angelogram Wi			Contemporary Practice	Fibrillation in Pediatric Patients	-
Teckwayashi Tauyoshi Ohen Novel Decorress Sportfeance of Asapa-123-Suppl-BMPP-Scringraphy in the Ohen Novel Decorress Recovery (all Nethrolands Sportfeance) of Let Werterlands Sportfeance of Asapa-123-Suppl-BMPP-Scringraphy in the Ohen Novel Decorress Recovery (all Nethrolands Sportfeance) of Let Werterlands Sportfeance (all Nethrolands Sportfeance) of Let Werterlands Sportfeance (all Nethrolands Sportfeance) of Let Werterlands Sportfeance (all Nethrolands Sportfeance) of Let Werterlands Sportfeance (all Nethrolands Sportfeance) of Let Werterlands (all Nethrolands Sport	Kobayashi	Tsuyoshi		Successful Percutaneous Coronary Intervention for Chronic Total	Nothing to Disclose
Voles	Kobayashi	Tsuyoshi		Significance of ¹²³ LBMIPP-Scintigraphy in the Recovery of Left Ventricular Systolic Dysfunction in Takotsubo Cardiomyopathy: Insight From the NEW TAKOTSUBO BMIPP	Nothing to Disclose
Month Mont	Kobayashi	Yohei		Three-Year Clinical Outcomes of the XIENCE/PROMUS Cobalt- Chromium Everolimus-Eluting Stent in Patients Treated With In-	Nothing to Disclose
Noting to Disclose Content	Kobayashi	Yoshio	Intravascular Imaging and Interventional	Semi-Quantitative Evaluation of Coronary Arterial Patency After Implantation of a Metallic Stent: A Comparison Between 320 Slice CT and Invasive Coronary Angiogram With Consideration of Stent Size, Length, and Type, as Well as the Specific Coronary Artery	Nothing to Disclose
Layer-Specific Firosis on CMR in Hypertopholic Cardiomyopathy Using Layer-Specific Stain TTE Analysis	Kobayashi	Yoshio	Insights From Echocardiography Use	Quantitative Distinction of LV Myocardium Classified by Presence or Absence of Fibrotic Change and/or Hypertrophic Change Confirmed by Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy	Nothing to Disclose
Non Invasive Imaging: New Technologies Allowed 3D Mycocardial Strain Determined by Existing 320-Site CT Nothing to Disclose	Kobayashi	Yoshio	Insights From Echocardiography Use	Layer-Specific Fibrosis on CMR in Hypertrophic Cardiomyopathy	Nothing to Disclose
Vari	Kobayashi	Yoshio	Non Invasive Imaging: New Technologies	A Novel 3D Myocardial Strain Determined by Existing 320-Slice CT Data Enhances Visual Assessment of Late Enhancement on CT for the Detection of Left Ventricular Myocardial Fibrosis in Non Ischemic	Nothing to Disclose
Sex Differences in the Risk Factors for Endothelial and Epidemblogy, Disparities, and Safety (Distructive Coronary Artery Disease)	Kobayashi	Yoshio	Non Invasive Imaging: New Technologies	Improved Diagnosis of Detection of Late Enhancement in Left Ventricular Myocardium Using 2nd Generation 320-Slice CT	Nothing to Disclose
Cobstructive Coronary Arter Disease Corona	Kobayashi			Sex Differences in the Risk Factors for Endothelial and Microvascular Dysfunction in Patients With Angina in the Absence of	RESEARCH/RESEARCH GRANTS - Boston Scientific
Kobayashi Yukari Innovative Use of Echocardiography Useriables to Predict Outcome Through Correlation Mapping in Patients With Dilated Cardiomyopathy Kobayashi Yukari Advances in HCM, PPCM and Other Cardiomyopathy Kobayashi Yukari Advances in HCM, PPCM and Other Cardiomyopathy Kobayashi Yukari Advances in HCM, PPCM and Other Cardiomyopathy Kober Lars Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door Failure Is Just a Revolving Door Failure Is Just a Revolving Door Failure Is Just a Revolving Door Failure Is Just a Revolving Door Failure Is Just a Revolving Door Failure Is Just a Revolving Door Failure Is Just a Revolving Door Failure Is Just a Revolving Door Failure Is Just a Revolving Door Failure Is Just a Revolving Door Failure Is Just a Revolving Door Failure Is Just a Revolving Door Failure Is Just a Revolving Door Failure Is Just a Revolving Door Failure Is Just a Revolving Tiest Hospitalization for Heart Failure Committee work,invited speaker for symposia and meetings Infarction Patients With ST-Segment Elevation Myocardial Infarction Patients With ST-Segment Elevation Myocardial Infarction Patients Failure Is There a Golden Rule for the Golden Years? Kochar Ajar Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in U.S. Community Practice Kochar Ajar Novel Developments in Acute Coronary Syndromes Kochar Ajar Novel Developments in Acute Coronary Syndromes Kochar Ajar Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndromes Kochar Ajar Interventional Cardiology: TAVR 3 Stroke and Cardiovascular Outcomes in Patients With Cardios Wolting to Disclose Kochar Ajar Interventional Cardiology: TAVR 3 Stroke and Cardiovascular Outcomes in Patients With Cardiology Interventional Cardiology: TAVR 3 Stroke and Cardiovascular Outcomes in Patients With Cardiology Interventional Cardiology: TAVR 3 Stroke and Cardiovascular Outcomes in Patients With Cardiology Interventional Cardiology: TAVR 3	Kobayashi			The Inflammasome Pathway Is Associated With Adverse Ventricular	Nothing to Disclose
Cutcome Through Correlation Mapping in Patients With Dilated Cardiomyopathy Kobayashi Yukari Advances in HCM, PPCM and Other Cardiomyopathies Heart Failure and Cardiomyopathies Heart Failure and Cardiomyopathies Heart Failure and Cardiomyopathies Heart Failure and Cardiomyopathies Heart Failure and Cardiomyopathies Heart Failure and Cardiomyopathies: Heart Failure and Cardiomyopathies: Heart Failure and Cardiomyopathies: Heart Failure and Cardiomyopathies: Heart Failure and Cardiomyopathies: Heart Failure and Cardiomyopathies: Heart Failure and Cardiomyopathies: Heart Failure and Cardiomyopathy Køber Lars Post-CAD/Mit Making Tough Predictions About the Future Individual Proadrenomedullin: A Prognostic Marker of Mortality and Heart Failure in Patients With ST-Segment Elevation Myocardial Infarction Midregional Proadrenomedullin: A Prognostic Marker of Mortality Commmittee work, invited speaker for symposia and meetings with STEMI - Is There a Golden Rule for the Golden Years? Kochar Ajar Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Kochar Ajar Innovations in Practice Management and Social Media Design Preliminary Data, Methods and Design Wits Test Medical Contact to Device Time in STEMI Patients Presenting Wits Test Medical Contact to Device Time in STEMI Patients Presenting Wits Test Medical Contact to Device Time in STEMI Patients Presenting Wits Morting to Disclose Kochar Ajar Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndromes Systems Accelerator Kochar Ajar Interventional Cardiology: TAVR 3 Stroke and Cardiovascular Outcomes in Patients With Carotid Nothing to Disclose Kochar Ajar Interventional Cardiology: TAVR 3 Stroke and Cardiovascular Outcomes in Patients With Carotid Nothing to Disclose	Kobayashi	Yukari	Innovative Use of Echocardiography	Identifying the Optimal Echocardiographic Variables to Predict	Nothing to Disclose
Cardiomyopathies Lars Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door Køber Lars Post-CAD/MI: Making Tough Predictions About the Future Post-CAD/MI: Making Tough Predictions About the Future Ajar STEMI Dilemmas: You Be the Judge Kochar Ajar Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Kochar Ajar Ajar Innovations in Practice Management and Social Media Novel Developments in Acute Coronary Syndromes Kochar Ajar Ajar Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome Kochar Ajar Interventional Cardiology: TAVR 3 Stroke and Cardiooxyopathy Evidence Based Therapy and Its Relation to Workforce Attachment Failure and Cardiomyopathy Evidence Based Therapy and Its Relation to Workforce Attachment Failure and Cardiomyopathy Evidence Based Therapy and Its Relation to Workforce Attachment Failure and Cardiomyopathy Evidence Based Therapy and Its Relation to Workforce Attachment Following First Hospitalization for Heart Failure Widdregional Proadrenomedullin: A Prognostic Marker of Mortality Communitee work,invited speaker for symposia and meetings Consult TaNT FEES/HONORARIA - Fee for Steering Communitee work,invited speaker for symposia and meetings Consult TaNT FEES/HONORARIA - Fee for Steering Communitee work,invited speaker for symposia and meetings Communitee work,invited speaker for symposia and meetings Communitee work,invited speaker for symposia and meetings Communitee work,invited speaker for symposia and meetings Communitee work,invited speaker for symposia and meetings Communitee work,invited speaker for Steering Communitee work,invited speaker for Steering Communitee work,invited speaker for symposia and meetings Communitee work,invited speaker for Steering Communitee work,invited speaker for Steering Communitee work,invited speaker for Steering Communitee work,invited speaker for Steering Communitee work,invited speaker for Steering Communitee wo	-			Outcome Through Correlation Mapping in Patients With Dilated Cardiomyopathy	Ç
Failure Is Just a Revolving Door Following First Hospitalization for Heart Failure Commmittee work,invited speaker for symposia and meetings Modern Post-CAD/MI: Making Tough Predictions About the Future with Ending of Predictions About the Future and Heart Failure in Patients With ST-Segment Elevation Myocardial Commmittee work,invited speaker for Steering and Heart Failure in Patients With ST-Segment Elevation Myocardial Commmittee work,invited speaker for Steering and Heart Failure in Patients With ST-Segment Elevation Myocardial Commmittee work,invited speaker for Steering and Heart Failure in Patients With ST-Segment Elevation Myocardial Commmittee work,invited speaker for Steering and Heart Failure in Patients With ST-Segment Elevation Myocardial Comsmittee work,invited speaker for symposia and meetings with ST-Segment Elevation Myocardial Comsmittee work,invited speaker for symposia and meetings of the Patients of Steeping and Heart Failure in Patients With ST-Segment Elevation Myocardial Comsmittee work,invited speaker for symposia and meetings with ST-Segment Elevation Myocardial Comsmittee work,invited speaker for Steering and Heart Failure in Patients With ST-Segment Elevation Myocardial Infarction Patients Presenting with ST-Segment Elevation Myocardial Infarction Patients Presenting Nothing to Disclose Ten-Year Mortality of Acute Myocardial Infarction Patients Presenting Vision Patients Presenting Nothing to Disclose Ten-Year Mortality of Acute Myocardial Infarction Patients Presenting Nothing to Disclose Ten-Year Mortality of Acute Myocardial Infarction Among Older Adults in Nothing to Disclose Ten-Year Mortality of Acute Myocardial Infarction Among Older Adults in Nothing to Disclose Ten-Year Mortality of Acute Myocardial Infarction Patients With Cardidose			Cardiomyopathies	Prognostication of Hypertrophic Cardiomyopathy	
Lars Post-CAD/MI: Making Tough Predictions About the Future Midregional Proadrenomedullin: A Prognostic Marker of Mortality the Future Again STEMI Dilemmas: You Be the Judge Case Presentation: Advanced Age/Advanced Dementia Presential Committee work, invited speaker for symposia and meetings Case Presentation: Advanced Age/Advanced Dementia Presential Nothing to Disclose			Failure Is Just a Revolving Door	Following First Hospitalization for Heart Failure	Commmittee work,invited speaker for symposia and meetings
Kochar Ajar STEMI Dilemmas: You Be the Judge Case Presentation: Advanced Age/Advanced Dementia Presenting with STEMI - Is There a Golden Rule for the Golden Years? Kochar Ajar Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Kochar Ajar Innovations in Practice Management and Social Media Demonstration Project for Post-Discharge STEMI Patients: Preliminary Data, Methods and Design Kochar Ajar Novel Developments in Acute Coronary Syndromes Kochar Ajar Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome Kochar Ajar Interventional Cardiology: TAVR 3 Stroke and Cardiovascular Outcomes in Patients With Carotid Nothing to Disclose Stroke and Cardiovascular Outcomes in Patients With Carotid Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose	Køber	Lars	Post-CAD/MI: Making Tough Predictions About	Midregional Proadrenomedullin: A Prognostic Marker of Mortality and Heart Failure in Patients With ST-Segment Elevation Myocardial Infarction	CONSULTANT FEES/HONORARIA - Fee for Steering
Stable Schemic Heart Disease and the Year in U.S. Community Practice Kochar Ajar Innovations in Practice Management and Social Media Practice Move Individual Project for Post-Discharge STEMI Patients: Preimary Data, Methods and Design Kochar Ajar Novel Developments in Acute Coronary Syndromes Kochar Ajar Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome Kochar Ajar Interventional Cardiology: TAVR 3 Stroke and Cardiovascular Outcomes in Patients With Carotic Mothing to Disclose Stroke and Cardiovascular Outcomes in Patients With Carotid Nothing to Disclose Stroke and Cardiovascular Outcomes in Patients With Carotid Nothing to Disclose	Kochar	Ajar	STEMI Dilemmas: You Be the Judge	Case Presentation: Advanced Age/Advanced Dementia Presenting	Nothing to Disclose
Ajar Innovations in Practice Management and Social Media Soc	Kochar	Ajar	Stable Ischemic Heart Disease and the Year in		Nothing to Disclose
Kochar Ajar Novel Developments in Acute Coronary Syndromes First Medical Contact to Device Time in STEMI Patients Presenting With Cardiogenic Shock: Insights From Mission, a Lifeline STEMI Systems Accelerator Kochar Ajar Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome Kochar Ajar Interventional Cardiology: TAVR 3 Stroke and Cardiovascular Outcomes in Patients With Carotid Nothing to Disclose	Kochar	Ajar	Innovations in Practice Management and	Demonstration Project for Post-Discharge STEMI Patients:	Nothing to Disclose
Kochar Ajar Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome Kochar Ajar Interventional Cardiology: TAVR 3 Stroke and Cardiovascular Outcomes in Patients With Carotid Nothing to Disclose Stroke and Cardiovascular Outcomes in Patients With Carotid Nothing to Disclose	Kochar	Ajar		First Medical Contact to Device Time in STEMI Patients Presenting With Cardiogenic Shock: Insights From Mission, a Lifeline STEMI	Nothing to Disclose
Kochar Ajar Interventional Cardiology: TAVR 3 Stroke and Cardiovascular Outcomes in Patients With Carotid Nothing to Disclose	Kochar	Ajar	Features of Patients With Acute Coronary Syndrome	Incidence of Recurrent Myocardial Infarction Among Older Adults in	Nothing to Disclose
	Kochar	Ajar	Interventional Cardiology: TAVR 3		Nothing to Disclose



	The same of the sa			l .
Last Name Kochilas	First Name Lazaros	Session Title Congenital Heart Disease: Progress in	Presentation Title Long-Term Transplant-Free Survival Following Surgery for	Disclosures CONSULTANT FEES/HONORARIA - Novartis Corporation
		Pediatric Heart Surgery	Coarctation of the Aorta: A Study From the Pediatric Cardiac Care	
Kochilas	Lazaros	Congenital Heart Disease Surgery: Updates and Innovations	Long-Term Transplant-Free Survival for Arterial Switch Versus Atrial Switch in Treatment of Transposition of the Great Arteries: A Study From the Pediatric Cardiac Care Consortium	CONSULTANT FEES/HONORARIA - Novartis Corporation
Kochman	Janusz	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	First Serial 12- and 24-Month Optical Coherence Tomography Assessment of Stemi Patients After the Generation of Absorb Bioresorbable Vascular Scaffold Implantation	SPEAKER'S BUREAU - St Jude
Kochman	Janusz	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Implantation in Patients With Bicuspid Aortic Valve Stenosis Utilizing the Next Generation Fully Retrievable and Repositionable Valve System: Early Results From the Multicenter Pol-Tavi Registry	SPEAKER'S BUREAU - St Jude
Koczo	Agnes	Advances in HCM, PPCM and Other Cardiomyopathies	Multi-Fetal Gestation, Breastfeeding, Delivery Method and Myocardial Recovery in Peripartum Cardiomyopathy: Results From the Multicenter IPAC Study	Nothing to Disclose
Kodali	Archana	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Long Term Sequelae of Kawasaki Disease	Nothing to Disclose
Kodali	Susheel	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	CONSULTANT FEES/HONORARIA - Claret Medical, Edwards Lifesciences, Meril Lifesciences; OTHER - Thubrikar Aortic Valve, Inc, VS Medtech
Kodali	Susheel	Great Minds Think Differently: Multidisciplinary Approach to Controversies in Cardiology	Panelist	CONSULTANT FEES/HONORARIA - Claret Medical, Edwards Lifesciences, Meril Lifesciences; OTHER - Thubrikar Aortic Valve, Inc, VS Medtech
Kodali	Susheel	Imaging for TAVR: Homing in on the Real Issues	Panelist	CONSULTANT FEES/HONORARIA - Claret Medical, Edwards Lifesciences, Meril Lifesciences; OTHER - Thubrikar Aortic Valve, Inc, VS Medtech
Kodali	Susheel	Imaging for TAVR: Homing in on the Real Issues	Leaflet Thickening with Advanced Imaging Techniques: What Does it Mean?	CONSULTANT FEES/HONORARIA - Claret Medical, Edwards Lifesciences, Meril Lifesciences; OTHER - Thubrikar Aortic Valve, Inc, VS Medtech
Kodali	Susheel	Test Yourself with Questions: General Cardiology Module 15	Faculty	CONSULTANT FEES/HONORARIA - Claret Medical, Edwards Lifesciences, Meril Lifesciences; OTHER - Thubrikar Aortic Valve, Inc, VS Medtech
Kodali	Susheel	Non Invasive Imaging: Expanding Clinical Applications	Does Patient Prosthesis Mismatch Defined by CT LVOT Area Predict Downstream Clinical Outcomes?	CONSULTANT FEES/HONORARIA - Claret Medical, Edwards Lifesciences, Meril Lifesciences; OTHER - Thubrikar Aortic Valve, Inc, VS Medtech
Kodali	Susheel	Interventional Cardiology: PCI and TAVR in Complex Patients	Refining the Classification of Severe, Symptomatic Aortic Stenosis Using Flow and Gradient Measurements to Predict Outcomes Post- Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Claret Medical, Edwards Lifesciences, Meril Lifesciences; OTHER - Thubrikar Aortic Valve, Inc, VS Medtech
Kodali	Susheel	Interventional Cardiology: TAVR 3	Initial Use of the Evolut Pro Self-Expanding Transcatheter Aortic Valve <i></i>	CONSULTANT FEES/HONORARIA - Claret Medical, Edwards Lifesciences, Meril Lifesciences; OTHER - Thubrikar Aortic Valve, Inc, VS Medtech
Kodali	Susheel	TAVR Outcomes Prognostication	High Baseline Valvuloarterial Impedence Predicts Worse 1-Year Outcomes After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Claret Medical,Edwards Lifesciences,Meril Lifesciences; OTHER - Thubrikar Aortic Valve, Inc,VS Medtech
Kodali	Susheel	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low- Flow Severe Aortic Stenosis and Less Reverse Remodeling After TAVR: A Partner 2 Trial Analysis	CONSULTANT FEES/HONORARIA - Claret Medical,Edwards Lifesciences,Meril Lifesciences; OTHER - Thubrikar Aortic Valve, Inc,VS Medtech
Kodali	Susheel	Refining TAVR Outcomes	Incidence and Outcomes of Patients Requiring Surgical Bail-Out During Transcatheter Aortic Valve Replacement: A Report From the NCDR® STS/ACC Transcatheter Valve Therapy (TVT) Registry	CONSULTANT FEES/HONORARIA - Claret Medical, Edwards Lifesciences, Meril Lifesciences; OTHER - Thubrikar Aortic Valve, Inc, VS Medtech
Kodali	Susheel	17. Interventional Cardiology: Aortic Valve Disease Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Claret Medical, Edwards Lifesciences, Meril Lifesciences; OTHER - Thubrikar Aortic Valve, Inc, VS Medtech
Kodali	Susheel	Interventional Challenging Cases: Team 2	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Claret Medical, Edwards Lifesciences, Meril Lifesciences; OTHER - Thubrikar Aortic Valve, Inc, VS Medtech
Koduri	Hemantha	FIT Clinical Decision Making: Non-Invasive	In the Forest of Comorbidities, Always Look for the Wild Type	Nothing to Disclose
Koduri	Hemantha	Imaging and Valvular Heart Disease Measuring Success in Cardiac Rehabilitation	Wrist Activity Tracking Devices and Support Programs: A Meta-	Nothing to Disclose
Koenig	Gerald	Coronary Intervention in Interventional	Analysis Innovative Technique to Achieve Hemostasis With Large Bore	Nothing to Disclose
Koenig	Gerald	Cardiology: Advanced Device Use Novel Developments in Acute Coronary	Access for Percutaneous Hemodynamic Support Devices Cardiac Electrical Biomarker Response During Percutaneous	Nothing to Disclose
Koenig	Wolfgang	Syndromes Biomarkers and Targets for Ischemic Heart Disease	Coronary Intervention Increased Concentrations of Soluble ST2 Independently Predict Cardiac and Total Mortality but Not Non-Fatal Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow- Up of the KAROLA Study	CONSULTANT FEES/HONORARIA - Amgen, Merck Sharpe and Dohme, Novartis, Pfizer, Roche, The Medicines Company; RESEARCH/IRESEARCH GRANTS - Abbott Laboratories, Beckmann, Singulex, SPEAKER'S BUREAU -
Kofoed	Klaus	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking	Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY	Actavis, AstraZeneca, SANOFI SPEAKER'S BUREAU - Toshiba Medical Corporation
Kofoed	Klaus	Clinical Trials Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Registries Coronary Calcium Characteristics as Predictors of Major Adverse Cardiac Events in Symptomatic Patients: Insights From the CORE320 Multinational Study	SPEAKER'S BUREAU - Toshiba Medical Corporation
Kofoed	Klaus	Fixing the Heart One Cell at a Time: The	Adipose Derived Stromal Cells for Refractory Angina: Results From	SPEAKER'S BUREAU - Toshiba Medical Corporation
Kogame	Norihiro	Ongoing Promise of Stem Cells The Evolving World of LVADs, Transplant and Other Novel Discoveries	MyStromalCell Trial Evaluation of Hemoconcentration Based Bioelectrical Vectorial Impedance Analysis Is Useful Risk Stratification in Acute	Nothing to Disclose
Kogame	Norihiro	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Decompensated Heart Failure Body Fat Percentage Evaluated by a Bioelectrical Impedance Analysis Provides Prognostic Value in Acute Heart Failure: Beyond	Nothing to Disclose
Kogut	James	Emerging Applications of Echocardiography	on the "Obesity Paradox" HEART Score Classification and Predictive Accuracy of Stress	Nothing to Disclose
Koh	Angela	Vascular Medicine: Novel Risk Measures in	Echocardiography in a Contemporary ED Observation Unit Cohort Sarcopenia and Vascular Function Among Community Elderly	Nothing to Disclose
Koh		Arterial Diseases Diabetes and Other Issues in Cardiovascular	Adiposity, Leanness or Both? Characterizing Measures of Adiposity	Nothing to Disclose
Koh	Jin-Sin	Prevention Acute Heart Failure: Evaluating Strategies to	and Leanness With Cardiovascular Remodeling Clinical Efficacy of High-Flow Oxygen Therapy Through Nasal	Nothing to Disclose
Koh	Jin-Sin	Prevent Readmissions Non Invasive Imaging: Prognostic Implications	Cannula in Patients With Acute Heart Failure Prognostic Value of Platelet-Fibrin Clot Strength on Occurrence of	Nothing to Disclose
Koh	Jin-Sin	of CT Angiography Antithrombotic Therapy in Ischemic Heart	Cardiovascular Events After Non-Cardiac Surgery Ticagrelor Versus Clopidogrel Is Associated With Better Recovery of	
		Disease	LV Function After Acute Myocardial Infarction	
Koh	Kwan Kon	Unusual Presentations of ACS	The Role of Coronary Response to Nitrate in Patients With Suspected Vasospastic Angina	Nothing to Disclose
Koh	Kwang	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy in South Korea and Talwan	Nothing to Disclose

Control of the contro				
Last Name Kohno	First Name Takashi	Session Title The Evolving World of LVADs, Transplant and	Presentation Title Performance of the MAGGIC Heart Failure Risk Score in Japanese	Disclosures Nothing to Disclose
		Other Novel Discoveries	Acute Heart Failure Patients: A Report From the West Tokyo Heart Failure Registry	-
Kohr	Lisa	Post-Surgical Care of Children with CHD: From ICU to Your Office	Co-Chair	Nothing to Disclose
Kohsaka	Shun	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Compliance to Updated AHA/ACC Quality Measures Among Patients With Atrial Fibrillation in Japan and Its Association With Their Quality of Life	RESEARCH/RESEARCH GRANTS - Bayer Yakuhin Ltd.; SPEAKER'S BUREAU - Bayer Yakuhin Ltd.,Bristol-Myers Squibb Company ,Pfizer Japan Inc.
Kohsaka	Shun	Interventional Complexity and Complications	Impact of Institutional and Operator Volume on Short-Term Outcomes of Percutaneous Coronary Intervention: A Report From Japanese Nationwide Registry	RESEARCH/RESEARCH GRANTS - Bayer Yakuhin Ltd.; SPEAKER'S BUREAU - Bayer Yakuhin Ltd.,Bristol-Myers Squibb Company, Pfizer Japan Inc.
Kohsaka	Shun	Unusual Presentations of ACS	C-Reactive Protein in Non-ST Elevation Myocardial Infarction Patients Is Useful in Improving Discrimination of Conventional Risk	RESEARCH/RESEARCH GRANTS - Bayer Yakuhin Ltd.; SPEAKER'S BUREAU - Bayer Yakuhin Ltd.,Bristol-Myers Squibb
Kohsaka	Shun	Unusual Presentations of ACS	Score: A Report From Multicenter PCI Registry Trend of Use in Transradial Intervention Among Elderly Patients in Japan According to Their Pre-Procedural Bleeding Risk	Company ,Pfizer Japan Inc. RESEARCH/RESEARCH GRANTS - Bayer Yakuhin Ltd.; SPEAKER'S BUREAU - Bayer Yakuhin Ltd.,Bristol-Myers Squibb
Koifman	Edward	Considerations in Antiplatelet Therapy and in	Trends in Discharge and Outcome of Dual Antiplatelet Therapy Post	Company ,Pfizer Japan Inc. Nothing to Disclose
Koifman	Edward	ACS Considerations in Antiplatelet Therapy and in ACS	Percutaneous Intervention in High Bleeding Risk Population Outpatient Trends in Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Primary Percutaneous Coronary Intervention	Nothing to Disclose
Koifman	Edward	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	In-Stent Restenosis of Drug-Eluting Stents: Incidence, Lesion Characteristics and Outcomes in Contemporary Practice Over the Last Decade - How Are They Different From De Novo Lesions?	Nothing to Disclose
Koifman	Edward	Interventional Cardiology: TAVR 2	Racial Disparities and Temporal Trends in Demographics and Clinical Characteristics of Patients Screened for Transcatheter Aortic Valve Replacement	Nothing to Disclose
Koifman	Edward	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Is There a Role for Invasive Electrophysiology Studies in Patients With Conduction Abnormalities Following Transcatheter Aortic Valve Replacement?	Nothing to Disclose
Koifman	Edward	Interventional Cardiology: TAVR 3	Antithrombotic Therapy Differences and Associated Outcomes in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Koifman	Edward	Interventional Cardiology: TAVR 3	Acute Aortic Regurgitation Post-Transcatheter Aortic Valve Replacement: Impact of Various Treatment Strategies	Nothing to Disclose
Koifman	Edward	Interventional Cardiology: PCI in Complex Patients	Long-Term Mortality in Percutaneous Coronary Intervention of Saphenous Vein Grafts From Real-World Registry Data	Nothing to Disclose
Kojima	Miho	Cutting Edge Vascular Medicine	Atheroprotective Effects of Tumor Necrosis Factor-Stimulated Gene-	Nothing to Disclose
Kokkou	Eleni	From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease	Dietary Consumption of Olive Oil and Cardiovascular Outcome in Patients With Coronary Artery Disease	Nothing to Disclose
Kokkou	Eleni	Uncovering the Intricacies of Vascular Function		Nothing to Disclose
Kolansky	Daniel	Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology	Coronary Intervention for Stable and Unstable Coronary Disease	CONSULTANT FEES/HONORARIA - American Board of Internal Medicine - Committee Member, Up To Date Medical Writing (Peer/Editor Reviewed)
Kolansky	Daniel	Engage @ ACC.17 Studio: Heart Teams in Action: Complex Coronary Revascularization	Penn Interventionalist	CONSULTANT FEES/HONORARIA - American Board of Internal Medicine - Committee Member, Up To Date Medical Writing (Peer/Editor Reviewed)
Kolansky	Daniel	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - American Board of Internal Medicine - Committee Member, Up To Date Medical Writing (Peer/Editor Reviewed)
Kolias	Theodore	Emerging Applications of Echocardiography	Understanding the Role of Strain Imaging in the Early Detection of Chagas Cardiomyopathy	Nothing to Disclose
Kolkailah	Ahmed	Interventional Cardiology: TAVR 3	The Incidence of Permanent Pacemaker Implantation With SAPIEN 3 Heart Valve - Implantation Depth: The Higher the Better?	Nothing to Disclose
Koller	Akos	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Acute Coronary Syndrome: The Risk to Be Young and Women	Nothing to Disclose
Koller	Martin	Advances in HCM, PPCM and Other Cardiomyopathies	NEOD001 Demonstrates Cardiac Biomarker Responses in Patients With Light Chain Amyloidosis: Results From the Phase 1/2 Study	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Prothena Bioscience Inc
Kolm	Paul	Innovations in Practice Management and Social Media	Predicting Readmission Risk Following Percutaneous Coronary Intervention at the Time of Admission	Nothing to Disclose
Kolm	Paul	Innovations in Practice Management and Social Media	Predicting Readmission Risk Following Coronary Artery Bypass Surgery at the Time of Admission	Nothing to Disclose
Kolodgie	Frank	Refining PCI Technique and Outcomes	mTors Inhibitors Increase Endothelial Permeability and Prevent Maturation: Uncovering the Mechanism of Neoatherosclerosis in Drug Eluting Stents	Nothing to Disclose
Kolodgie	Frank	25. Interventional Cardiology: Translation and Pre-clinical Research Team 1	Suggested Reviewer	Nothing to Disclose
Kolte	Dhaval	Interventional Cardiology: Translation and Pre- Clinical Research	Intramyocardial Autologous CD34+ Cell Therapy for Refractory Angina: A Meta-Analysis	Nothing to Disclose
Kolte	Dhaval	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Angiography Versus Optical Coherence Tomography Guided Percutaneous Coronary Intervention: A Meta-Analysis of Clinical	Nothing to Disclose
Kolte	Dhaval	Interventional Cardiology: TAVR 2	Outcomes Association of Chronic Renal Insufficiency With In-Hospital	Nothing to Disclose
Kolte	Dhaval	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Outcomes of Transcatheter Aortic Valve Replacement Sex Differences in Revascularization and In-Hospital Outcomes of Non-ST-Segment Elevation Myocardial Infarction in the United States	Nothing to Disclose
Kolte	Dhaval	Interventional Cardiology: TAVR 3	Regional Variations in In-Hospital Outcomes and Healthcare Resource Utilization in Patients Undergoing Transcatheter Aortic Valve Replacement in the United States	Nothing to Disclose
Kolte	Dhaval	Interventional Cardiology: TAVR 3	Infective Endocarditis After Transcatheter Aortic Valve Replacement: Insights From the Nationwide Readmissions Database	Nothing to Disclose
Kolte	Dhaval	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Association of Academic Year-End Changeover With Survival Rates After In-Hospital Cardiac Arrest: An Examination of the "July Effect"	Nothing to Disclose
Kolte	Dhaval	Optimizing the Care of ACS Patients	Weekend Versus Weekday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide Analysis	Nothing to Disclose
Kolte	Dhaval	Unusual Presentations of ACS	National Trends in Admissions for Chest Pain Evaluation: 2006 - 2013	Nothing to Disclose
Kolte	Dhaval	Highlights in Vascular Medicine Research	Thirty-Day Readmissions Following Endovascular or Surgical Treatment for Critical Limb Ischemia: Analysis of the Nationwide Readmissions Database	Nothing to Disclose
Koltowski	Lukasz	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	First Serial 12- and 24-Month Optical Coherence Tomography Assessment of Stemi Patients After the Generation of Absorb Bioresorbable Vascular Scaffold Implantation	CONSULTANT FEES/HONORARIA - MEDTRONIC; OTHER - Boston Scientific; RESEARCH/RESEARCH GRANTS - REVA, Medtronic, Abbott
			E	

and a second				I
Last Name	First Name	Session Title	Presentation Title	Disclosures
Koltowski	Lukasz	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Implantation in Patients With Bicuspid	CONSULTANT FEES/HONORARIA - MEDTRONIC; OTHER -
			Aortic Valve Stenosis Utilizing the Next Generation Fully Retrievable and Repositionable Valve System: Early Results From the Multicenter Pol-Tavi Registry	Boston Scientific; RESEARCH/RESEARCH GRANTS - REVA, Medtronic, Abbott
Koman	Eduard	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Eptifibatide for Treatment of Mechanical Aortic Valve Thrombus: A Novel Therapeutic Approach	Nothing to Disclose
Kompancaril	Sheryl	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Comparison of IABP With pLVAD in the Setting of Complex PCI and Cardiogenic Shock	Nothing to Disclose
Kondapalli	Ananya	Highlights in Vascular Medicine Research	Comparative Assessment of Subintimal Versus Intraluminal Crossing of Infrainguinal Chronic Total Occlusion Lesions	Nothing to Disclose
Kondo	Hirokazu	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Application of DAPT Score to Predict Ischemic and Bleeding Events in Japanese Patients Undergoing Drug-Eluting Stent Implantation: An Observation From a Pooled Cohort of the CREDO-Kyoto Cohort- 2, RESET, and NEXT Trials	Nothing to Disclose
Konen	Eli	Non Invasive Imaging: Expanding Clinical Applications	Impact of Different Calcium Locations of Mitral Annulus and Aortic Valve Cusps on Risk of Conduction Disturbances After	Nothing to Disclose
Konerman	Matthew	Kanu and Docey Chatterjee Lecture and Seminal Talks in Heart Failure: I Wanna New	Transcatheter Aortic Valve Implantation Who, When and How to Transition to Sacubitril/Valsartan	Nothing to Disclose
Konerman	Matthew	Drug: Updated Heart Failure Guidelines FIT Clinical Decision Making Reviewers 3	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Kong	William	Novel Echocardiographic Methods for Assessing Cardiac Function	Real Time Three-Dimensional Echocardiography in the Evaluation of Regional and Global Right Ventricular Systolic Function in Patients With Atrial Septal Defect Before and After Percutaneous Closure	Nothing to Disclose
Kong	William	Emerging Applications of Echocardiography	The Relation Between Atrial Septal Defect Area, Diameter and Shape Using Balloon Sizing and Three-Dimensional Transoesophageal Echocardiography During Percutaneous Closure Using Occlutech Device	Nothing to Disclose
Kong	William	New Technologies in Echocardiography	Novel Non-Invasive Left Ventricular Stiffness Index in Patients With Low-Flow Compared to Normal-Flow Severe Aortic Stenosis With Preserved Left Ventricular Ejection Fraction	Nothing to Disclose
Kong	Xiangyi	Diabetes and Other Issues in Cardiovascular Prevention	Efficacy of Folic Acid Supplementation on the Reduction of Stroke Risk: Interaction With Platelet Count	Nothing to Disclose
Konigstein	Maayan	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Absence of Clinical Triggering in Diabetic Patients With ST-Segment Elevation Myocardial Infarction Predicts Multiple Vessel Coronary Disease and Is Associated With Increased Mortality	Nothing to Disclose
Konik	Ewa	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	The RAC Sign: Retroaortic Anomalous Coronary Artery Visualization by Transthoracic Echocardiography	Nothing to Disclose
Konishi	Takao	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	A Case of Stent Thrombosis Caused by Metal Allergy Complicated With Protein S Deficiency and Heparin-Induced Thrombocytopenia	Nothing to Disclose
Kono	Alan	Risky Business: Predicting Outcomes in Heart Failure	ACC Poster Moderator	Nothing to Disclose
Konsola	Theodosia	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Vascular Function of Conduit Arteries Is Associated With Progress of Diabetic Retinopathy in Type 2 Diabetes	Nothing to Disclose
Konstam	Marvin	Overcoming Today's Challenges to Launching and Growing Your Academic Medical Career: An Interactive Tutorial	Co-Chair	CONSULTANT FEES/HONORARIA - Arbor,Faraday,Ironwood,Johnson & Johnson,Novo Nordisk Inc.,Pharmaln, Theravance, Inc.; DATA SAFETY MONITORING BOARD - Amgen,Novartis; OTHER - BMS; RESEARCH/RESEARCH GRANTS - OSUSKA
Konstam	Marvin	Heart Failure Patient Care: Transitioning the Cost, Care and Context: Joint Heart Failure Society of America and American College of Cardiology	Co-Chair	CONSULTANT FEES/HONORARIA - Arbor,Faraday,Ironwood,Johnson & Ramp;amp; Johnson,Novo Nordisk Inc.,Pharmaln, Theravance, Inc.; DATA SAFETY MONITORING BOARD - Amgen,Novartis; OTHER - BMS; RESEARCH/RESEARCH GRANTS - OSUSKA
Konstam	Marvin	Diabetes and Heart Failure: Are We Hitting The Sweet Spot	Co-Chair	CONSULTANT FEES/HONORARIA - Arbor,Faraday,Ironwood,Johnson & amp;amp; Johnson,Novo Nordisk Inc.,Pharmaln, Theravance, Inc.; DATA SAFETY MONITORING BOARD - Amgen,Novartis; OTHER - BMS; RESEARCH/RESEARCH GRANTS - OSUSKIA
Konstam	Marvin	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Impact of Glucagon Like Peptide-1 Agonist Therapy on Heart Rate in Advanced Systolic Heart Failure: An Analysis From the Functional Impact of GLP-1 for Heart Failure Treatment Study	CONSULTANT FEES/HONORARIA - Arbor, Faraday, Ironwood, Johnson & amp; amp; Johnson, Novo Nordisk Inc., Pharmain, Theravance, Inc.; DATA SAFETY MONITORING BOARD - Amgen, Novartis; OTHER - BMS; RESEARCH/RESEARCH GRANTS - Otsuka
Konstam	Marvin	FIT Clinical Decision Making Reviewers 5	ACC FIT Clinical Decision Making Reviewer	CONSULTANT FEES/HONORARIA - Arbor, Faraday, Ironwood, Johnson & amp; amp; Johnson, Novo Nordisk Inc., Pharmain, Theravance, Inc.; DATA SAFETY MONITORING BOAD - Amgen, Novartis; OTHER - BMS; RESEARCH/RESEARCH GRANTS - Otsuka
Konstantinides	Stavros	Multi-Disciplinary Care for Acute Pulmonary Embolism: The PE Response Team (PERT) Model	PE Management: Further Research Efforts from a Legend in the Field - Interviewee	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,Bristol-Myers Squibb Company ,Daiichi Sankyo,Pfizer Inc
Konstantinidis	Dimitris	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Insights on Diastolic Dysfunction of Treated Hypertensive Patients: Focusing on Hypertension Control & Treatment Resistance	Nothing to Disclose
Konstantinidis	Dimitris	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Left Ventricular Mass Versus Pulse Wave Velocity as Predictors of Coronary Artery Disease in Patients With Essential Hypertension: Data From a Greek 6-Year-Follow-Up Study	Nothing to Disclose
Konstantinidis	Dimitris	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Predictors of New-Onset Atrial Fibrillation in Essential Hypertensives	Nothing to Disclose
Konstantinou	Klio	Making Progress in Understanding Heart Failure	Prognostic Utility of Haemoglobin/Haematocrit Equations for Estimating Congestion Versus Calculated Plasma Volume Status in Chronic Heart Failure	Nothing to Disclose
Kontos	Michael	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Chronic Heart Failure Hospital Variation in Targeted Temperature Management for Acute Myocardial Infarction Patients Complicated by Out-of-Hospital Cardiac Arrest in the U.S.	CONSULTANT FEES/HONORARIA - Roche Diagnostics; SPEAKER'S BUREAU - MEC
Kontos	Michael	03. Acute and Stable Ischemic Heart Disease: Therapy Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Roche Diagnostics; SPEAKER'S BUREAU - MEC
Koo	Bon Kwon	Interventional Cardiology: Complex Patients/Comorbidities Team 1	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - St Jude Medical
Коо	Chieh Yang	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Obstructive Sleep Apnea and Diabetes Mellitus Have Synergistic Effects on Adverse Cardiac and Cerebrovascular Events in Patients Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Koo	Chieh Yang	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Impact of Mild Obstructive Sleep Apnea on and Cardiovascular Events After Percutaneous Coronary Intervention	Nothing to Disclose
Коор	Brendan	Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	Chronic Performance of Communicating Leadless Anti-Tachycardia Pacemaker and Subcutaneous Implantable Cardioverter	SALARY - Boston Scientific Corporation
		and Cillical EF and the Year IN Review	Pacemaker and Subcutaneous Implantable Cardioverter Defibrillator	



WASHINGTON, DC | MARCH 17 - 19 2017

The state of the s				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Kopecky	Stephen	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	CHAZDS2-VASc Score Predicts Incident Atrial Fibrillation/Flutter in a Referral Population	CONSULTANT FEES/HONORARIA - Prime Therapeutics; DATA SAFETY MONITORING BOARD - Applied Clinical Intelligence; OTHER - Bayer Healthcare, LLC; RESEARCH/RESEARCH GRANTS - Amgen,Genzyme,Regeneron
Kopecky	Stephen	03. Acute and Stable Ischemic Heart Disease: Therapy Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Prime Therapeutics; DATA SAFETY MONITORING BOARD - Applied Clinical Intelligence; OTHER - Bayer Healthcare, LLC; RESEARCH/RESEARCH GRANTS - Amgen,Genzyme,Regeneron
Koppula	Maheshwara	Emerging Developments in HFpEF and Arryhthmias	Effect of Diabetes Mellitus on Pulsatile Arterial Load and Hemodynamics in HFpEF	Nothing to Disclose
Korcarz	Claudia	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Total Testosterone With Progression of Carotid Atherosclerosis and Coronary Artery Calcium Score: The Multi- Ethnic Study of Atherosclerosis	Nothing to Disclose
Kordalis	Athanasios	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study	Nothing to Disclose
Koren	Michael	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Alirocumab Efficacy and Safety in Patients With Hypercholesterolemia and With or Without Clinical Atherosclerotic Cardiovascular Disease: Pooled Analysis of 10 ODYSSEY Randomized Trials	CONSULTANT FEES/HONORARIA - Ponte Vedra Cardiovascular Foundation; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Academy of Physicians in Clinical Research; OTHER - Blue Cross Blue Shield Florida; SALARY - J
Kormos	Robert	Controversies in Mitral Valve Surgery: Joint Symposium of the Society of Thoracic Surgeons and the American College of Cardiology	What to do if the left ventricle fails after mitral valve surgery	OTHER - HeartWare Inc
Kormos	Robert	Life After LVAD - The Good, The Bad and The Ugly		OTHER - HeartWare Inc
Kormos	Robert	Nuclear Cardiology: Beyond Perfusion	Regional Right Ventricular (RV) Function as Determined by Gated Blood Pool SPECT (GBPS) Provides Additive Value to Evaluation of Patients Undergoing Left Ventricular Assist Device (LVAD) Implantation	OTHER - HeartWare Inc
Kornberg	Robert	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Identifying the Etiologies and Trends of 30 Day Readmissions in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients: A National Population-Based Cohort Study	Nothing to Disclose
Kornberg	Robert	Arrhythmias and Clinical EP: Devices 3	Epicardial Lead Migration to the Spine With Development of Vertebral Abscess	Nothing to Disclose
Kornowski	Ran	Refining TAVR Outcomes	The Association of Coronary Artery Disease Severity and Pre Procedural Completeness of Revasclarization on Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Kornowski	Ran	21. Interventional Cardiology: Coronary Intervention: Devices Team 2	Suggested Reviewer	Nothing to Disclose
Kort	Smadar	Imaging in Valvular Heart Disease: Applying Guidelines to Clinical Practice and What to do if They Don't Fit	Moderate or Severe Aortic Stenosis How to Best Use Echo to Distinguish	Nothing to Disclose
Kort Koshy	Smadar Anoop	28. Non Invasive Imaging: Echo Team 1 Novel Arrhythmia Diagnostics, Therapeutics,	Suggested Reviewer Accuracy of Smart Watches in Arrhythmias: <i>SMARTS</i> Study	Nothing to Disclose Nothing to Disclose
Koshy	Anoop	and "Wearables Novel Arrhythmia Diagnostics, Therapeutics, and "Wearables	High Atrial Ectopy in Stroke: An Independent Risk Factor?	Nothing to Disclose
Kosiborod	Mikhail	Featured Clinical Research III	Lower Rates of Hospitalization for Heart Failure and All-Cause Death in New Users of SGLT-2 Inhibitors: The CVD-REAL Study	CONSULTANT FEES/HONORARIA - Amgen Inc.,AstraZeneca,Boehringer Ingelheim Pharmaceuticals, Inc,Eli Lilly and Company,GlaxoSmithKline,Glytec,Merck & Co., Inc.,Novo Nordisk Inc.,Sanofi-Aventis,ZS Pharma; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc.gilead,Sanofi-Aventis; SPEAKER'S BUREAU - Amgen Inc.
Kosiborod	Mikhail	Updates in Stable Ischemic Heart Disease	Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-World Impact of the Leader Trial on Improving Cardiovascular Outcomes in Patients With Diabetes at High Cardiovascular Risk	CONSULTANT FEES/HONORARIA - Amgen Inc. AstraZeneca Boehringer Ingelheim Pharmaceuticals, Inc, Eli Lilly and Company, GlaxoSmithKline, Glytec, Merck & amp; amp; Co., Inc., Novo Nordisk Inc., Sanofi-Aventis, ZS Pharma; RESEARCH/IRESEARCH GRANTS - AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., gliead, Sanofi-Aventis; SPEAKER'S BUREAU - Amgen Inc. Inc., gliead, Sanofi-Aventis; SPEAKER'S BUREAU - Amgen Inc.
Kosiborod	Mikhail	Therapy Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen Inc., AstraZeneca, Bookninger Ingelheim Pharmaceuticals, Inc, Eli Lilly and Company, GlaxoSmithKline, Glytec, Merck & Dengramp; Co., Inc., Novo Nordisk Inc., Sanofi-Aventis, ZS Pharma; RESEARCH/GRESEARCH GRANTS - AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., gilead, Sanofi-Aventis; SPEAKER'S BUREAU - Amgen Inc.
Kosinski	Andrzej	Insights From Echocardiography Use	Universal Use of Contrast to Detect Left Ventricular Thrombus in Patients With Reduced Ejection Fraction Is Not Associated With Improved Clinical or Cost-Effectiveness Outcomes	Nothing to Disclose
Kosiv	Katherine	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Congenital Heart Surgery in Patients With Trisomy 13 Associated With Lower In-Hospital Mortality	Nothing to Disclose
Kosmidou	Ioanna	Refining PCI Technique and Outcomes	Treatment of Left Main Coronary Artery Disease in Patients With Diabetes: 3-Year Outcomes Comparing CABG and PCI With Everolimus-Eluting Stents From the EXCEL Study	Nothing to Disclose
Kostis	John	Controversies in Hypertension	Should We Rely on Office Based BP Measurement? Yes!	CONSULTANT FEES/HONORARIA - ACI Clinical-Janssen Pharmacueticals, Aegerion, Merck, SANOFI; DATA SAFETY MONITORING BOARD - Palatin; OTHER - St. Jude Medical
Kostis	John	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Incidence of Bacterial Endocarditis in Relation to Changes in Guidelines	CONSULTANT FEES/HONORARIA - ACI Clinical-Janssen Pharmacueticals, Aegerion, Merck, SANOFI; DATA SAFETY MONITORING BOARD - Palatin; OTHER - St. Jude Medical
Kostis	John	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Relationship Between Incident Heart Failure and Dropout Rate in Randomized Clinical Trials of Antihypertensive Therapy	CONSULTANT FEES/HONORARIA - ACI Clinical-Janssen Pharmacueticals, Aegerion, Merck, SANOFI; DATA SAFETY MONITORING BOARD - Palatin; OTHER - St. Jude Medical
Kostis	John	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Temporal Trends and Outcomes of Emergent Coronary Artery Bypass Graft Surgery for ST-Segement Elevation Myocardial Infarction	CONSULTANT FEES/HONORARIA - ACI Clinical-Janssen Pharmacueticals,Aegerion,Merck,SANOFI; DATA SAFETY MONITORING BOARD - Palatin; OTHER - St. Jude Medical
Kostis	John	Interventional Cardiology: TAVR 2	Comparison of In-Hospital Outcomes of Transcatheter Aortic Valve Replacement in Men and Women	CONSULTANT FEES/HONORARIA - ACI Clinical-Janssen Pharmacueticals,Aegerion,Merck,SANOFI; DATA SAFETY MONITORING BOARD - Palatin; OTHER - St. Jude Medical
Kostis	John	Timely Topics in Acute Coronary Syndromes	Routine Invasive Versus Conservative Strategy for Elderly Patients Aged>75 Years With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS): A Meta-Analysis of Randomized Controlled Trials	CONSULTANT FEES/HONORARIA - ACI Clinical-Janssen Pharmacueticals Aegerion, Merck, SANOFI; DATA SAFETY MONITORING BOARD - Palatin; OTHER - St. Jude Medical
Kostis	John	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Association Between Myocardial Infarction Hospital Process of Care Scores With Clinical Outcomes in a Statewide Study	CONSULTANT FEES/HONORARIA - ACI Clinical-Janssen Pharmacueticals,Aegerion,Merck,SANOFI; DATA SAFETY MONITORING BOARD - Palatin; OTHER - St. Jude Medical
Kostis	John	Unusual Presentations of ACS	Decrease in the Rate of MI Case Fatality From 2000 to 2014	CONSULTANT FEES/HONORARIA - ACI Clinical-Janssen Pharmacueticals,Aegerion,Merck,SANOFI; DATA SAFETY MONITORING BOARD - Palatin; OTHER - St. Jude Medical



| ACC.17

WASHINGTON, DC | FRI•SAT•SUN

Contract of the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Kostis	John	New Insights Into Prediction and Treatment of Hypertension	The U-Shaped Relationship of Body Mass Index With All-Cause Mortality at Eight Years in the ALLHAT	CONSULTANT FEES/HONORARIA - ACI Clinical-Janssen Pharmacueticals, Aegerion, Merck, SANOFI; DATA SAFETY
Kostis	William	Acute Heart Failure: Evaluating Strategies to	Relationship Between Incident Heart Failure and Dropout Rate in	MONITORING BOARD - Palatin; OTHER - St. Jude Medical Nothing to Disclose
KOSUS	william	Prevent Readmissions	Randomized Clinical Trials of Antihypertensive Therapy	Induling to Disclose
Kostis Kostis	William William	Unusual Presentations of ACS	Decrease in the Rate of MI Case Fatality From 2000 to 2014 The U-Shaped Relationship of Body Mass Index With All-Cause	Nothing to Disclose
Costis		New Insights Into Prediction and Treatment of Hypertension	Mortality at Eight Years in the ALLHAT	Nothing to Disclose
Kostis	William	23. Interventional Cardiology: IVUS and Intravascular Physiology Team 2	Suggested Reviewer	Nothing to Disclose
Kostopoulos	Louie	Vascular Access and Hemostasis Issues	Clinical Efficacy of SoftSeal-STF Hemostatic Pad With Short Hold Time Compared to Traditional Manual Compression After	Nothing to Disclose
Kosztin	Annamária	Heart Failure and Cardiomyopathies: Heart	Transfemoral Catheterization Quality of Life Measured With Eurogol-5D Questionnaire Predicts	Nothing to Disclose
		Failure Gadgets Galore	Long Term Mortality and Echocardiographic Response in CRT Patients	
Kotseva	Kornelia	Innovations in Cardiovascular Risk Assessment and Reduction	Achievement of Risk Factor Targets in Patients at High Cardiovascular Risk in Europe: Results From EUROASPIRE IV Survey	Nothing to Disclose
Kottam	Anupama	FIT Clinical Decision Making: Non-Invasive	Cardiac Myeloid Sarcoma: A Diagnostic & Treatment Challenge	OTHER - none
Kottam	Anupama	Imaging and Valvular Heart Disease Structural Heart Interventions: Focus on Mitral	In-Hospital Outcomes After MitraClip Implantation in the United	OTHER - none
Kottam	Anupama	Valve, Left Atrial Appendage and HOCM Interventional Cardiology: PCI and TAVR in	States: 2010-2012 Economic Implications of Late Discharge After Transcatheter Aortic	OTHER - none
Kottam	Anupama	Complex Patients Emerging Developments in HFpEF and	Catheter Implantation Hospitalization Burden of Diastolic Heart Failure in the United	OTHER - none
Kollaiii	Anupama	Arryhthmias	States: 2007-2012	OTHER - Horie
Koulogiannis	Konstantinos	Structural Heart Interventions: What Does the Imager Need to know	Emerging Structural Interventions: Lessons for the Imager (Valve in Valve, Tricuspid Valve, Watchman)	CONSULTANT FEES/HONORARIA - Abbott Vascular, Edwards Lifesciences, MEDTRONIC
Koutagiar	losif	Advances in Cholesterol Measurement and	Beneficial Effect of Statin Therapy on Carotid Wall Temperatures in	Nothing to Disclose
		Management	Patients With Familial Hyperlipidemia Syndromes: Results From a Randomized Trial	
Koutagiar	losif	Changing the Natural History of Valve Disease	Zoledronic Acid Inhibits Aortic Valve Calcification: A PET/CT Study	Nothing to Disclose
Koutagiar	losif	With Medical Therapy Nuclear Cardiology: Beyond Perfusion	In Vivo Correlation of Carotid Temperatures and Pet/Fdg Uptake in	Nothing to Disclose
Kouz	Remi		Patients Undergoing Carotid Endarterectomy: Validation With Histology Refining the Classification of Severe, Symptomatic Aortic Stenosis	Nothing to Disclose
Kouz	Reilli	Interventional Cardiology: PCI and TAVR in Complex Patients	Using Flow and Gradient Measurements to Predict Outcomes Post-	Nothing to Disclose
Kouz	Remi	TAVR Outcomes Prognostication	Transcatheter Aortic Valve Replacement High Baseline Valvuloarterial Impedence Predicts Worse 1-Year	Nothing to Disclose
Kovach	Joshua	Redefining the "F" Word	Outcomes After Transcatheter Aortic Valve Replacement Cardiopulmonary Exercise Testing for Surgical Risk Stratification in	Nothing to Disclose
Kayaaia	lacan	Highlighted Original Research: Vascular	Adults With Congenital Heart Disease CD90 Marks a Population of Adventitial Mesenchymal Stem Cells in	CONSULTANT FEES/HONORARIA - MEDTRONIC;
Kovacic	Jason	Medicine and the Year in Review	the Human Aorta That Exhibit Diminished Angiogenic Potential in Patients With Ascending Aortic Aneurysms	RESEARCH/RESEARCH GRANTS - AstraZeneca
Kovacic	Jason	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Clinical Outcomes Associated With Impella Versus IABP Use in Stable Patients Undergoing High Risk Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - MEDTRONIC; RESEARCH/RESEARCH GRANTS - AstraZeneca
Kovacic	Jason	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Impella or Intra-Aortic Balloon Pump Support in Patients Undergoing High Risk Percutaneous Coronary Intervention: A Real World Single Center Experience	CONSULTANT FEES/HONORARIA - MEDTRONIC; RESEARCH/RESEARCH GRANTS - AstraZeneca
Kovacic	Jason		Angiographic Phenotype and Clinical Outcomes of Patients With	CONSULTANT FEES/HONORARIA - MEDTRONIC;
Kovacic	Jason	Revascularization and Outcomes Coronary Angiography, Intra-Vascular Imaging,	Malignancy Undergoing PCI Synergistic Effects of Coronary Calcification and Inflammation on	RESEARCH/RESEARCH GRANTS - AstraZeneca CONSULTANT FEES/HONORARIA - MEDTRONIC;
Kayaaia	Jason	Revascularization and Outcomes Interventional Cardiology: Stent Failure	Risks for Adverse Cardiovascular Events After PCI: Results From a Large Single-Center Registry Multimodality Intravascular Imaging to Evaluate Plaque	RESEARCH/RESEARCH GRANTS - AstraZeneca CONSULTANT FEES/HONORARIA - MEDTRONIC;
Kovacic	Jason	Analysis by Intravascuar Imaging	Characteristics in Patients With Diabetes Mellitus	RESEARCH/RESEARCH GRANTS - AstraZeneca
Kovacic	Jason	Novel Developments in Acute Coronary Syndromes	Trends in Incidence and Mortality Associated With Acute Kidney Injury in Patients Undergoing PCI for Acute Coronary Syndrome	CONSULTANT FEES/HONORARIA - MEDTRONIC; RESEARCH/RESEARCH GRANTS - AstraZeneca
Kovacic	Jason	Timely Topics in Acute Coronary Syndromes	Predictors of High Intensity Statin Use After Percutaneous Coronary	CONSULTANT FEES/HONORARIA - MEDTRONIC;
Kovacic	Jason	Optimizing the Care of ACS Patients	Interventions Underutilization of High Intensity Statins in a Contemporary High	RESEARCH/RESEARCH GRANTS - AstraZeneca CONSULTANT FEES/HONORARIA - MEDTRONIC;
			Risk PCI Population	RESEARCH/RESEARCH GRANTS - AstraZeneca
Kovacic	Jason	Interventional Complexity and Complications	Prediction of Acute Kidney Injury in Patients Undergoing Coronary Intervention Using Calculation of Serum Osmolality	CONSULTANT FEES/HONORARIA - MEDTRONIC; RESEARCH/RESEARCH GRANTS - AstraZeneca
Kovacic	Jason	Interventional Cardiology: PCI in Complex Patients	Risk and Impact of Diabetes Mellitus on Ischemic Events in Females	CONSULTANT FEES/HONORARIA - MEDTRONIC;
Kovacic	Jason	01. Acute and Stable Ischemic Heart Disease:	and Males After Percutaneous Coronary Intervention Suggested Reviewer	RESEARCH/RESEARCH GRANTS - AstraZeneca CONSULTANT FEES/HONORARIA - MEDTRONIC;
Kovacs	Adrienne	Basic Team 2 Patient-Centered Care in Adult Congenital	Panelist	RESEARCH/RESEARCH GRANTS - AstraZeneca Nothing to Disclose
		Heart Disease		-
Kovacs	Adrienne	Patient-Centered Care in Adult Congenital Heart Disease	An APPROACH to Understanding What Impacts Patient QOL: An International Perpective	Nothing to Disclose
Kovacs	Richard	Featured Clinical Research I	Panelist Panelist	CONSULTANT FEES/HONORARIA - Biomedical Systems, Theravance, Inc.; DATA SAFETY MONITORING BOARD - AStrZeneca Pharmaceuticals, Biotie, Eli Liliy and Company, Teva Pharmaceuticals; OTHER - Cook Incorporated Med Institute; RESEARCH/RESEARCH GRANTS - Armaron Pharmaceuticcals, Siemens
Kovacs	Richard	FIT Forum: Mix and Mingle	Sports Cardiology	CONSULTANT FEES/HONORARIA - Biomedical Systems, Theravance, Inc.; DATA SAFETY MONITORING BOARD - AStraZeneca Pharmaceuticals, Biotie, Eli Lilly and Company, Teva Pharmaceuticals; OTHER - Cook Incorporated Med Institute; RESEARCH/RESEARCH GRANTS - Armaron Pharmaceuticals. Siemens
Kovacs	Richard	The Athlete with Heart Disease: A Case Based Approach	Co-Chair	CONSULTANT FEES/HONORARIA - Biomedical Systems, Theravance, Inc.; DATA SAFETY MONITORING SOARD - AStrZeneca Pharmaceuticals, Biotile, Eli Liliy and Company, Teva Pharmaceuticals; OTHER - Cook Incorporated Med Institute; RESEARCH/RESEARCH GRANTS - Armaron Pharmaceuticals, Siemens
Kovacs	Richard	The Athlete with Heart Disease: A Case Based Approach	Panelist	CONSULTANT FEES/HONORARIA - Biomedical Systems, Theravance, Inc.; DATA SAFETY MONITORING BOARD - ASTAZeneca Pharmaceuticals, Biotie, Elii Lilly and Company, Teva Pharmaceuticals : OTHER - Cook Incorporated - Med Institute; RESEARCH/RESEARCH GRANTS - Armaron Pharmaceuticcals, Siemens

Contract of the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures CONSULTANT FEES/HONORARIA - Biomedical
Kovacs	Richard	Novel Determinants of Outcomes in VHD	Impact of Moderate Mitral Regurgitation on Patients: Mortality May Be Underestimated - Analysis of Clinical Data Repositories	CONSULTAIN 1 FESTHONDRARIA - BIOMEDICAI Systems, Theravance, Inc.; DATA SAFETY MONITORING BOARD - AstraZeneca Pharmaceuticals, Biotie, Eli Lilly and Company, Teva Pharmaceuticals; OTHER - Cook Incorporated - Med Institute; RESEARCH/RESEARCH GRANTS - Armaron Pharmaceuticcals, Siemens
Kovacs	Richard	Hearts and Soles: Multimodality Imaging in Athletes	Global & Basal Longitudinal Strain in NFL Combine Participants	
Kovelamudi	Swathi	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Complication Rates of Epicardial Ventricular Tachycardia Ablation: A Pooled Analysis	Nothing to Disclose
Kowal	Robert	Arrhythmias and Clinical EP: Devices 1	insertion of a Miniaturized Insertable Cardiac Monitor Outside the Traditional Hospital Setting: Results From the RIO 2 International Study	CONSULTANT FEES/HONORARIA - MEDTRONIC; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Baylor Heart and Vascular Hospital, Cardiovascular Provider Resources, Heart Rhythm Society
Kowey	Peter	Controversies in Atrial Fibrillation Management	Co-Chair	CONSULTANT FEES/HONORARIA - Astellas, Astra- Zeneca, Astra-Zeneca, Boehringer-Ingelheim, Bristol Myer Squibb, Chattern, Dalichi-Sankyo, Dendreon, Forest, Glaxo SmithKline, Johnson and Johnson, Johnson and Johnson, MEDTRONIC, Merck, Novarits, Ostuka, Pfizer, Portola, Roc he, Sanofi-Aventis, Shire; DATA SAFETY MONITORING BOARD - Eli Lilly; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY POLE - CardioNet
Kowey	Peter	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Does Frailty Alter the Benefits of Oral Anticoagulation in Patients With Atrial Fibrillation?	CONSULTANT FEES/HONORARIA - Astellas, Astra- Zeneca, Astra-Zeneca, Boehringer-Ingelheim, Bristol Myer Squibb, Chattem, Daichi-Sankyo, Dendreon, Forest, Glaxo Smithkline, Johnson and Johnson, Johnson and Johnson, MEDTRONIC, Merck, Novartis, Otsuka, Pfizer, Portola, Roc he, Sanoff-Aventis, Shire; DATA SAFETY MONITORING BOARD - Eli Lilly; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY POLE - CardioNet
Kowey	Peter	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insighis From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)	CONSULTANT FEES/HONORARIA - Astellas Astra- Zeneca Astra-Zeneca, Boehringer-Ingelheim, Bristol Myer Squibb, Chattem, Daichi-Sankyo, Dendreon, Forest, Glaxo SmithKline, Johnson and Johnson, Johnson and Johnson, MEDTRONIC, Merck, Novartis, Olsuka, Pfizer, Portola, Roc he, Sanofi-Aventis, Shire; DATA SAFETY MONITORING BOARD - EII LIIIy, OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - CardioNet
Kowlgi	Guru	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Left Main Coronary Artery Vasospasm Causing Complete Heart Block?? Dye Don't Lie!	Nothing to Disclose
Koyama	Kohei	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Intravascular Ultrasound Assessment of the Effects of Rotational Atherectomy in Calcified Coronary Artery Lesions	Nothing to Disclose
Koyama	Kohei	Interventional Cardiology: PCI in Complex Patients	Procedural Calcium Fracture and Its Effect on Stent Expansion Assessed by Optical Coherence Tomography	Nothing to Disclose
Kozak	Mark	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Transcatheter Tricuspid Valve Replacement: "Forgotten Valve", Challenging Management With Limited Treatment Options - Time to Gather Evidence	Nothing to Disclose
Kozak	Mark	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Assessing Inter-Rater Agreement of Experienced Interventional Cardiologists on Culprit Vessel in Patients With Multivessel Disease and Acute Non-STEMI	Nothing to Disclose
Kozak	Mark	Interventional Cardiology: TAVR 2	Death and Dialysis Risk After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Kozanecki	Artur	Cardiac Fibrosis and Heart Failure: The Next Frontier	Associations Between Serum Markers of Extracellular Matrix Metabolism, Fibrosis-Linked Micrornas (Mir-21, Mir-26, Mir-29, Mir- 30 And Mir-133a) and Right Ventricular Parameters in Dilated Cardiomyopathy	Nothing to Disclose
Kozanecki	Artur	Cardiac Fibrosis and Heart Failure: The Next Frontier	Relations Between Fibrosis-Linked Micrornas (Mir-21, Mir-26, Mir- 29, Mir-30 and Mir-133a) and Right Ventricular Morphology and Function in Dilated Cardiomyopathy	Nothing to Disclose
Kozma	Kinga	Novel Developments in Acute Coronary Syndromes	Predictors of Short- and Long-Term Mortality in Acute Coronary Syndrome Presenting as Out-of-Hospital Cardiac Arrest	Nothing to Disclose
Kragten	Hans	Arrhythmias and Clinical EP: Devices 1	Insertion of a Miniaturized Insertable Cardiac Monitor Outside the Traditional Hospital Setting: Results From the RIO 2 International Study	Nothing to Disclose
K-Raman	Purushothaman	Cutting Edge Vascular Medicine	Proprotein Convertase Subtilisin Kexin Type 9 Protein Expression Is Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Fibrous Plaques	Nothing to Disclose
K-Raman	Purushothaman	Highlights in Vascular Medicine Research	Morphological Features of Vascular Healing in Paclitaxel Coated Balloon Compared to Plain Old Balloon Angioplasty in Human Peripheral Artery Disease	Nothing to Disclose
Kramer	Christopher	Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A Symposium by Valentin Fuster)	Panelist	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Bayer; RESEARCH/RESEARCH GRANTS - Novartis
Kramer	Christopher	Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A	Imaging Diagnostic /Prognostic Approaches to Six Cardiomyopathies: Myocarditis, Dilated, Amyloid,Sarcoid,	CONSULTANT FEES/HONORARIA - Abbott Laboratories,Bayer; RESEARCH/RESEARCH GRANTS - Novartis
Kramer	Christopher	Symposium by Valentin Fuster) Multimodality Imaging in Heart Diseases: International Perspectives From the Gulf Heart Association, Thai Heart Association, and American College of Cardiology	Hypertrophic. Noncompaction Imaging in Hypertrophic Cardiomyopathy	CONSULTANT FEES/HONORARIA - Abbott Laboratories,Bayer; RESEARCH/RESEARCH GRANTS - Novartis
Kramer	Christopher	Role of Imaging in Peripheral Artery Disease	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Bayer; RESEARCH/RESEARCH GRANTS - Novartis
Kramer	Christopher	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Recurrent Focal Myocarditis With Microvascular Obstruction	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Bayer; RESEARCH/RESEARCH GRANTS - Novartis
Kramer	Christopher	31. Non Invasive Imaging: Sports and Exercise Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Laboratories,Bayer; RESEARCH/RESEARCH GRANTS - Novartis
Kramer	Daniel	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team 4	Suggested Reviewer	Nothing to Disclose
Krasuski	Richard	Core Curriculum: Moving from the Basics to Advanced Cases in Pulmonary Hypertension	WHO's Who? Differentiating the Types of PH	CONSULTANT FEES/HONORARIA - Actelion Pharmaceuticals,Bayer Healthcare Pharmaceuticals,Ventripoint; RESEARCH/RESEARCH GRANTS - Actelion Pharmaceuticals,Edwards Life Sciences,St. Jude Medical

Carry Contract of the Contract				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Krasuski	Richard	Understanding Pulmonary Vascular Disease: From Bench to Bedside	Pulmonary Vascular Response to Nitric Oxide and Subsequent Response to Advanced Medical Therapy in Incident Patients With Pulmonary Hypertension	CONSULTANT FEES/HONORARIA - Actelion Pharmaceuticals,Bayer Healthcare Pharmaceuticals,Ventripoint; RESEARCH/RESEARCH GRANTS - Actelion Pharmaceuticals,Edwards Life Sciences,St. Jude Medical
Krasuski	Richard	09. Congenital Heart Disease: Adult Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Actelion
THE SUSIN				Pharmaceuticals,Bayer Healthcare Pharmaceuticals,Ventripoint; RESEARCH/RESEARCH GRANTS - Actelion Pharmaceuticals,Edwards Life Sciences,St. Jude Medical
Kraus	William	Emerging Developments in HFpEF and Arryhthmias	Effects of Age and Comorbidities on Outcomes in Patients With Heart Failure From HF-ACTION	RESEARCH/RESEARCH GRANTS - Liposcience
Kraus	William	Why Can't We Be Friends? Controversies in Heart Failure Management	Prevalent Digoxin Use Is Not Associated With Increased Risk of Death or Hospitalization in Ambulatory Heart Failure Patients With a	RESEARCH/RESEARCH GRANTS - Liposcience
Krause	David	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Reduced Ejection Fraction Acute Lupus Myocarditis Treated With High Dose Steroids and Mycophenolate Mofetil	Nothing to Disclose
Krawchuk	Lindsey	Arrhythmias and Clinical EP: Basic 3	Entropy of Fibrillatory Waves Contributes to Differentiating	Nothing to Disclose
Krawchuk	Lindsey	Arrhythmias and Clinical EP: Basic 4	Paroxysmal From Persistent and Permanent Atrial Fibrillation Efficacy of Scattergram Analysis for Classifying Subtypes of Atrial	Nothing to Disclose
Krawczeski	Catherine	Predicting Outcomes in Pediatric Heart Disase	Fibrillation by Fourier Transform of Fibrillatory Waves Insurance Type Is Associated With Longer Hospital Duration but Similar Mortality Among Children Undergoing Congenital Heart	Nothing to Disclose
Krawczeski	Catherine	Finding Out What Works in Pediatric and Congenital Heart Disease	Surgery Prevalence and Risk Factors Associated With Chronic Kidney Disease in Patients With Single Ventricle Congenital Heart Disease After Fontan Palliation	Nothing to Disclose
Krawisz	Anna	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Prior Hospitalization Within 30 Days Predicts Increased Frequency of Death, Stroke, and Bleeding in Advanced Elderly Outpatients With Atrial Fibrillation	Nothing to Disclose
Kreutzer	Jacqueline	10. Congenital Heart Disease: Pediatric Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC; RESEARCH/RESEARCH GRANTS - MEDTRONIC,St Jude
Krieger	Eric	Special Hearts: The Challenge of Heart Failure in Congenital Heart Disease	Managing Heart Failure in ACHD: Do Conventional Therapies Work?	Medical Nothing to Disclose
Krieger	Eric	The Consequences of Sex: Women and	Panelist	Nothing to Disclose
Krieger	Eric	Pregnancy Across the Spectrum Congenital Heart Disease: To the Third Decade and Beyond	ACC Poster Moderator	Nothing to Disclose
Krieger Krim	Eric Selim	09. Congenital Heart Disease: Adult Team 1	Suggested Reviewer Use of TandemHeart as a Bridge to Surgery in a Patient With	Nothing to Disclose Nothing to Disclose
		Pulmonary Hypertension	Combined Obstructive and Cardiogenic Shock Due to Mechanical Mitral Valve Thrombosis	-
Krim	Selim	FIT Clinical Decision Making: Heart Failure and Cardiomyopathies	ACC Poster Moderator	Nothing to Disclose
Krim	Selim	FIT Clinical Decision Making Reviewers 5	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Krinochkin	Dmitriy	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	New Modification of Isometric Handgrip Stress Echocardiography for Detection of Coronary Artery Disease: Combination of Exercise and Emotional Stress Echocardiography	Nothing to Disclose
Krinochkin	Dmitriy	Cardiac Fibrosis and Heart Failure: The Next Frontier	Influence of Biomarkers of Inflammation, Myocardial Fibrosis, Catecholamines on the Survival of Congestive Heart Failure Patients Undergoing Cardiac Resynchronization Therapy	Nothing to Disclose
Krishnamoorthy	Parasuram	Considerations in Antiplatelet Therapy and in ACS	Chronovariability of Platelet Reactivity With the Hemodialysis Cycle	Nothing to Disclose
Krishnamoorthy	Parasuram	Updates on Risk Factors for Cardiovascular Disease	Cannabis Use Predicts Risks of Heart Failure and Cerebrovascular Accidents: Results from the National Inpatient Sample	Nothing to Disclose
Krishnamoorthy	Parasuram	Predicting the Future: Observations and Discoveries From Registries and Databases	Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample	Nothing to Disclose
Krishnamoorthy	Parasuram	Timely Topics in Acute Coronary Syndromes	Routine Invasive Versus Conservative Strategy for Elderly Patients Aged>75 Years With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS): A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Krishnamoorthy	Parasuram	Coronary Intervention in Interventional Cardiology: Core Concepts	White Blood Cell Count to Platelet Ratio: A Novel Biomarker of Outcomes in Patients With Circulatory Support on Left Ventricular Impella Assist Devices	Nothing to Disclose
Krishnamoorthy	Parasuram	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula	Nothing to Disclose
Krishnan	Kousik	05. Arrhythmias and Clinical EP: Devices Team 1	Suggested Reviewer	Nothing to Disclose
Krishnan	Prakash	Cutting Edge Vascular Medicine	Proprotein Convertase Subtilisin Kexin Type 9 Protein Expression Is Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Fibrous Plaques	CONSULTANT FEES/HONORARIA - Abbott,Bard,MEDTRONIC
Krishnan	Prakash	Interventional Cardiology: PCI in Complex Patients	Risk and Impact of Diabetes Mellitus on Ischemic Events in Females and Males After Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Abbott, Bard, MEDTRONIC
Krishnan	Prakash	Highlights in Vascular Medicine Research	Morphological Features of Vascular Healing in Paclitaxel Coated Balloon Compared to Plain Old Balloon Angioplasty in Human Peripheral Artery Disease	CONSULTANT FEES/HONORARIA - Abbott,Bard,MEDTRONIC
Krishnaswamy	Amar	Interventional Cardiology: TAVR 1	Novel Plane of Measurement to Evaluate Accurate Valve Size in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Krishnaswamy	Amar	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Veno-Arterial ECMO Program for Refractory Cardiogenic Shock in the Cardiac Intensive Care Unit: Feasibility and Outcome Data at a Large Tertiary Academic Center	Nothing to Disclose
Krishnaswamy	Amar	Interventional Cardiology: TAVR 2	Outcomes of Transcatheter Aortic Valve Replacement Without Balloon Predilation: A Systematic Review and Meta-Analysis	Nothing to Disclose
Krishnaswamy	Amar	Interventional Cardiology: TAVR 3	Comparison of Acute Elastic Recoil Between CoreValve and SAPIEN 3 Valves in Transcatheter Aortic Valve Replacement	Nothing to Disclose
Krishnaswamy	Amar	Interventional Cardiology: TAVR 3	Clinical Outcomes of Patients With Pacemaker Implantation After Transcatheter Aortic Valve Replacement: Meta-Analysis and Meta- Regression	Nothing to Disclose
Krishnaswamy	Amar	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Clevedipine as a Therapeutic and Cost-Effective Alternative to Sodium Nitroprusside in Patients With Aortic Dissection	Nothing to Disclose
Krishnaswamy	Amar	Insights From Echocardiography Use	After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Krishnaswamy	Amar	TAVR Outcomes Prognostication	Cardiac Plasticity Predicts Outcome After Transcatheter Aortic	Nothing to Disclose
Krishnaswamy	Amar	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology Team 3	Valve Replacement in Patients With Severe Aortic Stenosis Suggested Reviewer	Nothing to Disclose
Kristanto	William	Coronary Intervention in Interventional	Incidence and Predictors of Target Lesion Failure in a Multi-Ethnic	Nothing to Disclose
		Cardiology: Core Concepts	Asian Population Receiving the SYNERGY Coronary Stent: A Prospective All-Comers Registry	





The same of the sa				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Kristensen	Steen	New Perspectives on CAD Risk Factors	A Genetic Risk Score Predicts Cardiovascular Events in Patients	Nothing to Disclose
Kristiansen	Steen	Novel Imaging and Therapies in Heart Failure	With Stable Coronary Artery Disease Effect of Paroxetine Treatment on Left Ventricular Remodeling in an	Nothing to Disclose
Tuloudiloon	Cloon	There in aging and morapise in meant and is	In Vivo Rat Model of Myocardial Infarction	Trouming to Biodicoc
Kristinsdottir	Linda	Updates on Risk Factors for Cardiovascular	Carotid Plaque Area Is Increased in Patients With Acute Coronary	Nothing to Disclose
Krittanawong	Chayakrit	Disease Updates on Risk Factors for Cardiovascular	Syndrome and Dysglycemia Association Between Short and Long Sleep Duration and	Nothing to Disclose
rentaliawong	Chayakhi	Disease	Cardiovascular Outcomes? A Systematic Review and Meta-Analysis	Nothing to Disclose
Krittanawong	Chayakrit	Valvular Heart Disease: Aortic Stenosis	Sinus Rhythm Versus Atrial Fibrillation &: It Clinical Profile and	Nothing to Disclose
			Natural History of Patients With Severe Aortic Stenosis Managed Medically	
Krittayaphong	Rungroj	Multimodality Imaging in Heart Diseases:	Cardiac MRI Registry for Iron Overload in Patients With	Nothing to Disclose
		International Perspectives From the Gulf Heart Association, Thai Heart Association, and	Thalassemia	-
V	landana	American College of Cardiology	Does a Patient with an LVAD Ever Need an ICD	Nothing to Displace
Kron Kron	Jordana Jordana	Controversies in Device Therapy Stoke and Atrial Fibrillation: Innocent	Co-Chair	Nothing to Disclose Nothing to Disclose
		Bystander or Essential Ingredient		-
Kron	Jordana	Arrhythmias and Clinical EP: Devices 4	Implanted Cardiac Defibrillator and Pacemaker Lead Function in Patient With Cardiac Amyloidosis	Nothing to Disclose
Kronenberg	Marvin	FIT Clinical Decision Making: Prevention, Adult	Ebstein's Anomaly: Atypical Variant Presenting in Adulthood	Nothing to Disclose
		Congenital and Congenital Heart Disease		-
Kronmal	Richard	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Total Testosterone With Progression of Carotid Atherosclerosis and Coronary Artery Calcium Score: The Multi-	Nothing to Disclose
W	10. 5 - 1	O ISSUE Education and the Committee of t	Ethnic Study of Atherosclerosis	OONOU!! TANT FFFOUNDROP! TO THE TOTAL OF THE
Kronzon	ltzhak	Cutting Edge Innovations in Cardiovascular Imaging: Joint Symposium of the Japanese Circulation Society and American College of	Fusion Imaging to Guide Transcatheter Repair of Structural Heart Disorders	CONSULTANT FEES/HONORARIA - Philips healthcare
Kronzon	Itzhak	Cardiology FIT Clinical Decision Making: Non-Invasive	A Multi-Modality Approach Using Noninvasive and Invasive	CONSULTANT FEES/HONORARIA - Philips healthcare
		Imaging and Valvular Heart Disease	Techniques in the Treatment of a Patient With a Complicated Intra- Cardiac Mass	
Kronzon	Itzhak	FIT Clinical Decision Making: Prevention, Adult	Giant Right Coronary Artery Aneurysm Associated With a Coronary	CONSULTANT FEES/HONORARIA - Philips healthcare
		Congenital and Congenital Heart Disease	Cameral Fistula to the Right Atrium	
Kronzon	Itzhak	28. Non Invasive Imaging: Echo Team 5	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Philips healthcare
Kroon	Abraham	Novel Mechanical Devices for the Treatment	Endovascular Carotid Barostimulation for Resistant Hypertension: A	Nothing to Disclose
Krucoff	Mitchell	and Assessment of Hypertension Coronary Angiography, Intra-Vascular Imaging,	Safety and Proof-of-Principle Cohort Study White Blood Cell Count and Major Adverse Cardiovascular Events	CONSULTANT FEES/HONORARIA -
Kucon	Mitchell	Revascularization and Outcomes	After Broot Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study	Abbott,Angelmed,Biosensors,MEDTRONIC,OrbusNeich,Terumo; RESEARCH/RESEARCH GRANTS - Abbott,Angelmed,CSI,Eli Lilly,MEDTRONIC,OrbusNeich,Philips/Volcano,Terumo
Krucoff	Mitchell	Innovative Use of Echocardiography	The Impact of Rigorous Quality Improvement on 3D Echocardiography Image and Data Quality in an International	CONSULTANT FEES/HONORARIA - Abbott,Angelmed,Biosensors,MEDTRONIC,OrbusNeich,Terumo;
			Multisite Randomized Trial	RESEARCH/RESEARCH GRANTS - Abbott, Angelmed, CSI, Eli Lilly, MEDTRONIC, OrbusNeich, Philips/Volcano, Terumo
Krumerman	Andrew	Arrhythmias and Clinical EP: AF Miscellaneous	Diabetes Mellitus and the Development of Atrial Fibrillation in	CONSULTANT FEES/HONORARIA - Biotronik, Sentre Heart
		and Surgical Issues	Hispanics, Blacks and Whites	
Krumholz	Harlan	Are We There Yet? The Long Journey to Health Equity: Part II	Co-Chair	CONSULTANT FEES/HONORARIA - Element Science, IBM Watson, Premier, Inc.; OF FICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - ImageCOR; OTHER - UnitedHealth; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Me2Health; Me2Health; Me2Health; Me2Health; AUEPLEARCH/IRESEARCH GRANTS - Johnson and Johnson, Medtronic, Inc.
Krumholz	Harlan	Are We There Yet? The Long Journey to Health Equity: Part II	ACC-Talk: Race, Risk, Resilience: The 3R's of Health Disparities	CONSULTANT FEES/HONORARIA - Element Science, IBM Watson, Premier, Inc.; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - ImageCOR; OTHER - UnitedHealth; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Me2Health, Me2Health; RESEARCH/RESEARCH GRANTS - Johnson and Johnson, Medtronic, Inc.
Krumholz	Harlan	Are We There Yet? The Long Journey to	Moderator: Patient and Audience Interactive Panel Discussion	CONSULTANT FEES/HONORARIA - Element Science,IBM
		Health Equity: Part II		Watson, Premier, Inc.; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - ImageCOR; OTHER - UnitedHealth; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Me2Health, Me2Health, RESEARCH/RESEARCH GRANTS - Johnson and Johnson, Medtronic, Inc.
Krumholz	Harlan	FIT Forum: Mix and Mingle	Outcomes Research	CONSULTANT FEES/HONORARIA - Element Science,IBM
				Watson, Premier, Inc.; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - ImageCOR; OTHER - UnitedHealth; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Me2Health, Me2Health; RESEARCH/RESEARCH GRANTS - Johnson and Johnson, Medtronic, Inc.
Krumholz	Harlan	Kanu and Docey Chatterjee Lecture and	How Do I Know When it's working? Measuring Quality and Clinical	CONSULTANT FEES/HONORARIA - Element Science,IBM
		Seminal Talks in Heart Failure: I Wanna New Drug: Updated Heart Failure Guidelines	Outcomes for New Pharmacology?	Watson, Premier, Inc.; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - ImageCOR; OTHER - UnitedHealth; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Me2Health, Me2Health, RESEARCH/RESEARCH GRANTS - Johnson and Johnson, Medtronic, Inc.
Krumholz	Harlan	Acute Heart Failure: Evaluating Strategies to	Admission Types Among Patients With Heart Failure Cared for by	CONSULTANT FEES/HONORARIA - Element Science,IBM
		Prevent Readmissions	Accountable Care Organizations: Variation by Performance on a Measure of Risk Standardized Acute Admission Rates	Watson, Premier, Inc.; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - ImageCOR; OTHER - UnitedHealth; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Me2Health, Me2Health, RESEARCH/RESEARCH GRANTS - Johnson and Johnson, Medtronic, Inc.
Krumholz	Harlan	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Toward Identifying Personalized Prognosis in Hypertension: Variation in Early Responses in the Antihypertensive and Lipid- Lowening Treatment to Prevent Heart Attack Trial (ALLHAT)	CONSULTANT FEES/HONORARIA - Element Science, IBM Watson, Premier, Inc.; OF FICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - ImageCOR; OTHER - UnitedHealth; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Me2Health; ROL2Health; RESEARCH/RESEARCH GRANTS - Johnson and Johnson, Medtronic, Inc.

				<u> </u>
Last Name Krumholz	First Name Harlan	Session Title Cardiac Arrest, Diabetes, and Other High Risk	Presentation Title Mechanisms of Acute Myocardial Infarction in Young Women and	Disclosures CONSULTANT FEES/HONORARIA - Element Science, IBM
		Features of Patients With Acute Coronary Syndrome	Discharge Medication Patterns	Watson, Premier, Inc.; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - ImageCOR; OTHER - UnitedHealth; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Me2Health, Me2Health, RESEARCH/RESEARCH GRANTS - Johnson and Johnson, Medtronic, Inc.
Krumholz	Harlan	Innovations in Cardiovascular Risk Assessment and Reduction	Cost-Effectiveness of Coronary Artery Calcium Testing Among Statin Candidates According to the American College of Cardiology and American Heart Association Cholesterol Guidelines	CONSULTANT FEES/HONORARIA - Element Science, IBM Watson, Premier, Inc.; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - ImageCOR, OTHER - UnitedHealth; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Me2Health, Me2Health; RESEARCH/RESEARCH GRANTS - Johnson and Johnson, Medtronic, Inc.
Krumholz	Harlan	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Time to Acute Care Among Patients With Acute Myocardial Infarction in China: A Report From China Patient-Centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction	CONSULTANT FEES/HONORARIA - Element Science, IBM Watson, Premier, Inc.; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - ImageCOR; OTHER - UnitedHealth; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Me2Health, Me2Health, RESEARCH/RESEARCH GRANTS - Johnson and Johnson, Medtronic, Inc.
Krummen	David	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Sex Differences in Atrial Structural Remodeling and Serum Markers of Fibrosis at Presentation for Catheter Ablation	CONSULTANT FEES/HONORARIA - InsilicoMed; OTHER - Biotronic, Boston Scientific, MEDTRONIC, St. Jude Medical; RESEARCH/RESEARCH GRANTS - National Institutes of Health
Kruse	Eric	Innovative Use of Echocardiography	Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography	Nothing to Disclose
Kruse	Eric	New Technologies in Echocardiography	Three-Dimensional Echocardiographic Automated Quantification of Left Ventricular and Atrial Volumes Using Adaptive Analytics Algorithm: Feasibility in Non-Selected Patients	Nothing to Disclose
Kruyer	William	Highlighted Original Research: Non Invasive	Screening for Cardiovascular Disease in High Risk Occupations:	Nothing to Disclose
Krychtiuk	Konstantin	Imaging and the Year in Review Making Progress in Understanding Heart	The United States Air Force Approach Growth Differentiation Factor-15 Is Associated With Mortality in	Nothing to Disclose
Krychtiuk	Konstantin	Failure Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Patients With Severe Acute Heart Failure or Cardiogenic Shock Circulating Mitochondrial DNA Is Associated With Mortality in Patients With Acute Heart Failure	Nothing to Disclose
Krychtiuk	Konstantin	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Intestinal Fatty Acid Binding Protein Predicts Mortality in Patients With Acute Heart Failure or Cardiogenic Shock	Nothing to Disclose
Kubo	Shunsuke	Structural Heart Interventions: Focus on Mitral	Impact of Residual Left Atrial Appendage Trabeculations After WATCHMAN Device Implantation in Atrial Fibrillation Patients	Nothing to Disclose
Kubo	Takashi	Valve, Left Atrial Appendage and HOCM Interventional Cardiology: Intravascular Physiology and Endothelial Function	Comparison of Very Late Vascular Response Beyond 2 Years After Stent Implantation Between EES and BES: An OCT Sub-Study of	Nothing to Disclose
Kucharska-Newton	Anna	Improving Risk Assessment in Atherosclerosis	the NEXT Development and Validation of Prediction Models With Non- Traditional Markers for 10-Year Risk of Ischemic Leg Amputation Among Persons With Diabetes: The Atherosclerosis Risk In Communities (ARIC) Study	Nothing to Disclose
Kuchibhotla	Sudeep	Novel Developments in Acute Coronary Syndromes	Right-Sided Ventriculo-Arterial Coupling Indices Are Associated With Clinical Outcomes Among Patients Receiving Biventricular Impella (BiPella) Support for Cardiogenic Shock	Nothing to Disclose
Kuck	Karl-Heinz	Frontiers in Mitral Valve Disease and Treatment	Multicenter Trial of a Transfemoral System for Mitral Valve Annuloplasty: Up-to-2-Year Follow-Up Results	CONSULTANT FEES/HONORARIA - Biosense Webster,Edwards,St. Jude; SPEAKER'S BUREAU -
Küçükoglu	Mehmet Serdar	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Survival Analysis From THALES Study, A Large Nation-Wide Registry on Pulmonary Arterial Hypertension Associated With Congenital Heart Disease	MEDTRONIC CONSULTANT FEES/HONORARIA - Actelion, GSK, Pfizer, Bayer, Abdi İbrahim, ARIS,
Kuder	Julia	Vascular Access and Hemostasis Issues	Radial Versus Femoral Access for Coronary Angiography and Risk	Nothing to Disclose
Kudzoeva	Zalina	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	of Stroke: Findings From the LATITUDE-TIMI 60 Trial Time-to-Event Meta-Analysis for Bypass Grafting Versus Stenting in Multivessel Disease in Contemporary Era	Nothing to Disclose
Kuebler	Brandon	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Perivalvular Leak in Repaired Tetralogy of Fallot	Nothing to Disclose
Kugelmass	Aaron	STEMI in the Emerging World: International Perspectives From the Cardiological Society of India, Mexican Society of Cardiology, and	Regional STEMI Management in the U.S.	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC
Kugelmass		American College of Cardiology		ш
	Aaron	American College of Cardiology New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of	STEMI Care in the U.S.: 10 Years of Intense Focus	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC
Kugelmass	Aaron	American College of Cardiology New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology The Fundamentals of ACS Trials—Pitfalls in	STEMI Care in the U.S.: 10 Years of Intense Focus Process Measures like Door-to-Balloon do not Matter in 2017: Con	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA,
		American College of Cardiology New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in		OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC
Kugelmass	Aaron	American College of Cardiology New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints Highlighted Original Research: Acute and	Process Measures like Door-to-Balloon do not Matter in 2017: Con Understanding Readmissions in Medicare Beneficiaries During the	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA,
Kugelmass Kugelmass	Aaron Aaron	American College of Cardiology New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Acute Coronary Syndromes, Diagnosis,	Process Measures like Door-to-Balloon do not Matter in 2017: Con Understanding Readmissions in Medicare Beneficiaries During the 90-Day Follow-Up Period Following an AMI Admission What is the Impact of Complications During the Index Hospitalization on Resource Utilization During the 90-Day Follow-Up Period Associated With CABG Surgery Among Medicare Beneficiaries? Medicare Reimbursement Associated With an AMI Hospitalization	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC
Kugelmass Kugelmass Kugelmass	Aaron Aaron Aaron	American College of Cardiology New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Process Measures like Door-to-Balloon do not Matter in 2017: Con Understanding Readmissions in Medicare Beneficiaries During the 90-Day Follow-Up Period Following an AMI Admission What is the Impact of Complications During the Index Hospitalization on Resource Utilization During the 90-Day Follow-Up Period Associated With CABG Surgery Among Medicare Beneficiaries? Medicare Reimbursement Associated With an AMI Hospitalization and 90-Days Post-Discharge Optical Coherence Tomography Guided Percutaneous Coronary Intervention Compared With Other Imaging Guidance: A Meta-	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC
Kugelmass Kugelmass Kugelmass Kugelmass	Aaron Aaron Aaron Aaron	American College of Cardiology New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Acute Coronary Syndromes, Diagnosis, Management and Outcomes Interventional Cardiology. Stent Failure	Process Measures like Door-to-Balloon do not Matter in 2017: Con Understanding Readmissions in Medicare Beneficiaries During the 90-Day Follow-Up Period Following an AMI Admission What is the Impact of Complications During the Index Hospitalization on Resource Utilization During the 90-Day Follow-Up Period Associated With CABG Surgery Among Medicare Beneficiaries? Medicare Reimbursement Associated With an AMI Hospitalization and 90-Days Post-Discharge Optical Coherence Tomography Guided Percutaneous Coronary intervention Compared With Other Imaging Guidance: A Meta- Analysis Survival Analysis From THALES Study, A Large Nation-Wide Registry on Pulmonary Arterial Hypertension Associated With	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC
Kugelmass Kugelmass Kugelmass Kugelmass Kugelmass	Aaron Aaron Aaron Aaron Kayode	American College of Cardiology New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Acute Coronary Syndromes, Diagnosis, Management and Outcomes Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Imaging Pulmonary Vascular Disease Plus the	Process Measures like Door-to-Balloon do not Matter in 2017: Con Understanding Readmissions in Medicare Beneficiaries During the 90-Day Follow-Up Period Following an AMI Admission What is the Impact of Complications During the Index Hospitalization on Resource Utilization During the 90-Day Follow-Up Period Associated With CABG Surgery Among Medicare Beneficiaries? Medicare Reimbursement Associated With an AMI Hospitalization and 90-Days Post-Discharge Optical Coherence Tomography Guided Percutaneous Coronary Intervention Compared With Other Imaging Guidance: A Meta- Analysis Survival Analysis From THALES Study, A Large Nation-Wide	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC Nothing to Disclose
Kugelmass Kugelmass Kugelmass Kugelmass Kugelmass Kudelmass Kula Kulikowski Kulinski	Aaron Aaron Aaron Aaron Kayode Serdar Ewelina Jacquelyn	American College of Cardiology New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Acute Coronary Syndromes, Diagnosis, Management and Outcomes Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease Highlights in Vascular Medicine Research 32. Prevention: Clinical Team 1	Process Measures like Door-to-Balloon do not Matter in 2017: Con Understanding Readmissions in Medicare Beneficiaries During the 90-Day Follow-Up Period Following an AMI Admission What is the Impact of Complications During the Index Hospitalization on Resource Utilization During the 90-Day Follow-Up Period Associated With CABG Surgery Among Medicare Beneficiaries? Medicare Reimbursement Associated With an AMI Hospitalization and 90-Days Post-Discharge Optical Coherence Tomography Guided Percutaneous Coronary Intervention Compared With Other Imaging Guidance: A Meta-Analysis Survival Analysis From THALES Study, A Large Nation-Wide Registry on Pulmonary Arterial Hypertension Associated With Congenital Heart Disease Apabetalone (RVX-208) Lowers Cardiovascular Disease (CVD) in Diabetes Mellitus by a Mechanism Involving Microbiome Mediated Activity on the Complement Pathway	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC Nothing to Disclose SALARY - Resverlogix Corp Nothing to Disclose
Kugelmass Kugelmass Kugelmass Kugelmass Kugelmass Kuku Kula Kulikowski	Aaron Aaron Aaron Kayode Serdar Ewelina	American College of Cardiology New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Acute Coronary Syndromes, Diagnosis, Management and Outcomes Interventional Cardiology. Stent Failure Analysis by Intravascuar Imaging Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease Highlights in Vascular Medicine Research 32. Prevention: Clinical Team 1 Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Young Investigator Awards Competition:	Process Measures like Door-to-Balloon do not Matter in 2017: Con Understanding Readmissions in Medicare Beneficiaries During the 90-Day Follow-Up Period Following an AMI Admission What is the Impact of Complications During the Index Hospitalization on Resource Utilization During the 90-Day Follow-Up Period Associated With CABC Surgery Among Medicare Beneficiaries? Medicare Reimbursement Associated With an AMI Hospitalization and 90-Days Post-Discharge Optical Coherence Tomography Guided Percutaneous Coronary Intervention Compared With Other Imaging Guidance: A Meta-Analysis From THALES Study, A Large Nation-Wide Registry on Pulmonary Arterial Hypertension Associated With Congenital Heart Disease Apabetalone (RVX-208) Lowers Cardiovascular Disease (CVD) in Diabetes Melitus by a Mechanism Involving Microbiome Mediated Activity on the Complement Pathway Surgested Reviewer Association Between Body Mass Index and Outcomes Among Patients With Prevalent Atrial Fibrillation: A Meta-Analysis Scanning the Phenome to Uncover Piclotropic Effects of	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC Nothing to Disclose SALARY - Resverlogix Corp
Kugelmass Kugelmass Kugelmass Kugelmass Kuku Kula Kulikowski Kulinski Kulinski Kulikami	Aaron Aaron Aaron Aaron Kayode Serdar Ewelina Jacquelyn Nitin	American College of Cardiology New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Acute Coronary Syndromes, Diagnosis, Management and Outcomes Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease Highlights in Vascular Medicine Research 32. Prevention: Clinical Team 1 Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Young Investigator Awards Competition: Clinical Investigations Advances in Cholesterol Measurement and	Process Measures like Door-to-Balloon do not Matter in 2017: Con Understanding Readmissions in Medicare Beneficiaries During the 90-Day Follow-Up Period Following an AMI Admission What is the Impact of Complications During the Index Hospitalization on Resource Utilization During the 90-Day Follow-Up Period Associated With CABG Surgery Among Medicare Beneficiaries? Medicare Reimbursement Associated With an AMI Hospitalization and 90-Days Post-Discharge Optical Coherence Tomography Guided Percutaneous Coronary Intervention Compared With Other Imaging Guidance: A Meta-Analysis From THALES Study, A Large Nation-Wide Registry on Pulmonary Arterial Hypertension Associated With Congenital Heart Disease Apabetalone (RVX-208) Lowers Cardiovascular Disease (CVD) in Diabetes Mellitus by a Mechanism Involving Microbiome Mediated Activity on the Complement Pathway Sungested Reviewer Association Between Body Mass Index and Outcomes Among Patients With Prevalent Atrial Fibrillation: A Meta-Analysis Scanning the Phenome to Uncover Pleiotropic Effects of <ppcsk9- clinical="" decision="" familial<="" for="" ip-pysician="" on="" perspectives="" support="" td=""><td>OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC Nothing to Disclose SALARY - Resverlogix Corp Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose</td></ppcsk9->	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC Nothing to Disclose SALARY - Resverlogix Corp Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Kugelmass Kugelmass Kugelmass Kugelmass Kuku Kula Kulikowski Kulikowski Kulikowski Kulikowski Kulikowski Kulikowski Kulikowski	Aaron Aaron Aaron Aaron Kayode Serdar Ewelina Jacquelyn Nitin Iftikhar	American College of Cardiology New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Acute Coronary Syndromes, Diagnosis, Management and Outcomes Interventional Cardiology Stent Failure Analysis by Intravascuar Imaging Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease Highlights in Vascular Medicine Research 32. Prevention: Clinical Team 1 Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Young Investigator Awards Competition: Clinical Investigations Advances in Cholesterol Measurement and Management	Process Measures like Door-to-Balloon do not Matter in 2017: Con Understanding Readmissions in Medicare Beneficiaries During the 90-Day Follow-Up Period Following an AMI Admission What is the Impact of Complications During the Index Hospitalization on Resource Utilization During the 90-Day Follow-Up Period Associated With CABG Surgery Among Medicare Beneficiaries? Medicare Reimbursement Associated With an AMI Hospitalization and 90-Days Post-Discharge Optical Coherence Tomography Guided Percutaneous Coronary Intervention Compared With Other Imaging Guidance: A Meta- Analysis Survival Analysis From THALES Study, A Large Nation-Wide Registry on Pulmonary Arterial Hypertension Associated With Congenital Heart Disease Apabetalone (RVX-208) Lowers Cardiovascular Disease (CVD) in Diabetes Melitus by a Mechanism Involving Microbiome Mediated Activity on the Complement Pathway Suggested Reviewer Association Between Body Mass Index and Outcomes Among Patients With Prevalent Atrial Fibrillation: A Meta-Analysis Scanning the Phenome to Uncover Pleiotropic Effects of <pcsk9< p=""></pcsk9<>	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC Nothing to Disclose Nothing to Disclose SALARY - Resverlogix Corp Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Fukuda, Fukuda RESEARCH/RESEARCH GRANTS - Fukuda, Fukuda
Kugelmass Kugelmass Kugelmass Kugelmass Kuku Kula Kulikowski Kulikowski Kulikarni Kullo	Aaron Aaron Aaron Aaron Kayode Serdar Ewelina Jacquelyn Nitin	American College of Cardiology New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Acute Coronary Syndromes, Diagnosis, Management and Outcomes Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease Highlights in Vascular Medicine Research 32. Prevention: Clinical Team 1 Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Young Investigator Awards Competition: Clinical Investigations Advances in Cholesterol Measurement and	Process Measures like Door-to-Balloon do not Matter in 2017: Con Understanding Readmissions in Medicare Beneficiaries During the 90-Day Follow-Up Period Following an AMI Admission What is the Impact of Complications During the Index Hospitalization on Resource Utilization During the 90-Day Follow-Up Period Associated With CABG Surgery Among Medicare Beneficiaries? Medicare Reimbursement Associated With an AMI Hospitalization and 90-Days Post-Discharge Optical Coherence Tomography Guided Percutaneous Coronary Intervention Compared With Other Imaging Guidance: A Meta-Analysis From THALES Study, A Large Nation-Wide Registry on Pulmonary Arterial Hypertension Associated With Congenital Heart Disease Apabetalone (RVX-208) Lowers Cardiovascular Disease (CVD) in Diabetes Mellitus by a Mechanism Involving Microbiome Mediated Activity on the Complement Pathway Sungested Reviewer Association Between Body Mass Index and Outcomes Among Patients With Prevalent Atrial Fibrillation: A Meta-Analysis Scanning the Phenome to Uncover Pleiotropic Effects of <ppcsk9- clinical="" decision="" familial<="" for="" ip-pysician="" on="" perspectives="" support="" td=""><td>OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC Nothing to Disclose SALARY - Resverlogix Corp Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Fukuda, Fukuda</td></ppcsk9->	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AKKA, LLC Nothing to Disclose SALARY - Resverlogix Corp Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Fukuda, Fukuda



Contract of the contract of th				<u> </u>
Last Name Kullo	First Name Iftikhar	Session Title Vascular Medicine: Aortic and Peripheral	Presentation Title Association of Ankle Brachial Index With Limb Outcomes in	Disclosures RESEARCH/RESEARCH GRANTS - Fukuda, Fukuda
Kullo	Iftikhar	Artery Diseases Advancing Our Understanding of Aortic	Peripheral Artery Disease: A Community-Based Study Risk Factors Associated With Early- Versus Late-Accelerated	RESEARCH/RESEARCH GRANTS - Fukuda,Fukuda
		Disease	Growth Patterns in Patients With Abdominal Aortic Aneurysm	
Kullo	lftikhar	Contemporary Issues in Familial Hypercholesterolemia	the Community	RESEARCH/RESEARCH GRANTS - Fukuda,Fukuda
Kullo Kumada	Iftikhar Maki	32. Prevention: Clinical Team 4 Novel Strategies for Assessing and Improving	Suggested Reviewer Effect of Gene Polymorphism of Calpain-10 on the Risk of	RESEARCH/RESEARCH GRANTS - Fukuda,Fukuda Nothing to Disclose
		Adherence to Blood Pressure Lowering Therapies	Hypertension in Japanese Population	3
Kumar	Arnav	Insights From Echocardiography Use	Aortic Regurgitation Negatively Affects Left Ventricular Mechanics After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Kumar	Arnav	TAVR Outcomes Prognostication	Cardiac Plasticity Predicts Outcome After Transcatheter Aortic	Nothing to Disclose
Kumar	Gautam	Contemporary Role of Intracoronary Imaging:	Valve Replacement in Patients With Severe Aortic Stenosis Case Presentation: Coronary Dissection and Subintimal Hematoma	CONSULTANT FEES/HONORARIA - Abiomed,CSI Medical
Kumar	Gautam	Candid Conversation with Peers Maintenance of Clinical Competencies in	Co-Chair	Inc.,T3 labs / Emory,Trireme Medical LLC. CONSULTANT FEES/HONORARIA - Abiomed,CSI Medical
		Invasive Coronary Imaging and Coronary Physiology		Inc.,T3 labs / Emory,Trireme Medical LLC.
Kumar	Gautam	Maintenance of Clinical Competencies in Invasive Coronary Imaging and Coronary	Pitfalls in FFR Interpretation	CONSULTANT FEES/HONORARIA - Abiomed,CSI Medical Inc.,T3 labs / Emory,Trireme Medical LLC.
Kumar	Gautam	Physiology Test Yourself with Questions: Guidelines	Faculty	CONSULTANT FEES/HONORARIA - Abiomed,CSI Medical
Kumar	Gautam	Module 4: Stable Ischemic Heart Disease Engage @ ACC.17 Studio: FIT Jeopardy Battle	Co-Chair	Inc.,T3 labs / Emory,Trireme Medical LLC. CONSULTANT FEES/HONORARIA - Abiomed,CSI Medical
Kumar	Gautam	of the State Chapters I 02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Inc.,T3 labs / Emory,Trireme Medical LLC. CONSULTANT FEES/HONORARIA - Abiomed,CSI Medical
		Clinical Team 9		Inc.,T3 labs / Emory,Trireme Medical LLC.
Kumar	Mukund	Insights From Echocardiography Use	Trends and Use of Echocardiography in Patients With <i>Staphylococcus Aureus</i> Bacteremia: An Analysis Using the Nationwide Inpatient Sample (NIS) Data	Nothing to Disclose
Kumar	Nilay	Interventional Cardiology: TAVR 2	Comparative Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Chronic Kidney Disease	Nothing to Disclose
Kumar	Nilay	Vascular Medicine: Aortic and Peripheral	Regional Differences in Clinical Outcomes and Resource Utilization	Nothing to Disclose
	_	Artery Diseases	After Acute Ischemic Stroke Hospitalizations in the United States	
Kumar	Rajan	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Isolated Single Coronary Artery in Adult Population: A Contemporary Classification	Nothing to Disclose
Kumar	Saurabh	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Role of Ganglionic Plexus Ablation in Treatment of Atrial Fibrillation: A Systematic Review and Meta-Analysis	Nothing to Disclose
Kumar	Saurabh	Atrial Fibrillation and VT: Incorporating Novel	Catheter Ablation Versus Medical Therapy for Treatment of VT	Nothing to Disclose
		Risks Toward Decision Making	Associated With Structural Heart Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials	
Kumar	Suneel	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Right Sided Accessory Pathway Masquerading as LBBB with Cardiomyopathy: "Cure" With Catheter Ablation	Nothing to Disclose
Kumar	Sunil	Arrhythmias and Clinical EP: Devices 3	Cryoballoon Versus Radiofrequency Ablation of Atrial Fibrillation: In- Lab Complication Rates at a Large Volume Electrophysiology Center	Nothing to Disclose
Kumar	Varun	PCI for NSTEMI and Complex Patients With	Predictors of 90-Day Readmission and In Hospital Mortality	Nothing to Disclose
		Multiple Co-Morbidities	Amongst Patients Undergoing Percutaneous Coronary Interventions: Insights From a National Database	
Kumar	Varun	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Transcatheter Mitral Valve Repair (Mitraclip) in United States: Etiologies and Predictors of Readmission and In-Hospital Mortality From the Nationwide Readmission Database	Nothing to Disclose
Kumar	Varun	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Impact of Cardiac Devices on Readmission and Short Term Mortality in Patients With Heart Failure With Reduced Ejection Fraction: A Nationwide Study	Nothing to Disclose
Kumar	Vidhya	Non Invasive Imaging: Expanding Clinical	Non-Contrast Quantification of Myocardial Fibrosis With Dual	Nothing to Disclose
Kumar	Vishesh	Applications FIT Clinical Decision Making: Non-Invasive	Energy Computed Tomography An Alternative Approach to Treatment of Infective Endocarditis	Nothing to Disclose
Kumar	Vishesh	Imaging and Valvular Heart Disease Interventional Cardiology: Angiography,	Using AngioVac® Comparison of Procedural Efficacy of Coronary Angiography in	Nothing to Disclose
		Intravascular Imaging and Interventional CT/MR	Octogenarian, Nonagenarian and General Population	
Kumar	Vishesh	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Troponin Elevation Following Elective PCI Predicts Long Term	Nothing to Disclose
Kumar	Vishesh	Interventional Complexity and Complications	Factors Influencing Physician Selection of Radial Versus Femoral Approach in Non-Emergent Cases of CATH and PCI Procedures	Nothing to Disclose
Kumar	Vishesh	Interventional Complexity and Complications	Patient Characteristics as Predictors of Transradial Approach	Nothing to Disclose
Kumar	Vishesh	Interventional Complexity and Complications		Nothing to Disclose
Kumar	Vishesh	FIT Clinical Decision Making: Interventional	Transfemoral Versus Transradial Coronary Angiography A Case of Bilateral External Iliac Obstruction in Pediatric Male	Nothing to Disclose
	<u> </u>	Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Patient Managed With Angioplasty With a Drug Eluting Balloon	
Kumbhani	Dharam	What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young	Panelist	CONSULTANT FEES/HONORARIA - American College of Cardiology, Aralez, Somahlutions; RESEARCH/RESEARCH GRANTS - American College of Cardiology
Kumbhani	Dharam	Scientist Awardee Lecture Controversies in ACS Guidelines	Co-Chair	CONSULTANT FEES/HONORARIA - American College of Cardiology, Aralez, Somahlutions; RESEARCH/RESEARCH
Kumbhani	Dharam	Controversies in ACS Guidelines	DAPT Duration: It's More Than Just the Score	GRANTS - American College of Cardiology CONSULTANT FEES/HONORARIA - American College of Cardiology, Aralez, Somahlutions; RESEARCH/RESEARCH
Kumbhani	Dharam	Highlighted Original Research: Acute and	Co-Chair	CRANTS - American College of Cardiology CONSULTANT FEES/HONORARIA - American College of
		Stable Ischemic Heart Disease and the Year in Review		Cardiology,Aralez,Somahlutions; RESEARCH/RESEARCH GRANTS - American College of Cardiology
Kumbhani	Dharam	Interventional Cardiology: TAVR 3	Role of Hospital Volume in Identifying Low and High-performing Surgical Valve Centers in the United States	CONSULTANT FEES/HONORARIA - American College of Cardiology,Aralez,Somahlutions; RESEARCH/RESEARCH
Kumbhani	Dharam	Interventional Cardiology: TAVR 4	Depression as a Potential Therapeutic Target to Improve Quality of	GRANTS - American College of Cardiology CONSULTANT FEES/HONORARIA - American College of Cardiology Araba Somablutions: PESEAPCH/PESEAPCH
Vhh ai	Dharan	F @ ACC 47 Ch. ** - Martin A. **	Life After Transcatheter Aortic Valve Replacement	Cardiology,Aralez,Somahlutions; RESEARCH/RESEARCH GRANTS - American College of Cardiology
Kumbhani	Dharam	Engage @ ACC.17 Studio: Meet the Acute and Stable Heart Disease Legends	Co-Chair	CONSULTANT FEES/HONORARIA - American College of Cardiology,Aralez,Somahlutions; RESEARCH/RESEARCH GRANTS - American College of Cardiology
		Inc. A. January Olympia Inches de Marcel Biography	Suggested Reviewer	CONSULTANT FEES/HONORARIA - American College of
Kumbhani	Dharam	02. Acute and Stable Ischemic Heart Disease: Clinical Team 2	ouggested Newewer	Cardiology, Aralez, Somahlutions; RESEARCH/RESEARCH GRANTS - American College of Cardiology

and the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Kunadian	Vijayalakshmi	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Frail Older Patients Have a Greater Improvement in Physical Quality of Life Than Robust Patients at One Year Following Invasive	OTHER - none
		manapic co-morbidides	Treatment for Non-ST Elevation Acute Coronary Syndrome	
Kundu	Amartya	Valvular Heart Disease: Aortic Stenosis	Factors Associated With Rapid Progression of Aortic Stenosis in	Nothing to Disclose
randa	, and tyd	Tarvalar Floary Biocado: Florad Cloricolo	Patients With Bicuspid Aortic Valve: A Single Center Retrospective	realing to Blocked
Kunitomo	Yukiko	Innovations in Education	Study Cardiology Fellow Training and Perspective of the Informed	Nothing to Disclose
			Consent Process	
Kuo	Shinie	Non Invasive Imaging: Expanding Clinical Applications	Are There Sex Differences in Management of Coronary Artery Disease After Coronary CT Angiography?	Nothing to Disclose
Kupatt	Christian	Interventional Cardiology: PCI and TAVR in	Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter	Nothing to Disclose
		Complex Patients	Aortic Valve Replacement With Self-Expanding Valves: From the Bravo-3 Randomized Trial	
Kupfer	Stuart	The Intersection of Diabetes and ASCVD	Average Clinician Measured Blood Pressure Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes Following Acute	SALARY - Takeda Pharmaceuticals International
			Coronary Syndromes in the EXAMINE Trial	
Kupsky	Daniel	Risky Business: Predicting Outcomes in Heart Failure	Chronotropic Incompetence and Long-Term Risk of Heart Failure: The Henry Ford Exercise Testing Project	Nothing to Disclose
Kuramitsu	Shoichi	Interventional Cardiology: Intravascular	Long-Term Vascular Response to Permanent Polymer Everolimus-	Nothing to Disclose
		Physiology and Endothelial Function	Eluting Stent Compared With Biodegradable Polymer Biolimus- Eluting Stent: Five-Year Follow-Up Optical Coherence Tomography	
			Study	
Kuramitsu	Shoichi	Coronary Intervention in Interventional Cardiology: Core Concepts	Incidence and Clinical Impact of Longitudinal Stent Deformation After the PROMUS Element Platinum Chromium-Everolimus Eluting	Nothing to Disclose
			Stent Implantation	
Kuramitsu	Shoichi	Interventional Cardiology: PCI in Complex Patients	Three-Year Clinical Outcomes of the XIENCE/PROMUS Cobalt- Chromium Everolimus-Eluting Stent in Patients Treated With In-	Nothing to Disclose
	_		Stent Restenosis	
Kureshi	Faraz	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Outcomes of Concomitant Acute Kidney Injury and Hospital Acquired Anemia in Patients With Myocardial Infarction: The	Nothing to Disclose
Kurrandu	Katharina	Syndrome	TRIUMPH Study	Nothing to Displace
Kurgansky	Katherine	Emerging Developments in HFpEF and Arryhthmias	Serum Sodium Is Associated With Mortality in Heart Failure With Preserved Ejection Fraction in the U.S. Veteran Population	Nothing to Disclose
Kuroi	Akio	Interventional Cardiology: Intravascular	Comparison of Very Late Vascular Response Beyond 2 Years After	Nothing to Disclose
		Physiology and Endothelial Function	Stent Implantation Between EES and BES: An OCT Sub-Study of the NEXT	
Kurosawa	Koji	Emerging Applications of Echocardiography	Effect of Changing Strain Software Versions on Longitudinal Assessment of LV Function	Nothing to Disclose
Kurtz	Christopher	Joint American College of Cardiology/Journal	Primary Results of EBBINGHAUS, a Cognitive Study of Patients	OTHER - Amgen Inc.; SALARY - Amgen Inc.
		of the American Medical Association Late- Breaking Clinical Trials	Enrolled in the FOURIER Trial	
Kushner	Fred	Controversies in ACS Guidelines	Panelist	Nothing to Disclose
Kushner	Fred	02. Acute and Stable Ischemic Heart Disease: Clinical Team 3	Suggested Reviewer	Nothing to Disclose
Kushwaha	Sudhir	The Evolving World of LVADs, Transplant and	Effects of Diabetes Mellitus on Clinical Outcomes After Left	Nothing to Disclose
		Other Novel Discoveries	Ventricular Assist Device Implantation: A Single Institutional 9-Year Experience	
Kushwaha	Sudhir	Advanced Therapies = Advanced Trouble:	Sirolimus-Based Immunosuppression Mitigates Progression of	Nothing to Disclose
		VAD and Transplant Challenges	Cardiac Allograft Vasculopathy and Improves Cardiac Outcomes After Heart Transplantation: A Single Center 15-Year Follow-Up	
	F	D. L. (N IOD T l l	Study	Note: A Broken
Kusumoto	Fred	Role of Newer ICD Technologies for the Prevention of Sudden Cardiac Death	Co-Chair	Nothing to Disclose
Kusumoto	Fred	05. Arrhythmias and Clinical EP: Devices Team 2	Suggested Reviewer	Nothing to Disclose
Kusunose	Kenya	Novel Determinants of Outcomes in VHD	Valvuloarterial Impedance and Left Ventricular Global Longitudinal	Nothing to Disclose
			Strain Provide Incremental Prognostic Value in Patients With	-
			Significant Aortic Stenosis and Preserved Left Ventricular Ejection Fraction	
Kutalek	Steven	Arrhythmias and Clinical EP: Devices 1	Increased Shock Impedance Is Associated With Failed Subcutaneous Implantable Cardioverter Defibrillator Defibrillation	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,Sorin,Spectranetics Corp.
			Threshold Testing	
Kutty	Shelby	Adult Patients With Congenital Heart Disease: How Do They Compare?	Decreased Hepatic Elasticity in Young Adults After Biventricular Repair of Congenital Heart Disease	Nothing to Disclose
Kutty	Shelby	Arrhythmias and Clinical EP: Devices 2	Impact of Left Atrial Appendage Occlusion on Left Atrial Function	Nothing to Disclose
Kutyifa	Valentina	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Sustained Clinical Benefit of Cardiac Resynchronization Therapy in Patients With Relatively Preserved Ejection Fraction: A MADIT-CRT	Nothing to Disclose
W 1 %	Malargan		Long-Term Follow-Up Sub-Study	Note: A Broken
Kutyifa	Valentina	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Change in Renal Function During Extended Follow-Up After Left Ventricular Assist Device Implantation	Nothing to Disclose
Kutys	Robert	Complex Coronary Intervention: Left	Pathological Features of Left Main Stent Thrombosis	Nothing to Disclose
Kutys	Robert	Main/Bifurcations and Multivessel Disease Non Invasive Imaging: Expanding Clinical	Dual-Energy Coronary Computed Tomography Evaluation of High-	Nothing to Disclose
		Applications	Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients: Validation with Histopathologic Gold Standard	
Kutys	Robert	Coronary Intervention: Drug Eluting Stent and	Long-Term Pathological Result of Everolimus-Eluting Stent Versus	Nothing to Disclose
Kutys	Robert	Scaffolds Non Invasive Imaging: Prognostic Implications	Silolimus-Eluting Stent and Bare Metal Stent Quantitative Measurement of Coronary Intra-Plaque Necrotic Core	Nothing to Disclose
Nutyo	Nobelt	of CT Angiography	by Coronary CT Angiography in Victims of Autopsy-Proven Sudden	Trouming to Disclose
			Coronary Death: A Comparison to a Histologic Reference Standard	
Kutys	Robert	Non Invasive Imaging: New Technologies	Optimal Method for Necrotic Core Identification in Coronary Plaque	Nothing to Disclose
			With Dual-Energy Computed Tomography: Material Decomposition and Atomic Number	
Kutys	Robert	Unusual Presentations of ACS	Molecular Autopsy of Plaque Erosion-Induced Sudden Cardiac	Nothing to Disclose
Kuvin	Jeffrey	Opening Session and the Joint American	Death in Young Adults (18-35 Years Old) ACC.17 Preview	Nothing to Disclose
		College of Cardiology and Journal of American		- -
		College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture		
Kunin	loffroy	-	Chair	Nothing to Disclose
Kuvin Kuvin	Jeffrey Jeffrey	48th Annual Louis F. Bishop Lecture 48th Annual Louis F. Bishop Lecture	Chair Introduction of Janet S. Wright, MD, FACC	Nothing to Disclose
Kuvin	Jeffrey	FIT Forum: Mix and Mingle Joint American College of Cardiology/Journal	Education Chair	Nothing to Disclose Nothing to Disclose
Kuvin	Jeffrey	of the American Medical Association Late-	Glaii	Induling to Disclose
Kuvin	Jeffrey	Breaking Clinical Trials Innovations in Education	ACC In-Training Examination Predicts Outcomes on the ABIM	Nothing to Disclose
			Certification Examination	-
Kuvin	Jeffrey	42. Spotlight on Special Topics: Education, Innovation, Advocacy, Social Media,	Suggested Reviewer	Nothing to Disclose
		Leadership and Practice Management Team 1		
Kuvin	Jeffrey	LBCT reviewers	LB Reviewer	Nothing to Disclose
	,,		1==	

Congress of the same				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Kuznetsov	Vadim	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	New Modification of Isometric Handgrip Stress Echocardiography for Detection of Coronary Artery Disease: Combination of Exercise and Emotional Stress Echocardiography	Nothing to Disclose
Kuznetsov	Vadim	Cardiac Fibrosis and Heart Failure: The Next Frontier	Influence of Biomarkers of Inflammation, Myocardial Fibrosis, Catecholamines on the Survival of Congestive Heart Failure Patients Undergoing Cardiac Resynchronization Therapy	Nothing to Disclose
Kvasic	Jessica	Innovations in Cardiovascular Risk Assessment and Reduction	ACC/AHA Coronary Artery Calcium Score Guidelines May Underestimate Coronary Artery Disease in African-American Patients	Nothing to Disclose
Kwak	Choong Hwan	Acute Heart Failure: Evaluating Strategies to	Clinical Efficacy of High-Flow Oxygen Therapy Through Nasal	Nothing to Disclose
Kwak	Min Ji	Prevent Readmissions Interventional Cardiology: TAVR 3	Cannula in Patients With Acute Heart Failure Comparing Outcomes in COPD Patients Undergoing TAVR and	Nothing to Disclose
Kwan	Clara	TAVR Outcomes Prognostication	SAVR: A Propensity Matched Analyses Geriatric Assessment Tools and Outcome Prediction in	Nothing to Disclose
Kwan	Gene	40. Vascular Medicine: Non Coronary Arterial	Transcatheter Aortic Valve Replacement Suggested Reviewer	Nothing to Disclose
Kwan	Jennifer M.	Disease Team 2 FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	How a Cardiologist Diagnosed a Pheochromocytoma: Catecholamine-Induced Myocarditis	Nothing to Disclose
Kwan	Michael	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Patent Ductus Arteriosus: An Unusual Cause of High Output Cardiac Failure in an Elderly Patient	Nothing to Disclose
Kwan	Tak	Interventional Live Case Session II: CTO Transmission from Mid-America Heart Institute	Panelist	Nothing to Disclose
Kwan	Tak	(Kansas City, Missouri) Radial Access Mini-Symposium II	Case Presentation: Transpedal Intervention	Nothing to Disclose
Kwan	Tak	Head to Toe: Outcomes of Endovascular Interventions	Case Presentation: Transpecial intervention: Improving Procedural Success and Reducing Complications in Endovascular Treatment of Superficial Femoral Artery In-Stent Restenosis in the Presence of Obstructive Tibial Outflow Disease: Retrograde Transpedal Access Approach	Nothing to Disclose
Kwan	Tak	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Comparison of Adenosine Fractional Flow Reserve and Post- Contrast Instantaneous Wave-Free Ratio for Hemodynamic Assessment of Moderate Coronary Stenoses	Nothing to Disclose
Kwan	Tak	Interventional Complexity and Complications	Can Non-Procedural Patient Characteristics Predict In-Hospital Complications Following Elective Percutaneous Coronary Intervention? Implications for Same-Day Discharge	Nothing to Disclose
Kwan	Tak	Interventional Complexity and Complications	Temporal Trend of Incidence of Stent Thrombosis and In-Hospital	Nothing to Disclose
Kwan	Tak	Interventional Complexity and Complications	Mortality: Results From a National Real-World Registry Does Presence of Atrial Fibrillation Affect In-Hospital Mortality in	Nothing to Disclose
Kwan	Tak	Interventional Complexity and Complications	Patients Undergoing Percutaneous Coronary Intervention? Results From a Real-World Registry Does Gender Affect In-Hospital Mortality in Patients Presenting With	Nothing to Disclose
Kwan	Tak	Peripheral Arterial Disease, Risk, and	Stent Thrombosis? Results From a National Real-World Registry Transradial Versus Transpedal Access Approach for Endovascular	Nothing to Disclose
		Outcomes	Intervention of Superficial Femoral Artery Chronic Total Occlusion	Ç
Kwiatkowski	David	Finding Out What Works in Pediatric and Congenital Heart Disease	Prevalence and Risk Factors Associated With Chronic Kidney Disease in Patients With Single Ventricle Congenital Heart Disease After Fontan Palliation	Nothing to Disclose
Kwok	Chun Shing	Interventional Cardiology: TAVR 3	Meta-Analysis on Cerebral Embolic Protection Devices During Transcatheter Aortic Valve Implantation	Nothing to Disclose
Kwok	Sit-Yee	Adult Patients With Congenital Heart Disease: How Do They Compare?	Right and Left Ventricular Mechanics Are Altered in Adolescents and Adults Late After Repair of Subarterial Ventricular Septal Defects	Nothing to Disclose
Kwon	Deborah	Non Invasive Imaging: MR Characterization and Function	Time Varying Effect of Total Scar on Mortality in Patients With Cardiomyopathy Undergoing Cardiac Resynchronization Therapy	Nothing to Disclose
Kwon	Osung	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Anatomic Versus Ischemic Burden in Predicting Outcomes of Coronary Artery Disease: Data From IRIS-FFR Registry	Nothing to Disclose
Kwon	Osung	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Control Yvery Decases. Eval or The Inspiral Preprocedural Myocardial Infarction Definitions in Patients Underwent Percutaneous Conronary Intervention With Unprotected Left Main Coronary Artery Disease	Nothing to Disclose
Kwon	Osung	Refining PCI Technique and Outcomes	External Validation of DAPT Score in Two Large Cohorts	Nothing to Disclose
Kwon	Osung Sohee	CAD in Unique Patient Populations Arrhythmias and Clinical EP: Basic 3	Mortality of Patients With Previous Stroke Undergoing Drug-Eluting Stent Implantation Entropy of Fibrillatory Waves Contributes to Differentiating	Nothing to Disclose Nothing to Disclose
Kwon	Sohee	Arrhythmias and Clinical EP: Basic 4	Paroxysmal From Persistent and Permanent Atrial Fibrillation Efficacy of Scattergram Analysis for Classifying Subtypes of Atrial	Nothing to Disclose
Kwon	Sung Woo	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Fibrillation by Fourier Transform of Fibrillatory Waves Prognostic Impact of Alkaline Phosphatase Measured at the Time of Presentation in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial	Nothing to Disclose
Kwon	Younghoon	FIT Clinical Decision Making: Non-Invasive	Infarction Recurrent Focal Myocarditis With Microvascular Obstruction	Nothing to Disclose
Kwong	Raymond Y.	Imaging and Valvular Heart Disease Cardiovascular Magnetic Resonance A Fast	Cardiovascular Magnetic Resonance In the Guidelines: United	RESEARCH/RESEARCH GRANTS - Alynlam Pharmaceuticals
Kwong	Kayıllulu 1.	and Reliable Method to Change Patients' Therapy: Joint Symposium of the Society for Cardiovascular Magnetic Resonance and the American College of Cardiology	States	RESEARCH ORAN I S - Alythath Friaithaceuticals
Kwong	Raymond Y.	Clinical Applications of Cardiac MRI in 2017 29. Non Invasive Imaging: MR Team 2	Co-Chair	RESEARCH/RESEARCH GRANTS - Alynlam Pharmaceuticals RESEARCH/RESEARCH GRANTS - Alynlam Pharmaceuticals
Kwong Kwong	Raymond Y. Winghan	29. Non invasive imaging: Mrt 1 earn 2 Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Suggested Reviewer Edoxaban Therapy Increases Treatment Satisfaction and Reduces Utilization of Health Care Resources: An Analysis From the Edoxaban versus warfariN in subjectS UndeRgoing cardiovErsion of Artial Fibrillation (EMSURE-AF) Study	RESEARCH/IRESEARCH GRANTS - Alyniam Pharmaceuticais SALARY - Daiichi Sankyo, Inc.
Ку	Bonnie	Imaging of Cancer-Treatment Associated CV Toxicity: Applying Guidelines to Clinical Practice	Role for Echo in oncology patients. What to look for, how often and for how long?	CONSULTANT FEES/HONORARIA - Bristol Myers Squibb,Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Pfizer,Roche Diagnostics,Singulex
Ку	Bonnie	Heart Failure and Cancer Care	Co-Chair	CONSULTANT FEES/HONORARIA - Bristol Myers Squibb,Roche Diagnostics; RESEARCH/RESEARCH GRANTS -
La Gerche	Andre	The Abnormal ECG: Should I Worry about	Cardiomyopathy on ECG: HCM, ARVC, LVH, or None of the Above	Pfizer,Roche Diagnostics,Singulex Nothing to Disclose
Labedi	Mohamed	Sudden Death Risk in this Patient Arrhythmias and Clinical EP: Basic 2	Utility of an Esophageal Screening Protocol in Preventing Atrio-	Nothing to Disclose
Labib	Sherif	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Esophageal Fistula After Atrial Fibrillation Ablation Congenital Double-Chambered Left Ventricle Presenting as Monomorphic Ventricular Tachycardia	Nothing to Disclose
Labinaz	Marino	Novel Developments in Acute Coronary	Efficacy and Safety of Bivalirudin in Patients Undergoing	Nothing to Disclose
		Syndromes	Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction	

Last Name	First Name	Session Title	Presentation Title	Disclosures
Labinaz	Marino	Interventional Cardiology: TAVR 4	Serum Albumin as an Incremental Predictor of Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement:	Nothing to Disclose
Labovitz	Arthur	Controversies in Echocardiography	Results From the Multicenter Frailty-AVR Study POCUS: Everyone Should Be Able to Do an Echo Where and When	RESEARCH/RESEARCH GRANTS - BMS
Labovitz	Arthur	Emerging Applications of Echocardiography	it is Needed Clinical Characteristics and Changes of Valvuloarterial Impedence Severity in Patients Undergoing Transcatheter Aortic Valve	RESEARCH/RESEARCH GRANTS - BMS
LaCouture	Mike	Innovations in Practice Management and	Replacement for Severe Aortic Stenosis Improving Clinical Decisions in Dyslipidemia: Simulation-Based Medical Education in Action	Nothing to Disclose
LaCouture	Mike	Social Media Innovation in Practice Management, Advocacy, and Education	INTERIOR EQUIPMENT IN ACTION EFFECT TO A CHIEF THE ACTION OF THE ACTION	Nothing to Disclose
Lacro	Ronald	Congenital Heart Disease: Novel Insights in Pediatric Cardiology	Rhythm Abnormalities in Children and Young Adults With Marfan Syndrome	Nothing to Disclose
Ladewig	Dorothy	Arrhythmias and Clinical EP: Basic 4	External Cooling of the Myocardium Slows Electrical Conduction and Terminates Atrial Fibrillation	Nothing to Disclose
Ladia	Vatsal	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	A Rare Case of Rupture of Sinus of Valsalva Into Right Atrium	Nothing to Disclose
Laeeq	Rida	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Headache or Heartache: A Case of Reversible Cerebral Vasoconstriction Syndrome (RCVS) Likely Causing Coronary Vasospasms	Nothing to Disclose
Lafferty	James	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Vasopressors Vasopressors	Nothing to Disclose
Lagerqvist	Во	Novel Developments in Acute Coronary Syndromes	Prehospital Administration of Heparin Reduces the Risk of Vessel Occlusion in Patients With ST Elevation Myocardial Infarction: Secondary Analysis of the TASTE Trial	RESEARCH/RESEARCH GRANTS - Astra-Zenica
Lagu	Tara	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Smoking Cessation Therapies Are Persistently and Significantly Underutilized Among Hospitalized Smokers With Coronary Heart Disease	Nothing to Disclose
Lahewala	Sopan	Arrhythmias and Clinical EP: Basic 1	Atrial Fibrillation in Patients With Non-STEMI: Insights From a National Database	Nothing to Disclose
Lahewala	Sopan	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Insights Into Outcomes With Intracardiac Echocardiogram Use in Structural Interventions	Nothing to Disclose
Lahewala	Sopan	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Impact of Cardiac Devices on Readmission and Short Term Mortality in Patients With Heart Failure With Reduced Ejection Fraction: A Nationwide Study	Nothing to Disclose
Lahewala	Sopan	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Fraction: A Nation with Study CHADS-sub-2 and CHAS-sub-2VASc Scores as Predictors of Length of Stay and Cost of Care in Hospitalised Atrial Fibrillation Patients: Insights From a National Database	Nothing to Disclose
Laing	Susan	Vascular Medicine: New Insights Into Aortic and Peripheral Artery Diseases	The Prevalence of Subclinical Lower Extremity Peripheral Arterial Disease in Mexican Americans: Results From the Cameron County Hispanic Cohort Study	Nothing to Disclose
Lainscak	Mitja	Why Can't We Be Friends? Controversies in Heart Failure Management	Association Between Serum Potassium Level and Outcomes in Heart Failure With Reduced Ejection Fraction: A Cohort Study From the Swedish Heart Failure Registry	Nothing to Disclose
Laird	John	26. Interventional Cardiology: Vascular Access and Complications Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular, Bard Boston Scientific, Cordis, MEDTRONIC, Trivascular; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - AngloSlide, Biocardia, Eximo, PQ Bypass, Reflow Medical, Shockwave Medical, Syntevention; RESEARCH/RESEARCH GRANTS - WL Gore
Lakhani	Baqir	Arrhythmias and Clinical EP: Devices 2	Cost Analysis in Patients Discharged Home Same Day After Device Implantation	Nothing to Disclose
Lakhter	Vladimir	Head to Toe: Outcomes of Endovascular Interventions	Contemporary Nationwide Trends in Inferior Vena Cava Filter Implantation Rates in the United States and the Effect of Food and Drug Administration Advisory	Nothing to Disclose
Lakhter	Vladimir	Venous Investigation: The Dark Side	Nationwide Contemporary Trends in Adjunctive Angioplasty and Stenting at the Time of Catheter Directed Thrombolysis in Patients With Proximal Lower Extremity Deep Vein Thrombosis	Nothing to Disclose
Lakhter	Vladimir	Venous Investigation: The Dark Side	Sex Differences in the Use of Inferior Vena Cava Filters in Patients With Proximal Lower Extremity Deep Vein Thrombosis in the United States	Nothing to Disclose
Lakhter	Vladimir	Advances in Pathophysiology and Treatment of Thrombosis	Intracranial Hemorrhage in Patients Treated With Catheter Directed Thrombolysis	Nothing to Disclose
Lakkireddy	Dhanunjaya	Core Curriculum: Decisions on Afib: From Prevention to Cure	Shared Decision Making Regarding Antiarrhythmics versus Ablation: Is There a Cure for Afib?	Nothing to Disclose
Lakkireddy	Dhanunjaya	Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	Peri-Procedural Use of Novel Oral Anticoagulation Agents During Cardiac Device Implantation: Are They Safe?	Nothing to Disclose
Lakkireddy	Dhanunjaya	Arrhythmias and Clinical EP: Ventricular Tachycardia	Impact of Arrhythmia Duration and Index Left Ventricular Ejection Fraction on Recovery of Left Ventricular Function in Patients With Arrhythmia-Induced Cardiomyopathy	Nothing to Disclose
Lakkireddy	Dhanunjaya	Arrhythmias and Clinical EP: Devices 1	Amyumma-induced Cardiomyopathy implantable Cardioverter Defibrillator for the Prevention of Mortality in Non-Ischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Lakkireddy	Dhanunjaya	Arrhythmias and Clinical EP: Devices 1	Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients Undergoing Cardiac Implantable Electronic Device Implantation: A Meta-Analysis	Nothing to Disclose
Lakkireddy	Dhanunjaya Dhanunjaya	Arrhythmias and Clinical EP: Devices 2	Impact of Left Atrial Appendage Occlusion on Left Atrial Function	Nothing to Disclose
Lakkireddy	Dhanunjaya	Arrhythmias and Clinical EP: Devices 2	Long Term Safety and Efficacy of Left Atrial Appendage Closure With Lariat in Atrial Fibrillation: Is It Still Working at 5 Years? Peaul World Batteny Longovity of St. Lyde Medical Implications of the Communication of	Nothing to Disclose
Lakkireddy	Dhanunjaya	Arrhythmias and Clinical EP: Devices 2	Real World Battery Longevity of St. Jude Medical Implantable Cardioverter-Defibrillators Included in the Advisory for Premature Battery Depletion	Nothing to Disclose
Lakkireddy	Dhanunjaya	Atrial Fibrillation and VT: Unique Populations and Solutions	Use of an Esophageal Retractor to Prevent Thermal Injuries During Atrial Fibrillation Ablation: A Multi-Center Experience	Nothing to Disclose
Lakkireddy	Dhanunjaya	Atrial Fibrillation and VT: Unique Populations and Solutions	Sotalol Versus Other Anti-Arrhythmic Medications for Cardioversion of Atrial Fibrillation and Maintenance of Sinus Rhythm: Meta-Analysis of Randomized Controlled Studies	Nothing to Disclose
Latt County	Dhanunjaya	Arrhythmias and Clinical EP: Anticoagulation Issues	Meta-Analysis on the Efficacy and Safety of New Oral Anticoagulants Compared With Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation	Nothing to Disclose
Lakkireddy			IDente - Deleted Theoretics Fellowing Left Atrial Assessment Classes	Mathias to Disaless
Lakkireddy	Dhanunjaya	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Device-Related Thrombus Following Left Atrial Appendage Closure: A Clinical Conundrum	-
Lakkireddy Lakkireddy	Dhanunjaya	Electrophysiology Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	A Clinical Conundrum CHADS2 Score Predicts Outcomes of Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation	Nothing to Disclose
Lakkireddy		Electrophysiology Arrhythmias and Clinical EP: AF Miscellaneous	A Clinical Conundrum CHADS2 Score Predicts Outcomes of Radiofrequency Catheter	-



Last Name	First Name	Session Title	Presentation Title	Disclosures
Lakkireddy	Dhanunjaya	Atrial Fibrillation and VT: Incorporating Novel	Sotalol Versus Other Anti-Arrhythmic Agents for Prevention of Post-	Nothing to Disclose
		Risks Toward Decision Making	Operative Supraventricular Arrhythmias After Cardiac Surgery: Meta- Analysis of Randomized Controlled Studies	
Lakkireddy	Dhanunjaya	Atrial Fibrillation, Anticoagulation and Novel	Safety Profiles of Percutaneous Left Atrial Appendage Closure	Nothing to Disclose
		Device Therapies	Devices: An Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database From	
			2009 - 2016	
Lakkireddy	Dhanunjaya	FIT Clinical Decision Making: Arrhythmias and	ACC Poster Moderator	Nothing to Disclose
Lakkis	Nasser	Clinical Electrophysiology Interventional Cardiology: PCI in Complex	Clinical Outcomes of Patients With Human Immune Deficiency Virus	Nothing to Disclose
		Patients	After Coronary Revascularization: A Systematic Review and Meta-	
l al-add	Curren	22 Provention Clinical Toron 4	Analysis	Nething to Displace
Lakoski Lakshmanan	Susan Suvasini	32. Prevention: Clinical Team 4 Valvular Heart Disease: Aortic Stenosis	Suggested Reviewer Factors Associated With Rapid Progression of Aortic Stenosis in	Nothing to Disclose Nothing to Disclose
			Patients With Bicuspid Aortic Valve: A Single Center Retrospective	
Laliberte	Benjamin	Why Can't We Be Friends? Controversies in	Study Duration of Oral Loop Diuretics and 30-Day Readmission in Patients	Nothing to Disclose
		Heart Failure Management	With Acute Decompensated Heart Failure	-
Laliberté	François	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic	A Benefit-Risk Analysis of Recurrent Venous Thromboembolism in Patients Who Continued Versus Discontinued Rivaroxaban Therapy	RESEARCH/RESEARCH GRANTS - Janssen Scientific Affairs
		Disease and the Year in Review	After an Initial Six-Month Therapy	
Laliberté	François	Making Progress in Understanding Heart	Incremental Risk of Ischemic Stroke Over Time in Newly Diagnosed	RESEARCH/RESEARCH GRANTS - Janssen Scientific Affairs
Laliberté	François	Failure Antithrombotic Therapy in Ischemic Heart	Heart Failure Patients Without Atrial Fibrillation Rivaroxaban Users Have Significantly Less Treatment	RESEARCH/RESEARCH GRANTS - Janssen Scientific Affairs
Landorto	rangolo	Disease	Discontinuation Compared With Users of Other Oral Anticoagulants	THESE WAS INCLUDED A CONTROL OF SAME O
l al anda	Thomas	Considerations in Anti-latelet Theorem and in	in Non-Valvular Atrial Fibrillation	CONCULTANT FFFC/I IONIODADIA ALLEM Verriler CII FAD
LaLonde	Thomas	Considerations in Antiplatelet Therapy and in ACS	Readmission and Long-Term Mortality in Older Patients Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary	CONSULTANT FEES/HONORARIA - Abbott Vascular, GILEAD Sciences, MEDTRONIC; RESEARCH/RESEARCH GRANTS -
			Intervention: Insights From the Blue Cross Blue Shield of Michigan	Abbott Vascular, MEDTRONIC; SPEAKER'S BUREAU -
			Cardiovascular Consortium	AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company , Novartis Corporation
Lam	Buu-Khanh	Valvular Heart Disease: Mitral Valve Disease	Prognostic Significance of Mitral Stenosis Indices on Outcomes in	Nothing to Disclose
		1	Patients Following Mitral Valve Repair for Degenerative Mitral	-
Lam	Carolyn	The Evolving World of LVADs, Transplant and	Regurgitation Chronic Kidney Disease in Asian Patients With Heart Failure	Nothing to Disclose
	-	Other Novel Discoveries		-
Lam	Carolyn S.	13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	Nothing to Disclose
Lam	Latonia	Clinical Team 5 Coronary Angiography, Intra-Vascular Imaging,	Clinical Outcomes of Acute Ischemic Stroke Patients Stratified by	Nothing to Disclose
		Revascularization and Outcomes	Cardiac Troponin-I: A Retrospective Analysis	-
Lam	Phillip	Making Progress in Understanding Heart Failure	Orthopnea or Paroxysmal Nocturnal Dyspnea in Older Adults Without Prevalent Heart Failure Is a Predictor, but Not an	Nothing to Disclose
		rallule	Independent Risk Factor for Incident Heart Failure: Insights From	
			the Cardiovascular Health Study	
Lam	Phillip	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Among Older Heart Failure (HF) Patients With In-Hospital Acute Kidney Injury (AKI), an Improvement in Kidney Function Is	Nothing to Disclose
		r revent readmissions	Associated With a Higher Risk of Post-Discharge Mortality but Not	
			Readmission	
Lam	Phillip	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Heart Failure Hospitalization (HFH) Despite Digoxin Therapy Versus No HFH Despite Placebo in the Digitalis Investigation Group (DIG)	Nothing to Disclose
		Tailare is base a reconving Book	Trial: Insights Into Risk Factors for HFH in HF and Reduced Ejection	
	DL W		Fraction (HFrEF)	Notice to Breakers
Lam	Phillip	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Clinical Effectiveness of Spironolactone in Hospitalized Older Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or	Nothing to Disclose
		, , , , , , , , , , , , , , , , , , ,	Equal to 30 mL/min/1.73 m ²) Patients With Heart	
Lam	Phillip	Heart Failure and Cardiomyopathies: Heart	Failure Chronic Alpha Blocker Use and Outcomes in Older Male Medicare	Nothing to Disclose
Laiii	rillip	Failure Is Just a Revolving Door	Beneficiaries Hospitalized for Heart Failure	
Lam	Phillip	Why Can't We Be Friends? Controversies in	Adverse Outcomes With Use of Hydralazine and Nitrate	Nothing to Disclose
		Heart Failure Management	Combination Therapy in Hospitalized Older Non-Black Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)	
Lam	Wilson	Redefining the "F" Word	Use of Novel Oral Anticoagulants in Adult Fontan Patients	Nothing to Disclose
Lam	Wilson	Congenital Heart Disease: To the Third Decade and Beyond	Long-Term Follow-Up in Adult Survivors of Pulmonary Atresia With Intact Ventricular Septum	Nothing to Disclose
Lama	Claudia	FIT Clinical Decision Making: Non-Invasive	Persistent Hemodynamic Instability After Repaired Heart Injury Due	Nothing to Disclose
		Imaging and Valvular Heart Disease	to Penetrating Trauma: No Valvulopathy? Look Again	
Lamas	Gervasio	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	An Upside Down Perspective: Yoga Inversions in a Patient With Ascending Aortic Aneurysm	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Guided Delivery Systems, Inc.
Lamas	Gervasio	Insights Into Ischemic Heart Disease: Stable to		OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Guided
		Erosive Plaques	Excretion in Patients With Coronary Artery Disease: A Sentinel Biomarker?	Delivery Systems, Inc.
Lamberts	Morten	Atrial Fibrillation and VT: Specific Situations	Vitamin K Antagonist or Dabigatran in Patients With Atrial	RESEARCH/RESEARCH GRANTS - Bristol-Myers Squibb
Lammertsma	Adriaan	and Newer Outcome Measures Nuclear Cardiology: Quality	Fibrillation: The Importance of Time in Therapeutic Range Automatic SPECT Analysis Compared to Expert Visual Scoring for	Company OTHER - Philips healthcare; RESEARCH/RESEARCH GRANTS
	, sandan	5, ,	the Detection of Coronary Artery Disease	- AVID
Lammertsma	Adriaan	Advances in Chronic Total Occlusion	Effects of Successful Percutaneous Coronary Intervention of	OTHER - Philips healthcare; RESEARCH/RESEARCH GRANTS
		Intervention	Chronic Total Occlusions on Myocardial Perfusion and Left Ventricular Function	- AVID
Lammertsma	Adriaan	Noninvasive Assessment of Coronary Flow	Atherosclerotic Plaque Morphology Is Associated With Impaired	OTHER - Philips healthcare; RESEARCH/RESEARCH GRANTS
		Reserve: Clinical Implications	Myocardial Blood Flow and Fractional Flow Reserve, Independent	- AVID
Lamour	Jacqueline	Therapeutic Advances in Congenital Heart	of Luminal Obstruction Safety of Enalapril in Infants: Data From the Pediatric Heart Network	Nothing to Disclose
	· ·	Disease	Infant With Single Ventricle Trial	-
Lampert	Rachel	ECG Screening in Athletes: The Great Debate	ACC Talk: Talking to the Athlete with a Heart Rhythm Problem	CONSULTANT FEES/HONORARIA - MEDTRONIC;
				RESEARCH/RESEARCH GRANTS - Boston Scientific,GE Medical ,Medtronic,Inc,St Jude Medical
Lampert	Rachel	The Abnormal ECG: Should I Worry about	Co-Chair	CONSULTANT FEES/HONORARIA - MEDTRONIC;
		Sudden Death Risk in this Patient		RESEARCH/RESEARCH GRANTS - Boston Scientific,GE Medical ,Medtronic,Inc,St Jude Medical
Lampert	Rachel	06. Arrhythmias and Clinical EP: Other Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC;
				RESEARCH/RESEARCH GRANTS - Boston Scientific,GE
Lamy	Andre	Interventional Cardiology: TAVR 4	Serum Albumin as an Incremental Predictor of Mortality in Older	Medical ,Medtronic,Inc,St Jude Medical Nothing to Disclose
,			Adults Undergoing Transcatheter Aortic Valve Replacement:	0
Lange	Earnanda	32 Prevention: Clinical Toom 4	Results From the Multicenter Frailty-AVR Study	Nothing to Disclose
Lanas Lancellotti	Fernando Patrizio	32. Prevention: Clinical Team 4 28. Non Invasive Imaging: Echo Team 3	Suggested Reviewer Suggested Reviewer	Nothing to Disclose Nothing to Disclose
Landau	Heather	Advances in HCM, PPCM and Other	NEOD001 Demonstrates Cardiac Biomarker Responses in Patients	CONSULTANT FEES/HONORARIA - Prothena
		Cardiomyopathies	With Light Chain Amyloidosis: Results From the Phase 1/2 Study	
Landzberg	Michael	Sports and Exercise: Athletes with	Panelist	DATA SAFETY MONITORING BOARD - Actelion, CORVIA;
_		Congenital/Valvular Heart Disease Challenging		Harvard Clinical Research Institute; RESEARCH/RESEARCH
	1	Guidelines in Daily Practice		GRANTS - Actelion



and a				
Landzberg	First Name Michael	Session Title Special Hearts: The Challenge of Heart Failure in Congenital Heart Disease	Presentation Title ACHD and Heart Transplant: Challenges and Opportunities	Disclosures DATA SAFETY MONITORING BOARD - Actelion, CORVIA; Harvard Clinical Research Institute; RESEARCH/RESEARCH
Landzberg	Michael	Patient-Centered Care in Adult Congenital Heart Disease	Panelist	GRANTS - Actelion DATA SAFETY MONITORING BOARD - Actelion,CORVIA; Harvard Clinical Research Institute; RESEARCH/RESEARCH GRANTS - Actelion
Landzberg	Michael	Patient-Centered Care in Adult Congenital Heart Disease	Debate: The End of the Ultimate Fighter: Palliative Care in Adult Congenital Heart Disease (Con)	DATA SAFETY MONITORING BOARD - Actelion,CORVIA; Harvard Clinical Research Institute; RESEARCH/RESEARCH GRANTS - Actelion
Landzberg	Michael	Things That Matter in Adult Congenital Heart Disease	Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank	DATA SAFETY MONITORING BOARD - Actelion, Harvard Clinical Research Institute (HCRI) / Corvia Medical Inc.; RESEARCH/RESEARCH GRANTS - Actelion, Canada Heart Research Centre
Landzberg	Michael	Finding Out What Works in Pediatric and Congenital Heart Disease	Timely Detection of Pulmonary Arterial Hypertension in Patients With Repaired Congenital Heart Disease: Interim Results From the ACHD-QuERI Registry	DATA SAFETY MONITORING BOARD - Actelion, Harvard Clinical Research Institute (HCRI) / Corvia Medical Inc.; RESEARCH/RESEARCH GRANTS - Actelion, Canada Heart Research Centre
Lane	Mariellen	Innovations in Education	Fellow Outpatient Clinic: Discontinuing the Discontinuity	Nothing to Disclose
Lanfear	David	Core Curriculum: Mending the Failing Heart	Destination Therapy: Updates in LVAD and Artifical Hearts	CONSULTANT FEES/HONORARIA - HeartWare,Roche; OTHER - Novarits; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Hridaya; RESEARCH/RESEARCH GRANTS - Amgen,Janssen Pharmaceuticals, Inc,Novarits Corporation
Lanfear	David	Put Your Codon! Genetic Insights Into Heart Failure	Genetics of Heart Rate Observational Study (GenHRate)	CONSULTANT FEES/HONORARIA - HeartWare,Roche; OTHER - Novartis; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Hridaya; RESEARCH/RESEARCH GRANTS - Amgen,Janssen Pharmaceuticals, Inc,Novaris Corporation
Lanfear	David	13. Heart Failure and Cardiomyopathies: Clinical Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - HeartWare,Roche; OTHER - Novartis; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Hridaya; RESEARCH/RESEARCH GRANTS - Amgen,Janssen Pharmaceuticals, Inc.Novartis Corporation
Lang	Chim	Making Progress in Understanding Heart Failure	Prognostic Role of Neutrophil to Lymphocyte Ratio in Predicting Outcomes in Patients With Chronic Heart Failure	CONSULTANT FEES/HONORARIA - MSD,Novartis, Astra Zeneca, Servier
Lang	Roberto	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Implementation of a Wideband Late Gadolinium Enhancement Cardiac Magnetic Resonance Protocol to Improve Assessment of Myocardial Scar in Patients With Implantable Cardioverter Defibrillators	Nothing to Disclose
Lang	Roberto	Valvular Heart Disease: Aortic Regurgitation	Left Ventricular Mechanical Properties in Patients With Severe Aortic Insufficiency and Normal Ejection Fraction: Impact on Survival	Nothing to Disclose
Lang	Roberto	Innovative Use of Echocardiography	Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography	Nothing to Disclose
Lang	Roberto	Non Invasive Imaging: MR Scar and Perfusion	Multimodality Analysis of Abnormal Myocardial Perfusion in Post- Heart Transplant Recipients	Nothing to Disclose
Lang	Roberto	New Technologies in Echocardiography	Three-Dimensional Echocardiographic Automated Quantification of Left Ventricular and Atrial Volumes Using Adaptive Analytics Algorithm: Feasibility in Non-Selected Patients	Nothing to Disclose
Lang Lang	Roberto Sean	28. Non Invasive Imaging: Echo Team 2 Congenital Heart Disease: New Diagnostic	Suggested Reviewer Short Axis Diastolic Ventricular Area Ratio as a New Index in	Nothing to Disclose Nothing to Disclose
Lange	Rüdiger	Approaches in Congenital Heart Disease Finding Out What Works in Pediatric and	Screening Patients With Repaired Tetralogy of Fallot Morphological Appearance and Repair Strategies of Tricuspid	Nothing to Disclose
		Congenital Heart Disease	Regurgitation in Patients With Univentricular Heart and a Systemic Right Ventricle	-
Langholz	David	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Chemotherapy Induced Cardiotoxicity, Its Prevention, Treatment and Risk Factors	-
Langholz	David	Innovations in Advocacy and Patient Centered Care	Low-Risk Chest Pain Pathway: Outcomes and Implications in a Large Community Cohort	Nothing to Disclose
Langslet	Gisle	Advances in Cholesterol Measurement and Management	Efficacy and Safety of the PCSK9 Inhibitor Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin Therapy	CONSULTANT FEES/HONORARIA - Amgen,Boehringer Ingelheim Pharmaceuticals, Inc,Janssen Pharmaceuticals,SANOFI; OTHER - Regeneron
Langslet	Gisle	Advances in Cholesterol Measurement and Management	Alirocumab Titration Strategy Allows Individualized LDL-C Reduction in a Real World Setting: Results From ODYSSEY OLE (LONG TERM Cohort)	CONSULTANT FEES/HONORARIA - Amgen,Boehringer Ingelheim Pharmaceuticals, Inc,Janssen Pharmaceuticals,SANOFI; OTHER - Regeneron
Langslet	Gisle	Advances in Cholesterol Measurement and Management	On-Treatment LDL-C Levels When Alirocumab Dose Is Decreased From 150 to 75 mg Every 2 Weeks in Patients With Heterozygous Familial Hypercholesterolemia: Results From ODYSSEY OLE	CONSULTANT FEES/HONORARIA - Amgen,Boehringer Ingelheim Pharmaceuticals, Inc,Janssen Pharmaceuticals,SANOFI; OTHER - Regeneron
Langslet	Gisle	Advances in Cholesterol Measurement and Management	Only Eight Percent of Very High-Risk Familial Hypercholesterolemia Patients Achieve LDL-Cholesterol Target Despite Being on Maximal Conventional Lipid-Lowering Therapy	CONSULTANT FEES/HONORARIA - Amgen, Boehringer Ingelheim Pharmaceuticals, Inc, Janssen Pharmaceuticals, SANOFI; OTHER - Regeneron
Langslet	Gisle	Advances in Lipid Management	Treatment Effects of Alirocumab as an Add-On to Maximally Tolerated Dose of Statin in Patients With Heterozygous Familial Hypercholesterolemia and/or Atherosclerotic Cardiovascular Disease	CONSULTANT FEES/HONORARIA - Amgen,Boehringer Ingelheim Pharmaceuticals, Inc,Janssen Pharmaceuticals,SANOFI, OTHER - Regeneron
Langslet	Gisle	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Alirocumab Treatment in a Real World Setting: Safety Update From an Open-Label Treatment Extension to the ODYSSEY Program for Patients With Heterozygous Familial Hypercholesterolemia	CONSULTANT FEES/HONORARIA - Amgen,Boehringer Ingelheim Pharmaceuticals, Inc,Janssen Pharmaceuticals,SANOFI; OTHER - Regeneron
Lanham	Kena	Interdisciplinary Cardiovascular Team Collaboratives in Care	An Interdisciplinary Approach to a Successful Transition Home: Heart Failure Transitions Program	Nothing to Disclose
Lanier	Gregg	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Combined Heart-Kidney Transplantation in a Patient With Human Immunodeficiency Virus	SPEAKER'S BUREAU - Actelion,Bayer Healthcare Pharmaceuticals,Gilead Sciences, Inc.,United Therapeutics
Lanier	Gregg	The Evolving World of LVADs, Transplant and Other Novel Discoveries	arrhythmias in Hospitalized Heart Transplanted Patients: A United States National Study	SPEAKER'S BUREAU - Actelion, Bayer Healthcare Pharmaceuticals, Gilead Sciences, Inc., United Therapeutics
Lanier	Gregg	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Chagas Heart Disease: A United States National Study	SPEAKER'S BUREAU - Actelion, Bayer Healthcare Pharmaceuticals, Gilead Sciences, Inc., United Therapeutics
Lannon	Carole	Congenital Heart Disease: Advances in Quality Improvement for Pediatric Cardiac Care	Revenue Return on Investment for Center Involvement in a Quality Improvement Collaborative for a Rare Disease: National Pediatric Cardiology Quality Improvement Collaborative	Pnarmaceuticals, cilead Sciences, Inc. ,United I nerapeutics Nothing to Disclose
Lannon	Carole	Finding Out What Works in Pediatric and Congenital Heart Disease	Reduction in Interstage Growth Failure in Infants With Hypoplastic Left Heart Syndrome and Impact on Stage 2 Outcomes: A Report From the National Pediatric Cardiology Quality Improvement Collaborative	Nothing to Disclose
	+	Joint American College of Cardiology/New	Panelist	CONSULTANT FEES/HONORARIA - Keystone Heart;
Lansky	Alexandra	England Journal of Medicine Late-Breaking		SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals,Eli Lilly
Lansky	Alexandra		Update on Cerebral Protection Devices: Should This Be the Standard of Care?	SPEARER'S BURKAU - AstraZeneca Pharmaceuticals,Eil Liliy and Company,Merck &amp Co., Inc. CONSULTANT FEES/HONORARIA - Keystone Heart, SCHAKER'S BUREAU - AstraZeneca Pharmaceuticals,Eil Liliy and Company,Merck &amp Co., Inc.

Contract of the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Lansky	Alexandra	02. Acute and Stable Ischemic Heart Disease: Clinical Team 7	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Keystone Heart; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals,Eli Lilly and Company,Merck & Do., Inc.
Lansman	Steven	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Change in Aortomitral Annular Angle and Anterior Mitral Valve Leaflet Length After Transcatheter Aortic Valve Replacement: Implications for Transcatheter Mitral Valve Replacement?	Nothing to Disclose
Lansman	Steven	Interventional Cardiology: TAVR 4	Predictors of New Persistent Left Bundle Branch Block After	Nothing to Disclose
Lanz	Hans	Fibrillatory Arrhythmias: Outcomes With	Edwards Sapien 3 Transcatheter Aortic Valve Replacement Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First	SALARY - Daiichi Sankyo Inc.
Lapitan	Raul	Contemporary Practice New Strategies in Arrhythmias Management:	Experience From the ENGAGE AF TIMI 48 Trial Co-Chair	CONSULTANT FEES/HONORARIA - SERVIER Phils.
Г аркан	Raui	International Perspectives From the Philippine Heart Association, Russian Society of Cardiology, and American College of Cardiology	Со-Спая	BOREINGHER Phils.,LRI-Therapharma Ph.,PFIZER Phils. TAKEDA Phils.
Lappe	Donald	Interventional Cardiology: Translation and Pre- Clinical Research	Both the Novel NMR Biomarker of Inflammation, GlycA, and HS- CRP Are Independent and Additive Predictors of Future Cardiovascular Events Among Patients Undergoing Coronary Angiography: Results From the Intermountain Heart Collaborative Study	Nothing to Disclose
Lappe	Donald	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	The Association of Depression at Any Time to the Risk of Death Following Coronary Artery Disease Diagnosis: The Intermountain INSPIRE Registry	Nothing to Disclose
Lappe	Donald	Innovations in Practice Management and Social Media	Predicting 3-Year Risk of Incident Chronic Disease in Disease-Free Primary Care Patients: The Intermountain Chronic Disease Model (ICHRON)	Nothing to Disclose
Lappe	Donald	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	The Intermountain Major Adverse Cardiovascular Events Risk Scores Effectively and Efficiently Predict 1- to 3- Year Post-Stent MACE in Non-Myocardial Infarction Patients	Nothing to Disclose
Lappe	Donald	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Improvement of CHA ₂ DS ₂ -VASc Risk Stratification of Stroke and Mortality Using the Intermountain Risk Score Among Atrial Fibrillation Patients Undergoing Cardiac Catheterization	Nothing to Disclose
Lappe	Donald	Non Invasive Imaging: Prognostic Implications of CT Angiography	Cartietization of Future Cardiovascular Risk by Analysis of Various CT Coronary Angiography-Determined Quantitative Plaque Compositional Characteristics Among Patients With Diabetes Enrolled in the FACTOR-64 Study: The Importance of the Calcified Coronary Plaque	Nothing to Disclose
Larkin	Amy	Innovation in Practice Management, Advocacy, and Education	Effect of an Online Continuing Medical Education and Clinician Coaching Quality Improvement Initiative on Antiplatelet Medication Adherence and Hospital Readmissions in Patients With Acute Coronary Syndrome	Nothing to Disclose
LaRocca	Gina	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Fractional Flow Reserve Is a Sensitive but Not a Specific Detector of a High Risk Plaques	Nothing to Disclose
LaRocca	Gina	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Can Necrotic Core Volume Explain Ischemia Coronary Stenosis Mismatch in Some Cases?	Nothing to Disclose
Larose	Eric	Novel Determinants of Outcomes in VHD	Impact of Aortic Valve Calcification and Sex on Hemodynamic	Nothing to Disclose
Larose	Eric	Novel Determinants of Outcomes in VHD	Progression and Clinical Outcomes in Aortic Stenosis Relationship Between Proximal Aorta Morphology and Progression	Nothing to Disclose
			Rate of Aortic Stenosis	-
Larsen	Timothy	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Ventricular Tachycardia Triggered by Loperamide and Famotidine Abuse	Nothing to Disclose
Larson	David	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Influence of Cardiac Arrest and Cardiogenic Shock on Outcomes Among 4,500 Consecutive ST Elevation Myocardial Infarction Patients	Nothing to Disclose
Larson	David	Timely Topics in Acute Coronary Syndromes	Outcome and Characteristics of Shockable Versus Non-Shockable Cardiac Arrest in ST Elevation Myocardial Infarction at a Regional Transfer Center	Nothing to Disclose
LaRue	Shane	Risky Business: Predicting Outcomes in Heart Failure	ACC Poster Moderator	Nothing to Disclose
Lasa	Javier	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Characteristics, Risk Factors and Outcomes of Extracorporeal Membrane Oxygenation Use in the Pediatric Cardiac Intensive Care Unit	Nothing to Disclose
Laschinger	John	Post FDA Release Prosthetic Valve	Prosthetic Heart Valve Approval Process - Durability and Safety	Nothing to Disclose
Lashner	Michael	Surveillance - Watching for Signals FIT Clinical Decision Making: Prevention, Adult	Assessment Hemitruncus Arteriosus: A Rare Case of Hypoxia in Pregnancy	Nothing to Disclose
Lasic	Zoran	Congenital and Congenital Heart Disease The Best Coronary and Peripheral	Recurrent Spontaneous Coronary Artery Dissection in a Patient With	Nothing to Disclose
		Interventional Challenging Cases	Fibromuscular Dysplasia	-
Laslett	Lars	The Malpractice Minefield: How to Avoid, Navigate and Advocate	Co-Chair	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Alphabet,Berkshire Hathaway,Noninvasive Medical Technologies
Laslett	Lars	The Malpractice Minefield: How to Avoid, Navigate and Advocate	Being an Expert Witness: An Extension of Medical Practice	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Alphabet,Berkshire Hathaway,Noninvasive Medical Technologies
Lasorda	David	The Best Structural Interventional Challenging Cases	The First Case of Edward SAPIEN S3 Pulmonary Valve-in-Valve Deployment	SPEAKER'S BUREAU - Lilly
Lassen	Mats Højbjerg	Emerging Applications of Echocardiography	Ratio of Transmittal Early Filling Velocity to Early Diastolic Strain Rate Predicts Long Term Risk of Cardiovascular Morbidity and	Nothing to Disclose
Lassen	Thomas	Novel Imaging and Therapies in Heart Failure	Mortality in a Low Risk General Population Effect of Paroxetine Treatment on Left Ventricular Remodeling in an	Nothing to Disclose
Latanich	Christopher	Current Issues in Cardiovascular	In Vivo Rat Model of Myocardial Infarction (In)Equity in Primary Prevention Statin Treatment Among Diabetics	Nothing to Disclose
	·	Epidemiology, Disparities, and Safety Interventional Live Case Session I: Structural		CONSULTANT FEES/HONORARIA - 4-Tech Cardio,Abbott
Latib	Azeem	Transmission from Cleveland Clinic (Cleveland, Ohio)	Co-Chair	Vascular,Medtronic Advisory Board,Mitralign,Spectranetics,Valtech Cardio
Latib	Azeem	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	CONSULTANT FEES/HONORARIA - 4-Tech Cardio,Abbott Vascular,Medtronic Advisory Board,Mitralign,Spectranetics,Valtech Cardio
Latib	Azeem	Challenging Anatomies: Does TAVR Device Choice Matter	Management of the Horizontal Aorta	CONSULTANT FEES/HONORARIA - 4-Tech Cardio, Abbott Vascular, Medtronic Advisory Board, Mitralign, Spectranetics, Valtech Cardio
Latib	Azeem	The Tricuspid Valve: Not Forgotten, Just Misunderstood	Case: End-stage Tricuspid Regurgitation	CONSULTANT FEES/HONORARIA - 4-Tech Cardio, Abbott Vascular, Medtronic Advisory Board, Mitralign, Spectranetics, Valtech Cardio
Latib	Azeem	22. Interventional Cardiology: Coronary Intervention: Left Main, Multivessel, Bifurcation Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - 4-Tech Cardio, Abbott Vascular, Medtronic Advisory Board, Mitralign, Spectranetics, Valtech Cardio
Latif	Faisal	Core Curriculum: Head to Toe Catheter Based	Carotid Artery Stenting: Preserve the Brain	SPEAKER'S BUREAU - Abbott Vascular, Inc
Latif	Faisal	Interventions Innovations in Education	Differing Interpretations of the ACGME Survey Questions by Cardiovascular Fellows and Cardiovascular Faculty	SPEAKER'S BUREAU - Abbott Vascular, Inc
·	1			

	F N	O	P	la:t
Last Name Latif	Faisal	Session Title Engage @ ACC.17 Studio: FIT Jeopardy Battle	Presentation Title Moderator	Disclosures SPEAKER'S BUREAU - Abbott Vascular, Inc
Latsios	George	of the State Chapters III Vascular Access and Hemostasis Issues	Endothelial Dysfunction Post Transradial Access Coronary Catheterization: A Clinical Study and Meta-Analysis of Published	Nothing to Disclose
Latsios	George	Interventional Cardiology: TAVR 2	Literature The Effect of Mixed Aortic Valve Disease in Clinical Outcomes After	Nothing to Disclose
Latsios	George	Innovative Use of Echocardiography	Transcatheter Aortic Valve Replacement Impact on Long Term Mortality of Persistent Pulmonary	Nothing to Disclose
Latt	Htun	FIT Clinical Decision Making: Arrhythmias and	Hypertension After Transcatheter Aortic Valve Implantation Simple Atrial Flutter Ablation Causing Cardiogenic Shock, Mitral	Nothing to Disclose
Lau	Joe	Electrophysiology Vasculo-Oncology: What You Need to Know	Regurgitation and Complete Heart Block Debate: Optimal Treatment Approaches to Cancer-Induced	Nothing to Disclose
		About Vascular and Thrombotic Complications of Cancer and Cancer Therapeutics	Thrombosis: VKA vs LMWH vs DOACs: Pro-VKA	
Lau	Joe	Advances in Pathophysiology and Treatment of Thrombosis		Nothing to Disclose
	Wei	Interventional Cardiology: TAVR 4	Outcome-Based Cost Analysis of Transfemoral Transcatheter Aortic Valve Replacement Using Fascia Iliaca Compartment Block and Minimalist Conscious Sedation Approach Versus General Anesthesia	
		Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Determination of Calcium Score From CTA Contrast Images Using Standard Clinical Methods	Nothing to Disclose
Lau	Yuk Kong	Novel Echocardiographic Methods for Assessing Cardiac Function	2d Speckle Tracking Echocardiography in Identifying the Degree of Recoverability of Sub Clinical Right Ventricular Dysfunction in Patients With Newly Diagnosed Osa Receiving Cpap Therapy	Nothing to Disclose
Lau	Yuk Kong	ECG Screening and Risk Prediction	Cardiac Arrest and Non-Fatal Myocardial Injury Among Marathon Runners: 15 Years' Experience of the Hong Kong Standard Chartered Marathon	Nothing to Disclose
Lauck	Sandra	Interventional Cardiology: TAVR 4	Serum Albumin as an Incremental Predictor of Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement: Results From the Multicenter Frailty-AVR Study	CONSULTANT FEES/HONORARIA - Edwards Lifesciences
Laufs	Ulrich	Advances in Cholesterol Measurement and Management	Results From the windowner Frank-PAVS JOUR Consistent Low-Density Lipoprotein Cholesterol Lowering Efficacy of Alirocumab in High and Very High Cardiovascular Risk Patients With Low-Density Lipoprotein Cholesterol >100/70 mg/dL at Baseline	Nothing to Disclose
Lauridsen	Trine	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Ecohocardiographic Predictors for In-Hospital and 1-Year Outcomes in Left-Sided Infective Endocarditis: An Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort Study	Nothing to Disclose
Lautsch	Dominik	Advances in Cholesterol Measurement and Management	Frequency and Predictors of Cholesterol Goal Attainment in Patients With Coronary Heart Disease: Results From the Dyslipidemia International Study II	SALARY - Merck&Co, Inc.
Lautsch	Dominik	Advances in Cholesterol Measurement and Management	Low LDL-Cholesterol Target Value Attainment at the Time of Acute Coronary Syndrome (ACS) and Even 4 Months After the Acute Event Due to Lack of Adjustment in Lipid Lowering Treatment: Results From the Dyslipidemia International Study II ACS	SALARY - Merck&Co, Inc.
Lautsch	Dominik	Advances in Cholesterol Measurement and Management	Improvement of LDL-Cholesterol Goal Attainment in High-Risk Patients in Europe and Middle East Between 2008-09 and 2013-14: Results of DYSIS and DYSIS II CHD	SALARY - Merck&Co, Inc.
Lautsch	Dominik	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South-Africa, Middle East and China: Results of the Dyslipidemia International Study (DYSIS)	SALARY - Merck&Co, Inc.
Lautsch	Dominik	Diabetes and Other Issues in Cardiovascular Prevention	Does Concomitant Diabetes Mellitus Impact the Cholesterol Treatment Post Acs?	SALARY - Merck&Co, Inc.
Lavasani	Farangis	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prediction of Future Cardiovascular Risk by Analysis of Various CT Coronary Angiography-Determined Quantitative Plaque Compositional Characteristics Among Patients With Diabetes Enrolled in the FACTOR-64 Study: The Importance of the Calcified Coronary Plaque	Nothing to Disclose
Lavi	Shahar	Considerations in Antiplatelet Therapy and in ACS	Effects of Ticagrelor Versus Clopidogrel in Fibrinolytic-Treated STEMI Patients Undergoing Early PCI	CONSULTANT FEES/HONORARIA - AstraZeneca; RESEARCH/RESEARCH GRANTS - AstraZeneca
Lavi	Shahar	Uncovering the Intricacies of Vascular Function	Ticagrelor Improves Microvascular Function: Results of a Cross-	CONSULTANT FEES/HONORARIA - AstraZeneca; RESEARCH/RESEARCH GRANTS - AstraZeneca
Lavie	Carl	The Heavy Heart: Practicing Heart Failure Cardiology in an Obesity Epidemic	Over Study Co-Chair	RESEARCH/INESEARCH GRAND : - ASIIBZENIEGA CONSULTANT FEES/HONORARIA - Amarin,Amgen,Aralez,AstraZeneca,Boehringer Ingelheim,Bristol- Myers Squibb Company, DSM,Kowa pharmaceutical company,Mio Global,Pfizer,Sanofi/Regeneron,Upsher Smith
Lavie	Carl	Measuring Success in Cardiac Rehabilitation	Search for the Super-Responder: Progressive Increases in Fitness and an Association With Lower Mortality	CONSULTANT FEES/HONORARIA - Amarin, Amgen, Aralez, AstraZeneca, Boehringer Ingelheim, Bristol- Myers Squibb Company, DSM, Kowa pharmaceutical company, Mio Global, Pfizer, Sanofi/Regeneron, Upsher Smith
Lavie		Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering Therapies	Hypertension Control is Strongly Influenced by Patient's Health Capability	CONSULTANT FEES/HONORARIA - Amarin, Amgen, Aralez, AstraZeneca, Boehringer Ingelheim, Bristol- Myers Squibb Company, DSM, Kowa pharmaceutical company, Mio Global, Pfizer, Sanofi/Regeneron, Upsher Smith
Lavie	Carl	Obesity Management in 2017: Weighing the Issues	Fitness and the Obesity Paradox in Cardiac Rehabilitation: How Does Weight Loss Factor in?	CONSULTANT FEES/HONORARIA - Amarin,Amgen,Aralez,AstraZeneca,Boehringer Ingelheim,Bristol- Myers Squibb Company, DSM,Kowa pharmaceutical company,Mio Global,Pfizer,Sanofi/Regeneron,Upsher Smith
Lavie	Carl	34. Prevention: Rehabilitation Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amarin,Amgen,Aralez,AstraZeneca,Boehringer Ingelheim,Bristol- Myers Squibb Company, DSM,Kowa pharmaceutical company,Mio Global,Pfizer,Sanofi/Regeneron,Upsher Smith
Lavoie	Andrea	Considerations in Antiplatelet Therapy and in	Effects of Ticagrelor Versus Clopidogrel in Fibrinolytic-Treated STEMI Patients Undergoing Early PCI	Nothing to Disclose
Lavu	Madhav	Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	STEWN Patients Undergoing Early PCI Peri-Procedural Use of Novel Oral Anticoagulation Agents During Cardiac Device Implantation: Are They Safe?	Nothing to Disclose
Lavu	Madhav	Arrhythmias and Clinical EP: Devices 1	Implantable Cardioverter Defibrillator for the Prevention of Mortality in Non-Ischemic Cardiomyopathy: A Meta-Analysis of Randomized	Nothing to Disclose
Lavu	Madhav	Arrhythmias and Clinical EP: Devices 1	Controlled Trials Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients Undergoing Cardiac Implantable Electronic	Nothing to Disclose
1	Madhav	Arrhythmias and Clinical EP: Devices 2	Device Implantation: A Meta-Analysis Impact of Left Atrial Appendage Occlusion on Left Atrial Function	Nothing to Disclose
Lavu		Arrhythmias and Clinical EP: Devices 2	Real World Battery Longevity of St. Jude Medical Implantable	Nothing to Disclose

-				
Last Name Lavu	First Name Madhav	Session Title Atrial Fibrillation and VT: Unique Populations	Presentation Title Use of an Esophageal Retractor to Prevent Thermal Injuries During	Disclosures Nothing to Disclose
Lavu	wadnav	and Solutions	Atrial Fibrillation Ablation: A Multi-Center Experience	Nothing to Disclose
Lavu	Madhav	Atrial Fibrillation and VT: Unique Populations and Solutions	Sotalol Versus Other Anti-Arrhythmic Medications for Cardioversion of Atrial Fibrillation and Maintenance of Sinus Rhythm: Meta-Analysis of Randomized Controlled Studies	Nothing to Disclose
Lavu	Madhav	Arrhythmias and Clinical EP: Anticoagulation Issues	Meta-Analysis on the Efficacy and Safety of New Oral Anticoagulants Compared With Vitamin K Antagonists in Patients	Nothing to Disclose
Lavu	Madhav	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Undergoing Cardioversion for Atrial Fibrillation Left Atrial Appendage Ligation With Lariat Device: A Systematic Review and Meta-Analysis	Nothing to Disclose
Lavu	Madhav	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Efficacy of Catheter Ablation of Atrial Fibrillation in the Setting of Systolic Dysfunction: A Meta-Analysis of Randomized Control Trials	Nothing to Disclose
Lavu	Madhav	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Sotalol Versus Other Anti-Arrhythmic Agents for Prevention of Post- Operative Supraventricular Arrhythmias After Cardiac Surgery: Meta-	Nothing to Disclose
Lavu	Madhav	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Analysis of Randomized Controlled Studies Safety Profiles of Percutaneous Left Atrial Appendage Closure Devices: An Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database From	Nothing to Disclose
Law	lan	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	2009 - 2016 Suggested Reviewer	Nothing to Disclose
Lawless	Christine	31. Non Invasive Imaging: Sports and Exercise Team 1	Suggested Reviewer	OTHER - Privit
Lawley	Justin	Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	The Impact of Lifelong Exercise Training "Dose" on the Ventricular- Arterial Coupling	Nothing to Disclose
Lawrence	John	Late-Breaking Clinical Trials	Digoxin and Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?	SALARY - Bristol-Myers Squibb
Lawrence-Wright	Marilyn	Perspectives on Congenital Heart Disease: International Perspectives From the Caribbean Cardiac Society, Peruvian Society of Cardiology, and American College of Cardiology	Rheumatic Heart Disease: A Caribbean Perspective	Nothing to Disclose
Lawrie	Gerald	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Patient With a Systolic Murmur and Shock: Importance of the Physical	Nothing to Disclose
Lawson	Mark	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Ebstein's Anomaly: Atypical Variant Presenting in Adulthood	Nothing to Disclose
Lay	Amy	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Interstage Resource Utilization of Infants With Single Ventricle: Results of a Crossover Study	Nothing to Disclose
Layland	Jamie	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Decision Making Using Fractional Flow Reserve Is Associated With Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With Nstemi	Nothing to Disclose
Lazar	Jason	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Nailfold Capillaroscopy for the Identification of Microvascular Disease in African-Americans	Nothing to Disclose
Lazaros	George	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Prognostic Implications of Epicardial Fat Volume Quantification in Acute Pericarditis	Nothing to Disclose
Lazaros	George	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Omega-3 Polyunsaturated Fatty Acids May Favorably Affect Inflammatory Biomarkers & Novel Indices of Left Ventricle Function in Patients With Heart Failure	Nothing to Disclose
Lazkani	Mohamad	Advances in Chronic Total Occlusion Intervention	Hemodynamically-Supported PCI of Chronic Total Occlusions: A Case Series	Nothing to Disclose
Le	Dai-Trang	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Aortic Valve Replacement as a Treatment for Acute Renal Failure and Transfusion-Dependent Anemia: A Unique Presentation of <partonella p="" quintana<=""></partonella>	Nothing to Disclose
Le	Dai-Trang	Biomarkers and Targets for Ischemic Heart Disease	Ultrasound Increases Myocardial Blood Flow in Acute Myocardial Ischemia Without Reducing Infarct Size	Nothing to Disclose
Le	Dan	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	An Unusual Extrinsic Pulmonary Artery Compression Caused by Traumatic Cardiac Hernia	Nothing to Disclose
Le	Viet	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	The Association of Depression at Any Time to the Risk of Death Following Coronary Artery Disease Diagnosis: The Intermountain	Nothing to Disclose
Le May	Michel	Coronary Artery Disease Novel Developments in Acute Coronary Syndromes	INSPIRE Registry Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment	CONSULTANT FEES/HONORARIA - AstraZeneca; RESEARCH/RESEARCH GRANTS - Astra Zeneca,Sunovion
Leal	Miguel	Arrhythmias and Clinical EP: Devices 3	Elevation Myocardial Infarction Outcomes Following Implant of Semi-Permanent Pacemaker Versus Temporary Pacemaker	Pharmaceuticals OTHER - MEDTRONIC
Learn	Christopher	09. Congenital Heart Disease: Adult Team 1	Suggested Reviewer	OTHER - Actelion
Leavitt	Bruce	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Is CABG the Best Revascularization Strategy Among All Diabetics Subgroups With Multi-Vessel Disease in the Modern Era? A Multi- Center Analysis	Nothing to Disclose
Lebrun	Sandrine	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Severe Dissection Propagation During Diagnostic Angiography of a Young Female Presenting With Self Limiting Chest Pain: A Case of Spontaneous Coronary Artery Dissection	Nothing to Disclose
LeBude LeBude	Bryan Bryan	FIT Forum: Scholarship and Education FIT Clinical Decision Making: Multimodality	Co-Chair Gerbode Defect Leading to a Diagnosis of Endocarditis	Nothing to Disclose Nothing to Disclose
LeBude	Bryan	Imaging FIT Clinical Decision Making Reviewers 1	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Ledwidge	Mark	Innovations in Cardiovascular Risk Assessment and Reduction	Longitudinal Change in Soluble ST2 Versus B-type Natriuretic Peptide in Predicting Major Adverse Cardiovascular Events in Asymptomatic Patients in the Community	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Founder and shareholder of University spin-out Solvotrin Therapeutics
Ledwoch	Jakob	Non Invasive Imaging: MR Characterization and Function	Prognostic Value and Determinants of Left Atrial Function Assessed by Cardiac Magnetic Resonance in St-Segment Elevation Myocardial Infarction	Nothing to Disclose
Lee	Alexander	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Early Unloading With Impella Support in Acute MI With Cardiogenic Shock Linked to Decreased Infarct Size, In-Hospital Mortality, and	Nothing to Disclose
,	Amanda	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Hospital Length of Stay Influence of Low Versus High Dose on the Association of Loop Diurectic and Mortality in Patients With Heart Failure: Insights From the UNITE-HF Registry	Nothing to Disclose
Lee	Amanda			
Lee	Anson	Interventional Cardiology: TAVR 1	The Inflammasome Pathway Is Associated With Adverse Ventricular Remodeling Following Transcatheter Aortic Valve Replacement	Nothing to Disclose
			The Inflammasome Pathway Is Associated With Adverse Ventricular	Nothing to Disclose Nothing to Disclose

			· · · · · · · · · · · · · · · · · · ·
First Name		Presentation Title	Disclosures
Byron	Disease Patient and EP	Disease in the US	CONSULTANT FEES/HONORARIA - Biotronik, Boston Scientific; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - CardioNet: RESEARCH/RESEARCH GRANTS -
			MEDTRONIC,ZoII
Byron	Improving Outcomes in the Athlete With Cardiovascular Disease	Pre-Existing Cardiac Disease, Exercise, Male Sex, and Young Age Are Risk Factors for Sudden Death Following Energy Drink Consumption	CONSULTANT FEES/HONORARIA - Biotronik, Boston Scientific; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - CardioNet; RESEARCH/RESEARCH GRANTS -
Byron	Arrhythmias and Clinical EP: Devices 3	Safety of Transvenous Lead Removal Among Nonagenarians	MEDTRONIC,Zoll CONSULTANT FEES/HONORARIA - Biotronik,Boston Scientific;
	,		OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - CardioNet; RESEARCH/RESEARCH GRANTS - MEDTRONIC,Zoli
Byron	08. Arrhythmias and Clinical EP:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Biotronik, Boston Scientific;
	Supraventricular/ventricular Armytinmias Team 3		OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - CardioNet; RESEARCH/RESEARCH GRANTS - MEDTRONIC,ZOII
Cheol Hyun	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	The Prognostic Implications of Current Periprocedural Myocardial	Nothing to Disclose
		Conronary Intervention With Unprotected Left Main Coronary Artery Disease	
Cheol Hyun	Advances in Lipid Management	Lower Mortality in Patients With Vasospastic Angina Who Receive Statin Therapy: Data From the Asan Vasospastic Angina Registry	Nothing to Disclose
Cheol Whan	Late-Breaking Clinical Trials: Interventional	Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With Coronary Chronic Total Occlusion: DECISION CTO Randomized Trial	Nothing to Disclose
Cheol Whan	Interventional Cardiology: Intravascular	Anatomic Versus Ischemic Burden in Predicting Outcomes of	Nothing to Disclose
Cheol Whan	Complex Coronary Intervention: Left	The Prognostic Implications of Current Periprocedural Myocardial	Nothing to Disclose
	Main/Bifurcations and Multivessel Disease	Infarction Definitions in Patients Underwent Percutaneous Conronary Intervention With Unprotected Left Main Coronary Artery Disease	
Cheol Whan	Advances in Lipid Management	Lower Mortality in Patients With Vasospastic Angina Who Receive Statin Therapy: Data From the Asan Vasospastic Angina Registry	Nothing to Disclose
Cheol Whan	Refining PCI Technique and Outcomes CAD in Unique Patient Populations	External Validation of DAPT Score in Two Large Cohorts	Nothing to Disclose Nothing to Disclose
		Stent Implantation	-
Cneoimin	Intravascular Imaging and Interventional CT/MR	In-Stent Restenosis With Peri-Stent Calcium as Assessed by Optical Coherence Tomography	Nothing to Disclose
Cheolmin			Nothing to Disclose
		Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent Implantation	
Chi-Hang	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Obstructive Sleep Apnea and Diabetes Mellitus Have Synergistic Effects on Adverse Cardiac and Cerebrovascular Events in Patients Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Chi-Hang	Updates on Risk Factors for Cardiovascular	Obstructive Sleep Apnea and Coronary Risk in Health Screening	Nothing to Disclose
Chi-Hang	Acute Coronary Syndromes, Diagnosis,	Impact of Mild Obstructive Sleep Apnea on and Cardiovascular	Nothing to Disclose
Chi-Hang	Unusual Presentations of ACS	Prevalence and Evolution of Sleep Disordered Breathing in Acute	Nothing to Disclose
Chong You	From Diet to Drugs: Mechanistic Insight Into	Mutations in SCAP and AGXT2 Revealed by Exome Sequencing a	Nothing to Disclose
Dae Sung	Ischemic Heart Disease Arrhythmias and Clinical EP: Basic 3	Pedigree With Premature Myocardial Infarction Atrial Fibrillation Cycle Length Measured by Transesophageal Echocardiography: A Predictor for Maintaining Sinus Rhythm After	Nothing to Disclose
Daniel	29 Non Invasive Imaging: MR Team 1		CONSULTANT FEES/HONORARIA - Gilead Sciences, Inc. ;
			RESEARCH/RESEARCH GRANTS - Abbott Laboratories, CardiacAssist, Inc; SALARY - Takeda Pharmaceuticals North America (Salary, Spouse)
David	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Sex Differences in the Risk Factors for Endothelial and Microvascular Dysfunction in Patients With Angina in the Absence of	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,MEDTRONIC
David			CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston
David	Pulmonary Hypertension Anti-Platelet Therapies: Always a Sticky Topic	ACC Poster Moderator	Scientific,MEDTRONIC CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston
Do-Yun	Head to Toe: Outcomes of Endovascular	Comparison of Aortic Remodeling After Thoracic Endovascular	Scientific,MEDTRONIC Nothing to Disclose
	Interventions	Repair Between Acute/Subacute Versus Chronic Type B Aortic Dissection	-
Hang	Physiology and Endothelial Function	Implantation: Comparison Between First Generation and Second	Nothing to Disclose
Hang	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional	Association Between Syntax Score, and Pre- and Post-Stenting Optical Coherence Tomography Findings in Stable Angina Patients	Nothing to Disclose
Hang	The Inside View: Learning From Intracoronary Imaging	Prevalence and Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A Four-Year Follow-Up Study	Nothing to Disclose
Hong Seok	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Anomalous Left Coronary Artery Arising From Right Coronary Sinus With Interarterial Course	Nothing to Disclose
Hong Seok	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Transcatheter Aortic Valve Replacement in a Patient With Very Mobile Aortic Valve Mass	Nothing to Disclose
James	FIT Clinical Decision Making: Non-Invasive	B-Cell Lymphoma Associated Pericardial Tamponade With	Nothing to Disclose
	Imaging and Valvular Heart Disease	Conversion to Chylous Effusion During Pregnancy	Nothing to Disclose
	Applications	Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients: Validation with Histopathologic Gold Standard	
Ji Hyun	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired	Nothing to Disclose
Ji Hyun	Things That Begin With an "A" in Adult	Renal Function: The CONFIRM Registry Long-Term Cardiovascular Outcomes in Patients With Anomalous	Nothing to Disclose
, y	Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Coronary Arteries Wisualized by Coronary CT Angiography: The CONFIRM (COronary CT Angiography Evaluation For Clinical	• • • • • • • • • • • • • • • • • • • •
Ji Hyun	Innovations in Cardiovascular Risk Assessment and Reduction	Outcomes: An International multicenter) Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Nas#239;ve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	Nothing to Disclose
	Byron Byron Byron Byron Cheol Hyun Cheol Hyun Cheol Whan Ch	Byron Disease Patient and EP Byron Improving Outcomes in the Athlete With Cardiovascular Disease Byron Arrhythmias and Clinical EP: Devices 3 Byron O8. Arrhythmias and Clinical EP: Devices 3 Byron O8. Arrhythmias and Clinical EP: Supraventricular Arrhythmias Team 3 Cheol Hyun Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease Cheol Hyun Advances in Lipid Management Cheol Whan Late-Breaking Clinical Trials: Interventional Cheol Whan Interventional Cardiology: Intravascular Physiology and Endothelial Function Cheol Whan Coronary Intervention: Left Main/Bifurcations and Multivessel Disease Cheol Whan Advances in Lipid Management Cheol Whan Refining PCI Technique and Outcomes Cheol Whan Refining PCI Technique and Outcomes Cheol Whan Refining PCI Technique and Outcomes Cheol Whan Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Cheolmin Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Chi-Hang Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Chi-Hang Updates on Risk Factors for Cardiovascular Disease Chi-Hang Updates on Risk Factors for Cardiovascular Disease Chi-Hang Updates on Risk Factors of ACS Chong You From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Dae Sung Arrhythmias and Clinical EP: Basic 3 Daniel 29. Non Invasive Imaging: MR Team 1 David Current Issues in Cardiovascular Epidemiology, Disparities, and Safety David Fir Clinical Decision Making: Heart Failure and Pulmonary Hypertension David Current Issues in Cardiovascular Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Intravascul	Byron The Story of the Abuilt Corregental Heart Disease Peter to et of EP

Contract of the second				
Last Name Lee	First Name Ji Hyun	Session Title Non Invasive Imaging: Prognostic Implications of CT Angiography	Presentation Title Prognostic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry	Disclosures Nothing to Disclose
Lee	Ji Hyun	Non Invasive Imaging: Prognostic Implications	Prognosis of Obstructive and Non-Obstructive Stents by Coronary	Nothing to Disclose
Lee	Ji Hyun	of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Computed Tomographic Angiography: The CONFIRM Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Death: A Comparison to a Histologic Reference Standard	Nothing to Disclose
Lee	Ji Hyun	Diabetes and Other Issues in Cardiovascular Prevention	Implications of Statin Therapy Among Smokers With Severe Coronary Artery Calcification: An Analysis of the CONFIRM Registry	Nothing to Disclose
Lee	Ji Hyun	Non Invasive Imaging: New Technologies	Optimal Method for Necrotic Core Identification in Coronary Plaque With Dual-Energy Computed Tomography: Material Decomposition	Nothing to Disclose
Lee	Jiyong	Coronary Angiography, Intra-Vascular Imaging,	and Atomic Number Troponin Elevation Following Elective PCI Predicts Long Term	Nothing to Disclose
Lee	Jong-Young	Revascularization and Outcomes Late-Breaking Clinical Trials: Interventional	Survival Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With Coronary Chronic Total Occlusion: DECISION CTO Randomized	Nothing to Disclose
Lee	Joon	Innovations in Practice Management and Social Media	Trial Formal CPR Status Policy and Process Increased Documentation Rates	CONSULTANT FEES/HONORARIA - Edwards; RESEARCH/RESEARCH GRANTS - Boston
Lee	Joon	The Challenges of Outcome Prediction in Valvular Heart Disease	Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary	Scientific,MEDTRONIC,St. Jude CONSULTANT FEES/HONORARIA - Edwards; RESEARCH/RESEARCH GRANTS - Boston
Lee	Joon	TAVR Outcomes Prognostication	Hypertension Severity: Clinical Applications in the TAVR Era Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit	Scientific,MEDTRONIC,St. Jude CONSULTANT FEES/HONORARIA - Edwards; RESEARCH/RESEARCH GRANTS - Boston
Lee	Jung Myung	Coronary Angiography, Intra-Vascular Imaging,	Comparison of Timing of Non-Culprit Lesion Percutaneous	Scientific,MEDTRONIC,St. Jude Nothing to Disclose
Lee	Jung Myung	Revascularization and Outcomes Markers of Prognosis Associated With	Coronary Intervention in Myocardial Infarction Patients Incidence of Subclinical Atherosclerosis in Patients With Resistant	Nothing to Disclose
Lee	Jung Myung	Elevated Blood Pressure Innovations in Cardiovascular Risk Assessment	Hypertension The Predictive Value of Aortic Arch Calcification on Chest X-Ray for	Nothing to Disclose
Lee	Justin	and Reduction Complex Coronary Intervention: Left	Cardiovascular Events in Comparison With the Coronary Artery Calcium Score and the Framingham Risk Score Comparison of Two-Year Outcomes in Drug-Eluting Stents Versus	Nothing to Disclose
Lee	Justin	Main/Bifurcations and Multivessel Disease	Coronary Artery Bypass Grafting for Treatment of Unprotected Left Main Coronary Artery Disease in Elderly Patients: A Meta-Analysis	Noutling to Disclose
Lee	Justin	Innovations in Education	Coronary Angiography Simulation Training Improves Image Interpretation Skills of Trainees Independent of Their Stage of Training	Nothing to Disclose
Lee	Kerry	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Outcomes in Patients With Diabetes Mellitus and Suspected Coronary Artery Disease Following Non-Invasive Testing: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	DATA SAFETY MONITORING BOARD - Amgen, AstraZeneca, CardiaQ, Edwards, Merck; RESEARCH/RESEARCH GRANTS - MEDTRONIC
Lee	Kerry	New Perspectives on CAD Risk Factors	Discordances Between Predicted and Actual Risk of Adverse Events in Obese Patients With Suspected Cardiac Ischemia: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	DATA SAFETY MONITORING BOARD - Amgen, AstraZeneca, CardiaQ, Edwards, Merck; RESEARCH/RESEARCH GRANTS - MEDTRONIC
Lee	Ki Hong	Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	Renal Nerve Denervation Suppress Ventricular Arrhythmia in a Porcine Model After Acute Myocardial Infarction	Nothing to Disclose
Lee	Kwan	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Comparison of Two-Year Outcomes in Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Treatment of Unprotected Left Main Coronary Artery Disease in Elderly Patients: A Meta-Analysis	CONSULTANT FEES/HONORARIA - St. Jude Medical
Lee	Kwan	Innovations in Education	Coronary Angiography Simulation Training Improves Image Interpretation Skills of Trainees Independent of Their Stage of Training	CONSULTANT FEES/HONORARIA - St. Jude Medical
Lee	Kyounghoon	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Prognostic Value of Soluble ST2 in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention	Nothing to Disclose
Lee	Kyounghoon	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Prognostic Impact of Alkaline Phosphatase Measured at the Time of Presentation in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Lee	Kyounghoon	Unusual Presentations of ACS	The Role of Coronary Response to Nitrate in Patients With	Nothing to Disclose
Lee	Kyunghoon	Understanding Pulmonary Vascular Disease: From Bench to Bedside	Suspected Vasospastic Angina Apelin-13 Co-Treatment With Umbilical Cord Blood-Derived Mesenchymal Stem Cells Improves Engrafted Cell Survival and Inhibits Macrophage Activation in Pulmonary Arterial Hypertension	Nothing to Disclose
Lee	L. Veronica	Advances in Cholesterol Measurement and	Murine Model Contemporary Patterns of Lipid Testing in Primary and Secondary	SALARY - SANOFI
Lee	Moon-Hyoung	Management Arrhythmias and Clinical EP: Basic 1	Prevention Patients: Insights From the PALM Registry Exosome Derived From Atrial Fibrillation Patients Prevents Proarrhythmic Remodeling by Restoration of Acetylated Tubulin in	Nothing to Disclose
Lee	Moon-Hyoung	Arrhythmias and Clinical EP: Basic 1	Pacing Induced Tachycardia Model MicroRNA-26a From Hypoxic Human Mesenchymal Stem Cells: Derived Microvesicles Enhance Cardiac Conduction Following	Nothing to Disclose
Lee	Moon-Hyoung	Arrhythmias and Clinical EP: Basic 3	Myocardial Infarction Entropy of Fibrillatory Waves Contributes to Differentiating	Nothing to Disclose
Lee	Moon-Hyoung	Arrhythmias and Clinical EP: Basic 4	Paroxysmal From Persistent and Permanent Atrial Fibrillation Efficacy of Scattergram Analysis for Classifying Subtypes of Atrial Fibrillation by Fourier Transform of Fibrillatory Waves	Nothing to Disclose
Lee	Nae-Hee	Late-Breaking Clinical Trials: Interventional	Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With Coronary Chronic Total Occlusion: DECISION CTO Randomized Trial	Nothing to Disclose
Lee	Ran	Multi-Disciplinary Care for Acute Pulmonary Embolism: The PE Response Team (PERT) Model	Case Presentation: A Case of Acute Pulmonary Embolism - How Best to Manage?	Nothing to Disclose
Lee	Randall	Arrhythmias and Clinical EP: Devices 2	Long Term Safety and Efficacy of Left Atrial Appendage Closure With Lariat in Atrial Fibrillation: Is It Still Working at 5 Years?	CONSULTANT FEES/HONORARIA - SentreHeart, Inc; DATA SAFETY MONITORING BOARD - adagio, Inc; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Apama Medical, Inc,HMicro, Inc
Lee	Randall	Arrhythmias and Clinical EP: Devices 3	Transcatheter Closure of Residual Left Atrial Appendage Leaks Following Lariat Device Closure	CONSULTANT FEES/HONORARIA - SentreHeart, Inc; DATA SAFETY MONITORING BOARD - adagio, Inc; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Apama Medical, Inc,HMicro, Inc
Lee	Randall	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Left Atrial Appendage Ligation With Lariat Device: A Systematic Review and Meta-Analysis	CONSULTANT FEES/HONORARIA - SentreHeart, Inc; DATA SAFETY MONITORING BOARD - adagio, Inc; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Apama Medical,

THE REAL PROPERTY.				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Lee	Randall	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team 4	Suggested Reviewer	CONSULTANT FEES/HONORARIA - SentreHeart, Inc; DATA SAFETY MONITORING BOARD - adagio, Inc; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Apama Medical, Inc,HMicro, Inc
Lee	Richard	Interventional Cardiology: TAVR 3	Prosthetic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter Valve-in-Valve Implantation	Nothing to Disclose
Lee	Ronald	Coronary Intervention: Drug Eluting Stent and	Safety and Efficacy of Small Vessel Stenting With 2 mm Drug Eluting Stents in Real World Clinical Practice	Nothing to Disclose
Lee	Ronald	Scaffolds Coronary Intervention in Interventional Cardiology: Core Concepts	Leluting Sterils in Real World Clinical Practice Incidence and Predictors of Target Lesion Failure in a Multi-Ethnic Asian Population Receiving the SYNERGY Coronary Stent: A Prospective All-Comers Registry	Nothing to Disclose
Lee	Sang Hyun	Arrhythmias and Clinical EP: Basic 3	Atrial Fibrillation Cycle Length Measured by Transesophageal Echocardiography: A Predictor for Maintaining Sinus Rhythm After DC Cardioversion	Nothing to Disclose
Lee	Sang-Chol	Current Issues in Cardiovascular	Prevalence of Cardiomyopathy in the Korean Population	Nothing to Disclose
Lee	Sang-Eun	Epidemiology, Disparities, and Safety Non Invasive Imaging: Prognostic Implications of CT Angiography	Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Death: A Comparison to a Histologic Reference Standard	Nothing to Disclose
Lee	Sanghun	Arrhythmias and Clinical EP: Anticoagulation	Noac Adherence of the Patients With Nonvalvular Atrial Fibrillation	Nothing to Disclose
Lee	Sangjin	Issues 14. Heart Failure and Cardiomyopathies:	in Real Practice Suggested Reviewer	Nothing to Disclose
		Therapy Team 1		-
Lee	Seung-Hyun	Arrhythmias and Clinical EP: Basic 1	MicroRNA-26a From Hypoxic Human Mesenchymal Stem Cells: Derived Microvesicles Enhance Cardiac Conduction Following Myocardial Infarction	Nothing to Disclose
Lee	Seung-Whan	Late-Breaking Clinical Trials: Interventional	Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With Coronary Chronic Total Occlusion: DECISION CTO Randomized Trial	Nothing to Disclose
Lee	Seung-Whan	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Anatomic Versus Ischemic Burden in Predicting Outcomes of Coronary Artery Disease: Data From IRIS-FFR Registry	Nothing to Disclose
Lee	Seung-Whan	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	The Prognostic Implications of Current Periprocedural Myocardial Infarction Definitions in Patients Underwent Percutaneous Conronary Intervention With Unprotected Left Main Coronary Artery Disease	Nothing to Disclose
Lee	Seung-Whan	Advances in Lipid Management	Lower Mortality in Patients With Vasospastic Angina Who Receive Statin Therapy: Data From the Asan Vasospastic Angina Registry	Nothing to Disclose
Lee Lee	Seung-Whan Seung-Whan	Refining PCI Technique and Outcomes CAD in Unique Patient Populations	External Validation of DAPT Score in Two Large Cohorts Mortality of Patients With Previous Stroke Undergoing Drug-Eluting Stent Implantation	Nothing to Disclose Nothing to Disclose
Lee	Seung-Yul	Considerations in Antiplatelet Therapy and in ACS	Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multi-Vessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents	Nothing to Disclose
Lee	Shawn	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Early Versus Delayed Invasive Intervention for Non-ST Segment Elevation Myocardial Infarction in Patients Older Than 80 Years: A Nationwide Analysis	Nothing to Disclose
Lee	Shawn	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Impact of End Stage Renal Disease in Patients Hospitalized for Systolic and Diastolic Heart Failure: A Nationwide Analysis of 2013	Nothing to Disclose
Lee	Shawn Shawn	Arrhythmias and Clinical EP: Devices 3 Cardiac Arrest, Diabetes, and Other High Risk	Epicardial Lead Migration to the Spine With Development of Vertebral Abscess Low Socioeconomic Status Is Associated With Increased Inpatient	Nothing to Disclose Nothing to Disclose
		Features of Patients With Acute Coronary Syndrome	Mortality With Non ST-Elevation Myocardial Infarction: A Nationwide Analysis	-
Lee	Shawn	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Patients With Non ST-Segment Elevation Myocardial Infarction Utilizing Medicare/Medicaid Have Lower Adjusted Odds of In- Hospital Mortality: A Nationwide Analysis	Nothing to Disclose
Lee	Shawn	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Adjusted Odds of Inpatient Mortality for Non-ST Elevation Myocardial Infarction Is Not Affected by Day of Admission: A Nationwide Analysis	Nothing to Disclose
Lee	Shawn	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Early Versus Delayed Invasive Intervention for Non-ST Segment Elevation Myocardial Infarction Patients: A Nationwide Analysis	Nothing to Disclose
Lee	Shawn	Arrhythmias and Clinical EP: Devices 4	Subxiphoid Air Leading to Inappropriate Shock in a Subcutaneous Cardiac Defibrillator	Nothing to Disclose
Lee	Shawn	Unusual Presentations of ACS	Stress Induced Cardiomyopathy (Takotsubo Cardiomyopathy): Mortality, Gender and Admission Month Based on a Nationwide Sample During 2013	Nothing to Disclose
Lee	Shawn Suegene	Unusual Presentations of ACS Advances in Chronic Total Occlusion	Clinical Outcomes of the Treatment of Cocaine Induced Chest Pain With Beta Blockers: A Meta-Analysis Performance of J-CTO and PROGRESS CTO Scores in Predicting	Nothing to Disclose Nothing to Disclose
		Intervention	Angiographic Success and Long-Term Clinical Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions	
Lee	Sunki Sunki	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Novel Developments in Acute Coronary	Early Stage Loeffler's Endocarditis With Biventricular Involvement Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor	Nothing to Disclose Nothing to Disclose
	Carin	Syndromes Syndromes	Comparative Octobers of Anglotensin-Converting Enzyme Infinition and Anglotensin Receptor Blocker in Diabetic Hypertensive Acute Myocardial Infarction Patients: Results From the Korea Acute Myocardial Infarction Registry (KAMIR)	The state of the s
Lee	Sunki	Timely Topics in Acute Coronary Syndromes	Predictors of Mortality in Acute Myocardial Infarction Patients With Unprotected Left Main Coronary Artery Disease	Nothing to Disclose
Lee	Sunki	Advances in Chronic Total Occlusion	Impact of Percutaneous Coronary Intervention for Chronic Total	Nothing to Disclose
Lee	Tetsumin	Intervention Interventional Cardiology: Intravascular Physiology and Endothelial Function	Occlusion Patients With Near-Normal Left Ventricular Function Significance of Microcirculatory Resistance in Visual-Functional Mismatch Between Coronary Angiography and Fractional Flow	Nothing to Disclose
			Reserve in Non-Left Main Lesions	
Lee	Tetsumin	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Usefulness of Optical Coherence Tomography-Derived Morphometric Assessment to Predict Physiological Significance of Coronary Artery Stenosis and Determinants of Mismatch: Head-to- Head Comparison With Intravascular Ultrasound	Nothing to Disclose
Lee	Tommy	Refining PCI Technique and Outcomes	Three-Year Results From the EVOLVE II Randomized Trial: Late Clinical Outcomes With Bioresorbable Compared to Permanent Polymer Everolimus-Eluting	CONSULTANT FEES/HONORARIA - Boston Scientific
Lee	Veronica	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Lower On-Treatment Low-Density Lipoprotein Cholesterol Is Associated With Lower Cardiovascular Risk in Very High Risk Patients With Atherosclerotic Cardiovascular Disease: Analyses From the ODYSSEY Trials	Nothing to Disclose
Lee	Veronica	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Lower On-Treatment Low-Density Lipoprotein Cholesterol Is Associated With Lower Cardiovascular Risk in Women: Analyses From the ODYSSEY Trials of Alirocumab Versus Control	Nothing to Disclose
Lee	Wade	Why Can't We Be Friends? Controversies in	Mortality Effect of Icd in Primary Prevention of Non Ischemic	Nothing to Disclose
		Heart Failure Management	Cardiomyopathy: A Meta Analysis of Randomized Control Trials	



The state of the s				
Last Name	First Name Katherine	Session Title Updates on Pulmonary Embolism	Presentation Title The Long-Term Prognostic Value of Highly Sensitive Cardiac	Disclosures Nothing to Disclose
Lee Chuy		Management in 2017	Troponin I in Patients With Acute Pulmonary Embolism	-
Leef	George	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Success Rates by Ablation Lesion Set of Catheter Ablation for Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta- Analysis Study Cohort	Nothing to Disclose
Leef	George	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Secular Trends in Reported Success Rates of Catheter Ablation for Non-Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort	Nothing to Disclose
Leef	George	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Inclusion of Women in Studies of Catheter Ablation for Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study	Nothing to Disclose
Leeper	Nicholas	Maximally Effective Vascular Care: Vascular Collaborative Team Care in Action	Cohort Case Presentation #4: Panelist	Nothing to Disclose
Leeper	Nicholas	38. Vascular Medicine: Basic Team 1	Suggested Reviewer	Nothing to Disclose
Leezer	Scott	2017 Dan G. McNamara Lecture: The Future of Congenital Heart Research: Keeping the Patient-Centered Promise	Bridging the Patient Provider Research Gap: The Patient Perspective	Nothing to Disclose
Lefebvre	Patrick	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	A Benefit-Risk Analysis of Recurrent Venous Thromboembolism in Patients Who Continued Versus Discontinued Rivaroxaban Therapy After an Initial Six-Month Therapy	RESEARCH/RESEARCH GRANTS - Janssen Scientific Affairs, LLC
Lefebvre	Patrick	Making Progress in Understanding Heart Failure	Incremental Risk of Ischemic Stroke Over Time in Newly Diagnosed Heart Failure Patients Without Atrial Fibrillation	RESEARCH/RESEARCH GRANTS - Janssen Scientific Affairs, LLC
Lefebvre	Patrick	Antithrombotic Therapy in Ischemic Heart Disease	Rivaroxaban Users Have Significantly Less Treatment Discontinuation Compared With Users of Other Oral Anticoagulants in Non-Valvular Atrial Fibrillation	RESEARCH/RESEARCH GRANTS - Janssen Scientific Affairs, LLC
Lefevre	Cinira	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	What Are the Differences in Oral Anticoagulant Treatment Persistence in Non-Valvular Atrial Fibrillation in Europe? Real-World Studies in Three European Countries	SALARY - Bristol-Myers Squibb Company
Lefevre	Thierry	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve	CONSULTANT FEES/HONORARIA - Abbott,Boston
Lefevre	Thierry	Interventional Cardiology: TAVR 2	Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve	Scientific, Daiichi Sankyo, Direct Flow, Edwards, Lily, Terumo CONSULTANT FEES/HONORARIA - Abbott, Boston Scientific, Daiichi Sankyo, Direct Flow, Edwards, Lily, Terumo
Lefevre	Thierry	Interventional Cardiology: PCI and TAVR in Complex Patients	Replacement: From the WIN-TAVI Registry Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,Daiichi Sankyo,Direct Flow,Edwards,Lily,Terumo
Lefevre	Thiorny	15. Interventional Cardiology:	Bravo-3 Randomized Trial	CONSULTANT FEES/HONORARIA - Abbott,Boston
	Thierry	ACS/AMI/Hemodynamics and Pharmacology Team 2	Suggested Reviewer	Scientific,Daiichi Sankyo,Direct Flow,Edwards,Lily,Terumo
Lefkowitz	Martin	Making Progress in Understanding Heart Failure	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF	Nothing to Disclose
Lefkowitz	Martin	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Effect of Sacubitril/Valsartan Compared With Enalapril, According to Etiology in PARADIGM-HF	Nothing to Disclose
Lefkowitz	Martin	Hormones and Heart Failure	Low Urinary Cgmp/Bnp Ratio Is Associated With Worse Outcomes in Heart Failure but Is Increased by Treatment With Sacubitril/Valsartan: An Analysis of Paradigm-HF	Nothing to Disclose
Lefkowitz	Martin	The Old and the New: Impact of Heart Failure Drug Therapies	Influence of Sacubitril/Valsartan on Glycemic Control in Patients With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction	Nothing to Disclose
Lehman	E. Philip	Insights From Echocardiography Use	Universal Use of Contrast to Detect Left Ventricular Thrombus in Patients With Reduced Ejection Fraction Is Not Associated With	Nothing to Disclose
Lehr	Eric	36. Valvular Heart Disease: Clinical Team 3	Improved Clinical or Cost-Effectiveness Outcomes Suggested Reviewer	CONSULTANT FEES/HONORARIA - Edwards Life Sciences; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Pavmed
Lehtihet	Mikael		Association Between Erectile Dysfunction and Death or	Nothing to Disclose
Leifer	Eric	Revascularization and Outcomes Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Cardiovascular Outcomes After Myocardial Infarction Risk of Hospitalization or Death Due to Heart Failure With Intensive Glucose-Lowering Therapy in Diabetic Women: Subgroup Analyses by History of Cardiovascular Disease in the ACCORD Trial	Nothing to Disclose
Leigh	John	Non Invasive Imaging: Coronary Calcium	Coronary Artery Calcium Scores for Atherosclerotic Cardiovascular	Nothing to Disclose
Leiherer	Andreas	Scoring and CV Risk Assessment Updates on Risk Factors for Cardiovascular	Disease Risk Stratification in Smokers: MESA The Visceral Adiposity Index Predicts Cardiovascular Events Both in	Nothing to Disclose
Leiherer	Andreas	Disease Innovations in Cardiovascular Risk Assessment	Coronary Artery Disease Patients With and in Coronary Artery Disease Patients Without Diabetes ProBNP Strongly Predicts Future Vascular Events in Angiographied	Nothing to Disclose
		and Reduction	Coronary Patients With as Well as in Those Without the Metabolic Syndrome	-
Leiherer	Andreas	Diabetes and Other Issues in Cardiovascular Prevention	Non-Alcoholic Fatty Liver Disease Strongly Predicts Incident Diabetes in Patients With Coronary Artery Disease	Nothing to Disclose
Leiherer	Andreas	Diabetes and Other Issues in Cardiovascular Prevention	Single and Joint Effects of Obesity and of the Metabolic Syndrome on the Development of Diabetes in Patients With Coronary Atherosclerosis	Nothing to Disclose
Leiherer	Andreas	Diabetes and Other Issues in Cardiovascular Prevention	Non-Alcoholic Fatty Liver Disease in Coronary Artery Disease Patients: Association With Impaired Glucose Metabolism and With Future Cardiovascular Event Risk	Nothing to Disclose
Leiherer	Andreas	The Intersection of Diabetes and ASCVD	Remnant Cholesterol Predicts the Development of Type 2 Diabetes Mellitus in Patients With Established Coronary Artery Disease	Nothing to Disclose
Leipsic	Jonathan		Fractional Flow Reserve Is a Sensitive but Not a Specific Detector of	CONSULTANT FEES/HONORARIA - Circl CVI,Heartflow;
Leipsic	Jonathan	Revascularization and Outcomes Noninvasive Assessment of Coronary Flow	a High Risk Plaques Can Necrotic Core Volume Explain Ischemia Coronary Stenosis	SPEAKER'S BUREAU - Edwards Lifesciences,GE Healthcare CONSULTANT FEES/HONORARIA - Circl CVI,Heartflow;
Leipsic	Jonathon	Reserve: Clinical Implications Imaging for TAVR: Homing in on the Real	Mismatch in Some Cases? Panelist	SPEAKER'S BUREAU - Edwards Lifesciences,GE Healthcare CONSULTANT FEES/HONORARIA - CIRCL ,Edwards
		Issues		Lifesciences, Neovasc, Samsung, ValCare; RESEARCH/RESEARCH GRANTS - Heartflow Inc; SPEAKER'S BUREAU - GE Healthcare
Leipsic	Jonathon	Imaging for TAVR: Homing in on the Real Issues	How to Ensure the Best Prosthesis-patient Match?	CONSULTANT FEES/HONORARIA - CIRCL ,Edwards Lifesciences,Neovasc,Samsung,ValCare; RESEARCH/RESEARCH GRANTS - Heartflow Inc; SPEAKER'S BUREAU - GE Healthcare
Leipsic	Jonathon	Innovations in Valvular Heart Disease Diagnosis and Treatment	CT and CMR: New Imaging Tools for Advanced Valvular Assessment	CONSULTANT FEES/HONORARIA - CIRCL Edwards Lifesciences, Neovasc, Samsung, ValCare; RESEARCH/RESEARCH GRANTS - Heartflow Inc; SPEAKER'S BUREAU - GE Healthcare
Leipsic	Jonathon	Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology	Co-Chair	CONSULTANT FEES/HONORARIA - CIRCL ,Edwards Lifesciences, Neovasc, Samsung, ValCare; RESEARCH/RESEARCH GRANTS - Heartflow Inc; SPEAKER'S BUREAU - GE Healthcare
Leipsic	Jonathon	Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology	improving outcomes in transcatheter valvular therapies with MDCT	CONSULTANT FEES/HONORARIA - CIRCL ,Edwards Lifesciences,Neovasc,Samsung,ValCare; RESEARCH/RESEARCH GRANTS - Heartflow Inc; SPEAKER'S BUREAU - GE Healthcare



				I
Last Name	First Name	Session Title	Presentation Title	Disclosures
Leipsic	Jonathon	Interventional Cardiology: TAVR 1	Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: Insights From PARTNER 2A Trial	CONSULTANT FEES/HONORARIA - CIRCL ,Edwards Lifesciences,Neovasc,Samsung,ValCare; RESEARCH/RESEARCH GRANTS - Heartflow Inc; SPEAKER'S BUREAU - GE Healthcare
Leipsic	Jonathon	Non Invasive Imaging: Expanding Clinical Applications	Does Patient Prosthesis Mismatch Defined by CT LVOT Area Predict Downstream Clinical Outcomes?	CONSULTANT FEES/HONORARIA - CIRCL ,Edwards Lifesciences, Neovasc, Samsung, ValCare; RESEARCH/RESEARCH GRANTS - Heartflow Inc; SPEAKER'S BUREAU - GE Healthcare
Leipsic	Jonathon	Non Invasive Imaging: Prognostic Implications of CT Angiography	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	CONSULTANT FEES/HONORARIA - CIRCL ,Edwards Lifesciences, Neovasc, Samsung, ValCare; RESEARCH/RESEARCH GRANTS - Heartflow Inc; SPEAKER'S BUREAU - GE Healthcare
Leipsic	Jonathon	Unusual Presentations of ACS	Incidence and Predictors of Lesion Specific Ischemia by FFR-sub>CT: Learnings From the International ADVANCE Registry	CONSULTANT FEES/HONORARIA - CIRCL ,Edwards Lifesciences,Neovasc,Samsung,ValCare; RESEARCH/RESEARCH GRANTS - Heartflow Inc; SPEAKER'S BUREAU - GE Healthcare
Leipsic	Jonathon	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Atherosclerotic Plaque Morphology Is Associated With Impaired Myocardial Blood Flow and Fractional Flow Reserve, Independent of Luminal Obstruction	CONSULTANT FEES/HONORARIA - CIRCL ,Edwards Lifesciences,Neovasc,Samsung,ValCare; RESEARCH/RESEARCH GRANTS - Heartflow Inc; SPEAKER'S BUREAU - GE Healthcare
Leipsic	Jonathon	17. Interventional Cardiology: Aortic Valve Disease Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - CIRCL ,Edwards Lifesciences,Neovasc,Samsung,ValCare; RESEARCH/RESEARCH GRANTS - Heartflow Inc; SPEAKER'S BUREAU - GE Healthcare
Leiria	Tiago	ACC International Conferences Best Posters	Comparison of Different Lung Ultrasound Methodologies for Pulmonary Congestion Evaluation in Heart Failure Outpatients	Nothing to Disclose
Leiter	Lawrence	Featured Clinical Research I	LDL-C Reduction From 6 to 9 Months Following Single or Second Injection of Inclisiran a Novel siRNA Compound: Primary Efficacy and Safety Outcomes of the ORION 1 Trial	CONSULTANT FEES/HONORARIA - Aegerion, Amgen, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Inc, Merck, Novo Nordisk, Regeneron, SANOFI, servier; RESEARCH/RESEARCH GRANTS - Esperion, GSK, Kowa, Pizer, The Medicine Company
Leiter	Lawrence	The Intersection of Diabetes and ASCVD	Effects of Canagliflozin Versus Glimepiride on Inflammatory Biomarkers and Chemokines in Patients With Type 2 Diabetes Mellitus	CONSULTANT FEES/HONORARIA - Roche; RESEARCH/RESEARCH GRANTS - Roche
Leiter	Lawrence	The Intersection of Diabetes and ASCVD	Alirocumab Safety in Individuals With and Without Diabetes Mellitus: Pooled Data From 14 ODYSSEY Trials	CONSULTANT FEES/HONORARIA - Aegerion, Amgen, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Inc, Merck, Novo Nordisk, Regeneron, SANOFI, servier; RESEARCH/RESEARCH GRANTS - Esperion, GSK, Kowa, Pizer, The Medicine Company
Leja	Monika	Imaging of Cancer-Treatment Associated CV Toxicity: Applying Guidelines to Clinical Practice	Panelist	Nothing to Disclose
Leja LeJemtel	Monika Thierry	Advances in Imaging to Assess Cardiotoxicity 13. Heart Failure and Cardiomyopathies:	ACC Poster Moderator Suggested Reviewer	Nothing to Disclose Nothing to Disclose
Lejeune	Dominique	Clinical Team 3 Highlighted Original Research: Pulmonary	A Benefit-Risk Analysis of Recurrent Venous Thromboembolism in	RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals,
		Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Patients Who Continued Versus Discontinued Rivaroxaban Therapy After an Initial Six-Month Therapy	Inc
Lejeune	Dominique	Making Progress in Understanding Heart Failure	Incremental Risk of Ischemic Stroke Over Time in Newly Diagnosed Heart Failure Patients Without Atrial Fibrillation	RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals,
Lekakis	John	Innovations in Cardiovascular Risk Assessment and Reduction		Nothing to Disclose
Lekavich	Carolyn	Emerging Developments in HFpEF and Arryhthmias	Measures of Ventricular-Arterial Coupling and Incident Heart Failure Preserved Ejection Fraction: A Matched Case-Control Analysis	Nothing to Disclose
LeLeiko	Rebecca	40. Vascular Medicine: Non Coronary Arterial Disease Team 1	Suggested Reviewer	Nothing to Disclose
Lembo	Nicholas	Highlighted Original Research: Interventional Cardiology and the Year in Review	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific.MEDTRONIC
Lembo	Nicholas	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Differences and Level of Agreement in SYNTAX Score Assessment Between Site Operators and Angiographic Core Laboratory Readers: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,MEDTRONIC
Lembo	Nicholas	Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,MEDTRONIC
Lembo	Nicholas	Advances in Chronic Total Occlusion Intervention	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,MEDTRONIC
Lembo	Nicholas	Refining PCI Technique and Outcomes	Treatment of Left Main Coronary Artery Disease in Patients With Diabetes: 3-Year Outcomes Comparing CABG and PCI With Everolimus-Eluting Stents From the EXCEL Study	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,MEDTRONIC
Lembo	Nicholas	Refining PCI Technique and Outcomes	Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory Assessment: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,MEDTRONIC
Lembo	Nicholas	PCI Strategies and Outcomes Unique to Women	Sex Differences in Outcomes After Stenting or Bypass Surgery for Unprotected Left Main Disease	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific.MEDTRONIC
Lemesle	Gilles	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Silent Cerebral Microbleeds During TAVR: Insight From a Prospective Cerebral MRI Cohort	Nothing to Disclose
Lemesle	Gilles	Antithrombotic Therapy in Ischemic Heart Disease	Long-Term Outcome With Oral Anticoagulants With or Without Dual Antiplatelet Therapy After AMI: The Fast-Mi 2010 Registry	Nothing to Disclose
Lemor	Alejandro	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Early Versus Delayed Invasive Intervention for Non-ST Segment Elevation Myocardial Infarction in Patients Older Than 80 Years: A Nationwide Analysis	Nothing to Disclose
Lemor	Alejandro	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Impact of End Stage Renal Disease in Patients Hospitalized for Systolic and Diastolic Heart Failure: A Nationwide Analysis of 2013	Nothing to Disclose
Lemor	Alejandro	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Low Socioeconomic Status Is Associated With Increased Inpatient Mortality With Non ST-Elevation Myocardial Infarction: A Nationwide Analysis	Nothing to Disclose
Lemor	Alejandro	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Patients With Non ST-Segment Elevation Myocardial Infarction Utilizing Medicare/Medicaid Have Lower Adjusted Odds of In- Hospital Mortality: A Nationwide Analysis	Nothing to Disclose
Lemor	Alejandro	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Adjusted Odds of Inpatient Mortality for Non-ST Elevation Myocardial Infarction Is Not Affected by Day of Admission: A Nationwide Analysis	Nothing to Disclose
Lemor	Alejandro	Acute Coronary Syndromes, Diagnosis,	Early Versus Delayed Invasive Intervention for Non-ST Segment Elevation Myocardial Infarction Patients: A Nationwide Analysis	Nothing to Disclose
Lemor	Alejandro	Management and Outcomes Unusual Presentations of ACS	Stress Induced Cardiomyopathy (Takotsubo Cardiomyopathy): Mortality, Gender and Admission Month Based on a Nationwide	Nothing to Disclose
Lemor	Alejandro	Unusual Presentations of ACS	Sample During 2013 Clinical Outcomes of the Treatment of Cocaine Induced Chest Pain	Nothing to Disclose
	<u> </u>		With Beta Blockers: A Meta-Analysis	<u> </u>

Contract of the contract of th				l
Last Name Lempereur	First Name Mathieu	Session Title Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Presentation Title Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Previous Major Gastrointestinal Bleeding: Insight From the Applicator Cardiac Plus Multiconter Pagistry	Disclosures Nothing to Disclose
Lenihan	Daniel	Heart Failure and Cancer Care	Amplatzer Cardiac Plug Multicenter Registry Case Presentation: Cardiomyopathy with Herceptin When Should You Stop Herceptin, If Ever? Evidence to Practice Roundtable Discussion	CONSULTANT FEES/HONORARIA - Amgen,Bristol-Myers Squibb Company ,Prothena,Roche; RESEARCH/RESEARCH GRANTS - Takeda Pharmaceuticals North America, Inc
Lenihan	Daniel	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Myocarditis and Rhabdomyolysis Incidence With Immune Checkpoint Inhibitors	CONSULTANT FEES/HONORARIA - Amgen,Bristol-Myers Squibb Company ,Prothena,Roche; RESEARCH/RESEARCH GRANTS - Takeda Pharmaceuticals North America, Inc
Lennon	Ryan	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Elevated Uric Acid Is Associated With Increased Mortality in Women Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Leon	Martin	Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster)	Panelist	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster)		CONSULTANT FEES/HONORARIA - Abbott Laboratories,Boston Scientific,MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	Interventional Live Case Session III: Structural Transmission from Cleveland Clinic (Cleveland, Ohio)	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Laboratories,Boston Scientific,MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	FIT Forum: Mix and Mingle	Interventional Cardiology	CONSULTANT FEES/HONORARIA - Abbott Laboratories,Boston Scientific,MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	Late-Breaking Clinical Trials: Interventional	Chair	CONSULTANT FEES/HONORARIA - Abbott Laboratories,Boston Scientific,MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	CONSULTANT FEES/HONORARIA - Abbott Laboratories,Boston Scientific,MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	TAVR: What We've Learned and Where We Think We're Going!	The Future of Transcatheter Valve Therapies	CONSULTANT FEES/HONORARIA - Abbott Laboratories,Boston Scientific,MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	The Evolution of Angioplasty – 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Laboratories,Boston Scientific,MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	The Evolution of Angioplasty 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	The Evolution of Structural Heart Disease Management	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	The Evolution of Angioplasty — 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	Final Thoughts	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	Post FDA Release Prosthetic Valve Surveillance - Watching for Signals	Panelist	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	Highlighted Original Research: Interventional Cardiology and the Year in Review	Implications of Worsening Right Ventricular Function Following Transcatheter or Surgical Aortic Valve Replacement: Insights From PARTNER2A	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	Interventional Cardiology: TAVR 1	Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: Insights From PARTNER 2A Trial	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Morphologic Patterns of In-Stent Chronic Total Occlusions: An Intravascular Ultrasound Study	CONSULTANT FEES/HONORARIA - Abbott Laboratories,Boston Scientific,MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	Non Invasive Imaging: Expanding Clinical Applications	Does Patient Prosthesis Mismatch Defined by CT LVOT Area Predict Downstream Clinical Outcomes?	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	Interventional Cardiology: TAVR 2	Worsening Tricuspid Regurgitation and Increased Mortality After Aortic Valve Replacement: Insights From PARTNER2A	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	Interventional Cardiology: PCI and TAVR in Complex Patients	Refining the Classification of Severe, Symptomatic Aortic Stenosis Using Flow and Gradient Measurements to Predict Outcomes Post- Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	TAVR Outcomes Prognostication	High Baseline Valvuloarterial Impedence Predicts Worse 1-Year Outcomes After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling is Associated With Low- Flow Severe Aortic Stenosis and Less Reverse Remodeling After TAVR: A Partner 2 Trial Analysis	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	Refining TAVR Outcomes	Incidence and Outcomes of Patients Requiring Surgical Bail-Out During Transcatheter Aortic Valve Replacement: A Report From the NCDR® STS/ACC Transcatheter Valve Therapy (TVT) Redistry	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Leon	Martin	37. Valvular Heart Disease: Therapy Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Laboratories,Boston Scientific,MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Claret;
Leon	Martin	LBCT reviewers	LB Reviewer	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences CONSULTANT FEES/HONORARIA - Abbott Laboratories,Boston Scientific,MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINC/IPAL - Claret;
Leon Hernandez	Francisco Javier	FIT Clinical Decision Making: Non-Invasive	Left Atrium Undifferentiated Pleomorphic Sarcoma Mimicking Septal	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences Nothing to Disclose
Leonardi	Sergio	Imaging and Valvular Heart Disease Post-CAD/MI: Making Tough Predictions About	Asymmetric Hypertrophic Cardiomiopathy One-Year Mortality Increased in Patients With Peri-Procedural	Nothing to Disclose
		the Future	Myocardial Infarction: Insights From the CHAMPION Trials	
Leong	Darryl	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	An Unsuspected Case of Myocarditis Associated With Nivolumab Use	Nothing to Disclose

and a				
Last Name Leong	First Name Derek	Session Title Non Invasive Imaging: Applications in Novel	Presentation Title Angiographic Dye Prior to Combined Heart-Kidney Donation Does	Disclosures Nothing to Disclose
Leong	Derek	Disease States and Clinical Scenarios The Evolving World of LVADs, Transplant and	Not Appear to Harm Donor Kidney Function After Transplant Prognostic Risk Factors for Heart Failure Hospitalization in Women	Nothing to Disclose
Econg	Berek	Other Novel Discoveries	Without Obstructive Coronary Disease: An Ancillary Study From the Women's Ischemia Syndrome Evaluation (WISE)	Housing to Estatose
Leong	Thomas	Updates in Stable Ischemic Heart Disease	Predictors of Long-Term Resource Utilization After Incident Percutaneous Coronary Intervention	Nothing to Disclose
Leontyev	Sergey	Interventional Cardiology: TAVR 2	Different Impact of Gender on Early and Late Outcome After	Nothing to Disclose
Leontyev	Sergey	Interventional Cardiology: TAVR 2	Transcatheter Aortic Valve Replacement Higher B-Type Natriuretic Peptide Levels Predict Occurrence of	Nothing to Disclose
Leontyev	Sergey	Interventional Cardiology: TAVR 2	Acute Kidney Injury After Transcatheter Aortic Valve Replacement Impact of Myocardial Injury Indicated by Increased Creatinine Kinase-	Nothing to Disclose
2001.1,01	co.go,	and router a cardoogy.	Myocardial Band Levels on the Outcome After Transcatheter Aortic Valve Replacement: Results From a Prospective Single Center Registry	Totaling to Exceed
Leontyev	Sergey	Interventional Cardiology: TAVR 4	Impact of Cancer Disease on Outcome of Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Leopold	Jane	Interventional Cardiology: Translation and Pre- Clinical Research	Intramyocardial Autologous CD34+ Cell Therapy for Refractory Angina: A Meta-Analysis	Nothing to Disclose
Lerakis	Stamatios	Highlighted Original Research: Interventional Cardiology and the Year in Review	Implications of Worsening Right Ventricular Function Following Transcatheter or Surgical Aortic Valve Replacement: Insights From PARTNER2A	OTHER - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular
Lerakis	Stamatios	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Echocardiographic Predictors for In-Hospital and 1-Year Outcomes in Left-Sided Infective Endocarditis: An Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort Study	OTHER - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular
Lerakis	Stamatios	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Pulmonary Venous Waveforms Predict Ventricular Remodeling After Percutaneous Mitral Valve Repair	OTHER - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular
Lerakis	Stamatios	Interventional Cardiology: TAVR 2	Worsening Tricuspid Regurgitation and Increased Mortality After	OTHER - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott
Lerakis	Stamatios		Aortic Valve Replacement: Insights From PARTNER2A Reverse Takotsubo Cardiomyopathy Associated With Mediastinal	Vascular OTHER - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott
Lerakis	Stamatios	Pulmonary Hypertension TAVR Outcomes Prognostication	Paraganglioma Predictors and Clinical Outcomes of Next-Day Discharge After Transcatheter Aortic Valve Replacement	Vascular OTHER - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular
Lerakis	Stamatios	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low- Flow Severe Aortic Stenosis and Less Reverse Remodeling After TAVR: A Partner 2 Trial Analysis	OTHER - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott Vascular
Lerakis	Stamatios	28. Non Invasive Imaging: Echo Team 3	Suggested Reviewer	OTHER - Edwards Lifesciences; SPEAKER'S BUREAU - Abbott
Lerman	Amir	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Association of Coronary Epicardial Endothelial Dysfunction With Low Endothelial Shear Stress in Patients With Mild Coronary	Vascular CONSULTANT FEES/HONORARIA - Corindus,ltamar Medical
Lerman	Amir	Current Issues in Cardiovascular	Atherosclerosis Who Presented With Chest Pain Socioeconomic Environment and Digital Health Tool Usage and	CONSULTANT FEES/HONORARIA - Corindus, Itamar Medical
Lerman	Amir	Epidemiology, Disparities, and Safety Coronary Angiography, Intra-Vascular Imaging,	Outcomes: Is There a Digital Divide? Elevated Uric Acid Is Associated With Increased Mortality in Women	CONSULTANT FEES/HONORARIA - Corindus, Itamar Medical
Lerman	Amir	Revascularization and Outcomes FIT Clinical Decision Making: Prevention, Adult	Undergoing Percutaneous Coronary Intervention Chest Pain in a Patient With Anomalous Left Anterior Descending	CONSULTANT FEES/HONORARIA - Corindus, Itamar Medical
Eciman	Zum	Congenital and Congenital Heart Disease	Coronary Artery, Myocardial Bridging and Vasoconstriction: Identification of the Culprit Etiology and Management of a Challenging Combination	SONOETANTT EEGITONOTONIA COMMUNICATION MEGICAL
Lerman	Amir	Obesity Management in 2017: Weighing the Issues	Digital Health Intervention Usage Improves Weight loss in a Dose- Dependent Fashion	CONSULTANT FEES/HONORARIA - Corindus, Itamar Medical
Lerman	Amir	Advanced Therapies = Advanced Trouble: VAD and Transplant Challenges	Sirolimus-Based Immunosuppression Mitigates Progression of Cardiac Allograft Vasculopathy and Improves Cardiac Outcomes After Heart Transplantation: A Single Center 15-Year Follow-Up Study	CONSULTANT FEES/HONORARIA - Corindus, Itamar Medical
Lerman	Bruce	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System	OTHER - Perosphere, Inc
Lerman	Bruce	Stroke and AF: Thinking About the Heart	Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy: Insights Into Rates and Timing of Thrombus Resolution	OTHER - Perosphere, Inc
Lerman	Joseph	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Small Dense Low Density Lipoprotein Particle Number Relates to Coronary Plaque Burden Independent of Traditional Cardiovascular Risk Factors in Psoriasis	Nothing to Disclose
Lerman	Joseph	Non Invasive Imaging: Applications in Novel	Aortic Vascular Inflammation by 18-FDG PET/CT Associates With	Nothing to Disclose
Lerman	Joseph	Disease States and Clinical Scenarios Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	High-Risk Coronary Plaques in Young Psoriasis Patients Improvement in Cholesterol Efflux Capacity Is Associated With a Reduction in Aortic Wall Thickness by MRI Independent of Traditional CV Risk Factors	Nothing to Disclose
Lerman	Lilach	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Association of Coronary Epicardial Endothelial Dysfunction With Low Endothelial Shear Stress in Patients With Mild Coronary Atherosclerosis Who Presented With Chest Pain	CONSULTANT FEES/HONORARIA - Novartis Corporation; RESEARCH/RESEARCH GRANTS - AstraZeneca, Stealth Peptides
Lerman	Lilach	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Elevated Uric Acid Is Associated With Increased Mortality in Women Undergoing Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Novartis Corporation; RESEARCH/RESEARCH GRANTS - AstraZeneca, Stealth Peptides
Lerman	Lilach	Obesity Management in 2017: Weighing the Issues	Digital Health Intervention Usage Improves Weight loss in a Dose- Dependent Fashion	CONSULTANT FEES/HONORARIA - Novartis Corporation; RESEARCH/RESEARCH GRANTS - AstraZeneca, Stealth Peptides
Leshem	Eran	Cardiac Channelopathies: Novel Therapeutics and Clinical Challenges	Appropriate Primary Prophylactic Implantation of Defibrillator in Patients With Brugada Syndrome: Is There Any Difference Between Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events	Nothing to Disclose
Leshnower	Bradley	TAVR Outcomes Prognostication	Predictors and Clinical Outcomes of Next-Day Discharge After	CONSULTANT FEES/HONORARIA - CryoLife, Inc.
Lesiak	Maciej	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Replacement Transcatheter Aortic Valve Implantation in Patients With Bicuspid Aortic Valve Stenosis Utilizing the Next Generation Fully Retrievable and Repositionable Valve System: Early Results From the Multicenter Pol-Tavi Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals, Biotronik, Tryton Medical
Lettino	Maddalena	Advances in Cholesterol Measurement and Management	Mullicenter Poi-1 air Regissiy Consistent Low-Density Lipoprotein Cholesterol Lowering Efficacy of Alirocumab in High and Very High Cardiovascular Risk Patients With Low-Density Lipoprotein Cholesterol >100/70 mg/dL at Baseline	CONSULTANT FEES/HONORARIA - Astra Zeneca,Bayer Healthcare Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,Bristol-Myers Squibb Company, Daiichi Sankyo,Eil Lilly and Company,Pfizer Inc,Sanofi-Aventis; SPEAKER'S BUREAU - Amgen Inc.,Aspen,Merck & Co., Inc.
Leung	Melissa	Innovative Use of Echocardiography	Left Ventricular Systolic Recovery After St-Segment Elevation	Nothing to Disclose
Leung	Steve	Innovations in Advocacy and Patient Centered	Myocardial Infarction: Effect of Guideline-Based Therapy Status of Early Career Academic Cardiology: A Global Perspective	Nothing to Disclose
Leung	Steve	Care Engage @ ACC.17 Studio: FIT Jeopardy Battle	Moderator	Nothing to Disclose
		of the State Chapters IV		•

and a				<u> </u>
Leung	Steve	Session Title Arrhythmias and Heart Failure	Presentation Title Can the Ventricular-Arterial Coupling Ratio Predict Response to Cardiac Resynchronization Therapy for Patients Meeting Class Ila	Disclosures Nothing to Disclose
Lev	Eli	38. Vascular Medicine: Basic Team 2	Indications? Suggested Reviewer	CONSULTANT FEES/HONORARIA - Astra Zeneca,Eli
Levantsevych	Oleksiy	Traditional and Novel Factors Used to Assess	Inflammatory Response to Mental Stress and Mental Stress Induced	Lilly,Pfizer
Levantsevych	Oleksiy	the Risk of, and Used for the Treatment of, Coronary Artery Disease	Myocardial Ischemia	-
Levenson	Benny	Systemic Organ Involvement in Heart Failure: International Perspectives From the German Cardiac Society, Hellenic Society of Cardiology, and American College of Cardiology	Co-Chair	Nothing to Disclose
Levenson	Joshua	Innovations in Practice Management and Social Media	Formal CPR Status Policy and Process Increased Documentation Rates	Nothing to Disclose
Lever	Harry	Non Invasive Imaging: MR Scar and Perfusion	Incremental Prognostic Utility of Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy	Nothing to Disclose
Levi	Daniel	Congenital Heart Disease: Pediatric Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - B Braun,Edwards,pfm Medical
Levin	Benjamin	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Apical Hypertrophic Cardiomyopathy: A Case of Mimicry	Nothing to Disclose
Levin	Eleanor	Measuring Success in Cardiac Rehabilitation	Success of a Home-Based Cardiac Rehabilitation Program in a Population of Nearly 4 Million	Nothing to Disclose
Levin	Mark	Congenital Heart Disease: Progress in Pediatric Heart Surgery	General Anesthesia Risk in Williams Beuren Syndrome Patients in the Current Era	Nothing to Disclose
Levine	Benjamin	Sports and Exercise: Athletes with Congenital/Valvular Heart Disease Challenging Guidelines in Daily Practice	Panelist	Nothing to Disclose
Levine	Benjamin	Sports and Exercise: Athletes with Congenital/Valvular Heart Disease Challenging Guidelines in Daily Practice	What Makes Basketball Players so Special? Implications for Etiology of SCD in Athletes	Nothing to Disclose
Levine	Benjamin	Making Progress in Understanding Heart Failure	High Risk, Stage B Heart Failure: A Distinct Hemodynamic Profile	Nothing to Disclose
Levine	Benjamin	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Stiff Left Atrial Syndrome Following Multiple Ablations Diagnosed With Invasive Hemodynamic Exercise Testing	Nothing to Disclose
Levine	Benjamin	Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	The Impact of Lifelong Exercise Training "Dose" on the Ventricular- Arterial Coupling	Nothing to Disclose
Levine	Diane	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Seasonal Variation in In-Patient Mortality, Cost of Hospitalization and Length of Stay in Heart Failure Patients in the United States	Nothing to Disclose
Levine	Diane	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Regional Variation in Hospitalization Outcomes Among Patients Admitted for Heart Failure in the United States	Nothing to Disclose
Levine	Glenn	Cardiovascular Update for the Clinician I: Coronary Artery Disease – Challenges in 2017	Panelist	Nothing to Disclose
Levine	Glenn	(A Symposium by Dr. Valentin Fuster) Cardiovascular Update for the Clinician I: Coronary Artery Disease – Challenges in 2017	STEMI Versus NSTEMI vs STABLE CAD: Five Challenging Atherothrombotic Approaches	Nothing to Disclose
Levine	Glenn	(A Symposium by Dr. Valentin Fuster) Controversies in ACS Guidelines	What's New and Controversial in ACS Guidelines: The US	Nothing to Disclose
Levine	Glenn	Timing and Duration of DAPT: Controversy	Perspective Panelist	Nothing to Disclose
Levine	Glenn	and Consensus Timing and Duration of DAPT: Controversy	The Evolution of DAPT Duration	Nothing to Disclose
Levine	Glenn	and Consensus 02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Levitan	Emily	Clinical Team 8 Highlighted Original Research: Prevention and the Year in Review	PCSK9 Variants and Neurocognitive Impairment: Data From the REasons for Geographic and Racial Differences in Stroke	CONSULTANT FEES/HONORARIA - Amgen,Robinson Calcagnie Robinson Shapiro Davis; RESEARCH/RESEARCH
Levy	Jerrold	Joint American College of Cardiology/New	(REGARDS) Study Levosimendan in Patients With Left Ventricular Systolic Dysfunction	GRANTS - Amgen CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
		England Journal of Medicine Late-Breaking Clinical Trials	Undergoing Cardiac Surgery With Cardiopulmonary Bypass: Primary Results of the LEVO-CTS Trial	Pharmaceuticals, Inc,Instrumentation Labs; DATA SAFETY MONITORING BOARD - CSL Behring, Grifols; RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals, Inc.
Levy	Wayne	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Performance of the Seattle Heart Failure Model in Patients Discharged After Acute Heart Failure Hospitalization	OTHER - GE Healthcare; RESEARCH/RESEARCH GRANTS - Abbott, Novartis
Lewandowski	Thomas	Innovations in Practice Management and Social Media	Unlocking the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for	Nothing to Disclose
Lewin	Mark		Today's Complex Care Delivery ACC Poster Moderator	Nothing to Disclose
Lewin	Mark	Heart Disease 10. Congenital Heart Disease: Pediatric Team	Suggested Reviewer	Nothing to Disclose
LeWinter	Martin	FIT Clinical Decision Making: Prevention, Adult	New-Onset Platypnea Orthodeoxia and Old Patent Foramen Ovale:	CONSULTANT FEES/HONORARIA - Cytokinetics; RESEARCH/RESEARCH GRANTS - Novartis
Lewis	Basil	Congenital and Congenital Heart Disease Arrhythmias and Clinical EP: AF Miscellaneous	Close It or Not to Close It? Aortic Stenosis, but Not Mitral or Aortic Regurgitation, Is Associated	CONSULTANT FEES/HONORARIA - Amgen,Pfizer;
Lewis	Basil	and Surgical Issues Non Invasive Imaging: Prognostic Implications	With Adverse Outcomes With Atrial Fibrillation: Results From the ARISTOTLE Trial Can We Identify Plaques That Will Cause Acute Coronary	RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals,Bayer Healthcare Pharmaceuticals,Pfizer Inc CONSULTANT FEES/HONORARIA - Amgen,Pfizer;
Lowie	Bradley	of CT Angiography Vascular Medicine: Aortic and Peripheral	Syndromes? An 8 Year Prospective Study Based on CT Angiography in Asymptomatic Diabetics Association of Ankle Reachial Hoay With Limb Outcomes in	RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals,Bayer Healthcare Pharmaceuticals,Pfizer Inc
Lewis	Bradley	Artery Diseases	Association of Ankle Brachial Index With Limb Outcomes in Peripheral Artery Disease: A Community-Based Study	Nothing to Disclose
Lewis	Connie	Palliative Care for the 99% III: Skillbuilding: PC Encounters: What Would you do? Part II	Panelist	Nothing to Disclose
Lewis	Cora	Insights From Echocardiography Use	Relation of Left Ventricular Remodeling to Left Ventricular Diastolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	RESEARCH/RESEARCH GRANTS - Novo Nordisk
Lewis	Cora	Insights From Echocardiography Use	Relation of Left Ventricular Remodeling to Left Ventricular Systolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	RESEARCH/RESEARCH GRANTS - Novo Nordisk
Lewis	Eldrin	Innovative Use of Echocardiography	Echocardiographic Parameters Associated With Quality of Life in Ambulatory Patients With Heart Failure	CONSULTANT FEES/HONORARIA - Merck & Damp; Co., Inc., Novartis Corporation; RESEARCH/RESEARCH GRANTS - Amgen, Inc., Novartis, Inc., Sanofi Aventis
Lewis	Eldrin	Emerging Developments in HFpEF and Arryhthmias	Influence of Left Ventricular Ejection Fraction on Cause-Specific Mortality in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial	CONSULTANT FEES/HONORARIA - Merck & Drychologrammic Co., Inc., Novartis Corporation; RESEARCH/RESEARCH GRANTS - Amgen, Inc., Novartis, Inc., Sanofi Aventis
Lewis	Eldrin	FIT Clinical Decision Making: Heart Failure and Cardiomyopathies		CONSULTANT FEES/HONORARIA - Merck & Amp; amp; Co., Inc., Novartis Corporation; RESEARCH/RESEARCH GRANTS - Amgen, Inc., Novartis, Inc., Sanofi Aventis
	i .	i	Panelist	CONSULTANT FEES/HONORARIA - Ironwood,Luitpold

Lewis Gre Lewis Gre Lewis Jar Lewis Ma Lewis Ma Lewis Ma	regory	The OMICS in Pulmonary Hypertension	Presentation Title Metabolomics: Plasma Signatures of Right Ventricular and PulmonaryVascular Dysfunction Co-Chair	Disclosures CONSULTANT FEES/HONORARIA - Ironwood, Luitpold Pharmaceuticals, Inc, MyoKardia; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Novartis Corporation, SHAPE Systems, Steatih Peptides CONSULTANT FEES/HONORARIA - Ironwood, Luitpold
Lewis Jar Lewis Ma Lewis Ma Lewis Ma		Get into the Beat! Exercise to Promote CV		GRANTS - Abboit Laboratories, Novartis Corporation, SHAPE Systems, Stealth Peptides CONSULTANT FEES/HONORARIA - Ironwood, Luitpold
Lewis Jar Lewis Ma Lewis Ma Lewis Ma			Co-Chair	
Lewis Ma Lewis Ma Lewis Ma	innet			Pharmaceuticals, Inc,MyoKardia; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,Novartis Corporation,SHAPE Systems,Stealth Peptides
Lewis Ma		Innovative Use of Echocardiography	Effect of Blood Pressure Control on Left Ventricle Strain Using	Nothing to Disclose
Lewis Ma	atthew	Update in ACHD: The Time for Change is Now	Speckle Tracking Imaging Panelist	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
	atthew	Six Years of Making an IMPACT	Panelist	Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
I owis	atthew	Six Years of Making an IMPACT	Proximal Pulmonary Artery Stenting: Efficacy and Adverse Events	Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
LCWIS IVIA			Impact of Damaging de Novo Variants on Clinical Outcomes in	Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
Lewis Ma	atthew	and Translational Science Congenital Heart Disease: To the Third	Congenital Heart Disease The Systemic Right Ventricle in Transposition of the Great Arteries:	Pharmaceuticals, Inc CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
Lewis Sai	andra	The Malpractice Minefield: How to Avoid,	What Can We Learn From Serial Imaging? Co-Chair	Pharmaceuticals, Inc Nothing to Disclose
Lewis Sar	andra	Navigate and Advocate WIC Brown Bag Lunch Session: Publishing, Social Media and Negotiating the C-Suite: Tools for Success in Academia and Private Practice	Co-Chair	Nothing to Disclose
Leya Fer	erdinand		Aortic Valve Calcification Predicts Paravalvular Aortic Regurgitation After Self-Expanding Transcatheter Aortic Valve Replacement	Nothing to Disclose
Li Ca	andice		The Effect of Right Ventricular Compression on Cardiac Function in Pediatric Pectus Excavatum Patients	Nothing to Disclose
Li Da	anny	Unusual Presentations of ACS	Association of Cocaine and Amphetamine Use With Troponin I Concentrations	Nothing to Disclose
Li Do		Non Invasive Imaging: Applications in Novel	Impact of Cardiac Troponin I on the Presence of the Coronary Artery Plaque in Rheumatoid Arthritis patients	Nothing to Disclose
Li Do	ong	Non Invasive Imaging: Expanding Clinical Applications	The Utility of Left Atrial Appendage Hounsfield Unit and the Ratio of Left Atrial Appendage/Ascending Aorta Hounsfield Unit for Detecting Left Atrial Appendage Thrombus	Nothing to Disclose
Li Do		Applications	The Association of Ischemia on Single Photon Emission Computed Tomography-Myocardial Perfusion Image and Fractional Flow Reserve by Coronary Computed Tomographic Angiography	Nothing to Disclose
Li Do		Innovations in Cardiovascular Risk Assessment and Reduction	Association of Coronary Calcium, Carotid Wall Thickness and Carotid Plaque Progression With Low Density Lipoprotein and High Density Lipoprotein Particle Concentration Measured by Ion Mobility Testing: The Multi-Ethnic Study of Atherosclerosis (MESA)	Nothing to Disclose
Li Hu		Syndromes	Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Diabetic Hypertensive Acute Myocardial Infarction Patients: Results From the Korea Acute Myocardial Infarction Registry (KAMIR)	Nothing to Disclose
Li Hu	ı	Timely Topics in Acute Coronary Syndromes	Predictors of Mortality in Acute Myocardial Infarction Patients With Unprotected Left Main Coronary Artery Disease	Nothing to Disclose
Li Hu		Advances in Chronic Total Occlusion Intervention	Impact of Percutaneous Coronary Intervention for Chronic Total Occlusion Patients With Near-Normal Left Ventricular Function	Nothing to Disclose
Li Jia		Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Elevated Pulmonary Vascular Resistance Predicts Poor Response to Cardiac Resynchronization Therapy	Nothing to Disclose
Li Jia	anping	Assessing the Clinical Impact of Blood Pressure Lowering Therapies	Impact of Achieved Blood Pressure on First Stroke in Hypertensive Patients With Mild-to-Moderate Chronic Kidney Disease: A Post-Hoc Analysis of the China Stroke Primary Prevention Trial (CSPPT)	Nothing to Disclose
Li Jia			Serum Homocysteine Lowering by Long-Term Low-Dose Folic Acid: New Insight on <i>MTHFR</i> Gene-Folate Interaction From China Stroke Primary Prevention Trial	Nothing to Disclose
Li Jiai		Diabetes and Other Issues in Cardiovascular Prevention	Efficacy of Folic Acid Supplementation on the Reduction of Stroke Risk: Interaction With Platelet Count	Nothing to Disclose
Li Jin	ng ,	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Time to Acute Care Among Patients With Acute Myocardial Infarction in China: A Report From China Patient-Centered Evaluative Assessment of Cardiac Events Prospective Study of	Nothing to Disclose
Li Lin		Adult Patients With Congenital Heart Disease:	Acute Myocardial Infarction Decreased Hepatic Elasticity in Young Adults After Biventricular	Nothing to Disclose
Li Lin	ng ,	Arrhythmias and Clinical EP: Devices 2	Repair of Congenital Heart Disease Impact of Left Atrial Appendage Occlusion on Left Atrial Function Identifying Non-Heart Failure Patients With Elevated NT-proBNP	Nothing to Disclose
Li Lin	Ů	Prevent Readmissions	Levels in the Outpatient Setting: Opportunities for Prevention	Nothing to Disclose
	-		Among Patients Undergoing Complex Percutaneous Coronary Intervention	Nothing to Disclose
	ı	ACS	The Serial Platelet Function Testing Predicts Long-Term Prognosis Among Patients Undergoing Complex Percutaneous Coronary Intervention	Nothing to Disclose
		Interventional Cardiology: TAVR 1	TAVR Is Safe and Improves Cardiac Function in Patients With Extremely Low Ejection Fractions	Nothing to Disclose
		Revascularization and Outcomes	Troponin Elevation Following Elective PCI Predicts Long Term Survival	Nothing to Disclose
		CT/MR	Comparison of Procedural Efficacy of Coronary Angiography in Octogenarian, Nonagenarian and General Population	Nothing to Disclose
Li She	nenjing	Interventional Complexity and Complications	Patient Characteristics as Predictors of Transradial Approach Failure During Coronary Angiography Procedures	Nothing to Disclose
Li She	nenjing	Interventional Complexity and Complications	The Effect of Body Mass Index on Procedural Efficacy in Transfemoral Versus Transradial Coronary Angiography	Nothing to Disclose
Li Shi		Challenges in Percutaneous Interventions: International Perspectives From the Hong Kong College of Cardiology, Singapore Cardiac Society, and American College of Cardiology	Co-Chair	Nothing to Disclose
	nuang		Contemporary Patterns of Lipid Testing in Primary and Secondary Prevention Patients: Insights From the PALM Registry	Nothing to Disclose
Li Shi			Toward Identifying Personalized Prognosis in Hypertension:	
	nu-Xia	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Variation in Early Responses in the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)	Nothing to Disclose

Congress of the Congress of th				l
Last Name Li	First Name Sufang	Session Title From Diet to Drugs: Mechanistic Insight Into	Presentation Title Mutations in SCAP and AGXT2 Revealed by Exome Sequencing a	Disclosures Nothing to Disclose
Li	Wei	Ischemic Heart Disease Technical Advances in Transthoracic Echocardiography	Pedigree With Premature Myocardial Infarction Stroke Volume Determined Flow Reserve Does Not Predict the True Severity of Low-Flow Low-Gradient Aortic Stenosis and Is Not a Robust Marker of Contractile Reserve in Patients Undergoing Low-	Nothing to Disclose
Li	Wing Yi	Adult Patients With Congenital Heart Disease:	Dose Dobutamine Echocardiography Right and Left Ventricular Mechanics Are Altered in Adolescents	Nothing to Disclose
Li	Yi	How Do They Compare? Coronary Angiography, Intra-Vascular Imaging,	and Adults Late After Repair of Subarterial Ventricular Septal Defects Impact of a Switch From Dual Antiplatelet Therapy to Single	Nothing to Disclose
		Revascularization and Outcomes	Antiplatelet Therapy in Diabetes and Non-Diabetes Post ACS: Insights From the EPICOR and EPICOR-Asia Studies	
Li	Yi	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Diabetes Mellitus on Antithrombotic Management Patterns and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndrome: Insight From the EPICOR Asia Study	Nothing to Disclose
Li	Youbao	Assessing the Clinical Impact of Blood Pressure Lowering Therapies	Impact of Achieved Blood Pressure on First Stroke in Hypertensive Patients With Mild-to-Moderate Chronic Kidney Disease: A Post-Hoc Analysis of the China Stroke Primary Prevention Trial (CSPPT)	Nothing to Disclose
Li	Zhao	Toward Precision Medicine in the Treatment of	Triglyceride Glucose Index Is an Independent Risk Factor for	Nothing to Disclose
Li	Zhenping	Elevated Blood Pressure Arrhythmias and Clinical EP: Basic 2	Hypertension Atrial Fibrillation Is Associated With Severe Metabolic Disruption in	Nothing to Disclose
Li	Zhuokai	Interventional Cardiology: TAVR 3	Atrial Myocardium in Patients With Heart Failure Stroke and Cardiovascular Outcomes in Patients With Carotid	Nothing to Disclose
Liang	David	Interventional Cardiology: TAVR 1	Disease Undergoing TAVR: Insights From the STS/TVT Registry The Inflammasome Pathway Is Associated With Adverse Ventricular	CONSULTANT FEES/HONORARIA - Twelve, Inc;
	Dovid	Engage @ ACC.17 Studio: Heart Teams in	Remodeling Following Transcatheter Aortic Valve Replacement Stanford Imaging	RESEARCH/RESEARCH GRANTS - Philips healthcare CONSULTANT FEES/HONORARIA - Twelve, Inc;
Liang	David	Action: Complex Coronary Revascularization		RESEARCH/RESEARCH GRANTS - Philips healthcare
Liang	Jackson	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Using Cardiac Magnetic Resonance Imaging and Transthoracic Echocardiography to Predict Presence of Papillary Muscle-Based Ventricular Ectopy in Mitral Valve Prolapse	Nothing to Disclose
Liang	Jackson	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Anticoagulation Use and Incidence of Cerebrovascular Events and Major Bleeding After Catheter Ablation in Patients With Persistent and Longstanding Persistent Atrial Fibrillation	Nothing to Disclose
Liang	Li	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	The Impact of the Current Versus Prior Cardiac Resynchronization Guidelines on the Proportion of Hospitalized Heart Failure Patients Eliqible for Therapy	Nothing to Disclose
Liao	James	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Increased Tumor Necrosis Factor-α Levels in Patients With Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Instability and Are Associated With Higher Non-Surgical Bleeding	CONSULTANT FEES/HONORARIA - Asahi-Kasei Pharmaceuticals, Inc.
Liao	James	Young Investigator Awards Competition: Outcomes Research	A Bundled Intervention Including Early Consultation With a Cardiologist in the Emergency Department to Reduce Re- Hospitalizations and Healthcare Cost for High-Risk Urban Patients With Acute Decompensated Heart Failure	CONSULTANT FEES/HONORARIA - Asahi-Kasei Pharmaceuticals, Inc.
Liao	Ming	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Morphologic Patterns of In-Stent Chronic Total Occlusions: An Intravascular Ultrasound Study	Nothing to Disclose
Liao	Ming	Interventional Cardiology: PCI and TAVR in Complex Patients	Refining the Classification of Severe, Symptomatic Aortic Stenosis Using Flow and Gradient Measurements to Predict Outcomes Post-	Nothing to Disclose
Liao	Ming	TAVR Outcomes Prognostication	Transcatheter Aortic Valve Replacement High Baseline Valvuloarterial Impedence Predicts Worse 1-Year	Nothing to Disclose
Liao	Xinxue	The Intersection of Diabetes and ASCVD	Outcomes After Transcatheter Aortic Valve Replacement Anti-Diabetic Agents and Cardiovascular Outcomes in the Era of Novel Glucose-Lowing Drugs	Nothing to Disclose
Liao	Yi-Wen	Acute Coronary Syndromes, Diagnosis,	Bleeding Risk Models in Acute Coronary Syndrome: Meta-Analysis	Nothing to Disclose
Liberman	Joshua	Management and Outcomes Innovations in Practice Management and Social Media	of Performance Unlocking the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for Today's Complex Care Delivery	SPEAKER'S BUREAU - Regeneron
Liedtke	Michaela	Advances in HCM, PPCM and Other Cardiomyopathies	NEOD001 Demonstrates Cardiac Biomarker Responses in Patients With Light Chain Amyloidosis: Results From the Phase 1/2 Study	CONSULTANT FEES/HONORARIA - Amgen Inc., Pfizer Inc, Prothena, Takeda Pharmaceuticals North America, Inc; RESEARCH/RESEARCH GRANTS - Amgen Inc., Celgene Corporation, Novartis Corporation, Pfizer Inc, Prothena, Takeda Pharmaceuticals North America, Inc
Lietz	Katherine	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Impact of Surgical Bleeding on the Cost of Hospitalization for Left- Ventricular Assist Device Implantation	Nothing to Disclose
Lietz	Katherine	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Preoperative Predictors of Surgical Bleeding With Implantation of Durable Mechanical Circulatory Support Devices	Nothing to Disclose
Liew	Kai Soon	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Not All Shocks Are Created Equal: Acute Coronary Syndrome in the Setting of Panhypopituitarism	Nothing to Disclose
Light-McGroary	KellyAnn	Disease, and Vascular Medicine Palliative Care for the 99% I: Promoting Palliative Care: The Why and What of PC Therapy	Panelist	SALARY - United Health Group: Chief Medical Officer: Iowa Community and State (Medicaid)
Light-McGroary	KellyAnn	Palliative Care for the 99% II: Skillbuilding: PC Encounters: What Would you do? Part I	Co-Chair	SALARY - United Health Group: Chief Medical Officer: Iowa Community and State (Medicaid)
Ligon	Allen	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Transcatheter Ductal Stenting Versus Surgical Systemic-to- Pulmonary Artery Shunts: Altering Dogma at a High-Volume Institution	Nothing to Disclose
Lihn	Stacey	Congenital Heart Disease: Advances in Quality Improvement for Pediatric Cardiac Care	Revenue Return on Investment for Center Involvement in a Quality Improvement Collaborative for a Rare Disease: National Pediatric Cardiology Quality Improvement Collaborative	Nothing to Disclose
Lihn	Stacey	Finding Out What Works in Pediatric and Congenital Heart Disease	Reduction in Interstage Growth Failure in Infants With Hypoplastic Left Heart Syndrome and Impact on Stage 2 Outcomes: A Report From the National Pediatric Cardiology Quality Improvement	Nothing to Disclose
Liles	Jeffrey	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Collaborative Retrospective Analysis of Thrombogenic Biomarkers in Patients With Atrial Fibrillation Treated With Novel Oral Anticoagulants	Nothing to Disclose
Lilly	Scott	Engage @ ACC.17 Studio: Simulation I Congenital Heart Disease	Co-Chair	Nothing to Disclose
Lilly	Scott	Engage @ ACC.17 Studio: Simulation Session	Co-Chair	Nothing to Disclose
Lilly	Scott	II: Acute Heart Failure FIT Clinical Decision Making Reviewers 5	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Lim	D. Scott	Interventional Live Case Session III: Structural Transmission from Cleveland Clinic	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular, Edwards Lifesciences, Mitralign; RESEARCH/RESEARCH GRANTS -
Lim	D. Scott	(Cleveland, Ohio) The Forgotten Valves: Therapies for Triscuspid	Co-Chair	Abbott Vascular CONSULTANT FEES/HONORARIA - Abbott Vascular, Edwards
Lim	D. Scott	and Pulmonic Valve The Forgotten Valves: Therapies for Triscuspid	Trialign TV Repair: Case and Overview	Lifesciences,Mitralign; RESEARCH/RESEARCH GRANTS - Abbott Vascular CONSULTANT FEES/HONORARIA - Abbott Vascular,Edwards
		and Pulmonic Valve	<u> </u>	Lifesciences,Mitralign; RESEARCH/RESEARCH GRANTS - Abbott Vascular



The second second				<u> </u>
Last Name Lim	D. Scott	Session Title The Tricuspid Valve: Not Forgotten, Just Misunderstood	Presentation Title Tricuspid Regurgitation in Congenital Heart Disease	Disclosures CONSULTANT FEES/HONORARIA - Abbott Vascular,Edwards Lifesciences,Mitralign; RESEARCH/RESEARCH GRANTS -
Lim	D. Scott	24. Interventional Cardiology: Mitral and Structural Heart Disease Team 2	Suggested Reviewer	Abbott Vascular CONSULTANT FEES/HONORARIA - Abbott Vascular, Edwards Lifesciences, Mitralign; RESEARCH/RESEARCH GRANTS - Abbott Vascular
Lim	Hong Euy	Novel Developments in Acute Coronary Syndromes	Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Diabetic Hypertensive Acute Myocardial Infarction Patients: Results From the Korea Acute Myocardial Infarction Registry (KAMIR)	Nothing to Disclose
Lim	Hong Euy	Timely Topics in Acute Coronary Syndromes	Predictors of Mortality in Acute Myocardial Infarction Patients With Unprotected Left Main Coronary Artery Disease	Nothing to Disclose
Lim	Hong Euy	Advances in Chronic Total Occlusion	Impact of Percutaneous Coronary Intervention for Chronic Total	Nothing to Disclose
Lim	Michael	Intervention Maintenance of Clinical Competencies in Invasive Coronary Imaging and Coronary	Occlusion Patients With Near-Normal Left Ventricular Function FFR and Coronary Physiology	CONSULTANT FEES/HONORARIA - Abiomed, Acist Medical; SPEAKER'S BUREAU - MEDTRONIC
Lim	Michael	Physiology Interventional Cardiology: TAVR 3	Prosthetic Surgical Tissue Valve Enlargement Using a High- Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter	CONSULTANT FEES/HONORARIA - Abiomed, Acist Medical; SPEAKER'S BUREAU - MEDTRONIC
Lim	Michael	16. Interventional Cardiology: Angiography and	Valve-in-Valve Implantation Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abiomed, Acist Medical;
Lim	Michael	Interventional CT/MR Team 1 Interventional Challenging Cases: Team 3	ACC Challenging Case Reviewer	SPEAKER'S BUREAU - MEDTRONIC CONSULTANT FEES/HONORARIA - Abiomed, Acist Medical;
Lim	Sang-Wook	Novel Developments in Acute Coronary	Serial Measurements of Neutrophil Gelatinase-Associated Lipocalin	SPEAKER'S BUREAU - MEDTRONIC Nothing to Disclose
Line	Cara Mask	Syndromes	(NGAL): Prognostic Value in Stemi Patients Treated by Primary Percutaneous Coronary Intervention	Nething to Displace
Lim	Sang-Wook	Nuclear Cardiology: Beyond Perfusion	Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study	Nothing to Disclose
Lim	Toon Wei	Stroke and AF: Thinking About the Heart	The Prescribing of Antiplatelet Therapy Only in Patients With Nonvalvular Atrial Fibrillation: Results From the GARFIELD-AF Registry	CONSULTANT FEES/HONORARIA - MEDTRONIC,St Jude Medical; SALARY - Merck Singapore
Lim	Yeong-Min	Novel Developments in Acute Coronary Syndromes	Serial Measurements of Neutrophil Gelatinase-Associated Lipocalin (NGAL): Prognostic Value in Stemi Patients Treated by Primary Percutaneous Coronary Intervention	Nothing to Disclose
Lima	Eduardo	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Cost-Effectiveness Analysis and Quality of Life of On-Pump and Off- Pump Stable Multivessel Coronary Artery Bypass Grafting: MASS III Trial 5-Year Follow-Up	Nothing to Disclose
Lima	Joao	Making Progress in Understanding Heart Failure	Impact of Malignant Left Ventricular Function on Incident Heart Failure With Reduced Versus Preserved Ejection Fraction: The MESA Study	RESEARCH/RESEARCH GRANTS - Toshiba Medical Systems
Lima	Joao	Making Progress in Understanding Heart Failure	Impact of Malignant Left Ventricular Function on Incident Heart Failure in Older Adults: The MESA Study	RESEARCH/RESEARCH GRANTS - Toshiba Medical Systems
Lima	Joao	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Normal Findings on Noninvasive Cardiac Assessment and the Prediction of Heart Failure: The Multi-Ethnic Study of Atherosclerosis (MESA)	RESEARCH/RESEARCH GRANTS - Toshiba Medical Systems
Lima	Joao	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Association of Coronary Artery Calcium With Incident Peripheral Artery Disease: The Multi-Ethnic Study of Atherosclerosis	RESEARCH/RESEARCH GRANTS - Toshiba Medical Systems
Lima	Joao	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Calcium Characteristics as Predictors of Major Adverse Cardiac Events in Symptomatic Patients: Insights From the	RESEARCH/RESEARCH GRANTS - Toshiba Medical Systems
Lima	Joao	Innovations in Cardiovascular Risk Assessment	CORE320 Multinational Study Impact of Malignant Left Ventricular Hypertrophy on Incident	RESEARCH/RESEARCH GRANTS - Toshiba Medical Systems
Lima	Joao	and Reduction Innovations in Cardiovascular Risk Assessment	Asymptomatic Left Ventricular Dysfunction: The MESA Study Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in	RESEARCH/RESEARCH GRANTS - Toshiba Medical Systems
Lima	Joao	and Reduction Non Invasive Imaging: MR Scar and Perfusion	African Americans: The Jackson Heart Study Association of Right Atrial Function With Incident Atrial Fibrillation:	RESEARCH/RESEARCH GRANTS - Toshiba Medical Systems
			The Multi-Ethnic Study of Atherosclerosis (MESA)	•
Lima	Joao	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prediction of Future Cardiovascular Risk by Analysis of Various CT Coronary Angiography-Determined Quantitative Plaque Compositional Characteristics Among Patients With Diabetes Enrolled in the FACTOR-64 Study: The Importance of the Calcified Coronary Plaque	RESEARCH/RESEARCH GRANTS - Toshiba Medical Systems
Lima	Joao	Non Invasive Imaging: Prognostic Implications of CT Angiography	Coronary Artery Structural Remodeling by Computed Tomography and Echocardiographic Left Ventricular Mass Changes Over the Next 5 Years: The Coronary Artery Risk Development in Young Adults (CARDIA) Study	RESEARCH/RESEARCH GRANTS - Toshiba Medical Systems
Lima	Joao	Insights From Echocardiography Use	Relation of Left Ventricular Remodeling to Left Ventricular Diastolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	RESEARCH/RESEARCH GRANTS - Toshiba Medical Systems
Lima	Joao	Insights From Echocardiography Use	Relation of Left Ventricular Remodeling to Left Ventricular Systolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	RESEARCH/RESEARCH GRANTS - Toshiba Medical Systems
Lima	Joao	Improving Risk Assessment in Atherosclerosis	N-Terminal Pro B-Type Natriuretic Peptide, Race, and Flow- Mediated Dilation: Multi-Ethnic Study of Atherosclerosis	RESEARCH/RESEARCH GRANTS - Toshiba Medical Systems
Lima	Joao A.	29. Non Invasive Imaging: MR Team 1	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Toshiba Medical Systems
Limacher Lin	Marian Ben	32. Prevention: Clinical Team 4 New Technologies in Echocardiography	Suggested Reviewer Automated Detection of Mitral Valve Annular and Leaflet Geometry:	Nothing to Disclose Nothing to Disclose
Lin	C. Huie	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional	Echocardiography and CT Comparison Technique and Utility of CT Angiography Fluoroscopy Image Fusion to Guide Percutaneous Pulmonary Valve Implantation in Adults	DATA SAFETY MONITORING BOARD - ACI Clinical; SPEAKER'S BUREAU - Abiomed
Lin	C. Huie	CT/MR FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Closure of a Ventricular Septal Defect Complicated by Hemolysis Requiring Transcatheter Retrieval of Amplatzer Occluder	DATA SAFETY MONITORING BOARD - ACI Clinical; SPEAKER'S BUREAU - Abiomed
Lin	C. Huie	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Scimitar Syndrome in an Adult With Multiple Unsuccessful Surgical Repairs	DATA SAFETY MONITORING BOARD - ACI Clinical; SPEAKER'S BUREAU - Abiomed
Lin	C. Huie	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Atrial Septal Defect Closure in a Patient With Pulmonary Hypertension	DATA SAFETY MONITORING BOARD - ACI Clinical; SPEAKER'S BUREAU - Abiomed
Lin	C. Huie	Innovations in Education	Hands-On Transradial Access Skill Training on a Novel Cadaveric Model: Findings and Recommendations	DATA SAFETY MONITORING BOARD - ACI Clinical; SPEAKER'S BUREAU - Abiomed
Lin	C. Huie	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Treatment of Refractory Coronary Artery Spasm With Percutaneous Coronary Intervention	DATA SAFETY MONITORING BOARD - ACI Clinical; SPEAKER'S BUREAU - Abiomed
Lin	Chien-Jung	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Cardiomyopathy in Patients After Post-Transplant Cyclophosphamide-Based Hematopoietic Cell Transplantation	Nothing to Disclose
Lin	Chun	Engage @ ACC.17 Studio: FIT Jeopardy Battle of the State Chapters II	Moderator	DATA SAFETY MONITORING BOARD - ACI Clinical; SPEAKER'S BUREAU - Abiomed
Lin	Chun	41. Vascular Medicine: Venous Disease Team	Suggested Reviewer	DATA SAFETY MONITORING BOARD - ACI Clinical; SPEAKER'S BUREAU - Abiomed
Lin	David	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Anticoagulation Use and Incidence of Cerebrovascular Events and Major Bleeding After Catheter Ablation in Patients With Persistent and Longstanding Persistent Atrial Fibrillation	CONSULTANT FEES/HONORARIA - St. Jude Medical
Lin	Erica Lai Sze	Nuclear Cardiology: Prognosis	Serial Myocardial Perfusion Imaging in End-Stage Renal Disease	Nothing to Disclose



Carried States				,
Last Name Lin	First Name Fay	Session Title Non Invasive Imaging: Expanding Clinical	Presentation Title Dual-Energy Coronary Computed Tomography Evaluation of High-	Disclosures Nothing to Disclose
	. =,	Applications	Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients: Validation with Histopathologic Gold Standard	
Lin	Fay	Non Invasive Imaging: Coronary Calcium	Incremental Utility of Coronary Computed Tomographic	Nothing to Disclose
		Scoring and CV Risk Assessment	Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry	
Lin	Fay	Innovations in Cardiovascular Risk Assessment and Reduction	Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery	Nothing to Disclose
		and Reduction	Disease Detected by Coronary Computed Tomographic	
			Angiography: The CONFIRM-LT (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) Registry	
Lin	Fay	Non Invasive Imaging: Prognostic Implications	Prognostic Utility of Coronary Computed Tomographic Angiography	Nothing to Disclose
		of CT Angiography	Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry	
Lin	Fay	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography: The CONFIRM Registry	Nothing to Disclose
Lin	Fay	Non Invasive Imaging: Prognostic Implications	Quantitative Measurement of Coronary Intra-Plaque Necrotic Core	Nothing to Disclose
		of CT Angiography	by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Death: A Comparison to a Histologic Reference Standard	
Lin	Fay	Diabetes and Other Issues in Cardiovascular Prevention	Implications of Statin Therapy Among Smokers With Severe Coronary Artery Calcification: An Analysis of the CONFIRM Registry	Nothing to Disclose
Lin	Fay	Non Invasive Imaging: New Technologies	Optimal Method for Necrotic Core Identification in Coronary Plaque With Dual-Energy Computed Tomography. Material Decomposition and Atomic Number	Nothing to Disclose
Lin	Feng-Chang	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Ethnicity, Marital Status, and Neighborhood Poverty Influence Resuscitation of Out-of-Hospital Sudden Unexpected Deaths	Nothing to Disclose
Lin	Grace	Recognition of Specific Etiologies and	Panelist Panelist	RESEARCH/RESEARCH GRANTS - MEDTRONIC; SPEAKER'S
		Phenotypes in Heart Failure: Time for Precision		BUREAU - Pfizer Inc
Lin	Grace	Recognition of Specific Etiologies and Phenotypes in Heart Failure: Time for	Newer Imaging and Diagnostic Modalities in Heart Failure	RESEARCH/RESEARCH GRANTS - MEDTRONIC; SPEAKER'S BUREAU - Pfizer Inc
Lin	Grace	Precision Syncope: Challenges and Pitfalls: A Case-	Panelist	RESEARCH/RESEARCH GRANTS - MEDTRONIC; SPEAKER'S
		based Approach		BUREAU - Pfizer Inc
Lin	Grace	Syncope: Challenges and Pitfalls: A Case- based Approach	63 Year Old with Recently Diagnosed Cardiac Amyloidosis and Syncopal Spell	RESEARCH/RESEARCH GRANTS - MEDTRONIC; SPEAKER'S BUREAU - Pfizer Inc
Lin	Grace	Advances in HCM, PPCM and Other Cardiomyopathies	Utility of Routine Serum Free Light Chain Assay for Amyloidosis in Patients With Heart Failure	RESEARCH/RESEARCH GRANTS - MEDTRONIC; SPEAKER'S BUREAU - Pfizer Inc
Lin	Grace	Arrhythmias and Heart Failure	ACC Poster Moderator	RESEARCH/RESEARCH GRANTS - MEDTRONIC; SPEAKER'S
Lin	Jay	Atrial Fibrillation, Anticoagulation and Novel	Real World Evaluation of Major Bleeding Risk and Costs for All	BUREAU - Pfizer Inc CONSULTANT FEES/HONORARIA - BMS
		Device Therapies	Causes and Bleeding-Related Health Services Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Apixaban or Warfarin	consultant,Pfizer,sanofi consultant
Lin	Jeffrey	Nuclear Cardiology: Beyond Perfusion	Reduced Dose Oral Glucose Load Yields Excellent Myocardial PET Viability Images	Nothing to Disclose
Lin	Lily	Congenital Heart Disease: Innovations in	Right Ventricular Remodelling in Hypoplastic Left Heart Syndrome:	Nothing to Disclose
Lin	Mao-Shin	Single Ventricle Heart Disease Head to Toe: Outcomes of Endovascular	Impact of the Norwood and Hybrid Procedures Improvement of Pituitary Function After Carotid Revascularization	Nothing to Disclose
Lin	Mao-Shin	Interventions Head to Toe: Outcomes of Endovascular	for Abnormal Cerebral Perfusion Long Term Clinical Outcomes After Endovascular Recanalization in	Nothing to Disclose
		Interventions	Patients With Chronic Carotid Artery Occlusion	-
Lin	Shoa-Lin	Mechanisms of Vascular Inflammation in Atherogenesis	Baculoviruses-Mediated Superoxide Dismutase Gene Therapy Inhibits Smooth Muscle Cell Proliferation, Migration, Inflammation, and Reactive Oxygen Species in Balloon-Injured Arteries	Nothing to Disclose
Lin	Yongqing	Interventional Cardiology: Stent Failure	Comparison of Optical Coherence Tomography Versus Intravascular Ultrasound Detection of Tissue Protrusion and Acute	Nothing to Disclose
		Analysis by Intravascuar Imaging	Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting	
Lin	Yong-Qing	Cutting Edge Vascular Medicine	Stent Implantation Transplanted Perivascular Adipose Tissue Promotes Destabilization	Nothing to Disclose
			of Atherosclerotic Plaque in Apolipoprotein E-Deficient Mice	-
Lin	Zhenqiu	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Admission Types Among Patients With Heart Failure Cared for by Accountable Care Organizations: Variation by Performance on a	Nothing to Disclose
Linares Koloffon	Carlos		Measure of Risk Standardized Acute Admission Rates	Nothing to Disclose
Linares Kolollon	Carlos	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Normalizing Platelet Reactivity of Cardiovascular Patients on Ticagrelor Therapy Using Fresh Platelets: Ex Vivo Testing of the Functional Recovery Attained Within 48-Hours of Stopping	Nothing to Disclose
Lincoff	A.	Vascular Medicine: Emerging Concepts in	Treatment Clevedipine as a Therapeutic and Cost-Effective Alternative to	CONSULTANT FEES/HONORARIA - Abbott,Sanofi-
		Clinical Vascular Diseases	Sodium Nitroprusside in Patients With Aortic Dissection	Aventis,Sarepta; RESEARCH/RESEARCH GRANTS - Amgen,Astra Zeneca,Cardiovascular
				Systems, Cerenis, Covidien, CSL Behring, Edwards
				Lifesciences, Esperion, Ethicon, Infraredx, Janssen, Johnson & Ethicon, Juventas, Lilly, Medicines
Lincoff	Α.	02. Acute and Stable Ischemic Heart Disease:	Suggested Pavious	Comapny,MEDTRONIC,Novartis,Orexigen,Pfizer,Takeda CONSULTANT FEES/HONORARIA - Abbott,Sanofi-
Lilicon	Α.	02. Acute and Stable Ischemic Heart Disease: Clinical Team 8	Suggested Reviewer	Aventis, Sarepta; RESEARCH/RESEARCH GRANTS -
				Amgen,Astra Zeneca,Cardiovascular Systems,Cerenis,Covidien,CSL Behring,Edwards
				Lifesciences, Esperion, Ethicon, Infraredx, Janssen, Johnson
				& Johnson,Juventas,Lilly,Medicines Comapny,MEDTRONIC,Novartis,Orexigen,Pfizer,Takeda
Lincoff	A. Michael	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Association Between Homeostasis Model Assessment of Insulin Resistance and Survival in Diabetic Patients With Acute Coronary	CONSULTANT FEES/HONORARIA - Abbott, Sanofi- Aventis, Sarepta; RESEARCH/RESEARCH GRANTS -
		Syndrome Syndrome	Syndromes: Insights From the AleCardio Trial	Amgen, Astra Zeneca, Cardiovascular
				Systems, Cerenis, Covidien, CSL Behring, Edwards Lifesciences, Esperion, Ethicon, Infraredx, Janssen, Johnson
				& Johnson, Juventas, Lilly, Medicines Comapny, MEDTRONIC, Novartis, Orexigen, Pfizer, Takeda
	Johan	Stroke and AF: Thinking About the Heart	Risk of Stroke in Women and Men With Atrial Fibrillation and Only	Nothing to Disclose
Lindbäck			One Additional CHA2DS2-VASc Risk Factor	
	Cecilia	Heart Failure: Implementing the Guidelines	IA Case of Heart Failure With Reduced Flection Fraction and Atrial	Nothing to Disclose
Lindbäck Linde	Cecilia	Heart Failure: Implementing the Guidelines Into Practice; A Clinical Case-Based	A Case of Heart Failure With Reduced Ejection Fraction and Atrial Fibrillation	Nothing to Disclose
	Cecilia	Into Practice; A Clinical Case-Based Symposium: International Perspectives From the European Society of Cardiology and the		Nothing to Disclose
	Cecilia	Into Practice; A Clinical Case-Based Symposium: International Perspectives From		Nothing to Disclose Nothing to Disclose

WASHINGTON, DC | MARCH 17 - 19 2017

and a				
Last Name Lindenauer	Peter	Session Title Predicting Outcomes in Cardiac Rehabilitation	Presentation Title Smoking Cessation Is Strongly Associated With Attendance at	Disclosures Nothing to Disclose
Lindenfeld	Joann	Patients Palliative Care for the 99% III: Skillbuilding: PC	Cardiac Rehab: But Which Comes First? Panelist	CONSULTANT FEES/HONORARIA - Abbott,Boston
		Encounters: What Would you do? Part II		Scientific, CardioMEMS, CVRx, Jaansen, Novartis Corporation, Relypsa, Resmed; OTHER - St. Jude; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Novartis
indenfeld	Joann	Heart Failure: Implementing the Guidelines Into Practice; A Clinical Case-Based	A Case of End-Stage Heart Failure	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,CardioMEMS,CVRx,Jaansen,Novartis
		Symposium: International Perspectives From the European Society of Cardiology and the American College of Cardiology		Corporation,Relypsa,Resmed; OTHER - St. Jude; RESEARCH/RESEARCH GRANTS - Astra Zeneca,Novartis
Lindenfeld	JoAnn	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Surrogate Endpoints and the Differential Response to ASV for Sleep Apnea in HFrEF Versus HFpEF in the CAT-HF Trial	Scientific,CardioMEMS,CVRx,Jaansen,Novartis Corporation,Relypsa,Resmed; OTHER - St. Jude;
Lindenfeld	Joann	Leading Us Astray? Pacemakers in Cardiomyopathies	ACC Poster Moderator	RESEARCH/RESEARCH GRANTS - Astra Zeneca Novartis CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,CardioMEMS,CVRx,Jaansen,Novartis Corporation,Relypsa,Resmed; OTHER - St. Jude;
Linderbaum	Jane	Case Studies from the Guidelines for Clinicians	Co-Chair	RESEARCH/RESEARCH GRANTS - Astra Zeneca,Novartis Nothing to Disclose
Linderbaum	Jane	Case Studies from the Guidelines for Clinicians	Structural Heart Disease Cases	Nothing to Disclose
Linderbaum	Jane	Cardiovascular Team Cases: Team 1	Suggested Reviewer	Nothing to Disclose
Lindley Lindman	Kathryn Brian	Sex Disparity in VHD Outcomes Palliative Care for the 99% II: Skillbuilding: PC	ACC Poster Moderator Panelist	Nothing to Disclose CONSULTANT FEES/HONORARIA - Roche Diagnostics;
Lindman	Brian	Encounters: What Would you do? Part I Innovations in Valvular Heart Disease	New Biomarkers for Valvular Heart Disease Assessment	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,Roche Diagnostics CONSULTANT FEES/HONORARIA - Roche Diagnostics;
		Diagnosis and Treatment		RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,Roche Diagnostics
Lindman	Brian	Aortic Stenosis: Overview of the Hemodynamics and Ventricular Response	Co-Chair	CONSULTANT FEES/HONORARIA - Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,Roche Diagnostics
Lindman	Brian	Highlighted Original Research: Interventional Cardiology and the Year in Review	Implications of Worsening Right Ventricular Function Following Transcatheter or Surgical Aortic Valve Replacement: Insights From PARTNER2A	CONSULTANT FEES/HONORARIA - Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,Roche Diagnostics
Lindman	Brian	Interventional Cardiology: TAVR 1	Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: Insights From PARTNER 2A Trial	CONSULTANT FEES/HONORARIA - Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,Roche Diagnostics
Lindman	Brian	Making Progress in Understanding Heart Failure	Global Longitudinal Strain Predicts Sustained Recovery of LV Ejection Fraction in Heart Failure Patients on Evidence Based Medical Therapies	CONSULTANT FEES/HONORARIA - Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,Roche Diagnostics
Lindman	Brian	Interventional Cardiology: TAVR 2	Worsening Tricuspid Regurgitation and Increased Mortality After Aortic Valve Replacement: Insights From PARTNER2A	CONSULTANT FEES/HONORARIA - Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,Roche Diagnostics
Lindman	Brian	Interventional Cardiology: TAVR 4	Serum Albumin as an Incremental Predictor of Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement: Results From the Multicenter Frailty-AVR Study	CONSULTANT FEES/HONORARIA - Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,Roche Diagnostics
Lindman	Brian	Interventional Cardiology: TAVR 4	Depression as a Potential Therapeutic Target to Improve Quality of Life After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,Roche Diagnostics
Lindman	Brian	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low- Flow Severe Aortic Stenosis and Less Reverse Remodeling After TAVR: A Partner 2 Trial Analysis	CONSULTANT FEES/HONORARIA - Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,Roche Diagnostics
Lindner	Jonathan	Echocardiography: What is New in 2017	Co-Chair	RESEARCH/RESEARCH GRANTS - Astellas,Bracco,GE Healthcare
Lindner	Jonathan	Role of Imaging in Peripheral Artery Disease	Ultrasound Imaging in PAD	RESEARCH/RESEARCH GRANTS - Astellas,Bracco,GE Healthcare
Lindner	Jonathan	28. Non Invasive Imaging: Echo Team 3	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Astellas, Bracco, GE
Lindquist	Ingrid	Updates on Risk Factors for Cardiovascular	A Vaccine-Based Strategy for Reducing Cardiovascular Disease	Healthcare Nothing to Disclose
Lindsay	Bruce	Disease 05. Arrhythmias and Clinical EP: Devices Team 2	Risk Factors Suggested Reviewer	CONSULTANT FEES/HONORARIA - Biosence Webster,Boston Scientific,MEDTRONIC; OTHER - Boston
Lindsay	Mark	Vascular Medicine: Emerging Concepts in	Influence of Family History of Aortic Disease on Type B Aortic	Scientific,MEDTRONIC,St. Jude Nothing to Disclose
Lindsay	Martin	Clinical Vascular Diseases Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Dissection Segmental Circumferential Strain Derived From DENSE Predicts Improvement of Left Ventricular Function Post ST Elevation	Nothing to Disclose
Lindsay	Martin		Myocardial Infarction: The BHF MR-MI Study	Nothing to Disclose
Lindany	Martin	Syndrome Non Invasive Imaging: MR Structure and	Pathophysiological Insights Hypertension, Microvascular Pathology and Prognosis in Patients	Nothing to Disclose
Lindsay	Mitchell	Valuvular Heart Disease Interventional Cardiology: Intravascular	With an Acute ST-Segment Elevation Myocardial Infarction Decision Making Using Fractional Flow Reserve Is Associated With	Nothing to Disclose
		Physiology and Endothelial Function	Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With Nstemi	
Ling	Hua Zen	Making Progress in Understanding Heart Failure	Prognostic Utility of Haemoglobin/Haematocrit Equations for Estimating Congestion Versus Calculated Plasma Volume Status in Chronic Heart Failure	Nothing to Disclose
Ling	Lieng	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Chronic Kidney Disease in Asian Patients With Heart Failure	Nothing to Disclose
Ling	Lieng	Unusual Presentations of ACS	Prevalence and Evolution of Sleep Disordered Breathing in Acute Myocardial Infarction	Nothing to Disclose
Lingohr-Smith	Melissa	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Real World Evaluation of Major Bleeding Risk and Costs for All Causes and Bleeding-Related Health Services Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Apixaban or Warfarin	SALARY - Novosys Health
Link	Christopher	Nuclear Cardiology: Beyond Perfusion	Regional Right Ventricular (RV) Function as Determined by Gated Blood Pool SPECT (GBPS) Provides Additive Value to Evaluation of Patients Undergoing Left Ventricular Assist Device (LVAD)	Nothing to Disclose
Link	Christopher	Nuclear Cardiology: Quality	Implantation Repeatability of Appropriateness Category Allocation by Trained	Nothing to Disclose
Link	Mark	How Hypertrophic Cardiomyopathy Became A Contemporary Treatable Genetic Heart	Physicians Panelist	RESEARCH/RESEARCH GRANTS - Unequal Technologies
Link	Mark	Disease Fibrillatory Arrhythmias: Outcomes With	Antiarrhythmic Medications for Atrial Fibrillation Appear Reasonably	RESEARCH/RESEARCH GRANTS - Unequal Technologies
Link	Mark	Contemporary Practice Arrhythmias and Clinical EP: Basic 2	Safe in Hypertrophic Cardiomyopathy Atrial Fibrillation Is Associated With Low Cardiovascular Mortality in	RESEARCH/RESEARCH GRANTS - Unequal Technologies
	IVIGITY	, a.r.yaminas and omildal Er . Dasic 2	Hypertrophic Cardiomyopathy	The second control of the second control of



I and Marris	First Name	Consider Title	December 7 Mar.	Diselecture
Last Name Link	First Name Mark	Session Title 07. Arrhythmias and Clinical EP: Sports and Exercise Team 1	Presentation Title Suggested Reviewer	Disclosures RESEARCH/RESEARCH GRANTS - Unequal Technologies
Linke	Axel	Interventional Cardiology: TAVR 2	Different Impact of Gender on Early and Late Outcome After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Linke	Axel	Interventional Cardiology: TAVR 2	Hainscameter Actic valve Replacement Higher B-Type Natriuretic Peptide Levels Predict Occurrence of Acute Kidney Injury After Transcatheter Acrtic Valve Replacement	Nothing to Disclose
Linke	Axel	Interventional Cardiology: TAVR 2	Impact of Mycardial Injury Indicated by Increased Creatinine Kinases Mycardial Band Levels on the Outcome After Transcatheter Aortic Valve Replacement: Results From a Prospective Single Center Registry	Nothing to Disclose
Linke	Axel	Interventional Cardiology: PCI and TAVR in Complex Patients	Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the Bravo-3 Randomized Trial	Nothing to Disclose
Linke	Axel	Interventional Cardiology: TAVR 3	Does Balloon Predilatation Influence Outcome With the Lotus Valve: 30-Day Results From the RESPOND Study	Nothing to Disclose
Linke	Axel	Interventional Cardiology: TAVR 4	Impact of Cancer Disease on Outcome of Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Lip	Greg	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Rates of Stroke and Bleeding With Dabigatran 150 and 110 mg BID in Clinical Practice: The GLORIA-AF Registry	CONSULTANT FEES/HONORARIA - Astellas Pharma US,AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Biotronik, Boehringer Ingelheim Pharmaceuticals, Inc.,Bristol-Myers Squibb Company, Merck 8amp;amp; Co., Inc.,Pfizer Inc,Portola,Sanofi-Aventis; SPEAKER'S BUREAU - Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc.,Bristol-Myers Squibb Company, Pfizer Inc,Sanofi-Aventis
Lip	Gregory	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Incident Atrial Fibrillation According to Gender In Patients With Ischemic Stroke: A Nationwide Cohort Study	CONSULTANT FEES/HONORARIA - Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife and Dalichi-Sankyo. SPEAKER'S BUREAU - Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Dalichi-Sankyo
Lip	Gregory	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Persistence With Therapy in Patients With Atrial Fibrillation: The GLORIA-AF Registry	CONSULTANT FEES/HONORARIA - Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Inagelheim, Microlife and Dailchi-Sankyo. SPEAKER'S BUREAU - Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Dailchi- Sankyo
Lip	Gregory	Atrial Fibrillation and VT: Unique Populations and Solutions	Predictors of Anticoagulant Prescription in Patients With Atrial Fibrillation in North America: The GLORIA-AF Registry	CONSULTANT FEES/HONORARIA - Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife and Daiichi-Sankyo.; SPEAKER'S BUREAU - Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-
Lip	Gregory	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Increased Rate of Previous Stroke in Asymptomatic/Minimally Symptomatic Versus Symptomatic Patients With Newly Detected Atrial Fibrillation Worldwide: Results From the GLORIA-AF Registry	Sankyo CONSULTANT FEES/HONORARIA - Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife and Daiichi-Sankyo.; SPEAKER'S BUREAU - Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi- Sankyo
Lip	Gregory	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Edoxaban Therapy Increases Treatment Satisfaction and Reduces Utilization of Health Care Resources: An Analysis From the Edoxaban versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) Study	CONSULTANT FEES/HONORARIA - Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife and Daiichi-Sankyo.; SPEAKER'S BUREAU - Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi- Sankyo
Lip	Gregory	Stroke and AF: Thinking About the Heart	Predictors of Incident Atrial Fibrillation in Patients With Ischemic Stroke: A Nationwide Cohort Study	CONSULTANT FEES/HONORARIA - Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife and Dalichi-Sankyo. : SPEAKER'S BUREAU - Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Dalichi-Sankyo
Lipinski	Michael	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Is There a Role for Invasive Electrophysiology Studies in Patients With Conduction Abnormalities Following Transcatheter Aortic Valve Replacement?	RESEARCH/RESEARCH GRANTS - Medicure Inc
Lipner	Rebecca	Innovations in Education	ACC In-Training Examination Predicts Outcomes on the ABIM Certification Examination	Nothing to Disclose
Lippmann	Matthew	Interventional Cardiology: Structural Heart Disease	Safety and Feasibility of Rotational Atherectomy in Elderly Patients With Severe Aortic Stenosis and Calcific Coronary Artery Disease Undergoing Evaluation for Transcatheter Aortic Valve Replacement	Nothing to Disclose
Lipshultz	Steven	Heart Failure and Cancer Care	Debate: No One Should be Started on an ACE-Inhibitor or Angiotensin Receptor Blocker to Mitigate Cardiomyopathy with Cancer Therapy, Con	CONSULTANT FEES/HONORARIA - Clinigen Group plc; DATA SAFETY MONITORING BOARD - Axio Research
Lipska	Kasia	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Admission Types Among Patients With Heart Failure Cared for by Accountable Care Organizations: Variation by Performance on a Measure of Risk Standardized Acute Admission Rates	Nothing to Disclose
Lisko	John		Reverse Takotsubo Cardiomyopathy Associated With Mediastinal Paraganglioma	Nothing to Disclose
Liszkowski	Mark	Pulmonary Hypertension The Evolving World of LVADs, Transplant and Other Novel Discoveries	Changes in Prevalence, Progression and Outcomes of Coronary Allograft Vasculopathy Over 25 Years Following Cardiac Transplantation: A Single Center Experience	CONSULTANT FEES/HONORARIA - Bayer
L'Italien	Kaitlin	Congenital Heart Disease: New Diagnostic	Utility of Genetic Testing in Infants With Isolated Congenital Heart	Nothing to Disclose
Litt	Harold	Approaches in Congenital Heart Disease Great Debates in Cardiac CT	Disease Debate: Coronary CTA is the Test of Choice in Low-intermediate	RESEARCH/RESEARCH GRANTS - Siemens Medical Solutions
Litt	Harold	Great Debates in Cardiac CT	Risk Acute Chest Pain, Pro Rebuttal, Pro	RESEARCH/RESEARCH GRANTS - Siemens Medical Solutions
Little	Stephen	Imaging for TAVR: Homing in on the Real	Co-Chair	RESEARCH/RESEARCH GRANTS - Abbott
Little	Stephen	Innovations in Valvular Heart Disease	Co-Chair	Laboratories,Medtronic Inc RESEARCH/RESEARCH GRANTS - Abbott
Little	Stephen	Diagnosis and Treatment Innovations in Valvular Heart Disease	3D Bioprinting for Valvular Heart Disease and Individualized	Laboratories,Medtronic Inc RESEARCH/RESEARCH GRANTS - Abbott
Little	Stephen	Diagnosis and Treatment TAVR: What We've Learned and Where We	Interventions How Low Should We Go? The Transition to Low Risk	Laboratories,Medtronic Inc RESEARCH/RESEARCH GRANTS - Abbott
Little	Stephen	Think We're Going! Prosthetic Valve Assessment: Real or Illusion?	Down the Middle or On the Side: Transcatheter Solutions for	Laboratories,Medtronic Inc RESEARCH/RESEARCH GRANTS - Abbott
Little	Stephen	FIT Clinical Decision Making: Non-Invasive	Prosthetic Valve Leaks Successful Management of Acute Salmonella Aortitis	Laboratories,Medtronic Inc RESEARCH/RESEARCH GRANTS - Abbott
Little	Stephen	Imaging and Valvular Heart Disease Valvular Heart Disease: Mitral Valve Disease	Inter-Study Reproducibility of Mitral Regurgitation Quantitation Using	Laboratories,Medtronic Inc RESEARCH/RESEARCH GRANTS - Abbott
Little	Stephen	Structural Heart Interventions: Focus on Mitral	Cardiac Magnetic Resonance Imaging 3D Printed Patient-Specific Multi-Material Modeling of Mitral Valve	Laboratories,Medtronic Inc RESEARCH/RESEARCH GRANTS - Abbott
Little	Stephen		Apparatus Patient With a Systolic Murmur and Shock: Importance of the	Laboratories,Medtronic Inc RESEARCH/RESEARCH GRANTS - Abbott
Little	Stephen	Pulmonary Hypertension 28. Non Invasive Imaging: Echo Team 3	Physical Suggested Reviewer	Laboratories,Medtronic Inc RESEARCH/RESEARCH GRANTS - Abbott
Littrell	Rachel	FIT Clinical Decision Making: Arrhythmias and	Sarcoidosis Presenting as Complete Heart Block in a Young	Laboratories,Medtronic Inc Nothing to Disclose
		Electrophysiology	Morbidly Obese Patient With Severe Obstructive Sleep Apnea and on Beta Blocker	

Contract of the second				
Last Name Litwin	First Name Sheldon	Session Title Making Progress in Understanding Heart	Presentation Title Is There a Cardiomyopathy of Obesity? 10 Year Longitudinal Follow	Disclosures CONSULTANT FEES/HONORARIA - Bracco; OTHER - CVRx
		Failure	Up of Severely Obese Patients in the Utah Obesity Study	
Litwin	Sheldon	Imaging With Cardiac CT: The Case for Calcium	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Bracco; OTHER - CVRx
Litwin	Sheldon	New Perspectives on CAD Risk Factors	Discordances Between Predicted and Actual Risk of Adverse Events in Obese Patients With Suspected Cardiac Ischemia: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	CONSULTANT FEES/HONORARIA - Bracco; OTHER - CVRx
Litwin	Sheldon	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Bracco; OTHER - CVRx
Litwok	Yonathon	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Early Unloading With Impella Support in Acute MI With Cardiogenic Shock Linked to Decreased Infarct Size, In-Hospital Mortality, and Hospital Length of Stay	Nothing to Disclose
Liu	Christopher	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System	RESEARCH/RESEARCH GRANTS - Biosense Webster; SPEAKER'S BUREAU - St. Jude Medical
Liu	Christopher	Stroke and AF: Thinking About the Heart	Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy: Insights Into Rates and Timing of Thrombus Resolution	RESEARCH/RESEARCH GRANTS - Biosense Webster; SPEAKER'S BUREAU - St. Jude Medical
Liu	Hua	Congenital Heart Disease: Progress in	Validation of Technical Performance Score for Long-Term	Nothing to Disclose
Liu	Jim	Pediatric Heart Surgery FIT Clinical Decision Making: Non-Invasive	Outcomes in Congenital Heart Surgery: 10 Year Follow-Up Data Mitral Valve Regurgitation From Hypereosinophilic Syndrome	Nothing to Disclose
Liu	Kiang	Imaging and Valvular Heart Disease Insights From Echocardiography Use	Relation of Left Ventricular Remodeling to Left Ventricular Diastolic	Nothing to Disclose
			Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	
Liu	Kiang	Insights From Echocardiography Use	Relation of Left Ventricular Remodeling to Left Ventricular Systolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	Nothing to Disclose
Liu	Kiang	Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools	Association of 10-Year Change in Cardiovascular Risk Factors With Progression of Pericardial Adipose Tissue: The CARDIA Study	Nothing to Disclose
Liu	Lishun	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Serum Homocysteine Lowering by Long-Term Low-Dose Folic Acid: New Insight on <>MTHFR Gene-Folate Interaction From China Stroke Primary Prevention Trial	Nothing to Disclose
Liu	Michael	Congenital Heart Disease: Innovations in	Hypoplastic Left Heart Syndrome With Intact or Restrictive Atrial	Nothing to Disclose
Liu	Michael	Single Ventricle Heart Disease Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Septum:What Happens After Survival? From Fetus to Fontan: A Single Center Experience of Resource Utilization for Patients Diagnosed With Single Ventricle Cardiac	Nothing to Disclose
Liu	Shangyu	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Defects Baseline Serum High Density Lipoprotein Cholesterol Level Predicts Long-Term Clinical Outcomes in Patients With Heart Failure	Nothing to Disclose
15	China	-	Receiving Cardiac Resynchronization Therapy Long-Term Effects of Right Ventricular Pacing on Left Ventricular	Nething to Displace
Liu	Shuang	Novel Echocardiographic Methods for Assessing Cardiac Function	Systolic and Diastolic Function and Synchrony by Strain Imaging in Patients With Normal Baseline Left Ventricular Ejection Fraction	Nothing to Disclose
Liu	Shuang	Leading Us Astray? Pacemakers in Cardiomyopathies	Chronic Right Ventricular Pacing: Effects on Heart Failure Hospitalization and Mortality in the Presence of Normal Left Ventricular Ejection Fraction	Nothing to Disclose
Liu	Shuangbo	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease		Nothing to Disclose
Liu	Stanley	Innovations in Education	Electrocardiogram Training for Residents: A Curriculum Based on	Nothing to Disclose
Liu	Victor	Atrial Fibrillation and VT: Unique Populations and Solutions	Facebook and Twitter A Retrospective Study of the Effect of Colchicine Administration Timing on the Incidence of Post-Operative Atrial Fibrillation After a Non Transplant Cardiac Surgery	Nothing to Disclose
Liu	Xiaoqing	Congenital Heart Disease: New Diagnostic	Variation in Prenatal Diagnosis of Congenital Heart Defects in a	Nothing to Disclose
Liu	Yen-Wen	Approaches in Congenital Heart Disease Interventional Cardiology: Translation and Pre-	Population-Based Study in Southern China A Clonal Population of Allogeneic Bone Marrow Fibroblasts	SALARY - National Cheng Kung University Hospital
		Clinical Research	Indirectly Mitigates Damage in Myocardial Infarction The Impact of Echocardiography Parameter on the Outcome in	SALARY - National Cheng Kung University Hospital
Liu	Yen-Wen	Innovations in Cardiovascular Risk Assessment and Reduction	Patients Receiving Non-Cardiac Surgery	
Liu	Yong	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	The Contrast Volume to Creatinine Clearance Ratio Predicts Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Liu	Yuyin	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Early Versus Late Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome: Insights From the Examine Trial	Nothing to Disclose
Liu	Yuyin	The Intersection of Diabetes and ASCVD	Average Clinician Measured Blood Pressure Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes Following Acute	Nothing to Disclose
Liuzzo	Giovanna	Insights Into Ischemic Heart Disease: Stable to	Coronary Syndromes in the EXAMINE Trial Hyaluronic Acid, Hyaluronidase-2 and Acute Coronary Syndromes:	Nothing to Disclose
Liuzzo	Giovanna	Erosive Plaques Unusual Presentations of ACS	Possible Correlation With Plaque Erosion Matrix Metalloproteinase 9 Drives the Shedding of CD31 in Acute	Nothing to Disclose
Ljung	Rickard	Acute Coronary Syndromes, Diagnosis,	Coronary Syndromes High-Sensitivity Cardiac Troponin T Levels and Long-Term Mortality	Nothing to Disclose
Llanos-Chea	Fiorella	Management and Outcomes Atrial Fibrillation and VT: Unique Populations and Solutions	in Patients With Chest Pain A Retrospective Study of the Effect of Colchicine Administration Timing on the Incidence of Post-Operative Atrial Fibrillation After a	Nothing to Disclose
Llanos-Chea	Fiorella	The Challenges of Outcome Prediction in	Non Transplant Cardiac Surgery Gender-Based Outcomes in Diabetics Undergoing Transcatheter	Nothing to Disclose
Lloyd	Amelia	Valvular Heart Disease Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Aortic Valve Replacement Investigating the Smoker's Paradox by Gender: Differences in Survival Following Acute ST-Segment Elevation Myocardial	Nothing to Disclose
I I a cod	Amalia		Infarction	Nothing to Displace
Lloyd	Amelia	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Increased Risk of Acute ST-Segment Myocardial Infarction in Female Smokers: A Contemporary Demographic Study	Nothing to Disclose
Lloyd	Michael	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Refractory Electrical Storm as the Initial Presentation of Presumed Cardiac Sarcoidosis Treated With Left Stellate Ganglion Block	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Lloyd	Steven	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Antihypertensive Treatment Failure Not Attributable to Persistent Intravascular Fluid Retention as Determined by MRI-Measured Intracardiac Volumes	Nothing to Disclose
Lloyd-Jones	Donald	Making Progress in Understanding Heart Failure	Associations of HIV Related Factors With Adjudicated Heart Failure (HF) in an Electronic Cohort of HIV-Infected (HIV+) Persons	Nothing to Disclose
Lloyd-Jones	Donald	Current Issues in Cardiovascular	Sudden Cardiac Death Risk Distribution in the United States Population: Results From the National Health and Nutrition	Nothing to Disclose
		Epidemiology, Disparities, and Safety	Examination Survey (NHANES), 2005-2012	

The state of the s				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Lloyd-Jones	Donald	Non Invasive Imaging: Prognostic Implications of CT Angiography	Coronary Artery Structural Remodeling by Computed Tomography and Echocardiographic Left Ventricular Mass Changes Over the Next 5 Years: The Coronary Artery Risk Development in Young	Nothing to Disclose
Lloyd-Jones	Donald	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Adults (CARDIA) Study Atrial Fibrillation (AF) and Atrial Flutter (AFL) Prevalence and Characteristics for Persons With Human Immunodeficiency Virus	Nothing to Disclose
Lloyd-Jones	Donald	Insights From Echocardiography Use	(HIV+) and Matched Uninfected Controls Relation of Left Ventricular Remodeling to Left Ventricular Diastolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	Nothing to Disclose
Lloyd-Jones	Donald	Insights From Echocardiography Use	Relation of Left Ventricular Remodeling to Left Ventricular Systolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	Nothing to Disclose
Lloyd-Jones	Donald	32. Prevention: Clinical Team 6	Suggested Reviewer	Nothing to Disclose
Lluberas	Ricardo	New Perspectives on Structural Valve Disease: International Perspectives From the Emirates Cardiac Society, Latin American Society of Interventional Cardiology (SOLACI), and American College of Cardiology	Co-Chair	Nothing to Disclose
Lo Presti	Saberio	Emerging Developments in HFpEF and Arryhthmias	Prevalence of Transthyretin Cardiac Amyloidosis in Patients With Heart Failure and Preserved Ejection Fraction Using the ^{99m} Tc-Pyrophosphate Scintigraphy	Nothing to Disclose
Lo Presti	Saberio	Arrhythmias and Clinical EP: Devices 4	ECG Criteria for the Identification of Bi-Ventricular Pacing	Nothing to Disclose
Lobo	Ronstan	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Peripheral Endothelial Function Assessment of Patients on Ticagrelor Versus Clopidogrel Who Have Undergone Percutaneous Coronary Intervention: A Randomized, Crossover Study	Nothing to Disclose
Loccoh	Emefah	Understanding Pulmonary Vascular Disease: From Bench to Bedside	Potential Mediators of Right Heart Failure in Pulmonary Arterial	Nothing to Disclose
Lock	James	Congenital Heart Disease Surgery: Updates	Hypertension Targeted Increase in Pulmonary Blood Flow in a Bidirectional Glenn	Nothing to Disclose
Locke	Andrew	and Innovations Interdisciplinary Cardiovascular Care in	Circulation Thirteen Lives: Massive Pulmonary Embolism Causing Twelve	Nothing to Disclose
		Complex Scenarios	Episodes of Cardiac Arrest Managed by an Interdisciplinary Pulmonary Embolism Consult Team	-
Lockwood	Evan	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Concomitant Use of Antiplatelet and Oral Anticoagulation Among Patients With Atrial Fibrillation: Insights From the Prospective SPRINT-AF Registry	CONSULTANT FEES/HONORARIA - Bayer,BMS-Pfizer; RESEARCH/RESEARCH GRANTS - SJM; SPEAKER'S BUREAU - Boerhinger,MEDTRONIC
Loebe	Susanne	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Cardiac Magnetic Resonance Imaging After Radiofrequency Ablation of Ventricular Arrhythmias in Human Patients: Defining the Substrate and Visualizing the Outcome	Nothing to Disclose
Loehr	Laura	Improving Risk Assessment in Atherosclerosis	Development and Validation of Prediction Models With Non- Traditional Markers for 10-Year Risk of Ischemic Leg Amputation Among Persons With Diabetes: The Atherosclerosis Risk In Communities (ARIC) Study	Nothing to Disclose
Loffler	Adrian	FIT Clinical Decision Making: Non-Invasive	Recurrent Focal Myocarditis With Microvascular Obstruction	Nothing to Disclose
Loffler	Adrian	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Phlegmasia Cerulea Dolens With Circulatory Shock	Nothing to Disclose
Logue	Michael	Disease, and Vascular Medicine FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Unusual Presentation of Psuedo Stemi	Nothing to Disclose
Loh	Joshua	Disease, and Vascular Medicine Coronary Intervention: Drug Eluting Stent and Scaffolds	Safety and Efficacy of Small Vessel Stenting With 2 mm Drug Eluting Stents in Real World Clinical Practice	Nothing to Disclose
Loh	Joshua	Coronary Intervention in Interventional Cardiology: Core Concepts	Incidence and Predictors of Target Lesion Failure in a Multi-Ethnic Asian Population Receiving the SYNERGY Coronary Stent: A Prospective All-Comers Registry	Nothing to Disclose
Loh	Poay Huan	Coronary Intervention: Drug Eluting Stent and Scaffolds	Safety and Efficacy of Small Vessel Stenting With 2 mm Drug Eluting Stents in Real World Clinical Practice	Nothing to Disclose
Loh	Poay Huan	Coronary Intervention in Interventional Cardiology: Core Concepts	Incidence and Predictors of Target Lesion Failure in a Multi-Ethnic Asian Population Receiving the SYNERGY Coronary Stent: A Prospective All-Comers Registry	Nothing to Disclose
Lohr	Nicole	Innovations in Practice Management and Social Media	Unlocking the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for Today's Complex Care Delivery	Nothing to Disclose
Lokhnygina	Yuliya	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Patient-REported Preferences Affecting Revascularization Decisions (PREPARED): A Pilot Randomized Study of Shared Decision-Making	Nothing to Disclose
Lo-Kioeng-Shioe	Mallory	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Calcium Characteristics as Predictors of Major Adverse Cardiac Events in Symptomatic Patients: Insights From the CORE320 Multinational Study	Nothing to Disclose
Lokki	Marja-Liisa	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	A Risk Locus for Non-ST-Elevation Myocardial Infarction on Chromosome 1p13.3 Is Also Associated With Peripheral Artery Disease in Patients With Acute Coronary Syndrome	Nothing to Disclose
Loldrup Fosbøl	Emil	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Vitamin K Antagonist or Dabigatran in Patients With Atrial Fibrillation: The Importance of Time in Therapeutic Range	Nothing to Disclose
Loli	Akil	Structural Heart Interventions: Focus on Mitral	Comparing TEE With Angiographic Sizing of WATCHMAN Device	Nothing to Disclose
Lombardi	Guido	Valve, Left Atrial Appendage and HOCM Featured Clinical Research I	for Left Atrial Appendage Closure Native South American Tsimane Have the Lowest Levels of Coronary Atherosclerosis Ever Reported	Nothing to Disclose
Lombardi	William	Chronic Total Occlusion PCI: A Case-Based	Co-Chair	CONSULTANT FEES/HONORARIA - Vascular Solutions;
Lombardi	William	Review of Contemporary Techniques Chronic Total Occlusion PCI: A Case-Based	Case Presentation: Hybrid CTO	OTHER - Corindus, Spectranetics CONSULTANT FEES/HONORARIA - Vascular Solutions;
Lombardi	William	Review of Contemporary Techniques Complex PCI in 2017	CTO Update: Latest Developments	OTHER - Corindus, Spectranetics CONSULTANT FEES/HONORARIA - Vascular Solutions;
Lombardi	William	Overuse, Underuse or Just Right? Fundamental Debates in High Risk PCI in 2017	Chronic Total Occlusion PCI: Underused, Underappreciated	OTHER - Corindus, Spectranetics CONSULTANT FEES/HONORARIA - Vascular Solutions; OTHER - Corindus, Spectranetics
Lombardi	William	Training for Interventional Procedures: Who Should Do What, Where, When, How, and Why	Debate Pro: The Time for Even Tighter Regulations on Training Is Here	CONSULTANT FEES/HONORARIA - Vascular Solutions; OTHER - Corindus,Spectranetics
Lombardi	William	Advances in Chronic Total Occlusion Intervention	Association of Stress Test Risk Classification With Health Status Change After Chronic Total Occlusion PCI: Insights From the OPEN-ICTO Registry	CONSULTANT FEES/HONORARIA - Vascular Solutions; OTHER - Corindus, Spectranetics
Lombardi	William	Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	CONSULTANT FEES/HONORARIA - Vascular Solutions; OTHER - Corindus,Spectranetics
Lombardi	William	Advances in Chronic Total Occlusion Intervention	Hemodynamically-Supported PCI of Chronic Total Occlusions: A Case Series	CONSULTANT FEES/HONORARIA - Vascular Solutions; OTHER - Corindus,Spectranetics
Lombardi	William	Advances in Chronic Total Occlusion	Application and Outcomes of the Hybrid Approach to Chronic Total	CONSULTANT FEES/HONORARIA - Vascular Solutions;
		Intervention	Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	OTHER - Corindus,Spectranetics



Last Name	First Name	Session Title	Presentation Title	Disclosures
Lombardi	William	Advances in Chronic Total Occlusion Intervention	Impact of Sex on Physical Limitation & Patient Health Status After Chronic Total Occlusion Percutaneous Coronary Intervention: Propensity Matched Substudy of OPEN-CTO Registry	CONSULTANT FEES/HONORARIA - Vascular Solutions; OTHER - Corindus, Spectranetics
Lombardi	William	Advances in Chronic Total Occlusion Intervention	Health Status Benefits of Successful Chronic Total Occlusion PCI in Patients With Depressed Left Ventricular Systolic Function: Insights From the OPEN-CTO Registry	CONSULTANT FEES/HONORARIA - Vascular Solutions; OTHER - Corindus,Spectranetics
Lombardi	William	Coronary Intervention in Interventional Cardiology: Core Concepts	Combined Drug-Eluting Balloon and Brachytherapy to Treat In-Stent Restenosis: Early Safety and Efficacy	CONSULTANT FEES/HONORARIA - Vascular Solutions; OTHER - Corindus,Spectranetics
Lombardi	William	Refining PCI Technique and Outcomes	Appropriate Use Criteria and Health Status Outcomes After CTO PCI: Results From the OPEN CTO Registry	CONSULTANT FEES/HONORARIA - Vascular Solutions; OTHER - Corindus,Spectranetics
Lombardi	William	22. Interventional Cardiology: Coronary Intervention: Left Main, Multivessel, Bifurcation Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Vascular Solutions; OTHER - Corindus, Spectranetics
Lombardo	Dawn	Advances in HCM, PPCM and Other Cardiomyopathies	High Versus Standard Protein Diets in Obese Patients With Heart Failure: Effects on Chronic Disease Risks	Nothing to Disclose
London	Barry	Cardiac Channelopathies: Novel Therapeutics and Clinical Challenges	Compound <>SCN5A Mutation and <>FGF12 Variation Cause Brugada Syndrome	Nothing to Disclose
Longoria	James	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	S-Year Outcomes of a Staged Hybrid Surgical and Catheter-Based Ablation Approach for Treatment of Long-Standing Persistent Atrial Fibrillation	OTHER - AtriCure
Lonn	Eva	Strategies for Prevention of Cardiovascular Disease: International Perspectives From the Canadian Cardiovascular Society, Cardiac Society of Australia and New Zealand, and American College of Cardiology	Hope 3 Papers: Lessons in Prevention	CONSULTANT FEES/HONORARIA - Amgen, Bayer Healthcare Pharmaceuticals, Novartis canada, Sanofi-Aventis, Servier Canada; DATA SAFETY MONITORING BOARD - Resvirologix, The Medicines Company; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Bayer Healthcare Pharmaceuticals
Lonn	Eva	Emerging Concepts in Evaluation and Management of Hypertension	Panelist	CONSULTANT FEES/HONORARIA - Amgen Bayer Healthcare Pharmaceuticals, Novaris canada, Sanofi-Aventis, Servier Canada; DATA SAFETY MONITORING BOARD - Resvirologix, The Medicines Company, RESEARCH/RESEARCH GRANTS - Astra Zeneca, Bayer Healthcare Pharmaceuticals.
Lonn	Eva	Emerging Concepts in Evaluation and Management of Hypertension	Is Lowering Blood Pressure Effective for Primary Prevention: Implications of the HOPE-3 Trial	CONSULTANT FEES/HONORARIA - Amgen, Bayer Healthcare Pharmaceuticals, Novartis canada, Sanofi-Aventis, Servier Canada; DATA SAFETY MONITORING BOARD - Resvirologix, The Medicines Company, RESEARCH/RESEARCH GRANTS - Astra Zeneca, Bayer Healthcare Pharmaceuticals.
Loo	Germaine	Updates on Risk Factors for Cardiovascular Disease	Obstructive Sleep Apnea and Coronary Risk in Health Screening Clinic	Nothing to Disclose
Loo	Germaine	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Impact of Mild Obstructive Sleep Apnea on and Cardiovascular Events After Percutaneous Coronary Intervention	Nothing to Disclose
Lookstein	Robert	26. Interventional Cardiology: Vascular Access and Complications Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific, The Medicines Company, DATA SAFETY MONITORING BOARD - Shockwave
Loomba	Rohit	Congenital Heart Disease: Progress in Pediatric Heart Surgery	The Aortic Perfusion Score: A Novel Scoring System to Predict Death or Transplant in Children With Pulmonary Atresia With Intact Ventricular Septum	Nothing to Disclose
Lopatto	Jess	Arrhythmias and Clinical EP: Devices 2	Antibacterial Envelope Is Associated With Medical Cost Savings in Patients at High Risk for Cardiovascular Implantable Electronic Device Infection	SALARY - MEDTRONIC
Lopes	Ranato	Insights From Echocardiography Use	Universal Use of Contrast to Detect Left Ventricular Thrombus in Patients With Reduced Ejection Fraction is Not Associated With Improved Clinical or Cost-Effectiveness Outcomes	CONSULTANT FEES/HONORARIA - Bayer, Boehringer Ingleheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxosmithKline, MEDTRONIC, Merck & Co., Inc., Pfizer, Portola; RESEARCH/RESEARCH GRANTS - Bristol- Myers Squibb Company, Glaxo Smith Kline, MEDTRONIC, Pfizer Inc, Pfizer Inc.
Lopes	Renato	Late-Breaking Clinical Trials	Digoxin and Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?	CONSULTANT FEES/HONORARIA - Bayer, Boehringer Ingleheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxosmithKline, MEDTRONIC, Merck & Co., Inc., Pfizer, Portola; RESEARCH/RESEARCH GRANTS - Bristol- Myers Squibb Company, Glaxo Smith Kline, MEDTRONIC, Pfizer Inc, Pfizer Inc.
Lopes	Renato	Arrhythmias and Clinical EP: Anticoagulation Issues	Use of Interacting Drugs Did Not Modify Treatment Effects of Apixaban Versus Warfarin for Atrial Fibrillation: Results From the ARISTOTLE Trial	CONSULTANT FEES/HONORARIA - Bayer, Boehringer Ingleheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxosmithKline, MEDTRONIC, Merck & Damp; Co., Inc., Pfizer, Portola; RESEARCH/RESEARCH GRANTS - Bristol-Myers Squibb Company, Glaxo Smith Kline, MEDTRONIC, Pfizer Inc, Pfizer Inc., Pfizer Inc.
Lopes	Renato	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Aortic Stenosis, but Not Mitral or Aortic Regurgitation, is Associated With Adverse Outcomes With Atrial Fibrillation: Results From the ARISTOTLE Trial	CONSULTANT FEES/HONORARIA - Bayer, Boehringer ingleheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, MEDTRONIC, Merck & Drizer, Portola; RESEARCH/RESEARCH GRANTS - Bristol-Myers Squibb Company, Glaxo Smith Kline, MEDTRONIC, Pfizer Inc.
Lopes	Renato	Antithrombotic Therapy in Ischemic Heart Disease	Clopidogrel Is Not Commonly Used but Associated With Less Re- Hospitalization in Patients With Perioperative Myocardial Infarction Following CABG Surgery	CONSULTANT FEES/HONORARIA - Bayer, Boehringer Ingleheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, MEDTRONIC, Merck & Barp, amp; Co., Inc., Pfizer, Portola; RESEARCH/RESEARCH GRANTS - Bristol-Myers Squibb Company, Glaxo Smith Kline, MEDTRONIC, Pfizer Inc., Pfizer Inc.
Lopes	Renato	Unusual Presentations of ACS	The High Cost of Low Acuity Non ST-Segment Elevation Acute Coronary Syndrome Admissions to the Coronary Care Unit: An Analysis of National Population Health Data	CONSULTANT FEES/HONORARIA - Bayer, Boehringer ingleheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, MEDTRONIC, Merck & Damp; Co., Inc., Piizer, Portola; RESEARCH/RESEARCH GRANTS - Bristol-Myers Squibb Company, Glaxo Smith Kline, MEDTRONIC, Piizer Inc., Piizer Inc.
Lopes	Renato	Post-CAD/MI: Making Tough Predictions About the Future	Myocardial Infarction: Insights From the CHAMPION Trials	CONSULTANT FEES/HONORARIA - Bayer, Boehringer Ingleheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxosmithKline, MEDTRONIC, Merck & amp, amp; Co., Inc., Piizer, Portola; RESEARCH/RESEARCH GRANTS - Bristol- Myers Squibb Company, Glaxo Smith Kline, MEDTRONIC, Pfizer Inc., Pfizer Inc
Lopes	Renato	02. Acute and Stable Ischemic Heart Disease: Clinical Team 8	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Bayer, Boehringer Ingleheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxosmithKline, MEDTRONIC, Merck & Co., Inc., Pfizer, Portola; RESEARCH/RESEARCH GRANTS - Bristol- Myers Squibb Company, Glaxo Smith Kline, MEDTRONIC, Pfizer Inc, Pfizer Inc.
Lopez	J. Antonio	Featured Clinical Research III	Early Challenges for PSCK9 Inhibitor Prescriptions and Patients: Rejections and Rates Unfilled	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
		1	Incleditions and rates onlined	ROLE - Amgen, Inc.

Contract of the contract of th				
Last Name	First Name	Session Title Traditional and Novel Factors Used to Assess	Presentation Title Fractional Flow Reserve Derived From Coronary Computed	Disclosures CONSULTANT FEES/HONORARIA - MCS Meridian
Lopez	John	the Risk of, and Used for the Treatment of, Coronary Artery Disease	Fractional Flow Reserve Derived From Coronary Computed Tomography Safely Reduces Invasive Coronary Angiography Rates and Cost in Patients With Stable Coronary Artery Disease	Cardiovascular Systems, National Peer Review Corporation, St Jude Medical; DATA SAFETY MONITORING BOARD - Gore Medical, HCRI; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Medical Registry
				Reporting Systems; RESEARCH/RESEARCH GRANTS - St Jude Medical
Lopez	John	22. Interventional Cardiology: Coronary Intervention: Left Main, Multivessel, Bifurcation Team 2	Suggested Reviewer	CONSULTANT FEES/HONGRARIA - MCS Meridian Cardiovascular Systems, National Peer Review Corporation, St Jude Medical; DATA SAFETY MONITORING BOARD - Gore Medical, HCRI; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Medical Registry Reporting Systems; RESEARCH/RESEARCH GRANTS - St Jude
Lopez	Keila	Therapeutic Advances in Congenital Heart	Association of Fractures With Furosemide Therapy in Pediatric	Medical Nothing to Disclose
		Disease	Medicaid Patients With Congenital Heart Disease	-
Lopez	Leo	Finding Out What Works in Pediatric and Congenital Heart Disease	ACC Poster Moderator	Nothing to Disclose
Lopez	Leo	11. Congenital Heart Disease: Therapy Team	Suggested Reviewer	Nothing to Disclose
Lopez Diaz	Javier	Imaging and Infections: International Perspectives From the Spanish Society of Cardiology, Venezuelan Society of Cardiology, and American College of Cardiology	Epidemiology of Infective Endocarditis: A New Disease?	Nothing to Disclose
Lopez Pais	Javier	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Incidence, Clinical Profile and Prognosis of Patients With Myocardial Infarction With Non-Obstructive Coronary Arteries in the Real World	Nothing to Disclose
Lopez Palop	Ramon	Timely Topics in Acute Coronary Syndromes From Diet to Drugs: Mechanistic Insight Into	A New Prognosis Score to Predict Mortality in Patients Over 75 Years Old Undergoing Primary Angioplasty in Cardiogenic Shock	Nothing to Disclose
Lopez-Espina	Carlos	Ischemic Heart Disease	Assessment of Thrombogenicity and Antithrombotic Drug Response at the Bedside in Patients Presenting With Ischemic Stroke, TIA or Intracranial Hemorrhage	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Coramed; SALARY - Haemonetics
Lopez-Jimenez Lopez-Jimenez	Francisco Francisco	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Predicting Outcomes in Cardiac Rehabilitation	A Non-Cardiac Cause of Orthopnea The Association Between Waist-Hip Ratio With Long-Term	SPEAKER'S BUREAU - Amgen SPEAKER'S BUREAU - Amgen
•		Patients	Cardiovascular Events in Patients With Coronary Artery Disease: A Population-Based Historical Cohort Study	-
Lopez-Jimenez	Francisco	Non Invasive Imaging: Role of Exercise Testing	Exercise Test Predicts Both Cardiovascular and Non-Cardiovascular Mortality in Patients Without Cardiovascular Disease	SPEAKER'S BUREAU - Amgen
Lopez-Jimenez	Francisco	Obesity Management in 2017: Weighing the Issues	Digital Health Intervention Usage Improves Weight loss in a Dose- Dependent Fashion	SPEAKER'S BUREAU - Amgen
Lopez-Jimenez	Francisco	34. Prevention: Rehabilitation Team 1	Suggested Reviewer Stress Induced Cardiomyopathy Triggered by Chemotherapy: When	SPEAKER'S BUREAU - Amgen CONSULTANT FEES/HONORARIA - GLG
Lopez-Mattei	Juan	Making Progress in Understanding Heart Failure	Should Cancer Therapy Be Restarted?	
Lopez-Mattei	Juan	Optimizing the Care of ACS Patients	Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients	CONSULTANT FEES/HONORARIA - GLG
Lopez-Melgar	Beatriz	Highlights in Vascular Medicine Research	Global Plaque Burden by Carotid and Femoral 3D Vascular Ultrasound: The PESA (Progression and Early Detection of Subclinical Atherosclerosis) Study	Nothing to Disclose
Lordkipanidzé	Marie	Optimizing the Care of ACS Patients	Prevalence and Clinical Impact of Thrombocytopenia in Patients With Acute Coronary Syndromes: A Systematic Review and Meta- Analysis	Nothing to Disclose
Losquadro	Monica	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Optical Coherence Tomography Assessment of Coronary Atherectomy Effect: Comparison Between Orbital and Rotational Atherectomy in Severely Calcified Lesions	Nothing to Disclose
Lota	Amrit	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Cardiovascular Magnetic Resonance in Survivors of Sudden Cardiac Arrest: 14 Year Experience From a Tertiary Referral Centre in the United Kingdom	Nothing to Disclose
Lotfi	Amir	Novel Developments in Acute Coronary Syndromes	Comparison of Clinical Outcomes: Bivalirudin With Transfemoral Versus Heparin With Transradial in Patients With ST Segment Elevation Myocardial Infarction	Nothing to Disclose
Lotfi	Amir	FIT Clinical Decision Making: Multimodality Imaging	Ventricular Septal Dissection With Rupture and Large NeoCavity After Inferior ST Elevation Myocardial Infarction in a Patient With Recent Coronary Artery Bypass Grafts	Nothing to Disclose
Louise	Morgan	Coronary Angiography, Intra-Vascular Imaging,	Invasive Management Strategies and Anti-Thrombotic Treatments in	Nothing to Disclose
Love	Barry	Revascularization and Outcomes Fellows Bootcamp: Peripheral Vascular Disease and Structural Heart Disease	Patients With NSTE-ACS in China Pfo/asd/vsd	CONSULTANT FEES/HONORARIA - Abbott Laboratories
Love	Barry	Management Special Hearts: The Challenge of Heart Failure	Catheter-based Interventions in ACHD	CONSULTANT FEES/HONORARIA - Abbott Laboratories
Love	Barry	in Congenital Heart Disease The Forgotten Valves: Therapies for Triscuspid	Melody Transcatheter PV Replacement: Case and Overview	CONSULTANT FEES/HONORARIA - Abbott Laboratories
Love	Barry	and Pulmonic Valve FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Decision-Making in Congenitally Corrected Transposition of the	CONSULTANT FEES/HONORARIA - Abbott Laboratories
Love	Barry	FIT Clinical Decision Making: Prevention, Adult	Great Arteries The Fontan Fiasco: Strategies for Thromboembolic Management	CONSULTANT FEES/HONORARIA - Abbott Laboratories
Love	Barry	Congenital and Congenital Heart Disease Congenital Heart Disease: Novel Insights in	Rhythm Abnormalities in Children and Young Adults With Marfan	CONSULTANT FEES/HONORARIA - Abbott Laboratories
		Pediatric Cardiology Challenges in Percutaneous Interventions:	Syndrome Lessons From the Early Adoption of BVS Use	
Low	Adrian	International Perspectives From the Hong Kong College of Cardiology, Singapore Cardiac Society, and American College of Cardiology		CONSULTANT FEES/HONORARIA - Abbott, Boston Scientific, Kaneka, St Jude
Low	Adrian	Coronary Intervention: Drug Eluting Stent and Scaffolds	Safety and Efficacy of Small Vessel Stenting With 2 mm Drug Eluting Stents in Real World Clinical Practice	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,Kaneka,St Jude
Low	Adrian	Coronary Intervention in Interventional Cardiology: Core Concepts	Incidence and Predictors of Target Lesion Failure in a Multi-Ethnic Asian Population Receiving the SYNERGY Coronary Stent: A Prospective All-Comers Registry	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,Kaneka,St Jude
Low	Reginald	17. Interventional Cardiology: Aortic Valve Disease Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific,Direct Flow Medical
Lowery	Ray	Vascular Medicine: Emerging Concepts in	Kommerell Diverticulum Across the Ages: Destined for Dilation?	Nothing to Disclose
Lowisz	Joanna	Clinical Vascular Diseases FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Successful Hybrid Procedure in a Case of Unrepaired Hypoplastic Left Heart Syndrome	Nothing to Disclose
Lowisz	Joanna	FIT Clinical Decision Making: Prevention, Adult	Severe Ebstein's Anomaly Successfully Palliated With the Starnes	Nothing to Disclose
-	-	Congenital and Congenital Heart Disease	Procedure	•

Last Name	First Name	Session Title	Presentation Title	Disclosures
Loyalka	Pranav	Interventional Cardiology: PCI and TAVR in Complex Patients	Predicting Risk Factors for Permanent Pacemaker Placement Following Transcatheter Aortic Valve Replacement: A UTHealth Experience	Nothing to Disclose
Loyalka	Pranav	Interventional Cardiology: TAVR 3	Transapical TAVR Is Associated With Higher Morbidity and Mortality Compared to Transfemoral TAVR in Men but Not in Women	Nothing to Disclose
Loyalka	Pranav	The Challenges of Outcome Prediction in	Gender-Based Outcomes in Diabetics Undergoing Transcatheter	Nothing to Disclose
Lu	Dai-Yin	Valvular Heart Disease Advances in HCM, PPCM and Other	Aortic Valve Replacement Risk Profiles and Clinical Outcomes in Patients With Non-	Nothing to Disclose
Lu	Jimmy	Cardiomyopathies Vascular Medicine: Emerging Concepts in	Obstructive, Labile and Obstructive Hypertrophic Cardiomyopathy Kommerell Diverticulum Across the Ages: Destined for Dilation?	Nothing to Disclose
		Clinical Vascular Diseases	-	-
Lu	Jimmy	Congenital Heart Disease: Pediatric Team	Suggested Reviewer	Nothing to Disclose
Lu	Lingyun	Emerging Developments in HFpEF and Arryhthmias	Bleeding Risk of Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation and Heart Failure	Nothing to Disclose
Lu	Lingyun	The Old and the New: Impact of Heart Failure Drug Therapies	Safety of Alpha Blockers in Patients With Heart Failure	Nothing to Disclose
Lu	Michael	Highlighted Original Research: Non Invasive Imaging and the Year in Review	The Association of High Risk Plaque Features and Non-Invasive Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography in Patients With Acute Chest Pain: Results From the ROMICAT II Trial	Nothing to Disclose
Lu	Michael	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Outcomes in Patients With Diabetes Mellitus and Suspected Coronary Artery Disease Following Non-Invasive Testing: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	Nothing to Disclose
Lubitz	Steven	Innovative Use of Echocardiography	Effect of Left Atrial Remodeling on Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study	Nothing to Disclose
Lubitz	Steven	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Factors Predicting Longer Time to Anticoagulation Following a New Diagnosis of Atrial Fibrillation	Nothing to Disclose
Lucas	Alexandra	Novel Imaging and Therapies in Heart Failure	Global Longitudinal Strain in Patients With New Left Ventricular	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Viron
Lucas	Alexandra	The Evolving World of LVADs, Transplant and	Systolic Dysfunction After Anticancer Targeted Therapies Cardiomyopathy Associated With Targeted Anticancer Therapies in	Therapeutics Inc OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Viron
Lucas	Joseph	Other Novel Discoveries Cardiac Arrest, Diabetes, and Other High Risk	Electronic Health Records Hospital Variation in Targeted Temperature Management for Acute	Therapeutics Inc Nothing to Disclose
	·	Features of Patients With Acute Coronary Syndrome	Myocardial Infarction Patients Complicated by Out-of-Hospital Cardiac Arrest in the U.S.	
Lugo	Ricardo	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Catecholaminergic Polymorphic Ventricular Tachycardia and Peri- Partum Cardiomyopathy: A Perfect Sympathetic Storm?	Nothing to Disclose
Lui	George	Update in ACHD: The Time for Change is Now	Panelist	Nothing to Disclose
Lui	George	Coarctation of the Aorta, from Repair to Lifelong Care	Coarctation of the Aorta in Adulthood, Some Restrictions Apply	Nothing to Disclose
Lui	George	Engage @ ACC.17 Studio:The Newlywed	Participant, Team 3	Nothing to Disclose
Lumley	Matthew	Game for Pediatric Cardiac Providers Post-CAD/MI: Making Tough Predictions About the Future	Unravelling the Mechanisms of Mental Stress Induced Myocardial Ischaemia: Novel Insights From Intracoronary Measurements During Cardiac Catheterisation	SALARY - Pfizer Inc
Lumsden	Alan	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Technique and Utility of CT Angiography Fluoroscopy Image Fusion to Guide Percutaneous Pulmonary Valve Implantation in Adults	CONSULTANT FEES/HONORARIA - BSCI, Medtronic, VNUS, W.L. Gore, Maquet, Siemens; OWNERSHIP MITTEREST/PARTNERSHIP/PRINCIPAL - Hatch Medical, Northpoint Domain; SPEAKER'S BUREAU - BSCI, W.L. Gore, Medtronic
Lumsden	Alan	Innovations in Education	Hands-On Transradial Access Skill Training on a Novel Cadaveric Model: Findings and Recommendations	CONSULTANT FEES/HONORARIA - BSCI, Medtronic, VNUS, W.L. Gore, Maquet, Siemens; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Hatch Medical, Northpoint Domain; SPEAKER'S BUREAU - BSCI, W.L. Gore, Medtronic
Lumsden	Alan	41. Vascular Medicine: Venous Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - BSCI, Medtronic, VNUS, W.L. Gore, Maquet, Siemens; OWNERSHIP MITTEREST/PARTNERSHIP/PRINCIPAL - Hatch Medical, Northpoint Domain; SPEAKER'S BUREAU - BSCI, W.L. Gore, Medtronic
Lund	Lars	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Mortality and Morbidity in Patients With Heart Failure and Reduced Ejection Fraction Exposed to Digoxin: Comprehensive Data According to Atrial Fibrillation in 23,708 Patients From the Swedish Heart Failure Registry	CONSULTANT FEES/HONORARIA - AstaZeneca,Bayer,Relypsa,ViforPharma; RESEARCH/RESEARCH GRANTS - AstraZeneca,Boston Scientific; SPEAKER'S BUREAU - Novartis Corporation
Lund	Lars	Young Investigator Awards Competition: Clinical Investigations	Advanced Analytics Predicted Outcomes, Identified Clinically Distinct Subgroups, and Detected Heterogeneity in Response to Therapy in a Cohort of More Than 40,000 Heart Failure Patients	CONSULTANT FEES/HONORARIA - AstaZeneca, Bayer, Relypsa, ViforPharma; RESEARCH/RESEARCH GRANTS - AstraZeneca, Boston Scientific; SPEAKER'S BUREAU - Novartis Corporation
Lund	Lars	Why Can't We Be Friends? Controversies in Heart Failure Management	Association Between Serum Potassium Level and Outcomes in Heart Failure With Reduced Ejection Fraction: A Cohort Study From the Swedish Heart Failure Registry	CONSULTANT FEES/HONORARIA - AstaZeneca,Bayer, Relypsa,ViforPharma; RESEARCH/RESEARCH GRANTS - AstraZeneca,Boston Scientific; SPEAKER'S BUREAU - Novartis Corporation
Lundberg	Gina	WIC Brown Bag Lunch Session: Publishing, Social Media and Negotiating the C-Suite: Tools for Success in Academia and Private Practice	Establishing a Social Media Presence	Nothing to Disclose
Lundstrom	Robert	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Constrictive Pericarditis Due to Kawasaki Disease	Nothing to Disclose
Luni	Faraz khan	Why Can't We Be Friends? Controversies in Heart Failure Management	Mortality Effect of Icd in Primary Prevention of Non Ischemic Cardiomyopathy: A Meta Analysis of Randomized Control Trials	Nothing to Disclose
Lunze	Fatima	Predicting Outcomes in Pediatric Heart Disase	Risk Stratification of Children Undergoing Valve-Sparing Repair of	Nothing to Disclose
Luo	Yanting	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Tetralogy of Fallot Prognostic Value of Protein Biomarkers Predict Risk of Coronary Heart Disease Events: Results From Multi-Ethnic Study of	Nothing to Disclose
Lupi	Laura	Arrhythmias and Clinical EP: Syncope and	Atherosclerosis (MESA) Safe Multidisciplinary Management of New Therapies: The Ritmo	Nothing to Disclose
Lupi	Laura	Other EP Issues Interdisciplinary Cardiovascular Care in Complex Scenarios	Project (Real Time Continuous Web Monitoring) Prognostic Value of Myocardial Fibrosis Assessed by Cardiac Magnetic Resonance in Patient With Idiopathic Dilated	Nothing to Disclose
Lurz	Philipp	Novel Developments in Acute Coronary	Cardiomyopathy With Left Ventricual Systolic Dysfunction Outcome of Elderly Patients Undergoing Extracorporeal Life	CONSULTANT FEES/HONORARIA - Abbott
		Syndromes	Support in Refractory Cardiogenic Shock	Inc.,Biosensors,MEDTRONIC
Lutes	Jennifer	Great Minds Think Differently: Multidisciplinary Approach to Imaging	Panelist	Nothing to Disclose
Lutes	Jennifer	Interrupting DAPT for Surgery, Afib, or Bleeding	Panelist	Nothing to Disclose
Luther	Sarah	Personalized Skills Center: Drill and Practice (Heart Songs, ECG, Hand-Held Echo)	Heart Songs Moderator	Nothing to Disclose
Lutsey	Pamela	Innovations in Cardiovascular Risk Assessment	Vitamin D Levels and Autoantibodies in the Multi-Ethnic Study of	Nothing to Disclose
	1	and Reduction	Atherosclerosis (MESA): Implications for Cardiovascular Disease	İ

United Section of Proceedings of Process of	Congress of the second				
Care Leaves 1 Programme of Character Portugues and Cha	Last Name		Session Title		
Last Least Deposition of Processing States of Proce	Lutter	Christoph		Abluminal Coating Biodegradable Polymer Based Sirolimus-Eluting Metallic Stent Versus Conformal Coating Durable Polymer Based	Nothing to Disclose
Manage Propose to Michage Propose to Michage Propose to Michage Manage Michage Mic	Luz Leiria	Tiago Luiz	Arrhythmias and Clinical EP: Syncope and		Nothing to Disclose
Service Common Company (Company Compan	Ly	Samantha			Nothing to Disclose
See Fundament of the American Medical Application Application of the American Medical Application Application of the American Medical Application Appl		Carmen		Defining Risk Associated With Left Ventricular Hypertrophy Patterns	Nothing to Disclose
Office Annahom Market Table Challed Street Street Table Challed Street Street Table Challed Street Street Table Challed Street Street Table Challed Street Street Table Challed Street Street Table Challed Street Street Table Challed Street Street Table Challed Street Street Table Challed Street Street Table Challed Street Table S			and Function	as Assessed by Cardiac Magnetic Resonance Imaging	,
Consideration of the photocolon for the Propriets of the Companies and C	Lyilli	пагеі	of the American Medical Association Late- Breaking Clinical Trials	Hypertension: The REACH Trial	
Corgenit and Corporate Report Disease Ratinals Ratinal	Lyons	Kristin		Guidelines on the Proportion of Hospitalized Heart Failure Patients	Nothing to Disclose
Section Section (1997) Sectio	Lystash	John			Nothing to Disclose
Systems of Standard Control Process of Nationa	Lyubarova	Radmila			Nothing to Disclose
Consequence with Energy in Patients by Annual Foreign concerns with Consequence with Energy in Patients with Annual Foreign concerns with Security and Security of Security (1994). The Patients with Annual Foreign concerns with Security and Security (1994). The Patients with Annual Foreign and VT. Insurpating West Consequence of Security (1994). The Patients with Insurance Foreign concerns with Insurance Foreign	Lyubarova	Radmila	FIT Clinical Decision Making: Heart Failure and	Aspirin Induced Eosinophilia-Associated Coronary Artery	Nothing to Disclose
Contemporary Processor No. Chaegeroup Chaegeroup Rosecolorazione del Colorone Rosecolorazione Rosecolorazione del Colorone Rosecolorazione del Colorone Rosecolorazione del Colorone Rosecolorazione del Colorone Rosecolorazione del Colorone Rosecolorazione del Colorone Rosecolorazione del Colorone Rosecolorazione del Colorone Rosecolorazione del Colorone Rosecolorazione del Colorone Rosecolorazione del Colorone Rosecolorazione del Colorone Rosecolorazione del Colorone Rosecolorazione del Colorone Rosecolorazione del Coloron	Ma	Changsheng			CONSULTANT FEES/HONORARIA - Bayer Healthcare
Resource Control Profession and Outcomes Dispating of Character Service Servi			Contemporary Practice	GLORIA-AF Registry	Pharmaceuticals,Boehringer-Ingelheim,Bristol-Myers Squibb (BMS),Johnson & Department (BMS),Department (BM
Secretary Name			Revascularization and Outcomes	Patients With NSTE-ACS in China	Pharmaceuticals,Boehringer-Ingelheim,Bristol-Myers Squibb (BMS),Johnson & Dong;amp; Johnson,Pfizer
Alterogenesis Alternogenesis Wilson Jale Graftice Fibrors and Heart Failure. The Next Financiar Financiar Annual Librory Cardiac Fibrors and Heart Failure. The Next Financiar Financiar Cardiac Fibrors and Heart Failure. The Next Financiar Financiar Cardiac Fibrors and Heart Failure. The Next Financiar Financiar Cardiac Fibrors and Heart Failure. The Next Financiar Financiar Cardiac Fibrors and Heart Failure. The Next Financiar Financiar Annual Librory Financiar Financiar Annual Librory Financiar Annual Libro	Ma	Changsheng	Risks Toward Decision Making	in Clinical Practice: The GLORIA-AF Registry	Pharmaceuticals,Boehringer-Ingelheim,Bristol-Myers Squibb
Asset Proteins and Heart Failure. The Neat Froider Fro	Ma	Genshan		Inflammation & Detected Inflammatory Activation in Early-Stage	Nothing to Disclose
Lisong Cardiac Fiscos and Heart Failure. The Note Fromtier Fromtie	Ма	Jie		Wnt/β-catenin Signaling Pathway in the Myocardial Fibrosis After Acute Myocardial Infarction in Rats and Its Correlation With	Nothing to Disclose
Cardiology, Acute and Stable Inchemic Heat Dealests, and Vascular Medicine Varioter Heart Diseases. Minar Valve Diseases Analous Association Association Valvation Val	Ма	Lihong		The Cross-Talk of Salidroside on Tgf-β/Smads and Wnt/β-catenin Signaling Pathway in the Myocardial Fibrosis After Acute Myocardial Infarction in Rats and Its Correlation With	Nothing to Disclose
Masloud Joseph Valvalar Heart Disease: Mitral Valve Disease bedieved processory and Colorage material water and bedieved processors with a colorage material processors and	Maag	Ronald	Cardiology, Acute and Stable Ischemic Heart		Nothing to Disclose
Masloud Joseph Valudar Heart Disease: Andre Disease: Andre Disease: Andre Disease: Andre Disease: Andre Disease: Andre Stenoise Specialized Flew or Applicated Flew or Applicated Flew or Applicated Flew or Applicated Flew or Application Fl	Maalouf	Joseph		Independently Impact Survival of Degenerative Mitral Valve	Nothing to Disclose
Valuation Valu	Maalouf	Joseph	Valvular Heart Disease: Mitral Valve Disease	Quantitation of Degenerative Mitral Regurgitation: Reserved to the	Nothing to Disclose
Maslouf Vousef Novel Determinants of Outcomes in VHD Propession and Clinical Quitousmes in Ancie Quitousmes in April Q	Maalouf	Youssef	Valvular Heart Disease: Aortic Stenosis	Bicuspid Versus Tricuspid Aortic Valve Stenosis: Comparative Study of Clinical Characteristics and Outcomes Following Aortic Valve	Nothing to Disclose
Marcal Man Abhishek	Maalouf	Youssef	Novel Determinants of Outcomes in VHD	Impact of Aortic Valve Calcification and Sex on Hemodynamic	Nothing to Disclose
Macaulay Tracy Macaulay Tracy Distinct Decision Making: Heart Faiture and A Possible Simple Solution to a Challenging Problem in Management of Acute Decompensated Heart Faiture Management of Acute Decompensated Heart Faiture Moveste Corporation Northing to Disclose Macaulay Tracy Distinct Heart Faiture Care Vascular Vascular Care Vascular Vascu	Maan	Abhishek	Unusual Presentations of ACS	National Trends in Admissions for Chest Pain Evaluation: 2006 -	CONSULTANT FEES/HONORARIA - MEDTRONIC,MEDTRONIC; RESEARCH/RESEARCH GRANTS -
Macaulay Tracy Kanu and Docey Chatterjee Lecture and Seminal Talks in Heart Failure: Wanna New Drug: Updated Heart Failure: Wanna New Drug: Updated Heart Failure: Wanna New Drug: Updated Heart Failure: Wanna New Drug: Updated Heart Failure: Wanna New Drug: Updated Heart Failure: Wascular Care: Vascular Collaborative Team Care in Action Interdisciplinary Cardiovascular Care in Macaulary Tracy Masmally: Effective Vascular Care: Vascular Care: Vascular Collaborative Team Care in Action Interdisciplinary Cardiovascular Care in MacDonald Method The Evolving World of LVABs, Transplant and Other Novel Discoveries Umaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease Impact of Congenital He	Macaluso	Gregory	FIT Clinical Decision Making: Heart Failure and	A Possible Simple Solution to a Challenging Problem in	
Drug: Updated Heart Failure Guidelines Macaulary Tracy Maximally Effective Vascular Care: Vascular Care Vascular Collaborative Team Care in Action Macaulary Tracy Maximally Effective Vascular Care: Vascular Care Vascular (Collaborative Team Care in Action Macaulary Tracy Marcian Collaborative Team Care in Action Macaulary Tracy Macaulary Tracy Macaulary Tracy Macaulary Tracy Macaulary Tracy Macaulary Tracy Macaulary Tracy Macaulary Tracy Macaulary Macaulary Tracy Macaulary Tracy Macaulary Macaulary Tracy Tracy Tracy Tracy Tracy Tracy Macaulary Tracy Tr	Macaulay		Pulmonary Hypertension Kanu and Docey Chatterjee Lecture and	Management of Acute Decompensated Heart Failure	Novartis Corporation
Macaulay Tracy Interdisciplinary Cardiovascular Care in Action Macaulay Tracy Interdisciplinary Cardiovascular Care in Complex Scenarios MacDonald Michael The Evoling World of LVADs, Transplant and Other Novel Discoveries Macedo Transico Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease Plus the Impact of Congenital Heart Disease Plus the Impact of Congenital Heart Disease Plus the Impact of Congenital Heart Disease Plus the Impact of Congenital Heart Disease Plus the Impact of Congenital Heart Disease Plus the Impact of Congenital Heart Disease Plus the Impact of Congenital Heart Disease Plus the Impact of Congenital Heart Disease Plus the Impact of Congenital Heart Disease Impact of Congenital Plus Plus Plus Plus Plus Plus Plus Plu	Manaday	T	Drug: Updated Heart Failure Guidelines	Cons Proposition #4: Parallet	Nething to Displace
Complex Scenarios Run Transtinos Care Clinic			Collaborative Team Care in Action		-
Other Novel Discoveries Macedo Francisco Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease Macedo Thiago Innovation in Practice Management, Advocacy and Education Macedo Thiago Innovation in Practice Management, Advocacy and Education Macedo Thiago Which Test is Best for Pain in the Chest? Coronary Computed Tomography Angiography in the Emergency Macedo Thiago Which Test is Best for Pain in the Chest? Coronary Computed Tomography Angiography in the Emergency Macedo Thiago Which Test is Best for Pain in the Chest? Coronary Computed Tomography Angiography in the Emergency And Financia Macedo Thiago Which Test is Best for Pain in the Chest? Coronary Computed Tomography Angiography in the Emergency And Macedo Thiago Which Test is Best for Pain in the Chest? Coronary Computed Tomography Angiography in the Emergency And Macedo Thiago Which Test is Best for Pain in the Chest? Coronary Computed Tomography Angiography in the Emergency And Macedo Thiago Which Test is Best for Pain in the Chest? Coronary Computed Tomography Angiography in the Emergency And Macedo Thiago Which Test is Best for Pain in the Chest? Coronary Computed Tomography Angiography in the Emergency And Macedo Thiago Which Test is Best for Pain in the Chest? Coronary Computed Tomography Angiography in the Emergency And State Tomography Angiography in the Emergency And State Tomography Angiography in the Emergency And State Tomography Angiography in the Emergency And State Tomography Angiography in the Emergency And State Tomography Angiography in the Emergency And State Tomography Angiography in the Emergency Andio Emergency And State Tomography Angiography in the Emergency Andio Emergency Andio Emergency Andio Macedo Tomography Angiography in the Emergency Andio Emergency Andio Emergency Andio Emergency Andio Emergency Andio Emergency Andio Emergency Andio Emergency Andio Emergency Andio Emergency Andio Emergency Andio Emergency Andio Emergency Andio Emergency Another Emergency Another			Complex Scenarios	Run Transitions of Care Clinic	-
Impact of Congenital Heart Disease		Michael	Other Novel Discoveries	,	-
Innovation in Practice Management, Advocacy, Improvement in Quality Indicators Using NCDR® Registries: Nothing to Disclose in and Education	Macedo	Francisco		Volume by Echocardiography in Patients With Pulmonary	Nothing to Disclose
MacGillivray Thomas Atrial Fibrillation in Young and Unusual Populations: Children and Adult Congenital Heart Disease and Hemostasis Issues MacGillivray Thomas Atrial Fibrillation in Young and Unusual Populations: Children and Adult Congenital Heart Disease MacGillivray Thomas Novel Determinants of Outcomes in VHD Rationship Between Proximal Aorta Morphology and Progression Nothing to Disclose Mach Francois Joint American College of Cardiology.lournal of the American Medical Association Late Breaking Clinical Trials Mach Francois Timely Topics in Acute Coronary Syndromes Mach Francois Timely Topics in Acute Coronary Syndromes Mach Wascular Access and Hemostasis Issues Mach Vascular Access and Hemostasis Issues Mach Jane Life After LVAD - The Good, The Bad and The Ugly Mack Michael Featured Clinical Research II: Interventional Comparison of In-Hospital and 1-Yaer Outcomes of Teraldical Beplacer Linkey Art of Featured Clinical Research II: Interventional Clinical Teral Graphs of Teraldical Beplacer Linkey Art of Featured Clinical Research II: Interventional Clinical Teral Graphs of Teraldical Beplacer Linkey Art of Featured Clinical Research II: Interventional Clinical Teral Graphs of Teraldical Beplacer Linkey Art of Featured Clinical Research II: Interventional Comparison for Failed Surgical Bioprosthesis Versus Residence, MEDTRONIC Mack Michael Featured Clinical Research II: Interventional Clinical C	Macedo	Thiago		Improvement in Quality Indicators Using NCDR® Registries:	Nothing to Disclose
Artial Fibrillation in Young and Unusual Populations: Children and Adult Congenital Heart Disease MacGillivray Thomas Novel Determinants of Outcomes in VHD Novel Determinants of Outcomes in VHD Relationship Between Proximal Aorta Morphology and Progression Rate of Aortic Stenosis Mach Francois Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials Mach Francois Timely Topics in Acute Coronary Syndromes Machemis Nolan Vascular Access and Hemostasis Issues Mach Jane Life After LVAD - The Good, The Bad and The Ugly Mack Michael Featured Clinical Research II: Interventional Mack Michael Featured Clinical Research II: Interventional Mack Michael Featured Clinical Research II: Interventional Mack Michael Featured Clinical Research II: Interventional Mack Michael Featured Clinical Research II: Interventional Mack Michael Featured Clinical Research II: Interventional Mack Michael Featured Clinical Research II: Interventional Mack Michael Featured Clinical Research II: Interventional Mack Michael Featured Clinical Research II: Interventional Mack Michael Featured Clinical Research II: Interventional Mack Michael Featured Clinical Research II: Interventional Mack Michael Featured Clinical Research II: Interventional Mack Michael Featured Clinical Research II: Interventional Mack Michael Featured Clinical Research II: Interventional Mack Michael Featured Clinical Research II: Interventional Mack Michael Michael Featured Clinical Research II: Interventional Mack Michael Featured Clinical Research II: Interventional Mack Michael Michael Michael Featured Clinical Research II: Interventional Michael Micha	Macedo	Thiago		Coronary Computed Tomography Angiography in the Emergency Room: Rapid Exclusion of Coronary Artery Disease and the Fast Diagnosis of Acute Myocarditis Using Late Enhancement by	Nothing to Disclose
Relationship Between Proximal Aorta Morphology and Progression Nothing to Disclose Rate of Aortic Stenosis	MacGillivray	Thomas	Populations: Children and Adult Congenital	Can We Surgically Cure Atrial Fibrillation in ACHD?	Nothing to Disclose
Francois Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials	MacGillivray	Thomas			Nothing to Disclose
Francois Timely Topics in Acute Coronary Syndromes Gender-Related Outcomes in Elderly (>, 75 Years) Patients Presenting With Acute Coronary Syndromes: Results From the Swiss Acute Coronary Syndromes: Results From the Swiss Acute Coronary Syndromes: Results From the Swiss Acute Coronary Syndromes: Results From the Swiss Acute Coronary Syndrome Cohort	Mach	Francois	of the American Medical Association Late-	Primary Results of EBBINGHAUS, a Cognitive Study of Patients	Nothing to Disclose
Machernis Nolan Vascular Access and Hemostasis Issues Clinical Efficacy of SoftSeal-STF Hemostatic Pad With Short Hold Time Compared to Traditional Manual Compression After Transfemoral Catheterization Mack Michael Featured Clinical Research II: Interventional Real World Comparative Effectiveness of Transcatheter Versus Surgical Aorito Valve Replacement in the United States: An Analysis Lifesciences, MEDTRONIC From Two US Registries Linked to Medicare Data Mack Michael Featured Clinical Research II: Interventional Comparative Effectiveness of Transcatheter Versus Authority States: An Analysis Lifesciences, MEDTRONIC From Two US Registries Linked to Medicare Data Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Active Valve Replacement for Failed Surgical Bioprosthesis Versus Lifesciences, MEDTRONIC Mack Michael Featured Clinical Research II: Interventional Clinical Research II: Interventional Research II: Interventional Clinical Research II: Interventional Research II: Interven	Mach	Francois		Presenting With Acute Coronary Syndromes: Results From the	Nothing to Disclose
Mack Michael Life After LVAD - The Good, The Bad and The Ugify Mack Michael Featured Clinical Research II: Interventional Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data Mack Michael Featured Clinical Research II: Interventional Goografies of Interventional Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Lifesciences, MEDTRONIC RESEARCH GRANTS - Abbott Vascular, Edward Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Lifesciences, MEDTRONIC RESEARCH GRANTS - Abbott Vascular, Edward Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis From the STS/ACC TVT Registries Mack Michael Featured Clinical Research II: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edward Research II: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edward Research II: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edward Research II: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edward Research III: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Research III: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Research III: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Research III: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Research III: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Research III: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Research III: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Research III: Interventional Clinical Outcomes at 1-Year	Machernis	Nolan	Vascular Access and Hemostasis Issues	Clinical Efficacy of SoftSeal-STF Hemostatic Pad With Short Hold Time Compared to Traditional Manual Compression After	Nothing to Disclose
Mack Michael Featured Clinical Research II: Interventional Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis Lifesciences, MEDTRONIC From Two US Registries Linked to Medicare Data Mack Michael Featured Clinical Research II: Interventional Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Lifesciences, MEDTRONIC RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edward Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Lifesciences, MEDTRONIC Lifesciences, MEDTRONIC Native Aortic Stenosis From the STS/ACC TVT Registry Mack Michael Featured Clinical Research II: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edward Lifesciences, MEDTRONIC RESEARCH GRANTS - Abbott Vascular, Edward Research II: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edward Research II: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edward Research III: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Research III: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Research III: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Research III: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Research III: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Research III: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Research III: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Research III: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Research III: Interventional Clinical Outcomes at 1-Year After	MacIver	Jane			Nothing to Disclose
From Two US Registries Linked to Medicare Data Mack Michael Featured Clinical Research II: Interventional Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Active Valve Replacement for Failed Surgical Bioprosthesis Versus Lifesciences, MEDTRONIC Matek Michael Featured Clinical Research II: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edward Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edward RESEARCH/RESEARCH GRANTS - Abbott	Mack	Michael			RESEARCH/RESEARCH GRANTS - Abbott Vascular,Edwards
Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Lifesciences,MEDTRONIC Native Aortic Stenois From the STS/ACC TVT Registry Mack Michael Featured Clinical Research II: Interventional Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edward	Mack	Michael	Featured Clinical Research II: Interventional	From Two US Registries Linked to Medicare Data	RESEARCH/RESEARCH GRANTS - Abbott Vascular,Edwards
wack wild are predicted clinical research it. Interventional Culticomes at 1-year After Commercial Transcatheter Mitral RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edward Valve Repair in the United States Lifesciences, MEDTRONIC	Mook	Michael		Native Aortic Stenosis From the STS/ACC TVT Registry	Lifesciences,MEDTRONIC
	IVIACK	iviichaei	reatured Cirrical Research II: Interventional	Valve Repair in the United States	

Mack	First Name Michael	Session Title Joint American College of Cardiology/New England Journal of Medicine Late-Breaking	Presentation Title Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic	Disclosures RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edwards Lifesciences.MEDTRONIC
		Clinical Trials	Surgical Trials Network	·
Mack	Michael	Late-Breaking Clinical Trials	Comparative Effectiveness of Left Atrial Appendage Occlusion Among Atrial Fibrillation Patients Undergoing Cardiac Surgery: A Report From the Society of Thoracic Surgeons Adult Cardiac Surgery Database	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edwards Lifesciences, MEDTRONIC
Mack	Michael	Great Minds Think Differently: Multidisciplinary Approach to Controversies in Cardiology	Panelist	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edwards Lifesciences, MEDTRONIC
Mack	Michael	Valvular Heart Disease Guidelines The Evidence and the Gaps	What Changed? - The Scope of the VHD Focused Update: Aortic Stenosis	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edwards Lifesciences, MEDTRONIC
Mack	Michael	Mitral Valve Guidelines: Closing Knowledge	Discussion Leader	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Edwards
Mack	Michael	Gaps Transcatheter Mitral Valve Replacement	Review of TMVR Devices and Programs	Lifesciences,MEDTRONIC RESEARCH/RESEARCH GRANTS - Abbott Vascular,Edwards
Mack	Michael	Vascular Access and Hemostasis Issues	Real-Time Ultrasound Versus Fluoroscopy Guided Access for	Lifesciences,MEDTRONIC RESEARCH/RESEARCH GRANTS - Abbott Vascular,Edwards
Mack	Michael	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Replacement With the Sapien 3 Valve Stroke and Cardiovascular Outcomes in Patients With Carotid	Lifesciences,MEDTRONIC RESEARCH/RESEARCH GRANTS - Abbott Vascular,Edwards
Mack	Michael	Engage @ ACC.17 Studio: Cardiology Contest	Disease Undergoing TAVR: Insights From the STS/TVT Registry Cardiology Contestant	Lifesciences,MEDTRONIC RESEARCH/RESEARCH GRANTS - Abbott Vascular,Edwards
Mack	Michael	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low- Flow Severe Aortic Stenosis and Less Reverse Remodeling After TAVR: A Partner 2 Trial Analysis	Lifesciences,MEDTRONIC RESEARCH/RESEARCH GRANTS - Abbott Vascular,Edwards Lifesciences,MEDTRONIC
Mack	Michael	Prosthetic Valve Thrombosis: TAVR, Bio,	Incidence of Valve Leaflet Thrombosis in Transcatheter and	RESEARCH/RESEARCH GRANTS - Abbott Vascular,Edwards
Mack	Michael	Mech Now What?! Peripheral Arterial Disease, Risk, and	Surgical Bioprosthetic Aortic Valves by 4D CT Imaging Peripheral Artery Disease and Transcatheter Aortic Valve	Lifesciences,MEDTRONIC RESEARCH/RESEARCH GRANTS - Abbott Vascular,Edwards
Mack	Michael	Outcomes 17. Interventional Cardiology: Aortic Valve	Replacement Outcomes: A Report From the STS/TVT Registry Suggested Reviewer	Lifesciences,MEDTRONIC RESEARCH/RESEARCH GRANTS - Abbott Vascular,Edwards
Mack	Michael	Disease Team 3 Interventional Challenging Cases: Team 3	ACC Challenging Case Reviewer	Lifesciences,MEDTRONIC RESEARCH/RESEARCH GRANTS - Abbott Vascular,Edwards
Mackey-Bojack	Shannon	Advancing Our Understanding of Aortic	Clinical and Pathologic Findings of Aortic Dissection at Autopsy:	Lifesciences,MEDTRONIC CONSULTANT FEES/HONORARIA - Boston
MacPhail	Carolyn	Disease Joint American College of Cardiology/Journal	Review of 338 Cases Over 6 Decades e-Counseling for Self-Care Adherence Adds Therapeutic Benefit for	Scientific,MEDTRONIC,St Jude Nothing to Disclose
	-	of the American Medical Association Late- Breaking Clinical Trials	Hypertension: The REACH Trial	-
Madamanchi	Chaitanya	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Complete Heart Block on an Athlete's Screening ECG: Reason to Restrict?	Nothing to Disclose
Madan	Nidhi	Markers of Prognosis Associated With Elevated Blood Pressure	Isolated Systolic Hypertension and Pulse Pressure Are Associated With High-Sensitivity Cardiac Troponin-T and NT-pro BNP in Older Adults	Nothing to Disclose
Madan	Pankaj	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	A Mistaken Case of Ventricular Septal Defect: Importance of Physical Examination	SPEAKER'S BUREAU - GeneDx
Madan	Pankaj	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Patent Ductus Arteriosus: An Unusual Cause of High Output Cardiac Failure in an Elderly Patient	SPEAKER'S BUREAU - GeneDx
Madan	Shivank	Timely Topics in Acute Coronary Syndromes	Routine Invasive Versus Conservative Strategy for Elderly Patients Aged>75 Years With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS): A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Madan	Shivanshu	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Recurrent Syncope: An Unusual Presentation of Lymphoma	Nothing to Disclose
Madder	Ryan	Innovations in Practice Management and Social Media	Radiation Exposure Among Non-Physician Staff Members During Cardiac Catheterization and the Impact of Proactive Shielding	RESEARCH/RESEARCH GRANTS - Corindus Vascular Robotics,Infraredx
Madder	Ryan	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Variation in Intracoronary Lipid-Rich Plaque Detected by Near- Infrared Spectroscopy in Asymptomatic Individuals With High Coronary Artery Calcium Scores	RESEARCH/RESEARCH GRANTS - Corindus Vascular Robotics,Infraredx
Maddox	Thomas	Updates in Stable Ischemic Heart Disease	Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-World Impact of the Leader Trial on Improving Cardiovascular Outcomes in Patients With Diabetes at High Cardiovascular Risk	SPEAKER'S BUREAU - Creative Educational Concepts CME
Maddox	Thomas	Innovations in Practice Management and Social Media	Impact of Electronic Health Records on the Quality of Outpatient Cardiovascular Care Delivery in India: Insights From the American College of Cardiology's PINNACLE India Quality Improvement Program (PIQIP)	SPEAKER'S BUREAU - Creative Educational Concepts CME
Maddox	Thomas	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	A Retrospective Descriptive Analysis of PCI Patients by Indication for Treatment, Comorbidities, and Lipid Therapy Using Real-World, Linked NCDR Registry and Pharmacy Claims Data	SPEAKER'S BUREAU - Creative Educational Concepts CME
Maddox	Thomas	Advances in Lipid Management	Implications of the IMPROVE-IT Trial for Contemporary Cardiovascular Practice: An NCDR [®] Research to Practice (R2P) Project	SPEAKER'S BUREAU - Creative Educational Concepts CME
Maddox	Thomas	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Implications of the FDA Approval of PCSK9 Inhibitors for Contemporary Cardiovascular Practice: Findings From the NCDR [®] Research to Practice (R2P) Project	SPEAKER'S BUREAU - Creative Educational Concepts CME
Maddox	Thomas	03. Acute and Stable Ischemic Heart Disease: Therapy Team 3	Suggested Reviewer	SPEAKER'S BUREAU - Creative Educational Concepts CME
Madhavan	Mahesh	Interventional Cardiology: PCI and TAVR in Complex Patients	Long-Term Adverse Ischemic Outcomes After Percutaneous Coronary Intervention Among Patients With Versus Without Prior Coronary Artery Bypass Grafting: Analysis From 17 Randomized Trials	Nothing to Disclose
Madhavan	Malini	Atrial Fibrillation and VT: Specific Situations	Thans Does Frailty Alter the Benefits of Oral Anticoagulation in Patients With Atrial Fibrillation?	CONSULTANT FEES/HONORARIA - Convatec Inc.
Madhavan	Malini	and Newer Outcome Measures Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	With Atrial I-Ibrillation? Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin	CONSULTANT FEES/HONORARIA - Convatec Inc.
Madhavan	Malini Magnakahi	Stroke and AF: Thinking About the Heart	ACC Poster Moderator Status of Early Career Academic Cardiology: A Global Perspective	CONSULTANT FEES/HONORARIA - Convatec Inc.
Madhur	Meenakshi	Innovations in Advocacy and Patient Centered Care	, , , , , , , , , , , , , , , , , , , ,	Nothing to Disclose
Madhur Madias	Meenakshi Christopher	FIT Clinical Decision Making Reviewers 3 Arrhythmias and Heart Failure	ACC FIT Clinical Decision Making Reviewer Quadripolar Versus Bipolar Left Ventricular Leads in Cardiac	Nothing to Disclose Nothing to Disclose
Madias	Christopher	05. Arrhythmias and Clinical EP: Devices	Resynchronization Therapy: An Analysis From the NCDR Suggested Reviewer	Nothing to Disclose
Madiraju	SriGita	Team 1 Arrhythmias and Clinical EP: Devices 2	Selective Same Day Discharge After Biventricular Implantation as a	Nothing to Disclose
Madjid	Mohammad	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Value Based Strategy: Safe and Cost Effective Influenza Epidemics Are Associated With an Increased Risk of Ventricular Arrhythmia Therapies in Patients With Implantable Cardiac Defibrillators or Cardiac Resynchronization	Nothing to Disclose
Madmani	Mohammed Eid	Interventional Cardiology: Stent Failure	Defibrillators Does Post Pci Ffr Carry the Same Prognostic Weight as Non-	Nothing to Disclose
		Analysis by Intravascuar Imaging	Ischemic Ffr in Deferred Lesions?	g to Disclose

and the second				<u> </u>
Madu	First Name Chinedu	Session Title Innovations in Cardiovascular Risk Assessment and Reduction	Underestimate Coronary Artery Disease in African-American	Disclosures Nothing to Disclose
Madvig Mogensen	Ulrik	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Patients Evidence Based Therapy and Its Relation to Workforce Attachment Following First Hospitalization for Heart Failure	CONSULTANT FEES/HONORARIA - MSD, honoraria for lecture, Novo Nordisk Inc., MSD, honoraria for lecture
Mady	Charles	Population Specific Cardiomyopathies: From Exomes to Databases	Air Pollution in Myocardial Remodeling	Nothing to Disclose
Maeda	Katsuhide	Valvular Heart Disease: Aortic Regurgitation	Identification of Human Aortic Valve Leaflet Genes Associated With Disruption of Homeostasis in Aortic Regurgitation and Aortic Stenosis Patients	CONSULTANT FEES/HONORARIA - Heartware company
Maeder	Micha	Emerging Developments in HFpEF and Arryhthmias	Age Specific Hemodynamic Features in HFPEF: Implications for Therapy	Nothing to Disclose
Maehara	Akiko	Highlighted Original Research: Interventional Cardiology and the Year in Review	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,St Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific Corporation,St Jude Medical
Maehara	Akiko	Considerations in Antiplatelet Therapy and in ACS	Platelet Reactivity and Outcomes After PCI of Lesions With and Without In-Stent Restenosis: The ADAPT-DES Study	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,St Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific Corporation,St Jude Medical
Maehara	Akiko	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Atherosclerotic Plaque Morphology in Response to High Intensity Lipid Lowering Therapy by Multimodality Imaging Among Women and Men: A YELLOW-II Sub-study	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,St Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific Corporation,St Jude Medical
Maehara	Akiko	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Optical Coherence Tomography Assessment of Coronary Atherectomy Effect: Comparison Between Orbital and Rotational Atherectomy in Severely Calcified Lesions	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,St Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific Corporation,St Jude Medical
Maehara	Akiko	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Comparison of Coronary Calcification Detection Between Multi- Detector Computed Tomography and Optical Coherence Tomography	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,St Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific Corporation,St Jude Medical
Maehara	Akiko	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Morphologic Patterns of In-Stent Chronic Total Occlusions: An Intravascular Ultrasound Study	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation, St Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific Corporation, St Jude Medical
Maehara	Akiko	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	The Effectiveness of Excimer Laser Angioplasty to Treat Coronary In-Stent Restenosis With Peri-Stent Calcium as Assessed by Optical Coherence Tomography	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,St Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific Corporation,St Jude Medical
Maehara	Akiko	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Twelve Month Follow-Up Data From the ONYX CORE Trial: Angiographic and Clinical Performance of Next Generation Resolute Onyx Drug-Eluting Stent	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,St Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific Corporation,St Jude Medical
Maehara	Akiko	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Comparison of Optical Coherence Tomography Versus Intravascular Ultrasound Detection of Tissue Protrusion and Acute Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent Implantation	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,St Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific Corporation,St Jude Medical
Maehara	Akiko	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Intravascular Ultrasound Assessment of the Effects of Rotational Atherectomy in Calcified Coronary Artery Lesions	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,St Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific Corporation,St Jude Medical
Maehara	Akiko	Interventional Cardiology: PCI in Complex Patients	Chronic Stent Recoil During Follow-Up in Severely Calcified Coronary Artery Lesions: An Optical Coherence Tomography Study	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,St Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific Corporation,St Jude Medical
Maehara	Akiko	Interventional Cardiology: PCI in Complex Patients	Procedural Calcium Fracture and Its Effect on Stent Expansion Assessed by Optical Coherence Tomography	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,St Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific Corporation,St Jude Medical
Maehara	Akiko	23. Interventional Cardiology: IVUS and Intravascular Physiology Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,St Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific Corporation,St Jude Medical
Maehara	Akiko	Interventional Challenging Cases: Team 3	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,St Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific Corporation,St Jude Medical
Maekawa	Yuichiro	Unusual Presentations of ACS	C-Reactive Protein in Non-ST Elevation Myocardial Infarction Patients Is Useful in Improving Discrimination of Conventional Risk Score: A Report From Multicenter PCI Registry	Nothing to Disclose
Maeno	Yoshio	Refining TAVR Outcomes	Frame Geometry and Hemodynamic Findings of Sapien 3 Transcatheter Heart Valve in Patients With Bicuspid Aortic Valve Disease	Nothing to Disclose
Maffei	Erica	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography: The CONFIRM (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	Nothing to Disclose
Maganti	Kameswari	28. Non Invasive Imaging: Echo Team 1	Suggested Reviewer	Nothing to Disclose
Magaret	Craig	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Multiple Biomarkers for Predicting Major Adverse Cardiac Events in At-Risk Patients Undergoing Diagnostic Coronary Angiography: Results From the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study	CONSULTANT FEES/HONORARIA - Prevencio, Inc.
Magid	David	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Impact of Medical Liability Reform on Coronary Artery Disease Testing and Intervention	Nothing to Disclose
Magnani	Andrea	Emerging Developments in HFpEF and Arryhthmias	Prognostic Role of Ventricular-Arterial Coupling in Patients With Left Ventricular Dysfunction Submitted to Cardiac Resynchronization Therapy	Nothing to Disclose
Magne	Julien	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Impact of Renin-Angiotensin System Blockers on Long Term Survival Following Isolated Aortic Valve Replacement for Aortic Stenosis	Nothing to Disclose
Magne	Julien	Novel Determinants of Outcomes in VHD	Electrocardiographic Strain Is Associated With Reduced Survival After Surgical Aortic Valve Replacement for Aortic Stenosis	Nothing to Disclose
Magnusson	Martin	Making Progress in Understanding Heart Failure	NT-proBNP, Left Ventricular Structure and Function, and Long- Term Cardiovascular Events: Insights From a Prospective Population-Based Cohort Study	Nothing to Disclose
Magnusson	Martin	The Evolving World of LVADs, Transplant and Other Novel Discoveries	High-Sensitivity Troponin-T, Left Ventricular Size and Function, and Long-Term Outcomes in Clinically Stable, Apparently Healthy Older Subjects	Nothing to Disclose
Maguire	Andrew	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	What Are the Differences in Oral Anticoagulant Treatment Persistence in Non-Valvular Atrial Fibrillation in Europe? Real-World Studies in Three European Countries	Nothing to Disclose
Mah	Douglas	Arrhythmias and Clinical EP: Devices 1	Coronary Artery Compression by Epicardial Leads: More Common Than We Think	Nothing to Disclose
Mah	Douglas	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Idiopathic Fascicular Left Ventricular Tachycardia and Dilated Cardiomyopathy: An Unusual Combination in a 19-Year-Old College Athlete	Nothing to Disclose
Mah	Douglas	Congenital Heart Disease: Novel Insights in Pediatric Cardiology	Rhythm Abnormalities in Children and Young Adults With Marfan Syndrome	Nothing to Disclose
Mah	Kandice	Congenital Heart Disease: Innovations in	Right Ventricular Remodelling in Hypoplastic Left Heart Syndrome:	Nothing to Disclose
Mahadevan	Vaikom	Single Ventricle Heart Disease The Story of the Adult Congenital Heart	Impact of the Norwood and Hybrid Procedures Prevalence and Predictors of Atrial Tachyarrhythmias in Adult	CONSULTANT FEES/HONORARIA - Edwards Life Sciences,St
Mahadevan	Vaikom	Disease Patient and EP FIT Clinical Decision Making: Prevention, Adult	Fontan Patients Coronary Artery Fistula in Pulmonary Atresia With Intact Ventricular	Jude Medical; SPEAKER'S BUREAU - Actelion CONSULTANT FEES/HONORARIA - Edwards Life Sciences,St
		Congenital and Congenital Heart Disease	Septum Physiology: To Close or Not To Close ?	Jude Medical; SPEAKER'S BUREAU - Actelion



The state of the s					
Last Name Mahadevan	First Name Vaikom	Session Title Fontan in the Modern World	Presentation Title Prevalence of Elevated Body Mass Index and Its Association With	Disclosures CONSULTANT FEES/HONORARIA - Edwar	
Mahadevan	Vaikom	Arrhythmias and Clinical EP: Devices 3	Clinical Features in Adult Fontan Patients Transcatheter Closure of Residual Left Atrial Appendage Leaks	Jude Medical; SPEAKER'S BUREAU - Acteli CONSULTANT FEES/HONORARIA - Edwar	
Mahadevan	Vaikom	Redefining the "F" Word	Following Lariat Device Closure Prevalence and Predictors of Pacemaker Placement in Adult	Jude Medical; SPEAKER'S BUREAU - Acteli CONSULTANT FEES/HONORARIA - Edwar	
	Kenneth	The Fundamentals of ACS Trials—Pitfalls in	Fontan Patients Surrogate EndoointsProvide no Insight in ACS Trials: Pro	Jude Medical; SPEAKER'S BUREAU - Acteli CONSULTANT FEES/HONORARIA - Astraz	on
Mahaffey	remen	Cardiovascular Endpoints	Surrogate Entipolitis-Flovide to illisgift in AGS Trials: Flo	Pharmaceuticals, Boehringer Ingelheim Phan Inc, Bristol Myers Squibb, Janssen Pharmace & Amp; amp; Co., Inc., Novartis Corporation, Sp. Inc., WebMD; DATA SAFETY MONITORING Afferent, Ferring Pharmaceuticals, MyoKardia Ablym, Boehringer Ingleheim, Cardiometaloi Congress, Elsevier, GlaxoSmithKline, Oculeve, RESEARCH/RESEARCH GRANTS - Amger Pharmaceuticals, Janssen Pharmaceuticals, Inc, MEDTRONIC, Merck & Degram; Co., Inc Corporation, St Jude, Verily (Google)	maceuticals, titicals, Inc,Merck viringer,Theravance, BOARD - OTHER - c Health Portola,Radiometer; Inc.,AstraZeneca
Mahaffey	Kenneth	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of Periprocedural Myocardial Infarction in Contemporary PCI: Pooled Patient-Level Data From the CHAMPION Trials	CONSULTANT FEES/HONORARIA - Astra: Pharmaceuticals, Boehringer Ingelheim Phan Inc, Bristol Myers Squibb, Janssen Pharmacet & Bamp; Go., Inc., Novartis Corporation, Sp. Inc., WebMD; DATA SAFETY MONITORING Afferent, Ferring Pharmaceuticals, MyoKardia Ablynx, Boehringer Ingleheim, Cardiometaboli Congress, Elsevier, Glaxos mith Kline, Oculeve RESEARCH/RESEARCH GRANTS - Amger Pharmaceuticals, Janssen Pharmaceuticals, Inc, MEDTRONIC, Merck & Bamp; amp; Co., Inc Corporation, St Jude, Verily (Google)	maceuticals, titicals, Inc,Merck viringer,Theravance, BOARD - OTHER - c Health Portola,Radiometer; Inc.,AstraZeneca
Mahaffey	Kenneth	Arrhythmias and Clinical EP: Anticoagulation Issues	Thrombolytic Therapy in Anticoagulated Patients: Case Series From Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET AF)	CONSULTANT FEES/HONORARIA - Astraz Pharmaceuticals, Boehringer Ingeliehiem Phan Inc, Bristol Myers Squibb, Janssen Pharmaceut & Amparame, Bander Bander, Bander, Ban	maceuticals, titicals, Inc,Merck viringer,Theravance, BOARD - OTHER - c Health Portola,Radiometer; Inc.,AstraZeneca
Mahaffey	Kenneth	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Does Frailty Alter the Benefits of Oral Anticoagulation in Patients With Atrial Fibrillation?	CONSULTANT FEES/HONORARIA - Astra/ Pharmaceuticals, Boehringer Ingelheim Phan Inc, Bristol Myers Squibb, Janssen Pharmaceut &,amp, Co., Inc., Novartis Corporation, Sy Inc., WebMD: DATA SAFETY MONITORING Afferent, Ferring Pharmaceuticals, MyoKardia Ablynx, Boehringer Ingleheim, Cardiometaboli Congress, Elsevier, Glaxxoffikhline, Oculeve RESEARCH/RESEARCH GRANTS - Amger Pharmaceuticals, Janssen Pharmaceuticals, Inc, MEDTRONIC, Merck & Co., Inc Corporation, St Jude, Verily (Google)	maceuticals, titicals, Inc,Merck viringer,Theravance, BOARD - OTHER - c Health Portola,Radiometer; Inc.,AstraZeneca
Mahaffey	Kenneth	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)	CONSULTANT FEES/HONORARIA - Astraz Pharmaceuticals, Boehringer Ingelheim Phan Inc, Bristol Myers Squibb, Janssen Pharmaceute & Amp, and Pharmaceute & Amp, amp, Co., Inc., Novartis Corporation, Sp Inc., WebMD; DATA SAFETY MONITORING Afferent, Ferring Pharmaceuticals, MyoKardia Ablynx, Boehringer Ingleheim, Cardiometaboli Congress, Elsevier, Glaxos mith Kline, Oculeve RESEARCH/RESEARCH GRANTS - Amger Pharmaceuticals, Janssen Pharmaceuticals, Inc, MEDTRONIC, Merck & Demp, amp, amp, Co., Inc Corporation, St Jude, Verily (Google)	maceuticals, titicals, Inc,Merck viringer,Theravance, BOARD - OTHER - c Health Portola,Radiometer; Inc.,AstraZeneca
Mahaffey	Kenneth	Optimizing the Care of ACS Patients	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin: Insights From CHAMPION PHOENIX	CONSULTANT FEES/HONORARIA - Astraz Pharmaceuticals, Boehringer Ingelheim Phan Inc, Bristol Myers Squibb, Janssen Pharmaceut & Amparame, Co., Inc., Novartis Corporation, Sp Inc., WebMD; DATA SAFETY MONITORING Afferent, Ferring Pharmaceuticals, MyoKardia Ablynx, Boehringer Ingleheim, Cardiometaboli Congress, Elsevier, Glaxos Mithkline, Oculeve RESEARCH/RESEARCH GRANTS - Amger Pharmaceuticals, Janssen Pharmaceuticals, Inc, MEDTRONIC, Merck & Demp; Co., Inc Corporation, St Jude, Verily (Google)	maceuticals, titicals, Inc,Merck viringer,Theravance, BOARD - OTHER - c Health Portola,Radiometer; Inc.,AstraZeneca
Mahaffey	Kenneth	Post-CAD/MI: Making Tough Predictions About the Future	One-Year Mortality Increased in Patients With Peri-Procedural Myocardial Infarction: Insights From the CHAMPION Trials	CONSULTANT FEES/HONORARIA - Astraz Pharmaceuticals, Boehringer Ingelheim Pharn Inc, Bristol Myers Squibb, Janssen Pharmacet & Amp, and Pharmacet & Amp, and Pharmacet & Amp, and Pharmacet & Amp, and Pharmacet & Amp, and Pharmaceuticals, MyoKardia Ablynx, Boehringer Ingleheim, Cardiometaboli Congress, Elsevier, Glaxos Mithkline, Oculeve RESEARCH/RESEARCH GRANTS - Amger Pharmaceuticals, Janssen Pharmaceuticals, Inc, MEDTRONIC, Merck & Amp, amp; Co., Inc Corporation, St Jude, Verily (Google)	maceuticals, titicals, Inc,Merck viringer,Theravance, BOARD - OTHER - c Health Portola,Radiometer; Inc.,AstraZeneca

Secretic Notes of Particular Theorems Alvers a Sidisty Tool Secretic Store Corp. Fr Particular University of the Model of the Model of the Corp. Fr Particular University of the Model of the Model of the Model of the Model of the Model of the Model of the Model of the Model of the Model of the Model of the Model	Contract of the second				I
Citized Team 7 2 The Control Team 2 2 The	Last Name Mahaffey	Kenneth	Anti-Platelet Therapies: Always a Sticky Topic	Reduced With Cangrelor: Findings From CHAMPION PHOENIX	Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc,Bristol Myers Squibb, Janssen Pharmaceuticals, Inc,Merck & Amp; amp; Co., Inc., Novartis Corporation, Springer, Theravance, Inc., WebMD; DATA SAFETY MONITORING BOARD - Afferent, Ferring Pharmaceuticals, MyoKardia; OTHER - Ablymx, Boehringer Ingleheim, Cardiometabolic Health Congress, Elsevier, GlaxoSmithKline, Oculeve, Portola, Radiometer; RESEARCH/RESEARCH GRANTS - Amgen Inc., AstraZeneca Pharmaceuticals, Janssen Pharmaceuticals, Inc,MEDTRONIC, Merck & Amp, amp; Co., Inc., Novartis Corporation, St Jude, Verily (Google)
Malester Cester Other Economy Officer of LVADs, Transplant or Performance of the MAGIC Flear State Red Score in Jugarese Moring to Declare Cester Officer (1997) and the Cester Officer of Cester State Red Score in Jugarese Moring to Declare State Red Score in Jugarese Moring to Declare State Red Score in Jugarese Moring to Declare State Red Score in Jugarese Moring to Declare Red Score in Jugarese Moring	Mahaffey	Kenneth		Suggested Reviewer	Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc. Merck Inc. Bristol Myers Squibb., Janssen Pharmaceuticals, Inc., Merck & Amp; amp; Co., Inc., Novartis Corporation, Springer, Theravance, Inc., WebMD; DATA SAFETY MONITORING BOARD - Afferent, Ferring Pharmaceuticals, MyoKardia; OTHER - Ablym, Boehringer Ingleheim, Cardiometabolic Health Congress, Elsevier, GlavoSmithkline, Oculeve, Portola, Radiometer; RESEARCH/RESEARCH GRANTS - Amgen Inc., Astra Zeneca Pharmaceuticals, Janssen Pharmaceuticals, Inc., MEDTRONIC, Merck & Amp; pamp; Co., Inc., Novartis
Merer James Jersey Regulation: Symbis in Plan Sight Jersey Regulation Symbis in Plan Sight Jerse			The Evolving World of LVADs, Transplant and	Performance of the MAGGIC Heart Failure Risk Score in Japanese Acute Heart Failure Patients: A Report From the West Tokyo Heart	
Martiner James Poole Needmacros (Person Redmacros) (Person Needmac	Mahara	Keitaro	Tricuspid Regurgitation: Signals in Plain Sight	Impact of Atrial Fibrillation on Tricuspid Valve Annular Morphology in	Nothing to Disclose
Merler Manuscul Services Manus	Maher	James		Trends in Utilization of Inpatient Palliative Care Services and Racial Disparity of Disposition to Hospice Care Among Patients With Heart	SPEAKER'S BUREAU - Bayer
Members Members Management of the Composition of Composition (Composition of Comp	Maher	James	FIT Clinical Decision Making: Heart Failure and	Failure in the United States Between 2003 and 2012 Dissolve It or Take It Out: Excellent Outcome of Right-Sided Heart	SPEAKER'S BUREAU - Bayer
Maintenant Verum Congresial enter Disease (Perentition And Services Congresial enter Disease) Maintenant Heritary (Perentition William Congresial enter Disease) Maintenant Heritary (Perentition William Congresial enter Disease) Maintenant Heritary (Perentition William Congresial enter Disease) Maintenant Heritary (Perentition William Congresial enter Disease) Maintenant William Post Surgicial Congresia (Perentition William Congresia) Maintenant William Post Surgicial Congresia (Perentition William Congresia) Maintenant William Post Surgicial Congresia (Perentition William Congresia) Maintenant William Post Surgicial Congresia (Perentition William Congresia) Maintenant William Post Surgicial Congresia (Perentition William Congresia) Maintenant William Post Surgicial Congresia (Perentition William Congresia) Maintenant William Post Surgicial Congresia (Perentition William Congresia) Maintenant William Post Surgicial Congresia (Perentition William Congresia) Maintenant William Post Surgicial Congresia (Perentition William Congresia) Maintenant William Post Surgicial Congresia (Perentition William Congresia) Maintenant William Post Surgicial Congresia (Perentition William Congresia) Maintenant William Post Surgicial Congresia (Perentition William Congresia) Maintenant William Post Surgicial Congresia (Perentition William Congresia) Maintenant William Post Surgicial Congresia (Perentition William Congresia) Maintenant William Post Surgicial Congresia (Perentition William Congresia) Maintenant William Post Surgicial Congresia (Perentition William	Mahesh	Mahadevappa	Radiation from Diagnostic Imaging: Risk-		Nothing to Disclose
Matritood Hoddadd Toufk Meesuring Scooss in Cardidon Rehabilitation Matritood Hoddadd Toufk Meesuring Scooss in Cardidon Rehabilitation Matritood Hoddadd Toufk Meesuring Scooss in Cardidon Rehabilitation Matritood Hoddadd Toufk Meesuring Scooss in Cardidon Rehabilitation Matritood Hoddadd Toufk Arthythmiss and Cardidon Rehabilitation Matritood Hoddadd Toufk Arthythmiss and Secretary Matritood Hoddadd Toufk Arthythmiss and Secretary Matritood Hoddadd Toufk Matritood Hoddadd Toufk Matritood Hoddadd Matritood Hodd	Maheshwari	Varun	FIT Clinical Decision Making: Prevention, Adult	Adult With Unrepaired Pentalogy of Fallot Presenting With	Nothing to Disclose
Melmood Hedded Toufik Messuring Success in Cardioc Rehabilistion (Melmood Hedded Toufik Anthyl Tracking Devices and Support Programs: A Metes Melmood Hedded Toufik Anthyl Tracking Devices and Support Programs: A Metes Melmood Hedded Toufik Anthyl Tracking Devices and Support Programs: A Metes Melmood Hedded Toufik Anthyl Tracking Devices and Support Programs: A Metes Melmood Melm	Mahfood Haddad	Toufik		Therapeutic Hypothermia for In-Hospital Cardiac Arrest: A Meta-	Nothing to Disclose
Melhodo Ahmed FT Chical Document Matery Arrhythmas and Feat Failure Margoub Ahmed FT Chical Document Matery Arrhythmas and Experiment Matery And Section Matery Arrhythmas and Experiment Matery And Section Matery Arrhythmas and Experiment Matery And Section Matery Arrhythmas and Experiment Matery And Section Matery Arrhythmas and Experiment Matery And Section Matery Andrease in Chiestesper Matery M	Mahfood Haddad	Toufik		Wrist Activity Tracking Devices and Support Programs: A Meta-	Nothing to Disclose
Marbodu Ahmed STT Cinical Decision Making Arrhythmisa and Selection Procession Making and Procession Making Analysis and Pro	Mahfood Haddad	Toufik	Arrhythmias and Heart Failure	Prognostic Impact of Premature Atrial Complexes in the General	Nothing to Disclose
Manisha Christopher Advances in Choestero Measurement and Annagement of Management of Chiefer Measurement and Annagement of Management of Chiefer Measurement and Annagement of Chiefer Measurement and Annagement of Chiefer Measure	Mahgoub	Ahmed		Bidirectional Ventricular Tachycardia in Critically III Patients on	Nothing to Disclose
Mahle William Post-Surgical Care of Children with CHD Prom CLU by Voir Office Prom CLU by Voir Office Prom CLU by Voir Office Prom CLU by Voir Office Prom CLU by Voir Office Prom CLU by Voir Office Prom CLU by Voir Office Prom CLU by Voir Office Prom CLU by Voir Office Prom CLU by Voir Office Prom CLU by Voir Office Prom Clu by Voir Office	Mahida	Christopher	Advances in Cholesterol Measurement and	10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated	Nothing to Disclose
Mahmarian John Process Pain In the Emergency Important Role of SPECT Nuclear Imaging in the ED Conduct TATE FEESHONGRAFIA. Astellas Pharma; SPEAMER'S BUREAU - Astellas Pharma	Mahle	William			Nothing to Disclose
Department John Highlighted Original Research: Non Invasive Imaging and the Year in Review Memarian John Nuclear Cardiology: Quality Worker Wastion in the Use of Muclear Cardiology Camera Worker Wastion in the Use of Muclear Cardiology Camera Worker Wastion in the Use of Muclear Cardiology Camera Worker Wastion in the Use of Muclear Cardiology Camera Worker Wastion in the Use of Muclear Cardiology Camera Worker Wastion in the Use of Muclear Cardiology Camera Worker Wastion in the Use of Muclear Cardiology Camera Worker Wastion in the Use of Muclear Cardiology Camera Worker Wastion in the Use of Muclear Cardiology Camera Worker Wastion in the Use of Muclear Cardiology Camera Worker Wastion in the Use of Muclear Cardiology Protocols: Study Worker Wastion in the Use of Muclear Cardiology Protocols Study Worker Wastion in the Use of Muclear Cardiology Protocols Study Worker Wastion in the Use of Muclear Cardiology Protocols Study Worker Wastion in the Use of Muclear Cardiology Protocols Study Worker Wastion in the Use of Muclear Cardiology Protocols Study Worker Wastion in the Use of Muclear Cardiology Protocols Study Worker Wastion in the Use of Muclear Cardiology Protocols Study Worker Wastion in the Use of Muclear Cardiology Protocols Study Worker Wastion in the Use of Muclear Cardiology Protocols Study Worker Wastion in the Use of Muclear Cardiology Protocols Study Worker Wastion Protocols Study Worker Wastion Protocols Study Worker Wastion Protocols Study Worker Wastion Protocols Study Worker Wastion Protocols Study Worker Wastion Protocols Study Worker Wastion Protocols Study Worker Wastion Protocols Study Worker Wastion Protocols Protocols Study Worker Wastion Protocols Prot	Mahle	William		Suggested Reviewer	Nothing to Disclose
Mahmarian John Highlighted Original Research: Non Inwasive Imaging and the Year in Review Word Emergency Department Settings Mahmarian John Nuclear Cardiology: Quality Setsing: Comparison of Clinical and Euclear Cardiology Camera Technology, Reconstruction Software, and Acquisition Protocols: SPEAKER'S BUREAU. Astellas Pharma Wordselve Variation in the Use of Nuclear Cardiology Country Technology, Reconstruction Software, and Acquisition Protocols: SPEAKER'S BUREAU. Astellas Pharma; Principal From the ReA Nuclear Cardiology Protocols Study Mahmarian John 27. Non Invasive Imaging: CTAfultimodality, Angiography, and Non-CT Angiography Team 27. Non Invasive Imaging: CTAfultimodality, Angiography, and Non-CT Angiography Team 27. Non Invasive Imaging Control of Mahmarian 27. Non Invasive Imaging Control of Mahmarian 28. Setsian Set	Mahmarian	John		Important Role of SPECT/Nuclear Imaging in the ED	
Tochnology, Reconstruction Software, and Acquisition Protocols: Findings From the IAEA Nuclear Cardiology Protocols Study (INCAPS)			Imaging and the Year in Review	Testing: Comparison of Clinical and Economic Outcomes in Real- World Emergency Department Settings	SPEAKER'S BUREAU - Astellas Pharma
Angiography, and Non-CT Angiography Team 2 Great Minds Think Differently: Multidisciplinary Approach to Imaging Approach to Masing Mahmood Feroze Great Minds Think Differently: Multidisciplinary Approach to Imaging Approach Approach to Imaging Approach to Imaging Approach to Imaging Approach to Imaging Approach to Imaging Approach to Imaging Approach to Imaging Approach to Imaging Approach to Imaging Approach to Imaging Approach to Imaging Approach to Imaging Approach to Imaging Approach Approach Approach Approach Approach Approach Approac	Mahmarian	John	Nuclear Cardiology: Quality	Technology, Reconstruction Software, and Acquisition Protocols: Findings From the IAEA Nuclear Cardiology Protocols Study	
Approach to Imaging Approach Approac	Mahmarian	John		Suggested Reviewer	
Mahmoud Ahmed FIT Clinical Decision Making: Non-invasive imaging and Valvular Heart Disease FIT Clinical Decision Making: Non-invasive imaging and Valvular Heart Disease FIT Clinical Decision Making: Non-invasive imaging and Valvular Heart Disease FIT Clinical Decision Making: Non-invasive imaging and Valvular Heart Disease FIT Clinical Decision Making: Non-invasive imaging and Valvular Heart Disease FIT Clinical Decision Making: Non-invasive imaging and Valvular Heart Disease Fit Cardiac English Cardiac			Approach to Imaging	Our Surgical Colleagues	-
Imaging and Valvular Heart Disease Right Upper Lung Lobe Infiltrate Septic Cardiac Press Septic Press Se	Mahmood		Approach to Imaging	, , , , , ,	
Imaging and Valvular Heart Disease Infective Endocarditis Cardiec Arrest, Diabetes, and Other High Risk Early Invasive Strategy and In-Hospital Survival of Diabetics With Nothing to Disclose Nothing to Disclo			Imaging and Valvular Heart Disease	Right Upper Lung Lobe Infiltrate	-
Features of Patients With Acute Coronary Syndrome Mahmoud Ahmed PCI Strategies and Outcomes Unique to Women Mahmoud Ahmed PCI Strategies and Outcomes Unique to Women Mahmoud M			Imaging and Valvular Heart Disease	Infective Endocarditis	-
Mahmoud Karim Innovations in Cardiovascular Risk Assessment Hemodynamic Predictors of Left Ventricular Mass Index in the and Reduction Advances in Chronic Total Occlusion Intervention Intervention Intervention Ehitsham Advances in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Advances in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Advances in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Advances in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Advances in Chronic Total Occlusion Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry Abiomed; RESEARCH/RESEARCH GRANTS - Corindus; SPEAKER'S BUREAU - MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abiomed; RESEARCH/RESEARCH GRANTS - Corindus; SPEAKER'S BUREAU - MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abiomed; RESEARCH/RESEARCH GRANTS - Corindus; SPEAKER'S BUREAU - MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abiomed; RESEARCH/RESEARCH GRANTS - Corindus; SPEAKER'S BUREAU - MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abiomed; RESEARCH/RESEARCH GRANTS - Corindus; SPEAKER'S BUREAU - MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abiomed; RESEARCH/RESEARCH GRANTS - Corindus; SPEAKER'S BUREAU - MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abiomed; RESEARCH/RESEARCH GRANTS - Corindus; SPEAKER'S BUREAU - MEDTRONIC Mahnikopf Christian Arrhythmias and Clinical EP; Basic 5 Cryoballoon Ablation Targeting Left Atrial Fibrosis Produces Similar Outcomes in Paroxysmal and Persistent Atrial Fibrosis Produces Similar Outcomes in Paroxysmal and Persistent Atrial Fibrillation PE Management in the Community Setting BUREAU - Abbott Vascular	wahmoud	Ahmed	Features of Patients With Acute Coronary Syndrome	Non-ST-Elevation Myocardial Infarction: A Contemporary National Insight	Inotning to Disclose
Mahmoud Karim	Mahmoud	Ahmed		Women With Non-ST-Elevation Acute Coronary Syndrome: A	Nothing to Disclose
Ehtisham	Mahmoud			Hemodynamic Predictors of Left Ventricular Mass Index in the General Population	-
Mahmud Ehtisham Advances in Chronic Total Occlusion Intervention Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry Mahmud Ehtisham 21. Interventional Cardiology: Coronary Intervention: Devices Team 2 Suggested Reviewer CONSULTANT FEES/HONORARIA - Abbott Vascular, Corindus, Medicines Company, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abiomed; RESEARCH/RESEARCH GRANTS - Corindus; SPEAKER'S BUREAU - MEDTRONIC CONSULTANT FEES/HONORARIA - Abbott Vascular, Corindus, Medicines Company, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abiomed; RESEARCH/RESEARCH GRANTS - Corindus; SPEAKER'S BUREAU - MEDTRONIC OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abiomed; RESEARCH/RESEARCH GRANTS - Corindus; SPEAKER'S BUREAU - MEDTRONIC Outcomes in Paroxysmal and Persistent Atrial Fibrillation Maholic Robert Multi-Disciplinary Care for Acute Pulmonary Embolism: The PE Response Team (PERT) PE Management in the Community Setting CONSULTANT FEES/HONORARIA - EKOS corp; SPEAKER'S BUREAU - Abbott Vascular	Mahmud	Ehtisham	Advances in Chronic Total Occlusion	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From	Vascular, Corindus, Medicines Company, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abiomed; RESEARCH/RESEARCH GRANTS - Corindus;
Mahmud Ehtisham 21. Interventional Cardiology: Coronary Intervention: Devices Team 2 Suggested Reviewer CONSULTANT FEES/HONORARIA - Abbott Vascular, Corindus, Medicines Company, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abiomed: RESEARCH/RESEARCH GRANTS - Corindus; SPEAKER'S BUREAU - MEDTRONIC Mahnkopf Christian Arrhythmias and Clinical EP: Basic 5 Cryoballoon Ablation Targeting Left Atrial Fibrosis Produces Similar Outcomes in Paroxysmal and Persistent Atrial Fibrillation Outcomes in Paroxysmal and Persistent Atrial Fibrillation Maholic Robert Multi-Disciplinary Care for Acute Pulmonary Embolism: The PE Response Team (PERT) PE Management in the Community Setting BUREAU - Abbott Vascular	Mahmud	Ehtisham		Occlusion Percutaneous Coronary Intervention: An Update From a	CONSULTANT FEES/HONORARIA - Abbott Vascular, Corindus, Medicines Company, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abiomed; RESEARCH/RESEARCH GRANTS - Corindus;
Mahnkopf Christian Arrhythmias and Clinical EP: Basic 5 Cryoballoon Ablation Targeting Left Atrial Fibrosis Produces Similar Nothing to Disclose Outcomes in Paroxysmal and Persistent Atrial Fibrillation Maholic Robert Multi-Disciplinary Care for Acute Pulmonary Embolism: The PE Response Team (PERT) PE Management in the Community Setting BUREAU - Abbott Vascular	Mahmud		Intervention: Devices Team 2		CONSULTANT FEES/HONORARIA - Abbott Vascular Corindus Medicines Company MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Ablomed; RESEARCH/RESEARCH GRANTS - Corindus; SPEAKER'S BUREAU - MEDTRONIC
Maholic Robert Multi-Disciplinary Care for Acute Pulmonary Embolism: The PE Response Team (PERT) PE Management in the Community Setting CONSULTANT FEES/HONORARIA - EKOS corp; SPEAKER'S BUREAU - Abbott Vascular	·	Christian		Outcomes in Paroxysmal and Persistent Atrial Fibrillation	Nothing to Disclose
	Maholic	Robert	Embolism: The PE Response Team (PERT)	PE Management in the Community Setting	

Control of the contro				
Last Name Mahoney	First Name Paul	Session Title Great Minds Think Differently: Multidisciplinary Approach to Advanced Therapies	Presentation Title Panelist	Disclosures CONSULTANT FEES/HONORARIA - Boston Scientific,Edwards Lifescience,MEDTRONIC; SPEAKER'S BUREAU - Abbott
Mahoney	Paul	Great Minds Think Differently: Multidisciplinary Approach to Advanced Therapies	One More for the Heart Team: Expanding Your Practice to Include Complete Revascularization in Higher-risk Indicated Patients (CHIP)	Laboratories, Abiomed CONSULTANT FEES/HONORARIA - Boston Scientific, Edwards Lifescience, MEDTRONIC; SPEAKER'S BUREAU - Abbott Laboratories, Abiomed
Mahrous	Ahmad	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Prognostic Significance of Co-Existing Persistent Edema and Hemorrhage at 6 Months in Survivors of ST-Elevation Myocardial Infarction	Nothing to Disclose
Mahrous	Ahmad	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Incidence and Prognostic Implications of the Presence of Multiple Complex Plaques in Survivors of ST-Elevation Myocardial Infarction	Nothing to Disclose
Mahtta	Dhruv	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Septic Cardiac Tamponade as a Rare Presentation of Acute Infective Endocarditis	Nothing to Disclose
Maier	Willibald	Timely Topics in Acute Coronary Syndromes	Gender-Related Outcomes in Elderly (> 75 Years) Patients Presenting With Acute Coronary Syndromes: Results From the Swiss Acute Coronary Syndrome Cohort	Nothing to Disclose
Maini	Aneel	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Pulmonary Venous Waveforms Predict Ventricular Remodeling After Percutaneous Mitral Valve Repair	Nothing to Disclose
Maini	Brijeshwar	Featured Clinical Research III	Outcomes for 15,259 US Patients With Acute MI Cardiogenic Shock (AMICS) Supported With Impella	CONSULTANT FEES/HONORARIA - Abbott Vascular, Abiomed, MEDTRONIC, Siemens, SJM
Maini	Brijeshwar	Moderated, Case-Based TAVR Management	Panelist	CONSULTANT FEES/HONORARIA - Abbott
Maini	Brijeshwar	19. Interventional Cardiology: Complex	Suggested Reviewer	Vascular,Abiomed,MEDTRONIC,Siemens,SJM CONSULTANT FEES/HONORARIA - Abbott
Maini	Brijeshwar	Patients/Comorbidities Team 2 Interventional Challenging Cases: Team 3	ACC Challenging Case Reviewer	Vascular, Abiomed, MEDTRONIC, Siemens, SJM CONSULTANT FEES/HONORARIA - Abbott
Maisano	Francesco	Interventional Live Case Session III: Structural	Panelist	Vascular, Abiomed, MEDTRONIC, Siemens, SJM CONSULTANT FEES/HONORARIA - Abbott Laboratories, Abbott
Maisano	Francesco	Transmission from Cleveland Clinic (Cleveland, Ohio) Featured Clinical Research II: Interventional	Panelist	Vascular, MEDTRONIC, MEDTRONIC, St. Jude, St. Jude Medical, Valtech, Valtech Cardio, OTHER - 4Tech, Edwards Lifesciences, Edwards Lifesciences; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - 4Tech Cardio, Affix, Transseptal Solutions; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Abbott Vascular CONSULTANT FEES/HONORARIA - Abbott Laboratories, Abbott
				Vascular, MEDTRONIC, MEDTRONIC, St. Jude, St. Jude Medical, Valtech, Valtech Cardio; OTHER - 4Tech, Edwards Lifesciences, Edwards Lifesciences; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - 4Tech Cardio, Affix, Transseptal Solutions; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Abbott Vascular
Maisano	Francesco	Frontier in New Transcatheter Techniques	Transcatheter Tricuspid Valve Update	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Abbott Vascular, MEDTRONIC, MEDTRONIC, St Jude, St. Jude Medical, Valtech, Valtech Cardio; OTHER - 4Tech, Edwards Lifesciences, Edwards Lifesciences; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - 4Tech Cardio, Affix, Transseptal Solutions; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Abbott Vascular
Maisano	Francesco	Transcatheter Mitral Valve Replacement	Transcatheter Repair Will Be These Patients Best Option	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Abbott Vascular, MEDTRONIC, SHOTRONIC, SHJude, St. Jude Medical, Valtech, Valtech Cardio; OTHER - 4Tech, Edwards Lifesciences, Edwards Lifesciences; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - 4Tech Cardio, Affix, Transseptal Solutions; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Abbott Vascular
Maisano	Francesco	Interventional Cardiology: Structural Heart Disease	Syntax Score II in Patients With Coronary Artery Disease Undergoing Mitraclip: A New Approach to Risk Stratification	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Abbott Vascular MEDTRONIC, SHOTRONIC, SHude St. Jude Medical, Valtech, Valtech Cardio; OTHER - 4Tech, Edwards Lifesciences, Edwards Lifesciences, CoWRESHIP MITTEREST/PARTNERSHIP/PRINCIPAL - 4Tech Cardio, Affix, Transseptal Solutions; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Abbott Vascular
Maisano	Francesco	Frontiers in Mitral Valve Disease and Treatment	Multicenter Trial of a Transfemoral System for Mitral Valve Annuloplasty: Up-to-2-Year Follow-Up Results	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Abbott Vascular, MEDTRONIC, MEDTRONIC, St Jude, St. Jude Medical, Valtech, Valtech Cardio; OTHER - 4Tech, Edwards Lifesciences, Edwards Lifesciences; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - 4Tech Cardio, Affix, Transseptal Solutions; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Abbott Vascular
Maisano	Francesco	24. Interventional Cardiology: Mitral and Structural Heart Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Abbott Vascular, MEDTROINC, MEDTROINC, St Jude, St. Jude Medical, Valtech, Valtech Cardio; OTHER - 4Tech, Edwards Lifesciences, Edwards Lifesciences; OWNERSHIP INTEREST/PARTNERSHIP/PRINCI; PAL - 4Tech Cardio, Affix, Transseptal Solutions; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Abbott Vascular
Maisel	Alan	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Rationale and Methods of the Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE-HF) Study	CONSULTANT FEES/HONORARIA - Alere, Critical Diagnostics, Trinity
Maisel	Alan	13. Heart Failure and Cardiomyopathies: Clinical Team 8	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Alere, Critical Diagnostics, Trinity
Majithia	Arjun	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Challenges in Ibrutinib Associated Atrial Fibrillation	Nothing to Disclose
Majithia	Arjun	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Expanding the Role of Dexrazoxane for Cardioprotection: Use in a Patient With Pre-Existing Systolic Dysfunction and No Prior Anthracycline Exposure	Nothing to Disclose
Majkut	Krystyna	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Neurogenic Orthostatic Hypotension as an Unexpected Etiology of Recurrent Syncope Obscured by Atrial Flutter	Nothing to Disclose
Majkut	Krystyna	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Unexpected Atrial Thrombus Discovered Post Intraoperative Maze Procedure: The Dilemma of Thrombus Screening Before Percutaneous Pulmonary Vein Isolation	Nothing to Disclose
Majkut	Krystyna	FIT Clinical Decision Making: Arrhythmias and Clinical Electrophysiology	Voltage-Dependent Inappropriate Right Ventricular Capture by Right Atrial Lead Pacing as a Cause of Cardiac Resynchronization Therapy Non-Responder	Nothing to Disclose
Majmudar	Maulik	Healthcare Innovation for Your Practice: Focus on Personalized Digital Health	Co-Chair	CONSULTANT FEES/HONORARIA - AliveCor HUINNO,MC10,Nokia; OWNERSHIP INTEREST/PARTMERSHIP/PRINCIPAL - BioFourmis,Cardiogram,HiLabs; RESEARCH/RESEARCH GRANTS - EchoSense
Majmudar	Maulik	Healthcare Innovation for Your Practice: Focus on Personalized Digital Health	AF in the Era of Digital Health	CONSULTANT FEES/HONORARIA - AliveCor ,HUINNO,MC10,Nokia; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - BioFourmis, Cardiogram,HiLabs; RESEARCH/RESEARCH GRANTS - EchoSense

and the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Majumder	Abdullah	Emerging CV Problems in the Developing World: International Perspectives From the ACC Bangladesh Chapter, Indonesian Heart Association, and American College of	Will Rheumatic Fever and Rheumatic Heart Disease Disappear From Developing Countries Like Bangladesh?	Nothing to Disclose
Makan	Majesh	Cardiology Making Progress in Understanding Heart Failure	Global Longitudinal Strain Predicts Sustained Recovery of LV Ejection Fraction in Heart Failure Patients on Evidence Based	Nothing to Disclose
Makaryus	John	Innovations in Cardiovascular Risk Assessment	Medical Therapies ACC/AHA Coronary Artery Calcium Score Guidelines May	Nothing to Disclose
Maldan	Alvanh	and Reduction	Underestimate Coronary Artery Disease in African-American Patients	Nething to Displace
Makkar	Akash	Atrial Fibrillation and VT: Unique Populations and Solutions	Use of an Esophageal Retractor to Prevent Thermal Injuries During Atrial Fibrillation Ablation: A Multi-Center Experience	Nothing to Disclose
Makkar	Akash	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Watchman Device Associated Thrombi: A Novel Treatment Approach	Nothing to Disclose
Makkar	Raj	Fellows Bootcamp: Coronary Disease Management	Left Main / Bifurcation Disease	CONSULTANT FEES/HONORARIA - Abbott Vascular, MEDTRONIC, CORDIS; OTHER - Entourage Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, St. Jude Medical
Makkar	Raj	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	CONSULTANT FEES/HONORARIA - Abbott Vascular,MEDTRONIC, CORDIS; OTHER - Entourage Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,St. Jude Medical
Makkar	Raj	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries	CONSULTANT FEES/HONORARIA - Abbott Vascular/MEDTRONIC, CORDIS; OTHER - Entourage Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,St. Jude Medical
Makkar	Raj	Structural Heart Disease: Difficult Choices for the Heart Team	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular/MEDTRONIC, CORDIS; OTHER - Entourage Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, St. Jude Medical
Makkar	Raj	Left Main PCI: Why? When? How?	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular, MEDTRONIC, CORDIS; OTHER - Entourage Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, St. Jude Medical
Makkar	Raj	Left Main PCI: Why? When? How?	Left Main PCI: When and How to Use Circulatory Support	CONSULTANT FEES/HONORARIA - Abbott Vascular, MEDTRONIC, CORDIS; OTHER - Entourage Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, St. Jude Medical
Makkar	Raj	The Forgotten Valves: Therapies for Triscuspid and Pulmonic Valve	FORMA TV Repair: Case and Overview	CONSULTANT FEES/HONORARIA - Abbott Vascular,MEDTRONIC, CORDIS; OTHER - Entourage Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,St. Jude Medical
Makkar	Raj	Interventional Cardiology: TAVR 1	Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: Insights From PARTNER 2A Trial	CONSULTANT FEES/HONORARIA - Abbott Vascular,MEDTRONIC, CORDIS; OTHER - Entourage Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,St. Jude Medical
Makkar	Raj	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Percutaneous Coronary Intervention With Everolimus-Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy and the Impact of Diabetes Mellitus on Stent and Target Lesion Patency	CONSULTANT FEES/HONORARIA - Abbott Vascular,MEDTRONIC, CORDIS; OTHER - Entourage Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,St. Jude Medical
Makkar	Raj	Valvular Heart Disease With CKD or Cirrhosis	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Abbott Vascular,MEDTRONIC, CORDIS; OTHER - Entourage Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,St. Jude Medical
Makkar	Raj	Refining TAVR Outcomes	Frame Geometry and Hemodynamic Findings of Sapien 3 Transcatheter Heart Valve in Patients With Bicuspid Aortic Valve Disease	CONSULTANT FEES/HONORARIA - Abbott Vascular, MEDTRONIC, CORDIS; OTHER - Entourage Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, St. Jude Medical
Makkar	Raj	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low- Flow Severe Aortic Stenosis and Less Reverse Remodeling After TAVR: A Partner 2 Trial Analysis	CONSULTANT FEES/HONORARIA - Abbott Vascular,MEDTRONIC, CORDIS; OTHER - Entourage Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,St. Jude Medical
Makkar	Raj	22. Interventional Cardiology: Coronary Intervention: Left Main, Multivessel, Bifurcation Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular,MEDTRONIC, CORDIS; OTHER - Entourage Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,St. Jude Medical
Makkar	Raj	Interventional Challenging Cases: Team 3	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular, MEDTRONIC, CORDIS; OTHER - Entourage Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, St. Jude Medical
Makki	Issa	Atrial Fibrillation and VT: Unique Populations and Solutions	Paroxysmal or Persistent: A Tale of Two Flutters	Nothing to Disclose
Makkiya	Mohammed	Antithrombotic Therapy in Ischemic Heart Disease	Role of Anticoagulation Therapy After Anterior Wall ST-Elevation Myocardial Infraction in Preventing LV Thrombus: A Meta-Analysis and Meta-Regression	Nothing to Disclose
Makkiya	Mohammed	Beans, Beans, Good for Your Heart	Percutaneous Renal Denervation for Resistant Hypertension: An Updated Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Malahfji	Maan	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Closure of a Ventricular Septal Defect Complicated by Hemolysis Requiring Transcatheter Retrieval of Amplatzer Occluder	Nothing to Disclose
Malaisrie	S. Chris	Late-Breaking Clinical Trials	Comparative Effectiveness of Left Atrial Appendage Occlusion Among Atrial Fibrillation Patients Undergoing Cardiac Surgery: A Report From the Society of Thoracic Surgeons Adult Cardiac Surgery Database	CONSULTANT FEES/HONORARIA - Bolton; RESEARCH/RESEARCH GRANTS - MEDTRONIC; SPEAKER'S BUREAU - Abiomed,Edwards Lifesciences
Malaisrie	S. Chris	Highlighted Original Research: Interventional Cardiology and the Year in Review	Surgery Database Implications of Worsening Right Ventricular Function Following Transcatheter or Surgical Aortic Valve Replacement: Insights From PARTNER2A	CONSULTANT FEES/HONORARIA - Bolton; RESEARCH/RESEARCH GRANTS - MEDTRONIC; SPEAKER'S BUREAU - Abiomed,Edwards Lifesciences
Malaisrie	S. Chris	Interventional Cardiology: TAVR 2	Worsening Tricuspid Regurgitation and Increased Mortality After Aortic Valve Replacement: Insights From PARTNER2A	CONSULTANT FEES/HONORARIA - Bolton; RESEARCH/RESEARCH GRANTS - MEDTRONIC; SPEAKER'S BUREAU - Abiomed, Edwards Lifesciences
Malaisrie	S. Chris	Interventional Cardiology: TAVR 2	Intensity of Statin Therapy and Outcomes After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Bolton; RESEARCH/RESEARCH GRANTS - MEDTRONIC; SPEAKER'S BUREAU - Abiomed, Edwards Lifesciences
Malavade	Sharad	FIT Clinical Decision Making: Arrhythmias and Clinical Electrophysiology	Paradoxical Hypertensive Adverse Reaction to Nitroglycerine During Tilt Table Test Unmasking Undiagnosed Pheochromocytoma: A Case Report	Nothing to Disclose
Maldonado	Galo	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Independent Predictors of Mace at Different Time Points After the Treatment of Non-Selected Patients With Drug-Eluting Stents: An Analysis of the Desire Registry	Nothing to Disclose
Malenka	David	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Is CABG the Best Revascularization Strategy Among All Diabetics Subgroups With Multi-Vessel Disease in the Modern Era? A Multi- Center Analysis	CONSULTANT FEES/HONORARIA - WellPoint

Last Name Maleszewski		Session Title Valvular Heart Disease: Aortic Stenosis	Presentation Title Bicuspid Versus Tricuspid Aortic Valve Stenosis: Comparative Study	Disclosures Nothing to Disclose
Maleszewski	Joseph	Valvulai Healt Disease. Autilic Stellosis	of Clinical Characteristics and Outcomes Following Aortic Valve Replacement in an Age-Matched Cohort	Nothing to Disclose
Malhotra	Aneil	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Myocardial Fibrosis & Ventricular Arrhythmias in Athletes	Nothing to Disclose
Malhotra	Aneil	Hearts and Soles: Multimodality Imaging in	The Mixed Race Athlete's ECG: Not So Black and White	Nothing to Disclose
Malhotra	Saurabh	Athletes Interventional Cardiology: TAVR 1	Intraoperative Change in Myocardial Contractility With Transcatheter	Nothing to Disclose
			Aortic Valve Replacement Predicts Cardiovascular Outcomes	
Malhotra	Saurabh	Interventional Cardiology: TAVR 1	Temporal Change in Myocardial Contractility After Transcatheter Aortic Valve Replacement and Its Relationship With Quality of Life	Nothing to Disclose
Malhotra	Saurabh	Updates on Pulmonary Embolism Management in 2017	Rapid Improvement in Right Ventricular Systolic Function in Patients With Pulmonary Embolism Treated With Ultrasound-Assisted Catheter Directed Thrombolysis	Nothing to Disclose
Malhotra	Saurabh	Nuclear Cardiology: Quality	Increasing Equipment Vintage Predicts Poor Laboratory Quality and Delay in Accreditation: An Evaluation by IAC Echocardiography and Nuclear Accreditation Status	Nothing to Disclose
Malhotra	Saurabh	Non Invasive Imaging: Prognostic Implications of CT Angiography	HEART Score Does Not Predict the Severity of Anatomical Coronary Artery Disease in Patients Presenting to the Emergency Department With Chest Pain	Nothing to Disclose
Malhotra	Saurabh	30. Non Invasive Imaging: Nuclear Team 1	Suggested Reviewer	Nothing to Disclose
Malik		Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Cardiac Myosin Activator, Omecamtiv Mecarbil, Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure (COSMIC-HF)	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cytokinetics, Inc.; SALARY - Cytokinetics, Inc.
Malik	Rehan	Diabetes and Other Issues in Cardiovascular Prevention	Association of Ankle Brachial Index and Hemoglobin A1c With All- Cause and Cardiovascular Mortality: Results From the National Health and Nutrition Examination Survey 1999 to 2000	Nothing to Disclose
Malik	Shaista	Interventional Complexity and Complications	Gender Differences in Post Percutaneous Coronary Intervention Complications Following Acute Myocardial Infarction in the United	Nothing to Disclose
Malik	Shaista	32. Prevention: Clinical Team 6	States Suggested Reviewer	Nothing to Disclose
	Hari	Mechanical Support, Hemodynamic Support for Shock in High Risk Subsets; Hemodynamic	Panelist	Nothing to Disclose
Mallidi	Hari	Compromise Mechanical Support, Hemodynamic Support for Shock in High Risk Subsets; Hemodynamic Compromise	ЕСМО	Nothing to Disclose
Mallidi	Hari		Platypnea-Orthodeoxia in a Leukemia Patient With a Tricuspid Valve Mass	Nothing to Disclose
Mallidi	Jaya	Novel Developments in Acute Coronary Syndromes	Comparison of Clinical Outcomes: Bivalirudin With Transfemoral Versus Heparin With Transradial in Patients With ST Segment Elevation Myocardial Infarction	Nothing to Disclose
Mallikethi-Reddy	Sagar	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	In-Hospital Outcomes After MitraClip Implantation in the United States: 2010-2012	Nothing to Disclose
Mallikethi-Reddy	Sagar	Interventional Cardiology: PCI and TAVR in	Economic Implications of Late Discharge After Transcatheter Aortic	Nothing to Disclose
Mallikethi-Reddy	Sagar	Complex Patients Interventional Cardiology: PCI and TAVR in	Catheter Implantation Predictors of Early Discharge Home After Transcatheter Aortic	Nothing to Disclose
Mallikethi-Reddy	Sagar	Complex Patients Emerging Developments in HFpEF and	Valve Implantation Hospitalization Burden of Diastolic Heart Failure in the United	Nothing to Disclose
Mallipeddi	Vishnu Priya	Arryhthmias Vascular Medicine: Aortic and Peripheral	States: 2007-2012 Association of Ankle Brachial Index With Limb Outcomes in	Nothing to Disclose
Malloy	Rhynn	Artery Diseases Updates in Stable Ischemic Heart Disease	Peripheral Artery Disease: A Community-Based Study Evaluation of Anti-Anginal Agents for the Symptomatic Treatment of Chronic Stable Angina Using Mixed Treatment Comparison Meta-	Nothing to Disclose
Malone	Angela	Innovations in Advocacy and Patient Centered	Analysis Low-Risk Chest Pain Pathway: Outcomes and Implications in a	Nothing to Disclose
Malouf	Joseph	Care Novel Determinants of Outcomes in VHD	Large Community Cohort Coexisting Co-Morbidities Exacerbate Left Ventricular Diastolic Dysfunction and Prognosis in Patients With Severe Aortic Stenosis	Nothing to Disclose
Malta Hansen	Carolina	Innovation in Practice Management, Advocacy,	Early Defibrillation by First-Responders in Relation to Fire Stations:	Nothing to Disclose
Maltais	Simon	and Education New Technologies in Echocardiography	Optimal Benefit According to Location Mitral Annular Disjunction Prevalence and Physiologic	Nothing to Disclose
	-		Consequences in Degenerative Mitral Regurgitation: A Dynamic 3- Dimensional Echocardiographic Study	
Maltais	Simon	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Effects of Diabetes Mellitus on Clinical Outcomes After Left Ventricular Assist Device Implantation: A Single Institutional 9-Year Experience	Nothing to Disclose
Maltais	Simon	Advanced Therapies = Advanced Trouble: VAD and Transplant Challenges	Sirolimus-Based Immunosuppression Mitigates Progression of Cardiac Allograft Vasculopathy and Improves Cardiac Outcomes After Heart Transplantation: A Single Center 15-Year Follow-Up	Nothing to Disclose
Maludum	Obiora	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Study Impact of Electrocardiogram Changes on Mortality in Asymptomatic Patients With Sensis and Elevated Transpire	Nothing to Disclose
Mamas	Mamas	Revascularization and Outcomes Radial Access Mini-Symposium II	Patients With Sepsis and Elevated Troponin Radial Controversies 1: Does Increasing Radial Volume Decrease	Nothing to Disclose
Mamas	Mamas	Interventional Cardiology: TAVR 3	Femoral Access Proficiency? Meta-Analysis on Cerebral Embolic Protection Devices During Transcatheter Aortic Valve Implantation	Nothing to Disclose
Mamdani	Shafiq	Highlights in Vascular Medicine Research	Thirty-Day Readmissions Following Endovascular or Surgical Treatment for Critical Limb Ischemia: Analysis of the Nationwide	Nothing to Disclose
Mamdani	Shafiq	39. Vascular Medicine: Endovascular Therapy	Readmissions Database Suggested Reviewer	Nothing to Disclose
Mammen	Pradeep	Team 1 The Evolving World of LVADs, Transplant and	Cardiac Atrophy: A Novel Mechanism for Duchenne Muscular	CONSULTANT FEES/HONORARIA - Catabasis,HeartWare;
Mancarella	Gisella	Other Novel Discoveries Innovations in Advocacy and Patient Centered Care	Dystrophy (DMD)-Associated Cardiomyopathy Describing Collaboration Between Cardiology and Palliative Care: A National Survey Study of Current Practices, Challenges and Barriers	RESEARCH/RESEARCH GRANTS - CareDx,PhaseBio Nothing to Disclose
Mancini	Donna	Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A	Panelist	Nothing to Disclose
Mancini	Donna	Symposium by Valentin Fuster) Cardiovascular Update for the Clinician III: Cardio-Pulmonary Failure in 2017 (A	Recent Advances in LVADs and Myocardial Recovery An Evolving Alternative to Heart Transplantation	Nothing to Disclose
Mancini	Donna	Symposium by Valentin Fuster) 13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	Nothing to Disclose
Mancini	G. B. John	Clinical Team 4 Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Concomitant Use of Antiplatelet and Oral Anticoagulation Among Patients With Atrial Fibrillation: Insights From the Prospective SPRINT-AF Registry	CONSULTANT FEES/HONORARIA - Amgen,Boehringer Ingelheim Pharmaceuticals, Inc,Eil Lilly and Company,Merck,Pizer,Regeneron,sanofi- aventis/regeneron,servier

100				
Last Name Mancini	G. B. John	Session Title The PCSK9 Revolution: New Insights Into	Presentation Title Alirocumab Efficacy and Safety in Patients With	Disclosures CONSULTANT FEES/HONORARIA - Amgen,Boehringer
		Evaluation and Treatment	Hypercholesterolemia and With or Without Clinical Atherosclerotic Cardiovascular Disease: Pooled Analysis of 10 ODYSSEY Randomized Trials	Ingelheim Pharmaceuticals, Inc,Eli Lilly and Company,Merck,Pfizer,Regeneron,sanofi- aventis/regeneron,servier
Mancini	llaria	Improving Outcomes in the Athlete With Cardiovascular Disease	EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students	Nothing to Disclose
Mancone	Massimo	Improving Outcomes in the Athlete With Cardiovascular Disease	EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students	Nothing to Disclose
Manda	Yugandhar	Advances in HCM, PPCM and Other Cardiomyopathies	Childbirth Related Complications in Women With Hypertrophic Cardiomyopathy	Nothing to Disclose
Mandapati	Ravi	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	An Unusual Case of Far-Field P-Wave Oversensing Leading to Ventricular Overpacing and Undersensing of Sustained Ventricular	Nothing to Disclose
Mandel	Leonid	Interdisciplinary Cardiovascular Care in	Tachycardia Hand-Foot-and-Mouth (and Heart) Disease: Coxsackievirus A6 as a	Nothing to Disclose
Mandolini	Claudia	Complex Scenarios Emerging Basic Science in Ischemic Heart	Recently Recognized Cause of Acute Myocarditis Imbalance Between E-NOS and MRP4 Gene Expression in Type 2	Nothing to Disclose
		Disease	Diabetes Mellitus May Explain the Higher Risk of NSTEMI in Diabetic Subjects	ů
Mandras	Stacy	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Combined Obstructive and Cardiogenic Shock Due to Mechanical Mitral Valve Thrombosis	CONSULTANT FEES/HONORARIA - Actelion, Gilead Sciences, Inc.; SPEAKER'S BUREAU - Actelion, Gilead Sciences, Inc.
Mandrola	John	Social Media and the Cardiovascular Professionals: Lessons Learned and Future Applications	Co-Chair	Nothing to Disclose
Mandrola	John	Social Media and the Cardiovascular Professionals: Lessons Learned and Future Applications	Panelist	Nothing to Disclose
Mandrola	John	Social Media and the Cardiovascular Professionals: Lessons Learned and Future Applications	ACC-Talk: Lessons Learned from 10 Years of Social Media In Medicine	Nothing to Disclose
Mandrola	John	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Effectiveness of Coronary CT Angiography Versus Standard Care for the Assessment of Patients With Suspected Coronary Artery	Nothing to Disclose
Manfrini	Olivia	Coronary Artery Disease Cardiac Arrest, Diabetes, and Other High Risk	for the Assessment of Patients With Suspected Coronary Artery Disease: A Trial Sequential Analysis Acute Coronary Syndrome: The Risk to Be Young and Women	Nothing to Disclose
Ividiliilii	Olivia	Features of Patients With Acute Coronary Syndrome	Acute Colonary Syndrome. The Risk to be roung and women	Nothing to Disclose
Mangi	Abeel	Interventional Cardiology: TAVR 3	Initial Use of the Evolut Pro Self-Expanding Transcatheter Aortic Valve <i></i>	CONSULTANT FEES/HONORARIA - Thoratec Corporation
Mangi	Muhammad Asif	Arrhythmias and Clinical EP: Basic 4	Association of Non-Alcoholic Fatty Liver Disease With Heart Block: A Case Control Retrospective Study	Nothing to Disclose
Mangili	Leonardo	Contemporary Issues in Familial Hypercholesterolemia	Achilles Tendon Xanthomas Are Independently Associated With Severity of Subclinical Coronary Atherosclerosis in Familial Hypercholesterolemia	Nothing to Disclose
Mangili	Otavio	Contemporary Issues in Familial Hypercholesterolemia	Achilles Tendon Xanthomas Are Independently Associated With Severity of Subclinical Coronary Atherosclerosis in Familial	Nothing to Disclose
Mangion	Kenneth	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Hypercholesterolemia Segmental Circumferential Strain Derived From DENSE Predicts Improvement of Left Ventricular Function Post ST Elevation	Nothing to Disclose
Mangla	Aditya	The Best Coronary and Peripheral	Myocardial Infarction: The BHF MR-MI Study Recurrent Spontaneous Coronary Artery Dissection in a Patient With	SPEAKER'S BUREAU - Astra Zeneca
Mangla	Ashvarya	Interventional Challenging Cases FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Fibromuscular Dysplasia Fulminant Myocarditis With Cardiogenic Shock From Eosinophilic Myocarditis: Successfully Treated With Immunosuppresive Therapy	Nothing to Disclose
Mangla	Ashvarya	FIT Clinical Decision Making: Heart Failure and	With Complete Recovery of Cardiac Function Recurrence of Cardiac Sarcoidosis Post-Orthotropic Heart	Nothing to Disclose
Mangner	Norman	Pulmonary Hypertension Novel Developments in Acute Coronary	Transplant in the Background of Allograft Rejection Mild Hypothermia in Cardiogenic Shock Complicating Myocardial	Nothing to Disclose
Mangner	Norman	Syndromes Interventional Cardiology: TAVR 2	Infarction: The Randomized SHOCK-COOL Pilot Trial Different Impact of Gender on Early and Late Outcome After	Nothing to Disclose
Mangner	Norman	Interventional Cardiology: TAVR 2	Transcatheter Aortic Valve Replacement Higher B-Type Natriuretic Peptide Levels Predict Occurrence of	Nothing to Disclose
Mangner	Norman	Interventional Cardiology: TAVR 2	Acute Kidney Injury After Transcatheter Aortic Valve Replacement Impact of Myocardial Injury Indicated by Increased Creatinine Kinase	Nothing to Disclose
			Myocardial Band Levels on the Outcome After Transcatheter Aortic Valve Replacement: Results From a Prospective Single Center Registry	
Mangner	Norman	Interventional Cardiology: TAVR 4	Impact of Cancer Disease on Outcome of Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Mani	Агуа	Arrhythmias and Clinical EP: Basic 4	Deleterious Mutations in SCN10A Are Associated With Long QT Syndrome	Nothing to Disclose
Maniar	Hersh	Interventional Cardiology: TAVR 4	Depression as a Potential Therapeutic Target to Improve Quality of Life After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Maniar	Hersh	17. Interventional Cardiology: Aortic Valve Disease Team 3	Suggested Reviewer	Nothing to Disclose
Manikat	Richie	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Long Term Sequelae of Kawasaki Disease	Nothing to Disclose
Manintveld	Olivier	Arrhythmias and Clinical EP: Devices 1	Long-Term Outcome of Noncompaction Cardiomyopathy Patients With Implantable Cardioverter-Defibrillators Compared With Patients With Dilated or Hunestrophic Cardiomyopathy	Nothing to Disclose
Manintveld	Olivier	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Patients With Dilated or Hypertrophic Cardiomyopathy Older Age Combined With Reduced Renal Function Has a Strong Cumulative Adverse Effect on Survival in Left Ventricular Assist	Nothing to Disclose
Manintveld	Olivier	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Device Patients Sudden and Fatal Malfunction After Continuous-Flow Left Ventricular Assist Devices: An Urgent Call for Regular Inspections	Nothing to Disclose
Manintveld	Olivier	Advanced Therapies = Advanced Trouble: VAD and Transplant Challenges	Acute Kidney Injury Is Highly Frequent Early After Left Ventricular Assist Device Implantation With High Morbidity and Mortality Rates:	Nothing to Disclose
Manintveld	Olivier	Advanced Therapies = Advanced Trouble:	A Multicentre Study Proteinuria in Patients Receiving Left Ventricular Assist Devices Is	Nothing to Disclose
Mankad	Rekha	VAD and Transplant Challenges FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Highly Associated With Renal Failure and Mortality Patient With Superior Vena Cava Syndrome Equivalent	Nothing to Disclose
Mankad	Sunil	Disease, and Vascular Medicine Mitral Valve Guidelines: Closing Knowledge	Co-Chair	OTHER - Siemens Healthcare, Ultrasound Division
Mankad	Sunil	Gaps Mitral Valve Guidelines: Closing Knowledge	Discussion Leader	OTHER - Siemens Healthcare, Ultrasound Division
Mankad	Sunil	Gaps Test Yourself with Questions: Guidelines	Faculty	OTHER - Siemens Healthcare, Ultrasound Division
Mankad	Sunil	Module 1: Valvular Test Yourself with Questions: Guidelines	Chair	OTHER - Siemens Healthcare, Ultrasound Division
Mankad	Sunil	Module 1: Valvular Innovative Use of Echocardiography	Systolic Function and Cardiac Output on Echocardiography Do Not	OTHER - Siemens Healthcare, Ultrasound Division
	I		Predict Mortality After Cardiac Arrest	2 Sismons risulations, statesburid Division

The state of the s				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Mankad	Sunil	New Technologies in Echocardiography	Mitral Annular Disjunction Prevalence and Physiologic Consequences in Degenerative Mitral Regurgitation: A Dynamic 3- Dimensional Echocardiographic Study	OTHER - Siemens Healthcare, Ultrasound Division
Mankad	Sunil	Insights From Echocardiography Use	Diastolic Dysfunction by Doppler Echocardiography Predicts Mortality after Cardiac Arrest	OTHER - Siemens Healthcare, Ultrasound Division
Mankad	Sunil	Engage @ ACC.17 Studio: Cardiology Contest		OTHER - Siemens Healthcare, Ultrasound Division
Mankad	Sunil	28. Non Invasive Imaging: Echo Team 3	Suggested Reviewer	OTHER - Siemens Healthcare, Ultrasound Division
Mankame	Omkar	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Early Hydrodynamic Assessment of Intestinal Sub-Mucosa Bioscaffold for Mitral Valve Replacement	Nothing to Disclose
Mankwe	Abaram	Emerging Developments in HFpEF and Arryhthmias	Association Between CD ₄ ⁺ Lymphocyte Count and Left Ventricular Diastolic Function and Geometry in Newly Diagnosed Highly Active Antiretroviral Therapy (HAART) Naive HIV/AIDS Patients Seen at University of Port Harcourt	Nothing to Disclose
Mann	Douglas	Eugene Braunwald Lecture on Future Directions in Cardiovascular Medicine and the Best of JACC Journals	Teaching Hospital, Port Harcourt, Rivers State Panelist	Nothing to Disclose
Mann	Douglas	Eugene Braunwald Lecture on Future Directions in Cardiovascular Medicine and the Best of JACC Journals	Best of JACC: Basic to Translational Science in 2016	Nothing to Disclose
Mann	Douglas	Featured Clinical Research III	Co-Chair	Nothing to Disclose
Mann	Douglas	Overcoming Today's Challenges to Launching and Growing Your Academic Medical Career: An Interactive Tutorial	Building an Academic Career in 2017: Managing the Challenges	Nothing to Disclose
Mann	Douglas	Evolving Therapies in Heart Failure: Gazing Into the Crystal Ball	Autonomic Modulation in Heart Failure: A Viable Target?	Nothing to Disclose
Mann	Douglas	Making Progress in Understanding Heart Failure	Global Longitudinal Strain Predicts Sustained Recovery of LV Ejection Fraction in Heart Failure Patients on Evidence Based	Nothing to Disclose
Mann	Douglas	Cardiac Fibrosis and Heart Failure: The Next	Medical Therapies Impaired Autophagic Flux Contributes to the Accumulation of	Nothing to Disclose
Mann	Douglas	Frontier 12. Heart Failure and Cardiomyopathies: Basic	Ubiquitinated Proteins in a Mouse Model of Heart Failure Suggested Reviewer	Nothing to Disclose
		Team 2	Diagnosis of ST-Elevation Myocardial Infarction in the Presence of	-
Manne	Janaki Rami Reddy	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Left Bundle Branch Block With a Modified Sgarbossa Rule	Nothing to Disclose
Manning	Warren	Updates on Pulmonary Embolism Management in 2017	Evaluation of Right Ventricular Strain by Echocardiography, Computed Tomography, and Electrocardiography in Patients With Acute Pulmonary Embolism	CONSULTANT FEES/HONORARIA - Merck and Company; OTHER - Samsung Electronics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - General Electric
Manning	Warren	Arrhythmias and Clinical EP: AF Ablation	Association of Adverse Clinical Outcomes in Patients With Acute Pulmonary Embolism and Coronary Artery Calcifications Visualized on Computed Tomography	CONSULTANT FEES/HONORARIA - Merck and Company; OTHER - Samsung Electronics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - General Electric
Manning	Warren	Innovations in Education	On-Call Transthoracic Echocardiographic Interpretation by First Year Cardiology Fellows: Comparison With Experienced Readers	CONSULTANT FEES/HONORARIA - Merck and Company; OTHER - Samsung Electronics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - General Electric
Manoharan	Ganesh	Interventional Live Case Session I: Structural Transmission from Cleveland Clinic (Cleveland, Ohio)	Panelist	CONSULTANT FEES/HONORARIA - Boston Scientific, Medtroni CoreValve, St Judes Medical
Manoharan	Ganesh	TAVR Changing the Paradigm for the	Co-Chair	CONSULTANT FEES/HONORARIA - Boston Scientific,Medtroni
Manoharan	Ganesh	Treatment of Valve Disease 17. Interventional Cardiology: Aortic Valve	Suggested Reviewer	Consultant Fees/Honoraria - Boston Scientific, Medtroni
Mansoor	Hend	Disease Team 3 Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Risk Prediction for In-Hospital Mortality in Women With ST-Elevation Myocardial Infarction: A Machine Learning Approach	CoreValve,St Judes Medical Nothing to Disclose
Mansoor	Hend	Syndrome Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Early Invasive Strategy and In-Hospital Survival of Diabetics With Non-ST-Elevation Myocardial Infarction: A Contemporary National Insight	Nothing to Disclose
Mansoor	Hend	PCI Strategies and Outcomes Unique to Women	Early Invasive Strategy Versus Initial Conservative Strategy in Women With Non-ST-Elevation Acute Coronary Syndrome: A Propensity Score Matched Nationwide Analysis	Nothing to Disclose
Mansour	Moussa	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues		CONSULTANT FEES/HONORARIA - Biosense Webster MEDTRONIC, St Jude Medical; RESEARCH/RESEARCH GRANTS - Biosense Webster, St Jude Medical
Mansour	Samer	Highlighted Original Research: Interventional Cardiology and the Year in Review	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	Nothing to Disclose
Mansour	Samer	Interventional Cardiology: Intravascular	Appropriateness of Coronary Artery Bypass Grafting Based on	Nothing to Disclose
Mansour	Samer	Physiology and Endothelial Function Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Fractional Flow Reserve Lesions Assessment Differences and Level of Agreement in SYNTAX Score Assessment	Nothing to Disclose
Mansour	Samer	Novel Imaging and Therapies in Heart Failure	Between Site Operators and Angiographic Core Laboratory Readers: Insights From the EXCEL Trial Novel Infarct Sparing Drug Protects the Heart Against Ischemia-	Nothing to Disclose
Mansour	Samer	Antiplatelet and Antithrombotic Agents in	Reperfusion (I/R) Injury Comparison of Triple Antithrombotic Therapy to Ticagrelor-Based	Nothing to Disclose Nothing to Disclose
Mansour	Samer	Ischemic Heart Disease Refining PCI Technique and Outcomes	Dual Antiplatelet Therapy for Left Ventricle Dysfunction Following STEMI Using Natural Randomization: A Retrospective Pilot Study Treatment of Left Main Coronary Artery Disease in Patients With	Nothing to Disclose
			Diabetes: 3-Year Outcomes Comparing CABG and PCI With Everolimus-Eluting Stents From the EXCEL Study	_
Mansour	Samer	Refining PCI Technique and Outcomes	Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory Assessment: Insights From the EXCEL Trial	Nothing to Disclose
Mansuri	Uvesh	Arrhythmias and Clinical EP: Basic 2	Comparison of 30-Day Readmission Rate, Cost, and Predictors in Atrial Fibrillation Patients Treated With Versus Without Endovascular Ablation	Nothing to Disclose
Mansuri	Uvesh	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	30-Day Unplanned Readmission Rates, Cost, Predictors, and Causes of Hospitalization in Acute Myocardial Infarction Patients	Nothing to Disclose
Mantha	Aditya	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Impact of Utilizing Fractional Flow Reserve With Percutaneous Coronary Intervention on Readmissions: An Analysis of the 2013 National Readmissions Database	Nothing to Disclose
Mantha	Aditya	Interventional Cardiology: TAVR 3	Transfemoral Versus Transapical Transcatheter Aortic Valve Replacement: An Analysis of 2013 National Readmission and Inpatient Sample Databases	Nothing to Disclose
Mantha	Aditya	New Technologies in Echocardiography	The Effect of Transcatheter Aortic Valve Replacement on Subclinical Cardiac Function Using Speckle Tracking Echocardiography	Nothing to Disclose
Mantovani	Francesca	New Technologies in Echocardiography	Mitral Annular Disjunction Prevalence and Physiologic Consequences in Degenerative Mitral Regurgitation: A Dynamic 3- Dimensional Echocardiographic Study	Nothing to Disclose
Mantovani	Lorenzo	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Early Mortality in Patients With New Onset Atrial Fibrillation: Results From the GARFIELD-AF Registry	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc,Daiichi Sankyo,King Pharmaceuticals, Inc. (now part of Pfizer - October 2010); DATA SAFETY MONITORING BOARD - Bayer Healthcare Pharmaceuticals

Last Name	First Name	Session Title	Presentation Title	Disclosures
Manvelian	Garen	Advances in Cholesterol Measurement and Management	Efficacy and Safety of the PCSK9 Inhibitor Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin Therapy	SALARY - Regeneron
Manvelian	Garen	Advances in Cholesterol Measurement and Management	Alirocumab Titration Strategy Allows Individualized LDL-C Reduction in a Real World Setting: Results From ODYSSEY OLE (LONG TERM Cohort)	SALARY - Regeneron
Manvelian	Garen	Advances in Cholesterol Measurement and Management	On-Treatment LDL-C Levels When Alirocumab Dose Is Decreased From 150 to 75 mg Every 2 Weeks in Patients With Heterozygous Familial Hypercholesterolemia: Results From ODYSSEY OLE	SALARY - Regeneron
Manvelian	Garen	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Alirocumab Treatment in a Real World Setting: Safety Update From an Open-Label Treatment Extension to the ODYSSEY Program for Patients With Heterozygous Familial Hypercholesterolemia	SALARY - Regeneron
Mao	Chad	Exercise in Congenital Heart Disease	US Military Service and Congenital Heart Disease: Who Can Serve in Uniform and Why	Nothing to Disclose
Mao	Frances	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	RVOT-VTI/PASP: A Novel Non-Invasive Metric of Pulmonary Arterial Compliance and Diastolic Pressure Gradient Status in Heart Failure With Preserved Ejection Fraction	Nothing to Disclose
Mao	Tiffany	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Angiosarcoma	Nothing to Disclose
Maor	Elad	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Acute Changes in Left Atrial Pressure Following MitraClip are Associated With Long Term Improvement in 6 Min Walk Distance	Nothing to Disclose
Maor	Elad	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Transcatheter Mitral Valve Repair (Mitraclip) in United States: Etiologies and Predictors of Readmission and In-Hospital Mortality From the Nationwide Readmission Database	Nothing to Disclose
Maor	Elad	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Transcatheter Mitral Valve Repair (Mitra Clip) in United States: Length of Stay and Cost of Hospitalizations From the Nationwide Readmission Database	Nothing to Disclose
Maor	Elad	Interventional Cardiology: TAVR 4	Transacatheter Aortic Valve Replacement And Malignancy Rapid Ventricular Pacing During TAVR Is Associated With Poor	Nothing to Disclose Nothing to Disclose
Maor	Elad	Interventional Cardiology: TAVR 4	Short- and Long-Term Outcome	3
Maqsood	Khawar	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Blocked Artery, or Blocked Bowel?!	Nothing to Disclose
Marabini Martinelli	Ana Elisa	Making Progress in Understanding Heart Failure	Lipid Transfer to HDL in Patients With Heart Failure Was Diminished and Is Correlated With Severity of the Disease	Nothing to Disclose
Marana	Ivana	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Renal Replacement Therapy in Patients With Acute Myocardial Infarction: Rate of Use, Clinical Predictors and Relationship With In- Hospital Mortality	Nothing to Disclose
Maras	Patrizia	Updates in Stable Ischemic Heart Disease	The Close Relationship Between Drug Intolerance and Major Cardiac and Cerebrovascular Events After an Acute Coronary Syndrome or Coronary Revascularization	Nothing to Disclose
Maras	Patrizia	Predicting Outcomes in Cardiac Rehabilitation Patients	Predictors of Major Adverse Cardiac Events in Long-Term Follow- Up After Cardiac Rehabilitation	Nothing to Disclose
Marban	Eduardo	Non Invasive Imaging: MR Characterization and Function	An Unrestrained Proinflammatory M1 Macrophage Population Induced by Iron Nanocrystals Impairs Myocardial Healing After Hemorrhagic Infarction	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Capricor Therapeutics, Inc., Capricor Therapeutics, Inc.
Marber	Michael	Featured Clinical Research I	MR-INFORM: Stress Perfusion Imaging to Guide the Management of Patients With Stable Coronary Artery Disease	RESEARCH/RESEARCH GRANTS - GlaxoSmithKline
Marber	Michael	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Direct Comparison of Cardiac Myosin-Binding Protein C to Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction	RESEARCH/RESEARCH GRANTS - GlaxoSmithKline
Marber	Michael	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Cardiac Myosin-Binding Protein C as Alternative to Cardiac Troponin T for the Diagnosis of Acute Myocardial Infarction in the Very Early Phase	RESEARCH/RESEARCH GRANTS - GlaxoSmithKline
Marber	Michael	Post-CAD/MI: Making Tough Predictions About the Future	Unravelling the Mechanisms of Mental Stress Induced Myocardial Ischaemia: Novel Insights From Intracoronary Measurements During Cardiac Catheterisation	Nothing to Disclose
Marcano	Ana	Novel Developments in Acute Coronary Syndromes	Underuse of Potent Oral P2y ₁₂ Inhibitors in Women With an Acute Coronary Syndrome, Despite Having a Higher Risk Profile Than Male Patients	Nothing to Disclose
Marchetti	Maria Francesca	Advances in HCM, PPCM and Other	Tako Tsubo Cardiomyopathy or Myocarditis?	Nothing to Disclose
Marchetti	Maria Francesca	Cardiomyopathies Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Reperfusion Delays in Women With STEMI	Nothing to Disclose
Marchlinski	Francis	Meeting of the Minds: HF and EP Decision Making for Complex Patients	Panelist	CONSULTANT FEES/HONORARIA - Biosense Webster Inc, Biotronik, Boston Scientific, MEDTRONIC, St Jude Medical; RESEARCH/RESEARCH GRANTS - Biosense Webster Inc, Boston Scientific, MEDTRONIC, St Jude Medical
Marchlinski	Francis	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Anticoagulation Use and Incidence of Cerebrovascular Events and Major Bleeding After Catheter Ablation in Patients With Persistent and Longstanding Persistent Atrial Fibrillation	CONSULTANT FEES/HONORARIA - Biosense Webster Inc, Biotronik, Boston Scientific, MEDTRONIC, St Jude Medical; RESEARCH/RESEARCH GRANTS - Biosense Webster Inc, Boston Scientific, MEDTRONIC, St Jude Medical
Marcu	Bogdan	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Double Chambered Right Ventricle Causing RVOT Obstruction in Adulthood: It Is Not Pulmonary Hypertension!	Nothing to Disclose
Mardekian	Jack	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Real World Evaluation of Major Bleeding Risk and Costs for All Causes and Bleeding-Related Health Services Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Apixaban or Warfarin	SALARY - Pfizer Inc
Marek	Joseph	ECG Screening and Risk Prediction	ECG Screening of Young Adults for Sudden Cardiac Death Risk in Primary Care Offices	Nothing to Disclose
Marella	William	Post FDA Release Prosthetic Valve Surveillance - Watching for Signals	Independent Observation: Are MDR's Enough?	Nothing to Disclose
Marenzi	Giancarlo	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Renal Replacement Therapy in Patients With Acute Myocardial Infarction: Rate of Use, Clinical Predictors and Relationship With In-	Nothing to Disclose
Marenzi	Giancarlo	Post-CAD/MI: Making Tough Predictions About	Hospital Mortality A New Score for Risk Stratification of Patients With Acute	Nothing to Disclose
Margolis	Gilad	the Future Acute Coronary Syndromes, Diagnosis,	Myocardial Infarction Based on the PEGASUS-TIMI 54 Criteria Incidence and Outcomes of Early Left Ventricular Thrombus	Nothing to Disclose
-		Management and Outcomes The Burden of Heart Failure: International	Formation Following ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention Advanced Tissue Phenotyping in Nonischemic Cardiomyopathy	CONSULTANT FEES/HONORARIA - GlaxoSmithKline,Janssen
Margulies	Kenneth	The Burden of Heart Failure: International Perspectives From the Chilean Society of Cardiology, Colombian Society of Cardiology, and American College of Cardiology	Provenced Tissue Phenotyping in Nonischemic Cardiomyopathy	CONSULTANT FEES/HONOKRARIA - GlaxoSmithkline, Janssen Pharmaceuticals, Inc,Merck & amp; amp; Co., Inc., Pfizer Inc; OTHER - Luitpold Pharmaceuticals, Inc, Novartis Corporation, Stemedica; RESEARCH/RESEARCH GRANTS - Biosense Webster, GlaxoSmithKline, Luitpold Pharmaceuticals, Inc,Merck & amp; amp; Co., Inc., Thoratec, Inc.

Last Name	First Name	Session Title	Presentation Title	Disclosures
Margulies	Kenneth	Diabetes and Heart Failure: Are We Hitting The Sweet Spot	Panelist	CONSULTANT FEES/HONORARIA - GlaxoSmithKline,Janssen Pharmaceuticals, Inc,Merck & Dec., Inc.,Pfizer Inc;
		The owest oper		OTHER - Luitpold Pharmaceuticals, Inc,Novartis
				Corporation, Stemedica; RESEARCH/RESEARCH GRANTS -
				Biosense Webster, Glaxo Smith Kline, Luitpold Pharmaceuticals,
Margulies	Kenneth	Diabetes and Heart Failure: Are We Hitting	The Role of GLP-1 Agonists in Heart Failure Post-FIGHT	Inc,Merck & Department of the Consultant FEES/HONORARIA - GlaxoSmithKline,Janssen
ivialgulies	Remieur	The Sweet Spot	The Role of GET-1 Agonists in Flear Challer Fost-1 GFT	Pharmaceuticals, Inc,Merck & Discontinuing Co., Inc., Pfizer Inc;
				OTHER - Luitpold Pharmaceuticals, Inc, Novartis
				Corporation, Stemedica; RESEARCH/RESEARCH GRANTS -
				Biosense Webster, GlaxoSmithKline, Luitpold Pharmaceuticals, Inc, Merck & Dr, amp; Co., Inc., Thoratec, Inc.
Marhefka	Gregary	FIT Clinical Decision Making: Arrhythmias and	Flecainide and Traumatic Syncope: Don't Forget It	Nothing to Disclose
		Electrophysiology		
Marhefka	Gregary	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Anterolateral Papillary Muscle Rupture: A Rare Complication of Acute Myocardial Infarction	Nothing to Disclose
		Disease, and Vascular Medicine	Acute Myocardia illiarction	
Mariani	Justin	Emerging Developments in HFpEF and	Age Specific Hemodynamic Features in HFPEF: Implications for	Nothing to Disclose
		Arryhthmias	Therapy	
Marin Neto	Jose Antonio	Arrhythmias and Clinical EP: Devices 1	Electrical Storm in Chagas Heart Disease Patients With Implantable Cardioverter Defibrillator - Clinical Predictors, Outcome and	Nothing to Disclose
			Arrhythmic Characteristics: A Prospective Registry From a University	
			Hospital	
Marino	Amy	Advances in HCM, PPCM and Other	Multi-Fetal Gestation, Breastfeeding, Delivery Method and	Nothing to Disclose
		Cardiomyopathies	Myocardial Recovery in Peripartum Cardiomyopathy: Results From the Multicenter IPAC Study	
Marino	Bradley	Finding Out What Works in Pediatric and	Prevalence and Risk Factors Associated With Chronic Kidney	Nothing to Disclose
		Congenital Heart Disease	Disease in Patients With Single Ventricle Congenital Heart Disease	
Marina	Daola	Interventional Cardiology - TAVE 2	After Fontan Palliation	Nothing to Displace
Marino	Paolo	Interventional Cardiology: TAVR 2	Dual Antiplatelet Therapy Versus Single Antiplatelet Regimen With or Without Anticoagulation in Transcatheter Aortic Valve	Nothing to Disclose
<u></u>	<u> </u>	<u> </u>	Replacement: Indirect Comparison and Meta-Analysis	
Marino	Paolo	Emerging Developments in HFpEF and	Prognostic Role of Ventricular-Arterial Coupling in Patients With Left	Nothing to Disclose
		Arryhthmias	Ventricular Dysfunction Submitted to Cardiac Resynchronization Therapy	
Marino	Paolo	13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	Nothing to Disclose
		Clinical Team 4		-
Marino Vigo	Carlos Ramiro	Perspectives on Congenital Heart Disease:	Pulmonary Hypertension in Congenital Heart Diseases in Peru	Nothing to Disclose
		International Perspectives From the Caribbean Cardiac Society, Peruvian Society of		
		Cardiology, and American College of		
		Cardiology		
Mark	Daniel	Traditional and Novel Factors Used to Assess	Outcomes in Patients With Diabetes Mellitus and Suspected	CONSULTANT FEES/HONORARIA - MEDTRONIC;
		the Risk of, and Used for the Treatment of, Coronary Artery Disease	Coronary Artery Disease Following Non-Invasive Testing: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study	RESEARCH/RESEARCH GRANTS - AstraZeneca,Bristol Myers Squibb,Eli Lilly,gilead,Merck & Dr., Inc.,Oxygen
		Colonary Artery Disease	for Evaluation of Chest Pain)	Therapeutics
Mark	Daniel	New Perspectives on CAD Risk Factors	Discordances Between Predicted and Actual Risk of Adverse Events	CONSULTANT FEES/HONORARIA - MEDTRONIC;
			in Obese Patients With Suspected Cardiac Ischemia: Insights From	RESEARCH/RESEARCH GRANTS - AstraZeneca, Bristol Myers
			the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	Squibb,Eli Lilly,gilead,Merck & Dr., Inc.,Oxygen Therapeutics
				Therapeutics
Iwarkert	Ronald	Coronary Angiography, Intra-Vascular Imaging.	II ong Term Mortality Rates of U.S. Veterans With Bundle Branch	Nothing to Disclose
Markert	Ronald	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Long Term Mortality Rates of U.S. Veterans With Bundle Branch Blocks Presenting for Coronary Angiography	Nothing to Disclose
Markert Markert	Ronald	Revascularization and Outcomes Innovations in Advocacy and Patient Centered	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in	Nothing to Disclose Nothing to Disclose
Markert	Ronald	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population	Nothing to Disclose
		Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in	
Markert Marketou	Ronald Maria	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study	Nothing to Disclose Nothing to Disclose
Markert	Ronald	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter	Nothing to Disclose
Markert Marketou	Ronald Maria	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-duided Catheter Ablation of Left Ventricular Summit Arrhymias Accessible via the	Nothing to Disclose Nothing to Disclose
Markert Marketou	Ronald Maria	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter	Nothing to Disclose Nothing to Disclose
Marketou Markowitz	Ronald Maria Steven	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist	Nothing to Disclose Nothing to Disclose Nothing to Disclose
Marketou Markowitz	Ronald Maria Steven	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy. Insights Into Rates and Timing	Nothing to Disclose Nothing to Disclose Nothing to Disclose
Marketou Markowitz Markowitz	Ronald Maria Steven Steven	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remonte Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy: Insights Into Rates and Timing of Thrombus Resolution	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Marketou Markowitz	Ronald Maria Steven	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy. Insights Into Rates and Timing	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Marketou Markowitz Markowitz Markowitz Marmagiolis	Ronald Maria Steven Steven Kostas	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy: Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Marketou Markowitz Markowitz	Ronald Maria Steven Steven	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy. Insights Into Rates and Timing of Thrombus Resolution Impact of Perprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Marketou Markowitz Markowitz Markowitz Marmagiolis Marmagkiolis	Ronald Maria Steven Steven Kostas Konstantinos	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy: Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Marketou Markowitz Markowitz Markowitz Marmagiolis	Ronald Maria Steven Steven Kostas	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy. Insights Into Rates and Timing of Thrombus Resolution Impact of Perprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Marketou Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis	Ronald Maria Steven Steven Kostas Konstantinos Konstantinos	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrilliation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy: Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Falling Arteriovenous Grafts Failure: A Meta-Analysis	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Marketou Markowitz Markowitz Markowitz Marmagiolis Marmagkiolis	Ronald Maria Steven Steven Kostas Konstantinos	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V:	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy. Insights Into Rates and Timing of Thrombus Resolution Impact of Perprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Diseases 3-Month and 6-Month Primary Patency With Stent Versus Balloon	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Marketou Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis	Ronald Maria Steven Steven Kostas Konstantinos Konstantinos	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrilliation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy: Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Falling Arteriovenous Grafts Failure: A Meta-Analysis	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Marketou Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis	Ronald Maria Steven Steven Kostas Konstantinos Konstantinos	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Abiation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Cardiovascular Update for the Clinician V: Cardiovascular Update for the Clinician V: Cardiovascular Update for the Clinician V: Cardiovascular Update for the Clinician V:	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Armythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy: Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis Panelist <-> ✓->-✓	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Marketou Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Marmagkiolis	Ronald Maria Steven Steven Kostas Konstantinos Konstantinos	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A ISM Symposium by Valentin Fuster) Valvalurar Heart Disease, IHSS and Aorta - 2017 Valvalurar Heart Disease, IHSS and Aorta - 2017	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfariar Therapy. Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing
Marketou Markowitz Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Marmagkiolis Marmagkiolis Marmagkiolis	Ronald Maria Steven Steven Kostas Konstantinos Barry Barry	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster)	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarian Therapy. Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Falling Arteriovenous Grafts Failure: A Meta-Analysis Panelist <	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing
Marketou Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Marmagkiolis	Ronald Maria Steven Steven Kostas Konstantinos Konstantinos	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A ISM Symposium by Valentin Fuster) Valvalurar Heart Disease, IHSS and Aorta - 2017 Valvalurar Heart Disease, IHSS and Aorta - 2017	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Armythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy: Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis Panelist <-> ✓->-✓	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing
Marketou Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron Maron	Ronald Maria Steven Steven Kostas Konstantinos Konstantinos Barry Barry	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Abiation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy: Insights Inlo Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis Panelist <	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing
Marketou Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron Maron	Ronald Maria Steven Steven Kostas Konstantinos Konstantinos Barry Barry	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologists and the American	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy: Insights Inlo Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis Panelist <	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing
Marketou Markowitz Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron Maron Maron Maron	Ronald Maria Steven Steven Kostas Konstantinos Barry Barry Barry Barry	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologists and the American College of Cardiology	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarian Therapy: Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Falling Arteriovenous Grafts Failure: A Meta-Analysis Panelist In Patient Management In Patient Versus Balloon Angioplasty for Falling Arteriovenous Grafts Failure: A Meta-Analysis Panelist In Patient Versus Balloon Angioplasty for Falling Arteriovenous Grafts Failure: A Meta-Analysis Panelist In Patient Versus Balloon Angioplasty for Falling Arteriovenous Grafts Failure: A Meta-Analysis Panelist In Patient Versus Balloon Angioplasty for Falling Arteriovenous Grafts Failure: A Meta-Analysis Panelist In Patient Versus Balloon Angioplasty for Falling Arteriovenous Grafts Failure: A Meta-Analysis Panelist In Patient Versus Balloon Angioplasty for Falling Arteriovenous Grafts Failure: A Meta-Analysis	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing
Marketou Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Marmagkiolis Maron Maron	Ronald Maria Steven Steven Kostas Konstantinos Konstantinos Barry Barry	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologists and the American	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy: Insights Inlo Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis Panelist <	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing
Marketou Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron Maron Maron Maron	Ronald Maria Steven Steven Kostas Konstantinos Barry Barry Barry Barry	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease; Joint Symposium of the Association of Black Cardiologists and the American College of Cardiology Fibrillatory Arrhythmias: Outcomes With	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Armythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy: Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis Panelist Co-Chair Update on Management of Hypertrophic Cardiomyopathy (HOCM Antiarrhythmic Medications for Atrial Fibrillation Appear Reasonably Safe in Hypertrophic Cardiomyopathy Afrial Fibrillation Is Associated With Low Cardiovascular Mortality in	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing
Marketou Markowitz Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron Maron Maron Maron Maron Maron	Ronald Maria Steven Steven Kostas Konstantinos Konstantinos Barry Barry Barry Barry Barry Barry	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologists and the American College of Cardiology Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Arrhythmias and Clinical EP: Basic 2	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfariar Therapy. Insights Into Rates and Timing of Thrombus Resolution Impact of Perprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis Panelist <->-/P-Hyperthrophic Cardiomyopathy Genetics, Natural History and Evolving Management of Hypertrophic Cardiomyopathy (HOCM Antiarrhythmic Medications for Atrial Fibrillation Appear Reasonably Safe in Hypertrophic Cardiomyopathy Atrial Fibrillation is Associated With Low Cardiovascular Mortality in Hypertrophic Cardiomyopathy Atrial Fibrillation is Associated With Low Cardiovascular Mortality in Hypertrophic Cardiomyopathy	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing
Marketou Markowitz Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron Maron Maron Maron	Ronald Maria Steven Steven Kostas Konstantinos Barry Barry Barry Barry Barry	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologyist and the American College of Cardiology Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Armythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy: Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis Panelist Co-Chair Update on Management of Hypertrophic Cardiomyopathy (HOCM Antiarrhythmic Medications for Atrial Fibrillation Appear Reasonably Safe in Hypertrophic Cardiomyopathy Afrial Fibrillation Is Associated With Low Cardiovascular Mortality in	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing
Marketou Markowitz Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron Maron Maron Maron Maron Maron	Ronald Maria Steven Steven Kostas Konstantinos Konstantinos Barry Barry Barry Barry Barry Barry	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiology Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Arrhythmias and Clinical EP: Basic 2 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1 What is the PROMISE of ISCHEMIA: A 2017	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarian Therapy. Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Falling Arteriovenous Grafts Fallure: A Meta-Analysis Panelist Panelist Panelist	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing
Marketou Markowitz Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron	Ronald Maria Steven Steven Kostas Konstantinos Konstantinos Barry Barry Barry Barry Barry Barry Barry Barry Barry Barry Barry	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologists and the American College of Cardiology Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Arrhythmias and Clinical EP: Basic 2 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1 What is the PROMSE of ISCHEMIA: A 2017 Update on Structural and the Douglas P.	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy. Insights Into Rates and Timing of Thrombus Resolution Impact of Perprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis Panelist	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing Nothing to Disclose
Marketou Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron	Ronald Maria Steven Steven Kostas Konstantinos Konstantinos Barry Barry Barry Barry Barry Barry Barry Barry Barry Barry Barry	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologists and the American College of Cardiology Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Arrhythmias and Clinical EP: Basic 2 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1 What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Youge	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarian Therapy. Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Falling Arteriovenous Grafts Fallure: A Meta-Analysis Panelist Panelist Panelist	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing Nothing to Disclose
Markert Marketou Markowitz Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron	Ronald Maria Steven Steven Kostas Konstantinos Barry Barry Barry Barry Barry Barry Barry David	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologyists and the American College of Cardiology Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Arrhythmias and Clinical EP: Basic 2 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1 What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Armythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarian Therapy: Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Falling Arteriovenous Grafts Fallure: A Meta-Analysis Panelist In Park Procedural Transpedal Access for the Management of Complex Peripheral Arterial Disease Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease Safety and Efficacy of Transpedal Access for the Management of Management Office of Transpedal Access for the Management Office of Transpedal	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing Nothing to Disclose Nothing to Disclose
Markert Marketou Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron	Ronald Maria Steven Steven Kostas Konstantinos Konstantinos Barry Barry Barry Barry Barry Barry Barry Barry Barry Barry Barry	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologists and the American College of Cardiology Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Arrhythmias and Clinical EP: Basic 2 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1 What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture Great Debates in Ischemia 2017 Beyond the Usual Suspects - Other	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarian Therapy. Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Falling Arteriovenous Grafts Fallure: A Meta-Analysis Panelist Panelist Panelist	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing
Markett Marketou Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron	Ronald Maria Steven Steven Kostas Konstantinos Barry Barry Barry Barry Barry Barry David David	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologists and the American College of Cardiology Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Arrhythmias and Clinical EP: Basic 2 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1 What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angian and the Douglas P Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture Great Debates in Ischemia 2017 Beyond the Usual Suspects - Other	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy. Insights Into Rates and Timing of Thrombus Resolution Impact of Perprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis Panelist <-> <-> <> <> <> <> <> <>	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx. Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx. Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx. Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx. Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx. Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx. Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx. Genetic testing Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Markett Marketou Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron	Ronald Maria Steven Steven Kostas Konstantinos Konstantinos Barry Barry Barry Barry Barry Barry David	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologys Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Arrhythmias and Clinical EP: Basic 2 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1 What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture Great Debates in Ischemia 2017 Beyond the Usual Suspects - Other Dimensions in Prevention	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarian Therapy. Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis Panelist □ <□ ○ ← ○ ← → ← ← ← ← ← ← ← ← ← ← ← ← ← ← ←	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing Nothing to Disclose Nothing to Disclose
Marketou Markowitz Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron	Ronald Maria Steven Steven Kostas Konstantinos Barry Barry Barry Barry Barry Barry David David	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologists and the American College of Cardiology Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Arrhythmias and Clinical EP: Basic 2 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1 What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angian and the Douglas P Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture Great Debates in Ischemia 2017 Beyond the Usual Suspects - Other	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Armythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticagulant and Warfarin Therapy: Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis Panelist In Panelist In Patient Medications for Atrial Fibrillation Appear Reasonably Safe in Hypertrophic Cardiomyopathy Artial Fibrillation is Associated With Low Cardiovascular Mortality in Hypertrophic Cardiomyopathy Artial Fibrillation is Associated With Low Cardiovascular Mortality in Hypertrophic Cardiomyopathy Artial Fibrillation is Associated With Low Cardiovascular Mortality in Hypertrophic Cardiomyopathy Artial Fibrillation is Associated With Low Cardiovascular Mortality in Hypertrophic Cardiomyopathy Co-Chair Co-Chair Co-Chair Guidelines Allowing Control of Hypertension in Non-Diabetics Greater Than 60 Years Old at up to 150 mmHg Average Systolic	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Marketou Markowitz Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron	Ronald Maria Steven Steven Kostas Konstantinos Barry Barry Barry Barry Barry Barry David David	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologys Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Arrhythmias and Clinical EP: Basic 2 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1 What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture Great Debates in Ischemia 2017 Beyond the Usual Suspects - Other Dimensions in Prevention	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarian Therapy; Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Falling Arteriovenous Grafts Failure: A Meta-Analysis Panelist Impact of Preprocedural Thrombocytopenia on Safety of Performing Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Falling Arteriovenous Grafts Failure: A Meta-Analysis Panelist Impact of Prespondent of Hypertrophic Cardiomyopathy Genetics, Natural History and Evolving Management of Hypertrophic Cardiomyopathy Artial Fibrillation is Associated With Low Cardiovascular Mortality in Hypertrophic Cardiomyopathy Suggested Reviewer Putting it All Together: Design and Rationale of the Ongoing is CHEMIA Trial Co-Chair Co-Chair Guidelines Allowing Control of Hypertension in Non-Diabetics Greater Than 60 Years Old at up to 150 mmHg Average Systolic Blood Pressure Increases Patient Mortality in Veterans Predictors of Statin Use for Patients With LDL Cholesterol Above	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Marketou Marketou Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron	Ronald Maria Steven Steven Kostas Konstantinos Konstantinos Barry Barry Barry Barry Barry David David David David David	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologists and the American College of Cardiology Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Arrhythmias and Clinical EP: Basic 2 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1 What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture Great Debates in Ischemia 2017 Beyond the Usual Suspects - Other Dimensions in Prevention Assessing the Clinical Impact of Blood Pressure Lowering Therapies	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarin Therapy. Insights Into Rates and Timing of Thrombus Resolution Impact of Perprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Failing Arteriovenous Grafts Failure: A Meta-Analysis Panelist Co-Chair Update on Management of Hypertrophic Cardiomyopathy (HOCM Antiarrhythmic Medications for Atrial Fibrillation Appear Reasonably Safe in Hypertrophic Cardiomyopathy Atrial Fibrillation is Associated With Low Cardiovascular Mortality in Hypertrophic Cardiomyopathy Suggested Reviewer Putting it All Together: Design and Rationale of the Ongoing is CHEMIA Trial Co-Chair Co-Chair Co-Chair Cuidelines Allowing Control of Hypertension in Non-Diabetics Greater Than 60 Years Old at up to 150 mmHg Average Systolic Blood Pressure Increases Patient Mortality in Veterans Predictors of Statin Use for Patients With LOL Cholesterol Above 190mg/dL: Insights From the Veterans Affairs Health Care System	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Marketou Markowitz Markowitz Markowitz Marmagiolis Marmagkiolis Marmagkiolis Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron Maron	Ronald Maria Steven Steven Steven Kostas Konstantinos Konstantinos Barry Barry Barry Barry Barry Bradley David David David	Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care Novel Mechanical Devices for the Treatment and Assessment of Hypertension Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation Stroke and AF: Thinking About the Heart Optimizing the Care of ACS Patients Head to Toe: Outcomes of Endovascular Interventions Venous Investigation: The Dark Side Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Cardiovascular Update for the Clinician V: Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster) Genetic Testing for Cardiomyopathies Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologists and the American College of Cardiology Fibrillatory Arrhythmias: Outcomes With Contemporary Practice Arrhythmias and Clinical EP: Basic 2 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1 What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture Great Debates in Ischemia 2017 Beyond the Usual Suspects - Other Dimensions in Prevention Assessing the Clinical Impact of Blood Pressure Lowering Therapies	Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System Outcomes of Patients With Atrial Fibrillation and Left Atrial Thrombus Despite Continuous Non-Vitamin K Antagonist Anticoagulant and Warfarian Therapy; Insights Into Rates and Timing of Thrombus Resolution Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients Safety and Efficacy of Transpedal Access for the Management of Complex Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Falling Arteriovenous Grafts Failure: A Meta-Analysis Panelist Impact of Preprocedural Thrombocytopenia on Safety of Performing Peripheral Arterial Disease 3-Month and 6-Month Primary Patency With Stent Versus Balloon Angioplasty for Falling Arteriovenous Grafts Failure: A Meta-Analysis Panelist Impact of Prespondent of Hypertrophic Cardiomyopathy Genetics, Natural History and Evolving Management of Hypertrophic Cardiomyopathy Artial Fibrillation is Associated With Low Cardiovascular Mortality in Hypertrophic Cardiomyopathy Suggested Reviewer Putting it All Together: Design and Rationale of the Ongoing is CHEMIA Trial Co-Chair Co-Chair Guidelines Allowing Control of Hypertension in Non-Diabetics Greater Than 60 Years Old at up to 150 mmHg Average Systolic Blood Pressure Increases Patient Mortality in Veterans Predictors of Statin Use for Patients With LDL Cholesterol Above	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing CONSULTANT FEES/HONORARIA - Gene Dx: Genetic testing Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose



March March					
Name	Maron	First Name Martin	Contemporary Treatable Genetic Heart	Presentation Title Co-Chair	
Name of the process o	Maron	Martin		Panelist	
Name of the process o	Maron	Martin	Genetic Testing for Cardiomyopathies		CONSULTANT FEES/HONORARIA - GILEAD
Name of Service Programs and Contract Product Product 2 per programs and Contract Product Product 2 per product Product 2 per product Product 2 per product	Maron	Martin		Antiarrhythmic Medications for Atrial Fibrillation Appear Reasonably	CONSULTANT FEES/HONORARIA - GILEAD
Septide Chrosopher Septide Processing Processing Septide Processing Septide Se	Maron	Martin		Atrial Fibrillation Is Associated With Low Cardiovascular Mortality in	CONSULTANT FEES/HONORARIA - GILEAD
Manuscular Christopher Manuscular September (1997) Manuscular Christopher Manuscular Ma	Maroules	Christopher	Imaging the Athlete's Heart	Pooled Cohort Equation and Coronary Artery Calcium in Retired	
Maryan Maryan	Maroules	Christopher	Hearts and Soles: Multimodality Imaging in	Ascending Aortic Dimensions in Former National Football League	Nothing to Disclose
According Committee Comm	Marques	Hugo	Non Invasive Imaging: Prognostic Implications	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation	Nothing to Disclose
Manipul Discord Anrighmost portion of the Passes Proceedings of the Passes Proceedings of the Passes Passes	Marques	Juan		Myocarditis, Heart Failure and Arrhythmias in Patients With Zika	SALARY - Medical Director MSD Mexico
Marroyuthe Nerself Arrhythmise and Clinical EP Base 2 Arrhythmise and Clinical EP Base 2 Arrhythmise and Clinical EP Base 2 Arrhythmise and Clinical EP Base 2 Arrhythmise and Clinical EP Base 2 Arrhythmise and Clinical EP Base 2 Arrhythmise and Clinical EP Base 3 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 5 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise and Clinical EP Base 4 Arrhythmise	Marroquin	Oscar			Nothing to Disclose
Samourhe Anthyrmise and Circuit FP (Base) 2 Anthyrmise and Circuit FP (Base) 2 Anthyrmise and Circuit FP (Base) 3 Anthyrmise and Circuit FP (Base) 3 Anthyrmise and Circuit FP (Base) 3 Anthyrmise and Circuit FP (Base) 3 Anthyrmise and Circuit FP (Base) 3 Anthyrmise and Circuit FP (Base) 3 Anthyrmise and Circuit FP (Base) 3 Anthyrmise and Circuit FP (Base) 3 Anthyrmise and Circuit FP (Base) 3 Anthyrmise and Circuit FP (Base) 3 Anthyrmise and Circuit FP (Base) 3 Anthyrmise and Circuit FP (Base) 3 Anthyrmise and Circuit FP (Base) 3 Anthyrmise and Circuit FP (Base) 4 Anthyrmise and Circu	Marroquin Donday	Luis		Diagnostic Utility of Goldberger's Electrocardiographic Triad in	Nothing to Disclose
Outcome in Parcoyama and President Alvara Fortifiston Wheeler Discover, Books on Security, Cardioc, OWNERSHIP WHITE SELECT PATHERSHIPP PRINCE, Ampter in White Selection of Clinical EPP Supreviolon, Selection of Clinical EPP Supreviolon, Selection of Clinical EPP Supreviolon, Selection of Clinical EPP Supreviolon, Selection of Clinical EPP Supreviolon, Selection of Clinical EPP Supreviolon, Selection of Clinical EPP Supreviolon, Selection of Clinical EPP Supreviolon, Selection of Clinical EPP Supreviolon, Selection of Clinical EPP Supreviolon, Selection of Clinical EPP Supreviolon, Selection of Clinical EPP Supreviolon, Selection of	Marrouche	Nassir		Utility of an Esophageal Screening Protocol in Preventing Atrio-	Webster, Biotronik, Boston Scientific, e.Cardio; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Arapeen Medical, Cardiac Designs, Marrek, MRI Interventions, Sentiomed, Utal Medical Solutions; RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim
Norman Nina Audrey			08. Arrhythmias and Clinical EP:	Outcomes in Paroxysmal and Persistent Atrial Fibrillation	CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik, Boston Scientific, eCardio; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Arapeen Medical, Cardiac Designs, Marrek, MRI Interventions, Sentiomed, Ulah Medical Solutions; RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim Phamaceuticals, Inc. CONSULTANT FEES/HONORARIA - Biosense
Marshall Audrey Highlighted Organ Research Congenital Highlighted Organ Research Congenital Highlighted Organ Research Congenital Highlighted Organ Research Congenital Highlighted Organ Research Congenital Highlighted Organ Research Congenital Highlighted Organ Research Congenital Highlighted Organ Research Congenital Highlighted Organ Research Congenital Highlighted Organ Research Congenital Highlighted Organ Research Congenital Highlighted Organ Research Congenital Research Conge			5		INTEREST/PARTNERSHIP/PRINCIPAL - Arapeen Medical,Cardiac Designs,Marrek,MRI Interventions,Sentiomed, Utah Medical Solutions; RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim
Marshall Audrey Marginate Original Research Congenital Heart Disease and the Year in Review Vavivolety Are Associated Visible Benchmark of Year Marking Marking Notices and Proventine Research Congenital Heart Disease Surgery Updates and Invocation and Earth Marking Progress in Understanding Heart Research Congenital Heart Disease Surgery Updates and Invocation Research	Marsan	Nina			Nothing to Disclose
Martens Peter Making Progress in Inderstanding Heart Failure and Making Progress in Inderstanding Heart Failure and Rethouse Special Fredom to Not Received Profession of Patients With Heart Failure and Rethouse Special Profession in Not Received Profession of Provent Readmissions of Provent Re	Marshall	Audrey	Highlighted Original Research: Congenital	Early Hemodynamic Changes After Fetal Aortic Stenosis	Nothing to Disclose
Martens Peter Making Progress in Understanding Heart Refuter (Equitating Strategies) Refused Ejection Fractions In Not Revealed to the Not Revealed to the Not Revealed to the Not Revealed to the Not Revealed to the Not Revealed to the Not Revealed to the Not Revealed to the Not Revealed to the Not Revealed to the Not Revealed to the Not Revealed to the Not Revealed to the Noting to Disclose Martin Angel Fitt Clinical Decision Making, Non-Invested Immaining and Valvular Heart Disease Martin Cindy Nove Electroadilographic Methods for Assessing Cardioc Function Martin Cindy New Technologies in Echnocardiography Martin Cindy New Technologies in Echnocardiography Martin Cindy New Technologies in Echnocardiography Martin Genard Six Years of Making an MPACT Martin Genard Six Years of Making an MPACT Martin Great Updates on Risk Factors for Cardiovascular Updates on Risk F	Marshall	Audrey			Nothing to Disclose
Martin Angel Frictinical Decision Nations (National Decision Natio	Martens	Pieter	Making Progress in Understanding Heart	Intravascular Volume Expansion in Patients With Heart Failure and Reduced Ejection Fraction Is Not Revealed by Changes in Cardiac	Nothing to Disclose
Martin Angel FTT Clinical Decision Making; Non-Invasive Imaging and Valukar Head Desease Martin Cindy Novel Echocardiographic Methods for Assessing Cardiac Function Assessing Cardiac	Martens	Pieter		Cardiac Resynchronization Therapy With Versus Without a Defibrillator: Clinical Insights From Device Interrogation and Mode of	Nothing to Disclose
Martin Cindy Novel Echocardiographic Methods for Assessing Cardiac Function Particular Prolitation Cardiac Acrea Trateate With Pinnary Angioplasty and Estracorporated Membrane Oxogenation Secretary Programs of Cardiac Functions (Programs of Cardiac Functions) (Programs of Cardiac Funct	Martin	Angel			Nothing to Disclose
Martin Cindy New Technologies in Echocardiography Transhovacic Echocardiography to Guide Extracorporate Nothing to Disclose No	Martin	Cindy	Novel Echocardiographic Methods for	Refractory Ventricular Fibrillation Cardiac Arrest Treated With	Nothing to Disclose
Martin Gerard Six Years of Making an IMPACT ACC Talit: The IMPACT Registry Can Be Used by Families to Shop Nothing to Disclose Martin Greg Updates on Risk Factors for Cardiovascular Disease Martin Greg Updates on Risk Factors for Cardiovascular Disease Martin Greg Updates on Risk Factors for Cardiovascular Disease Martin Mary Hunt Highlighted Original Research: Congenital Heart Disease and the Year in Review Replacement in the Native Right Ventricular Outflow Tract: A National Heart Disease and the Year in Review Replacement in the Native Right Ventricular Outflow Tract: A National Heart Disease and the Year in Review Replacement in the Native Right Ventricular Outflow Tract: A National Heart Disease and the Year in Review Replacement in the Native Right Ventricular Outflow Tract: A National Heart Disease and the Year in Review Replacement in the Native Right Ventricular Outflow Tract: A National Problems Reglacement in the Native Right Ventricular Outflow Tract: A National Research: Congenital Heart Disease States and Feasibility of Meloty Transcatheter Pulmonary Valve Replacement in the Native Right Ventricular Outflow Tract: A National Problems Research: Congenital Heart Disease and Feasibility of Meloty Transcatheter Pulmonary Valve Replacement in the Native Right Ventricular Outflow Tract: A National Vascular Edwards Life Science, MEDTRONIC Martin Randolph Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Research: Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Research: Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Research: Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Research: Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Research: Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Research: Complex Decisions in Mitral Valve Care:	Martin	Cindy	New Technologies in Echocardiography	Transthoracic Echocardiography to Guide Extracorporeal Membrane Oxygenation Decannulation After Refractory Ventricular Fibrillation Cardiac Arrest Treated With Primary Angioplasty: A	Nothing to Disclose
for the Best Center Updates on Risk Factors for Cardiovascular Disease Martin Greg Updates on Risk Factors for Cardiovascular Disease Martin Mary Hunt Highlighted Original Research: Congenital Heart Disease and the Year in Review Minicenter Study Martin Randolph The Tricuspid Valve: Not Forgotten, Just Misunderstood Martin Randolph Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Martin Randolph Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Martin Randolph Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Martin Randolph Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Martin Randolph Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Martin Randolph Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Martin Randolph Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Martin Randolph Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Martin Randolph Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Acc Challenging Case Reviewer Panelist Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Complex D					
Disease Disease			· ·	for the Best Center	<u> </u>
Martin Martin Martin Planticular Original Research: Congenital Heart Disease and the Year in Review Replacement in the Native Right Ventricular Outflow Tract: A Multicenter Study Multicenter Study Multicenter Study Co-Chair Sudicenter Study Co-Chair Disease and the Year in Review Multicenter Study Co-Chair Disease and the Year in Review Multicenter Study Co-Chair Disease and the Year in Review Multicenter Study Co-Chair Disease and the Year in Review Multicenter Study Co-Chair Disease Replacement in the Native Replacement in the Native Right Ventricular Outflow Tract: A Multicenter Study Disease Study Labs; SPEAKER'S BUREAU - Abbott Vascular, Edwards Life Science, MEDTRONIC Disease, and Treatment Diseases Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Diseases Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Diseases Disease D			Disease		
Heart Disease and the Year in Review Martin Randolph The Tricuspid Valve: Not Forgotten, Just Misunderstood Misund		_	Disease		-
Martin Randolph Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Randolph Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Presented Presentation of Treatment Presentation of		-	Heart Disease and the Year in Review	Replacement in the Native Right Ventricular Outflow Tract: A Multicenter Study	-
Individualizing Assessment, Diagnosis, and Treatment Treatment			Misunderstood		Labs; SPEAKER'S BUREAU - Abbott Vascular,Edwards Life Science,MEDTRONIC
Individualizing Assessment, Diagnosis, and Treatment Randolph Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment Martin Randolph Randolph Randolph Randolph Randolph Interventional Challenging Cases: Team 3 ACC Challenging Case Reviewer ACC Challenging Case		,	Individualizing Assessment, Diagnosis, and Treatment	and Management of MR	Labs; SPEAKER'S BUREAU - Abbott Vascular,Edwards Life Science,MEDTRONIC
Individualizing Assessment, Diagnosis, and Treatment Randolph Interventional Challenging Cases: Team 3 ACC Challenging Case Reviewer ACC Challenging Case Reviewer OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bay Labs; SPEAKER'S BUREAU - Abbott Vascular, Edwards Life Science, MEDTRONIC Martin Seth Great Debates in Preventive Cardiology Co-Chair Consultant FEEs/HONORARIA - Amgen Inc., Quest Diagnostics, Sanofi-Regeneron; RESEARCH/RESEARCH GRANTS - Aetna Foundation, Apple, Google Martin Seth Advances in Cholesterol Measurement and Management Martin Seth Advances in Cholesterol Measurement and Management Martin Seth Advances in Cholesterol Measurement and Management Martin Seth Advances in Cholesterol Measurement and Management Management Impact of Evolocumab Therapy in Patients With Discordance Between LDL-C and LDL-P Between LDL-C and LDL-P Between LDL-C and LDL-P CONSULTANT FEES/HONORARIA - Amgen Inc., Quest Diagnostics, Sanofi-Regeneron; RESEARCH/RESEARCH GRANTS - Aetna Foundation, Apple, Google CONSULTANT FEES/HONORARIA - Amgen Inc., Quest Diagnostics, Sanofi-Regeneron; RESEARCH/RESEARCH GRANTS - Aetna Foundation, Apple, Google CONSULTANT FEES/HONORARIA - Amgen Inc., Quest Diagnostics, Sanofi-Regeneron; RESEARCH/RESEARCH GRANTS - Aetna Foundation, Apple, Google CONSULTANT FEES/HONORARIA - Amgen Inc., Quest Diagnostics, Sanofi-Regeneron; RESEARCH/RESEARCH GRANTS - Aetna Foundation, Apple, Google CONSULTANT FEES/HONORARIA - Amgen Inc., Quest Diagnostics, Sanofi-Regeneron; RESEARCH/RESEARCH		,	Individualizing Assessment, Diagnosis, and Treatment	-	Labs; SPEAKER'S BUREAU - Abbott Vascular,Edwards Life Science,MEDTRONIC
Labs; SPEAKER'S BUREAU - Abbott Vascular, Edwards Life Science, MEDTRONIC Martin Seth Great Debates in Preventive Cardiology Co-Chair ConSULTANT FEES/HONORARIA - Amgen Inc., Quest Diagnostics, Sanofi-Regeneror, RESEARCH/RESEARCH GRANTS - Aetina Foundation, Apple, Google Martin Seth Advances in Cholesterol Measurement and Management Status Martin Seth Advances in Cholesterol Measurement and Management Status Martin Seth Advances in Cholesterol Measurement and Management Martin Seth Advances in Cholesterol Measurement and Management Martin Seth Advances in Cholesterol Measurement and Management Martin Seth Advances in Cholesterol Measurement and Management Martin Seth Advances in Cholesterol Measurement and Management Martin Martin Seth Advances in Cholesterol Measurement and Management Martin Martin Seth Advances in Cholesterol Measurement and Management Martin Martin Seth Advances in Cholesterol Measurement and Management Martin Martin Martin Seth Advances in Cholesterol Measurement and Management Martin Martin Martin Martin Seth Advances in Cholesterol Measurement and Management Martin Martin Martin Martin Seth Advances in Cholesterol Measurement and Management Martin Mar			Individualizing Assessment, Diagnosis, and Treatment		Labs; SPEAKER'S BUREAU - Abbott Vascular,Edwards Life Science,MEDTRONIC
Diagnostics, Sanofi-Regeneron; RESEARCH/RESEARCH		,			Labs; SPEAKER'S BUREAU - Abbott Vascular,Edwards Life Science,MEDTRONIC
Management Estmatting Low-Density Lipoprotein-Cholesterol Based on Fasting Diagnostics, Sanofi-Regeneron; RESEARCH/RESEARCH Status Status GRANTS - Aetna Foundation, Apple, Google Management Managem					Diagnostics,Sanofi-Regeneron; RESEARCH/RESEARCH GRANTS - Aetna Foundation,Apple,Google
Martin Seth Advances in Cholesterol Measurement and Management Impact of Evolocumab Therapy in Patients With Discordance CONSULTANT FEES/HONORARIA - Amgen Inc., Quest Between LDL-C and LDL-P Diagnostics, Sanofi-Regeneron; RESEARCH/RESEARCH GRANTS - Aetna Foundation, Apple, Google Martin Seth Current Issues in Cardiovascular Health Disparities Among Patients With Familial CONSULTANT FEES/HONORARIA - Amgen Inc., Quest Diagnostics, Sanofi-Regeneron; RESEARCH/RESEARCH Diagnostics, Sanofi-Regeneron; RESEARCH/RESEARCH	Martin	Seth		Estimating Low-Density Lipoprotein-Cholesterol Based on Fasting	Diagnostics,Sanofi-Regeneron; RESEARCH/RESEARCH
Martin Seth Current Issues in Cardiovascular Health Disparities Among Patients With Familial CONSULTANT FEES/HONORARIA - Amgen Inc., Quest Hypercholesterolemia in the CASCADE-FH Patient Registry Diagnostics, Sanofi-Regeneron; RESEARCH/RESEARCH	Martin	Seth		Impact of Evolocumab Therapy in Patients With Discordance	CONSULTANT FEES/HONORARIA - Amgen Inc., Quest Diagnostics, Sanofi-Regeneron; RESEARCH/RESEARCH
GRANTS - Aetna Foundation, Apple, Google	Martin	Seth			CONSULTANT FEES/HONORARIA - Amgen Inc., Quest Diagnostics, Sanofi-Regeneron; RESEARCH/RESEARCH

Congress of the Congress of th				I
Last Name Martin	First Name Seth	Session Title Arrhythmias and Clinical EP: AF Miscellaneous	Presentation Title Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation	Disclosures CONSULTANT FEES/HONORARIA - Amgen Inc.,Quest
ividi Ui i	Jelli	and Surgical Issues	Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Stroke Among Whites and Blacks: The Atherosclerosis Risk In Communities (ARIC) Study	Diagnostics,Sanofi-Regeneron; RESEARCH/RESEARCH GRANTS - Aetna Foundation,Apple,Google
Martin	Seth	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Alirocumab Efficacy and Safety in Patients With Hypercholesterolemia and With or Without Clinical Atherosclerotic Cardiovascular Disease: Pooled Analysis of 10 ODYSSEY	CONSULTANT FEES/HONORARIA - Amgen Inc.,Quest Diagnostics,Sanofi-Regeneron; RESEARCH/RESEARCH GRANTS - Aetna Foundation,Apple,Google
			Randomized Trials	GRANTS - Aetha Foundation, Apple, Google
Martin	Seth	New Insights Into Prediction and Treatment of Hypertension	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Amgen Inc., Quest Diagnostics, Sanofi-Regeneron; RESEARCH/RESEARCH GRANTS - Aetna Foundation, Apple, Google
Martin	Seth	32. Prevention: Clinical Team 6	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen Inc.,Quest Diagnostics,Sanofi-Regeneron; RESEARCH/RESEARCH
Martin	Tim	Great Minds Think Differently: Multidisciplinary Approach to Controversies in Cardiology	Panelist	GRANTS - Aetna Foundation, Apple, Google Nothing to Disclose
Martin Mariscal	Maria Luisa	Arrhythmias and Clinical EP: Devices 1	Pharmacological Treatment Alone Versus Treatment Combined	Nothing to Disclose
		·	With Implantable Cardioverter-Defibrillator Therapy in Patients Over 75 Years	
Martinez	Claudia	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Cardiac Pain, Just Not From the Heart	Nothing to Disclose
Martinez	Fernando	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Prognostic Importance of Blood Pressure and Heart Rate in Chronic Obstructive Pulmonary Disease: The SUMMIT Trial	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, Genentech, Inc, GlaxoSmithKline, Ikaria/Bellerophon, Kadman, Novartis Corporation, Nycomed/Takeda, Pearl, Sepracor Inc. (renamed Sunovion Pharmaceuticals inc.) SkyePharma. Theravance, Inc., Veracyte; DATA SAFETY MONITORING BOARD - Biogen Idec; RESEARCH/RESEARCH GRANTS - Bayer Healthcare Pharmaceuticals
Martinez	Fernando	Innovations in Cardiovascular Risk Assessment and Reduction	High-Sensitivity Cardiac Troponin I and Risk of Cardiovascular Events in Patients With COPD and Heightened Cardiovascular Risk: A Biomarker Sub-Study of the SUMMIT Trial	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc,Genentech, Inc,GlaxoSmithKline,Ikaria/Bellerophon,Kadman,Novartis Corporation,Nycomed/Takeda,Pearl,Sepracor Inc. (renamed Sunovion Pharmaceuticals Inc),SkyePharma,Theravance, Inc.,Veracyte: DATA SAFETY MONITORING BOARD - Biogen Idec; RESEARCH/IRESEARCH GRANTS - Bayer Healthcare Pharmaceuticals
Martinez	Matthew	How Hypertrophic Cardiomyopathy Became A Contemporary Treatable Genetic Heart Disease	Panelist	Nothing to Disclose
Martinez	Matthew	Test Yourself with Questions: General	Faculty	Nothing to Disclose
Martinez	Matthew	Cardiology Module 15 Personalized Skills Center: Drill and Practice	Heart Songs Moderator	Nothing to Disclose
Martinez	Matthew	(Heart Songs, ECG, Hand-Held Echo) Personalized Skills Center: Hands-On	Heart Failure and Valvular Heart Disease	Nothing to Displace
		Simulation - Heart Failure and Valvular Heart Disease		Nothing to Disclose
Martinez	Matthew	Personalized Skills Center: Hands-On Simulation - Heart Failure and Valvular Heart Disease	Heart Failure and Valvular Heart Disease	Nothing to Disclose
Martinez	Matthew	Personalized Skills Center: Hands-On Simulation - Heart Failure and Valvular Heart Disease	Heart Failure and Valvular Heart Disease	Nothing to Disclose
Martinez	Matthew	31. Non Invasive Imaging: Sports and Exercise Team 1	Suggested Reviewer	Nothing to Disclose
Martinez Parachini	Jose	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Contemporary Use of Laser During Percutaneous Coronary Intervention: Results From the Laser Veterans Affairs (LAVA) Multicenter Registry	Nothing to Disclose
Martinez Peredo	Carlos Gustavo	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Incidence, Clinical Profile and Prognosis of Patients With Myocardial Infarction With Non-Obstructive Coronary Arteries in the Real World	Nothing to Disclose
Martinez-Rios	Marco	The Challenges of Outcome Prediction in Valvular Heart Disease	Right Ventricle Free Wall Strain Predicts Post-Surgical Low Cardiac Output Syndrome in Patients Undergoing Aortic Valve Replacement	Nothing to Disclose
Martinez-Sanchez	Carlos	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Derivation and Validation of a Simple Inflammation Based Risk Score for Predicting In-Hospital Mortality in Acute Coronary	Nothing to Disclose
Martins	Vitor	Syndrome ACC International Conferences Best Posters	Syndrome Comparison of Different Lung Ultrasound Methodologies for	Nothing to Disclose
Marwan	Mohamed	Challenges in Cardiac CT: Case-Based	Pulmonary Congestion Evaluation in Heart Failure Outpatients Cardiac CT to Guide Atrial Appendage and other non-TAVR	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,
		Discussions	Cardiovascular Interventions	Siemens Healthcare
Marwick	Thomas	Imaging of Cancer-Treatment Associated CV Toxicity: Applying Guidelines to Clinical Practice	Co-Chair	RESEARCH/RESEARCH GRANTS - GE Medical Systems
Marwick	Thomas	Heart Failure and Cancer Care	Case Presentation: How to Detect Cardiac Injury with Cardiotoxic Chemotherapy Is Ejection Fraction Still the Gold Standard? Evidence to Practice Roundtable Discussion	RESEARCH/RESEARCH GRANTS - GE Medical Systems
Marwick	Thomas	Emerging Applications of Echocardiography	Effect of Changing Strain Software Versions on Longitudinal Assessment of LV Function	RESEARCH/RESEARCH GRANTS - GE Medical Systems
Marwick	Thomas	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Left Atrial Function and Role in Prediction of Heart Failure	RESEARCH/RESEARCH GRANTS - GE Medical Systems
Marwick Marx	Thomas Gerald	Innovative Use of Echocardiography Predicting Outcomes in Pediatric Heart Disase	Independent Association of Atrial Mechanics With Risk of Incident Atrial Fibrillation Risk Stratification of Children Undergoing Valve-Sparing Repair of	RESEARCH/RESEARCH GRANTS - GE Medical Systems Nothing to Disclose
		_	Tetralogy of Fallot	
März	Winfried	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Circulating PCSK9 Is Not Associated With All-Cause and Cardiovascular Mortality	SALARY - Synlab Services GmbH
Marzal	Domingo	02. Acute and Stable Ischemic Heart Disease: Clinical Team 8	Suggested Reviewer	Nothing to Disclose
Marzec	Lucas	Atrial Fibrillation and VT: Unique Populations and Solutions	Presence of Mid-Myocardial Substrate Is Associated With Need for Multiple Ablations in Patients With Non-Ischemic Cardiomyopathy and Ventricular Arrhythmias	Nothing to Disclose
Marzec	Lucas	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Early Recurrence of Ventricular Tachycardia Predicts Increased Mortality Among Patients With Severe Heart Failure	Nothing to Disclose
Marzec	Lucas	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Safety and Outcomes of Catheter Ablation for Treatment of Refractory Ventricular Arrhythmias in Patients With Advanced Heart	Nothing to Disclose
Marzo	Kevin	Innovations in Advocacy and Patient Centered Care	Failure Patient Perceptions on the Impact of Caffeine Consumption After a Myocardial Infarction or Percutaneous Coronary Intervention	Nothing to Disclose
Masand	Prakash	Non Invasive Imaging: Role of Exercise Testing	Stress Myocardial Perfusion Imaging in Anomalous Aortic Origin of a	Nothing to Disclose
	L		Coronary Artery: Results Following a Standardized Approach	

				<u> </u>
Last Name	First Name	Session Title	Presentation Title	Disclosures
Mascarenhas	Vernon	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Replacement Patients With Atrial Fibrillation Are at High Risk for Stroke and Bleeding: A Rationale for Consideration of Transcatheter Aortic Valve Replacement and Left	Nothing to Disclose
Mascio	Christopher	Congenital Heart Disease: Innovations in	Atrial Appendage Closure as Complementary Therapies Impact of Home Monitoring Program on Interstage Mortality and	Nothing to Disclose
Masi	Filippo	Single Ventricle Heart Disease Cardiac Arrest, Diabetes, and Other High Risk	Stage II Outcomes Impact of Admission Plasma Glucose Level on Myocardial Perfusion	Nothing to Disclose
Masi	Filippo	Features of Patients With Acute Coronary Syndrome Antiplatelet and Antithrombotic Agents in	in St-Segment Elevation Myocardial Infarction (STEMI) Patients Time Related Benefit of Antiplatelet Therapy on Coronary	Nothing to Disclose
iviasi	т шрро	Ischemic Heart Disease	Reperfusion in ST-Elevation Myocardial Infarction (STEMI) Patients	reduling to Disclose
Maskoun	Waddah	Arrhythmias and Clinical EP: Devices 3	Near Zero Fluoroscopy Implantation of a Dual Chamber Pacemaker in Pregnancy Using Electroanatomical Mapping	
Mason	Pamela	Syncope: Challenges and Pitfalls: A Case- based Approach	Panelist	CONSULTANT FEES/HONORARIA - Boston Scientific; RESEARCH/RESEARCH GRANTS - Boston Scientific,MEDTRONIC; SPEAKER'S BUREAU - MEDTRONIC
Mason	Pamela	Syncope: Challenges and Pitfalls: A Case- based Approach	50 Year Old with History of Refractory Vasovagal Syncope and Hip Fracture	CONSULTANT FEES/HONORARIA - Boston Scientific; RESEARCH/RESEARCH GRANTS - Boston Scientific,MEDTRONIC; SPEAKER'S BUREAU - MEDTRONIC
Mason	Pamela	06. Arrhythmias and Clinical EP: Other Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific; RESEARCH/RESEARCH GRANTS - Boston Scientific,MEDTRONIC; SPEAKER'S BUREAU - MEDTRONIC
Mason	R.	Uncovering the Intricacies of Vascular Function	Atorvastatin Active Metabolite Inhibits Oxidation of ApoB-Containing Lipoprotein Particles of Different Sizes Measured <i>In Vitro</i> Under Hyperglycemic Conditions	RESEARCH/RESEARCH GRANTS - Amarin, Pfizer
Masoomi	Reza	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Timely Use of Right Heart Catheterization Is Associated With Reduced In-Hospital Mortality in Patients With Congestive Heart Failure: Insight From the United States National Inpatient Sample Database	Nothing to Disclose
Masotti	Monica	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Therapeutic Hypothermia in Post-Cardiac Arrest Syndrome: Role of Neuron-Specific Enolase as Early Predictor of Neurological Status at Discharge	Nothing to Disclose
Masoudi	Frederick	7th Annual ACC China Chapter Session: Endless Change and Evolution in Cardiovascular Prevention and Rehabilitation	Improving the Quality of Prevention and Referral for Cardiac Rehabilitation in Clinical Practice	Nothing to Disclose
Masoudi	Frederick	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Impact of Medical Liability Reform on Coronary Artery Disease Testing and Intervention	Nothing to Disclose
Masoudi	Frederick	Advances in Lipid Management	Implications of the IMPROVE-IT Trial for Contemporary Cardiovascular Practice: An NCDR [®] Research to Practice (R2P) Project	Nothing to Disclose
Masoudi	Frederick	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Triactice (NZE) 77 inject. Time to Acute Care Among Patients With Acute Myocardial Infarction in China: A Report From China Patient-Centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction	Nothing to Disclose
Masoudi	Frederick	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Implications of the FDA Approval of PCSK9 Inhibitors for Contemporary Cardiovascular Practice: Findings From the NCDR [®] Research to Practice (R2P) Project	Nothing to Disclose
Masoudi	Frederick	02. Acute and Stable Ischemic Heart Disease: Clinical Team 8	Suggested Reviewer	Nothing to Disclose
Masri	Ahmad	FIT Clinical Decision Making: Heart Failure and	When the Liver Gets Sacked by the Heart Sac: A Diagnostic	Nothing to Disclose
Masri	Ahmad	Pulmonary Hypertension FIT Clinical Decision Making: Heart Failure and	Challenge of Mixed Heart and Liver Pathology Subclavian Artery Stenosis Precipitating Ischemic Cardiomyopahty	Nothing to Disclose
Masri	Ahmad	Pulmonary Hypertension Emerging Applications for Imaging Cardiac	Predictors of a Positive Technetium Pyrophosphate Scan in Patients	Nothing to Disclose
Masri	S. Carolina	Amyloidosis: Nuclear Cardiology 14. Heart Failure and Cardiomyopathies:	With Suspected Cardiac Amyloidosis Suggested Reviewer	Nothing to Disclose
		Therapy Team 3		-
Massaro	Joseph	Considerations in Antiplatelet Therapy and in ACS	Impact of Coronary Anatomical Complexity on the Effect of Extended Duration Dual Antiplatelet Therapy: An Analysis From the Dual Antiplatelet Therapy Study	CONSULTANT FEES/HONORARIA - Abbott Vascular,Cardiovascular Clinical Sciences,MEDTRONIC; SALARY - Harvard Clinical Research Institute
Massberg	Steffen	Frontiers in Mitral Valve Disease and Treatment	Transcatheter Treatment of Severe Tricuspid Regurgitation Using the MitraClip System in Patients With and Without Pacemaker Leads	Nothing to Disclose
Masso	Anthony	Featured Clinical Research I	Results of MRI-Based Screening Study of 5130 Candidates for Sports Participation	Nothing to Disclose
Mastuda	Junji	Unusual Presentations of ACS	Comparison Between Angioscopic and Optical Coherence Tomographic Assessment of Instent Restenosis	Nothing to Disclose
Masvidal	Daniel	Nuclear Cardiology: Coronary Flow	Reduced Flow Capacity as Measured by Cardiac Positron Emission Tomography Predicts Ventricular Tachyarrhythmia in Patients With	Nothing to Disclose
Matar	Fadi	Emerging Applications of Echocardiography	an ICD Clinical Characteristics and Changes of Valvuloarterial Impedence Severity in Patients Undergoing Transcatheter Aortic Valve	Nothing to Disclose
Matetzky	Shlomi	Anti-Platelet Therapies: Always a Sticky Topic	Replacement for Severe Aortic Stenosis Chewing Versus Traditional Swallowing of Ticagrelor to Accelerate	Nothing to Disclose
Mathbout	Mohammad	Novel Mechanisms Underlying Ischemia-	Platelet Inhibition in ST Elevation Myocardial Infarction: The CHEERS-STEMI Study Sphingosine-1 Phosphate Is a Novel Biomarker That Correlates	Nothing to Disclose
Mather	Paul	Reperfusion Injury in AMI Systemic Organ Involvement in Heart Failure:	With Stem Cell Mobilization and Clinical Outcomes in Patients With ST-Elevation Myocardial Infarction Co-Chair	Nothing to Disclose
iviau ici	raui	International Perspectives From the German Cardiac Society, Hellenic Society of Cardiology, and American College of Cardiology	Co-Cital	Todaling to Disclose
Mather	Paul	Systemic Organ Involvement in Heart Failure: International Perspectives From the German Cardiac Society, Hellenic Society of Cardiology, and American College of Cardiology	introduction to Session	Nothing to Disclose
Mather	Paul	The Burden of Heart Failure: International Perspectives From the Chilean Society of Cardiology, Colombian Society of Cardiology, and American College of Cardiology	Co-Chair	Nothing to Disclose
Mather	Paul	The Burden of Heart Failure: International Perspectives From the Chilean Society of Cardiology, Colombian Society of Cardiology, and American College of Cardiology	Introduction to Session	Nothing to Disclose
Mather	Paul	Distinct Phenotypes in HFpEF: Beyond	Co-Chair	Nothing to Disclose
Mather	Paul	Ejection Fraction Acute Heart Failure: Evaluating Strategies to	Severe Physical Inactivity Persists Following Acute Heart Failure in	Nothing to Disclose
		Prevent Readmissions	Patients With Sleep Disordered Breathing	

Martier Paul Wysers (1994) And access in teach, Price and other Security of Control of C	and a				<u> </u>
Control Contro	Last Name Mather	First Name	Session Title Advances in HCM_PPCM and Other	Presentation Title Extended Course of Recovery in Patients With Peripartum	Disclosures Nothing to Disclose
Million Maria Million Maria Million Maria Million			Cardiomyopathies	Cardiomyopathy Assessed by Left Ventricular Wall Distensibility	-
Marker Joseph J. Communication of the Communicatio	Mather	Paul		ACC Poster Moderator	Nothing to Disclose
More William Common March State Common Commo	Mather	Paul	13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	Nothing to Disclose
And we will be a service of the company of the comp	Mathew	Jacob		Murphy's Law Incarnate: The Case of the Disintegrating Coronary	Nothing to Disclose
Notice Notes of Programme of Programme of Notes of Programme of Notes of Programme of Notes o				Artery	
Transport Activity of Control (1997) Transport Activity Office (1997) Tr	Mathew	Jehu	Atrial Fibrillation and VT: Unique Populations		Nothing to Disclose
Selection Vergheber Verghe			and Solutions		
Microsoph Micros	Mathew	Verghese		Fractional Flow Reserve Derived From Coronary Computed	CONSULTANT FEES/HONORARIA - Lake Region Medical
States (1992) See thouse language Extra Court and Court of See the Court o					
School Sc			28. Non Invasive Imaging: Echo Team 3	Suggested Reviewer	
Mother Morbal Projections on and Christopher of Parties Desired Projection for 1 Tables 2 Obstacl Projection of Morbal Projection of Morbal Projection of Morbal Projection of Morbal Projection of Morbal Projection of Morbal Projection of Morbal Projection And Christopher (Morbal Projection of Morbal P	Mathiasen	Anders			Nothing to Disclose
Website Wilder Wilder Wilder Wilder Wilder Michael Decomes for One Repair and Displacement Wilder All Inc. Nitro Repair Service for Company and an Endocational Challergoon The Ball Shrutard interactional Challergoon The Ball Shrutard interactional Challergoon The Ball Shrutard interactional Challergoon The Ball Shrutard interactional Challergoon The Ball Shrutard interactional Challergoon The Ball Shrutard interactional Challergoon The Ball Shrutard interactional Challergoon The Ball Shrutard interactional Challergoon The Ball Shrutard interactional Challergoon An Shrutard Neither Neither Neither Neither Neither Neither Neither Neither Neither Neither Prediction Neither Neither Prediction Website Shrutard Prediction Neither Prediction Neither Prediction Neither Prediction Neither Neithe	Mathier	Michael			Nothing to Disclose
Notes Allon Security From Registers and Databases (Consequent Version College (Consequent Version College) (Consequent Version Colle					
Motivar Carina Description of Company of Transposed Market Personalistant Level Closure for Recurrent Market Personalistant Company of Transport Information of Transport Personalistant Company of Transport Information of Transport Personalistant Company of Transport Information of Transport Personalistant Company of Transport Information of Transport Personalistant Company of Transport Information of Transport Personalistant Company of Transport Information of Transport Personalistant Company of Transport Information of Transport Personalistant Company of Transport Personalistant Personalistant Company of Transport Personalistant Personalistant Company of Transport Personalistant Personalistant Company of Transport Personalistant Company of Transport Personalistant Company of	Mathier	Michael			Nothing to Disclose
Memory West by Control Provided Provid	Mathur	Atish		Transapical Mitral Paravalvular Leak Closure for Recurrent	Nothing to Disclose
Method Need Printers Need Printers	Mathur	Kanika			Nothing to Disclose
Matter the Mission Vermitted Amphies and Bucket Death Prevention Vermitted Amphies Vermitted Amphi			Disease	Infant With Single Ventricle Trial	-
Segetiment New PowerSon PowerS	Mathuria	Nilesh			Nothing to Disclose
Assal Descis is Associated Visit Precentation of ACS Include Presentations of ACS Include Pres				Experience	
The files were included as the company of the compa	mathuria	Nilesh		ventricular I achycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A	Notning to Disclose
Political With Cardiovasculas Shock in Jugons The Recibility From Supplemental Characteristics of ACS Tellstyp Ususual Presentations of ACS Asson Asson Asson Asson Asson Asson Antitytimes and Clinical EP-A Fabilistic Antitytimes and Clinical EP-A Fabilistic Asson Antitytimes and Clinical EP-A Fabilistic Asson Antitytimes and Clinical EP-A Fabilistic Asson Antitytimes and Clinical EP-A Fabilistic Asson Antitytimes and Clinical EP-A Fabilistic Asson Asson Antitytimes and Clinical EP-A Fabilistic Asson Antitytimes and Clinical EP-A Fabilistic Asson Antitytimes and Clinical EP-A Fabilistic Asson Asson Antitytimes and Clinical EP-A Fabilistic Asson Asson Antitytimes and Clinical EP-A Fabilistic Asson Asson Asson Antitytimes and Clinical EP-A Fabilistic Asson Asson Antitytimes and Clinical EP-Devices 2 Comprehenses Strategy to Receive the Emergent Cardiac Cardiocard Strategy to Biological Antitytimes and Clinical EP-Devices 2 Comprehenses Strategy to Receive the Emergent Cardiac Cardiocard Strategy to Biological Antitytimes and Clinical EP-Devices 2 Comprehenses Strategy to Receive the Emergent Cardiac Cardiocard Strategy to Biological Antitytimes and Clinical EP-Devices 2 Comprehenses Strategy to Receive the Emergent Cardiocard Strategy to Biological Antitytimes and Clinical EP-Devices 2 Comprehenses Strategy to Receive the Interventional Cardiocard Antitytimes and Clinical EP-Devices 2 Comprehenses Strategy to Receive the Interventional Cardiocard Antitytimes and C	Mataka	Tataura		Thirteen Year Institutional Experience	ODEAKEDIO DI DEALI. De collegione de
Inganese Crustation Scotey Process Registery Unusual Presentations of ACS Association Debender information Train and Short From Mortality in SPEMER'S BUREAU - Bayer Healthcurse Pharmac-decisis AS Sections From Ace Short Registery Mados Asian Asian Association Sheemed From Ace Short Registery Association Sheemed From Ace Short Registery Association of Sheemed From Ace Short Registery Association of Association Association of Association Association of Association Association of Association Association of Association Association of Association of Association Association of Association Association of Association Association of Association Association of Association Association of Association Association of Association Association of Association Association Association of Association Association of Association Association Association of Association Association of Association Associat	iviatoba	ı etsuya	Unusual Presentations of ACS		SPEAKER'S BUREAU - Bayer Healthcare Pharmaceuticals,MSD
Peleter With Cardingsoms Stock Completioning Action Coronary Soundations From the Stock Register	Mataka	Tataura	Have al Proportetions (100)	Japanese Circulation Society Shock Registry	ODEAKEDIC DUDEAU Davasili siituu Biranii siituu Bir
Motion Jason Workers on Pulmonary Emplotion Services From the Shock Registry Control of Services Servi	Matoba	l etsuya	Unusual Presentations of ACS		SPEAKER'S BUREAU - Bayer Healthcare Pharmaceuticals,MSD
Martine Management in 2017 Computed Tomography, and Electrocardography in Patients With Acade Advances in Patients With Acade Advances in Patients With Acade Advances in Patients With Acade Advances in Patients With Acade Advances in Patients With Acade Advances in Patients With Acade Advances in Patients With Acade Advances in Computed Tomography Malton Jason Unusual Presentations of ACS Sorvine Patients Referred to Emergent Cardio-Cardio	Mataa	lacan	Undetee on Dulmonery Embeliam	Syndrome: From Jcs Shock Registry	Nothing to Displace
Mates Asson Arthyfirmiae and Clinical EP, AF Abdaton Association of Acherea Chinical Customer's in Plateira With Acule Authors Asson Unusual Presentations of ACS Sinval of Pateira Referred for Emergent Cardiac Catheterization for ST-Electrical Microbia Customer's Microbia Customer's Catheterization for ST-Electrical Microbia Microbia Related Clinical Research in Interventional Related Clinical Research in Interventional Related Clinical Research in Interventional Related Clinical Research interventional Related Clinical Research Research Research Related Related Clinical Related Related Related Clinical Research Related R	iviatos	Jason		Computed Tomography, and Electrocardiography in Patients With	Inothing to Disclose
Matos Asson Unusual Presentations of ACS Unusual Presentations of ACS Unusual Presentations of ACS Arthydrinias and Clinical EP: Devices 2 Comprohensive Strategy of Reduce the incidence of Lead Mathematical Research is Interventional Strategy of Reduce the incidence of Lead Mathematical Research is Interventional Strategy of Reduce the incidence of Lead Mathematical Research is Interventional Strategy of Reduce the incidence of Lead Mathematical Research is Interventional Strategy of Reduce the incidence of Lead Mathematical Research is Interventional Strategy of Reduce the incidence of Lead Mathematical Research is Interventional Research is Interventional Comparative Effectiveness of Transcratefier Versus Suggical Acritic Valve Replacement in the United States. An Analysis From TV vol Stephenic Landed by Moderac Data Mathematical Research	Matos	lason	Arrhythmias and Clinical EP: AE Ablation		Nothing to Disclose
Mateouxika Asian Unusual Presentations of ACS Survival of Patterns Referred for Emergent Cardiac Cardiac Cardiac Cambeteration North Patterns William (1998) Mateouxika Round Feature Clinical Research It Interventional Disadogener for Cardiac Indianable Electron Devices Mateouxika Round Feature Clinical Research It Interventional Surgical Actor Ver Ne Replacement in the Linical State. An Analysis Mateouxika Round Highlighted Original Research Interventional Cardiology and Persent Patterns New Crisical Apil Patterns Mateouxika Round Violence Research Interventional Cardiology and Persent Research Unioning Research Interventional Cardiology and Persent Research Unioning Research Interventional Cardiology Tay Research Cardiology Tay Research Interventional Cardiology Tay Research	iviatos	383011	Armytimias and Cimical Er . Ar Ablation	Pulmonary Embolism and Coronary Artery Calcifications Visualized	Nothing to Disclose
Matsouaka Roland Personal Cinical EP Devices 2 Comprehense Strategy in Relation Receivance Water (Companies Technical Feedbace (Companies Technical Processes) Matsouaka Roland Featherd Cinical Research it Neterventional Sungial Acritic Valve Replacement in the United States. An Analysis Research Companies Technical Englandmatic Replacement in the United States. An Analysis Sungial Acritic Valve Replacement in the United States. An Analysis Sungial Acritic Valve Replacement in the United States. An Analysis Sungial Acritic Valve Replacement in the United States. An Analysis Sungial Acritic Valve Replacement in the United States. An Analysis Sungial Acritic Valve Replacement in the United States. An Analysis Sungial Acritic Valve Replacement in the United States. An Analysis Sungial Acritic Valve Replacement in the United States. An Analysis Sungial Acritic Valve Replacement in the United States. An Analysis Sungial Replacement in Companies of Mark States of Netherland Companies of Mark Valve Valve Replacement in Companies of Mark Valve	Matos	lason	Unusual Presentations of ACS		Nothing to Disclose
Matsouaka Roland Featured Clinical Research II: Interventional Research II	iviatos	383011	Official Fresentations of ACS		Nothing to Disclose
Matsouaka Roland Featured Clinical Research II: Interventional Research II	Matre	Nancy	Arrhythmias and Clinical EP: Devices 2	Comprehensive Strategy to Reduce the Incidence of Lead	Nothing to Disclose
Matsouaka Roland Highlighted Orghal Research: Interventional Competition of Matsouaka Roland Highlighted Orghal Research: Interventional Competition of Matsouaka Roland September (1997) Registry Medical Competition of Matsouaka Roland Rolan				Dislodgment for Cardiac Implantable Electronic Devices	-
Malsouaka Roland Gradology and the Year Reyew Replacement. Incidence, Anticogalant Strategy, and Outcomes Nothing to Disclose Replacement. Incidence, Anticogalant Strategy, and Outcomes Nothing to Disclose Replacement. Incidence, Anticogalant Strategy, and Outcomes Nothing to Disclose Replacement. Incidence, Anticogalant Strategy, and Outcomes Nothing to Disclose Outcomes Research Malsouaka Roland Interventional Cardiology, TAVR 2 Interventional Cardiology, TAVR 2 Interventional Cardiology, TAVR 2 Interventional Cardiology, TAVR 2 Interventional Cardiology, TAVR 2 Interventional Cardiology, TAVR 3 Interventional Cardiology, TavR 3 Interventional Cardiology, TavR 3 Interventional Cardiology, TavR 3 Interventional Cardiology, TavR 3 Interventional Cardiology, TavR 3 Interventional Cardiology, TavR 3 Interventional Cardiology, TavR 3 Interventional Cardiology, TavR 3 Interventional Cardiology, TavR 3 Interventional Cardiology, TavR 3 Interventional Cardiology, TavR 3 Interventiona	Matsouaka	Roland	Featured Clinical Research II: Interventional		Nothing to Disclose
Cardology and the Year is Review Replacement. hodence, Antiocagularist Strategy, and Cutomoms Nohing to Disclose	Material	Bulletin	United to 10 to 15	From Two US Registries Linked to Medicare Data	Number to Produce
Fature Patents and Long-Term Survival Among Highest and Lowest Petroming Hospitals, Prindings From Get With the Guidelines-Heart Failure	Maisouaka			Replacement: Incidence, Anticoagulant Strategy, and Outcomes	Nothing to Disclose
Lowest Performing Hospitals, Findings From Get With the Guidelines-Heart Failure Roland Interventional Cardiology: TAVR 2 Prevalence and Outcomes of Meral Stenosis in Patients Undergoing Providence and Outcomes of Meral Stenosis in Patients Undergoing Providence and Outcomes of Meral Stenosis in Patients Undergoing Providence and Outcomes of Meral Stenosis in Patients Undergoing Providence and Outcomes of Meral Stenosis in Patients Undergoing Providence and Outcomes of Meral Stenosis in Patients Undergoing Providence and Outcomes of Patients Providence and Timing of Revascularization on Outcomes of Patients Undergoing Providence Archite Valve Replacement: Insights From STS/ACC TVT Registry Patients of Red Blood Cell Transfusion and Associated Outcomes Patients of Red Blood Cell Transfusion and Associated Outcomes Disease Dis	Matsouaka	Roland			Nothing to Disclose
Matsouaka Roland Interventional Cardiology, TAVR 2 Prevalence and Outcomes of Mitral Stenosis in Padage From the Society of Thoracis Surgeons/American College of Cardiology (TSIACC) Transcatheter Avait Valve Replacement Indings From the Society of Thoracis Surgeons/American College of Cardiology (TSIACC) Transcatheter Valve Replacement Indings From the Society of Thoracis Surgeons/American College of Cardiology (TSIACC) Transcatheter Valve Replacement Insights From STSIACC TVT Registry Matsouaka Roland Interventional Cardiology, TAVR 2 Interventional Cardiology, TAVR 3 Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patterns to Horacing in TAVR: Risplacement Insights From STSIACC TVT Registry Matsouaka Roland Therapeutic Advances in Congenital Heart Disease Disease On Company Interventional Cardiology and Underweight Status on Perioperative On the Effect of Obesity and Underweight Status on Perioperative On the Effect of Obesity and Underweight Status on Perioperative On the Effect of Obesity and Underweight Status on Perioperative On the Effect of Obesity and Underweight Status on Perioperative On the Effect of Obesity and Underweight Status on Perioperative On the Effect of Obesity and Underweight Status on Perioperative On the Effect of Obesity and Underweight Status on Perioperative On the Effect of Obesity and Underweight Status on Perioperative On the Effect of Obesity and Underweight Status on Perioperative On the Effect of Obesity and Underweight Status on Perioperative On the Effect of Obesity and Underweight Status on Perioperative On the Status of Perioperative On the Status of Perioperative On the Status of Perioperative On the Status of Perioperative On the Status of Perioperative On the Status of Perioperative On the Status of Perioperative On the Status of Perioperative On the Status of Perioperative On the Status of Perioperative On the Status of Perioperative On the Status of Perioperative On the Status of Perioperative On the Status of Perioperative On the Status of Periopera			Cuttomes research	Lowest Performing Hospitals, Findings From Get With the	
Matsouaka Roland Interventional Cardiology: TAVR 2 Impact of the Presence of Coronary Flety Disease and Timing of Reveaucidarzation on Outcomes of Patients Undergoing Trans- Society Actic Valve Replacement: Insight From TSSACC DYT Registry Matsouaka Roland Interventional Cardiology: TAVR 3 Patients of Real Blood Cell Transant and Associated Outcomes In Patients of Real Blood Cell Transant and Associated Outcomes In Patients of Real Blood Cell Transant and Associated Outcomes In Patients of Real Blood Cell Transant and Associated Outcomes In Patients of Real Blood Cell Transant and Associated Outcomes In Patients of Real Blood Cell Transant and Associated Outcomes In Patients of Real Blood Cell Transant and Associated Outcomes In Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Registry Matsouaka Roland Therapeutic Advances in Congenital Heart Disease In Patients With Congenital Heart Disease: An Analysis of Data From the Society of Thoracic Surgeons Congenital Heart Surgery Databage Matsumoto Matsumoto Naoya Nuclear Cardiology: Coronary Flow Matsumoto Naoya Nuclear Cardiology: Coronary Flow Diagnostic Performance of Hybrid Assessment With Stress Only Myocardial Perfusion Single Photon Emission Computed Tomography Using Semiconductor Assessment With Stress Only Myocardial Perfusion Single Photon Emission Computed Tomography Using Semiconductor Tomography Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology, Angiography, Intravascular Imaging and Interventional Cardiology, Stephen Flature Matsumura Mitsuaki Interventional Cardiology, PCI in Complex Patients Matsumura Mitsuaki Interventional Cardiology, PCI in Complex Patients Matsumora Mitsuaki Interventional Cardiology, PCI in Complex Patients Matsumora Mitsuaki Interventional Cardiology, PCI in Complex Patients Matsumora Mitsuaki Interventional Cardiology, PCI in Complex Patients Matsumora Mitsuaki Interventional Cardiology, PCI in Complex Patients Matsumora Mitsuaki Interventional	Matsouaka	Roland	Interventional Cardiology: TAVR 2		Nothing to Disclose
Matsouaka Roland Interventional Cardiology: TAVR 2 Impact of the Presence of Coronary Artery Diseases and Timing of Revascularization on Outcomes of Patients Undergoing Trans-Catheter Antic Valve Replacement: Insights From STSACC TVT Registry Matsouaka Roland Interventional Cardiology: TAVR 3 Registry Matsouaka Roland Therapeutic Advances in Congenital Heart Disease Roland Disease in Congenital Heart Disease Roland Disease Roland Disease Roland Disease Roland Disease Roland Disease Roland Disease Roland Disease Roland R				Transcatheter Aortic Valve Replacement: Findings From the Society	,
Matsouaka Roland Interventional Cardiology: TAVR 2 Impact of the Presence of Coronary Artery Disease and Timing of Revissoularization on Outcomes of Patients Undergoing Trans-Catheter Ancit Valve Replacement: Insights From STS/ACC TVT Registry Matsouaka Roland Interventional Cardiology: TAVR 3 Patients of Red Blood Cell Transfusion and Associated Outcomes in Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Matsouaka Roland Therapeutic Advances in Congenital Heart Disease Patients of Red Blood Cell Transfusion and Associated Outcomes in Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Matsumoto Renji Non Invasive Imaging: MR Structure and Valuvular Heart Disease Patients With Congenital Heart Disease. An Analysis of Data From the Society of Thoracic Surgeons Congenital Heart Surgery Database Walsumoto Naoya Nuclear Cardiology: Coronary Flow High-Intervention Data From the Society of Thoracic Surgeons Congenital Heart Surgery Database Walsumoto Naoya Nuclear Cardiology: Coronary Flow Disease. An Analysis of Data From the Society of Thoracic Surgeons Congenital Heart Surgery Database Walsumoto Naoya Nuclear Cardiology: Coronary Flow Disease. An Analysis of Data From the Society of Thoracic Surgeons Congenital Heart Surgery Database Walsumoto Naoya Nuclear Cardiology: Coronary Flow Disease. An Analysis of Data From the Society of Thoracic Surgery Database Walsumoto Naoya Nuclear Cardiology: Coronary Flow Disease. An Analysis of Data From the Society of Thoracic Surgery Database Walsumura Mitsuaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Sent Failure Detector Computed Tomography Versus Intravascular Uniformation Acute Sent Prography Nothing to Disclose Intravascular Uniformation Acute Sent Prography Nothing to Disclose Intravascular Uniformation Acute Sent Prography Nothing to Disclose Intravascular Uniformation Acute Sent Prography Nothing to Disclose Nothing t					
Revascularization on Outcomes of Patients Undergoing Trans- Catheter Andric Valve Replacement. Insights From STS/ACC TVT Registry Registry Registry Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Registry Residence of Red Blood Cell Transfusion and Associated Outcomes in Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Registry Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Registry Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Registry Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Registry Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Registry Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Registry Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Residence of Patients Undergoing TAVR: Insights for the STS/ACC TVT Residence of Patients Undergoing TAVR: Insights of the STS/ACC TVT Residence of Patients Undergoing TAVR: Insights of Undergoing TAVR: Insights of Undergoing TAVR: Insights of Undergoing TavR. Insights of Undergoing TavR. Insights of Undergoing TavR. Insights of Undergoing TavR. Insights of Undergoing TavR. Insights of Undergoing TavR. Insights of Undergoing Ta	Matarialia	Delegal	later resting at Condinter w. TAV/D 2	, , ,	Nathing to Displace
Matsouaka Roland Interventional Cardiology: TAVR 3 Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patients Undergroing TAVR: Insights for the STS/ACC TVT Registry Matsouaka Roland Therapeutic Advances in Congenital Heart Disease Outcomes in Patients Undergroing TAVR: Insights for the STS/ACC TVT Registry Matsumoto Kenji Non Invasive Imaging: MR Structure and Valuvular Heart Disease Patients (Uniform Society of Thoracio Surgeons Congenital Heart Surgery Database High-Intensity Culprit Plaque on Noncontrast T1-Weigted Magnetic Resonance Imaging as a Novel Determinant of Major Adverse Cardiac and Cerebrovascular Events After Percutaneous Coronary Intervention Matsumoto Naoya Nuclear Cardiology: Coronary Flow Diagnostic Performance of Hybrid Assessment With Stress Only Myocardial Pertusion Single Photon Emission Computed Tomography Using Semiconductor Gamma Camera and Rest Myocardial Star Findingship of Disclose Computed Tomography Using Semiconductor Gamma Camera and Rest Myocardial Star Findingship of Disclose Patients of Computed Tomography and Optical Coherence Only Computed Tomography and Optical Coherence Only Camera Camera and Rest Myocardial Star Findingship of Disclose Only Camera Camera and Rest Myocardial Star Findingship of Disclose Only Camera Camera and Rest Myocardial Star Findingship of Tomography and Optical Coherence Only Camera Camera and Rest Myocardial Star Findingship of Disclose Only Camera Camera and Rest Myocardial Star Findingship of Disclose Only Camera Camera and Rest Myocardial Star Findingship of Disclose Only Camera Camera and Rest Myocardial Star Findingship of Disclose Only Camera Camera Camera and Rest Myocardial Star Findingship of Disclose Only Camera Camera and Rest Myocardial Star Findingship of Disclose Only Camera Camera Camera and Rest Myocardial Star Findingship of Disclose Only Camera C	Maisouaka	Roland	Interventional Cardiology: TAVR 2		Nothing to Disclose
Matsouaka Roland					
Matsouaka Roland Therapeutic Advances in Congenital Heart Disease Cardiocand Fefetor of Obesity and Underweight Status on Perioperative Outcomes in Patients With Congenital Heart Disease: An Analysis of Data From the Society of Thoracic Surgeons Congenital Heart Disease: An Analysis of Data From the Society of Thoracic Surgeons Congenital Heart Surgery Database High-Intensity Cupit Plaque on Noncontrast 11-Weighed Magnetic Resonance Imaging as a Novel Determinant of Major Adverse Cardiac and Cerebrovascular Events After Percutaneous Coronary Intervention Diagnostic Performance of Hybrid Assessment With Stress Only Movacrdial Perfusion Single Photon Emission Computed Tomography Using Semiconductor Garma Cardinare and Rest Myocardial Part Findings Obtained From 320 Detector Row Computed Tomography and Optical Coherence Tomography and Optical Coherence Tomography and Optical Coherence Tomography and Optical Coherence Tomography Coherence Tomog	Matsouaka	Roland	Interventional Cardiology: TAVR 3		Nothing to Disclose
Matsumura Mitsuaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cr7NRR Mitsumura Mitsuaki Interventional Cardiology: Stent Failure Analysis by Intravascular Imaging and Interventional Cardiology: Corn price Matsumura Mitsuaki Interventional Cardiology: Corn price Matsumura Mitsuaki Interventional Cardiology: Corn price Matsumura Mitsuaki Interventional Cardiology: Corn price Matsumura Mitsuaki Interventional Cardiology: Corn price Matsumura Mitsuaki Interventional Cardiology: Corn price Matsumura Mitsuaki Interventional Cardiology: Corn price Matsumura Mitsuaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Stent Failure Analysis by Intravascular Imaging and Interventional Cardiology: Stent Failure Analysis by Intravascular Imaging and Interventional Cardiology: Stent Failure Analysis by Intravascular Imaging and Interventional Cardiology: Stent Failure Analysis by Intravascular Imaging and Interventional Cardiology: Stent Failure Analysis by Intravascular Imaging and Interventional Cardiology: Stent Failure Analysis by Intravascular Imaging and Interventional Cardiology: PCI in Complex Analysis by Intravascular Imaging and Interventional Cardiology: PCI in Complex Analysis by Intravascular Imaging and Interventional Cardiology: PCI in Complex Analysis by Intravascular Imaging and Interventional Cardiology: PCI in Complex Analysis by Intravascular Imaging and Interventional Cardiology: PCI in Complex Analysis by Intravascular Imaging and Interventional Cardiology: PCI in Complex Analysis by Intravascular Imaging and Interventional Cardiology: PCI in Complex Analysis by Intravascular Imaging and Interventional Cardiology: PCI in Complex Analysis by Intravascular Imaging and Interventional Cardiology: PCI in Complex Analysis by Intravascular Imaging and Interventional Cardiology: PCI in Complex Analysis by Intravascular Imaging and Interventional Cardiology: PCI in Complex Analysis by Intravascular Imaging and Interventional Cardiol					
Data From the Society of Thoracic Surgeons Congenital Heart Surgery Database Matsumoto Kenji Non invasive Imaging: MR Structure and Valuvular Heart Disease High-Intensity Culprit Plaque on Noncontrast T1-Weigted Magnetic Resonance Imaging as a Novel Determinant of Major Adverse Cardiac and Cerebrovascular Events After Percutaneous Coronary Intervention Diagnostic Performance of Hybrid Assessment With Stress Only Mycardial Perfusion Single Photon Emission Computed Tomography Inspection Chamma Camera and Rest Mycardial Sear Findings Obtained From 320 Detector Row Computed Tomography Computed Tomography Interventional Cardiology: Angiography, Interventional Cardiology: Angiography, Interventional Cardiology: Angiography, Interventional Cardiology: Angiography, Interventional Cardiology: Angiography, Interventional Cardiology: Angiography, Interventional Cardiology: Angiography Interventional Cardiology: Angiography Interventional Cardiology: Angiography Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Mitsuaki Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Mitsuaki Interventional Cardiology: PCI in Complex Patients Mitsuaki Interventional Cardiology: PCI in Complex Patients Interventional Cardiology: Intravascular Physiology and Endothelial Function Matsuo Hitoshi Unusual Presentations of ACS Incidence and Predictors of Lesion Specific Ischemia by Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Procedural Calcium Fracture and its Effect on Stent Expansion Assessed by Optical Coherence Tomography Instantaneous Wave-Free Ratio Scout Pullback (IFR Scout) Pre- Angioplasty Pedicits Hemodynamic Outcome in Humans With Coronary Aftery Disease Primary Results of International Nothing to Disclose Primary Results of International Nothing to Disclose Nothing to Disclose Primary Results of International ADVANCE	Matsouaka	Roland		Effect of Obesity and Underweight Status on Perioperative	Nothing to Disclose
Matsumoto Kenji Non Invasive Imaging: MR Structure and Valuvular Heart Disease Service In Matsumoto Naoya Nuclear Cardiology: Coronary Flow Disgnostic Performance of Hybrid Assessment With Stress Only Myocardial Perfusion Single Photon Emission Computed Tomography Using Semiconductor Gamma Camera and Rest Myocardial Sear Findings Obtained From 320 Detector Row Computed Tomography Using Semiconductor Gamma Camera and Rest Myocardial Sear Findings Obtained From 320 Detector Row Computed Tomography Using Semiconductor Gamma Camera and Rest Myocardial Sear Findings Obtained From 320 Detector Row Computed Tomography Intravascular Imaging and Interventional CT/MR Comparison of Coronary Calcification Detection Between Multi-Detector Computed Tomography Intravascular Imaging and Interventional CT/MR Tomography Intravascular Imaging and Interventional CT/MR Tomography Intravascular Imaging and Interventional CT/MR Comparison of Coronary Calcification Detection Between Multi-Detector Computed Tomography Intravascular Imaging and Interventional CT/MR Comparison of Coronary Calcification Detection Between Multi-Detector Comparison of Coronary Calcification Detection Between Multi-Detector Comparison of Coronary Calcification Detection Between Multi-Detector Comparison of Coronary Calcification Detection of Tissue Protection and Calcification Detection of Tissue Profusion and Acute Stent-Vesses of Excimer Laser Angioplasty to Treat Coronary Institute Comparison of Optical Coherence Tomography Versus Intravascular Ultrasound Detection of Tissue Profusion and Acute Stent-Vesses Mild Malapoposition in 498 Patients After Drug-Elluting Stent Implantation Institute I			Disease		
Valuvular Heart Disease Resonance Imaging as a Novel Determinant of Major Adverse Cardiac and Cerebrovascular Events After Percutaneous Coronary Intervention				Surgery Database	
Cardiac and Cerebrovascular Events After Percutaneous Coronary Interventional Cardiology: Coronary Flow Diagnostic Performance of Hybrid Assessment With Stress Only Myocardial Perfixion Single Photon Emission Computed Tomography Using Semiconductor Gamma Camera and Rest Myocardial Sear Findings Obtained From 320 Detector Row Computed Tomography Using Semiconductor Gamma Camera and Rest Myocardial Sear Findings Obtained From 320 Detector Row Computed Tomography Companison of Coronary Calcification Detection Between Multi-Detector Computed Tomography and Optical Coherence Tomography Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Computed Tomography Intravascular Imaging and Interventional Coherence Tomography Intravascular Imaging Analysis by Intravascuar Imaging Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Intravascular Ultrasound Detection of Tissue Protrusion and Acute Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent Implantation Interventional Cardiology: Intravascular Physiology and Endothelial Function Interventional Cardiology: Intravascular Physiology and Endothelial Function Interventional Cardiology: Intravascular Physiology and Endothelial Function Interventional Cardiology: Intravascular Physiology and Endothelial Function Interventional Cardiology: Intravascular Physiology and Endothelial Function Interventional Cardiology: Intravascular Physiology and Endothelial Function Interventional Cardiology: Intravascular Physiology and Endothelial Function Interventional Cardiology: Intravascular Physiology and Endothelial Function Interventional Cardiology: Intravascular Physiology and Endothelial Function Interventional Cardiology: Intravascular Physiology and Endothelial Function Interventional Cardiology: Intravascular Physiology Proceediates Hemodynamic Outcome in Humans With Coronary Primary Results of Intervational Physiology Intravascular Physiology	Matsumoto	Kenji			Nothing to Disclose
Matsumoto Naoya Nuclear Cardiology: Coronary Flow Diagnostic Performance of Hybrid Assessment With Stress Only Myocardial Perfusion Single Photon Emission Computed Tomography Using Semiconductor Gamma Camera and Rest Myocardial Scar Findings Obtained From 320 Detector Row Computed Tomography Matsumura Mitsuaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography Matsumura Mitsuaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Stent Failure Analysis by Intravascular Imaging and Interventional Coherence Tomography Matsumura Mitsuaki Interventional Cardiology: Stent Failure Analysis by Intravascular Imaging Intravascular Ultrasound Detection of Tissue Protrusion and Acute Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent Implantation Matsumura Mitsuaki Interventional Cardiology: PC in Complex Patients Interventional Cardiology: Intravascular Physiology and Endothelial Function Matsuo Hitoshi Unusual Presentations of ACS Diagnostic Performance of Hybrid Assessment With Coronary Photon Emission Computed Tomography Coronary Calcification Detection Detection Detection Detection Detection Detection Detection Detection Detection Detection Performance of Optical Coherence Tomography Coherence Tomography Nothing to Disclose Nothing to Disclose Nothing to Disclose Patients Analysis by Intravascular Physiology and Endothelial Function Multicentre iFR GRADIENT Registry Matsuo Matsuo Hitoshi Unusual Presentations of ACS Incidence and Predictors of Lesion Specific Ischemia by FFR-sub-CT-/slub-: Learnings From the International ADVANCE				Cardiac and Cerebrovascular Events After Percutaneous Coronary	
Mitsuaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cardiology: Stent Failure Analysis by Intravascular Imaging and Interventional Cardiology: Stent Failure Analysis by Intravascular Imaging and Interventional Cardiology: Analysis by Intravascular Imaging Analysis by Intravascular Imaging Analysis by Intravascular Imaging Analysis by Intravascular Imaging Analysis by Intravascular Imaging Analysis by Intravascular Imaging Analysis by Intravascular Imaging Analysis by Intravascular Imaging Analysis by Intravascular Imaging Analysis by Intravascular Imaging Analysis by Intravascular Imaging Analysis Analysis by Intravascular Imaging Analysis Analysis by Intravascular Imaging Analysis Analysis Analysis by Intravascular Imaging Analysis Analy	Matsumoto	Naova	Nuclear Cardiology: Coronary Flow		Nothing to Disclose
Matsumura Mitsuaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Matsumura Mitsuaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Matsumura Mitsuaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Mitsuaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Matsumura Mitsuaki Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Matsumura Mitsuaki Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Matsumura Mitsuaki Interventional Cardiology: PCI in Complex Patients Matsumura Mitsuaki Interventional Cardiology: PCI in Complex Patients Matsumura Mitsuaki Interventional Cardiology: PCI in Complex Physiology and Endothelial Function Matsuo Hitoshi Unusual Presentations of ACS Incidence and Predictors of Lesion Specific Ischemia by FFR-sub-CT-/slub-: Learnings From the International ADVANCE Matsuo Hitoshi Unusual Presentations of ACS Mitsuaki Interventional Cardiology: PCI in Complex Presub-CT-/slub-: Learnings From the International ADVANCE		1		Myocardial Perfusion Single Photon Emission Computed	- I
Matsumura Mitsuaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CrynMR (Comparison of Coronary Calcification Detection Between Multi-Detector Computed Tomography and Optical Coherence Tomography Mitsuaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CrynMR (CrynMR) Matsumura Mitsuaki Interventional Cardiology: Stent Failure Analysis by Intravascular Imaging and Interventional Comparison of Optical Coherence Tomography Versus Intravascular Ultrasound Detection of Tissue Protrusion and Acute Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Sten					
Intravascular Imaging and Interventional CT/MR Mitsuaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Mitsumura Mitsuaki Interventional Cardiology: Stent Failure Analysis by Intravascular Imaging and Interventional Comparison of Optical Coherence Tomography Versus Intravascular Imaging and Interventional Comparison of Optical Coherence Tomography Versus Intravascular Imaging Analysis by Intravascular Imaging Mitsuaki Interventional Cardiology: Stent Failure Analysis by Intravascular Imaging Mitsuaki Interventional Cardiology: PCI in Complex Patients Mitsuaki Interventional Cardiology: PCI in Complex Patients Intravascular Calcium Fracture and its Effect on Stent Expansion Assessed by Optical Coherence Tomography Mitsuaki Interventional Cardiology: Intravascular Physiology and Endothelial Function Intravascular Imaginates Physiology and Endothelial Function Physiology and Endothelial Function Interventional Multicentre IFR GRADIENT Registry Matsuo Hitoshi Unusual Presentations of ACS Incidence and Predictors of Lesion Specific Ischemia by FFR-sub-CT-/slub-: Learnings From the International ADVANCE	Mateumura	Mitsuaki	Interventional Cardiology Angiography	Computed Tomography	Nothing to Disclose
Mitsuaki Interventional Cardiology: Angiography, Intravascular Imaging and Interventional Cortinum (CTMMR) Mitsuaki Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Mitsuaki Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Mitsuaki Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Mitsuaki Interventional Cardiology: PCI in Complex Stent Imaginal Mitsuaki Interventional Cardiology: PCI in Complex Patients Mitsuaki Interventional Cardiology: PCI in Complex Patients Mitsuaki Interventional Cardiology: PCI in Complex Patients Mitsuaki Interventional Cardiology: Intravascular Physiology and Endothelial Function Matsuo Hitoshi Unusual Presentations of ACS Incidence and Predictors of Lesion Specific Ischemia by FFR-sub>CT-/slub-: Learnings From the International ADVANCE Matsuo Hitoshi Unusual Presentations of ACS Incidence and Predictors of Learnings From the International ADVANCE	maioumuld	IVIIIOUANI	Intravascular Imaging and Interventional	Detector Computed Tomography and Optical Coherence	Trouming to Discluse
Intravascular Imaging and Interventional CT/MR CT/MR CIMR Mitsuaki Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Stent Image Stent Lessel Wall Malapposition in 498 Patients After Drug-Eluting Stent Implantation Mitsuaki Interventional Cardiology: PCI in Complex Stent Implantation Mitsuaki Interventional Cardiology: PCI in Complex Assessed by Optical Coherence Tomography Versus Intravascular Ultrasound Detection of Tissue Protrusion and Acute Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent Implantation Matsumura Mitsuaki Interventional Cardiology: PCI in Complex Assessed by Optical Coherence Tomography Matsuo Hitoshi Interventional Cardiology: Intravascular Physiology and Endothelial Function Analysis by Predicts Hemodynamic Outcome in Humans With Coronaly Artery Disease: Primary Results of Intervational Multicentre iFR GRADIENT Registry Matsuo Hitoshi Unusual Presentations of ACS Incidence and Predictors of Lesion Specific Ischemia by FFR _{CT}	Matsumura	Mitsuaki			Nothing to Disclose
Matsumura Mitsuaki Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Intravascuar Imaging Mitsuaki Interventional Cardiology: PCI in Complex Stent Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent Implantation Procedural Calcium Fracture and its Effect on Stent Expansion Assessed by Optical Coherence Tomography Matsuo Hitoshi Interventional Cardiology: Intravascular Physiology and Endothelial Function Multicentre iFR GRADIENT Registry Matsuo Hitoshi Unusual Presentations of ACS Mothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Procedural Calcium Fracture and its Effect on Stent Expansion Assessed by Optical Coherence Tomography Nothing to Disclose Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International Multicentre iFR GRADIENT Registry Incidence and Predictors of Lesion Specific Ischemia by FFR _{CT Nothing to Disclose Nothing to Disclose}		····touciti	Intravascular Imaging and Interventional	In-Stent Restenosis With Peri-Stent Calcium as Assessed by Optical	Tourning to Discitor
Analysis by Intravascual Imaging Intravascual Intravascual Intravascual Intravascual Intravascual Intravascual Intravascual Intravascual Intravascual Intravascual Intravascual Intravascual Interventional Cardiology: PCI in Complex Patients Interventional Cardiology: PCI in Complex Patients Interventional Cardiology: Intravascual Interventional Cardiology: Intravascual Interventional Cardiology: Intravascual Interventional Cardiology: Intravascual Instantaneous Wave-Free Ratio Scout Pullback (IFR Scout) Pre-Angioplasty Predicts Hemodynamic Outcome in Humans With Coronay Artery Disease: Primary Results of Intervational Multicentre IFR GRADIENT Registry Incidence and Predictors of Lesion Specific Ischemia by FFR-sub>CT-/slub>: Learnings From the International ADVANCE	Matsumura	Mitsuaki			Nothing to Disclose
Stent Implantation				Intravascular Ultrasound Detection of Tissue Protrusion and Acute	
Matsumura Mitsuaki Interventional Cardiology: PCI in Complex Procedural Calcium Fracture and its Effect on Stent Expansion Assessed by Optical Coherence Tomography Matsuo Hitoshi Interventional Cardiology: Intravascular Physiology and Endothelial Function Interventional Cardiology: Intravascular Physiology and Endothelial Function Standard Physiology and Endothelial Function Coronary Artery Disease: Primary Results of International Multicentre iFR GRADIENT Registry Matsuo Hitoshi Unusual Presentations of ACS Incidence and Predictors of Lesion Specific Ischemia by FFR-sub>CT-/slub>: Learnings From the International ADVANCE					
Matsuo Hitoshi Interventional Cardiology: Intravascular Physiology and Endothelial Function Souther Physiology and Endothelial Function Souther Physiology and Endothelial Function Souther Physiology and Endothelial Function Souther Physiology and Endothelial Function Souther Physiology Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International Multicentre iFR GRADIENT Registry Matsuo Hitoshi Unusual Presentations of ACS Incidence and Predictors of Lesion Specific Ischemia by FFR _{CT}	Matsumura	Mitsuaki		Procedural Calcium Fracture and Its Effect on Stent Expansion	Nothing to Disclose
Physiology and Endothelial Function Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Atery Diseases: Primary Results of International Multicentre iFR GRADIENT Registry Matsuo Hitoshi Unusual Presentations of ACS Incidence and Predictors of Lesion Specific Ischemia by FFR-sub>CT-/slub>- Learnings From the International ADVANCE	Matsuo	Hitoshi			Nothing to Disclose
Multicentre iFR GRADIENT Registry Matsuo Hitoshi Unusual Presentations of ACS Incidence and Predictors of Lesion Specific Ischemia by FFR-sub>CT-/slub>: Learnings From the International ADVANCE				Angioplasty Predicts Hemodynamic Outcome in Humans With	<u> </u>
Matsuo Hitoshi Unusual Presentations of ACS Incidence and Predictors of Lesion Specific Ischemia by Nothing to Disclose FFR _{CT} : Learnings From the International ADVANCE				Multicentre iFR GRADIENT Registry	
	Matsuo	Hitoshi	Unusual Presentations of ACS	Incidence and Predictors of Lesion Specific Ischemia by	Nothing to Disclose



Last Name Matsuo	First Name Yoshiki	Session Title	Presentation Title	Disclosures
		Interventional Cardiology: Intravascular Physiology and Endothelial Function	Comparison of Very Late Vascular Response Beyond 2 Years After Stent Implantation Between EES and BES: An OCT Sub-Study of	Nothing to Disclose
Matsuoka	Hiroshi	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	the NEXT Differences in Chronic Angioscopic Findings With Different Stent Types in Patients With and Without Diabetes Mellitus: Sub-Analysis of a Report From Japanese Multicenter Registry	Nothing to Disclose
Matsushita	Kunihiro	Updates on Risk Factors for Cardiovascular Disease	Retinopathy and Risk of Sudden Cardiac Death: The ARIC Study	CONSULTANT FEES/HONORARIA - Apex,Kyowa Hakko Kirin; SPEAKER'S BUREAU - Fukuda Denshi
Matsushita	Kunihiro	Markers of Prognosis Associated With Elevated Blood Pressure	Isolated Systolic Hypertension and Pulse Pressure Are Associated With High-Sensitivity Cardiac Troponin-T and NT-pro BNP in Older Adults	CONSULTANT FEES/HONORARIA - Apex,Kyowa Hakko Kirin; SPEAKER'S BUREAU - Fukuda Denshi
Matsushita	Kunihiro	Improving Risk Assessment in Atherosclerosis	Development and Validation of Prediction Models With Non- Traditional Markers for 10-Year Risk of Ischemic Leg Amputation Among Persons With Diabetes: The Atherosclerosis Risk In Communities (ARIC) Study	CONSULTANT FEES/HONORARIA - Apex,Kyowa Hakko Kirin; SPEAKER'S BUREAU - Fukuda Denshi
Matsuura	Hirohide	Unusual Presentations of ACS	Association Between Presentation Time and Short-Term Mortality in Patients With Cardiogenic Shock Complicating Acute Coronary Syndrome: From Jcs Shock Registry	Nothing to Disclose
Mattathil	Stephanie	Interventional Complexity and Complications	Use of the RenalGuard System to Prevent Contrast Induced Kidney Injury: A Meta-Analysis	Nothing to Disclose
Matteau	Alexis	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Appropriateness of Coronary Artery Bypass Grafting Based on Fractional Flow Reserve Lesions Assessment	SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals
Matteau	Alexis	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Comparison of Triple Antithrombotic Therapy to Ticagrelor-Based Dual Antiplatelet Therapy for Left Ventricle Dysfunction Following	SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals
Matter	Christian	Timely Topics in Acute Coronary Syndromes	STEMI Using Natural Randomization: A Retrospective Pilot Study Gender-Related Outcomes in Elderly (>, 75 Years) Patients Presenting With Acute Coronary Syndromes: Results From the	CONSULTANT FEES/HONORARIA - Eli Lilly and Company,Roche
Matthai	William	19. Interventional Cardiology: Complex	Swiss Acute Coronary Syndrome Cohort Suggested Reviewer	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Intuitive
Matto	Faisal	Patients/Comorbidities Team 2 Congenital Heart Disease: Progress in	S-Nitrosohemoglobin Levels After Transfusion Predict Outcome of	Surgical, Johnson & amp; amp; Johnson Nothing to Disclose
Mauermann	William	Pediatric Heart Surgery Engage @ ACC.17 Studio: Heart Teams in	Pediatric BypassSurgery Mayo Cardiac Anesthesiologist	Nothing to Disclose
Maur	Pamela	Action: Complex Coronary Revascularization Feeling the Pressure - Tough Cases in	Case Presentation: Resistant or Non-Compliant? Evaluation and	Nothing to Disclose
		Hypertension	Management of Difficult-to-Control Hypertension	-
Maurer	Gerald	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Gender Differences in Short- and Long-Term Mortality in the Vienna STEMI Registry	-
Maurer	Mathew	Palliative Care for the 99% I: Promoting Palliative Care: The Why and What of PC Therapy	Co-Chair	CONSULTANT FEES/HONORARIA - Bio Reference Labs, inc,Eidos, inc,St. Jude's Medical ; DATA SAFETY MONITORING BOARD - Prothena, Inc; RESEARCH/RESEARCH GRANTS - Alnylam Inc,FoldRx Pharmaceuticals Inc.,Novartis Inc
Maurer	Mathew	Effective Medication Management in the Older Adults with CVD: Pharmacology Program I	Panelist	CONSULTANT FEES/HONORARIA - Bio Reference Labs, Inc,Eidos, Inc,St. Jude's Medical; DATA SAFETY MONITORING BOARD - Prothena, Inc; RESEARCH/RESEARCH GRANTS - Alnylam Inc,FoldRx Pharmaceuticals Inc.,Novartis Inc
Maurer	Mathew	FIT Forum: Mix and Mingle	 	CONSULTANT FEES/HONORARIA - Bio Reference Labs, Inc, Eidos, Inc, St. Jude's Medical ; DATA SAFETY MONITORING BOARD - Prothena, Inc; RESEARCH/RESEARCH GRANTS - Alnylam Inc, FoldRx Pharmaceuticals Inc., Novartis Inc
Maurer	Mathew	Distinct Phenotypes in HFpEF: Beyond Ejection Fraction	The Challenge of ATTR Cardiac Amyloid: is it Treatable?	CONSULTANT FEES/HONORARIA - Bio Reference Labs, Inc, Eidos, Inc, St. Jude's Medical ; DATA SAFETY MONITORING BOARD - Prothena, Inc; RESEARCH/RESEARCH GRANTS - Alnylam Inc, FoldRx Pharmaceuticals Inc., Novartis Inc
Maurer	Mathew	Cardiac Rehab in 2017: Tailoring The Approach to the Times	Co-Chair	CONSULTANT FEES/HONORARIA - Bio Reference Labs, Inc, Eidos, Inc, St. Jude's Medical ; DATA SAFETY MONITORING BOARD - Prothena, Inc; RESEARCH/RESEARCH GRANTS - Alnylam Inc, FoldRx Pharmaceuticals Inc., Novartis Inc
Maurer	Mathew	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Low Dietary Sodium Intake Is Associated With Low Energy Intake and Dietary Micronutrient Deficiency in Elderly Patients Hospitalized for Heart Failure	CONSULTANT FEES/HONORARIA - Bio Reference Labs, Inc, Eidos, Inc, St. Jude's Medical ; DATA SAFETY MONITORING BOARD - Prothena, Inc; RESEARCH/RESEARCH GRANTS - Alnylam Inc, FoldRx Pharmaceuticals Inc., Novartis Inc
Maurer	Mathew	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Evaluation of Changes in Weight as Part of Frailty Assessment in Patients With Advanced Heart Failure Receiving a Left Ventricular Assist Device	CONSULTANT FEES/HONORARIA - Bio Reference Labs, Inc, Eidos, Inc, St. Jude's Medical; DATA SAFETY MONITORING BOARD - Prothena, Inc; RESEARCH/RESEARCH GRANTS - Alnylam Inc, FoldRx Pharmaceuticals Inc., Novartis Inc
Maurer	Mathew	Innovations in Advocacy and Patient Centered Care	Describing Collaboration Between Cardiology and Palliative Care: A National Survey Study of Current Practices, Challenges and Barriers	CONSULTANT FEES/HONORARIA - Bio Reference Labs, Inc, Eidos, Inc, St. Jude's Medical; DATA SAFETY MONITORING BOARD - Prothena, Inc; RESEARCH/RESEARCH GRANTS - Alnylam Inc, FoldRx Pharmaceuticals Inc., Novartis Inc
Maurer	Mathew	Emerging Applications for Imaging Cardiac Amyloidosis: Nuclear Cardiology	Fluorine-18 Sodium Fluoride Positron Emission Tomography for Imaging Transthyretin Cardiac Amyloidosis	CONSULTANT FEES/HONORARIA - Bio Reference Labs, Inc, Eidos, Inc, St. Jude's Medical ; DATA SAFETY MONITORING BOARD - Prothena, Inc; RESEARCH/RESEARCH GRANTS - Alnylam Inc, FoldRx Pharmaceuticals Inc., Novartis Inc
Maurer	Mathew	13. Heart Failure and Cardiomyopathies: Clinical Team 6	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Bio Reference Labs, Inc, Eidos, Inc, St. Jude's Medical; DATA SAFETY MONITORING BOARD - Prothena, Inc; RESEARCH/RESEARCH GRANTS - Alnylam Inc, FoldRx Pharmaceuticals Inc., Novartis Inc
Mauri	Laura	Late-Breaking Clinical Trials: Deep Dive II	Panelist	CONSULTANT FEES/HONORARIA - Amgen Inc., AstraZeneca Pharmaceuticals, Biotronik, Corvia, Daiichi Sankyo, Eli Lilly and Company, Recor, Sanofi-Aventis, St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Amgen Inc., Biotronik, Boehringer Ingelheim Pharmaceuticals, Inc, Boston Scientific, Corvia
Mauri	Laura	Controversies in ACS Guidelines	Co-Chair	CONSULTANT FEES/HONORARIA - Amgen Inc., AstraZeneca Pharmaceuticals, Biotronik, Corvia, Daiichi Sankyo, Eli Lilly and Company, Recor, Sanoff-Aventis, St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Amgen Inc., Biotronik, Boehringer Ingelheim Pharmaceuticals, Inc, Boston Scientific, Corvia

Naver I March Land Controlled from ACC Glades feed Controlled from ACC Glades feed Controlled from ACC Glades feed Controlled from ACC Glades feed Controlled from ACC Glades from ACC Glades from the Effect of Controlled from ACC Glades from the Effect of Controlled from ACC Glades from ACC Glades from the Effect of Controlled from ACC Glades from ACC Glades from the Effect of Controlled from ACC Glades from ACC Glades from the Effect of Controlled from ACC Glades from ACC Glades from the Effect of Controlled from ACC Glades	Carlot Carlot				<u> </u>
Name Consideration in Artistance Theory and in Acquired Theory and Acquired The	Last Name				
Security of the control of the contr	mauri	Laura	Controversies in ACS Guidelines	DAPT Duration: DAPT Score is All You Need	Pharmaceuticals,Biotronik,Corvia,Daiichi Sankyo,Eli Lilly and Company,Recor,Sanofi-Aventis,St. Jude Medical;
Second Districts To Land Anglosed Horsey, An Anabora From Item By Control Plant Contro					Inc.,Biotronik,Boehringer Ingelheim Pharmaceuticals, Inc,Boston Scientific,Corvia
Surgicial Control (1997). Per Visional Study of African Study (1997). Per Visional Study of African Study (1997). Per Visional Study of African Study (1997). Per Visional Study (1997)	Mauri	Laura		Extended Duration Dual Antiplatelet Therapy: An Analysis From the	Pharmaceuticals,Biotronik,Corvia,Daiichi Sankyo,Eli Lilly and Company,Recor,Sanofi-Aventis,St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Amgen
Record of State and Outcome and Antherwent of Secondary Prevention Gods After PC Physics and State Is allow I state of the Committee of State Is allow I state of State Is allow I state Is allow Is allow I state Is allow Is allow I state Is allow Is allow I state Is allow Is allow Is allow Is allow Is allow Is allow Is allow Is allow Is allow Is allow Is allow Is allow Is allow Is allow Is allow Is allow Is allow Is allow					Scientific, Corvia
Coloniary Resident North Feed Coloniary Programme Peed Coloniary Col	Mauri	Laura			Pharmaceuticals,Biotronik,Corvia,Daiichi Sankyo,Eli Lilly and Company,Recor,Sanofi-Aventis,St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Amgen Inc.,Biotronik,Boehringer Ingelheim Pharmaceuticals, Inc,Boston
Mayorich Norwal Mayori	Mauri	Laura		Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen Inc., AstraZeneca
Insignify and the Year in Review Transchool Flow Desired Exchange From Concepts Computed From Part Control Computed Control Computed Control			Chincal Feath 3		Company,Recor,Sanofi-Aventis,St. Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Amgen Inc.,Biotronik,Boehringer Ingelheim Pharmaceuticals, Inc,Boston
Newtonials Newtonial Part Bedes Studiosal Interventional Collegations of Newtonian Accordance of Newtonian Accordance of Newtonian Newto	Maurovich-Horvat	Pal		Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography in Patients With Acute Chest Pain:	Nothing to Disclose
Nerson North Country Programation on Programment of Control Ductomers of Note Day Dechapter After Source Country (No. 1) (1982)	Mavromatis	Kreton			CONSULTANT FEES/HONORARIA - Direct Flow Medical
Stage	Mavromatis	Kreton			CONSULTANT FEES/HONORARIA - Direct Flow Medical
Clinical Team 4	Mawri	Sagger		Predictors of Late Bleeding in the TAVR Population	
Clinical Research CPA-Ne Independent and Additive Predictions of Future Control Action Security Predictions of Future Control Action Security Predictions of Prediction Security Predictions of Prediction Security Predictions of Predictions of Prediction Security Predictions of Predictions Security Predictions of Predictions Security Prediction	May	Christopher	Clinical Team 4		Nothing to Disclose
The Risks of and Usef for the Treatment of Contenty Antry Disease Disgosts. The Intermountain Mary Media and Management and Scotal Marka Scotal Mark	May	Heidi		CRP Are Independent and Additive Predictors of Future Cardiovascular Events Among Patients Undergoing Coronary Angiography: Results From the Intermountain Heart Collaborative	Nothing to Disclose
May Hed Anythymines and Circiant EP. AF Miscellateurs and Surgical Issues May Hedd Anythymines and Circiant EP. AF Miscellateurs and Surgical Issues May Hedd Not heapth maging. Prognostic Implication of CT Angography. Prognostic Implication	May	Heidi	the Risk of, and Used for the Treatment of,	The Association of Depression at Any Time to the Risk of Death Following Coronary Artery Disease Diagnosis: The Intermountain	Nothing to Disclose
Staffication of Stroke and Mortally Using the Intermountain Raks Score Among Ama First Index Operates Undergoing class Core Among Ama First Index Operates Undergoing class of CT Angography of C	May	Heidi		Primary Care Patients: The Intermountain Chronic Disease Model	Nothing to Disclose
Oconoary Anglography Colemnical Characteristics Among Palents May Diabetes Enrolled in the FACTOR 45 Shuly. The Importance of the Calcifed Enrolled in the FACTOR 45 Shuly. The Importance of the Calcifed Enrolled in the FACTOR 45 Shuly. The Importance of the Calcifed Enrolled in the FACTOR 45 Shuly. The Importance of the Calcifed Enrolled in the FACTOR 45 Shuly. The Importance of the Calcifed Enrolled in the FACTOR 45 Shuly. The Importance of the Calcifed Enrolled in the FACTOR 45 Shuly. The Importance of the Calcifed Enrolled En	May	Heidi		Stratification of Stroke and Mortality Using the Intermountain Risk Score Among Atrial Fibrillation Patients Undergoing Cardiac	Nothing to Disclose
May Alan Device Therapies Device Therapies Device Therapies Device Therapies Device Therapies Device Therapies Device Therapies Device Chinal Research III Part Marking Progress in Understanding Heart Failure Alans Will Low Risk Chades-bub-2-cubes-be-84880-11 William Making Progress in Understanding Heart Failure Patients Will Low Risk Chades-bub-2-cubes-be-84880-11 William Making Progress in Understanding Heart Failure Patients Will Low Risk Chinal Research III Researc	May	Heidi		Coronary Angiography-Determined Quantifative Plaque Compositional Characteristics Among Patients With Diabetes Enrolled in the FACTOR-64 Study: The Importance of the Calcified	Nothing to Disclose
Making Progress in Understanding Heart Failure Making Progress in Understanding Heart Failure Maya Making Progress in Understanding Heart Failure Maya Juan Making Progress in Understanding Heart Failure Maya Juan Maya Juan Put Your Codon! Genetic Insights Into Heart Failure A North and Failure John A Night at the Movies with Some Congential Heart Surgeons – How Do They Actually Do Thart?—John Surgeons – How Do They Actually Do Thart?—John Surgeons — How Do They Actually Do Tha	May	Heidi		Patients With Low Risk Chads ₂ ≤1 With	Nothing to Disclose
Maya Juan Making Progress in Understanding Heart Failure of Longer Failure S Juan Innovations in Advocacy and Patient Centered Care Care Pury Vol. Codon! Genetic Insights into Heart Care Pury Vol. Codon! Genetic Insights into Heart Failure Patients Pury Vol. Codon! Genetic Insights into Heart Failure Patients Pury Vol. Codon! Genetic Insights into Heart Failure Patients Pury Vol. Codon! Genetic Insights into Heart Failure S Just at the Moves with Some Congenital Heart Surgeons - How Do They Actually Do Thar? - Joint Symposum of the American Association for Thorack Surgeons and the American College of Cardiology Mayer John A Night at the Moves with Some Congenital Heart Surgeons - How Do They Actually Do Thar? - Joint Symposum of the American College of Cardiology Mayer John A Night at the Moves with Some Congenital Heart Surgeons - How Do They Actually Do Thar? - Joint Symposum of the American College of Cardiology Mayer John A Night at the Moves with Some Congenital Heart Surgeons - How Do They Actually Do Association for Thorack Surgeons and the American College of Cardiology Mayer John Congenital Heart Desized Service Purpless of Prediction Tool for Congenital Heart Surgery Length of Stay Mayer John Pediatric Heart Surgery Firt Clinical Decision Making: Arrhythmias and Electrophysiology Mayo Martha Failure S Just a Recolving Door Mayhofer Thomas Heart Failure and Cardiomyopathies-Heart Failure S Just a Recolving Door Mayer Agnes Non threaside of Vascular Function Mayhofer Thomas Surgeon Search Non Invasive Inaging and the Year in Review Inaging and the Year in Review Fractional Flow Reserve Derived France Consumption Surgeons Progress on Prediction Tool for Congenital Heart Surgery Length of Stay Produced Stay Service Paint Repair Surgeons and Non Invasive Inaging and the Year in Review Inaging and the Year in Review Inaging and the Year in Review Inaging and the Year in Review Inaging and the Year in Review Inaging Review Inaging Service In Review Inaging Service In Review Inaging Service In Revie	Maya	Juan	Featured Clinical Research III		
Juan	Maya	Juan		Serial Assessment of Heart Rate and Beta Blocker Use in Chronic Heart Failure Patients With Reduced Ejection Fraction in a Large	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
Mayer	Maya	Juan		Characteristics of Patients Approved and Denied Access to PCSK9i	
A light at the Moves with Some Congenital Heart Surgeons - How Do They Actually Do That?: Joint Symposium of the American Association for Thorace Surgeons and the American College of Cardology	Maya	Juan	Put Your Codon! Genetic Insights Into Heart		OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
That?: Joint Symposium of the American Association for Thoracic Surgeons and the American College of Cardiology A Night at the Movies with Some Congential Heart Surgeons — How Do They Actually Do That?: Joint Symposium of the American Association for Thoracic Surgeons and the American College of Cardiology A Night at the Movies with Some Congential Heart Surgeons — How Do They Actually Do That?: Joint Symposium of the American Association for Thoracic Surgeons and the American College of Cardiology Video	Mayer	John	A Night at the Movies with Some Congenital	Panelist (Panel Discussion II)	
A Night at the Movies with Some Congenital Heart Surgens – How Do They Actually Do That?: Joint Symposium of the American Association for Thoracis Curgeons and the American College of Cardiology Mayor John Congenital Heart Disease: Progress in Pediatric Heart Surgery Fit Clinical Decision Making: Arrhythmias and Electrophysiology Maytov Evgeny Fit Clinical Decision Making: Arrhythmias and Electrophysiology Martha Heart Failure and Cardionypathies: Heart Failure surgery Agnes Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension Mayrhofer Thomas Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Sula Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Sula Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Sula Advances in Humonary Apterial Hypertension Mazimba Sula Advances in Humonary Apterial Hypertension Aleas of Appleance Area (Cardionypopathies) Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Sula Advances in Humonary Apterial Hypertension Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Sula Advances in Humonary Appertension Mazimba Sula Advances in Humonary Appertension Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Advances in Humonary Appertension Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Advances in Humonary Appertension Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Advances in Humonary Appertension Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Advances in Humonary Appertension Advances in Humonary Appertension Advances in Humonary Appertension Advances in Humonary Appertension Advances in Humonary Appertension Advances in Humonary Appertension Advances in Humonary Appertension Advances in Humonary Appertension Advances in Humonary Appertension Advances in Humonary Appertension Advances in Humonary Appertension Advances in Humonary Appertension Advances in Humonary Appe			That?: Joint Symposium of the American Association for Thoracic Surgeons and the		
Mayer John Congenital Heart Disease: Progress in Pediatric Heart Surgery Pediatric Heart Surgery	Mayer	John	A Night at the Movies with Some Congenital Heart Surgeons How Do They Actually Do That?: Joint Symposium of the American Association for Thoracic Surgeons and the	Patient: "Traditional" One-Patch Repair (with Division of the Superior Bridging Leaflet) (with Accompanying Surgical	DATA SAFETY MONITORING BOARD - Medtronic Inc
Evgeny FIT Clinical Decision Making: Arrhythmias and Electrophysiology A Case of Brugada Syndrome Diagnosed After Conversion of Seemingly Lone Atrial Fibrillation A Case of Brugada Syndrome Diagnosed After Conversion of Seemingly Lone Atrial Fibrillation A Case of Brugada Syndrome Diagnosed After Conversion of Seemingly Lone Atrial Fibrillation A Case of Brugada Syndrome Diagnosed After Conversion of Seemingly Lone Atrial Fibrillation A Case of Brugada Syndrome Diagnosed After Conversion of Seemingly Lone Atrial Fibrillation A Case of Brugada Syndrome Diagnosed After Conversion of Seemingly Lone Atrial Fibrillation A Case of Brugada Syndrome Diagnosed After Conversion of Seemingly Lone Atrial Fibrillation A Case of Brugada Syndrome Diagnosed After Conversion of Seemingly Lone Atrial Fibrillation A Case of Brugada Syndrome Diagnosed After Conversion of Seemingly Lone Atrial Fibrillation A Case of Brugada Syndrome Diagnosed After Conversion of Seemingly Lone Atrial Fibrillation A Case of Appical Cardian Cynrolic Lone Advances in Pulmonary Arterial Hypertension A Case of Brugada Syndrome Diagnosed After Conversion of Seemingly Lone Atrial Fibrillation Activated Diagnosed After Conversion of Seemingly Lone Atrial Fibrillation Activate Diagnosed After Conversion of Seemingly Lone Atrial Fibrillation Activate Diagnosed After Conversion of Read Semingly Lone Atrial Fibrillation Activate Diagnosed After Conversion of Rask SALARY - Relypsa	Mayer	John	Congenital Heart Disease: Progress in	Prediction Tool for Congenital Heart Surgery Length of Stay	DATA SAFETY MONITORING BOARD - Medtronic Inc
Mayo Martha Heart Failure and Cardiomyopathies: Heart Failure (Failure In Just a Revolving Door Invasive Imaging: MR Heart Failure (Failure) (Fail	Maykov	Evgeny	FIT Clinical Decision Making: Arrhythmias and		Nothing to Disclose
Agnes	Mayo	Martha	Heart Failure and Cardiomyopathies: Heart	Treatment With Patiromer Decreases Aldosterone in Patients With Heart Failure, Chronic Kidney Disease, and Hyperkalemia on RAAS	SALARY - Relypsa
Mayrhofer Thomas Highlighted Original Research: Non Invasive Imaging and the Year in Review The Association of High Risk Plaque Features and Non-Invasive Fractional Flow Reserve Derived From Corronary Computed Tomography Angiography in Patients With Acute Chest Pain: Results From the ROMICAT II Trial Mazaris Sawas Uncovering the Intricacies of Vascular Function Interpret of Natural Chios Mastic Supplementation on Endothelial Function and Arterial Stiffness in Smokers Mazimba Sula Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Guided Therapy is Associated With Worsening Renal Function Systemic Arterial Pulsatility Index (SAPi) Predicts Adverse Cardiomyopathies Outcomes in Advanced Heart Failure Patients Next When All Else Is Failing? Mazimba Sula FIT Clinical Decision Making: Heart Failure and A Case of Alypical Cardiac Tamponade With Isolated Left Pulmonary Hypertension Pulmonary Arterial Hypertension Pulmonary Systemic Pulse Pressure Ratio Is Associated With Advances in Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypertension Advances in Pulmonary Hypertension	Мауг	Agnes		Fibroblast Growth Factor 23 as Novel Biomarker for Early Risk	Nothing to Disclose
Tomography Angiography in Patients With Acute Chest Pain: Results From the ROMICAT II Trial Mazaris Sawas Uncovering the Intricacies of Vascular Function The Impact of Natural Chios Mastic Supplementation on Endothelial Function and Arterial Stiffness in Smokers Function and Arterial Stiffness in Smokers Function and Arterial Stiffness in Smokers Function and Arterial Stiffness in Smokers Function and Arterial Stiffness in Smokers Function and Arterial Stiffness in Smokers Function and Arterial Stiffness in Smokers Function and Arterial Stiffness in Smokers Function and Arterial Stiffness in Smokers Function and Arterial Stiffness in Smokers Function and Arterial Stiffness in Smokers Function and Arterial Stiffness in Smokers Function and Arterial Stiffness in Smokers Function and Arterial Stiffness in Smokers Function and Arterial Stiffness in Smokers Function and Arterial Stiffness in Smokers Function and Arterial Fulsion Pressure Ratio Impact of Application and Arterial Stiffness in Smokers Function and Arterial Plain Pressure Ratio Is Associated With Acute Chest Pain: Results Form the RoMICAT II Trial Function The Impact of Nathing to Disclose Function and Arterial Plain Pressure Ratio Is Associated With Acute Chest Pain: Results Function Interest Failure and Acute Chest Pain: Results Function Interest Failure Patients Interest Function Interest Failure Patients Impact of Cardiogenic Shock with or without Mechanical Circulatory Support on Short-Term and Long-Term Survival in Heart Failure Hospitalizations Impact of Cardiogenic Shock with or without Mechanical Circulatory Support on Short-Term and Long-Term Survival in Heart Failure Hospitalizations Impact of Cardiogenic Shock with or without Mechanical Circulatory Support on Short-Term and Long-Term Survival in Heart Failure Hospitalizations Impact of Cardiogenic Shock with or without Mechanical Circulatory Support on Short-Term and Long-Term Survival in Heart Failure Hospitalizations Impact of Cardiogenic Shock with or without Mechanical Circulatory Noth	Mayrhofer	Thomas	Highlighted Original Research: Non Invasive	The Association of High Risk Plaque Features and Non-Invasive	Nothing to Disclose
Function and Arterial Stiffness in Smokers Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Mazimba Sula Advances in HCM, PPCM and Other Cardiomyopathies Mazimba Sula Heart Failure and Cardiomyopathies: What Next When All Else Is Failing? Mazimba Sula FIT Clinical Decision Making: Heart Failure and Advances in Pulmonary Hypertension Mazimba Sula Advances in Pulmonary Arterial Hypertension Mazimba Sula Advances in Pulmonary Arterial Hypertension Advances in Pulmonary Arterial Hypertension Pulmonary Hypertension Advances in Pulmonary Arterial Hypertension Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypertension				Tomography Angiography in Patients With Acute Chest Pain: Results From the ROMICAT II Trial	
Mazimba Sula Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Cardiomyopathies Sula Advances in HCM, PPCM and Other Cardiomyopathies Sula Heart Failure and Cardiomyopathies: What Next When All Else Is Failing? Support on Short-Term and Long-Term Survival in Heart Failure Hospitalizations Mazimba Sula FIT Clinical Decision Making: Heart Failure and Cardiomyopathies What Next When All Else Is Failing? Support on Short-Term and Long-Term Survival in Heart Failure Hospitalizations Mazimba Sula FIT Clinical Decision Making: Heart Failure and Advances of Alphjeal Cardiac Tamponade With Isolated Left Ventricular Compression Mazimba Sula Advances in Pulmonary Arterial Hypertension Advance Clinical Outcomes in Acute Pulmonary Hypertension Pulmonary Hypertension Advanced Pulmonary Hypertension Pulmonary Hypertension Advance Clinical Outcomes in Group 1 Pulmonary Hypertension Nothing to Disclose		Savvas	-	Function and Arterial Stiffness in Smokers	3
Mazimba Sula Advances in HCM, PPCM and Other Cardiomyopathies Outcomes in Advanced Heart Failure Patients Mazimba Sula Heart Failure and Cardiomyopathies: What Next When All Else Is Failing? Mazimba Sula FIT Clinical Decision Making: Heart Failure and Advanced Heart Failure Patients Mazimba Sula FIT Clinical Decision Making: Heart Failure and Advanced Heart Failure and Long-Term Survival in Heart Failure Hospitalizations Mazimba Sula FIT Clinical Decision Making: Heart Failure and A Case of Atypical Cardiac Tamponade With Isolated Left Ventricular Compression Mazimba Sula Advances in Pulmonary Arterial Hypertension Mazimba Sula Advances in Pulmonary Arterial Hypertension Mazimba Sula Advances in Group 1 Pulmonary Hypertension Nothing to Disclose Nothing to Disclose Nothing to Disclose	Mazimba	Sula		Changes in Renal Perfusion Pressure During Hemodynamically	Nothing to Disclose
Mazimba Sula Heart Failure and Cardiomyopathies: What Next When All Else Is Failing? Support on Short-Term and Long-Term Survival in Heart Failure Hospitalizations Mazimba Sula FIT Clinical Decision Making: Heart Failure and A Case of Alypical Cardiac Tamponade With Isolated Left Pulmonary Hypertension Ventrical Compression Mazimba Sula Advances in Pulmonary Arterial Hypertension Pulmonary-Systemic Pulse Pressure Ratio Is Associated With Adverse Clinical Outcomes in Group 1 Pulmonary Hypertension Adverse Clinical Outcomes in Group 1 Pulmonary Hypertension Nothing to Disclose	Mazimba	Sula	Advances in HCM, PPCM and Other	Systemic Arterial Pulsatility Index (SAPi) Predicts Adverse	Nothing to Disclose
Mazimba Sula FIT Clinical Decision Making: Heart Failure and A Case of Atypical Cardiac Tamponade With Isolated Left Nothing to Disclose Ventricular Compression Mazimba Sula Advances in Pulmonary Arterial Hypertension Advances in Group 1 Pulmonary Hypertension Adverse Clinical Outcomes in Group 1 Pulmonary Hypertension Adverse Clinical Outcomes in Group 1 Pulmonary Hypertension	Mazimba	Sula	Heart Failure and Cardiomyopathies: What	Impact of Cardiogenic Shock with or without Mechanical Circulatory Support on Short-Term and Long-Term Survival in Heart Failure	Nothing to Disclose
Mazimba Sula Advances in Pulmonary Arterial Hypertension Pulmonary-Systemic Pulse Pressure Ratio Is Associated With Adverse Clinical Outcomes in Group 1 Pulmonary Hypertension	Mazimba	Sula		A Case of Atypical Cardiac Tamponade With Isolated Left	Nothing to Disclose
Mazine Amine Highlights in Vascular Medicine Research Yield Genetic Testing in Patients With Thoracic Aortic Disease Nothing to Disclose	Mazimba	Sula	Advances in Pulmonary Arterial Hypertension	Pulmonary-Systemic Pulse Pressure Ratio Is Associated With	Nothing to Disclose
	Mazine	Amine	Highlights in Vascular Medicine Research	Yield of Genetic Testing in Patients With Thoracic Aortic Disease	Nothing to Disclose

and a				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Mazur	Alexander	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Gender Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Medicare Patients With Newly Diagnosed Arial Fibrillation:	Nothing to Disclose
		This is a second of the second	A Propensity Matched Analysis	
Mazurek	Jeremy	The Nuts and Bolts of Pulmonary Hypertension	Panelist	Nothing to Disclose
Manusali	lanam.	in Left Heart Disease	The First stine of WILO 2 Distriction is the sector in	Nething to Displace
Mazurek	Jeremy	The Nuts and Bolts of Pulmonary Hypertension in Left Heart Disease	The Evaluation of WHO 2 Pulmonary Hypertension	Nothing to Disclose
Mazurek	Jeremy	Imaging Pulmonary Vascular Disease Plus the	RVOT-VTI/PASP: A Novel Non-Invasive Metric of Pulmonary Arterial	Nothing to Disclose
		Impact of Congenital Heart Disease	Compliance and Diastolic Pressure Gradient Status in Heart Failure With Preserved Ejection Fraction	
Mazurek	Jeremy	Advances in Pulmonary Arterial Hypertension	Pulmonary-Systemic Pulse Pressure Ratio Is Associated With	Nothing to Disclose
Mazaron	Coronny	Transaction annotary rational ryportonoism	Adverse Clinical Outcomes in Group 1 Pulmnonary Hypertension	Trouming to Biodicoc
Mazza	Victor	Atrial Fibrillation and VT: Incorporating Novel	Comparison of In-Hospital Outcomes of Septic Shock Patients With	Nothing to Disclose
		Risks Toward Decision Making	and Without Atrial Fibrillation: A Retrospective Propensity-Matched Analysis	
Mazzaferri	Ernest	PCI for NSTEMI and Complex Patients With	Platelet Reactivity and Outcomes After PCI of Saphenous Vein	OTHER - CardioKinetix
M 6 2	E	Multiple Co-Morbidities	Grafts Versus Native Coronary Arteries: The ADAPT-DES Study	OTHER CONTROL
Mazzaferri	Ernest	Advances in Chronic Total Occlusion Intervention	Is Platelet Reactivity Associated With Ischemic Events Following Successful Chronic Total Occlusion Percutaneous Coronary	OTHER - CardioKinetix
			Intervention	
Mazzella	Anthony	PCI for NSTEMI and Complex Patients With	Management and Outcomes of Non-ST Elevation Myocardial	Nothing to Disclose
Mazzella	Anthony	Multiple Co-Morbidities Interventional Cardiology: PCI in Complex	Infarction in Patients Hospitalized for Non-Cardiac Conditions Outcomes After Invasive Management of Inpatient Onset of Non ST-	Nothing to Disclose
		Patients	Elevation Myocardial Infarction	
Mbai	Mackenzi	Interventional Cardiology: PCI and TAVR in	Calcification in the Basal Septum, but Not Membranous Septal	Nothing to Disclose
		Complex Patients	Length, Predicts AV Conduction Disturbance and Pacemaker Implantation Following Transcatheter Aortic Valve Replacement	
			With a Balloon-Expandable Valve (S3)	
McAlister	Finlay	Unusual Presentations of ACS	The High Cost of Low Acuity Non ST-Segment Elevation Acute	Nothing to Disclose
			Coronary Syndrome Admissions to the Coronary Care Unit: An Analysis of National Population Health Data	
McAlister	Finlay	Percutaneous Coronary Intervention: Lessons	Nine Year Trends in Cause-Specific Mortality After Percutaneous	Nothing to Disclose
	,	From the Real World	Coronary Intervention: Observations From the Alberta Provincial	
			Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Registry	
McAllister	David	Blips, Trops, and Chips: New Ways to	High-Sensitivity Cardiac Troponin I and the Diagnosis of Obstructive	CONSULTANT FEES/HONORARIA - Roche
		Diagnose CAD	Coronary Artery Disease in Patients With Suspected Stable Angina	
Ma Alliata a	Desie	Advences in UCM DDOM and Other	I is the price of Control of Cont	Nething to Displace
McAllister	Paris	Advances in HCM, PPCM and Other Cardiomyopathies	Living in a Food Desert Is Associated With an Early Hazard of Death and Hospitalization in Heart Failure Patients	Nothing to Disclose
McAndrew	Thomas	Considerations in Antiplatelet Therapy and in	Effect of Thrombotic and Bleeding Risk According to Platelet	Nothing to Disclose
		ACS	Reactivity on 2-Year Mortality: The ADAPT-DES Study	
McAndrew	Thomas	Considerations in Antiplatelet Therapy and in ACS	Platelet Reactivity and Outcomes After PCI of Lesions With and Without In-Stent Restenosis: The ADAPT-DES Study	Nothing to Disclose
McAndrew	Thomas	PCI for NSTEMI and Complex Patients With	Platelet Reactivity and Outcomes After PCI of Saphenous Vein	Nothing to Disclose
		Multiple Co-Morbidities	Grafts Versus Native Coronary Arteries: The ADAPT-DES Study	-
McAndrew	Thomas	Vascular Access and Hemostasis Issues	Mortality, Length of Stay, and Cost Implications of Procedural Bleeding After Contemporary Percutaneous Interventions Involving	Nothing to Disclose
			Large-Bore Catheters	
McAndrew	Thomas	Advances in Chronic Total Occlusion	Is Platelet Reactivity Associated With Ischemic Events Following	Nothing to Disclose
		Intervention	Successful Chronic Total Occlusion Percutaneous Coronary Intervention	
McAreavey	Dorothea	Evolution of Critical Care Cardiology and the	Morphogenesis and Morphology of the CICU	Nothing to Disclose
,		CICU		
McBane	Robert	Vascular Medicine: Emerging Concepts in	Risk of Re-Dissection in Segmental Arterial Mediolysis	RESEARCH/RESEARCH GRANTS - Bristol-Myers Squibb
McBane	Robert	Clinical Vascular Diseases FIT Clinical Decision Making: Interventional	Massive Embolism in Transit: Confirming the Destination	Company RESEARCH/RESEARCH GRANTS - Bristol-Myers Squibb
		Cardiology, Acute and Stable Ischemic Heart		Company
M.D.	D. L. J	Disease, and Vascular Medicine	O	DECEMBER OF A POLICE PARTY OF THE
McBane	Robert	40. Vascular Medicine: Non Coronary Arterial Disease Team 2	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Bristol-Myers Squibb Company
McBride	Kim	Congenital Heart Disease: New Diagnostic	Utility of Genetic Testing in Infants With Isolated Congenital Heart	Nothing to Disclose
M.D.C.	A I .	Approaches in Congenital Heart Disease	Disease	Notice to Bright
McBrien	Angela	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Impact of Maternal Diabetes on First & Early Second Trimester Fetal Cardiovascular Health	Nothing to Disclose
McCabe	James	Interventional Live Case Session III: Structural	Panelist	CONSULTANT FEES/HONORARIA - Abiomed, Edwards
		Transmission from Cleveland Clinic		
McCabe	James	(Cleveland, Ohio) Debates on Current Hot Topics in Coronary	Debate Pro: Hemodynamic Support Can Provide Important Benefits	CONSULTANT FEES/HONORARIA - Abiomed, Edwards
ooabe	Janico	Intervention	and Is Underused!	
McCabe	James	Interventional Cardiology: PCI and TAVR in	Management of Patients With Cardiac Arrest in New York Before	CONSULTANT FEES/HONORARIA - Abiomed,Edwards
McCabe	James	Complex Patients Advances in Chronic Total Occlusion	and After Public Reporting Policy Changes Hemodynamically-Supported PCI of Chronic Total Occlusions: A	CONSULTANT FEES/HONODADIA Abismod Edwards
Micoape	odilico	Intervention	Case Series	CONSULTANT FEES/HONORARIA - Abiomed, Edwards
McCabe	James	Advances in Chronic Total Occlusion	Health Status Benefits of Successful Chronic Total Occlusion PCI in	CONSULTANT FEES/HONORARIA - Abiomed, Edwards
		Intervention	Patients With Depressed Left Ventricular Systolic Function: Insights	
McCabe	James	FIT Clinical Decision Making: Interventional	From the OPEN-CTO Registry An Unusual Case of Hypoxia: Platypnea-Orthodeoxia Syndrome	CONSULTANT FEES/HONORARIA - Abiomed, Edwards
		Cardiology, Acute and Stable Ischemic Heart		TELESTION OF STATE AND OTHER LAWRINGS
	12. 1.	Disease, and Vascular Medicine	Defends and Market and Defends	ON ARY No of Ores
McCague	Kevin	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Rationale and Methods of the Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During	SALARY - Novartis Corporation
	<u> </u>	. a.a.o war a romar El Tor Near:	Entresto Therapy for Heart Failure (PROVE-HF) Study	
McCann	Gerry	Featured Clinical Research I	MR-INFORM: Stress Perfusion Imaging to Guide the Management	RESEARCH/RESEARCH GRANTS - Bayer Healthcare
McCarthy	Cian	Traditional and Novel Factors Used to Assess	of Patients With Stable Coronary Artery Disease Multiple Biomarkers for Predicting Major Adverse Cardiac Events in	Pharmaceuticals Nothing to Disclose
ivicCatuty	Cidil	the Risk of, and Used for the Treatment of,	At-Risk Patients Undergoing Diagnostic Coronary Angiography:	Induling to Disclose
		Coronary Artery Disease	Results From the Catheter Sampled Blood Archive in	
MaCaulo	Dring	Innovation in Description	Cardiovascular Diseases (CASABLANCA) Study	Nething to Displace
McCauley	Brian	Innovation in Practice Management, Advocacy, and Education	Using Mobile Device Technology and Spaced Education Adaptive Learning Algorithms to Teach ECG Interpretation	Nothing to Disclose
McClellan	Mark	How to Redesign a Care Delivery Team in	Panelist	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
		Preparation for MACRA and MIPS		ROLE - Johnson & Amp; amp; Johnson
McClellan	Mark	How to Redesign a Care Delivery Team in Preparation for MACRA and MIPS	The Policy-maker's Perspective	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Johnson & Diploman (September 1997)
McClelland	Robyn	Non Invasive Imaging: Coronary Calcium	­The Utility of Minimal Coronary Artery Calcification for	Nothing to Disclose
		Scoring and CV Risk Assessment	Predicting Carotid Artery Disease: Results From the Multi-Ethnic	· ·
McClurken	lames	Palliative Care for the 90% I: Promoting	Study of Atherosclerosis (MESA)	Nothing to Disclose
McClurken	James	Palliative Care for the 99% I: Promoting Palliative Care: The Why and What of PC	Debate: Palliative Care in TAVR Prolongs Meaningful Life!!	Nothing to Disclose
		Therapy		
McClurken	James	Structural Heart Disease: Difficult Choices for	Co-Chair	Nothing to Disclose
McClurken	James	the Heart Team Post FDA Release Prosthetic Valve	Co-Chair	Nothing to Disclose
		Surveillance - Watching for Signals		

				<u> </u>
McClurken	First Name James	Session Title Highlighted Original Research: Valvular Heart	Presentation Title Co-Chair	Disclosures Nothing to Disclose
McClurken	James	Disease and the Year in Review Engage @ ACC.17 Studio: Ask the Valvular	Co-Chair	Nothing to Disclose
		Heart Disease Experts		
McConkey	Nathaniel	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	That Is Not a Seizure, It's VT: A Unique Presentation of Acquired Long QT Syndrome	Nothing to Disclose
McConnachie	Alex	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Decision Making Using Fractional Flow Reserve Is Associated With Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With Nstemi	Nothing to Disclose
McConnell	Patrick	Young Investigator Awards Competition: Basic and Translational Science	LVAD-Associated von Willebrand Factor Degradation Fragments Alter Angiogenesis: A Mechanistic Link Between LVAD Support, Gastrointestinal Angiodysplasia, and Bleeding?	CONSULTANT FEES/HONORARIA - ClearCath, CorMatrix; RESEARCH/RESEARCH GRANTS - Thoratec Corporation
McCord	James	Novel Developments in Acute Coronary Syndromes	How Often Does Troponin Elevation Identify Acute Myocardial Infarction in the Emergency Department?	CONSULTANT FEES/HONORARIA - Roche, Siemens; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Society of Cardiovascular Patient Care (SCPC); RESEARCH/RESEARCH GRANTS - Roche, Siemens
McCord	James	Novel Developments in Acute Coronary Syndromes	Cardiac Electrical Biomarker Response During Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Roche, Siemens; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Society of Cardiovascular Patient Care (SCPC); RESEARCH/RESEARCH GRANTS - Roche, Siemens
McCord	James	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Is Duration of Symptoms Predictive of Acute Myocardial Inferction?	CONSULTANT FEES/HONORARIA - Roche, Siemens; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Society of Cardiovascular Patient Care (SCPC); RESEARCH/RESEARCH GRANTS - Roche, Siemens
McCoy	Lisa	Optimizing the Care of ACS Patients	Contemporary Patterns of GP Ilb/Illa Inhibitor Use in Patients With Acute Myocardial Infarction Undergoing PCI: Insights From the TRANSLATE ACS Study	Nothing to Disclose
McCracken	Courtney	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Long-Term Transplant-Free Survival Following Surgery for Coarctation of the Aorta: A Study From the Pediatric Cardiac Care Consortium	Nothing to Disclose
McCracken	Courtney	Congenital Heart Disease: Innovations in	Long Term Outcomes After the Fontan Procedure in Patients With	Nothing to Disclose
McCrindle	Brian	Single Ventricle Heart Disease Congenital Heart Disease: Novel Insights in Pediatric Cardiology	Single Ventricle: A Meta-Analysis Rhythm Abnormalities in Children and Young Adults With Marfan Syndrome	CONSULTANT FEES/HONORARIA - Aegerion, Janssen; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
McCrindle	Brian	11. Congenital Heart Disease: Therapy Team	Suggested Reviewer	CellAegis CONSULTANT FEES/HONORARIA - Aegerion, Janssen; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
McCulloch	Charles	The Story of the Adult Congenital Heart	Prevalence and Predictors of Atrial Tachyarrhythmias in Adult	CellAegis Nothing to Disclose
McCulloch	Charles	Disease Patient and EP Fontan in the Modern World	Fontan Patients Prevalence of Elevated Body Mass Index and Its Association With	Nothing to Disclose
McCulloch	Charles	Redefining the "F" Word	Clinical Features in Adult Fontan Patients Prevalence and Predictors of Pacemaker Placement in Adult	Nothing to Disclose
McCullough	Matthew	Interventional Cardiology: PCI in Complex	Fontan Patients Clinical Presentation, Natural History and Management of Coronary	Nothing to Disclose
		Patients	Artery Ectasia	-
McCullough	Peter	The Heavy Heart: Practicing Heart Failure Cardiology in an Obesity Epidemic	Panelist	Nothing to Disclose
McCullough	Peter	The Heavy Heart: Practicing Heart Failure Cardiology in an Obesity Epidemic	Is There a Role for Bariatric Surgery in Heart Failure Patients with Obesity?	Nothing to Disclose
McCullough	Peter	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Changes in Renal Perfusion Pressure During Hemodynamically Guided Therapy Is Associated With Worsening Renal Function	Nothing to Disclose
McCullough	Peter	Advances in HCM, PPCM and Other	Systemic Arterial Pulsatility Index (SAPi) Predicts Adverse	Nothing to Disclose
McCullough	Peter	Cardiomyopathies The Great K Debate Continues: Updates and Controversies in Heart Failure Management	Outcomes in Advanced Heart Failure Patients Understanding Side-effect Management	Nothing to Disclose
McCullough	Peter	Heart Failure and Cardiomyopathies: Clinical Team 6	Suggested Reviewer	Nothing to Disclose
McCullough	Stephen	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Acute Echo-Guided Management of Cardiogenic Shock After Anterior Myocardial Infarction Complicated by Dynamic Left	Nothing to Disclose
McCully	Robert	Valvular Heart Disease: Aortic Stenosis	Ventricular Outflow Tract Obstruction Sinus Rhythm Versus Atrial Fibrillation & It Clinical Profile and Natural History of Patients With Severe Aortic Stenosis Managed	Nothing to Disclose
McDaniel	Michael	Maintenance of Clinical Competencies in Invasive Coronary Imaging and Coronary	Medically IVUS Imaging: Tips, Tricks and Pitfalls	CONSULTANT FEES/HONORARIA - Medicure
McDermott	Mary	Physiology Meet the New LE PAD Guidelines: Case-	Exercise: Structured or Unstructured, in Parallel or in Series?	RESEARCH/RESEARCH GRANTS - Novartis
McDonald	Daniel	Based Examples of Optimal Vascular Care Interventional Cardiology: TAVR 2	Short- and Mid-Term Outcomes After Transcatheter Aortic Valve Replacement in Patients With Renal Insufficiency Not on	Nothing to Disclose
McDonald	Kenneth	Innovations in Cardiovascular Risk Assessment and Reduction	Hemodialysis Longitudinal Change in Soluble ST2 Versus B-type Natriuretic Peptide in Predicting Major Adverse Cardiovascular Events in Asymptomatic Patients in the Community	CONSULTANT FEES/HONORARIA - Alere,BG Medicine,Cruinn Diagnostics,Menarini,Novartis,servier; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - SOLVOTRIN; RESEARCH/RESEARCH GRANTS - MSD,Pitzer,Roche,Takeda
McDonald	Mark	Congenital Heart Disease: Advances in Quality Improvement for Pediatric Cardiac Care	Revenue Return on Investment for Center Involvement in a Quality Improvement Collaborative for a Rare Disease: National Pediatric Cardiology Quality Improvement Collaborative	Nothing to Disclose
McDonnell	Marie	Diabetes and Heart Failure: Are We Hitting	Panelist	Nothing to Disclose
McDonnell	Marie	The Sweet Spot Diabetes and Heart Failure: Are We Hitting	Could SGLT-2 Inhibitors Improve Heart Failure Outcomes?	Nothing to Disclose
McElhinney	Doff	The Sweet Spot Surgical and Transcatheter Valve Therapy for	Panelist	CONSULTANT FEES/HONORARIA - MEDTRONIC
McElhinney	Doff	Congenital Heart Disease Precision Medicine: It's Hot, But What Is It?	Co-Chair	CONSULTANT FEES/HONORARIA - MEDTRONIC
McElhinney	Doff	Predicting Outcomes in Pediatric Heart Disase	Insurance Type Is Associated With Longer Hospital Duration but Similar Mortality Among Children Undergoing Congenital Heart Surgery	CONSULTANT FEES/HONORARIA - MEDTRONIC
McEntegart	Margaret	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Prognostic Significance of Co-Existing Persistent Edema and Hemorrhage at 6 Months in Survivors of ST-Elevation Myocardial Infarction	Nothing to Disclose
McEntogert			Decision Making Using Fractional Flow Reserve Is Associated With	Nothing to Disclose
McEntegart	Margaret	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With Nstemi	
McEntegart McEntegart	Margaret Margaret		Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With	Nothing to Disclose

The state of the s				
Last Name McEntegart	First Name Margaret	Session Title Cardiac Arrest, Diabetes, and Other High Risk	Presentation Title Current Smoking, Microvascular Pathology and Adverse Outcome	Disclosures Nothing to Disclose
-	_	Features of Patients With Acute Coronary Syndrome	After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights	ů
McEntegart	Margaret	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Incidence and Prognostic Implications of the Presence of Multiple Complex Plaques in Survivors of ST-Elevation Myocardial Infarction	Nothing to Disclose
McEntegart	Margaret	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Hypertension, Microvascular Pathology and Prognosis in Patients With an Acute ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
McEvoy	John	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Coronary Artery Calcium and Incident Hypertension in a Population- Based Cohort: The Multi-Ethnic Study of Atherosclerosis	Nothing to Disclose
McEvoy	John	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium Scores for Atherosclerotic Cardiovascular Disease Risk Stratification in Smokers: MESA	Nothing to Disclose
McEvoy	John	Markers of Prognosis Associated With Elevated Blood Pressure	Isolated Systolic Hypertension and Pulse Pressure Are Associated With High-Sensitivity Cardiac Troponin-T and NT-pro BNP in Older Adults	Nothing to Disclose
McGrew	Frank	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Effective Control of Atrial Fibrillation Can Be Achieved With Very Low Doses of Amiodarone	Nothing to Disclose
McGrew	Frank	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Influence of Low Versus High Dose on the Association of Loop Diurectic and Mortality in Patients With Heart Failure: Insights From the UNITE-HF Registry	Nothing to Disclose
McGuire	Darren	Updates in Stable Ischemic Heart Disease	Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-World Impact of the Leader Trial on Improving Cardiovascular Outcomes in Patients With Diabetes at High Cardiovascular Risk	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim, Lexicon, Merck, Novo Nordisk Inc., Sanofi-Aventis; DATA SAEFTY MONITORING BOARD - GlaxoSmithKline, Janssen; RESEARCH/RESEARCH GRANTS - AstraZeneca, Boehringer Ingelheim, Eisai, Eli Lilly, Merck, Novo Nordisk
McGuire	Darren	Innovations in Advocacy and Patient Centered Care	Racial and Ethnic Differences in Cardiovascular Biomarkers	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Lexicon, Merck, Novo Nordisk Inc., Sanofi-Aventis; DATA SAFETY MONITORING BOARD - GlaxoSmithKline, Janssen; RESEARCH/RESEARCH GRANTS - AstraZeneca, Boehringer Ingelheim, Eisai, Eli Lilly, Merck, Novo Nordisk
McGuire	Darren	32. Prevention: Clinical Team 6	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim, Lexicon, Merck, Novo Nordisk Inc., Sanofi-Aventis; DATA SAETTY MONTORING BOARD - GlaxoSmithkline, Janssen; RESEARCH/RESEARCH GRANTS - AstraZeneca, Boehringer Ingelheim, Eisai, Eli Lilly, Merck, Novo Nordisk
McGurk	Siobhan	Interventional Cardiology: TAVR 3	The Incidence of Permanent Pacemaker Implantation With SAPIEN 3 Heart Valve - Implantation Depth: The Higher the Better?	Nothing to Disclose
McHorney	Colleen	Antithrombotic Therapy in Ischemic Heart Disease	Rivaroxaban Users Have Significantly Less Treatment Discontinuation Compared With Users of Other Oral Anticoagulants in Non-Valvular Atrial Fibrillation	Nothing to Disclose
McHugh	Kimberly	Congenital Heart Disease: Progress in Pediatric Heart Surgery	The Association of Technical Performance With Postoperative Complications and Hospital Costs for the Norwood Operation	Nothing to Disclose
McHugh	Kimberly	Predicting Outcomes in Pediatric Heart Disase	ACC Poster Moderator	Nothing to Disclose
McIlvennan	Colleen	Innovations in Advocacy and Patient Centered Care	Describing Collaboration Between Cardiology and Palliative Care: A National Survey Study of Current Practices, Challenges and Barriers	Nothing to Disclose
McInerney	Angela	Arrhythmias and Clinical EP: Devices 4	Safety of Left Atrial Appendage Closure in an Unselected High Risk Cohort: Results From the Beaumont Hospital Left Atrial Appendage Closure Registry	Nothing to Disclose
McIntyre	William	Atrial Fibrillation and VT: Unique Populations and Solutions	Predictors of Anticoagulant Prescription in Patients With Atrial Fibrillation in North America: The GLORIA-AF Registry	Nothing to Disclose
McKay	Josh	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Therapeutic Dilemma in a Case With Coronary Artery Aneurysm and Large Thrombus Burden	Nothing to Disclose
McKay	Joshua	Innovations in Education	Hands-On Transradial Access Skill Training on a Novel Cadaveric Model: Findings and Recommendations	Nothing to Disclose
McKenney	James	Advances in Lipid Management	Alirocumab in High-Risk Patients With Baseline LDL-C ≥160 mg/dL: Findings From the Compassionate Use Program	Nothing to Disclose
McKenzie	Emmett	Coarctation of the Aorta, from Repair to Lifelong Care	The Many Surgical Options for Repair of Coarctation	Nothing to Disclose
McKenzie	Emmett	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Is a Pulsatile Glenn an Adequate Alternative for Long-Term Palliation in Patients With Single Ventricle Physiology?	Nothing to Disclose
McKenzie	Emmett	Non Invasive Imaging: Role of Exercise Testing		Nothing to Disclose
McLaughlin	Mary Ann	Updates on Risk Factors for Cardiovascular Disease	Exposure to Particulate Matter in World Trade Center Law Enforcement and Its Relationship to Cardiovascular Risk	Nothing to Disclose
McLaughlin	Vallerie	Demystifying and Managing Pulmonary Hypertension and RV Dysfunction: It Takes a Village	Panel Discussion Moderator	CONSULTANT FEES/HONORARIA - Actelion,Bayer,CareMark,St. Judes Medical,SteadyMed,United Therpeutics; RESEARCH/RESEARCH GRANTS - Actelion,Bayer,Eiger
McLaughlin	Vallerie	Core Curriculum: Moving from the Basics to Advanced Cases in Pulmonary Hypertension	Chair	CONSULTANT FEES/HONORARIA - Actelion,Bayer,CareMark,St. Judes Medical,SteadyMed,United Therpeutics; RESEARCH/RESEARCH GRANTS - Actelion,Bayer,Eiger
McLaughlin	Vallerie	Finding Out What Works in Pediatric and Congenital Heart Disease	Timely Detection of Pulmonary Arterial Hypertension in Patients With Repaired Congenital Heart Disease: Interim Results From the ACHD-QuERI Registry	CONSULTANT FEES/HONORARIA - Actelion, Bayer, CareMark, St. Judes Medical, SteadyMed, United Therpeutics; RESEARCH/RESEARCH GRANTS - Actelion, Bayer, Eiger
McLaughlin	Vallerie	35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 2	Suggested Reviewer	Activition, Bayer, Eiger CONSULTANT FEES/HONORARIA - Actelion, Bayer, CareMark St. Judes Medical, SteadyMed, United Therpeutics; RESEARCH/RESEARCH GRANTS - Actelion, Bayer, Eiger
McLeod	Christopher	Valvular Heart Disease Guidelines The Evidence and the Gaps	What Changed? - The Scope of the VHD Focused Update:Surgical Considerations	Nothing to Disclose
McLeod	Christopher	Biomarkers and Targets for Ischemic Heart Disease	Serial Assessment of Thrombogenicity and Hemodynamics in Patients With Type II Diabetes Observed in a Clinical Research Unit: Evidence for Circadian Changes in Clot Formation	Nothing to Disclose
McLeod	Christopher	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Azygos Vein Isolation as Treatment for a Complex Case of Atrial Arrhythmia	Nothing to Disclose
McLeod	Christopher	From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease	Assessment of Thrombogenicity and Antithrombotic Drug Response at the Bedside in Patients Presenting With Ischemic Stroke, TIA or Intracranial Hemorrhage	Nothing to Disclose
McLeod	Christopher	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Syncope in the Setting of Two Zebras	Nothing to Disclose
McLeod	Christopher	Things That Matter in Adult Congenital Heart Disease	Outcomes of Cardiac Pacing in the Adult Fontan Population	Nothing to Disclose

				l
McManus	David	Session Title Innovative Use of Echocardiography	Presentation Title Effect of Left Atrial Remodeling on Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham	Disclosures CONSULTANT FEES/HONORARIA - Bristol-Myers Squibb Company ,Pfizer Inc,Samsung Electronics, Inc.,Thomas Lytle;
McManus	David	Innovative Use of Echocardiography	Offspring Study Left Atrial Function Index as a Predictor of Cardiovascular Disease and Atrial Fibrillation: Data From the Framingham Offspring Study	RESEARCH/RESEARCH GRANTS - Biotronik, Phillips CONSULTANT FEES/HONORARIA - Bristol-Myers Squibb Company , Pfizer Inc, Samsung Electronics, Inc., Thomas Lytle;
McManus	David	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Depression and Atrial Fibrillation: A Case-Report of Intentional Flecainide Overdose	RESEARCH/RESEARCH GRANTS - Biotronik, Philips CONSULTANT FEES/HONORARIA - Bristol-Myers Squibb Company , Pfizer Inc, Samsung Electronics, Inc., Thomas Lytle;
McMurray	John	Featured Clinical Research III	Paroxysmal Atrial Fibrillation Is Associated With Worse Clinical	RESEARCH/RESEARCH GRANTS - Biotronik, Phillips OTHER - Amgen Inc., Novartis Corporation, Novartis
			Outcomes Than Persistent/Permanent Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction	Pharmaceuticals; RESEARCH/RESEARCH GRANTS - Amgen Inc.,Novartis Corporation,Novartis Corporation,Novartis Pharmaceuticals
McMurray	John	Making Progress in Understanding Heart Failure	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF	OTHER - Amgen Inc.,Novartis Corporation,Novartis Pharmaceuticals; RESEARCH/RESEARCH GRANTS - Amgen Inc.,Novartis Corporation,Novartis Pharmaceuticals
McMurray	John	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Cardiac Myosin Activator, Omecamtiv Mecarbil, Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure (COSMIC-HF)	OTHER - Amgen Inc.,Novartis Corporation,Novartis Pharmaceuticals; RESEARCH/RESEARCH GRANTS - Amgen Inc.,Novartis Corporation,Novartis Pharmaceuticals
McMurray	John	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Effect of Sacubitril/Valsartan Compared With Enalapril, According to Etiology in PARADIGM-HF	OTHER - Amgen Inc., Novartis Corporation, Novartis Pharmaceuticals; RESEARCH/RESEARCH GRANTS - Amgen Inc., Novartis Corporation, Novartis Pharmaceuticals
McMurray	John	Hormones and Heart Failure	Low Urinary Cgmp/Bnp Ratio Is Associated With Worse Outcomes in Heart Failure but Is Increased by Treatment With Sacubitril/Valsartan: An Analysis of Paradigm-HF	OTHER - Amgen Inc.,Novartis Corporation,Novartis Pharmaceuticals; RESEARCH/RESEARCH GRANTS - Amgen Inc.,Novartis Corporation,Novartis Pharmaceuticals
McMurray	John J. V.	The Old and the New: Impact of Heart Failure Drug Therapies	Influence of Sacubitril/Valsartan on Glycemic Control in Patients With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction	OTHER - Amgen Inc.,Novartis Corporation,Novartis Pharmaceuticals; RESEARCH/RESEARCH GRANTS - Amgen Inc.,Novartis Corporation,Novartis Pharmaceuticals
McMurtry	M. Sean	41. Vascular Medicine: Venous Disease Team	Suggested Reviewer	Nothing to Disclose
McNair	Patrick	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Submassive Pulmonary Embolism With Concomitant Paradoxical Embolism Through Patent Foramen Ovale	Nothing to Disclose
McNamara	David	FIT Clinical Decision Making: Valvular Heart Disease and Pericardial Disease	Effusive-Constrictive Pericarditis Associated With Schmidt	Nothing to Disclose
McNamara	Dennis	Pregnancy and Heart Disease	Syndrome Panelist	CONSULTANT FEES/HONORARIA - GE Healthcare,Sanofi Pasteur; RESEARCH/RESEARCH GRANTS - Arbor Pharmaceutical
McNamara	Dennis	Pregnancy and Heart Disease	Peripartum Cardiomyopathy – Long term Outcomes and Management Options	CONSULTANT FEES/HONORARIA - GE Healthcare,Sanofi Pasteur; RESEARCH/RESEARCH GRANTS - Arbor Pharmaceutical
McNamara	Dennis	Novel Echocardiographic Methods for Assessing Cardiac Function	Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain	CONSULTANT FEES/HONORARIA - GE Healthcare,Sanofi Pasteur; RESEARCH/RESEARCH GRANTS - Arbor Pharmaceutical
McNamara	Dennis	Advances in HCM, PPCM and Other Cardiomyopathies	Extended Course of Recovery in Patients With Peripartum Cardiomyopathy Assessed by Left Ventricular Wall Distensibility	CONSULTANT FEES/HONORARIA - GE Healthcare,Sanofi Pasteur; RESEARCH/RESEARCH GRANTS - Arbor Pharmaceutical
McNamara	Dennis	Advances in HCM, PPCM and Other Cardiomyopathies	Multi-Fetal Gestation, Breastfeeding, Delivery Method and Myocardial Recovery in Peripartum Cardiomyopathy: Results From the Multicenter IPAC Study	CONSULTANT FEES/HONORARIA - GE Healthcare,Sanofi Pasteur; RESEARCH/RESEARCH GRANTS - Arbor Pharmaceutical
McNamara	Dennis	Put Your Codon! Genetic Insights Into Heart Failure	G-Protein Receptor Kinase 5 Polymorphisms and Outcomes in the African American Heart Failure Trial: Results From the Genetic Risk Assessment of Heart Failure in African-Americans Sub-Study	CONSULTANT FEES/HONORARIA - GE Healthcare,Sanofi Pasteur; RESEARCH/RESEARCH GRANTS - Arbor Pharmaceutical
McNamara	Dennis	13. Heart Failure and Cardiomyopathies: Clinical Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - GE Healthcare,Sanofi Pasteur; RESEARCH/RESEARCH GRANTS - Arbor Pharmaceutical
McNamara	Robert	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Does 3-Hour Point of Care Troponin I Predict 6-Hour Point of Care Troponin I for Patients in a Chest Pain Unit	OTHER - Pfizer Inc
McNeely	David	FIT Forum: Acing the Transition: What FITs Need to Know to Launch A Successful Career	Co-Chair	Nothing to Disclose
McNeely	David	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Comparison of Transesophageal Echocardiography and Computed Tomography Angiography for Left Atrial Appendage Evaluation Prior to WATCHMAN Implantation	Nothing to Disclose
McNeely	David	FIT Clinical Decision Making: Acute Coronary Syndrome and Vascular Medicine	Takayasu Arteritis Presenting as Syncope and "Pseudo- Hypotension" in a Young Caucasian Woman	Nothing to Disclose
McNeely McNeill	David Albert	FIT Clinical Decision Making Reviewers 5 Trends in Coronary Syndromes: International Perspectives From the ACC Great Britain and Ireland Chapter, Israel Heart Society, and American College of Cardiology	ACC FIT Clinical Decision Making Reviewer Co-Chair	Nothing to Disclose Nothing to Disclose
McNitt	Scott	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Sustained Clinical Benefit of Cardiac Resynchronization Therapy in Patients With Relatively Preserved Ejection Fraction: A MADIT-CRT Long-Term Follow-Up Sub-Study	Nothing to Disclose
McNitt	Scott	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Change in Renal Function During Extended Follow-Up After Left Ventricular Assist Device Implantation	Nothing to Disclose
McNulty	Edward	Updates in Stable Ischemic Heart Disease	Predictors of Long-Term Resource Utilization After Incident Percutaneous Coronary Intervention	Nothing to Disclose
McNulty	Steven	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Hemoconcentration During Management of Patients With Acute Heart Failure and Cardiorenal Syndrome: Insights From CARRESS-HF	Nothing to Disclose
McNulty	Steven	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Impact of Glucagon Like Peptide-1 Agonist Therapy on Heart Rate in Advanced Systolic Heart Failure: An Analysis From the Functional Impact of GLP-1 for Heart Failure Treatment Study	Nothing to Disclose
McNulty	Steven	The Old and the New: Impact of Heart Failure Drug Therapies	Liraglutide and Weight Loss Among Patients With Advanced Heart Failure and a Reduced Ejection Fraction: Insights From the FIGHT Trial	Nothing to Disclose
McPherson	John	Overcoming Today's Challenges to Launching and Growing Your Academic Medical Career: An Interactive Tutorial	Thriving in Academia Ii: Clinician-Educator	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Agrin, Inc.
McPherson	John	Test Yourself with Questions: Guidelines Module 4: Stable Ischemic Heart Disease	Faculty	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Agrin, Inc.
McPherson	John	Innovations in Education	Update on the ABIM's Competency Based Pilot in Internal Medicine- Cardiology	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Agrin, Inc.
McPherson	John	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Agrin, Inc.
	•	1	1	

Contract of the contract of th				
Last Name Meadows	First Name	Session Title	Presentation Title	Disclosures
ivieadows	Jeffery	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Safety and Feasibility of Melody Transcatheter Pulmonary Valve Replacement in the Native Right Ventricular Outflow Tract: A Multicenter Study	Nothing to Disclose
Meadows	Jeffery	Fontan in the Modern World	Prevalence of Elevated Body Mass Index and Its Association With Clinical Features in Adult Fontan Patients	Nothing to Disclose
Meany	Brendan	Coronary Intervention in Interventional	Facilitation of Stent Delivery With the GuideLiner Catheter	Nothing to Disclose
Meave	Aloha	Cardiology: Advanced Device Use Emerging Developments in HFpEF and	Diagnostic Utility of Goldberger's Electrocardiographic Triad in	Nothing to Disclose
Meave	Aloha	Arryhthmias Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Predicting Left Ventricular Dysfunction in Chagas' Heart Disease QRS Fragmentation Predicts Myocardial Fibrosis, Left Ventricular Dysfunction and Ventricular Tachycardia in Chagas´ Disease	Nothing to Disclose
Mada	Daniamin			Nothing to Displace
Meder	Benjamin	MicroRNAs and Beyond in Vascular Medicine	Disturbed Expression of Immunoregulatory Long Noncoding RNAs in Circulating Immune Cells From Patients With Early Myocardial Infarction	Nothing to Disclose
Meder	Benjamin	Mechanisms of Vascular Inflammation in Atherogenesis	Deficiency of Long Noncoding RNA <i>Malat1</i> Causes Immune System Deregulation and Accelerated Atherosclerosis in Apo E ^{-/-} Mice	Nothing to Disclose
Medina	Jesús	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of a Switch From Dual Antiplatelet Therapy to Single Antiplatelet Therapy in Diabetes and Non-Diabetes Post ACS: Insights From the EPICOR and EPICOR-Asia Studies	SALARY - AstraZeneca Pharmaceuticals
Medina	Jesús	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Predictors of Ischemic Events Within and After 1 Year After an Acute Coronary Syndrome: Results From the EPICOR Registry	SALARY - AstraZeneca Pharmaceuticals
Medina	Jose	Predicting Outcomes in Cardiac Rehabilitation Patients	The Association Between Waist-Hip Ratio With Long-Term Cardiovascular Events in Patients With Coronary Artery Disease: A	Nothing to Disclose
Maded	Christeehee	leter retire all in Core Consider It Oterratural	Population-Based Historical Cohort Study	CONCULTANT FFFCUIONOPADIA Postes Caisatés Falunda
Meduri	Christopher	Interventional Live Case Session I: Structural Transmission from Cleveland Clinic (Cleveland, Ohio)	Panelist	CONSULTANT FEES/HONORARIA - Boston Scientific,Edwards Lifesciences Mittralign; OTHER - Mittralign; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,MEDTRONIC; SPEAKER'S BUREAU - Edwards Lifesciences,MEDTRONIC
Meduri	Christopher	Great Minds Think Differently: Multidisciplinary Approach to Advanced Therapies	Keep it Simple: Minimally Invasive Strategies for TAVR	CONSULTANT FEES/HONORARIA - Boston Scientific,Edwards Lifesciences, Mitralign; OTHER - Mitralign; RESEARCH/IRESEARCH GRANTS - Edwards Lifesciences, MEDTRONIC; SPEAKER'S BUREAU - Edwards Lifesciences, MEDTRONIC
Meduri	Christopher	Moderated, Case-Based TAVR Management	Panelist	CONSULTANT FEES/HONORARIA - Boston Scientific,Edwards Lifesciences, Mitralign; OTHER - Mitralign; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, MEDTRONIC; SPEAKER'S BUREAU - Edwards
Meduri	Christopher	Moderated, Case-Based TAVR Management	Case Presentation: TAVR in MAC, Reducing the Risk of LVOT Obstruction	Lifesciences,MEDTRONIC CONSULTANT FEES/HONORARIA - Boston Scientific,Edwards Lifesciences,Mitralign; OTHER - Mitralign; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences,MEDTRONIC; SPEAKER'S BUREAU - Edwards Lifesciences,MEDTRONIC
Medvedofsky	Diego	Innovative Use of Echocardiography	Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography	Nothing to Disclose
Medvedofsky	Diego	New Technologies in Echocardiography	Three-Dimensional Echocardiographic Automated Quantification of Left Ventricular and Atrial Volumes Using Adaptive Analytics	Nothing to Disclose
Meeks	Brandi	Novel Developments in Acute Coronary	Algorithm: Feasibility in Non-Selected Patients Incidence and Predictors of No Reflow Phenomenon: Insights From	Nothing to Disclose
Meemook	Krissada	Syndromes Structural Heart Interventions: Focus on Mitral	the TOTAL Trial Impact of Residual Left Atrial Appendage Trabeculations After	Nothing to Disclose
Meemook	Krissada	Valve, Left Atrial Appendage and HOCM Structural Heart Interventions: Focus on Mitral	WATCHMAN Device Implantation in Atrial Fibrillation Patients Anemia Predicts Mortality in Atrial Fibrillation Patients Undergoing	Nothing to Disclose
Meemook	Krissada	Valve, Left Atrial Appendage and HOCM Interventional Cardiology: Structural Heart	Left Atrial Appendage Occlusion Using WATCHMAN Device Long-Term Durability of Percutaneous Mitral Valve Repair Using	Nothing to Disclose
Meems	Laura	Disease Young Investigator Awards Competition: Basic	MitraClip System: 8-Year Follow-Up NPA7, a First in Class Dual Receptor Activator With Cardio-	Nothing to Disclose
		and Translational Science	Renoprotective Properties <i> In Vivo</i>	-
Meems	Laura	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Intrarenal Renin Angiotensin System Activation: Pathophysiologic and Therapeutic Implications in Acute Decompensated Heart Failure	Nothing to Disclose
Meeran	Talha	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Non-Invasive Quantification of Cardiac Output With Phase Velocity Mapping in Patients With Pulmonary Hypertension	Nothing to Disclose
Meeran	Talha	Advances in Pulmonary Arterial Hypertension	A Cross Comparison Study of Right Ventricular Hypertrophy With Electrocardiography and Cardiac Magnetic Resonance in Patients	Nothing to Disclose
Meeusen	Jeffrey		With Pulmonary Hypertension Plasma Ceramide Concentrations Predict Risk of Cardiovascular	Nothing to Disclose
Mefford	Matthew	and Reduction Highlighted Original Research: Prevention and the Year in Review	Events PCSK9 Variants and Neurocognitive Impairment: Data From the REasons for Geographic and Racial Differences in Stroke	Nothing to Disclose
Mefford	Matthew	Advances in Cholesterol Measurement and Management	(REGARDS) Study Psychosocial Factors and Statin Intolerance: Data From the REasons for Geographic And Racial Differences in Stroke	Nothing to Disclose
Mefford	Matthew	Acute Coronary Syndromes, Diagnosis,	(REGARDS) Study Trends in the Use of High-Intensity Statin Therapy After Myocardial	Nothing to Disclose
Meguro	Kentaro	Management and Outcomes Antiplatelet and Antithrombotic Agents in	Infarction, 2011-2014 Stent Edge Strut on Normal Segment Is Less Covered in Early	Nothing to Disclose
Meguro	Kentaro	Ischemic Heart Disease Unusual Presentations of ACS	Phase After Drug Eluting Stent Implantation Lower Eicosapentaenoic Acid to Arachidonic Acid Ratio Is	Nothing to Disclose
Mehan	Mike	Advances in Cholesterol Measurement and Management	Associated With Intraplaque Cholesterol Crystals: An Optical Coherence Tomography Study Plasma Eicosapentaenoic Acid and the Eicosapentaenoic Acid to Arachidonic Acid Ratio in 8,010 Patients With Severely Elevated	SALARY - Boston Heart Diagnostics
Mehdirad	Ali	FIT Clinical Decision Making: Arrhythmias and	LDL-C (>190 mg/dl): Cause for Alarm? Neurogenic Orthostatic Hypotension as an Unexpected Etiology of	Nothing to Disclose
Mehdirad	Ali	Electrophysiology FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Recurrent Syncope Obscured by Atrial Flutter Unexpected Atrial Thrombus Discovered Post Intraoperative Maze Procedure: The Dilemma of Thrombus Screening Before	Nothing to Disclose
Mehdirad	Ali	FIT Clinical Decision Making: Arrhythmias and Clinical Electrophysiology	Percutaneous Pulmonary Vein Isolation Voltage-Dependent Inappropriate Right Ventricular Capture by Right Atrial Lead Pacing as a Cause of Cardiac Resynchronization	Nothing to Disclose
Mehilli	Julinda	Interventional Cardiology: TAVR 2	Therapy Non-Responder Impact of Single Versus Dual Anti Platelet Therapy on Early	Nothing to Disclose
			Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: From the WIN-TAVI Registry	
Mehilli Mehra	Julinda Anilkumar	Interventional Challenging Cases: Team 3 FIT Clinical Decision Making: Non-Invasive	ACC Challenging Case Reviewer Supravalvular Aortic Stenosis: A Rare Complication of Familial	Nothing to Disclose Nothing to Disclose
Mehra	Mandeep	Imaging and Valvular Heart Disease Clinical Challenges in the Cardiac Care Unit	Hypercholesterolemia Presenting as Cardiogenic Shock Management of Right Ventricular Failure in the CCU	CONSULTANT FEES/HONORARIA - J and J.MEDTRONIC,St.
		(CCU)	-	Jude Medical, Teva Pharmaceuticals CONSULTANT FEES/HONORARIA - J and J,MEDTRONIC, St. Jude Medical, Teva Pharmaceuticals
Mehra	Mandeep	Meeting of the Minds: HF and EP Decision Making for Complex Patients	Panelist	CONSULTANT FEES/HONORARIA - J and J,MEDTRONIC,St. Jude Medical,Teva Pharmaceuticals



Control of the contro				
Last Name Mehra	First Name Mandeep	Session Title 14. Heart Failure and Cardiomyopathies:	Presentation Title Suggested Reviewer	Disclosures CONSULTANT FEES/HONORARIA - J and J,MEDTRONIC,St.
Mehra	Vishal	Therapy Team 1 Contemporary Issues in Familial	The Hidden Burden of EHR-Identified Familial	Jude Medical,Teva Pharmaceuticals Nothing to Disclose
Mehran	Roxana	Hypercholesterolemia FIT Forum: Mix and Mingle	Hypercholesterolemia: Mortality and Clinical Outcomes 	



-		910		
Last Name Mehran	First Name Roxana	Session Title Core Curriculum: Revascularization in Special Populations	Presentation Title Chair	Disclosures CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems Inc, Medicines Company, Medscape, Merck & Bamp; amp; Co., Inc, Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular/AstraZeneca, AUM Cardiovascular Inc, Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli Lilly/DSI, MEDTRONIC, Novariis Pharmaceuticals, OrbusNeich, The Medicines Company, Watermark Research Partners
Mehran	Roxana	Highlighted Original Research: Interventional Cardiology and the Year in Review	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems Inc, Medicines Company, Mediscape, Merck & amp; amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular/AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli LillyDSI, MEDTRONIC, Novaris Pharmaceuticals, OrbusNeich, The Medicines Company, Watermark Research Partners
Mehran	Roxana	Considerations in Antiplatelet Therapy and in ACS	Effect of Thrombotic and Bleeding Risk According to Platelet Reactivity on 2-Year Mortality: The ADAPT-DES Study	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems inc. Medicines Company, Medscape, Merck & amp, amp; Co., inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli Lilly/DSI,MEOTRONIC, Novartis Pharmaceuticals, OrbusNeich, The Medicines Company, Watermark Research Partners
Mehran	Roxana	Considerations in Antiplatelet Therapy and in ACS	Platelet Reactivity and Outcomes After PCI of Lesions With and Without In-Stent Restenosis: The ADAPT-DES Study	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems Inc, Medicines Company, Mediscape, Merck & amp, amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMo Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli LillyDSI,MEDTRONIC, Novaris Pharmaceuticalis, OrbusNeich, The Medicines Company, Watermark Research Partners
Mehran	Roxana	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Atherosclerotic Plaque Morphology in Response to High Intensity Lipid Lowering Therapy by Multimodality Imaging Among Women and Men: A YELLOW-II Sub-study	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems Inc, Medicines Company, Medscape, Merck & amp, amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli Lilly/DSI,MEOTRONIC, Novartis Pharmaceuticals, OrbusNeich, The Medicines Company, Watermark Research Partners
Mehran	Roxana	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Platelet Reactivity and Outcomes After PCI of Saphenous Vein Grafts Versus Native Coronary Arteries: The ADAPT-DES Study	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems Inc. Medicines Company, Medscape, Merck & amp; amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company; RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca, AUM Cardiovascular Inc, Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli Lilly/DSI,MEOTRONIC, Novartis Pharmaceuticals, OrbusNeich, The Medicines Company, Watermark Research Partners
Mehran	Roxana	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Comparing PCI Outcomes in the Very Elderly: Does Age Matter? A Report From Outcomes of Septuagenarians, Octogenarians and Nonagenarians After PCI	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems Inc, Medicines Company, Medscape, Merck & Amp, amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company; RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca, AUM Cardiovascular Inc, Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli LillyDSI,MEDTRONIC, Novartis Pharmaceuticals, OrbusNeich, The Medicines Company, Watermark Research Partners



Carry Contract of the Contract				
Last Name	First Name		Presentation Title	Disclosures
Mehran	Roxana	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Twelve Month Follow-Up Data From the ONYX CORE Trial: Angiographic and Clinical Performance of Next Generation Resolute Onyx Drug-Eluting Stent	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems Inc, Medicines Company, Medscape, Merck & amp; amp; Co., Inc., Shanghai Braccosine Pharmaceutical Copr, The Medicines Company, DATA SAFETY MONITORING BOARD - Watemark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company; RESEARCH/RESEARCH GRANTS - Abbott Vascular/AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli Lilly/DSI.MEDTRONIC, Novaris Pharmaceuticals, OrbusNeich, TI Medicines Company, Watermark Research Partners
Mehran	Roxana	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Clinical Outcomes Associated With Impella Versus IABP Use in Stable Patients Undergoing High Risk Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems inc, Medicines Company, Medscape, Merck & amp; amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli Lilly/DSI, MEDTRONIC, Novartis Pharmaceuticals, OrbusNeich, TI Medicines Company, Watermark Research Partners
Mehran	Roxana	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Impella or Intra-Aortic Balloon Pump Support in Patients Undergoing High Risk Percutaneous Coronary Intervention: A Real World Single Center Experience	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems Inc, Medicines Company, Medscape, Merck & Ramp; amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceutical, Inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company; RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli Lilly/DSI,MEDTRONIC, Novartis Pharmaceuticals, OrbusNeich, Ti Medicines Company, Watermark Research Partners
Mehran	Roxana	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Differences and Level of Agreement in SYNTAX Score Assessment Between Site Operators and Angiographic Core Laboratory Readers: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Boston Scientific,Cardiovascular Systems inc,Medicines Company,Medscape,Merck & Amp,amp, Co., Inc.,Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Watemark Research Partners; OTHER - Janssen Pharmaceuticals, Inc,Osprey Medical, WebMD, Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular,AstraZeneca,AUM Cardiovascular Inc.,Bayer Healthcare Pharmaceuticals,Beth Israel Deaconess Medical Center,Bristol-Myers Squibb Company, CSL Behring, Eli Lily/DSI,MEDTRONIC, Novaris Pharmaceuticals,OrbusNeich,TI Medicines Company, Watermark Research Partners
Mehran	Roxana	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems Inc, Medicines Company, Medscape, Merck & Ramp; amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Elii Llily/DSI, MEDTRONIC, Novartis Pharmaceuticals, OrbusNeich, Ti Medicines Company, Watermark Research Partners
Mehran	Roxana	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Angiographic Phenotype and Clinical Outcomes of Patients With Malignancy Undergoing PCI	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems inc, Medicines Company, Medscape, Merck & amp;amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular-AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli LIII/yDSI, MEDTRONIC, Novartis Pharmaceuticals, OrbusNeich, TI Medicines Company, Watermark Research Partners
Mehran	Roxana	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems Inc, Medicines Company, Medscape, Merck & Amp; amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company; RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eii Lilly/DSI,MEDTRONIC, Novartis Pharmaceuticals, OrbusNeich, Ti Medicines Company, Watermark Research Partners



Contract of the contract of th				
	First Name	Session Title	Presentation Title	Disclosures
Mehran	Roxana	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Synergistic Effects of Coronary Calcification and Inflammation on Risks for Adverse Cardiovascular Events After PCI: Results From a Large Single-Center Registry	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems Inc, Medicines Company, Medscape, Merck & Amp; amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMo, Wiley Blackwell Publishing Company; RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli Lilly/DSI.MEDTRONIC, Novartis Pharmaceuticals, OrbusNeich, Th Medicines Company, Watermark Research Partners
Mehran	Roxana	Vascular Access and Hemostasis Issues	Mortality, Length of Stay, and Cost Implications of Procedural Bleeding After Contemporary Percutaneous Interventions Involving Large-Bore Catheters	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems Inc, Medicines Company, Medscape, Merck & Amp; amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli LIII/VDSI, MEDTRONIC, Novartis Pharmaceuticals, OrbusNeich, Th Medicines Company, Watermark Research Partners
Mehran	Roxana	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Multimodality Intravascular Imaging to Evaluate Plaque Characteristics in Patients With Diabetes Mellitus	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems Inc, Medicines Company, Medscape, Merck & Amp, amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company; RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli Lilly/DSI,MEDTRONIC, Novartis Pharmaceuticals, OrbusNeich, Th Medicines Company, Watermark Research Partners
Mehran	Roxana	Novel Developments in Acute Coronary Syndromes	Trends in Incidence and Mortality Associated With Acute Kidney Injury in Patients Undergoing PCI for Acute Coronary Syndrome	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Boston Scientific,Cardiovascular Systems Inc,Medicines Company,Medscape,Merck &,amp; Co., Inc.,Shanghai BraccoSine Pharmaceutical Corp,The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc.Osprey Medical, WebMo, Wiley Blackwell Publishing Company; RESEARCH/RESEARCH GRANTS - Abbott Vascular,AstraZeneca,AUM Cardiovascular Inc.,Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli Lilly/DSI,MEDTRONIC, Novartis Pharmaceuticals, OrbusNeich,Th Medicines Company, Watermark Research Partners
Mehran	Roxana	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: From the WIN-TAVI Registry	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems Inc, Medicines Company, Medscape, Merck & Amp, amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli Islly/DSI, MEDTRONIC, Novartis Pharmaceuticals, OrbusNeich, Th Medicines Company, Watermark Research Partners
Mehran	Roxana	Interventional Cardiology: PCI and TAVR in Complex Patients	Long-Term Adverse Ischemic Outcomes After Percutaneous Coronary Intervention Among Patients With Versus Without Prior Coronary Artery Bypass Grafting: Analysis From 17 Randomized Trials	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems inc, Medicines Company, Medscape, Merck & Amp; amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli Islly/DSI,MEDTRONIC, Novartis Pharmaceuticals, OrbusNeich, Th Medicines Company, Watermark Research Partners
Mehran	Roxana	Interventional Cardiology: PCI and TAVR in Complex Patients	Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the Bravo-3 Randomized Trial	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems Inc, Medicines Company, Medscape, Merck Aamp; amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company; RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Elii Lilly/DSI,MEDTRONIC, Novartis Pharmaceuticals, OrbusNeich, Th Medicines Company, Watermark Research Partners



Last Name Mehran	First Name Roxana	Session Title Interventional Cardiology: PCI and TAVR in Complex Patients	Presentation Title Timing and Algorithm of Permanent Pacemaker Implantation After TAVR	Disclosures CONSULTANT FEES/HONORARIA - Astraz CONSULTANT FEES/HONORARIA - Astraz Pharmaceuticals, Boston Scientific, Cardiovass Inc., Medicines Company, Medscape, Merck & alnc., Shanghal BraccoSine Pharmaceutical Company, DATA SAFETY MONITORING BC Research Partners; OTHER - Janssen Pharn Inc, Osprey Medical, WebMD, Wiley Blackwell Company, RESEARCH/RESEARCH GRANT Vascular, AstraZeneca, AUM Cardiovascular In Healthcare Pharmaceuticals, Beth Israel Deac Center, Bristol-Myers Squibb Company, CSL Lilly/DSI, MEDTRONIC, Novartis Pharmaceutic Medicines Company, Watermark Research P.	cular Systems mp;amp; Co., prp,The Medicines NARD - Waternark naceuticals, Publishing 'Se - Abbott ncBayer coness Medical Behring, Eli cals,OrbusNeich,The artners
Mehran	Roxana	Timely Topics in Acute Coronary Syndromes	Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions	CONSULTANT FEES/HONORARIA - Astraz Pharmaceuticals,Boston Scientific,Cardiovas Inc,Medicines Company,Medscape,Merck & Inc,Shanghai BraccoSine Pharmaceutical C Company; DATA SAFETY MONITORING BC Research Partners; OTHER - Janssen Pharn Inc,Osprey Medical,WebMD,Wiley Blackwell Company; RESEARCH/RESEARCH GRANT Vascular AstraZeneca,AUM Cardiovascular In Healthcare Pharmaceuticals,Beth Israel Dea Center, Bristol-Myers Squibb Company, CSL Lilly/DSI,MEDTRONIC,Novartis Pharmaceutic Medicines Company,Watermark Research P.	cular Systems imp; amp; Co., prp, The Medicines NARD - Waternark naceuticals, Publishing 'S - Abbott nc., Bayer coness Medical Behring, Eli cals, OrbusNeich, The artners
Mehran	Roxana	Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes	CONSULTANT FEES/HONORARIA - AstraZ Pharmaceuticals,Boston Scientific,Cardiovas Inc,Medicines Company,Medscape,Merck & Inc.,Shanghai BraccoSine Pharmaceutical C Company; DATA SAFETY MONITORING BC Research Partners; OTHER - Janssen Pharm Inc,Osprey Medical,WebMD,Wiley Blackwell Company; RESEARCH/RESEARCH GRANT Vascular,AstraZeneca,AUM Cardiovascular In Healthcare Pharmaceuticals,Beth Israel Dea Center,Bristol-Myers Squibb Company; CSL Lilly/DSI,MEDTRONIC, Novartis Pharmaceutif Medicines Company,Watermark Research P.	cular Systems mp;amp; Co., prp, The Medicines NARD - Watemark naceuticals, Publishing 'S - Abbott nc.,Bayer coness Medical Behring, Eli cals,OrbusNeich,The
Mehran	Roxana	Non Invasive Imaging: Prognostic Implications of CT Angiography	The Relationship Between Pericardial Adipose Tissue Volume, Atherosclerotic Plaque Type and Cardiovascular Risk: A High Risk Plaque Biolmage Sub-Study	CONSULTANT FEES/HONORARIA - Astraz Pharmaceuticals, Boston Scientific, Cardiovas Inc., Medicines Company, Medscape, Merck & Inc., Shanghai BraccoSine Pharmaceutical Company, DATA SAFETY MONITORING BC Research Partners; OTHER - Janssen Pharm Inc., Osprey Medical, Webbid, Wiley Blackwell Company; RESEARCH/RESEARCH GRANT Vascular, AstraZeneca, AUM Cardiovascular In Healthcare Pharmaceuticals, Beth Israel Deac Center, Bristol-Myers Squibb Company, CSL Lilly/DSI, MEDTRONIC, Novartis Pharmaceutic Medicines Company, Watermark Research P.	cular Systems imp;amp; Co., orp,The Medicines oARD - Waternark naceuticals, Publishing 'S - Abbott nc.,Bayer coness Medical Behring ,Eli cals,OrbusNeich,The
Mehran	Roxana	Advances in Chronic Total Occlusion Intervention	is Platelet Reactivity Associated With Ischemic Events Following Successful Chronic Total Occlusion Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - AstraZ Pharmaceuticals, Boston Scientific, Cardiovasa inc, Medicines Company, Medscape, Merck & Inc., Shanghai BraccoSine Pharmaceutical Ci. Company; DATA SAFETY MONITORING BC. Research Partners; OTHER - Janssen Pharn Inc, Osprey Medical, WebMD, Wiley Blackwell Company; RESEARCH/RESEARCH GRANT Vascular, AstraZeneca, AUM Cardiovascular I Healthcare Pharmaceuticals, Beth Israel Deau Center, Bristol-Myers Squibb Company, CSL Lilly/DSI,MEDTRONIC, Novartis Pharmaceutik Medicines Company, Watermark Research P.	cular Systems mp;amp; Co., prp, The Medicines NARD - Waternark naceuticals, Publishing 'S - Abbott nc.,Bayer coness Medical Behring, Eli cals,OrbusNeich,The
Mehran	Roxana	Optimizing the Care of ACS Patients	Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population	CONSULTANT FEES/HONORARIA - AstraZ Pharmaceuticals, Boston Scientific, Cardiovasa Inc, Medicines Company, Medscape, Merck & Inc., Shanghai BraccoSine Pharmaceutical Company; DATA SAFETY MONITORING BC Research Partners; OTHER - Janssen Pharn Inc, Osprey Medical, WebMD, Wiley Blackwell Company; RESEARCH/RESEARCH GRANT Vascular, AstraZeneca, AUM Cardiovascular In Healthcare Pharmaceuticals, Beth Israel Deac Center, Bristol-Myers Squibb Company, CSL LIII/yDSI,MEDTRONIC, Novartis Pharmaceutic Medicines Company, Watermark Research P.	cular Systems mp;amp; Co., orp, The Medicines NARD - Watemark naceuticals, Publishing 'S - Abbott nc.,Bayer coness Medical Behring, Eli cals,OrbusNeich,The
Mehran	Roxana	Interventional Complexity and Complications	Prediction of Acute Kidney Injury in Patients Undergoing Coronary Intervention Using Calculation of Serum Osmolality	CONSULTANT FEES/HONORARIA - AstraZ Pharmaceuticals, Boston Scientific, Cardiovas Inc, Medicines Company, Medscape, Merc As Inc., Shanghai BraccoSine Pharmaceutical C. Company; DATA SAFETY MONITORING BC. Company; DATA SAFETY MONITORING BC. Research Partners; OTHER - Janssen Pharn Inc, Osprey Medical, WebMD, Wiley Blackwell Company; RESEARCH/RESEARCH GRANT Vascular AstraZeneca, AUM Cardiovascular In Healthcare Pharmaceuticals, Beth Israel Dea Center, Bristol-Myers Squibb Company, CSL Lilly/DSI,MEDTRONIC, Novartis Pharmaceutic Medicines Company, Watermark Research P.	cular Systems imp;amp; Co., orp;The Medicines ARD - Waternark naceuticals, Publishing 'S - Abbott nc.,Bayer coness Medical Behring ,Eli cals,OrbusNeich,The



and a				<u> </u>
Last Name Mehran	First Name Roxana	Session Title Interventional Cardiology: PCI in Complex Patients	Presentation Title Risk and Impact of Diabetes Mellitus on Ischemic Events in Females and Males After Percutaneous Coronary Intervention	Disclosures CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Boston Scientific,Cardiovascular Systems Inc,Medicines Company,Medscape,Merck & Bamp;amp, Co., Inc.,Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company; DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc,Osprey Medical, WebMD, Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular AstraZeneca,AUM Cardiovascular Inc.,Bayer Healthcare Pharmaceuticals,Beth Israel Deaconess Medical Center,Bristol-Myers Squibb Company, CSL Behring, Eli Lilly/DSI,MEDTRONIC,Novartis Pharmaceuticals,OrbusNeich,The Medicines Company,Watermark Research Partners
Mehran	Roxana	Interventional Cardiology: PCI in Complex Patients	Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated Heparin Following Transcatheter Aortic Valve Replacement: Results From the Bravo-3 Randomized Trial	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Boston Scientific,Cardiovascular Systems Inc,Medicines Company,Medscape,Merck & Co., Inc.,Shanghai BraccoSine Pharmaceutical Corp,The Medicines Company; DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc,Osprey Medical,WebMD,Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular,AstraZeneca,AUM Cardiovascular Inc.,Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center,Bristol-Myers Squibb Company, CSL Behring, Eli Lilly/DSI,MEDTRONIC, Novartis Pharmaceuticals, OrbusNeich,The Medicines Company, Watermark Research Partners
Mehran	Roxana	Refining PCI Technique and Outcomes	Treatment of Left Main Coronary Artery Disease in Patients With Diabetes: 3-Year Outcomes Comparing CABG and PCI With Everolimus-Eluting Stents From the EXCEL Study	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Boston Scientific,Cardiovascular Systems Inc,Medicines Company,Mediscape,Merck & Co., Inc,Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc,Osprey Medical,WebMD,Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular,AstraZeneca,AUM Cardiovascular Inc.,Bayer Healthcare Pharmaceuticals,Beth Israel Deaconess Medical Center,Bristol-Myers Squibb Company, CSL Behring, Eli Lilly/DSI,MEDTRONIC,Novartis Pharmaceuticals,OrbusNeich,The Medicines Company,Watermark Research Partners
Mehran	Roxana	Refining PCI Technique and Outcomes	Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory Assessment: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals Boston Scientific, Cardiovascular Systems Inc, Medicines Company, Medscape, Merck & amp;amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical WebhD, Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli Lilly/DSI,MEDTRONIC, Novaris Pharmaceuticals, OrbusNeich, The Medicines Company, Watermark Research Partners
Mehran	Roxana	19. Interventional Cardiology: Complex Patients/Comorbidities Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Boston Scientific,Cardiovascular Systems Inc,Medicines Company,Medscape,Merck & Co., Inc,Shanghai BraccoSine Pharmaceutical Corp,The Medicines Company; DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc,Osprey Medical,WebMD,Wiley Blackwell Publishing Company; RESEARCH/RESEARCH GRANTS - Abbott Vascular/AstraZeneca AUM Cardiovascular Inc,Bayer Healthcare Pharmaceuticals,Beth Israel Deaconess Medical Center,Bristol-Myers Squibb Company, CSL Behring, Eli Lilly/DSI,MEDTRONIC,Novartis Pharmaceuticals,OrbusNeich,The Medicines Company,Watermark Research Partners
Mehran	Roxana	Interventional Challenging Cases: Team 3	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boston Scientific, Cardiovascular Systems Inc, Medicines Company, Medscape, Merck & amp; amp; Co., Inc., Shanghai BraccoSine Pharmaceutical Corp, The Medicines Company, DATA SAFETY MONITORING BOARD - Waternark Research Partners; OTHER - Janssen Pharmaceuticals, Inc, Osprey Medical, WebMD, Wiley Blackwell Publishing Company, RESEARCH/RESEARCH GRANTS - Abbott Vascular AstraZeneca, AUM Cardiovascular Inc., Bayer Healthcare Pharmaceuticals, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb Company, CSL Behring, Eli Lilly/DSI,MEDTRONIC, Novartis Pharmaceuticals, OrbusNeich, The Medicines Company, Watermark Research Partners
Mehrotra	Praveen	The Best Structural Interventional Challenging	To Close or Not to Close: Percutaneous Treatment of Acquired	Nothing to Disclose
Mehrotra	Praveen	Cases Interventional Cardiology: TAVR 1	Gerbode Defect Hands Down: Operator Hand Versus Torso Radiation Exposure	Nothing to Disclose
Mehrotra	Praveen	Interventional Cardiology: TAVR 1	During Transcatheter Aortic Valve Replacement Provider Radiation Exposure During Transcatheter Aortic Valve	Nothing to Disclose
Mehrotra Mehta	Praveen Ashwani	36. Valvular Heart Disease: Clinical Team 1 Interventional Cardiology: Structural Heart Disease	Replacement Suggested Reviewer Safety and Feasibility of Rotational Atherectomy in Elderly Patients With Severe Aortic Stenosis and Calcific Coronary Artery Disease Undergoing Evaluation for Transcatheter Aortic Valve Replacement	Nothing to Disclose Nothing to Disclose
Mehta	Ashwani	Interventional Cardiology: PCI in Complex Patients	Clinical Presentation, Natural History and Management of Coronary Artery Ectasia	Nothing to Disclose
Mehta	Cyrus	The Intersection of Diabetes and ASCVD	Average Clinician Measured Blood Pressure Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes Following Acute Coronary Syndromes in the EXAMINE Trial	Nothing to Disclose
Mehta	Davendra	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Impact of End Stage Renal Disease in Patients Hospitalized for Systolic and Diastolic Heart Failure: A Nationwide Analysis of 2013	Nothing to Disclose
Mehta	Davendra	Arrhythmias and Clinical EP: Devices 4	Subxiphoid Air Leading to Inappropriate Shock in a Subcutaneous Cardiac Defibrillator	Nothing to Disclose

Contract of the second				
Mehta	First Name Davendra	Session Title Unusual Presentations of ACS	Presentation Title Stress Induced Cardiomyopathy (Takotsubo Cardiomyopathy): Mortality, Gender and Admission Month Based on a Nationwide	Disclosures Nothing to Disclose
Mehta	Hetal	FIT Clinical Decision Making: Arrhythmias and	Sample During 2013 Flecainide and Traumatic Syncope: Don't Forget It	Nothing to Disclose
Mehta	Hetal	Electrophysiology FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Anterolateral Papillary Muscle Rupture: A Rare Complication of Acute Myocardial Infarction	Nothing to Disclose
Mehta	Kartik	Disease, and Vascular Medicine Arrhythmias and Clinical EP: Devices 2		Nothing to Disclose
Mehta	Laxmi	Are We There Yet? The Long Journey to	Implantation Co-Chair	Nothing to Disclose
Mehta	Laxmi	Health Equity: Part III Are We There Yet? The Long Journey to	Introduction to Session	Nothing to Disclose
Mehta	Nehal	Health Equity: Part III Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Small Dense Low Density Lipoprotein Particle Number Relates to Coronary Plaque Burden Independent of Traditional Cardiovascular Risk Factors in Psoriasis	Nothing to Disclose
Mehta	Nehal	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Aortic Vascular Inflammation by 18-FDG PET/CT Associates With High-Risk Coronary Plaques in Young Psoriasis Patients	Nothing to Disclose
Mehta	Nehal	Vascular Medicine: New Insights Into Aortic and Peripheral Artery Diseases	Improvement in Cholesterol Efflux Capacity Is Associated With Improvement in Vascular Inflammation by 18- FDG PET CT in Psoriasis	Nothing to Disclose
Mehta	Nehal	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Improvement in Cholesterol Efflux Capacity Is Associated With a Reduction in Aortic Wall Thickness by MRI Independent of Traditional CV Risk Factors	Nothing to Disclose
Mehta	Nehal	Updates on Risk Factors for Cardiovascular Disease	Visceral but Not Subcutaneous Adipose Tissue Associates With Vascular Inflammation by 18-FDG PET/CT in Psoriasis	Nothing to Disclose
Mehta	Nehal	01. Acute and Stable Ischemic Heart Disease: Basic Team 2	Suggested Reviewer	Nothing to Disclose
Mehta	Neil	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Estimating Cancer Risk Associated With Ionizing Radiation Exposure During Atrial Fibrillation Ablation	Nothing to Disclose
Mehta	Nikhil	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Exposure During Atrial Fibrillation Ablation A Case of Unexplained Syncope and Type 1 Inducible Brugada Syndrome	Nothing to Disclose
Mehta	Nikhil	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Transient Brugada Pattern in Diabetic Ketoacidosis	Nothing to Disclose
Mehta	Nikhil	FIT Clinical Decision Making: Arrhythmias and	Treating Sustained Ventricular Tachycardia With Digoxin	Nothing to Disclose
Mehta	Puja	Electrophysiology Angina in the Absence of Obstructive CAD.	Expert Review: Evaluating for and Treating Endothelial Dysfunction	RESEARCH/RESEARCH GRANTS - General Electric, Gilead
Mehta	Puja	What Do We Do With These Patients? Get into the Beat! Exercise to Promote CV	Co-Chair	Sciences, Inc. RESEARCH/RESEARCH GRANTS - General Electric, Gilead
Mehta	Puja	Health Obesity Management in 2017: Weighing the	ACC Poster Moderator	Sciences, Inc. RESEARCH/RESEARCH GRANTS - General Electric, Gilead
Mehta	Puja	O1. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Sciences, Inc. RESEARCH/RESEARCH GRANTS - General Electric, Gilead
Mehta	Rajendra	Basic Team 2 Joint American College of Cardiology/New England Journal of Medicine Late-Breaking	Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery With Cardiopulmonary Bypass:	Sciences, Inc. Nothing to Disclose
Mehta	Rupa	Clinical Trials Young Investigator Awards Competition: Outcomes Research	Primary Results of the LEVO-CTS Trial A Bundled Intervention Including Early Consultation With a Cardiologist in the Emergency Department to Reduce Re- Hospitalizations and Healthcare Cost for High-Risk Urban Patients	CONSULTANT FEES/HONORARIA - Astellas Pharma
Mehta	Shamir	Considerations in Antiplatelet Therapy and in	With Acute Decompensated Heart Failure Effects of Ticagrelor Versus Clopidogrel in Fibrinolytic-Treated	RESEARCH/RESEARCH GRANTS - AstraZeneca
Mehta	Shamir	ACS Novel Developments in Acute Coronary	STEMI Patients Undergoing Early PCI Incidence and Predictors of No Reflow Phenomenon: Insights From	Pharmaceuticals,Boston Scientific RESEARCH/RESEARCH GRANTS - AstraZeneca
Mehta	Shamir	Syndromes Novel Developments in Acute Coronary Syndromes	the TOTAL Trial Utility of Unfractionated Heparin in Transradial Cardiac Catheterization: A Systematic Review and Meta-Analysis of	Pharmaceuticals,Boston Scientific RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals,Boston Scientific
Mehta	Shamir	02. Acute and Stable Ischemic Heart Disease:	Randomized Studies Suggested Reviewer	RESEARCH/RESEARCH GRANTS - AstraZeneca
Meier	Bernhard	Clinical Team 8 Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Previous Major Gastrointestinal Bleeding: Insight From the Amplatzer Cardiac Plug Multicenter Registry	Pharmaceuticals.Boston Scientific CONSULTANT FEESHONORARIA - Abbott,AGA medical,Boston Scientific,Cordis,MEDTRONIC,St. Jude; RESEARCH/RESEARCH GRANTS - Abbott,AGA medical,Boston Scientific,Cordis,MEDTRONIC,St. Jude; SPEAKER'S BUREAU - Abbott,AGA medical,Boston Scientific,Cordis,MEDTRONIC
Meireles	George	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Intravascular Imaging Comparison of Two Metallic Limus-Eluting Stents Abluminally Coated With Biodegradable Polymers: IVUS and OCT Results of the DESTINY Trial	Nothing to Disclose
Mejia Lopez	Eliany	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Submassive Pulmonary Embolism With Concomitant Paradoxical Embolism Through Patent Foramen Ovale	Nothing to Disclose
Mejia Lopez	Eliany		A Case of Atypical Cardiac Tamponade With Isolated Left Ventricular Compression	Nothing to Disclose
Mejia-Lopez	Eliany	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Changes in Renal Perfusion Pressure During Hemodynamically Guided Therapy Is Associated With Worsening Renal Function	Nothing to Disclose
Melby	Spencer	Interventional Cardiology: TAVR 4	Depression as a Potential Therapeutic Target to Improve Quality of Life After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Melduni	Rowlens	Valvular Heart Disease: Aortic Stenosis	Sinus Rhythm Versus Atrial Fibrillation & It Clinical Profile and Natural History of Patients With Severe Aortic Stenosis Managed Medically	Nothing to Disclose
Melduni	Rowlens	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Valvular Surgery With or Without Left Atrial Appendage Excision for Atrial Fibrillation: A CHA2DS2VASc Matched Analysis of	Nothing to Disclose
Mele	Eduardo	Resistant Hypertension in the Pulmonary and Systemic Beds: International Perspectives From the ACC Argentina Chapter, Korean Society of Cardiology, and American College of Cardiology	Thromboembolic Outcomes in a National Database Co-Chair	Nothing to Disclose
Melendez	Giselle	The Evolving World of LVADs, Transplant and	Frequency of Transition From Stage A to B or C Heart Failure After	Nothing to Disclose
Melendez	Giselle	Other Novel Discoveries Advances in Imaging to Assess Cardiotoxicity	Potentially Cardiotoxic Chemotherapy Decreases in Left Ventricular Mass and Not Left Ventricular Ejection Fraction Are Associated With Heart Failure Symptoms in Cancer Patients Six Months After Potentially Cardiotoxic Chemotherapy	Nothing to Disclose
Melendez-Ramirez	Gabriela	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	QRS Fragmentation Predicts Myocardial Fibrosis, Left Ventricular Dysfunction and Ventricular Tachycardia in Chagas´ Disease	Nothing to Disclose
Melenovsky	Vojtech	Emerging Developments in HFpEF and Arryhthmias	The Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: An Invasive- Echocardiographic Study	Nothing to Disclose
Melenovsky	Vojtech	Emerging Developments in HFpEF and Arryhthmias	Arterial Reserve Limitations in Heart Failure With Preserved Ejection Fraction and the Beneficial Effects of Sodium Nitrite	Nothing to Disclose

Contract of the contract of th				I
Last Name Melgarejo Rojas	First Name Enrique	Session Title The Burden of Heart Failure: International	Presentation Title Co-Chair	Disclosures Nothing to Disclose
Weigarejo Rojas	Lilique	Perspectives From the Chilean Society of	CO-Offaii	Nothing to Disclose
		Cardiology, Colombian Society of Cardiology, and American College of Cardiology		
Meliga	Emanuele	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve	Nothing to Disclose
			Replacement: From the WIN-TAVI Registry	
Melnitchouk	Serguei	Novel Determinants of Outcomes in VHD	Relationship Between Proximal Aorta Morphology and Progression Rate of Aortic Stenosis	Nothing to Disclose
Meloni	Luigi	Advances in HCM, PPCM and Other	Tako Tsubo Cardiomyopathy or Myocarditis?	Nothing to Disclose
Melquist	Stacey	Cardiomyopathies Highlighted Original Research: Vascular	RNAi-Based Therapeutic Targeting Factor 12 as a Prophylactic	SALARY - Arrowhead Pharmaceuticals
		Medicine and the Year in Review	Treatment for Thromboembolism	
Memon	Shermeen	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	(In)Equity in Primary Prevention Statin Treatment Among Diabetics	Nothing to Disclose
Memon	Shermeen	Non Invasive Imaging: Expanding Clinical Applications	Aortic Valve Calcification Predicts Paravalvular Aortic Regurgitation After Self-Expanding Transcatheter Aortic Valve Replacement	Nothing to Disclose
Menachem	Jonathan	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	RVOT-VTI/PASP: A Novel Non-Invasive Metric of Pulmonary Arterial Compliance and Diastolic Pressure Gradient Status in Heart Failure	Nothing to Disclose
Maria III dada	0.1		With Preserved Ejection Fraction	CONOUL TANT FEFOUR ON OR AREA DATA A LANGUE MEDITIONIO
Mena-Hurtado	Carlos	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Radiotracer Imaging Allows for Assessment of Serial Changes in Angiosome Foot Perfusion Following Revascularization and Predicts	CONSULTANT FEES/HONORARIA - Bard, Cook, MEDTRONIC
			Limb Salvage Outcomes in Patients With Critical Limb Ischemia	
Mena-Hurtado	Carlos	Nuclear Cardiology: Beyond Perfusion	Radiotracer Imaging of Angiosome Foot Perfusion Correlates With	CONSULTANT FEES/HONORARIA - Bard, Cook, MEDTRONIC
			Ankle-Brachial Index and Differentiates Critical Limb Ischemia Patients From Healthy Subjects	
Menard	Matthew	Maximally Effective Vascular Care: Vascular	Case Presentation #2: Panelist	CONSULTANT FEES/HONORARIA - Aralez, Proteon
Menard	Matthew	Collaborative Team Care in Action Maximally Effective Vascular Care: Vascular	Case Presentation #4: Panelist	CONSULTANT FEES/HONORARIA - Aralez, Proteon
		Collaborative Team Care in Action		
Menard	Matthew	Clinical Assessment and Revascularization for Critical Limb Ischemia	Surgical Therapies for CLI	CONSULTANT FEES/HONORARIA - Aralez, Proteon
Mendelsohn	Farrell	Novel Mechanical Devices for the Treatment	Endovascular Carotid Barostimulation for Resistant Hypertension: A	Nothing to Disclose
Mendelson	Marla	and Assessment of Hypertension FIT Clinical Decision Making: Interventional	Safety and Proof-of-Principle Cohort Study Exertional Chest Pain and Dynamic ST-Segment Changes in a	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart	Pregnant Patient With Systemic Lupus Erythematosus: A Case of	
Mendes	Lisa	Disease, and Vascular Medicine Stress Echocardiography: Best Practices and	Preeclampsia-Induced Ischemia Co-Chair	Nothing to Disclose
Mandaa	Lina	Emerging Applications Test Yourself with Questions: General	Equility	Nothing to Displace
Mendes	Lisa	Cardiology Module 14	Faculty	Nothing to Disclose
Mendes	Lisa	Innovations in Education	Update on the ABIM's Competency Based Pilot in Internal Medicine- Cardiology	Nothing to Disclose
Mendes	Lisa	Engage @ ACC.17 Studio: FIT Jeopardy Battle		Nothing to Disclose
Mendes	Lisa	of the State Chapters II FIT Clinical Decision Making: Acute Coronary	Takayasu Arteritis Presenting as Syncope and "Pseudo-	Nothing to Disclose
		Syndrome and Vascular Medicine	Hypotension" in a Young Caucasian Woman	-
Mendes	Lucas	Nuclear Cardiology: Prognosis	Rest Myocardial Perfusion Imaging in the Management of Chest Pain: A Feasible and Secure Protocol in a Brazilian Emergency	Nothing to Disclose
Mandista Harrandan	l	FIT Clinical Decision Melitary Multimedality	Department	Nothing to Displace
Mendieta Hernandez	Juan	FIT Clinical Decision Making: Multimodality Imaging	Ventricular Septal Dissection With Rupture and Large NeoCavity After Inferior ST Elevation Myocardial Infarction in a Patient With	Nothing to Disclose
Mendirichaga	Rodrigo	Arrhythmias and Clinical EP: Ventricular	Recent Coronary Artery Bypass Grafts Percutaneous Epicardial Mapping and Ablation of Ventricular	Nothing to Disclose
		Tachycardia	Tachycardia: A Systematic Review of Safety Outcomes	-
Mendirichaga	Rodrigo	Advances in HCM, PPCM and Other Cardiomyopathies	Extended Remission and Late Re-Decompensation of Dilated Cardiomyopathy Associated With a Novel Ribonucleic Acid Binding	Nothing to Disclose
Mary de	0		Motif Protein 20 (RBM20) Mutation	OONOU TANT FFFOUNDADIA
Mendiz	Oscar	New Perspectives on Structural Valve Disease: International Perspectives From the Emirates	Expanding Indications of TAVR	CONSULTANT FEES/HONORARIA - AstraZeneca,MEDTRONIC,Terumo,Terumo
		Cardiac Society, Latin American Society of Interventional Cardiology (SOLACI), and		
		American College of Cardiology		
Mendoza	Dorinna	FIT Clinical Decision Making: Heart Failure and	Constrictive Pericarditis Due to Kawasaki Disease	Nothing to Disclose
		Pulmonary Hypertension		-
Mendoza	Ivan	Imaging and Infections: International Perspectives From the Spanish Society of	Cardiac Involvement in Zika and Chikungunya Virus Infection	Nothing to Disclose
		Cardiology, Venezuelan Society of Cardiology, and American College of Cardiology		
Mendoza	Ivan	Emerging Developments in HFpEF and Arryhthmias	Myocarditis, Heart Failure and Arrhythmias in Patients With Zika	Nothing to Disclose
Mendoza	Ivan	Emerging Developments in HFpEF and	Myocarditis, Heart Failure and Arrhythmias in Patients With Zika	Nothing to Disclose
Menegus	Mark	Arryhthmias Cardiac Arrest, Diabetes, and Other High Risk	Sex Differences in Revascularization and In-Hospital Outcomes of	Nothing to Disclose
1		Features of Patients With Acute Coronary Syndrome	Non-ST-Segment Elevation Myocardial Infarction in the United States	
Menegus	Mark	Interventional Cardiology: TAVR 3	Regional Variations in In-Hospital Outcomes and Healthcare	Nothing to Disclose
			Resource Utilization in Patients Undergoing Transcatheter Aortic Valve Replacement in the United States	
Menegus	Mark	Antithrombotic Therapy in Ischemic Heart	Role of Anticoagulation Therapy After Anterior Wall ST-Elevation	Nothing to Disclose
		Disease	Myocardial Infraction in Preventing LV Thrombus: A Meta-Analysis and Meta-Regression	
Menegus	Mark	Arrhythmias and Clinical EP: Syncope and	Association of Academic Year-End Changeover With Survival Rates	Nothing to Disclose
		Other EP Issues	After In-Hospital Cardiac Arrest: An Examination of the "July Effect"	
Menegus	Mark	Optimizing the Care of ACS Patients	Weekend Versus Weekday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide	Nothing to Disclose
			Analysis	
Meneguz-Moreno	Rafael	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Independent Pre Procedural Echocardiographic Predictors of Mitral Valve Restenosis After Percutaneous Mitral Balloon Valvuloplasty in	Nothing to Disclose
		, zore and reportudge and record	a Large Consecutive Cohort Followed Up to Two Decades	
Meneguz-Moreno	Rafael	Interventional Cardiology: Structural Heart	Initial Results and Long-Term Follow-Up of Percutaneous Mitral	Nothing to Disclose
		Disease	Valvuloplasty in Patients With Pulmonary Hypertension	-
Meneguz-Moreno	Rafael	Frontiers in Mitral Valve Disease and Treatment	Predictors of Immediate and Very Late Events After Percutaneous Mitral Valvuloplasty	Nothing to Disclose
Meneveau	Nicolas	Interventional Cardiology: PCI in Complex Patients	Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated Heparin Following Transcatheter Aortic Valve Replacement: Results	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals,
		I dicino	From the Bravo-3 Randomized Trial	Inc,Bristol-Myers Squibb Company ,Edwards Lifesciences,St Jude
[I	1		Medical

Last Name	First Name	Session Title	Presentation Title	Disclosures
Meneveau	Nicolas	Unusual Presentations of ACS	Characteristics and Outcomes of Patients Discharged Without Statins After an Acute Myocardial Infarction: An Analysis From the Combined FAST-MI 2005-2010 Cohorts	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb Company, Edwards Lifesciences, St Jude Medical
Menezes	Fernando	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	The Role of Oral Beta Blocker in a Real-World Population With Non- ST Segment Elevation Acute Coronary Syndromes	Nothing to Disclose
Menezes	Fernando	Antithrombotic Therapy in Ischemic Heart Disease	Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease	Nothing to Disclose
Meng	Xiaoping	7th Annual ACC China Chapter Session: Endless Change and Evolution in Cardiovascular Prevention and Rehabilitation	Effectiveness Evaluation for AMI Patients' Cardio-Pulmonary Rehabilitation	Nothing to Disclose
Mengesha	Tadele	Considerations in Antiplatelet Therapy and in	Contemporary Outcomes of Anterior Segment ST-Elevation	Nothing to Disclose
Mengesha	Tadele	ACS Arrhythmias and Clinical EP: Basic 3	Myocardial Infarction: A Large 10-Year Tertiary Care Experience Impact of Obstructive Sleep Apnea Severity on Cardiac Events in	Nothing to Disclose
Mengesha	Tadele	Vascular Access and Hemostasis Issues	Patients With Normal or Prolonged Ventricular Repolarization Clinical Efficacy of SoftSeal-STF Hemostatic Pad With Short Hold Time Compared to Traditional Manual Compression After	Nothing to Disclose
Mengesha	Tadele	Interventional Cardiology: PCI and TAVR in Complex Patients	Transfemoral Catheterization The Risk of Adverse Coronary Events Is Higher in Patients With Severe Obstructive Sleep Apnea Following Percutaneous Coronary Intervention	Nothing to Disclose
Menon	Vandana	Acute Heart Failure: Evaluating Strategies to	A Simple Predictive Score for Pre-Admission Identification of Risk of	Nothing to Disclose
Menon	Venu	Prevent Readmissions Clinical Challenges in the Cardiac Care Unit	30-Day Hospital Readmission or Death in Heart Failure There's More Than the Heart in the CCU	Nothing to Disclose
Menon	Venu	GCCU) Global Perspectives in the Treatment of ST Elevation Myocardial Infarction: Successes,	Co-Chair	Nothing to Disclose
Menon	Venu	Failures, and Challenges Recent ACS Trials: Relevance to My Daily	Co-Chair	Nothing to Disclose
Menon	Venu	Practice Acute Cardiogenic Shock: Progress, Paradigm,	Co-Chair	Nothing to Disclose
Menon	Venu	and Unresolved Problems Acute Cardiogenic Shock: Progress, Paradigm,	The Top 5 Reasons We Fail to Succeed When Managing	Nothing to Disclose
Menon	Venu	and Unresolved Problems Coronary Intervention in Interventional	Cardiogenic Shock in 2017 Veno-Arterial ECMO Program for Refractory Cardiogenic Shock in	Nothing to Disclose
Menon	Venu	Cardiology: Advanced Device Use Valvular Heart Disease: Aortic Regurgitation	the Cardiac Intensive Care Unit: Feasibility and Outcome Data at a Large Tertiary Academic Center Etiology, Patient Characteristics and Surgical Outcomes of Acute	Nothing to Disclose
			Severe Aortic Regurgitation Declining Survival With Decreasing Exercise Time on Treadmill:	Nothing to Disclose
Menon	Venu	Updates on Risk Factors for Cardiovascular Disease	Lessons From a 25-Year Cohort	,
Menon	Venu	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Baseline Characteristics, Management and Outcomes in Mitral Valve Prolapse With Manifest Ventricular Automaticity	Nothing to Disclose
Menon	Venu	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Clevedipine as a Therapeutic and Cost-Effective Alternative to Sodium Nitroprusside in Patients With Aortic Dissection	Nothing to Disclose
Menon	Venu	Post-CAD/MI: Making Tough Predictions About the Future	ACC Poster Moderator	Nothing to Disclose
Menon	Venu	Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	Referral for Pharmacologic Testing, a Marker of Poor Exercise Capacity, Confers a Higher Risk of Short and Long Term Mortality Than Most Traditional Cardiac Risk Factors Except Age	Nothing to Disclose
Menon	Venu	New Perspectives on CAD Risk Factors	Changing Trends of Atherosclerotic Risk Factors Among Patients With Acute Myocardial Infarction and Acute Ischemic Stroke	Nothing to Disclose
Menon	Venu	02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Menon	Venu	Clinical Team 1 Interventional Challenging Cases: Team 3	ACC Challenging Case Reviewer	Nothing to Disclose
Mentias	Amgad	Non Invasive Imaging: MR Scar and Perfusion	Incremental Prognostic Utility of Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy	Nothing to Disclose
Mentz	Robert	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Timing and Clinical Predictors of Early Versus Late Readmission Among Patients Hospitalized for Acute Heart Failure: Insights From ASCEND-HF	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc.;HeartWare,Janssen,Luitpold Pharmaceuticals, Inc.;Thoratec; RESEARCH/RESEARCH GRANTS - Amgen,AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb Company (SILEAD Sciences,GlaxoSmithKline,Luitpold Pharmaceuticals, Inc,MEDTRONIC,Merck & Amp,amp; Co., Inc.,Novartis Corporation,Otsuka Pharmaceutical Co., Resemed
Mentz	Robert	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Hemoconcentration During Management of Patients With Acute Heart Failure and Cardiorenal Syndrome: Insights From CARRESS- HF	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc.;HeartWare, Janssen, Luitpold Pharmaceuticals, Inc.;Thoratec; RESEARCH/RESEARCH GRANTS - Amgen, AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb Company, GILEAD Sciences, GlaxoSmithKline, Luitpold Pharmaceuticals, Inc.,MEDTRONIC,Merck & Dr., 200, Inc., Novartis Corporation, Olsuka Pharmaceutical Co., Resmed
Mentz	Robert	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Time of Presentation Among Patients Hospitalized for Acute Heart Failure (Clinical Characteristics, Initial Therapies and Outcomes): Insights From ASCEND-HF	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc.HeartWare, Janssen, Luitpold Pharmaceuticals, Inc.Thoratec; RESEARCH/RESEARCH GRANTS - Amgen, AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb Company, GILEAD Sciences, GlaxoSmithKline, Luitpold Pharmaceuticals, Inc, MEDTRONIC, Merck & Amp; amp; Co., Inc., Novartis Corporation, Otsuka Pharmaceutical Co., Resemed
Mentz	Robert	Emerging Developments in HFpEF and Arryhthmias	Effects of Age and Comorbidities on Outcomes in Patients With Heart Failure From HF-ACTION	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc, HeartWare, Janssen, Lutipold Pharmaceuticals, Inc, Thoratice; RESEARCH/RESEARCH GRANTS - Amgen, AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb Company, GILEAD Sciences, GlaxoSmithKline, Lutipold Pharmaceuticals, Inc, MEDTRONIC, Merck & Amp, amp; Co., Inc., Novartis Corporation, Otsuka Pharmaceutical Co., Resemed
Mentz	Robert	Why Can't We Be Friends? Controversies in Heart Failure Management	Prevalent Digoxin Use Is Not Associated With Increased Risk of Death or Hospitalization in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc., HeartWare, Janssen, Luitpold Pharmaceuticals, Inc., Thoratice; RESEARCH/RESEARCH GRANTS - Amgen, AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb Company, GILEAD Sciences, GlaxoSmithKline, Luitpold Pharmaceuticals, Inc., MEDTRONIC, Merck & Amp; amp; Co., Inc., Novartis Corporation, Otsuka Pharmaceutical Co., Resemed

March Tell	W. T.				<u> </u>
Part Table Sharperpoint Part Table Sharperpoint Part Table Sharperpoint Part Table Sharperpoint Part	Last Name	First Name	Session Title	Presentation Title	Disclosures
Novel 1992 And Sevent Control Service Services (Services Services	Mentz	Robert		Heart Failure With Reduced Ejection Fraction: A Cohort Study From	Pharmaceuticals, Inc,HeartWare,Janssen,Luitpold Pharmaceuticals, Inc,Thoratec ; RESEARCH/RESEARCH
Record					Healthcare Pharmaceuticals,Bristol-Myers Squibb Company ,GILEAD Sciences,GlaxoSmithKline,Luitpold Pharmaceuticals, Inc,MEDTRONIC,Merck & Co., Inc.,Novartis
Fairber and Richard Special Prison Region from the FOST Professor Control of the	Mentz	Robert	The Old and the New: Impact of Heart Failure	I iraniutide and Weight Loss Among Patients With Advanced Heart	
Service	Wenz	Robert		Failure and a Reduced Ejection Fraction: Insights From the FIGHT	Pharmaceuticals, Inc, HeartWare, Janssen, Luitpold Pharmaceuticals, Inc, Thoratec; RESEARCH/RESEARCH GRANTS - Amgen, AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb Company, GILEAD Sciences, GlaxoSmithKline, Luitpold Pharmaceuticals, Inc, MEDTRONIC, Merck & Amp; amp; Co., Inc., Novartis
Marcial	Meraj	Perwaiz	Complications of PCI: Case Reviews	Case Presentation: Perforation	CONSULTANT FEES/HONORARIA - Abiomed Inc., Medtronic
Mary Services. Concept Number Products	Meraj	Perwaiz	PCI for NSTEMI and Complex Patients With		CONSULTANT FEES/HONORARIA - Abiomed Inc., Medtronic
Personal Conditions Animated Devices Use	Merai	Perwaiz			
Symbol Obsession Pervisite Previsite Obsession Pervisite Obsession Pervisite Obsession Pervisite Obsession Pervisite Obsession Pervisite Obsession Pervisite Obsession Pervisite	-		Cardiology: Advanced Device Use	Cardiogenic Shock	Inc.; RESEARCH/RESEARCH GRANTS - Medtronic Inc.
Description of the Control of the Co	-		Syndromes	With Acute Coronary Syndrome	Inc.; RESEARCH/RESEARCH GRANTS - Medtronic Inc.
Secretary With Annual Secretary Systems (1997) Personal Design Control Processing Contro	Meraj	Perwaiz			
Moreign Province Antiquement and Antipromotion Agents in Seventional Youngs United Concept (March Moreign Province) and Antipromotion Agents (March Province) and Agents (March Province	Meraj	Perwaiz	Optimizing the Care of ACS Patients	Unfractionated Heparin Is Superior to Bivalirudin in Transradial	
Mercade Marco Anthony Intervention February (1997) A processor of Vision Intervention February (1997) A processor of Vision Intervention February (1997) A processor of Vision Intervention February (1997) A processor of Vision Intervention	Meraj	Perwaiz		Bivalirudin Versus Unfractionated Heparin Monotherapy in	CONSULTANT FEES/HONORARIA - Abiomed Inc., Medtronic
Morositer Moro Morositer March Control (1997). A price and State (Inches) (1997). A price of the control (1997) and the control (1997) an	Morai	Ponyois		Adverse Outcomes	
Mercanic Murco Fil Control Dicasion Nakang Mathemotility Reciping 9th Gold, Pullimonility in aging in a 5th Year Cide Protect Micros Rosa Laura Congenital Heart Disease. Invasions in Superior Reciping 9th Gold, Pullimonility in aging in a 5th Year Cide Protect Micros Rosa Laura Congenital Heart Disease. Approaches in Congenital Heart Disease. Approaches in Congenital Heart Disease. Approaches in Congenital Heart Disease. Approaches in Congenital Heart Disease. Micros III Market Mathew Reciping 10 Market Mathematics of Control Mathematics (Control Mathematics Approaches in Congenital Heart Disease. Approaches in Congenital Heart Disease. Micros III Mathematics Arthylmines Colorones Will Control Mathematics Scholmes and Acquation Prophocies Facility For Indiancy Arthylmines Colorones Will Control Mathematics Scholmes and Acquation Prophocies Study Protection Protection Scholmes and Acquation Prophocies Study Protection Protection Scholmes and Acquation Protection Scholmes and Acq	-		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	From latrogenic Right Coronary Artery Dissection Managed With Impella CP and Impella RP	Inc.; RESEARCH/RESEARCH GRANTS - Medtronic Inc.
Mercar Posts August Designation Naverg Malmodality in Sodge Person Company (1997) and Sodge Members (1997) and Sodge Memb	Mercader	Marco	Arrhythmias and Clinical EP: Devices 2		
Marcor Rosa Laura Congrental Heart Desease Involvations in Impact of Home Method Program on Internage Montality and Section (1998) Marcor Rosa Approaches in Congretal Heart Disease Approaches	Mercader	Marco		Bridging the Gap: Multimodality Imaging in a 56 Year Old Patient	OTHER - Amazon; OWNERSHIP
Approaches Laura Congenital Head Disease: New Disproaches Replit Venification Contraction Research to Reduced in Children and Approaches Replit Venification Contraction Research to Replication Replit Venification Contraction Research to Replication Repli	Mercer-Rosa	Laura	Congenital Heart Disease: Innovations in	Impact of Home Monitoring Program on Interstage Mortality and	
Morecus Methode Variation in the Use of National Controllogy Chamero, Worldward Variation in the Use of National Controllogy Chamero, Worldward Variation in the Use of National Controllogy Chamero, Worldward Variation in the Use of National Controllogy Chamero, Worldward Variation in the Use of National Variation in the Use of National Variation in the Use of National Variation in Controllogy Protected Study (MCAPS) Morecus Michael Controllogy Arthythmiae Colutionate Private Medical Controllogy Protected Study (MCAPS) Morecus Michael Controllogy Arthythmiae Colutionate Private Medical Private Variation in Controllogy Controllogy Controllogy Protected Study (MCAPS) Morecus Michael Controllogy Controllog	Mercer-Rosa	Laura	Congenital Heart Disease: New Diagnostic	Right Ventricular Contractile Reserve Is Reduced in Children and	Nothing to Disclose
Mercuri Michele Farinatory Arrhythmass Culticanes With Enrollege From the IAA Nuclear Cardiology Produces Study Michele Arrhythmass and Culticated EP. Affected and the IAA Nuclear Cardiology Produces Study Michele Arrhythmass and Culticated EP. Affected and the IAA Nuclear Cardiology Produces Study Michele Arrhythmass and Culticated EP. Affected and the IAA Nuclear Cardiology Produces Study Michele Arrhythmass and Culticated EP. Affected and the IAA Nuclear Cardiology Arrhythmas and Culticated EP. Affected Arrhythmass And Cardiology Arrhythmass Cardiology Cardiology Cardiology Cardiology T.AVF 3 An Interventional Cardiology T.AVF 3 An Interventional Cardiology T.AVF 3 An Interventional Cardiology T.AVF 3 An Interventional Cardiology T.AVF 3 An Interventional Cardiology T.AVF 3 An Interventional Cardiology T.AVF 3 An Interventional Cardiology T.AVF 3 An Interventional Cardiology T.AVF 3 An Interventional Cardiology T.AVF 3 An Interventional Cardiology T.AVF 3 An Interventional Cardiology T.AVF 3 An Interventional Cardiology T.AVF 3 An Interventional Cardiology Cardiol	Manaziri	Mathani		Study	Nething to Displace
Contemporary Practice	Mercuri	Mathew	Nuclear Cardiology: Quality	Technology, Reconstruction Software, and Acquisition Protocols: Findings From the IAEA Nuclear Cardiology Protocols Study	Nothing to Disclose
Mercuri Mchele Arthyfimias and Clinical EP. AF Mocellaneous and Surgicula EP. AF Mocellaneous and Surgicula EP. AF Mocellaneous and Surgicula EP. AF Mocellaneous and Surgicula EP. AF Mocellaneous and Surgicula EP. AF Mocellaneous and Surgicula EP. AF Mocellaneous and Surgicula EP. AF Mocellaneous and Surgicula EP. AF Mocellaneous and Surgicula EP. AF Mocellaneous and Surgicula EP. AF Mocellaneous and Surgicula EP. AF Mocellaneous EP. AF Mocel	Mercuri	Michele			SALARY - Daiichi Sankyo
Microsin Michele Stroke and AF: Thinking About the Heart and Active Miligrancy. An Analysin of ENAGAE AF: Timil 48 Not investion and Active Miligrancy. An Analysin of ENAGAE AF: Timil 48 Not investion and Cardiology: TAVR 3 (Edge Valve System: Results From the LOTUS Edge Feability) frish the New Generation LOTUS (Edge Valve System: Results From the LOTUS Edge Feability) frish the New Generation LOTUS (Edge Valve System: Results From the LOTUS Edge Feability) frish the New Generation LOTUS (Edge Valve System: Results From the LOTUS Edge Feability) frish the New Generation LOTUS (Edge Valve System: Results From the LOTUS Edge Feability) frish the New Generation Lotus (Edge Valve System: Results From the LOTUS Edge Feability) frish the New Generation Lotus (Edge Valve System: Results From the LOTUS Edge Feability) frish the New Generation Lotus (Edge Valve System: Results From the LOTUS Edge Feability) frish Middle Micronic Vascular Morpholy (Edge Valve System: Results From the LOTUS Edge Feability) frish Middle Micronic Vascular Morpholy (Edge Valve System: Results From the EVOXX El Randowski Evore Vascular Morpholy (Edge Valve System: Results From the LOTUS Edge Feability) frish Middle Micronic Vascular Morpholy (Edge Valve System: Results From the LOTUS Edge Feability) frish Middle Micronic Vascular Morpholy (Edge Valve System: Results From the LOTUS Edge Feability) frish Middle Micronic Vascular Morpholy (Edge Valve	Mercuri	Michele	Arrhythmias and Clinical EP: AF Miscellaneous	Association of Genetic Risk Score with Burden of Atrial Fibrillation:	SALARY - Daiichi Sankyo
Meredith Isin Sterventional Cardiology, TAVR 3 Site Report of Clinical Outcomes With the Next-Generation LOTUS Edge Passibility Trial Medical Meditionic Vascular First Report of Clinical Controller Stephen Non-Invasive Imaging, Prognostic Implications of CT Angiography OCT Angiography	Mercuri	Michele		Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation	SALARY - Daiichi Sankyo
Edge Valve System: Results From the LOTUS Edge Feasibility Trial Medical Medician Vascular	Maradith	lan	Interventional Cardiology, TAVP 3	Randomized Clinical Trial	CONSULTANT EEES/HONODADIA Roston Scientific Elivir
Meredith Ian Refining PCI Technique and Outcomes Care Service Cardiovascular Events: insights Medical Meditronic Vascular Refining PCI Technique and Outcomes Care Service Ser				Edge Valve System: Results From the LOTUS Edge Feasibility Trial	Medical,Medtronic Vascular
Clinical Outcomes With Bioresorbable Compared to Permanent Medical Meditonic Vascular			of CT Angiography	Morphology Predicts Major Adverse Cardiovascular Events: Insights From a 19,943 Patient Meta-Analysis	Medical,Medtronic Vascular
Of the American Medical Association Late- Exportation Mimetic on Coronary Afterosclerosis: Results of the BUREAU_MEDTRONIC,St_Jude Medical CARAT Stilling Ching Trials				Clinical Outcomes With Bioresorbable Compared to Permanent Polymer Everolimus-Eluting	Medical,Medtronic Vascular
Failure Gadgete Galore Long Term Mortality and Echocardiographic Response in CRT BUREAU - MEDTRONIC, St. Jude Medical Patients Patien	Merkely	Bela	of the American Medical Association Late- Breaking Clinical Trials	Lipoprotein Mimetic on Coronary Atherosclerosis: Results of the CARAT Study	BUREAU - MEDTRONIC,St. Jude Medical
Merloco Anthony Anthony Non Invasive Imaging: MR Characterization And Function Anthony Michael Anthony Michael Anthony Anthony Anthony Anthony Non Invasive Imaging: MR Characterization And Function Free-Breathing Michael FIT Forum: Acing the Transition: What FiTs Need to Know to Launch A Successful Career Merloco Messe Gardos Mon Invasive Imaging: Role of Exercise Testing Single Ventricle Heart Disease: Innovations in Single Ventricle Heart Disease: Innovations in Single Ventricle Heart Disease Merloco Mon Invasive Imaging: Role of Exercise Testing Single Ventricle Heart Disease Messe Messe Messe Messe Messe Messe Messe Messe Messe Messe Messe Messe Messe Messenger John Messenger John Messenger John Messenger John Messenger John Antiplatelet and Antithrombotic Agents in Ischemic Heart Diseases Messenger John Antiplatelet and Antithrombotic Agents in Ischemic Heart Diseases Messenger John Messenger John Antiplatelet and Antithrombotic Agents in Ischemic Heart Diseases Messenger John Messenger John Messenger John Antiplatelet and Antithrombotic Agents in Ischemic Heart Diseases Messenger John Messenger John Messenger John Antiplatelet and Antithrombotic Agents in Ischemic Heart Diseases Messenger John Messenger John Messenger John Messenger John Antiplatelet and Antithrombotic Agents in Ischemic Heart Diseases Messenger John Messenger John Messenger John Messenger John Messenger John Antiplatelet and Antithrombotic Agents in Ischemic Heart Diseases Messenger John Mes	Merkely	Bela		Long Term Mortality and Echocardiographic Response in CRT	
Merril	Merkely	Bela	Non Invasive Imaging: Role of Exercise Testing		
Merhall Michael FIT Forum: Acing the Transition: What FITS Need to Know to Launch A Successful Career Need to Know to Launch A Successful Career Need to Know to Launch A Successful Career Need to Know to Launch A Successful Career Need to Know to Launch A Successful Career Need to Know to Launch A Successful Career Need to Know to Launch A Successful Career Need to Know to Launch A Successful Career Need to Launch A Successful Career Need to Launch A Successful Career Need to Launch A Successful Career Need to Launch A Successful Career Need to Launch A Successful Career Need to Launch A Successful Particular Remodelling in Hypoplastic Left Heart Syndrome: Nothing to Disclose Impact of the Norwood and Hybrid Procedures Nothing to Disclose Single Ventricle Heart Disease Surgical Heart Disease	Merlocco	Anthony			Nothing to Disclose
Mery Carlos Congenital Heart Disease Impact of the Norwood and Hybrid Procedures Single Ventricle Heart Disease Innovations in Single Ventricle Heart Disease Single Ventricle Heart Disease Pallaidon in Patients With Single Ventricle Physiology? Nothing to Disclose Pallaidon in Patients With Single Ventricle Physiology? Nothing to Disclose Normal Mercent	Merrill	Michael	FIT Forum: Acing the Transition: What FITs		Nothing to Disclose
Carlos Congenital Heart Disease: Innovations in Single Ventricle Heart Disease Palliation in Patients With Single Ventricle Physiology?	Mertens	Luc			Nothing to Disclose
Single Ventricle Heart Disease Palliation in Patients With Single Ventricle Physiology?	Mery	Carlos		Impact of the Norwood and Hybrid Procedures Is a Pulsatile Glenn an Adequate Alternative for Long-Term	Nothing to Disclose
Coronary Artery Results Following a Standardized Approach Messe Steven Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Chinical Trials Clinical Trials Messenger John FIT Forum: Mix and Mingle Outcomes Research Messenger John Novel Echocardiographic Methods for Assessing Cardiac Function Messenger John Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease: Bededing and Premature Antiplatelet Therapy Discontinuation After Myocardial Infarction Among Patients With Chronic Kidney Disease Messenger John John John Antiplatelet and Stable Ischemic Heart Disease: Basic Team 2 Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Metha Davendra Mero Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Coronary Artery Protection Devices During Surgical Aortic Valve Replaced Approach Cerebral Embolic Protection Devices During Surgical Aortic Valve Replaced Approach Cerebral Embolic Protection Devices During Surgical Aortic Valve Replaced Approach Cerebral Embolic Protection Devices During Surgical Aortic Valve Replaced Approach Cerebral Embolic Protection Devices During Surgical Aortic Valve Replaced Approach Cerebral Embolic Protection Devices During Surgical Aortic Valve Replaced Approach Cerebral Embolic Protection Devices During Surgical Aortic Valve Replaced Approach Cerebral Embolic Protection Devices During Surgical Aortic Valve Cerebral Embolic Protection Devices During Surgical Aortic Valve Cerebral Embolic Protection Devices During Surgical Aortic Valve Cerebral Embolic Protection Prevent Readmissions Cerebral Embolic Prevent Readmission Agenating Englacement A Randomized Trial Front the Cardiothoracc Surgical Aortic Valve Cerebral Englacement A Randomized Trial Front the Cardiothoracc Surgical Protection Patients Older Than 80 Years: A Nothing to Disclose Consultant Fellure: Insights Fron Consultant Fellure: Insights Fron Consultant Fellure: Insights Fron Consultant Valve Annulus and Se	-		Single Ventricle Heart Disease	Palliation in Patients With Single Ventricle Physiology?	ů
England Journal of Medicine Late-Breaking Cinical Trials Surgical Trials Prownth Cardiothoracic Surgical Trials Network				Coronary Artery: Results Following a Standardized Approach	•
Messenger John Novel Echocardiographic Methods for Assessing Cardiac Function Novel Echocardiographic Methods for Assessing Cardiac Function Novel Echocardiographic Methods for Expandable Transactatheter Aortic Valve Replacement on the Dimensions of the Mitral Valve Annulus and Mitral Regurgitation Severity Messenger John Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease Messenger John O1. Acute and Stable Ischemic Heart Disease: Suggested Reviewer Basic Team 2 Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Metha Davendra Davendra Merco Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Consultant Fees/HONORARIA - none Consultant Fees/HONORARIA - none Davadra Plate Finance Consultant Fees/Honorary Acute Disease Early Versus Delayed Invasive Intervention for Acute Heart Readmissions Timing and Clinical Predictors of Early Versus Late Readmission Timing and Clinical Predictors of Early Versus Late Readmission Consultant Fees/Honorary Acute Disease Consultant Fees/Honorary Antery Disease Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Consultant Fees/Honorary Interpolation for Acute Heart Failure: Insights From			England Journal of Medicine Late-Breaking Clinical Trials	Replacement: A Randomized Trial From the Cardiothoracic Surgical Trials Network	
Assessing Cardiac Function Expandable Transcatheter Aortic Valve Replacement on the Dimensions of the Mitral Valve Annulus and Mitral Regurgitation Severity Messenger John Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease: Messenger John O1. Acute and Stable Ischemic Heart Disease: Bieeding and Premature Antiplatelet Therapy Discontinuation After Mycoardial Infarction Among Patients With Chronic Kidney Disease Messenger John O1. Acute and Stable Ischemic Heart Disease: Basic Team 2 Messerli Franz Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Aftery Disease and Preserved Left Ventricular Function Metha Davendra PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities Metra Marco Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Annong Patients Hospitalized for Acute Heart Failure: Insights From DATA SAFETY MONITORING BOARD - Novate Medical			FIT Forum: Mix and Mingle Novel Echocardiographic Methods for		
Messenger John Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease Messenger John On Acute and Stable Ischemic Heart Disease: Basic Team 2 Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease and Preserved Left Ventricular Function Metha Davendra PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities Metra Marco Marco Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Metha Ischemic Heart Disease: Bleeding and Premature Antiplatelet Therapy Discontinuation After Myocardial Infarction Among Patients Hospitals With Chronic Kidney Disease DATA SAFETY MONITORING BOARD - Novate Medical DATA SAFETY MONITORING BOARD - Novate Medical DATA SAFETY MONITORING BOARD - Novate Medical DATA SAFETY MONITORING BOARD - Novate Medical DATA SAFETY MONITORING BOARD - Novate Medical CONSULTANT FEES/HONORARIA - Pfizer, Abbott, Servier, Medtronic, Ipca Laboratories Ltd., Daiichi-Sankyo, Menarini Metra Marco Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Among Patients Hospitalized for Acute Heart Failure: Insights From	gg.			Expandable Transcatheter Aortic Valve Replacement on the Dimensions of the Mitral Valve Annulus and Mitral Regurgitation	S. S. S. S. S. S. S. S. S. S. S. S. S. S
Basic Team 2	Messenger	John		Bleeding and Premature Antiplatelet Therapy Discontinuation After	DATA SAFETY MONITORING BOARD - Novate Medical
Messerii Franz Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease and Preserved Left Ventricular Function Metronic, Ipca Laboratories Ltd., Dalichi-Sankyo, Menarini Metronic PC for NSTEMI and Complex Patients With Multiple Co-Morbidities Metro Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Metra Marco Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Messenger	John		Suggested Reviewer	DATA SAFETY MONITORING BOARD - Novate Medical
Coronary Artery Disease	Messerli	Franz	Traditional and Novel Factors Used to Assess		
Multiple Co-Morbidities Elevation Myocardial Infarction in Patients Older Than 80 Years: A Nationwide Analysis Metra Marco Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Among Patients Hospitalized for Acute Heart Failure: Insights From CONSULTANT FEES/HONORARIA - none	Metha	Davendra	Coronary Artery Disease		·
Prevent Readmissions Among Patients Hospitalized for Acute Heart Failure: Insights From			Multiple Co-Morbidities	Elevation Myocardial Infarction in Patients Older Than 80 Years: A Nationwide Analysis	-
	ivietra	iviarco		Among Patients Hospitalized for Acute Heart Failure: Insights From	CONSULTANT FEES/HUNUKARIA - none

Last Name	First Name	Session Title	Presentation Title	Disclosures
Metra	Marco	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Time of Presentation Among Patients Hospitalized for Acute Heart Failure (Clinical Characteristics, Initial Therapies and Outcomes): Insights From ASCEND-HF	CONSULTANT FEES/HONORARIA - none
Metra	Marco	14. Heart Failure and Cardiomyopathies: Therapy Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - none
Metzger	D. Christopher	18. Interventional Cardiology: Carotid and Endovascular Intervention Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular,Bard,Boston Scientific,Cordis,MEDTRONIC,Trivascular
Metzger	D. Christopher	Interventional Challenging Cases: Team 3	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular,Bard,Boston Scientific,Cordis,MEDTRONIC,Trivascular
Metzger	David	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Platelet Reactivity and Outcomes After PCI of Saphenous Vein Grafts Versus Native Coronary Arteries: The ADAPT-DES Study	CONSULTANT FEES/HONORARIA - Abbott Vascular,Bard,Boston Scientific,Cordis,MEDTRONIC,Trivascular
Metzger	David	Advances in Chronic Total Occlusion Intervention	Is Platelet Reactivity Associated With Ischemic Events Following Successful Chronic Total Occlusion Percutaneous Coronary	CONSULTANT FEES/HONORARIA - Abbott Vascular,Bard,Boston Scientific,Cordis,MEDTRONIC,Trivascular
Metzler	Bernhard	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Intervention Antecedent Hypertension and Myocardial Injury in Patients With Reperfused ST-Elevation Myocardial Infarction	Nothing to Disclose
Metzler	Bernhard	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Fibroblast Growth Factor 23 as Novel Biomarker for Early Risk Stratification After ST-Elevation Myocardial Infarction	Nothing to Disclose
Mewissen	Mark W.	Interventional Complexity and Complications	Percutaneous Femoral Artery Access Strategies in Patients Undergoing Peripheral Vascular Intervention: Trends of Use and In- Hospital Outcomes	CONSULTANT FEES/HONORARIA - Endologix,MEDTRONIC
Meyer	David	Congenital Heart Disease Surgery: Updates and Innovations	Promoting Pulmonary Arterial Growth via Right Ventricular to Pulmonary Artery Conduit Placement in Children With Pulmonary Atresia and Hypoplastic Pulmonary Arteries	Nothing to Disclose
Meyer	Theo	FIT Clinical Decision Making: Non-Invasive	Distinguishing True Versus Pseudo Aortic Valve Stenosis in a	Nothing to Disclose
Meyer	Theo	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Prevention, Adult	Patient With No Contractile Reserve A Mimicker of Rheumatic Heart Disease: Congenital Polyvalvular	Nothing to Disclose
Meyghani	Zahra	Congenital and Congenital Heart Disease Vascular Medicine: Novel Risk Measures in	Disease Association of Coronary Artery Calcium With Incident Peripheral	Nothing to Disclose
Mezue	Kenechukwu	Arterial Diseases Considerations in Antiplatelet Therapy and in	Artery Disease: The Multi-Ethnic Study of Atherosclerosis Chronovariability of Platelet Reactivity With the Hemodialysis Cycle	Nothing to Disclose
Mi	Xiaojuan	ACS Heart Failure and Cardiomyopathies: Is Heart	Heart Failure With Reduced Ejection Fraction Care Patterns in the	Nothing to Disclose
Michaels	Alexander	Failure With a Normal EF for Real? Acute Heart Failure: Evaluating Strategies to	Outpatient Practice Setting: Initial Findings From CHAMP-HF No MAGGIC in Predicting Heart Failure Readmissions	Nothing to Disclose
Michalis		Prevent Readmissions Interventional Cardiology: Intravascular		-
Michalis	Lampros	Physiology and Endothelial Function	Association of Coronary Epicardial Endothelial Dysfunction With Low Endothelial Shear Stress in Patients With Mild Coronary Atherosclerosis Who Presented With Chest Pain	Nothing to Disclose
Michaud Finch	Jennifer	Hearts and Soles: Multimodality Imaging in Athletes	Temporal Sequence of Athlete's Heart Regression During Prescribed Exercise Detraining: <i>Diagnostic Implications</i>	Nothing to Disclose
Michelena	Hector	The Spectrum of Aortic Regurgitation and Aortic Pathology	Case: Bicuspid Aortic Regurgitation	Nothing to Disclose
Michelena	Hector	Making Progress in Understanding Heart Failure	Left Atrial Enlargement in Patients With Ventricular Dysfunction: Innocent Bystander or Meaningful Determinant of Survival?	Nothing to Disclose
Michelena	Hector	Making Progress in Understanding Heart	Is Frailty a Mirror of Underlying Hemodynamic Alteration in Patients	Nothing to Disclose
Michelena	Hector	Failure Valvular Heart Disease: Mitral Valve Disease	With Left Ventricular Dysfunction? Quantitation of Degenerative Mitral Regurgitation: Reserved to the	Nothing to Disclose
Michelena	Hector	Valvular Heart Disease: Aortic Stenosis	Specialized Few or Applicable to Routine Clinical Practice? Bicuspid Versus Tricuspid Aortic Valve Stenosis: Comparative Study of Clinical Characteristics and Outcomes Following Aortic Valve	Nothing to Disclose
Michelena	Hector	New Technologies in Echocardiography	Replacement in an Age-Matched Cohort Mitral Annular Disjunction Prevalence and Physiologic Consequences in Degenerative Mitral Regurgitation: A Dynamic 3-	Nothing to Disclose
Michelena	Hector	Emerging Developments in HFpEF and Arryhthmias	Dimensional Echocardiographic Study Atrial Fibrillation Link to Excess Mortality in Patients With Left Ventricular Dysfunction: Linked to Rapid Ventricular Response or Independent Prognostic Marker?	Nothing to Disclose
Michelena	Hector	Novel Determinants of Outcomes in VHD	Impact of Aortic Valve Calcification and Sex on Hemodynamic Progression and Clinical Outcomes in Aortic Stenosis	Nothing to Disclose
Michelena	Hector	Technical Advances in Transthoracic	E/e' Short- and Long-Term Independent Prognostic Role in	Nothing to Disclose
Michelis	Katherine	Echocardiography Highlighted Original Research: Vascular Medicine and the Year in Review	Patients With Left Ventricular Dysfunction CD90 Marks a Population of Adventitial Mesenchymal Stem Cells in the Human Aorta That Exhibit Diminished Angiogenic Potential in	Nothing to Disclose
Michelongona	Archontoula	Interventional Cardiology: TAVR 2	Patients With Ascending Aortic Aneurysms The Effect of Mixed Aortic Valve Disease in Clinical Outcomes After	Nothing to Disclose
Michelongona	Archontoula	Innovative Use of Echocardiography	Transcatheter Aortic Valve Replacement Impact on Long Term Mortality of Persistent Pulmonary	Nothing to Disclose
Michels	Michelle	Arrhythmias and Clinical EP: Devices 1	Hypertension After Transcatheter Aortic Valve Implantation Long-Term Outcome of Noncompaction Cardiomyopathy Patients	Nothing to Disclose
		·	With Implantable Cardioverter-Defibrillators Compared With Patients With Dilated or Hypertrophic Cardiomyopathy	-
Michels	Michelle	Advances in HCM, PPCM and Other Cardiomyopathies	Yield and Long-Term Outcome of Family Screening in Hypertrophic Cardiomyopathy	Nothing to Disclose
Michelsen	Marie	Novel Echocardiographic Methods for Assessing Cardiac Function	Coronary Microvascular Dysfunction Affects the Myocardial Contractile Reserve in Women With Angina and No Obstructive Coronary Artery Disease	Nothing to Disclose
Michelsen	Marie	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Effect of Ramipril on Microvascular Function and Symptoms in Normotensive Women With Microvascular Angina: A Randomized	Nothing to Disclose
Michler	Robert	Controversies in Mitral Valve Surgery: Joint Symposium of the Society of Thoracic Surgeons and the American College of	Controlled Trial Treatment of MR in Patients with Reduced EF: What are our options?	Nothing to Disclose
Michos	Erin	Cardiology Innovations in Cardiovascular Risk Assessment and Reduction	Vitamin D Levels and Autoantibodies in the Multi-Ethnic Study of Atherosclerosis (MESA): Implications for Cardiovascular Disease	CONSULTANT FEES/HONORARIA - Siemens Diagnostics
Michos	Erin	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Stroke Among Whites and Blacks: The Atherosclerosis Risk In	CONSULTANT FEES/HONORARIA - Siemens Diagnostics
Michos	Erin	32. Prevention: Clinical Team 6	Communities (ARIC) Study Suggested Reviewer	CONSULTANT FEES/HONORARIA - Siemens Diagnostics
Mick	Stephanie	Interventional Cardiology: TAVR 1	Novel Plane of Measurement to Evaluate Accurate Valve Size in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Mick Mick	Stephanie Stephanie	Valvular Heart Disease: Mitral Valve Disease	Gender Differences in the Etiology of Mitral Valve Disease	Nothing to Disclose
Mick	Stephanie	Interventional Cardiology: TAVR 2	Outcomes of Transcatheter Aortic Valve Replacement Without Balloon Predilation: A Systematic Review and Meta-Analysis	Nothing to Disclose
Mick	Stephanie	Interventional Cardiology: TAVR 3	Comparison of Acute Elastic Recoil Between CoreValve and SAPIEN 3 Valves in Transcatheter Aortic Valve Replacement	Nothing to Disclose
Mick	Stephanie	Interventional Cardiology: TAVR 3	Clinical Outcomes of Patients With Pacemaker Implantation After Transcatheter Aortic Valve Replacement: Meta-Analysis and Meta-	Nothing to Disclose
	1		Regression	



Land Marris	Terror Management	lo colo a mile	December 200	Pinter and
Last Name Mick	Stephanie	Insights From Echocardiography Use	Presentation Title Aortic Regurgitation Negatively Affects Left Ventricular Mechanics	Disclosures Nothing to Disclose
Mick	Stephanie	TAVR Outcomes Prognostication	After Transcatheter Aortic Valve Replacement Cardiac Plasticity Predicts Outcome After Transcatheter Aortic	Nothing to Disclose
Miedema	Michael	Prevention of ASCVD Over the Lifespan: A Case-based Approach	Valve Replacement in Patients With Severe Aortic Stenosis My 52 Year Old Patient with Hypertension and Smoking with a Coronary Calcium Score of 0. Should I Discuss Statin Use with This	Nothing to Disclose
Miedema	Michael	Highlighted Original Research: Prevention and	Patient? The Effect of Proprotein Convertase Subtilisin-Kexin Type 9	Nothing to Disclose
		the Year in Review	Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 16,721 Patients From 33 Randomized Clinical Trials	g to Excellent
Mieres	Jennifer	Are We There Yet? The Long Journey to Health Equity: Part II	Co-Chair	Nothing to Disclose
Mieres	Jennifer	Are We There Yet? The Long Journey to Health Equity: Part II	Session Summary	Nothing to Disclose
Mieres	Jennifer	Change is Good! Lifestyle Strategies in the Patient with ASCVD and Diabetes	Panelist	Nothing to Disclose
Mieres	Jennifer	Change is Good! Lifestyle Strategies in the Patient with ASCVD and Diabetes	Integrating Culture and Language: Care of the Patient with DiaBetes	Nothing to Disclose
Mieres	Jennifer	WIC Brown Bag Lunch Session: Publishing, Social Media and Negotiating the C-Suite: Tools for Success in Academia and Private Practice	Establishing a Social Media Presence	Nothing to Disclose
Mieres	Jennifer	01. Acute and Stable Ischemic Heart Disease: Basic Team 2	Suggested Reviewer	Nothing to Disclose
Miglioranza	Marcelo	ACC International Conferences Best Posters	Comparison of Different Lung Ultrasound Methodologies for	Nothing to Disclose
Mihaila	Sorina	Novel Imaging and Therapies in Heart Failure	Pulmonary Congestion Evaluation in Heart Failure Outpatients Gestational Hypertension and Preeclampsia Are Associated With	Nothing to Disclose
Mihajlovic	Vesna	Cardiac Arrest, Diabetes, and Other High Risk	Subclinical Left Ventricular Systolic and Diastolic Dysfunction A Meta-Analysis of the Effect of Targeted Temperature	Nothing to Disclose
		Features of Patients With Acute Coronary Syndrome	Management on Mortality and Neurological Outcome	
Mihalatos	Dennis	Interventional Cardiology: TAVR 3	The Natural History of Paravalvular Regurgitation After Transarterial Valve Implantation for Severe Aortic Stenosis: One Center Experience	Nothing to Disclose
Mihalcea	Diana	Novel Imaging and Therapies in Heart Failure	Gestational Hypertension and Preeclampsia Are Associated With Subclinical Left Ventricular Systolic and Diastolic Dysfunction	Nothing to Disclose
Mihaljevic	Tomislav	Valvular Heart Disease: Mitral Valve Disease	Gender Differences in the Etiology of Mitral Valve Disease	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,Intuitive Surgical; SPEAKER'S BUREAU - Intuitive Surgical
Mihos	Christos	Novel Determinants of Outcomes in VHD	Relationship Between Proximal Aorta Morphology and Progression Rate of Aortic Stenosis	Nothing to Disclose
Mikami	Yoko	Non Invasive Imaging: MR Characterization and Function	Defining Risk Associated With Left Ventricular Hypertrophy Patterns as Assessed by Cardiac Magnetic Resonance Imaging	Nothing to Disclose
Mikhail	Ghada	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: From the WIN-TAVI Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular
Mikhail	Ghada	Interventional Cardiology: PCI in Complex Patients	Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated Heparin Following Transcatheter Aortic Valve Replacement: Results From the Bravo-3 Randomized Trial	CONSULTANT FEES/HONORARIA - Abbott Vascular
Mikhaylov	Evgeny	New Strategies in Arrhythmias Management: International Perspectives From the Philippine Heart Association, Russian Society of Cardiology, and American College of Cardiology	Management of Ventricular Tachycardia in Structural Heart Disease: Electrophysiology and Beyond	CONSULTANT FEES/HONORARIA - Biosense Webster, Boston Scientific; SPEAKER'S BUREAU - Boehringer Ingelheim Pharmaceuticals, Inc.MEDTRONIC, Pfizer Inc
Mikolich	Brandon	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Role of Longitudinal Fiber Dysfunction in Stress Induced Left Ventricular Dilatation	Nothing to Disclose
Mikolich	J. Ronald	Non Invasive Imaging: MR Structure and	Role of Longitudinal Fiber Dysfunction in Stress Induced Left Ventricular Dilatation	Nothing to Disclose
Mikulicic	Fran	Valuvular Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography	Long-Term Prognostic Value of Computed Tomography-Derived Corrected Contrast Opacification Decrease in Patients With	Nothing to Disclose
Milani	Loredano	13. Heart Failure and Cardiomyopathies:	Coronary Stenosis Suggested Reviewer	Nothing to Disclose
Milani	Richard	Clinical Team 6 Measuring Success in Cardiac Rehabilitation	Search for the Super-Responder: Progressive Increases in Fitness	Nothing to Disclose
Milani	Richard	Acute Heart Failure: Evaluating Strategies to	and an Association With Lower Mortality Improving Heart Failure Unit Readmission Prediction	Nothing to Disclose
Milani	Richard	Prevent Readmissions Novel Strategies for Assessing and Improving	Hypertension Control Is Strongly Influenced by Patient's Health	Nothing to Disclose
		Adherence to Blood Pressure Lowering Therapies	Capability	
Milani	Richard		Does Weight Loss Factor in?	Nothing to Disclose
Milazzo	Valentina	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Renal Replacement Therapy in Patients With Acute Myocardial Infarction: Rate of Use, Clinical Predictors and Relationship With In- Hospital Mortality	Nothing to Disclose
Milazzo	Valentina	Post-CAD/MI: Making Tough Predictions About the Future	A New Score for Risk Stratification of Patients With Acute Myocardial Infarction Based on the PEGASUS-TIMI 54 Criteria	Nothing to Disclose
Miles	Jeremy	Innovative Use of Echocardiography	High Prevalence of Apical Hypertrophic Cardiomyopathy Noted in Non-White Patients Referred for Clinical Echocardiography	Nothing to Disclose
Milev	Sandra	Diabetes and Other Issues in Cardiovascular Prevention	Comparison of the Use of Cardiovascular Risk Equations by Health Technology Assessment Bodies and Clinical Guidelines	SALARY - Evidera
Miliou	Antigoni	Diabetes and Endothelial Dysfucntion in Heart Failure	Technology Assessment Bodies and Clinical Guidelines Association of Endothelial Dysfunction With Biomarkers of Inflammation, Myocardial Fibrosis and Left Ventricle Strain in Patients With Heart Failure	Nothing to Disclose
Militello	Michael	Vascular Medicine: Emerging Concepts in	Clevedipine as a Therapeutic and Cost-Effective Alternative to	Nothing to Disclose
Milkas	Anastasios	Clinical Vascular Diseases Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Sodium Nitroprusside in Patients With Aortic Dissection Insights on Diastolic Dysfunction of Treated Hypertensive Patients: Focusing on Hypertension Control & Treatment Resistance	Nothing to Disclose
Miller	Charles	Fibrillatory Arrhythmias: Outcomes With	Antiarrhythmic Medications for Atrial Fibrillation Appear Reasonably	Nothing to Disclose
Miller	D. Craig	Contemporary Practice Interventional Cardiology: TAVR 1	Safe in Hypertrophic Cardiomyopathy Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: Insights From PARTNER 2A Trial	CONSULTANT FEES/HONORARIA - Medtronic CardioVascular Division, Inc.,GenTaC/NHLBI under contract to RTI; OTHER - Edwards Lifesciences, LLC; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,Edwards Lifesciences, LLC,Edwards Lifesciences, LLC,Medtronic Core Valve
Miller	D. Craig	Interventional Cardiology: TAVR 1	The Inflammasome Pathway Is Associated With Adverse Ventricular Remodeling Following Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Medtronic CardioVascular Division, Inc.,GenTAC/NHLBI under contract to RTI, OTHER - Edwards Lifesciences, LLC, RESEARCH/RESEARCH GRANTS - Abbott Laboratories,Edwards Lifesciences, LLC,Edwards Lifesciences, LLC,Medtronic Core Valve



Last Name	First Name	Session Title	Presentation Title	Disclosures
Miller	Edward		Effusive-Constrictive Pericarditis in a Patient With Hypereosinophilic	CONSULTANT FEES/HONORARIA - GE, Inc;
Miller	Jordan	Pulmonary Hypertension Novel Determinants of Outcomes in VHD	Syndrome Impact of Aortic Valve Calcification and Sex on Hemodynamic	RESEARCH/RESEARCH GRANTS - Bracco Nothing to Disclose
Willion	oordan	Trover Beterminants of Galcomes in VIIB	Progression and Clinical Outcomes in Aortic Stenosis	Trouming to Disclose
Miller	Jordan	38. Vascular Medicine: Basic Team 2	Suggested Reviewer	Nothing to Disclose
Miller	Julie	Non Invasive Imaging: Coronary Calcium	Coronary Calcium Characteristics as Predictors of Major Adverse	Nothing to Disclose
		Scoring and CV Risk Assessment	Cardiac Events in Symptomatic Patients: Insights From the CORE320 Multinational Study	
Miller	Michael	Change is Good! Lifestyle Strategies in the	Panelist	CONSULTANT FEES/HONORARIA - Amgen,Gemphire;
Willion	Wildride	Patient with ASCVD and Diabetes	i direist	OTHER - Amarin, Pfizer
Miller	Michael	Change is Good! Lifestyle Strategies in the	Nutrition to Lower Triglycerides and Improve Glycemic Control	CONSULTANT FEES/HONORARIA - Amgen, Gemphire;
		Patient with ASCVD and Diabetes		OTHER - Amarin,Pfizer
Miller	Michael	32. Prevention: Clinical Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen, Gemphire;
Miller	Robert	Young Investigator Awards Competition:	Cost Effectiveness of Continuous Flow Left Ventricular Assist	OTHER - Amarin,Pfizer Nothing to Disclose
	T TOBOTT	Outcomes Research	Devices for Destination Therapy in End Stage Heart Failure Patients	Trouming to 2.00000
			Ineligible for Cardiac Transplantation	
Miller	Robert	Non Invasive Imaging: MR Characterization	Defining Risk Associated With Left Ventricular Hypertrophy Patterns	Nothing to Disclose
Miller	Robert	and Function Updates in Stable Ischemic Heart Disease	as Assessed by Cardiac Magnetic Resonance Imaging Beta Blocker Post ACS in Patients With Preserved Left Ventricular	Nothing to Disclose
Willion	ROBERT	opuates in otable isolicinie ricari biscuse	Systolic Function	Trouming to Disclose
Miller	Robert	Acute Heart Failure: Evaluating Strategies to	Kidney Function, Angiotensin-Converting-Enzyme Inhibitor or	Nothing to Disclose
		Prevent Readmissions	Angiotensin II Receptor Blocker Use, and Survival Following	
Addiss	Tadd	Nuclear Cardialana Barrad Barraia	Hospitalization for Heart Failure: A Cohort Study	Nothing to Displace
Miller	Todd	Nuclear Cardiology: Beyond Perfusion	The Impact of Cardiopulmonary Testing on Downstream Evaluation in Patients Who Undergo Myocardial Perfusion Imaging	Nothing to Disclose
			in rations with ordergo wyocardar rendsion inaging	
Miller	Wayne	Making Progress in Understanding Heart	Left Atrial Enlargement in Patients With Ventricular Dysfunction:	Nothing to Disclose
		Failure	Innocent Bystander or Meaningful Determinant of Survival?	
Miller	Wayne	Making Progress in Understanding Heart	Is Frailty a Mirror of Underlying Hemodynamic Alteration in Patients	Nothing to Disclose
Miller	Wayne	Failure Emerging Developments in HFpEF and	With Left Ventricular Dysfunction? Atrial Fibrillation Link to Excess Mortality in Patients With Left	Nothing to Disclose
	. vayiic	Arryhthmias	Ventricular Dysfunction: Linked to Rapid Ventricular Response or	Trouming to Disciose
<u></u>	<u> </u>		Independent Prognostic Marker?	
Miller	Wayne	Technical Advances in Transthoracic	E/e' Short- and Long-Term Independent Prognostic Role in	Nothing to Disclose
M-11-	Niekelee	Echocardiography	Patients With Left Ventricular Dysfunction	CONCULTANT FEEGUIONODADIA ALLEM DE CONCULTANT
Mills	Nicholas	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Optimal Risk Stratification Pathways for Patients With Suspected Acute Coronary Syndrome	CONSULTANT FEES/HONORARIA - Abbott Diagnostics,Roche Diagnostics,Singulex
1		Syndrome	Product Goronary Syndrome	Diagnosios, olliguies
Mills	Nicholas			CONSULTANT FEES/HONORARIA - Abbott Diagnostics,Roche
		and Reduction	Events in Patients With COPD and Heightened Cardiovascular Risk:	Diagnostics,Singulex
			A Biomarker Sub-Study of the SUMMIT Trial	
Mills	Nicholas	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Age and the Effectiveness of Risk Stratification and Diagnostic Thresholds for Myocardial Infarction With High-Sensitivity Cardiac	CONSULTANT FEES/HONORARIA - Abbott Diagnostics,Roche Diagnostics,Singulex
		Management and Outcomes	Troponin	Diagnostics, Singulex
Mills	Nicholas	Acute Coronary Syndromes, Diagnosis,	Is It Safe to Use High-Sensitivity Cardiac Troponin T to Rule out	CONSULTANT FEES/HONORARIA - Abbott Diagnostics, Roche
		Management and Outcomes	Myocardial Infarction at Presentation?	Diagnostics, Singulex
Mills	Nicholas	Acute Coronary Syndromes, Diagnosis,	High-Sensitivity Cardiac Troponin and the Classification of	CONSULTANT FEES/HONORARIA - Abbott Diagnostics,Roche
Mills	Nicholas	Management and Outcomes Blips, Trops, and Chips: New Ways to	Myocardial Infarction High-Sensitivity Cardiac Troponin I and the Diagnosis of Obstructive	Diagnostics,Singulex CONSULTANT FEES/HONORARIA - Abbott Diagnostics,Roche
IVIIIIS	NICHOIAS	Diagnose CAD	Coronary Artery Disease in Patients With Suspected Stable Angina	Diagnostics, Singulex
Milman	Anat	Cardiac Channelopathies: Novel Therapeutics	Appropriate Primary Prophylactic Implantation of Defibrillator in	Nothing to Disclose
William				
William		and Clinical Challenges	Patients With Brugada Syndrome: Is There Any Difference Between	
Name of the second seco		and Clinical Challenges	Patients From Western and Asian countries? Data From a	
Willing I		and Clinical Challenges		
Min	Daniel	and Clinical Challenges Nuclear Cardiology: Beyond Perfusion	Patients From Western and Asian countries? Data From a	Nothing to Disclose
Min		Nuclear Cardiology: Beyond Perfusion	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study	,
	Daniel James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal	CONSULTANT FEES/HONORARIA - Heartflow; OTHER -
Min		Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Min		Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study	CONSULTANT FEES/HONORARIA - Heartflow; OTHER -
Min		Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Min Min	James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Min	James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/ICT Study Co-Chair Risk prediction beyond stenosis. What CT is teaching us about	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER -
Min Min Min	James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PETI/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX
Min Min	James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic	CONSULTANT FEES/HONORARIA - Heartflow; OTHER- Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER -
Min Min Min	James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PETI/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX
Min Min Min	James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry.	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX
Min Min Min	James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - ARIOLES, CLEERLY, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER -
Min Min Min	James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The COMFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Min Min Min	James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - ARIOLES, CLEERLY, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER -
Min Min Min	James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The COMFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Min Min Min Min Min	James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Altherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX
Min Min Min	James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imagling: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry Smoking and its Relationship With Long Term Events: Further	CONSULTANT FEES/HONORARIA - Heartflow; OTHER- Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - CONSULTANT FEES/HONORARIA - Heartflow; OTHER -
Min Min Min Min Min	James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Arineta;
Min Min Min Min Min	James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imagling: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry Smoking and its Relationship With Long Term Events: Further	CONSULTANT FEES/HONORARIA - Heartflow; OTHER- Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - CONSULTANT FEES/HONORARIA - Heartflow; OTHER -
Min Min Min Min Min	James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (Coronary CT Angiography Evaluation For Clinical Outcomes: An InterNational Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER -
Min Min Min Min Min Min Min	James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naï:ve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse	CONSULTANT FEES/HONORARIA - Heartflow; OTHER- Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Min Min Min Min Min Min Min Min Min Min	James James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography angiography and Events: The CONFIRM Registry	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX
Min Min Min Min Min Min Min	James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography. The CONFIRM-LT (Coronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX
Min Min Min Min Min Min Min Min Min Min	James James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American Conjude of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry Prognostic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Dislouent Swith No Beyond Coronary Artery Dislouent Swith No Beyond Coronary Artery Dislouent Swith No Beyond Coronary Artery Calcium Score in Diabetic Patients With No Beyond Coronary Artery Calcium Score in Diabetic Patients With No Beyond Coronary Artery Calcium Score in Diabetic Patients With No	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX
Min Min Min Min Min Min Min Min Min Min	James James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naï:ve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry Prognostic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX
Min Min Min Min Min Min Min Min Min Min	James James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American Conjuncted Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (Coronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry Prognostic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX
Min Min Min Min Min Min Min Min Min Min	James James James James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naï:ve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry Prognostic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX
Min Min Min Min Min Min Min Min Min Min	James James James James James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry Prognosic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX
Min Min Min Min Min Min Min Min Min Min	James James James James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography. The CONFIRM-LT (Coronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry Ethnic Differences of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography: The CONFIRM Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX
Min Min Min Min Min Min Min Min Min Min	James James James James James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry Prognosic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta ; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX
Min Min Min Min Min Min Min Min Min Min	James James James James James James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naï:ve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-I (COronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry Prognostic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography: The CONFIRM Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Cathador Cardiovascular Cathador	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX
Min Min Min Min Min Min Min Min Min Min	James James James James James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American Conjueted Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Diabetes and Other Issues in Cardiovascular	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry Prognosic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography In Victims of Autopsy-P	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Min Min Min Min Min Min Min Min Min Min	James James James James James James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naï:ve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-I (COronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry Prognostic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography: The CONFIRM Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Cathador Cardiovascular Cathador	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX
Min Min Min Min Min Min Min Min Min Min	James James James James James James James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American Conjuted Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Diabetes and Other Issues in Cardiovascular Prevention	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry Prognosic Utility of Coronary Cardioum Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography: Prognosis of Obstructive Angiography: The CONFIRM Registry Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography in Victims of Autopsy-Proven Sudden Coronary Cardiovascular Events: A Comparison to a Histologic Reference Standard Implications of Statin Therapy Among Smokers With Severe Coronary Artery Calcilication: An Analysis of the CONFIRM Registry	CONSULTANT FEES/HONORARIA - Heartflow; OTHER-Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER-Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX EVERTARY OF THE ARITHERS OF THE ARITHERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MIDDX
Min Min Min Min Min Min Min Min Min Min	James James James James James James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American Conjueted Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Diabetes and Other Issues in Cardiovascular	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry Prognosic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography In Victims of Autopsy-P	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX
Min Min Min Min Min Min Min Min Min Min	James James James James James James James James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American Computed Tomography and the American Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Diabetes and Other Issues in Cardiovascular Prevention	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry Prognostic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patents With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography: The CONFIRM Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary Cathy Computed Tomographic Angiography: The CONFIRM Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary Cathy Computed Tomographic Angiography: The CONFIRM Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary Computed Tomographic Angiography: The CONFIRM Registry Optimal Method for Necrotic Core Identification in Coronary Plaque With Dual-Energy Computed Tomography: Material Decomposition and Atomic Number	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - B
Min Min Min Min Min Min Min Min Min Min	James James James James James James James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American Conputed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naï:ve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry Prognostic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography: The CONFIRM Registry Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography in Victims of Autopsy-Proven Sudden Coronary Ocathic A Comparison to a Histologic Reference Standard Implications of Statin Therapy Amnog Smokers With Severe Coronary Artery Calcidication: An Analysis of the CONFIRM Registry Optimal Method for Necrotic Core Identification in Coronary Plaque With Dual-Energy Computed Tomography, Material Decomposition	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - B
Min Min Min Min Min Min Min Min Min Min	James James James James James James James James James James James	Nuclear Cardiology: Beyond Perfusion Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American Computed Tomography and the American Computed Tomography and the American College of Cardiology Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography Diabetes and Other Issues in Cardiovascular Prevention	Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study Co-Chair Risk prediction beyond stenosis- What CT is teaching us about coronary atherosclerosis Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry Prognostic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patents With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography: The CONFIRM Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary Cathy Computed Tomographic Angiography: The CONFIRM Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary Cathy Computed Tomographic Angiography: The CONFIRM Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary Computed Tomographic Angiography: The CONFIRM Registry Optimal Method for Necrotic Core Identification in Coronary Plaque With Dual-Energy Computed Tomography: Material Decomposition and Atomic Number	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - B

Last Name	First Name	Session Title	Presentation Title	Disclosures
Min	James	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Atherosclerotic Plaque Morphology Is Associated With Impaired Myocardial Blood Flow and Fractional Flow Reserve, Independent	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta : OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
		Reserve: Clinical Implications	of Luminal Obstruction	Bespoke Medical Devices, Cleerly, MDDX
Min	James	16. Interventional Cardiology: Angiography and Interventional CT/MR Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Heartflow; OTHER - Arineta; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Bespoke Medical Devices, Cleerly, MDDX
Min	Sarah	Advances in Cholesterol Measurement and Management	10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy: Post-Commercialization Study	Nothing to Disclose
Miname	Marcio	Contemporary Issues in Familial Hypercholesterolemia	Achilles Tendon Xanthomas Are Independently Associated With Severity of Subclinical Coronary Atherosclerosis in Familial Hypercholesterolemia	Nothing to Disclose
Minami	Yoshiyasu	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Neointimal Pattern and Clinical Outcome After Drug-Eluting Stent Implantation: Comparison Between First Generation and Second	Nothing to Disclose
Minami	Yoshiyasu	Antiplatelet and Antithrombotic Agents in	Generation Drug-Eluting Stents Stent Edge Strut on Normal Segment Is Less Covered in Early	Nothing to Disclose
Minami	Yoshiyasu	Ischemic Heart Disease Unusual Presentations of ACS	Phase After Drug Eluting Stent Implantation Lower Eicosapentaenoic Acid to Arachidonic Acid Ratio Is	Nothing to Disclose
			Associated With Intraplaque Cholesterol Crystals: An Optical Coherence Tomography Study	-
Minasian	Sarkis	Cutting Edge Vascular Medicine	A Novel Necroptosis Inhibitors (Necrosulfonamide and Necrostatin- 1s) Demonstrate Therapeutic Potential for Myocardial Ischemia- Reperfusion Injury	Nothing to Disclose
Minasyan	Hasmik	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	A Rare Case of Isolated Renal Cell Carcinoma Metastasis to the Left Ventricle	Nothing to Disclose
Minges	Karl	Interventional Cardiology: PCI and TAVR in Complex Patients	Utilization of Heart Teams in the United States: Results From the Translating Outstanding Performance in Percutaneous Coronary	Nothing to Disclose
Minich	L. LuAnn	Congenital Heart Disease: Innovations in	Intervention (TOP PCI) Study Do Pediatric Cardiologists Follow the Sports Restriction	Nothing to Disclose
Minissian	Margo	Single Ventricle Heart Disease Featured Clinical Research I	Recommendations for Children With a Bicuspid Aortic Valve? Panelist	RESEARCH/RESEARCH GRANTS - National Institutes of
	Margo	Angina in the Absence of Obstructive CAD.	Co-Chair	Health,NIHF RESEARCH/RESEARCH GRANTS - National Institutes of
Minissian	_	What Do We Do With These Patients?		Health,NIHF
Minissian	Margo	The Consequences of Sex: Women and Pregnancy Across the Spectrum	Co-Chair	RESEARCH/RESEARCH GRANTS - National Institutes of Health,NIHF
Minissian	Margo	Get into the Beat! Exercise to Promote CV	Panelist	RESEARCH/RESEARCH GRANTS - National Institutes of
Minissian	Margo	Health Get into the Beat! Exercise to Promote CV	Practical Tips for Getting Your Patients to Move	Health,NIHF RESEARCH/RESEARCH GRANTS - National Institutes of
Minissian	Margo	Health 02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Health,NIHF RESEARCH/RESEARCH GRANTS - National Institutes of
		Clinical Team 8		Health,NIHF
Minnier	Jessica	Biomarkers and Targets for Ischemic Heart Disease	Ultrasound Increases Myocardial Blood Flow in Acute Myocardial Ischemia Without Reducing Infarct Size	Nothing to Disclose
Minnier	Jessica	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Discordant Response of Low Density Lipoprotein Cholesterol and Lp(a) Levels to Monoclonal Antibodies Targeting Proprotein Convertase Subtilisin/Kexin Type 9	Nothing to Disclose
Mintz	Gary	Contemporary Role of Intracoronary Imaging:	Panelist	CONSULTANT FEES/HONORARIA -
Mintz	Gary	Candid Conversation with Peers Contemporary Role of Intracoronary Imaging:	Is Intracoronary Imaging to Identify Vulnerable Plaque Still	ACIST,BostonScientific,Volcano CONSULTANT FEES/HONORARIA -
Mintz	Gary	Candid Conversation with Peers Left Main PCI: Why? When? How?	Relevant? Panelist	ACIST,BostonScientific,Volcano CONSULTANT FEES/HONORARIA -
Mintz	•	Left Main PCI: Why? When? How?	How to Assess the Left Main Using Physiology and Imaging	ACIST,BostonScientific,Volcano CONSULTANT FEES/HONORARIA -
IVIII ILZ	Gary	-		ACIST,BostonScientific,Volcano
Mintz	Gary	The Evolution of Angioplasty 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	The Evolution of Imaging and Physiologic Assessment	CONSULTANT FEES/HONORARIA - ACIST,BostonScientific,Volcano
Mintz	Gary	Highlighted Original Research: Interventional Cardiology and the Year in Review	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	CONSULTANT FEES/HONORARIA - ACIST,BostonScientific,Volcano
Mintz	Gary	Interventional Cardiology: Intravascular	Optical Coherence Tomography Assessment of Coronary	CONSULTANT FEES/HONORARIA -
Mintz	Gary	Physiology and Endothelial Function Interventional Cardiology: Angiography,	Atherectomy Effect: Comparison Between Orbital and Rotational Atherectomy in Severely Calcified Lesions Morphologic Patterns of In-Stent Chronic Total Occlusions: An	ACIST,BostonScientific,Volcano CONSULTANT FEES/HONORARIA -
Mintz	Gary	Intravascular Imaging and Interventional CT/MR Interventional Cardiology: Angiography,	Intravascular Ultrasound Study The Effectiveness of Excimer Laser Angioplasty to Treat Coronary	ACIST,BostonScientific,Volcano CONSULTANT FEES/HONORARIA -
		Intravascular Imaging and Interventional CT/MR	In-Stent Restenosis With Peri-Stent Calcium as Assessed by Optical Coherence Tomography Comparison of Optical Coherence Tomography Versus	ACIST,BostonScientific,Volcano CONSULTANT FEES/HONORARIA -
Mintz	Gary	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Intravascular Ultrasound Detection of Tissue Protrusion and Acute Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent Implantation	ACIST, Boston Scientific, Volcano
Mintz	Gary	Interventional Cardiology: Stent Failure	Intravascular Ultrasound Assessment of the Effects of Rotational Atherectomy in Calcified Coronary Artery Lesions	CONSULTANT FEES/HONORARIA - ACIST,BostonScientific,Volcano
Mintz	Gary	Analysis by Intravascuar Imaging Interventional Cardiology: PCI in Complex Patients	Chronic Stent Recoil During Follow-Up in Severely Calcified Coronary Artery Lesions: An Optical Coherence Tomography Study	CONSULTANT FEES/HONORARIA - ACIST, Boston Scientific, Volcano
Mintz	Gary	Interventional Cardiology: PCI in Complex	Procedural Calcium Fracture and Its Effect on Stent Expansion	CONSULTANT FEES/HONORARIA -
Mintz	Gary	Patients 23. Interventional Cardiology: IVUS and	Assessed by Optical Coherence Tomography Suggested Reviewer	ACIST,BostonScientific,Volcano CONSULTANT FEES/HONORARIA -
	•	Intravascular Physiology Team 1		ACIST,BostonScientific,Volcano
Minutello	Robert	Interventional Cardiology: TAVR 1	Baseline Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Increased Mortality After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Medinol
Minutello	Robert	Interventional Cardiology: TAVR 2	The Influence of Gender on In-Hospital Clinical Outcomes in Hispanics Following Surgical and Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Medinol
Minutello	Robert	Interventional Cardiology: TAVR 2	Does Intra-Aortic Balloon Pump Placement During Hospitalization Course for Transcatheter Aortic Valve Replacement Portent a Worse Clinical Outcome?	CONSULTANT FEES/HONORARIA - Medinol
Minutello	Robert	Interventional Cardiology: TAVR 3	Periprocedural Blood Transfusions in Patients Undergoing	CONSULTANT FEES/HONORARIA - Medinol
Minutello	Robert	Outcomes in Valvular Heart Disease	Transcatheter Aortic Valve Replacement In-Hospital Clinical Outcomes Following Concomitant Coronary Artery Bypass Graft and Heart Valve Surgery in Women	CONSULTANT FEES/HONORARIA - Medinol
Minutello	Robert	Sex Disparity in VHD Outcomes	The Impact of Gender on In-Hospital Clinical Outcomes Following Isolated Mitral or Aortic Heart Valve Surgery	CONSULTANT FEES/HONORARIA - Medinol
Mir	Hassan	FIT Clinical Decision Making: Heart Failure and	An Unsuspected Case of Myocarditis Associated With Nivolumab	Nothing to Disclose
Miranda	William	Pulmonary Hypertension Case Studies from the Guidelines for Clinicians	Use Congenital Heart Disease Cases	Nothing to Disclose
				-
Miranda	William	Valvular Heart Disease: Endocarditis	Infective Endocarditis Following Transcutaneous Aortic Valve Implantation: Clinical, Echocardiographic and Hemodynamic Features	Nothing to Disclose

Congress of				
Last Name	First Name	Session Title Innovative Use of Echocardiography	Presentation Title	Disclosures
Miranda	William		E/e' > 15 Performs Poorly in Patients With Elevated Left Filling Pressures and Atrial Fibrillation/Flutter: A Simultaneous Doppler-Catheterization Study	Nothing to Disclose
Miranda	William	Insights From Echocardiography Use	Miscalculation of Right Atrial Pressure by Echocardiography in Patients With Structural Heart Disease: A Simultaneous Echocardiography-Catheterization Study	Nothing to Disclose
Miranda	William	Novel Determinants of Outcomes in VHD	Coexisting Co-Morbidities Exacerbate Left Ventricular Diastolic Dysfunction and Prognosis in Patients With Severe Aortic Stenosis	Nothing to Disclose
Miranda	William	Prosthetic Valve Thrombosis: TAVR, Bio,	Poor Outcome of Thrombolysis in Right-Sided Mechanical Valve	Nothing to Disclose
Miranda Rivas	Gustavo Roberto	Mech Now What?! Perspectives on Congenital Heart Disease: International Perspectives From the Caribbean Cardiac Society, Peruvian Society of Cardiology, and American College of Cardiology	Thrombosis: Largest Single Center Experience Adult Congenital Heart diseases in Peruvian Population	Nothing to Disclose
Mirhedayati Roudsari	Hadi	Non Invasive Imaging: Expanding Clinical Applications	Dual-Energy Coronary Computed Tomography Evaluation of High- Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients: Validation with Histopathologic Gold Standard	Nothing to Disclose
Mirhedayati Roudsari	Hadi	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry	Nothing to Disclose
Mirhedayati Roudsari	Hadi	Innovations in Cardiovascular Risk Assessment and Reduction		Nothing to Disclose
Mirhedayati Roudsari	Hadi	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prognosic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry	Nothing to Disclose
Mirhedayati Roudsari	Hadi	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prognosis of Obstructive and Non-Obstructive Stents by Coronary Computed Tomographic Angiography: The CONFIRM Registry	Nothing to Disclose
Mirhedayati Roudsari	Hadi	Non Invasive Imaging: Prognostic Implications of CT Angiography	Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Death: A Comparison to a Histologic Reference Standard	Nothing to Disclose
Mirhedayati Roudsari	Hadi	Diabetes and Other Issues in Cardiovascular Prevention	Implications of Statin Therapy Among Smokers With Severe Coronary Artery Calcification: An Analysis of the CONFIRM Registry	Nothing to Disclose
Mirhedayati Roudsari	Hadi	Non Invasive Imaging: New Technologies	Optimal Method for Necrotic Core Identification in Coronary Plaque With Dual-Energy Computed Tomography: Material Decomposition and Atomic Number	Nothing to Disclose
Mirhosseini	Alireza	Arrhythmias and Clinical EP: Devices 1	Lower All-Cause Mortality in Younger Patients With Prophylactic Implantable Cardioverter Defibrillator Compared to Elderly Subjects: A Systemic Review and Meta-Analysis	Nothing to Disclose
Mirhosseini	Alireza	Atrial Fibrillation and VT: Unique Populations and Solutions	Reduced Mortality Benefit With Prophylactic Implantable Cardioverter Defibrillator in Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis	Nothing to Disclose
Mironov	Nikolay	FIT Clinical Decision Making: Arrhythmias and	A Case of Brugada Syndrome Diagnosed After Conversion of	Nothing to Disclose
Mirro	Michael	Electrophysiology Contemporary Management of Anticoagulation in High-risk Patients with Atrial Fibrillation	Seemingly Lone Atrial Fibrillation What's Quality Got to Do with It? I Just Want to Treat My Patient: Case-based Learning with ARS	CONSULTANT FEES/HONORARIA - iRhythm Technology,McKesson,VisCardia,Zoll; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Medical Informatics Enginerring; RESEARCH/RESEARCH GRANTS - Biotornik,Janssen Pharmaceuticals, Inc,St Jude Medical
Mirro	Michael	Innovations in Practice Management and Social Media	Designing Tailored Health Messaging to Enhance Patient-Centered Care in Non-Valvular Atrial Fibrillation	CONSULTANT FEES/HONORARIA - iRhythm Technology, McKesson, VisCardia, Zoll; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Medical Informatics Enginerring; RESEARCH/RESEARCH GRANTS - Biotornik, Janssen Pharmaceuticals, Inc.St. Jude Medical
Mirro	Michael	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Use of Wearable Cardioverter Defibrillator Associated With Clinical Guideline Compliance in Management of Heart Failure With Reduced Ejection Fraction	CONSULTANT FEES/HONORARIA - IRhythm Technology,McKesson,VisCardia,Zoll; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Medical Informatics Enginerring; RESEARCH/RESEARCH GRANTS - Biotomik,Janssen Pharmaceuticals, Inc.St Jude Medical
Mirza	Murtaza		Potential Life Threatening Cardiac Toxicity From an Easily Accessible Over the Counter Drug	Nothing to Disclose
Mirza	Murtaza	Pulmonary Hypertension Can CABG Patch CAD?	Minimally Invasive CABG Reduces Target Vessel Revascularizations in Comparison to PCI Without Increased Major	Nothing to Disclose
Mirza	Sajid		Adverse Events: A Meta-Analysis of Randomized Trials Dissolve It or Take It Out: Excellent Outcome of Right-Sided Heart Clot In Transit	Nothing to Disclose
Misra	Arunima	Pulmonary Hypertension Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Clot In-Transit Educational Strategy for Management of Heart Failure Markedly Reduces 90-Day Emergency Department and Hospital Readmissions in Un- and Underinsured Patients	Nothing to Disclose
Misra	Sanjay	Meet the New LE PAD Guidelines: Case-	Now What Would You Do: Which Diagnostic Test/s for This Patient?	DATA SAFETY MONITORING BOARD - Flextent
Misra	Suman	Predicting the Future: Observations and	Trends in Pulmonary Hypertension Hospitalizations: Insights From a	Nothing to Disclose
Misselwitz	Frank	Discoveries From Registries and Databases Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	National Database Treatment and Outcomes of Patients With Nonvalvular Atrial Fibrillation According to Guideline-Defined Anticoagulation Theopholds: Results From the CAREIEL D. A.F. Resister.	SALARY - Employee of Bayer
Misselwitz	Frank	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Thresholds: Results From the GARFIELD-AF Registry Early Mortality in Patients With New Onset Atrial Fibrillation: Results From the GARFIELD-AF Registry	SALARY - Employee of Bayer
Misselwitz	Frank	Stroke and AF: Thinking About the Heart	The Prescribing of Antiplatelet Therapy Only in Patients With Nonvalvular Atrial Fibrillation: Results From the GARFIELD-AF Registry	SALARY - Employee of Bayer
Missov	Emil	Novel Echocardiographic Methods for Assessing Cardiac Function	Registry Echocardiographic Evidence for Left Ventricular Recovery After Refractory Ventricular Fibrillation Cardiac Arrest Treated With Primary Angioplasty and Extracorporeal Membrane Oxygenation	Nothing to Disclose
Missov	Emil	New Technologies in Echocardiography	Finitiary Anglopiasy and Extractorporeal memorane oxygenation Transthroacis Echocardiography to Guide Extracorporeal Membrane Oxygenation Decannulation After Refractory Ventricular Fibrillation Cardiac Arrest Treated With Primary Anglopiasty: A Turndown Protocol	Nothing to Disclose
Missov	Emil	Vascular Medicine: Aortic and Peripheral Artery Diseases	Acute Aortic Dissection in Patients Without a History of Hypertension	Nothing to Disclose
Missri	Jose	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Can CHA2DS2-VASc Score Be Used as a Predictor of Contrast Induced Nephropathy After Cardiac Catheterization?	Nothing to Disclose
Misumida	Naoki	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Association Between Asian Ethnicity and a Higher Rate of Blood Transfusion in ST-Elevation Myocardial Infarction	Nothing to Disclose
Mital	Seema	Precision Medicine: It's Hot, But What Is It?	Panelist	Nothing to Disclose

				I
Last Name	First Name	Session Title	Presentation Title	Disclosures
Mital Mitchell	Seema Gary	Precision Medicine: It's Hot, But What Is It? Innovative Use of Echocardiography	Genetics Can Map the Way to Individualized Therapy in CHD Left Atrial Function Index as a Predictor of Cardiovascular Disease	Nothing to Disclose CONSULTANT FEES/HONORARIA - Merck, Novartis;
WIRCHCH	Cary	innovative ose of Echocardiography	and Atrial Fibrillation: Data From the Framingham Offspring Study	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
				Cardiovascular Engineering, Inc.
Mitchell	James	Vascular Access and Hemostasis Issues	TAVR Using Transcarotid Vascular Access: In-Hospital and Intermediate Term Outcomes	Nothing to Disclose
Mitchell	Joshua	FIT Clinical Decision Making Reviewers 7	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Mitchell	Kyle	Interventional Cardiology: PCI and TAVR in	Timing and Algorithm of Permanent Pacemaker Implantation After	Nothing to Disclose
A Pt. L. II	N.C. I I	Complex Patients	TAVR	OMANEDOLIID INTERECT/DADTNEROLIID/DDINOIDAL A
Mitchell	Michael	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Exome Sequencing Reveals Novel Variants in <i>TMEM59L</i> and <i>KLHL26</i> Associated With a Familial Case of Ebstein’s	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Ariosa Diagnostics,MD Interactive,TAI Diagnostics
		7 pproduction in congernal reduct blooded	Anomaly and Left Ventricular Noncompaction	-
Mitchell	Michael	Congenital Heart Disease Surgery: Updates	Anatomic Repair of Congenitally Corrected Transposition Results in	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Ariosa
		and Innovations	Excellent Survival and Functional Status at Intermediate Term Follow-Up	Diagnostics,MD Interactive,TAI Diagnostics
Mitomo	Satoru	Advances in Chronic Total Occlusion	Impact of Target Vessel on Long-Term Cardiac Mortality After	Nothing to Disclose
		Intervention	Successful Percutaneous Coronary Intervention for Chronic Total	-
Mitrani	Raul	Updates on Risk Factors for Cardiovascular	Occlusion: Japanese Multicenter Registry Hospital Admissions for Chest Pain Associated With Cocaine use in	Nothing to Disclose
IVIIII ariii	Naui	Disease	the United States	Nothing to Disclose
Mitrani	Raul	Arrhythmias and Clinical EP: Basic 3	Seasonal Trends in Sudden Cardiac Death: A Study From the	Nothing to Disclose
Mitroni	Paul	Arrhythmias and Clinical EP: Syncope and	Largest Inpatient Database Mortality Rates and Cost of Hospital Admissions for Syncope in the	Nothing to Displace
Mitrani	Raul	Other EP Issues	United States	Nothing to Disclose
Mitsuishi	Rintaro	Mechanisms of Vascular Inflammation in	Rivaroxaban Attenuates Cardiac Remodeling Due to Intermittent	Nothing to Disclose
		Atherogenesis	Hypoxia by Suppressing the Synergistic Effects of Par-1 and Par-2	
Mittal	Mayank	FIT Clinical Decision Making: Prevention, Adult	41-Year-Old Patient With Double Inlet Left Ventricle Without	Nothing to Disclose
· · · · · · · · · · · · · · · · · · ·		Congenital and Congenital Heart Disease	Pulmonic Stenosis Presenting With Eisenmenger's	Trouming to Biodicoc
			Syndrome	
Mitter	Sumeet	Imaging the Athlete's Heart	Deformation Analysis Can Be Performed on Post-Exercise Images in National Basketball Association Draft Eligible Players With Good	Nothing to Disclose
	<u> </u>		Reproducibility	
Mitter	Sumeet	Advances in Imaging to Assess Cardiotoxicity	Speckle-Tracking Strain Imaging in Breast Cancer Patients Treated	Nothing to Disclose
			With Newer Non-Anthracycline, Trastuzumab-Based Regimens	
Miura	Mizuki	Unusual Presentations of ACS	The Impact of Residual Syntax Score in ACS Patients With LV	Nothing to Disclose
			Dysfunction	ů .
Mixon	Timothy	Core Curriculum: ACS: What Would You Do?	Chair	CONSULTANT FEES/HONORARIA - Edwards Lifescience
Mixon	Timothy	FIT Clinical Decision Making: Non-Invasive	Successful Percutaneous Valve-In-Valve Intervention for Bio-	CONSULTANT FEES/HONORARIA - Edwards Lifescience
		Imaging and Valvular Heart Disease	Prosthetic Mitral Valve Failure	
Miyachi	Hideki	Cutting Edge Vascular Medicine	Transmural Macrophage Migration in Tissue Engineered Vascular Graft Promotes Extracellular Matrix Formation for Vascular	Nothing to Disclose
			Remodeling More Than Host Circulating Inflammatory Cell	
			Migration	
Miyake	Christina	10. Congenital Heart Disease: Pediatric Team	Suggested Reviewer	Nothing to Disclose
Miyata	Hiroaki	Interventional Complexity and Complications	Impact of Institutional and Operator Volume on Short-Term	Nothing to Disclose
wiyata	i iii daki	interventional complexity and complexitoris	Outcomes of Percutaneous Coronary Intervention: A Report From	Two thing to Disclose
			Japanese Nationwide Registry	
Miyauchi	Katsumi	Unusual Presentations of ACS	Combined Serum Albumin and C-Rective Protein Levels Predict	Nothing to Disclose
			Long-Term Outcomes in Patients With Coronary Artery Disease After a First Percutaneous Coronary Intervention	
Miyauchi	Katsumi	CAD in Unique Patient Populations	Prognostic Impact of Geriatric Nutritional Risk Index in Patients	Nothing to Disclose
Mizrahi	Eddy	Diabetes and Other Issues in Cardiovascular	Undergoing Percutaneous Coronary Intervention Predictive Risk Stratification Using HEART and Thrombolysis in	Nothing to Disclose
WIZIAIII	Eudy	Prevention	Myocardial Infarction Scores in Low Risk Chest Pain Patients: An	Nothing to Disclose
			Urban Community Based Hospital Study	
Mizuguchi	Yukio	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Hyperdense Artery Sign on Computed Tomography in Acute Coronary Syndrome	Nothing to Disclose
Mizuno	Atsushi	Interventional Cardiology: Intravascular	Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre-	Nothing to Disclose
		Physiology and Endothelial Function	Angioplasty Predicts Hemodynamic Outcome in Humans With	3
			Coronary Artery Disease: Primary Results of International Multicentre iFR GRADIENT Registry	
Mlynarska	Agnieszka	Heart Failure and Cardiomyopathies: Heart	Frailty as a Predictor of Negative Outcomes After Cardiac	Nothing to Disclose
	-	Failure Gadgets Galore	Resynchronization Therapy	-
Mlynarski	Rafal	Heart Failure and Cardiomyopathies: Heart	Frailty as a Predictor of Negative Outcomes After Cardiac	Nothing to Disclose
Moat	Neil	Failure Gadgets Galore Opening Session and the Joint American	Resynchronization Therapy Panelist	CONSULTANT FEES/HONORARIA - Direct Flow, MEDTRONIC;
mout		College of Cardiology and Journal of American		SPEAKER'S BUREAU - Edwards, Mitralign, Tendyne/Abbott
		College of Cardiology Late-Breaking Clinical		
		Trials Featuring the Simon Dack Lecture		
Moat	Neil	Frontier in New Transcatheter Techniques	Panelist	CONSULTANT FEES/HONORARIA - Direct Flow,MEDTRONIC;
Mant		·	TAVD Value in Value for Disco.	SPEAKER'S BUREAU - Edwards, Mitralign, Tendyne/Abbott
Moat	Neil	TAVR for Degenerated Surgical Valves: What You Need to Know from A to Z	TAVR Valve-in-Valve for Prior Surgical Non-stented Valves	CONSULTANT FEES/HONORARIA - Direct Flow, MEDTRONIC; SPEAKER'S BUREAU - Edwards, Mitralign, Tendyne/Abbott
Moat	Neil	17. Interventional Cardiology: Aortic Valve	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Direct Flow,MEDTRONIC;
		Disease Team 3		SPEAKER'S BUREAU - Edwards, Mitralign, Tendyne/Abbott
Moazami	Nader	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Veno-Arterial ECMO Program for Refractory Cardiogenic Shock in the Cardiac Intensive Care Unit: Feasibility and Outcome Data at a	Nothing to Disclose
		Cardiology. Advanced Device Ose	Large Tertiary Academic Center	
Moazzami	Kasra	Acute Heart Failure: Evaluating Strategies to	Trends in Utilization of Inpatient Palliative Care Services and Racial	Nothing to Disclose
		Prevent Readmissions	Disparity of Disposition to Hospice Care Among Patients With Heart Failure in the United States Between 2003 and 2012	
Moazzami	Kasra	New Insights Into Prediction and Treatment of	Dietary Sodium Intake Among United States Adults With	Nothing to Disclose
		Hypertension	Hypertension, 1999-2012	•
Moceri	Pamela	Updates on Pulmonary Embolism	Diuretics Versus Fluid Loading in Acute Submassive Pulmonary	Nothing to Disclose
Moceri	Pamela	Management in 2017 Innovative Use of Echocardiography	Embolism Early Detection of Cardiac Involvement in Sarcoidosis With 2-	Nothing to Disclose
		0.1,	Dimensional Speckle-Tracking Echocardiography	<u> </u>
Modaff	Daniel	Arrhythmias and Clinical EP: Devices 3	Outcomes Following Implant of Semi-Permanent Pacemaker	Nothing to Disclose
Modi	Kalgi	Vascular Access and Hemostasis Issues	Versus Temporary Pacemaker Standard Versus Low-Dose Heparin Use on Access-Related	Nothing to Disclose
IWIOUI	raigi	vasculai Access and memostasis issues	Complications After Coronary Angiography Through Radial Access:	I Votining to Disclose
			A Meta-Analysis of Randomized Controlled Trials	
Modi	Kalgi	Advances in HCM, PPCM and Other	Extended Course of Recovery in Patients With Peripartum	Nothing to Disclose
Modi	Simon	Cardiomyopathies Advances in HCM, PPCM and Other	Cardiomyopathy Assessed by Left Ventricular Wall Distensibility Younger Age, Positive Family History and Reverse Curve	Nothing to Disclose
		Cardiomyopathies	Morphology Predict Informative Results From Gene Panel Analysis	
		• •	for Hypertrophic Cardiomyopathy (HCM)	
Mody	Kanika	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	An Unusual Case of Anemia in a Heart Transplant Patient	Nothing to Disclose
-				

and the second				
Last Name Mody	First Name Kanika	Session Title 13. Heart Failure and Cardiomyopathies:	Presentation Title Suggested Reviewer	Disclosures Nothing to Disclose
		Clinical Team 2		
Moe Moe	Tabitha Tabitha	Fontan in the Modern World 09. Congenital Heart Disease: Adult Team 2	Macitentan Use as Serial Therapy in Failing Fontan Physiology Suggested Reviewer	Nothing to Disclose Nothing to Disclose
Moffett	Brady	Therapeutic Advances in Congenital Heart	Association of Fractures With Furosemide Therapy in Pediatric	Nothing to Disclose
Mogali	Kiran	Disease FIT Clinical Decision Making: Interventional	Medicaid Patients With Congenital Heart Disease Coronary Artery Bypass Graft Pseudoaneurysm From Saphenous	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart	Vein Graft Stent Rupture	3
Mogali	Kiran	Disease, and Vascular Medicine FIT Clinical Decision Making Reviewers 3	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Mogelvang	Rasmus	Emerging Applications of Echocardiography	Ratio of Transmittal Early Filling Velocity to Early Diastolic Strain	Nothing to Disclose
			Rate Predicts Long Term Risk of Cardiovascular Morbidity and Mortality in a Low Risk General Population	
Mogelvang	Rasmus	Innovative Use of Echocardiography	The Left Atrium Emptying Fraction as a Predictor of Cardiovascular	Nothing to Disclose
			Morbidity and Mortality in a Low Risk General Population	
Mogensen	Ulrik	Featured Clinical Research III	Paroxysmal Atrial Fibrillation Is Associated With Worse Clinical	CONSULTANT FEES/HONORARIA - MSD, honoraria for
			Outcomes Than Persistent/Permanent Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction	lecture, Novo Nordisk Inc., MSD, honoraria for lecture
Moghtaderi	Ali	Traditional and Novel Factors Used to Assess	Impact of Medical Liability Reform on Coronary Artery Disease Testing and Intervention	Nothing to Disclose
		the Risk of, and Used for the Treatment of, Coronary Artery Disease	resung and intervention	
Mohamed Kelli	Heval	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Association Between Circulating Progenitor Cells and Outcomes in Patients With Coronary Artery Disease	Nothing to Disclose
		Coronary Artery Disease	Fatients With Colonary Artery Disease	
Mohamed Kelli	Heval	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Inflammatory Response to Mental Stress and Mental Stress Induced Myocardial Ischemia	Nothing to Disclose
		Coronary Artery Disease	,	
Mohamed Kelli	Heval	Updates on Risk Factors for Cardiovascular Disease	Changes in Body Fat Distribution Is Associated With Oxidative Stress	Nothing to Disclose
Mohamed Kelli	Heval	Advances in HCM, PPCM and Other	Living in a Food Desert Is Associated With an Early Hazard of Death	Nothing to Disclose
Mohamed Kelli	Heval	Cardiomyopathies The Evolving World of LVADs, Transplant and	and Hospitalization in Heart Failure Patients Progenitor Cells and Clinical Outcomes in Patients With Heart	Nothing to Disclose
		Other Novel Discoveries	Failure	
Mohamed Kelli	Heval	Unusual Presentations of ACS	Circulating Progenitor Cells Levels and Outcomes in Acute Myocardial Infarction	Nothing to Disclose
Mohamedali	Burhan		Fulminant Myocarditis With Cardiogenic Shock From Eosinophilic	Nothing to Disclose
		Pulmonary Hypertension	Myocarditis: Successfully Treated With Immunosuppresive Therapy With Complete Recovery of Cardiac Function	
Mohamedali	Burhan	FIT Clinical Decision Making: Heart Failure and	Recurrence of Cardiac Sarcoidosis Post-Orthotropic Heart	Nothing to Disclose
Mohammed	Selma	Pulmonary Hypertension Distinct Phenotypes in HFpEF: Beyond	Transplant in the Background of Allograft Rejection Case Presentation	Nothing to Disclose
		Ejection Fraction		-
Mohammed	Selma	Distinct Phenotypes in HFpEF: Beyond Ejection Fraction	Case Presentation	Nothing to Disclose
Mohan	Mohapradeep	Making Progress in Understanding Heart	Prognostic Role of Neutrophil to Lymphocyte Ratio in Predicting	Nothing to Disclose
Mohanad	Ahmad	Failure Variations in Management of STEMI:	Outcomes in Patients With Chronic Heart Failure Management of STEMI in Egypt: Unusual Case Presentations	Nothing to Disclose
		International Perspectives From the Egyptian	Эрг энгэг эгг эгг эгг эгг эгг эгг эгг эгг	······································
		Society of Cardiology, Pakistan Cardiac Society, and American College of Cardiology		
Mohananey	Divyanshu	Revascularization and Myocardial Preservation	Temporal Trends and Outcomes of Emergent Coronary Artery	Nothing to Disclose
		in Acute and Stable Ischemic Heart Disease	Bypass Graft Surgery for ST-Segement Elevation Myocardial Infarction	
Mohananey	Divyanshu	Interventional Cardiology: TAVR 2	Comparison of In-Hospital Outcomes of Transcatheter Aortic Valve Replacement in Men and Women	Nothing to Disclose
Mohananey	Divyanshu	Interventional Cardiology: TAVR 3	Clinical Outcomes of Patients With Pacemaker Implantation After	Nothing to Disclose
			Transcatheter Aortic Valve Replacement: Meta-Analysis and Meta- Regression	
Mohananey	Divyanshu	Antithrombotic Therapy in Ischemic Heart	Role of Anticoagulation Therapy After Anterior Wall ST-Elevation	Nothing to Disclose
		Disease	Myocardial Infraction in Preventing LV Thrombus: A Meta-Analysis and Meta-Regression	
Mohananey	Divyanshu	Advances in Chronic Total Occlusion	Trends and In-Hospital Outcomes of Patients Admitted With ST	Nothing to Disclose
		Intervention	Elevation Myocardial Infarction and Chronic Total Occlusions: Insights From a National Database	
Mohanty	Mitra	Atrial Fibrillation and VT: Unique Populations	Use of an Esophageal Retractor to Prevent Thermal Injuries During	Nothing to Disclose
Mohanty	Prasant	and Solutions Arrhythmias and Clinical EP: AF Ablation	Atrial Fibrillation Ablation: A Multi-Center Experience Long-Term Outcome of Pulmonary Vein Isolation With and Without	Nothing to Disclose
Monanty	radam	7 amyummac ana cimical El 17 a 7 anadon	Focal Impulse and Rotor Modulation (FIRM) Mapping: Results From	Treating to Discisso
Mohanty	Prasant	Arrhythmias and Clinical EP: AF Miscellaneous	a Meta-Analysis CHADS2 Score Predicts Outcomes of Radiofrequency Catheter	Nothing to Disclose
-		and Surgical Issues	Ablation in Patients With Atrial Fibrillation	-
Mohanty	Sanghamitra	Arrhythmias and Clinical EP: AF Ablation	Long-Term Outcome of Pulmonary Vein Isolation With and Without Focal Impulse and Rotor Modulation (FIRM) Mapping: Results From	Nothing to Disclose
Mohant:	Canabait	Arrhythmine and Olisias ED: AE Alders	a Meta-Analysis	Nothing to Displace
Mohanty	Sanghamitra	Arrhythmias and Clinical EP: AF Ablation	Long-Term Risk of Recurrent Arrhythmia in Patients With Typical Atrial Flutter Undergoing Pulmonary Vein Antrum Isolation or Cavo-	Nothing to Disclose
Mohanty	Sanghamitra	Atrial Fibrillation and VT: Incorporating Novel	Tricuspid Isthmus Ablation With Permanent Isolation Left Atrial Appendage Flow Velocity to Predict Persistent Left Atrial	Nothing to Disclose
-	_	Risks Toward Decision Making	Appendage Isolation	-
Mohanty	Sanghamitra	Innovation in Practice Management, Advocacy, and Education	Importance of Twitter During Cardiology Conferences	Nothing to Disclose
Mohiaddin	Raad	Innovative Approaches for Reducing Risk and	Cardiovascular Magnetic Resonance in Survivors of Sudden	CONSULTANT FEES/HONORARIA - Novartis Pharma
		Improving Outcomes With Ablation	Cardiac Arrest: 14 Year Experience From a Tertiary Referral Centre in the United Kingdom	
Mohler	Peter	Understanding Pulmonary Vascular Disease:	Potential Mediators of Right Heart Failure in Pulmonary Arterial	Nothing to Disclose
Mohr	Friedrich	From Bench to Bedside Interventional Cardiology: TAVR 2	Hypertension Different Impact of Gender on Early and Late Outcome After	Nothing to Disclose
			Transcatheter Aortic Valve Replacement	-
Mohr	Friedrich	Interventional Cardiology: TAVR 2	Higher B-Type Natriuretic Peptide Levels Predict Occurrence of Acute Kidney Injury After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Mohr	Friedrich	Interventional Cardiology: TAVR 2	Impact of Myocardial Injury Indicated by Increased Creatinine Kinase	Nothing to Disclose
			Myocardial Band Levels on the Outcome After Transcatheter Aortic Valve Replacement: Results From a Prospective Single Center	
			Registry	
Mohr	Friedrich	Interventional Cardiology: TAVR 4	Impact of Cancer Disease on Outcome of Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Mohri	Masahiro	Unusual Presentations of ACS	Clinical Characteristics and In-Hospital Mortality of Very Elderly	Nothing to Disclose
	<u> </u>		Patients With Cardiovascular Shock in Japan: The Results From Japanese Circulation Society Shock Registry	
Mohri	Masahiro	Unusual Presentations of ACS	Association Between Presentation Time and Short-Term Mortality in	Nothing to Disclose
	1		Patients With Cardiogenic Shock Complicating Acute Coronary Syndrome: From Jcs Shock Registry	

Mohty	First Name Dania Dania	Session Title Highlighted Original Research: Valvular Heart Disease and the Year in Review	Presentation Title Impact of Renin-Angiotensin System Blockers on Long Term Survival Following Isolated Aortic Valve Replacement for Aortic Stenosis	Disclosures Nothing to Disclose
-	Dania	Disease and the fear in Review		
-				
		Novel Determinants of Outcomes in VHD	Electrocardiographic Strain Is Associated With Reduced Survival After Surgical Aortic Valve Replacement for Aortic Stenosis	Nothing to Disclose
Mojaddedi	Sanaullah	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Right Upper Lung Lobe Infiltrate	Nothing to Disclose
Mojadidi	Mohammad	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Right Upper Lung Lobe Infiltrate	Nothing to Disclose
Mojadidi	Mohammad	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Early Invasive Strategy and In-Hospital Survival of Diabetics With Non-ST-Elevation Myocardial Infarction: A Contemporary National Insight	Nothing to Disclose
Mojadidi	Mohammad	FIT Clinical Decision Making: Arrhythmias and	An Exciting Wide Complex Tachycardia	Nothing to Disclose
Mojadidi	Mohammad	Electrophysiology FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Coronary Artery Bypass Graft Pseudoaneurysm From Saphenous Vein Graft Stent Rupture	Nothing to Disclose
Moles	Victor	35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1	Suggested Reviewer	Nothing to Disclose
	Victor	FIT Clinical Decision Making Reviewers 6	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
	David	Peer-reviewed Publishing	Co-Chair	DATA SAFETY MONITORING BOARD - Jannsen Pharmaceuticals; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals
Moliterno	David	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study	DATA SAFETY MONITORING BOARD - Jannsen Pharmaceuticals; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals
Moliterno	David	03. Acute and Stable Ischemic Heart Disease: Therapy Team 2	Suggested Reviewer	DATA SAFETY MONITORING BOARD - Jannsen Pharmaceuticals; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals
Møller	Jacob	Making Progress in Understanding Heart Failure	NT-proBNP, Left Ventricular Structure and Function, and Long- Term Cardiovascular Events: Insights From a Prospective	Nothing to Disclose
Møller	Jacob	Cardiac Arrest, Diabetes, and Other High Risk	Population-Based Cohort Study Association Between QRS Duration on Prehospital	Nothing to Disclose
		Features of Patients With Acute Coronary Syndrome	Electrocardiogram and Early Outcome in Patients With ST Segment Elevation Myocardial Infarction	
Möllmann	Helge	Interventional Cardiology: TAVR 3	Multicenter Evaluation of the ACURATE Neo Transfemoral Transcatheter Heart Valve: Clinical Results and Propensity Matched Comparison With SAPIEN 3	Nothing to Disclose
Möllmann	Helge	Interventional Cardiology: TAVR 4	Multicenter Evaluation of Prosthesis Oversizing for the SAPIEN 3 Transcatheter Heart Valve: Impact on New Pacemaker Implantations	Nothing to Disclose
Molossi	Silvana	ECG Screening in Athletes: The Great Debate	Co-Chair	Nothing to Disclose
Molossi	Silvana	Non Invasive Imaging: Role of Exercise Testing	Stress Myocardial Perfusion Imaging in Anomalous Aortic Origin of a Coronary Artery: Results Following a Standardized Approach	Nothing to Disclose
Molossi	Silvana	31. Non Invasive Imaging: Sports and Exercise Team 1	Suggested Reviewer	Nothing to Disclose
Moltrasio	Marco	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Renal Replacement Therapy in Patients With Acute Myocardial Infarction: Rate of Use, Clinical Predictors and Relationship With In-	Nothing to Disclose
Momin	Wafi	FIT Clinical Decision Making: Non-Invasive	Hospital Mortality Successful Percutaneous Valve-In-Valve Intervention for Bio-	Nothing to Disclose
Momose	Mitsuru	Imaging and Valvular Heart Disease Nuclear Cardiology: Coronary Flow	Prosthetic Mitral Valve Failure Patient Based Territorial Coronary Flow Analysis by Voronoi	Nothing to Disclose
Momose	Mitsuru	Non Invasive Imaging: MR Structure and	Algorithm With ¹³ N Ammonia PET CTA Fusion Cardiac Diffusion Weighted Image in Patients With Cardiac	Nothing to Disclose
Monaco	James	Valuvular Heart Disease FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Sarcoidosis: Comparison to ¹⁸ F-fludeoxyglcose PET Misleading Leads: Hemothorax From Very Late Spontaneous Coronary Sinus Lead Perforation 13 Years After CRT-D	Nothing to Disclose
Monaghan	Mark	28. Non Invasive Imaging: Echo Team 3	Implantation Suggested Reviewer	RESEARCH/RESEARCH GRANTS - GE Medical ,Philips Medical Systems,TomTec; SPEAKER'S BUREAU - Edwards Lifesciences,Philips Medical Systems,Siemens Medical Systems
Monahan	Ken	FIT Clinical Decision Making: Acute Coronary	Takayasu Arteritis Presenting as Syncope and "Pseudo-	Nothing to Disclose
Monda	Keri	Syndrome and Vascular Medicine Featured Clinical Research III	Hypotension" in a Young Caucasian Woman Early Challenges for PSCK9 Inhibitor Prescriptions and Patients:	SALARY - Amgen Inc.
Monda	Keri		Rejections and Rates Unfilled PCSK9 Variants and Neurocognitive Impairment: Data From the	SALARY - Amgen Inc.
		the Year in Review	REasons for Geographic and Racial Differences in Stroke (REGARDS) Study	
Monda	Keri	Advances in Cholesterol Measurement and Management	Prevalence and Correlates of Statin Side Effects and Willingness to Be Re-Challenged on a Statin: Data From the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study	SALARY - Amgen Inc.
Monda	Keri	Advances in Cholesterol Measurement and Management	Psychosocial Factors and Statin Intolerance: Data From the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study	SALARY - Amgen Inc.
Monda	Keri	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	A Retrospective Descriptive Analysis of PCI Patients by Indication for Treatment, Comorbidities, and Lipid Therapy Using Real-World, Linked NCDR Registry and Pharmacy Claims Data	SALARY - Amgen Inc.
Monda	Keri	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Trends in the Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011-2014	SALARY - Amgen Inc.
Mondal	Pratik	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	In-Hospital Outcomes and Hospitalizations for Acute Rheumatic Heart Disease: A United States National Study	Nothing to Disclose
Mondal	Pratik	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Prevalence and In-Hospital Outcomes of Uremic and Dialysis Pericarditis: A United States National Study	Nothing to Disclose
Mondal	Pratik	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Etiology and Predictors of 30-Day Unplanned Readmission Rates After Left Ventricular Assist Device Placement	Nothing to Disclose
Moneghetti	Kegan	Interventional Cardiology: TAVR 1	The Inflammasome Pathway Is Associated With Adverse Ventricular Remodeling Following Transcatheter Aortic Valve Replacement	Nothing to Disclose
Moneghetti	Kegan	Imaging the Athlete's Heart	Addressing Reference Echocardiographic Parameters in Athletic Screening: A College Football-Based Study Focusing on the	Nothing to Disclose
Moneghetti	Kegan	Innovative Use of Echocardiography	Implications of Race and Correction for Body Composition Identifying the Optimal Echocardiographic Variables to Predict Outcome Through Correlation Mapping in Patients With Dilated	Nothing to Disclose
Moneghetti	Kegan	Advances in HCM, PPCM and Other	Cardiomyopathy Integrating Myocardial Strain and Exercise Performance Into	Nothing to Disclose
	Lisa	Cardiomyopathies Innovations in Practice Management and	Prognostication of Hypertrophic Cardiomyopathy Accelerator 2 SUSTAIN, A U.S. Regional Systems of Care	Nothing to Disclose
Monk				
	Lisa	Social Media Innovation in Practice Management, Advocacy,	Demonstration Project for Post-Discharge STEMI Patients: Preliminary Data, Methods and Design Early Defibrillation by First-Responders in Relation to Fire Stations:	Nothing to Disclose

Contract of the second				l
Last Name Monrad	First Name	Session Title Cardiac Arrest, Diabetes, and Other High Risk	Presentation Title Sex Differences in Revascularization and In-Hospital Outcomes of	Disclosures Nothing to Disclose
Monrad	Ernest	Features of Patients With Acute Coronary Syndrome	Sex Differences in Revascularization and In-Hospital Outcomes of Non-ST-Segment Elevation Myocardial Infarction in the United States	Nothing to Disclose
Monrad	Ernest	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Association of Academic Year-End Changeover With Survival Rates After In-Hospital Cardiac Arrest: An Examination of the "July Effect"	Nothing to Disclose
Monrad	Ernest	Optimizing the Care of ACS Patients	Weekend Versus Weekday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide Analysis	Nothing to Disclose
Monsalvo	Maria Laura	Advances in Cholesterol Measurement and	Impact of Evolocumab Therapy in Patients With Discordance	SALARY - Amgen, Inc.
Monsalvo	Maria Laura	Management Heart Failure and Cardiomyopathies: What	Between LDL-C and LDL-P The Cardiac Myosin Activator, Omecamtiv Mecarbil, Improves Left	SALARY - Amgen, Inc.
Montalogoat	Gilles	Next When All Else Is Failing? Antiplatelet and Antithrombotic Agents in	Ventricular Myocardial Deformation in Chronic Heart Failure (COSMIC-HF) Mineralocorticoid Receptor Antagonists in Patients With Acute	CONSULTANT FEES/HONORARIA -
Montalescot	Gilles	Ischemic Heart Disease	Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Trials	Acultude, Amgen, AstraZeneca, Bayer, Berlin Chimie AG, BMS, Boehringer-Ingelheim, Brigham Women's Hospital, Cardivascular Research Foundation, CME Resources, Daiichi-Sankyo, Eli-Lilly, Europa Organisation, Höpitaux Universitaires de Genève, Lead-Up, Medcon International, MEDTRONIC, Menarini, MSD, Pfizer, Sanofi- Aventis, Stentys, The Medicines Company, TIMI Study Group, Universitat Basel, WebMD, Zoll Medical; RESEARCH/RESEARCH GRANTS - ADIR, AstraZeneca, BMS, Celladon, Daiichi-Sankyo, Eli- Lilly, Fédération Française de Cardiologie, gilead, ICAN, Janssen- Cilag, Pfizer, Recor, Sanofi-Aventis, Stentys
Montgomery	Daniel	Vascular Medicine: Novel Risk Measures in	Body Mass Index and Acute Aortic Dissection	Nothing to Disclose
Montgomery	Daniel	Arterial Diseases Vascular Medicine: Emerging Concepts in	Influence of Family History of Aortic Disease on Type B Aortic	Nothing to Disclose
Montgomery	Daniel	Clinical Vascular Diseases Beans, Beans, Good for Your Heart	Dissection Analysis of the Timing of Thoracic Endovascular Aortic Repair and	Nothing to Disclose
Montgomery	Daniel	Vascular Medicine: Aortic and Peripheral Artery Diseases	Its Indications and Outcomes in Type B Aortic Dissection Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of	Nothing to Disclose
Montgomery	Daniel	Vascular Medicine: Aortic and Peripheral	Acute Aortic Dissection Uncontrolled Hypertension in Acute Aortic Dissection Follow-Up	Nothing to Disclose
Montgomery	Daniel	Artery Diseases Vascular Medicine: Aortic and Peripheral	Acute Aortic Dissection in Patients Without a History of Hypertension	Nothing to Disclose
Montisci	Roberta	Artery Diseases Advances in HCM, PPCM and Other	Tako Tsubo Cardiomyopathy or Myocarditis?	Nothing to Disclose
Montisci	Roberta	Cardiomyopathies Cardiac Arrest, Diabetes, and Other High Risk	Reperfusion Delays in Women With STEMI	Nothing to Disclose
		Features of Patients With Acute Coronary Syndrome		-
Montori	Victor	Innovations in Cardiovascular Risk Assessment and Reduction	Making for Primary Prevention Statin Therapy	Nothing to Disclose
Moody Moody-Williams	William Jean	Nuclear Cardiology: Prognosis 48th Annual Louis F. Bishop Lecture	Serial Myocardial Perfusion Imaging in End-Stage Renal Disease Panelist	Nothing to Disclose Nothing to Disclose
Mookadam	Farouk	Highlights in Vascular Medicine Research	The Addition of Renal Impairment to the CHA2DS2-VASc Score as	Nothing to Disclose
Moon	Jae-Youn	Novel Developments in Acute Coronary	a Predictor of Thromboembolism and Mortality in Patients Without Atrial Fibrillation Serial Measurements of Neutrophil Gelatinase-Associated Lipocalin	Nothing to Disclose
		Syndromes	(NGAL): Prognostic Value in Stemi Patients Treated by Primary Percutaneous Coronary Intervention	
Moon	James	Great Debates in Cardiac MRI	Debate Pro: T1 and T2 Mapping: Ready for Widespread Utilization?	Nothing to Disclose
Moon	Jeonggeun	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Prognostic Impact of Alkaline Phosphatase Measured at the Time of Presentation in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Moon	Jeonggeun	Interventional Cardiology: Structural Heart	Effect of PFO Closure for Prevention of Recurrent Stroke or TIA in	Nothing to Disclose
Mooney	John	Disease Non Invasive Imaging: Expanding Clinical	Highly Selected Patients With Cryptogenic Stroke Does Patient Prosthesis Mismatch Defined by CT LVOT Area	Nothing to Disclose
Mooney	Michael	Applications 19. Interventional Cardiology: Complex Patients/Comorbidities Team 2	Predict Downstream Clinical Outcomes? Suggested Reviewer	Nothing to Disclose
Mooney	Paula	Controversies in Hypertension	Co-Chair	Nothing to Disclose
Moon-Grady	Anita	10. Congenital Heart Disease: Pediatric Team 3	Suggested Reviewer	Nothing to Disclose
Moore	Hans	Assessing the Clinical Impact of Blood Pressure Lowering Therapies	Guidelines Allowing Control of Hypertension in Non-Diabetics Greater Than 60 Years Old at up to 150 mmHg Average Systolic Blood Pressure Increases Patient Mortality in Veterans	Nothing to Disclose
Moore	Hans	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Characteristics and Incidence of Atrial Fibrillation in US Veteran Centenarians	Nothing to Disclose
Moore	JoEllyn	Arrhythmias and Clinical EP: Devices 4	High Battery Impedance in the Pacemaker Dependent Patient: Early Recognition and Collaborative Management of InSync III CRT-P Device Failures	Nothing to Disclose
Moore	Nicholas	Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	Effectiveness and Safety of Direct Oral Anticoagulants Compared With Vitamin-K Antagonists: Initial Results From a Cohort Study in the Nationwide French Claims and Hospitalization Database (SNIIRAM)	CONSULTANT FEES/HONORARIA - Pfizer Inc; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc,Bristol Myers Squibb,Pierre Fabre Pharmaceuticals Inc
Moore	Peter	Unusual Presentations of ACS	Association of Cocaine and Amphetamine Use With Troponin I Concentrations	Nothing to Disclose
Moore	Phillip	Assuring Quality in the Cath Lab: Documentation, Appropriate Use, Peer Review, and Public Reporting	Reducing Radiation Risk: QI San Francisco Expierence	RESEARCH/RESEARCH GRANTS - Gore,St Jude Medical
Moore	Phillip	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Coronary Artery Fistula in Pulmonary Atresia With Intact Ventricular Septum Physiology. To Close or Not To Close ?	RESEARCH/RESEARCH GRANTS - Gore,St Jude Medical
Moore	Ryan	Heart Failure and Cardiomyopathies: What	Spironolactone Therapy for Cardiomyopathy in Duchenne Muscular	Nothing to Disclose
Moorman	Randall	Next When All Else Is Failing? Arrhythmias and Clinical EP: Syncope and	Dystrophy Continuous Monitoring of Cardiorespiratory Dynamics Detects	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
		Other EP Issues	Clinical Deterioration in Acute Care Patients	ROLE - Advanced Medical Predictive Devices, Diagnostics and Displays
Moorthy	Nagaraja	Timely Topics in Acute Coronary Syndromes	Acute Coronary Syndrome in Retroviral Positive Patients Challenges and Dilemmas With Special Emphasis on Coronary Revascularization	Nothing to Disclose
Mooss	Aryan	Atrial Fibrillation and VT: Unique Populations	Sotalol Versus Other Anti-Arrhythmic Medications for Cardioversion	RESEARCH/RESEARCH GRANTS - Glaxo smith kline
		and Solutions	of Atrial Fibrillation and Maintenance of Sinus Rhythm: Meta- Analysis of Randomized Controlled Studies	,Pfizer,Bristol MyersSquibb



Control of the contro				<u> </u>
Last Name Mooss	First Name Aryan	Session Title Atrial Fibrillation and VT: Incorporating Novel	Presentation Title Sotalol Versus Other Anti-Arrhythmic Agents for Prevention of Post-	Disclosures RESEARCH/RESEARCH GRANTS - Glaxo smith kline
		Risks Toward Decision Making	Operative Supraventricular Arrhythmias After Cardiac Surgery: Meta- Analysis of Randomized Controlled Studies	,Pfizer,Bristol MyersSquibb
Moquete	Ellen	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic Surgical Trials Network	Nothing to Disclose
Mora	Samia	Great Debates in Preventive Cardiology	Fasting vs Non-fasting Lipid Testing - Fasting is Unnecessary for Lipid Testing	CONSULTANT FEES/HONORARIA - Amgen,Pfizer; RESEARCH/RESEARCH GRANTS - Atherotech
Mora	Samia	32. Prevention: Clinical Team 1	Suggested Reviewer	Diagnostics,QUEST CONSULTANT FEES/HONORARIA - Amgen,Pfizer; RESEARCH/RESEARCH GRANTS - Atherotech Diagnostics,QUEST
Morady	Fred	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Anticoagulation Protocol After Radiofrequency Ablation of Infarct- Related Ventricular Tachycardia: Institutional Experience and Outcomes	OTHER - Accutus
Morady	Fred	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	OTHER - Accutus
Morais	José	Interventional Cardiology: TAVR 4	Serum Albumin as an Incremental Predictor of Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement: Results From the Multicenter Frailty-AVR Study	Nothing to Disclose
Moran	Andrew	New Insights Into Prediction and Treatment of	Cost-Effectiveness of Intensive Blood Pressure Goals in Patients	Nothing to Disclose
Morant	Kareem	Hypertension FIT Clinical Decision Making: Non-Invasive	With Prior Cardiovascular Disease Atrial Fibrillation in Aortic Stenosis: A Diagnostic and Therapeutic	Nothing to Disclose
Mor-Avi	Victor	Imaging and Valvular Heart Disease Valvular Heart Disease: Aortic Regurgitation	Challenge Left Ventricular Mechanical Properties in Patients With Severe Aortic	Nothing to Disclose
			Insufficiency and Normal Ejection Fraction: Impact on Survival	
Mor-Avi	Victor	Innovative Use of Echocardiography	Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography	Nothing to Disclose
Mor-Avi	Victor	Non Invasive Imaging: MR Scar and Perfusion	Multimodality Analysis of Abnormal Myocardial Perfusion in Post- Heart Transplant Recipients	Nothing to Disclose
Mor-Avi	Victor	New Technologies in Echocardiography	Three-Dimensional Echocardiographic Automated Quantification of Left Ventricular and Atrial Volumes Using Adaptive Analytics	Nothing to Disclose
Mordi	lfy	Highlighted Original Research: Non Invasive	Algorithm: Feasibility in Non-Selected Patients Prognostic Significance of Co-Existing Persistent Edema and	Nothing to Disclose
		Imaging and the Year in Review	Hemorrhage at 6 Months in Survivors of ST-Elevation Myocardial Infarction	
Moreira	Adriana	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Independent Predictors of Mace at Different Time Points After the Treatment of Non-Selected Patients With Drug-Eluting Stents: An Analysis of the Desire Registry	Nothing to Disclose
Moreland	Jason	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	The Feasibility and Safety of Same Day Discharge for All Comers After Elective Percutaneous Coronary Interventions	Nothing to Disclose
Moreno	Pedro	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Atherosclerotic Plaque Morphology in Response to High Intensity Lipid Lowering Therapy by Multimodality Imaging Among Women and Men: A YELLOW-II Sub-study	CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S BUREAU - saint Jude
Moreno	Pedro	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Clinical Outcomes Associated With Impella Versus IABP Use in Stable Patients Undergoing High Risk Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S BUREAU - saint Jude
Moreno	Pedro	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Impella or Intra-Aortic Balloon Pump Support in Patients Undergoing High Risk Percutaneous Coronary Intervention: A Real World Single Center Experience	CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S BUREAU - saint Jude
Moreno	Pedro	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Angiographic Phenotype and Clinical Outcomes of Patients With Malignancy Undergoing PCI	CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S BUREAU - saint Jude
Moreno	Pedro	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Synergistic Effects of Coronary Calcification and Inflammation on Risks for Adverse Cardiovascular Events After PCI: Results From a Large Single-Center Registry	CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S BUREAU - saint Jude
Moreno	Pedro	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Fractional Flow Reserve Is a Sensitive but Not a Specific Detector of a High Risk Plagues	CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S BUREAU - saint Jude
Moreno	Pedro	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Multimodality Intravascular Imaging to Evaluate Plaque Characteristics in Patients With Diabetes Mellitus	CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S BUREAU - saint Jude
Moreno	Pedro	Novel Developments in Acute Coronary Syndromes	Trends in Incidence and Mortality Associated With Acute Kidney	CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S BUREAU - saint Jude
Moreno	Pedro	Cutting Edge Vascular Medicine	Injury in Patients Undergoing PCI for Acute Coronary Syndrome Proprotein Convertase Subtilisin Kexin Type 9 Protein Expression Is Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Fibrous Plaques	CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S BUREAU - saint Jude
Moreno	Pedro	Innovations in Cardiovascular Risk Assessment	Optical Coherence Tomography of Culprit Lesions in Patients With	CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S
Moreno	Pedro	and Reduction Coronary Intervention: Drug Eluting Stent and Scaffolds	Prior Cerebrovascular Events Compared to Controls Efficacy and Safety of Everolimus-Eluting Stents Versus Slow- Release Zotarolimus-Eluting Stents: A Direct Comparison Meta- Analysis of 29,286 Patients - Years of Follow-Up From Randomized	BUREAU - saint Jude CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S BUREAU - saint Jude
Moreno	Pedro	Timely Topics in Acute Coronary Syndromes	Controlled Trials Predictors of High Intensity Statin Use After Percutaneous Coronary	CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S
Moreno	Pedro	Optimizing the Care of ACS Patients	Interventions Underutilization of High Intensity Statins in a Contemporary High	BUREAU - saint Jude CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S
Moreno	Pedro	Interventional Complexity and Complications	Risk PCI Population Prediction of Acute Kidney Injury in Patients Undergoing Coronary	BUREAU - saint Jude CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S
Moreno	Pedro	Interventional Cardiology: PCI in Complex	Intervention Using Calculation of Serum Osmolality Risk and Impact of Diabetes Mellitus on Ischemic Events in Females	BUREAU - saint Jude CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S
Moreno	Pedro	Patients Noninvasive Assessment of Coronary Flow	and Males After Percutaneous Coronary Intervention Can Necrotic Core Volume Explain Ischemia Coronary Stenosis	BUREAU - saint Jude CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S
Moreno		Reserve: Clinical Implications Highlights in Vascular Medicine Research	Mismatch in Some Cases? Morphological Features of Vascular Healing in Paclitaxel Coated	BUREAU - saint Jude CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S
Moreno		02. Acute and Stable Ischemic Heart Disease:	Balloon Compared to Plain Old Balloon Angioplasty in Human Peripheral Artery Disease Suggested Reviewer	BUREAU - saint Jude CONSULTANT FEES/HONORARIA - Infraredx; SPEAKER'S
Moret		Clinical Team 2 Non Invasive Imaging: Prognostic Implications	Long-Term Prognostic Value of Computed Tomography-Derived	BUREAU - saint Jude Nothing to Disclose
		of CT Angiography	Corrected Contrast Opacification Decrease in Patients With Coronary Stenosis	Ü
Moreu	Jose	Timely Topics in Acute Coronary Syndromes	A New Prognosis Score to Predict Mortality in Patients Over 75 Years Old Undergoing Primary Angioplasty in Cardiogenic Shock	Nothing to Disclose
Moreyra	Abel	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Incidence of Bacterial Endocarditis in Relation to Changes in Guidelines	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Boston Scientific
Moreyra	Abel	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Relationship Between Incident Heart Failure and Dropout Rate in Randomized Clinical Trials of Antihypertensive Therapy	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Boston Scientific
Moreyra	Abel	New Insights Into Prediction and Treatment of Hypertension	The U-Shaped Relationship of Body Mass Index With All-Cause Mortality at Eight Years in the ALLHAT	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Boston Scientific
Morgan	Charity	Making Progress in Understanding Heart Failure	Orthopnea or Paroxysmal Nocturnal Dyspnea in Older Adults Without Prevalent Heart Failure is a Predictor, but Not an Independent Risk Factor for Incident Heart Failure: Insights From the Cardiovascular Health Study	Nothing to Disclose

and a second				
Last Name	First Name	Session Title	Presentation Title Among Older Heart Failure (HF) Patients With In-Hospital Acute	Disclosures Nothing to Disclose
Morgan	Charity	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Among Older Heart Failure (HF) Patients With In-Hospital Acute Kidney Injury (AKI), an Improvement in Kidney Function Is Associated With a Higher Risk of Post-Discharge Mortality but Not Readmission	Nothing to Disclose
Morgan	Charity	Advances in Lipid Management	Hydrophilic Versus Lipophilic Statins in Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Morgan	Charity	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Heart Failure Hospitalization (HFH) Despite Digoxin Therapy Versus No HFH Despite Placebo in the Digitalis Investigation Group (DIG) Trial: Insights Into Risk Factors for HFH in HF and Reduced Ejection Fraction (HFrEF)	Nothing to Disclose
Morgan	Charity	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Clinical Effectiveness of Spironolactone in Hospitalized Older Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or Equal to 30 mL/min/1.73 m ²) Patients With Heart	Nothing to Disclose
Morgan	Charity	Why Can't We Be Friends? Controversies in Heart Failure Management	Failure Adverse Outcomes With Use of Hydralazine and Nitrate Combination Therapy in Hospitalized Older Non-Black Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)	Nothing to Disclose
Morgenstern	Daniel	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Role of Longitudinal Fiber Dysfunction in Stress Induced Left Ventricular Dilatation	Nothing to Disclose
Morgenstern	Rachelle	Emerging Applications for Imaging Cardiac	Fluorine-18 Sodium Fluoride Positron Emission Tomography for	Nothing to Disclose
Mori	Hiroyoshi	Amyloidosis: Nuclear Cardiology Head to Toe: Outcomes of Endovascular Interventions	Imaging Transthyretin Cardiac Amyloidosis Safety and Efficacy of Zilver PTX Drug Eluting Stent Implantation Following Drug Coated Balloon Inflation Versus POBA in Healthy Swine Model	CONSULTANT FEES/HONORARIA - Abbott Vascular Japan,Goodman
Mori	Hiroyoshi	Interventional Cardiology: Translation and Pre- Clinical Research	Endothelial Maturation and Function Following Implantation of Abluminal Coating Biodegradable Polymer Based Sirolimus-Eluting Metallic Stent Versus Conformal Coating Durable Polymer Based Everolimus Eluting Stent	CONSULTANT FEES/HONORARIA - Abbott Vascular Japan,Goodman
Mori	Hiroyoshi	Population Specific Cardiomyopathies: From	Racial Difference in Genetic Variants Associated With Hypertrophic	CONSULTANT FEES/HONORARIA - Abbott Vascular
Mori	Hiroyoshi	Exomes to Databases Complex Coronary Intervention: Left	Cardiomyopathy Pathological Features of Left Main Stent Thrombosis	Japan,Goodman CONSULTANT FEES/HONORARIA - Abbott Vascular
Mori	Hiroyoshi	Main/Bifurcations and Multivessel Disease Coronary Intervention: Drug Eluting Stent and	Long-Term Pathological Result of Everolimus-Eluting Stent Versus	Japan,Goodman CONSULTANT FEES/HONORARIA - Abbott Vascular
Mori	Hiroyoshi	Scaffolds Unusual Presentations of ACS	Silolimus-Eluting Stent and Bare Metal Stent Molecular Autopsy of Plaque Erosion-Induced Sudden Cardiac	Japan,Goodman CONSULTANT FEES/HONORARIA - Abbott Vascular
Mori		Refining PCI Technique and Outcomes	Death in Young Adults (18-35 Years Old) mTors Inhibitors Increase Endothelial Permeability and Prevent	Japan, Goodman CONSULTANT FEES/HONORARIA - Abbott Vascular
	Hiroyoshi	-	Maturation: Uncovering the Mechanism of Neoatherosclerosis in Drug Eluting Stents	Japan,Goodman
Moriarty	John	The Best Structural Interventional Challenging Cases	Microcoil Embolization of an Aortic Root Pseudoaneurysm Through a Transthoracic Approach	CONSULTANT FEES/HONORARIA - Angiodynamics inc,Argon Medical,Penumbra Medical
Moriarty	Patrick	Advances in Cholesterol Measurement and Management	Efficacy and Safety of the PCSK9 Inhibitor Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin Therapy	CONSULTANT FEES/HONORARIA - Aegerion, Duke University, Genzyme, Lisis Pharmaceuticals, Inc., Kowa Pharmacuticals America Inc. Lilly USA, LLC, Regeneron, Sanofi- Aventis; RESEARCH/RESEARCH GRANTS - Amgen Inc., Genzyme, Isis Pharmaceuticals, Inc., Kaneka, Novartis Corporation, Pfizer Inc, Regeneron, Sanofi-Aventis; SPEAKER'S BUREAU - National Lipid Association
Morice	Marie	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: From the WIN-TAVI Registry	Nothing to Disclose
Morillo	Carlos	The Burden of Heart Failure: International Perspectives From the Chilean Society of Cardiology, Colombian Society of Cardiology, and American College of Cardiology	New Insight Into Trypanocidal Treatment: The BENEFIT & STOP-CHAGAS Trials	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,Boston Scientific; OTHER - MEDTRONIC; RESEARCH/RESEARCH GRANTS - Merck & Dept. Co., Inc.
Morillo	Carlos	Controversies in Atrial Fibrillation Management	Who and When to Implant an ILR in A Stroke Patient and What to do with the Data	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,Boston Scientific; OTHER - MEDTRONIC; RESEARCH/RESEARCH GRANTS - Merck & Co., Inc.
Morillo	Carlos	Syncope: What's New	Contemporary Management of the Patient with POTS: What Can We Offer in 2017?	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,Boston Scientific; OTHER - MEDTRONIC; RESEARCH/RESEARCH GRANTS - Merck & Co., Inc.
Morillo	Carlos	Syncope: Challenges and Pitfalls: A Case- based Approach	Panelist	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,Boston Scientific; OTHER - MEDTRONIC; RESEARCH/RESEARCH GRANTS - Merck & Co., Inc.
Morillo	Carlos	Syncope: Challenges and Pitfalls: A Case- based Approach	22 Year Old Football Player with Recent Onset Palpitations and Dizzy Spells	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,Boston Scientific; OTHER - MEDTRONIC; RESEARCH/RESEARCH GRANTS - Merck & Co., Inc.
Morimoto	Takeshi	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Application of DAPT Score to Predict Ischemic and Bleeding Events in Japanese Patients Undergoing Drug-Eluting Stent Implantation: An Observation From a Pooled Cohort of the CREDO-Kyoto Cohort- 2, RESET, and NEXT Trials	SPEAKER'S BUREAU - AstraZeneca K.K.,Daiichi-Sankyo
Morin	Daniel	Nuclear Cardiology: Coronary Flow	Reduced Flow Capacity as Measured by Cardiac Positron Emission Tomography Predicts Ventricular Tachyarrhythmia in Patients With an ICD	RESEARCH/RESEARCH GRANTS - Boston Scientific,MEDTRONIC; SPEAKER'S BUREAU - Biotronik,Boeringer-Ingelheim,Boston Scientific,Medtronic, Inc.,Zoll
Morinaga	Takashi	Interventional Cardiology: PCI in Complex Patients	Three-Year Clinical Outcomes of the XIENCE/PROMUS Cobalt- Chromium Everolimus-Eluting Stent in Patients Treated With In- Stent Restenosis	Nothing to Disclose
Morine	Kevin	Young Investigator Awards Competition: Basic and Translational Science	Rbmp9	Nothing to Disclose
Morino	Yoshihiro	Unusual Presentations of ACS	Incidence and Predictors of Lesion Specific Ischemia by FFR _{CT} : Learnings From the International ADVANCE	CONSULTANT FEES/HONORARIA - Abbott Vascular, Terumo; SPEAKER'S BUREAU - Boston Scientific, Daiichi Sankyo, Sanofi-
Moris	Cesar	Interventional Cardiology: TAVR 2	Registry Effect of Body Mass Index on Mortality After Transcatheter Aortic	Aventis,St Jude Medical CONSULTANT FEES/HONORARIA - Advisor,Medtronic
Morita	Yukiko	The Evolving World of LVADs, Transplant and	Valve Implantation: J-Shaped Curve B-Type Natriuretic Peptide Levels Is a Useful Prognostic Marker in	Corevalve proctor Nothing to Disclose
Morledge	Michael	Other Novel Discoveries Obesity Management in 2017: Weighing the	the Patients With Eosinophilic Granulomatosis With Polyangiitis Fitness and the Obesity Paradox in Cardiac Rehabilitation: How	Nothing to Disclose
		Issues	Does Weight Loss Factor in?	-
Morlend Moroi	Robert	The Evolving World of LVADs, Transplant and Other Novel Discoveries The Evolving World of LVADs, Transplant and Other Novel Discoveries	Cardiac Atrophy: A Novel Mechanism for Duchenne Muscular Dystrophy (DMD)-Associated Cardiomyopathy Evaluation of Hemoconcentration Based Bioelectrical Vectorial Impedance Analysis Is Useful Risk Stratification in Acute	Nothing to Disclose Nothing to Disclose
Moroi	Masao	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Decompensated Heart Failure Body Fat Percentage Evaluated by a Bioelectrical Impedance Analysis Provides Prognostic Value in Acute Heart Failure: Beyond on the ᡌObesity Paradoxᡍ	Nothing to Disclose
Morrical	Brandon	Improving Outcomes in the Athlete With	Exercise Testing in Pediatric Patients: Objective Versus Subjective	Nothing to Disclose
<u> </u>	J	Cardiovascular Disease	Effort	



Congress of the same				
Last Name	First Name	Session Title	Presentation Title	Disclosures Nothing to Disclose
Morrical	Brandon	Adult Patients With Congenital Heart Disease: How Do They Compare?	Exercise Capacity After Repair of Ebstein Anomaly in Adults: The Cone Era	-
Morris	Alanna	Making Progress in Understanding Heart Failure	Ambulatory Actigraphy Monitoring of Patients With Heart Failure With Reduced Ejection Fraction Predicts 6-Minute Walk Distance	Nothing to Disclose
Morris	Alanna	Advances in HCM, PPCM and Other Cardiomyopathies	Living in a Food Desert Is Associated With an Early Hazard of Death and Hospitalization in Heart Failure Patients	Nothing to Disclose
Morris	Amy	Point of Care Ultrasound (POCUS): The Future or a Fad?	Panelist	Nothing to Disclose
Morris	Amy	Point of Care Ultrasound (POCUS): The Future or a Fad?	POCUS: The Critical Care Perspective	Nothing to Disclose
Morris	Dennis	Novel Developments in Acute Coronary Syndromes	Right-Sided Ventriculo-Arterial Coupling Indices Are Associated With Clinical Outcomes Among Patients Receiving Biventricular Impella (BiPella) Support for Cardiogenic Shock	CONSULTANT FEES/HONORARIA - Boston Scientific; SPEAKER'S BUREAU - Astra Zeneca,Lilly
Morris	Dennis	Coronary Intervention in Interventional Cardiology: Core Concepts	White Blood Cell Count to Platelet Ratio: A Novel Biomarker of Outcomes in Patients With Circulatory Support on Left Ventricular Impella Assist Devices	CONSULTANT FEES/HONORARIA - Boston Scientific; SPEAKER'S BUREAU - Astra Zeneca,Lilly
Morris	Lauren	Great Minds Think Differently: Multidisciplinary Approach to Controversies in Cardiology	Co-Chair	CONSULTANT FEES/HONORARIA - Edwards, Medtronic, Abiomed, Abbott
Morris	Lauren	Great Minds Think Differently: Multidisciplinary Approach to Imaging	Co-Chair	CONSULTANT FEES/HONORARIA - Edwards, Medtronic, Abiomed, Abbott
Morris	Lauren		Co-Chair	CONSULTANT FEES/HONORARIA - Edwards, Medtronic, Abiomed, Abbott
Morris	Lauren	Imaging for TAVR: Homing in on the Real	Panelist	CONSULTANT FEES/HONORARIA - Edwards, Medtronic,
Morris	Pamela	Issues Opening Session and the Joint American College of Cardiology and Journal of American College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture	Panelist	Abiomed, Abbott CONSULTANT FEES/HONORARIA - Amgen Inc. AstraZeneca, Sanofi Regeneron; RESEARCH/RESEARCH GRANTS - Amgen Inc.
Morris	Pamela	Who Should Benefit From Preventive Cardiology?: International Perspectives From the European Society of Cardiology and the American College of Cardiology	Update on the Management of Dyslipidemia	CONSULTANT FEES/HONORARIA - Amgen Inc.,AstraZeneca,Sanofi Regeneron; RESEARCH/RESEARCH GRANTS - Amgen Inc.
Morris	Pamela	7th Annual ACC China Chapter Session: Endless Change and Evolution in Cardiovascular Prevention and Rehabilitation	Guidelines for the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: Implications for Management of Dyslipidemia in China	CONSULTANT FEES/HONORARIA - Amgen Inc., AstraZeneca, Sanofi Regeneron; RESEARCH/RESEARCH GRANTS - Amgen Inc.
Morris	Pamela	Coming to Consensus in a New Era: The Role of Non-statin Therapies in ASCVD Risk Reduction	Co-Chair	CONSULTANT FEES/HONORARIA - Amgen Inc., AstraZeneca, Sanofi Regeneron; RESEARCH/RESEARCH GRANTS - Amgen Inc.
Morris	Pamela	Dyslipidemias: A Potpourri of Complexities	Co-Chair	CONSULTANT FEES/HONORARIA - Amgen Inc., AstraZeneca, Sanofi Regeneron; RESEARCH/RESEARCH GRANTS - Amgen Inc.
Morris	Pamela	Core Curriculum: Healthcare for the Masses	"I Didn't Inhale": Alternative Nicotine Products and CVD	CONSULTANT FEES/HONORARIA - Amgen Inc., AstraZeneca, Sanofi Regeneron; RESEARCH/RESEARCH GRANTS - Amgen Inc.
Morris	Pamela	Recent Trends in Combination Therapy: Managing Cholesterol Even in the Most Resistant	Chair	CONSULTANT FEES/HONORARIA - Amgen Inc., AstraZeneca, Sanofi Regeneron; RESEARCH/RESEARCH GRANTS - Amgen Inc.
Morris	Pamela	Recent Trends in Combination Therapy: Managing Cholesterol Even in the Most Resistant	Introduction to Session and ARS Technology: CME Done Differently	CONSULTANT FEES/HONORARIA - Amgen Inc.,AstraZeneca,Sanofi Regeneron; RESEARCH/RESEARCH GRANTS - Amgen Inc.
Morris	Pamela	Recent Trends in Combination Therapy: Managing Cholesterol Even in the Most Resistant	Putting It All Together: The 2016 ECDP on Non-Statin Therapies	CONSULTANT FEES/HONORARIA - Amgen Inc., AstraZeneca, Sanofi Regeneron; RESEARCH/RESEARCH GRANTS - Amgen Inc.
Morris	Pamela	Recent Trends in Combination Therapy: Managing Cholesterol Even in the Most Resistant	What Questions Still Remain and Closing Remarks	CONSULTANT FEES/HONORARIA - Amgen Inc., AstraZeneca, Sanofi Regeneron; RESEARCH/RESEARCH GRANTS - Amgen Inc.
Morris	Shaine	10. Congenital Heart Disease: Pediatric Team	Suggested Reviewer	Nothing to Disclose
Morrow	David	STEMI Dilemmas: You Be the Judge	Winning the Battle, Losing the War? Management of Patient who Develops Acute Shock Following Successful PCI for Inferior Wall MI	CONSULTANT FEES/HONORARIA - Abbott, Daiichi Sankyo, DiaDexus, Eli Lilly and Co, gilead, GlaxoSmithKline, Merck and Company, Novartis, Provencio, Radiometer, Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Abbott, Amgen, AstraZeneca, Athera, Daichii Sankyo, Ltd, Eisai Corporation, Eli Lilly and Co., GlaxoSmithKline, Johnson Asmp; amp; Johnson, Merck and Company, Novartis Pharmaceuticals, Roche Diagnostics, Sanofi-Aventis, Singulex
Morrow	David	Mechanical Support, Hemodynamic Support for Shock in High Risk Subsets; Hemodynamic Compromise	Panelist	CONSULTANT FEES/HONORARIA - Abbott, Daichi Sankyo, DiaDexus, Eli Lilly and Co.gilead, GlaxoSmithKline, Merck and Company, Novartis, Provencio, Radiometer, Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Abbott, Amgen, AstraZeneca, Althera, Daichi Sankyo Ltd, Eisai Corporation, Eli Lilly and Co., GlaxoSmithKline, Johnson & amp; Johnson, Merck and Company, Novartis Pharmaceuticals, Roche Diagnostics, Sanoti-Aventis, Singulex
Morrow	David	Mechanical Support, Hemodynamic Support for Shock in High Risk Subsets; Hemodynamic Compromise	Hypothermia and Out of Hospital Arrest	CONSULTANT FEES/HONORARIA - Abbott, Daichi Sankyo, DiaDexus, Eli Lilly and Co.gilead, GlaxoSmithKline, Merck and Company, Novartis, Provencio, Radiometer, Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Abbott, Amgen, AstraZeneca, Althera, Daichi Sankyo Ltd, Eisai Corporation, Eli Lilly and Co., GlaxoSmithKline, Johnson & Demon, Merck and Company, Novartis Pharmaceuticals, Roche Diagnostics, Sanofi-Aventis, Singulex
Morrow	David	Evolution of Critical Care Cardiology and the CICU	Finding Mentorship and Research Opportunities in Critical Care Cardiology	CONSULTANT FEES/HONORARIA - Abbott, Daiichi Sankyo, DiaDexus, Eli Lilly and Co.glead, GlaxoSmithKline, Merck and Company, Novaris, Provencio, Radiometer, Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Abbott, Amgen, AstraZeneca, Athera, Daichii Sankyo, Ltd, Eisai Corporation, Eli Lilly and Co., GlaxoSmithKline, Johnson & amp; Johnson, Merck and Company, Novarits Pharmaceuticals, Roche Diagnostics, Sanofi-Aventis, Singulex
Morrow	David	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Cystatin C Is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial	Priamaceuticals Nocine Dagijousios, Santini-Aventius, Singliuex CONSULTANT FEES/HONORARIIA - Abbott Dalichi Sankyo, DiaDexus, Eli Lilly and Co.gliead, GlaxoSmithKline, Merck and Company, Movartis, Provencio, Radiometer, Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Abbott, Amgen, AstraZeneca, Athera, Daichii Sankyo Ltd, Eisai Corporation, Eli Lilly and Co., GlaxoSmithKline, Johnson & Ampany, Novartis Pharmaceuticals, Roche Diagnostics, Sanofi-Aventis, Singulex

Const.				
Last Name Morrow	First Name David	Session Title Vascular Access and Hemostasis Issues	Presentation Title Radial Versus Femoral Access for Coronary Angiography and Risk	Disclosures CONSULTANT FEES/HONORARIA - Abbott, Daiichi
			of Stroke: Findings From the LATITUDE-TIMI 60 Trial	Sankyo, DiaDexus, Eli Lilly and Co, gilead, GlaxoSmithKline, Merck and Company, Novarits, Provencio, Radiometer, Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Abbott, Amgen, AstraZeneca, Athera, Daichii Sankyo Ltd, Eisai Corporation, Eli Lilly and Co., GlaxoSmithKline, Johnson & amp; amp; Johnson, Merck and Company, Novartis Pharmaceuticals, Roche Diagnostics, Sanofi-Aventis, Singulex
Morrow	David	Post-CAD/MI: Making Tough Predictions About the Future	Risk Stratification With the TIMI Risk Score for Secondary Prevention Among Patients With Diabetes and Elevated Cardiovascular Risk	CONSULTANT FEES/HONORARIA - Abbott, Daichi Sankyo, DiaDexus, Eli Lilly and Co,gilead, GlaxoSmithKline, Merck and Company, Novartis, Provencio, Radiometer, Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Abbott, Amegn. AstraZeneca, Athera, Daichi Sankyo Ltd, Eisai Corporation, Eli Lilly and Co., GlaxoSmithKline, Johnson & mp., amp., Johnson, Merck, and Company, Novartis Pharmaceuticals, Roche Diagnostics, Sanofi-Aventis, Singulex
Morrow	David	02. Acute and Stable Ischemic Heart Disease: Clinical Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott, Dalichi Sankyo, DiaDexus, Eli Lilly and Co, gliead, GlaxoSmithKline, Merck and Company, Novartis, Provencio, Radiometer, Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Abbott, Amgen, AstraZeneca, Athera, Daichi Sankyo Ltd, Eisai Corporation, Eli Lilly and Co., GlaxoSmithKline, Johnson & Mamp, ampr., Johnson, Merck and Company, Novartis Pharmaceuticals, Roche Diagnostics, Sanofi-Aventis, Singulex
Morsy	Mohamed	Novel Echocardiographic Methods for Assessing Cardiac Function	Clinical and Echocardiographic Predictors of Atrial Fibrillation in Trauma Patients	Nothing to Disclose
Morsy	Mohamed	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	An Updated Comprehensive Meta-Analysis Comparing Drug-Eluting Stents With Bare Metal Stents in Saphenous Vein Graft Interventions	Nothing to Disclose
Morsy	Mohamed	Antithrombotic Therapy in Ischemic Heart Disease	Shorter- Versus Longer-Duration Triple Antithrombotic Therapy for Patients With Coronary Stents Who Require Oral Anticoagulation: An Updated Comprehensive Meta-Analysis	Nothing to Disclose
Morsy	Mohamed	Ventricular Arrhythmias and Sudden Death Prevention	Prophylactic Defibrillator Implantation in Patients With Non-Ischemic Cardiomyopathy: An Updated Comprehensive Meta-Analysis of Randomized Controlled Trials	-
Morsy	Mohamed	Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells	An Updated Comprehensive Meta-Analysis of Randomized Trials Evaluating the Efficacy of Stem Cell Therapy for Refractory Angina	Nothing to Disclose
Moryusef	Angele	Advances in Lipid Management	Use of High-Intensity Statin Therapy Post-Acute Coronary Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody, Versus Placebo: Interim Baseline Data	OTHER - own stock in sanofi; SALARY - full time employee of sanofi
Mosca	Susanna	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Renal Replacement Therapy in Patients With Acute Myocardial Infarction: Rate of Use, Clinical Predictors and Relationship With In-Hospital Mortality	Nothing to Disclose
Moschos	Marilita	MicroRNAs and Beyond in Vascular Medicine	Association of Endothelial Dysfunction and Arterial Wall Elastic Properties With Systemic Inflammation in Patients With Pseudoexfoliative Glaucoma	Nothing to Disclose
Moscucci	Mauro	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Percutaneous Coronary Intervention in Adults Age 75 Years or Older With ST Elevation Myocardial Infarction and Cardiogenic Shock	OTHER - Gilead Sciences, Inc. ,Lippincott Williams and Wilkins
Moscucci	Mauro	Diabetes and Other Issues in Cardiovascular Prevention	Prevention of Venous Thromboembolism in Hospitalized Patients: From Inadequate to Over-Prophylaxis	OTHER - Gilead Sciences, Inc. ,Lippincott Williams and Wilkins
Moscucci	Mauro	Diabetes and Other Issues in Cardiovascular Prevention	Venous Thromboembolism Prophylaxis: Need of Continuous Assessment Due to Changes in Risk During the Same Hospitalization	OTHER - Gilead Sciences, Inc. ,Lippincott Williams and Wilkins
Moscucci	Mauro	Interventional Complexity and Complications	Variability in Transfemoral Access for Coronary Angiography and Interventions: Results From an International Survey	OTHER - Gilead Sciences, Inc. ,Lippincott Williams and Wilkins
Moscucci	Mauro	03. Acute and Stable Ischemic Heart Disease: Therapy Team 2	Suggested Reviewer	OTHER - Gilead Sciences, Inc. ,Lippincott Williams and Wilkins
Mosenzon	Ofri	Highlighted Original Research: Prevention and the Year in Review	Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial	SPEAKER'S BUREAU - AstraZeneca/Bristol Myers Squibb
Mosenzon	Ofri	Post-CAD/MI: Making Tough Predictions About the Future	Risk Stratification With the TIMI Risk Score for Secondary Prevention Among Patients With Diabetes and Elevated Cardiovascular Risk	SPEAKER'S BUREAU - AstraZeneca/Bristol Myers Squibb
Moses	Jeffrey	Interventional Live Case Session II: CTO Transmission from Mid-America Heart Institute (Kansas City, Missouri)	Panelists	Nothing to Disclose
Moses	Jeffrey	Featured Clinical Research III	Outcomes for 15,259 US Patients With Acute MI Cardiogenic Shock (AMICS) Supported With Impella	Nothing to Disclose
Moses	Jeffrey	Practicum on Tools for CHIP (Complex and Higher-Risk Procedures in Indicated Patients)	What Is Higher-Risk PCI	Nothing to Disclose
Moses	Jeffrey	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Optical Coherence Tomography Assessment of Coronary Atherectomy Effect: Comparison Between Orbital and Rotational Atherectomy in Severely Calcified Lesions	Nothing to Disclose
Moses	Jeffrey	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Morphologic Patterns of In-Stent Chronic Total Occlusions: An Intravascular Ultrasound Study	Nothing to Disclose
Moses	Jeffrey	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	The Effectiveness of Excimer Laser Angioplasty to Treat Coronary In-Stent Restenosis With Peri-Stent Calcium as Assessed by Optical Coherence Tomography	Nothing to Disclose
Moses	Jeffrey	Advances in Chronic Total Occlusion Intervention	Association of Stress Test Risk Classification With Health Status Change After Chronic Total Occlusion PCI: Insights From the OPEN- CTO Registry	Nothing to Disclose
Moses	Jeffrey	Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	Nothing to Disclose
Moses	Jeffrey	Advances in Chronic Total Occlusion Intervention	Hemodynamically-Supported PCI of Chronic Total Occlusions: A Case Series	Nothing to Disclose
Moses	Jeffrey	Advances in Chronic Total Occlusion Intervention	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	Nothing to Disclose
Moses	Jeffrey	Refining PCI Technique and Outcomes	Appropriate Use Criteria and Health Status Outcomes After CTO PCI: Results From the OPEN CTO Registry	Nothing to Disclose
Moses Moskowitz	Jeffrey Alan	19. Interventional Cardiology: Complex Patients/Comorbidities Team 2 Joint American College of Cardiology/New	Suggested Reviewer Cerebral Embolic Protection Devices During Surgical Aortic Valve	Nothing to Disclose Nothing to Disclose
Mosleh	Wassim	England Journal of Medicine Late-Breaking Clinical Trials Arrhythmias and Clinical EP: AF Ablation	Replacement: A Randomized Trial From the Cardiothoracic Surgical Trials Network Improvement in Cost and Efficiency in Electrophysiology Laboratory	Nothing to Disclose
			by Cardiac Computed Tomography to Exclude Left Atrial Appendage Thrombus Prior to Atrial Fibrillation Ablation	

Control of the Contro				
Last Name Moslehi	First Name Javid	Session Title The Evolving World of LVADs, Transplant and Other Novel Discoveries	Presentation Title Myocarditis and Rhabdomyolysis Incidence With Immune Checkpoint Inhibitors	Disclosures CONSULTANT FEES/HONORARIA - acceleron, Ariad, Bristol- Myers Squibb, Daiichi Sankyo, heat biologics, Incyte, Millennium, Novartis Corporation, Pfizer Inc, Pharmacyclics, Inc., RGenix, StemcentFx, Takeda Pharmaceuticals North America, Inc, Vertex
Mosley	Thomas	Advances in Cholesterol Measurement and Management	Association of Remnant-Like Particle Cholesterol and Low-Density Lipoprotein Triglyceride With Incidence of Cardiovascular Events:	Nothing to Disclose
Moss	Arthur	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	The ARIC Study <b<></b<> √I> Sustained Clinical Benefit of Cardiac Resynchronization Therapy in Patients With Relatively Preserved Ejection Fraction: A MADIT-CRT Long-Term Follow-Up Sub-Study	CONSULTANT FEES/HONORARIA - GILEAD Sciences; RESEARCH/RESEARCH GRANTS - Boston Scientific
Moss	Lisa	Interventional Cardiology: TAVR 1	Hands Down: Operator Hand Versus Torso Radiation Exposure During Transcatheter Aortic Valve Replacement	Nothing to Disclose
Moss	Travis	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Impact of Cardiogenic Shock with or without Mechanical Circulatory Support on Short-Term and Long-Term Survival in Heart Failure Hospitalizations	Nothing to Disclose
Moss	Travis	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Continuous Monitoring of Cardiorespiratory Dynamics Detects Clinical Deterioration in Acute Care Patients	Nothing to Disclose
Mostafa	Ashraf	Outer En issues FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Ultrasound Assisted Catheter Directed Thrombolysis and Percutaneous Right Ventricular Mechanical Assist Device for the Management of Massive Pulmonary Embolism With Refractory Right Ventricular Failure: Playing Chess With Pulmonary Embolism	Nothing to Disclose
Motiwala	Shweta	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Multiple Biomarkers for Predicting Major Adverse Cardiac Events in At-Risk Patients Undergoing Diagnostic Coronary Angiography: Results From the Catheter Sampled Blood Archive in	Nothing to Disclose
Motiwala	Shweta	Innovative Use of Echocardiography	Cardiovascular Diseases (CASABLANCA) Study Echocardiographic Parameters Associated With Quality of Life in Ambulatory Patients With Heart Failure	Nothing to Disclose
Mott	Brian	Biomarkers and Targets for Ischemic Heart	Amoulatory Patients With Heart Failure Ultrasound Increases Myocardial Blood Flow in Acute Myocardial Ischemia Without Reducing Infarct Size	Nothing to Disclose
Mouhayar	Elie	Disease Vasculo-Oncology: What You Need to Know About Vascular and Thrombotic Complications of Cancer and Cancer Therapeutics	Schemid Williou Reducing Infact 3/2e Chemotherapeutic-Associated Hypertension: Molecular Basis	Nothing to Disclose
Mouhayar	Elie	Optimizing the Care of ACS Patients	Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients	Nothing to Disclose
Mouratoglou	Sofia	Predicting the Future: Observations and Discoveries From Registries and Databases	Left Ventricular Filling Rate Predicts Clinical Failure in Patients With Precapillary Pulmonary Hypertension	Nothing to Disclose
Mourouzis	Konstantinos	Diabetes and Endothelial Dysfucntion in Heart Failure	Association of Endothelial Dysfunction With Biomarkers of Inflammation, Myocardial Fibrosis and Left Ventricle Strain in Patients With Heart Failure	Nothing to Disclose
Mourouzis	Konstantinos	Uncovering the Intricacies of Vascular Function	The Impact of Natural Chios Mastic Supplementation on Endothelial Function and Arterial Stiffness in Smokers	Nothing to Disclose
Moussa Moussa	Issam Issam	CAD in Unique Patient Populations 02. Acute and Stable Ischemic Heart Disease:	ACC Poster Moderator Suggested Reviewer	Nothing to Disclose Nothing to Disclose
Moussa Pacha	Homam	Clinical Team 6 Interventional Cardiology: TAVR 3	Antithrombotic Therapy Differences and Associated Outcomes in	Nothing to Disclose
M	No. 1	Note and the first of the first	Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement	
Moyer Moyer	Virgina Virgina	Value, Advocacy and the Future of Adult Congenital and Pediatric Cardiology Value, Advocacy and the Future of Adult	Panelist Demonstrating Value through Life-long Learning	Nothing to Disclose Nothing to Disclose
Mozid	Abdul	Congenital and Pediatric Cardiology Considerations in Antiplatelet Therapy and in	Bivalirudin Versus Heparin in Primary PCI: Clinical Outcomes and	Nothing to Disclose
Mudd	James	ACS Should I Stay or Should I Go? Tough Cases in	Cost Analysis From a Large Retrospective Cohort Co-Chair	Nothing to Disclose
Muddassir	Salman	MCS and Transplant Heart Failure and Cardiomyopathies: Is Heart	Comparison of B-Type Natriuretic Peptide Assays for Identifying	Nothing to Disclose
		Failure With a Normal EF for Real?	Adverse Events in Patients With Chronic Obstructive Pulmonary Disease: Meta-Analysis of Randomized and Non-Randomized Studies	
Mueller	Christian	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Direct Comparison of Cardiac Myosin-Binding Protein C to Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction	CONSULTANT FEES/HONORARIA - Several diagnostic and therapeutic companies; RESEARCH/RESEARCH GRANTS - Several diagnostic companies
Muhlestein	J.	Interventional Cardiology: Translation and Pre- Clinical Research	Both the Novel NMR Biomarker of Inflammation, GlycA, and HS- CRP Are Independent and Additive Predictors of Future Cardiovascular Events Among Patients Undergoing Coronary Angiography: Results From the Intermountain Heart Collaborative Study	SPEAKER'S BUREAU - BMS/Pfizer
Muhlestein	J.	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	SPEAKER'S BUREAU - BMS/Pfizer
Muhlestein	J.	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	The Intermountain Major Adverse Cardiovascular Events Risk Scores Effectively and Efficiently Predict 1- to 3- Year Post-Stent MACE in Non-Myocardial Infarction Patients	SPEAKER'S BUREAU - BMS/Pfizer
Muhlestein	J.	Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes	
Muhlestein	J.	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prediction of Future Cardiovascular Risk by Analysis of Various CT Coronary Angiography-Determined Quantitative Plaque Compositional Characteristics Among Patients With Diabetes Enrolled in the FACTOR-64 Study: The Importance of the Calcified Coronary Plaque	SPEAKER'S BUREAU - BMS/Pfizer
Muhlestein	Joseph	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	The Association of Depression at Any Time to the Risk of Death Following Coronary Artery Disease Diagnosis: The Intermountain INSPIRE Registry	SPEAKER'S BUREAU - BMS/Pfizer
Muhlestein	Joseph	Innovations in Practice Management and Social Media	Predicting 3-Year Risk of Incident Chronic Disease in Disease-Free Primary Care Patients: The Intermountain Chronic Disease Model (ICHRON)	SPEAKER'S BUREAU - BMS/Pfizer
Muhlestein	Joseph	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues		SPEAKER'S BUREAU - BMS/Pfizer
Muhlestein	Joseph	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues		SPEAKER'S BUREAU - BMS/Pfizer
Muhyaldeen	Sahrkaw	The Story of the Adult Congenital Heart Disease Patient and EP	Prevalence or Atrial Fibriliation Prevalence and Predictors of Atrial Tachyarrhythmias in Adult Fontan Patients	Nothing to Disclose
Muhyaldeen	Sahrkaw	Redefining the "F" Word	Provided Patients Prevalence and Predictors of Pacemaker Placement in Adult Fontan Patients	Nothing to Disclose
Muhyaldeen	Sahrkaw	FIT Clinical Decision Making: Heart Failure and Cardiomyopathies	Pointain Fatients A Case of Familial Dilated Cardiomyopathy With a Reversible Phenotype: The Utility of Genetic Testing and Genotype-Specific Treatment	Nothing to Disclose
Mukete	Bertrand	Logistical Challenges in STEMI	Fit Case # 1: Post-Operative STEMI	Nothing to Disclose



Control of the contro				l
Last Name Mukherjee	First Name Ashis	Session Title FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Presentation Title Transcatheter Aortic Valve Replacement in a Patient With Very Mobile Aortic Valve Mass	Disclosures Nothing to Disclose
Mukherjee	Debabrata	Disease, and Vascular Medicine STEMI Dilemmas: You Be the Judge	Co-Chair	Nothing to Disclose
Mukherjee	Debabrata	21. Interventional Cardiology: Coronary Intervention: Devices Team 2 Interventional Challenging Cases: Team 3	Suggested Reviewer	Nothing to Disclose Nothing to Disclose
Mukherjee Mulder	Debabrata Barbara	Congenital Heart Disease: To the Third Decade and Beyond	ACC Challenging Case Reviewer The Systemic Right Ventricle in Transposition of the Great Arteries: What Can We Learn From Serial Imaging?	Nothing to Disclose Nothing to Disclose
Mulder	Hillary	Considerations in Antiplatelet Therapy and in ACS	Dual Antiplatelet Therapy Utilization and Cardiovascular Outcomes Among Black and White Patients Treated With Drug Eluting Stents	Nothing to Disclose
Mulder	Hillary	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Aortic Stenosis, but Not Mitral or Aortic Regurgitation, Is Associated With Adverse Outcomes With Atrial Fibrillation: Results From the ARISTOTLE Trial	Nothing to Disclose
Mullens	Wilfried	Making Progress in Understanding Heart Failure	Intravascular Volume Expansion in Patients With Heart Failure and Reduced Ejection Fraction Is Not Revealed by Changes in Cardiac Filling Pressures	Nothing to Disclose
Mullens	Wilfried	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Cardiac Resynchronization Therapy With Versus Without a Defibrillator: Clinical Insights From Device Interrogation and Mode of Death Analysis	Nothing to Disclose
Mullens	Wilfried	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Bioimpedance Algorithms in Implantable Electronic Cardiac Devices: Relevant Diagnostics or Waste of Time?	Nothing to Disclose
Müller-Wieland	Dirk	Advances in Cholesterol Measurement and Management	Efficacy and Safety of the PCSK9 Inhibitor Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin Therapy	CONSULTANT FEES/HONORARIA - Amgen Inc. AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc,Merck & amp,amp; Co., Inc.,Novartis Corporation,NovoNordisk, Sanofi-Aventis; SPEAKER'S BUREAU - Amgen Inc.
Mulliken	Jennifer	Novel Echocardiographic Methods for Assessing Cardiac Function	Use of Diastolic Parameters on Transthoracic Echocardiogram to Predict Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation	Nothing to Disclose
Mulpuru	Siva	Ventricular Arrhythmias in the Coronary Care Unit: Contemporary Solutions to an Old Problem	Role of Hemodynamic Support and Revascularization in VT Storm	Nothing to Disclose
Mulpuru	Siva	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Complication Rates of Epicardial Ventricular Tachycardia Ablation: A Pooled Analysis	Nothing to Disclose
Mulvagh	Sharon	Echocardiography: What is New in 2017	Perfusion Echo: Now That There is a CPT Code, is it Ready to Be Done in My Lab?	RESEARCH/RESEARCH GRANTS - Bracco Imaging,GE Healthcare,Lantheus Medical Imaging
Mulvagh	Sharon	WIC Brown Bag Lunch Session: Publishing, Social Media and Negotiating the C-Suite: Tools for Success in Academia and Private Practice	Establishing a Social Media Presence	RESEARCH/RESEARCH GRANTS - Bracco Imaging,GE Healthcare,Lantheus Medical Imaging
Munger	Mark	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Reduced Risk of NSAID Induced Adverse Events With Concomitant Use of Misoprostol	Nothing to Disclose
Munger	Thomas	ECG Screening and Risk Prediction	Wolff-Parkinson-White Pattern and Sudden Cardiac Death: A Retrospective Cohort Community Study From Olmsted County, Minnesota	Nothing to Disclose
Muniz	Javier	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years	CONSULTANT FEES/HONORARIA - Data analysis
Munoz	Daniel	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Underutilization of Statin Therapy Among Participants in a Lung Cancer Screening Program With a High Incidence of Cardiovascular Events	Nothing to Disclose
Munoz	Ricardo	Post-Surgical Care of Children with CHD: From ICU to Your Office	Debate: Sedation Following Infant Cardiac Surgery: We're Not Doing Enough (Pro)	Nothing to Disclose
Muñoz Gonzalez	Ezequiel	Making Progress in Understanding Heart Failure	Stress Induced Cardiomyopathy Triggered by Chemotherapy: When Should Cancer Therapy Be Restarted?	Nothing to Disclose
Muñoz Gonzalez	Ezequiel	Optimizing the Care of ACS Patients	Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients	Nothing to Disclose
Muñoz-García	Antonio J.	Interventional Cardiology: TAVR 2	Effect of Body Mass Index on Mortality After Transcatheter Aortic Valve Implantation: J-Shaped Curve	Nothing to Disclose
Muntendam	Pieter	Non Invasive Imaging: Prognostic Implications of CT Angiography	The Relationship Between Pericardial Adipose Tissue Volume, Atherosclerotic Plaque Type and Cardiovascular Risk: A High Risk Plaque Biolmage Sub-Study	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - scPharmaceuticals Inc
Muntner	Paul	Advances in Cholesterol Measurement and Management	Prevalence and Correlates of Statin Side Effects and Willingness to Be Re-Challenged on a Statin: Data From the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study	CONSULTANT FEES/HONORARIA - Amgen Inc.; RESEARCH/RESEARCH GRANTS - Amgen Inc.
Muntner	Paul	Advances in Cholesterol Measurement and Management	Psychosocial Factors and Statin Intolerance: Data From the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study	CONSULTANT FEES/HONORARIA - Amgen Inc.; RESEARCH/RESEARCH GRANTS - Amgen Inc.
Muntner	Paul	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Use of Recommended and Contraindicated Statins in HIV Patients	CONSULTANT FEES/HONORARIA - Amgen Inc.; RESEARCH/RESEARCH GRANTS - Amgen Inc.
Muntner	Paul	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Trends in the Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011-2014	CONSULTANT FEES/HONORARIA - Amgen Inc.; RESEARCH/RESEARCH GRANTS - Amgen Inc.
Murai	Tadashi	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Relationship Between Coronary Physiological Parameters and Cardiac Biomarkers in Patients Undergoing Invasive Coronary Angiography	Nothing to Disclose
Murai	Tadashi	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Significance of Microcirculatory Resistance in Visual-Functional Mismatch Between Coronary Angiography and Fractional Flow Reserve in Non-Left Main Lesions	Nothing to Disclose
Murai	Tadashi	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Relationship Between Optical Coherence Tomography-Defined In- Stent Neoatherosclerosis and Out-Stent Arterial Remodeling Assessed by Serial Intravascular Ultrasound Examinations in Late and Very Late Drug-Eluting Stent Failure	Nothing to Disclose
Murai	Tadashi	Unusual Presentations of ACS	Comparison Between Angioscopic and Optical Coherence Tomographic Assessment of Instent Restenosis	Nothing to Disclose
Murai	Tadashi	Unusual Presentations of ACS	Predictors and Clinical Significance of High-Sensitivity Cardiac Troponin-I Elevation After Diagnostic Coronary Angiography	Nothing to Disclose
Murai	Tadashi	Unusual Presentations of ACS	Multimodality Coronary Imaging to Predict Periprocedural Myocardial Necrosis After Elective Percutaneous Coronary Intervention	Nothing to Disclose
Murai	Tadashi	Unusual Presentations of ACS	Comparison of Neointimal Appearance Assessed by Optical Coherence Tomography Between Bare-Metal Stents and Sirolimus-Eluting Stents Beyond 10 Years From Implantation	Nothing to Disclose
Murali	Srinivas	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Co-Chair	CONSULTANT FEES/HONORARIA - Actelion,Bayer; RESEARCH/RESEARCH GRANTS - Cardiokinetics,CVRx; SPEAKER'S BUREAU - Actelion, Inc
Muraoka	Yoshitaka	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Long-Term Vascular Response to Permanent Polymer Everolimus- Eluting Stent Compared With Biodegradable Polymer Biolimus- Eluting Stent: Five-Year Follow-Up Optical Coherence Tomography Study	Nothing to Disclose



Congress of				
Last Name Murata	First Name Koichiro	Session Title Coronary Intervention in Interventional	Presentation Title Superiority of Everolimus-Eluting Stents Over Sirolimus-Eluting	Disclosures Nothing to Disclose
Murata	Tatsunori	Cardiology: Core Concepts Arrhythmias and Clinical EP: Anticoagulation	Stents in Long-Term Safety and Efficacy Bleeding Risk Among Japanese Non-Valvular Atrial Fibrillation	OTHER - Crecon Medical Assessment Inc.
Marata	rateurion	Issues	Patients Initiated on Apixaban, Dabigatran, Rivaroxaban or Warfarin in the Real World	ornar order medicar assessment me.
Mureebe	Lelia	Aorto-iliac Disease and Treatment: Practice at	Debate: Stenosis of the Common Femoral Artery Should Be	Nothing to Disclose
Muresan	Adina	"The Edge" in Peripheral Intervention From Diet to Drugs: Mechanistic Insight Into	Treated with Surgery Assessment of Thrombogenicity and Antithrombotic Drug Response	Nothing to Disclose
		Ischemic Heart Disease	at the Bedside in Patients Presenting With Ischemic Stroke, TIA or Intracranial Hemorrhage	-
Murgo	Joseph	Timely Topics in Acute Coronary Syndromes	Evaluation of Exercise Response in Young Adults in a High Risk Occupation: Submaximal Invasive Cardiopulmonary Exercise Testing in Active Duty Soldiers	Nothing to Disclose
Murphy	Daniel	2017 Dan G. McNamara Lecture: The Future of Congenital Heart Research: Keeping the Patient-Centered Promise	Welcome and Reflecting on McNamara Lecture	Nothing to Disclose
Murphy	Sabina	Fibrillatory Arrhythmias: Outcomes With	Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First	CONSULTANT FEES/HONORARIA - Amarain, Merck
		Contemporary Practice	Experience From the ENGAGE AF TIMI 48 Trial	& Co., Inc.; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals,Daiichi Sankyo,GlaxoSmithKline,Merck & Co., Inc.
Murphy	Sabina	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Cystatin C Is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An	CONSULTANT FEES/HONORARIA - Amarain, Merck & amp; amp; Co., Inc.; RESEARCH/RESEARCH GRANTS -
		Coronary Artery Disease	Analysis From the SOLID-TIMI 52 Trial	AstraZeneca Pharmaceuticals,Daiichi Sankyo,GlaxoSmithKline,Merck & Co., Inc.
Murphy	Sabina	Stroke and AF: Thinking About the Heart	Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Active Malignancy: An Analysis of ENGAGE AF - Timi 48 Randomized Clinical Trial	CONSULTANT FEES/HONORARIA - Amarin Pharmaceuticals,Eli Lilly
Murray	Michael	Effective Medication Management in the Older	Approaches to Optimizing Adherence in the Elderly CV Population	Nothing to Disclose
		Adults with CVD: Pharmacology Program I		
Mursleen	Asma	Interventional Cardiology: TAVR 1	Intraoperative Change in Myocardial Contractility With Transcatheter Aortic Valve Replacement Predicts Cardiovascular Outcomes	Nothing to Disclose
Mursleen	Asma	Interventional Cardiology: TAVR 1	Temporal Change in Myocardial Contractility After Transcatheter Aortic Valve Replacement and Its Relationship With Quality of Life	Nothing to Disclose
Murthy	Venkatesh	Imaging of Myocardial Blood Flow: A	PET Myocardial Blood Flow Quantification: The Gold Standard	CONSULTANT FEES/HONORARIA - Bracco Diagnostics, lonetix;
		Multimodality Approach		OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abbott Laboratories, Amgen, Bristol-Myers Squibb, Cardinal Health, General Electric, MEDTRONIC, Merck, Mylan Laboratories, Pfizer, Teva Pharmaceuticals; RESEARCH/RESEARCH GRANTS - INVIA Medical Imaging Solutions
Murthy	Venkatesh	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Integrating Hyperemic Myocardial Blood Flow and Coronary Flow Reserve for Predicting Cardiovascular Mortality Outcomes in Patients With Known or Suspected Ischemic Heart Disease	CONSULTANT FEES/HONORARIA - Bracco Diagnostics, lonetix, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abbott Laboratories, Amgen, Bristol-Myers Squibb, Cardinal Health, General Electric, MEDTRONIC, Merck, Mylan Laboratories, Pfizer, Teva Pharmaceuticals; RESEARCH/RESEARCH GRANTS - INVIA Medical Imaging Solutions
Murthy	Venkatesh	Young Investigator Awards Competition: Clinical Investigations	Impaired Coronary Flow Reserve Is Associated With Diastolic Dysfunction and HFpEF Outcomes in Patients Without Overt CAD	CONSULTANT FEES/HONORARIA - Bracco Diagnostics, lonetix, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abbott Laboratories, Amgen, Bristol-Myers Squibb, Cardinal Health, General Electric, MEDTRONIC, Merck, Mylan Laboratories, Pfizer, Teva Pharmaceuticals; RESEARCH/RESEARCH GRANTS - INVIA Medical Imaging Solutions
Murthy	Venkatesh	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Patterns of Downstream Cardiac Procedures After Nuclear Myocardial Perfusion Imaging in the United States, 2008-2012	CONSULTANT FEES/HONORARIA - Bracco Diagnostics, lonetix; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abbott Laboratories, Amgen, Bristol-Myers Squibb, Cardinal Health, General Electric, MEDTRONIC, Merck, Mylan Laboratories, Pfizer, Teva Pharmaceuticals; RESEARCH/RESEARCH GRANTS - INVIA Medical Imaging Solutions
Murthy	Venkatesh	Innovations in Cardiovascular Risk Assessment and Reduction	Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African Americans: The Jackson Heart Study	CONSULTANT FEES/HONORARIA - Bracco Diagnostics, lonetix; OWNERSHIP INTEREST/PARTMERSHIP/PRINCIPAL - Abbott Laboratories, Amgen, Bristol-Myers Squibb, Cardinal Health, General Electric, MEDTRONIC, Merck, Mylan Laboratories, Pfizer, Teva Pharmaceuticals; RESEARCH/RESEARCH GRANTS - INVIA Medical Imaging Solutions
Musa	Ameer	Population Specific Cardiomyopathies: From	Racial Differences in Heart Failure Admissions & Outcomes Among Patients With HIV	Nothing to Disclose
Muse	Evan	Exomes to Databases Young Investigator Awards Competition: Basic and Translational Science	Cell-Specific Discrimination of Desmosterol and Desmosterol Mimetics Confers Selective Regulation of LXR and SREBP	Nothing to Disclose
Muser	Daniele	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Pathways in Macrophages Anticoagulation Use and Incidence of Cerebrovascular Events and Major Bleeding After Catheter Ablation in Patients With Persistent	Nothing to Disclose
Mushtaq	Saima	Non Invasive Imaging: MR Heart Failure and	and Longstanding Persistent Atrial Fibrillation Prognostic Stratification in Patients With ST-Elevation Myocardial	Nothing to Disclose
	Saima	Pulmonary Hypertension Non Invasive Imaging: MR Structure and	Infaction Over Transthoracic Echocardiography by CMR Diagnostic Value of Qt Evaluation in Anterior ST Segment Elevation	ŭ .
Mushtaq		Valuvular Heart Disease	Myocardial Infarction for Prediction of Myocardial Salvage Index, as Compared to CMR	Nothing to Disclose
Muslem	Rahat	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Older Age Combined With Reduced Renal Function Has a Strong Cumulative Adverse Effect on Survival in Left Ventricular Assist Device Patients	Nothing to Disclose
Muslem	Rahat	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Sudden and Fatal Malfunction After Continuous-Flow Left Ventricular Assist Devices: An Urgent Call for Regular Inspections	Nothing to Disclose
Muslem	Rahat	Advanced Therapies = Advanced Trouble: VAD and Transplant Challenges	Acute Kidney Injury Is Highly Frequent Early After Left Ventricular Assist Device Implantation With High Morbidity and Mortality Rates:	Nothing to Disclose
Muslem	Rahat	Advanced Therapies = Advanced Trouble:	A Multicentre Study Proteinuria in Patients Receiving Left Ventricular Assist Devices Is	Nothing to Disclose
Musser	Carl	VAD and Transplant Challenges FIT Clinical Decision Making: Arrhythmias and	Highly Associated With Renal Failure and Mortality Third Degree Heart Block as the Initial Presentation of Cardiac	Nothing to Disclose
		Electrophysiology	Sarcoidosis	-
Mustafina	Irina	Timely Topics in Acute Coronary Syndromes	Systemic Pentraxin 3 Is a Potential Biomarker to Differentiate Plaque Erosion From Plaque Rupture in Acute Coronary Syndrome Patients	Nothing to Disclose

Control of the contro				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Mustapha	Jihad	Head to Toe: Outcomes of Endovascular	Safety and Efficacy of Transpedal Access for the Management of	CONSULTANT FEES/HONORARIA - Abbott Vascular, Bard
		Interventions	Complex Peripheral Arterial Disease	Peripheral Vascular,Cardiovascular Systems, Inc.,Cook
				Medical,Cordis,Lutonix,MEDTRONIC,Terumo Medical; RESEARCH/RESEARCH GRANTS - Bard Peripheral
				Vascular, Biotronik, Boston Science Corp, Cardiovascular Systems
				Inc,MEDTRONIC,Spectranetics,Terumo,TriReme
Muthalaly	Rahul	Non Invasive Imaging: Prognostic Implications	Computed Tomography Coronary Angiography Derived Plaque	Nothing to Disclose
,		of CT Angiography	Morphology Predicts Major Adverse Cardiovascular Events: Insights	
			From a 19,943 Patient Meta-Analysis	
Mutharasan	Raja	Heart Failure Patient Care: Transitioning the	Who Pays for the Infrastructure?	Nothing to Disclose
		Cost, Care and Context: Joint Heart Failure		
		Society of America and American College of Cardiology		
Mutharasan	Raja	Innovations in Practice Management and	Heart Failure Care Transitions: Queuing Theory-Based Cost-	Nothing to Disclose
Matraradan	raju	Social Media	Effectiveness Analysis of Outpatient Clinic Capacity Sizing	Trouming to Broslood
Mutharasan	Raja	Acute Heart Failure: Evaluating Strategies to	Screening of Patients With Simple Clinical Parameters Early in	Nothing to Disclose
		Prevent Readmissions	Hospitalization Is Highly Sensitive for Detection of Heart Failure	
			Hospitalization	
Mutharasan	Raja	Interdisciplinary Cardiovascular Team	Multidisciplinary Heart Failure Transitional Care Team to Impact	Nothing to Disclose
Mutharasan	Raja	Collaboratives in Care Innovations in Advocacy and Patient Centered	Readmissions Impact of Multidisciplinary Heart Failure Transitional Care	Nothing to Disclose
ividulai asali	rtaja	Care	Interventions on Disparities in 30-Day Readmission Rates	Nothing to Disclose
Mutharasan	Raja	FIT Clinical Decision Making: Interventional	Exertional Chest Pain and Dynamic ST-Segment Changes in a	Nothing to Disclose
	•	Cardiology, Acute and Stable Ischemic Heart	Pregnant Patient With Systemic Lupus Erythematosus: A Case of	-
		Disease, and Vascular Medicine	Preeclampsia-Induced Ischemia	
Myaskovsky	Larissa	Arrhythmias and Clinical EP: Devices 2	Persistent Gender Disparities in Implantable Cardioverter-	Nothing to Disclose
M. andresa	Debed	Andrethanian and Clinical ED: Common and	Defibrillator Therapy	DATA CAFETY MONITORING DOADD. 7-11
Myerburg	Robert	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Mortality Rates and Cost of Hospital Admissions for Syncope in the United States	DATA SAFETY MONITORING BOARD - Zoll
Myers	Jonathan	Featured Clinical Research I	Testing Safety and Efficacy: The Randomized Exploratory Study of	Nothing to Disclose
,0.0		Coodini	Exercise Training in Hypertrophic Cardiomyopathy (RESET-HCM)	
<u></u>	<u> </u>	<u> </u>		
Myers	Jonathan	Advances in HCM, PPCM and Other	Integrating Myocardial Strain and Exercise Performance Into	Nothing to Disclose
	ļ	Cardiomyopathies	Prognostication of Hypertrophic Cardiomyopathy	Li di Cara di
Mygind	Naja	Novel Echocardiographic Methods for	Coronary Microvascular Dysfunction Affects the Myocardial	Nothing to Disclose
		Assessing Cardiac Function	Contractile Reserve in Women With Angina and No Obstructive Coronary Artery Disease	
Mygind	Naja	Vascular Medicine: Novel Risk Measures in	Effect of Ramipril on Microvascular Function and Symptoms in	Nothing to Disclose
ygiiiu	aju	Arterial Diseases	Normotensive Women With Microvascular Angina: A Randomized	Totaling to Disciose
	1		Controlled Trial	
Mygind	Naja	Fixing the Heart One Cell at a Time: The	Adipose Derived Stromal Cells for Refractory Angina: Results From	Nothing to Disclose
,,,		Ongoing Promise of Stem Cells	MyStromalCell Trial	•
Myrmel	Truls	Vascular Medicine: Novel Risk Measures in	Body Mass Index and Acute Aortic Dissection	Nothing to Disclose
		Arterial Diseases		
Myrmel	Truls	Vascular Medicine: Aortic and Peripheral	Predictive Factors for Rapid Aortic Growth Following Acute Type A	Nothing to Disclose
		Artery Diseases	Aortic Dissection Patients: A Study From the International Registry of	
Mirmol	Truls	Vascular Medicine: Aortic and Peripheral	Acute Aortic Dissection Uncontrolled Hypertension in Acute Aortic Dissection Follow-Up	Nothing to Disclose
Myrmel	Tiuis	Artery Diseases	Officeritioned hypertension in Acute Aortic Dissection Follow-op	Nothing to Disclose
Mysore	Manu	Advances in Pulmonary Arterial Hypertension	Pulmonary-Systemic Pulse Pressure Ratio Is Associated With	Nothing to Disclose
,		, , , , , , ,	Adverse Clinical Outcomes in Group 1 Pulmnonary Hypertension	
Na	Jin Oh	Novel Developments in Acute Coronary	Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor	Nothing to Disclose
		Syndromes	and Angiotensin Receptor Blocker in Diabetic Hypertensive Acute	
			Myocardial Infarction Patients: Results From the Korea Acute	
	r. or	Time I Take in the I comment of the I	Myocardial Infarction Registry (KAMIR)	Made and Brands
Na	Jin Oh	Timely Topics in Acute Coronary Syndromes	Predictors of Mortality in Acute Myocardial Infarction Patients With Unprotected Left Main Coronary Artery Disease	Nothing to Disclose
Na	Jin Oh	Advances in Chronic Total Occlusion	Impact of Percutaneous Coronary Intervention for Chronic Total	Nothing to Disclose
		Intervention	Occlusion Patients With Near-Normal Left Ventricular Function	
Nabi	Faisal	Highlighted Original Research: Valvular Heart	Diffuse Interstitial and Regional Replacement Fibrosis in Chronic	Nothing to Disclose
		Disease and the Year in Review	Primary Mitral Regurgitation: Insights From Cardiovascular Magnetic	
			Resonance	
Nabi	Faisal	Non Invasive Imaging: MR Characterization	Elevated Myocardial Extracellular Volume Fraction (ECV) and Its	Nothing to Disclose
Nabi	Faisal	and Function Valvular Heart Disease: Mitral Valve Disease	Prognostic Significance in Diabetic Individuals Inter-Study Reproducibility of Mitral Regurgitation Quantitation Using	Nothing to Disclose
INADI	FdiSdi	Valvulal Healt Disease. Willial Valve Disease	Cardiac Magnetic Resonance Imaging	Nothing to Disclose
Nabi	Faisal	Non Invasive Imaging: MR Structure and	Quantitative Measurements on Cardiac Magnetic Resonance to	Nothing to Disclose
	<u>1 · · · · </u>	Valuvular Heart Disease	Differentiate Benign Versus Malignant Masses: A Pilot Study	-
Naccarelli	Gerald	Fibrillatory Arrhythmias: Outcomes With	Rates of Oral Anticoagulant Use, While Improving Over Time,	CONSULTANT FEES/HONORARIA - AstraZeneca
		Contemporary Practice	Remain Low Among Hospitalized Patients With Atrial Fibrillation	Pharmaceuticals,Boehringer-Ingelheim,Bristol Myers
N	0	According to the control of the cont	N Second Bloods Avg	Squibb, Daiichi-Sankyo, Glaxo-Smith-Kline, Janssen, Pfizer
Naccarelli	Gerald	Atrial Fibrillation and VT: Incorporating Novel	Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation:	CONSULTANT FEES/HONORARIA - AstraZeneca
	1	Risks Toward Decision Making	Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)	Pharmaceuticals,Boehringer-Ingelheim,Bristol Myers Squibb,Daiichi-Sankyo,Glaxo-Smith-Kline,Janssen,Pfizer
Naccarelli	Gerald	06. Arrhythmias and Clinical EP: Other Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - AstraZeneca
		,		Pharmaceuticals,Boehringer-Ingelheim,Bristol Myers
				Squibb, Daiichi-Sankyo, Glaxo-Smith-Kline, Janssen, Pfizer
Naderi	Sahar	Understanding Spontaneous Coronary Artery	What do We Advise with Regard to Medications, Exercise,	Nothing to Disclose
		Dissection (SCAD): What We Know, What We	Pregnancy, and Risk of Recurrence?	
Nadkarni	Cirioh	Don't Know Heart Failure and Cardiomyopathies: What	Etiology and Prodictors of 20 Day Hardeneyd Day desirate Day	Nothing to Disclose
Nadkarni	Girish	Next When All Else Is Failing?	Etiology and Predictors of 30-Day Unplanned Readmission Rates After Left Ventricular Assist Device Placement	Nothing to Disclose
Nadpara	Pramit	Young Investigator Awards Competition:	Comparison of a Pharmacist-Physician Collaborative Care Model to	Nothing to Disclose
supuru		Outcomes Research	Standard Care on the Time to Reach Goal Blood Pressure for	
	<u> </u>		Patients With Hypertension	
Nadpara	Pramit	Novel Strategies for Assessing and Improving	Comparison of a Pharmacist-Physician Collaborative Care Model to	Nothing to Disclose
		Adherence to Blood Pressure Lowering	Standard Care on the Time to Reach Goal Blood Pressure for	
Nodro	lmad	Therapies	Patients Presenting With Urgent Hypertension	Nothing to Disclose
Nadra	lmad	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Renal Function-Based Contrast Dosing to Define "Prognostic" Contrast Dose Limits for Percutaneous Coronary Intervention - The	Nothing to Disclose
		110 vascularization and Outcomes	Prognostic Implication of the Contrast Volume: Glomerular Filtration	
		1	Ratio in 44,082 Patients From the British Columbia Cardiac Registry	
			,, , , , , Shari Solumbia Sarada Negistry	
Nadra	lmad	Coronary Angiography, Intra-Vascular Imaging,	Variation in Practice and Concordance With Guideline Criteria for	Nothing to Disclose
		Revascularization and Outcomes	Length of Stay After Elective Percutaneous Coronary Intervention	
Nadruz Junior	Wilson	Advances in Lipid Management	Impact of Statin Therapy on Collagen Turnover and Left Ventricle	Nothing to Disclose
			Function After ST-Elevation Myocardial Infarction: A Randomized	
			Clinical Trial	
Nadruz Junior	Wilson	Non Invasive Imaging: MR Scar and Perfusion	Doxorubicin-Associated Cardiac Tissue Remodeling in Breast	Nothing to Disclose
Nag	Tonusri	FIT Clinical Decision Making: Arrhythmias and	Cancer Patients: A Cardiac Magnetic Resonance Study Sinus Node Dysfunction in Batten Disease: A Rare Manifestation of	Nothing to Disclose
Nag	i Jiluali	Electrophysiology	a Rare Disease	1100 mily to Disciose
Nagabandi	Arun	FIT Clinical Decision Making: Arrhythmias and	Vagal Nerve Stimulator Therapy: An Unusual Cause of	Nothing to Disclose
	<u>l </u>	Electrophysiology	Symptomatic Bradycardia	<u> </u>



Nagae	First Name Ayumu	Session Title Endovascular Therapy: Running From Risk	Presentation Title Impact of Decrease in Blood Pressure After Endovascular Therapy	Disclosures Nothing to Disclose
Nagajothi	Nagapradeep	Vascular Access and Hemostasis Issues	for Renal Artery Stenosis Mid Femoral Head Is Not the Ideal Fluroscopic Landmark for	SPEAKER'S BUREAU - Astra Zeneca
		FIT Clinical Decision Making: Interventional	Common Femoral Artery Puncture A Rare Case of Chronic Persistent Troponin Elevation	SPEAKER'S BUREAU - Astra Zeneca
Nagajothi	Nagapradeep	Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	·	
Naganuma	Toru	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Impact of Kissing Balloon Inflation After Single Stent Implantation for Left Main Distal Bifurcation Lesions: New Tokyo Registry	Nothing to Disclose
Naganuma	Toru	Advances in Chronic Total Occlusion Intervention	Impact of Target Vessel on Long-Term Cardiac Mortality After Successful Percutaneous Coronary Intervention for Chronic Total	Nothing to Disclose
Naganuma	Toru	Interventional Cardiology: TAVR 4	Occlusion: Japanese Multicenter Registry Transcatheter Aortic Valve Implantation in Patients With an Extremely Small Annulus	Nothing to Disclose
Naganuma	Toru	The Evolving World of LVADs, Transplant and	Significance of ¹²³ I-BMIPP-Scintigraphy in the	Nothing to Disclose
		Other Novel Discoveries	Recovery of Left Ventricular Systolic Dysfunction in Takotsubo Cardiomyopathy: Insight From the NEW TAKOTSUBO BMIPP Registry	
Nagao	Ken	Unusual Presentations of ACS	Clinical Characteristics and In-Hospital Mortality of Very Elderly Patients With Cardiovascular Shock in Japan: The Results From Japanese Circulation Society Shock Registry	Nothing to Disclose
Nagao	Ken	Unusual Presentations of ACS	Association Between Presentation Time and Short-Term Mortality in Patients With Cardiogenic Shock Complicating Acute Coronary Syndrome: From Jcs Shock Registry	Nothing to Disclose
Nagel	Eike	Featured Clinical Research I	MR-INFORM: Stress Perfusion Imaging to Guide the Management of Patients With Stable Coronary Artery Disease	CONSULTANT FEES/HONORARIA - Bayer Healthcare, Philips healthcare; RESEARCH/RESEARCH GRANTS - Bayer Healthcare, CVI42, Medis, Philips healthcare
Nagel	Eike	Cardiovascular Magnetic Resonance A Fast	Coronary Artery Disease: A 20 Minute Examination	CONSULTANT FEES/HONORARIA - Bayer Healthcare, Philips
		and Reliable Method to Change Patients' Therapy: Joint Symposium of the Society for Cardiovascular Magnetic Resonance and the		healthcare; RESEARCH/RESEARCH GRANTS - Bayer Healthcare, CVI42, Medis, Philips healthcare
Nagel	Eike	American College of Cardiology 29. Non Invasive Imaging: MR Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Bayer Healthcare, Philips
				healthcare; RESEARCH/RESEARCH GRANTS - Bayer Healthcare,CVI42,Medis,Philips healthcare
Nagueh	Sherif	Controversies in Echocardiography	Pro: The New Diastolic Echo Guidelines are All I Need for Assessment of Filling Pressures	Nothing to Disclose
Nagueh	Sherif	Echocardiographic Assessment of LV Diastolic Function The New ASE/EACVI Guidelines 2016 Update: Joint Symposium of the American Society of Echocardiography and the American College of Cardiology	the Same?	Nothing to Disclose
Nagueh	Sherif	Non Invasive Imaging: MR Characterization	Elevated Myocardial Extracellular Volume Fraction (ECV) and Its	Nothing to Disclose
Nagueh	Sherif	and Function 28. Non Invasive Imaging: Echo Team 4	Prognostic Significance in Diabetic Individuals Suggested Reviewer	Nothing to Disclose
Nagy	Klaudia Vivien	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Quality of Life Measured With Euroqol-5D Questionnaire Predicts Long Term Mortality and Echocardiographic Response in CRT Patients	Nothing to Disclose
Naidu	Srihari	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular,Abiomed,MyoKardia
Nair	Ajith	FIT Clinical Decision Making: Heart Failure and Cardiomyopathies	SynCardia Meets CardioMEMS: A Loeffler's Story	Nothing to Disclose
Nair	Ajith	Heart Failure and Cardiomyopathies: Clinical Team 1	Suggested Reviewer	Nothing to Disclose
Nair	Devaki	Non Invasive Imaging: Prognostic Implications	Carotid Plaque Is Predictive of Cardio Vascular Events in	Nothing to Disclose
Nair	Dinesh	of CT Angiography Challenges in Percutaneous Interventions: International Perspectives From the Hong Kong College of Cardiology, Singapore Cardiac Society, and American College of Cardiology	Asymptomatic Diabetes: A Prospective Study Challenging Cases With Bioresorbable Vascular Scaffolds	Nothing to Disclose
Nairooz	Ramez	Valvular Disease Populations at Risk	National and Regional Trends in Surgical Aortic Valve Replacement	Nothing to Disclose
Nairooz	Ramez	Coronary Intervention: Drug Eluting Stent and Scaffolds	in the TAVR Era Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold Versus Second Generation Des in Coronary Artery Disease: A Meta-	Nothing to Disclose
Naji	Peyman	FIT Clinical Decision Making: Interventional	Analysis Cardioembolic Stroke Due to Takotsubo Cardiomyopathy, Truly	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Rare or Under-Recognized?	-
Nakagawa	Susumu	Unusual Presentations of ACS	Trend of Use in Transradial Intervention Among Elderly Patients in Japan According to Their Pre-Procedural Bleeding Risk	Nothing to Disclose
Nakagawa	Yoshihisa	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Application of DAPT Score to Predict Ischemic and Bleeding Events in Japanese Patients Undergoing Drug-Eluting Stent Implantation: An Observation From a Pooled Cohort of the CREDO-Kyoto Cohort- 2, RESET, and NEXT Trials	Nothing to Disclose
Nakahara	Takehiro	Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI	Fv-Hsp70 Protects Myocardium From Ischemic/Reperfusion Injury	Nothing to Disclose
Nakahara	Takehiro	Advances in Imaging to Assess Cardiotoxicity	<pre>^{99m}Tc-Duramycin Imaging Detects Doxorubicin</pre>	Nothing to Disclose
Nakajima	Hiroyoshi	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Cardiac Injury Before Onset of Ventricular Dysfunction Elevated Right Sided Heart Pressure Is Associated With Malnutrition in Heart Failure Patients With Reduced Ejection Fraction	Nothing to Disclose
Nakajima	Hiroyoshi	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Identifying Novel Phenotypes of Acute Decompensated Heart Failure Using Cluster Analysis of Clinical Variables	Nothing to Disclose
Nakajima	Yoshifumi	Structural Heart Interventions: Focus on Mitral	Impact of Residual Left Atrial Appendage Trabeculations After	Nothing to Disclose
Nakajima	Yoshifumi	Valve, Left Atrial Appendage and HOCM Structural Heart Interventions: Focus on Mitral	WATCHMAN Device Implantation in Atrial Fibrillation Patients Anemia Predicts Mortality in Atrial Fibrillation Patients Undergoing	Nothing to Disclose
Nakajima	Yoshifumi	Valve, Left Atrial Appendage and HOCM Interventional Cardiology: Structural Heart	Left Atrial Appendage Occlusion Using WATCHMAN Device Long-Term Durability of Percutaneous Mitral Valve Repair Using	Nothing to Disclose
Nakama	Yasuharu	Disease Interventional Cardiology: Stent Failure	MitraClip System: 8-Year Follow-Up Differences in Chronic Angioscopic Findings With Different Stent	Nothing to Disclose
Nakamura	Mamoo	Analysis by Intravascuar Imaging Structural Heart Interventions: Focus on Mitral	Types in Patients With and Without Diabetes Mellitus: Sub-Analysis of a Report From Japanese Multicenter Registry Impact of Residual Left Atrial Appendage Trabeculations After	Nothing to Disclose
Nakamura	Mamoo	Valve, Left Atrial Appendage and HOCM Structural Heart Interventions: Focus on Mitral	WATCHMAN Device Implantation in Atrial Fibrillation Patients Anemia Predicts Mortality in Atrial Fibrillation Patients Undergoing	Nothing to Disclose
		Valve, Left Atrial Appendage and HOCM	Left Atrial Appendage Occlusion Using WATCHMAN Device	-
Nakamura	Mamoo	Interventional Cardiology: Structural Heart Disease	Long-Term Durability of Percutaneous Mitral Valve Repair Using MitraClip System: 8-Year Follow-Up	Nothing to Disclose
Nakamura	Masato	Interventional Complexity and Complications	Impact of Institutional and Operator Volume on Short-Term Outcomes of Percutaneous Coronary Intervention: A Report From	SPEAKER'S BUREAU - Daiichi Sankyo, Sanofi, AstraZeneka, Terumo, Boston Scientific, Medtronic, Abott vascular
<u> </u>		1	Japanese Nationwide Registry	I

Selection of the Evening vision of LVADs. Transplant and Evening Selection of the Reconstruction Based Selections of Vestion of Selection of Nationary (1997) and the Selection of Select	Contract of the Contract of th				
Sheeting Control (Section Control) Sheeting Co			Session Title The Evolving World of LVADs Transplant and		
Anderson State Control Number Contro	Nakamura		Other Novel Discoveries	Impedance Analysis Is Useful Risk Stratification in Acute Decompensated Heart Failure	Terumo, Boston Scientific, Medtronic, Abott vascular
Signature Signat	Nakamura	Masato		Analysis Provides Prognostic Value in Acute Heart Failure: Beyond	SPEAKER'S BUREAU - Daiichi Sankyo, Sanofi, AstraZeneka, Terumo, Boston Scientific, Medtronic, Abott vascular
Service Servic	Nakamura	Sunao		Provisional Versus Elective Two-Stenting Strategy for Unprotected	Nothing to Disclose
Nationary States of Project Vision of Transport Control Transport	Nakamura	Sunao			Nothing to Disclose
Nakamura Darso Other Concepts and Speringson and Sp	Nakamura	Sunao	Advances in Chronic Total Occlusion	Impact of Target Vessel on Long-Term Cardiac Mortality After Successful Percutaneous Coronary Intervention for Chronic Total	Nothing to Disclose
Notamenta Sursoo Services Control Presponse Presponse Control Presponse Presponse Control Presponse C	Nakamura	Sunao		Significance of ¹²³ I-BMIPP-Scintigraphy in the Recovery of Left Ventricular Systolic Dysfunction in Takotsubo Cardiomyopathy: Insight From the NEW TAKOTSUBO BMIPP	Nothing to Disclose
Notamental Notamental Notamental Proposition of Explane 10 on the Risk of Membrane to Record Proposition of Poliphan (Poliphan of Capitan 10 on the Risk of Membrane to Record Proposition of Poliphan (Poliphan of Poliphan o	Nakamura	Sunao	Endovascular Therapy: Running From Risk	The Impact of Patent Below the Knee Vessels on Stenting for	Nothing to Disclose
Nationals Nationals National Conference on Notes (Nationals Nationals Conference Nationals Nationals Conference Nationals Nationals (Nationals Nationals Conference Nationals Na	Nakamura	Yosikazu	Adherence to Blood Pressure Lowering	Effect of Gene Polymorphism of Calpain-10 on the Risk of	Nothing to Disclose
Nationalist Rive Apolications (Proporting Circuit) (Provided Circuit)	Nakanishi	Rine	Non Invasive Imaging: Applications in Novel		Nothing to Disclose
Reference of the company of the comp	Nakanishi	Rine	Non Invasive Imaging: Expanding Clinical	The Utility of Left Atrial Appendage Hounsfield Unit and the Ratio of	Nothing to Disclose
Applications Rine Novel Developments in Acute Coronary Syndrome	Nakanishi	Rine		Left Atrial Appendage Thrombus	Nothing to Disclose
Nationals Syndromes Syndromes Patents Will ST-Segment Elevation Nycoration Infraction	Ivakailisili	Time		Tomography-Myocardial Perfusion Image and Fractional Flow	Notining to Disclose
Nakarishi Rine Normale manging Coronary Calcium Abertaceticate (MESA) Nakarishi Rine Normale manging Coronary Calcium Abertaceticate (MESA) Normale (MESA) N	Nakanishi	Rine		Patients With ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Scoring and CV Risk Assessment Atherosclerosis and Coronary Artery Calcium Floore: The Malty			Scoring and CV Risk Assessment	Prognostic Value of Protein Biomarkers Predict Risk of Coronary Heart Disease Events: Results From Multi-Ethnic Study of Atherosclerosis (MESA)	-
Scoring and CV Risk Assessment Plaque Progression Determined by Quantifative Coronary Artery Plaque Analysis Anal	Nakanishi	Rine	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Atherosclerosis and Coronary Artery Calcium Score: The Multi- Ethnic Study of Atherosclerosis	Nothing to Disclose
Soring and CV Risk Assessment Security Area Predicting Carolis Area Disease Results From the Multi-Ethnic Sudy of Atherosclerosis (MESA)	Nakanishi	Rine		Plaque Progression Determined by Quantitative Coronary Artery	Nothing to Disclose
Rine Innovations in Cardiovascular Risk Assessment Association of Coronary Calcium, Carolid Wall Thicheness and and Reduction Annual Reduc	Nakanishi	Rine		Predicting Carotid Artery Disease: Results From the Multi-Ethnic	Nothing to Disclose
Masahima Interventional Cardiology, PCI in Complex Pedictors for 2-Year Cardiovascular Events After Rotablation in Patients (action of Patients National Patients) Patients (action of Patients) Patients (action of Patients) Patients (action of Patients) Patients (action of Patients) Patients) Patients (action of Patients) Patients) Patients (action of Patients) Patients) Patients (action of Patients) Patients) Patients) Patients (action of Patients) P	Nakanishi	Rine		Association of Coronary Calcium, Carotid Wall Thickness and Carotid Plaque Progression With Low Density Lipoprotein and High Density Lipoprotein Particle Concentration Measured by Ion Mobility	Nothing to Disclose
Revascularization and Mycocardial Preservation Revalue and Stable Ischemic Heart Disease ST Segment Elevation Acute Coronary Syndromes ST Segment Elevation Acute Coronary Syndromes ST Segment Elevation Acute Coronary Syndromes ST Segment Elevation Acute Coronary Syndromes ST Segment Elevation Acute Coronary Syndromes ST Segment Elevation Acute Coronary Syndromes ST Segment Elevation Acute Coronary Syndromes ST Segment Elevation Acute Coronary After) Stable Coronary After) Stable Coronary After) Stable Coronary After) Stable Coronary After) Stable			Interventional Cardiology: PCI in Complex	Predictors for 2-Year Cardiovascular Events After Rotablation in	
Disease Platelet Aggregation in Patients With Stable Coronary Artery Disease Nakayama Nama The Evolving World of LVADs, Transplant and B-Type Natruretic Peptide Levels is a Useful Prognostic Marker in Nothing to Disclose Nothing to Disclose Nothing to Disclose Nakayama Naoki The Evolving World of LVADs, Transplant and Patients With Econophilic Granulomatosis With Polyangilis Nothing to Disclose Nothing t	Nakashima	Carlos	Revascularization and Myocardial Preservation	The Role of Oral Beta Blocker in a Real-World Population With Non-	Nothing to Disclose
Nakayama	Nakashima	Carlos		Platelet Aggregation in Patients With Stable Coronary Artery	Nothing to Disclose
Nacki	Nakayama	Mina		B-Type Natriuretic Peptide Levels Is a Useful Prognostic Marker in	Nothing to Disclose
Natibangii Sanem	Nakayama	Naoki	The Evolving World of LVADs, Transplant and	B-Type Natriuretic Peptide Levels Is a Useful Prognostic Marker in	Nothing to Disclose
Nallamothu Brahmajee What is the PROMISE of ISCHEMIA. A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture Voung Investigator Awards Competition: Outcomes Research Outcomes Research Outcomes Research PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities Outcomes Research Ou	Nalbantgil	Sanem		Comparisons of Invasive and Non-Invasive Cardiac Output	Nothing to Disclose
Nallamothu Brahmajee Young Investigator Awards Competition: Outcomes Research Outcomes Research	Nallamothu	Brahmajee	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young		CONSULTANT FEES/HONORARIA - UnitedHealthcare
PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities Consultant Feesth Month Multiple College of Multiple Co-Morbidities Consultant Feesth Month Multiple College of Mu	Nallamothu	Brahmajee	Young Investigator Awards Competition:	Chair	CONSULTANT FEES/HONORARIA - UnitedHealthcare
Nallamothu Brahmajee Interventional Cardiology: PCI and TAVR in Complex Patients Utilization of Heart Teams in the United States: Results From the Translating Outstanding Performance in Percutaneous Coronary Intervention (TOP PCI) Study Consumeration of Policy Study Contemporary Intervention (TOP PCI) Study Contemporary Intervention (ToP PCI) Study Contemporary Intervention (ToP PCI) Study Contemporary Intervention (ToP PCI) Study Contemporary Intervention (ToP PCI) Study Contemporary Intervention (ToP PCI) Study Contemporary Intervention (ToP PCI) Study Contemporary Intervention (ToP PCI) Study Contemporary Intervention (ToP PCI) Intervention (ToP PCI) Intervention (ToP PCI) Intervention (ToP PCI) Intervention (ToP PCI) Interventio	Nallamothu	Brahmajee	PCI for NSTEMI and Complex Patients With	Coronary Intervention in the United States: A National Readmission	CONSULTANT FEES/HONORARIA - UnitedHealthcare
Role of Hospital Volume in Identifying Low and High-performing Surgical Valve Centers in the United States	Nallamothu	Brahmajee		Utilization of Heart Teams in the United States: Results From the Translating Outstanding Performance in Percutaneous Coronary	CONSULTANT FEES/HONORARIA - UnitedHealthcare
Namba Chang-Wook Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging Intravascuar Unaging Intravascuar Unaging Intravascuary Intravascua	Nallamothu	Brahmajee	Interventional Cardiology: TAVR 3	Role of Hospital Volume in Identifying Low and High-performing	CONSULTANT FEES/HONORARIA - UnitedHealthcare
Namba Sayaka Antiplatelet and Antithrombotic Agents in Stent Edge Strut on Normal Segment Is Less Covered in Early Nothing to Disclose Namba Sayaka Unusual Presentations of ACS Lower Eicosapentaenoic Acid to Arachidonic Acid Ratio Is Associated With Intraplaque Cholesterol Crystals: An Optical Coherence Tomography Study Offer Properties Offer Pro	Nam	Chang-Wook		Five Year Outcomes of Fractional Flow Reserve Guided Versus Intravascular Ultrasound Guided Percutaneous Coronary	Nothing to Disclose
Namba Sayaka Unusual Presentations of ACS Lower Eicosapentaenoic Acid to Arachidonic Acid Ratio Is Associated With Intraplaque Cholesterol Crystals: An Optical Coherence Tomography Study	Namba	Sayaka		Stent Edge Strut on Normal Segment Is Less Covered in Early	Nothing to Disclose
Nambi Vijay Great Debates in Cardiac CT Debates: The Optimal Screening Test for Assessing Cardiovascular Risk is3D Carotid Plaque Ultrasound, Con Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens OTHER - Roche Diagno	Namba	Sayaka		Lower Eicosapentaenoic Acid to Arachidonic Acid Ratio Is Associated With Intraplaque Cholesterol Crystals: An Optical	Nothing to Disclose
Nambi Vijay Advances in Cholesterol Measurement and Management Association of Remnant-Like Particle Cholesterol and Low-Density Lipoprotein Triglyceride With Incidence of Cardiovascular Events: The ARIC Study-v≥/i> OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens Nambi Vijay Contemporary Issues in Familial Hypercholesterolemia ACC Poster Moderator Hypercholesterolemia OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens Nambi Vijay 32. Prevention: Clinical Team 6 Suggested Reviewer OTHER - Roche Diagnositics/ Baylor College of OTHER - Roche Diagnositics/ Baylor College of Medicine, Siemens	Nambi	Vijay	Great Debates in Cardiac CT	Debate: The Optimal Screening Test for Assessing Cardiovascular	
Nambi Vijay Contemporary Issues in Familial ACC Poster Moderator OTHER - Roche Diagnositics/ Baylor College of Hypercholesterolemia Medicine, Siemens Nambi Vijay 32. Prevention: Clinical Team 6 Suggested Reviewer OTHER - Roche Diagnositics/ Baylor College of	Nambi	Vijay		Association of Remnant-Like Particle Cholesterol and Low-Density Lipoprotein Triglyceride With Incidence of Cardiovascular Events:	OTHER - Roche Diagnositics/ Baylor College of
Nambi Vijay 32. Prevention: Clinical Team 6 Suggested Reviewer OTHER - Roche Diagnositics/ Baylor College of	Nambi	Vijay			
Medicine,Siemens	Nambi	Vijay		Suggested Reviewer	OTHER - Roche Diagnositics/ Baylor College of
Nanavaty Sukrut Interventional Cardiology: Intravascular Comparison of Adenosine Fractional Flow Reserve and Post-Contrast Instantaneous Wave-Free Ratio for Hemodynamic Nothing to Disclose	Nanavaty	Sukrut	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Contrast Instantaneous Wave-Free Ratio for Hemodynamic	
Assessment of Moderate Coronary Stenoses Nanavaty Sukrut Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real? Failure With a Normal EF for Real? Failure With Preserved Ejection Fraction: A Meta-Analysis	Nanavaty	Sukrut		Efficacy of Phosphodiesterase-5 Inhibitor in Patients With Heart	Nothing to Disclose

Last Name Nanavaty	First Name Sukrut	Session Title Interventional Complexity and Complications	Presentation Title Can Non-Procedural Patient Characteristics Predict In-Hospital Complications Following Elective Percutaneous Coronary	Disclosures Nothing to Disclose
Nanavaty	Sukrut	Interventional Complexity and Complications	Intervention? Implications for Same-Day Discharge Temporal Trend of Incidence of Stent Thrombosis and In-Hospital	Nothing to Disclose
Nanavaty	Sukrut	Interventional Complexity and Complications	Mortality: Results From a National Real-World Registry Does Presence of Atrial Fibrillation Affect In-Hospital Mortality in Patients Undergoing Percutaneous Coronary Intervention? Results	Nothing to Disclose
Nanavaty	Sukrut	Interventional Complexity and Complications	From a Real-World Registry Does Gender Affect In-Hospital Mortality in Patients Presenting With	Nothing to Disclose
Nanavaldana	Chana	Francisco Develormento in US-SS and	Stent Thrombosis? Results From a National Real-World Registry	Nething to Displace
Nanayakkara	Shane	Emerging Developments in HFpEF and Arryhthmias	Age Specific Hemodynamic Features in HFPEF: Implications for Therapy	Nothing to Disclose
Nanda Nanda	Sudip Vivek	Advances in HCM, PPCM and Other Cardiomyopathies 38. Vascular Medicine: Basic Team 1	Childbirth Related Complications in Women With Hypertrophic Cardiomyopathy Suggested Reviewer	Nothing to Disclose Nothing to Disclose
Nanduri	Sudheer	Novel Developments in Acute Coronary Syndromes	Central Fractional Pulse Pressure Predicts Cardiac Power Index in Patients With Acute Coronary Syndrome	Nothing to Disclose
Nanjundappa	Aravinda	Interventional Challenging Cases: Team 3	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Cook,Edwards,Gore,Pfizer Pharmaceuticals; SPEAKER'S BUREAU - Astra Zeneca,Janssen Pharmaceuticals
Nannapaneni	Nischala	Arrhythmias and Clinical EP: Basic 2	Utility of an Esophageal Screening Protocol in Preventing Atrio- Esophageal Fistula After Atrial Fibrillation Ablation	Nothing to Disclose
Nap	Alexander	Advances in Chronic Total Occlusion Intervention	Effects of Successful Percutaneous Coronary Intervention of Chronic Total Occlusions on Myocardial Perfusion and Left Ventricular Function	Nothing to Disclose
Naqvi	Ali	The Inside View: Learning From Intracoronary Imaging	Hybrid IVUS/OCT: "Probing" the Future	Nothing to Disclose
Naqvi	Syed Yaseen	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Contrast Echocardiography Versus Cardiac Magnetic Resonance for the Diagnosis of Left Ventricular Thrombus	Nothing to Disclose
Naqvi	Tasneem	Great Debates in Cardiac CT	Debate: The OptimalScreening Test for Assessing Cardiovascular Risk is3D Carotid PlaqueUltrasound, Pro	Nothing to Disclose
Naqvi Naqvi	Tasneem Tasneem	Great Debates in Cardiac CT Novel Echocardiographic Methods for	Rebuttal, Pro Long-Term Effects of Right Ventricular Pacing on Left Ventricular	Nothing to Disclose Nothing to Disclose
Nami	Topped	Assessing Cardiac Function	Systolic and Diastolic Function and Synchrony by Strain Imaging in Patients With Normal Baseline Left Ventricular Ejection Fraction	Nothing to Displace
Naqvi	Tasneem	Leading Us Astray? Pacemakers in Cardiomyopathies	Chronic Right Ventricular Pacing: Effects on Heart Failure Hospitalization and Mortality in the Presence of Normal Left Ventricular Ejection Fraction	Nothing to Disclose
Naraen	Akriti	Advances in HCM, PPCM and Other Cardiomyopathies	Younger Age, Positive Family History and Reverse Curve Morphology Predict Informative Results From Gene Panel Analysis for Hypertrophic Cardiomyopathy (HCM)	Nothing to Disclose
Narang Narang	Akhil Akhil	FIT Forum: Scholarship and Education FIT Forum: Stump the Professor	Co-Chair Co-Chair	Nothing to Disclose Nothing to Disclose
Narang	Akhil	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Implementation of a Wideband Late Gadolinium Enhancement Cardiac Magnetic Resonance Protocol to Improve Assessment of Myocardial Scar in Patients With Implantable Cardioverter Defibrillators	Nothing to Disclose
Narang	Akhil	Valvular Heart Disease: Aortic Regurgitation	Left Ventricular Mechanical Properties in Patients With Severe Aortic Insufficiency and Normal Ejection Fraction: Impact on Survival	Nothing to Disclose
Narang	Akhil	Non Invasive Imaging: MR Scar and Perfusion	Multimodality Analysis of Abnormal Myocardial Perfusion in Post- Heart Transplant Recipients	Nothing to Disclose
Narang	Akhil	Engage @ ACC.17 Studio: Meet the Acute and Stable Heart Disease Legends	, 3, ,	Nothing to Disclose
Narang Narasimhan	Akhil Calambur	FIT Clinical Decision Making Reviewers 1 The Evolving World of LVADs, Transplant and Other Novel Discoveries	ACC FIT Clinical Decision Making Reviewer Chronic Kidney Disease in Asian Patients With Heart Failure	Nothing to Disclose CONSULTANT FEES/HONORARIA - MEDTRONIC, Sanofi Aventis; RESEARCH/RESEARCH GRANTS - Biosense
Narayanasamy	Hemalatha	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Rocking Prosthetic Valve 1 Year After Surgery: A Case of Untreated Takayasu Arteritis	Webster, Daichi Sankyo, Eli Lilly, St Jude Nothing to Disclose
Narezkina	Anya	Emerging Developments in HFpEF and Arryhthmias	Differences Between Ethnic Groups in Comorbidities Do Not Influence Readmission Risk in Patients With Heart Failure and	Nothing to Disclose
Narichania	Aalap	FIT Clinical Decision Making: Arrhythmias and	Preserved Ejection Fraction Torsades de Pointes Following Insulin Infusion in a Patient With	Nothing to Disclose
Narula	Jagat	Electrophysiology Featured Clinical Research I	Hyperosmolar Hyperglycemic State Native South American Tsimane Have the Lowest Levels of	Nothing to Disclose
Narula	Jagat	FIT Forum: Mix and Mingle	Coronary Atherosclerosis Ever Reported Imaging	Nothing to Disclose
Narula	Jagat	Eugene Braunwald Lecture on Future Directions in Cardiovascular Medicine and the Best of JACC Journals	Panelist	Nothing to Disclose
Narula	Jagat	Eugene Braunwald Lecture on Future Directions in Cardiovascular Medicine and the Best of JACC Journals	Best of JACC: Imaging in 2016	Nothing to Disclose
Narula	Jagat	Recognition of Specific Etiologies and Phenotypes in Heart Failure: Time for Precision	Panelist	Nothing to Disclose
Narula	Jagat	Point of Care Ultrasound (POCUS): The Future or a Fad?	Panelist	Nothing to Disclose
Narula	Jagat	Point of Care Ultrasound (POCUS): The Future or a Fad?	Integration of POCUS into Medical Education: Training and Standards	Nothing to Disclose
Narula	Jagat	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Year in Review Speaker	Nothing to Disclose
Narula	Jagat	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Atherosclerotic Plaque Morphology in Response to High Intensity Lipid Lowering Therapy by Multimodality Imaging Among Women and Men: A YELLOW-II Sub-study	Nothing to Disclose
Narula	Jagat	Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI	Fv-Hsp70 Protects Myocardium From Ischemic/Reperfusion Injury	Nothing to Disclose
Narula	Jagat	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	T1 Mapping in Patients With Heart Failure With Preserved Ejection Fraction Detects Increased Interstitial Myocardial Fibrosis and Assesses the Severity of Heart Failure	Nothing to Disclose
Narula	Jagat	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Fractional Flow Reserve Is a Sensitive but Not a Specific Detector of a High Risk Plaques	Nothing to Disclose
Narula	Jagat	Updates on Risk Factors for Cardiovascular Disease	Retinopathy and Risk of Sudden Cardiac Death: The ARIC Study	Nothing to Disclose
Narula	Jagat	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Multimodality Intravascular Imaging to Evaluate Plaque Characteristics in Patients With Diabetes Mellitus	Nothing to Disclose
Narula	Jagat	Innovations in Cardiovascular Risk Assessment and Reduction		Nothing to Disclose
Narula	Jagat	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Atherosclerotic Plaque Morphology Is Associated With Impaired Myocardial Blood Flow and Fractional Flow Reserve, Independent of Luminal Obstruction	Nothing to Disclose
Narula	Jagat	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Can Necrotic Core Volume Explain Ischemia Coronary Stenosis Mismatch in Some Cases?	Nothing to Disclose
	1	p. 1000. 70. Oninous imprioautitis	processor at Come Odoco:	

Control of the contro				
Last Name Narula	First Name Jagat	Session Title The Inside View: Learning From Intracoronary	Presentation Title Investigation of Novel Drug Targets Implicated in High-Dose Statin	Disclosures Nothing to Disclose
INdiuid	Jayat	Imaging	Therapy From Yellow-II Trial: Towards Personalized Lipid Lowering Therapies	Nothing to Disclose
Narula	Jagat	Advances in Imaging to Assess Cardiotoxicity	-sup>99mTc-Duramycin Imaging Detects Doxorubicin Cardiac Injury Before Onset of Ventricular Dysfunction	Nothing to Disclose
Narula	Navneet	Novel Mechanisms Underlying Ischemia-	Fv-Hsp70 Protects Myocardium From Ischemic/Reperfusion Injury	Nothing to Disclose
Narula	Navneet	Reperfusion Injury in AMI Advances in Imaging to Assess Cardiotoxicity	<pre>^{99m}Tc-Duramycin Imaging Detects Doxorubicin</pre>	Nothing to Disclose
Narula	Tara	FIT Forum: Mix and Mingle	Cardiac Injury Before Onset of Ventricular Dysfunction 	Nothing to Disclose
Nascimento	Bruno	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Increased Left Atrial Compliance Is an Independent Predictor of Improved Functional Capacity After Percutaneous Mitral Valvuloplasty	Nothing to Disclose
Nasir	Khurram	Great Debates in Cardiac CT	Debate: Calcium Scoring Outperforms Risk Scores for Optimizing Appropriate Primary Preventative Therapies and Should be More Broadly Performed, Pro	Nothing to Disclose
Nasir	Khurram	Arrhythmias and Clinical EP: Basic 1	Variation in the Use of Direct Oral Anticoagulants and Associated Cost Implications: Findings From the Medical Expenditure Panel Survey 2010 to 2013	Nothing to Disclose
Nasir	Khurram	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Modelling the U.S. Population Health Benefits of Further Low- Density Lipoprotein Cholesterol Reduction With Alirocumah Among Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia Patients With Elevated Low-Density Lipoprotein Cholesterol	CONSULTANT FEES/HONORARIA - Quest Diagnostic,Regeneron
Nasir	Khurram	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Lipid Abnormalities in Young Patients With Myocardial Infarction	CONSULTANT FEES/HONORARIA - Quest Diagnostic,Regeneron
Nasir	Khurram	Current Issues in Cardiovascular	Women Who Experience Myocardial Infarction at a Young Age	CONSULTANT FEES/HONORARIA - Quest
Nasir	Khurram	Epidemiology, Disparities, and Safety Toward Precision Medicine in the Treatment of	Have Worse Survival Compared With Men Coronary Artery Calcium and Incident Hypertension in a Population-	Diagnostic,Regeneron Nothing to Disclose
		Elevated Blood Pressure	Based Cohort: The Multi-Ethnic Study of Atherosclerosis	
Nasir	Khurram	Innovations in Cardiovascular Risk Assessment and Reduction	Cost-Effectiveness of Coronary Artery Calcium Testing Among Statin Candidates According to the American College of Cardiology and American Heart Association Cholesterol Guidelines	Nothing to Disclose
Nasir	Khurram	Unusual Presentations of ACS	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival	Nothing to Disclose
Nasir	Khurram	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Quest Diagnostic,Regeneron
Nasr	Youssef	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Proof Is in the Paclitaxel: Catheter Directed Intracoronary Paclitaxel as Salvage Therapy for Refractory Cardiac Allograft Vasculopathy	Nothing to Disclose
Nassa	Giovanni	Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI	Activating Stimuli Modulate Pre-mRNA Maturation in Platelets: A Novel Mechanism That Regulates Platelet Function?	Nothing to Disclose
Nassif	Michael	Emerging Developments in HFpEF and Arryhthmias	Impact of Serial Heart Failure Health Status on Clinical Outcomes in HFpEF: A Static or Dynamic Phenomenon?	Nothing to Disclose
Nassif	Michael	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Current More Important Than Past: Interpreting Serial Heart Failure Specific Health Status in Heart Failure Patients With Reduced Ejection Fraction	Nothing to Disclose
Natale	Andrea	Arrhythmias and Clinical EP: Devices 1	Implantable Cardioverter Defibrillator for the Prevention of Mortality in Non-Ischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials	CONSULTANT FEES/HONORARIA - Biosense Webster, Boston Scientific, MEDTRONIC, St. Jude Medical/Abbott
Natale	Andrea	Arrhythmias and Clinical EP: Devices 1	Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients Undergoing Cardiac Implantable Electronic Device Implantation: A Meta-Analysis	CONSULTANT FEES/HONORARIA - Biosense Webster,Boston Scientific,MEDTRONIC,St. Jude Medical/Abbott
Natale	Andrea	Arrhythmias and Clinical EP: AF Ablation	Long-Term Outcome of Pulmonary Vein Isolation With and Without Focal Impulse and Rotor Modulation (FIRM) Mapping: Results From a Meta-Analysis	CONSULTANT FEES/HONORARIA - Biosense Webster, Boston Scientific, MEDTRONIC, St. Jude Medical/Abbott
Natale	Andrea	Arrhythmias and Clinical EP: AF Ablation	Long-Term Risk of Recurrent Arrhythmia in Patients With Typical Atrial Flutter Undergoing Pulmonary Vein Antrum Isolation or Cavo- Tricuspid Isthmus Ablation With Permanent Isolation	CONSULTANT FEES/HONORARIA - Biosense Webster,Boston Scientific,MEDTRONIC,St. Jude Medical/Abbott
Natale	Andrea	Atrial Fibrillation and VT: Unique Populations and Solutions	Use of an Esophageal Retractor to Prevent Thermal Injuries During Atrial Fibrillation Ablation: A Multi-Center Experience	CONSULTANT FEES/HONORARIA - Biosense Webster,Boston Scientific,MEDTRONIC,St. Jude Medical/Abbott
Natale	Andrea	Atrial Fibrillation and VT: Unique Populations and Solutions	Sotalol Versus Other Anti-Arrhythmic Medications for Cardioversion of Atrial Fibrillation and Maintenance of Sinus Rhythm: Meta-	CONSULTANT FEES/HONORARIA - Biosense Webster, Boston Scientific, MEDTRONIC, St. Jude Medical/Abbott
Natale	Andrea	Arrhythmias and Clinical EP: Anticoagulation Issues	Analysis of Randomized Controlled Studies Meta-Analysis on the Efficacy and Safety of New Oral Anticoagulants Compared With Vitamin K Antagonists in Patients	CONSULTANT FEES/HONORARIA - Biosense Webster, Boston Scientific, MEDTRONIC, St. Jude Medical/Abbott
Natale	Andrea	Arrhythmias and Clinical EP: AF Miscellaneous	Undergoing Cardioversion for Atrial Fibrillation	CONSULTANT FEES/HONORARIA - Biosense Webster, Boston
Natale	Andrea	and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous	Ablation in Patients With Atrial Fibrillation Left Atrial Appendage Ligation With Lariat Device: A Systematic	Scientific,MEDTRONIC,St. Jude Medical/Abbott CONSULTANT FEES/HONORARIA - Biosense Webster,Boston
Natale	Andrea	and Surgical Issues Innovative Approaches for Reducing Risk and	Review and Meta-Analysis Efficacy of Catheter Ablation of Atrial Fibrillation in the Setting of	Scientific,MEDTRONIC,St. Jude Medical/Abbott CONSULTANT FEES/HONORARIA - Biosense Webster,Boston
		Improving Outcomes With Ablation	Systolic Dysfunction: A Meta-Analysis of Randomized Control Trials	Scientific,MEDTRONIC,St. Jude Medical/Abbott
Natale	Andrea	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Sotalol Versus Other Anti-Arrhythmic Agents for Prevention of Post- Operative Supraventricular Arrhythmias After Cardiac Surgery: Meta- Analysis of Randomized Controlled Studies	CONSULTANT FEES/HONORARIA - Biosense Webster, Boston Scientific, MEDTRONIC, St. Jude Medical/Abbott
Natale	Andrea	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Left Atrial Appendage Flow Velocity to Predict Persistent Left Atrial Appendage Isolation	CONSULTANT FEES/HONORARIA - Biosense Webster, Boston Scientific, MEDTRONIC, St. Jude Medical/Abbott
Natale	Andrea	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Safety Profiles of Percutaneous Left Atrial Appendage Closure Devices: An Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database From 2009 - 2016	CONSULTANT FEES/HONORARIA - Biosense Webster,Boston Scientific,MEDTRONIC,St. Jude Medical/Abbott
Natale	Andrea	Innovation in Practice Management, Advocacy, and Education	Importance of Twitter During Cardiology Conferences	CONSULTANT FEES/HONORARIA - Biosense Webster, Boston Scientific, MEDTRONIC, St. Jude Medical/Abbott
Natalini	Gabriel	Personalized Skills Center: Drill and Practice (Heart Songs, ECG, Hand-Held Echo)	Heart Songs Moderator	Nothing to Disclose
Natarajan	Balaji	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Small Dense Low Density Lipoprotein Particle Number Relates to Coronary Plaque Burden Independent of Traditional Cardiovascular Risk Factors in Psoriasis	Nothing to Disclose
Natarajan	Balaji	Innovations in Education	Risk Factors in Feotiasis Coronary Angiography Simulation Training Improves Image Interpretation Skills of Trainees Independent of Their Stage of Training	Nothing to Disclose
Natarajan	Madhu	Vascular Access and Hemostasis Issues	Assessment of the Safety of Performing Coronary Angioplasty Without Interrupting Oral Anticoagulants	Nothing to Disclose
Natarajan	Madhu	Novel Developments in Acute Coronary	Incidence and Predictors of No Reflow Phenomenon: Insights From	Nothing to Disclose
Nathan	Meena	Syndromes Highlighted Original Research: Congenital Heart Disease and the Year in Review	the TOTAL Trial Aortic Valve Repair in the Pediatric Population: Midterm Outcomes Comparing Leaflet Repair Using Autologous Pericardium Versus	Nothing to Disclose
Nathan	Meena	Congenital Heart Disease: Progress in	Porcine Intestinal Submucosa (CorMatrix [®]) A Red Cell Preservation Strategy Reduces Postoperative	Nothing to Disclose
		Pediatric Heart Surgery	Transfusions in Pediatric Heart Surgery Patients	-

and a				
Last Name Nathan	First Name Meena	Session Title Congenital Heart Disease: Progress in	Presentation Title Validation of Technical Performance Score for Long-Term	Disclosures Nothing to Disclose
		Pediatric Heart Surgery	Outcomes in Congenital Heart Surgery: 10 Year Follow-Up Data	-
Nathan	Meena	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Prediction Tool for Congenital Heart Surgery Length of Stay	Nothing to Disclose
Nathan	Meena	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Technical Performance Score Can Predict Post-Discharge Reinterventions in Partial and Transitional Atrioventricular Septal Defect Repair	Nothing to Disclose
Nathan	Meena	Congenital Heart Disease: Progress in	The Association of Technical Performance With Postoperative	Nothing to Disclose
Nathan	Meena	Pediatric Heart Surgery Congenital Heart Disease: Progress in	Complications and Hospital Costs for the Norwood Operation Residual Atrioventricular Valve Regurgitation Pre-Discharge Is	Nothing to Disclose
		Pediatric Heart Surgery	Associated With Post-Discharge Reinterventions Following Complete Atrio Ventricular Septal Defect Repair	-
Nathan	Meena	Predicting Outcomes in Pediatric Heart Disase	Risk Stratification of Children Undergoing Valve-Sparing Repair of Tetralogy of Fallot	Nothing to Disclose
Nathan	Sandeep	Mechanical Support, Hemodynamic Support for Shock in High Risk Subsets; Hemodynamic	Case Presentation: Management of the Right Ventricular Support	CONSULTANT FEES/HONORARIA - Cardiovascular Systems, Inc,Janssen,Medinol USA,Medtronic, Inc.,Merit Medical; SPEAKER'S BUREAU - Astra Zeneca
Nathan	Sandeep	Compromise 01. Acute and Stable Ischemic Heart Disease: Basic Team 1	Suggested Reviewer	SPEAKER'S BUREAU - ASI'A ZERIECA CONSULTANT FEES/HONORARIA - Cardiovascular Systems, Inc.,Janssen,Medinol USA,Medtronic, Inc.,Merit Medical; SPEAKER'S BUREAU - Astra Zeneca
Nathan	Steven	Hot Topics and Great Debates in Pulmonary Hypertension	Debate: Be it Resolved: It is Time to Treat Pulmonary Hypertension Secondary to Chronic Lung Disease with PAH Specific Therapies (Con)	GONSULTANT FEES/HONORARIA - Bayer, Boerhinger- Ingelheim, gilead, Roche, United Therapeutics; RESEARCH/IRESEARCH GRANTS - gilead, United Therapeutics; SPEAKER'S BUREAU - Boerhinger- Ingelheim, gilead, Roche, United Therapeutics
Natsuaki	Masahiro	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	in Japanese Patients Undergoing Drug-Eluting Stent Implantation: An Observation From a Pooled Cohort of the CREDO-Kyoto Cohort- 2, RESET, and NEXT Trials	Nothing to Disclose
Natsumeda	Makoto	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Role of Gender on Mesenchymal Stem Cell Therapy in Non- lschemic Dilated Cardiomyopathy: A Sub-Analysis of the POSEIDON-DCM Trial	Nothing to Disclose
Nattel	Stanley	04. Arrhythmias and Clinical EP: Basic Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen Inc., Xention; RESEARCH/RESEARCH GRANTS - Cardiome, OMEICOS
Nattiv	Jonathan	Arrhythmias and Clinical EP: Anticoagulation Issues	Does Stroke Risk Influence the Decision to Anticoagulate Post Percutaneous Coronary Intervention Patients With Atrial Fibrillation:	Nothing to Disclose
Navar	Ann	Featured Clinical Research III	A Review of 3850 Patients Early Challenges for PSCK9 Inhibitor Prescriptions and Patients: Rejections and Rates Unfilled	Nothing to Disclose
Navar	Ann	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Recurrent Cardiovascular Event Rates in a Contemporary Cohort of 829,498 Adults With Atherosclerotic Cardiovascular Disease	Nothing to Disclose
Navar	Ann Marie	Coronary Artery Disease Advances in Cholesterol Measurement and	Contemporary Patterns of Lipid Testing in Primary and Secondary	Nothing to Disclose
Navar	Ann Marie	Management The PCSK9 Revolution: New Insights Into	Prevention Patients: Insights From the PALM Registry Implications of the FDA Approval of PCSK9 Inhibitors for	Nothing to Disclose
inavai	Ann wane	Evaluation and Treatment	Implications of the FDA Approval of PCSAS limitotions for Contemporary Cardiovascular Practice: Findings From the NCDR [®] Research to Practice (R2P) Project	Nothing to Disclose
Navia	Jose	Interventional Cardiology: TAVR 1	Novel Plane of Measurement to Evaluate Accurate Valve Size in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Navia	Jose	Interventional Cardiology: TAVR 2	Outcomes of Transcatheter Aortic Valve Replacement Without	Nothing to Disclose
Navid	Forozan	The Challenges of Outcome Prediction in Valvular Heart Disease	Balloon Predilation: A Systematic Review and Meta-Analysis Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary	Nothing to Disclose
Navid	Forozan	TAVR Outcomes Prognostication	Hypertension Severity: Clinical Applications in the TAVR Era Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in	Nothing to Disclose
Nawathe	Pooja	Congenital Heart Disease: Advances in Quality Improvement for Pediatric Cardiac Care	TAVR Patients: Time to Integrate the Right Side Unit Making Perioperative Handoff Communication Count by Improving Safety and Quality in a New Congenital Heart Program	Nothing to Disclose
Nayak	Aditi	Nuclear Cardiology: Quality	Repeatability of Appropriateness Category Allocation by Trained	Nothing to Disclose
Nayak	Hemal	05. Arrhythmias and Clinical EP: Devices Team 2	Physicians Suggested Reviewer	CONSULTANT FEES/HONORARIA - Biotronik, Boston Scientific, Bristol-Myers Squibb Company
Nayeri	Arash	Advances in Chronic Total Occlusion Intervention	Trends and In-Hospital Outcomes of Patients Admitted With ST Elevation Myocardial Infarction and Chronic Total Occlusions:	MEDTRONIC, Pfizer, Sorin Group, St. Jude Medical Nothing to Disclose
			Insights From a National Database	
Nazarian	Saman	Tough Clinical Problems in Patients with Implantable Electronic Devices	How to Do MRIs in Patients with Implantable Devices	CONSULTANT FEES/HONORARIA - Biosense Webster Inc,CardioSolv,St Jude Medical; RESEARCH/RESEARCH GRANTS - Biosense Webster Inc
Nazarian	Saman	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Stroke Among Whites and Blacks: The Atherosclerosis Risk In Communities (ARIC) Study	CONSULTANT FEES/HONORARIA - Biosense Webster Inc,CardioSolv,St Jude Medical; RESEARCH/RESEARCH GRANTS - Biosense Webster Inc
Nazarian	Saman	Non Invasive Imaging: MR Scar and Perfusion	Association of Right Atrial Function With Incident Atrial Fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA)	CONSULTANT FEES/HONORARIA - Biosense Webster Inc, CardioSolv, St Jude Medical; RESEARCH/RESEARCH
Nazarian	Saman	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	GRANTS - Biosense Webster Inc CONSULTANT FEES/HONORARIA - Biosense Webster Inc,CardioSolv,St Jude Medical; RESEARCH/RESEARCH
Nazif	Tamim	5 Interventional Live Case Session III: Structural Transmission from Cleveland Clinic	Panelist	GRANTS - Biosense Webster Inc Nothing to Disclose
Nazif	Tamim	(Cleveland, Ohio) Moderated, Case-Based TAVR Management	Case Presentation: Use of the Mitraclip Concomitant with TAVR	Nothing to Disclose
Nazif	Tamim	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Morphologic Patterns of In-Stent Chronic Total Occlusions: An Intravascular Ultrasound Study	Nothing to Disclose
Nazif	Tamim	Interventional Cardiology: PCI and TAVR in Complex Patients	Refining the Classification of Severe, Symptomatic Aortic Stenosis Using Flow and Gradient Measurements to Predict Outcomes Post-	Nothing to Disclose
Nazif	Tamim	TAVR Outcomes Prognostication	Transcatheter Aortic Valve Replacement High Baseline Valvuloarterial Impedence Predicts Worse 1-Year	Nothing to Disclose
Nazir	Noreen	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Outcomes After Transcatheter Aortic Valve Replacement implementation of a Wideband Late Gadolinium Enhancement Cardiac Magnetic Resonance Protocol to Improve Assessment of Myccardial Scar in Patients With Implantable Cardioverter	Nothing to Disclose
Nazir	Noreen	Valvular Heart Disease: Aortic Regurgitation	Defibrillators Left Ventricular Mechanical Properties in Patients With Severe Aortic Insufficiency and Normal Ejection Fraction: Impact on Survival	Nothing to Disclose
Ndukwu	Ifesinachi	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Hydroxychloroquine Overdose Presenting as Acquired QT Interval Prolongation and Torsade de Pointes	Nothing to Disclose
Ndumele	Chiadi	32. Prevention: Clinical Team 4	Suggested Reviewer	Nothing to Disclose
Neal	Bruce	Featured Clinical Research I	Effects of Different Front-of-Pack Food Labelling Formats on the Healthiness of Food Purchases a Randomized Trial	Nothing to Disclose

Control of the contro				
Last Name	First Name Milan	Session Title Coronary Syndromes Revisited: International	Presentation Title Co-Chair	Disclosures
Nedeljkovic	IVIIIdii	Perspectives From the ACC Italy Chapter,	CO-Cridii	Nothing to Disclose
		ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology		
Nederend	Marieke	Improving Outcomes in the Athlete With Cardiovascular Disease	Exercise Testing in Pediatric Patients: Objective Versus Subjective Effort	Nothing to Disclose
Neeland	lan	Updates on Risk Factors for Cardiovascular Disease	Enor. Impact of Exercise and Pharmacologic Interventions on Changes in Visceral Adiposity: A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Neeland	lan	Updates on Risk Factors for Cardiovascular	Is There a Link Between Family History of Cardiometabolic Disease	Nothing to Disclose
Neeland	lan	Disease Innovations in Advocacy and Patient Centered	and Body Fat Profile? Racial and Ethnic Differences in Cardiovascular Biomarkers	Nothing to Disclose
Neff	David	Care	Genetic Target Validation for ATP-Citrate Lyase Inhibition	Nothing to Disclose
Negishi	Kazuaki	the Year in Review Emerging Applications of Echocardiography	Effect of Changing Strain Software Versions on Longitudinal	Nothing to Disclose
		0 0 11	Assessment of LV Function	-
Negishi	Kazuaki	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Left Atrial Function and Role in Prediction of Heart Failure	Nothing to Disclose
Negishi	Kazuaki	Innovative Use of Echocardiography	Independent Association of Atrial Mechanics With Risk of Incident Atrial Fibrillation	Nothing to Disclose
Negishi	Tomoko	Emerging Applications of Echocardiography	Effect of Changing Strain Software Versions on Longitudinal Assessment of LV Function	Nothing to Disclose
Neill	John	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Atrial Septal Defect Closure in a Patient With Pulmonary Hypertension	Nothing to Disclose
Nekkanti	Rajasekhar	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	An Unusual Extrinsic Pulmonary Artery Compression Caused by Traumatic Cardiac Hernia	Nothing to Disclose
Nelson	Daniel	Interventional Complexity and Complications	Variability in Transfemoral Access for Coronary Angiography and	Nothing to Disclose
Nelson	John	Advances in Cholesterol Measurement and	Interventions: Results From an International Survey Plasma Eicosapentaenoic Acid and the Eicosapentaenoic Acid to	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Pfizer;
	_	Management	Arachidonic Acid Ratio in 8,010 Patients With Severely Elevated LDL-C (>190 mg/dl): Cause for Alarm?	SPEAKER'S BUREAU - Amarin Pharma,Amgen,Arbor,AstraZeneca Pharmaceuticals,Boston Heart Diagnostics Corporation,Kowa,Regeneron,Sanofi-Aventis
Nemer	Georges	Population Specific Cardiomyopathies: From Exomes to Databases	Targeted and Exome Sequencing of 27 Lebanese Patients With Cardiomyopathies: Novel Variants in Known Genes, and Potential Novel Genes	Nothing to Disclose
Nerlekar	Nitesh	Non Invasive Imaging: Prognostic Implications of CT Angiography	Computed Tomography Coronary Angiography Derived Plaque Morphology Predicts Major Adverse Cardiovascular Events: Insights From a 19,943 Patient Meta-Analysis	Nothing to Disclose
Nesbitt	Gillian	Test Yourself with Questions: Guidelines Module 1: Valvular	Faculty	Nothing to Disclose
Nessel	Christopher	Arrhythmias and Clinical EP: Anticoagulation Issues	Thrombolytic Therapy in Anticoagulated Patients: Case Series From Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET AF)	SALARY - Janssen Research and Development
Nesser	Hans	Aortic Stenosis: Overview of the	Panelist	OTHER - Novartis; SPEAKER'S BUREAU - Toshiba
Nesser	Hans	Hemodynamics and Ventricular Response Aortic Stenosis: Overview of the	The Ventricular-Valvular-Arterial Relationship	OTHER - Novartis; SPEAKER'S BUREAU - Toshiba
Neumann	F	PCI for NSTEMI and Complex Patients With	Platelet Reactivity and Outcomes After PCI of Saphenous Vein	Nothing to Disclose
Neumann	Franz-Josef	Multiple Co-Morbidities Late-Breaking Clinical Trials: Interventional	Grafts Versus Native Coronary Arteries: The ADAPT-DES Study FFR Guided Acute Complete Revascularization Versus Culprit Lesion Only Treatment in Patients Presenting With ST-Segment Elevation Myocardial Infarction and Multi Vessel Disease: The	Nothing to Disclose
Neumann	Franz-Josef	Advances in Chronic Total Occlusion Intervention	COMPARE-ACUTE Trial Is Platelet Reactivity Associated With Ischemic Events Following Successful Chronic Total Occlusion Percutaneous Coronary	Nothing to Disclose
Neupane	Saroj	Arrhythmias and Clinical EP: Ventricular	Intervention Prognostic Impact of In-Hospital Cardiac Arrest Ratio in Patients	Nothing to Disclose
Neutel	Joel	Tachycardia Assessing the Clinical Impact of Blood	With In-Hospital Cardiac Arrest Additivity of Nebivolol/Valsartan Single-Pill Combinations Versus	Nothing to Disclose
Newburger	Jane	Pressure Lowering Therapies FIT Forum: Mix and Mingle	Other Approved Single-Pill Combinations for Hypertension 	CONSULTANT FEES/HONORARIA - Bristol-Myer-Squibb,Daiichi
		Ů	-	Sankyo,Merck; OTHER - Bristol-Myers Squibb Company ,Novartis,Pfizer Inc
Newburger	Jane	2017 Dan G. McNamara Lecture: The Future of Congenital Heart Research: Keeping the	Interview With Dr. Gail Pearson, MD, FACC	CONSULTANT FEES/HONORARIA - Bristol-Myer-Squibb, Daiichi Sankyo, Merck; OTHER - Bristol-Myers Squibb Company
Newburger	Jane	Patient-Centered Promise Perspectives on Congenital Heart Disease:	Co-Chair	,Novartis,Pfizer Inc CONSULTANT FEES/HONORARIA - Bristol-Myer-Squibb,Daiichi
		International Perspectives From the Caribbean Cardiac Society, Peruvian Society of Cardiology, and American College of Cardiology		Sankyo,Merck; OTHER - Bristol-Myers Squibb Company ,Novartis,Pfizer Inc
Newburger	Jane	Perspectives on Congenital Heart Disease: International Perspectives From the Caribbean Cardiac Society, Peruvian Society of Cardiology, and American College of	Introduction to Session	CONSULTANT FEES/HONORARIA - Bristol-Myer-Squibb, Daiichi Sankyo, Merck; OTHER - Bristol-Myers Squibb Company ,Novartis, Pfizer Inc
Newburger	Jane	Cardiology Congenital Heart Disease: Progress in Pediatric Heart Surgery	Validation of Technical Performance Score for Long-Term Outcomes in Congenital Heart Surgery: 10 Year Follow-Up Data	CONSULTANT FEES/HONORARIA - Bristol-Myer-Squibb, Daiichi Sankyo, Merck; OTHER - Bristol-Myers Squibb Company
Newby	David	FIT Clinical Decision Making: Non-Invasive	Multi-Modality Imaging Assessment of a Left Ventricular Mass	,Novartis,Pfizer Inc CONSULTANT FEES/HONORARIA - Eli-Lilly,
		Imaging and Valvular Heart Disease		Roche,GSK,Pfizer, AstraZeneca, MSD, BMS, Boeringer Ingelheim,Toshiba; DATA SAFETY MONITORING BOARD - UCB
Newby	David	Elevated Blood Pressure	Prognostic Importance of Blood Pressure and Heart Rate in Chronic Obstructive Pulmonary Disease: The SUMMIT Trial	Roche,GSK,Pfizer, AstraZeneca, MSD, BMS, Boeringer Ingelheim,Toshiba; DATA SAFETY MONITORING BOARD - UCB
Newby	David	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Optimal Risk Stratification Pathways for Patients With Suspected Acute Coronary Syndrome	CONSULTANT FEES/HONORARIA - EII-Lilly, Roche,GSK,Pfizer, AstraZeneca, MSD, BMS, Boeringer Ingelheim,Toshiba; DATA SAFETY MONITORING BOARD - UCB
Newby	David	Innovations in Cardiovascular Risk Assessment and Reduction	High-Sensitivity Cardiac Troponin I and Risk of Cardiovascular Events in Patients With COPD and Heightened Cardiovascular Risk: A Biomarker Sub-Study of the SUMMIT Trial	CONSULTANT FEES/HONORARIA - EI-Lilly, Roche,GSK,Pfizer, AstraZeneca, MSD, BMS, Boeringer Ingelheim,Toshiba; DATA SAFETY MONITORING BOARD - UCB
Newby	David	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Age and the Effectiveness of Risk Stratification and Diagnostic Thresholds for Myocardial Infarction With High-Sensitivity Cardiac Troponin	CONSULTANT FEES/HONORARIA - Eil-Lilly, Roche, GSK, Pfizer, AstraZeneca, MSD, BMS, Boeringer Ingelheim, Toshiba; DATA SAFETY MONITORING BOARD - UCB
Newby	David	Features of Patients With Acute Coronary Syndrome Innovations in Cardiovascular Risk Assessment and Reduction Acute Coronary Syndromes, Diagnosis,	Acute Coronary Syndrome High-Sensitivity Cardiac Troponin I and Risk of Cardiovascular Events in Patients With COPD and Heightened Cardiovascular Risk: A Biomarker Sub-Study of the SUMMIT Trial Age and the Effectiveness of Risk Stratification and Diagnostic Thresholds for Myocardial Infarction With High-Sensitivity Cardiac	Roche, GSK, Pfizer, AstraZeneca, MSD, BMS, Boeringer Ingelheim, Toshiba; DATA SAFETY MONITORING BOARD CONSULTANT FEES/HONORARIA - Eli-Lilly, Roche, GSK, Pfizer, AstraZeneca, MSD, BMS, Boeringer Ingelheim, Toshiba; DATA SAFETY MONITORING BOARD CONSULTANT FEES/HONORARIA - Eli-Lilly, Roche, GSK, Pfizer, AstraZeneca, MSD, BMS, Boeringer

Last Name	First Name	Session Title	Presentation Title	Disclosures
Newby	David	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	High-Sensitivity Cardiac Troponin and the Classification of Myocardial Infarction	CONSULTANT FEES/HONORARIA - EI-Lilly, Roche,GSK,Pfizer, AstraZeneca, MSD, BMS, Boeringer Ingelheim,Toshiba; DATA SAFETY MONITORING BOARD - UCB
Newby	David	Blips, Trops, and Chips: New Ways to Diagnose CAD	High-Sensitivity Cardiac Troponin I and the Diagnosis of Obstructive Coronary Artery Disease in Patients With Suspected Stable Angina	CONSULTANT FEES/HONORARIA - EII-LIIIy, Roche,GSK,Pfizer, AstraZeneca, MSD, BMS, Boeringer Ingelheim,Toshiba; DATA SAFETY MONITORING BOARD - UCB
Newby	L. Kristin	Antithrombotic Therapy in Ischemic Heart Disease	Clopidogrel Is Not Commonly Used but Associated With Less Re- Hospitalization in Patients With Perioperative Myocardial Infarction Following CABG Surgery	CONSULTANT FEES/HONORARIA - Biokler, DemeRx, MedScape/TheHeart org, Merck and Company, Metanomics, Philips healthcare, Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Amylin, Bristol-Myers Squibb Company, Glaws Drith Kline, Sanoff-Aventis, Verily Life Sciences (formerly Google Life Sciences)
Newby	L. Kristin	Unusual Presentations of ACS	The High Cost of Low Acuity Non ST-Segment Elevation Acute Coronary Syndrome Admissions to the Coronary Care Unit: An Analysis of National Population Health Data	CONSULTANT FEES/HONORARIA - Biokier, DemeRx, MedScape/TheHeart.org, Merck and Company, Metanomics, Philips healthcare, Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Amylin, Bristol-Myers Squibb Company, Glaws Dritth Kline, Sanofi-Aventis, Verily Life Sciences (formerly Google Life Sciences)
Newby	L. Kristin	02. Acute and Stable Ischemic Heart Disease: Clinical Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Bibldier, DemeRx, MedScape/TheHeart.org, Merck and Company, Metanomics, Philips healthcare, Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Amylin, Bristol-Myers Squibb Company, Glaws Drith Kline, Sanofif-Aventis, Verily Life Sciences (formerly Google Life Sciences)
Nezarat	Negin	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Impact of Cardiac Troponin I on the Presence of the Coronary Artery Plaque in Rheumatoid Arthritis patients	Nothing to Disclose
Nezarat	Negin	Non Invasive Imaging: Expanding Clinical Applications	The Utility of Left Atrial Appendage Hounsfield Unit and the Ratio of Left Atrial Appendage/Ascending Aorta Hounsfield Unit for Detecting Left Atrial Appendage Thrombus	Nothing to Disclose
Nezarat	Negin	Non Invasive Imaging: Expanding Clinical Applications	The Association of Ischemia on Single Photon Emission Computed Tomography-Myocardial Perfusion Image and Fractional Flow Reserve by Coronary Computed Tomographic Angiography	Nothing to Disclose
Nezarat	Negin	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Prognostic Value of Protein Biomarkers Predict Risk of Coronary Heart Disease Events: Results From Multi-Ethnic Study of Atherosclerosis (MESA)	Nothing to Disclose
Nezarat	Negin	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Total Testosterone With Progression of Carotid Atherosclerosis and Coronary Artery Calcium Score: The Multi- Ethnic Study of Atherosclerosis	Nothing to Disclose
Nezarat	Negin	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Coronary Artery Calcium Progression With Coronary Plaque Progression Determined by Quantitative Coronary Artery Plaque Analysis	Nothing to Disclose
Nezarat	Negin	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	­The Utility of Minimal Coronary Artery Calcification for Predicting Carotid Artery Disease: Results From the Multi-Ethnic Study of Atherosclerosis (MESA)	Nothing to Disclose
Nezarat	Negin	Innovations in Cardiovascular Risk Assessment and Reduction		Nothing to Disclose
Ng	Qimin	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Aortic Vascular Inflammation by 18-FDG PET/CT Associates With High-Risk Coronary Plaques in Young Psoriasis Patients	Nothing to Disclose
Ng	Qimin	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Improvement in Cholesterol Efflux Capacity Is Associated With a Reduction in Aortic Wall Thickness by MRI Independent of Traditional CV Risk Factors	Nothing to Disclose
Ngarmukos	Tachapong	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Worldwide Prevalence of Brugada Syndrome: A Systematic Review and Meta-Analysis	Nothing to Disclose
Ngarmukos	Tachapong	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Chronic Kidney Disease in Asian Patients With Heart Failure	Nothing to Disclose
Ngiam	Nicholas	New Technologies in Echocardiography	Novel Non-Invasive Left Ventricular Stiffness Index in Patients With Low-Flow Compared to Normal-Flow Severe Aortic Stenosis With Preserved Left Ventricular Ejection Fraction	Nothing to Disclose
Nguyen	Daniel	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Important Hemodynamic Considerations in the Management of an Adult With Unrepaired Pentalogy of Fallot Presenting With Necrotizing Fasciitis and Sepsis	Nothing to Disclose
Nguyen	Daniel	Nuclear Cardiology: Quality	Repeatability of Appropriateness Category Allocation by Trained Physicians	Nothing to Disclose
Nguyen	Duy	Atrial Fibrillation and VT: Unique Populations and Solutions	Presence of Mid-Myocardial Substrate Is Associated With Need for Multiple Ablations in Patients With Non-Ischemic Cardiomyopathy and Ventricular Arrhythmias	Nothing to Disclose
Nguyen	Duy	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Early Recurrence of Ventricular Tachycardia Predicts Increased Mortality Among Patients With Severe Heart Failure	Nothing to Disclose
Nguyen	Duy	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Safety and Outcomes of Catheter Ablation for Treatment of Refractory Ventricular Arrhythmias in Patients With Advanced Heart Failure	Nothing to Disclose
Nguyen	Hoai	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Cardiomyopathy Associated With Targeted Anticancer Therapies in Electronic Health Records	Nothing to Disclose
Nguyen	Kim-Lien	Interventional Cardiology: TAVR 1	The Use of Magnetic Resonance Imaging With Ferumoxytol for Annulus Sizing in Patients With Chronic Kidney Disease Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Nguyen	Lisa	Interdisciplinary Cardiovascular Team Care Delivery: Quality, Safety, and Satisfaction	An Interventional Role for Clinical Pharmacists in Pulmonary Arterial Hypertension Pharmacotherapy	Nothing to Disclose
Nguyen	Patricia	Radiation from Diagnostic Imaging: Risk- benefit Analysis	Panelist	Nothing to Disclose
Nguyen	Patricia	Radiation from Diagnostic Imaging: Risk- benefit Analysis	Radiation Risks: Genomic and Proteomic Analysis	Nothing to Disclose
Nguyen	Tom	FIT Forum: Mix and Mingle	CT Surgery	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St. Jude Medical
Nguyen	Tom	TAVR: What We've Learned and Where We Think We're Going!	A Challenging Case: Heart Team to the Rescue!	CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St. Jude Medical
Nguyen	Tom	Interventional Cardiology: PCI and TAVR in Complex Patients	Timing and Algorithm of Permanent Pacemaker Implantation After TAVR	CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St. Jude Medical
Nguyen	Tom	Interventional Cardiology: TAVR 3	Transapical TAVR Is Associated With Higher Morbidity and Mortality Compared to Transfemoral TAVR in Men but Not in Women	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St. Jude Medical
Nguyen	Tom	The Challenges of Outcome Prediction in Valvular Heart Disease	Gender-Based Outcomes in Diabetics Undergoing Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St. Jude Medical
Nguyen	Tom	TAVR Outcomes Prognostication	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St. Jude Medical
Nguyen	Vidang	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Endocarditis? When Positron Emission Tomography Makes the Final Diagnosis	Nothing to Disclose

				<u> </u>
Last Name Nguyen-Trong	First Name Phuong-Khanh	Session Title Coronary Intervention in Interventional	Presentation Title Contemporary Use of Laser During Percutaneous Coronary	Disclosures Nothing to Disclose
		Cardiology: Advanced Device Use	Intervention: Results From the Laser Veterans Affairs (LAVA) Multicenter Registry	
Nguyen-Trong	Phuong-Khanh	Innovations in Advocacy and Patient Centered Care	Diverse Perspectives and Training Paths in Cardiology: An Analysis of Authorship in the <i>Journal of the American College of Cardiology</i>	Nothing to Disclose
Ngwa	Julius	Heart Failure and Cardiomyopathies: Heart	Comparative Effects of Metoprolol and Nebivolol on Blood Pressure	Nothing to Disclose
Niaz	Talha	Failure Is Just a Revolving Door Predicting Outcomes in Pediatric Heart Disase	Control in African-Americans Growth Dynamics of Aorta in Bicuspid Aortic Valve Patients From	Nothing to Disclose
Niazi	Imran	Arrhythmias and Clinical EP: Basic 3	Infancy to Young Adult Age Impact of Obstructive Sleep Apnea Severity on Cardiac Events in Patients With Normal or Prolonged Ventricular Repolarization	CONSULTANT FEES/HONORARIA - Medtronic Inc., Osprey Medical, St. Jude Medical Inc., OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Medtronic Inc.; RESEARCH/RESEARCH GRANTS - Biotronik Inc., Boston Scientific Corp., Bristol-Myers Squibb Co., Janssen Pharmaceuticals, Medtronic Inc., Sanoff-Winthrop Pharmaceuticals, Sanoff-Winthrop Pharmaceuticals, Sanoff-Winthrop Pharmaceuticals, Sanoff-Winthrop Pharmaceuticals, Sanoff-Winthrop Pharmaceuticals
Niazi	lmran	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Incremental Value of Estimated Glomerular Filtration Rate in Improving Stroke Risk Stratification in Patients With and Without Artial Fibrillation Considered to Be Low Risk by CHA ₂ DS ₂ VASc Score	CONSULTANT FEES/HONORARIA - Meditronic Inc., Osprey Medical, St. Jude Medical Inc.; OWNERSHIP INTERES/HONORARIA - Meditronic Inc., Osprey Medical, St. Jude Medical Inc.; OWNERSHIP INTERES/HOATNERSHIP/PRINCIPAL - Meditronic Inc.; RESEARCH/RESEARCH GRANTS - Biotronik Inc., Boston Scientific Corp., Bristol-Myers Squibb Co., Janssen Pharmaceuticals, Meditronic Inc., Sanoff-Winthrop Pharmaceuticals, Sanoff-Winthrop Pharmaceuticals, Sanoff-Winthrop Pharmaceuticals, Sanoff-Winthrop Pharmaceuticals
Niazi	Kareem	Innovations in Cardiovascular Risk Assessment and Reduction	ACC/AHA Coronary Artery Calcium Score Guidelines May Underestimate Coronary Artery Disease in African-American Patients	Nothing to Disclose
Niazi	Osama	FIT Clinical Decision Making: Heart Failure and	Acute Pulmonary and Paradoxical Embolism Treated With Catheter	Nothing to Disclose
Niazi	Osama	Pulmonary Hypertension Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Based Thrombectomy Comparison of In-Hospital Outcomes of Septic Shock Patients With and Without Atrial Fibrillation: A Retrospective Propensity-Matched Applying	Nothing to Disclose
Nicholls	Stephen	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	Analysis Effect of Serial Infusions of CER-001, a Pre-Beta High-Density Lipoprotein Mimetic on Coronary Atherosclerosis: Results of the CARAT Study	CONSULTANT FEES/HONORARIA - AstraZeneca,Boehringer Ingelheim, CSL Behring, Merck Schering-Plough, Omthera, Roche, Sanofi-Regeneron, Takeda; RESEARCH/RESEARCH GRANTS - Amgen, AstraZeneca, AtheroNova, Cerenis, Eli Lilly, Novaris, Reseverlogix
Nicholls	Stephen	Advances in Cholesterol Measurement and Management	Atherogenic Lipoprotein Variability Correlates With Coronary Atheroma Progression: Insights From Serial Intravascular Ultrasonography	CONSULTANT FEES/HONORARIA - AstraZeneca,Boehringer Ingelheim, CSL Behring, Merck Schering-Plough, Omthera,Roche, Sanofi-Regeneron, Takeda; RESEARCH/RESEARCH GRANTS - Amgen,AstraZeneca,AtheroNova,Cerenis,Eli Lilly,Novaris,
Nicholls	Stephen	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Association Between Homeostasis Model Assessment of Insulin Resistance and Survival in Diabetic Patients With Acute Coronary Syndromes: Insights From the AleCardio Trial	CONSULTANT FEES/HONORARIA - AstraZeneca,Boehringer Ingelheim,CSL Behring, Merck Schering-Plough, Omthera, Roche, Sanofi-Regeneron, Takeda; RESEARCH/RESEARCH GRANTS - Amgen,AstraZeneca,AtheroNova,Cerenis,Eli Lilly,Novaris,
Nicholson	William	Advances in Chronic Total Occlusion Intervention	Performance of J-CTO and PROGRESS CTO Scores in Predicting Angiographic Success and Long-Term Clinical Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions	CONSULTANT FEES/HONORARIA - Abbott Laboratories, asahi intecc, Boston Scientific, Vascular Solutions; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abbott Vascul
Nickenig	Georg	Frontiers in Mitral Valve Disease and Treatment	Multicenter Trial of a Transfemoral System for Mitral Valve Annuloplasty: Up-to-2-Year Follow-Up Results	Nothing to Disclose
Nickolaus	Michelle	Clinical Challenges in the Cardiac Care Unit	Panelist	Nothing to Disclose
Nicol	Kelly	(CCU) Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Feasibility of Rapidly Creating High Resolution Virtual Three- Dimensional Models of Anomalous Aortic Origin of Coronary	Nothing to Disclose
Nicolas	Debry	Joint American College of Cardiology/New	Arteries Silent Cerebral Microbleeds During TAVR: Insight From a	Nothing to Disclose
		England Journal of Medicine Late-Breaking Clinical Trials	Prospective Cerebral MRI Cohort	
Nicolau	Jose	PPIs in the Era of Prolonged DAPT Should We or Shouldn't We?: Pharmacology III	Panelist	CONSULTANT FEES/HONORARIA - Astra- Zeneca,Bayer,Bohering Ingelheim,DalCor,Pfizer Inc,SANOFI; RESEARCH/RESEARCH GRANTS - Astra- Zeneca,Cardiorentis,Novartis
Nicolau	Jose	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	The Role of Oral Beta Blocker in a Real-World Population With Non- ST Segment Elevation Acute Coronary Syndromes	CONSULTANT FEES/HONORARIA - Astra- Zeneca,Bayer,Bohering Ingelheim,DalCor,Pfizer Inc,SANOFI; RESEARCH/RESEARCH GRANTS - Astra- Zeneca,Cardiorentis,Novartis
Nicolau	Jose	Emerging Basic Science in Ischemic Heart Disease	Platelet Aggregability, Coagulation, Fibrinolysis and Inflammation in Patients With Coronary Artery Disease and Previous Cerebrovascular Ischemic Event	CONSULTANT FEES/HONORARIA - Astra- Zeneca, Bayer, Bohering Ingelheim, DalCor, Pfizer Inc., SANOFI; RESEARCH/RESEARCH GRANTS - Astra- Zeneca, Cardiorentis, Novartis
Nicolau	Jose	Antithrombotic Therapy in Ischemic Heart Disease	Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease	CONSULTANT FEES/HONORARIA - Astra- Zeneca.Bayer, Bohering Ingelheim, DalCor, Pfizer Inc, SANOFI; RESEARCH/RESEARCH GRANTS - Astra- Zeneca.Cardiorentis.Novartis
Nie	Shao-Ping	Updates in Stable Ischemic Heart Disease	Coronary Calcification as a Mechanism of Plaque/Media Shrinkage: A Multimodality Intracoronary Imaging Study	Nothing to Disclose
Nielsen	Jens	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	A Multimodality intractionary imaging Study Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Previous Major Gastrointestinal Bleeding: Insight From the Amplatzer Cardiac Plug Multicenter Registry	CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik
Nielsen	Jens	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Amplazer Cardiac Plug Multicenter Registry Risk Assessment of Recurrent Atrial Fibrillation After Antiarrhythmic Medication or Catheter Ablation: The Impact of Age and Supraventricular Ectopic Complexes	CONSULTANT FEES/HONORARIA - Biosense Webster, Biotronik
Nieman	Koen	Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American	Supraventricular Ectopic Complexes Coronary CT in the ED in the setting of HS-Troponins	RESEARCH/RESEARCH GRANTS - Bayer Health Care,GE Healthcare,Heartflow,Siemens
		College of Cardiology		
Nieman	Koen	College of Cardiology Unusual Presentations of ACS	Incidence and Predictors of Lesion Specific Ischemia by FFR _{CT} : Learnings From the International ADVANCE	RESEARCH/RESEARCH GRANTS - Bayer Health Care,GE Healthcare,Heartflow,Siemens
Nieman Nieman	Koen	Unusual Presentations of ACS 27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team		

	First Name Christoph	Session Title Vascular Medicine: Novel Risk Measures in	Presentation Title Body Mass Index and Acute Aortic Dissection	Disclosures Nothing to Disclose	
	•	Arterial Diseases	•	-	
Nienaber (Christoph	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Influence of Family History of Aortic Disease on Type B Aortic Dissection	Nothing to Disclose	
Nienaber (Christoph	Beans, Beans, Good for Your Heart	Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection	Nothing to Disclose	
Nienaber (Christoph	Vascular Medicine: Aortic and Peripheral Artery Diseases	Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of	Nothing to Disclose	
Nienaber (Christoph	Vascular Medicine: Aortic and Peripheral Artery Diseases	Acute Aortic Dissection Uncontrolled Hypertension in Acute Aortic Dissection Follow-Up	Nothing to Disclose	
Nienaber (Christoph	Vascular Medicine: Aortic and Peripheral	Acute Aortic Dissection in Patients Without a History of Hypertension	Nothing to Disclose	
Nieves F	Ricardo	Artery Diseases Emerging Applications for Imaging Cardiac	Predictors of a Positive Technetium Pyrophosphate Scan in Patients	Nothing to Disclose	
Nihoyannopoulos F	Petros	Amyloidosis: Nuclear Cardiology Structural Heart Interventions: What Does the Imager Need to know	With Suspected Cardiac Amyloidosis Evolving Role of Imaging in TAVR	Nothing to Disclose	
	Petros	Which Test Is Best for Pain in the Chest?	ACC Poster Moderator	Nothing to Disclose	
Nii	Masaki	Congenital Heart Disease: Novel Insights in Pediatric Cardiology	The Evolution of Atrioventricular Valve Function in Patients With Heterotaxy Syndrome: A Longitudinal Assessment From Fetus to Late After Fontan Operation	Nothing to Disclose	
	Takayuki	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Relationship Between Coronary Physiological Parameters and Cardiac Biomarkers in Patients Undergoing Invasive Coronary Angiography	Nothing to Disclose	
Niida	Takayuki	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Significance of Microcirculatory Resistance in Visual-Functional Mismatch Between Coronary Angiography and Fractional Flow Reserve in Non-Left Main Lesions	Nothing to Disclose	
Niida	Takayuki	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Usefulness of Optical Coherence Tomography-Derived Morphometric Assessment to Predict Physiological Significance of Coronary Artery Stenosis and Determinants of Mismatch: Head-to- Head Comparison With Intravascular Ultrasound	Nothing to Disclose	
Niida	Takayuki	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Relationship Between Optical Coherence Tomography-Defined In- Stent Neoatherosclerosis and Out-Stent Arterial Remodeling Assessed by Serial Intravascular Ultrasound Examinations in Late and Very Late Drug-Eluting Stent Failure	Nothing to Disclose	
Niida	Takayuki	Unusual Presentations of ACS	Comparison Between Angioscopic and Optical Coherence	Nothing to Disclose	
Niida	Takayuki	Unusual Presentations of ACS	Tomographic Assessment of Instent Restenosis Predictors and Clinical Significance of High-Sensitivity Cardiac	Nothing to Disclose	
Niida	Takayuki	Unusual Presentations of ACS	Troponin-I Elevation After Diagnostic Coronary Angiography Multimodality Coronary Imaging to Predict Periprocedural	Nothing to Disclose	
			Myocardial Necrosis After Elective Percutaneous Coronary Intervention		
	Takayuki	Unusual Presentations of ACS	Comparison of Neointimal Appearance Assessed by Optical Coherence Tomography Between Bare-Metal Stents and Sirolimus- Eluting Stents Beyond 10 Years From Implantation	Nothing to Disclose	
Niikura I	Hiroki	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Evaluation of Hemoconcentration Based Bioelectrical Vectorial Impedance Analysis Is Useful Risk Stratification in Acute Decompensated Heart Failure	Nothing to Disclose	
Niikura I		The Evolving World of LVADs, Transplant and Other Novel Discoveries	Body Fat Percentage Evaluated by a Bioelectrical Impedance Analysis Provides Prognostic Value in Acute Heart Failure: Beyond on the "Obesity Paradox"	Nothing to Disclose	
Nijjar F		Interventional Cardiology: PCI and TAVR in Complex Patients	Calcification in the Basal Septum, but Not Membranous Septal Length, Predicts AV Conduction Disturbance and Pacemaker Implantation Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve (S3)	Nothing to Disclose	
Nijjer	Sukhjinder	Coronary Physiology and Microcirculation	Case Presentation: Simultaneous Pressure and Flow Measurements	Nothing to Disclose	
Nijjer		Interventional Cardiology: Intravascular Physiology and Endothelial Function	Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International	Nothing to Disclose	
Nijjer S	Sukhjinder	23. Interventional Cardiology: IVUS and	Multicentre iFR GRADIENT Registry Suggested Reviewer	Nothing to Disclose	
	Petra	Intravascular Physiology Team 2 Making Progress in Understanding Heart	Intravascular Volume Expansion in Patients With Heart Failure and Reduced Ejection Fraction Is Not Revealed by Changes in Cardiac	Nothing to Disclose	
Nijst F	Petra	Failure Acute Heart Failure: Evaluating Strategies to	Filling Pressures Cardiac Resynchronization Therapy With Versus Without a	Nothing to Disclose	
Nijveldt F	Robin	Prevent Readmissions Advances in Chronic Total Occlusion	Defibrillator: Clinical Insights From Device Interrogation and Mode of Death Analysis Effects of Successful Percutaneous Coronary Intervention of	Nothing to Disclose	
	Evgenia	Intervention	Chronic Total Occlusions on Myocardial Perfusion and Left Ventricular Function Panelist	CONSULTANT FEES/HONORARIA - MEDTR	ONIC
	Evgenia Evgenia	21. Interventional Cardiology: Coronary	Suggested Reviewer	CONSULTANT FEES/HONORARIA - MEDTR	
Ning I	Hongyan	Intervention: Devices Team 1 Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Sudden Cardiac Death Risk Distribution in the United States Population: Results From the National Health and Nutrition	Nothing to Disclose	
Nishiguchi 7	Tsuyoshi	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Examination Survey (NHANES), 2005-2012 Comparison of Very Late Vascular Response Beyond 2 Years After Stent Implantation Between EES and BES: An OCT Sub-Study of	Nothing to Disclose	
Nishimura N	Marin	Advances in HCM, PPCM and Other Cardiomyopathies	the NEXT The Prevalence and Clinical Significance of Compacted Myocardium in Dilated Cardiomyopathy: A Contrast	Nothing to Disclose	
Nishimura F	Rick	Teaching with Intent: Secrets from the Masters	Echocardiography Study Co-Chair	Nothing to Disclose	
Nishimura F	Rick	I Teaching with Intent: Secrets from the Masters	Mock MOC Session (A Team Competition)	Nothing to Disclose	
Nishimura F	Rick	Teaching with Intent: Secrets from the Masters	Session Summary	Nothing to Disclose	
	Rick	II .	Co-Chair	Nothing to Disclose	
	Rick	II .	Mastering the Art of Masterful Presenting	Nothing to Disclose	
Nishimura F	Rick	Teaching with Intent: Secrets from the Masters	Co-Chair	Nothing to Disclose	
Nishimura F	Rick	Teaching with Intent: Secrets from the Masters	Simulation: Small Group Case Conference	Nothing to Disclose	
Nishimura F	Rick	Teaching with Intent: Secrets from the Masters	Intensive Summary	Nothing to Disclose	
Nishimura F	Rick	FIT Forum: Mix and Mingle	Education	Nothing to Disclose	
	Dick				
Nishimura F	Rick	Valvular Heart Disease Guidelines The Evidence and the Gaps Valvular Heart Disease Guidelines The	Co-Chair Facilitated Discussion: What's Unknown?- Outstanding	Nothing to Disclose Nothing to Disclose	

and the second				<u> </u>
Last Name Nishimura	First Name Rick	Session Title Highlighted Original Research: Valvular Heart	Presentation Title Isolated Tricuspid Valve Surgery: Repair Versus Replacement	Disclosures Nothing to Disclose
Nishimura	Rick	Disease and the Year in Review Valvular Disease Populations at Risk	Isolated Tricuspid Valve Surgery: National Trends and Outcomes	Nothing to Disclose
Nishimura	Rick	Innovative Use of Echocardiography	Isolated Throuspio Valve Surgery. National Trends and Outcomes E/e' > 15 Performs Poorly in Patients With Elevated Left Filling Pressures and Atrial Fibrillation/Flutter: A Simultaneous Doppler-Catheterization Study	
Nishimura	Rick	Insights From Echocardiography Use	Miscalculation of Right Atrial Pressure by Echocardiography in Patients With Structural Heart Disease: A Simultaneous Echocardiography-Catheterization Study	Nothing to Disclose
Nishimura Nishimura	Rick Rick	Sex Disparity in VHD Outcomes Prosthetic Valve Thrombosis: TAVR, Bio,	Gender Differences in Isolated Tricuspid Valve Surgery Poor Outcome of Thrombolysis in Right-Sided Mechanical Valve	Nothing to Disclose Nothing to Disclose
		Mech Now What?!	Thrombosis: Largest Single Center Experience	-
Nishimura	Rick	Tricuspid Regurgitation: Signals in Plain Sight	Isolated Functional Tricuspid Regurgitation: A Population in Need of Treatment	Nothing to Disclose
Nishiyama	Takahiko	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Compliance to Updated AHA/ACC Quality Measures Among Patients With Atrial Fibrillation in Japan and Its Association With Their Quality of Life	Nothing to Disclose
Nissen	Steven	FIT Forum: Mix and Mingle	Clinical Research	RESEARCH/RESEARCH GRANTS - AbbVie, Inc.,Amgen,Astra Zeneca,Eli Lilly,Esperion Therapeutics,MEDTRONIC,Novartis,Novo Nordisk,Orexigen,Pfizer,Resverlogix,Takeda,The Medicines Company
Nissen	Steven	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	Effect of Serial Infusions of CER-001, a Pre-Beta High-Density Lipoprotein Mirnetic on Coronary Atherosclerosis: Results of the CARAT Study	RESEARCH/RESEARCH GRANTS - AbbVie, Inc.,Amgen,Astra Zeneca, Eli Lilly, Esperion Therapeutics,MEDTRONIC, Novartis,Novo Nordisk,Orexigen,Pfizer,Resverlogix,Takeda,The Medicines Company
Nissen	Steven	Change is Good! Lifestyle Strategies in the Patient with ASCVD and Diabetes	Panelist	RESEARCH/RESEARCH GRANTS - AbbVie, Inc.,Amgen,Astra Zeneca,Eii Lilly,Esperion Therapeutics,MEDTRONIC,Novartis,Novo Nordisk,Orexigen,Pfizer,Resverlogix,Takeda,The Medicines
Nissen	Steven	Change is Good! Lifestyle Strategies in the Patient with ASCVD and Diabetes	How Much Weight Loss is Necessary to Improve Glycemic Control?	Company RESEARCH/RESEARCH GRANTS - AbbVie, Inc.,Amgen,Astra Zeneca,Eli Lilly,Esperion Therapeutics,MEDTRONIC,Novartis,Novo Nordisk,Orexigen,Pfizer,Resverlogix,Takeda,The Medicines Company
Nissen	Steven	Advances in Cholesterol Measurement and Management	Atherogenic Lipoprotein Variability Correlates With Coronary Atheroma Progression: Insights From Serial Intravascular Ultrasonography	RESEARCH/RESEARCH GRANTS - AbbVie, Inc.,Amgen,Astra Zeneca,Eli Lilly,Esperion Therapeutics,MEDTRONIC,Novartis,Novo Nordisk,Orexigen,Pfizer,Resverlogix,Takeda,The Medicines Company
Nissen	Steven	The Intersection of Diabetes and ASCVD	Average Clinician Measured Blood Pressure Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes Following Acute Coronary Syndromes in the EXAMINE Trial	RESEARCH/RESEARCH GRANTS - AbbVie, Inc., Amgen, Astra Zeneca, Eli Lilly, Esperion Therapeutics, MEDTRONIC, Novartis, Novo Nordisk, Orexigen, Pfizer, Resverlogix, Takeda, The Medicines Company
Niu	Jianli	Vascular Access and Hemostasis Issues	Pilot Trial Comparison of a Kaolin-Based Hemostatic Pad (QuikClot® Radial™) Versus Mechanical Compression (TR Band®) to Reduce Compression Time Following Transradial Access	Nothing to Disclose
Niwa	Koichiro	The Story of the Adult Congenital Heart Disease Patient and EP	Arrhythmia Burden & Outcomes in Eisenmenger Syndrome	Nothing to Disclose
Nketiah	Emmanuel	Novel Developments in Acute Coronary Syndromes	Cardiac Electrical Biomarker Response During Percutaneous Coronary Intervention	Nothing to Disclose
Nkhoma	Ella	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Trends in 30-Day Outcomes Following Acute Heart Failure Hospitalizations in a Large Real World Database, 2008 - 2014	SALARY - Bristol-Myers Squibb Company
Nkomo	Vuyisile	Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologists and the American College of Cardiology	Epidemiology of Valvular Heart Disease with a Focus on Minority Health	Nothing to Disclose
Nkomo	Vuyisile	Valvular Heart Disease: Endocarditis	Infective Endocarditis Following Transcutaneous Aortic Valve Implantation: Clinical, Echocardiographic and Hemodynamic Features	Nothing to Disclose
Nkomo	Vuyisile	Making Progress in Understanding Heart Failure	Left Atrial Enlargement in Patients With Ventricular Dysfunction: Innocent Bystander or Meaningful Determinant of Survival?	Nothing to Disclose
Nkomo	Vuyisile	Making Progress in Understanding Heart	Is Frailty a Mirror of Underlying Hemodynamic Alteration in Patients	Nothing to Disclose
Nkomo	Vuyisile	Failure FIT Clinical Decision Making: Non-Invasive	With Left Ventricular Dysfunction? Atrial Fibrillation in Aortic Stenosis: A Diagnostic and Therapeutic	Nothing to Disclose
Nkomo	Vuyisile	Imaging and Valvular Heart Disease Valvular Heart Disease: Mitral Valve Disease	Challenge Quantitation of Degenerative Mitral Regurgitation: Reserved to the	Nothing to Disclose
Nkomo	Vuyisile	Structural Heart Interventions: Focus on Mitral	Specialized Few or Applicable to Routine Clinical Practice? 3D Printing for Procedural Simulation of Transcatheter Mitral Valve	Nothing to Disclose
Nkomo	Vuyisile	Valve, Left Atrial Appendage and HOCM Interventional Cardiology: TAVR 2	Replacement in Patients With Mitral Annular Calcification Prognostic Value of Baseline N-Terminal Prohormone Type Natriuretic Peptide Measurement in Chronic Lung Disease Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve	Nothing to Disclose
Nkomo	Vuyisile	Innovative Use of Echocardiography	Replacement The Association Between Echocardiographic Laboratory	Nothing to Disclose
Nkomo	Vuyisile	Valvular Heart Disease: Aortic Stenosis	Accreditation and the Quality of Imaging and Reporting Bicuspid Versus Tricuspid Aortic Valve Stenosis: Comparative Study of Clinical Characteristics and Outcomes Following Aortic Valve Replacement in an Ace Matched Cohort	Nothing to Disclose
Nkomo	Vuyisile	Valvular Heart Disease: Aortic Stenosis	Replacement in an Age-Matched Cohort Sinus Rhythm Versus Atrial Fibrillation & It Clinical Profile and Natural History of Patients With Severe Aortic Stenosis Managed Medically	Nothing to Disclose
Nkomo	Vuyisile	Interventional Cardiology: TAVR 3	Comparative Outcome of Paravalvular Leak Following Surgical	Nothing to Disclose
Nkomo	Vuyisile	New Technologies in Echocardiography	Versus Transcatheter Aortic Valve Replacement Novel Echocardiographic Measurements Detect Increased Myocardial Stiffness in Patients With Severe Organic Mitral Requigitation	Nothing to Disclose
Nkomo	Vuyisile	Emerging Developments in HFpEF and Arryhthmias	Atrial Fibrillation Link to Excess Mortality in Patients With Left Ventricular Dysfunction: Linked to Rapid Ventricular Response or Independent Prognostic Marker?	Nothing to Disclose
Nkomo	Vuyisile	Insights From Echocardiography Use	Echocardiographic Parameters of Myocardial Performance After Transapical Versus Transfemoral Transcatheter Aortic Valve Replacement	Nothing to Disclose
Nkomo	Vuyisile	Novel Determinants of Outcomes in VHD	Coexisting Co-Morbidities Exacerbate Left Ventricular Diastolic Dysfunction and Prognosis in Patients With Severe Aortic Stenosis	Nothing to Disclose
Nkomo	Vuyisile	Prosthetic Valve Thrombosis: TAVR, Bio, Mech Now What?!	Outcome of Anticoagulation Therapy for Bioprosthetic Valve Thrombosis: A Prospective Study	Nothing to Disclose
	Vuyisile	Technical Advances in Transthoracic	E/e' Short- and Long-Term Independent Prognostic Role in	Nothing to Disclose

	Tei			[n
Last Name Nkomo	First Name Vuyisile	Session Title Tricuspid Regurgitation: Signals in Plain Sight	Presentation Title Isolated Functional Tricuspid Regurgitation: A Population in Need of	Disclosures Nothing to Disclose
Numero	V delle	37. Valvular Heart Disease: Therapy Team 1	Treatment Supported Parisman	Nething to Displace
Nkomo Nochrina	Vuyisile Olga	Cardiac Fibrosis and Heart Failure: The Next	Suggested Reviewer Influence of Biomarkers of Inflammation, Myocardial Fibrosis,	Nothing to Disclose Nothing to Disclose
		Frontier	Catecholamines on the Survival of Congestive Heart Failure Patients Undergoing Cardiac Resynchronization Therapy	-
Noguchi	Masahiko	Insights From Echocardiography Use	Value of Automated and Semi-Automated Measurement by Novel	Nothing to Disclose
			Three-Dimensional Echocardiography Software for Aortic Annulus Sizing in Candidates of Transcatheter Aortic Valve Replacement:	
NI-L-2-	A 7	00. 4 d. 15 d. 15 d. 15 d. 15 d.	Comparison With Multi-Detector Computed Tomography	Note: A Broken
Noheria	Amit	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	Nothing to Disclose
Nahaia	A=:	1	Constant Projection	Nothing to Displace
Nohria	Anju	Heart Failure and Cardiomyopathies: Clinical Team 6	Suggested Reviewer	Nothing to Disclose
Noiseux	Nicolas	Highlighted Original Research: Interventional Cardiology and the Year in Review	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	Nothing to Disclose
Noiseux	Nicolas	Interventional Cardiology: Intravascular	Appropriateness of Coronary Artery Bypass Grafting Based on	Nothing to Disclose
Noiseux	Nicolas	Physiology and Endothelial Function Novel Imaging and Therapies in Heart Failure	Fractional Flow Reserve Lesions Assessment Novel Infarct Sparing Drug Protects the Heart Against Ischemia-	Nothing to Disclose
			Reperfusion (I/R) Injury	
Noiseux	Nicolas	Interventional Cardiology: TAVR 4	Serum Albumin as an Incremental Predictor of Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement:	Nothing to Disclose
Noiseux	Nicolas	Refining PCI Technique and Outcomes	Results From the Multicenter Frailty-AVR Study Treatment of Left Main Coronary Artery Disease in Patients With	Nothing to Disclose
Noiseux	INICOIAS	ixening For reclinique and outcomes	Diabetes: 3-Year Outcomes Comparing CABG and PCI With	Nothing to Disclose
Nolan	Mark	Toward Precision Medicine in the Treatment of	Everolimus-Eluting Stents From the EXCEL Study Left Atrial Function and Role in Prediction of Heart Failure	Nothing to Disclose
		Elevated Blood Pressure		
Nolan	Mark	Innovative Use of Echocardiography	Independent Association of Atrial Mechanics With Risk of Incident Atrial Fibrillation	Nothing to Disclose
Nolan	Rob	Joint American College of Cardiology/Journal	e-Counseling for Self-Care Adherence Adds Therapeutic Benefit for	Nothing to Disclose
		of the American Medical Association Late- Breaking Clinical Trials	Hypertension: The REACH Trial	
Nolan	Susan	Personalized Skills Center: Drill and Practice (Heart Songs, ECG, Hand-Held Echo)	Heart Songs Moderator	Nothing to Disclose
Noma	Shigetaka	Unusual Presentations of ACS	C-Reactive Protein in Non-ST Elevation Myocardial Infarction	Nothing to Disclose
			Patients Is Useful in Improving Discrimination of Conventional Risk Score: A Report From Multicenter PCI Registry	
Noma	Shigetaka	Unusual Presentations of ACS	Trend of Use in Transradial Intervention Among Elderly Patients in	Nothing to Disclose
Nombela-Franco	Luis	Interventional Cardiology: TAVR 3	Japan According to Their Pre-Procedural Bleeding Risk Meta-Analysis on Cerebral Embolic Protection Devices During	Nothing to Disclose
Nona	Paul	Innovations in Cardiovascular Risk Assessment	Transcatheter Aortic Valve Implantation Do Cardiovascular Health Screening Programs and Focused	Nothing to Disclose
Nona	raui	and Reduction	Counseling Have Impact on Patient Habits and Lifestyle Change?	Nothing to Disclose
Norby	Faye	Updates on Risk Factors for Cardiovascular	Early Results of the Heart Smart Screening Program Retinopathy and Risk of Sudden Cardiac Death: The ARIC Study	Nothing to Disclose
-		Disease		
Nordestgaard	Boerge	Harnessing the Power of Genetics to Prevent ASCVD	The Enigmatic Particle – New Frontiers in Lp(a)	CONSULTANT FEES/HONORARIA - Sanofi, Regeneron, Aegerion, AstraZeneca, Amgen, Kowa and IONIS
Norgaard	Bjarne	Patient-Centered Imaging: Quality of Cardiac	CT-FFR and CT-Perfusion: Ready for Widespread Utilization?	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Edwards
	-	CT Evidence		Lifesciences, Heartflow, Siemens
Norgaard	Bjarne	Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American	Changing practice with non-invasive FFRCT- The Danish Experience	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, Heartflow, Siemens
Norgoord	Bjarne	College of Cardiology Traditional and Novel Factors Used to Assess	Fractional Flow Reserve Derived From Coronary Computed	RESEARCH/RESEARCH GRANTS - Edwards
Norgaard	bjane	the Risk of, and Used for the Treatment of,	Tomography Safely Reduces Invasive Coronary Angiography Rates	Lifesciences, Heartflow, Siemens
Norgaard	Bjarne	Coronary Artery Disease Coronary Angiography, Intra-Vascular Imaging,	and Cost in Patients With Stable Coronary Artery Disease Fractional Flow Reserve Is a Sensitive but Not a Specific Detector of	RESEARCH/RESEARCH GRANTS - Edwards
	-	Revascularization and Outcomes	a High Risk Plaques	Lifesciences, Heartflow, Siemens
Norgaard	Bjarne	Unusual Presentations of ACS	Incidence and Predictors of Lesion Specific Ischemia by FFR _{CT} : Learnings From the International ADVANCE	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, Heartflow, Siemens
Norgaard	Bjarne	Noninvasive Assessment of Coronary Flow	Registry Can Necrotic Core Volume Explain Ischemia Coronary Stenosis	RESEARCH/RESEARCH GRANTS - Edwards
Norhammar	Anna	Reserve: Clinical Implications Featured Clinical Research III	Mismatch in Some Cases?	Lifesciences,Heartflow,Siemens Nothing to Disclose
Nomamma			Lower Rates of Hospitalization for Heart Failure and All-Cause Death in New Users of SGLT-2 Inhibitors: The CVD-REAL Study	
Norrington	Karl	Making Progress in Understanding Heart Failure	Prognostic Utility of Haemoglobin/Haematocrit Equations for Estimating Congestion Versus Calculated Plasma Volume Status in	Nothing to Disclose
Namia	Made		Chronic Heart Failure	Nething to Displace
Norris	Mark	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Kommerell Diverticulum Across the Ages: Destined for Dilation?	Nothing to Disclose
North	Lauren	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Exome Sequencing Reveals Novel Variants in <i>TMEM59L</i> and <i>KLHL26</i> Associated With a Familial Case of Ebstein’s	Nothing to Disclose
Name of	Deter	-	Anomaly and Left Ventricular Noncompaction	Nething to Displace
Noseworthy	Peter	Young Investigator Awards Competition: Outcomes Research	A Comparison of Kidney Function Decline in Atrial Fibrillation Patients Treated With Non-Vitamin K Antagonist Oral	Nothing to Disclose
Noseworthy	Peter	Innovative Approaches for Reducing Risk and	Anticoagulants or Warfarin Atrial Fibrillation Is Associated With Worse Outcomes in Patients	Nothing to Disclose
-		Improving Outcomes With Ablation	With Cirrhosis	
Noseworthy	Peter	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	Nothing to Disclose
Noutong Njapo	Steve	5 FIT Clinical Decision Making: Heart Failure and	Left Ventricular Assist Device Outflow Tract Thrombus Following a	Nothing to Disclose
Novak	Eric	Pulmonary Hypertension Making Progress in Understanding Heart	Successful Sleeve Gastrostomy Global Longitudinal Strain Predicts Sustained Recovery of LV	Nothing to Disclose
	_	Failure	Ejection Fraction in Heart Failure Patients on Evidence Based Medical Therapies	5
Novak	Eric	Interventional Cardiology: TAVR 4	Depression as a Potential Therapeutic Target to Improve Quality of Life After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Novotny	Samantha	Interventional Cardiology: TAVR 2	Impact of Chronic Kidney Disease on Mortality in Adults Undergoing	Nothing to Disclose
Nowak	Richard	Novel Developments in Acute Coronary	Balloon Aortic Valvuloplasty How Often Does Troponin Elevation Identify Acute Myocardial	CONSULTANT FEES/HONORARIA - Roche
		Syndromes	Infarction in the Emergency Department?	Diagnostics, Siemens
Nowak	Richard	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Is Duration of Symptoms Predictive of Acute Myocardial Infarction?	CONSULTANT FEES/HONORARIA - Roche Diagnostics, Siemens
Nozza	Anna	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Association Between Homeostasis Model Assessment of Insulin Resistance and Survival in Diabetic Patients With Acute Coronary	Nothing to Disclose
N	A.C.	Syndrome	Syndromes: Insights From the AleCardio Trial	Nullius to Birds
Nsair	Ali	Put Your Codon! Genetic Insights Into Heart Failure	ACC Poster Moderator	Nothing to Disclose
Nsair	Ali	12. Heart Failure and Cardiomyopathies: Basic Team 2	Suggested Reviewer	Nothing to Disclose
L	<u> </u>	I Calli Z	I	

Congress of the congress of th				I
Last Name	First Name Alan	Session Title Advances in HCM, PPCM and Other	Presentation Title Long-Term Outcomes of Childhood Left Ventricular Non-	Disclosures Nothing to Disclose
Nugent		Cardiomyopathies	Compaction: Results From a National Population-Based Study	
Nugent	Alan	10. Congenital Heart Disease: Pediatric Team 3	Suggested Reviewer	Nothing to Disclose
Nugent	Matthew	Biomarkers and Targets for Ischemic Heart Disease	Ultrasound Increases Myocardial Blood Flow in Acute Myocardial Ischemia Without Reducing Infarct Size	Nothing to Disclose
Numasawa	Yohei	Unusual Presentations of ACS	C-Reactive Protein in Non-ST Elevation Myocardial Infarction Patients Is Useful in Improving Discrimination of Conventional Risk Score: A Report From Multicenter PCI Registry	Nothing to Disclose
Numasawa	Yohei	Unusual Presentations of ACS	Trend of Use in Transradial Intervention Among Elderly Patients in Japan According to Their Pre-Procedural Bleeding Risk	Nothing to Disclose
Nunes	Maria	36. Valvular Heart Disease: Clinical Team 2	Suggested Reviewer	Nothing to Disclose
Nunes	Maria do Carmo	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Increased Left Atrial Compliance Is an Independent Predictor of Improved Functional Capacity After Percutaneous Mitral Valvuloplasty	Nothing to Disclose
Nunez	Eduardo	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Performance of the Seattle Heart Failure Model in Patients Discharged After Acute Heart Failure Hospitalization	Nothing to Disclose
Nusairat	Leen	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Two Birds, One Stone: Citalopram for Neurocardiogenic Syncope and Irritable Bowel Syndrome	Nothing to Disclose
Nwosu	Chukwunweike	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	A "Mind Blowing" Case of Left Atrial-Esophageal Fistula Leading to Tension Pneumocephalus and Sudden Death	Nothing to Disclose
Obagi	Aref	Novel Developments in Acute Coronary Syndromes	Compliance and Bleeding Using Updated AHA and ACC Heparin Dosing Guidelines for Non-ST Elevation Myocardial Infarction Patients	Nothing to Disclose
Obarski	Timothy	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Mitral Valve Regurgitation From Hypereosinophilic Syndrome	Nothing to Disclose
Obeid	Slayman	Interventional Cardiology: Structural Heart Disease	Syntax Score II in Patients With Coronary Artery Disease Undergoing Mitraclip: A New Approach to Risk Stratification	Nothing to Disclose
Obeid	Slayman	Timely Topics in Acute Coronary Syndromes	Gender-Related Outcomes in Elderly (> 75 Years) Patients Presenting With Acute Coronary Syndromes: Results From the Swiss Acute Coronary Syndrome Cohort	Nothing to Disclose
Oberst	Leslie	FIT Clinical Decision Making: Non-Invasive	Cardiac Magnetic Resonance Imaging Illustrating an Asymptomatic,	Nothing to Disclose
Oberst	Leslie	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Interventional	Large Inferobasilar Left Ventricular Aneurysm Ventricular Papillary Fibroelastoma Presenting as Peripheral Artery	Nothing to Disclose
Obideen	Malik	Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Traditional and Novel Factors Used to Assess	Disease Inflammatory Response to Mental Stress and Mental Stress Induced	Nathing to Disclose
		the Risk of, and Used for the Treatment of, Coronary Artery Disease	Myocardial Ischemia	-
Obokata	Masaru	Emerging Developments in HFpEF and Arryhthmias	The Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: An Invasive- Echocardiographic Study	Nothing to Disclose
Obokata	Masaru	Emerging Developments in HFpEF and Arryhthmias	Arterial Reserve Limitations in Heart Failure With Preserved Ejection Fraction and the Beneficial Effects of Sodium Nitrite	Nothing to Disclose
Obokata	Masaru	Emerging Developments in HFpEF and Arryhthmias	Utility of Cardiopulmonary Exercise Testing to Diagnose and Phenotype Heart Failure With Preserved Ejection Fraction	Nothing to Disclose
O'Brien	Cashel	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Sex Differences in Rates of 30-Day Readmission in Patients Discharged After Acute Myocardial Infarction in the United States	Nothing to Disclose
O'Brien	Emily	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Health Disparities Among Patients With Familial Hypercholesterolemia in the CASCADE-FH Patient Registry	CONSULTANT FEES/HONORARIA - Portola Pharmaceuticals; RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim Pharmaceuticals, Inc,Bristol-Myers Squibb Company ,GlaxoSmithKline,Janssen Pharmaceuticals, Inc
O'Brien	Emily	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)	CONSULTANT FEES/HONORARIA - Portola Pharmaceuticals; RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim Pharmaceuticals, Inc,Bristol-Myers Squibb Company ,GlaxoSmithKline,Janssen Pharmaceuticals, Inc
O'Brien	James	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Interstage Resource Utilization of Infants With Single Ventricle: Results of a Crossover Study	Nothing to Disclose
O'Brien	Sean	Featured Clinical Research II: Interventional	Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data	Nothing to Disclose
Obuchowski	Nancy	Non Invasive Imaging: MR Characterization	Time Varying Effect of Total Scar on Mortality in Patients With	CONSULTANT FEES/HONORARIA -
Obunai	Kotaro	and Function Insights From Echocardiography Use	Cardiomyopathy Undergoing Cardiac Resynchronization Therapy Value of Automated and Semi-Automated Measurement by Novel Three-Dimensional Echocardiography Software for Aortic Annulus Sizing in Candidates of Transcatheter Aortic Valve Replacement:	CVUS,Hologic,iCAD,Siemens Nothing to Disclose
O'Byrne	Megan	Congenital Heart Disease: Innovations in	Comparison With Multi-Detector Computed Tomography Association of Increased Total Atrial Volume With Clinical Heart	Nothing to Disclose
O'Byrne	Michael	Single Ventricle Heart Disease	Failure Status in Hypoplastic Left Heart Syndrome Unusual Presentation for Primary Bacterial Percarditis	Nothing to Disclose
O'Byrne	Michael	Therapeutic Advances in Congenital Heart Disease	Effect of Obesity and Underweight Status on Perioperative Outcomes in Patients With Congenital Heart Disease: An Analysis of Data From the Society of Thoracic Surgeons Congenital Heart	Nothing to Disclose
O'Byrne	Michael	Finding Out What Works in Pediatric and Congenital Heart Disease	Surgery Database Risk of Catastrophic Outcome Following Cardiac Catheterization for Pulmonary Hypertension: An Analysis of Data From the Impact Registry	Nothing to Disclose
Occhetta	Eraldo	Emerging Developments in HFpEF and Arryhthmias	Prognostic Role of Ventricular-Arterial Coupling in Patients With Left Ventricular Dysfunction Submitted to Cardiac Resynchronization	Nothing to Disclose
Ochiai	Masahiko	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Therapy Optical Coherence Tomography Assessment of Coronary Atherectomy Effect: Comparison Between Orbital and Rotational	SPEAKER'S BUREAU - Abbott Vascular, Asahi Intecc Co, Boston Scientific Co, Terumo Co
Ochiai	Masahiko	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Atherectomy in Severely Calcified Lesions Morphologic Patterns of In-Stent Chronic Total Occlusions: An Intravascular Ultrasound Study	SPEAKER'S BUREAU - Abbott Vascular, Asahi Intecc Co, Boston Scientific Co, Terumo Co
Ochiai	Masahiko	Advances in Chronic Total Occlusion Intervention	The Impact of Recanalization of Chronic Total Occuluded Coronary Artery on Electrophysiological Substrate of Left Ventricle	SPEAKER'S BUREAU - Abbott Vascular, Asahi Intecc Co, Boston Scientific Co, Terumo Co
Ochiai	Masahiko	Interventional Cardiology: PCI in Complex Patients	Chronic Stent Recoil During Follow-Up in Severely Calcified Coronary Artery Lesions: An Optical Coherence Tomography Study	SPEAKER'S BUREAU - Abbott Vascular, Asahi Intecc Co, Boston Scientific Co, Terumo Co
Ochiai	Masahiko	20. Interventional Cardiology: Coronary	Suggested Reviewer	SPEAKER'S BUREAU - Abbott Vascular, Asahi Intecc Co, Boston
Ochiai	Masahiko	Intervention: CTO Team 1 Interventional Challenging Cases: Team 3	ACC Challenging Case Reviewer	Scientific Co,Terumo Co SPEAKER'S BUREAU - Abbott Vascular,Asahi Intecc Co,Boston
O'Connell	Eoin		Longitudinal Change in Soluble ST2 Versus B-type Natriuretic	Scientific Co,Terumo Co Nothing to Disclose
		and Reduction	Peptide in Predicting Major Adverse Cardiovascular Events in Asymptomatic Patients in the Community	

and the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
O'Connor	Christopher	Eugene Braunwald Lecture on Future Directions in Cardiovascular Medicine and the Best of JACC Journals	Panelist	CONSULTANT FEES/HONORARIA - AbbVie, Inc.,Actelion Pharmaceuticals Ltd,Bayer,Bristol Myers Squibb,Cardiorentis,Merck & Co., Inc.,Resmed,Roche Diagnostics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Biscardia, LLC;
O'Connor	Christopher	Eugene Braunwald Lecture on Future Directions in Cardiovascular Medicine and the Best of JACC Journals	Best of JACC: Heart Failure in 2016	RESEARCH/RESEARCH GRANTS - Roche Diagnostics CONSULTANT FEESIHO/NORARIA - AbbVie, Inc., Actelion Pharmaceuticals Ltd, Bayer, Bristol Myers Squibb, Cardiorentis, Merck & Bamp; amp; Co., Inc., Resmed, Roche Diagnostics; OWNERSHIP; INTEREST/PARTNERSHIP/PRINICIPAL - Biscardia, LLC; RESEARCH/RESEARCH GRANTS - Roche Diagnostics
O'Connor	Christopher	Readmission in Heart Failure: Questions Unanswered	Debate: Disparities in Readmission: It Is Not Only the Hospitals Fault, Con	CONSULTANT FEES/HONORARIA - AbbVie, inc., Actelion Pharmaceuticals Ltd, Bayer, Bristol Myers Squibb, Cardiorentis, Merck & Bamp; amp; Co., Inc., Resmed, Roche Diagnostics; OWNERSHIP INTEREST/PARTNERSHIP/PRIINCIPAL - Biscardia, LLC; RESEARCHRESEARCH GRANTS - Roche Diagnostics
O'Connor	Christopher	Peer-reviewed Publishing	Best Practices With Social Media for Journals and Readers	CONSULTANT FEES/HONORARIA - AbbVie, Inc.,Actelion Pharmaceuticals Ltd,Bayer,Bristol Myers Squibb,Cardiorentis,Merck & Co., Inc.,Resmed,Roche Diagnostics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Biscardia, LLC; RESEARCH/IRESEARCH GRANTS - Roche Diagnostics
O'Connor	Christopher	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Year in Review Speaker	CONSULTANT FEES/HONORARIA - AbbVie, Inc.,Actelion Pharmaceuticals Ltd,Bayer,Bristol Myers Squibb,Cardiorentis,Merck & Co., Inc.,Resmed,Roche Diagnostics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Biscardia, LLC; RESEARCH/RESEARCH GRANTS - Roche Diagnostics
O'Connor	Christopher	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Surrogate Endpoints and the Differential Response to ASV for Sleep Apnea in HFrEF Versus HFpEF in the CAT-HF Trial	CONSULTANT FEES/HONORARIA - AbbVie, Inc.,Actelion Pharmaceuticals Ltd,Bayer,Bristol Myers Squibb,Cardiorentis,Merck & Co., Inc.,Resmed,Roche Diagnostics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Biscardia, LLC; RESEARCH/RESEARCH GRANTS - Roche Diagnostics
O'Connor	Christopher	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Timing and Clinical Predictors of Early Versus Late Readmission Among Patients Hospitalized for Acute Heart Failure: Insights From ASCEND-HF	CONSULTANT FEES/HONORARIA - AbbVie, Inc.,Actelion Pharmaceuticals Ltd,Bayer,Bristol Myers Squibb,Cardiorentis,Merck & Co., Inc.,Resmed,Roche Diagnostics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Biscardia, LLC; RESEARCH/RESEARCH GRANTS - Roche Diagnostics
O'Connor	Christopher	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Severe Physical Inactivity Persists Following Acute Heart Failure in Patients With Sleep Disordered Breathing	CONSULTANT FEES/HONORARIA - AbbVie, Inc.,Actelion Pharmaceuticals Ltd,Bayer,Bristol Myers Squibb,Cardiorentis,Merck & Co., Inc.,Resmed,Roche Diagnostics; OWNERSHIP INTEREST/PARTNERSHIP/PRIINCIPAL - Biscardia, LLC; RESEARCH/RESEARCH GRANTS - Roche Diagnostics
O'Connor	Christopher	Why Can't We Be Friends? Controversies in Heart Failure Management	Prevalent Digoxin Use Is Not Associated With Increased Risk of Death or Hospitalization in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction	CONSULTANT FEES/HONORARIA - AbbVie, inc., Actelion Pharmaceuticals Ltd, Bayer, Bristol Myers Squibb, Cardiorentis, Merck & Bamp; amp; Co., Inc., Resmed, Roche Diagnostics; OWNERSHIP INTEREST/PARTNERSHIP/PRIINCIPAL - Biscardia, LLC; RESEARCH/RESEARCH GRANTS - Roche Diagnostics
O'Connor	Christopher	14. Heart Failure and Cardiomyopathies: Therapy Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - AbbVie, Inc.,Actelion Pharmaceuticals Ltd,Bayer,Bristol Myers Squibb,Cardiorentis,Merck & Co., Inc.,Resmed,Roche Diagnostics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Biscardia, LLC; RESEARCH/RESEARCH GRANTS - Roche Diagnostics
O'Connor	Matthew	Congenital Heart Disease: To the Third Decade and Beyond	ACC Poster Moderator	Nothing to Disclose
Odeh	Khalil	Mechanisms of Vascular Inflammation in Atherogenesis	Comparative Study on Catheter-Directed Thrombolysis - Continuous Tissue Plasminogen Activator Versus Angiojet Catheter Power Pulse Spray Rheolytic Thrombectomy Outcome Study: Single- Center Experience	Nothing to Disclose
Odeh	Raed	ACC International Conferences Best Posters	Nurse-Led Cardiovascular Disease Management Program Impact of 30-Day Readmission in Patients With Heart Failure	Nothing to Disclose
Odland	Hans Henrik	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Myocardial Contractile Reserve Verified With Dual Chamber Right Ventricular Pacing Predicts Response to Cardiac Resynchronization Therapy	Nothing to Disclose
O'Donoghue	Michelle	Timing and Duration of DAPT: Controversy and Consensus	Co-Chair	RESEARCH/RESEARCH GRANTS - Astra Zeneca,Eisai,GlaxoSmithKline,Janssen Pharmaceuticals, Inc,Merck & Co., Inc.
O'Donoghue	Michelle	Timing and Duration of DAPT: Controversy and Consensus	Panelist	RESEARCH/RESEARCH GRANTS - Astra Zeneca,Eisai,GlaxoSmithKline,Janssen Pharmaceuticals, Inc,Merck & Dr., Inc.
O'Donoghue	Michelle	Timing and Duration of DAPT: Controversy and Consensus	Lifelong DAPT for All	RESEARCH/RESEARCH GRANTS - Astra Zeneca, Eisai, Glaxo Smith Kline, Janssen Pharmaceuticals, Inc, Merck & Dramp; Co., Inc.
O'Donoghue	Michelle	Interrupting DAPT for Surgery, Afib, or Bleeding	Co-Chair	RESEARCH/RESEARCH GRANTS - Astra Zeneca, Eisai, GlaxoSmithKline, Janssen Pharmaceuticals, Inc, Merck & Dr., Inc.
O'Donoghue	Michelle	Young Investigator Awards Competition: Clinical Investigations	Judge	RESEARCH/RESEARCH GRANTS - Astra Zeneca, Eisai, GlaxoSmithKline, Janssen Pharmaceuticals, Inc.Merck & Dramp; Co., Inc.
O'Donoghue	Michelle	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Cystatin C Is Associated With the Risk of Adverse Outcomes Independent of Established and Novel Cardiorenal Markers: An Analysis From the SOLID-TIMI 52 Trial	RESEARCH/RESEARCH GRANTS - Astra Zeneca, Eisai, GlaxoSmithKline, Janssen Pharmaceuticals, Inc, Merck & Denne Co., Inc.
O'Donoghue	Michelle	Vascular Access and Hemostasis Issues	Radial Versus Femoral Access for Coronary Angiography and Risk of Stroke: Findings From the LATITUDE-TIMI 60 Trial	RESEARCH/RESEARCH GRANTS - Astra Zeneca, Eisai, GlaxoSmithKline, Janssen Pharmaceuticals, Inc, Merck & Description (Co., Inc.)
Oechslin	Erwin	Redefining the "F" Word	Late Complications and Cardiopulmonary Performance in Adults With Fontan Physiology: Rv-Dominant Versus Those With Lv- Dominant or Unseptated Ventricles	CONSULTANT FEES/HONORARIA - Actelion
Oehler	Elise	New Technologies in Echocardiography	Novel Echocardiographic Measurements Detect Increased Myocardial Stiffness in Patients With Severe Organic Mitral Regurgitation	Nothing to Disclose
Oesterle Oestreich	Adam Brett	FIT Clinical Decision Making Reviewers 7 Interventional Cardiology: PCI and TAVR in Complex Patients	ACC FIT Clinical Decision Making Reviewer Calcification in the Basal Septum, but Not Membranous Septal Length, Predicts AV Conduction Disturbance and Pacemaker Implantation Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve (S3)	Nothing to Disclose Nothing to Disclose

Organic State of Country of State of Country (1982) Organic State	Contract of the second				
Section Modes Sectio	Last Name				
Control Cont	Oeigen	william		Cardiovascular Care Delivery in India: Insights From the American College of Cardiology's PINNACLE India Quality	Nothing to Disclose
	Oevrehus	Kristian		Can Necrotic Core Volume Explain Ischemia Coronary Stenosis	Nothing to Disclose
Part Section Part Section Part Section Sec	O'Gara	Patrick			Nothing to Disclose
Part Part	O'Gara	Patrick	Teaching with Intent: Secrets from the Masters	Mock MOC Session (A Team Competition)	Nothing to Disclose
Section Sect	O'Gara	Patrick	Teaching with Intent: Secrets from the Masters	Session Summary	Nothing to Disclose
Porcision Porcis	O'Gara	Patrick	Teaching with Intent: Secrets from the Masters	Co-Chair	Nothing to Disclose
Forces Particle Parti	O'Gara	Patrick	Teaching with Intent: Secrets from the Masters	ACC-Talk: How Does Rick Tick?	Nothing to Disclose
Control Control of Con	O'Gara	Patrick	Teaching with Intent: Secrets from the Masters	Principles of a Great ACC-Talk (interviewee)	Nothing to Disclose
Core Coronary and Systems Disease (A. Peres C. Coronary and Systems Disease) (A. Peres C. Coronary and Systems Disease) (A. Peres C. Coronary and Systems Disease) (A. Peres C. Coronary and Systems Disease) (A. Peres C. Coronary and Systems Disease) (A. Peres C. Coronary and Systems Disease) (A. Peres C. Coronary and Systems Disease) (A. Peres C. Coronary C. Peres C. Coronary C. Peres C. Coronary C. Peres C. Coronary C. Peres C. Coronary C. Peres C. Coronary C. Peres	O'Gara	Patrick	Teaching with Intent: Secrets from the Masters II	Session Summary	Nothing to Disclose
Course Course part of Systems (Crease A) Force Condenses and College of Control of Vivolute Hard Document (1) Force Control of Con	O'Gara	Patrick	Chronic Coronary and Systemic Disease (A	Panelist	Nothing to Disclose
Visual Friend Losson. NSS and Autor 1 2017 Petitol. Pe	O'Gara	Patrick	Chronic Coronary and Systemic Disease (A Symposium by Valentin Fuster)	Reduce Excess Salt and Personalize BP Target	Nothing to Disclose
Valuator Fiscan Disease, IRSS and Anna 2017 Disease Definition D	O'Gara	Patrick	Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster)		Nothing to Disclose
Content			Valvular Heart Disease, IHSS and Aorta - 2017 (A Symposium by Valentin Fuster)	Therapy to TMVR	Ç
Fergland Journal of Medicines Late Friendley O'Clare Particl O'Clare O'Clare Particl O'Clare Particl O'Clare O'Clare O'Clare O'Clare O'Clare O'Clare Particl O'Clare O					
O'Clare Period: Control Period			England Journal of Medicine Late-Breaking Clinical Trials	Replacement: A Randomized Trial From the Cardiothoracic Surgical Trials Network	
O'Gran Patrick Valvalar fear Disease Guidelines — The Vertebroat with the Guidelines — The Vertebroat with the Guidelines — The Vertebroat with the Guidelines — The Vertebroat with the Guidelines — The Vertebroat with the Guidelines — The Vertebroat with the Guidelines — The Vertebroat with the Guidelines — The Vertebroat with the Guidelines — The Vertebroat with the Guidelines — The Vertebroat with the Guidelines — The Vertebroat with the Guidelines — The Vertebroat with the Guidelines — The Vertebroat — Patrick Valoriar Marchane Emerging Concepts in Clinical Valoriation Emerging Concepts in Concepts in Clinical Valoriation Emerging Concepts in Clinical Valoriation Emerging Concepts in Clinical Valoriation Emerging Concepts in Clinical Valoriation Emerging Concepts in Clinical Valoriation Emerging Concepts in Clinical Valoriation Emerging Concepts in Clinical Valoriation Emerging Concepts in Clinical Valoriation Emerging Concepts in Clinical Valoriation Emerging Concepts in Clinic	O'Gara O'Gara		Valvular Heart Disease Guidelines The		
O'Gran Patrick Valvalar Heart Disease Guidenine – The Valvalar Heart Disease Guidenine – The Valvalar Heart Disease Color of the Vectors and the Gage O'Gran Patrick Valvalar Heart Disease Valvalar Disease Valvalar Heart Disease Valvalar Disease Valvalar Heart Disease Valvalar Disease Valvalar Heart Disease Valvalar Heart Disease Valvalar Heart Disease Valvalar Heart Disease Valvalar Heart Disease Valvalar Disease Valvalar	O'Gara	Patrick	Valvular Heart Disease Guidelines The		Nothing to Disclose
O'Clare Patrick Valuative Heart Diseases Cultivines — The Called Sequence Some Disease Nothing to Discose O'Clare Patrick Vascular Medicine : Emerging Concepts in Temporary Temporary Nothing to Discose O'Clare Patrick Vascular Medicine : Emerging Concepts in Temporary Temporary Nothing to Discose O'Clare Patrick Vascular Medicine : Emerging Concepts in Temporary Temporary Nothing to Discose O'Clare Patrick Vascular Medicine : Artis and Perpharial Artis Vibrage Nothing to Discose O'Clare Patrick Vascular Medicine : Artis and Perpharial Artis Vibrage Nothing to Discose O'Clare Patrick Vascular Medicine : Artis and Perpharial Artis Vibrage Nothing to Discose O'Clare Patrick Vascular Medicine : Artis and Perpharial Artis Vibrage Nothing to Discose O'Clare Patrick Vascular Medicine : Artis and Perpharial Artis Vibrage Nothing to Discose O'Clare Patrick Vascular Medicine : Artis and Perpharial Artis Vibrage Nothing to Discose O'Clare Patrick Vascular Medicine : Artis of Discose :	O'Gara	Patrick	Valvular Heart Disease Guidelines The	Facilitated Discussion: What's Unknown? - Outstanding	Nothing to Disclose
O'Gran Partick Innovations in Education Educat			Valvular Heart Disease Guidelines The Evidence and the Gaps	ARS-based Wrap Up Segment	-
O'Glara Patrick Vascular Medicine: Emerging Concepts in Chineal Vascular Medicine: A many and Perapheral International Construction of Management Patrick Vascular Medicine: Annual and Perapheral International Control Medicine: Annual Persentation in Patrick Vascular Medicine: Annual Persentation in Patrick Vascular Medicine: Annual Persentation in Patrick Vascular Medicine: Annual Persentation in Patrick Vascular Medicine: Annual Persentation of ACS Optian Manabu Unusual Presentations of ACS Optian Manabu Unusual Presentations of ACS Optian Manabu Unusual Presentations of ACS Optian Manabu Unusual Presentations of ACS Optian Manabu Unusual Presentations of ACS Optian Manabu Unusual Presentations of ACS Optian Manabu Unusual Presentations of ACS Optian Manabu Unusual Presentations of ACS Optian Manabu Unusual Presentations of ACS Optian Manabu Unusual Presentations of ACS Optian Manabu Unusual Presentations of ACS Optian Manabu Unusual Presentations of ACS Optian Manabu Unusual Presentations of ACS Optian Manabu Unusual Presentation of ACS Optian Manabu Unusual Presentation of ACS Optian Manabu Unusual Presentation of ACS Optian Manabu Unusual Presentation of International Manabu Unusual Presentation of International Manabu Unusual Presentation of International Manabu Unusual Presentation of International Manabu Unusual Presentation of International Manabu Unusual Presentation of International Manabu Unusual Presentation of International Manabu Unusual Presentation of International Manabu Unusual Presentation of International Manabu Unusual Presentation of International Manabu Unusual Presentation of International Manabu Unusual Presentation of International Manabu Unusual Presentation of International Manabu Unusual Presentation of International Manabu Unusual Presentation of International Manabu Unusual Presentation of International Manabu Unusual Presentation of International Manabu Unusual Presentational Presentational Presentation of International Presentations of International Manabu Unusual Presentational				Teaching Tomorrow's Teachers: An Innovative Model of Clinician-	
O'Gran Patrick O'Gran Patrick	O'Gara	Patrick		Influence of Family History of Aortic Disease on Type B Aortic	Nothing to Disclose
Patrick Manabu Unasual Presentations of ACS Association Releven Presentation Time and Short-Term Mortality in Northing to Disclose	O'Gara	Patrick	Vascular Medicine: Aortic and Peripheral		Nothing to Disclose
Association Between Presentation Time and Short-Term Mortality in Nothing to Disclose Patients With Cardiogenic Shock Complicating Nothing Accordance Patients With Cardiogenic Shock Complicating Nothing Accordance Patients (Nothing Nothing Nothing Nothing Nothing to Disclose Patients (Nothing Nothin	O'Gara	Datrick		Suggested Paviower	Nothing to Disclose
Ogita Manabu Unusual Presentations of ACS Combined Serum Albumin and C-Rective Protein Levels Predict Levels Pr				Association Between Presentation Time and Short-Term Mortality in Patients With Cardiogenic Shock Complicating Acute Coronary	
Ogunbayo Golahan Arhythmias and Clinical EP- Devices 1 Copunbayo Golahan Population Specific Cardiomyopathies: From Exemption Population Specific Cardiomyopathies: From Exemption Population Specific Cardiomyopathies: From Exemption Population Specific Cardiomyopathies: From Exemption Population Specific Cardiomyopathies: From Exemption Population Specific Cardiomyopathies: From Exemption Population Specific Cardiomyopathies: From Exemption Population Specific Cardiomyopathies: From Reviscularization and Myocardial Preservation In Acute and Stable Ischemic Heart Disease Ogunbayo Golahan Arhythmias and Clinical EP- AF Miscellaneous and Surgical Issues Ogunbayo Golahan Arhythmias and Clinical EP- AF Miscellaneous and Surgical Issues Ogunbayo Golahan Arhythmias and Clinical EP- AF Miscellaneous and Surgical Issues Ogunbayo Golahan Arhythmias and Clinical EP- AF Miscellaneous and Surgical Issues Ogunbayo Golahan Arhythmias and Clinical EP- AF Miscellaneous and Surgical Issues Ogunbayo Golahan Arhythmias and Clinical EP- AF Miscellaneous and Surgical Issues Ogunbayo Golahan Arhythmia Arhy	Ogita	Manabu	Unusual Presentations of ACS	Combined Serum Albumin and C-Rective Protein Levels Predict Long-Term Outcomes in Patients With Coronary Artery Disease	Nothing to Disclose
Company Comp	Ogita	Manabu	CAD in Unique Patient Populations	Prognostic Impact of Geriatric Nutritional Risk Index in Patients	Nothing to Disclose
Cogunbayo Cholahan Population Specific Cardiomyopathies: From Exemes to Database Exemes to Database Armog Patients With HIV Revascularization and Myocardial Preservation Acute and Stable Isolation Acut	Ogunbayo	Gbolahan	Arrhythmias and Clinical EP: Devices 1	Characteristics and Clinical Predictors of 11,569 Pneumothoraces Associated With Cardiac Implantable Electronic Device Procedures:	Nothing to Disclose
Globlahan Revascularization and Myocardial Preservation in Acute and Stable between Heart Disease Myocardial Infarction: New Early is Too Early? Globlahan Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Infarction Arrhythmia in Arrhythmias Valvular Heart Disease: Arrhythmia Miscellaneous and Arrhythmias Arrhythmias Arrhythmias and Clinical EP: AF Miscellaneous and Arrhythmias and Clinical EP: AF Miscellaneous and Arrhythmias and Arrhythmias Arhythmias Arrhythmias Arrhythmias Arrhythmias Arrhythmias Arr	Ogunbayo	Gbolahan	Population Specific Cardiomyopathies: From Exomes to Databases	Racial Differences in Heart Failure Admissions & Outcomes	Nothing to Disclose
Arial Fibrilation: A CHAZDSZVASC Matched Analysis of Thromboembolic Outnobembolic Outn	Ogunbayo	Gbolahan	Revascularization and Myocardial Preservation	Coronary Artery Bypass Graft Surgery after Acute ST Elevation	Nothing to Disclose
Golahan	Ogunbayo	Gbolahan		Atrial Fibrillation: A CHA2DS2VASc Matched Analysis of	Nothing to Disclose
Spots	Ogunbayo	Gbolahan		Coronary Artery Bypass Graft Surgery With or Without Left Atrial Appendage (LAA) Excision for Atrial Fibrillation: A CHA2DS2VASc Matched Analysis of Thromboembolic Outcomes in a National	Nothing to Disclose
Association Between Asian Ethnicity and a Higher Rate of Blood Management and Outcomes Association Between Asian Ethnicity and a Higher Rate of Blood Management and Outcomes Innovation in Practice Management, Advocacy, and Education Innovation in Practice Management, Advocacy, and Education Innovation in Practice Management, Advocacy, and Education Innovation in Practice Management, Advocacy, and Education Innovation in Practice Management, Advocacy, and Education Innovation in Practice Management, Advocacy, and Education Innovation in Practice Management, Advocacy, and Education Innovation in Practice Management, Advocacy, and Education Innovation in Practice Management, Advocacy, and Education Innovation in Practice Management, Advocacy, and Education Innovation in Practice Management, Advocacy, and Education Innovation in Practice Management, Advocacy, and Education Innovation in Practice Management, Advocacy, and Education Innovation in Practice Management, Advocacy, and Education Innovation in Practice Management, Advocacy, and Education Innovation in Practice Management, Advocacy, and Education Innovation in Practice Management, Advocacy, and Education Information Innovation Patients With Mocardial Infarction Registery (KAMIR) Nothing to Disclose	Ogunbayo	Gbolahan		Outcomes of Intra-Aortic Balloon Pump Use in Myocarditis	Nothing to Disclose
Comparative Outcomes of Agiotensin-Converting Enzyme Inhibitor and Agrocacy and Education Novel Developments in Acute Coronary Syndromes Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Diabetic Hypertensive Acute Myocardial Infarction Registry (KAMIR)	Ogunbayo	Gbolahan	Acute Coronary Syndromes, Diagnosis,	Association Between Asian Ethnicity and a Higher Rate of Blood	Nothing to Disclose
On Dong Joo Novel Developments in Acute Coronary Syndromes Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Diabetic Hypertensive Acute Myocardial Infarction Patients: Results From the Korea Acute Myocardial Infarction Patients With Unprotected Left Main Coronary Artery Disease Oh Dong Joo Advances in Chronic Total Occlusion Intervention Occlusion Patients With Near-Normal Left Ventricular Function Oh II-Young Emerging Developments in HFpEF and Arrythmias With Mara-Normal Left Ventricular Function Oh Jae Echocardiographic Assessment of LV Diastolic Function — The New ASE/EACVI Guidelines — 2016 Update: Joint Symposium of the American Society of Echocardiography and the American College of Cardiology Oh Jae Innovative Use of Echocardiography Innovative Use of Echocardiography Comparative Outcomes of Angiotensin Receptor Blocker in Diabetic Hypertensive Auditorion Patients With Mora-Normal Patients With Word Infarction Patients With Infarction Patients With Infarction Patients With Near-Normal Left Ventricular Function Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Without Atrial Fibrillation Diastolic Assessment in Specific Entities: Atrial Fibrillation, Patients With Artial Fibrillation, Patients With Artery Disease On Hypertrophic Cardiomyopathy and Restrictive Disease On Hypertrophic Cardiomyopathy and Restrictive Disease On Hypertrophic Cardiomyopathy and Hemodynamic Features Infective Endocarditis Following Transcutaneous Aortic Valve Implantation: Clinical, Echocardiography and Hemodynamic Features Filing Pressures and Atrial Fibrillation/Flutter: A Simultaneous On High Patients With Elevated Left Filing Pressures and Atrial Fibrillation/Flutter: A Simultaneous	Ogunbayo	Gbolahan	Innovation in Practice Management, Advocacy,	Lets Put the Trials to a Test: A 23 Year Review of United States Food and Drug Administration (FDA) Records of Cardiovascular	Nothing to Disclose
Dong Joo Timely Topics in Acute Coronary Syndromes Predictors of Mortality in Acute Myocardial Infarction Patients With Nothing to Disclose Unprotected Left Main Coronary Artery Disease Unprotected Left Main Coronary Artery Disease Nothing to Disclose Unprotected Left Main Coronary Artery Disease Nothing to Disclose Nothing to Dis	Oh	Dong Joo		Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Diabetic Hypertensive Acute Myocardial Infarction Patients: Results From the Korea Acute	Nothing to Disclose
Oh Il-Young Emerging Developments in HFpEF and Arryhthmias Centrol Profice Industrial Centrol Profice Industrial Centrol Profice Industrial Centrol Industrial Centro	Oh	Dong Joo	Timely Topics in Acute Coronary Syndromes	Predictors of Mortality in Acute Myocardial Infarction Patients With	Nothing to Disclose
Oh II-Young Emerging Developments in HFpEF and Arryhthmias Arryhthmias Echocardiographic Assessment of LV Diastolic Function – The New ASE/EACVI Guidelines – 2016 Update: Joint Symposium of the American Society of Echocardiography and the American College of Cardiology Oh Jae Valvular Heart Disease: Endocarditis Innovative Use of Echocardiography Innovative Use of Echocardiography Risk of Stroke and Thromboembolism for Heart Failure With and Without Atrial Fibrillation, Houngard Systems (Without Atrial Fibrillation, Hypertrophic Cardiomyopathy and Restrictive Disease OTHER - Echo Core Lab for Medtronic Core Valve Infective Endocarditis Following Transcutaneous Aortic Valve Implantation: Clinical, Echocardiographic and Hemodynamic Features Oh Jae Innovative Use of Echocardiography Elé' > 15 Performs Poorly in Patients With Elevated Left Filling Pressures and Atrial Fibrillation/Flutter: A Simultaneous	Oh	Dong Joo		Impact of Percutaneous Coronary Intervention for Chronic Total	Nothing to Disclose
Oh Jae Echocardiographic Assessment of LV Diastolic Function - The New ASE/EACVI Guidelines - 2016 Update: Joint Symposium of the American Society of Echocardiography and the American College of Cardiology Oh Jae Valvular Heart Disease: Endocarditis Innovative Use of Echocardiography Innovative Use of Echocardiography Jae Innovative Use of Echocardiography Ele␁ > 15 Performs Poorly in Patients With Elevated Left Filling Pressures and Atrial Fibrillation/Flutter: A Simultaneous OTHER - Echo Core Lab for Medtronic Core Valve Inspiration: Clinical, Echocardiographic and Hemodynamic Features Ele␁ > 15 Performs Poorly in Patients With Elevated Left Filling Pressures and Atrial Fibrillation/Flutter: A Simultaneous	Oh	II-Young	Emerging Developments in HFpEF and	Risk of Stroke and Thromboembolism for Heart Failure With and	Nothing to Disclose
Implantation: Clinical, Echocardiographic and Hemodynamic Features Oh Jae Innovative Use of Echocardiography E/e' > 15 Performs Poorly in Patients With Elevated Left OTHER - Echo Core Lab for Medtronic Core Valve Filling Pressures and Atrial Fibrillation/Flutter: A Simultaneous	Oh	Jae	Echocardiographic Assessment of LV Diastolic Function The New ASE/EACVI Guidelines 2016 Update: Joint Symposium of the American Society of Echocardiography and the	Diastolic Assessment in Specific Entities: Atrial Fibrillation,	OTHER - Echo Core Lab for Medtronic Core Valve
Oh Jae Innovative Use of Echocardiography E/e␁ > 15 Performs Poorly in Patients With Elevated Left OTHER - Echo Core Lab for Medtronic Core Valve Filling Pressures and Atrial Fibrillation/Flutter: A Simultaneous	Oh	Jae	Valvular Heart Disease: Endocarditis	Implantation: Clinical, Echocardiographic and Hemodynamic	OTHER - Echo Core Lab for Medtronic Core Valve
	Oh	Jae	Innovative Use of Echocardiography	E/e' > 15 Performs Poorly in Patients With Elevated Left Filling Pressures and Atrial Fibrillation/Flutter: A Simultaneous	OTHER - Echo Core Lab for Medtronic Core Valve

Congress of the Congress of th				l
Oh	First Name Jae	Session Title Novel Determinants of Outcomes in VHD	Presentation Title Coexisting Co-Morbidities Exacerbate Left Ventricular Diastolic Dysfunction and Prognosis in Patients With Severe Aortic Stenosis	Disclosures OTHER - Echo Core Lab for Medtronic Core Valve
Oh	Pyung Chun	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Prognostic Value of Soluble ST2 in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention	Nothing to Disclose
Oh	Pyung Chun	Understanding Pulmonary Vascular Disease: From Bench to Bedside	Apelin-13 Co-Treatment With Umbilical Cord Blood-Derived Mesenchymal Stem Cells Improves Engrafted Cell Survival and Inhibits Macrophage Activation in Pulmonary Arterial Hypertension Murine Model	Nothing to Disclose
Oh	Pyung Chun	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Prognostic Impact of Alkaline Phosphatase Measured at the Time of Presentation in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Oh	Pyung Chun	Interventional Cardiology: Structural Heart Disease	Effect of PFO Closure for Prevention of Recurrent Stroke or TIA in Highly Selected Patients With Cryptogenic Stroke	Nothing to Disclose
Oh	Seil	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Treatment and Outcomes of Patients With Nonvalvular Atrial Fibrillation According to Guideline-Defined Anticoagulation Thresholds: Results From the GARFIELD-AF Registry	CONSULTANT FEES/HONORARIA - St. Jude Medical International
O'Hair	Daniel	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Valvuloplasty in Woman With Heterotaxy Syndrome	Nothing to Disclose
Ohman	Erik	Fellows Bootcamp: Coronary Disease Management	ACS: STEMI and Thrombus	CONSULTANT FEES/HONORARIA - Abbott Vascular/Abiomed AstraZeneca_Faculty Connection, Medscape_Merck & Amp;amp; Co., Inc.,St. Jude Medical_Stealth Pharmaceutical_The Medicines Company; DATA SAFETY MONITORING BOARD - Biotie, Boehringer Ingelheim Pharmaceuticals, Inc; RESEARCH/RESEARCH GRANTS - Daiichi Sankyo, Eli Lilly and Company,GILEAD Sciences, Janssen Pharmaceuticals
Ohman	Erik	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	A Randomized Trial Evaluating Clinically Significant Bleeding With Low-Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, for Patients After Acute Coronary Syndromes	CONSULTANT FEES/HONORARIA - Abbott Vascular/Abiomed AstraZeneca_Faculty Connection, Medscape, Merck & Amppamp; Co., Inc.,St. Jude Medical_Stealth Pharmaceutical, The Medicines Company; DATA SAFETY MONITORING BOARD - Biotie, Boehringer Ingelheim Pharmaceuticals, Inc; RESEARCH/RESEARCH GRANTS - Dailchi Sankyo, Eli Lilly and Company, GILEAD Sciences, Janssen Pharmaceuticals
Ohman	Erik	The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints	Defining Myocardial Infarction in ACS – Does the Size and Clinical Scenario Really Matter?	CONSULTANT FEES/HONORARIA - Abbott Vascular Abiomed ,AstraZeneca, Faculty Connection, Medscape, Merck & Amp, amp. Co., Inc.,St. Jude Medical, Stealth Pharmaceutical, The Medicines Company; DATA AAFETY MONITORING BOARD - Biotie, Boehringer Ingelheim Pharmaceuticals, Inc.; RESEARCH/RESEARCH GRANTS - Daiichi Sankyo, Eli Lilly and Company, GILEAD Sciences, Janssen Pharmaceuticals
Ohman	Erik	03. Acute and Stable Ischemic Heart Disease: Therapy Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular/Abiomed AstraZeneca_Faculty Connection, Medscape, Merck & Amppamp; Co., Inc.,St. Jude Medical_Stealth Pharmaceutical, The Medicines Company; DATA SAFETY MONITORING BOARD - Biotie, Boehringer Ingelheim Pharmaceuticals, Inc; RESEARCH/RESEARCH GRANTS - Dailchi Sankyo, Eli Lilly and Company, GILEAD Sciences, Janssen Pharmaceuticals
Ohman	Magnus	Featured Clinical Research III	Outcomes for 15,259 US Patients With Acute MI Cardiogenic Shock (AMICS) Supported With Impella	CONSULTANT FEES/HONORARIA - Abbott Vascular/Abiomed AstraZeneca, Faculty Connection, Medscape, Merck & Amp; amp; Co., Inc.,St. Jude Medical, Steatth Pharmaceutical, The Medicines Company; DATA SAFETY MONITORING BOARD - Biotie, Boehringer Ingelheim Pharmaceuticals, Inc; RESEARCH/RESEARCH GRANTS - Dailchi Sankyo,Eli Lilly and Company,GILEAD Sciences,Janssen Pharmaceuticals
Ohsawa	Naoto	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Primary Cardiac Lymphoma: Early Initiation of Chemotherapy Is Critical to Save Lives of Patients	Nothing to Disclose
Ohyama	Yoshiaki	Vascular Medicine: Novel Risk Measures in	Association of Coronary Artery Calcium With Incident Peripheral	Nothing to Disclose
Ohyama	Yoshiaki	Arterial Diseases Insights From Echocardiography Use	Artery Disease: The Multi-Ethnic Study of Atherosclerosis Relation of Left Ventricular Remodeling to Left Ventricular Diastolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	Nothing to Disclose
Ohyama	Yoshiaki	Insights From Echocardiography Use	Relation of Left Ventricular Remodeling to Left Ventricular Systolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	Nothing to Disclose
Ohye	Richard	Five Controversies in Single Ventricle Management	After 10 Years We Finally Know the Best Surgical Approach for Stage One Operation	Nothing to Disclose
Oikonomou	Evangelos	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Prognostic Implications of Epicardial Fat Volume Quantification in Acute Pericarditis	Nothing to Disclose
Oikonomou	Evangelos	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Omega-3 Polyunsaturated Fatty Acids May Favorably Affect Inflammatory Biomarkers & Novel Indices of Left Ventricle Function in Patients With Heart Failure	Nothing to Disclose
Oikonomou	Evangelos	MicroRNAs and Beyond in Vascular Medicine	Association of Endothelial Dysfunction and Arterial Wall Elastic Properties With Systemic Inflammation in Patients With Pseudoexfoliative Glaucoma	Nothing to Disclose
Oikonomou	Evangelos	Diabetes and Endothelial Dysfucntion in Heart Failure	Association of Endothelial Dysfunction With Biomarkers of Inflammation, Myocardial Fibrosis and Left Ventricle Strain in Patients With Heart Failure	Nothing to Disclose
Oikonomou	Evangelos	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Vascular Function of Conduit Arteries Is Associated With Progress of Diabetic Retinopathy in Type 2 Diabetes	Nothing to Disclose
Oikonomou	Evangelos	Vascular Access and Hemostasis Issues	Endothelial Dysfunction Post Transradial Access Coronary Catheterization: A Clinical Study and Meta-Analysis of Published Literature	Nothing to Disclose
Oikonomou Oikonomou	Evangelos Evangelos	From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Uncovering the Intricacies of Vascular Function	Dietary Consumption of Olive Oil and Cardiovascular Outcome in Patients With Coronary Artery Disease The Impact of Natural Chios Mastic Supplementation on Endothelial	Nothing to Disclose Nothing to Disclose
Ojala	Tina	Congenital Heart Disease: New Diagnostic	Function and Arterial Stiffness in Smokers Cardiovascular Health of Offspring of Diabetic Mothers From the	Nothing to Disclose
-		Approaches in Congenital Heart Disease	Fetus Through Late Infancy Stages	-
Ojo	Amole	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Sinus Node Dysfunction in Batten Disease: A Rare Manifestation of a Rare Disease	Nothing to Disclose
Ojo	Amole	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Valvular Surgery With or Without Left Atrial Appendage Excision for Atrial Fibrillation: A CHA2DS2VASc Matched Analysis of Thromboembolic Outcomes in a National Database	Nothing to Disclose
Ojo	Amole	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Coronary Artery Bypass Graft Surgery With or Without Left Atrial Appendage (LAA) Excision for Atrial Fibrillation: A CHAZDSZVASc Matched Analysis of Thromboembolic Outcomes in a National Database	Nothing to Disclose

The state of the s				
Last Name Ojo	First Name Amole	Session Title Interventional Cardiology: TAVR 4	Presentation Title Predictors of New Persistent Left Bundle Branch Block After	Disclosures Nothing to Disclose
Ojo	Amole	Innovation in Practice Management, Advocacy,	Edwards Sapien 3 Transcatheter Aortic Valve Replacement Lets Put the Trials to a Test: A 23 Year Review of United States	Nothing to Disclose
		and Education	Food and Drug Administration (FDA) Records of Cardiovascular Disease Clinical Trials	Ç
Okabe	Toshimasa	Arrhythmias and Clinical EP: Devices 2	Comprehensive Strategy to Reduce the Incidence of Lead Dislodgment for Cardiac Implantable Electronic Devices	Nothing to Disclose
Okabe	Toshitaka	Advances in Chronic Total Occlusion Intervention	The Impact of Recanalization of Chronic Total Occuluded Coronary Artery on Electrophysiological Substrate of Left Ventricle	Nothing to Disclose
Okabe	Toshitaka	Interventional Cardiology: PCI in Complex Patients	Chronic Stent Recoil During Follow-Up in Severely Calcified Coronary Artery Lesions: An Optical Coherence Tomography Study	Nothing to Disclose
Okada	Kozo	Head to Toe: Outcomes of Endovascular Interventions	Peri-Strut Low Intensity Area Predicts Neointimal Progression Associated With Late Enlargement of Self-Expanding Nitinol Stents in Superficial Femoral Arteries: An Optical Coherence Tomography Study	Nothing to Disclose
Okada	Mariana	Innovation in Practice Management, Advocacy, and Education	Improvement in Quality Indicators Using NCDR® Registries: First International Experience	Nothing to Disclose
Okasha	Nireen	Variations in Management of STEMI: International Perspectives From the Egyptian Society of Cardiology, Pakistan Cardiac Society, and American College of Cardiology	Management of STEMI in Egypt: Achievements and Challenges	Nothing to Disclose
Okin	Peter	Assessing the Clinical Impact of Blood Pressure Lowering Therapies	Effect of Antihypertensive Therapy on Development of Incident Conduction System Disease in Hypertensive Patients: The LIFE Study	Nothing to Disclose
Okin	Peter	Interventional Cardiology: TAVR 1	Baseline Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Increased Mortality After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Okogbue	ljeoma	Personalized Skills Center: Drill and Practice	Heart Songs Moderator	Nothing to Disclose
Okoh	Alexis	(Heart Songs, ECG, Hand-Held Echo) Interventional Cardiology: PCI and TAVR in Complex Patients	Non-Trans Femoral Trans Catheter Aortic Valve Replacement in Nonagenarians With Severe Aortic Stenosis: A Matched Case-	Nothing to Disclose
Okonko	Darlington	Making Progress in Understanding Heart Failure	Control Pilot Study Prognostic Utility of Haemoglobin/Haematocrit Equations for Estimating Congestion Versus Calculated Plasma Volume Status in	RESEARCH/RESEARCH GRANTS - Pharmacosmos; SPEAKER'S BUREAU - Pharmacosmos
Oktay	Ahmet	FIT Clinical Decision Making: Non-Invasive	Chronic Heart Failure Transcatheter Aortic Valve Replacement for Aortic Regurgitation as	Nothing to Disclose
Oktay	Ahmet	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	a Bridge for Combined Liver and Kidney Transplantation Use of TandemHeart as a Bridge to Surgery in a Patient With Combined Obstructive and Cardiogenic Shock Due to Mechanical	Nothing to Disclose
Okubagzi	Petros	Interventional Cardiology: TAVR 2	Mitral Valve Thrombosis Racial Dispartites and Temporal Trends in Demographics and Clinical Characteristics of Patients Screened for Transcatheter Aortic Valve Replacement	Nothing to Disclose
Okubagzi	Petros	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Noncovarive Reprocenses: Its There a Role for Invasive Electrophysiology Studies in Patients With Conduction Abnormalities Following Transcatheter Aortic Valve Replacement?	Nothing to Disclose
Okubo	Ryo	Novel Developments in Acute Coronary Syndromes	Left Ventricular End-Diastolic Pressure Predicts Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Independently of Left Ventricular Systolic Function	Nothing to Disclose
Okumura	Ken	Late-Breaking Clinical Trials	Safety and Efficacy of Uninterrupted Anticoagulation With Dabigatran Etexilate Versus Warfarin in Patients Undergoing Catheter Ablation of Atrial Fibrillation: The RE-CIRCUIT Study	Nothing to Disclose
Okwuosa	lke	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	HeartMate II Pump Stops: The Short to Short Phenomenon	Nothing to Disclose
Okwuosa	Tochi	FIT Clinical Decision Making: Non-Invasive	Fibrosing Mediastinitis-Related Pulmonary Artery and Vein Stenosis	Nothing to Disclose
Okwuosa	Tochi	Imaging and Valvular Heart Disease Updates on Risk Factors for Cardiovascular	Limiting Chemotherapy Associations Between Exercise Prior to and Around the Time of	Nothing to Disclose
		Disease	Cancer Diagnosis and Subsequent Cardiovascular Events in Women With Breast Cancer: A Women's Health Initiative (WHI) Analysis	
Ola	Olatunde	Innovation in Practice Management, Advocacy, and Education	Lets Put the Trials to a Test: A 23 Year Review of United States Food and Drug Administration (FDA) Records of Cardiovascular Disease Clinical Trials	Nothing to Disclose
Oldenburg	Olaf	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Surrogate Endpoints and the Differential Response to ASV for Sleep Apnea in HFrEF Versus HFpEF in the CAT-HF Trial	CONSULTANT FEES/HONORARIA - LIVANOVA,Novartis Corporation,Resmed; RESEARCH/RESEARCH GRANTS - Resmed
Oldenburg	Olaf	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Sleep Duration and Quality in Heart Failure Patients	CONSULTANT FEES/HONORARIA - LIVANOVA, Novartis Corporation, Resmed; RESEARCH/RESEARCH GRANTS - Resmed
Oldenburg	Rogier	Advances in HCM, PPCM and Other	Yield and Long-Term Outcome of Family Screening in Hypertrophic Cardiomyopathy	
Oldgren	Jonas	Cardiomyopathies Stroke and AF: Thinking About the Heart	Risk of Stroke in Women and Men With Atrial Fibrillation and Only	CONSULTANT FEES/HONORARIA - Bayer,Boehringer-
Oldroyd	Keith	Highlighted Original Research: Non Invasive Imaging and the Year in Review	One Additional CHA2DS2-VASc Risk Factor Prognostic Significance of Co-Existing Persistent Edema and Hemorrhage at 6 Months in Survivors of ST-Elevation Myocardial Infarction	Ingelheim, Bristol-Myers Squibb, Pfizer CONSULTANT FEES/HONORARIA - Astra Zeneca, Boston Scientific; DATA SAFETY MONITORING BOARD - Cardiac Dimensions; RESEARCH/RESEARCH GRANTS - St Jude
Oldroyd	Keith	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Decision Making Using Fractional Flow Reserve Is Associated With Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With	Medical CONSULTANT FEES/HONORARIA - Astra Zeneca, Boston Scientific; DATA SAFETY MONITORING BOARD - Cardiac Dimensions; RESEARCH/RESEARCH GRANTS - St Jude
Oldroyd	Keith	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Nstemi Segmental Circumferential Strain Derived From DENSE Predicts Improvement of Left Ventricular Function Post ST Elevation Myocardial Infarction: The BHF MR-MI Study	Medical CONSULTANT FEES/HONORARIA - Astra Zeneca,Boston Scientific; DATA SAFETY MONITORING BOARD - Cardiac Dimensions; RESEARCH/RESEARCH GRANTS - St Jude Medical
Oldroyd	Keith	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Intravascular Ultrasound Assessment of the Effects of Rotational Atherectomy in Calcified Coronary Artery Lesions	ONSULTANT FEES/HONORARIA - Astra Zeneca,Boston Scientific; DATA SAFETY MONITORING BOARD - Cardiac Dimensions; RESEARCH/RESEARCH GRANTS - St Jude Medical
Oldroyd	Keith	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Current Smoking, Microvascular Pathology and Adverse Outcome After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights	CONSULTANT FEES/HONORARIA - Astra Zeneca,Boston Scientific; DATA SAFETY MONITORING BOARD - Cardiac Dimensions; RESEARCH/RESEARCH GRANTS - St Jude Medical
Oldroyd	Keith	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	incidence and Prognostic Implications of the Presence of Multiple Complex Plaques in Survivors of ST-Elevation Myocardial Infarction	CONSULTANT FEES/HONORARIA - Astra Zeneca,Boston Scientific; DATA SAFETY MONITORING BOARD - Cardiac Dimensions; RESEARCH/RESEARCH GRANTS - St Jude Medical
Oldroyd	Keith	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Hypertension, Microvascular Pathology and Prognosis in Patients With an Acute ST-Segment Elevation Myocardial Infarction	CONSULTANT FEES/HONORARIA - Astra Zeneca,Boston Scientific; DATA SAFETY MONITORING BOARD - Cardiac Dimensions; RESEARCH/RESEARCH GRANTS - St Jude Medical
				· · · · · · · · · · · · · · · · · · ·

and the second				<u> </u>
Last Name O'Leary	First Name Edward	Session Title Innovative Use of Echocardiography	Presentation Title The Predictive Value of Microvascular Defects Observed During	Disclosures CONSULTANT FEES/HONORARIA - Volcano Corporation
O Louiy	Loward	iniovative osc of Echocardiography	Demand Stress Myocardial Contrast Echocardiography and Quantitative Measurements of Stenosis and Microvascular	CONSCENSIVE ELECTRONICIONALE VOICE LE COMPONICION
O'Leary	Jared	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Resistance Obtained During Invasive Hemodynamics Lack of a Tricuspid Regurgitation Velocity and Pulmonary Hypertension: Absence of Evidence Is Not Evidence of Absence	Nothing to Disclose
O'Leary	Jared	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Ebstein's Anomaly: Atypical Variant Presenting in Adulthood	Nothing to Disclose
O'Leary	Jared	FIT Clinical Decision Making: Arrhythmias and	Catecholaminergic Polymorphic Ventricular Tachycardia and Peri-	Nothing to Disclose
O'Leary	Patrick	Electrophysiology Congenital Heart Disease: Innovations in	Partum Cardiomyopathy: A Perfect Sympathetic Storm? Association of Increased Total Atrial Volume With Clinical Heart	Nothing to Disclose
Olenchock	Ben	Single Ventricle Heart Disease Evolution of Critical Care Cardiology and the CICU	Failure Status in Hypoplastic Left Heart Syndrome 1. Finding Mentorship and Research Opportunities in Critical Care Cardiology	CONSULTANT FEES/HONORARIA - Bristol-Myers Squibb Company ,Fulcrum Therapeutics
Olet	Susan	Advances in HCM, PPCM and Other Cardiomyopathies	Marked Respiratory Related Variation in LVOT Gradients in Hypertrophic Cardiomyopathy in Obese HCM Patients With Sleep- Disordered Breathing	Nothing to Disclose
Olet	Susan	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	incremental Value of Estimated Glomerular Filtration Rate in Improving Stroke Risk Stratification in Patients With and Without Atrial Fibrillation Considered to Be Low Risk by CHAcsub>2DS ₂ VASc Score	Nothing to Disclose
Olet	Susan	Mechanisms of Vascular Inflammation in Atherogenesis	Comparative Study on Catheter-Directed Thrombolysis - Continuous Tissue Plasminogen Activator Versus Angiojet Catheter Power Pulse Spray Rheolytic Thrombectomy Outcome Study: Single- Center Experience	Nothing to Disclose
Olin	Jeffrey	Vascular Diagnoses Cardiologists Should not Miss: A Case-based Approach	Co-Chair	CONSULTANT FEES/HONORARIA - Fibromusuciar Dysplasia Society of America (Non Profit): OTHER - Astra Zenica; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Northwind; RESEARCH/RESEARCH GRANTS - Astra Zenica
Olin	Jeffrey	Vascular Diagnoses Cardiologists Should not Miss: A Case-based Approach	Case Presentation: Young Woman with Myocardial Infarction	CONSULTANT FEES/HONORARIA - Fibromusuclar Dysplasia Society of America (Non Profit): OTHER - Astra Zenica; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Northwind; RESEARCH/RESEARCH GRANTS - Astra Zenica
Olivecrona	Goran	Novel Developments in Acute Coronary Syndromes	Prehospital Administration of Heparin Reduces the Risk of Vessel Occlusion in Patients With ST Elevation Myocardial Infarction: Secondary Analysis of the TASTE Trial	CONSULTANT FEES/HONORARIA - Edwards Lifesciences, EPS Vascular; OTHER - Biosensors; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - All of It; SPEAKER'S BUREAU - Aztrazeneca BBraun
Oliveira	Guilherme	Emerging Applications of Echocardiography	Trends in Cardiac Imaging in Patients Receiving Cardiotoxic Chemotherapy	CONSULTANT FEES/HONORARIA - AMGEM,Novartis,St. Jude Medical
Oliveira	Guilherme	14. Heart Failure and Cardiomyopathies:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - AMGEM,Novartis,St. Jude Medical
Oliver	Beth	Therapy Team 3 Innovations in Advocacy and Patient Centered	Interventional Cardiology Nurses Perceptions of Their Work	Nothing to Disclose
Oliver	Beth	Care Innovations in Advocacy and Patient Centered	Environment Cardiology Nurse Practitioners' Structural Empowerment and Job	Nothing to Disclose
Olivier	Christoph	Care Post-CAD/MI: Making Tough Predictions About	Satisfaction One-Year Mortality Increased in Patients With Peri-Procedural	Nothing to Disclose
Olivieri	Laura	the Future Non Invasive Imaging: MR Characterization	Myocardial Infarction: Insights From the CHAMPION Trials Validation of CMR-Derived Left Ventricular Strain Measurements by	Nothing to Disclose
Olorunfemi	Odunayo	and Function Arrhythmias and Clinical EP: Devices 1	Free-Breathing Motion-Corrected Cine Imaging Characteristics and Clinical Predictors of 11,569 Pneumothoraces	Nothing to Disclose
			Associated With Cardiac Implantable Electronic Device Procedures: Results From a Large National Database	-
Olorunfemi	Odunayo	Population Specific Cardiomyopathies: From Exomes to Databases	Racial Differences in Heart Failure Admissions & Outcomes Among Patients With HIV	Nothing to Disclose
Olorunfemi	Odunayo	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Coronary Artery Bypass Graft Surgery after Acute ST Elevation Myocardial Infarction: How Early is Too Early?	Nothing to Disclose
Olorunfemi	Odunayo	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Sinus Node Dysfunction in Batten Disease: A Rare Manifestation of a Rare Disease	Nothing to Disclose
Olorunfemi	Odunayo	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Valvular Surgery With or Without Left Atrial Appendage Excision for Atrial Fibrillation: A CHA2DS2VASc Matched Analysis of	Nothing to Disclose
Olorunfemi	Odunayo	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Thromboembolic Outcomes in a National Database Coronary Artery Bypass Graft Surgery With or Without Left Atrial Appendage (LAA) Excision for Atrial Fibrillation: A CHA2DS2VASc Matched Analysis of Thromboembolic Outcomes in a National	Nothing to Disclose
Olorunfemi	Odunayo	Heart Failure and Cardiomyopathies: What	Database Outcomes of Intra-Aortic Balloon Pump Use in Myocarditis	Nothing to Disclose
Olorunfemi	Odunayo	Next When All Else Is Failing? Acute Coronary Syndromes, Diagnosis,	Complicated by Cardiogenic Shock Association Between Asian Ethnicity and a Higher Rate of Blood	Nothing to Disclose
Olorunfemi	Odunayo	Management and Outcomes Innovation in Practice Management, Advocacy, and Education	Transfusion in ST-Elevation Myocardial Infarction Lets Put the Trials to a Test: A 23 Year Review of United States Food and Drug Administration (FDA) Records of Cardiovascular	Nothing to Disclose
Olsen	Flemming Javier	Emerging Applications of Echocardiography	Disease Clinical Trials Ratio of Transmittal Early Filling Velocity to Early Diastolic Strain Rate Predicts Long Term Risk of Cardiovascular Morbidity and	Nothing to Disclose
Olsen	Flemming Javier	Innovative Use of Echocardiography	Mortality in a Low Risk General Population Usefulness of Left Ventricular Speckle Tracking Echocardiography in Diagnosing Paroxysmal Atrial Fibrillation in Ischemic Stroke and	Nothing to Disclose
Olsen	Flemming Javier	Innovative Use of Echocardiography	Transient Ischemic Attack Patients Presence of Post-Systolic Shortening by Tissue Doppler Imaging is an Independent Predictor of Heart Failure in Patients Following ST-Seament Elevation Myocardial Infarction	Nothing to Disclose
Olsen	Flemming Javier	Insights From Echocardiography Use	Segment Elevation Myocardial Infarction	Nothing to Disclose
Olsen	Michael	Making Progress in Understanding Heart Failure	Disease Diagnostics in Patients with Stable Angina Pectoris NT-proBNP, Left Ventricular Structure and Function, and Long- Term Cardiovascular Events: Insights From a Prospective Population-Based Cohort Study	OTHER - AstraZeneca Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc
Olsen	Michael	Emerging Developments in HFpEF and Arryhthmias	Left Ventricular Hypertrophy and Subsequent Cardiovascular Risk: Does It Matter How It Is Diagnosed?	OTHER - AstraZeneca Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals. Inc
Olsen	Michael	The Evolving World of LVADs, Transplant and Other Novel Discoveries	High-Sensitivity Troponin-T, Left Ventricular Size and Function, and Long-Term Outcomes in Clinically Stable, Apparently Healthy Older Subjects	OTHER - AstraZeneca Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc
Olsen	Peter Skov	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Short- and Long-Term Cause of Death Following Coronary Artery Bypass Grafting in a Cohort of 33,980 Patients: A Nationwide Study	Nothing to Disclose
Olshansky	Brian	Syncope: What's New	Syncope: When to Worry	CONSULTANT FEES/HONORARIA - Boehringer Ingleheim, Daiichi Sankyo, Lundbeck Inc., On-X; DATA SAFETY MONITORING BOARD - Amarin
Olshansky	Brian	Arrhythmias and Clinical EP: Ventricular Tachycardia	Impact of Arrhythmia Duration and Index Left Ventricular Ejection Fraction on Recovery of Left Ventricular Function in Patients With	CONSULTANT FEES/HONORARIA - Boehringer Ingleheim,Daiichi Sankyo,Lundbeck Inc.,On-X; DATA SAFETY

Contract of the second				<u> </u>
Clshansky	First Name Brian	Session Title FIT Clinical Decision Making: Non-Invasive	Presentation Title Persistent Left Atrial Appendage Thrombus in the Setting of an	Disclosures CONSULTANT FEES/HONORARIA - Boehringer
Olehaneku	Brian	Imaging and Valvular Heart Disease	Indolent Glioblastoma Multiforme	Ingleheim, Daiichi Sankyo, Lundbeck Inc., On-X; DATA SAFETY MONITORING BOARD - Amarin CONSULTANT FEES/HONORARIA - Boehringer
Olshansky	Бпап	Arrhythmias and Clinical EP: AF Ablation	Novel Oral Anticoagulant Discontinuation Before Atrial Fibrillation Ablation and Excessive Heparin Requirements	Ingleheim, Daiichi Sankyo, Lundbeck Inc., On-X; DATA SAFETY MONITORING BOARD - Amarin
Olshansky	Brian	Atrial Fibrillation and VT: Unique Populations and Solutions	Predictors of Anticoagulant Prescription in Patients With Atrial Fibrillation in North America: The GLORIA-AF Registry	CONSULTANT FEES/HONORARIA - Boehringer Ingleheim,Daiichi Sankyo,Lundbeck Inc.,On-X; DATA SAFETY MONITORING BOARD - Amarin
Olshansky	Brian	06. Arrhythmias and Clinical EP: Other Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boehringer Ingleheim, Daiichi Sankyo, Lundbeck Inc., On-X; DATA SAFETY MONITORING BOARD - Amarin
Olshove	Vincent	Congenital Heart Disease: Advances in Quality Improvement for Pediatric Cardiac Care	Making Perioperative Handoff Communication Count by Improving Safety and Quality in a New Congenital Heart Program	Nothing to Disclose
Olson	Kristoff	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Sudden Cardiac Death Risk Distribution in the United States Population: Results From the National Health and Nutrition Examination Survey (NHANES), 2005-2012	Nothing to Disclose
Olson	Thomas	Emerging Developments in HFpEF and Arryhthmias	The Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: An Invasive-Echocardiographic Study	Nothing to Disclose
Olson	Thomas	Emerging Developments in HFpEF and Arryhthmias	Arterial Reserve Limitations in Heart Failure With Preserved Ejection Fraction and the Beneficial Effects of Sodium Nitrite	Nothing to Disclose
Olson	Thomas	Emerging Developments in HFpEF and	Utility of Cardiopulmonary Exercise Testing to Diagnose and	Nothing to Disclose
Olson	Timothy	Arryhthmias Predicting Outcomes in Pediatric Heart Disase	Phenotype Heart Failure With Preserved Ejection Fraction Growth Dynamics of Aorta in Bicuspid Aortic Valve Patients From	Nothing to Disclose
Olusanya	Adebayo	FIT Clinical Decision Making: Heart Failure and	Infancy to Young Adult Age Use of Pharmacomechanical Thrombectomy in a Patient With	Nothing to Disclose
Olusanya	Adebayo	Pulmonary Hypertension Atrial Fibrillation and VT: Incorporating Novel	Acute Pulmonary Embolism and Imminent Hemodynamic Collapse at Very High Risk for Cerebral Hemorrhage Comparison of In-Hospital Outcomes of Septic Shock Patients With	Nothing to Disclose
-		Risks Toward Decision Making	and Without Atrial Fibrillation: A Retrospective Propensity-Matched Analysis	-
O'Malley	Ryan	Interventional Cardiology: TAVR 1	The Inflammasome Pathway Is Associated With Adverse Ventricular Remodeling Following Transcatheter Aortic Valve Replacement	Nothing to Disclose
Omar	Abdullah	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Biventricular Stress Induced Cardiomyopathy Managed With Impella CP and Pulmonary Vasodilators	Nothing to Disclose
Omar	Al Fazir	From Cardiovascular Risk Factors to Acute and Stable Coronary Syndrome: International Perspectives From the Inter-American Society of Cardiology, National Heart Association of Malaysia, and American College of Cardiology	Perils and Rewards in Building a STEMI Network - Lessons From the Malaysian STEMI Network "MySTEMI"	Nothing to Disclose
Omar	Alaa	Innovative Use of Echocardiography	Concordance of Conventional 2D-Doppler Versus Speckle Tracking Echocardiography-Based Classification of Left Ventricular Diastolic Function	Nothing to Disclose
Omar	Hesham	Coronary Intervention in Interventional Cardiology: Advanced Device Use	QRS Duration Alterations After Left Ventricular Assist Device Implantation in Patients With Advanced Heart Disease	Nothing to Disclose
Omar	Hesham	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	The Benign Nature of Discharge Hyponatremia in Heart Failure Patients With Normal Admission Sodium: Analysis From the ESCAPE Trial	Nothing to Disclose
Omar	Wally	Emerging Developments in HFpEF and Arryhthmias	Implantable Cardioverter Defibrillators for the Prevention of Mortality in Patients With Non-Ischemic Cardiomyopathy: A Meta-Analysis of Randomized Control Trials	Nothing to Disclose
Omeara	Eileen	Emerging Developments in HFpEF and Arryhthmias	Influence of Left Ventricular Ejection Fraction on Cause-Specific Mortality in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial	Nothing to Disclose
Omer	Mohamed	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	A Challenging Cardiomyopathy Diagnosis: Do Not Be Anchored by an Initial Impression	Nothing to Disclose
Omid-Fard	Nima	Non Invasive Imaging: Prognostic Implications of CT Angiography	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	Nothing to Disclose
Omiya	Kazuto	Arrhythmias and Clinical EP: Devices 4	A New Suture Material in the Field of Cardiac Device Implantation	Nothing to Disclose
Omland	Torbjorn	Heart Failure and Cancer Care	Debate: Every Patient Should be Started on an ACE-Inhibitor or Angiotensin Receptor Blocker to Mitigate Cardiomyopathy with Cancer Therapy, Pro	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Novaris Corporation, Roche Diagnostics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cardillor; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, AstraZeneca
Ommen	Steve	How Hypertrophic Cardiomyopathy Became A Contemporary Treatable Genetic Heart Disease	Panelist	Nothing to Disclose
Omondi	Arthur	Markers of Prognosis Associated With Elevated Blood Pressure	Prevalence and Prognostic Significance of Cardiac Troponin-T Elevation in Patients Admitted With Hypertensive Crises	Nothing to Disclose
Omondi	Arthur	Antithrombotic Therapy in Ischemic Heart Disease	Role of Anticoagulation Therapy After Anterior Wall ST-Elevation Myocardial Infraction in Preventing LV Thrombus: A Meta-Analysis	Nothing to Disclose
Omondi	Arthur	Beans, Beans, Good for Your Heart	and Meta-Regression Percutaneous Renal Denervation for Resistant Hypertension: An Updated Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Omran	Jad	FIT Clinical Decision Making Reviewers 7	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
O'Murchu	Brian	New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology	FFR to Prevent Inappropriate Coronary Revascularization: Can Data Rehabilitate the Zealous Stake Holders?	Nothing to Disclose
O'Murchu	Brian	Infectious Endocarditis: Comprehensive Perspectives	ACC Poster Moderator	Nothing to Disclose
O'Neill	Brian	Great Minds Think Differently: Multidisciplinary	Pre-procedure Planning: Case Based Imaging. Tricuspid	Nothing to Disclose
O'Neill	Kellen	Approach to Imaging Insights From Echocardiography Use	Regurgitation Trends and Use of Echocardiography in Patients With '>Staphylococcus Aureus Bacteremia: An Analysis Using the Nationwide Inpatient Sample (NIS) Data	Nothing to Disclose
O'Neill	William	Featured Clinical Research III	Nationwide Inpatient Sample (NIS) Data Outcomes for 15,259 US Patients With Acute MI Cardiogenic Shock (AMICS) Supported With Impella	CONSULTANT FEES/HONORARIA - Abbott, Boston Scientific, Edwards Lifesciences, MEDTRONIC; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - neovasc inc
O'Neill	William	Overuse, Underuse or Just Right? Fundamental Debates in High Risk PCI in 2017	Hemodynamic Support for High Risk PCI: Critical for Patients and Providers	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,Edwards Lifesciences,MEDTRONIC; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE -
				neovasc inc



WASHINGTON, DC | MARCH 17 - 19 2017

Last Name	First Name	Session Title	Presentation Title	Disclosures
O'Neill	William	The Evolution of Angioplasty 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	The Evolution of ACS/STEMI Care and Adjunct Pharmacotherapy	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,Edwards Lifesciences,MEDTRONIC; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - neovasc inc
O'Neill	William	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Innovative Technique to Achieve Hemostasis With Large Bore Access for Percutaneous Hemodynamic Support Devices	CONSULTANT FEES/HONORARIA - Abbott, Boston Scientific, Edwards Lifesciences, MEDTRONIC; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - neovasc inc
O'Neill	William	Interventional Cardiology: TAVR 2	Death and Dialysis Risk After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,Edwards Lifesciences,MEDTRONIC; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - neovasc inc
O'Neill	William	Valvular Heart Disease: Aortic Stenosis	Outcomes and Their Predictors in Acute Transcatheter Aortic Heart Valve-in-Transcatheter Aortic Heart Valve Therapy	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,Edwards Lifesciences,MEDTRONIC; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - neovasc inc
O'Neill	William	Interventional Cardiology: Structural Heart Disease	Transcatheter Mitral Valve-in-Ring Implantation After Failure of Surgical Mitral Ring Annuloplasty	CONSULTANT FEES/HONORARIA - Abbott, Boston Scientific, Edwards Lifesciences, MEDTRONIC; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - neovasc inc
O'Neill	William	Interventional Cardiology: TAVR 3	Predictors of Late Bleeding in the TAVR Population	CONSULTANT FEES/HONORARIA - Abbott,Boston Scientific,Edwards Lifesciences,MEDTRONIC; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - neovasc inc
O'Neill	William	21. Interventional Cardiology: Coronary Intervention: Devices Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott, Boston Scientific, Edwards Lifesciences, MEDTRONIC; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - neovasc inc
Ong	Geraldine	Aortic Stenosis: Overview of the	Case: Moderate Aortic Stenosis with Reduced EF	Nothing to Disclose
Ong	Jeanne	Hemodynamics and Ventricular Response Acute Coronary Syndromes, Diagnosis,	Impact of Mild Obstructive Sleep Apnea on and Cardiovascular	Nothing to Disclose
Ong	Peter	Management and Outcomes Unusual Presentations of ACS	Events After Percutaneous Coronary Intervention Gender Differences in Patients With Vasomotor Disorders	CONSULTANT FEES/HONORARIA - Bayer Healthcare
Onishi	Takayuki	New Perspectives on CAD Risk Factors	According to Acetylcholine Provocation in a European Population Index of Microcirculatory Resistance for Predicting Severity of Myocardial Injury and Cardiac Function After ST-Segment Elevation Myocardial Infarction: A Cardiac Magnetic Resonance Imaging	Pharmaceuticals,Berlin Chemie Nothing to Disclose
Onishi	Yuko	New Perspectives on CAD Risk Factors	Study Index of Microcirculatory Resistance for Predicting Severity of Myocardial Injury and Cardiac Function After ST-Segment Elevation Myocardial Infarction: A Cardiac Magnetic Resonance Imaging	Nothing to Disclose
Onitsuka	Ken	Unusual Presentations of ACS	Study Clinical Characteristics and In-Hospital Mortality of Very Elderly Patients With Cardiovascular Shock in Japan: The Results From Japanese Circulation Society Shock Registry	Nothing to Disclose
Ono	Masamichi	Finding Out What Works in Pediatric and Congenital Heart Disease	Morphological Appearance and Repair Strategies of Tricuspid Regurgitation in Patients With Univentricular Heart and a Systemic Right Ventricle	Nothing to Disclose
Onodera	Tomoya	Coronary Intervention in Interventional	Superiority of Everolimus-Eluting Stents Over Sirolimus-Eluting	Nothing to Disclose
Ontiveros Mercado	Heriberto	Cardiology: Core Concepts ACC International Conferences Best Posters	Stents in Long-Term Safety and Efficacy Macrophage Migration Inhibitory Factor Serum Levels and Its Association With Acute Coronary Syndrome in Patients With Diabetes Mellitus Type 2 From Western Mexico	Nothing to Disclose
Onuma	Yoshinobu	Updates in Stable Ischemic Heart Disease	Coronary Calcification as a Mechanism of Plaque/Media Shrinkage: A Multimodality Intracoronary Imaging Study	Nothing to Disclose
Onuma	Yoshinobu	Coronary Intervention: Drug Eluting Stent and Scaffolds	Early, Late and Very Late Incidence of Bioresorbable Scaffold Thrombosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials and Observational Registries	Nothing to Disclose
Ooi	Henry	Interdisciplinary Cardiovascular Team Collaboratives in Care	Intravenous Furosemide in the Ambulatory Setting for the Management of a Complex Heart Failure Patient	Nothing to Disclose
Oparil	Suzanne	Hypertension: Evolving Evidence, Changing Guidelines	Co-Chair	CONSULTANT FEES/HONORARIA - Actelion Clinical Researci (essential HTN/resistant HTN AdBd; 06/2016); Lundbeck (Neurogenic Orthostatic Hypotension AdBd; 04/2016); Novo Nordisk, Inc. (GLP-1 Cardiology AdBd; 10/2016); OTHER - NIH/NHLBI, WHF/ESH/EPH, and Takeda; RESEARCH/RESEARCH GRANTS - AstraZeneca AB (Duke Univ), Bayer Healthcare Pharmaceuticals, Inc., NIH/NHLBI, WHLBI (Brigham and Women's Hosp. Chr CVD Prev), Novartis
Oparil	Suzanne	Controversies in Hypertension	Should We Rely on Office Based BP Measurement? No!	CONSULTANT FEES/HONORARIA - Actelion Clinical Researc (essential HTN/resistant HTN AdBd; 06/2016); Lundbeck (Neurogenic Orthostatic Hypotension AdBd; 04/2016); Novo Nordisk, Inc. (GLP-1 Cardiology AdBd; 10/2016); OTHER - NIH/NHLBI, WHF/ESHLEPH, and Takeda; RESEARCH/RESEARCH GRANTS - AstraZeneca AB (Duke Univ), Bayer Healthcare Pharmaceuticals, Inc., NIH/NHLBI, WHLBI (Brigham and Women's Hosp. Chr CVD Prev), Novartis
Oparil	Suzanne	Feeling the Pressure - Tough Cases in Hypertension	Panelist	CONSULTANT FEES/HONORARIA - Actelion Clinical Researci (essential HTN/resistant HTN AdBd; 06/2016); Lundbeck (Neurogenic Orthostatic Hypotension AdBd; 04/2016); Novo Nordisk, Inc. (GLP-1 Cardiology AdBd; 10/2016); OTHER - NIH/NHLBI, WHF/ESH/EPH, and Takeda; RESEARCH/RESEARCH GRANTS - AstraZeneca AB (Duke Univ), Bayer Healthcare Pharmaceuticals, Inc., NIH/NHLBI, NHLBI (Brigham and Women's Hosp. Cntr CVD Prev), Novartis
Oparil	Suzanne	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Antihypertensive Treatment Failure Not Attributable to Persistent Intravascular Fluid Retention as Determined by MRI-Measured Intracardiac Volumes	CONSULTANT FEES/HONORARIA - Actelion Clinical Researc (essential HTN/resistant HTN AdBd; 06/2016); Lundbeck (Neurogenic Orthostatic Hypotension AdBd; 04/2016); Novo Nordisk, Inc. (GLP-1 Cardiology AdBd; 10/2016); OTHER - NIH/NHLBI, WHF/ESHLEPH, and Takeda; RESEARCH/RESEARCH GRANTS - AstraZeneca AB (Duke Univ), Bayer Healthcare Pharmaceuticals, Inc., NIH/NHLBI, WHLBI (Brigham and Women's Hosp. Chr CVD Prev), Novartis
Oparil Opolski	Suzanne	33. Prevention: Hypertension Team 2 Coronary Angiography Intra-Vascular Imaging	Suggested Reviewer First Serial 12- and 24-Month Optical Coherence Tomography	CONSULTANT FEES/HONORARIA - Actelion Clinical Researc (essential HTN/resistant HTN Addb; 06/2016); Lundbeck (Neurogenic Orthostatic Hypotension Addb; 04/2016); Novo Nordisk, Inc. (GLP-1 Cardiology Addb; 10/2016); OTHER - NIH/NHLBI, WHF/ESH/EPH, and Takeda; RESEARCH/RESEARCH GRANTS - AstraZeneca AB (Duke Univ), Bayer Healthcare Pharmaceuticals, Inc., NIH/NHLBI, NHLBI (Brigham and Women's Hosp. Cntr CVD Prev), Novartis Nothing to Disclose
- Сроюн	5.20g0i2	Revascularization and Outcomes	Assessment of Stemi Patients After the Generation of Absorb	Tourney to Discisse
	1	1	Bioresorbable Vascular Scaffold Implantation	

Opotowsky	First Name Alexander	Session Title Things That Matter in Adult Congenital Heart Disease	Presentation Title Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult	Disclosures RESEARCH/RESEARCH GRANTS - Actelion Pharmaceuticals,Roche Diagnostics
Oral	Hakan	FIT Clinical Decision Making: Arrhythmias and	Congenital Heart Biobank Risk Stratification of Sudden Cardiac Death in Hypertrophic	CONSULTANT FEES/HONORARIA - Acutus; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Oral	Hakan	Electrophysiology 08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Cardiomyopathy Suggested Reviewer	CONSULTANT FEES/HONORARIA - Acutus; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Orban	Mathias	Frontiers in Mitral Valve Disease and Treatment	Transcatheter Treatment of Severe Tricuspid Regurgitation Using the MitraClip System in Patients With and Without Pacemaker	Nothing to Disclose
Oren	Michal	Making Progress in Understanding Heart	Leads Clinical Trials of Cardiotoxicity in Breast Cancer	Nothing to Disclose
Oren	Ohad	Failure Making Progress in Understanding Heart	Clinical Trials of Cardiotoxicity in Breast Cancer	Nothing to Disclose
Orgeron	Gabriela	Failure Ventricular Arrhythmias and Sudden Death Prevention	Appropriate Implantable Cardioverter Defibrillator Interventions in Probands and Family Members With Arrhythmogenic Right Ventricular Cardiomyopathy Dysplasia	Nothing to Disclose
Orkaby	Ariela	Updates on Risk Factors for Cardiovascular Disease	Walking Pace Is Inversely Associated With Risk of Death and Cardiovascular Disease: The Physicians' Health Study	Nothing to Disclose
Orkaby	Ariela	Emerging Developments in HFpEF and Arryhthmias	Serum Sodium Is Associated With Mortality in Heart Failure With	Nothing to Disclose
Oropeza-Almazan	Yuriana	Diabetes and Endothelial Dysfucntion in Heart Failure	Preserved Ejection Fraction in the U.S. Veteran Population Hypothyroidism Modulates Mitochondrial Calcium Uniporter Expression and Causes Cardioprotection Decresing Mitochondrial Permeability Transition Pore Opening	Nothing to Disclose
O'Rourke	Daniel	Highlights in Vascular Medicine Research	Cancer and Arterial Thrombosis Risk: Insights From the 2012 National Inpatient Sample	Nothing to Disclose
Orr	Nicole	Cardiac Rehab in 2017: Tailoring The Approach to the Times	Panelist Panelist	Nothing to Disclose
Orringer	Carl	Coming to Consensus in a New Era: The Role of Non-statin Therapies in ASCVD Risk	Panelist	Nothing to Disclose
Ordinana	0-4	Reduction	Milest Websel according the Deat There Veges Frage Cuideling to	Nething to Displace
, and the second	Carl	Recent Trends in Combination Therapy: Managing Cholesterol Even in the Most Resistant	What We've Learned in the Past Three Years: From Guideline to Consensus Pathway	Nothing to Disclose
Ortel	Thomas	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	The Effect of Race on the Antiplatelet Effects of Ticagrelor and Aspirin	CONSULTANT FEES/HONORARIA - Instrumentation Laboratories
	Daniel	Interventional Complexity and Complications	Percutaneous Femoral Artery Access Strategies in Patients Undergoing Peripheral Vascular Intervention: Trends of Use and In- Hospital Outcomes	Nothing to Disclose
Ortiz	Daniel	Insights From Echocardiography Use	Gabapentinoids Therapy Is Associated With Higher Doses of Atropine and Dobutamine in Stress Echocardiography	Nothing to Disclose
Ortiz	Daniel	Percutaneous Coronary Intervention: Lessons From the Real World	Outcomes in Patients Undergoing Cardiac Catheterization and Therapeutic Hypothermia After Cardiac Arrest	Nothing to Disclose
Orvin	Katia	Refining TAVR Outcomes	The Association of Coronary Artery Disease Severity and Pre Procedural Completeness of Revasclarization on Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Osawa	Kazuhiro	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Impact of Cardiac Troponin I on the Presence of the Coronary Artery Plaque in Rheumatoid Arthritis patients	Nothing to Disclose
Osawa	Kazuhiro	Non Invasive Imaging: Expanding Clinical Applications	The Utility of Left Atrial Appendage Hounsfield Unit and the Ratio of Left Atrial Appendage/Ascending Aorta Hounsfield Unit for Detecting Left Atrial Appendage Thrombus	Nothing to Disclose
Osawa	Kazuhiro	Non Invasive Imaging: Expanding Clinical Applications	The Association of Ischemia on Single Photon Emission Computed Tomography-Myocardial Perfusion Image and Fractional Flow Reserve by Coronary Computed Tomographic Angiography	Nothing to Disclose
Osawa	Kazuhiro	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Prognostic Value of Protein Biomarkers Predict Risk of Coronary Heart Disease Events: Results From Multi-Ethnic Study of Atherosclerosis (MESA)	Nothing to Disclose
Osawa	Kazuhiro	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Total Testosterone With Progression of Carotid Atherosclerosis and Coronary Artery Calcium Score: The Multi- Ethnic Study of Atherosclerosis	Nothing to Disclose
Osawa	Kazuhiro	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Coronary Artery Calcium Progression With Coronary Plaque Progression Determined by Quantitative Coronary Artery Plaque Analysis	Nothing to Disclose
Osawa	Kazuhiro	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	­The Utility of Minimal Coronary Artery Calcification for Predicting Carotid Artery Disease: Results From the Multi-Ethnic Study of Atherosclerosis (MESA)	Nothing to Disclose
Osawa	Kazuhiro	Innovations in Cardiovascular Risk Assessment and Reduction	Association of Coronary Calcium, Carotid Wall Thickness and Carotid Plaque Progression With Low Density Lipoprotein and High Density Lipoprotein Particle Concentration Measured by Ion Mobility Testing: The Multi-Ethnic Study of Atherosclerosis (MESA)	Nothing to Disclose
Osborne	Christina	Novel Developments in Acute Coronary Syndromes	Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Osborne	Michael	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Integrating Hyperemic Myocardial Blood Flow and Coronary Flow Reserve for Predicting Cardiovascular Mortality Outcomes in Patients With Known or Suspected Ischemic Heart Disease	Nothing to Disclose
Osborne	Michael	Young Investigator Awards Competition: Clinical Investigations	Impaired Coronary Flow Reserve Is Associated With Diastolic Dysfunction and HFpEF Outcomes in Patients Without Overt CAD	Nothing to Disclose
Osborne	Michael	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Relationship of Coronary Flow Reserve With Body Mass Index and Adverse Outcomes in Patients Without Overt Ischemic Heart Disease: Implications for Metabolic Surgery Eliqibility	Nothing to Disclose
Osborne	Michael	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Association Between Coronary Flow Reserve and Adverse Cardiovascular Events Along a Continuum of Metabolic Disease in Symptomatic Patients Without Overt Coronary Artery Disease	Nothing to Disclose
Osborne	Whitney	Adult Patients With Congenital Heart Disease: How Do They Compare?	Factors Associated With Completion of Advanced Directives in Adults With Congenital Heart Disease	Nothing to Disclose
Osei	Kofi	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Wireless Monitoring for Heart Failure Patients: A Meta-Analysis	Nothing to Disclose
Óskarsdóttir	Erna	Updates on Risk Factors for Cardiovascular Disease	Carotid Plaque Area Is Increased in Patients With Acute Coronary Syndrome and Dysglycemia	Nothing to Disclose
Osman	Ibrahim	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	An Unusual Extrinsic Pulmonary Artery Compression Caused by Traumatic Cardiac Hernia	OTHER - nothing to disclose
Osman	Ibrahim	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Traumatic Cardiac Hernia Double Chambered Right Ventricle Causing RVOT Obstruction in Adulthood: It Is Not Pulmonary Hypertension!	OTHER - nothing to disclose
Oster	Matthew	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Long-Term Transplant-Free Survival Following Surgery for Coarctation of the Aorta: A Study From the Pediatric Cardiac Care Consortium	Nothing to Disclose
Oster	Matthew	Congenital Heart Disease Surgery: Updates and Innovations	Long-Term Transplant-Free Survival for Arterial Switch Versus Atrial Switch in Treatment of Transposition of the Great Arteries: A Study	Nothing to Disclose

Østergaard	First Name Lauge	Session Title Valvular Heart Disease: Endocarditis	Presentation Title Risk of Infective Endocarditis Associated With Concomitant Pacemaker Among Patients Undergoing Aortic Valve Replacement:	Disclosures Nothing to Disclose
Østergaard	Lauge	Infectious Endocarditis: Comprehensive	A Nationwide Study Risk Factors Associated With Infective Endocarditis After Aortic	Nothing to Disclose
Ostfeld	Robert	Perspectives Lifestyle Changes to Reduce Cardiovascular	Valve Replacement Nutrition Deserts and ASCVD Risk	CONSULTANT FEES/HONORARIA - Pinnacle Foods; OTHER -
Ostfeld	Robert	Risk 32. Prevention: Clinical Team 4	Suggested Reviewer	Eating You Alive; SPEAKER'S BUREAU - Remedy Food CONSULTANT FEES/HONORARIA - Pinnacle Foods; OTHER -
				Eating You Alive; SPEAKER'S BUREAU - Remedy Food
Ostrowsky	Jacob	Congenital Heart Disease: Progress in Pediatric Heart Surgery	S-Nitrosohemoglobin Levels After Transfusion Predict Outcome of Pediatric BypassSurgery	Nothing to Disclose
Ota	Takeyoshi	Innovative Use of Echocardiography	Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography	Nothing to Disclose
Ota	Takeyoshi	Beans, Beans, Good for Your Heart	Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection	Nothing to Disclose
Ota	Takeyoshi	Vascular Medicine: Aortic and Peripheral Artery Diseases	Uncontrolled Hypertension in Acute Aortic Dissection Follow-Up	Nothing to Disclose
Otaki	Yuka	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium in the Elderly: Prevalence, Severity, and	Nothing to Disclose
Otaki	Yuka	Nuclear Cardiology: Quality	Association With All-Cause Mortality Rest Scan Does Not Improve Automatic Machine Learning	Nothing to Disclose
			Prediction of Major Adverse Coronary Events After High Speed Myocardial Perfusion Imaging	
Otaki	Yuka	Nuclear Cardiology: Coronary Flow	Patient Motion Significantly Affects Measurements of Quantitative Global Regional Myocardial Blood Flow Assessment by Dynamic Pet	Nothing to Disclose
Otaki	Yuka	Non Invasive Imaging: New Technologies	Improvement in LDL Is Associated With Decrease in Non-Calcified Plaque Volume on CTA as Measured by Automated Quantitative Software	Nothing to Disclose
Otaki	Yuka	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Relationship Between Whole Vessel Quantitative Plaque Characteristics and Noninvasive Fractional Flow Reserve From Coronary Computed Tomography Angiography	Nothing to Disclose
Otaki	Yuka	Imaging With Cardiac CT: The Case for Calcium	Hormone Replacement Therapy Is Associated With Less Coronary Atherosclerosis and Lower Mortality	Nothing to Disclose
Otsuka	Fumiyuki	Head to Toe: Outcomes of Endovascular Interventions	Area Coulous and Lower Mortage Predicts Neointimal Progression Associated With Late Enlargement of Self-Expanding Nitinol Stents in Superficial Femoral Arteries: An Optical Coherence Tomography Study	Nothing to Disclose
Otsuka	Fumiyuki	25. Interventional Cardiology: Translation and	Suggested Reviewer	Nothing to Disclose
Otsuki	Hisao	Pre-clinical Research Team 1 Optimizing the Care of ACS Patients	Novel Utilization of DAPT Score as a Predictor of Long-Term Clinical Outcomes in Hemodialysis Patients on Prolonged Dual	Nothing to Disclose
Otsuki	Hisao	Interventional Cardiology: PCI in Complex	Antiplatelet Therapy After Coronary Intervention Predictors for 2-Year Cardiovascular Events After Rotablation in	Nothing to Disclose
Otto	Catherine	Patients Valvular Heart Disease Guidelines The	Severe Calcified Lesion What's New? - Reasons for Updating the 2014 VHD Guideline	Nothing to Disclose
		Evidence and the Gaps		
Otto	Catherine	Aortic Stenosis: Overview of the Hemodynamics and Ventricular Response	Co-Chair	Nothing to Disclose
Otto	Catherine	Imaging in Valvular Heart Disease: Applying Guidelines to Clinical Practice and What to do if They Don't Fit	How do I Incorporate the ACC/AHA Valve Guidelines in My Practice	Nothing to Disclose
Otto	Catherine	WIC Brown Bag Lunch Session: Publishing, Social Media and Negotiating the C-Suite: Tools for Success in Academia and Private Practice	Writing and Publishing Effectively	Nothing to Disclose
Otto	Catherine	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Intramural Hematoma or Aortitis: A Diagnostic Dilemma	Nothing to Disclose
Otto Otvos	Catherine James	36. Valvular Heart Disease: Clinical Team 1 Interventional Cardiology: Translation and Pre-	Suggested Reviewer Both the Novel NMR Biomarker of Inflammation, GlycA, and HS-	Nothing to Disclose SALARY - LabCorp
		Clinical Research	CRP Are Independent and Additive Predictors of Future Cardiovascular Events Among Patients Undergoing Coronary Angiography: Results From the Intermountain Heart Collaborative Study	
Ou	Yanqiu	Congenital Heart Disease: New Diagnostic	Variation in Prenatal Diagnosis of Congenital Heart Defects in a	Nothing to Disclose
Ou	Yanqiu	Approaches in Congenital Heart Disease Impact of Prenatal Environment on Congenital	Population-Based Study in Southern China Maternal Blood Trace Element Levels and Risks for Fetal	Nothing to Disclose
Oudiz	Ronald	Heart Disease 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1	Congenital Heart Defects in Guangdong, China Suggested Reviewer	CONSULTANT FEES/HONORARIA - Actelion,gilead,United Therapeutics; DATA SAFETY MONITORING BOARD -
				MEDTRONIC; RESEARCH/RESEARCH GRANTS - Actelion,Bayer,gilead,Lung LLC,United Therapeutics
Ouyang	David	Advanced Therapies = Advanced Trouble: VAD and Transplant Challenges	Differential Outcomes of Temporary Mechanical Circulatory Support Devices by Procedural Timing and Clinical Indication	
Ouyang	Pamela	New Insights Into Prediction and Treatment of Hypertension	ACC Poster Moderator	Nothing to Disclose
Ouyang Ouzounian	Pamela Maral	32. Prevention: Clinical Team 5 Vascular Medicine: New Insights Into Aortic	Suggested Reviewer Differentiating Between Familial and Sporadic Thoracic Aortic	Nothing to Disclose Nothing to Disclose
		and Peripheral Artery Diseases	Aneurysms and Dissections	-
Ouzounian	Maral	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Body Mass Index and Acute Aortic Dissection	Nothing to Disclose
Ouzounian	Maral	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Influence of Family History of Aortic Disease on Type B Aortic Dissection	Nothing to Disclose
Overbey	Jessica	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic Surgical Trials Network	Nothing to Disclose
Overgaard	Christopher	Novel Developments in Acute Coronary Syndromes	One-Year Outcome of Acute Stent Thrombosis: Insights From the Total Trial	Nothing to Disclose
Ovrehus	Kristian	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes		Nothing to Disclose
Owan	Theophilus	Novel Developments in Acute Coronary	Central Fractional Pulse Pressure Predicts Cardiac Power Index in	Nothing to Disclose
Owlia	Mina	Syndromes Logistical Challenges in STEMI	Patients With Acute Coronary Syndrome Fit Case #4: Elderly Patient Presenting in Cardiogenic Shock without	Nothing to Disclose
Ownby	Evan	Mentoring the Care Team: FITs, Early Career	Reachable Family Mentoring the Early Career Professional: Integrated Health Care	Nothing to Disclose
Oyenuga	Olusegun	Professionals and CV Team Members FIT Clinical Decision Making: Arrhythmias and	System Recurrent Atrial Myxoma, Right Atriotomy and Sinus Node	Nothing to Disclose
Ozaki	Yuichi	Electrophysiology Interventional Cardiology: Intravascular	Dysfunction Comparison of Very Late Vascular Response Beyond 2 Years After	Nothing to Disclose
		Physiology and Endothelial Function	Stent Implantation Between EES and BES: An OCT Sub-Study of the NEXT	-
Ozawa	Koya	Non Invasive Imaging: New Technologies	A Novel 3D Myocardial Strain Determined by Existing 320-Slice CT Data Enhances Visual Assessment of Late Enhancement on CT for the Detection of Left Ventricular Myocardial Fibrosis in Non Ischemic Cardiomyopathy	Nothing to Disclose

Last Name Ozcan Ozcan Ozdemir Ozdemir Ozdemir Ozdemir Ozdemir Ozdemir Pachariyanon Pachariyanon Pack Pack Pack	Cevher Cevher Nihal Nihal Nihal Nihal Nihal Pavida Pal Quinn Quinn Quinn	Session Title Arrhythmias and Clinical EP: Basic 2 Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease Understanding Pulmonary Vascular Disease: From Bench to Bedside Understanding Pulmonary Vascular Disease: From Bench to Bedside Predicting Pulmonary Vascular Disease: From Bench to Bedside Predicting the Future: Observations and Discoveries From Registries and Databases Predicting the Future: Observations and Discoveries From Registries and Databases Interventional Cardiology: TAVR 2 Nuclear Cardiology: Beyond Perfusion Current Issues in Cardiovascular Epidemiology, Disparties, and Safety Predicting Outcomes in Cardiac Rehabilitation Patients FiT Clinical Decision Making: Multimodality Imaging Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	Atrial Fibrillation Is Associated With Severe Metabolic Disruption in Atrial Myocardium in Patients With Heart Failure Incidence, Predictors, and Outcome of Postoperative Atrial Fibrillation in Patients Receiving Continuous Flow Left Ventricular Assist Devices Clinical, Biochemical, Neurohumoral, Echocardiographic and Hemodynamic Characteristics in Relation to Survival in Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: Insights From Euphrates Study Short-Term Intravenous Iloprost Treatment Improves Clinical Status and Neurohumoral Measures in Clinical Worsening Episodes of Precapillary Pulmonary Hypertension Regardless of the Background Treatments: Insights From Euphrates Study The Impaired Endothelium-Dependent and Endothelium-Independent Systemic Arterial Vasociliatory Reserve in Pulmonary Hypertension Regardless of the Clinical Group Pulmonary Vascular Resistance, but Not Diastolic Pulmonary Gradient, May Predict Survival in Pulmonary Hypertension: Insights From Euphrates Study The Correlates and Prognostic Impact of Pulmonary Arterial Pulse Pressures, Diastolic and Transpulmonary Pressure Gradients in Pulmonary Hypertension: Ostali Compression of Left Main Coronary Artery by Aneurysmal Pulmonary Artery. Insights From Euphrates Study An Ignored but Not Unusual Complication of Severe Pulmonary Hypertension: Ostali Compression of Left Main Coronary Artery by Aneurysmal Pulmonary Artery. Insights From Euphrates Study Prognostic Value of Baseline N-Terminal Prohormone Type Natriuretic Peptide Measurement in Chronic Lung Disease Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Molecular Imaging of Myocardial Cannabinoid Type 1 Receptor Upregulation in Obesity Smoking Cessation Therapies Are Persistently and Significantly Underutilized Among Hospitalized Smokers With Coronary Heart Disease	Disclosures Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Ozdemir Ozdemir Ozdemir Ozdemir Ozdemir Ozdemir Ozdemir Pachariyanon Pachar Pack Pack Pack Pack	Cevher Nihal Nihal Nihal Nihal Nihal Pavida Pal Quinn Quinn Quinn	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease Understanding Pulmonary Vascular Disease: From Bench to Bedside Understanding Pulmonary Vascular Disease: From Bench to Bedside Predicting the Future: Observations and Databases Predicting the Future: Observations and Databases Predicting the Future: Observations and Databases Predicting the Future: Observations and Discoveries From Registries and Databases Interventional Cardiology: TAVR 2 Nuclear Cardiology: Beyond Perfusion Current Issues in Cardiovascular Epidemiology, Dispartites, and Safety Predicting Outcomes in Cardiac Rehabilitation Patients FIT Clinical Decision Making: Multimodality Imaging Physical Activity and Prevention of	Arial Myocardium in Patients With Heart Failure incidence, Predictors, and Outcome of Postoperative Atrial Fibrillation in Patients Receiving Continuous Flow Left Ventricular Assist Devices Clinical, Biochemical, Neurohumoral, Echocardiographic and Hemodynamic Characteristics in Relation to Survival in Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: Insights From Euphrates Study Short-Term Intravenous lioprost Treatment Improves Clinical Status and Neurohumoral Measures in Clinical Worsening Episodes of Precapillary Pulmonary Hypertension Regardless of the Background Treatments: Insights From Euphrates Study The Impaired Endothelium-Dependent and Endothelium- Independent Systemic Arterial Vasodilatory Reserve in Pulmonary Hypertension Regardless of the Clinical Group Pulmonary Vascular Resistance, but Not Diastolic Pulmonary Gradient, May Predict Survival in Pulmonary Hypertension: Insights From Euphrates Study The Correlates and Prognostic Impact of Pulmonary Arterial Pulse Pressures, Diastolic and Transpulmonary Pressure Gradients in Pulmonary Hypertension: Insights From Euphrates Study An Ignored but Not Unusual Complication of Severe Pulmonary Hypertension - Ostal Compression of Left Main Coronary Artery by Aneurysmal Pulmonary Artery: Insights From Euphrates Study Prognostic Value of Baseline N-Terminal Prohormone Type Natriuretic Peptide Measurement in Chronic Lung Disease Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Molecular Imaging of Myocardial Cannabinoid Type 1 Receptor Upregulation in Obesity Smoking Cessation Therapies Are Persistently and Significantly Underutilized Among Hospitalized Smokers With Coronary Heart Disease Smoking Cessation is Strongly Associated With Attendance at Cardiac Rehab: But Which Comes First? Ventricular Septal Dissection With Rupture and Large NeoCavity After Inferior ST Elevation Myocardial Infarction in a Patient With	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Ozdemir Ozdemir Ozdemir Ozdemir Ozdemir Ozdemir Pachariyanon Pacher Pack Pack Pack	Nihal Nihal Nihal Nihal Nihal Pavida Pal Quinn Quinn Quinn	and Newer Outcome Measures Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease Understanding Pulmonary Vascular Disease: From Bench to Bedside Understanding Pulmonary Vascular Disease: From Bench to Bedside Predicting the Future: Observations and Discoveries From Registries and Databases Predicting the Future: Observations and Discoveries From Registries and Databases Predicting the Future: Observations and Discoveries From Registries and Databases Interventional Cardiology: Tavra 2 Nuclear Cardiology: Beyond Perfusion Current Issues in Cardiovascular Epidemiology, Disparties, and Safety Predicting Outcomes in Cardiac Rehabilitation Patincial Decision Making: Multimodality Imaging Physical Activity and Prevention of	Eibrilation in Patients Receiving Continuous Flow Left Ventricular Assist Devices Clinical, Biochemical, Neurohumoral, Echocardiographic and Hemodynamic Characteristics in Relation to Survival in Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: Insights From Euphrates Study Short-Term Intravenous Iloprost Treatment Improves Clinical Status and Neurohumoral Measures in Clinical Worsening Episodes of Precapillary Pulmonary Hypertension Regardless of the Background Treatments: Insights From Euphrates Study The Impaired Endothelium-Dependent and Endothelium-Independent Systemic Arterial Vasodilatory Reserve in Pulmonary Hypertension Regardless of the Clinical Group Pulmonary Vascular Resistance, but Not Diastolic Pulmonary Gradient, May Predict Survival in Pulmonary Hypertension: Insights From Euphrates Study The Correlates and Prognostic Impact of Pulmonary Arterial Pulse Pressures, Diastolic and Transpulmonary Pressure Gradients in Pulmonary Hypertension: Insights From Euphrates Study Prognostic Value of Baseline N-Terminal Prohormone Type Natruretic Peptide Measurement in Chronic Lung Disease Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Molecular Imaging of Myocardial Cannabinoid Type 1 Receptor Upregulation in Obesity Smoking Cessation Therapies Are Persistently and Significantly Underutilized Among Hospitalized Smokers With Coronary Heart Disease Smoking Cessation is Strongly Associated With Attendance at Cardiac Rehab: But Which Comes First? Ventricular Septal Dissection With Rupture and Large NeoCavity After Inferior ST Elevation Myocardial Infarction in a Patient With	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Ozdemir Ozdemir Ozdemir Ozdemir Ozdemir Pachariyanon Pachar Pack Pack Pack Pack	Nihal Nihal Nihal Nihal Pavida Pal Quinn Quinn Quinn	Impact of Congenifal Heart Disease Understanding Pulmonary Vascular Disease: From Bench to Bedside Understanding Pulmonary Vascular Disease: From Bench to Bedside Predicting the Future: Observations and Discoveries From Registries and Databases Predicting the Future: Observations and Databases Predicting the Future: Observations and Discoveries From Registries and Databases Predicting the Future: Observations and Discoveries From Registries and Databases Interventional Cardiology: TAVR 2 Nuclear Cardiology: Beyond Perfusion Current Issues in Cardiovascular Epidemiology, Dispartites, and Safety Predicting Outcomes in Cardiac Rehabilitation Patients FIT Clinical Decision Making: Multimodality Imaging Physical Activity and Prevention of	Hemodynamic Characteristics in Relation to Survival in Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: Insights From Euphrates Study Short-Term Intravenous lioprost Treatment Improves Clinical Status and Neurohumoral Measures in Clinical Worsening Episodes of Precapillary Pulmonary Hypertension Regardless of the Background Treatments: Insights From Euphrates Study The Impaired Endothelium-Dependent and Endothelium-Independent Systemic Arterial Vasodilatory Reserve in Pulmonary Hypertension Regardless of the Clinical Group Pulmonary Vascular Resistance, but Not Diastolic Pulmonary Gradient, May Predict Survival in Pulmonary Hypertension: Insights From Euphrates Study The Correlates and Prognostic Impact of Pulmonary Arterial Pulse Pressures, Diastolic and Transpulmonary Pressure Gradients in Pulmonary Hypertension: Insights From Euphrates Study An Ignored but Not Unusual Complication of Severe Pulmonary Hypertension - Ostal Compression of Left Main Coronary Artery by Aneurysmal Pulmonary Artery. Insights From Euphrates Study Prognostic Value of Baseline N-Terminal Prohormone Type Natriuretic Peptide Measurement in Chronic Lung Disease Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Molecular Imaging of Myocardial Cannabinoid Type 1 Receptor Upregulation in Obesity Smoking Cessation Therapies Are Persistently and Significantly Underutilized Among Hospitalized Smokers With Coronary Heart Disease Smoking Cessation Is Strongly Associated With Attendance at Cardiac Rehab: But Which Comes First? Ventricular Septal Dissection With Rupture and Large NeoCavity After Inferior ST Elevation Myocardial Infarction in a Patient With	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Ozdemir Ozdemir Ozdemir Ozdemir Pachariyanon Pacher Pack Pack Pack Pack	Nihal Nihal Nihal Nihal Pavida Pal Quinn Quinn Quinn	From Bench to Bedside Understanding Pulmonary Vascular Disease: From Bench to Bedside Predicting the Future: Observations and Discoveries From Registries and Databases Predicting the Future: Observations and Discoveries From Registries and Databases Predicting the Future: Observations and Discoveries From Registries and Databases Predicting the Future: Observations and Discoveries From Registries and Databases Interventional Cardiology: TAVR 2 Nuclear Cardiology: Beyond Perfusion Current Issues in Cardiovascular Epidemiology, Disparties, and Safety Predicting Outcomes in Cardiac Rehabilitation Patients FIT Clinical Decision Making: Multimodality Imaging Physical Activity and Prevention of	and Neurohumoral Measures in Clinical Worsening Episodes of Precapillary Pulmonary Hypertension Regardless of the Background Treatments: Insights From Euphrates Study The Impaired Endothelium-Dependent and Endothelium-Independent Systemic Arterial Vasodilatory Reserve in Pulmonary Hypertension Regardless of the Clinical Group Prulmonary Vascular Resistance, but Not Diastolic Pulmonary Prulmonary Gradient, May Predict Survival in Pulmonary Hypertension: Insights From Euphrates Study The Correlates and Prognostic Impact of Pulmonary Arterial Pulse Pressures, Diastolic and Transpulmonary Pressure Gradients in Pulmonary Hypertension: Insights From Euphrates Study An Ignored but Not Unusual Complication of Severe Pulmonary Hypertension - Ostal Compression of Left Main Coronary Artery by Aneurysmal Pulmonary Artery. Insights From Euphrates Study Prognostic Value of Baseline N-Terminal Prohormone Type Natriuretic Peptide Measurement in Chronic Lung Disease Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Molecular Imaging of Myocardial Cannabinoid Type 1 Receptor Upregulation in Obesity Smoking Cessation Therapies Are Persistently and Significantly Underutilized Among Hospitalized Smokers With Coronary Heart Disease Smoking Cessation Is Strongly Associated With Attendance at Cardiac Rehab: But Which Comes First? Ventricular Septal Dissection With Rupture and Large Neo-Cavity After Inferior ST Elevation Myocardial Infarction in a Patient With	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Ozdemir Ozdemir Pachariyanon Pacher Pack Pack Pack	Nihal Nihal Nihal Pavida Pal Quinn Quinn Quinn	From Bench to Bedside Predicting the Future: Observations and Discoveries From Registries and Databases Predicting the Future: Observations and Discoveries From Registries and Databases Predicting the Future: Observations and Discoveries From Registries and Databases Predicting the Future: Observations and Discoveries From Registries and Databases Interventional Cardiology: TAVR 2 Nuclear Cardiology: Beyond Perfusion Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Predicting Outcomes in Cardiac Rehabilitation Patients FIT Clinical Decision Making: Multimodality Imaging Physical Activity and Prevention of	The Impaired Endothelium-Dependent and Endothelium-Independent Systemic Arterial Vasodilatory Reserve in Pulmonary Hypertension Regardless of the Clinical Group Pulmonary Vascular Resistance, but Not Diastolic Pulmonary Gradient, May Predict Survival in Pulmonary Hypertension: Insights From Euphrates Study The Correlates and Prognostic Impact of Pulmonary Arterial Pulse Pressures, Diastolic and Transpulmonary Pressure Gradients in Pulmonary Hypertension: Insights From Euphrates Study An Ignored but Not Unsusual Complication of Severe Pulmonary Hypertension - Ostial Compression of Left Main Coronary Artery by Aneurysmal Pulmonary Artery. Insights From Euphrates Study Prognostic Value of Baseline N-Terminal Prohormone Type Natriuretic Peptide Measurement in Chronic Lung Disease Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Molecular Imaging of Myocardial Cannabinoid Type 1 Receptor Upregulation in Obesity Smoking Cessation Therapies Are Persistently and Significantly Underutilized Among Hospitalized Smokers With Coronary Heart Disease Smoking Cessation is Strongly Associated With Attendance at Cardiac Rehab: But Which Comes First? Ventricular Septal Dissection With Rupture and Large NeoCavity After Inferior ST Elevation Myocardial Infarction in a Patient With	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Ozdemir Ozdemir Pachariyanon Pacher Pack Pack Pack Pack	Nihal Nihal Pavida Pal Quinn Quinn Quinn	Discoveries From Registries and Databases Predicting the Future: Observations and Discoveries From Registries and Databases Predicting the Future: Observations and Discoveries From Registries and Databases Predicting the Future: Observations and Discoveries From Registries and Databases Interventional Cardiology: TAVR 2 Nuclear Cardiology: Beyond Perfusion Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Predicting Outcomes in Cardiac Rehabilitation Patients FIT Clinical Decision Making: Multimodality Imaging Physical Activity and Prevention of	Gradient, May Predict Survival in Pulmonary Hypertension: Insights From Euphrates Study The Correlates and Prognostic Impact of Pulmonary Arterial Pulse Pressures, Diastolic and Transpulmonary Pressure Gradients in Pulmonary Hypertension: Insights From Euphrates Study An Ignored but Not Unusual Complication of Severe Pulmonary Hypertension - Ostial Compression of Left Main Coronary Artery by Aneurysmal Pulmonary Artery: Insights From Euphrates Study Prognostic Value of Baseline N-Terminal Prohormone Type Natriuretic Peptide Measurement in Chronic Lung Disease Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Molecular Imaging of Myocardial Cannabinoid Type 1 Receptor Upregulation in Obesity Smoking Cessation Therapies Are Persistently and Significantly Underutilized Among Hospitalized Smokers With Coronary Heart Disease Smoking Cessation is Strongly Associated With Attendance at Cardiac Rehab: But Which Comes First? Ventricular Septal Dissection With Rupture and Large NeoCavity After Inferior ST Elevation Myocardial Infarction in a Patient With	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Ozdemir Pachariyanon Pacher Pack Pack Pack Pack	Nihal Pavida Pal Quinn Quinn Quinn Quinn	Discoveries From Registries and Databases Predicting the Future: Observations and Discoveries From Registries and Databases Interventional Cardiology: TAVR 2 Nuclear Cardiology: Beyond Perfusion Current Issues in Cardiovascular Epidemiology, Disparties, and Safety Predicting Outcomes in Cardiac Rehabilitation Patients FIT Clinical Decision Making: Multimodality Imaging Physical Activity and Prevention of	Pressures, Diastolic and Transpulmonary Pressure Gradients in Pulmonary Hypertension: Insights From Euphrates Study An Ignored but Not Unusual Complication of Severe Pulmonary Hypertension - Ostial Compression of Left Main Coronary Artery by Aneurysmal Pulmonary Artery. Insights From Euphrates Study Prognostic Value of Baseline N-Terminal Prohormone Type Natriuretic Peptide Measurement in Chronic Lung Disease Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Molecular Imaging of Myocardial Cannabinoid Type 1 Receptor Upregulation in Obesity Smoking Cessation Therapies Are Persistently and Significantly Underutilized Among Hospitalized Smokers With Coronary Heart Disease Smoking Cessation is Strongly Associated With Attendance at Cardiac Rehab: But Which Comes First? Ventricular Septal Dissection With Rupture and Large NeoCavity After Inferior ST Elevation Myocardial Infarction in a Patient With	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pachariyanon Pacher Pack Pack Pack Pack	Pavida Pal Quinn Quinn Quinn Quinn	Discoveries From Registries and Databases Interventional Cardiology: TAVR 2 Nuclear Cardiology: Beyond Perfusion Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Predicting Outcomes in Cardiac Rehabilitation Patients FIT Clinical Decision Making: Multimodality Imaging Physical Activity and Prevention of	Hypertension - Ostal Compression of Left Main Coronary Artery by Aneurysmal Pulmonary Artery: Insights From Euphrates Study Prognostic Value of Baseline N-Terminal Prohormone Type Natriuretic Peptide Measurement in Chronic Lung Disease Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Molecular Imaging of Myocardial Cannabinoid Type 1 Receptor Upregulation in Obesity Smoking Cessation Therapies Are Persistently and Significantly Underutilized Among Hospitalized Smokers With Coronary Heart Disease Smoking Cessation is Strongly Associated With Attendance at Cardiac Rehab: But Which Comes First? Ventricular Septal Dissection With Rupture and Large NeoCavity After Inferior ST Elevation Myocardial Infarction in a Patient With	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pacher Pack Pack Pack	Pal Quinn Quinn Quinn Quinn	Nuclear Cardiology: Beyond Perfusion Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Predicting Outcomes in Cardiac Rehabilitation Patients FIT Clinical Decision Making: Multimodality Imaging Physical Activity and Prevention of	Natriuretic Peptide Measurement in Chronic Lung Disease Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Molecular Imaging of Myocardial Cannabinoid Type 1 Receptor Upregulation in Obesity Smoking Cessation Therapies Are Persistently and Significantly Underutilized Among Hospitalized Smokers With Coronary Heart Disease Smoking Cessation Is Strongly Associated With Attendance at Cardiac Rehab: But Which Comes First? Ventricular Septal Dissection With Rupture and Large NeoCavity After Inferior ST Elevation Myocardial Infarction in a Patient With	Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pack Pack Pack Pack	Quinn Quinn Quinn Quinn	Current Issues in Cardiovascular Epidemiology, Disparties, and Safety Predicting Outcomes in Cardiac Rehabilitation Patients FIT Clinical Decision Making: Multimodality Imaging Physical Activity and Prevention of	Upregulation in Obesity Smoking Cessation Therapies Are Persistently and Significantly Underutilized Among Hospitalized Smokers With Coronary Heart Disease Smoking Cessation is Strongly Associated With Attendance at Cardiac Rehab: But Which Comes First? Ventricular Septal Dissection With Rupture and Large NeoCavity After Inferior ST Elevation Myocardial Infarction in a Patient With	Nothing to Disclose Nothing to Disclose
Pack Pack	Quinn Quinn Quinn	Epidemiology, Disparities, and Safety Predicting Outcomes in Cardiac Rehabilitation Patients FIT Clinical Decision Making: Multimodality Imaging Physical Activity and Prevention of	Smoking Cessation Therapies Are Persistently and Significantly Underutilized Among Hospitalized Smokers With Coronary Heart Disease Smoking Cessation Is Strongly Associated With Attendance at Cardiac Rehab: But Which Comes First? Ventricular Septal Dissection With Rupture and Large NeoCavity After Inferior ST Elevation Myocardial Infarction in a Patient With	Nothing to Disclose
Pack Pack	Quinn	Patients FIT Clinical Decision Making: Multimodality Imaging Physical Activity and Prevention of	Smoking Cessation Is Strongly Associated With Attendance at Cardiac Rehab: But Which Comes First? Ventricular Septal Dissection With Rupture and Large NeoCavity After Inferior ST Elevation Myocardial Infarction in a Patient With	-
Pack	Quinn	FIT Clinical Decision Making: Multimodality Imaging Physical Activity and Prevention of	Ventricular Septal Dissection With Rupture and Large NeoCavity After Inferior ST Elevation Myocardial Infarction in a Patient With	Nothing to Disclose
			December Common Automorphy Common Comfo	
	Quinn	Cardiometabolic Disease. Exercise is Medicine	Recent Coronary Artery Bypass Grafts ACC Poster Moderator	Nothing to Disclose
Pack		34. Prevention: Rehabilitation Team 1	Suggested Reviewer	Nothing to Disclose
				Laboratories, Aperture Diagnostics, Biosense Webster, Inc., Bostor Scientific, CardioFocus, Cardionisght, Johnson & Amp; amp; Johnson, MediaSphere Medical, LLC, Medtronic, Inc., Siemens AG, St. Jude Medical; OTHER - Blackwell Publishing, St. Jude/ESI RESEARCH/RESEARCH GRANTS - Acuson, American Heart Association, Biosense Webster, Inc., Boston Scientific, CardioFocus, CardioInsight, Endosense, Hansen Medical, Medtronic CryoCath, National Institutes of Health, Siemens, St. Jude Medical, Thermedical
Packer	Milton	Featured Clinical Research III	Paroxysmal Atrial Fibrillation is Associated With Worse Clinical Outcomes Than Persistent/Permanent Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction	CONSULTANT FEES/HONORARIA - Abbvie, Actelion, Ampen, AstraZeneca Pharmaceuticals, BioControl, Boston Scientific, CardioKinetix, CardioMEMS, Cardiorentis, Cytokinetix, Jan ssen, Luminox, Novartis, Piïcer, Philip Morris, SANOFI, UCB
Packer	Milton	Making Progress in Understanding Heart Failure	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF	CONSULTANT FEES/HONORARIA - Abbvie, Actelion, Amgen, AstraZeneca Pharmaceuticals, BioControl, Boston Scientific, CardioKinetix, CardioMEMS, Cardiorentis, Cytokinetix, Jan ssen, Luminox, Novartis, Piïcer, Philip Morris, SANOFI, UCB
Packer	Milton	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Effect of Sacubitril/Valsartan Compared With Enalapril, According to Etiology in PARADIGM-HF	CONSULTANT FEES/HONORARIA - Abbvie, Actelion, Amgen, AstraZeneca Pharmaceuticals, BioControl, Boston Scientific, CardioKinetix, CardioMEMS, Cardiorentis, Cytokinetix, Jan ssen, Luminox, Novartis, Pitzer, Philip Morris, SANOFI, UCB
Packer	Milton	Hormones and Heart Failure	Low Urinary Cgmp/Bnp Ratio Is Associated With Worse Outcomes in Heart Failure but Is increased by Treatment With Sacublitril/Valsartan: An Analysis of Paradigm-HF	CONSULTANT FEES/HONORARIA - Abbvie, Actelion, Amgen, AstraZeneca Pharmaceuticals, BioControl, Boston Scientific, CardioKinetix, CardioMEMS, Cardiorentis, Cytokinetix, Jan ssen, Luminox, Novartis, Pizer, Philip Morris, SANOFI, UCB
Packer	Milton	The Old and the New: Impact of Heart Failure Drug Therapies	Influence of Sacubitril/Valsartan on Glycemic Control in Patients With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction	CONSULTANT FEES/HONORARIA - Abbvie, Actelion, Amgen, AstraZeneca Pharmaceuticals, BioControl, Boston Scientific, CardioKinettx, CardioMEMS, Cardiorentis, Cytokinetix, Jan ssen, Luminox, Novartis, Pitzer, Philip Morris, SANOFI, UCB
Padala		Interventional Cardiology: Translation and Pre- Clinical Research	Novel Preclinical Assessment of Transcatheter Mitral Valve Replacement by Micro Computed Tomography: µCT Imaging Guided Histopathological Evaluation	CONSULTANT FEES/HONORARIA - NeoChord, St Jude Medica
Padala	Santosh	Atrial Fibrillation and VT: Unique Populations	Risk Score Model for Predicting Occurrence of Complications in	Nothing to Disclose
Padala	Santosh	and Solutions Atrial Fibrillation and VT: Unique Populations and Solutions	Patients Undergoing Atrial Fibrillation Ablation Difference in Quality of Life Outcomes Between Atrial Fibrillation Catheter Ablation and Anti Arrhythmic Drugs: A Systematic Review	Nothing to Disclose
Padang	Ratnasari	Innovative Use of Echocardiography	and Meta-Analysis The Association Between Echocardiographic Laboratory	Nothing to Disclose
Padang	Ratnasari	Interventional Cardiology: TAVR 3	Accreditation and the Quality of Imaging and Reporting Comparative Outcome of Paravalvular Leak Following Surgical	Nothing to Disclose
Padang	Ratnasari	New Technologies in Echocardiography	Versus Transcatheter Aortic Valve Replacement Novel Echocardiographic Measurements Detect Increased Myocardial Stiffness in Patients With Severe Organic Mitral	Nothing to Disclose
Padang	Ratnasari	Advancing Our Understanding of Aortic Disease	Regurgitation Intracranial Aneurysms in Patients With Bicuspid Aortic Valve: Prevalence and Predictors of Occurence	Nothing to Disclose
Padera	Robert	Advances in HCM, PPCM and Other Cardiomyopathies	Misdiagnosis of Cardiac Amyloidosis Type by Standard	OTHER - MEDTRONIC, TransMedics, Inc.
Padera	Robert	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Prevalence of Monoclonal Gammopathy of Unknown Significance in Wild Type Transthyretin Amyloidosis Patients	OTHER - MEDTRONIC, TransMedics, Inc.
Padilla Ibarra	Jorge	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		Nothing to Disclose

Chr. March				I
Last Name Paez	First Name Diana	Session Title Nuclear Cardiology: Quality	Presentation Title Worldwide Variation in the Use of Nuclear Cardiology Camera Technology, Reconstruction Software, and Acquisition Protocols: Findings From the IAEA Nuclear Cardiology Protocols Study (INCAPS)	Disclosures Nothing to Disclose
Pagani	Francis	Cardiogenic Shock: Drugs to Devices	Panelist	Nothing to Disclose
Pagani	Francis	Cardiogenic Shock: Drugs to Devices	What a Cardiologist Needs to Know About ECMO	Nothing to Disclose
Pagani	Francis	Give Me a Beat! Mechanical Support of Cardiogenic Shock	What a Cardiologist Needs to Know About ECMO	Nothing to Disclose
Pagani	Francis	Treatment Strategies for End Stage Heart Failure: Medications, Machines and Everything in Between	End-Stage HF: LVADs Will Be Better Than Transplant	Nothing to Disclose
Pagidipati	Neha	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Ten-Year Mortality of Acute Myocardial Infarction Patients Treated in U.S. Community Practice	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Physician Partners LLC; OWNERSHIP NTEREST/PARTNERSHIP/PRINCIPAL - Florida Medical Associates, LLC, Freedom Health, Inc, RXAdvance, LLC
Pagidipati	Neha	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Outcomes in Patients With Diabetes Mellitus and Suspected Coronary Artery Disease Following Non-Invasive Testing; Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Physician Partners LLC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Florida Medical Associates, LLC, Freedom Health, Inc.RXAdvance, LLC
Pagidipati	Neha	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Examination of hs-CRP Elevation in Patients With History of Myocardial Infarction in the U.S.	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Physician Partners LLC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Florida Medical Associates, LLC, Freedom Health, Inc.RXAdvance, LLC
Pagidipati	Neha	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Incidence of Recurrent Myocardial Infarction Among Older Adults in U.S. Community Practice	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Physician Partners LLC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Florida Medical Associates, LLC, Freedom Health, Inc, RXAdvance, LLC
Pagidipati	Neha	New Perspectives on CAD Risk Factors	Discordances Between Predicted and Actual Risk of Adverse Events in Obese Patients With Suspected Cardiac Ischemia: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Physician Partners LLC; OWNERSHIP NTEREST/PARTNERSHIP/PRINCIPAL - Florida Medical Associates, LLC, Freedom Health, Inc, RXAdvance, LLC
Pahuja	Mohit	Predicting the Future: Observations and Discoveries From Registries and Databases	Trends in Pulmonary Hypertension Hospitalizations: Insights From a National Database	Nothing to Disclose
Pahuja Pai	Mohit Ramdas	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	National Database 30-Day Unplanned Readmission Rates, Cost, Predictors, and Causes of Hospitalization in Acute Myocardial Infarction Patients Anomalous Left Coronary Artery Arising From Right Coronary Sinus	Nothing to Disclose
Pai	Ramdas	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Anomalous Lett Coronary Artery Arising From Right Coronary Sinus With Interarterial Course	Nothing to Disclose
Pai	Ramdas	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Right Sided Accessory Pathway Masquerading as LBBB with Cardiomyopathy: "Cure" With Catheter Ablation	Nothing to Disclose
Pai	Ramdas	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Transcatheter Aortic Valve Replacement in a Patient With Very Mobile Aortic Valve Mass	Nothing to Disclose
Paixao	Andre	32. Prevention: Clinical Team 5	Suggested Reviewer	Nothing to Disclose
Pak	Esther	Give Me a Beat! Mechanical Support of	Prolonging the Inevitable: Incorporating Palliative Care Earlier in the	Nothing to Disclose
Pak	Hui-Nam	Cardiogenic Shock Arrhythmias and Clinical EP: Basic 1	Process Exosome Derived From Atrial Fibrillation Patients Prevents Proarrhythmic Remodeling by Restoration of Acetylated Tubulin in	Nothing to Disclose
Pak	Hui-Nam	Arrhythmias and Clinical EP: Basic 1	Pacing Induced Tachycardia Model MicroRNA-26a From Hypoxic Human Mesenchymal Stem Cells: Derived Microvesicles Enhance Cardiac Conduction Following	Nothing to Disclose
Palac	Robert	Highlights in Vascular Medicine Research	Myocardial Infarction Cancer and Arterial Thrombosis Risk: Insights From the 2012 National Inpatient Sample	CONSULTANT FEES/HONORARIA - M2S, Lebanon, NH
Palacios	Igor	24. Interventional Cardiology: Mitral and Structural Heart Disease Team 2	Suggested Reviewer	OTHER - Siemens
Palamaner Subash Shantha	Ghanshyam	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Gender Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Medicare Patients With Newly Diagnosed Arial Fibrillation: A Propensity Matched Analysis	Nothing to Disclose
Palamaner Subash Shantha	Ghanshyam	Things That Matter in Adult Congenital Heart Disease	Gender Differences in Rates of Hospitalizations for Decompensated Heart Failure Among Adults With Congenital Heart Diseases in the	Nothing to Disclose
Palaniappan	Latha	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	United States: A 15 Year Experience Nativity Status and Cardiovascular Disease Mortality Among Hispanics	Nothing to Disclose
Palazzo	Angela	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Gender on Mortality and Percutaneous Coronary Intervention in Non ST-Segment Elevation Myocardial Infarction: A Nationwide Analysis	Nothing to Disclose
Palazzo	Angela	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Non ST-Segment Elevation Myocardial Infarction Patient Outcomes in Teaching Hospital: A Nationwide Analysis	Nothing to Disclose
Palee	Siripong	Management and Outcomes Diabetes and Endothelial Dysfucntion in Heart Failure	Lack of Testosterone in Obese-Insulin Resistant Condition Aggravates Cardiometabolic Dysfunction Through the Impairment of	Nothing to Disclose
Palee	Siripong	Hormones and Heart Failure	Cardiac Mitochondrial Function Estrogen Deprivation Aggravates Cardiometabolic Dysfunction and Intracellular Calcium Dyshomeostasis in Obese-Insulin Resistance	Nothing to Disclose
Palfy	Julia Anna	Arrhythmias and Clinical EP: Devices 1	Rats Pharmacological Treatment Alone Versus Treatment Combined With Implantable Cardioverter-Defibrillator Therapy in Patients Over	Nothing to Disclose
Palileo	Edwin	Highlighted Original Research: Non Invasive Imaging and the Year in Review	75 Years Screening for Cardiovascular Disease in High Risk Occupations: The United States Air Force Approach	Nothing to Disclose
Palmer	Dean	Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	The Impact of Lifelong Exercise Training "Dose" on the Ventricular- Arterial Coupling	Nothing to Disclose
Palmer	James	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Investigating the Smoker's Paradox by Gender: Differences in Survival Following Acute ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Palmer	James	Current Issues in Cardiovascular	Increased Risk of Acute ST-Segment Myocardial Infarction in	Nothing to Disclose
Palmerini	Tullio	Epidemiology, Disparities, and Safety Considerations in Antiplatelet Therapy and in ACS	Female Smokers: A Contemporary Demographic Study Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multi-Vessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents	RESEARCH/RESEARCH GRANTS - Eli Lilly and Company; SPEAKER'S BUREAU - Abbott Vascular
Palomo	Andres	Updates on Risk Factors for Cardiovascular Disease	winn rewell-cereiation brug-Elumig Steinis Associations Between Exercise Prior to and Around the Time of Cancer Diagnosis and Subsequent Cardiovascular Events in Women With Breast Cancer: A Women's Health Initiative (WHI) Analysis	Nothing to Disclose
Pan	Stephen	FIT Clinical Decision Making: Arrhythmias and	Genetic Testing for Diagnosis of Progressive Cardiac Conduction	Nothing to Disclose
Panaich	Sidakpal	Electrophysiology Arrhythmias and Clinical EP: Basic 1	Disease Atrial Fibrillation in Patients With Non-STEMI: Insights From a	Nothing to Disclose
Panaich	Sidakpal	PCI for NSTEMI and Complex Patients With	National Database Predictors of 90-Day Readmission and In Hospital Mortality	Nothing to Disclose
	•	Multiple Co-Morbidities	Amongst Patients Undergoing Percutaneous Coronary Interventions: Insights From a National Database	-
Panaich	Sidakpal	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Acute Changes in Left Atrial Pressure Following MitraClip are Associated With Long Term Improvement in 6 Min Walk Distance	Nothing to Disclose

Last Name	First Name	Session Title	Presentation Title	Disclosures
Panaich	Sidakpal	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Insights Into Outcomes With Intracardiac Echocardiogram Use in Structural Interventions	Nothing to Disclose
Panaich	Sidakpal	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Transcatheter Mitral Valve Repair (Mitraclip) in United States: Etiologies and Predictors of Readmission and In-Hospital Mortality From the Nationwide Readmission Database	Nothing to Disclose
Panaich	Sidakpal	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Transcatheter Mitral Valve Repair (Mitra Clip) in United States: Length of Stay and Cost of Hospitalizations From the Nationwide Readmission Database	Nothing to Disclose
Panaich	Sidakpal	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Atrial Fibrillation Is Associated With Worse Outcomes in Patients With Cirrhosis	Nothing to Disclose
Panaich	Sidakpal	Timely Topics in Acute Coronary Syndromes	Percutaneous Coronary Intervention Is Associated With Decreased Mortality in NSTEMI Patients With Advanced CKD	Nothing to Disclose
Panaich	Sidakpal	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Impact of Hereditary Causes of Thrombosis on Ischemic Stroke Between the Years 2008 Through 2012: Nationwide Inpatient Sample Data Analysis	Nothing to Disclose
Panchal	Hemang	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	In-Hospital Mortality in Percutaneous Coronary Stenting of Bifurcation Versus Non-Bifurcation Lesions in Acute ST-Elevation Myocardial Infarction	Nothing to Disclose
Panchal	Hemang	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	National Trend in Total Charges for Multivessel Percutaneous Coronary Intervention in Patients With Diabetes Melitus in the United States: Nationwide Inpatient Sample From the Year 2006 to 2011	Nothing to Disclose
Panchal	Hemang	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	An Unusual Case of Intramural Hematoma Following Percutaneous Coronary Intervention	Nothing to Disclose
Panchangam	Chaitanya	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Acute Necrotizing Eosinophilic Myocarditis Presenting as Sudden Cardiac Arrest in a Teenager	Nothing to Disclose
Pancholy	Maitri	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Comparison of Adenosine Fractional Flow Reserve and Post- Contrast Instantaneous Wave-Free Ratio for Hemodynamic Assessment of Moderate Coronary Stenoses	Nothing to Disclose
Pancholy	Maitri	Interventional Complexity and Complications	Can Non-Procedural Patient Characteristics Predict In-Hospital Complications Following Elective Percutaneous Coronary Intervention? Implications for Same-Day Discharge	Nothing to Disclose
Pancholy	Maitri	Interventional Complexity and Complications	Temporal Trend of Incidence of Stent Thrombosis and In-Hospital Mortality: Results From a National Real-World Registry	Nothing to Disclose
Pancholy	Maitri	Interventional Complexity and Complications	Does Presence of Atrial Fibrillation Affect In-Hospital Mortality in Patients Undergoing Percutaneous Coronary Intervention? Results From a Real-World Registry	Nothing to Disclose
Pancholy	Maitri	Interventional Complexity and Complications	Does Gender Affect In-Hospital Mortality in Patients Presenting With Stent Thrombosis? Results From a National Real-World Registry	Nothing to Disclose
Pancholy	Samir	Fellows Bootcamp: Interventional Basics	Transradial Intervention	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - VasoInnovations Inc; SPEAKER'S BUREAU - MEDTRONIC,Pfizer,Terumo Medical
Pancholy	Samir	Radial Access Mini-Symposium I	Co-Chair	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - VasoInnovations Inc; SPEAKER'S BUREAU - MEDTRONIC,Pfizer,Terumo Medical
Pancholy	Samir	Radial Access Mini-Symposium I	Tips for Successful Radial Access	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - VasoInnovations Inc; SPEAKER'S BUREAU - MEDTRONIC,Pfizer,Terumo Medical
Pancholy	Samir	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Comparison of Adenosine Fractional Flow Reserve and Post- Contrast Instantaneous Wave-Free Ratio for Hemodynamic Assessment of Moderate Coronary Stenoses	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - VasoInnovations Inc; SPEAKER'S BUREAU - MEDTRONIC,Pfizer,Terumo Medical
Pancholy	Samir	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Efficacy of Phosphodiesterase-5 Inhibitor in Patients With Heart Failure With Preserved Ejection Fraction: A Meta-Analysis	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - VasoInnovations Inc; SPEAKER'S BUREAU - MEDTRONIC,Pfizer,Terumo Medical
Pancholy	Samir	Atrial Fibrillation and VT: Unique Populations and Solutions	Difference in Quality of Life Outcomes Between Atrial Fibrillation Catheter Ablation and Anti Arrhythmic Drugs: A Systematic Review and Meta-Analysis	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - VasoInnovations Inc; SPEAKER'S BUREAU - MEDTRONIC,Pfizer,Terumo Medical
Pancholy	Samir	Interventional Complexity and Complications	Does Presence of Atrial Fibrillation Affect In-Hospital Mortality in Patients Undergoing Percutaneous Coronary Intervention? Results From a Real-World Registry	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - VasoInnovations Inc; SPEAKER'S BUREAU - MEDTRONIC,Pfizer,Terumo Medical
Pancholy	Samir	02. Acute and Stable Ischemic Heart Disease: Clinical Team 9	Suggested Reviewer	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - VasoInnovations Inc; SPEAKER'S BUREAU - MEDTRONIC,Pfizer,Terumo Medical
Pande	Ashvin	40. Vascular Medicine: Non Coronary Arterial Disease Team 1	Suggested Reviewer	Nothing to Disclose
Pandey	Ambarish	Updates on Risk Factors for Cardiovascular Disease	Association of Objectively Measured Sedentary Time, Physical Activity and Cardiorespiratory Fitness Levels with Cardiometabolic Risk Factors and Cardiac Structure and Function: Findings From the Dallas Heart Study	Nothing to Disclose
Pandey	Ambarish	Updates on Risk Factors for Cardiovascular Disease		Nothing to Disclose
Pandey	Ambarish	Interventional Cardiology: TAVR 2	Comparative Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Chronic Kidney Disease	Nothing to Disclose
Pandey	Ambarish	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues		Nothing to Disclose
Pandey	Ambarish	Interventional Cardiology: TAVR 3	Role of Hospital Volume in Identifying Low and High-performing Surgical Valve Centers in the United States	Nothing to Disclose
Pandey	Ambarish	Emerging Developments in HFpEF and Arryhthmias	Implantable Cardioverter Defibrillators for the Prevention of Mortality in Patients With Non-Ischemic Cardiomyopathy: A Meta-Analysis of Randomized Control Trials	Nothing to Disclose
Pandey	Ambarish	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Burden of 30-Day Readmissions in Acute Myocardial Infarction and Heart Failure in the United States: A National Perspective	Nothing to Disclose
Pandey	Amitabh	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	New Shortness of Breath, Old Problems	Nothing to Disclose
Pandey	Amitabh	Redefining the "F" Word	Fontan Circulation	Nothing to Disclose
Pandey	Arjun	Toward Precision Medicine in the Treatment of Elevated Blood Pressure FIT Clinical Decision Making: Interventional	The Impact of Diet-Induced Weight Loss on Non-Dipping Circadian Blood Pressure Patterns	Nothing to Disclose
Pandey	Arvind	Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	An "Obstructed" View of Hypertension: When Low Really Means High	Nothing to Disclose
Pandey Pandey	Ashok Avinash	Measuring Success in Cardiac Rehabilitation Predicting Outcomes in Cardiac Rehabilitation	Acute and Sub-Acute Hemodynamic Effects of Restorative Yoga Lower Educational Levels May Be an Important Determinant of	Nothing to Disclose Nothing to Disclose
		Patients	Adherence to Evidenced-Based Therapies in Post-MI Patients	ů .
Pandey	Beneet	Arrhythmias and Clinical EP: Basic 3	Impact of Obstructive Sleep Apnea Severity on Cardiac Events in Patients With Normal or Prolonged Ventricular Repolarization	Nothing to Disclose
Pandey	Beneet	Interventional Cardiology: PCI and TAVR in Complex Patients	The Risk of Adverse Coronary Events Is Higher in Patients With Severe Obstructive Sleep Apnea Following Percutaneous Coronary	Nothing to Disclose
			Intervention	

Last Name	First Name	Session Title	Presentation Title	Disclosures
Pandey	Shashi	Interventional Complexity and Complications	Initial Experience of 265 Cases of Trans Ulnar Access Angioplasty: Interim Analysis of a Single Centre Observational Study From AJULAST (AJmer ULnar Angioplasty Study) Cohort	Nothing to Disclose
Pandian	Natesa	Controversies in Echocardiography	Con: Strain is a Research Tool, Just Tell Me the LVEF	OTHER - Siemens Ultrasound; SPEAKER'S BUREAU -
Pandian	Natesa	Innovations in Valvular Heart Disease	Co-Chair	Lantheus, Toshiba OTHER - Siemens Ultrasound; SPEAKER'S BUREAU -
		Diagnosis and Treatment		Lantheus, Toshiba
Pandian	Natesa	Controversies in Mitral Valve Surgery: Joint Symposium of the Society of Thoracic Surgeons and the American College of Cardiology	Panelist	OTHER - Siemens Ultrasound; SPEAKER'S BUREAU - Lantheus,Toshiba
Pandian	Natesa	FIT Clinical Decision Making: Non-Invasive	Successful Management of Acute Salmonella Aortitis	OTHER - Siemens Ultrasound; SPEAKER'S BUREAU -
Pandian	Natesa	Imaging and Valvular Heart Disease Engage @ ACC.17 Studio: Ask the Valvular	Master of Ceremony	Lantheus,Toshiba OTHER - Siemens Ultrasound; SPEAKER'S BUREAU -
Panikkath	Ragesh	Heart Disease Experts Put Your Codon! Genetic Insights Into Heart Failure	Paricalcitol Effects on Heart Failure in Experimental Metabolic Syndrome: New Pathways Discovered Using Next Generation Sequencing	Lantheus,Toshiba Nothing to Disclose
Panjrath	Gurusher	Readmission in Heart Failure: Questions Unanswered	Co-Chair	SPEAKER'S BUREAU - Amgen Inc.
Panjrath	Gurusher	Treatment Strategies for End Stage Heart Failure: Medications, Machines and Everything in Between	Co-Chair	SPEAKER'S BUREAU - Amgen Inc.
Panjrath	Gurusher	Why Can't We Be Friends? Controversies in	ACC Poster Moderator	SPEAKER'S BUREAU - Amgen Inc.
Panjrath	Gurusher	Heart Failure Management 13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	SPEAKER'S BUREAU - Amgen Inc.
Pant	Sadip	Clinical Team 4 PCI for NSTEMI and Complex Patients With	Thirty-Day Readmission Rate and Cost After Percutaneous	Nothing to Disclose
	•	Multiple Co-Morbidities	Coronary Intervention in the United States: A National Readmission Database Analysis	
Pantazopoulos	John	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Steep Decrease in the Rate of Myocardial Infarction From 2000 to 2008	Nothing to Disclose
Pantazopoulos Panza	John Gregory	Unusual Presentations of ACS Featured Clinical Research III	Decrease in the Rate of MI Case Fatality From 2000 to 2014 The Effect of High-Dose Atorvastatin on Neuronal Activity and	Nothing to Disclose Nothing to Disclose
Panza	Julio	Cardiac Arrest, Diabetes, and Other High Risk	Cognitive Function Sex Differences in Revascularization and In-Hospital Outcomes of	Nothing to Disclose
		Features of Patients With Acute Coronary Syndrome	Non-ST-Segment Elevation Myocardial Infarction in the United States	
Panza	Julio	Interventional Cardiology: TAVR 3	Regional Variations in In-Hospital Outcomes and Healthcare Resource Utilization in Patients Undergoing Transcatheter Aortic Valve Replacement in the United States	Nothing to Disclose
Panza	Julio	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Combined Heart-Kidney Transplantation in a Patient With Human Immunodeficiency Virus	Nothing to Disclose
Panza	Julio	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Management of Takotsubo Cardiomyopathy Complicated by Left Ventricular Outflow Tract Obstruction	Nothing to Disclose
Panza	Julio	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Association of Academic Year-End Changeover With Survival Rates After In-Hospital Cardiac Arrest: An Examination of the "July Effect"	Nothing to Disclose
Panza	Julio	The Evolving World of LVADs, Transplant and	Arrhythmias in Hospitalized Heart Transplanted Patients: A United	Nothing to Disclose
Panza	Julio	Other Novel Discoveries The Evolving World of LVADs, Transplant and	States National Study Chagas Heart Disease: A United States National Study	Nothing to Disclose
Panza	Julio	Other Novel Discoveries FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Spontaneous Coronary Artery Dissection in a Transplanted Heart	Nothing to Disclose
Paolo	Raggi	Disease, and Vascular Medicine Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Inflammatory Response to Mental Stress and Mental Stress Induced Myocardial Ischemia	OTHER - none
Paone	Darien	Coronary Artery Disease Interventional Cardiology: TAVR 2	Short- and Mid-Term Outcomes After Transcatheter Aortic Valve Replacement in Patients With Renal Insufficiency Not on	Nothing to Disclose
Paone	Gaetano	Interventional Cardiology: Structural Heart	Hemodialysis Transcatheter Mitral Valve-in-Ring Implantation After Failure of	CONSULTANT FEES/HONORARIA - Edwards Lifesciences
Paone	Gaetano	Disease Interventional Cardiology: TAVR 3	Surgical Mitral Ring Annuloplasty Predictors of Late Bleeding in the TAVR Population	CONSULTANT FEES/HONORARIA - Edwards Lifesciences
Papadakis	Michael	The Abnormal ECG: Should I Worry about	Borderline ECG Findings: Do These Really not Count?	Nothing to Disclose
Papadakis	Michael	Sudden Death Risk in this Patient Imaging the Athlete's Heart	General Population Screening for Sudden Cardiac Death in Young Individuals: Is It Feasible, Is It Justifiable & How Much Does It	Nothing to Disclose
Papadakis	Michael	Hearts and Soles: Multimodality Imaging in	Cost? The Mixed Race Athlete's ECG: Not So Black and White	Nothing to Disclose
Papadakis	Michael	Athletes 31. Non Invasive Imaging: Sports and Exercise	Suggested Reviewer	Nothing to Disclose
Papademetriou	Vasilios	Team 1 Assessing the Clinical Impact of Blood	Guidelines Allowing Control of Hypertension in Non-Diabetics	Nothing to Disclose
		Pressure Lowering Therapies	Greater Than 60 Years Old at up to 150 mmHg Average Systolic Blood Pressure Increases Patient Mortality in Veterans	ů
Papademetriou	Vasilios	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study	Nothing to Disclose
Papafaklis	Michail	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Association of Coronary Epicardial Endothelial Dysfunction With Low Endothelial Shear Stress in Patients With Mild Coronary Atherosclerosis Who Presented With Chest Pain	Nothing to Disclose
Papageorgiou	Nikolaos	From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease	Dietary Consumption of Olive Oil and Cardiovascular Outcome in Patients With Coronary Artery Disease	Nothing to Disclose
Papageorgiou	Nikolaos	Uncovering the Intricacies of Vascular Function	The Impact of Natural Chios Mastic Supplementation on Endothelial	Nothing to Disclose
Papalia	Francesco	Making Progress in Understanding Heart Failure	Function and Arterial Stiffness in Smokers Prognostic Utility of Haemoglobin/Haematocrit Equations for Estimating Congestion Versus Calculated Plasma Volume Status in	Nothing to Disclose
Papamikroulis	George-Angelo	MicroRNAs and Beyond in Vascular Medicine	Chronic Heart Failure Association of Endothelial Dysfunction and Arterial Wall Elastic Properties With Systemic Inflammation in Patients With	Nothing to Disclose
Papamikroulis	George-Angelo	Diabetes and Endothelial Dysfucntion in Heart Failure	Pseudoexfoliative Glaucoma Association of Endothelial Dysfunction With Biomarkers of Inflammation, Myocardial Fibrosis and Left Ventricle Strain in	Nothing to Disclose
Papamikroulis	George-Angelo	Uncovering the Intricacies of Vascular Function	Patients With Heart Failure The Impact of Natural Chios Mastic Supplementation on Endothelial	Nothing to Disclose
Papanikolaou	Angelos	Heart Failure and Cardiomyopathies: Is Heart	Function and Arterial Stiffness in Smokers Omega-3 Polyunsaturated Fatty Acids May Favorably Affect	Nothing to Disclose
		Failure With a Normal EF for Real?	Inflammatory Biomarkers & Novel Indices of Left Ventricle Function in Patients With Heart Failure Endothelial Dysfunction Post Transradial Access Coronary	
Papanikolaou	Angelos	Vascular Access and Hemostasis Issues	Endothelial Dystunction Post Transradial Access Coronary Catheterization: A Clinical Study and Meta-Analysis of Published Literature	Nothing to Disclose
Papayannis	Aristotelis	Innovations in Cardiovascular Risk Assessment	Association Between Serum Collagen Biomarkers and Coronary	Nothing to Disclose

Papayannis An Pape Lir Pape Lir Papernov An Pappas Pa		Session Title Non Invasive Imaging: Prognostic Implications		
Pape Lir Pape Lir Papernov An Pappas Pa			Presentation Title	Disclosures
Pape Lir Papernov An Pappas Pa		of CT Angiography	Coronary Artery Structural Remodeling by Computed Tomography and Echocardiographic Left Ventricular Mass Changes Over the	Nothing to Disclose
Pape Lir Papernov An Pappas Pa	nda		Next 5 Years: The Coronary Artery Risk Development in Young	
Pape Lir Papernov An Pappas Pa	ilda	Valvular Heart Disease: Aortic Stenosis	Adults (CARDIA) Study Factors Associated With Rapid Progression of Aortic Stenosis in	Nothing to Disclose
Papernov An Pappas Pa		Valvulai Fleat Disease. Autile Steriosis	Patients With Bicuspid Aortic Valve: A Single Center Retrospective	Nothing to Disclose
Papernov An Pappas Pa		Dance Dance Condition Valuable	Study	Nothing to Disclose
Pappas Pa	nga	Beans, Beans, Good for Your Heart	Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection	Nothing to Disclose
**	nna		Change in Renal Function During Extended Follow-Up After Left	Nothing to Disclose
	atroklos	Other Novel Discoveries Vascular Medicine: Emerging Concepts in	Ventricular Assist Device Implantation Influence of Family History of Aortic Disease on Type B Aortic	RESEARCH/RESEARCH GRANTS - HeartWare, Thoratec
Pappas Th	ationios	Clinical Vascular Diseases	Dissection	Corporation
	homas	Interventional Cardiology: Angiography,	The Effectiveness of Excimer Laser Angioplasty to Treat Coronary	Nothing to Disclose
		Intravascular Imaging and Interventional CT/MR	In-Stent Restenosis With Peri-Stent Calcium as Assessed by Optical Coherence Tomography	
Paquette Mi	iney	Fibrillatory Arrhythmias: Outcomes With	Persistence With Therapy in Patients With Atrial Fibrillation: The	SALARY - Boehringer Ingelheim Pharmaceuticals Ltd.
Paquette Mi	iney	Contemporary Practice Atrial Fibrillation and VT: Incorporating Novel	GLORIA-AF Registry Rates of Stroke and Bleeding With Dabigatran 150 and 110 mg BID	SALARY - Boehringer Ingelheim Pharmaceuticals Ltd.
	•	Risks Toward Decision Making	in Clinical Practice: The GLORIA-AF Registry	
Paradis Je	ean-Michel	Interventional Cardiology: TAVR 4	Clinical Study of the Impact of Preexisting Patient-Prosthesis Mismatch on Valve-in-Valve Performance	Nothing to Disclose
Paradis Je	ean-Michel	Frontiers in Mitral Valve Disease and	Significant Mitral Regurgitation in Patients Undergoing Transcatheter	Nothing to Disclose
		Treatment	Aortic Valve Replacement: Evolution and Imaging Predictors of	
Parakh Ka	apil	Healthcare Innovation for Your Practice: Focus	Improvement Patient Engagement in the Digital Era	SALARY - Google
		on Personalized Digital Health		-
Parakh Ne	eeraj	Insights Into Ischemic Heart Disease: Stable to Erosive Plaques	Immuno-Histopathology of Intracoronary Thrombus Aspirated During Primary Percutaneous Intervention for ST Elevation	Nothing to Disclose
			Myocardial Infarction and Its Clinical Significance	
Parashar Ak	khil	Emerging Developments in HFpEF and Arryhthmias	Implantable Cardioverter Defibrillators for the Prevention of Mortality in Patients With Non-Ischemic Cardiomyopathy: A Meta-Analysis of	Nothing to Disclose
		, ary mainings	Randomized Control Trials	
Parashara De	eepak	Acute Heart Failure: Evaluating Strategies to	Timely Use of Right Heart Catheterization Is Associated With	Nothing to Disclose
,		Prevent Readmissions	Reduced In-Hospital Mortality in Patients With Congestive Heart Failure: Insight From the United States National Inpatient Sample	
			Database	
Parashara De	eepak	Updates on Risk Factors for Cardiovascular Disease	Prevalence of Abnormal Ankle Brachial Index in Obese and Non- Obese Subjects, and Association of Abnormal Ankle Brachial Index	Nothing to Disclose
		Discuse	With All-Cause and Cardiovascular Mortality in These Groups:	
		,	Results From National Health and Nutrition Examination Survey 1999-2000	
Parashara De	eepak	Diabetes and Other Issues in Cardiovascular	Association of Ankle Brachial Index and Hemoglobin A1c With All-	Nothing to Disclose
		Prevention	Cause and Cardiovascular Mortality: Results From the National	3
Parashara De	eepak	Advanced Therapies = Advanced Trouble:	Health and Nutrition Examination Survey 1999 to 2000 Independent Association of Symptomatic Peripheral Arterial Disease	Nothing to Disclose
r didonard		VAD and Transplant Challenges	for Adverse Outcomes, Poor Graft Survival and Length of Hospital	Thouming to Discusse
		,	Stay Following Heart Transplantation: An Analysis of 22,820 Heart Transplants From the UNOS Database	
Paraskevopoulos Th	heodore	MicroRNAs and Beyond in Vascular Medicine	Association of Endothelial Dysfunction and Arterial Wall Elastic	Nothing to Disclose
,		,	Properties With Systemic Inflammation in Patients With	
Parastatidis loa	annis	Structural Heart Interventions: Focus on Mitral	Pseudoexfoliative Glaucoma Pulmonary Venous Waveforms Predict Ventricular Remodeling	Nothing to Disclose
Taradatata		Valve, Left Atrial Appendage and HOCM	After Percutaneous Mitral Valve Repair	
Pareek Ma	anan	Making Progress in Understanding Heart Failure	NT-proBNP, Left Ventricular Structure and Function, and Long- Term Cardiovascular Events: Insights From a Prospective	Nothing to Disclose
		raliule	Population-Based Cohort Study	
Pareek Ma	anan	Emerging Developments in HFpEF and	Left Ventricular Hypertrophy and Subsequent Cardiovascular Risk:	Nothing to Disclose
Pareek Ma	anan	Arryhthmias The Evolving World of LVADs, Transplant and	Does It Matter How It Is Diagnosed? High-Sensitivity Troponin-T, Left Ventricular Size and Function, and	Nothing to Disclose
		Other Novel Discoveries	Long-Term Outcomes in Clinically Stable, Apparently Healthy Older	
Parekh Dh	haval	Core Curriculum: Rhythm and the Blues: Still	Subjects Common Misfirings of the Heart: Implications in ACHD	Nothing to Disclose
		Young at Heart	-	-
Pargaonkar Ve	edant	Angina in the Absence of Obstructive CAD. What Do We Do With These Patients?	Case Presentation: Myocardial Bridge	Nothing to Disclose
Pargaonkar Ve	edant	Current Issues in Cardiovascular	Sex Differences in the Risk Factors for Endothelial and	Nothing to Disclose
,		Epidemiology, Disparities, and Safety	Microvascular Dysfunction in Patients With Angina in the Absence of Obstructive Coronary Artery Disease	
Parhofer Kla	aus	Advances in Cholesterol Measurement and	The Effect of PCSK9 Inhibition on LDL-Subfractions in Patients With	Nothing to Disclose
		Management	Severe LDL-Hypercholesterolemia	-
Parhofer Kla	aus	Updates on Risk Factors for Cardiovascular Disease	Walnut-Enriched Diet Reduces Lipids in Healthy Caucasian Subjects, Independent of Recommended Macronutrient	Nothing to Disclose
			Replacement	
Parides Mi	ichael	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking	Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic	Nothing to Disclose
		Clinical Trials	Surgical Trials Network	
Paridon Ste	tephen	Exercise in Congenital Heart Disease	Weightlifting and Congenital Heart Disease: Getting the Pump	Nothing to Disclose
Paridon Sto	tephen	Congenital Heart Disease: New Diagnostic	Pumped Up Right Ventricular Contractile Reserve Is Reduced in Children and	Nothing to Disclose
	•	Approaches in Congenital Heart Disease	Adolescents With Tetralogy of Fallot: A Stress Echocardiographic	
Į.	nkit	Structural Heart Interventions: Focus on Mitral	Study Pulmonary Venous Waveforms Predict Ventricular Remodeling	Nothing to Disclose
Parikh An		Valve, Left Atrial Appendage and HOCM	After Percutaneous Mitral Valve Repair	-
	evang	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Apical Hypertrophic Cardiomyopathy: A Case of Mimicry	Nothing to Disclose
		Non Invasive Imaging: MR Structure and	Heart Rate Response During Regadenoson Stress Cardiac	Nothing to Disclose
Parikh De	evang	Valuvular Heart Disease	Magnetic Resonance Imaging Is a Predictor of Adverse Cardiovascular Outcomes	
Parikh De	evang	·		
Parikh De	evang	International CV Centers of Excellence:	NCDR and ACC International Center of Excellence - The Indian	Nothing to Disclose
Parikh De	-	Leveraging the NCDR for Achieving High	NCDR and ACC International Center of Excellence - The Indian Experience	Nothing to Disclose
Parikh De Parikh Ke	eyur	Leveraging the NCDR for Achieving High Quality Care	Experience	-
Parikh De Parikh De Parikh Ke	-	Leveraging the NCDR for Achieving High	Experience Evaluation of a New Radiation Protection Technology (Cardio-TRAP®) in Transradial Percutaneous Coronary Intervention	Nothing to Disclose Nothing to Disclose
Parikh De Parikh Ke Parikh Ke	eyur eyur	Leveraging the NCDR for Achieving High Quality Care Interventional Complexity and Complications	Experience Evaluation of a New Radiation Protection Technology (Cardio-TRAP®) in Transradial Percutaneous Coronary Intervention Procedures	Nothing to Disclose
Parikh De Parikh Ke Parikh Ke	eyur	Leveraging the NCDR for Achieving High Quality Care	Experience Evaluation of a New Radiation Protection Technology (Cardio-TRAP®) in Transradial Percutaneous Coronary Intervention Procedures That is Not a Seizure, It's VT: A Unique Presentation of Acquired Long QT Syndrome	-
Parikh De Parikh De Parikh Ke Parikh Ke Parikh Ke	eyur eyur	Leveraging the NCDR for Achieving High Quality Care Interventional Complexity and Complications FIT Clinical Decision Making: Arrhythmias and Electrophysiology Understanding Pulmonary Vascular Disease:	Experience Evaluation of a New Radiation Protection Technology (Cardio-TRAP®) in Transradial Percutaneous Coronary Intervention Procedures That Is Not a Seizure, It's VT: A Unique Presentation of Acquired Long QT Syndrome Julimonary Vascular Response to Nitric Oxide and Subsequent	Nothing to Disclose
Parikh De Parikh Ke Parikh Ke Parikh Ke	eyur eyur hushboo	Leveraging the NCDR for Achieving High Quality Care Interventional Complexity and Complications FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Experience Evaluation of a New Radiation Protection Technology (Cardio-TRAP®) in Transradial Percutaneous Coronary Intervention Procedures That Is Not a Seizure, It's VT: A Unique Presentation of Acquired Long OT Syndrome Pulmonary Vascular Response to Nitric Oxide and Subsequent Response to Advanced Medical Therapy in Incident Patients With	Nothing to Disclose Nothing to Disclose
Parikh De Parikh Ke Parikh Ke Parikh Ke Parikh Ki Parikh Ki	eyur eyur hushboo	Leveraging the NCDR for Achieving High Quality Care Interventional Complexity and Complications FIT Clinical Decision Making: Arrhythmias and Electrophysiology Understanding Pulmonary Vascular Disease:	Experience Evaluation of a New Radiation Protection Technology (Cardio-TRAP®) in Transradial Percutaneous Coronary Intervention Procedures That Is Not a Seizure, It's VT: A Unique Presentation of Acquired Long QT Syndrome Julimonary Vascular Response to Nitric Oxide and Subsequent	Nothing to Disclose Nothing to Disclose



(Mary and and and and and and and and and and				
Parikh	Manish	Session Title Interventional Live Case Session V: Complex Coronary and Physiology from Mid-America	Presentation Title Panelist	Disclosures CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific, MEDTRONIC, Philips; SPEAKER'S BUREAU - CSI
Parikh	Manish	Heart Institute (Kansas City, Missouri) Fellows Bootcamp: Coronary Disease	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston
Parikh	Manish	Management Fellows Bootcamp: Coronary Disease	Multivessel Disease: When to Perform PCI or Refer to Surgery?	Scientific,MEDTRONIC,Philips; SPEAKER'S BUREAU - CSI CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston
Parikh	Manish	Management Interventional Cardiology: Angiography,	Morphologic Patterns of In-Stent Chronic Total Occlusions: An	Scientific,MEDTRONIC,Philips; SPEAKER'S BUREAU - CSI CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston
Parikh	Manish	Intravascular Imaging and Interventional CT/MR Advances in Chronic Total Occlusion	Intravascular Ultrasound Study	Scientific,MEDTRONIC,Philips; SPEAKER'S BUREAU - CSI CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston
		Intervention	Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	Scientific,MEDTRONIC,Philips; SPEAKER'S BUREAU - CSI
Parikh	Manish	Advances in Chronic Total Occlusion Intervention	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific, MEDTRONIC, Philips; SPEAKER'S BUREAU - CSI
Parikh	Manish	Interventional Challenging Cases: Team 3	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific, MEDTRONIC, Philips; SPEAKER'S BUREAU - CSI
Parikh	Nisha	Innovative Use of Echocardiography	Effect of Left Atrial Remodeling on Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study	Nothing to Disclose
Parikh	Nisha	Innovative Use of Echocardiography	Left Atrial Function Index as a Predictor of Cardiovascular Disease and Atrial Fibrillation: Data From the Framingham Offspring Study	Nothing to Disclose
Parikh Parikh	Nisha Parth	32. Prevention: Clinical Team 6 Interventional Complexity and Complications	Suggested Reviewer Evaluation of a New Radiation Protection Technology (Cardio-	Nothing to Disclose Nothing to Disclose
		and rondonal complexity and complications	TRAP®) in Transradial Percutaneous Coronary Intervention Procedures	. Committee of the comm
Parikh	Puja	Interventional Cardiology: TAVR 2	Impact of Chronic Kidney Disease on Mortality in Adults Undergoing	Nothing to Disclose
Parikh	Rushi	FIT Clinical Decision Making: Heart Failure and	Balloon Aortic Valvuloplasty Whole Heart of the Matter	Nothing to Disclose
Parikh	Sachin	Pulmonary Hypertension FIT Clinical Decision Making: Heart Failure and	For the love of Loeffler	Nothing to Disclose
Parikh	Sahil	Pulmonary Hypertension Fellows Bootcamp: Peripheral Vascular	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott
Palikii	Sanii	Peniows Bootcamp, Penipinetal Vascular Disease and Structural Heart Disease Management		Vascular Abiomed, Boston Scientific, MEDTRONIC, Spectranetics, St. Jude Medical, Terumo; DATA SAFETY MONITORING BOARD - Silk Road Medical; RESEARCH/IRESEARCH GRANTS - Abiomed, AstraZeneca Pharmaceuticals, Lutoniv/CR Bard, MEDTRONIC; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals, Lutoniv/CR Bard, Spectranetics, St. Jude Medical, Terumo, The Medicines Company
Parikh	Sahil	Fellows Bootcamp: Peripheral Vascular Disease and Structural Heart Disease Management		CONSULTANT FEES/HONORARIA - Abbott Vascular, Abiomed, Boston Scientific, MEDTRONIC, Spectranetics, St. Jude Medical, Terumo; DATA SAFETY MONITORING BOARD - Silk Road Medical; RESEARCH/RESEARCH GRANTS - Abiomed, AstraZeneca Pharmaceuticals, Lutoniv/CR Bard, MEDTRONIC; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals, Lutoniv/CR Bard, Spectranetics, St. Jude Medical, Terumo, The Medicines Company
Parikh	Sahil	Fellows Bootcamp: Coronary Disease Management	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular, Abiomed, Boston Scientific, MEDTRONIC, Spectranetics, St. Jude Medical, Terumo; DATA SAFETY MONITORING BOARD - Silk Road Medical; RESEARCH/RESEARCH GRANTS - Abiomed, AstraZeneca Pharmaceuticals, Lutoniv/CR Bard, MEDTRONIC; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals, Lutoniv/CR Bard, Spectranetics, St. Jude Medical, Terumo, The Medicines Company
Parikh	Sahil	Controversies and Strategies for Endovascular Treatment of the Femoropopliteal Segment	Complications Associated with Femoropopliteal Intervention: How They Happen, How to Deal with Them, and How to Avoid Them	CONSULTANT FEES/HONORARIA - Abbott Vascular, Abiomed, Boston Scientific, MEDTRONIC, Spectranetics, St. Jude Medical, Terumo; DATA SAFETY MONITORING BOARD - Silk Road Medical; RESEARCH/RESEARCH GRANTS - Abiomed, AstraZeneca Pharmaceuticals, Lutoniv/CR Bard, MEDTRONIC; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals, Lutoniv/CR Bard, Spectranetics, St. Jude Medical, Terumo, The Medicines Company
Parikh	Sahil	Clinical Assessment and Revascularization for Critical Limb Ischemia		CONSULTANT FEES/HONORARIA - Abbott Vascular, Abiomed, Boston Scientific, MEDTRONIC, Spectranetics, St. Jude Medical, Terumo; DATA SAFETY MONITORING BOARD - Silk Road Medical; RESEARCH/RESEARCH GRANTS - Abiomed, AstraZeneca Pharmaceuticals, Lutoniv/CR Bard, MEDTRONIC; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals, Lutoniv/CR Bard, Spectranetics, St. Jude Medical, Terumo, The Medicines Company
Parikh	Sahil	Critical Limb Ischemia		CONSULTANT FEES/HONORARIA - Abbott Vascular Abiomed,Boston Scientific,MEDTRONIC,Spectranetics,St. Jude Medical,Terumo; DATA SAFETY MONITORING BOARD - Silk Road Medical; RESEARCH/RESEARCH GRANTS - Abiomed,AstraZeneca Pharmaceuticals,Lutoniv/CR Bard,MEDTRONIC; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals,Lutoniv/CR Bard,Spectranetics,St. Jude Medical,Terumo,The Medicines Company
Parikh	Sahil	Interventional Cardiology: Vascular Access and Complications Team 1 Highlighted Original Research: Arrhythmias		CONSULTANT FEES/HONORARIA - Abbott Vascular, Abiomed, Boston Scientific, MEDTRONIC, Spectranetics, St. Jude Medical, Terumo; DATA SAFETY MONITORING BOARD - Silk Road Medical; RESEARCH/RESEARCH GRANTS - Abiomed, AstraZeneca Pharmaceuticals, Lutoniv/CR Bard, MEDTRONIC; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals, Lutoniv/CR Bard, Spectranetics, St. Jude Medical, Terumo, The Medicines Company Nothing to Disclose
Parikh		r ngringrited Original Research: Armythmias		INOUTHING TO DISCLOSE
Parikh	Valay	and Clinical EP and the Year in Review	Cardiac Device Implantation: Are They Safe?	
Parikh Parikh Parikh	Valay Valay Valay		Implantable Cardioverter Defibrillator for the Prevention of Mortality in Non-Ischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose Nothing to Disclose

W. A.					
Last Name	First Name	Session Title	Presentation Title	Disclosures	
Parikh	Valay	Arrhythmias and Clinical EP: Devices 2	Impact of Left Atrial Appendage Occlusion on Left Atrial Function	Nothing to Disclose Nothing to Disclose	
Parikh	Valay	Arrhythmias and Clinical EP: Devices 2	Long Term Safety and Efficacy of Left Atrial Appendage Closure With Lariat in Atrial Fibrillation: Is It Still Working at 5 Years?	Nothing to Disclose	
Parikh	Valay	Atrial Fibrillation and VT: Unique Populations	Use of an Esophageal Retractor to Prevent Thermal Injuries During	Nothing to Disclose	
Parikh	Voley	and Solutions	Atrial Fibrillation Ablation: A Multi-Center Experience Meta-Analysis on the Efficacy and Safety of New Oral	Nothing to Disclose	
Pankn	Valay	Arrhythmias and Clinical EP: Anticoagulation Issues	Anticoagulants Compared With Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation	Nothing to Disclose	
Parikh	Valay	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	CHADS2 Score Predicts Outcomes of Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation	Nothing to Disclose	
Parikh	Valay	Arrhythmias and Clinical EP: AF Miscellaneous	Left Atrial Appendage Ligation With Lariat Device: A Systematic	Nothing to Disclose	
Parikh	Valay	and Surgical Issues Innovative Approaches for Reducing Risk and	Review and Meta-Analysis Efficacy of Catheter Ablation of Atrial Fibrillation in the Setting of	Nothing to Disclose	
	_	Improving Outcomes With Ablation	Systolic Dysfunction: A Meta-Analysis of Randomized Control Trials		
Parikh	Valay	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Safety Profiles of Percutaneous Left Atrial Appendage Closure Devices: An Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database From 2009 - 2016	Nothing to Disclose	
Parikh	Victoria	Advances in HCM, PPCM and Other Cardiomyopathies	Systolic Dysfunction Without LV Dilatation in a Cohort of Patients With Lamin A/C Cardiomyopathy	Nothing to Disclose	
Parikh	Victoria	Interdisciplinary Cardiovascular Care in	Interdisciplinary Peripartum Care of the Patient With Diastolic Heart	Nothing to Disclose	
Parikh	Vishal	Complex Scenarios Emerging Applications of Echocardiography	Failure in Non-Obstructive Hypertrophic Cardiomyopathy Clinical Characteristics and Changes of Valvuloarterial Impedence	Nothing to Disclose	
			Severity in Patients Undergoing Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis		
Parikh	Vishal	Arrhythmias and Clinical EP: Devices 3	Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention	Nothing to Disclose	
Park	Bryan	Updates on Risk Factors for Cardiovascular Disease	Impact of Exercise and Pharmacologic Interventions on Changes in Visceral Adiposity: A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose	
Park	Chang Gyu	Novel Developments in Acute Coronary	Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor	Nothing to Disclose	
		Syndromes	and Angiotensin Receptor Blocker in Diabetic Hypertensive Acute Myocardial Infarction Patients: Results From the Korea Acute Myocardial Infarction Registry (KAMIR)		
Park	Chang Gyu	Timely Topics in Acute Coronary Syndromes	Predictors of Mortality in Acute Myocardial Infarction Patients With	Nothing to Disclose	
Park	Chang Gyu	Advances in Chronic Total Occlusion	Unprotected Left Main Coronary Artery Disease Impact of Percutaneous Coronary Intervention for Chronic Total	Nothing to Disclose	
		Intervention	Occlusion Patients With Near-Normal Left Ventricular Function	-	
Park	David	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Genetic Testing for Diagnosis of Progressive Cardiac Conduction Disease	Nothing to Disclose	
Park	Duk-Woo	Late-Breaking Clinical Trials: Interventional	Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With Coronary Chronic Total Occlusion: DECISION CTO Randomized Trial	Nothing to Disclose	
Park	Duk-Woo	Resistant Hypertension in the Pulmonary and	Co-Chair	Nothing to Disclose	
		Systemic Beds: International Perspectives From the ACC Argentina Chapter, Korean Society of Cardiology, and American College of Cardiology			
Park	Duk-Woo	Resistant Hypertension in the Pulmonary and Systemic Beds: International Perspectives From the ACC Argentina Chapter, Korean Society of Cardiology, and American College of Cardiology	New Era of Interventional Treatment in Pulmonary Hypertension	Nothing to Disclose	
Park	Duk-Woo	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	The Prognostic Implications of Current Periprocedural Myocardial Infarction Definitions in Patients Underwent Percutaneous Conronary Intervention With Unprotected Left Main Coronary Artery Disease	Nothing to Disclose	
Park	Duk-Woo	Advances in Lipid Management	Lower Mortality in Patients With Vasospastic Angina Who Receive	Nothing to Disclose	
Park	Duk-Woo	Refining PCI Technique and Outcomes	Statin Therapy: Data From the Asan Vasospastic Angina Registry External Validation of DAPT Score in Two Large Cohorts	Nothing to Disclose	
Park	Duk-Woo	CAD in Unique Patient Populations	Mortality of Patients With Previous Stroke Undergoing Drug-Eluting Stent Implantation	Nothing to Disclose	
Park	Hyelim	Arrhythmias and Clinical EP: Basic 1	Exosome Derived From Atrial Fibrillation Patients Prevents Proarrhythmic Remodeling by Restoration of Acetylated Tubulin in	Nothing to Disclose	
Park	Hyelim	Arrhythmias and Clinical EP: Basic 1	Pacing Induced Tachycardia Model MicroRNA-26a From Hypoxic Human Mesenchymal Stem Cells: Derived Microvesicles Enhance Cardiac Conduction Following	Nothing to Disclose	
_			Myocardial Infarction		
Park	Hyewon	Arrhythmias and Clinical EP: Basic 1	Exosome Derived From Atrial Fibrillation Patients Prevents Proarrhythmic Remodeling by Restoration of Acetylated Tubulin in Pacing Induced Tachycardia Model	Nothing to Disclose	
Park	Hyewon	Arrhythmias and Clinical EP: Basic 1	MicroRNA-26a From Hypoxic Human Mesenchymal Stem Cells: Derived Microvesicles Enhance Cardiac Conduction Following Myocardial Infarction	Nothing to Disclose	
Park	Hyoung-Seob	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Five Year Outcomes of Fractional Flow Reserve Guided Versus Intravascular Ultrasound Guided Percutaneous Coronary	Nothing to Disclose	
Park	Hyung Bok	Resistant Hypertension in the Pulmonary and	Intervention in Intermediate Coronary Artery Disease New Era of Pharmacological Treatment in Pulmonary Hypertension	Nothing to Disclose	
· w/K	yung bok	Systemic Beds: International Perspectives From the ACC Argentina Chapter, Korean Society of Cardiology, and American College of Cardiology	Total and a manuscrogular readment in runnollary rypertension	realing to Distribution	
Park	Hyung Bok	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired	Nothing to Disclose	
Park	Hyung Bok	Non Invasive Imaging: Prognostic Implications of CT Angiography	Renal Function: The CONFIRM Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden	Nothing to Disclose	
Park	Hyung Bok	Non Invasive Imaging: New Technologies	Coronary Death: A Comparison to a Histologic Reference Standard Novel Three-Dimensional Geometric Method Using Computed	Nothing to Disclose	
			Tomography for Predicting the Incomplete Occlusion of Left Atrial Appendage Closure	· ·	
Park	Hyung-Bok	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Smoking as a Key Predictor of CAD Among Asymptomatic and Extremely Low Coronary Artery Calcium Score Patients	Nothing to Disclose	
Park	Jae Yoon	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Management of a Giant Calcific Coronary Artery Aneurysm	Nothing to Disclose	
Park	Jeong Rang	Disease, and Vascular Medicine Non Invasive Imaging: Prognostic Implications	Prognostic Value of Platelet-Fibrin Clot Strength on Occurrence of	Nothing to Disclose	
Park	Jin-Joo	of CT Angiography Emerging Developments in HFpEF and	Cardiovascular Events After Non-Cardiac Surgery Risk of Stroke and Thromboembolism for Heart Failure With and	Nothing to Disclose	
	- SIII - UUU	Arryhthmias	Without Atrial Fibrillation	יייייייייייייייייייייייייייייייייייייי	

Carried Contract of the Contra				
Last Name	First Name Mahn Won	Session Title Innovations in Cardiovascular Risk Assessment	Presentation Title Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve	Disclosures Nothing to Disclose
Park	Mann won	innovations in Cardiovascular Risk Assessment and Reduction	Ameroscierotic Carolovascular Disease HISK in Statin-Na6#299/e Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter)	Nothing to Disclose
Park	Mahn Won	Non Invasive Imaging: Prognostic Implications of CT Angiography	Registry Prognostic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry	Nothing to Disclose
Park	Mahn Won	Non Invasive Imaging: Prognostic Implications	Prognosis of Obstructive and Non-Obstructive Stents by Coronary	Nothing to Disclose
Park	Mahn Won	of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Computed Tomographic Angiography: The CONFIRM Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Death: A Comparison to a Histologic Reference Standard	Nothing to Disclose
Park	Myung	Distinct Phenotypes in HFpEF: Beyond	Management of patients with HFpEF and Pulmonary HTN	CONSULTANT FEES/HONORARIA - Actelion
Park	Myung	Ejection Fraction The Forgotten Chamber: The Right Ventricle in	Co-Chair	Pharmaceuticals,Bayer,St. Jude,United Therapeutics CONSULTANT FEES/HONORARIA - Actelion
Park	Myung	Heart Failure 14. Heart Failure and Cardiomyopathies:	Suggested Reviewer	Pharmaceuticals,Bayer,St. Jude,United Therapeutics CONSULTANT FEES/HONORARIA - Actelion
Park	Sang-Don	Therapy Team 3 Cardiac Arrest, Diabetes, and Other High Risk	Prognostic Impact of Alkaline Phosphatase Measured at the Time of	Pharmaceuticals,Bayer,St. Jude,United Therapeutics Nothing to Disclose
. un	oang son	Features of Patients With Acute Coronary Syndrome	Presentation in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction	Totaling to Excoord
Park	Seong-Mi	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Concentric Remodeling and Diastolic Dysfunction: From the WISE-CVD Study	Nothing to Disclose
Park	Seong-Wook	Late-Breaking Clinical Trials: Interventional	Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With Coronary Chronic Total Occlusion: DECISION CTO Randomized Trial	Nothing to Disclose
Park	Seong-Wook	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	The Prognostic Implications of Current Periprocedural Myocardial Infarction Definitions in Patients Underwent Percutaneous Conronary Intervention With Unprotected Left Main Coronary Artery Disease	Nothing to Disclose
Park	Seong-Wook	Advances in Lipid Management	Lower Mortality in Patients With Vasospastic Angina Who Receive	Nothing to Disclose
Park	Seung-Jung	Late-Breaking Clinical Trials: Interventional	Statin Therapy: Data From the Asan Vasospastic Angina Registry Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With Coronary Chronic Total Occlusion: DECISION CTO Randomized Trial	CONSULTANT FEES/HONORARIA - Abbott, Cordis, Boston Scientific, Medtronic; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioVascular Research Foundation
Park	Seung-Jung	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	CONSULTANT FEES/HONORARIA - Abbott, Cordis, Boston Scientific, Medtronic; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioVascular Research Foundation
Park	Seung-Jung	Late-Breaking Clinical Trials: Deep Dive II	Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With Coronary Chronic Total Occlusion: DECISION CTO Randomized Trial	CONSULTANT FEES/HONORARIA - Abbott, Cordis, Boston Scientific, Medtronic; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioVascular Research Foundation
Park	Seung-Jung	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Anatomic Versus Ischemic Burden in Predicting Outcomes of Coronary Artery Disease: Data From IRIS-FFR Registry	CONSULTANT FEES/HONORARIA - Abbott, Cordis, Boston Scientific, Medtronic; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioVascular Research Foundation
Park	Seung-Jung	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	The Prognostic Implications of Current Periprocedural Myocardial Infarction Definitions in Patients Underwent Percutaneous Conronary Intervention With Unprotected Left Main Coronary Artery Disease	CONSULTANT FEES/HONORARIA - Abbott, Cordis, Boston Scientific, Medtronic; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioVascular Research Foundation
Park	Seung-Jung	Advances in Lipid Management	Lower Mortality in Patients With Vasospastic Angina Who Receive Statin Therapy: Data From the Asan Vasospastic Angina Registry	CONSULTANT FEES/HONORARIA - Abbott, Cordis, Boston Scientific, Medtronic; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioVascular Research Foundation
Park	Seung-Jung	Refining PCI Technique and Outcomes	External Validation of DAPT Score in Two Large Cohorts	CONSULTANT FEES/HONORARIA - Abbott, Cordis, Boston Scientific, Medtronic; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioVascular
Park	Seung-Jung	CAD in Unique Patient Populations	Mortality of Patients With Previous Stroke Undergoing Drug-Eluting Stent Implantation	Research Foundation CONSULTANT FEES/HONORARIA - Abbott, Cordis, Boston Scientific, Medtronic; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioVascular
Park	Seung-Jung	22. Interventional Cardiology: Coronary Intervention: Left Main, Multivessel, Bifurcation Team 2	Suggested Reviewer	Research Foundation CONSULTANT FEES/HONORARIA - Abbott, Cordis, Boston Scientific, Medtronic; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioVascular
Park	Soon	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Effects of Diabetes Mellitus on Clinical Outcomes After Left Ventricular Assist Device Implantation: A Single Institutional 9-Year Experience	Research Foundation CONSULTANT FEES/HONORARIA - Cleveland Clinic, Thoratec
Park	Sung Hun	Novel Developments in Acute Coronary Syndromes	Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Diabetic Hypertensive Acute Myocardial Infarction Patients: Results From the Korea Acute Myocardial Infarction Registry (KAMIR)	Nothing to Disclose
Park	Sung Hun	Timely Topics in Acute Coronary Syndromes	Predictors of Mortality in Acute Myocardial Infarction Patients With	Nothing to Disclose
Park	Sung Hun	Advances in Chronic Total Occlusion	Unprotected Left Main Coronary Artery Disease Impact of Percutaneous Coronary Intervention for Chronic Total	Nothing to Disclose
Park	Sung-Ji	Intervention From Diet to Drugs: Mechanistic Insight Into	Occlusion Patients With Near-Normal Left Ventricular Function Fimasartan Protect Cardiac Myocyte Damage in Ischemic Heart	Nothing to Disclose
Park	Yong	Novel Determinants of Outcomes in VHD	Diseases Relationship Between Proximal Aorta Morphology and Progression	Nothing to Disclose
Park	Yong Hyun	Arrhythmias and Clinical EP: Basic 3	Rate of Aortic Stenosis Atrial Fibrillation Cycle Length Measured by Transesophageal Echocardiography: A Predictor for Maintaining Sinus Rhythm After	Nothing to Disclose
Park	Yongwhi	Acute Heart Failure: Evaluating Strategies to	DC Cardioversion Clinical Efficacy of High-Flow Oxygen Therapy Through Nasal	Nothing to Disclose
Park	Yongwhi	Prevent Readmissions Coronary Angiography, Intra-Vascular Imaging,	Cannula in Patients With Acute Heart Failure Impact of Platelet-Fibrin Clot Strength on Occurrence of In-Stent	Nothing to Disclose
Park	Yongwhi	Revascularization and Outcomes Non Invasive Imaging: Prognostic Implications	Restenosis in Patient With Drug Eluting Stent Prognostic Value of Platelet-Fibrin Clot Strength on Occurrence of	Nothing to Disclose
Park	Yongwhi	of CT Angiography Antithrombotic Therapy in Ischemic Heart	Cardiovascular Events After Non-Cardiac Surgery Ticagrelor Versus Clopidogrel Is Associated With Better Recovery of	
Parker	Matthew	Disease Valvular Heart Disease: Aortic Stenosis	LV Function After Acute Myocardial Infarction Factors Associated With Rapid Progression of Aortic Stenosis in	Nothing to Disclose
		2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2	Patients With Bicuspid Aortic Valve: A Single Center Retrospective Study	3

Constitution of the second				<u> </u>
Last Name Parkkonen	First Name Olavi	Session Title Traditional and Novel Factors Used to Assess	Presentation Title A Risk Locus for Non-ST-Elevation Myocardial Infarction on	Disclosures Nothing to Disclose
Fairkonen	Olavi	the Risk of, and Used for the Treatment of, Coronary Artery Disease	Chromosome 1p13.3 Is Also Associated With Peripheral Artery Disease in Patients With Acute Coronary Syndrome	Nothing to Disclose
Parmar	Sneha	Updates in Stable Ischemic Heart Disease	Effect of Hospital Intervention on Smoking Cessation 30 Days After Admission for Acute Coronary Syndrome	Nothing to Disclose
Parod	Eric	Young Investigator Awards Competition: Outcomes Research	Comparison of a Pharmacist-Physician Collaborative Care Model to Standard Care on the Time to Reach Goal Blood Pressure for Patients With Hypertension	Nothing to Disclose
Parod	Eric	Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering Therapies	Comparison of a Pharmacist-Physician Collaborative Care Model to Standard Care on the Time to Reach Goal Blood Pressure for Patients Presenting With Urgent Hypertension	Nothing to Disclose
Parrillo	Joseph	Clinical Challenges in the Cardiac Care Unit (CCU)	Co-Chair	CONSULTANT FEES/HONORARIA - Artisan,Beckman Coulter,Cytosorbents; DATA SAFETY MONITORING BOARD - NHLBI Heart Failure Network Data Safety Monitoring Board
Parsons	Christine	Highlights in Vascular Medicine Research	The Addition of Renal Impairment to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Atrial Fibrillation	Nothing to Disclose
Parthiban	Anitha	New Technologies in Echocardiography	Accuracy and Reproducibility of Automated 3D Echocardiographic Analysis of Left Ventricular Size and Ejection Fraction in Childhood Cancer Survivors	Nothing to Disclose
Parviz	Yasir	Considerations in Antiplatelet Therapy and in ACS	Comparison of P2y ₁₂ Inhibitors for Mortality and Stent Thrombosis in Patients With Acute Coronary Syndromes: Single Centre Study of 10,793 Consecutive 'Real-World' Patients	Nothing to Disclose
Parwani	Purvi	Innovations in Education	Understanding Social Media Usage Related to Cardiology: Underlying Motivation and Untapped Opportunities	Nothing to Disclose
Parwani	Purvi	FIT Clinical Decision Making Reviewers 3	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Parzynski	Craig	Arrhythmias and Heart Failure	Quadripolar Versus Bipolar Left Ventricular Leads in Cardiac Resynchronization Therapy: An Analysis From the NCDR	Nothing to Disclose
Pasala	Tilak	Core Curriculum: Valvular Heart Disease	Paravalvular Regurgitation: When is it a Concern and How to Avoid	Nothing to Disclose
Pasala	Tilak	Management Issues The Best Structural Interventional Challenging	the OR Transapical Mitral Paravalvular Leak Closure for Recurrent	Nothing to Disclose
Pascual	Isaac	Cases Interventional Cardiology: TAVR 2	Paravalvular Leak Effect of Body Mass Index on Mortality After Transcatheter Aortic	Nothing to Disclose
Pascual	Thomas	Nuclear Cardiology: Quality	Valve Implantation: J-Shaped Curve Worldwide Variation in the Use of Nuclear Cardiology Camera	Nothing to Disclose
Pascuai	Thomas		Technology, Reconstruction Software, and Acquisition Protocols: Findings From the IAEA Nuclear Cardiology Protocols Study (INCAPS)	
Pasquali	Sara	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Characteristics, Risk Factors and Outcomes of Extracorporeal Membrane Oxygenation Use in the Pediatric Cardiac Intensive Care Unit	Nothing to Disclose
Pasquali	Sara	Congenital Heart Disease: Progress in Pediatric Heart Surgery	The Association of Technical Performance With Postoperative Complications and Hospital Costs for the Norwood Operation	Nothing to Disclose
Pasquali	Sara	10. Congenital Heart Disease: Pediatric Team	Suggested Reviewer	Nothing to Disclose
Pasricha	Venu	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Nailfold Capillaroscopy for the Identification of Microvascular Disease in African-Americans	Nothing to Disclose
Pasrija	Chetan	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic	Peripheral Anatomic Distribution of Thrombus Does Not Adversely Affect Outcomes in Patients Undergoing Surgical Pulmonary	Nothing to Disclose
Passman	Rod	Disease and the Year in Review 05. Arrhythmias and Clinical EP: Devices Team 2	Embolectomy for Submassive and Massive Pulmonary Embolism Suggested Reviewer	CONSULTANT FEES/HONORARIA - Biotronik,Boehringer Ingelhim,Bristol Myers Squibb,Janssen Pharmaceuticals, Inc,MEDTRONIC; SPEAKER'S BUREAU - Pfizer
Pastor	Darwin	Novel Echocardiographic Methods for Assessing Cardiac Function	Clinical Validation of ASE 2016 Guidelines for Evaluating Left Ventricular Diastolic Dysfunction	Nothing to Disclose
Pastori	Daniele	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	History of Atrial Fibrillation in a First-Degree Relative and Risk of Cardiovascular Events	Nothing to Disclose
Pasupula	Deepak Kumar	Predicting the Future: Observations and	Pulmonary Vascular Resistance Predicts Mortality in End-Stage	Nothing to Disclose
Patel	Aarti	Discoveries From Registries and Databases FIT Clinical Decision Making: Non-Invasive	Renal Disease Patients With Pulmonary Hypertension An Incidentally Detected Right Ventricular Pseudoaneurysm	Nothing to Disclose
Patel	Aarti	Imaging and Valvular Heart Disease Emerging Applications of Echocardiography	Clinical Characteristics and Changes of Valvuloarterial Impedence Severity in Patients Undergoing Transcatheter Aortic Valve	Nothing to Disclose
Patel	Aashay	Arrhythmias and Clinical EP: Devices 2	Replacement for Severe Aortic Stenosis Role of Implantable Defibrillators in Primary Prevention of Mortality	Nothing to Disclose
Patel	Aashay	Arrhythmias and Heart Failure	in Non-Ischemic Cardiomyopathy Patients Prognostic Impact of Premature Atrial Complexes in the General	Nothing to Disclose
Patel	Achint	Heart Failure and Cardiomyopathies: What	Population: A Meta-Analysis of Observational Studies Etiology and Predictors of 30-Day Unplanned Readmission Rates	Nothing to Disclose
		Next When All Else Is Failing?	After Left Ventricular Assist Device Placement	-
Patel	Akash	Arrhythmias and Clinical EP: Basic 5	Tachyarrhythmia Not Associated With Mortality During Single Ventricle Reconstruction	Nothing to Disclose
Patel	Amish	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Long Term Mortality Rates of U.S. Veterans With Bundle Branch Blocks Presenting for Coronary Angiography	Nothing to Disclose
Patel	Amish	Innovations in Advocacy and Patient Centered Care	Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population	Nothing to Disclose
Patel	Amisha	Interventional Cardiology: PCI and TAVR in Complex Patients	Refining the Classification of Severe, Symptomatic Aortic Stenosis Using Flow and Gradient Measurements to Predict Outcomes Post- Transcatheter Aortic Valve Replacement	Nothing to Disclose
Patel	Amisha	TAVR Outcomes Prognostication	High Baseline Valvuloarterial Impedence Predicts Worse 1-Year Outcomes After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Patel	Amit	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Implementation of a Wideband Late Gadolinium Enhancement Cardiac Magnetic Resonance Protocol to Improve Assessment of Myocardial Scar in Patients With Implantable Cardioverter	RESEARCH/RESEARCH GRANTS - Astellas Pharma, Myocardial Solutions, Philips
Patel	Amit	Innovative Use of Echocardiography	Defibrillators Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography	RESEARCH/RESEARCH GRANTS - Astellas
Patel	Amit	Non Invasive Imaging: MR Scar and Perfusion	Impiantation using 3D Ecnocardiography Multimodality Analysis of Abnormal Myocardial Perfusion in Post- Heart Transplant Recipients	Pharma,Myocardial Solutions,Philips RESEARCH/RESEARCH GRANTS - Astellas Pharma,Myocardial Solutions,Philips
Patel	Amit	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Astellas Pharma,Myocardial Solutions,Philips
Patel	Apoor	FIT Clinical Decision Making: Arrhythmias and	Intractable Ventricular Tachycardia Secondary to Right Ventricular	Nothing to Disclose
Patel	Apurva	Electrophysiology Head to Toe: Outcomes of Endovascular Interventions	Outflow Tract Embryonal Rhabdomyosarcoma Improving Procedural Success and Reducing Complications in Endovascular Treatment of Superficial Femoral Artery In-Stent Restenosis in the Presence of Obstructive Tibial Outflow Disease: Retrograde Transpedal Access Approach	Nothing to Disclose

Last Name Patel	First Name Apurva	Session Title Interventional Complexity and Complications	Presentation Title Evaluation of a New Radiation Protection Technology (Cardio-	Disclosures Nothing to Disclose
			TRAP®) in Transradial Percutaneous Coronary Intervention Procedures	
Patel	Apurva	Peripheral Arterial Disease, Risk, and Outcomes	Transradial Versus Transpedal Access Approach for Endovascular Intervention of Superficial Femoral Artery Chronic Total Occlusion	Nothing to Disclose
Patel	Ayan	Pregnancy and Heart Disease	Panelist	CONSULTANT FEES/HONORARIA - Cardiovascular Clinical
Patel	Ayan	Pregnancy and Heart Disease	Valvular Heart Disease in Pregnancy	Studies (echo core lab),Up To Date CONSULTANT FEES/HONORARIA - Cardiovascular Clinical
Patel	Billal	Acute Coronary Syndromes, Diagnosis,	A Direct Comparison of Accelerated Discharge Strategies Utilising a	Studies (echo core lab),Up To Date Nothing to Disclose
		Management and Outcomes	Single High Sensitivity Troponin T in Suspected Acute Coronary Syndromes: Prospective Cohort Study of Undetectable Troponin T Versus Low Risk Timi, Grace and Heart Scores (the Macros Study- Mersey Acute Coronary Syndrome Rule-Out Study)	
Patel	Brijesh	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Atrial Fibrillation on Outcomes in Patients Hospitalized With ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Patel	Chetan	Heart Failure and Cardiomyopathies: Therapy Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - HeartWare Inc,Thoratec Corporation
Patel	Dhara	Predicting the Future: Observations and		Nothing to Disclose
Patel	Dhara	Discoveries From Registries and Databases Acute Coronary Syndromes, Diagnosis,	National Database 30-Day Unplanned Readmission Rates, Cost, Predictors, and	Nothing to Disclose
Patel	Dilesh	Management and Outcomes Arrhythmias and Clinical EP: Devices 2	Causes of Hospitalization in Acute Myocardial Infarction Patients Comprehensive Strategy to Reduce the Incidence of Lead	Nothing to Disclose
Patel	Dilesh	Arrhythmias and Clinical EP: Devices 3	Dislodgment for Cardiac Implantable Electronic Devices Cryoballoon Versus Radiofrequency Ablation of Atrial Fibrillation: In- Lab Complication Rates at a Large Volume Electrophysiology	Nothing to Disclose
Petal	Disease	Making Progress in Understanding Heart	Center	Nothing to Diopless
Patel	Divyang	Making Progress in Understanding Heart Failure	The Role of Baseline Versus Long-Term Follow-Up Ejection Fraction in Predicting Adverse Events Among Primary Prevention Implantable Cardioverter Defibrillator Recipients	Nothing to Disclose
Patel	Gaurav	Interventional Complexity and Complications	Can Non-Procedural Patient Characteristics Predict In-Hospital Complications Following Elective Percutaneous Coronary Intervention? Implications for Same-Day Discharge	Nothing to Disclose
Patel	Gaurav	Interventional Complexity and Complications	Temporal Trend of Incidence of Stent Thrombosis and In-Hospital Mortality: Results From a National Real-World Registry	Nothing to Disclose
Patel	Gaurav	Interventional Complexity and Complications	Mortality. Results From a National Real-World Registry Does Presence of Atrial Fibrillation Affect In-Hospital Mortality in Patients Undergoing Percutaneous Coronary Intervention? Results From a Real-World Registry	Nothing to Disclose
Patel	Gaurav	Interventional Complexity and Complications		Nothing to Disclose
Patel	Hamang	13. Heart Failure and Cardiomyopathies: Clinical Team 1	Suggested Reviewer	Nothing to Disclose
Patel	Harshali	Making Progress in Understanding Heart Failure	Serial Assessment of Heart Rate and Beta Blocker Use in Chronic Heart Failure Patients With Reduced Ejection Fraction in a Large	SALARY - Amgen Inc.
Patel	Hena	FIT Clinical Decision Making: Non-Invasive	Integrated Healthcare Network Fibrosing Mediastinitis-Related Pulmonary Artery and Vein Stenosis	Nothing to Disclose
Patel	Hena	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Arrhythmias and	Limiting Chemotherapy Mapping of the His Bundle to Recruit LBBB During Permanent	Nothing to Disclose
Patel	Himanshu	Electrophysiology Maximally Effective Vascular Care: Vascular	Pacemaker Implantation: Insight Into the Site of LBBB Case Presentation #3: Panelist	CONSULTANT FEES/HONORARIA - Edwards
Patel	Himanshu	Collaborative Team Care in Action Vascular Medicine: Novel Risk Measures in	Body Mass Index and Acute Aortic Dissection	Inc.,MEDTRONIC,WL Gore Inc. CONSULTANT FEES/HONORARIA - Edwards
Patel	Himanshu	Arterial Diseases Beans, Beans, Good for Your Heart	Analysis of the Timing of Thoracic Endovascular Aortic Repair and	Inc.,MEDTRONIC,WL Gore Inc. CONSULTANT FEES/HONORARIA - Edwards
			Its Indications and Outcomes in Type B Aortic Dissection	Inc.,MEDTRONIC,WL Gore Inc.
Patel	Hiren	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Aspirin Induced Eosinophilia-Associated Coronary Artery Vasospasm Presenting as Takotsubo Cardiomyopathy	Nothing to Disclose
Patel	Hiten	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Left Ventricular Dilation: Patent Ductus Arteriosus Versus Chronic Severe Mitral Regurgitaiton	Nothing to Disclose
Patel	Hiten	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Ventricular Tachycardia in a Patient With Coexisting Brugada Syndrome and Coronary Vasospasm	Nothing to Disclose
Patel	Hiten	New Technologies in Echocardiography	Left Atrial Volume Index Over Late Diastolic Mitral Annular Velocity: A New Non-Invasive Parameter for Measurement of Left Ventricular End Diastolic Pressure	Nothing to Disclose
Patel	Hiten	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	33 Year Old Female With Sudden Cardiac Arrest	Nothing to Disclose
Patel	Jaideep	Disease, and Vascular Medicine Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium and Estimated Cardiovascular Disease Risk in Five Racial/Ethnic Groups Living in the US: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA)	Nothing to Disclose
Patel	Jay	Interventional Cardiology: TAVR 4	Depression as a Potential Therapeutic Target to Improve Quality of Life After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Patel	Jeetvan	Advances in Lipid Management	Cardiologist Perspectives in Treatment of Dyslipidemia Patients With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Other Lipid Lowering Therapies	SALARY - Amgen Inc.
Patel	Jeetvan	Advances in Lipid Management	Persistence and Adherence With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Clinical Practice	SALARY - Amgen Inc.
Patel	Jeetvan	Innovations in Advocacy and Patient Centered Care	Characteristics of Patients Approved and Denied Access to PCSK9i	SALARY - Amgen Inc.
Patel	Jeetvan	Diabetes and Other Issues in Cardiovascular Prevention	Therapy by Payers Clinical Characteristics of Early Adopters of Proprotein Convertase Subtilisin/Kexin Type 9 inhibitors (PCSK9i)	SALARY - Amgen Inc.
Patel	Jigar	Intervention Interventional Cardiology: Structural Heart Disease	Submism/Kexin Type 9 Innibitors (PCSK9I) Safety and Feasibility of Rotational Atherectomy in Elderly Patients With Severe Aortic Stenosis and Calcific Coronary Artery Disease Undergoing Evaluation for Transcatheter Aortic Valve Replacement	Nothing to Disclose
Patel	Jignesh	Non Invasive Imaging: Applications in Novel	Angiographic Dye Prior to Combined Heart-Kidney Donation Does	RESEARCH/RESEARCH GRANTS - Alexion
Patel	Jignesh	Disease States and Clinical Scenarios Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Not Appear to Harm Donor Kidney Function After Transplant Percutaneous Coronary Intervention With Everolimus-Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy and the Impact	Pharmaceuticals,Alnylam Pharmaceuticals,Pfizer Inc RESEARCH/RESEARCH GRANTS - Alexion Pharmaceuticals,Alnylam Pharmaceuticals,Pfizer Inc
Patel	Jignesh	Heart Failure and Cardiomyopathies: What	of Diabetes Mellitus on Stent and Target Lesion Patency Etiology and Predictors of 30-Day Unplanned Readmission Rates	Nothing to Disclose
Patel	Jignesh	Next When All Else Is Failing? 13. Heart Failure and Cardiomyopathies:	After Left Ventricular Assist Device Placement Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Alexion
Patel	Keval	Clinical Team 2 FIT Clinical Decision Making: Interventional	Management of Pulmonary Artery Graft Occlusion Using High	Pharmaceuticals,Alnylam Pharmaceuticals,Pfizer Inc Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Performance Coronary Equipment	-
Patel	Keyur	Imaging the Athlete's Heart	Differential American-Style Football Training Intensities and Cardiac and Vascular Remodeling Patterns	Notning to Disclose

				l l
	First Name Kinjan	Session Title PCI for NSTEMI and Complex Patients With	Presentation Title The Feasibility and Safety of Same Day Discharge for All Comers	Disclosures Nothing to Disclose
	•	Multiple Co-Morbidities	After Elective Percutaneous Coronary Interventions	
	Kiritkumar	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	External Femoral-Femoral Bypass for Acute Limb Ischemia	Nothing to Disclose
Patel	Krishna	Highlighted Original Research: Vascular Medicine and the Year in Review	Non-Adherence to the Joint ACC/AHA 2013 Lipid Performance Guidelines in Peripheral Arterial Disease: Insights From the PORTRAIT Registry	Nothing to Disclose
Patel	Krishna		Reliability and Responsiveness of Seattle Angina Questionnaire in Women With Coronary Artery Disease	Nothing to Disclose
Patel	Krishna	Optimizing Treatment of Peripheral Artery	Smoking Behavior and Access to Smoking Cessation Support Following a Diagnosis of Peripheral Arterial Disease: Insights From the International PORTRAIT Registry	Nothing to Disclose
Patel	Kunal		Left Ventricular Dilation: Patent Ductus Arteriosus Versus Chronic Severe Mitral Regurgitaiton	Nothing to Disclose
Patel	Kunal		Ventricular Tachycardia in a Patient With Coexisting Brugada	Nothing to Disclose
Patel	Kunal	Cardiology, Acute and Stable Ischemic Heart	Syndrome and Coronary Vasospasm 33 Year Old Female With Sudden Cardiac Arrest	Nothing to Disclose
Patel	Manesh		Primary Results of DEFINE-FLAIR: A Multi-Centre, Prospective, International, Randomized, Blinded Comparison of Clinical Outcomes and Cost Efficiencies of iFR and FFR Decision-Making for Physiological Guided Coronary Revascularization	CONSULTANT FEES/HONORARIA - Bayer Healthcare, Genzyme, Medscape - theheart.org, Merck; RESEARCH/RESEARCH GRANTS - AHRQ, Astra Zeneca, Jansen, Johnson and Johnson, Maquet, National Heart Lung and Blood Institute, PCORI
Patel	Manesh		Debate: Non-invasive risk stratification is the Optimal Gatekeeper for Revascularization in Stable Angina: Pro	CONSULTANT FEES/HONORARIA - Bayer Healthcare,Genzyme,Medscape - theheart.org,Merck; RESEARCH/IRESEARCH GRANTS - AHRQ,Astra Zeneca,Jansen,Johnson and Johnson,Maquet,National Heart Lung and Blood Institute,PCORI
Patel	Manesh	Born To Run: Geographic Variation in PAD Diagnosis, Treatment and Outcomes	Revascularization: Carotid Revascularization Among Medicare Beneficiaries	CONSULTANT FEES/HONORARIA - Bayer Healthcare,Genzyme,Medscape - theheart org,Merck; RESEARCH/IRESEARCH GRANTS - AHRQ,Astra Zeneca,Jansen,Johnson and Johnson,Maquet,National Heart Lung and Blood Institute,PCORI
Patel	Manesh		Thrombolytic Therapy in Anticoagulated Patients: Case Series From Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET AF)	CONSULTANT FEES/HONORARIA - Bayer Healthcare,Genzyme,Medscape - theheart.org,Merck; RESEARCH/IRESEARCH GRANTS - AHRQ,Astra Zeneca,Jansen,Johnson and Johnson,Maquet,National Heart Lung and Blood Institute,PCORI
Patel	Manesh	Ischemic Heart Disease	Patient-REported Preferences Affecting Revascularization Decisions (PREPARED): A Pilot Randomized Study of Shared Decision- Making	CONSULTANT FEES/HONORARIA - Bayer Healthcare,Genzyme,Medscape - theheart.org,Merck; RESEARCH/IRESEARCH GRANTS - AHRQ,Astra Zeneca,Jansen,Johnson and Johnson,Maquet,National Heart Lung and Blood Institute,PCORI
Patel	Manesh		Incidence and Predictors of Lesion Specific Ischemia by FFR _{CT} : Learnings From the International ADVANCE Registry	CONSULTANT FEES/HONORARIA - Bayer Healthcare, Genzyme, Medscape - theheart.org, Merck; RESEARCH/IRESEARCH GRANTS - AHRQ, Astra Zeneca, Jansen, Johnson and Johnson, Maquet, National Heart Lung and Blood Institute, PCORI
Patel	Manesh	02. Acute and Stable Ischemic Heart Disease: Clinical Team 5	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Bayer Healthcare, Genzyme, Medscape - theheart.org, Merck; RESEARCH/IRESEARCH GRANTS - AHRQ, Astra Zeneca, Jansen, Johnson and Johnson, Maquet, National Heart Lung and Blood Institute, PCORI
Patel	Manisha	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Congenital Double-Chambered Left Ventricle Presenting as Monomorphic Ventricular Tachycardia	Nothing to Disclose
Patel	Milan	Vascular Medicine: Aortic and Peripheral Artery Diseases	Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection	Nothing to Disclose
Patel	Mit		The Way to a Man's Heart: Through His Quadriceps	Nothing to Disclose
Patel	Mit	Pulmonary Hypertension FIT Clinical Decision Making: Multimodality	Ventricular Septal Dissection With Rupture and Large NeoCavity	Nothing to Disclose
,		Imaging	After Inferior ST Elevation Myocardial Infarction in a Patient With	
Patel	Mitul	Advances in Chronic Total Occlusion	Recent Coronary Artery Bypass Grafts The Impact of Epicardial Collateral Use on the Outcomes of Chronic	SPEAKER'S BUREAU - Astra Zeneca
	Mitul	Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	SPEAKER'S BUREAU - Astra Zeneca
Patel	Mitul	Intervention Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	SPEAKER'S BUREAU - Astra Zeneca
Patel Patel	Mitul	Intervention Advances in Chronic Total Occlusion Intervention FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry Use of Pharmacomechanical Thrombectomy in a Patient With Acute Pulmonary Embolism and Imminent Hemodynamic Collapse at Very High Risk for Cerebral Hemorrhage	SPEAKER'S BUREAU - Astra Zeneca Nothing to Disclose
Patel Patel	Mitul Monali Nainesh	Intervention Advances in Chronic Total Occlusion Intervention FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry Use of Pharmacomechanical Thrombectomy in a Patient With Acute Pulmonary Embolism and Imminent Hemodynamic Collapse at Very High Risk for Cerebral Hemorrhage Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample	SPEAKER'S BUREAU - Astra Zeneca Nothing to Disclose Nothing to Disclose
Patel Patel	Mitul	Intervention Advances in Chronic Total Occlusion Intervention FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases Personalized Skills Center: Drill and Practice	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry Use of Pharmacomechanical Thrombectomy in a Patient With Acute Pulmonary Embolism and Imminent Hemodynamic Collapse at Very High Risk for Cerebral Hemorrhage Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study	SPEAKER'S BUREAU - Astra Zeneca Nothing to Disclose
Patel Patel Patel Patel	Mitul Monali Nainesh	Intervention Advances in Chronic Total Occlusion Intervention FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases Personalized Skills Center: Drill and Practice (Heart Songs, ECG, Hand-Held Echo)	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry Use of Pharmacomechanical Thrombectomy in a Patient With Acute Pulmonary Embolism and Imminent Hemodynamic Collapse at Very High Risk for Cerebral Hemorrhage Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Heart Songs Moderator Atrial Fibrillation in Patients With Non-STEMI: Insights From a	SPEAKER'S BUREAU - Astra Zeneca Nothing to Disclose Nothing to Disclose
Patel Patel Patel Patel Patel	Mitul Monali Nainesh	Intervention Advances in Chronic Total Occlusion Intervention FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases Personalized Skills Center: Drill and Practice (Heart Songs, ECG, Hand-Held Echo) Arrhythmias and Clinical EP: Basic 1	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry Use of Pharmacomechanical Thrombectomy in a Patient With Acute Pulmonary Embolism and Imminent Hemodynamic Collapse at Very High Risk for Cerebral Hemorrhage Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Heart Songs Moderator Atrial Fibrillation in Patients With Non-STEMI: Insights From a National Database AngioVac Cannula for Management of Device Related Vegetative	SPEAKER'S BUREAU - Astra Zeneca Nothing to Disclose Nothing to Disclose Nothing to Disclose
Patel Patel Patel Patel Patel Patel Patel	Mitul Monali Nainesh Nainesh	Intervention Advances in Chronic Total Occlusion Intervention FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases Personalized Skills Center: Drill and Practice (Heart Songs, ECG, Hand-Held Echo) Arrhythmias and Clinical EP: Basic 1 Arrhythmias and Clinical EP: Devices 2	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry Use of Pharmacomechanical Thrombectomy in a Patient With Acute Pulmonary Embolism and Imminent Hemodynamic Collapse at Very High Risk for Cerebral Hemorrhage Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Heart Songs Moderator Atrial Fibrillation in Patients With Non-STEMI: Insights From a National Database AngioVac Cannula for Management of Device Related Vegetative Growth	SPEAKER'S BUREAU - Astra Zeneca Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Patel Patel Patel Patel Patel Patel Patel Patel Patel	Mitul Monali Nainesh Nainesh Neil	Intervention Advances in Chronic Total Occlusion Intervention FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases Personalized Skills Center: Drill and Practice (Heart Songs, ECG, Hand-Held Echo) Arrhythmias and Clinical EP: Basic 1 Arrhythmias and Clinical EP: Devices 2 Arrhythmias and Clinical EP: Basic 1 Structural Heart Interventions: Focus on Mitral	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry Use of Pharmacomechanical Thrombectomy in a Patient With Acute Pulmonary Embolism and Imminent Hemodynamic Collapse at Very High Risk for Cerebral Hemorrhage Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Heart Songs Moderator Atrial Fibrillation in Patients With Non-STEMI: Insights From a National Database AngioVac Cannula for Management of Device Related Vegetative Growth Atrial Fibrillation in Patients With Non-STEMI: Insights From a National Database Transcatheter Mitral Valve Repair (Mitraclip) in United States: Etiologies and Predictors of Readmission and In-Hospital Mortality	SPEAKER'S BUREAU - Astra Zeneca Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel	Mitul Monali Nainesh Nainesh Neil Nikhil	Intervention Advances in Chronic Total Occlusion Intervention FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases Personalized Skills Center: Drill and Practice (Heart Songs, ECG, Hand-Held Echo) Arrhythmias and Clinical EP: Basic 1 Arrhythmias and Clinical EP: Devices 2 Arrhythmias and Clinical EP: Basic 1 Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry Use of Pharmacomechanical Thrombectomy in a Patient With Acute Pulmonary Embolism and Imminent Hemodynamic Collapse at Very High Risk for Cerebral Hemorrhage Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Heart Songs Moderator Atrial Fibrillation in Patients With Non-STEMI: Insights From a National Database AngioVac Cannula for Management of Device Related Vegetative Growth Atrial Fibrillation in Patients With Non-STEMI: Insights From a National Database Transcatheter Mitral Valve Repair (Mitraclip) in United States: Etiologies and Predictors of Readmission and In-Hospital Mortality From the Nationwide Readmission Database	SPEAKER'S BUREAU - Astra Zeneca Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel	Mitul Monali Nainesh Nainesh Neil Nikhil Nilay	Intervention Advances in Chronic Total Occlusion Intervention FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases Personalized Skills Center: Drill and Practice (Heart Songs, ECG, Hand-Held Echo) Arrhythmias and Clinical EP: Basic 1 Arrhythmias and Clinical EP: Basic 1 Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM Acute Heart Failure: Evaluating Strategies to	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry Use of Pharmacomechanical Thrombectomy in a Patient With Acute Pulmonary Embolism and Imminent Hemodynamic Collapse at Very High Risk for Cerebral Hemorrhage (Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Heart Songs Moderator Atrial Fibrillation in Patients With Non-STEMI: Insights From a National Database ArgioVac Cannula for Management of Device Related Vegetative Growth Atrial Fibrillation in Patients With Non-STEMI: Insights From a National Database Transcatheter Mitral Valve Repair (Mitraclip) in United States: Euloogies and Previde Readmission and In-Hospital Mortality From the Nationwide Readmission Database Transcatheter Mitral Valve Repair (Mitraclip) in United States: Length of Stay and Cost of Hospitalizations From the Nationwide Readmission Database Identifying the Etiologies and Trends of 30 Day Readmissions in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients: A	SPEAKER'S BUREAU - Astra Zeneca Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel	Mitul Monali Nainesh Nainesh Neil Nikhil Nilay Nilay	Intervention Advances in Chronic Total Occlusion Intervention FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases Personalized Skills Center: Drill and Practice (Heart Songs, EGG, Hand-Held Echo) Arrhythmias and Clinical EP: Basic 1 Arrhythmias and Clinical EP: Devices 2 Arrhythmias and Clinical EP: Basic 1 Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry Use of Pharmacomechanical Thrombectomy in a Patient With Acute Pulmonary Embolism and Imminent Hemodynamic Collapse at Very High Risk for Cerebral Hemorrhage Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Heart Songs Moderator Atrial Fibrillation in Patients With Non-STEMI: Insights From a National Database AngioVac Cannula for Management of Device Related Vegetative Growth Atrial Fibrillation in Patients With Non-STEMI: Insights From a National Database Transcatheter Mitral Valve Repair (Mitraclip) in United States: Etiologies and Predictors of Readmission Database Transcatheter Mitral Valve Repair (Mitra Clip) in United States: Etiologies and Predictors of Readmission From the Nationwide Readmission Database Itength of Stay and Cost of Hospitalizations From the Nationwide Readmission Database	SPEAKER'S BUREAU - Astra Zeneca Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel	Mitul Monali Nainesh Nainesh Neil Nikhil Nilay Nilay Nilay Nilay	Intervention Advances in Chronic Total Occlusion Intervention FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases Personalized Skills Center: Drill and Practice (Heart Songs, ECG, Hand-Held Echo) Arrhythmias and Clinical EP: Basic 1 Arrhythmias and Clinical EP: Basic 1 Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry Use of Pharmacomechanical Thrombectomy in a Patient With Acute Pulmonary Embolism and Imminent Hemodynamic Collapse at Very High Risk for Cerebral Hemorrhage Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Heart Songs Moderator Artial Fibrillation in Patients With Non-STEMI: Insights From a National Database AngioVac Cannula for Management of Device Related Vegetative Growth Artial Fibrillation in Patients With Non-STEMI: Insights From a National Database Transcatheter Mitral Valve Repair (Mitracilip) in United States: Etiologies and Predictors of Readmission and In-Hospital Mortality From the Nationwide Readmission Database Transcatheter Mitral Valve Repair (Mitracilip) in United States: Length of Stay and Cost of Hospitalizations From the Nationwide Readmission Database Identifying the Etiologies and Trends of 30 Day Readmissions in Heart Failure With Preserved Ejection Fraction (HFPEF) Patients: A National Population-Based Cohort Study Atrial Fibrillation in Sassociated With Worse Outcomes in Patients With Cirrhosis	SPEAKER'S BUREAU - Astra Zeneca Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel Patel	Mitul Monali Nainesh Nainesh Neil Nikhil Nilay Nilay Nilay	Intervention Advances in Chronic Total Occlusion Intervention FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases Personalized Skills Center: Drill and Practice (Heart Songs, ECG, Hand-Held Echo) Arrhythmias and Clinical EP: Basic 1 Arrhythmias and Clinical EP: Basic 1 Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry Use of Pharmacomechanical Thrombectomy in a Patient With Acute Pulmonary Embolism and Imminent Hemodynamic Collapse at Very High Risk for Cerebral Hemorrhage Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Heart Songs Moderator Atrial Fibrillation in Patients With Non-STEMI: Insights From a National Database ArgioVac Cannula for Management of Device Related Vegetative Growth Atrial Fibrillation in Patients With Non-STEMI: Insights From a National Database Transcatheter Mitral Valve Repair (Mitracip) in United States: Etiologies and Predictors of Readmission and In-Hospital Mortality From the Nationwide Readmission Database Transcatheter Mitral Valve Repair (Mitra Cip) in United States: Length of Stay and Cost of Hospitalizations From the Nationwide Readmission Database Identifying the Etiologies and Trends of 30 Day Readmissions in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients: A National Population-Based Cohort Study	SPEAKER'S BUREAU - Astra Zeneca Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose

Figure Part	
Deuts Chargages Obtation Program of Deuts and Production of Security Program of Deuts and Production of Security Program of Deuts and Production of Security Program of Deuts and Production of Security Program of Deuts and Production of Security Program of Deuts and Production of Security Program of Deuts and Production of Security Program of Deuts and Program of Deuts and Production of Security Program of Deuts and Program o	
Legislation of Right Fortions for Cardionescription and Englanding Control (1997). A process of the Control (1997) of the United States of Control (1997) of the United States of Control (1997). A process of Control (1997) of the United States of Contro	
Page Non-Number Displace on Risk Factors for Cardiovasculary Non-Number Displace Non-Number Displace Non-Number Displace Di	
Need number Need number	
Parel	
Paged Niew New New Control of Conditions of TAVR 3 And Andre Regulgitation Post-Transachitest Andre View Northing to Disclose New North	
Pate Norw Protectional Cardiology TAVR 3 Protections of Cardiology TAVR 3 Protections and Cardiology TAVR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiology TavR 3 Protections of Cardiolog	
Papel National International Cardiology, TAVR 3 Siles of Anderse Outcomes in Treatment Modalises for Severe Anto- Denotes in Facinetis Declaration Papel Nishaard International Composition Papel Parahva Parahva Parahva Papel Parahva Parahva Papel Parahva Parahva Papel Parahva Parahva Papel Papel Parahva Papel Papel Parahva Papel Papel Parahva Papel Pape	
Patel Neshant	
Final Franks Fire Clinical Decision Making Non-Invested Integration of Volume Thrombus. A strong and Volume Thrombus integration of Volume Thrombus. A strong to Disclose Novel Thrombus integration of Volume Integration Integ	
Pastel Parshva Improving Outcomes for Reducing Risk and Improving Continues With Advanced Continues in Patients Improving Continues With Advanced Continues in Accordance With Continues With Advanced Continues in Accordance With Advanced Information in the United States in Accordance With Advanced Information in the United States in Accordance With Advanced Information i	
Patel Pertha Carbon Review Protections of Complexity Protections of Control Intervention is Addicated With Decreased Nothing to Disclose Protections of Control Intervention is Addicated With Decreased Nothing to Disclose Protections of Control Interventional Complexity and Complexity on Control Intervention is Addicated With Sold Turnor Control Intervention Interventional Complexity and Complexity on Control Intervention Interventional Complexity and Complexity on Control Intervention Interventional Complexity and Complexity on Control Intervention Interventional Complexity and Complexity on Control Interventional Control Interventional Complexity and Complexity on Control Interventional Control Interve	
Patel Pranav Interventional Complexity and Complications (Part Proposition Complexity of National Marking of National Complexity and Complexity of National Complexity of National Complexity and Complexity of National Complexity o	
Patel Pranav Interventional Complexity and Complication on Senter Defendence in Prod Perculaneous Concern y Intervention (Senter Defendence in Prod Perculaneous Concern) Intervention (Senter Defendence in Prod Perculaneous Concern) Intervention (Senter Defendence in Prod Perculaneous Concern) Intervention (Senter Defendence in Prod Perculaneous Concern) Interventional Confidency, Acute and Stable between Heart Interventional Confidency, Acute and Stable between Heart Interventional Confidence, Interventional Confidence in Production (Senter) Interventional Confidence in Production (Senter) Interventional Confidence in Concerns (Senter) Interventional Confidence in Concerns (Senter) Interventional Confidence in Concerns (Senter) Interventional Confidence in Concerns (Senter) Interventional Concerns (Senter) Interve	
Pastel Pranaw Interventional Complesely and Complications Complication	
Parel	
Patel Pransu The Inside Wew Learning Form Infacoronary Hybrid IVUS/OCT: 889220 Probing&88221; the Future Nothing to Disclose Patel Prashant Amylyminas and Clinical EP. Base 1 Amylyminas and Clinical EP. Base 1 Amylyminas and Clinical EP. Base 1 Amylyminas and Complex Patents With Machige Co-Abrobidities Patel Prashant Surctural Heart Interventions: Focus on Miral Patel Prashant Surctural Heart Interventions: Focus on Miral Patel Prashant Hyberchlosestredenia Patel Prashant Hyberchlosestredenia Patel Prashant Hyberchlosestredenia Patel Prashant Hyberchlosestredenia Patel Prashant Hyberchlosestredenia Patel Prujan FT Clinical Decision Making: Prevention, Adult Pernahular Leak in Repared Tetralogy of Fallot Patel Ravi FT Clinical Decision Making: Prevention, Adult Pernahular Leak in Repared Tetralogy of Fallot Patel Ruchir Coronary Interventions Cardiology, Advaned and State Is between Heart Disease Patel Ruchir Coronary Interventions Cardiology, Advaned Device Use Patel Saima Highlights in Vascular Medicine Patel Saima Highlights in Vascular Medicine Patel Saima Highlights in Vascular Medicine Patel Saima Highlights in Vascular Medicine Patel Saima Arrhythmias and Clinical EP. Base 2 Patel Saima Arrhythmias and Clinical EP. Base 2 Patel Saima Arrhythmias and Clinical EP. Base 2 Patel Saima Arrhythmias and Clinical EP. Base 2 Patel Sint Prediction Repaired Practical Saima Practical Saima Patel Sint Prediction Repaired Practical Saima Practical Saima Patel Sint Prediction Repaired Practical Saima Practical Saima Patel Sint Prediction Repaired Practical Saima Practical Saima Patel Sint Prediction Repaired Practical Saima Practical Saima Patel Sint Prediction Repaired Practical Saima Practical Saima Patel Sint Prediction Repaired Practical Saima Practical Saima Practical Saima Practical Saima Practical Saima Practical Saima Practical Saima Practical Saima Practical Saima Practical Saima Practical Saima Practical Saima Practical Saima Practical Saima Pr	
Patel	
Patel Prashant PCI for NSTEMI and Complex Patents With Multiple Co-Morbidities Nultiple Co-Morbidities Structural Heart Interventions: Focus on Miral Valve, Left Atrial Appending and HCCM Prashant Structural Heart Interventions: Focus on Miral Valve, Left Atrial Appending and HCCM Patents of Pate	
Patel Prashant Pict for NSTEM and Complex Patients With Mustiple Co-Morbidities Mustip	
Patel Prashant Structural Heart Interventions Focus on Mirral Valve, Left Ayrial Appendage and HOCO. Structural Heart Interventions Nothing to Disclose Nothing to Disclose Patel Prashant Contemporary Issues in Familial Hypercholesterolemis Hypercholestero	
Patel Prashant Contemporary Issues in Familial Hypercholesterofemis Mand Clinical Outcomes Prevention Adult Preventio	
Hypercholesterolemia Hypercholesterolemia	
Patel Ravi FiT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Patel Ruchir Coronary Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Patel Ruchir Coronary Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Patel Ruchir Coronary Interventional Cardiology, Advanced Device Use Patel Ruchir Valvular Heart Diseases Acute Stenosis Outcomes and Tene Precidence in Access for Percelampsis-Induced Ischemia Use Acute Valvular Heart Disease Acute Stenosis Outcomes and Tene Precidence in Acute Valvular Heart Disease (Acute Stenosis Outcomes and Tene Precidence in Acute Valve Therapy) Patel Salma Highlights in Vascular Medicine Research Highlights in Vascular Medicine Research Highlights in Vascular Medicine Research Tene Addition of Renal Angiogenesis Is Suppressed in Phyeroxia-Nothing to Disclose a Predictor of Thromboembolism and Mortality in Patents Without Attended Pronochal Angiogenesis Is Suppressed in Phyeroxia-Nothing to Disclose Induced Bronochal Angiogenesis Is Suppressed in Phyeroxia-Nothing to Disclose Induced Bronochal Angiogenesis Is Suppressed in Phyeroxia-Nothing to Disclose Induced Bronochal Angiogenesis Is Suppressed in Phyeroxia-Nothing to Disclose Induced Bronochal Angiogenesis Is Suppressed in Phyeroxia-Nothing to Disclose Induced Bronochal Angiogenesis Is Suppressed in Phyeroxia-Nothing to Disclose Induced Bronochal Angiogenesis Is Suppressed in Phyeroxia-Nothing to Disclose Induced Bronochal Phyeroxia-Nothing to Disclose Induced Bronochal Angiogenesis Is Suppressed in Phyeroxia-Nothing to Disclose Induced Bronochal Angiogenesis Is Suppressed in Phyeroxia-Nothing to Disclose Induced Bronochal Angiogenesis Is Suppressed in Phyeroxia-Nothing to Disclose Induced Bronochal Phyeroxia-Nothing to Disclose Induced Bronochal Angiogenesis Is Suppressed in Phyeroxia-Nothing to Disclose Induced Bronochal Angiogenesis Is Suppressed in Phyeroxia-Nothing to Disclose Indu	
Cardiology, Acute and Stable Ischemic Heart Pregnant Patient With Systemic Lupus Enythematosus: A Case of Disease, and Vascular Medicine Preclampsis Holds Schemia Preclampsis Holds Schemia Preclampsis Holds Schemia Preclampsis Holds Schemia Preclampsis Holds Schemia Preclampsis Holds Schemia Preclampsis Holds Schemia Preclampsis Holds Schemia Preclampsis Holds Preclampsis Holds Schemia Preclampsis Holds Preclampsis H	
Ruchir Coronary Intervention in Interventional Innovative Technique to Achieve Hemostasis With Large Bore Cardiology, Advanced Device Use Access for Percutaneous Hemodynamic Support Devices	
Patel Salma Highlights in Vascular Medicine Research The Predictors in Acute Transcatheter Adric Heart Valve Therapy	
Patel Salma	
Patel Saurabhkumar MicroRNAs and Beyond in Vascular Medicine MicroRNA-133 Mediated Angiogenesis Is Suppressed in Hyperoxia-Induced Bronchopulmonary Dysplasia MicroRNA-135 Mediated Bronchopulmonary Dysplasia MicroRNA-135 Mediated Bronchopulmonary Dysplasia MicroRNA-135 Mediated Bronchopulmonary Dysplasia MicroRNA-135 Mediated Bronchopulmonary Dysplasia MicroRNA-135 Mediated Bronchopulmonary Dysplasia MicroRNA-135 Mediated Bronchopulmonary Dysplasia MicroRNA-135 Mediated Bronchopulmonary Dysplasia MicroRNA-135 Mediated Bronchopulmonary Dysplasia MicroRNA-135 Mediated Bronchopulmonary Dysplasia MicroRNA-135 Mediated Programment Dysplasia MicroRNA-135 Mediated Programment Dysplasia MicroRNA-135 Mediated Bronchopulmonary Dysplasia MicroRNA-135 Mediated Bronchopulmonary Dysplasia MicroRNA-135 Mediated Bronchopulmonary Dysplasia Mothing to Disclose MicroRNA-135 Mediated With Versia Without Educational Programment Dysplasia Mothing to Disclose After Fontan Palliation Pateits Treated With Versia Without Endovascular Ablation Trends in Pulmonary Hypertension Hospitalizations: Insights From a Nothing to Disclose Management and Outcomes Management and Outc	
Patel Shanti	
Next When All Else Is Failing?	
Congenital Heart Disease Disease in Patients With Single Ventricle Congenital Heart Disease After Fontan Palliation	
Arial Fibrillation Patients Treated With Versus Without Endowascular Ablation Patel Smit Predicting the Future: Observations and Discoveries From Registries and Databases National Databases Patel Smit Acute Coronary Syndromes, Diagnosis, Acute Osphania and Outcomes Osphania and Outco	
Endovascular Ablation	
Discoveries From Registries and Databases National Databases	
Management and Outcomes Causes of Hospitalization in Acute Myocardial Infarction Patients	
Patel Tejas Radial Access Mini-Symposium "Must Know" Techniques for Traversing the Arm and Chest Nothing to Disclose Vasculature Vasculature Comparison of Adenosine Fractional Flow Reserve and Post-Contrast Instantaneous Wave-Free Ratio for Hemodynamic Assessment of Moderate Coronary Stenoses Patel Tejas Heart Failure and Cardiomyopathies: Is Heart Efficacy of Phosphodiesterase-5 Inhibitor in Patients With Heart Failure With a Normal EF for Real? Failure With Preserved Ejection Fraction: A Meta-Analysis Patel Tejas Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Prevent Readmissions Prevent Readmissions Can Non-Procedural Patient Characteristics Predict In-Hospital Complications Complications Following Elective Percutaneous Coronary Intervention? Implications for Same-Day Discharge Nothing to Disclose Nothing to Disclose Nothing to Disclose Can Non-Procedural Patient Characteristics Predict In-Hospital Nothing to Disclose Complications Following Elective Percutaneous Coronary Nothing to Disclose Nothing	
Patel Tejas Interventional Cardiology: Intravascular Physiology and Endothelial Function Comparison of Adenosine Fractional Flow Reserve and Post-Contrast Instantaneous Wave-Free Ratio for Hemodynamic Assessment of Moderate Coronary Stenoses Patel Tejas Heart Failure and Cardiomyopathies: Is Heart Efficacy of Phosphodiesterase-5 Inhibitor in Patients With Heart Nothing to Disclose Failure With a Normal EF for Real? Patel Tejas Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Prevent Readmissions Prevent Readmissions Prevent Readmissions Can Non-Procedural Patient Characteristics Predict In-Hospital Complications Following Elective Percutaneous Coronary Intervention? Implications for Same-Day Discharge	
Patel Tejas Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real? Patel Tejas Heart Failure With a Normal EF for Real? Patel Tejas Acute Heart Failure Evaluating Strategies to Present Readmissions Patel Tejas Acute Heart Failure Evaluating Strategies to Present Readmissions Patel Tejas Acute Heart Failure Strategies to Prevent Readmissions Patel Tejas Interventional Complexity and Complications Patel Tejas Interventional Complexity and Complications Can Non-Procedural Patient Characteristics Predict In-Hospital Complications Following Elective Percutaneous Coronary Intervention? Implications for Same-Day Discharge	
Patel Tejas	
Patel Tejas Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Risk of Hospitalization or Death Due to Heart Failure With Intensive Glucose-Lowering Therapy in Diabetic Women: Subgroup Analyses by History of Cardiovascular Disease in the ACCORD Trial Patel Tejas Interventional Complexity and Complications Can Non-Procedural Patient Characteristics Predict In-Hospital Complications Following Elective Percutaneous Coronary Intervention? Implications for Same-Day Discharge	-
Patel Tejas Interventional Complexity and Complications Can Non-Procedural Patient Characteristics Predict In-Hospital Complications Complications Following Elective Percutaneous Coronary Intervention? Implications for Same-Day Discharge	
Complications Following Elective Percutaneous Coronary Intervention? Implications for Same-Day Discharge	
Patel Tejas Interventional Complexity and Complications Temporal Trend of Incidence of Stent Thrombosis and In-Hospital Nothing to Disclose	
Mortality: Results From a National Real-World Registry	
Patients Undergoing Percutaneous Coronary Intervention? Results From a Real-World Registry	
Patel Tejas Interventional Complexity and Complications Does Gender Affect In-Hospital Mortality in Patients Presenting With Stent Thrombosis? Results From a National Real-World Registry	
Patel Tejas Interventional Complexity and Complications Variability in Transfermoral Access for Coronary Angiography and Interventional Survey	
Interventions: Results From an International Survey	
Chemotherapy	
Prevent Readmissions Patel Toral Innovations in Cardiovascular Risk Assessment Red Cell Distribution Width (RDW) Predicts Major Adverse Cardiac Nothing to Disclose	
and Reduction Events in Systemic Lupus Erythematosus	
Patel Vishal Arrhythmias and Clinical EP: Ventricular Prognostic Impact of In-Hospital Cardiac Arrest Ratio in Patients With In-Hospital Cardiac Arrest	
Patel Yash Emerging Developments in HFpEF and Serum Sodium Is Associated With Mortality in Heart Failure With Nothing to Disclose Preserved Ejection Fraction in the U.S. Veteran Population	



Patelis	First Name Nikolaos	Session Title Nuclear Cardiology: Beyond Perfusion	Presentation Title In Vivo Correlation of Carotid Temperatures and Pet/Fdg Uptake in Patients Undergoing Carotid Endarterectomy: Validation With	Disclosures Nothing to Disclose
Patlolla	Harish	Updates in Stable Ischemic Heart Disease	Histology Effect of Hospital Intervention on Smoking Cessation 30 Days After	Nothing to Disclose
Patnaik	Amar	Insights Into Ischemic Heart Disease: Stable to	Admission for Acute Coronary Syndrome Is Vitamin D Deficiency a Risk Factor for Severe Coronary Artery	Nothing to Disclose
Patnaik	Soumya	Erosive Plaques Acute Heart Failure: Evaluating Strategies to	Disease and Acute Coronary Syndrome Seasonal and Regional Variations in Heart Failure Admissions and	Nothing to Disclose
Patrascu	Natalia	Prevent Readmissions Novel Imaging and Therapies in Heart Failure	Mortality in the United States Gestational Hypertension and Preeclampsia Are Associated With	Nothing to Disclose
Pattanakuhar	Sintip	Emerging Developments in HFpEF and Arryhthmias	Subclinical Left Ventricular Systolic and Diastolic Dysfunction Decreased Heart Rate Variability Is Associated With Increased Cardiac Iron Deposit Determined by Cardiac T2* MRI and Decreased Left Ventricular Function in Transfusion Dependent	Nothing to Disclose
Pattanshetty	Deepak	Advances in HCM, PPCM and Other Cardiomyopathies	Thalassemia Patients Takotsubo Cardiomyopathy (TCM) Increases Risk of Lethal Arrhythmias	Nothing to Disclose
Patterson	J. Herb	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Heart Failure With Reduced Ejection Fraction Care Patterns in the Outpatient Practice Setting: Initial Findings From CHAMP-HF	CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals; RESEARCH/RESEARCH GRANTS - Amgen, Novartis Pharmaceuticals, Otsuka America Pharmaceutical, Inc.
Patterson	J. Herbert	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Influence of Low Versus High Dose on the Association of Loop Diurectic and Mortality in Patients With Heart Failure: Insights From the UNITE-HF Registry	CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals; RESEARCH/RESEARCH GRANTS - Amgen, Novartis Pharmaceuticals, Otsuka America Pharmaceutical, Inc.
Patterson	Tiffany	Post-CAD/MI: Making Tough Predictions About the Future	Unravelling the Mechanisms of Mental Stress Induced Myocardial Ischaemia: Novel Insights From Intracoronary Measurements During Cardiac Catheterisation	Nothing to Disclose
Patti	Giuseppe	13. Heart Failure and Cardiomyopathies: Clinical Team 5	Suggested Reviewer	Nothing to Disclose
Patton	Kristen	Late-Breaking Clinical Trials	Panelist	Nothing to Disclose
Patton	Kristen	Common Arrhythmia Problems: The Experts Approach	Co-Chair Panelist	Nothing to Disclose Nothing to Disclose
Patton Patton	Kristen Kristen	Syncope: Challenges and Pitfalls: A Case- based Approach Syncope: Challenges and Pitfalls: A Case-	Panelist 32 Year Old with Syncope and Family History of Sudden Death	Nothing to Disclose
Patton	Kristen	based Approach Test Yourself with Questions: Guidelines	Faculty	Nothing to Disclose
Patton	Kristen	Module 3: Atrial Fibrillation Test Yourself with Questions: Guidelines	Moderator	
		Module 3: Atrial Fibrillation		Nothing to Disclose
Patton	Kristen	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	Nothing to Disclose
Paudel	Govinda	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Association of Increased Total Atrial Volume With Clinical Heart Failure Status in Hypoplastic Left Heart Syndrome	Nothing to Disclose
Paul Paul	Erin Timir	Innovations in Education Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Fellow Outpatient Clinic: Discontinuing the Discontinuity In-Hospital Mortality in Percutaneous Coronary Stenting of Bifurcation Versus Non-Bifurcation Lesions in Acute ST-Elevation	Nothing to Disclose Nothing to Disclose
Paul	Timir	Complex Coronary Intervention: Left	Myocardial Infarction National Trend in Total Charges for Multivessel Percutaneous	Nothing to Disclose
Faui	1111111	Main/Bifurcations and Multivessel Disease	Coronary Intervention in Patients With Diabetes Mellitus in the United States: Nationwide Inpatient Sample From the Year 2006 to 2011	Notifing to Disclose
Paul	Timir	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	A Rare Cause of Syncope	Nothing to Disclose
Paul	Timir	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	An Unusual Case of Intramural Hematoma Following Percutaneous Coronary Intervention	Nothing to Disclose
Pavao	Maria Licia	Arrhythmias and Clinical EP: Devices 1	Electrical Storm in Chagas Heart Disease Patients With Implantable Cardioverter Defibrillator - Clinical Predictors, Outcome and Arrhythmic Characteristics: A Prospective Registry From a University Hospital	Nothing to Disclose
Pavlides	Gregory	Innovative Use of Echocardiography	The Predictive Value of Microvascular Defects Observed During Demand Stress Myocardial Contrast Echocardiography and Quantitative Measurements of Stenosis and Microvascular Resistance Obtained During Invasive Hemodynamics	Nothing to Disclose
Pawade	Tania	Blips, Trops, and Chips: New Ways to Diagnose CAD	High-Sensitivity Cardiac Troponin I and the Diagnosis of Obstructive Coronary Artery Disease in Patients With Suspected Stable Angina	Nothing to Disclose
Pawar	Sumeet	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Etiology and Predictors of 30-Day Unplanned Readmission Rates After Left Ventricular Assist Device Placement	Nothing to Disclose
Paydak	Hakan	Arrhythmias and Clinical EP: Devices 3	Importance of Right Ventricular Lead Positioning in Determining	Nothing to Disclose
Paydak	Hakan	Arrhythmias and Clinical EP: Basic 3	Outcomes of Cardiac Resynchronization Therapy Seasonal Trends in Sudden Cardiac Death: A Study From the Largest Inpatient Database	Nothing to Disclose
Payne	Jason	Interventional Cardiology: Intravascular	Outcomes of Fractional Flow Reserve Based Deferral in Saphenous Vein Graft Lesions	Nothing to Disclose
Payne	Jason	Physiology and Endothelial Function Arrhythmias and Clinical EP: Devices 3	Near Zero Fluoroscopy Implantation of a Dual Chamber Pacemaker	Nothing to Disclose
Payne	Jason	Interventional Cardiology: Stent Failure	in Pregnancy Using Electroanatomical Mapping Does Post Pci Ffr Carry the Same Prognostic Weight as Non- lschemic Ffr in Deferred Lesions?	Nothing to Disclose
Peacock	W. Frank	Analysis by Intravascuar Imaging Imaging of Chest Pain in the Emergency Department	Co-Chair	CONSULTANT FEES/HONORARIA - Alere, Beckman, Boehringer Ingelheim Pharmaceuticals, Inc, Cardiorentis, Daichi-Sankyo, Instrumentation Laboratories, Jamssen, Novartis, Relypsa, The Medicine's Company, ZS Pharma; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Comprehensive Research Associates, Emergencies in Medicine; RESEARCH/RESEARCH GRANTS - Alere, Banyan, Preventico, Roche, The Medicine's Company
Peacock	W. Frank	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Educational Strategy for Management of Heart Failure Markedly Reduces 90-Day Emergency Department and Hospital Readmissions in Un- and Underinsured Patients	CONSULTANT FEES/HONORARIA - Alere, Beckman, Boehringer Ingelheim Pharmaceuticals, Inc, Cardiorentis, Daichi-Sankyo, Instrumentation Laboratories, Janssen, Novartis, Relypsa, The Medicine's Company, ZS Pharma; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Comprehensive Research Associates, Emergencies in Medicine; RESEARCH/RESEARCH GRANTS - Alere, Banyan, Prevenico, Roche, The Medicine's Company
Pearson	Gail	2017 Dan G. McNamara Lecture: The Future of Congenital Heart Research: Keeping the Patient-Centered Promise	ACC.17 Dan G. McNamara Lecture: NHLBI's Investment in Pediatric Cardiovascular Research: Past, Present, and Future	Nothing to Disclose
Peden	Brad	Updates on Risk Factors for Cardiovascular Disease	Association of Objectively Measured Sedentary Time, Physical Activity and Cardiorespiratory Fitness Levels with Cardiometabolic Risk Factors and Cardiac Structure and Function: Findings From the Dallas Heart Study	Nothing to Disclose

Last Name	First Name	Session Title	Presentation Title	Disclosures
Pedersen	Sune	Innovative Use of Echocardiography	Presence of Post-Systolic Shortening by Tissue Doppler Imaging is an Independent Predictor of Heart Failure in Patients Following ST- Segment Elevation Myocardial Infarction	Nothing to Disclose
Pedersen	Terje	Opening Session and the Joint American College of Cardiology and Journal of American College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture	Segment Elevation involcation infaction Primary Results of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial	Nothing to Disclose
Pedersen	Terje	Joint American College of Cardiology/Journal of the American Medical Association Late-	Primary Results of EBBINGHAUS, a Cognitive Study of Patients Enrolled in the FOURIER Trial	Nothing to Disclose
Pedersen	Wesley	Breaking Clinical Trials 24. Interventional Cardiology: Mitral and Structural Heart Disease Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular; OTHER - Lake Regions Medical; OWNERSHIP
Pedicino	Daniela	Insights Into Ischemic Heart Disease: Stable to Erosive Plaques	Hyaluronic Acid, Hyaluronidase-2 and Acute Coronary Syndromes: Possible Correlation With Plaque Erosion	INTEREST/PARTNERSHIP/PRINCIPAL - Intervalve Nothing to Disclose
Pedicino	Daniela	Unusual Presentations of ACS	Matrix Metalloproteinase 9 Drives the Shedding of CD31 in Acute Coronary Syndromes	Nothing to Disclose
Pedlar	Charles	Hearts and Soles: Multimodality Imaging in Athletes	Temporal Sequence of Athlete’s Heart Regression During Prescribed Exercise Detraining: <i>Diagnostic Implications</i>	Nothing to Disclose
Pelargonio	Gemma	Arrhythmias and Clinical EP: AF Ablation	Long-Term Risk of Recurrent Arrhythmia in Patients With Typical Atrial Flutter Undergoing Pulmonary Vein Antrum Isolation or Cavo- Tricuspid Isthmus Ablation With Permanent Isolation	Nothing to Disclose
Pelech	Andrew	Congenital Heart Disease: Progress in Pediatric Heart Surgery	The Aortic Perfusion Score: A Novel Scoring System to Predict Death or Transplant in Children With Pulmonary Atresia With Intact Ventricular Septum	Nothing to Disclose
Pellegrini	Costanza	Interventional Cardiology: TAVR 3	Wethicular Septiment Multicenter Evaluation of the ACURATE Neo Transfermoral Transcatheter Heart Valve: Clinical Results and Propensity Matched Comparison With SAPIEN 3	Nothing to Disclose
Pellegrini	Costanza	Interventional Cardiology: TAVR 4	Multicenter Evaluation of Prosthesis Oversizing for the SAPIEN 3 Transcatheter Heart Valve: Impact on New Pacemaker Implantations	Nothing to Disclose
Pellegrino	Grazia	Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI	Activating Stimuli Modulate Pre-mRNA Maturation in Platelets: A Novel Mechanism That Regulates Platelet Function?	Nothing to Disclose
Pellegrino	Grazia	MicroRNAs and Beyond in Vascular Medicine	Colchicine Exerts Antithrombotic Properties in oxLDL-Treated Endothelial Cells via Inhibition of Tissue Factor Expression and Activity	Nothing to Disclose
Pellegrino	Grazia	Cutting Edge Vascular Medicine	Colchicine Inhibits Platelet Aggregation <i>In Vitro </i> With Cofilin and LIM Domain Kinase 1, the Main Kinases Involved in Cytoskeleton Rearrangement	Nothing to Disclose
Pelliccia	Antonio	07. Arrhythmias and Clinical EP: Sports and Exercise Team 1	Suggested Reviewer	Nothing to Disclose
Pellikka	Patricia	Echocardiographic Assessment of LV Diastolic Function — The New ASE/EACVI Guidelines — 2016 Update: Joint Symposium of the American Society of Echocardiography and the American College of Cardiology	Case presentations: Estimation of Filling Pressures in the Dyspneic Patient	RESEARCH/RESEARCH GRANTS - GE Healthcare
Pellikka	Patricia	Stress Echocardiography: Best Practices and Emerging Applications	Introducing the Diastolic Stress Test	RESEARCH/RESEARCH GRANTS - GE Healthcare
Pellikka	Patricia	Point of Care Ultrasound (POCUS): The Future or a Fad?	Co-Chair	RESEARCH/RESEARCH GRANTS - GE Healthcare
Pellikka	Patricia	Novel Echocardiographic Methods for Assessing Cardiac Function	Subclinical Myocardial Alterations in Cardiac Sarcoidosis	RESEARCH/RESEARCH GRANTS - GE Healthcare
Pellikka	Patricia	Innovative Use of Echocardiography	The Association Between Echocardiographic Laboratory Accreditation and the Quality of Imaging and Reporting	RESEARCH/RESEARCH GRANTS - GE Healthcare
Pellikka	Patricia	Valvular Heart Disease: Aortic Stenosis	Bicuspid Versus Tricuspid Aortic Valve Stenosis: Comparative Study of Clinical Characteristics and Outcomes Following Aortic Valve Replacement in an Age-Matched Cohort	RESEARCH/RESEARCH GRANTS - GE Healthcare
Pellikka	Patricia	Valvular Heart Disease: Aortic Stenosis	Sinus Rhythm Versus Atrial Fibrillation & It Clinical Profile and Natural History of Patients With Severe Aortic Stenosis Managed Medically	RESEARCH/RESEARCH GRANTS - GE Healthcare
Pellikka	Patricia	Interventional Cardiology: TAVR 3	Comparative Outcome of Paravalvular Leak Following Surgical Versus Transcatheter Aortic Valve Replacement	RESEARCH/RESEARCH GRANTS - GE Healthcare
Pellikka	Patricia	New Technologies in Echocardiography	Novel Echocardiographic Measurements Detect Increased Myocardial Stiffness in Patients With Severe Organic Mitral Regurgitation	RESEARCH/RESEARCH GRANTS - GE Healthcare
Pellikka	Patricia	Insights From Echocardiography Use	Echocardiographic Parameters of Myocardial Performance After Transapical Versus Transfemoral Transcatheter Aortic Valve Replacement	RESEARCH/RESEARCH GRANTS - GE Healthcare
Pellikka	Patricia	Novel Determinants of Outcomes in VHD	Coexisting Co-Morbidities Exacerbate Left Ventricular Diastolic Dysfunction and Prognosis in Patients With Severe Aortic Stenosis	RESEARCH/RESEARCH GRANTS - GE Healthcare
Pellikka	Patricia	Prosthetic Valve Thrombosis: TAVR, Bio, Mech Now What?!	Outcome of Anticoagulation Therapy for Bioprosthetic Valve Thrombosis: A Prospective Study	RESEARCH/RESEARCH GRANTS - GE Healthcare
Pellikka	Patricia	New Perspectives on CAD Risk Factors	Discordances Between Predicted and Actual Risk of Adverse Events in Obese Patients With Suspected Cardiac Ischemia: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	RESEARCH/RESEARCH GRANTS - GE Healthcare
Pellikka	Patricia	36. Valvular Heart Disease: Clinical Team 1	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - GE Healthcare
Pelosi	Frank	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team 4	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific, MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Avicenna Medical Systems; RESEARCH/RESEARCH GRANTS - Medtronic, Inc
Pemberton	Heather	Unusual Presentations of ACS	Survival of Patients Referred for Emergent Cardiac Catheterization for ST-Elevation Myocardial Infarction Without Culprit Lesions	Systems; RESEARCH/RESEARCH GRANTS - Meditronic, Inc. Nothing to Disclose
Pena	Adam	Novel Echocardiographic Methods for Assessing Cardiac Function	Coronary Microvascular Dysfunction Affects the Myocardial Contractile Reserve in Women With Angina and No Obstructive Coronary Artery Disease	Nothing to Disclose
Pena	Jacobo	Innovations in Cardiovascular Risk Assessment and Reduction	Optical Coherence Tomography of Culprit Lesions in Patients With Prior Cerebrovascular Events Compared to Controls	Nothing to Disclose
Peña de Leon	Edilberto	Updates on Risk Factors for Cardiovascular Disease	Association of Anxious and Depressive Symptomatology With Cardiovascular Disease Among Patients From Different States in Mexico: REDECAR Study	Nothing to Disclose
Pencina	Michael	Featured Clinical Research II: Interventional	Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data	CONSULTANT FEES/HONORARIA - admittance, Knobbe; DATA SAFETY MONITORING BOARD - Cardiovasculr Sciences Foundation, DC Devices , Theracos
Pencina	Michael	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Recurrent Cardiovascular Event Rates in a Contemporary Cohort of 829,498 Adults With Atherosclerotic Cardiovascular Disease	CONSULTANT FEES/HONORARIA - admittance, Knobbe; DATA SAFETY MONITORING BOARD - Cardiovasculr Sciences Foundation, DC Devices, Theracos
Pencina	Michael	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Examination of hs-CRP Elevation in Patients With History of Myocardial Infarction in the U.S.	CONSULTANT FEES/HONORARIA - admittance,Knobbe; DATA SAFETY MONITORING BOARD - Cardiovasculr Sciences
		Coronary Artery Disease	<u> </u>	Foundation,DC Devices ,Theracos

Last Name Pendyal	First Name Akshay	Session Title Coming to Consensus in a New Era: The Role of Non-statin Therapies in ASCVD Risk	Presentation Title Improving Outcomes in ACS	Disclosures Nothing to Disclose
Peng	Lynn	Reduction Highlighted Original Research: Congenital Heart Disease and the Year in Review	Safety and Feasibility of Melody Transcatheter Pulmonary Valve Replacement in the Native Right Ventricular Outflow Tract: A Multicenter Study	OTHER - First Databank
Penicka	Martin	Emerging Applications of Echocardiography	Effect of Changing Strain Software Versions on Longitudinal	Nothing to Disclose
Penicka	Martin	Non Invasive Imaging: Expanding Clinical Applications	Assessment of LV Function Left Atrial Appendage Occlusion Facilitated by Three Dimensional Rotational Angiography Alone Is Safe and Anatomically Superior to Trasoesophageal Echocardiography	Nothing to Disclose
Penn	Marc	Unusual Presentations of ACS	Outcomes of Immediate Versus Delayed Intervention in Patients Presenting 24 -72 Hours After Myocardial Infarction	CONSULTANT FEES/HONORARIA - Oakwood Medical Ventures; DATA SAFETY MONITORING BOARD - NIH CHF Network; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Black Beret Life Sciences, Juventas Therapeutics; OWNERSHIP MITEREST/PARTNERSHIP/PRINCIPAL - Cleveland Heart Lab; RESEARCH/RESEARCH GRANTS - Athersys, Inc.
Pennell	Dudley	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Cardiovascular Magnetic Resonance in Survivors of Sudden Cardiac Arrest: 14 Year Experience From a Tertiary Referral Centre in the United Kingdom	CONSULTANT FEES/HONORARIA - Apotex,CVIS,Siemens
Pennell	Dudley	Antithrombotic Therapy in Ischemic Heart Disease	Changes in Thrombotic Parameters in Patients With Refractory Angina and Raised Lipoprotein(a) Treated With Lipoprotein Apheresis	CONSULTANT FEES/HONORARIA - Apotex,CVIS,Siemens
Pepe	Martino	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Admission Plasma Glucose Level on Myocardial Perfusion in St-Segment Elevation Myocardial Infarction (STEMI) Patients	Nothing to Disclose
Pepe	Martino	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Time Related Benefit of Antiplatelet Therapy on Coronary Reperfusion in ST-Elevation Myocardial Infarction (STEMI) Patients	Nothing to Disclose
Pepi	Mauro	Non Invasive Imaging: MR Heart Failure and	Prognostic Stratification in Patients With ST-Elevation Myocardial	Nothing to Disclose
Pepi	Mauro	Pulmonary Hypertension Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Infaction Over Transthoracic Echocardiography by CMR Diagnostic Value of Qt Evaluation in Anterior ST Segment Elevation Myocardial Infarction for Prediction of Myocardial Salvage Index, as Compared to CMR	Nothing to Disclose
Pepine	Carl	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes		Nothing to Disclose
Pepine	Carl	Novel Imaging and Therapies in Heart Failure	Global Longitudinal Strain in Patients With New Left Ventricular Systolic Dysfunction After Anticancer Targeted Therapies	Nothing to Disclose
Pepine	Carl	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Cardiomyopathy Associated With Targeted Anticancer Therapies in Electronic Health Records	Nothing to Disclose
Pepine	Carl	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Prognostic Risk Factors for Heart Failure Hospitalization in Women Without Obstructive Coronary Disease: An Ancillary Study From the Women's Ischemia Syndrome Evaluation (WISE)	Nothing to Disclose
Pepine	Carl	New Insights Into Prediction and Treatment of Hypertension	Relationship Between Diastolic Blood Pressure and All-Cause Mortality With Lower Systolic Blood Pressure Among Hypertensive Patients With Coronary Artery Disease: Long-Term Follow-Up of the US Cohort of the International Verapamil SR-Trandolapril Study (INVEST)	Nothing to Disclose
Percell	Robert	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues		SPEAKER'S BUREAU - Biosense Webster, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Johnson and Johnson, Pfizer Inc., St. Jude Medical
Percell	Robert	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Sans Fluoro: A First Year Experience (SAy No Series to FLUOROscopy)	SPEAKER'S BUREAU - Biosense Webster, Boehringer Ingelheim Pharmaceuticals, Inc, Janssen Pharmaceuticals, Inc, Johnson and Johnson, Pfizer Inc, St. Jude Medical
Pereira	Naveen	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Effects of Diabetes Mellitus on Clinical Outcomes After Left Ventricular Assist Device Implantation: A Single Institutional 9-Year Experience	Nothing to Disclose
Pereira	Naveen	Advanced Therapies = Advanced Trouble: VAD and Transplant Challenges	Sirolimus-Based Immunosuppression Mitigates Progression of Cardiac Allograft Vasculopathy and Improves Cardiac Outcomes After Heart Transplantation: A Single Center 15-Year Follow-Up Study	Nothing to Disclose
Perera	Divaka	Featured Clinical Research I	MR-INFORM: Stress Perfusion Imaging to Guide the Management of Patients With Stable Coronary Artery Disease	Nothing to Disclose
Perera	Divaka	Post-CAD/MI: Making Tough Predictions About the Future	Unravelling the Mechanisms of Mental Stress Induced Myocardial Ischaemia: Novel Insights From Intracoronary Measurements During Cardiac Catheterisation	Nothing to Disclose
Peretto	Giovanni	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Cardiac Catherination Role of Endomyocardial Biopsy in Patients With Structural Heart Disease and Normal Coronary Arteries Presenting With Ventricular Arrhythmias	Nothing to Disclose
Peretto	Giovanni	Post-CAD/MI: Making Tough Predictions About		Nothing to Disclose
Perez	Antonio	the Future Risky Business: Predicting Outcomes in Heart	The HOSPITAL Readmission Model Poorly Predicts 30-Day	Nothing to Disclose
Pérez	Guillermo Javier	Failure Cardiac Channelopathies: Novel Therapeutics and Clinical Challenges	Rehospitalization in Heart Failure Eficacy and Safety of Flecainide to Reduce Exercise-Induced Ventricular Arrhythmias and the Arrhythmic Window in Patients With	Nothing to Disclose
Perez de Prado	Armando	Timely Topics in Acute Coronary Syndromes	Catecholaminergic Polymorphic Ventricular Tachycardia A New Prognosis Score to Predict Mortality in Patients Over 75	Nothing to Disclose
Perez-Downes	Julio	FIT Clinical Decision Making: Non-Invasive	Years Old Undergoing Primary Angioplasty in Cardiogenic Shock Cardiac Magnetic Resonance Imaging Illustrating an Asymptomatic,	Nothing to Disclose
Perez-Downes	Julio	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Large Inferobasilar Left Ventricular Aneurysm Ventricular Papillary Fibroelastoma Presenting as Peripheral Artery Disease	Nothing to Disclose
Perez-Montessoro	Viridiana	Disease, and Vascular Medicine ACC International Conferences Best Posters	HER2 Positive Breast Cancer and Subclinical Cardiotoxicity by Echocardiogram 2D Strain: Does Chemotherapy Sequence Matter?	Nothing to Disclose
Perino	Alexander	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Success Rates by Ablation Lesion Set of Catheter Ablation for Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta- Analysis Study Cohort	Nothing to Disclose
Perino	Alexander	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Secular Trends in Reported Success Rates of Catheter Ablation for Non-Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort	Nothing to Disclose
Perino	Alexander	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Inclusion of Women in Studies of Catheter Ablation for Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort	Nothing to Disclose
Perk	Gila	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	An Unexpected Guest in the Right Ventricle	Nothing to Disclose
Perlman	Gidon	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	Nothing to Disclose



WASHINGTON, DC | MARCH 17 - 19 2017

The same of the sa				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Perola	Markus	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	A Risk Locus for Non-ST-Elevation Myocardial Infarction on Chromosome 1p13.3 Is Also Associated With Peripheral Artery Disease in Patients With Acute Coronary Syndrome	Nothing to Disclose
Perpetua	Elizabeth	TAVR: What We've Learned and Where We Think We're Going!	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Edwards Lifesciences
Perpetua	Elizabeth	Cardiovascular Team Cases: Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott
Perrault	Louis	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking	Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic	Laboratories,Edwards Lifesciences Nothing to Disclose
Perrault	Louis	Clinical Trials Interventional Cardiology: TAVR 4	Surgical Trials Network Serum Albumin as an Incremental Predictor of Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement:	Nothing to Disclose
Реггу	Andrew	Making Progress in Understanding Heart	Results From the Multicenter Frailty-AVR Study Global Longitudinal Strain Predicts Sustained Recovery of LV	Nothing to Disclose
Реггу	Gilbert	Failure Non Invasive Imaging: MR Characterization	Ejection Fraction in Heart Failure Patients on Evidence Based Medical Therapies Left Ventricular Torsion Shear Angle Volume Approach for Non-	Nothing to Disclose
		and Function	Invasive Evaluation of Diastolic Dysfunction in Preserved Ejection Fraction	
Perry	Tjorvi	Interventional Cardiology: TAVR 4	Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Pershad	Ashish	Chronic Total Occlusion PCI: A Case-Based Review of Contemporary Techniques	Case Presentation: Retrograde Case Through Septal Collateral Step-by-step	CONSULTANT FEES/HONORARIA - Abiomed,asahi intecc,Boston Scientific; SPEAKER'S BUREAU - Abbott Laboratories,Edwards Lifesciences,MEDTRONIC
Pershad	Ashish	FIT Forum: Stump the Professor	Persistence Pays Off: A Rare Case of Platypnea-Orthodeoxia Syndrome Due to a Patent Foramen Ovale	CONSULTANT FEES/HONORARIA - Abiomed,asahi intecc,Boston Scientific; SPEAKER'S BUREAU - Abbott Laboratories,Edwards Lifesciences,MEDTRONIC
Pershad	Ashish	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Comparing TEE With Angiographic Sizing of WATCHMAN Device for Left Atrial Appendage Closure	CONSULTANT FEES/HONORARIA - Abiomed, asahi intecc, Boston Scientific; SPEAKER'S BUREAU - Abbott Laboratories, Edwards Lifesciences, MEDTRONIC
Pershad	Ashish	Advances in Chronic Total Occlusion Intervention	Hemodynamically-Supported PCI of Chronic Total Occlusions: A Case Series	CONSULTANT FEES/HONORARIA - Abiomed,asahi intecc,Boston Scientific; SPEAKER'S BUREAU - Abbott
Pershad	Ashish	Advances in Chronic Total Occlusion	Impact of Sex on Physical Limitation & Patient Health Status	Laboratories, Edwards Lifesciences, MEDTRONIC CONSULTANT FEES/HONORARIA - Abiomed, asahi
		Intervention	After Chronic Total Occlusion Percutaneous Coronary Intervention: Propensity Matched Substudy of OPEN-CTO Registry	intecc,Boston Scientific; SPEAKER'S BUREAU - Abbott Laboratories,Edwards Lifesciences,MEDTRONIC
Pershad	Ashish	21. Interventional Cardiology: Coronary Intervention: Devices Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abiomed, asahi intecc, Boston Scientific; SPEAKER'S BUREAU - Abbott Laboratories, Edwards Lifesciences, MEDTRONIC
Perticone	Francesco	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	History of Atrial Fibrillation in a First-Degree Relative and Risk of Cardiovascular Events	Nothing to Disclose
Pesaro	Antonio	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	High Non-High-Density Lipoprotein Cholesterol Levels Predict Enhanced Periprocedural Inflammatory Response Following	Nothing to Disclose
	F	De latin Control of the French Control	Percutaneous Coronary Intervention in Stable Ischemic Heart Disease Patients	N. H. C. L. D. C. L. C.
Pessoa	Fernanda	Population Specific Cardiomyopathies: From Exomes to Databases	Air Pollution in Myocardial Remodeling	Nothing to Disclose
Peters	Andrew	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Hemitruncus Arteriosus: A Rare Case of Hypoxia in Pregnancy	Nothing to Disclose
Peters	Anthony	Innovations in Practice Management and Social Media	The Impact of Patient Activation in Patients Post-Myocardial Infarction	Nothing to Disclose
Peters	Anthony	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Impact of Cardiogenic Shock with or without Mechanical Circulatory Support on Short-Term and Long-Term Survival in Heart Failure Hospitalizations	Nothing to Disclose
Petersen	John	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Coronary Microvascular Dysfunction Is Related to Left Ventricular Concentric Remodeling and Diastolic Dysfunction: From the WISE- CVD Study	Nothing to Disclose
Petersen	Steffen	29. Non Invasive Imaging: MR Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Circle Cardiovascular Imaging Inc.,GSK
Petersen-Aranguren	Fernando	Updates on Risk Factors for Cardiovascular Disease	Association of Anxious and Depressive Symptomatology With Cardiovascular Disease Among Patients From Different States in Mexico: REDECAR Study	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Centro de Investigacion Cardiologica
Peterson	Brandon	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Effectiveness of Coronary CT Angiography Versus Standard Care for the Assessment of Patients With Suspected Coronary Artery	Nothing to Disclose
Peterson	Brandon	Coronary Artery Disease FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Disease: A Trial Sequential Analysis Transcatheter Tricuspid Valve Replacement: "Forgotten Valve", Challenging Management With Limited Treatment	Nothing to Disclose
Peterson	Brandon	Emerging Applications of Echocardiography	Options - Time to Gather Evidence HEART Score Classification and Predictive Accuracy of Stress	Nothing to Disclose
Peterson	Eric	FIT Forum: Mix and Mingle	Echocardiography in a Contemporary ED Observation Unit Cohort Clinical Research	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Genentech, Janssen, Merck & Dengramp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International RESEARCH/RESEARCH GRANTS - Bayer, Daiichi Sankyo, Janssen, Merck & Amp; amp; Co., Inc.
Peterson	Eric	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	Co-Chair	Sankyo, Janssen, Meric K admp; amp; Co., Inc. CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dailichi Sankyo, Genentech, Janssen, Merck & amp; amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International RESEARCH/RESEARCH GRANTS - Bayer, Dailichi Sankyo, Janssen, Merck & Amp; amp; Co., Inc.
Peterson	Eric	Featured Clinical Research II: Interventional	Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Genentech, Janssen, Merck & amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International RESEARCH/RESEARCH GRANTS - Bayer, Daiichi Sankyo, Janssen, Merck & amp; Co., Inc.
Peterson	Eric	Late-Breaking Clinical Trials	Comparative Effectiveness of Left Atrial Appendage Occlusion Among Atrial Fibrillation Patients Undergoing Cardiac Surgery: A Report From the Society of Thoracic Surgeons Adult Cardiac Surgery Database	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Genentech, Janssen, Merck & amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International RESEARCH/RESEARCH GRANTS - Bayer, Daiichi Sankyo, Janssen, Merck & amp; Co., Inc.
Peterson	Eric	Featured Clinical Research III	Early Challenges for PSCK9 Inhibitor Prescriptions and Patients: Rejections and Rates Unfilled	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dailchi Sankyo, Genentech, Janssen, Merck & Bamp; amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International RESEARCH/RESEARCH GRANTS - Bayer, Dailchi Sankyo, Jansen, Merck & Bamp; amp; Co., Inc.

Carry Contract of the Contract				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Peterson	Eric	Acute Cardiogenic Shock: Progress, Paradigm, and Unresolved Problems	The Double Edged Sword of Public Reporting in AMI and Shock	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dalichi Sankyo, Genentech, Janssen, Merck & amp; amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCH/RESEARCH GRANTS - Bayer, Dalichi Sankyo, Janssen, Merck & amp; amp; Co., Inc.
Peterson	Eric	Core Curriculum: Special Topic: Practical Tips: Changes in Healthcare Affecting My Practice	Practical Tips: Incorporating Quality Both Inpatient and Outpatient	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dalichi Sankyo, Genentech, Janssen, Merck Aamy, amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCH/RESEARCH GRANTS - Bayer, Dalichi Sankyo, Janssen, Merck Aamp; amp; Co., Inc.
Peterson	Eric	Highlighted Original Research: Interventional Cardiology and the Year in Review	New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: Incidence, Anticoagulant Strategy, and Outcomes	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dalichi Sankyo, Genentech, Janssen, Merck & amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCH/RESEARCH GRANTS - Bayer, Dalichi Sankyo, Janssen, Merck & amp; Co., Inc.
Peterson	Eric	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Patterns of Angina and Antianginal Medication Use Among Patients Following MI Treated With PCI: Insights From TRANSLATE-ACS	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dalichi Sankyo, Genentech, Janssen, Merck & amp; amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCH/RESEARCH GRANTS - Bayer, Dalichi Sankyo, Janssen, Merck & amp; amp; Co., Inc.
Peterson	Eric	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Ten-Year Mortality of Acute Myocardial Infarction Patients Treated in U.S. Community Practice	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dalichi Sankyo, Genentech, Janssen, Merck & amp; amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCH/RESEARCH GRANTS - Bayer, Dalichi Sankyo, Janssen, Merck & amp; amp; Co., Inc.
Peterson	Eric	Advances in Cholesterol Measurement and Management	Contemporary Patterns of Lipid Testing in Primary and Secondary Prevention Patients: Insights From the PALM Registry	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dalichi Sankyo, Genentech, Janssen, Merck & amp; amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCH/RESEARCH GRANTS - Bayer, Dalichi Sankyo, Janssen, Merck & amp; amp; Co., Inc.
Peterson	Eric	Making Progress in Understanding Heart Failure	Incremental Risk of Ischemic Stroke Over Time in Newly Diagnosed Heart Failure Patients Without Atrial Fibrillation	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dalichi Sankyo, Genentech, Janssen, Merck & amp; amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCH/RESEARCH GRANTS - Bayer, Dalichi Sankyo, Janssen, Merck & amp; amp; Co., Inc.
Peterson	Eric	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Recurrent Cardiovascular Event Rates in a Contemporary Cohort of 829,498 Adults With Atherosclerotic Cardiovascular Disease	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dalichi Sankyo, Genentech, Janssen, Merck & amp; amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCH/RESEARCH GRANTS - Bayer, Dalichi Sankyo, Janssen, Merck & amp; amp; Co., Inc.
Peterson	Eric	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Does Frailty Alter the Benefits of Oral Anticoagulation in Patients With Atrial Fibrillation?	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dalichi Sankyo, Genentech, Janssen, Merck & amp; Co., Inc. Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCH/RESEARCH GRANTS - Bayer, Dalichi Sankyo, Janssen, Merck & amp; Co., Inc.
Peterson	Eric	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Incidence of Recurrent Myocardial Infarction Among Older Adults in U.S. Community Practice	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dalichi Sankyo, Genentech, Janssen, Merck & amp; amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCH/RESEARCH GRANTS - Bayer, Dalichi Sankyo, Janssen, Merck & amp; amp; Co., Inc.
Peterson	Eric	Interventional Cardiology: TAVR 3	Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelmein, Dalichi Sankyo, Genentech, Janssen, Merck & amp; amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCH/RESEARCH GRANTS - Bayer, Dalichi Sankyo, Janssen, Merck & amp; amp; Co., Inc.
Peterson	Eric	Interventional Cardiology: TAVR 3	Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing TAVR: Insights From the STS/TVT Registry	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dalichi Sankyo, Genentech, Janssen, Merck &, amp; Co., Inc. Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCH/RESEARCH GRANTS - Bayer, Dalichi Sankyo, Janssen, Merck & amp; Co., Inc.
Peterson	Eric	Antithrombotic Therapy in Ischemic Heart Disease	Rivaroxaban Users Have Significantly Less Treatment Discontinuation Compared With Users of Other Oral Anticoagulants in Non-Valvular Atrial Fibrillation	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dalichi Sankyo, Genentech, Janssen, Merck &, amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCH/RESEARCH GRANTS - Bayer, Dalichi Sankyo, Jansen, Merck & RampNTS - Boyer, Dalichi Sankyo, Jansen, Merck & RampNTS - Co., Proceedings of the Control
Peterson	Eric	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dalichi Sankyo, Genentech, Janssen, Merck &, amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCH/RESEARCH GRANTS - Bayer, Dalichi Sankyo, Janssen, Merck &, amp; Co., Inc.
Peterson	Eric	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Bleeding and Premature Antiplatelet Therapy Discontinuation After Myocardial Infarction Among Patients With Chronic Kidney Disease	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dalichi Sankyo, Genentech, Janssen, Merck &, amp; Co., Inc. Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCH/RESEARCH GRANTS - Bayer, Dalichi Sankyo, Janssen, Merck & amp; Co., Inc.
Peterson	Eric	Anti-Platelet Therapies: Always a Sticky Topic	Antiplatelet Therapy Changes for MI Patients With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS Study	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Dalichi Sankyo, Genentech, Janssen, Merck & amp; amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCHRESEARCH (GRANTS - Bayer, Dalichi Sankyo, Janssen, Merck & amp; amp; Co., Inc.
Peterson	Eric	02. Acute and Stable Ischemic Heart Disease: Clinical Team 8	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Astra Zenecca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Genentech, Janssen, Merck & amp, amp; Co., Inc., Regeneron, SANOFI, Valeant Pharmaceuticals International; RESEARCHRESEARCH (GRANTS - Bayer, Daiichi Sankyo, Janssen, Merck & amp; amp; Co., Inc.

-				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Peterson	Gail	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Echocardiographic Predictors for In-Hospital and 1-Year Outcomes in Left-Sided Infective Endocarditis: An Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort Study	Nothing to Disclose
Peterson	Mark	Interventional Cardiology: TAVR 4	Serum Albumin as an Incremental Predictor of Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement: Results From the Multicenter Frailty-AVR Study	OTHER - Edwards Lifesciences
Peterson	Mark	Vascular Medicine: Aortic and Peripheral Artery Diseases	Uncontrolled Hypertension in Acute Aortic Dissection Follow-Up	OTHER - Edwards Lifesciences
Peterson	Mark	Vascular Medicine: Aortic and Peripheral Artery Diseases	Acute Aortic Dissection in Patients Without a History of Hypertension	OTHER - Edwards Lifesciences
Petillo	Florentina	Interventional Cardiology: TAVR 3	The Natural History of Paravalvular Regurgitation After Transarterial Valve Implantation for Severe Aortic Stenosis: One Center Experience	Nothing to Disclose
Petit	Christopher	A Night at the Movies with Some Congenital Heart Surgeons How Do They Actually Do That?: Joint Symposium of the American Association for Thoracic Surgeons and the American College of Cardiology	Panelist (Panel Discussion I)	Nothing to Disclose
Petit	Christopher	A Night at the Movies with Some Congenital Heart Surgeons How Do They Actually Do That?: Joint Symposium of the American Association for Thoracic Surgeons and the American College of Cardiology	Optimal Management of the Cyanotic Neonatal Tetralogy of Fallot Patient: Neonatalstent/Catheter-Based Palliation, to be Followed by Subsequent Repair (with Accompanying Surgical Video)	Nothing to Disclose
Petit	Christopher	Coarctation of the Aorta, from Repair to Lifelong Care	Co-Chair	Nothing to Disclose
Petit	Christopher	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Transcatheter Ductal Stenting Versus Surgical Systemic-to- Pulmonary Artery Shunts: Altering Dogma at a High-Volume Institution	Nothing to Disclose
Petit	Christopher	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Long Term Outcomes After the Fontan Procedure in Patients With Single Ventricle: A Meta-Analysis	Nothing to Disclose
Petraco da Cunha	Ricardo	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International	Nothing to Disclose
Petrasko	Marian	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Multicentre iFR GRADIENT Registry Spontaneous Coronary Artery Dissection in Alport Syndrome	Nothing to Disclose
Petrie	Mark	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Decision Making Using Fractional Flow Reserve Is Associated With Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With Nstermi	CONSULTANT FEES/HONORARIA - dachi sankyo,Maquet,Novartis Corporation
Petrie	Mark	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Segmental Circumferential Strain Derived From DENSE Predicts Improvement of Left Ventricular Function Post ST Elevation Myocardial Infarction: The BHF MR-MI Study	CONSULTANT FEES/HONORARIA - dachi sankyo,Maquet,Novartis Corporation
Petrie	Mark	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Current Smoking, Microvascular Pathology and Adverse Outcome After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights	CONSULTANT FEES/HONORARIA - dachi sankyo,Maquet,Novartis Corporation
Petrie	Mark	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Incidence and Prognostic Implications of the Presence of Multiple Complex Plaques in Survivors of ST-Elevation Myocardial Infarction	CONSULTANT FEES/HONORARIA - dachi sankyo,Maquet,Novartis Corporation
Petronio	Anna	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: From the WIN-TAVI Registry	Nothing to Disclose
Petrossian	George	Interventional Cardiology: TAVR 3	The Natural History of Paravalvular Regurgitation After Transarterial Valve Implantation for Severe Aortic Stenosis: One Center Experience	RESEARCH/RESEARCH GRANTS - Gore, MEDTRONIC
Pettersson	Gosta	Valvular Heart Disease: Endocarditis	Comparison of Non-Surgical and Surgical Therapy for Prosthetic Valve Endocarditis: A Propensity Score-Adjusted Study	Nothing to Disclose
Pettersson	Gosta	Valvular Heart Disease: Aortic Regurgitation	Etiology, Patient Characteristics and Surgical Outcomes of Acute Severe Aortic Regurgitation	Nothing to Disclose
Pfeffer	Marc	Preventing ASCVD in Diabetes: Are These New Drugs for Real?	GLP-1 Agonists: Lessons Learned from LEADER	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, DalCor, Genzyme Corporation, Gilead Sciences, Inc. GlaxoSmithKline, Janssen Pharmaceuticals, Inc, Novartis, Novo Nordisk Inc., Relypsa, Sanoft-Aventis, Thrasos Therapuetics; OTHER - DalCor, Novartis; RESEARCH/RESEARCH GRANTS - Novartis
Pfeffer	Marc	Emerging Developments in HFpEF and Arryhthmias	Influence of Left Ventricular Ejection Fraction on Cause-Specific Mortality in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, DalCor, Genzyme Corporation, Gilead Sciences, Inc., GlaxoSmithKline, Janssen Pharmaceuticals, Inc, Novartis, Novo Nordisk Inc., Relypsa, Sanofi-Aventis Thrasos Therapuetics; OTHER - DalCor, Novartis; RESEARCH/RESEARCH GRANTS - Novartis
Pfetsch	Vanessa	Biomarkers and Targets for Ischemic Heart Disease	Increased Concentrations of Soluble ST2 Independently Predict Cardiac and Total Mortality but Not Non-Fatal Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow- Up of the KAROLA Study	Nothing to Disclose
Pham	Duc Thinh	Novel Developments in Acute Coronary Syndromes	Right-Sided Ventriculo-Árterial Coupling Indices Are Associated With Clinical Outcomes Among Patients Receiving Biventricular Impella (BiPella) Support for Cardiogenic Shock	CONSULTANT FEES/HONORARIA - CardiacAssist, Inc., HeartWare, Inc., Thoratec, Inc.; RESEARCH/RESEARCH GRANTS - CardiacAssist, HeartWare, Inc.
Pham-Hung	Eric	Redefining the "F" Word	Late Complications and Cardiopulmonary Performance in Adults With Fontan Physiology: Rv-Dominant Versus Those With Lv- Dominant or Unseptated Ventricles	Nothing to Disclose
Phan	Timothy	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Acquisition of Time-Resolved Brachial Pressure Waveforms From Cuff-Based Pulse Volume Recordings	Nothing to Disclose
Phan	Timothy	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Heart-Femoral Pulse Wave Velocity Is a Stronger Marker of Arterial Aging Than Carotid-Femoral Pulse Wave Velocity	Nothing to Disclose
Phan	Timothy	Markers of Prognosis Associated With Elevated Blood Pressure	Cardio-Femoral Vascular Index: A New Marker of Arterial Aging	Nothing to Disclose
Phan	Timothy	Markers of Prognosis Associated With Elevated Blood Pressure	Decreased Aortic Inertance Is Independently Associated With Left Ventricular Hypertrophy: Role in Ventricular-Arterial Coupling	Nothing to Disclose
Phelan	Dermot	Imaging the Athlete's Heart	Pooled Cohort Equation and Coronary Artery Calcium in Retired National Football League Athletes	Nothing to Disclose
Phelan	Dermot	Hearts and Soles: Multimodality Imaging in Athletes	Ascending Aortic Dimensions in Former National Football League Athletes	Nothing to Disclose
Phelan	Dermot	Novel Arrhythmia Diagnostics, Therapeutics, and "Wearables	Variable Accuracy of Commercially Available Wearable Heart Rate	Nothing to Disclose
Phelan	Dermot	31. Non Invasive Imaging: Sports and Exercise Team 1	Monitors Suggested Reviewer	Nothing to Disclose
Phillips	Alistair	Special Hearts: The Challenge of Heart Failure in Congenital Heart Disease	Co-Chair	Nothing to Disclose



and the second				
Last Name Phillips	First Name Alistair	Session Title Congenital Heart Disease: Advances in Quality	Presentation Title Making Perioperative Handoff Communication Count by Improving	Disclosures Nothing to Disclose
		Improvement for Pediatric Cardiac Care	Safety and Quality in a New Congenital Heart Program	· ·
Phillips	Alistair	Engage @ ACC.17 Studio:The Newlywed Game for Pediatric Cardiac Providers	Co-Chair	Nothing to Disclose
Phillips	Alistair	09. Congenital Heart Disease: Adult Team 1	Suggested Reviewer	Nothing to Disclose
Phillips	John	FIT Clinical Decision Making Reviewers 7	ACC FIT Clinical Decision Making Reviewer	CONSULTANT FEES/HONORARIA - Endologix; SPEAKER'S BUREAU - Astra Zeneca, Bayer Healthcare Pharmaceuticals, Cook Medical, Gore Medical, Janssen Pharmaceuticals, Inc
Phillips	Kenneth	Innovations in Practice Management and Social Media	Unlocking the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for Today's Complex Care Delivery	Nothing to Disclose
Phillips	Sabrina	Imaging in Valvular Heart Disease: Applying Guidelines to Clinical Practice and What to do if They Don't Fit	The Tricuspid Valve – Why Should I Pay Attention to this Valve ?	Nothing to Disclose
Phillips	Sabrina	Engage @ ACC.17 Studio: FIT Jeopardy Battle of the State Chapters I	Judge	Nothing to Disclose
Phrommintikul	Arintaya	Emerging Developments in HFpEF and	Decreased Heart Rate Variability Is Associated With Increased	Nothing to Disclose
		Arryhthmias	Cardiac Iron Deposit Determined by Cardiac T2* MRI and Decreased Left Ventricular Function in Transfusion Dependent Thalassemia Patients	
Piacková	Edita	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Gender Differences in Short- and Long-Term Mortality in the Vienna STEMI Registry	Nothing to Disclose
Piana	Robert	Interventional Cardiology: TAVR 4	Depression as a Potential Therapeutic Target to Improve Quality of Life After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Axio Research,HCRI,W.L. Gore & Dramp; Associates, Inc; DATA SAFETY MONITORING BOARD - Terumo; OTHER - Cardiovascular Peer Review, LLC
Pianou	Nikoletta	Nuclear Cardiology: Beyond Perfusion	Increased Subclinical Systemic AND Vascular Inflammation in Familial Combined Hyperlipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission Tomography Study	Nothing to Disclose
Pianou	Nikoletta	Nuclear Cardiology: Beyond Perfusion	In Vivo Correlation of Carotid Temperatures and Pet/Fdg Uptake in Patients Undergoing Carotid Endarterectomy: Validation With Histology	Nothing to Disclose
Pianou	Nikoletta	Cutting Edge Vascular Medicine	Familial Combined Hyperlipidemia Is Characterized by Higher Arterial AND Hepatic Fluorodeoxyglucose Uptake Compared to Heterozygous Familial Hypercholesterolemia	Nothing to Disclose
Piazza	Gregory	Challenging the Standard of Care: Emerging Concepts in VTE Treatment and Prevention	Co-Chair	CONSULTANT FEES/HONORARIA - BCRI,exithera,Optum; RESEARCH/RESEARCH GRANTS - BMS,Daiichi,EKOS,Janssen Pharmaceuticals, Inc,Thrombosis Research Institute
Piazza	Gregory	Challenging the Standard of Care: Emerging Concepts in VTE Treatment and Prevention	Extended Duration Anticoagulation as the New Standard? Dissolving the Illusion of Provoked vs. Unprovoked VTE	CONSULTANT FEES/HONORARIA - BCRI, exithera, Optum; RESEARCH/RESEARCH GRANTS - BMS, Daiichi, EKOS, Jansser Pharmaceuticals, Inc, Thrombosis Research Institute
Piazza	Gregory	Challenging the Standard of Care: Emerging Concepts in VTE Treatment and Prevention	Pharmacomechanical Therapy for DVT to Prevent Post-thrombotic Syndrome	CONSULTANT FEES/HONORARIA - BCRI, exithera, Optum; RESEARCH/RESEARCH GRANTS - BMS, Daiichi, EKOS, Jansser Pharmaceuticals, Inc, Thrombosis Research Institute
Piazza	Gregory	Vasculo-Oncology: What You Need to Know About Vascular and Thrombotic Complications of Cancer and Cancer Therapeutics	Co-Chair	CONSULTANT FEES/HONORARIA - BCRI, exithera, Optum; RESEARCH/RESEARCH GRANTS - BMS, Daiichi, EKOS, Janssen Pharmaceuticals, Inc, Thrombosis Research Institute
Piazza	Gregory	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Prior Hospitalization Within 30 Days Predicts Increased Frequency of Death, Stroke, and Bleeding in Advanced Elderly Outpatients With Atrial Fibrillation	CONSULTANT FEES/HONORARIA - BCRI, exithera, Optum; RESEARCH/RESEARCH GRANTS - BMS, Daiichi, EKOS, Jansser Pharmaceuticals, Inc, Thrombosis Research Institute
Piazza	Gregory	Highlights in Vascular Medicine Research	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - BCRI, exithera, Optum; RESEARCH/RESEARCH GRANTS - BMS, Daiichi, EKOS, Jansser Pharmaceuticals, Inc, Thrombosis Research Institute
Piazza	Gregory	Advances in Pathophysiology and Treatment of Thrombosis	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - BCRI, exithera, Optum; RESEARCH/RESEARCH GRANTS - BMS, Daiichi, EKOS, Jansser Pharmaceuticals, Inc, Thrombosis Research Institute
Piazza	Gregory	38. Vascular Medicine: Basic Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - BCRI, exithera, Optum; RESEARCH/RESEARCH GRANTS - BMS, Daiichi, EKOS, Jansser Pharmaceuticals, Inc, Thrombosis Research Institute
Piazza	Nicolo	Interventional Cardiology: TAVR 4	Serum Albumin as an Incremental Predictor of Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement: Results From the Multicenter Frailty-AVR Study	CONSULTANT FEES/HONORARIA - HighLife,MEDTRONIC,MicroPort, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardiaQ,HighLife; RESEARCH/RESEARCH GRANTS - Boston Scientifc,MEDTRONIC
Piazza	Nicolo	24. Interventional Cardiology: Mitral and Structural Heart Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - HighLife, MEDTRONIC, MicroPort, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardiaQ, HighLife; RESEARCH/RESEARCH GRANTS - Boston Scientife, MEDTRONIC
Pibarot	Philippe	Highlighted Original Research: Interventional Cardiology and the Year in Review	Implications of Worsening Right Ventricular Function Following Transcatheter or Surgical Aortic Valve Replacement: Insights From PARTNER2A	RESEARCH/RESEARCH GRANTS - Cardiac Phoenix,Edwards Lifesciences.,MEDTRONIC,V-Wave Ltd.
Pibarot	Philippe	Interventional Cardiology: TAVR 1	Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: Insights From PARTNER 2A Trial	RESEARCH/RESEARCH GRANTS - Cardiac Phoenix,Edwards Lifesciences.,MEDTRONIC,V-Wave Ltd.
Pibarot	Philippe	Interventional Cardiology: TAVR 1	Effect of Valve Oversizing on Leaflet Bending Stress in the CoreValve: An In Vitro Study	RESEARCH/RESEARCH GRANTS - Cardiac Phoenix,Edwards Lifesciences,,MEDTRONIC,V-Wave Ltd.
Pibarot	Philippe	Non Invasive Imaging: Expanding Clinical Applications	Does Patient Prosthesis Mismatch Defined by CT LVOT Area Predict Downstream Clinical Outcomes?	RESEARCH/RESEARCH GRANTS - Cardiac Phoenix,Edwards Lifesciences.,MEDTRONIC,V-Wave Ltd.
Pibarot	Philippe	Interventional Cardiology: TAVR 2	Worsening Tricuspid Regurgitation and Increased Mortality After Aortic Valve Replacement: Insights From PARTNER2A	RESEARCH/RESEARCH GRANTS - Cardiac Phoenix,Edwards Lifesciences.,MEDTRONIC,V-Wave Ltd.
Pibarot	Philippe	Interventional Cardiology: TAVR 4	Clinical Study of the Impact of Preexisting Patient-Prosthesis	RESEARCH/RESEARCH GRANTS - Cardiac Phoenix, Edwards
Pibarot	Philippe	Novel Determinants of Outcomes in VHD	Mismatch on Valve-in-Valve Performance Impact of Aortic Valve Calcification and Sex on Hemodynamic	Lifesciences.,MEDTRONIC,V-Wave Ltd. RESEARCH/RESEARCH GRANTS - Cardiac Phoenix,Edwards
Pibarot		Novel Determinants of Outcomes in VHD	Progression and Clinical Outcomes in Aortic Stenosis Relationship Between Proximal Aorta Morphology and Progression	Lifesciences.,MEDTRONIC,V-Wave Ltd. RESEARCH/RESEARCH GRANTS - Cardiac Phoenix,Edwards
	Philippe		Rate of Aortic Stenosis	Lifesciences.,MEDTRONIC,V-Wave Ltd.
Pibarot	Philippe	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low- Flow Severe Aortic Stenosis and Less Reverse Remodeling After TAVR: A Partner 2 Trial Analysis	RESEARCH/RESEARCH GRANTS - Cardiac Phoenix,Edwards Lifesciences.,MEDTRONIC,V-Wave Ltd.
Pibarot	Philippe	Frontiers in Mitral Valve Disease and Treatment	Significant Mitral Regurgitation in Patients Undergoing Transcatheter Aortic Valve Replacement: Evolution and Imaging Predictors of Improvement	RESEARCH/RESEARCH GRANTS - Cardiac Phoenix,Edwards Lifesciences.,MEDTRONIC,V-Wave Ltd.

				<u> </u>
Last Name Pibarot	First Name Philippe	Session Title 28. Non Invasive Imaging: Echo Team 4	Presentation Title Suggested Reviewer	Disclosures RESEARCH/RESEARCH GRANTS - Cardiac Phoenix,Edwards
Picard Picatoste	Michael Belen	28. Non Invasive Imaging: Echo Team 4 Non Invasive Imaging: MR Characterization and Function	Suggested Reviewer Myocardial Oxygenation Using Blood Level-Oxygen Dependent Sequence in Magnetic Resonance Determines Myocardial	Lifesciences, MEDTRONIC, V-Wave Ltd. Nothing to Disclose Nothing to Disclose
Piccini	Jonathan	FIT Forum: Scholarship and Education	Energetics and Capillary Density How to Write and Revise a Manuscript	CONSULTANT FEES/HONORARIA - Johnson & Dengamp; Johnson, MEDTRONIC, Spectranetics; OTHER - GSK; RESEARCH/RESEARCH GRANTS - ARCA biopharma, Boston Scientific, Gilead Sciences, Inc., Johnson & Dengamp; Johnson, Resmed, St Jude Medical
Piccini	Jonathan	Late-Breaking Clinical Trials	Comparative Effectiveness of Left Atrial Appendage Occlusion Among Atrial Fibrillation Patients Undergoing Cardiac Surgery: A Report From the Society of Thoracic Surgeons Adult Cardiac Surgery Database	CONSULTANT FEES/HONORARIA - Johnson & amp; Johnson, MEDTRONIC, Spectranetics; OTHER - GSK; RESEARCH/RESEARCH GRANTS - ARCA biopharma, Boston Scientific, Gilead Sciences, Inc., Johnson & amp; amp; Johnson, Resmed, St Jude Medical
Piccini	Jonathan	Role of Newer ICD Technologies for the Prevention of Sudden Cardiac Death	Co-Chair	CONSULTANT FEES/HONORARIA - Johnson & amp; amp; Johnson, MEDTRONIC, Spectranetics; OTHER - GSK; RESEARCH/RESEARCH GRANTS - ARCA biopharma, Boston Scientific, Gilead Sciences, Inc., Johnson & amp; amp; Johnson, Resmed, St Jude Medical
Piccini	Jonathan	Fundamentals of LAA Closure	Co-Chair	CONSULTANT FEES/HONORARIA - Johnson & amp; Johnson, MEDTRONIC, Spectranetics; OTHER - GSK; RESEARCH/RESEARCH GRANTS - ARCA biopharma, Boston Scientific, Gilead Sciences, Inc., Johnson & amp; amp; Johnson, Resmed, St Jude Medical
Piccini	Jonathan	Fundamentals of LAA Closure	Is AF Ablation Sufficient to Reduce Thromboembolic Risk and Eliminate OACs?	CONSULTANT FEES/HONORARIA - Johnson & amp; Johnson, MEDTRONIC, Spectranetics; OTHER - GSK; RESEARCH/RESEARCH GRANTS - ARCA biopharma, Boston Scientific, Gilead Sciences, Inc., Johnson & amp; amp; Johnson, Resmed, St Jude Medical
Piccini	Jonathan	Fundamentals of LAA Closure	Optimizing Post-Procedure Anticoagulation After LAA Closure: DAPT, Warfarin, or NOACs?	CONSULTANT FEES/HONORARIA - Johnson & amp; Johnson,MEDTRONIC,Spectranetics; OTHER - GSK; RESEARCH/RESEARCH GRANTS - ARCA biopharma,Boston Scientific,Gilead Sciences, Inc., Johnson & amp; Johnson,Resmed,St Jude Medical
Piccini	Jonathan	Highlighted Original Research: Interventional Cardiology and the Year in Review	New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: Incidence, Anticoagulant Strategy, and Outcomes	CONSULTANT FEES/HONORARIA - Johnson & Dempinion of Consultant FEES/HONORARIA - Johnson & Dempinion, Johnson, MEDTROINC, Spectranetics; OTHER - GSK; RESEARCH/BRESEARCH GRANTS - ARCA biopharma, Boston Scientific, Gillead Sciences, Inc., Johnson & Dempinion, Scientific, Gillead Sciences, Inc., Johnson & Dempinion, Scientific, Gillead Sciences, Inc., Johnson Resmed, St Jude Medical
Piccini	Jonathan	Arrhythmias and Clinical EP: Anticoagulation Issues	Thrombolytic Therapy in Anticoagulated Patients: Case Series From Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET AF)	
Piccini	Jonathan	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Does Frailty Alter the Benefits of Oral Anticoagulation in Patients With Atrial Fibrillation?	CONSULTANT FEES/HONORARIA - Johnson & amp; Johnson,MEDTRONIC, Spectranetics; OTHER - GSK; RESEARCH/RESEARCH GRANTS - ARCA biopharma,Boston Scientific, Gilead Sciences, Inc., Johnson & amp; amp; Johnson, Resmed,St Jude Medical
Piccini	Jonathan	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)	CONSULTANT FEES/HONORARIA - Johnson & Johnson,MEDTRONIC,Spectranetics; OTHER - GSK; RESEARCH/RESEARCH GRANTS - ARCA biopharma,Boston Scientific,Gilead Sciences, Inc., Johnson & Johnson,Resmed,St Jude Medical
Piccolo	Raffaele	Timely Topics in Acute Coronary Syndromes	Time to Treatment With Melatonin and Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction: Insights From the MARIA (Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty) Trial	Nothing to Disclose
Pichard	Augusto	Considerations in Antiplatelet Therapy and in ACS	Trends in Discharge and Outcome of Dual Antiplatelet Therapy Post Percutaneous Intervention in High Bleeding Risk Population	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical
Pichard	Augusto	Considerations in Antiplatelet Therapy and in ACS	Outpatient Trends in Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Primary Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical
Pichard	Augusto	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	In-Stent Restenosis of Drug-Eluting Stents: Incidence, Lesion Characteristics and Outcomes in Contemporary Practice Over the Last Decade - How Are They Different From De Novo Lesions?	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical
Pichard	Augusto	Interventional Cardiology: TAVR 2	Racial Disparities and Temporal Trends in Demographics and Clinical Characteristics of Patients Screened for Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical
Pichard	Augusto	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Is There a Role for Invasive Electrophysiology Studies in Patients With Conduction Abnormalities Following Transcatheter Aortic Valve Replacement?	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical
Pichard	Augusto	Interventional Cardiology: TAVR 3	Antithrombotic Therapy Differences and Associated Outcomes in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical
Pichard	Augusto	Interventional Cardiology: TAVR 3	Acute Aortic Regurgitation Post-Transcatheter Aortic Valve Replacement: Impact of Various Treatment Strategies	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical
Pichard	Augusto	Interventional Cardiology: PCI in Complex Patients	Long-Term Mortality in Percutaneous Coronary Intervention of Saphenous Vein Grafts From Real-World Registry Data	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical
Pickett	Stephen	Non Invasive Imaging: MR Characterization	Elevated Myocardial Extracellular Volume Fraction (ECV) and Its	Nothing to Disclose
Piek	Jan	and Function Interventional Cardiology: Intravascular Physiology and Endothelial Function	Prognostic Significance in Diabetic Individuals instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International Multicentre IFR GRADIENT Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular, Miracor
Pignatelli	Pasquale	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	History of Atrial Fibrillation in a First-Degree Relative and Risk of Cardiovascular Events	Nothing to Disclose
Pillarisetti	Jayasree	Arrhythmias and Clinical EP: Devices 1	Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients Undergoing Cardiac Implantable Electronic Device Implantation: A Meta-Analysis	Nothing to Disclose
Pimentel	Rhea	Arrhythmias and Clinical EP: Devices 2	Real World Battery Longevity of St. Jude Medical Implantable Cardioverter-Defibrillators included in the Advisory for Premature Battery Depletion	SPEAKER'S BUREAU - Biotronik, Boston Scientific, Janssen Pharmaceuticals, MEDTRONIC, St Jude Medical
Pina	lleana	Are We There Yet? The Long Journey to Health Equity: Part III	Advancing Health Equity by Professional Education	CONSULTANT FEES/HONORARIA - Relypsa,Relypsa
Pina Pina	lleana lleana	Core Curriculum: Mending the Failing Heart Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Chair Influence of Low Versus High Dose on the Association of Loop Diurectic and Mortality in Patients With Heart Failure: Insights From	CONSULTANT FEES/HONORARIA - Relypsa,Relypsa CONSULTANT FEES/HONORARIA - Relypsa,Relypsa
1			the UNITE-HF Registry	1

Contract of the contract of th				
Last Name Pina	First Name Ileana	Session Title Why Can't We Be Friends? Controversies in Heart Failure Management	Presentation Title Prevalent Digoxin Use Is Not Associated With Increased Risk of Death or Hospitalization in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction	Disclosures CONSULTANT FEES/HONORARIA - Relypsa,Relypsa
Pina	lleana	Interdisciplinary Cardiovascular Team Care Delivery: Quality, Safety, and Satisfaction	Patient Navigator Team Approach Successfully Reduces 30-Day Heart Failure Readmission Rate	CONSULTANT FEES/HONORARIA - Relypsa,Relypsa
Pina	lleana	13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Relypsa,Relypsa
Pineda Maldonado	Andres	Clinical Team 5 Interventional Cardiology: TAVR 2	The Impact of Preoperative Renal Dysfunction on the Outcomes of Patients Undergoing Surgical Versus Transcatheter Aortic Valve Replacement: An Analysis From the CoreValve US Pivotal High Risk Trial	Nothing to Disclose
Pineda Maldonado	Andres	Refining TAVR Outcomes	Risk Tital Incidence and Outcomes of Patients Requiring Surgical Bail-Out During Transcatheter Aortic Valve Replacement: A Report From the NCDR® STS/ACC Transcatheter Valve Therapy (TVT) Registry	Nothing to Disclose
Pineiro	Daniel	16th Annual Maseri-Florio International Lecture		Nothing to Disclose
Pineiro	Daniel	16th Annual Maseri-Florio International Lecture	Interview with Huon Gray, MD, FACC and Q&A with the Audience	Nothing to Disclose
Pineiro	Daniel	Technical Advances in Transthoracic Echocardiography	ACC Poster Moderator	Nothing to Disclose
Pineiro	Daniel	28. Non Invasive Imaging: Echo Team 4	Suggested Reviewer	Nothing to Disclose
Pinney	Sean	Should I Stay or Should I Go? Tough Cases in MCS and Transplant	Panelist	CONSULTANT FEES/HONORARIA - Acorda Therapeutics, Inc.,CareDX Inc.,St. Jude Medical Inc.
Pinney	Sean	Treatment Strategies for End Stage Heart Failure: Medications, Machines and Everything in Between	End-Stage HF: Heart Transplant is Always the Best Option	CONSULTANT FEES/HONORARIA - Acorda Therapeutics, Inc.,CareDX Inc.,St. Jude Medical Inc.
Pinney	Sean	The Great K Debate Continues: Updates and Controversies in Heart Failure Management	Case Challenges: Caring for the Hyper K Patient - from Drugs to Dialysis	CONSULTANT FEES/HONORARIA - Acorda Therapeutics, Inc.,CareDX Inc.,St. Jude Medical Inc.
Pinney	Sean	Heart Failure and Cardiomyopathies: Clinical Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Acorda Therapeutics, Inc.,CareDX Inc.,St. Jude Medical Inc.
Pinto	Duane	TAVR for Degenerated Surgical Valves: What You Need to Know from A to Z	TAVR in Degeneratvie Surgical MV Replacement	CONSULTANT FEES/HONORARIA - Abiomed,Boston Scientific,Kyruus,Medicines Company,MEDTRONIC,St. Jude,UpToDate; DATA SAFETY MONITORING BOARD - Covidien
Pinto	Duane	Overuse, Underuse or Just Right? Fundamental Debates in High Risk PCI in 2017	Take More High Risk Cases to the Cath Lab! Physician Risk Aversion is Harming Patients	CONSULTANT FEES/HONORARIA - Abiomed,Boston Scientific,Kyruus,Medicines Company,MEDTRONIC,St. Jude,UpToDate; DATA SAFETY MONITORING BOARD - Covidien
Pinto	Duane	Controversies Surrounding TAVR: 2017 and Beyond	The Minimalist Approach: Unrealistic Exburance or the New Standard of Care?	CONSULTANT FEES/HONORARIA - Abiomed,Boston Scientific,Kyruus,Medicines Company,MEDTRONIC,St. Jude,UpToDate; DATA SAFETY MONITORING BOARD - Covidien
Pinto	Duane	Moderated, Case-Based TAVR Management	Co-Chair	CONSULTANT FEES/HONORARIA - Abiomed,Boston Scientific,Kyruus,Medicines Company,MEDTRONIC,St. Jude,UpToDate; DATA SAFETY MONITORING BOARD - Covidien
Pinto	Duane	Interventional Cardiology: PCI and TAVR in Complex Patients	Management of Patients With Cardiac Arrest in New York Before and After Public Reporting Policy Changes	CONSULTANT FEES/HONORARIA - Abiomed,Boston Scientific,Kyruus,Medicines Company,MEDTRONIC,St. Jude,UpToDate; DATA SAFETY MONITORING BOARD - Covidien
Pinto	Duane	Unusual Presentations of ACS	Survival of Patients Referred for Emergent Cardiac Catheterization for ST-Elevation Myocardial Infarction Without Culprit Lesions	CONSULTANT FEES/HONORARIA - Abiomed,Boston Scientific,Kyruus,Medicines Company,MEDTRONIC,St. Jude,UpToDate; DATA SAFETY MONITORING BOARD - Covidien
Pinto	Duane	21. Interventional Cardiology: Coronary Intervention: Devices Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abiomed, Boston Scientific, Kyruus, Medicines Company, MEDTRONIC, St. Jude, UpToDate; DATA SAFETY MONITORING BOARD -
Pinto	Duane	Interventional Challenging Cases: Team 4	ACC Challenging Case Reviewer	Covidien CONSULTANT FEES/HONORARIA - Abiomed, Boston Scientific,Kyruus,Medicines Company,MEDTRONIC,St. Jude,UpToDate; DATA SAFETY MONITORING BOARD - Covidien
Pinto	Fausto	Emerging Applications for Imaging Cardiac Amyloidosis: Nuclear Cardiology	How Useful Is ^{99m} Tc-DPD Scintigraphy in Diagnosis of Cardiac Amyloidosis in Transthyretin V30M Familial Amyloid Polyneuropathy?	Nothing to Disclose
Pinto	Nelangi	Congenital Heart Disease: Innovations in	Do Pediatric Cardiologists Follow the Sports Restriction	Nothing to Disclose
Pir	Syed Haris A.	Single Ventricle Heart Disease Nuclear Cardiology: Beyond Perfusion	Recommendations for Children With a Bicuspid Aortic Valve? The Increasing Burden of Amyloidosis From Apex to Base: New	Nothing to Disclose
Pir	Syed Haris A.	Vascular Medicine: Emerging Concepts in	Insights From Technetium-99m Pyrophosphate Imaging Normal Diameter of the Ascending Aorta in Adults: The Impact of	Nothing to Disclose
Pirat	Bahar	Clinical Vascular Diseases 36. Valvular Heart Disease: Clinical Team 2	Stricter Criteria on Selection of Subjects Free of Disease Suggested Reviewer	Nothing to Disclose
Pirbaglou	Meysam	Arrhythmias and Clinical EP: AF Ablation	Determination of the Ideal Contact Force Required During Pulmonary Vein Antrum Isolation (PVAI)	Nothing to Disclose
Pirelli	Luigi	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	An Unexpected Guest in the Right Ventricle	Nothing to Disclose
Pisani Pisani	Barbara Barbara	Cardiogenic Shock: Drugs to Devices Cardiogenic Shock: Drugs to Devices	Panelist Hemodynamic Monitoring and Drug Therapy for Cardiogenic Shock	Nothing to Disclose Nothing to Disclose
Pisani	Barbara	Give Me a Beat! Mechanical Support of	Hemodynamic Monitoring and Drug Therapy for Cardiogenic Shock	Nothing to Disclose
Piskorz	Daniel Leonardo	Cardiogenic Shock Resistant Hypertension in the Pulmonary and Systemic Beds: International Perspectives From the ACC Argentina Chapter, Korean	Pathophysiology of Resistant Hypertension	Nothing to Disclose
Pislaru	Cristina	Society of Cardiology, and American College of Cardiology New Technologies in Echocardiography	Novel Echocardiographic Measurements Detect Increased Myocardial Stiffness in Patients With Severe Organic Mitral	Nothing to Disclose
Pislaru	Sorin	Town Hall Meeting: Pitfalls of Assessing	Regurgitation Case: Is 2+ Functional Regurgitation Severe?	Nothing to Disclose
Pislaru	Sorin	Valvular Heart Disease Severity Valvular Heart Disease: Endocarditis	Infective Endocarditis Following Transcutaneous Aortic Valve Implantation: Clinical, Echocardiographic and Hemodynamic	Nothing to Disclose
Pislaru	Sorin	Valvular Heart Disease: Mitral Valve Disease	Features Left Atrium Volume Index Measurement in Routine Practice: Does It Independently Impact Survival of Degenerative Mitral Valve	Nothing to Disclose
Pislaru	Sorin	Interventional Cardiology: TAVR 2	Disease? Prognostic Value of Baseline N-Terminal Prohormone Type Natriuretic Peptide Measurement in Chronic Lung Disease Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve	Nothing to Disclose
Pislaru	Sorin	Innovative Use of Echocardiography	Replacement Systolic Function and Cardiac Output on Echocardiography Do Not	Nothing to Disclose
		1	Predict Mortality After Cardiac Arrest	

and a second				
Pislaru	Sorin	Session Title Valvular Heart Disease: Aortic Stenosis	Presentation Title Bicuspid Versus Tricuspid Aortic Valve Stenosis: Comparative Study of Clinical Characteristics and Outcomes Following Aortic Valve	Disclosures Nothing to Disclose
Pislaru	Sorin	Valvular Heart Disease: Aortic Stenosis	Replacement in an Age-Matched Cohort Sinus Rhythm Versus Atrial Fibrillation & It Clinical Profile and Natural History of Patients With Severe Aortic Stenosis Managed	Nothing to Disclose
Pislaru	Sorin	Interventional Cardiology: TAVR 3	Medically Comparative Outcome of Paravalvular Leak Following Surgical Versus Transcatheter Aortic Valve Replacement	Nothing to Disclose
Pislaru	Sorin	New Technologies in Echocardiography	Novel Echocardiographic Measurements Detect Increased Myocardial Stiffness in Patients With Severe Organic Mitral	Nothing to Disclose
Pislaru	Sorin	Insights From Echocardiography Use	Regurgitation Diastolic Dysfunction by Doppler Echocardiography Predicts	Nothing to Disclose
Pislaru	Sorin	Engage @ ACC.17 Studio: Heart Teams in Action: Complex Coronary Revascularization	Mortality after Cardiac Arrest Mayo Imaging Cardiologist	Nothing to Disclose
Pislaru	Sorin	Novel Determinants of Outcomes in VHD	Coexisting Co-Morbidities Exacerbate Left Ventricular Diastolic Dysfunction and Prognosis in Patients With Severe Aortic Stenosis	Nothing to Disclose
Pislaru	Sorin	Prosthetic Valve Thrombosis: TAVR, Bio, Mech Now What?!	Outcome of Anticoagulation Therapy for Bioprosthetic Valve Thrombosis: A Prospective Study	Nothing to Disclose
Pislaru	Sorin	Tricuspid Regurgitation: Signals in Plain Sight		Nothing to Disclose
Pitman	Roger	Innovations in Cardiovascular Risk Assessment and Reduction	Resting Amygdalar Activity Associates With Future Changes in Adiposity: Implications for Atherosclerotic Disease	Nothing to Disclose
Pitsiou	Georgia	Predicting the Future: Observations and Discoveries From Registries and Databases		Nothing to Disclose
Pitt	Bertram	FIT Forum: Mix and Mingle	Heart Failure	CONSULTANT FEES/HONORARIA - Astra Zeneca, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc. juvenits, Novartis, Pizer, Relypsa, Stealth Peptides, Takeda, tricida; OTHER - Relypsa; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - DaVinci therapeutics, scPharmaceuticals
Pitt	Bertram	Emerging Developments in HFpEF and Arryhthmias	Influence of Left Ventricular Ejection Fraction on Cause-Specific Mortality in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial	CONSULTANT FEES/HONORARIA - Astra Zeneca,Bayer,Boehringer Ingelheim Pharmaceuticals, Inc,juventis, Novartis,Pfizer,Relypsa,Stealth Peptides,Takeda,tricida; OTHER - Relypsa; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - DaVinci therapeutics,scPharmaceuticals
Pitt	Bertram	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Heart Failure Hospitalization (HFH) Despite Digoxin Therapy Versus No HFH Despite Placebo in the Digitalis Investigation Group (DIG) Trial: Insights Into Risk Factors for HFH in HF and Reduced Ejection Fraction (HFrEF)	CONSULTANT FEES/HONORARIA - Astra Zeneca,Bayer,Boehinger Ingelheim Pharmaceuticals, Inc, juventis, Novartis, Pfizer, Relypsa, Stealth Peptides, Takeda, tricida; OTHER - Relypsa; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - DaVinci therapeutics, scPharmaceuticals
Pitt	Bertram	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Treatment With Patiromer Decreases Aldosterone in Patients With Heart Failure, Chronic Kidney Disease, and Hyperkalemia on RAAS Inhibitors	CONSULTANT FEES/HONORARIA - Astra Zeneca,Bayer,Boehringer Ingelheim Pharmaceuticals, Inc,juventis, Novartis, Pfizer,Relypsa,Stealth Peptides,Takeda,tricida; OTHER - Relypsa; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - DaVinci therapeutics,scPharmaceuticals
Pitt	Bertram	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Clinical Effectiveness of Spironolactone in Hospitalized Older Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or Equal to 30 mL/min/1.73 m ²) Patients With Heart Failure	CONSULTANT FEES/HONORARIA - Astra Zeneca,Bayer,Boehringer Ingelheim Pharmaceuticals, Inc,juventis, Novartis, Pfizer, Relypsa, Stealth Peptides, Takeda, tricida; OTHER - Relypsa; OWNERSHIP INTEREST/PARTNERSHIP/IRINCIPAL - DaVinci therapeutics, scPharmaceuticals
Pitt	Bertram	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Mineralocorticoid Receptor Antagonists in Patients With Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Trials	CONSULTANT FEES/HONORARIA - Astra Zeneca, Bayer, Boehninger Ingelheim Pharmaceuticals, Inc.; Juvenis, Novartis, Pizer, Relypsa, Stealth Peptides, Takeda, tricida; OTHER - Relypsa; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - DaVinci therapeutics, scPharmaceuticals
Pitt	Bertram	The Great K Debate Continues: Updates and Controversies in Heart Failure Management	Case Challenges: Caring for the Hyper K Patient - from Drugs to Dialysis	CONSULTANT FEES/HONORARIA - Astra Zeneca, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc.; Juvenis, Novartis, Pizer, Relypsa, Stealth Peptides, Takeda, tricida; OTHER - Relypsa; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - DaVinci therapeutics. scPharmaceuticals
Pitt	Bertram	Why Can't We Be Friends? Controversies in Heart Failure Management	Association Between Serum Potassium Level and Outcomes in Heart Failure With Reduced Ejection Fraction: A Cohort Study From the Swedish Heart Failure Registry	CONSULTANT FEES/HONORARIA - Astra Zeneca, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc. juventis, Novartis, Pizer, Relypsa, Stealth Peptides, Takeda, tricida; OTHER - Relypsa; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - DaVinci therapeutics. scPharmaceuticals
Pizarro	Christian	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Too Close for Comfort: Aortopulmonary Fistula After Balloon Dilation in Arterial Switch With LeCompte Maneuver	Nothing to Disclose
Plana	Juan	Controversies in Echocardiography	Pro: Strain is the New EF it Should Be Part of the Echo Protocol	Nothing to Disclose
Plana	Juan	Imaging of Cancer-Treatment Associated CV Toxicity: Applying Guidelines to Clinical Practice	Imaging LV dysfunction related to cancer therapy. It will be easy to reconcile the ASE/EACVI, NCCN and ASCO guidelines and recommendations.	Nothing to Disclose
Planer	David	Refining TAVR Outcomes	The Association of Coronary Artery Disease Severity and Pre Procedural Completeness of Revasclarization on Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Playford	Martin	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Small Dense Low Density Lipoprotein Particle Number Relates to Coronary Plaque Burden Independent of Traditional Cardiovascular Risk Factors in Psoriasis	Nothing to Disclose
Playford	Martin	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Aortic Vascular Inflammation by 18-FDG PET/CT Associates With High-Risk Coronary Plaques in Young Psoriasis Patients	Nothing to Disclose
Playford	Martin	Vascular Medicine: New Insights Into Aortic and Peripheral Artery Diseases	Improvement in Cholesterol Efflux Capacity Is Associated With Improvement in Vascular Inflammation by 18- FDG PET CT in Psoriasis	Nothing to Disclose
Playford	Martin	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Improvement in Cholesterol Efflux Capacity Is Associated With a Reduction in Aortic Wall Thickness by MRI Independent of Traditional CV Risk Factors	Nothing to Disclose
Playford	Martin	Updates on Risk Factors for Cardiovascular Disease	Visceral but Not Subcutaneous Adipose Tissue Associates With Vascular Inflammation by 18-FDG PET/CT in Psoriasis	Nothing to Disclose
Plein	Sven	Featured Clinical Research I	MR-INFORM: Stress Perfusion Imaging to Guide the Management of Patients With Stable Coronary Artery Disease	RESEARCH/RESEARCH GRANTS - Philips healthcare
Pletcher	Mark	The Story of the Adult Congenital Heart Disease Patient and EP	Safety of Transvenous Lead Removal in Adult Congenital Heart Disease in the US	Nothing to Disclose
Pletcher Ploutz	Mark Michelle	Arrhythmias and Clinical EP: Devices 3 Heart Failure and Cardiomyopathies: What	Safety of Transvenous Lead Removal Among Nonagenarians Spironolactone Therapy for Cardiomyopathy in Duchenne Muscular	Nothing to Disclose Nothing to Disclose
		Next When All Else Is Failing?	Dystrophy	

				<u> </u>
Last Name Plunkitt	First Name Kenneth	Session Title Arrhythmias and Clinical EP: Devices 2	Presentation Title Selective Same Day Discharge After Biventricular Implantation as a	Disclosures RESEARCH/RESEARCH GRANTS - St Jude Medical
Plutzky	Jorge	Preventing ASCVD in Diabetes: Are These	Value Based Strategy: Safe and Cost Effective Co-Chair	CONSULTANT FEES/HONORARIA - Amgen
Plutzky	Jorge	New Drugs for Real?	Co-Criair	CONSOLTAIN TEST/INDIVOKANE - AITIGHT Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc, Cowen, Janssen Pharmaceuticals, Inc, NovoNordisk, SANOFI; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Novellon, Vivus
Plutzky	Jorge	Preventing ASCVD in Diabetes: Are These New Drugs for Real?	Translating Trials into Practice: How Should the New Evidence Affect Treatment Guidelines?	CONSULTANT FEES/HONORARIA - Amgen Inc. AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc,Cowen,Janssen Pharmaceuticals, Inc,NovoNordisk,SANOFI; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Novelion,Vivus
Plutzky	Jorge	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Lipid Abnormalities in Young Patients With Myocardial Infarction	CONSULTANT FEES/HONORARIA - Amgen Inc. AstraZeneca Boehringer Ingelheim Pharmaceuticals, Inc,Cowen,Janssen Pharmaceuticals, Inc,NovoNordisk,SANOFI; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Novelin,Vivus
Plutzky	Jorge	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Women Who Experience Myocardial Infarction at a Young Age Have Worse Survival Compared With Men	CONSULTANT FEES/HONORARIA - Amgen Inc. AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc, Cowen, Janssen Pharmaceuticals, Inc, NovoNordisk, SANOFI; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Novelion, Visus
Plutzky	Jorge	Breakthrough Therapies: Your Role in Protecting the Heart of Your Patients with Diabetes	Breakthrough Therapies: Glycemic Management and Cardiovascular Disease	CONSULTANT FEES/HONORARIA - Amgen inc. AstraZeneca, Boehringer Ingelheim Pharmaceuticals, inc, Cowen, Janssen Pharmaceuticals, inc, NovoNordisk, SANOFI; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Novelion, Visus
Plutzky	Jorge	Breakthrough Therapies: Your Role in Protecting the Heart of Your Patients with Diabetes	Pragmatic Conversations: Your Role in Protecting the Heart - Panel Debate	CONSULTANT FEES/HONORARIA - Amgen Inc. AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc, Cowen, Janssen Pharmaceuticals, Inc, NovoNordisk, SANOFI; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Novelin, Vivus
Plutzky	Jorge	32. Prevention: Clinical Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen Inc. AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc,Cowen,Janssen Pharmaceuticals, Inc,NovoNordisk,SANOFI; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Novelion,Visus
Po	Jose Ricardo	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Coronary Artery Mycotic Aneurysm: A Rare Presentation of Tricuspid Valve Endocarditis	Nothing to Disclose
Po	Jose Ricardo	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Non-Invasive Quantification of Cardiac Output With Phase Velocity Mapping in Patients With Pulmonary Hypertension	Nothing to Disclose
Pochettino	Alberto	The Tricuspid Valve: Not Forgotten, Just Misunderstood	Who are Optimal Candidates for Surgical or Transcatheter Tricuspid	Nothing to Disclose
Poci	Nertila	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Clinical, Biochemical, Neurohumoral, Echocardiographic and Hemodynamic Characteristics in Relation to Survival in Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: Insights From Euphrates Study	Nothing to Disclose
Poci	Nertila	Understanding Pulmonary Vascular Disease: From Bench to Bedside	Short-Term Intravenous lioprost Treatment Improves Clinical Status and Neurohumoral Measures in Clinical Worsening Episodes of Precapillary Pulmonary Hypertension Regardless of the Background Treatments: Insights From Euphrates Study	Nothing to Disclose
Poci	Nertila	Predicting the Future: Observations and Discoveries From Registries and Databases	Pulmonary Vascular Resistance, but Not Diastolic Pulmonary Gradient, May Predict Survival in Pulmonary Hypertension: Insights From Euphrates Study	Nothing to Disclose
Poci	Nertila	Predicting the Future: Observations and Discoveries From Registries and Databases	The Correlates and Prognostic Impact of Pulmonary Arterial Pulse Pressures, Diastolic and Transpulmonary Pressure Gradients in Pulmonary Hypertension: Insights From Euphrates Study	Nothing to Disclose
Pocock	Stuart	Behind the Curtain: Inside Look into JACC and Peer-reviewed Publishing	Best Practices With Statistical Analyses and Their Presentation	Nothing to Disclose
Pocock	Stuart	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	Nothing to Disclose
Pocock	Stuart	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study	Nothing to Disclose
Pocock	Stuart	Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes	Nothing to Disclose
Pocock	Stuart	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Predictors of Ischemic Events Within and After 1 Year After an Acute Coronary Syndrome: Results From the EPICOR Registry	Nothing to Disclose
Pocock	Stuart	Refining PCI Technique and Outcomes	Treatment of Left Main Coronary Artery Disease in Patients With Diabetes: 3-Year Outcomes Comparing CABG and PCI With Everolimus-Eluting Stents From the EXCEL Study	Nothing to Disclose
Pocock	Stuart	Refining PCI Technique and Outcomes	Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory Assessment: Insights From the EXCEL Trial	Nothing to Disclose
Pocock	Stuart	Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools	Predictive Values of the Ideal Cardiovascular Health and the Fuster- BEWAT Scores for Detecting Subclinical Atherosclerosis in Healthy Individuals	Nothing to Disclose
Pocock	Stuart	Improving Risk Assessment in Atherosclerosis	Subclinical Atherosclerosis in the Absence of Cardiovascular Risk Factors: Pre-Risk Status in the PESA (Progression of Early Subclinical Atherosclerosis) Study	Nothing to Disclose
Pocock	Stuart J.	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of a Switch From Dual Antiplatelet Therapy to Single Antiplatelet Therapy in Diabetes and Non-Diabetes Post ACS: Insights From the EPICOR and EPICOR-Asia Studies	Nothing to Disclose
Podesta	Carlos	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	An Upside Down Perspective: Yoga Inversions in a Patient With Ascending Aortic Aneurysm	Nothing to Disclose
Podlesnikar	Tomaz	Interventional Cardiology: TAVR 1	Sizing Aortic Valve Annulus for Transcatheter Aortic Valve Prosthesis Selection: Impact of Aortic Valve Calcification Burden on the Agreement Between Automated 3-Dimensional Transesophageal Echocardiography and Multidetector Row Computed Tomography	Nothing to Disclose
Podolec	Piotr	Cardiac Fibrosis and Heart Failure: The Next Frontier	Associations Between Serum Markers of Extracellular Matrix Metabolism, Fibrosis-Linked Micrornas (Mir-21, Mir-26, Mir-29, Mir- 30 And Mir-133a) and Right Ventricular Parameters in Dilated Cardiomyopathy	Nothing to Disclose
Poess	Janine	Non Invasive Imaging: MR Characterization and Function	Prognostic Value and Determinants of Left Atrial Function Assessed by Cardiac Magnetic Resonance in St-Segment Elevation Myocardial Infarction	SPEAKER'S BUREAU - Astra Zeneca
Poess	Janine	Novel Developments in Acute Coronary Syndromes	Outcome of Elderly Patients Undergoing Extracorporeal Life Support in Refractory Cardiogenic Shock	SPEAKER'S BUREAU - Astra Zeneca

and a second				<u> </u>
Last Name Pogue	First Name Kristen	Session Title Hot Topics and Great Debates in Pulmonary	Presentation Title Co-Chair	Disclosures CONSULTANT FEES/HONORARIA - Actavis, Merck & Discrete Amp; amp;
oguc	raisteri	Hypertension	SO OTAL	Co., Inc., The Medicines Company, The Medicines
				Company, Visante, Inc; RESEARCH/RESEARCH GRANTS - Merck & DREAD; Co., Inc.; SPEAKER'S BUREAU -
				Actavis, Merck & Dr. (amp; amp; Co., Inc.)
Pogue	Kristen	Demystifying and Managing Pulmonary	Panelist	CONSULTANT FEES/HONORARIA - Actavis, Merck & Company, amp;
		Hypertension and RV Dysfunction: It Takes a Village		Co., Inc.,The Medicines Company,The Medicines Company,Visante, Inc; RESEARCH/RESEARCH GRANTS -
				Merck & Dr.; amp; Co., Inc.; SPEAKER'S BUREAU -
Poh	Kian Keong	Advances in Cholesterol Measurement and	Frequency and Predictors of Cholesterol Goal Attainment in	Actavis,Merck & Disclose Nothing to Disclose
	radiritoong	Management	Patients With Coronary Heart Disease: Results From the	Thouming to Discussion
Deb	Kina Kanan	Advances in Chalanteral Management and	Dyslipidemia International Study II	Nething to Displace
Poh	Kian Keong	Advances in Cholesterol Measurement and Management	Low LDL-Cholesterol Target Value Attainment at the Time of Acute Coronary Syndrome (ACS) and Even 4 Months After the Acute	Nothing to Disclose
			Event Due to Lack of Adjustment in Lipid Lowering Treatment:	
Poh	Kian Keong	New Technologies in Echocardiography	Results From the Dyslipidemia International Study II ACS Novel Non-Invasive Left Ventricular Stiffness Index in Patients With	Nothing to Disclose
			Low-Flow Compared to Normal-Flow Severe Aortic Stenosis With	
Poh	Kian-Keong	36. Valvular Heart Disease: Clinical Team 3	Preserved Left Ventricular Ejection Fraction Suggested Reviewer	Nothing to Disclose
Pohost	Gerald	29. Non Invasive Imaging: MR Team 1	Suggested Reviewer	OTHER - Hollywood Heart and Vascular Institute;
				RESEARCH/RESEARCH GRANTS - General Electric
Pokharel	Yashashwi	Cardiac Arrest, Diabetes, and Other High Risk	Outcomes of Concomitant Acute Kidney Injury and Hospital	HealthCare,Gilead Sciences, Inc. Nothing to Disclose
i olalaroi	T donadiiiii	Features of Patients With Acute Coronary	Acquired Anemia in Patients With Myocardial Infarction: The	Thouming to Discussion
Pokharel	Yashashwi	Syndrome Innovations in Cardiovascular Risk Assessment	TRIUMPH Study High-Sensitivity C-reactive Protein and Health Status Outcomes	Nothing to Disclose
FORMATE	Tasilasiiwi	and Reduction	After Myocardial Infarction	Nothing to disclose
Pokharel	Yashashwi	Emerging Developments in HFpEF and	Impact of Serial Heart Failure Health Status on Clinical Outcomes in	Nothing to Disclose
Pokharel	Yashashwi	Arryhthmias Heart Failure and Cardiomyopathies: Heart	HFpEF: A Static or Dynamic Phenomenon? Current More Important Than Past: Interpreting Serial Heart Failure	Nothing to Disclose
	. ac. acitwi	Failure Is Just a Revolving Door	Specific Health Status in Heart Failure Patients With Reduced	
Dekemey	Coop	-	Ejection Fraction Rates of Oral Anticoagulant Use, While Improving Over Time.	CONSULTANT FEES/HONORARIA - Boston
Pokorney	Sean	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Rates of Oral Anticoagulant Use, While Improving Over Time, Remain Low Among Hospitalized Patients With Atrial Fibrillation	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC; RESEARCH/RESEARCH GRANTS -
L			- '	Boston Scientific, Gilead Sciences, Inc.
Polak	Joseph	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	­The Utility of Minimal Coronary Artery Calcification for Predicting Carotid Artery Disease: Results From the Multi-Ethnic	Nothing to Disclose
		Scotting and CV Risk Assessment	Study of Atherosclerosis (MESA)	
Polin	Glenn	Nuclear Cardiology: Coronary Flow	Reduced Flow Capacity as Measured by Cardiac Positron Emission	SPEAKER'S BUREAU - Pfizer/BMS
			Tomography Predicts Ventricular Tachyarrhythmia in Patients With an ICD	
Polk	Donna	Featured Clinical Research III	The Effect of High-Dose Atorvastatin on Neuronal Activity and	Nothing to Disclose
Polk	Donna	From Cardiovascular Risk Factors to Acute	Cognitive Function Primary and Secondary Prevention: Current Practices and	Nothing to Disclose
POIK	Donna	and Stable Coronary Syndrome: International	Opportunities for Improvement?	Nothing to Disclose
		Perspectives From the Inter-American Society		
		of Cardiology, National Heart Association of Malaysia, and American College of Cardiology		
		Malaysia, and American conege of cardiology		
Polk	Donna	Current Issues in Cardiovascular	Lipid Abnormalities in Young Patients With Myocardial Infarction	Nothing to Disclose
Polk	Donna	Epidemiology, Disparities, and Safety Current Issues in Cardiovascular	Women Who Experience Myocardial Infarction at a Young Age	Nothing to Disclose
		Epidemiology, Disparities, and Safety	Have Worse Survival Compared With Men	-
Polk	Donna	Engage @ ACC.17 Studio: Cardiology Contest	Cardiology Contestant	Nothing to Disclose
Polk	Donna	Engage @ ACC.17 Studio: FIT Jeopardy Battle	Judge	Nothing to Disclose
D. II		of the State Chapters IV	O	Nulling to Birds
Polk Polk	Donna Donna	32. Prevention: Clinical Team 6 FIT Clinical Decision Making Reviewers 2	Suggested Reviewer ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose Nothing to Disclose
Pollack	Simcha	Non Invasive Imaging: Coronary Calcium	Determination of Calcium Score From CTA Contrast Images Using	Nothing to Disclose
Pollack	Simcha	Scoring and CV Risk Assessment Interventional Cardiology: TAVR 3	Standard Clinical Methods The Natural History of Paravalvular Regurgitation After Transarterial	Nothing to Disclose
FOIIdCK	Sillicia	interventional Cardiology. TAVK 3	Valve Implantation for Severe Aortic Stenosis: One Center	Nothing to Disclose
			Experience	
Pollak	Amy	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Chest Pain in a Patient With Anomalous Left Anterior Descending Coronary Artery, Myocardial Bridging and Vasoconstriction:	Nothing to Disclose
]		Contact and Congenitar real Disease	Identification of the Culprit Etiology and Management of a	
Dollar	Wolfgan-	MicroPNAs and Power die Vesseles Market	Challenging Combination	Nothing to Displace
Poller	Wolfgang	MicroRNAs and Beyond in Vascular Medicine	Disturbed Expression of Immunoregulatory Long Noncoding RNAs in Circulating Immune Cells From Patients With Early Myocardial	Nothing to Disclose
			Infarction	
Poller	Wolfgang	Mechanisms of Vascular Inflammation in	Deficiency of Long Noncoding RNA <i>Malat1</i> Causes Immune System Deregulation and Accelerated Atherosclerosis in Apo	Nothing to Disclose
•		Atherogenesis		
		Atherogenesis	E ^{-/-} Mice	
Pollet	Mark	FIT Clinical Decision Making: Non-Invasive	E ^{-/-} Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid	Nothing to Disclose
Pollet Pollet	Mark Mark	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	E ^{-/-} Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Angiosarcoma	-
		FIT Clinical Decision Making: Non-Invasive	E-sup>-/(sup> Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Anglosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional	Nothing to Disclose Nothing to Disclose
Pollet	Mark	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations and Solutions	E ^{-/-(sup> Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Angiosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience}	Nothing to Disclose
		FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations	E-sup>-/(sup> Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Anglosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional	-
Pollet Pollet	Mark Mark	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations and Solutions Ventricular Arrhythmias and Sudden Death Prevention	E ^{-/-/-(sup> Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Angiosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience}	Nothing to Disclose Nothing to Disclose
Pollet	Mark	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations and Solutions Ventricular Arrhythmias and Sudden Death	E-sup>-\-(-\sup>-\sup-\sup-\sup-\sup-\sup-\sup-\sup-\sup	Nothing to Disclose
Pollet Pollet	Mark Mark	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations and Solutions Ventricular Arrhythmias and Sudden Death Prevention	E-sup>-/-/-sup> Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Angiosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve Bias From Categorizing Body Mass Index When Assessing the	Nothing to Disclose Nothing to Disclose
Pollet Pollet Pollock Pollock	Mark Mark Benjamin Benjamin	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations and Solutions Ventricular Arrhythmias and Sudden Death Prevention Vascular Access and Hemostasis Issues Can CABG Patch CAD?	E-sup>-/(sup> Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Anglosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve Bias From Categorizing Body Mass Index When Assessing the Association With Post-CABG Mortality	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pollet Pollock	Mark Mark Benjamin	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations and Solutions Ventricular Arrhythmias and Sudden Death Prevention Vascular Access and Hemostasis Issues	E-sup>-/(sup> Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Angiosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve Bias From Categorizing Body Mass Index When Assessing the Association With Dest-CABG Mortality Long Term Mortality Rates of U.S. Veterans With Bundle Branch	Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pollet Pollet Pollock Pollock	Mark Mark Benjamin Benjamin	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations and Solutions Ventricular Arrhythmias and Sudden Death Prevention Vascular Access and Hemostasis Issues Can CABG Patch CAD? Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Innovations in Advocacy and Patient Centered	E-sup>-/(sup> Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Angiosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve Bias From Categorizing Body Mass Index When Assessing the Association With Post-CABG Mortality Long Term Mortality Rates of U.S. Veterans With Bundle Branch Blocks Presenting for Coronary Anglography Long Term Mortality Rates of Premature Coronary Artery Disease in	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pollet Pollet Pollock Pollock Pollock Pollock	Mark Mark Benjamin Benjamin Jonathan	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations and Solutions Ventricular Arrhythmias and Sudden Death Prevention Vascular Access and Hemostasis Issues Can CABG Patch CAD? Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care	E-sup>-\footnotesize \text{Nice} Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Angiosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience Real-Time Uitrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve Bias From Categorizing Body Mass Index When Assessing the Association With Post-CABG Mortality Long Term Mortality Rates of U.S. Veterans With Bundle Branch Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pollet Pollet Pollock Pollock Pollock	Mark Mark Benjamin Benjamin Jonathan	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations and Solutions Ventricular Arrhythmias and Sudden Death Prevention Vascular Access and Hemostasis Issues Can CABG Patch CAD? Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Innovations in Advocacy and Patient Centered	Esup»-I-«Isup» Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Angiosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve Bias From Categorizing Body Mass Index When Assessing the Association With Post-CABG Mortality Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Sex Differences in Outcomes After Stenting or Bypass Surgery for Unprotected Left Main Disease	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pollet Pollet Pollock Pollock Pollock Pollock	Mark Mark Benjamin Benjamin Jonathan	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations and Solutions Ventricular Arrhythmias and Sudden Death Prevention Vascular Access and Hemostasis Issues Can CABG Patch CAD? Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care PCI Strategies and Outcomes Unique to Women Innovations in Risk Assessment: Novel	E-sup>-/(sup> Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Angiosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve Bias From Categorizing Body Mass Index When Assessing the Association With Post-CABG Mortality Long Term Mortality Rates of U.S. Veterans With Bundle Branch Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Sex Differences in Outcomes After Stenting or Bypass Surgery for Unprotected Left Main Disease Association of 10-Year Change in Cardiovascular Risk Factors With	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pollet Pollock Pollock Pollock Pollock Pollock Pollock	Mark Mark Benjamin Benjamin Jonathan Jonathan Jose	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations and Solutions Ventricular Arrhythmias and Sudden Death Prevention Vascular Access and Hemostasis Issues Can CABG Patch CAD? Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care PCI Strategies and Outcomes Unique to Women	Esup»-I-«Isup» Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Angiosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve Bias From Categorizing Body Mass Index When Assessing the Association With Post-CABG Mortality Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Sex Differences in Outcomes After Stenting or Bypass Surgery for Unprotected Left Main Disease	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pollet Pollock Pollock Pollock Pollock Pollock Pollock	Mark Mark Benjamin Benjamin Jonathan Jonathan Jose	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations and Solutions Ventricular Arrhythmias and Sudden Death Prevention Vascular Access and Hemostasis Issues Can CABG Patch CAD? Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care PCI Strategies and Outcomes Unique to Women Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools Highlighted Original Research: Interventional	E-sup>-/(sup> Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Anglosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality. A Thirteen Year Institutional Experience Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve Bias From Categorizing Body Mass Index When Assessing the Association With Post-CABG Mortality Long Term Mortality Rates of U.S. Veterans With Bundle Branch Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Sex Differences in Outcomes After Stenting or Bypass Surgery for Unprotected Left Main Disease Association of 10-Year Change in Cardiovascular Risk Factors With Progression of Pericardial Adipose Tissue: The CARDIA Study Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pollet Pollet Pollock Pollock Pollock Pollock Pollock Pollock Pollock Polmar Polonsky Pomar	Mark Mark Benjamin Benjamin Jonathan Jonathan Jose Tamar	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations and Solutions Ventricular Arrhythmias and Sudden Death Prevention Vascular Access and Hemostasis Issues Can CABG Patch CAD? Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care PCI Strategies and Outcomes Unique to Women Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools Highlighted Original Research: Interventional Cardiology and the Year in Review	Esup»-I(sup» Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Angiosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve Bias From Categorizing Body Mass Index When Assessing the Association With Post-CABG Mortality Long Term Mortality Rates of U. S. Veterans With Bundle Branch Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Sex Differences in Outcomes After Stenting or Bypass Surgery for Unprotected Left Main Disease Association of 10-Year Change in Cardiovascular Risk Factors With Progression of Pericardial Adipose Tissue: The CARDIA Study Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pollet Pollet Pollock Pollock Pollock Pollock Pollock Pollock Pollock Pollock Pollock Pollock	Mark Mark Benjamin Benjamin Jonathan Jonathan Jose Tamar	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations and Solutions Ventricular Arrhythmias and Sudden Death Prevention Vascular Access and Hemostasis Issues Can CABG Patch CAD? Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care PCI Strategies and Outcomes Unique to Women Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools Highlighted Original Research: Interventional	Esup»-I-clsup» Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Angiosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve Bias From Categorizing Body Mass Index When Assessing the Association With Post-CABG Mortality Long Term Mortality Rates of U.S. Veterans With Bundle Branch Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Sex Differences in Outcomes After Stenting or Bypass Surgery for Unprotected Left Main Disease Association of 10-Year Change in Cardiovascular Risk Factors With Progression of Pericardial Adipose Tissue: The CARDIA Study Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial Differences and Level of Agreement in SYNTAX Score Assessment Between Site Corporatory	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pollet Pollet Pollock Pollock Pollock Pollock Pollock Pollock Polmar Polonsky Pomar Pomar	Mark Mark Benjamin Benjamin Jonathan Jonathan Jose Tamar Jose	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations and Solutions Ventricular Arrhythmias and Sudden Death Prevention Vascular Access and Hemostasis Issues Can CABG Patch CAD? Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care PCI Strategies and Outcomes Unique to Women Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools Highlighted Original Research: Interventional Cardiology and the Year in Review Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	E-sup>-/-/-sup> Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Angiosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve Bias From Categorizing Body Mass Index When Assessing the Association With Post-CABG Mortality Long Term Mortality Rates of U.S. Veterans With Bundle Branch Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Sex Differences in Outcomes After Stenting or Bypass Surgery for Unprotected Left Main Disease Association of 10-Year Change in Cardiovascular Risk Factors With Progression of Pericardial Adipose Tissue: The CARDIA Study Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial Differences and Level of Agreement in SYNTAX Score Assessment Between Site Operators and Angiographic Core Laboratory Readers: Insights From the EXCEL Trial	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Pollet Pollet Pollock Pollock Pollock Pollock Pollock Pollock Pollock Pollock Polmar Polonsky Pomar	Mark Mark Benjamin Benjamin Jonathan Jonathan Jose Tamar	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease Atrial Fibrillation and VT: Unique Populations and Solutions Ventricular Arrhythmias and Sudden Death Prevention Vascular Access and Hemostasis Issues Can CABG Patch CAD? Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Innovations in Advocacy and Patient Centered Care PCI Strategies and Outcomes Unique to Women Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools Highlighted Original Research: Interventional Cardiology and the Year in Review Complex Coronary Intervention: Left	Esup»-I-clsup» Mice Recurrent Pericardial Effusion Due to Primary Cardiac Epithelioid Angiosarcoma The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve Bias From Categorizing Body Mass Index When Assessing the Association With Post-CABG Mortality Long Term Mortality Rates of U.S. Veterans With Bundle Branch Blocks Presenting for Coronary Angiography Long Term Mortality Rates of Premature Coronary Artery Disease in Young U.S. Veteran Population Sex Differences in Outcomes After Stenting or Bypass Surgery for Unprotected Left Main Disease Association of 10-Year Change in Cardiovascular Risk Factors With Progression of Pericardial Adipose Tissue: The CARDIA Study Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial Differences and Level of Agreement in SYNTAX Score Assessment Between Site Corporatory	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose



and a				
Last Name Pomerantsev	First Name Eugene	Session Title Coronary Angiography, Intra-Vascular Imaging,	Presentation Title Association Between Predicted Risk of Recurrent Ischemic Events	Disclosures Nothing to Disclose
Pomerantsev	Eugene	Revascularization and Outcomes Innovations in Advocacy and Patient Centered	and Achievement of Secondary Prevention Goals After PCI Employing the Multidisciplinary Heart Team Approach for Complex	Nothing to Disclose
Pongkan	Wanpitak	Care Revascularization and Myocardial Preservation	Coronary Artery Disease: A Single Center Experience Beta-Cryptoxanthin Exerts Better Cardioprotection Against Cardiac	Nothing to Disclose
		in Acute and Stable Ischemic Heart Disease	Ischemia-Reperfusion Injury Than Astaxanthin via Protecting Mitochondrial Dysfunction in Mice	
Poniros	Angelica	Interventional Cardiology: TAVR 1	"Cusp Overlap" View Facilitates Accurate Fluoro- Guided Implantation of Self-Expanding Valve in TAVR	Nothing to Disclose
Poniros	Angelica	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Change in Aortomitral Annular Angle and Anterior Mitral Valve Leaflet Length After Transcatheter Aortic Valve Replacement: Implications for Transcatheter Mitral Valve Replacement?	Nothing to Disclose
Poniros	Angelica	Interventional Cardiology: TAVR 4	Predictors of New Persistent Left Bundle Branch Block After Edwards Sapien 3 Transcatheter Aortic Valve Replacement	Nothing to Disclose
Ponnapureddy	Rakesh	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Change in Utilization Trends of Percutaneous Atrial Septal Defect Closure Post 2008 ACC/AHA Guidelines for Adults With Congenital Heart Disease	Nothing to Disclose
Pontone	Gianluca	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Fractional Flow Reserve Derived From Coronary Computed Tomography Safely Reduces Invasive Coronary Angiography Rates and Cost in Patients With Stable Coronary Artery Disease	Nothing to Disclose
Pontone	Gianluca	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Prognostic Stratification in Patients With ST-Elevation Myocardial Infaction Over Transthoracic Echocardiography by CMR	Nothing to Disclose
Pontone	Gianluca	Non Invasive Imaging: Prognostic Implications of CT Angiography	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	Nothing to Disclose
Pontone	Gianluca	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Diagnostic Value of Qt Evaluation in Anterior ST Segment Elevation Myocardial Infarction for Prediction of Myocardial Salvage Index, as Compared to CMR	Nothing to Disclose
Pontone	Gianluca	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team 2	Suggested Reviewer	Nothing to Disclose
Poole	Jeanne	Heart Rhythm Disorders: Today and Tomorrow	Subcutaneous ICD: Should the Subcutaneous ICD Be the "New Normal" for Primary Prevention Defibrillators? Case Studies	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,Physio Control,St. Jude Medical
Poole	Jeanne	Quickfire ECG for Experts	Panelist	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,Physio Control,St. Jude Medical
Poole	Jeanne	Controversies in Device Therapy	Should This Patient Receive a Subcutaneous ICD for Primary Prevention	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,Physio Control,St. Jude Medical
Poole	Jeanne	05. Arrhythmias and Clinical EP: Devices	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston
Poon	Michael	Team 2 FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	A Multi-Modality Approach Using Noninvasive and Invasive Techniques in the Treatment of a Patient With a Complicated Intra-	Scientific,MEDTRONIC,Physio Control,St. Jude Medical Nothing to Disclose
Poon	Michael	Which Test Is Best for Pain in the Chest?	Cardiac Mass Downstream Testing Utilization Following Obstructive Coronary Computed Tomographic Angiography (CCTA) in the ED Evaluation of Low to Intermediate Risk Acute Chest Pain	Nothing to Disclose
Poon	Michael	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team	Suggested Reviewer	Nothing to Disclose
Poornima	Indu	FIT Clinical Decision Making: Non-Invasive	An Unprecedented Case of Primary Cardiac Lymphoma Exclusive	Nothing to Disclose
Popescu	Bogdan	Imaging and Valvular Heart Disease Emerging Applications of Echocardiography	to the Left Ventricle: A Diagnostic and Therapeutic Challenge Effect of Changing Strain Software Versions on Longitudinal	Nothing to Disclose
Popma	Jeffrey	FIT Forum: Mix and Mingle	Assessment of LV Function hterventional Cardiology	CONSULTANT FEES/HONORARIA - Boston Scientific,Direct Flow Medical; RESEARCH/RESEARCH GRANTS - Abbott
Popma	Jeffrey	Complications of PCI: Case Reviews	Co-Chair	Vascular, Abiomed, Boston Scientific, MEDTRONIC CONSULTANT FEES/HONORARIA - Boston Scientific, Direct Flow Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, MEDTRONIC
Popma	Jeffrey	Imaging for TAVR: Homing in on the Real Issues	Multimodality Imaging Footprints of High-Risk TAVR	Vascular, Abiomed, Boston Scientific, MEDTRONIC CONSULTANT FEES/HONORARIA - Boston Scientific, Direct Flow Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, MEDTRONIC
Popma	Jeffrey	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Effect of Baseline Aortic Regurgitation on Mortality in the Core Valve US Pivotal High Risk Trial	Vascular, Abiomed, Boston Scientific, MEDTRONIC CONSULTANT FEES/HONORARIA - Boston Scientific, Direct Flow Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, MEDTRONIC
Popma	Jeffrey	Interventional Cardiology: TAVR 2	The Impact of Preoperative Renal Dysfunction on the Outcomes of Patients Undergoing Surgical Versus Transcatheter Aortic Valve Replacement: An Analysis From the CoreValve US Pivotal High	Vascular, Audiomed, Doston Scientific, NIC Trooned CONSULTANT FEES/HONORARIA - Boston Scientific, Direct Flow Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, MEDTRONIC
Popma	Jeffrey	Interventional Cardiology: TAVR 2	Risk Trial Impact of Balloon Pre-Dilatation on Hemodynamics and Clinical Outcomes After Transcatheter Aortic Valve Replacement With the Self-Expanding CoreValve Prosthesis	CONSULTANT FEES/HONORARIA - Boston Scientific,Direct Flow Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Abiomed,Boston Scientific,MEDTRONIC
Popma	Jeffrey	Interventional Cardiology: TAVR 3	Initial Use of the Evolut Pro Self-Expanding Transcatheter Aortic Valve <i></i>	Vascular, Automed, Boston Scientific, MicD TroNNC CONSULTANT FEES/HONORARIA - Boston Scientific, Direct Flow Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, MEDTRONIC
Popma	Jeffrey	Interventional Cardiology: TAVR 4	Serum Albumin as an Incremental Predictor of Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement: Results From the Multicenter Frailty-AVR Study	Vascular, Abiomed, Boston Scientific, MEDTRONIC CONSULTANT FEES/HONORARIA - Boston Scientific, Direct Flow Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, MEDTRONIC
Popma	Jeffrey	17. Interventional Cardiology: Aortic Valve Disease Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific, Direct Flow Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Abiomed, Boston Scientific, MEDTRONIC
Popma-Almonacid	Alexandra	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Twelve Month Follow-Up Data From the ONYX CORE Trial: Angiographic and Clinical Performance of Next Generation Resolute Onyx Drug-Eluting Stent	RESEARCH/RESEARCH GRANTS - Abbott Vascular,Abiomed,Boston Scientific
Popovic Popovic	Zoran	Valvular Heart Disease: Mitral Valve Disease	Warfarin Use and Progression of Mitral Annular Calcification	Nothing to Disclose
Popovic	Zoran	Interventional Cardiology: TAVR 2	Outcomes of Transcatheter Aortic Valve Replacement Without Balloon Predilation: A Systematic Review and Meta-Analysis	Nothing to Disclose
Popovic	Zoran	Non Invasive Imaging: MR Scar and Perfusion	Incremental Prognostic Utility of Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy	Nothing to Disclose
Popovic	Zoran	Insights From Echocardiography Use	Aortic Regurgitation Negatively Affects Left Ventricular Mechanics After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Popovic	Zoran	TAVR Outcomes Prognostication	Cardiac Plasticity Predicts Outcome After Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis	Nothing to Disclose
Poppas	Athena	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Panelist	OTHER - GE stock
Poppas	Athena	Cutting Edge Innovations in Cardiovascular Imaging: Joint Symposium of the Japanese Circulation Society and American College of Cardiology	Co-Chair	OTHER - GE stock
Poppas	Athena	Pregnancy and Heart Disease	Co-Chair The Triguenid Value: Not forgetten, Just Misunderstood	OTHER - GE stock OTHER - GE stock
Poppas	Athena	The Tricuspid Valve: Not Forgotten, Just Misunderstood	TheTricuspid Valve: Not forgotten, Just Misunderstood	
Poppas	Athena	Tricuspid Regurgitation: Signals in Plain Sight	Echocardiographic Predictors of Tricuspid Ring Failure	OTHER - GE stock

The second second				I
Poppas	First Name Athena	Session Title 42. Spotlight on Special Topics: Education, Innovation, Advocacy, Social Media,	Presentation Title Suggested Reviewer	OTHER - GE stock
		Leadership and Practice Management Team 1		
Poppas	Athena	LBCT reviewers	LB Reviewer	OTHER - GE stock
Pordy	Robert	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Lower On-Treatment Low-Density Lipoprotein Cholesterol Is Associated With Lower Cardiovascular Risk in Very High Risk Patients With Atherosclerotic Cardiovascular Disease: Analyses From the ODYSSEY Trials	SALARY - Regeneron
Pordy	Robert	Advances in Lipid Management	Use of High-Intensity Statin Therapy Post-Acute Coronary Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9	SALARY - Regeneron
Pordy	Robert	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Monoclonal Antibody, Versus Placebo: Interim Baseline Data Lower On-Treatment Low-Density Lipoprotein Cholesterol Is Associated With Lower Cardiovascular Risk in Women: Analyses	SALARY - Regeneron
Porras	Diego	Syndrome Surgical and Transcatheter Valve Therapy for	From the ODYSSEY Trials of Alirocumab Versus Control Hybrid Approach to Pulmonary Valve Replacement	Nothing to Disclose
Porras	Diego	Congenital Heart Disease Arrhythmias and Clinical EP: Devices 1	Coronary Artery Compression by Epicardial Leads: More Common	Nothing to Disclose
Port	Steven C.	Nuclear Cardiology: Beyond Perfusion	Than We Think The Increasing Burden of Amyloidosis From Apex to Base: New	Nothing to Disclose
Port	Steven C.	Insights From Echocardiography Use	Insights From Technetium-99m Pyrophosphate Imaging Gabapentinoids Therapy Is Associated With Higher Doses of	Nothing to Disclose
Port	Zachary	FIT Clinical Decision Making: Arrhythmias and	Atropine and Dobutamine in Stress Echocardiography Syncope in Elderly: How About Checking Carotid	Nothing to Disclose
Porter	Thomas	Electrophysiology Stress Echocardiography: Best Practices and Emerging Applications	Hypersensitivity??? Is Contrast Finally Ready for Perfusion Stress Echo?	OTHER - Bracco; RESEARCH/RESEARCH GRANTS - Astellas Pharmacueticals,GE Healthcare,Lantheus Medical
-				Imaging, Philips Research North America
Porter	Thomas	Innovative Use of Echocardiography	The Predictive Value of Microvascular Defects Observed During Demand Stress Myocardial Contrast Echocardiography and Quantitative Measurements of Stenosis and Microvascular Resistance Obtained During Invasive Hemodynamics	OTHER - Bracco; RESEARCH/RESEARCH GRANTS - Astellas Pharmacueticals,GE Healthcare,Lantheus Medical Imaging,Philips Research North America
Porter	Thomas	New Technologies in Echocardiography	Microvascular Blood Flow Abnormalities in Patients With Peripheral Vascular Disease and Abnormal Versus Normal Ankle Brachial Indices	OTHER - Bracco; RESEARCH/RESEARCH GRANTS - Astellas Pharmacueticals,GE Healthcare,Lantheus Medical Imaging,Philips Research North America
Porter	Thomas	28. Non Invasive Imaging: Echo Team 4	Suggested Reviewer	OTHER - Bracco; RESEARCH/RESEARCH GRANTS - Astellas Pharmacueticals,GE Healthcare,Lantheus Medical Imaging,Philips Research North America
Poterucha	Joseph	Predicting Outcomes in Pediatric Heart Disase	Growth Dynamics of Aorta in Bicuspid Aortic Valve Patients From Infancy to Young Adult Age	Nothing to Disclose
Pothineni	Naga Venkata	Valvular Disease Populations at Risk	National and Regional Trends in Surgical Aortic Valve Replacement in the TAVR Era	Nothing to Disclose
Pothineni	Naga Venkata	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Outcomes of Fractional Flow Reserve Based Deferral in Saphenous Vein Graft Lesions	Nothing to Disclose
Pothineni	Naga Venkata	Interventional Cardiology: Stent Failure	Does Post Pci Ffr Carry the Same Prognostic Weight as Non-	Nothing to Disclose
Pothineni	Naga Venkata	Analysis by Intravascuar Imaging Innovative Approaches for Reducing Risk and	Ischemic Ffr in Deferred Lesions? Complication Rates of Epicardial Ventricular Tachycardia Ablation:	Nothing to Disclose
Potluri	Rahul	Improving Outcomes With Ablation Highlighted Original Research: Acute and	A Pooled Analysis Characterization and Outcomes of Spontaneous Coronary Artery	Nothing to Disclose
		Stable Ischemic Heart Disease and the Year in Review	Dissection Patients Presenting With an Acute Coronary Syndrome: Insights From the ACALM Registry	
Potluri	Srinivasa	Vascular Access and Hemostasis Issues	Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve	Nothing to Disclose
Potter	Brian	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Appropriateness of Coronary Artery Bypass Grafting Based on Fractional Flow Reserve Lesions Assessment	CONSULTANT FEES/HONORARIA - servier; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals; SPEAKER'S BUREAU - Bayer Healthcare Pharmaceuticals
Potter	Brian	Antithrombotic Therapy in Ischemic Heart Disease	Time-Trends in Antithrombotic Management of Patients With AF/Flutter Treated With Coronary Stents: An International Multicenter Restrospective Analysis	CONSULTANT FEES/HONORARIA - servier; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals; SPEAKER'S BUREAU - Bayer Healthcare Pharmaceuticals
Potter	Brian	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Comparison of Triple Antithrombotic Therapy to Ticagrelor-Based Dual Antiplatelet Therapy for Left Ventricle Dysfunction Following STEMI Using Natural Randomization: A Retrospective Pilot Study	CONSULTANT FEES/HONORARIA - servier; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals; SPEAKER'S BUREAU - Bayer Healthcare
Povsic	Thomas	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	A Randomized Trial Evaluating Clinically Significant Bleeding With Low-Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, for Patients After Acute Coronary Syndromes	Pharmaceuticals CONSULTANT FEES/HONORARIA - capricor,Eli Lilly; DATA SAFETY MONITORING BOARD - Pluristem; RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals,
Povsic	Thomas	What's New in the World of STEMI?	Debate Con: Stem Cells in MI- Hope or Hype	Inc CONSULTANT FEES/HONORARIA - capricor, Eli Lilly; DATA SAFETY MONITORING BOARD - Pluristem; RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals,
Povsic	Thomas	Refining PCI Technique and Outcomes	ACC Poster Moderator	Inc CONSULTANT FEES/HONORARIA - capricor, Eli Lilly, DATA SAFETY MONITORING BOARD - Pluristem; RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals, Inc
Powell	Andrew	Cardiovascular Magnetic Resonance A Fast and Reliable Method to Change Patients' Therapy: Joint Symposium of the Society for Cardiovascular Magnetic Resonance and the American College of Cardiology	Impact on Decision Making in Adults With Repaired Tetralogy of Fallot: CMR As Game Changer	Nothing to Disclose
Powell	Andrew	Congenital Heart Disease: Pediatric Team	Suggested Reviewer	Nothing to Disclose
Powell-Wiley	Tiffany	Updates on Risk Factors for Cardiovascular	Visceral but Not Subcutaneous Adipose Tissue Associates With	Nothing to Disclose
Power	John	Disease Personalized Skills Center: Drill and Practice	Vascular Inflammation by 18-FDG PET/CT in Psoriasis Heart Songs Moderator	Nothing to Disclose
Power	John		In an Era of TAVR How Can Cardiology Fellow Auscultation Skills	Nothing to Disclose
Power	Juliette	and Education Innovations in Education	Be Improved An Online Murmur Curriculum Improves Medical Students' Ability to	Nothing to Disclose
Power	Juliette	Personalized Skills Center: Drill and Practice	Correctly Identify Cardiac Murmurs Heart Songs Moderator	Nothing to Disclose
Power	Juliette	(Heart Songs, ECG, Hand-Held Echo) Innovation in Practice Management, Advocacy,	In an Era of TAVR How Can Cardiology Fellow Auscultation Skills	Nothing to Disclose
Prabhakar	Sharma	and Education Put Your Codon! Genetic Insights Into Heart	Paricalcitol Effects on Heart Failure in Experimental Metabolic	Nothing to Disclose
		Failure	Syndrome: New Pathways Discovered Using Next Generation Sequencing	-
Prabhu	Sumanth	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Among Older Heart Failure (HF) Patients With In-Hospital Acute Kidney Injury (AKI), an Improvement in Kidney Function Is Associated With a Higher Risk of Post-Discharge Mortality but Not Readmission	DATA SAFETY MONITORING BOARD - Genzyme Corporation; RESEARCH/RESEARCH GRANTS - Aastrom

Last Name	First Name	Session Title	Presentation Title	Disclosures
Prabhu	Sumanth	Emerging Developments in HFpEF and Arryhthmias	Left Ventricular Mechanical Properties Assessed by Single Beat Method in Early Stages of Diastolic Dysfunction/Heart Failure With Preserved Ejection Fraction	DATA SAFETY MONITORING BOARD - Genzyme Corporation; RESEARCH/RESEARCH GRANTS - Aastrom
Prabhu	Sumanth	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Anomalous Presentation of Acute Coronary Syndrome: Successful Thrombolysis in a Patient Presenting With Inferior STEMI and Anomalous Right Coronary Artery	DATA SAFETY MONITORING BOARD - Genzyme Corporation; RESEARCH/RESEARCH GRANTS - Aastrom
Pradhan	Aruna	Mechanisms of Vascular Inflammation in	ACC Poster Moderator	RESEARCH/RESEARCH GRANTS - Kowa Research Institute
Prakash	Ashwin	Arrhythmias and Clinical EP: Devices 1	Coronary Artery Compression by Epicardial Leads: More Common	Nothing to Disclose
Prakash	Roshan	Acute Coronary Syndromes, Diagnosis,	Than We Think Angiographic Healing of Spontaneous Coronary Artery Dissection	Nothing to Disclose
Prasad	Abhiram	Management and Outcomes Interventional Challenging Cases: Team 4	ACC Challenging Case Reviewer	Nothing to Disclose
Prasad	Anand	The Best Coronary and Peripheral Interventional Challenging Cases	ACC Panelist	CONSULTANT FEES/HONORARIA - Osprey Medical; RESEARCH/RESEARCH GRANTS - Acist Medical; SPEAKER'S BUREAU - Abiomed,AstraZeneca,Gilead Sciences, Inc.
Prasad	Anand	The Best Coronary and Peripheral Interventional Challenging Cases	Use of the Impella CP Catheter for Refractory Cardiogenic Shock Following Acute Aortic Dissection and Surgical Repair	CONSULTANT FEES/HONORARIA - Osprey Medical; RESEARCH/RESEARCH GRANTS - Acist Medical; SPEAKER'S BUREAU - Abiomed,AstraZeneca,Gilead Sciences, Inc.
Prasad	Anand	Head to Toe: Outcomes of Endovascular Interventions	Atherectomy Is Associated With Lower Rates of Repeat Intervention After Below Knee Peripheral Vascular Intervention	CONSULTANT FEES/HONORARIA - Osprey Medical; RESEARCH/RESEARCH GRANTS - Acist Medical; SPEAKER'S BUREAU - Abiomed,AstraZeneca,Gilead Sciences, Inc.
Prasad	Anand	Head to Toe: Outcomes of Endovascular Interventions	Utilization of Distal Embolic Protection in Infrainguinal Peripheral Arterial Intervention: Insights From the Multicenter XLPAD Registry	CONSULTANT FEES/HONORARIA - Osprey Medical; RESEARCH/RESEARCH GRANTS - Acist Medical; SPEAKER'S BUREAU - Abiomed,AstraZeneca,Gilead Sciences, Inc.
Prasad	Anand	Head to Toe: Outcomes of Endovascular Interventions	Association of Cigarette Smoking With Procedural Cost of Lower Extremity Endovascular Intervention	CONSULTANT FEES/HONORARIA - Osprey Medical; RESEARCH/RESEARCH GRANTS - Acist Medical; SPEAKER'S BUREAU - Abiomed,AstraZeneca,Gilead Sciences, Inc.
Prasad	Anand	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Relationship of Biomarkers of Oxidized Lipoproteins to Ethnicity, Subclinical Atherosclerosis and Cardiovascular Events Over a 10.5 Year Follow-Up in the Dallas Heart Study	CONSULTANT FEES/HONORARIA - Osprey Medical; RESEARCH/RESEARCH GRANTS - Acist Medical; SPEAKER'S BUREAU - Abiomed,AstraZeneca,Gilead Sciences, Inc.
Prasad	Anand	Vascular Medicine: New Insights Into Aortic and Peripheral Artery Diseases	The Prevalence of Subclinical Lower Extremity Peripheral Arterial Disease in Mexican Americans: Results From the Cameron County Hispanic Cohort Study	CONSULTANT FEES/HONORARIA - Osprey Medical; RESEARCH/RESEARCH GRANTS - Acist Medical; SPEAKER'S BUREAU - Abiomed,AstraZeneca,Gilead Sciences, Inc.
Prasad	Anand	Interventional Complexity and Complications	Use of the RenalGuard System to Prevent Contrast Induced Kidney Injury: A Meta-Analysis	CONSULTANT FEES/HONORARIA - Osprey Medical; RESEARCH/RESEARCH GRANTS - Acist Medical; SPEAKER'S BUREAU - Abiomed, AstraZeneca, Gilead Sciences, Inc.
Prasad	Anand	Endovascular Therapy: Running From Risk	Predictors of Procedural Complications in Infrainguinal Endovascular Interventions	CONSULTANT FEES/HONORARIA - Osprey Medical; RESEARCH/RESEARCH GRANTS - Acist Medical; SPEAKER'S BUREAU - Abiomed, Astra Zeneca, Gilead Sciences, Inc.
Prasad	Anand	Endovascular Therapy: Running From Risk	Contrast-Induced Nephropathy Following Peripheral Angiography With Carbon Dioxide Versus Iodinated Contrast Media: A Systematic Review and Meta-Analysis of Current Literature	CONSULTANT FEES/HONORARIA - Osprey Medical; RESEARCH/RESEARCH GRANTS - Acist Medical; SPEAKER'S BUREAU - Abiomed,AstraZeneca,Gilead Sciences, Inc.
Prasad	Anand	Highlights in Vascular Medicine Research	Comparative Assessment of Subintimal Versus Intraluminal Crossing of Infrainguinal Chronic Total Occlusion Lesions	CONSULTANT FEES/HONORARIA - Osprey Medical; RESEARCH/RESEARCH GRANTS - Acist Medical; SPEAKER'S BUREAU - Abiomed,AstraZeneca,Gilead Sciences, Inc.
Prasad	Megha	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Elevated Uric Acid Is Associated With Increased Mortality in Women Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Prasad	Sanjay	Young Investigator Awards Competition:	Integrated Analysis of the Clinical Manifestations and Phenotypic	SPEAKER'S BUREAU - Bayer-Schering
Prasad	Sanjay	Clinical Investigations Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Drivers of Titin Cardiomyopathy Cardiovascular Magnetic Resonance in Survivors of Sudden Cardiac Arrest: 14 Year Experience From a Tertiary Referral Centre	SPEAKER'S BUREAU - Bayer-Schering
Pratchayasakul	Wasana	Interventional Cardiology: Translation and Pre- Clinical Research	in the United Kingdom Combined Prebiotics and Probiotics Treatment Is Not Superior to Single Regimen for Cardioprotection in Obese-Insulin Resistant	Nothing to Disclose
Pratchayasakul	Wasana	Hormones and Heart Failure	Rats Estrogen Deprivation Aggravates Cardiometabolic Dysfunction and Intracellular Calcium Dyshomeostasis in Obese-Insulin Resistance	Nothing to Disclose
Prato	Frank	Non Invasive Imaging: MR Characterization and Function	Rats An Unrestrained Proinflammatory M1 Macrophage Population Induced by Iron Nanocrystals Impairs Myocardial Healing After	Nothing to Disclose
Prato	Frank	Nuclear Cardiology: Coronary Flow	Hemorrhagic Infarction Precisely Controlled Arterial CO2 Can Potentiate Myocardial Blood	Nothing to Disclose
Drata	launa	Coronany Angiography, Intro Vangular Imaging	Flow to the Same Extent as Adenosine: A Preclinical Study in Canines With 13N-Ammonia PET	OTHER. The Medicines Company
Prats	Jayne	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	PCI: Pooled Patient-Level Data From the CHAMPION Trials	OTHER - The Medicines Company
Prats	Jayne	Optimizing the Care of ACS Patients	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin: Insights From CHAMPION PHOENIX	OTHER - The Medicines Company
Prats	Jayne	Anti-Platelet Therapies: Always a Sticky Topic	Ischemic Events Occur Early in Patients Undergoing PCI and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX	OTHER - The Medicines Company
Pray	Christopher	Nuclear Cardiology: Quality	Repeatability of Appropriateness Category Allocation by Trained Physicians	Nothing to Disclose
Prazeres	Carlos	Which Test Is Best for Pain in the Chest?	Coronary Computed Tomography Angiography in the Emergency Room: Rapid Exclusion of Coronary Artery Disease and the Fast Diagnosis of Acute Myocarditis Using Late Enhancement by Computed Tomography	Nothing to Disclose
Preiss	David	Advances in Cholesterol Measurement and Management	Impact of Evolocumab Therapy in Patients With Discordance Between LDL-C and LDL-P	CONSULTANT FEES/HONORARIA - Sanofi-Aventis
Prejean	Shane	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Anomalous Presentation of Acute Coronary Syndrome: Successful Thrombolysis in a Patient Presenting With Inferior STEMI and Anomalous Right Coronary Artery	Nothing to Disclose
Premer	Courtney	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Role of Gender on Mesenchymal Stem Cell Therapy in Non- lschemic Dilated Cardiomyopathy: A Sub-Analysis of the POSEIDON-DCM Trial	Nothing to Disclose
Premjee	Mohammed	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Does the Convergent Ablation Procedure Affect Left Atrial Contractile Function?	Nothing to Disclose
Prendergast	Bernard	Valvular Heart Disease Guidelines The Evidence and the Gaps	ESC Valve Guidelines: similarities and differences	SPEAKER'S BUREAU - Boston Scientific, Edwards Lifesciences
Presbitero	Patrizia	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: From the WIN-TAVI Registry	Nothing to Disclose

Contract of the second				
Last Name Prescott	First Name Eva	Session Title Who Should Benefit From Preventive Cardiology?: International Perspectives From the European Society of Cardiology and the	Presentation Title Women: Any Specific Conditions?	Disclosures Nothing to Disclose
Prescott	Eva	American College of Cardiology Unusual Presentations of ACS	Gender Differences in Patients With Vasomotor Disorders According to Acetylcholine Provocation in a European Population	Nothing to Disclose
Prescott	Margaret	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Rationale and Methods of the Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE-HF) Study	OTHER - Novartis Pharmaceuticals; SALARY - Novartis Pharmaceuticals
Prescott	Margaret	Hormones and Heart Failure	Low Urinary Cgmp/Bnp Ratio Is Associated With Worse Outcomes in Heart Failure but Is Increased by Treatment With Sacubitril/Valsartan: An Analysis of Paradigm-HF	OTHER - Novartis Pharmaceuticals; SALARY - Novartis Pharmaceuticals
Pressel	Sara	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Toward Identifying Personalized Prognosis in Hypertension: Variation in Early Responses in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)	Nothing to Disclose
Pressel	Sara	New Insights Into Prediction and Treatment of Hypertension	The U-Shaped Relationship of Body Mass Index With All-Cause Mortality at Eight Years in the ALLHAT	Nothing to Disclose
Pressman	Gregg	Considerations in Antiplatelet Therapy and in ACS	Chronovariability of Platelet Reactivity With the Hemodialysis Cycle	Nothing to Disclose
Pressman	Gregg	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Migration of the Prosthetic Mitral Valve After Transcatheter Mitral Valve Replacement for Severe Calcific Mitral Stenosis	Nothing to Disclose
Presson	Angela	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Do Pediatric Cardiologists Follow the Sports Restriction Recommendations for Children With a Bicuspid Aortic Valve?	Nothing to Disclose
Price	Matthew	Imaging for Left Atrial Appendage and Paravalvular Leak Closure: A Case Based Approach	Panelist	CONSULTANT FEES/HONORARIA - Accriva AstraZeneca, Boston Scientific, Daiichi Sankyo/Eli Lilly, MEDTRONIC, St Jude Medical, Terumo, The Medicines Company, W.L. Gore; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Iverson Genetics; SPEAKER'S BUREAU - AstraZeneca, Boston Scientific, DSI/Eli Lilly & Damp, amp; Co.
Price	Matthew	Imaging for Left Atrial Appendage and Paravalvular Leak Closure: A Case Based Approach	Intra-Procedural Imaging: TEE, ICE and Fluoro- Bringing it All Together	CONSULTANT FEES/HONORARIA - Accriva AstraZeneca, Boston Scientific, Daiichi Sankyo/Eli Lilly MEDTRONIC, St Jude Medical, Terumo, The Medicines Company, W.L. Gore; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Iverson Genetics; SPEAKER'S BUREAU - AstraZeneca, Boston Scientific, DSI/Eli Lilly & Ampjamp; Co.
Price	Matthew	Interrupting DAPT for Surgery, Afib, or Bleeding	Panelist	CÓNSULTANT FEES/HONORARIA - Accriva AstraZeneca, Boston Scientific, Daiichi Sankyo/Eli Lilly, MEDTRONIC, St Jude Medical, Terumo, The Medicines Company, W.L. Gore; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Iverson Genetics; SPEAKER'S BUREAU - AstraZeneca, Boston Scientific, DSI/Eli Lilly & Damp, amp; Co.
Price	Matthew	Interrupting DAPT for Surgery, Afib, or Bleeding	Switching DAPT: How Do You Do It?	CÓNSULTANT FEES/HONORARIA - Accriva AstraZeneca, Boston Scientific, Daiichi Sankyo/Eli Lilly, MEDTRONIC, St Jude Medical, Terumo, The Medicines Company, W.L. Gore; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Iverson Genetics; SPEAKER'S BUREAU - AstraZeneca, Boston Scientific, DSI/Eli Lilly & Damp, amp; Co.
Price	Matthew	Fundamentals of LAA Closure	Co-Chair	CONSULTANT FEES/HONORARIA - Accriva AstraZeneca, Boston Scientific, Dalichi Sankyo/Eli Lilly, MEDTRONIC, St Jude Medical, Terumo, The Medicines Company, W.L. Gore; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Iverson Genetics; SPEAKER'S BUREAU - AstraZeneca, Boston Scientific, DSI/Eli Lilly & Dampamp; Co.
Price	Matthew	Fundamentals of LAA Closure	Case Presentation: Suboptimal versus Optimal Transseptal Puncture	CONSULTANT FEES/HONORARIA - Accriva AstraZeneca, Boston Scientific, Daiichi Sankyo/Eli Lilly,MEDTRONIC,St Jude Medical,Terumo, The Medicines Company,W.L. Gore; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Iverson Genetics; SPEAKER'S BUREAU - AstraZeneca,Boston Scientific,DSI/Eli Lilly & Co.
Price	Matthew	Fundamentals of LAA Closure	Case Presentation: Thrombus After LAA Closure	CONSULTANT FEES/HONORARIA - CONSULTANT FEES/HONORARIA - Accriva AstraZeneca, Boston Scientific, Daiichi Sankyo/Eli Lilly,MEDTRONIC,St Jude Medical,Terumo, The Medicines Company,W.L. Gore; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Iverson Genetics; SPEAKER'S BUREAU - AstraZeneca,Boston Scientific,DSI/Eli Lilly & Co.
Price	Matthew	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Twelve Month Follow-Up Data From the ONYX CORE Trial: Angiographic and Clinical Performance of Next Generation Resolute Onyx Drug-Eluting Stent	CONSULTANT FEES/HONORARIA - Accriva_AstraZeneca_Boston_Scientific_Dalichi_Sankyo/Eli Lilly_MEDTRONIC.St_Jude Medical_Terumo,The Medicines Company,W.L_Gore, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Iverson Genetics; SPEAKER'S BUREAU - AstraZeneca_Boston Scientific_DS/Eli Lilly_&_amp; Co.
Price	Matthew	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of Periprocedural Myocardial Infarction in Contemporary PCI: Pooled Patient-Level Data From the CHAMPION Trials	CONSULTANT FEES/HONORARIA - Accriva AstraZeneca, Boston Scientific, Dairchi Sankyo/Eli Lilly, MEDTRONIC, St. Jude Medical, Terumo, The Medicines Company, W.L. Gore; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Iverson Genetics; SPEAKER'S BUREAU - AstraZeneca, Boston Scientific, DSI/Eli Lilly & Damp, amp; Co.
Price	Matthew	Optimizing the Care of ACS Patients	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin: Insights From CHAMPION PHOENIX	CONSULTANT FEES/HONORARIA - Accriva AstraZeneca, Boston Scientific, Dairchi Sankyo/Eli Lilly,MEDTRONIC, St. Jude Medical, Terumo, The Medicines Company,W.L. Gore; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Iverson Genetics; SPEAKER'S BUREAU - AstraZeneca, Boston Scientific, DSI/Eli Lilly & Damp, amp; Co.
Price	Matthew	Post-CAD/MI: Making Tough Predictions About the Future	One-Year Mortality Increased in Patients With Peri-Procedural Myocardial Infarction: Insights From the CHAMPION Trials	CONSULTANT FEES/HONORARIA - Accriva, AstraZeneca, Boston Scientific, Daich i Sankyo/Eli Lilly, MEDTRONIC, St Jude Medical, Terumo, The Medicines Company, W.L. Gore; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Iverson Genetics; SPEAKER'S BUREAU - AstraZeneca, Boston Scientific, DSI/Eli Lilly & Mamp; amp; Co.

Contract of the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Price	Matthew	Anti-Platelet Therapies: Always a Sticky Topic	Ischemic Events Occur Early in Patients Undergoing PCI and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX	CONSULTANT FEES/HONORARIA - Accriva, Astra Zeneca, Boston Scientific, Daiichi Sankyo/Eli
			Reduced With Cangrelor, Findings From Chawrion Frozinia	Lilly,MEDTRONIC,St Jude Medical,Terumo,The Medicines
				Company,W.L. Gore; OWNERSHIP
				INTEREST/PARTNERSHIP/PRINCIPAL - Iverson Genetics;
				SPEAKER'S BUREAU - AstraZeneca, Boston Scientific, DSI/Eli Lilly & DSI/Eli
Price	Matthew	03. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	CONSULTANT FEES/HONORARIA -
1100	induitor.	Therapy Team 3		Accriva, AstraZeneca, Boston Scientific, Daiichi Sankyo/Eli
				Lilly,MEDTRONIC,St Jude Medical,Terumo,The Medicines
				Company,W.L. Gore; OWNERSHIP
				INTEREST/PARTNERSHIP/PRINCIPAL - Iverson Genetics; SPEAKER'S BUREAU - AstraZeneca,Boston Scientific,DSI/Eli
				Lilly & Dorte A Grand Control of
Priori	Silvia	04. Arrhythmias and Clinical EP: Basic Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Ambry Genetics, Boston
				Scientific,MEDTRONIC,Medtronic Inc ; OWNERSHIP
				INTEREST/PARTNERSHIP/PRINCIPAL - Audentes Therapeutics Inc; RESEARCH/RESEARCH GRANTS - Gilead Sciences, Inc.
				ine, Nederworth Country - Gileau delendes, inc.
Pritchett	Allison	Acute Heart Failure: Evaluating Strategies to	Educational Strategy for Management of Heart Failure Markedly	OTHER - St. Jude Stock
		Prevent Readmissions	Reduces 90-Day Emergency Department and Hospital Readmissions in Un- and Underinsured Patients	
Prosnitz	Aaron	Highlighted Original Research: Congenital	Early Hemodynamic Changes After Fetal Aortic Stenosis	Nothing to Disclose
		Heart Disease and the Year in Review	Valvuloplasty Are Associated With Biventricular Circulation at Birth	3
D	F	La contraction of the contractio	5 1000 011 015 10	Notice to Broaders
Prout	Emilie	Innovations in Practice Management and Social Media	Formal CPR Status Policy and Process Increased Documentation Rates	Nothing to Disclose
Prueksaritanond	Suartcha	Arrhythmias and Clinical EP: Devices 1	Characteristics and Clinical Predictors of 11,569 Pneumothoraces	Nothing to Disclose
1			Associated With Cardiac Implantable Electronic Device Procedures:	=
Drantowale:	Erio	OS Arrhythmics and Clinical ED: Other Towns	Results From a Large National Database	CONSULTANT FEES/HONORARIA - Abbott/Topera
Prystowsky	Eric	06. Arrhythmias and Clinical EP: Other Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott/Topera EP,CardioNet,MEDTRONIC; OFFICER, DIRECTOR, TRUSTEE,
				OR OTHER FIDUCIARY ROLE - Stereotaxis; OTHER -
				Stereotaxis
Ptaszynska	Agata	Emerging Developments in HFpEF and	Prognostic Significance of Left Ventricular Diastolic Dysfunction	Nothing to Disclose
1		Arryhthmias	Progression in Patients With Heart Failure With Preserved Ejection Fraction: The I-PRESERVE Trial	
Ptaszynski	Pawel	Highlighted Original Research: Arrhythmias	Ivabradine in Patients With Symptomatic Inapprioprate Sinus	CONSULTANT FEES/HONORARIA - Biosence
1		and Clinical EP and the Year in Review	Tachycardia: Long-Term Observational Study	Webster, MEDTRONIC; SPEAKER'S BUREAU - Boston Scientific
Du .	Daniel	Innovative Use of Enhanced:	Loft Ventricular Clohal Longitudinal Strain Products All Course	Nothing to Disclose
Pu	Daniel	Innovative Use of Echocardiography	Left Ventricular Global Longitudinal Strain Predicts All-Cause Mortality in Patients With Mitral Regurgitation and Ischemic Heart	Nothing to Disclose
			Disease but Not in Nonischemic Mitral Regurgitation	
Pu	Min	Valvular Disease Populations at Risk	Risk Stratification Predicts Survival in Patients With Low Gradient	Nothing to Disclose
			Preserved Left Ventricular Ejection Fraction and Severe Aortic	
Pu	Min	Valvular Heart Disease: Aortic Stenosis	Stenosis After Aortic Valve Intervention Surgical Risk Scores Outweigh Echocardiographic Severity of Aortic	Nothing to Disclose
	IVIII I	valvalar ricari biscasc. Nortic dichosis	Stenosis for Determining Prognosis in Patients With Low Gradient	Nothing to Disclose
			Severe Aortic Stenosis and Preserved Left Ventricular Function	
D	Mar Salarana	Land to O to the Allet to Mills	FIG. AL. C. D. C. D. C. C. All	Notice to Bright
Pucci	Mariateresa	Improving Outcomes in the Athlete With Cardiovascular Disease	EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000	Nothing to Disclose
		Gardiovasculai Biscasc	Young Italian Students	
Puchalski	Michael	Congenital Heart Disease: Innovations in	Do Pediatric Cardiologists Follow the Sports Restriction	Nothing to Disclose
Puchner	Stefan	Single Ventricle Heart Disease Highlighted Original Research: Non Invasive	Recommendations for Children With a Bicuspid Aortic Valve? The Association of High Risk Plaque Features and Non-Invasive	Nothing to Displace
Puchner	Stelan	Imaging and the Year in Review	Fractional Flow Reserve Derived From Coronary Computed	Nothing to Disclose
		99	Tomography Angiography in Patients With Acute Chest Pain:	
			Results From the ROMICAT II Trial	
Puig	Oscar	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Comprehensive Next Generation Sequencing Assay for Identifying Pathogenic Variants Associated With Cardiovascular Diseases	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Phosphorus Inc; SALARY - Phosphorus Inc
Pujara	Deep	Atrial Fibrillation and VT: Unique Populations	The Prevalence and Distribution of Ventricular Arrhythmias Prior to	Nothing to Disclose
1		and Solutions	Ventricular Assist Device Implantation: A Thirteen Year Institutional	J
		ALCO PROBLEM	Experience	Nutrice to District
Pujara	Deep	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	5-Year Outcomes of a Staged Hybrid Surgical and Catheter-Based Ablation Approach for Treatment of Long-Standing Persistent Atrial	Nothing to Disclose
1		and Newer Outcome Measures	Fibrillation	
Pujara	Deep	Ventricular Arrhythmias and Sudden Death	Ventricular Tachycardia Early After Implantation of a Ventricular	Nothing to Disclose
		Prevention	Assist Device Is Associated With Increased Long Term Mortality: A	
Pullatt	Raja	New Technologies in Echocardiography	Thirteen Year Institutional Experience Left Atrial Volume Index Over Late Diastolic Mitral Annular Velocity:	Nothing to Disclose
. Shall	raju	1.15. Teamologics in Echocal diographly	A New Non-Invasive Parameter for Measurement of Left Ventricular	Touring to Disciose
			End Diastolic Pressure	
Punjabi	Naresh	Heart Failure and Cardiomyopathies: Is Heart	Surrogate Endpoints and the Differential Response to ASV for Sleep	OTHER - Phillips-Respironics,Resmed; RESEARCH/RESEARCH GRANTS - Resmed
Punjabi	Naresh	Failure With a Normal EF for Real? The Evolving World of LVADs, Transplant and	Apnea in HFrEF Versus HFpEF in the CAT-HF Trial Sleep Duration and Quality in Heart Failure Patients	OTHER - Phillips-Respironics,Resmed;
		Other Novel Discoveries		RESEARCH/RESEARCH GRANTS - Resmed
Punzi	Henry	Assessing the Clinical Impact of Blood	Additivity of Nebivolol/Valsartan Single-Pill Combinations Versus	CONSULTANT FEES/HONORARIA - Allergan, Inc, AstraZeneca
ĺ		Pressure Lowering Therapies	Other Approved Single-Pill Combinations for Hypertension	Pharmaceuticals; RESEARCH/RESEARCH GRANTS - Actelion, Allergan, Inc, AstraZeneca Pharmaceuticals, Boehringer
ĺ				Actelion, Allergan, Inc, AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, Ferrer Internacional S.A., National
ĺ				Institutes of Health
Purga	Scott	FIT Clinical Decision Making: Arrhythmias and	The Brugada Syndrome Mimicking an Acute Inferior ST Elevation	Nothing to Disclose
Duraell	Irion	Electrophysiology	Myocardial Infarction	Nothing to Displace
Pursell	Irion	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Ethnicity, Marital Status, and Neighborhood Poverty Influence Resuscitation of Out-of-Hospital Sudden Unexpected Deaths	Nothing to Disclose
Purushothaman	Meerarani	Interventional Cardiology: Intravascular	Atherosclerotic Plaque Morphology in Response to High Intensity	Nothing to Disclose
		Physiology and Endothelial Function	Lipid Lowering Therapy by Multimodality Imaging Among Women	
Purushothaman	Meerarani	Cutting Edge Vascular Medicine	and Men: A YELLOW-II Sub-study Proprotein Convertase Subtilisin Kexin Type 9 Protein Expression Is	Nothing to Disclose
r urusrioiridifidifi	ivieei ai di li	Cutany Euge vascular Medicine	Increased in Lipid Rich Human Atherosclerotic Plaques Compared	140thing to Disclose
			to Fibrous Plaques	
Purushothaman	Meerarani	Highlights in Vascular Medicine Research	Morphological Features of Vascular Healing in Paclitaxel Coated	Nothing to Disclose
			Balloon Compared to Plain Old Balloon Angioplasty in Human Peripheral Artery Disease	
Purushothaman	Meerarani	The Inside View: Learning From Intracoronary	Investigation of Novel Drug Targets Implicated in High-Dose Statin	Nothing to Disclose
. a. coouiuiilaii	co.urum	Imaging	Therapy From Yellow-II Trial: Towards Personalized Lipid Lowering	
			Therapies	
Pushkarev	Georgiy	Traditional and Novel Factors Used to Assess	New Modification of Isometric Handgrip Stress Echocardiography for	Nothing to Disclose
		the Risk of, and Used for the Treatment of, Coronary Artery Disease	Detection of Coronary Artery Disease: Combination of Exercise and Emotional Stress Echocardiography	
Puskas	John	Highlighted Original Research: Interventional	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome	OTHER - Scanlan Inc
		Cardiology and the Year in Review	After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	

and the				ļ
Last Name	First Name	Session Title	Presentation Title	Disclosures OTHER - Scanlan Inc
Puskas	John	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Differences and Level of Agreement in SYNTAX Score Assessment Between Site Operators and Angiographic Core Laboratory Readers: Insights From the EXCEL Trial	OTHER - Scanian Inc
Puskas	John	Refining PCI Technique and Outcomes	Treatment of Left Main Coronary Artery Disease in Patients With Diabetes: 3-Year Outcomes Comparing CABG and PCI With Everolimus-Eluting Stents From the EXCEL Study	OTHER - Scanlan Inc
Puskas	John	Refining PCI Technique and Outcomes	Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory Assessment: Insights From the EXCEL Trial	OTHER - Scanlan Inc
Puthumana	Jyothy	Imaging the Athlete's Heart	Deformation Analysis Can Be Performed on Post-Exercise Images in National Basketball Association Draft Eligible Players With Good	Nothing to Disclose
Puthumana	Jyothy	Technical Advances in Transthoracic	Reproducibility Safety of Perflutren-Based Echocardiographic Contrast Agent	Nothing to Disclose
		Echocardiography	Administration in the Setting of a Patent Foramen Ovale (PFO): A Multicenter Study Conducted in Tertiary Care Centers Based in the New York/Chicago Metropolitan Areas	
Putthapiban	Prapaipan	Arrhythmias and Clinical EP: Syncope and	Worldwide Prevalence of Brugada Syndrome: A Systematic Review	Nothing to Disclose
Puwanant	Sarinya	Other EP Issues Emerging Applications of Echocardiography	and Meta-Analysis Echocardiographic Assessment of Right Ventricular Function in Acute Right Ventricular Failure Identified by Hemodynamic Criteria	Nothing to Disclose
Puymirat	Etienne	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Ischemic and Bleeding Events in the Real World Population of	Nothing to Disclose
Puymirat	Etienne	Antithrombotic Therapy in Ischemic Heart	Stented Patients in the FAST-MI 2005 Cohort Long-Term Outcome With Oral Anticoagulants With or Without Dual	Nothing to Disclose
Puymirat	Etienne	Disease Unusual Presentations of ACS	Antiplatelet Therapy After AMI: The Fast-Mi 2010 Registry Characteristics and Outcomes of Patients Discharged Without Statins After an Acute Myocardial Infarction: An Analysis From the	Nothing to Disclose
Pyeritz	Reed	Vascular Medicine: Aortic and Peripheral	Combined FAST-MI 2005-2010 Cohorts Predictive Factors for Rapid Aortic Growth Following Acute Type A	Nothing to Disclose
		Artery Diseases	Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection	Nothing to Disclose
Pyeritz	Reed	Vascular Medicine: Aortic and Peripheral Artery Diseases	Uncontrolled Hypertension in Acute Aortic Dissection Follow-Up	,
Pylarinou	Voula	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Insights on Diastolic Dysfunction of Treated Hypertensive Patients: Focusing on Hypertension Control & Treatment Resistance	Nothing to Disclose
Pyne	Christopher	Radial Access Mini-Symposium I	Transradial Primary PCI: Data and Technique	Nothing to Disclose
Pyne	Christopher	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Congenital Double-Chambered Left Ventricle Presenting as Monomorphic Ventricular Tachycardia	Nothing to Disclose
Pyo	Robert	Interventional Live Case Session IV: Complex Coronary Transmission from St. Vincent Hospital (Indianapolis, IN)	Panelist	Nothing to Disclose
Pyo	Robert	Complications of PCI: Case Reviews	Case Presentation: A Case Where I Needed Hemodynamic Support but Didn't Use it	Nothing to Disclose
Pyo	Robert	Interventional Cardiology: TAVR 2	Association of Chronic Renal Insufficiency With In-Hospital	Nothing to Disclose
Pyo	Robert	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Outcomes of Transcatheter Aortic Valve Replacement Sex Differences in Revascularization and In-Hospital Outcomes of Non-ST-Segment Elevation Myocardial Infarction in the United	Nothing to Disclose
Pyo	Robert	Syndrome Interventional Cardiology: TAVR 3	States Regional Variations in In-Hospital Outcomes and Healthcare Resource Utilization in Patients Undergoing Transcatheter Aortic	Nothing to Disclose
Pyo	Robert	Optimizing the Care of ACS Patients	Valve Replacement in the United States Weekend Versus Weekday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide	Nothing to Disclose
Qamar	Arman	Challenging the Standard of Care: Emerging	Analysis Case Presentation: Patient with VTE Following Recent Myocardial	Nothing to Disclose
Qamar	Arman	Concepts in VTE Treatment and Prevention Current Issues in Cardiovascular	Infarction Lipid Abnormalities in Young Patients With Myocardial Infarction	Nothing to Disclose
Qamar	Arman	Epidemiology, Disparities, and Safety Current Issues in Cardiovascular	Women Who Experience Myocardial Infarction at a Young Age	Nothing to Disclose
Qamar	Arman	Epidemiology, Disparities, and Safety Novel Developments in Acute Coronary	Have Worse Survival Compared With Men Comparison of Troponin Peaks Between Type 1 and Type 2	Nothing to Disclose
		Syndromes	Myocardial Infarction	
Qamar	Arman	The Evolving World of LVADs, Transplant and Other Novel Discoveries	High-Sensitivity Troponin-T, Left Ventricular Size and Function, and Long-Term Outcomes in Clinically Stable, Apparently Healthy Older Subjects	Nothing to Disclose
Qamar	Arman	Unusual Presentations of ACS	Differing Outcomes of Type 1 and Type 2 Myocardial Infarction and Their Impact on Overall Non-ST Elevation Myocardial Infarction Mortality Rates	Nothing to Disclose
Qamar	Arman	Unusual Presentations of ACS	Long-Term Survival	Nothing to Disclose
Qamar Qasim	Arman Atif	FIT Clinical Decision Making Reviewers 4 Innovations in Education	ACC FIT Clinical Decision Making Reviewer A Novel Educational Approach for Novice Echocardiographers	Nothing to Disclose RESEARCH/RESEARCH GRANTS - Abbott
Qayyum	Abbas Ali	Fixing the Heart One Cell at a Time: The	Adipose Derived Stromal Cells for Refractory Angina: Results From	Vascular,MEDTRONIC Nothing to Disclose
		Ongoing Promise of Stem Cells	MyStromalCell Trial	
Qazi	Saadia	Predicting the Future: Observations and Discoveries From Registries and Databases	Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study	Nothing to Disclose
Qian	Zhiyong	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Super-Response to Cardiac Resynchronization Therapy in Heart Failure Patients With Left Bundle Branch Block and Homogeneous Left Ventricular Contraction Pattern	Nothing to Disclose
Qian	Zhiyong	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Assessment of Left Ventricular Contraction Patterns Using Gated SPECT MPI to Improve Cardiac Resynchronization Therapy Response	Nothing to Disclose
Qin	Xianhui	Assessing the Clinical Impact of Blood Pressure Lowering Therapies	Impact of Achieved Blood Pressure on First Stroke in Hypertensive Patients With Mild-to-Moderate Chronic Kidney Disease: A Post-Hoc Analysis of the China Stroke Primary Prevention Trial (CSPPT)	Nothing to Disclose
Qin	Xianhui	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Serum Homocysteine Lowering by Long-Term Low-Dose Folic Acid: New Insight on <>MTHFR Gene-Folate Interaction From China Stroke Primary Prevention Trial	Nothing to Disclose
Qin	Xianhui	Diabetes and Other Issues in Cardiovascular	Stroke Primary Prevention Trial Efficacy of Folic Acid Supplementation on the Reduction of Stroke Risk: Interaction With Platelet Count	Nothing to Disclose
Qintar	Mohammed	Prevention Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Reliability and Responsiveness of Seattle Angina Questionnaire in Women With Coronary Artery Disease	Nothing to Disclose
Qintar	Mohammed	Coronary Artery Disease Innovations in Cardiovascular Risk Assessment		Nothing to Disclose
Qintar	Mohammed	and Reduction Advances in Chronic Total Occlusion	After Myocardial Infarction Association of Stress Test Risk Classification With Health Status	Nothing to Disclose
		Intervention	Change After Chronic Total Occlusion PCI: Insights From the OPEN- CTO Registry	<u> </u>
· · · · · · · · · · · · · · · · · · ·				

Backs Windows Part of STEELER STOCK Opening Fallow Will Applied Co. Michael Market Co.					
Section 1997 - Portion of Technologies Pathologies (Pathologies Pa					
De company de la company and Place Inc. Service de la company and Pla	Qısu	∠hang			SALARY - Bristol-Myers Squibb Company, Pfizer Inc I am an employee of STATinMED Research, which is a paid consultant
Multiple Charlestonia Court Sept. 1 In the Thart Follow of Palace of Charleston (Charleston) Palacetonia Court Sept. 1 Institute Charlestonia Co				Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin in the US Medicare Population	Bristol-Myers Squibb company and Pfizer Inc.
Lauder Note of Control Advanced program (1) Lauder Note of Contro	Qiu	Weiliang		of Life Than Robust Patients at One Year Following Invasive	Nothing to Disclose
Auder Name Applier Direct State of the Company of State St	Quader	Nishath	Interventional Cardiology: TAVR 4		Nothing to Disclose
See See of and buyer for the Treatment of June 10 and Contract American Section 1 and 10 and	Quader	Nishath			Nothing to Disclose
Duration Cardiac Announce Linearies (March 1987). Accordance (March 19	Quadros	Kenneth	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,		Nothing to Disclose
Audician Control of American Control of Control	Quagliara	Donato	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary		Nothing to Disclose
Assessing Cardie Funding Begrandate Transcribed Funds volus on Marked spread part of the Mark Andread Cardia and Marked Andrea Cardia Adultah Intervenenced Cardialogy TAMS 2 Composers of in Hospital Culciforms of Transcribed Andrea Cardia Advanced Marked Appoint Marked Andrea Cardialogy TAMS 2 Composers of in Hospital Culciforms Andrea Cardialogy Andrea Cardialog	Quagliara	Donato	Antiplatelet and Antithrombotic Agents in		Nothing to Disclose
Designer of Michael Graft Moor Thirt Dimension / Multidisciplanty Graft Moor Thirt Dimension / Multidisciplanty Graft Moor Thirt Dimension / Multidisciplanty Graft Moor Discourse of Discourse (A) Angrain in Management of Discourse (A) Angrain in Management (Quaife	Robert		Expandable Transcatheter Aortic Valve Replacement on the Dimensions of the Mitral Valve Annulus and Mitral Regurgitation	RESEARCH/RESEARCH GRANTS - Philips Medical
Constanting Time Officer (Constanting Constanting) (Interesting Auditory) Varies Delection and Why? Constanting Time Officer (Constanting Constanting	Quddus	Abdullah	Interventional Cardiology: TAVR 2	Comparison of In-Hospital Outcomes of Transcatheter Aortic Valve	Nothing to Disclose
Agence In Algories of the Algories of Colorations (A.C.) Algories (In Algories) (In A	Querijero	Michael			CONSULTANT FEES/HONORARIA - Edwards Life
Diseased Samon Procedural case of Samon Procedural, and Post Diseased Samon Procedural and Post Diseased Samon Procedural Case Samon Procedural Case Samon Procedural Case Samon Procedural Case Samon Procedural Case Samon Procedural Case Samon Procedural Case Samon Procedural Case Samon Procedural Case Samon Procedural Case Samon Procedural Case Samon Procedural Case Samon Procedural Case Samon Procedural Case Samon Procedural Case Samon Procedural Case Samon Procedural Samon Pr	Quesada	Odayme	Angina in the Absence of Obstructive CAD.	Case Presentation: Microvascular Dysfunction	
Aproach Parallel Para	Quesada	Ramon	Imaging for Left Atrial Appendage and		
Junesarda Ramon Fundamentals of LAA Closure Anticipating and Managing Complications of LAA Closure Consult I ANT FESS-MONRAPARIA. Asked B Subtoness Mage Information and Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology, Acute and State between Land Cardiology and Cardiological International Cardiology, Acute and State between Land Cardiology and Cardiological International Cardiology and Cardiology and Cardiology and Cardiological International Cardiology and Cardiological International Cardiology and Cardiological International Cardiology and Cardiological International Cardiology and Cardiological International Cardiology and Cardiological International Cardiology and Cardiology and Cardiological International Cardiology and Cardiological International Cardiological International Cardiological International Cardiology and Cardiological International Cardiology and Cardiological International Cardiological International Cardiology and Cardiological International Cardiological International Cardiological International Cardiological International Cardiological International Cardiological International Cardiological International Cardiological International Cardiological International Cardiological International Cardiological International Cardiological International Cardiological International Cardiological International Cardiological International Cardiological Inte	Juesada	Ramon	Approach	1 Tooddia E Taldalon	
Labonomies SSC. St. Judes Merit Abbetet. St. Judes Bit Supplied Federater All Supplied Federater The Circial Decision Marking interventional Supplied Federater The Circial Decision Marking interventional Supplied Federater The Circial Decision Marking interventional Supplied Federater The Circial Decision Marking interventional Supplied Federater The Circial Decision Marking interventional Supplied Federater All Professes, and Vascorial Medicine The Circial Decision Marking interventional Policy of Circial Professes And Patients Williams and Clinical EF-Synopop and Professes Private Control of the Morth Important Professor Of the Morth Important Peritor of the Morth Important Peritorial Professor Of the Morth Important Peritorial					Laboratories, BSC, St Jude, Merrit, Abbott, St Jude, BSC, GORE,
Juristans Ouerada Raymundo Fil Cinical Decision Making interventional Curdicioly, Autor and Stable bethemos her infrastructure for amen Ovade Curdicioly, Autor and Stable bethemos her infrastructure for amen Ovade National Planting and Cinical EP Spricope and Other PI Busses and Cinical EP Spricope and Other PI Busses and Cinical EP Spricope and Other PI Busses and Cinical EP Spricope and Other PI Busses and Cinical EP Spricope and Other PI Busses and Cinical EP Spricope and Other PI Busses and Cinical EP Spricope and Other PI Busses and Piece Pi Command Pincard Health Teathers: Evaluating Strategies to Prevent Report Pincard Pinc				, , , , , , , , , , , , , , , , , , , ,	Laboratories,BSC,St Jude,Merrit,Abbott, St Jude,BSC,GORE,
Cardiology, Acute and Stable Inchemic Heart Debates, and Various Medicine Other EP Issues Other EP Issues Control of the Noted Important Heart Transplant Referral Corner to Control of the Noted Important Heart Transplant Referral Corner to Control of the Noted Important Heart Transplant Referral Corner to Control of the Noted Important Heart Transplant Referral Corner to Control of the Noted Important Heart Transplant Referral Corner to Control of the Noted Important Heart Transplant Referral Corner to Control of the Noted Important Heart Transplant Referral Corner to Control of the Noted Important Heart Transplant Referral Corner to Corn					
Correct pictors (and important Healt Transplant Referral Noting to Disclose Correct on Colombia, South American South Process (Author) (Au			Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Paradoxical Embolism via a Patent Foramen Ovale	-
Regar of Congenital Heart Disease Name of Conge	Quintero	Alvaro	Arrhythmias and Clinical EP: Syncope and	From a Cohort of the Most Important Heart Transplant Referral	Nothing to Disclose
Pervenent Readmissions Advances in Cholesterd Measurement and Management Advances in Cholesterd Measurement and Management Advances in Cholesterd Measurement and Management Heart Disease and the Versir Review More Management Heart Disease and the Versir Review More Management Heart Disease and the Versir Review More Management Measurement and Management Measurement and Management Measurement and Management Measurement and Management Measurement and Management Measuremen	Quiros-Tejeira	Ruben			Nothing to Disclose
Advances in Cholesterol Measurement and Menagement Althar Al	Quisel	Tom			SALARY - Evidation Health
Altrar Highlighted Orginal Research: Corgential Heart Disease and the Year in Review Non Invasive Imaging; Role of Exercise Testing States Mocrafial Perfusion Imaging in Anomalous Aortic Origin of a Morbing to Disclose FIT Clinical Docision Making Prevention, Adulticenter Study Altrarian Mahammad FIT Clinical Docision Making, Prevention, And Congential Heart Diseases Disease Mocrafial Perfusion Imaging in Anomalous Aortic Origin of a Norbing to Disclose Congenital Anal Congential Heart Diseases Disease Innovations in Amplitate Therapy and in Use of Amplitated and Amplitations in Amplitate Therapy and in Use of Amplitations and Amplitations in Amplitations i	Quispe	Renato	Advances in Cholesterol Measurement and	Estimating Low-Density Lipoprotein-Cholesterol Based on Fasting	Nothing to Disclose
Abter Non Invasive Imaging: Role of Exercise Testing Stress Mycardial Perfusion Imaging in Anomalous Anti-Origin of a location Non Invasive Imaging: Role of Exercise Testing Stress Mycardial Perfusion Imaging in Anomalous Anti-Origin of a location Non-Invasive Imaging: Role of Exercise Testing Protection Non-Invasive Imaging: Role of Exercise Testing Protection Non-Invasive Imaging: Coronary Attery Disease Non-Invasive Imaging: Coronary Attery Disease Non-Invasive Imaging: Coronary Attery Disease Non-Invasive Imaging: Coronary Calcium N	Qureshi	Athar		Safety and Feasibility of Melody Transcatheter Pulmonary Valve Replacement in the Native Right Ventricular Outflow Tract: A	Nothing to Disclose
Dureshi Muhammad Fit Clinical Decision Making: Prevention, Adult Delivery and Management of Complete Ectopia Cordis: A Nothing to Disclose	Qureshi	Athar	Non Invasive Imaging: Role of Exercise Testing	Stress Myocardial Perfusion Imaging in Anomalous Aortic Origin of a	Nothing to Disclose
Single Ventricle Heart Disease Failure Status in Hypoplastic Left Heart Syndrome Nothing to Disclose	Qureshi	Muhammad		Delivery and Management of Complete Ectopia Cordis: A	Nothing to Disclose
ACS Troponin Elevation: Insights From Type I III Study Corronary Angiography, Intra-Vascular Imaging, Impact of Electrocardiogram Changes on Mortality in Asymptomatic Nothing to Disclose Patients With Sepsis and Elevated Troponin Disease Risk Stratification in Smokers; MESA Disease and Other Issues in Cardiovascular Disease Risk Stratification in Smokers; MESA Disease and Other Issues in Cardiovascular Blood Pressure Indices and Other Issues in Cardiovascular Machine Learning to Define the Association Between Cardiorespiratory Fitness and All-Cause Mortality: The FIT (Henry Ford Exercise Testing) Project Dispatch Risk Stratification in Smokers; MESA Dispatch Risk Risk Pactors for Cardiovascular Dispatch	Qureshi	Muhammad			Nothing to Disclose
Dureshi Waqas Coronary Angiography, Intra-Vascular Imaging Pathest With Sepsia and Cardiovascular Scoring and CV Risk Assessment Disease Risk Stratification in Browners (Cardiovascular Disease Risk Stratification in Browners) (Cardiovascular Disease Risk Stratification in Browners) (Cardiovascular Disease Risk Stratification in Browners) (Cardiovascular Disease Risk Stratification in Browners) (Cardiovascular Disease Risk Stratification in Browners) (Cardiovascular Disease Risk Stratification in Browners) (Cardiovascular Mothing to Disease) (Cardiovascular Mothing	Qureshi	Waqas	Considerations in Antiplatelet Therapy and in	Use of Antiplatelets and Anticoagulants in Septic Patients With	Nothing to Disclose
Non Invasive Imaging: Coronary Calcium	Qureshi	Waqas		Impact of Electrocardiogram Changes on Mortality in Asymptomatic	Nothing to Disclose
Diabetes and Other Issues in Cardiovascular Blood Pressure Indices and Cardiovascular Mortality in Diabetics Prevention and Non Diabetics and Diabetics and Non Diabetics and Diabetics and Non Diabetics and Diab	Qureshi	Waqas	Non Invasive Imaging: Coronary Calcium	Coronary Artery Calcium Scores for Atherosclerotic Cardiovascular	Nothing to Disclose
Waqas Non Invasive Imaging: Role of Exercise Testing Using Machine Learning to Define the Association Between Cardiorespiratory Fines and All-Cause Mortality: The FIT (Henry Ford Exercise Testing) Project	Qureshi	Waqas	Diabetes and Other Issues in Cardiovascular	Blood Pressure Indices and Cardiovascular Mortality in Diabetics	Nothing to Disclose
Risky Business: Predicting Outcomes in Heart Failure: Duyyumi Arshed Get into the Beat! Exercise to Promote CV Health Duyyumi Arshed Get into the Beat! Exercise to Promote CV Health Duyyumi Arshed Get into the Beat! Exercise to Promote CV Health Duyyumi Arshed Get into the Beat! Exercise to Promote CV Health Duyyumi Arshed Get into the Beat! Exercise to Promote CV Health Duyyumi Arshed Imaging the Athlete's Heart Differential American-Style Football Training Intensities and Cardiac Cardiocell; RESEARCH/RESEARCH GRANTS - N Institutes of Health Duyyumi Arshed Imaging the Athlete's Heart Differential American-Style Football Training Intensities and Cardiac Cardiocell; RESEARCH/RESEARCH GRANTS - N Institutes of Health Duyyumi Arshed Imaging the Athlete's Heart Sleep Disordered Breathing and Cardiovascular Correlates in Collegiste American Style Football Participants Duyyumi Arshed Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Redefining the "F" Word Biomarker Profile in Adults With Fontan Circulation Disease Ownership In Interest Part Research Grants - N Institutes of Health Disease Ownership Interest Part Research Grants - N Institutes of Health Disease Ownership Interest Part Research Grants - N Institutes of Health Disease Ownership Interest Part Research Grants - N Institutes of Health Disease Ownership Interest Part Research Grants - N Institutes of Health Disease Ownership Interest Part Research Grants - N Institutes of Health Disease Ownership Interest Part Research Grants - N Institutes of Health Disease Ownership Interest Part Research Grants - N Institutes of Health Disease Ownership Interest Part Research Grants - N Institutes of Health Disease Ownership Interest Part	Qureshi	Waqas		Using Machine Learning to Define the Association Between	Nothing to Disclose
Duyyumi Arshed Get into the Beat! Exercise to Promote CV Health Duyyumi Arshed Get into the Beat! Exercise to Promote CV Health Duyyumi Arshed Get into the Beat! Exercise to Promote CV Health Duyyumi Arshed Get into the Beat! Exercise to Promote CV Health Duyyumi Arshed Get into the Beat! Exercise to Promote CV Health Duyyumi Arshed Imaging the Athlete's Heart Differential American-Style Football Training Intensities and Cardiac CardioCeli; RESEARCH/RESEARCH GRANTS - N Institutes of Health Duyyumi Arshed Imaging the Athlete's Heart Sleep Disordered Breathing and Cardiavascular Correlates in Collegiate American Style Football Participants Duyyumi Arshed Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Redefining the "F" Word Biomarker Profile in Adults With Fontan Circulation Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional Redefining the "F" Word Disease Traditional	Qureshi	Wagas	Risky Business: Predicting Outcomes in Heart	Ford Exercise Testing) Project	Nothing to Disclose
Health Get into the Beat! Exercise to Promote CV Health Duyyumi Arshed Get into the Beat! Exercise to Promote CV Health Differential American-Style Football Training Intensities and Cardiac Arshed Imaging the Athlete's Heart Differential American-Style Football Training Intensities and Cardiac Arshed Imaging the Athlete's Heart Differential American-Style Football Training Intensities and Cardiac Arshed Imaging the Athlete's Heart Differential American-Style Football Training Intensities and Cardiac Arshed Imaging the Athlete's Heart Differential American-Style Football Training Intensities and Cardiac Arshed Imaging the Athlete's Heart Sleep Disordered Breathing and Cardiovascular Correlates in Collegiate American Style Football Participants Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Redefining the "F" Word Biomarker Profile in Adults With Fontan Circulation Traditional Cardio-Cell; RESEARCH/RESEARCH GRANTS - N Institutes of Health OWNERSHIP INTEREST/PARTNERSHIP/PRINCI Cardio-Cell; RESEARCH/RESEARCH GRANTS - N Institutes of Health OWNERSHIP INTEREST/PARTNERSHIP/PRINCI Cardio-Cell; RESEARCH/RESEARCH GRANTS - N Institutes of Health Cardio-Cell; RESEARCH/RESEARCH GRANTS - N Institutes of Health Disease			Failure	The Henry Ford Exercise Testing Project	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Health Arshed Imaging the Athlete's Heart Differential American-Style Football Training Intensities and Cardiac and Vascular Remodeling Patterns Differential American-Style Football Training Intensities and Cardiac and Vascular Remodeling Patterns Duyyumi Arshed Imaging the Athlete's Heart Sleep Disordered Breathing and Cardiovascular Correlates in Institues of Health Institutes of Health Collegiate American Style Football Participants Duyyumi Arshed Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Redefining the "F" Word Biomarker Profile in Adults With Fontan Circulation Duyyumi Arshed Redefining the "F" Word Biomarker Profile in Adults With Fontan Circulation Duyyumi Arshed Redefining the "F" Word Biomarker Profile in Adults With Fontan Circulation Duyyumi Arshed Redefining the "F" Word Biomarker Profile in Adults With Fontan Circulation Duyyumi Arshed Redefining the "F" Word Biomarker Profile in Adults With Fontan Circulation Duyyumi Arshed Redefining the "F" Word Biomarker Profile in Adults With Fontan Circulation Duyyumi Arshed Redefining the "F" Word Biomarker Profile in Adults With Fontan Circulation Duyyumi Arshed Redefining the "F" Word Biomarker Profile in Adults With Fontan Circulation			Health		CardioCell; RESEARCH/RESEARCH GRANTS - National Institues of Health
and Vascular Remodeling Patterns CardioCell; RESEARCH/RESEARCH GRANTS - N Institutes of Health Duyyumi Arshed Imaging the Athlete's Heart Sleep Disordered Breathing and Cardiovascular Correlates in Collegiate American Style Football Participants Duyyumi Arshed Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Redefining the "F" Word Disease Biomarker Profile in Adults With Fontan Circulation Disease Character Breathing and Cardiovascular Disease Institutes of Health DownERSHIP INTEREST/PARTNERSHIP/PRINCI CardioCell; RESEARCH/RESEARCH GRANTS - N Institutes of Health Disease Character Cardiovascular Disease Disease Character Cardiovascular Disease Character Cardiovascular Disease Disease Character Cardiovascular Disease Character Cardiovascular Disease Character Cardiovascular Disease Character Cardiovascular Disease Character Cardiovascular Disease Character Cardiovascular Disease Character Cardiovascular Disease Character Cardiovascular Disease Character Cardiovascular Disease Character Cardiovascular Disease Character Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular			Health		CardioCell; RESEARCH/RESEARCH GRANTS - National Institues of Health
Collegiate American Style Football Participants CardioCell; RESEARCH/RESEARCH GRANTS - N Institute of Health Duyyumi Arshed Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease				and Vascular Remodeling Patterns	CardioCell; RESEARCH/RESEARCH GRANTS - National Institues of Health
the Risk of, and Used for the Treatment of, Coronary Artery Disease Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Updates on Risk Factors for Cardiovascular Disease Updates on Risk Factors for Cardiovascular Disease Arshed Updates on Risk Factors for Cardiovascular Disease Arshed Updates on Risk Factors for Cardiovascular Disease Disease Arshed Updates on Risk Factors for Cardiovascular Disease Disease Disease Arshed Redefining the "F" Word Biomarker Profile in Adults With Fontan Circulation Disease Cardioceli; RESEARCH/RESEARCH GRANTS - N Institutes of Health OWNERSHIP INTEREST/PARTNERSHIP/PRINCI Cardioceli; RESEARCH/RESEARCH GRANTS - N Institutes of Health OWNERSHIP INTEREST/PARTNERSHIP/PRINCI Cardioceli; RESEARCH/RESEARCH GRANTS - N Institutes of Health OWNERSHIP INTEREST/PARTNERSHIP/PRINCI Cardioceli; RESEARCH/RESEARCH GRANTS - N Institutes of Health OWNERSHIP INTEREST/PARTNERSHIP/PRINCI Cardioceli; RESEARCH/RESEARCH GRANTS - N Institutes of Health OWNERSHIP INTEREST/PARTNERSHIP/PRINCI Cardioceli; RESEARCH/RESEARCH GRANTS - N Institutes of Health OWNERSHIP INTEREST/PARTNERSHIP/PRINCI Cardioceli; RESEARCH/RESEARCH GRANTS - N Institutes of Health OWNERSHIP INTEREST/PARTNERSHIP/PRINCI Cardioceli; RESEARCH/RESEARCH GRANTS - N Institutes of Health OWNERSHIP INTEREST/PARTNERSHIP/PRINCI Cardioceli; RESEARCH/RESEARCH GRANTS - N Institutes of Health OWNERSHIP INTEREST/PARTNERSHIP/PRINCI Cardioceli; RESEARCH/RESEARCH GRANTS - N Institutes of Health				Collegiate American Style Football Participants	
the Risk of, and Used for the Treatment of, Coronary Artery Disease Quyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Quyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Quyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Quyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Quyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Quyyumi Arshed Redefining the "F" Word Quyyumi Arshed Redefining the "F" Word Quyyumi Arshed Redefining the "F" Word Disease Quyyumi Arshed Redefining the "F" Word Disease Quyyumi Arshed Redefining the "F" Word Disease Disease Quyyumi Arshed Redefining the "F" Word Disease Disease Disease Disease Quyyumi Arshed Redefining the "F" Word Disease Dis			the Risk of, and Used for the Treatment of, Coronary Artery Disease	Patients With Coronary Artery Disease	
Duyyumi Arshed Updates on Risk Factors for Cardiovascular Disease Central Obesity Predicts Circulating Progenitor Cell Levels OWNERSHIP INTEREST/PARTNERSHIP/PRINCI CardioCell; RESEARCH/RESEARCH GRANTS - N Institues of Health Disease Changes in Body Fat Distribution is Associated With Oxidative Stress OWNERSHIP INTEREST/PARTNERSHIP/PRINCI CardioCell; RESEARCH/RESEARCH GRANTS - N Institues of Health Disease Arshed Redefining the "F" Word Biomarker Profile in Adults With Fontan Circulation OWNERSHIP INTEREST/PARTNERSHIP/PRINCI CardioCell; RESEARCH/RESEARCH GRANTS - N Institues of Health OWNERSHIP INTEREST/PARTNERSHIP/PRINCI CardioCell; RESEARCH/RESEARCH GRANTS - N Institues of Health OWNERSHIP INTEREST/PARTNERSHIP/PRINCI CardioCell; RESEARCH/RESEARCH GRANTS - N Institues of Health	Quyyumi	Arshed	the Risk of, and Used for the Treatment of,		OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioCell; RESEARCH/RESEARCH GRANTS - National Institues of Health
Duyyumi Arshed Updates on Risk Factors for Cardiovascular Changes in Body Fat Distribution is Associated With Oxidative Stress OwnERSHIP INTEREST/PARTNERSHIP/PRINCI CardioCalt; RESEARCH/RESEARCH GRANTS - N Institutes of Health Duyyumi Arshed Redefining the "F" Word Biomarker Profile in Adults With Fontan Circulation OwnERSHIP INTEREST/PARTNERSHIP/PRINCI CardioCell; RESEARCH/RESEARCH GRANTS - N CardioCell; RESEARCH/RESEARCH GRANTS - N CardioCell; RESEARCH/RESEARCH GRANTS - N CardioCell; RESEARCH/RESEARCH GRANTS - N CardioCell; RESEARCH/RESEARCH GRANTS - N CardioCell; RESEARCH/RESEARCH GRANTS - N CardioCell; RESEARCH/RESEARCH GRANTS - N CardioCell; RESEARCH/RESEARCH GRANTS - N CardioCell; RESEARCH/RESEARCH GRANTS - N CardioCell; RESEARCH/RESEARCH GRANTS - N CardioCell; RESEARCH/RESEARCH GRANTS - N CardioCell; RESEARCH/RESEARCH GRANTS - N CardioCell; RESEARCH/RESEARCH GRANTS - N CardioCell; RESEARCH/RESEARCH GRANTS - N CardioCell; RESEARCH/RESEARCH GRANTS - N CARDIOCELL RESEARCH	Quyyumi	Arshed	Updates on Risk Factors for Cardiovascular	Central Obesity Predicts Circulating Progenitor Cell Levels	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioCell; RESEARCH/RESEARCH GRANTS - National
Duyyumi Arshed Redefining the "F" Word Biomarker Profile in Adults With Fontan Circulation OWNERSHIP INTEREST/PARTNERSHIP/PRINCI CardioCell; RESEARCH/RESEARCH GRANTS - N	Quyyumi	Arshed	Disease	Changes in Body Fat Distribution Is Associated With Oxidative Stress	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioCell; RESEARCH/RESEARCH GRANTS - National
	Quyyumi	Arshed	Redefining the "F" Word	Biomarker Profile in Adults With Fontan Circulation	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioCell; RESEARCH/RESEARCH GRANTS - National Institues of Health
Ouyyumi Arshed The Evolving World of LVADs, Transplant and Progenitor Cells and Clinical Outcomes in Patients With Heart OWNERSHIP INTEREST/PARTNERSHIP/PRINCI	Quyyumi	Arshed			OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioCell; RESEARCH/RESEARCH GRANTS - National

Last Name Quyyumi	First Name Arshed	Session Title Unusual Presentations of ACS	Presentation Title Circulating Progenitor Cells Levels and Outcomes in Acute Myocardial Infarction	Disclosures OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioCell; RESEARCH/RESEARCH GRANTS - National
Quyyumi	Arshed	Congenital Heart Disease: To the Third Decade and Beyond	Red Blood Cell Distribution Width and Outcomes in Fontan Patients	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - CardioCell; RESEARCH/RESEARCH GRANTS - National
Raatikainen	Pekka	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Treatment and Outcomes of Patients With Nonvalvular Atrial Fibrillation According to Guideline-Defined Anticoagulation	Institues of Health Nothing to Disclose
Raatikainen	Pekka	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Thresholds: Results From the GARFIELD-AF Registry Risk Assessment of Recurrent Atrial Fibrillation After Antiarrhythmic Medication or Catheter Ablation: The Impact of Age and	Nothing to Disclose
Raaz	Uwe	Uncovering the Intricacies of Vascular Function	Supraventricular Ectopic Complexes Non-Coding RNAs Comprehensively Counteract Adverse Arterial	Nothing to Disclose
Raaz	Uwe	38. Vascular Medicine: Basic Team 2	Remodeling and Stiffening in Type 2 Diabetes Suggested Reviewer	Nothing to Disclose
Rab	Syed	Maintenance of Clinical Competencies in Invasive Coronary Imaging and Coronary Physiology	Co-Chair	Nothing to Disclose
Rab	Syed	02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Rabbani	Leroy	Clinical Team 1 02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	OTHER - device companies and drug companies- multicenter
Rabbat	Mark	Clinical Team 2 Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Fractional Flow Reserve Derived From Coronary Computed Tomography Safely Reduces Invasive Coronary Angiography Rates	clinical trials-CIVT-Columbia University Medical Center Nothing to Disclose
Rabbat	Mark	Coronary Artery Disease Non Invasive Imaging: Expanding Clinical Applications	and Cost in Patients With Stable Coronary Artery Disease Aortic Valve Calcification Predicts Paravalvular Aortic Regurgitation After Self-Expanding Transcatheter Aortic Valve Replacement	Nothing to Disclose
Rabbat	Mark	Unusual Presentations of ACS	Incidence and Predictors of Lesion Specific Ischemia by	Nothing to Disclose
			FFR _{CT} : Learnings From the International ADVANCE Registry	Nothing to Disclose
Räber	Lorenz	Timely Topics in Acute Coronary Syndromes	Gender-Related Outcomes in Elderly (> 75 Years) Patients Presenting With Acute Coronary Syndromes: Results From the Swiss Acute Coronary Syndrome Cohort	, and the second
Rabinowitz	Edon	Congenital Heart Disease Surgery: Updates and Innovations	Promoting Pulmonary Arterial Growth via Right Ventricular to Pulmonary Artery Conduit Placement in Children With Pulmonary Atresia and Hypoplastic Pulmonary Arteries	Nothing to Disclose
Rached	Fabiana	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	High Non-High-Density Lipoprotein Cholesterol Levels Predict Enhanced Periprocedural Inflammatory Response Following Percutaneous Coronary Intervention in Stable Ischemic Heart Disease Patients	Nothing to Disclose
Racine	Normand	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Changes in Prevalence, Progression and Outcomes of Coronary Allograft Vasculopathy Over 25 Years Following Cardiac Transplantation: A Single Center Experience	Nothing to Disclose
Rade	Jeffrey	Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI	Non-Platelet Thromboxane Generation Is an Independent Predictor of Late-Term Mortality After Coronary After Bypass Graft Surgery	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Gener Electric; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,capricor,lschemix,PLC Medical Systems
Rade	Jeffrey	01. Acute and Stable Ischemic Heart Disease: Basic Team 1	Suggested Reviewer	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Gener Electric; RESEARCH/RESEARCH GRANTS - Abbott
Rader	Daniel	Advances in Cholesterol Measurement and Management	Efficacy and Safety of the PCSK9 Inhibitor Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin Therapy	Laboratories, capricor, Ischemix, PLC Medical Systems CONSULTANT FEES/HONORARIA - Aegerion Pharmaceuticals, Alnylam, Eli Lilly, Medlmmune, Inc, Novartis, Pfizer; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Staten Bio, VascularStrategies
Radford	Martha	02. Acute and Stable Ischemic Heart Disease: Clinical Team 4	Suggested Reviewer	Nothing to Disclose
Radi	Basuni	Emerging CV Problems in the Developing World: International Perspectives From the ACC Bangladesh Chapter, Indonesian Heart Association, and American College of Cardiology	Cardiac Rehabilitation in a Tertiary Center Hospital: Lessons From a Developing Country	Nothing to Disclose
Radjenovic	Aleksandra	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Prognostic Significance of Co-Existing Persistent Edema and Hemorrhage at 6 Months in Survivors of ST-Elevation Myocardial Infarction	Nothing to Disclose
Radjenovic	Aleksandra	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Current Smoking, Microvascular Pathology and Adverse Outcome After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights	Nothing to Disclose
Radjenovic	Aleksandra	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Hypertension, Microvascular Pathology and Prognosis in Patients With an Acute ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Radtke	Wolfgang	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease		CONSULTANT FEES/HONORARIA - Otsuka Pharmaceuticals,St.Jude Medical/AGA Medical Corporation
Radtke	Wolfgang	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	A Giant Strikes Back: Recurrent Thrombosis of Recanalized Giant Aneursym in Kawasaki Disease	CONSULTANT FEES/HONORARIA - Otsuka Pharmaceuticals,St.Jude Medical/AGA Medical Corporation
Radu	Dan-Andrei	Disease, and Vascular Medicine Arrhythmias and Clinical EP: Devices 2	Left Bunde Branch Block Is Incomplete in the Majority of Patients With Heart Failure Due to Systolic Left Ventricle Dysfunction: A	Nothing to Disclose
Raeisi-Giglou	Pejman	Non Invasive Imaging: MR Scar and Perfusion	Simple Intraprocedural Demonstration Incremental Prognostic Utility of Late Gadolinium Enhancement in	Nothing to Disclose
Raff	Gilbert	Non Invasive Imaging: Applications in Novel	Hypertrophic Cardiomyopathy Is There an Association Between Vitamin D Deficiency and Disease	RESEARCH/RESEARCH GRANTS - Heartflow
Raff	Gilbert	Disease States and Clinical Scenarios Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta,	Severity on Coronary CT Angiography? Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography. The	RESEARCH/RESEARCH GRANTS - Heartflow
- "		Artery and Anomalous?	CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) Registry	
Raff	Gilbert	Non Invasive Imaging: Prognostic Implications of CT Angiography	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	RESEARCH/RESEARCH GRANTS - Heartflow
Raff	Gilbert	Unusual Presentations of ACS	Incidence and Predictors of Lesion Specific Ischemia by FFR _{CT} : Learnings From the International ADVANCE	RESEARCH/RESEARCH GRANTS - Heartflow
Raff	Gilbert	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team	Registry Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Heartflow
Dobbi	Hazim	1	Biveligudia Versus Hanger- in Driver - DOI: Clinical Control	Nothing to Disclose
Rahbi	Hazim	Considerations in Antiplatelet Therapy and in ACS	Bivalirudin Versus Heparin in Primary PCI: Clinical Outcomes and Cost Analysis From a Large Retrospective Cohort	Nothing to Disclose
Rahbi	Hazim	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Predictors of Survival From Out-of-Hospital Cardiac Arrest	Nothing to Disclose

Last Name Rahman				•
	First Name	Session Title	Presentation Title	Disclosures
Railliall	Afzalur	Emerging CV Problems in the Developing World: International Perspectives From the	Co-Chair	Nothing to Disclose
		ACC Bangladesh Chapter, Indonesian Heart		
		Association, and American College of		
		Cardiology		
Rahmani	Maziar	Arrhythmias and Clinical EP: Devices 2	Chagas Heart Disease: A Comparison of Clinical and Intraoperative Pacing Parameters	Nothing to Disclose
Rahmani	Sina	Non Invasive Imaging: Applications in Novel	Impact of Cardiac Troponin I on the Presence of the Coronary	Nothing to Disclose
		Disease States and Clinical Scenarios	Artery Plaque in Rheumatoid Arthritis patients	Ÿ
Rahmani	Sina	Non Invasive Imaging: Expanding Clinical	The Utility of Left Atrial Appendage Hounsfield Unit and the Ratio of	Nothing to Disclose
		Applications	Left Atrial Appendage/Ascending Aorta Hounsfield Unit for Detecting Left Atrial Appendage Thrombus	
Rahmani	Sina	Non Invasive Imaging: Expanding Clinical	The Association of Ischemia on Single Photon Emission Computed	Nothing to Disclose
		Applications	Tomography-Myocardial Perfusion Image and Fractional Flow	
			Reserve by Coronary Computed Tomographic Angiography	
Rahmani	Sina	Non Invasive Imaging: Coronary Calcium	Prognostic Value of Protein Biomarkers Predict Risk of Coronary	Nothing to Disclose
		Scoring and CV Risk Assessment	Heart Disease Events: Results From Multi-Ethnic Study of	
			Atherosclerosis (MESA)	
Rahmani	Sina	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Total Testosterone With Progression of Carotid Atherosclerosis and Coronary Artery Calcium Score: The Multi-	Nothing to Disclose
		Scoring and CV Risk Assessment	Ethnic Study of Atherosclerosis	
Rahmani	Sina	Non Invasive Imaging: Coronary Calcium	Association of Coronary Artery Calcium Progression With Coronary	Nothing to Disclose
		Scoring and CV Risk Assessment	Plaque Progression Determined by Quantitative Coronary Artery	
Rahmani	Sina	Non Invasive Imaging: Coronary Calcium	Plaque Analysis ­The Utility of Minimal Coronary Artery Calcification for	Nothing to Disclose
i varii i arii	Silia	Scoring and CV Risk Assessment	Predicting Carotid Artery Disease: Results From the Multi-Ethnic	Nothing to Disclose
		ŭ	Study of Atherosclerosis (MESA)	
Rahmani	Sina	Innovations in Cardiovascular Risk Assessment	Association of Coronary Calcium, Carotid Wall Thickness and	Nothing to Disclose
		and Reduction	Carotid Plaque Progression With Low Density Lipoprotein and High Density Lipoprotein Particle Concentration Measured by Ion Mobility	
			Testing: The Multi-Ethnic Study of Atherosclerosis (MESA)	
D	District	Number of the Control		Notice to Produce
Raijmakers	Pieter	Nuclear Cardiology: Quality	Automatic SPECT Analysis Compared to Expert Visual Scoring for the Detection of Coronary Artery Disease	Nothing to Disclose
Raijmakers	Pieter	Advances in Chronic Total Occlusion	Effects of Successful Percutaneous Coronary Intervention of	Nothing to Disclose
1, 1, 1, 1, 1, 1		Intervention	Chronic Total Occlusions on Myocardial Perfusion and Left	<u> </u>
Deline et : ::	Dieter	Nacional Assessment (C	Ventricular Function	Nething to Displace
Raijmakers	Pieter	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Atherosclerotic Plaque Morphology Is Associated With Impaired Myocardial Blood Flow and Fractional Flow Reserve, Independent	Nothing to Disclose
		reserve. Officeal implications	of Luminal Obstruction	
Raina	Amresh	Non Invasive Imaging: MR Heart Failure and	Non-Invasive Quantification of Cardiac Output With Phase Velocity	CONSULTANT FEES/HONORARIA - Actelion, Gilead Sciences,
		Pulmonary Hypertension	Mapping in Patients With Pulmonary Hypertension	Inc. ,United Therapeutics; SPEAKER'S BUREAU - Bayer
Raina	Sameer	Valvular Heart Disease: Endocarditis	Trend and Outcomes of Infective Endocarditis Treated With Surgical	Healthcare Pharmaceuticals Nothing to Disclose
rtania	Camedi	Varvalar Floari Biocaco. Enacoaralio	Valvular Replacement Insight From the Nationwide Inpatient	Trouming to Discusse
			Sample	
Raina	Sameer	Outcomes in Valvular Heart Disease	Increasing Healthcare Resource Utilization After Valve Replacement Surgery in the United States	Nothing to Disclose
Raina	Sameer	Valvular Heart Disease With CKD or Cirrhosis	Trends and Outcomes of Aortic Valve Replacement in Patient With	Nothing to Disclose
			End Stage Renal Disease on Hemodialysis: A 10-Year U.S.	3
			Perspective	
Rajadorai	Jeyamalar	From Cardiovascular Risk Factors to Acute and Stable Coronary Syndrome: International	Malaysian Clinical Practice Guidelines on Management of Acute Coronary Syndrome and Relevant Data From the Malaysian	Nothing to Disclose
		Perspectives From the Inter-American Society	National Cardiovascular Disease Registry NCVD ACS	
			9 ,	
		of Cardiology, National Heart Association of		
		of Cardiology, National Heart Association of Malaysia, and American College of Cardiology		
Rajagonalan	Rharath	Malaysia, and American College of Cardiology	Co_Chair	Nothing to Disclose
Rajagopalan Rajagopalan	Bharath Bharath		Co-Chair ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan		Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With	
Rajagopalan	Bharath	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Rajagopalan Rajagopalan	Bharath Navin	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain	Nothing to Disclose Nothing to Disclose
Rajagopalan	Bharath	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With	Nothing to Disclose
Rajagopalan Rajagopalan	Bharath Navin	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the	Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan	Bharath Navin Navin	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape	Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan	Bharath Navin Navin Priya	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan	Bharath Navin Navin Priya Sanjay Sanjay	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan	Bharath Navin Navin Priya Sanjay	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology; Angiography,	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan	Bharath Navin Navin Priya Sanjay Sanjay	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan	Bharath Navin Navin Priya Sanjay Sanjay	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology; Angiography,	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan	Bharath Navin Navin Priya Sanjay Sanjay Anil	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Anglography, Intravascular Imaging and Interventional CT/MR	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajappan	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan	Bharath Navin Navin Priya Sanjay Sanjay Anil	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Anjorgraphy, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carotto Plaque Is Predictive of Cardio Vascular Events in	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajappan	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carotid Plaque Is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajapopalan Rajapopalan Rajapopal	Bharath Navin Navin Priya Sanjay Sanjay Anil Roby	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carotid Plaque Is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbC/Beta-Thalassemia Patients With Pulmonary Arterial	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajapopal Rajaphan Rajaphan	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh Roby Teewin	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carotid Plaque Is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Sanofi-Aventis
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajapopalan Rajapopalan Rajapopal	Bharath Navin Navin Priya Sanjay Sanjay Anil Roby	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carotid Plaque Is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Hypertension Linical Burden and Cost Analysis of Pulmonary Hypertension in	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajappan Rajaphan Rajaphan Rajaphan Rajaphan Rajaphan Rajaphan	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh Roby Teewin	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Health Failure Management FIT Clinical Besides of Management FIT Clinical States and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Anglioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Biosans: Carotid Plaque Is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbC/Beta-Thalassemia Patients With Pulmonary Arterial Hypertension Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Research/Research Grants - Sanofi-Aventis Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajapopal Rajaphan Rajaphan	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh Roby Teewin	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MIR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases FIT Clinical Decision Making: Interventional	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carotid Piaque is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbC/Beta-Thalassemia Patients With Pulmonary Arterial Hypertension Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Sanofi-Aventis
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajappan Rajaphan Rajaphan Rajaphan Rajaphan Rajaphan Rajaphan	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh Roby Teewin	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Anglioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Biosans: Carotid Plaque Is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbC/Beta-Thalassemia Patients With Pulmonary Arterial Hypertension Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Research/Research Grants - Sanofi-Aventis Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajapan Rajapan Rajapan Rajapan Rajapan Ram	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh Roby Teewin	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carotid Plaque is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inlandel Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Hypertension Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Sanofi-Aventis Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajappan Rajappan Rajappan Rajappan Rajapan Rajapan Rajapan Rajapan Rajapan Rajapan	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh Roby Teewin Pradhum Pradhum Suresh	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine PCI for NSTEMI and Compilex Patients With Multiple Co-Mortbidities	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Anglioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carotid Plaque Is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula Percutaneous Coronary Intervention (PCI) Outcomes and Hospital Outliers in California	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Sanofi-Aventis Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajapopalan Rajapopalan Rajapopalan Rajapopalan Rajarapan Rajarapan Ram Ram	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh Roby Teewin Pradhum Pradhum Suresh Gabriel	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MIR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine PCI for NSTEMI and Complex Patients With Multiple Co-Morbiolities Innovations in Education	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carrotid Plaque Is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Hypertension Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Diseases: A Cross Sectional Study From the National Inpatient Sample Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula Percutaneous Coronary Intervention (PCI) Outcomes and Hospital Outliers in California Fellow Outpetient Clinic: Discontinuing the Discontinuity	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajappan Rajappan Rajappan Rajappan Rajapan Rajapan Rajapan Rajapan Rajapan Rajapan	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh Roby Teewin Pradhum Pradhum Suresh	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine PCI for NSTEMI and Compilex Patients With Multiple Co-Mortbidities	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carotid Plaque Is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula Percutaneous Coronary Intervention (PCI) Outcomes and Hospital Outliers in California Fellow Outpatient Clinic: Discontinuing the Discontinuity Effect of Left Atrial Remodeling on Prediction of Incident Atrial	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Sanofi-Aventis Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajapopalan Rajapan Rajapan Ram Ram	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh Roby Teewin Pradhum Pradhum Suresh Gabriel	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MIR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine PCI for NSTEMI and Complex Patients With Multiple Co-Morbiolities Innovations in Education	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carrotid Plaque Is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Hypertension Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Diseases: A Cross Sectional Study From the National Inpatient Sample Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula Percutaneous Coronary Intervention (PCI) Outcomes and Hospital Outliers in California Fellow Outpetient Clinic: Discontinuing the Discontinuity	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajapopalan Rajapan Rajapan Ram Ram	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh Roby Teewin Pradhum Pradhum Suresh Gabriel	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MIR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine PCI for NSTEMI and Complex Patients With Multiple Co-Morbiolities Innovations in Education	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angloplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carotid Plaque Is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Prometics With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula Percutaneous Coronary Intervention (PCI) Outcomes and Hospital Outliers in California Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Discontinuity Left Artial Remodeling on Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study Left Artial Remodeling on Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajappan Rajappan Rajam Rajappan Ram Ram Ram Rama Rama Rama	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh Roby Teewin Pradhum Pradhum Suresh Gabriel Vasan	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities Innovative Use of Echocardiography	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carrotid Plaque Is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Hypertension Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula Percutaneous Coronary Intervention (PCI) Outcomes and Hospital Outliers in California Fellow Outpatient Clinic: Discontinuing the Discontinuity Effect of Left Atrial Remodeling on Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Sanofi-Aventis Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajappan Rajappan Rajappan Rama Rama Rama Rama Ramachandran	Bharath Navin Navin Priya Sanjay Sanjay Sanjay Anil Saurabh Teewin Pradhum Pradhum Suresh Gabriel Vasan	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities Innovative Use of Echocardiography Innovative Use of Echocardiography	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carottd Plaque Is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Hypertension Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula Percutaneous Coronary Intervention (PCI) Outcomes and Hospital Outliers in California Fellow Outpatient Clinic: Discontinuing the Discontinuity Effect of Left Atrial Remodeling on Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study Left Atrial Function Index as a Predictor of Cardiovascular Disease and Atrial Fibrillation: Data From the Framingham Offspring Study	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Sanofi-Aventis Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajappan Rajappan Rakhit Rakyhao Ram Ram Ram Rama	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh Roby Teewin Pradhum Pradhum Suresh Gabriel Vasan	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities Innovative Use of Echocardiography	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angloplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carotid Plaque Is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Prometics With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula Percutaneous Coronary Intervention (PCI) Outcomes and Hospital Outliers in California Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Discontinuity Left Artial Remodeling on Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study Left Artial Remodeling on Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Sanofi-Aventis Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajappan Rajappan Rajappan Rajappan Rakhit Rakyhao Ram Ram Ram Rama Ramachandran Ramachandran	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh Roby Teewin Pradhum Pradhum Suresh Gabriel Vasan Vasan Ronnie	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities Innovative Use of Echocardiography Innovative Use of Echocardiography Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Diseases	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Anglioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carotid Plaque Is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Prometics With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula Percutaneous Coronary Intervention (PCI) Outcomes and Hospital Outliers in California Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study Left Arrial Remodeling on Prediction of Incident Atrial Fibrillation: Data From the Framingham Offspring Study Inflammatory Response to Mental Stress and Mental Stress Induced Myocardial Ischemia	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Sanofi-Aventis Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajappan Rajaphan Rajaphan Rajaphan Rajaphan Rakhit Rakyhao Ram Ram Ram Ram Ram Rama Ramachandran	Bharath Navin Navin Priya Sanjay Sanjay Sanjay Anil Saurabh Teewin Pradhum Pradhum Suresh Gabriel Vasan	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Anglography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Anglography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine PCI for NSTEMI and Complex Patients With Multiple Co-Morbiotidies Innovations in Education Innovative Use of Echocardiography Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease New Perspectives on Structural Valve Disease:	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carrotid Plaque is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Hypertension Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula Percutaneous Coronary Intervention (PCI) Outcomes and Hospital Outliers in California Fellow Outpatient Clinic: Discontinuing the Discontinuity Effect of Left Atrial Remodeling on Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study Left Atrial Function Index as a Predictor of Cardiovascular Disease and Atrial Fibrillation: Data From the Framingham Offspring Study Inflammatory Response to Mental Stress and Mental Stress Induced Myocardial Ischemia	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Sanofi-Aventis Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajappan Rajaphan Rajapan Rajapan Rama Rama Rama Rama Rama Ramachandran Ramadan	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh Roby Teewin Pradhum Pradhum Suresh Gabriel Vasan Vasan Ronnie	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine PCI for NSTEMI and Complex Patients With Multiple Co-horbidities Innovative Use of Echocardiography Innovative Use of Echocardiography Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease New Perspectives on Structural Valve Disease.	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Anglioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carotid Plaque Is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Prometics With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula Percutaneous Coronary Intervention (PCI) Outcomes and Hospital Outliers in California Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Discontinuity Fellow Outpatient Clinic: Discontinuing the Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study Left Arrial Remodeling on Prediction of Incident Atrial Fibrillation: Data From the Framingham Offspring Study Inflammatory Response to Mental Stress and Mental Stress Induced Myocardial Ischemia	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Sanofi-Aventis Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajappan Rajappan Rajapan Rama Rama Rama Rama Rama Ramachandran Ramadan	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh Roby Teewin Pradhum Pradhum Suresh Gabriel Vasan Vasan Ronnie	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities Innovative Use of Echocardiography Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease New Perspectives on Structural Valve Disease: International Perspectives From the Emirates Cardiac Society, Latin American Society of Interventional Cardiology (SOLACI), and	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carrotid Plaque is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Hypertension Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula Percutaneous Coronary Intervention (PCI) Outcomes and Hospital Outliers in California Fellow Outpatient Clinic: Discontinuing the Discontinuity Effect of Left Atrial Remodeling on Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study Left Atrial Function Index as a Predictor of Cardiovascular Disease and Atrial Fibrillation: Data From the Framingham Offspring Study Inflammatory Response to Mental Stress and Mental Stress Induced Myocardial Ischemia	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Sanofi-Aventis Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajagopalan Rajappan Rajappan Rajappan Rajappan Rakhit Rakyhao Ram Ram Ram Rama Ramachandran Ramachandran	Bharath Navin Navin Priya Sanjay Sanjay Anil Saurabh Roby Teewin Pradhum Pradhum Suresh Gabriel Vasan Vasan Ronnie	Malaysia, and American College of Cardiology FIT Forum: Mix and Mingle FIT Clinical Decision Making Reviewers 1 Novel Echocardiographic Methods for Assessing Cardiac Function The Great K Debate Continues: Updates and Controversies in Heart Failure Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine FIT Forum: Mix and Mingle Role of Imaging in Peripheral Artery Disease Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MIR Things That Matter in Adult Congenital Heart Disease Non Invasive Imaging: Prognostic Implications of CT Angiography Advances in Pulmonary Arterial Hypertension Predicting the Future: Observations and Discoveries From Registries and Databases FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine PCI for NSTEMI and Complex Patients With Multiple Co-Morbiolities Innovations in Education Innovative Use of Echocardiography Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease New Perspectives on Structural Valve Disease: International Perspectives From the Emirates Cardiac Society, Latin American Society of	ACC FIT Clinical Decision Making Reviewer Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain Review the Current Landscape ST Elevation Myocardial Infarction in a Young Adult: Expect the Unexpected Basic Science Application of CT Imaging for PAD Pilot Study of Dynamic Coronary Roadmap During Coronary Angioplasty Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank Carrotid Plaque is Predictive of Cardio Vascular Events in Asymptomatic Diabetes: A Prospective Study Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Hypertension Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula Percutaneous Coronary Intervention (PCI) Outcomes and Hospital Outliers in California Fellow Outpatient Clinic: Discontinuing the Discontinuity Effect of Left Atrial Remodeling on Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study Left Atrial Function Index as a Predictor of Cardiovascular Disease and Atrial Fibrillation: Data From the Framingham Offspring Study Inflammatory Response to Mental Stress and Mental Stress Induced Myocardial Ischemia	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose RESEARCH/RESEARCH GRANTS - Sanofi-Aventis Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose

and the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Ramakrishna	Harish	Antithrombotic Therapy in Ischemic Heart Disease	Role of Anticoagulation Therapy After Anterior Wall ST-Elevation Myocardial Infraction in Preventing LV Thrombus: A Meta-Analysis and Meta-Regression	Nothing to Disclose
Ramalingam	Tirunelveli	The Inside View: Learning From Intracoronary Imaging	Hybrid IVUS/OCT: "Probing" the Future	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - OCT Medical Imaging Inc
Raman	Subha	Role of Imaging in Peripheral Artery Disease	Role of Contrast and Non-Contrast MR in PAD	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - EXCMR; RESEARCH/RESEARCH GRANTS - Siemens
Raman	Subha	Non Invasive Imaging: Expanding Clinical Applications	Non-Contrast Quantification of Myocardial Fibrosis With Dual Energy Computed Tomography	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - EXCMR: RESEARCH/RESEARCH GRANTS - Siemens
Raman	Subha	Acute Heart Failure: Evaluating Strategies to	Risk of Hospitalization or Death Due to Heart Failure With Intensive	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
		Prevent Readmissions	Glucose-Lowering Therapy in Diabetic Women: Subgroup Analyses by History of Cardiovascular Disease in the ACCORD Trial	ROLE - EXCMR; RESEARCH/RESEARCH GRANTS - Siemens
Raman	Subha	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Misleading Leads: Hemothorax From Very Late Spontaneous Coronary Sinus Lead Perforation 13 Years After CRT-D Implantation	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - EXCMR; RESEARCH/RESEARCH GRANTS - Siemens
Raman	Subha	29. Non Invasive Imaging: MR Team 2	Suggested Reviewer	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - EXCMR; RESEARCH/RESEARCH GRANTS - Siemens
Ramanathan	Kodangudi	Antithrombotic Therapy in Ischemic Heart Disease	Shorter- Versus Longer-Duration Triple Antithrombotic Therapy for Patients With Coronary Stents Who Require Oral Anticoagulation: An Updated Comprehensive Meta-Analysis	Nothing to Disclose
Ramanathan	Kodangudi	Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells	An Updated Comprehensive Meta-Analysis of Randomized Trials Evaluating the Efficacy of Stem Cell Therapy for Refractory Angina	Nothing to Disclose
Ramanathan	Krishnan	Coronary Angiography, Intra-Vascular Imaging,		Nothing to Disclose
Ramaswamy	Sharan	Revascularization and Outcomes Congenital Heart Disease: Progress in	Cardiac Troponin-I: A Retrospective Analysis Early Hydrodynamic Assessment of Intestinal Sub-Mucosa	Nothing to Disclose
Rambihar	Sherryn	Pediatric Heart Surgery Innovations in Education	Bioscaffold for Mitral Valve Replacement Echo Milestones: A Novel Simulation-Based Echocardiography	Nothing to Disclose
			Competence Tool for Formative Assessment in Cardiology Training	
Rambod	Mehdi	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	New-Onset Platypnea Orthodeoxia and Old Patent Foramen Ovale: Close It or Not to Close It?	Nothing to Disclose
Rambod	Mehdi	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Looking for a Clot: Paget-Schroetter Syndrome as Cause of Chronic Thromboembolic Pulmonary Hypertension	
Rame	J.	The OMICS in Pulmonary Hypertension	Co-Chair	CONSULTANT FEES/HONORARIA - Actelion Pharmaceuticals, Bayer Pharmaceuticals; RESEARCH/RESEARCH GRANTS - HeartWare Corporation, Thoratec Corporation, United Therapeutics
Rame	J.	The Forgotten Chamber: The Right Ventricle in Heart Failure	RV Failure in HFrEF: Managing Failure From Both Sides	CONSULTANT FEES/HONORARIA - Actelion Pharmaceuticals,Bayer Pharmaceuticals; RESEARCH/RESEARCH GRANTS - HeartWare
Rame	J.	13. Heart Failure and Cardiomyopathies: Clinical Team 8	Suggested Reviewer	Corporation,Thoratec Corporation,United Therapeutics CONSULTANT FEES/HONORARIA - Actelion Pharmaceuticals,Bayer Pharmaceuticals; RESEARCH/RESEARCH GRANTS - HeartWare
Ramee	Stephen	Controversies Surrounding TAVR: 2017 and Beyond	Management of Concomitant CAD: When to Leave Versus Tackling the Disease Preoperatively	Corporation,Thoratec Corporation,United Therapeutics CONSULTANT FEES/HONORARIA - Edwards,MEDTRONIC; OTHER - Ocular Therapeutics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Large Bore,
Ramee	Stephen	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Transcatheter Aortic Valve Replacement for Aortic Regurgitation as a Bridge for Combined Liver and Kidney Transplantation	LLC, Marvenray CONSULTANT FEES/HONORARIA - Edwards, MEDTRONIC; OTHER - Ocular Therapeutics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Large Bore,
Ramee	Stephen	Interventional Cardiology: TAVR 2	Transcatheter Aortic Valve Replacement in End Stage Liver Disease	LLC, Marvenray CONSULTANT FEES/HONORARIA - Edwards, MEDTRONIC; OTHER - Ocular Therapeutics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Large Bore,
Ramee	Stephen	FIT Clinical Decision Making: Acute Coronary Syndrome and Vascular Medicine	ACC Poster Moderator	LLC, Marvenray CONSULTANT FEES/HONORARIA - Edwards, MEDTRONIC; OTHER - Ocular Therapeutics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Large Bore,
Ramee	Stephen	02. Acute and Stable Ischemic Heart Disease: Clinical Team 4	Suggested Reviewer	LLC, Marvenray CONSULTANT FEES/HONORARIA - Edwards, MEDTRONIC; OTHER - Ocular Therapeutics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Large Bore,
Ramires	Felix	Population Specific Cardiomyopathies: From Exomes to Databases	Air Pollution in Myocardial Remodeling	LLC,Marvenray Nothing to Disclose
Ramires	Jose		Cost-Effectiveness Analysis and Quality of Life of On-Pump and Off- Pump Stable Multivessel Coronary Artery Bypass Grafting: MASS III	Nothing to Disclose
Ramires	Jose	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Trial 5-Year Follow-Up The Role of Oral Beta Blocker in a Real-World Population With Non- ST Segment Elevation Acute Coronary Syndromes	Nothing to Disclose
Ramires	Jose	Antithrombotic Therapy in Ischemic Heart Disease	Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery	Nothing to Disclose
Ramirez	Juan	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Disease Holter Findings in Orthotopic Heart Transplantation Patients: Results From a Cohort of the Most Important Heart Transplant Referral	Nothing to Disclose
Ramirez Del Val	Fernando	Interventional Cardiology: TAVR 3	Center in Colombia, South America The Incidence of Permanent Pacemaker Implantation With SAPIEN 3 Heart Valve - Implantation Depth: The Higher the Better?	Nothing to Disclose
Ramkumar	Satish		Left Atrial Function and Role in Prediction of Heart Failure	Nothing to Disclose
Ramkumar	Satish	Elevated Blood Pressure Innovative Use of Echocardiography	Independent Association of Atrial Mechanics With Risk of Incident	Nothing to Disclose
Ramlawi	Basel	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional	Atrial Fibrillation Technique and Utility of CT Angiography Fluoroscopy Image Fusion to Guide Percutaneous Pulmonary Valve Implantation in Adults	CONSULTANT FEES/HONORARIA - Atricure Inc.,Sorin; RESEARCH/RESEARCH GRANTS - Baxter Inc.,Medtronic Inc.
Ramm	Cassandra	CT/MR Emerging Applications of Echocardiography	Association Between Global Echocardiography-Based Cardiac Calcium Score and the Clinical Outcomes After Transcatheter	Nothing to Disclose
Ramos	Auristela	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Aortic Valve Replacement Independent Pre Procedural Echocardiographic Predictors of Mitral Valve Restenosis After Percutaneous Mitral Balloon Valvuloplasty in a Large Consecutive Cohort Followed Up to Two Decades	Nothing to Disclose
Ramos	Auristela	Interventional Cardiology: Structural Heart	Initial Results and Long-Term Follow-Up of Percutaneous Mitral	Nothing to Disclose
Ramos	Auristela	Disease Frontiers in Mitral Valve Disease and	Valvuloplasty in Patients With Pulmonary Hypertension Predictors of Immediate and Very Late Events After Percutaneous	Nothing to Disclose
	1	Treatment	Mitral Valvuloplasty	-

Last Name	First Name	Session Title	Presentation Title	Disclosures
Ramos	Lafayete	Innovations in Advocacy and Patient Centered Care	What Is the Importance of Preoperative Electrocardiogram in Hypertensive Patients for Moderate/High Risk Noncardiac Surgery?	Nothing to Disclose
Ramos Bondy	Beatrix	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	A Single-Center Randomized Study An Updated Comprehensive Meta-Analysis Comparing Drug-Eluting Stents With Bare Metal Stents in Saphenous Vein Graft	Nothing to Disclose
Ramos Bondy	Beatrix	Ventricular Arrhythmias and Sudden Death Prevention	Interventions Prophylactic Defibrillator Implantation in Patients With Non-Ischemic Cardiomyopathy: An Updated Comprehensive Meta-Analysis of	Nothing to Disclose
Rampal	Upamanyu	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Randomized Controlled Trials Left Ventricular Dilation: Patent Ductus Arteriosus Versus Chronic Severe Mitral Regurgitaiton	Nothing to Disclose
Rampal	Upamanyu	FIT Clinical Decision Making: Arrhythmias and	Ventricular Tachycardia in a Patient With Coexisting Brugada	Nothing to Disclose
Rampal	Upamanyu	Electrophysiology New Technologies in Echocardiography	Syndrome and Coronary Vasospasm Left Atrial Volume Index Over Late Diastolic Mitral Annular Velocity: A New Non-Invasive Parameter for Measurement of Left Ventricular	Nothing to Disclose
Ramu	Vijay	FIT Clinical Decision Making: Arrhythmias and	End Diastolic Pressure A Rare Cause of Syncope	Nothing to Disclose
Ramu	Vijay	Electrophysiology FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	A Rare Case of Rupture of Sinus of Valsalva Into Right Atrium	Nothing to Disclose
Ramzy	Danny	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries	Nothing to Disclose
Rana	Jamal	Updates in Stable Ischemic Heart Disease	Predictors of Long-Term Resource Utilization After Incident Percutaneous Coronary Intervention	Nothing to Disclose
Rana	Jamal	Updates on Risk Factors for Cardiovascular Disease	Levels of Obesity and Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Community-Based Cohort	Nothing to Disclose
Rana	Jamal	Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools	Association of 10-Year Change in Cardiovascular Risk Factors With Progression of Pericardial Adipose Tissue: The CARDIA Study	Nothing to Disclose
Rana Ranadive	Jamal Nandkishara	32. Prevention: Clinical Team 2	Suggested Reviewer	Nothing to Disclose SPEAKER'S BUREAU - Bristol-Myers Squibb Company
	Nandkishore	Innovations in Practice Management and Social Media	Unlocking the Power of Data: Information Technology Implementation for Smarter Management and Resource Use for Today's Complex Care Delivery	, , , ,
Randall Randhawa	Otelio Ekamjeet	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door FIT Clinical Decision Making: Heart Failure and	Comparative Effects of Metoprolol and Nebivolol on Blood Pressure Control in African-Americans Management of Massive Hemoptysis in Post Chemotherapy Post	Nothing to Disclose Nothing to Disclose
		Pulmonary Hypertension	Transplant Patient With Extracorporeal Membrane Oxygenation (ECMO)	-
Randolph	Tiffany	Insights From Echocardiography Use	Universal Use of Contrast to Detect Left Ventricular Thrombus in Patients With Reduced Ejection Fraction Is Not Associated With Improved Clinical or Cost-Effectiveness Outcomes	Nothing to Disclose
Rane	Pallavi	Advances in Lipid Management	Cardiologist Perspectives in Treatment of Dyslipidemia Patients With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Other Lipid Lowering Therapies	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Amgen Inc.; SALARY - Amgen Inc.
Rane	Pallavi	Advances in Lipid Management	Persistence and Adherence With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Clinical Practice	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Amgen Inc.; SALARY - Amgen Inc.
Rane	Pallavi	Innovations in Advocacy and Patient Centered Care	Characteristics of Patients Approved and Denied Access to PCSK9i Therapy by Payers	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Amgen Inc.; SALARY - Amgen Inc.
Rane	Pallavi	Diabetes and Other Issues in Cardiovascular	Clinical Characteristics of Early Adopters of Proprotein Convertase	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Amgen Inc.; SALARY - Amgen Inc.
Rangan	Bavana	Prevention Highlighted Original Research: Prevention and the Year in Review	Subtilisin/Kevin Type 9 inhibitors (PCSK9i) The Effect of Proprotein Convertase Subtilisin-Kevin Type 9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 16,721 Patients From 33	RESEARCH/RESEARCH GRANTS - Infraredx Inc.,The Spectranetics Corporation
Rangan	Bavana	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Randomized Clinical Trials Contemporary Use of Laser During Percutaneous Coronary Intervention: Results From the Laser Veterans Affairs (LAVA) Multicenter Registry	RESEARCH/RESEARCH GRANTS - Infraredx Inc.,The Spectranetics Corporation
Rangan	Bavana	Coronary Intervention in Interventional Cardiology: Advanced Device Use	A Meta-Analysis of Contemporary Lesion Modification Strategies During Percutaneous Coronary Intervention in 244,665 Patients From 21 Studies	RESEARCH/RESEARCH GRANTS - Infraredx Inc.,The Spectranetics Corporation
Rangan	Bavana	Innovations in Advocacy and Patient Centered Care	Diverse Perspectives and Training Paths in Cardiology: An Analysis of Authorship in the <i>Journal of the American College of Cardiology</i>	RESEARCH/RESEARCH GRANTS - Infraredx Inc.,The Spectranetics Corporation
Rangan	Bavana	Advances in Chronic Total Occlusion Intervention	Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions Improves Peak Oxygen Uptake During Cardiopulmonary Exercise Testing	RESEARCH/RESEARCH GRANTS - Infraredx Inc.,The Spectranetics Corporation
Rangan	Bavana	Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	RESEARCH/RESEARCH GRANTS - Infraredx Inc.,The Spectranetics Corporation
Rangan	Bavana	Advances in Chronic Total Occlusion Intervention	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	RESEARCH/RESEARCH GRANTS - Infraredx Inc.,The Spectranetics Corporation
Rangaswami	Janani	Considerations in Antiplatelet Therapy and in ACS	Chronovariability of Platelet Reactivity With the Hemodialysis Cycle	Nothing to Disclose
Rangaswami	Janani	Predicting the Future: Observations and Discoveries From Registries and Databases	Clinical Burden and Cost Analysis of Pulmonary Hypertension in Patients With Chronic Kidney Disease: A Cross Sectional Study From the National Inpatient Sample	Nothing to Disclose
Rangaswami	Janani	Coronary Intervention in Interventional Cardiology: Core Concepts	White Blood Cell Count to Platelet Ratio: A Novel Biomarker of Outcomes in Patients With Circulatory Support on Left Ventricular Impella Assist Devices	Nothing to Disclose
Rangaswami	Janani	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Coronary Steal From a Left Internal Mammary Artery Bypass Graft via High Output Hemodialysis Arteriovenous Fistula	Nothing to Disclose
Ranjan	Pragya	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Downstream Effects of False Positive Activation of the Cardiac Catheterization Lab	Nothing to Disclose
Ranjan	Ravi	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team 5	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Biosense Webster,MEDTRONIC,St Jude
Ranjit	John	Novel Echocardiographic Methods for Assessing Cardiac Function	Echocardiographic Evidence for Left Ventricular Recovery After Refractory Ventricular Fibrillation Cardiac Arrest Treated With Primary Angioplasty and Extracorporeal Membrane Oxygenation	RESEARCH/RESEARCH GRANTS - Thoratec , Heartware
Rankin	J. Scott	Interventional Cardiology: TAVR 2	Outcomes of Transcatheter and Surgical Aortic Valve Replacement in Patients With Hepatic Cirrhosis: Insight From Nationwide Inpatient Sample	CONSULTANT FEES/HONORARIA - Admedus Corp,Atricure USA,BioStable Science and Engineering Inc
Rankin	J. Scott	Valvular Heart Disease With CKD or Cirrhosis	Trends and Outcomes of Mitral Valve Replacement in Patients With Hepatic Cirrhosis: Insight From National Inpatient Sample	CONSULTANT FEES/HONORARIA - Admedus Corp, Atricure
Ranney	David	Highlighted Original Research: Valvular Heart	Surgery for Patients With Bicuspid Aortopathy: Validation of the	USA,BioStable Science and Engineering Inc Nothing to Disclose
Ranney	David	Disease and the Year in Review Interventional Cardiology: TAVR 4	2016 ACC/AHA Guidelines Clarification Predictors of Mortality After TAVR in a "Real World" Setting	Nothing to Disclose

Contract of the contract of th				l
Rao	Shreya	Session Title Updates on Risk Factors for Cardiovascular Disease	Presentation Title Impact of Exercise and Pharmacologic Interventions on Changes in Visceral Adiposity: A Meta-Analysis of Randomized Controlled Trials	Disclosures Nothing to Disclose
Rao	Sunil	Featured Clinical Research II: Interventional	Panelist	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc,Cardinal,Corindus,CSI,MEDTRONIC
Rao	Sunil	Radial Access Mini-Symposium I	Co-Chair	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc, Cardinal, Corindus, CSI, MEDTRONIC
Rao	Sunil	Radial Access Mini-Symposium II	Co-Chair	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc, Cardinal, Corindus, CSI, MEDTRONIC
Rao	Sunil	Highlighted Original Research: Interventional Cardiology and the Year in Review	Co-Chair	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc, Cardinal, Corindus, CSI, MEDTRONIC
Rao	Sunil	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc,Cardinal,Corindus,CSI,MEDTRONIC
Rao	Sunil	Coronary Angiography, Intra-Vascular Imaging,	Variation in Practice and Concordance With Guideline Criteria for Length of Stay Affer Elective Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc,Cardinal,Corindus,CSI,MEDTRONIC
Rao	Sunil	Revascularization and Outcomes Novel Developments in Acute Coronary Syndromes	Incidence and Predictors of No Reflow Phenomenon: Insights From the TOTAL Trial	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc, Cardinal, Corindus, CSI, MEDTRONIC
Rao	Sunil	Innovative Use of Echocardiography	The Impact of Rigorous Quality Improvement on 3D Echocardiography Image and Data Quality in an International	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc,Cardinal,Corindus,CSI,MEDTRONIC
Rao	Sunil	FIT Clinical Decision Making: Arrhythmias and	Multisite Randomized Trial Alternating Bundle Branch Block: Clinical Considerations	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
Rao	Sunil	Electrophysiology Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary	Pharmaceuticals, Inc,Cardinal,Corindus,CSI,MEDTRONIC CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc,Cardinal,Corindus,CSI,MEDTRONIC
Rao	Sunil	Interventional Cardiology: TAVR 3	Syndromes Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patients Undergoing TAVR: Insights for the STS/ACC TVT	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc,Cardinal,Corindus,CSI,MEDTRONIC
Rao	Sunil	Interventional Complexity and Complications	Registry Variability in Transfemoral Access for Coronary Angiography and	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
Rao	Sunil	Interventional Challenging Cases: Team 4	Interventions: Results From an International Survey ACC Challenging Case Reviewer	Pharmaceuticals, Inc,Cardinal,Corindus,CSI,MEDTRONIC CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
Rao	Vivek	36. Valvular Heart Disease: Clinical Team 2	Suggested Reviewer	Pharmaceuticals, Inc,Cardinal,Corindus,CSI,MEDTRONIC CONSULTANT FEES/HONORARIA - CorMatrix Cardiovascular,Medtronic Inc ,Thoratec
Rao	Vivkek	Acute Cardiogenic Shock: Progress, Paradigm, and Unresolved Problems	Panelist	CONSULTANT FEES/HONORARIA - CorMatrix Cardiovascular,MEDTRONIC,Thoratec
Raphael	Claire	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Acute Changes in Left Atrial Pressure Following MitraClip are Associated With Long Term Improvement in 6 Min Walk Distance	Nothing to Disclose
Rasania	Suraj	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Comparing PCI Outcomes in the Very Elderly: Does Age Matter? A Report From Outcomes of Septuagenarians, Octogenarians and Nonagenarians After PCI	Nothing to Disclose
Rashed	Ahmed	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Ultrasound Assisted Catheter Directed Thrombolysis and Percutaneous Right Ventricular Mechanical Assist Device for the Management of Massive Pulmonary Embolism With Refractory Right Ventricular Failure: Playing Chess With Pulmonary Embolism	Nothing to Disclose
Rashed	Ahmed	FIT Clinical Decision Making: Acute Coronary Syndrome and Vascular Medicine	Use of Ultrasound Assisted Catheter Directed Thrombolysis in	Nothing to Disclose
Rashed	Wafa	Arrhythmias and Clinical EP: AF Miscellaneous	Treatment of Aortic Thrombi Influence of Beta-Blockers on Mortality in Chronic Heart Failure	Nothing to Disclose
Rashid	Hashrul	and Surgical Issues Non Invasive Imaging: Prognostic Implications of CT Angiography	Patients With Atrial Fibrillation: Findings From the Gulf-Safe Computed Tomography Coronary Angiography Derived Plaque Morphology Predicts Major Adverse Cardiovascular Events: Insights From a 19,943 Patient Meta-Analysis	Nothing to Disclose
Rashid	Mohammed	Novel Developments in Acute Coronary Syndromes	Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Raskind-Hood Raskind-Hood	Cheryl Cheryl	Redefining the "F" Word Congenital Heart Disease: To the Third	Adults With Congenital Heart Disease: Lost in Care Prevalence and Incidence of Heart Failure in Adolescents and	Nothing to Disclose Nothing to Disclose
Rasool	Shereen	Decade and Beyond Toward Precision Medicine in the Treatment of	Adults With Repaired Tetralogy of Fallot Coronary Artery Calcium and Incident Hypertension in a Population-	Nothing to Disclose
Rassi	Andrew	Elevated Blood Pressure Interventional Cardiology: TAVR 4	Based Cohort: The Multi-Ethnic Study of Atherosclerosis Serum Albumin as an Incremental Predictor of Mortality in Older	Nothing to Disclose
Itassi	Andrew	interventional Cardiology. 1AVIC4	Adults Undergoing Transcatheter Aortic Valve Replacement: Results From the Multicenter Frailty-AVR Study	Nothing to Disclose
Rastogi	Ujjwal	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Asymptomatic Coronary Arteriovenous Fistula: When to Close?	Nothing to Disclose
Ratanapo	Supawat		Biventricular Stress Induced Cardiomyopathy Managed With Impella CP and Pulmonary Vasodilators	Nothing to Disclose
Ratchford	Elizabeth	Pulmonary Hypertension 40. Vascular Medicine: Non Coronary Arterial Disease Team 2		OTHER - AstraZeneca Pharmaceuticals; RESEARCH/RESEARCH GRANTS - Novartis; SALARY -
Rathman	Lisa	Can You See Me Now? Sensors For	Three Challenging Patient Cases Using Sensors	MedImmune (owned by AstraZeneca) CONSULTANT FEES/HONORARIA - MEDTRONIC, Novartis
Rathod	Rahul	Monitoring Heart Failure Five Controversies in Single Ventricle	Cardiac MRI Has Proven its Value in Management of Patients with	Corporation,St Jude RESEARCH/RESEARCH GRANTS - Bristol-Myers
Rathod	Rahul	Management 10. Congenital Heart Disease: Pediatric Team	the Fontan Operation Suggested Reviewer	Squibb,inVentiv Health RESEARCH/RESEARCH GRANTS - Bristol-Myers
Ratnayaka	Kanishka	3 10. Congenital Heart Disease: Pediatric Team	Suggested Reviewer	Squibb,inVentiv Health Nothing to Disclose
Rattanawong	Pattara	Atrial Fibrillation and VT: Unique Populations	Association Between Atrial Fibrillation and Sudden Cardiac Death: A	Nothing to Disclose
Rattanawong	Pattara	and Solutions Toward Precision Medicine in the Treatment of	Systematic Review and Meta-Analysis Pulse Pressure as a Predictor of Renal Function Progression Over 3-	Nothing to Disclose
Rattanawong	Pattara	Elevated Blood Pressure Arrhythmias and Clinical EP: Syncope and	Year Follow-Up in African American Population Worldwide Prevalence of Brugada Syndrome: A Systematic Review	Nothing to Disclose
Rauch	Antoine	Other EP Issues Joint American College of Cardiology/New England Journal of Medicine Late-Breaking	and Meta-Analysis Silent Cerebral Microbleeds During TAVR: Insight From a Prospective Cerebral MRI Cohort	Nothing to Disclose
Rauch-Kroenert	Ursula	Clinical Trials Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Increased Rate of Previous Stroke in Asymptomatic/Minimally Symptomatic Versus Symptomatic Patients With Newly Detected Atrial Fibrillation Worldwide: Results From the GLORIA-AF Registry	Nothing to Disclose
Rauch-Kröhnert	Ursula	MicroRNAs and Beyond in Vascular Medicine	Disturbed Expression of Immunoregulatory Long Noncoding RNAs in Circulating Immune Cells From Patients With Early Myocardial	Nothing to Disclose
Rauch-Kröhnert	Ursula	Mechanisms of Vascular Inflammation in Atherogenesis	Infarction Deficiency of Long Noncoding RNA <i>Malat1</i> System Deregulation and Accelerated Atherosclerosis in Apo	Nothing to Disclose
Rauseo	Adriana	FIT Clinical Decision Making: Interventional	E ^{-/-} Mice Non ST-Segment Elevation Myocardial Infarction Secondary to	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Paradoxical Embolism via a Patent Foramen Ovale	



1				
Last Name Ravishankar	First Name Chitra	Session Title Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Presentation Title Impact of Home Monitoring Program on Interstage Mortality and Stage II Outcomes	Disclosures CONSULTANT FEES/HONORARIA - Danone Medical
Raviv	Gabriel	From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease	Assessment of Thrombogenicity and Antithrombotic Drug Response at the Bedside in Patients Presenting With Ischemic Stroke, TIA or Intracranial Hemorrhage	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Corammed Technologies, LLC
Ray	Kausik	Featured Clinical Research I	LDL-C Reduction From 6 to 9 Months Following Single or Second Injection of Inclisiran a Novel siRNA Compound: Primary Efficacy and Safety Outcomes of the ORION 1 Trial	CONSULTANT FEES/HONORARIA - Aegerion, Algorithm, Amgen, Astra Zeneca, Boehringer Ingelheim, Cerenis, Eli Lilly and Company, Esperion, ISIS Pharma, Kowa, Medicines Company, MSD, Novartis, Pfizer, Regeneron, Resverlogix, SANOFI, T akeda; DATA SAFETY MONITORING BOARD - AbbVie, Inc.; RESEARCH/RESEARCH GRANTS - Kowa, Pfizer, Regeneron
Ray	Kausik	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	Effect of Serial Infusions of CER-001, a Pre-Beta High-Density Lipoprotein Mimetic on Coronary Atherosclerosis: Results of the CARAT Study	CONSULTANT FEES/HONORARIA - Aegerion,Algorithm,Amgen,Astra Zeneca,Boehringer Ingelheim, Cerenis,Eli Lilly and Company,Esperion,ISIS Pharma,Kowa,Medicines Company,MSD,Novartis,Pfzer,Regeneron,Resverlogix,SANOFI,T akeda; DATA SAFETY MONITORING BOARD - AbbVie, Inc.; RESEARCH/RESEARCH GRANTS - Kowa,Pfizer,Regeneron
Ray	Kausik	Dyslipidemias: A Potpourri of Complexities	Very Low LDL-C Levels: Friend or Foe?	CONSULTANT FEESHONORARIA - Aegerion Algorithm Amgen Astra Zeneca Boehringer Ingelheim, Cerenis, Eli Lilly and Company, Esperion, ISIS Pharma, Kowa, Medicines Company, MSD, Novartis, Pfizer, Regeneron, Resverlogis, SANOFI, T akeda; DATA SAFETY MONITORING BOARD - AbbVie, Inc.; RESEARCHRESEARCH GRANTS - Kowa, Pfizer, Regeneron
Ray	Kausik	Highlighted Original Research: Prevention and the Year in Review	Genetic Target Validation for ATP-Citrate Lyase Inhibition	CONSULTANT FEES/HONORARIA - Aegerion, Algorithm, Amgen, Astra Zeneca, Boehringer Ingelheim, Cerenis, Eli Lilly and Company, Esperion, ISIS Pharma, Kowa, Medicines Company, MSD, Novartis, Pfizer, Regeneron, Resverlogix, SANOFI, T akeda; DATA SAFETY MONITORING BOARD - AbbVie, Inc.; RESEARCH/RESEARCH GRANTS - Kowa, Pfizer, Regeneron
Ray	Kausik	Advances in Cholesterol Measurement and Management	Efficacy and Safety of the PCSK9 Inhibitor Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin Therapy	CONSULTANT FEES/HONORARIA - Aegerion, Algorithm, Amgen, Astra Zeneca, Boehringer Ingelheim, Cerenis, Eli Lilly and Company, Esperion, ISIS Pharma, Kowa, Medicines Company, MSD, Novartis, Pfizer, Regeneron, Resverlogix, SANOFI, T akeda; DATA SAFETY MONITORING BOARD - AbbVie, Inc.; RESEARCH/RESEARCH GRANTS - Kowa, Pfizer, Regeneron
Ray	Kausik	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Lower On-Treatment Low-Density Lipoprotein Cholesterol Is Associated With Lower Cardiovascular Risk in Very High Risk Patients With Atherosclerotic Cardiovascular Disease: Analyses From the ODYSSEY Trials	CONSULTANT FEES/HONORARIA - Aegerion,Algorithm,Amgen,Astra Zeneca,Boehringer Ingelheim, Cerenis,Eli Lilly and Company,Esperion,ISIS Pharma,Kowa,Medicines Company,MSD,Novartis,Pfizer,Regeneron,Resverlogix,SANOFI,T akeda; DATA SAFETY MONITORING BOARD - AbbVie, Inc.; RESEARCH/RESEARCH GRANTS - Kowa,Pfizer,Regeneron
Ray	Kausik	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Lower On-Treatment Low-Density Lipoprotein Cholesterol Is Associated With Lower Cardiovascular Risk in Women: Analyses From the ODYSSEY Trials of Alirocumab Versus Control	CONSULTANT FEES/HONORARIA - Aegerion, Algorithm, Amgen, Astra Zeneca, Boehringer Ingelheim, Cerenis, Eli Lilly and Company, Esperion, ISIS Pharma, Kowa, Medicines Company, MSD, Novartis, Pfizer, Regeneron, Resverlogix, SANOFI, T akeda; DATA SAFETY MONITORING BOARD - AbbVie, Inc.; RESEARCH/RESEARCH GRANTS - Kowa, Pfizer, Regeneron
Ray	Scott	Nuclear Cardiology: Beyond Perfusion	The Increasing Burden of Amyloidosis From Apex to Base: New Insights From Technetium-99m Pyrophosphate Imaging	Nothing to Disclose
Rayarao	Geetha	Advances in Pulmonary Arterial Hypertension	A Cross Comparison Study of Right Ventricular Hypertrophy With Electrocardiography and Cardiac Magnetic Resonance in Patients With Pulmonary Hypertension	Nothing to Disclose
Rayarao	Geetha	Arrhythmias and Clinical EP: Basic 5	Pulmonary Vein Remodeling Following Pulmonary Vein Isolation in Patients With Atrial Fibrillation Are They an Epiphenomena a Predictive Cardiac MRI Study	Nothing to Disclose
Rayarao	Geetha	Insights Into Ischemic Heart Disease: Stable to	Clinical Operating Points for Non-Invasive Cardiac Imaging	Nothing to Disclose
Raymond	Timothy	Erosive Plaques FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Modalities Lead to Low Detection of Coronary Artery Disease Proof is in the Paclitaxel: Catheter Directed Intracoronary Paclitaxel as Salvage Therapy for Refractory Cardiac Allograft Vasculopathy	Nothing to Disclose
Raz	Itamar	Highlighted Original Research: Prevention and the Year in Review	Blood Pressure, Subclinical Myocardial Injury and Cardiovascular Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial	CONSULTANT FEES/HONORARIA - AstraZeneca, Diabetes Medical Center, FuturRx Ltd, Gili Medical, Insuline Medical Kamada Ltd., Nephrogenex Inc.; OTHER - AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Glucome Ltd, Insuline Medical Labstyle Innovations, Labstyle Innovations Ltd, Merck & Despeny, Co., inc., Novo Nordisk Inc., Orgenesis, Orgenesis, Sanofl-Aventis, SmartZyme Innovation Ltd, SmartZyme Innovation Ltd.; SPEAKER'S BUREAU - AstraZeneca/Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Johnson & Despension, Sonofl-Aventis, Teva Pharmaceuticals in Corporation, Novo Nordisk Inc., Sanofi-Aventis, Teva Pharmaceuticals
Raz	ltamar	the Future	Risk Stratification With the TIMI Risk Score for Secondary Prevention Among Patients With Diabetes and Elevated Cardiovascular Risk	CONSULTANT FEES/HONORARIA - AstraZeneca Diabetes Medical Center, FuturRx Ltd, Gili Medical, Insuline Medical, Mamada Ltd., Nephrogenex Inc.; OTHER - AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Liliy and Company, Glucome Ltd, Insuline Medical, Labstyle Innovations, Labstyle Innovations Ltd, Merck & amp; amp; Co., Inc., Novo Nordisk Inc., Orgenesis, Orogenesis, Sanofi-Aventis, SmartZyme Innovation Ltd, SmartZyme Innovation Ltd.; SPEAKER'S BUREAU - AstraZeneca/Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Liliy and Company, Johnson & amp; amp; Johnson, Merck & amp; amp; Co., Inc., Novartis Corporation, Novo Nordisk Inc., Sanofi-Aventis, Teva Pharmaceuticals
Raza	Anoshia	Interventional Cardiology: TAVR 1	"Cusp Overlap" View Facilitates Accurate Fluoro- Guided Implantation of Self-Expanding Valve in TAVR	Nothing to Disclose
Raza	Anoshia	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Pneumopericardium: A Rare Presentation of Gastro-Pericardial Fistula	Nothing to Disclose
Raza	Anoshia	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Sinus Node Dysfunction in Batten Disease: A Rare Manifestation of a Rare Disease	Nothing to Disclose
Raza	Anoshia	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Immunodeficiency Virus	Nothing to Disclose
Raza	Anoshia	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Management of Takotsubo Cardiomyopathy Complicated by Left Ventricular Outflow Tract Obstruction	Nothing to Disclose

Raza	First Name Anoshia	Session Title FIT Clinical Decision Making: Interventional	Presentation Title Spontaneous Coronary Artery Dissection in a Transplanted Heart	Disclosures Nothing to Disclose
ruzu	7 ti tootiita	Cardiology, Acute and Stable Ischemic Heart	Sportaneous seronary ratery Escociari in a manapiante mount	realing to Bissiose
Raza	Jaffar	Disease, and Vascular Medicine The Best Coronary and Peripheral	Recurrent Spontaneous Coronary Artery Dissection in a Patient With	Nothing to Disclose
		Interventional Challenging Cases	Fibromuscular Dysplasia	· ·
Raza	Munis	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Chemotherapy Induced Cardiotoxicity, Its Prevention, Treatment and Risk Factors	Nothing to Disclose
Raza	Samreen	FIT Clinical Decision Making: Prevention, Adult	Sudden Cardiac Death: A Rare but Treatable Cause	Nothing to Disclose
		Congenital and Congenital Heart Disease		
Razavi	Mehdi	Vascular Access and Hemostasis Issues	Mortality, Length of Stay, and Cost Implications of Procedural	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Saranas
			Bleeding After Contemporary Percutaneous Interventions Involving Large-Bore Catheters	
Razavi	Mehdi	08. Arrhythmias and Clinical EP:	Suggested Reviewer	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Saranas
		Supraventricular/Ventricular Arrhythmias Team 1		
Reardon	Leigh	Patient-Centered Care in Adult Congenital Heart Disease	Co-Chair	SPEAKER'S BUREAU - Actelion
Reardon	Leigh	09. Congenital Heart Disease: Adult Team 2	Suggested Reviewer	SPEAKER'S BUREAU - Actelion
Reardon	Michael	Opening Session and the Joint American College of Cardiology and Journal of American	Transcatheter Aortic Valve Replacement With a Self-Expanding Bioprosthesis Compared With Surgical Aortic Valve Replacement in	RESEARCH/RESEARCH GRANTS - MEDTRONIC
		College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture	Patients at Intermediate Surgical Risk: First Results From the SURTAVI Clinical Trial	
		Thats readuling the Simon Dack Lecture	SOCIAVI Cillical Tilal	
Reardon	Michael	Late-Breaking Clinical Trials: Deep Dive I	Transcatheter Aortic Valve Replacement With a Self-Expanding Bioprosthesis Compared With Surgical Aortic Valve Replacement in	RESEARCH/RESEARCH GRANTS - MEDTRONIC
			Patients at Intermediate Surgical Risk: First Results From the	
Reardon	Michael	Frontier in New Transcatheter Techniques	SURTAVI Clinical Trial Co-Chair	RESEARCH/RESEARCH GRANTS - MEDTRONIC
Reardon	Michael	Challenging Anatomies: Does TAVR Device	Management of the Small Aortic Root	RESEARCH/RESEARCH GRANTS - MEDTRONIC
Reardon	Michael	Choice Matter TAVR: What We've Learned and Where We	Program Volume and Correlation to Outcomes: The Dilemma of	RESEARCH/RESEARCH GRANTS - MEDTRONIC
		Think We're Going!	Low Volume TAVR Centers	
Reardon Reardon	Michael Michael	Moderated, Case-Based TAVR Management Highlighted Original Research: Valvular Heart	Co-Chair Effect of Baseline Aortic Regurgitation on Mortality in the Core Valve	RESEARCH/RESEARCH GRANTS - MEDTRONIC RESEARCH/RESEARCH GRANTS - MEDTRONIC
		Disease and the Year in Review	US Pivotal High Risk Trial	
Reardon	Michael	Valvular Heart Disease: Mitral Valve Disease	Inter-Study Reproducibility of Mitral Regurgitation Quantitation Using Cardiac Magnetic Resonance Imaging	RESEARCH/RESEARCH GRANTS - MEDTRONIC
Reardon	Michael	Interventional Cardiology: TAVR 2	Platelets and von Willebrand Factor Interactions After Transcatheter Aortic Valve Replacement (TAVR): Association With	RESEARCH/RESEARCH GRANTS - MEDTRONIC
			Thrombocytopenia and Thrombosis	
Reardon	Michael	Interventional Cardiology: TAVR 2	The Impact of Preoperative Renal Dysfunction on the Outcomes of Patients Undergoing Surgical Versus Transcatheter Aortic Valve	RESEARCH/RESEARCH GRANTS - MEDTRONIC
			Replacement: An Analysis From the CoreValve US Pivotal High	
Reardon	Michael	Interventional Cardiology: TAVR 2	Risk Trial Impact of Balloon Pre-Dilatation on Hemodynamics and Clinical	RESEARCH/RESEARCH GRANTS - MEDTRONIC
			Outcomes After Transcatheter Aortic Valve Replacement With the	
Reardon	Michael	Interventional Cardiology: TAVR 3	Self-Expanding CoreValve Prosthesis Initial Use of the Evolut Pro Self-Expanding Transcatheter Aortic	RESEARCH/RESEARCH GRANTS - MEDTRONIC
Doordon	Michael	Non Invasive Imaging: MR Structure and	Valve <i></i> Quantitative Measurements on Cardiac Magnetic Resonance to	RESEARCH/RESEARCH GRANTS - MEDTRONIC
Reardon	iviicriaei	Valuvular Heart Disease	Differentiate Benign Versus Malignant Masses: A Pilot Study	RESEARCH/RESEARCH GRANTS - MED I RONIC
Rebeyka	Ivan	Impact of Prenatal Environment on Congenital Heart Disease	Umbilical Arterial Blood Flow in the Third Trimester and Its Association With Clinical and Neurodevelopmental Outcomes in	Nothing to Disclose
			Children With Critical Neonatal Congenital Heart Disease	
Redberg	Rita	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Effectiveness of Coronary CT Angiography Versus Standard Care for the Assessment of Patients With Suspected Coronary Artery	Nothing to Disclose
D. H	NA . III	Coronary Artery Disease	Disease: A Trial Sequential Analysis	Note: A Broken
Reddy	Madhu	Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	Peri-Procedural Use of Novel Oral Anticoagulation Agents During Cardiac Device Implantation: Are They Safe?	Nothing to Disclose
Reddy	Madhu	Arrhythmias and Clinical EP: Devices 1	Implantable Cardioverter Defibrillator for the Prevention of Mortality in Non-Ischemic Cardiomyopathy: A Meta-Analysis of Randomized	Nothing to Disclose
			Controlled Trials	
Reddy	Madhu	Arrhythmias and Clinical EP: Devices 1	Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients Undergoing Cardiac Implantable Electronic	Nothing to Disclose
			Device Implantation: A Meta-Analysis	
Reddy Reddy	Madhu Madhu	Arrhythmias and Clinical EP: Devices 2 Arrhythmias and Clinical EP: Devices 2	Impact of Left Atrial Appendage Occlusion on Left Atrial Function Long Term Safety and Efficacy of Left Atrial Appendage Closure	Nothing to Disclose Nothing to Disclose
-		· ·	With Lariat in Atrial Fibrillation: Is It Still Working at 5 Years?	Ÿ
Reddy	Madhu	Arrhythmias and Clinical EP: Devices 2	Real World Battery Longevity of St. Jude Medical Implantable Cardioverter-Defibrillators Included in the Advisory for Premature	Nothing to Disclose
Reddy	Madhu	Atrial Fibrillation and VT: Unique Populations	Battery Depletion Use of an Esophageal Retractor to Prevent Thermal Injuries During	Nothing to Disclose
-		and Solutions	Atrial Fibrillation Ablation: A Multi-Center Experience	,
Reddy	Madhu	Atrial Fibrillation and VT: Unique Populations and Solutions	Sotalol Versus Other Anti-Arrhythmic Medications for Cardioversion of Atrial Fibrillation and Maintenance of Sinus Rhythm: Meta-	Nothing to Disclose
			Analysis of Randomized Controlled Studies	
Reddy	Madhu	Arrhythmias and Clinical EP: Anticoagulation Issues	Meta-Analysis on the Efficacy and Safety of New Oral Anticoagulants Compared With Vitamin K Antagonists in Patients	Nothing to Disclose
Reddy	Madhu	FIT Clinical Decision Making: Arrhythmias and	Undergoing Cardioversion for Atrial Fibrillation Device-Related Thrombus Following Left Atrial Appendage Closure:	Nothing to Disclose
-		Electrophysiology	A Clinical Conundrum	
Reddy	Madhu	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	CHADS2 Score Predicts Outcomes of Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation	Nothing to Disclose
Reddy	Madhu	Arrhythmias and Clinical EP: AF Miscellaneous	Left Atrial Appendage Ligation With Lariat Device: A Systematic	Nothing to Disclose
Reddy	Madhu	and Surgical Issues Innovative Approaches for Reducing Risk and	Review and Meta-Analysis Efficacy of Catheter Ablation of Atrial Fibrillation in the Setting of	Nothing to Disclose
1		Improving Outcomes With Ablation	Systolic Dysfunction: A Meta-Analysis of Randomized Control Trials	
Reddy	Madhu	Atrial Fibrillation and VT: Incorporating Novel	Sotalol Versus Other Anti-Arrhythmic Agents for Prevention of Post-	Nothing to Disclose
		Risks Toward Decision Making	Operative Supraventricular Arrhythmias After Cardiac Surgery: Meta- Analysis of Randomized Controlled Studies	
Reddy	Madhu	Atrial Fibrillation, Anticoagulation and Novel	Safety Profiles of Percutaneous Left Atrial Appendage Closure	Nothing to Disclose
		Device Therapies	Devices: An Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database From	
			2009 - 2016	
Reddy	Satyajit	Head to Toe: Outcomes of Endovascular Interventions	Contemporary Nationwide Trends in Inferior Vena Cava Filter Implantation Rates in the United States and the Effect of Food and	Nothing to Disclose
Daddi	Cat with		Drug Administration Advisory	Nething to Displace
Reddy	Satyajit	Venous Investigation: The Dark Side	Nationwide Contemporary Trends in Adjunctive Angioplasty and Stenting at the Time of Catheter Directed Thrombolysis in Patients	Nothing to Disclose
Reddy	Satyajit	Venous Investigation: The Dark Side	With Proximal Lower Extremity Deep Vein Thrombosis Sex Differences in the Use of Inferior Vena Cava Filters in Patients	Nothing to Disclose
y	Catyajit	10.1000 IIIVOSIIgation. The Dark Side	With Proximal Lower Extremity Deep Vein Thrombosis in the United	
L	1	l	States	



and a				<u> </u>
Reddy	First Name Satyajit		Presentation Title Intracranial Hemorrhage in Patients Treated With Catheter Directed	Disclosures Nothing to Disclose
Reddy	Vivek	Thrombosis Cardiovascular Update for the Clinician IV: Electrical Failure 2017 Rhythm Disorders (A Symposium by Valentin Fuster)	Thrombolysis Panelist	CONSULTANT FEES/HONORARIA - Biosense-Webster, Bc Scientific, CardioFocus, CardioInsight, Coherex, EBR, Impulse Dynamics, Medtronic-Cryocath, Philips, Sentreheart, St. Jude Medicai; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIF ACT, Acutus Medical, Cibiem, Circa, DC Devices ,GDS, Javelin, Keystone, Magnetecs, Middlepeak, Perseus, Vytr S
Reddy	Vivek	Cardiovascular Update for the Clinician IV: Electrical Failure 2017 Rhythm Disorders (A Symposium by Valentin Fuster)	Left Atrial Appendage Closure as Alternative toAnticoagulants	CONSULTANT FEES/HONORARIA - Biosense-Webster, Bo Scientific, CardioFocus, CardioInsight, Coherex, EBR, Impulse Dynamics, Medtronic-Cryocath, Philips, Sentreheart, St Jude Medical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIF ACT, Acutus Medical, Cibiem, Circa, DC Devices ,GDS, Javelin, Keystone, Magnetecs, Middlepeak, Perseus, Vytr S
Reddy	Vivek	Cardiovascular Update for the Clinician IV: Electrical Failure 2017 Rhythm Disorders (A Symposium by Valentin Fuster)	VentricularTachycardia - Catheter Ablation Who?, How?, When?	CONSULTANT FEES/HONORARIA - Biosense-Webster, Bc Scientific, CardioFocus, CardioInsight, Ooherex, EBR, Impulse Dynamics, Meditonic-Cryocath, Philips, Sentreheart, St. Jude Medical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIF ACT. Acutus Medical, Cibiem, Circa, DC Devices (GDS, Javelin, Keystone, Magnetecs, Middlepeak, Perseus, Vytre
Reddy	Vivek	Heart Rhythm Disorders: Today and Tomorrow	Left Atrial Appendage Interventions Cases: When to Consider Plugging, Tying, Both, or Neither?	CONSULTANT FEES/HONORARIA - Biosense-Webster, Bc Scientific, CardioFocus, CardioInsight, Coherex, EBR, Impulse Dynamics, Medtronic-Cryocath, Philips, Sentreheart, St Jude Medicai; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIF ACT, Acutus Medical, Cibiem, Circa, DC Devices ,GDS, Javelin, Keystone, Magnetecs, Middlepeak, Perseus, Vytr S
Reddy	Vivek	Meeting of the Minds: HF and EP Decision Making for Complex Patients	Panelist	CONSULTANT FEES/HONORARIA - Biosense-Webster, Bo Scientific, CardioFocus, CardioInsight, Coherex, EBR, Impulse Dynamics, Medronic-Cryocath, Philips, Sentreheart, St. Jude Medical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIF ACT. Acutus Medical, Cibiem, Circa, DC Devices (GDS, Javelin, Keystone, Magnetecs, Middlepeak, Perseus, Vytre
Reddy	Vivek	Meeting of the Minds: HF and EP Decision Making for Complex Patients	Percutaneous Hemodynamic Support in the EP Lab	GONSULTANT FEES/HONORARIA - Biosense-Webster, Bc Scientific, CardioFocus, CardioInsight, Coherex, EBR, Impulse Dynamics, Medtronic-Cryocath, Philips, Sentreheart, St. Jude Medicai; OWHERSHIP INTEREST/PARTNERSHIP/PRINCIF ACT, Acutus Medical, Cibiem, Circa, DC Devices ,GDS, Javelin, Keystone, Magnetecs, Middlepeak, Perseus, Vytr S
Reddy	Vivek	Fundamentals of LAA Closure	Synthesis of the Clinical Data for Transcatheter LAA Closure for Stroke Prevention	CONSULTANT FEES/HONORARIA - Biosense-Webster, Bo Scientific, Cardio-Fous, Cardiolinsight, Coherex, EBR, Impulse Dynamics, Medtronic-Cryocath, Philips, Sentreheart, St. Jude Medical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIF ACT, Acutus Medical, Cibiem, Circa, DC Devices (GDS, Javelin, Keystone, Magnetecs, Middlepeak, Perseus, Vytr S. Particular Company (Company Compa
Reddy	Yogesh	Emerging Developments in HFpEF and Arryhthmias	The Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: An Invasive- Echocardiographic Study	Nothing to Disclose
Reddy	Yogesh	Emerging Developments in HFpEF and Arryhthmias	Arterial Reserve Limitations in Heart Failure With Preserved Ejection Fraction and the Beneficial Effects of Sodium Nitrite	Nothing to Disclose
Reddy	Yogesh	Emerging Developments in HFpEF and	Utility of Cardiopulmonary Exercise Testing to Diagnose and	Nothing to Disclose
Redfern	Julie	Arryhthmias Strategies for Prevention of Cardiovascular Disease: International Perspectives From the Canadian Cardiovascular Society, Cardiac Society of Australia and New Zealand, and American College of Cardiology	Phenotype Heart Failure With Preserved Ejection Fraction Application of Digital Technology to Primary and Secondary Prevention in CVD	Nothing to Disclose
Redfield	Margaret	Featured Clinical Research III	Reduction in Heart Failure Hospitalizations With Ambulatory Hemodynamic Monitoring Seen in Clinical Trials Is Maintained in the 'Real World'	CONSULTANT FEES/HONORARIA - Acetilion, HFSA, Ironwood, MEDTRONIC, Merck & amp; amp; C Inc; DATA SAFETY MONITORING BOARD - Corvia; RESEARCH/RESEARCH GRANTS - MEDTRONIC, Pfizer, SI Jude
Redfield	Margaret	Hot Topics and Great Debates in Pulmonary Hypertension	The Challenges of and Approaches to Managing Pulmonary Hypertension in HFpEF	CONSULTANT FEES/HONORARIA - Acetilion, HFSA, Ironwood, MEDTRONIC, Merck & amp; amp; C Inc.; DATA SAFETY MONITORING BOARD - Corvia; RESEARCH/RESEARCH GRANTS - MEDTRONIC, Pfizer, SI Jude
Redfield	Margaret	Recognition of Specific Etiologies and Phenotypes in Heart Failure: Time for Precision	Panelist	CONSULTANT FEES/HONORARIA - Acetilion, HFSA, Ironwood, MEDTRONIC, Merck & amp; amp; C Inc; DATA SAFETY MONITORING BOARD - Corvia; RESEARCH/RESEARCH GRANTS - MEDTRONIC, Pfizer, SI Jude
Redfield	Margaret	Recognition of Specific Etiologies and Phenotypes in Heart Failure: Time for Precision	identifying Targets for Therapy in HFpEF	CONSULTANT FEES/HONORARIA - Acetilion. HFSA, Ironwood. MEDTRONIC. Merck & amp; amp; C Inc; DATA SAFETY MONITORING BOARD - Corvia; RESEARCH/RESEARCH GRANTS - MEDTRONIC. Pfizer, SI Jude
Redfield	Margaret	12. Heart Failure and Cardiomyopathies: Basic Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Acetilion, HFSA, Ironwood, MEDTARONIC, Merck & amp; amp; C Inc; DATA SAFETY MONITORING BOARD - Corvia; RESEARCH/RESEARCH GRANTS - MEDTRONIC, Pfizer, SI Jude
Redfors	Bjorn	Debates: Is There Really a Sex Difference in CV Presentation, Care, and Outcomes?	Women Are Less Likely to Get Secondary Prevention Medications and Cardiac Rehab: PRO	Nothing to Disclose
Redfors	Bjorn	Considerations in Antiplatelet Therapy and in	Platelet Reactivity and Outcomes After PCI of Lesions With and	Nothing to Disclose
Redfors	Bjorn	ACS PCI for NSTEMI and Complex Patients With	Without In-Stent Restenosis: The ADAPT-DES Study Platelet Reactivity and Outcomes After PCI of Saphenous Vein	Nothing to Disclose
Redfors	Bjorn	Multiple Co-Morbidities Vascular Access and Hemostasis Issues	Grafts Versus Native Coronary Arteries: The ADAPT-DES Study Mortality, Length of Stay, and Cost Implications of Procedural Bleeding After Contemporary Percutaneous Interventions Involving Large-Bore Catheters	Nothing to Disclose
Redfors	Bjorn	Interventional Cardiology: PCI and TAVR in Complex Patients	Long-Term Adverse Ischemic Outcomes After Percutaneous Coronary Intervention Among Patients With Versus Without Prior Coronary Artery Bypass Grafting: Analysis From 17 Randomized Trials	Nothing to Disclose
Redfors	Bjorn	Advances in Chronic Total Occlusion Intervention	Is Platelet Reactivity Associated With Ischemic Events Following Successful Chronic Total Occlusion Percutaneous Coronary Intervention	Nothing to Disclose

and the second				
Redwood	First Name Simon	Session Title Post-CAD/MI: Making Tough Predictions About	Presentation Title Unravelling the Mechanisms of Mental Stress Induced Myocardial	Disclosures RESEARCH/RESEARCH GRANTS - Boston Scientific
		the Future	Ischaemia: Novel Insights From Intracoronary Measurements During Cardiac Catheterisation	
Reece	T. Brett	Vascular Medicine: Aortic and Peripheral Artery Diseases	Uncontrolled Hypertension in Acute Aortic Dissection Follow-Up	Nothing to Disclose
Reece	T. Brett	Vascular Medicine: Aortic and Peripheral Artery Diseases	Acute Aortic Dissection in Patients Without a History of Hypertension	Nothing to Disclose
Reed	Brent	Why Can't We Be Friends? Controversies in Heart Failure Management	Duration of Oral Loop Diuretics and 30-Day Readmission in Patients With Acute Decompensated Heart Failure	Nothing to Disclose
Reed	Guy	Timely Topics in Acute Coronary Syndromes	Predictors of True ST-Segment Elevation Myocardial Infarction in Cocaine Positive Patients	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Translational Sciences
Reed	Guy	Innovations in Advocacy and Patient Centered Care	Prolonged Inter-facility Transfer Times and Hospital Length of Stay in Insured Patients with ST-elevation Myocardial Infarction	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Translational Sciences
Reeder	Guy	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Acute Changes in Left Atrial Pressure Following MitraClip are Associated With Long Term Improvement in 6 Min Walk Distance	CONSULTANT FEES/HONORARIA - Up-To-Date
Reeder	Guy	Insights From Echocardiography Use	Resoluted With District Transport Transcription of Myocardial Performance After Transapical Versus Transfemoral Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Up-To-Date
Reeves	Gordon	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Severe Physical Inactivity Persists Following Acute Heart Failure in Patients With Sleep Disordered Breathing	Nothing to Disclose
Refaat	Marwan	Population Specific Cardiomyopathies: From Exomes to Databases	Targeted and Exome Sequencing of 27 Lebanese Patients With Cardiomyopathies: Novel Variants in Known Genes, and Potential Novel Genes	Nothing to Disclose
Refaat	Marwan	Population Specific Cardiomyopathies: From Exomes to Databases	Targeted and Exome Sequencing of 27 Lebanese Patients With Cardiomyopathies: Novel Variants in Known Genes, and Potential Novel Genes	OTHER - none
Refaat	Marwan	Arrhythmias and Clinical EP: Basic 3	Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome	Nothing to Disclose
Refaat	Marwan	Arrhythmias and Clinical EP: Basic 3	Genomic and Proteomic Study of the Inflammatory Pathway in	OTHER - none
Refaat	Marwan	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Patients With Atrial Fibrillation and Cardiometabolic Syndrome Impact of Treatment Crossovers on Clinical Outcomes in the Rate and Rhythm Control Strategies for Atrial Fibrillation: InsightsFrom the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) Trial	Nothing to Disclose
Refaat	Marwan	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Management). Trial Impact of Treatment Crossovers on Clinical Outcomes in the Rate and Rhythm Control Strategies for Atrial Fibrillation: InsightsFrom the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) Trial	OTHER - none
Regar	Evelyn	23. Interventional Cardiology: IVUS and Intravascular Physiology Team 1	Suggested Reviewer	OTHER - institution Erasmus MC receives honoraria
Regev Regev	Ehud Ehud	Interventional Cardiology: TAVR 4 Interventional Cardiology: TAVR 4	Transacatheter Aortic Valve Replacement And Malignancy Rapid Ventricular Pacing During TAVR Is Associated With Poor	Nothing to Disclose Nothing to Disclose
Regev	Ehud	Refining TAVR Outcomes	Short- and Long-Term Outcome The Association of Coronary Artery Disease Severity and Pre	Nothing to Disclose
		-	Procedural Completeness of Revasclarization on Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement	
Regev	Ehud	Anti-Platelet Therapies: Always a Sticky Topic	Chewing Versus Traditional Swallowing of Ticagrelor to Accelerate Platelet Inhibition in ST Elevation Myocardial Infarction: The CHEERS-STEMI Study	Nothing to Disclose
Regueiro	Ander	Frontiers in Mitral Valve Disease and Treatment	Significant Mitral Regurgitation in Patients Undergoing Transcatheter Aortic Valve Replacement: Evolution and Imaging Predictors of Improvement	Nothing to Disclose
Rehan	Harmeet	Diabetes and Other Issues in Cardiovascular Prevention	Self-Reported Morisky Eight Item Medication Adherence Scale for Statins Concords With Pill Court Method and Correlates With Serum Lipid Profile Parameters and Serum Hydroxymethylglutaryl Coenzyme A Reductase Levels	Nothing to Disclose
Rehman	Mobeen	Insights From Echocardiography Use	Novel Echocardiographic Variables in the Diagnosis of Acute Pulmonary Embolism	Nothing to Disclose
Reichek	Nathaniel	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Fullionary Enrollments Determination of Calcium Score From CTA Contrast Images Using Standard Clinical Methods	OTHER - Johnson & Dong; Johnson; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Abbvie, Aetna, Amgen Inc., Sanofi-Aventis; RESEARCH/RESEARCH GRANTS - Novartis
Reid	Christopher	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Outcomes of Pre-Loading Versus In-Lab Loading With Prasugrel and Ticagrelor in Patients With Acute Coronary Syndromes (ACS) Undergoing Percutaneous Coronary Intervention (PCI)	Nothing to Disclose
Reid	Kimberly	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Interstage Resource Utilization of Infants With Single Ventricle: Results of a Crossover Study	Nothing to Disclose
Reilly	John	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Endovascular Carotid Barostimulation for Resistant Hypertension: A Safety and Proof-of-Principle Cohort Study	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - JNJ,Pfizer,VideoMedicine; SPEAKER'S BUREAU - Astra Zeneca
Reilly	John	Peripheral Arterial Disease, Risk, and Outcomes	ACC Poster Moderator	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - JNJ,Pfizer,VideoMedicine; SPEAKER'S BUREAU - Astra Zeneca
Reilly	John	26. Interventional Cardiology: Vascular Access and Complications Team 2	Suggested Reviewer	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - JNJ,Pfizer,VideoMedicine; SPEAKER'S BUREAU - Astra Zeneca
Reindl	Martin	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Fibroblast Growth Factor 23 as Novel Biomarker for Early Risk Stratification After ST-Elevation Myocardial Infarction	Nothing to Disclose
Reinstadler	Sebastian	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Stratification After S1-Elevation Myocardial Injury in Patients With Antecedent Hypertension and Myocardial Injury in Patients With Reperfused ST-Elevation Myocardial Infarction	Nothing to Disclose
Reinstadler	Sebastian	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Repended ST-Elevation Myocardial Infarction Fibroblast Growth Factor 23 as Novel Biomarker for Early Risk Stratification After ST-Elevation Myocardial Infarction	Nothing to Disclose
Reis	Jared	Innovations in Cardiovascular Risk Assessment	Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in	Nothing to Disclose
Reis	Jared	and Reduction Insights From Echocardiography Use	African Americans: The Jackson Heart Study Relation of Left Ventricular Remodeling to Left Ventricular Diastolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	Nothing to Disclose
Reis	Jared	Insights From Echocardiography Use	Development in Young Adults (CARDIA) Study Relation of Left Ventricular Rendeling to Left Ventricular Systolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	Nothing to Disclose
Reis	Steven	Innovations in Cardiovascular Risk Assessment and Reduction	Ideal Cardiovascular Health Metrics in Couples: A Community-	Nothing to Disclose
Reisman	Mark	and Reduction FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Based Population Study Unusual Transcatheter Aortic Valve Replacement Complication: Aorto-RV Cameral Fistula	CONSULTANT FEES/HONORARIA - Boston Scientific
Reiss	Allison	Cutting Edge Vascular Medicine	Pro-Atherogenic Properties of Plasma From Patients With Type 1 Diabetes Mellitus: Effects on Macrophage Lipid Handling	Nothing to Disclose
Reiter	Russel	Timely Topics in Acute Coronary Syndromes	Diabetes Meilirus: Enects on Macrophage Lipio Handling Time to Treatment With Melatonin and Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction: Insights From the Mack (Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty) Trial	Nothing to Disclose
Reitman	Arthur	Refining PCI Technique and Outcomes	Three-Year Results From the EVOLVE II Randomized Trial: Late Clinical Outcomes With Bioresorbable Compared to Permanent	SPEAKER'S BUREAU - Boston Scientific Corporation

Control of the Contro				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Rejjal	Loui	FIT Clinical Decision Making: Non-Invasive	Transcatheter Aortic Valve Replacement for Aortic Regurgitation as	Nothing to Disclose
Domolo::	Alon	Imaging and Valvular Heart Disease	a Bridge for Combined Liver and Kidney Transplantation	DECEMBOL/DECEMBOL/ CRANTO ALL COMP
Remaley	Alan	Updates on Risk Factors for Cardiovascular Disease	A Vaccine-Based Strategy for Reducing Cardiovascular Disease Risk Factors	RESEARCH/RESEARCH GRANTS - AlphaCore Pharma
Remley	Karen	48th Annual Louis F. Bishop Lecture	Panelist	Nothing to Disclose
Renard	Brian	Which Test Is Best for Pain in the Chest?	Coronary CT Angiography in the Emergency Department Provides	Nothing to Disclose
			an Opportune Window for Initiation of Evidence-Based Medical	3
			Therapy	
Renner	Elizabeth	Innovation in Practice Management, Advocacy,	Evaluating the Role of Anticoagulation Clinical Pharmacists for	Nothing to Disclose
D I	E.S.	and Education	Coordinating Periprocedural Anticoagulation	Note: To Bridge
Resendes	Erica	Highlighted Original Research: Prevention and the Year in Review	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors on Clinical Outcomes in Patients With	Nothing to Disclose
		the real in Review	Hypercholesterolemia: A Meta-Analysis of 16,721 Patients From 33	
			Randomized Clinical Trials	
Resendes	Erica	Coronary Intervention in Interventional	Contemporary Use of Laser During Percutaneous Coronary	Nothing to Disclose
		Cardiology: Advanced Device Use	Intervention: Results From the Laser Veterans Affairs (LAVA)	
_			Multicenter Registry	
Resendes	Erica	Innovations in Advocacy and Patient Centered	Diverse Perspectives and Training Paths in Cardiology: An Analysis	Nothing to Disclose
		Care	of Authorship in the <i>Journal of the American College of Cardiology</i>	
Resnic	Frederic	Assuring Quality in the Cath Lab:	Debate Con: Quality Assurance in the Cath Lab, More External	Nothing to Disclose
T COMIO	11000110	Documentation, Appropriate Use, Peer	Oversight Is Needed	Trouming to Biodicco
		Review, and Public Reporting		
Resnic	Frederic	PCI in the Era of Public Accountability:	Panelist	Nothing to Disclose
		Managing Risks to Patients, Providers, and		
		Institutions		
Resnic	Frederic	PCI in the Era of Public Accountability:	How to (and How Not to) Practice PCI in a Public Reporting	Nothing to Disclose
		Managing Risks to Patients, Providers, and	Environment	
Resor	Charles	Institutions Coronary Angiography, Intra-Vascular Imaging,	Association Between Predicted Risk of Recurrent Ischemic Events	Nothing to Disclose
1/6901	Cildiles	Revascularization and Outcomes	and Achievement of Secondary Prevention Goals After PCI	INOUTHING TO DISCHOSE
Reverberi	Claudio	Improving Outcomes in the Athlete With	The Heart Sentinel App for Automatic Detection and Alerting in	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
1		Cardiovascular Disease	Cardiac Arrest During Outdoor Sports: Ventricular Fibrillation	Parachute-app LLC
	<u></u>		Simulations and Preliminary Data in Athletes	• •
Revishvili	Amiran	New Strategies in Arrhythmias Management:	Hybrid Approach to Treating Persistent or Longstanding Atrial	CONSULTANT FEES/HONORARIA - Amycard LLC,Beringer
İ		International Perspectives From the Philippine	Fibrillation Treatment	Ingelheim, Biosense Webster, Biotronik, Boston
İ		Heart Association, Russian Society of		Scientific,MEDTRONIC,Sanofi-Aventis
1		Cardiology, and American College of Cardiology		
Reyes	Eugene	The Evolving World of LVADs, Transplant and	Chronic Kidney Disease in Asian Patients With Heart Failure	CONSULTANT FEES/HONORARIA - E. Merck
Reyes	Eugene	Other Novel Discoveries	Chionic Nuney Disease in Asian Patients With Heart Palitie	CONSULTANT FEES/HONORARIA - E. MEICK
Reynbakh	Olga	Arrhythmias and Clinical EP: Devices 3	Epicardial Lead Migration to the Spine With Development of	Nothing to Disclose
rtoynballi	o.gu	7 amyannao ana omnoa en escribes s	Vertebral Abscess	Trouming to 2 looses
Reynolds	Harmony	STEMI Dilemmas: You Be the Judge	Smoke but no Fire: STEMI Presentation with non Obstructive	RESEARCH/RESEARCH GRANTS - St Jude Medical
•	·		Disease by Angiography	
Reynolds	Harmony	Core Curriculum: ACS: What Would You Do?	MI with Non-obstructive CAD: Management Strategies	RESEARCH/RESEARCH GRANTS - St Jude Medical
Reynolds	Harmony	Acute Coronary Syndromes, Diagnosis,	ST-Segment Elevation and Cardiac Magnetic Resonance Imaging	RESEARCH/RESEARCH GRANTS - St Jude Medical
		Management and Outcomes	Findings in Myocardial Infarction With Non-Obstructive Coronary Arteries	
Reynolds	Harmony	Unusual Presentations of ACS	Takotsubo Cardiomyopathy Versus Apical Infarction in Patients With	RESEARCH/RESEARCH GRANTS - St Jude Medical
rtcyriolas	riamony	Chastai i resentations of Acc	Myocardial Infarction and Non-Obstructive Coronary Artery Disease	TREDEFINOTIFICEDEFINOTIFICITION OF OUR BUILDING
			(MINOCA)	
Reynolds	Harmony	02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - St Jude Medical
,	,	Clinical Team 1		
Reynolds	Kristi	Advances in Cholesterol Measurement and	Trends in Statin Use Among Adults in an Integrated Health Care	RESEARCH/RESEARCH GRANTS - Amarin, Amgen Inc., CLS
		Management	Delivery System: Impact of the 2013 Guideline on the Treatment of	Bering,iRhythm,Novartis Corporation,Regeneron,Sanofi-Aventis
			Blood Cholesterol	
Reynolds	Matthew	Highlighted Original Research: Acute and	Understanding Readmissions in Medicare Beneficiaries During the	CONSULTANT FEES/HONORARIA - Edwards
		Stable Ischemic Heart Disease and the Year in Review	90-Day Follow-Up Period Following an AMI Admission	Lifesciences,MEDTRONIC,St. Jude Medical; RESEARCH/RESEARCH GRANTS - MEDTRONIC
Reynolds	Matthew	Coronary Angiography, Intra-Vascular Imaging,	What is the Impact of Complications During the Index Hospitalization	CONSULTANT FEES/HONORARIA - Edwards
rtcyriolas	Wateriew	Revascularization and Outcomes	on Resource Utilization During the 90-Day Follow-Up Period	Lifesciences.MEDTRONIC.St. Jude Medical:
			Associated With CABG Surgery Among Medicare Beneficiaries?	RESEARCH/RESEARCH GRANTS - MEDTRONIC
Reynolds	Matthew	Innovative Approaches for Reducing Risk and	Does the Convergent Ablation Procedure Affect Left Atrial	CONSULTANT FEES/HONORARIA - Edwards
		Improving Outcomes With Ablation	Contractile Function?	Lifesciences,MEDTRONIC,St. Jude Medical;
L				RESEARCH/RESEARCH GRANTS - MEDTRONIC
Reynolds	Matthew	Coronary Intervention: Drug Eluting Stent and	A Cost-Effective Analysis of Short Duration Dual Anti-Platelet	CONSULTANT FEES/HONORARIA - Edwards
1		Scaffolds	Therapy (Dapt) With a Bioabsorbable Polymer Stent Platform	Lifesciences,MEDTRONIC,St. Jude Medical;
İ		1	Versus Longer Duration Dapt With a Durable Polymer Drug-Eluting Stent in a Patient Population Undergoing Elective Percutaneous	RESEARCH/RESEARCH GRANTS - MEDTRONIC
1		1	Coronary Intervention	
Reynolds	Matthew	Acute Coronary Syndromes, Diagnosis,	Medicare Reimbursement Associated With an AMI Hospitalization	CONSULTANT FEES/HONORARIA - Edwards
,		Management and Outcomes	and 90-Days Post-Discharge	Lifesciences,MEDTRONIC,St. Jude Medical;
		_		RESEARCH/RESEARCH GRANTS - MEDTRONIC
Reynolds	Matthew	The PCSK9 Revolution: New Insights Into	Impact of Statin Intolerance Rates on Need for Ezetimibe and/or	CONSULTANT FEES/HONORARIA - Edwards
1		Evaluation and Treatment	PCSK9 Inhibitors for Meeting Low-Density Lipoprotein Goals in a	Lifesciences, MEDTRONIC, St. Jude Medical;
Dozond-	Davila	Development and March 1915	Real-World Cohort With Atherosclerotic Cardiovascular Disease	RESEARCH/RESEARCH GRANTS - MEDTRONIC
Rezende	Paulo	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Cost-Effectiveness Analysis and Quality of Life of On-Pump and Off- Pump Stable Multivessel Coronary Artery Bypass Grafting: MASS III	Nothing to Disclose
1		III Acute and Stable Ischemic Heart Disease	Pump Stable Multivessel Coronary Artery Bypass Grafting: MASS III Trial 5-Year Follow-Up	
Rha	Seung-Woon	Late-Breaking Clinical Trials: Interventional	Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With	Nothing to Disclose
	Coung-1100H	23.0 S/Calking Onlinear Trials, Interventional	Coronary Chronic Total Occlusion: DECISION CTO Randomized	Trouming to Disciose
1		1	Trial	
Rha	Seung-Woon	Novel Developments in Acute Coronary	Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor	Nothing to Disclose
		Syndromes	and Angiotensin Receptor Blocker in Diabetic Hypertensive Acute	
		1	Myocardial Infarction Patients: Results From the Korea Acute	
DI.	0	Total Totals 1 1 2	Myocardial Infarction Registry (KAMIR)	N. C. L. B. J.
Rha	Seung-Woon	Timely Topics in Acute Coronary Syndromes	Predictors of Mortality in Acute Myocardial Infarction Patients With	Nothing to Disclose
Rha	Seung-Woon	Advances in Chronic Total Occlusion	Unprotected Left Main Coronary Artery Disease Impact of Percutaneous Coronary Intervention for Chronic Total	Nothing to Disclose
ruid	Seurig-vvoon	Advances in Chronic Total Occlusion Intervention	Impact of Percutaneous Coronary Intervention for Chronic Total Occlusion Patients With Near-Normal Left Ventricular Function	Nothing to Disclose
Rhyne	Rhonda	Traditional and Novel Factors Used to Assess	Multiple Biomarkers for Predicting Major Adverse Cardiac Events in	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
Tanyine	Monua	the Risk of, and Used for the Treatment of,	At-Risk Patients Undergoing Diagnostic Coronary Angiography:	ROLE - Prevencio, Inc.
		Coronary Artery Disease	Results From the Catheter Sampled Blood Archive in	TOZZ TOVOROD, IIIO.
		,, 5,0000	Cardiovascular Diseases (CASABLANCA) Study	
Riaz	Haris	Why Can't We Be Friends? Controversies in	Mortality Effect of Icd in Primary Prevention of Non Ischemic	Nothing to Disclose
		Heart Failure Management	Cardiomyopathy: A Meta Analysis of Randomized Control Trials	-
Riaz	Haris	Obesity Management in 2017: Weighing the	A Meta-Analysis of Cardiovascular Safety of FDA Approved Anti	Nothing to Disclose
	ļ	Issues	Obesity Drugs	
Ribbeck	Amanda	Updates on Pulmonary Embolism	Rapid Improvement in Right Ventricular Systolic Function in Patients	Nothing to Disclose
1		Management in 2017	With Pulmonary Embolism Treated With Ultrasound-Assisted	
	i .	Î.	Catheter Directed Thrombolysis	İ

Last Name Ribeiro	First Name Henrique	Session Title Innovation in Practice Management, Advocacy,	Presentation Title Improvement in Quality Indicators Using NCDR® Registries:	Disclosures Nothing to Disclose
Ribichini	Flavio	and Education Interventional Cardiology: Intravascular Physiology and Endothelial Function	First International Experience Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With	Nothing to Disclose
			Coronary Artery Disease: Primary Results of International Multicentre iFR GRADIENT Registry	
Ricci	Beatrice	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Acute Coronary Syndrome: The Risk to Be Young and Women	Nothing to Disclose
Ricciardi	Mark	Interventional Cardiology: TAVR 2	Intensity of Statin Therapy and Outcomes After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Abbott Laboratories
Rich	Jonathan	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Severe Physical Inactivity Persists Following Acute Heart Failure in Patients With Sleep Disordered Breathing	CONSULTANT FEES/HONORARIA - HeartWare; SPEAKER'S BUREAU - Bayer Healthcare Pharmaceuticals,Novartis,Otsuka Pharmaceutical Co.
Rich	Jonathan	35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - HeartWare; SPEAKER'S BUREAU - Bayer Healthcare Pharmaceuticals,Novartis,Otsuka Pharmaceutical Co.
Rich Rich	Michael Michael	FIT Forum: Mix and Mingle Structural Heart Disease: Difficult Choices for the Heart Team	 Panelist	Nothing to Disclose Nothing to Disclose
Rich	Michael	13. Heart Failure and Cardiomyopathies: Clinical Team 5	Suggested Reviewer	Nothing to Disclose
Richards	Lauren	Arrhythmias and Clinical EP: Basic 3	Impact of Obstructive Sleep Apnea Severity on Cardiac Events in Patients With Normal or Prolonged Ventricular Repolarization	Nothing to Disclose
Richards	Mark	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Obstructive Sleep Apnea and Diabetes Mellitus Have Synergistic Effects on Adverse Cardiac and Cerebrovascular Events in Patients Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Richards	Mark	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Chronic Kidney Disease in Asian Patients With Heart Failure	Nothing to Disclose
Richards	Mark	Unusual Presentations of ACS	Prevalence and Evolution of Sleep Disordered Breathing in Acute Myocardial Infarction	Nothing to Disclose
Richardson	Jori	Arrhythmias and Clinical EP: Devices 2	Selective Same Day Discharge After Biventricular Implantation as a Value Based Strategy: Safe and Cost Effective	RESEARCH/RESEARCH GRANTS - St Jude Medical
Richardson	Travis	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Idiopathic Ventricular Tachycardia Arising From the Left Ventricular Summit Treated With Endocardial Catheter Ablation Followed by	Nothing to Disclose
Richardt	Gert	Late-Breaking Clinical Trials: Interventional	Cardiac Sympathectomy FFR Guided Acute Complete Revascularization Versus Culprit Lesion Only Treatment in Patients Presenting With ST-Segment Elevation Myocardial Infarction and Multi Vessel Disease: The	CONSULTANT FEES/HONORARIA - Abbott Vascular,Biotronik,Boston Scientific
Richmond	Robert	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	COMPARE-ACUTE Trial Valvuloplasty in Woman With Heterotaxy Syndrome	Nothing to Disclose
Richter	Dimitri	Innovations in Cardiovascular Risk Assessment and Reduction	Most Patients With Acute Coronary Syndromes Are Already at High Risk Prior to the Event and Lipid Management Is Underachieved Both Before and After Hospitalization: The Phaethon Study	CONSULTANT FEES/HONORARIA - AABOTT LABORATORIES,Astra Zeneca,galenica,MSD,Novartis,Pfizer
Ricketts	Amy	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Interstage Resource Utilization of Infants With Single Ventricle: Results of a Crossover Study	Nothing to Disclose
Rico Mesa	Juan	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Holter Findings in Orthotopic Heart Transplantation Patients: Results From a Cohort of the Most Important Heart Transplant Referral Center in Colombia, South America	Nothing to Disclose
Ridker	Paul	Opening Session and the Joint American College of Cardiology and Journal of American College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture	Safety and Cardiovascular Event Efficacy of Bococizumab Among	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,CSL Behring, Přízer,SANOR1, Teva; OWNERSHIP iNTEREST/PARTNERSHIP/PRINCIPAL - Brigham and Women's Hospital; RESEARCH/RESEARCH GRANTS - Kowa Pharmaceuticals,National Heart Lung and Blood Institute (MHLBI),Novartis,Přízer
Ridker	Paul	Late-Breaking Clinical Trials: Deep Dive I	Safety and Cardiovascular Event Efficacy of Bococizumab Among 27,000 High Risk Patients	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,CSL Behring, Pfizer,SANOFI, Teva; OWNERSHIP iNTEREST/PARTNERSHIP/PRINCIPAL - Brigham and Women's Hospital; RESEARCH/RESEARCH GRANTS - Kowa Pharmaceuticals,National Heart Lung and Blood Institute (NHLBI),Novartis,Pfizer
Ridker	Paul	Are We There Yet? Update on Trials Testing New Therapeutics for Prevention of ASCVD	Panelist	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,CSL Behring, Pfizer,SANOFI, Tevar, L OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Brigham and Women's Hospital: RESEARCH/RESEARCH GRANTS - Kowa Pharmaceuticals, National Heart Lung and Blood Institute (NHLBI),Novartis,Pfizer
Ridker	Paul	Are We There Yet? Update on Trials Testing New Therapeutics for Prevention of ASCVD	Beyond Lipids - Anti-inflammatory Treatment for Cardiovascular Disease Prevention	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, CSL Behring , Pfizer, SANOFI, Teva; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Brigham and Women's Hospital; RESEARCH/RESEARCH GRANTS - Kowa Pharmaceuticals, National Heart Lung and Blood Institute (NHLBI), Novartis, Pfizer
Ridner	Michael	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team 1	Suggested Reviewer	Nothing to Disclose
Ridocci-Soriano	Francisco	Non Invasive Imaging: MR Scar and Perfusion	Mean Pulmonary Artery Velocity Estimated by Cardiac Magnetic Resonance as an Early Prognostic Indicator in Heart Failure With Reduced Ejection Fraction Irrespective of Right Ventricular Function	Nothing to Disclose
Riebman	Jerome	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Rationale and Methods of the Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE-HF) Study	OTHER - Novartis Pharmaceuticals Corp
Riedy	Katherine	Novel Echocardiographic Methods for Assessing Cardiac Function	Use of Diastolic Parameters on Transthoracic Echocardiogram to Predict Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation	Nothing to Disclose
Rief	Matthias	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Calcium Characteristics as Predictors of Major Adverse Cardiac Events in Symptomatic Patients: Insights From the CORE320 Multinational Study	Nothing to Disclose
Riello	Ralph	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		SPEAKER'S BUREAU - Janssen Pharmaceuticals, Inc
Riemer	R. Kirk	Valvular Heart Disease: Aortic Regurgitation	Identification of Human Aortic Valve Leaflet Genes Associated With Disruption of Homeostasis in Aortic Regurgitation and Aortic Stenosis Patients	Nothing to Disclose
Rieu	Régis	Interventional Cardiology: TAVR 1	Effect of Valve Oversizing on Leaflet Bending Stress in the CoreValve: An In Vitro Study	Nothing to Disclose
Rieu	Régis	Interventional Cardiology: TAVR 4	Clinical Study of the Impact of Preexisting Patient-Prosthesis Mismatch on Valve-in-Valve Performance	Nothing to Disclose
Rifaie	Osama	Innovative Use of Echocardiography	Concordance of Conventional 2D-Doppler Versus Speckle Tracking	Nothing to Disclose
			Echocardiography-Based Classification of Left Ventricular Diastolic Function	

				l l
	First Name	Session Title	Presentation Title	Disclosures
rigattieri	stefano	Featured Clinical Research II: Interventional	Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD Matrix Study	Nothing to Disclose
Rigolin	Vera	Echocardiography: What is New in 2017	Co-Chair	SALARY - Pfizer
Rigolin	Vera	Structural Heart Interventions: What Does the	Imaging in Peri-valvular Leak Interventions: Tips and Tricks	SALARY - Pfizer
-		Imager Need to know		
Rigolin	Vera	Imaging the Athlete's Heart	Deformation Analysis Can Be Performed on Post-Exercise Images in National Basketball Association Draft Eligible Players With Good Reproducibility	SALARY - Pfizer
Rigolin	Vera	Engage @ ACC.17 Studio: Cardiology Contest	Cardiology Contestant	SALARY - Pfizer
Rigolin	Vera	Tricuspid Regurgitation: Signals in Plain Sight	ACC Poster Moderator	SALARY - Pfizer
Rigolin	Vera	36. Valvular Heart Disease: Clinical Team 3	Suggested Reviewer	SALARY - Pfizer
Rigotti	Nancy	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Smoking Cessation Therapies Are Persistently and Significantly Underutilized Among Hospitalized Smokers With Coronary Heart Disease	CONSULTANT FEES/HONORARIA - Pfizer; RESEARCH/RESEARCH GRANTS - Nabi Biopharmaceuticals,Pfizer
Rihal	Charanjit	Interventional Live Case Session III: Structural Transmission from Cleveland Clinic (Cleveland, Ohio)	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott,Edward Life Sciences
Rihal	Charanjit	Imaging for Left Atrial Appendage and Paravalvular Leak Closure: A Case Based Approach	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott,Edward Life Sciences
Rihal	Charanjit	Imaging for Left Atrial Appendage and Paravalvular Leak Closure: A Case Based Approach	Paravalvular Leak: Overriding Principals and Pre-Procedural Criteria	CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott,Edward Life Sciences
Rihal	Charanjit	PFO Closure, PV Leak, and VSD Repair	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott,Edward Life Sciences
Rihal	Charanjit	PFO Closure, PV Leak, and VSD Repair	Treatment of Mitral PV Leak: Basic Approaches and Outcomes	CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott,Edward Life Sciences
Rihal	Charanjit	Valvular Heart Disease: Endocarditis	Infective Endocarditis Following Transcutaneous Aortic Valve Implantation: Clinical, Echocardiographic and Hemodynamic	CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott,Edward Life
Rihal	Charanjit	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Features Acute Changes in Left Atrial Pressure Following MitraClip are Associated With Long Term Improvement in 6 Min Walk Distance	Sciences CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott,Edward Life Sciences
Rihal	Charanjit	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Transcatheter Mitral Valve Repair (Mitraclip) in United States: Etiologies and Predictors of Readmission and In-Hospital Mortality	CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott,Edward Life
Rihal	Charanjit	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	From the Nationwide Readmission Database Transcatheter Mitral Valve Repair (Mitra Clip) in United States: Length of Stay and Cost of Hospitalizations From the Nationwide	Sciences CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott,Edward Life
Rihal	Charanjit	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Readmission Database 3D Printing for Procedural Simulation of Transcatheter Mitral Valve Replacement in Patients With Mitral Annular Calcification	Sciences CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott,Edward Life
Rihal	Charanjit	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Elevated Uric Acid Is Associated With Increased Mortality in Women Undergoing Percutaneous Coronary Intervention	Sciences CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott, Edward Life
Rihal	Charanjit	Interventional Cardiology: TAVR 2	Association of Chronic Renal Insufficiency With In-Hospital Outcomes of Transcatheter Aortic Valve Replacement	Sciences CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott, Edward Life
Rihal	Charanjit	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Sex Differences in Revascularization and In-Hospital Outcomes of Non-ST-Segment Elevation Myocardial Infarction in the United	Sciences CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott,Edward Life
Rihal	Charanjit	Syndrome Interventional Cardiology: TAVR 3	States Regional Variations in In-Hospital Outcomes and Healthcare	Sciences CONSULTANT FEES/HONORARIA - Abbott Vascular;
Rihal	Charanjit	Interventional Cardiology: TAVR 3	Resource Utilization in Patients Undergoing Transcatheter Aortic Valve Replacement in the United States Comparative Outcome of Paravalvular Leak Following Surgical	RESEARCH/RESEARCH GRANTS - Abbott,Edward Life Sciences CONSULTANT FEES/HONORARIA - Abbott Vascular;
Rihal	Charanjit	Insights From Echocardiography Use	Versus Transcatheter Aortic Valve Replacement Echocardiographic Parameters of Myocardial Performance After	RESEARCH/RESEARCH GRANTS - Abbott,Edward Life Sciences CONSULTANT FEES/HONORARIA - Abbott Vascular;
			Transapical Versus Transfemoral Transcatheter Aortic Valve Replacement	RESEARCH/RESEARCH GRANTS - Abbott,Edward Life Sciences
Rihal	Charanjit	Engage @ ACC.17 Studio: Heart Teams in Action: Complex Coronary Revascularization	Mayo Interventionalist	CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott,Edward Life Sciences
Rihal	Charanjit	Refining TAVR Outcomes	Incidence and Outcomes of Patients Requiring Surgical Bail-Out During Transcatheter Aortic Valve Replacement: A Report From the NCDR® STS/ACC Transcatheter Valve Therapy (TVT) Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott,Edward Life Sciences
Rihal	Charanjit	Frontiers in Mitral Valve Disease and Treatment	Long Term Outcomes of Patients Undergoing Percutaneous and Surgical Mitral Paravalvular Leak Repair	CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott,Edward Life Sciences
Rihal	Charanjit	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular; RESEARCH/RESEARCH GRANTS - Abbott,Edward Life Sciences
Riley	Hayden	Predicting Outcomes in Cardiac Rehabilitation	Smoking Cessation Is Strongly Associated With Attendance at	Nothing to Disclose
Riley	Michael	Patients Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Cardiac Rehab: But Which Comes First? Anticoagulation Use and Incidence of Cerebrovascular Events and Major Bleeding After Catheter Ablation in Patients With Persistent	Nothing to Disclose
Riley	Robert	Advances in Chronic Total Occlusion Intervention	and Longstanding Persistent Atrial Fibrillation Hemodynamically-Supported PCI of Chronic Total Occlusions: A Case Series	Nothing to Disclose
Rinaldi	Michael	PCI for NSTEMI and Complex Patients With	Platelet Reactivity and Outcomes After PCI of Saphenous Vein	CONSULTANT FEES/HONORARIA - Abbott, Boston
Rinaldi	Michael	Multiple Co-Morbidities Advances in Chronic Total Occlusion	Grafts Versus Native Coronary Arteries: The ADAPT-DES Study Is Platelet Reactivity Associated With Ischemic Events Following	Scientific, Volcano; SPEAKER'S BUREAU - ewards CONSULTANT FEES/HONORARIA - Abbott, Boston
		Intervention	Successful Chronic Total Occlusion Percutaneous Coronary Intervention	Scientific, Volcano; SPEAKER'S BUREAU - ewards
Rinfret	Stéphane	Interventional Live Case Session II: CTO Transmission from Mid-America Heart Institute	Panelist	CONSULTANT FEES/HONORARIA - Boston Scientific
Rinfret	Stéphane	(Kansas City, Missouri) Chronic Total Occlusion PCI: A Case-Based Review of Contemporary Techniques	Case Presentation: Radial CTO	CONSULTANT FEES/HONORARIA - Boston Scientific
Rinfret	Stéphane	20. Interventional Cardiology: Coronary Intervention: CTO Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific
Ring	Michael	Public Reporting and NCDR: The Decision to Report Your Data Before the Feds Decide	NCDR and Regional Hospital Public Reporting: The Washington State	CONSULTANT FEES/HONORARIA - Boston Scientific; OTHER - MEDTRONIC; SPEAKER'S BUREAU - Amgen Inc.
Ringel	Richard	Predicting Outcomes in Pediatric Heart Disase	ACC Poster Moderator	Nothing to Disclose
Rink	Lawrence	Improving Outcomes in the Athlete With	American Heart Association Preparticipation Cardiovascular	Nothing to Disclose
Ritt	Luiz Eduardo	Cardiovascular Disease Measuring Success in Cardiac Rehabilitation	Screening of Competitive Athletes History Elements Applied to a Diverse International Screening Program Stair Step Test and Sitting Rising Chair Test as Predictors of	Nothing to Disclose
· sist	Luiz Ludardo		Maximal Oxigen Uptake	Treating to Disciose

(P) T				
Ritvo	First Name Paul	Session Title Arrhythmias and Clinical EP: AF Ablation	Presentation Title Determination of the Ideal Contact Force Required During	Disclosures Nothing to Disclose
Rivera	Manuel	Arrhythmias and Clinical EP: Ventricular	Pulmonary Vein Antrum Isolation (PVAI) Percutaneous Epicardial Mapping and Ablation of Ventricular	Nothing to Disclose
Rivera	Manuel	Tachycardia Heart Failure and Cardiomyopathies: Heart	Tachycardia: A Systematic Review of Safety Outcomes A Meta-Analysis of Randomized Controlled Trials on Vagus Nerve	Nothing to Disclose
Rivera-Rodriguez	Agustin	Failure Gadgets Galore Non Invasive Imaging: MR Structure and	Stimulation for the Heart Failure Management QRS Fragmentation Predicts Myocardial Fibrosis, Left Ventricular	Nothing to Disclose
		Valuvular Heart Disease	Dysfunction and Ventricular Tachycardia in Chagas´ Disease	
Rivers	Joshua	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Small Dense Low Density Lipoprotein Particle Number Relates to Coronary Plaque Burden Independent of Traditional Cardiovascular Risk Factors in Psoriasis	Nothing to Disclose
Rivers	Joshua	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Aortic Vascular Inflammation by 18-FDG PET/CT Associates With High-Risk Coronary Plaques in Young Psoriasis Patients	Nothing to Disclose
Rivers	Joshua	Vascular Medicine: New Insights Into Aortic and Peripheral Artery Diseases	Improvement in Cholesterol Efflux Capacity is Associated With Improvement in Vascular Inflammation by 18- FDG PET CT in Psoriasis	Nothing to Disclose
Rivers	Joshua	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Improvement in Cholesterol Efflux Capacity Is Associated With a Reduction in Aortic Wall Thickness by MRI Independent of Traditional CV Risk Factors	Nothing to Disclose
Rivers	Joshua	Updates on Risk Factors for Cardiovascular Disease	Visceral but Not Subcutaneous Adipose Tissue Associates With Vascular Inflammation by 18-FDG PET/CT in Psoriasis	Nothing to Disclose
Rivner	Harold	Arrhythmias and Clinical EP: Ventricular	Percutaneous Epicardial Mapping and Ablation of Ventricular	Nothing to Disclose
Rivner	Harold	Tachycardia Cutting Edge Vascular Medicine	Tachycardia: A Systematic Review of Safety Outcomes A Meta-Analysis of Bivalirudin Versus Argatroban for the Treatment	Nothing to Disclose
Rizik	David	Debates on Current Hot Topics in Coronary	of Heparin-Induced Thrombocytopenia Debate Pro: Yes, Bioresorbable Scaffolds Represent the Future of	OTHER - Abbott Vascular, Cordis; SPEAKER'S BUREAU -
Rizik	David	Intervention Challenging PCI: Tips and Tricks from the	PCI Case Presentation: Wiring Angulated Side Branches and Crushed	Boston Scientific OTHER - Abbott Vascular, Cordis; SPEAKER'S BUREAU -
Rizik	David	Experts Bioresorbable Vascular Scaffolds,	Stents Debate Con: Appropriate Patient Selection- BVS Can and Should	Boston Scientific OTHER - Abbott Vascular, Cordis; SPEAKER'S BUREAU -
		Bioresorbable Polymer and Polymer Free Metallic DES	Be Used More Broadly	Boston Scientific
Rizopoulos	Dimitris	Emerging Developments in HFpEF and Arryhthmias	Sex Differences in Risk Factors for Longitudinal Changes in Left Ventricular Diastolic Function: The Rotterdam Study	Nothing to Disclose
Rizvi	Asim	Non Invasive Imaging: Expanding Clinical Applications	Dual-Energy Coronary Computed Tomography Evaluation of High- Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients: Validation with Histopathologic Gold Standard	Nothing to Disclose
Rizvi	Asim	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Incremental Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Scoring for Predicting Major Adverse Cardiac Events According to Impaired Renal Function: The CONFIRM Registry	Nothing to Disclose
Rizvi	Asim	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography. The CONFIRM (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	Nothing to Disclose
Rizvi	Asim	Innovations in Cardiovascular Risk Assessment and Reduction	Atherosclerotic Cardiovascular Disease Risk in Statin-Naïve Asymptomatic Patients With Non-Obstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography: The CONFIRM-LT (COronary CT Angiography Evaluation For Clinical Outcomes: An InterNational Multicenter)	Nothing to Disclose
Rizvi	Asim	Non Invasive Imaging: Prognostic Implications of CT Angiography	Registry Prognostic Utility of Coronary Computed Tomographic Angiography Beyond Coronary Artery Calcium Score in Diabetic Patients With No Symptoms or Non-Typical Chest Pain: The CONFIRM Registry	Nothing to Disclose
Rizvi	Asim	Non Invasive Imaging: Prognostic Implications	Prognosis of Obstructive and Non-Obstructive Stents by Coronary	Nothing to Disclose
Rizvi	Asim	of CT Angiography Non Invasive Imaging: Prognostic Implications of CT Angiography	Computed Tomographic Angiography: The CONFIRM Registry Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Death: A Comparison to a Histologic Reference Standard	Nothing to Disclose
Rizvi	Asim	Diabetes and Other Issues in Cardiovascular Prevention	Implications of Statin Therapy Among Smokers With Severe Coronary Artery Calcification: An Analysis of the CONFIRM Registry	Nothing to Disclose
Rizvi	Asim	Non Invasive Imaging: New Technologies	Optimal Method for Necrotic Core Identification in Coronary Plaque With Dual-Energy Computed Tomography: Material Decomposition and Atomic Number	Nothing to Disclose
Rizzi Coelho Filho	Otavio	Non Invasive Imaging: MR Scar and Perfusion	Doxorubicin-Associated Cardiac Tissue Remodeling in Breast Cancer Patients: A Cardiac Magnetic Resonance Study	Nothing to Disclose
Robbins	Jeremy	Predicting the Future: Observations and Discoveries From Registries and Databases	Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study	Nothing to Disclose
Roberto	Samuel	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Long Term Mortality Rates of U.S. Veterans With Bundle Branch	Nothing to Disclose
Roberto	Samuel	FIT Clinical Decision Making: Arrhythmias and	Blocks Presenting for Coronary Angiography Simple Atrial Flutter Ablation Causing Cardiogenic Shock, Mitral Requiritation and Complete Heart Block	Nothing to Disclose
Roberto	Samuel	Electrophysiology FIT Clinical Decision Making: Arrhythmias and	Sources of Inappropriate ICD Shocks, Look for Inside and Outside	Nothing to Disclose
Roberto	Samuel	Electrophysiology Innovations in Advocacy and Patient Centered	of the Heart Long Term Mortality Rates of Premature Coronary Artery Disease in	Nothing to Disclose
Roberts	Jonathan	Care Vascular Access and Hemostasis Issues	Young U.S. Veteran Population Pilot Trial Comparison of a Kaolin-Based Hemostatic Pad	Nothing to Disclose
			(QuikClot® Radial™) Versus Mechanical Compression (TR Band®) to Reduce Compression Time Following Transradial Access	
Roberts	Louise	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Outcomes of Pre-Loading Versus In-Lab Loading With Prasugrel and Ticagrelor in Patients With Acute Coronary Syndromes (ACS) Undergoing Percutaneous Coronary Intervention (PCI)	Nothing to Disclose
Roberts	Louise	Novel Arrhythmia Diagnostics, Therapeutics, and "Wearables	Accuracy of Smart Watches in Arrhythmias: <i>SMARTS</i> Study	Nothing to Disclose
Roberts	Louise	Novel Arrhythmia Diagnostics, Therapeutics, and "Wearables	High Atrial Ectopy in Stroke: An Independent Risk Factor?	Nothing to Disclose
Roberts	Madhur	Engage @ ACC.17 Studio: FIT Jeopardy Battle	Moderator	Nothing to Disclose
Robertson	Charlene	of the State Chapters II Impact of Prenatal Environment on Congenital Heart Disease	Umbilical Arterial Blood Flow in the Third Trimester and Its Association With Clinical and Neurodevelopmental Outcomes in	Nothing to Disclose
Robertson	Gregory	Advances in Chronic Total Occlusion Intervention	Children With Critical Neonatal Congenital Heart Disease Performance of J-CTO and PROGRESS CTO Scores in Predicting Angiographic Success and Long-Term Clinical Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Avinger Medical; SPEAKER'S BUREAU - Abbott Laboratories
Robich	Michael	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Is CABG the Best Revascularization Strategy Among All Diabetics Subgroups With Multi-Vessel Disease in the Modern Era? A Multi-	Nothing to Disclose

				l
Last Name Robinson	First Name Bradley	Session Title The Story of the Adult Congenital Heart	Presentation Title Acquired Long-Term Cardiac Rhythm and Conduction	Disclosures Nothing to Disclose
Robinson	Jennifer	Disease Patient and EP Opening Session and the Joint American	Abnormalities After Arterial Switch Operation Panelist	CONSULTANT FEES/HONORARIA - Akcea/lonis,Amgen,Eli Lilly
KODIIISOII	Jennier	College of Cardiology and Journal of American	raneist	and Company, Esperion, Merck & amp; amp; Co., Inc., Pfizer, Sanofi-
		College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture		Regeneron; RESEARCH/RESEARCH GRANTS - Amarin,Amgen,Astra Zeneca,Eli Lilly and
				Company,ESAI,Esperion,Glaxo Smith
Robinson	Jennifer	Advances in Cholesterol Measurement and	Contemporary Patterns of Lipid Testing in Primary and Secondary	Kline,Merck,Pfizer,Regeneron,Sanofi-Aventis,Takeda CONSULTANT FEES/HONORARIA - Akcea/lonis,Amgen,Eli Lilly
		Management	Prevention Patients: Insights From the PALM Registry	and Company, Esperion, Merck & amp; amp; Co., Inc., Pfizer, Sanofi-
				Regeneron; RESEARCH/RESEARCH GRANTS - Amarin,Amgen,Astra Zeneca,Eli Lilly and
				Company,ESAI,Esperion,Glaxo Smith Kline,Merck,Pfizer,Regeneron,Sanofi-Aventis,Takeda
Robinson	Jennifer	Advances in Cholesterol Measurement and	Consistent Low-Density Lipoprotein Cholesterol Lowering Efficacy of	CONSULTANT FEES/HONORARIA - Akcea/Ionis, Amgen, Eli Lilly
		Management	Alirocumab in High and Very High Cardiovascular Risk Patients With Low-Density Lipoprotein Cholesterol >100/70 mg/dL at	and Company, Esperion, Merck & amp; amp; Co., Inc., Pfizer, Sanofi- Regeneron; RESEARCH/RESEARCH GRANTS -
			Baseline	Amarin,Amgen,Astra Zeneca,Eli Lilly and
				Company,ESAI,Esperion,Glaxo Smith Kline,Merck,Pfizer,Regeneron,Sanofi-Aventis,Takeda
Robinson	Jennifer	Advances in Lipid Management	Alirocumab Reduces Major Cardiovascular Events in Individuals	CONSULTANT FEES/HONORARIA - Akcea/lonis,Amgen,Eli Lilly
			With Atherosclerotic Cardiovascular Disease: A Post-Hoc Analysis of ODYSSEY LONG TERM	and Company, Esperion, Merck & Department, Co., Inc., Pfizer, Sanofi- Regeneron; RESEARCH/RESEARCH GRANTS -
				Amarin,Amgen,Astra Zeneca,Eli Lilly and Company,ESAI,Esperion,Glaxo Smith
				Kline,Merck,Pfizer,Regeneron,Sanofi-Aventis,Takeda
Robinson	Newell	Interventional Cardiology: TAVR 3	The Natural History of Paravalvular Regurgitation After Transarterial Valve Implantation for Severe Aortic Stenosis: One Center	Nothing to Disclose
			Experience	
Robinson	Simon	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Renal Function-Based Contrast Dosing to Define "Prognostic" Contrast Dose Limits for Percutaneous Coronary Intervention - The	Nothing to Disclose
			Prognostic Implication of the Contrast Volume: Glomerular Filtration	
			Ratio in 44,082 Patients From the British Columbia Cardiac Registry	
Robinson	Simon	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Variation in Practice and Concordance With Guideline Criteria for Length of Stay After Elective Percutaneous Coronary Intervention	Nothing to Disclose
Robinson	Victoria	FIT Clinical Decision Making: Heart Failure and	A Case of Familial Dilated Cardiomyopathy With a Reversible	Nothing to Disclose
		Cardiomyopathies	Phenotype: The Utility of Genetic Testing and Genotype-Specific Treatment	
Roby	Matthew	FIT Clinical Decision Making: Prevention, Adult	Endarteritis Complicating Aortic Coarctation Diagnosed by Transesophageal Echocardiogram	Nothing to Disclose
		Congenital and Congenital Heart Disease		
Rocco	Elena	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Safe Multidisciplinary Management of New Therapies: The Ritmo Project (Real Time Continuous Web Monitoring)	Nothing to Disclose
Rochitte	Carlos	Contemporary Issues in Familial	Achilles Tendon Xanthomas Are Independently Associated With	Nothing to Disclose
		Hypercholesterolemia	Severity of Subclinical Coronary Atherosclerosis in Familial Hypercholesterolemia	
Rochitte Rodante	Carlos Justin	29. Non Invasive Imaging: MR Team 1 Non Invasive Imaging: Applications in Novel	Suggested Reviewer Small Dense Low Density Lipoprotein Particle Number Relates to	Nothing to Disclose Nothing to Disclose
rodante	Justin	Disease States and Clinical Scenarios	Coronary Plaque Burden Independent of Traditional Cardiovascular	Nothing to Disclose
Rodante	Justin	Non Invasive Imaging: Applications in Novel	Risk Factors in Psoriasis Aortic Vascular Inflammation by 18-FDG PET/CT Associates With	Nothing to Disclose
		Disease States and Clinical Scenarios	High-Risk Coronary Plaques in Young Psoriasis Patients	-
Rodante	Justin	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Improvement in Cholesterol Efflux Capacity Is Associated With a Reduction in Aortic Wall Thickness by MRI Independent of	Nothing to Disclose
Rodante	Justin	Updates on Risk Factors for Cardiovascular	Traditional CV Risk Factors Visceral but Not Subcutaneous Adipose Tissue Associates With	Nothing to Disclose
		Disease	Vascular Inflammation by 18-FDG PET/CT in Psoriasis	-
Roda-Renzelli	Anthony	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	The Feasibility and Safety of Same Day Discharge for All Comers After Elective Percutaneous Coronary Interventions	Nothing to Disclose
Rodeheffer	Richard	Making Progress in Understanding Heart Failure	Incidence of Preclinical (Stage A and B) Heart Failure in the General Population	Nothing to Disclose
Rodeheffer	Richard	The Evolving World of LVADs, Transplant and	Neurohumoral Activation and Long-Term Cardiovascular Outcomes	Nothing to Disclose
Rodes-Cabau	Josep	Other Novel Discoveries Interventional Cardiology: TAVR 4	in Chronic Kidney Disease: A Population-Based Cohort Clinical Study of the Impact of Preexisting Patient-Prosthesis	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Rodes-Cabau			Mismatch on Valve-in-Valve Performance Three-Year Results From the EVOLVE II Randomized Trial: Late	Inc.,MEDTRONIC,St Jude,V-Wave RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Roues-Cabau	Josep	Refining PCI Technique and Outcomes	Clinical Outcomes With Bioresorbable Compared to Permanent	Inc.,MEDTRONIC,St Jude,V-Wave
Rodes-Cabau	Josep	24. Interventional Cardiology: Mitral and	Polymer Everolimus-Eluting Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
	·	Structural Heart Disease Team 1		Inc.,MEDTRONIC,St Jude,V-Wave
Rodés-Cabau	Josep	Frontiers in Mitral Valve Disease and Treatment	Significant Mitral Regurgitation in Patients Undergoing Transcatheter Aortic Valve Replacement: Evolution and Imaging Predictors of	RESEARCH/RESEARCH GRANTS - Boston Scientific, Sanofi
			Improvement	Aventis / BMS; SPEAKER'S BUREAU - Astra Zeneca,St Jude Medical
Rodgers	George	Interdisciplinary Cardiovascular Team Care	ACC Poster Moderator	Nothing to Disclose
Rodgers	George	Delivery: Quality, Safety, and Satisfaction Cardiovascular Team Cases: Team 2	Suggested Reviewer	Nothing to Disclose
Rodgers	Jo	Acute Heart Failure: Evaluating Strategies to	Readmissions for Patients Discharged With Acute Decompensated Heart Failure and Reduced Versus Preserved Ejection Fraction: The	Nothing to Disclose
		Prevent Readmissions	Atherosclerosis Risk in Communities Study	
Rodriguez	Alexis	Updates on Risk Factors for Cardiovascular Disease	Hospital Admissions for Chest Pain Associated With Cocaine use in the United States	Nothing to Disclose
Rodriguez	Alexis	Arrhythmias and Clinical EP: Syncope and	Mortality Rates and Cost of Hospital Admissions for Syncope in the	Nothing to Disclose
Rodriguez	Fatima	Other EP Issues Advances in Cholesterol Measurement and	United States Predictors of Statin Use for Patients With LDL Cholesterol Above	Nothing to Disclose
_	Fatina a	Management	190mg/dL: Insights From the Veterans Affairs Health Care System	Nething to Displace
Rodriguez	Fatima	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Nativity Status and Cardiovascular Disease Mortality Among Hispanics	Nothing to Disclose
Rodriguez Rodriguez	Fred Fred	Redefining the "F" Word Redefining the "F" Word	Biomarker Profile in Adults With Fontan Circulation Adults With Congenital Heart Disease: Lost in Care	Nothing to Disclose Nothing to Disclose
Rodriguez	Fred	Congenital Heart Disease: To the Third	Red Blood Cell Distribution Width and Outcomes in Fontan Patients	Nothing to Disclose
Rodriguez	Fred	Decade and Beyond Congenital Heart Disease: To the Third	Prevalence and Incidence of Heart Failure in Adolescents and	Nothing to Disclose
		Decade and Beyond	Adults With Repaired Tetralogy of Fallot	
Rodriguez	Fred	Things That Matter in Adult Congenital Heart Disease	ACC Poster Moderator	Nothing to Disclose
Rodriguez	L. Leonardo	Highlighted Original Research: Interventional Cardiology and the Year in Review	Implications of Worsening Right Ventricular Function Following Transcatheter or Surgical Aortic Valve Replacement: Insights From	Nothing to Disclose
			PARTNER2A	
Rodriguez	L. Leonardo	Interventional Cardiology: TAVR 2	Worsening Tricuspid Regurgitation and Increased Mortality After Aortic Valve Replacement: Insights From PARTNER2A	Nothing to Disclose
Rodriguez	L. Leonardo	Insights From Echocardiography Use	Aortic Regurgitation Negatively Affects Left Ventricular Mechanics	Nothing to Disclose
	l	l .	After Transcatheter Aortic Valve Replacement	



Last Name Rodriguez	First Name L. Leonardo	Session Title TAVR Outcomes Prognostication	Presentation Title Cardiac Plasticity Predicts Outcome After Transcatheter Aortic	Disclosures Nothing to Disclose
Rodriguez	Leonardo	Interventional Cardiology: TAVR 1	Valve Replacement in Patients With Severe Aortic Stenosis Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis	Nothing to Disclose
-		-	After Aortic Valve Replacement: Insights From PARTNER 2A Trial	-
Rodriguez Zanella	Hugo	The Challenges of Outcome Prediction in Valvular Heart Disease	Right Ventricle Free Wall Strain Predicts Post-Surgical Low Cardiac Output Syndrome in Patients Undergoing Aortic Valve Replacement	Nothing to Disclose
Rodriguez-Granillo	Alfredo	25. Interventional Cardiology: Translation and Pre-clinical Research Team 1	Suggested Reviewer	Nothing to Disclose
Rodwin	Benjamin	Arrhythmias and Clinical EP: Basic 1	Variation in the Use of Direct Oral Anticoagulants and Associated	Nothing to Disclose
			Cost Implications: Findings From the Medical Expenditure Panel Survey 2010 to 2013	
Roe	Matthew	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	A Randomized Trial Evaluating Clinically Significant Bleeding With Low-Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, for Patients After Acute Coronary Syndromes	CONSULTANT FEES/HONORARIA - Amgen, Astra Zeneca, Boehringer ingelheim Pharmaceuticals, Inc, MyoKardia, Quest Diagnostics; OTHER - Bristol-Myers Squibb Company, Daiichi-Sankyo, Eli Lilly and Company, Merck, Pri-Med; RESEARCH/RESEARCH GRANTS - Eli Lilly, Familial Hypercholesterolemia Foundation, Ferring Pharmaceuticals, Janssen Pharmaceuticals, Sanofi-Aventis
Roe	Matthew	Advances in Lipid Management	Use of High-Intensity Statin Therapy Post-Acute Coronary Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody, Versus Placebo: Interim Baseline Data	CONSULTANT FEES/HONORARIA - Amgen,Astra Zeneca, Boehringer Ingelheim Pharmaceuticals, Inc,MyoKardia, Quest Diagnostics; OTHER - Bristol-Myers Squibb Company, Dalichi-Sankyo, Eli Lilly and Company,Merck,Pri-Med; RESEARCH/RESEARCH GRANTS - Eli Lilly,Familial Hypercholesterolemia Foundation,Ferring Pharmaceuticals,Janssen Pharmaceuticals,Sanofi-Aventis
Roe	Matthew	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Hospital Variation in Targeted Temperature Management for Acute Myocardial Infarction Patients Complicated by Out-of-Hospital Cardiac Arrest in the U.S.	CONSULTANT FEES/HONORARIA - Amgen, Astra Zeneca, Boehringer Ingelheim Pharmaceuticals, Inc, MyoKardia, Quest Diagnostics; OTHER - Bristol-Myers Squibb Company, Daiichl-Sankyo, Eli Lilly and Company, Merck, Pri-Med; RESEARCH/RESEARCH GRANTS - Eli Lilly, Familial Hypercholesterolemia Foundation, Ferring Pharmaceuticals, Janssen Pharmaceuticals, Sanofi-Aventis
Roe	Matthew	03. Acute and Stable Ischemic Heart Disease: Therapy Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen, Astra Zeneca, Boehringer Ingelheim Pharmaceuticals, Inc, MyoKardia, Quest Diagnostics; OTHER - Bristol-Myers Squibb Company, Daiichi-Sankyo, Eli Lilly and Company, Merck, Pri-Med; RESEARCH/RESEARCH GRANTS - Eli Lilly, Familial Hypercholesterolemia Foundation, Ferring Pharmaceuticals, Janssen Pharmaceuticals, Sanofi-Aventis
Roebuck	Amelia	Innovations in Practice Management and	Designing Tailored Health Messaging to Enhance Patient-Centered	Nothing to Disclose
Roebuck	Amelia	Social Media Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Care in Non-Valvular Atrial Fibrillation Use of Wearable Cardioverter Defibrillator Associated With Clinical Guideline Compliance in Management of Heart Failure With	Nothing to Disclose
Roelke	Marc	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Reduced Ejection Fraction Syncope in Elderly: How About Checking Carotid Hypersensitivity???	CONSULTANT FEES/HONORARIA - Boston Scientific, Bristol- Myers Squibb Company, MEDTRONIC; DATA SAFETY MONTORING BOARD - Abott, RESEARCH/RESEARCH GRANTS - Abott Medical; SPEAKER'S BUREAU - Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc
Roesle	Michele	Highlighted Original Research: Prevention and the Year in Review	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 16,721 Patients From 33 Randomized Clinical Trials	Nothing to Disclose
Roesle	Michele	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Contemporary Use of Laser During Percutaneous Coronary Intervention: Results From the Laser Veterans Affairs (LAVA) Multicenter Registry	Nothing to Disclose
Roesle	Michele	Coronary Intervention in Interventional Cardiology: Advanced Device Use	A Meta-Analysis of Contemporary Lesion Modification Strategies During Percutaneous Coronary Intervention in 244,665 Patients From 21 Studies	Nothing to Disclose
Roesle	Michele	Innovations in Advocacy and Patient Centered Care	Diverse Perspectives and Training Paths in Cardiology: An Analysis of Authorship in the <i>Journal of the American College of Cardiology</i>	Nothing to Disclose
Roesle	Michele	Advances in Chronic Total Occlusion Intervention	Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions Improves Peak Oxygen Uptake During Cardiopulmonary Exercise Testing	Nothing to Disclose
Roettig	Mayme	Global Perspectives in the Treatment of ST Elevation Myocardial Infarction: Successes,	Panelist Panelist	Nothing to Disclose
Roettig	Mayme	Failures, and Challenges Innovations in Practice Management and Social Media	Accelerator 2 SUSTAIN, A U.S. Regional Systems of Care Demonstration Project for Post-Discharge STEMI Patients:	Nothing to Disclose
Roettig	Mayme	Novel Developments in Acute Coronary Syndromes	Preliminary Data, Methods and Design First Medical Contact to Device Time in STEMI Patients Presenting With Cardiogenic Shock: Insights From Mission, a Lifeline STEMI	Nothing to Disclose
Roffidal	Louise	Uncovering the Intricacies of Vascular Function		Nothing to Disclose
Roger	Veronique	Advances in Cholesterol Measurement and	Diabetes Mellitus Contemporary Patterns of Lipid Testing in Primary and Secondary	Nothing to Disclose
	·	Management	Prevention Patients: Insights From the PALM Registry Time in Therapeutic Range Predicts Mortality and Cerebrovascular	-
Roger	Veronique	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Events in Atrial Fibrillation Patients Treated With Warfarin	Nothing to Disclose
Roger	Veronique	New Technologies in Echocardiography	Dynamic Changes of Mitral Apparatus in Acute Myocardial Infarction With Ischemic Mitral Regurgitation: Prospective 3D Quantitative Echocardiographic Study	
Rogers	Campbell	Highlighted Original Research: Non Invasive Imaging and the Year in Review	The Association of High Risk Plaque Features and Non-Invasive Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography in Patients With Acute Chest Pain: Results From the ROMICAT II Trial	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - HeartFlow Inc.
Rogers	Campbell	Unusual Presentations of ACS	Incidence and Predictors of Lesion Specific Ischemia by FFR-sub>CT: Learnings From the International ADVANCE Registry	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - HeartFlow Inc.
Rogers	Jason	Imaging Transcatheter Mitral Valve Repair and	Overview of Current Transcatheter Mitral Valve Repair and	CONSULTANT FEES/HONORARIA - Boston
Rogers	Jason	Replacement Transcatheter Mitral Valve Repair	Replacement Strategies Co-Chair	Scientific,Millipede,MVRx CONSULTANT FEES/HONORARIA - Boston
Rogers	Jason	Transcatheter Mitral Valve Repair	Optimizing Clip Alignment for Grasping	Scientific,Millipede,MVRx CONSULTANT FEES/HONORARIA - Boston
	Jason	The Forgotten Valves: Therapies for Triscuspid		Scientific,Millipede,MVRx CONSULTANT FEES/HONORARIA - Boston
Rogers		and Pulmonic Valve	Therapies	Scientific,Millipede,MVRx
Rogers	Jason	Fundamentals of LAA Closure	Transseptal Puncture for LAA Closure	CONSULTANT FEES/HONORARIA - Boston Scientific,Millipede,MVRx
Rogers	Jason	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Percutaneous Coronary Intervention (PCI) Outcomes and Hospital Outliers in California	CONSULTANT FEES/HONORARIA - Boston Scientific,Millipede,MVRx

Last Name Rogers	First Name Jason	Session Title 37. Valvular Heart Disease: Therapy Team 1	Presentation Title Suggested Reviewer	Disclosures CONSULTANT FEES/HONORARIA - Boston
-				Scientific,Millipede,MVRx
Rogers	Joseph	Should I Stay or Should I Go? Tough Cases in MCS and Transplant	Panelist	RESEARCH/RESEARCH GRANTS - HeartWare
Rogers	Joseph	Controversies in Mitral Valve Surgery: Joint Symposium of the Society of Thoracic Surgeons and the American College of Cardiology	Co-Chair	RESEARCH/RESEARCH GRANTS - HeartWare
Rogers	Joseph		Valvular Complications Following LVAD	RESEARCH/RESEARCH GRANTS - HeartWare
Rogers	Kelly	Antithrombotic Therapy in Ischemic Heart Disease	Shorter- Versus Longer-Duration Triple Antithrombotic Therapy for Patients With Coronary Stents Who Require Oral Anticoagulation:	Nothing to Disclose
Rogers	Kelly	Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells	An Updated Comprehensive Meta-Analysis An Updated Comprehensive Meta-Analysis of Randomized Trials Evaluating the Efficacy of Stem Cell Therapy for Refractory Angina	Nothing to Disclose
Rogers	Paul	Nuclear Cardiology: Coronary Flow	Reduced Flow Capacity as Measured by Cardiac Positron Emission Tomography Predicts Ventricular Tachyarrhythmia in Patients With an ICD	Nothing to Disclose
Rogers	Toby	Great Minds Think Differently: Multidisciplinary Approach to Controversies in Cardiology	Last Resort Access for TAVR: Treating Patients That Don't Have Access- Trancaval and Carotid	Nothing to Disclose
Rogers	Toby	Considerations in Antiplatelet Therapy and in ACS	Trends in Discharge and Outcome of Dual Antiplatelet Therapy Post Percutaneous Intervention in High Bleeding Risk Population	Nothing to Disclose
Rogers	Toby	Considerations in Antiplatelet Therapy and in ACS	Outpatient Trends in Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Primary Percutaneous Coronary Intervention	Nothing to Disclose
Rogers	Toby	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	In-Stent Restenosis of Drug-Eluting Stents: Incidence, Lesion Characteristics and Outcomes in Contemporary Practice Over the Last Decade - How Are They Different From De Novo Lesions?	Nothing to Disclose
Rogers	Toby	Interventional Cardiology: TAVR 2	Racial Disparities and Temporal Trends in Demographics and Clinical Characteristics of Patients Screened for Transcatheter Aortic Valve Replacement	Nothing to Disclose
Rogers	Toby	Interventional Cardiology: TAVR 2	Impact of Balloon Pre-Dilatation on Hemodynamics and Clinical Outcomes After Transcatheter Aortic Valve Replacement With the Self-Expanding CoreValve Prosthesis	Nothing to Disclose
Rogers	Toby	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Is There a Role for Invasive Electrophysiology Studies in Patients With Conduction Abnormalities Following Transcatheter Aortic Valve Replacement?	Nothing to Disclose
Rogers	Toby	Interventional Cardiology: TAVR 3	Antithrombotic Therapy Differences and Associated Outcomes in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Rogers	Toby	Interventional Cardiology: TAVR 3	Acute Aortic Regurgitation Post-Transcatheter Aortic Valve Replacement: Impact of Various Treatment Strategies	Nothing to Disclose
Rogers	Toby	Interventional Cardiology: PCI in Complex Patients	Long-Term Mortality in Percutaneous Coronary Intervention of Saphenous Vein Grafts From Real-World Registry Data	Nothing to Disclose
Rohatgi	Anand	Innovations in Advocacy and Patient Centered Care	Racial and Ethnic Differences in Cardiovascular Biomarkers	CONSULTANT FEES/HONORARIA - Cleveland HeartLab,CSL Behring; OTHER - Eli Lilly and Company; RESEARCH/RESEARCH GRANTS - Merck
Rohatgi	Anand	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Cleveland HeartLab,CSL Behring; OTHER - Eli Lilly and Company; RESEARCH/RESEARCH GRANTS - Merck
Rohatgi	Anand	02. Acute and Stable Ischemic Heart Disease: Clinical Team 8	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Cleveland HeartLab,CSL Behring; OTHER - Eli Lilly and Company; RESEARCH/RESEARCH GRANTS - Merck
Roig	Eulalia	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years	Nothing to Disclose
Rojas-Marte	Geurys		Abnormalities in General Population Order Than Porty Years Use of Pharmacomechanical Thrombectomy in a Patient With Acute Pulmonary Embolism and Imminent Hemodynamic Collapse at Very High Risk for Cerebral Hemorrhage	Nothing to Disclose
Rojas-Marte	Geurys	Pulmonary Hypertension	Dissolve It or Take It Out: Excellent Outcome of Right-Sided Heart Clot In-Transit	Nothing to Disclose
Rokos Roldan	Ivan Carlos	Logistical Challenges in STEMI FIT Clinical Decision Making: Non-Invasive	Panelist Hypertrophic Obstructive Cardiomyopathy-Like Pathophysiology	Nothing to Disclose Nothing to Disclose
		Imaging and Valvular Heart Disease	Post Mitral Valve Repair	
Roldan	Paola	Novel Echocardiographic Methods for Assessing Cardiac Function	Comparison of the Effects of Balloon Expandable and Self Expandable Transcatheter Aortic Valve Replacement on the Dimensions of the Mitral Valve Annulus and Mitral Regurgitation Severity	Nothing to Disclose
Romano	Jennifer	Surgical and Transcatheter Valve Therapy for Congenital Heart Disease	Co-Chair	Nothing to Disclose
Romano	Jennifer	Surgical and Transcatheter Valve Therapy for Congenital Heart Disease	Debate: The Ross is the Best Aortic Valve Replacement for Adolescents (Con)	Nothing to Disclose
Romano	Jennifer	Vascular Medicine: Emerging Concepts in	Kommerell Diverticulum Across the Ages: Destined for Dilation?	Nothing to Disclose
Tomano				
Romano	Simone	Clinical Vascular Diseases Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Heart Rate Response During Regadenoson Stress Cardiac Magnetic Resonance Imaging Is a Predictor of Adverse Cardiovascular Outcomes	Nothing to Disclose
		Clinical Vascular Diseases Non Invasive Imaging: MR Structure and Valuvular Heart Disease Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Magnetic Resonance Imaging Is a Predictor of Adverse Cardiovascular Outcomes Impact of Home Monitoring Program on Interstage Mortality and Stage II Outcomes	
Romano	Simone	Clinical Vascular Diseases Non Invasive Imaging: MR Structure and Valuvular Heart Disease Congenital Heart Disease: Innovations in Single Ventricle Heart Disease The Evolving World of LVADs, Transplant and Other Novel Discoveries	Magnetic Resonance Imaging Is a Predictor of Adverse Cardiovascular Outcomes Impact of Home Monitoring Program on Interstage Mortality and Stage II Outcomes Cardiomyopathy in Patients After Post-Transplant Cyclophosphamide-Based Hematopoietic Cell Transplantation	Nothing to Disclose
Romano	Simone Jonathan	Clinical Vascular Diseases Non Invasive Imaging: MR Structure and Valuvular Heart Disease Congenital Heart Disease: Innovations in Single Ventricle Heart Disease The Evolving World of LVADs, Transplant and Other Novel Discoveries Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of	Magnetic Resonance Imagling Is a Predictor of Adverse Cardiovascular Outcomes Impact of Home Monitoring Program on Interstage Mortality and Stage II Outcomes Cardiomyopathy in Patients After Post-Transplant	Nothing to Disclose Nothing to Disclose
Romano Rome Romee Romeo	Simone Jonathan Rizwan	Clinical Vascular Diseases Non Invasive Imaging: MR Structure and Valuvular Heart Disease Congenital Heart Disease: Innovations in Single Ventricle Heart Disease The Evolving World of LVADs, Transplant and Other Novel Discoveries Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and	Magnetic Resonance Imaging Is a Predictor of Adverse Cardiovascular Outcomes Impact of Home Monitoring Program on Interstage Mortality and Stage II Outcomes Cardiomyopathy in Patients After Post-Transplant Cyclophosphamide-Based Hematopoietic Cell Transplantation	Nothing to Disclose Nothing to Disclose Nothing to Disclose
Romano Rome Romee Romeo Romero	Simone Jonathan Rizwan Francesco Maria Maria	Clinical Vascular Diseases Non Invasive Imaging: MR Structure and Valuvular Heart Disease Congenital Heart Disease: Innovations in Single Ventricle Heart Disease The Evolving World of LVADs, Transplant and Other Novel Discoveries Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease Coronary Intervention: Drug Eluting Stent and Scaffolds	Magnetic Resonance Imaging Is a Predictor of Adverse Cardiovascular Outcomes Impact of Home Monitoring Program on Interstage Mortality and Stage II Outcomes Cardiomyoapthy in Patients After Post-Transplant Cyclophosphamide-Based Hematopoietic Cell Transplantation Invasive Functional Evaluation of CAD Pathological Features of Left Main Stent Thrombosis Long-Term Pathological Result of Everolimus-Eluting Stent Versus Stolimus-Eluting Stent and Bare Metal Stent	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Romano Rome Romee Romeo Romero	Simone Jonathan Rizwan Francesco Maria	Clinical Vascular Diseases Non Invasive Imaging: MR Structure and Valuvular Heart Disease Congenital Heart Disease: Innovations in Single Ventricle Heart Disease The Evolving World of LVADs, Transplant and Other Novel Discoveries Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease Coronary Intervention: Turg Eluting Stent and	Magnetic Resonance Imaging Is a Predictor of Adverse Cardiovascular Outcomes Impact of Home Monitoring Program on Interstage Mortality and Stage II Outcomes Cardiomyopathy in Patients After Post-Transplant Cyclophosphamide-Based Hematopoietic Cell Transplantation Invasive Functional Evaluation of CAD Pathological Features of Left Main Stent Thrombosis Long-Term Pathological Result of Everolimus-Eluting Stent Versus	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Romano Rome Romee Romeo Romero Romero Romero Daza Ronderos	Simone Jonathan Rizwan Francesco Maria Maria Angelica Maria Ricardo	Clinical Vascular Diseases Non Invasive Imaging: MR Structure and Valuvular Heart Disease Congenital Heart Disease: Innovations in Single Ventricle Heart Disease The Evolving World of LVADs, Transplant and Other Novel Discoveries Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology Complex Coronary Intervention: Left Main/Pitrurcations and Multivessel Disease Coronary Intervention: Drug Eluting Stent and Scaffolds Arrhythmias and Clinical EP: Devices 1	Magnetic Resonance Imaging Is a Predictor of Adverse Cardiovascular Outcomes Impact of Home Monitoring Program on Interstage Mortality and Stage II Outcomes Cardiovasopathy in Patients After Post-Transplant Cyclophosphamide-Based Hematopoietic Cell Transplantation Invasive Functional Evaluation of CAD Pathological Features of Left Main Stent Thrombosis Long-Term Pathological Result of Everolimus-Eluting Stent Versus Stolimus-Eluting Stent and Bare Metal Stent Pharmacological Treatment Alone Versus Treatment Combined With Implantable Cardioverter-Defibrillator Therapy in Patients Over 75 Years Case: High Gradient Across a Surgical Aortic Prosthesis	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Romano Rome Romee Romeo Romero Romero Romero Daza	Simone Jonathan Rizwan Francesco Maria Maria Angelica Maria	Clinical Vascular Diseases Non Invasive Imaging: MR Structure and Valuvular Heart Disease Congenital Heart Disease: Innovations in Single Ventricle Heart Disease The Evolving World of LVADs, Transplant and Other Novel Discoveries Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease Coronary Intervention: Drug Eluting Stent and Scaffolds Arrhythmias and Clinical EP: Devices 1	Magnetic Resonance Imaging Is a Predictor of Adverse Cardiovascular Outcomes Impact of Home Monitoring Program on Interstage Mortality and Stage II Outcomes Cardiomyopathy in Patients After Post-Transplant Cyclophosphamide-Based Hematopoietic Cell Transplantation Invasive Functional Evaluation of CAD Pathological Features of Left Main Stent Thrombosis Long-Term Pathological Result of Everolimus-Eluting Stent Versus Stolimus-Eluting Stent and Bare Metal Stent Pharmacological Treatment Alone Versus Treatment Combined With Implantable Cardioverter-Defibrillator Therapy in Patients Over 75 Years	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Romano Rome Romee Romeo Romero Romero Romero Daza Ronderos	Simone Jonathan Rizwan Francesco Maria Maria Angelica Maria Ricardo	Clinical Vascular Diseases Non Invasive Imaging: MR Structure and Valuvular Heart Disease Congenital Heart Disease: Innovations in Single Ventricle Heart Disease The Evolving World of LVADs, Transplant and Other Novel Discoveries Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease Coronary Intervention: Drug Eluting Stent and Scaffolds Arrhythmias and Clinical EP: Devices 1 Prosthetic Valve Assessment: Real or Illusion? The Challenges of Outcome Prediction in	Magnetic Resonance Imaging Is a Predictor of Adverse Cardiovascular Outcomes Impact of Home Monitoring Program on Interstage Mortality and Stage II Outcomes Cardiomyoaptaty in Patients After Post-Transplant Cyclophosphamide-Based Hematopoietic Cell Transplantation Invasive Functional Evaluation of CAD Pathological Features of Left Main Stent Thrombosis Long-Term Pathological Result of Everolimus-Eluting Stent Versus Silolimus-Eluting Stent and Bare Metal Stent Pharmacological Treatment Alone Versus Treatment Combined With Implantable Cardioverter-Defibrillator Therapy in Patients Over 75 Years Case: High Gradient Across a Surgical Aortic Prosthesis How Well Does the STS Risk Score Predict Late Survival After	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Romano Rome Romee Romeo Romero Romero Romero Daza Ronderos Rongione	Simone Jonathan Rizwan Francesco Maria Maria Angelica Maria Ricardo Anthony	Clinical Vascular Diseases Non Invasive Imaging: MR Structure and Valuvular Heart Disease Congenital Heart Disease: Innovations in Single Ventricle Heart Disease The Evolving World of LVADs, Transplant and Other Novel Discoveries Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease Coronary Intervention: Drug Eluting Stent and Scaffolds Arrhythmias and Clinical EP: Devices 1 Prosthetic Valve Assessment: Real or Illusion? The Challenges of Outcome Prediction in Valvular Heart Disease	Magnetic Resonance Imaging Is a Predictor of Adverse Cardiovascular Outcomes Impact of Home Monitoring Program on Interstage Mortality and Stage II Outcomes Cardiomyoapthy in Patients After Post-Transplant Cyclophosphamide-Based Hematopoietic Cell Transplantation Invasive Functional Evaluation of CAD Pathological Features of Left Main Stent Thrombosis Long-Term Pathological Result of Everolimus-Eluting Stent Versus Silolimus-Eluting Stent and Bare Metal Stent Pharmacological Treatment Alone Versus Treatment Combined With Implantable Cardioverter-Defibrillator Therapy in Patients Over 75 Years Case: High Gradient Across a Surgical Aortic Prosthesis How Well Does the STS Risk Score Predict Late Survival After Cardiac Surgery? Association of Ankle Brachial Index With Limb Outcomes in Peripheral Artery Disease: A Community-Based Study Predictors of Survival From Out-of-Hospital Cardiac Arrest	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose DATA SAFETY MONITORING BOARD - Merck; OTHER -



Last Name Ropers	First Name Dieter	Session Title 27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team	Presentation Title Suggested Reviewer	Disclosures Nothing to Disclose
Rørth	Rasmus	1 Atrial Fibrillation and VT: Specific Situations	Vitamin K Antagonist or Dabigatran in Patients With Atrial	Nothing to Disclose
Rørth	Rasmus	and Newer Outcome Measures Heart Failure and Cardiomyopathies: Heart	Fibrillation: The Importance of Time in Therapeutic Range Evidence Based Therapy and Its Relation to Workforce Attachment	Nothing to Disclose
Rørth	Rasmus	Failure Is Just a Revolving Door Post-CAD/MI: Making Tough Predictions About the Future	Following First Hospitalization for Heart Failure Midregional Proadrenomedullin: A Prognostic Marker of Mortality and Heart Failure in Patients With ST-Segment Elevation Myocardial	Nothing to Disclose
Rosamond	Thomas	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Infarction The Intracavitary Coronary Artery: A Rare Anomaly With Implications for Invasive Cardiac Procedures - Demonstration by	Nothing to Disclose
Rosamond	Wayne	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Coronary Computed Tomography Angiography Readmissions for Patients Discharged With Acute Decompensated Heart Failure and Reduced Versus Preserved Ejection Fraction: The	Nothing to Disclose
Rosamond	Wayne	Updates on Risk Factors for Cardiovascular	Atherosclerosis Risk in Communities Study Retinopathy and Risk of Sudden Cardiac Death: The ARIC Study	Nothing to Disclose
Rosano	Giuseppe	Disease Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Mortality and Morbidity in Patients With Heart Failure and Reduced Ejection Fraction Exposed to Digoxin: Comprehensive Data According to Atrial Fibrillation in 23,708 Patients From the Swedish Heart Failure Registry	Nothing to Disclose
Rosas	Paola	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Cardiac Myosin Binding Protein-C De-Phosphorylation Mediated Slowing of Cross-Detachment Worsens Heart Failure	Nothing to Disclose
Rose	Geoffrey	Public Reporting and NCDR: The Decision to Report Your Data Before the Feds Decide	Our response to YELP ratings for our physicians	Nothing to Disclose
Rose	Geoffrey	36. Valvular Heart Disease: Clinical Team 3	Suggested Reviewer	Nothing to Disclose
Rose-Jones	Lisa	Engage @ ACC.17 Studio: FIT Jeopardy Battle of the State Chapters I		Nothing to Disclose
Roselli	Eric	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Clevedipine as a Therapeutic and Cost-Effective Alternative to Sodium Nitroprusside in Patients With Aortic Dissection	CONSULTANT FEES/HONORARIA - Bolton,Cook,Edwards Lifesciences,Gore,MEDTRONIC,Sorin,St Jude,Terumo; OTHER - Direct Flow Medical; RESEARCH/RESEARCH GRANTS - MEDTRONIC
Rosen	Stacey	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Early Unloading With Impella Support in Acute MI With Cardiogenic Shock Linked to Decreased Infarct Size, In-Hospital Mortality, and Hospital Length of Stay	Nothing to Disclose
Rosenbaum	Andrew		Myocarditis Presenting as Refractory Endocarditis After Surgical	Nothing to Disclose
Rosenbaum	Marlon	Pulmonary Hypertension Young Investigator Awards Competition: Basic	Valve Replacement Impact of Damaging de Novo Variants on Clinical Outcomes in	Nothing to Disclose
Rosenbaum	Marlon	and Translational Science Congenital Heart Disease: To the Third	Congenital Heart Disease The Systemic Right Ventricle in Transposition of the Great Arteries:	Nothing to Disclose
Rosenblatt	Andrew	Decade and Beyond FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	What Can We Learn From Serial Imaging? The Geneticist With Unfortunate Genes: Coronary Artery Disease in Myotonic Dystrophy	Nothing to Disclose
Rosendael	Philippe	Interventional Cardiology: TAVR 1	Sizing Aortic Valve Annulus for Transcatheter Aortic Valve Prosthesis Selection: Impact of Aortic Valve Calcification Burden on the Agreement Between Automated 3-Dimensional Transesophageal Echocardiography and Multidetector Row	Nothing to Disclose
Rosenfeld	Lynda	06. Arrhythmias and Clinical EP: Other Team 2	Computed Tomography Suggested Reviewer	OTHER - Boston Scientific
Rosenfield	Kenneth	Aorto-iliac Disease and Treatment: Practice at	Reducing Occupational Hazards During Complex Peripheral	CONSULTANT FEES/HONORARIA -
		"The Edge" in Peripheral Intervention	Intervention	Abbott Accelmed, Amgen, Cardinal Health, Cruzar Systems, Eximo, Shockwave Medical, Surmodics, The Medicines Company, ValCare, VIVA Physicians; OTHER - Vortex/AngioDynamics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Access Vascular, CardioMEMS, Contego Medical, Endospan, Icon Medical Corp. JanaCare, MD Insider, Medical Simulation, Micell Technologies, PQ Bypass, Primacea; RESEARCH/RESEARCH GRANTS - Abbott, Atrium Medical Group, Bard
Rosenfield	Kenneth	Aorto-liac Disease and Treatment: Practice at "The Edge" in Peripheral Intervention	Debate: Stenosis of the Common Femoral Artery Is Fair Game for Endovascular Therapy	CONSULTANT FEES/HONIORARIA - Abbott,Accelmed,Amgen,Cardinal Health,Cruzar Systems,Eximo,Shockwave Medical,Surmodics,The Medicines Company,ValCare,VIVA Physicians; OTHER - Vortex/Angiolynamics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Access Vascular,CardioMEMS,Contego Medical,Endospan,Icon Medical Corp,JanaCare,MD Insider,Medical Simulation,Micell Technologies,PQ Bypass,Primacear, RESEARCH/RESEARCH GRANTS - Abbott,Arium Medical Group,Bard
Rosenfield	Kenneth	Great Minds Think Differently: Multidisciplinary Approach to Imaging	Panelist	CONSULTANT FEES/HONORARIA - Abbott.Accelmed.Amgen,Cardinal Health,Cruzar Systems,Eximo,Shockwave Medical,Surmodics,The Medicines Company,ValCare,VIVA Physicians; OTHER - Vortex/Angiolynamics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Access Vascular,CardioMEMS,Contego Medical,Endospan,Ioon Medical Corp,JanaCare,MD Insider,Medical Simulation,Micell Technologies,PQ Bypass,Primacea; RESEARCH/RESEARCH GRANTS - Abbott,Afrium Medical Group,Bard
Rosenfield	Kenneth	The Evolution of Angioplasty – 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	Panelist	CONSULTANT FEES/HONORARIA- Abbott,Accelmed,Ampen,Cardinal Health,Cruzar Systems,Eximo,Shockwave Medical,Surmodics,The Medicines Company,ValCare,VIVA Physicians; OTHER- Vortex/Angiolymamics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Access Vascular,CardioMEMS,Contego Medical,Endospan,Icon Medical Corp.JanaCare,MD Insider,Medical Simulation,Micell Technologies,PQ Bypass,Primacea; RESEARCH/RESEARCH GRANTS - Abott,Atrium Medical Group, Bard
Rosenfield	Kenneth	Multi-Disciplinary Care for Acute Pulmonary Embolism: The PE Response Team (PERT) Model	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott, Accelmed, Amgen, Cardinal Health, Cruzar Systems, Eximo, Shockwave Medical, Surmodics, The Medicines Company, ValCare, VIVA Physicians; OTHER - Vortev/AngioDynamics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Access Vascular, CardioMEMS, Contego Medical, Endospan, Icon Medical Corp., JanaCare, MD Insider, Medical Simulation, Micell Technologies, PQ Bypass, Primacea; RESEARCH/RESEARCH GRANTS - Abbott, Arrium Medical Group, Bard

March Marc	Control of the contro				
Company Comp	Last Name Rosenfield		Embolism: The PE Response Team (PERT)		CONSULTANT FEES/HONORARIA - Abbott.Accelmed,Amgen,Cardinal Health,Cruzar Systems,Eximo,Shockwave Medical,Surmodics,The Medicines Company,ValCare,VIVA Physicians; OTHER - Vortex/AngioDynamics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Access
Cordings, Access and Stable between level Output: on Virtual Months Outpu	Rosenfield	Kenneth	EIT Clinical Decision Making: Interventional	Successful Intra-Anriic Ralloon Pump, Supported Percutaneous	Corp,JanaCare,MD Insider,Medical Simulation,Micell Technologies,PQ Bypass,Primacea; RESEARCH/RESEARCH GRANTS - Abbott,Atrium Medical Group,Bard
Recented. Recented.	rosemed	remen	Cardiology, Acute and Stable Ischemic Heart	Coronary Intervention in a Patient With a Late Presenting Myocardial Infarction, Multivessel Coronary Artery Disease Complicated by Heparin-Induced Thrombocytopenia, Biventricular Thrombus, and	Abbott Accelmed, Amgen, Cardinal Health, Cruzar Systems, Eximo, Shockwave Medical, Surmodics, The Medicines Company, ValCare, VIVA Physicians; OTHER - Vortex/AngioDynamics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Access Vascular, CardioMEMS, Contego Medical, Endospan, Icon Medical Corp., JanaCare, MD Insider, Medical Simulation, Micell Technologies, PO Bypass, Primacea; RESEARCH/RESEARCH
Noterinal Negation Marginaria (Company System) Reservant Signation (Company System) Reservant Signation (Company System) Reservant Signation (Company System) Reservant Signation (Company System) Reservant Reservant Signation (Company System) Reservant Reservant Signation (Company System) Reservant Reservant Signation (Company System) Reservant Reservant System (Company System) Reservant Reservant System (Company System) Reservant Reservant System (Company System) Reservant Reservant System (Company System) Reservant Reservant System (Company System) Reservant Reservant System (Company System) Reservant Reservant System (Company System) Reservant Reservant System (Company System) Reservant Re	Rosenfield		Endovascular Intervention Team 1		Abbott, Accelmed, Amgen, Cardinal Health, Cruzar Systems, Eximo, Shockwave Medical, Surmodics, The Medicines Company, ValCare, VIVA Physicians; OTHER - Vortex/AngioDynamics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Access Vascular, CardioMEMS, Contego Medical, Endospan, Icon Medical Corp., JanaCare, MD Insider, Medical Simulation, Micell Technologies, PQ Bypass, Primacea; RESEARCH/RESEARCH GRANTS - Abbott, Atrium Medical Group, Bard
Repetate Margar Varies Collegiones Col	Rosenhek	Raphael		Co-Chair	
Let hierd besues here loops On Ye Wilds Direct and builds allogues of the Percentage	Rosenhek	·	Mitral Valve Guidelines: Closing Knowledge Gaps	Guidelines Evolved?	CONSULTANT FEES/HONORARIA - Abbott Laboratories,Edwards Lifesciences,LIVANOVA,Valtech
Rosenson Ros	Rosenkranz	Stephan	Left Heart Disease: Have Hope Oh Ye Who	Hypertension Due to Left Heart Disease: Hemodynamics or	
Rosenson Robert Rosenson Robert Rosenson Robert Rosenson Robert Rosenson Robert Rosenson Robert Rosenson Robert Rosenson Robert Rosenson Robert Rosenson Robert Rosenson Robert Rosenson Robert Advances in Chelesterol Measurement and Resource (Septigable on a Statis - Data From the Riseason Export (RocARCS) Study Rosenson Robert Rosenson Robert Rosenson Robert Advances in Chelesterol Measurement and Rosenson Rosenson Robert Rosenson Robert Rosenson Robert Advances in Chelesterol Measurement and Personal Company Rose Rosenson Sand Alertisis, RESEARCH (Robert Robert Robert Sand Rosenson) Rosenson Robert Advances in Chelesterol Measurement and Personal Company Rose Rosenson Rosenson Rosenson Robert Advances in Chelesterol Measurement and Personal Rosenson Rosenson Robert Current Issues in Cardovascular Exportmixology, Dispartee, and Safety Use of Rocommended and Contratradicated Stafers in HIV Patients Exportmixology, Dispartee, and Safety Rosenson Robert Acute Coronary Syndromene, Diagnoss, Management And Advances in Company Rose Rosenson Sand Alertisis, RESOARCH (RoseNACS) Robert Rosenson Robert Acute Coronary Syndromene, Diagnoss, Management and Advances in Company Rose Respersons Sand Alertisis, RESOARCH (RoseNACS) Robert Rosenson Rose	Rosenson	Robert	Beyond the Usual Suspects - Other		RESEARCH/RESEARCH GRANTS - Amgen, Astra
Rosenson Ros	Rosenson	Robert	Dyslipidemias: A Potpourri of Complexities		RESEARCH/RESEARCH GRANTS - Amgen, Astra Zeneca, Esperion, Medicines Company
Be Re-Challenged on a Statin Data From the REasons for Geographs And Racial Differences in Stroke (REACHRDS) Study (REACHRDS)	Rosenson	Robert		REasons for Geographic and Racial Differences in Stroke	Company,Kowa,Regeneron,Sanofi Aventis; RESEARCH/RESEARCH GRANTS - Amgen,Astra
Rosenson Robert Current Issues in Cardiovasoular (ESCARCIS) Sluty (See ARCHRESEARCH GRANTS - Amgen. Astra Zereca Esperion, Medicines Company, Kows Regeneron, Sandri Aventis, Research (ESCARCH) See ARCHRESEARCH GRANTS - Amgen. Astra Zereca Esperion, Medicines Company, Kows Regeneron, Medicines Company, Company, Kows Regeneron, Medicines Company, Company	Rosenson	Robert		Be Re-Challenged on a Statin: Data From the REasons for	RESEARCH/RESEARCH GRANTS - Amgen, Astra Zeneca, Esperion, Medicines Company
Rosenson Robert Acute Coronary Syndromes, Diagnosis, Management and Outcomes Interaction, 2011-2014 Interactive Statin Therapy After Myocardial RESEARCH (GRANTS - Amgen. Astra Zeneca. Esperion. Medicines Company Co	Rosenson	Robert		REasons for Geographic And Racial Differences in Stroke	Company,Kowa,Regeneron,Sanofi Aventis; RESEARCH/RESEARCH GRANTS - Amgen,Astra Zeneca,Esperion,Medicines Company
Management and Outcomes Infarction, 2011-2014 Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Zeneca, Esperion, Middines Company Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHIESEARCH RGANTS - Ampen, Astra Company, Kowa, Repeneron, Sanoli Aventis; RESEARCHI	Rosenson	Robert		Use of Recommended and Contraindicated Statins in HIV Patients	Company,Kowa,Regeneron,Sanofi Aventis; RESEARCH/RESEARCH GRANTS - Amgen,Astra
Rosenson Robert The PCSKS Revolution: New insights into Evaluation and Treatment Evaluation and Treatment Surface American Company, Kowa Registerion, Sand Tax Acce American Company, Kowa Registeri	Rosenson	Robert			RESEARCH/RESEARCH GRANTS - Amgen, Astra
Rosenthal Geoffrey FIT Clinical Decision Making: Prevention, Adult Important Hemodynamic Considerations in the Management of an Adult With Unrepaired Pentalogy of Fallot Presenting With Necroturing Fascilis and Sepsis Adult With Unrepaired Pentalogy of Fallot Presenting With Necroturing Fascilis and Sepsis Adult With Unrepaired Pentalogy of Fallot Presenting With Necroturing Fascilis and Sepsis Adult With Unrepaired Pentalogy of Fallot Presenting With Necroturing Fascilis and Sepsis Adult With Unrepaired Pentalogy of Fallot Presenting With Necroturing Fascilis and Sepsis Adult With Unrepaired Pentalogy of Fallot Presenting With Necroturing Fascilis and Sepsis Adult With Unrepaired Pentalogy of Fallot Presenting With Necroturing Fascilis and Sepsis Adult With Unrepaired Pentalogy of Fallot Presenting With Necroturing Fascilis and Sepsis Adult With Unrepaired Pentalogy of Fallot Presenting With Necroturing Fascilis and Sepsis Adult With Unrepaired Pentalogy of Fallot Presenting With Necroturing Fascilis and Sepsis Adult With Unrepaired Pentalogy of Fallot Presenting With Necroturing Fascilis and Sepsis Adult With Unrepaired Pentalogy of Fallot Presenting With Necroturing Fascilis and Sepsis Adult With Unrepaired Pentalogy of Fallot Presenting With Necroturing Fascilis and Sepsis Adult With Unrepaired Pentalogy of Fallot Presenting With Necroturing Fascilis and Sepsis Adult With Unrepaired Pentalogy of Fallot Presenting With Necroturing Fascilis and Sepsis Adult With Unrepaired Pentalogy of Fallot Presenting With Necroturing Fascilis and Sepsis Adult With Unrepaired Pentalogy of Fallot Presenting With Pentalogy of Fallot Presenting With Pentalogy of Fallot Presenting With Pentalogy of Fallot Presenting With Pentalogy of Fallot Presenting With Pentalogy of Fallot Presenting With Pentalogy of Fallot Presenting With Pentalogy of Fallot Presenting With Pentalogy of Fallot Presenting With Pentalogy of Fallot Presenting With Pentalogy of Fallot Presenting With Pentalogy of Fallot Presenting With Pentalogy of Fallot Pres	Rosenson	Robert		ACC Poster Moderator	RESEARCH/RESEARCH GRANTS - Amgen, Astra
Congenital and Congenital Heart Disease Adult With Unrepaired Pentalogy of Fallot Presenting With	Rosenson				CONSULTANT FEES/HONORARIA - Akcea,Amgen,Eli Lilly and Company,Kowa,Regeneron,Sanofi Aventis; RESEARCH/RESEARCH GRANTS - Amgen,Astra Zeneca,Esperion,Medicines Company
Pulmonary Hypertension	Rosenthal	Geoffrey	Congenital and Congenital Heart Disease	Adult With Unrepaired Pentalogy of Fallot Presenting With Necrotizing Fasciitis and Sepsis	SALARY - University of Maryland School of Medicine
Reduced Flow Capacity as Measured by Cardiac Postron Emission Tomography Predicts Ventricular Tachyarrhythmia in Patients With an ICD	Rosenthal	Todd		Use of TandemHeart as a Bridge to Surgery in a Patient With Combined Obstructive and Cardiogenic Shock Due to Mechanical Mitral Valve Thrombosis	Nothing to Disclose
Embolism: The PE Response Team (PERT) Model Ross Alexander FIT Clinical Decision Making: Heart Failure and Complete Thrombotic Occlusion of TAVR Valve in Patient With Pulmonary Hypertension Continuous Flow LVAD Ross Stian Heart Failure and Cardiomyopathies: Heart Failure and Continuous Flow LVAD Ross Stian Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore Ventricular Pacing Predicts Response to Cardiac Resynchronization Therapy Rossano Joseph 10. Congenital Heart Disease: Pediatric Team 2 2 Rossello Xavier Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Andrea Management and Outcomes Andrea Management and Management and Management and Management Management and Management and Management and Management and Management and Management and Management and Management and Management and Management Allorous Early Evidence From Administrative Claims, EMR and ManagenAstraZeneca,Merck Aliconary Staffs on the EPICON Representation of TaVR Valve in Patients With Dual Chamber Right Ventricular Dyschoration Nothing to Disclose CONSULTANT FEES/HONORARIA - Janssen Pharmaceuticals, Novarits Corporation Nothing to Disclose CONSULTANT FEES/HONORARIA - Mothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Acute Coronary Syndrome: Results From the EPICOR Registry Left Atrial Enlargement in Patients With Ventricular Dysfunction: Indicent Bystander or Meaningful Determinant of Survival? Eli Advances in Cholesterol Measurement and Management Management Aliconary Stephenes on Maximally Tolerated Statin Therapy Contrasting US Patients With Type 2 Diabetes on Maximally SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Aliconary Evidence From Administrative Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Aliconary Evidence From Administrative Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Aliconary Evidence From Administrative Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Aliconary Evidence	Rosenthal		'	Reduced Flow Capacity as Measured by Cardiac Positron Emission Tomography Predicts Ventricular Tachyarrhythmia in Patients With an ICD	-
Ross Alexander FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Pulmo	Rosovsky	Rachel	Embolism: The PE Response Team (PERT)	Panelist	Nothing to Disclose
Failure Gadgets Galore Ventricular Pacing Predicts Response to Cardiac Resynchronization Therapy	Ross	Alexander	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Continuous Flow LVAD	-
Rossano Joseph 10. Congenital Heart Disease: Pediatric Team 2 Rossello Xavier Coronary Angiography, Intra-Vascular Imaging, Impact of a Switch From Dual Antiplatelet Therapy to Single Autiplatelet Therapy in Diabetes and Non-Diabetes Post ACS: Insights From the EPICOR and EPICOR-Asia Studies Rossello Xavier Acute Coronary Syndromes, Diagnosis, Management and Outcomes Management and Outcomes Acute Coronary Syndrome: Results From the EPICOR Registry Rossi Andrea Making Progress in Understanding Heart Failure Roth Eli Advances in Cholesterol Measurement and Management Management and Management Management and Management Series Widence From Administrative Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Management Management Management Management Management Management Management Management Management Series Widence From Administrative Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Management Management Management Management Management Management Management Management Management Series Widence From Administrative Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Management	Ross	Stian		Ventricular Pacing Predicts Response to Cardiac Resynchronization	Nothing to Disclose
Rossello Xavier Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes Angioletel Therapy in Diabetes and Non-Diabetes Post ACS: Insights From the EPICOR and EPICOR-Asia Studies Rossello Xavier Acute Coronary Syndromes, Diagnosis, Management and Outcomes Acute Coronary Syndromes: Results From the EPICOR Registry Rossi Andrea Making Progress in Understanding Heart Individual Epicor Meaningful Determinant of Survival? Roth Eli Advances in Cholesterol Measurement and Management Survival Sevents of Contrasting US Patients With Type 2 Diabetes on Maximally September of Contrasting US Patients With Type 2 Diabetes on Maximally September of Contrasting US Patients With Type 2 Diabetes on Maximally September Octors and Management Alicorated Statin Therapy Contrasting US Patients With a Fill Versus a Prescription for Management September Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Alicorate Staff September Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Alicorate Staff September Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Alicorated Staff September Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Alicorated Staff September Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Alicorated Staff September Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Alicorated Staff September Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Specific September Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Specific September Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Specific September Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Specific September Claims, EMR and Specific September Claims, EMR and SPEAKER'S BUREAU - Amarin, Amgen, AstraZeneca, Merck Specific September Claims, EMR and Specific September Claims, EMR and Specific September Claims, EMR and Specific September Claims, EMR and Specific			2	Suggested Reviewer	Pharmaceuticals, Novartis Corporation
Rossello Xavier Acute Coronary Syndromes, Diagnosis, Management and Outcomes Acute Coronary Syndrome: Results From the EPICOR Registry Nothing to Disclose Andrea Making Progress in Understanding Heart Left Atrial Enlargement in Patients With Ventricular Dysfunction: Innocent Bystander or Meaningful Determinant of Survival?	Rossello	Xavier		Antiplatelet Therapy in Diabetes and Non-Diabetes Post ACS:	
Rossi Andrea Making Progress in Understanding Heart Failure Left Atrial Enlargement in Patients With Ventricular Dysfunction: Incoent Bystander or Meaningful Determinant of Survival? Roth Eli Advances in Cholesterol Measurement and Management Eli Advances in Cholesterol Measurement and Management Eli Advances in Cholesterol Measurement and Management Eli Advances in Cholesterol Measurement and Management Salter	Rossello	Xavier		Predictors of Ischemic Events Within and After 1 Year After an	Nothing to Disclose
Roth Eli Advances in Cholesterol Measurement and Management and Management Eli Advances in Cholesterol Measurement and Management Eli Advances in Cholesterol Measurement and Management Eli Advances in Cholesterol Measurement and Management Service Advances in Cholesterol Measurement and Management Service Advances in Cholesterol Measurement and Management Service Manageme	Rossi	Andrea	Making Progress in Understanding Heart	Left Atrial Enlargement in Patients With Ventricular Dysfunction:	Nothing to Disclose
Roth Eli Advances in Cholesterol Measurement and Contrasting US Patients With a Fill Versus a Prescription for Management Alirocumab: Early Evidence From Administrative Claims, EMR and SPEAKER'S BUREAU - Amarin,Amgen,AstraZeneca,Merck	Roth	Eli	Advances in Cholesterol Measurement and	Efficacy and Safety of the PCSK9 Inhibitor Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally	
	Roth	Eli		Contrasting US Patients With a Fill Versus a Prescription for Alirocumab: Early Evidence From Administrative Claims, EMR and	

Contract of the second				<u> </u>
Last Name Roth	Crosser	Session Title Acute Heart Failure: Evaluating Strategies to	Presentation Title Capacity for Heart Failure Diagnosis and Treatment in Sub-Saharan	Disclosures Nothing to Disclose
	Gregory	Prevent Readmissions	Africa: Ánalysis of the Access, Bottlenecks, Costs, and Equity Study in Kenya and Uganda	· ·
Roth	James	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	An Unexpected Complication of Wolf Parkinson White Accessory Pathway Radiofrequency Ablation and Subsequent Clinical Dilemma	CONSULTANT FEES/HONORARIA - Medtronic Regional Consultant Board
Roth	Stephen	Predicting Outcomes in Pediatric Heart Disase	Insurance Type Is Associated With Longer Hospital Duration but Similar Mortality Among Children Undergoing Congenital Heart Surgery	Nothing to Disclose
Rothenbuhler	Martina	Featured Clinical Research II: Interventional	Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD Matrix Study	Nothing to Disclose
Rothman	Kenneth	Fibrillatory Arrhythmias: Outcomes With	Sylinomes. The RAD Wadit Study Persistence With Therapy in Patients With Atrial Fibrillation: The GLORIA-AF Registry	Nothing to Disclose
Rothman	Kenneth	Contemporary Practice Atrial Fibrillation and VT: Incorporating Novel	Rates of Stroke and Bleeding With Dabigatran 150 and 110 mg BID	Nothing to Disclose
Rothschild	Daniel	Risks Toward Decision Making Arrhythmias and Clinical EP: Devices 4	in Clinical Practice: The GLORIA-AF Registry Pacemaker-Induced Tricuspid Regurgitation Is Uncommon Immediate Post-Implant	Nothing to Disclose
Rothschild	Matan	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Coular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia	Nothing to Disclose
Rothstein	Peter	Atrial Fibrillation and VT: Unique Populations and Solutions	Presence of Mid-Myocardial Substrate Is Associated With Need for Multiple Ablations in Patients With Non-Ischemic Cardiomyopathy and Ventricular Arrhythmias	Nothing to Disclose
Rothstein	Peter	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Early Recurrence of Ventricular Tachycardia Predicts Increased Mortality Among Patients With Severe Heart Failure	Nothing to Disclose
Rothstein	Peter	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Safety and Outcomes of Catheter Ablation for Treatment of Refractory Ventricular Arrhythmias in Patients With Advanced Heart Failure	Nothing to Disclose
Rotmans	Joris	Novel Echocardiographic Methods for	Prognostic Implications of Left Ventricular Global Longitudinal Strain	Nothing to Disclose
Rottbauer	Wolfgang	Assessing Cardiac Function Interventional Cardiology: TAVR 3	in Stage 4 and 5 Chronic Kidney Disease Patients Apixaban in Atrial Fibrillation Patients With Renal Insufficiency After	Nothing to Disclose
Rottbauer	Wolfgang	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Replacement One Year Outcome in Patients Undergoing Transfemoral Aortic Valve Replacement (TAVR) With the Repositionable and Retrievable Boston Scientific Lotus Valve Compared With the Balloon-Expandable Edwards Sapien 3 Device	Nothing to Disclose
Rottbauer	Wolfgang	Refining TAVR Outcomes		Nothing to Disclose
Roubin	Gary	The Evolution of Angioplasty – 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	The Evolution of Peripheral Vascular Intervention	OTHER - Cook, Inc.; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Essential Medical Inc.
Roubin	Gary	18. Interventional Cardiology: Carotid and Endovascular Intervention Team 1	Suggested Reviewer	OTHER - Cook, Inc.; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Essential Medical Inc.
Roudsari	Hadi Mirhedayati	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography. The CONFIRM (COronary CT Angiography Evaluation For Clinical	Nothing to Disclose
Rouleau	Jean	Featured Clinical Research III	Outcomes: An InteRnational Multicenter) Registry Paroxysmal Atrial Fibrillation Is Associated With Worse Clinical Outcomes Than Persistent/Permanent Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction	CONSULTANT FEES/HONORARIA - Novartis Corporation
Rouleau	Jean	Making Progress in Understanding Heart Failure	With reart allute and Neudoed Ejection Taction Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF	CONSULTANT FEES/HONORARIA - Novartis Corporation
Rouleau	Jean	Emerging Developments in HFpEF and Arryhthmias	Influence of Left Ventricular Ejection Fraction on Cause-Specific Mortality in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial	CONSULTANT FEES/HONORARIA - Novartis Corporation
Rouleau	Jean	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Effect of Sacubitril/Valsartan Compared With Enalapril, According to Etiology in PARADIGM-HF	CONSULTANT FEES/HONORARIA - Novartis Corporation
Rouleau	Jean	Hormones and Heart Failure	Low Urinary Cgmp/Bnp Ratio Is Associated With Worse Outcomes in Heart Failure but is Increased by Treatment With Sacubitril/Valsartan: An Analysis of Paradigm-HF	CONSULTANT FEES/HONORARIA - Novartis Corporation
Rouleau	Jean	The Old and the New: Impact of Heart Failure Drug Therapies	Influence of Sacubitril/Valsartan on Glycemic Control in Patients With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction	CONSULTANT FEES/HONORARIA - Novartis Corporation
Rouphael	Carol	Updates on Risk Factors for Cardiovascular Disease	Declining Survival With Decreasing Exercise Time on Treadmill: Lessons From a 25-Year Cohort	Nothing to Disclose
Rouphael	Carol	Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	Referral for Pharmacologic Testing, a Marker of Poor Exercise Capacity, Confers a Higher Risk of Short and Long Term Mortality Than Most Traditional Cardiac Risk Factors Except Age	Nothing to Disclose
Rouse	Caroline	Pregnancy Complicated by Valvular/Congenital Heart Disease: Clinical	Case Presentation: Pregnancy Complicated by Severe Aortic Stenosis	Nothing to Disclose
Rousselle	Serge	Interventional Cardiology: Translation and Pre- Clinical Research	Novel Preclinical Assessment of Transcatheter Mitral Valve Replacement by Micro Computed Tomography: 8#181;CT Imaging Guided Histopathological Evaluation	CONSULTANT FEES/HONORARIA - Amaranth,Boston Scientific,Covidien,CR Bard,CryoLife, Jack Skirball Center for Innovation (SCCR),MEDTRONIC,Mercator,NeoGraft,ReVA Medical,St Jude Medical,Stentys,Terumo,Teva,VivaSure
Rousselle	Serge	Interventional Cardiology: Translation and Pre- Clinical Research	Deliverability and Safety of a Novel Non-Invasive, Ultrasound-Based Renal Nerve Ablation System in a Large Preclinical Model via Histopathological Evaluation	CONSULTANT FEES/HONORARIA - Amaranth,Boston Scientific,Covidien,CR Bard,CryoLife ,Jack Skirball Center for Innovation (SCCR),MEDTRONIC,Mercator,NeoGraft,REVA
Rove	Jessica Yu	Engage @ ACC.17 Studio: Heart Teams in	Case Presentation by FIT: Is A Hybrid Revascularization Strategy	Medical,St Jude Medical,Stentys,Terumo,Teva,VivaSure Nothing to Disclose
Rove	Jessica Yu	Action: Complex Coronary Revascularization Engage @ ACC.17 Studio: Meet the Acute and	Indicated? FIT Interviewer (CT Surgery Resident)	Nothing to Disclose
Rovner	Marshall	Stable Heart Disease Legends Emerging Developments in HFpEF and	Is Continuous Outpatient Milrinone Therapy Appropriate in Stage D	SALARY - The Medical Affairs Company
Rowan	Christopher	Arryhthmias Featured Clinical Research I	Heart Failure Patients With Underlying Ventricular Tachycardia Native South American Tsimane Have the Lowest Levels of	Nothing to Disclose
Rowin	Ethan	How Hypertrophic Cardiomyopathy Became A Contemporary Treatable Genetic Heart	Coronary Atherosclerosis Ever Reported Case Presentation: Part I	Nothing to Disclose
Rowin	Ethan	Disease How Hypertrophic Cardiomyopathy Became A Contemporary Treatable Genetic Heart	Case Presentation: Part II	Nothing to Disclose
Rowin	Ethan	Disease How Hypertrophic Cardiomyopathy Became A Contemporary Treatable Genetic Heart	Case Presentation: Part III	Nothing to Disclose
Rowin	Ethan	Disease Genetic Testing for Cardiomyopathies	Case Presentation in Hypertophic Cardiomyopathy	Nothing to Disclose
Rowin	Ethan	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Antiarrhythmic Medications for Atrial Fibrillation Appear Reasonably Safe in Hypertrophic Cardiomyopathy	Nothing to Disclose
Rowin	Ethan	Arrhythmias and Clinical EP: Basic 2	Atrial Fibrillation Is Associated With Low Cardiovascular Mortality in Hypertrophic Cardiomyopathy	Nothing to Disclose
Roy	Debanshu	The Best Coronary and Peripheral	Use of the Impella CP Catheter for Refractory Cardiogenic Shock	Nothing to Disclose
		Interventional Challenging Cases	Following Acute Aortic Dissection and Surgical Repair	

		To a series		
Roy	First Name Nathalie	Session Title Update in ACHD: The Time for Change is Now	Presentation Title Surgery is Still in: Class I Indications for Surgical Intervention in	Disclosures Nothing to Disclose
Roy	Shubha Deep	Structural Heart Interventions: Focus on Mitral	ACHD Change in Utilization Trends of Percutaneous Atrial Septal Defect	Nothing to Disclose
,	·	Valve, Left Atrial Appendage and HOCM	Closure Post 2008 ACC/AHA Guidelines for Adults With Congenital Heart Disease	
Roy	Shubha Deep	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Congenital Absence of Left Main Coronary Artery in a Transplanted Heart: A Diagnostic Dilemma and a Therapeutic Challenge	Nothing to Disclose
		Disease, and Vascular Medicine		No. 10 Production
Rozanski	Alan	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium in the Elderly: Prevalence, Severity, and Association With All-Cause Mortality	Nothing to Disclose
Rozanski	Alan	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Impact of Cardiac Devices on Readmission and Short Term Mortality in Patients With Heart Failure With Reduced Ejection	Nothing to Disclose
Rozanski	Alan	Non Invasive Imaging: New Technologies	Fraction: A Nationwide Study Improvement in LDL Is Associated With Decrease in Non-Calcified	Nothing to Disclose
1 (OZGITSKI	, and the second	Tron invasive imaging. New Teelinologies	Plaque Volume on CTA as Measured by Automated Quantitative Software	reduing to Disclose
Rozanski	Alan	Imaging With Cardiac CT: The Case for	Hormone Replacement Therapy Is Associated With Less Coronary	Nothing to Disclose
Rozema	Tamika	Calcium FIT Clinical Decision Making: Prevention, Adult	Atherosclerosis and Lower Mortality Cor Triatriatum: A Tale of Two Membranes	Nothing to Disclose
		Congenital and Congenital Heart Disease		
Ru	Liu	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Impact of Gender Difference in Clinical Presentation on Long-Term Outcomes in Chinese Patients Undergoing Percutaneous Coronary	Nothing to Disclose
Rubal	Bernard	Syndrome Timely Topics in Acute Coronary Syndromes	Intervention Evaluation of Exercise Response in Young Adults in a High Risk	Nothing to Disclose
rabai	Bernard	Timely Topics in Acute Goronary Cyndromes	Occupation: Submaximal Invasive Cardiopulmonary Exercise Testing in Active Duty Soldiers	reduing to Disclose
rubartelli	paolo	Featured Clinical Research II: Interventional	Radiation Exposure and Vascular Access in Acute Coronary	Nothing to Disclose
Rubenfire	Melvyn	Structural Heart Interventions: Focus on Mitral	Syndromes: The RAD Matrix Study In-Hospital Outcomes After MitraClip Implantation in the United	Nothing to Disclose
Rubenfire	Melvyn	Valve, Left Atrial Appendage and HOCM Structural Heart Interventions: Focus on Mitral	States: 2010-2012 In-Hospital Outcomes After MitraClip Implantation in the United	RESEARCH/RESEARCH GRANTS - Amgen,Pfizer
Rubenfire	Melvyn	Valve, Left Atrial Appendage and HOCM Interventional Cardiology: PCI and TAVR in	States: 2010-2012 Economic Implications of Late Discharge After Transcatheter Aortic	Nothing to Disclose
		Complex Patients	Catheter Implantation	,
Rubenfire	Melvyn	Interventional Cardiology: PCI and TAVR in Complex Patients	Economic Implications of Late Discharge After Transcatheter Aortic Catheter Implantation	RESEARCH/RESEARCH GRANTS - Amgen,Pfizer
Rubenfire	Melvyn	Interventional Cardiology: PCI and TAVR in Complex Patients	Predictors of Early Discharge Home After Transcatheter Aortic Valve Implantation	Nothing to Disclose
Rubenfire	Melvyn	Interventional Cardiology: PCI and TAVR in Complex Patients	Predictors of Early Discharge Home After Transcatheter Aortic Valve Implantation	RESEARCH/RESEARCH GRANTS - Amgen,Pfizer
Rubenfire	Melvyn	Emerging Developments in HFpEF and Arryhthmias	Hospitalization Burden of Diastolic Heart Failure in the United States: 2007-2012	Nothing to Disclose
Rubenfire	Melvyn	Emerging Developments in HFpEF and	Hospitalization Burden of Diastolic Heart Failure in the United	RESEARCH/RESEARCH GRANTS - Amgen,Pfizer
Rubenfire	Melvyn	Arryhthmias 32. Prevention: Clinical Team 5	States: 2007-2012 Suggested Reviewer	Nothing to Disclose
Rubenfire Rubin	Melvyn Lewis	32. Prevention: Clinical Team 5 Demystifying and Managing Pulmonary	Suggested Reviewer Panelist	RESEARCH/RESEARCH GRANTS - Amgen,Pfizer CONSULTANT FEES/HONORARIA - Actelion,Arena
		Hypertension and RV Dysfunction: It Takes a Village		Pharmaceuticals,Karos,SoniVie
Rubin	Lewis	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic	MELODY-1: A Pilot Study of Macitentan in Pulmonary Hypertension Due to Left Ventricular Dysfunction	CONSULTANT FEES/HONORARIA - Actelion, Arena Pharmaceuticals, Karos, SoniVie
		Disease and the Year in Review	·	
Rubin	Lewis	Bridge From the Basics: Translational Research in Pulmonary Hypertension	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Actelion, Arena Pharmaceuticals, Karos, SoniVie
Rubini	Maria	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Direct Comparison of Cardiac Myosin-Binding Protein C to Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction	Nothing to Disclose
Rubino	Mara	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Renal Replacement Therapy in Patients With Acute Myocardial Infarction: Rate of Use, Clinical Predictors and Relationship With In- Hospital Mortality	Nothing to Disclose
Rubino	Mara	Post-CAD/MI: Making Tough Predictions About the Future	A New Score for Risk Stratification of Patients With Acute Myocardial Infarction Based on the PEGASUS-TIMI 54 Criteria	Nothing to Disclose
Rubinshtein	Ronen	Trends in Coronary Syndromes: International Perspectives From the ACC Great Britain and Ireland Chapter, Israel Heart Society, and American College of Cardiology	Co-Chair	RESEARCH/RESEARCH GRANTS - Arineta inc.
Rubinshtein	Ronen	Non Invasive Imaging: Prognostic Implications of CT Angiography	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	RESEARCH/RESEARCH GRANTS - Arineta inc.
Rubinshtein	Ronen	Non Invasive Imaging: Prognostic Implications of CT Angiography	Can We Identify Plaques That Will Cause Acute Coronary Syndromes? An 8 Year Prospective Study Based on CT	RESEARCH/RESEARCH GRANTS - Arineta inc.
Rubio Campal	Jose	Arrhythmias and Clinical EP: Devices 1	Angiography in Asymptomatic Diabetics Pharmacological Treatment Alone Versus Treatment Combined	Nothing to Disclose
,			With Implantable Cardioverter-Defibrillator Therapy in Patients Over 75 Years	
Rubis	Pawel	Cardiac Fibrosis and Heart Failure: The Next Frontier	Associations Between Serum Markers of Extracellular Matrix Metabolism, Fibrosis-Linked Micrornas (Mir-21, Mir-26, Mir-29, Mir- 30 And Mir-133a) and Right Ventricular Parameters in Dilated	Nothing to Disclose
Rubis	Pawel	Cardiac Fibrosis and Heart Failure: The Next Frontier	Cardiomyopathy Relations Between Fibrosis-Linked Micrornas (Mir-21, Mir-26, Mir- 29, Mir-30 and Mir-133a) and Right Ventricular Morphology and Function in Dilated Cardiomyopathy	Nothing to Disclose
Rudd	James	Non Invasive Imaging: Prognostic Implications of CT Angiography	The Relationship Between Pericardial Adipose Tissue Volume, Atherosclerotic Plaque Type and Cardiovascular Risk: A High Risk Plaque Biolmage Sub-Study	Nothing to Disclose
Rudd	Nancy	Highlighted Original Research: Congenital	Re-Intervention During the Interstage Period: A Report From the National Pediatric Cardiology Quality Improvement Collaborative	Nothing to Disclose
Ruddy	Terrence	Heart Disease and the Year in Review Imaging of Myocardial Blood Flow: A	SPECT Myocardial Blood: an Emerging Modality	RESEARCH/RESEARCH GRANTS - Advanced Accelerator
		Multimodality Approach		Applications,GE Healthcare; SPEAKER'S BUREAU - GE Healthcare
Rudnicka-Sosin	Lucyna	Cardiac Fibrosis and Heart Failure: The Next Frontier	Associations Between Serum Markers of Extracellular Matrix Metabolism, Fibrosis-Linked Micrornas (Mir-21, Mir-26, Mir-29, Mir- 30 And Mir-133a) and Right Ventricular Parameters in Dilated Cardiomyopathy	Nothing to Disclose
Rudnicka-Sosin	Lucyna	Cardiac Fibrosis and Heart Failure: The Next	Relations Between Fibrosis-Linked Micrornas (Mir-21, Mir-26, Mir-	Nothing to Disclose
		Frontier	29, Mir-30 and Mir-133a) and Right Ventricular Morphology and Function in Dilated Cardiomyopathy	
Rueda-Ochoa	Oscar	Emerging Developments in HFpEF and Arryhthmias	Sex Differences in Risk Factors for Longitudinal Changes in Left Ventricular Diastolic Function: The Rotterdam Study	Nothing to Disclose
Ruel	Marc	Issues in the Treatment of Coronary Disease: Joint Symposium of the American Heart Association and the American College of Cardiology	Panelist	CONSULTANT FEES/HONORARIA - MEDTRONIC



Contract of the contract of th				
Last Name Ruel	First Name Marc	Session Title Issues in the Treatment of Coronary Disease: Joint Symposium of the American Heart Association and the American College of	Presentation Title Alternate Approaches to CABG: Are they Better?	Disclosures CONSULTANT FEES/HONORARIA - MEDTRONIC
Ruff	Christian	Cardiology Test Yourself with Questions: Guidelines	Faculty	CONSULTANT FEES/HONORARIA - Bayer Healthcare
Ruff	Christian	Module 3: Atrial Fibrillation Fibrillatory Arrhythmias: Outcomes With	Edoxaban Versus Warfarin in Atrial Fibrillation Ablation: First	Pharmaceuticals,Boehringer Ingelheim,Daiichi Sankyo CONSULTANT FEES/HONORARIA - Bayer Healthcare
Ruff	Christian	Contemporary Practice Atrial Fibrillation and VT: Unique Populations	Experience From the ENGAGE AF TIMI 48 Trial Outcomes of Asian Patients With Atrial Fibrillation Compared to Non-	Pharmaceuticals,Boehringer Ingelheim,Daiichi Sankyo CONSULTANT FEES/HONORARIA - Bayer Healthcare
Ruff	Christian	and Solutions Arrhythmias and Clinical EP: AF Miscellaneous		Pharmaceuticals,Boehringer Ingelheim,Daiichi Sankyo CONSULTANT FEES/HONORARIA - Bayer Healthcare
Ruff	Christian	and Surgical Issues Stroke and AF: Thinking About the Heart	An ENGAGE AF-TIMI 48 Analysis Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation	Pharmaceuticals,Boehringer Ingelheim,Daiichi Sankyo CONSULTANT FEES/HONORARIA - Bayer Healthcare
Dufus Danaiah	Chara	Manufacture and Hamadasia Januar	and Active Malignancy: An Analysis of ENGAGE AF - Timi 48 Randomized Clinical Trial Mid Femoral Head Is Not the Ideal Fluroscopic Landmark for	Pharmaceuticals,Boehringer Ingelheim,Daiichi Sankyo
Rufus Ponniah Rufus Ponniah	Sharan	Vascular Access and Hemostasis Issues FIT Clinical Decision Making: Interventional	Common Femoral Artery Puncture A Rare Case of Chronic Persistent Troponin Elevation	Nothing to Disclose Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	·	CONSULTANT FEES/HONORARIA - Edwards
Ruggiero	Nicholas	The Best Structural Interventional Challenging Cases	To Close or Not to Close: Percutaneous Treatment of Acquired Gerbode Defect	Lifesciences, Novartis Corporation, St. Jude Medical; OTHER - Boehringer Ingelheim Pharmaceuticals, Inc
Ruggiero	Nicholas	Interventional Cardiology: TAVR 1	Hands Down: Operator Hand Versus Torso Radiation Exposure During Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,Novartis Corporation,St. Jude Medical; OTHER - Boehringer Ingelheim Pharmaceuticals, Inc
Ruggiero	Nicholas	Interventional Cardiology: TAVR 1	Provider Radiation Exposure During Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,Novartis Corporation,St. Jude Medical; OTHER - Boehringer Ingelheim Pharmaceuticals, Inc
Ruggiero	Nicholas	24. Interventional Cardiology: Mitral and Structural Heart Disease Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,Novartis Corporation,St. Jude Medical; OTHER - Boehringer Ingelheim Pharmaceuticals, Inc
Ruhl	Jeffrey	Contemporary Issues in Familial Hypercholesterolemia	The Hidden Burden of EHR-Identified Familial Hypercholesterolemia: Mortality and Clinical Outcomes	Nothing to Disclose
Ruiz	Carlos	The Best Structural Interventional Challenging Cases	Transapical Mitral Paravalvular Leak Closure for Recurrent Paravalvular Leak	CONSULTANT FEES/HONORARIA - Cardiac Implants, Sorin, Valtech; OTHER - BioInspire; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Entourage, Mirkasist, Vascular Therapies; RESEARCH/RESEARCH GRANTS - Philips, St. Jude Medical
Rumberger	John	 Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team 	Suggested Reviewer	Nothing to Disclose
Rumsfeld Rumsfeld	John John	FIT Forum: Mix and Mingle Healthcare Innovation for Your Practice: Focus	Outcomes Research Opening Remarks	DATA SAFETY MONITORING BOARD - Astellas Pharma US DATA SAFETY MONITORING BOARD - Astellas Pharma US
Rumsfeld	John	on Personalized Digital Health Post FDA Release Prosthetic Valve	Panelist	DATA SAFETY MONITORING BOARD - Astellas Pharma US
		Surveillance - Watching for Signals		
Rumsfeld	John	Interventional Cardiology: TAVR 2	Direct Home Discharge and Likelihood of 30-Day Hospital Readmission After Transcatheter Aortic Valve Replacement (TAVR): Findings From the STS/ACC TVT Registry	DATA SAFETY MONITORING BOARD - Astellas Pharma US
Rumsfeld	John	Advances in Lipid Management	Implications of the IMPROVE-IT Trial for Contemporary Cardiovascular Practice: An NCDR [®] Research to Practice (R2P) Project	DATA SAFETY MONITORING BOARD - Astellas Pharma US
Ruskin	Jeremy	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Impact of Treatment Crossovers on Clinical Outcomes in the Rate and Rhythm Control Strategies for Atrial Fibrillation: insightsFrom the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) Trial	CONSULTANT FEES/HONORARIA - Advanced Medical Education Inc., Biosense Webster, Boehringer Ingelheim Pharmaceuticals, Inc.Cardiome, Daiichi Sankyo, Gilead Sciences, Inc., Sanofi Aventis, World Care Clinical; DATA SAFETY MONITORING BOARD - Abott, Novartis, OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - PharmacoKinesis; OTHER - CardioInsight, Element Science, MEDTRONIC, Pfizer; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Amgen, Cameron Health, InfoBionic, NewPace Medical, Portola, Regeneron
Russell	Raymond	Imaging of Cancer-Treatment Associated CV Toxicity: Applying Guidelines to Clinical Practice	Nuclear Cardiology: A useful imaging modality in Cardio-Oncology	SALARY - Novartis
Russell	Raymond	Engage @ ACC.17 Studio: FIT Jeopardy Battle of the State Chapters II	Judge	SALARY - Novartis
Russell	Stuart	Treatment Strategies for End Stage Heart Failure: Medications, Machines and Everything in Between	Identifying Stage D Heart Failure - When Do Patients Cross the Line?	DATA SAFETY MONITORING BOARD - Thoratec ; OTHER - Amgen
Russell	Stuart	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	A Bridge Over Water: Successful Implementation of a Heart Failure Bridge Clinic (HFBC) to Reduce Heart Failure (HF) Hospitalizations	DATA SAFETY MONITORING BOARD - Thoratec ; OTHER - Amgen
Russell	Stuart	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Older Age Combined With Reduced Renal Function Has a Strong Cumulative Adverse Effect on Survival in Left Ventricular Assist Device Patients	DATA SAFETY MONITORING BOARD - Thoratec ; OTHER - Amgen
Russell	Stuart	Advanced Therapies = Advanced Trouble: VAD and Transplant Challenges	Acute Kidney Injury Is Highly Frequent Early After Left Ventricular Assist Device Implantation With High Morbidity and Mortality Rates: A Multicentre Study	DATA SAFETY MONITORING BOARD - Thoratec ; OTHER - Amgen
Russell	Stuart	Advanced Therapies = Advanced Trouble: VAD and Transplant Challenges	Proteinuria in Patients Receiving Left Ventricular Assist Devices Is Highly Associated With Renal Failure and Mortality	DATA SAFETY MONITORING BOARD - Thoratec ; OTHER -
Russell	Stuart	14. Heart Failure and Cardiomyopathies: Therapy Team 2	Suggested Reviewer	Arrigen DATA SAFETY MONITORING BOARD - Thoratec ; OTHER - Amgen
Russo	Andrea	Controversies in Arrhythmia Management: Joint Symposium of the Heart Rhythm Society and the American College of Cardiology	Co-Chair	CONSULTANT FEES/HONORARIA - Biotronik, Boston Scientific, MEDTRONIC, St. Jude; OTHER - Biotronik, MEDTRONIC; RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim Pharmaceuticals, Inc, Boston Scientific, MEDTRONIC
Russo	Andrea	Controversies in Device Therapy	Should This Patient with AF Discovered on Pacemaker be Anti Coagulated?	CONSULTANT FEES/HONORARIA - Biotronik, Boston Scientific, MEDTRONIC, St. Jude; OTHER - Biotronik, MEDTRONIC; RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim Pharmaceuticals, Inc, Boston Scientific, MEDTRONIC
Russo	Andrea	Contemporary Management of Anticoagulation in High-risk Patients with Atrial Fibrillation	Co-Chair	CONSULTANT FEES/HONORARIA - Biotronik, Boston Scientific, MEDTRONIC, St. Jude; OTHER - Biotronik, MEDTRONIC; RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim Pharmaceuticals, Inc, Boston Scientific, MEDTRONIC
Russo	Andrea	06. Arrhythmias and Clinical EP: Other Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Biotronik, Boston Scientific, MEDTRONIC, St. Jude; OTHER - Biotronik, MEDTRONIC; RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim Pharmaceuticals, Inc, Boston Scientific, MEDTRONIC

and the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Russo	Cesare	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Heart Failure Phenotyping by Latent Class Analysis Identifies	SALARY - Bristol-Myers Squibb Company
Russo	Cesare	Emerging Developments in HFpEF and	Subpopulations at High Risk of Mortality and Readmissions: Insights From a Real World Database Prognostic Significance of Left Ventricular Diastolic Dysfunction	SALARY - Bristol-Myers Squibb Company
		Arryhthmias	Progression in Patients With Heart Failure With Preserved Ejection Fraction: The I-PRESERVE Trial	
Russo	Juan	Novel Developments in Acute Coronary Syndromes	Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Russo	Mark	Interventional Cardiology: TAVR 1	Assessment of Right Sided Hemodynamic Parameters as Predictors of Early Outcomes After Transcatheter Aortic Valve Replacement	SPEAKER'S BUREAU - Edwards Lifesciences
Russo	Mark	Emerging Applications of Echocardiography	A New Modified Continuity Equation for Calculation of Aortic Valve Area by Integrating 3-D Measurements of LVOT Planimetry and	SPEAKER'S BUREAU - Edwards Lifesciences
Russo	Mark	Emerging Applications of Echocardiography	LVOT Flow Mapping Direct Comparison of Aortic Valve Area by 3-D TEE Planimetry and	SPEAKER'S BUREAU - Edwards Lifesciences
Russo	Mark	Interventional Cardiology: PCI and TAVR in Complex Patients	4-D Dynamic Cardiac CT Planimetry Non-Trans Femoral Trans Catheter Aortic Valve Replacement in Nonagenarians With Severe Aortic Stenosis: A Matched Case-	SPEAKER'S BUREAU - Edwards Lifesciences
Russo	Mark	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Control Pilot Study Percutaneous Management of Severe Aortic Insufficiency Complicating Prolonged Left Ventricular Assist Device Support	SPEAKER'S BUREAU - Edwards Lifesciences
Russo	Pat	Population Specific Cardiomyopathies: From	Hospitalization Expenditure by New York Heart Association (NYHA)	SALARY - Novartis
Russo	Robert	Exomes to Databases 23. Interventional Cardiology: IVUS and	Classification in Heart Failure (HF) Patients in China Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Biotronik,Boston
Ryan	John	Intravascular Physiology Team 1 Hot Topics and Great Debates in Pulmonary	Co-Chair	Scientific,St. Jude Medical Nothing to Disclose
Ryan	John	Hypertension Core Curriculum: Moving from the Basics to	Approaches to the Management of PH	Nothing to Disclose
Ryan	John	Advanced Cases in Pulmonary Hypertension 35. Pulmonary Hypertension and Pulmonary	Suggested Reviewer	Nothing to Disclose
Ryan	Kathleen	Thrombo-embolic Disease Team 1 Predicting Outcomes in Pediatric Heart Disase	Insurance Type Is Associated With Longer Hospital Duration but	Nothing to Disclose
			Similar Mortality Among Children Undergoing Congenital Heart Surgery	-
Ryan	Thomas	Making Progress in Understanding Heart Failure	Contemporary Use of Heart Failure Medications in Pediatric Patients With Dilated Cardiomyopathy	
Rychik	Jack	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Hypoplastic Left Heart Syndrome With Intact or Restrictive Atrial Septum:What Happens After Survival?	Nothing to Disclose
Rychik	Jack	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	From Fetus to Fontan: A Single Center Experience of Resource Utilization for Patients Diagnosed With Single Ventricle Cardiac Defects	Nothing to Disclose
Rymer	Jennifer	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Bleeding and Premature Antiplatelet Therapy Discontinuation After Myocardial Infarction Among Patients With Chronic Kidney Disease	Nothing to Disclose
Ryo-Koriyama	Keiko	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Simplified Measures of Right Ventricular and Atrial Remodeling Are Predictive of Outcomes in Patients With Pulmonary Hypertension	Nothing to Disclose
Rzeszut	Anne	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Acute Decompensated Heart Failure: The Journey From Patients' Perspective	Nothing to Disclose
Rzeszut	Anne	Innovations in Advocacy and Patient Centered Care	Status of Early Career Academic Cardiology: A Global Perspective	Nothing to Disclose
Saad	Ahmad Shukri	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Not All Shocks Are Created Equal: Acute Coronary Syndrome in the Setting of Panhypopituitarism	Nothing to Disclose
Saad	Marwan	Coronary Intervention: Drug Eluting Stent and Scaffolds	Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold Versus Second Generation Des in Coronary Artery Disease: A Meta-Analysis	Nothing to Disclose
Saade	Georges	Heart Failure: From Pathophysiology to Socio- Economic Impact: International Perspectives From the Lebanese Cardiac Society, Taiwan Society of Cardiology, and American College of Cardiology	Ventricular Assist Device for Heart Failure: The Lebanese Experience	Nothing to Disclose
Saavedra	Pablo	Arrhythmias and Clinical EP: AF Ablation	Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism in Patients Undergoing Left Atrial Catheter Ablation Procedures for Paroxysmal or Persistent (Non-Permanent) Atrial Fibrillation and Left Atrial Flutter	Nothing to Disclose
Saba	Samir	Arrhythmias and Clinical EP: Devices 2	Persistent Gender Disparities in Implantable Cardioverter- Defibrillator Therapy	RESEARCH/RESEARCH GRANTS - Boston Scientific, Medtronic Inc., St Jude Medical
Saba	Samir	Arrhythmias and Clinical EP: AF Ablation	Characterization of Pulmonary Vein Reconnection Post Cryoballoon Ablation	RESEARCH/RESEARCH GRANTS - Boston Scientific, Medtronic Inc., St Jude Medical
Sabanayagam	Aarthi	The Story of the Adult Congenital Heart Disease Patient and EP	Prevalence and Predictors of Atrial Tachyarrhythmias in Adult	Nothing to Disclose
Sabanayagam	Aarthi	Adult Patients With Congenital Heart Disease: How Do They Compare?	Fontan Patients Mortality in Pregnant Women With Congenital Heart Disease: A Subanalysis of the California Pregnancy-Associated Mortality	Nothing to Disclose
Sabanayagam	Aarthi	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Review Coronary Artery Fistula in Pulmonary Atresia With Intact Ventricular Septum Physiology: To Close or Not To Close ?	Nothing to Disclose
Sabanayagam	Aarthi	Fontan in the Modern World	Prevalence of Elevated Body Mass Index and Its Association With	Nothing to Disclose
Sabanayagam	Aarthi	Redefining the "F" Word	Clinical Features in Adult Fontan Patients Prevalence and Predictors of Pacemaker Placement in Adult	Nothing to Disclose
Sabate	Manel	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Fontan Patients Differences and Level of Agreement in SYNTAX Score Assessment Between Site Operators and Angiographic Core Laboratory	CONSULTANT FEES/HONORARIA - Abbott Laboratories,MEDTRONIC
Sabate	Manel	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Readers: Insights From the EXCEL Trial Therapeutic Hypothermia in Post-Cardiac Arrest Syndrome: Role of Neuron-Specific Enolase as Early Predictor of Neurological Status	CONSULTANT FEES/HONORARIA - Abbott Laboratories MEDTRONIC
Sabate	Manel	Syndrome Refining PCI Technique and Outcomes	at Discharge Treatment of Left Main Coronary Artery Disease in Patients With	CONSULTANT FEES/HONORARIA - Abbott
Sahata	Manel	Perining PCI Technique and Outress	Diabetes: 3-Year Outcomes Comparing CABG and PCI With Everolimus-Eluting Stents From the EXCEL Study	Laboratories,MEDTRONIC
Sabate	Manel	Refining PCI Technique and Outcomes	Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory Assessment: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - Abbott Laboratories,MEDTRONIC
Sabate	Manel	PCI Strategies and Outcomes Unique to Women	Sex Differences in Outcomes After Stenting or Bypass Surgery for Unprotected Left Main Disease	CONSULTANT FEES/HONORARIA - Abbott Laboratories,MEDTRONIC
Sabaté	Manel	Highlighted Original Research: Interventional Cardiology and the Year in Review	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	CONSULTANT FEES/HONORARIA - Abbott Laboratories,MEDTRONIC

and a				
Last Name Sabatine	First Name Marc	Session Title Opening Session and the Joint American College of Cardiology and Journal of American College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture	Presentation Title Primary Results of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial	Disclosures CONSULTANT FEES/HONORARIA - Amgen Inc., CVS Caremark, Esperion, Jonis, Medimmune, Inc., Merck & amp; amp; Co., Inc.; RESEARCH/RESEARCH GRANTS - Amgen Inc., Astra2enea, Dailichi- Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen Research Development, Medimmune, Inc, Merck & amp; amp; Co., Inc., Novaris Corporation, Pizer Inc. Poxel; Takeda
Sabatine	Marc	Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials	Primary Results of EBBINGHAUS, a Cognitive Study of Patients Enrolled in the FOURIER Trial	Inc., Novaris Corporation, Prizer Inc., Poxel, Takeda Pharmaceuticals North America, Inc CONSULTANT FEES/HONORARIA - Amgen Inc., CVS Caremark, Esperion, Jonis, Medimmune, Inc., Merck & amp; amp; Co., Inc.; RESEARCH/RESEARCH GRANTS - Amgen Inc., AstraZeneca, Daiichi Sankyo, Eisai, GiaxoSmithKline, Intarcia, Janssen Research Development, Medimmune, Inc, Merck & amp; amp; Co., Inc., Novaris Corporation, Prizer Inc, Poxel; Takeda
Sabatine	Marc	Late-Breaking Clinical Trials: Deep Dive I	Primary Results of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial and Primary Results of EBBINGHAUS, a Cognitive Study of Patients Enrolled in the FOURIER Trial	Pharmaceuticals North America, Inc CONSULTANT FEES/HONORARIA - Amgen Inc.,CVS Caremark,Esperion,Ionis,Medimmune, Inc.Merck & Bamp, amp; Co., Inc.; RESEARCH/RESEARCH GRANTS - Amgen Inc.,AstraZeneca,Dalichi Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen Research Development, Medimmune, Inc.,Merck & Ampyamp, Co., Inc.,Novartis Corporation,Pfizer Inc,Poxel,Takeda
Sabatine	Marc	Vascular Access and Hemostasis Issues	Radial Versus Femoral Access for Coronary Angiography and Risk of Stroke: Findings From the LATITUDE-TIMI 60 Trial	Pharmaceuticals North America, Inc CONSULTANT FEES/HONORARIA - Amgen Inc.,CVS Caremark,Esperion,Ionis,MedImmune, Inc,Merck & amp;amp; Co., Inc.; RESEARCH/RESEARCH GRANTS - Amgen Inc.,AstraZeneca,Daiichi Sankyo,Eisai,GlawSmithtKline,Intarcia,Janssen Research Development ,MedImmune, Inc,Merck & amp;amp; Co., Inc.,Novartis Corporation,Pfizer Inc,Poxel,Takeda Pharmaceuticals North America, Inc
Sabatine	Marc	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Association of Genetic Risk Score with Burden of Atrial Fibrillation: An ENGAGE AF-TIMI 48 Analysis	CONSULTANT FEES/HONORARIA - Amgen Inc.,CVS Caremark,Esperion,Ionis,Medimunue, Inc.Merck & Demonstration on the Co., Inc.; RESEARCH/BRESEARCH GRANTS - Amgen Inc.,AstraZeneca,Dailchi- Sankyo,Eisai,GlaxoSmithKline,Intarcia,Janssen Research Development, MedImmune, Inc,Merck & Demonstration,Prizer Inc.,Poxel,Takeda Pharmaceuticals North America, Inc
Sabatine	Marc	02. Acute and Stable Ischemic Heart Disease: Clinical Team 9	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen Inc.,CVS Caremark,Esperion,Jonis,MedImmune, Inc,Merck & Demorary, Co., Inc., RESEARCH/BESEARCH GRANTS - Amgen Inc., AstraZeneca, Dailchi Sankyo,Eisai,GlaxoSmithKline,Intarcia,Janssen Research Development, MedImmune, Inc,Merck & Demorary, Co., Inc., Novartis Corporation,Pfizer Inc,Poxel,Takeda Pharmaceuticals North America, Inc
Sabbag	Avi	Anti-Platelet Therapies: Always a Sticky Topic	Chewing Versus Traditional Swallowing of Ticagrelor to Accelerate Platelet Inhibition in ST Elevation Myocardial Infarction: The CHEERS-STEMI Study	Nothing to Disclose
Sabbah	Hani	Young Investigator Awards Competition: Basic and Translational Science	Chair	CONSULTANT FEES/HONORARIA - Bayer Healthcare, Merck & Description of the Composition of t
Sabbah	Hani	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Long-Term Therapy With Elamipretide Normalizes Activation of the Mitochondrial Signal Transducer and Activator of Transcription 3 (mSTAT3) in of Left Ventricular Myocardium of Dogs With Chronic Heart Failure	CONSULTANT FEES/HONORARIA - Bayer Healthcare,Merck & Co., Inc.,Novartis Corporation,Stealth Biotherapeutics, Inc.; RESEARCH/IRESEARCH GRANTS - Bayer Healthcare,Merck & Co., Inc.,Novartis Corporation,Stealth Biotherapeutics
Sabbah	Hani	Heart Failure and Cardiomyopathies: Clinical Team 5	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Bayer Healthcare,Merck & amp;amp; Co., Inc.,Novartis Corporation, Stealth Biotherapeutics, Inc.; RESEARCH/RESEARCH GRANTS - Bayer Healthcare,Merck & amp;amp; Co., Inc.,Novartis Corporation,Stealth Biotherapeutics
Sabe Sabe	Marwa Marwa	Cardiogenic Shock: Drugs to Devices Interdisciplinary Cardiovascular Care in Complex Scenarios	Co-Chair Thirteen Lives: Massive Pulmonary Embolism Causing Twelve Episodes of Cardiac Arrest Managed by an Interdisciplinary	Nothing to Disclose Nothing to Disclose
Saberi	Sara	Featured Clinical Research I	Pulmonary Embolism Consult Team Testing Safety and Efficacy: The Randomized Exploratory Study of Exercise Training in Hypertrophic Cardiomyopathy (RESET-HCM)	Nothing to Disclose
Sabik	Joseph	Highlighted Original Research: Interventional Cardiology and the Year in Review	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,Medistem,MEDTRONIC,Sorin;
Sabik	Joseph	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Differences and Level of Agreement in SYNTAX Score Assessment Between Site Operators and Angiographic Core Laboratory	RESEARCH/RESEARCH GRANTS - Abbott,Edwards,St Jude CONSULTANT FEES/HONORARIA - Edwards Lifesciences,Medistem,MEDTRONIC,Sorin;
Sabik	Joseph	Refining PCI Technique and Outcomes	Readers: Insights From the EXCEL Trial Treatment of Left Main Coronary Artery Disease in Patients With Diabetes: 3-Year Outcomes Comparing CABG and PCI With	RESEARCH/RESEARCH GRANTS - Abbott,Edwards,St Jude CONSULTANT FEES/HONORARIA - Edwards Lifesciences,Medistem,MEDTRONIC,Sorin;
Sabik	Joseph	Refining PCI Technique and Outcomes	Everolimus-Eluting Stents From the EXCEL Study Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory	RESEARCH/RESEARCH GRANTS - Abbott,Edwards,St Jude CONSULTANT FEES/HONORARIA - Edwards Lifesciences,Medistem,MEDTRONIC,Sorin;
Sabik	Joseph	PCI Strategies and Outcomes Unique to Women	Assessment: Insights From the EXCEL Trial Sex Differences in Outcomes After Stenting or Bypass Surgery for Unprotected Left Main Disease	RESEARCH/RESEARCH GRANTS - Abbott,Edwards,St Jude CONSULTANT FEES/HONORARIA - Edwards Lifesciences,Medistem,MEDTRONIC,Sorin;
Sacco	Ralph	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	­The Utility of Minimal Coronary Artery Calcification for Predicting Carotid Artery Disease: Results From the Multi-Ethnic	RESEARCH/RESEARCH GRANTS - Abbott,Edwards,St Jude CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
Sachdeva	Ritu	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Study of Atherosclerosis (MESA) Long Term Outcomes After the Fontan Procedure in Patients With Single Ventricle: A Meta-Analysis	Nothing to Disclose
Sachdeva	Ritu	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Does Tricuspid Annular Plane Systolic Excursion (TAPSE) Adequately Describe Right Ventricular Function in Hypoplastic Left Heart Syndrome?	Nothing to Disclose
Sachdeva	Ritu	10. Congenital Heart Disease: Pediatric Team 3	Suggested Reviewer	Nothing to Disclose
Sachdeva	Shagun	Congenital Heart Disease Surgery: Updates and Innovations	Anatomic Repair of Congenitally Corrected Transposition Results in Excellent Survival and Functional Status at Intermediate Term Follow-Up	Nothing to Disclose
Sadeghi Sadek	Mehran Hesham	30. Non Invasive Imaging: Nuclear Team 2 12. Heart Failure and Cardiomyopathies: Basic	Suggested Reviewer Suggested Reviewer	SALARY - Boehringer Ingelheim Pharmaceuticals, Inc Nothing to Disclose
Caden	oonam	Team 2	Suggested (Actioner)	Treating to Disciose

Control of the contro				
Last Name Sadiq	First Name Immad	Session Title FIT Clinical Decision Making: Prevention, Adult	Presentation Title latrogenic Diversion of Inferior Vena Cava to Left Atrium After	Disclosures Nothing to Disclose
01		Congenital and Congenital Heart Disease	Surgical Closure of Atrial Septal Defect	N. W. J. P. J.
Saeed	Anum	Advances in Cholesterol Measurement and Management	Association of Remnant-Like Particle Cholesterol and Low-Density Lipoprotein Triglyceride With Incidence of Cardiovascular Events: The ARIC Study <i></i>	Nothing to Disclose
Saeed	Ibrahim	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	A Challenging Cardiomyopathy Diagnosis: Do Not Be Anchored by an Initial Impression	Nothing to Disclose
Saely	Christoph	Updates on Risk Factors for Cardiovascular Disease	The Visceral Adiposity Index Predicts Cardiovascular Events Both in Coronary Artery Disease Patients With and in Coronary Artery Disease Patients Without Diabetes	Nothing to Disclose
Saely	Christoph	Innovations in Cardiovascular Risk Assessment and Reduction		Nothing to Disclose
Saely	Christoph	Diabetes and Other Issues in Cardiovascular	Non-Alcoholic Fatty Liver Disease Strongly Predicts Incident	Nothing to Disclose
Saely	Christoph	Prevention Diabetes and Other Issues in Cardiovascular Prevention	Diabetes in Patients With Coronary Artery Disease Single and Joint Effects of Obesity and of the Metabolic Syndrome on the Development of Diabetes in Patients With Coronary	Nothing to Disclose
Saely	Christoph	Diabetes and Other Issues in Cardiovascular Prevention	Atherosclerosis Non-Alcoholic Fatty Liver Disease in Coronary Artery Disease Patients: Association With Impaired Glucose Metabolism and With Future Cardiovascular Event Risk	Nothing to Disclose
Saely	Christoph	The Intersection of Diabetes and ASCVD		Nothing to Disclose
Saenz	Gloria	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Holter Findings in Orthotopic Heart Transplantation Patients: Results From a Cohort of the Most Important Heart Transplant Referral Center in Colombia, South America	Nothing to Disclose
Safarova	Maya	Young Investigator Awards Competition: Clinical Investigations	Scanning the Phenome to Uncover Pleiotropic Effects of <i>PCSK9</i>	Nothing to Disclose
Safarova	Maya	Advances in Cholesterol Measurement and Management	Physician Perspectives on Clinical Decision Support for Familial Hypercholesterolemia	Nothing to Disclose
Safarova	Maya	Innovations in Practice Management and	Mining Electronic Health Records for Familial Hypercholesterolemia	Nothing to Disclose
Safarova	Maya	Social Media Contemporary Issues in Familial		Nothing to Disclose
Safdar	Basmah	Hypercholesterolemia Traditional and Novel Factors Used to Assess	the Community Does 3-Hour Point of Care Troponin I Predict 6-Hour Point of Care	Nothing to Disclose
Safdar	Basmah	the Risk of, and Used for the Treatment of, Coronary Artery Disease Cardiac Arrest, Diabetes, and Other High Risk	Troponin I for Patients in a Chest Pain Unit Mechanisms of Acute Myocardial Infarction in Young Women and	Nothing to Disclose
		Features of Patients With Acute Coronary Syndrome	Discharge Medication Patterns	
Safian	Robert	Interventional Cardiology: TAVR 4	Outcome-Based Cost Analysis of Transfemoral Transcatheter Aortic Valve Replacement Using Fascia Iliaca Compartment Block and Minimalist Conscious Sedation Approach Versus General Anesthesia	Nothing to Disclose
Safian	Robert	39. Vascular Medicine: Endovascular Therapy Team 1	Suggested Reviewer	Nothing to Disclose
Safirstein	Jordan	Engage @ ACC.17 Studio: FIT Jeopardy Battle of the State Chapters III	Moderator	CONSULTANT FEES/HONORARIA - MEDTRONIC, Svelte Medical
Safley	David	Refining PCI Technique and Outcomes	Appropriate Use Criteria and Health Status Outcomes After CTO PCI: Results From the OPEN CTO Registry	RESEARCH/RESEARCH GRANTS - Merck Pharmaceuticals
Saggar	Rajan	Hot Topics and Great Debates in Pulmonary Hypertension	Debate: Be it Resolved: It is Time to Treat Pulmonary Hypertension Secondary to Chronic Lung Disease with PAH Specific Therapies ((Pro)	Nothing to Disclose
Saguner	Ardan	Arrhythmias and Clinical EP: AF Ablation	High Density Mapping for Gap Identification After Pulmonary Vein	Nothing to Disclose
Saha	Sandeep	FIT Clinical Decision Making Reviewers 6	Isolation ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Sahai	Gagan	Advances in Imaging to Assess Cardiotoxicity	^{99m} Tc-Duramycin Imaging Detects Doxorubicin Cardiac Injury Before Onset of Ventricular Dysfunction	Nothing to Disclose
Sahbaz	Jasmin	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Important Hemodynamic Considerations in the Management of an Adult With Unrepaired Pentalogy of Fallot Presenting With Necrotizing Fasciitis and Sepsis	Nothing to Disclose
Sahni	Sheila	Core Curriculum: Revascularization in Special Populations	To Stent or Not: Tough Decisions Regarding Left Main CAD	Nothing to Disclose
Sahu	Deepak Kumar	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Health-Economics of Measuring High-Sensitive Cardiac Troponin at Different Cut-Offs in Non-ST Segment Elevation Myocardial Infarction Patients Within 6 Hours From Emergency Room	Nothing to Disclose
Said	Sameh	Frontiers in Mitral Valve Disease and	Presentation Long Term Outcomes of Patients Undergoing Percutaneous and	Nothing to Disclose
Said	Sarmad	Treatment FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Surgical Mitral Paravalvular Leak Repair Combined Migraine and Platypnea-Orthodeoxia Syndrome Due to Combined Atrial Septal Defect and Patent Foramen Ovale	Nothing to Disclose
Said	Sarmad	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Double Right Coronary Artery Engendering Inadequate Blood Supply to the Inferior Left Ventricular Wall	Nothing to Disclose
Said	Zaid	Arrhythmias and Clinical EP: AF Ablation	Improvement in Cost and Efficiency in Electrophysiology Laboratory by Cardiac Computed Tomography to Exclude Left Atrial Appendage Thrombus Prior to Atrial Fibrillation Ablation	Nothing to Disclose
Saidi	Arwa	Update in ACHD: The Time for Change is Now		Nothing to Disclose
Saidi	Arwa	Exercise in Congenital Heart Disease	A Practical Approach to Exercise Recommendations in Congenital	Nothing to Disclose
Saito	Daiga	Novel Developments in Acute Coronary Syndromes	Heart Disease Left Ventricular End-Diastolic Pressure Predicts Outcomes in Patients With ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Saito	Shigeo	Advances in Chronic Total Occlusion Intervention	Independently of Left Ventricular Systolic Function The Impact of Recanalization of Chronic Total Occuluded Coronary Artery on Electrophysiological Substrate of Left Ventricle	Nothing to Disclose
Saito	Shigeo	Interventional Cardiology: PCI in Complex Patients	Chronic Stent Recoil During Follow-Up in Severely Calcified Coronary Artery Lesions: An Optical Coherence Tomography Study	Nothing to Disclose
Sakaki	Masayuki	Head to Toe: Outcomes of Endovascular Interventions	Late Intervention After Endovascular Aneurysm Repair for Abdominal Aortic Aneurysm: National Hospital Organization	RESEARCH/RESEARCH GRANTS - Century Medical ,Edwards Lifesciences
Sakhuja	Rahul	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Network Study in Japan Digit Ischemia Work-Up and an Uncommon Diagnosis: Hypothenar Hammer Syndrome	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,MEDTRONIC
Sakwa	Marc	Interventional Cardiology: TAVR 4	Outcome-Based Cost Analysis of Transfemoral Transcatheter Aortic Valve Replacement Using Fascia Iliaca Compartment Block and Minimalist Conscious Sedation Approach Versus General Anesthesia	CONSULTANT FEES/HONORARIA - Estech,St. Jude
Salahuddin	Usman	Arrhythmias and Clinical EP: AF Miscellaneous	Association Between Body Mass Index and Outcomes Among	Nothing to Disclose
	L	and Surgical Issues	Patients With Prevalent Atrial Fibrillation: A Meta-Analysis	

WASHINGTON, DC | MARCH 17 - 19 2017

-				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Salam	Amar	Revascularization and Myocardial Preservation	Do Women Benefit From Early Coronary Artery Bypass Graft and	Nothing to Disclose
		in Acute and Stable Ischemic Heart Disease	Percutaneous Coronary Interventions in Acute Coronary Syndromes: Answers From the Second Gulf Registry of Acute Coronary Events	
Salama	Amr	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Treating Sustained Ventricular Tachycardia With Digoxin	Nothing to Disclose
Salami	Joseph	Arrhythmias and Clinical EP: Basic 1	Variation in the Use of Direct Oral Anticoagulants and Associated Cost Implications: Findings From the Medical Expenditure Panel Survey 2010 to 2013	Nothing to Disclose
Salcedo	Ernesto	Novel Echocardiographic Methods for	Comparison of the Effects of Balloon Expandable and Self	RESEARCH/RESEARCH GRANTS - Philips Ultrasound
		Assessing Cardiac Function	Expandable Transcatheter Aortic Valve Replacement on the Dimensions of the Mitral Valve Annulus and Mitral Regurgitation Severity	
Salciccioli	Louis	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Nailfold Capillaroscopy for the Identification of Microvascular Disease in African-Americans	Nothing to Disclose
Saleh	Layth	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Outcomes of Remote Magnetic Navigation-Guided Catheter Ablation of Left Ventricular Summit Arrhythmias Accessible via the Coronary Venous System	Nothing to Disclose
Saleh	Yehia	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Think Syndromic	Nothing to Disclose
Salemi	Arash	Interventional Cardiology: TAVR 2	Does Intra-Aortic Balloon Pump Placement During Hospitalization Course for Transcatheter Aortic Valve Replacement Portent a	CONSULTANT FEES/HONORARIA - Edwards Lifesciences
Salemi	Arash	Interventional Cardiology: TAVR 3	Worse Clinical Outcome? Periprocedural Blood Transfusions in Patients Undergoing Transactive Active Periprocedural	CONSULTANT FEES/HONORARIA - Edwards Lifesciences
Salemi	Arash	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Replacement Transcatheter Aortic Valve Implantation Is Safe in Patients With Left	CONSULTANT FEES/HONORARIA - Edwards Lifesciences
Salemi	Vera	Population Specific Cardiomyopathies: From	Atrial Thrombus or Spontaneous Echo Contrast Air Pollution in Myocardial Remodeling	Nothing to Disclose
Salerno	Michael	Exomes to Databases FIT Clinical Decision Making: Non-Invasive	Recurrent Focal Myocarditis With Microvascular Obstruction	RESEARCH/RESEARCH GRANTS - Astra Zeneca, Siemens
Salerno	Michael	Imaging and Valvular Heart Disease Acute Coronary Syndromes, Diagnosis,	Prediction of 30-Day Readmissions in Patients Admitted for Acute	Healthcare RESEARCH/RESEARCH GRANTS - Astra Zeneca, Siemens
Salerno	Michael	Management and Outcomes 29. Non Invasive Imaging: MR Team 1	Myocardial Infarction (AMI) Suggested Reviewer	Healthcare RESEARCH/RESEARCH GRANTS - Astra Zeneca, Siemens
Salerno	Tomas	Atrial Fibrillation and VT: Specific Situations	Perioperative Administration of Amiodarone or Beta Blockers in	Healthcare Nothing to Disclose
		and Newer Outcome Measures	Cardiac Surgery. Which Is More Effective in Reducing Postoperative Atrial Fibrillation?	-
Saliba	Walid	Advances in HCM, PPCM and Other Cardiomyopathies	Atrial Thrombus in Patients With Cardiac Amyloidosis: Prevalence and Implications for Therapy	CONSULTANT FEES/HONORARIA - Boston Scientific,J&J,MEDTRONIC,St Jude Medical
Saliba	Walid	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific, J& amp; J,MEDTRONIC, St Jude Medical
Salinas	Pablo	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International	Nothing to Disclose
Salisbury	Adam	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Multicentre iFR GRADIENT Registry Outcomes of Concomitant Acute Kidney Injury and Hospital Acquired Anemia in Patients With Myocardial Infarction: The	CONSULTANT FEES/HONORARIA - MEDTRONIC
Salisbury	Adam	Syndrome Advances in Chronic Total Occlusion Intervention	TRIUMPH Study Association of Stress Test Risk Classification With Health Status Change After Chronic Total Occlusion PCI: Insights From the OPEN- CTO Registry	CONSULTANT FEES/HONORARIA - MEDTRONIC
Salisbury	Adam	Refining PCI Technique and Outcomes	Appropriate Use Criteria and Health Status Outcomes After CTO PCI: Results From the OPEN CTO Registry	CONSULTANT FEES/HONORARIA - MEDTRONIC
Salmon	Joelle	Interventional Cardiology: TAVR 2	Racial Disparities and Temporal Trends in Demographics and Clinical Characteristics of Patients Screened for Transcatheter	Nothing to Disclose
Salmon	Richard	Innovations in Cardiovascular Risk Assessment and Reduction	Aortic Valve Replacement Evaluation of the CardioSmart Population Health Management Initiative: Changes in Health Risks and Participant Satisfaction	Nothing to Disclose
Saltiel	Frank	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Impact of Hereditary Causes of Thrombosis on Ischemic Stroke Between the Years 2008 Through 2012: Nationwide Inpatient Sample Data Analysis	OTHER - Merit Medical; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals
Saltzman	Heath	Arrhythmias and Clinical EP: Devices 1	Increased Shock Impedance Is Associated With Failed Subcutaneous Implantable Cardioverter Defibrillator Defibrillation	CONSULTANT FEES/HONORARIA - azoi,Boston Scientific,Johnson & amp;amp; Johnson,Sorin,Zoll
Saluja	Amardeep	FIT Clinical Decision Making: Arrhythmias and	Threshold Testing Searching for a Trigger in Resistant Ventricular Tachycardia in Post	CONSULTANT FEES/HONORARIA - MEDTRONIC,St Jude
Salvatella	Neus	Electrophysiology Timely Topics in Acute Coronary Syndromes	Acute Myocardial Infarction A New Prognosis Score to Predict Mortality in Patients Over 75	Nothing to Disclose
Salvi	Nicolo'	Improving Outcomes in the Athlete With	Years Old Undergoing Primary Angioplasty in Cardiogenic Shock EKG Abnormalities Distribution Between Competitive Athletes, Non	Nothing to Disclose
0	5	Cardiovascular Disease	Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students	
Sam	Flora	Advances in HCM, PPCM and Other Cardiomyopathies	VE/VCO2 Is a Powerful Predictor of Mortality in Wild-Type Transthyretin Amyloidosis	Nothing to Disclose
Samad	Fatima	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Athlete's Heart Versus Apical Hypertrophic Cardiomyopathy: Look Again!	Nothing to Disclose
Samad	Fatima	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease		Nothing to Disclose
Samad	Zainab	Valvular Heart Disease With CKD or Cirrhosis	Low Utilization of Surgical Intervention to Treat Severe Aortic Stenosis in Patients With Chronic Kidney Disease	RESEARCH/RESEARCH GRANTS - BD STAR, Gilead Sciences Inc.
Samady	Habib	Interventional Live Case Session V: Complex Coronary and Physiology from Mid-America Heart Institute (Kansas City, Missouri)	Panelist	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Global Genomics Group; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Forrest Pharmaceuticals Inc.,MEDTRONIC,NIH,St.
Samady	Habib	Coronary Physiology and Microcirculation	Panelist	Jude Medical, Toshiba, Volcano Corp. OWNERSHIP INTEREST-PARTINERSHIP/PRINCIPAL - Global Genomics Group, RESEARCH/RESEARCH GRANTS - Abbott Vascular, Forrest Pharmaceuticals Inc., MEDTRONIC, NIH, St. Jude Medical, Toshiba, Volcano Corp.
Samady	Habib	Coronary Physiology and Microcirculation	Is Endothelial Function and Vasospasm Assessment Relevant in 2017?	Jude Medical, Toshiba, Volcano Corp. OWNERSHIP INTEREST/PARTINERSHIP/PRINCIPAL - Global Genomics Group; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Forrest Pharmaceuticals Inc., MEDTRONIC, NIH, St. Jude Medical, Toshiba, Volcano Corp.
Samady	Habib	Maintenance of Clinical Competencies in Invasive Coronary Imaging and Coronary Physiology	Application of Coronary Physiology and Imaging in the Cath Lab	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Global Genomics Group; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Forrest Pharmaceuticals Inc.,MEDTRONIC,NIH,St. Jude Medical, Toshiba, Volcano Corp.
Samady	Habib	Coronary Intervention: Drug Eluting Stent and Scaffolds	Efficacy and Safety of Everolimus-Eluting Stents Versus Slow- Release Zotarolimus-Eluting Stents: A Direct Comparison Meta- Analysis of 29,286 Patients - Years of Follow-Up From Randomized Controlled Trials	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Global Genomics Group; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Forrest Pharmaceuticals Inc.,MEDTRONIC,NIH,St. Jude Medical, Toshiba, Volcano Corp.

1				<u> </u>
Last Name Samady	First Name Habib	Session Title Advances in Chronic Total Occlusion	Presentation Title Performance of J-CTO and PROGRESS CTO Scores in Predicting	Disclosures OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Global
Camacy	Habib	Intervention	Angiographic Success and Long-Term Clinical Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions	Genomics Group; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Forrest Pharmaceuticals Inc., MEDTRONIC, NIH, St. Jude Medical, Toshiba, Volcano Corp.
Samady	Habib	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Revascularization in an Athlete Youth With Complex Aneurysmal Coronary Stenosis	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Global Genomics Group; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Forrest Pharmaceuticals Inc.,MEDTRONIC,NIH,St. Jude Medical, Toshiba, Volcano Corp.
Samady	Habib	23. Interventional Cardiology: IVUS and Intravascular Physiology Team 2	Suggested Reviewer	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Global Genomics Group; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Forrest Pharmaceuticals Inc.,MEDTRONIC,NIH,St. Jude Medical, Toshiba, Volcano Corp.
Sambatakos	Peter	Innovations in Education	Fellow Outpatient Clinic: Discontinuing the Discontinuity	Nothing to Disclose
Samman Tahhan	Ayman	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Association Between Circulating Progenitor Cells and Outcomes in Patients With Coronary Artery Disease	Nothing to Disclose
Samman Tahhan	Ayman	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Inflammatory Response to Mental Stress and Mental Stress Induced Myocardial Ischemia	Nothing to Disclose
Samman Tahhan	Ayman	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	A Severe Case of Statin-Associated Autoimmune Myopathy	Nothing to Disclose
Samman Tahhan	Ayman	The Evolving World of LVADs, Transplant and		Nothing to Disclose
Samman Tahhan	Ayman	Other Novel Discoveries Unusual Presentations of ACS	Failure Circulating Progenitor Cells Levels and Outcomes in Acute	Nothing to Disclose
Sampaio	Marcio	Which Test Is Best for Pain in the Chest?	Myccardial Infarction Coronary Computed Tomography Angiography in the Emergency Room: Rapid Exclusion of Coronary Artery Disease and the Fast Diagnosis of Acute Myocarditis Using Late Enhancement by	Nothing to Disclose
Samtani	Sonia	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Computed Tomography A Case of Defibrillation Threshold Testing Failure With Subcutaneous Implantable Defibrillator Implantation in a Hypertrophic Cardiomyopathy Patient	Nothing to Disclose
Samuels	Bruce	Coronary Physiology and Microcirculation	Panelist	CONSULTANT FEES/HONORARIA - Volcano Corporation;
Samuels	Bruce	Coronary Physiology and Microcirculation	Case Presentation: Step by Step Description of Coronary Reactivity	SPEAKER'S BUREAU - Abbott Vascular CONSULTANT FEES/HONORARIA - Volcano Corporation;
Samuels	Bruce	Non Invasive Imaging: MR Scar and Perfusion	Testing in the Cath Lab Hyperemic Subendocardial-to-Subepicardial Perfusion Ratio as a	SPEAKER'S BUREAU - Abbott Vascular CONSULTANT FEES/HONORARIA - Volcano Corporation;
Samuels	Bruce	23. Interventional Cardiology: IVUS and	Surrogate Marker for Coronary Endothelial Dysfunction: Initial Results in Women With Microvascular Dysfunction Suggested Reviewer	SPEAKER'S BUREAU - Abbott Vascular CONSULTANT FEES/HONORARIA - Volcano Corporation;
		Intravascular Physiology Team 2		SPEAKER'S BUREAU - Abbott Vascular
Samyn	Margaret	10. Congenital Heart Disease: Pediatric Team 2	Suggested Reviewer	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - GE Healthcare,Johnson and Johnson,MEDTRONIC,Pfizer,Philips,Siemens; SALARY - GE Healthcare
San Antonio Dharandas	Rodolfo	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Therapeutic Hypothermia in Post-Cardiac Arrest Syndrome: Role of Neuron-Specific Enolase as Early Predictor of Neurological Status at Discharge	
Sanaani	Abdallah	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	In-Hospital Outcomes and Hospitalizations for Acute Rheumatic Heart Disease: A United States National Study	Nothing to Disclose
Sanaani	Abdallah	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Change in Aortomitral Annular Angle and Anterior Mitral Valve Leaflet Length After Transcatheter Aortic Valve Replacement: Implications for Transcatheter Mitral Valve Replacement?	Nothing to Disclose
Sanaani	Abdallah	FIT Clinical Decision Making: Heart Failure and	Management of Takotsubo Cardiomyopathy Complicated by Left	Nothing to Disclose
Sanaani	Abdallah	Pulmonary Hypertension The Evolving World of LVADs, Transplant and	Ventricular Outflow Tract Obstruction Chagas Heart Disease: A United States National Study	Nothing to Disclose
Sanam	Kumar	Other Novel Discoveries Arrhythmias and Clinical EP: Devices 4	Long-Term Use of the Wearable Cardiovertor Defibrillator in ICD	Nothing to Disclose
		-	Explant Patients	-
Sanchez	Javier	Arrhythmias and Clinical EP: AF Ablation	Long-Term Risk of Recurrent Arrhythmia in Patients With Typical Atrial Flutter Undergoing Pulmonary Vein Antrum Isolation or Cavo- Tricuspid Isthmus Ablation With Permanent Isolation	Nothing to Disclose
Sanchez	Javier	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Left Atrial Appendage Flow Velocity to Predict Persistent Left Atrial Appendage Isolation	Nothing to Disclose
Sanchez	Robert	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Recurrent Cardiovascular Event Rates in a Contemporary Cohort of 829,498 Adults With Atherosclerotic Cardiovascular Disease	SALARY - Regeneron
Sanchez	Robert	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Modelling the U.S. Population Health Benefits of Further Low- Density Lipoprotein Cholesterol Reduction With Alirocumab Among Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia Patients With Elevated Low-Density Lipoprotein Cholesterol	SALARY - Regeneron
Sanchez	Robert	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Impact of Statin Intolerance Rates on Need for Ezetimibe and/or PCSK9 Inhibitors for Meeting Low-Density Lipoprotein Goals in a Real-World Cohort With Atherosclerotic Cardiovascular Disease	SALARY - Regeneron
Sanchis	Juan	Acute Heart Failure: Evaluating Strategies to	Performance of the Seattle Heart Failure Model in Patients Discharged After Acute Heart Failure Hospitalization	Nothing to Disclose
Sanchis	Juan	Prevent Readmissions Timely Topics in Acute Coronary Syndromes	A New Prognosis Score to Predict Mortality in Patients Over 75	Nothing to Disclose
Sanchorawala	Vaishali	Advances in HCM, PPCM and Other Cardiomyopathies	Years Old Undergoing Primary Angioplasty in Cardiogenic Shock NEOD001 Demonstrates Cardiac Biomarker Responses in Patients With Light Chain Amyloidosis: Results From the Phase 1/2 Study	Nothing to Disclose
Sandeman	Dennis	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Optimal Risk Stratification Pathways for Patients With Suspected Acute Coronary Syndrome	Nothing to Disclose
Sandeman	Dennis	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Age and the Effectiveness of Risk Stratification and Diagnostic Thresholds for Myocardial Infarction With High-Sensitivity Cardiac Troponin	Nothing to Disclose
Sandeman	Dennis	Acute Coronary Syndromes, Diagnosis,	Is It Safe to Use High-Sensitivity Cardiac Troponin T to Rule out	Nothing to Disclose
Sandeman	Dennis	Management and Outcomes Acute Coronary Syndromes, Diagnosis,	Myocardial Infarction at Presentation? High-Sensitivity Cardiac Troponin and the Classification of	Nothing to Disclose
Sander	Gary	Management and Outcomes Uncovering the Intricacies of Vascular Function	Myocardial Infarction Dapagliflozin Improves Arterial Stiffness in Patients With Type 2	Nothing to Disclose
Sanders	David	Non Invasive Imaging: Prognostic Implications	Diabetes Mellitus Ethnic Differences of Coronary Atherosclerosis in Computed	Nothing to Disclose
		of CT Angiography	Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry	-
Sanders	Jes	Making Progress in Understanding Heart Failure	Associations of HIV Related Factors With Adjudicated Heart Failure (HF) in an Electronic Cohort of HIV-Infected (HIV+) Persons	Nothing to Disclose
Sanders	Jes	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Atrial Fibrillation (AF) and Atrial Flutter (AFL) Prevalence and Characteristics for Persons With Human Immunodeficiency Virus	Nothing to Disclose

Contract of the contract of th				I
Last Name Sanders	First Name Prashanthan	Session Title Arrhythmias and Clinical EP: Devices 1	Presentation Title Insertion of a Miniaturized Insertable Cardiac Monitor Outside the	Disclosures CONSULTANT FEES/HONORARIA - Biosense-Webster, Boston
Salivers	Flashanulan	Annyunnas and Cimical Er. Devices 1	Insertation of a will adult zero insertation Carolac worldood considering Traditional Hospital Setting: Results From the RIO 2 International Study	Scientific,CathRx,MEDTRONIC,Merck & Amp; amp; Co., Inc.,Sanofi-Aventis,servier, St. Jude Medical; RESEARCH/RESEARCH GRANTS - Biotronik,Boston Scientific,MEDTRONIC,MEDTRONIC,Sorin,St. Jude Medical; SPEAKER'S BUREAU - Biosense-Webster,MEDTRONIC,St Jude
Sanderson	John E.	Non Invasive Imaging: Role of Exercise Testing	Impaired Left Ventricular Longitudinal Functional Reserve in Patients With Psoriatic Arthritis: A Low-Level Bicycle Ergometer	Medical Nothing to Disclose
Sandesara	Pratik	Traditional and Novel Factors Used to Assess	Exercise Test Association Between Circulating Progenitor Cells and Outcomes in	Nothing to Disclose
Sandesara	Pratik	the Risk of, and Used for the Treatment of, Coronary Artery Disease Traditional and Novel Factors Used to Assess	Patients With Coronary Artery Disease Inflammatory Response to Mental Stress and Mental Stress Induced	Nothing to Disclose
Canadoara		the Risk of, and Used for the Treatment of, Coronary Artery Disease	Myocardial Ischemia	
Sandesara	Pratik	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	A Severe Case of Statin-Associated Autoimmune Myopathy	Nothing to Disclose
Sandesara	Pratik	Updates on Risk Factors for Cardiovascular Disease	Central Obesity Predicts Circulating Progenitor Cell Levels	Nothing to Disclose
Sandesara	Pratik	Updates on Risk Factors for Cardiovascular Disease	Changes in Body Fat Distribution Is Associated With Oxidative Stress	Nothing to Disclose
Sandesara	Pratik	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Progenitor Cells and Clinical Outcomes in Patients With Heart Failure	Nothing to Disclose
Sandesara	Pratik	Unusual Presentations of ACS	Circulating Progenitor Cells Levels and Outcomes in Acute Myocardial Infarction	Nothing to Disclose
Sandfort	Veit	Non Invasive Imaging: Applications in Novel	Aortic Vascular Inflammation by 18-FDG PET/CT Associates With	Nothing to Disclose
Sandfort	Veit	Disease States and Clinical Scenarios Non Invasive Imaging: Coronary Calcium	High-Risk Coronary Plaques in Young Psoriasis Patients Coronary Artery Calcium Scores for Atherosclerotic Cardiovascular	Nothing to Disclose
Sandhu	Amneet	Scoring and CV Risk Assessment Atrial Fibrillation and VT: Unique Populations and Solutions	Disease Risk Stratification in Smokers: MESA Presence of Mid-Myocardial Substrate Is Associated With Need for Multiple Ablations in Patients With Non-Ischemic Cardiomyopathy	Nothing to Disclose
0			and Ventricular Arrhythmias	Nullius to Birelius
Sandhu	Gurpreet	Interventional Cardiology: TAVR 2	Prognostic Value of Baseline N-Terminal Prohormone Type Natriuretic Peptide Measurement in Chronic Lung Disease Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Sandhu	Gurpreet	Pulmonary Hypertension	Integrated Use of Perfusion SPECT/CTA Fusion Imaging and Pulmonary Balloon Angioplasty for Chronic Pulmonary Thromboembolism	Nothing to Disclose
Sandhu	Roopinder	Percutaneous Coronary Intervention: Lessons From the Real World	Nine Year Trends in Cause-Specific Mortality After Percutaneous Coronary Intervention: Observations From the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Registry	Nothing to Disclose
Sandhu	Uday	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Non ST-Segment Elevation Myocardial Infarction Secondary to Paradoxical Embolism via a Patent Foramen Ovale	Nothing to Disclose
Sandoval	Julio	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Derivation and Validation of a Simple Inflammation Based Risk Score for Predicting In-Hospital Mortality in Acute Coronary Syndrome	CONSULTANT FEES/HONORARIA - Bayer; SPEAKER'S BUREAU - Bayer
Sandri	Marcus	Novel Developments in Acute Coronary Syndromes	Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: The Randomized SHOCK-COOL Pilot Trial	Nothing to Disclose
Sandvall	Breck	Vascular Access and Hemostasis Issues	Access Site and Bleeding Outcomes With Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Pulmonary Embolism: Internal Jugular Versus Common Femoral Vein	Nothing to Disclose
Sang	Charlie	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Double Chambered Right Ventricle Causing RVOT Obstruction in Adulthood: It Is Not Pulmonary Hypertension!	Nothing to Disclose
Sang Hoon	Kim	Novel Developments in Acute Coronary Syndromes	Serial Measurements of Neutrophil Gelatinase-Associated Lipocalin (NGAL): Prognostic Value in Stemi Patients Treated by Primary Percutaneous Coronary Intervention	Nothing to Disclose
Sangaralingham	Jeson	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Intrarenal Renin Angiotensin System Activation: Pathophysiologic and Therapeutic Implications in Acute Decompensated Heart Failure	Nothing to Disclose
Sangaralingham	Lindsey	Young Investigator Awards Competition: Outcomes Research	A Comparison of Kidney Function Decline in Atrial Fibrillation Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin	Nothing to Disclose
Sangha	Rajbir	Arrhythmias and Clinical EP: AF Ablation	Dofetilide Associated QT Prolongation: Actual Versus Ideal Body Weight to Calculate Dosing	CONSULTANT FEES/HONORARIA - MEDTRONIC,St Jude Medical
Sangodkar	Sandeep	FIT Clinical Decision Making: Non-Invasive	Seeing Is Believing: Utilizing Multiple Imaging Modalities in Difficult to Characterize Left Ventricle Outflow Obstruction	Nothing to Disclose
Sanguankeo	Anawin	Atrial Fibrillation and VT: Unique Populations and Solutions	Association Between Atrial Fibrillation and Sudden Cardiac Death: A Systematic Review and Meta-Analysis	Nothing to Disclose
Sanidas	Elias	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Carotid Plaque Inflammation in Patients With Diabetes Mellitus and Coronary Artery Disease	Nothing to Disclose
Sanin	Veronika	Biomarkers and Targets for Ischemic Heart Disease	Increased Concentrations of Soluble ST2 Independently Predict Cardiac and Total Mortality but Not Non-Fatal Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow- lung the ARD (A Study	Nothing to Disclose
Sanjay	Sharma		Up of the KAROLA Study Myocardial Fibrosis & Ventricular Arrhythmias in Athletes	Nothing to Disclose
Sankaramangalam	Kesavan	Pulmonary Hypertension Interventional Cardiology: TAVR 2	Impact of Active Coronary Artery Disease on the Early and 1 Year Mortality of Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis	Nothing to Disclose
Sankaramangalam	Kesavan	Interventional Cardiology: TAVR 3	Comparison of Acute Elastic Recoil Between CoreValve and	Nothing to Disclose
Sankhla	Vineet	Interventional Complexity and Complications	SAPIEN 3 Valves in Transcatheter Aortic Valve Replacement Evaluation of a New Radiation Protection Technology (Cardio- TRAP®) in Transradial Percutaneous Coronary Intervention	Nothing to Disclose
Sano	Koichi	Non Invasive Imaging: New Technologies	Procedures Improved Diagnosis of Detection of Late Enhancement in Left Ventricular Myocardium Using 2nd Generation 320-Slice CT	Nothing to Disclose
Santana	Orlando	Emerging Developments in HFpEF and Arryhthmias	Reconstructed With FIRST in Non-Ischemic Cardiomyopathy Prevalence of Transthyretin Cardiac Amyloidosis in Patients With Heart Failure and Preserved Ejection Fraction Using the	Nothing to Disclose
Santangeli	Pasquale	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	sup>99mTc-Pyrophosphate Scintigraphy Anticoagulation Use and Incidence of Cerebrovascular Events and Major Bleeding After Catheter Ablation in Patients With Persistent and Longstanding Persistent Atrial Fibrillation	Nothing to Disclose
Santanna	Roberto	ACC International Conferences Best Posters	Comparison of Different Lung Ultrasound Methodologies for Pulmonary Congestion Evaluation in Heart Failure Outpatients	Nothing to Disclose
	Lyn	Interventional Cardiology: PCI in Complex	Procedural Calcium Fracture and Its Effect on Stent Expansion	Nothing to Disclose

Last Name	First Name	Session Title	Presentation Title	Disclosures
Santos	Raul	Emerging Issues in CV Disease Management: International Perspectives From the Brazilian Society of Cardiology, Turkish Society of Cardiology, and American College of Cardiology	Familial Hypercholesterolemia: Challenges in Developing Countries	CONSULTANT FEES/HONORARIA - Amgen,Biolab,Boehringer ingelheim Pharmaceuticals, Inc,Eli- Lilly,Genzyme,Kowa,Pfizer,Sanofi/Regeneron; SPEAKER'S BUREAU - Merck,Praxis Laboratories
Santos	Raul	Advances in Cholesterol Measurement and	Statin Eligibility in Primary Prevention: From a Risk-Based Strategy	CONSULTANT FEES/HONORARIA - Amgen,Biolab,Boehringer
		Management	to a Personalized Approach Based on the Predicted Cardiovascular Benefit	Ingelheim Pharmaceuticals, Inc,Eli- Lilly,Genzyme,Kowa,Pfizer,Sanofi/Regeneron; SPEAKER'S BUREAU - Merck,Praxis Laboratories
Santos	Raul	Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	Physical Activity Level Changes and the Occurrence of Non- Alcoholic Fatty-Liver Disease: A Prospective Longitudinal Follow Up Study	CONSULTANT FEES/HONORARIA - Amgen,Biolab,Boehringer Ingelheim Pharmaceuticals, Inc,Eil- Lilly, Genzyme, Kowa, Přízer, Sanofi/Regeneron; SPEAKER'S BUREAU - Merck,Praxis Laboratories
Santos	Raul	Contemporary Issues in Familial Hypercholesterolemia	Achilles Tendon Xanthomas Are Independently Associated With Severity of Subclinical Coronary Atherosclerosis in Familial Hypercholesterolemia	CONSULTANT FEES/HONORARIA - Amgen,Biolab,Boehringer Ingelheim Pharmaceuticals, Inc,Eli- Lilly, Genzyme, Kowa, Pfizer, Sanofi/Regeneron; SPEAKER'S BUREAU - Merck,Praxis Laboratories
Santos	Simone	Advances in Lipid Management	Impact of Statin Therapy on Collagen Turnover and Left Ventricle Function After ST-Elevation Myocardial Infarction: A Randomized Clinical Trial	Nothing to Disclose
Santos-Gallego	Carlos	Non Invasive Imaging: MR Characterization and Function	Myocardial Oxygenation Using Blood Level-Oxygen Dependent Sequence in Magnetic Resonance Determines Myocardial Energetics and Capillary Density	Nothing to Disclose
Santos-Gallego	Carlos	Non Invasive Imaging: MR Characterization	T1 Mapping Assesses Diagnosis, Severity and Prognosis in Acute	Nothing to Disclose
Santos-Gallego	Carlos	and Function Non Invasive Imaging: MR Heart Failure and	Myocarditis T1 Mapping in Patients With Heart Failure With Preserved Ejection	Nothing to Disclose
		Pulmonary Hypertension	Fraction Detects Increased Interstitial Myocardial Fibrosis and Assesses the Severity of Heart Failure	-
Santos-Gallego	Carlos	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Mild Rheumatic Valvular Heart Disease Is Associated With Interstitial Myocardial Fibrosis: A T1 Mapping Study	Nothing to Disclose
Santoso	Anwar	Emerging CV Problems in the Developing World: International Perspectives From the ACC Bangladesh Chapter, Indonesian Heart Association, and American College of Cardiology	Dyslipidemia and Hypertension and the Impact on CVD	Nothing to Disclose
Santoso Santoso	Anwar Teguh	32. Prevention: Clinical Team 5 Late-Breaking Clinical Trials: Interventional	Suggested Reviewer Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With Coronary Chronic Total Occlusion: DECISION CTO Randomized	Nothing to Disclose Nothing to Disclose
Sanz	Javier	29. Non Invasive Imaging: MR Team 2	Trial Suggested Reviewer	Nothing to Disclose
Sanz Salvo	Angel	Non Invasive Imaging: MR Characterization and Function	Myocardial Oxygenation Using Blood Level-Oxygen Dependent Sequence in Magnetic Resonance Determines Myocardial Energetics and Capillary Density	Nothing to Disclose
Sanz Salvo	Angel	Non Invasive Imaging: MR Characterization and Function	T1 Mapping Assesses Diagnosis, Severity and Prognosis in Acute Myocarditis	Nothing to Disclose
Sanz Salvo	Angel	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	T1 Mapping in Patients With Heart Failure With Preserved Ejection Fraction Detects Increased Interstitial Myocardial Fibrosis and Assesses the Severity of Heart Failure	Nothing to Disclose
Sanz Salvo	Angel	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Fractional Flow Reserve Is a Sensitive but Not a Specific Detector of a High Risk Plaques	Nothing to Disclose
Sanz Salvo	Angel	Non Invasive Imaging: MR Structure and	Mild Rheumatic Valvular Heart Disease Is Associated With Interstitial	Nothing to Disclose
Sanz Salvo	Angel	Valuvular Heart Disease Noninvasive Assessment of Coronary Flow	Myocardial Fibrosis: A T1 Mapping Study Can Necrotic Core Volume Explain Ischemia Coronary Stenosis	Nothing to Disclose
Sapontis	James	Reserve: Clinical Implications Advances in Chronic Total Occlusion Intervention	Mismatch in Some Cases? Association of Stress Test Risk Classification With Health Status Change After Chronic Total Occlusion PCI: Insights From the OPEN- CTO Registry	Nothing to Disclose
Sapontis	James	Advances in Chronic Total Occlusion Intervention	In The Registry Impact of Sex on Physical Limitation 8#38; Patient Health Status After Chronic Total Occlusion Percutaneous Coronary Intervention: Propensity Matched Substudy of OPEN-CTO Registry	Nothing to Disclose
Sapontis	James	Advances in Chronic Total Occlusion Intervention	Health Status Benefits of Successful Chronic Total Occlusion PCI in Patients With Depressed Left Ventricular Systolic Function: Insights From the OPEN-CTO Registry	Nothing to Disclose
Sapontis	James	Refining PCI Technique and Outcomes	Appropriate Use Criteria and Health Status Outcomes After CTO	Nothing to Disclose
Sara	Jaskanwal	Interventional Cardiology: Intravascular Physiology and Endothelial Function	PCI: Results From the OPEN CTO Registry Association of Coronary Epicardial Endothelial Dysfunction With Low Endothelial Shear Stress in Patients With Mild Coronary	Nothing to Disclose
Saraf	Anita	Redefining the "F" Word	Atherosclerosis Who Presented With Chest Pain Biomarker Profile in Adults With Fontan Circulation	Nothing to Disclose
Saraf	Anita	Congenital Heart Disease: To the Third Decade and Beyond	Red Blood Cell Distribution Width and Outcomes in Fontan Patients	Nothing to Disclose
Saraf	Anita	Congenital Heart Disease: To the Third Decade and Beyond	Prevalence and Incidence of Heart Failure in Adolescents and Adults With Repaired Tetralogy of Fallot	Nothing to Disclose
Sarano	Maurice	Making Progress in Understanding Heart Failure	Left Atrial Enlargement in Patients With Ventricular Dysfunction: Innocent Bystander or Meaningful Determinant of Survival?	RESEARCH/RESEARCH GRANTS - Edwards LLC
Sarano	Maurice	Making Progress in Understanding Heart Failure	Is Frailty a Mirror of Underlying Hemodynamic Alteration in Patients With Left Ventricular Dysfunction?	RESEARCH/RESEARCH GRANTS - Edwards LLC
Sarano	Maurice	New Technologies in Echocardiography	Mitral Annular Disjunction Prevalence and Physiologic Consequences in Degenerative Mitral Regurgitation: A Dynamic 3- Dimensional Echocardiographic Study	RESEARCH/RESEARCH GRANTS - Edwards LLC
Sarano	Maurice	Emerging Developments in HFpEF and Arryhthmias	Artial Fibrillation Link to Excess Mortality in Patients With Left Ventricular Dysfunction: Linked to Rapid Ventricular Response or Independent Prognostic Marker?	RESEARCH/RESEARCH GRANTS - Edwards LLC
Sarano	Maurice	Technical Advances in Transthoracic Echocardiography	E/e' Short- and Long-Term Independent Prognostic Role in Patients With Left Ventricular Dysfunction	RESEARCH/RESEARCH GRANTS - Edwards LLC
Saravolatz	Louis	From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease	Cardioplegic Arrest Is Associated With Overexpression of Opioid Receptors Delta and Kappa in Diabetic and Non-Diabetic Patients	Nothing to Disclose
Sarcon	Annahita	Risky Business: Predicting Outcomes in Heart Failure	Undergoing On-Pump Cardiac Surgery A Novel Clinical Score (InterTAK Score) to Distinguish Takotsubo	Nothing to Disclose
Sardana	Mayank	Fallure FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Syndrome From Acute Coronary Syndrome Coronary Cameral Fistulas and Coronary Artery Aneurysms in a Patient With Acute Heart Failure: A Hybrid Case	Nothing to Disclose
Sardana	Mayank	Innovative Use of Echocardiography	Effect of Left Atrial Remodeling on Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study	Nothing to Disclose
Sardana	Mayank	Innovative Use of Echocardiography	Left Atrial Function Index as a Predictor of Cardiovascular Disease and Atrial Fibrillation: Data From the Framingham Offspring Study	Nothing to Disclose
Sardana	Mayank	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Depression and Atrial Fibrillation: A Case-Report of Intentional Flecainide Overdose	Nothing to Disclose
Sardana	Mayank	FIT Clinical Decision Making Reviewers 2	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Sardar	Partha	Valvular Disease Populations at Risk	National and Regional Trends in Surgical Aortic Valve Replacement in the TAVR Era	Nothing to Disclose

				<u> </u>
Last Name	First Name	Session Title	Presentation Title	Disclosures
Sardar	Partha	Coronary Intervention: Drug Eluting Stent and Scaffolds	Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold Versus Second Generation Des in Coronary Artery Disease: A Meta- Analysis	Nothing to Disclose
Sardella	Gennaro	Featured Clinical Research II: Interventional	Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD Matrix Study	Nothing to Disclose
Sardella	Gennaro	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve	Nothing to Disclose
Sardella	Gennaro	Interventional Cardiology: PCI and TAVR in Complex Patients	Replacement: From the WIN-TAVI Registry Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the	Nothing to Disclose
Sardella	Gennaro	21. Interventional Cardiology: Coronary	Bravo-3 Randomized Trial Suggested Reviewer	Nothing to Disclose
Sareen	Nishtha	Intervention: Devices Team 2 FIT Clinical Decision Making: Interventional	External Femoral-Femoral Bypass for Acute Limb Ischemia	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine		-
Sargeant	Jarred	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Comparison of Two-Year Outcomes in Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Treatment of Unprotected Left Main Coronary Artery Disease in Elderly Patients: A Meta-Analysis	Nothing to Disclose
Saric	Muhamed	The Spectrum of Aortic Regurgitation and Aortic Pathology	Case: Acute Severe AR	OTHER - Siemens; SPEAKER'S BUREAU - MEDTRONIC,Philips
Saric	Muhamed	Structural Heart Interventions: What Does the Imager Need to know	Imaging in Mitral Valve Interventions: E-clip and Beyond	OTHER - Siemens; SPEAKER'S BUREAU - MEDTRONIC,Philips
Saric	Muhamed	Novel Echocardiographic Methods for Assessing Cardiac Function	Use of Diastolic Parameters on Transthoracic Echocardiogram to Predict Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation	OTHER - Siemens; SPEAKER'S BUREAU - MEDTRONIC,Philips
Saric	Muhamed	Interventional Cardiology: TAVR 2	Short- and Mid-Term Outcomes After Transcatheter Aortic Valve Replacement in Patients With Renal Insufficiency Not on Hemodialysis	OTHER - Siemens; SPEAKER'S BUREAU - MEDTRONIC,Philips
Saric	Muhamed	36. Valvular Heart Disease: Clinical Team 2	Suggested Reviewer	OTHER - Siemens; SPEAKER'S BUREAU - MEDTRONIC, Philips
Sarma Sarma	Amy Satyam	FIT Clinical Decision Making Reviewers 5 Making Progress in Understanding Heart	ACC FIT Clinical Decision Making Reviewer High Risk, Stage B Heart Failure: A Distinct Hemodynamic Profile	Nothing to Disclose Nothing to Disclose
Sarma	Satyam	Failure FIT Clinical Decision Making: Arrhythmias and	Stiff Left Atrial Syndrome Following Multiple Ablations Diagnosed	Nothing to Disclose
Sarma	Satyam	Electrophysiology Physical Activity and Prevention of	With Invasive Hemodynamic Exercise Testing The Impact of Lifelong Exercise Training "Dose" on the Ventricular-	Nothing to Disclose
		Cardiometabolic Disease: Exercise Is Medicine	Arterial Coupling	·
Sarnoski	Christopher	Interventional Cardiology: TAVR 4	Outcomes of Trans-Catheter Aortic Valve Replacement in Nonagenarians	Nothing to Disclose
Sarswat	Nitasha Samantha	Innovative Use of Echocardiography	Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography Clinical Outcomes Associated With Impella Versus IABP Use in	Nothing to Disclose Nothing to Disclose
Sartori		Coronary Intervention in Interventional Cardiology: Advanced Device Use	Stable Patients Undergoing High Risk Percutaneous Coronary Intervention	_
Sartori	Samantha	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Impella or Intra-Aortic Balloon Pump Support in Patients Undergoing High Risk Percutaneous Coronary Intervention: A Real World Single Center Experience	Nothing to Disclose
Sartori	Samantha	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	Nothing to Disclose
Sartori	Samantha	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study	Nothing to Disclose
Sartori	Samantha	Novel Developments in Acute Coronary Syndromes	Trends in Incidence and Mortality Associated With Acute Kidney Injury in Patients Undergoing PCI for Acute Coronary Syndrome	Nothing to Disclose
Sartori	Samantha	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: From the WIN-TAVI Registry	Nothing to Disclose
Sartori	Samantha	Timely Topics in Acute Coronary Syndromes	Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions	Nothing to Disclose
Sartori	Samantha	Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes	Nothing to Disclose
Sartori	Samantha	Non Invasive Imaging: Prognostic Implications of CT Angiography	The Relationship Between Pericardial Adipose Tissue Volume, Atherosclerotic Plaque Type and Cardiovascular Risk: A High Risk Plaque Biolmage Sub-Study	Nothing to Disclose
Sartori	Samantha	Optimizing the Care of ACS Patients	Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population	Nothing to Disclose
Sartori	Samantha	Interventional Complexity and Complications	Prediction of Acute Kidney Injury in Patients Undergoing Coronary Intervention Using Calculation of Serum Osmolality	Nothing to Disclose
Sartori	Samantha	Interventional Cardiology: PCI in Complex Patients	Risk and Impact of Diabetes Mellitus on Ischemic Events in Females and Males After Percutaneous Coronary Intervention	Nothing to Disclose
Sartori	Samantha	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Countering the Anti-Platelet Effects of Ticagrelor With Platelet Concentrates Within 48 Hours of a Loading Dose: Ex Vivo Testing of Time-Effect on Functional Recovery in Patients With Cardiovascular	Nothing to Disclose
Sas	Rozsa	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Disease The Presence of Fragmented QRS Complexes Early After Acute Myocardial Infarction Is Associated With Subsequent Lack of Favorable Left Ventricular Remodeling	Nothing to Disclose
Sasiela	William	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Favorable Lett Ventricular Remodeling impact of Statin Intolerance Rates on Need for Ezetimibe and/or PCSK9 Inhibitors for Meeting Low-Density Lipoprotein Goals in a Real-World Cohort With Atherosclerotic Cardiovascular Disease	OTHER - Regeneron Pharmaceuticals
Sasikumar	Navaneetha	Innovations in Pediatric Catheterization and EP: Mending, Fixing and Predicting	Ductal Origin of an Isolated Pulmonary Artery: Initial Stenting Followed by Unifocalization	Nothing to Disclose
Sathiyakumar	Vasanth	Advances in Cholesterol Measurement and Management	Comparison of the Novel Method Versus the Friedewald Equation in Estimating Low-Density Lipoprotein-Cholesterol Based on Fasting Status	Nothing to Disclose
Satler	Lowell	Considerations in Antiplatelet Therapy and in ACS	Status Trends in Discharge and Outcome of Dual Antiplatelet Therapy Post Percutaneous Intervention in High Bleeding Risk Population	CONSULTANT FEES/HONORARIA - Abbott; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals.BSCI.Medicines Co
Satler	Lowell	Considerations in Antiplatelet Therapy and in ACS	Outpatient Trends in Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Primary Percutaneous Coronary	CONSULTANT FEES/HONORARIA - Abbott; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals,BSCI,Medicines Co
Satler	Lowell	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Intervention In-Stent Restenosis of Drug-Eluting Stents: Incidence, Lesion Characteristics and Outcomes in Contemporary Practice Over the	CONSULTANT FEES/HONORARIA - Abbott; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals,BSCI,Medicines Co
Satler	Lowell	Interventional Cardiology: TAVR 2	Last Decade - How Are They Different From De Novo Lesions? Racial Disparities and Temporal Trends in Demographics and Clinical Characteristics of Patients Screened for Transcatheter	CONSULTANT FEES/HONORARIA - Abbott, SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals, BSCI, Medicines Co
Satler	Lowell		Aortic Valve Replacement Is There a Role for Invasive Electrophysiology Studies in Patients	CONSULTANT FEES/HONORARIA - Abbott; SPEAKER'S
		and Surgical Issues	With Conduction Abnormalities Following Transcatheter Aortic Valve Replacement?	BUREAU - AstraZeneca Pharmaceuticals,BSCI,Medicines Co



The same of the sa				
Last Name Satler	First Name Lowell	Session Title Interventional Cardiology: TAVR 3	Presentation Title Antithrombotic Therapy Differences and Associated Outcomes in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic	Disclosures CONSULTANT FEES/HONORARIA - Abbott; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals,BSCI,Medicines Co
Satler	Lowell	Interventional Cardiology: TAVR 3	Valve Replacement Acute Aortic Regurgitation Post-Transcatheter Aortic Valve	CONSULTANT FEES/HONORARIA - Abbott; SPEAKER'S
Satler	Lowell	Interventional Cardiology: PCI in Complex	Replacement: Impact of Various Treatment Strategies Long-Term Mortality in Percutaneous Coronary Intervention of	BUREAU - AstraZeneca Pharmaceuticals,BSCI,Medicines Co CONSULTANT FEES/HONORARIA - Abbott; SPEAKER'S
Sato	Katsumasa	Patients Advances in Chronic Total Occlusion Intervention	Saphenous Vein Grafts From Real-World Registry Data Impact of Target Vessel on Long-Term Cardiac Mortality After Successful Percutaneous Coronary Intervention for Chronic Total	BUREAU - AstraZeneca Pharmaceuticals,BSCI,Medicines Co Nothing to Disclose
Sato	Katsumasa	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Occlusion: Japanese Multicenter Registry Significance of ¹²³ 1-BMIPP-Scintigraphy in the Recovery of Left Ventricular Systolic Dysfunction in Takotsubo Cardiomyopathy: Insight From the NEW TAKOTSUBO BMIPP Registry	Nothing to Disclose
Sato	Kengo	Cutting Edge Vascular Medicine	Atheroprotective Effects of Tumor Necrosis Factor-Stimulated Gene-	Nothing to Disclose
Sato	Kimi	Interventional Cardiology: TAVR 1	Novel Plane of Measurement to Evaluate Accurate Valve Size in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Sato Sato	Kimi Kimi	Valvular Heart Disease: Mitral Valve Disease Insights From Echocardiography Use	Warfarin Use and Progression of Mitral Annular Calcification Aortic Regurgitation Negatively Affects Left Ventricular Mechanics	Nothing to Disclose Nothing to Disclose
Sato	Kimi	TAVR Outcomes Prognostication	After Transcatheter Aortic Valve Replacement Cardiac Plasticity Predicts Outcome After Transcatheter Aortic	Nothing to Disclose
Sato	Tetsuya	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Valve Replacement in Patients With Severe Aortic Stenosis Differences in Chronic Angioscopic Findings With Different Stent Types in Patients With and Without Diabetes Mellitus: Sub-Analysis	Nothing to Disclose
Sattar	Naveed	Advances in Cholesterol Measurement and Management	of a Report From Japanese Multicenter Registry Impact of Evolocumab Therapy in Patients With Discordance Between LDL-C and LDL-P	CONSULTANT FEES/HONORARIA - Amgen Inc.,AstraZeneca,Sanofi-Aventis
Sattar	Naveed	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Current Smoking, Microvascular Pathology and Adverse Outcome After Acute ST-Segment Elevation Myocardial Infarction: New	CONSULTANT FEES/HONORARIA - Amgen Inc.,AstraZeneca,Sanofi-Aventis
Satya	Kumar	Syndrome FIT Clinical Decision Making: Non-Invasive	Pathophysiological Insights Unloading the Left Ventricle: A Case of Mechanical Circulatory	Nothing to Disclose
Satzer	Michael	Imaging and Valvular Heart Disease Innovations in Education	Support in Acute Aortic Insufficiency Fellow Outpatient Clinic: Discontinuing the Discontinuity	Nothing to Disclose
Saucedo	Jorge	03. Acute and Stable Ischemic Heart Disease: Therapy Team 2	Suggested Reviewer Presence of Mid Myccardial Substrate is Associated With Need for	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Vascular Solutions CONSULTANT EEES/HONOBARIA Biospass Webster Rostor
Sauer	William	Atrial Fibrillation and VT: Unique Populations and Solutions	Presence of Mid-Myocardial Substrate Is Associated With Need for Multiple Ablations in Patients With Non-Ischemic Cardiomyopathy and Ventricular Arrhythmias	CONSULTANT FEES/HONORARIA - Biosense Webster, Boston Scientific, MEDTRONIC, St Jude Medical
Sauer	William	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Early Recurrence of Ventricular Tachycardia Predicts Increased Mortality Among Patients With Severe Heart Failure	CONSULTANT FEES/HONORARIA - Biosense Webster,Boston Scientific,MEDTRONIC,St Jude Medical
Sauer	William	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Safety and Outcomes of Catheter Ablation for Treatment of Refractory Ventricular Arrhythmias in Patients With Advanced Heart	CONSULTANT FEES/HONORARIA - Biosense Webster,Boston Scientific,MEDTRONIC,St Jude Medical
Saurav	Alok	Arrhythmias and Clinical EP: Devices 2	Failure Role of Implantable Defibrillators in Primary Prevention of Mortality in Non-Ischemic Cardiomyopathy Patients	Nothing to Disclose
Savage	Michael	Trends in Coronary Syndromes: International Perspectives From the ACC Great Britain and Ireland Chapter, Israel Heart Society, and American College of Cardiology	Antiplatelet Options for the ACS Patient: Which Drug and for How Long?	Nothing to Disclose
Savage	Michael	The Best Structural Interventional Challenging Cases	To Close or Not to Close: Percutaneous Treatment of Acquired Gerbode Defect	Nothing to Disclose
Savage	Michael	Interventional Cardiology: TAVR 1	Hands Down: Operator Hand Versus Torso Radiation Exposure During Transcatheter Aortic Valve Replacement	Nothing to Disclose
Savage	Michael	Interventional Cardiology: TAVR 1	Provider Radiation Exposure During Transcatheter Aortic Valve Replacement	Nothing to Disclose
Savani	Chirag	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Predictors of 90-Day Readmission and In Hospital Mortality Amongst Patients Undergoing Percutaneous Coronary Interventions: Insights From a National Database	Nothing to Disclose
Savani	Chirag	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Impact of Cardiac Devices on Readmission and Short Term Mortality in Patients With Heart Failure With Reduced Ejection Fraction: A Nationwide Study	Nothing to Disclose
Savani	Chirag	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	CHADS ₂ and CHA ₂ DS ₂ VASc Scores as Predictors of Length of Stay and Cost of Care in Hospitalised Atrial Fibrillation	Nothing to Disclose
Savani	Ghanshyambhai	Updates on Risk Factors for Cardiovascular Disease	Patients: Insights From a National Database Hospital Admissions for Chest Pain Associated With Cocaine use in the United States	Nothing to Disclose
Savani	Ghanshyambhai	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Mortality Rates and Cost of Hospital Admissions for Syncope in the United States	Nothing to Disclose
Savard	Winnie	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Impact of Maternal Diabetes on First & Early Second Trimester Fetal Cardiovascular Health	Nothing to Disclose
Savarese	Gianluigi	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Mortality and Morbidity in Patients With Heart Failure and Reduced Ejection Fraction Exposed to Digoxin: Comprehensive Data According to Atrial Fibrillation in 23,708 Patients From the Swedish Heart Failure Registry	Nothing to Disclose
Savarese	Gianluigi	Why Can't We Be Friends? Controversies in Heart Failure Management	Association Between Serum Potassium Level and Outcomes in Heart Failure With Reduced Ejection Fraction: A Cohort Study From the Swedish Heart Failure Registry	Nothing to Disclose
Saw	Jacqueline	Understanding Spontaneous Coronary Artery Dissection (SCAD): What We Know, What We Don't Know	Overview of SCAD: Demographics and Prevalence	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific Corporation, St Jude Medical; OTHER - Boston Scientific, St Jude Medical; RESEARCHRESEARCH GRANTS - Abbott Vascular, AstraZeneca, Boston Scientific Corporation, servier, St Jude Medical; SPEAKER'S BUREAU - AstraZeneca, Bayer Healthcare Pharmaceuticals, Sunovion
Saw	Jacqueline	Imaging for Left Atrial Appendage and Paravalvular Leak Closure: A Case Based Approach	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific Corporation, St Jude Medical; OTHER - Boston Scientific, St Jude Medical; FESEARCH - Boston Scientific, St Jude Medical; FESEARCH GRANTS - Abbott Vascular, AstraZeneca, Boston Scientific Corporation, servier, St Jude Medical; SPEAKER'S BUREAU - AstraZeneca, Bayer Healthcare Pharmaceuticals, Sunovion
Saw	Jacqueline	imaging for Left Atrial Appendage and Paravalvular Leak Closure: A Case Based Approach	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific Corporation, St Jude Medical; OTHER - Boston Scientific, St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular, AstraZeneca, Boston Scientific Corporation, servier, St Jude Medical; SPEAKER'S BUREAU - AstraZeneca, Bayer Healthcare Pharmaceuticals, Sunovion
Saw	Jacqueline	Imaging for Left Atrial Appendage and Paravalvular Leak Closure: A Case Based Approach	LAA Imaging- CT/MRI Imaging: Getting Down to Basics	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific Corporation, St Jude Medical; OTHER - Boston Scientific, St Jude Medical; RESEARCH GRANTS - Abbott Vascular, AstraZeneca, Boston Scientific Corporation, servier, St Jude Medical; SPEAKER'S BUREAU - AstraZeneca, Bayer Healthcare Pharmaceuticals, Sunovion

Last Name				l l
Saw	First Name Jacqueline	Session Title Imaging for Left Atrial Appendage and	Presentation Title Post Procedure Imaging: Understanding the Post Implant Evaluation	Disclosures CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston
Jaw	Jacqueille	Paravalvular Leak Closure: A Case Based	and its Impact on Anticoagulation Strategy	Scientific Corporation, St Jude Medical; OTHER - Boston
		Approach		Scientific,St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Vascular.AstraZeneca.Boston Scientific
				Corporation, servier, St Jude Medical; SPEAKER'S BUREAU -
Cour	langualina	Fundamentals of LAA Closure	Panelist	AstraZeneca,Bayer Healthcare Pharmaceuticals,Sunovion CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston
Saw	Jacqueline	Fundamentals of LAA Closure	Panelist	Scientific Corporation, St Jude Medical; OTHER - Boston
				Scientific,St Jude Medical; RESEARCH/RESEARCH GRANTS -
				Abbott Vascular, AstraZeneca, Boston Scientific Corporation, servier, St Jude Medical; SPEAKER'S BUREAU -
				AstraZeneca,Bayer Healthcare Pharmaceuticals,Sunovion
Saw	Jacqueline	Fundamentals of LAA Closure	Synthesizing Imaging (Echo, CT, and Fluoroscopy) to Define Anatomic Suitability for LAA Closure	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific Corporation, St Jude Medical; OTHER - Boston
				Scientific,St Jude Medical; RESEARCH/RESEARCH GRANTS -
1				Abbott Vascular, AstraZeneca, Boston Scientific Corporation, servier, St Jude Medical; SPEAKER'S BUREAU -
				AstraZeneca,Bayer Healthcare Pharmaceuticals,Sunovion
Saw	Jacqueline	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Angiographic Healing of Spontaneous Coronary Artery Dissection	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific Corporation, St Jude Medical; OTHER - Boston
				Scientific,St Jude Medical; RESEARCH/RESEARCH GRANTS -
				Abbott Vascular, AstraZeneca, Boston Scientific Corporation, servier, St Jude Medical; SPEAKER'S BUREAU -
				AstraZeneca,Bayer Healthcare Pharmaceuticals,Sunovion
Saw	Jacqueline	Unusual Presentations of ACS	Clinical Predictors of Recurrent Dissection After Spontaneous Coronary Artery Dissection	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific Corporation, St Jude Medical; OTHER - Boston
			Solonary rately Bassocion	Scientific,St Jude Medical; RESEARCH/RESEARCH GRANTS -
				Abbott Vascular, AstraZeneca, Boston Scientific Corporation, servier, St Jude Medical; SPEAKER'S BUREAU -
				AstraZeneca,Bayer Healthcare Pharmaceuticals,Sunovion
Sawada	Stephen	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Higher Beta-Blocker Dose Versus Lower Heart Rate in Patients With Heart Failure Due to Systolic Dysfunction	Nothing to Disclose
Sawada	Stephen	Advances in HCM, PPCM and Other Cardiomyopathies	Differential Effects of Amyloidosis on Right Ventricular Longitudinal and Circumferential Fiber Function	Nothing to Disclose
Sawano	Mitsuaki	Atrial Fibrillation and VT: Incorporating Novel	Compliance to Updated AHA/ACC Quality Measures Among	Nothing to Disclose
İ		Risks Toward Decision Making	Patients With Atrial Fibrillation in Japan and Its Association With Their Quality of Life	
Sawano	Mitsuaki	The Evolving World of LVADs, Transplant and	Performance of the MAGGIC Heart Failure Risk Score in Japanese	Nothing to Disclose
I		Other Novel Discoveries	Acute Heart Failure Patients: A Report From the West Tokyo Heart Failure Registry	
Sawano	Mitsuaki	Unusual Presentations of ACS	C-Reactive Protein in Non-ST Elevation Myocardial Infarction	Nothing to Disclose
			Patients Is Useful in Improving Discrimination of Conventional Risk Score: A Report From Multicenter PCI Registry	
Sawano	Mitsuaki	Unusual Presentations of ACS	Trend of Use in Transradial Intervention Among Elderly Patients in	Nothing to Disclose
Sawant	Abhishek	Interventional Cardiology: TAVR 4	Japan According to Their Pre-Procedural Bleeding Risk Predictors of Poor Quality of Life After Transcatheter Aortic Valve	Nothing to Disclose
Jawani	Abhishek		Replacement	Nothing to Disclose
Sawaya	Fadi	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking	Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY	Nothing to Disclose
		Clinical Trials	Registries	
Sawyer	Douglas	Heart Failure and Cancer Care	Debate: There is No Evidence for a Diet and Exercise Regimen to Mitigate Cardiomyopathy with Cancer Therapy	RESEARCH/RESEARCH GRANTS - Acorda Therapeutics, Inc.
Saxena	Shikhar	Innovative Use of Echocardiography	A Comparison of Two-Dimensional Echocardiography Parameters	SPEAKER'S BUREAU - Pfizer and Bristol Meyer
Ì			With Cardiac Magnetic Resonance Imaging in the Assessment of Right Ventricular Function Post Orthotopic Heart Transplantation	
Saxon	John	Interventional Cardiology: TAVR 3	Prosthetic Surgical Tissue Valve Enlargement Using a High-	Nothing to Disclose
I			Pressure Balloon (Fracturing the Ring) to Facilitate Transcatheter Valve-in-Valve Implantation	
Saxon	John	Advances in Chronic Total Occlusion	Association of Stress Test Risk Classification With Health Status	Nothing to Disclose
I		Intervention	Change After Chronic Total Occlusion PCI: Insights From the OPEN- CTO Registry	
Saxon	John	Refining PCI Technique and Outcomes	Appropriate Use Criteria and Health Status Outcomes After CTO	Nothing to Disclose
Saxonhouse	Sherry	Tough Clinical Problems in Patients with	PCI: Results From the OPEN CTO Registry Co-Chair	
	,			Nothing to Disclose
		Implantable Electronic Devices		Nothing to Disclose
Saxonhouse Saxonhouse	Sherry	Implantable Electronic Devices ECG Screening and Risk Prediction	ACC Poster Moderator Suggested Reviewer	Nothing to Disclose
Saxonhouse	Sherry	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1	Suggested Reviewer	Nothing to Disclose Nothing to Disclose
		Implantable Electronic Devices ECG Screening and Risk Prediction	Suggested Reviewer Differences Among African Americans and White Patients	Nothing to Disclose
Saxonhouse Sayad	Sherry Dany	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3	Suggested Reviewer Differences Among African Americans and White Patients Undergoing implantable Cardioverter Defibrillator Implantation for Primary Prevention	Nothing to Disclose Nothing to Disclose Nothing to Disclose
Saxonhouse Sayad	Sherry	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage	Nothing to Disclose Nothing to Disclose
Saxonhouse	Sherry Dany	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD	Nothing to Disclose Nothing to Disclose Nothing to Disclose
Sayad Sayer Sayer	Sherry Dany Gabriel Gabriel	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Sayad Sayer Sayer Sayer Sayer	Sherry Dany Gabriel Gabriel Sonny	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography Timely Topics in Acute Coronary Syndromes	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Sayad Sayer Sayer	Sherry Dany Gabriel Gabriel	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography	Suggested Reviewer Differences Among African Americans and White Patients Undergoing implantable Cardioverter Defibrillator implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Sayad Sayer Sayer Sayer Sayer	Sherry Dany Gabriel Gabriel Sonny	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography Timely Topics in Acute Coronary Syndromes Optimizing the Care of ACS Patients Antithrombotic Therapy in Ischemic Heart	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Venticular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population Effects of Low Molecular Weight Heparin Versus Dabigatran on	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Sayand Sayer Sayer Sayer Sayseng Sayseng	Sherry Dany Gabriel Gabriel Sonny Sonny	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography Timely Topics in Acute Coronary Syndromes Optimizing the Care of ACS Patients	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 30 Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Sayand Sayar Sayer Sayer Sayseng Sayseng Scanavini Filho Scantlebury	Sherry Dany Gabriel Gabriel Sonny Sonny Marco Dawn	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography Timely Topics in Acute Coronary Syndromes Optimizing the Care of ACS Patients Antithrombotic Therapy in Ischemic Heart Disease FIT Clinical Decision Making Reviewers 6	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals
Sayand Sayer Sayer Sayer Sayer Sayseng Sayseng Sayseng Scanavini Filho	Sherry Dany Gabriel Gabriel Sonny Sonny Marco	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography Timely Topics in Acute Coronary Syndromes Optimizing the Care of ACS Patients Antithrombotic Therapy in Ischemic Heart Disease	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hernodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Sayand Sayer Sayer Sayer Sayseng Sayseng Scanavini Filho Scantlebury Scarabelli	Sherry Dany Gabriel Gabriel Sonny Sonny Marco Dawn Tiziano	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography Timely Topics in Acute Coronary Syndromes Optimizing the Care of ACS Patients Antithrombotic Therapy in Ischemic Heart Disease FIT Clinical Decision Making Reviewers 6 From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease ACC FIT Clinical Decision Making Reviewer Cardioplegic Arrest is Associated With Overexpression of Opioid Receptors Delta and Kappa in Diabetic and Non-Diabetic Patients Undergoing On-Pump Cardios Surgery	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals Nothing to Disclose
Sayand Sayar Sayer Sayer Sayseng Sayseng Scanavini Filho Scantlebury	Sherry Dany Gabriel Gabriel Sonny Sonny Marco Dawn	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography Timely Topics in Acute Coronary Syndromes Optimizing the Care of ACS Patients Antithrombotic Therapy in Ischemic Heart Disease FIT Clinical Decision Making Reviewers 6 From Diet to Drugs: Mechanistic Insight Into	Suggested Reviewer Differences Among African Americans and White Patients Undergoing implantable Cardioverter Defibrillator implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease ACC FIT Clinical Decision Making Reviewer Cardioplegic Arrest is Associated With Overexpression of Opioid Receptors Delta and Kappa in Diabetic and Non-Diabetic Patients	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals
Sayand Sayer Sayer Sayer Sayseng Sayseng Scanavini Filho Scantlebury Scarabelli Scarparo	Sherry Dany Gabriel Gabriel Sonny Sonny Marco Dawn Tiziano	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography Timely Topics in Acute Coronary Syndromes Optimizing the Care of ACS Patients Antithrombotic Therapy in Ischemic Heart Disease FIT Clinical Decision Making Reviewers 6 From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Improving Outcomes in the Athlete With Cardiovascular Disease	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 30 Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggreation in Patients With Stable Coronary Artery Diseases ACC FIT Clinical Decision Making Reviewer Cardioplegic Arrest is Associated With Overexpression of Opioid Receptors Delta and Kappa in Diabetic and Non-Diabetic Patients Undergoing On-Pump Cardiac Surgery EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Sayand Sayer Sayer Sayer Sayseng Sayseng Scanavini Filho Scantlebury Scarabelli	Sherry Dany Gabriel Gabriel Sonny Sonny Marco Dawn Tiziano	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography Timely Topics in Acute Coronary Syndromes Optimizing the Care of ACS Patients Antithrombotic Therapy in Ischemic Heart Disease FIT Clinical Decision Making Reviewers 6 From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Improving Outcomes in the Athlete With Cardiovascular Disease Evolving Therapies in Heart Failure: Gazing	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions Underutilization of High Intensity Statin is a Contemporary High Risk PCI Population Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease ACC FIT Clinical Decision Making Reviewer Cardioplegic Arrest Is Associated With Overexpression of Opioid Receptors Delta and Kappa in Diabetic and Non-Diabetic Patients Undergoing On-Pump Cardiac Surgery EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals Nothing to Disclose CONSULTANT FEES/HONORARIA - AstraZeneca
Sayand Sayer Sayer Sayer Sayseng Sayseng Scanavini Filho Scantlebury Scarabelli Scarparo Schaer	Sherry Dany Gabriel Gabriel Sonny Sonny Marco Dawn Tiziano Paola Gary	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography Timely Topics in Acute Coronary Syndromes Optimizing the Care of ACS Patients Antithrombotic Therapy in Ischemic Heart Disease FIT Clinical Decision Making Reviewers 6 From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Improving Outcomes in the Athlete With Cardiovascular Disease Evolving Therapies in Heart Failure: Gazing Into the Crystal Ball	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions Underutilization of High Intensity Statin Sin a Contemporary High Risk PCI Population Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease ACC FIT Clinical Decision Making Reviewer Cardioplegic Arrest Is Associated With Overexpression of Opioid Receptors Delta and Kappa in Diabetic and Non-Diabetic Patients Undergoing On-Pump Cardiac Surgery EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students Co-Chair	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals Nothing to Disclose CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, The Medicines Company; OTHER - Juventas, Vericel
Saxonhouse Sayad Sayer Sayer Sayseng Sayseng Scanavini Filho Scantlebury Scarabelli Scarparo Schaer	Sherry Dany Gabriel Gabriel Sonny Sonny Marco Dawn Tiziano	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography Timely Topics in Acute Coronary Syndromes Optimizing the Care of ACS Patients Antithrombotic Therapy in Ischemic Heart Disease FIT Clinical Decision Making Reviewers 6 From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Improving Outcomes in the Athlete With Cardiovascular Disease Evolving Therapies in Heart Failure: Gazing Into the Crystal Ball Palliative Care for the 99% II: Skillbuilding: PC	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 30 Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggreation in Patients With Stable Coronary Artery Diseases ACC FIT Clinical Decision Making Reviewer Cardioplegic Arrest is Associated With Overexpression of Opioid Receptors Delta and Kappa in Diabetic and Non-Diabetic Patients Undergoing On-Pump Cardiac Surgery EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals Nothing to Disclose CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, The Medicines Company; OTHER -
Saxonhouse Sayad Sayer Sayer Sayer Sayseng Sayseng Scanavini Filho Scantlebury Scarabelli Scarparo Schaer	Sherry Dany Gabriel Gabriel Sonny Sonny Marco Dawn Tiziano Paola Gary	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography Timely Topics in Acute Coronary Syndromes Optimizing the Care of ACS Patients Antithrombotic Therapy in Ischemic Heart Disease FIT Clinical Decision Making Reviewers 6 From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Improving Outcomes in the Athlete With Cardiovascular Disease Evolving Therapies in Heart Failure: Gazing Into the Crystal Ball Palliative Care for the 99% II: Skillbuilding: PC Encounters: What Would you do? Part I Palliative Care for the 99% III: Skillbuilding: PC Encounters: What Would you do? Part I	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions Underutilization of High Intensity Statin Sin a Contemporary High Risk PCI Population Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease ACC FIT Clinical Decision Making Reviewer Cardioplegic Arrest Is Associated With Overexpression of Opioid Receptors Delta and Kappa in Diabetic and Non-Diabetic Patients Undergoing On-Pump Cardiac Surgery EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students Co-Chair	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals Nothing to Disclose CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, The Medicines Company; OTHER - Juventas, Vericel
Saxonhouse Sayad Sayer Sayer Sayseng Sayseng Scanavini Filho Scantebury Scarabelli Scarparo Schafer Schafer	Sherry Dany Gabriel Gabriel Sonny Sonny Marco Dawn Tiziano Paola Gary Kava	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography Timely Topics in Acute Coronary Syndromes Optimizing the Care of ACS Patients Antithrombotic Therapy in Ischemic Heart Disease FIT Clinical Decision Making Reviewers 6 From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Improving Outcomes in the Athlete With Cardiovascular Disease Evolving Therapies in Heart Failure: Gazing Into the Crystal Ball Pallitative Care for the 99% II: Skillbuilding: PC Encounters: What Would you do? Part I Pallitative Care for the 99% II: Skillbuilding: PC Encounters: What Would you do? Part I Pallitative Care for the 99% II: Skillbuilding: PC Encounters: What Would you do? Part I Pallitative: What Would you do? Part I	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease ACC FIT Clinical Decision Making Reviewer Cardioplegic Arrest Is Associated With Overexpression of Opioid Receptors Delta and Kappa in Diabetic and Non-Diabetic Patients Undergoing On-Pump Cardios Surgery EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students Co-Chair	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals Nothing to Disclose CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, The Medicines Company; OTHER - Juventas, Vericel Nothing to Disclose Nothing to Disclose Nothing to Disclose
Saxonhouse Sayar Sayer Sayer Sayseng Sayseng Scanavini Filho Scantlebury Scarabelli Scarparo Schaer	Sherry Dany Gabriel Gabriel Sonny Sonny Marco Dawn Tiziano Paola Gary Kava	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography Timely Topics in Acute Coronary Syndromes Optimizing the Care of ACS Patients Antithrombotic Therapy in Ischemic Heart Disease FIT Clinical Decision Making Reviewers 6 From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Improving Outcomes in the Athlete With Cardiovascular Disease Evolving Therapies in Heart Failure: Gazing Into the Crystal Ball Palliative Care for the 99% II: Skillbuilding: PC Encounters: What Would you do? Part I Palliative Care for the 99% III: Skillbuilding: PC Encounters: What Would you do? Part I	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions Underutilization of High Intensity Statin in a Contemporary High Risk PCI Population Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease ACC FIT Clinical Decision Making Reviewer Cardioplegic Arrest Is Associated With Overexpression of Opioid Receptors Delta and Kappa in Diabetic and Non-Diabetic Patients Undergoing On-Pump Cardiac Surgery EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students Co-Chair Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals Nothing to Disclose CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals. The Medicines Company, OTHER - Juventas, Vericel Nothing to Disclose
Saxonhouse Sayar Sayer Sayer Sayseng Sayseng Scanavini Filho Scarabelli Scarabelli Scarabelli Schafer Schafer Schafer	Sherry Dany Gabriel Gabriel Sonny Sonny Marco Dawn Tiziano Paola Gary Kava Ulrich	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography Timely Topics in Acute Coronary Syndromes Optimizing the Care of ACS Patients Antithrombotic Therapy in Ischemic Heart Disease FIT Clinical Decision Making Reviewers 6 From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Improving Outcomes in the Athlete With Cardiovascular Disease Evolving Therapies in Heart Failure: Gazing Into the Crystal Ball Palliative Care for the 99% II: Skillbuilding: PC Encounters: What Would you do? Part I Palliative Care for the 99% II: Skillbuilding: PC Encounters: What Would you do? Part II Interventional Cardiology: PCI and TAVR in Complex Patients	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 30 Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease ACC FIT Clinical Decision Making Reviewer Cardioplegic Arrest is Associated With Overexpression of Opioid Receptors Delta and Kappa in Diabetic and Non-Diabetic Patients Undergoing On-Pump Cardiac Surgery EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students Co-Chair Panelist Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the Bravo-3 Randomized Trial	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals Nothing to Disclose CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals. The Medicines Company, OTHER - Juventas, Vericel Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose
Saxonhouse Sayad Sayer Sayer Sayseng Sayseng Scanavini Filho Scantebury Scarabelli Scarparo Schafer Schafer	Sherry Dany Gabriel Gabriel Sonny Sonny Marco Dawn Tiziano Paola Gary Kava	Implantable Electronic Devices ECG Screening and Risk Prediction 04. Arrhythmias and Clinical EP: Basic Team 1 Arrhythmias and Clinical EP: Devices 3 Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Innovative Use of Echocardiography Timely Topics in Acute Coronary Syndromes Optimizing the Care of ACS Patients Antithrombotic Therapy in Ischemic Heart Disease FIT Clinical Decision Making Reviewers 6 From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Improving Outcomes in the Athlete With Cardiovascular Disease Evolving Therapies in Heart Failure: Gazing Into the Crystal Ball Palliative Care for the 99% II: Skillbuilding: PC Encounters: What Would you do? Part I Palliative Care for the 99% III: Skillbuilding: PC Encounters: What Would you do? Part I I Palliative Care for the 99% III: Skillbuilding: PC Encounters: What Would you do? Part I I Palliative Care for the 99% III: Skillbuilding: PC Encounters: What Would you do? Part I I I Interventional Cardiology: PCI and TAVR in	Suggested Reviewer Differences Among African Americans and White Patients Undergoing Implantable Cardioverter Defibrillator Implantation for Primary Prevention Correlation of Noninvasive Assessment of Lung Fluid Percentage With Invasively Measured Hemodynamics Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions Underutilization of High Intensity Statin in a Contemporary High Risk PCI Population Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease ACC FIT Clinical Decision Making Reviewer Cardioplegic Arrest Is Associated With Overexpression of Opioid Receptors Delta and Kappa in Diabetic and Non-Diabetic Patients Undergoing On-Pump Cardiac Surgery EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students Co-Chair Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals Nothing to Disclose CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, The Medicines Company; OTHER - Juventas, Vericel Nothing to Disclose Nothing to Disclose Nothing to Disclose



and the same				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Schainfeld	Robert	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Digit Ischemia Work-Up and an Uncommon Diagnosis: Hypothenar Hammer Syndrome	Nothing to Disclose
Schalij	Martin	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	The SHIVA Follow-Up Study: 10-Year Incidence Rates of Cardiovascular Events in South Asian Descendants in the Netherlands	RESEARCH/RESEARCH GRANTS - Biotronik,Boston Scientific,MEDTRONIC
Schalij	Martin	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes		RESEARCH/RESEARCH GRANTS - Biotronik,Boston Scientific,MEDTRONIC
Schalij	Martin	Innovative Use of Echocardiography	Left Ventricular Systolic Recovery After St-Segment Elevation Myocardial Infarction: Effect of Guideline-Based Therapy	RESEARCH/RESEARCH GRANTS - Biotronik,Boston Scientific,MEDTRONIC
Schalij	Martin	Non Invasive Imaging: MR Scar and Perfusion	Functional Consequences of Myocardial Scar After Myocardial Infarction: Characterization of Myocardial Scar Extent With Late Gadolinium Contrast Enhanced Cardiac Magnetic Resonance and Impact on Multilayer Global Longitudinal Strain on Speckle Tracking Echocardiography	RESEARCH/RESEARCH GRANTS - Biotronik,Boston Scientific,MEDTRONIC
Schalij	Martin	Arrhythmias and Clinical EP: Devices 4	Increased Complexity of Transvenous Lead Removals With Unaltered Effectivity: Promising Results Will Benefit Device Patients	RESEARCH/RESEARCH GRANTS - Biotronik,Boston Scientific,MEDTRONIC
Schaller	Robert	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Anticoagulation Use and Incidence of Cerebrovascular Events and Major Bleeding After Catheter Ablation in Patients With Persistent and Longstanding Persistent Atrial Fibrillation	Nothing to Disclose
Schampaert	Erick	Highlighted Original Research: Interventional Cardiology and the Year in Review	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	CONSULTANT FEES/HONORARIA - Abbott Vascular, AstraZeneca, MEDTRONIC, St-Jude Medical, Volcan RESEARCH/RESEARCH GRANTS - Abbott Laboratories
Schampaert	Erick	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Differences and Level of Agreement in SYNTAX Score Assessment Between Site Operators and Angiographic Core Laboratory Readers: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - Abbott Vascular, AstraZeneca, MEDTRONIC, St-Jude Medical, Volcan RESEARCH/RESEARCH GRANTS - Abbott Laboratories
Schampaert	Erick	Refining PCI Technique and Outcomes	Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory Assessment: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - Abbott Vascular, AstraZeneca, MEDTRONIC, St-Jude Medical, Volcan RESEARCH/RESEARCH GRANTS - Abbott Laboratories
Schampaert	Erick	Interventional Challenging Cases: Team 4	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular, AstraZeneca, MEDTRONIC, St-Jude Medical, Volcan RESEARCH/RESEARCH GRANTS - Abbott Laboratories
Scheel	Janet	10. Congenital Heart Disease: Pediatric Team 3	Suggested Reviewer	Nothing to Disclose
Schein	Jeff	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	A Benefit-Risk Analysis of Recurrent Venous Thromboembolism in Patients Who Continued Versus Discontinued Rivaroxaban Therapy After an Initial Six-Month Therapy	SALARY - Dr. Schein is an employee of Johnson & Dohnson & Dohnson
Schein	Jeff	Interventional Cardiology: PCI in Complex Patients	Impact of Comorbid Coronary Artery Disease and Severe Peripheral Artery Disease on Major Adverse Cardiovascular Events	SALARY - Dr. Schein is an employee of Johnson & Dohnson & Dohnson
Schein	Jeffrey	Making Progress in Understanding Heart Failure	Incremental Risk of Ischemic Stroke Over Time in Newly Diagnosed Heart Failure Patients Without Atrial Fibrillation	SALARY - Dr. Schein is an employee of Johnson & Dohnson & Dohnson
Schein	Jeffrey	Antithrombotic Therapy in Ischemic Heart Disease	Rivaroxaban Users Have Significantly Less Treatment Discontinuation Compared With Users of Other Oral Anticoagulants in Non-Valvular Atrial Fibrillation	SALARY - Dr. Schein is an employee of Johnson & Dohnson Johnson
Scheinerman	S. Jacob	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	An Unexpected Guest in the Right Ventricle	Nothing to Disclose
Scheinman	Melvin	Common Arrhythmia Problems: The Experts Approach	Panelist	CONSULTANT FEES/HONORARIA - Medtronic,St. Jude,bo scientific,Biotronik,Janseen; DATA SAFETY MONITORING BOARD - Gilead Sciences, Inc.
Schenk	Ashley	Interdisciplinary Cardiovascular Care in	Management of Complex Cardiovascular Patients in a Pharmacist-	Nothing to Disclose
Scherrer-Crosbie	Marielle	Complex Scenarios Imaging of Cancer-Treatment Associated CV Toxicity: Applying Guidelines to Clinical	Run Transitions of Care Clinic Co-Chair	Nothing to Disclose
Scherrer-Crosbie	Marielle	Practice Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Changes in Citric Acid Metabolism Are Associated With the Development of Anthracycline-Induced Cardiotoxicity in Mice and in	Nothing to Disclose
Scherrer-Crosbie	Marielle	Advances in Imaging to Assess Cardiotoxicity	Patients ACC Poster Moderator	Nothing to Disclose
Scherrer-Crosbie	Marielle	28. Non Invasive Imaging: Echo Team 4	Suggested Reviewer	Nothing to Disclose
Scherzer	Rebecca	Unusual Presentations of ACS	Association of Cocaine and Amphetamine Use With Troponin I Concentration	CONSULTANT FEES/HONORARIA - Merck & Comp; Colline.
Schettle	Sarah	Cardiovascular Procedures That Push the Line: High-Risk or Futility of Care?	Panelist High Risk Vs. Futility in Mechanical Support Devices (LVAD, ECMO,	Nothing to Disclose
Schettle Schettle	Sarah Sarah	Cardiovascular Procedures That Push the Line: High-Risk or Futility of Care? The Evolving World of LVADs, Transplant and	High Risk vs. Futility in Mechanical Support Devices (LVAD, ECMO, IABP) Effects of Diabetes Mellitus on Clinical Outcomes After Left	Nothing to Disclose Nothing to Disclose
		Other Novel Discoveries	Ventricular Assist Device Implantation: A Single Institutional 9-Year Experience	-
Scheurer	Mark	Congenital Heart Disease: Progress in Pediatric Heart Surgery	The Association of Technical Performance With Postoperative Complications and Hospital Costs for the Norwood Operation	Nothing to Disclose
Schevchuck	Alex	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Seeing Is Believing: Utilizing Multiple Imaging Modalities in Difficult to Characterize Left Ventricle Outflow Obstruction	Nothing to Disclose
Schiaffini	Giammarco	Improving Outcomes in the Athlete With Cardiovascular Disease	EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000 Young Italian Students	Nothing to Disclose
Schiele	Francois	Advances in Cholesterol Measurement and Management	Consistent Low-Density Lipoprotein Cholesterol Lowering Efficacy of Alirocumab in High and Very High Cardiovascular Risk Patients With Low-Density Lipoprotein Cholesterol >100/70 mg/dL at Baseline	CONSULTANT FEES/HONORARIA - Amgen Inc., Astra Zeneca, Daiichi Sankyo, Eli Lilly and Company, GSK, Merck & Damp; Co., Inc., Sanofi Aventis
Schiele	Francois	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Discriminant Value of the DAPT Score to Predict Long-Term Ischemic and Bleeding Events in the Real World Population of Stented Patients in the FAST-MI 2005 Cohort	CONSULTANT FEES/HONORARIA - Amgen Inc.,Astra Zeneca,Daiichi Sankyo,Eii Lilly and Company,GSK,Merck & Co., Inc.,Sanofi Aventis
Schiele	Francois	Antithrombotic Therapy in Ischemic Heart Disease	Long-Term Outcome With Oral Anticoagulants With or Without Dual Antiplatelet Therapy After AMI: The Fast-Mi 2010 Registry	CONSULTANT FEES/HONORARIA - Amgen Inc., Astra Zeneca, Daiichi Sankyo, Eli Lilly and Company, GSK, Merck & amp; amp; Co., Inc., Sanofi Aventis
Schiele	Francois	Unusual Presentations of ACS	Characteristics and Outcomes of Patients Discharged Without Statins After an Acute Myocardial Infarction: An Analysis From the Combined FAST-MI 2005-2010 Cohorts	CONSULTANT FEES/HONORARIA - Amgen Inc.,Astra Zeneca,Daiichi Sankyo,Eii Lilly and Company,GSK,Merck & Co., Inc.,Sanofi Aventis
Schiller	Nelson	Innovative Use of Echocardiography	Effect of Left Atrial Remodeling on Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study	SPEAKER'S BUREAU - General Electric HealthCare,Lanthe
Schiller	Nelson	Innovative Use of Echocardiography	Left Atrial Function Index as a Predictor of Cardiovascular Disease and Atrial Fibrillation: Data From the Framingham Offspring Study	SPEAKER'S BUREAU - General Electric HealthCare,Lanthe
Schiller Schilling	Nelson Richard	28. Non Invasive Imaging: Echo Team 4 Late-Breaking Clinical Trials	Suggested Reviewer Safety and Efficacy of Uninterrupted Anticoagulation With Dabigatran Etexilate Versus Warfarin in Patients Undergoing Catheter Ablation of Atrial Fibrillation: The RE-CIRCUIT Study	SPEAKER'S BUREAU - General Electric HealthCare,Lanthe Nothing to Disclose

Last Name Schillinger	First Name Wolfgang	Session Title Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Presentation Title Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Previous Major Gastrointestinal Bleeding: Insight From the	Disclosures CONSULTANT FEES/HONORARIA - Abbott Vascular,AGA medical,Edwards Lifesciences
Schindler	John	The Challenges of Outcome Prediction in Valvular Heart Disease	Amplatzer Cardiac Plug Multicenter Registry Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity. Clinical Applications in the TAVR Era	Nothing to Disclose
Schindler	John	TAVR Outcomes Prognostication	Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in	Nothing to Disclose
Schindler	Thomas	PET Myocardial Perfusion Imaging: Practical	TAVR Patients: Time to Integrate the Right Side Unit Co-Chair	RESEARCH/RESEARCH GRANTS - Siemens Medical Solutions
Schindler	Thomas	Considerations- A Case-Based Discussion Imaging of Myocardial Blood Flow: A	Co-Chair	RESEARCH/RESEARCH GRANTS - Siemens Medical Solutions
Schindler	Thomas	Multimodality Approach Nuclear Cardiology: Beyond Perfusion	Molecular Imaging of Myocardial Cannabinoid Type 1 Receptor	RESEARCH/RESEARCH GRANTS - Siemens Medical Solutions
Schindler	Thomas	30. Non Invasive Imaging: Nuclear Team 1	Upregulation in Obesity Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Siemens Medical Solutions
Schinkel	Arend	Arrhythmias and Clinical EP: Devices 1	Long-Term Outcome of Noncompaction Cardiomyopathy Patients With Implantable Cardioverter-Defibrillators Compared With Patients With Dilated or Hypertrophic Cardiomyopathy	Nothing to Disclose
Schinkel	Arend	Advances in HCM, PPCM and Other	Yield and Long-Term Outcome of Family Screening in Hypertrophic Cardiomyopathy	Nothing to Disclose
Schlam	llana	Cardiomyopathies Advances in Cholesterol Measurement and Management	Cardiomyopathy 10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy: Post-Commercialization Study	Nothing to Disclose
Schlam	llana	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Ocular Vascular Occlusion in 302 Patients: A Diagnostic Window to Familial and Acquired Thrombophilia	Nothing to Disclose
Schmidhofer	Mark	Innovations in Practice Management and	Formal CPR Status Policy and Process Increased Documentation	Nothing to Disclose
Schmidt	André	Social Media Arrhythmias and Clinical EP: Devices 1	Rates Electrical Storm in Chagas Heart Disease Patients With Implantable Cardioverter Defibrillator - Clinical Predictors, Outcome and Arrhythmic Characteristics: A Prospective Registry From a University Hospital	Nothing to Disclose
Schmidt	Morten	Adult Patients With Congenital Heart Disease: How Do They Compare?	Risk of Stroke in Adult Patients With Congenital Heart Disease Compared With the General Population: A Danish Nationwide Population-Based Cohort Study	Nothing to Disclose
Schmidt	Morten	Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering Therapies	17-Year Nationwide Trends in Antihypertensive Drug Use in Denmark	Nothing to Disclose
Schmidt	Samuel	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Risk Stratification of Patients Suspected of Coronary Artery Disease Using an Acoustic Detection Algorithm	CONSULTANT FEES/HONORARIA - Consultant job For Acarix A/S in Denmark; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Shareholder in Acarix AS
Schmidt	Stanley	Outcomes in Valvular Heart Disease	Trends and Outcomes of Permanent Pacemaker Implantation After Mitral Valve Replacement: A 10 Year U.S. Analysis	Nothing to Disclose
Schmidt	Torrey	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Assessing Inter-Rater Agreement of Experienced Interventional Cardiologists on Culprit Vessel in Patients With Multivessel Disease and Acute Non-STEMI	Nothing to Disclose
Schneibel	Erik	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Left Ventricular Assist Device Outflow Tract Thrombus Following a Successful Sleeve Gastrostomy	Nothing to Disclose
Schnittger	Ingela	Interventional Cardiology: TAVR 1	The Inflammasome Pathway Is Associated With Adverse Ventricular Remodeling Following Transcatheter Aortic Valve Replacement	Nothing to Disclose
Schnittger	Ingela	Innovative Use of Echocardiography	Identifying the Optimal Echocardiographic Variables to Predict Outcome Through Correlation Mapping in Patients With Dilated Cardiomyopathy	Nothing to Disclose
Schnohr	Peter	Innovative Use of Echocardiography	The Left Atrium Emptying Fraction as a Predictor of Cardiovascular Morbidity and Mortality in a Low Risk General Population	Nothing to Disclose
Schnug	Renee	Adult Patients With Congenital Heart Disease: How Do They Compare?	Obstructive Sleep Apnea in Adult Congenital Heart Disease: Who Is at Risk?	Nothing to Disclose
Schoenfeld	Matthew	Novel Echocardiographic Methods for Assessing Cardiac Function	Use of Diastolic Parameters on Transthoracic Echocardiogram to Predict Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation	Nothing to Disclose
Schoenhagen Scholte	Paul Arthur	Interventional Challenging Cases: Team 4 Non Invasive Imaging: Coronary Calcium	ACC Challenging Case Reviewer Coronary Calcium Characteristics as Predictors of Major Adverse	Nothing to Disclose Nothing to Disclose
Schouver	Elie Dan	Scoring and CV Risk Assessment Updates on Pulmonary Embolism	Cardiac Events in Symptomatic Patients: Insights From the CORE320 Multinational Study Diuretics Versus Fluid Loading in Acute Submassive Pulmonary	Nothing to Disclose
Schouver	Elie Dan	Management in 2017 Innovative Use of Echocardiography	Embolism Early Detection of Cardiac Involvement in Sarcoidosis With 2-	Nothing to Disclose
Schreiber	Theodore	Featured Clinical Research III	Dimensional Speckle-Tracking Echocardiography Outcomes for 15,259 US Patients With Acute MI Cardiogenic Shock	-
Schreiber	Theodore	Interventional Cardiology: TAVR 3	(AMICS) Supported With Impella Transcatheter Versus Surgical Aortic Valve Replacement in	Nothing to Disclose
Schreiber	Theodore		Diabetes Melitus: From the Nationwide Inpatient Sample Ultrasound Assisted Catheter Directed Thrombolysis and Percutaneous Right Ventricular Mechanical Assist Device for the Management of Massive Pulmonary Embolism With Refractory Right Ventricular Failure: Playing Chess With Pulmonary Embolism	Nothing to Disclose
Schreiber	Theodore	FIT Clinical Decision Making: Acute Coronary	Use of Ultrasound Assisted Catheter Directed Thrombolysis in	Nothing to Disclose
Schreiner	Pamela	Syndrome and Vascular Medicine Insights From Echocardiography Use	Treatment of Aortic Thrombi Relation of Left Ventricular Remodeling to Left Ventricular Diastolic Function Measures at Middle Age: Coronary Artery Risk	Nothing to Disclose
Schreiner	Pamela	Insights From Echocardiography Use	Development in Young Adults (CARDIA) Study Relation of Left Ventricular Remodeling to Left Ventricular Systolic Function Measures at Middle Age: Coronary Artery Risk	Nothing to Disclose
Schrey	Donita	Interdisciplinary Cardiovascular Team Care	Development in Young Adults (CARDIA) Study See You in 7: An Advanced Practice Provider Post PCI Clinic	Nothing to Disclose
Schricker	Amir	Delivery: Quality, Safety, and Satisfaction 08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Improving Transition of Care Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Electrophysiology
Schroeder	Bethany	Vascular Medicine: Venous Disease	Low Dose Systemic Thrombolysis and New Oral Anticoagulants in	Nothing to Disclose
Schuetz	Rebecca	Interdisciplinary Cardiovascular Team	the Treatment of Large Thrombi in the Right Heart Poor Adherence in Young Patients With Heart Failure	Nothing to Disclose
Schuetz	Rebecca	Collaboratives in Care Interdisciplinary Cardiovascular Care in	Simple Technology Improves Access and Outcomes for Patients	Nothing to Disclose
Schuetz	Rebecca	Complex Scenarios Interdisciplinary Cardiovascular Team Care	With Low Socioeconomic Status Homelessness and Heart Failure: A Novel Prescription	Nothing to Disclose
Schuetz	Rebecca	Delivery: Quality, Safety, and Satisfaction Interdisciplinary Cardiovascular Team Care Delivery: Quality, Safety, and Satisfaction	Heart Failure Hotline as an Innovation to Address Medication Issues	-



and a				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Schuijf	Joanne	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Calcium Characteristics as Predictors of Major Adverse Cardiac Events in Symptomatic Patients: Insights From the CORE320 Multinational Study	SALARY - Since recently employee Toshiba Medical Systems Europe
Schuler	Gerhard	Non Invasive Imaging: MR Characterization and Function	Prognostic Value and Determinants of Left Atrial Function Assessed by Cardiac Magnetic Resonance in St-Segment Elevation	Nothing to Disclose
Schuler	Gerhard	Novel Developments in Acute Coronary Syndromes	Myocardial Infarction Impact of Timing of Intra-Aortic Balloon Counterpulsation on Mortality in Cardiogenic Shock: A Sub-Analysis of the IABP-SHOCK	Nothing to Disclose
Schuler	Gerhard	Novel Developments in Acute Coronary	II-Trial Mild Hypothermia in Cardiogenic Shock Complicating Myocardial	Nothing to Disclose
Schuler	Gerhard	Syndromes Novel Developments in Acute Coronary	Infarction: The Randomized SHOCK-COOL Pilot Trial Outcome of Elderly Patients Undergoing Extracorporeal Life	Nothing to Disclose
Schuler	Gerhard	Syndromes Interventional Cardiology: TAVR 2	Support in Refractory Cardiogenic Shock Different Impact of Gender on Early and Late Outcome After	Nothing to Disclose
Schuler	Gerhard	Interventional Cardiology: TAVR 2	Transcatheter Aortic Valve Replacement Higher B-Type Natriuretic Peptide Levels Predict Occurrence of	Nothing to Disclose
Schuler	Gerhard	Interventional Cardiology: TAVR 2	Acute Kidney Injury After Transcatheter Aortic Valve Replacement Impact of Myocardial Injury Indicated by Increased Creatinine Kinase-	Nothing to Disclose
			Myocardial Band Levels on the Outcome After Transcatheter Aortic Valve Replacement: Results From a Prospective Single Center Registry	· · · · · · · · · · · · · · · · · · ·
Schuler	Gerhard	Interventional Cardiology: TAVR 4	Impact of Cancer Disease on Outcome of Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Schulman-Marcus	Joshua	Diabetes and Other Issues in Cardiovascular Prevention	Implications of Statin Therapy Among Smokers With Severe Coronary Artery Calcification: An Analysis of the CONFIRM Registry	Nothing to Disclose
Schulte	Phillip	Valvular Heart Disease With CKD or Cirrhosis	Low Utilization of Surgical Intervention to Treat Severe Aortic Stenosis in Patients With Chronic Kidney Disease	Nothing to Disclose
Schulze	P. Christian	12. Heart Failure and Cardiomyopathies: Basic	Suggested Reviewer	Nothing to Disclose
Schulz-Menger	Jeanette	Team 2 Featured Clinical Research I	MR-INFORM: Stress Perfusion Imaging to Guide the Management	CONSULTANT FEES/HONORARIA - Bayer Healthcare
Schulz-Menger	Jeanette	29. Non Invasive Imaging: MR Team 1	of Patients With Stable Coronary Artery Disease Suggested Reviewer	Pharmaceuticals; SPEAKER'S BUREAU - Berlin Chemie CONSULTANT FEES/HONORARIA - Bayer Healthcare
Schumacher	Stefan	Nuclear Cardiology: Quality	Automatic SPECT Analysis Compared to Expert Visual Scoring for	Pharmaceuticals; SPEAKER'S BUREAU - Berlin Chemie Nothing to Disclose
Schumacher	Stefan	Advances in Chronic Total Occlusion	the Detection of Coronary Artery Disease Effects of Successful Percutaneous Coronary Intervention of	Nothing to Disclose
		Intervention	Chronic Total Occlusions on Myocardial Perfusion and Left Ventricular Function	Nothing to Disclose
Schumaecker	Matthew	Personalized Skills Center: Drill and Practice (Heart Songs, ECG, Hand-Held Echo)	Heart Songs Moderator	,
Schunkert	Heribert	Interventional Cardiology: TAVR 3	Multicenter Evaluation of the ACURATE Neo Transfemoral Transcatheter Heart Valve: Clinical Results and Propensity Matched Comparison With SAPIEN 3	CONSULTANT FEES/HONORARIA - AstraZeneca, SERVIER, Boehringer-Ingelheim, MSD, Berlin-Chemie
Schunkert	Heribert	Interventional Cardiology: TAVR 4	Multicenter Evaluation of Prosthesis Oversizing for the SAPIEN 3 Transcatheter Heart Valve: Impact on New Pacemaker Implantations	CONSULTANT FEES/HONORARIA - AstraZeneca, SERVIER, Boehringer-Ingelheim, MSD, Berlin-Chemie
Schussler	Jeffrey	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Takotsubo Cardiomyopathy in the Setting of Complete Heart Block	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Cor Medical Technologies
Schuster	Andreas	Uncovering the Intricacies of Vascular Function	Non-Coding RNAs Comprehensively Counteract Adverse Arterial Remodeling and Stiffening in Type 2 Diabetes	Nothing to Disclose
Schwamm	Lee	Atrial Fibrillation and VT: Unique Populations and Solutions	Low Stroke Incidence in Persistent Atrial Fibrillation Ablation With Multi-Electrode Phased Radio-Frequency Technology: Preliminary Results From VICTORY AF Study	CONSULTANT FEES/HONORARIA - Lundbeck,MEDTRONIC; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Lifelmage; RESEARCH/RESEARCH GRANTS - Genentech, Inc
Schwartz	Gregory	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	Effect of Serial Infusions of CER-001, a Pre-Beta High-Density Lipoprotein Mimetic on Coronary Atherosclerosis: Results of the CARAT Study	Nothing to Disclose
Schwartz	Gregory	Advances in Lipid Management	Use of High-Intensity Statin Therapy Post-Acute Coronary Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody, Versus Placebo: Interim Baseline Data	Nothing to Disclose
Schwartz	Gregory	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Association Between Homeostasis Model Assessment of Insulin Resistance and Survival in Diabetic Patients With Acute Coronary Syndromes: Insights From the AleCardio Trial	Nothing to Disclose
Schwartz	llana	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Long Term Outcomes After the Fontan Procedure in Patients With Single Ventricle: A Meta-Analysis	Nothing to Disclose
Schwartz	Peter	04. Arrhythmias and Clinical EP: Basic Team 1	Suggested Reviewer	Nothing to Disclose
Schwartz	Robert	25. Interventional Cardiology: Translation and Pre-clinical Research Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific,Edwards Lifesciences; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - BackBeat Medical
Schwartz	Ronald	State of the Art Nuclear Cardiology: SPECT Myocardial Perfusion Imaging	Image Acquisition and Processing: Novel Hardware and Software Applications	SPEAKER'S BUREAU - Astellas
Schwartz	Ronald	State of the Art Nuclear Cardiology: SPECT	Image Interpretation: Rapid Fire Case Review	SPEAKER'S BUREAU - Astellas
Schwartz	Ronald	Myocardial Perfusion Imaging Radiation from Diagnostic Imaging: Risk-	Panelist	SPEAKER'S BUREAU - Astellas
Schwartz	Ronald	benefit Analysis 30. Non Invasive Imaging: Nuclear Team 1	Suggested Reviewer	SPEAKER'S BUREAU - Astellas
Schwartz	Steven	Post-Surgical Care of Children with CHD: From ICU to Your Office	Co-Chair	CONSULTANT FEES/HONORARIA - Novartis AG
Schwartz	Steven	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Standardization of Peri-Operative Management After Norwood Operation Has Not Improved 1 Year Outcomes	CONSULTANT FEES/HONORARIA - Novartis AG
Schwartz	Todd	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Influence of Low Versus High Dose on the Association of Loop Diurectic and Mortality in Patients With Heart Failure: Insights From the UNITE-HF Registry	Nothing to Disclose
Schweitzer	Paul (Pavol)	Timely Topics in Acute Coronary Syndromes	The Unit E-Hr Registry Emergency Room Evaluation of Patients With Cardiac Complaints and New Left Bundle Branch Block: The Utility of the Sgarbossa and Modified Soarbossa Criteria	Nothing to Disclose
Sciahbasi	Alessandro	Featured Clinical Research II: Interventional	Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD Matrix Study	Nothing to Disclose
Sciria	Christopher	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Syndromes: The RAD Matrix Study Mechanisms of Acute Myocardial Infarction in Young Women and Discharge Medication Patterns	Nothing to Disclose
Scirica	Benjamin	Syndrome Clinical Challenges in the Cardiac Care Unit (CCU)	Takotsubo Cardiomyopathy: I am Seeing it Everywhere!	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Biogen Idec, Boehringer Ingelheim Pharmaceuticals, Inc,Dr. Reddy's Laboratories Inc.,Forest Laboratories, GE Healthcare, GlaxoSmithKline, Health [at] Scale, Lexicon,Merck & Dec, Inc.,St. Jude Medical; RESEARCH/RESEARCH GRANTS - AstraZeneca, Dalichi- Sankyo, Eisai,Merck, Poxel

Contract of the second				l .
Last Name Scirica Scirica	First Name Benjamin Benjamin	Session Title The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints Highlighted Original Research: Prevention and	Presentation Title Co-Chair Blood Pressure, Subclinical Myocardial Injury and Cardiovascular	Disclosures CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Biogen Idec, Boehringer Ingelheim Pharmaceuticals, Inc, Dr. Reddy's Laboratories Inc, Forest Laboratories, GE Healthcare, GlaxoSmithKline, Health [at] Scale, Lexicon, Merck & amp; amp; Co., Inc, St. Jude Medical; RESEARCH/IRESEARCH GRANTS - AstraZeneca, Daiichi- Sankyo, Eisai, Merck, Poxel CONSULTANT FEES/HONORARIA - AstraZeneca
		the Year in Review	Outcomes Among Patients With Diabetes and High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial	Pharmaceuticals, Biogen Idec, Boehringer Ingelheim Pharmaceuticals, Inc, Dr. Reddy's Laboratories Inc., Forest Laboratories, GE Healthcare, GlaxoSmithKline, Health [at] Scale, Lexicon, Merck & amp;amp; Co., Inc., St. Jude Medical; RESEARCH/RESEARCH GRANTS - AstraZeneca, Daiichi- Sankyo, Eisai, Merck, Powel
Scirica	Benjamin	Breakthrough Therapies: Your Role in Protecting the Heart of Your Patients with Diabetes	Deciphering the Findings: The Latest Clinical Trials and Evidence in CVD and Diabetes	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Joigoen Idec, Beochringer Ingelheim Pharmaceuticals, Inc,Dr. Reddy's Laboratories Inc.,Forest Laboratories,GE Healthcare,GlaxoSmithKline,Health [at] Scale,Lexicon,Merck & amp;amp; Co., Inc.,St. Jude Medical; RESEARCH/RESEARCH GRANTS - AstraZeneca, Dalichi-Sankyo, Eisai,Merck,Poxel
Scirica	Benjamin	Post-CAD/MI: Making Tough Predictions About the Future	Risk Stratification With the TIMI Risk Score for Secondary Prevention Among Patients With Diabetes and Elevated Cardiovascular Risk	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Biogen Idec, Boehringer Ingelheim Pharmaceuticals, Inc, Dr. Reddy's Laboratories Inc, Forest Laboratories, ISE Healthcare, GlaxoSmithKline, Health [at] Scale, Lexicon, Merck & Ampr, amp. Co., Inc. St. Jude Medical; RESEARCH/IRESEARCH GRANTS - AstraZeneca, Daiichi- Sankyo, Eisai, Merck, Poxel
Scirica Scirica	Benjamin Benjamin	Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells 03. Acute and Stable Ischemic Heart Disease:	ACC Poster Moderator Suggested Reviewer	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Biogen Idec, Boehringer Ingelheim Pharmaceuticals, Inc, Dr. Reddy's Laboratories Inc., Forest Laboratories, GE Healthcare, GlaxoSmithKline, Health [at] Scale, Lexicon, Merck & amp;amp; Co., Inc., St. Jude Medical; RESEARCH/RESEARCH GRANTS - AstraZeneca, Daiichi- Sankyo, Eisai, Merck, Poxel CONSULTANT FEES/HONORARIA - AstraZeneca
		Therapy Team 1		Pharmaceuticals, Biogen Idec, Boehringer Ingelheim Pharmaceuticals, Inc.Dr. Reddy's Laboratories Inc., Forest Laboratories, GE Healthcare, GlaxoSmithKline, Health [at] Scale, Lexicon, Merck & amp;amp; Co., Inc., St. Jude Medical; RESEARCH/RESEARCH GRANTS - AstraZeneca, Daiichi- Sankyo, Eisai, Merck, Poxel
Scolaro	Bianca	Advances in Cholesterol Measurement and Management	Effect of Nutraceuticals Combined With Statins on LDL Cholesterol Depends on the Sterol Synthesizer/Absorber Profile of the Patients	RESEARCH/RESEARCH GRANTS - Bionatus Ltda,Chocolife Ltda,Leão Alimentos e Bebidas
Scordo Scott	Kristine Christopher	Cardiovascular Team Cases: Team 2 Making Progress in Understanding Heart	Suggested Reviewer Incidence of Preclinical (Stage A and B) Heart Failure in the General	Nothing to Disclose Nothing to Disclose
Scott	Christopher	Failure Innovations in Education	Population Associations Between Cardiology Fellowship Applicants'	Nothing to Disclose
Scott	Christopher	Valvular Heart Disease: Aortic Stenosis	Characteristics and Subsequent Clinical Performance Sinus Rhythm Versus Atrial Fibrillation & It Clinical Profile and Natural History of Patients With Severe Aortic Stenosis Managed	Nothing to Disclose
Scott	Christopher	Interventional Cardiology: TAVR 3	Medically Comparative Outcome of Paravalvular Leak Following Surgical	Nothing to Disclose
Scott	Christopher	The Evolving World of LVADs, Transplant and		Nothing to Disclose
Scott	Christopher	Other Novel Discoveries Vascular Medicine: Aortic and Peripheral Artery Diseases	in Chronic Kidney Disease: A Population-Based Cohort Association of Ankle Brachial Index With Limb Outcomes in Peripheral Artery Disease: A Community-Based Study	Nothing to Disclose
Scott	Luis	Novel Echocardiographic Methods for Assessing Cardiac Function	Long-Term Effects of Right Ventricular Pacing on Left Ventricular Systolic and Diastolic Function and Synchrony by Strain Imaging in Patients With Normal Baseline Left Ventricular Ejection Fraction	Nothing to Disclose
Scott	Luis	Leading Us Astray? Pacemakers in Cardiomyopathies	Chronic Right Ventricular Pacing: Effects on Heart Failure Hospitalization and Mortality in the Presence of Normal Left	Nothing to Disclose
Scott	Ronald	Advances in Cholesterol Measurement and Management	Ventricular Ejection Fraction Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol	RESEARCH/RESEARCH GRANTS - Sanofi/Regeneron
Scudeler	Thiago	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Cost-Effectiveness Analysis and Quality of Life of On-Pump and Off- Pump Stable Multivessel Coronary Artery Bypass Grafting: MASS III Trial 5-Year Follow-Up	Nothing to Disclose
Seals	A. Allen	STEMI in the Emerging World: International Perspectives From the Cardiological Society of India, Mexican Society of Cardiology, and American College of Cardiology	Co-Chair	Nothing to Disclose
Seals	A. Allen	STEMI in the Emerging World: International Perspectives From the Cardiological Society of India, Mexican Society of Cardiology, and American College of Cardiology	Introduction to Session	Nothing to Disclose
Seals	A. Allen	Cardiac Rehab in 2017: Tailoring The Approach to the Times	Reimbursement for Cardiac Rehab in 2017: Are MDs Still Required for Supervision?	Nothing to Disclose
Sebag	lgal	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Hypertrophic Cardiomyopathy as a Manifestation of Anderson-Fabry Disease	SPEAKER'S BUREAU - Lantheus
Secemsky	Eric	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Sex Differences in Rates of 30-Day Readmission in Patients Discharged After Acute Myocardial Infarction in the United States	Nothing to Disclose
Secemsky	Eric	Coronary Intervention: Drug Eluting Stent and Scaffolds	A Cost-Effective Analysis of Short Duration Dual Anti-Platelet Therapy (Dapt) With a Bioabsorbable Polymer Stent Platform Versus Longer Duration Dapt With a Durable Polymer Drug-Eluting Stent in a Patient Population Undergoing Elective Percutaneous Coronary Intervention	Nothing to Disclose
Secemsky	Eric	Optimizing Treatment of Peripheral Artery Disease	Nationwide Readmissions Following Lower Extremity Arterial Procedures	Nothing to Disclose
Sechtem	Udo	Beans, Beans, Good for Your Heart	Analysis of the Timing of Thoracic Endovascular Aortic Repair and Its Indications and Outcomes in Type B Aortic Dissection	Nothing to Disclose
Sechtem	Udo	Unusual Presentations of ACS	Gender Differences in Patients With Vasomotor Disorders According to Acetylcholine Provocation in a European Population	Nothing to Disclose
Sechtem	Udo	Vascular Medicine: Aortic and Peripheral Artery Diseases	Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection	Nothing to Disclose
Sedehi	Daniel	Evolution of Critical Care Cardiology and the CICU	Preparing for Evolving Roles of the Cardiologist in the CICU	Nothing to Disclose
Sedhai	Yub Raj	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Can CHA2DS2-VASc Score Be Used as a Predictor of Contrast Induced Nephropathy After Cardiac Catheterization?	Nothing to Disclose
L	1	IO DAMES	l	<u> </u>

Last Name See	First Name Claudia	Session Title Valvular Disease Populations at Risk	Presentation Title Surgical Risk and Therapy of Severe Symptomatic Degenerative	Disclosures Nothing to Disclose
See	Claudia	Valvular Heart Disease: Mitral Valve Disease	Mitral Valve Regurgitation in the Contemporary Era Guideline-Adherence and Survival for Asymptomatic Patients With	Nothing to Disclose
Seed	Mike	Congenital Heart Disease: Innovations in	Severe Mitral Valve Regurgitation Standardization of Peri-Operative Management After Norwood	Nothing to Disclose
Seeger	Julia	Single Ventricle Heart Disease Interventional Cardiology: TAVR 3	Operation Has Not Improved 1 Year Outcomes Apixaban in Atrial Fibrillation Patients With Renal Insufficiency After	Nothing to Disclose
Seeger	Julia	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Replacement One Year Outcome in Patients Undergoing Transfemoral Aortic	Nothing to Disclose
- coogo.	Gana	and to the first of the first o	Valve Replacement (TAVR) With the Repositionable and Retrievable Boston Scientific Lotus Valve Compared With the Balloon-Expandable Edwards Sapien 3 Device	
Seeger	Julia	Refining TAVR Outcomes	Significant Reduction of Cerebral Ischemic Events With the Sentinel Cerebral Emboli Protection Device in Patients With Transcatheter Aortic Valve Replacement	Nothing to Disclose
Seferovic	Jelena	The Old and the New: Impact of Heart Failure Drug Therapies	Influence of Sacubitril/Valsartan on Glycemic Control in Patients With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction	Nothing to Disclose
Segal	Jonathan	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Clinical Effectiveness of Spironolactone in Hospitalized Older Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or Equal to 30 mL/min/1.73 m ²) Patients With Heart Failure	Nothing to Disclose
Segal	Jonathan	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Chronic Alpha Blocker Use and Outcomes in Older Male Medicare Beneficiaries Hospitalized for Heart Failure	Nothing to Disclose
Segal	Jonathan	Why Can't We Be Friends? Controversies in Heart Failure Management	Adverse Outcomes With Use of Hydralazine and Nitrate Combination Therapy in Hospitalized Older Non-Black Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)	Nothing to Disclose
Segev	Amit	Non Invasive Imaging: Expanding Clinical Applications	Impact of Different Calcium Locations of Mitral Annulus and Aortic Valve Cusps on Risk of Conduction Disturbances After Transcatheter Aortic Valve Implantation	CONSULTANT FEES/HONORARIA - Boeringer,MEDTRONIC,Pfizer; OTHER - Edwards Lifesciences
Segev	Amit	Interventional Cardiology: TAVR 4	Transacatheter Aortic Valve Replacement And Malignancy	CONSULTANT FEES/HONORARIA - Boeringer,MEDTRONIC,Pfizer; OTHER - Edwards Lifesciences
Segev	Amit	Interventional Cardiology: TAVR 4	Rapid Ventricular Pacing During TAVR Is Associated With Poor Short- and Long-Term Outcome	CONSULTANT FEES/HONORARIA - Boeringer, MEDTRONIC, Pfzer; OTHER - Edwards Lifesciences
Segev	Amit	Refining TAVR Outcomes	Short- and Long-Term Outcome The Association of Coronary Artery Disease Severity and Pre Procedural Completeness of Revasclarization on Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement	Boeringer, MIEDTRONIC, Prizer; OTHER - Edwards Lifesciences CONSULTANT FEES/HONORARIA - Boeringer, MEDTRONIC, Pfizer; OTHER - Edwards Lifesciences
Segev	Amit	Anti-Platelet Therapies: Always a Sticky Topic	Chewing Versus Traditional Swallowing of Ticagrelor to Accelerate Platelet Inhibition in ST Elevation Myocardial Infarction: The CHEERS-STEMI Study	CONSULTANT FEES/HONORARIA - Boeringer,MEDTRONIC,Pfizer; OTHER - Edwards Lifesciences
Seheult	Roger	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	A Benefit-Risk Analysis of Recurrent Venous Thromboembolism in Patients Who Continued Versus Discontinued Rivaroxaban Therapy After an Initial Six-Month Therapy	CONSULTANT FEES/HONORARIA - Janssen: Pharmaceutical Companies of Johnson & Donson &
Seidelmann	Sara	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Integrating Hyperemic Myocardial Blood Flow and Coronary Flow Reserve for Predicting Cardiovascular Mortality Outcomes in Patients With Known or Suspected Ischemic Heart Disease	Nothing to Disclose
Seidelmann	Sara	Nuclear Cardiology: Prognosis	Myocardial Scar but Not Ischemia Predicts Defibrillator Shocks and Sudden Cardiac Death in Patients With Reduced Left Ventricular Ejection Fraction	Nothing to Disclose
Seidelmann	Sara	Arrhythmias and Clinical EP: Basic 4	Deleterious Mutations in SCN10A Are Associated With Long QT Syndrome	Nothing to Disclose
Seidl	Karlheinz	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Increased Rate of Previous Stroke in Asymptomatic/Minimally Symptomatic Versus Symptomatic Patients With Newly Detected Atrial Fibrillation Worldwide: Results From the GLORIA-AF Registry	Nothing to Disclose
Seidler	Tim	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Echocardiographic Estimation of Mean Pulmonary Artery Pressure: A Comparison of Different Approaches to Predict Pulmonary Hypertension	Nothing to Disclose
Seiler	Amber	Novel Arrhythmia Diagnostics, Therapeutics, and "Wearables	Incidence of Implantable Loop Recorders Upgraded to Pacemakers/Implanted Cardiac Defibrillators	CONSULTANT FEES/HONORARIA - MEDTRONIC; SPEAKER'S BUREAU - MEDTRONIC
Sekaran	Nishant	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Outcomes in Patients With Diabetes Mellitus and Suspected Coronary Artery Disease Following Non-Invasive Testing: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	Nothing to Disclose
Sekiguchi	Haruki	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Rapid Resolution of Tendon Xanthomas in Elder Heterozygous Familial Hyperchorestelemia Treated With Evolocumab	Nothing to Disclose
Seliger	Stephen	Making Progress in Understanding Heart Failure	Impact of Malignant Left Ventricular Function on Incident Heart Failure With Reduced Versus Preserved Ejection Fraction: The MESA Study	OTHER - AbbVie, Inc.; RESEARCH/RESEARCH GRANTS - Roche, Inc
Seliger	Stephen	Making Progress in Understanding Heart Failure	Impact of Malignant Left Ventricular Function on Incident Heart Failure in Older Adults: The MESA Study	OTHER - AbbVie, Inc.; RESEARCH/RESEARCH GRANTS - Roche, Inc
Seliger	Stephen		Impact of Malignant Left Ventricular Hypertrophy on Incident Asymptomatic Left Ventricular Dysfunction: The MESA Study	OTHER - AbbVie, Inc.; RESEARCH/RESEARCH GRANTS - Roche, Inc
Sellke	Frank	Issues in the Treatment of Coronary Disease: Joint Symposium of the American Heart Association and the American College of	Co-Chair	Nothing to Disclose
Sellke	Frank	Cardiology Interventional Cardiology: TAVR 3	Infective Endocarditis After Transcatheter Aortic Valve Replacement: Insights From the Nationwide Readmissions Database	Nothing to Disclose
Selton-Suty	Christine	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Echocardiographic Predictors for In-Hospital and 1-Year Outcomes in Left-Sided Infective Endocarditis: An Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort	Nothing to Disclose
Selvanayagam	Joseph	Featured Clinical Research I	Study MR-INFORM: Stress Perfusion Imaging to Guide the Management	Nothing to Disclose
Selvaraj	Senthil	Updates on Risk Factors for Cardiovascular	of Patients With Stable Coronary Artery Disease Walking Pace Is Inversely Associated With Risk of Death and Cardiovascular Disease. The Physicians 849217. Health Study	Nothing to Disclose
Selvaraj	Senthil	Disease Predicting the Future: Observations and Discoveries From Registries and Databases	Cardiovascular Disease: The Physicians' Health Study Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study	Nothing to Disclose
Selzman	Craig	FIT Clinical Decision Making: Heart Failure and	Complete Thrombotic Occlusion of TAVR Valve in Patient With	Nothing to Disclose
Semigran	Marc	Pulmonary Hypertension Deciphering Pulmonary Hypertension Due to Left Heart Disease: Have Hope Oh Ye Who Enter	Continuous Flow LVAD Debate: Combined Post- and Precapillary Pulmonary Hypertension Should Be Treated (Pro)	SALARY - MyoKardia
Semigran	Marc	The Nuts and Bolts of Pulmonary Hypertension	Panelist	SALARY - MyoKardia
Semigran	Marc	in Left Heart Disease The Nuts and Bolts of Pulmonary Hypertension	Treatment of Pulmonary Hypertension in HFrEF; What Are the	SALARY - MyoKardia
Semsarian	Christopher	in Left Heart Disease How Hypertrophic Cardiomyopathy Became A	Options? Panelist	Nothing to Disclose
		Contemporary Treatable Genetic Heart Disease		

		To a series		[
Semsarian	First Name Christopher	Session Title The Athlete with Heart Disease: A Case Based	Presentation Title Heart Disease and Risk in Athletic Individuals	Disclosures Nothing to Disclose
Semsarian	Christopher	Approach Advances in HCM, PPCM and Other	Non-Familial Hypertrophic Cardiomyopathy: Prevalence, Natural	Nothing to Disclose
Sen	Priyanka	Cardiomyopathies FIT Clinical Decision Making: Heart Failure and	History and Clinical Implications SynCardia Meets CardioMEMS: A Loeffler's Story	Nothing to Disclose
Sen	Sayan	Cardiomyopathies Late-Breaking Clinical Trials: Interventional	Primary Results of DEFINE-FLAIR: A Multi-Centre, Prospective,	CONSULTANT FEES/HONORARIA - Phillips
		-	International, Randomized, Blinded Comparison of Clinical Outcomes and Cost Efficiencies of iFR and FFR Decision-Making for Physiological Guided Coronary Revascularization	
Sen	Sayan	Coronary Physiology for the Assessment of Stable CAD	Panelist	CONSULTANT FEES/HONORARIA - Phillips
Sen	Sayan	Coronary Physiology for the Assessment of Stable CAD	Do We Need Cut-Off Points? FFR as a Continuum of Risk	CONSULTANT FEES/HONORARIA - Phillips
Sen	Sayan	Coronary Physiology and Microcirculation	Are FFR/iFR Valid in the Infarct Bed in Acute NSTEMI and STEMI?	CONSULTANT FEES/HONORARIA - Phillips
Sen	Sayan	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International	CONSULTANT FEES/HONORARIA - Phillips
Sen	Sayan	23. Interventional Cardiology: IVUS and	Multicentre iFR GRADIENT Registry Suggested Reviewer	CONSULTANT FEES/HONORARIA - Phillips
Senapati	Alpana	Intravascular Physiology Team 1 FIT Clinical Decision Making: Non-Invasive	Importance of Exercise Hemodynamics in Patients With Primary	Nothing to Disclose
Senecal	Conor	Imaging and Valvular Heart Disease Current Issues in Cardiovascular	Mitral Regurgitation Socioeconomic Environment and Digital Health Tool Usage and	Nothing to Disclose
Seneviratna	Aruni	Epidemiology, Disparities, and Safety Unusual Presentations of ACS	Outcomes: Is There a Digital Divide? Prevalence and Evolution of Sleep Disordered Breathing in Acute	Nothing to Disclose
Seneviratne	Sujith	Non Invasive Imaging: Prognostic Implications	Myocardial Infarction Computed Tomography Coronary Angiography Derived Plaque	SPEAKER'S BUREAU - Toshiba
		of CT Angiography	Morphology Predicts Major Adverse Cardiovascular Events: Insights From a 19,943 Patient Meta-Analysis	
Sengeløv	Morten	Innovative Use of Echocardiography	Presence of Post-Systolic Shortening by Tissue Doppler Imaging is an Independent Predictor of Heart Failure in Patients Following ST- Segment Elevation Myocardial Infarction	Nothing to Disclose
Senges	Jochen	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Increased Rate of Previous Stroke in Asymptomatic/Minimally Symptomatic Versus Symptomatic Patients With Newly Detected	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc
		and Notice Catasine incasarse	Atrial Fibrillation Worldwide: Results From the GLORIA-AF Registry	· namasocasas, mo
Senges	Jochen	Heart Failure and Cardiomyopathies: Heart	Representativeness of the Paradigm Heart Failure Population in Real Life	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc
Sengupta	Jay	Failure Is Just a Revolving Door Arrhythmias and Clinical EP: Devices 4	Real Lie An Investigation of the Evolution of Implantable Cardiac Monitors: A Comparison of Reveal XT-sup>TM-/sup> and Reveal LINQ-sup>TM-/sup> Based on Accuracy Measurements and Patient Outcomes Post-Device Implant	Nothing to Disclose
Sengupta	Jay	Arrhythmias and Clinical EP: Devices 4	High Battery Impedance in the Pacemaker Dependent Patient: Early Recognition and Collaborative Management of InSync III CRT-P Device Failures	Nothing to Disclose
Sengupta	Partho	Echocardiography: What is New in 2017	3D Printing and Holographic Images: Is the Future Here?	CONSULTANT FEES/HONORARIA - Intel; RESEARCH/RESEARCH GRANTS - Forest Labs.,Heart Test Labs,Hitachi-Aloka
Sengupta	Partho	The Forgotten Valves: Therapies for Triscuspid and Pulmonic Valve	Functional Tricuspid Regurgitation: Echocardiographic Imaging	CONSULTANT FEES/HONORARIA - Intel; RESEARCH/RESEARCH GRANTS - Forest Labs.,Heart Test Labs,Hitachi-Aloka
Sengupta	Partho	Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI	Fv-Hsp70 Protects Myocardium From Ischemic/Reperfusion Injury	CONSULTANT FEES/HONORARIA - Intel; RESEARCH/RESEARCH GRANTS - Forest Labs.,Heart Test Labs,Hitachi-Aloka
Sengupta	Partho	Innovative Use of Echocardiography	Concordance of Conventional 2D-Doppler Versus Speckle Tracking Echocardiography-Based Classification of Left Ventricular Diastolic Function	CONSULTANT FEES/HONORARIA - Intel; RESEARCH/RESEARCH GRANTS - Forest Labs.,Heart Test Labs,Hitachi-Aloka
Sengupta	Partho	Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment	Interactive Case Challenge in the Management of MR	CONSULTANT FEES/HONORARIA - Intel; RESEARCH/RESEARCH GRANTS - Forest Labs.,Heart Test Labs,Hitachi-Aloka
Sengupta	Partho	Complex Decisions in Mitral Valve Care: Individualizing Assessment, Diagnosis, and Treatment	Panelist	CONSULTANT FEES/HONORARIA - Intel; RESEARCH/RESEARCH GRANTS - Forest Labs.,Heart Test Labs,Hitachi-Aloka
Sengupta	Partho	Advances in Imaging to Assess Cardiotoxicity	^{99m} Tc-Duramycin Imaging Detects Doxorubicin Cardiac Injury Before Onset of Ventricular Dysfunction	CONSULTANT FEES/HONORARIA - Intel; RESEARCH/RESEARCH GRANTS - Forest Labs.,Heart Test Labs,Hitachi-Aloka
Sengupta	Partho	28. Non Invasive Imaging: Echo Team 4	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Intel; RESEARCH/RESEARCH GRANTS - Forest Labs.,Heart Test Labs,Hitachi-Aloka
Sengupta	Souma	Highlighted Original Research: Non Invasive Imaging and the Year in Review	The Association of High Risk Plaque Features and Non-Invasive Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography in Patients With Acute Chest Pain: Results From the ROMICAT II Trial	Nothing to Disclose
Senior	Roxy	Technical Advances in Transthoracic Echocardiography	Stroke Volume Determined Flow Reserve Does Not Predict the True Severity of Low-Flow Low-Gradient Aortic Stenosis and Is Not a Robust Marker of Contractile Reserve in Patients Undergoing Low- Dose Dobutamine Echocardiography	CONSULTANT FEES/HONORARIA - Bracco,Milan Italy,Lantheus Medical Imaging,Lantheus,Milwaukee,USA,Philips
Senior	Roxy	02. Acute and Stable Ischemic Heart Disease: Clinical Team 9	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Bracco, Milan Italy, Lantheus Medical Imaging, Lantheus, Milwaukee, USA, Philips
Seo	Hong-Seog	Novel Developments in Acute Coronary Syndromes	Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Diabetic Hypertensive Acute Myocardial Infarction Patients: Results From the Korea Acute Myocardial Infarction Registry (KAMIR)	Nothing to Disclose
Seo	Hong-Seog	Timely Topics in Acute Coronary Syndromes	Predictors of Mortality in Acute Myocardial Infarction Patients With Unprotected Left Main Coronary Artery Disease	Nothing to Disclose
Seo	Hong-Seog	Advances in Chronic Total Occlusion Intervention	Impact of Percutaneous Coronary Intervention for Chronic Total Occlusion Patients With Near-Normal Left Ventricular Function	Nothing to Disclose
Seo	Yong-Sung	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Smoking as a Key Predictor of CAD Among Asymptomatic and Extremely Low Coronary Artery Calcium Score Patients	Nothing to Disclose
Sepulveda	Pablo	02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Sequeira	Reginald	Clinical Team 6 FIT Clinical Decision Making: Non-Invasive	Subacute Stroke From Multiple Cardiac Papillary Fibroelastoma	Nothing to Disclose
Seres	Tamas	Imaging and Valvular Heart Disease Novel Echocardiographic Methods for Assessing Cardiac Function	With Post-Operative Recurrence Comparison of the Effects of Balloon Expandable and Self Expandable Transcatheter Aortic Valve Replacement on the Dimensions of the Mitral Valve Annulus and Mitral Regurgitation Severity	Nothing to Disclose
Sergie	Ziad	Technical Advances in Transthoracic Echocardiography	Severity Safety of Perflutren-Based Echocardiographic Contrast Agent Administration in the Setting of a Patent Foramen Ovale (PFO): A Multicenter Study Conducted in Tertiary Care Centers Based in the New York/Cinzago Metropolitan Areas	Nothing to Disclose



Last Name Serhal	First Name Maya	Session Title Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Presentation Title Family History of Arterial Disorders in Patients With Spontaneous Coronary Artery Dissection	Disclosures Nothing to Disclose
Sermer	Mathew	Congenital Heart Disease: To the Third Decade and Beyond	Twenty Year Trends in Maternal and Perinatal Complications in Pregnant Women With Heart Disease	Nothing to Disclose
Serrano	Carlos	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	High Non-High-Density Lipoprotein Cholesterol Levels Predict Enhanced Periprocedural Inflammatory Response Following Percutaneous Coronary Intervention in Stable Ischemic Heart Disease Patients	Nothing to Disclose
Serrano Antolin	Jose Maria	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years	Nothing to Disclose
Serruys	Patrick	Late-Breaking Clinical Trials: Interventional	Primary Results of DEFINE-FLAIR: A Multi-Centre, Prospective, International, Randomized, Blinded Comparison of Clinical Outcomes and Cost Efficiencies of IFR and FFR Decision-Making for Physiological Guided Coronary Revascularization	CONSULTANT FEES/HONORARIA - Abbott Laboratories, AstraZeneca Pharmaceuticals, Biotronik, Cardialysis B.V., GLG Research, MEDTRONIC, Q3 Medical, Qualimed, Sino Medical Sciences Technology Inc. Tianjin China, Société Europa Digital & amp; amp; Publishing, St Jude Medical, St. Jude Medical, Stentys France, Svelte Medical Systems Inc., Volcano Europe BVBA, Xeltis
Serruys	Patrick	The Evolution of Angioplasty 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	The Evolution of PCI	CONSULTANT FEES/HONORARIA - Abbott Laboratories, AstraZeneca Pharmaceuticals, Biotronik, Cardialysis B.V., GLG Research, MEDTRONIC, Q3 Medical, Qualimed, Sino Medical Sciences Technology Inc. Tiarjin China, Société Europa Digital & mp; pamp; Publishing, St Jude Medical, St. Jude Medical, Stentys France, Svelte Medical Systems Inc., Volcano Europe BVBA, Xeltis
Serruys	Patrick	Bioresorbable Vascular Scaffolds, Bioresorbable Polymer and Polymer Free Metallic DES	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Laboratories, AstraZeneca Pharmaceuticals, Biotronik, Cardialysis B. V., GLG Research, MEDTRONIC, Q3 Medical, Qualimed, Sino Medical Sciences Technology Inc. Tianjin China, Société Europa Digital & Description (St. Jude Medical, St. Jude Medical, Stentys France, Svelte Medical Systems Inc., Volcano Europe BVBA, Xeltis
Serruys	Patrick	Highlighted Original Research: Interventional Cardiology and the Year in Review	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	CONSULTANT FEES/HONORARIA - Abbott Laboratories, AstraZeneca Pharmaceuticals, Biotronik, Cardialysis B.V., GLG Research, MEDTRONIC, Q3 Medical, Qualimed, Sino Medical Sciences Technology Inc. Tianjin China, Société Europa Digital & amp; amp; Publishing, St Jude Medical, St. Jude Medical, Stentys France, Svelte Medical Systems Inc., Volcano Europe BVBA, Xeltis
Serruys	Patrick	Updates in Stable Ischemic Heart Disease	Coronary Calcification as a Mechanism of Plaque/Media Shrinkage: A Multimodality Intracoronary Imaging Study	CONSULTANT FEES/HONORARIA - Abbott Laboratories, AstraZeneca Pharmaceuticals, Biotronik, Cardialysis B.V.,GLG Research, MEDTRONIC, Q3 Medical, Qualimed, Sino Medical Sciences Technology Inc. Tianjin China, Société Europa Digital & amp; amp; Publishing, St Jude Medical, St. Jude Medical, Stentys France, Svelte Medical Systems Inc., Volcano Europe BVBA, Xeltis
Serruys	Patrick	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Differences and Level of Agreement in SYNTAX Score Assessment Between Site Operators and Angiographic Core Laboratory Readers: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - Abbott Laboratories, AstraZeneca Pharmaceuticals, Biotronik, Cardialysis B.V.,GLG Research, MEDTRONIC, Q3 Medical, Qualimed, Sino Medical Sciences Technology Inc. Tianjin China, Société Europa Digital & Bamp,amp; Publishing, St Jude Medical, St. Jude Medical, Stentys France, Svelte Medical Systems Inc., Volcano Europe BVBA, Xeltis
Serruys	Patrick	Coronary Intervention: Drug Eluting Stent and Scaffolds	Early, Late and Very Late Incidence of Bioresorbable Scaffold Thrombosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials and Observational Registries	CONSULTANT FEES/HONORARIA - Abbott Laboratories, AstraZeneca Pharmaceuticals, Biotronik, Cardialysis B.V., GLG Research, MEDTRONIC, Q3 Medical, Qualimed, Sino Medical Sciences Technology Inc. Tianjin China, Société Europa Digital & Bamp;amp; Publishing, St Jude Medical, St. Jude Medical, Stentys France, Svelte Medical Systems Inc., Volcano Europe BVBA, Xeltis
Serruys	Patrick	Refining PCI Technique and Outcomes	Treatment of Left Main Coronary Artery Disease in Patients With Diabetes: 3-Year Outcomes Comparing CABG and PCI With Everolimus-Eluting Stents From the EXCEL Study	CONSULTANT FEES/HONORARIA - Abbott Laboratories, AstraZeneca Pharmaceuticals, Biotronik, Cardialysis B.V.,GLG Research, MEDTRONIC, Q3 Medical, Qualimed, Sino Medical Sciences Technology Inc. Tianjin China, Société Europa Digital & amp.; amp; Publishing, St Jude Medical, St. Jude Medical, Stenty, France, Svelte Medical Systems Inc., Volcano Europe BVBA, Xeltis
Serruys	Patrick	Refining PCI Technique and Outcomes	Final 3-Year Clinical Outcomes of Patients Treated With Everolimus- Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents: A Propensity Score Comparison of Patients Enrolled in the Extend and SPIRIT Trials	CONSULTANT FEES/HONORARIA - Abbott Laboratories, AstraZeneca Pharmaceuticals, Biotronik, Cardialysis B.V.,GLG Research, MEDTRONIC, Q3 Medical, Qualimed, Sino Medical Sciences Technology Inc. Tianjin China, Société Europa Digital & amp.; amp; Publishing, St Jude Medical, St. Jude Medical, Stentys France, Svelte Medical Systems Inc., Volcano Europe BVBA, Xeltis
Serruys	Patrick	Refining PCI Technique and Outcomes	Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory Assessment: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - Abbott Laboratories, AstraZeneca Pharmaceuticals, Biotronik, Cardialysis B.V.,GLG Research, MEDTRONIC, Q3 Medical, Qualimed, Sino Medical Sciences Technology Inc. Tianjin China, Société Europa Digital & amp; amp; Publishing, St Jude Medical, St. Jude Medical, Stentys France, Sveite Medical Systems Inc., Volcano Europe BVBA, Xeltis
Serruys	Patrick	PCI Strategies and Outcomes Unique to Women	Sex Differences in Outcomes After Stenting or Bypass Surgery for Unprotected Left Main Disease	CONSULTANT FEES/HONORARIA - Abbott Laboratories, AstraZeneca Pharmaceuticals, Biotronik, Cardialysis B.V., GLG Research, MEDTRONIC, Q3 Medical, Qualimed, Sino Medical Sciences Technology Inc. Tianjin China, Société Europa Digital & amp., amp; Publishing, St Jude Medical, St. Jude Medical, Stentys France, Svelte Medical Systems Inc., Volcano Europe BVBA, Xeltis

Congress of				
Last Name Serruys	First Name Patrick	Session Title 26. Interventional Cardiology: Vascular Access and Complications Team 1	Presentation Title Suggested Reviewer	Disclosures CONSULTANT FEES/HONORARIA - Abbott Laboratories, AstraZeneca Pharmaceuticals, Biotronik, Cardialysis B.V., GLG Research, MEDTRONIC, Q3 Medical, Qualimed, Sino Medical Sciences Technology Inc. Tianjin China, Société Europa Digital & Discourage Construction Construction Construction Construction Medical, Stentys France, Sveite Medical Systems Inc., Volcano Europe BVBA, Xeltis
Sesay	Isata	Arrhythmias and Clinical EP: Devices 4	Implanted Cardiac Defibrillator and Pacemaker Lead Function in	Nothing to Disclose
Seslar	Stephen	08. Arrhythmias and Clinical EP:	Patient With Cardiac Amyloidosis Suggested Reviewer	Nothing to Disclose
Catarah Channa	Comon	Supraventricular/Ventricular Arrhythmias Team 2	Identificants Chalesian and Trends of 20 Day Deadainsians in	Nething to Displace
Setareh-Shenas	Saman	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Identifying the Etiologies and Trends of 30 Day Readmissions in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients: A National Population-Based Cohort Study Techniques and Outcomes of Bioresorbable Vascular Scaffolds in	Nothing to Disclose
Seth	Ashok	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	the Treatment of Coronary Bifurcation Lesions: One Scaffold Strategy Versus Two Scaffold Strategy	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific, MEDTRONIC, Meril life sciences
Seth	Milan	Considerations in Antiplatelet Therapy and in ACS	Readmission and Long-Term Mortality in Older Patients Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation
Seth	Milan	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Percutaneous Coronary Intervention in Patients With Recent Gastrointestinal Bleeding: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation
Seth	Milan	Percutaneous Coronary Intervention: Lessons From the Real World	Outcomes After Percutaneous Coronary Intervention Among Patients With a History of Transient Ischemic Attack or Cerebrovascular Accident: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation
Sethi	Abhishek	Arrhythmias and Clinical EP: Devices 4	An Investigation of the Evolution of Implantable Cardiac Monitors: A Comparison of Reveal XT-sup>TM LINQ ^{TM LINQ^{TM Each of Accuracy Measurements and Patient Outcomes Post-Device Implant}}	Nothing to Disclose
Sethi	Pooja	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	A Rare Cause of Syncope	Nothing to Disclose
Sethi	Pooja	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	One Should Not Presume Patients Lie, but Tests Might	Nothing to Disclose
Sethi	Rishi	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Obstructive Sleep Apnea and Diabetes Mellitus Have Synergistic Effects on Adverse Cardiac and Cerebrovascular Events in Patients Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Sethi	Sanjum	Interventional Cardiology: TAVR 1	The Use of Magnetic Resonance Imaging With Ferumoxytol for Annulus Sizing in Patients With Chronic Kidney Disease Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Seto	Arnold	Fellows Bootcamp: Interventional Basics	Access: Small and Large Bore, U/S	CONSULTANT FEES/HONORARIA - Medicure; RESEARCH/RESEARCH GRANTS - Acist Medical,Amgen Inc.,Bristol-Myers Squibb Company ,Osprey Medical,Volcano Corporation; SPEAKER'S BUREAU - Jannsen Pharmaceuticals
Seto	Arnold	The Best Coronary and Peripheral Interventional Challenging Cases	ACC Panelist	CONSULTANT FEES/HONORARIA - Medicure; RESEARCH/RESEARCH GRANTS - Acist Medical,Amgen Inc.,Bristol-Myers Squibb Company ,Osprey Medical,Volcano Corporation; SPEAKER'S BUREAU - Jannsen Pharmaceuticals
Seto	Arnold	CAD in Unique Patient Populations	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Medicure; RESEARCH/RESEARCH GRANTS - Acist Medical,Amgen Inc.,Bristol-Myers Squibb Company, Osprey Medical,Volcano Corporation; SPEAKER'S BUREAU - Jannsen Pharmaceuticals
Seto	Arnold	23. Interventional Cardiology: IVUS and Intravascular Physiology Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Medicure; RESEARCH/RESEARCH GRANTS - Acist Medical, Amgen Inc., Bristol-Myers Squibb Company ,Osprey Medical, Volcano Corporation; SPEAKER'S BUREAU - Jannsen Pharmaceuticals
Setty	Natraj	Timely Topics in Acute Coronary Syndromes	Acute Coronary Syndrome in Retroviral Positive Patients Challenges and Dilemmas With Special Emphasis on Coronary Revascularization	
Sever	Peter	Opening Session and the Joint American College of Cardiology and Journal of American College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture	Primary Results of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial	CONSULTANT FEES/HONORARIA - Amgen Inc.; RESEARCH/RESEARCH GRANTS - Pfizer
Sewani	Asif	Arrhythmias and Clinical EP: Devices 3	Importance of Right Ventricular Lead Positioning in Determining Outcomes of Cardiac Resynchronization Therapy	Nothing to Disclose
Sexson	Kristen		Stress Myocardial Perfusion Imaging in Anomalous Aortic Origin of a Coronary Artery: Results Following a Standardized Approach	Nothing to Disclose
Sfendouraki	Elisavet	Advances in HCM, PPCM and Other Cardiomyopathies	Unique Characteristics of the Mitral Valve in Patients With Hypertrophic Cardiomyopathy Have Emerged Using Real-Time Three Dimensional Transesophageal Echocardiography	Nothing to Disclose
Shacham	Yacov	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Absence of Clinical Triggering in Diabetic Patients With ST-Segment Elevation Myocardial Infarction Predicts Multiple Vessel Coronary Disease and Is Associated With Increased Mortality	Nothing to Disclose
Shacham	Yacov	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Incidence and Outcomes of Early Left Ventricular Thrombus Formation Following ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention	Nothing to Disclose
Shafer	Keri	Personalized Skills Center: Hands-On Simulation - Congenital Heart Disease	Congenital Heart Disease	Nothing to Disclose
Shafer	Keri	Personalized Skills Center: Hands-On Simulation - Congenital Heart Disease	Congenital Heart Disease	Nothing to Disclose
Shafer	Keri	Engage @ ACC.17 Studio: Simulation I Congenital Heart Disease	Simulation Faculty	Nothing to Disclose
Shah	Ajay	Featured Clinical Research I	MR-INFORM: Stress Perfusion Imaging to Guide the Management of Patients With Stable Coronary Artery Disease	Nothing to Disclose
Shah	Ajay	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Echocardiographic Estimation of Mean Pulmonary Artery Pressure: A Comparison of Different Approaches to Predict Pulmonary Hypertension	Nothing to Disclose
Shah	Alpesh	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Therapeutic Dilemma in a Case With Coronary Artery Aneurysm and Large Thrombus Burden	Nothing to Disclose
Shah	Amil	Young Investigator Awards Competition: Clinical Investigations	Impaired Coronary Flow Reserve Is Associated With Diastolic Dysfunction and HFpEF Outcomes in Patients Without Overt CAD	CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals
Shah	Amil	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Readmissions for Patients Discharged With Acute Decompensated Heart Failure and Reduced Versus Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study	CONSULTANT FEES/HONORARIA - Novartis Pharmaceuticals
Shah	Amit	Young Investigator Awards Competition: Clinical Investigations	Feasibility of a Smartphone-Delivered Cardiac Rehabilitation Program Amongst Veterans	Nothing to Disclose

and the same					
Last Name	First Name	Session Title	Presentation Title	Disclosures	
Shah	Amit	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Inflammatory Response to Mental Stress and Mental Stress Induced Myocardial Ischemia	Nothing to Disclose	
Shah	Amit	Diabetes and Other Issues in Cardiovascular Prevention	Blood Pressure Indices and Cardiovascular Mortality in Diabetics and Non Diabetics	Nothing to Disclose	
Shah	Anoop	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Coronary Artery Aneurysm in a Patient With Systemic Lupus Erythematosus	Nothing to Disclose	
Shah	Anoop	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Optimal Risk Stratification Pathways for Patients With Suspected Acute Coronary Syndrome	CONSULTANT FEES/HONORARIA - Receive Abbott Diagnostics	d honoraria from
Shah	Anoop	Syndrome Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Age and the Effectiveness of Risk Stratification and Diagnostic Thresholds for Myocardial Infarction With High-Sensitivity Cardiac	CONSULTANT FEES/HONORARIA - Receive Abbott Diagnostics	d honoraria from
Shah	Anoop	Acute Coronary Syndromes, Diagnosis,	Troponin Is It Safe to Use High-Sensitivity Cardiac Troponin T to Rule out	CONSULTANT FEES/HONORARIA - Receive	d honoraria from
Shah	Anoop	Management and Outcomes Blips, Trops, and Chips: New Ways to Diagnose CAD	Myocardial Infarction at Presentation? High-Sensitivity Cardiac Troponin I and the Diagnosis of Obstructive Coronary Artery Disease in Patients With Suspected Stable Angina	Abbott Diagnostics Nothing to Disclose	
Shah	Arpit	The Art and the Science of Decision Making in	The Decision Case Presentation: New-onset Atrial Fibrillation Following PCI with DES	Nothing to Disclose	
Shah	Bimal	Coronary Artery Disease Fibrillatory Arrhythmias: Outcomes With	Rates of Oral Anticoagulant Use, While Improving Over Time,	SALARY - Premier	
Shah	Binita	Contemporary Practice Complications of PCI: Case Reviews	Remain Low Among Hospitalized Patients With Atrial Fibrillation Case Presentation: STEMI Gone Wrong	CONSULTANT FEES/HONORARIA - Philips \	
Shah	Binita	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era:	RESEARCH/RESEARCH GRANTS - Siemans CONSULTANT FEES/HONORARIA - Philips \ RESEARCH/RESEARCH GRANTS - Siemans	/olcano;
Shah	Binita	Interventional Cardiology: TAVR 2	Insights From the PARIS Study Short- and Mid-Term Outcomes After Transcatheter Aortic Valve Replacement in Patients With Renal Insufficiency Not on	CONSULTANT FEES/HONORARIA - Philips N RESEARCH/RESEARCH GRANTS - Siemans	
Shah	Binita	Anti-Platelet Therapies: Always a Sticky Topic	Hemodialysis ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Philips \	
Shah	Binita	02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Siemans CONSULTANT FEES/HONORARIA - Philips \ RESEARCH/RESEARCH GRANTS - Siemans	/olcano;
Shah	Dipak	Clinical Team 9 Arrhythmias and Clinical EP: Devices 4	Long-Term Use of the Wearable Cardiovertor Defibrillator in ICD Explant Patients	CONSULTANT FEES/HONORARIA - Zoll; SP BUREAU - Bristol-Myers Squibb Company ,Jar	EAKER'S
Shah	Dipan	Clinical Applications of Cardiac MRI in 2017	Co-Chair	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Abbott V	/ascular,Astellas
Shah	Dipan	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Diffuse Interstitial and Regional Replacement Fibrosis in Chronic Primary Mitral Regurgitation: Insights From Cardiovascular Magnetic	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Abbott \ Pharmaceuticals	/ascular,Astellas
Shah	Dipan	Non Invasive Imaging: MR Characterization	Resonance Elevated Myocardial Extracellular Volume Fraction (ECV) and Its	RESEARCH/RESEARCH GRANTS - Abbott V	/ascular,Astellas
Shah	Dipan	and Function Valvular Heart Disease: Mitral Valve Disease	Prognostic Significance in Diabetic Individuals Inter-Study Reproducibility of Mitral Regurgitation Quantitation Using	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Abbott V	/ascular,Astellas
Shah	Dipan	Non Invasive Imaging: MR Structure and	Cardiac Magnetic Resonance Imaging Quantitative Measurements on Cardiac Magnetic Resonance to	Pharmaceuticals RESEARCH/RESEARCH GRANTS - Abbott V	/ascular,Astellas
Shah	Harshil	Valuvular Heart Disease Arrhythmias and Clinical EP: Basic 1	Differentiate Benign Versus Malignant Masses: A Pilot Study Atrial Fibrillation in Patients With Non-STEMI: Insights From a	Pharmaceuticals Nothing to Disclose	
Shah	Harshil	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	National Database Predictors of 90-Day Readmission and In Hospital Mortality Amongst Patients Undergoing Percutaneous Coronary	Nothing to Disclose	
Shah	Harshil	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Interventions: Insights From a National Database Transcatheter Mitral Valve Repair (Mitraclip) in United States: Etiologies and Predictors of Readmission and In-Hospital Mortality	Nothing to Disclose	
Shah	Harshil	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	From the Nationwide Readmission Database Transcatheter Mitral Valve Repair (Mitra Clip) in United States: Length of Stay and Cost of Hospitalizations From the Nationwide	Nothing to Disclose	
Shah	Harshil	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Readmission Database Impact of Cardiac Devices on Readmission and Short Term Mortality in Patients With Heart Failure With Reduced Ejection	Nothing to Disclose	
Shah	Harshil	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Fraction: A Nationwide Study CHADS ₂ and CHA ₂ DS ₂ VASc Scores as Predictors of Length of Stay and Cost of Care in Hospitalised Atrial Fibrillation	Nothing to Disclose	
Shah	Kevin	Innovations in Practice Management and	Patients: Insights From a National Database Social Media Following and Cardiology Journal Impact Factor	Nothing to Disclose	
Shah	Kevin	Social Media	An Atypical Presentation of a Common Cardiomyopathy	Nothing to Disclose	
Shah	Keyur	Pulmonary Hypertension Arrhythmias and Clinical EP: Devices 4	Implanted Cardiac Defibrillator and Pacemaker Lead Function in	CONSULTANT FEES/HONORARIA - Care Do	
Shah	Mahek	Acute Heart Failure: Evaluating Strategies to	Patient With Cardiac Amyloidosis Seasonal and Regional Variations in Heart Failure Admissions and	RESEARCH/RESEARCH GRANTS - Alnylam, SPEAKER'S BUREAU - Amgen Inc. Nothing to Disclose	
Shah	Mahek	Prevent Readmissions Cardiac Arrest, Diabetes, and Other High Risk	Mortality in the United States Impact of Atrial Fibrillation on Outcomes in Patients Hospitalized	Nothing to Disclose	
Shah	Manan	Features of Patients With Acute Coronary Syndrome FIT Clinical Decision Making: Non-Invasive	With ST-Segment Elevation Myocardial Infarction Acute Echo-Guided Management of Cardiogenic Shock After	Nothing to Disclose	
Shah	Maully	Imaging and Valvular Heart Disease Congenital Heart Disease: Novel Insights in	Anterior Myocardial Infarction Complicated by Dynamic Left Ventricular Outflow Tract Obstruction Rhythm Abnormalities in Children and Young Adults With Marfan	RESEARCH/RESEARCH GRANTS - Medtron	ic, Inc
Shah	Moneal	Pediatric Cardiology FIT Clinical Decision Making: Non-Invasive	Syndrome Cardiac Amyloidosis Masquerading as Severe Low-Flow, Low-	Nothing to Disclose	-,
Shah	Nikhil	Imaging and Valvular Heart Disease Valvular Heart Disease: Aortic Stenosis	Gradient, Low-Ejection Fraction Aortic Stenosis: "All That Glitters Is Not Gold" Factors Associated With Rapid Progression of Aortic Stenosis in	Nothing to Disclose	
			Patients With Bicuspid Aortic Valve: A Single Center Retrospective Study	ů	
Shah	Nilay	Young Investigator Awards Competition: Outcomes Research	A Comparison of Kidney Function Decline in Atrial Fibrillation Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin	Nothing to Disclose	
Shah	Nishant	FIT Clinical Decision Making Reviewers 4	ACC FIT Clinical Decision Making Reviewer	OWNERSHIP INTEREST/PARTNERSHIP/PR Electric	
Shah	Palak	13. Heart Failure and Cardiomyopathies: Clinical Team 7	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Haemor Corp,HeartWare	netics
Shah	Parth	Advances in Cholesterol Measurement and Management	10-Year Cardiovascular Risk Reduction, Efficacy and Safety of Alirocumab and Evolocumab, in Addition to Maximal Tolerated Cholesterol Lowering Therapy: Post-Commercialization Study	Nothing to Disclose	
Shah	Pinak	Interventional Cardiology: TAVR 1	Impact of Flow, Gradient, and Left Ventricular Function on Outcomes After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Edward Jude Medical	s Lifesciences,St.
Shah	Prediman	Kanu and Docey Chatterjee Lecture and Seminal Talks in Heart Failure: I Wanna New Drug: Updated Heart Failure Guidelines	Introduction of Dr. Jessup as the Kanu and Docey Chatterjee Lecturer	RESEARCH/RESEARCH GRANTS - Cardiova	ax

Last Name First Name Shah Predima Shah Predima Shah Priyank Shah Rahmar Shah Rahmar Shah Rahmar Shah Rahmar Shah Rahmar Shah Raijan Shah Rasi Shah Ravi Shah Ravi Shah Ravi Shah Ravi Shah Sachin Shah Sachin Shah Sangeet Shah Sangeet Shah Sanjiv	man / h man / h man / h nk F c c c c c c c c	Are We There Yet? Update on Trials Testing New Therapeutics for Prevention of ASCVD Advances in Lipid Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Ventricular Arrhythmias and Sudden Death Prevention Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease: Therapy Team 1 Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Epidemiology, Disparities, and Safety Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: MR Scar and Perfusion	Presentation Title Co-Chair Treatment Effects of Alirocumab as an Add-On to Maximally Tolerated Dose of Statin in Patients With Heterozygous Farmilial Hypercholesterolemia and/or Atherosclerotic Cardiovascular Disease 33 Year Old Female With Sudden Cardiac Arrest An Updated Comprehensive Meta-Analysis Comparing Drug-Eluting Stents With Bare Metal Stents in Saphenous Vein Graft Interventions Shorter- Versus Longer-Duration Triple Antithrombotic Therapy for Patients With Coronary Stents Who Require Oral Anticoagulation: An Updated Comprehensive Meta-Analysis Prophylactic Defibrillator Implantation in Patients With Non-Ischemic Cardiomyopathy: An Updated Comprehensive Meta-Analysis of Randomized Controlled Trials An Updated Comprehensive Meta-Analysis of Randomized Trials Evaluating the Efficacy of Stem Cell Therapy for Refractory Angina Proof Is in the Paclitaxel: Catheter Directed Intracoronary Paclitaxel as Salvage Therapy for Refractory Cardiac Allograft Vasculopathy Suggested Reviewer Lipid Abnormalities in Young Patients With Myocardial Infarction Women Who Experience Myocardial Infarction at Young Age Have Worse Survival Compared With Men Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in	Nothing to Disclose
Shah Priyank Shah Rahmar Shah Rahmar Shah Rahmar Shah Rahmar Shah Rajan Shah Rashme Shah Ravi Shah Ravi Shah Ravi Shah Ravi Shah Shah Ravi Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sachin	man / Finan /	Advances in Lipid Management FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Ventricular Arrhythmias and Sudden Death Prevention Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine 03. Acute and Stable Ischemic Heart Disease: Therapy Team 1 Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: MR Scar and Perfusion	Tolerated Dose of Statin in Patients With Heterozygous Familial Hypercholesterolemia and/or Atherosclerotic Cardiovascular Disease 33 Year Old Female With Sudden Cardiac Arrest An Updated Comprehensive Meta-Analysis Comparing Drug-Eluting Stents With Bare Metal Stents in Saphenous Vein Graft Interventions Shorter- Versus Longer-Duration Triple Antithrombotic Therapy for Patients With Coronary Stents Who Require Oral Anticoagulation: An Updated Comprehensive Meta-Analysis Prophylactic Defibrillator Implantation in Patients With Non-Ischemic Cardiomyopathy: An Updated Comprehensive Meta-Analysis of Randomized Controlled Trials An Updated Comprehensive Meta-Analysis of Randomized Trials Evaluating the Efficacy of Stem Cell Therapy for Refractory Angina Proof Is in the Paclitaxel: Catheter Directed Intracoronary Paclitaxel as Salvage Therapy for Refractory Cardiac Allograft Vasculopathy Suggested Reviewer Lipid Abnormalities in Young Patients With Myocardial Infarction Women Who Experience Myocardial Infarction at a Young Age Have Worse Survival Compared With Men	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - GILEAD Sciences Nothing to Disclose
Shah Rahmar Shah Rahmar Shah Rahmar Shah Rahmar Shah Rajan Shah Ravi Shah Ravi Shah Ravi Shah Ravi Shah Ravi Shah Sachin Shah Sachin Shah Sachin Shah Sangeet Shah Sangeet Shah Sangeet Shah Sangiv	anan Finan F	Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Ventricular Arrhythmias and Sudden Death Prevention Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease: Therapy Team 1 Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Innovations in Cardiovascular Epidemiology, Disparities, and Safety Innovations in Cardiovascular Risk Assessment and Reduction	33 Year Old Female With Sudden Cardiac Arrest An Updated Comprehensive Meta-Analysis Comparing Drug-Eluting Stents With Bare Metal Stents in Saphenous Vein Graft Interventions Shorter- Versus Longer-Duration Triple Antithrombotic Therapy for Patients With Coronary Stents Who Require Oral Anticoagulation: An Updated Comprehensive Meta-Analysis Prophylactic Defibrillator Implantation in Patients With Non-Ischemic Cardiomyopathy: An Updated Comprehensive Meta-Analysis of Randomized Controlled Trials An Updated Comprehensive Meta-Analysis of Randomized Trials Evaluating the Efficacy of Stem Cell Therapy for Refractory Angina Proof Is in the Pacilitaxel: Catheter Directed Intracoronary Pacilitaxel as Salvage Therapy for Refractory Cardiac Allograft Vasculopathy Suggested Reviewer Lipid Abnormalities in Young Patients With Myocardial Infarction Women Who Experience Myocardial Infarction at a Young Age Have Worse Survival Compared With Men	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - GILEAD Sciences Nothing to Disclose
Shah Rahmar Shah Rahmar Shah Rahmar Shah Rajan Shah Rashme Shah Ravi Shah Ravi Shah Ravi Shah Ravi Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sachin	nan Fi	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Ventricular Arrhythmias and Sudden Death Prevention Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease. and Vascular Medicine 03. Acute and Stable Ischemic Heart Disease: Therapy Team 1 Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Imnovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: MR Scar and Perfusion	Stents With Bare Metal Stents in Saphenous Vein Graft Interventions Shorter- Versus Longer-Duration Triple Antithrombotic Therapy for Patients With Coronary Stents Who Require Oral Anticoagulation: An Updated Comprehensive Meta-Analysis Prophylactic Defibrillator Implantation in Patients With Non-Ischemic Cardiomyopathy: An Updated Comprehensive Meta-Analysis of Randomized Controlled Trials An Updated Comprehensive Meta-Analysis of Randomized Trials Evaluating the Efficacy of Stem Cell Therapy for Refractory Angina Proof Is in the Paclitaxel: Catheter Directed Intracoronary Paclitaxel as Salvage Therapy for Refractory Cardiac Allograft Vasculopathy Suggested Reviewer Lipid Abnormalities in Young Patients With Myocardial Infarction Women Who Experience Myocardial Infarction at a Young Age Have Worse Survival Compared With Men	Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - GILEAD Sciences Nothing to Disclose
Shah Rahmar Shah Rajan Shah Rajan Shah Rashme Shah Ravi Shah Ravi Shah Ravi Shah Ravi Shah Ravi Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sangeet	mee C C E E E E E E E E E E E E E E E E E	Ventricular Arrhythmias and Sudden Death Prevention Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells The Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine 33. Acute and Stable Ischemic Heart Disease: Therapy Team 1 Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: MR Scar and Perfusion	Shorter-Versus Longer-Duration Triple Antithrombotic Therapy for Patients With Coronary Stents Who Require Oral Anticoagulation: An Updated Comprehensive Meta-Analysis Prophylactic Defibrillator Implantation in Patients With Non-Ischemic Cardiomyopathy: An Updated Comprehensive Meta-Analysis of Randomized Controlled Trials An Updated Comprehensive Meta-Analysis of Randomized Trials Evaluating the Efficacy of Stem Cell Therapy for Refractory Angina Salvage Therapy for Refractory Cardiac Allograft Vasculopathy Suggested Reviewer Lipid Abnormalities in Young Patients With Myocardial Infarction Women Who Experience Myocardial Infarction at a Young Age Have Worse Survival Compared With Men Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in	Nothing to Disclose Nothing to Disclose Nothing to Disclose OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - GILEAD Sciences Nothing to Disclose
Shah Rahmar Shah Rajan Shah Rashme Shah Ravi Shah Ravi Shah Ravi Shah Ravi Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sangeet	mee () () () () () () () () () (Prevention Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicinie 33. Acute and Stable Ischemic Heart Disease: Therapy Team 1 Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: MR Scar and Perfusion	Prophylactic Defibrillator Implantation in Patients With Non-Ischemic Cardiomyopathy: An Updated Comprehensive Meta-Analysis of Randomized Controlled Trials An Updated Comprehensive Meta-Analysis of Randomized Trials Evaluating the Efficacy of Stem Cell Therapy for Refractory Angina Proof Is in the Paclitaxel: Catheter Directed Intracoronary Paclitaxel as Salvage Therapy for Refractory Cardiac Allograft Vasculopathy Suggested Reviewer Lipid Abnormalities in Young Patients With Myocardial Infarction Women Who Experience Myocardial Infarction at a Young Age Have Worse Survival Compared With Men Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in	Nothing to Disclose Nothing to Disclose OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - GILEAD Sciences Nothing to Disclose
Shah Rajan Shah Rashme Shah Ravi Shah Ravi Shah Ravi Shah Ravi Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sangeet Shah Sangeet	C C C C C C C C C C	Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells Time: The Ongoing Promise of Stem Cells Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine 33. Acute and Stable Ischemic Heart Disease: Therapy Team 1 Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: MR Scar and Perfusion Non Invasive Imaging: MR Scar and Perfusion	An Updated Comprehensive Meta-Analysis of Randomized Trials Evaluating the Efficacy of Stem Cell Therapy for Refractory Angina Proof Is in the Paclitaxel: Catheter Directed Intracoronary Paclitaxel as Salvage Therapy for Refractory Cardiac Allograft Vasculopathy Suggested Reviewer Lipid Abnormalities in Young Patients With Myocardial Infarction Women Who Experience Myocardial Infarction at a Young Age Have Worse Survival Compared With Men Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in	Nothing to Disclose OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - GILEAD Sciences Nothing to Disclose
Shah Rashme Shah Ravi Shah Ravi Shah Ravi Shah Ravi Shah Ravi Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sangeet Shah Sangeet	mee C I I I I I I I I I I I I I I I I I I I	Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicinie 03. Acute and Stable Ischemic Heart Disease: Therapy Team 1 Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: MR Scar and Perfusion Non Invasive Imaging: MR Scar and Perfusion	as Salvage Therapy for Refractory Cardiac Allograft Vasculopathy Suggested Reviewer Lipid Abnormalities in Young Patients With Myocardial Infarction Women Who Experience Myocardial Infarction at a Young Age Have Worse Survival Compared With Men Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - GILEAD Sciences Nothing to Disclose
Shah Ravi Shah Ravi Shah Ravi Shah Ravi Shah Ravi Shah Sachin Shah Sachin Shah Sachin Shah Sangeet Shah Sangeet Shah Sangeet Shah Sangiv	mee () () () () () () () () () (03. Acute and Stable Ischemic Heart Disease: Therapy Team 1 Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: MR Scar and Perfusion	Lipid Abnormalities in Young Patients With Myocardial Infarction Women Who Experience Myocardial Infarction at a Young Age Have Worse Survival Compared With Men Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in	Sciences Nothing to Disclose
Shah Ravi Shah Ravi Shah Ravi Shah Ravi Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sangeet Shah Sangeet		Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: MR Scar and Perfusion	Women Who Experience Myocardial Infarction at a Young Age Have Worse Survival Compared With Men Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in	Nothing to Disclose
Shah Ravi Shah Ravi Shah Ravi Shah Sachin Shah Sachin Shah Sachin Shah Sangeet Shah Sangeet Shah Sanjiv		Current Issues in Cardiovascular Epidemiology, Disparities, and Safety Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: MR Scar and Perfusion	Have Worse Survival Compared With Men Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in	Nothing to Disclose
Shah Ravi Shah Ravi Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sangeet Shah Sangeet Shah Sangeet	in F	Innovations in Cardiovascular Risk Assessment and Reduction Non Invasive Imaging: MR Scar and Perfusion	Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in	
Shah Ravi Shah Ravi Shah Sachin Shah Sachin Shah Sachin Shah Sangeet Shah Sangeet Shah Sangeet	E	and Reduction Non Invasive Imaging: MR Scar and Perfusion		Nothing to Disclose
Shah Ravi Shah Sachin Shah Sachin Shah Sachin Shah Sachin Shah Sangeet Shah Sangeet Shah Sangeet	in F In II In F	5 5	African Americans: The Jackson Heart Study	-
Shah Sachin Shah Sachin Shah Sachin Shah Sangeet Shah Sangeet Shah Sangeet	in F in I in F		Doxorubicin-Associated Cardiac Tissue Remodeling in Breast Cancer Patients: A Cardiac Magnetic Resonance Study	Nothing to Disclose
Shah Sachin Shah Sachin Shah Sangeet Shah Sangeet Shah Sangeet	E 	Unusual Presentations of ACS	Type 2 Myocardial Infarction in Young Patients Portends a Worse Long-Term Survival	Nothing to Disclose
Shah Sachin Shah Sangeet Shah Sangeet Shah Sangiv	in II Ii		Challenges in Ibrutinib Associated Atrial Fibrillation	Nothing to Disclose
Shah Sangeet Shah Sangiv	in F		Does the Convergent Ablation Procedure Affect Left Atrial	Nothing to Disclose
Shah Sangeet Shah Sanjiv	F	Improving Outcomes With Ablation FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Contractile Function? Expanding the Role of Dexrazoxane for Cardioprotection: Use in a Patient With Pre-Existing Systolic Dysfunction and No Prior	Nothing to Disclose
Shah Sanjiv	eeta (Core Curriculum: Imaging the Heart: Choosing	Anthracycline Exposure Cases of Cardiac Mass Assessment: Fundamentalas of Echo and	Nothing to Disclose
Shah Sanjiv		Wisely Test Yourself with Questions: Guidelines	MRI Faculty	Nothing to Disclose
	M	Module 1: Valvular	•	
Shah Sanjiv		Making Progress in Understanding Heart Failure	Associations of HIV Related Factors With Adjudicated Heart Failure (HF) in an Electronic Cohort of HIV-Infected (HIV+) Persons	CONSULTANT FEES/HONORARIA - American Board of Internal Medicine AstraZeneca Pharmaceuticals,Bayer,Merck,Novartis; RESEARCH/IRESEARCH GRANTS - Actelion,American Heart Association,National Institutes of Health; SPEAKER'S BUREAU - Pulmonary Hypertension Association
			Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study	CONSULTANT FEES/HONORARIA - American Board of Internal Medicine, AstraZeneca Pharmaceuticals, Bayer, Merck, Novartis; RESEARCH/RESEARCH GRANTS - Actelion, American Heart Association, National Institutes of Health, SPEAKER'S BUREAU - Pulmonary Hypertension Association
Shah Sanjiv		Emerging Developments in HFpEF and Arryhthmias	Influence of Left Ventricular Ejection Fraction on Cause-Specific Mortality in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial	CONSULTANT FEES/HONORARIA - American Board of Internal Medicine, AstraZeneca Pharmaceuticals, Bayer, Merck, Novartis; RESEARCH/RESEARCH GRANTS - Action, American Heart Association, National Institutes of Health; SPEAKER'S BUREAU - Pulmonary Hypertension Association
Shah Sanjiv			Atrial Fibrillation (AF) and Atrial Flutter (AFL) Prevalence and Characteristics for Persons With Human Immunodeficiency Virus (HIV+) and Matched Uninfected Controls	CONSULTANT FEES/HONORARIA - American Board of Internal Medicine, AstraZeneca Pharmaceuticals, Bayer, Merck, Novartis; RESEARCH/RESEARCH (RANTS - Action, American Heart Association, National Institutes of Health; SPEAKER'S BUREAU - Pulmonary Hypertension Association
Shah Shailee	ee \		Comparison of Non-Surgical and Surgical Therapy for Prosthetic Valve Endocarditis: A Propensity Score-Adjusted Study	Nothing to Disclose
Shah Shilpa			Standardization of Peri-Operative Management After Norwood Operation Has Not Improved 1 Year Outcomes	Nothing to Disclose
Shah Shivang			Characterization of Pulmonary Vein Reconnection Post Cryoballoon	Nothing to Disclose
Shah Srushti			Ablation Angiographic Phenotype and Clinical Outcomes of Patients With	Nothing to Disclose
Shah Srushti	nti (Revascularization and Outcomes Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Malignancy Undergoing PCI Synergistic Effects of Coronary Calcification and Inflammation on Risks for Adverse Cardiovascular Events After PCI: Results From a	Nothing to Disclose
Shah Srushti	nti (Optimizing the Care of ACS Patients	Large Single-Center Registry Underutilization of High Intensity Statins in a Contemporary High	Nothing to Disclose
Shah Srushti	nti I	Interventional Complexity and Complications	Risk PCI Population Prediction of Acute Kidney Injury in Patients Undergoing Coronary	Nothing to Disclose
Shah Srushti		Interventional Cardiology: PCI in Complex	Intervention Using Calculation of Serum Osmolality	Nothing to Disclose
	F	Patients	and Males After Percutaneous Coronary Intervention	-
Shah Sunay	ŀ		Case Presentation by FIT: Complex Coronary Revascularization Requiring Hemodynamic Support	Nothing to Disclose
Shah Tara		FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Pitfalls in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy: Importance of Epicardial Voltage Mapping	Nothing to Disclose
Shah Tina	[Distinct Phenotypes in HFpEF: Beyond Ejection Fraction	Case Presentation	Nothing to Disclose
Shah Tina	[Distinct Phenotypes in HFpEF: Beyond	Case Presentation	Nothing to Disclose
Shah Tina		Ejection Fraction Engage @ ACC.17 Studio: FIT Jeopardy Battle	Moderator	Nothing to Disclose
Shah Zubair	C	of the State Chapters I	Boron Based Hgf Memetic Molecule Has Cardioprotective Role	Nothing to Disclose
Shah Zubair	ir /	Clinical Research Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Against Ischemia-Reperfusion Injury Timely Use of Right Heart Catheterization Is Associated With Reduced In-Hospital Mortality in Patients With Congestive Heart Failure: Insight From the United States National Inpatient Sample	Nothing to Disclose

and a				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Shah	Zubair	Updates on Risk Factors for Cardiovascular Disease	Prevalence of Abnormal Ankle Brachial Index in Obese and Non- Obese Subjects, and Association of Abnormal Ankle Brachial Index	Nothing to Disclose
		Diocaco	With All-Cause and Cardiovascular Mortality in These Groups:	
			Results From National Health and Nutrition Examination Survey	
Shah	Zubair	Diabetes and Other Issues in Cardiovascular	1999-2000 Association of Ankle Brachial Index and Hemoglobin A1c With All-	Nothing to Disclose
Silali	Zubali	Prevention	Cause and Cardiovascular Mortality: Results From the National	Nothing to Disclose
			Health and Nutrition Examination Survey 1999 to 2000	
Shahanavaz	Shabana	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Safety and Feasibility of Melody Transcatheter Pulmonary Valve	Nothing to Disclose
		Heart Disease and the Year in Review	Replacement in the Native Right Ventricular Outflow Tract: A Multicenter Study	
shaheen	sameh	Variations in Management of STEMI:	Co-Chair	Nothing to Disclose
		International Perspectives From the Egyptian		
		Society of Cardiology, Pakistan Cardiac Society, and American College of Cardiology		
Shahian	David	Featured Clinical Research II: Interventional	Real-World Comparative Effectiveness of Transcatheter Versus	Nothing to Disclose
			Surgical Aortic Valve Replacement in the United States: An Analysis	
Shahreyar	Muhammad	Revascularization and Myocardial Preservation	From Two US Registries Linked to Medicare Data An Updated Comprehensive Meta-Analysis Comparing Drug-Eluting	Nothing to Disclose
Silailleyai	iviunammau	in Acute and Stable Ischemic Heart Disease	Stents With Bare Metal Stents in Saphenous Vein Graft	Nothing to Disclose
			Interventions	
Shahreyar	Muhammad	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Incremental Value of Estimated Glomerular Filtration Rate in Improving Stroke Risk Stratification in Patients With and Without	Nothing to Disclose
		improving Outcomes With Abiation	Atrial Fibrillation Considered to Be Low Risk by	
			CHA ₂ DS ₂ VASc Score	
Shahreyar	Muhammad	Antithrombotic Therapy in Ischemic Heart	Shorter- Versus Longer-Duration Triple Antithrombotic Therapy for	Nothing to Disclose
		Disease	Patients With Coronary Stents Who Require Oral Anticoagulation: An Updated Comprehensive Meta-Analysis	
Shaikh	Shakil		The Way to a Man's Heart: Through His Quadriceps	Nothing to Disclose
01-71	Ob a Lit	Pulmonary Hypertension		-
Shaikh	Shakil	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	A Rare Cause of Myocardial Injury in a Patient With Systemic Lupus Erythematosus: Hydroxychloroquine Induced Cardiomyopathy	Nothing to Disclose
<u> </u>	<u> </u>	aionary rryportension	2. ya.aatooda. Tryaroxyanioroquine induced Cardiomyopathy	
Shaikh	Shakil	FIT Clinical Decision Making: Interventional	Blocked Artery, or Blocked Bowel?!	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart		
Shakoor	Muhammad	Disease, and Vascular Medicine Novel Developments in Acute Coronary	Comparison of Clinical Outcomes: Bivalirudin With Transfemoral	Nothing to Disclose
	anamiidu	Syndromes	Versus Heparin With Transradial in Patients With ST Segment	
OL-II-I	01	-	Elevation Myocardial Infarction	No. 12 - 12 - Brookers
Shalhub	Sherene	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Influence of Family History of Aortic Disease on Type B Aortic	Nothing to Disclose
Shalhub	Sherene	Beans, Beans, Good for Your Heart	Analysis of the Timing of Thoracic Endovascular Aortic Repair and	Nothing to Disclose
			Its Indications and Outcomes in Type B Aortic Dissection	
Shallow	Charlene	Innovations in Practice Management and	Utilization of a Clinical Ladder Process as a Strategy to Facilitate the	Nothing to Disclose
		Social Media	Orientation of an Advanced Practice Provider Into a Cardiology Practice	
Shallow	Charlene	Interdisciplinary Cardiovascular Team Care	See You in 7: An Advanced Practice Provider Post PCI Clinic	Nothing to Disclose
Chaman	l/h = d = -	Delivery: Quality, Safety, and Satisfaction	Improving Transition of Care	Nething to Displace
Shameer	Khader	The Inside View: Learning From Intracoronary Imaging	Investigation of Novel Drug Targets Implicated in High-Dose Statin Therapy From Yellow-II Trial: Towards Personalized Lipid Lowering	Nothing to Disclose
			Therapies	
Shami	Waseem	FIT Clinical Decision Making: Prevention, Adult	Combined Migraine and Platypnea-Orthodeoxia Syndrome Due to	Nothing to Disclose
		Congenital and Congenital Heart Disease	Combined Atrial Septal Defect and Patent Foramen Ovale	
Shami	Waseem	FIT Clinical Decision Making: Prevention, Adult	Double Right Coronary Artery Engendering Inadequate Blood	Nothing to Disclose
		Congenital and Congenital Heart Disease	Supply to the Inferior Left Ventricular Wall	-
Shamim	Shariq	FIT Clinical Decision Making: Interventional	Congenital Absence of Left Main Coronary Artery in a Transplanted	Nothing to Disclose
Silailiilii	Shariq	Cardiology, Acute and Stable Ischemic Heart	Heart: A Diagnostic Dilemma and a Therapeutic Challenge	Nothing to Disclose
		Disease, and Vascular Medicine		
Shammas	Andrew	Head to Toe: Outcomes of Endovascular Interventions	Atherectomy Is Associated With Lower Rates of Repeat Intervention After Below Knee Peripheral Vascular Intervention	Nothing to Disclose
Shammas	Andrew	Head to Toe: Outcomes of Endovascular	Utilization of Distal Embolic Protection in Infrainguinal Peripheral	Nothing to Disclose
		Interventions	Arterial Intervention: Insights From the Multicenter XLPAD Registry	3
01	A	5 1 5 5 5 5 5		Null'action District
Shammas	Andrew	Endovascular Therapy: Running From Risk	Predictors of Procedural Complications in Infrainguinal Endovascular Interventions	Nothing to Disclose
Shammas	Andrew	Highlights in Vascular Medicine Research	Comparative Assessment of Subintimal Versus Intraluminal	Nothing to Disclose
			Crossing of Infrainguinal Chronic Total Occlusion Lesions	•
Shammas	Nicolas	The Best Coronary and Peripheral Interventional Challenging Cases	Recanalization of Total Occlusion of the Superficial Femoral Artery and Profunda Femoris Using the Transcollateral Approach	CONSULTANT FEES/HONORARIA - Boston Scientific, Medicines Co.; OTHER - Abbott, Boston
		interventional Challenging Cases	and Fromitia Femoris Osing the Hallscollateral Approach	Scientific, Cordis, MEDTRONIC, St Jude's;
				RESEARCH/RESEARCH GRANTS - Boston
				Scientific,Covidien,CSI; SPEAKER'S BUREAU - Boehringer Inghelheim,gilead
Shammas	Nicolas	Head to Toe: Outcomes of Endovascular	Atherectomy Is Associated With Lower Rates of Repeat Intervention	CONSULTANT FEES/HONORARIA - Boston
		Interventions	After Below Knee Peripheral Vascular Intervention	Scientific, Medicines Co.; OTHER - Abbott, Boston
				Scientific,Cordis,MEDTRONIC,St Jude's;
				RESEARCH/RESEARCH GRANTS - Boston Scientific,Covidien,CSI; SPEAKER'S BUREAU - Boehringer
				Inghelheim,gilead
Shammas	Nicolas	Head to Toe: Outcomes of Endovascular	Utilization of Distal Embolic Protection in Infrainguinal Peripheral	CONSULTANT FEES/HONORARIA - Boston
		Interventions	Arterial Intervention: Insights From the Multicenter XLPAD Registry	Scientific, Medicines Co.; OTHER - Abbott, Boston Scientific, Cordis, MEDTRONIC, St Jude's;
				RESEARCH/RESEARCH GRANTS - Boston
				Scientific,Covidien,CSI; SPEAKER'S BUREAU - Boehringer
Chamman	Nicolas	Hood to Too: Outcome of Factoring	Accopiation of Cigaratta Constitute With December 1	Inghelheim,gilead
Shammas	Nicolas	Head to Toe: Outcomes of Endovascular Interventions	Association of Cigarette Smoking With Procedural Cost of Lower Extremity Endovascular Intervention	CONSULTANT FEES/HONORARIA - Boston Scientific, Medicines Co.; OTHER - Abbott, Boston
				Scientific,Cordis,MEDTRONIC,St Jude's;
				RESEARCH/RESEARCH GRANTS - Boston
				Scientific,Covidien,CSI; SPEAKER'S BUREAU - Boehringer Inghelheim.gilead
Shammas	Nicolas	Endovascular Therapy: Running From Risk	Predictors of Procedural Complications in Infrainguinal	CONSULTANT FEES/HONORARIA - Boston
			Endovascular Interventions	Scientific, Medicines Co.; OTHER - Abbott, Boston
				Scientific,Cordis,MEDTRONIC,St Jude's; RESEARCH/RESEARCH GRANTS - Boston
				Scientific,Covidien,CSI; SPEAKER'S BUREAU - Boehringer
				Inghelheim,gilead
Shammas	Nicolas	Highlights in Vascular Medicine Research	Comparative Assessment of Subintimal Versus Intraluminal	CONSULTANT FEES/HONORARIA - Boston
			Crossing of Infrainguinal Chronic Total Occlusion Lesions	Scientific,Medicines Co.; OTHER - Abbott,Boston Scientific,Cordis,MEDTRONIC,St Jude's;
				RESEARCH/RESEARCH GRANTS - Boston
				Scientific,Covidien,CSI; SPEAKER'S BUREAU - Boehringer
		1	1	Inghelheim,gilead

Carry Control				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Shamoon	Fayez	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Statin Intensity and Outcome in Patients With Acute Heart Failure With Preserved Ejection Fraction	Nothing to Disclose
Shamoon	Fayez	FIT Clinical Decision Making: Prevention, Adult	Left Ventricular Dilation: Patent Ductus Arteriosus Versus Chronic	Nothing to Disclose
		Congenital and Congenital Heart Disease	Severe Mitral Regurgitaiton	· ·
Chaman	F	Characian the Natural History of Value Disease	Chating the good to a Tours Outcome Deat Counties Andie Volum	Nething to Displace
Shamoon	Fayez	Changing the Natural History of Valve Disease With Medical Therapy	Statins Use and Long Term Outcome Post Surgical Aortic Valve Replacement	Nothing to Disclose
Shamoon	Fayez	FIT Clinical Decision Making: Arrhythmias and	Ventricular Tachycardia in a Patient With Coexisting Brugada	Nothing to Disclose
0.1	_	Electrophysiology	Syndrome and Coronary Vasospasm	
Shamoon	Fayez	New Technologies in Echocardiography	Left Atrial Volume Index Over Late Diastolic Mitral Annular Velocity: A New Non-Invasive Parameter for Measurement of Left Ventricular	Nothing to Disclose
			End Diastolic Pressure	
Shamoon	Fayez	FIT Clinical Decision Making: Interventional	33 Year Old Female With Sudden Cardiac Arrest	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine		
Shamoun	Fadi	FIT Clinical Decision Making: Non-Invasive	Pathologic Plumbing: Utilizing Multi-Modality Imaging in the	Nothing to Disclose
		Imaging and Valvular Heart Disease	Diagnosis of a Patient With Pulmonary Vein to Azygos System	· ·
Shamoun	Fadi	Vascular Medicine: Emerging Concepts in	Fistula and Decompensated Valvular Cardiomyopathy Risk of Re-Dissection in Segmental Arterial Mediolysis	Nothing to Disclose
Shanloun	raui	Clinical Vascular Diseases	Risk of Re-Dissection in Segmental Arterial Mediolysis	Nothing to disclose
Shamoun	Fadi	Highlights in Vascular Medicine Research	The Addition of Renal Impairment to the CHA2DS2-VASc Score as	Nothing to Disclose
			a Predictor of Thromboembolism and Mortality in Patients Without Atrial Fibrillation	
Shanbhag	Anusha	Innovative Approaches for Reducing Risk and	Complication Rates of Epicardial Ventricular Tachycardia Ablation:	Nothing to Disclose
		Improving Outcomes With Ablation	A Pooled Analysis	-
Shanbhag	Anusha	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Aortic Regurgitation Due to Aortic Dissection: Complication Post Coronary Artery Bypass Surgery	Nothing to Disclose
		Disease, and Vascular Medicine	Colonary Artery Bypass Surgery	
Shanbhag	Sujata	FIT Clinical Decision Making: Non-Invasive	Reversible Severe Right Heart Failure and Tricuspid Regurgitation	Nothing to Disclose
Charbban	Cuinta	Imaging and Valvular Heart Disease	From Thyrotoxicosis	Nething to Displace
Shanbhag	Sujata	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Importance of Physical Exam in Identifying a Coronary-Cameral Fistula	Nothing to Disclose
		0		
Shang	Qing	Non Invasive Imaging: Role of Exercise Testing		Nothing to Disclose
			Patients With Psoriatic Arthritis: A Low-Level Bicycle Ergometer Exercise Test	
Shani	Jacob	TAVR Outcomes Prognostication	Geriatric Assessment Tools and Outcome Prediction in	Nothing to Disclose
			Transcatheter Aortic Valve Replacement	
Shannon	Francis	Interventional Cardiology: TAVR 4	Outcome-Based Cost Analysis of Transfemoral Transcatheter Aortic Valve Replacement Using Fascia Iliaca Compartment Block and	CONSULTANT FEES/HONORARIA - St Jude Medical; DATA SAFETY MONITORING BOARD - MEDTRONIC; OWNERSHIP
			Minimalist Conscious Sedation Approach Versus General	INTEREST/PARTNERSHIP/PRINCIPAL - Biostar, Micardia Inc
			Anesthesia	
Shantha	Ghanshyam	Non Invasive Imaging: Expanding Clinical	Diagnostic Accuracy of Coronary Computed Tomography Angiography in Aortic Stenosis Patients Referred for Aortic Valve	Nothing to Disclose
	Palamaner Subash	Applications	Replacement: Systematic Review and Meta-Analysis	
Shantouf	Ronney	Novel Imaging and Therapies in Heart Failure	Rethinking the Role of Coronary Angiography in the Evaluation of	Nothing to Disclose
Charies	Minhaal	When Chandal Desert France Description	Heart Failure With Reduced Ejection Fraction in Young Patients	CONCULTANT FEFCULONOBADIA Alexies Assess Decree OF
Shapiro	Michael	Who Should Benefit From Preventive Cardiology?: International Perspectives From	Role of Biomarkers and Imaging in CVD Prevention	CONSULTANT FEES/HONORARIA - Alexion,Amgen,Bracco,GE Healthcare; RESEARCH/RESEARCH GRANTS -
		the European Society of Cardiology and the		Akcea,Amarin,Amgen Inc.
		American College of Cardiology		
Shapiro	Michael	Harnessing the Power of Genetics to Prevent ASCVD	Co-Chair	CONSULTANT FEES/HONORARIA - Alexion,Amgen,Bracco,GE Healthcare; RESEARCH/RESEARCH GRANTS -
		7.007.5		Akcea,Amarin,Amgen Inc.
Shapiro	Michael	Great Debates in Preventive Cardiology	Co-Chair	CONSULTANT FEES/HONORARIA - Alexion, Amgen, Bracco, GE
				Healthcare; RESEARCH/RESEARCH GRANTS - Akcea,Amarin,Amgen Inc.
Shapiro	Michael	Test Yourself with Questions: General	Moderator	CONSULTANT FEES/HONORARIA - Alexion, Amgen, Bracco, GE
· ·		Cardiology Module 14		Healthcare; RESEARCH/RESEARCH GRANTS -
Shapiro	Michael	The PCSK9 Revolution: New Insights Into	Discordant Response of Low Density Lipoprotein Cholesterol and	Akcea,Amarin,Amgen Inc. CONSULTANT FEES/HONORARIA - Alexion,Amgen,Bracco,GE
опарио	Wichaci	Evaluation and Treatment	Lp(a) Levels to Monoclonal Antibodies Targeting Proprotein	Healthcare; RESEARCH/RESEARCH GRANTS -
			Convertase Subtilisin/Kexin Type 9	Akcea,Amarin,Amgen Inc.
Shapiro	Michael	32. Prevention: Clinical Team 5	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Alexion, Amgen, Bracco, GE Healthcare; RESEARCH/RESEARCH GRANTS -
				Akcea,Amarin,Amgen Inc.
Sharif	Behzad	Non Invasive Imaging: MR Scar and Perfusion	Hyperemic Subendocardial-to-Subepicardial Perfusion Ratio as a	Nothing to Disclose
			Surrogate Marker for Coronary Endothelial Dysfunction: Initial	
Sharif	Behzad	Non Invasive Imaging: MR Scar and Perfusion	Results in Women With Microvascular Dysfunction Assessment of Myocardial Perfusion Reserve Index Using	Nothing to Disclose
			Adenosine Versus Regadenoson Among Healthy Female Subjects	-
Sharif	Behzad	Nuclear Cardiology: Coronary Flow	Precisely Controlled Arterial CO2 Can Potentiate Myocardial Blood	Nothing to Disclose
			Flow to the Same Extent as Adenosine: A Preclinical Study in Canines With 13N-Ammonia PET	
Sharifi	Mohsen	Vascular Medicine: Venous Disease	Low Dose Systemic Thrombolysis and New Oral Anticoagulants in	Nothing to Disclose
Chadren			the Treatment of Large Thrombi in the Right Heart	-
Sharkey	Scott	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Influence of Cardiac Arrest and Cardiogenic Shock on Outcomes Among 4,500 Consecutive ST Elevation Myocardial Infarction	Nothing to Disclose
		Syndrome	Patients	
Sharkey	Scott	Timely Topics in Acute Coronary Syndromes	Outcome and Characteristics of Shockable Versus Non-Shockable	Nothing to Disclose
			Cardiac Arrest in ST Elevation Myocardial Infarction at a Regional Transfer Center	
Sharma	Abhinav	Traditional and Novel Factors Used to Assess	Outcomes in Patients With Diabetes Mellitus and Suspected	RESEARCH/RESEARCH GRANTS - Roche Diagnostics, Takeda
		the Risk of, and Used for the Treatment of,	Coronary Artery Disease Following Non-Invasive Testing: Insights	Pharmaceuticals North America, Inc
		Coronary Artery Disease	From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	
Sharma	Abhinav	Cardiac Arrest, Diabetes, and Other High Risk	Early Versus Late Cardiovascular Events in Patients With Type 2	RESEARCH/RESEARCH GRANTS - Roche Diagnostics, Takeda
		Features of Patients With Acute Coronary	Diabetes Mellitus and Acute Coronary Syndrome: Insights From the	Pharmaceuticals North America, Inc
Sharma	Abhinav	Syndrome The Old and the New: Impact of Heart Failure	Examine Trial Liraglutide and Weight Loss Among Patients With Advanced Heart	RESEARCH/RESEARCH GRANTS - Roche Diagnostics,Takeda
Giailia	A DIIII I A V	Drug Therapies	Failure and a Reduced Ejection Fraction: Insights From the FIGHT	Pharmaceuticals North America, Inc
			Trial	
Sharma	Abhishek	Revascularization and Myocardial Preservation	Temporal Trends and Outcomes of Emergent Coronary Artery	Nothing to Disclose
		in Acute and Stable Ischemic Heart Disease	Bypass Graft Surgery for ST-Segement Elevation Myocardial Infarction	
Sharma	Abhishek	Timely Topics in Acute Coronary Syndromes	Routine Invasive Versus Conservative Strategy for Elderly Patients	Nothing to Disclose
1			Aged>75 Years With Non-ST Elevation Acute Coronary	
			Syndrome (NSTE-ACS): A Meta-Analysis of Randomized Controlled Trials	
Sharma	Abhishek	Interventional Cardiology: TAVR 4	Outcomes of Trans-Catheter Aortic Valve Replacement in	Nothing to Disclose
			Nonagenarians	-
Sharma	Aditya	Vascular Diagnoses Cardiologists Should not Miss: A Case-based Approach	Case Presentation: Young Woman with Stroke and Pulsatile Tinnitus	Nothing to Disclose
Sharma	Aditya	40. Vascular Medicine: Non Coronary Arterial	Suggested Reviewer	Nothing to Disclose
		Disease Team 1		-



Sharma	First Name Garima	Acute Heart Failure: Evaluating Strategies to	Presentation Title Acute Decompensated Heart Failure: The Journey From	Disclosures Nothing to Disclose
Sharma	Garima	Prevent Readmissions Personalized Skills Center: Drill and Practice	Patients' Perspective Heart Songs Moderator	Nothing to Disclose
Sharma	Krishna	(Heart Songs, ECG, Hand-Held Echo) Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering Therapies	25 Year Trends in Hypertension Awareness, Treatment and Control in India and UN Sustainable Development Goals	Nothing to Disclose
Sharma	Mala		Change in Aortomitral Annular Angle and Anterior Mitral Valve Leaflet Length After Transcatheter Aortic Valve Replacement: Implications for Transcatheter Mitral Valve Replacement?	Nothing to Disclose
Sharma	Parikshit	Role of Newer ICD Technologies for the Prevention of Sudden Cardiac Death	Case Presentation - Wearable Cardioverter Defibrillator	CONSULTANT FEES/HONORARIA - MEDTRONIC
Sharma	Parikshit		Risk Score Model for Predicting Occurrence of Complications in Patients Undergoing Atrial Fibrillation Ablation	CONSULTANT FEES/HONORARIA - MEDTRONIC
Sharma	Parikshit		Difference in Quality of Life Outcomes Between Atrial Fibrillation Catheter Ablation and Anti Arrhythmic Drugs: A Systematic Review and Meta-Analysis	CONSULTANT FEES/HONORARIA - MEDTRONIC
Sharma	Parikshit	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Mapping of the His Bundle to Recruit LBBB During Permanent Pacemaker Implantation: Insight Into the Site of LBBB	CONSULTANT FEES/HONORARIA - MEDTRONIC
Sharma	Puza	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Ten-Year Mortality of Acute Myocardial Infarction Patients Treated in U.S. Community Practice	SALARY - Novartis Pharmaceutical Corporation, Novartis Pharmaceuticals corporation
Sharma	Puza	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Examination of hs-CRP Elevation in Patients With History of Myocardial Infarction in the U.S.	SALARY - Novartis Pharmaceutical Corporation, Novartis Pharmaceuticals corporation
Sharma	Puza	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Incidence of Recurrent Myocardial Infarction Among Older Adults in U.S. Community Practice	SALARY - Novartis Pharmaceutical Corporation, Novartis Pharmaceuticals corporation
Sharma	Puza		High-Sensitivity C-reactive Protein and Health Status Outcomes After Myocardial Infarction	SALARY - Novartis Pharmaceutical Corporation, Novartis Pharmaceuticals corporation
Sharma	Raman	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Vasospastic Angina: A Rare Case of Ergonavine Positivity and Curative Vagotomy	Nothing to Disclose
Sharma	Samin	Practicum on Tools for CHIP (Complex and Higher-Risk Procedures in Indicated Patients)	Managing Calcium in the Cath Lab: Current Tools and How to Improve Your Atherectomy Skills	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Complex PCI in 2017	Case Presentation: Illustrative Bifurcation Calcific Case	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Atherosclerotic Plaque Morphology in Response to High Intensity Lipid Lowering Therapy by Multimodality Imaging Among Women and Men: A YELLOW-II Sub-study	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Comparing PCI Outcomes in the Very Elderly: Does Age Matter? A Report From Outcomes of Septuagenarians, Octogenarians and Nonagenarians After PCI	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Clinical Outcomes Associated With Impella Versus IABP Use in Stable Patients Undergoing High Risk Percutaneous Coronary Intervention	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Impella or Intra-Aortic Balloon Pump Support in Patients Undergoing High Risk Percutaneous Coronary Intervention: A Real World Single Center Experience	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Revascularization and Outcomes	Angiographic Phenotype and Clinical Outcomes of Patients With Malignancy Undergoing PCI	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Revascularization and Outcomes	Synergistic Effects of Coronary Calcification and Inflammation on Risks for Adverse Cardiovascular Events After PCI: Results From a Large Single-Center Registry	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Multimodality Intravascular Imaging to Evaluate Plaque Characteristics in Patients With Diabetes Mellitus	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Novel Developments in Acute Coronary Syndromes	Trends in Incidence and Mortality Associated With Acute Kidney Injury in Patients Undergoing PCI for Acute Coronary Syndrome	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: From the WIN-TAVI Registry	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Cutting Edge Vascular Medicine	Proprotein Convertase Subtilisin Kexin Type 9 Protein Expression Is Increased in Lipid Rich Human Atherosclerotic Plaques Compared to Fibrous Plaques	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Innovations in Cardiovascular Risk Assessment and Reduction	Optical Coherence Tomography of Culprit Lesions in Patients With Prior Cerebrovascular Events Compared to Controls	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Timely Topics in Acute Coronary Syndromes	Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Optimizing the Care of ACS Patients	Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Interventional Complexity and Complications	Prediction of Acute Kidney Injury in Patients Undergoing Coronary Intervention Using Calculation of Serum Osmolality	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Interventional Cardiology: PCI in Complex Patients	Risk and Impact of Diabetes Mellitus on Ischemic Events in Females and Males After Percutaneous Coronary Intervention	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Disease, and Vascular Medicine	Vasospastic Angina: A Rare Case of Ergonavine Positivity and Curative Vagotomy	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Highlights in Vascular Medicine Research	Morphological Features of Vascular Healing in Paclitaxel Coated Balloon Compared to Plain Old Balloon Angioplasty in Human Peripheral Artery Disease	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	Imaging	Investigation of Novel Drug Targets Implicated in High-Dose Statin Therapy From Yellow-II Trial: Towards Personalized Lipid Lowering Therapies	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Samin	22. Interventional Cardiology: Coronary Intervention: Left Main, Multivessel, Bifurcation Team 2	Suggested Reviewer	SPEAKER'S BUREAU - Abbott Vascular Inc., Boston Scientific Corp., Cardiovascular Systems Inc, TriReme, The Medicine Company
Sharma	Sanjay	Imaging the Athlete's Heart	General Population Screening for Sudden Cardiac Death in Young Individuals: Is It Feasible, Is It Justifiable & How Much Does It Cost?	Nothing to Disclose
Sharma	Sanjay	Hearts and Soles: Multimodality Imaging in Athletes	The Mixed Race Athlete's ECG: Not So Black and White	Nothing to Disclose
Sharma	Saurabh	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Migration of the Prosthetic Mitral Valve After Transcatheter Mitral Valve Replacement for Severe Calcific Mitral Stenosis	Nothing to Disclose

Contract of the second				<u> </u>
Last Name Sharma	First Name Sunita	Session Title FIT Clinical Decision Making: Prevention, Adult	Presentation Title Congenital Double-Chambered Left Ventricle Presenting as	Disclosures Nothing to Disclose
Silailia	Sunita	Congenital and Congenital Heart Disease	Monomorphic Ventricular Tachycardia	Nothing to Disclose
Sharma	Umesh	Arrhythmias and Clinical EP: AF Ablation	Improvement in Cost and Efficiency in Electrophysiology Laboratory by Cardiac Computed Tomography to Exclude Left Atrial Appendage Thrombus Prior to Atrial Fibrillation Ablation	Nothing to Disclose
Sharma	Umesh	Non Invasive Imaging: Prognostic Implications of CT Angiography	HEART Score Does Not Predict the Severity of Anatomical Coronary Artery Disease in Patients Presenting to the Emergency Department With Chest Pain	Nothing to Disclose
Sharp	Andrew	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International	CONSULTANT FEES/HONORARIA - MEDTRONIC, Volcano
Shave	Robert	Hearts and Soles: Multimodality Imaging in Athletes	Multicentre iFR GRADIENT Registry Temporal Sequence of Athlete's Heart Regression During Prescribed Exercise Detraining: <i>Diagnostic Implications</i>	Nothing to Disclose
Shavelle	David	Featured Clinical Research III	Reduction in Heart Failure Hospitalizations With Ambulatory Hemodynamic Monitoring Seen in Clinical Trials is Maintained in the 'Real World'	RESEARCH/RESEARCH GRANTS - Abbott Vascular, AbioMed Inc, St Jude Medical Inc; SPEAKER'S BUREAU - MEDTRONIC, St Jude Medical Inc
Shavelle	David	Valvular Disease Populations at Risk	National and Regional Trends in Surgical Aortic Valve Replacement in the TAVR Era	RESEARCH/RESEARCH GRANTS - Abbott Vascular, AbioMed Inc, St Jude Medical Inc; SPEAKER'S BUREAU - MEDTRONIC, St Jude Medical Inc
Shavelle	David	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	High Procedural and Device Related Success With the CardioMEMS HF System for Heart Failure: Observations From the CardioMEMS™ Post Approval Study	RESEARCH/RESEARCH GRANTS - Abbott Vascular, AbioMed Inc, St Jude Medical Inc; SPEAKER'S BUREAU - MEDTRONIC, St Jude Medical Inc
Shavelle	David	36. Valvular Heart Disease: Clinical Team 3	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Abbott Vascular, AbioMed Inc, St Jude Medical Inc; SPEAKER'S BUREAU - MEDTRONIC, St Jude Medical Inc
Shaw	Leslee	State of the Art Nuclear Cardiology: SPECT	Risk Stratification and Prognosis: Evidence and Outcomes	Nothing to Disclose
Shaw	Leslee	Myocardial Perfusion Imaging The Art and the Science of Decision Making in Coronary Artery Disease	The Art: The Beauty of a Test is in the Eye of the Beholder	Nothing to Disclose
Shaw	Leslee	Patient-Centered Imaging: Quality of Cardiac CT Evidence	Value-Based CT: Cost-Effectiveness and Resource Utilization after Cardiovascular CT	Nothing to Disclose
Shaw	Leslee	Clinical Utility of Cardiac CT in 2017: Joint Symposium of the Society of Cardiovascular Computed Tomography and the American College of Cardiology	Risk Stratification of the asymptomatic patient with CACS	Nothing to Disclose
Shaw	Leslee	Non Invasive Imaging: Prognostic Implications of CT Angiography	Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	Nothing to Disclose
Shaw	Leslee	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Progenitor Cells and Clinical Outcomes in Patients With Heart Failure	Nothing to Disclose
Shaw	Leslee	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team 2	Suggested Reviewer	Nothing to Disclose
Shaw	Linda	Considerations in Antiplatelet Therapy and in ACS	Dual Antiplatelet Therapy Utilization and Cardiovascular Outcomes Among Black and White Patients Treated With Drug Eluting Stents	Nothing to Disclose
Shaw	Linda	Making Progress in Understanding Heart Failure	The Role of Baseline Versus Long-Term Follow-Up Ejection Fraction in Predicting Adverse Events Among Primary Prevention Implantable Cardioverter Defibrillator Recipients	Nothing to Disclose
Shaw	Linda	Nuclear Cardiology: Prognosis	The Prognostic Value of Diastolic and Systolic Mechanical Left Ventricular Dyssynchrony Among Patients With Coronary Heart Disease	Nothing to Disclose
She	Jianqing	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Rupture of Right Sinus of Valsalva Presenting as Myocardial Infarction	Nothing to Disclose
Shea	Steven	New Insights Into Prediction and Treatment of Hypertension	Collagen Turnover Markers Predict New Onset of Hypertension in Normotensive Subjects: The Multi-Ethnic Study of Atherosclerosis	Nothing to Disclose
Shearer	Robyn	Vascular Access and Hemostasis Issues	Clinical Efficacy of SoftSeal-STF Hemostatic Pad With Short Hold Time Compared to Traditional Manual Compression After Transfemoral Catheterization	Nothing to Disclose
Shearer	Robyn L.	Considerations in Antiplatelet Therapy and in	Contemporary Outcomes of Anterior Segment ST-Elevation	Nothing to Disclose
Shehab	Abdullah	ACS New Perspectives on Structural Valve Disease: International Perspectives From the Emirates Cardiac Society, Latin American Society of Interventional Cardiology (SOLACI), and American College of Cardiology	Myocardial Infarction: A Large 10-Year Tertiary Care Experience Co-Chair	Nothing to Disclose
Shehata	Michael	FIT Clinical Decision Making: Arrhythmias and	Wide Complex Tachycardia in a 51-Year-Old Man: Ventricular	CONSULTANT FEES/HONORARIA - Boston Scientific; DATA
Sheidaii	Nasim	Rectrophysiology Non Invasive Imaging: Applications in Novel	Tachycardia Until Proven Otherwise? Impact of Cardiac Troponin I on the Presence of the Coronary	SAFETY MONITORING BOARD - St. Jude Medical Nothing to Disclose
Sheikh	Ali	Disease States and Clinical Scenarios Arrhythmias and Clinical EP: AF Ablation	Artery Plaque in Rheumatoid Arthritis patients Improvement in Cost and Efficiency in Electrophysiology Laboratory by Cardiac Computed Tomography to Exclude Left Atrial	Nothing to Disclose
Sheikh	Farooq	Life After LVAD - The Good, The Bad and The	Appendage Thrombus Prior to Atrial Fibrillation Ablation The Patient Voice - Life after VAD	Nothing to Disclose
Sheikh	Muhammad Adil	FIT Clinical Decision Making: Non-Invasive	Things to Consider When Shopping for a Shunt: A Diagnostic Challenge	Nothing to Disclose
Sheikh	Muhammad Adil	Imaging and Valvular Heart Disease Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Challenge Seasonal Variation in In-Patient Mortality, Cost of Hospitalization and Length of Stay in Heart Failure Patients in the United States	Nothing to Disclose
Sheikh	Muhammad Adil	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Regional Variation in Hospitalization Outcomes Among Patients Admitted for Heart Failure in the United States	Nothing to Disclose
Sheikh	Muhammad Adil	Obesity Management in 2017: Weighing the Issues	A Meta-Analysis of Cardiovascular Safety of FDA Approved Anti Obesity Drugs	Nothing to Disclose
Sheikh-Taha	Marwan	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Potentially Inappropriate Home Medications Among Older Patients With Cardiovascular Disease Admitted to a Cardiology Service in USA	Nothing to Disclose
Shekar	Prem	Interventional Cardiology: TAVR 3	The Incidence of Permanent Pacemaker Implantation With SAPIEN 3 Heart Valve - Implantation Depth: The Higher the Better?	-
Shelby	Shaija	Adult Patients With Congenital Heart Disease: How Do They Compare?	Decreased Hepatic Elasticity in Young Adults After Biventricular Repair of Congenital Heart Disease	CONSULTANT FEES/HONORARIA - none
Sheldon	Robert	Syncope: What's New	Pacing for Recurrent Vasovagal Syncope	RESEARCH/RESEARCH GRANTS - AA Pharma,Apotex Corp,Apotex Corp
Sheldon	Seth	Common Arrhythmia Problems: The Experts Approach	Case Presentation	Nothing to Disclose
Sheldon	Seth	Arrhythmias and Clinical EP: Devices 2	Real World Battery Longevity of St. Jude Medical Implantable Cardioverter-Defibrillators Included in the Advisory for Premature Battery Depletion	Nothing to Disclose
Sheldon	Seth	Arrhythmias and Heart Failure	ACC Poster Moderator	Nothing to Disclose
Shelton	Marc	Mentoring the Care Team: FITs, Early Career Professionals and CV Team Members	Mentoring the Early Career Professional - Administrative Opportunites	Nothing to Disclose

WASHINGTON, DC | MARCH 17 - 19 2017

Section Proceedings Section Telescope Telescope Telescop		
Springer (1997) and 1997 through the Control of Control	ion Title Disclosures	11:0
Servine Annual Authorison of Telephysis (Politics of Servine Insert Programme) in Programme (Politics of Servine Insert Programme (Politics of Servine Inse		AtriCure,Edwards
Silvents Annaly Anthromotocis Entancy in Colorane Hast Transports (Entangs better Placement at a) and the Confedence Hast Transports (Controlled Control Active to the Colorane Control Controlled Control Con	Sizing in Patients With Chronic Kidney Disease Undergoing Lifesciences, Sorin Group	AtriCure,Edwards
Sen Uniform Control of Managery Companies of Experimental Control of Company Companies of Company Companies of Company	r Adherence After Drug Eluting Stent Placement at a Nothing to Disclose	
Expland Inspiration Insp	Heart Association Preparticipation Cardiovascular of Competitive Athletes History Elements Applied to a	
See Mylere Merce Merce More Determinants of Outcomes in VHD Merce See Myre Collection and Collections in VHD Merce See Myre Collection and Collections in VHD Merce More Determinants of Collections in VHD Merce More Determinants of Collections in VHD Merce More Determinants of Collections in VHD Merce More Determinants of Collections in VHD Merce More Determinants of Collections in VHD Merce More Determinants of Collections in VHD Merce More Determinants More	on of Coronary Calcification Detection Between Multi- Computed Tomography and Optical Coherence	
Rate of Americ Standard Sharron Sharron Anhythmats and Clinical EP-AF Allation Procedures for Personal Reliance Present Stories and Michigan Sharron S	Aortic Valve Calcification and Sex on Hemodynamic Nothing to Disclose	
Procession Procession Proce	ortic Stenosis	
Simple Win-Numary Syncope Challenges and Pathline A Case. Do-Differ Do-Differ Nothing to Discisione Simple Syncope Discisione Simple Syncope Discisione Simple Syncope Discisione Simple Syncope Discisione Simple Syncope Discisione Simple Syncope Discisione Simple Syncope Discisione Simple Syncope Discisione Simple Syncope Discisione Simple Syncope Discisione Simple Syncope Discisione Simple Syncope Discisione Simple Syncope Discisione Simple Syncope Discisione Simple Syncope Discisione	embolism in Patients Undergoing Left Atrial Catheter rocedures for Paroxysmal or Persistent (Non-Permanent) illation and Left Atrial Flutter	
Sien Wirk-Kuang Sproope: Challenges and Pitalis. A Case- based Approach Shen Wirk-Kuang Research Proprieta v Vaccular Medicine Research Proprieta v Vaccular Medicine Research Proprieta v Vaccular Medicine Research Proprieta v Vaccular Medicine Research Proprieta v Vaccular Medicine Research Proprieta v Vaccular Medicine Control En Singent Wirk-Kuang Signature Vivo Control State of Province Architecture Vivo Control	Syncope in 2017 and Beyond: Summary and Highlights Nothing to Disclose	
Second Content Seco		
Sen Wir-Klang September Character Superventional Archyterholized and Archyterholized Archyterh	or of Thromboembolism and Mortality in Patients Without	
Calcium Score and the Clinical Outcomes After Transcambers Cartific Score and the Clinical Outcomes After Transcambers Assessment of the Warter Replacement and Reduction Advances in HCML PFCM and Offier Cartific Classes The Multi-Elmino Study of Atheroscenerias (MEA) Advances in HCML PFCM and Offier Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Cartific Manager in Part Assessment Charge in		
Sinency Chelan Incovations in Cardiovascular Rak Assessment Association Between Serum Collagen Biomarkers and Corrosal And Service And Ser	Score and the Clinical Outcomes After Transcatheter	-
Sheppard Richard Advances in HCM, PFCM and Other Cardiorropopthyses Secondary Patients With Perspatual Nothing to Disclose Cardiorropopthyses Secondary Patients Secondary Patients Secondary Patients Secondary Patients Secondary Patients Pa	on Between Serum Collagen Biomarkers and Coronary Nothing to Disclose	
Siner Salman Imaging the Athlete's Heart Seep Boordeed Festivating and Cardiovascular Correlates in Nothing to Disclose Chemical State of Medical Transport and Collegiste American Style Football Participants Sherer Jeffrey Effective Medication Management in the Older Adults with CVD: Pharmacology Program In Program Company of Collegiste American Style Football Participants Sherer Jeffrey Effective Medication Management in the Older Adults with CVD: Pharmacology Program In Program Company of Collegiste American Style Football Participants Sherer Management in the Older Adults with CVD: Pharmacology Program In Program Company of Collegiste American Style Football Participants Sherer Sherin Inse Nuclear Cardiology Beyond Perfusion Company of Collegiste Adults And Volumes in Patients With Significantly Reduced England Program of CVT SPECT and Cardiac RMP Derived Cardiac Function and Volumes in Patients With Significantly Reduced Program of CVT SPECT and Cardiac RMP Derived Cardiac Function and Volumes in Patients With Significantly Reduced Program of CVT SPECT and Cardiac RMP Derived Cardiac Function and Volumes in Patients With Significantly Reduced Program of CVT SPECT and Cardiac RMP Derived Cardiac Function and Volumes in Patients With Significantly Reduced Program of CVT SPECT and Cardiac RMP Derived Cardiac Function and Volumes in Patients With Significantly Reduced Program of CVT SPECT and Cardiac RMP Derived Cardiac Function and Volumes in Patients With Significantly Reduced Program of CVT SPECT and Cardiac RMP Derived Cardiac Function and Volumes in Patients With Significant RMP Derived Cardiac Program of CVT SPECT and Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RMP Derived Cardiac RM	Course of Recovery in Patients With Peripartum Nothing to Disclose	
Sherazi Saadia The Evolving World of LVADs, Transplant and Other Novel Discoveries Other Novel Discove	ular Remodeling Patterns	
Other Novel Discoveries Sherry Seffective Medication Management in the Older Strategies for Reducting Oversea and De-prescribing of Medications Nothing to Disclose Sherrifi Nes Nuclear Cardiology: Beyond Perfusion Cardiology and the Section Cardiology and the Section Cardiology and the Section Cardiology and the Section Cardiology and the Section Cardiology and the Section Cardiology and the Section Cardiology and the Section Cardiology and the Section Cardiology and the Section Cardiology and the Section Cardiology and the Section Cardiology and the Section Cardiology and the Section Cardiology And the Section Cardiology And the Section Cardiology Tax Section Cardiology Tax Section Card	American Style Football Participants	
Adults with CVD: Pharmacology Program I In the Elderly CV Patient Interventional Cardiology: Beyond Perfusion Companison of CZT SPECT and Cardiac MR Derived		
Function and Volumes in Patients With Significantly Reduced Ejection Fraction	for Reducing Overuse and De-prescribing of Medications Nothing to Disclose	
Sherman Eugene The Malpractice Mmelfeld: How to Avoid, Navigate and Advocate The Malpractice Mmelfeld: How to Avoid, Navigate and Advocate The Malpractice Mmelfeld: How to Avoid, Navigate and Advocate CVS, Davia Healthcare partners (DVA), HCA, Zimn (ZMM); SPEAKER'S BUREAU - Astra-Zeneca Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Populations: Children and Adult Congenital Heart Disease Populations: Children and Populations: Children and Populations: Children and Populations: Children and Populations: Children and Populations: Children and Populations: Children and Populations and Province Adult Congenital Heart Disease Populations: Children and Populations: Children and Populations: Children and Populations: Children and Populations and Province Adult Children and Populations and Province Adult Children and Populations and Province Adult Children and Populations and Province Adult Children and Province Adult Children and Populations and Province Adult Children and Populations and Province Adult Children and Populations and Province Adult Children and Populations and Province Adult Children and Populations and Province Adult Children and Province Adult Children and Province Adult Children and Province	and Volumes in Patients With Significantly Reduced	
Navigate and Advocate Toh, Nor? (CVS), Davita Healthcare partners (DVA), HCA_Zimp	cherence Tomography of Culprit Lesions in Patients With Nothing to Disclose ebrovascular Events Compared to Controls	
Populations: Children and Adult Congenital Heart Disease Atrial Fibrillation in Young and Unusual Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Adult Congenital Heart Disease Populations: Children and Populations: C	(CVS),Davita Healthcare part	A), HCA, Zimmer Holdings
Populations: Children and Adult Congenital Heart Disease		
Coronary Artery Disease Disease and Prior Stents		
Matthew		Boehringer Ingelheim
Sherwood Matthew Interventional Cardiology: TAVR 3 Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patterns of Red Blood Cell Transfusion in Patterns of Red Blood Cell Transfusion in Patterns of Red Blood Cell Transfusion in Patterns of Red Blood Cell Transfusion in Patterns of Red Blood Cell Transfusion in Patterns of Red Blood Cell Transfusion in Patterns of Red Blood Cell Transfusion in Patterns of Red Blood Science In Patterns of Red Blood Science In Patterns of Red Blood Science In Patterns of Red Blood Science In Patterns of Red Blood Science In Patterns of Red Blood Science In Patterns of Red Blood Science In Patterns of Red Blood Science In Patterns of Red Blood Science In Patterns of Red Blood Science In Patterns of Red Blood Science In Patterns of Red Blood Science In Patterns of Red Blood Science In Patterns of Research In Patterns of Research Indicates In Patterns of Research Indicates In Patterns of Research Indicates In Patterns of Research Indicates In Patterns of Research Indicates Indicates Indicates Indicates Indicates Indicates Indicates Indicates Indicates Indicates Indicates Indicates Indicates Indicates Indicates Indicates Indicat	et Atrial Fibrillation Following Transcatheter Aortic Valve CONSULTANT FEES/HONG	Boehringer Ingelheim
Sheth Tej	of Red Blood Cell Transfusion and Associated Outcomes CONSULTANT FEES/HONG	Boehringer Ingelheim
Shetty Vijay	L Trial	GE Medical
Channel mRNA Splicing Ruijing Interventional Cardiology: Translation and Pre- Clinical Research Heart Disease Ruijing Impact of Prenatal Environment on Congenital Heart Disease Shi Victor Making Progress in Understanding Heart Failure Shi Victor Heart Failure and Cardiomyopathies: Heart Shi Victor Heart Failure and Cardiomyopathies: Heart Failure Elisose Insights From PARADIGM-HF Shi Victor Hormones and Heart Failure Shi Victor Hormones and Heart Failure Shi Victor Hormones and Heart Failure Shi Victor Hormones and Heart Failure Shi Victor Hormones and Heart Failure Shi Victor Hormones and Heart Failure Shi Victor Hormones and Heart Failure Shi Victor Hormones and Heart Failure Shi Victor Hormones and Heart Failure Shi Victor Hormones and Heart Failure Shi Victor The Old and the New: Impact of Heart Failure Shi Victor The Old and the New: Impact of Heart Failure Shi Victor The Old and the New: Impact of Heart Failure Shi Victor The Old and the New: Impact of Heart Failure Shi Victor The Old and the New: Impact of Heart Failure Shi Victor The Old and the New: Impact of Heart Failure Shi Victor The Old and the New: Impact of Heart Failure Shi Victor The Old and the New: Impact of Heart Failure Shi Ni Victor The Old and the New: Impact of Heart Failure Shi Ni Ni Victor The Old and the New: Impact of Heart Failure Shi Ni Ni Ni Ni Ni Ni Ni Ni Ni Ni Ni Ni Ni	nd Predictors of 30-Day Unplanned Readmission Rates Nothing to Disclose Ventricular Assist Device Placement	
Clinical Research	mRNA Splicing	
Ruijing	tinal Epithelium Derived MiRNAs Shape the Microbiota Nothing to Disclose	
Shi Victor Making Progress in Understanding Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF Shi Victor Heart Failure and Cardiomyopathies: Heart Editory in PARADIGM-HF Shi Victor Hormones and Heart Failure Low Urinary Cgmp/Bnp Ratio Is Associated With Worse Outcomes in Heart Failure but Is Increased by Treatment With Sacubifili/Valsartan. An Analysis of Paradigm-HF Shi Victor The Old and the New: Impact of Heart Failure Influence of Sacubitril/Valsartan on Glycemic Control in Patients With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction	Exosomal miRNAs in Diabetes Contribute to the Cardiac Nothing to Disclose	
Shi Victor Heart Failure and Cardiomyopathies: Heart Failure Effect of Sacubitril/Valsartan Compared With Enalapril, According to THER - Novartis Effect of Sacubitril/Valsartan Compared With Enalapril, According to OTHER - Novartis Ebiology in PARADIGM-HF Shi Victor Hormones and Heart Failure Low Urinary Cgmp/Bipp Ratio Is Associated With Worse Outcomes in Heart Failure but Is Increased by Treatment With Sacubitril/Valsartan. An Analysis of Paradigm-HF Shi Victor The Old and the New: Impact of Heart Failure Influence of Sacubitril/Valsartan on Glycemic Control in Patients With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction	haracteristics and Outcomes of Patients With Heart Failure OTHER - Novartis used Ejection Fraction and Chronic Obstructive Pulmonary	
Shi Victor Hormones and Heart Failure Low Urinary Cgmp/Bnp Ratio Is Associated With Worse Outcomes in Heart Failure but Is Increased by Treatment With Sacubifiti/Valsartar. An Analysis of Paradigm-HF Shi Victor The Old and the New: Impact of Heart Failure Influence of Sacubitril/Valsartar on Glycemic Control in Patients Drug Therapies With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction	Sacubitril/Valsartan Compared With Enalapril, According to OTHER - Novartis	
Shi Victor The Old and the New: Impact of Heart Failure Influence of Sacubitril/Valsartan on Glycemic Control in Patients Drug Therapies With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction	ny Cgmp/Bnp Ratio Is Associated With Worse Outcomes allure but Is Increased by Treatment With Valsartan: An Analysis of Paradigm-HF	
	of Sacubitril/Valsartan on Glycemic Control in Patients OTHER - Novartis	
Cardiomyopathies Compaction: Results From a National Population-Based Study	on: Results From a National Population-Based Study	
Shi Xu Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review Development of Anthracycline-Induced Cardiotoxicity in Mice and in Patients Nothing to Disclose	in Citric Acid Metabolism Are Associated With the Nothing to Disclose	
Shiffman Dov Arrhythmias and Clinical EP: AF Miscellaneous Association of Genetic Risk Score with Burden of Atrial Fibrillation: SALARY - Quest Diagnostics and Surgical Issues An ENGAGE AF-TIMI 48 Analysis		
Shikany James Updates on Risk Factors for Cardiovascular Frailty as a Risk Factor for Cardiovascular Versus Non- Cardiovascular Mortality in Elderty Men: Results From the Outcomes of Sleep Disorders in Older Men (MrOS Sleep) Study	a Risk Factor for Cardiovascular Versus Non- scular Mortality in Elderly Men: Results From the	
Culcomes of Steep Disorders in Order Merit (MIOS Steep) Study Chi Young Valvular Heart Disease: Aortic Stenosis Comparisons of Flow-Gradient Patterns in Severe Aortic Stenosis Nothing to Disclose Between Bicuspid Aortic Valves and Tricuspid Aortic Valves	ons of Flow-Gradient Patterns in Severe Aortic Stenosis Nothing to Disclose	

and the second				I
Last Name	First Name	Session Title	Presentation Title	Disclosures
Shim	Min	Novel Developments in Acute Coronary Syndromes	Comparative Outcomes of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Diabetic Hypertensive Acute	Nothing to Disclose
			Myocardial Infarction Patients: Results From the Korea Acute	
Shim	Min	Timely Topics in Acute Coronary Syndromes	Myocardial Infarction Registry (KAMIR) Predictors of Mortality in Acute Myocardial Infarction Patients With	Nothing to Disclose
Silliii	IVIII I	Timely Topics in Acute Colonary Syndromes	Unprotected Left Main Coronary Artery Disease	Nothing to Disclose
Shim	Min	Advances in Chronic Total Occlusion	Impact of Percutaneous Coronary Intervention for Chronic Total	Nothing to Disclose
Shimada	Kenei	Intervention Non Invasive Imaging: MR Structure and	Occlusion Patients With Near-Normal Left Ventricular Function High-Intensity Culprit Plaque on Noncontrast T1-Weigted Magnetic	Nothing to Disclose
Onimada	rener	Valuvular Heart Disease	Resonance Imaging as a Novel Determinant of Major Adverse	Nothing to Disclose
			Cardiac and Cerebrovascular Events After Percutaneous Coronary	
Shimada	Yuichi	Updates on Risk Factors for Cardiovascular	Intervention Bariatric Surgery Is Associated With Reduced Risk and Cost of	Nothing to Disclose
		Disease	Emergency Department Visits and Hospitalizations for	
Shimada	Yuichi	Advances in HCM, PPCM and Other	Cardiovascular Disease Diagnostic Value of Metabolite Profiling in Hypertrophic	Nothing to Disclose
Sillillada	Tulchi	Cardiomyopathies	Cardiomyopathy	Nothing to Disclose
Shimizu	Wataru	The Evolving World of LVADs, Transplant and	Chronic Kidney Disease in Asian Patients With Heart Failure	Nothing to Disclose
Shimohama	Takao	Other Novel Discoveries Antiplatelet and Antithrombotic Agents in	Stent Edge Strut on Normal Segment Is Less Covered in Early	Nothing to Disclose
		Ischemic Heart Disease	Phase After Drug Eluting Stent Implantation	
Shimohama	Takao	Unusual Presentations of ACS	Lower Eicosapentaenoic Acid to Arachidonic Acid Ratio Is Associated With Intraplaque Cholesterol Crystals: An Optical	Nothing to Disclose
			Coherence Tomography Study	
Shin	Andrew	Engage @ ACC.17 Studio:The Newlywed	Participant, Team 3	Nothing to Disclose
Shin	Andrew	Game for Pediatric Cardiac Providers Predicting Outcomes in Pediatric Heart Disase	Insurance Type Is Associated With Longer Hospital Duration but	Nothing to Disclose
Onin	Aldiew	Tredicting Outcomes in Fedicatio Ficure Disase	Similar Mortality Among Children Undergoing Congenital Heart	Nothing to Disclose
Chin	Dong Ho	Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Thereses & Considerations in Antipletal & Considerations in Antipletal & Considerations in Antipletal & Considerations in Antipletal & Considerations in Antipletal & Considerations in Antipletal & Considerations in Antipletal & Considerations in Antipletal & Considerations in Antipletal & Considerations in Antipletal & Considerations in Antipletal & Considerations in Antipletal & Considerations in Antipel & Considerations in Anti	Surgery Association Retuces Duration of Dual Antiplotolet Therapy and	Nothing to Displace
Shin	Dong-Ho	Considerations in Antiplatelet Therapy and in ACS	Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multi-Vessel Disease on Outcomes in Patients Treated	Nothing to Disclose
	1		With Newer-Generation Drug-Eluting Stents	
Shin	Lisa	Innovations in Cardiovascular Risk Assessment and Reduction	Resting Amygdalar Activity Associates With Future Changes in Adiposity: Implications for Atherosclerotic Disease	Nothing to Disclose
Shinlapawittayatorn	Krekwit	Updates in Stable Ischemic Heart Disease	Vagus Nerve Stimulation Requires Both Ipsilateral and Contralateral	Nothing to Disclose
		1	Efferent Vagal Activity to Fully Exert Its Cardioprotection Against	-
Shinlapawittayatorn	Krekwit	Antithrombotic Therapy in Ischemic Heart	Cardiac Ischemia/Reperfusion Injury High-Dose Humanin Analogue Applied During Ischemia Provides	Nothing to Disclose
араткауакотт		Disease	Cardioprotection Against Ischemia-Reperfusion Injury Through	
Chinasi	Lineld	Antiquated and Antithonous best a Annual in	Attenuating Mitochondrial Dysfunction	Nething to Displace
Shiomi	Hiroki	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Application of DAPT Score to Predict Ischemic and Bleeding Events in Japanese Patients Undergoing Drug-Eluting Stent Implantation:	Nothing to Disclose
			An Observation From a Pooled Cohort of the CREDO-Kyoto Cohort-	
Chinman	Luctio	FIT Clinical Decision Making: Arrhythmias and	2, RESET, and NEXT Trials Torsades de Pointes Following Insulin Infusion in a Patient With	Nothing to Displace
Shipman	Justin	Electrophysiology	Hyperosmolar Hyperglycemic State	Nothing to Disclose
Shirai	Remina	Cutting Edge Vascular Medicine	Atheroprotective Effects of Tumor Necrosis Factor-Stimulated Gene-	Nothing to Disclose
Shirai	Shinichi	Interventional Cardiology: Intravascular	6 Long-Term Vascular Response to Permanent Polymer Everolimus-	Nothing to Disclose
Siliai	Sillilicili	Physiology and Endothelial Function	Eluting Stent Compared With Biodegradable Polymer Biolimus-	Nothing to Disclose
			Eluting Stent: Five-Year Follow-Up Optical Coherence Tomography	
Shirai	Shinichi	Interventional Cardiology: TAVR 4	Study Transcatheter Aortic Valve Implantation in Patients With an	Nothing to Disclose
Office			Extremely Small Annulus	-
Shirai	Shinichi	Coronary Intervention in Interventional	Incidence and Clinical Impact of Longitudinal Stent Deformation	Nothing to Disclose
		Cardiology: Core Concepts	After the PROMUS Element Platinum Chromium-Everolimus Eluting Stent Implantation	
Shirai	Shinichi	Interventional Cardiology: PCI in Complex	Three-Year Clinical Outcomes of the XIENCE/PROMUS Cobalt-	Nothing to Disclose
		Patients	Chromium Everolimus-Eluting Stent in Patients Treated With In- Stent Restenosis	
Shirai	Shinichi	Unusual Presentations of ACS	The Impact of Residual Syntax Score in ACS Patients With LV	Nothing to Disclose
Chinali	Ciriob	Tank Varianci (with Overhead Dadiebie	Dysfunction	Nething to Displace
Shirali	Girish	Test Yourself with Questions: Pediatric Cardiology	Co-Chair	Nothing to Disclose
Shirali	Girish	Congenital Heart Disease: Innovations in	Interstage Resource Utilization of Infants With Single Ventricle:	Nothing to Disclose
Shirali	Girish	Single Ventricle Heart Disease New Technologies in Echocardiography	Results of a Crossover Study Accuracy and Reproducibility of Automated 3D Echocardiographic	Nothing to Disclose
Oman	Cilibil	recimologies in Editocal diography	Analysis of Left Ventricular Size and Ejection Fraction in Childhood	Trouming to Discluse
OL: II	0	140.00	Cancer Survivors	Notice to Breaten
Shirali	Girish	Congenital Heart Disease: Pediatric Team	Suggested Reviewer	Nothing to Disclose
Shirani	Jamshid		Temporal Trends and Outcomes of Emergent Coronary Artery	Nothing to Disclose
		in Acute and Stable Ischemic Heart Disease	Bypass Graft Surgery for ST-Segement Elevation Myocardial Infarction	
Shirani	Jamshid	Interventional Cardiology: TAVR 2	Comparison of In-Hospital Outcomes of Transcatheter Aortic Valve	Nothing to Disclose
		3.7	Replacement in Men and Women	-
Shirani	Jamshid	Advances in HCM, PPCM and Other Cardiomyopathies	Childbirth Related Complications in Women With Hypertrophic Cardiomyopathy	Nothing to Disclose
Shirani	Jamshid	Things That Begin With an "A" in Adult	Isolated Single Coronary Artery in Adult Population: A	Nothing to Disclose
		Congenital Heart Disease: What Is Aorta,	Contemporary Classification	
Shirani	Jamshid	Artery and Anomalous? Interventional Cardiology: TAVR 4	Outcomes of Trans-Catheter Aortic Valve Replacement in	Nothing to Disclose
		3.7	Nonagenarians	Ÿ
Shirani	Jamshid	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Cardiovascular Complications and In-Hospital Outcomes of Chagas' Disease in the United States From 2003-2011	Nothing to Disclose
Shishehbor	Mehdi	Controversies and Strategies for Endovascular	Emerging Strategies for Crossing Femoropopliteal CTO: Many	CONSULTANT FEES/HONORARIA - Boston
		Treatment of the Femoropopliteal Segment	Strategies, Many Devices, but What About an Algorithm?	Scientific,Medtronics
Shishehbor	Mehdi	Complications of PCI: Case Reviews	Case Presentation: Bleeding Complication	CONSULTANT FEES/HONORARIA - Boston
		·	,	Scientific, Medtronics
Shishehbor	Mehdi	Maximally Effective Vascular Care: Vascular Collaborative Team Care in Action	Case Presentation #4: Panelist	CONSULTANT FEES/HONORARIA - Boston Scientific,Medtronics
Shishehbor	Mehdi	Meet the New LE PAD Guidelines: Case-	LE Revascularization for CLI: When, How and Why.	CONSULTANT FEES/HONORARIA - Boston
		Based Examples of Optimal Vascular Care	·	Scientific, Medtronics
Shishehbor	Mehdi	Core Curriculum: Head to Toe Catheter Based Interventions	Limb Ischemia: Tales of Success in Saving Limbs	CONSULTANT FEES/HONORARIA - Boston Scientific,Medtronics
Shishehbor	Mehdi	The Best Coronary and Peripheral	ACC Panelist	CONSULTANT FEES/HONORARIA - Boston
		Interventional Challenging Cases		Scientific, Medtronics
Shishehbor	Mehdi	Highlights in Vascular Medicine Research	Thirty-Day Readmissions Following Endovascular or Surgical Treatment for Critical Limb Ischemia: Analysis of the Nationwide	CONSULTANT FEES/HONORARIA - Boston Scientific,Medtronics
	1		Readmissions Database	
Shishehbor	Mehdi	39. Vascular Medicine: Endovascular Therapy	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston
<u> </u>	1	Team 1	L	Scientific,Medtronics

Last Name Shivapour	First Name Jill	Session Title FIT Clinical Decision Making: Prevention, Adult	Presentation Title Cor Triatriatum: A Tale of Two Membranes	Disclosures Nothing to Disclose
Silivapoui	JIII	Congenital and Congenital Heart Disease	Col Trialitaturii. A Tale of Two Wellibrailes	Nothing to Disclose
Shlofmitz	Richard	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Optical Coherence Tomography Assessment of Coronary Atherectomy Effect: Comparison Between Orbital and Rotational Atherectomy in Severely Calcified Lesions	SPEAKER'S BUREAU - CSI
Shlofmitz	Richard	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	The Effectiveness of Excimer Laser Angioplasty to Treat Coronary In-Stent Restenosis With Peri-Stent Calcium as Assessed by Optical Coherence Tomography	SPEAKER'S BUREAU - CSI
Shlofmitz	Richard	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Twelve Month Follow-Up Data From the ONYX CORE Trial: Angiographic and Clinical Performance of Next Generation Resolute Onyx Drug-Eluting Stent	SPEAKER'S BUREAU - CSI
Shlofmitz	Richard	Interventional Cardiology: PCI in Complex Patients	Procedural Calcium Fracture and Its Effect on Stent Expansion Assessed by Optical Coherence Tomography	SPEAKER'S BUREAU - CSI
Shlofmitz	Richard	23. Interventional Cardiology: IVUS and	Suggested Reviewer	SPEAKER'S BUREAU - CSI
Shlyakhto	Evgeny	Intravascular Physiology Team 2 New Strategies in Arrhythmias Management:	Co-Chair	CONSULTANT FEES/HONORARIA - Merck Sharp & Description (CONSULTANT FEES/HONORARIA)
		International Perspectives From the Philippine Heart Association, Russian Society of Cardiology, and American College of Cardiology		Dohme; SPEAKER'S BUREAU - Boehringer- Ingelheim,Krka,Novartis Corporation,Pfizer,servier
Shoben	Abigail	Arrhythmias and Clinical EP: Devices 3	Cryoballoon Versus Radiofrequency Ablation of Atrial Fibrillation: In- Lab Complication Rates at a Large Volume Electrophysiology Center	RESEARCH/RESEARCH GRANTS - Pfizer
Shoemaker	Moore	Arrhythmias and Clinical EP: AF Ablation	Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism in Patients Undergoing Left Atrial Catheter Ablation Procedures for Paroxysmal or Persistent (Non-Permanent) Atrial Fibrillation and Left Atrial Flutter	Nothing to Disclose
Shokr	Mohamed	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Ultrasound Assisted Catheter Directed Thrombolysis and Percutaneous Right Ventricular Mechanical Assist Device for the Management of Massive Pulmonary Embolism With Refractory Right Ventricular Failure: Playing Chess With Pulmonary Embolism	Nothing to Disclose
Shokr	Mohamed	FIT Clinical Decision Making: Acute Coronary Syndrome and Vascular Medicine	Use of Ultrasound Assisted Catheter Directed Thrombolysis in Treatment of Aortic Thrombi	Nothing to Disclose
Sholler	Gary	Advances in HCM, PPCM and Other Cardiomyopathies	Long-Term Outcomes of Childhood Left Ventricular Non- Compaction: Results From a National Population-Based Study	Nothing to Disclose
Shor	Robert	Emerging CV Problems in the Developing World: International Perspectives From the ACC Bangladesh Chapter, Indonesian Heart Association, and American College of Cardiology	Confidencial results from a reduction reputation-based study	Nothing to Disclose
Shor	Robert	Emerging CV Problems in the Developing World: International Perspectives From the ACC Bangladesh Chapter, Indonesian Heart Association, and American College of Cardiology	Introduction to Session	Nothing to Disclose
Shor	Robert	Mentoring the Care Team: FITs, Early Career Professionals and CV Team Members	Mentoring the Early Career Professional: Leadership Skills	Nothing to Disclose
Shrader	Peter	Current Issues in Cardiovascular	Health Disparities Among Patients With Familial	Nothing to Disclose
Shrestha	Nabin	Epidemiology, Disparities, and Safety Valvular Heart Disease: Endocarditis	Hypercholesterolemia in the CASCADE-FH Patient Registry Comparison of Non-Surgical and Surgical Therapy for Prosthetic	Nothing to Disclose
Shrestha	Nabin	Valvular Heart Disease: Aortic Regurgitation	Valve Endocarditis: A Propensity Score-Adjusted Study Etiology, Patient Characteristics and Surgical Outcomes of Acute Severe Aortic Regurgitation	Nothing to Disclose
Shroff	Adhir	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	How a Cardiologist Diagnosed a Pheochromocytoma: Catecholamine-Induced Myocarditis	CONSULTANT FEES/HONORARIA - Cardiovascular Systems Incorporated,MEDTRONIC; SPEAKER'S BUREAU - Medicine's Company
Shroff	Gautam	Innovative Use of Echocardiography	Prognostic Utility of Hand-Carried Ultrasound Compared to Clinical and Laboratory Assessment of Decongestion to Predict Outcomes in Hospitalized Patients With Heart Failure	Nothing to Disclose
Shroff	Gautam	Insights From Echocardiography Use	Comparison of Clinical Exam, Patient Symptoms and Hand-Carried Ultrasound in Assessing Decongestion of Hospitalized Patients With Heart Failure	Nothing to Disclose
Shroff	Gautam	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Management of Impacted Intramyocardial Shrapnel Due to Gunshot Wound	Nothing to Disclose
Shuaib	Ashfaq	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Concomitant Use of Antiplatelet and Oral Anticoagulation Among Patients With Atrial Fibrillation: Insights From the Prospective SPRINT-AF Registry	Nothing to Disclose
Shukla	Anuj	Novel Echocardiographic Methods for Assessing Cardiac Function	Clinical and Echocardiographic Predictors of Atrial Fibrillation in Trauma Patients	Nothing to Disclose
Shukla	Parag	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Improvement in Cholesterol Efflux Capacity Is Associated With a Reduction in Aortic Wall Thickness by MRI Independent of Traditional CV Risk Factors	Nothing to Disclose
Shulman	Eric	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues		Nothing to Disclose
Shunk	Kendrick	The Best Coronary and Peripheral Interventional Challenging Cases	Percutaneous Revitalization of an Atretic Left Internal Mammary to Left Anterior Descending Coronary Artery Bypass Graft Using Sub- Intimal Tracking and Re-Entry Technique	CONSULTANT FEES/HONORARIA - MedeonBio,TransAortic Medical, Inc.; OTHER - Abbott Vascular,Edwards,MEDTRONIC; RESEARCH/RESEARCH GRANTS - Infraredx,Medinol,Siemens Medical Systems
Shuros	Allan	Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	Chronic Performance of Communicating Leadless Anti-Tachycardia Pacemaker and Subcutaneous Implantable Cardioverter Defibrillator	SALARY - Boston Scientific
Shyu	Kou-Gi	Heart Failure: From Pathophysiology to Socio- Economic Impact: International Perspectives From the Lebanese Cardiac Society, Taiwan Society of Cardiology, and American College of Cardiology	Co-Chair	Nothing to Disclose
Siasos	Gerasimos	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Association of Coronary Epicardial Endothelial Dysfunction With Low Endothelial Shear Stress in Patients With Mild Coronary Atherosclerosis Who Presented With Chest Pain	Nothing to Disclose
Siasos	Gerasimos	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Omega-3 Polyunsaturated Fatty Acids May Favorably Affect Inflammatory Biomarkers & Novel Indices of Left Ventricle Function in Patients With Heart Failure	Nothing to Disclose
Siasos	Gerasimos	MicroRNAs and Beyond in Vascular Medicine	Association of Endothelial Dysfunction and Arterial Wall Elastic Properties With Systemic Inflammation in Patients With Pseudoexfoliative Glaucoma	Nothing to Disclose
Siasos	Gerasimos	Diabetes and Endothelial Dysfucntion in Heart Failure	Association of Endothelial Dysfunction With Biomarkers of Inflammation, Myocardial Fibrosis and Left Ventricle Strain in Patients With Heart Failure	Nothing to Disclose
Siasos	Gerasimos	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Vascular Function of Conduit Arteries Is Associated With Progress of Diabetic Retinopathy in Type 2 Diabetes	Nothing to Disclose
		, it con an infocused	от ответно политоралну ит туре и гланетез	ı

Last Name	First Name	Session Title	Presentation Title	Disclosures
Siasos	Gerasimos	Vascular Access and Hemostasis Issues	Endothelial Dysfunction Post Transradial Access Coronary Catheterization: A Clinical Study and Meta-Analysis of Published	Nothing to Disclose
Siasos	Gerasimos	From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease	Literature Dietary Consumption of Olive Oil and Cardiovascular Outcome in Patients With Coronary Artery Disease	Nothing to Disclose
Siasos	Gerasimos	Uncovering the Intricacies of Vascular Function	The Impact of Natural Chios Mastic Supplementation on Endothelial Function and Arterial Stiffness in Smokers	Nothing to Disclose
Siasou	Georgia	MicroRNAs and Beyond in Vascular Medicine	Association of Endothelial Dysfunction and Arterial Wall Elastic Properties With Systemic Inflammation in Patients With Pseudoexfoliative Glaucoma	Nothing to Disclose
Siasou	Georgia	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Vascular Function of Conduit Arteries Is Associated With Progress of Diabetic Retinopathy in Type 2 Diabetes	Nothing to Disclose
Sibbing	Dirk	03. Acute and Stable Ischemic Heart Disease: Therapy Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Daiichi Sankyo,Eli Lilly,Roche Diagnostics; RESEARCH/RESEARCH GRANTS - Roche Diagnostics; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals,Bayer Vital,Pfizer Inc
Sibley	Janice	Teaching with Intent: Secrets from the Masters	ADDIE Instructional Design Model: How Can it Help me?	Nothing to Disclose
Sibley	Janice	Innovations in Education	Teaching Tomorrow's Teachers: An Innovative Model of Clinician- Educator Development for Trainees	Nothing to Disclose
Sica	Domenic	Feeling the Pressure - Tough Cases in Hypertension	Panelist	Nothing to Disclose
Sicari	Rosa	ACC International Conferences Best Posters	Comparison of Different Lung Ultrasound Methodologies for Pulmonary Congestion Evaluation in Heart Failure Outpatients	Nothing to Disclose
Siddiqui	Anwar J.	Post-CAD/MI: Making Tough Predictions About the Future	Percutaneous Coronary Intervention (PCI) Has Better Prognosis Than Conservative Treatment in Patient Over 80 Years During Non ST-Elevation Myocardial Infarction (NSTEMI)	Nothing to Disclose
Siddiqui	Fayez	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Things to Consider When Shopping for a Shunt: A Diagnostic Challenge	Nothing to Disclose
Siddiqui	Fayez	Emerging Developments in HFpEF and Arryhthmias	Hospitalization Burden of Diastolic Heart Failure in the United States: 2007-2012	Nothing to Disclose
Siddiqui	Mohammed	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Anthypertensive Treatment Failure Not Attributable to Persistent Intravascular Fluid Retention as Determined by MRI-Measured Intracardiac Volumes	Nothing to Disclose
Sidhu	Mandeep	What is the PROMISE of ISCHEMIA: A 2017 Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Awardee Lecture	Co-Chair	Nothing to Disclose
Sidhu	Rajbir	Timely Topics in Acute Coronary Syndromes	Emergency Room Evaluation of Patients With Cardiac Complaints and New Left Bundle Branch Block: The Utility of the Sgarbossa and Modified Soarbossa Criteria	Nothing to Disclose
Sidney	Stephen	Insights From Echocardiography Use	Relation of Left Ventricular Remodeling to Left Ventricular Diastolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	Nothing to Disclose
Sidney	Stephen	Insights From Echocardiography Use	Relation of Left Ventricular Remodeling to Left Ventricular Systolic Function Measures at Middle Age: Coronary Artery Risk Development in Young Adults (CARDIA) Study	Nothing to Disclose
Siegart	Nicolle	Cutting Edge Vascular Medicine	Pro-Atherogenic Properties of Plasma From Patients With Type 1 Diabetes Mellitus: Effects on Macrophage Lipid Handling	Nothing to Disclose
Siegel	Craig	Refining PCI Technique and Outcomes	Three-Year Results From the EVOLVE II Randomized Trial: Late Clinical Outcomes With Bioresorbable Compared to Permanent Polymer Everolimus-Eluting	Nothing to Disclose
Siegel	Robert	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries	SPEAKER'S BUREAU - Philips Ultrasound
Siegel	Robert	36. Valvular Heart Disease: Clinical Team 2	Suggested Reviewer	SPEAKER'S BUREAU - Philips Ultrasound
Siehr Sierra-Galan	Stephanie Lilia	FIT Clinical Decision Making Reviewers 5 Cardiovascular Magnetic Resonance A Fast and Reliable Method to Change Patients' Therapy. Joint Symposium of the Society for Cardiovascular Magnetic Resonance and the American College of Cardiology	ACC FIT Clinical Decision Making Reviewer Case Presentation/ACC Talk	Nothing to Disclose Nothing to Disclose
Sierra-Galan	Lilia	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team	Suggested Reviewer	Nothing to Disclose
Sietsema	Kathy	1 Innovations in Cardiovascular Risk Assessment and Reduction	The Prognostic Value of CPET: Association With Coronary Artery Calcium Score	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals,Boots,Cerexa,CHPA,Clarus,Kytehra,McNeil (Pinney Assoc),Merck & Co., Inc.,Novartis Corporation,NoVO-NORDISK,NPS,PharmaApprove,Takeda Pharmaceuticals North America, Inc,Trius; OTHER - MGC Diagnostics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Calistoga,Catabasis
Sievert	Horst	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Previous Major Gastrointestinal Bleeding: Insight From the Amplatzer Cardiac Plug Multicenter Registry	CONSULTANT FEES/HONORARIA - Abbott, Ablative Solutions Acoredis Ancona Heart, bioventrix, Boston Scientific, Carag, Cardiac Dimensions, Cardiokinetix, CELONOVA, CGuard, Cibiem, Coherex, Comed B.V., Contego Medical, CSI, CVRx, eV3, FlowCardia, Gardia Medical, Gore, Hemotheq, InspireMD, Kona Medical, Liferech, Lumen Biomedical, Maquet Getinge Group, MEDTRONIC, Occlutech, pfm, Sentreheart, Svelte Medical System, Tendyne, Trivascular, Inc., Valtech, Varyan, Vascular Dynamics, Venus Medical, OTHER - CardioKinetix, RESEARCH/RESEARCH GRANTS - SJM
Sievert	Horst	24. Interventional Cardiology: Mitral and Structural Heart Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott, Ablative Solutions Accredis Ancona Heart, bioventrix, Boston Scientific, Carag, Cardiac Dimensions, Cardiokinetix, CELONOVA, CGuard, Cibiem, Coherex, Comed B N., Contego Medical, CSI, CVRx, eV3, FlowCardia, Gardia Medical, Gore, Hemotheq, InspireMD, Kona Medical, Life Tech, Lumen Biomedical, Maquet Getinge Group, MEDTRONIC, Occlutech, pfm, Sentreheart, Svelte Medical System, Tendyne, Trivascular, Inc., Vallech, Varyan, Vascular Dynamics, Venus Medicai; OTHER - Cardiokinetix, RESEARCH/RESEARCH GRANTS - SJM

Contract of the second				I
Last Name Sievert	First Name Horst	Session Title Interventional Challenging Cases: Team 4	Presentation Title ACC Challenging Case Reviewer	Disclosures CONSULTANT FEES/HONORARIA - Abbott, Ablative Solutions, Acoredis, Ancona Heart, bioventrix, Boston Scientific, Caragi, Cardiac Dimensions, CardioKinetix, CELONOVA, CGuard, Cibiem, Coherex, Comed B.V., Contego Medical, CSI, CVRx, eV3, FlowCardia, Gardia Medical, Gore, Hemotheq, InspireMD, Kona Medical, Life Tech, Lumen Biomedical, Maquet Getinge Group, MEDTRONIC, Occlutech, pfm, Sentreheart, Svette Medical System, Tendyne, Trivascular, Inc., Valtech, Varyan, Vascular
				Dynamics, Venus Medical; OTHER - CardioKinetix; RESEARCH/RESEARCH GRANTS - SJM
Signorovitch	James	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Treatment Patterns and Resource Use of Heart Failure Patients on Medicaid in Five States in the US	SALARY - I am a salaried employee of Analysis Group Inc, which has received funding for consulting and research from BMS
Sigurdsson	Gardar	Interventional Cardiology: TAVR 1	Prognostic Value of Right Ventricular Function Assessed by Cardiac Computed Tomography in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Sigurdsson	Gardar	Non Invasive Imaging: Expanding Clinical Applications	Diagnostic Accuracy of Coronary Computed Tomography Angiography in Aortic Stenosis Patients Referred for Aortic Valve Replacement: Systematic Review and Meta-Analysis	Nothing to Disclose
Sigurdsson	Gardar	Things That Matter in Adult Congenital Heart Disease	Gender Differences in Rates of Hospitalizations for Decompensated Heart Failure Among Adults With Congenital Heart Diseases in the United States: A 15 Year Experience	Nothing to Disclose
Silber	Sigmund	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology Team 3	Suggested Reviewer	Nothing to Disclose
Silbernagel	Günther	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Circulating PCSK9 Is Not Associated With All-Cause and Cardiovascular Mortality	CONSULTANT FEES/HONORARIA - Amgen Inc.; OTHER - Amgen Inc.; RESEARCH/RESEARCH GRANTS - Amgen Inc.,Sanofi-Aventis; SPEAKER'S BUREAU - Sanofi-Aventis
Silka	Michael	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Contemporary Causes and Outcomes of Out of Hospital Ventricular Fibrillation in Pediatric Patients	Nothing to Disclose
Silva	José Carlos	Advances in Lipid Management	Impact of Statin Therapy on Collagen Turnover and Left Ventricle Function After ST-Elevation Myocardial Infarction: A Randomized Clinical Trial	Nothing to Disclose
Silva	Thiago	Advances in Lipid Management	Impact of Statin Therapy on Collagen Turnover and Left Ventricle Function After ST-Elevation Myocardial Infarction: A Randomized Clinical Trial	Nothing to Disclose
Silva	Thiago	Non Invasive Imaging: MR Scar and Perfusion	Doxorubicin-Associated Cardiac Tissue Remodeling in Breast Cancer Patients: A Cardiac Magnetic Resonance Study	Nothing to Disclose
Silver	Kevin	Unusual Presentations of ACS	Outcomes of Immediate Versus Delayed Intervention in Patients Presenting 24 -72 Hours After Myocardial Infarction	Nothing to Disclose
Silver	Michelle	Arrhythmias and Clinical EP: Basic 2	Utility of an Esophageal Screening Protocol in Preventing Atrio-	Nothing to Disclose
Silver	Michelle	Arrhythmias and Clinical EP: Basic 5	Esophageal Fistula After Atrial Fibrillation Ablation Cryoballoon Ablation Targeting Left Atrial Fibrosis Produces Similar	Nothing to Disclose
Silverberg	Bruce	Personalized Skills Center: Drill and Practice	Outcomes in Paroxysmal and Persistent Atrial Fibrillation Heart Songs Moderator	Nothing to Disclose
Silverman	Joanna	(Heart Songs, ECG, Hand-Held Echo) Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Small Dense Low Density Lipoprotein Particle Number Relates to Coronary Plaque Burden Independent of Traditional Cardiovascular	Nothing to Disclose
Silverman	Joanna	Non Invasive Imaging: Applications in Novel	Risk Factors in Psoriasis Aortic Vascular Inflammation by 18-FDG PET/CT Associates With	Nothing to Disclose
Silverman	Joanna	Disease States and Clinical Scenarios Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	High-Risk Coronary Plaques in Young Psoriasis Patients Improvement in Cholesterol Efflux Capacity Is Associated With a Reduction in Aortic Wall Thickness by MRI Independent of	Nothing to Disclose
Silversides	Candice	Redefining the "F" Word	Traditional CV Risk Factors Late Complications and Cardiopulmonary Performance in Adults With Fontan Physiology: Rv-Dominant Versus Those With Lv-	Nothing to Disclose
Silversides	Candice	Congenital Heart Disease: To the Third	Dominant or Unseptated Ventricles Twenty Year Trends in Maternal and Perinatal Complications in	Nothing to Disclose
Silvestre	Odilson	Decade and Beyond Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Pregnant Women With Heart Disease Natural Disasters and Risk of Myocaardial Infarction: A Systematic Review and Meta-Analysis	Nothing to Disclose
Silvestry	Frank	Coronary Artery Disease 24. Interventional Cardiology: Mitral and	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - DC Devices
-		Structural Heart Disease Team 1		
,	Scott	Should I Stay or Should I Go? Tough Cases in MCS and Transplant	Panelist	CONSULTANT FEES/HONORARIA - HeartWare,Thoratec
Sim		From Cardiovascular Risk Factors to Acute and Stable Coronary Syndrome: International Perspectives From the Inter-American Society of Cardiology, National Heart Association of Malaysia, and American College of Cardiology	Co-Chair	Nothing to Disclose
Simard Simard	Louis	Novel Determinants of Outcomes in VHD Novel Determinants of Outcomes in VHD	Impact of Aortic Valve Calcification and Sex on Hemodynamic Progression and Clinical Outcomes in Aortic Stenosis Pre-Operative Longitudinal Strain and Strain Rate as Predictors of	Nothing to Disclose
			Impaired Post-Operative Ejection Fraction in Patients Operated for Pure Aortic Regurgitation	Nothing to Disclose
	ŭ	Fontan in the Modern World	Towards a Better Predictive Model of Adverse Events in Adult Fontan Patients	Nothing to Disclose
Simon		Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Understanding Readmissions in Medicare Beneficiaries During the 90-Day Follow-Up Period Following an AMI Admission	Nothing to Disclose
Simon	April	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	What is the Impact of Complications During the Index Hospitalization on Resource Utilization During the 90-Day Follow-Up Period Associated With CABG Surgery Among Medicare Beneficiaries?	Nothing to Disclose
Simon	April	Acute Coronary Syndromes, Diagnosis,	Medicare Reimbursement Associated With an AMI Hospitalization	Nothing to Disclose
Simon	DaJuanicia	Management and Outcomes Atrial Fibrillation and VT: Specific Situations	and 90-Days Post-Discharge Does Frailty Alter the Benefits of Oral Anticoagulation in Patients	Nothing to Disclose
Simon	DaJuanicia	and Newer Outcome Measures Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	With Atrial Fibrillation? Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment	Nothing to Disclose
Simon	Mandy	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	of Atrial Fibrillation (ORBIT-AF) Multiple Biomarkers for Predicting Major Adverse Cardiac Events in At-Risk Patients Undergoing Diagnostic Coronary Angiography. Results From the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study	Nothing to Disclose
Simon	Marc	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Cardiovascular Diseases (CASABLANCA) Study Simplified Measures of Right Ventricular and Atrial Remodeling Are Predictive of Outcomes in Patients With Pulmonary Hypertension	RESEARCH/RESEARCH GRANTS - Aires Pharmaceuticals



Last Name	First Name	Session Title	Presentation Title	Disclosures
Simon	Marc	Nuclear Cardiology: Beyond Perfusion	Regional Right Ventricular (RV) Function as Determined by Gated Blood Pool SPECT (GBPS) Provides Additive Value to Evaluation of Patients Undergoing Left Ventricular Assist Device (LVAD)	RESEARCH/RESEARCH GRANTS - Aires Pharmaceuticals
Simon	Marc	New Technologies in Echocardiography	Implantation Assessment of Right Ventricular Energy Loss and Efficiency Using Novel Vector Flow Mapping	RESEARCH/RESEARCH GRANTS - Aires Pharmaceuticals
Simon	Tabassome	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Discriminant Value of the DAPT Score to Predict Long-Term Ischemic and Bleeding Events in the Real World Population of Stented Patients in the FAST-MI 2005 Cohort	CONSULTANT FEES/HONORARIA - AstraZeneca, Astellas, Bayer, BMS, Lilly, MSD, Novartis, Sanofi.; RESEARCH/FRESEARCH GRANTS - Astra-Zeneca, Bayer, Daichi-Sankyo, Eli-Lilly, Glaxo-Smith-Kline, MSD, Novartis, Sanofi
Simon	Tabassome	Antithrombotic Therapy in Ischemic Heart Disease	Long-Term Outcome With Oral Anticoagulants With or Without Dual Antiplatelet Therapy After AMI: The Fast-Mi 2010 Registry	CONSULTANT FEES/HONORARIA - AstraZeneca, Astellas, Bayer, BMS, Lilly, MSD, Novartis, Sanofi.; RESEARCH/RESEARCH GRANTS - Astra-Zeneca, Bayer, Daichi-Sankyo, Eli-Lilly, Glaxo-Smith-Kline, MSD, Novartis, Sanofi
Simon	Tabassome	Unusual Presentations of ACS	Characteristics and Outcomes of Patients Discharged Without Statins After an Acute Myocardial Infarction: An Analysis From the Combined FAST-MI 2005-2010 Cohorts	GOONSULTANT FEES/HONORARIA - AstraZeneca, Astellas, Bayer, BMS, Lilly, MSD, Novartis, Sanofi.; RESEARCH/FRESEARCH GRANTS - Astra-Zeneca, Bayer, Daichi-Sankyo, Eli-Lilly, Glaxo-Smith-Kline, MSD, Novartis, Sanofi
Simone	Amy	Great Minds Think Differently: Multidisciplinary Approach to Controversies in Cardiology	Case Presentation: THV When There Is More Than One Valve Involved? MR and AS (Surgical Versus THV Options)	CONSULTANT FEES/HONORARIA - Edwards Lifesciences
Simone	Amy	Structural Heart Disease: Difficult Choices for the Heart Team	Co-Chair	CONSULTANT FEES/HONORARIA - Edwards Lifesciences
Simone	Amy	TAVR: What We've Learned and Where We Think We're Going!	Patient Selection: Who Benefits the Most and Who Benefits the Least?	CONSULTANT FEES/HONORARIA - Edwards Lifesciences
Simone	Amy	TAVR Outcomes Prognostication	Predictors and Clinical Outcomes of Next-Day Discharge After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Edwards Lifesciences
Simonetti	Orlando	Cardiovascular Magnetic Resonance A Fast and Reliable Method to Change Patients' Therapy: Joint Symposium of the Society for Cardiovascular Magnetic Resonance and the American College of Cardiology	Co-Chair	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - EXCMR, Inc; RESEARCH/RESEARCH GRANTS - Cook MEDInstitute, Siemens
Simonetti	Orlando	Non Invasive Imaging: Expanding Clinical Applications	Non-Contrast Quantification of Myocardial Fibrosis With Dual Energy Computed Tomography	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - EXCMR, Inc; RESEARCH/RESEARCH GRANTS - Cook MEDInstitute, Siemens
Simonini	Americo	Considerations in Antiplatelet Therapy and in ACS	Novel Biomarker Algorithmic Panel Measuring Permutations of Immune Response to Cardiac Endothelial Injury and Global Risk Factors Identifies Patients at Risk of Acute Coronary Syndrome	Nothing to Disclose
Simonton	Charles	Highlighted Original Research: Interventional Cardiology and the Year in Review	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	SALARY - Abbott Vascular
Simonton	Charles	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Differences and Level of Agreement in SYNTAX Score Assessment Between Site Operators and Angiographic Core Laboratory Readers: Insights From the EXCEL Trial	SALARY - Abbott Vascular
Simonton	Charles	Refining PCI Technique and Outcomes	Treatment of Left Main Coronary Artery Disease in Patients With Diabetes: 3-Year Outcomes Comparing CABG and PCI With Everolimus-Eluting Stents From the EXCEL Study	SALARY - Abbott Vascular
Simonton	Charles	Refining PCI Technique and Outcomes	Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory	SALARY - Abbott Vascular
Simonton	Charles	PCI Strategies and Outcomes Unique to	Assessment: Insights From the EXCEL Trial Sex Differences in Outcomes After Stenting or Bypass Surgery for	SALARY - Abbott Vascular
Simpson	Brian	Women Current Issues in Cardiovascular	Unprotected Left Main Disease Ethnicity, Marital Status, and Neighborhood Poverty Influence Resuscitation of Out-of-Hospital Sudden Unexpected Deaths	Nothing to Disclose
Simpson	Joanne	Epidemiology, Disparities, and Safety Heart Failure and Cardiomyopathies: Heart	Effect of Sacubitril/Valsartan Compared With Enalapril, According to Etiology in PARADIGM-HF	Nothing to Disclose
Simpson	Leo	Failure Is Just a Revolving Door Atrial Fibrillation and VT: Unique Populations and Solutions	The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience	Nothing to Disclose
Simpson	Leo	Ventricular Arrhythmias and Sudden Death Prevention	Experience Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience	Nothing to Disclose
Simpson	Leo	FIT Clinical Decision Making: Heart Failure and Cardiomyopathies		Nothing to Disclose
Simpson	Pippa	Highlighted Original Research: Congenital	Re-Intervention During the Interstage Period: A Report From the	Nothing to Disclose
Simpson	Pippa	Heart Disease and the Year in Review Redefining the "F" Word	National Pediatric Cardiology Quality Improvement Collaborative Cardiopulmonary Exercise Testing for Surgical Risk Stratification in	Nothing to Disclose
Simpson	Ross	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Adults With Congenital Heart Disease Ethnicity, Marital Status, and Neighborhood Poverty Influence Resuscitation of Out-of-Hospital Sudden Unexpected Deaths	CONSULTANT FEES/HONORARIA - Liposcience, Merck, Pfizer; SALARY - Carolina Center for Medical Excellence
Sims	Daniel	Markers of Prognosis Associated With	Prevalence and Prognostic Significance of Cardiac Troponin-T	Nothing to Disclose
Sims	Jason	Elevated Blood Pressure Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Elevation in Patients Admitted With Hypertensive Crises Utility of Cardiac Computed Tomography Scanning in the Diagnosis and Pre-Operative Evaluation of Patients With Infective Endocarditis	Nothing to Disclose
Simsek	Evrim	Advances in Pulmonary Arterial Hypertension	Comparisons of Invasive and Non-Invasive Cardiac Output	Nothing to Disclose
Simsic	Janet	Congenital Heart Disease: New Diagnostic	Measurment Methods in Pulmonary Hypertension Utility of Genetic Testing in Infants With Isolated Congenital Heart	Nothing to Disclose
Sinagra	Gianfranco	Approaches in Congenital Heart Disease Updates in Stable Ischemic Heart Disease	Disease The Close Relationship Between Drug Intolerance and Major Cardiac and Cerebrovascular Events After an Acute Coronary	Nothing to Disclose
Sinagra	Gianfranco	Advances in HCM, PPCM and Other	Syndrome or Coronary Revascularization Integrating Myocardial Strain and Exercise Performance Into	Nothing to Disclose
Sinagra	Gianfranco	Cardiomyopathies Predicting Outcomes in Cardiac Rehabilitation	Prognostication of Hypertrophic Cardiomyopathy Predictors of Major Adverse Cardiac Events in Long-Term Follow-	Nothing to Disclose
Sinak	Lawrence	Patients FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Up After Cardiac Rehabilitation Prompt Recognition and Intervention for Cardiac Tamponade Secondary to Gastro-Pericardial Fistula: A Successful Heart Team	Nothing to Disclose
Singer	Daniel	Arrhythmias and Clinical EP: Anticoagulation Issues	Effort Thrombolytic Therapy in Anticoagulated Patients: Case Series From Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET AF)	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim, Bristol-Myers Squibb, CVS Health, Johnson and Johnson, Inc.,MEDTRONIC; RESEARCH/RESEARCH GRANTS Boehringer Ingelheim Pharmaceuticals, Inc,Bristol-Myers Squibb Company "Johnson & Empresser Springer Company "Johnson & Empresser Springer Company "Johnson & Empresser Springer
Singer	Daniel	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim, Bristol-Myers Squibb, CVS Health, Johnson and Johnson, Inc.,MEDTRONIC; RESEARCH/RESEARCH GRANTS Boehringer Ingelheim Pharmaceuticals, Inc,Bristol-Myers Squibb Company, Johnson & Denson, Johnson, Medtronic, Inc.



Section Time	Contract of the second				
Montage Description Head Description Continued to Microsoft Services (Continued Description) (Continue			Non Invasive Imaging: MR Heart Failure and	Implementation of a Wideband Late Gadolinium Enhancement Cardiac Magnetic Resonance Protocol to Improve Assessment of Myocardial Scar in Patients With Implantable Cardioverter	
Segle Annie Control of the Control o	Singh	Amitoj		Bypass Graft Surgery for ST-Segement Elevation Myocardial	Nothing to Disclose
Significant Control (Control Planch Rev.) Significant Control (Cont	Singh	Amitoj			Nothing to Disclose
Signify Americ Signif	Singh	Amitoj	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Impact of Atrial Fibrillation on Outcomes in Patients Hospitalized	Nothing to Disclose
Sign) Armed Control (VAIDs Transparents) Conditionated of Unique Strategies and State of Uniq	Singh	Amitoj			Nothing to Disclose
Compared Control (1987 PM) Available Control (1987 PM)	Singh	Amitoj		Cardiovascular Complications and In-Hospital Outcomes of Chagas'	Nothing to Disclose
Simple	Singh	Anmol	Coronary Intervention in Interventional	Comparison of IABP With pLVAD in the Setting of Complex PCI and	Nothing to Disclose
Singh Annesder Accordance (Control Con	Singh	Avinainder	Current Issues in Cardiovascular		Nothing to Disclose
Singh Amender Accesses in FLAS PCAL and Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) And Cities Strip Amender College Control (Charles) Strip Amender College Control	Singh	Avinainder	Current Issues in Cardiovascular		Nothing to Disclose
Singh Annancer The Pooling yourself (Vision), Franciscus and Provision of Supplication Annance of Management (Vision of Supplication Annance) The Pooling Supplication (Vision of Supplication Annance) The Pooling Su	Singh	Avinainder	Advances in HCM, PPCM and Other	Misdiagnosis of Cardiac Amyloidosis Type by Standard	Nothing to Disclose
Singh Mented (Circular) Excess billion and Stable Settems (Foreign Annual Processes Annual Settems (Cartering Pathy). Trial young to Disclose (Circular) Excess billion and Stable Settems (Cartering Pathy). Trial young to Disclose (Circular) Excess billion and Stable Settems (Cartering Pathy). Trial young to Disclose (Circular) Excess billion and Stable Settems (Cartering Pathy). Trial young to Disclose (Circular) Excesses	Singh	Avinainder	The Evolving World of LVADs, Transplant and	Prevalence of Monoclonal Gammopathy of Unknown Significance in	Nothing to Disclose
Singh Anneed Certificity, Assist and State Design Making processor controlled Certificity, Assist and State Design Making State Certificity, Assist and Stat	Singh	Avinainder		Type 2 Myocardial Infarction in Young Patients Portends a Worse	Nothing to Disclose
Singh Palasamana Interventional Cardotogy TAVR 1 September 1 Interventional Cardotogy TAVR 2 Interventional Cardotogy TAVR 2 Interventional Cardotogy TAVR 2 Interventional Cardotogy TAVR 2 Interventional Cardotogy TAVR 2 Interventional Cardotogy TAVR 2 Interventional Cardotogy TAVR 2 Oceanitary And Cardotogy TAVR 2 Oceanitary And Cardotogy TAVR 2 Oceanitary And Cardotogy TAVR 2 Oceanitary And Cardotogy TAVR 2 Oceanitary And Cardotogy TAVR 2 Oceanitary And Cardotogy TAVR 2 Oceanitary And Cardotogy TAVR 2 Oceanitary And Cardotogy TAVR 2 Oceanitary And Cardotogy TAVR 3 Oceanitary Cardotogy TAVR 3 Oceanitary Cardotogy Tavr 3 Oceanitary Cardotogy Tavr 3 Oceanitary Cardotogy Tavr 3 Oceanitary Cardotogy Tavr 3 Oceanitary Cardotogy Tavr 3 Oceanitary Cardotogy Tavr 3 Oceanitary Cardotogy Tavr 3 Oceanitary Cardotogy Tavr 3 Oceanitary Cardotogy Tavr 3 Oceanitary Cardotogy Tavr 3 Oceanitary Cardotogy Tavr 3 Oceanitary Cardot	Singh	Avneet	Cardiology, Acute and Stable Ischemic Heart	Cardioembolic Stroke Due to Takotsubo Cardiomyopathy, Truly	Nothing to Disclose
Singh Harsmann Interventional Cardiology TAVR 2 The Influence of General on National Customers National Custom	Singh	Harsimran		Hypertrophy Is Associated With Increased Mortality After	Nothing to Disclose
Singh Harsmann Interventional Cardiology, TAVR 2 Obes hits A-Artic Sallocon hump Pleasment During hospitalization Course for Transcriptor Artic Value Registerment Profession Assistance of Cardiology, TAVR 3 Singh Harsmann In Tomical Decision Making, Heart Failure and Pleasment Profession Assistance of Pleasment Profession As	Singh	Harsimran	Interventional Cardiology: TAVR 2	The Influence of Gender on In-Hospital Clinical Outcomes in Hispanics Following Surgical and Transcatheter Aortic Valve	Nothing to Disclose
Page Page	Singh	Harsimran	Interventional Cardiology: TAVR 2	Does Intra-Aortic Balloon Pump Placement During Hospitalization Course for Transcatheter Aortic Valve Replacement Portent a	Nothing to Disclose
Singh	Singh	Harsimran	Interventional Cardiology: TAVR 3	Periprocedural Blood Transfusions in Patients Undergoing	Nothing to Disclose
Mariaman	Singh	Harsimran		Fulminant Myocarditis and Coronary Aneurysms in a Patient With	Nothing to Disclose
Harsmann Sex Digarry in VPD Customes Solidar Mark of Active Hard Vision Solidar Active Hard Vis	Singh	Harsimran		In-Hospital Clinical Outcomes Following Concomitant Coronary	Nothing to Disclose
Metally Effect of Earl of Primary Prevention of Non schemic Metally Effect of Earl of Primary Prevention of Non schemic Singh Seal Application With Congressia to International Primary Prevention of Non Schemic Singh Jagmeet First Name Constitution Primary Prevention of Non Schemic Primary Pr	Singh	Harsimran	Sex Disparity in VHD Outcomes	The Impact of Gender on In-Hospital Clinical Outcomes Following	Nothing to Disclose
Singh Seari Adult Patients With Comparity Syndrome How Do They Comparity Syndrome How Do They Comparity Syndrome Prevention of sudden Cardea Card	Singh	Hemindermeet		Mortality Effect of Icd in Primary Prevention of Non Ischemic	Nothing to Disclose
Singh Jagmeet Fit Forum: Acing the Transation What Makes a New Her Valuable CORSULTANT FEESHONDRARIA - Bactorak Boston Sentific Line Nava MEDTRARIA - Bactorak Boston Sentif	Singh	Isani	Adult Patients With Congenital Heart Disease:	Worse Outcomes in Hospitalizations of Women With Turner	Nothing to Disclose
Singh Jagmeet Can You See Me Now? Sensors For Monitoring Heart Failure Singh Jagmeet Can You See Me Now? Sensors For Monitoring Heart Failure Singh Jagmeet Can You See Me Now? Sensors For Monitoring Heart Failure Singh Jagmeet Can You See Me Now? Sensors For Monitoring Heart Failure Singh Jagmeet Can You See Me Now? Sensors For Monitoring Heart Failure Singh Jagmeet Role of Newer ICD Technologies for the Prevention of Sudden Cardiac Death Prevention of Sudden Cardiac Death Prevention of Sudden Cardiac Death Singh Jagmeet Role of Newer ICD Technologies for the Prevention of Sudden Cardiac Death Failure Singh Jagmeet Role of Newer ICD Technologies for the Prevention of Sudden Cardiac Death Failure Singh Jagmeet Role of Newer ICD Technologies for the Prevention of Sudden Cardiac Death Failure Singh Jagmeet Role of Newer ICD Technologies for the Prevention of Sudden Cardiac Death Failure Singh Jagmeet Role of Newer ICD Technologies for the Prevention of Sudden Cardiac Death Failure Singh Jagmeet Role of Newer ICD Technologies for the Prevention of Sudden Cardiac Death Failure Cardionyopathy Patients? Singh Jagmeet Making Progress in Understanding Heart Failure Singh Jagmeet Making Progress in Understanding Heart Failure Failure Cardiology, Acute and Stable Isohemic Heart Failure Cardiology, Acute and Stable Isohemic Heart Failure Singh Jasmeet Evaluating Strategies to Prevent Readmissions Singh Mammohan Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Singh Mammohan Rander Readmissions Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Mammohan Rander Readmissions Acute Heart Failure Sential Students Readmissions Acute Heart Failure Sential Students Readmissions Acute Heart Failure Sential Students Readmissions Acute Heart Failure Sential Students Readmissions Singh Mammohan Rander Readmissions Acute Heart Failure Sential Students Readmissions Acute Heart Failure Sential Students Readmissions Prevent Readmissions Acute Heart Failure Sential Stu	Singh	Jagmeet	FIT Forum: Acing the Transition: What FITs		Scientific,Liva Nova,MEDTRONIC,St. Jude Medical; DATA SAFETY MONITORING BOARD - RESPICARDIA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific,St. Jude
Monitoring Heart Failure Failure Scientific, Liva Now AEDTRONIC, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH (GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH (GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH (GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH (GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH (GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH (GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD - RESPICATION Inc.; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical: DATA SAFETY MONITORING BOARD -			Monitoring Heart Failure		Scientific,Liva Nova,MEDTRONIC,St. Jude Medical; DATA SAFETY MONITORING BOARD - RESPICARDIA inc; RESEARCH/RESEARCH GRANTS - Boston Scientific,St. Jude Medical
Prevention of Sudden Cardiac Death Scientific Liva Nova MEDTRONIC, St. Jude Medical; DATA SAFETY MONITORING BOADD. RESPICABDIA hic; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical; DATA SAFETY MONITORING BOADD. RESPICABDIA hic; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical; DATA SAFETY MONITORING BOADD. RESPICABDIA hic; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical; DATA SAFETY MONITORING BOADD. RESPICABDIA hic; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical; DATA SAFETY MONITORING BOADD. RESPICABDIA hic; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical; DATA SAFETY MONITORING BOADD. RESPICABDIA hic; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical; DATA SAFETY MONITORING BOADD. RESPICABDIA hic; Cardiology, Acute and Stable Isohemic Heart Disease, and Vascular Medicine and Cardiology, Acute and Stable Isohemic Heart Disease, and Vascular Medicine in Medical CP and Impelia RP Suggested Reviewer Intervention: Left Mini, Multivessel, Bufurcation Team 2 Literation and Cardiology, Coronary Intervention: Left Mini, Multivessel, Bufurcation Team 2 Literation Scientific, St. Jude Medical; DATA SAFETY MONITORING BOADD. RESPICABDIA hic; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical; DATA SAFETY MONITORING BOADD. RESPICABDIA hic; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical; DATA SAFETY MONITORING BOADD. RESPICABDIA hic; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical; DATA SAFETY MONITORING BOADD. RESPICABDIA hic; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical; DATA SAFETY MONITORING BOADD. RESPICABDIA hic; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical; DATA SAFETY MONITORING BOADD. RESPICABDIA hic; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical; DATA SAFETY MONITORING BOADD. RESPICABDIA hic; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical; DATA SAFETY MONITORING BOADD. RESPICABDIA hic; RESEARCH/RESEARCH GRANTS -	Singh	Jagmeet	Monitoring Heart Failure		Scientific,Liva Nova,MEDTRONIC,St. Jude Medical; DATA SAFETY MONITORING BOARD - RESPICARDIA inc; RESEARCH/RESEARCH GRANTS - Boston Scientific,St. Jude Medical
Singh Jagmeet Role of Newer ICD Technologies for the Prevention of Sudden Cardiac Death Should We Use a Vest in Newly Diagnosed Nonischemic Cardiomyopathy Patients? Solentific Liva Nova-MEDTRONICS, LJude Medical, DATA SAFETY MONITORING BOARD - RESPICARDUA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical Cardiomyopathy Patients? Circulating Concentrations of Orexin A Are Associated With Left Ventricular Reverse Remodeling and Clinical Outcomes Following Cardiac Resynchronization Therapy Solentific, Liva Nova-MEDTRONICS, LJude Medical; DATA SAFETY MONITORING BOARD - RESPICARDUA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical; DATA SAFETY MONITORING BOARD - RESPICARDUA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical DATA SAFETY MONITORING BOARD - RESPICARDUA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical DATA SAFETY MONITORING BOARD - RESPICARDUA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical DATA SAFETY MONITORING BOARD - RESPICARDUA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical DATA SAFETY MONITORING BOARD - RESPICARDUA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical DATA SAFETY MONITORING BOARD - RESPICARDUA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical DATA SAFETY MONITORING BOARD - RESPICARDUA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical DATA SAFETY MONITORING BOARD - RESPICARDUA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical DATA SAFETY MONITORING BOARD - RESPICARDUA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical DATA SAFETY MONITORING BOARD - RESPICARDUA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical DATA SAFETY MONITORING BOARD - RESPICARDUA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical DATA SAFETY MONITORING BOARD - RESPICARDUA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical DATA SAFETY MONITORING BOAR	Singh	Jagmeet		Panelist	Scientific,Liva Nova,MEDTRONIC,St. Jude Medical; DATA SAFETY MONITORING BOARD - RESPICARDIA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific,St. Jude
Failure Ventricular Reverse Remodeling and Clinical Outcomes Following Cardiac Resynchronization Therapy Ventricular Reverse Remodeling and Clinical Outcomes Following Cardiac Resynchronization Therapy SparFTY MONITORING BOADAD. RESPICARDIA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific, St. Jude Medical Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease, and Vascular Medicine Disease Disease, and Vascular Medicine Disease Disease, and Vascular Medicine Disease Disease, and Vascular Medicine Disease Dise	Singh	Jagmeet			Scientific,Liva Nova,MEDTRONIC,St. Jude Medical; DATA SAFETY MONITORING BOARD - RESPICARDIA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific,St. Jude
Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Singh Jasvindar 22. Interventional Cardiology: Coronary Intervention: Left Main, Multivessel, Bifurcation Team 2 Singh Manmohan Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Singh Manmohan Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Singh Manmohan Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Singh Manmohan Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Singh Manmohan FIT Clinical Decision Making: Arrhythmias and Electrophysiology Admitted for Heart Failure in the United States Admitted for Heart Failure in the United States Nothing to Disclose Nothing to Disclose Admitted for Heart Failure in the United States Nothing to Disclose Nothing	Singh	Jagmeet		Ventricular Reverse Remodeling and Clinical Outcomes Following	Scientific,Liva Nova,MEDTRONIC,St. Jude Medical; DATA SAFETY MONITORING BOARD - RESPICARDIA Inc; RESEARCH/RESEARCH GRANTS - Boston Scientific,St. Jude
Singh Jasvindar 22. Interventional Cardiology, Coronary Intervention: Left Main, Multivessel, Bifurcation Team 2 Suggested Reviewer Nothing to Disclose	Singh	Jaspreet	Cardiology, Acute and Stable Ischemic Heart	From latrogenic Right Coronary Artery Dissection Managed With	
Seasonal Variation in In-Patient Mortality, Cost of Hospitalization and Nothing to Disclose Nothing to Dis	Singh	Jasvindar	22. Interventional Cardiology: Coronary Intervention: Left Main, Multivessel, Bifurcation Team 2	Suggested Reviewer	
Singh Manmohan Acute Heart Failure: Evaluating Strategies to Prevent Readmissions Regional Variation in Hospitalization Outcomes Among Patients Nothing to Disclose Admitted for Heart Failure in the United States Nothing to Disclose Nothing to Discl	Singh	Manmohan	Acute Heart Failure: Evaluating Strategies to		Nothing to Disclose
Singh Manmohan FIT Clinical Decision Making: Arrhythmias and Electrophysiology Atrial Arrhythmias and Insights From Echocardiography Use Novel Echocardiographic Variables in the Diagnosis of Acute Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Pulmonary Embolism Narendra Arrhythmias and Clinical EP: Anticoagulation Issues Characteristics	Singh	Manmohan	Acute Heart Failure: Evaluating Strategies to	Regional Variation in Hospitalization Outcomes Among Patients	-
Novel Echocardiography Use Novel Echocardiographic Variables in the Diagnosis of Acute Nothing to Disclose	Singh	Manmohan	FIT Clinical Decision Making: Arrhythmias and	Hiatal Hernia: An Unconventional but Potentially Curable Cause of	Nothing to Disclose
Singh Narendra Arrhythmias and Clinical EP: Anticoagulation Suses Arrhythmias and Clinical EP: Anticoagulation Narendra Arrhythmias and Clinical EP: Anticoagulation Choices Reflect Significant Differences in Afrial Fibrillation Patient Sankyo, jaansen pharma, Novartis Corporation Consultant Use of Antiplatelet and Oral Anticoagulation Among Consultant Use of Antiplatelet and Oral Anticoagulation Among Consultant Use of Antiplatelet and Oral Anticoagulation Among Consultant Use of Antiplatelet and Oral Anticoagulation Among Consultant Treatment Sankyo, jaansen pharma, Novartis Corporation Consultant Teesthon Noraris Consultant Teesthon Consultant Teesthon Sankyo, jaansen pharma, Novartis Corporation Sankyo, jaansen pharma, Novartis Corporation Consultant Teesthon Noraris Consultant Teesthon Consultant	Singh	Manmohan	Insights From Echocardiography Use	Novel Echocardiographic Variables in the Diagnosis of Acute	Nothing to Disclose
Singh Narendra Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures and Newer Outcome Measures Singh Narendra The Evolving World of LVADs, Transplant and Other Novel Discoveries The Evolving World of LVADs, Transplant and Other Novel Discoveries Singh Narendra The Evolving World of LVADs, Transplant and Other Novel Discoveries Singh Narendra The Evolving World of LVADs, Transplant and Other Novel Discoveries Singh Narendra The Evolving World of LVADs, Transplant and Other Novel Discoveries Singh Narendra The Evolving World of LVADs, Transplant and Other Novel Discoveries Singh Narendra The Evolving World of LVADs, Transplant and Other Novel Discoveries Singh Narendra The Evolving World of LVADs, Transplant and Other Novel Discoveries Singh Narendra Atria Fibrillation Androg Consultant Anticoagulation Among Consultant Fibrillation: Specific Stituation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Students Anticoagulation Among Consultant Fibrillation: Specific Student	Singh	Narendra		Marked Physician Variability in Oral Anticoagulant Treatment Choices Reflect Significant Differences in Atrial Fibrillation Patient	Ingelheim,Pfizer/BMS; SPEAKER'S BUREAU - Daiichi
Singh Narendra The Evolving World of LVADs, Transplant and Coronary Artery Disease Learning and Algorithm Development CONSULTANT FEES/HONORARIA - Astra Zeneca, Boehringer-Ingelheim, Pfizer/BMS; SPEAKER'S BUREAU - Daiichi	Singh	Narendra		Concomitant Use of Antiplatelet and Oral Anticoagulation Among Patients With Atrial Fibrillation: Insights From the Prospective	CONSULTANT FEES/HONORARIA - Astra Zeneca, Boehringer- Ingelheim, Pfizer/BMS; SPEAKER'S BUREAU - Daiichi
	Singh	Narendra	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Coronary Artery Disease Learning and Algorithm Development	CONSULTANT FEES/HONORARIA - Astra Zeneca,Boehringer- Ingelheim,Pfizer/BMS; SPEAKER'S BUREAU - Daiichi

and the same of th				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Singh	Prachi	Diabetes and Other Issues in Cardiovascular Prevention	Rapid Rise in Insulin Secretion After Energy Drink Intake in Healthy Adults: A Randomized, Double Blind, Placebo Controlled Clinical Trial	Nothing to Disclose
Singh	Rajvir	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	High Blood Pressure on Discharge From Acute Decompensated Heart Failure in Patients With Type 2 Diabetes Is Associated With Decreased 12-Month Mortality: Findings From the Gulf-Care	Nothing to Disclose
Singh	Rajvir	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Do Women Benefit From Early Coronary Artery Bypass Graft and Percutaneous Coronary Interventions in Acute Coronary Syndromes: Answers From the Second Gulf Registry of Acute Coronary Events	Nothing to Disclose
Singh	Rajvir	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Patients With Atrial Fibrillation: Findings From the Gulf-Safe	Nothing to Disclose
Singh	Shailendra	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Early Unloading With Impella Support in Acute MI With Cardiogenic Shock Linked to Decreased Infarct Size, In-Hospital Mortality, and Hospital Length of Stay	Nothing to Disclose
Singh	Sukhchain	Arrhythmias and Clinical EP: Devices 1	Lower All-Cause Mortality in Younger Patients With Prophylactic Implantable Cardioverter Defibrillator Compared to Elderly Subjects: A Systemic Review and Meta-Analysis	Nothing to Disclose
Singh	Sukhchain	Atrial Fibrillation and VT: Unique Populations and Solutions	Reduced Mortality Benefit With Prophylactic Implantable Cardioverter Defibrillator in Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis	Nothing to Disclose
Singh	Sukhchain	Can CABG Patch CAD?	Minimally Invasive CABG Reduces Target Vessel Revascularizations in Comparison to PCI Without Increased Major Adverse Events: A Meta-Analysis of Randomized Trials	Nothing to Disclose
Singh	Sunil	Arrhythmias and Clinical EP: Devices 3	Transcatheter Closure of Residual Left Atrial Appendage Leaks Following Lariat Device Closure	Nothing to Disclose
Singh	Tamanna	Imaging the Athlete's Heart	Addressing Reference Echocardiographic Parameters in Athletic Screening: A College Football-Based Study Focusing on the Implications of Race and Correction for Body Composition	Nothing to Disclose
Singh	Vasvi	Interventional Cardiology: TAVR 1	Intraoperative Change in Myocardial Contractility With Transcatheter Aortic Valve Replacement Predicts Cardiovascular Outcomes	Nothing to Disclose
Singh	Vasvi	Interventional Cardiology: TAVR 1	Temporal Change in Myocardial Contractility After Transcatheter	Nothing to Disclose
Singh	Vikas	Updates on Risk Factors for Cardiovascular	Aortic Valve Replacement and Its Relationship With Quality of Life Hospital Admissions for Chest Pain Associated With Cocaine use in	Nothing to Disclose
Singh-Gupta	Vinita	Disease Heart Failure and Cardiomyopathies: Heart	the United States Long-Term Therapy With Elamipretide Normalizes Activation of the	Nothing to Disclose
· ·		Failure Is Just a Revolving Door	Mitochondrial Signal Transducer and Activator of Transcription 3 (mSTAT3) in of Left Ventricular Myocardium of Dogs With Chronic Heart Failure	
Singhvi	Aditi	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	latrogenic Diversion of Inferior Vena Cava to Left Atrium After Surgical Closure of Atrial Septal Defect	Nothing to Disclose
Singhvi	Aditi	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Right Ventricular Outflow Tract Obstruction Caused by Isolated Sinus of Valsalva Aneurysm	Nothing to Disclose
Sinha	Archana	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	Isolated Single Coronary Artery in Adult Population: A Contemporary Classification	Nothing to Disclose
Sinha	Shashank	Teaching with Intent: Secrets from the Masters II	Preparing to Chair a Session at the Annual Meeting (interviewee)	Nothing to Disclose
Sinha Sinha	Shashank Shashank	FIT Forum: Stump the Professor Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Co-Chair Patterns of Downstream Cardiac Procedures After Nuclear Myocardial Perfusion Imaging in the United States, 2008-2012	Nothing to Disclose Nothing to Disclose
Sinha	Shashank	Innovations in Education	Teaching Tomorrow's Teachers: An Innovative Model of Clinician-	Nothing to Disclose
Sinha	Shashank	Next Steps to Optimal Medical Therapy for	Educator Development for Trainees Clinical Facilitator	Nothing to Disclose
Sinha	Shashank	Heart Failure Patients Leading Us Astray? Pacemakers in	ACC Poster Moderator	Nothing to Disclose
Sinha	Shashank	Cardiomyopathies FIT Clinical Decision Making Reviewers 5	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Sinisalo	Juha	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	A Risk Locus for Non-ST-Elevation Myocardial Infarction on Chromosome 1p13.3 Is Also Associated With Peripheral Artery Disease in Patients With Acute Coronary Syndrome	Nothing to Disclose
Sinner	Gregory	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Guideline-Directed Medical Therapy Before CRT: Is It Always Necessary?	Nothing to Disclose
Sinner	Gregory	Arrhythmias and Heart Failure	Can the Ventricular-Arterial Coupling Ratio Predict Response to Cardiac Resynchronization Therapy for Patients Meeting Class Ila Indications?	Nothing to Disclose
Sinusas	Albert	Molecular Imaging in Heart Failure	Co-Chair	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MicroVide, LLC; RESEARCH/RESEARCH GRANTS - GE Healthcare, Lantheus, Merck & amp; amp; Co., Inc., MIFCOR, Novartis
Sinusas	Albert	Molecular Imaging in Heart Failure	Imaging of Myocardial Remodeling	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MicroVide, LLC; RESEARCH/RESEARCH GRANTS - GE Healthcare, Lantheus, Merck & Dryng, 100, 110, 110, 110, 110, 110, 110, 11
Sinusas	Albert	Role of Imaging in Peripheral Artery Disease	Co-Chair	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MicroVide, LLC; RESEARCH/RESEARCH GRANTS - GE Healthcare, Lantheus, Merck & amp; amp; Co., Inc., MIFCOR, Novartis
Sinusas	Albert	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Radiotracer Imaging Allows for Assessment of Serial Changes in Angiosome Foot Perfusion Following Revascularization and Predicts Limb Salvage Outcomes in Patients With Critical Limb Ischemia	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MicroVide, LLC; RESEARCH/RESEARCH GRANTS - GE Healthcare, Lantheus, Merck & amp; amp; Co., Inc., MIFCOR, Novartis
Sinusas	Albert	Non Invasive Imaging: Expanding Clinical Applications	Computed Tomographic Angiography Can Reliably Assess Epicardial Coronary Vasoreactivity in Response to Adenosine and Dobutamine	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MicroVide, LLC; RESEARCH/RESEARCH GRANTS - GE Healthcare, Lantheus, Merck & amp; amp; Co., Inc., MIFCOR, Novartis
Sinusas	Albert	Nuclear Cardiology: Beyond Perfusion	Radiotracer Imaging of Angiosome Foot Perfusion Correlates With Ankle-Brachial Index and Differentiates Critical Limb Ischemia Patients From Healthy Subjects	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MicroVide, LLC; RESEARCH/RESEARCH GRANTS - GE Healthcare, Lantheus, Merck & amp; amp; Co., Inc., MIFCOR, Novartis
Siontis	Georgios	Unusual Presentations of ACS	Non-Invasive Functional and Anatomical Diagnostic Testing for Patients With Low-Risk Acute Coronary Syndromes: A Network Meta-Analysis of Diagnostic Randomized Controlled Trials	Nothing to Disclose
Siontis	Konstantinos	FIT Clinical Decision Making Reviewers 3	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Siores	Elias	Advances in Cholesterol Measurement and Management	Beneficial Effect of Statin Therapy on Carotid Wall Temperatures in Patients With Familial Hyperlipidemia Syndromes: Results From a Randomized Trial	Nothing to Disclose
Siqueira	Dimytri	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Independent Pre Procedural Echocardiographic Predictors of Mitral Valve Restenosis After Percutaneous Mitral Balloon Valvuloplasty in a Large Consecutive Cohort Followed Up to Two Decades	Nothing to Disclose

Contract of the second				l
Last Name Siqueira	First Name Dimytri	Session Title Interventional Cardiology: Structural Heart	Presentation Title Initial Results and Long-Term Follow-Up of Percutaneous Mitral	Disclosures Nothing to Disclose
·	Dimytri	Disease Frontiers in Mitral Valve Disease and	Valvuloplasty in Patients With Pulmonary Hypertension Predictors of Immediate and Very Late Events After Percutaneous	Nothing to Disclose
Siqueira	·	Treatment	Mitral Valvuloplasty	-
Siraj	Aisha	Arrhythmias and Clinical EP: Devices 3	Near Zero Fluoroscopy Implantation of a Dual Chamber Pacemaker in Pregnancy Using Electroanatomical Mapping	Nothing to Disclose
Siraj	Aisha	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Aortic Regurgitation Due to Aortic Dissection: Complication Post Coronary Artery Bypass Surgery	Nothing to Disclose
Sirna	Sara	Current Issues in Cardiovascular	(In)Equity in Primary Prevention Statin Treatment Among Diabetics	Nothing to Disclose
Sirna	Sara	Epidemiology, Disparities, and Safety Infectious Endocarditis: Comprehensive	ACC Poster Moderator	Nothing to Disclose
Sisson	Evan	Perspectives Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering	Standard Care on the Time to Reach Goal Blood Pressure for	Nothing to Disclose
Siu	Samuel	Therapies Congenital Heart Disease: To the Third	Patients Presenting With Urgent Hypertension Twenty Year Trends in Maternal and Perinatal Complications in	Nothing to Disclose
Sivak	Joseph	Decade and Beyond Valvular Heart Disease With CKD or Cirrhosis	Pregnant Women With Heart Disease Low Utilization of Surgical Intervention to Treat Severe Aortic	Nothing to Disclose
	· ·		Stenosis in Patients With Chronic Kidney Disease	-
Sivarajan	Veena	Congenital Heart Disease: Advances in Quality Improvement for Pediatric Cardiac Care	Making Perioperative Handoff Communication Count by Improving Safety and Quality in a New Congenital Heart Program	Nothing to Disclose
Sivarajan	Venkatesan	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Co-Chair	Nothing to Disclose
Sivaram	Chittur	Innovations in Education	Update on the ABIM's Competency Based Pilot in Internal Medicine- Cardiology	CONSULTANT FEES/HONORARIA - MEDTRONIC
Sivaram	Chittur	Innovations in Education	Differing Interpretations of the ACGME Survey Questions by	CONSULTANT FEES/HONORARIA - MEDTRONIC
Sivaram	Chittur	Engage @ ACC.17 Studio: FIT Jeopardy Battle	Cardiovascular Fellows and Cardiovascular Faculty Judge	CONSULTANT FEES/HONORARIA - MEDTRONIC
	Chittur	of the State Chapters II Engage @ ACC.17 Studio: FIT Jeopardy Battle		CONSULTANT FEES/HONORARIA - MEDTRONIC
Sivaram		of the State Chapters IV		
Sivaram	Chittur	Innovation in Practice Management, Advocacy, and Education	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - MEDTRONIC
Sivaram	Chittur	FIT Clinical Decision Making: Valvular Heart Disease and Pericardial Disease	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - MEDTRONIC
Sivaram	Chittur	FIT Clinical Decision Making Reviewers 1	ACC FIT Clinical Decision Making Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC
Sivasambu	Bhradeev	Updates in Stable Ischemic Heart Disease	ST Elevation Myocardial Infarction in Nonagenarians: Review of Outcomes in National Inpatient Database	Nothing to Disclose
Sivasambu	Bhradeev	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Ready for Take-Off ?	Nothing to Disclose
Siwamogatham	Sarawut	Emerging Applications of Echocardiography	Echocardiographic Assessment of Right Ventricular Function in Acute Right Ventricular Failure Identified by Hemodynamic Criteria	Nothing to Disclose
Skaarup	Kristoffer	Innovative Use of Echocardiography	Usefulness of Left Ventricular Speckle Tracking Echocardiography in Diagnosing Paroxysmal Atrial Fibrillation in Ischemic Stroke and	Nothing to Disclose
Skaf	Sabah	Imaging Transcatheter Mitral Valve Repair and	Transient Ischemic Attack Patients Mitraclip: TEE Essentials for an Effective Screening and Patient	Nothing to Disclose
Skaf	Sabah	Replacement Imaging for Left Atrial Appendage and	Selection LAA Imaging- TEE: Getting Down to Basics	Nothing to Disclose
Skelding	Kimberly	Paravalvular Leak Closure: A Case Based Approach Radial Access Mini-Symposium II	Co-Chair	CONSULTANT FEES/HONORARIA - MEDTRONIC;
_				RESEARCH/RESEARCH GRANTS - Abbott, AstraZeneca Pharmaceuticals, Medinol, MEDTRONIC, Stentys, Tryton Medical
Skelding	Kimberly	21. Interventional Cardiology: Coronary Intervention: Devices Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC; RESEARCH/RESEARCH GRANTS - Abbott, AstraZeneca Pharmaceuticals, Medinol, MEDTRONIC, Stentys, Tryton Medical
Skelton	Thomas	Predicting the Future: Observations and Discoveries From Registries and Databases	Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study	Nothing to Disclose
Skolnick	Adam	Cardiovascular Procedures That Push the Line: High-Risk or Futility of Care?	Co-Chair	Nothing to Disclose
Skolnick	Adam	Novel Echocardiographic Methods for Assessing Cardiac Function	Use of Diastolic Parameters on Transthoracic Echocardiogram to Predict Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation	Nothing to Disclose
Skolnick	Adam	02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Skopicki	Hal	Clinical Team 2 Readmission in Heart Failure: Questions	Driving Care to Home: A180 Degree Approach to Enhance Care	RESEARCH/RESEARCH GRANTS - Novartis Corporation;
Skorton	David	Unanswered Opening Session and the Joint American	ACC.17 Simon Dack Lecture. Values: How the Arts and the	SPEAKER'S BUREAU - Novartis Corporation Nothing to Disclose
OKONON	Bavia	College of Cardiology and Journal of American College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture		Nothing of Discrete
Skoumas	Ioannis	Advances in Cholesterol Measurement and Management	Beneficial Effect of Statin Therapy on Carotid Wall Temperatures in Patients With Familial Hyperlipidemia Syndromes: Results From a Randomized Trial	Nothing to Disclose
Skoumas	Ioannis	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Association of Abdominal Aortic Wall Inflammation, Hepatic Fluorodeoxyglucose Uptake AND Visceral Adipose Tissue Biological Activity in Patients With Dyslipidemias	Nothing to Disclose
Skoumas	Ioannis	Nuclear Cardiology: Beyond Perfusion	Towns in Yaderia (Transcription of Alba Vascular Inflammation in Familial Combined Hyperlipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission Tomography Study	Nothing to Disclose
Skoumas	Ioannis	Cutting Edge Vascular Medicine	Familial Combined Hyperlipidemia Is Characterized by Higher Arterial AND Hepatic Fluorodeoxyglucose Uptake Compared to Heterozygous Familial Hypercholesterolemia	Nothing to Disclose
Skouri	Hadi	Population Specific Cardiomyopathies: From Exomes to Databases	Targeted and Exome Sequencing of 27 Lebanese Patients With Cardiomyopathies: Novel Variants in Known Genes, and Potential Novel Genes	Nothing to Disclose
Skurk	Carsten	MicroRNAs and Beyond in Vascular Medicine	Disturbed Expression of Immunoregulatory Long Noncoding RNAs in Circulating Immune Cells From Patients With Early Myocardial Infarction	Nothing to Disclose
Skurk	Carsten	Mechanisms of Vascular Inflammation in Atherogenesis	Deficiency of Long Noncoding RNA <>Malat1 System Deregulation and Accelerated Atherosclerosis in Apo E ^{-/-} Mice	Nothing to Disclose
Slawsky	Mara	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		Nothing to Disclose
Slim	Ahmad	Patient-Centered Imaging: Quality of Cardiac	Coverage and Reimbursement for Cardiac CT: Current Status	Nothing to Disclose
<u> </u>	1	CT Evidence	<u> </u>	

WASHINGTON, DC | MARCH 17 - 19 2017

Last Name	First Name	Session Title	Presentation Title	Disclosures	
Slocum	Nicklaus	Percutaneous Coronary Intervention: Lessons From the Real World	Outcomes After Percutaneous Coronary Intervention Among Patients With a History of Transient Ischemic Attack or	Nothing to Disclose	
			Cerebrovascular Accident: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium		
Slomka	Piotr	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium in the Elderly: Prevalence, Severity, and Association With All-Cause Mortality	OTHER - Cedars-Sinai software royalties; RESEARCH/RESEARCH GRANTS - NIH,Siem Systems	nens Medical
Slomka	Piotr	Nuclear Cardiology: Quality	Rest Scan Does Not Improve Automatic Machine Learning Prediction of Major Adverse Coronary Events After High Speed	OTHER - Cedars-Sinai software royalties; RESEARCH/RESEARCH GRANTS - NIH, Siem	nens Medical
Slomka	Piotr	Nuclear Cardiology: Coronary Flow	Myocardial Perfusion Imaging Precisely Controlled Arterial CO2 Can Potentiate Myocardial Blood Flow to the Same Extent as Adenosine: A Preclinical Study in	Systems OTHER - Cedars-Sinai software royalties; RESEARCH/RESEARCH GRANTS - NIH,Siem	nens Medical
Slomka	Piotr	Nuclear Cardiology: Coronary Flow	Canines With 13N-Ammonia PET Patient Motion Significantly Affects Measurements of Quantitative Global Regional Myocardial Blood Flow Assessment by Dynamic	Systems OTHER - Cedars-Sinai software royalties; RESEARCH/RESEARCH GRANTS - NIH,Siem	nens Medical
Slomka	Piotr	Non Invasive Imaging: New Technologies	Pet Improvement in LDL Is Associated With Decrease in Non-Calcified	Systems OTHER - Cedars-Sinai software royalties;	
Slomka	Piotr	Noninvasive Assessment of Coronary Flow	Plaque Volume on CTA as Measured by Automated Quantitative Software Relationship Between Whole Vessel Quantitative Plaque	RESEARCH/RESEARCH GRANTS - NIH, Siem Systems OTHER - Cedars-Sinai software royalties;	iens Medical
Slomka	Piotr	Reserve: Clinical Implications Imaging With Cardiac CT: The Case for	Characteristics and Noninvasive Fractional Flow Reserve From Coronary Computed Tomography Angiography Hormone Replacement Therapy Is Associated With Less Coronary	RESEARCH/RESEARCH GRANTS - NIH, Siem Systems OTHER - Cedars-Sinai software royalties;	nens Medical
		Calcium	Atherosclerosis and Lower Mortality	RESEARCH/RESEARCH GRANTS - NIH, Siem Systems	nens Medical
Slomka	Teresa	Novel Echocardiographic Methods for Assessing Cardiac Function	Clinical and Echocardiographic Predictors of Atrial Fibrillation in Trauma Patients	Nothing to Disclose	
Slomka	Teresa	Ventricular Arrhythmias and Sudden Death Prevention	Prophylactic Defibrillator Implantation in Patients With Non-Ischemic Cardiomyopathy: An Updated Comprehensive Meta-Analysis of	Nothing to Disclose	
Slosky	David	The Evolving World of LVADs, Transplant and	Randomized Controlled Trials Myocarditis and Rhabdomyolysis Incidence With Immune	Nothing to Disclose	
Slovut	David	Other Novel Discoveries Interventional Cardiology: TAVR 2	Checkpoint Inhibitors Association of Chronic Renal Insufficiency With In-Hospital	Nothing to Disclose	
			Outcomes of Transcatheter Aortic Valve Replacement	-	
Slovut	David	Interventional Cardiology: TAVR 3	Regional Variations in In-Hospital Outcomes and Healthcare Resource Utilization in Patients Undergoing Transcatheter Aortic Valve Replacement in the United States	Nothing to Disclose	
Slovut	David	Interventional Cardiology: TAVR 3	Transcatheter Versus Surgical Aortic Valve Replacement in Diabetes Mellitus: From the Nationwide Inpatient Sample	Nothing to Disclose	
Slovut	David	Optimizing the Care of ACS Patients	Weekend Versus Weekday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide	Nothing to Disclose	
Smalling	Richard	Interventional Cardiology: PCI and TAVR in Complex Patients	Analysis Predicting Risk Factors for Permanent Pacemaker Placement Following Transcatheter Aortic Valve Replacement: A UTHealth Experience	CONSULTANT FEES/HONORARIA - Edwards Jude Structural Heart, RESEARCH/RESEARCI Abbott Structural Heart, Claret Medical, Edwards	H GRANTS -
Smalling	Richard	Interventional Cardiology: TAVR 3	Transapical TAVR Is Associated With Higher Morbidity and Mortality Compared to Transfemoral TAVR in Men but Not in Women	Jude Structural Heart CONSULTANT FEES/HONORARIA - Edwards Jude Structural Heart, RESEARCH/RESEARCI Abbott Structural Heart, Claret Medical, Edwards	H GRANTS -
Smalling	Richard	Interventional Cardiology: TAVR 3	Comparing Outcomes in COPD Patients Undergoing TAVR and SAVR: A Propensity Matched Analyses	Jude Structural Heart CONSULTANT FEES/HONORARIA - Edwards Jude Structural Heart; RESEARCH/RESEARCI Abbott Structural Heart, Claret Medical, Edwards Jude Structural Heart	H GRANTS -
Smalling	Richard	The Challenges of Outcome Prediction in Valvular Heart Disease	Gender-Based Outcomes in Diabetics Undergoing Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Edwards Jude Structural Heart; RESEARCH/RESEARCI Abbott Structural Heart, Claret Medical, Edwards Jude Structural Heart	H GRANTS -
Smart	Frank	Novel Imaging and Therapies in Heart Failure	Unmasking Diastolic Failure	CONSULTANT FEES/HONORARIA - CardioKi Advisory Board; DATA SAFETY MONITORING Medical	BOARD - St. Jude
Smart	Frank	Advances in HCM, PPCM and Other Cardiomyopathies	Increased Prevalence of Left Ventricular Noncompaction in Certain Populations May Confer Increased Risk of Catastrophic Events	CONSULTANT FEES/HONORARIA - CardioKi Advisory Board; DATA SAFETY MONITORING Medical	
Smedira	Nicholas	How Hypertrophic Cardiomyopathy Became A Contemporary Treatable Genetic Heart Disease	Panelist	Nothing to Disclose	
Smedira	Nicholas	Non Invasive Imaging: MR Scar and Perfusion	Incremental Prognostic Utility of Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy	Nothing to Disclose	
Smeets	Christophe	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Bioimpedance Algorithms in Implantable Electronic Cardiac Devices: Relevant Diagnostics or Waste of Time?	Nothing to Disclose	
Smer	Aiman	Measuring Success in Cardiac Rehabilitation	Wrist Activity Tracking Devices and Support Programs: A Meta- Analysis	Nothing to Disclose	
Smiderle Gelain	Marco	Emerging Developments in HFpEF and Arryhthmias	Sex Differences in Risk Factors for Longitudinal Changes in Left Ventricular Diastolic Function: The Rotterdam Study	Nothing to Disclose	
Smilowitz	Nathaniel	STEMI Dilemmas: You Be the Judge	Case Presentation: Smoke but No Fire - STEMI Presentation with Non Obstructive Disease by Angiography	Nothing to Disclose	
Smiseth	Otto	Controversies in Echocardiography	Con: I Like the New Diastolic Guidelines, but I Still Need More Data	Nothing to Disclose	
Smiseth	Otto	Echocardiographic Assessment of LV Diastolic Function The New ASE/EACVI Guidelines 2016 Update: Joint Symposium of the American Society of Echocardiography and the American College of Cardiology	Co-Chair	Nothing to Disclose	
Smith	Carin	Contemporary Issues in Familial Hypercholesterolemia	Familial Hypercholesterolemia: Awareness, Detection and Control in the Community	RESEARCH/RESEARCH GRANTS - Abbvie	
Smith	Craig	Non Invasive Imaging: Expanding Clinical Applications	Does Patient Prosthesis Mismatch Defined by CT LVOT Area Predict Downstream Clinical Outcomes?	OTHER - Edwards Lifesciences	
Smith	Donald	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Predict Downstream Clinical Culcionnes? Countering the Anti-Platelet Effects of Ticagrelor With Platelet Concentrates Within 48 Hours of a Loading Dose: Ex Vivo Testing of Time-Effect on Functional Recovery in Patients With Cardiovascular Disease	RESEARCH/RESEARCH GRANTS - Amgen, S	Sanofi-Regeneron
Smith	Emily	Arrhythmias and Clinical EP: Basic 4	Deleterious Mutations in SCN10A Are Associated With Long QT Syndrome	Nothing to Disclose	
Smith	Eric	Young Investigator Awards Competition: Outcomes Research	A Hospital Level Analysis of 30-Day Readmission Rates for Heart Failure Patients and Long-Term Survival Among Highest and Lowest Performing Hospitals, Findings From Get With the Guidelines-Heart Failure	Nothing to Disclose	
Smith	Justin	Arrhythmias and Clinical EP: Devices 2	AngioVac Cannula for Management of Device Related Vegetative Growth	Nothing to Disclose	
Smith	Larry	The Malpractice Minefield: How to Avoid, Navigate and Advocate	What to Know About Malpractice Insurance and Strategies to Responding to a Malpractice Claim	Nothing to Disclose	
Smith	Lavone	Advances in HCM, PPCM and Other	Systemic Arterial Pulsatility Index (SAPi) Predicts Adverse	Nothing to Disclose	
		Cardiomyopathies	Outcomes in Advanced Heart Failure Patients		



Last Name	First Name	Session Title	Presentation Title	Disclosures
Smith	Lavone	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Impact of Cardiogenic Shock with or without Mechanical Circulatory Support on Short-Term and Long-Term Survival in Heart Failure Hospitalizations	Nothing to Disclose
Smith	Lavone	Advances in Pulmonary Arterial Hypertension	Pulmonary-Systemic Pulse Pressure Ratio Is Associated With	Nothing to Disclose
Smith	Lindsey	Innovations in Advocacy and Patient Centered	Adverse Clinical Outcomes in Group 1 Pulmnonary Hypertension Low-Risk Chest Pain Pathway: Outcomes and Implications in a	Nothing to Disclose
Smith	Sidney	Care Cardiovascular Update for the Clinician II:	Large Community Cohort Four Challenges on Lipid Evaluation and Management. Familal LDL-	Nothing to Disclose
0	0.1	Chronic Coronary and Systemic Disease (A Symposium by Valentin Fuster)	C, ApoB, HDL Efflux Capacity and PSCK9Inhibitors	N. W. C. D. C.
Smith	Sidney	Opening Session and the Joint American College of Cardiology and Journal of American College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture	Panelist	Nothing to Disclose
Smith	Sidney	Hypertension: Evolving Evidence, Changing Guidelines	Panelist	Nothing to Disclose
Smith	Sidney	Hypertension: Evolving Evidence, Changing Guidelines	2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)	Nothing to Disclose
Smith	Sidney	Coming to Consensus in a New Era: The Role of Non-statin Therapies in ASCVD Risk Reduction	Co-Chair	Nothing to Disclose
Smith	Sidney	Issues in the Treatment of Coronary Disease: Joint Symposium of the American Heart Association and the American College of Cardiology	Panelist	Nothing to Disclose
Smith	Sidney	Issues in the Treatment of Coronary Disease: Joint Symposium of the American Heart Association and the American College of Cardiology	Primary and Secondary Prevention	Nothing to Disclose
Smith	Thomas	Palliative Care for the 99% I: Promoting Palliative Care: The Why and What of PC Therapy	 	CONSULTANT FEES/HONORARIA - American Board of International Medicine, write test questions for HPM,Up To Date (co-editor, not pain symptoms)
Smith Smith	Thomas	Transcatheter Mitral Valve Repair	Essential Echocardiographic Imaging for Mitral Regurgitation	CONSULTANT FEES/HONORARIA - Abbott Vascular CONSULTANT FEES/HONORARIA - Abbott Vascular
	Thomas	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Percutaneous Coronary Intervention (PCI) Outcomes and Hospital Outliers in California	
Smithson	Shaun	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Treatment of Refractory Coronary Artery Spasm With Percutaneous Coronary Intervention	Nothing to Disclose
Smits	Pieter	Late-Breaking Clinical Trials: Interventional	FFR Guided Acute Complete Revascularization Versus Culprit Lesion Only Treatment in Patients Presenting With ST-Segment Elevation Myocardial Infarction and Multi Vessel Disease: The COMPARE-ACUTE Trial	CONSULTANT FEES/HONORARIA - AbbVie, Inc.,Medinol; RESEARCH/RESEARCH GRANTS - AbbVie, Inc.,AbbVie, Inc.,S Jude,Terumo
Smits	Pieter	Late-Breaking Clinical Trials: Deep Dive II	FFR Guided Acute Complete Revascularization Versus Culprit Lesion Only Treatment in Patients Presenting With ST-Segment Elevation Myocardial Infarction and Multi Vessel Disease: The COMPARE-ACUTE Trial	CONSULTANT FEES/HONORARIA - AbbVie, Inc.,Medinol; RESEARCH/RESEARCH GRANTS - AbbVie, Inc.,AbbVie, Inc.,S Jude,Terumo
Smolderen	Kim	I Can Do WHAT After My Heart Attack?	Panelist	RESEARCH/RESEARCH GRANTS - Merck & Dright - Merck & Drigh
Smolderen	Kim	I Can Do WHAT After My Heart Attack?	Why Am I Sad?	RESEARCH/RESEARCH GRANTS - Merck & Dryamp; Co., Inc.
Smolderen	Kim	Highlighted Original Research: Vascular Medicine and the Year in Review	Non-Adherence to the Joint ACC/AHA 2013 Lipid Performance Guidelines in Peripheral Arterial Disease: Insights From the PORTRAIT Registry	Nothing to Disclose
Smolderen	Kim	Optimizing Treatment of Peripheral Artery Disease	Smoking Behavior and Access to Smoking Cessation Support Following a Diagnosis of Peripheral Arterial Disease: Insights From the International PORTRAIT Registry	RESEARCH/RESEARCH GRANTS - Merck & Dramp; Co., Inc
Snarr	Brian	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Hypoplastic Left Heart Syndrome With Intact or Restrictive Atrial Septum:What Happens After Survival?	Nothing to Disclose
Snider	James	Innovations in Cardiovascular Risk Assessment and Reduction		Nothing to Disclose
Snipelisky	David	FIT Forum: Mix and Mingle	Co-Chair	Nothing to Disclose
Snipelisky Snow	David Thomas	FIT Clinical Decision Making Reviewers 2 Coronary Angiography, Intra-Vascular Imaging,	ACC FIT Clinical Decision Making Reviewer Variation in Practice and Concordance With Guideline Criteria for	Nothing to Disclose Nothing to Disclose
Snyder	Christopher	Revascularization and Outcomes FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Length of Stay After Elective Percutaneous Coronary Intervention Cor Triatriatum: A Tale of Two Membranes	Nothing to Disclose
So	Derek	Novel Developments in Acute Coronary Syndromes	Efficacy and Safety of Bivalirudin in Patients Undergoing Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment	RESEARCH/RESEARCH GRANTS - Lilly Canada, Spartan Bioscience Inc.
Soares Fernandes	Gustavo	Heart Failure and Cardiomyopathies: Heart	Elevation Myocardial Infarction A Meta-Analysis of Randomized Controlled Trials on Vagus Nerve	Nothing to Disclose
Sobieszczyk	Piotr	Failure Gadgets Galore Interventional Cardiology: TAVR 1	Stimulation for the Heart Failure Management Impact of Flow, Gradient, and Left Ventricular Function on	Nothing to Disclose
Sobieszczyk	Piotr	Interventional Cardiology: TAVR 3	Outcomes After Transcatheter Aortic Valve Replacement The Incidence of Permanent Pacemaker Implantation With SAPIEN 3 Heart Valve - Implantation Depth: The Higher the Better?	Nothing to Disclose
Soble	Jeffrey	Evolution of Critical Care Cardiology and the CICU	Co-Chair	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - TeleHealth Robotics; OWNERSHIP
Soble	Jeffrey	Evolution of Critical Care Cardiology and the CICU	Questions for Discussion	INTEREST/PARTNERSHIP/PRINCIPAL - Ascend HIT OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - TeleHealth Robotics; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Ascend HIT
Sobol	Tim	Acute Heart Failure: Evaluating Strategies to	Impact of an Inpatient Electronic Medical Record Heart Failure	INTEREST/PARTNERSHIP/PRINCIPAL - Ascend HII Nothing to Disclose
Sobral Sousa	Antônio Carlos	Prevent Readmissions Timely Topics in Acute Coronary Syndromes	Checklist on Readmissions Health Insurance Related Disparities in Reperfusion and Mortality for Patients With ST Segment Elevation Myocardial Infarction in	RESEARCH/RESEARCH GRANTS - Investigator
Sodhi	Gurpreet	Innovative Use of Echocardiography	Sergipe, Brazil Effect of Blood Pressure Control on Left Ventricle Strain Using	Nothing to Disclose
Soga	Yoshimitsu	Interventional Cardiology: PCI in Complex Patients	Speckle Tracking Imaging Three-Year Clinical Outcomes of the XIENCE/PROMUS Cobalt- Chromium Everolimus-Eluting Stent in Patients Treated With In-	Nothing to Disclose
Soga	Yoshimitsu	Endovascular Therapy: Running From Risk	Stent Restenosis Impact of Decrease in Blood Pressure After Endovascular Therapy	Nothing to Disclose
Sogade	Felix	Ventricular Arrhythmias and Sudden Death	for Renal Artery Stenosis ACC Poster Moderator	RESEARCH/RESEARCH GRANTS - MEDTRONIC; SPEAKER
Sohail	Muhammad	Prevention Arrhythmias and Clinical EP: Devices 2	Antibacterial Envelope Is Associated With Medical Cost Savings in	BUREAU - BMS CONSULTANT FEES/HONORARIA -
Coriali	wunammdu	ramyalililas and Clinical EF. Devices 2	Antibacterial Envelope is Associated With inedical Cost Savings in Patients at High Risk for Cardiovascular Implantable Electronic Device Infection	MEDTRONIC,Spectranetics,TYRX Inc. (Monmouth Junction, NJ)



Service Control Service Servic	Contract of the contract of th				<u> </u>
Source Course of Part of Course of Course of the Course of Part of Course of Part of Course of Part of	Sokos	George	Failure: Medications, Machines and Everything	Presentation Title Co-Chair	BUREAU - Actelion Pharmacruticals, Bayer
School Control (Control (Institute in Christians) Control (I	Sokos	George	Treatment Strategies for End Stage Heart Failure: Medications, Machines and Everything	Chronic Inotrope Therapy in End Stage HF: Is Mortality Everything?	RESEARCH/RESEARCH GRANTS - Resmed; SPEAKER'S BUREAU - Actelion Pharmacruticals,Bayer
Sergell Cerebral Control course in Control course in Control course in Control Contro	Solangi	Zeeshan	Current Issues in Cardiovascular		
Service Control Processing Mode of CANDA, Transport and District Control Processing Mode Control Pro	Solangi	Zeeshan	Current Issues in Cardiovascular	Prevalence and In-Hospital Outcomes of Uremic and Dialysis	Nothing to Disclose
School Pales Pa	Solangi	Zeeshan		Arrhythmias in Hospitalized Heart Transplanted Patients: A United	Nothing to Disclose
Protect Redemberson Pales Pa		Pallavi			Nothing to Disclose
Publication of Publication and Statement Internation and Imministry International Control Control Publication (Control Decision Markey) International Control Publication (Control Publication International Contr			Prevent Readmissions	Disparity of Disposition to Hospice Care Among Patients With Heart Failure in the United States Between 2003 and 2012	-
Column	Solanki		Pulmonary Hypertension	Acute Pulmonary Embolism and Imminent Hemodynamic Collapse at Very High Risk for Cerebral Hemorrhage	ů
Solmon Silburge Solmon Silburge Solmon Silburge Solmon Silburge Solmon Silburge Solmon Silburge Solmon Silburge Solmon Silburge Solmon Silburge Solmon Solmon Silburge Solmon Sol			Pulmonary Hypertension	Clot In-Transit	-
Percent Procedure Proced			Congenital and Congenital Heart Disease	Anomalous Left Coronary Artery Arising From the Pulmonary Artery in an Adult Patient	-
Schreiber Disease of the Resident Certification of Control C	Soliman	Elsayed		Prediction of Heart Failure: The Multi-Ethnic Study of	Nothing to Disclose
Estayed Disablete and Other Issues in Castiforceal and Castiforceal Modeliny in Disabletic Modeling Disabletic D	Soliman	Elsayed	Non Invasive Imaging: MR Scar and Perfusion	Association of Right Atrial Function With Incident Atrial Fibrillation:	Nothing to Disclose
Somers Osames The Southurn of Anticin Repurphisms of And Description of Anticin Repurphisms of Anticin Entry (1997) Somers Osames	Soliman	Elsayed		Blood Pressure Indices and Cardiovascular Mortality in Diabetics	Nothing to Disclose
Source Source Section of Description Section S	Soliman	Osama	The Spectrum of Aortic Regurgitation and	Acute vs Chronic Aortic Regurgitation: Is There a Difference in	Nothing to Disclose
Schman Osama Osama Osama Osama And Michael And And And And And And And And And And	Soliman	Osama	Heart Failure and Cardiomyopathies: What	A Weaning Marker From Veno-Arterial Extra Corporeal Membrane	Nothing to Disclose
Deleter Mit Leit Verticular Acad Devices by Use of Sudingual Mit Control (1997) Agriculture in Presental Continuement Presental Suggested by Vertical Academy (1997) Agriculture in Presental Suggested by Vertical Residence of Control (1997) Agriculture in Presental Suggested by Vertical Residence Organization After Incident Control (1997) Academy (1	Soliman	Osama	Next When All Else Is Failing?		-
Metiline Workshort Dudates in State Inchmine Treat Disease Predictions of Long Team Resource Utilization After Incident Wolfrig to Disclose			Pulmonary Hypertension	Patients With Left Ventricular Assist Devices by Use of Sublingual Microcirculatory Imaging	-
Perculaneous Coronary Intervention Decision Perculaneous Control Society Perculaneous			Heart Failure Management	Arterial Extracorporeal Membrane Oxygenation	-
Disease Cardiovascular Risk Equation in a Large Community Rissed Cohort The OMICS is Platimanary Hyperferiorism Cardiovascular Risk Equation in a Large Community Rissed Cohort Solomon Michael The OMICS is Platimanary Hyperferiorism Cardiovascular Risk Equation in a Large Community Rissed Cohort Robins of Child Cohort Cohort Michael Colomon	Solomon	Matthew	Updates in Stable Ischemic Heart Disease	Percutaneous Coronary Intervention	Nothing to Disclose
Solomon Michael The OMICS in Primorany Hippertension Co-Char Nothing to Disclose Solomon Michael Evolution of Critical Care Cardiology and the Co-Char Nothing to Disclose Solomon Michael Evolution of Critical Care Cardiology and the Co-Char Nothing to Disclose Solomon Michael Evolution of Critical Care Cardiology and the Co-Char Nothing to Disclose Solomon Michael Evolution of Critical Care Cardiology and the Co-Char Nothing to Disclose Solomon Robert Audit Policy Solomon Primoral Residence Cardiology and the Procession of Discussion of Discussion of Discussion of Disclose Solomon Robert Audit Corcorasy Syndromes, Dapprose, Manual Cardiology Syndromes, Dapprose, Manual Cardiology Syndromes, Dapprose, Manual Cardiology Syndromes, Dapprose, Manual Cardiology Syndromes, Dapprose, Manual Cardiology Syndromes, Dapprose, Will Healt Failure and Robert Cardiology Syndromes, Dapprose, Will Healt Failure and Cardiomyopathies and the Verain Review On Primord Syndromes Primord Synd	Solomon	Matthew			Nothing to Disclose
Solomon Michael Ciclus or Critical Care Cardiology and the Ciclus Michael Ciclus of Critical Care Cardiology and the Ciclus of Critical Care Cardiology and the Ciclus of Critical Care Cardiology and the Ciclus of Critical Care Cardiology and the Ciclus of Critical Care Cardiology and the Ciclus of Critical Care Cardiology and the Ciclus of Critical Care Cardiology and the Ciclus of Critical Care Cardiology and the Ciclus of Critical Care Cardiology and the Ciclus of Care Cardiology and the Ciclus of Care Cardiology and the Ciclus of					
Solomon Michael Colution of Critical Care Cardiology and the OLestions for Discussion (Oceaning Solomon Michael Colution of Critical Care Cardiology and the OLestions for Discussion (Oceaning Solomon Robert Column) (Oceaning Solomo			Evolution of Critical Care Cardiology and the		
Solomon Michael Evolution of Critical Care Cardiology and the OLU Host Control (CUL) Host	Solomon	Michael	Evolution of Critical Care Cardiology and the	Questions for Discussion	Nothing to Disclose
Solomon Robert Acute Heart Failure (Failure (Failure) (F	Solomon	Michael	Evolution of Critical Care Cardiology and the	Questions for Discussion	Nothing to Disclose
Solomon Robert Acute Coronary Syndromes, Diagnose, Management and Outcomes Peradictive of Acute Myocardial Infarction? Nothing to Disclose Management and Outcomes Peradictive of Acute Myocardial Infarction? Nothing to Disclose Control of Peradictive of Acute Myocardial Infarction? Nothing to Disclose Peradictive of Acute Myocardial Infarction? Nothing to Disclose Peradictive of Acute Myocardial Infarction? Nothing to Disclose Peradictive of Acute Myocardial Infarction? Nothing to Disclose Peradictive of Acute Myocardial Infarction? Nothing to Disclose Peradictive of Acute Myocardial Infarction? Nothing to Disclose Peradictive of Acute Myocardial Infarction? Nothing to Disclose Peradictive of Acute Myocardial Infarction. Nature of Patients With Reliable With Reli	Solomon	Robert	Acute Heart Failure: Evaluating Strategies to	No MAGGIC in Predicting Heart Failure Readmissions	Nothing to Disclose
Solomon Scott Featured Clinical Research III Outcomes Than Persistent/Persiented Filiation in Patients to Multi-Content Than Persistent/Persiented Filiation in Patients to Multi-Content Than Persistent/Persiented Filiation in Patients to Multi-Content Than Persistent/Persistent Filiation in Patients to Multi-Content Than Persistent/Persistent Filiation in Patients to Multi-Content Than Persistent Filiation (Patients Multi-Content Than Persistent/Persistent Filiation) Patients to Multi-Content Than Persistent Filiation (Patients Multi-Content Than Persistent Persistent Filiation) Patients Multi-Content Persistent Filiation (Patients Multi-Content Persistent Filiation) Patients Multi-Content Persistent Filiation (Patients Multi-Content Persistent Filiation) Patients Multi-Content Persistent Filiation (Patients Multi-Content Persistent Filiation) Patients Multi-Content Persistent Filiation (Patients Multi-Content Persistent) Persistent Filiation (Patients Multi-Content Persistent Filiation) Patients Multi-Content Filiation (Patients Multi-Content Filiation) Patients Multi-Content Filiation (Patients Multi-Content Filiation) Patients Multi-Content Filiation (Patients Multi-Content Filiation) Patients Multi-Content Filiation (Patients Multi-Content Filiation) Patients Multi-Content Filiation (Patients Multi-Content Filiation) Patients Multi-Content Filiation (Patients Multi-Content Filiation) Patients Multi-Content Filiation (Patients Multi-Content Filiation) Patients Multi-Content Filiation (Patients Multi-Content Filiation) Patients Multi-Content Filiation (Patients Multi-Content Filiation) Patients Multi-Content Filiation (Patients Multi-Content Filiation) Patients Multi-Content Filiation (Patients Multi-Content Filiation) Patients Multi-Content Filiation (Patients Multi-Content Filiation) Patients Multi-Content Filiation (Patients Multi-Content Filiation) Patients Multi-Content Filiation (Patients Multi-Content Filiation) Patients Multi-Content Filiation (Patients Multi-Content Filiation) Patients Multi-Content	Solomon	Robert	Acute Coronary Syndromes, Diagnosis,	Is Duration of Symptoms Predictive of Acute Myocardial Infarction?	Nothing to Disclose
and Cardiomyopathies and the Year in Review Palents With Relatively Preserved Ejection Fraction: A MADIT-CRT Long-Term Follow-Up Sub-Study Monitor Rise Boads - GSK, Theracos: RESEARCH/RESEARCH GRANTS - Abbott.Ampen Boston Scentific Novaritis, Novaritis, Takeda; DATA SAFETY MONITORING BOADS - GSK, Theracos: RESEARCH/RESEARCH GRANTS - Abbott.Ampen Boston Scentific Novaritis Novaritis, Sakoritis, Novaritis, Takeda; DATA SAFETY Monitoring Emersion Therapy for Heart Failure (PROVE-HF) Study Emersion Therapy for Heart Failure (PROVE-HF) Study Emersion Therapy for Heart Failure (PROVE-HF) Study Ampen. Bayer, GSK, Novaritis, Novaritis, Takeda; DATA SAFETY MONITORING BOADS - GSK, Theracos: RESEARCH/RESEARCH GRANTS - Abbott.Ampen Boston Scentific Novaritis Novaritis, Takeda; DATA SAFETY MONITORING BOADS - GSK, Theracos: RESEARCH/RESEARCH GRANTS - Abbott.Ampen Boston Scentific Novaritis Novaritis, Takeda; DATA SAFETY MONITORING BOADD - GSK, Theracos: RESEARCH/RESEARCH GRANTS - Abbott.Ampen Boston Scentific Novaritis Novaritis, Takeda; DATA SAFETY MONITORING BOADD - GSK, Theracos: RESEARCH/RESEARCH GRANTS - Abbott.Ampen Boston Scentific Novaritis Novaritis, Takeda; DATA SAFETY MONITORING BOADD - GSK, Theracos: RESEARCH/RESEARCH GRANTS - Abbott.Ampen Boston Scentific Novaritis Novaritis, Takeda; DATA SAFETY MONITORING BOADD - GSK, Theracos: RESEARCH/RESEARCH GRANTS - Abbott.Ampen Boston Scentific Novaritis Novaritis, Takeda; DATA SAFETY MONITORING BOADD - GSK, Theracos: RESEARCH/RESEARCH GRANTS - Abbott.Ampen Boston Scentific Novaritis Novaritis, Takeda; DATA SAFETY MONITORING BOADD - GSK, Theracos: RESEARCH/RESEARCH GRANTS - Abbott.Ampen Boston Scentific Novaritis Novaritis, Takeda; DATA SAFETY MONITORING BOADD - GSK, Theracos: RESEARCH/RESEARCH GRANTS - Abbott.Ampen Boston Scentific Novaritis Novaritis, Takeda; DATA SAFETY MONITORING BOADD - GSK, Theracos: RESEARCH/RESEARCH GRANTS - Abbott.Ampen Boston Scentific Novaritis Novaritis, Takeda; DATA SAFETY MONITORING BOADD - GSK, Theracos: RESEARCH/RESEARCH GRANTS - Abbott.Am	Solomon	Scott	Featured Clinical Research III	Outcomes Than Persistent/Permanent Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction	Amgen,Bayer,GSK,Novartis,Novartis,Takeda; DATA SAFETY MONITORING BOARD - GSK,Theracos; RESEARCH/RESEARCH GRANTS - Abbott,Amgen,Boston
Failure With a Normal EF for Real? Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE-HF) Study Amgen, Bayer, GSK, Novartis, Novartis, Stakeda, DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCHRESEARCH GRANTS - Abbott, Amgen, Boston Scientific, Novartis, Novartis, Stakeda, DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCHRESEARCH GRANTS - Abbott, Amgen, Boston Scientific, Novartis, Novartis, Stakeda, DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCHRESEARCH GRANTS - Abbott, Amgen, Boston Grant Stakeda, DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCHRESEARCH GRANTS - Abbott, Amgen, Boston Scientific, Novartis, Stakeda, DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCHRESEARCH GRANTS - Abbott, Amgen, Boston Scientific, Novartis, Stakeda; DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCHRESEARCH GRANTS - Abbott, Amgen, Boston Scientific, Novartis, Stakeda; DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCHRESEARCH GRANTS - Abbott, Amgen, Boston Scientific, Novartis, Stakeda; DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCHRESEARCH GRANTS - Abbott, Amgen, Boston Scientific, Novartis, Stakeda; DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCHRESEARCH GRANTS - Abbott, Amgen, Boston Scientific, Novartis, Takeda; DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCHRESEARCH GRANTS - Abbott, Amgen, Boston Scientific, Novartis, Novartis, Stakeda; DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCHRESEARCH GRANTS - Abbott, Amgen, Boston Scientific, Novartis, Novartis, Stakeda; DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCHRESEARCH GRANTS - Abbott, Amgen, Boston Scientific, Novartis, Novartis, Stakeda; DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCHRESEARCH GRANTS - Abbott, Amgen, Boston Scientific, Novartis, Novartis, Stakeda; DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCHRESEARCH GRANTS - Abbott, Amgen, Boston Scientific, Novartis, Novartis, Stakeda; DATA SAFETY MONITO			and Cardiomyopathies and the Year in Review	Patients With Relatively Preserved Ejection Fraction: A MADIT-CRT Long-Term Follow-Up Sub-Study	Amgen,Bayer,GSK,Novartis,Novartis,Takeda; DATA SAFETY MONITORING BOARD - GSK,Theracos; RESEARCHRESEARCH GRANTS - Abbott,Amgen,Boston Scientific,Novartis,Novartis,SANOFI,Teva,Ventripoint
Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF Solomon Scott Emerging Developments in HFpEF and Arryhthmias Influence of Left Ventricular Ejection Fraction on Cause-Specific Arryhthmias Mortality in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial Failure and Cardiomyopathies: Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial Solomon Scott Heart Failure and Cardiomyopathies: Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial Effect of Sacubitril/Valsartan Compared With Enalapril, According to Ejection Fraction: The CONSULTANT FEESHONGRARIA Amgen. Bayer. GSK. Novartis. Novartis. SANOFIL Teva. Ventripoint Solomon Scott Heart Failure and Cardiomyopathies: Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial Effect of Sacubitril/Valsartan Compared With Enalapril, According to Ejection Fraction: The CONSULTANT FEESHONGRARIA Amgen. Bayer. GSK. Novartis. Novartis. SANOFIL Teva. Ventripoint Solomon Scott Hormones and Heart Failure Low Urinary Cgmp/Bnp Ratio is Associated With Worse Outcomes in Heart Failure but is Increased by Treatment With Montroll Robert Scanding Novartis. Novartis. Pathod. Amgen. Bayer. GSK. Novartis. Novartis. Pathod. Amgen. Bayer. GSK. Novartis. Novartis. Pathod.	Solomon	Scott		Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE-HF) Study	Amgen,Bayer,GSK,Novartis,Novartis,Takeda; DATA SAFETY MONITORING BOARD - GSK,Theracos; RESEARCH/RESEARCH GRANTS - Abbott,Amgen,Boston Scientific,Novartis,Novartis,SANOFI,Teva,Ventripoint
Arryhthmias Mortality in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial Amgen, Bayer, GSK, Novartis, Novartis, Takeda, DATA SAFETY MONITORING BOARD - GSK, Theracos: RESEARCHRESEARCH GRANTS - Abbott, Amgen, Boston Scientific, Novartis, Novartis, SANOFI, Teva, Ventripoint Effect of Sacubitril/Valsartan Compared With Enalapril, According to CONSULTANT FEESHNONGARIA - Amgen, Bayer, GSK, Novartis, Novartis, Takeda; DATA SAFETY MONITORING BOARD - GSK, Theracos: RESEARCHRESEARCH GRANTS - Abbott, Amgen, Bayer, GSK, Novartis, Novartis, Takeda; DATA SAFETY MONITORING BOARD - GSK, Theracos: RESEARCHGESEARCH GRANTS - Abbott, Amgen, Bayer, GSK, Novartis, Novartis, Takeda; DATA SAFETY MONITORING BOARD - GSK, Theracos: RESEARCHGESEARCH GRANTS - Abbott, Amgen, Bayer, GSK, Novartis, Novartis, Takeda; DATA SAFETY MONITORING BOARD - GSK, Theracos: RESEARCHGESEARCH GRANTS - Abbott, Amgen, Bayer, GSK, Novartis, Novartis, Takeda; DATA SAFETY MONITORING BOARD - GSK, Theracos: RESEARCHGESEARCH GRANTS - Abbott, Amgen, Bayer, GSK, Novartis, Novartis, Takeda; DATA SAFETY MONITORING BOARD - GSK, Theracos: RESEARCHGESEARCH GRANTS - Abbott, Amgen, Bayer, GSK, Novartis, Novartis, Takeda; DATA SAFETY MONITORING BOARD - GSK, Theracos: RESEARCHGESEARCH GRANTS - Abbott, Amgen, Bayer, GSK, Novartis, Novartis, Takeda; DATA SAFETY MONITORING BOARD - GSK, Theracos: RESEARCHGESEARCH GRANTS - Abbott, Amgen, Bayer, GSK, Novartis, Novartis, Takeda; DATA SAFETY MONITORING BOARD - GSK, Theracos: RESEARCHGESEARCH GRANTS - Abbott, Amgen, Bayer, GSK, Novartis, Novartis, Novartis, SANOFI, Teva, Ventripoint Defibrillator Soltis Brian Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review Pacemaker and Subcutaneous Implantable Cardioverter Defibrillator Nuclear Cardiology: Current Applications and Best Practices. Joint Symposium of the American Society of Nuclear Cardiology and the American College of Cardiology of Nuclear Cardiology and the American College of Cardiology of Nuclear Cardiology and the American Soci	Solomon	Scott		With Reduced Ejection Fraction and Chronic Obstructive Pulmonary	Amgen,Bayer,GSK,Novartis,Novartis,Takeda; DATA SAFETY MONITORING BOARD - GSK,Theracos; RESEARCH/RESEARCH GRANTS - Abbott,Amgen,Boston Scientific,Novartis,Novartis,SANOFI,Teva,Ventripoint
Failure Is Just a Revolving Door Etiology in PARADIGM-HF Amgen, Bayer, GSK, Novartis, Novartis, Takeda; DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCH/RESEARCH GRANTS - Abbott, Amgen, Boston Scientific, Novartis, Novartis, Novartis, SANDFI, Teva, Ventripoint Solomon Scott Hormones and Heart Failure Low Urinary Cgmp/Bnp Ratio Is Associated With Worse Outcomes in Heart Failure but Is Increased by Treatment With Sacublirtil/Alsartan: An Analysis of Paradigm-HF Solomon Scott The Old and the New: Impact of Heart Failure Drug Therapies The Old and the New: Impact of Heart Failure Drug Therapies Influence of Sacubitril/Valsartan on Glycemic Control in Patients With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction Fraction Solomon Prem Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review Soman Prem Nuclear Cardiology: Current Applications and Best Practices: Joint Symposium of the American Society of Nuclear Cardiology and the American College of Cardiology RESEARCH/RESEARCH GRANTS - Astellas Pharma US	Solomon	Scott		Mortality in Heart Failure With Preserved Ejection Fraction: The	Amgen,Bayer,GSK,Novartis,Novartis,Takeda; DATA SAFETY MONITORING BOARD - GSK,Theracos; RESEARCH/RESEARCH GRANTS - Abbott,Amgen,Boston
Solomon Scott Hormones and Heart Failure Low Urinary Cgmp/Bnp Ratio Is Associated With Worse Outcomes in Heart Failure but Is Increased by Treatment With Sacubitril/Valsartan: An Analysis of Paradigm-HF Sacubitril/Valsartan: An Analysis of Paradigm-HF Solomon Solomon Scott The Old and the New: Impact of Heart Failure but Influence of Sacubitril/Valsartan on Glycemic Control in Patients Drug Therapies Influence of Sacubitril/Valsartan on Glycemic Control in Patients Drug Therapies Influence of Sacubitril/Valsartan on Glycemic Control in Patients Drug Therapies Influence of Sacubitril/Valsartan on Glycemic Control in Patients October 1	Solomon	Scott			Amgen,Bayer,GSK,Novartis,Novartis,Takeda; DATA SAFETY MONITORING BOARD - GSK,Theracos; RESEARCH/RESEARCH GRANTS - Abbott,Amgen,Boston
Solomon Scott The Old and the New: Impact of Heart Failure Drug Therapies Influence of Sacubitril/Valsartan on Glycemic Control in Patients With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction Fraction Fraction Soltis Brian Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review Defibrillator Soman Prem Nuclear Cardiology: Current Applications and Best Practices: Joint Symposium of the American Society of Nuclear Cardiology and the American College of Cardiology Influence of Sacubitril/Valsartan on Glycemic Control in Patients With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction CONSULTANT FEES/HONORARIA - Amen, Bayer, GSK, Novartis, Novartis, Novartis, Novartis, Takeda; DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCH/RESEARCH GRANTS - Abbott, Amgen, Bayer, GSK, Novartis, Novartis, Novartis, SANOFI, Teva, Ventripoint SALARY - Boston Scientific SALARY - Boston Scientific Nuclear Cardiology: Risk Stratification RESEARCH/RESEARCH GRANTS - Astellas Pharma US RESEARCH/RESEARCH GRANTS - Astellas Pharma US	Solomon	Scott	Hormones and Heart Failure	in Heart Failure but Is Increased by Treatment With	CONSULTANT FEES/HONORARIA - Amgen,Bayer,GSK,Novariis,Novariis,Takeda; DATA SAFETY MONITORING BOARD - GSK,Theracos; RESEARCH/RESEARCH GRANTS - Abbott,Amgen,Boston
and Clinical EP and the Year in Review Pacemaker and Subcutaneous Implantable Cardioverter Defibrillator Soman Prem Nuclear Cardiology: Current Applications and Best Practices: Joint Symposium of the American Society of Nuclear Cardiology and the American College of Cardiology and the American College of Cardiology RESEARCH/RESEARCH GRANTS - Astellas Pharma US RESEARCH/RESEARCH GRANTS - Astellas Pharma US			Drug Therapies	With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction	CONSULTANT FEES/HONORARIIA - Amgen Bayer, GSK, Novartis, Novartis, Takeda; DATA SAFETY MONITORING BOARD - GSK, Theracos; RESEARCH/RESEARCH GRANTS - Abbott, Amgen, Boston Scientific, Novartis, Novartis, SANOFI, Teva, Ventripoint
Soman Prem Nuclear Cardiology: Current Applications and Best Practices: Joint Symposium of the American Society of Nuclear Cardiology and the American College of Cardiology and	Soltis	Brian		Pacemaker and Subcutaneous Implantable Cardioverter	SALARY - Boston Scientific
	Soman	Prem	Best Practices: Joint Symposium of the American Society of Nuclear Cardiology and		RESEARCH/RESEARCH GRANTS - Astellas Pharma US
	Soman	Prem		Debate Con: Stress MRI is the Test of Choice for Ischemia	RESEARCH/RESEARCH GRANTS - Astellas Pharma US



and a second				
Last Name Soman	Prem	Session Title Radiation from Diagnostic Imaging: Risk-	Presentation Title Panelist	Disclosures RESEARCH/RESEARCH GRANTS - Astellas Pharma US
Soman	Prem	benefit Analysis Radiation from Diagnostic Imaging: Risk-	ACC Talk: Radiation Debate: The Main Considerations	RESEARCH/RESEARCH GRANTS - Astellas Pharma US
Soman	Prem	benefit Analysis Nuclear Cardiology: Beyond Perfusion	Regional Right Ventricular (RV) Function as Determined by Gated Blood Pool SPECT (GBPS) Provides Additive Value to Evaluation of Patients Undergoing Left Ventricular Assist Device (LVAD) Implantation	RESEARCH/RESEARCH GRANTS - Astellas Pharma US
Soman	Prem	Predicting the Future: Observations and Discoveries From Registries and Databases	Pulmonary Vascular Resistance Predicts Mortality in End-Stage Renal Disease Patients With Pulmonary Hypertension	RESEARCH/RESEARCH GRANTS - Astellas Pharma US
Soman	Prem	Nuclear Cardiology: Quality	Increasing Equipment Vintage Predicts Poor Laboratory Quality and Delay in Accreditation: An Evaluation by IAC Echocardiography and Nuclear Accreditation Status	RESEARCH/RESEARCH GRANTS - Astellas Pharma US
Soman	Prem	Nuclear Cardiology: Quality	Repeatability of Appropriateness Category Allocation by Trained Physicians	RESEARCH/RESEARCH GRANTS - Astellas Pharma US
Soman	Prem	Emerging Applications for Imaging Cardiac Amyloidosis: Nuclear Cardiology	Predictors of a Positive Technetium Pyrophosphate Scan in Patients With Suspected Cardiac Amyloidosis	RESEARCH/RESEARCH GRANTS - Astellas Pharma US
Soman	Prem	30. Non Invasive Imaging: Nuclear Team 1	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Astellas Pharma US
Soman	Prem	FIT Clinical Decision Making Reviewers 4	ACC FIT Clinical Decision Making Reviewer	RESEARCH/RESEARCH GRANTS - Astellas Pharma US
Somaratne	Ransi	Highlighted Original Research: Prevention and the Year in Review	PCSK9 Variants and Neurocognitive Impairment: Data From the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study	OTHER - Amgen, Inc; SALARY - Amgen Inc.
Somaratne	Ransi	Advances in Cholesterol Measurement and Management	Impact of Evolocumab Therapy in Patients With Discordance Between LDL-C and LDL-P	OTHER - Amgen, Inc; SALARY - Amgen Inc.
Somers	Virend	Predicting Outcomes in Cardiac Rehabilitation Patients	The Association Between Waist-Hip Ratio With Long-Term Cardiovascular Events in Patients With Coronary Artery Disease: A Population-Based Historical Cohort Study	CONSULTANT FEES/HONORARIA - GlaxoSmithkline, Price Waterhouse Coopers, Resmed Respicardia, Rhonda Grey, Sorin Group, U-Health; OTHER - Mayo Health Solutions and their industry partners; RESEARCH/RESEARCH GRANTS - Phillips Respironics Foundation
Somers	Virend	ECG Screening and Risk Prediction	Wolff-Parkinson-White Pattern and Sudden Cardiac Death: A Retrospective Cohort Community Study From Olmsted County, Minnesota	CONSULTANT FEES/HONORARIA - GlaxoSmithkline, Price Waterhouse Coopers, Resmed, Respicardia, Rhonda Grey, Sorin Group, U-Health; OTHER - Mayo Health Solutions and their industry partners; RESEARCH/RESEARCH GRANTS - Phillips Respironics Foundation
Sondergaard	Lars	Featured Clinical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	CONSULTANT FEES/HONORARIA - MEDTRONIC; RESEARCH/RESEARCH GRANTS - MEDTRONIC
Sondergaard	Lars	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries	CONSULTANT FEES/HONORARIA - MEDTRONIC; RESEARCH/RESEARCH GRANTS - MEDTRONIC
Song	David	Arrhythmias and Clinical EP: Anticoagulation Issues	Marked Physician Variability in Oral Anticoagulant Treatment Choices Reflect Significant Differences in Atrial Fibrillation Patient Characteristics	Nothing to Disclose
Song	Hong-Ning	Novel Imaging and Therapies in Heart Failure	Evaluation of Left Ventricular Systolic Function After Renal Sympathetic Denervation by Layer-Specific Two-Dimensional Speckle Tracking Imaging	Nothing to Disclose
Song	Lei	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Morphologic Patterns of In-Stent Chronic Total Occlusions: An Intravascular Ultrasound Study	RESEARCH/RESEARCH GRANTS - Boston Scientific
Song	Lei	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	The Effectiveness of Excimer Laser Angioplasty to Treat Coronary In-Stent Restenosis With Peri-Stent Calcium as Assessed by Optical Coherence Tomography	RESEARCH/RESEARCH GRANTS - Boston Scientific
Song	Steven	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Nailfold Capillaroscopy for the Identification of Microvascular Disease in African-Americans	Nothing to Disclose
Song	Yun	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Serum Homocysteine Lowering by Long-Term Low-Dose Folic Acid: New Insight on <i>MTHFR</i> Gene-Folate Interaction From China Stroke Primary Prevention Trial	Nothing to Disclose
Song	Yun	Diabetes and Other Issues in Cardiovascular Prevention	Efficacy of Folic Acid Supplementation on the Reduction of Stroke Risk: Interaction With Platelet Count	Nothing to Disclose
Soni	Krishan	The Best Coronary and Peripheral Interventional Challenging Cases	Percutaneous Revitalization of an Atretic Left Internal Mammary to Left Anterior Descending Coronary Artery Bypass Graft Using Sub- Intimal Tracking and Re-Entry Technique	Nothing to Disclose
Soni	Ronak	Arrhythmias and Clinical EP: Basic 2	Comparison of 30-Day Readmission Rate, Cost, and Predictors in Atrial Fibrillation Patients Treated With Versus Without Endovascular Ablation	Nothing to Disclose
Soni	Ronak	Predicting the Future: Observations and Discoveries From Registries and Databases	Trends in Pulmonary Hypertension Hospitalizations: Insights From a National Database	Nothing to Disclose
Soni	Ronak	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	30-Day Unplanned Readmission Rates, Cost, Predictors, and Causes of Hospitalization in Acute Myocardial Infarction Patients	Nothing to Disclose
Sonoda	Shinjo	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Long-Term Vascular Response to Permanent Polymer Everolimus- Eluting Stent Compared With Biodegradable Polymer Biolimus- Eluting Stent: Five-Year Follow-Up Optical Coherence Tomography Study	Nothing to Disclose
Sonoda	Taketo	Unusual Presentations of ACS		Nothing to Disclose
Sood	Abhinav	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Identifying Non-Heart Failure Patients With Elevated NT-proBNP Levels in the Outpatient Setting: Opportunities for Prevention	Nothing to Disclose
Sood	Aditya	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	A Rush of Blood to the Head: Anomalous Superior Vena Cava Drainage to Left Atrium	Nothing to Disclose
Sood	Aditya	Interventional Cardiology: PCI and TAVR in Complex Patients	Predictors of Early Discharge Home After Transcatheter Aortic Valve Implantation	Nothing to Disclose
Sood	Aditya	Insights From Echocardiography Use	Novel Echocardiographic Variables in the Diagnosis of Acute Pulmonary Embolism	Nothing to Disclose
Sood	Arvind	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Decision Making Using Fractional Flow Reserve Is Associated With Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With Nstemi	Nothing to Disclose
Sookhu	Suraj	Technical Advances in Transthoracic Echocardiography	Safety of Perflutren-Based Echocardiographic Contrast Agent Administration in the Setting of a Patent Foramen Ovale (PFO): A Multicenter Study Conducted in Tertiary Care Centers Based in the New York/Chicago Metropolitan Areas	Nothing to Disclose
Soomro Sopko	Khalida George	Variations in Management of STEMI: International Perspectives From the Egyptian Society of Cardiology, Pakistan Cardiac Society, and American College of Cardiology Acute Heart Failure: Evaluating Strategies to	Local Experience of Intracoronary GPIIb/Illa Use in STEMI Risk of Hospitalization or Death Due to Heart Fallure With Intensive	Nothing to Disclose Nothing to Disclose
		Prevent Readmissions	Glucose-Lowering Therapy in Diabetic Women: Subgroup Analyses by History of Cardiovascular Disease in the ACCORD Trial	
Sorajja	Dan	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Rocking Prosthetic Valve 1 Year After Surgery: A Case of Untreated Takayasu Arteritis	
Sorajja	Dan	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Torsades de Pointes Following Insulin Infusion in a Patient With Hyperosmolar Hyperglycemic State	Nothing to Disclose



WASHINGTON, DC | MARCH 17 - 19 2017

Last Name	First Name	Session Title	Presentation Title	Disclosures
Sorajja	Dan	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	Nothing to Disclose
Sorajja	Paul	Featured Clinical Research II: Interventional	Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Valve Repair in the United States	CONSULTANT FEES/HONORARIA - Abbott Vascular,Lake Region Medical,MEDTRONIC; SPEAKER'S BUREAU - Abbott Vascular,Boston Scientific
Sorajja	Paul	Imaging Transcatheter Mitral Valve Repair and Replacement	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular,Lake Region Medical,MEDTRONIC; SPEAKER'S BUREAU - Abbott Vascular,Boston Scientific
Sorajja	Paul	Imaging Transcatheter Mitral Valve Repair and Replacement	Case Presentation: Mitral Valve in Valve and Native Percutaneous Mitral Valve Replacement	CONSULTANT FEES/HONORARIA - Abbott Vascular, Lake Region Medical, MEDTRONIC; SPEAKER'S BUREAU - Abbott Vascular, Boston Scientific
Sorajja	Paul	Transcatheter Mitral Valve Repair	Transseptal Puncture for MitraClip: Starting Right	Vascular, Boston Scientific CONSULTANT FEES/HONORARIA - Abbott Vascular, Lake Region Medical, MEDTRONIC; SPEAKER'S BUREAU - Abbott Vascular, Boston Scientific
Sorajja	Paul	PFO Closure, PV Leak, and VSD Repair	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular,Lake Region Medical,MEDTRONIC; SPEAKER'S BUREAU - Abbott Vascular,Boston Scientific
Sorajja	Paul	PFO Closure, PV Leak, and VSD Repair	Treatment of Aortic PV Leak for TAVR and SAVR	CONSULTANT FEES/HONORARIA - Abbott Vascular,Lake Region Medical,MEDTRONIC; SPEAKER'S BUREAU - Abbott Vascular,Boston Scientific
Sorajja	Paul	Core Curriculum: ACS: What Would You Do?	Cath Lab Nightmare Cases: When Time is of the Essence	CONSULTANT FEES/HONORARIA - Abbott Vascular,Lake Region Medical,MEDTRONIC; SPEAKER'S BUREAU - Abbott Vascular,Boston Scientific
Sorajja	Paul	The Best Structural Interventional Challenging Cases	ACC Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular,Lake Region Medical,MEDTRONIC; SPEAKER'S BUREAU - Abbott Vascular,Boston Scientific
Sorajja	Paul	Valvular Disease Populations at Risk	Surgical Risk and Therapy of Severe Symptomatic Degenerative Mitral Valve Regurgitation in the Contemporary Era	CONSULTANT FEES/HONORARIA - Abbott Vascular,Lake Region Medical,MEDTRONIC; SPEAKER'S BUREAU - Abbott Vascular,Boston Scientific
Sorajja	Paul	Valvular Heart Disease: Mitral Valve Disease	Guideline-Adherence and Survival for Asymptomatic Patients With Severe Mitral Valve Regurgitation	CONSULTANT FEES/HONORARIA - Abbott Vascular,Lake Region Medical,MEDTRONIC; SPEAKER'S BUREAU - Abbott Vascular,Boston Scientific
Sorajja	Paul	Innovations in Advocacy and Patient Centered Care	Diverse Perspectives and Training Paths in Cardiology: An Analysis of Authorship in the <i>Journal of the American College of Cardiology</i>	CONSULTANT FEES/HONORARIA - Abbott Vascular,Lake Region Medical,MEDTRONIC; SPEAKER'S BUREAU - Abbott Vascular,Boston Scientific
Sorajja	Paul	Interventional Cardiology: TAVR 4	Minimalist Approach to Cardiac Anesthesia and Outcome in Patients Undergoing Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Abbott Vascular,Lake Region Medical,MEDTRONIC; SPEAKER'S BUREAU - Abbott Vascular,Boston Scientific
Sorajja	Paul	37. Valvular Heart Disease: Therapy Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular,Lake Region Medical,MEDTRONIC; SPEAKER'S BUREAU - Abbott Vascular,Boston Scientific
Sorensen	Jacob	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Cardiac Myosin-Binding Protein C as Alternative to Cardiac Troponin T for the Diagnosis of Acute Myocardial Infarction in the Very Early Phase	CONSULTANT FEES/HONORARIA - Roche Diagnostics
Sorensen	Jens	Valvular Heart Disease: Mitral Valve Disease	Volumetric Quantification of Regurgitant Volume in Asymptomatic Severe Degenerative Mitral Regurgitation by Echocardiography and Cardiac MRI With Independent Validation of Forward Stroke Volume by Positron Emission Tomography	Nothing to Disclose
Sorrell	Vincent	Arrhythmias and Heart Failure	Can the Ventricular-Arterial Coupling Ratio Predict Response to Cardiac Resynchronization Therapy for Patients Meeting Class Ila Indications?	Nothing to Disclose
Sorrentino	Robert	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Vagal Nerve Stimulator Therapy: An Unusual Cause of Symptomatic Bradycardia	Nothing to Disclose
Sorrentino	Sabato	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Clinical Outcomes Associated With Impella Versus IABP Use in Stable Patients Undergoing High Risk Percutaneous Coronary Intervention	Nothing to Disclose
Sorrentino	Sabato	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Impella or Intra-Aortic Balloon Pump Support in Patients Undergoing High Risk Percutaneous Coronary Intervention: A Real World Single Center Experience	Nothing to Disclose
Sosa	Fernando	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Optical Coherence Tomography Assessment of Coronary Atherectomy Effect: Comparison Between Orbital and Rotational Atherectomy in Severely Calcified Lesions	SALARY - St. Jude Medical ,Inc.
Sosa	Fernando	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	The Effectiveness of Excimer Laser Angioplasty to Treat Coronary In-Stent Restenosis With Peri-Stent Calcium as Assessed by Optical Coherence Tomography	SALARY - St. Jude Medical ,Inc.
Sosa	Fernando	Interventional Cardiology: PCI in Complex Patients	Procedural Calcium Fracture and Its Effect on Stent Expansion Assessed by Optical Coherence Tomography	SALARY - St. Jude Medical ,Inc.
Sosa	Jose Manuel	Perspectives on Congenital Heart Disease: International Perspectives From the Caribbean Cardiac Society, Peruvian Society of Cardiology, and American College of Cardiology	Co-Chair	Nothing to Disclose
Sosa Liprandi	Alvaro	From Cardiovascular Risk Factors to Acute and Stable Coronary Syndrome: International Perspectives From the Inter-American Society of Cardiology, National Heart Association of Malaysia, and American College of Cardiology	Polypill in the Management of Secondary Prevention in Countries With High Cardiovascular Risk in Latin America: A Look at the Future of Secondary Prevention	CONSULTANT FEES/HONORARIA - Pfizer Inc; RESEARCH/RESEARCH GRANTS - Trevena; SPEAKER'S BUREAU - Ferrer,Pfizer Inc,Sanofi-Aventis
Sosnovik	David	Molecular Imaging in Heart Failure	Co-Chair	Nothing to Disclose
osnovik otomi	David Yohei	Molecular Imaging in Heart Failure Updates in Stable Ischemic Heart Disease	Imaging of Myocardial Inflammation Coronary Calcification as a Mechanism of Plaque/Media Shrinkage: A Multimodality Intracoronary Imaging Study	Nothing to Disclose Nothing to Disclose
otomi	Yohei	Coronary Intervention: Drug Eluting Stent and Scaffolds	Early, Late and Very Late Incidence of Bioresorbable Scaffold Thrombosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials and Observational Registries	Nothing to Disclose
Sotoodehnia	Nona	Updates on Risk Factors for Cardiovascular Disease	Retinopathy and Risk of Sudden Cardiac Death: The ARIC Study	Nothing to Disclose
Soukas	Peter	Aorto-liac Disease and Treatment: Practice at "The Edge" in Peripheral Intervention	Case Presentation: My Most Challenging Aorto-iliac Intervention of the Year	DATA SAFETY MONITORING BOARD - Maquet; RESEARCH/RESEARCH GRANTS - Bard, Cordis Endovascular, intact Vascular, JUVENTAS THERAPEUTICS, INC., Spectranetics, W. L. Gore
Soukas	Peter	Highlights in Vascular Medicine Research	Thirty-Day Readmissions Following Endovascular or Surgical Treatment for Critical Limb Ischemia: Analysis of the Nationwide Readmissions Database	DATA SAFETY MONITORING BOARD - Maquet; RESEARCH/RESEARCH GRANTS - Bard, Cordis Endovascular, intact Vascular, JUVENTAS THERAPEUTICS, INC., Spectranetics, W. L. Gore
Soukas	Peter	39. Vascular Medicine: Endovascular Therapy Team 1	Suggested Reviewer	DATA SAFETY MONITORING BOARD - Maquet; RESEARCH/RESEARCH GRANTS - Bard, Cordis Endovascular, Intact Vascular, JUVENTAS THERAPEUTICS, INC., Spectranetics, W. L. Gore
Sousa	Amanda	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Independent Predictors of Mace at Different Time Points After the Treatment of Non-Selected Patients With Drug-Eluting Stents: An Analysis of the Desire Registry	RESEARCH/RESEARCH GRANTS - Instituto Dante Pazzanes de Cardiologia

and the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Sousa	Amanda	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Independent Pre Procedural Echocardiographic Predictors of Mitral Valve Restenosis After Percutaneous Mitral Balloon Valvuloplasty in	RESEARCH/RESEARCH GRANTS - Instituto Dante Pazzanese de Cardiologia
			a Large Consecutive Cohort Followed Up to Two Decades	-
Sousa	Amanda	Interventional Cardiology: Structural Heart Disease	Initial Results and Long-Term Follow-Up of Percutaneous Mitral Valvuloplasty in Patients With Pulmonary Hypertension	RESEARCH/RESEARCH GRANTS - Instituto Dante Pazzanese de Cardiología
Sousa	Amanda	Frontiers in Mitral Valve Disease and	Predictors of Immediate and Very Late Events After Percutaneous	RESEARCH/RESEARCH GRANTS - Instituto Dante Pazzanese
Sousa	J. Eduardo	Treatment PCI for NSTEMI and Complex Patients With	Mitral Valvuloplasty Independent Predictors of Mace at Different Time Points After the	de Cardiologia Nothing to Disclose
		Multiple Co-Morbidities	Treatment of Non-Selected Patients With Drug-Eluting Stents: An Analysis of the Desire Registry	_
Southern	Danielle	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	The Presence of Fragmented QRS Complexes Early After Acute Myocardial Infarction Is Associated With Subsequent Lack of Favorable Left Ventricular Remodeling	Nothing to Disclose
Southern	Danielle	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Ventricular Arrhythmia at Primary PCI for ST-Elevation Myocardial Infarction Predicts 30-Day but Not Long-Term Mortality	Nothing to Disclose
Souza	Cristiano	Innovations in Advocacy and Patient Centered Care	What Is the Importance of Preoperative Electrocardiogram in Hypertensive Patients for Moderate/High Risk Noncardiac Surgery? A Single-Center Randomized Study	Nothing to Disclose
Souza	Rogerio	Demystifying and Managing Pulmonary Hypertension and RV Dysfunction: It Takes a Village	Panelist	CONSULTANT FEES/HONORARIA - Actelion, Bayer, GSK, Pfizer
Sozzi	Fabiola	Innovations in Pediatric Catheterization and	Treatment of Congenital Coronary Fistula	Nothing to Disclose
Spahillari	Aferdita	EP: Mending, Fixing and Predicting Innovations in Education	On-Call Transthoracic Echocardiographic Interpretation by First	Nothing to Disclose
Coobillari	Aferdita	Innovations in Cardiovascular Risk Assessment	Year Cardiology Fellows: Comparison With Experienced Readers Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in	Nothing to Disclose
Spahillari	Aleruita	and Reduction	African Americans: The Jackson Heart Study	-
Spalding	James	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Stress Myocardial Perfusion Imaging Versus Exercise Treadmill Testing: Comparison of Clinical and Economic Outcomes in Real- World Emergency Department Settings	Nothing to Disclose
Spatz	Erica	Arrhythmias and Clinical EP: Basic 1	Variation in the Use of Direct Oral Anticoagulants and Associated Cost Implications: Findings From the Medical Expenditure Panel Survey 2010 to 2013	Nothing to Disclose
Spatz	Erica	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Admission Types Among Patients With Heart Failure Cared for by Accountable Care Organizations: Variation by Performance on a Measure of Risk Standardized Acute Admission Rates	Nothing to Disclose
Spatz	Erica	Innovations in Education	Cardiology Fellow Training and Perspective of the Informed Consent Process	Nothing to Disclose
Spatz	Erica	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Toward Identifying Personalized Prognosis in Hypertension: Variation in Early Responses in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)	Nothing to Disclose
Spatz	Erica	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Mechanisms of Acute Myocardial Infarction in Young Women and Discharge Medication Patterns	Nothing to Disclose
Spatz	Erica	Innovations in Advocacy and Patient Centered	Status of Early Career Academic Cardiology: A Global Perspective	Nothing to Disclose
Spaulding	Christian	Care 15. Interventional Cardiology:	Suggested Reviewer	CONSULTANT FEES/HONORARIA -
		ACS/AMI/Hemodynamics and Pharmacology Team 3		Medpass,MEDTRONIC,Zoll; RESEARCH/RESEARCH GRANTS Biosensors; SPEAKER'S BUREAU - AstraZeneca,Lilly
Speidl	Walter	Making Progress in Understanding Heart Failure	Growth Differentiation Factor-15 Is Associated With Mortality in Patients With Severe Acute Heart Failure or Cardiogenic Shock	Nothing to Disclose
Speidl	Walter	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Circulating Mitochondrial DNA Is Associated With Mortality in Patients With Acute Heart Failure	Nothing to Disclose
Speidl	Walter	Acute Heart Failure: Evaluating Strategies to	Intestinal Fatty Acid Binding Protein Predicts Mortality in Patients	Nothing to Disclose
Speight	Martina	Prevent Readmissions Great Minds Think Differently: Multidisciplinary	With Acute Heart Failure or Cardiogenic Shock Implementation of the Heart Team: Challenges in Practice	CONSULTANT FEES/HONORARIA - Edwards Lifesciences;
		Approach to Controversies in Cardiology		OTHER - Hawthorne Effect, Inc.
Spence	Mark	The Story of the Adult Congenital Heart Disease Patient and EP	Arrhythmia Burden & Outcomes in Eisenmenger Syndrome	CONSULTANT FEES/HONORARIA - Boston Scientific
Spencer	Kirk	Controversies in Echocardiography	Con: HOCUS POCUS I am Calling the Echo Lab for a 'Real' Echo	OTHER - Philips
Spencer	Kirk	Young Investigator Awards Competition: Outcomes Research	A Bundled Intervention Including Early Consultation With a Cardiologist in the Emergency Department to Reduce Re- Hospitalizations and Healthcare Cost for High-Risk Urban Patients	OTHER - Phillips
Spencer	Kirk	Valvular Heart Disease: Aortic Regurgitation	With Acute Decompensated Heart Failure Left Ventricular Mechanical Properties in Patients With Severe Aortic Insufficiency and Normal Ejection Fraction: Impact on Survival	OTHER - Philips
Spencer	Kirk	28. Non Invasive Imaging: Echo Team 4	Suggested Reviewer	OTHER - Philips
Sperling	Laurence	Are We There Yet? The Long Journey to Health Equity: Part I	Co-Chair	Nothing to Disclose
Sperling	Laurence	Are We There Yet? The Long Journey to	Session Summary	Nothing to Disclose
Sperling	Laurence	Health Equity: Part I Updates in Stable Ischemic Heart Disease	Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-World Impact of the Leader Trial on Improving	Nothing to Disclose
			Cardiovascular Outcomes in Patients With Diabetes at High Cardiovascular Risk	
Sperling	Laurence	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Association Between Circulating Progenitor Cells and Outcomes in Patients With Coronary Artery Disease	Nothing to Disclose
Sperling	Laurence	Coronary Artery Disease Updates on Risk Factors for Cardiovascular	Central Obesity Predicts Circulating Progenitor Cell Levels	Nothing to Disclose
Sperling	Laurence	Disease Updates on Risk Factors for Cardiovascular	Changes in Body Fat Distribution Is Associated With Oxidative Stress	Nothing to Disclose
Sperling	Laurence	Disease Unusual Presentations of ACS	Circulating Progenitor Cells Levels and Outcomes in Acute	Nothing to Disclose
· -			Myocardial Infarction ACC Poster Moderator	-
Sperling	Laurence	Obesity Management in 2017: Weighing the Issues		Nothing to Disclose
Sperling Sperry	Laurence Brett	33. Prevention: Hypertension Team 1 Advances in HCM, PPCM and Other	Suggested Reviewer Atrial Thrombus in Patients With Cardiac Amyloidosis: Prevalence	Nothing to Disclose Nothing to Disclose
Sperry		Cardiomyopathies	and Implications for Therapy	3
Spertus	John	FIT Forum: Mix and Mingle	Outcomes Research	CONSULTANT FEES/HONORARIA - Amgen Bayer Healthcare Pharmaceuticals, Copyright for SAQ, KCCQ and PAQ, Novartis, United Healthcare Scientific Advisory Board; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Health Outcomes Sciences; RESEARCH/RESEARCH GRANTS - American College of Cardiology Foundation, Lilly



Contract of the second				<u> </u>
Last Name Spertus	First Name John	Session Title Highlighted Original Research: Vascular	Presentation Title Non-Adherence to the Joint ACC/AHA 2013 Lipid Performance	Disclosures CONSULTANT FEES/HONORARIA - Amgen, Bayer Healthcare
Opertus	John	Medicine and the Year in Review	Guidelines in Peripheral Arterial Disease: Insights From the PORTRAIT Registry	Pharmaceuticals, Copyright for SAQ, KCCQ and PAQ, Novartis, United Healthcare Scientific Advisory Board; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Health Outcomes Sciences; RESEARCH/RESEARCH GRANTS -
				American College of Cardiology Foundation, Lilly
Spertus	John	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Heart Failure With Reduced Ejection Fraction Care Patterns in the Outpatient Practice Setting: Initial Findings From CHAMP-HF	CONSULTANT FEES/HONORARIA - Amgen, Bayer Healthcare Pharmaceuticals, Copyright for SAQ, KCCQ and PAQ, Novartis, United Healthcare Scientific Advisory Board; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Health Outcomes Sciences; RESEARCH/RESEARCH GRANTS - American College of Cardiology Foundation, Lilly
Spertus	John	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Reliability and Responsiveness of Seattle Angina Questionnaire in Women With Coronary Artery Disease	CONSULTANT FEES/HONORARIA - Amgen, Bayer Healthcare Pharmaceuticals, Copyright for SAQ, KCCQ and PAQ, Novaris, United Healthcare Scientific Advisory Board; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Health Outcomes Sciences; RESEARCH/RESEARCH GRANTS - American College of Cardiology Foundation, Lilly
Spertus	John	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Outcomes of Concomitant Acute Kidney Injury and Hospital Acquired Anemia in Patients With Myocardial Infarction: The TRIUMPH Study	CONSULTANT FEES/HONORARIA - Amgen,Bayer Healthcare Pharmaceuticals,Copyright for SAQ, KCCQ and PAQ,Novaris,United Healthcare Scientific Advisory Board; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Health Outcomes Sciences; RESEARCH/IRESEARCH GRANTS - American College of Cardiology Foundation,Lilly
Spertus	John	Innovations in Cardiovascular Risk Assessment and Reduction	High-Sensitivity C-reactive Protein and Health Status Outcomes After Myocardial Infarction	CONSULTANT FEES/HOVBARIA - Amgen,Bayer Healthcare Pharmaceuticals,Copyright for SAQ, KCCQ and PAQ, Novatis, United Healthcare Scientific Advisory Board; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Health Outcomes Sciences; RESEARCH/IRESEARCH GRANTS - American College of Cardiology Foundation,Lilly
Spertus	John	Emerging Developments in HFpEF and Arryhthmias	Impact of Serial Heart Failure Health Status on Clinical Outcomes in HFpEF: A Static or Dynamic Phenomenon?	CONSULTANT FEES/HONORARIA - Amgen, Bayer Healthcare Pharmaceuticals, Copyright for SAQ, KCCQ and PAQ, Novaris, United Healthcare Scientific Advisory Board; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Health Outcomes Sciences; RESEARCH/RESEARCH GRANTS - American College of Cardiology Foundation, Lilly
Spertus	John	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Time to Acute Care Among Patients With Acute Myocardial Infarction in China: A Report From China Patient-Centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction	CONSULTANT FEES/HONORARIA Amgen, Bayer Healthcare Phamaceuticals, Copyright for SAQ, KCCQ and PAQ, Novaris, United Healthcare Scientific Advisory Board; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Health Outcomes Sciences; RESEARCH/RESEARCH GRANTS - American College of Cardiology Foundation, Lilly
Spertus	John	Advances in Chronic Total Occlusion Intervention	Association of Stress Test Risk Classification With Health Status Change After Chronic Total Occlusion PCI: Insights From the OPEN- CTO Registry	CONSULTANT FEES/HONORARIA. Amgen,Bayer Healthcare Pharmaceuticals,Copyright for SAQ, KCCQ and PAQ,Novaris,United Healthcare Scientific Advisory Board; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Health Outcomes Sciences; RESEARCH/RESEARCH GRANTS - American College of Cardiology Foundation,Lilly
Spertus	John	Advances in Chronic Total Occlusion Intervention	Impact of Sex on Physical Limitation & Patient Health Status After Chronic Total Occlusion Percutaneous Coronary Intervention: Propensity Matched Substudy of OPEN-CTO Registry	CONSULTANT FEES/HONORARIA - Amgen, Bayer Healthcare Pharmaceuticals, Copyright for SAQ, KCCQ and PAQ, Novaris, United Healthcare Scientific Advisory Board; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Health Outcomes Sciences; RESEARCH/RESEARCH GRANTS - American College of Cardiology Foundation, Lilly
Spertus	John	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Current More Important Than Past: Interpreting Serial Heart Failure Specific Health Status in Heart Failure Patients With Reduced Ejection Fraction	Consult The Cardiology Foundation, Link CONSULTANT FEES/HONORARIA - Amgen, Bayer Healthcare Pharmaceuticals, Copyright for SAQ, KCCQ and PAQ, Novartis, United Healthcare Scientific Advisory Board; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Health Outcomes Sciences; RESEARCH/IRESEARCH GRANTS - American College of Cardiology Foundation, Lilly
Spertus	John	Refining PCI Technique and Outcomes	Appropriate Use Criteria and Health Status Outcomes After CTO PCI: Results From the OPEN CTO Registry	CONSULTANT FEES/HONORARIA - Amgen,Bayer Healthcare Pharmaceuticals,Copyright for SAQ, KCCQ and PAQ,Novaris,United Healthcare Scientific Advisory Board; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Health Outcomes Sciences; RESEARCH/RESEARCH GRANTS - American College of Cardiology Foundation,Lilly
Spertus	John	Optimizing Treatment of Peripheral Artery Disease	Smoking Behavior and Access to Smoking Cessation Support Following a Diagnosis of Peripheral Arterial Disease: Insights From the International PORTRAIT Registry	CONSULTANT FEES/HONORARIA - Amgen,Bayer Healthcare Pharmaceuticals,Copyright for SAQ, KCCQ and PAQ,Novaris,United Healthcare Scientific Advisory Board; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Health Outcomes Sciences; RESEARCH/IRESEARCH GRANTS - American College of Cardiology Foundation,Lilly
Spertus	John	02. Acute and Stable Ischemic Heart Disease: Clinical Team 7	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen,Bayer Healthcare Pharmaceuticals,Copyright for SAQ, KCCQ and PAQ,Novaris,United Healthcare Scientific Advisory Board; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Health Outcomes Sciences; RESEARCH/RESEARCH GRANTS - American College of Cardiology Foundation,Lilly
Spevack	Daniel	Innovative Use of Echocardiography	High Prevalence of Apical Hypertrophic Cardiomyopathy Noted in Non-White Patients Referred for Clinical Echocardiography	Nothing to Disclose
Spiering	Wilko		Endovascular Carotid Barostimulation for Resistant Hypertension: A	CONSULTANT FEES/HONORARIA - Vascular Dynamics;
Spies	Christian	and Assessment of Hypertension The Tricuspid Valve: The New Frontier	Safety and Proof-of-Principle Cohort Study The Magnitude and Impact of Isolated and Secondary Tricuspid Regurgitation on Outcomes	RESEARCH/RESEARCH GRANTS - Vascular Dynamics CONSULTANT FEES/HONORARIA - Edwards Lifesciences,MEDTRONIC; SPEAKER'S BUREAU - Abbott Laboratories
Spies	Christian	Imaging Transcatheter Mitral Valve Repair and Replacement	Co-Chair	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,MEDTRONIC; SPEAKER'S BUREAU - Abbott Laboratories
Spies	Christian	Imaging Transcatheter Mitral Valve Repair and Replacement	Case Presentation: Complex Mitraclip and Transcatheter Mitral Valve in Ring	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,MEDTRONIC; SPEAKER'S BUREAU - Abbott Laboratories
Spilias	Nikolaos	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Reverse Takotsubo Cardiomyopathy Associated With Mediastinal Paraganglioma	Nothing to Disclose
Spinler	Sarah	When Anticoagulation Needs to be Stopped What Are the Options? Pharmacology II	Paragangiioma Panelist	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc; SPEAKER'S BUREAU - Bristol-Myers
Spinthakis	Nikolaos	Antiplatelet and Antithrombotic Agents in	Comparative Effects of Different P2Y ₁₂ Inhibitors on	Squibb Company Nothing to Disclose
Spitaleri	Giosafat	Ischemic Heart Disease Refining PCI Technique and Outcomes	Global Thrombotic Status in Coronary Artery Disease Comparison of Verapamil Versus Heparin Therapy on Procedural Success During Transradial Coronary Procedures (Vermut Study)	Nothing to Disclose
Sposito	Andrei	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Alirocumab Efficacy and Safety in Patients With Hypercholesterolemia and With or Without Clinical Atherosclerotic Cardiovascular Disease: Pooled Analysis of 10 ODYSSEY Randomized Trials	CONSULTANT FEES/HONORARIA - Amgen Inc., AstraZeneca Pharmaceuticals, Janssen Pharmaceuticals, Inc, Sanofi-Aventis
· · ·				·

WASHINGTON, DC | MARCH 17 - 19 2017

Const.				I
Last Name Spratt	First Name James	Session Title Advances in Chronic Total Occlusion Intervention	Presentation Title Effects of Successful Percutaneous Coronary Intervention of Chronic Total Occlusions on Myocardial Perfusion and Left	Disclosures CONSULTANT FEES/HONORARIA - Abbott Laboratories,Boston Scientific
Spratt	James	20. Interventional Cardiology: Coronary	Ventricular Function Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott
		Intervention: CTO Team 1 Heart Failure and Cardiomyopathies: What	Spironolactone Therapy for Cardiomyopathy in Duchenne Muscular	Laboratories, Boston Scientific CONSULTANT FEES/HONORARIA - Capricor
Spurney	Christopher	Next When All Else Is Failing?	Dystrophy	Therapeutics, Nicox Pharmaceutical Company, TrophyNOD
Spyropoulos	Jelena	Innovations in Practice Management and Social Media	Improving Clinical Decisions in Dyslipidemia: Simulation-Based Medical Education in Action	Nothing to Disclose
Spyropoulos	Jelena	Innovations in Advocacy and Patient Centered Care	Effectiveness of Medical Education in Thrombosis and Anticoagulation Management: Focus on Appropriate Use of NOACs	Nothing to Disclose
Spyrou	George	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Association of Abdominal Aortic Wall Inflammation, Hepatic Fluorodeoxyglucose Uptake AND Visceral Adipose Tissue Biological Activity in Patients With Dyslipidemias	Nothing to Disclose
Spyrou	George	Nuclear Cardiology: Beyond Perfusion	Increased Subclinical Systemic AND Vascular Inflammation in Familial Combined Hyperlipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission Tomography Study	Nothing to Disclose
Spyrou	George	Nuclear Cardiology: Beyond Perfusion	In Vivo Correlation of Carotid Temperatures and Pet/Fdg Uptake in Patients Undergoing Carotid Endarterectomy: Validation With Histology	Nothing to Disclose
Spyrou	George	Cutting Edge Vascular Medicine	Familial Combined Hyperlipidemia Is Characterized by Higher Arterial AND Hepatic Fluorodeoxyglucose Uptake Compared to Heterozygous Familial Hypercholesterolemia	Nothing to Disclose
Squiers	John	Vascular Access and Hemostasis Issues	Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Aortic Valve Replacement With the Sapien 3 Valve	Nothing to Disclose
Sra	Jasbir	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Incremental Value of Estimated Glomerular Filtration Rate in Improving Stroke Risk Stratification in Patients With and Without Atrial Fibrillation Considered to Be Low Risk by CHA _{2/sub>DS_{2/sub>VASc Score}}	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - APN Health
Srichai-Parsia	Monvadi	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team	Suggested Reviewer	Nothing to Disclose
Srinivasan	Manivannan	Antiplatelet and Antithrombotic Agents in	Comparative Effects of Different P2Y ₁₂ Inhibitors on	Nothing to Disclose
Srinivasan	Ranjini	Ischemic Heart Disease Innovations in Education	Global Thrombotic Status in Coronary Artery Disease Fellow Outpatient Clinic: Discontinuing the Discontinuity	Nothing to Disclose
Srivastava	Ajay	Great Minds Think Differently: Multidisciplinary Approach to Advanced Therapies	Case Presentation: HF Management- Options for the Failing Heart	Nothing to Disclose
Srivastava	Anjili	Innovations in Advocacy and Patient Centered Care	Patient Perceptions on the Impact of Caffeine Consumption After a Myocardial Infarction or Percutaneous Coronary Intervention	Nothing to Disclose
Srivastava	Anshul	Making Progress in Understanding Heart Failure	Home Telehealth Reduces Adverse Outcomes in Heart Failure	Nothing to Disclose
Srivastava	Mukta	Innovations in Education	Electrocardiogram Training for Residents: A Curriculum Based on Facebook and Twitter	Nothing to Disclose
Srivastava	Shubhika	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Feasibility of Rapidly Creating High Resolution Virtual Three- Dimensional Models of Anomalous Aortic Origin of Coronary Arteries	Nothing to Disclose
Srivathsan	Komandoor	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - St Jude; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cardioreal; SPEAKER'S BUREAU - Biosense Webster
Srivatsa	Uma	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	Nothing to Disclose
Stables	Rod	Advances in HCM, PPCM and Other Cardiomyopathies	Younger Age, Positive Family History and Reverse Curve Morphology Predict Informative Results From Gene Panel Analysis for Hypertrophic Cardiomyopathy (HCM)	CONSULTANT FEES/HONORARIA - Astra Zeneca; RESEARCH/RESEARCH GRANTS - Astra Zeneca,The Medicines Company
Stables	Rod	Optimizing the Care of ACS Patients	Safety of Heparin Compared With Bivalirudin in Patients Undergoing Transradial Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Astra Zeneca; RESEARCH/RESEARCH GRANTS - Astra Zeneca,The Medicines Company
Stack	Richard	The Evolution of Angioplasty 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	The Physician as Inventor	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Synecor, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aegis Surgical LLC,Atrius LLC,NeuroTronik
Stacy	Mitchel	Role of Imaging in Peripheral Artery Disease	Radiotracer Imaging for PAD	Nothing to Disclose
Stacy	Mitchel	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Radiotracer Imaging Allows for Assessment of Serial Changes in Angiosome Foot Perfusion Following Revascularization and Predicts Limb Salvage Outcomes in Patients With Critical Limb Ischemia	Nothing to Disclose
Stacy	Mitchel	Nuclear Cardiology: Beyond Perfusion	Radiotracer Imaging of Angiosome Foot Perfusion Correlates With Ankle-Brachial Index and Differentiates Critical Limb Ischemia Patients From Healthy Subjects	Nothing to Disclose
Staehli	Barbara	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Association Between Homeostasis Model Assessment of Insulin Resistance and Survival in Diabetic Patients With Acute Coronary Syndromes: Insights From the AleCardio Trial	Nothing to Disclose
Staehli	Barbara	Timely Topics in Acute Coronary Syndromes	Gender-Related Outcomes in Elderly (> 75 Years) Patients Presenting With Acute Coronary Syndromes: Results From the Swiss Acute Coronary Syndrome Cohort	Nothing to Disclose
Stahl	Eric	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Association Between Circulating Progenitor Cells and Outcomes in Patients With Coronary Artery Disease	Nothing to Disclose
Stahl	Eric	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	A Severe Case of Statin-Associated Autoimmune Myopathy	Nothing to Disclose
Stahl	Eric	Updates on Risk Factors for Cardiovascular Disease	Central Obesity Predicts Circulating Progenitor Cell Levels	Nothing to Disclose
Stahl	Eric	Advances in Chronic Total Occlusion Intervention	Performance of J-CTO and PROGRESS CTO Scores in Predicting Angiographic Success and Long-Term Clinical Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions	Nothing to Disclose
Stahl	Eric	The Evolving World of LVADs, Transplant and	Progenitor Cells and Clinical Outcomes in Patients With Heart	Nothing to Disclose
Stahl	Eric	Other Novel Discoveries Unusual Presentations of ACS	Failure Circulating Progenitor Cells Levels and Outcomes in Acute	Nothing to Disclose
Stainback	Raymond	FIT Clinical Decision Making: Non-Invasive	Myocardial Infarction Coronary Artery Aneurysm in a Patient With Systemic Lupus	Nothing to Disclose
Stainback	Raymond	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Non-Invasive	Erythematosus Cerebral Embolization From Caseous Mitral Annular Calcification	Nothing to Disclose
Stambler	Bruce	Imaging and Valvular Heart Disease 05. Arrhythmias and Clinical EP: Devices	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific; DATA
		Team 1 Interdisciplinary Cardiovascular Team		SAFETY MONITORING BOARD - MEDTRONIC
Stamos	Thomas	Collaboratives in Care	Poor Adherence in Young Patients With Heart Failure	Nothing to Disclose
Stamos	Thomas	Interdisciplinary Cardiovascular Care in Complex Scenarios	Simple Technology Improves Access and Outcomes for Patients With Low Socioeconomic Status	Nothing to Disclose

(M. Standard				<u> </u>
Last Name Stamos	First Name Thomas	Session Title Interdisciplinary Cardiovascular Team Care	Presentation Title Homelessness and Heart Failure: A Novel Prescription	Disclosures Nothing to Disclose
		Delivery: Quality, Safety, and Satisfaction	·	-
Stamos	Thomas	Interdisciplinary Cardiovascular Team Care Delivery: Quality, Safety, and Satisfaction	Heart Failure Hotline as an Innovation to Address Medication Issues	Nothing to Disclose
Stanger	Dylan	Coronary Angiography, Intra-Vascular Imaging,	Clinical Outcomes of Acute Ischemic Stroke Patients Stratified by	Nothing to Disclose
Stanger	Dylan	Revascularization and Outcomes Cardiac Arrest, Diabetes, and Other High Risk	Cardiac Troponin-I: A Retrospective Analysis A Meta-Analysis of the Effect of Targeted Temperature	Nothing to Disclose
Cango	S y a	Features of Patients With Acute Coronary	Management on Mortality and Neurological Outcome	Thousing to Blockood
Staniloae	Cezar	Syndrome Interventional Cardiology: TAVR 3	Initial Use of the Evolut Pro Self-Expanding Transcatheter Aortic	Nothing to Disclose
			Valve <i></i>	-
Stanislawski	Maggie	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Coronary Atherectomy for Treatment of Calcified Coronary Artery Lesions Is Associated With Increased Procedural Success and	Nothing to Disclose
			Lower Procedural Complication Rates: Insights From a National	
Stankovic	Goran	Cardiac Arrest, Diabetes, and Other High Risk	Veteran Cohort Acute Coronary Syndrome: The Risk to Be Young and Women	Nothing to Disclose
		Features of Patients With Acute Coronary Syndrome		
Stankovic	Goran	22. Interventional Cardiology: Coronary	Suggested Reviewer	Nothing to Disclose
		Intervention: Left Main, Multivessel, Bifurcation Team 1		
Stanojevic	Dusan	Interventional Cardiology: PCI in Complex	Clinical Presentation, Natural History and Management of Coronary	CONSULTANT FEES/HONORARIA - St. Jude Medical
Stanova	Viktoria	Patients Interventional Cardiology: TAVR 1	Artery Ectasia Effect of Valve Oversizing on Leaflet Bending Stress in the	Nothing to Disclose
Starc	James	FIT Clinical Decision Making: Prevention, Adult	CoreValve: An In Vitro Study An Unusual Aortic Arch Aneurysm Following Arterial Switch With	Nothing to Disclose
Starc	James	Congenital and Congenital Heart Disease	Concern for Dissection	Nothing to Disclose
Starc	Thomas	Innovations in Education	Fellow Outpatient Clinic: Discontinuing the Discontinuity	Nothing to Disclose
Stark	Stephen	Atrial Fibrillation and VT: Specific Situations	5-Year Outcomes of a Staged Hybrid Surgical and Catheter-Based	Nothing to Disclose
		and Newer Outcome Measures	Ablation Approach for Treatment of Long-Standing Persistent Atrial Fibrillation	
Starling	Randall	Evolving Therapies in Heart Failure: Gazing Into the Crystal Ball	Co-Chair	CONSULTANT FEES/HONORARIA - MEDTRONIC, Novartis; RESEARCH/RESEARCH GRANTS - Abbott, Cardiac
		-		Dimensions,MEDTRONIC,National Institutes of Health,Novartis
Starling	Randall	Evolving Therapies in Heart Failure: Gazing Into the Crystal Ball	New Medications in the HF Pipeline	CONSULTANT FEES/HONORARIA - MEDTRONIC, Novartis; RESEARCH/RESEARCH GRANTS - Abbott, Cardiac
				Dimensions,MEDTRONIC,National Institutes of Health,Novartis
Starling	Randall	Salt, Water and the Kidney in Heart Failure	Panelist	CONSULTANT FEES/HONORARIA - MEDTRONIC, Novartis; RESEARCH/RESEARCH GRANTS - Abbott, Cardiac
Otasliaa	Randall	Salt, Water and the Kidney in Heart Failure	In all actions of Decad Durf matter for Machanical Circulators	Dimensions, MEDTRONIC, National Institutes of Health, Novartis
Starling	Randali	Sait, Water and the Kidney in Heart Failure	Implications of Renal Dysfunction for Mechanical Circulatory Support and Cardiac Transplantation	CONSULTANT FEES/HONORARIA - MEDTRONIC,Novartis; RESEARCH/RESEARCH GRANTS - Abbott,Cardiac
Starling	Randall	Acute Heart Failure: Evaluating Strategies to	Timing and Clinical Predictors of Early Versus Late Readmission	Dimensions,MEDTRONIC,National Institutes of Health,Novartis CONSULTANT FEES/HONORARIA - MEDTRONIC,Novartis;
Carming	randan	Prevent Readmissions	Among Patients Hospitalized for Acute Heart Failure: Insights From	RESEARCH/RESEARCH GRANTS - Abbott, Cardiac
Starling	Randall	Acute Heart Failure: Evaluating Strategies to	ASCEND-HF Time of Presentation Among Patients Hospitalized for Acute Heart	Dimensions,MEDTRONIC,National Institutes of Health,Novartis CONSULTANT FEES/HONORARIA - MEDTRONIC,Novartis;
		Prevent Readmissions	Failure (Clinical Characteristics, Initial Therapies and Outcomes): Insights From ASCEND-HF	RESEARCH/RESEARCH GRANTS - Abbott, Cardiac Dimensions, MEDTRONIC, National Institutes of Health, Novartis
Starling	Randall	Acute Heart Failure: Evaluating Strategies to	Impact of an Inpatient Electronic Medical Record Heart Failure	CONSULTANT FEES/HONORARIA - MEDTRONIC, Novartis;
		Prevent Readmissions	Checklist on Readmissions	RESEARCH/RESEARCH GRANTS - Abbott, Cardiac Dimensions, MEDTRONIC, National Institutes of Health, Novartis
Starling	Randall	Risky Business: Predicting Outcomes in Heart	The HOSPITAL Readmission Model Poorly Predicts 30-Day	CONSULTANT FEES/HONORARIA - MEDTRONIC, Novartis;
		Failure	Rehospitalization in Heart Failure	RESEARCH/RESEARCH GRANTS - Abbott, Cardiac Dimensions, MEDTRONIC, National Institutes of Health, Novartis
Starling	Randall	Heart Failure and Cardiomyopathies: Therapy Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC, Novartis; RESEARCH/RESEARCH GRANTS - Abbott, Cardiac
				Dimensions,MEDTRONIC,National Institutes of Health,Novartis
Starovoytov	Andrew	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Clinical Outcomes of Acute Ischemic Stroke Patients Stratified by Cardiac Troponin-I: A Retrospective Analysis	Nothing to Disclose
Starovoytov	Andrew	Acute Coronary Syndromes, Diagnosis,	Angiographic Healing of Spontaneous Coronary Artery Dissection	Nothing to Disclose
Starovoytov	Andrew	Management and Outcomes Unusual Presentations of ACS	Clinical Predictors of Recurrent Dissection After Spontaneous	Nothing to Disclose
	Konstantinos	Changing the Natural History of Valve Disease	Coronary Artery Dissection Zoledronic Acid Inhibits Aortic Valve Calcification: A PET/CT Study	Nothing to Disclose
Stathogiannis		With Medical Therapy	·	ů .
Stathogiannis	Konstantinos	Interventional Cardiology: TAVR 2	The Effect of Mixed Aortic Valve Disease in Clinical Outcomes After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Stathogiannis	Konstantinos	Innovative Use of Echocardiography	Impact on Long Term Mortality of Persistent Pulmonary	Nothing to Disclose
Statile	Christopher	Congenital Heart Disease: Advances in Quality	Hypertension After Transcatheter Aortic Valve Implantation Standardizing the Care of Outpatient Pediatric Syncope and	Nothing to Disclose
		Improvement for Pediatric Cardiac Care	Dizziness: A Lesson in Utilization and Charge Reduction	
Stauber	Bradley	Innovations in Education	Decreasing Fluoroscopy Time for Percutaneous Coronary	Nothing to Disclose
Stavroulakis	Konstantinos	Optimizing Treatment of Peripheral Artery	Intervention With Fellows in an Academic Training Program Statin Therapy Is Associated With Increased Amputation Free	Nothing to Disclose
Stearns	Sally	Disease Acute Heart Failure: Evaluating Strategies to	Survival Among Patients With Critical Limb Ischemia Readmissions for Patients Discharged With Acute Decompensated	Nothing to Disclose
Occamo	Cally	Prevent Readmissions	Heart Failure and Reduced Versus Preserved Ejection Fraction: The	Treating to Disclose
Stebbins	Amanda	Featured Clinical Research II: Interventional	Atherosclerosis Risk in Communities Study Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral	Nothing to Disclose
			Valve Repair in the United States	•
Stebbins	Amanda	Interventional Cardiology: TAVR 2	Impact of the Presence of Coronary Artery Disease and Timing of Revascularization on Outcomes of Patients Undergoing Trans-	Nothing to Disclose
			Catheter Aortic Valve Replacement: Insights From STS/ACC TVT Registry	
Stebbins	Amanda	Why Can't We Be Friends? Controversies in	Prevalent Digoxin Use Is Not Associated With Increased Risk of	Nothing to Disclose
		Heart Failure Management	Death or Hospitalization in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction	
Steckelberg	James	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Utility of Cardiac Computed Tomography Scanning in the Diagnosis and Pre-Operative Evaluation of Patients With Infective Endocarditis	Nothing to Disclose
Stecker	Eric	Arrhythmias and Clinical EP: Ventricular Tachycardia	Health Insurance Expansion and Incidence of Out-of-Hospital Cardiac Arrest: A Pilot Study in a US Metropolitan Community	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Hygeia / Desi MD
Steckman	David	FIT Clinical Decision Making: Arrhythmias and	The Brugada Syndrome Mimicking an Acute Inferior ST Elevation	Nothing to Disclose
Steeds	Richard	Electrophysiology Nuclear Cardiology: Prognosis	Myocardial Infarction Serial Myocardial Perfusion Imaging in End-Stage Renal Disease	Nothing to Disclose
Steele	Lloyd	Current Issues in Cardiovascular	Investigating the Smoker's Paradox by Gender: Differences	Nothing to Disclose
		Epidemiology, Disparities, and Safety	in Survival Following Acute ST-Segment Elevation Myocardial Infarction	
Steele	Lloyd	Current Issues in Cardiovascular	Increased Risk of Acute ST-Segment Myocardial Infarction in	Nothing to Disclose
		Epidemiology, Disparities, and Safety	Female Smokers: A Contemporary Demographic Study	<u>L</u>



Contract of the contract of th				l l
<u>Last Name</u> Steen	First Name Dylan	Session Title Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Presentation Title Recurrent Cardiovascular Event Rates in a Contemporary Cohort of 829,498 Adults With Atherosclerotic Cardiovascular Disease	Disclosures CONSULTANT FEES/HONORARIA - Regeneron, Sanofi-Aventis
Steen	Henning	Coronary Artery Disease Featured Clinical Research I	MR-INFORM: Stress Perfusion Imaging to Guide the Management	Nothing to Disclose
Stefanadis	Christodoulos	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	of Patients With Stable Coronary Artery Disease Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a	Nothing to Disclose
Stefanadis	Christodoulos	Advances in HCM, PPCM and Other Cardiomyopathies	National Multicenter 1-Year-Follow-Up Study Unique Characteristics of the Mitral Valve in Patients With Hypertrophic Cardiomyopathy Have Emerged Using Real-Time	Nothing to Disclose
Stefanadis	Christodoulos	Uncovering the Intricacies of Vascular Function	Three Dimensional Transesophageal Echocardiography The Impact of Natural Chios Mastic Supplementation on Endothelial	Nothing to Disclose
Stefanescu	Ada	Teaching with Intent: Secrets from the Masters	Function and Arterial Stiffness in Smokers Panelist	Nothing to Disclose
Stefanescu	Ada	III	Simulation: Patient Encounter (Physician)	Nothing to Disclose
Stefanescu	Ada	III Teaching with Intent: Secrets from the Masters	360 Degree Feedback Session (Trainee)	Nothing to Disclose
Stefanescu	Ada	III Six Years of Making an IMPACT	Panelist	Nothing to Disclose
Stefanescu	Ada	FIT Clinical Decision Making Reviewers 7	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Steffel	Jan	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice		CONSULTANT FEES/HONORARIA - Astra Zeneca AfriCure, Bayer Healtheare Pharmaceuticals, Biosense Webster, Biotronik, Boehringer Ingelheim Pharmaceuticals, Inc, Boston Scientific, Bristol-Myers Squibb Company, Dailchi Sankyo, MED TRONIC, Novarits Corporation, Prizer, Sanofi- Aventis, St. Jude Medical Zoll; OWNERSHIP INTERESTIPARTNERSHIPPIRINCIPAL - CorXL; RESEARCH/RESEARCH GRANTS - Bayer Healthcare Pharmaceuticals, Biosense Webster, Biotronik, Boston Scientific, Dailor, Sankyo, MEDTRONIC, St. Jude Medical
Steffenino	Giuseppe	Highlighted Original Research: Interventional Cardiology and the Year in Review	Clinical, Angiographic and Procedural Correlates of Absorb Scaffold Thrombosis: A Matched Multicenter Registry Analysis	Nothing to Disclose
Steg	Philippe	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	A Randomized Trial Evaluating Clinically Significant Bleeding With Low-Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, for Patients After Acute Coronary Syndromes	CONSULTANT FEES/HONORARIA - Amarin, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, CSL Behring, Daiichi-Sankyo, Eli Lilly, Janssen Pharmaceuticals, Inc, Merck, & amp; Co., Inc., Novartis, Pfizer Inc, Regeneron, Sanofi-Aventis, The Medicines Company; RESEARCH/RESEARCH GRANTS - Merck & amp; Co., Inc., Sanofi-Aventis, Servier; SPEAKER'S BUREAU - Amgen Inc.
Steg	Philippe	Late-Breaking Clinical Trials: Deep Dive II		CONSULTANT FEES/HONORARIA - Amarin AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, CSL Behring, Daiichi-Sankyo, Eli Lilly, Janssen Pharmaceuticals, Inc, Merck & amp; amp; Co., Inc., Novartis; Pfizer Inc, Regeneron, Sanofi-Aventis, The Medicines Company; RESEARCH/RESEARCH GRANTS - Merck & amp; amp; Co., Inc., Sanofi-Aventis, servier; SPEAKER'S BUREAU - Amgen Inc.
Steg	Philippe	Late-Breaking Clinical Trials: Deep Dive II	Panelist	CONSULTANT FEES/HONORARIA - Amarin AstraZeneaa Bayer, BMS Boehringer-Ingelheim, CSL Behring , Daiichi-Sankyo, Eli Lilly, Janssen Pharmaceuticals, Inc, Merck & amp, amp; Co., Inc., Novartis, Pfizer Inc, Regeneron, Sanoft-Aventis, The Medicines Company; RESEARCH/IRESEARCH GRANTS - Merck & amp; amp; Co., Inc., Sanoff-Aventis, servier, SPEAKER'S BUREAU - Amgen Inc.
Steg	Philippe	Recent ACS Trials: Relevance to My Daily Practice	Panelist	CONSULTANT FEES/HONORARIA - Amarin, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, CSL Behring, Daiichi-Sankyo, Eli Lilly, Janssen Pharmaceuticals, Inc, Merck & amp; amp; Co., Inc., Novartis, Pfizer Inc, Regeneron, Sanofi-Aventis, The Medicines Company; RESEARCH/RESEARCH GRANTS - Merck & amp; amp; Co., Inc., Sanofi-Aventis, servier; SPEAKER'S BUREAU - Amgen Inc.
Steg	Philippe	The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints		CONSULTANT FEES/HONORARIA - Amarin AstraZeneaa Bayer, BMS Boehringer-Ingelheim, CSL Behring , Daiichi-Sankyo, Eli Lilly, Janssen Pharmaceuticals, Inc, Merck & amp, amp; Co., Inc., Novartis, Pfizer Inc, Regeneron, Sanoft-Aventis, The Medicines Company; RESEARCH/IRESEARCH GRANTS - Merck & amp; amp; Co., Inc., Sanoff-Aventis, servier, SPEAKER'S BUREAU - Amgen Inc.
Steg	Philippe	Highlighted Original Research: Prevention and the Year in Review		CONSULTANT FEES/HONORARIA - Amarin, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, CSL Behring, Daiichi-Sankyo, Eli Lilly, Janssen Pharmaceuticals, Inc, Merck, & amp; Co., Inc., Novartis; Pfizer Inc, Regeneron, Sanofi-Aventis, The Medicines Company; RESEARCH/RESEARCH GRANTS - Merck & amp; Co., Inc., Sanofi-Aventis, servier; SPEAKER'S BUREAU - Amgen Inc.
Steg	Philippe	Considerations in Antiplatelet Therapy and in ACS	Dual Antiplatelet Therapy Study	CONSULTANT FEES/HONORARIA - Amarin, AstraZeneca, Bayer, BMS, Bosen Pharmaceuticals, Inc, Merck & Amp; amp; Co., Inc., Novartis, Pfizer Inc, Regeneron, Sanofi-Aventis, The Medicines Company; RESEARCH/RESEARCH GRANTS - Merck & Amp; amp; Co., Inc., Sanofi-Aventis, Servier; SPEAKER'S BUREAU - Amgen Inc.
Steg		Revascularization and Outcomes		CONSULTANT FEES/HONORARIA - Amarin, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, CSL Behring, Daichi-Sankyo, Eli Lilly, Janssen Pharmaceuticals, Inc, Merck & Elicanor, Co., Inc., Novartis, Pfizer Inc, Regeneron, Sanofi-Aventis, The Medicines Company, RESEARCH/RESEARCH GRANTS - Merck & amp; amp; Co., Inc., Sanofi-Aventis, servier; SPEAKER'S BUREAU - Amgen Inc.
Steg	Philippe	Advances in Lipid Management	Monoclonal Antibody, Versus Placebo: Interim Baseline Data	CONSULTANT FEES/HONORARIA - Amarin, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, CSL Behring, Daichi-Sarky, Cell, Lilly, Jamssen Pharmaceuticals, Inc, Merck & Bamp; amp; Co., Inc., Novartis, Pfizer Inc, Regeneron, Sanofi-Aventis, The Medicines Company, RESEARCH/RESEARCH GRANTS - Merck & Bamp; amp; Co., Inc., Sanofi-Aventis, Servier; SPEAKER'S BUREAU - Amgen Inc.
Steg	Philippe	Optimizing the Care of ACS Patients	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin: Insights From CHAMPION PHOENIX	CONSULTANT FEES/HONORARIA - Amarin, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, CSL Behring, Dalichi-Sankyo, Eli Lilly, Janssen Pharmaceuticals, Inc, Merck & Bamp, amp; Co., Inc., Novartis, Pfizer Inc, Regeneron, Sanofi-Aventis, The Medicines Company, RESEARCH/RESEARCH GRANTS - Merck & Bamp; amp; Co., Inc., Sanofi-Aventis, Servier; SPEAKER'S BUREAU - Amgen Inc.

Contract of the second				<u> </u>
Last Name Steg	First Name Philippe	Session Title Post-CAD/MI: Making Tough Predictions About	Presentation Title One-Year Mortality Increased in Patients With Peri-Procedural	Disclosures CONSULTANT FEES/HONORARIA -
lotog	Тіттрре	the Future	Myocardial Infarction: Insights From the CHAMPION Trials	Amarin,AstraZeneca,Bayer,BMS,Boehringer-Ingelheim,CSL Behring ,Daiichi-Sankyo,Eli Lilly,Janssen Pharmaceuticals, Inc,Merck & Co., Inc.,Novartis,Pfizer
				Inc,Regeneron,Sanofi-Aventis,The Medicines Company; RESEARCH/RESEARCH GRANTS - Merck & Derkon, amp; Co., Inc.,Sanofi-Aventis,servier; SPEAKER'S BUREAU - Amgen Inc.
Steg	Philippe	Post-CAD/MI: Making Tough Predictions About the Future	Risk Stratification With the TIMI Risk Score for Secondary Prevention Among Patients With Diabetes and Elevated	CONSULTANT FEES/HONORARIA - Amarin, Astra Zeneca, Bayer, BMS, Boehringer-Ingelheim, CSL
		ine i didie	Cardiovascular Risk	Behring ,Daiichi-Sankyo,Eli Lilly,Janssen Pharmaceuticals, Inc,Merck & Description (Samp, 2008), Inc.,Novartis,Pfizer
				Inc,Regeneron,Sanofi-Aventis,The Medicines Company, RESEARCH/RESEARCH GRANTS - Merck & DREAMP; Co., Inc.,Sanofi-Aventis,servier; SPEAKER'S BUREAU - Amgen Inc.
Steg	Philippe	Anti-Platelet Therapies: Always a Sticky Topic	Ischemic Events Occur Early in Patients Undergoing PCI and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX	CONSULTANT FEES/HONORARIA - Amarin,AstraZeneca,Bayer,BMS,Boehringer-Ingelheim,CSL
				Behring , Daiichi-Sankyo, Eli Lilly, Janssen Pharmaceuticals, Inc, Merck & amp, jamp; Co., Inc., Novartis, Pferer Inc, Regeneron, Sanofi-Aventis, The Medicines Company; RESEARCH/RESEARCH GRANTS - Merck & amp; amp; Co.,
Steg	Philippe	15. Interventional Cardiology:	Suggested Reviewer	Inc.,Sanofi-Aventis,servier; SPEAKER'S BUREAU - Amgen Inc. CONSULTANT FEES/HONORARIA -
		ACS/AMI/Hemodynamics and Pharmacology Team 3		Amarin, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, CSL Behring, Daiichi-Sankyo, Eli Lilly, Janssen Pharmaceuticals, Inc, Merck & Bamp; amp; Co., Inc., Novartis, Pfizer Inc, Regeneron, Sanofi-Aventis, The Medicines Company, RESEARCH/RESEARCH GRANTS - Merck & Bamp; amp; Co., Sanofi-Aventis, The Medicines Company, RESEARCH/RESEARCH GRANTS - Merck & Bamp; amp; Co., Sanofi-Aventis
Stehlik	Josef		Complete Thrombotic Occlusion of TAVR Valve in Patient With	Inc.,Sanofi-Aventis,servier; SPEAKER'S BUREAU - Amgen Inc. Nothing to Disclose
Stehlik	Josef	Pulmonary Hypertension 13. Heart Failure and Cardiomyopathies:	Continuous Flow LVAD Suggested Reviewer	Nothing to Disclose
Stein	Evan	Clinical Team 6 Are We There Yet? Update on Trials Testing	Panelist	CONSULTANT FEES/HONORARIA -
		New Therapeutics for Prevention of ASCVD		Adnexus/BMS,Amgen,CVS/caremark,Gemphire,Ionis, Genzyme,Moderna,Regeneron/Sanofi ,Roche,The Medicines Co
Stein	Evan	Are We There Yet? Update on Trials Testing New Therapeutics for Prevention of ASCVD	The Evolution of PCSK9 Inhibitors - Pipedream or Evidence-based Reality?	CONSULTANT FEES/HONORARIA - Adnexus/BMS,Amgen,CVS/caremark,Gemphire,Ionis,
01.0		·		Genzyme,Moderna,Regeneron/Sanofi ,Roche,The Medicines Co
Stein	James	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Total Testosterone With Progression of Carotid Atherosclerosis and Coronary Artery Calcium Score: The Multi- Ethnic Study of Atherosclerosis	DATA SAFETY MONITORING BOARD - Eli Lilly and Company; OTHER - Up To Date, Wisconsin Alumni Research Foundation
Stein	James	Innovations in Cardiovascular Risk Assessment and Reduction	Association of Coronary Calcium, Carotid Wall Thickness and Carotid Plaque Progression With Low Density Lipoprotein and High Density Lipoprotein Particle Concentration Measured by Ion Mobility Testing: The Multi-Ethnic Study of Atherosclerosis (MESA)	DATA SAFETY MONITORING BOARD - Eil Lilly and Company; OTHER - Up To Date, Wisconsin Alumni Research Foundation
Steinberg	Benjamin	Role of Newer ICD Technologies for the Prevention of Sudden Cardiac Death	Case Presentation - Subcutaneous ICD	CONSULTANT FEES/HONORARIA - BMS/Pfizer; OTHER - Biotronik,MEDTRONIC; RESEARCH/RESEARCH GRANTS - Boston Scientific,Janssen Pharmaceuticals, Inc
Steinberg	Daniel	Refining TAVR Outcomes	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,Terumo Interventional Systems; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,Edwards Lifesciences,MEDTRONIC
Steinberg	Daniel	Frontiers in Mitral Valve Disease and Treatment	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,Terumon Interventional Systems; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,Edwards Lifesciences,MEDTRONIC
Steinberg	Daniel	01. Acute and Stable Ischemic Heart Disease: Basic Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,Terumo Interventional Systems; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,Edwards Lifesciences,MEDTRONIC
Steinberg	Jonathan	Role of Newer ICD Technologies for the Prevention of Sudden Cardiac Death	Panelist	CONSULTANT FEES/HONORARIA - Ablative Solutions, AliveCor , Allergan, Inc, Biosense-Webster, Boston-
Steinberg	Jonathan	Role of Newer ICD Technologies for the	Subcutaneous ICDs: Who, When and Why?	Scientific,InCarda,Jansen,MEDTRONIC,Now Cardio CONSULTANT FEES/HONORARIA - Ablative Solutions,AliveCor
		Prevention of Sudden Cardiac Death		,Allergan, Inc,Biosense-Webster,Boston- Scientific,InCarda,Jansen,MEDTRONIC,Now Cardio
Steiner	Jill	Pregnancy Complicated by Valvular/Congenital Heart Disease: Clinical Management and Challenging Cases	Case Presentation: Pregnancy Complicated by Recurrent Prosthetic Valve Thrombosis	Nothing to Disclose
Steiner	Jill	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Palliative Care: A Critical Treatment Tool for Decision Making in Advanced Heart Disease	Nothing to Disclose
Steiner	Robert	Imaging With Cardiac CT: The Case for Calcium	Coronary Artery Calcium on Noncontrast Thoracic CT Scans and All Cause Mortality: The Copd Gene Cohort	Nothing to Disclose
Steingart	Richard	Imaging of Cancer-Treatment Associated CV Toxicity: Applying Guidelines to Clinical Practice	Panelist	Nothing to Disclose
Steinhubl	Steven	Innovations in Practice Management and Social Media	Remote Digital Recruitment and Enrollment in a Nationwide Trial of Screening for Undiagnosed Atrial Fibrillation Using a Self-Applied ECG Recording Patch Sensor: Lessons From the mSToPS Trial	CONSULTANT FEES/HONORARIA - AirStrip,AstraZeneca; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Vantage Health
Steinvil	Arie	Considerations in Antiplatelet Therapy and in ACS	Trends in Discharge and Outcome of Dual Antiplatelet Therapy Post Percutaneous Intervention in High Bleeding Risk Population	
Steinvil	Arie	Considerations in Antiplatelet Therapy and in ACS	Outpatient Trends in Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Primary Percutaneous Coronary	Nothing to Disclose
1	Arie	PCI for NSTEMI and Complex Patients With	Intervention In-Stent Restenosis of Drug-Eluting Stents: Incidence, Lesion Characteristics and Outcomes in Contemporary Practice Over the	Nothing to Disclose
Steinvil	Arie	Multiple Co-Morbidities		
Steinvil Steinvil	Arie	Multiple Co-Morbidities Interventional Cardiology: TAVR 2	Last Decade - How Are They Different From De Novo Lesions? Racial Disparities and Temporal Trends in Demographics and Clinical Characteristics of Patients Screened for Transcatheter	Nothing to Disclose
		•	Last Decade - How Are They Different From De Novo Lesions? Racial Dispartities and Temporal Trends in Demographics and Clinical Characteristics of Patients Screened for Transcatheter Aortic Valve Replacement Is There a Role for Invasive Electrophysiology Studies in Patients With Conduction Abnormalities Following Transcatheter Aortic Valve	Nothing to Disclose Nothing to Disclose
Steinvil	Arie	Interventional Cardiology: TAVR 2 Arrhythmias and Clinical EP: AF Miscellaneous	Last Decade - How Are They Different From De Novo Lesions? Racial Dispartiles and Temporal Trends in Demographics and Clinical Characteristics of Patients Screened for Transcatheter Aortic Valve Replacement Is There a Role for Invasive Electrophysiology Studies in Patients With Conduction Abnormalities Following Transcatheter Aortic Valve Replacement? Antithrombotic Therapy Differences and Associated Outcomes in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic	-
Steinvil Steinvil	Arie Arie	Interventional Cardiology: TAVR 2 Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Last Decade - How Are They Different From De Novo Lesions? Racial Dispartites and Temporal Trends in Demographics and Clinical Characteristics of Patients Screened for Transcatheter Aortic Valve Replacement Is There a Role for Invasive Electrophysiology Studies in Patients With Conduction Abnormalities Following Transcatheter Aortic Valve Replacement? Antithrombotic Therapy Differences and Associated Outcomes in	Nothing to Disclose



WASHINGTON, DC | MARCH 17 - 19 2017

Congress of the Congress of th				
Last Name Stelzer	First Name Paul	Session Title Highlighted Original Research: Vascular	Presentation Title CD90 Marks a Population of Adventitial Mesenchymal Stem Cells in	Disclosures CONSULTANT FEES/HONORARIA - CryoLife
SIGIZGI	raui	Medicine and the Year in Review	the Human Aorta That Exhibit Diminished Angiogenic Potential in Patients With Ascending Aortic Aneurysms	CONSULTANT I EESHIONONANIA - CIYUElle
Stephenson	Elizabeth	Congenital Heart Disease: Pediatric Team	Suggested Reviewer	Nothing to Disclose
Stern	Eric	Innovations in Education	Update on the ABIM's Competency Based Pilot in Internal Medicine- Cardiology	Nothing to Disclose
Stern	Kenan	Congenital Heart Disease: Novel Insights in Pediatric Cardiology	Clinical Yield of Fetal Echocardiography for Suboptimal Cardiac Visualization on Obstetric Ultrasound	Nothing to Disclose
Steury	Rachel	Adult Patients With Congenital Heart Disease: How Do They Compare?	Factors Associated With Completion of Advanced Directives in Adults With Congenital Heart Disease	Nothing to Disclose
Stevens	Louis-Mathieu	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Appropriateness of Coronary Artery Bypass Grafting Based on Fractional Flow Reserve Lesions Assessment	Nothing to Disclose
Stevens	Louis-Mathieu	Novel Imaging and Therapies in Heart Failure	Novel Infarct Sparing Drug Protects the Heart Against Ischemia- Reperfusion (I/R) Injury	Nothing to Disclose
Stevens	Scott	Late-Breaking Clinical Trials	GIFT of Warfarin: Benefit of Pharmacogenetic Dosing	RESEARCH/RESEARCH GRANTS - Bayer, Bristol-Myers Squibb
Stevens	Steven	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team 5	Suggested Reviewer	Nothing to Disclose
Stevenson	Lynne	FIT Forum: Mix and Mingle	heart Failure	OTHER - Medtronic Inc ,St Jude Medical; RESEARCH/RESEARCH GRANTS - Novartis,St Jude Medical
Stevenson	Lynne	Can You See Me Now? Sensors For Monitoring Heart Failure	Panelist	OTHER - Medtronic Inc ,St Jude Medical; RESEARCH/RESEARCH GRANTS - Novartis,St Jude Medical
Stevenson	Lynne	Can You See Me Now? Sensors For Monitoring Heart Failure	Under Pressure: Pulmonary Artery Sensors	OTHER - Medtronic Inc ,St Jude Medical; RESEARCH/RESEARCH GRANTS - Novartis,St Jude Medical
Stevenson	Lynne	Innovative Use of Echocardiography	Echocardiographic Parameters Associated With Quality of Life in Ambulatory Patients With Heart Failure	OTHER - Medtronic Inc ,St Jude Medical; RESEARCH/RESEARCH GRANTS - Novartis,St Jude Medical
Stevenson	Lynne	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	High Procedural and Device Related Success With the CardioMEMS HF System for Heart Failure: Observations From the CardioMEMS™ Post Approval Study	OTHER - Medtronic Inc ,St Jude Medical; RESEARCH/RESEARCH GRANTS - Novartis,St Jude Medical
Stevenson	Lynne	14. Heart Failure and Cardiomyopathies: Therapy Team 2	Suggested Reviewer	OTHER - Medtronic Inc ,St Jude Medical; RESEARCH/RESEARCH GRANTS - Novartis,St Jude Medical
Stevenson	William	FIT Forum: Mix and Mingle	Electrophysiology	CONSULTANT FEES/HONORARIA - St Jude Medical; OTHER -
Stevenson	William	Late-Breaking Clinical Trials	Panelist	patent for needle ablation CONSULTANT FEES/HONORARIA - St Jude Medical; OTHER - patent for needle ablation
Stevenson	William	Clinical Challenges in the Cardiac Care Unit	Management of Cardiac Arrhythmias in the CCU	CONSULTANT FEES/HONORARIA - St Jude Medical; OTHER -
Stevenson	William	(CCU) Ventricular Arrhythmias in the Coronary Care Unit: Contemporary Solutions to an Old	When Should I Do Catheter Ablation for Ventricular Arrhythmia in the CICU	patent for needle ablation CONSULTANT FEES/HONORARIA - St Jude Medical; OTHER - patent for needle ablation
Stevenson	William	Problem Quickfire ECG for Experts	Co-Chair	CONSULTANT FEES/HONORARIA - St Jude Medical; OTHER -
Stevenson	William	Nuclear Cardiology: Prognosis	Myocardial Scar but Not Ischemia Predicts Defibrillator Shocks and Sudden Cardiac Death in Patients With Reduced Left Ventricular	patent for needle ablation CONSULTANT FEES/HONORARIA - St Jude Medical; OTHER - patent for needle ablation
Stevenson	William	06. Arrhythmias and Clinical EP: Other Team 1	Ejection Fraction Suggested Reviewer	CONSULTANT FEES/HONORARIA - St Jude Medical; OTHER -
Steverson	Alexandra	Making Progress in Understanding Heart Failure	Associations of HIV Related Factors With Adjudicated Heart Failure (HF) in an Electronic Cohort of HIV-Infected (HIV+) Persons	patent for needle ablation Nothing to Disclose
Steverson	Alexandra	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Atrial Fibrillation (AF) and Atrial Flutter (AFL) Prevalence and Characteristics for Persons With Human Immunodeficiency Virus	Nothing to Disclose
Stewart	Allan	Highlighted Original Research: Vascular Medicine and the Year in Review	(HIV+) and Matched Uninfected Controls CD90 Marks a Population of Adventitial Mesenchymal Stem Cells in the Human Aorta That Exhibit Diminished Angiogenic Potential in	Nothing to Disclose
Stewart	Andrew	Traditional and Novel Factors Used to Assess	Patients With Ascending Aortic Aneurysms Glycemic Control in Insulin and Non-Insulin Dependent Diabetic	Nothing to Disclose
Ou and	A . d .	the Risk of, and Used for the Treatment of, Coronary Artery Disease	Patients With ST Elevation Myocardial Infarction Predicts Time to Presentation	N. W. J. D. J.
Stewart	Andrew	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Ischemic Time and Risk Factors Associated With the Incidence of Cardiogenic Shock in Patients Presenting With ST Elevation Myocardial Infarction	Nothing to Disclose
Stewart	Andrew	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Impact of Demographics and Socioeconomic Status on Mode of Transportation and Time to Presentation in Patients With ST Elevation Myocardial Infarction	Nothing to Disclose
Stewart	Garrick	Test Yourself with Questions: General Cardiology Module 15	Faculty	Nothing to Disclose
Stewart	Garrick	Test Yourself with Questions: General Cardiology Module 15	Moderator	Nothing to Disclose
Stewart	Ralph	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Bleeding Risk Models in Acute Coronary Syndrome: Meta-Analysis of Performance	RESEARCH/RESEARCH GRANTS - GlaxoSmithKline
Stewart	William	36. Valvular Heart Disease: Clinical Team 1 Featured Clinical Research I	Suggested Reviewer	Nothing to Disclose
Stieglitz	Jonathan		Native South American Tsimane Have the Lowest Levels of Coronary Atherosclerosis Ever Reported	Nothing to Disclose
Stiermaier	Thomas	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Antecedent Hypertension and Myocardial Injury in Patients With Reperfused ST-Elevation Myocardial Infarction	Nothing to Disclose
Stojakovic	Tatjana	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Circulating PCSK9 Is Not Associated With All-Cause and Cardiovascular Mortality	Nothing to Disclose
Stoler	Robert	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Effect of Baseline Aortic Regurgitation on Mortality in the Core Valve US Pivotal High Risk Trial	CONSULTANT FEES/HONORARIA - Boston Scientific - Lotus Proctor,Boston Scientific: Advisory Board,Medtronic: Advisory Board, Corevalve Proctor
Stolfo	Davide	Advances in HCM, PPCM and Other Cardiomyopathies	Integrating Myocardial Strain and Exercise Performance Into Prognostication of Hypertrophic Cardiomyopathy	Nothing to Disclose
Stoller	Douglas	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Stiff Left Atrial Syndrome Following Multiple Ablations Diagnosed With Invasive Hemodynamic Exercise Testing	Nothing to Disclose
Stone	Gregg	Cardiovascular Update for the Clinician I: Coronary Artery Disease – Challenges in 2017 (A Symposium by Dr. Valentin Fuster)	Panelist	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Vavez, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	Cardiovascular Update for the Clinician I: Coronary Artery Disease – Challenges in 2017 (A Symposium by Dr. Valentin Fuster)	STEMI Versus NSTEMI Versus STABLE CAD - Post PCI DAPT Duration Scoring the Complexity of Disease and of Stent	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP NTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies

Contract of the second				l .
Last Name Stone	First Name Gregg	Session Title Late-Breaking Clinical Trials: Interventional	Presentation Title Everolimus-Eluting Bioresorbable Vascular Scaffolds in Patients	Disclosures CONSULTANT FEES/HONORARIA - Ablative
		Č	With Coronary Artery Disease: Two-Year Outcomes From the ABSORB III Trial	Solutions,BackBeat Medical,Coherex,Guided Delivery Systems,Medical Development Technologies,Miracor,Neovasc,Reva,TherOx,Vascular Dynamics,V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria,Biostar family funds,Cagent,Caliber,Medfocus family funds,micardia ,Qool Therapeutics,Vascular Nonotransfer Technologies
Stone	Gregg	Featured Clinical Research II: Interventional	Co-Chair	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	Left Main PCI: Why? When? How?	Panelist	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	Left Main PCI: Why? When? How?	insights from EXCEL and NOBLE	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nontransfer Technologies
Stone	Gregg	Transcatheter Mitral Valve Repair	Co-Chair	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nontransfer Technologies
Stone	Gregg	Transcatheter Mitral Valve Repair	MitraClip: Current Data Overview	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nontransfer Technologies
Stone	Gregg	The Evolution of Angioplasty – 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	Co-Chair	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nontransfer Technologies
Stone	Gregg	The Evolution of Angioplasty – 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	The Evolution of PCI	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	The Evolution of Angioplasty – 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	Final Thoughts	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nontransfer Technologies
Stone	Gregg	Highlighted Original Research: Interventional Cardiology and the Year in Review	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	Highlighted Original Research: Interventional Cardiology and the Year in Review	Clinical, Angiographic and Procedural Correlates of Absorb Scaffold Thrombosis: A Matched Multicenter Registry Analysis	
Stone	Gregg	Considerations in Antiplatelet Therapy and in ACS	Effect of Thrombotic and Bleeding Risk According to Platelet Reactivity on 2-Year Mortality: The ADAPT-DES Study	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	Considerations in Antiplatelet Therapy and in ACS	Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multi-Vessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents	CONSULTANT FEES/HONORARIA - Ablative

and the second				
Last Name Stone	First Name Gregg	Session Title Considerations in Antiplatelet Therapy and in ACS	Presentation Title Platelet Reactivity and Outcomes After PCI of Lesions With and Without In-Stent Restenosis: The ADAPT-DES Study	Disclosures CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family tunds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Introduction of the CALM II Study. A Multi-Center, Blinded, Sham- Controlled Pivotal Trial of an Endovascular Carotid Barostimulation Implant for the Treatment of Resistant Hypertension	CONSULTANT FEES/HONORARIA - Abilative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Vave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Platelet Reactivity and Outcomes After PCI of Saphenous Vein Grafts Versus Native Coronary Arteries: The ADAPT-DES Study	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Differences and Level of Agreement in SYNTAX Score Assessment Between Site Operators and Angiographic Core Laboratory Readers: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - Abiative Solutions, Backbeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERS-HIP INTEREST/PARTNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nondransfer Technologies
Stone	Gregg	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of Periprocedural Myocardial Infarction in Contemporary PCI: Pooled Patient-Level Data From the CHAMPION Trials	CONSULTANT FEES/HONORARIA - Abiative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	Interventional Cardiology: PCI and TAVR in Complex Patients	Long-Term Adverse Ischemic Outcomes After Percutaneous Coronary Intervention Among Patients With Versus Without Prior Coronary Artery Bypass Grafting: Analysis From 17 Randomized Trials	CONSULTANT FEES/HONORARIA - Abilative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	Coronary Intervention: Drug Eluting Stent and Scaffolds	Efficacy and Safety of Everolimus-Eluting Stents Versus Slow- Release Zotarolimus-Eluting Stents: A Direct Comparison Meta- Analysis of 29,286 Patients - Years of Follow-Up From Randomized Controlled Trials	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Vaver, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	Advances in Chronic Total Occlusion Intervention	Is Platelet Reactivity Associated With Ischemic Events Following Successful Chronic Total Occlusion Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	Optimizing the Care of ACS Patients	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin: Insights From CHAMPION PHOENIX	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	Optimizing the Care of ACS Patients	Contemporary Patterns of GP lib/Illa Inhibitor Use in Patients With Acute Myocardial Infarction Undergoing PCI: Insights From the TRANSLATE ACS Study	CONSULTANT FEES/HONORARIA - Abiative Solutions, Backbeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERS-HIP INTEREST/PARTNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nondransfer Technologies
Stone	Gregg	Refining PCI Technique and Outcomes	Treatment of Left Main Coronary Artery Disease in Patients With Diabetes: 3-Year Outcomes Comparing CABG and PCI With Everolimus-Eluting Stents From the EXCEL Study	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	Refining PCI Technique and Outcomes	Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory Assessment: Insights From the EXCEL Trial	CONSULTANT FEES/HONORARIA - Abilative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	Post-CAD/MI: Making Tough Predictions About the Future	One-Year Mortality Increased in Patients With Peri-Procedural Myocardial Infarction: Insights From the CHAMPION Trials	CONSULTANT FEES/HONORARIA - Ablative Solutions, BackBeat Medical, Coherex, Guided Delivery Systems, Medical Development Technologies, Miracor, Neovasc, Reva, TherOx, Vascular Dynamics, V-Wave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies

(M. The state of t				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Stone	Gregg	PCI Strategies and Outcomes Unique to	Sex Differences in Outcomes After Stenting or Bypass Surgery for	CONSULTANT FEES/HONORARIA - Ablative
		Women	Unprotected Left Main Disease	Solutions,BackBeat Medical,Coherex,Guided Delivery
				Systems, Medical Development
				Technologies, Miracor, Neovasc, Reva, TherOx, Vascular
				Dynamics,V-Wave; OWNERSHIP
				INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family funds, Cagent, Caliber, Medfocus family funds, micardia, Qool
				Tunds, Cagent, Caliber, Mediocus ramily runds, micardia, Qool Therapeutics. Vascular Nonotransfer Technologies
Stone	Greag	Anti-Platelet Therapies: Always a Sticky Topic	Ischemic Events Occur Early in Patients Undergoing PCI and Are	Therapeutics, Vascular Nonotransfer Technologies CONSULTANT FEES/HONORARIA - Ablative
Storie	Gregg	Anti-Platelet Therapies: Always a Sticky Topic	Reduced With Cangrelor: Findings From CHAMPION PHOENIX	Solutions, BackBeat Medical, Coherex, Guided Delivery
			Reduced Willi Caligraior. Findings From Chawfion Phoenix	Systems, Medical Development
				Technologies, Miracor, Neovasc, Reva, TherOx, Vascular
				Dynamics,V-Wave; OWNERSHIP
				INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family
				funds, Cagent, Caliber, Medfocus family funds, micardia, Qool
				Therapeutics, Vascular Nonotransfer Technologies
Stone	Gregg	LBCT reviewers	LB Reviewer	CONSULTANT FEES/HONORARIA - Ablative
				Solutions,BackBeat Medical,Coherex,Guided Delivery
				Systems,Medical Development
				Technologies, Miracor, Neovasc, Reva, Ther Ox, Vascular
				Dynamics,V-Wave; OWNERSHIP
				INTEREST/PARTNERSHIP/PRINCIPAL - Aria, Biostar family
				funds, Cagent, Caliber, Medfocus family funds, micardia, Qool Therapeutics, Vascular Nonotransfer Technologies
Stone	Mia	Public Reporting and NCDR: The Decision to	Co-Chair	Nothing to Disclose
Storie	IVIId	Report Your Data Before the Feds Decide	CO-Citali	Nothing to Disclose
Stone	Neil	Featured Clinical Research III	Panelist	Nothing to Disclose
Stone	Neil	Prevention of ASCVD Over the Lifespan: A	Co-Chair	Nothing to Disclose
Otoric	THE III	Case-based Approach	O Onai	Nothing to Disclose
Stone	Neil	Great Debates in Preventive Cardiology	Risk Assessment in Primary Prevention of ASCVD -	Nothing to Disclose
	1	and a second sec	Recommendations for Statin Therapy in Primary Prevention Should	
			Be Based on the Pooled Cohort Equation	
Stone	Neil	Highlighted Original Research: Prevention and		Nothing to Disclose
		the Year in Review		-
Stone	Neil	Interventional Cardiology: TAVR 2	Intensity of Statin Therapy and Outcomes After Transcatheter Aortic	Nothing to Disclose
			Valve Replacement	
Stone	Peter	Interventional Cardiology: Intravascular	Association of Coronary Epicardial Endothelial Dysfunction With	Nothing to Disclose
		Physiology and Endothelial Function	Low Endothelial Shear Stress in Patients With Mild Coronary	
			Atherosclerosis Who Presented With Chest Pain	
Storey	Robert	Considerations in Antiplatelet Therapy and in	Comparison of P2y ₁₂ Inhibitors for Mortality and Stent	CONSULTANT FEES/HONORARIA -
		ACS	Thrombosis in Patients With Acute Coronary Syndromes: Single	Aspen,AstraZeneca,Correvio,Medscape,PlaqueTec,The
			Centre Study of 10,793 Consecutive 'Real-World'	Medicines Company, ThermoFisher Scientific; OTHER -
			Patients	MEDTRONIC; RESEARCH/RESEARCH GRANTS - AstraZeneca
Stouffer	George	Coronary Physiology for the Assessment of	Panelist	Nothing to Disclose
Stouliei	George	Stable CAD	ranensi	Nothing to disclose
Stouffer	George	Coronary Physiology for the Assessment of	Case Presentation: Physiology Guided PCI	Nothing to Disclose
2.0001	300.g0	Stable CAD	Table 1 occurrence 1 of the same of the sa	
Stouffer	George	Cutting Edge Vascular Medicine	Rap1 Mediates Thrombin-Induced Proliferation and Focal Adhesion	Nothing to Disclose
1			Formation in Smooth Muscle Cells	1 -
Stouffer	George	Interventional Complexity and Complications	Characteristics and Outcomes of Patients With Clinically Silent Peri-	Nothing to Disclose
			Procedural Hemoglobin Drops as Compared to Patients With Overt	
			Bleeding Following Percutaneous Coronary Intervention	
Stout	Karen	FIT Forum: Mix and Mingle	Congenital HD Pediatric and Adult	Nothing to Disclose
Stout	Karen	Update in ACHD: The Time for Change is Now	Co-Chair	Nothing to Disclose
01. 1	17	Harter Adult The Tree Colores in No.	Time () Oh and () A OH D Market David A	Market and Breathan
Stout	Karen	Update in ACHD: The Time for Change is Now		Nothing to Disclose
Ctavit	Verse	FIT Olivinal Desirina Malvinas Description Adult	the 2016 Guidelines	Nothing to Displace
Stout	Karen	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Palliative Care: A Critical Treatment Tool for Decision Making in Advanced Heart Disease	Nothing to Disclose
		Congenital and Congenital Fleart Disease	Advanced Fleat Disease	
Stout	Karen	FIT Clinical Decision Making: Interventional	Unusual Transcatheter Aortic Valve Replacement Complication:	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart	Aorto-RV Cameral Fistula	
		Disease, and Vascular Medicine		
Stout	Karen	09. Congenital Heart Disease: Adult Team 1	Suggested Reviewer	Nothing to Disclose
Stout	Megan	Coronary Intervention in Interventional	QRS Duration Alterations After Left Ventricular Assist Device	Nothing to Disclose
		Cardiology: Advanced Device Use	Implantation in Patients With Advanced Heart Disease	-
Strachan	Fiona	Cardiac Arrest, Diabetes, and Other High Risk	Optimal Risk Stratification Pathways for Patients With Suspected	Nothing to Disclose
		Features of Patients With Acute Coronary	Acute Coronary Syndrome	
		Syndrome		
Strachan	Fiona	Acute Coronary Syndromes, Diagnosis,	Age and the Effectiveness of Risk Stratification and Diagnostic	Nothing to Disclose
		Management and Outcomes	Thresholds for Myocardial Infarction With High-Sensitivity Cardiac	
Strachan	Fions	Aguta Caranani Sundressas Disessasis	Troponin	Nothing to Displace
Strachan	Fiona	Acute Coronary Syndromes, Diagnosis,	High-Sensitivity Cardiac Troponin and the Classification of	Nothing to Disclose
Strange	lulian	Management and Outcomes	Myocardial Infarction Bivalirudin Versus Heparin in Primary PCI: Clinical Outcomes and	Nothing to Disclose
Strange	Julian	Considerations in Antiplatelet Therapy and in ACS	Cost Analysis From a Large Retrospective Cohort	Nothing to Disclose
Strange	Julian	PCI for NSTEMI and Complex Patients With	Predictors of Survival From Out-of-Hospital Cardiac Arrest	Nothing to Disclose
Cuango	Januari	Multiple Co-Morbidities	. 155.55.5 or our vivar 1 form out-of-10spital Gardiac Arrest	Trouming to Disciose
Strassle	Paula	Emerging Applications of Echocardiography	Association Between Global Echocardiography-Based Cardiac	Nothing to Disclose
		Jung 1 manual of Editoda diography	Calcium Score and the Clinical Outcomes After Transcatheter	J
			Aortic Valve Replacement	
Strassle	Paula	Novel Developments in Acute Coronary	Comparison of Troponin Peaks Between Type 1 and Type 2	Nothing to Disclose
	<u> </u>	Syndromes	Myocardial Infarction	
Strassle	Paula	Interventional Complexity and Complications	Characteristics and Outcomes of Patients With Clinically Silent Peri-	Nothing to Disclose
			Procedural Hemoglobin Drops as Compared to Patients With Overt	
	1		Bleeding Following Percutaneous Coronary Intervention	
Strassle	Paula	Unusual Presentations of ACS	Differing Outcomes of Type 1 and Type 2 Myocardial Infarction and	Nothing to Disclose
			Their Impact on Overall Non-ST Elevation Myocardial Infarction	
01	0	0	Mortality Rates	Number to Breaters
Strauss	Craig	Complex Coronary Intervention: Left	Multivessel Versus Culprit-Only PCI in Patients With Non-ST	Nothing to Disclose
		Main/Bifurcations and Multivessel Disease	Segment Elevation Myocardial Infarction and Multivessel Disease:	
Strauga	Crain	Timely Topics in Assits Course Court	Results From the PROMETHEUS Study	Nothing to Displace
Strauss	Craig	Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated	Nothing to Disclose
			With Percutaneous Coronary Intervention for Acute Coronary Syndromes	
Strbad	Martina	Finding Out What Works in Pediatric and	Morphological Appearance and Repair Strategies of Tricuspid	Nothing to Disclose
Gubau	iviai ui id	Congenital Heart Disease	Regurgitation in Patients With Univentricular Heart and a Systemic	Trouming to Disclose
		OS. Igoriikai Ficart Discase	Right Ventricle	
Strom	Jordan	Highlighted Original Research: Acute and	Sex Differences in Rates of 30-Day Readmission in Patients	Nothing to Disclose
	- 3. 00	Stable Ischemic Heart Disease and the Year in	Discharged After Acute Myocardial Infarction in the United States	
		Review	garante states and states	
Strom	Jordan	Interventional Cardiology: PCI and TAVR in	Management of Patients With Cardiac Arrest in New York Before	Nothing to Disclose
L	<u> </u>	Complex Patients	and After Public Reporting Policy Changes	
			•	-

Submberg	First Name Kurt	Session Title Arrhythmias and Clinical EP: Devices 1	Presentation Title Insertion of a Miniaturized Insertable Cardiac Monitor Outside the Traditional Hospital Setting: Results From the RIO 2 International	Disclosures SALARY - MEDTRONIC
Stroup I	Richard	Congenital Heart Disease: Innovations in	Study Interstage Resource Utilization of Infants With Single Ventricle:	Nothing to Disclose
Stuckey	Thomas	Single Ventricle Heart Disease PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Results of a Crossover Study Platelet Reactivity and Outcomes After PCI of Saphenous Vein Grafts Versus Native Coronary Arteries: The ADAPT-DES Study	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation,Medicure; SPEAKER'S BUREAU - Medicines
Stuckey	Thomas	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era:	Company CONSULTANT FEES/HONORARIA - Boston Scientific Corporation, Medicure; SPEAKER'S BUREAU - Medicines
Stuckey	Thomas	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Insights From the PARIS Study Coronary Artery Disease Learning and Algorithm Development Study: Early Analysis of Ejection Fraction Evaluation	Company CONSULTANT FEES/HONORARIA - Boston Scientific Corporation, Medicure; SPEAKER'S BUREAU - Medicines
Studyvin :	Sarah	Heart Failure and Cardiomyopathies: Is Heart	Statin Intensity and Outcome in Patients With Acute Heart Failure	Company Nothing to Disclose
Studyvin	Sarah	Failure With a Normal EF for Real? FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	With Preserved Ejection Fraction Late Presentation of Total Anomalous Pulmonary Venous Connection	Nothing to Disclose
Studyvin	Sarah	Changing the Natural History of Valve Disease	Statins Use and Long Term Outcome Post Surgical Aortic Valve	Nothing to Disclose
Studyvin		With Medical Therapy FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Replacement Coil Embolization of latrogenic Pulmonary Artery Pseudoaneurysm	Nothing to Disclose
Stuijfzand		Disease, and Vascular Medicine Nuclear Cardiology: Quality	Automatic SPECT Analysis Compared to Expert Visual Scoring for	RESEARCH/RESEARCH GRANTS - Abbott Vascular
Stuijfzand	Wijnand	Advances in Chronic Total Occlusion Intervention	the Detection of Coronary Artery Disease Effects of Successful Percutaneous Coronary Intervention of Chronic Total Occlusions on Myocardial Perfusion and Left Ventricular Function	RESEARCH/RESEARCH GRANTS - Abbott Vascular
Stuijfzand	Wijnand	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Atherosclerotic Plaque Morphology Is Associated With Impaired Myocardial Blood Flow and Fractional Flow Reserve, Independent of Luminal Obstruction	RESEARCH/RESEARCH GRANTS - Abbott Vascular
Stulak	John	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Effects of Diabetes Mellitus on Clinical Outcomes After Left Ventricular Assist Device Implantation: A Single Institutional 9-Year Experience	Nothing to Disclose
Stulak .	John	Advanced Therapies = Advanced Trouble: VAD and Transplant Challenges	Sirolimus-Based Immunosuppression Mitigates Progression of Cardiac Allograft Vasculopathy and Improves Cardiac Outcomes After Heart Transplantation: A Single Center 15-Year Follow-Up Study	Nothing to Disclose
Stys	Adam	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	An Alternative Approach to Treatment of Infective Endocarditis Using AngioVac®	Nothing to Disclose
Stys	Adam	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Comparison of Procedural Efficacy of Coronary Angiography in Octogenarian, Nonagenarian and General Population	Nothing to Disclose
Stys	Adam	Interventional Complexity and Complications	Factors Influencing Physician Selection of Radial Versus Femoral Approach in Non-Emergent Cases of CATH and PCI Procedures	Nothing to Disclose
Stys	Adam	Interventional Complexity and Complications	Patient Characteristics as Predictors of Transradial Approach Failure During Coronary Angiography Procedures	Nothing to Disclose
Stys	Adam	Interventional Complexity and Complications	The Effect of Body Mass Index on Procedural Efficacy in Transfemoral Versus Transradial Coronary Angiography	Nothing to Disclose
Stys		FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	A Case of Bilateral External Iliac Obstruction in Pediatric Male Patient Managed With Angioplasty With a Drug Eluting Balloon	Nothing to Disclose
Stys		Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Comparison of Procedural Efficacy of Coronary Angiography in Octogenarian, Nonagenarian and General Population	Nothing to Disclose
Stys	Tomasz	Interventional Complexity and Complications	Factors Influencing Physician Selection of Radial Versus Femoral Approach in Non-Emergent Cases of CATH and PCI Procedures	Nothing to Disclose
Stys	Tomasz	Interventional Complexity and Complications	Patient Characteristics as Predictors of Transradial Approach Failure During Coronary Angiography Procedures	Nothing to Disclose
Stys	Tomasz	Interventional Complexity and Complications	The Effect of Body Mass Index on Procedural Efficacy in Transfemoral Versus Transradial Coronary Angiography	Nothing to Disclose
Su	Wilber	Arrhythmias and Clinical EP: AF Ablation	Early Experience of Topera Rotor Mapping for the Treatment of Recurrent Atrial Fibrillation Following Prior Pulmonary Vein Isolation	CONSULTANT FEES/HONORARIA - MEDTRONIC,St. Jude Medical
Su	Wilber	Arrhythmias and Clinical EP: Devices 3	Prospective Cryoballoon Dosing Study Based on Time-to-Isolation	CONSULTANT FEES/HONORARIA - MEDTRONIC,St. Jude Medical
Su	Wilber	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Left Atrial Tachycardia Ablation During Pregnancy: A Successful Ablation With Near- Zero Fetal Radiation Exposure	CONSULTANT FEES/HONORARIA - MEDTRONIC,St. Jude Medical
Su 2	Zhaohui	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	A Simple Predictive Score for Pre-Admission Identification of Risk of 30-Day Hospital Readmission or Death in Heart Failure	Nothing to Disclose
Suarez	Aldo	Updates on Risk Factors for Cardiovascular Disease	Association of Anxious and Depressive Symptomatology With Cardiovascular Disease Among Patients From Different States in Mexico: REDECAR Study	Nothing to Disclose
Subbarao	Roopa	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension		Nothing to Disclose
Sud	Karan	Highlighted Original Research: Vascular Medicine and the Year in Review	Burden of Repeat Admissions Among Patients With Critical Limb Ischemia	Nothing to Disclose
Sud I	Karan	New Perspectives on CAD Risk Factors	Changing Trends of Atherosclerotic Risk Factors Among Patients With Acute Myocardial Infarction and Acute Ischemic Stroke	Nothing to Disclose
Sudasena I	Daryl	Valvular Heart Disease: Aortic Stenosis	Outcomes and Their Predictors in Acute Transcatheter Aortic Heart Valve-in-Transcatheter Aortic Heart Valve Therapy	Nothing to Disclose
Suddendorf	Scott	Arrhythmias and Clinical EP: Basic 4	External Cooling of the Myocardium Slows Electrical Conduction and Terminates Atrial Fibrillation	Nothing to Disclose
Sudhakar I		Atrial Fibrillation and VT: Unique Populations and Solutions	The Prevalence and Distribution of Ventricular Arrhythmias Prior to Ventricular Assist Device Implantation: A Thirteen Year Institutional Experience	Nothing to Disclose
Sudhakar	Deepthi	Ventricular Arrhythmias and Sudden Death Prevention	Ventricular Tachycardia Early After Implantation of a Ventricular Assist Device Is Associated With Increased Long Term Mortality: A Thirteen Year Institutional Experience	Nothing to Disclose
Sudhakar		FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	A Rush of Blood to the Head: Anomalous Superior Vena Cava Drainage to Left Atrium	Nothing to Disclose
Sudhakar I	Rajeev	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Hiatal Hernia: An Unconventional but Potentially Curable Cause of Atrial Arrhythmias	Nothing to Disclose
Sudhakar I	Rajeev	Interventional Cardiology: PCI and TAVR in Complex Patients	Predictors of Early Discharge Home After Transcatheter Aortic Valve Implantation	Nothing to Disclose
Suematsu	Yoshihiro	Non Invasive Imaging: New Technologies	Medium Contrast Enhancement Pattern of Left Atrial Appendage in Cardiac CT Predicts Stroke Risk in Patients With Atrial Fibrillation	Nothing to Disclose
Sueta		Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Readmissions for Patients Discharged With Acute Decompensated Heart Failure and Reduced Versus Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study	Nothing to Disclose

Contract of				l
Last Name	First Name	Session Title	Presentation Title	Disclosures
Suffredini	John	Arrhythmias and Heart Failure	Can the Ventricular-Arterial Coupling Ratio Predict Response to Cardiac Resynchronization Therapy for Patients Meeting Class Ila Indications?	Nothing to Disclose
Sugahara	Masataka	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Simplified Measures of Right Ventricular and Atrial Remodeling Are Predictive of Outcomes in Patients With Pulmonary Hypertension	Nothing to Disclose
Sugahara	Masataka	Novel Echocardiographic Methods for Assessing Cardiac Function	Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain	Nothing to Disclose
Sugahara	Masataka	Advances in HCM, PPCM and Other Cardiomyopathies	Extended Course of Recovery in Patients With Peripartum Cardiomyopathy Assessed by Left Ventricular Wall Distensibility	Nothing to Disclose
Sugahara	Masataka	New Technologies in Echocardiography	Assessment of Right Ventricular Energy Loss and Efficiency Using	Nothing to Disclose
Sugeng	Lissa	New Technologies in Echocardiography	Novel Vector Flow Mapping Automated Detection of Mitral Valve Annular and Leaflet Geometry:	SPEAKER'S BUREAU - Lantheus, Siemens Healthcare
Sugeng	Lissa	36. Valvular Heart Disease: Clinical Team 2	Echocardiography and CT Comparison Suggested Reviewer	SPEAKER'S BUREAU - Lantheus, Siemens Healthcare
Sugiyama	Hirofumi	Coronary Intervention in Interventional	Superiority of Everolimus-Eluting Stents Over Sirolimus-Eluting	Nothing to Disclose
Suh	William	Cardiology: Core Concepts Interventional Cardiology: TAVR 1	Stents in Long-Term Safety and Efficacy The Use of Magnetic Resonance Imaging With Ferumoxytol for	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St
Suithichaiyakul	Taworn	Multimodality Imaging in Heart Diseases:	Annulus Sizing in Patients With Chronic Kidney Disease Undergoing Transcatheter Aortic Valve Replacement Co-Chair	Jude Medical Nothing to Disclose
-		International Perspectives From the Gulf Heart Association, Thai Heart Association, and American College of Cardiology		
Sukhumthammarat	Weera	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Worldwide Prevalence of Brugada Syndrome: A Systematic Review and Meta-Analysis	Nothing to Disclose
Sukul	Devraj	Considerations in Antiplatelet Therapy and in ACS	Readmission and Long-Term Mortality in Older Patients Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan	Nothing to Disclose
Sukul	Devraj	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Cardiovascular Consortium Percutaneous Coronary Intervention in Patients With Recent Gastrointestinal Bleeding: Insights From the Blue Cross Blue Shield	Nothing to Disclose
Sukul	Devraj	Percutaneous Coronary Intervention: Lessons	of Michigan Cardiovascular Consortium Outcomes After Percutaneous Coronary Intervention Among	Nothing to Disclose
		From the Real World	Patients With a History of Transient Ischemic Attack or Cerebrovascular Accident: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium	
Sukul Sulaiman	Devraj Samian	FIT Clinical Decision Making Reviewers 2 Arrhythmias and Clinical EP: Basic 3	ACC FIT Clinical Decision Making Reviewer Impact of Obstructive Sleep Apnea Severity on Cardiac Events in	Nothing to Disclose Nothing to Disclose
		1	Patients With Normal or Prolonged Ventricular Repolarization	
Sulaiman	Samian	Interventional Cardiology: PCI and TAVR in Complex Patients	The Risk of Adverse Coronary Events Is Higher in Patients With Severe Obstructive Sleep Apnea Following Percutaneous Coronary Intervention	Nothing to Disclose
Sule	Sachin	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	In-Hospital Outcomes and Hospitalizations for Acute Rheumatic Heart Disease: A United States National Study	Nothing to Disclose
Sule	Sachin	Current Issues in Cardiovascular	Prevalence and In-Hospital Outcomes of Uremic and Dialysis	Nothing to Disclose
Sule	Sachin	Epidemiology, Disparities, and Safety The Evolving World of LVADs, Transplant and	Pericarditis: A United States National Study Arrhythmias in Hospitalized Heart Transplanted Patients: A United	Nothing to Disclose
Sule	Sachin	Other Novel Discoveries The Evolving World of LVADs, Transplant and	States National Study Chagas Heart Disease: A United States National Study	Nothing to Disclose
		Other Novel Discoveries		-
Suleman	Javed	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Clinical Outcomes Associated With Impella Versus IABP Use in Stable Patients Undergoing High Risk Percutaneous Coronary Intervention	SPEAKER'S BUREAU - Daichi / Eli Lilly
Suleman	Javed	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Multimodality Intravascular Imaging to Evaluate Plaque Characteristics in Patients With Diabetes Mellitus	SPEAKER'S BUREAU - Daichi / Eli Lilly
Suleman	Javed	Timely Topics in Acute Coronary Syndromes	Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions	SPEAKER'S BUREAU - Daichi / Eli Lilly
Sulemanjee	Nasir	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Incremental Value of Estimated Glomerular Filtration Rate in Improving Stroke Risk Stratification in Patients With and Without Atrial Fibrillation Considered to Be Low Risk by CHA _{2/sub>DS_{2/s/sub>VASc Score}}	Nothing to Disclose
Sullivan	Lonnie	Considerations in Antiplatelet Therapy and in ACS	Dual Antiplatelet Therapy Utilization and Cardiovascular Outcomes Among Black and White Patients Treated With Drug Eluting Stents	Nothing to Disclose
Sullivan	Malachy	Highlights in Vascular Medicine Research	Cancer and Arterial Thrombosis Risk: Insights From the 2012 National Inpatient Sample	Nothing to Disclose
Sultan	Adnan	Emerging Basic Science in Ischemic Heart	Serum Prolidase Activity in Stable Coronary Artery Disease and	Nothing to Disclose
Suma	Valentin	Disease Technical Advances in Transthoracic Echocardiography	Acute Myocardial Infarction Safety of Perflutren-Based Echocardiographic Contrast Agent Administration in the Setting of a Patent Foramen Ovale (PFO): A Multicenter Study Conducted in Tertiary Care Centers Based in the	Nothing to Disclose
Sun	Benjamin	Syncope: What's New	New York/Chicago Metropolitan Areas Syncope Evaluation in the Emergency Room: Who Doesn't Need	Nothing to Disclose
Sun	Jianjun	Antiplatelet and Antithrombotic Agents in	Admission? Efficacy and Safety of Novel Oral P2y ₁₂ Receptor	Nothing to Disclose
		Ischemic Heart Disease	Inhibitors in St-Segment Elevation Myocardial Infarction Patients Undergoing Pci: A Systematic Review and Meta-Analysis	
Sun	Jie	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Hemoconcentration During Management of Patients With Acute Heart Failure and Cardiorenal Syndrome: Insights From CARRESS-HF	Nothing to Disclose
Sun	Tao	Updates on Risk Factors for Cardiovascular Disease	Association Between Short and Long Sleep Duration and Cardiovascular Outcomes? A Systematic Review and Meta-Analysis	Nothing to Disclose
Sun	Wensheng	Advances in Cholesterol Measurement and Management	Association of Remnant-Like Particle Cholesterol and Low-Density Lipoprotein Triglyceride With Incidence of Cardiovascular Events: The ARIC Study<>	Nothing to Disclose
Sun	Yan	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Inflammatory Response to Mental Stress and Mental Stress Induced Myocardial Ischemia	Nothing to Disclose
Sun	Yingxian	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Triglyceride Glucose Index Is an Independent Risk Factor for Hypertension	Nothing to Disclose
Sundboll	Jens	Vascular Medicine: Venous Disease	Risk of Cancer After Upper-Extremity Deep Vein Thrombosis: A	Nothing to Disclose
Sundboll	Jens	Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering	Population-Based Cohort Study 17-Year Nationwide Trends in Antihypertensive Drug Use in Denmark	Nothing to Disclose
i .		Therapies	Risk of Cancer After Lower Limb Arterial Thrombosis: A Population-	Nothing to Disclose
Sundboll	Jens	Advances in Pathophysiology and Treatment of		
Sundboll	Jens	Advances in Pathophysiology and Treatment of Thrombosis	Based Cohort Study	-
Sundboll Sundt Sundt	Jens Thoralf Thoralf			OTHER - Thrasos OTHER - Thrasos

Last Name Sundt	First Name Thoralf	Session Title Innovations in Advocacy and Patient Centered	Presentation Title Employing the Multidisciplinary Heart Team Approach for Complex	Disclosures OTHER - Thrasos
Sundt	Thoralf	Care Vascular Medicine: Aortic and Peripheral Artery Diseases	Coronary Artery Disease: A Single Center Experience Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of	OTHER - Thrasos
Sundt	Thoralf	Novel Determinants of Outcomes in VHD	Acute Aortic Dissection Relationship Between Proximal Aorta Morphology and Progression	OTHER - Thrasos
Sung	Jung Hoon	Novel Developments in Acute Coronary	Rate of Aortic Stenosis Serial Measurements of Neutrophil Gelatinase-Associated Lipocalin	Nothing to Disclose
	-	Syndromes	(NGAL): Prognostic Value in Stemi Patients Treated by Primary Percutaneous Coronary Intervention	
Sung	Jung Hoon	Nuclear Cardiology: Beyond Perfusion	Prolonged Inflammation Led to Aortic Valve Sclerosis: Longitudinal PET/CT Study	Nothing to Disclose
Sung	Shih-Hsien	Emerging Developments in HFpEF and Arryhthmias	The Role of Pulmonary Function Test in Patients With Heart Failure With Preserved Ejection Fraction: Looking Beyond Chronic Obstruction Pulmonary Disease	Nothing to Disclose
Sunjic	Igor	Diabetes and Other Issues in Cardiovascular Prevention	Patients Leaving Against Medical Advice: Can We Prevent Unnecessary Testing and Reduce Costs in the Evaluation of Acute Ischemic Heart Disease?	Nothing to Disclose
Sunu	Ismoyo	Emerging CV Problems in the Developing World: International Perspectives From the ACC Bangladesh Chapter, Indonesian Heart Association, and American College of Cardiology	Co-Chair	Nothing to Disclose
Supariwala	Azhar	Interventional Cardiology: PCI and TAVR in Complex Patients	Comparison of Radiation Exposure Between Interventional and Noninvasive Cardiologist During Structural Cardiac Interventions	Nothing to Disclose
Supple	Gregory	Meeting of the Minds: HF and EP Decision Making for Complex Patients	Who Is the High Risk Patient in the EP Lab?	CONSULTANT FEES/HONORARIA - Biotronik, Johnson & Johnson, MEDTRONIC, St. Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific.MEDTRONIC
Supple	Gregory	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Anticoagulation Use and Incidence of Cerebrovascular Events and Major Bleeding After Catheter Ablation in Patients With Persistent and Longstanding Persistent Atrial Fibrillation	Scientific, MEDTRONIC CONSULTANT FEES/HONORARIA - Biotronik, Johnson & Dramp; Amp; Johnson, MEDTRONIC, St. Jude Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific, MEDTRONIC
Sureddi	Ravi	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Right Sided Accessory Pathway Masquerading as LBBB with Cardiomyopathy: "Cure" With Catheter Ablation	Scientific,MED I RONIC Nothing to Disclose
Suri	Rakesh	Featured Clinical Research II: Interventional	Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis From the STS/ACC TVT Registry	CONSULTANT FEES/HONORARIA - Sorin - National PI
Suri	Rakesh	Late-Breaking Clinical Trials	Native Additional Sterious From the STSACC 17th Fedgatry Comparative Effectiveness of Left Afrail Appendage Occlusion Among Atrial Fibrillation Patients Undergoing Cardiac Surgery: A Report From the Society of Thoracic Surgeons Adult Cardiac Surgery Database	CONSULTANT FEES/HONORARIA - Sorin - National PI
Suri	Rakesh	New Technologies in Echocardiography	Mitral Annular Disjunction Prevalence and Physiologic Consequences in Degenerative Mitral Regurgitation: A Dynamic 3- Dimensional Echocardiographic Study	CONSULTANT FEES/HONORARIA - Sorin - National PI
Suri	Rakesh	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low- Flow Severe Aortic Stenosis and Less Reverse Remodeling After TAVR: A Partner 2 Trial Analysis	CONSULTANT FEES/HONORARIA - Sorin - National PI
Suri	Ranjit	Arrhythmias and Clinical EP: Devices 4	Subxiphoid Air Leading to Inappropriate Shock in a Subcutaneous Cardiac Defibrillator	RESEARCH/RESEARCH GRANTS - St Jude Medical; SPEAKER'S BUREAU - Boehringer Ingelheim Pharmaceuticals, Inc,Johnson & Dengamp; Johnson, Zoll
Surikova	Jelena	Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials	e-Counseling for Self-Care Adherence Adds Therapeutic Benefit for Hypertension: The REACH Trial	Nothing to Disclose
Suryapranata	Harry	Interventional Cardiology: TAVR 2	Dual Antiplatelet Therapy Versus Single Antiplatelet Regimen With or Without Anticoagulation in Transcatheter Aortic Valve Replacement: Indirect Comparison and Meta-Analysis	Nothing to Disclose
Susco	Benjamin	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Cardiac Amyloidosis Masquerading as Severe Low-Flow, Low- Gradient, Low-Ejection Fraction Aortic Stenosis: "All That Glitters Is Not Gold"	Nothing to Disclose
Susco	Benjamin	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	An Unprecedented Case of Primary Cardiac Lymphoma Exclusive to the Left Ventricle: A Diagnostic and Therapeutic Challenge	Nothing to Disclose
Susen	Sophie	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Silent Cerebral Microbleeds During TAVR: Insight From a Prospective Cerebral MRI Cohort	Nothing to Disclose
Suskin	Neville	Predicting Outcomes in Cardiac Rehabilitation	Lower Educational Levels May Be an Important Determinant of Adherence to Evidenced-Based Therapies in Post-MI Patients	Nothing to Disclose
Sutherland	James	Patients Featured Clinical Research I	Native South American Tsimane Have the Lowest Levels of	Nothing to Disclose
Sutherland	M Linda	Featured Clinical Research I	Coronary Atherosclerosis Ever Reported Native South American Tsimane Have the Lowest Levels of Coronary Atherosclerosis Ever Reported	Nothing to Disclose
Suttirut	Paramaporn	Innovations in Advocacy and Patient Centered Care		Nothing to Disclose
Sutton Suwa	Nadia Satoru	FIT Clinical Decision Making Reviewers 4 Unusual Presentations of ACS	ACC FIT Clinical Decision Making Reviewer Clinical Characteristics and In-Hospital Mortality of Very Elderly Patients With Cardiovascular Shock in Japan: The Results From	Nothing to Disclose Nothing to Disclose
Suwa	Satoru	Unusual Presentations of ACS	Patients With Cardiogenic Shock Complicating Acute Coronary	Nothing to Disclose
Suwa	Satoru	Unusual Presentations of ACS	Syndrome: From Jcs Shock Registry Combined Serum Albumin and C-Rective Protein Levels Predict Long-Term Outcomes in Patients With Coronary Artery Disease	Nothing to Disclose
Suwa	Satoru	CAD in Unique Patient Populations	After a First Percutaneous Coronary Intervention Prognostic Impact of Geriatric Nutritional Risk Index in Patients Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Suzuki	Masahiro	Unusual Presentations of ACS	C-Reactive Protein in Non-ST Elevation Myocardial Infarction Patients Is Useful in Improving Discrimination of Conventional Risk	Nothing to Disclose
Suzuki	Masahiro	Unusual Presentations of ACS	Score: A Report From Multicenter PCI Registry Trend of Use in Transradial Intervention Among Elderly Patients in Japan According to Their Pre-Procedural Bleeding Risk	Nothing to Disclose
Suzuki	Toru	Vascular Medicine: Aortic and Peripheral Artery Diseases	Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection	Nothing to Disclose
Suzuki	Toru	Vascular Medicine: Aortic and Peripheral	Acute Aortic Dissection Uncontrolled Hypertension in Acute Aortic Dissection Follow-Up	Nothing to Disclose
Suzuki	Yasuyuki	Artery Diseases Nuclear Cardiology: Coronary Flow	Diagnostic Performance of Hybrid Assessment With Stress Only Myocardial Perfusion Single Photon Emission Computed Tomography Using Semiconductor Gamma Camera and Rest	Nothing to Disclose
			Myocardial Scar Findings Obtained From 320 Detector Row Computed Tomography	

				l
Svatikova	First Name Anna	Session Title FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Presentation Title Patient With Superior Vena Cava Syndrome Equivalent	Disclosures CONSULTANT FEES/HONORARIA - Sophos Capital Management
Svensson	Lars	Disease, and Vascular Medicine Featured Clinical Research II: Interventional	Comparison of In-Hospital and 1-Year Outcomes of Transcatheter	OTHER - Cardiosolutions,Posthorax
			Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis From the STS/ACC TVT Registry	
Svensson	Lars	Highlighted Original Research: Interventional Cardiology and the Year in Review	Implications of Worsening Right Ventricular Function Following Transcatheter or Surgical Aortic Valve Replacement: Insights From PARTNER2A	OTHER - Cardiosolutions,Posthorax
Svensson Svensson	Lars Lars	Valvular Heart Disease: Mitral Valve Disease Interventional Cardiology: TAVR 2	Gender Differences in the Etiology of Mitral Valve Disease Worsening Tricuspid Regurgitation and Increased Mortality After	OTHER - Cardiosolutions,Posthorax OTHER - Cardiosolutions,Posthorax
Svensson	Lars	Interventional Cardiology: TAVR 2	Aortic Valve Replacement: Insights From PARTNER2A Impact of Active Coronary Artery Disease on the Early and 1 Year	OTHER - Cardiosolutions,Posthorax
Syeneson	Lars	Interventional Cardiology: TAVR 2	Mortality of Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis Outcomes of Transcatheter Aortic Valve Replacement Without	OTHER - Cardiosolutions,Posthorax
Svensson		.,	Balloon Predilation: A Systematic Review and Meta-Analysis	
Svensson	Lars	Novel Determinants of Outcomes in VHD	Valvuloarterial Impedance and Left Ventricular Global Longitudinal Strain Provide Incremental Prognostic Value in Patients With Significant Aortic Stenosis and Preserved Left Ventricular Ejection Fraction	OTHER - Cardiosolutions,Posthorax
Svetlichnaya	Jana	Deciphering Pulmonary Hypertension Due to Left Heart Disease: Have Hope Oh Ye Who Enter	65 Year Old Referred with Combined Post and Precapillary Pulmonary Hypertension: What Next?	Nothing to Disclose
Sviglin	Helena	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Risk of Hospitalization or Death Due to Heart Failure With Intensive Glucose-Lowering Therapy in Diabetic Women: Subgroup Analyses by History of Cardiovascular Disease in the ACCORD Trial	Nothing to Disclose
Swaminathan	Madhav	Controversies in Mitral Valve Surgery: Joint Symposium of the Society of Thoracic Surgeons and the American College of	Intraop TEE pre/post: assessing nuances, 3D	Nothing to Disclose
Swaminathan	Rajesh	Cardiology Mastering Cath Lab Leadership and	How to Incorporate Quality Metrics in Your Daily Practice	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Boston
	, rajos.	Economics in a New Era: A Joint Symposium by the Society of Cardiovascular Angiography and Interventions and the American College of Cardiology	To the second dealing methods in real dealy realised	Scientific,Portola Pharmaceuticals
Swaminathan	Rajesh	Interventional Cardiology: TAVR 1	Baseline Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Increased Mortality After Transcatheter Aortic Valve Replacement	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Boston Scientific,Portola Pharmaceuticals
Swaminathan	Sethuraman	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Exit Procedure for Fetal Mediastinal Teratoma With Large Pericardial Effusion	Nothing to Disclose
Swarup	Vijay	Atrial Fibrillation and VT: Unique Populations and Solutions	Use of an Esophageal Retractor to Prevent Thermal Injuries During Atrial Fibrillation Ablation: A Multi-Center Experience	Nothing to Disclose
Swarup	Vijay	Innovative Approaches for Reducing Risk and	Watchman Device Associated Thrombi: A Novel Treatment	Nothing to Disclose
Swarup	Vijay	Improving Outcomes With Ablation Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Approach Safety Profiles of Percutaneous Left Atrial Appendage Closure Devices: An Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database From 2009 - 2016	Nothing to Disclose
Swedberg	Karl	Making Progress in Understanding Heart Failure	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary	CONSULTANT FEES/HONORARIA - Amgen, Novartis, servier
Swedberg	Karl	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Disease: Insights From PARADIGM-HF Effect of Sacubitril/Valsartan Compared With Enalapril, According to Etiology in PARADIGM-HF	CONSULTANT FEES/HONORARIA - Amgen, Novartis, servier
Swedberg	Karl	Hormones and Heart Failure	Low Urinary Cgmp/Bnp Ratio Is Associated With Worse Outcomes in Heart Failure but Is Increased by Treatment With Sacubitril/Valsartan: An Analysis of Paradigm-HF	CONSULTANT FEES/HONORARIA - Amgen, Novartis, servier
Swedberg	Karl	The Old and the New: Impact of Heart Failure Drug Therapies	With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction	CONSULTANT FEES/HONORARIA - Amgen, Novartis, servier
Sweeney	Michael	Highlights in Vascular Medicine Research	Apabetalone (RVX-208) Lowers Cardiovascular Disease (CVD) in Diabetes Mellitus by a Mechanism Involving Microbiome Mediated Activity on the Complement Pathway	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Resverlogix
Sweeney Claussen	Andrea	Interventional Cardiology: TAVR 4	Minimalist Approach to Cardiac Anesthesia and Outcome in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Sweeny	Joseph	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Comparing PCI Outcomes in the Very Elderly: Does Age Matter? A Report From Outcomes of Septuagenarians, Octogenarians and	Nothing to Disclose
Sweeny	Joseph	Coronary Angiography, Intra-Vascular Imaging,		Nothing to Disclose
Sweeny	Joseph	Revascularization and Outcomes Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Malignancy Undergoing PCI Synergistic Effects of Coronary Calcification and Inflammation on Risks for Adverse Cardiovascular Events After PCI: Results From a	Nothing to Disclose
Sweeny	Joseph	Interventional Cardiology: Stent Failure	Large Single-Center Registry Multimodality Intravascular Imaging to Evaluate Plaque	Nothing to Disclose
-	Joseph	Analysis by Intravascuar Imaging Timely Topics in Acute Coronary Syndromes	Characteristics in Patients With Diabetes Mellitus Predictors of High Intensity Statin Use After Percutaneous Coronary	Nothing to Disclose
Sweeny	· ·	3 ,	Interventions	•
Swein	Joseph	Optimizing the Care of ACS Patients	Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population Intensity of Statin Therapy and Outcomes After Transcatheter Aortic	Nothing to Disclose
Sweitzer	Ranya	Interventional Cardiology: TAVR 2 ACC Research Awards	Intensity of Statin Therapy and Outcomes After Transcatheter Aortic Valve Replacement Moderator	Nothing to Disclose CONSULTANT FEES/HONORARIA - Acorda Therapeutics,
Sweitzer	Nancy		Influence of Left Ventricular Ejection Fraction on Cause-Specific	Inc,MEDTRONIC; RESEARCH/RESEARCH GRANTS - Corvia Medical,Merck,Novartis CONSULTANT FEES/HONORARIA - Acorda Therapeutics,
SWEILZEI	realicy	Emerging Developments in HFpEF and Arryhthmias	Influence of Left Ventricular Ejection Fraction on Cause-Specific Mortality in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial	CONSULTANT FEES/HONORARIA - ACORDA TRETAPEUTICS, Inc,MEDTRONIC; RESEARCH/RESEARCH GRANTS - Corvia Medical,Merck,Novartis
Sweitzer	Nancy	14. Heart Failure and Cardiomyopathies: Therapy Team 2	Suggested Reviewer	Medical, Merck, Novartis CONSULTANT FEES/HONORARIA - Acorda Therapeutics, Inc, MEDTRONIC; RESEARCH/RESEARCH GRANTS - Corvia Medical, Merck, Novartis
Swerdlow	Charles	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Wide Complex Tachycardia in a 51-Year-Old Man: Ventricular Tachycardia Until Proven Otherwise?	Nothing to Disclose
Swetz	Keith	Innovations in Advocacy and Patient Centered Care	Tachycardia Until Proven Otherwise? Describing Collaboration Between Cardiology and Palliative Care: A National Survey Study of Current Practices, Challenges and Barriers	Nothing to Disclose
Swiger	Kristopher	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Underutilization of Statin Therapy Among Participants in a Lung Cancer Screening Program With a High Incidence of Cardiovascular Events	Nothing to Disclose
Swiger	Kristopher	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Drug Induced QT Prolongation With Arsenic Trioxide in the Treatment of Acute Promyelocytic Leukemia	Nothing to Disclose
Sydo	Nora	Non Invasive Imaging: Role of Exercise Testing	Exercise Test Predicts Both Cardiovascular and Non-Cardiovascular	Nothing to Disclose
			Mortality in Patients Without Cardiovascular Disease	

Special		Disclosures				
Approach Valuational stakete Value would reflective Energing Concepts in Value would reflective Energing Concepts in Value would reflect to the concept of the American Concepts in Value of the Contemporary Preference		Nothing to Disclose		Session Title Non Invasive Imaging: Role of Exercise Testing	Tibor	Last Name Sydó
Synd Mutabliar Control Vascular Medicine Emerging Concepts in South Street Cities and Street Cities an		Nothing to Disclose	·		Faisal	Syed
Symbols (Coloring Col		Nothing to Disclose		Vascular Medicine: Emerging Concepts in	Muhammad Nabeel	Syed
Contemporary Psycholo Mularbabbar April Canada April April Special		Nothing to Disclose			Mushabbar	Syed
Disease States and Clinical Scenarios Andreas Changing the Natural History of View Deale Active Professes With Medical Therapy With Medical Therapy With Medical Therapy With Medical Therapy History Control Cardiology TAVR 2 The Effect of Medication A PETICT Study Andreas Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use of Echocardography Innovative Use Office Use Off		Nothing to Disclose	With Atrial Fibrillation Treated With Novel Oral Anticoagulants Aortic Valve Calcification Predicts Paravalvular Aortic Regurgitation	Contemporary Practice Non Invasive Imaging: Expanding Clinical	Mushabbar	
Symetos Andreas Interventional Cardiology: TAVR 2 The Effect of Maed Antits Valve Disease in Clinical Outcomes After Nothing to Disclose Interventional Cardiology: TAVR 2 The Effect of Maed Antits Valve Disease in Clinical Outcomes After Antity Valve Disease in Clinical Outcomes After Antity Valve Disease in Clinical Outcomes After Antity Valve Disease in Clinical Outcomes After Antity Valve Disease in Clinical Outcomes After Antity Valve Disease in Clinical Outcomes After Antity Valve Disease in Clinical Outcomes After Antity Valve Disease in Clinical Outcomes After Antity Valve Disease in Clinical Outcomes After Antity Valve Disease in Clinical Outcomes After Antity Valve Disease in Clinical Outcomes After Antity Valve Disease in Clinical Outcomes After Antity Valve Disease in Clinical Outcomes After Antity Valve Disease in Clinical Outcomes After Antity Valve Disease in Clinical Outcomes After Antity Valve Disease in Clinical Outcomes After Antity Valve Disease in Clinical Outcomes After After After Valve Disease After After Valve Disease After After Valve Disease After After Valve Disease After Valve Disease Disease After Valve Disease			Fluorodeoxyglucose Uptake AND Visceral Adipose Tissue Biological Activity in Patients With Dyslipidemias	Disease States and Clinical Scenarios	Andreas	Synetos
Synetos Andreass Innovetive Use of Echocardography Inpact on Long Term Moting for Persistent Pulmonary Hypertension After Transcatheter Active Valve Projection (1997) (19		•	•	With Medical Therapy	Andreas	Synetos
Andreass Cutting Edge Vascular Medicine Finalization Combined Hyperiplemis in Characte		Nothing to Disclose		Interventional Cardiology: TAVR 2	Andreas	Synetos
Arterial AND Hepatic Fluorodeoxyllucose Uptake Compared to Hebertopycoper Familiar Hypernoblesteriority Hypernoble		Nothing to Disclose		Innovative Use of Echocardiography	Andreas	Synetos
Fallure Gadgets Galore Long Term Mortality and Echocardographic Response in CRT Patients		Nothing to Disclose	Arterial AND Hepatic Fluorodeoxyglucose Uptake Compared to Heterozygous Familial Hypercholesterolemia		Andreas	Synetos
Beyond Molly Moderated, Case-Based TAVR Management Case Presentation. TAVR in Patient with Prior Miral Prosthesis Consultant FEESHPHONGARIA - Edwards Scentip Molly Vascular Access and Hemostasis Issues Transcatched Acrite Value Replacement With the Splen 3 Value Consultant FEESHPHONGARIA - Edwards Scentip Molly Refring TAVR Outcomes ACG Poster Moderator ACG Poster Moderator Consultant FEESHPHONGARIA - Edwards Mech. Now What? Prosthetic Value * Trombosis: TAVR, Bio, Mech. Now What? Prosthetic Value * Trombosis: TAVR, Bio, Mech. Now What? Consultant FEESHPHONGARIA - Edwards		Nothing to Disclose	Long Term Mortality and Echocardiographic Response in CRT		Gábor	Széplaki
Szerlip Molly Vascular Access and Hemostasis Issues Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatheter Acrit Valve Replacement With the Sapien 3 Valve Sciences MEDITRONIC Szerlip Molly Refining TAVR Outcomes ACC Poster Moderator Consult TaXT EESHMONGRARIA - Edwards Szerlip Molly Prosthetic Valve Thrombosis: TAVR, Bio, Nach. Now Watt? Szerlip Molly Prosthetic Valve Thrombosis: TAVR, Bio, Nach. Now Watt? Szerlip Molly Prosthetic Valve Thrombosis: TAVR, Bio, Nach. Now Watt? Szerlip Molly Prosthetic Valve Thrombosis: TAVR, Bio, Nach. Now Watt? Szerlip Molly Prosthetic Valve Thrombosis: TAVR, Bio, Nach. Now Watt? Szerlip Molly Prosthetic Valve Thrombosis: TAVR, Bio, Nach. Now Watt? Szerlip Molly Prosthetic Valve Thrombosis: TAVR, Bio, Nach. N	Is Life		Is ESRD a Contraindicaiton to TAVR?		Molly	Szerlip
Szerlip Molly Vascular Access and Hemostasis Issues Real-Time Ultrasound Versus Fluoroscopy Guided Access for Transcatherter Antic Valve Replacement With the Sapien 3 Valve CONSULTANT FEESHHONGARIA - Edwards Szerlip Molly Prosthetic Valve Thrombosis: TAVR, Bio, Mech Now Whar?	Is Life	CONSULTANT FEES/HONORARIA - Edward	Case Presentation: TAVR in Patient with Prior Mitral Prosthesis		Molly	Szerlip
Szerlip Molly Refining TAIR Outcomes ACC Poster Moderator CONSULTANT FEES/HONGRARIA - Edwards Molly Prosthetic Valve Thrombosis: TAVR, Bio, Mech., Now What?]	Is Life	CONSULTANT FEES/HONORARIA - Edward		Vascular Access and Hemostasis Issues	Molly	Szerlip
Mech Now What?! Szeto Wilson Controversies Surrounding TAVR: 2017 and Beyond Consultant FEESI-MONCRARIA - Microhite RESEARCHRESEARCH GRANTS - 80tion Me RESEARCHRESEARCH GRANTS - 80tion Me RESEARCHRESEARCH GRANTS - 80tion Me RESEARCHRESEARCH GRANTS - 80tion Me RESEARCHRESEARCH GRANTS - 80tion Me RESEARCHRESEARCH GRANTS - 80tion Me RESEARCHRESEARCH GRANTS - 80tion Me RESEARCHRESEARCH GRANTS - 80tion Me RESEARCHRESEARCH GRANTS - 80tion Me RESEARCHRESEARCH GRANTS - 80tion Me RESEARCHRESEARCH GRANTS - 80tion Me RESEARCHRESEARCH GRANTS - 80tion Me RESEARCHRESEARCH GRANTS - 80tion Me RESEARCHRESEARCH GRANTS - 80tion Me RESEARCHRESEARCH GRANTS - 80tion Me RESEARCHRESEARCH GRANTS - 80tion Me RESEARCHRESEARCH GRANTS - 80tion Me Revascularization on Outcomes of Patients Undergoing Trans- Catheter Active Valve Recember Linsights From STS/ACC TVI Registry Szill-Torok Tamas Arrhythmias and Clinical EP: Devices 1 Long-Term Outcome of Noncompaction Cardiomyopathry Patients With Implantable Cardioverter-Defibrillators Compared With Patients With Dilated or Longopathry Although Strip Medical Strip		CONSULTANT FEES/HONORARIA - Edward Sciences, MEDTRONIC	ACC Poster Moderator	-		
Szeto Wilson Interventional Cardiology: TAVR 1		Sciences,MEDTRONIC	Surgical Bioprosthetic Aortic Valves by 4D CT Imaging	Mech Now What?!	-	
Extremely Low Ejection Fractions RESEARCH/RESEARCH GRANTS - Bolton Me Scientific, Edwards Lifesciences, LIVANOVA, MEI Revascularization on Outcomes of Patients Undergoing Trans-Catheter Andric Valve Replacement: Insights From STS/ACC TV/Scientific, Edwards Lifesciences, LIVANOVA, MEI Registry	Medical,Boston EDTRONIC	RESEARCH/RESEARCH GRANTS - Bolton I Scientific,Edwards Lifesciences,LIVANOVA,M	and TAVR Valves			Szeto
Revascularization on Outcomes of Patients Undergoing Trans- Catheter Arctiv Alve Replacement: Insights From STS/ACC TVT Registry Szili-Torok Tamas Arrhythmias and Clinical EP: Devices 1 Long-Term Outcome of Noncompaction Cardiomyopathy Patients With Impliantable Cardioverter-Defibrillators Compared With Patients With Dilated or Hypertrophic Cardiomyopathy Patients With Dilated or Hypertrophic Cardiomyopathy Szklo Moyses Innovations in Cardiovascular Risk Assessment Vitamin Humbil-Ethnic Study of and Reduction Artherosclerosis (MESA): Implications for Cardiovascular Disease Szwast Anita Congenital Heart Disease: Innovations in Single Ventricle Heart Disease Szymonifka Jackie Making Progress in Understanding Heart Failure Tabachnick Deborah Challenging Anatomies: Does TAVR Device Choice Matter Tabachnick Deborah Tabaca Rashed FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Dileman FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Tabit Corey Young Investigator Awards Competition: Outcomes Research Archythmias and Clinical Dicersions on Outcomes Research Archythmias and Clinical Derivers Profit Value Patients With Dilated or Hypertrophic Cardiomyopathy Patients With Dilated or Hypertrophic Cardiomyopathy Patients With Dilated or Hypertrophic Cardiomyopathy Nothing to Disclose Nothing to Disclose	Medical, Boston	RESEARCH/RESEARCH GRANTS - Bolton I		Interventional Cardiology: TAVR 1	Wilson	Szeto
Szili-Torok	Medical,Boston	RESEARCH/RESEARCH GRANTS - Bolton I	Revascularization on Outcomes of Patients Undergoing Trans- Catheter Aortic Valve Replacement: Insights From STS/ACC TVT	Interventional Cardiology: TAVR 2	Wilson	Szeto
Innovations in Cardiovascular Risk Assessment Vlamin D Levels and Autoantbodies in the Multi-Ethnic Study of and Reduction Antherosclerosis (MESA): Implications for Cardiovascular Disease Antita Congenital Heart Disease: Innovations in Single Ventricle Heart Disease Szymonifka Jackie Making Progress in Understanding Heart Failure Making Progress in Understanding Heart Failure Cardiovascular Disease Nothing to Disclose Stage II Outcomes Stage II Outcomes Nothing to Disclose Nothing to Disclose Stage II Outcomes Stage II Outcomes Orexin A Are Associated With Left Ventricular Reverse Remodeling and Clinical Outcomes Following Cardiac Resynchronization Therapy Cardiac Resynchronization Therapy Cardiac Resynchronization Therapy Anatomy-specific Choice for Non-transfemoral TAVR Nothing to Disclose Nothing to Disclose Othing to Di		Nothing to Disclose	Long-Term Outcome of Noncompaction Cardiomyopathy Patients With Implantable Cardioverter-Defibrillators Compared With	Arrhythmias and Clinical EP: Devices 1	Tamas	Szili-Torok
Szwast		Nothing to Disclose	Vitamin D Levels and Autoantibodies in the Multi-Ethnic Study of		Moyses	Szklo
Szymonifka Jackie Making Progress in Understanding Heart Failure Ground Failure Cardiac Resynchronization of Orexin A Are Associated With Left Ventricular Reverse Remodeling and Clinical Outcomes Following Cardiac Resynchronization Therapy Tabachnick Deborah Challenging Anatomies: Does TAVR Device Choice Matter Tabachnick Deborah Moderated, Case-Based TAVR Management Case Presentation: TAVR in Mitral Annulur Calcification Nothing to Disclose Tabaza Luai FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Pulmonary Hypertension Pathway Radiofrequency Ablation and Subsequent Clinical Dilemma Tabbaa Rashed FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Vasconstriction Syndrome (RCVS) Likely Causing Coronary Vascopasms Tabit Corey Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Increased Tumor Necrosis Factor-α Levels in Patients With Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Increased Tumor Necrosis Factor-α Levels in Patients With Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Increased Tumor Necrosis Factor-α Levels in Patients With Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Increased Tumor Necrosis Factor-α Levels in Patients With Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Increased Tumor Necrosis Factor-α Levels in Patients With Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Increased Tumor Necrosis Factor-α Levels in Patients With Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Increased Tumor Necrosis Factor-α Levels in Patients With Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Increased Tumor Necrosis Factor-α Levels in Patients With Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Increased Tumor Necrosis Factor-α Levels in Patients With Co		Nothing to Disclose	Impact of Home Monitoring Program on Interstage Mortality and	Congenital Heart Disease: Innovations in	Anita	Szwast
Tabachnick Deborah Challenging Anatomies: Does TAVR Device Choice for Non-transfemoral TAVR Nothing to Disclose Choice Matter Tabachnick Deborah Moderated, Case-Based TAVR Management Case Presentation: TAVR in Mitral Annulur Calcification Nothing to Disclose Mothing to Disclose Personal Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypertension Pablabaa Rashed FIT Clinical Decision Making: Interventional Cardiology, Acute and Slable Ischemic Heart Disease, and Vascular Medicine Tabit Corey Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Instability and Are Associated With Higher Non-Surgical Bleeding Nothing to Disclose Pathaba (Corey Voung Investigator Awards Competition: A Bundled Intervention Including Early Consultation With a Curdiologist in the Emergency Department to Reduce Re-Hospitalizations and Healthcare Cost for High-Risk Urban Patients		Nothing to Disclose	Circulating Concentrations of Orexin A Are Associated With Left Ventricular Reverse Remodeling and Clinical Outcomes Following	Making Progress in Understanding Heart	Jackie	Szymonifka
Tabachnick Deborah Moderated, Case-Based TaVR Management Case Presentation: TAVR in Mitral Annulur Calcification Nothing to Disclose Tabaza Luai FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension Pulmonary Hypertension Pulmonary Hypertension Pathway Radiofrequency Ablation and Subsequent Clinical Dilemma Tabbaa Rashed FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Vasconstriction Syndrome (RCVS) Likely Causing Coronary Vascopasms Tabit Corey Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review Continuous-Flow Left Venticular Assist Devices Mediate Vascular Medicine Corey Young Investigator Awards Competition: A Bundled Intervention Including Early Consultation With a Corrollogist in the Emergency Department to Reduce Re-Hospitalizations and Healthcare Cost for High-Risk Urban Patients Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose A Bundled Intervention Including Early Consultation With a Cardiologist in the Emergency Department to Reduce Re-Hospitalizations and Healthcare Cost for High-Risk Urban Patients		Nothing to Disclose			Deborah	Tabachnick
Pathway Radiofrequency Ablation and Subsequent Clinical Dilemma Rashed FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Tabit Corey Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Corey Young Investigator Awards Competition: A Bundled Intervention Including Early Consultation With a Cardiologist in the Emergency Department to Reduce Re- Hospitalizations and Healthcare Cost for High-Risk Urban Patients Nothing to Disclose Nothing to Disclose A Bundled Intervention Including Early Consultation With a Cardiologist in the Emergency Department to Reduce Re- Hospitalizations and Healthcare Cost for High-Risk Urban Patients				Moderated, Case-Based TAVR Management		
Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Tabit Corey Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review Continuous-Flow Left Venticular Assist Devices Mediate Vascular Instability and Are Assist Devices Mediate Vascular Instability and Are Associated With Higher Non-Surgical Bleeding Tabit Corey Young Investigator Awards Competition: Outcomes Research Outcomes Research A Bundled Intervention Including Early Consultation With a Cardiologist in the Emergency Department to Reduce Re- Hospitalizations and Healthcare Cost for High-Risk Urban Patients			Pathway Radiofrequency Ablation and Subsequent Clinical Dilemma	Pulmonary Hypertension		
and Cardiomyopathies and the Year in Review Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Instability and Are Associated With Higher Non-Surgical Bleeding Tabit Corey Young Investigator Awards Competition: A Bundled Intervention Including Early Consultation With a Outcomes Research Cardiologist in the Emergency Department to Reduce Re-Hospitalizations and Healthcare Cost for High-Risk Urban Patients			Vasoconstriction Syndrome (RCVS) Likely Causing Coronary Vasospasms	Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine		
Outcomes Research Cardiologist in the Emergency Department to Reduce Re- Hospitalizations and Healthcare Cost for High-Risk Urban Patients			Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Instability and Are Associated With Higher Non-Surgical Bleeding	and Cardiomyopathies and the Year in Review	-	
With Acute Decompensated Heart Failure		Nothing to Disclose	Cardiologist in the Emergency Department to Reduce Re- Hospitalizations and Healthcare Cost for High-Risk Urban Patients With Acute Decompensated Heart Failure		Corey	Tabit
Tabit Corey 40. Vascular Medicine: Non Coronary Arterial Suggested Reviewer Nothing to Disclose		Nothing to Disclose	Suggested Reviewer	Disease Team 1	Corey	Tabit
Tachjian Ara Unusual Presentations of ACS Survival of Patients Referred for Emergent Cardiac Catheterization Nothing to Disclose for ST-Elevation Myocardial Infarction Without Culprit Lesions		Nothing to Disclose		Unusual Presentations of ACS	Ara	Tachjian
Tada Norio Interventional Cardiology: TAVR 4 Transcatheter Aortic Valve Implantation in Patients With an Extremely Small Annulus		Nothing to Disclose		Interventional Cardiology: TAVR 4	Norio	Tada
Tada Norio Coronary Intervention in Interventional Cardiology: Core Concepts A Randomized Comparison of Frequency of Radial Artery Occlusion and Symptomatic Radial Artery Spasm Associated With Transradial Coronary Intervention Using 6.5-Fr Sheathless Guide Catheter-sup-7TM-/sup-> Versus 6.0-Fr Glidesheath Slender-sup-7TM-/sup-> Versus 6.0-Fr Glidesheath	ors International	RESEARCH/RESEARCH GRANTS - Biosen:	A Randomized Comparison of Frequency of Radial Artery Occlusion and Symptomatic Radial Artery Spasm Associated With Transradial Coronary Intervention Using 6.5-Fr Sheathless Guide Catheter TM Versus 6.0-Fr Glidesheath		Norio	Tada
Tadros Peter Interventional Cardiology: TAVR 1 Safety and Efficacy of Using Pressure Wire With Dobutamin Infusion in Thermoynamic Assessment of Low Flow Low Gradient Aortic Shenosis	ls		Safety and Efficacy of Using Pressure Wire With Dobutamin Infusion in Themoynamic Assessment of Low Flow Low Gradient Aortic	Interventional Cardiology: TAVR 1	Peter	Tadros
Tadros Peter Interventional Cardiology: PCI and TAVR in Hemodynamic Assessment of Low Flow, Low Gradient Severe CONSULTANT FEES/HONORARIA - Edwards Aortic Stenosis With Preserved EF Using a Pressure Wire Lifesciences,MEDTRONIC,ST. Jude's	İs		Hemodynamic Assessment of Low Flow, Low Gradient Severe		Peter	Tadros
Aortic Stenoss With Preserved Er Using a Pressure Wire Interventional Cardiology: Structural Heart Disease Aortic Stenoss With Preserved Er Using a Pressure Wire Lifesciences,MED I RONIC,S1. Jude's Aortic Stenoss With Preserved Er Using a Pressure Wire Lifesciences,MED I RONIC,S1. Jude's With Severe Aortic Stenosis and Calcific Coronary Artery Disease Undergoing Evaluation for Transcatheter Aortic Valve Replacement	is	CONSULTANT FEES/HONORARIA - Edward	Safety and Feasibility of Rotational Atherectomy in Elderly Patients With Severe Aortic Stenosis and Calcific Coronary Artery Disease	Interventional Cardiology: Structural Heart	Peter	Tadros
	Is	CONSULTANT FEES/HONORARIA - Edward Lifesciences,MEDTRONIC,ST. Jude's	Catheterization Evaluation of Severe Aortic Stenosis With Preserved	Interventional Cardiology: Structural Heart Disease	Peter	Tadros
Disease Discrepancy Between Echocardiographic and Cardiac Lifesciences,MEDTRONIC,ST. Jude's Catheterization Evaluation of Severe Aortic Stenosis With Preserved			Election Fraction	<u> </u>	1	
Discrepancy Between Echocardiographic and Cardiac Lifesciences,MEDTRONIC,ST. Jude's	ls		Initial Use of the Evolut Pro Self-Expanding Transcatheter Aortic	Interventional Cardiology: TAVR 3	Peter	Tadros

WASHINGTON, DC | MARCH 17 - 19 2017

Last Name	First Name	Session Title	Presentation Title	Disclosures
Taduru	Siva Sagar	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Change in Utilization Trends of Percutaneous Atrial Septal Defect Closure Post 2008 ACC/AHA Guidelines for Adults With Congenital Heart Disease	Nothing to Disclose
Taduru	Siva Sagar	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Congenital Absence of Left Main Coronary Artery in a Transplanted Heart: A Diagnostic Dilemma and a Therapeutic Challenge	Nothing to Disclose
Tafur Soto	Jose	Interventional Cardiology: TAVR 2	Transcatheter Aortic Valve Replacement in End Stage Liver Disease	Nothing to Disclose
Taggart	Nathaniel	Adult Patients With Congenital Heart Disease: How Do They Compare?	Exercise Capacity After Repair of Ebstein Anomaly in Adults: The Cone Era	Nothing to Disclose
Tahara	Satoko	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Significance of ¹²³ I-BMIPP-Scintigraphy in the Recovery of Left Ventricular Systolic Dysfunction in Takotsubo Cardiomyopathy: Insight From the NEW TAKOTSUBO BMIPP Registry	Nothing to Disclose
Tai	Bee-Choo	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Obstructive Sleep Apnea and Diabetes Mellitus Have Synergistic Effects on Adverse Cardiac and Cerebrovascular Events in Patients Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Tai	Bee-Choo	Updates on Risk Factors for Cardiovascular Disease	Obstructive Sleep Apnea and Coronary Risk in Health Screening Clinic	Nothing to Disclose
Tai	Bee-Choo	Unusual Presentations of ACS	Prevalence and Evolution of Sleep Disordered Breathing in Acute Myocardial Infarction	Nothing to Disclose
Taibo Urquia	Mikel	Arrhythmias and Clinical EP: Devices 1	Pharmacological Treatment Alone Versus Treatment Combined With Implantable Cardioverter-Defibrillator Therapy in Patients Over 75 Years	Nothing to Disclose
Tajik	A. Jamil	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Athlete's Heart Versus Apical Hypertrophic Cardiomyopathy: Look Again!	Nothing to Disclose
Tajik	A. Jamil	Emerging Applications of Echocardiography	Dilated Mid-Ascending Aorta in Hypertrophic Cardiomyopathy Is Associated With Dynamic Left Ventricular Outflow Tract Obstruction and Not With Genetic Abnormalities	Nothing to Disclose
Tajik	A. Jamil	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Mitral Regurgitation Secondary to Mitral Arcade in Two Brothers	Nothing to Disclose
Tajik	A. Jamil	Arrhythmias and Clinical EP: Basic 3	Impact of Obstructive Sleep Apnea Severity on Cardiac Events in Patients With Normal or Prolonged Ventricular Repolarization	Nothing to Disclose
Tajik	A. Jamil	Nuclear Cardiology: Beyond Perfusion	The Increasing Burden of Amyloidosis From Apex to Base: New Insights From Technetium-99m Pyrophosphate Imaging	Nothing to Disclose
Tajik	A. Jamil	Advances in HCM, PPCM and Other Cardiomyopathies	Marked Respiratory Related Variation in LVOT Gradients in Hypertrophic Cardiomyopathy in Obese HCM Patients With Sleep- Disordered Breathing	Nothing to Disclose
Tajik	A. Jamil	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Incremental Value of Estimated Glomerular Filtration Rate in Improving Stroke Risk Stratification in Patients With and Without Atrial Fibrillation Considered to Be Low Risk by CHA _{2/sub>DS_{2/s/sub>VASc Score}}	Nothing to Disclose
Tajik	A. Jamil	Interventional Cardiology: PCI and TAVR in Complex Patients	The Risk of Adverse Coronary Events Is Higher in Patients With Severe Obstructive Sleep Apnea Following Percutaneous Coronary Intervention	Nothing to Disclose
Tajik	A. Jamil	Vascular Medicine: Emerging Concepts in Clinical Vascular Diseases	Normal Diameter of the Ascending Aorta in Adults: The Impact of Stricter Criteria on Selection of Subjects Free of Disease	Nothing to Disclose
Tajik	A. Jamil	FIT Clinical Decision Making: Heart Failure and Cardiomyopathies	Cardiac Amyloidosis Masquerading as Hypertrophic Cardiomyopathy: The Importance of Multimodality Imaging	Nothing to Disclose
Tajsic	Milos	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Copeptin and High-Sensitivity Troponin I in Patients With Chest Pain	Nothing to Disclose
Takagi	Hisato	Interventional Cardiology: TAVR 3	and Recent Syncope Transcatheter Versus Surgical Aortic Valve Replacement in Diabetes Mellitus: From the Nationwide Inpatient Sample	Nothing to Disclose
Takagi	Kensuke	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Significance of sup=123Recovery of Left Ventricular Systolic Dysfunction in Takotsubo Cardiomyopathy: Insight From the NEW TAKOTSUBO BMIPP Registry	Nothing to Disclose
Takahashi	Akihiko	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Hyperdense Artery Sign on Computed Tomography in Acute Coronary Syndrome	Nothing to Disclose
Takahashi	Toshiyuki	Unusual Presentations of ACS	Trend of Use in Transradial Intervention Among Elderly Patients in Japan According to Their Pre-Procedural Bleeding Risk	Nothing to Disclose
Takahashi	Yui	Cutting Edge Vascular Medicine	Atheroprotective Effects of Tumor Necrosis Factor-Stimulated Gene-	Nothing to Disclose
Takaoka	Hiroyuki	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Semi-Quantitative Evaluation of Coronary Arterial Patency After Implantation of a Metallic Stent: A Comparison Between 320 Slice CT and Invasive Coronary Angiogram With Consideration of Stent Size, Length, and Type, as Well as the Specific Coronary Artery Implanted	Nothing to Disclose
Takaoka	Hiroyuki	Insights From Echocardiography Use	Quantitative Distinction of LV Myocardium Classified by Presence or Absence of Fibrotic Change and/or Hypertrophic Change Confirmed by Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy and 2D Speckle Tracking TTE	Nothing to Disclose
Takaoka	Hiroyuki	Insights From Echocardiography Use	Quantitative Differentiation of LV Myocardium With and Without Layer-Specific Fibrosis on CMR in Hypertrophic Cardiomyopathy Using Layer-Specific Strain TTE Analysis	Nothing to Disclose
Takaoka	Hiroyuki	Non Invasive Imaging: New Technologies	A Novel 3D Myocardial Strain Determined by Existing 320-Slice CT Data Enhances Visual Assessment of Late Enhancement on CT for the Detection of Left Ventricular Myocardial Fibrosis in Non Ischemic Cardiomyopathy	Nothing to Disclose
Takaoka	Hiroyuki	Non Invasive Imaging: New Technologies	Improved Diagnosis of Detection of Late Enhancement in Left Ventricular Myocardium Using 2nd Generation 320-Slice CT Reconstructed With FIRST in Non-Ischemic Cardiomyopathy	Nothing to Disclose
Takatsuki	Seiji	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Compliance to Updated AHA/ACC Quality Measures Among Patients With Atrial Fibrillation in Japan and Its Association With Their Quality of Life	Nothing to Disclose
Takehiko	Kido	Interventional Cardiology: PCI in Complex Patients	Chronic Stent Recoil During Follow-Up in Severely Calcified Coronary Artery Lesions: An Optical Coherence Tomography Study	Nothing to Disclose
Takeji	Yasuaki	Unusual Presentations of ACS	The Impact of Residual Syntax Score in ACS Patients With LV Dysfunction	Nothing to Disclose
Takeji	Yasuaki	Peripheral Arterial Disease, Risk, and Outcomes	Impact of Clinical Frailty for Patients With Critical Limb Ischemia	Nothing to Disclose
Takeshima	Taro	Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering Therapies	Effect of Gene Polymorphism of Calpain-10 on the Risk of Hypertension in Japanese Population	Nothing to Disclose
Takeuchi	Masaaki	28. Non Invasive Imaging: Echo Team 4	Suggested Reviewer	Nothing to Disclose
Talavera	Pedro	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Prevalence and Clinical Significance of Electrocardiographic Abnormalities in General Population Older Than Forty Years	Nothing to Disclose
Taleb	Adam	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Coronary Cameral Fistulas and Coronary Artery Aneurysms in a Patient With Acute Heart Failure: A Hybrid Case	Nothing to Disclose

Contract of the second				
<u>Last Name</u> Tallaj	Jose	Session Title Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association	Presentation Title Current Status of LVADS and Transplant	Disclosures RESEARCH/RESEARCH GRANTS - Actelion,Pfizer Inc
Tallaj	Jose	of Black Cardiologists and the American College of Cardiology Advances in HCM, PPCM and Other	Systemic Arterial Pulsatility Index (SAPi) Predicts Adverse	RESEARCH/RESEARCH GRANTS - Actelion,Pfizer Inc
-		Cardiomyopathies	Outcomes in Advanced Heart Failure Patients	
Tallaj	Jose	Emerging Developments in HFpEF and Arryhthmias	Left Ventricular Mechanical Properties Assessed by Single Beat Method in Early Stages of Diastolic Dysfunction/Heart Failure With Preserved Ejection Fraction	RESEARCH/RESEARCH GRANTS - Actelion, Pfizer Inc
Tallaj	Jose	Heart Failure and Cardiomyopathies: Clinical Team 6	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Actelion, Pfizer Inc
Tam	James	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	An Unusual Cause of Atrial Fibrillation	SALARY - Spouse is employee of Merck
Tam	James	Unusual Presentations of ACS	Characteristics of Acute Coronary Syndrome Presentation in Young Patients	SALARY - Spouse is employee of Merck
Tam	Lai-Shan	Non Invasive Imaging: Role of Exercise Testing	Impaired Left Ventricular Longitudinal Functional Reserve in Patients With Psoriatic Arthritis: A Low-Level Bicycle Ergometer	Nothing to Disclose
Tam	Marty	FIT Clinical Decision Making Reviewers 3	Exercise Test ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Tamaki	Nagara	Vascular Medicine: Aortic and Peripheral Artery Diseases	Molecular Determinants of Functional Changes and Fibrosis Determined by Novel Automated Oscillometric Approach to Measure Brachial Artery Vascular Volume Elastic Modulus in Chronic Kidney Disease	CONSULTANT FEES/HONORARIA - none
Tamarappoo	Balaji	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium in the Elderly: Prevalence, Severity, and Association With All-Cause Mortality	Nothing to Disclose
Tamarappoo	Balaji	Non Invasive Imaging: MR Scar and Perfusion	Assessment of Myocardial Perfusion Reserve Index Using Adenosine Versus Regadenoson Among Healthy Female Subjects	Nothing to Disclose
Tamarappoo	Balaji	Nuclear Cardiology: Quality	Rest Scan Does Not Improve Automatic Machine Learning Prediction of Major Adverse Coronary Events After High Speed Myocardial Perfusion Imaging	Nothing to Disclose
Tamarappoo	Balaji	Non Invasive Imaging: New Technologies	Improvement in LDL is Associated With Decrease in Non-Calcified Plaque Volume on CTA as Measured by Automated Quantitative Software	Nothing to Disclose
Tamarappoo	Balaji	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Relationship Between Whole Vessel Quantitative Plaque Characteristics and Noninvasive Fractional Flow Reserve From Coronary Computed Tomography Angiography	Nothing to Disclose
Tamarappoo	Balaji	Imaging With Cardiac CT: The Case for Calcium	Hormone Replacement Therapy Is Associated With Less Coronary Atherosclerosis and Lower Mortality	Nothing to Disclose
Tamburino	Corrado	Frontiers in Mitral Valve Disease and Treatment	Multicenter Trial of a Transfemoral System for Mitral Valve Annuloplasty: Up-to-2-Year Follow-Up Results	CONSULTANT FEES/HONORARIA - MEDTRONIC; SPEAKER'S BUREAU - Abbott Laboratories
Tamin	Syahidah	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Echocardiographic Predictors for In-Hospital and 1-Year Outcomes in Left-Sided Infective Endocarditis: An Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort Study	Nothing to Disclose
Tamis-Holland	Jacqueline	Global Perspectives in the Treatment of ST Elevation Myocardial Infarction: Successes, Failures, and Challenges	Panelist	Nothing to Disclose
Tamis-Holland	Jacqueline	The Art and the Science of Decision Making in Coronary Artery Disease	Co-Chair	Nothing to Disclose
Tamis-Holland	Jacqueline	Controversies in ACS Guidelines	Management of Non Culprit Artery in STEMI: I Prefer a Staged	Nothing to Disclose
Tamis-Holland	Jacqueline	Revascularization and Myocardial Preservation in Acute and Stable Ischemic Heart Disease	Approach to Care! Downstream Effects of False Positive Activation of the Cardiac Catheterization Lab	Nothing to Disclose
Tamis-Holland	Jacqueline	Personalized Skills Center: Hands-On Simulation - Acute Heart Failure	Acute Heart Failure	Nothing to Disclose
Tamis-Holland	Jacqueline	Personalized Skills Center: Hands-On Simulation - Acute Heart Failure	Acute Heart Failure	Nothing to Disclose
Tamis-Holland	Jacqueline	Personalized Skills Center: Hands-On Simulation - Acute Heart Failure	Acute Heart Failure	Nothing to Disclose
Tamis-Holland	Jacqueline	02. Acute and Stable Ischemic Heart Disease: Clinical Team 1	Suggested Reviewer	Nothing to Disclose
Tamura	Toshihiro	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Application of DAPT Score to Predict Ischemic and Bleeding Events in Japanese Patients Undergoing Drug-Eluting Stent Implantation: An Observation From a Pooled Cohort of the CREDO-Kyoto Cohort- 2, RESET, and NEXT Trials	Nothing to Disclose
Tan	Huay-Cheem	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Obstructive Sleep Apnea and Diabetes Mellitus Have Synergistic Effects on Adverse Cardiac and Cerebrovascular Events in Patients Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Tan	Huay-Cheem	Coronary Intervention: Drug Eluting Stent and Scaffolds	Safety and Efficacy of Small Vessel Stenting With 2 mm Drug Eluting Stents in Real World Clinical Practice	Nothing to Disclose
Tan	Huay-Cheem	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Impact of Mild Obstructive Sleep Apnea on and Cardiovascular Events After Percutaneous Coronary Intervention	Nothing to Disclose
Tan	Huay-Cheem	Coronary Intervention in Interventional Cardiology: Core Concepts	Incidence and Predictors of Target Lesion Failure in a Multi-Ethnic Asian Population Receiving the SYNERGY Coronary Stent: A	Nothing to Disclose
Tan	Jack	Challenges in Percutaneous Interventions: International Perspectives From the Hong Kong College of Cardiology, Singapore Cardiac Society, and American College of Cardiology	Prospective All-Comers Registry Co-Chair	CONSULTANT FEES/HONORARIA - Elixir; RESEARCH/RESEARCH GRANTS - Abbott Diagnoistics,Beckman
Tan	Li-Ling	Unusual Presentations of ACS	Prevalence and Evolution of Sleep Disordered Breathing in Acute	Nothing to Disclose
Tan	Mary	Finding Out What Works in Pediatric and Congenital Heart Disease	Myocardial Infarction Timely Detection of Pulmonary Arterial Hypertension in Patients With Repaired Congenital Heart Disease: Interim Results From the	Nothing to Disclose
Tan	Nicholas	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	ACHD-QuERI Registry Tracing the Cause of Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia	Nothing to Disclose
Tan	Ning	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Thermormagic relargiectasia The Contrast Volume to Creatinine Clearance Ratio Predicts Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Tan	Ru-San	Diabetes and Other Issues in Cardiovascular Prevention	Disease Undergoing Percutaneous Coronary intervention Adiposity, Leanness or Both? Characterizing Measures of Adiposity and Leanness With Cardiovascular Remodeling	CONSULTANT FEES/HONORARIA - AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Bristol Myers Squibb, Pfizer, servier; RESEARCH/RESEARCH GRANTS - Bayer, Boehringer Ingelheim, J. & J. Merck Sharp & Dohme, Novartis, Pfizer, Portola
Tan	Weiyi	FIT Clinical Decision Making: Non-Invasive	A Confusing Case of Pulmonary Hypertension With Mixed Valvular	Nothing to Disclose
Tanabe	Kengo	Imaging and Valvular Heart Disease The Evolving World of LVADs, Transplant and	Disease and Cryptogenic Cirrhosis Elevated Right Sided Heart Pressure Is Associated With Malnutrition	Nothing to Disclose
		Other Novel Discoveries	in Heart Failure Patients With Reduced Ejection Fraction	

Last Name Tanabe	First Name Kengo	Session Title The Evolving World of LVADs, Transplant and	Presentation Title Identifying Novel Phenotypes of Acute Decompensated Heart	Disclosures CONSULTANT FEES/HONORARIA - Abbott
Tallabe	Religo	Other Novel Discoveries	Failure Using Cluster Analysis of Clinical Variables	Vascular,Goodman,Kaneka,Otsuka Pharmaceutical
				Co., Pfizer, Terumo, Toshiba, Zeon Medical; SPEAKER'S BUREAU AstraZeneca, Biosensors, Daiichi-
				Sankyo,Mochida,MSD,SANOFI,Tanabe Mitsubishi
Tanajak	Pongpan	Interventional Cardiology: Translation and Pre- Clinical Research	Combined Prebiotics and Probiotics Treatment Is Not Superior to	Nothing to Disclose
			Single Regimen for Cardioprotection in Obese-Insulin Resistant Rats	
Tanajak	Pongpan	Updates in Stable Ischemic Heart Disease	Vagus Nerve Stimulation Requires Both Ipsilateral and Contralateral	Nothing to Disclose
			Efferent Vagal Activity to Fully Exert Its Cardioprotection Against Cardiac Ischemia/Reperfusion Injury	
Tanaka	Atsushi	Interventional Cardiology: Intravascular	Comparison of Very Late Vascular Response Beyond 2 Years After	Nothing to Disclose
		Physiology and Endothelial Function	Stent Implantation Between EES and BES: An OCT Sub-Study of the NEXT	
Tanaka	Kazuki	Interventional Cardiology: PCI in Complex	Predictors for 2-Year Cardiovascular Events After Rotablation in	Nothing to Disclose
Tanaka	Makoto	Patients Interventional Cardiology: TAVR 4	Severe Calcified Lesion Transcatheter Aortic Valve Implantation in Patients With an	Nothing to Disclose
			Extremely Small Annulus	
Tanaka	Nobuhiro	Unusual Presentations of ACS	Clinical Characteristics and In-Hospital Mortality of Very Elderly Patients With Cardiovascular Shock in Japan: The Results From	Nothing to Disclose
			Japanese Circulation Society Shock Registry	
Tanaka	Nobuhiro	Unusual Presentations of ACS	Association Between Presentation Time and Short-Term Mortality in Patients With Cardiogenic Shock Complicating Acute Coronary	Nothing to Disclose
			Syndrome: From Jcs Shock Registry	
Tanaka	Rika	Joint American College of Cardiology/Journal of the American Medical Association Late-	e-Counseling for Self-Care Adherence Adds Therapeutic Benefit for Hypertension: The REACH Trial	Nothing to Disclose
		Breaking Clinical Trials	**	
Tandar	Anwar	Valvular Heart Disease: Aortic Stenosis	Valve Thrombosis Following Transcatheter Aortic Valve Replacement: Implications of Reduced Cardiac Output	Nothing to Disclose
Tandon	Animesh	Congenital Heart Disease: New Diagnostic	Mitral Valve Phase Contrast Imaging Is a More Reproducible	Nothing to Disclose
		Approaches in Congenital Heart Disease	Method of Determining Cardiac Rest Periods for Whole-Heart Coronary Magnetic Resonance Angiography in Congenital Heart	
			Disease Than 4 Chamber Cine	
Tandon	Karman	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Intramural Hematoma or Aortitis: A Diagnostic Dilemma	Nothing to Disclose
	<u> </u>	Disease, and Vascular Medicine		
Tandon	Navdeep	Non Invasive Imaging: MR Structure and	Role of Longitudinal Fiber Dysfunction in Stress Induced Left	Nothing to Disclose
Tandon	Neeraj	Valuvular Heart Disease Vascular Access and Hemostasis Issues	Ventricular Dilatation Standard Versus Low-Dose Heparin Use on Access-Related	Nothing to Disclose
	'		Complications After Coronary Angiography Through Radial Access:	,
Tandon	Rudhir	Non Invasive Imaging: Expanding Clinical	A Meta-Analysis of Randomized Controlled Trials Diagnostic Accuracy of Coronary Computed Tomography	Nothing to Disclose
		Applications	Angiography in Aortic Stenosis Patients Referred for Aortic Valve	, and the second
Tandon	Tarun	Redefining the "F" Word	Replacement: Systematic Review and Meta-Analysis Atrial Diastolic "Suction": An Important Contributor to	Nothing to Disclose
		_	Fontan Circulation	
Tandri	Harikrishna	Genetic Testing for Cardiomyopathies	Implications of Genetic Testing for Arrthymogenic Right Ventricular Dysplasia	CONSULTANT FEES/HONORARIA - St Jude Medical
Tandri	Harikrishna	Ventricular Arrhythmias and Sudden Death	Appropriate Implantable Cardioverter Defibrillator Interventions in	CONSULTANT FEES/HONORARIA - St Jude Medical
		Prevention	Probands and Family Members With Arrhythmogenic Right Ventricular Cardiomyopathy Dysplasia	
Tanel	Ronn	Arrhythmias and Clinical EP: Basic 5	Tachyarrhythmia Not Associated With Mortality During Single	CONSULTANT FEES/HONORARIA - St Jude Medical; OTHER -
Tanem	Jena	Highlighted Original Research: Congenital	Ventricle Reconstruction Re-Intervention During the Interstage Period: A Report From the	MEDTRONIC,St Jude Medical Nothing to Disclose
		Heart Disease and the Year in Review	National Pediatric Cardiology Quality Improvement Collaborative	-
Tang	Delphine	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Searching for a Trigger in Resistant Ventricular Tachycardia in Post Acute Myocardial Infarction	Nothing to Disclose
Tang	Fengming	Updates in Stable Ischemic Heart Disease	Using the Diabetes Collaborative Registry (DCR) to Estimate the	Nothing to Disclose
			Potential Real-World Impact of the Leader Trial on Improving Cardiovascular Outcomes in Patients With Diabetes at High	
			Cardiovascular Risk	
Tang	Fengming	Advances in Lipid Management	Implications of the IMPROVE-IT Trial for Contemporary Cardiovascular Practice: An NCDR [®] Research to	Nothing to Disclose
			Practice (R2P) Project	
Tang	Gilbert	Interventional Cardiology: TAVR 1	"Cusp Overlap" View Facilitates Accurate Fluoro- Guided Implantation of Self-Expanding Valve in TAVR	OTHER - MEDTRONIC, Proctor for Transcatheter Valve Procedures with Edwards Lifesciences
Tang	Gilbert	Structural Heart Interventions: Focus on Mitral	Change in Aortomitral Annular Angle and Anterior Mitral Valve	OTHER - MEDTRONIC, Proctor for Transcatheter Valve
		Valve, Left Atrial Appendage and HOCM	Leaflet Length After Transcatheter Aortic Valve Replacement:	Procedures with Edwards Lifesciences
Tang	Gilbert	Interventional Cardiology: TAVR 4	Implications for Transcatheter Mitral Valve Replacement? Predictors of New Persistent Left Bundle Branch Block After	OTHER - MEDTRONIC, Proctor for Transcatheter Valve
	Hall Old	FIT OF COLUMN AND COLU	Edwards Sapien 3 Transcatheter Aortic Valve Replacement	Procedures with Edwards Lifesciences
Tang	Hak Chiaw	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Takayasu's Arteritis Causing Coronary Artery Vasospasm and Cardiac Arrest	Nothing to Disclose
_	ļ	Disease, and Vascular Medicine		
Tang	Richard	Non Invasive Imaging: MR Characterization and Function	An Unrestrained Proinflammatory M1 Macrophage Population Induced by Iron Nanocrystals Impairs Myocardial Healing After	Nothing to Disclose
_	ļ		Hemorrhagic Infarction	
Tang	Richard	Diabetes and Endothelial Dysfucntion in Heart Failure	Mast Cell-Dependent Conversion of Siderophages Into Foam Cells Is a Hallmark of Early Fat Infiltration in Hemorrhagic Myocardial	Nothing to Disclose
_			Infarctions	
Tang	Richard	Biomarkers and Targets for Ischemic Heart Disease	Fat Accumulation in the Peri-Infarct Border Zone of Hemorrhagic Myocardial Infarction Is Mediated by Persistent Iron Deposits	Nothing to Disclose
Tang	Richard	Emerging Basic Science in Ischemic Heart	Myocardial Hemorrhage After Coronary Ischemia-Reperfusion	Nothing to Disclose
		Disease	Leads to an Iron-Mediated, Self-Perpetuating Loop of Foam Cell and Ceroid Accumulation	
Tang	Richard	Nuclear Cardiology: Coronary Flow	Precisely Controlled Arterial CO2 Can Potentiate Myocardial Blood	Nothing to Disclose
			Flow to the Same Extent as Adenosine: A Preclinical Study in Canines With 13N-Ammonia PET	
Tang	W. H. Wilson	Making Progress in Understanding Heart	Exercise Intolerance and Proportional Pulse Pressure Response in	CONSULTANT FEES/HONORARIA - Cardiac Community Core
	W. H. Wilson	Failure Making Progress in Understanding Heart	Patients With Chronic Heart Failure Impact of Proportional Pulse Pressure on Exercise Tolerance and	Lab, LLC
Tang	VV. 11. VVIISUII	Failure	Clinical Outcomes in Patients With Heart Failure With Reduced	CONSULTANT FEES/HONORARIA - Cardiac Community Core Lab, LLC
Tong	W H Wile		Ejection Fraction	CONCLITANT EEEC/HONODADIA CO
Tang	W. H. Wilson	Emerging Developments in HFpEF and Arryhthmias	Paradoxical Impact of Proportional Pulse Pressure on Mortality in Patients With Heart Failure With Preserved Ejection Fraction	CONSULTANT FEES/HONORARIA - Cardiac Community Core Lab, LLC
Tang	W. H. Wilson	The Evolving World of LVADs, Transplant and	Circulating Intestinal Fatty Acid-Binding Protein (I-FABP) Levels	CONSULTANT FEES/HONORARIA - Cardiac Community Core
		Other Novel Discoveries	Portends Higher Risk of Adverse Clinical Outcomes in Advanced Decompensated Heart Failure	Lab, LLC
Tang	Wai Hong	Heart Failure Patient Care: Transitioning the	New Technology: Who, When and How?	CONSULTANT FEES/HONORARIA - Cardiac Community Core
		Cost, Care and Context: Joint Heart Failure Society of America and American College of		Lab, LLC
-		Cardiology		
Tang	Wai Hong	Beyond the Usual Suspects - Other Dimensions in Prevention	Panelist	CONSULTANT FEES/HONORARIA - Cardiac Community Core Lab, LLC
	1	Dimensions in Frevention	I	ILAU, LLU



and the second				
Last Name Tang	Wai Hong	Session Title Beyond the Usual Suspects - Other	Presentation Title Novel Pathways in Atherogenesis: Intersection of the GI Microbiome	Disclosures CONSULTANT FEES/HONORARIA - Cardiac Community Core
Tang	Wai Hong	Dimensions in Prevention Salt, Water and the Kidney in Heart Failure	and ASCVD Panelist	Lab, LLC CONSULTANT FEES/HONORARIA - Cardiac Community Core
Tang	Wai Hong	Salt, Water and the Kidney in Heart Failure	Management of Patients with Acute Heart Failure Cardiorenal	Lab, LLC CONSULTANT FEES/HONORARIA - Cardiac Community Core
Tang	Wai Hong	Making Progress in Understanding Heart	Syndrome: Have We Made Progress? Intravascular Volume Expansion in Patients With Heart Failure and	Lab, LLC CONSULTANT FEES/HONORARIA - Cardiac Community Core
Tang	Wai Hong	Failure Acute Heart Failure: Evaluating Strategies to	Reduced Ejection Fraction Is Not Revealed by Changes in Cardiac Filling Pressures Time of Presentation Among Patients Hospitalized for Acute Heart	Lab, LLC CONSULTANT FEES/HONORARIA - Cardiac Community Core
rang		Prevent Readmissions	Failure (Clinical Characteristics, Initial Therapies and Outcomes): Insights From ASCEND-HF	Lab, LLC
Tang	Wai Hong	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	The Prognostic Role of Prior Heart Failure Hospitalizations in Patients With Severe Symptomatic and Recurrent Heart Failure: Insights From ESCAPE	CONSULTANT FEES/HONORARIA - Cardiac Community Core Lab, LLC
Tang	Wai Hong	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Identifying Non-Heart Failure Patients With Elevated NT-proBNP Levels in the Outpatient Setting: Opportunities for Prevention	CONSULTANT FEES/HONORARIA - Cardiac Community Core Lab, LLC
Tang	Wai Hong	Emerging Developments in HFpEF and Arryhthmias	The Association of Thick Left Ventricular Hypertrophy With Cardiovascular Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From the TOPCAT Trial	CONSULTANT FEES/HONORARIA - Cardiac Community Core Lab, LLC
Tang	Wai Hong	Risky Business: Predicting Outcomes in Heart Failure	The HOSPITAL Readmission Model Poorly Predicts 30-Day Rehospitalization in Heart Failure	CONSULTANT FEES/HONORARIA - Cardiac Community Core Lab, LLC
Tang	Wai Hong	14. Heart Failure and Cardiomyopathies:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Cardiac Community Core Lab, LLC
Tang	Xiao-Fang	Therapy Team 3 Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Impact of Gender Difference in Clinical Presentation on Long-Term Outcomes in Chinese Patients Undergoing Percutaneous Coronary	Nothing to Disclose
Tangcharoen	Tarinee	Syndrome Multimodality Imaging in Heart Diseases:	Intervention Cardiac MRI for Tissue Characterization in Patients With Congenital	Nothing to Disclose
		International Perspectives From the Gulf Heart Association, Thai Heart Association, and American College of Cardiology	Heart Disease	
Tanguay	Jean-Francois	Interventional Live Case Session VI: Bioresorbable Scaffolds and Imaging from St. Vincent Hospital (Indianapolis, IN)	Panelist	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - GE Healthcare:
		vincent nospital (indianapolis, iiv)		RESEARCH/RESEARCH GRANTS - Abbott Laboratories; SPEAKER'S BUREAU - Abbott Laboratories, AstraZeneca
Tanguay	Jean-Francois	Bioresorbable Vascular Scaffolds,	Panelist	Pharmaceuticals,Bayer Healthcare Pharmaceuticals CONSULTANT FEES/HONORARIA - Bayer Healthcare
		Bioresorbable Polymer and Polymer Free Metallic DES		Pharmaceuticals; OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - GE Healthcare; RESEARCH/RESEARCH GRANTS - Abbott Laboratories; SPEAKER'S BUREAU - Abbott Laboratories, AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals
Tanguturi	Varsha	FIT Forum: Acing the Transition: What FITs	Co-Chair	Nothing to Disclose
		Need to Know to Launch A Successful Career		
Tanguturi Tani	Varsha Lloyd	FIT Clinical Decision Making Reviewers 6 10. Congenital Heart Disease: Pediatric Team	ACC FIT Clinical Decision Making Reviewer Suggested Reviewer	Nothing to Disclose Nothing to Disclose
Taniguchi	Norimasa	3 FIT Clinical Decision Making: Non-Invasive	Hyperdense Artery Sign on Computed Tomography in Acute	Nothing to Disclose
Tanimoto	Shuzou	Imaging and Valvular Heart Disease The Evolving World of LVADs, Transplant and	Coronary Syndrome Elevated Right Sided Heart Pressure Is Associated With Malnutrition	Nothing to Disclose
		Other Novel Discoveries	in Heart Failure Patients With Reduced Ejection Fraction	-
Tanimoto	Shuzou	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Identifying Novel Phenotypes of Acute Decompensated Heart Failure Using Cluster Analysis of Clinical Variables	Nothing to Disclose
Tankazyan	Hambik	Interventional Cardiology: TAVR 2	Impact of the Presence of Coronary Artery Disease and Timing of Revascularization on Outcomes of Patients Undergoing Trans-Catheter Aortic Valve Replacement: Insights From STS/ACC TVT	Nothing to Disclose
Tan-Mesiatowsky	Caroline Liong Eng	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Registry The Presence of Fragmented QRS Complexes Early After Acute Myocardial Infarction Is Associated With Subsequent Lack of Favorable Left Ventricular Remodeling	Nothing to Disclose
Tanner	Rikki	Advances in Cholesterol Measurement and Management	Prevalence and Correlates of Statin Side Effects and Willingness to Be Re-Challenged on a Statin: Data From the REasons for	Nothing to Disclose
Tanner	Rikki	Advances in Cholesterol Measurement and	Geographic And Racial Differences in Stroke (REGARDS) Study Psychosocial Factors and Statin Intolerance: Data From the	Nothing to Disclose
		Management	REasons for Geographic And Racial Differences in Stroke (REGARDS) Study	
Tantiworawit	Adisak	Emerging Developments in HFpEF and Arryhthmias	Decreased Heart Rate Variability Is Associated With Increased Cardiac Iron Deposit Determined by Cardiac T2* MRI and Decreased Left Ventricular Function in Transfusion Dependent	Nothing to Disclose
Tantry	Udaya	Biomarkers and Targets for Ischemic Heart Disease	Thalassemia Patients Serial Assessment of Thrombogenicity and Hemodynamics in Patients With Type II Diabetes Observed in a Clinical Research Unit:	Nothing to Disclose
Tantry	Udaya	From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease	Evidence for Circadian Changes in Clot Formation Assessment of Thrombogenicity and Antithrombotic Drug Response at the Bedside in Patients Presenting With Ischemic Stroke, TIA or	Nothing to Disclose
Tantry	Udaya	Advances in Lipid Management	Intracranial Hemorrhage HDL3: A Marker of Coronary Artery Disease Severity and	Nothing to Disclose
Tantry	Udaya	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Inflammation in Patients on Statin Therapy Early Coronary Angiography in Patients With Out-of-Hospital Cardiac Arrest Without ST-Elevation Myocardial Infarction: A Meta-	Nothing to Disclose
Тао	Ningchao	Syndrome Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Analysis of 1,460 Patients Super-Response to Cardiac Resynchronization Therapy in Heart Failure Patients With Left Bundle Branch Block and Homogeneous	Nothing to Disclose
Tao	Ningchao	Heart Failure and Cardiomyopathies: Heart	Left Ventricular Contraction Pattern Elevated Pulmonary Vascular Resistance Predicts Poor Response	Nothing to Disclose
Tao	Ningchao	Failure Gadgets Galore Heart Failure and Cardiomyopathies: Heart	Assessment of Left Ventricular Contraction Patterns Using Gated	Nothing to Disclose
		Failure Gadgets Galore	SPECT MPI to Improve Cardiac Resynchronization Therapy Response	, and the second
Tapson	Victor	35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Actelion, Bayer, Daiichi Sankyo,gilead, Janssen, Lung Biotechnology, REATA, United Therapeutics; RESEARCH/RESEARCH GRANTS - Arena, EKOS / BTG, Inari Medical
Taqueti	Viviany	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Integrating Hyperemic Myocardial Blood Flow and Coronary Flow Reserve for Predicting Cardiovascular Mortality Outcomes in Patients With Known or Suspected Ischemic Heart Disease	Nothing to Disclose
Taqueti	Viviany	Young Investigator Awards Competition: Clinical Investigations	Impaired Coronary Flow Reserve Is Associated With Diastolic Dysfunction and HFpEF Outcomes in Patients Without Overt CAD	Nothing to Disclose
Taqueti	Viviany	Nuclear Cardiology: Prognosis	Myocardial Scar but Not Ischemia Predicts Defibrillator Shocks and Sudden Cardiac Death in Patients With Reduced Left Ventricular	Nothing to Disclose
			Ejection Fraction	

and the second				
Last Name Taqueti	First Name Viviany	Session Title Noninvasive Assessment of Coronary Flow	Presentation Title Relationship of Coronary Flow Reserve With Body Mass Index and	Disclosures Nothing to Disclose
. ,		Reserve: Clinical Implications	Adverse Outcomes in Patients Without Overt Ischemic Heart	
Taqueti	Viviany	Noninvasive Assessment of Coronary Flow	Disease: Implications for Metabolic Surgery Eligibility Association Between Coronary Flow Reserve and Adverse	Nothing to Disclose
	-	Reserve: Clinical Implications	Cardiovascular Events Along a Continuum of Metabolic Disease in Symptomatic Patients Without Overt Coronary Artery Disease	-
Tara	Shuhei	Cutting Edge Vascular Medicine	Transmural Macrophage Migration in Tissue Engineered Vascular Graft Promotes Extracellular Matrix Formation for Vascular Remodeling More Than Host Circulating Inflammatory Cell Migration	Nothing to Disclose
Tarallo	Roberta	Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI	Activating Stimuli Modulate Pre-mRNA Maturation in Platelets: A Novel Mechanism That Regulates Platelet Function?	Nothing to Disclose
Tarasova	Olga	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	T Wave Alternans and Torsade de Pointes: The Fatal Twist	Nothing to Disclose
Tarbine	Sergio	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Clinical Outcomes After Implantation of Absorb BVS in a Real World Setting, With Pre- and Post-Dilatation, Guided by Intravascular	Nothing to Disclose
T17	live Objects		Ultrasound & Optical Coherence Tomography	CONOUNTANT EFFOUNDING PRODUCTION
Tardif	Jean Claude	Opening Session and the Joint American College of Cardiology and Journal of American College of Cardiology Late-Breaking Clinical Trials Featuring the Simon Dack Lecture	Safety and Cardiovascular Event Efficacy of Bococizumab Among 27,000 High Risk Patients	CONSULTANT FEES/HONORARIA - Pfizer, servier; OWNERSHIP inTEREST/PARTNERSHIP/PRINCIPAL - DalCor; RESEARCH/RESEARCH GRANTS - Amarin, Astra- Zeneca, DalCor, Eli-Lilly, Hoffmann-Laroche, Merck, Pfizer, servier
Tardif	Jean Claude	The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints	Surrogate Endpoints Provide no Insight in ACS Trials: Con	CONSULTANT FEES/HONORARIA - Pfizer, servier; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - DalCor; RESEARCH/RESEARCH GRANTS - Amarin, Astra- Zeneca, DalCor, Eil-Lilly, Hoffmann-Laroche, Merck, Pfizer, servier
Tardif	Jean Claude	New Perspectives on CAD Risk Factors	Discordances Between Predicted and Actual Risk of Adverse Events in Obese Patients With Suspected Cardiac Ischemia: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	CONSULTANT FEES/HONORARIA - Pfizer, servier; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - DalCor; RESEARCH/RESEARCH GRANTS - Amarin, Astra- Zeneca, DalCor, Eil-Lilly, Hoffmann-Laroche, Merck, Pfizer, servier
Tardif	Jean-Claude	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Association Between Homeostasis Model Assessment of Insulin Resistance and Survival in Diabetic Patients With Acute Coronary Syndromes: Insights From the AleCardio Trial	CONSULTANT FEES/HONORARIA - Pfizer, servier; OWNERSHIP INI TEREST/PARTHERSHIP/PRINCIPAL - DalCor; RESEARCH/RESEARCH GRANTS - Amarin, Astra- Zeneca, DalCor, Eli-Lilly, Hoffmann-Laroche, Merck, Pfizer, servier
Tariq	Afnan	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Impact of Utilizing Fractional Flow Reserve With Percutaneous Coronary Intervention on Readmissions: An Analysis of the 2013 National Readmissions Database	Nothing to Disclose
Tariq	Afnan	Interventional Cardiology: TAVR 3	Transfemoral Versus Transapical Transcatheter Aortic Valve Replacement: An Analysis of 2013 National Readmission and Inpatient Sample Databases	Nothing to Disclose
Tariq	Ali	Emerging Developments in HFpEF and Arryhthmias	Effect of Diabetes Mellitus on Pulsatile Arterial Load and Hemodynamics in HFpEF	Nothing to Disclose
Tariq	Sohaib	FIT Clinical Decision Making: Non-Invasive	Pneumopericardium: A Rare Presentation of Gastro-Pericardial	Nothing to Disclose
Tariq	Sohaib	Imaging and Valvular Heart Disease Current Issues in Cardiovascular	Fistula In-Hospital Outcomes and Hospitalizations for Acute Rheumatic	Nothing to Disclose
Tariq	Sohaib	Epidemiology, Disparities, and Safety Current Issues in Cardiovascular	Heart Disease: A United States National Study Prevalence and In-Hospital Outcomes of Uremic and Dialysis	Nothing to Disclose
·		Epidemiology, Disparities, and Safety	Pericarditis: A United States National Study	-
Tariq	Sohaib	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Sinus Node Dysfunction in Batten Disease: A Rare Manifestation of a Rare Disease	Nothing to Disclose
Tariq	Sohaib	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Combined Heart-Kidney Transplantation in a Patient With Human Immunodeficiency Virus	Nothing to Disclose
Tariq	Sohaib	FIT Clinical Decision Making: Heart Failure and	Management of Takotsubo Cardiomyopathy Complicated by Left	Nothing to Disclose
Tariq	Sohaib	Pulmonary Hypertension The Evolving World of LVADs, Transplant and	Ventricular Outflow Tract Obstruction Arrhythmias in Hospitalized Heart Transplanted Patients: A United	Nothing to Disclose
Tariq	Sohaib	Other Novel Discoveries The Evolving World of LVADs, Transplant and	States National Study Chagas Heart Disease: A United States National Study	Nothing to Disclose
Tariq	Sohaib	Other Novel Discoveries FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Spontaneous Coronary Artery Dissection in a Transplanted Heart	Nothing to Disclose
Tarkin	Jason	Disease, and Vascular Medicine Non Invasive Imaging: Prognostic Implications of CT Angiography	The Relationship Between Pericardial Adipose Tissue Volume, Atherosclerotic Plaque Type and Cardiovascular Risk: A High Risk	Nothing to Disclose
Tarricone	Arthur	Highlights in Vascular Medicine Research	Plaque Biolmage Sub-Study Morphological Features of Vascular Healing in Paclitaxel Coated Balloon Compared to Plain Old Balloon Angioplasty in Human	Nothing to Disclose
Tarumi	Takashi	Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	Peripheral Artery Disease The Impact of Lifelong Exercise Training "Dose" on the Ventricular-Arterial Coupling	Nothing to Disclose
T	Akira			Nothing to Disclose
Taruya	Ania	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Stent Implantation Between EES and BES: An OCT Sub-Study of the NEXT	, and the second
Tase	Adrian	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Trimetazidine Added-On Therapy Could Lower the Risk of Incidental Left Ventricular Dysfunction With or Without Heart Failure in Epirubicinum Recipients for Breast Cancer	Nothing to Disclose
Tashman	Ra'Ad	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Dissolve It or Take It Out: Excellent Outcome of Right-Sided Heart Clot In-Transit	Nothing to Disclose
Tastet	Lionel	Novel Determinants of Outcomes in VHD	Impact of Aortic Valve Calcification and Sex on Hemodynamic	Nothing to Disclose
Tastet	Lionel	Novel Determinants of Outcomes in VHD	Progression and Clinical Outcomes in Aortic Stenosis Relationship Between Proximal Aorta Morphology and Progression	Nothing to Disclose
Tastet	Lionel	Novel Determinants of Outcomes in VHD	Rate of Aortic Stenosis Pre-Operative Longitudinal Strain and Strain Rate as Predictors of Impaired Post-Operative Election Fraction in Patients Operated for	Nothing to Disclose
Tattersall	Matthew	Non Invasive Imaging: Coronary Calcium	Pure Aortic Regurgitation Association of Total Testosterone With Progression of Carotid	Nothing to Disclose
		Scoring and CV Risk Assessment	Atherosclerosis and Coronary Artery Calcium Score: The Multi- Ethnic Study of Atherosclerosis Association of Coronary Calcium, Carotid Wall Thickness and	-
Tattersall	Matthew	Innovations in Cardiovascular Risk Assessment and Reduction	Carotid Plaque Progression With Low Density Lipoprotein and High Density Lipoprotein Particle Concentration Measured by Ion Mobility Testing: The Multi-Ethnic Study of Atherosclerosis (MESA)	Nothing to Disclose
Taubert	Kathryn	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Invasive Management Strategies and Anti-Thrombotic Treatments in Patients With NSTE-ACS in China	Nothing to Disclose
Tavella	Rosanna	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	ST-Segment Elevation and Cardiac Magnetic Resonance Imaging Findings in Myocardial Infarction With Non-Obstructive Coronary Arteries	Nothing to Disclose
Tawakol	Ahmed	Innovations in Cardiovascular Risk Assessment and Reduction	Resting Amygdalar Activity Associates With Future Changes in Adiposity: Implications for Atherosclerotic Disease	CONSULTANT FEES/HONORARIA - Actelion,Amgen Inc.,Genentech,Takeda; RESEARCH/RESEARCH GRANTS -
Tawney	Adam	Insights From Echocardiography Use	Impact of Echo Contrast Agents on Ventricular Assist Devices (VAD)	Actelion,Genentech,Takeda Nothing to Disclose
Tay	Edgar	Coronary Intervention: Drug Eluting Stent and	Hemodynamics: Are They Safe to Use? Safety and Efficacy of Small Vessel Stenting With 2 mm Drug	Nothing to Disclose
		Scaffolds	Eluting Stents in Real World Clinical Practice	<u> </u>



Control of the contro				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Тау	Edgar	Coronary Intervention in Interventional Cardiology: Core Concepts	Incidence and Predictors of Target Lesion Failure in a Multi-Ethnic Asian Population Receiving the SYNERGY Coronary Stent: A Prospective All-Comers Registry	Nothing to Disclose
Tayal	Rajiv	Interventional Cardiology: TAVR 1	Assessment of Right Sided Hemodynamic Parameters as Predictors of Early Outcomes After Transcatheter Aortic Valve Replacement	SPEAKER'S BUREAU - Edwards Lifesciences
Tayal	Rajiv	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Percutaneous Management of Severe Aortic Insufficiency Complicating Prolonged Left Ventricular Assist Device Support	SPEAKER'S BUREAU - Edwards Lifesciences
Tayal	Upasana	Clinical Applications of Cardiac MRI in 2017	Assessment of Cardiomyopathy	Nothing to Disclose
Tayal	Upasana	Young Investigator Awards Competition: Clinical Investigations	Integrated Analysis of the Clinical Manifestations and Phenotypic Drivers of Titin Cardiomyopathy	Nothing to Disclose
Tayal	Upasana	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Cardiovascular Magnetic Resonance in Survivors of Sudden Cardiac Arrest: 14 Year Experience From a Tertiary Referral Centre in the United Kingdom	Nothing to Disclose
Taylor	Allen	32. Prevention: Clinical Team 5	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen; SPEAKER'S BUREAU - SANOFI
Taylor	Anne	Put Your Codon! Genetic Insights Into Heart Failure	G-Protein Receptor Kinase 5 Polymorphisms and Outcomes in the African American Heart Failure Trial: Results From the Genetic Risk Assessment of Heart Failure in African-Americans Sub-Study	Nothing to Disclose
Taylor	Ben	Featured Clinical Research III	Early Challenges for PSCK9 Inhibitor Prescriptions and Patients: Rejections and Rates Unfilled	SALARY - Amgen Inc.
Taylor	Ben	Advances in Cholesterol Measurement and Management	Prevalence and Correlates of Statin Side Effects and Willingness to Be Re-Challenged on a Statin: Data From the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study	SALARY - Amgen Inc.
Taylor	Ben	Advances in Cholesterol Measurement and Management	Psychosocial Factors and Statin Intolerance: Data From the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study	SALARY - Amgen Inc.
Taylor	Ben	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Use of Recommended and Contraindicated Statins in HIV Patients	SALARY - Amgen Inc.
Taylor	Ben	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Trends in the Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011-2014	SALARY - Amgen Inc.
Taylor	Benjamin	Diabetes and Other Issues in Cardiovascular Prevention	Observed Versus Predicted Cardiovascular Event Rates in Primary Prevention Diabetic Patients Receiving High-Intensity Statins in the	RESEARCH/RESEARCH GRANTS - Amgen Inc.
Taylor	Beth	Featured Clinical Research III	United Kingdom The Effect of High-Dose Atorvastatin on Neuronal Activity and	RESEARCH/RESEARCH GRANTS - Regeneron
Taylor	Carolyn	Coronary Angiography, Intra-Vascular Imaging,	Cognitive Function Clinical Outcomes of Acute Ischemic Stroke Patients Stratified by	Nothing to Disclose
Taylor	Carolyn	Revascularization and Outcomes Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Cardiac Troponin-I: A Retrospective Analysis Detection of Heart Failure With Preserved Ejection Fraction in Single Ventricle Physiology: Insights From the Pediatric Heart	Nothing to Disclose
Taylor	David	The Tricuspid Valve: Not Forgotten, Just	Network Fontan Cross-Sectional Study Public Use Dataset Tricuspid Regurgitation Following Orthotopic Heart Transplant	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
Taylor	David	Misunderstood Everything you Wanted to Know About Heart	Co-Chair	ROLE - International Society for Heart and Lung Transplantation OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
Taylor	David	Transplant but Were Afraid to Ask 14. Heart Failure and Cardiomyopathies:	Suggested Reviewer	ROLE - International Society for Heart and Lung Transplantation OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
Taylor	Michael	Therapy Team 1 Coarctation of the Aorta, from Repair to	Everything You Need to Know About Imaging Coarctation of the	ROLE - International Society for Heart and Lung Transplantation Nothing to Disclose
Taylor	Michael	Lifelong Care Non Invasive Imaging: MR Scar and Perfusion	Aorta The Effect of Right Ventricular Compression on Cardiac Function in	Nothing to Disclose
Taylor	Michael	Heart Failure and Cardiomyopathies: What	Pediatric Pectus Excavatum Patients Spironolactone Therapy for Cardiomyopathy in Duchenne Muscular	Nothing to Disclose
Tayon	Kevin	Next When All Else Is Failing? Arrhythmias and Clinical EP: Devices 2	Dystrophy Selective Same Day Discharge After Biventricular Implantation as a	Nothing to Disclose
Tcheng	James	Assuring Quality in the Cath Lab:	Value Based Strategy: Safe and Cost Effective Co-Chair	CONSULTANT FEES/HONORARIA - Cardiovascular Systems,
3		Documentation, Appropriate Use, Peer Review, and Public Reporting		Inc.,International Guidelines Central,Philips Medical Systems; DATA SAFETY MONITORING BOARD - AstraZeneca Pharmaceuticals
Tcheng	James	Assuring Quality in the Cath Lab: Documentation, Appropriate Use, Peer Review, and Public Reporting	The Standardized Cath Report: Let's All Agree on This	CONSULTANT FEES/HONORARIA - Cardiovascular Systems, Inc.,International Guidelines Central, Philips Medical Systems; DATA SAFETY MONITORING BOARD - AstraZeneca Pharmaceuticals
Tchetche	Didier	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: From the WIN-TAVI Registry	Nothing to Disclose
Tchetche	Didier	Interventional Cardiology: PCI and TAVR in Complex Patients	Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the	Nothing to Disclose
Tea	Isaac	FIT Clinical Decision Making: Non-Invasive	Bravo-3 Randomized Trial Caught Between a Thrombus and a Hard Place: Thrombolysis as	Nothing to Disclose
Tea	leage	Imaging and Valvular Heart Disease	First Line Therapy for the Management of Prosthetic Valve Thrombosis Longitudinal Change in Soluble ST2 Versus R. type Natriuretic	Nothing to Disclose
Tea	Isaac	Innovations in Cardiovascular Risk Assessment and Reduction	Peptide in Predicting Major Adverse Cardiovascular Events in Asymptomatic Patients in the Community	Nothing to Disclose
Tea	Isaac	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Phlegmasia Cerulea Dolens: A Painful Blue Foot in the Setting of Normal Arterial Circulation	Nothing to Disclose
Teague	Heather	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Small Dense Low Density Lipoprotein Particle Number Relates to Coronary Plaque Burden Independent of Traditional Cardiovascular Risk Factors in Psoriasis	Nothing to Disclose
Teague	Heather	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Aortic Vascular Inflammation by 18-FDG PET/CT Associates With High-Risk Coronary Plaques in Young Psoriasis Patients	Nothing to Disclose
Teague	Heather	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Improvement in Cholesterol Efflux Capacity Is Associated With a Reduction in Aortic Wall Thickness by MRI Independent of Traditional CV Risk Factors	Nothing to Disclose
Tebaldi	Matteo	Featured Clinical Research II: Interventional	Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD Matrix Study	Nothing to Disclose
Tebaldi	Matteo	Refining PCI Technique and Outcomes	Comparison of Verapamil Versus Heparin Therapy on Procedural Success During Transradial Coronary Procedures (Vermut Study)	Nothing to Disclose
Tedford	Ryan	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	HeartMate II Pump Stops: The Short to Short Phenomenon	CONSULTANT FEES/HONORARIA - Abiomed, St Jude Medical; OTHER - Actelion; RESEARCH/RESEARCH GRANTS - Boston Scientific, St Jude Medical
Tedford	Ryan	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Older Age Combined With Reduced Renal Function Has a Strong Cumulative Adverse Effect on Survival in Left Ventricular Assist Device Patients	CONSULTANT FEES/HONORARIA - Abiomed, St Jude Medical; OTHER - Actelion; RESEARCH/RESEARCH GRANTS - Boston Scientific, St Jude Medical
Tedford	Ryan	Advanced Therapies = Advanced Trouble: VAD and Transplant Challenges	Acute Kidney Injury Is Highly Frequent Early After Left Ventricular Assist Device Implantation With High Morbidity and Mortality Rates: A Multicentre Study	CONSULTANT FEES/HONORARIA - Abiomed, St Jude Medical; OTHER - Actelion; RESEARCH/RESEARCH GRANTS - Boston Scientific, St Jude Medical
1				

Contract of the second				
Last Name Tedford	Ryan	Session Title 35. Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease Team 2	Presentation Title Suggested Reviewer	Disclosures CONSULTANT FEES/HONORARIA - Abiomed, St Jude Medical; OTHER - Actelion; RESEARCH/RESEARCH GRANTS - Boston
				Scientific,St Jude Medical
Teerlink	John	Imaging and Infections: International Perspectives From the Spanish Society of	Co-Chair	CONSULTANT FEES/HONORARIA - Amgen,Cardio3 Bioscience/ Celyad,CardioMEMS,Cytokinetics,
		Cardiology, Venezuelan Society of Cardiology, and American College of Cardiology		Inc.,Novartis,Relypsa,St. Jude Medical,Trevena,ZS Pharma; RESEARCH/RESEARCH GRANTS - Amgen,Baver Healthcare
				Pharmaceuticals,Bristol-Myers Squibb Company Novartis,Novartis
Teerlink	John	Imaging and Infections: International	Introduction to Session	CONSULTANT FEES/HONORARIA - Amgen, Cardio3
		Perspectives From the Spanish Society of Cardiology, Venezuelan Society of Cardiology,		Bioscience/ Celyad, CardioMEMS, Cytokinetics, Inc., Novartis, Relypsa, St. Jude Medical, Trevena, ZS Pharma;
		and American College of Cardiology		RESEARCH/RESEARCH GRANTS - Amgen,Bayer Healthcare Pharmaceuticals,Bristol-Myers Squibb Company
Teerlink	John	Acute Heart Failure: Evaluating Strategies to	Time of Presentation Among Patients Hospitalized for Acute Heart	,Novartis,Novartis CONSULTANT FEES/HONORARIA - Amgen,Cardio3
1 001111111		Prevent Readmissions	Failure (Clinical Characteristics, Initial Therapies and Outcomes): Insights From ASCEND-HF	Bioscience/ Celyad, CardioMEMS, Cytokinetics, Inc., Novartis, Relypsa, St. Jude Medical, Trevena, ZS Pharma;
			IIISIGHIS FIOHI ASCEND-HF	RESEARCH/RESEARCH GRANTS - Amgen, Bayer Healthcare
				Pharmaceuticals,Bristol-Myers Squibb Company ,Novartis,Novartis
Teerlink	John	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	The Cardiac Myosin Activator, Omecamtiv Mecarbil, Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure	CONSULTANT FEES/HONORARIA - Amgen, Cardio3 Bioscience/ Celyad, CardioMEMS, Cytokinetics,
		, and the second	(COSMIC-HF)	Inc.,Novartis,Relypsa,St. Jude Medical,Trevena,ZS Pharma; RESEARCH/RESEARCH GRANTS - Amgen,Bayer Healthcare
				Pharmaceuticals,Bristol-Myers Squibb Company ,Novartis,Novartis
Teerlink	John	13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen, Cardio3
		Clinical Team 8		Bioscience/ Celyad, CardioMEMS, Cytokinetics, Inc., Novartis, Relypsa, St. Jude Medical, Trevena, ZS Pharma;
				RESEARCH/RESEARCH GRANTS - Amgen,Bayer Healthcare Pharmaceuticals,Bristol-Myers Squibb Company
Tefera	Leben	Arrhythmiae and Clinical ED: AE Miscellaneous	Risk of Atrial Fibrillation in Human Immunodeficiency Virus Infection	,Novartis,Novartis Nothing to Disclose
		and Surgical Issues	in the Era of Antiretroviral Therapy	,
Teh	Andrew	Novel Arrhythmia Diagnostics, Therapeutics, and "Wearables	Accuracy of Smart Watches in Arrhythmias: <i>SMARTS</i> Study	Nothing to Disclose
Teh	Andrew	Novel Arrhythmia Diagnostics, Therapeutics, and "Wearables	High Atrial Ectopy in Stroke: An Independent Risk Factor?	Nothing to Disclose
Teleb	Mohamed	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Combined Migraine and Platypnea-Orthodeoxia Syndrome Due to Combined Atrial Septal Defect and Patent Foramen Ovale	Nothing to Disclose
Teleb	Mohamed	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Double Right Coronary Artery Engendering Inadequate Blood Supply to the Inferior Left Ventricular Wall	Nothing to Disclose
Telila	Tesfaye	Structural Heart Interventions: Focus on Mitral	In-Hospital Outcomes After MitraClip Implantation in the United	Nothing to Disclose
Telila	Tesfaye	Valve, Left Atrial Appendage and HOCM Interventional Cardiology: TAVR 3	States: 2010-2012 Transcatheter Versus Surgical Aortic Valve Replacement in	Nothing to Disclose
Tellez	Armando	Interventional Cardiology: Translation and Pre-	Diabetes Mellitus: From the Nationwide Inpatient Sample Novel Preclinical Assessment of Transcatheter Mitral Valve	Nothing to Disclose
		Clinical Research	Replacement by Micro Computed Tomography: µCT Imaging Guided Histopathological Evaluation	
Tellez	Armando	Interventional Cardiology: Translation and Pre- Clinical Research	Deliverability and Safety of a Novel Non-Invasive, Ultrasound-Based Renal Nerve Ablation System in a Large Preclinical Model via Histopathological Evaluation	Nothing to Disclose
Temple	Joel	The Story of the Adult Congenital Heart Disease Patient and EP	Acquired Long-Term Cardiac Rhythm and Conduction Abnormalities After Arterial Switch Operation	Nothing to Disclose
Temple	Joel	FIT Clinical Decision Making: Arrhythmias and	So Excited He Just Can't Hide It: Acquired Fasciculoventricular	Nothing to Disclose
Temple	Joel	Electrophysiology FIT Clinical Decision Making: Arrhythmias and	Preexcitation in Danon Disease Sudden Cardiac Arrest in a Patient With Thyroid Storm	Nothing to Disclose
Templin	Christian	Electrophysiology Risky Business: Predicting Outcomes in Heart	A Novel Clinical Score (InterTAK Score) to Distinguish Takotsubo	Nothing to Disclose
Temtanakitpaisan	Yutthapong	Failure FIT Clinical Decision Making: Prevention, Adult	Syndrome From Acute Coronary Syndrome Coronary Cameral Fistulas and Coronary Artery Aneurysms in a	Nothing to Disclose
		Congenital and Congenital Heart Disease	Patient With Acute Heart Failure: A Hybrid Case	
Ten Berg	Jurrien	Interventional Cardiology: PCI in Complex Patients	Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated Heparin Following Transcatheter Aortic Valve Replacement: Results From the Bravo-3 Randomized Trial	Nothing to Disclose
Tenekecioglu	Erhan	Updates in Stable Ischemic Heart Disease	Coronary Calcification as a Mechanism of Plaque/Media Shrinkage: A Multimodality Intracoronary Imaging Study	Nothing to Disclose
Tenekecioglu	Erhan	Coronary Intervention: Drug Eluting Stent and	Early, Late and Very Late Incidence of Bioresorbable Scaffold	Nothing to Disclose
_		Scaffolds	Thrombosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials and Observational Registries	
Tentolouris	Nikolaos	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Vascular Function of Conduit Arteries Is Associated With Progress of Diabetic Retinopathy in Type 2 Diabetes	Nothing to Disclose
Teo	Eliza	Novel Determinants of Outcomes in VHD	Relationship Between Proximal Aorta Morphology and Progression Rate of Aortic Stenosis	Nothing to Disclose
Teraguchi	lkuko	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Comparison of Very Late Vascular Response Beyond 2 Years After Stent Implantation Between EES and BES: An OCT Sub-Study of the NEXT	OTHER - Walayama Medical University
Terayama	Yasuo	Arrhythmias and Clinical EP: Anticoagulation Issues	Bleeding Risk Among Japanese Non-Valvular Atrial Fibrillation Patients Initiated on Apixaban, Dabigatran, Rivaroxaban or Warfarin	CONSULTANT FEES/HONORARIA - Pfizer Japan, Inc
			in the Real World	
Terentes-Printzios	Dimitrios	Innovations in Cardiovascular Risk Assessment and Reduction	Most Patients With Acute Coronary Syndromes Are Already at High Risk Prior to the Event and Lipid Management Is Underachieved Both Before and After Hospitalization: The Phaethon Study	Nothing to Disclose
Tereshchenko	Larisa	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	ECG Referral by a Cardiologist Is Associated With Life-Saving Effect in a Large Tertiary Healthcare System Patient Population	RESEARCH/RESEARCH GRANTS - Investigator-initiated research project funded by Medtronic, Inc,Investigator-initiated research project funded by Boston Scientific,Investigator-initiated research project funded by Gilead Sciences, Inc.
Tereshchenko	Larisa	Arrhythmias and Clinical EP: Basic 2	High Frequency Content of the Surface ECG Correlates With the Presence of Sympathetic Nerves in the Ventricles of the Heart	RESEARCH/RESEARCH GRANTS - Investigator-initiated research project funded by Meditronic, Inc, Investigator-initiated research project funded by Meditronic, Inc, Investigator-initiated research project funded by Goston Scientific, Investigator-initiated research project funded by Gilead Sciences, Inc.
Terkelsen	Christian	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Cardiac Myosin-Binding Protein C as Alternative to Cardiac Troponin T for the Diagnosis of Acute Myocardial Infarction in the Very Early Phase	Nothing to Disclose
Terre	Juan	Interventional Cardiology: PCI and TAVR in Complex Patients	Refining the Classification of Severe, Symptomatic Aortic Stenosis Using Flow and Gradient Measurements to Predict Outcomes Post-	Nothing to Disclose
Terre	Juan	TAVR Outcomes Prognostication	Transcatheter Aortic Valve Replacement High Baseline Valvuloarterial Impedence Predicts Worse 1-Year	Nothing to Disclose
			Outcomes After Transcatheter Aortic Valve Replacement	

Congress of the congress of th				l
Teruya	First Name Sergio	Session Title Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Presentation Title Evaluation of Changes in Weight as Part of Frailty Assessment in Patients With Advanced Heart Failure Receiving a Left Ventricular	Disclosures Nothing to Disclose
Teshome	Meron	Nuclear Cardiology: Prognosis	Assist Device The Prognostic Value of Serial Stress Myocardial Perfusion Imaging in Asymptomatic End-Stage Renal Disease Patients Awaiting Kidney	Nothing to Disclose
Teuteberg	Jeffrey	The Forgotten Chamber: The Right Ventricle in Heart Failure	Transplantation RV Failure After LVAD: Predictable and Preventable?	CONSULTANT FEES/HONORARIA - Abiomed,CareDx,MEDTRONIC; OTHER - Abbott Laboratories;
Teuteberg	Jeffrey	Nuclear Cardiology: Beyond Perfusion	Regional Right Ventricular (RV) Function as Determined by Gated Blood Pool SPECT (GBPS) Provides Additive Value to Evaluation of Patients Undergoing Left Ventricular Assist Device (LVAD)	SPEAKER'S BUREAU - Abiomed, CareDx, MEDTRONIC CONSULTANT FEES/HONORARIA - Abiomed, CareDx, MEDTRONIC; OTHER - Abbott Laboratories; SPEAKER'S BUREAU - Abiomed, CareDx, MEDTRONIC
Teuteberg	Jeffrey	13. Heart Failure and Cardiomyopathies: Clinical Team 6	Implantation Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abiomed,CareDx,MEDTRONIC; OTHER - Abbott Laboratories;
Teuteberg	Winifred	Innovations in Practice Management and	Formal CPR Status Policy and Process Increased Documentation	SPEAKER'S BUREAU - Abiomed, CareDx, MEDTRONIC Nothing to Disclose
Teutsch	Christine	Social Media Fibrillatory Arrhythmias: Outcomes With	Rates Persistence With Therapy in Patients With Atrial Fibrillation: The GLORIA-AF Registry	SALARY - Boehringer Ingelheim Pharma GmbH & Department of the Control of the Cont
Teutsch	Christine	Contemporary Practice Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Increased Rate of Previous Stroke in Asymptomatic/Minimally Symptomatic Versus Symptomatic Patients With Newly Detected Atrial Fibrillation Worldwide: Results From the GLORIA-AF Registry	KG SALARY - Boehringer Ingelheim Pharma GmbH & Bamp; Co. KG
Teutsch	Christine	Atrial Fibrillation and VT: Incorporating Novel	Rates of Stroke and Bleeding With Dabigatran 150 and 110 mg BID	SALARY - Boehringer Ingelheim Pharma GmbH & Department of the Control of the Cont
Tfelt-Hansen	Jacob	Risks Toward Decision Making Cardiac Channelopathies: Novel Therapeutics and Clinical Challenges	in Clinical Practice: The GLORIA-AF Registry Appropriate Primary Prophylactic Implantation of Defibrillator in Patients With Brugada Syndrome: Is There Any Difference Between Patients From Western and Asian countries? Data From a Multicenter Survey Involving 246 Patients With Arrhythmic Events	KG Nothing to Disclose
Thaden	Jeremy	Innovative Use of Echocardiography	The Association Between Echocardiographic Laboratory Accreditation and the Quality of Imaging and Reporting	Nothing to Disclose
Thaden	Jeremy	Valvular Heart Disease: Aortic Stenosis	Bicuspid Versus Tricuspid Aortic Valve Stenosis: Comparative Study of Clinical Characteristics and Outcomes Following Aortic Valve Replacement in an Age-Matched Cohort	Nothing to Disclose
Thaden	Jeremy	Valvular Heart Disease: Aortic Stenosis	Sinus Rhythm Versus Atrial Fibrillation & It Clinical Profile and Natural History of Patients With Severe Aortic Stenosis Managed Medically	Nothing to Disclose
Thakkar	Akanksha	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Technique and Utility of CT Angiography Fluoroscopy Image Fusion to Guide Percutaneous Pulmonary Valve Implantation in Adults	Nothing to Disclose
Thakkar	Akanksha	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Closure of a Ventricular Septal Defect Complicated by Hemolysis Requiring Transcatheter Retrieval of Amplatzer Occluder	Nothing to Disclose
Thakkar	Akanksha	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Quantitative Measurements on Cardiac Magnetic Resonance to Differentiate Benign Versus Malignant Masses: A Pilot Study	Nothing to Disclose
Thakkar	Badal	Highlighted Original Research: Vascular Medicine and the Year in Review	Burden of Repeat Admissions Among Patients With Critical Limb Ischemia	Nothing to Disclose
Thakkar	Badal	Updates on Risk Factors for Cardiovascular Disease	Hospital Admissions for Chest Pain Associated With Cocaine use in the United States	Nothing to Disclose
Thakkar	Badal	New Perspectives on CAD Risk Factors	Changing Trends of Atherosclerotic Risk Factors Among Patients With Acute Myocardial Infarction and Acute Ischemic Stroke	Nothing to Disclose
Thakkar	Harsh	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Partial Anomalous Pulmonary Venous Connection Presenting as Eisenmenger's Syndrome	Nothing to Disclose
Thaler	David	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Panelist	CONSULTANT FEES/HONORARIA - AGA Medical/St Jude/Abbott
Thaler	David	PFO Closure, PV Leak, and VSD Repair	Debate: PFO Closure Has a Clear Benefit and Indication	CONSULTANT FEES/HONORARIA - AGA Medical/St Jude/Abbott
Tham	Edythe	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Right Ventricular Remodelling in Hypoplastic Left Heart Syndrome: Impact of the Norwood and Hybrid Procedures	Nothing to Disclose
Thamilarasan	Maran	Non Invasive Imaging: MR Scar and Perfusion	Incremental Prognostic Utility of Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy	Nothing to Disclose
Thapa	Jhapat	Interventional Cardiology: PCI and TAVR in Complex Patients	Hemodynamic Assessment of Low Flow, Low Gradient Severe Aortic Stenosis With Preserved EF Using a Pressure Wire	Nothing to Disclose
Thapa	Jhapat	Interventional Cardiology: Structural Heart Disease	The Impact of Transaortic Gradient and Transaortic Flow on the Discrepancy Between Echocardiographic and Cardiac Cardiac Valuation of Severe Aortic Stenosis With Preserved Ejection Fraction	Nothing to Disclose
Thavendiranathan	Paaladinesh	Emerging Applications of Echocardiography		Nothing to Disclose
Thawabi	Mohammad	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Statin Intensity and Outcome in Patients With Acute Heart Failure	Nothing to Disclose
Thawabi	Mohammad	Fillure With a Normal EF for Real? FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	With Preserved Ejection Fraction Late Presentation of Total Anomalous Pulmonary Venous Connection	Nothing to Disclose
Thawabi	Mohammad	Changing the Natural History of Valve Disease With Medical Therapy	Statins Use and Long Term Outcome Post Surgical Aortic Valve Replacement	Nothing to Disclose
Thawabi	Mohammad	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Replacement Percutaneous Management of Severe Aortic Insufficiency Complicating Prolonged Left Ventricular Assist Device Support	Nothing to Disclose
Thawabi	Mohammad	Fill Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Confinating Prototiged Left Vertification Assist Device Support Coil Embolization of latrogenic Pulmonary Artery Pseudoaneurysm	Nothing to Disclose
Theertham	Arjun	Insights From Echocardiography Use	Trends and Use of Echocardiography in Patients With <i>Staphylococcus Aureus</i> Bacteremia: An Analysis Using the Nationwide Inpatient Sample (NIS) Data	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MRK; PFE
Themistoclakis	Sakis	Arrhythmias and Clinical EP: AF Ablation	Nation/well injude in Sample (wis) Data Long-Term Risk of Recurrent Arrhythmia in Patients With Typical Atrial Flutter Undergoing Pulmonary Vein Antrum Isolation or Cavo- Tricuspid Isthmus Ablation With Permanent Isolation	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals, Biosense Webster, Daiichi Sankyo; RESEARCH/RESEARCH GRANTS - Boehringer Ingelheim Pharmaceuticals, Inc,Bristol-Myers Squibb Company
Theodosios	Bisdas	Optimizing Treatment of Peripheral Artery Disease	Statin Therapy Is Associated With Increased Amputation Free Survival Among Patients With Critical Limb Ischemia	Nothing to Disclose
THEOGOSIOS			Long-Term Outcome of Noncompaction Cardiomyopathy Patients	CONSULTANT FEES/HONORARIA - Boston Scientific
Theuns	Dominic	Arrhythmias and Clinical EP: Devices 1	With Implantable Cardioverter-Defibrillators Compared With	
	Dominic Ashwin	FIT Clinical Decision Making: Non-Invasive	With Implantable Cardioverter-Defibrillators Compared With Patients With Dilated or Hypertrophic Cardiomyopathy An Unprecedented Case of Primary Cardiac Lymphoma Exclusive	Nothing to Disclose
Theuns		·	With Implantable Cardioverter-Defibrillators Compared With Patients With Dilated or Hypertrophic Cardiomyopathy	Nothing to Disclose Nothing to Disclose

-				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Thiele	Holger	Featured Clinical Research I	MR-INFORM: Stress Perfusion Imaging to Guide the Management of Patients With Stable Coronary Artery Disease	RESEARCH/RESEARCH GRANTS - Maquet Cardiovascular, Teleflex Medical, Terumo, The Medicines Company, SPEAKER'S BUREAU - Astra Zeneca, Boehringer Ingelheim Lilly Germany
Thiele	Holger	Clinical Challenges in the Cardiac Care Unit (CCU)	Management of Mechanical Circulatory Support Devices in the CCU	RESEARCH/RESEARCH GRANTS - Maquet Cardiovascular, Teleflex Medical, Terumo, The Medicines Company, SPEAKER'S BUREAU - Astra Zeneca, Boehringer
Thiele	Holger	Debates on Current Hot Topics in Coronary Intervention	Debate Con: Hemodynamic Support Devices Should Be Selectively Used!	Ingelheim,Lilly Germany RESEARCH/RESEARCH GRANTS - Maquet Cardiovascular, Teleflex Medical,Terumo,The Medicines Company, SPEAKER'S BUREAU - Astra Zeneca,Boehringer
Thiele	Holger	Controversies in ACS Guidelines	Optimal Timing of Coronary Angiography in Patients with Non ST Elevation ACS: Stay Cool and Plan for Cath Tomorrow - or Monday	Ingelheim,Lilly Germany RESEARCH/RESEARCH GRANTS - Maquet Cardiovascular, Teleflex Medical,Terumo,The Medicines Company, SPEAKER'S BUREAU - Astra Zeneca,Boehringer
Thiele	Holger	Mechanical Support, Hemodynamic Support for Shock in High Risk Subsets; Hemodynamic Compromise	Panelist	Ingelheim,Lilly Germany RESEARCH/RESEARCH GRANTS - Maquet Cardiovascular, Teleflex Medical,Terumo,The Medicines Company, SPEAKER'S BUREAU - Astra Zeneca,Boehringer
Thiele	Holger	Mechanical Support, Hemodynamic Support for Shock in High Risk Subsets; Hemodynamic Compromise	Balloon Pump	Ingelheim_Lilly Germany RESEARCH/RESEARCH GRANTS - Maquet Cardiovascular, Teleflex Medical, Terumo, The Medicines Company, SPEAKER'S BUREAU - Astra Zeneca, Boehringer
Thiele	Holger	Non Invasive Imaging: MR Characterization and Function	Prognostic Value and Determinants of Left Atrial Function Assessed by Cardiac Magnetic Resonance in St-Segment Elevation Myocardial Infarction	Cardiovascular,Teleflex Medical,Terumo,The Medicines Company; SPEAKER'S BUREAU - Astra Zeneca,Boehringer
Thiele	Holger	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Antecedent Hypertension and Myocardial Injury in Patients With Reperfused ST-Elevation Myocardial Infarction	Ingelheim Lilly Germany RESEARCH/RESEARCH GRANTS - Maquet Cardiovascular, Teleflex Medical, Terumo, The Medicines Company, SPEAKER'S BUREAU - Astra Zeneca, Boehringer
Thiele	Holger	Novel Developments in Acute Coronary Syndromes	Impact of Timing of Intra-Aortic Balloon Counterpulsation on Mortality in Cardiogenic Shock: A Sub-Analysis of the IABP-SHOCK II-Trial	Ingelheim Lilly Germany RESEARCH/RESEARCH GRANTS - Maquet Cardiovascular, Teleflex Medical, Terumo, The Medicines Company, SPEAKER'S BUREAU - Astra Zeneca, Boehringer Ingelheim, Lilly Germany
Thiele	Holger	Novel Developments in Acute Coronary Syndromes	Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: The Randomized SHOCK-COOL Pilot Trial	RESEARCH/RESEARCH GRANTS - Maquet Cardiovascular, Teleflex Medical,Terumo,The Medicines Company, SPEAKER'S BUREAU - Astra Zeneca,Boehringer Ingelheim,Lilly Germany
Thiele	Holger	Novel Developments in Acute Coronary Syndromes	Outcome of Elderly Patients Undergoing Extracorporeal Life Support in Refractory Cardiogenic Shock	RESEARCH/RESEARCH GRANTS - Maquet Cardiovascular, Teleflex Medical, Terumo, The Medicines Company, SPEAKER'S BUREAU - Astra Zeneca, Boehringer Ingelheim, Lilly Germany
Thiruvoipati	Thejasvi	Interventional Complexity and Complications	Timing Matters - Hydration Strategies to Reduce Contrast Induced Nephropathy After Peripheral Vascular Interventions: Observations From the Blue Cross Blue Shield Cardiovascular Consortium (BMC2)	Nothing to Disclose
Thohan	Vinay	Advances in HCM, PPCM and Other	Extended Course of Recovery in Patients With Peripartum	Nothing to Disclose
Thomas	Gregory	Cardiomyopathies Featured Clinical Research I	Cardiomyopathy Assessed by Left Ventricular Wall Distensibility Native South American Tsimane Have the Lowest Levels of Coronary Atherosclerosis Ever Reported	CONSULTANT FEES/HONORARIA - Astellas; RESEARCH/RESEARCH GRANTS - Celladon,Esperion,Gilead Sciences, Inc. ,Lilly,Pfizer Inc,Regado Biosciences,Sanofi
Thomas	James	Echocardiography: What is New in 2017	Automated Quantification in Systolic Assessment and Valvular Heart	Aventis,St Judes; SPEAKER'S BUREAU - Astellas CONSULTANT FEES/HONORARIA - Abbott,Edwards,General
Thomas	James	Imaging the Athlete's Heart	Disease Deformation Analysis Can Be Performed on Post-Exercise Images in National Basketball Association Draft Eligible Players With Good Reproducibility	Electric CONSULTANT FEES/HONORARIA - Abbott, Edwards, General Electric
Thomas	James	Valvular Heart Disease: Mitral Valve Disease	Warfarin Use and Progression of Mitral Annular Calcification	CONSULTANT FEES/HONORARIA - Abbott,Edwards,General Electric
Thomas	James	28. Non Invasive Imaging: Echo Team 5	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott,Edwards,General Electric
Thomas	Kevin	Considerations in Antiplatelet Therapy and in ACS	Dual Antiplatelet Therapy Utilization and Cardiovascular Outcomes Among Black and White Patients Treated With Drug Eluting Stents	CONSULTANT FEES/HONORARIA - Bristol Meyers Squibb,Pfizer Inc
Thomas	Kevin	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Incidence of Atrial Fibrillation in Black Patients Post Atrial Flutter Ablation	CONSULTANT FEES/HONORARIA - Bristol Meyers Squibb, Pfizer Inc
Thomas	Laine	Featured Clinical Research II: Interventional	Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data	Nothing to Disclose
Thomas	Laine	Late-Breaking Clinical Trials	Digoxin and Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?	Nothing to Disclose
Thomas	Laine	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Heart Failure With Reduced Ejection Fraction Care Patterns in the Outpatient Practice Setting: Initial Findings From CHAMP-HF	Nothing to Disclose
Thomas	Laine	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Outpatient Practice Setting, Initial Findings From CHAMP-HF Does Frailty Alter the Benefits of Oral Anticoagulation in Patients With Atrial Fibrillation?	Nothing to Disclose
Thomas	Laine	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)	Nothing to Disclose
Thomas	Randal	Predicting Outcomes in Cardiac Rehabilitation Patients	The Association Between Waist-Hip Ratio With Long-Term Cardiovascular Events in Patients With Coronary Artery Disease: A Population-Based Historical Cohort Study	Nothing to Disclose
Thomas	Randal	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	CHA2DS2-VASc Score Predicts Incident Atrial Fibrillation/Flutter in a Referral Population	Nothing to Disclose
Thomas	Randell	Innovative Use of Echocardiography	Left Atrial Function Index as a Predictor of Cardiovascular Disease and Atrial Fibrillation: Data From the Framingham Offspring Study	Nothing to Disclose
Thomas	Scott	Joint American College of Cardiology/Journal of the American Medical Association Late- Breaking Clinical Trials	e-Counseling for Self-Care Adherence Adds Therapeutic Benefit for Hypertension: The REACH Trial	
Thomas	Vincent	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Survival From Out-of-Hospital Cardiac Arrest and Its Relationship to Health Insurance Status in the Young	-
Thomopoulos	Costas	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study	Nothing to Disclose
Thompson	Craig	Advances in Chronic Total Occlusion	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY



Contract of the second				<u> </u>
Last Name Thompson	First Name Paul	Session Title Featured Clinical Research III	Presentation Title The Effect of High-Dose Atorvastatin on Neuronal Activity and	Disclosures CONSULTANT FEES/HONORARIA - Astra Zenica.Merck.Sanolfi
Inompson	Paul	Featured Clinical Research III	The Effect of High-Dose Atorvastatin on Neuronal Activity and Cognitive Function	LONSULTAIN TEES/HUNUKARIA - ASTR ZENICA, MERCK, SANDIII Aventis; OTHER - Abbvie, General Electric, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - JA Wiley Publishing, Johson & ampr.amp; Johnson; RESEARCH/RESEARCH GRANTS - Amarin
				Pharmaceuticals, Esperion Pharmaceuticals, Genomas, Pfizer, Regeneron
Thompson	Paul	Sports and Exercise: Athletes with Congenital/Valvular Heart Disease Challenging Guidelines in Daily Practice	I am a Disqualified Collegiate Athlete: Here is My Opinion	CONSULTANT FEES/HONORARIA - Astra Zenica Merck, Sanolfi Aventis; OTHER - Abbvie, General Electric; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - JA Wiley Publishing, Johson & Bamp; amp; Johnson; RESEARCH/RESEARCH GRANTS - Amarin Pharmaceuticals, Esperion Pharmaceuticals, Genomas, Pfizer, Regeneron
Thompson	Paul	The Athlete with Heart Disease: A Case Based Approach	A Master's Athlete Post-MI	CONSULTANT FEES/HONORARIA - Astra Zenica Merck, Sanolfi Aventis, OTHER - Abbvie, General Electric, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - JA Wiley Publishing, Johson & amp; amp; Johnson; RESEARCH/RESEARCH GRANTS - Amarin Pharmaceuticals, Esperion
Thompson	Paul	Get into the Beat! Exercise to Promote CV Health	Panelist	Pharmaceuticals, Genomas, Pfizer, Regeneron CONSULTANT FEES/HONORARIA - Astra Zenica, Merck, Sanolfi Aventis; OTHER - Abbvie, General Electric; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - JA Wiley Publishing, Johson & Bamp; amp; Johnson; RESEARCH/RESEARCH GRANTS - Amarin Pharmaceuticals, Esperion
Thompson	Paul	Get into the Beat! Exercise to Promote CV Health	Can There Be Too Much of A Good Thing? Duration and Extent of Exercise for CVD Reduction	Pharmaceuticals, Genomas, Pfizer, Regeneron CONSULTANT FEES/HONORARIA - Astra Zenica, Merck, Sanolfi Aventis; OTHER - Abbvie, General Electric, OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - JA Wiley Publishing, Johson & Bamp; Johnson; RESEARCH/RESEARCH GRANTS - Amarin Pharmaceuticals, Esperion Pharmaceuticals, Genomas, Pfizer, Regeneron
Thompson	Paul	Highlighted Original Research: Prevention and the Year in Review	Co-Chair	CONSULTANT FEES/HONORARIA - Astra Zenica, Merck, Sanolfi Aventis; OTHER - Abbvie, General Electric; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - JA Wiley Publishing, Johson & Bamp; amp; Johnson; RESEARCH/RESEARCH GRANTS - Amarin Pharmaceuticals, Esperion Pharmaceuticals, Genomas, Pfizer, Regeneron
Thompson	Paul	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Comparison of Procedural Efficacy of Coronary Angiography in Octogenarian, Nonagenarian and General Population	Nothing to Disclose
Thompson	Paul	Interventional Complexity and Complications	Factors Influencing Physician Selection of Radial Versus Femoral Approach in Non-Emergent Cases of CATH and PCI Procedures	Nothing to Disclose
Thompson	Paul	Interventional Complexity and Complications	Patient Characteristics as Predictors of Transradial Approach Failure During Coronary Angiography Procedures	Nothing to Disclose
Thompson	Paul	Interventional Complexity and Complications	The Effect of Body Mass Index on Procedural Efficacy in	Nothing to Disclose
Thompson	Paul	07. Arrhythmias and Clinical EP: Sports and Exercise Team 1	Transfemoral Versus Transradial Coronary Angiography Suggested Reviewer	CONSULTANT FEES/HONORARIA - Astra Zenica, Merck, Sanolfi Aventis; OTHER - Abbvie, General Electric; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - JA Wiley Publishing, Johson & Bamp; amp; Johnson; RESEARCH/RESEARCH GRANTS - Amarin Pharmaceuticals, Esperion Pharmaceuticals, Genomas, Pfizer, Regeneron
Thompson	Randall	Featured Clinical Research I	Native South American Tsimane Have the Lowest Levels of Coronary Atherosclerosis Ever Reported	Nothing to Disclose
Thompson	Randall	State of the Art Nuclear Cardiology: SPECT Myocardial Perfusion Imaging	Co-Chair	Nothing to Disclose
Thomson	Louise	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Coronary Microvascular Dysfunction Is Related to Left Ventricular Concentric Remodeling and Diastolic Dysfunction: From the WISE-CVD Study	Nothing to Disclose
Thomson	Louise	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium in the Elderly: Prevalence, Severity, and Association With All-Cause Mortality	Nothing to Disclose
Thomson	Louise	Non Invasive Imaging: MR Scar and Perfusion	Assessment of Myocardial Perfusion Reserve Index Using Adenosine Versus Regadenoson Among Healthy Female Subjects	Nothing to Disclose
Thomson	Louise	Non Invasive Imaging: New Technologies	Improvement in LDL Is Associated With Decrease in Non-Calcified Plaque Volume on CTA as Measured by Automated Quantitative Software	Nothing to Disclose
Thomson	Louise	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Relationship Between Whole Vessel Quantitative Plaque Characteristics and Noninvasive Fractional Flow Reserve From Coronary Computed Tomography Angiography	Nothing to Disclose
Thomson	Louise	Imaging With Cardiac CT: The Case for Calcium	Hormone Replacement Therapy Is Associated With Less Coronary Atherosclerosis and Lower Mortality	Nothing to Disclose
Thordsen	Sarah	Advancing Our Understanding of Aortic Disease	Clinical and Pathologic Findings of Aortic Dissection at Autopsy: Review of 338 Cases Over 6 Decades	Nothing to Disclose
Thornhill	Laurence	Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI	A Ticagrelor Loading Results in Increased Plasma S-Nitrosothiols Formation Acutely in Patients With Stable Angina Undergoing Pci but Not on Chronic Therapy: Possible Evidence of an Acute Pleiotropic Effect	Nothing to Disclose
Thourani	Vinod	FIT Forum: Mix and Mingle	CT Surgery	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott
				Medical Boston Scientific Edwards Lifesciences MEDTRONIC
Thourani	Vinod	Featured Clinical Research II: Interventional	Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data	Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC
Thourani	Vinod	Featured Clinical Research II: Interventional	Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis From the STS/ACC TVT Registra.	CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC
Thourani	Vinod	Featured Clinical Research II: Interventional Featured Clinical Research II: Interventional	Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis From the STS/ACC TVT Registry Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Valve Repair in the United States	CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical, RESEARCH/RESEARCH GRANTS - Abbott Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC
Thourani	Vinod	Featured Clinical Research II: Interventional Featured Clinical Research II: Interventional Joint American College of Cardiology/New England Journal of Medicine Late-Breaking	Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis From the STS/ACC TVT Registry Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Valve Repair in the United States Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic	CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical, RESEARCH/RESEARCH GRANTS - Abbott Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical, ESESEARCH/RESEARCH GRANTS - Abbott Medical, Boston Scientific, Edwards Lifesciences, St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott
Thourani	Vinod	Featured Clinical Research II: Interventional Featured Clinical Research II: Interventional Joint American College of Cardiology/New	Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis From the STS/ACC TVT Registry Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Valve Repair in the United States Cerebral Embolic Protection Devices During Surgical Aortic Valve	CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical, RESEARCH/RESEARCH GRANTS - Abbott Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St

Contract of the Contract of th				
Last Name Thourani	First Name Vinod	Session Title Controversies Surrounding TAVR: 2017 and Beyond	Presentation Title Co-Chair	Disclosures CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott
Thourani	Vinod	Highlighted Original Research: Interventional Cardiology and the Year in Review	New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: Incidence, Anticoagulant Strategy, and Outcomes	Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC
Thourani	Vinod	Interventional Cardiology: TAVR 1	Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: Insights From PARTNER 2A Trial	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott
Thourani	Vinod	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Pulmonary Venous Waveforms Predict Ventricular Remodeling After Percutaneous Mitral Valve Repair	Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott
Thourani	Vinod	Non Invasive Imaging: Expanding Clinical Applications	Does Patient Prosthesis Mismatch Defined by CT LVOT Area Predict Downstream Clinical Outcomes?	Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott
Thourani	Vinod	Interventional Cardiology: TAVR 2	Impact of the Presence of Coronary Artery Disease and Timing of Revascularization on Outcomes of Patients Undergoing Trans-	Medical,Boston Scientific,Edwards Lifesciences,MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott
Thourani	Vinod	Interventional Cardiology: PCI and TAVR in	Catheter Aortic Valve Replacement: Insights From STS/ACC TVT Registry Timing and Algorithm of Permanent Pacemaker Implantation After	Medical,Boston Scientific,Edwards Lifesciences,MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St
Thourani	Vinod	Complex Patients Interventional Cardiology: TAVR 3	TAVR Stroke and Cardiovascular Outcomes in Patients With Carotid	Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical,Boston Scientific,Edwards Lifesciences,MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St
Thourani	Vinod	Complex Decisions in Mitral Valve Care:	Disease Undergoing TAVR: Insights From the STS/TVT Registry Interactive Case Challenge in the Management of MR	Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical,Boston Scientific,Edwards Lifesciences,MEDTRONIC CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St
	Vinod	Individualizing Assessment, Diagnosis, and Treatment Complex Decisions in Mitral Valve Care:	Panelist	Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical,Boston Scientific,Edwards Lifesciences,MEDTRONIC
Thourani		Individualizing Assessment, Diagnosis, and Treatment		CONSULTANT FEES/HONORARIA - Edwards Lifesciences, St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical, Boston Scientific, Edwards Lifesciences, MEDTRONIC
Thourani	Vinod	TAVR Outcomes Prognostication	Predictors and Clinical Outcomes of Next-Day Discharge After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical,Boston Scientific,Edwards Lifesciences,MEDTRONIC
Thourani	Vinod	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low- Flow Severe Aortic Stenosis and Less Reverse Remodeling After TAVR: A Partner 2 Trial Analysis	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical,Boston Scientific,Edwards Lifesciences,MEDTRONIC
Thourani	Vinod	Peripheral Arterial Disease, Risk, and Outcomes	Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes: A Report From the STS/TVT Registry	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical,Boston Scientific,Edwards Lifesciences,MEDTRONIC
Thourani	Vinod	17. Interventional Cardiology: Aortic Valve Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Edwards Lifesciences,St Jude Medical; RESEARCH/RESEARCH GRANTS - Abbott Medical,Boston Scientific,Edwards Lifesciences,MEDTRONIC
Thummasorn	Savitree	Updates in Stable Ischemic Heart Disease	Vagus Nerve Stimulation Requires Both Ipsilateral and Contralateral Efferent Vagal Activity to Fully Exert Its Cardioprotection Against Cardiac Ischemia/Reperfusion Injury	
Thummasorn	Savitree	Antithrombotic Therapy in Ischemic Heart Disease	High-Dose Humanin Analogue Applied During Ischemia Provides Cardioprotection Against Ischemia-Reperfusion Injury Through Attenuating Mitochondrial Dysfunction	Nothing to Disclose
Thuresson	Marcus	Featured Clinical Research III	Lower Rates of Hospitalization for Heart Failure and All-Cause Death in New Users of SGLT-2 Inhibitors: The CVD-REAL Study	Nothing to Disclose
Thygesen	Kristian	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Cardiac Myosin-Binding Protein C as Alternative to Cardiac Troponin T for the Diagnosis of Acute Myocardial Infarction in the Very Early Phase	Nothing to Disclose
Tian	Lei	Population Specific Cardiomyopathies: From Exomes to Databases	Whole Genome Sequencing in Four Hypertrophic Cardiomyopathy Families With Sudden Cardiac Death	Nothing to Disclose
Tian	Xiaqiu	Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells	Adiponectin Improves the Survival and Therapeutic Efficacy of Mesenchymal Stem Cells in Acute Myocardial Infarction Model Through the AMPK Pathway	Nothing to Disclose
Tian	Ye	Advances in Lipid Management	Ezetimibe Real-World Effectiveness at Reaching Low-Density Lipoprotein Goal Among Patients With Atherosclerotic Cardiovascular Disease: A Retrospective Database Study in the	CONSULTANT FEES/HONORARIA - Sanofi-Aventis
Tierney	Elif	10. Congenital Heart Disease: Pediatric Team	United States Suggested Reviewer	Nothing to Disclose
Tighiouart	Mourad	Nuclear Cardiology: Coronary Flow	Precisely Controlled Arterial CO2 Can Potentiate Myocardial Blood Flow to the Same Extent as Adenosine: A Preclinical Study in Canines With 13N-Ammonia PET	Nothing to Disclose
Tilbury	R. Thomas	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Management of a Giant Calcific Coronary Artery Aneurysm	Nothing to Disclose
Tilkemeier	Peter	State of the Art Nuclear Cardiology: SPECT Myocardial Perfusion Imaging	Structured Reporting: Read it Then Report it Right	Nothing to Disclose
Timimi	Farris	Innovations in Practice Management and Social Media	Social Media in Academic Cardiology: The #ACC16 Experience	Nothing to Disclose
Tina	Pittman Wagers	Understanding Spontaneous Coronary Artery Dissection (SCAD): What We Know, What We Don't Know	Panelist	Nothing to Disclose
Ting	Christopher	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	No MAGGIC in Predicting Heart Failure Readmissions	Nothing to Disclose
Ting	Jeanette	Unusual Presentations of ACS	Prevalence and Evolution of Sleep Disordered Breathing in Acute Myocardial Infarction	Nothing to Disclose
Ting	Windsor	Interventional Cardiology: PCI in Complex Patients	Impact of Comorbid Coronary Artery Disease and Severe Peripheral Artery Disease on Major Adverse Cardiovascular Events	SPEAKER'S BUREAU - Janssen Pharmaceuticals, Inc
Tingo Tisdale	Jennifer James	Innovations in Education Atrial Fibrillation and VT: Incorporating Novel	Fellow Outpatient Clinic: Discontinuing the Discontinuity Intravenous Amiodarone for Prevention of Atrial Fibrillation	Nothing to Disclose RESEARCH/RESEARCH GRANTS - American College of
Tisudie	James	Risks Toward Decision Making	Following Esophagectomy: A Propensity Score-Matched Analysis	Clinical Pharmacy,American Heart Association,Heart Rhythm Society,Indiana University/Indiana University Health/Indiana
Tishler	Brielle	Congenital Heart Disease: Progress in	A Red Cell Preservation Strategy Reduces Postoperative	University Clinical Translational Sciences Institute Nothing to Disclose
Tishler	Brielle	Pediatric Heart Surgery Congenital Heart Disease: Progress in	Transfusions in Pediatric Heart Surgery Patients Validation of Technical Performance Score for Long-Term	Nothing to Disclose
Tishler	Brielle	Pediatric Heart Surgery Congenital Heart Disease: Progress in Pediatric Heart Surgery	Outcomes in Congenital Heart Surgery: 10 Year Follow-Up Data Technical Performance Score Can Predict Post-Discharge Reinterventions in Partial and Transitional Atrioventricular Septal	Nothing to Disclose
Tishler	Brielle	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Defect Repair Residual Atrioventricular Valve Regurgitation Pre-Discharge Is Associated With Post-Discharge Reinterventions Following Complete Atrio Ventricular Septal Defect Repair	Nothing to Disclose
Tison	Geoffrey	Innovations in Education	Understanding Social Media Usage Related to Cardiology:	Nothing to Disclose
Tita	Cristina	FIT Clinical Decision Making: Interventional	Underlying Motivation and Untapped Opportunities Proof Is in the Paclitaxel: Catheter Directed Intracoronary Paclitaxel	Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	as Salvage Therapy for Refractory Cardiac Allograft Vasculopathy	

Congress of the same				<u> </u>
Last Name	First Name	Session Title	Presentation Title	Disclosures
Tito	Antonio	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Admission Plasma Glucose Level on Myocardial Perfusion in St-Segment Elevation Myocardial Infarction (STEMI) Patients	Nothing to Disclose
Tito	Antonio	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Time Related Benefit of Antiplatelet Therapy on Coronary Reperfusion in ST-Elevation Myocardial Infarction (STEMI) Patients	Nothing to Disclose
Tiyyagura	Satish	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Ventricular Tachycardia in a Patient With Coexisting Brugada Syndrome and Coronary Vasospasm	Nothing to Disclose
Tjong	Fleur	Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	Chronic Performance of Communicating Leadless Anti-Tachycardia Pacemaker and Subcutaneous Implantable Cardioverter Defibrillator	CONSULTANT FEES/HONORARIA - Boston Scientific,St. Jude Medical
Tobis	Jonathan	Interventional Challenging Cases: Team 4	ACC Challenging Case Reviewer	DATA SAFETY MONITORING BOARD - angel medical system OTHER - Cardiac Dimensions
Toda	Mikihito	Novel Developments in Acute Coronary Syndromes	Left Ventricular End-Diastolic Pressure Predicts Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Independently of Left Ventricular Systolic Function	Nothing to Disclose
Todd	Derick	Advances in HCM, PPCM and Other Cardiomyopathies	Younger Age, Positive Family History and Reverse Curve Morphology Predict Informative Results From Gene Panel Analysis for Hypertrophic Cardiomyopathy (HCM)	Nothing to Disclose
Toft Sorensen	Henrik	Vascular Medicine: Venous Disease	Risk of Cancer After Upper-Extremity Deep Vein Thrombosis: A Population-Based Cohort Study	Nothing to Disclose
Toft Sorensen	Henrik		Risk of Cancer After Lower Limb Arterial Thrombosis: A Population-	Nothing to Disclose
Tojo	Taiki	Thrombosis Antiplatelet and Antithrombotic Agents in	Based Cohort Study Stent Edge Strut on Normal Segment Is Less Covered in Early	Nothing to Disclose
Tojo	Taiki	Ischemic Heart Disease Unusual Presentations of ACS	Phase After Drug Eluting Stent Implantation Lower Eicosapentaenoic Acid to Arachidonic Acid Ratio Is	Nothing to Disclose
			Associated With Intraplaque Cholesterol Crystals: An Optical Coherence Tomography Study	-
Tokgoz	Hacer Ceren	Understanding Pulmonary Vascular Disease: From Bench to Bedside	Short-Term Intravenous Iloprost Treatment Improves Clinical Status and Neurohumoral Measures in Clinical Worsening Episodes of Precapillary Pulmonary Hypertension Regardless of the Background Treatments: Insights From Euphrates Study	Nothing to Disclose
Tokgoz	Hacer Ceren	Predicting the Future: Observations and Discoveries From Registries and Databases	Pulmonary Vascular Resistance, but Not Diastolic Pulmonary Gradient, May Predict Survival in Pulmonary Hypertension: Insights From Euphrates Study	Nothing to Disclose
Tokgoz	Hacer Ceren	Predicting the Future: Observations and Discoveries From Registries and Databases	An Ignored but Not Unusual Complication of Severe Pulmonary Hypertension - Ostial Compression of Left Main Coronary Artery by Aneurysmal Pulmonary Artery: Insights From Euphrates Study	Nothing to Disclose
Tokgoz Demircan	Hacer Ceren	Understanding Pulmonary Vascular Disease: From Bench to Bedside	The Impaired Endothelium-Dependent and Endothelium- Independent Systemic Arterial Vasodilatory Reserve in Pulmonary Hypertension Regardless of the Clinical Group	Nothing to Disclose
Tokgoz Demircan	Hacer Ceren	Predicting the Future: Observations and Discoveries From Registries and Databases	The Correlates and Prognostic Impact of Pulmonary Arterial Pulse Pressures, Diastolic and Transpulmonary Pressure Gradients in Pulmonary Hypertension: Insights From Euphrates Study	Nothing to Disclose
Tokgoz Demirel	Hacer Ceren	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Clinical, Biochemical, Neurohumoral, Echocardiographic and Hemodynamic Characteristics in Relation to Survival in Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: Insights From Euphrates Study	Nothing to Disclose
Tokgozoglu	Sadberk Lale	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease		CONSULTANT FEES/HONORARIA - Abott, Actelion, Amgen, ASTRA, Bayer, Boehringer, Daiichi Sankyo, Merck, Mylan, Novartis, Pfizer, Recordati, SANOFI, servier
Tokgözoglu	Lale	Emerging Issues in CV Disease Management: International Perspectives From the Brazilian Society of Cardiology, Turkish Society of Cardiology, and American College of Cardiology	Secondary Prevention in Europe and Turkey: What did we learn from the Euroaspire IV Study?	CONSULTANT FEES/HONORARIA - Abott, Actelion, Amgen, ASTRA, Bayer, Boehringer, Dalichi Sankyo, Merck, Mylan, Novartis, Pfizer, Recordati, SANOFI, servier
Tokgözoglu	Lale	33. Prevention: Hypertension Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abott,Actelion,Amgen,ASTRA,Bayer,Boehringer,Daiichi Sankyo,Merck,Mylan,Novartis,Pfizer,Recordati,SANOFI,servier
Toklu	Bora	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Predictors of Flow-Limiting Fractional Flow Reserve in Coronary Lesions With Intermediate Instantaneous Wave-Free Ratio	Nothing to Disclose
Toklu	Bora	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Renin Angiotensin System Inhibitors in Patients With Coronary Artery Disease and Preserved Left Ventricular Function	Nothing to Disclose
Tokue	Masahide	Coronary Artery Disease The Evolving World of LVADs, Transplant and Other Novel Discoveries	Evaluation of Hemoconcentration Based Bioelectrical Vectorial Impedance Analysis Is Useful Risk Stratification in Acute	RESEARCH/RESEARCH GRANTS - intervention
Tokue	Masahide	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Decompensated Heart Failure Body Fat Percentage Evaluated by a Bioelectrical Impedance Analysis Provides Prognostic Value in Acute Heart Failure: Beyond	RESEARCH/RESEARCH GRANTS - intervention
Talaatiaa	A16	And thering and Clinical ED. Devices 4	on the "Obesity Paradox"	Nething to Displace
Tolentino Toleva	Alfonso Olga	Arrhythmias and Clinical EP: Devices 4 Unusual Presentations of ACS	ECG Criteria for the Identification of Bi-Ventricular Pacing Characteristics of Acute Coronary Syndrome Presentation in Young	Nothing to Disclose SPEAKER'S BUREAU - Astra-Zeneca,Bristol-Myers Squibb
Tolstrup	Kirsten	FIT Clinical Decision Making: Non-Invasive	Patients Seeing Is Believing: Utilizing Multiple Imaging Modalities in Difficult	Company Nothing to Disclose
Toma	Catalin	Imaging and Valvular Heart Disease Complex Coronary Intervention: Left	to Characterize Left Ventricle Outflow Obstruction Multivessel Versus Culprit-Only PCI in Patients With Non-ST	CONSULTANT FEES/HONORARIA - St Jude Medical
Toma	Catalin	Main/Bifurcations and Multivessel Disease Timely Topics in Acute Coronary Syndromes	Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study Use of Potent P2y12 Inhibitors in African-American Patients Treated	CONSULTANT FEES/HONORARIA - St Jude Medical
Toma	Catalin	Advances in Chronic Total Occlusion	With Percutaneous Coronary Intervention for Acute Coronary Syndromes The Impact of Epicardial Collateral Use on the Outcomes of Chronic	CONSULTANT FEES/HONORARIA - St Jude Medical
		Intervention	Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	
Toma	Catalin	Advances in Chronic Total Occlusion Intervention	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	CONSULTANT FEES/HONORARIA - St Jude Medical
Tomaniak	Mariusz	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	First Serial 12- and 24-Month Optical Coherence Tomography Assessment of Stemi Patients After the Generation of Absorb Bioresorbable Vascular Scaffold Implantation	Nothing to Disclose
Tomasdottir	Maria	Stroke and AF: Thinking About the Heart	Risk of Stroke in Women and Men With Atrial Fibrillation and Only One Additional CHA2DS2-VASc Risk Factor	Nothing to Disclose
Tomassini	Francesco	Featured Clinical Research II: Interventional	Radiation Exposure and Vascular Access in Acute Coronary	CONSULTANT FEES/HONORARIA - Boeringher Ingelheim
Tomey	Matthew	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Syndromes: The RAD Matrix Study Acute Echo-Guided Management of Cardiogenic Shock After Anterior Myocardial Infarction Complicated by Dynamic Left Ventricular Outflow Tract Obstruction	Nothing to Disclose
Tomita-Mitchell	Aoy	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Ventricular Outriow Tract Obstruction Exome Sequencing Reveals Novel Variants in <i>TMEM59L</i> and <i>KLHL26</i> Associated With a Familial Case of Ebstein’s Anomaly and Left Ventricular Noncompaction	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - MDinteractive,TAI Diagnostics; RESEARCH/RESEARCH GRANTS - Ariosa Diagnostics
Tomizawa	Nobuo	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Anomaly and Lett Ventricular Noncompaction Significance of	

				<u> </u>
Last Name Tomlinson	First Name Brian	Session Title Non Invasive Imaging: Role of Exercise Testing	Presentation Title Impaired Left Ventricular Longitudinal Functional Reserve in Patients With Psoriatic Arthritis: A Low-Level Bicycle Ergometer	Disclosures CONSULTANT FEES/HONORARIA - Amgen Inc., Sanofi-Aventis; SPEAKER'S BUREAU - Amgen Inc., Merck Serono, Sanofi-Aventis
Tommaso	Carl	Training for Interventional Procedures: Who Should Do What, Where, When, How, and	Exercise Test How: Operator Guidelines Documents	Nothing to Disclose
Tommaso	Carl	Why 02. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Tomoi	Yusuke	Clinical Team 4 Endovascular Therapy: Running From Risk	Impact of Decrease in Blood Pressure After Endovascular Therapy	Nothing to Disclose
Tompkins	Christine	Atrial Fibrillation and VT: Unique Populations and Solutions	for Renal Artery Stenosis Presence of Mid-Myocardial Substrate Is Associated With Need for Multiple Ablations in Patients With Non-Ischemic Cardiomyopathy and Ventricular Arrhythmias	CONSULTANT FEES/HONORARIA - Spectranetics
Tompkins	Christine	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Early Recurrence of Ventricular Tachycardia Predicts Increased Mortality Among Patients With Severe Heart Failure	CONSULTANT FEES/HONORARIA - Spectranetics
Tompkins	Christine	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Safety and Outcomes of Catheter Ablation for Treatment of Refractory Ventricular Arrhythmias in Patients With Advanced Heart Failure	CONSULTANT FEES/HONORARIA - Spectranetics
Tondo	Claudio	Arrhythmias and Clinical EP: AF Ablation	Long-Term Risk of Recurrent Arrhythmia in Patients With Typical Atrial Flutter Undergoing Pulmonary Vein Antrum Isolation or Cavo- Tricuspid Isthmus Ablation With Permanent Isolation	Nothing to Disclose
Tong	Carl	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Cardiac Myosin Binding Protein-C De-Phosphorylation Mediated Slowing of Cross-Detachment Worsens Heart Failure	Nothing to Disclose
Tong	Carl	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Acute Decompensated Heart Failure: The Journey From Patients' Perspective	Nothing to Disclose
Tong	Carl	Innovations in Advocacy and Patient Centered Care	Status of Early Career Academic Cardiology: A Global Perspective	Nothing to Disclose
Tong	Matthew	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Cardiac Amyloidosis Masquerading as Severe Low-Flow, Low- Gradient, Low-Ejection Fraction Aortic Stenosis: "All That Glitters Is Not Gold"	Nothing to Disclose
Tong	Matthew	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Non-Invasive Quantification of Cardiac Output With Phase Velocity Mapping in Patients With Pulmonary Hypertension	Nothing to Disclose
Tong	Matthew	Advances in Pulmonary Arterial Hypertension	Napping in Fatients with Full formitted by Pryber tension A Cross Comparison Study of Right Ventricular Hypertrophy With Electrocardiography and Cardiac Magnetic Resonance in Patients With Pulmonary Hypertension	Nothing to Disclose
Toole	Rena	Technical Advances in Transthoracic Echocardiography	Safety of Perflutren-Based Echocardiographic Contrast Agent Administration in the Setting of a Patent Foramen Ovale (PFO): A Multicenter Study Conducted in Tertiary Care Centers Based in the New York/Chicago Metropolitan Areas	Nothing to Disclose
Toomu	Avinash	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Sex Differences in Atrial Structural Remodeling and Serum Markers of Fibrosis at Presentation for Catheter Ablation	SALARY - Critical Diagnostics
Toor	Iqbal	Young Investigator Awards Competition: Basic and Translational Science	IL-4/IL-13 Signalling Modulates the Inflammatory Response in the Infarcted Adult Mouse Heart to Enhance Cardiac Repair and Remodelling	Nothing to Disclose
Topalian	Simon	Updates on Pulmonary Embolism Management in 2017	Ultrasound Accelerated Catheter Directed Lytic Therapy for Management of Pulmonary Embolism: Impact of Procedural Timing on Echocardiographic Outcomes and Safety	Nothing to Disclose
Topel	Matthew	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Association Between Circulating Progenitor Cells and Outcomes in Patients With Coronary Artery Disease	Nothing to Disclose
Topel	Matthew	Updates on Risk Factors for Cardiovascular Disease	Central Obesity Predicts Circulating Progenitor Cell Levels	Nothing to Disclose
Topel	Matthew	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Progenitor Cells and Clinical Outcomes in Patients With Heart Failure	Nothing to Disclose
Topel	Matthew	Unusual Presentations of ACS	Circulating Progenitor Cells Levels and Outcomes in Acute Myocardial Infarction	Nothing to Disclose
Topilsky	Yan	Emerging Developments in HFpEF and Arryhthmias	Impact of Rv Dysfunction and End-Diastolic Pulmonary Artery Pressure Estimated From Analysis of Tricuspid Regurgitant Velocity Spectrum in Patients With Preserved Ejection Fraction	Nothing to Disclose
Topilsky	Yan	Insights From Echocardiography Use	Intervention Versus Observation in Symptomatic Patients With Normal Flow-Low Gradient Severe Aortic Stenosis	Nothing to Disclose
Torguson	Rebecca	Considerations in Antiplatelet Therapy and in ACS	Trends in Discharge and Outcome of Dual Antiplatelet Therapy Post Percutaneous Intervention in High Bleeding Risk Population	Nothing to Disclose
Torguson	Rebecca	Considerations in Antiplatelet Therapy and in ACS	Outpatient Trends in Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Primary Percutaneous Coronary Intervention	Nothing to Disclose
Torguson	Rebecca	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	In-Stent Restenosis of Drug-Eluting Stents: Incidence, Lesion Characteristics and Outcomes in Contemporary Practice Over the Last Decade - How Are They Different From De Novo Lesions?	Nothing to Disclose
Torguson	Rebecca	Interventional Cardiology: TAVR 2	Racial Disparities and Temporal Trends in Demographics and Clinical Characteristics of Patients Screened for Transcatheter Aortic Valve Replacement	Nothing to Disclose
Torguson	Rebecca	and Surgical Issues	Is There a Role for Invasive Electrophysiology Studies in Patients With Conduction Abnormalities Following Transcatheter Aortic Valve Replacement?	Nothing to Disclose
Torguson	Rebecca	Interventional Cardiology: TAVR 3	Antithrombotic Therapy Differences and Associated Outcomes in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Torguson	Rebecca	Interventional Cardiology: TAVR 3	Acute Aortic Regurgitation Post-Transcatheter Aortic Valve Replacement: Impact of Various Treatment Strategies	Nothing to Disclose
Torguson	Rebecca	Interventional Cardiology: PCI in Complex Patients	Long-Term Mortality in Percutaneous Coronary Intervention of Saphenous Vein Grafts From Real-World Registry Data	Nothing to Disclose
Torii	Sho	Head to Toe: Outcomes of Endovascular Interventions	Safety and Efficacy of Zilver PTX Drug Eluting Stent Implantation Following Drug Coated Balloon Inflation Versus POBA in Healthy Swine Model	Nothing to Disclose
Torii	Sho	Interventional Cardiology: Translation and Pre- Clinical Research	Endothelial Maturation and Function Following Implantation of Abluminal Coating Biodegradable Polymer Based Sirolimus-Eluting Metallic Stent Versus Conformal Coating Durable Polymer Based Everolimus Eluting Stent	Nothing to Disclose
Torii	Sho	Population Specific Cardiomyopathies: From Exomes to Databases	Racial Difference in Genetic Variants Associated With Hypertrophic Cardiomyopathy	Nothing to Disclose
Torii	Sho	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Pathological Features of Left Main Stent Thrombosis	Nothing to Disclose
Torii	Sho	Non Invasive Imaging: Expanding Clinical Applications	Dual-Energy Coronary Computed Tomography Evaluation of High- Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients: Validation with Histopathologic Gold Standard	Nothing to Disclose
Torii	Sho	Coronary Intervention: Drug Eluting Stent and Scaffolds	Validation with instopatiologic Gold Standard Long-Term Pathological Result of Everolimus-Eluting Stent Versus Silolimus-Eluting Stent and Bare Metal Stent	Nothing to Disclose
Torii	Sho	Non Invasive Imaging: Prognostic Implications of CT Angiography	Guantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Death: A Comparison to a Histologic Reference Standard	Nothing to Disclose

Last Name	First Name	Session Title	Presentation Title	Disclosures
Torii	Sho	Non Invasive Imaging: New Technologies	Optimal Method for Necrotic Core Identification in Coronary Plaque With Dual-Energy Computed Tomography: Material Decomposition and Atomic Number	Nothing to Disclose
Torii	Sho	Unusual Presentations of ACS	Molecular Autopsy of Plaque Erosion-Induced Sudden Cardiac Death in Young Adults (18-35 Years Old)	Nothing to Disclose
Toro	Saleem	Non Invasive Imaging: MR Characterization and Function	Time Varying Effect of Total Scar on Mortality in Patients With Cardiomyopathy Undergoing Cardiac Resynchronization Therapy	Nothing to Disclose
Torp-Pedersen	Christian	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Short- and Long-Term Cause of Death Following Coronary Artery Bypass Grafting in a Cohort of 33,980 Patients: A Nationwide Study	CONSULTANT FEES/HONORARIA - Brief consultations with numerous pharmaceutical companies, Steerin committee
Torp-Pedersen	Christian	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Vitamin K Antagonist or Dabigatran in Patients With Atrial Fibrillation: The Importance of Time in Therapeutic Range	memberships of studies CONSULTANT FEES/HONORARIA - Brief consultations with numerous pharmaceutical companies, Steerin committee
Torp-Pedersen	Christian	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Evidence Based Therapy and Its Relation to Workforce Attachment Following First Hospitalization for Heart Failure	memberships of studies CONSULTANT FEES/HONORARIA - Brief consultations with numerous pharmaceutical companies, Steerin committee
Torp-Pedersen	Christian	Post-CAD/MI: Making Tough Predictions About the Future	and Heart Failure in Patients With ST-Segment Elevation Myocardial	
Torre-Amione	Guillermo	Diabetes and Endothelial Dysfucntion in Heart Failure	Infarction Interleukin 18 Impairs Excitation Contraction Coupling in Cardiomyocytes and Predicts Mortality in Acute Decompensated	memberships of studies Nothing to Disclose
Toth	Peter	Advances in Cholesterol Measurement and	Heart Failure Impact of Evolocumab Therapy in Patients With Discordance	CONSULTANT FEES/HONORARIA - AbbVie,
		Management	Between LDL-C and LDL-P	Inc.,Amarin,Amgen,AstraZeneca,Gemphire,Kowa,Merck,Regene on; SPEAKER'S BUREAU - Amarin,Amgen,Kowa,Merck,Regeneron-Sanofi
Toth	Peter	Advances in Lipid Management	HDL3: A Marker of Coronary Artery Disease Severity and Inflammation in Patients on Statin Therapy	Nothing to Disclose
Toth	Peter	32. Prevention: Clinical Team 5	Suggested Reviewer	CONSULTANT FEES/HONORARIA - AbbVie, Inc., Amarin, Amgen, AstraZeneca, Gemphire, Kowa, Merck, Regene on; SPEAKER'S BUREAU - Amarin, Amgen, Kowa, Merck, Regeneron-Sanofi
Tousoulis	Dimitris	Advances in Cholesterol Measurement and Management	Beneficial Effect of Statin Therapy on Carotid Wall Temperatures in Patients With Familial Hyperlipidemia Syndromes: Results From a Randomized Trial	Nothing to Disclose
Tousoulis	Dimitris	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Prognostic Implications of Epicardial Fat Volume Quantification in Acute Pericarditis	Nothing to Disclose
Tousoulis	Dimitris	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Association of Abdominal Aortic Wall Inflammation, Hepatic Fluorodeoxyglucose Uptake AND Visceral Adipose Tissue Biological Activity in Patients With Dyslipidemias	Nothing to Disclose
Tousoulis	Dimitris	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Omega-3 Polyunsaturated Fatty Acids May Favorably Affect Inflammatory Biomarkers & Novel Indices of Left Ventricle Function in Patients With Heart Failure	Nothing to Disclose
Tousoulis	Dimitris	MicroRNAs and Beyond in Vascular Medicine	Association of Endothelial Dysfunction and Arterial Wall Elastic Properties With Systemic Inflammation in Patients With Pseudoexfoliative Glaucoma	Nothing to Disclose
Tousoulis	Dimitris	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study	Nothing to Disclose
Tousoulis	Dimitris	Diabetes and Endothelial Dysfucntion in Heart Failure	Association of Endothelial Dysfunction With Biomarkers of Inflammation, Myocardial Fibrosis and Left Ventricle Strain in Patients With Heart Failure	Nothing to Disclose
Tousoulis	Dimitris	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Vascular Function of Conduit Arteries Is Associated With Progress of Diabetic Retinopathy in Type 2 Diabetes	Nothing to Disclose
Tousoulis	Dimitris	Changing the Natural History of Valve Disease With Medical Therapy	Zoledronic Acid Inhibits Aortic Valve Calcification: A PET/CT Study	Nothing to Disclose
Tousoulis	Dimitris	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Left Ventricular Mass Versus Pulse Wave Velocity as Predictors of Coronary Artery Disease in Patients With Essential Hypertension: Data From a Greek 6-Year-Follow-Up Study	Nothing to Disclose
Tousoulis	Dimitris	Vascular Access and Hemostasis Issues	Endothelial Dysfunction Post Transradial Access Coronary Catheterization: A Clinical Study and Meta-Analysis of Published Literature	Nothing to Disclose
Tousoulis	Dimitris	Interventional Cardiology: TAVR 2	The Effect of Mixed Aortic Valve Disease in Clinical Outcomes After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Tousoulis	Dimitris	Nuclear Cardiology: Beyond Perfusion	Increased Subclinical Systemic AND Vascular Inflammation in Familial Combined Hyperlipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission	Nothing to Disclose
Tousoulis	Dimitris	Nuclear Cardiology: Beyond Perfusion	Tomography Study In Vivo Correlation of Carotid Temperatures and Pet/Fdg Uptake in Patients Undergoing Carotid Endarterectomy: Validation With	Nothing to Disclose
Tousoulis	Dimitris	Innovative Use of Echocardiography	Histology Impact on Long Term Mortality of Persistent Pulmonary Hypertension After Transcatheter Aortic Valve Implantation	Nothing to Disclose
Tousoulis	Dimitris	Advances in HCM, PPCM and Other Cardiomyopathies	Unique Characteristics of the Mitral Valve in Patients With Hypertrophic Cardiomyopathy Have Emerged Using Real-Time	Nothing to Disclose
Tousoulis	Dimitris	From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease	Three Dimensional Transesophageal Echocardiography Dietary Consumption of Olive Oil and Cardiovascular Outcome in Patients With Coronary Artery Disease	Nothing to Disclose
Tousoulis	Dimitris	Cutting Edge Vascular Medicine	Familial Combined Hyperlipidemia Is Characterized by Higher Arterial AND Hepatic Fluorodeoxyglucose Uptake Compared to Heterozygous Familial Hypercholesterolemia	Nothing to Disclose
Tousoulis	Dimitris	Innovations in Cardiovascular Risk Assessment and Reduction	Intereozogous Familian Insperioriosescrientima. Most Patients With Acute Coronary Syndromes Are Already at High Risk Prior to the Event and Lipid Management Is Underachieved Both Before and After Hospitalization: The Phaethon Study	Nothing to Disclose
Tousoulis	Dimitris	Uncovering the Intricacies of Vascular Function	The Impact of Natural Chios Mastic Supplementation on Endothelial Function and Arterial Stiffness in Smokers	Nothing to Disclose
Toutouzas	Konstantinos	Advances in Cholesterol Measurement and Management	Punction and Arterial Stiffness in Smokers Beneficial Effect of Statin Therapy on Carotid Wall Temperatures in Patients With Familial Hyperlipidemia Syndromes: Results From a Randomized Trial	SALARY - Athens Medical School
Toutouzas	Konstantinos	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Randomized Thai Association of Abdominal Aortic Wall Inflammation, Hepatic Fluorodeoxyglucose Uptake AND Visceral Adipose Tissue Biological Activity in Patients With Dyslipidemias	SALARY - Athens Medical School
Toutouzas	Konstantinos	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Carotid Plaque Inflammation in Patients With Diabetes Mellitus and Coronary Artery Disease	SALARY - Athens Medical School
Toutouzas	Konstantinos	Changing the Natural History of Valve Disease With Medical Therapy	Zoledronic Acid Inhibits Aortic Valve Calcification: A PET/CT Study	SALARY - Athens Medical School
Toutouzas	Konstantinos	Vascular Access and Hemostasis Issues	Endothelial Dysfunction Post Transradial Access Coronary Catheterization: A Clinical Study and Meta-Analysis of Published Literature	SALARY - Athens Medical School
Toutouzas	Konstantinos	Interventional Cardiology: TAVR 2	Literature The Effect of Mixed Aortic Valve Disease in Clinical Outcomes After Transcatheter Aortic Valve Replacement	SALARY - Athens Medical School

and a				<u> </u>
Last Name	First Name	Session Title	Presentation Title	Disclosures SALARY - Athens Medical School
Toutouzas	Konstantinos	Nuclear Cardiology: Beyond Perfusion	Increased Subclinical Systemic AND Vascular Inflammation in Familial Combined Hyperlipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission Tomography Study	SALARY - Ameris Medical School
Toutouzas	Konstantinos	Nuclear Cardiology: Beyond Perfusion	In Vivo Correlation of Carotid Temperatures and Pet/Fdg Uptake in Patients Undergoing Carotid Endarterectomy: Validation With Histology	SALARY - Athens Medical School
Toutouzas	Konstantinos	Innovative Use of Echocardiography	Impact on Long Term Mortality of Persistent Pulmonary Hypertension After Transcatheter Aortic Valve Implantation	SALARY - Athens Medical School
Toutouzas	Konstantinos	Cutting Edge Vascular Medicine	Familial Combined Hyperlipidemia Is Characterized by Higher Arterial AND Hepatic Fluorodeoxyglucose Uptake Compared to Heterozygous Familial Hypercholesterolemia	SALARY - Athens Medical School
Touyz	Rhian	Hypertension: Evolving Evidence, Changing Guidelines	Co-Chair	Nothing to Disclose
Townend Toyoda	Jonathan Nana	Nuclear Cardiology: Prognosis Infectious Endocarditis: Comprehensive	Serial Myocardial Perfusion Imaging in End-Stage Renal Disease Long-Term Benefits of Repair Versus Replacement for Acute Native	Nothing to Disclose Nothing to Disclose
		Perspectives FIT Clinical Decision Making: Prevention, Adult	Mitral Valve Endocarditis	,
Tozzi	Meghan	Congenital and Congenital Heart Disease	Decision-Making in Congenitally Corrected Transposition of the Great Arteries	Nothing to Disclose
Tozzi	Robert	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Decision-Making in Congenitally Corrected Transposition of the Great Arteries	Nothing to Disclose
Trabattoni	Daniela	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: From the WIN-TAVI Registry	Nothing to Disclose
Trabulsi	Almoutassim	Sex Disparity in VHD Outcomes	Contemporary Trends and Outcomes of Isolated Aortic Valve Replacement in Females in The United States: Understanding the Gender Gap	Nothing to Disclose
Trachanellis	Sofoklis	Nuclear Cardiology: Beyond Perfusion	In Vivo Correlation of Carotid Temperatures and Pet/Fdg Uptake in Patients Undergoing Carotid Endarterectomy: Validation With Histology	Nothing to Disclose
Tracy	Cynthia	Heart Rhythm Disorders: Today and Tomorrow		Nothing to Disclose
Tracy	Cynthia	Arrhythmias and Clinical EP: Devices 2		Nothing to Disclose
Tracy	Cynthia	02. Acute and Stable Ischemic Heart Disease:	Pacing Parameters Suggested Reviewer	Nothing to Disclose
Tracy	Russell	Clinical Team 4 New Insights Into Prediction and Treatment of	Collagen Turnover Markers Predict New Onset of Hypertension in	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Trager	Lena	Hypertension Arrhythmias and Clinical EP: Devices 4	Normotensive Subjects: The Multi-Ethnic Study of Atherosclerosis High Battery Impedance in the Pacemaker Dependent Patient: Early	Haematologic Technologies, Inc Nothing to Disclose
	Patrick		Recognition and Collaborative Management of InSync III CRT-P Device Failures	-
Trainor		Emerging Basic Science in Ischemic Heart Disease	Serum Prolidase Activity in Stable Coronary Artery Disease and Acute Myocardial Infarction	Nothing to Disclose
Trankle	Cory	Emerging Developments in HFpEF and Arryhthmias	Early Diastolic Mitral Annular Velocity at Peak Exercise Determines Peak Aerobic Exercise Capacity in Heart Failure With Preserved Ejection Fraction	Nothing to Disclose
Trantalis	George	Interventional Cardiology: TAVR 2	The Effect of Mixed Aortic Valve Disease in Clinical Outcomes After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Trasca	Livia	Novel Imaging and Therapies in Heart Failure	Gestational Hypertension and Preeclampsia Are Associated With Subclinical Left Ventricular Systolic and Diastolic Dysfunction	Nothing to Disclose
Travin	Mark	Nuclear Cardiology: Current Applications and Best Practices: Joint Symposium of the American Society of Nuclear Cardiology and the American College of Cardiology	Nuclear Imaging in Heart Failure	Nothing to Disclose
Travis	Arlene	Innovations in Advocacy and Patient Centered Care	Interventional Cardiology Nurses Perceptions of Their Work Environment	Nothing to Disclose
Travis	Arlene	Innovations in Advocacy and Patient Centered	Cardiology Nurse Practitioners' Structural Empowerment and Job	Nothing to Disclose
Trebnick	April	Care Making Progress in Understanding Heart Failure	Satisfaction Serial Assessment of Heart Rate and Beta Blocker Use in Chronic Heart Failure Patients With Reduced Ejection Fraction in a Large Integrated Healthcare Network	SALARY - Harvard Clinical Research Institute
Trejo Velasco	Blanca	Non Invasive Imaging: MR Scar and Perfusion	Integrated readificate Network Mean Pulmonary Artery Velocity Estimated by Cardiac Magnetic Resonance as an Early Prognostic Indicator in Heart Failure With Reduced Ejection Fraction Irrespective of Right Ventricular Function	Nothing to Disclose
Tremblay-Gravel	Maxime	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Changes in Prevalence, Progression and Outcomes of Coronary Allograft Vasculopathy Over 25 Years Following Cardiac Transplantation: A Single Center Experience	Nothing to Disclose
Tremmel	Jennifer	Understanding Spontaneous Coronary Artery Dissection (SCAD): What We Know, What We Don't Know	Co-Chair	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,Terumo; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Recor
Tremmel	Jennifer	Debates: Is There Really a Sex Difference in CV Presentation, Care, and Outcomes?	Co-Chair	INTEREST/PARTNERSHIP/PRINCIPAL - RECOI CONSULTANT FEES/HO/NORARIA - Boston Scientific,MEDTRONIC,Terumo; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Recor
Tremmel	Jennifer	Debates: Is There Really a Sex Difference in CV Presentation, Care, and Outcomes?	Launching the Debates: Understanding the Difference Between Sex and Gender	INTEREST/PARTNERSHIP/PRINCIPAL - RECOR CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,Terumo; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Recor
Tremmel	Jennifer	Angina in the Absence of Obstructive CAD. What Do We Do With These Patients?	Co-Chair	INTERESTIFART INCRESHIP INVERTED BOSTON CONSULTANT FEES/HONORARIA - Boston Scientific, MEDTRONIC, Terumo; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Recor
Tremmel	Jennifer	Angina in the Absence of Obstructive CAD. What Do We Do With These Patients?	Expert Review: Evaluating for and Treating Myocardial Bridges	INTEREST/PARTNERSHIP/PRINCIPAL - RECOI CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC, Terumo; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Recor
Tremmel	Jennifer	Challenging PCI: Tips and Tricks from the Experts	Case Presentation: Challenging Radial PCI	CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,Terumo; OWNERSHIP
Tremmel	Jennifer	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Sex Differences in the Risk Factors for Endothelial and Microvascular Dysfunction in Patients With Angina in the Absence of	INTEREST/PARTNERSHIP/PRINCIPAL - Recor CONSULTANT FEES/HONORARIA - Boston Scientific,MEDTRONIC,Terum; OWNERSHIP
Trento	Alfredo	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Obstructive Coronary Artery Disease Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries	INTEREST/PARTNERSHIP/PRINCIPAL - Recor Nothing to Disclose
Trevisan	Marco	Arrhythmias and Clinical EP: AF Miscellaneous	Association of Genetic Risk Score with Burden of Atrial Fibrillation:	Nothing to Disclose
Tricoci	Pierluigi	and Surgical Issues 03. Acute and Stable Ischemic Heart Disease:	An ENGAGE AF-TIMI 48 Analysis Suggested Reviewer	CONSULTANT FEES/HONORARIA - CSL Behring ,Merck;
		Therapy Team 2		RESEARCH/RESEARCH GRANTS - Amgen Inc., ČSL Behring ,Merck,Regenraon,Sanofi-Aventis
Triedman	John	Value, Advocacy and the Future of Adult Congenital and Pediatric Cardiology	ACC-Talk: Knowledge is Savings: Provider Behavior Changes When we Know Cost	OTHER - AltaThera Pharmaceutical,Biosense Webster, Inc.,St Jude Medical,UpToDate, Inc
Triedman	John	Congenital Heart Disease: Progress in Pediatric Heart Surgery	Prediction Tool for Congenital Heart Surgery Length of Stay	OTHER - AltaThera Pharmaceutical,Biosense Webster, Inc.,St Jude Medical,UpToDate, Inc
Trilesskaya	Marina	Novel Echocardiographic Methods for	Clinical Validation of ASE 2016 Guidelines for Evaluating Left	Nothing to Disclose
Triicookaya	Widi ii id	Assessing Cardiac Function	Ventricular Diastolic Dysfunction	=

1				<u> </u>
Last Name Trimarchi	First Name Santi	Session Title Vascular Medicine: Novel Risk Measures in	Presentation Title Body Mass Index and Acute Aortic Dissection	Disclosures Nothing to Disclose
		Arterial Diseases	.,	Ÿ
Trimarchi	Santi	Vascular Medicine: Aortic and Peripheral Artery Diseases	Predictive Factors for Rapid Aortic Growth Following Acute Type A Aortic Dissection Patients: A Study From the International Registry of Acute Aortic Dissection	Nothing to Disclose
Trimarco	Bruno	Cutting Edge Vascular Medicine	Colchicine Inhibits Platelet Aggregation <i>In Vitro </i> by Interfering With Cofilin and LIM Domain Kinase 1, the Main Kinases Involved in Cytoskeleton Rearrangement	Nothing to Disclose
Tripathi	Avnish	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Thirty-Day Readmission Rate and Cost After Percutaneous Coronary Intervention in the United States: A National Readmission Database Analysis	Nothing to Disclose
Trivedi	Chintan	Arrhythmias and Clinical EP: AF Ablation	Long-Term Outcome of Pulmonary Vein Isolation With and Without Focal Impulse and Rotor Modulation (FIRM) Mapping: Results From a Meta-Analysis	Nothing to Disclose
Trivedi	Chintan	Arrhythmias and Clinical EP: AF Ablation	Long-Term Risk of Recurrent Arrhythmia in Patients With Typical Atrial Flutter Undergoing Pulmonary Vein Antrum Isolation or Cavo- Tricuspid Isthmus Ablation With Permanent Isolation	Nothing to Disclose
Trivedi	Chintan	Atrial Fibrillation and VT: Incorporating Novel	Left Atrial Appendage Flow Velocity to Predict Persistent Left Atrial	Nothing to Disclose
Trivedi	Chintan	Risks Toward Decision Making Innovation in Practice Management, Advocacy,	Appendage Isolation Importance of Twitter During Cardiology Conferences	Nothing to Disclose
Trivi	Marcelo	and Education Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	High Sensitive Troponin T, Grace Score and Timi Score to Predict Adverse Cardiovascular Events	Nothing to Disclose
Trnkus	Amanda	Coronary Artery Disease Interventional Complexity and Complications	Non-Femoral Access Is Associated With 30-Day Mortality in Frail	Nothing to Disclose
Trocio	Jeffrey	Arrhythmias and Clinical EP: Anticoagulation Issues	Patients Undergoing Transcatheter Aortic Valve Replacement Real-World Comparison of Major Bleeding and Associated Costs Among Oral Anticoagulant-Naïve Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or	SALARY - Pfizer
Trocio	Jeffrey	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Warfarin in the US Medicare Population Real World Evaluation of Major Bleeding Risk and Costs for All Causes and Bleeding-Related Health Services Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Apixaban	SALARY - Pfizer
Trocio	Jeffrey	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	or Warfarin Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Compared to Warfarin Among Non-Valvular Atrial Fibrillation	SALARY - Pfizer
Trohman	Richard	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Patients in the US Medicare Population Mapping of the His Bundle to Recruit LBBB During Permanent Pacemaker Implantation: Insight Into the Site of LBBB	OTHER - Heart Rhythm Society; SPEAKER'S BUREAU - Daiichi Sankyo
Trohman	Richard	05. Arrhythmias and Clinical EP: Devices Team 1	Suggested Reviewer	OTHER - Heart Rhythm Society; SPEAKER'S BUREAU - Daiichi Sankyo
Trolle Lagerros	Ylva	Coronary Angiography, Intra-Vascular Imaging,	Association Between Erectile Dysfunction and Death or	Nothing to Disclose
Tromp	Jasper	Revascularization and Outcomes The Evolving World of LVADs, Transplant and	Cardiovascular Outcomes After Myocardial Infarction Chronic Kidney Disease in Asian Patients With Heart Failure	Nothing to Disclose
Tron	Christophe	Other Novel Discoveries Interventional Cardiology: PCI and TAVR in Complex Patients	Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the	Nothing to Disclose
Tron	Christophe	Interventional Cardiology: TAVR 4	Bravo-3 Randomized Trial Incidence, Predictive and Prognostic Factors of Hopitalization for Congestive Heart Failure in Patients Implanted With Tavr Between	Nothing to Disclose
Trongtorsak	Angkawipa	Heart Failure and Cardiomyopathies: Is Heart	2010 and 2014 at Rouen University Hospital Effect of Coenzyme Q10 on Left Ventricular Remodeling and	Nothing to Disclose
Truesdell	Alexander	Failure With a Normal EF for Real? 26. Interventional Cardiology: Vascular Access	Mortality in Patients With Heart Failure: A Meta-Analysis Suggested Reviewer	Nothing to Disclose
Trujillo	John	and Complications Team 1 Updates on Pulmonary Embolism	Ultrasound Accelerated Catheter Directed Lytic Therapy for	Nothing to Disclose
		Management in 2017	Management of Pulmonary Embolism: Impact of Procedural Timing on Echocardiographic Outcomes and Safety	
Trumble	Benjamin	Featured Clinical Research I	Native South American Tsimane Have the Lowest Levels of Coronary Atherosclerosis Ever Reported	Nothing to Disclose
Truong	Huu Tam	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Contemporary Use of Laser During Percutaneous Coronary Intervention: Results From the Laser Veterans Affairs (LAVA) Multicenter Registry	Nothing to Disclose
Truong	Quynh	Challenges in Cardiac CT: Case-Based Discussions	Co-Chair	CONSULTANT FEES/HONORARIA - Aralez Pharmaceuticals,Heartflow; RESEARCH/RESEARCH GRANTS - Qi Imaging
Truong	Quynh	Making Progress in Understanding Heart Failure	Circulating Concentrations of Orexin A Are Associated With Left Ventricular Reverse Remodeling and Clinical Outcomes Following Cardiac Resynchronization Therapy	CONSULTANT FEES/HONORARIA - Aralez Pharmaceuticals, Heartflow; RESEARCH/RESEARCH GRANTS - Qi Imaqinq
Truong	Quynh	FIT Clinical Decision Making: Arrhythmias and Clinical Electrophysiology	A Novel Complication and Treatment Strategy in Pacemaker- Induced Superior Vena Cava Syndrome	CONSULTANT FEES/HONORARIA - Aralez Pharmaceuticals, Heartflow; RESEARCH/RESEARCH GRANTS -
Tsai	Emily	ACC Research Awards	Therapeutic Potential of Myocardial SolubleGuanylyl Cyclase Stimulation in Right Ventricular Dysfunction: Microdomains ofNovel Cardioprotective cGMP Signaling Mechanisms	Nothing to Disclose
Tsai	Shane	Adult Patients With Congenital Heart Disease:	Decreased Hepatic Elasticity in Young Adults After Biventricular	Nothing to Disclose
Tsai	Shirling	How Do They Compare? Head to Toe: Outcomes of Endovascular	Repair of Congenital Heart Disease Association of Cigarette Smoking With Procedural Cost of Lower	Nothing to Disclose
Tsai	Thomas	Interventions 26. Interventional Cardiology: Vascular Access	Extremity Endovascular Intervention Suggested Reviewer	Nothing to Disclose
Tsalamandris	Sotirios	and Complications Team 1 Heart Failure and Cardiomyopathies: Is Heart	Omega-3 Polyunsaturated Fatty Acids May Favorably Affect	Nothing to Disclose
		Failure With a Normal EF for Real?	Inflammatory Biomarkers & Novel Indices of Left Ventricle Function in Patients With Heart Failure	
Tsalamandris	Sotirios	MicroRNAs and Beyond in Vascular Medicine	Association of Endothelial Dysfunction and Arterial Wall Elastic Properties With Systemic Inflammation in Patients With Pseudoexfoliative Glaucoma	Nothing to Disclose
Tsalamandris	Sotirios	Diabetes and Endothelial Dysfucntion in Heart Failure	Association of Endothelial Dysfunction With Biomarkers of Inflammation, Myocardial Fibrosis and Left Ventricle Strain in Patients With Heart Failure	Nothing to Disclose
Tsalamandris	Sotirios	From Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease	Dietary Consumption of Olive Oil and Cardiovascular Outcome in Patients With Coronary Artery Disease	Nothing to Disclose
Tsalamandris	Sotirios	Uncovering the Intricacies of Vascular Function	The Impact of Natural Chios Mastic Supplementation on Endothelial Function and Arterial Stiffness in Smokers	Nothing to Disclose
Tsang	Michael	Innovative Use of Echocardiography	The Association Between Echocardiographic Laboratory Accreditation and the Quality of Imaging and Reporting	Nothing to Disclose
Tsao	Connie	Innovative Use of Echocardiography	Effect of Left Atrial Remodeling on Prediction of Incident Atrial Fibrillation With CHARGE-AF Score: Data From the Framingham Offspring Study	Nothing to Disclose
Tsao	Connie	Innovative Use of Echocardiography	Onspring Study Left Atrial Function Index as a Predictor of Cardiovascular Disease and Atrial Fibrillation: Data From the Framingham Offspring Study	Nothing to Disclose
Tschiltz	Nancy	Interdisciplinary Cardiovascular Team	Multidisciplinary Cardiovascular Team Review Captures Preclinical	Nothing to Disclose
L	j	Collaboratives in Care	Disease	

Control of the contro				<u> </u>
Last Name Tschiltz	First Name Nancy	Session Title Diabetes and Other Issues in Cardiovascular	Presentation Title Arresting Insulin Resistance With an Integrative Health Intervention	Disclosures Nothing to Disclose
Tseng	Andrew	Prevention Arrhythmias and Clinical EP: Devices 3	Prospective Cryoballoon Dosing Study Based on Time-to-Isolation	Nothing to Disclose
Tseng	Zian	The Story of the Adult Congenital Heart	Prevalence and Predictors of Atrial Tachyarrhythmias in Adult	RESEARCH/RESEARCH GRANTS - NIH/NHLBI R01 HL1020
Tseng	Zian	Disease Patient and EP Redefining the "F" Word	Fontan Patients Prevalence and Predictors of Pacemaker Placement in Adult	RESEARCH/RESEARCH GRANTS - NIH/NHLBI R01 HL1020
Tsiachris	Dimitris	Novel Mechanical Devices for the Treatment	Fontan Patients Blood Pressure Response to Catheter-Based Renal Sympathetic	CONSULTANT FEES/HONORARIA - Johnson and Johnson;
Islacilis	Diffillitis	and Assessment of Hypertension	Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study	OTHER - Boston Scientific,MEDTRONIC
Tsiachris	Dimitris	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Predictors of New-Onset Atrial Fibrillation in Essential Hypertensives	CONSULTANT FEES/HONORARIA - Johnson and Johnson; OTHER - Boston Scientific,MEDTRONIC
Tsiamis	Eleftherios	Advances in Cholesterol Measurement and Management	Beneficial Effect of Statin Therapy on Carotid Wall Temperatures in Patients With Familial Hyperlipidemia Syndromes: Results From a	Nothing to Disclose
Tsiamis	Eleftherios	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Randomized Trial Association of Abdominal Aortic Wall Inflammation, Hepatic Fluorodeoxyglucose Uptake AND Visceral Adipose Tissue Biological	Nothing to Disclose
Tsiamis	Eleftherios	Vascular Access and Hemostasis Issues	Activity in Patients With Dyslipidemias Endothelial Dysfunction Post Transradial Access Coronary	Nothing to Disclose
i siailis	Liettrierios	vasculai Access and Hemostasis Issues	Catheterization: A Clinical Study and Meta-Analysis of Published Literature	Nothing to Disclose
Tsiamis	Eleftherios	Interventional Cardiology: TAVR 2	The Effect of Mixed Aortic Valve Disease in Clinical Outcomes After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Tsiamis	Eleftherios	Nuclear Cardiology: Beyond Perfusion	Increased Subclinical Systemic AND Vascular Inflammation in Familial Combined Hyperlipidemia Compared to Heterozygous Hypercholesterolemia: Insights From a Positron Emission Tomography Study	Nothing to Disclose
Tsiamis	Eleftherios	Innovative Use of Echocardiography	Impact on Long Term Mortality of Persistent Pulmonary	Nothing to Disclose
Tsiamis	Eleftherios	Cutting Edge Vascular Medicine	Hypertension After Transcatheter Aortic Valve Implantation Familial Combined Hyperlipidemia Is Characterized by Higher	Nothing to Disclose
			Arterial AND Hepatic Fluorodeoxyglucose Uptake Compared to Heterozygous Familial Hypercholesterolemia	-
Tsigkou	Vasiliki	Uncovering the Intricacies of Vascular Function	The Impact of Natural Chios Mastic Supplementation on Endothelial Function and Arterial Stiffness in Smokers	Nothing to Disclose
Tsigoulis	Michelle	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Concomitant Use of Antiplatelet and Oral Anticoagulation Among Patients With Atrial Fibrillation: Insights From the Prospective	Nothing to Disclose
Tsimikas	Sotirios	Young Investigator Awards Competition: Basic	SPRINT-AF Registry Cell-Specific Discrimination of Desmosterol and Desmosterol	OTHER - Patents via UCSD; SALARY - Ionis Pharmaceuticals
Tsimikas	Sotirios	and Translational Science Traditional and Novel Factors Used to Assess	Mimetics Confers Selective Regulation of LXR and SREBP Pathways in Macrophages Relationship of Biomarkers of Oxidized Lipoproteins to Ethnicity,	OTHER - Patents via UCSD; SALARY - Ionis Pharmaceuticals
TSITTIKAS	Sourios	the Risk of, and Used for the Treatment of, Coronary Artery Disease	Subclinical Atherosclerosis and Cardiovascular Events Over a 10.5 Year Follow-Up in the Dallas Heart Study	
Tsimikas	Sotirios	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Pro-Inflammatory Interleukin-1 Genotypes Affect the Association of C-Reactive Protein for Angiographically Determinedcoronary Artery Disease and Cardiovascular Events	OTHER - Patents via UCSD; SALARY - Ionis Pharmaceuticals
Tsimploulis	Apostolos	Making Progress in Understanding Heart Failure	Orthopnea or Paroxysmal Nocturnal Dyspnea in Older Adults Without Prevalent Heart Failure is a Predictor, but Not an Independent Risk Factor for Incident Heart Failure: Insights From the Cardiovascular Health Study	Nothing to Disclose
Tsimploulis	Apostolos	Heart Failure and Cardiomyopathies: Heart	Heart Failure Hospitalization (HFH) Despite Digoxin Therapy Versus	Nothing to Disclose
		Failure Is Just a Revolving Door	No HFH Despite Placebo in the Digitalis Investigation Group (DIG) Trial: Insights Into Risk Factors for HFH in HF and Reduced Ejection Fraction (HFrEF)	
Tsioufis	Konstantinos	Systemic Organ Involvement in Heart Failure:	Worsening Renal Function in Acute Heart Failure: Is it Really Bad?	Nothing to Disclose
		International Perspectives From the German Cardiac Society, Hellenic Society of Cardiology, and American College of Cardiology		
Tsioufis	Konstantinos	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study	Nothing to Disclose
Tsioufis	Konstantinos	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Insights on Diastolic Dysfunction of Treated Hypertensive Patients: Focusing on Hypertension Control & Treatment Resistance	Nothing to Disclose
Tsioufis	Konstantinos		Predictors of New-Onset Atrial Fibrillation in Essential Hypertensives	Nothing to Disclose
Tsioufis	Konstantinos	Elevated Blood Pressure 33. Prevention: Hypertension Team 1	Suggested Reviewer	Nothing to Disclose
Tsuboi	Shuta	Unusual Presentations of ACS	Combined Serum Albumin and C-Rective Protein Levels Predict Long-Term Outcomes in Patients With Coronary Artery Disease	Nothing to Disclose
Tsuboi	Shuta	CAD in Unique Patient Populations	After a First Percutaneous Coronary Intervention Prognostic Impact of Geriatric Nutritional Risk Index in Patients	Nothing to Disclose
Tsuda	Ryan	Coronary Intervention in Interventional	Undergoing Percutaneous Coronary Intervention Contemporary Use of Laser During Percutaneous Coronary	Nothing to Disclose
		Cardiology: Advanced Device Use	Intervention: Results From the Laser Veterans Affairs (LAVA) Multicenter Registry	-
Tsuda	Takeshi	The Story of the Adult Congenital Heart Disease Patient and EP	Acquired Long-Term Cardiac Rhythm and Conduction Abnormalities After Arterial Switch Operation	Nothing to Disclose
Tsujita	Kenichi	Advances in Chronic Total Occlusion Intervention	Impact of Target Vessel on Long-Term Cardiac Mortality After Successful Percutaneous Coronary Intervention for Chronic Total	Nothing to Disclose
Tsujita	Kenichi	The Evolving World of LVADs, Transplant and	Occlusion: Japanese Multicenter Registry B-Type Natriuretic Peptide Levels Is a Useful Prognostic Marker in	Nothing to Disclose
Tsutsui	Rayji	Other Novel Discoveries Valvular Heart Disease: Mitral Valve Disease	the Patients With Eosinophilic Granulomatosis With Polyangiitis Warfarin Use and Progression of Mitral Annular Calcification	Nothing to Disclose
Tsutsui	Rayji	FIT Clinical Decision Making: Heart Failure and	Pulmonary Hypertension in Left Atrial Sarcoma	Nothing to Disclose
Tueroff	Anke	Pulmonary Hypertension The Evolving World of LVADs, Transplant and Other Navel Discoveries	Sleep Duration and Quality in Heart Failure Patients	Nothing to Disclose
Tufaro	Vincenzo	Other Novel Discoveries Emerging Applications of Echocardiography	Functional and Hemodynamic Response During Exercise in Heart	Nothing to Disclose
Tumolo	Alexis	Teaching with Intent: Secrets from the Masters	Failure Intermediate Versus Reduced Ejection Fraction Case Presenter: Small Group Case Conference	Nothing to Disclose
Tumolo	Alexis	III Feeling the Pressure - Tough Cases in	My 28 yo Pregnant Female with Blood Pressure of 158/92 mmHg at	-
		Hypertension	16 Weeks Gestation. I Need Help!	-
Tumolo	Alexis	Atrial Fibrillation and VT: Unique Populations and Solutions	Presence of Mid-Myocardial Substrate Is Associated With Need for Multiple Ablations in Patients With Non-Ischemic Cardiomyopathy and Ventricular Arrhythmias	Nothing to Disclose
Tumolo	Alexis	FIT Clinical Decision Making: Arrhythmias and	Atrio-Ventricular Pacing Dysynchrony Manifest as Pseudo-Pulsus	Nothing to Disclose
Tumolo	Alexis	Electrophysiology Innovative Approaches for Reducing Risk and	Paradoxus Early Recurrence of Ventricular Tachycardia Predicts Increased	Nothing to Disclose
Tumolo	Alexis	Improving Outcomes With Ablation Atrial Fibrillation and VT: Incorporating Novel	Mortality Among Patients With Severe Heart Failure Safety and Outcomes of Catheter Ablation for Treatment of	Nothing to Disclose
		Risks Toward Decision Making	Refractory Ventricular Arrhythmias in Patients With Advanced Heart Failure	

1				
Last Name Tumscitz	First Name Carlo	Session Title Refining PCI Technique and Outcomes	Presentation Title Comparison of Verapamil Versus Heparin Therapy on Procedural Success During Transradial Coronary Procedures (Vermut Study)	Disclosures Nothing to Disclose
Tun	Han	Arrhythmias and Clinical EP: Anticoagulation Issues	Does Stroke Risk Influence the Decision to Anticoagulate Post Percutaneous Coronary Intervention Patients With Atrial Fibrillation:	Nothing to Disclose
Tung	Roderick	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	A Review of 3850 Patients Implementation of a Wideband Late Gadolinium Enhancement Cardiac Magnetic Resonance Protocol to Improve Assessment of Myocardial Scar in Patients With Implantable Cardioverter	OTHER - St Jude Medical
Tung	Roderick	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Defibrillators Incidence, Predictors, and Outcome of Postoperative Atrial Fibrillation in Patients Receiving Continuous Flow Left Ventricular	OTHER - St Jude Medical
Tung	Roderick	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Assist Devices Electroanatomic Characterization of Hypoplastic Left Heart Ventricular Tachycardia: Transaortic Transmembranous Ventricular	OTHER - St Jude Medical
Tung	Roderick	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Septal Approach via Magnetic Navigation Suggested Reviewer	OTHER - St Jude Medical
Tunhasiriwet	Anusith	Updates on Risk Factors for Cardiovascular Disease	Association Between Short and Long Sleep Duration and Cardiovascular Outcomes? A Systematic Review and Meta-Analysis	Nothing to Disclose
Tuppo	Ehab	Acute Coronary Syndromes, Diagnosis,	Steep Decrease in the Rate of Myocardial Infarction From 2000 to	Nothing to Disclose
Tuppo	Ehab	Management and Outcomes Unusual Presentations of ACS	2008 Decrease in the Rate of MI Case Fatality From 2000 to 2014	Nothing to Disclose
Turagam	Mohit	Arrhythmias and Clinical EP: Devices 1	Implantable Cardioverter Defibrillator for the Prevention of Mortality in Non-Ischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Turagam	Mohit	Arrhythmias and Clinical EP: Devices 1	Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients Undergoing Cardiac Implantable Electronic Device Implantation: A Meta-Analysis	Nothing to Disclose
Turagam	Mohit	Interventional Cardiology: Translation and Pre- Clinical Research	Intramyocardial Autologous CD34+ Cell Therapy for Refractory Angina: A Meta-Analysis	Nothing to Disclose
Turagam	Mohit	Arrhythmias and Clinical EP: Devices 2	Impact of Left Atrial Appendage Occlusion on Left Atrial Function	Nothing to Disclose
Turagam	Mohit	Arrhythmias and Clinical EP: Devices 2	Real World Battery Longevity of St. Jude Medical Implantable Cardioverter-Defibrillators Included in the Advisory for Premature Battery Depletion	Nothing to Disclose
Turagam	Mohit	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Angiography Versus Optical Coherence Tomography Guided Percutaneous Coronary Intervention: A Meta-Analysis of Clinical Outcomes	Nothing to Disclose
Turagam	Mohit	Arrhythmias and Clinical EP: Anticoagulation Issues	Meta-Analysis on the Efficacy and Safety of New Oral Anticoagulants Compared With Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation	Nothing to Disclose
Turagam	Mohit	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Left Atrial Appendage Ligation With Lariat Device: A Systematic Review and Meta-Analysis	Nothing to Disclose
Turagam	Mohit	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Efficacy of Catheter Ablation of Atrial Fibrillation in the Setting of Systolic Dysfunction: A Meta-Analysis of Randomized Control Trials	Nothing to Disclose
Turagam	Mohit	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Safety Profiles of Percutaneous Left Atrial Appendage Closure Devices: An Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database From 2009 - 2016	Nothing to Disclose
Turakhia	Mintu	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Success Rates by Ablation Lesion Set of Catheter Ablation for Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta- Analysis Study Cohort	CONSULTANT FEES/HONORARIA - Medtronic Inc., Precision Health Economics, St Jude Medical, St. Jude Medical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - thryva_Zipline Medical; RESEARCH/RESEARCH GRANTS - Medtronic Inc., Sentreheart Inc
Turakhia	Mintu	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Secular Trends in Reported Success Rates of Catheter Ablation for Non-Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort	CONSULTANT FEES/HONORARIA - Medtronic Inc., Precision Health Economics, St Jude Medical, St. Jude Medical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - thryva. Zipline Medical; RESEARCH/RESEARCH GRANTS - Medtronic Inc., Sentreheart Inc
Turakhia	Mintu	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Inclusion of Women in Studies of Catheter Ablation for Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort	CONSULTANT FEES/HONORARIA - Medtronic Inc, Precision Health Economics, St Jude Medical, St. Jude Medical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - thryva, Zipline Medical; RESEARCH/RESEARCH GRANTS - Medtronic Inc, Sentreheart Inc
Turek	Joseph		MCS in ACHD: Can We Overcone the Anatomic Barriers?	CONSULTANT FEES/HONORARIA - HeartWare
Turi	Zoltan	in Congenital Heart Disease 26. Interventional Cardiology: Vascular Access	Suggested Reviewer	DATA SAFETY MONITORING BOARD - Mitralign; OTHER -
Turk	Ahmad	and Complications Team 2	The Way to a Man's Heart: Through His Quadriceps	MEDTRONIC,St. Jude Medical Nothing to Disclose
Turk	Ahmad	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	A Rare Cause of Myocardial Injury in a Patient With Systemic Lupus Erythematosus: Hydroxychloroquine Induced Cardiomyopathy	Nothing to Disclose
Turk	Ahmad	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Blocked Artery, or Blocked Bowel?!	Nothing to Disclose
Turner	Ellen	Interdisciplinary Cardiovascular Team Collaboratives in Care	Multidisciplinary Cardiovascular Team Review Captures Preclinical Disease	Nothing to Disclose
Turner	Ellen	Diabetes and Other Issues in Cardiovascular	Arresting Insulin Resistance With an Integrative Health Intervention	Nothing to Disclose
Turner	Jeffrey	Prevention Arrhythmias and Clinical EP: Devices 3	Cryoballoon Versus Radiofrequency Ablation of Atrial Fibrillation: In- Lab Complication Rates at a Large Volume Electrophysiology	Nothing to Disclose
Turner	Melanie	Innovations in Advocacy and Patient Centered	Center Status of Early Career Academic Cardiology: A Global Perspective	Nothing to Disclose
Turner	Stuart	Care Heart Failure and Cardiomyopathies: Is Heart	Heart Failure With Reduced Ejection Fraction Care Patterns in the	SALARY - Novartis Pharmaceuticals corporation
Turner	Stuart	Failure With a Normal EF for Real? Heart Failure and Cardiomyopathies: Is Heart	Outpatient Practice Setting: Initial Findings From CHAMP-HF Treatment Patterns and Resource Use of Heart Failure Patients on	SALARY - Novartis Pharmaceuticals corporation
		Failure With a Normal EF for Real?	Medicaid in Five States in the US	
Turpie	Alexander	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Treatment and Outcomes of Patients With Nonvalvular Atrial Fibrillation According to Guideline-Defined Anticoagulation Thresholds: Results From the GARFIELD-AF Registry	CONSULTANT FEES/HONORARIA - Bayer Schering Pharma; Astellas; Portola; Takeda; Eisai; Pfizer
Turpie	Alexander	Arrhythmias and Clinical EP: Anticoagulation Issues	Real-World Versus Randomized Trial Outcomes in Similar Populations of Rivaroxaban-Treated Patients With Nonvalvular Atrial Fibrillation in ROCKET AF and XANTUS	CONSULTANT FEES/HONORARIA - Bayer Schering Pharma; Astellas; Portola; Takeda; Eisai; Pfizer
Turpie	Alexander	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Early Mortality in Patients With New Onset Atrial Fibrillation: Results From the GARFIELD-AF Registry	CONSULTANT FEES/HONORARIA - Bayer Schering Pharma; Astellas; Portola; Takeda; Eisai; Pfizer
Turrentine	Mark	Surgical and Transcatheter Valve Therapy for Congenital Heart Disease	Debate: The Ross is the Best Aortic Valve Replacement for Adolescents (Pro)	Nothing to Disclose
Tuwairqi	Khaled	Novel Developments in Acute Coronary Syndromes	Central Fractional Pulse Pressure Predicts Cardiac Power Index in Patients With Acute Coronary Syndrome	Nothing to Disclose

Contract of the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Tuzcu	E. Murat	Featured Clinical Research II: Interventional	Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data	Nothing to Disclose
Tuzcu	E. Murat	Featured Clinical Research II: Interventional	Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis From the STS/ACC TVT Registry	Nothing to Disclose
Tuzcu	E. Murat	Controversies Surrounding TAVR: 2017 and	Panelist Panelist	Nothing to Disclose
Tuzcu	E. Murat	Beyond Interventional Cardiology: TAVR 2	Outcomes of Transcatheter Aortic Valve Replacement Without Balloon Predilation: A Systematic Review and Meta-Analysis	Nothing to Disclose
Tuzcu	E. Murat	Interventional Cardiology: TAVR 3	Clinical Outcomes of Patients With Pacemaker Implantation After Transcatheter Aortic Valve Replacement: Meta-Analysis and Meta-	Nothing to Disclose
Tuzcu	Murat	Advances in Cholesterol Measurement and Management	Regression Atherogenic Lipoprotein Variability Correlates With Coronary Atheroma Progression: Insights From Serial Intravascular	Nothing to Disclose
Tweddell	James	Congenital Heart Disease: Advances in Quality Improvement for Pediatric Cardiac Care	Ultrasonography Revenue Return on Investment for Center Involvement in a Quality Improvement Collaborative for a Rare Disease: National Pediatric	OTHER - Cor Matrix
Tweddell	James	Congenital Heart Disease Surgery: Updates and Innovations	Cardiology Quality Improvement Collaborative Anatomic Repair of Congenitally Corrected Transposition Results in Excellent Survival and Functional Status at Intermediate Term	OTHER - Cor Matrix
Tweddell	James	Finding Out What Works in Pediatric and Congenital Heart Disease	Follow-Up Reduction in Interstage Growth Failure in Infants With Hypoplastic Left Heart Syndrome and Impact on Stage 2 Outcomes: A Report From the National Pediatric Cardiology Quality Improvement Collaborative	OTHER - Cor Matrix
Tweet	Marysia	PCI Strategies and Outcomes Unique to Women	Postpartum and Pregnancy-Associated Spontaneous Coronary Artery Dissection: Presentation, Clinical Features and Outcomes	Nothing to Disclose
Tweet	Marysia	FIT Clinical Decision Making Reviewers 3	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Twerenbold	Raphael	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Direct Comparison of Cardiac Myosin-Binding Protein C to Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction	Nothing to Disclose
Tworetzky	Wayne	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Early Hemodynamic Changes After Fetal Aortic Stenosis Valvuloplasty Are Associated With Biventricular Circulation at Birth	Nothing to Disclose
Tworetzky	Wayne	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Melody Valve Placement for Mitral Valve Dysplasia Syndrome	Nothing to Disclose
Tyagi	Gaurav	Interventional Cardiology: TAVR 2	Impact of the Presence of Coronary Artery Disease and Timing of Revascularization on Outcomes of Patients Undergoing Trans- Catheter Aortic Valve Replacement: Insights From STS/ACC TVT Registry	Nothing to Disclose
Tybjaerg-Hansen	Anne	Dyslipidemias: A Potpourri of Complexities	Remnant Cholesterol: Overlooked and Under-appreciated?	Nothing to Disclose
Tyler Tyler	Jaret Jaret	Arrhythmias and Clinical EP: Devices 2 Arrhythmias and Clinical EP: Devices 3	Comprehensive Strategy to Reduce the Incidence of Lead Dislodgment for Cardiac Implantable Electronic Devices Cryoballoon Versus Radiofrequency Ablation of Atrial Fibrillation: In-	Nothing to Disclose Nothing to Disclose
			Lab Complication Rates at a Large Volume Electrophysiology Center	-
Tyler	Jaret	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Misleading Leads: Hemothorax From Very Late Spontaneous Coronary Sinus Lead Perforation 13 Years After CRT-D Implantation	Nothing to Disclose
Tyson	Clark	Innovation in Practice Management, Advocacy, and Education	Early Defibrillation by First-Responders in Relation to Fire Stations: Optimal Benefit According to Location	Nothing to Disclose
Tzani	Aspasia	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Proteomics Discovery of Biomarkers for Atrial Fibrillation in Patients With Cardiovascular Disease	Nothing to Disclose
Tzanis	Georgios	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Carotid Plaque Inflammation in Patients With Diabetes Mellitus and Coronary Artery Disease	Nothing to Disclose
Tziakas	Dimitrios	Interventional Complexity and Complications	Comparison of CIN Risk Prediction Models: A Prospective Cohort Study	Nothing to Disclose
Tzikas	Apostolos	Fundamentals of LAA Closure	Panelist	CONSULTANT FEES/HONORARIA - St. Jude Medical Inc.
Tzikas	Apostolos	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Previous Major Gastrointestinal Bleeding: Insight From the Amplatzer Cardiac Plug Multicenter Registry	CONSULTANT FEES/HONORARIA - St. Jude Medical Inc.
Tzou	Wendy	Atrial Fibrillation and VT: Unique Populations and Solutions	Presence of Mid-Myocardial Substrate Is Associated With Need for Multiple Ablations in Patients With Non-Ischemic Cardiomyopathy and Ventricular Arrhythmias	CONSULTANT FEES/HONORARIA - Biosense Webster, Boston Scientific, MEDTRONIC
Tzou	Wendy	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Early Recurrence of Ventricular Tachycardia Predicts Increased Mortality Among Patients With Severe Heart Failure	CONSULTANT FEES/HONORARIA - Biosense Webster, Boston Scientific.MEDTRONIC
Tzou	Wendy	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Safety and Outcomes of Catheter Ablation for Treatment of Refractory Ventricular Arrhythmias in Patients With Advanced Heart Failure	CONSULTANT FEES/HONORARIA - Biosense Webster, Boston Scientific, MEDTRONIC
Tzou	Wendy	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Biosense Webster,Boston Scientific,MEDTRONIC
Uddin	Poulina	Redefining the "F" Word	Atrial Diastolic "Suction": An Important Contributor to Fontan Circulation	Nothing to Disclose
Udelson	James	Featured Clinical Research I	Co-Chair	CONSULTANT FEES/HONORARIA - Lantheus Medical Imaging,Stealth; DATA SAFETY MONITORING BOARD - gilead,GSK; OTHER - Abbott Laboratories,Editor - Circulation Heart Failure - AHA,Pfizer/GSK
Udelson	James	Diabetes and Heart Failure: Are We Hitting The Sweet Spot	Co-Chair	CONSULTANT FEES/HONORARIA - Lantheus Medical Imaging,Steatht; DATA SAFETY MONITORING BOARD - gilead,GSK; OTHER - Abbott Laboratories,Editor - Circulation Heart Failure - AHA,Pfizer/GSK
Udelson	James	New Perspectives on CAD Risk Factors	Discordances Between Predicted and Actual Risk of Adverse Events in Obese Patients With Suspected Cardiac Ischemia: Insights From the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain)	CONSULTANT FEES/HONORARIA - Lantheus Medical Imaging,Steatht; DATA SAFETY MONITORING BOARD - gilead,GSK; OTHER - Abbott Laboratories,Editor - Circulation Heart Failure - AHA,Pfizer/GSK
Udelson	James	30. Non Invasive Imaging: Nuclear Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Lantheus Medical Imaging, Steatht; DATA SAFETY MONITORING BOARD - gilead, GSK, OTHER - Abbott Laboratories, Editor - Circulation Heart Failure - AHA, Pfzer/GSK
Ueberham	Laura		Isolated Cardiac Sarcoidosis Mimicking Hypertrophic Cardiomyopathy	Heart Failure - AHA,Pfizer/GSK Nothing to Disclose
Ueda	Hiroshi	Pulmonary Hypertension Interventional Cardiology: Stent Failure	Multimodality Intravascular Imaging to Evaluate Plaque	Nothing to Disclose
Ueda	Ikuko	Analysis by Intravascuar Imaging Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Characteristics in Patients With Diabetes Mellitus Compliance to Updated AHA/ACC Quality Measures Among Patients With Atrial Fibrillation in Japan and Its Association With	Nothing to Disclose
Ueda	lkuko	Unusual Presentations of ACS	Their Quality of Life C-Reactive Protein in Non-ST Elevation Myocardial Infarction	Nothing to Disclose
			Patients Is Useful in Improving Discrimination of Conventional Risk Score: A Report From Multicenter PCI Registry	

Contract of the second				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Uehara	Masae	Non Invasive Imaging: New Technologies	A Novel 3D Myocardial Strain Determined by Existing 320-Slice CT	Nothing to Disclose
			Data Enhances Visual Assessment of Late Enhancement on CT for the Detection of Left Ventricular Myocardial Fibrosis in Non Ischemic Cardiomyopathy	
Uehara	Masae	Non Invasive Imaging: New Technologies	Improved Diagnosis of Detection of Late Enhancement in Left	Nothing to Disclose
			Ventricular Myocardium Using 2nd Generation 320-Slice CT Reconstructed With FIRST in Non-Ischemic Cardiomyopathy	3
Ueki	Yasushi	Unusual Presentations of ACS	Clinical Characteristics and In-Hospital Mortality of Very Elderly Patients With Cardiovascular Shock in Japan: The Results From	Nothing to Disclose
Uemura	Shiro	Interventional Complexity and Complications	Japanese Circulation Society Shock Registry Impact of Institutional and Operator Volume on Short-Term	CONSULTANT FEES/HONORARIA - Nara Medical University
Genura	Sillo	interventional complexity and complexions	Outcomes of Percutaneous Coronary Intervention: A Report From Japanese Nationwide Registry	CONSULTANT I LEGITIONONANIA - INdia injedical University
Ugoeke	Nene	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	In-Hospital Mortality in Percutaneous Coronary Stenting of Bifurcation Versus Non-Bifurcation Lesions in Acute ST-Elevation	Nothing to Disclose
Ugwu	Justin	Diabetes and Other Issues in Cardiovascular	Myocardial Infarction Experience With Application of 2014 American College of	Nothing to Disclose
- Ogwa	ousuii	Prevention	Cardiology/American Heart Association Guideline for Pre-Operative Cardiovascular Evaluation for Non-Cardiac Surgery in the Primary Care Setting	Housing to Discisse
Ukaigwe	Anene	Vascular Access and Hemostasis Issues	Efficacy and Safety of Transulnar Compared to Transradial Arterial Access in Patients Undergoing Coronary Angiography: A Systematic	Nothing to Disclose
Ullah	Rafath	Interventional Cardiology: PCI and TAVR in Complex Patients	Review and Meta-Analysis The Risk of Adverse Coronary Events Is Higher in Patients With Severe Obstructive Sleep Apnea Following Percutaneous Coronary	Nothing to Disclose
Ullah	Rafath	Mechanisms of Vascular Inflammation in	Intervention Comparative Study on Catheter-Directed Thrombolysis - Continuous	Nothing to Displace
Ollan	Raidui	Atherogenesis	Continuous Plasminogen Activator Versus Angiojet Catheter Power Pulse Spray Rheolytic Thrombectomy Outcome Study: Single-Center Experience	Nothing to Disclose
Ullal	Ajayram	Interventional Cardiology: TAVR 1	Baseline Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Increased Mortality After	Nothing to Disclose
Umapathi	Priya	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Transcatheter Aortic Valve Replacement HeartMate II Pump Stops: The Short to Short Phenomenon	Nothing to Disclose
Umbarger	Linda	Arrhythmias and Clinical EP: AF Miscellaneous	CHADS2 Score Predicts Outcomes of Radiofrequency Catheter	Nothing to Disclose
Ummat	Bianca	and Surgical Issues Arrhythmias and Clinical EP: Devices 2	Ablation in Patients With Atrial Fibrillation Chagas Heart Disease: A Comparison of Clinical and Intraoperative	Nothing to Disclose
		· ·	Pacing Parameters	-
Ummat	Bianca	FIT Clinical Decision Making: Multimodality Imaging	Bridging the Gap: Multimodality Imaging in a 56 Year Old Patient With Sudden Death	Nothing to Disclose
Undemir	Cenap	Interventional Cardiology: TAVR 1	"Cusp Overlap" View Facilitates Accurate Fluoro-	Nothing to Disclose
Undemir	Cenap	Structural Heart Interventions: Focus on Mitral	Guided Implantation of Self-Expanding Valve in TAVR Change in Aortomitral Annular Angle and Anterior Mitral Valve	Nothing to Disclose
		Valve, Left Atrial Appendage and HOCM	Leaflet Length After Transcatheter Aortic Valve Replacement: Implications for Transcatheter Mitral Valve Replacement?	-
Underwood	Stephen	Nuclear Cardiology: Quality	Automatic SPECT Analysis Compared to Expert Visual Scoring for the Detection of Coronary Artery Disease	CONSULTANT FEES/HONORARIA - General Electric HealthCare,Stock option, Rapidscan Inc
Ungar	Leo	Young Investigator Awards Competition:	Racial Differences in Quality of Care and Outcomes After Acute	Nothing to Disclose
Ungi	Imre	Outcomes Research Highlighted Original Research: Interventional	Coronary Syndrome Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome	Nothing to Disclose
Ungi	iiiie	Cardiology and the Year in Review	After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	Nothing to disclose
Ungi	Imre	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Contemporary Use of Laser During Percutaneous Coronary Intervention: Results From the Laser Veterans Affairs (LAVA)	Nothing to Disclose
Ungi	Imre	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Between Site Operators and Angiographic Core Laboratory	Nothing to Disclose
Ungi	Imre	Advances in Chronic Total Occlusion Intervention	Readers: Insights From the EXCEL Trial The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From	Nothing to Disclose
Ungi	Imre	Refining PCI Technique and Outcomes	a Contemporary Multicenter Registry Outcomes of PCI Versus CABG in Left Main Disease According to	Nothing to Disclose
			SYNTAX Score by Site Versus Angiographic Core Laboratory Assessment: Insights From the EXCEL Trial	
Upadhya	Bharathi	Valvular Heart Disease: Aortic Stenosis	Surgical Risk Scores Outweigh Echocardiographic Severity of Aortic Stenosis for Determining Prognosis in Patients With Low Gradient Severe Aortic Stenosis and Preserved Left Ventricular Function	Nothing to Disclose
Upadhyay	Gaurav	05. Arrhythmias and Clinical EP: Devices	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Biosense
I I a a dib	Dani	Team 2		Webster, Biotronik, Boston Scientific, MEDTRONIC; RESEARCH/RESEARCH GRANTS - Biotronik, MEDTRONIC
Upadhyay	Rani	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Idiopathic Effusive Constrictive Pericarditis in a Patient With Cystic Fibrosis: A Case Report With Multi-Modality Imaging	Nothing to Disclose
Upadhyay	Rani	FIT Clinical Decision Making: Non-Invasive	Supravalvular Aortic Stenosis: A Rare Complication of Familial	Nothing to Disclose
Upadhyay	Rani	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Hypercholesterolemia Presenting as Cardiogenic Shock Challenges During Pregnancy With Marfan Syndrome and an Ascending Aortic Aneurysm	Nothing to Disclose
Upadhyay	Shailendra	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	latrogenic Diversion of Inferior Vena Cava to Left Atrium After Surgical Closure of Atrial Septal Defect	Nothing to Disclose
Upadhyay	Shailendra	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Right Ventricular Outflow Tract Obstruction Caused by Isolated Sinus of Valsalva Aneurysm	Nothing to Disclose
Upala	Sikarin	Atrial Fibrillation and VT: Unique Populations and Solutions	Association Between Atrial Fibrillation and Sudden Cardiac Death: A Systematic Review and Meta-Analysis	Nothing to Disclose
Upchurch	Gilbert	Vascular Medicine: Novel Risk Measures in	Body Mass Index and Acute Aortic Dissection	Nothing to Disclose
•	Santock	Arterial Diseases	An House al Aortio Arch Angunom Following Adda Coultable 1979	Nothing to Disclose
Uppu	Santosh	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	An Unusual Aortic Arch Aneurysm Following Arterial Switch With Concern for Dissection	Nothing to Disclose
Uppu	Santosh	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Feasibility of Rapidly Creating High Resolution Virtual Three- Dimensional Models of Anomalous Aortic Origin of Coronary Arteries	Nothing to Disclose
Upshaw	Jenica	Heart Failure and Cancer Care	Debate: Every Patient Should be Prescribed a Diet and Exercise	Nothing to Disclose
Urban	Alexander	Innovations in Advocacy and Patient Centered	Regimen to Mitigate Cardiomyopathy with Cancer Therapy Prolonged Inter-facility Transfer Times and Hospital Length of Stay	Nothing to Disclose
		Care	in Insured Patients with ST-elevation Myocardial Infarction	
Urban	Matthew	New Technologies in Echocardiography	Lipoproteins, Statin Therapy, Carotid Atherosclerotic Plaque Vulnerability and Stiffness: A Study of Novel Ultrasound Methods Utilizing Microbubble Contrast Enhancement and Shear Wave	Nothing to Disclose
Uretsky	Barry	Interventional Cardiology: Intravascular	Elastography Outcomes of Fractional Flow Reserve Based Deferral in Saphenous	Nothing to Disclose
		Physiology and Endothelial Function	Vein Graft Lesions	•

Carried States				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Uretsky	Barry	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Does Post Pci Ffr Carry the Same Prognostic Weight as Non- Ischemic Ffr in Deferred Lesions?	Nothing to Disclose
Uretsky	Barry	Advances in Chronic Total Occlusion	The Impact of Epicardial Collateral Use on the Outcomes of Chronic	Nothing to Disclose
,	*	Intervention	Total Occlusion Percutaneous Coronary Intervention: Insights From	
11	D		a Contemporary Multicenter Registry	Number of Product
Uretsky	Barry	Advances in Chronic Total Occlusion Intervention	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a	Nothing to Disclose
			Contemporary Multicenter U.S. Registry	
Uretsky	Seth	Which Test Is Best for Pain in the Chest?	Outcomes in Patient With Chest Pain Evaluated Using Coronary	Nothing to Disclose
			Computed Tomography Angiography Versus Stress Imaging: A Meta-Analysis of Randomized Trials	
Uribe	Carlo	Featured Clinical Research I	Results of MRI-Based Screening Study of 5130 Candidates for	Nothing to Disclose
			Sports Participation	-
Uriel	Nir	Life After LVAD - The Good, The Bad and The	VAD Thrombosis and Bleeding	CONSULTANT FEES/HONORARIA - MEDTRONIC, Novartis
		Ugly		Corporation; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,MEDTRONIC
Uriel	Nir	Highlighted Original Research: Heart Failure	Increased Tumor Necrosis Factor-α Levels in Patients With	CONSULTANT FEES/HONORARIA - MEDTRONIC, Novartis
		and Cardiomyopathies and the Year in Review	Continuous-Flow Left Ventricular Assist Devices Mediate Vascular	Corporation; RESEARCH/RESEARCH GRANTS - Abbott
Uriel	Nir	Acute Heart Failure: Evaluating Strategies to	Instability and Are Associated With Higher Non-Surgical Bleeding Correlation of Noninvasive Assessment of Lung Fluid Percentage	Laboratories,MEDTRONIC CONSULTANT FEES/HONORARIA - MEDTRONIC,Novartis
Offici	INII	Prevent Readmissions	With Invasively Measured Hemodynamics	Corporation; RESEARCH/RESEARCH GRANTS - Abbott
				Laboratories,MEDTRONIC
Uriel	Nir	Atrial Fibrillation and VT: Specific Situations	Incidence, Predictors, and Outcome of Postoperative Atrial	CONSULTANT FEES/HONORARIA - MEDTRONIC, Novartis
		and Newer Outcome Measures	Fibrillation in Patients Receiving Continuous Flow Left Ventricular Assist Devices	Corporation; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,MEDTRONIC
Uriel	Nir	Innovative Use of Echocardiography	Assessment of Left Ventricular Rotational Mechanics Post-LVAD	CONSULTANT FEES/HONORARIA - MEDTRONIC, Novartis
			Implantation Using 3D Echocardiography	Corporation; RESEARCH/RESEARCH GRANTS - Abbott
Uriel	Nir	Non Invasive Imaging: MR Scar and Perfusion	Multimodality Analysis of Abnormal Myocardial Perfusion in Post-	Laboratories,MEDTRONIC CONSULTANT FEES/HONORARIA - MEDTRONIC,Novartis
Offici	INII	Non invasive imaging, IVIR Scal and Penusion	Heart Transplant Recipients	Corporation; RESEARCH/RESEARCH GRANTS - Abbott
				Laboratories,MEDTRONIC
Uriel	Nir	13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC, Novartis
		Clinical Team 6		Corporation; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,MEDTRONIC
Urja	Prakrity	Insights From Echocardiography Use	Trends and Use of Echocardiography in Patients With	Nothing to Disclose
1			<i>Staphylococcus Aureus</i> Bacteremia: An Analysis Using the	=
Usia	Deal sit :	Arrhythmias and Heart Failure	Nationwide Inpatient Sample (NIS) Data	Nething to Displace
Urja	Prakrity	Arrnythmias and Heart Failure	Prognostic Impact of Premature Atrial Complexes in the General Population: A Meta-Analysis of Observational Studies	Nothing to Disclose
Usui	Eisuke	Interventional Cardiology: Intravascular	Significance of Microcirculatory Resistance in Visual-Functional	Nothing to Disclose
		Physiology and Endothelial Function	Mismatch Between Coronary Angiography and Fractional Flow	
Usui	Eisuke	Interventional Cardiology: Angiography,	Reserve in Non-Left Main Lesions Usefulness of Optical Coherence Tomography-Derived	Nothing to Disclose
Osui	Lisuke	Intravascular Imaging and Interventional	Morphometric Assessment to Predict Physiological Significance of	Nothing to Disclose
		CT/MR	Coronary Artery Stenosis and Determinants of Mismatch: Head-to-	
D. 3	Et. I.		Head Comparison With Intravascular Ultrasound	Notice to Breaters
Usui	Eisuke	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional	Relationship Between Optical Coherence Tomography-Defined In- Stent Neoatherosclerosis and Out-Stent Arterial Remodeling	Nothing to Disclose
		CT/MR	Assessed by Serial Intravascular Ultrasound Examinations in Late	
			and Very Late Drug-Eluting Stent Failure	
Usui	Eisuke	Unusual Presentations of ACS	Comparison Between Angioscopic and Optical Coherence Tomographic Assessment of Instent Restenosis	Nothing to Disclose
Usui	Eisuke	Unusual Presentations of ACS	Predictors and Clinical Significance of High-Sensitivity Cardiac	Nothing to Disclose
			Troponin-I Elevation After Diagnostic Coronary Angiography	
Usui	Eisuke	Unusual Presentations of ACS	Multimodality Coronary Imaging to Predict Periprocedural	Nothing to Disclose
			Myocardial Necrosis After Elective Percutaneous Coronary Intervention	
Usui	Eisuke	Unusual Presentations of ACS	Comparison of Neointimal Appearance Assessed by Optical	Nothing to Disclose
			Coherence Tomography Between Bare-Metal Stents and Sirolimus-	
Utagi	Basavaraj	Insights Into Ischemic Heart Disease: Stable to	Eluting Stents Beyond 10 Years From Implantation Immuno-Histopathology of Intracoronary Thrombus Aspirated	Nothing to Disclose
Otagi	Dasavaraj	Erosive Plaques	During Primary Percutaneous Intervention for ST Elevation	Nothing to Disclose
			Myocardial Infarction and Its Clinical Significance	
Vaara	Satu	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	A Risk Locus for Non-ST-Elevation Myocardial Infarction on Chromosome 1p13.3 Is Also Associated With Peripheral Artery	Nothing to Disclose
		Coronary Artery Disease	Disease in Patients With Acute Coronary Syndrome	
Vaccarino	Viola	Traditional and Novel Factors Used to Assess	Inflammatory Response to Mental Stress and Mental Stress Induced	Nothing to Disclose
		the Risk of, and Used for the Treatment of,	Myocardial Ischemia	
Vaccarino	Viola	Coronary Artery Disease Updates on Risk Factors for Cardiovascular	Central Obesity Predicts Circulating Progenitor Cell Levels	Nothing to Disclose
- Cassarino	·ioiu	Disease	Sound Speaky Fredress Shouldtring Frogeritton Cent Levels	Trouming to Disclose
Vaccarino	Viola	Updates on Risk Factors for Cardiovascular	Changes in Body Fat Distribution Is Associated With Oxidative Stress	Nothing to Disclose
Vaccarino	Viola	Disease The Evolving World of LVADs, Transplant and	Progenitor Cells and Clinical Outcomes in Patients With Heart	Nothing to Disclose
Vaccarino	viola	Other Novel Discoveries	Failure	Induling to Disclose
Vacek	James	Updates on Risk Factors for Cardiovascular	Prevalence of Abnormal Ankle Brachial Index in Obese and Non-	Nothing to Disclose
1		Disease	Obese Subjects, and Association of Abnormal Ankle Brachial Index	
			With All-Cause and Cardiovascular Mortality in These Groups: Results From National Health and Nutrition Examination Survey	
			1999-2000	
Vacek	James	Arrhythmias and Clinical EP: AF Miscellaneous	CHADS2 Score Predicts Outcomes of Radiofrequency Catheter	Nothing to Disclose
\/\/-	1	and Surgical Issues	Ablation in Patients With Atrial Fibrillation	Nething to Directors
Vacek	James	Diabetes and Other Issues in Cardiovascular Prevention	Association of Ankle Brachial Index and Hemoglobin A1c With All- Cause and Cardiovascular Mortality: Results From the National	Nothing to Disclose
	<u> </u>		Health and Nutrition Examination Survey 1999 to 2000	
Vachiery	Jean-Luc	Deciphering Pulmonary Hypertension Due to	Co-Chair	Nothing to Disclose
1		Left Heart Disease: Have Hope Oh Ye Who Enter		
Vachiery	Jean-Luc	Highlighted Original Research: Pulmonary	MELODY-1: A Pilot Study of Macitentan in Pulmonary Hypertension	Nothing to Disclose
,		Hypertension and Venous Thrombo-embolic	Due to Left Ventricular Dysfunction	
Mada	l. atia	Disease and the Year in Review	Conditions and the in Delicate Affice Co. 1	Nething to Directors
Vader	Justin	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Cardiomyopathy in Patients After Post-Transplant Cyclophosphamide-Based Hematopoietic Cell Transplantation	Nothing to Disclose
Vader	Justin	Hormones and Heart Failure	ACC Poster Moderator	Nothing to Disclose
Vaduganathan	Muthiah	PPIs in the Era of Prolonged DAPT Should	Panelist	Nothing to Disclose
Vaduganathan	Muthiah	We or Shouldn't We?: Pharmacology III	NT proPNP Left Ventrioules Structure and Frenchise	Nothing to Disclose
Vaduganathan	Muthiah	Making Progress in Understanding Heart Failure	NT-proBNP, Left Ventricular Structure and Function, and Long- Term Cardiovascular Events: Insights From a Prospective	Nothing to Disclose
			Population-Based Cohort Study	
Vaduganathan	Muthiah	Coronary Angiography, Intra-Vascular Imaging,	Impact of Periprocedural Myocardial Infarction in Contemporary	Nothing to Disclose
Vaduganathan	Muthiah	Revascularization and Outcomes Emerging Developments in HFpEF and	PCI: Pooled Patient-Level Data From the CHAMPION Trials Left Ventricular Hypertrophy and Subsequent Cardiovascular Risk:	Nothing to Disclose
- aaaganaanan		Arryhthmias	Does It Matter How It Is Diagnosed?	Trouming to Disclose
			Cangrelor Versus Clopidogrel on a Background of Unfractionated	Nothing to Disclose
Vaduganathan	Muthiah	Optimizing the Care of ACS Patients	Heparin: Insights From CHAMPION PHOENIX	Nothing to Disclose

Content	and a second				I
Separation Mode		First Name Muthiah		Long-Term Outcomes in Clinically Stable, Apparently Healthy Older	
Volument Acc. 2. A Secretary Control Control of Secretary Secretary Control of Secretary Secretary Control of Secretary Secretary Control of Secretary Secretary Control of Secretary Secretary Control of Secretary Secretary Control of Secretary Secretary Control of Secretary Secretary Control of Secretary Secretary Control of Secretary Secretary Control of Secretary Secretar	Vaghasia	Nishit		Impact of Electrocardiogram Changes on Mortality in Asymptomatic	Nothing to Disclose
Value	Vahanian	Alec	Frontiers in Mitral Valve Disease and	Multicenter Trial of a Transfemoral System for Mitral Valve	CONSULTANT FEES/HONORARIA - Abbott Vascular, Edwards
Septiment of the company of the comp	Vahanian	Alex		Annuloplasty: Up-to-2-Year Follow-Up Results Suggested Reviewer	Lifesciences, Valtech CONSULTANT FEES/HONORARIA - Abbott Vascular, Edwards
Septiment of Control Control Services Control Services Septiment of Note Services Control Services Septiment of Note Services Control Services Serv	Vahidkhah	Koohyar			
	Vahl	Torsten		Refining the Classification of Severe, Symptomatic Aortic Stenosis	Nothing to Disclose
Marcian Marcian Marcian Experience in Patrician Company Marciang Marcian Marciang Marcian Marciang Marcian Marciang Marcian Marciang Marcian Marciang Marcian Marciang Marcian Marciang Marcian Marciang Marcian Marciang Marciang Marciang Marciang Marciang Marciang Marciang Marciang Marciang Marciang Marciang Marciang Marciang Marciang	Vahl	Torsten	TAVR Outcomes Prognostication	High Baseline Valvuloarterial Impedence Predicts Worse 1-Year	Nothing to Disclose
Applied Appl	Vaidva	Aniali	Hot Topics and Great Debates in Pulmonary		CONSULTANT FEES/HONORARIA - Actelion, Bayer Healthcare
Nemerous control of Deplication in Total search of Company Personal Personal Company Personal Personal Company Personal Per			Hypertension	Questions	Pharmaceuticals, Gilead Sciences, Inc., United Therapeutics; OTHER - Bayer Healthcare Pharmaceuticals
Seguing — Seguing — Seguing — Seguing — Seguing December (Company) American Disease — No. 1997; Company (Company) — Seguing —	Vaidya	Anjali	Hypertension and RV Dysfunction: It Takes a	Co-Chair	Pharmaceuticals, Gilead Sciences, Inc., United Therapeutics;
Value	Vaidya	Anjali	Imaging Pulmonary Vascular Disease Plus the	Compliance and Diastolic Pressure Gradient Status in Heart Failure	CONSULTANT FEES/HONORARIA - Actelion,Bayer Healthcare Pharmaceuticals,Gilead Sciences, Inc. ,United Therapeutics;
Posture layer Posture laye	Vaidya	Anjali			CONSULTANT FEES/HONORARIA - Actelion,Bayer Healthcare Pharmaceuticals,Gilead Sciences, Inc. ,United Therapeutics;
Non-Invasion Impairing	Vaidya	Dhananjay	Innovations in Education		
Valerine Val	Vaidya	Dhananjay		Association of Total Testosterone With Progression of Carotid	CONSULTANT FEES/HONORARIA - MBC Inc
Valente North Course (Valente Valente	Vaidya	Gaurang	3	Ethnic Study of Atherosclerosis Reciprocal Changes in STEMI: Ischemia at Distance or Reciprocal	Nothing to Disclose
Vision to House A Search Vision Control Decision Means (Price Decision Means (Price Decision Means (Price Decision Means (Price Decision Means (Price Decision Means) (Price Decision M	Vaidya	Vaibhav			Nothing to Disclose
Valentian Senha Adances in HCM, PFCM and OPer Asta Thrombus in Plastents Win Cordina Annicotors Prevalence Adants Incompliant in Adaption Provided Asta Thrombus in Plastents Windows Or Thrombus Adaption Provided Asta Thrombus in Plastents Windows Or Thrombus Adaption Provided Asta Thrombus in Plastents Windows Or Thrombus Adaption Provided Asta Thrombus in Plastents Windows Or Thrombus Adaption Provided Asta Thrombus in Plastents Windows Or Thrombus Adaption Provided Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Thrombus Asta Thrombus in Plastents Windows Or Throm	Vaikom House	Aswathy	Pulmonary Hypertension FIT Clinical Decision Making Reviewers 4		Nothing to Disclose
Area Marie Schmider Anne Murie Special Hearts (Centered Hearts) (Compared Heart Disease) (Compar	Vakamudi	Sneha	Valvular Heart Disease: Mitral Valve Disease		
Procedural Completiones of Revisabilitation on Christian in Petitions Undergraphy Transcribations After Native Registeration (Valentia Schridt Vale Registeration American College of Cardiology and Patent Certain Valentia Cardiology and Patent Certain Valentia Cardiology Sepond Perfusion Valentia Cardiology	vakamudi	Snena		and Implications for Therapy	Nothing to Disclose
Valentia Wiching In Scholare Invalentia Announce Invalentia Care Invalentia Schinder Invalentia Schind	Vaknin Assa	Hana	Refining TAVR Outcomes	The Association of Coronary Artery Disease Severity and Pre Procedural Completeness of Revasclarization on Mortality in	Nothing to Disclose
Valente	Valencia	Victor	Care	Interventions on Disparities in 30-Day Readmission Rates	Nothing to Disclose
Valente				Upregulation in Obesity	-
Second Congential Heart Disease Congential	Valente		Valvular/Congenital Heart Disease: Clinical Management and Challenging Cases		Nothing to Disclose
Valentine Anne Marie Innovations in Advocacy and Patient Centeried Status of Early Career Academic Cardiology: A Global Perspective Nothing to Disclose			in Congenital Heart Disease		-
Valente			Innovations in Advocacy and Patient Centered		
Valentine Anne Marie Engage @ ACC. 17 Studio. Simulation I	Valente	Anne Marie	Personalized Skills Center: Hands-On	Congenital Heart Disease	Nothing to Disclose
Valentine C. Michael Emerging Issues in CV Disease Management: International Perspectives From the Paral Society of Cardiology, and American College of Cardiology. Turkish Society of Cardiology. And American College of Cardiology. And American College of Cardiology. And American College of Cardiology. And American College of Cardiology. And American College of Cardiology. And American College of Cardiology. And American College of Cardiology. And American College of Cardiology. And American College of Cardiology. And American College of Cardiology. And American College of Cardiology and American College of Cardiology and American College of Cardiology. And America	Valente	Anne Marie	Engage @ ACC.17 Studio: Simulation I	Simulation Faculty	Nothing to Disclose
Valentine C. Michael Emerging Issues in CV Disease Management: Introduction to Session Nothing to Disclose	Valentine	C. Michael	Emerging Issues in CV Disease Management: International Perspectives From the Brazilian Society of Cardiology, Turkish Society of Cardiology, and American College of	Co-Chair	Nothing to Disclose
Valentine C. Michael New Perspectives and Updates in STEM Care Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology	Valentine	C. Michael	International Perspectives From the Brazilian Society of Cardiology, Turkish Society of Cardiology, and American College of	Introduction to Session	Nothing to Disclose
Valentine C. Michael New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology Coronary Syndromes Revisited: International Republic of Srpska, and American College of Cardiology Coronary Syndromes Revisited: International Republic of Srpska, and American College of Cardiology Coronary Syndromes Revisited: International Republic of Srpska, and American College of Cardiology Coronary Syndromes Revisited: International Republic of Srpska, and American College of Cardiology Coronary Syndromes Revisited: International Republic of Srpska, and American College of Cardiology Coronary Spring International Review	Valentine	C. Michael	New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of	Co-Chair	Nothing to Disclose
Valentine C. Michael Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology Valentine C. Michael Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology Valentine C. Michael Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology Valentine C. Michael Core Curriculum: Special Topic: Practical Tips: Chair Changes in Healthcare Affecting My Practice Valentine C. Michael C. Michael Accoptight on Special Topics: Education, Innovation, Advocacy, Social Media, Leadership and Practice Management Team 1 Valentino Michael Fit Clinical Decision Making: Arrhythmias and Electrophysiology Valentino Michael Fit Clinical Decision Making: Arrhythmias and Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Valgimigli Marco Featured Clinical Research II: Interventional Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD Matrix Study Separate Stable Sureau Study Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Separate It Nothing to Disclose Anterolateral Papillary Muscle Rupture: A Rare Complication of Acute Myocardial Infarction Separate Application Acute Myocardial Infarction Separate Application Acute Myocardial Infarction Separate Acute Myocardial Infarction Separate Acute Myocardial Infarction Separate Acute Myocardial Infarction Separate Acute Myocardial Infarction Separate Acute Myocardial Infarction Separate Acute Myocardial Infarction Separate Acute Myocardial Infarction Separate Acute Myocardial Infarction Separate Acute Myocardial Infarction Separate Acute Myocardial Infarction Separate Acute Myocardial Infarction Separate Acute Myocardial	Valentine	C. Michael	New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of	Introduction to Session	Nothing to Disclose
Valentine C. Michael Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of Cardiology Valentine C. Michael Core Curriculum: Special Topic: Practical Tips: Chair Changes in Healthcare Affecting My Practice Valentine C. Michael C. Michael A. Spotlight on Special Topics: Education, Innovation, Advocacy, Social Media, Leadership and Practice Management Team to Innovation, Advocacy, Social Media, Leadership and Practice Management Team Valentino Michael FIT Clinical Decision Making: Arrhythmias and Electrophysiology Valentino Michael FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Valgimigli Marco Featured Clinical Research II: Interventional Featured Clinical Research II: Interventional Syndromes: The RAD Matrix Study Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose SPEAKER'S BUREAU - Abbott Vascular, Astra Zeneca	Valentine	C. Michael	Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of	Co-Chair	Nothing to Disclose
Valentine C. Michael Core Curriculum: Special Topic: Practical Tips: Chair Changes in Healthcare Affecting My Practice Valentine C. Michael 42. Spotlight on Special Topics: Education, Innovation, Advocacy, Social Media, Leadership and Practice Management Team 1 Valentino Michael FIT Clinical Decision Making: Arrhythmias and Electrophysiology Valentino Michael FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Valgimigli Marco Featured Clinical Research II: Interventional Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD Matrix Study Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose SPEAKER'S BUREAU - Abbott Vascular, Astra Zeneca	Valentine	C. Michael	Coronary Syndromes Revisited: International Perspectives From the ACC Italy Chapter, ACC Consortium Chapter of Serbia and Republic of Srpska, and American College of	Introduction to Session	Nothing to Disclose
Innovation, Advocacy, Social Media, Leadership and Practice Management Team 1			Core Curriculum: Special Topic: Practical Tips: Changes in Healthcare Affecting My Practice		Ç
Electrophysiology	Valentine	C. Michael	Innovation, Advocacy, Social Media, Leadership and Practice Management Team 1	Suggested Reviewer	Nothing to Disclose
Valentino Michael FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Featured Clinical Research II: Interventional Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD Matrix Study Anterolateral Papillary Muscle Rupture: A Rare Complication of Acute Myocardial Infarction Anterolateral Papillary Muscle Rupture: A Rare Complication of Acute Myocardial Infarction Anterolateral Papillary Muscle Rupture: A Rare Complication of Acute Myocardial Infarction Anterolateral Papillary Muscle Rupture: A Rare Complication of Acute Myocardial Infarction Anterolateral Papillary Muscle Rupture: A Rare Complication of Acute Myocardial Infarction SPEAKER'S BUREAU - Abbott Vascular, Astra Zeneca	Valentino	Michael		Flecainide and Traumatic Syncope: Don't Forget It	Nothing to Disclose
Valgimigli Marco Featured Clinical Research II: Interventional Radiation Exposure and Vascular Access in Acute Coronary SPEAKER'S BUREAU - Abbott Vascular, Astra Zeneca Syndromes: The RAD Matrix Study	Valentino	Michael	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart		Nothing to Disclose
	Valgimigli	Marco			SPEAKER'S BUREAU - Abbott Vascular, Astra Zeneca
Padier Oction Patricia Access Militrary in position in Padier Oction Patricia Access Patricia Oction Patricia Patricia Oction Patricia Patricia Oction Patricia Patri	Valgimigli	Marco	Radial Access Mini-Symposium II	Radial Controversies 2: Is Testing for Dual Circulation Mandatory	SPEAKER'S BUREAU - Abbott Vascular, Astra Zeneca



	Te:	In a star Title	D	let
Valgimigli	First Name Marco	Session Title The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints	Presentation Title Composite Endpoints in ACS Trials Should Include Bleeding: Pro	Disclosures SPEAKER'S BUREAU - Abbott Vascular, Astra Zeneca
Valgimigli	Marco	Interventional Complexity and Complications	Variability in Transfemoral Access for Coronary Angiography and	SPEAKER'S BUREAU - Abbott Vascular, Astra Zeneca
Valgimigli	Marco	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology	Interventions: Results From an International Survey Suggested Reviewer	SPEAKER'S BUREAU - Abbott Vascular, Astra Zeneca
Valina-Toth	Anna Liza	Team 2 Non Invasive Imaging: Applications in Novel	Is There an Association Between Vitamin D Deficiency and Disease	Nothing to Disclose
Vallabhajosyula	Prashanth	Disease States and Clinical Scenarios Interventional Cardiology: TAVR 1	Severity on Coronary CT Angiography? TAVR Is Safe and Improves Cardiac Function in Patients With Extremely Low Ejection Fractions	Nothing to Disclose
Vallakati	Ajay	Arrhythmias and Clinical EP: AF Miscellaneous	CHADS2 Score Predicts Outcomes of Radiofrequency Catheter	Nothing to Disclose
Vallejo-Vaz	Antonio	and Surgical Issues Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Ablation in Patients With Atrial Fibrillation Lower On-Treatment Low-Density Lipoprotein Cholesterol Is Associated With Lower Cardiovascular Risk in Very High Risk Patients With Atherosclerotic Cardiovascular Disease: Analyses From the ODYSSEY Trials	Nothing to Disclose
Vallejo-Vaz	Antonio	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Lower On-Treatment Low-Density Lipoprotein Cholesterol Is Associated With Lower Cardiovascular Risk in Women: Analyses From the ODYSSEY Trials of Alirocumab Versus Control	Nothing to Disclose
Vallurupalli	Srikanth	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Correlation Between Echocardiographic Pulmonary Artery Pressure Estimates and Right Heart Catheterization Measurements in Patients Undergoing Liver Transplant Evaluation: A Single Center Study	Nothing to Disclose
Vallurupalli	Srikanth	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Aortic Regurgitation Due to Aortic Dissection: Complication Post Coronary Artery Bypass Surgery	Nothing to Disclose
Valsdottir	Linda	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Sex Differences in Rates of 30-Day Readmission in Patients Discharged After Acute Myocardial Infarction in the United States	Nothing to Disclose
Vamvakidou	Anastasia	Technical Advances in Transthoracic Echocardiography	Stroke Volume Determined Flow Reserve Does Not Predict the True Severity of Low-Flow Low-Gradient Aortic Stenosis and Is Not a Robust Marker of Contractile Reserve in Patients Undergoing Low- Dose Dobutamine Echocardiography	Nothing to Disclose
Van Arsdell	Glen	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Standardization of Peri-Operative Management After Norwood Operation Has Not Improved 1 Year Outcomes	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Boston Scientific,Cell Aegis,MEDTRONIC
Van Bakel	Adrian	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Dispersion High Consultation of Loop Dispersion of Loop Dispersion and Mortality in Patients With Heart Failure: Insights From the UNITE-HF Registry	CONSULTANT FEES/HONORARIA - St Jude Medical; RESEARCH/RESEARCH GRANTS - Amgen,Cardioxyl,MEDTRONIC,Novartis
Van Belle	Eric	Late-Breaking Clinical Trials: Interventional	Panelist	CONSULTANT FEES/HONORARIA - Saint Jude
Van Belle	Eric	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Silent Cerebral Microbleeds During TAVR: Insight From a Prospective Cerebral MRI Cohort	Medical,Volcano CONSULTANT FEES/HONORARIA - Saint Jude Medical,Volcano
Van Boven	Ad	Highlighted Original Research: Interventional Cardiology and the Year in Review	Impact of Final Minimal Stent Area by IVUS on 3-Year Outcome After PCI of Left Main Coronary Artery Disease: The EXCEL Trial	Nothing to Disclose
Van Boven	Ad	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Differences and Level of Agreement in SYNTAX Score Assessment Between Site Operators and Angiographic Core Laboratory	Nothing to Disclose
Van Boven	Ad	Refining PCI Technique and Outcomes	Readers: Insights From the EXCEL Trial Outcomes of PCI Versus CABG in Left Main Disease According to SYNTAX Score by Site Versus Angiographic Core Laboratory	Nothing to Disclose
van de Hoef	T.	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Assessment: Insights From the EXCEL Trial Integrating Hyperemic Myocardial Blood Flow and Coronary Flow Reserve for Predicting Cardiovascular Mortality Outcomes in	CONSULTANT FEES/HONORARIA - Miracor Medical Systems GmbH; SPEAKER'S BUREAU - Boston Scientific,St. Jude
van de Hoef	Tim	23. Interventional Cardiology: IVUS and Intravascular Physiology Team 2	Patients With Known or Suspected Ischemic Heart Disease Suggested Reviewer	Medical, Volcano Corporation CONSULTANT FEES/HONDARARIA - Miracor Medical Systems GmbH; SPEAKER'S BUREAU - Boston Scientific, St. Jude
van de Ven	Peter	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Atherosclerotic Plaque Morphology Is Associated With Impaired Myocardial Blood Flow and Fractional Flow Reserve, Independent of Luminal Obstruction	Medical, Volcano Corporation Nothing to Disclose
Van de Werf	Frans	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes		CONSULTANT FEES/HONORARIA - AstraZeneca,Boehringer Ingelheim; RESEARCH/RESEARCH GRANTS - Merck & Denny; Co., Inc.
Van de Werf	Frans	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Diabetes Mellitus on Antithrombotic Management Patterns and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndrome: Insight From the EPICOR Asia Study	CONSULTANT FEES/HONORARIA - AstraZeneca,Boehringer Ingelheim; RESEARCH/RESEARCH GRANTS - Merck & Description of the control of
Van de Werf	Frans	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Predictors of Ischemic Events Within and After 1 Year After an Acute Coronary Syndrome: Results From the EPICOR Registry	CONSULTANT FEES/HONORARIA - AstraZeneca,Boehringer Ingelheim; RESEARCH/RESEARCH GRANTS - Merck & Description
van der Bijl	Pieter	Leading Us Astray? Pacemakers in Cardiomyopathies	Functional Mitral Regurgitation and Cardiac Resynchronization Therapy: Evolution and Impact on Outcome	Nothing to Disclose
Van der Heyden	Jan	Novel Mechanical Devices for the Treatment	Endovascular Carotid Barostimulation for Resistant Hypertension: A	Nothing to Disclose
van der Heyden	Jan	and Assessment of Hypertension Frontiers in Mitral Valve Disease and	Safety and Proof-of-Principle Cohort Study Multicenter Trial of a Transfemoral System for Mitral Valve	Nothing to Disclose
van der Laarse	Amoud	Treatment Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Annuloplasty: Up-to-2-Year Follow-Up Results Plasma LDL-Cholesterol Level Is Independently Associated With Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention	Nothing to Disclose
Van Diepen	Sean	Acute Cardiogenic Shock: Progress, Paradigm, and Unresolved Problems	Pharmacologic Approaches for Cardiogenic Shock: Best Practices	RESEARCH/RESEARCH GRANTS - Tenax harmaceutics
Van Diepen	Sean	Evolution of Critical Care Cardiology and the CICU	Finding Mentorship and Research Opportunities in Critical Care Cardiology	RESEARCH/RESEARCH GRANTS - Tenax harmaceutics
Van Diepen	Sean	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Hospital Variation in Targeted Temperature Management for Acute Myocardial Infarction Patients Complicated by Out-of-Hospital	RESEARCH/RESEARCH GRANTS - Tenax harmaceutics
Van Diepen	Sean	Syndrome Unusual Presentations of ACS	Cardiac Arrest in the U.S. The High Cost of Low Acuity Non ST-Segment Elevation Acute Coronary Syndrome Admissions to the Coronary Care Unit: An Analysis of National Population Health Data	RESEARCH/RESEARCH GRANTS - Tenax harmaceutics
van Domburg	Ron	Why Can't We Be Friends? Controversies in	A Novel Score to Predict Outcome in Patients Supported by Veno-	Nothing to Disclose
van Erven	Lieselot	Heart Failure Management Arrhythmias and Clinical EP: Devices 4	Arterial Extracorporeal Membrane Oxygenation Increased Complexity of Transvenous Lead Removals With Unaltered Effectivity: Promising Results Will Benefit Device Patients	CONSULTANT FEES/HONORARIA - MEDTRONIC
Van Gaal	Luc	The Intersection of Diabetes and ASCVD	Effects of Canagliflozin Versus Glimepiride on Inflammatory Biomarkers and Chemokines in Patients With Type 2 Diabetes Mellitus	OTHER - Astra Zeneca, Boehringer Ingelheim Pharmaceuticals, Inc, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Merck Aamp; amp; Co., Inc., Novo Nordisk Inc., SANOFI; SPEAKER'S BUREAU - Astra Zeneca, Boehringer Ingelheim Pharmaceuticals, Inc, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Merck Aamp; amp; Co., Inc., Novo Nordisk Inc, SANOFI
				damp,amp, od., mc.,novo nordisk mc.,o/mor i

Contract of the Contract of th				
Last Name	First Name	Session Title Controversies in Arrhythmia Management:	Presentation Title Should Asymptomatic Patients with WPW Undergo Ablation?	Disclosures
Van Hare	George	Joint Symposium of the Heart Rhythm Society and the American College of Cardiology	Should Asymptomatic Patients with WPW Ondergo Abiation?	Nothing to Disclose
Van Herendael	Hugo	Innovations in Practice Management and Social Media	Evaluating Smartphone Based Photoplesythmography as a Screening Solution for Atrial Fibrillation: A Digital Tool to Detect Afib?	Nothing to Disclose
Van Kimmenade	Roland	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Multiple Biomarkers for Predicting Major Adverse Cardiac Events in At-Risk Patients Undergoing Diagnostic Coronary Angiography: Results From the Catheter Sampled Blood Archive in	CONSULTANT FEES/HONORARIA - Bayer Healthcare Pharmaceuticals
Van Mieghem	Nicolas	TAVR Changing the Paradigm for the Treatment of Valve Disease	Cardiovascular Diseases (CASABLANCA) Study Moderate Aortic Stenosis and Heart Failure: Should They Be Offered TAVR?	CONSULTANT FEES/HONORARIA - PulseCath; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Boston Scientific,Claret Medical,MEDTRONIC
Van Mieghem	Nicolas	Aortic Stenosis: Overview of the Hemodynamics and Ventricular Response	The Expanding Indications for TAVR	CONSULTANT FEES/HONORARIA - PulseCath; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Boston Scientific,Claret Medical,MEDTRONIC
Van Mieghem	Nicolas	Interventional Cardiology: TAVR 2	Impact of Single Versus Dual Anti Platelet Therapy on Early Outcomes in Women Undergoing Transcatheter Aortic Valve Replacement: From the WIN-TAVI Registry	CONSULTANT FEES/HONORARIA - PulseCath; RESEARCH/RESEARCH GRANTS - Abbott Vascular,Boston Scientific,Claret Medical,MEDTRONIC
Van Mieghem	Nicolas	Interventional Cardiology: TAVR 3	Does Balloon Predilatation Influence Outcome With the Lotus Valve: 30-Day Results From the RESPOND Study	CONSULTANT FEES/HONORARIA - PulseCath; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston Scientific, Claret Medical, MEDTRONIC
van Mourik	Martijn	Non Invasive Imaging: Expanding Clinical	Prevention of Contrast-Induced Nephropathy for Computed	Nothing to Disclose
	-	Applications	Tomography (CT)-Scanning in TAVR Work-Up: One-Hour Hydration With Sodium Bicarbonate Is Not Inferior to 24-Hour Saline Hydration	
van Rossum	Albert	Nuclear Cardiology: Quality	Automatic SPECT Analysis Compared to Expert Visual Scoring for the Detection of Coronary Artery Disease	SALARY - VU University Medical Center Amsterdam, The
van Rossum	Albert	Advances in Chronic Total Occlusion Intervention	Effects of Successful Percutaneous Coronary Intervention of Chronic Total Occlusions on Myocardial Perfusion and Left	Netherlands SALARY - VU University Medical Center Amsterdam, The Netherlands
B	I All and		Ventricular Function	
van Rossum	Albert	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Atherosclerotic Plaque Morphology Is Associated With Impaired Myocardial Blood Flow and Fractional Flow Reserve, Independent of Luminal Obstruction	SALARY - VU University Medical Center Amsterdam, The Netherlands
Van Royen	Niels	Coronary Physiology and Microcirculation	Novel Physiologic Indices to Predict Functional Recovery During STEMI	CONSULTANT FEES/HONORARIA - MEDTRONIC; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,Astra Zeneca,Biotronik,St Jude,Volcano
Van Royen	Niels	Nuclear Cardiology: Quality	Automatic SPECT Analysis Compared to Expert Visual Scoring for the Detection of Coronary Artery Disease	CONSULTANT FEES/HONORARIA - MEDTRONIC; RESEARCH/RESEARCH GRANTS - Abbott Laboratories, Astra Zeneca, Biotronik, St Jude, Volcano
Van Royen	Niels	Advances in Chronic Total Occlusion Intervention	Effects of Successful Percutaneous Coronary Intervention of Chronic Total Occlusions on Myocardial Perfusion and Left Ventricular Function	CONSULTANT FEES/HONORARIA - MEDTRONIC; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,Astra Zeneca,Biotronik,St Jude,Volcano
Van Royen	Niels	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Atherosclerotic Plaque Morphology Is Associated With Impaired Myocardial Blood Flow and Fractional Flow Reserve, Independent of Luminal Obstruction	CONSULTANT FEES/HONORARIA - MEDTRONIC; RESEARCH/RESEARCH GRANTS - Abbott Laboratories,Astra Zeneca,Biotronik,St Jude,Volcano
van Slegtenhorst	Marjon	Advances in HCM, PPCM and Other Cardiomyopathies	Yield and Long-Term Outcome of Family Screening in Hypertrophic Cardiomyopathy	Nothing to Disclose
Van Tassell	Benjamin	Young Investigator Awards Competition: Outcomes Research	Comparison of a Pharmacist-Physician Collaborative Care Model to Standard Care on the Time to Reach Goal Blood Pressure for Patients With Hypertension	Nothing to Disclose
Van Tassell	Benjamin	Making Progress in Understanding Heart	Arterial Elastance Drives Ventilatory Inefficiency in Systolic Heart	Nothing to Disclose
Van Tassell	Benjamin	Failure Emerging Developments in HFpEF and Arryhthmias	Failure Early Diastolic Mitral Annular Velocity at Peak Exercise Determines Peak Aerobic Exercise Capacity in Heart Failure With Preserved Ejection Fraction	Nothing to Disclose
Van Tassell	Benjamin	Novel Strategies for Assessing and Improving Adherence to Blood Pressure Lowering Therapies	Comparison of a Pharmacist-Physician Collaborative Care Model to Standard Care on the Time to Reach Goal Blood Pressure for Patients Presenting With Urgent Hypertension	Nothing to Disclose
Van Velzen	Hannah	Advances in HCM, PPCM and Other Cardiomyopathies	Yield and Long-Term Outcome of Family Screening in Hypertrophic Cardiomyopathy	Nothing to Disclose
Van Vugt	Stijn	Arrhythmias and Clinical EP: AF Miscellaneous	Novel Approach for Risk Differentiation in Atrial Fibrillation Patients	CONSULTANT FEES/HONORARIA - Bayer Healthcare
Vandermolen	Justin	and Surgical Issues Innovative Approaches for Reducing Risk and	With Polypharmacy Estimating Cancer Risk Associated With Ionizing Radiation	Pharmaceuticals Nothing to Disclose
Vandervoort	Pieter	Improving Outcomes With Ablation Innovations in Practice Management and	Exposure During Atrial Fibrillation Ablation Evaluating Smartphone Based Photoplesythmography as a	Nothing to Disclose
W I I	Pi-1	Social Media	Screening Solution for Atrial Fibrillation: A Digital Tool to Detect Afib?	N. W. C. C.
Vandervoort	Pieter	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Bioimpedance Algorithms in Implantable Electronic Cardiac Devices: Relevant Diagnostics or Waste of Time?	Nothing to Disclose
Vannan	Mani	Echocardiography: What is New in 2017	Taking 3D to the Next Level: Fusion Imaging, Heart Model, What is Next?	RESEARCH/RESEARCH GRANTS - Abbott Laboratories; SPEAKER'S BUREAU - Siemens
Vannan	Mani	Innovations in Valvular Heart Disease Diagnosis and Treatment	Assessment of Regurgitant Volume: 3D Flow with Echo	RESEARCH/RESEARCH GRANTS - Abbott Laboratories; SPEAKER'S BUREAU - Siemens
Vannan	Mani	28. Non Invasive Imaging: Echo Team 5	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Abbott Laboratories;
Vanoosterhout	Stacie	Innovations in Practice Management and	Radiation Exposure Among Non-Physician Staff Members During	SPEAKER'S BUREAU - Siemens Nothing to Disclose
Vanoosterhout	Stacie	Social Media Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Cardiac Catheterization and the Impact of Proactive Shielding Variation in Intracoronary Lipid-Rich Plaque Detected by Near- Infrared Spectroscopy in Asymptomatic Individuals With High	Nothing to Disclose
Van't Hof	Jeremy	Maximally Effective Vascular Care: Vascular		Nothing to Disclose
Van't Hof	Jeremy	Collaborative Team Care in Action Maximally Effective Vascular Care: Vascular	DVT Case Presentation #2: A 48 Year Old Man with Right Calf	Nothing to Disclose
	· ·	Collaborative Team Care in Action	Claudication Effect of Diabetes Mellitus on Pulsatile Arterial Load and	
Varakantam	Swapna	Emerging Developments in HFpEF and Arryhthmias	Hemodynamics in HFpEF	Nothing to Disclose
Varbella	Ferdinando	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Provisional Versus Elective Two-Stenting Strategy for Unprotected True Left Main Bifurcation Lesions: A Sub-Study From Fails 2 Study	RESEARCH/RESEARCH GRANTS - Medtronic, Boston, Terumo, SORIN, St. Jude, Cordis,, Biosensors. Astra Zeneca, The Medicine Company, Eli Lilly.; SPEAKER'S BUREAU - Biosensors
Vardas	Panagiotis	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Blood Pressure Response to Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension: Data From a National Multicenter 1-Year-Follow-Up Study	Nothing to Disclose
Vardas	Panagiotis	Innovations in Cardiovascular Risk Assessment and Reduction	Nost Patients With Acute Coronary Syndromes Are Already at High Risk Prior to the Event and Lipid Management is Underachieved Both Before and After Hospitalization: The Phaethon Study	Nothing to Disclose
Varga	Zoltan	Nuclear Cardiology: Beyond Perfusion	Molecular Imaging of Myocardial Cannabinoid Type 1 Receptor	Nothing to Disclose
Vargas	Kris	Arrhythmias and Clinical EP: Syncope and	Upregulation in Obesity Copeptin and High-Sensitivity Troponin I in Patients With Chest Pain	Nothing to Disclose
Varma	Niraj	Other EP Issues Non Invasive Imaging: MR Characterization	and Recent Syncope Time Varying Effect of Total Scar on Mortality in Patients With	CONSULTANT FEES/HONORARIA - Biotronik, Medtronic, St
· anna	· anaj	and Function	Cardiomyopathy Undergoing Cardiac Resynchronization Therapy	Jude Medical, Sorin, Zoll

Last Name	First Name	Session Title	Presentation Title	Disclosures
Vaseghi	Marmar	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	Nothing to Disclose
Vasileiou	Panagiotis	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Prognostic Implications of Epicardial Fat Volume Quantification in Acute Pericarditis	Nothing to Disclose
Vasiljevic	Zorana	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Acute Coronary Syndrome: The Risk to Be Young and Women	Nothing to Disclose
Vasquez	Elsa	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Holter Findings in Orthotopic Heart Transplantation Patients: Results From a Cohort of the Most Important Heart Transplant Referral Center in Colombia, South America	Nothing to Disclose
Vassallo	Maria Giovanna	Improving Outcomes in the Athlete With Cardiovascular Disease	EKG Abnormalities Distribution Between Competitive Athletes, Non Competitive Athletes and Non Athletes in a Population of 12,000	Nothing to Disclose
Vassileva	Christina	Town Hall Meeting: Pitfalls of Assessing	Young Italian Students Discussion Leader	Nothing to Disclose
Vassileva	Christina	Valvular Heart Disease Severity Controversies in Mitral Valve Surgery: Joint	Mitral Valve Repair: Should we Repair all Ages, even if Complex?	Nothing to Disclose
vassiieva	Official	Symposium of the Society of Thoracic Surgeons and the American College of Cardiology	militari varie (repair. Ground ne repair air Ages, even ir complex:	Notaling to Disclose
Vasu	Sujethra	Valvular Disease Populations at Risk	Risk Stratification Predicts Survival in Patients With Low Gradient Preserved Left Ventricular Ejection Fraction and Severe Aortic Stenosis After Aortic Valve Intervention	Nothing to Disclose
Vasu	Sujethra	Valvular Heart Disease: Aortic Stenosis	Surgical Risk Scores Outweigh Echocardiographic Severity of Aortic Stenosis for Determining Prognosis in Patients With Low Gradient Severe Aortic Stenosis and Preserved Left Ventricular Function	Nothing to Disclose
Vasudev	Rahul	FIT Clinical Decision Making: Arrhythmias and	Ventricular Tachycardia in a Patient With Coexisting Brugada	Nothing to Disclose
Vasudev	Rahul	Electrophysiology New Technologies in Echocardiography	Syndrome and Coronary Vasospasm Left Atrial Volume Index Over Late Diastolic Mitral Annular Velocity:	Nothing to Disclose
Votes	Ded October	Ant the size of Obside ED De San O	A New Non-Invasive Parameter for Measurement of Left Ventricular End Diastolic Pressure	N. H. C. C.
Vatasescu	Radu-Gabriel	Arrhythmias and Clinical EP: Devices 2	Left Bunde Branch Block Is Incomplete in the Majority of Patients With Heart Failure Due to Systolic Left Ventricle Dysfunction: A Simple Intraprocedural Demonstration	Nothing to Disclose
Vathesatogkit	Prin	Arrhythmias and Clinical EP: Syncope and	Worldwide Prevalence of Brugada Syndrome: A Systematic Review	Nothing to Disclose
Vatterott	Anna	Other EP Issues Interventional Cardiology: TAVR 4	and Meta-Analysis Depression as a Potential Therapeutic Target to Improve Quality of	Nothing to Disclose
Vavalle	John	Emerging Applications of Echocardiography	Life After Transcatheter Aortic Valve Replacement Association Between Global Echocardiography-Based Cardiac	CONSULTANT FEES/HONORARIA - St Jude Medical;
vavalle			Calcium Score and the Clinical Outcomes After Transcatheter Aortic Valve Replacement	RESEARCH/RESEARCH GRANTS - Cardiovascular Systems Inc
Vavalle	John	Interventional Complexity and Complications	Characteristics and Outcomes of Patients With Clinically Silent Peri- Procedural Hemoglobin Drops as Compared to Patients With Overt Bleeding Following Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - St Jude Medical; RESEARCH/RESEARCH GRANTS - Cardiovascular Systems Inc
Vavalle	John	Refining PCI Technique and Outcomes	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - St Jude Medical; RESEARCH/RESEARCH GRANTS - Cardiovascular Systems Inc
Vavalle	John	Frontiers in Mitral Valve Disease and Treatment	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - St Jude Medical; RESEARCH/RESEARCH GRANTS - Cardiovascular Systems Inc
Vavere	Andrea	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Calcium Characteristics as Predictors of Major Adverse Cardiac Events in Symptomatic Patients: Insights From the CORE320 Multinational Study	Nothing to Disclose
Vavolizza	Rick	Congenital Heart Disease: Novel Insights in Pediatric Cardiology	Clinical Yield of Fetal Echocardiography for Suboptimal Cardiac Visualization on Obstetric Ultrasound	Nothing to Disclose
Vavuranakis	Manolis	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Vascular Function of Conduit Arteries Is Associated With Progress of Diabetic Retinopathy in Type 2 Diabetes	CONSULTANT FEES/HONORARIA - Proctor Medtronic
Vavuranakis	Manolis	From Diet to Drugs: Mechanistic Insight Into	Dietary Consumption of Olive Oil and Cardiovascular Outcome in	CONSULTANT FEES/HONORARIA - Proctor Medtronic
Vavuranakis	Manolis	Ischemic Heart Disease Uncovering the Intricacies of Vascular Function	Patients With Coronary Artery Disease The Impact of Natural Chios Mastic Supplementation on Endothelial	CONSULTANT FEES/HONORARIA - Proctor Medtronic
Vaze	Aditya	Highlighted Original Research: Interventional	Function and Arterial Stiffness in Smokers Safety of Same Day Discharge Following PCI for Non-ST Elevation	Nothing to Disclose
		Cardiology and the Year in Review	Acute Coronary Syndromes	-
Vaze	Aditya	Innovative Use of Echocardiography	Left Atrial Function Index as a Predictor of Cardiovascular Disease and Atrial Fibrillation: Data From the Framingham Offspring Study	Nothing to Disclose
Vazquez	Rafael	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Bimodal Prognosis of Patients Hospitalized With Suspected Acute Coronary Syndrome in Whom the Diagnosis Is Not Confirmed	Nothing to Disclose
Veenhuyzen	George	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Ventricular Arrhythmia at Primary PCI for ST-Elevation Myocardial Infarction Predicts 30-Day but Not Long-Term Mortality	Nothing to Disclose
Veer	Manik	The Best Structural Interventional Challenging	The First Case of Edward SAPIEN S3 Pulmonary Valve-in-Valve	Nothing to Disclose
Veer	Manik	Cases FIT Clinical Decision Making: Non-Invasive	Deployment Coronary Artery Mycotic Aneurysm: A Rare Presentation of	Nothing to Disclose
Veerasamy	Manivannan	Imaging and Valvular Heart Disease Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Tricuspid Valve Endocarditis Variation in Intracoronary Lipid-Rich Plaque Detected by Near- Infrared Spectroscopy in Asymptomatic Individuals With High	Nothing to Disclose
Veerasamy	Murugapathy	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Coronary Artery Calcium Scores Frail Older Patients Have a Greater Improvement in Physical Quality of Life Than Robust Patients at One Year Following Invasive Treatment for Non-ST Elevation Acute Coronary Syndrome	Nothing to Disclose
Vega	Ana Maria	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of a Switch From Dual Antiplatelet Therapy to Single Antiplatelet Therapy in Diabetes and Non-Diabetes Post ACS:	SALARY - AstraZeneca Pharmaceuticals
Vega	Ana Maria	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Insights From the EPICOR and EPICOR-Asia Studies Impact of Diabetes Mellitus on Antithrombotic Management Patterns and Long-Term Clinical Outcomes in Patients With Acute Coronary	SALARY - AstraZeneca Pharmaceuticals
Vegesna	Ashok	Syndrome Heart Failure and Cardiomyopathies: Is Heart	Syndrome: Insight From the EPICOR Asia Study Treatment Patterns and Resource Use of Heart Failure Patients on	Nothing to Disclose
Vejlstrup	Niels	Failure With a Normal EF for Real? Advances in Pulmonary Arterial Hypertension	Medicaid in Five States in the US Exercise During Cardiac Magnetic Resonance Imaging Dilates the	Nothing to Disclose
		, , ,	Right Ventricle and Compresses the Left Ventricle in Pulmonary Arterial Hypertension	-
Vejlstrup	Niels	Advances in Pulmonary Arterial Hypertension	Optimizing Assessment of Right Ventricular Stroke Volume Using Flow Cardiovascular Magnetic Resonance Imaging in Pulmonary Arterial Hypertension	Nothing to Disclose
Vejlstrup	Niels	Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells	Adipose Derived Stromal Cells for Refractory Angina: Results From MyStromalCell Trial	Nothing to Disclose
Velagapudi	Poonam	Arrhythmias and Clinical EP: Devices 1	Implantable Cardioverter Defibrillator for the Prevention of Mortality in Non-Ischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Velagapudi	Poonam	Arrhythmias and Clinical EP: Devices 1	Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus	Nothing to Disclose
			Warfarin in Patients Undergoing Cardiac Implantable Electronic Device Implantation: A Meta-Analysis	



W. T.				
Last Name Velagapudi	First Name Poonam	Session Title Interventional Cardiology: Translation and Pre-	Presentation Title Intramyocardial Autologous CD34+ Cell Therapy for Refractory	Disclosures Nothing to Disclose
- '		Clinical Research	Angina: A Meta-Analysis	Nothing to Disclose
Velagapudi	Poonam	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Angiography Versus Optical Coherence Tomography Guided Percutaneous Coronary Intervention: A Meta-Analysis of Clinical Outcomes	Ç
Velagapudi	Poonam	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	41-Year-Old Patient With Double Inlet Left Ventricle Without Pulmonic Stenosis Presenting With Eisenmenger's Syndrome	Nothing to Disclose
Velagapudi	Poonam	Arrhythmias and Clinical EP: Anticoagulation Issues	Meta-Analysis on the Efficacy and Safety of New Oral Anticoagulants Compared With Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation	Nothing to Disclose
Velagapudi	Poonam	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Concerning and Device: A Systematic Review and Meta-Analysis	Nothing to Disclose
Velagapudi	Poonam	Engage @ ACC.17 Studio: FIT Jeopardy Battle of the State Chapters II	Moderator	Nothing to Disclose
Velagapudi	Poonam	FIT Clinical Decision Making Reviewers 4	ACC FIT Clinical Decision Making Reviewer	Nothing to Disclose
Velasco	Alejandro	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Antihypertensive Treatment Failure Not Attributable to Persistent Intravascular Fluid Retention as Determined by MRI-Measured Intracardiac Volumes	Nothing to Disclose
Velasquez	Alex	Atrial Fibrillation and VT: Unique Populations and Solutions	A Retrospective Study of the Effect of Colchicine Administration Timing on the Incidence of Post-Operative Atrial Fibrillation After a Non Transplant Cardiac Surgery	Nothing to Disclose
Velazquez	Eric	Surgical Therapies for Heart Failure Patients: Stage A-C	Panelist	CONSULTANT FEES/HONORARIA - Amgen Inc.,Merck & Co., Inc.,Novartis Corporation; RESEARCH/RESEARCH GRANTS - Alnylam, Inc.,Amgen Inc.,Novartis Corporation,Pfizer Inc
Velazquez	Eric	Surgical Therapies for Heart Failure Patients: Stage A-C	Debate Con: Mitral Valve Surgery Should Always Be Considered for the Patient with Reduced Ejection Fraction	CONSULTANT FEES/HONORARIA - Amgen Inc.,Merck & Co., Inc.,Novartis Corporation; RESEARCH/RESEARCH GRANTS - Alnylam, Inc.,Amgen Inc.,Novartis Corporation,Pfizer Inc
Velazquez	Eric	Imaging Transcatheter Mitral Valve Repair and Replacement	How to Maintain Outcomes and Quality with Increasingly Performed TMVR Therapies: Imaging Options	CONSULTANT FEES/HONORARIA - Amgen Inc.,Merck & Co., Inc.,Novartis Corporation; RESEARCH/RESEARCH GRANTS - Alnylam, Inc.,Amgen Inc.,Novartis Corporation,Pfizer Inc
Velazquez	Eric	Making Progress in Understanding Heart Failure	The Role of Baseline Versus Long-Term Follow-Up Ejection Fraction in Predicting Adverse Events Among Primary Prevention Implantable Cardioverter Defibrillator Recipients	CONSULTANT FEES/HONORARIA - Amgen Inc.,Merck & Co., Inc.,Novartis Corporation; RESEARCH/RESEARCH GRANTS - Alnylam, Inc.,Amgen Inc.,Novartis Corporation,Pfizer Inc
Velazquez	Eric	Innovative Use of Echocardiography	The Impact of Rigorous Quality Improvement on 3D Echocardiography Image and Data Quality in an International Multisite Randomized Trial	CONSULTANT FEES/HONORARIA - Amgen Inc.,Merck & Co., Inc.,Novartis Corporation; RESEARCH/RESEARCH GRANTS - Alnylam, Inc.,Amgen Inc.,Novartis Corporation,Pfizer Inc
Velazquez	Eric	Emerging Developments in HFpEF and Arryhthmias	Measures of Ventricular-Arterial Coupling and Incident Heart Failure Preserved Ejection Fraction: A Matched Case-Control Analysis	CONSULTANT FEES/HONORARIA - Amgen Inc.,Merck & Co., Inc.,Novartis Corporation; RESEARCH/RESEARCH GRANTS - Alnylam, Inc.,Amgen Inc.,Novartis Corporation,Pfizer Inc
Velazquez	Eric	Valvular Heart Disease With CKD or Cirrhosis	Low Utilization of Surgical Intervention to Treat Severe Aortic Stenosis in Patients With Chronic Kidney Disease	CONSULTANT FEES/HONORARIA - Amgen Inc.,Merck &,amp; Co., Inc.,Novartis Corporation; RESEARCH/RESEARCH GRANTS - Alnylam, Inc.,Amgen Inc.,Novartis Corporation,Pfizer Inc
Velazquez	Eric	The Old and the New: Impact of Heart Failure Drug Therapies	Liraglutide and Weight Loss Among Patients With Advanced Heart Failure and a Reduced Ejection Fraction: Insights From the FIGHT Trial	CONSULTANT FEES/HONORARIA - Amgen Inc.,Merck &,amp; Co., Inc.,Novartis Corporation; RESEARCH/RESEARCH GRANTS - Alnylam, Inc.,Amgen Inc.,Novartis Corporation,Pfizer Inc
Veldtman	Gruschen	The Story of the Adult Congenital Heart Disease Patient and EP	Arrhythmia Burden & Outcomes in Eisenmenger Syndrome	Nothing to Disclose
Veldtman	Gruschen	09. Congenital Heart Disease: Adult Team 1	Suggested Reviewer	Nothing to Disclose
Vemulapalli	Sreekanth	Featured Clinical Research II: Interventional	Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis From the STS/ACC TVT Registry	CONSULTANT FEES/HONORARIA - Novella, Premiere; OTHER - Abbott Vascular, Phillips Medical Systems; RESEARCH/IRESEARCH GRANTS - Abbott Vascular, Agency for Healthcare Research and Quality, American College of Cardiology, American College of Cardiology, Society of Thoracic Surgeons
Vemulapalli	Sreekanth	Featured Clinical Research II: Interventional	Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Valve Repair in the United States	CONSULTANT FEES/HONORARIA - Novella, Premiere; OTHER - Abbott Vascular, Phillips Medical Systems; RESEARCH/IRESEARCH GRANTS - Abbott Vascular, Agency for Healthcare Research and Quality, American College of Cardiology, American College of Cardiology, Society of Thoracic Surgeons
Vemulapalli	Sreekanth	Imaging for TAVR: Homing in on the Real Issues	TEE During TAVR: Is It Necessary or an Added Reassurance	CONSULTANT FEES/HONORARIA - Novella, Premiere; OTHER - Abbott Vascular, Phillips Medical Systems; RESEARCH/RESEARCH (RANITS - Abbott Vascular, Agency for Healthcare Research and Quality, American College of Cardiology, American College of Cardiology, Society of Thoracic Surgeons
Vemulapalli	Sreekanth	Imaging Transcatheter Mitral Valve Repair and Replacement	Panelist	CONSULTANT FEES/HONORARIA - Novella, Premiere; OTHER - Abbott Vascular, Phillips Medical Systems; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Agency for Healthcare Research and Quality, American College of Cardiology, American College of Cardiology, Society of Thoracic Surgeons
Vemulapalli	Sreekanth	Imaging for Left Atrial Appendage and Paravalvular Leak Closure: A Case Based Approach	Co-Chair	CONSULTANT FEES/HONORARIA - Novella, Premiere; OTHER - Abbott Vascular, Phillips Medical Systems; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Agency for Healthcare Research and Quality, American College of Cardiology, American College of Cardiology, Society of Thoracic Surregons
Vemulapalli	Sreekanth	Highlighted Original Research: Interventional Cardiology and the Year in Review	New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: Incidence, Anticoagulant Strategy, and Outcomes	CONSULTANT FEES/HONORARIA - Novella, Premiere; OTHER - Abbott Vascular, Phillips Medical Systems; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Agency for Healthcare Research and Quality, American College of Cardiology, American College of Cardiology, Society of Thoracic Surgeons
Vemulapalli	Sreekanth	Interventional Cardiology: TAVR 2	Prevalence and Outcomes of Mitral Stenosis in Patients Undergoing Transcatheter Aortic Valve Replacement: Findings From the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) Transcatheter Valve Therapies (TVT) Registry	CONSULTANT FEES/HONORARIA - Novella, Premiere; OTHER - Abbott Vascular, Phillips Medical Systems; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Agency for Healthcare Research and Quality, American College of Cardiology, American College of Cardiology, Society of Thoracic Surgeons
Vemulapalli	Sreekanth	Interventional Cardiology: TAVR 2	Impact of the Presence of Coronary Artery Disease and Timing of Revascularization on Outcomes of Patients Undergoing Trans- Catheter Aortic Valve Replacement: Insights From STS/ACC TVT Registry	CONSULTANT FEES/HONORARIA - Novella, Premiere; OTHER - Abbott Vascular, Phillips Medical Systems; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Agency for Healthcare Research and Quality, American College of Cardiology, American College of Cardiology, Society of Thoracic Surgeons



Sensiver in the received Carelong, TAMP 2 The received flowering the part of the State of the S	and the second				<u> </u>
Resilience for Triscopter And Year Signatures And Triscopter And	Last Name	First Name	Session Title	Presentation Title	Disclosures
Sealers Description Contact Contact Description Contact Contact Contact Description Contact	vemulapalii	Steekanin	interventional Carolology: TAVR 2	Readmission After Transcatheter Aortic Valve Replacement	- Abbott Vascular, Phillips Medical Systems; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Agency for Healthcare Research and Quality, American College of Cardiology, American College of Cardiology, Society of Thoracic
Development T-AMT begins - Administration - Administratio	Vemulapalli	Sreekanth	interventional Cardiology: TAVR 3	in Patients Undergoing TAVR: Insights for the STS/ACC TVT Registry	CONSULTANT FEES/HONORARIA - Novella, Premiere; OTHER - Abbott Vascular, Phillips Medical Systems; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Agency for Healthcare Research and Quality, American College of Cardiology, American College of Cardiology, American College of Cardiology, Society of Thoracic Surgeons
Somewhat programs of the progr	Vemulapalli	Sreekanth	Interventional Cardiology: TAVR 3		RESEARCH/RESEARCH GRANTS - Abbott Vascular, Agency for Healthcare Research and Quality, American College of Cardiology, American College of Cardiology, Society of Thoracic
Sententifib Description Africal Disease, Fisik, and Outcomes of North Programs (Control Valve Registroment Outcomes of North Programs (Control Valve Registroment Outcomes of North Programs (Control Valve Registroment Outcomes of North Programs (Control Valve Annual Programs (Con	Vemulapalli	Sreekanth	Refining TAVR Outcomes	During Transcatheter Aortic Valve Replacement: A Report From the NCDR® STS/ACC Transcatheter Valve Therapy (TVT)	CONSULTANT FEES/HONORARIA - Novella, Premiere; OTHER - Abbott Vascular, Philips Medical Systems; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Agency for Healthcare Research and Quality, American College of Cardiology, American College of Cardiology, Society of Thoracic
Physicistory and Endothiellal Function William William Analysis by International Complete Services of the Company of Control Company of Control Contro	Vemulapalli	Sreekanth			CONSULTANT FEES/HONORARIA - Novella, Premiere; OTHER - Abbott Vascular, Philips Medical Systems; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Agency for Healthcare Research and Quality, American College of Cardiology, American College of Cardiology, American College of Cardiology, American College of Cardiology, Society of Thoracic
Vergreyvik Yulija Consolation in Patients William Diabetes Mellius Vergreyvik Yulija The Instité Wee Learning Form Infanctionary Vergreyvik The Instité Wee Learning Form Infanctionary Vergreyvik The Instité Wee Learning Form Infanctionary Vergreyvik The Instité Wee Learning Form Infanctionary Vergreyvik The Instité Wee Learning Form Infanctionary Vergreyvik The Instité Wee Learning Form Infanctionary Vergreyvik The Instité Wee Learning Form Infanctionary Vergreyvik The Institute			Physiology and Endothelial Function	Lipid Lowering Therapy by Multimodality Imaging Among Women and Men: A YELLOW-II Sub-study	-
wergeruyk Yulya har Residence Prince Learning From Instancomary Investigation of New Born 1997 agrees president in Region Date Statistics of the Management of Health Statistics of Health Statistics of the Management of Health Statistics of the Management of Health Statistics of		· ·	Analysis by Intravascuar Imaging	Characteristics in Patients With Diabetes Mellitus	-
Imaging Theregy from Yellows IT File: Towards Personalized Lips Lowering Advances in INCA, PPCM and Other Cardiomyposities Verkalaraman Ganeeth Noel Arrytembra Diagnostics, Therapeutics, Verkalaraman Presanna Presanna Presanna Reseaudistration and Outcomes Reseaudistration Reseaudistration and Outcomes Reseaudistration Reseaudistr			and Reduction	Prior Cerebrovascular Events Compared to Controls	-
Cardiomypopathies September Cardiomypopathy Have Emerged Using Real-Time Three Dimensional Transcoptional Encountry of provided in Three Dimensional Transcoptional Encountry of Provided Encoun	Vengrenyuk	Yuliya	Imaging	Therapy From Yellow-II Trial: Towards Personalized Lipid Lowering	Nothing to Disclose
Verhalzermann Prasentin Pr	Venieri	Erifili		Hypertrophic Cardiomyopathy Have Emerged Using Real-Time	Nothing to Disclose
Revescularization and Outcomes Morel Arrighman Praeaman Praeaman Praeaman Praeaman Praeaman Revescularization and Outcomes Morel Arrighman Revescularization Fil Cinical Decision Making Preventions, Aust An Independent Rex Factor More Arrighman Annand Fil Cinical Decision Making Prevention, Aust An Independent Rex Factor More Arrighman Annand Annand Annand Annand Interventional Cardiology TAVR 2 Comparative Outcomes of Transcallation Versus Signal Antic Value Registered of Comparative Outcomes Signal Antic Value Registered of Comparative Outcomes Signal Antic Value Registered of Comparative Outcomes Signal Antic Value Registered of Comparative Outcomes Signal Antic Value Registered of Comparative Outcomes Signal Antic Value Registered of Comparative Outcomes of Transcallation Versus Signal Antic Value Registered of Comparative Outcomes of Transcallation Versus Signal Antic Value Registered of Comparative Outcomes of Transcallation Versus Signal Antic Value Registered of Comparative Outcomes of Transcallation of Loop Durectic and Mortality in Patients With Healt Failure Insights From the UNITE Intervention Comparative Outcomes of Transcallation of Loop Durectic and Mortality in Patients With Healt Failure Insights From the United Transcallation of Comparative Intervention Comparative Outcomes of Transcallation of Comparative Intervention Comparative Outcomes of Transcallation of Comparative Intervention Comparative Outcomes of Comparative Outcomes of Transcallation Outcomes Outcomes of Transcallation of Comparative Outcomes of Transcallation Outcomes Outcomes of Transcallation Outcomes Outcomes of Transcallation Outcomes O	Venkataraman	Ganesh		Pauses Detected by Insertable Cardiac Monitors in Patients With	
Versitation	Venkataraman	Prasanna		and Ticagrelor in Patients With Acute Coronary Syndromes (ACS)	Nothing to Disclose
Verskateman	Venkataraman	Prasanna			Nothing to Disclose
Ventura Hector Heart Fature and Cardiomyopathies. Is Heart Heart Fature with a Normal EF for Real? Ventura Hector Novel Strategies for Assessing and Improvide Markeners to Blood Pressure Lowering Atherence to Blood Pressure Lowering Threagles Ventura Hector The Great K Debate Continues: Updates and Controverses in Heart Fature Management Octroverses in Heart Fature Management Adherence to Blood Pressure Lowering Threagles Ventura Hector The Great K Debate Continues: Updates and Controverses in Heart Fature Management Octroverses in Heart Fature Management Management Octroverses in Heart Fature Management M	Venkatesh	Kiran	FIT Clinical Decision Making: Prevention, Adult		Nothing to Disclose
Hector	Venkatraman	Anand	Interventional Cardiology: TAVR 2		Nothing to Disclose
Ventura	Ventura	Hector		Influence of Low Versus High Dose on the Association of Loop Diurectic and Mortality in Patients With Heart Failure: Insights From	Nothing to Disclose
Ventura Hector	Ventura	Hector	Adherence to Blood Pressure Lowering	Hypertension Control is Strongly Influenced by Patient's Health	Nothing to Disclose
Ventura Hector 14. Heart Failure and Cardiomyopathies: Transcatheter Aortic Valve Replacement in End Stage Liver Disease ConSULTANT FEESHONORARIA - Edwards Lifesciences, SANOFI	Ventura	Hector	The Great K Debate Continues: Updates and		Nothing to Disclose
Verruge	Ventura	Hector	14. Heart Failure and Cardiomyopathies:	Suggested Reviewer	Nothing to Disclose
Verbrugg	Ventura	Laurie		Transcatheter Aortic Valve Replacement in End Stage Liver Disease	
Verbrugge	Ver Lee	Peter		Subgroups With Multi-Vessel Disease in the Modern Era? A Multi-	Nothing to Disclose
Verbrugge Frederik	Verbrugge	Frederik		Intravascular Volume Expansion in Patients With Heart Failure and Reduced Ejection Fraction Is Not Revealed by Changes in Cardiac	Nothing to Disclose
Verdino Raiph Test Yourself with Questions: General Cardiomyopathies: Heart Failure and Cardiomyopathies: Relevant Diagnostics or Waste of Time? CONSULTANT FEES/HONORARIA - Biosense Webster, Jude Medical, Zoli; OFFICER, DIRECTOR, TRUSTEE, OF OTHER FIDUCIARY ROLE - LifeWatch, Inc Consultant FEES/HONORARIA - Biosense Webster, Jude Medical, Zoli; OFFICER, DIRECTOR, TRUSTEE, OF OTHER FIDUCIARY ROLE - LifeWatch, Inc Consultant FEES/HONORARIA - Biosense Webster, Jude Medical, Zoli; OFFICER, DIRECTOR, TRUSTEE, OF OTHER FIDUCIARY ROLE - LifeWatch, Inc Consultant FEES/HONORARIA - Biosense Webster, Jude Medical, Zoli; OFFICER, DIRECTOR, TRUSTEE, OF OTHER FIDUCIARY ROLE - LifeWatch, Inc Consultant FEES/HONORARIA - Biosense Webster, Jude Medical, Zoli; OFFICER, DIRECTOR, TRUSTEE, OF OTHER FIDUCIARY ROLE - LifeWatch, Inc Consultant Or Without Anticoagulation in Transcatheter Aortic Valve Replacement. Indirect Comparison and Meta-Analysis Verdoia Monica Antithrombotic Therapy in Ischemic Heart Disease Vitamin D Binding Protein R87041 Polymorphism and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor Vitamin D Binding Protein R87041 Polymorphism and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor Vitamin D Binding Protein R87041 Polymorphism and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor Vitamin D Binding Protein R87041 Polymorphism and High Polymorphism and High Polymorphism and High Polymorphism and High Polymorphism and High Polymorphism and High Polymorphism of High Polymorphism and High Polymorphism (Polymorphism and High Polymorphism and High Polymorphism (Polymorphism and High Polymorphism and High Polymorphism and High Polymorphism (Polymorphism and High Polymorphism and High Polymorphism and High Polymorphism (Polymorphism and High Polymorphism and High Polymorphism and High Polymorphism (Polymorphism	Verbrugge	Frederik		Cardiac Resynchronization Therapy With Versus Without a Defibrillator: Clinical Insights From Device Interrogation and Mode of	Nothing to Disclose
Verdino Ralph Test Yourself with Questions: General Cardiology Module 15 CAPPER CAP	Verbrugge	Frederik		Bioimpedance Algorithms in Implantable Electronic Cardiac	Nothing to Disclose
Verdino Ralph Fit Clinical Decision Making: Arrhythmias and Clinical Electrophysiology Consult_AntifeEs/HONORARIA - Biosense Webster, Jude Medical, Zoli; OFFICER, DIRECTOR, TRUSTEE, OF OTHER FIDUCIARY ROLE - LifeWatch, Inc OTHER FIDUCIARY Repland on The Nothing to Disclose Pagelace and High Polemens of Pagelace on Transport of Pagela	Verdino	Ralph	Test Yourself with Questions: General		CONSULTANT FEES/HONORARIA - Biosense Webster, St. Jude Medical, Zoll; OFFICER, DIRECTOR, TRUSTEE, OR
Verdoia	Verdino	Ralph		ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Biosense Webster, St. Jude Medical, Zoll; OFFICER, DIRECTOR, TRUSTEE, OR
Verdoia Monica Antithrombotic Therapy in Ischemic Heart Disease States and Clinical Decision Making Reviewers 7 ACC FIT Clinical Decision Making Reviewers 7 ACC FIT Clinical Decision Making Reviewer States and Clinical Scenarios Experience at a High Volume Center Scenario	Verdoia	Monica	Interventional Cardiology: TAVR 2	or Without Anticoagulation in Transcatheter Aortic Valve	
Verdoia Monica FIT Clinical Decision Making Reviewers 7 ACC FIT Clinical Decision Making Reviewer Nothing to Disclose	Verdoia	Monica		Vitamin D Binding Protein Rs7041 Polymorphism and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy	Nothing to Disclose
Disease States and Clinical Scenarios Experience at a High Volume Center				ACC FIT Clinical Decision Making Reviewer	
Attial Fibrillation, Anticoagulation and Novel Early Mortality in Patients With New Onset Atrial Fibrillation: Results CONSULTANT FEES/HONORARIA - AstraZeneca, Boet Nonvalvular Atrial Fibrillation: Results CONSULTANT FEES/HONORARIA - AstraZeneca, Boet Nonvalvular Atrial Fibrillation: Results CONSULTANT FEES/HONORARIA - AstraZeneca, Boet Nonvalvular Atrial Fibrillation: Results CONSULTANT FEES/HONORARIA - AstraZeneca, Boet Nonvalvular Atrial Fibrillation: Results From the GARFIELD-AF Registry CONSULTANT FEES/HONORARIA - AstraZeneca, Boet Nonvalvular Atrial Fibrillation: Results From the GARFIELD-AF Registry Regis			Disease States and Clinical Scenarios	Experience at a High Volume Center	
Verheugt Freek		Freek		Novel Approach for Risk Differentiation in Atrial Fibrillation Patients	CONSULTANT FEES/HONORARIA - AstraZeneca, Boehringer- Ingelheim, Bayer Healthcare, BMS/Pfizer, Daiichi-Sankyo
Verheugt Freek Stroke and AF: Thinking About the Heart The Prescribing of Antiplatelet Therapy Only in Patients With Nonvalvular Atrial Fibrillation: Results From the GARFIELD-AF Ingelheim, Bayer Healthcare, BMS/Pfizer, Dalichi-Sankyo Registry Verma Atul Late-Breaking Clinical Trials Safety and Efficacy of Uninterrupted Anticoagulation With CONSULTANT FEES/HONORARIA - Meditronic Inc;	Verheugt	Freek	Atrial Fibrillation, Anticoagulation and Novel	Early Mortality in Patients With New Onset Atrial Fibrillation: Results	CONSULTANT FEES/HONORARIA - AstraZeneca, Boehringer- Ingelheim, Bayer Healthcare, BMS/Pfizer, Daiichi-Sankyo
Verma Atul Late-Breaking Clinical Trials Safety and Efficacy of Uninterrupted Anticoagulation With CONSULTANT FEES/HONORARIA - Medtronic Inc;	Verheugt	Freek		The Prescribing of Antiplatelet Therapy Only in Patients With Nonvalvular Atrial Fibrillation: Results From the GARFIELD-AF	CONSULTANT FEES/HONORARIA - AstraZeneca, Boehringer- Ingelheim, Bayer Healthcare, BMS/Pfizer, Daiichi-Sankyo
Catheter Ablation of Atrial Fibrillation: The RE-CIRCUIT Study Webster, St Jude Medical	Verma	Atul	Late-Breaking Clinical Trials	Safety and Efficacy of Uninterrupted Anticoagulation With Dabigatran Etexilate Versus Warfarin in Patients Undergoing	RESEARCH/RESEARCH GRANTS - Bayer Inc, Biosense



Contract of the second				<u> </u>
Last Name Verma	Atul	Session Title Arrhythmias and Clinical EP: AF Ablation	Presentation Title Determination of the Ideal Contact Force Required During Pulmonary Vein Antrum Isolation (PVAI)	Disclosures CONSULTANT FEES/HONORARIA - Medtronic Inc; RESEARCH/RESEARCH GRANTS - Bayer Inc,Biosense Webster, St Jude Medical
Verma	Atul	Atrial Fibrillation and VT: Unique Populations and Solutions	Evaluation of Long-Term Success Rate of Outflow Tract Ablation in Patients With Ventricular Tachycardia	CONSULTANT FEES/HONORARIA - Medtronic Inc; RESEARCH/RESEARCH GRANTS - Bayer Inc,Biosense Webster,St Jude Medical
Verma	Atul	Atrial Fibrillation and VT: Unique Populations and Solutions	Low Stroke Incidence in Persistent Atrial Fibrillation Ablation With Multi-Electrode Phased Radio-Frequency Technology: Preliminary Results From VICTORY AF Study	CONSULTANT FEES/HONORARIA - Medtronic Inc; RESEARCH/RESEARCH GRANTS - Bayer Inc,Biosense Webster,St Jude Medical
Verma	Atul	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Effects of Induction Before Ventricular Tachycardia Ablation on Long-Term Success Rate	CONSULTANT FEES/HONORARIA - Medtronic Inc; RESEARCH/RESEARCH GRANTS - Bayer Inc,Biosense Webster,St Jude Medical
Verma	Beni	Arrhythmias and Clinical EP: Devices 4	Cardiac Resynchronization Therapy (CRT) Upgrade in Patients With Pacemakers is Associated With Higher Mortality Compared to De- Novo	Nothing to Disclose
Verma	Divya Ratan	FIT Forum: Stump the Professor	Persistence Pays Off: A Rare Case of Platypnea-Orthodeoxia Syndrome Due to a Patent Foramen Ovale	Nothing to Disclose
Verma	Divya Ratan	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Comparing TEE With Angiographic Sizing of WATCHMAN Device for Left Atrial Appendage Closure	Nothing to Disclose
Verma	Divya Ratan	Novel Developments in Acute Coronary	Central Fractional Pulse Pressure Predicts Cardiac Power Index in Patients With Acute Coronary Syndrome	Nothing to Disclose
Verma	Divya Ratan	Syndromes Advances in Chronic Total Occlusion Intervention	Impact of Sex on Physical Limitation & Patient Health Status After Chronic Total Occlusion Percutaneous Coronary Intervention: Propensity Matched Substudy of OPEN-CTO Registry	Nothing to Disclose
Verma	Rajiv	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Late Presentation of Total Anomalous Pulmonary Venous Connection	Nothing to Disclose
Verma	Sunil	Insights Into Ischemic Heart Disease: Stable to Erosive Plaques	Immuno-Histopathology of Intracoronary Thrombus Aspirated During Primary Percutaneous Intervention for ST Elevation Myocardial Infarction and Its Clinical Significance	Nothing to Disclose
Vermilye	Katherine	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Infocardial Infarction and its Clinical Significance Sustained Clinical Benefit of Cardiac Resynchronization Therapy in Patients With Relatively Preserved Ejection Fraction: A MADIT-CRT Long-Term Follow-Up Sub-Study	Nothing to Disclose
Vernalis	Marina	Interdisciplinary Cardiovascular Team	Multidisciplinary Cardiovascular Team Review Captures Preclinical	Nothing to Disclose
Vernalis	Marina	Collaboratives in Care Diabetes and Other Issues in Cardiovascular Prevention	Disease Arresting Insulin Resistance With an Integrative Health Intervention	Nothing to Disclose
Verrier	Richard	O8. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	OTHER - GE Healthcare; RESEARCH/RESEARCH GRANTS - GILEAD Sciences, Incarda Therapeutics, LIVANOVA
Ververeli	Charilila-Loukia	3 Diabetes and Endothelial Dysfucntion in Heart Failure	Association of Endothelial Dysfunction With Biomarkers of Inflammation, Myocardial Fibrosis and Left Ventricle Strain in	Nothing to Disclose
Vest	Amanda	Heart Failure: Implementing the Guidelines	Patients With Heart Failure A Case of Heart Failure With Preserved Ejection Fraction	Nothing to Disclose
		Into Practice; A Clinical Case-Based Symposium: International Perspectives From the European Society of Cardiology and the American College of Cardiology		
Vest	Amanda	The Heavy Heart: Practicing Heart Failure	Panelist	Nothing to Disclose
Vest	Amanda	Cardiology in an Obesity Epidemic The Heavy Heart: Practicing Heart Failure Cardiology in an Obesity Epidemia	Medical and Lifestyle Strategies for Weight Loss in Heart Failure	Nothing to Disclose
Vest	Amanda	Cardiology in an Obesity Epidemic Diabetes and Heart Failure: Are We Hitting	Panelist	Nothing to Disclose
Vest	Amanda	The Sweet Spot Diabetes and Heart Failure: Are We Hitting	Insulin Resistance and the Metabolic State in Advanced Systolic	Nothing to Disclose
Vest	Amanda	The Sweet Spot Diabetes and Heart Failure: Are We Hitting	Heart Failure Pharmacological Glycemic Management is an Important	Nothing to Disclose
Vest	Amanda	The Sweet Spot The Nuts and Bolts of Pulmonary Hypertension	Component of Heart Failure Therapy, Con Case Presentation in Pulmonary Hypertension Due to Left Heart	Nothing to Disclose
Vest	Amanda	in Left Heart Disease Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	Fallure The Impact of Glucagon Like Peptide-1 Agonist Therapy on Heart Rate in Advanced Systolic Heart Failure: An Analysis From the	Nothing to Disclose
Vestbo	Jørgen	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Functional Impact of GLP-1 for Heart Failure Treatment Study Prognostic Importance of Blood Pressure and Heart Rate in Chronic Obstructive Pulmonary Disease: The SUMMIT Trial	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, Chiesi, GlaxoSmithkline, Novartis Corporation; DATA SAFETY MONITORING BOARD - Novartis Corporation; SPEAKER'S BUREAU - AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, Chiesi, Novartis Corporation
Vestbo	Jørgen	Innovations in Cardiovascular Risk Assessment and Reduction	High-Sensitivity Cardiac Troponin I and Risk of Cardiovascular Events in Pateints With COPD and Heightened Cardiovascular Risk: A Biomarker Sub-Study of the SUMMIT Trial	Inc, Chiesi, GlaxoSmithkline, Novartis Corporation: DATA SAFETY MONITORING BOARD - Novartis Corporation: SPEAKETS BUREAU - AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc, Chiesi, Novartis Corporation
Vetrovec	George	Mechanical Support, Hemodynamic Support for Shock in High Risk Subsets; Hemodynamic Compromise	Panelist	CONSULTANT FEES/HONORARIA - Abiomed, Merck; OTHER - Quintiles; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Johnson & Dongamp; Johnson, Merck, Pfizer
Victor	Brett	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Eptifibatide for Treatment of Mechanical Aortic Valve Thrombus: A Novel Therapeutic Approach	Nothing to Disclose
Vidovich	Mladen	Radial Access Mini-Symposium I	Recognizing and Dealing with Complications of Transradial Procedures	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation, Cordis, CSI,Merit Medical, St. Jude Medical; OTHER - Merit Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific; SPEAKER'S BUREAU - Eli Lilly/Dai Ichi Sankyo
Vidovich	Mladen	Maintenance of Clinical Competencies in Invasive Coronary Imaging and Coronary Physiology	OCT Imaging: Tips, Tricks and Pitfalls	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation, Cordis, CSI, Merit Medical, St. Jude Medical; CTHER - Merit Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific; SPEAKER'S BUREAU - Eli Lilly/Dai Ichi Sankyo
Vidovich	Mladen	Maintenance of Clinical Competencies in Invasive Coronary Imaging and Coronary Physiology	Case Presentation: OCT	Scientific, SPEARER'S BUREAU - Ell LillyDal Ichi Sainky CONSULTANT FEES/HONORARIA - Boston Scientific Corporation, Cordis, CSI, Merit Medical, St. Jude Medical; OTHER - Merit Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific; SPEAKER'S BUREAU - Eli LillyDal Ichi Sankyo
Vidovich	Mladen	Vascular Access and Hemostasis Issues	Distal Perfusion Is Maintained in Veteran Subjects Undergoing Transradial Cardiac Catheterization	Scientific; SPEARER'S BUREAU - EIL LIII/JUBI IGNI SARKYO CONSULTANT FEES/HONORARIA - Boston Scientific Corporation, Cordis, CSI, Merit Medical, St. Jude Medical; OTHER - Merit Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific; SPEAKER'S BUREAU - EIL LIII/JOBI Ichi Sankyo
Vidovich	Mladen	Timely Topics in Acute Coronary Syndromes	Kidney Transplantation: Does It Affect Outcomes for Percutaneous Coronary Intervention in Patients Presenting With Acute Myocardial Infarction? Analysis From Nationwide Inpatient Sample (NIS)	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation, Cordis, CSI, Merit Medical, St. Jude Medical; OTHER - Merit Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific; SPEAKER'S BUREAU - Eli Lilly/Dai Ichi Sankyo



Contract of the second				
Last Name Vidovich	First Name Mladen	Session Title The Inside View: Learning From Intracoronary	Presentation Title ACC Poster Moderator	Disclosures CONSULTANT FEES/HONORARIA - Boston Scientific
VIGOVICIT	Wilducii	Imaging	7001 Osici moderator	Corporation, Cordis, CSI, Merit Medical, St. Jude Medical; OTHER Merit Medical; RESEARCH/RESEARCH GRANTS - Boston Scientific; SPEAKER'S BUREAU - Eli Lilly/Dai Ichi Sankyo
Vij	Aviral	Nuclear Cardiology: Prognosis	The Prognostic Value of Serial Stress Myocardial Perfusion Imaging in Asymptomatic End-Stage Renal Disease Patients Awaiting Kidney Transplantation	Nothing to Disclose
Vijapurkar	Ujjwala	Fibrillatory Arrhythmias: Outcomes With	Rates of Oral Anticoagulant Use, While Improving Over Time,	Nothing to Disclose
Vijapurkar	Ujjwala	Contemporary Practice The Intersection of Diabetes and ASCVD	Remain Low Among Hospitalized Patients With Atrial Fibrillation Effects of Canagliflozin Versus Glimepiride on Inflammatory Biomarkers and Chemokines in Patients With Type 2 Diabetes	Nothing to Disclose
Vijay	Pooja	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Mellitus Clinical Outcomes Associated With Impella Versus IABP Use in Stable Patients Undergoing High Risk Percutaneous Coronary	Nothing to Disclose
Vijay	Pooja	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Intervention Impella or Intra-Aortic Balloon Pump Support in Patients Undergoing High Risk Percutaneous Coronary Intervention: A Real	Nothing to Disclose
Vijay	Pooja	Coronary Angiography, Intra-Vascular Imaging,	World Single Center Experience	Nothing to Disclose
		Revascularization and Outcomes	Malignancy Undergoing PCI	ů
Vijay	Pooja	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Risks for Adverse Cardiovascular Events After PCI: Results From a Large Single-Center Registry	Nothing to Disclose
Vijay	Pooja	Novel Developments in Acute Coronary Syndromes	Trends in Incidence and Mortality Associated With Acute Kidney Injury in Patients Undergoing PCI for Acute Coronary Syndrome	Nothing to Disclose
∕ijay	Pooja	Optimizing the Care of ACS Patients	Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population	Nothing to Disclose
/ijay	Pooja	Interventional Complexity and Complications	Prediction of Acute Kidney Injury in Patients Undergoing Coronary	Nothing to Disclose
/ijay	Pooja	Interventional Cardiology: PCI in Complex	Intervention Using Calculation of Serum Osmolality Risk and Impact of Diabetes Mellitus on Ischemic Events in Females	Nothing to Disclose
/ijayaraman	Pugazhendhi	Patients Tough Clinical Problems in Patients with	and Males After Percutaneous Coronary Intervention His Bundle Pacing; The New Kid on the Block: Who, When and How	CONSULTANT FEES/HONORARIA - Boston Scientific;
	ŭ	Implantable Electronic Devices	-	SPEAKER'S BUREAU - MEDTRONIC
Vijayaraman	Pugazhendhi	PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	A Novel Approach to Pre-Procedural Planning of Percutaneous Interventions: Value of 3D Printing and Fluoroscopic Evaluation	CONSULTANT FEES/HONORARIA - Boston Scientific; SPEAKER'S BUREAU - MEDTRONIC
Vijayaraman	Pugazhendhi	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Replacement Patients With Atrial Fibrillation Are at High Risk for Stroke and Bleeding: A Rationale for Consideration of Transcatheter Aortic Valve Replacement and Left Atrial Appendage Closure as Complementary Therapies	CONSULTANT FEES/HONORARIA - Boston Scientific; SPEAKER'S BUREAU - MEDTRONIC
Vijayaraman	Pugazhendhi	Arrhythmias and Clinical EP: Devices 4	Cardiac Resynchronization Therapy (CRT) Upgrade in Patients With Pacemakers Is Associated With Higher Mortality Compared to De- Novo	CONSULTANT FEES/HONORARIA - Boston Scientific; SPEAKER'S BUREAU - MEDTRONIC
/ijayaraman /iles-Gonzalez	Pugazhendhi Juan	06. Arrhythmias and Clinical EP: Other Team 1 Updates on Risk Factors for Cardiovascular	Suggested Reviewer Hospital Admissions for Chest Pain Associated With Cocaine use in	CONSULTANT FEES/HONORARIA - Boston Scientific; SPEAKER'S BUREAU - MEDTRONIC Nothing to Disclose
		Disease	the United States	<u> </u>
Viles-Gonzalez	Juan	Arrhythmias and Clinical EP: Basic 3	Seasonal Trends in Sudden Cardiac Death: A Study From the Largest Inpatient Database	Nothing to Disclose
/iles-Gonzalez	Juan	Arrhythmias and Clinical EP: Syncope and Other EP Issues	Mortality Rates and Cost of Hospital Admissions for Syncope in the United States	Nothing to Disclose
Viles-Gonzalez	Juan	Why Can't We Be Friends? Controversies in	Cardiac Resynchronization Therapy in Inotropic-Dependent Heart	Nothing to Disclose
Villa	Clara	Heart Failure Management Arrhythmias and Clinical EP: Syncope and	Failure Patients: A Systematic Review and Meta-Analysis Safe Multidisciplinary Management of New Therapies: The Ritmo	Nothing to Disclose
Villa	Guillermo	Other EP Issues Diabetes and Other Issues in Cardiovascular	Project (Real Time Continuous Web Monitoring) Observed Versus Predicted Cardiovascular Event Rates in Primary	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
Villa	Guillermo	Prevention	Prevention Diabetic Patients Receiving High-Intensity Statins in the United Kingdom Comparison of the Use of Cardiovascular Risk Equations by Health	ROLE - Amgen; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Amgen OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY
		Diabetes and Other Issues in Cardiovascular Prevention	Technology Assessment Bodies and Clinical Guidelines	ROLE - Amgen; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Amgen
Villablanca	Pedro	Interventional Cardiology: TAVR 2	Comparison of In-Hospital Outcomes of Transcatheter Aortic Valve Replacement in Men and Women	Nothing to Disclose
Villablanca	Pedro	Interventional Cardiology: TAVR 2	Association of Chronic Renal Insufficiency With In-Hospital Outcomes of Transcatheter Aortic Valve Replacement	Nothing to Disclose
Villablanca	Pedro	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Sex Differences in Revascularization and In-Hospital Outcomes of Non-ST-Segment Elevation Myocardial Infarction in the United States	Nothing to Disclose
Villablanca	Pedro	Interventional Cardiology: TAVR 3	Regional Variations in In-Hospital Outcomes and Healthcare Resource Utilization in Patients Undergoing Transcatheter Aortic	Nothing to Disclose
Villablanca	Pedro	Antithrombotic Therapy in Ischemic Heart Disease	Valve Replacement in the United States Role of Anticoagulation Therapy After Anterior Wall ST-Elevation Myocardial Infraction in Preventing LV Thrombus: A Meta-Analysis	Nothing to Disclose
Villablanca	Pedro	Arrhythmias and Clinical EP: Syncope and Other EP Issues	and Meta-Regression Association of Academic Year-End Changeover With Survival Rates After In-Hospital Cardiac Arrest: An Examination of the "July Effect"	Nothing to Disclose
Villablanca	Pedro	Advances in Chronic Total Occlusion Intervention	Trends and In-Hospital Outcomes of Patients Admitted With ST Elevation Myocardial Infarction and Chronic Total Occlusions:	Nothing to Disclose
Villablanca	Pedro	Optimizing the Care of ACS Patients	Insights From a National Database Weekend Versus Weekday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide	Nothing to Disclose
Villablanca Spinetto	Pedro	Markers of Prognosis Associated With Elevated Blood Pressure	Analysis Prevalence and Prognostic Significance of Cardiac Troponin-T Elevation in Patients Admitted With Hypertensive Crises	Nothing to Disclose
Villablanca Spinetto	Pedro	Beans, Beans, Good for Your Heart	Percutaneous Renal Denervation for Resistant Hypertension: An Updated Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
/illarraga	Hector	Novel Echocardiographic Methods for	Subclinical Myocardial Alterations in Cardiac Sarcoidosis	Nothing to Disclose
/illarreal	Daniel	Assessing Cardiac Function Unusual Presentations of ACS	Reciprocal Changes in STEMI: Ischemia at Distance or Reciprocal	Nothing to Disclose
/illines	Todd	Patient-Centered Imaging: Quality of Cardiac	Reflection of ST-Elevation Current Randomized Trials Driving CT-Guided Care	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
/illines	Todd	CT Evidence Great Debates in Cardiac CT	Debate: Coronary CTA Should Be the Initial Test in Most Patients	Pharmaceuticals CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
			with Stable Chest Pain, Pro	Pharmaceuticals
/illines	Todd	Great Debates in Cardiac CT	Rebuttal,Con	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals
Villines	Todd	Radiation from Diagnostic Imaging: Risk- benefit Analysis	Panelist	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals
Villines	Todd	Interdisciplinary Cardiovascular Team Collaboratives in Care	Multidisciplinary Cardiovascular Team Review Captures Preclinical Disease	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
Villines	Todd	Things That Beart Disease: What Is Aorta, Artery and Anomalous?	Loisdase Long-Term Cardiovascular Outcomes in Patients With Anomalous Coronary Arteries Wisualized by Coronary CT Angiography: The CONFIRM (COronary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter) Registry	Pharmaceuticals CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals



Last Name	Et and Marian			
Villines	First Name Todd	Session Title Non Invasive Imaging: Prognostic Implications of CT Angiography	Presentation Title Smoking and its Relationship With Long Term Events: Further Insights From the CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry	Disclosures CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals
Villines	Todd	Diabetes and Other Issues in Cardiovascular	Arresting Insulin Resistance With an Integrative Health Intervention	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
Villines	Todd	Prevention 27. Non Invasive Imaging: CT/Multimodality,	Suggested Reviewer	Pharmaceuticals CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
Vincent	Julie	Angiography, and Non-CT Angiography Team 2 Engage @ ACC.17 Studio:The Newlywed	Participant, Team 2	Pharmaceuticals CONSULTANT FEES/HONORARIA - MEDTRONIC; OTHER - St
		Game for Pediatric Cardiac Providers		Jude Medical; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences
Vincent Vincent	Robert Robert	Six Years of Making an IMPACT Six Years of Making an IMPACT	Co-Chair Creating an IMPACT: Establishing a Congenital Catheterization	Nothing to Disclose Nothing to Disclose
Vincent	Robert	Highlighted Original Research: Congenital	Registry from Scratch Transcatheter Ductal Stenting Versus Surgical Systemic-to-	Nothing to Disclose
		Heart Disease and the Year in Review	Pulmonary Artery Shunts: Altering Dogma at a High-Volume Institution	-
Vincent	Robert	Interventional Cardiology: Translation and Pre- Clinical Research	Boron Based Hgf Memetic Molecule Has Cardioprotective Role Against Ischemia-Reperfusion Injury	Nothing to Disclose
Vinding	Naja Emborg	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Vitamin K Antagonist or Dabigatran in Patients With Atrial Fibrillation: The Importance of Time in Therapeutic Range	Nothing to Disclose
Vinereanu	Dragos	Emerging Applications of Echocardiography	Effect of Changing Strain Software Versions on Longitudinal Assessment of LV Function	RESEARCH/RESEARCH GRANTS - GSK,Pfizer-BMS
Vinereanu	Dragos	Arrhythmias and Clinical EP: Anticoagulation Issues	Use of Interacting Drugs Did Not Modify Treatment Effects of Apixaban Versus Warfarin for Atrial Fibrillation: Results From the ARISTOTLE Trial	RESEARCH/RESEARCH GRANTS - GSK,Pfizer-BMS
Vinereanu	Dragos	Novel Imaging and Therapies in Heart Failure	Gestational Hypertension and Preeclampsia Are Associated With	RESEARCH/RESEARCH GRANTS - GSK,Pfizer-BMS
Vinereanu	Dragos	Arrhythmias and Clinical EP: AF Miscellaneous	Subclinical Left Ventricular Systolic and Diastolic Dysfunction Aortic Stenosis, but Not Mitral or Aortic Regurgitation, Is Associated	RESEARCH/RESEARCH GRANTS - GSK,Pfizer-BMS
Vininius Forraira	Maroon	and Surgical Issues	With Adverse Outcomes With Atrial Fibrillation: Results From the ARISTOTLE Trial What Is the Importance of Preoperative Electrocardiogram in	Nothing to Disclose
Vinicius Ferreira	Marcos	Innovations in Advocacy and Patient Centered Care	Hypertensive Patients for Moderate/High Risk Noncardiac Surgery? A Single-Center Randomized Study	Nothing to Disclose
Vinnakota	Sravya	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Neurohumoral Activation and Long-Term Cardiovascular Outcomes in Chronic Kidney Disease: A Population-Based Cohort	Nothing to Disclose
Violi	Francesco	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	History of Atrial Fibrillation in a First-Degree Relative and Risk of Cardiovascular Events	Nothing to Disclose
Virani	Salim	Prevention of ASCVD Over the Lifespan: A	Co-Chair	Nothing to Disclose
Virani	Salim	Case-based Approach Advances in Cholesterol Measurement and	Predictors of Statin Use for Patients With LDL Cholesterol Above	Nothing to Disclose
Virani	Salim	Management Advances in Cholesterol Measurement and	190mg/dL: Insights From the Veterans Affairs Health Care System Contemporary Patterns of Lipid Testing in Primary and Secondary	Nothing to Disclose
Virani	Salim	Management Advances in Cholesterol Measurement and	Prevention Patients: Insights From the PALM Registry Association of Remnant-Like Particle Cholesterol and Low-Density	Nothing to Disclose
		Management	Lipoprotein Triglyceride With Incidence of Cardiovascular Events: The ARIC Study <i></i>	
Virani	Salim	Arrhythmias and Clinical EP: Basic 1	Variation in the Use of Direct Oral Anticoagulants and Associated Cost Implications: Findings From the Medical Expenditure Panel Survey 2010 to 2013	Nothing to Disclose
Virani	Salim	Innovations in Practice Management and Social Media	Impact of Electronic Health Records on the Quality of Outpatient Cardiovascular Care Delivery in India: Insights From the American College of Cardiology's PINNACLE India Quality Improvement Program (PICIP)	Nothing to Disclose
Virani	Salim	Advances in Lipid Management	Implications of the IMPROVE-IT Trial for Contemporary Cardiovascular Practice: An NCDR [®] Research to Practice (R2P) Project	Nothing to Disclose
Virani	Salim	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Stroke Among Whites and Blacks: The Atherosclerosis Risk In Communities (ARIC) Study	Nothing to Disclose
Virani	Salim	Interventional Cardiology: PCI in Complex Patients		Nothing to Disclose
Virani	Salim	Recent Trends in Combination Therapy: Managing Cholesterol Even in the Most	2013: AHA/ACC Blood Cholesterol Guidelines: Are We Following the Guidelines	Nothing to Disclose
Virani	Salim	Resistant The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Implications of the FDA Approval of PCSK9 Inhibitors for Contemporary Cardiovascular Practice: Findings From the	Nothing to Disclose
Virani	Salim	32. Prevention: Clinical Team 3	NCDR [®] Research to Practice (R2P) Project Suggested Reviewer	Nothing to Disclose
Virk	Hartaj	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Ventricular Tachycardia in a Patient With Coexisting Brugada Syndrome and Coronary Vasospasm	Nothing to Disclose
Virmani	Renu	The Evolution of Angioplasty 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	Panelist	CONSULTANT FEES/HONORARIA - 480 Medical / Arsenal Medical /Abott Vascular, Boston Scientific, CBard / Lutonix, Inc. ,Medtronic AVE, Microport Medical, OrbusNeich, Terumo, W. L. Gore; SPEAKER'S BUREAU - Merck
Virmani	Renu	Head to Toe: Outcomes of Endovascular Interventions	Safety and Efficacy of Zilver PTX Drug Eluting Stent Implantation Following Drug Coated Balloon Inflation Versus POBA in Healthy Swine Model	CONSULTANT FEES/HONORARIA - 480 Medical / Arsenal Medical Abbott Vascular, Boston Scientific, CBard / Lutonix, Inc. , Medtronic AVE, Microport Medical, Orbusheich, Terumo, W. L. Gore; SPEAKER'S BUREAU - Merck
Virmani	Renu	Interventional Cardiology: Translation and Pre- Clinical Research	Endothelial Maturation and Function Following Implantation of Abluminal Coating Biodegradable Polymer Based Sirolimus-Eluting Metallic Stent Versus Conformal Coating Durable Polymer Based Everolimus Eluting Stent	CONSULTANT FEES/HONORARIA - 480 Medical / Arsenal Medical, Abbott Vascular, Boston Scientific, CBard / Lutonix, Inc., Medironic AVE, Microport Medical, OrbusNeich, Terumo, W. L. Gore; SPEAKER'S BUREAU - Merck
Virmani	Renu	Population Specific Cardiomyopathies: From Exomes to Databases	Everoimus Eutung stent Racial Difference in Genetic Variants Associated With Hypertrophic Cardiomyopathy	CONSULTANT FEES/HONORARIA - 480 Medical / Arsenal Medical, Abbott Vascular, Boston Scientific, CBard / Lutonix, Inc., Medtronic AVE, Microport Medical, OrbusNeich, Terumo, W. L.
Virmani	Renu	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Pathological Features of Left Main Stent Thrombosis	Gore; SPEAKER'S BUREAU - Merck CONSULTANT FEES/HONORARIA - 480 Medical / Arsenal Medical, Abbott Vascular, Boston Scientific, CBard / Lutonix, Inc. Medtronic AVE, Microport Medical, OrbusNeich, Terumo, W. L. Gore; SPEAKER'S BUREAU - Merck
Virmani	Renu	Non Invasive Imaging: Expanding Clinical Applications	Dual-Energy Coronary Computed Tomography Evaluation of High- Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients: Validation with Histopathologic Gold Standard	COCNSULTANT FEES/HONORARIA - 480 Medical / Arsenal Medical Abobat Vascular, Boston Scientific, CBard / Lutonix, Inc. ,Medtronic AVE. Microport Medical, OrbusNeich, Terumo, W. L. Gore; SPEAKER'S BUREAU - Merck
Virmani	Renu	Coronary Intervention: Drug Eluting Stent and Scaffolds	Long-Term Pathological Result of Everolimus-Eluting Stent Versus Silolimus-Eluting Stent and Bare Metal Stent	CONSULTANT FEES/HONORARIA - 480 Medical / Arsenal Medical Abbott Vascular, Boston Scientific, CBard / Lutonix, Inc. , Medtronic AVE, Microport Medical, OrbusNeich, Terumo, W. L. Gore; SPEAKER'S BUREAU - Merck
Virmani	Renu	Non Invasive Imaging: Prognostic Implications of CT Angiography	Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Death: A Comparison to a Histologic Reference Standard	CONSULTANT FEES/HONORARIA - 480 Medical / Arsenal Medical Abbott Vascular, Boston Scientific, CBard / Lutonix, Inc. ,Medtronic AVE, Microport Medical, OrbusNeich, Terumo, W. L. Gore; SPEAKER'S BUREAU - Merck

Contract of the Contract of th				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Virmani	Renu	Non Invasive Imaging: New Technologies	Optimal Method for Necrotic Core Identification in Coronary Plaque With Dual-Energy Computed Tomography: Material Decomposition and Atomic Number	CONSULTANT FEES/HONORARIA - 480 Medical / Arsenal Medical, Abbott Vascular, Boston Scientific, CBard / Lutonix, Inc. , Medtronic AVE, Microport Medical, OrbusNeich, Terumo, W. L.
Virmani	Renu	Unusual Presentations of ACS	Molecular Autopsy of Plaque Erosion-Induced Sudden Cardiac Death in Young Adults (18-35 Years Old)	Gore; SPEAKER'S BUREAU - Merck CONSULTANT FEES/HONORARIA - 480 Medical / Arsenal Medical,Abbott Vascular,Boston Scientific,CBard / Lutonix, Inc.
				,Medtronic AVE,Microport Medical,OrbusNeich,Terumo,W. L. Gore; SPEAKER'S BUREAU - Merck
Virmani	Renu	Refining PCI Technique and Outcomes	mTors Inhibitors Increase Endothelial Permeability and Prevent Maturation: Uncovering the Mechanism of Neoatherosclerosis in Drug Eluting Stents	CONSULTANT FEES/HONORARIA - 480 Medical / Arsenal Medical Abbott Vascular, Boston Scientific, CBard / Lutonix, Inc. , Medtronic AVE, Microport Medical, OrbusNeich, Terumo, W. L. Gore; SPEAKER'S BUREAU - Merck
Virmani	Renu	26. Interventional Cardiology: Vascular Access and Complications Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - 480 Medical / Arsenal Medical Abbott Vascular, Boston Scientific, CBard / Lutonix, Inc. , Medtronic AVE, Microport Medical, OrbusNeich, Terumo, W. L. Gore; SPEAKER'S BUREAU - Merck
Vis	Maartje	Non Invasive Imaging: Expanding Clinical	Prevention of Contrast-Induced Nephropathy for Computed	Nothing to Disclose
VIS	waarge	Applications	Tomography (CT)-Scanning in TAVR Work-Up: One-Hour Hydration With Sodium Bicarbonate Is Not Inferior to 24-Hour Saline Hydration	Houring to Escribe
Vishnevsky	Alec	The Best Structural Interventional Challenging Cases	To Close or Not to Close: Percutaneous Treatment of Acquired Gerbode Defect	Nothing to Disclose
Vishnevsky	Alec	Interventional Cardiology: TAVR 1	Hands Down: Operator Hand Versus Torso Radiation Exposure During Transcatheter Aortic Valve Replacement	Nothing to Disclose
Vishnevsky	Alec	Interventional Cardiology: TAVR 1	Provider Radiation Exposure During Transcatheter Aortic Valve Replacement	Nothing to Disclose
Vishnevsky	Alec	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Anterolateral Papillary Muscle Rupture: A Rare Complication of Acute Myocardial Infarction	Nothing to Disclose
Viskin	Sami	Quickfire ECG for Experts	Panelist	CONSULTANT FEES/HONORARIA - Boston Scientific European Strategy Advisory Board
Visovatti	Scott	Demystifying and Managing Pulmonary Hypertension and RV Dysfunction: It Takes a Village	Management of Acute Right Ventricular Failure	Nothing to Disclose
Visovatti	Scott	Bridge From the Basics: Translational Research in Pulmonary Hypertension	ACC Poster Moderator	Nothing to Disclose
Visveswaran	Gautam	Timely Topics in Acute Coronary Syndromes	Routine Invasive Versus Conservative Strategy for Elderly Patients Aged>75 Years With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS): A Meta-Analysis of Randomized Controlled Trials	CONSULTANT FEES/HONORARIA - MAQUET Cardiovascular LLC.
Vita	Tomas	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Integrating Hyperemic Myocardial Blood Flow and Coronary Flow Reserve for Predicting Cardiovascular Mortality Outcomes in Patients With Known or Suspected Ischemic Heart Disease	Nothing to Disclose
Vita	Tomas	Nuclear Cardiology: Prognosis	Myocardial Scar but Not Ischemia Predicts Defibrillator Shocks and Sudden Cardiac Death in Patients With Reduced Left Ventricular Ejection Fraction	Nothing to Disclose
Vita	Tomas	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Relationship of Coronary Flow Reserve With Body Mass Index and Adverse Outcomes in Patients Without Overt Ischemic Heart Disease: Implications for Metabolic Surgery Eligibility	Nothing to Disclose
Vita	Tomas	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	Association Between Coronary Flow Reserve and Adverse Cardiovascular Events Along a Continuum of Metabolic Disease in Symptomatic Patients Without Overt Coronary Artery Disease	Nothing to Disclose
Vitola	Joao	State of the Art Nuclear Cardiology: SPECT Myocardial Perfusion Imaging	Co-Chair	Nothing to Disclose
Vitola	Joao	Nuclear Cardiology: Quality	Worldwide Variation in the Use of Nuclear Cardiology Camera Technology, Reconstruction Software, and Acquisition Protocols: Findings From the IAEA Nuclear Cardiology Protocols Study (INCAPS)	Nothing to Disclose
Vittinghoff	Eric	The Story of the Adult Congenital Heart Disease Patient and EP	Safety of Transvenous Lead Removal in Adult Congenital Heart Disease in the US	Nothing to Disclose
Vittinghoff	Eric	Arrhythmias and Clinical EP: Devices 3	Safety of Transvenous Lead Removal Among Nonagenarians	Nothing to Disclose
Vivas	David	Novel Developments in Acute Coronary Syndromes	Underuse of Potent Oral P2y ₁₂ Inhibitors in Women With an Acute Coronary Syndrome, Despite Having a Higher Risk Profile Than Male Patients	Nothing to Disclose
Vlachopoulos	Charalambos	Innovations in Cardiovascular Risk Assessment and Reduction	Most Patients With Acute Coronary Syndromes Are Already at High Risk Prior to the Event and Lipid Management Is Underachieved Both Before and After Hospitalization: The Phaethon Study	CONSULTANT FEES/HONORARIA - Servier, MSD, Amgen, Boehringer, Angelini, Menarini, Novartis, Sanofi, PharmaSwiss, Mylan
Vlismas	Peter	Markers of Prognosis Associated With Elevated Blood Pressure	Prevalence and Prognostic Significance of Cardiac Troponin-T Elevation in Patients Admitted With Hypertensive Crises	Nothing to Disclose
Vlismas	Peter	Beans, Beans, Good for Your Heart	Percutaneous Renal Denervation for Resistant Hypertension: An Updated Meta-Analysis of Randomized Controlled Trials	Nothing to Disclose
Vo	Lien	Arrhythmias and Clinical EP: Anticoagulation Issues	Real-World Comparison of Major Bleeding and Associated Costs Among Oral Anticoagulant-Naïve Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin in the US Medicare Population	Nothing to Disclose
Vo	Lien	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Compared to Warfarin Among Non-Valvular Atrial Fibrillation Patients in the US Medicare Population	Nothing to Disclose
Vo Vo	Minh Minh	Complex PCI in 2017 Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in	Case Presentation: Illustrative CTO- History and Angiogram Characterization and Outcomes of Spontaneous Coronary Artery Dissection Patients Presenting With an Acute Coronary Syndrome:	Nothing to Disclose Nothing to Disclose
Voeller	Heinz	Review Why Can't We Be Friends? Controversies in Heart Failure Management	Insights From the ACALM Registry Remote Telemonitoring in Chronic Heart Failure Does Not Reduce Healthcare Cost but Improves Quality of Life: Endpoints of the CardioBBEAT Trial	Nothing to Disclose
Vogel	Birgit	Coronary Intervention in Interventional Cardiology: Advanced Device Use	CardiobBEAT Final Clinical Outcomes Associated With Impella Versus IABP Use in Stable Patients Undergoing High Risk Percutaneous Coronary Intervention	Nothing to Disclose
Vogel	Birgit	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Intervention In	Nothing to Disclose
Vogel	Birgit	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	Nothing to Disclose
Vogel	Birgit	Novel Developments in Acute Coronary Syndromes	Trends in Incidence and Mortality Associated With Acute Kidney Injury in Patients Undergoing PCI for Acute Coronary Syndrome	Nothing to Disclose
Vogel	Birgit	Timely Topics in Acute Coronary Syndromes	Predictors of High Intensity Statin Use After Percutaneous Coronary Interventions	Nothing to Disclose
Vogel	Birgit	Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes	Nothing to Disclose
Vogel	Birgit	Optimizing the Care of ACS Patients	Underutilization of High Intensity Statins in a Contemporary High Risk PCI Population	Nothing to Disclose
			· · · · · · · · · · · · · · · · · · ·	



Control of the Contro				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Vogel	Birgit	Interventional Complexity and Complications	Prediction of Acute Kidney Injury in Patients Undergoing Coronary Intervention Using Calculation of Serum Osmolality	Nothing to Disclose
Vogel	Birgit	Interventional Cardiology: PCI in Complex Patients	Risk and Impact of Diabetes Mellitus on Ischemic Events in Females and Males After Percutaneous Coronary Intervention	Nothing to Disclose
Vogel	Birgit	Interventional Cardiology: PCI in Complex Patients	Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated Heparin Following Transcatheter Aortic Valve Replacement: Results From the Bravo-3 Randomized Trial	Nothing to Disclose
Vogiatzi	Georgia	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Omega-3 Polyunsaturated Fatty Acids May Favorably Affect Inflammatory Biomarkers & Novel Indices of Left Ventricle Function in Patients With Heart Failure	Nothing to Disclose
Vogiatzi	Georgia	MicroRNAs and Beyond in Vascular Medicine	Association of Endothelial Dysfunction and Arterial Wall Elastic Properties With Systemic Inflammation in Patients With Pseudoexfoliative Glaucoma	Nothing to Disclose
Vogiatzi	Georgia	Diabetes and Endothelial Dysfucntion in Heart Failure	Association of Endothelial Dysfunction With Biomarkers of Inflammation, Myocardial Fibrosis and Left Ventricle Strain in	Nothing to Disclose
Vogiatzi	Georgia	Vascular Access and Hemostasis Issues	Patients With Heart Failure Endothelial Dysfunction Post Transradial Access Coronary Catheterization: A Clinical Study and Meta-Analysis of Published	Nothing to Disclose
Vogiatzi	Georgia	From Diet to Drugs: Mechanistic Insight Into	Literature Dietary Consumption of Olive Oil and Cardiovascular Outcome in	Nothing to Disclose
Vogiatzi	Georgia	Ischemic Heart Disease Uncovering the Intricacies of Vascular Function	Patients With Coronary Artery Disease The Impact of Natural Chios Mastic Supplementation on Endothelial	Nothing to Disclose
Voigt	Andrew	Arrhythmias and Clinical EP: AF Ablation	Function and Arterial Stiffness in Smokers Characterization of Pulmonary Vein Reconnection Post Cryoballoon	Nothing to Disclose
			Ablation	
Voigt	Jens-Uwe	Echocardiography: What is New in 2017	Speckle Tracking, Strain, and Velocity Vortex Imaging: How to Best Implement to My Daily Practice	Nothing to Disclose
Voisine	Pierre	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic Surgical Trials Network	Nothing to Disclose
Volgman	Annabelle	Debates: Is There Really a Sex Difference in CV Presentation, Care, and Outcomes?	Women Have Different Symptoms Than Men: CON	OTHER - none
Volgman	Annabelle	Core Curriculum: Decisions on Afib: From	Afib Anticoagulation: Jumping From Risk Calculator Tools to	OTHER - none
Volgman	Annabelle	Prevention to Cure Young Investigator Awards Competition: Basic	Pharmacologic Options Judge	OTHER - none
Vollema	Elise	and Translational Science Interventional Cardiology: TAVR 1	Sizing Aortic Valve Annulus for Transcatheter Aortic Valve	Nothing to Disclose
Volidina		and to make a data and grant to	Prosthesis Selection: Impact of Aortic Valve Calcification Burden on the Agreement Between Automated 3-Dimensional Transesophageal Echocardiography and Multidetector Row Computed Tomography	Nothing to District
Voloshyna	Iryna	Cutting Edge Vascular Medicine	Pro-Atherogenic Properties of Plasma From Patients With Type 1	Nothing to Disclose
von Bardeleben	Ralph Stephan	Core Curriculum: Valvular Heart Disease Management Issues	Diabetes Mellitus: Effects on Macrophage Lipid Handling Clipping Severe Mitral Regurgitation: When Medications Alone Just Won't Suffice	CONSULTANT FEES/HONORARIA - Philips Health Care, Siemens Medical Systems; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boehringer Ingelheim
Von Bardeleben	Ralph Stephan	Frontiers in Mitral Valve Disease and Treatment	Multicenter Trial of a Transfemoral System for Mitral Valve Annuloplasty: Up-to-2-Year Follow-Up Results	CONSULTANT FEES/HONORARIA - Philips Health Care, Siemens Medical Systems; RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boehringer Ingelheim
von Coll	Sonja	Measuring Success in Cardiac Rehabilitation	Success of a Home-Based Cardiac Rehabilitation Program in a	Nothing to Disclose
Vonbank	Alexander	Updates on Risk Factors for Cardiovascular	Population of Nearly 4 Million The Visceral Adiposity Index Predicts Cardiovascular Events Both in	Nothing to Disclose
Vonbank	Alexander	Disease Innovations in Cardiovascular Risk Assessment	Coronary Artery Disease Patients With and in Coronary Artery Disease Patients Without Diabetes ProBNP Strongly Predicts Future Vascular Events in Angiographied	Nothing to Disclose
		and Reduction	Coronary Patients With as Well as in Those Without the Metabolic Syndrome	
Vonbank	Alexander	Diabetes and Other Issues in Cardiovascular Prevention	Non-Alcoholic Fatty Liver Disease Strongly Predicts Incident Diabetes in Patients With Coronary Artery Disease	Nothing to Disclose
Vonbank	Alexander	Diabetes and Other Issues in Cardiovascular Prevention	Single and Joint Effects of Obesity and of the Metabolic Syndrome on the Development of Diabetes in Patients With Coronary Atherosclerosis	Nothing to Disclose
Vonbank	Alexander	Diabetes and Other Issues in Cardiovascular Prevention	Non-Alcoholic Fatty Liver Disease in Coronary Artery Disease Patients: Association With Impaired Glucose Metabolism and With Future Cardiovascular Event Risk	Nothing to Disclose
Vonbank	Alexander	The Intersection of Diabetes and ASCVD	Remnant Cholesterol Predicts the Development of Type 2 Diabetes Mellitus in Patients With Established Coronary Artery Disease	Nothing to Disclose
Vongpatanasin	Wanpen	Antithrombotic Therapy in Ischemic Heart	Ticagrelor Adherence After Drug Eluting Stent Placement at a	Nothing to Disclose
Vontobel	Jan	Disease Non Invasive Imaging: Coronary Calcium	Large Academic Medical Center Prospective Evaluation of Low-Dose Coronary Calcium Scoring With	Nothing to Disclose
Voora	Deepak	Scoring and CV Risk Assessment Antiplatelet and Antithrombotic Agents in	Reduced Tube Voltage The Effect of Race on the Antiplatelet Effects of Ticagrelor and	RESEARCH/RESEARCH GRANTS - AstraZeneca
		Ischemic Heart Disease	Aspirin Influence of Sex on Platelet Response to Aspirin and Ticagrelor	Pharmaceuticals RESEARCH/RESEARCH GRANTS - AstraZeneca
Voora	Deepak	Anti-Platelet Therapies: Always a Sticky Topic		Pharmaceuticals
Voors	Adriaan	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Timing and Clinical Predictors of Early Versus Late Readmission Among Patients Hospitalized for Acute Heart Failure: Insights From ASCEND-HF	CONSULTANT FEES/HONORARIA - Amgen Inc., Bayer AG, Boehringer Ingelheim, Cardio3Biosciences, Celladon, Merck/MSD, Novartis Pharma, servier, Torrent, Trevena, Vifor
Voors	Adriaan	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Time of Presentation Among Patients Hospitalized for Acute Heart Failure (Clinical Characteristics, Initial Therapies and Outcomes): Insights From ASCEND-HF	CONSULTANT FEES/HONORARIA - Amgen Inc.,Bayer AG,Boehringer Ingelheim,Cardio3Biosciences,Celladon,Merck/MSD,Novartis
Vora	Amit	Left Main PCI: Why? When? How?	Case Presentation: Bifurcation Distal Left Main Disease Covering	Pharma,servier,Torrent,Trevena,Vifor Nothing to Disclose
Vora	Amit	Highlighted Original Research: Interventional	Clinical Scenario and Imaging New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve	Nothing to Disclose
Vora	Amit	Cardiology and the Year in Review Interventional Cardiology: TAVR 3	Replacement: Incidence, Anticoagulant Strategy, and Outcomes Patterns of Red Blood Cell Transfusion and Associated Outcomes in Patients Undergoing TAVR: Insights for the STS/ACC TVT	Nothing to Disclose
Vorobiof	Gabriel	Interventional Cardiology: TAVR 1	Registry The Use of Magnetic Resonance Imaging With Ferumoxytol for Annulus Sizing in Patients With Chronic Kidney Disease Undergoing	CONSULTANT FEES/HONORARIA - Lantheus Medical Imaging,St. Jude Medical
Vorobiof	Gabriel	New Technologies in Echocardiography	Transcatheter Aortic Valve Replacement The Effect of Transcatheter Aortic Valve Replacement on Subclinical Cardiac Function Using Speckle Tracking	CONSULTANT FEES/HONORARIA - Lantheus Medical Imaging,St. Jude Medical
Vorobiof	Gabriel	The Evolving World of LVADs, Transplant and	Echocardiography Incidence and Factors Associated With New-Onset	CONSULTANT FEES/HONORARIA - Lantheus Medical
Vorovich	Esther	Other Novel Discoveries Everything you Wanted to Know About Heart Transplant but Were Afraid to Ask	Cardiomyopathies Following Liver Transplantation Panelist	Imaging,St. Jude Medical CONSULTANT FEES/HONORARIA - My husband John Leedle worked as a biomedical engineer at Rex Medical, LP- a company
Vorovich	Esther	Everything you Wanted to Know About Heart	The Dark Side of Transplant - Post-Transplant Complications	that designs interventional radiology devices CONSULTANT FEES/HONORARIA - My husband John Leedle
- OTOTIOI	_50101	Transplant but Were Afraid to Ask	The Sark Glob of Transplant - Pose Transplant ComplicationS	worked as a biomedical engineer at Rex Medical, LP- a company that designs interventional radiology devices

Versiche Met 12 in 1995 in 199	and the same of th				
Security Country Count				Presentation Title	Disclosures
Victoria Vic	Vialickx	Fascai	Bioresorbable Polymer and Polymer Free	Patienst	Nothing to Disclose
Vicinity Month	Vuckovic	Karen	Interdisciplinary Cardiovascular Team	Poor Adherence in Young Patients With Heart Failure	Nothing to Disclose
Visitions Manual Interdiscentary Continued and Force of Continued	Vuckovic	Karen	Interdisciplinary Cardiovascular Care in		Nothing to Disclose
Vivolación Venidal Amphirmia and Cinical EP Dovices Information and Cinical EP Dovices	Vuckovic	Karen	Interdisciplinary Cardiovascular Team Care		Nothing to Disclose
Visitabilità Visitabilità visitabilità del Circle IP Conces 1 Visitabilità Visitab	Vuckovic	Karen	Interdisciplinary Cardiovascular Team Care	Heart Failure Hotline as an Innovation to Address Medication Issues	Nothing to Disclose
Note that we will be compared to the process of the Amongs	Vuddanda	Venkat		in Non-Ischemic Cardiomyopathy: A Meta-Analysis of Randomized	Nothing to Disclose
Verdados Ver	Vuddanda	Venkat	Arrhythmias and Clinical EP: Devices 1	Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients Undergoing Cardiac Implantable Electronic	Nothing to Disclose
Vocantal Voc	Vuddanda	Venkat	Arrhythmias and Clinical EP: Devices 2	Real World Battery Longevity of St. Jude Medical Implantable Cardioverter-Defibrillators Included in the Advisory for Premature	Nothing to Disclose
Verdacted with classified in plant general congray Respector. Antifyriting and Congray Respector. Anti	Vuddanda	Venkat		Meta-Analysis on the Efficacy and Safety of New Oral Anticoagulants Compared With Vitamin K Antagonists in Patients	Nothing to Disclose
Verdated set with michael Current tousers of Cardiovascoural Set Wilderford Set Notes (1997) and Set Set Set Set Set Set Set Set Set Set	Vuddanda	Venkat Lakshmi Kishan		Peri-Procedural Use of Novel Oral Anticoagulation Agents During	Nothing to Disclose
Verkat Lachern Krabe Verkat La	Vuddanda	Venkat Lakshmi Kishan	Current Issues in Cardiovascular	In-Hospital Outcomes and Hospitalizations for Acute Rheumatic	Nothing to Disclose
Verland Lakemin Kelana Amfari Fritation and Chinace IP Devese 2 Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Lakemin Kelana Amfari Fritation and VT Linkser Populations Verland Bella	Vuddanda	Venkat Lakshmi Kishan	Current Issues in Cardiovascular	Prevalence and In-Hospital Outcomes of Uremic and Dialysis	Nothing to Disclose
Verball Liskerini Kellan American	Vuddanda	Venkat Lakshmi Kishan			Nothing to Disclose
Vockbard ab Vorhald Lakshrin Kothan Pit Climica Decease Nature, professional professional Confes	Vuddanda	Venkat Lakshmi Kishan			Nothing to Disclose
Verbat Lastern Kotten (Artern Control	Vuddanda	Venkat Lakshmi Kishan	FIT Clinical Decision Making: Arrhythmias and	Device-Related Thrombus Following Left Atrial Appendage Closure:	Nothing to Disclose
Verland Labarini Karbam procedure Approaches for Rectang Plast and Spring Control Control Adultion of Altan Fertiliation in the Sering of Improving Quorses of LVADs, Transplant and Control Record Execution (Control Record Exec	Vuddanda	Venkat Lakshmi Kishan	Arrhythmias and Clinical EP: AF Miscellaneous	Left Atrial Appendage Ligation With Lariat Device: A Systematic	Nothing to Disclose
Verhal Lakshin ishalan Verhal Lakshin ishalan Verhal Lakshin ishalan Verhal Lakshin ishalan Verhal Lakshin ishalan Verhal Lakshin ishalan Verhal Lakshin ishalan Verhal Lakshin ishalan Verhal Lakshin ishalan Area Firatision, Alticoagulation and Novel December Verhalan Lakshin ishalan Lakshin ishalan Verhalan Lakshin ishalan Lakshin ishalan Lakshin ishalan Lakshin ishalan Lakshin ishalan Lakshin ishalan Lakshin ishalan Lakshin ishalan Lakshin ishalan Lak	Vuddanda	Venkat Lakshmi Kishan	Innovative Approaches for Reducing Risk and	Efficacy of Catheter Ablation of Atrial Fibrillation in the Setting of	Nothing to Disclose
Verkat Lastmin Klamba The Evolving World of LYANDA. Transplant and Other Novel Education of Section (1997). The Control of Section of Section (1997). The Control of Section of Section (1997). The Control of Section (1997) of Section (1997). The Control of Section (1997) of Section (1997). The Control of Section (1997) of Section (1997). The Control of Section (1997) of Section (1997) of Section (1997). The Control of Section (1997) of Section (1997) of Section (1997). The Control of Section (1997) of Section (1	Vuddanda	Venkat Lakshmi Kishan			Nothing to Disclose
Vendanda Western Kicharla Asia Fibrillation, Anticoogulation and Novel Device Through and School Device Through and School Device Through and School School Through and School Sc	Vuddanda	Venkat Lakshmi Kishan	The Evolving World of LVADs, Transplant and		Nothing to Disclose
Visitorio (Maria Structural Heart Inferventions Focus on Meral Value, Left Anal Appending and IVA Appe	Vuddanda	Venkat Lakshmi Kishan	Atrial Fibrillation, Anticoagulation and Novel	Devices: An Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database From	Nothing to Disclose
VulthArahel Wasawat Arab Fibrillation and VT. Unique Populations Systematic Review and Make Analysis Systematic Review and Make Analysis Property Processor Property Processor Public Pressors as a Procedor of Rear Faculation Public Pressors Publ	Vukicevic	Marija		3D Printed Patient-Specific Multi-Material Modeling of Mitral Valve	Nothing to Disclose
Vultifixanit Wasawat Toward Precision Medicine in the Treatment of Pulse Pressure as a Precision of Renat Pulcition Progression Over 3 Nothing to Disclose	Vutthikraivit	Wasawat			Nothing to Disclose
Vestage Vest	Vutthikraivit	Wasawat			Nothing to Disclose
Wastern Jill Scotia Media Innovations in Practice Management and Social Media Innovations in Practice Management and Social Media Social Media Social Media Social Media Social Media Social Media Social Media Unusual Presentations of ACS Combined Digital Recruitment and Enrollment in a Nationwide Trial of Screening for Undiagnosed After Intrinsical Professional Programs of Central Professional Programs of Central Professional Programs of Central Professional Programs of Central Professional Programs of Central Professional Programs of Central Professional Programs of Central Professional Programs of Central Professional Programs of Central Professional Programs of Central Professional Programs of Central Professional Programs of Central Professional			Elevated Blood Pressure	Year Follow-Up in African American Population	-
Social Media Social Media Screening for Undiagnosed Arial Fibrillation Using a Self-Applied CGR Recording Paths Sensor Lessons From the mis 17 oF 5 Trial Combined Serum Albumin and C-Rective Protein Levels Predict Combined Serum Albumin and C-Rective Protein Levels Predict Combined Serum Albumin and C-Rective Protein Levels Predict Combined Serum Albumin and C-Rective Protein Levels Predict Combined Serum Albumin and C-Rective Protein Levels Predict Combined Serum Albumin and C-Rective Protein Levels Predict Combined Serum Albumin and C-Rective Protein Levels Combined Serum Albumin and C-Rective Protein Levels Combined Serum Albumin and C-Rective Protein Levels Combined Serum Albumin and C-Rective Protein Levels Combined Serum Albumin and C-Rective Protein Levels Combined Serum Albumin and C-Rective Protein Levels Combined Serum Albumin and C-Rective Protein Levels Combined Serum Albumin and C-Rective Protein Levels Combined Serum Albumin and C-Rective Protein Levels Combined Serum Albumin and C-Rective Protein Compiler Serum Combined Serum Albumin and C-Rective Protein Compiler Serum Combined Serum Albumin and C-Rective Protein Compiler Serum Compi			Other EP Issues	and Meta-Analysis	-
Long_Term Outcomes in Paleints With Coronary Artery Disease After a First Perculations			Social Media	Screening for Undiagnosed Atrial Fibrillation Using a Self-Applied ECG Recording Patch Sensor: Lessons From the mSToPS Trial	-
Maddell Christen Interdisciplinary Cardiovascular Care in Complex Scenarios Mothing to Disclose Mo				Long-Term Outcomes in Patients With Coronary Artery Disease After a First Percutaneous Coronary Intervention	-
Syndrome Syndrome			·	Undergoing Percutaneous Coronary Intervention	-
Care	Waddell	Christen	Complex Scenarios	Syndrome	Nothing to Disclose
Rishi Acute Coronary Syndromes, Diagnosis, Management and Outcomes Management and Outcomes Coronary Syndrome (Anagement and Outcomes Coronary Syndrome (Anagement and Outcomes Coronary Syndrome (Anagement and Outcomes Coronary Syndrome (Anagement and Outcomes Coronary Syndrome (Anagement and Outcome Coronary Syndrome (Anagement and Outcome Coronary Syndrome (Anagement and Outcome Coronary Syndrome (Anagement and Outcome of Dual Antiplatelet Therapy Potonic Roses) Maisman Ron Considerations in Antiplatelet Therapy and in Acids Acids Coronary Syndrome (Anige	Wade	Rolin			RESEARCH/RESEARCH GRANTS - Amgen, Medisafe
Ricardo	Wadhera	Rishi	Acute Coronary Syndromes, Diagnosis,	Statin Utilization Patterns During Inpatient Admissions for Acute	Nothing to Disclose
Salman	Wage	Ricardo	Innovative Approaches for Reducing Risk and	Cardiovascular Magnetic Resonance in Survivors of Sudden Cardiac Arrest: 14 Year Experience From a Tertiary Referral Centre	Nothing to Disclose
Waites Salman Diabetes and Other Issues in Cardiovascular Prevention Association of Ankle Brachial Index and Hemoglobin A1c With All-Cause and Cardiovascular Mortality: Results From the National Health and Nutrition Examination Survey 1999 to 2000 Nothing to Disclose Nothin	Waheed	Salman		Prevalence of Abnormal Ankle Brachial Index in Obese and Non- Obese Subjects, and Association of Abnormal Ankle Brachial Index With All-Cause and Cardiovascular Mortality in These Groups: Results From National Health and Nutrition Examination Survey	Nothing to Disclose
Waites	Waheed	Salman		Association of Ankle Brachial Index and Hemoglobin A1c With All- Cause and Cardiovascular Mortality: Results From the National	Nothing to Disclose
International Perspectives From the Emirates Cardiac Society, Latin American Society of Interventional Cardiology (SOLACI), and American College of Cardiology Wakabayashi Tadamasa Interventional Cardiology: Intravascular Physiology and Endothelial Function Significance of Intermediate Coronary Artery Stenosis Assessed by Fractional Flow Reserve Waksman Ron Considerations in Antiplatelet Therapy and in ACS Waksman Ron Considerations in Antiplatelet Therapy and in ACS Waksman Ron Considerations in Antiplatelet Therapy and in ACS Waksman Ron Considerations in Antiplatelet Therapy and in ACS Waksman Ron Considerations in Antiplatelet Therapy and in ACS Waksman Ron Considerations in Antiplatelet Therapy and in ACS Waksman Ron Considerations in Antiplatelet Therapy and in ACS Waksman Ron Considerations in Antiplatelet Therapy and in ACS Waksman Ron Considerations in Antiplatelet Therapy and in ACS Waksman Ron Considerations in Antiplatelet Therapy and in ACS Waksman Ron Considerations in Antiplatelet Therapy and in ACS Considerations in Antiplatelet Therapy and in ACS Waksman Ron Considerations in Antiplatelet Therapy and in ACS Considerations in Antiplatelet Therapy and in ACS Considerations in Antiplatelet Therapy and in ACS Consultant FEES/HONORARIA - Abbott Vascular, Amgen Inc., Biosensors, Biotronik, Boston Scientific Consultant FEES/HONORARIA - Abbott Vascular, Amgen Inc., Biosensors, Biotronik, Boston Scientific Consultant FEES/HONORARIA - Abbott Vascular, Amgen Inc., Biosensors, Biotronik, Boston Scientific	Waites	Thad	International Perspectives From the Emirates Cardiac Society, Latin American Society of Interventional Cardiology (SOLACI), and		Nothing to Disclose
Physiology and Endothelial Function Significance of Intermediate Coronary Artery Stenosis Assessed by Fractional Flow Reserve Waksman Ron Considerations in Antiplatelet Therapy and in ACS Waksman Ron Considerations in Antiplatelet Therapy and in ACS Waksman Ron Considerations in Antiplatelet Therapy and in ACS Waksman Ron Considerations in Antiplatelet Therapy and in ACS Considerations in Antiplatelet Therapy and in ACS Considerations in Antiplatelet Therapy and in ACS Coronary Syndrome and Primary Percutaneous Coronary Intervention Waksman Ron PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities Characteristics and Outcomes in Contemporary Practice Over the Inc., Biosensors, Biotronik, Boston Scientific CONSULTANT FEES/HONORARIA - Abbott Vascular, Amgen Inc., Biosensors, Biotronik, Boston Scientific ConSULTANT FEES/HONORARIA - Abbott Vascular, Amgen Inc., Biosensors, Biotronik, Boston Scientific ConSULTANT FEES/HONORARIA - Abbott Vascular, Amgen Inc., Biosensors, Biotronik, Boston Scientific Inc., Biosensors, Biotronik, Boston Scientific Inc., Biosensors, Biotronik, Boston Scientific Inc., Biosensors, Biotronik, Boston Scientific	Waites	Thad	International Perspectives From the Emirates Cardiac Society, Latin American Society of Interventional Cardiology (SOLACI), and	Introduction to Session	Nothing to Disclose
Waksman Ron Considerations in Antiplatelet Therapy and in ACS Trends in Discharge and Outcome of Dual Antiplatelet Therapy Post CONSULTANT FEES/HONORARIA - Abbott Vascular,Amgen Percutaneous Intervention in High Bleeding Risk Population Inc.,Biosensors,Biotronik,Boston Scientific Considerations in Antiplatelet Therapy and in ACS Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Following Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Following Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consultant Trends in Dual Antiplatelet Therapy Pollowing Acute Consult	Wakabayashi	Tadamasa		Significance of Intermediate Coronary Artery Stenosis Assesed by	Nothing to Disclose
Waksman Ron Considerations in Antiplatelet Therapy and in ACS Outpatient Trends in Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Primary Percutaneous Coronary Inc.,Biosensors,Biotronik,Boston Scientific Inc.,Biosensors,Biotronik,Boston Scientific Coronary Inc.,Biosensors,Biotron	Waksman	Ron		Trends in Discharge and Outcome of Dual Antiplatelet Therapy Post	
Waksman Ron PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities In-Stent Restenosis of Drug-Eluting Stents: Incidence, Lesion CONSULTANT FEES/HONORARIA - Abbott Vascular, Amgen Characteristics and Outcomes in Contemporary Practice Over the Inc., Biosensors, Biotronik, Boston Scientific	Waksman	Ron	Considerations in Antiplatelet Therapy and in	Outpatient Trends in Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Primary Percutaneous Coronary	CONSULTANT FEES/HONORARIA - Abbott Vascular, Amgen
	Waksman	Ron		In-Stent Restenosis of Drug-Eluting Stents: Incidence, Lesion Characteristics and Outcomes in Contemporary Practice Over the	

Contract of the second				<u> </u>
Last Name Waksman	First Name Ron	Session Title Interventional Cardiology: Stent Failure	Presentation Title Optical Coherence Tomography Guided Percutaneous Coronary	Disclosures CONSULTANT FEES/HONORARIA - Abbott Vascular, Amgen
anoman		Analysis by Intravascuar Imaging	Intervention Compared With Other Imaging Guidance: A Meta- Analysis	Inc.,Biosensors,Biotronik,Boston Scientific
Waksman	Ron	Interventional Cardiology: TAVR 2	Racial Disparities and Temporal Trends in Demographics and Clinical Characteristics of Patients Screened for Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Abbott Vascular,Amgen Inc.,Biosensors,Biotronik,Boston Scientific
Waksman	Ron	Interventional Cardiology: TAVR 2	Impact of Balloon Pre-Dilatation on Hemodynamics and Clinical Outcomes After Transcatheter Aortic Valve Replacement With the Self-Expanding CoreValve Prosthesis	CONSULTANT FEES/HONORARIA - Abbott Vascular, Amgen Inc., Biosensors, Biotronik, Boston Scientific
Waksman	Ron	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	With Conduction Abnormalities Following Transcatheter Aortic Valve Replacement?	
Waksman	Ron	Interventional Cardiology: TAVR 3	Antithrombotic Therapy Differences and Associated Outcomes in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Abbott Vascular, Amgen Inc., Biosensors, Biotronik, Boston Scientific
Waksman	Ron	Interventional Cardiology: TAVR 3	Acute Aortic Regurgitation Post-Transcatheter Aortic Valve Replacement: Impact of Various Treatment Strategies	CONSULTANT FEES/HONORARIA - Abbott Vascular, Amgen Inc., Biosensors, Biotronik, Boston Scientific
Waksman	Ron	Interventional Cardiology: PCI in Complex	Long-Term Mortality in Percutaneous Coronary Intervention of Saphenous Vein Grafts From Real-World Registry Data	CONSULTANT FEES/HONORARIA - Abbott Vascular,Amgen Inc.,Biosensors,Biotronik,Boston Scientific
Waksman	Ron	Patients 15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular,Amgen Inc.,Biosensors,Biotronik,Boston Scientific
Wald	Joyce	Team 3 Give Me a Beat! Mechanical Support of Cardiogenic Shock	Co-Chair	CONSULTANT FEES/HONORARIA - MEDTRONIC; OTHER - MEDTRONIC
Wald	Joyce	Everything you Wanted to Know About Heart Transplant but Were Afraid to Ask	Panelist	CONSULTANT FEES/HONORARIA - MEDTRONIC; OTHER - MEDTRONIC
Wald	Joyce	Everything you Wanted to Know About Heart	The Chosen Ones - Patient Selection for Heart Transplant	CONSULTANT FEES/HONORARIA - MEDTRONIC; OTHER -
Wald	Joyce	Transplant but Were Afraid to Ask 13. Heart Failure and Cardiomyopathies:	Suggested Reviewer	MEDTRONIC CONSULTANT FEES/HONORARIA - MEDTRONIC; OTHER -
		Clinical Team 1		MEDTRONIC
Wald	Rachel	Congenital Heart Disease: To the Third Decade and Beyond	Twenty Year Trends in Maternal and Perinatal Complications in Pregnant Women With Heart Disease	Nothing to Disclose
Waldo	Albert	04. Arrhythmias and Clinical EP: Basic Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Cardiovascular, AtriCure, Biosense Webster, Millestone Pharmaceuticals; DATA SAFETY MONITORING BOARD - Gilead Sciences, Inc.; RESEARCH/RESEARCH GRANTS - GILEAD Sciences; SPEAKER'S BUREAU - Bristol-Myers Squibb, Pfizer
Waldo	Oral	Novel Echocardiographic Methods for Assessing Cardiac Function	Long-Term Effects of Right Ventricular Pacing on Left Ventricular Systolic and Diastolic Function and Synchrony by Strain Imaging in Patients With Normal Baseline Left Ventricular Ejection Fraction	Nothing to Disclose
Waldo	Oral	Leading Us Astray? Pacemakers in Cardiomyopathies	Chronic Right Ventricular Pacing: Effects on Heart Failure Hospitalization and Mortality in the Presence of Normal Left Ventricular Ejection Fraction	Nothing to Disclose
Waldo	Stephen	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Coronary Atherectomy for Treatment of Calcified Coronary Artery Lesions Is Associated With Increased Procedural Success and Lower Procedural Complication Rates: Insights From a National Veteran Cohort	Nothing to Disclose
Waldo	Stephen	Interventional Cardiology: PCI and TAVR in	Management of Patients With Cardiac Arrest in New York Before	Nothing to Disclose
Walfridsson	Hakan	Complex Patients Atrial Fibrillation and VT: Incorporating Novel	and After Public Reporting Policy Changes Risk Assessment of Recurrent Atrial Fibrillation After Antiarrhythmic	Nothing to Disclose
Weller	D. I	Risks Toward Decision Making	Medication or Catheter Ablation: The Impact of Age and Supraventricular Ectopic Complexes	
Walinsky	Paul	Interventional Cardiology: TAVR 1	Hands Down: Operator Hand Versus Torso Radiation Exposure During Transcatheter Aortic Valve Replacement	Nothing to Disclose
Walinsky	Paul	Interventional Cardiology: TAVR 1	Provider Radiation Exposure During Transcatheter Aortic Valve Replacement	Nothing to Disclose
Walinsky	Paul	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Anterolateral Papillary Muscle Rupture: A Rare Complication of Acute Myocardial Infarction	Nothing to Disclose
Walizer	Elaine	Interdisciplinary Cardiovascular Team	Multidisciplinary Cardiovascular Team Review Captures Preclinical	Nothing to Disclose
Walizer	Elaine	Collaboratives in Care Diabetes and Other Issues in Cardiovascular	Disease Arresting Insulin Resistance With an Integrative Health Intervention	Nothing to Disclose
Wall	Sabrina	Prevention Uncovering the Intricacies of Vascular Function	Ticagrelor Improves Microvascular Function: Results of a Cross-	Nothing to Disclose
		-	Over Study	
Wallentin	Lars	Late-Breaking Clinical Trials	Digoxin and Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?	CONSULTANT FEES/HONORARIA - Abbott AstraZeneca Boehringer-Ingelheim, Bristol-Myers Squibb/Pface, GlaxoSmithKline, Pfacer Inc; RESEARCH/RESEARCH GRANTS - AstraZeneca, Boehringer- Ingelheim, Bristol-Myers Squibb/Pfacer, GlaxoSmithKline, Merck/Schering-Plough, Pfacer Inc, Roche Diagnostics
Wallentin	Lars	Arrhythmias and Clinical EP: Anticoagulation Issues	Use of Interacting Drugs Did Not Modify Treatment Effects of Apixaban Versus Warfarin for Atrial Fibrillation: Results From the ARISTOTLE Trial	CONSULTANT FEES/HONORARIA - Abbott,AstraZeneca,Boehringer-Ingelheim,Bristol-Myers SquibD/Pizer,GlaxoSmithKline,Prizer Inc; RESEARCH/RESEARCH GRANTS - AstraZeneca,Boehringer- Ingelheim,Bristol-Myers SquibD/Pizer,GlaxoSmithKline,Merck/Schering-Plough,Pfizer Inc,Roche Diagnostics
Wallentin	Lars	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Aortic Stenosis, but Not Mitral or Aortic Regurgitation, is Associated With Adverse Outcomes With Atrial Fibrillation: Results From the ARISTOTLE Trial	CONSULTANT FEES/HONORARIA - Abbott.AstraZeneca.Boehringer-Ingelheim,Bristol-Myers Squibb/Pfizer,GlaxoSmithKline,Pfizer Inc; RESEARCH/RESEARCH GRANTS - AstraZeneca,Boehringer- Ingelheim,Bristol-Myers Squibb/Pfizer,GlaxoSmithKline,Merck/Schering-Plough,Pfizer Inc,Roche Diagnostics
Wallentin	Lars	02. Acute and Stable Ischemic Heart Disease: Clinical Team 9	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott.AstraZeneca Boehringer-Ingelheim,Bristol-Myers Squibb/Pfizer,GlaxoSmithkline,Pfizer Inc; RESEARCH/RESEARCH GRANTS - AstraZeneca,Boehringer- Ingelheim,Bristol-Myers Squibb/Pfizer,GlaxoSmithkline,Merck/Schering-Plough,Pfizer Inc,Roche Diagnostics
Waller	Alfonso	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Trends in Utilization of Inpatient Palliative Care Services and Racial Disparity of Disposition to Hospice Care Among Patients With Heart Failure in the United States Between 2003 and 2012	Nothing to Disclose
Waller	Alfonso	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Comparison of In-Hospital Outcomes of Septic Shock Patients With and Without Atrial Fibrillation: A Retrospective Propensity-Matched	Nothing to Disclose
			Analysis	
Waller	Edmund	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease Updates on Risk Factors for Cardiovascular	Analysis Association Between Circulating Progenitor Cells and Outcomes in Patients With Coronary Artery Disease Central Obesity Predicts Circulating Progenitor Cell Levels	Nothing to Disclose

Waster Smull Stand Passed Works of CASA, Transplant and Profess of Cast and Christian Accounts in Packets to Waster Stand Cast Accounts and Accounts in Packets Stand Accounts and Accounts	Contract of the second				
	Last Name Waller		Session Title The Evolving World of LVADs, Transplant and		Disclosures Nothing to Disclose
Model Control (1987) Applied			Other Novel Discoveries	Failure	-
Mary State Color of Color Programs (Color Programs Color of Color Color Color Programs Color of Color Color Programs Color of Color	Waller	Edmund	Unusual Presentations of ACS		Nothing to Disclose
Water State Country (1997) Water State Country (Walling	Jackie			Therapeutics,corcept,Crown Biosciences,exelixis,NewGen,OxiGene,Prothena,Upsher-Smith Laboratories Inc.;
Visible Visi	Walsh	Mary	Palliative Care: The Why and What of PC	 	
Water Name September Septe	Walsh	Mary		Co-Chair	Nothing to Disclose
March Next	Walsh	Mary	16th Annual Maseri-Florio International Lecture	Introduction to Session	Nothing to Disclose
Water Name Security	Walsh	Mary	16th Annual Maseri-Florio International Lecture		Nothing to Disclose
International College of Certification Page				Chair	
Wash Mary Month Peor Failure: Evaluating Statistics 2 Strong Experimental Income Relation (CTO Transmission from MA-America Heart Entholor Transmission	waisn	iwary	Into Practice; A Clinical Case-Based Symposium: International Perspectives From the European Society of Cardiology and the	Co-Chair	
Percent Residence Local Service 1.7 Perspectives Virial Simon Recentificate Local Service 1.7 Perspectives Virial Simon Percent Residence Local Service 1.7 Perspectives Virial Simon Percent Conference Local Service 1.7 Perspectives Virial Simon Percent Conference Local Service 1.7 Perspectives Virial Simon Management Conference Local Service Loc					
Worth Simon		-	Prevent Readmissions	Patients' Perspective	
Weight Processor Indicated Priefers of Successor Information of Connect Total Occusions on Management of Connect Total Occusions on Management of Connect Total Occusions on Management of Connect Total Occusions on Management of Connect Total Occusions on Management on Management of Connect Total Occusions on Management of Connect Total Occusions on Management on M	Walsh	Simon	Transmission from Mid-America Heart Institute (Kansas City, Missouri)		Scientific,MEDTRONIC,Vascular Solutions
Vision Usy Ann Emerging Applications of Echocardiography Varieties Usy Ann Emerging Applications of Echocardiography Varieties Varieties Usy Ann Emerging Applications of Echocardiography Varieties	Walsh	Simon		Managing Risk and Complications in the Cath Lab	
Wallers Darren Oerre	Walsh	Simon		Chronic Total Occlusions on Myocardial Perfusion and Left	
without with the common that the section of the New Sciences NES-RACHERS-RACHE	Walson	Lily Ann	Emerging Applications of Echocardiography	Dilated Mid-Ascending Aorta in Hypertrophic Cardiomyopathy Is Associated With Dynamic Left Ventricular Outflow Tract Obstruction	Nothing to Disclose
Walters Nyan insights From Echocardiography Use Trends and Use of Echocardiography in Patients With Use of Echocardiography in Patients With Use of Echocardiography in Patients With Use of Echocardiography in Patients With Use of Echocardiography in Patients With Use of Echocardiography in Patients With Use of Echocardiography in Patients With Use of Echocardiography in Patients With Use of Echocardiography in Patients With Use of Echocardiography in Patients With Use of Echocardiography in Patients With Use of Echocardiography in Patients With Use of Echocardiography in Patients With Use of Echocardiography in Patients With Use of Echocardiography in Patients With Use of Echocardiography in Patients With With Use Clinical Results and Propensity Matched Companies Control of Patients With With Use Clinical Results and Propensity Matched Companies Control of Patients With With Use Clinical Results and Propensity Matched Companies Control of Patients With With Use Clinical Results and Propensity Matched Companies Control of Patients With With Use Clinical Results of Patients With With Use Clinical Results of Patients With With Use Clinical Results of Patients With With Use Clinical Results of Patients With With Use Clinical Results of Patients With With Use Clinical Results of Patients With With Use Clinical Results of Patients With With Use Clinical Results of Patients With With Use Clinical Results of Patients With With Use Clinical Results of Patients With With With With With With With With	Walters	Darren	Interventional Cardiology: TAVR 3	First Report of Clinical Outcomes With the Next-Generation LOTUS	GRANTS - Abbott Laboratories, Amgen Inc., Biosensors, Boston, Boston Scientific, Boston Scientific, Boston Scientific, DC Devices, Edwards Lifesciences, FREEDOM, Jannsen
Walters Ryan Insights From Echocardography Use Fernda and Use of Echocardography in Patients Will Selaphylococous Aurenaus Peacherms Anchorage Use Selaphylococous Aurenaus Peacherms Anchorage Use Selaphylococous Aurenaus Peacherms Anchorage Use Selaphylococous Aurenaus Peacherms Anchorage Use Selaphylococous Aurenaus Peacherms Anchorage Use Selaphylococous Aurenaus Peacherms Selaphylococous Peacherms Selaphylococous Peacherms Selaphylococous Peacherms Selaphylococous Peacherms Selaphylococous Peacherms Selaphylococous Peacherms Selaphylococous Peacherms	Walters	Ryan			Nothing to Disclose
Visible	Walters	Ryan			Nothing to Disclose
Transcatheter Near Clinical Results and Propensity Matched Comparison With SAPIE 3 Waither Thomas Interventional Cardiology; TAVR 4 Mattheward Science Scien				<i>Staphylococcus Aureus</i> Bacteremia: An Analysis Using the Nationwide Inpatient Sample (NIS) Data	-
Mailton-Shirley Melissa Social Media and the Cardiovascular Professionals: Lessons Learned and Future Panelist Professionals: Lessons Learned and Future Panelist Professionals: Lessons Learned and Future Panelist Professionals: Lessons Learned and Future Applications AcC-Talk: Engaging Patients Online and Managing Digital Access Professionals: Leasons Learned and Future Applications AcC-Talk: Engaging Patients Online and Managing Digital Access Nothing to Disclose Professionals: Leasons Learned and Future Applications AcC-Talk: Engaging Patients Online and Managing Digital Access Nothing to Disclose Nothing to Disclose Mortality in Patients With Mitral Repurptation and Interventional Cardiology, Acute and Stable Ischemic Heart Mortality in Patients With Mitral Repurptation and Interventional Cardiology, Acute and Stable Ischemic Heart Mortality in Patients With Mitral Repurptation and Interventional Cardiology, Acute and Stable Ischemic Heart Mortality in Patients Mortality i				Transcatheter Heart Valve: Clinical Results and Propensity Matched Comparison With SAPIEN 3	-
Parellat Portessionals Lessons Learned and Future Applications Parellat Portessionals Lessons Learned and Future Applications Portuge Applications Portuge Applications Portuge Applications Applications AcC Tails: Engaging Patents Online and Managing Digital Access Nothing to Disclose AcC Tails: Engaging Patents Online and Managing Digital Access Nothing to Disclose AcC Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Online and Managing Digital Access Acc Tails: Engaging Patents Mith Managing Digital Access A	Walther	Thomas	Interventional Cardiology: TAVR 4	Transcatheter Heart Valve: Impact on New Pacemaker	SPEAKER'S BUREAU - Edwards Lifesciences,SJM,Symetis
Watton-Shirley Melissa Social Media and the Cardiovascular Professionals: Lessons Learned and Future Applications Applications Innovative Use of Echocardiography Left Ventricular Global Longitudinal Strain Predicts All-Cause Morting to Disclose	Walton-Shirley	Melissa	Professionals: Lessons Learned and Future		Nothing to Disclose
Man	Walton-Shirley	Melissa	Social Media and the Cardiovascular Professionals: Lessons Learned and Future		Nothing to Disclose
Wan Rahimi Shah Wan Faizal FIT Clinical Decision Making; Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine Acute Cardiogenis Photoxic Progress, Paradigm, and Unresolved Problems Acute Cardiogenis Photoxic Progress, Paradigm, and Unresolved Problems Acute Cardiogenis Photoxic Progress, Paradigm, and Unresolved Problems Acute Cardiogenis Photoxic Progress, Paradigm, and Unresolved Problems Acute Cardiogenis Photoxic Progress, Paradigm, and Unresolved Problems Acute Cardiogenis Photoxic Progress, Paradigm, and Unresolved Problems Acute Cardiogenis Photoxic Progress, Paradigm, and Unresolved Problems Acute Cardiology, TAVR 2 Beath and Dialysis Risk After Transcatheter Versus Surgical Acute Valve Replacement: Intel United States: An Analysis From Two US Registries Linked to Medicare Detail Progress and Timing of Disclose Nothing to Disclose	Wan	Ningxin		Mortality in Patients With Mitral Regurgitation and Ischemic Heart	Nothing to Disclose
Matthew Acute Cardiogenic Shock: Progress, Paradign and Unresolved Problems Acute Cardiogenic Shock: Progress, Paradign Panelist and Unresolved Problems Acute Cardiogenic Shock: Progress, Paradign Panelist and Unresolved Problems Acute Cardiogenic Shock: Progress, Paradign Panelist and Dialysis Pisk After Transcatheter Versus Nothing to Disclose Nothin	Wan Rahimi Shah	Wan Faizal	Cardiology, Acute and Stable Ischemic Heart	Not All Shocks Are Created Equal: Acute Coronary Syndrome in the	Nothing to Disclose
Real-World Comparative Effectiveness of Transcatheter Versus Surgical Antiv Valve Replacement in the United States: An Analysis From Two US Registries Linked to Medicare Data	Wanat	Matthew	Acute Cardiogenic Shock: Progress, Paradigm,	Panelist	
Mang Alice Interventional Cardiology: TAVR 2 Death and Dialysis Risk After Transcatheter Aortic Valve Replacement Replacement Replacement (Interventional Cardiology: TAVR 2 Impact of the Presence of Coronary Artery Disease and Timing of Revascularizon on Outcomes of Patients Undergoing Trans. Catheter Aortic Valve Replacement: insights From STS/ACC TVT Registry	Wang	Alice		Surgical Aortic Valve Replacement in the United States: An Analysis	
Replacement Replacement Replacement Replacement Replacement Replacement Replacement Replacement Replacement Replacement Replacement Revascularization on Outcomes of Patients Undergoing Trans-Catheter Aortic Valve Replacement: Insights From STS/ACC TVT Registry Revascularization on Outcomes of Patients Undergoing Trans-Catheter Aortic Valve Replacement: Insights From STS/ACC TVT Registry Revascularization on Outcomes of Patients Undergoing Trans-Catheter Aortic Valve Replacement: Insights From STS/ACC TVT Registry Revascularization in Patients Revascularization	Wang	Alice	Interventional Cardiology: TAVR 2	From Two US Registries Linked to Medicare Data Death and Dialysis Risk After Transcatheter Aortic Valve	Nothing to Disclose
Revascularization on Outcomes of Patients Undergoing Trans- Catheter Aortic Valve Replacement: Insights From STS/ACC TVT Registry Arrhythmias and Clinical EP: AF Miscellaneous And Surgical Issues Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease and Structural Heart Disease Management Andrew An	-			Replacement	
Adice Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues With Adverse Outcomes With Arrial Fibrillation: Results Associated Antithrombotic Therapy in Ischemic Heart Disease Clinical Team 3 Adrice Antithrombotic Therapy in Ischemic Heart Disease Antithrombotic Therapy in Ischemic Heart Disease Clinical Team 3 Adrice Antithrombotic Therapy in Ischemic Heart ARISTOTLE Trial Clipidograft Is Not Commonly Used but Associated With Less Re-Hospitalization in Patients With Perioperative Myocardial Infarction Following CABG Surgery Andrew Interventional Cardiology: TAVR 4 Predictors of Mortality After TAVR in a "Real World" Setting Nothing to Disclose Wang Andrew Fellows Bootcamp: Peripheral Vascular Disease Management Wang Andrew Highlighted Original Research: Valvular Heart Disease Management Disease and Structural Heart Disease Management Disease and the Year in Review Interventional Cardiology: TAVR 4 Predictors for In-Hospital and 1-Year Outcomes Sciences Myokardia Wang Andrew Highlighted Original Research: Valvular Heart Disease and the Year in Review International Collaboration on Endocarditis: An Analysis From the Interventional Cardiology: TAVR 4 Predictors of Mortality After TAVR in a "Real World" Setting CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular, GILEAD Sciences Myokardia Wang Andrew Interventional Cardiology: TAVR 4 Predictors of Mortality After TAVR in a "Real World" Setting CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular, GILEAD Sciences Myokardia Wang Andrew 36. Valvular Heart Disease: Clinical Team 3 Suggested Reviewer CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular, GILEAD Sciences Myokardia Wang Andrew 36. Valvular Heart Disease: Clinical Team 3 Suggested Reviewer CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular, GILEAD Sciences Myokardia	vvang	Airce	interventional Cardiology. TAVR 2	Revascularization on Outcomes of Patients Undergoing Trans- Catheter Aortic Valve Replacement: Insights From STS/ACC TVT	Nothing to Disclose
Wang Alice Antithrombotic Therapy in Ischemic Heart Disease Clinical Team 3 Clopidogrel Is Not Commonly Used but Associated With Less Rehospitalization in Patients With Perioperative Myocardial Infarction Following CABG Surgery Nothing to Disclose	Wang	Alice		Aortic Stenosis, but Not Mitral or Aortic Regurgitation, Is Associated With Adverse Outcomes With Atrial Fibrillation: Results From the	Nothing to Disclose
Wang Andrew Fellows Bootcamp: Peripheral Vascular Disease and Structural Heart Disease Mitral Therapies Mitral Therapies Consultant Fees/Honoraria Consultant Fees/Honoraria Consultant Fees/Honoraria Read World" Setting Nothing to Disclose Consultant Fees/Honoraria Consultant Fees/Honoraria Read World" Setting Nothing to Disclose Consultant Fees/Honoraria Read World" Setting Nothing to Disclose Consultant Fees/Honoraria Read World" Setting Research: Valvular Heart Disease Mitral Therapies Consultant Fees/Honoraria Read World" Setting Consultant Fees/Honoraria Research: Valvular Heart Disease Andrew Highlighted Original Research: Valvular Heart Disease Consultant Fees/Honoraria Echocardiographic Predictors for In-Hospital and 1-Year Outcomes in Left-Sided Infective Endocarditis: An Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort Study Sciences, MyoKardia Consultant Fees/Honoraria Research: Valvular Heart Metabolics; Research: Re	Wang	Alice		Clopidogrel Is Not Commonly Used but Associated With Less Re- Hospitalization in Patients With Perioperative Myocardial Infarction	Nothing to Disclose
Disease and Structural Heart Disease RESEARCH/IRESEARCH GRANTS - Abbott Vascular,GILEAD Sciences,MyoKardia Andrew Highlighted Original Research: Valvular Heart Disease and the Year in Review 2016 ACC/AHA Guidelines Clarification 2016 ACC/AHA Guidelines Clarification Sciences,MyoKardia CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/IRESEARCH GRANTS - Abbott Vascular,GILEAD Sciences,MyoKardia Sciences,MyoKardia CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/IRESEARCH GRANTS - Abbott Vascular,GILEAD Sciences,MyoKardia Sciences,My	Wang			Predictors of Mortality After TAVR in a "Real World" Setting	
Disease and the Year in Review 2016 ACC/AHA Guidelines Clarification RESEARCH/RESEARCH GRANTS - Abbott Vascular,GILEAD Sciences,MyoKardia Wang Andrew Highlighted Original Research: Valvular Heart Disease and the Year in Review Interventional Cardiology: TAVR 4 Predictors of Mortality After TAVR in a "Real World" Setting Wang Andrew	-		Disease and Structural Heart Disease Management	·	RESEARCH/RESEARCH GRANTS - Abbott Vascular,GILEAD Sciences,MyoKardia
Wang Andrew Highlighted Original Research: Valvular Heart Disease and the Year in Review In Left-Sided Infective Endocarditis: An Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort Study Wang Andrew Interventional Cardiology: TAVR 4 Predictors of Mortality After TAVR in a "Real World" Setting CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular, GILEAD Sciences, MyoKardia CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular, GILEAD Sciences, MyoKardia CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular, GILEAD Sciences, MyoKardia CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular, GILEAD Sciences, MyoKardia CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular, GILEAD Sciences, MyoKardia CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular, GILEAD Sciences, MyoKardia CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular, GILEAD Sciences, MyoKardia CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular, GILEAD Sciences, MyoKardia CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular, GILEAD Sciences, MyoKardia CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEA	Wang	Andrew		2016 ACC/AHA Guidelines Clarification	RESEARCH/RESEARCH GRANTS - Abbott Vascular, GILEAD
RESEARCH/RESEARCH GRANTS - Abbott Vascular,GILEAD Sciences,MyoKardia Wang Andrew 36. Valvular Heart Disease: Clinical Team 3 Suggested Reviewer CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular,GILEAD	Wang		Disease and the Year in Review	in Left-Sided Infective Endocarditis: An Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort Study	CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular,GILEAD Sciences,MyoKardia
Wang Andrew 36. Valvular Heart Disease: Clinical Team 3 Suggested Reviewer CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular, GILEAD	Wang	Andrew	Interventional Cardiology: TAVR 4	Predictors of Mortality After TAVR in a "Real World" Setting	RESEARCH/RESEARCH GRANTS - Abbott Vascular, GILEAD
	Wang	Andrew	36. Valvular Heart Disease: Clinical Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Heart Metabolics; RESEARCH/RESEARCH GRANTS - Abbott Vascular,GILEAD



and the second				
Last Name	Chan Hung	Session Title Heart Failure: From Pathophysiology to Socio-	Presentation Title	Disclosures Nothing to Disclose
Wang	Chao-Hung	Economic Impact: International Perspectives	Diagnostic and Prognostic Value of Metabolomics in Heart Failure	Nothing to Disclose
		From the Lebanese Cardiac Society, Taiwan		
		Society of Cardiology, and American College of Cardiology		
Wang	Chun-Chieh	Heart Failure: From Pathophysiology to Socio-	Acute Systolic Heart Failure Registry in Taiwan	Nothing to Disclose
		Economic Impact: International Perspectives From the Lebanese Cardiac Society, Taiwan		
		Society of Cardiology, and American College		
		of Cardiology		
Wang	Dee Dee	Interventional Cardiology: TAVR 2	Death and Dialysis Risk After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Wang	Dee Dee	Valvular Heart Disease: Aortic Stenosis	Outcomes and Their Predictors in Acute Transcatheter Aortic Heart	Nothing to Disclose
10/	Dan Dan	later anti-one Condinter of Charles and I land	Valve-in-Transcatheter Aortic Heart Valve Therapy	Nothing to Displace
Wang	Dee Dee	Interventional Cardiology: Structural Heart Disease	Transcatheter Mitral Valve-in-Ring Implantation After Failure of Surgical Mitral Ring Annuloplasty	Nothing to Disclose
Wang	Dee Dee	Interventional Cardiology: TAVR 3	Predictors of Late Bleeding in the TAVR Population	Nothing to Disclose
Wang	Feng	Arrhythmias and Clinical EP: Anticoagulation Issues	Bleeding Risk Among Japanese Non-Valvular Atrial Fibrillation Patients Initiated on Apixaban, Dabigatran, Rivaroxaban or Warfarin	SALARY - Bristol-Myers Squibb Company
			in the Real World	
Wang	Frances	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium in the Elderly: Prevalence, Severity, and Association With All-Cause Mortality	Nothing to Disclose
Wang	Frances	Non Invasive Imaging: New Technologies	Improvement in LDL Is Associated With Decrease in Non-Calcified	Nothing to Disclose
			Plaque Volume on CTA as Measured by Automated Quantitative	
Wang	Frances	Imaging With Cardiac CT: The Case for	Software Hormone Replacement Therapy Is Associated With Less Coronary	Nothing to Disclose
-		Calcium	Atherosclerosis and Lower Mortality	-
Wang	Guoying	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Joint Effect of Maternal Plasma Homocysteine and Prepregnancy Obesity on Child Blood Pressure: A Prospective Birth Cohort Study	Nothing to Disclose
Wang	Hongjian	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Joint Effect of Maternal Plasma Homocysteine and Prepregnancy Obesity on Child Blood Pressure: A Prospective Birth Cohort Study	Nothing to Disclose
			Obesity on Child blood Fressure. A Prospective Birth Conort Study	
Wang	Hongjian	Innovations in Cardiovascular Risk Assessment	Joint Association of Maternal Plasma Folate and Cardiometabolic	Nothing to Disclose
Wang	Huan-Huan	and Reduction Cardiac Arrest, Diabetes, and Other High Risk	Risk Factors With Child Blood Pressure Impact of Gender Difference in Clinical Presentation on Long-Term	Nothing to Disclose
wang	i idan i idan	Features of Patients With Acute Coronary	Outcomes in Chinese Patients Undergoing Percutaneous Coronary	Trouming to bisclose
Wang	Jing-Feng	Syndrome Cutting Edge Vascular Medicine	Intervention Transplanted Perivascular Adipose Tissue Promotes Destabilization	Nothing to Disclose
vvalig	omy-r eng	Saturing Lage vascular Medicine	of Atherosclerotic Plaque in Apolipoprotein E-Deficient Mice	Induling to Disclose
14/	Art III Ar	A. I. C		Notice to Produce
Wang	Michael Tzu Min	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Bleeding Risk Models in Acute Coronary Syndrome: Meta-Analysis of Performance	Nothing to Disclose
Wang	Paul	Quickfire ECG for Experts	Panelist	CONSULTANT FEES/HONORARIA - Amgen, Janssen
				Pharmaceuticals, Inc,MEDTRONIC,St. Jude Medical; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
				VytronUS; RESEARCH/RESEARCH GRANTS - ARCA
NAZ	D	00. Asta there's a set Office (FD)	0	biopharma, Inc.,AtriCure,CardioFocus,MEDTRONIC,Siemens
Wang	Paul	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen, Janssen Pharmaceuticals, Inc, MEDTRONIC, St. Jude Medical;
		1		OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
				VytronUS; RESEARCH/RESEARCH GRANTS - ARCA biopharma, Inc.,AtriCure,CardioFocus,MEDTRONIC,Siemens
Wang	Ping	Advances in Cholesterol Measurement and	10-Year Cardiovascular Risk Reduction, Efficacy and Safety of	Nothing to Disclose
_	_	Management	Alirocumab and Evolocumab, in Addition to Maximal Tolerated	
Wang	Ping	Vascular Medicine: Novel Risk Measures in	Cholesterol Lowering Therapy: Post-Commercialization Study Ocular Vascular Occlusion in 302 Patients: A Diagnostic Window to	Nothing to Disclose
-		Arterial Diseases	Familial and Acquired Thrombophilia	-
Wang	Stephen	Arrhythmias and Clinical EP: AF Ablation	Dofetilide Associated QT Prolongation: Actual Versus Ideal Body Weight to Calculate Dosing	Nothing to Disclose
Wang	Thomas	Improving Risk Assessment in Atherosclerosis	N-Terminal Pro B-Type Natriuretic Peptide, Race, and Flow-	CONSULTANT FEES/HONORARIA - Pfizer,Roche
			Mediated Dilation: Multi-Ethnic Study of Atherosclerosis	Diagnostics,Singulex; OTHER - Patent applications; RESEARCH/RESEARCH GRANTS - Brahms,Critical
				Diagnostics, Diasorin, Inc., Siemens Healthcare
	_			Diagnostics,Singulex
Wang	Tom	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Bleeding Risk Models in Acute Coronary Syndrome: Meta-Analysis of Performance	Nothing to Disclose
Wang	Tracy	Highlighted Original Research: Acute and	Patterns of Angina and Antianginal Medication Use Among Patients	CONSULTANT FEES/HONORARIA - Astra Zeneca,Eli
		Stable Ischemic Heart Disease and the Year in Review	Following MI Treated With PCI: Insights From TRANSLATE-ACS	Lily,Merck,Premier, Inc; RESEARCH/RESEARCH GRANTS - AstraZeneca,Boston Scientific,Bristol-Myers Squibb Company ,Eli
				Lilly/Daiichi Sankyo Alliance,gilead,Regeneron
Wang	Tracy	Highlighted Original Research: Acute and	Ten-Year Mortality of Acute Myocardial Infarction Patients Treated in	CONSULTANT FEES/HONORARIA - Astra Zeneca, Eli
		Stable Ischemic Heart Disease and the Year in Review	O.S. Community Fractice	Lily,Merck,Premier, Inc; RESEARCH/RESEARCH GRANTS - AstraZeneca,Boston Scientific,Bristol-Myers Squibb Company,Eli
14/	T		Double of the second of the se	Lilly/Daiichi Sankyo Alliance,gilead,Regeneron
Wang	Tracy	Advances in Cholesterol Measurement and Management	Contemporary Patterns of Lipid Testing in Primary and Secondary Prevention Patients: Insights From the PALM Registry	CONSULTANT FEES/HONORARIA - Astra Zeneca, Eli Lily, Merck, Premier, Inc; RESEARCH/RESEARCH GRANTS -
		29011011		AstraZeneca,Boston Scientific,Bristol-Myers Squibb Company ,Eli
Wang	Tracy	Considerations in Antiplatelat Theresees 1	Dual Antiplatelet Therapy Utilization and Cardiovascular Outcomes	Lilly/Daiichi Sankyo Alliance,gilead,Regeneron CONSULTANT FEES/HONORARIA - Astra Zeneca,Eli
Wang	Tracy	Considerations in Antiplatelet Therapy and in ACS	Among Black and White Patients Treated With Drug Eluting Stents	Lily,Merck,Premier, Inc; RESEARCH/RESEARCH GRANTS -
				AstraZeneca,Boston Scientific,Bristol-Myers Squibb Company ,Eli
Wang	Tracy	Traditional and Novel Factors Used to Assess	Examination of hs-CRP Elevation in Patients With History of	Lilly/Daiichi Sankyo Alliance,gilead,Regeneron CONSULTANT FEES/HONORARIA - Astra Zeneca,Eli
3		the Risk of, and Used for the Treatment of,	Myocardial Infarction in the U.S.	Lily,Merck,Premier, Inc; RESEARCH/RESEARCH GRANTS -
		Coronary Artery Disease		AstraZeneca,Boston Scientific,Bristol-Myers Squibb Company ,Eli Lilly/Daiichi Sankvo Alliance,gilead.Regeneron
Wang	Tracy	Cardiac Arrest, Diabetes, and Other High Risk	Hospital Variation in Targeted Temperature Management for Acute	CONSULTANT FEES/HONORARIA - Astra Zeneca, Eli
		Features of Patients With Acute Coronary	Myocardial Infarction Patients Complicated by Out-of-Hospital	Lily,Merck,Premier, Inc; RESEARCH/RESEARCH GRANTS -
		Syndrome	Cardiac Arrest in the U.S.	AstraZeneca,Boston Scientific,Bristol-Myers Squibb Company ,Eli Lilly/Daiichi Sankyo Alliance,gilead,Regeneron
Wang	Tracy	Cardiac Arrest, Diabetes, and Other High Risk	Incidence of Recurrent Myocardial Infarction Among Older Adults in	CONSULTANT FEES/HONORARIA - Astra Zeneca,Eli
		Features of Patients With Acute Coronary Syndrome	U.S. Community Practice	Lily,Merck,Premier, Inc; RESEARCH/RESEARCH GRANTS - AstraZeneca,Boston Scientific,Bristol-Myers Squibb Company, Eli
		•		Lilly/Daiichi Sankyo Alliance,gilead,Regeneron
Wang	Tracy	Optimizing the Care of ACS Patients	Contemporary Patterns of GP IIb/IIIa Inhibitor Use in Patients With	CONSULTANT FEES/HONORARIA - Astra Zeneca, Eli
			Acute Myocardial Infarction Undergoing PCI: Insights From the TRANSLATE ACS Study	Lily,Merck,Premier, Inc; RESEARCH/RESEARCH GRANTS - AstraZeneca,Boston Scientific,Bristol-Myers Squibb Company, Eli
			·	Lilly/Daiichi Sankyo Alliance,gilead,Regeneron
Wang	Tracy	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Bleeding and Premature Antiplatelet Therapy Discontinuation After Myocardial Infarction Among Patients With Chronic Kidney Disease	CONSULTANT FEES/HONORARIA - Astra Zeneca, Eli Lily, Merck, Premier, Inc; RESEARCH/RESEARCH GRANTS -
		issues in the interest of the	my observation minimum realistics with onlone Muney Disease	AstraZeneca,Boston Scientific,Bristol-Myers Squibb Company ,Eli
L]		Lilly/Daiichi Sankyo Alliance,gilead,Regeneron

and a				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Wang	Tracy	Anti-Platelet Therapies: Always a Sticky Topic	Antiplatelet Therapy Changes for MI Patients With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS Study	CONSULTANT FEES/HONORARIA - Astra Zeneca,Eli Lily,Merck,Permier, Inc; RESEARCH/RESEARCH GRANTS - AstraZeneca,Boston Scientific,Bristol-Myers Squibb Company ,Eli Lilly/Daiichi Sankyo Alliance,gilead,Regeneron
Wang	Tracy	03. Acute and Stable Ischemic Heart Disease: Therapy Team 2	Suggested Reviewer	CONSULTANT FEES/HOORARIA - Astra Zeneca, Eli Lily, Merck, Premier, Inc; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Boston Scientific, Bristol-Myers Squibb Company, Eli Lilly/Dalichi Sankyo, Alliance, gilead, Regeneron
Wang	Xiao	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Comparison of Optical Coherence Tomography Versus Intravascular Ultrasound Detection of Tissue Protrusion and Acute Stent-Vessel Wall Malapposition in 498 Patients After Drug-Eluting Stent Implantation	Nothing to Disclose
Wang	Xiaobin	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Serum Homocysteine Lowering by Long-Term Low-Dose Folic Acid: New Insight on <i>MTHFR</i> Gene-Folate Interaction From China Stroke Primary Prevention Trial	Nothing to Disclose
Wang	Xiaobin	Innovations in Cardiovascular Risk Assessment and Reduction		Nothing to Disclose
Wang	Xiaozeng	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Diabetes Mellitus on Antithrombotic Management Patterns and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndrome: Insight From the EPICOR Asia Study	Nothing to Disclose
Wang	Xunzhang	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Wide Complex Tachycardia in a 51-Year-Old Man: Ventricular Tachycardia Until Proven Otherwise?	Nothing to Disclose
Wang	Ying	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Left Atrial Function and Role in Prediction of Heart Failure	Nothing to Disclose
Wang	Ying	Innovative Use of Echocardiography	Independent Association of Atrial Mechanics With Risk of Incident	Nothing to Disclose
Wang	Yun	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Atrial Fibrillation Sex Differences in Rates of 30-Day Readmission in Patients Discharged After Acute Myocardial Infarction in the United States	Nothing to Disclose
Wang	Zhao	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Neointimal Pattern and Clinical Outcome After Drug-Eluting Stent Implantation: Comparison Between First Generation and Second Generation Drug-Eluting Stents	Nothing to Disclose
Wang	Zhao	The Inside View: Learning From Intracoronary Imaging	Prevalence and Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A Four-Year Follow-Up Study	Nothing to Disclose
Wang	Zhen	Updates on Risk Factors for Cardiovascular Disease	Association Between Short and Long Sleep Duration and Cardiovascular Outcomes? A Systematic Review and Meta-Analysis	Nothing to Disclose
Wang	Zhen	Non Invasive Imaging: Prognostic Implications of CT Angiography	Prognostic Value of Segment Involvement Score Compared to Other Measures of Coronary Atherosclerosis by Computed Tomography: A Systematic Review and Meta-Analysis	Nothing to Disclose
Wang	Zuyue	FIT Clinical Decision Making: Multimodality Imaging	Gerbode Defect Leading to a Diagnosis of Endocarditis	Nothing to Disclose
Wangüemert Pérez	Fernando	Cardiac Channelopathies: Novel Therapeutics and Clinical Challenges	Eficacy and Safety of Flecainide to Reduce Exercise-Induced Ventricular Arrhythmias and the Arrhythmic Window in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia	Nothing to Disclose
Ward	Chad	Interventional Cardiology: TAVR 1	Prognostic Value of Right Ventricular Function Assessed by Cardiac Computed Tomography in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Ward	R. Parker	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team	Suggested Reviewer	Nothing to Disclose
Ware	James	Young Investigator Awards Competition: Clinical Investigations	Integrated Analysis of the Clinical Manifestations and Phenotypic Drivers of Titin Cardiomyopathy	Nothing to Disclose
Ware	James	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Cardiovascular Magnetic Resonance in Survivors of Sudden Cardiac Arrest: 14 Year Experience From a Tertiary Referral Centre in the United Kingdom	Nothing to Disclose
Warisawa	Takayuki	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Significance of ¹²³ I-BMIPP-Scintigraphy in the Recovery of Left Ventricular Systolic Dysfunction in Takotsubo Cardiomyopathy: Insight From the NEW TAKOTSUBO BMIPP Registry	Nothing to Disclose
Warner	Alberta	Emerging Developments in HFpEF and Arryhthmias	Bleeding Risk of Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation and Heart Failure	Nothing to Disclose
Warner	Alberta	The Old and the New: Impact of Heart Failure Drug Therapies	Safety of Alpha Blockers in Patients With Heart Failure	Nothing to Disclose
Warner	John	Overcoming Today's Challenges to Launching and Growing Your Academic Medical Career: An Interactive Tutorial	AMCs Under Siege: Facing the New Realities	Nothing to Disclose
Warnes	Carole	FIT Forum: Mix and Mingle	Congenital HD Pediatric & Adult	Nothing to Disclose
Warnes	Carole	Pregnancy Complicated by Valvular/Congenital Heart Disease: Clinical Management and Challenging Cases	Co-Chair	Nothing to Disclose
Warnes	Carole	Pregnancy Complicated by Valvular/Congenital Heart Disease: Clinical Management and Challenging Cases	Panelist	Nothing to Disclose
Warnes	Carole	Core Curriculum: Rhythm and the Blues: Still Young at Heart	Chair	Nothing to Disclose
Warnes Warnes	Carole Carole	FIT Forum: Stump the Professor Congenital Heart Disease: To the Third	Stump the Professor Judge Outcomes of Non-Cardiac Procedures in Adult Fontan Patients	Nothing to Disclose Nothing to Disclose
Warnes	Carole	Decade and Beyond Things That Matter in Adult Congenital Heart	Outcomes of Cardiac Pacing in the Adult Fontan Population	Nothing to Disclose
Warshofsky	Mark	Disease 01. Acute and Stable Ischemic Heart Disease:	Suggested Reviewer	Nothing to Disclose
Wase	Abdul	Basic Team 2 FIT Clinical Decision Making: Arrhythmias and	Sources of Inappropriate ICD Shocks, Look for Inside and Outside	Nothing to Disclose
Wasfy	Jason	Electrophysiology Highlighted Original Research: Acute and	of the Heart Sex Differences in Rates of 30-Day Readmission in Patients	CONSULTANT FEES/HONORARIA - gilead,New England
Wasfy	Meagan	Stable Ischemic Heart Disease and the Year in Review I Can Do WHAT After My Heart Attack?	Discharged After Acute Myocardial Infarction in the United States Co-Chair	Comparative Effectiveness Council,QPID Health; SALARY - Massachusetts General Physicians Organization Nothing to Disclose
Wasty Wasty	Meagan Meagan	Hearts and Soles: Multimodality Imaging in	Temporal Sequence of Athlete's Heart Regression During	Nothing to Disclose Nothing to Disclose
Washam	Jeffrey	Athletes Arrhythmias and Clinical EP: Anticoagulation Issues	Prescribed Exercise Detraining: <i>Diagnostic Implications</i> Use of Interacting Drugs Did Not Modify Treatment Effects of Apixaban Versus Warfarin for Atrial Fibrillation: Results From the	Nothing to Disclose
Wasiak	Sylwia	Highlights in Vascular Medicine Research	ARISTOTLE Trial Apabetalone (RVX-208) Lowers Cardiovascular Disease (CVD) in Diabetes Mellitus by a Mechanism Involving Microbiome Mediated	SALARY - Resverlogix Corp.
Wasserman	Karlman	Innovations in Cardiovascular Risk Assessment	Activity on the Complement Pathway The Prognostic Value of CPET: Association With Coronary Artery	Nothing to Disclose
Wasserman	Karlman	and Reduction Non Invasive Imaging: Role of Exercise Testing		Nothing to Disclose
	<u> </u>	l	Coronary Artery Disease	

and a				
Last Name	First Name	Session Title	Presentation Title Primary Results of the Further Cardiovascular Outcomes Research	Disclosures SALARY - Amgen, Inc
Wasserman	Scott	Opening Session and the Joint American College of Cardiology and Journal of American		SALARY - Amgen, inc
		College of Cardiology Late-Breaking Clinical	Trial	
		Trials Featuring the Simon Dack Lecture		
Wassouf	Marwan	Nuclear Cardiology: Prognosis	The Prognostic Value of Serial Stress Myocardial Perfusion Imaging	Nothing to Disclose
			in Asymptomatic End-Stage Renal Disease Patients Awaiting Kidney Transplantation	
Wasty	Najam	Interventional Cardiology: TAVR 1	Assessment of Right Sided Hemodynamic Parameters as Predictors	Nothing to Disclose
,	.,.	3,	of Early Outcomes After Transcatheter Aortic Valve Replacement	3
Watanabe	Eri	Non Invasive Imaging: MR Structure and	Cardiac Diffusion Weighted Image in Patients With Cardiac	Nothing to Disclose
vvatariabe	Lii	Valuvular Heart Disease	Sarcoidosis: Comparison to ¹⁸ F-fludeoxyglcose PET	Nothing to Disclose
Watanabe	Hirotoshi	Antiplatelet and Antithrombotic Agents in	Application of DAPT Score to Predict Ischemic and Bleeding Events	Nothing to Disclose
		Ischemic Heart Disease	in Japanese Patients Undergoing Drug-Eluting Stent Implantation: An Observation From a Pooled Cohort of the CREDO-Kyoto Cohort-	
			2, RESET, and NEXT Trials	
Watanabe	Hiroyuki	Insights From Echocardiography Use	Value of Automated and Semi-Automated Measurement by Novel Three-Dimensional Echocardiography Software for Aortic Annulus	Nothing to Disclose
			Sizing in Candidates of Transcatheter Aortic Valve Replacement:	
Watanabe	La cart	No di Bondo di Anto Company	Comparison With Multi-Detector Computed Tomography	Notice to Breakers
vvatariabe	Ippei	Novel Developments in Acute Coronary Syndromes	Left Ventricular End-Diastolic Pressure Predicts Outcomes in Patients With ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
			Independently of Left Ventricular Systolic Function	
Watanabe	Kouki	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Differences in Chronic Angioscopic Findings With Different Stent Types in Patients With and Without Diabetes Mellitus: Sub-Analysis	Nothing to Disclose
		Analysis by intravascual imaging	of a Report From Japanese Multicenter Registry	
Watanabe	Nozomi	New Technologies in Echocardiography	Dynamic Changes of Mitral Apparatus in Acute Myocardial Infarction	Nothing to Disclose
			With Ischemic Mitral Regurgitation: Prospective 3D Quantitative Echocardiographic Study	
Watanabe	Rena	Cutting Edge Vascular Medicine	Atheroprotective Effects of Tumor Necrosis Factor-Stimulated Gene-	Nothing to Disclose
Watanabe	Shin	Heart Failure and Cardiomyopathies: Is Heart	6 LV Unloading Using Impella CP Improves LA Pressure, Function,	Nothing to Disclose
vvalanaue	51111	Failure With a Normal EF for Real?	and Stiffness in Ischemic Pig Model	Nothing to Disclose
Watanabe	Shin	Novel Developments in Acute Coronary	LV Unloading using an Impella CP Improves Coronary Flow and	Nothing to Disclose
Watanabe	Takuya	Syndromes Cutting Edge Vascular Medicine	Infarct Zone Perfusion Atheroprotective Effects of Tumor Necrosis Factor-Stimulated Gene-	Nothing to Disclose
		0 0	6	
Watanabe	Yusuke	Complex Coronary Intervention: Left	Impact of Kissing Balloon Inflation After Single Stent Implantation for	Nothing to Disclose
Watanabe	Yusuke	Main/Bifurcations and Multivessel Disease Interventional Cardiology: TAVR 4	Left Main Distal Bifurcation Lesions: New Tokyo Registry Transcatheter Aortic Valve Implantation in Patients With an	Nothing to Disclose
			Extremely Small Annulus	
Watanabe	Yusuke	Endovascular Therapy: Running From Risk	The Impact of Patent Below the Knee Vessels on Stenting for Chronic Total Occlusions in the Superficial Femoropopliteal Artery	Nothing to Disclose
Waterloo	Clare	Novel Echocardiographic Methods for	Clinical Validation of ASE 2016 Guidelines for Evaluating Left	Nothing to Disclose
		Assessing Cardiac Function	Ventricular Diastolic Dysfunction	
Watkins	Stuart	Highlighted Original Research: Non Invasive Imaging and the Year in Review	Prognostic Significance of Co-Existing Persistent Edema and Hemorrhage at 6 Months in Survivors of ST-Elevation Myocardial	Nothing to Disclose
			Infarction	
Watkins	Stuart	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Decision Making Using Fractional Flow Reserve Is Associated With Lower Rates of Incomplete Revascularization Compared With	Nothing to Disclose
		r nysiology and Endotheliai i diretion	Angiographic Guided Decision Making Amongst Patients With	
			Nstemi	
Watkins	Stuart	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	Segmental Circumferential Strain Derived From DENSE Predicts Improvement of Left Ventricular Function Post ST Elevation	Nothing to Disclose
			Myocardial Infarction: The BHF MR-MI Study	
Watkins	Stuart	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Current Smoking, Microvascular Pathology and Adverse Outcome After Acute ST-Segment Elevation Myocardial Infarction: New	Nothing to Disclose
		Syndrome	Pathophysiological Insights	
Watkins	Stuart	Acute Coronary Syndromes, Diagnosis,	Incidence and Prognostic Implications of the Presence of Multiple	Nothing to Disclose
		Management and Outcomes	Complex Plaques in Survivors of ST-Elevation Myocardial Infarction	
Watkins	Stuart	Non Invasive Imaging: MR Structure and	Hypertension, Microvascular Pathology and Prognosis in Patients	Nothing to Disclose
Watson	Chris	Valuvular Heart Disease Innovations in Cardiovascular Risk Assessment	With an Acute ST-Segment Elevation Myocardial Infarction Longitudinal Change in Soluble ST2 Versus B-type Natriuretic	Nothing to Disclose
vvaison	Ciliis	and Reduction	Peptide in Predicting Major Adverse Cardiovascular Events in	Nothing to Disclose
\\/	Daniel	Interpreting a Condition of TAVID 2	Asymptomatic Patients in the Community	CDEAVED'S DUDEAU MEDEDONIS
Watson	Daniel	Interventional Cardiology: TAVR 3	Initial Use of the Evolut Pro Self-Expanding Transcatheter Aortic Valve <i></i>	SPEAKER'S BUREAU - MEDTRONIC
Watson	Karol	Joint American College of Cardiology/Journal	Panelist	CONSULTANT FEES/HONORARIA - Amgen Inc., Astra
		of the American Medical Association Late- Breaking Clinical Trials		Zeneca,Daiichi Sankyl,GSK; DATA SAFETY MONITORING BOARD - Merck
Watson	Karol	Current Issues in Cardiovascular	Health Disparities Among Patients With Familial	CONSULTANT FEES/HONORARIA - Amgen Inc., Astra
		Epidemiology, Disparities, and Safety	Hypercholesterolemia in the CASCADE-FH Patient Registry	Zeneca,Daiichi Sankyl,GSK; DATA SAFETY MONITORING
Watson	Karol	Breakthrough Therapies: Your Role in	Clinical Facilitator	BOARD - Merck CONSULTANT FEES/HONORARIA - Amgen Inc., Astra
		Protecting the Heart of Your Patients with		Zeneca,Daiichi Sankyl,GSK; DATA SAFETY MONITORING
Watson	Karol	Diabetes Breakthrough Therapies: Your Role in	Pragmatic Conversations: Your Role in Protecting the Heart - Panel	BOARD - Merck CONSULTANT FEES/HONORARIA - Amgen Inc., Astra
**atouri	i da oi	Protecting the Heart of Your Patients with	Debate Programme Conversations: Your Role in Protecting the Heart - Panel	Zeneca,Daiichi Sankyl,GSK; DATA SAFETY MONITORING
NA/-1	NA - III	Diabetes		BOARD - Merck
Watson	Matthew	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Intravenous Amiodarone for Prevention of Atrial Fibrillation Following Esophagectomy: A Propensity Score-Matched Analysis	Nothing to Disclose
Watts	James	Timely Topics in Acute Coronary Syndromes	Evaluation of Exercise Response in Young Adults in a High Risk	Nothing to Disclose
			Occupation: Submaximal Invasive Cardiopulmonary Exercise Testing in Active Duty Soldiers	
Watts	Thomas	Arrhythmias and Clinical EP: Devices 3	Importance of Right Ventricular Lead Positioning in Determining	Nothing to Disclose
		,	Outcomes of Cardiac Resynchronization Therapy	3
Wayangankar	Siddharth	03. Acute and Stable Ischemic Heart Disease: Therapy Team 3	Suggested Reviewer	Nothing to Disclose
Wazni	Oussama	Advances in HCM, PPCM and Other	Atrial Thrombus in Patients With Cardiac Amyloidosis: Prevalence	CONSULTANT FEES/HONORARIA - Boston
Wozni	Ouggama	Cardiomyopathies 08. Arrhythmias and Clinical EP:	and Implications for Therapy	Scientific,Spectranetics CONSULTANT FEES/HONORARIA - Boston
Wazni	Oussama	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific, Spectranetics
		4		•
Webb	Gary	Finding Out What Works in Pediatric and Congenital Heart Disease	Timely Detection of Pulmonary Arterial Hypertension in Patients With Repaired Congenital Heart Disease: Interim Results From the	Nothing to Disclose
		3	ACHD-QuERI Registry	
Webb	Gary	09. Congenital Heart Disease: Adult Team 2 Featured Clinical Research II: Interventional	Suggested Reviewer	Nothing to Disclose CONSULTANT FEES/HONORARIA - Abbott Edwards
Webb	John	reatured Cililical Research II: Interventional	Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	Lifesciences, St Jude Medical; RESEARCH/RESEARCH
			· · ·	GRANTS - Siemens
Webb	John	Imaging for TAVR: Homing in on the Real Issues	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott,Edwards Lifesciences,St Jude Medical; RESEARCH/RESEARCH
				GRANTS - Siemens
•				



Last Name Webb	John	Session Title Controversies Surrounding TAVR: 2017 and Beyond	Presentation Title Panelist	Disclosures CONSULTANT FEES/HONORARIA - Abbott,Edwards Lifesciences,St Jude Medical; RESEARCH/RESEARCH GRANTS - Siemens
Webb	John	The Evolution of Angioplasty – 40 Years of Innovation: Joint Symposium of TCT and the American College of Cardiology	Panelist	CONSULTANT FEES/HONORARIA - Abbott,Edwards Lifesciences,St Jude Medical; RESEARCH/RESEARCH GRANTS - Siemens
Webb	John	Transcatheter Mitral Valve Replacement	TMV Replacement Will Be These Patients Best Option	CONSULTANT FEES/HONORARIA - Abbott,Edwards Lifesciences,St Jude Medical; RESEARCH/RESEARCH GRANTS - Siemens
Webb	John	Interventional Cardiology: TAVR 1	Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: Insights From PARTNER 2A Trial	CONSULTANT FEES/HONORARIA - Abbott,Edwards Lifesciences,St Jude Medical; RESEARCH/RESEARCH GRANTS - Siemens
Webb	John	Non Invasive Imaging: Expanding Clinical Applications	Does Patient Prosthesis Mismatch Defined by CT LVOT Area Predict Downstream Clinical Outcomes?	CONSULTANT FEES/HONORARIA - Abbott,Edwards Lifesciences,St Jude Medical; RESEARCH/RESEARCH GRANTS - Siemens
Webb	John	Interventional Cardiology: PCI and TAVR in Complex Patients	Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the Bravo-3 Randomized Trial	CONSULTANT FEES/HONORARIA - Abbott,Edwards Lifesciences,St Jude Medical; RESEARCH/RESEARCH GRANTS - Siemens
Webb	John	Interventional Cardiology: TAVR 4	Serum Albumin as an Incremental Predictor of Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement: Results From the Multicenter Frailty-AVR Study	CONSULTANT FEES/HONORARIA - Abbott,Edwards Lifesciences,St Jude Medical; RESEARCH/RESEARCH GRANTS - Siemens
Weber	Brittany	FIT Forum: Stump the Professor	Use of ¹⁸ F-Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for Diagnosing Prosthetic Valve Perivalvular Abscess	Nothing to Disclose
Weber	Michael	Controversies in Hypertension	SPRINT - Do These Results Translate to Practice in the Real World? No!	CONSULTANT FEES/HONORARIA - Ablative Solutions, Allergan, Inc, Astellas Pharma US, Boston Scientific, Eli Lilly and Company, MEDTRONIC, Novartis, Recor; SPEAKER'S BUREAU - Menarini, Merck & amp; Co., Inc.
Weber	Michael	33. Prevention: Hypertension Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Ablative Solutions, Allergan, Inc, Astellas Pharma US, Boston Scientific, Eli Lilly and Company, MEDTRONIC, Novartis, Recor; SPEAKER'S BUREAU - Menarini, Merck & amp; Co., Inc.
Webster	Mark	Strategies for Prevention of Cardiovascular Disease: International Perspectives From the Canadian Cardiovascular Society, Cardiac Society of Australia and New Zealand, and American College of Cardiology	Co-Chair	CONSULTANT FEES/HONORARIA - Adept Medical; OTHER- Concert Medical; RESEARCH/RESEARCH GRANTS - Biotrace Medical, Biotronik, Boston Scientific, Edwards Lifesciences, Metavention, Valencia Medical
Webster	Mark	Clinical Challenges in the Cardiac Care Unit (CCU)	Panelist	CONSULTANT FEES/HONORARIA - Adept Medical; OTHER - Concert Medical; RESEARCH/RESEARCH GRANTS - Biotrace Medical, Biotronik, Boston Scientific, Edwards Lifesciences, Metavention, Valencia Medical
Webster	Mark	Global Perspectives in the Treatment of ST Elevation Myocardial Infarction: Successes, Failures, and Challenges	SNAPSHOT of STEMI Care in the Southern Hemisphere: The New Zealand Experience	CONSULTANT FEES/HONORARIA - Adept Medical; OTHER - Concert Medical; RESEARCH/RESEARCH GRANTS - Biotrace Medical, Biotronik, Boston Scientific, Edwards Lifesciences, Metavention, Valencia Medical
Wedel	Hans	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Association Between Homeostasis Model Assessment of Insulin Resistance and Survival in Diabetic Patients With Acute Coronary Syndromes: Insights From the AleCardio Trial	CONSULTANT FEES/HONORARIA - Astra-Zeneca,Hoffman-La Roche,Pfizer
Wedell Wedell	Robin Robin	I Can Do WHAT After My Heart Attack? Cardiac Rehab in 2017: Tailoring The Approach to the Times	Panelist Panelist	Nothing to Disclose Nothing to Disclose
Wegscheider	Karl	Why Can't We Be Friends? Controversies in Heart Failure Management	Remote Telemonitoring in Chronic Heart Failure Does Not Reduce Healthcare Cost but Improves Quality of Life: Endpoints of the CardioBBEAT Trial	CONSULTANT FEES/HONORARIA - Resmed
Wei	Janet	Change is Good! Lifestyle Strategies in the Patient with ASCVD and Diabetes	Co-Chair	Nothing to Disclose
Wei	Janet	Angina in the Absence of Obstructive CAD. What Do We Do With These Patients?	Expert Review: Evaluating for and Treating Coronary Vasospasm	Nothing to Disclose
Wei	Janet	The Consequences of Sex: Women and Pregnancy Across the Spectrum	Panelist	Nothing to Disclose
Wei	Janet	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Coronary Microvascular Dysfunction Is Related to Left Ventricular Concentric Remodeling and Diastolic Dysfunction: From the WISE- CVD Study	Nothing to Disclose
Wei	Janet	Non Invasive Imaging: MR Scar and Perfusion	Hyperemic Subendocardial-to-Subepicardial Perfusion Ratio as a Surrogate Marker for Coronary Endothelial Dysfunction: Initial Results in Women With Microvascular Dysfunction	Nothing to Disclose
Wei	Janet	Non Invasive Imaging: MR Scar and Perfusion	Assessment of Myocardial Perfusion Reserve Index Using Adenosine Versus Regadenoson Among Healthy Female Subjects	Nothing to Disclose
Wei	Janet	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Prognostic Risk Factors for Heart Failure Hospitalization in Women Without Obstructive Coronary Disease: An Ancillary Study From the Women's Ischemia Syndrome Evaluation (WISE)	Nothing to Disclose
Wei	Jessica	Innovations in Practice Management and Social Media	Impact of Electronic Health Records on the Quality of Outpatient Cardiovascular Care Delivery in India: Insights From the American College of Cardiology's PINNACLE India Quality Improvement Program (PIQIP)	Nothing to Disclose
Wei	Rong	Advances in Cholesterol Measurement and Management	Trends in Statin Use Among Adults in an Integrated Health Care Delivery System: Impact of the 2013 Guideline on the Treatment of Blood Cholesterol	Nothing to Disclose
Weichert	Arlette	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Association Between Homeostasis Model Assessment of Insulin Resistance and Survival in Diabetic Patients With Acute Coronary Syndromes: Insights From the AleCardio Trial	SALARY - Employee of F. Hoffmann-La Roche Ltd/Genentech
Weigold	William	Patient-Centered Imaging: Quality of Cardiac CT Evidence	Co-Chair	Nothing to Disclose
Weigold	William	Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	Left Ventricular Assist Device Evaluation Using Cardiac CT: Initial Experience at a High Volume Center	Nothing to Disclose
Weigold	William	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team 1	Suggested Reviewer	Nothing to Disclose
Weinberg	Ido	40. Vascular Medicine: Non Coronary Arterial Disease Team 2	Suggested Reviewer	Nothing to Disclose
Weinberg	Mitchell	39. Vascular Medicine: Endovascular Therapy Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Cardiovascular Systems, Inc,MEDTRONIC; RESEARCH/RESEARCH GRANTS - Cardiovascular Systems Inc.
Weiner	Bonnie	Debates: Is There Really a Sex Difference in CV Presentation, Care, and Outcomes?	There is a Gender Bias in Cardiac Care: CON	CONSULTANT FEES/HONORARIA - Somahultion, Stryker; DATA SAFETY MONITORING BOARD - Biocardia; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Imaging Core Lab Services; RESEARCH/RESEARCH GRANTS - ASAII, MicroVention
Weinert	Lynn	Innovative Use of Echocardiography	Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography	Nothing to Disclose
Weinert	Lynn	New Technologies in Echocardiography	Three-Dimensional Echocardiographic Automated Quantification of Left Ventricular and Atrial Volumes Using Adaptive Analytics	Nothing to Disclose
			Algorithm: Feasibility in Non-Selected Patients	



Last Name Weintraub	First Name Robert	Session Title Advances in HCM, PPCM and Other	Presentation Title Long-Term Outcomes of Childhood Left Ventricular Non-	Disclosures CONSULTANT FEES/HONORARIA - Actelion
Weintraub	William	Cardiomyopathies Interventional Cardiology: TAVR 1	Compaction: Results From a National Population-Based Study Safety and Efficacy of Using Pressure Wire With Dobutamin Infusion in Themoynamic Assessment of Low Flow Low Gradient Aortic	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals
Weintraub	William	Innovations in Practice Management and	Stenosis Predicting Readmission Risk Following Percutaneous Coronary	CONSULTANT FEES/HONORARIA - AstraZeneca
		Social Media	Intervention at the Time of Admission	Pharmaceuticals
Weintraub	William	Innovations in Practice Management and Social Media	Predicting Readmission Risk Following Coronary Artery Bypass Surgery at the Time of Admission	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals
Weintraub	William	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals
Weintraub	William	Interventional Cardiology: PCI and TAVR in	Hemodynamic Assessment of Low Flow, Low Gradient Severe Aortic Stenosis With Preserved EF Using a Pressure Wire	CONSULTANT FEES/HONORARIA - AstraZeneca
Weintraub	William	Complex Patients Interventional Cardiology: Structural Heart	The Impact of Transaortic Gradient and Transaortic Flow on the	Pharmaceuticals CONSULTANT FEES/HONORARIA - AstraZeneca
		Disease	Discrepancy Between Echocardiographic and Cardiac Catheterization Evaluation of Severe Aortic Stenosis With Preserved Ejection Fraction	Pharmaceuticals
Weintraub	William	Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals
Weintraub	William	Post-CAD/MI: Making Tough Predictions About the Future		CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals
Weintraub	William	New Insights Into Prediction and Treatment of	Cost-Effectiveness of Intensive Blood Pressure Goals in Patients	CONSULTANT FEES/HONORARIA - AstraZeneca
Weintraub	William	Hypertension 01. Acute and Stable Ischemic Heart Disease:	With Prior Cardiovascular Disease Suggested Reviewer	Pharmaceuticals CONSULTANT FEES/HONORARIA - AstraZeneca
Weir	Matthew	Basic Team 2 Heart Failure and Cardiomyopathies: Heart	Treatment With Patiromer Decreases Aldosterone in Patients With	Pharmaceuticals CONSULTANT FEES/HONORARIA - Astra-Zeneca,Boehringer
		Failure Is Just a Revolving Door	Heart Failure, Chronic Kidney Disease, and Hyperkalemia on RAAS Inhibitors	Ingelheim Pharmaceuticals, Inc,Boston Scientific,Janssen,MSD,Relypsa,Sanofi-Aventis
Weisel	Richard	Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials	Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic Surgical Trials Network	Nothing to Disclose
Weiss	Allen	Non Invasive Imaging: MR Characterization and Function	T1 Mapping Assesses Diagnosis, Severity and Prognosis in Acute Myocarditis	Nothing to Disclose
Weiss	Allen	Non Invasive Imaging: MR Heart Failure and Pulmonary Hypertension	T1 Mapping in Patients With Heart Failure With Preserved Ejection Fraction Detects Increased Interstitial Myocardial Fibrosis and Assesses the Severity of Heart Failure	Nothing to Disclose
Weiss	Allen	Arrhythmias and Clinical EP: Devices 3	Epicardial Lead Migration to the Spine With Development of Vertebral Abscess	Nothing to Disclose
Weiss	Allen	Non Invasive Imaging: MR Structure and Valuvular Heart Disease	Mild Rheumatic Valvular Heart Disease Is Associated With Interstitial Myocardial Fibrosis: A T1 Mapping Study	Nothing to Disclose
Weiss	Brendan	Advances in HCM, PPCM and Other Cardiomyopathies	MCD001 Demonstrates Cardiac Biomarker Responses in Patients With Light Chain Amyloidosis: Results From the Phase 1/2 Study	CONSULTANT FEES/HONORARIA - AInylam; DATA SAFETY MONITORING BOARD - Novartis Corporation; RESEARCH/RESEARCH GRANTS - Janssen Pharmaceuticals, Inc, Prothena Biosciences
Weiss	Jessica	FIT Forum: Stump the Professor	Persistence Pays Off: A Rare Case of Platypnea-Orthodeoxia Syndrome Due to a Patent Foramen Ovale	Nothing to Disclose
Weiss	Jessica		Comparing TEE With Angiographic Sizing of WATCHMAN Device	Nothing to Disclose
Weiss	Raul	Valve, Left Atrial Appendage and HOCM Arrhythmias and Clinical EP: Devices 2	for Left Atrial Appendage Closure Comprehensive Strategy to Reduce the Incidence of Lead	CONSULTANT FEES/HONORARIA - Boston Scientific;
Weiss	Raul	Arrhythmias and Clinical EP: Devices 3	Dislodgment for Cardiac Implantable Electronic Devices Cryoballoon Versus Radiofrequency Ablation of Atrial Fibrillation: In-	RESEARCH/RESEARCH GRANTS - MEDTRONIC,St Jude Medical; SPEAKER'S BUREAU - Biotronik CONSULTANT FEES/HONORARIA - Boston Scientific;
			Lab Complication Rates at a Large Volume Electrophysiology Center	RESEARCH/RESEARCH GRANTS - MEDTRONIC,St Jude Medical; SPEAKER'S BUREAU - Biotronik
Weiss	Robert	Advances in Lipid Management	Treatment Effects of Alirocumab as an Add-On to Maximally Tolerated Dose of Statin in Patients With Heterozygous Familial Hypercholesterolemia and/or Atherosclerotic Cardiovascular Disease	RESEARCH/RESEARCH GRANTS - Amgen,Genzyme,JNJ,Pfizer,Regeneron,SANOFI
Weiss	Sandra	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study	Nothing to Disclose
Weiss	Sandra	Timely Topics in Acute Coronary Syndromes	Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes	Nothing to Disclose
Weissman	Gaby	Engage @ ACC.17 Studio: Cardiology Contest	Cardiology Contestant	Nothing to Disclose
Weissman	Gaby	Engage @ ACC.17 Studio: FIT Jeopardy Battle	Judge	Nothing to Disclose
Weissman	Neil	of the State Chapters IV Controversies in Echocardiography	Co-Chair	RESEARCH/RESEARCH GRANTS - Abbott Vascular,Boston
Weissman	Neil	Structural Heart Interventions: What Does the	Co Chair	Scientific,DirectFlow,Edwards Lifescience,MEDTRONIC,Sorin,St Jude RESEARCH/RESEARCH GRANTS - Abbott Vascular,Boston
		Imager Need to know	Co-Chair	Scientific,DirectFlow,Edwards Lifescience,MEDTRONIC,Sorin,St Jude
Weissman	Neil	Point of Care Ultrasound (POCUS): The Future or a Fad?	Panelist	RESEARCH/RESEARCH GRANTS - Abbott Vascular,Boston Scientific,DirectFlow,Edwards Lifescience,MEDTRONIC,Sorin,St Jude
Weissman	Neil	Point of Care Ultrasound (POCUS): The Future or a Fad?	Putting POCUS in Perspective What does the Future Hold?	RESEARCH/RESEARCH GRANTS - Abbott Vascular,Boston Scientific,DirectFlow,Edwards Lifescience,MEDTRONIC,Sorin,St Jude
Weissman	Neil	Interventional Cardiology: TAVR 1	Outcomes of the Different Flow/Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: Insights From PARTNER 2A Trial	RESEARCH/RESEARCH GRANTS - Abbott Vascular,Boston Scientific,DirectFlow,Edwards Lifescience,MEDTRONIC,Sorin,St Jude
Weissman	Neil	Non Invasive Imaging: Expanding Clinical Applications	Does Patient Prosthesis Mismatch Defined by CT LVOT Area Predict Downstream Clinical Outcomes?	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Boston Scientific, DirectFlow, Edwards Lifescience, MEDTRONIC, Sorin, St
Weissman	Neil	Refining TAVR Outcomes	Concentric Left Ventricular Remodeling Is Associated With Low- Flow Severe Aortic Stenosis and Less Reverse Remodeling After	Jude RESEARCH/RESEARCH GRANTS - Abbott Vascular,Boston Scientific,DirectFlow,Edwards Lifescience,MEDTRONIC,Sorin,St
Weissman	Neil	28. Non Invasive Imaging: Echo Team 5	TAVR: A Partner 2 Trial Analysis Suggested Reviewer	Jude RESEARCH/RESEARCH GRANTS - Abbott Vascular,Boston Scientific,DirectFlow,Edwards Lifescience,MEDTRONIC,Sorin,St
Weisz	Alessandro	Novel Mechanisms Underlying Ischemia-	Activating Stimuli Modulate Pre-mRNA Maturation in Platelets: A	Jude Nothing to Disclose
Weisz	Giora	Reperfusion Injury in AMI PPIs in the Era of Prolonged DAPT Should	Novel Mechanism That Regulates Platelet Function? Panelist	CONSULTANT FEES/HONORARIA -
		We or Shouldn't We?: Pharmacology III		AngioSlide, AstraZenica, Calore, Corindus, MEDTRONIC, Vectorious; OTHER - Eco-Fusion, Medivizor, MI Medical Incentives; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Filterlex
Weisz	Giora	Interventional Live Case Session V: Complex Coronary and Physiology from Mid-America	Panelist	CONSULTANT FEES/HONORARIA - AngioSlide, AstraZenica, Calore, Corindus, MEDTRONIC, Vectoriou



Contract of the second				<u> </u>
Last Name Weisz	First Name Giora	Session Title Complex PCI in 2017	Presentation Title Thrombus Removal: New Trials, New Guidelines, New Perspectives	Disclosures CONSULTANT FEES/HONORARIA -
Weisz	Giora	Complex PCF III 2017	on Patient Selection	AngioSlide, AstraZenica, Calore, Corindus, MEDTRONIC, Vectorious; OTHER - Eco-Fusion, Medivizor, MI Medical Incentives; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Filterlex
Weisz	Giora	Considerations in Antiplatelet Therapy and in ACS	Platelet Reactivity and Outcomes After PCI of Lesions With and Without In-Stent Restenosis: The ADAPT-DES Study	CONSULTANT FEES/HONORARIA - AngioSilde, AstraZenica, Calore, Corindus, MEDTRONIC, Vectoriou s, OTHER - Eco-Fusion, Medivizor, MI Medical Incentives; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Filterlex
Weisz	Giora	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study	CONSULTANT FEES/HONORARIA - AngioSilde, AstraZenica, Calore, Corindus, MEDTRONIC, Vectoriou s; OTHER - Eco-Fusion, Medivizor, MI Medical Incentives; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Filterlex
Weisz	Giora	Advances in Chronic Total Occlusion Intervention	Is Platelet Reactivity Associated With Ischemic Events Following Successful Chronic Total Occlusion Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - AngioSilde, AstraZenica, Calore, Corindus, MEDTRONIC, Vectoriou s; OTHER - Eco-Fusion, Medivizor, MI Medical Incentives; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Filterlex
Weisz	Giora	21. Interventional Cardiology: Coronary Intervention: Devices Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - AngioSilde, AstraZenica, Calore, Corindus, MEDTRONIC, Vectoriou s; OTHER - Eco-Fusion, Medivizor, MI Medical Incentives; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Filterlex
Welch	Terrence	Test Yourself with Questions: General Cardiology Module 14	Faculty	Nothing to Disclose
Welch	Terrence	Arrhythmias and Clinical EP: AF Ablation	Dofetilide Associated QT Prolongation: Actual Versus Ideal Body Weight to Calculate Dosing	Nothing to Disclose
Welch	Terrence	Insights From Echocardiography Use	Advances in 3D Echocardiography: Automated Software Improves the Learning Curve and Clinical Implementation in a Real World Setting for Quantitative Assessment of Left Ventricular Ejection Fraction	Nothing to Disclose
Welji	Amynah	Great Minds Think Differently: Multidisciplinary Approach to Advanced Therapies	Panelist	Nothing to Disclose
Well Wells	Andrew	Redefining the "F" Word	Adults With Congenital Heart Disease: Lost in Care Efficacy and Safety of Bivalirudin in Patients Undergoing	Nothing to Disclose
	George	Novel Developments in Acute Coronary Syndromes	Pharmacoinvasive Strategy Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction	Nothing to Disclose
Wells	Gretchen	Advances in HCM, PPCM and Other Cardiomyopathies	Extended Course of Recovery in Patients With Peripartum Cardiomyopathy Assessed by Left Ventricular Wall Distensibility	Nothing to Disclose
Wells	Philip	Joint American College of Cardiology/Journal of the American Medical Association Late-	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism	Nothing to Disclose
Wells	Quinn	Breaking Clinical Trials FIT Forum: Acing the Transition: What FITs Need to Know to Launch A Successful Career	The Elevator Speech	Nothing to Disclose
Wells	Quinn	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Racial Differences in Patients Referred for Right Heart Catheterization and Risk of Pulmonary Hypertension	Nothing to Disclose
Wells	Quinn	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Lack of a Tricuspid Regurgitation Velocity and Pulmonary Hypertension: Absence of Evidence Is Not Evidence of Absence	Nothing to Disclose
Wells	Quinn	Markers of Prognosis Associated With Elevated Blood Pressure	Direct Transition to Dilated Cardiomyopathy Without Antecedent Left Ventricular Hypertrophy Is Uncommon Among Hypertensive	Nothing to Disclose
Welsh	Paul	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Subjects in a Large Clinical Cohort Current Smoking, Microvascular Pathology and Adverse Outcome After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights	Nothing to Disclose
Welsh	Robert	Joint American College of Cardiology/Journal	A Randomized Trial Evaluating Clinically Significant Bleeding With	CONSULTANT FEES/HONORARIA - Astra
		of the American Medical Association Late- Breaking Clinical Trials	Low-Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, for Patients After Acute Coronary Syndromes	Zeneca,Bayer,Boehringer Ingelheim,Edwards Lifesciences,Eli Lilly,MEDTRONIC,Roche,servier
Welsh	Robert	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Characterization and Outcomes of Spontaneous Coronary Artery Dissection Patients Presenting With an Acute Coronary Syndrome: Insights From the ACALM Registry	CONSULTANT FEES/HONORARIA - Astra Zeneca,Bayer,Boehringer Ingelheim,Edwards Lifesciences,Eli Lilly,MEDTRONIC,Roche,servier
Welsh	Robert	Novel Developments in Acute Coronary Syndromes	Utility of Unfractionated Heparin in Transradial Cardiac Catheterization: A Systematic Review and Meta-Analysis of Randomized Studies	CONSULTANT FEES/HONORARIA - Astra Zeneca,Bayer,Boehringer Ingelheim,Edwards Lifesciences,Eli Lilly,MEDTRONIC,Roche,servier
Welsh	Robert	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Real World Relationships Between Baseline Q Waves, Time From Symptom Onset and Clinical Outcomes in ST-Segment Elevation Myocardial Infarction Patients: Insight From the Vital Heart Response Registry	CONSULTANT FEES/HONORARIA - Astra Zeneca,Bayer,Boehringer Ingelheim,Edwards Lifesciences,Eli Lilly,MEDTRONIC,Roche,servier
Welt	Frederick	Debates on Current Hot Topics in Coronary Intervention	Debate Con: No, the Newer Technologies Are Interesting but Shouldn't Replace Current Generation DES	CONSULTANT FEES/HONORARIA - Medtronic Inc; RESEARCH/RESEARCH GRANTS - MEDTRONIC,Siemen's Inc
Welt	Frederick	Overuse, Underuse or Just Right? Fundamental Debates in High Risk PCI in 2017	Hemodynamic Support for High Risk PCI: Stop the Madness-	CONSULTANT FEES/HONORARIA - MEDTRONIC, SIEMEN'S INC RESEARCH/RESEARCH GRANTS - MEDTRONIC, Siemen's Inc
Welt	Frederick	Bioresorbable Vascular Scaffolds, Bioresorbable Polymer and Polymer Free	Debate Pro: Appropriate Patient Selection: BVS Should Be Used Very Selectively	CONSULTANT FEES/HONORARIA - Medtronic Inc; RESEARCH/RESEARCH GRANTS - MEDTRONIC, Siemen's Inc
Welt	Frederick	Metallic DES Interventional Cardiology: TAVR 4	Depression as a Potential Therapeutic Target to Improve Quality of	CONSULTANT FEES/HONORARIA - Medtronic Inc; RESEARCH/RESEARCH GRANTS - MEDTRONIC, Siemen's Inc
Welty	Francine	32. Prevention: Clinical Team 5	Life After Transcatheter Aortic Valve Replacement Suggested Reviewer	DATA SAFETY MONITORING BOARD - Boerhinger-Ingelheim
Weng	Cindy	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Safety and Feasibility of Melody Transcatheter Pulmonary Valve Replacement in the Native Right Ventricular Outflow Tract: A Multicenter Study	OTHER - University of Utah
Weng	Hsin-Yi	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Do Pediatric Cardiologists Follow the Sports Restriction Recommendations for Children With a Bicuspid Aortic Valve?	OTHER - University of Utah
Wenger	Nanette	Single Verifice relationsesse Effective Medication Management in the Older Adults with CVD: Pharmacology Program I	Recommendations for Children volume a Bicuspid Adrilic valve? Drug Prescribing in Older Adults with CVD: The Scope of the Problem	CONSULTANT FEES/HONORARIA - Amgen, AstraZeneca, GILEAD Sciences, Merck; RESEARCH/RESEARCH GRANTS - Alnylam Pharmaceuticals, Gilead Sciences (formerly CV Therapeutics), NHLBI, Pfizer, Society for Women's Health Research
Wenger	Nanette	Debates: Is There Really a Sex Difference in CV Presentation, Care, and Outcomes?	Panelist	CONSULTANT FEES/HONORARIA - Amgen AstraZeneca, GILEAD Sciences, Merck; RESEARCH/RESEARCH GRANTS - Alnylam Pharmaceuticals, Gilead Sciences (formerly CV Therapeutics), NHLBI, Pfizer, Society for Women's Health Research
Wenger	Nanette	Core Curriculum: Special Topic: Cardiac Issues During The Golden Years and Beyond	Chair	Kesearch CONSULTANT FEES/HONORARIA - Amgen, AstraZeneca, GILEAD Sciences, Merck; RESEARCH/RESEARCH GRANTS - Alnylam Pharmaceuticals, Gilead Sciences (formerly CV Therapeutics), NHLBI, Pfizer, Society for Women's Health Research
Werdan	Karl	Novel Developments in Acute Coronary Syndromes	Impact of Timing of Intra-Aortic Balloon Counterpulsation on Mortality in Cardiogenic Shock: A Sub-Analysis of the IABP-SHOCK	Nothing to Disclose
		Syndromes	II-Trial	



Control of the Contro		la i mi		
Werner	First Name Gerald	Session Title 20. Interventional Cardiology: Coronary Intervention: CTO Team 1	Presentation Title Suggested Reviewer	Disclosures RESEARCH/RESEARCH GRANTS - Siemens
Wernovsky	Gil	Post-Surgical Care of Children with CHD: From ICU to Your Office	Interviewee: Neurodevelopmental Care	Nothing to Disclose
West	Kristin	Innovations in Education	Teaching Tomorrow's Teachers: An Innovative Model of Clinician- Educator Development for Trainees	Nothing to Disclose
Weston	Susan	Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation	Time in Therapeutic Range Predicts Mortality and Cerebrovascular Events in Atrial Fibrillation Patients Treated With Warfarin	Nothing to Disclose
Wheeler	David	Considerations in Antiplatelet Therapy and in ACS	Chronovariability of Platelet Reactivity With the Hemodialysis Cycle	Nothing to Disclose
Wheeler	Matthew	Featured Clinical Research I	Testing Safety and Efficacy: The Randomized Exploratory Study of Exercise Training in Hypertrophic Cardiomyopathy (RESET-HCM)	CONSULTANT FEES/HONORARIA - Array Biopharma,MyoKardia Inc; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Personalis Inc; RESEARCH/RESEARCH GRANTS - Heart Metabolics,MyoKardia Inc
Wheeler	Matthew	Imaging the Athlete's Heart	Addressing Reference Echocardiographic Parameters in Athletic Screening: A College Football-Based Study Focusing on the Implications of Race and Correction for Body Composition	CONSULTANT FEES/HONORARIA - Array Biopharma, Myokardia Inc; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Personalis Inc; RESEARCH/RESEARCH GRANTS - Heart Metabolics, MyoKardia Inc
Wheeler	Matthew	Innovative Use of Echocardiography	Identifying the Optimal Echocardiographic Variables to Predict Outcome Through Correlation Mapping in Patients With Dilated Cardiomyopathy	CONSULTANT FEES/HONORARIA - Array Biopharma, MyoKardia Inc; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Personalis Inc; RESEARCH/RESEARCH GRANTS - Heart Metabolics, MyoKardia Inc
Wheeler	Matthew	Advances in HCM, PPCM and Other Cardiomyopathies	Integrating Myocardial Strain and Exercise Performance Into Prognostication of Hypertrophic Cardiomyopathy	CONSULTANT FEES/HONORARIA - Array Biopharma, MyoKardia Inc; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Personalis Inc; RESEARCH/RESEARCH GRANTS - Heart Metabolics, MyoKardia Inc
Wheeler	Matthew	Advances in HCM, PPCM and Other Cardiomyopathies	Systolic Dysfunction Without LV Dilatation in a Cohort of Patients With Lamin A/C Cardiomyopathy	CONSULTANT FEES/HONORARIA - Array Biopharma, MyoKardia Inc; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Personalis Inc; RESEARCH/RESEARCH GRANTS - Heart Metabolics, MyoKardia Inc
Wheeler	Matthew	Interdisciplinary Cardiovascular Care in Complex Scenarios	Interdisciplinary Peripartum Care of the Patient With Diastolic Heart Failure in Non-Obstructive Hypertrophic Cardiomyopathy	CONSULTANT FEES/HONORARIA - Array Biopharma, MyoKardia Inc; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Personalis Inc; RESEARCH/RESEARCH GRANTS - Heart Metabolics, MyoKardia Inc
Whellan	David	Readmission in Heart Failure: Questions Unanswered	Can Technology Tackle Readmissions in Big Populations?	CONSULTANT FEES/HONORARIA - Aralez Pharmaceutical AstraZeneca, Clinlogics, CVRx, Fibrogen; RESEARCH/RESEARCH GRANTS - CVR Global Inc, Johnson and Johnson, National Institutes of Health, Resmed
Whellan	David	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Surrogate Endpoints and the Differential Response to ASV for Sleep Apnea in HFrEF Versus HFpEF in the CAT-HF Trial	CONSULTANT FEES/HONORARIA - Aralez Pharmaceutical AstraZeneca, Clinlogics, CVRx, Fibrogen; RESEARCH/RESEARCH GRANTS - CVR Global Inc, Johnson and Johnson, National Institutes of Health, Resmed
Whellan	David	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Severe Physical Inactivity Persists Following Acute Heart Failure in Patients With Sleep Disordered Breathing	CONSULTANT FEES/HONORARIA - Aralez Pharmaceutical AstraZeneca (Clinlogics, CVRx, Fibrogen; RESEARCH/RESEARCH GRANTS - CVR Global Inc, Johnson and Johnson, National Institutes of Health, Resmed
Whellan	David	Why Can't We Be Friends? Controversies in Heart Failure Management	Prevalent Digoxin Use Is Not Associated With Increased Risk of Death or Hospitalization in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction	CONSULTANT FEES/HONORARIA - Aralez Pharmaceutical, AstraZeneca, Clinlogics, CVRx, Fibrogen; RESEARCH/RESEARCH GRANTS - CVR Global Inc, Johnson and Johnson, National Institutes of Health, Resmed
Whelton	Paul	Hypertension: Evolving Evidence, Changing Guidelines	Panelist	Nothing to Disclose
Whelton	Paul	Hypertension: Evolving Evidence, Changing Guidelines	Evolution of U.S. Hypertension Guidelines	Nothing to Disclose
Whisenant	Brian	Interventional Live Case Session III: Structural Transmission from Cleveland Clinic (Cleveland, Ohio)	Panelist	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, Johnson & amp; amp; Johnson; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Coherex Medical; SPEAKER'S BUREAU - Edwards medical
Whisenant	Brian	TAVR: What We've Learned and Where We Think We're Going!	Conscious Sedation in TAVR: Patient Versus Institutional Benefits	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, Johnson & Dong, Johnson; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Coherex Medical; SPEAKER'S BUREAU - Edwards medical
Whisenant	Brian	Transcatheter Mitral Valve Repair	MitraClip Case Example: Functional MR	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, Johnson & Dong, Johnson; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Coherex Medical; SPEAKER'S BUREAU - Edwards medical
Whisenant	Brian	Interventional Cardiology: TAVR 4	Depression as a Potential Therapeutic Target to Improve Quality of Life After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, Johnson & amp; amp; Johnson; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Coherex Medical; SPEAKER'S BUREAU - Edwards medical
Whisenant	Brian	24. Interventional Cardiology: Mitral and Structural Heart Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Laboratories, Boston Scientific, Johnson & Dong, Johnson; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Coherex Medical; SPEAKER'S BUREAU - Edwards medical
Whitbourn	Robert	Refining PCI Technique and Outcomes	Final 3-Year Clinical Outcomes of Patients Treated With Everolimus- Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents: A Propensity Score Comparison of Patients Enrolled in the Extend and SPIRIT Trials	Nothing to Disclose
White	C. Michael	Featured Clinical Research III	The Effect of High-Dose Atorvastatin on Neuronal Activity and Cognitive Function	Nothing to Disclose
White	Christopher	The Evolution of Angioplasty 40 Years of Innovation: Joint Symposium of TCT and the	The Evolution of Peripheral Vascular Intervention	CONSULTANT FEES/HONORARIA - Neovasc; OTHER - Neovasc, Surmodics; RESEARCH/RESEARCH GRANTS -
White	Christopher	American College of Cardiology 18. Interventional Cardiology: Carotid and Endovascular Intervention Team 1	Suggested Reviewer	AstraZeneca Pharmaceuticals, Crest-2 Trial CONSULTANT FEES/HONORARIA - Neovasc; OTHER - Neovasc, Surmodics; RESEARCH/RESEARCH GRANTS - AstraZeneca Pharmaceuticals, Crest-2 Trial
White	Harvey	The Art and the Science of Decision Making in Coronary Artery Disease	Co-Chair	Astrazeneca Pharmaceuticals, Crest-2 Trial Nothing to Disclose
White	Harvey	Coronary Artery Disease Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Impact of Periprocedural Myocardial Infarction in Contemporary PCI: Pooled Patient-Level Data From the CHAMPION Trials	Nothing to Disclose
White	Harvey	Advances in Lipid Management	P.C.: Pooled Patient-Level Data From the CHAMPION Trais Use of High-Intensity Statin Therapy Post-Acute Coronary Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody, Versus Placebo: Interim Baseline Data	Nothing to Disclose
White	Harvey	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Bleeding Risk Models in Acute Coronary Syndrome: Meta-Analysis of Performance	Nothing to Disclose
White	Harvey	Optimizing the Care of ACS Patients	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin: Insights From CHAMPION PHOENIX	Nothing to Disclose



Last Name White	First Name Harvey	Session Title Post-CAD/MI: Making Tough Predictions About	Presentation Title One-Year Mortality Increased in Patients With Peri-Procedural	Disclosures Nothing to Disclose
White	Harvey	the Future Anti-Platelet Therapies: Always a Sticky Topic	Myocardial Infarction: Insights From the CHAMPION Trials Ischemic Events Occur Early in Patients Undergoing PCI and Are	Nothing to Disclose
White	Harvey	15. Interventional Cardiology:	Reduced With Cangrelor: Findings From CHAMPION PHOENIX Suggested Reviewer	Nothing to Disclose
		ACS/AMI/Hemodynamics and Pharmacology Team 2		
White	James	Non Invasive Imaging: MR Characterization and Function	Defining Risk Associated With Left Ventricular Hypertrophy Patterns as Assessed by Cardiac Magnetic Resonance Imaging	CONSULTANT FEES/HONORARIA - Medtronic USA; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cohesic Inc.; RESEARCH/RESEARCH GRANTS - Circle Cardiovascular Inc.,Medtronic Canada
White	James	Updates in Stable Ischemic Heart Disease	Beta Blocker Post ACS in Patients With Preserved Left Ventricular Systolic Function	CONSULTANT FEES/HONORARIA - Medironic USA; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cohesic Inc.; RESEARCH/RESEARCH GRANTS - Circle Cardiovascular Inc.,Medironic Canada
White	James	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	The Presence of Fragmented QRS Complexes Early After Acute Myocardial Infarction is Associated With Subsequent Lack of Favorable Left Ventricular Remodeling	CONSULTANT FEES/HONORARIA - Medtronic USA; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Cohesic Inc.; RESEARCH/RESEARCH GRANTS - Circle Cardiovascular Inc.,Medtronic Canada
White White	Maria Michael	Cardiovascular Team Cases: Team 2 Arrhythmias and Clinical EP: Ventricular	Suggested Reviewer Therapeutic Hypothermia for In-Hospital Cardiac Arrest: A Meta-	Nothing to Disclose Nothing to Disclose
White	Michel	Tachycardia Making Progress in Understanding Heart Failure	Analysis Orthopnea or Paroxysmal Nocturnal Dyspnea in Older Adults Without Prevalent Heart Failure Is a Predictor, but Not an Independent Risk Factor for Incident Heart Failure: Insights From	RESEARCH/RESEARCH GRANTS - Pfizer; SPEAKER'S BUREAU - Novartis Pharma Canada
White	Michel	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	the Cardiovascular Health Study Clinical Effectiveness of Spironolactone in Hospitalized Older Eligible (EF Less Than or Equal to 35% and eGFR Greater Than or Equal to 30 mL/min/1.73 m ^{2^{) Patients With Heart}}	RESEARCH/RESEARCH GRANTS - Pfizer; SPEAKER'S BUREAU - Novartis Pharma Canada
White	Michel	Heart Failure and Cardiomyopathies: Heart	Failure Chronic Alpha Blocker Use and Outcomes in Older Male Medicare	RESEARCH/RESEARCH GRANTS - Pfizer; SPEAKER'S
White	Michel	Failure Is Just a Revolving Door The Evolving World of LVADs, Transplant and Other Novel Discoveries	Beneficiaries Hospitalized for Heart Failure Changes in Prevalence, Progression and Outcomes of Coronary Allograft Vasculopathy Over 25 Years Following Cardiac Transplantation: A Single Center Experience	BUREAU - Novartis Pharma Canada RESEARCH/RESEARCH GRANTS - Pfizer; SPEAKER'S BUREAU - Novartis Pharma Canada
White	Michel	Why Can't We Be Friends? Controversies in Heart Failure Management	Adverse Outcomes With Use of Hydralazine and Nitrate Combination Therapy in Hospitalized Older Non-Black Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)	RESEARCH/RESEARCH GRANTS - Pfizer; SPEAKER'S BUREAU - Novartis Pharma Canada
White	Roger	Innovative Use of Echocardiography	Systolic Function and Cardiac Output on Echocardiography Do Not Predict Mortality After Cardiac Arrest	Nothing to Disclose
White	Roger	Insights From Echocardiography Use	Diastolic Dysfunction by Doppler Echocardiography Predicts Mortality after Cardiac Arrest	Nothing to Disclose
White	Roseann	Updates in Stable Ischemic Heart Disease	Predictors of Long-Term Resource Utilization After Incident	Nothing to Disclose
White	William	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Percutaneous Coronary Intervention Early Versus Late Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome: Insights From the Examine Trial	CONSULTANT FEES/HONORARIA - Novartis Corporation, Takeda Pharmaceuticals North America, Inc; DATA SAFETY MONITORING BOARD - Teva Pharmaceuticals; OTHER - AstraZeneca Pharmaceuticals; RESEARCH/IRESEARCH GRANTS - National Institutes of Health
White	William	The Intersection of Diabetes and ASCVD	Average Clinician Measured Blood Pressure Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes Following Acute Coronary Syndromes in the EXAMINE Trial	CONSULTANT FEES/HONORARIA - Novariis Corporation, Takeda Pharmaceuticals North America, Inc; DATA SAFETY MONITORING BOARD - Teva Pharmaceuticals; OTHER - AstraZeneca Pharmaceuticals; RESEARCH/IRESEARCH GRANTS - National Institutes of Health
Whiteson	Jonathan	Cardiac Rehab in 2017: Tailoring The Approach to the Times	Panelist	Nothing to Disclose
Whiteson	Jonathan	Cardiac Rehab in 2017: Tailoring The	Tailoring Cardiac Rehab to the Diagnosis: Angina, PCI, CABG, or	Nothing to Disclose
Whitman	Glenn	Approach to the Times Advanced Therapies = Advanced Trouble:	Comorbidity Proteinuria in Patients Receiving Left Ventricular Assist Devices Is	Nothing to Disclose
Wicky	Stephan	VAD and Transplant Challenges 18. Interventional Cardiology: Carotid and	Highly Associated With Renal Failure and Mortality Suggested Reviewer	Nothing to Disclose
Widder	Julian	Endovascular Intervention Team 1 Interventional Cardiology: PCI in Complex Patients	Incidence of Acute Kidney Injury With Bivalirudin or Unfractionated Heparin Following Transcatheter Aortic Valve Replacement: Results	Nothing to Disclose
Widmer	Robert	Cardiac Rehab in 2017: Tailoring The	From the Bravo-3 Randomized Trial Does Benefit of Cardiac Rehab Vary by Age, Sex, Race, Indication?	CONSULTANT FEES/HONORARIA - UpToDate
Widmer	Robert	Approach to the Times Innovations in Practice Management and	Social Media in Academic Cardiology: The #ACC16 Experience	CONSULTANT FEES/HONORARIA - UpToDate
Widmer	Robert	Social Media Current Issues in Cardiovascular	Socioeconomic Environment and Digital Health Tool Usage and	CONSULTANT FEES/HONORARIA - UpToDate
Widmer	Robert	Epidemiology, Disparities, and Safety Obesity Management in 2017: Weighing the	Outcomes: Is There a Digital Divide? Digital Health Intervention Usage Improves Weight loss in a Dose-	CONSULTANT FEES/HONORARIA - UpToDate
Wiegers	Susan	Issues Stress Echocardiography: Best Practices and	Dependent Fashion Co-Chair	OTHER - Merck & DTHER - Merck
_		Emerging Applications		Corp
Wiegers	Susan	Imaging of Chest Pain in the Emergency Department	Echo for Acute Chest Pain: Proven and Underutilized	OTHER - Merck & Dry; Co., Inc.; SALARY - Covance/Lab Corp
Wiegers	Susan	36. Valvular Heart Disease: Clinical Team 1	Suggested Reviewer	OTHER - Merck & Dry; Co., Inc.; SALARY - Covance/Lab Corp
Wijntjens	Gilbert	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre- Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International Multicentre iFR GRADIENT Registry	Nothing to Disclose
Wilansky	Susan	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Pathologic Plumbing: Utilizing Multi-Modality Imaging in the Diagnosis of a Patient With Pulmonary Vein to Azygos System Fistula and Decompensated Valvular Cardiomyopathy	Nothing to Disclose
Wilber	David	Cardiovascular Update for the Clinician IV: Electrical Failure 2017 Rhythm Disorders (A Symposium by Valentin Fuster)	Panelist	CONSULTANT FEES/HONORARIA - Biosense Webster, MEDTRONIC, MEDTRONIC, St Jude Medical; RESEARCH/RESEARCH GRANTS - Sentre Heart, Thermedical
Wilber	David	Cardiovascular Update for the Clinician IV: Electrical Failure 2017 Rhythm Disorders (A Symposium by Valentin Fuster)	Innovations in Device Therapy and Follow-up Results Subcutaneous ICDs, CRTs New Indications, Leadless Pacemakers	CONSULTANT FEES/HONORARIA - Biosense Webster, MEDTRONIC, MEDTRONIC, St Jude Medical; RESEARCH/RESEARCH GRANTS - Sentre Heart, Thermedical
Wilber	David	FIT Forum: Mix and Mingle	Electrophysiology	CONSULTANT FEES/HONORARIA - Biosense Webster,MEDTRONIC,MEDTRONIC,St Jude Medical; RESEARCH/RESEARCH GRANTS - Sentre Heart,Thermedical
Wilber	David	Late-Breaking Clinical Trials	Panelist	CONSULTANT FEES/HONORARIA - Biosense Webster, MEDTRONIC, MEDTRONIC, St Jude Medical;
Wilber	David	Eugene Braunwald Lecture on Future Directions in Cardiovascular Medicine and the Best of JACC Journals	Panelist	RESEARCH/RESEARCH GRANTS - Sentre Heart, Thermedical CONSULTANT FEES/HONORARIA - Biosense Webster, MEDTRONIC, MEDTRONIC, St Jude Medical; RESEARCH/RESEARCH GRANTS - Sentre Heart, Thermedical
Wilber	David	Eugene Braunwald Lecture on Future Directions in Cardiovascular Medicine and the	Best of JACC: Clinical Electrophysiology in 2016	CONSULTANT FEES/HONORARIA - Biosense Webster, MEDTRONIC, MEDTRONIC, St Jude Medical;
		Best of JACC Journals		RESEARCH/RESEARCH GRANTS - Sentre Heart, Thermedical

Last Name Wilber	First Name David	Session Title Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	Presentation Title Year in Review Speaker	Disclosures CONSULTANT FEES/HONORARIA - Biosense Webster, MEDTRONIC, MEDTRONIC, St Jude Medical; RESEARCH/RESEARCH GRANTS - Sentre Heart. Thermedical
Wildgoose	Peter	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	A Benefit-Risk Analysis of Recurrent Venous Thromboembolism in Patients Who Continued Versus Discontinued Rivaroxaban Therapy After an Initial Six-Month Therapy	SALARY - Janssen Pharmaceuticals, Inc
Wildi	Karin	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Direct Comparison of Cardiac Myosin-Binding Protein C to Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction	Nothing to Disclose
Wilensky	Robert	19. Interventional Cardiology: Complex Patients/Comorbidities Team 2	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Johnson & Do
Wiley	Jose	Interventional Live Case Session VI: Bioresorbable Scaffolds and Imaging from St. Vincent Hospital (Indianapolis, IN)	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular,AngioDynamics,MEDTRONIC
Wiley	Jose	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Sex Differences in Revascularization and In-Hospital Outcomes of Non-ST-Segment Elevation Myocardial Infarction in the United States	CONSULTANT FEES/HONORARIA - Abbott Vascular,AngioDynamics,MEDTRONIC
Wiley	Jose	Antithrombotic Therapy in Ischemic Heart Disease	Role of Anticoagulation Therapy After Anterior Wall ST-Elevation Myocardial Infraction in Preventing LV Thrombus: A Meta-Analysis and Meta-Regression	CONSULTANT FEES/HONORARIA - Abbott Vascular,AngioDynamics,MEDTRONIC
Wiley	Jose	Beans, Beans, Good for Your Heart	Percutaneous Renal Denervation for Resistant Hypertension: An Updated Meta-Analysis of Randomized Controlled Trials	CONSULTANT FEES/HONORARIA - Abbott Vascular,AngioDynamics,MEDTRONIC
Wiley	Jose	Optimizing the Care of ACS Patients	Weekend Versus Weekday Presentation for ST-Segment Elevation Myocardial Infarction: Findings From a United States Nationwide Analysis	CONSULTANT FEES/HONORARIA - Abbott Vascular,AngioDynamics,MEDTRONIC
Wiley	Mark	Interventional Cardiology: TAVR 1	Safety and Efficacy of Using Pressure Wire With Dobutamin Infusion in Themoynamic Assessment of Low Flow Low Gradient Aortic Stenosis	CONSULTANT FEES/HONORARIA - St. Jude Medical; OTHER - Edwards Lifescience
Wiley	Mark	Interventional Cardiology: PCI and TAVR in	Hemodynamic Assessment of Low Flow, Low Gradient Severe	CONSULTANT FEES/HONORARIA - St. Jude Medical; OTHER -
Wiley	Mark	Complex Patients Interventional Cardiology: Structural Heart Disease	Aortic Stenosis With Preserved EF Using a Pressure Wire Safety and Feasibility of Rotational Atherectomy in Elderly Patients With Severe Aortic Stenosis and Calcific Coronary Artery Disease Undergoing Evaluation for Transcatheter Aortic Valve Replacement	Edwards Lifescience CONSULTANT FEES/HONORARIA - St. Jude Medical; OTHER - Edwards Lifescience
Wiley	Mark	Interventional Cardiology: Structural Heart Disease	The Impact of Transaortic Gradient and Transaortic Flow on the Discrepancy Between Echocardiographic and Cardiac Catheterization Evaluation of Severe Aortic Stenosis With Preserved Ejection Fraction	CONSULTANT FEES/HONORARIA - St. Jude Medical; OTHER - Edwards Lifescience
Wiley	Mark	Interventional Cardiology: PCI in Complex Patients	Clinical Presentation, Natural History and Management of Coronary Artery Ectasia	CONSULTANT FEES/HONORARIA - St. Jude Medical; OTHER - Edwards Lifescience
Wilkins-Haug	Louise	Highlighted Original Research: Congenital Heart Disease and the Year in Review	Early Hemodynamic Changes After Fetal Aortic Stenosis Valvuloplasty Are Associated With Biventricular Circulation at Birth	Nothing to Disclose
Wilkinson	Michael	ACC Research Awards	The Impact of Time Restricted Feeding (TRF) In Improving the Health of Patients with Metabolic Syndrome	Nothing to Disclose
Wilkoff	Bruce	05. Arrhythmias and Clinical EP: Devices Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific,ConvaTec,MEDTRONIC,Spectranetics,St. Jude Medical
William	Preethi	The Art and the Science of Decision Making in Coronary Artery Disease	The Decision Case Presentation: Atypical Symptoms with Elevated High-sensitivity Troponin-ACS or not?	Nothing to Disclose
Williams	Andrew	Arrhythmias and Clinical EP: AF Ablation	Early Experience of Topera Rotor Mapping for the Treatment of Recurrent Atrial Fibrillation Following Prior Pulmonary Vein Isolation	Nothing to Disclose
Williams Williams	Andrew Andrew	Arrhythmias and Clinical EP: Devices 3 FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Prospective Cryoballoon Dosing Study Based on Time-to-Isolation Left Atrial Tachycardia Ablation During Pregnancy: A Successful Ablation With Near- Zero Fetal Radiation Exposure	Nothing to Disclose Nothing to Disclose
Williams	Brent	Arrhythmias and Clinical EP: Basic 5	A Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation	Nothing to Disclose
Williams	Bryan	Novel Mechanical Devices for the Treatment and Assessment of Hypertension	Introduction of the CALM II Study: A Multi-Center, Blinded, Sham-Controlled Pivotal Trial of an Endovascular Carotid Barostimulation Implant for the Treatment of Resistant Hypertension	CONSULTANT FEES/HONORARIA - MEDTRONIC, Vascular Dynamics, Inc.
Williams	Byron	Structural Heart Interventions: Focus on Mitral Valve, Left Atrial Appendage and HOCM	Long-Term Outcomes of Alcohol Septal Ablation in Young Patients With Hypertrophic Cardiomyopathy	Nothing to Disclose
Williams	Celeste	Hormones and Heart Failure	ACC Poster Moderator	CONSULTANT FEES/HONORARIA - Otsuka Pharmaceutical Co.; SPEAKER'S BUREAU - Novartis Corporation, Zoll LifeVest
Williams	Celeste	13. Heart Failure and Cardiomyopathies: Clinical Team 7	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Otsuka Pharmaceutical Co.; SPEAKER'S BUREAU - Novartis Corporation, Zoll LifeVest
Williams	Eric	Teaching with Intent: Secrets from the Masters	Introduction and Session Overview	Nothing to Disclose
Williams	Eric	Teaching with Intent: Secrets from the Masters	Principles of a Great ACC-Talk (interviewer)	Nothing to Disclose
Williams	Eric	Teaching with Intent: Secrets from the Masters	Interview: Mastering the Art of Masterful Moderating (Dr. Nishimura will interview Dr. Williams)	Nothing to Disclose
Williams	Eric	Teaching with Intent: Secrets from the Masters	Introduction and Session Overview	Nothing to Disclose
Williams	Ismee	Highlighted Original Research: Congenital	Co-Chair	Nothing to Disclose
Williams	Ismee	Heart Disease and the Year in Review Impact of Prenatal Environment on Congenital	ACC Poster Moderator	Nothing to Disclose
Williams	Ismee	Heart Disease 10. Congenital Heart Disease: Pediatric Team	Suggested Reviewer	Nothing to Disclose
Williams	Kim	Are We There Yet? The Long Journey to	Co-Chair	Nothing to Disclose
Williams	Kim	Health Equity: Part I Are We There Yet? The Long Journey to Health Equity: Part I	Case Presentation: Highlight and Foster the Discussion on CV Health Issues and Improved Health Outcomes Through a Lens of	Nothing to Disclose
Williams	Kim	Featured Clinical Research I	Health Equity Panelist	Nothing to Disclose
Williams	Kim	7th Annual ACC China Chapter Session: Endless Change and Evolution in Cardiovascular Prevention and Rehabilitation	Co-Chair	Nothing to Disclose
Williams	Kim	7th Annual ACC China Chapter Session: Endless Change and Evolution in Cardiovascular Prevention and Rehabilitation	Introduction to Session	Nothing to Disclose
Williams	Kim	Issues in the Treatment of Coronary Disease: Joint Symposium of the American Heart Association and the American College of Cardiology	Co-Chair	Nothing to Disclose
Williams	Kim	Nuclear Cardiology: Current Applications and Best Practices: Joint Symposium of the American Society of Nuclear Cardiology and the American College of Cardiology	Co-Chair	Nothing to Disclose
Williams	Kim	Lifestyle Changes to Reduce Cardiovascular Risk	Knowing What to Avoid: Practical Tips for Patient Counseling	Nothing to Disclose
Williams	Kim	Engage @ ACC.17 Studio: Cardiology Contest	Cardiology Contestant	Nothing to Disclose

WASHINGTON, DC | MARCH 17 - 19 2017

1				
Last Name Williams	First Name Kim	Session Title 27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team	Presentation Title Suggested Reviewer	Disclosures Nothing to Disclose
Williams	Kim	3 LBCT reviewers	LB Reviewer	Nothing to Disclose
Williams	Marlene	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	The Relationship Between Depression and Adverse Cardiovascular Events: Examining Serotonin-Driven Platelet Activation as a Factor	Nothing to Disclose
Williams	Mathew	Frontier in New Transcatheter Techniques	Devices Approved in the US: SAPIEN 3 and Evolut	CONSULTANT FEES/HONORARIA - Abbott Vascular, Edwards Lifesciences; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, MEDTRONIC
Williams	Mathew	Structural Heart Disease: Difficult Choices for the Heart Team	Speed Bumps for TAVR: Warning, Warning! Heavy Calcium in LVOT/Severe MAC, Low Cor Ht	CONSULTANT FEES/HONORARIA - Abbott Vascular, Edwards Lifesciences; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, MEDTRONIC
Williams	Mathew	Moderated, Case-Based TAVR Management	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vascular, Edwards Lifesciences; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, MEDTRONIC
Williams	Mathew	Interventional Cardiology: TAVR 2	Short- and Mid-Term Outcomes After Transcatheter Aortic Valve Replacement in Patients With Renal Insufficiency Not on Hemodialysis	CONSULTANT FEES/HONORARIA - Abbott Vascular, Edwards Lifesciences; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, MEDTRONIC
Williams	Mathew	Interventional Cardiology: TAVR 2	Direct Home Discharge and Likelihood of 30-Day Hospital Readmission After Transcatheter Aortic Valve Replacement (TAVR): Findings From the STS/ACC TVT Registry	CONSULTANT FEES/HONORARIA - Abbott Vascular, Edwards Lifesciences; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, MEDTRONIC
Williams	Mathew	Interventional Cardiology: TAVR 3	Initial Use of the Evolut Pro Self-Expanding Transcatheter Aortic Valve <i></i>	CONSULTANT FEES/HONORARIA - Abbott Vascular, Edwards Lifesciences; RESEARCH/RESEARCH GRANTS - Edwards Lifesciences, MEDTRONIC
Williams	Mathew	24. Interventional Cardiology: Mitral and Structural Heart Disease Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular, Edwards Lifesciences; RESEARCH/RESEARCH GRANTS - Edwards
Williams	Mathew	Interventional Challenging Cases: Team 4	ACC Challenging Case Reviewer	Lifesciences,MEDTRONIC CONSULTANT FEES/HONORARIA - Abbott Vascular,Edwards Lifesciences; RESEARCH/RESEARCH GRANTS - Edwards
Williams	Matthew	Structural Heart Disease: Difficult Choices for	Lead Off Case Conclusion - Decisions, Procedure, Outcome	Lifesciences,MEDTRONIC Nothing to Disclose
Williams	Matthew	the Heart Team Interventional Cardiology: TAVR 1	TAVR Is Safe and Improves Cardiac Function in Patients With Extremely Low Ejection Fractions	Nothing to Disclose
Williams	Michelle	Blips, Trops, and Chips: New Ways to Diagnose CAD	High-Sensitivity Cardiac Troponin I and the Diagnosis of Obstructive Coronary Artery Disease in Patients With Suspected Stable Angina	Nothing to Disclose
Williams	Richard	Exercise in Congenital Heart Disease	Co-Chair	Nothing to Disclose
Williams	Richard	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Do Pediatric Cardiologists Follow the Sports Restriction Recommendations for Children With a Bicuspid Aortic Valve?	Nothing to Disclose
Williams Williams	Roberta Rupert	FIT Forum: Mix and Mingle Post-CAD/MI: Making Tough Predictions About the Future	Congenital HD Pediatric and Adult Unravelling the Mechanisms of Mental Stress Induced Myocardial Ischaemia: Novel Insights From Intracoronary Measurements During Cardiac Catheterisation	Nothing to Disclose Nothing to Disclose
Williams	Stephen	Advances in Lipid Management	Cardiac Camelersation Early Detection of the Unexpected, Harmful, Pharmacologic Effects of Torcetrapib: A Retrospective Proteomics Analysis of Plasma Samples From the ILLUMINATE Trial	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - SomaLogic Inc.
Williamson	Eric	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Integrated Use of Perfusion SPECT/CTA Fusion Imaging and Pulmonary Balloon Angioplasty for Chronic Pulmonary Thromboembolism	Nothing to Disclose
Wilmot	Ivan	Making Progress in Understanding Heart Failure	Contemporary Use of Heart Failure Medications in Pediatric Patients With Dilated Cardiomyopathy	Nothing to Disclose
Wilmot	Kobina	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Inflammatory Response to Mental Stress and Mental Stress Induced Myocardial Ischemia	Nothing to Disclose
Wilner	Bryan	Updates on Risk Factors for Cardiovascular Disease	Is There a Link Between Family History of Cardiometabolic Disease and Body Fat Profile?	Nothing to Disclose
Wilson	B. Hadley	From Cardiovascular Risk Factors to Acute and Stable Coronary Syndrome: International Perspectives From the Inter-American Society of Cardiology, National Heart Association of Malaysia, and American College of Cardiology	Co-Chair	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation
Wilson	B. Hadley	From Cardiovascular Risk Factors to Acute and Stable Coronary Syndrome: International Perspectives From the Inter-American Society of Cardiology, National Heart Association of Malaysia, and American College of Cardiology	Introduction to Session	CONSULTANT FEES/HONORARIA - Boston Scientific Corporation
Wilson	Eelin	Non Invasive Imaging: Expanding Clinical Applications	Direct and Indirect Costs Comparison of Cardiac Diagnostic Pathway in Coronary Artery Disease: CCTA as the Optimal Gateway to ICA	Nothing to Disclose
Wilson	Michael	Arrhythmias and Clinical EP: AF Ablation	Improvement in Cost and Efficiency in Electrophysiology Laboratory by Cardiac Computed Tomography to Exclude Left Atrial Appendage Thrombus Prior to Atrial Fibrillation Ablation	Nothing to Disclose
Wilson	Peter	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Progenitor Cells and Clinical Outcomes in Patients With Heart Failure	Nothing to Disclose
Wilson Wilson	Peter Walter	32. Prevention: Clinical Team 5 Valvular Heart Disease: Endocarditis	Suggested Reviewer Infective Endocarditis Following Transcutaneous Aortic Valve	Nothing to Disclose Nothing to Disclose
	Walter		Infective Endocarditis Following Transcutaneous Adritic Valve Implantation: Clinical, Echocardiographic and Hemodynamic Features Utility of Cardiac Computed Tomography Scanning in the Diagnosis	-
Wilson		Non Invasive Imaging: Applications in Novel Disease States and Clinical Scenarios	and Pre-Operative Evaluation of Patients With Infective Endocarditis	Nothing to Disclose
Wilton	Stephen	Non Invasive Imaging: MR Characterization and Function	Defining Risk Associated With Left Ventricular Hypertrophy Patterns as Assessed by Cardiac Magnetic Resonance Imaging	CONSULTANT FEES/HONORARIA - ARCA biopharma, Inc.,Boehringer Ingelheim Pharmaceuticals, Inc; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Wilton	Stephen	Updates in Stable Ischemic Heart Disease	Beta Blocker Post ACS in Patients With Preserved Left Ventricular Systolic Function	CONSULTANT FEES/HONORARIA - ARCA biopharma, Inc.,Boehringer Ingelheim Pharmaceuticals, Inc; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Wilton	Stephen	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Kidney Function, Angiotensin-Converting-Enzyme Inhibitor or Angiotensin II Receptor Blocker Use, and Survival Following Hospitalization for Heart Failure: A Cohort Study	CONSULTANT FEES/HONORARIA - ARCA biopharma, Inc.,Boehringer Ingelheim Pharmaceuticals, Inc; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Wilton	Stephen	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	The Presence of Fragmented QRS Complexes Early After Acute Myocardial Infarction Is Associated With Subsequent Lack of Favorable Left Ventricular Remodeling	CONSULTANT FEES/HONORARIA - ARCA biopharma, Inc.,Boehringer Ingelheim Pharmaceuticals, Inc; RESEARCH/RESEARCH GRANTS - St. Jude Medical
Wilton	Stephen	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Ventricular Arrhythmia at Primary PCI for ST-Elevation Myocardial Infarction Predicts 30-Day but Not Long-Term Mortality	CONSULTANT FEES/HONORARIA - ARCA biopharma, Inc.,Boehringer Ingelheim Pharmaceuticals, Inc;
Winchester	David	Updates in Stable Ischemic Heart Disease	Overuse and Underuse of Cardiovascular Services Associated With	RESEARCH/RESEARCH GRANTS - St. Jude Medical OTHER - Roche
Windecker	Stephan	Featured Clinical Research II: Interventional	Elevation in Cardiac Troponin Radiation Exposure and Vascular Access in Acute Coronary	Nothing to Disclose
	l	l	Syndromes: The RAD Matrix Study	



Last Name Windecker	First Name Stephan	Session Title The Evolution of Angioplasty 40 Years of Innovation: Joint Symposium of TCT and the	Presentation Title Panelist	Disclosures Nothing to Disclose
		American College of Cardiology		
Windecker Windecker	Stephan Stephan	Fundamentals of LAA Closure Interventional Cardiology: PCI and TAVR in Complex Patients	Patient Selection for LAA Closure: European Perspective Effect of Bivalirudin Versus Unfractionated Heparin in Transcatheter Aortic Valve Replacement With Self-Expanding Valves: From the Bravo-3 Randomized Trial	Nothing to Disclose Nothing to Disclose
Windecker	Stephan	Timely Topics in Acute Coronary Syndromes	Gender-Related Outcomes in Elderly (> 75 Years) Patients Presenting With Acute Coronary Syndromes: Results From the Swiss Acute Coronary Syndrome Cohort	Nothing to Disclose
Windecker	Stephan	Interventional Complexity and Complications	Variability in Transfemoral Access for Coronary Angiography and Interventions: Results From an International Survey	Nothing to Disclose
Windecker	Stephan	Unusual Presentations of ACS	Non-Invasive Functional and Anatomical Diagnostic Testing for Patients With Low-Risk Acute Coronary Syndromes: A Network Meta-Analysis of Diagnostic Randomized Controlled Trials	Nothing to Disclose
Windecker	Stephan	Refining PCI Technique and Outcomes	Three-Year Results From the EVOLVE II Randomized Trial: Late Clinical Outcomes With Bioresorbable Compared to Permanent Polymer Everolimus-Eluting	Nothing to Disclose
Windecker	Stephan	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology Team 3	Suggested Reviewer	Nothing to Disclose
Winter	Michiel	Congenital Heart Disease: To the Third Decade and Beyond	The Systemic Right Ventricle in Transposition of the Great Arteries: What Can We Learn From Serial Imaging?	Nothing to Disclose
Winther	Simon	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Risk Stratification of Patients Suspected of Coronary Artery Disease Using an Acoustic Detection Algorithm	RESEARCH/RESEARCH GRANTS - Acarix A/S
Winther	Simon	Coronary Artery Disease PCI for NSTEMI and Complex Patients With Multiple Co-Morbidities	Prognostic Value of Coronary Computed Tomography Angiography, Myocardial Perfusion Imaging and Invasive Coronary Angiography in Kidney Transplantation Candidates: A Prospective Cohort Study	RESEARCH/RESEARCH GRANTS - Acarix A/S
Wisdom	Kimberlydawn	Are We There Yet? The Long Journey to Health Equity: Part II	Panelist	Nothing to Disclose
Wisdom	Kimberlydawn	Are We There Yet? The Long Journey to	Leading the Charge in Addressing Disparities: Practical Approaches	Nothing to Disclose
Wisniowska-Smialek	Sylwia	Health Equity: Part III Cardiac Fibrosis and Heart Failure: The Next Frontier	Associations Between Serum Markers of Extracellular Matrix Metabolism, Fibrosis-Linked Micrornas (Mir-21, Mir-26, Mir-29, Mir- 30 And Mir-133a) and Right Ventricular Parameters in Dilated Cardiomyopathy	Nothing to Disclose
Wisniowska-Smialek	Sylwia	Cardiac Fibrosis and Heart Failure: The Next Frontier	Relations Between Fibrosis-Linked Micrornas (Mir-21, Mir-26, Mir- 29, Mir-30 and Mir-133a) and Right Ventricular Morphology and Function in Dilated Cardiomyopathy	Nothing to Disclose
Witberg	Guy	Refining TAVR Outcomes	The Association of Coronary Artery Disease Severity and Pre Procedural Completeness of Revasclarization on Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Witbrodt	Bradley	Young Investigator Awards Competition:	Feasibility of a Smartphone-Delivered Cardiac Rehabilitation	Nothing to Disclose
Witbrodt	Bradley	Clinical Investigations Making Progress in Understanding Heart	Program Amongst Veterans Ambulatory Actigraphy Monitoring of Patients With Heart Failure	Nothing to Disclose
Withman	Glen	Failure The Evolving World of LVADs, Transplant and Other Novel Discoveries	With Reduced Ejection Fraction Predicts 6-Minute Walk Distance Older Age Combined With Reduced Renal Function Has a Strong Cumulative Adverse Effect on Survival in Left Ventricular Assist Device Patients	Nothing to Disclose
Withman	Glen	Advanced Therapies = Advanced Trouble: VAD and Transplant Challenges	Acute Kidney Injury Is Highly Frequent Early After Left Ventricular Assist Device Implantation With High Morbidity and Mortality Rates: A Multicentre Study	Nothing to Disclose
Witt	Chance	Things That Begin With an "A" in Adult Congenital Heart Disease: What Is Aorta, Artery and Anomalous?	The RAC Sign: Retroaortic Anomalous Coronary Artery Visualization by Transthoracic Echocardiography	Nothing to Disclose
Witt	Chance	Arrhythmias and Clinical EP: Basic 4	External Cooling of the Myocardium Slows Electrical Conduction and Terminates Atrial Fibrillation	Nothing to Disclose
Wittekind	Samuel	Therapeutic Advances in Congenital Heart Disease	Improved Exercise Performance in Pediatric Fontan Patients After Cardiac Rehabilitation	Nothing to Disclose
Witteles	Ronald	FIT Clinical Decision Making: Heart Failure and		DATA SAFETY MONITORING BOARD - Roche;
Witzenbichler	Bernhard	Pulmonary Hypertension Considerations in Antiplatelet Therapy and in	Platelet Reactivity and Outcomes After PCI of Lesions With and	RESEARCH/RESEARCH GRANTS - Alnylam, Pfizer CONSULTANT FEES/HONORARIA - Volcano Corp.
Witzenbichler	Bernhard	ACS PCI for NSTEMI and Complex Patients With	Without In-Stent Restenosis: The ADAPT-DES Study Platelet Reactivity and Outcomes After PCI of Saphenous Vein	CONSULTANT FEES/HONORARIA - Volcano Corp.
Witzenbichler	Bernhard	Multiple Co-Morbidities Coronary Angiography, Intra-Vascular Imaging,	Grafts Versus Native Coronary Arteries: The ADAPT-DES Study	CONSULTANT FEES/HONORARIA - Volcano Corp.
		Revascularization and Outcomes	After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study	·
Witzenbichler Witzke	Bernhard Christian	Interventional Challenging Cases: Team 4 FIT Clinical Decision Making: Interventional	ACC Challenging Case Reviewer Migration of the Prosthetic Mitral Valve After Transcatheter Mitral	CONSULTANT FEES/HONORARIA - Volcano Corp. Nothing to Disclose
		Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Valve Replacement for Severe Calcific Mitral Stenosis	
Witztum	Joseph	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Relationship of Biomarkers of Oxidized Lipoproteins to Ethnicity, Subclinical Atherosclerosis and Cardiovascular Events Over a 10.5 Year Follow-Up in the Dallas Heart Study	CONSULTANT FEES/HONORARIA - Cymabay,Intercept Pharm,Isis,Prometheus
Witztum	Joseph	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Pro-Inflammatory Interleukin-1 Genotypes Affect the Association of C-Reactive Protein for Angiographically Determinedcoronary Artery Disease and Cardiovascular Events	CONSULTANT FEES/HONORARIA - Cymabay,Intercept Pharm,Isis,Prometheus
Wiviott	Stephen	The Fundamentals of ACS Trials—Pitfalls in Cardiovascular Endpoints	Rationale for Standardized Definitions - Academic Perspective	CONSULTANT FEES/HONORARIA - Aegerion, Angelmed, Aralez, Arena, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc, Boston Clinical Research Institute, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Icon, Jansser Pharmaceuticals, Inc, Lexioon, Medscape, Sanofi-Aventis, XOMA; DATA SAFETY MONITORING BOARD - Allergan, Inc; RESEARCH/RESEARCH GRANTS - AstraZeneca, Bristol-Myers Squibb Company, Daiichi Sankyo, Eisa, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Merck; SALARY - Merck
Wiviott	Stephen	Test Yourself with Questions: Guidelines Module 4: Stable Ischemic Heart Disease	Faculty	CONSULTANT FEES/HONORARIA - Aegerion, Angelmed, Aralez, Arena, Astra Zeneca, Boehringer Ingelheim Pharmaceuticals, Inc, Boston Clinical Research Institute, Bristol-Myers Squibb, Dalichi Sankyo, Eli Lilly, Icon, Jansser Pharmaceuticals, Inc, Lexicon, Medscape, Sanofi-Aventis, XOMA; DATA SAFETY MONITORING BOARD - Allergna, Inc; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Bristol-Myers Squibb Company, Daiichi Sankyo, Eisai, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Merck; SALARY - Merck

Contract of the Contract of th				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Wiviott	Stephen	03. Acute and Stable Ischemic Heart Disease: Therapy Team 3	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Aegerion, Angelmed, Aralez, Arena, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc, Boston Clinical Research Institute, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Izon, Janssen Pharmaceuticals, Inc, Lexicon, Medscape, Sanofi-Aventis, XOMA; DATA SAFETY MONITORING BOARD - Allergan, Inc; RESEARCH/IRESEARCH GRANTS - AstraZeneca, Bristol-Myers Squibb Company, Daiichi Sankyo, Eisai, Eli Lilly and
Machala	Halasa	Used Failure and Condingues attains to Used	Course to Forderick and the Differential December to ACV/for Class	Company, Janssen Pharmaceuticals, Inc, Merck; SALARY - Merck
Woehrle	Holger	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Surrogate Endpoints and the Differential Response to ASV for Sleep Apnea in HFrEF Versus HFpEF in the CAT-HF Trial	
Woehrle	Jochen	Interventional Cardiology: TAVR 3	Does Balloon Predilatation Influence Outcome With the Lotus Valve: 30-Day Results From the RESPOND Study	Nothing to Disclose
Woehrle	Jochen	Interventional Cardiology: TAVR 3	Apixaban in Atrial Fibrillation Patients With Renal Insufficiency After Transcatheter Aortic Valve Replacement	RESEARCH/RESEARCH GRANTS - Boston Scientific
Woehrle	Jochen	Interventional Cardiology: TAVR 3	One Year Outcome in Patients Undergoing Transfemoral Aortic Valve Replacement (TAVR) With the Repositionable and Retrievable Boston Scientific Lotus Valve Compared With the	RESEARCH/RESEARCH GRANTS - Boston Scientific
Woehrle	Jochen	Refining TAVR Outcomes	Balloon-Expandable Edwards Sapien 3 Device Significant Reduction of Cerebral Ischemic Events With the Sentinel Cerebral Emboli Protection Device in Patients With Transcatheter	RESEARCH/RESEARCH GRANTS - Boston Scientific
Wohns	David	Considerations in Antiplatelet Therapy and in ACS	Aortic Valve Replacement Readmission and Long-Term Mortality in Older Patients Treated With Ticagreior Versus Prasugrel After Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan	CONSULTANT FEES/HONORARIA - Abiomed, Medicines Company
Wohns	David	Percutaneous Coronary Intervention: Lessons From the Real World	Cardiovascular Consortium Outcomes After Percutaneous Coronary Intervention Among Patients With a History of Transient Ischemic Attack or Cerebrovascular Accident: Insights From the Blue Cross Blue Shield	CONSULTANT FEES/HONORARIA - Abiomed,Medicines Company
Woitek	Felix	Interventional Cardiology: TAVR 2	of Michigan Cardiovascular Consortium Different Impact of Gender on Early and Late Outcome After	Nothing to Disclose
Woitek	Felix	Interventional Cardiology: TAVR 2	Transcatheter Aortic Valve Replacement Higher B-Type Natriuretic Peptide Levels Predict Occurrence of Acute Kidney Injury After Transcatheter Aortic Valve Replacement	Nothing to Disclose
Woitek	Felix	Interventional Cardiology: TAVR 2	Impact of Myocardial Injury Indicated by Increased Creatinine Kinase Myocardial Band Levels on the Outcome After Transcatheter Aortic Valve Replacement: Results From a Prospective Single Center Registry	Nothing to Disclose
Woitek	Felix	Interventional Cardiology: TAVR 4	Impact of Cancer Disease on Outcome of Patients Undergoing Transcatheter Aortic Valve Replacement	Nothing to Disclose
Wojdyla	Daniel	Late-Breaking Clinical Trials	Digoxin and Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?	Nothing to Disclose
Wojdyla	Daniel	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Recurrent Cardiovascular Event Rates in a Contemporary Cohort of 829,498 Adults With Atherosclerotic Cardiovascular Disease	Nothing to Disclose
Wojdyla	Daniel	Arrhythmias and Clinical EP: Anticoagulation Issues	Use of Interacting Drugs Did Not Modify Treatment Effects of Apixaban Versus Warfarin for Atrial Fibrillation: Results From the ARISTOTLE Trial	Nothing to Disclose
Wojdyla	Daniel	Emerging Developments in HFpEF and Arryhthmias	Effects of Age and Comorbidities on Outcomes in Patients With Heart Failure From HF-ACTION	Nothing to Disclose
Wojdyla	Daniel	Antithrombotic Therapy in Ischemic Heart Disease	Clopidogrel Is Not Commonly Used but Associated With Less Re- Hospitalization in Patients With Perioperative Myocardial Infarction Following CABG Surgery	Nothing to Disclose
Wojta	Johann	Making Progress in Understanding Heart Failure	Growth Differentiation Factor-15 Is Associated With Mortality in Patients With Severe Acute Heart Failure or Cardiogenic Shock	Nothing to Disclose
Wojta	Johann	Acute Heart Failure: Evaluating Strategies to	Circulating Mitochondrial DNA Is Associated With Mortality in	Nothing to Disclose
Wojta	Johann	Prevent Readmissions Acute Heart Failure: Evaluating Strategies to	Patients With Acute Heart Failure Intestinal Fatty Acid Binding Protein Predicts Mortality in Patients	Nothing to Disclose
Wokhlu	Anita	Prevent Readmissions New Insights Into Prediction and Treatment of Hypertension	With Acute Heart Failure or Cardiogenic Shock Relationship Between Diastolic Blood Pressure and All-Cause Mortality With Lower Systolic Blood Pressure Among Hypertensive Patients With Coronary Artery Disease: Long-Term Follow-Up of the US Cohort of the International Verapamil SR-Trandolapril Study (INVEST)	Nothing to Disclose
Wolber	Thomas	Arrhythmias and Clinical EP: AF Ablation	High Density Mapping for Gap Identification After Pulmonary Vein Isolation	Nothing to Disclose
Wolfe	Jonathan	Predicting the Future: Observations and Discoveries From Registries and Databases	Pulmonary Vascular Resistance Predicts Mortality in End-Stage Renal Disease Patients With Pulmonary Hypertension	Nothing to Disclose
Wolfel	Eugene	Innovative Approaches for Reducing Risk and	Early Recurrence of Ventricular Tachycardia Predicts Increased	SPEAKER'S BUREAU - Medical Education Resources, Inc
Wolfel	Eugene	Improving Outcomes With Ablation Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Mortality Among Patients With Severe Heart Failure Safety and Outcomes of Catheter Ablation for Treatment of Refractory Ventricular Arrhythmias in Patients With Advanced Heart Failure	SPEAKER'S BUREAU - Medical Education Resources, Inc
Wolff	Matthew	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Three-Year Outcomes in 'Real-World' Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus U.S. Post-Approval Study (PE- Plus PAS)	Nothing to Disclose
Wolinsky	David	30. Non Invasive Imaging: Nuclear Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Astellas; SPEAKER'S
Wong	Ching-Han Priscilla	Non Invasive Imaging: Role of Exercise Testing	Impaired Left Ventricular Longitudinal Functional Reserve in Patients With Psoriatic Arthritis: A Low-Level Bicycle Ergometer Exercise Test	BUREAU - Astellas Nothing to Disclose
Wong	Darrin	Advances in HCM, PPCM and Other Cardiomyopathies	The Prevalence and Clinical Significance of Compacted Myocardium in Dilated Cardiomyopathy: A Contrast Echocardiography Study	Nothing to Disclose
Wong	David	Interventional Cardiology: PCI in Complex Patients	Clinical Outcomes of Patients With Human Immune Deficiency Virus After Coronary Revascularization: A Systematic Review and Meta- Analysis	Nothing to Disclose
Wong	Dennis	Non Invasive Imaging: Prognostic Implications of CT Angiography	Computed Tomography Coronary Angiography Derived Plaque Morphology Predicts Major Adverse Cardiovascular Events: Insights From a 19,943 Patient Meta-Analysis	Nothing to Disclose
Wong	Garrett	Innovations in Education	Decreasing Fluoroscopy Time for Percutaneous Coronary Intervention With Fellows in an Academic Training Program	SPEAKER'S BUREAU - AngioScore, Astra Zeneca, Astra Zeneca, Boehringer Ingelheim, DSI/Lilly
Wong	Graham	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Hospital Variation in Targeted Temperature Management for Acute Myocardial Infarction Patients Complicated by Out-of-Hospital Cardiac Arrest in the U.S.	CONSULTANT FEES/HONORARIA - Astra Zeneca; OTHER - Bard Canada
Wong	Graham	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	A Meta-Analysis of the Effect of Targeted Temperature Management on Mortality and Neurological Outcome	CONSULTANT FEES/HONORARIA - Astra Zeneca; OTHER - Bard Canada
Wong	Jia Ing	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Sarcopenia and Vascular Function Among Community Elderly	Nothing to Disclose
Wong	Jia Ing	Diabetes and Other Issues in Cardiovascular Prevention	Adiposity, Leanness or Both? Characterizing Measures of Adiposity and Leanness With Cardiovascular Remodeling	Nothing to Disclose



Wong	Jonathan	Session Title FIT Clinical Decision Making: Arrhythmias and	Presentation Title Ventricular Fibrillation Arrest From an Atrioesophageal Fistula: A	Disclosures Nothing to Disclose
Wong	Nathan	Electrophysiology Advances in Cholesterol Measurement and	Unique Clinical Presentation Combined LDL-C and Lipoprotein (a) Levels in Prediction of	CONSULTANT FEES/HONORARIA - Amgen, Merck & Discounty (Consultant Fees/Honoraria - Amgen, Merck & Discounty)
3		Management	Residual Atherosclerotic Cardiovascular Disease Risk: The AIM- HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes)	Co., Inc.,Pfizer; RESEARCH/RESEARCH GRANTS - Amgen,GILEAD Sciences,Regeneron; SPEAKER'S BUREAU - Regneron,SANOFI
Wong	Nathan	Considerations in Antiplatelet Therapy and in ACS	Novel Biomarker Algorithmic Panel Measuring Permutations of Immune Response to Cardiac Endothelial Injury and Global Risk Factors Identifies Patients at Risk of Acute Coronary Syndrome	CONSULTANT FEES/HONORARIA - Amgen,Merck & Demp; Co., Inc.,Pfizer; RESEARCH/RESEARCH GRANTS - Amgen,GILEAD Sciences,Regeneron; SPEAKER'S BUREAU - Regneron,SANOFI
Wong	Nathan	Updates in Stable Ischemic Heart Disease	Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-World Impact of the Leader Trial on Improving Cardiovascular Outcomes in Patients With Diabetes at High Cardiovascular Risk	CONSULTANT FEES/HONORARIA - Amgen,Merck & Dempirer Co., Inc.,Pfizer; RESEARCH/RESEARCH GRANTS - Amgen,GILEAD Sciences,Regeneron; SPEAKER'S BUREAU - Regneron,SANOFI
Wong	Nathan	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	Predicting Cardiovascular Risk in Statin-Treated Patients: The AIM- HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Residual Risk Score	CONSULTANT FEES/HONORARIA - Amgen, Merck & Amp; co., Inc., Pfizer; RESEARCH/RESEARCH GRANTS - Amgen, GILEAD Sciences, Regeneron; SPEAKER'S BUREAU - Regneron, SANOFI
Wong	Nathan	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Total Testosterone With Progression of Carotid Atherosclerosis and Coronary Artery Calcium Score: The Multi- Ethnic Study of Atherosclerosis	CONSULTANT FEES/HONORARIA - Amgen,Merck & Department of the Co., Inc., Pfizer; RESEARCH/RESEARCH GRANTS - Amgen,GILEAD Sciences, Regeneron; SPEAKER'S BUREAU - Regneron, SANOFI
Wong	Nathan	Innovations in Cardiovascular Risk Assessment and Reduction	Association of Coronary Calcium, Carotid Wall Thickness and Carotid Plaque Progression With Low Density Lipoprotein and High Density Lipoprotein Particle Concentration Measured by Ion Mobility Testing: The Multi-Ethnic Study of Atherosclerosis (MESA)	CÓNSULTANT FEES/HONORARIA - Amgen,Merck &,amp; Co., Inc.,Pfizer, RESEARCH/RESEARCH GRANTS - Amgen,GILEAD Sciences,Regeneron; SPEAKER'S BUREAU - Regneron,SANOFI
Wong	Nathan	Non Invasive Imaging: Prognostic Implications of CT Angiography	Ethnic Differences of Coronary Atherosclerosis in Computed Tomography Angiography and Subsequent Risk of Major Adverse Cardiovascular Events: The CONFIRM Registry	CONSULTANT FEES/HONORARIA - Amgen,Merck & Demp; Co., Inc.,Pfizer; RESEARCH/RESEARCH GRANTS - Amgen,GILEAD Sciences, Regeneron; SPEAKER'S BUREAU - Regeneron, SANOFI
Wong	Nathan	32. Prevention: Clinical Team 6	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Amgen,Merck & Dempirer Co., Inc., Pfizer; RESEARCH/RESEARCH GRANTS - Amgen,GILEAD Sciences, Regeneron; SPEAKER'S BUREAU - Regneron, SANOFI
Wong	Norman	Highlights in Vascular Medicine Research	Apabetalone (RVX-208) Lowers Cardiovascular Disease (CVD) in Diabetes Mellitus by a Mechanism Involving Microbiome Mediated Activity on the Complement Pathway	OFFICER, DIRECTOR, TRUSTEE, OR OTHER FIDUCIARY ROLE - Resverlogix Corporation; SALARY - Resverlogix Corporation
Wong	Shing-Chiu	Interventional Cardiology: TAVR 1	Baseline Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Increased Mortality After Transcatheter Aortic Valve Replacement	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Medtronics
Wong	Shing-Chiu	Interventional Cardiology: TAVR 2	The Influence of Gender on In-Hospital Clinical Outcomes in Hispanics Following Surgical and Transcatheter Aortic Valve Replacement	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Medtronics
Wong	Shing-Chiu	Interventional Cardiology: TAVR 2	Does Intra-Aortic Balloon Pump Placement During Hospitalization Course for Transcatheter Aortic Valve Replacement Portent a Worse Clinical Outcome?	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Medtronics
Wong	Shing-Chiu	Interventional Cardiology: TAVR 3	Periprocedural Blood Transfusions in Patients Undergoing Transcatheter Aortic Valve Replacement	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Medtronics
Wong	Shing-Chiu	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Implantation Is Safe in Patients With Left Atrial Thrombus or Spontaneous Echo Contrast	RESEARCH/RESEARCH GRANTS - Abbott Vascular,Medtronics
Wong	Shing-Chiu	Outcomes in Valvular Heart Disease	In-Hospital Clinical Outcomes Following Concomitant Coronary Artery Bypass Graft and Heart Valve Surgery in Women	RESEARCH/RESEARCH GRANTS - Abbott Vascular, Medtronics
Wong	Shing-Chiu	Sex Disparity in VHD Outcomes	The Impact of Gender on In-Hospital Clinical Outcomes Following Isolated Mitral or Aortic Heart Valve Surgery	RESEARCH/RESEARCH GRANTS - Abbott
Wong	Wai Shun	Arrhythmias and Clinical EP: Devices 4	Pacemaker-Induced Tricuspid Regurgitation Is Uncommon Immediate Post-Implant	Vascular,Medtronics Nothing to Disclose
Wong	Wei Xiang	Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease	Comparison of Two-Year Outcomes in Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Treatment of Unprotected Left Main Coronary Artery Disease in Elderly Patients: A Meta-Analysis	Nothing to Disclose
Wong	Wei Xiang	Innovations in Education	Coronary Angiography Simulation Training Improves Image Interpretation Skills of Trainees Independent of Their Stage of Training	Nothing to Disclose
Wong	Yiu Tung Anthony Suwakon	Refining PCI Technique and Outcomes Updates in Stable Ischemic Heart Disease	External Validation of DAPT Score in Two Large Cohorts Vagus Nerve Stimulation Requires Both Ipsilateral and Contralateral	Nothing to Disclose Nothing to Disclose
Wongjaikam	Suwakon	opuates in Stable ischemic neart Disease	Vagus Nerve Similaration Requires both paraterial and Contralateral Efferent Vagal Activity to Fully Exert Its Cardioprotection Against Cardiac Ischemia/Reperfusion Injury	Nothing to Disclose
Woo	Jong-Shin	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Comparison of Timing of Non-Culprit Lesion Percutaneous Coronary Intervention in Myocardial Infarction Patients	Nothing to Disclose
Woo	Jong-Shin	Markers of Prognosis Associated With Elevated Blood Pressure		Nothing to Disclose
Woo	Jong-Shin	Innovations in Cardiovascular Risk Assessment and Reduction		Nothing to Disclose
Woo	Kel Vin	Understanding Pulmonary Vascular Disease: From Bench to Bedside	Impact of Endothelial Fibroblast Growth Factors on Pulmonary Hypertension	Nothing to Disclose
Woo	Y. Joseph	Can CABG Patch CAD?	Effectiveness of a Second Arterial Conduit for Multi Vessel Coronary Bypass: A State-Wide Analysis of 60,897 Patients	
Woo	Yeongmin	Head to Toe: Outcomes of Endovascular Interventions	Comparison of Aortic Remodeling After Thoracic Endovascular Repair Between Acute/Subacute Versus Chronic Type B Aortic Dissection	Nothing to Disclose
Wood	David	Are We There Yet? The Long Journey to Health Equity: Part I	Panelist	Nothing to Disclose
Wood	David	Are We There Yet? The Long Journey to Health Equity: Part I	ACC-Talk:Global Burden of Cardiovascular Disease - the Challenges to Achieving HealthEquity	Nothing to Disclose
Wood	David	Interventional Live Case Session I: Structural Transmission from Cleveland Clinic (Cleveland, Ohio)	Panelist	CONSULTANT FEES/HONORARIA - Edwards Lifesciences, MEDTRONIC, St. Jude Medical; RESEARCH/RESEARCH GRANTS - Astra Zeneca, Boston Scientific, Edwards Lifesciences, St. Jude Medical
Wood	Malissa	Understanding Spontaneous Coronary Artery Dissection (SCAD): What We Know, What We Don't Know	After the Event: Looking for the Etiology	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc
Wood	Malissa	32. Prevention: Clinical Team 6	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc
Woods	Ronald	Congenital Heart Disease Surgery: Updates and Innovations	Anatomic Repair of Congenitally Corrected Transposition Results in Excellent Survival and Functional Status at Intermediate Term Follow-Up	Nothing to Disclose
Worku	Berhane	Interventional Cardiology: TAVR 3	Transcatheter Aortic Valve Implantation Is Safe in Patients With Left Atrial Thrombus or Spontaneous Echo Contrast	Nothing to Disclose
Worthley	Stephen	Joint American College of Cardiology/Journal	Effect of Serial Infusions of CER-001, a Pre-Beta High-Density	CONSULTANT FEES/HONORARIA - St Jude Medical
		of the American Medical Association Late- Breaking Clinical Trials	Lipoprotein Mimetic on Coronary Atherosclerosis: Results of the CARAT Study	



		a i Bui		
Last Name Wright	First Name Jackson	Session Title Joint American College of Cardiology/Journal of the American Medical Association Late-	Presentation Title Panelist	Disclosures Nothing to Disclose
Wright	Jackson	Breaking Clinical Trials Emerging Concepts in Evaluation and	Panelist	Nothing to Disclose
Wright	Jackson	Management of Hypertension Emerging Concepts in Evaluation and	Thresholds or Targets: Reconciling the Results of the SPRINT,	Nothing to Disclose
Wright	Jackson	Management of Hypertension 33. Prevention: Hypertension Team 1	ACCORD and HOPE-3 Trials Suggested Reviewer	Nothing to Disclose
Wright	Janet	48th Annual Louis F. Bishop Lecture	Bishop Lecture: Million Hearts: Results, Road Rash, and Lessons for Making More Progress, Faster	Nothing to Disclose
Wright	R	Featured Clinical Research I	LDL-C Reduction From 6 to 9 Months Following Single or Second Injection of Inclisiran a Novel siRNA Compound: Primary Efficacy and Safety Outcomes of the ORION 1 Trial	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,Pfizer Inc,Sanofi Regeneron,The Medicines Company
Wright	R.	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Alirocumab Efficacy and Safety in Patients With Hypercholesterolemia and With or Without Clinical Atherosclerotic Cardiovascular Disease: Pooled Analysis of 10 ODYSSEY Randomized Trials	CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals,Boehringer Ingelheim Pharmaceuticals, Inc,Pfizer Inc,Sanofi Regeneron,The Medicines Company
Wright	R. Scott	FIT Forum: Mix and Mingle		CONSULTANT FEES/HONORARIA - AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc,Pfizer Inc,Sanofi Regeneron,The Medicines Company
Wright	Samuel	Updates in Stable Ischemic Heart Disease	CSL112 Enhances the Ability of Serum to Efflux Cholesterol in Patients With Moderate Renal Impairment	SALARY - CSL Behring
Wright	Scott	Innovations in Practice Management and Social Media	Severity of Illness Assessment in the Cardiac Intensive Care Unit (CICU): Application of the APACHE IV Predicted Mortality Score	CONSULTANT FEES/HONORARIA - Astra Zeneca, Pfizer, Sanofi Regeneron, The Medicines Company
Wruck	Lisa	Why Can't We Be Friends? Controversies in Heart Failure Management	Prevalent Digoxin Use Is Not Associated With Increased Risk of Death or Hospitalization in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction	Nothing to Disclose
Wu	Angie	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Time of Presentation Among Patients Hospitalized for Acute Heart Failure (Clinical Characteristics, Initial Therapies and Outcomes): Insights From ASCEND-HF	Nothing to Disclose
Wu	Angie	Antithrombotic Therapy in Ischemic Heart Disease	Clopidogrel Is Not Commonly Used but Associated With Less Re- Hospitalization in Patients With Perioperative Myocardial Infarction Following CABG Surgery	Nothing to Disclose
Wu	Clement	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	The Use of a Newer Generation Radiation Reduction Algorithm Has Led to Lower Radiation Doses in Coronary Angiography: A Two Year Single-Center Retrospective Analysis	Nothing to Disclose
Wu	Colin	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Association of Coronary Artery Calcium With Incident Peripheral Artery Disease: The Multi-Ethnic Study of Atherosclerosis	Nothing to Disclose
Wu	Fred	Things That Matter in Adult Congenital Heart Disease	Red Cell Distribution Width Predicts Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank	Nothing to Disclose
Wu	Joseph	Interventional Cardiology: TAVR 1	The Inflammasome Pathway Is Associated With Adverse Ventricular Remodeling Following Transcatheter Aortic Valve Replacement	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Stem Cell Theranostics
Wu	Joseph	12. Heart Failure and Cardiomyopathies: Basic Team 2	Suggested Reviewer	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Stem Cell Theranostics
Wu	Kai Yi	Noninvasive Assessment of Coronary Flow Reserve: Clinical Implications	In the Presence of Significant Epicardial Coronary Disease, Diabetes Mellitus Is Further Associated With Reduced Myocardial Flow Reserve	Nothing to Disclose
Wu	Liya	Advances in Cholesterol Measurement and	The Effect of PCSK9 Inhibition on LDL-Subfractions in Patients With	Nothing to Disclose
Wu	Liya	Management Updates on Risk Factors for Cardiovascular Disease	Severe LDL-Hypercholesterolemia Walnut-Enriched Diet Reduces Lipids in Healthy Caucasian Subjects, Independent of Recommended Macronutrient Replacement	Nothing to Disclose
Wu	Michelle	Insights Into Ischemic Heart Disease: Stable to Erosive Plaques	Replacement Clinical Operating Points for Non-Invasive Cardiac Imaging Modalities Lead to Low Detection of Coronary Artery Disease	Nothing to Disclose
Wu	Robby	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	To Close or Not to Close: Work-Up and Management of an Acquired Gerbode Defect	Nothing to Disclose
Wu	Yuping	Disease, and Vascular Medicine Valvular Heart Disease: Aortic Regurgitation	Etiology, Patient Characteristics and Surgical Outcomes of Acute	Nothing to Disclose
Wu	Yuping	Updates on Risk Factors for Cardiovascular	Severe Aortic Regurgitation Declining Survival With Decreasing Exercise Time on Treadmill:	Nothing to Disclose
Wu	Yuping	Disease Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	Lessons From a 25-Year Cohort Referral for Pharmacologic Testing, a Marker of Poor Exercise Capacity, Confers a Higher Risk of Short and Long Term Mortality	Nothing to Disclose
Wunderlich	Nina	24. Interventional Cardiology: Mitral and	Than Most Traditional Cardiac Risk Factors Except Age Suggested Reviewer	Nothing to Disclose
Wyman	Janet	Structural Heart Disease Team 1 Interventional Cardiology: TAVR 3	Predictors of Late Bleeding in the TAVR Population	Nothing to Disclose
Wyman	Janet	Interdisciplinary Cardiovascular Team Care Delivery: Quality, Safety, and Satisfaction	ACC Poster Moderator	Nothing to Disclose
	Janet	Cardiovascular Team Cases: Team 1	Suggested Reviewer	Nothing to Disclose
Wyman	R. Michael	Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From	Scientific,Bridgepoint,Terumo; SPEAKER'S BUREAU - Abbott
Wyman	Ray	Advances in Chronic Total Occlusion Intervention	a Contemporary Multicenter Registry Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a	Vascular CONSULTANT FEES/HONORARIA - Abbott Vascular,Asahi,Boston Scientific
Wymer	David	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart	Contemporary Multicenter U.S. Registry Coronary Artery Bypass Graft Pseudoaneurysm From Saphenous Vein Graft Stent Rupture	Nothing to Disclose
Wynant	Willy	Disease, and Vascular Medicine Antithrombotic Therapy in Ischemic Heart Disease	Rivaroxaban Users Have Significantly Less Treatment Discontinuation Compared With Users of Other Oral Anticoagulants	RESEARCH/RESEARCH GRANTS - Janssen Scientific Affairs
Wypasek	Ewa	Cardiac Fibrosis and Heart Failure: The Next Frontier	in Non-Valvular Atrial Fibrillation Associations Between Serum Markers of Extracellular Matrix Metabolism, Fibrosis-Linked Micrornas (Mir-21, Mir-26, Mir-29, Mir- 30 And Mir-133a) and Right Ventricular Parameters in Dilated	Nothing to Disclose
Wypasek	Ewa	Cardiac Fibrosis and Heart Failure: The Next Frontier	30 And Mir-133a) and Right Ventricular Parameters in Dilated Cardiomyopathy Relations Between Fibrosis-Linked Micrornas (Mir-21, Mir-26, Mir-29, Mir-30 and Mir-133a) and Right Ventricular Morphology and	Nothing to Disclose
Wyse	George	06. Arrhythmias and Clinical EP: Other Team 1	Function in Dilated Cardiomyopathy Suggested Reviewer	DATA SAFETY MONITORING BOARD - Bayer
Wysokinski	Waldemar	Vascular Medicine: Emerging Concepts in	Risk of Re-Dissection in Segmental Arterial Mediolysis	Health,Boehringer Ingelheim,Daichii,Portola CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
Wyss	Fernando Stuardo	Clinical Vascular Diseases From Cardiovascular Risk Factors to Acute and Stable Coronary Syndrome: International Perspectives From the Inter-American Society of Cardiology, National Heart Association of Malaysia, and American College of Cardiology	What Influences Cardiovascular Risk and Its Impact on Secondary Prevention in Latin America	Pharmaceuticals, Inc., Daiichi Sankyo, Inc RESEARCH/RESEARCH GRANTS - Sanofi, Bayer, MSD, Novartis, Takeda,
Xavier	Denis	Arrhythmias and Clinical EP: Anticoagulation Issues	Use of Interacting Drugs Did Not Modify Treatment Effects of Apixaban Versus Warfarin for Atrial Fibrillation: Results From the ARISTOTLE Trial	RESEARCH/RESEARCH GRANTS - AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cadila Pharma, Pfizer, sanofi aventis

Last Name				·
	First Name	Session Title	Presentation Title	Disclosures
Xi	Li	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Time to Acute Care Among Patients With Acute Myocardial Infarction in China: A Report From China Patient-Centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction	Nothing to Disclose
Xiang	Dingcheng	New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of Cardiology	Current Situation of China Chest Pain Center	Nothing to Disclose
Xiang	Yajie	Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?	Effects of Spironolactone on the Prognosis of Heart Failure Patients With Preserved Ejection Fraction: A Meta-Analysis of Randomized Clinical Trials	Nothing to Disclose
Xiao	Yongling	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic	A Benefit-Risk Analysis of Recurrent Venous Thromboembolism in Patients Who Continued Versus Discontinued Rivaroxaban Therapy After an Initial Six-Month Therapy	RESEARCH/RESEARCH GRANTS - Janssen Scientific Affairs
Xiao	Yunbin	Disease and the Year in Review Bridge From the Basics: Translational Research in Pulmonary Hypertension	Platelet Derived Growth Factor Promotes the Warburg Effect in Pulmonary Arterial Smooth Muscle Cells via Activating the Phosphatidyl Inositol 3-Kinase Signaling Pathway and Hypoxia-	Nothing to Disclose
Xiaoqing	Liu	Impact of Prenatal Environment on Congenital	Inducible Factor 1-Alpha Maternal Blood Trace Element Levels and Risks for Fetal	Nothing to Disclose
Xie	Eric	Heart Disease Non Invasive Imaging: MR Scar and Perfusion	Congenital Heart Defects in Guangdong, China Association of Right Atrial Function With Incident Atrial Fibrillation:	Nothing to Disclose
Xie	Feng	Innovative Use of Echocardiography	The Multi-Ethnic Study of Atherosclerosis (MESA) The Predictive Value of Microvascular Defects Observed During Demand Stress Myocardial Contrast Echocardiography and Quantitative Measurements of Stenosis and Microvascular Resistance Obtained During Invasive Hemodynamics	Nothing to Disclose
Xie	Feng	New Technologies in Echocardiography	Microvascular Blood Flow Abnormalities in Patients With Peripheral Vascular Disease and Abnormal Versus Normal Ankle Brachial Indices	Nothing to Disclose
Xie	Joe	The Art and the Science of Decision Making in Coronary Artery Disease	The Decision Case Presentation: Low-intermediate Risk Chest Pain	Nothing to Disclose
Xing	Lei	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Association Between Syntax Score, and Pre- and Post-Stenting Optical Coherence Tomography Findings in Stable Angina Patients	Nothing to Disclose
Xing	Lei	The Inside View: Learning From Intracoronary Imaging	Prevalence and Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A Four-Year Follow-Up Study	Nothing to Disclose
Xu	Benjamin	Diabetes and Other Issues in Cardiovascular Prevention	Efficacy of Folic Acid Supplementation on the Reduction of Stroke Risk: Interaction With Platelet Count	Nothing to Disclose
Xu	Jack	Arrhythmias and Clinical EP: Devices 3	Importance of Right Ventricular Lead Positioning in Determining Outcomes of Cardiac Resynchronization Therapy	Nothing to Disclose
Xu	Jiaqiong	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Diffuse Interstitial and Regional Replacement Fibrosis in Chronic Primary Mitral Regurgitation: Insights From Cardiovascular Magnetic Resonance	Nothing to Disclose
Xu	Jing-Jing	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Gender Difference in Clinical Presentation on Long-Term Outcomes in Chinese Patients Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Xu	Meng	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review	Racial Differences in Patients Referred for Right Heart Catheterization and Risk of Pulmonary Hypertension	Nothing to Disclose
Xu	Meng	Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Lack of a Tricuspid Regurgitation Velocity and Pulmonary Hypertension: Absence of Evidence Is Not Evidence of Absence	Nothing to Disclose
Xu	Richard	Diabetes and Other Issues in Cardiovascular	Efficacy of Folic Acid Supplementation on the Reduction of Stroke	Nothing to Disclose
Xu	Xiao	Prevention Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Risk: Interaction With Platelet Count Toward Identifying Personalized Prognosis in Hypertension: Variation in Early Responses in the Antihypertensive and Lipid-	Nothing to Disclose
Xu	Yining	FIT Clinical Decision Making: Heart Failure and	Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Hypertrophic Cardiomyopathy as a Manifestation of Anderson-Fabry	Nothing to Disclose
Yabe	Takayuki	Pulmonary Hypertension Novel Developments in Acute Coronary	Disease Left Ventricular End-Diastolic Pressure Predicts Outcomes in	Nothing to Disclose
Yadav	Madhur	Syndromes Diabetes and Other Issues in Cardiovascular Prevention	Patients With ST-Segment Elevation Myocardial Infarction Independently of Left Ventricular Systolic Function Self-Reported Morisky Eight Item Medication Adherence Scale for Statins Concords With Pill Count Method and Correlates With	Nothing to Disclose
Yadav	Pradeep	FIT Clinical Decision Making: Non-Invasive	Serum Lipid Profile Parameters and Serum Hydroxymethylglutaryl Coenzyme A Reductase Levels Transcatheter Tricuspid Valve Replacement: "Forgotten	Nothing to Disclose
Yadav	Pradeep	Imaging and Valvular Heart Disease Interventional Cardiology: TAVR 2	Valve", Challenging Management With Limited Treatment Options - Time to Gather Evidence Death and Dialysis Risk After Transcatheter Aortic Valve	Nothing to Disclose
Yadlapati	Ajay	Technical Advances in Transthoracic	Replacement Safety of Perflutren-Based Echocardiographic Contrast Agent	Nothing to Disclose
	- 3-7	Echocardiography	Administration in the Setting of a Patent Foramen Ovale (PFO): A Multicenter Study Conducted in Tertiary Care Centers Based in the New York/Chicago Metropolitan Areas	
Yagoub	Hatim	Coronary Intervention in Interventional Cardiology: Advanced Device Use	Facilitation of Stent Delivery With the GuideLiner Catheter	Nothing to Disclose
Yahagi	Kazuyuki	Non Invasive Imaging: Expanding Clinical Applications	Dual-Energy Coronary Computed Tomography Evaluation of High- Risk Atherosclerotic Plaque in Sudden Cardiac Death Patients: Validation with Histopathologic Gold Standard	Nothing to Disclose
Yahagi	Kazuyuki	Non Invasive Imaging: Prognostic Implications of CT Angiography	Quantitative Measurement of Coronary Intra-Plaque Necrotic Core by Coronary CT Angiography in Victims of Autopsy-Proven Sudden Coronary Death: A Comparison to a Histologic Reference Standard	Nothing to Disclose
Yahagi	Kazuyuki	Non Invasive Imaging: New Technologies	Optimal Method for Necrotic Core Identification in Coronary Plaque With Dual-Energy Computed Tomography: Material Decomposition and Atomic Number	Nothing to Disclose
Yahagi	Kazuyuki	The Evolving World of LVADs, Transplant and Other Novel Discoveries	and Atomic Number Elevated Right Sided Heart Pressure Is Associated With Malnutrition in Heart Failure Patients With Reduced Ejection Fraction	Nothing to Disclose
Yahagi	Kazuyuki	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Identifying Novel Phenotypes of Acute Decompensated Heart Failure Using Cluster Analysis of Clinical Variables	Nothing to Disclose
Yakubov	Steven	TAVR for Degenerated Surgical Valves: What You Need to Know from A to Z	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific; SPEAKER'S BUREAU - MEDTRONIC
Yakubov	Steven	TAVR for Degenerated Surgical Valves: What You Need to Know from A to Z	TAVR Valve-in-Valve for Prior Surgical Stented Valves	SCIENTIFIC; SPEAKER'S BUREAU - MEDTRONIC CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific; SPEAKER'S BUREAU - MEDTRONIC
1	Ctovon	PFO Closure, PV Leak, and VSD Repair	Case Presentation: Aortic PV Leak After Self-expanding TAVR	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston
Yakubov	Steven			
	Steven	Interventional Cardiology: TAVR 2	The Impact of Preoperative Renal Dysfunction on the Outcomes of Patients Undergoing Surgical Versus Transcatheter Aortic Valve Replacement: An Analysis From the CoreValve US Pivotal High Risk Trial	Scientific; SPEAKER'S BUREAU - MEDTRONIC CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific; SPEAKER'S BUREAU - MEDTRONIC

Control of the Contro				
Last Name Yakubov	First Name Steven	Session Title 24. Interventional Cardiology: Mitral and	Presentation Title Suggested Reviewer	Disclosures CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston
Yakushiji	Tadayuki	Structural Heart Disease Team 2 Interventional Cardiology: PCI in Complex	Chronic Stent Recoil During Follow-Up in Severely Calcified	Scientific; SPEAKER'S BUREAU - MEDTRONIC Nothing to Disclose
-	-	Patients	Coronary Artery Lesions: An Optical Coherence Tomography Study	-
Yamada	Takeshi	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Hyperdense Artery Sign on Computed Tomography in Acute Coronary Syndrome	Nothing to Disclose
Yamaguchi	Junichi	Optimizing the Care of ACS Patients	Novel Utilization of DAPT Score as a Predictor of Long-Term Clinical Outcomes in Hemodialysis Patients on Prolonged Dual	Nothing to Disclose
Yamaguchi	Junichi	Interventional Cardiology: PCI in Complex Patients	Antiplatelet Therapy After Coronary Intervention Predictors for 2-Year Cardiovascular Events After Rotablation in Severe Calcified Lesion	Nothing to Disclose
Yamaguchi	Tomoyuki	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Comparison of Very Late Vascular Response Beyond 2 Years After Stent Implantation Between EES and BES: An OCT Sub-Study of	Nothing to Disclose
Yamaji	Kyohei	Interventional Complexity and Complications	the NEXT Impact of Institutional and Operator Volume on Short-Term Outcomes of Percutaneous Coronary Intervention: A Report From	Nothing to Disclose
Yamaji	Yuhei	Unusual Presentations of ACS	Japanese Nationwide Registry The Impact of Residual Syntax Score in ACS Patients With LV Dysfunction	Nothing to Disclose
Yamamoto	Erika	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Neointimal Pattern and Clinical Outcome After Drug-Eluting Stent Implantation: Comparison Between First Generation and Second	Nothing to Disclose
Yamamoto	Hideya	Non Invasive Imaging: Role of Exercise Testing	Generation Drug-Eluting Stents The Non-Invasive Physiological Detection of Myocardial Ischemia in	Nothing to Disclose
Yamamoto	Masanori	Interventional Cardiology: TAVR 4	Coronary Artery Disease Transcatheter Aortic Valve Implantation in Patients With an	Nothing to Disclose
			Extremely Small Annulus	-
Yamamoto	Myong Hwa	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Optical Coherence Tomography Assessment of Coronary Atherectomy Effect: Comparison Between Orbital and Rotational Atherectomy in Severely Calcified Lesions	Nothing to Disclose
Yamamoto	Myong Hwa	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Intravascular Ultrasound Assessment of the Effects of Rotational Atherectomy in Calcified Coronary Artery Lesions	Nothing to Disclose
Yamamoto	Myong Hwa	Advances in Chronic Total Occlusion Intervention	The Impact of Recanalization of Chronic Total Occuluded Coronary Artery on Electrophysiological Substrate of Left Ventricle	Nothing to Disclose
Yamamoto	Myong Hwa	Interventional Cardiology: PCI in Complex Patients	Chronic Stent Recoil During Follow-Up in Severely Calcified Coronary Artery Lesions: An Optical Coherence Tomography Study	Nothing to Disclose
Yamamuro	Megumi	The Evolving World of LVADs, Transplant and	B-Type Natriuretic Peptide Levels Is a Useful Prognostic Marker in the Patients With Eosinophilic Granulomatosis With Polyangiitis	Nothing to Disclose
Yamanaka	Futoshi	Other Novel Discoveries Interventional Cardiology: TAVR 4	Transcatheter Aortic Valve Implantation in Patients With an	Nothing to Disclose
Yamani	Mohamad	14. Heart Failure and Cardiomyopathies:	Extremely Small Annulus Suggested Reviewer	Nothing to Disclose
Yamano	Takashi	Therapy Team 1 Interventional Cardiology: Intravascular	Comparison of Very Late Vascular Response Beyond 2 Years After	Nothing to Disclose
Yamashita	Kennosuke	Physiology and Endothelial Function Advances in Chronic Total Occlusion	Stent Implantation Between EES and BES: An OCT Sub-Study of the NEXT The Impact of Recanalization of Chronic Total Occuluded Coronary	Nothing to Disclose
		Intervention	Artery on Electrophysiological Substrate of Left Ventricle	-
Yamashita	Kennosuke	Interventional Cardiology: PCI in Complex Patients	Chronic Stent Recoil During Follow-Up in Severely Calcified Coronary Artery Lesions: An Optical Coherence Tomography Study	Nothing to Disclose
Yamat	Megan	Innovative Use of Echocardiography	Assessment of Left Ventricular Rotational Mechanics Post-LVAD Implantation Using 3D Echocardiography	Nothing to Disclose
Yamat	Megan	New Technologies in Echocardiography	Three-Dimensional Echocardiographic Automated Quantification of Left Ventricular and Atrial Volumes Using Adaptive Analytics	Nothing to Disclose
Yamauchi	Melissa	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Algorithm: Feasibility in Non-Selected Patients Do Pediatric Cardiologists Follow the Sports Restriction Recommendations for Children With a Bicuspid Aortic Valve?	Nothing to Disclose
Yamawaki	Masahiro	Interventional Cardiology: Intravascular	Instantaneous Wave-Free Ratio Scout Pullback (iFR Scout) Pre-	Nothing to Disclose
		Physiology and Endothelial Function	Angioplasty Predicts Hemodynamic Outcome in Humans With Coronary Artery Disease: Primary Results of International Multicentre iFR GRADIENT Registry	
Yan	Linda	Arrhythmias and Clinical EP: Anticoagulation Issues	Marked Physician Variability in Oral Anticoagulant Treatment Choices Reflect Significant Differences in Atrial Fibrillation Patient Characteristics	Nothing to Disclose
Yan	Wang	New Perspectives and Updates in STEMI Care: Joint Symposium of the Chinese Society of Cardiology and American College of		Nothing to Disclose
Yanagisawa	Ryo	Cardiology Interventional Cardiology: TAVR 4	Transcatheter Aortic Valve Implantation in Patients With an	Nothing to Disclose
Yanagisawa	Ryoji	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Extremely Small Annulus Integrated Use of Perfusion SPECT/CTA Fusion Imaging and Pulmonary Balloon Angioplasty for Chronic Pulmonary	Nothing to Disclose
Yanagisawa	Tomoyoshi	Antiplatelet and Antithrombotic Agents in	Thromboembolism Stent Edge Strut on Normal Segment Is Less Covered in Early	Nothing to Disclose
Yancy	Clyde	Ischemic Heart Disease Are We There Yet? The Long Journey to	Phase After Drug Eluting Stent Implantation Panelist	Nothing to Disclose
Yancy	Clyde	Health Equity: Part I Are We There Yet? The Long Journey to	Cardiovascular Care and Health Disparities: The Magnitude of the	Nothing to Disclose
-		Health Equity: Part I	Issue	Ÿ
Yancy Yancy	Clyde Clyde	FIT Forum: Scholarship and Education FIT Forum: Mix and Mingle	How to Find a Research Mentor 	Nothing to Disclose Nothing to Disclose
Yancy	Clyde	Kanu and Docey Chatterjee Lecture and Seminal Talks in Heart Failure: I Wanna New Drug: Updated Heart Failure Guidelines	The Updated Heart Failure Guidelines - Incorporating New Therapeutics	Nothing to Disclose
Yancy	Clyde	Focus on Structural and Valvular Heart Disease: Joint Symposium of the Association of Black Cardiologists and the American	Impact of Hypertensive and non-ischemic Cardiomyopathies on Minority Health Hypertensive/Nonischemic Cardiomyopathy	Nothing to Disclose
Yancy	Clyde	College of Cardiology Young Investigator Awards Competition: Outcomes Research	A Hospital Level Analysis of 30-Day Readmission Rates for Heart Failure Patients and Long-Term Survival Among Highest and Lowest Performing Hospitals, Findings From Get With the	Nothing to Disclose
Yancy	Clyde	Innovations in Practice Management and	Guidelines-Heart Failure Heart Failure Care Transitions: Queuing Theory-Based Cost-	Nothing to Disclose
Yancy	Clyde	Social Media Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Effectiveness Analysis of Outpatient Clinic Capacity Sizing The Impact of the Current Versus Prior Cardiac Resynchronization Guidelines on the Proportion of Hospitalized Heart Failure Patients	Nothing to Disclose
Yancy	Clyde	Acute Heart Failure: Evaluating Strategies to	Eligible for Therapy Screening of Patients With Simple Clinical Parameters Early in	Nothing to Disclose
		Prevent Readmissions	Hospitalization Is Highly Sensitive for Detection of Heart Failure Hospitalization	-
Yancy	Clyde	Innovations in Advocacy and Patient Centered Care	Impact of Multidisciplinary Heart Failure Transitional Care Interventions on Disparities in 30-Day Readmission Rates	Nothing to Disclose



Control of the contro				<u> </u>
Last Name Yancy	First Name Clyde	Session Title Next Steps to Optimal Medical Therapy for	Presentation Title Chair	Disclosures Nothing to Disclose
-	-	Heart Failure Patients		-
Yancy	Clyde	Next Steps to Optimal Medical Therapy for Heart Failure Patients	Introduction to Session and ARS Technology: CME Done Differently	Nothing to Disclose
Yancy	Clyde	Next Steps to Optimal Medical Therapy for	What's on the Horizon for Heart Failure	Nothing to Disclose
Yancy	Clyde	Heart Failure Patients Next Steps to Optimal Medical Therapy for	Concluding Remarks	Nothing to Disclose
Yancy	Clyde	Heart Failure Patients Put Your Codon! Genetic Insights Into Heart	G-Protein Receptor Kinase 5 Polymorphisms and Outcomes in the	Nothing to Disclose
Tancy	Ciyac	Failure	African American Heart Failure Trial: Results From the Genetic Risk Assessment of Heart Failure in African-Americans Sub-Study	Notifing to Discrete
Yandrapalli	Srikanth	FIT Clinical Decision Making: Non-Invasive	Pneumopericardium: A Rare Presentation of Gastro-Pericardial	Nothing to Disclose
Yandrapalli	Srikanth	Imaging and Valvular Heart Disease Current Issues in Cardiovascular	Fistula In-Hospital Outcomes and Hospitalizations for Acute Rheumatic	Nothing to Disclose
Yandrapalli	Srikanth	Epidemiology, Disparities, and Safety Current Issues in Cardiovascular	Heart Disease: A United States National Study Prevalence and In-Hospital Outcomes of Uremic and Dialysis	Nothing to Disclose
		Epidemiology, Disparities, and Safety	Pericarditis: A United States National Study	
Yandrapalli Yandrapalli	Srikanth Srikanth	Arrhythmias and Clinical EP: Devices 2 Structural Heart Interventions: Focus on Mitral	Impact of Left Atrial Appendage Occlusion on Left Atrial Function Change in Aortomitral Annular Angle and Anterior Mitral Valve	Nothing to Disclose Nothing to Disclose
		Valve, Left Atrial Appendage and HOCM	Leaflet Length After Transcatheter Aortic Valve Replacement: Implications for Transcatheter Mitral Valve Replacement?	-
Yandrapalli	Srikanth	FIT Clinical Decision Making: Heart Failure and	Management of Takotsubo Cardiomyopathy Complicated by Left	Nothing to Disclose
Yandrapalli	Srikanth	Pulmonary Hypertension The Evolving World of LVADs, Transplant and	Ventricular Outflow Tract Obstruction Arrhythmias in Hospitalized Heart Transplanted Patients: A United	Nothing to Disclose
Yandrapalli	Srikanth	Other Novel Discoveries The Evolving World of LVADs, Transplant and	States National Study Chagas Heart Disease: A United States National Study	Nothing to Disclose
		Other Novel Discoveries	,	
Yandrapalli	Srikanth	FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	Spontaneous Coronary Artery Dissection in a Transplanted Heart	Nothing to Disclose
Yang	Bin	Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic	Racial Differences in Patients Referred for Right Heart Catheterization and Risk of Pulmonary Hypertension	Nothing to Disclose
		Disease and the Year in Review		
Yang	Eric	The Best Structural Interventional Challenging Cases	Microcoil Embolization of an Aortic Root Pseudoaneurysm Through a Transthoracic Approach	CONSULTANT FEES/HONORARIA - American College of Physicians, Good Samaritan Medical Center, Los Angeles, CA, United Therapeutics; RESEARCH/RESEARCH GRANTS - Sanofi Aventis
Yang	Eric	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Diffuse Interstitial and Regional Replacement Fibrosis in Chronic Primary Mitral Regurgitation: Insights From Cardiovascular Magnetic	RESEARCH/RESEARCH GRANTS - gilead
Yang	Eric	Interventional Cardiology: TAVR 1	Resonance The Use of Magnetic Resonance Imaging With Ferumoxytol for	CONSULTANT FEES/HONORARIA - American College of
Tang			Annulus Sizing in Patients With Chronic Kidney Disease Undergoing Transcatheter Aortic Valve Replacement	Physicians,Good Samaritan Medical Center, Los Angeles, CA,United Therapeutics; RESEARCH/RESEARCH GRANTS - Sanofi Aventis
Yang	Eric	Non Invasive Imaging: MR Characterization and Function	Elevated Myocardial Extracellular Volume Fraction (ECV) and Its Prognostic Significance in Diabetic Individuals	RESEARCH/RESEARCH GRANTS - gilead
Yang	Eric	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	A Confusing Case of Pulmonary Hypertension With Mixed Valvular Disease and Cryptogenic Cirrhosis	CONSULTANT FEES/HONORARIA - American College of Physicians,Good Samaritan Medical Center, Los Angeles, CA,United Therapeutics; RESEARCH/RESEARCH GRANTS - Sanofi Aventis
Yang	Eric	Valvular Heart Disease: Mitral Valve Disease	Inter-Study Reproducibility of Mitral Regurgitation Quantitation Using	RESEARCH/RESEARCH GRANTS - gilead
Yang	Eric	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease	Cardiac Magnetic Resonance Imaging Scimitar Syndrome in an Adult With Multiple Unsuccessful Surgical Repairs	RESEARCH/RESEARCH GRANTS - gilead
Yang	Eric	Non Invasive Imaging: MR Structure and	Quantitative Measurements on Cardiac Magnetic Resonance to	RESEARCH/RESEARCH GRANTS - gilead
Yang	Guodong	Valuvular Heart Disease Interventional Cardiology: Translation and Pre-	Differentiate Benign Versus Malignant Masses: A Pilot Study Host Intestinal Epithelium Derived MiRNAs Shape the Microbiota	Nothing to Disclose
	-	Clinical Research	and Its Implication in Cardiovascular Diseases	-
Yang	Guodong	Impact of Prenatal Environment on Congenital Heart Disease	Maternal Exosomal miRNAs in Diabetes Contribute to the Cardiac Development Deficiency	Nothing to Disclose
Yang	Hong	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Left Atrial Function and Role in Prediction of Heart Failure	Nothing to Disclose
Yang	Hong	Innovative Use of Echocardiography	Independent Association of Atrial Mechanics With Risk of Incident	Nothing to Disclose
Yang	Hsin-Jung	Non Invasive Imaging: MR Characterization and Function	Atrial Fibrillation An Unrestrained Proinflammatory M1 Macrophage Population Induced by Iron Nanocrystals Impairs Myocardial Healing After	Nothing to Disclose
Yang	Hsin-Jung	Diabetes and Endothelial Dysfucntion in Heart	Hemorrhagic Infarction Mast Cell-Dependent Conversion of Siderophages Into Foam Cells	Nothing to Disclose
		Failure	Is a Hallmark of Early Fat Infiltration in Hemorrhagic Myocardial Infarctions	
Yang	Hsin-Jung	Biomarkers and Targets for Ischemic Heart	Fat Accumulation in the Peri-Infarct Border Zone of Hemorrhagic	Nothing to Disclose
Yang	Hsin-Jung	Disease Emerging Basic Science in Ischemic Heart Disease	Myocardial Infarction Is Mediated by Persistent Iron Deposits Myocardial Hemorrhage After Coronary Ischemia-Reperfusion Leads to an Iron-Mediated, Self-Perpetuating Loop of Foam Cell	Nothing to Disclose
Yang	Hsin-Jung	Nuclear Cardiology: Coronary Flow	and Ceroid Accumulation Precisely Controlled Arterial CO2 Can Potentiate Myocardial Blood Flow to the Same Extent as Adenosine: A Preclinical Study in	Nothing to Disclose
Yang	Joseph	The Best Coronary and Peripheral Interventional Challenging Cases	Canines With 13N-Ammonia PET Percutaneous Revitalization of an Atretic Left Internal Mammary to Left Anterior Descending Coronary Artery Bypass Graft Using Sub-	Nothing to Disclose
Yang	Qing	Coronary Angiography, Intra-Vascular Imaging,	Intimal Tracking and Re-Entry Technique Invasive Management Strategies and Anti-Thrombotic Treatments in	Nothing to Disclose
Yang	Sushan	Revascularization and Outcomes FIT Clinical Decision Making: Prevention, Adult	Patients With NSTE-ACS in China Ebstein’:s Anomaly: Atvoical Variant Presenting in Adulthood	Nothing to Disclose
		Congenital and Congenital Heart Disease	,	3
Yang	Sushan	Improving Risk Assessment in Atherosclerosis	N-Terminal Pro B-Type Natriuretic Peptide, Race, and Flow- Mediated Dilation: Multi-Ethnic Study of Atherosclerosis	Nothing to Disclose
Yang	Wei	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Percutaneous Renal Sympathetic Denervation Improves the Cardiac Function And Reduces Icd (Electrical) Discharges in Severe Heart Failure Patients With Narrow Qrs Complexes and Icd Implantation	Nothing to Disclose
Yang	Wei	Diabetes and Other Issues in Cardiovascular Prevention	Predictive Risk Stratification Using HEART and Thrombolysis in Myocardial Infarction Scores in Low Risk Chest Pain Patients: An Urban Community Based Hospital Study	Nothing to Disclose
Yang	Ying	Cutting Edge Vascular Medicine	Transplanted Perivascular Adipose Tissue Promotes Destabilization of Atherosclerotic Plaque in Apolipoprotein E-Deficient Mice	Nothing to Disclose
Yang	YueJin	Fixing the Heart One Cell at a Time: The	Adiponectin Improves the Survival and Therapeutic Efficacy of	Nothing to Disclose
		Ongoing Promise of Stem Cells	Mesenchymal Stem Cells in Acute Myocardial Infarction Model Through the AMPK Pathway	

and the same of th				I
Yannopoulos	First Name Demetris	Session Title Novel Echocardiographic Methods for	Presentation Title Echocardiographic Evidence for Left Ventricular Recovery After	Disclosures Nothing to Disclose
		Assessing Cardiac Function	Refractory Ventricular Fibrillation Cardiac Arrest Treated With Primary Angioplasty and Extracorporeal Membrane Oxygenation	
Yao	David	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Severe Aortic Insufficiency Due to a Perimembranous Ventricular Septal Defect	Nothing to Disclose
Yao	Xiaoxi	Young Investigator Awards Competition: Outcomes Research	A Comparison of Kidney Function Decline in Atrial Fibrillation Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin	Nothing to Disclose
Yao	Yi	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Gender Difference in Clinical Presentation on Long-Term Outcomes in Chinese Patients Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Yao	Yuyu	Mechanisms of Vascular Inflammation in Atherogenesis	Anti Connective Tissue Growth Factor Reduced Plaque Inflammation & Detected Inflammatory Activation in Early-Stage Carotid Atherosclerotic Lesions	Nothing to Disclose
Yap	Jonathan	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Chronic Kidney Disease in Asian Patients With Heart Failure	Nothing to Disclose
Yap	Sing-Chien	Arrhythmias and Clinical EP: Devices 1	Long-Term Outcome of Noncompaction Cardiomyopathy Patients With Implantable Cardioverter-Defibrillators Compared With Patients With Dilated or Hypertrophic Cardiomyopathy	Nothing to Disclose
Yaranov	Dmitry	FIT Clinical Decision Making: Prevention, Adult Congenital and Congenital Heart Disease		Nothing to Disclose
Yarlagadda	Vivek	Atrial Fibrillation and VT: Unique Populations and Solutions	Sotalol Versus Other Anti-Arrhythmic Medications for Cardioversion of Atrial Fibrillation and Maintenance of Sinus Rhythm: Meta-Analysis of Randomized Controlled Studies	Nothing to Disclose
Yaroslavskaya	Elena	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of, Coronary Artery Disease	New Modification of Isometric Handgrip Stress Echocardiography for Detection of Coronary Artery Disease: Combination of Exercise and Emotional Stress Echocardiography	Nothing to Disclose
Yashima	Fumiaki	Interventional Cardiology: TAVR 4	Transcatheter Aortic Valve Implantation in Patients With an Extremely Small Annulus	Nothing to Disclose
Yasuda	Jumpei	Cardiac Fibrosis and Heart Failure: The Next Frontier	T3 Peptide, an Active Fragment of Tumstatin, Stimulates Migration of Cardiac Fibroblasts and Exerts Cytoprotective Effect on H9c2	Nothing to Disclose
Yates	Julie	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Cardiomyoblasts Prognostic Importance of Blood Pressure and Heart Rate in Chronic Obstructive Pulmonary Disease: The SUMMIT Trial	Nothing to Disclose
Yates	Julie	Innovations in Cardiovascular Risk Assessment and Reduction	Obstructive Pulmonary Disease: The SUMMIT Thai High-Sensitivity Cardiac Troponin I and Risk of Cardiovascular Events in Patients With COPD and Heightened Cardiovascular Risk: A Biomarker Sub-Study of the SUMMIT Trial	Nothing to Disclose
Yaylali	Yalin	Advances in Pulmonary Arterial Hypertension	Increased Erythrocyte Aggregation and Decreased Erythrocyte	Nothing to Disclose
Yazaki	Yoshiyuki	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Deformability in Patients With Pulmonary Arterial Hypertension Evaluation of Hemoconcentration Based Bioelectrical Vectorial Impedance Analysis Is Useful Risk Stratification in Acute	Nothing to Disclose
Yazaki	Yoshiyuki	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Decompensated Heart Failure Body Fat Percentage Evaluated by a Bioelectrical Impedance Analysis Provides Prognostic Value in Acute Heart Failure: Beyond	Nothing to Disclose
Yazdani	Momina	Considerations in Antiplatelet Therapy and in ACS	on the "Obesity Paradox" Comparison of P2y-sub-12/slub- Inhibitors for Mortality and Stent Thrombosis in Patients With Acute Coronary Syndromes: Single Centre Study of 10,793 Consecutive 'Real-World' Patients	Nothing to Disclose
Ye	Siqin	Innovations in Cardiovascular Risk Assessment and Reduction	The Impact of an Informatics Intervention on Shared Decision- Making for Primary Prevention Statin Therapy	Nothing to Disclose
Ye	Yumei	Diabetes and Endothelial Dysfucntion in Heart Failure	Dapagliflozin Attenuates Diabetic Cardiomyopathy and the Activation of the NLRP3/ASC Inflammasome in Mice With Type-2	Nothing to Disclose
Ye	Yumei	Emerging Basic Science in Ischemic Heart Disease	Diabetes: A Glucose-Lowering and SGLT-2 Independent Effect DPP4 Inhibition by Linagliptin Prevents Cardiac Dysfunction and	Nothing to Disclose
Ye	Zi	Vascular Medicine: New Insights Into Aortic	Inflammation by Targeting the NIrp3/Asc Inflammasome The Association of Human Leukocyte Antigen Phenotypes With	Nothing to Disclose
Ye	Zi	and Peripheral Artery Diseases Advancing Our Understanding of Aortic	Abdominal Aortic Aneurysm Expansion Risk Factors Associated With Early- Versus Late-Accelerated	Nothing to Disclose
Yeadon	Michele	Disease Born To Run: Geographic Variation in PAD	Growth Patterns in Patients With Abdominal Aortic Aneurysm Co-Chair	Nothing to Disclose
Yeboah	Joseph	Diagnosis, Treatment and Outcomes Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Coronary Artery Calcium and Incident Hypertension in a Population- Based Cohort: The Multi-Ethnic Study of Atherosclerosis	Nothing to Disclose
Yeboah	Joseph	Non Invasive Imaging: Coronary Calcium	Coronary Artery Calcium and Estimated Cardiovascular Disease	Nothing to Disclose
		Scoring and CV Risk Assessment	Risk in Five Racial/Ethnic Groups Living in the US: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA)	
Yeboah	Joseph	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Coronary Artery Calcium Scores for Atherosclerotic Cardiovascular Disease Risk Stratification in Smokers: MESA	Nothing to Disclose
Yeboah	Joseph	Diabetes and Other Issues in Cardiovascular Prevention	Blood Pressure Indices and Cardiovascular Mortality in Diabetics and Non Diabetics	Nothing to Disclose
Yeboah	Joseph	Innovations in Risk Assessment: Novel Biomarkers and Risk Prediction Tools	Association of 10-Year Change in Cardiovascular Risk Factors With Progression of Pericardial Adipose Tissue: The CARDIA Study	Nothing to Disclose
Yeboah	Joseph	Improving Risk Assessment in Atherosclerosis	N-Terminal Pro B-Type Natriuretic Peptide, Race, and Flow- Mediated Dilation: Multi-Ethnic Study of Atherosclerosis	Nothing to Disclose
Yee	Jimmy	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	An Alternative Approach to Treatment of Infective Endocarditis Using AngioVac®	Nothing to Disclose
Yee	Jimmy	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Comparison of Procedural Efficacy of Coronary Angiography in Octogenarian, Nonagenarian and General Population	Nothing to Disclose
Yee	Jimmy	Interventional Complexity and Complications	Factors Influencing Physician Selection of Radial Versus Femoral Approach in Non-Emergent Cases of CATH and PCI Procedures	Nothing to Disclose
Yee	Jimmy	Interventional Complexity and Complications	Patient Characteristics as Predictors of Transradial Approach	Nothing to Disclose
Yee	Jimmy	Interventional Complexity and Complications	Failure During Coronary Angiography Procedures The Effect of Body Mass Index on Procedural Efficacy in Transfemoral Versus Transradial Coronary Angiography	Nothing to Disclose
Yeh	Robert	PCI in the Era of Public Accountability: Managing Risks to Patients, Providers, and Institutions	Transremoral versus Transradial Coronary Angiography Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular, Boston Scientific; RESEARCH/RESEARCH GRANTS - Abiomed, Boston Scientific; SALARY - Baim Institute for Clinical Research
Yeh	Robert	PCI in the Era of Public Accountability: Managing Risks to Patients, Providers, and Institutions	Contemporary External Challenges to Coronary Revascularization	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific; RESEARCH/RESEARCH GRANTS - Abiomed,Boston Scientific; SALARY - Baim Institute for Clinical Research
Yeh	Robert	Overuse, Underuse or Just Right? Fundamental Debates in High Risk PCI in 2017	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular,Boston Scientific; RESEARCH/RESEARCH GRANTS - Abiomed,Boston



Last Name	First Name	Session Title	Presentation Title	Disclosures	
Yeh	Robert	Mechanical Support, Hemodynamic Support for Shock in High Risk Subsets; Hemodynamic Compromise	Panelist	CONSULTANT FEES/HONORARIA - Abbott Vaso Scientific; RESEARCH/RESEARCH GRANTS - Ab Scientific; SALARY - Baim Institute for Clinical Res	piomed,Boston earch
Yeh	Robert	Mechanical Support, Hemodynamic Support for Shock in High Risk Subsets; Hemodynamic Compromise	IMPELLA and Tandem Heart	CONSULTANT FEES/HONORARIA - Abbott Vaso Scientific; RESEARCH/RESEARCH GRANTS - Ab Scientific; SALARY - Baim Institute for Clinical Res	piomed,Boston earch
Yeh	Robert	Highlighted Original Research: Acute and Stable Ischemic Heart Disease and the Year in Review	Sex Differences in Rates of 30-Day Readmission in Patients Discharged After Acute Myocardial Infarction in the United States	CONSULTANT FEES/HONORARIA - Abbott Vaso Scientific; RESEARCH/RESEARCH GRANTS - At Scientific; SALARY - Baim Institute for Clinical Res	oiomed,Boston
Yeh	Robert	The Best Coronary and Peripheral Interventional Challenging Cases	ACC Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vasc Scientific; RESEARCH/RESEARCH GRANTS - At Scientific; SALARY - Baim Institute for Clinical Res	oiomed,Boston
Yeh	Robert	Considerations in Antiplatelet Therapy and in ACS	Impact of Coronary Anatomical Complexity on the Effect of Extended Duration Dual Antiplatelet Therapy: An Analysis From the Dual Antiplatelet Therapy Study	CONSULTANT FEES/HONORARIA - Abbott Vasc Scientific; RESEARCH/RESEARCH GRANTS - Ab Scientific; SALARY - Baim Institute for Clinical Res	oiomed,Boston
Yeh	Robert	Interventional Cardiology: PCI and TAVR in Complex Patients	Management of Patients With Cardiac Arrest in New York Before and After Public Reporting Policy Changes	CONSULTANT FEES/HONORARIA - Abbott Vasc Scientific; RESEARCH/RESEARCH GRANTS - Ab Scientific; SALARY - Baim Institute for Clinical Res	oiomed,Boston
Yeh	Robert	Coronary Intervention: Drug Eluting Stent and Scaffolds	A Cost-Effective Analysis of Short Duration Dual Anti-Platelet Therapy (Dapt) With a Bioabsorbable Polymer Stent Platform Versus Longer Duration Dapt With a Durable Polymer Drug-Eluting Stent in a Patient Population Undergoing Elective Percutaneous Coronary Intervention	CONSULTANT FEES/HONORARIA - Abbott Vass Scientific; RESEARCH/RESEARCH GRANTS - Ab Scientific; SALARY - Baim Institute for Clinical Res	oiomed,Boston
Yeh	Robert	Innovations in Advocacy and Patient Centered Care	Employing the Multidisciplinary Heart Team Approach for Complex Coronary Artery Disease: A Single Center Experience	CONSULTANT FEES/HONORARIA - Abbott Vaso Scientific; RESEARCH/RESEARCH GRANTS - At Scientific; SALARY - Baim Institute for Clinical Res	oiomed,Boston
Yeh	Robert	Advances in Chronic Total Occlusion Intervention	The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry	CONSULTANT FEES/HONORARIA - Abbott Vasc Scientific; RESEARCH/RESEARCH GRANTS - At Scientific; SALARY - Baim Institute for Clinical Res	oiomed,Boston
Yeh	Robert	Advances in Chronic Total Occlusion Intervention	Application and Outcomes of the Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: An Update From a Contemporary Multicenter U.S. Registry	CONSULTANT FEES/HONORARIA - Abbott Vaso Scientific; RESEARCH/RESEARCH GRANTS - At Scientific; SALARY - Baim Institute for Clinical Res	oiomed,Boston
Yeh	Robert	Advances in Chronic Total Occlusion Intervention	Impact of Sex on Physical Limitation & Patient Health Status After Chronic Total Occlusion Percutaneous Coronary Intervention: Propensity Matched Substudy of OPEN-CTO Registry	CONSULTANT FEES/HONORARIA - Abbott Vaso Scientific; RESEARCH/RESEARCH GRANTS - At Scientific; SALARY - Baim Institute for Clinical Res	oiomed,Boston
Yeh	Robert	The PCSK9 Revolution: New Insights Into Evaluation and Treatment	Implications of the FDA Approval of PCSK9 Inhibitors for Contemporary Cardiovascular Practice: Findings From the NCDR [®] Research to Practice (R2P) Project	CONSULTANT FEES/HONORARIA - Abbott Vasc Scientific; RESEARCH/RESEARCH GRANTS - At Scientific; SALARY - Baim Institute for Clinical Res	oiomed,Boston
Yeh	Robert	Optimizing Treatment of Peripheral Artery Disease	Nationwide Readmissions Following Lower Extremity Arterial Procedures	CONSULTANT FEES/HONORARIA - Abbott Vasc Scientific; RESEARCH/RESEARCH GRANTS - Ab Scientific; SALARY - Baim Institute for Clinical Res	oiomed,Boston
Yen	Michael	Hearts and Soles: Multimodality Imaging in	Assessment of Coronary Atherosclerosis Using Calcium Scores in	Nothing to Disclose	
Yeo	llhwan	Athletes Interventional Cardiology: TAVR 2	Short and Long Distance Runners The Influence of Gender on In-Hospital Clinical Outcomes in Hispanics Following Surgical and Transcatheter Aortic Valve Replacement	Nothing to Disclose	
Yeo	Ilhwan	Outcomes in Valvular Heart Disease	In-Hospital Clinical Outcomes Following Concomitant Coronary	Nothing to Disclose	
Yeo	Ilhwan	Sex Disparity in VHD Outcomes	Artery Bypass Graft and Heart Valve Surgery in Women The Impact of Gender on In-Hospital Clinical Outcomes Following	Nothing to Disclose	
Yeo	Khung Keong	Interventional Cardiology: Angiography,	Isolated Mitral or Aortic Heart Valve Surgery The Use of a Newer Generation Radiation Reduction Algorithm Has	CONSULTANT FEES/HONORARIA - Abbott Vaso	cular,Boston
		Intravascular Imaging and Interventional CT/MR	Led to Lower Radiation Doses in Coronary Angiography: A Two Year Single-Center Retrospective Analysis	Scientific, Menarini; RESEARCH/RESEARCH GRA MEDTRONIC; SPEAKER'S BUREAU - Abbott Vas	NTS -
Yeo	Tiong Cheng	New Technologies in Echocardiography	Novel Non-Invasive Left Ventricular Stiffness Index in Patients With Low-Flow Compared to Normal-Flow Severe Aortic Stenosis With Preserved Left Ventricular Ejection Fraction	Nothing to Disclose	
Yerokun	Babatunde	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Surgery for Patients With Bicuspid Aortopathy: Validation of the 2016 ACC/AHA Guidelines Clarification	Nothing to Disclose	
Yerokun	Babatunde	Interventional Cardiology: TAVR 2	Prevalence and Outcomes of Mitral Stenosis in Patients Undergoing Transcatheter Aortic Valve Replacement: Findings From the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) Transcatheter Valve Therapies (TVT) Registry	Nothing to Disclose	
Yerokun Yerokun	Babatunde Babatunde	Interventional Cardiology: TAVR 4 Therapeutic Advances in Congenital Heart Disease	Predictors of Mortality After TAVR in a "Real World" Setting Effect of Obesity and Underweight Status on Perioperative Outcomes in Patients With Congenital Heart Disease: An Analysis of Data From the Society of Thoracic Surgeons Congenital Heart Surgery Database	Nothing to Disclose Nothing to Disclose	
Yetman	Angela	Adult Patients With Congenital Heart Disease: How Do They Compare?	Decreased Hepatic Elasticity in Young Adults After Biventricular Repair of Congenital Heart Disease	Nothing to Disclose	
Yeung	Alan	Interventional Cardiology: TAVR 1	The Inflammasome Pathway Is Associated With Adverse Ventricular Remodeling Following Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Abbott Vascular,MEDTRONIC; RESEARCH/RESEARCH Boston Scientific,Edwards,MEDTRONIC	GRANTS -
Yeung	Alan	Current Issues in Cardiovascular Epidemiology, Disparities, and Safety	Sex Differences in the Risk Factors for Endothelial and Microvascular Dysfunction in Patients With Angina in the Absence of Obstructive Coronary Artery Disease	CONSULTANT FEES/HONORARIA - Abbott Vascular,MEDTRONIC; RESEARCH/RESEARCH Boston Scientific,Edwards,MEDTRONIC	GRANTS -
Yeung	Susanna	Adult Patients With Congenital Heart Disease: How Do They Compare?	Right and Left Ventricular Mechanics Are Altered in Adolescents and Adults Late After Repair of Subarterial Ventricular Septal	Nothing to Disclose	
Yiangou	Kyriakos	Systemic Organ Involvement in Heart Failure: International Perspectives From the German Cardiac Society, Hellenic Society of Cardiology, and American College of Cardiology	Defects Anemia in Cardiorenal Syndrome: From Pathophysiology to Therapeutic Considerations	Nothing to Disclose	
Yildiz	Mehmet	Cardiology FIT Clinical Decision Making: Interventional Cardiology, Acute and Stable Ischemic Heart Disease, and Vascular Medicine	ST Segment Elevation Myocardial Infarction Related to Coronary Artery Embolization and Concomitant Acute Embolic Stroke	Nothing to Disclose	
Yilmaz	Dilek	Arrhythmias and Clinical EP: Devices 4	Increased Complexity of Transvenous Lead Removals With Unaltered Effectivity: Promising Results Will Benefit Device Patients	Nothing to Disclose	

Contract of the Contract of th				
Last Name Yilmaz	First Name Fatih	Session Title Imaging Pulmonary Vascular Disease Plus the Impact of Congenital Heart Disease	Presentation Title Clinical, Biochemical, Neurohumoral, Echocardiographic and Hemodynamic Characteristics in Relation to Survival in Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: Insights From Euphrates Study	Disclosures Nothing to Disclose
Yilmaz	Fatih	Understanding Pulmonary Vascular Disease: From Bench to Bedside	Short-Term Intravenous lioprost Treatment Improves Clinical Status and Neurohumoral Measures in Clinical Worsening Episodes of Precapillary Pulmonary Hypertension Regardless of the Background Treatments: Insights From Euphrates Study	Nothing to Disclose
Yilmaz	Fatih	Understanding Pulmonary Vascular Disease: From Bench to Bedside	The Impaired Endothelium-Dependent and Endothelium- Independent Systemic Arterial Vasodilatory Reserve in Pulmonary Hypertension Regardless of the Clinical Group	Nothing to Disclose
Yilmaz	Fatih	Predicting the Future: Observations and Discoveries From Registries and Databases	Pulmonary Vascular Resistance, but Not Diastolic Pulmonary Gradient, May Predict Survival in Pulmonary Hypertension: Insights From Euphrates Study	Nothing to Disclose
Yilmaz	Fatih	Predicting the Future: Observations and Discoveries From Registries and Databases	The Correlates and Prognostic Impact of Pulmonary Arterial Pulse Pressures, Diastolic and Transpulmonary Pressure Gradients in Pulmonary Hypertension: Insights From Euphrates Study	Nothing to Disclose
Yilmaz	Fatih	Predicting the Future: Observations and Discoveries From Registries and Databases	An Ignored but Not Unusual Complication of Severe Pulmonary Hypertension - Ostial Compression of Left Main Coronary Artery by Aneurysmal Pulmonary Artery: Insights From Euphrates Study	Nothing to Disclose
Yilmaz	Mehmet	Arrhythmias and Clinical EP: Anticoagulation Issues	Local Transvamic Acid for Prevention of Bleeding Complications During Cardiac Device Implantation of Patients on Chronic Direct Oral Anticoagulants	RESEARCH/RESEARCH GRANTS - Amgen Inc.,Bayer Healthcare Pharmaceuticals,Bayer Healthcare Pharmaceuticals,Cardiorentis (TRUE-AHF study),Novartis (Aliskiren Phase III trials in Acute and Chronic Heart Failure),Novartis (LC2696),Novartis Corporation
Yilmaz	Mehmet	Heart Failure and Cardiomyopathies: Clinical Team 2	Suggested Reviewer	RESEARCH/RESEARCH GRANTS - Amgen Inc.,Bayer Healthcare Pharmaceuticals,Bayer Healthcare Pharmaceuticals.Cardiorentis (TRUE-AHF study),Novartis (Aliskiren Phase III trials in Acute and Chronic Heart Failure),Novartis (L/2596),Novartis Corporation
Yin	Dong	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Morphologic Patterns of In-Stent Chronic Total Occlusions: An Intravascular Ultrasound Study	Nothing to Disclose
Yin	Dong	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	The Effectiveness of Excimer Laser Angioplasty to Treat Coronary In-Stent Restenosis With Peri-Stent Calcium as Assessed by Optical Coherence Tomography	Nothing to Disclose
Yin Ying	Wei-Hsian Ru	32. Prevention: Clinical Team 3 Cutting Edge Vascular Medicine	Suggested Reviewer Transplanted Perivascular Adipose Tissue Promotes Destabilization of Atherosclerotic Plaque in Apolipoprotein E-Deficient Mice	Nothing to Disclose Nothing to Disclose
Yingchoncharoen	Teerapat	Advances in Pulmonary Arterial Hypertension	Effect of Inhaled Nebulized Nitrite on Pulmonary Arterial Pressure in HbE/Beta-Thalassemia Patients With Pulmonary Arterial Hypertension	CONSULTANT FEES/HONORARIA - Menarini, Novartis, servier
Yook	Paul	Head to Toe: Outcomes of Endovascular Interventions	Peri-Strut Low Intensity Area Predicts Neointimal Progression Associated With Late Enlargement of Self-Expanding Nitinol Stents in Superficial Femoral Arteries: An Optical Coherence Tomography Study	CONSULTANT FEES/HONORARIA - Shockwave; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - A neumed, Biocardia, Bioparadox, Cyberheart, Cylograft, Guided Delivery Systems, Hansen Medical, Heartflow, In Vivo Technologies, Luminatal, Mercator Med Systems, Neodyne, NSYZ, Thermocure, TherOx, Vascular Imaging, Vascular Pathways, Voyage Medical, VyfronUS, XDx; RESEARCH/RESEARCH GRANTS - Abbott Vascular, BD Medical, Boston Scientific, Covidien, Edwards Life Sciences, Johnson& amp; Johnson, Maquet, MEDTRONIC, St Jude Medical Foundation, Stryker
Yoda	Shunichi	Nuclear Cardiology: Coronary Flow	Diagnostic Performance of Hybrid Assessment With Stress Only Myocardial Perfusion Single Photon Emission Computed Tomography Using Semiconductor Gamma Camera and Rest Myocardial Scar Findings Obtained From 320 Detector Row Computed Tomography	Nothing to Disclose
Yoganathan	Ajit	TAVR for Degenerated Surgical Valves: What	Does Depth of Implantation for TAVR in Prior SAVR Makes a	CONSULTANT FEES/HONORARIA - Boston Scientific, Sorin
Yogeswaran	Vidhushei	You Need to Know from A to Z Innovations in Pediatric Catheterization and	Difference? Outcome of Preoperative Electrophysiology Study in Patients With	Biomedica,St. Jude Medical Nothing to Disclose
Yokokawa	Miki	EP: Mending, Fixing and Predicting Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Ebstein Anomaly Anticoagulation Protocol After Radiofrequency Ablation of Infarct- Related Ventricular Tachycardia: Institutional Experience and Outcomes	Nothing to Disclose
Yonemoto	Naohiro	Unusual Presentations of ACS	Clinical Characteristics and In-Hospital Mortality of Very Elderly Patients With Cardiovascular Shock in Japan: The Results From Japanese Circulation Society Shock Registry	Nothing to Disclose
Yonemoto	Naohiro	Unusual Presentations of ACS	Association Between Presentation Time and Short-Term Mortality in Patients With Cardiogenic Shock Complicating Acute Coronary Syndrome: From Jcs Shock Registry	Nothing to Disclose
Yonetsu	Taishi	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Relationship Between Coronary Physiological Parameters and Cardiac Biomarkers in Patients Undergoing Invasive Coronary Angiography	Nothing to Disclose
Yonetsu	Taishi	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Significance of Microcirculatory Resistance in Visual-Functional Mismatch Between Coronary Angiography and Fractional Flow Reserve in Non-Left Main Lesions	Nothing to Disclose
Yonetsu	Taishi	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Usefulness of Optical Coherence Tomography-Derived Morphometric Assessment to Predict Physiological Significance of Coronary Artery Stenosis and Determinants of Mismatch: Head-to- Head Comparison With Intravascular Ultrasound	Nothing to Disclose
Yonetsu	Taishi	Interventional Cardiology: Angiography, Intravascular Imaging and Interventional CT/MR	Relationship Between Optical Coherence Tomography-Defined In- Stent Neoatherosclerosis and Out-Stent Arterial Remodeling Assessed by Serial Intravascular Ultrasound Examinations in Late and Very Late Drug-Eluting Stent Failure	Nothing to Disclose
Yonetsu	Taishi	Unusual Presentations of ACS	Comparison Between Angioscopic and Optical Coherence Tomographic Assessment of Instent Restenosis	Nothing to Disclose
Yonetsu	Taishi	Unusual Presentations of ACS	Predictors and Clinical Significance of High-Sensitivity Cardiac	Nothing to Disclose
Yonetsu	Taishi	Unusual Presentations of ACS	Troponin-I Elevation After Diagnostic Coronary Angiography Multimodality Coronary Imaging to Predict Periprocedural Myocardial Necrosis After Elective Percutaneous Coronary Intervention	Nothing to Disclose
Yonetsu	Taishi	Unusual Presentations of ACS	Comparison of Neointimal Appearance Assessed by Optical Coherence Tomography Between Bare-Metal Stents and Sirolimus- Eluting Stents Beyond 10 Years From Implantation	Nothing to Disclose
Yong	Celina	Young Investigator Awards Competition:	Racial Differences in Quality of Care and Outcomes After Acute	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL -
Yoon	Andrew	Outcomes Research FIT Clinical Decision Making: Non-Invasive	Coronary Syndrome Idiopathic Effusive Constrictive Pericarditis in a Patient With Cystic	CorDynamix, Inc Nothing to Disclose
Yoon	Hyuck Jun	Imaging and Valvular Heart Disease Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Fibrosis: A Case Report With Multi-Modality Imaging Five Year Outcomes of Fractional Flow Reserve Guided Versus Intravascular Ultrasound Guided Percutaneous Coronary	Nothing to Disclose
Yoon	Namsik	Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	Intervention in Intermediate Coronary Artery Disease Renal Nerve Denervation Suppress Ventricular Arrhythmia in a Porcine Model After Acute Myocardial Infarction	Nothing to Disclose
	1	Janu Cilnical Er and the Year In Review	proforme woder After Acute wyocardial infarction	

Control of the Contro				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Yoon	Namsik	Arrhythmias and Clinical EP: Basic 5	Transmural Conduction Time in Early Repolarization Syndrome	Nothing to Disclose
Yoon	Cuna Han	Featured Clinical Research II: Interventional	Model Procedural and Clinical Outcomes in Transcatheter Aortic Valve	Nothing to Disclose
10011	Sung-Han	reatured Clinical Research II: Interventional	Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis	Nothing to Disclose
Yoshikawa	Tsutomu	The Evolving World of LVADs, Transplant and	Performance of the MAGGIC Heart Failure Risk Score in Japanese	Nothing to Disclose
Tooriiilawa	routoma	Other Novel Discoveries	Acute Heart Failure Patients: A Report From the West Tokyo Heart	Trouming to Biodicco
			Failure Registry	
Yoshikawa	Yusuke	Antiplatelet and Antithrombotic Agents in	Application of DAPT Score to Predict Ischemic and Bleeding Events	Nothing to Disclose
		Ischemic Heart Disease	in Japanese Patients Undergoing Drug-Eluting Stent Implantation: An Observation From a Pooled Cohort of the CREDO-Kyoto Cohort-	
			2, RESET, and NEXT Trials	
Yoshimura	Takahiro	Interventional Cardiology: Intravascular	Atherosclerotic Plaque Morphology in Response to High Intensity	Nothing to Disclose
		Physiology and Endothelial Function	Lipid Lowering Therapy by Multimodality Imaging Among Women	· ·
			and Men: A YELLOW-II Sub-study	
Yoshimura	Takahiro	Interventional Cardiology: Stent Failure Analysis by Intravascuar Imaging	Multimodality Intravascular Imaging to Evaluate Plaque Characteristics in Patients With Diabetes Mellitus	Nothing to Disclose
Yoshinaga	Keiichiro	Vascular Medicine: Aortic and Peripheral	Molecular Determinants of Functional Changes and Fibrosis	RESEARCH/RESEARCH GRANTS - A&D Co, LtD
		Artery Diseases	Determined by Novel Automated Oscillometric Approach to	
			Measure Brachial Artery Vascular Volume Elastic Modulus in	
W. L.	17.30	District of the Public Control of the Public	Chronic Kidney Disease	Number of Briefs
Youker	Keith	Diabetes and Endothelial Dysfucntion in Heart Failure	Interleukin 18 Impairs Excitation Contraction Coupling in Cardiomyocytes and Predicts Mortality in Acute Decompensated	Nothing to Disclose
		Tallare	Heart Failure	
Young	James	Are We There Yet? The Long Journey to	Panelist - The Patient Perspective	Nothing to Disclose
		Health Equity: Part II		
Young	Kathleen	Making Progress in Understanding Heart	Incidence of Preclinical (Stage A and B) Heart Failure in the General	Nothing to Disclose
Vouna	Luciana	Failure Congenital Heart Disease: Novel Insights in	Population Rhythm Abnormalities in Children and Young Adults With Marfan	Nothing to Disclose
Young	Lucidild	Pediatric Cardiology	Syndrome	I Votining to Disclose
Young	Luciana	Therapeutic Advances in Congenital Heart	ACC Poster Moderator	Nothing to Disclose
		Disease		
Young	Luciana	11. Congenital Heart Disease: Therapy Team	Suggested Reviewer	Nothing to Disclose
V	Minhaal	1	Faralacian the Multidiation of the Association of the Control of t	Nething to Displace
Young	Michael	Innovations in Advocacy and Patient Centered Care	Employing the Multidisciplinary Heart Team Approach for Complex Coronary Artery Disease: A Single Center Experience	Nothing to Disclose
Young	Michael	FIT Clinical Decision Making: Interventional	Digit Ischemia Work-Up and an Uncommon Diagnosis: Hypothenar	Nothing to Disclose
	1	Cardiology, Acute and Stable Ischemic Heart	Hammer Syndrome	··
		Disease, and Vascular Medicine	•	
Young	Michael	Engage @ ACC.17 Studio: FIT Jeopardy Battle	Moderator	Nothing to Disclose
V	Dahaliah	of the State Chapters I	Association of Total Tostostones With December of Countil	Nothing to Displace
Young	Rebekah	Non Invasive Imaging: Coronary Calcium Scoring and CV Risk Assessment	Association of Total Testosterone With Progression of Carotid Atherosclerosis and Coronary Artery Calcium Score: The Multi-	Nothing to Disclose
		Scoring and CV Risk Assessment	Ethnic Study of Atherosclerosis	
Younis	Arwa	Diabetes and Other Issues in Cardiovascular	Impaired Fasting Glucose Is the Major Determinant of the 20-Year	Nothing to Disclose
		Prevention	Mortality Risk Associated With Metabolic Syndrome in Non-Diabetic	
V	F	Later Control of the	Patients With Stable Coronary Artery Disease	Number of Briefs
Younis	Eman	Interdisciplinary Cardiovascular Team Collaboratives in Care	Heparin Induced Thrombocytopenia With Thrombosis: A Case Study	Nothing to Disclose
Yousif	Nasser	Cutting Edge Vascular Medicine	Vitamin D Attenuates Myocardial Injury Following Ischemia	Nothing to Disclose
			Reperfusion via Modulates Erk1-2 Signaling Pathway	
Yousman	Wina	Complex Coronary Intervention: Left	Comparison of Two-Year Outcomes in Drug-Eluting Stents Versus	Nothing to Disclose
		Main/Bifurcations and Multivessel Disease	Coronary Artery Bypass Grafting for Treatment of Unprotected Left	
			Main Coronary Artery Disease in Elderly Patients: A Meta-Analysis	
Yousman	Wina	Innovations in Education	Coronary Angiography Simulation Training Improves Image	Nothing to Disclose
			Interpretation Skills of Trainees Independent of Their Stage of	
			Training	
Yow	Eric	Innovative Use of Echocardiography	The Impact of Rigorous Quality Improvement on 3D	Nothing to Disclose
			Echocardiography Image and Data Quality in an International Multisite Randomized Trial	
Yu	Во	Timely Topics in Acute Coronary Syndromes	Systemic Pentraxin 3 Is a Potential Biomarker to Differentiate	Nothing to Disclose
	50	Timoly replace in readic continuity cylinicalises	Plaque Erosion From Plaque Rupture in Acute Coronary Syndrome	Trouming to Biodicco
			Patients	
Yu	Во	The Inside View: Learning From Intracoronary	Prevalence and Clinical Significance of Lipid-Rich Plaque Detected	Nothing to Disclose
		Imaging	by Optical Coherence Tomography: A Four-Year Follow-Up Study	
Yu	Cheuk-Man	Non Invasive Imaging: Role of Exercise Testing	Impaired Left Ventricular Longitudinal Functional Reserve in	Nothing to Disclose
1		Tradito imaging. Note of Exclose Testing	Patients With Psoriatic Arthritis: A Low-Level Bicycle Ergometer	
			Exercise Test	
Yu	Cheuk-Man	The Evolving World of LVADs, Transplant and	Chronic Kidney Disease in Asian Patients With Heart Failure	Nothing to Disclose
V6.	Mathania a	Other Novel Discoveries	Condo Difference in Book Brown	Nething to Displace
Yu	Katherine	Interventional Complexity and Complications	Gender Differences in Post Percutaneous Coronary Intervention	Nothing to Disclose
1	1	1	Complications Following Acute Myocardial Infarction in the United States	
Yu	Katherine	FIT Clinical Decision Making: Interventional	Ventricular Septal Rupture and Subsequent Longitudinal Septal	Nothing to Disclose
ĺ	1	Cardiology, Acute and Stable Ischemic Heart	Tissue Tear in a Late Presenting Inferior Myocardial Infarction	
Vii	Liloi	Disease, and Vascular Medicine	Optograpatio Approach Madulatos Cardias Comenthatia Comitiva to	Nothing to Displace
Yu	Lilei	Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review	Optogenetic Approach Modulates Cardiac Sympathetic Ganglion to Protect Against Ischemia Related Ventricular Arrhythmias	Nothing to Disclose
Yu	Lilei	Arrhythmias and Clinical EP: Basic 4	Gut Microbes-Derived Metabolite Trimethylamine N-Oxide	Nothing to Disclose
1	1	1	Facilitates the Progression of "Atrial Fibrillation Begets Atrial	· -
İ	İ	1	Fibrillation": A Potential Link Between Gut Microbes and	
VII	Tay Chyi	Heart Failure and Cardiomyopathies: Is Heart	Atrial Fibrillation Treatment Patterns and Resource Use of Heart Failure Patients on	OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - Novartis
Yu	Tzy-Chyi	Failure With a Normal EF for Real?	Medicaid in Five States in the US	OWNERSHIP IN LERES LIPAR LINERSHIP/PRINCIPAL - Novartis Pharmaceuticals corporation; SALARY - Novartis
1	1	. and o with a redifficient for Redif	modical and the orace in the OO	Pharmaceuticals corporation; SALARY - Novartis Pharmaceuticals corporation
Yuan	Lijun	Interventional Cardiology: Translation and Pre-	Host Intestinal Epithelium Derived MiRNAs Shape the Microbiota	Nothing to Disclose
	ļ.,.	Clinical Research	and Its Implication in Cardiovascular Diseases	
Yuan	Lijun	Impact of Prenatal Environment on Congenital	Maternal Exosomal miRNAs in Diabetes Contribute to the Cardiac	Nothing to Disclose
Yubbu	Putri	Heart Disease ACC International Conferences Best Posters	Development Deficiency Assessment of Left Ventricular Strain and Its Clinical Correlations in	OTHER - Nil
. 3000			Isolated Left Ventricular Non-Compaction	
Yumul	Roya	Nuclear Cardiology: Coronary Flow	Precisely Controlled Arterial CO2 Can Potentiate Myocardial Blood	Nothing to Disclose
İ	1		Flow to the Same Extent as Adenosine: A Preclinical Study in	
V	Hann In 1	Traditional and No. of France 11.	Canines With 13N-Ammonia PET	Nething to Displace
Yun	Hong Jun	Traditional and Novel Factors Used to Assess the Risk of, and Used for the Treatment of,	Patterns of Downstream Cardiac Procedures After Nuclear Myocardial Perfusion Imaging in the United States, 2008-2012	Nothing to Disclose
1	ĺ	Coronary Artery Disease	inyocardiai r enusion imaging in the officed States, 2000-2012	
Yun	Sung-Cheol	Late-Breaking Clinical Trials: Interventional	Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With	Nothing to Disclose
İ	1 -		Coronary Chronic Total Occlusion: DECISION CTO Randomized	
V	Chi Viii	Name Cales and the Add at a	Trial	Nething to Displace
Yung	Chi Yui	Novel Echocardiographic Methods for Assessing Cardiac Function	2d Speckle Tracking Echocardiography in Identifying the Degree of Recoverability of Sub Clinical Right Ventricular Dysfunction in	Nothing to Disclose
İ	İ	Assessing Cardiac r unction	Patients With Newly Diagnosed Osa Receiving Cpap Therapy	
-	•			

The same of the sa				
Last Name	First Name	Session Title	Presentation Title	Disclosures
Yunis	Adil	Advances in HCM, PPCM and Other Cardiomyopathies	VE/VCO2 Is a Powerful Predictor of Mortality in Wild-Type Transthyretin Amyloidosis	Nothing to Disclose
Yunus	Fahd	Fibrillatory Arrhythmias: Outcomes With Contemporary Practice	Success Rates by Ablation Lesion Set of Catheter Ablation for Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta- Analysis Study Cohort	Nothing to Disclose
Yunus	Fahd	Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures	Secular Trends in Reported Success Rates of Catheter Ablation for Non-Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort	Nothing to Disclose
Yunus	Fahd	Atrial Fibrillation and VT: Incorporating Novel Risks Toward Decision Making	Inclusion of Women in Studies of Catheter Ablation for Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort	Nothing to Disclose
Yusuf	Syed	Optimizing the Care of ACS Patients	Impact of Preprocedural Thrombocytopenia on Safety of Performing Percutaneous Coronary Intervention in Cancer Patients	Nothing to Disclose
Yzeiraj	Edlira	Arrhythmias and Clinical EP: Devices 3	Variability in Left Ventricular Ejection Fraction by Radionuclide	Nothing to Disclose
			Multigated Acquisition Scan Versus Echocardiography: Implications for Primary Prevention Implantable Cardioverter Defibrillators	
Zachariah	Justin	Get into the Beat! Exercise to Promote CV Health	Panelist	Nothing to Disclose
Zachariah	Justin	Get into the Beat! Exercise to Promote CV Health	State of Exercise Science for CV Health Promotion	Nothing to Disclose
Zack	Chad	Highlighted Original Research: Valvular Heart Disease and the Year in Review	Isolated Tricuspid Valve Surgery: Repair Versus Replacement	Nothing to Disclose
Zack Zack	Chad Chad	Valvular Disease Populations at Risk Head to Toe: Outcomes of Endovascular	Isolated Tricuspid Valve Surgery: National Trends and Outcomes Contemporary Nationwide Trends in Inferior Vena Cava Filter	Nothing to Disclose Nothing to Disclose
Zaalı	Chad	Interventions	Implantation Rates in the United States and the Effect of Food and Drug Administration Advisory	-
Zack	Chad	Venous Investigation: The Dark Side	Nationwide Contemporary Trends in Adjunctive Angioplasty and Stenting at the Time of Catheter Directed Thrombolysis in Patients With Proximal Lower Extremity Deep Vein Thrombosis	Nothing to Disclose
Zack	Chad	Venous Investigation: The Dark Side	Sex Differences in the Use of Inferior Vena Cava Filters in Patients With Proximal Lower Extremity Deep Vein Thrombosis in the United States	Nothing to Disclose
Zack	Chad	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Contemporary Utilization of Immediate Coronary Angiography in the Management of Out-of-Hospital Cardiac Arrest	Nothing to Disclose
Zack	Chad	Arrhythmias and Clinical EP: Basic 4	External Cooling of the Myocardium Slows Electrical Conduction and Terminates Atrial Fibrillation	Nothing to Disclose
Zack	Chad	FIT Clinical Decision Making: Heart Failure and		Nothing to Disclose
Zack	Chad	Pulmonary Hypertension Insights From Echocardiography Use	Echocardiographic Parameters of Myocardial Performance After	Nothing to Disclose
Zaalı	Chad	Advances in Dalbank violence and Treatment of	Transapical Versus Transfemoral Transcatheter Aortic Valve Replacement	Nething to Diselect
Zack	Chad	Advances in Pathophysiology and Treatment of Thrombosis	Thrombolysis	Nothing to Disclose
Zack	Chad	Frontiers in Mitral Valve Disease and Treatment	Long Term Outcomes of Patients Undergoing Percutaneous and Surgical Mitral Paravalvular Leak Repair	Nothing to Disclose
Zado	Erica	Meeting of the Minds: HF and EP Decision Making for Complex Patients	Panelist	Nothing to Disclose
Zado	Erica	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Anticoagulation Use and Incidence of Cerebrovascular Events and Major Bleeding After Catheter Ablation in Patients With Persistent and Longstanding Persistent Atrial Fibrillation	Nothing to Disclose
Zadura	Mariusz	Novel Developments in Acute Coronary Syndromes	Extracorporeal Circulatory Life Support Is Superior to Intra-Aortic Balloon Pump in Acute Coronary Syndrome and Cardiogenic Shock	Nothing to Disclose
Zafar	Mohammad	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Normalizing Platelet Reactivity of Cardiovascular Patients on Ticagrelor Therapy Using Fresh Platelets: Ex Vivo Testing of the Functional Recovery Attained Within 48-Hours of Stopping Treatment	Nothing to Disclose
Zafar	Mohammad	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Countering the Anti-Platelet Effects of Ticagrelor With Platelet Concentrates Within 48 Hours of a Loading Dose: Ex Vivo Testing of Time-Effect on Functional Recovery in Patients With Cardiovascular Disease	Nothing to Disclose
Zafari	A. Maziar	Young Investigator Awards Competition: Clinical Investigations	Feasibility of a Smartphone-Delivered Cardiac Rehabilitation Program Amongst Veterans	Nothing to Disclose
Zafrir	Barak	Advances in Cholesterol Measurement and Management	Clinical Features and Gaps in the Management of Familial Hypercholesterolemia With Prevalent Cardiovascular Disease	RESEARCH/RESEARCH GRANTS - Sanofi Israel
Zagidullin	Naufal	Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes	Nephroprotective Effects Of Remote Ischemic Preconditioning In Coronary Angiography	Nothing to Disclose
Zagidullin	Naufal	Timely Topics in Acute Coronary Syndromes	Systemic Pentraxin 3 Is a Potential Biomarker to Differentiate Plaque Erosion From Plaque Rupture in Acute Coronary Syndrome	Nothing to Disclose
Zaha	Vlad	FIT Clinical Decision Making: Valvular Heart	Patients Effusive-Constrictive Pericarditis Associated With Schmidt	Nothing to Disclose
Zahler	David	Disease and Pericardial Disease Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary	Syndrome Absence of Clinical Triggering in Diabetic Patients With ST-Segment Elevation Myocardial Infarction Predicts Multiple Vessel Coronary Disease and le Assessated With Ingressed Medality	Nothing to Disclose
Zahr	Firas	Syndrome Interventional Cardiology: TAVR 1	Disease and Is Associated With Increased Mortality Prognostic Value of Right Ventricular Function Assessed by Cardiac Computed Tomography in Patients Undergoing Transcatheter Aortic	Nothing to Disclose
Zahr	Firas	Interventional Cardiology: TAVR 2	Valve Replacement Prevalence and Outcomes of Mitral Stenosis in Patients Undergoing	Nothing to Disclose
			Transcatheter Aortic Valve Replacement: Findings From the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) Transcatheter Valve Therapies (TVT) Registry	
Zaid	Syed	Interventional Cardiology: TAVR 1	"Cusp Overlap" View Facilitates Accurate Fluoro- Guided Implantation of Self-Expanding Valve in TAVR	Nothing to Disclose
Zaidan	Mohammad	Coronary Intervention in Interventional	Innovative Technique to Achieve Hemostasis With Large Bore	Nothing to Disclose
Zaidi	Amir	Cardiology: Advanced Device Use The Story of the Adult Congenital Heart	Access for Percutaneous Hemodynamic Support Devices Prevalence and Predictors of Atrial Tachyarrhythmias in Adult	CONSULTANT FEES/HONORARIA - Medtronic Inc ,St Jude
Zaidi	Amir	Disease Patient and EP Redefining the "F" Word	Fontan Patients Prevalence and Predictors of Pacemaker Placement in Adult	Medical CONSULTANT FEES/HONORARIA - Medtronic Inc ,St Jude
Zaidi	Syed Ali	09. Congenital Heart Disease: Adult Team 1	Fontan Patients Suggested Reviewer	Medical Nothing to Disclose
Zajarias	Alan	Interventional Live Case Session I: Structural	Panelist	CONSULTANT FEES/HONORARIA - Abiomed; OTHER -
Zeissies	Alaa	Transmission from Cleveland Clinic (Cleveland, Ohio)	Danalist	Edwards Lifescience
Zajarias	Alan	Featured Clinical Research II: Interventional	Panelist	CONSULTANT FEES/HONORARIA - Abiomed; OTHER - Edwards Lifescience
Zajarias	Alan	Challenging Anatomies: Does TAVR Device Choice Matter	Co-Chair	CONSULTANT FEES/HONORARIA - Abiomed; OTHER - Edwards Lifescience
Zajarias	Alan	TAVR: What We've Learned and Where We Think We're Going!	Co-Chair	CONSULTANT FEES/HONORARIA - Abiomed; OTHER - Edwards Lifescience
-				



-				<u> </u>
Last Name Zajarias	First Name Alan	Session Title Test Yourself with Questions: General	Presentation Title Faculty	Disclosures CONSULTANT FEES/HONORARIA - Abiomed; OTHER -
Zajarias	Alan	Cardiology Module 15 Highlighted Original Research: Interventional	Implications of Worsening Right Ventricular Function Following	Edwards Lifescience CONSULTANT FEES/HONORARIA - Abiomed; OTHER -
		Cardiology and the Year in Review	Transcatheter or Surgical Aortic Valve Replacement: Insights From PARTNER2A	Edwards Lifescience
Zajarias	Alan	Interventional Cardiology: TAVR 2	Worsening Tricuspid Regurgitation and Increased Mortality After Aortic Valve Replacement: Insights From PARTNER2A	CONSULTANT FEES/HONORARIA - Abiomed; OTHER - Edwards Lifescience
Zajarias	Alan	Interventional Cardiology: TAVR 4	Depression as a Potential Therapeutic Target to Improve Quality of Life After Transcatheter Aortic Valve Replacement	CONSULTANT FEES/HONORARIA - Abiomed; OTHER - Edwards Lifescience
Zajarias	Alan	Interventional Challenging Cases: Team 4	ACC Challenging Case Reviewer	CONSULTANT FEES/HONORARIA - Abiomed; OTHER - Edwards Lifescience
Zakaria	Dala	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Short Axis Diastolic Ventricular Area Ratio as a New Index in Screening Patients With Repaired Tetralogy of Fallot	Nothing to Disclose
Zakaria	Sammy	Innovations in Education	Electrocardiogram Training for Residents: A Curriculum Based on Facebook and Twitter	Nothing to Disclose
Zakka	Patrick	Population Specific Cardiomyopathies: From Exomes to Databases	Targeted and Exome Sequencing of 27 Lebanese Patients With Cardiomyopathies: Novel Variants in Known Genes, and Potential Novel Genes	Nothing to Disclose
Zakka	Patrick	Arrhythmias and Clinical EP: Basic 3	Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome	Nothing to Disclose
Zaman	Junaid	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	Wide Complex Tachycardia in a 51-Year-Old Man: Ventricular Tachycardia Until Proven Otherwise?	Nothing to Disclose
Zaman	Muhammad	FIT Clinical Decision Making: Arrhythmias and Electrophysiology	An Exciting Wide Complex Tachycardia	Nothing to Disclose
Zamani	Payman	Emerging Developments in HFpEF and Arryhthmias	Effect of Diabetes Mellitus on Pulsatile Arterial Load and Hemodynamics in HFpEF	Nothing to Disclose
Zambetti	Benjamin	Timely Topics in Acute Coronary Syndromes	Predictors of True ST-Segment Elevation Myocardial Infarction in Cocaine Positive Patients	Nothing to Disclose
Zambetti	Benjamin	Innovations in Advocacy and Patient Centered Care	Prolonged Inter-facility Transfer Times and Hospital Length of Stay in Insured Patients with ST-elevation Myocardial Infarction	Nothing to Disclose
Zannad	Faiez	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Early Versus Late Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome: Insights From the Examine Trial	CONSULTANT FEES/HONORARIA - Bayer, biomérieux, Biotronik, Gambro, Janssen, Mitsubishi, Novartis, Pfizer, Resmed, servier, St. Jude Medical, Takeda; OWNERSHIP INTERESTI/PARTNERSHIP/PRINCIPAL - cardiorenal diagnostics; RESEARCH/RESEARCH GRANTS - Boston Scientific; SPEAKER'S BUREAU - AstraZeneca, Daiichi Sankyo
Zannad	Faiez	Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease	Mineralocorticoid Receptor Antagonists in Patients With Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Trials	CONSULTANT FEES/HONORARIA - Bayer, biomérieux, Biotronik, Gambro, Janssen, Mitsubishi, Novartis, Plīzer, Resmed, servier, St. Jude Medical, Takeda; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - cardiorenal diagnostics; RESEARCH/RESEARCH GRANTS - Boston Scientific; SPEAKER'S BUREAU - AstraZeneca, Daiichi Sankyo
Zannad	Faiez	The Intersection of Diabetes and ASCVD	Average Clinician Measured Blood Pressure Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes Following Acute Coronary Syndromes in the EXAMINE Trial	CONSULTANT FEES/HONORARIA - Bayer, biomérieux, Biotronik, Gambro, Janssen, Mitsubishi, Novartis, Pfizer, Resmed, servier, St. Jude Medical, Takeda; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - cardiorenal diagnostics; RESEARCH/RESEARCH GRANTS - Boston Scientific; SPEAKER'S BUREAU - AstraZeneca, Dairbii Sankyo
Zanolin	Daniela	Updates on Risk Factors for Cardiovascular Disease	The Visceral Adiposity Index Predicts Cardiovascular Events Both in Coronary Artery Disease Patients With and in Coronary Artery Disease Patients Without Diabetes	Nothing to Disclose
Zanolin	Daniela	Innovations in Cardiovascular Risk Assessment and Reduction	ProBNP Strongly Predicts Future Vascular Events in Angiographied Coronary Patients With as Well as in Those Without the Metabolic Syndrome	Nothing to Disclose
Zanolin	Daniela	Diabetes and Other Issues in Cardiovascular Prevention	Non-Alcoholic Fatty Liver Disease Strongly Predicts Incident Diabetes in Patients With Coronary Artery Disease	Nothing to Disclose
Zanolin	Daniela	Diabetes and Other Issues in Cardiovascular Prevention	Single and Joint Effects of Obesity and of the Metabolic Syndrome on the Development of Diabetes in Patients With Coronary Atherosclerosis	Nothing to Disclose
Zanolin	Daniela	Diabetes and Other Issues in Cardiovascular Prevention	Non-Alcoholic Fatty Liver Disease in Coronary Artery Disease Patients: Association With Impaired Glucose Metabolism and With Future Cardiovascular Event Risk	Nothing to Disclose
Zanolin	Daniela	The Intersection of Diabetes and ASCVD	Remnant Cholesterol Predicts the Development of Type 2 Diabetes Mellitus in Patients With Established Coronary Artery Disease	Nothing to Disclose
Zareba	Wojciech	Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review	Sustained Clinical Benefit of Cardiac Resynchronization Therapy in Patients With Relatively Preserved Ejection Fraction: A MADIT-CRT Long-Term Follow-Up Sub-Study	CONSULTANT FEES/HONORARIA - iCardiac Technologies; RESEARCH/RESEARCH GRANTS - Boston Scientific,GILEAD Sciences,Zoll
Zareh	Meena	FIT Clinical Decision Making: Non-Invasive	Idiopathic Effusive Constrictive Pericarditis in a Patient With Cystic	Nothing to Disclose
Zareh	Meena	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Non-Invasive	Fibrosis: A Case Report With Multi-Modality Imaging Supravalvular Aortic Stenosis: A Rare Complication of Familial	Nothing to Disclose
Zareh	Meena	Imaging and Valvular Heart Disease FIT Clinical Decision Making: Prevention, Adult	Hypercholesterolemia Presenting as Cardiogenic Shock Challenges During Pregnancy With Marfan Syndrome and an	Nothing to Disclose
		Congenital and Congenital Heart Disease	Ascending Aortic Aneurysm	
Zaremski	Lynn	Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	Hispanics, Blacks and Whites	Nothing to Disclose
Zaromytidou	Marina	Interventional Cardiology: Intravascular Physiology and Endothelial Function	Association of Coronary Epicardial Endothelial Dysfunction With Low Endothelial Shear Stress in Patients With Mild Coronary	Nothing to Disclose
Zarrini	Parham	Non Invasive Imaging: MR Scar and Perfusion	Atherosclerosis Who Presented With Chest Pain Assessment of Myocardial Perfusion Reserve Index Using Adenosine Versus Regadenoson Among Healthy Female Subjects	Nothing to Disclose
Zarrini	Parham	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Adenosine Versus Regadenoson Among Healthy Female Subjects Prognostic Risk Factors for Heart Failure Hospitalization in Women Without Obstructive Coronary Disease: An Ancillary Study From the Women's Ischemia Syndrome Evaluation (WISE)	Nothing to Disclose
Zavalloni	Dennis	Featured Clinical Research II: Interventional	Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD Matrix Study	Nothing to Disclose
Zavitz	Kenton	Joint American College of Cardiology/Journal of the American Medical Association Late-	Syndromes: The RAD Matrix Study Primary Results of EBBINGHAUS, a Cognitive Study of Patients Enrolled in the FOURIER Trial	SALARY - Cambridge Cognition
Zdradzinski	Michael	Breaking Clinical Trials Understanding Pulmonary Vascular Disease: From Bench to Bedside	Pulmonary Vascular Response to Nitric Oxide and Subsequent Response to Advanced Medical Therapy in Incident Patients With	Nothing to Disclose
Zeiher	Andreas	Advances in Lipid Management	Pulmonary Hypertension Use of High-Intensity Statin Therapy Post-Acute Coronary Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9	CONSULTANT FEES/HONORARIA - Baxter Healthcare, Sanofiá/ventis; OWNERSHIP INTEREST/PARTNERSHIP/PRINCIPAL - t2cure;
Zeller	Tanja	MicroRNAs and Beyond in Vascular Medicine	Monoclonal Antibody, Versus Placebo: Interim Baseline Data Disturbed Expression of Immunoregulatory Long Noncoding RNAs in Circulating Immune Cells From Patients With Early Myocardial Infarction	RESEARCH/RESEARCH GRANTS - t2cure Nothing to Disclose
Zeman	Robert	FIT Clinical Decision Making: Multimodality	Bridging the Gap: Multimodality Imaging in a 56 Year Old Patient	Nothing to Disclose
Zeng	Xin	Imaging 36. Valvular Heart Disease: Clinical Team 2	With Sudden Death Suggested Reviewer	Nothing to Disclose
				· · · · · · · · · · · · · · · · · · ·

Control of the contro				
Last Name Zeng	First Name Yaping	Session Title Updates in Stable Ischemic Heart Disease	Presentation Title Coronary Calcification as a Mechanism of Plaque/Media Shrinkage:	Disclosures Nothing to Disclose
Zenses	Anne-Sophie	Interventional Cardiology: TAVR 1	A Multimodality Intracoronary Imaging Study Effect of Valve Oversizing on Leaflet Bending Stress in the	Nothing to Disclose
Zenses	Anne-Sophie	Interventional Cardiology: TAVR 4	CoreValve: An In Vitro Study Clinical Study of the Impact of Preexisting Patient-Prosthesis	Nothing to Disclose
Zeymer	Uwe	Acute Coronary Syndromes, Diagnosis,	Mismatch on Valve-in-Valve Performance Predictors of Ischemic Events Within and After 1 Year After an	CONSULTANT FEES/HONORARIA - Astra
Zeymer	Uwe	Management and Outcomes Heart Failure and Cardiomyopathies: Heart	Acute Coronary Syndrome: Results From the EPICOR Registry Representativeness of the Paradigm Heart Failure Population in	Zeneca,BMS,Boehringer-Ingelheim,Novartis Corporation,Pfizer,Sanofi-Aventis,The Medicines Company, SPEAKER'S BUREAU - Biotronik,Daiichi Sankyo CONSULTANT FEES/HONORARIA - Astra
		Failure Is Just a Revolving Door	Real Life	Zeneca,BMS,Boehringer-Ingelheim,Novartis Corporation,Pfizer,Sanofi-Aventis,The Medicines Company; SPEAKER'S BUREAU - Biotronik,Daiichi Sankyo
Zhan	Yang	FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension	Hypertrophic Cardiomyopathy as a Manifestation of Anderson-Fabry Disease	Nothing to Disclose
Zhang	Hongju	Valvular Heart Disease: Aortic Stenosis	Sinus Rhythm Versus Atrial Fibrillation & It Clinical Profile and Natural History of Patients With Severe Aortic Stenosis Managed Medically	Nothing to Disclose
Zhang	Jia-Hui	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Impact of Gender Difference in Clinical Presentation on Long-Term Outcomes in Chinese Patients Undergoing Percutaneous Coronary Intervention	Nothing to Disclose
Zhang	Lili	Innovative Use of Echocardiography	Left Ventricular Global Longitudinal Strain Predicts All-Cause Mortality in Patients With Mitral Regurgitation and Ischemic Heart Disease but Not in Nonischemic Mitral Regurgitation	Nothing to Disclose
Zhang	Qisu	Atrial Fibrillation, Anticoagulation and Novel Device Therapies	Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Compared to Warfarin Among Non-Valvular Atrial Fibrillation Patients in the US Medicare Population	SALARY - Bristol-Myers Squibb Company, Pfizer Inc I am an employee of STATinMED Research, which is a paid consultant to Bristol-Myers Squibb company and Pfizer Inc.
Zhang	Rong	Physical Activity and Prevention of Cardiometabolic Disease: Exercise Is Medicine	The Impact of Lifelong Exercise Training "Dose" on the Ventricular- Arterial Coupling	Nothing to Disclose
Zhang	Shaosong	Timely Topics in Acute Coronary Syndromes	Systemic Pentraxin 3 Is a Potential Biomarker to Differentiate Plaque Erosion From Plaque Rupture in Acute Coronary Syndrome Patients	Nothing to Disclose
Zhang	Shaosong	The Inside View: Learning From Intracoronary Imaging	Prevalence and Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A Four-Year Follow-Up Study	Nothing to Disclose
Zhang	Shu	Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore	Baseline Serum High Density Lipoprotein Cholesterol Level Predicts Long-Term Clinical Outcomes in Patients With Heart Failure Receiving Cardiac Resynchronization Therapy	Nothing to Disclose
Zhang	Shu	The Evolving World of LVADs, Transplant and Other Novel Discoveries	Chronic Kidney Disease in Asian Patients With Heart Failure	Nothing to Disclose
Zhang	Tuo	Interventional Complexity and Complications	New Definition of Ci-Aki: Combined Serum Creatinine and Cystatin	Nothing to Disclose
Zhang	Xin	Updates on Pulmonary Embolism Management in 2017	C Ultrasound Accelerated Catheter Directed Lytic Therapy for Management of Pulmonary Embolism: Impact of Procedural Timing	Nothing to Disclose
Zhang	Xuemei	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	on Echocardiographic Outcomes and Safety From Fetus to Fontan: A Single Center Experience of Resource Utilization for Patients Diagnosed With Single Ventricle Cardiac	Nothing to Disclose
Zhang	Yan	Toward Precision Medicine in the Treatment of Elevated Blood Pressure	Defects Serum Homocysteine Lowering by Long-Term Low-Dose Folic Acid: New Insight on <i>MTHFR</i> Gene-Folate Interaction From China	Nothing to Disclose
Zhang	Van	Diabetes and Other Issues in Cardiovascular	Stroke Primary Prevention Trial Efficacy of Folic Acid Supplementation on the Reduction of Stroke	Nothing to Disclose
Zhang	Yan	Prevention	Risk: Interaction With Platelet Count	-
Zhang	Zugui	New Insights Into Prediction and Treatment of Hypertension	Cost-Effectiveness of Intensive Blood Pressure Goals in Patients With Prior Cardiovascular Disease	Nothing to Disclose
Zhao	David	Valvular Heart Disease: Aortic Stenosis	Surgical Risk Scores Outweigh Echocardiographic Severity of Aortic Stenosis for Determining Prognosis in Patients With Low Gradient Severe Aortic Stenosis and Preserved Left Ventricular Function	CONSULTANT FEES/HONORARIA - Boston Scientific; OTHER - Edwards, MEDTRONIC
Zhao	David	02. Acute and Stable Ischemic Heart Disease: Clinical Team 2	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Boston Scientific; OTHER - Edwards, MEDTRONIC
Zhao	Di	Innovations in Cardiovascular Risk Assessment	Vitamin D Levels and Autoantibodies in the Multi-Ethnic Study of	Nothing to Disclose
Zhao	Di	and Reduction Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues	and Stroke Among Whites and Blacks: The Atherosclerosis Risk In	Nothing to Disclose
Zhao	Hong	Acute Coronary Syndromes, Diagnosis,	Communities (ARIC) Study Trends in the Use of High-Intensity Statin Therapy After Myocardial	Nothing to Disclose
Zhao	Lianbi	Management and Outcomes Interventional Cardiology: Translation and Pre-	Infarction, 2011-2014 Host Intestinal Epithelium Derived MiRNAs Shape the Microbiota	Nothing to Disclose
		Clinical Research	and Its Implication in Cardiovascular Diseases	ů .
Zhao	Lianbi	Impact of Prenatal Environment on Congenital Heart Disease	Maternal Exosomal miRNAs in Diabetes Contribute to the Cardiac Development Deficiency	Nothing to Disclose
Zhao	Qi	Making Progress in Understanding Heart Failure	Heart Failure Patients Without Atrial Fibrillation	Nothing to Disclose
Zhao	Qi	Interventional Cardiology: PCI in Complex Patients	Impact of Comorbid Coronary Artery Disease and Severe Peripheral Artery Disease on Major Adverse Cardiovascular Events	Nothing to Disclose
Zhao	Yan	Biomarkers and Targets for Ischemic Heart Disease	Ultrasound Increases Myocardial Blood Flow in Acute Myocardial Ischemia Without Reducing Infarct Size	RESEARCH/RESEARCH GRANTS - Oregon Health & Driversity Science University
Zhao	Yanglu	Considerations in Antiplatelet Therapy and in ACS	Novel Biomarker Algorithmic Panel Measuring Permutations of Immune Response to Cardiac Endothelial Injury and Global Risk Factors Identifies Patients at Risk of Acute Coronary Syndrome	CONSULTANT FEES/HONORARIA - GD Bioscience
Zhao	Yanru	MicroRNAs and Beyond in Vascular Medicine	Mir-30c Protects Diabetic Nephropathy by Suppressing Epithelial-to- Mesenchymal Transition in Db/db Mice	OTHER - none
Zheng	Gonghui	Timely Topics in Acute Coronary Syndromes	Systemic Pentraxin 3 Is a Potential Biomarker to Differentiate Plaque Erosion From Plaque Rupture in Acute Coronary Syndrome Patients	Nothing to Disclose
Zheng	Xin	Acute Coronary Syndromes, Diagnosis, Management and Outcomes	Time to Acute Care Among Patients With Acute Myocardial Infarction in China: A Report From China Patient-Centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction	Nothing to Disclose
Zheng	Yinggan	Cardiac Arrest, Diabetes, and Other High Risk Features of Patients With Acute Coronary Syndrome	Real World Relationships Between Baseline Q Waves, Time From Symptom Onset and Clinical Outcomes in ST-Segment Elevation Myocardial Infarction Patients: Insight From the Vital Heart Response Registry	Nothing to Disclose
Zhong	Liang	Vascular Medicine: Novel Risk Measures in Arterial Diseases	Sarcopenia and Vascular Function Among Community Elderly	Nothing to Disclose
Zhong	Liang	Diabetes and Other Issues in Cardiovascular Prevention	Adiposity, Leanness or Both? Characterizing Measures of Adiposity and Leanness With Cardiovascular Remodeling	Nothing to Disclose
Zhong	Ming	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Bioprosthetic Mitral Valve Thrombosis Secondary to Hypereosinophilic Syndrome	Nothing to Disclose
Zhou	Anyu	The Evolving World of LVADs, Transplant and	Ventricular Assist Device Decreases Abnormal Cardiac Sodium	Nothing to Disclose
L	1	Other Novel Discoveries	Channel mRNA Splicing	<u> </u>



Contract of the Contract of th				l l
Last Name Zhou	First Name Jenny	Session Title Heart Failure and Cardiomyopathies: Is Heart	Presentation Title Treatment Patterns and Resource Use of Heart Failure Patients on	Disclosures Nothing to Disclose
Zhou	Qing	Failure With a Normal EF for Real? Emerging Basic Science in Ischemic Heart	Medicaid in Five States in the US Thrombolysis in Coronary Micro-Circulation Occlusion by	Nothing to Disclose
	9	Disease	Dodecafluoropentane Acoustic Vaporizable Nano-Droplet With Ultrasound Irradiation	
Zhou	Yingling	PCI for NSTEMI and Complex Patients With	The Contrast Volume to Creatinine Clearance Ratio Predicts Contrast-Induced Nephropathy in Patients With Chronic Kidney	Nothing to Disclose
		Multiple Co-Morbidities	Disease Undergoing Percutaneous Coronary Intervention	
Zhu	Jianbing	Biomarkers and Targets for Ischemic Heart Disease	Mir-499 Protects the Rat Heart Against Ischemia/Reperfusion Injury Through Pdcd4 During Ischemic Postconditioning-Regulated	Nothing to Disclose
Zhu	Shuiqing	Population Specific Cardiomyopathies: From Exomes to Databases	Hospitalization Expenditure by New York Heart Association (NYHA) Classification in Heart Failure (HF) Patients in China	Nothing to Disclose
Zhu	Yinchun	Timely Topics in Acute Coronary Syndromes	Systemic Pentraxin 3 Is a Potential Biomarker to Differentiate Plaque Erosion From Plaque Rupture in Acute Coronary Syndrome Patients	Nothing to Disclose
Zhuang	Jian	Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease	Variation in Prenatal Diagnosis of Congenital Heart Defects in a Population-Based Study in Southern China	Nothing to Disclose
Zhuang	Xiaodong	The Intersection of Diabetes and ASCVD	Anti-Diabetic Agents and Cardiovascular Outcomes in the Era of Novel Glucose-Lowing Drugs	Nothing to Disclose
Ziada	Khaled	Novel Mechanisms Underlying Ischemia- Reperfusion Injury in AMI	Sphingosine-1 Phosphate Is a Novel Biomarker That Correlates With Stem Cell Mobilization and Clinical Outcomes in Patients With ST-Elevation Myocardial Infarction	Nothing to Disclose
Ziada	Khaled	15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology Team 3	Suggested Reviewer	Nothing to Disclose
Ziada Ziaeian	Khaled Boback	Interventional Challenging Cases: Team 4 ACC Research Awards	ACC Challenging Case Reviewer Race/Ethnic Differences in Outcomes AmongHospitalized Patients	Nothing to Disclose Nothing to Disclose
			with Heart Failure with a Preserved Ejection Fraction(HFpEF)"	
Zidar	James	Interventional Cardiology: Carotid and Endovascular Intervention Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular, Medtronic Vascular; SPEAKER'S BUREAU - Amgen Inc.
Zielonka	Benjamin	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	Hypoplastic Left Heart Syndrome With Intact or Restrictive Atrial Septum:What Happens After Survival?	Nothing to Disclose
Zielonka	Benjamin	Congenital Heart Disease: Innovations in Single Ventricle Heart Disease	From Fetus to Fontan: A Single Center Experience of Resource Utilization for Patients Diagnosed With Single Ventricle Cardiac	Nothing to Disclose
Zieman	Susan	Cardiovascular Procedures That Push the	Defects Panelist	Nothing to Disclose
Zieman	Susan	Line: High-Risk or Futility of Care? Cardiovascular Procedures That Push the	Procedural Concerns in Patients with Cognitive Impairment	Nothing to Disclose
Zier	Lucas	Line: High-Risk or Futility of Care? The Story of the Adult Congenital Heart	Prevalence and Predictors of Atrial Tachyarrhythmias in Adult	Nothing to Disclose
Zier	Lucas	Disease Patient and EP Fontan in the Modern World	Fontan Patients Prevalence of Elevated Body Mass Index and Its Association With	Nothing to Disclose
			Clinical Features in Adult Fontan Patients	-
Zier	Lucas	Arrhythmias and Clinical EP: Devices 3	Transcatheter Closure of Residual Left Atrial Appendage Leaks Following Lariat Device Closure	Nothing to Disclose
Ziffer	Jack	27. Non Invasive Imaging: CT/Multimodality, Angiography, and Non-CT Angiography Team 1	Suggested Reviewer	Nothing to Disclose
Ziffra	Jeffrey	FIT Clinical Decision Making: Non-Invasive Imaging and Valvular Heart Disease	Persistent Left Atrial Appendage Thrombus in the Setting of an Indolent Glioblastoma Multiforme	Nothing to Disclose
ZijIstra	Felix	Heart Failure and Cardiomyopathies: What Next When All Else Is Failing?	A Weaning Marker From Veno-Arterial Extra Corporeal Membrane Oxygenation Using a Novel Microcirculatory Imaging	OTHER - Erasmus MC
Zile	Michael	Featured Clinical Research III	Paroxysmal Atrial Fibrillation Is Associated With Worse Clinical Outcomes Than Persistent/Permanent Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction	CONSULTANT FEES/HONORARIA - Abbott, AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Bristol- Myers Squibb Company, CVRx, Eli Lilly and Gompany, Merck, Novartis; RESEARCH/RESEARCH GRANTS - Department of VA, MEDTRONIC, NIH; SALARY - Medical University of South Carolina
Zile	Michael	Making Progress in Understanding Heart Failure	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF	Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Bristol- Myers Squibb Company, CVRx,Eil Lilly and Company, Merck, Novartis; RESEARCH/RESEARCH GRANTS - Department of VA, MEDTRONIC, NIH; SALARY - Medical University of South Carolina
Zile	Michael	Heart Failure and Cardiomyopathies: Heart Failure Is Just a Revolving Door	Effect of Sacubitril/Valsartan Compared With Enalapril, According to Etiology in PARADIGM-HF	CONSULTANT FEES/HONORARIA - Abbott,AstraZeneca Pharmaceuticals,Bayer Healthcare Pharmaceuticals,Bristol- Myers Squibb Company, CVRx,Eil Lilly and Company,Merck, Novartis; RESEARCH/RESEARCH GRANTS - Department of VA,MEDTRONIC,NIH; SALARY - Medical University of South Carolina
Zile	Michael	Hormones and Heart Failure	Low Urinary Cgmp/Bnp Ratio Is Associated With Worse Outcomes in Heart Failure but is Increased by Treatment With Sacubitril/Valsartan: An Analysis of Paradigm-HF	CONSULTANT FEES/HONORARIA - Abbott, AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Bristol- Myers Squibb Company, CVRx, Eli Lilly and Company, Merck, Novartis; RESEARCH/RESEARCH GRANTS - Department of VA, MEDTRONIC, NIH; SALARY - Medical University of South Carolina
Zile	Michael	The Old and the New: Impact of Heart Failure Drug Therapies	Influence of Sacubitril/Valsartan on Glycemic Control in Patients With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction	CONSULTANT FEES/HONORARIA - Abbott AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Bristol- Myers Squibb Company, CVRx,Eil Lilly and Company, Merck, Novartis; RESEARCH/RESEARCH GRANTS - Department of VA
Zimetbaum	Peter	08. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias Team 1	Suggested Reviewer	CONSULTANT FEES/HONORARIA - MEDTRONIC
Zimmerman	Chloe	Acute Heart Failure: Evaluating Strategies to Prevent Readmissions	Admission Types Among Patients With Heart Failure Cared for by Accountable Care Organizations: Variation by Performance on a Measure of Risk Standardized Acute Admission Rates	Nothing to Disclose
Zimmerman	Frank	ECG Screening and Risk Prediction	Reads of the Standard Acute Authorities Rates ECG Screening of Young Adults for Sudden Cardiac Death Risk in Primary Care Offices	Nothing to Disclose
Zimmermann	Rodney	Considerations in Antiplatelet Therapy and in ACS	Frimary Care Utrices Effects of Ticagrelor Versus Clopidogrel in Fibrinolytic-Treated STEMI Patients Undergoing Early PCI	CONSULTANT FEES/HONORARIA - Astra-Zenica,Boeringer- Ingelheim; RESEARCH/RESEARCH GRANTS - Eli-Lilly Canada,Schering-Plough; SPEAKER'S BUREAU - Astra-
Zimmet	Jeffrey	The Best Coronary and Peripheral Interventional Challenging Cases	Percutaneous Revitalization of an Atretic Left Internal Mammary to Left Anterior Descending Coronary Artery Bypass Graft Using Sub- Intimal Tracking and Re-Entry Technique	Zeneca,Boehringer-Ingelheim,Merck-Frosst Nothing to Disclose
Zinman	Bernard	Highlighted Original Research: Prevention and the Year in Review	Consistent Effect of Empagliflozin on Composite Outcomes Related to Heart Failure: Results From EMPA-REG OUTCOME	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim Pharmaceuticals, Inc
Zinman	Bernard	Innovations in Cardiovascular Risk Assessment	Are the Cardiovascular Risk Reductions Seen With Empagliflozin in	CONSULTANT FEES/HONORARIA - Boehringer Ingelheim
		and Reduction	the EMPA-REG OUTCOME Trial Explained by Conventional Cardiovascular Risk Factors?	Pharmaceuticals, Inc

Common Control	Carried States				
Dece Double of Prince in the out Manage Common Comm	Last Name	First Name	Session Title	Presentation Title	Disclosures
Upode or Riskle Angroad of the Pougue P Joseph Link Mark Composite Touring Oxygen O		Douglas	FIT Forum: Mix and Mingle	Electrophysiology	Nothing to Disclose
Designed Designed	Zipes	Douglas	Update on Stable Angina and the Douglas P. Zipes, MD, MACC, Distinguished Young	Introduction of the Douglas P. Zipes Award Recipient	Nothing to Disclose
Martine Method with the control of t	Zipes	Douglas	04. Arrhythmias and Clinical EP: Basic Team 1	Suggested Reviewer	Nothing to Disclose
Wilson	Zipse	Matthew		Multiple Ablations in Patients With Non-Ischemic Cardiomyopathy	Nothing to Disclose
Surjey and Customers of Carleter Allation for Treatment of Management of	Zipse	Matthew		Early Recurrence of Ventricular Tachycardia Predicts Increased	Nothing to Disclose
Earning Montage (From Det 15 Drugs, Mechanistic ingight told profess) Min Control (Management III) 2017 William (Section of the Control of Management III) 2017 Cogrid (Ministry Control of Management III) 2017 Cogrid (Ministry Control of Ministry Control of Management III) 2017 Cogrid (Ministry Control of Ministry Control	Zipse	Matthew	Atrial Fibrillation and VT: Incorporating Novel	Safety and Outcomes of Catheter Ablation for Treatment of Refractory Ventricular Arrhythmias in Patients With Advanced Heart	Nothing to Disclose
David Update on Pulmoney Entodolism Reput Perincular Systilic Function in Patients SPEAKER SIDERALY - Aboned Anti-Zervece Pharmaceutic With Pulmons/ Perincular Trainable With Plansound - Assistant Constitution Constitut	Zisimos	Konstantinos		Dietary Consumption of Olive Oil and Cardiovascular Outcome in	Nothing to Disclose
Compile William Feature Clinical Research Chart Chart Chart FEESH-ONGRARIA - About Vascular OTHE Compile Chart Chart Feest Feeture appearement with GE Healthcare Chart Feeture appearement with	Zlotnick	David	Updates on Pulmonary Embolism	Rapid Improvement in Right Ventricular Systolic Function in Patients With Pulmonary Embolism Treated With Ultrasound-Assisted	SPEAKER'S BUREAU - Abiomed, Astra Zeneca Pharmaceuticals
Combat William Country Fitting of Assessing William William Country William Country Co	Zoghbi	William	Featured Clinical Research I		CONSULTANT FEES/HONORARIA - Abbott Vascular; OTHER - Licensing agreement with GF Healthcare
William Consult Part Decidents to China Consult Part Con	Zoghbi	William		Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular; OTHER -
Copin Wilson Milliam International Copins of They Don't File Milliam International Copins of They Don't File Milliam International Copins of Market Report Worker Heart Milliam International Copins of Market Report Worker Heart Milliam International Copins of Market Report Worker Heart Milliam International Copins of Market Report Worker Heart Milliam International Copins of Market Report Worker Heart Milliam International Copins of Market Worker Worker Milliam International Copins of Market Worker Worker Milliam International Copins of Market Worker Milliam Internatio	Zoghbi	William	Imaging in Valvular Heart Disease: Applying Guidelines to Clinical Practice and What to do	Co-Chair	CONSULTANT FEES/HONORARIA - Abbott Vascular; OTHER -
Milliam Highighted Original Research: Valvular Heart Near in Review Speaker Versi in Rev	Zoghbi	William	Guidelines to Clinical Practice and What to do	How Do the New Echo Guidelines Change My Practice	CONSULTANT FEES/HONORARIA - Abbott Vascular; OTHER - Licensing agreement with GE Healthcare
Non Invasive Imaging, MR Characterization Elevated Myocardial Extracellular Volume Fraction (ECV) and b CONSULTANT FEES/HONDRARIA - Abbott Vasoular, OTHE	Zoghbi	William	Highlighted Original Research: Valvular Heart	Year in Review Speaker	CONSULTANT FEES/HONORARIA - Abbott Vascular; OTHER - Licensing agreement with GE Healthcare
Fire Clinical Decision Making Non-Imassive Imaging and Valutal Heart Disease Imaging and Valutal Heart Disease Interest Vision (Proposition) (Interest Vis	Zoghbi	William	Non Invasive Imaging: MR Characterization		CONSULTANT FEES/HONORARIA - Abbott Vascular; OTHER -
Value Valu	Zoghbi	William	FIT Clinical Decision Making: Non-Invasive	Importance of Exercise Hemodynamics in Patients With Primary	CONSULTANT FEES/HONORARIA - Abbott Vascular; OTHER -
Fill Clinical Decision Making, Heart Falure and Patent With a Systolic Murmur and Shock: Importance of the Pulmorany Hypertension Physicial Physicial Polysical Physicial Communication Physical Physicial Physicial Communication Physicial Communication Physicial Communication Physicial Communication Physicial Communication Physicial Communication Physicial Communication Physicial Communication Physicial Communication Physicial Communication Physicial Communication Physicial Physicial Communication Physicial Communication Physicial	Zoghbi	William	Valvular Heart Disease: Mitral Valve Disease	Inter-Study Reproducibility of Mitral Regurgitation Quantitation Using	CONSULTANT FEES/HONORARIA - Abbott Vascular; OTHER -
Engage @ ACC.17 Studio. Cardiology Contestant Consult TANT FEESH-NORCRARIA - Abbott Vascular; OTHEL Consult TANT FEESH-NORCRARIA - Consult Vascular; OTHEL Consult TANT FEESH-NORCRARIA - Consult Vascular; OTHEL Consult TANT FEESH-NORCRARIA - Consult Vascular; OTHEL Consult TANT FEESH-NORCRARIA - Consult Vascular; OTHEL Consult TANT FEESH-NORCRARIA - Consult Vascular; OTHEL Consult TANT FEESH-NORCRARIA - Consult Vascular; OTHEL Consult TANT FEESH-NORCRARIA - Consult Vascular; OTHEL Consult TANT FEESH-NORCRARIA - Consult TANT FEESH-NORCRARIA - Consult TANT FEESH-NORCRARIA - Consult TANT FEESH-NORCRARIA - Consult TANT FEESH-NORCRARIA - Consult TANT FEESH-NORCRARIA - Consult TAN	Zoghbi	William		Patient With a Systolic Murmur and Shock: Importance of the	CONSULTANT FEES/HONORARIA - Abbott Vascular; OTHER -
Milliam 28. Non Invasive Imaging: Echo Team 5 Suggested Reviewer Consult_NATF FEESHONORARIA - Abbott Vascular; OTHEL	Zoghbi	William	Engage @ ACC.17 Studio: Cardiology Contest		CONSULTANT FEES/HONORARIA - Abbott Vascular; OTHER -
Theodoros Heart Falure and Cardiomyopathies: Is Heart Falure with a Normal E For Real? Promotion Form Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Form Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Form Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Form Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Form Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Form Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Form Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Form Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Form Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Form Diet to Drugs: Mechanistic Insight Into Ischemic Heart Disease Form Diet Into Into Ischemic Heart Disease Form Dietary Congenital Heart Disease Form Dietary Proprietary Form Dietary Congenital Heart Disease Form Dietary Congenital Heart Disease Form Dietary Proprietary Form Dietary Proprietary Form Dietary Form Dietary Form Dietary Form Dietary Form Dietary Form Dietary Form Dietary Form Dietary Form Dietary Form Dietary Form Dietary Form Dietary Form Dietary Form Dietary Form Dietary Form Dieta	Zoghbi	William	28. Non Invasive Imaging: Echo Team 5	Suggested Reviewer	CONSULTANT FEES/HONORARIA - Abbott Vascular; OTHER -
Theodoros From Diet to Drugs. Mechanistic Insight Into Schemic Heart Diseases Patients With Coronary Disease Nothing to Disclose	Zografos	Theodoros		Inflammatory Biomarkers & Novel Indices of Left Ventricle	Nothing to Disclose
Trends and Use of Echocardioparby in Patients With	Zografos	Theodoros		Dietary Consumption of Olive Oil and Cardiovascular Outcome in	Nothing to Disclose
Interventional Cardiology: TAVR 3	Zook	Nina		Trends and Use of Echocardiography in Patients With <i>Staphylococcus Aureus</i> Bacteremia: An Analysis Using the	Nothing to Disclose
Congenital and Congenital Heart Disease Severe Hypercholesterolemia Severe Hypercholestero	Zorn	George	Interventional Cardiology: TAVR 3	Initial Use of the Evolut Pro Self-Expanding Transcatheter Aortic	CONSULTANT FEES/HONORARIA - Edwards,MEDTRONIC
Failure Gadgets Galore Laft Venticular Contraction Pattern Jiangang Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore Zou Jiangang Heart Failure and Cardiomyopathies: Heart Failure Gadgets Galore Leaving Vascular Resistance Predicts Poor Response to Cardiac Resynchronization Therapy Leaving Vascular Resistance Predicts Poor Response to Cardiac Resynchronization Therapy Leaving Vascular Resistance Predicts Poor Response to Cardiac Resynchronization Therapy Leaving Vascular Resistance Predicts Poor Response to Cardiac Resynchronization Therapy Leaving Vascular Resistance Predicts Poor Response Lo Cardiac Resynchronization Therapy Response Zou Jiangang Leading Us Astray? Pacemakers in Cardiomyopathies Cardiomyopathies Zubaid Mohamed Multimodality Imaging in Heart Diseases: International Perspectives From the Gulf Heart Association, Thai Heart Association, and American College of Cardiology Zubaid Mohammad Arrythmias and Clinical EP: AF Miscellaneous and Surgical Issues Zucker Mark Emerging Developments in HFpEF and Arrythmias Arrythmias 13. Heart Failure and Cardiomyopathies: Clinical Team 3 Zucker Orgenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease Zucker Orgenital Heart Disease: New Diagnostic Approaches in Congenital Heart Disease Left Atrial Stiffness: A New Noninvasive Index That May Serve as a Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose Nothing to Disclose	Zorzanelli Rocha	Viviane			Nothing to Disclose
Jiangang	Zou	Jiangang		Failure Patients With Left Bundle Branch Block and Homogeneous	Nothing to Disclose
Jiangang	Zou	Jiangang		Elevated Pulmonary Vascular Resistance Predicts Poor Response	Nothing to Disclose
Jiangang Leading Us Astray? Pacemakers in Cardiomyopathies Spect Guided Lv Lead Placement for Incremental Benefits to Crt Nothing to Disclose Efficacy. A Prospective Multicenter Randomized Controlled Trial	Zou	Jiangang	Heart Failure and Cardiomyopathies: Heart	Assessment of Left Ventricular Contraction Patterns Using Gated SPECT MPI to Improve Cardiac Resynchronization Therapy	Nothing to Disclose
Mohamed Multimodality Imaging in Heart Diseases: International Perspectives From the Gulf Heart Association, Thai Heart Association, and American College of Cardiology Influence of Beta-Blockers on Mortality in Chronic Heart Failure Nothing to Disclose Arrythmias and Clinical EP: AF Miscellaneous Influence of Beta-Blockers on Mortality in Chronic Heart Failure Nothing to Disclose Patients With Atrial Fibrillation: Findings From the Gulf-Safe Sugression Sugressio	Zou	Jiangang		Spect Guided Lv Lead Placement for Incremental Benefits to Crt	Nothing to Disclose
Mohammad	Zubaid	Mohamed	Multimodality Imaging in Heart Diseases: International Perspectives From the Gulf Heart Association, Thai Heart Association, and		Nothing to Disclose
Emerging Developments in HFpEF and Arryhthmias Is Continuous Outpatient Milrinone Therapy Appropriate in Stage D Arryhthmias Is Continuous Outpatient Milrinone Therapy Appropriate in Stage D Heart Failure Patients With Underlying Ventricular Tachycardia Nothing to Disclose	Zubaid	Mohammad	Arrhythmias and Clinical EP: AF Miscellaneous		Nothing to Disclose
August	Zucker	Mark	Emerging Developments in HFpEF and	Is Continuous Outpatient Milrinone Therapy Appropriate in Stage D	Nothing to Disclose
Zuckerberg Jeremy Congenital Heart Disease: New Diagnostic Left Atrial Stiffress: A New Noninvasive Index That May Serve as a Approaches in Congenital Heart Disease Surrogate Marker of Left Ventricular Disatolic Dysfunction in Children Zusman Oren Insights From Echocardiography Use Intervention Versus Observation in Symptomatic Patients With Normal Flow-Low Gradient Severe Aortic Stenosis	Zucker	Mark	13. Heart Failure and Cardiomyopathies:		Nothing to Disclose
Zusman Oren Insights From Echocardiography Use Intervention Versus Observation in Symptomatic Patients With Northing to Disclose Normal Flow-Low Gradient Severe Aortic Stenosis	Zuckerberg	Jeremy	Congenital Heart Disease: New Diagnostic	Surrogate Marker of Left Ventricular Diastolic Dysfunction in	Nothing to Disclose
	Zusman	Oren	Insights From Echocardiography Use	Intervention Versus Observation in Symptomatic Patients With	Nothing to Disclose
	Zwas	Donna	32. Prevention: Clinical Team 2		Nothing to Disclose